<SEC-DOCUMENT>0001628280-22-021959.txt : 20220809
<SEC-HEADER>0001628280-22-021959.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220809162427
ACCESSION NUMBER:		0001628280-22-021959
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		221148705

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ameh-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:4d426055-c9f8-47bb-b397-a8331168ec1c,g:285e3d39-8563-4e90-906d-af4a3a14867e,d:479e2a4965a945a4983dec200085612c--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ameh="http://www.apollomed.net/20220630" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ameh-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY18zLTEtMS0xLTEwNTAzMw_78f29bb1-7d33-42f1-bb86-e88eaab7c095">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY180LTEtMS0xLTEwNTAzMw_cff088d1-f3e2-4c52-ad43-5d8aae76f0b5">2022</ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY181LTEtMS0xLTEwNTAzMw_082d2862-d676-4f84-adaa-880706de1ad3">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY182LTEtMS0xLTEwNTAzMw_31d7f0e3-5724-4fea-8a3f-8fe6e7f94a15">0001083446</ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY183LTEtMS0xLTEwNTAzMw_b7a1b471-4a27-4018-9ada-b7abb0828c6c">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ameh-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c6e0513e0f49708c1b538585500a39_I20220725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i9892fbf73a5e432fabdabd8425173fdd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d5be84e39c452ebc3a62ac694ca372_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i18ee389c560146fb90a980c9883bc5fa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f53a8587f754ab6949ab18fac933790_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17f14c3de074b09a519d4ae7cec2374_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0075948a15c34ea7995a87ab515a831e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4594d1cdf8403b9b1d586438ae5595_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064787fbd3b34338bc355bea54602fa0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bb88e8e61844678858e6f1049c3b8d8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if532127b9ae74868b84354daf327af15_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd9383c56a049e39c988fe1d699c8c8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f66c15a9774d3f9a542401fdc90d05_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d18e1861dd47459e3afc0e2f4d6b6c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3be1ea17a2242b89f05c2d9c603ef7f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9a9c63b74748ea9144996c4ffcebfc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f72a8ae1ecb4b9f95f49782044f3034_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb94590e3da4131815186c8ad836fbd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b2dce3af564d37aace93fa3edc0576_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie13819d6ef7341d7adfe25db4589fb16_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f55ac666634d8790450c2efbff1301_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84494cd24411430cb3a73d2b634c4e8f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b4615fc163545a386d6cb61eafec12b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b39506fda1c403390a1a7356060a43f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b2701ff7a24a1dbb0e0cba3406cd91_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5154423056f643eca603328d7cdb95e7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18329a0408e04ac0bf921293f4606d37_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia504157a512f402581af013fb57df905_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4a0d5b297a4f7fb66c1516ac86205f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief358036295248deb2d6fc4f17ab1fd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6b90da5220a49248e3a42f5d7bcee8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01c1ed4406f45fd89cc7c596242ac42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id232a7c63cea47fb908b2d31d1507b26_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibabb570e56704819be46a35a99056cfd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia07784125551442e88d85eea79a1a397_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b2a5b59bb6c4986b7c1a50b1f8a0aad_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c6cc256e341493aa571df5da6b6662f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d98f2c383be4f0caf317615c3e90bdd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75d2dd3b8a394e94b24002551af97de8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffe3f233a5ee47f89e7da633077e4a16_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eff61b12ade44188aa16b4c6f4691fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79a98933176041edb09daa8e6a031ae2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdb8cb1f443c409ebb880abdbfb1b50b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1b4fc11728e4a119e9ff7d187016bbd_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2be7890574c4c2e850a4bef6af34746_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a4ee78dedb4bf0bb4d2dcdbf5e685c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a647777c9a41638828e0bb054b607d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d4945b7a5d144dcb44613757de6b733_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf67c623dc9c4fdb87ffe7f1a5f0fd33_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee1f7e2940144fe09e63a4985d202a33_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a86084d3064273846f20df1dc58121_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71714e79a7ff4ae58ec405207709ae87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0ac6532c5744fbe9e81dcf735c713ea_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2095839d0b164a5db420348af27d9e8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieabf5dd86df34cefa162b01e549f2f27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb56e0f9f67490fa0624de03cbc6dfc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic700b6fc892341ebbf97cebcb5258f90_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05d89e7c53fa4a70b5fb4595708da067_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida30c669e01848049f134a3f777ea180_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbece1b8c5604d32bef8c1b3bee0e06e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86bed315c9104a5ea8f38b47de37821f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744f0bbbd4024a33b8e4daec9c49bb16_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae2d6eb6ccba48b09c3e8ac6b7c4c666_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11090e9d37df449c8a39e89447069685_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b9bd5984e7487dae4a1cd249a6cdf0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f5ec933f8d44cc38f55f6394cb7637c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i949844556a7b4f6492884ecdd3ff6253_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42578d05def24550adcdf005d6e174fd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1d976a9d4c3495092aef7049971c567_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28f106f492574f71ad887c17b3f0e3b8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb3286d909fa4f44a7673a684b27d8d7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f3de9a3211f43939fba721ad717140d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic123e707f5444ec8a2f129ff7fd69271_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9165a0fe2b24da295ead9547c7c43f7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4becb57108e844a2af77734d782c9546_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if607fd60c6ba4a7fb898dea28d8f0d05_D19990701-19990731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-07-01</xbrli:startDate><xbrli:endDate>1999-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife69969a467049b7822c63de16e05840_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d59e759a6d143e7b8673d525e1641d4_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i25b2318042034ef8ada1dff3ae0fa2ee_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab9ce1fe319c40f3b5143a3c664cb2f8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b9dc946cce64aeda656fa396f8ac5d9_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b76bb6ee687447b91d65e6261285c67_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ab29ee2b194190ba48aff50a9eca6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05247cd849de40dc8290e15a895f802d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ed4c08298bb425782e0cb29c6843164_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910383234e6d43a5b4e0907b9f2f7fa3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>ameh:plan</xbrli:measure></xbrli:unit><xbrli:context id="i87ad3733808d4ed680a72e6a21ac142d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="clinic"><xbrli:measure>ameh:clinic</xbrli:measure></xbrli:unit><xbrli:context id="i9c45553f306743bb86ff185b451d6f0d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i447febb4f2414ccebd0319ff3c12007a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd0b89cf94234e64a6168f357c2f6a9a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i784b5366266c4d4796ca24adc088b8b9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id084c1a48f8149359167ebc980bdd4fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34200d16ebcc4e9bb848e910e7f98470_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa25ff896fef4a548c62b034ce2acbd1_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb19f36b5434e40bf55b16ef65f34a6_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i156059eff9374f1087488e472de06542_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c78dbde3d4043f6906cce86f5541c87_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ameh:segment</xbrli:measure></xbrli:unit><xbrli:context id="ic233432b45644a51a10accdc3eb97bec_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91813fbebd0e4a15b55763b7872a8b9d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47269e9c8fe6491f87cf108347ce40c5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if90f9dac9afe48d79cdaf54cd044093f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7357682f6a2743c2ac4f7e64822ecf5d_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76567744587f40f8a8c7ac4dc85fa166_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:ClinigenceHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5121d03a9a469ba0192b0be3dd0589_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c6d1fd56384e02a5c02ddcb77d7181_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a54db22a27477ea703d051e51b7b7e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a475831b3ad4c928ce6c91ff40dfea6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd641546fc50456c8010d886a4880874_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1650503a7572464f88699d1599fc1c65_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ebf943246644d74b344ccfecdd85d8f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d2f76f1af7d4a4495f8e7c418f0efb7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e97022e423b48fea6becfdd26749dca_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2badd64b1fb94f4b81b6475e7e2cd34d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb83156e733243f9acced43816434206_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ac7abfe0eed4e0d8d7b27ded03a5f9f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15db0ac3886408985bfd7a1c444afb4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d317985c314aa188d6771db1792d94_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0d411993ee4352bb911f910f1c404e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aae7fb197fa4ed39a801149bd5cd532_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i357d85714b284f7ab7bee3970e56bf57_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i038860cc692f4bb888a5b7ef1486e53a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide23e89dd9c645c281e278662449b4a1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee8745d85894cceb97642891fcbce9f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c92edeb4a78489988df0cc478c477de_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia113d3dba3ad4fa2ba4bbae8dbeb4ab8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0285c80acf4fbe88b94c417e7bfb83_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93342f091b4c43cc846afa98f4943123_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f48dc88c7645149c0e2929fbcd7d42_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee529e7087e4e4c9dacd669a0e96636_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13934575582a4f6586ab0fd0252a2087_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb54c28e4db64ef2a4baf3b30dcfcf81_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2afd3f4b4d624a81a9706ec95cb3912e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie41c112f00c54f2ab3512eeb222e2e58_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i460a5116e6b044ad9ebfe9b19f40bfcf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46c346b0625d406694128d5527d8d3bd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb8f797e4a8146a98eb727afc3cbfc49_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f75606e37874c68b458b76513cab432_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i413730c561f44bcba0f3b2bc0c6bd449_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98c80c14bf5e41c684783fbcf0d76f0e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40b21462ffcb4d248cd6645a35f7a449_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eb00088282a4dc5afc8c52b83d0ac33_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7561cc5bf6ca4e669a3141d449e8fa2c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia91f40c8ef0543eeb07c574e983655c3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68316a8a436c493fabb213bb9156c632_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib880959e27194e62aaeab4f273874a1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i973177a3369f4442a2135e79cc6ef154_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5acd511331764617bdfd48af40f038ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86fb54a8136643a1965dda0ad2e9f39b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i934b31b2b19e4a32b408f256d19446bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i122754df236048089b5aad3001c4b1c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36676e73486c494b80fb603caae18d98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a386beebfbf4060bbe4c09d5f5884a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b68bdf1a0ce449889193821c0c74169_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>ameh:unit</xbrli:measure></xbrli:unit><xbrli:context id="i55dadf9db838467e8bd65105322d821f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ea699729524e1aab10b333d7661bd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9094212bb5af45d98da492230880c142_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib11bf9964618458792c11fd0405c0f72_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c9d9247680949b3a7da52ee73653a69_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d3d4f8cd081436bbfc05d32afdfc31b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b9aa026e81e4b4980bee034ca869c69_I20220419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:JadeHealthCareMedicalGroupIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaa3b499908f486889ee0e616dda90c0_I20220127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfe001bbfd543a79e230f9c3c472476_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c6e0a57fc72447ea515eb651ec8f63e_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7afe0c314bdd4919be94c4d4216e8769_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i262bc0262fcd480086498ee92acb8f62_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8083c97bad35410980739e54dd0c355c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2afdae606f3c4b4ca48b6404b58bf723_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73b45a52891f4ab8bf993b978064f4ce_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id92ca545c5d242b29c14e8abfbafa3e4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb520c05360c4639917455a159462d8a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db7ef9235b34c04b4683c753d0c0add_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i823f7c34a37842bc853d7a95f895358c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff8b2ce2fa64fbd861752a596120f74_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c456a4d4324d7da4299e68e3469d32_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id77f5a844c054b76ab43bfd594454e29_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6b39a8c15b94db1bef62c56c6cdfa11_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342650b110d948c68305b913d3337797_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idad1fcac77ba4ee7876fddfc937c8526_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22617db5966243a29e90deea438fe6e4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c3aca5f37e4c7bbce9e471da9b2690_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70a8b50fadb34ecbbeb48a0a4e675fb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id386caca65614b57ae15aeb43ddc272e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c5b1b731c04326a701c1dbf4c69a1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b382a0954bd416284c02bcaa5a318da_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c47fd9f6a0a4bb2a1714812fdf72b1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47aaf649d7d949a184692e09d23490b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d39193fee394abbb9705dc0a37fb365_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ccff1d9ca534ab0b567fd1dc05bd91a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ecea1ee1cca4bd5b0f7613a433ccb86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfde020db2314ef08cf9d768e4c6d60f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d17a700c65498dbbc648590a1e5c5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b2bbf4c0d7e4582a1a0fef1a71f7b4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90be308939140e9a4a7cb933f276390_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6903a2d9d4664df8a794cb162687a0c1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2206b47d6e7b424d9b62ab32b0338026_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cad2048a753446186dfdb8373edee28_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0127b82d0c494786e6a5b4bd61c173_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0edd220c6943ef81f9294e13541194_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7cf8eaa6bf64eeab771048f5de4564f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifff5051e4aad447bb1d4f5b0b052cdff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib410a832400244ff85bff3debb332a3f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a601ca89014f5eacda8b352cd397cf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadd8800c72bb483c99ceb9c97149a818_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie80aa85c869b4960834df7f5663464ac_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6dd79fb668d4396a088c5c7da4ad9bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e059681a7204193b3ca300c44829e19_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcfcf46929264addbb83d541b8cf9a81_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11fbddce8b34653bf1c488090c280ed_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a62c94039149c4add47ae7f2b1df0a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ac857e621104221a59862c04c79506c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i788d07c210dd4f958d756e23167c1e15_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e73f5506934b76adfdd854acffd935_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia30f4a1733a0428ea9411e847f714b94_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i456a03746030449991737ef8d57a4456_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71de6782da243ac87254390580b0b61_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72155c35fa2747b5984527dcf5162a43_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f30d164f6d743639946b82e4328af58_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36766b59fdb44c0cb8d7da462b05fbef_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f907a840be46e2aeb32432dd66fea0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb35d81b629041debdd1e5e0eb5500ac_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6baa1c84dac349f5acf23c66fef27140_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8cbe9a274f944c9b33a5afce066df48_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if465b8aea2ce4908904e4ad93a86b298_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i018d7b4e12a2489aa9b33f4323e5c611_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016ca3434597421199937a03ff2fc17f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ef92aed16c481bb3060e0e03050169_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef0c4478a2c41e38132323c3a052804_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa17eff6b8c744cfad25e00a8a815d59_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed8a2f220bd4feda2e865edfbd8e716_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief5224c7fb984c28ae95700de5da6e27_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e8315cdc8946c3bd924c645f5730ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39e02afca44c4aedafa732851dd3802b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i227316615eba44afb5e1909846c71eeb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46a28bb2bc244c43b885f7f0afdb1949_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i268b6755560b4788af5c509f2650c3ba_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13da4e8ee17d47e9819397b6faff3bfc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fd70ca2db774b288ae5881780641231_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ddac981e5724f7faa52da42366eb5b0_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d95aff18be44aaabba0d95b213fe04d_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica0c755f6f5a456cb7c1e3039165cf31_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74659971142042e9b4b1ecd398a5632a_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68a73980d9cb441dbb6fdd887b9503f8_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd5ac37956bd4d08909d1dd390134c6d_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0858a8d9fe0c4b65b4073669668a0c6b_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica9c3cfdeff84d0eac173b74662af814_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d5365ccd50e40b48292e6b69f44ba5f_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf671f1c4d984ad4b56737e8bb018cf4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i767518e6c72e4e4997ab25645b106efc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i778bae90463c48628833fa5514d45310_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i846ff05d31aa414e88893b18094681fe_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2940bbecd004561861f01abb0ebad96_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca1ca2ff65840868df912f9f0aaa96a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b355b7c0d4a4f3bac5ad6619d970628_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86197b3338a4a568e33693944e72e99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78dd2608d34c4de8a4f893d06e8f8f22_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d1265e36d640f2adebf0f735428064_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc4faa451635444dacf9694e218dd3e4_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdae08981f5e4104934ad51fe3b95303_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22fc5dfea7e84f638573c274ba9b23e4_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2cd92e83f7b437bb51b5c89f701b464_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85593b22935b45e4be1ee177e8ad7239_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eae04016bb447e0bddc4f0591df991a_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95eae60963324a459007367c1b4ab420_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1261394f1654823b8118f1c41514f21_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88159173edb49298d65e5a36a704517_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic938e3d247da4baf8c4e436b6ba4e60b_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fa6d96494224426b248b59ceab8cebb_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f21d618be04c29bad9cca5524c19b7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="financial_ratio"><xbrli:measure>ameh:financial_ratio</xbrli:measure></xbrli:unit><xbrli:context id="i161df59378d54e2c9c35ef127c00a692_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ed2f9093db4b03b46f940a69391343_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59abeea171b4680ac8fc59615e1a446_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe69f802279e4ce8a230a2252301ea51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia874564b3f7f46f0bb91acc1285b389e_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff008a8379447cea04496a4e74019b5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if16717b8edf54956a5b44e5ed8302e3b_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1041f899e3243769086c3764cd3193a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74c97c8e257e4a02a64730b6e0e41ade_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7a043471da464fa12812657a6fb838_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11705a1bed9740c793f74a813ac7350e_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icccdfccc60d849bda7a0fa9d6cda8ea8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d4b6704bd1a4f1b8e67da94daf68ad5_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5739754d4c764531a08a2b6ba1d03922_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06c44df5942487d9c597ef8cdee2e34_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7979125d864b698864f3e49061ba20_I20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:A120HellmanLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if75e16a418bd4b0ca6e69d9bda0b4418_D20220125-20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:A120HellmanLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-25</xbrli:startDate><xbrli:endDate>2022-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i282ab48d547a409c91b0e2e1d8c055d7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:A120HellmanLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8efee8b6417740c295818b5927155453_D20220125-20220125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:A120HellmanLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-25</xbrli:startDate><xbrli:endDate>2022-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb7f86e0def4c95962563988d781f2f_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d752a197404d5bac408b2154757c13_D20230101-20231201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f39746c41a9450889b8b440c4bb1e87_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cbd40ee0c194527bd610419cab4d09d_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i693a573b995242e69ae791b297318006_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc384eaf4734dd0be96fd82579c39f6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26057f05b68400bab7e17c33a599861_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039231bd37b04500b07453d76940704d_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice27ac69897e45d1b5b34a56355dc920_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00309c0459be4ba3b15e9b6033b0acaf_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5bf58fac1b43f9a4c5a689c4268856_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aefdbbfc23740e3971470e4cc27ff41_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c708cdfd53f41a8b290faf3f23f5186_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6a946f84384708a367fa93594947f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7680ae5461b4b2486caea091e4e82f8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4a852313e0c4ddd88001a38595d3390_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9902cb6392bf40fe99762875e13589c3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7dca31d301345ef9166cc408559e908_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0383372507bb45108200170dddd5ac63_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2743e935ace9464cab6ca597868b375a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ea51d5f00d45e9bc091bc8a1a88beb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaffd866f998541ff9a904994be9fae46_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2d277b4082486a82df6f70b19d1989_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd41ced8b31471c86f3e5b810861eef_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice144ed20675466b9ffd1ea1b947c8df_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117ec78443b64325bf4c2ac950fb25a7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ff7d682f2d94d5c926e3c35381ee58f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d1d13fa98564dafaead4c073177d336_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i204ae706d04f42e492b4e0e310f1dad8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd7b521efd0406a9d8f97afd5c8feb7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13efa678914f4d7f98b3e9aeb1cd61d8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1957cc255c424d8d39c550b3fb4230_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e67912a5d449dbb5d6e4854647fa10_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafd2b1c8b5514ddf938ef5e9deed8686_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27162b4c30e1433389aa44bb606e1201_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16a45d3b518b423aaab4649221f9e190_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib521230a737a4886950b1519bb58fa8f_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675bd27f6f9449a7b867a0997a6672c7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03ceea72d6fa40489f52e559fb181611_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6840db3bf9284ad4ab822cbf059964ce_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i114ccddf4f7649a6848a22c64dbc33c9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c54372981e0483384beb5dc3115d981_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76936fef1e6b40c18740fd16b3eda56d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if150202c05234c61a08e030fc794aca5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59a47c483aa24f5c89caa7bb1cdec67d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f9f34bf3fb48cebfa73e5b388e465b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72fbf8622a44da7b8b232c28510f1a8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1726507efb5f4fa09d9993c3857c283a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia172d03ffb5f4a4181d8f9c79bac7f77_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ae41c7e0b64fbeb8ec11b3c8e12d1b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fa8e1b5460411992308ed07575a1f1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b559e5023334ee3b95e75fa03c7d652_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb082a42a8f04b7f8520726fad9dbed0_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2c519a88fb425cafa67a6ac705ce13_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e887d2baae4779bc16fb980480b5cb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a80af6894a14c43a89ecebb723dcfe1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d8d52a080a44e86a886bce63a285724_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab323e1b397418fb339066bb405899c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b3980ecb88c467597f9070419028889_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica63af2bcd74490792c66cc16aa7cd45_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f665909db64084bcae52d7869044f6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i720010c532d04ae38a15375c00f6c278_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658af4a1b5524e469c86ffaf726d3a51_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8069e38106d34794bbbea1a815263bf1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686c7f250f0e4d35824cd656b22866ad_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ba4984e1d0947a59e1755baeb841f28_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ce7049b8564902b4714f05408d23cc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f93bbd717a34da48676ae33c98e2878_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d5e8e10ad4481ab709154b84b5e390_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b66c55e1084cb1b52c404c22c765cf_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i570036110c9340efa486b231d649cf09_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if91fffa5808944f686a081038f37122c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3873e858d6954dc9a1e7b2ebfd958d51_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0924e12aa8d4ee4b2641423ceba4881_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf42668aa8fc4595af61af9ed0dceace_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1340961fa52f41c78bd6a84fc6c342d9_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd9786f0dd94c12a12df172b4e36ceb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06340797df8f4752a83e03326162b898_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff12e49686f34776bca7427f81b46a8e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i493e02bb89bd49aaa06143a91d99bd2e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be6c5a1eee74540ac2a07c4971194b7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e5cc9cbbc44c1ca2da76b30137a3ab_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0933e3ac6e9444cca9e2cf27d88e1e4d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id668620835dc4bb0acb31d65a5da7f73_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib853e0afcc864f9fb37c1a57ebf20e0d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ed1fb4cb8784d2baa6d489ba5f6e31c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fb8594254234c10bce4ca7cad2d7f34_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b1510e6b3e48aab9201dae55a97382_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84ea8946f574e32a5be27bbbc154f24_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52933dc179ba4dbc8f26c1943d99f3ed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608f29a5f13e45cfa7a9e81eef3d1ed6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i103376726f94415da0aa6fb6fa1625f1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0fe166dd3574c6b86ee5fd3faa41fb8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0213948f1599453ab721957923ae20aa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1c490153ac4f1cb6028c98823533b4_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if433cdd244a24b8e8f0de5c3a6d6a9da_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d25dc960744271ba14d5a22e01a9f4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcbf57723d89405ea64c036cc63fb0eb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if451ab4e4ce44c71a99f29e2c5e07e30_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fb1b871a5524ffcbf6e9b30520d3b46_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87972789a91f4575b4ee414751a09b0d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94083cc9f0fc4e369ee64217a4f7e9fc_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba052b72bbb34b62be83891b4561a8d2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad69ae1f414c4d90bc9075012d5d4d30_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib23158de6e644cdd9bc4e3523331c1e9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie446c27adcbd42b59894a90417c05196_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f46457a64ad499c901e9853b8d0ba22_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706352fc1d254fd5a5e36dc095d71cfe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib64616cababe4909a842281a3ca6fa56_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i817afcd7d5c442c2b55faa40b0d1a8f5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e8720f09834880b0eb68cb4dfd69c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea207f25a4494db3b8ca98bec38b0cf3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09d176d59d3c498f8f2c88e2c37d402e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i535c48c761b74aa9ac2acbd6ebd3be28_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica66f014fe6849c9a087191711c14b58_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4b065ecad2c4dd18600860d892995a7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd5950728274396a47ab8be6047ebba_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id604da4cbf9d48cd853c3313a4b215d1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad190507ff44da9b6ffe950ec0a7c48_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b1e7c7a12844a52bcf3c60b54e403b8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe4add77b0642b587fbbdfc4e0469d7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie500388613f5490c85227584adbecd21_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i082d8e652b86490ea5c3fe0dfaaaa3c7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib08d24f28e4a48f99ec3872354ff7790_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49102b8554a1457c8a1f914d3daaa7f9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if79c2773d57946a3995aed561a9def52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15757c3b5f1f4c7ca17b41a6d3ae72fa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1ed3c5e65d4fbbb94a7b74e3634086_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMy0xLTEtMTA1MDMz_2860dc71-c30f-4d36-9d2b-2b6da5f2a16f id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMy0xLTEtMTA1MDMz_96d8734d-278f-4b05-bd0d-3a9b0d93f835 id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMS0xLTEtMTA1MDMz_64c937bf-077b-4e30-b5bb-928744b95c0c id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMS0xLTEtMTA1MDMz_879e3f2a-2d77-4bd2-8991-2d1f0da3e422" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfMTA2MA_e79a5d46-a43c-413a-bc83-e685f7b001b9" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i479e2a4965a945a4983dec200085612c_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDg5_19d6a612-e1a6-456b-a22f-3c3cd489ca9b">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6MzUxN2U1ZDY0NjNkNDMwMjkxNDUyMGFmMDMxMmMyYTYvdGFibGVyYW5nZTozNTE3ZTVkNjQ2M2Q0MzAyOTE0NTIwYWYwMzEyYzJhNl8wLTAtMS0xLTEwNTAzMw_c57f3077-ac00-4f84-a4d7-300ef8c9c88c">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8xMjM_c38eeef4-22f9-4389-9b05-6dc6ac1b0c4e">June 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6ZDFhNGYzMDZlOWFjNDQ3OTk0ZWI1NDk4Zjg1NjBiZjkvdGFibGVyYW5nZTpkMWE0ZjMwNmU5YWM0NDc5OTRlYjU0OThmODU2MGJmOV8wLTAtMS0xLTEwNTAzMw_a52b8b74-1e00-479b-9b9c-f247ece0bdf4">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from &#160;___&#160;to ___.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk3_ca8e1cd2-01c5-4856-af94-2a6d4bf1d525">001-37392</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><img src="ameh-20220630_g1.jpg" alt="ameh-20220630_g1.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDg2_2402becc-bacf-4fec-a146-30deef335a82">Apollo Medical Holdings, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6M2YzY2M1ZDNkNzBiNGMyNjk3MDA1MGIzYTllMmU4YmYvdGFibGVyYW5nZTozZjNjYzVkM2Q3MGI0YzI2OTcwMDUwYjNhOWUyZThiZl8wLTAtMS0xLTEwNTAzMw_1cf7f2ec-6e6e-47d2-945b-aa9b476575a3">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6M2YzY2M1ZDNkNzBiNGMyNjk3MDA1MGIzYTllMmU4YmYvdGFibGVyYW5nZTozZjNjYzVkM2Q3MGI0YzI2OTcwMDUwYjNhOWUyZThiZl8wLTEtMS0xLTEwNTAzMw_664499c0-ed0f-4226-a700-1093eddfbf36">95-4472349</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDkz_06cfe7f5-b286-4976-808e-3b2906717f74">1668 S. Garfield Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk4_a1825bdc-e1f0-4687-b7b7-aedb2350b0db" continuedAt="i7c72c4364d0e4bd2a28503a91727de85">2</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i7c72c4364d0e4bd2a28503a91727de85" continuedAt="i029976e9df584f3687f6fc89c9f6e66d">nd</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i029976e9df584f3687f6fc89c9f6e66d"> Floor</ix:continuation>, <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk5_6062f94c-c9e1-46bc-8e67-874a237e0de1">Alhambra</ix:nonNumeric>, <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDkw_68e7ffe9-5b2c-4359-8e19-2528b1852b75">California</ix:nonNumeric> <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDg3_a2c2432f-74c0-418e-a477-0e2856ece631">91801</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDkx_1097f8a4-5177-4222-bc67-85085a680db2">626</ix:nonNumeric>) <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDky_60710762-c42b-464d-94be-9e652a4f589f">282-0288</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of Each Class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6YmYwZjRkZDM4NWRmNGZiMDhiMmFjNmFhNzUxZTQ1Y2YvdGFibGVyYW5nZTpiZjBmNGRkMzg1ZGY0ZmIwOGIyYWM2YWE3NTFlNDVjZl8xLTAtMS0xLTEwNTAzMw_a2219952-7269-4d8c-b92e-46a4c03f7865">Common Stock, $0.001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6YmYwZjRkZDM4NWRmNGZiMDhiMmFjNmFhNzUxZTQ1Y2YvdGFibGVyYW5nZTpiZjBmNGRkMzg1ZGY0ZmIwOGIyYWM2YWE3NTFlNDVjZl8xLTItMS0xLTEwNTAzMw_a2e00427-163b-4e1d-be1d-1f20c1664d77">AMEH</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDg4_9dd44ab5-57df-489e-9ab8-e2f86ce158c4">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk0_34ba8685-536d-48a2-aa87-8eb9c79345cb">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6MmFmNzE2NzVmNGJiNGM4NjkxZGRlNWZhODg1NjNhZDUvdGFibGVyYW5nZToyYWY3MTY3NWY0YmI0Yzg2OTFkZGU1ZmE4ODU2M2FkNV8wLTAtMS0xLTEwNTAzMw_95ee2093-766f-49a0-abaa-35cfd4abc268">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6MmFmNzE2NzVmNGJiNGM4NjkxZGRlNWZhODg1NjNhZDUvdGFibGVyYW5nZToyYWY3MTY3NWY0YmI0Yzg2OTFkZGU1ZmE4ODU2M2FkNV8xLTMtMS0xLTEwNTAzMw_1acc22e1-1b0c-4722-9856-e100dcc3d3cb">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6MmFmNzE2NzVmNGJiNGM4NjkxZGRlNWZhODg1NjNhZDUvdGFibGVyYW5nZToyYWY3MTY3NWY0YmI0Yzg2OTFkZGU1ZmE4ODU2M2FkNV8yLTMtMS0xLTEwNTAzMw_74b95e79-3567-4583-90f7-fc3e34694771">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk2_4bb5b724-8750-40cf-a9c0-1625c3c70f48">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; No</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July&#160;25, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i71c6e0513e0f49708c1b538585500a39_I20220725" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8xOTg5_05b5490b-d575-4e11-9693-fa9734909ff7">56,461,468</ix:nonFraction> shares of common stock of the registrant, $0.001 par value per share, issued and outstanding.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q FILING</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PAGE</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_13">Introductory Note</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_13">Note About Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_13">5</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_16">PART I</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_19">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_19">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_22">Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_22">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_25">Consolidated Statements of Income for the Three and Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_25">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_31">Consolidated Statements of Mezzanine and Stockholders</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_142">&#8217;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_31"> Equity for the Three and Six Months Ended June 30, 2022 and 2021</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_31">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_34">Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_34">12</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_37">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_37">14</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_142">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_142">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_142">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_193">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_193">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_193">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_196">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_196">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_196">71</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_199">PART II</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_199">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_202">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_202">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_202">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_205">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_205">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_205">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_208">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_208">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_208">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_211">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_211">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_211">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_214">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_214">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_214">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_217">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_217">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_217">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_220">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_220">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i479e2a4965a945a4983dec200085612c_220">73</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glossary</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:28.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care IPA, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC Healthcare Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AIPBP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All-Inclusive Population-Based Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed Hospitalists, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH 2 Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APA ACO, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allied Physicians of California, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Access Primary Care Medical Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA Designated Shareholder Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bay Area Hospitalist Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDSC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Concourse Diagnostic Surgery Center, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Department of Managed Healthcare</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Medical Group of Southern California</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GPDC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global and Professional Direct Contracting </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Source MSO Inc., a California corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC International Cancer Center, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">independent practice association</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maverick Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MPP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Property Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next Generation Accountable Care Organization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMIOC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacific Medical Imaging and Oncology Center, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern California Heart Centers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Labs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Clinical Laboratories </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-8 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care Acquisition Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable interest entity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL Partners, LLC</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i479e2a4965a945a4983dec200085612c_13"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTORY NOTE</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Apollo Medical Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;) and &#8220;ApolloMed&#8221; refers to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) have not reviewed any statements contained in this Report, including statements describing the participation of APA ACO, Inc. (&#8220;APAACO&#8221;) in the Next Generation Accountable Care Organization (&#8220;NGACO&#8221;) model, or the Global and Professional Direct Contracting (&#8220;GPDC&#8221;) model. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names and trademarks of the Company and its subsidiaries referred to herein, and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of federal and state securities laws, including, but not limited to, any statements about our business, financial condition, operating results, plans, objectives, expectations, and intentions, any projections of earnings, revenue, EBITDA, Adjusted EBITDA, or other financial items, such as projected payments from CMS and our future liquidity; any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our company; any statements concerning proposed services, developments, mergers, or acquisitions; any statements regarding the outlook on our NGACO, GPDC model, or strategic transactions; any statements regarding management&#8217;s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms, such as &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;think,&#8221; &#8220;plan,&#8221; &#8220;envision,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;budgeted,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K, for the year ended&#160;December&#160;31, 2021, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February&#160;28, 2022, including the risk factors discussed under the heading &#8220;Risk Factors&#8221; in Part I, Item IA thereof. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements.</span></div><div id="i479e2a4965a945a4983dec200085612c_16"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i479e2a4965a945a4983dec200085612c_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNS0xLTEtMS0xMDUwMzM_5aa098eb-961d-466e-a4e3-a0c8a91cba69">234,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNS0zLTEtMS0xMDUwMzM_81e37584-5106-4f71-ae62-15042c06d31b">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNy0xLTEtMS0xMDUwMzM_c8bfbf9e-f371-4a17-b15a-9cb29e1e163a">39,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNy0zLTEtMS0xMDUwMzM_be1a247b-ee3a-4739-90aa-a968f5c45ea9">53,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOC0xLTEtMS0xMDUwMzM_94d290f0-e37a-4eb8-a06d-9f8486383cac">67,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOC0zLTEtMS0xMDUwMzM_a307f174-b534-4ffe-b414-0c6671f59cb5">10,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOS0xLTEtMS0xMDUwMzM_7a279611-c543-4c32-bf1c-6bd069bf2dee">81,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOS0zLTEtMS0xMDUwMzM_ad252704-9c54-43ee-bb7a-1b537d2a5ec5">69,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOS0xLTEtMS0xMjI1NTI_9c7275b4-46c5-452c-8027-7f277aac814a">12,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOS0zLTEtMS0xMjI1NTI_e032b9ed-3c93-446e-a455-dba6c643aef5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTAtMS0xLTEtMTA1MDMz_290e4367-4398-46e1-8025-106c0df9c382">13,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTAtMy0xLTEtMTA1MDMz_280e4ea2-e46b-44f0-9ba6-136913ee45fd">9,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTEtMS0xLTEtMTA1MDMz_55d3eb65-dbe6-4f32-8a73-f2e5087995ce">12,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTEtMy0xLTEtMTA1MDMz_c3fa49b6-91f1-4f34-be2b-cf44a3e8b7e1">18,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTItMS0xLTEtMTA1MDMz_34cbcec4-6d98-468e-8254-07da1054567c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTItMy0xLTEtMTA1MDMz_31a4066b-1eaa-4b8e-828e-f9daecf5c5cc">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTQtMS0xLTEtMTA1MDMz_c30dee08-df11-4414-9770-78f1d0908633">461,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTQtMy0xLTEtMTA1MDMz_365b5fc9-2bb4-4302-a127-df6da42d0232">398,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTctMS0xLTEtMTA1MDMz_0503a425-5762-45f1-b9e2-f7723f2108a0">87,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTctMy0xLTEtMTA1MDMz_a1a6b81d-c3ca-4665-9721-0911fcb7565b">53,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTgtMS0xLTEtMTA1MDMz_f8e469e2-4b6d-48f0-b1ee-ed6fdccefac3">76,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTgtMy0xLTEtMTA1MDMz_b2c3b5d1-4b93-441b-901c-0e9709cfee66">82,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTktMS0xLTEtMTA1MDMz_b5ff595f-4ea5-479b-a098-76d1eaba59a6">253,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTktMy0xLTEtMTA1MDMz_0149b10a-9b9f-47ce-b8e0-8d23bd0fdbd8">253,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjAtMS0xLTEtMTA1MDMz_0a2a3de7-2fce-491c-bf31-47c7ecfd4398">539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjAtMy0xLTEtMTA1MDMz_5d36f0d7-5e06-43ea-b44a-7b9a68eddf57">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjAtMS0xLTEtMTE4Nzk4_546a69e7-d602-459d-a0b3-eef63781d203">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjAtMy0xLTEtMTE4Nzk4_a1c3677c-458f-4d3e-8d46-5815c355649c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjItMS0xLTEtMTA1MDMz_67b54762-b9cc-4eed-a176-22e8032efb29">43,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjItMy0xLTEtMTA1MDMz_d17bbeef-24a6-4ac9-bdf3-d9273e0d9ac9">41,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in privately held entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjMtMS0xLTEtMTA1MDMz_f1c333db-167f-4483-a0d9-ba428ace1961">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjMtMy0xLTEtMTA1MDMz_33440294-92f6-4829-9696-5cca79ef87ac">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjQtMS0xLTEtMTA1MDMz_781584dc-59fb-4ebc-bc3b-aadfe08f360b">19,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjQtMy0xLTEtMTA1MDMz_eaab6a96-aa7c-4e30-8b3e-baf275eff7a8">15,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjUtMS0xLTEtMTA1MDMz_30739b3b-a138-40df-80e4-a3176c627d4b">5,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjUtMy0xLTEtMTA1MDMz_64bbc4b8-b1a4-41bf-ba69-44b783dade47">5,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjctMS0xLTEtMTA1MDMz_07dda8a2-79a1-4707-97dd-b7b8d68118e9">490,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjctMy0xLTEtMTA1MDMz_fbb298b9-dff2-4228-9faf-17070b05375e">453,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMS0xLTEtMTA1MDMz_879e3f2a-2d77-4bd2-8991-2d1f0da3e422">951,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMy0xLTEtMTA1MDMz_2860dc71-c30f-4d36-9d2b-2b6da5f2a16f">852,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities, mezzanine equity, and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzUtMS0xLTEtMTA1MDMz_d6a1813c-0d52-417b-aa48-1b2a3d2333d3">59,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzUtMy0xLTEtMTA1MDMz_5e73f53a-5f64-4e80-b104-8d8b7082adc5">43,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzYtMS0xLTEtMTA1MDMz_1dfc91b7-9bb9-42b9-8191-bf60fa0aaf67">6,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzYtMy0xLTEtMTA1MDMz_06d14225-0b81-478d-a479-8ce1a2e41f2d">10,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzctMS0xLTEtMTA1MDMz_814679f8-2804-4b99-a5d1-c4b653a3c36c">112,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzctMy0xLTEtMTA1MDMz_1cb90e74-daef-48ca-bc1d-32d48220a5a0">55,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzgtMS0xLTEtMTA1MDMz_770d86fb-9d59-4c25-b04e-32557d1df839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzgtMy0xLTEtMTA1MDMz_e456af33-54e8-4114-981f-f094534875c1">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzktMS0xLTEtMTA1MDMz_b166db4a-b97b-425a-8cb2-4bc982c7f546">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzktMy0xLTEtMTA1MDMz_cb92b514-633b-4732-8855-bcdacc319cea">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDAtMS0xLTEtMTA1MDMz_9c405dfe-9e07-4f6b-b750-7546d46dbf87">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDAtMy0xLTEtMTA1MDMz_fe15b881-cc08-4126-9b23-b96f408a5dab">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDEtMS0xLTEtMTA1MDMz_0f1b9a2c-41b0-4765-a063-6cb2a4e42c52">3,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDEtMy0xLTEtMTA1MDMz_2b4cdfec-4b38-4075-ab7e-974733ffb4c6">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDItMS0xLTEtMTA1MDMz_c90ae4c0-e29b-42bf-8b84-bbc61e18c6cb">2,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDItMy0xLTEtMTA1MDMz_e6c623be-2736-40ea-833b-c4235c44b9bc">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDQtMS0xLTEtMTA1MDMz_57125b2c-10a4-49d3-95e3-624880e1ae7b">185,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDQtMy0xLTEtMTA1MDMz_908919d0-1f26-421c-9ee5-3158f951c9f6">115,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDctMS0xLTEtMTA1MDMz_7d0ce5b7-ff45-487a-80b5-03e77cdf2622">9,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDctMy0xLTEtMTA1MDMz_cedd50bd-8143-4b5f-8093-4309827b3267">9,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDgtMS0xLTEtMTA1MDMz_9183495c-0e17-4811-9d61-9fcf1643e09b">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDgtMy0xLTEtMTA1MDMz_86a896dd-eaf1-4a52-a5fe-8356e743f93e">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDktMS0xLTEtMTA1MDMz_73cf8011-aa23-4b23-8225-527bfb9fe7fd">16,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDktMy0xLTEtMTA1MDMz_6fff5ad4-3b33-49cf-b73e-92f184206eb9">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTAtMS0xLTEtMTA1MDMz_b9e07420-dedb-406a-8d29-8651ec672153">199,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTAtMy0xLTEtMTA1MDMz_2de700d1-a3fb-44eb-a251-44e7ff4ec0c8">182,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTEtMS0xLTEtMTA1MDMz_b216b7ca-8d3c-486d-8b27-a8be8ca14c82">13,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTEtMy0xLTEtMTA1MDMz_89224268-949a-43a9-a2e3-4be70648163f">14,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTMtMS0xLTEtMTA1MDMz_2f19abb6-29bb-4765-a2a6-847515b172a6">239,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTMtMy0xLTEtMTA1MDMz_8342670f-b8ad-449b-9e84-9c4f23588c0e">220,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMS0xLTEtMTA1MDMz_64c937bf-077b-4e30-b5bb-928744b95c0c">425,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMy0xLTEtMTA1MDMz_96d8734d-278f-4b05-bd0d-3a9b0d93f835">336,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and contingencies (Note 12)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTctMS0xLTEtMTA1MDMz_73e4ee3c-58c6-4ffb-ad7d-7e7cd78d04a0"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTctMy0xLTEtMTA1MDMz_4e850fea-efc6-48de-be89-1e0aa1b259e7"></ix:nonFraction>Mezzanine equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjAtMS0xLTEtMTA1MDMz_6d730a79-fd5f-4a8b-9e2b-207f955c7b74">39,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjAtMy0xLTEtMTA1MDMz_dd0708ee-4618-4ee5-adc5-b939ce616aa0">55,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMzA_395a8700-3a34-4553-850b-eefd6b204844"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMzA_e10e5f15-630b-4c52-9f92-465e63ab6062">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfNTQ_1027a51f-da37-4ff3-9fb2-4d62881b336a"><ix:nonFraction unitRef="shares" contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfNTQ_6f27ba78-2c94-47aa-86ef-7090fb51df59">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series B Preferred stock); <ix:nonFraction unitRef="shares" contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMTQ3_87285f80-0eef-4654-86b1-02847325c1ae"><ix:nonFraction unitRef="shares" contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMTQ3_f537c510-3190-4954-94c0-5b5e5e407859">1,111,111</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMTYx_a6acd68c-a0e4-4c11-8383-a29267bdba22"><ix:nonFraction unitRef="shares" contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMTYx_b232f7d0-4e2f-41ce-a1b5-ea0e08aebc90">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMS0xLTEtMTA1MDMz_49db4f8f-6516-46c2-b1f1-18a6ecc4d6da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMy0xLTEtMTA1MDMz_4ba9e67a-bf37-4827-96e2-4cb5ea0585ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMzA_60062cbf-e5db-4ca4-b0da-8d8a2bbe6a51"><ix:nonFraction unitRef="usdPerShare" contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMzA_8fb57d65-2f70-4c86-b946-ba9576b215a9">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfNTQ_22c1c97a-ec4e-4a21-82b1-b9f05b41442e"><ix:nonFraction unitRef="shares" contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfNTQ_f982f683-0fa7-46ca-a029-a7139710d56a">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series A Preferred stock); <ix:nonFraction unitRef="shares" contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMTQ3_4a61d477-af42-4a78-ad8f-894142163e84"><ix:nonFraction unitRef="shares" contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMTQ3_8b3869d9-f889-45da-a362-6d281a4b0852">555,555</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMTYx_29f77757-26ab-41f3-8c86-2e5ee6ee402b"><ix:nonFraction unitRef="shares" contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMTYx_7079cbf6-3ab8-411f-85a2-a22189b86025">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMS0xLTEtMTA1MDMz_295df315-ed3a-44c2-b1db-19eb80e4636e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMy0xLTEtMTA1MDMz_3a5d4cbc-835d-4991-a53e-004c55c2abaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfMTg_78e866c3-6db1-4fbb-9395-854cb7857b2b"><ix:nonFraction unitRef="usdPerShare" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfMTg_80279408-0a55-452d-9d45-bcd42feb445a">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNDI_042fba4a-a8de-425c-bd84-42ef49e64512"><ix:nonFraction unitRef="shares" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNDI_85c4a342-f2ed-4060-92b4-e9917c8d7c2d">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNjQ_2c0c441a-763a-4eee-98ca-b8a585853a82"><ix:nonFraction unitRef="shares" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNjQ_d97fb815-2c79-44af-b84e-923851c80fd1">44,719,710</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNzE_13bab55b-50b9-4e39-a0f5-53aaa7039a74"><ix:nonFraction unitRef="shares" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNzE_d92e7aa0-55f8-4b1a-bac3-363ecc4889db">44,630,873</ix:nonFraction></ix:nonFraction> shares issued and outstanding, excluding <ix:nonFraction unitRef="shares" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfMTE1_6c67a296-fac0-4ef4-8e72-db58cc314cd9">11,175,702</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfMTIy_1b784929-22c0-4f59-a1d9-dc58cc5f4c3e">10,925,702</ix:nonFraction> treasury shares, as of June&#160;30, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMS0xLTEtMTA1MDMz_c7299942-2656-4480-a04e-5eab5677afa2">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMy0xLTEtMTA1MDMz_ffb3ba8b-1837-41eb-89fc-80164574e8b8">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjYtMS0xLTEtMTA1MDMz_b3c491dd-8c56-4bc2-8b55-48fe72c63775">310,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjYtMy0xLTEtMTA1MDMz_e034ff8d-861d-4dd8-a99d-19f6008542d6">310,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjctMS0xLTEtMTA1MDMz_71a3d586-ee8a-4626-a353-7cb9b23b45bd">169,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjctMy0xLTEtMTA1MDMz_f349fd15-516c-4c36-b369-8140ff63b70e">143,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjgtMS0xLTEtMTA1MDMz_bb72dcca-c2cf-42f3-90de-19d4f8db6717">479,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjgtMy0xLTEtMTA1MDMz_dd675c82-5283-4b22-b1ef-9f001f951b5c">454,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzAtMS0xLTEtMTA1MDMz_804be551-23e7-4704-9b2b-473a59223a4d">5,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzAtMy0xLTEtMTA1MDMz_da7ffed8-d729-4667-a73f-74fd14423d9f">5,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzItMS0xLTEtMTA1MDMz_f72826a1-7c6a-4aaf-8441-defbae800795">485,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzItMy0xLTEtMTA1MDMz_33c02867-5812-4de3-8993-e73c02b59630">460,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities, mezzanine equity, and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzQtMS0xLTEtMTA1MDMz_3f908de8-ce1d-4385-bf1b-3ae57023c34e">951,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzQtMy0xLTEtMTA1MDMz_5882b9c5-2912-4311-80d0-cdf6f011ad3f">852,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfMTA2MA_e79a5d46-a43c-413a-bc83-e685f7b001b9" footnoteRole="http://www.xbrl.org/2003/role/footnote">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $<ix:nonFraction unitRef="usd" contextRef="i0075948a15c34ea7995a87ab515a831e_I20220630" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNDcx_5766b851-757b-436b-9644-c6107362adf3">599.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNDc4_a81e2481-69ce-462c-b4e8-d211205b5192">567.0</ix:nonFraction>&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $<ix:nonFraction unitRef="usd" contextRef="i0075948a15c34ea7995a87ab515a831e_I20220630" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNjYy_0da6ab9a-1603-48fd-94f5-27a9c0b97291">143.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNjY5_eedc1b82-2d8b-4d30-ad50-4fea661797e0">91.7</ix:nonFraction>&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $<ix:nonFraction unitRef="usd" contextRef="i0075948a15c34ea7995a87ab515a831e_I20220630" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNzM1_fc8d8ddc-b0cb-494b-987f-9bce394dc4e4">431.3</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="i0075948a15c34ea7995a87ab515a831e_I20220630" decimals="-5" name="us-gaap:DueFromAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNzcw_152e8092-d3f6-4d62-9690-14e602891817">36.0</ix:nonFraction>&#160;million of amounts due from affiliates as of June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfODE3_70afb0cb-3622-44f9-bd31-56cb42acc33c">802.8</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231" decimals="-5" name="us-gaap:DueToAffiliateCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfODUy_66c3c74f-fa0c-4106-bbea-5b8f6feb75c1">6.6</ix:nonFraction>&#160;million of amounts due from affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</ix:footnote></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4594d1cdf8403b9b1d586438ae5595_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMy0xLTEtMS0xMDUwMzM_65a0f403-4d1d-4f54-b7df-2bc6d56dc5bd">227,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064787fbd3b34338bc355bea54602fa0_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMy0zLTEtMS0xMDUwMzM_c2f4cf36-82a9-4ed1-99a3-d629cc76853c">144,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bb88e8e61844678858e6f1049c3b8d8_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMy01LTEtMS0xMDUwMzM_d2985c3c-bd7d-410b-a69f-d484f6a3b387">449,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if532127b9ae74868b84354daf327af15_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMy03LTEtMS0xMDUwMzM_9e7d39cf-e7f9-4651-bf7c-91872fbe3d98">289,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd9383c56a049e39c988fe1d699c8c8_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNC0xLTEtMS0xMDUwMzM_83582d73-f5ee-4502-a859-26ba0c0bbd07">18,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f66c15a9774d3f9a542401fdc90d05_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNC0zLTEtMS0xMDUwMzM_4d7d69b8-da2d-4a66-bb7b-e4b911861dbd">16,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d18e1861dd47459e3afc0e2f4d6b6c_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNC01LTEtMS0xMDUwMzM_661b6a4b-db22-4a3e-81ce-38289a453c02">36,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3be1ea17a2242b89f05c2d9c603ef7f_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNC03LTEtMS0xMDUwMzM_a5e96562-ab32-41f3-b776-ca535cfa9459">34,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9a9c63b74748ea9144996c4ffcebfc_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNS0xLTEtMS0xMDUwMzM_ba3a6e58-1964-4fc2-972e-651244b0d736">9,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f72a8ae1ecb4b9f95f49782044f3034_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNS0zLTEtMS0xMDUwMzM_966fff99-a574-4386-b941-edb0870d3afa">8,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fb94590e3da4131815186c8ad836fbd_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNS01LTEtMS0xMDUwMzM_b28e7c5f-3707-406a-a786-9aa40a4cd603">20,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b2dce3af564d37aace93fa3edc0576_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNS03LTEtMS0xMDUwMzM_58f8297e-9239-4916-83f3-8941d1ed2d08">16,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13819d6ef7341d7adfe25db4589fb16_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNi0xLTEtMS0xMDUwMzM_eace319a-d548-4177-8e23-c8dc03cbf941">11,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f55ac666634d8790450c2efbff1301_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNi0zLTEtMS0xMDUwMzM_749d0bc6-97b7-4784-9ebd-655b4e6c07c8">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84494cd24411430cb3a73d2b634c4e8f_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNi01LTEtMS0xMDUwMzM_942bccbf-98e5-4eed-90ee-7c7f1f2f5869">22,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4615fc163545a386d6cb61eafec12b_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNi03LTEtMS0xMDUwMzM_5e71aac7-6773-4452-aaf7-0ea479966097">7,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b39506fda1c403390a1a7356060a43f_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNy0xLTEtMS0xMDUwMzM_46ac567f-2d3b-4b4f-89e1-241ddf699ce4">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b2701ff7a24a1dbb0e0cba3406cd91_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNy0zLTEtMS0xMDUwMzM_253a945f-6bb2-4232-918a-8647822e4b24">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5154423056f643eca603328d7cdb95e7_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNy01LTEtMS0xMDUwMzM_855643c5-db3a-4b08-99e6-a4fddb162d2c">3,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18329a0408e04ac0bf921293f4606d37_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNy03LTEtMS0xMDUwMzM_a41368a7-c011-4a41-8f7a-5a2daa4461bd">3,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfOS0xLTEtMS0xMDUwMzM_53ff02ac-eb54-4321-b951-c12affc23a4d">269,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfOS0zLTEtMS0xMDUwMzM_110c39bc-e391-4f75-8afb-336d65158bf4">175,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfOS01LTEtMS0xMDUwMzM_e084c259-2863-4cc2-87f6-445c37b69e9b">532,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfOS03LTEtMS0xMDUwMzM_6137055a-c77b-4bbd-9b62-e6172b01006b">351,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTItMS0xLTEtMTA1MDMz_4c509069-781c-4d40-9183-404d983b10e5">230,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTItMy0xLTEtMTA1MDMz_25f19757-dca0-4a30-9c28-869bdd78cf47">136,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTItNS0xLTEtMTA1MDMz_e6541785-8e43-477a-aa97-1ab4c41593f3">450,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTItNy0xLTEtMTA1MDMz_160c60a3-bc93-47c5-aeef-d660a5b609e8">276,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTMtMS0xLTEtMTA1MDMz_a7f4ac19-5b68-4d20-8738-9774b67ea66a">19,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTMtMy0xLTEtMTA1MDMz_30968990-4e56-4f31-b97a-a6200932f877">14,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTMtNS0xLTEtMTA1MDMz_0f2d40f7-28d2-45c2-a012-0a4c9ab6cdc6">31,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTMtNy0xLTEtMTA1MDMz_01df37f0-74c9-48aa-8011-782255f3fe95">23,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTQtMS0xLTEtMTA1MDMz_d82ac8cb-af5e-4cf0-ba80-da3f55099718">4,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTQtMy0xLTEtMTA1MDMz_5c82a4f7-fbbd-4ad6-aa1a-1bed9e631072">4,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTQtNS0xLTEtMTA1MDMz_ee85cef6-1081-4e74-b7e4-e95da083f3d3">8,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTQtNy0xLTEtMTA1MDMz_1d44efab-ffb8-4ea4-96e1-841e265acf2e">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTgtMS0xLTEtMTA1MDMz_9ada4b13-c3b5-4ee8-a236-390ae6a7bda5">254,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTgtMy0xLTEtMTA1MDMz_7c7c32b3-1d05-4944-ae68-71fa86e4609c">154,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTgtNS0xLTEtMTA1MDMz_9a013597-8774-4f46-a05c-2b33967ce16d">491,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTgtNy0xLTEtMTA1MDMz_4fd23721-8a1e-43a8-b560-e56420acc58c">308,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjAtMS0xLTEtMTA1MDMz_3b48789e-f7e3-4d7d-86a9-cd766b2952ee">15,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjAtMy0xLTEtMTA1MDMz_3df43adc-913f-42af-a08f-9d1f4daabc1a">20,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjAtNS0xLTEtMTA1MDMz_0dde5bf0-943b-462b-9779-dc1c1e7fa25d">41,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjAtNy0xLTEtMTA1MDMz_7df9716d-376e-4271-b7fe-3136b9a1fb88">42,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjMtMS0xLTEtMTA1MDMz_bf6e1bb7-cb43-4162-a756-b5e534397526">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjMtMy0xLTEtMTA1MDMz_465e4be5-f9ec-4138-b12b-b1c3987b7321">3,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjMtNS0xLTEtMTA1MDMz_c9045de7-34e2-4ff7-97bf-282a19904733">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjMtNy0xLTEtMTA1MDMz_9a2a4e28-981c-43eb-98ac-3f5c615a3a17">3,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjUtMS0xLTEtMTA1MDMz_2092e919-26b3-4d87-bccd-af91fe59cdd5">1,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjUtMy0xLTEtMTA1MDMz_d0017e9c-f3df-4f18-aa72-287db5ec5e19">1,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjUtNS0xLTEtMTA1MDMz_acaf2b27-3d5e-4b87-9dec-73923037978a">2,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjUtNy0xLTEtMTA1MDMz_b233f089-0c10-45d1-800b-f1e8e01421b4">3,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjYtMS0xLTEtMTA1MDMz_2f547897-97b1-4f8c-af8d-af08ae34393f">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjYtMy0xLTEtMTA1MDMz_4d14773c-80c0-4a44-8957-d63ab9cb568f">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjYtNS0xLTEtMTA1MDMz_1e3ad0ec-b3ef-4acd-9583-0acb83bd6fb5">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjYtNy0xLTEtMTA1MDMz_9a24ca06-c55b-49c3-9531-c33ab4b681a3">912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjctMS0xLTEtMTA1MDMz_063dc286-8aa6-405e-8b5e-602fabf6ad5b">1,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjctMy0xLTEtMTA1MDMz_58eabaf6-f3f1-4fdc-8328-f1b53b476a72">83,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjctNS0xLTEtMTA1MDMz_dbf9eef3-b009-49ca-9528-48f5de221d5c">10,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjctNy0xLTEtMTA1MDMz_fef57e9d-87bf-4161-a825-ef0aa0dd8894">83,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjgtMS0xLTEtMTA1MDMz_ea172800-9779-4777-8f98-f1fc5408a398">3,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjgtMy0xLTEtMTA1MDMz_5e436fb3-c787-4d63-8939-fd2ab7231a37">15,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjgtNS0xLTEtMTA1MDMz_f6292bfe-678c-4db9-a817-85a957482edc">3,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjgtNy0xLTEtMTA1MDMz_1ae137b4-5d68-498d-9cbb-648e83770dc5">14,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzAtMS0xLTEtMTA1MDMz_3a2165df-2952-48d6-99bc-fcabba1c2226">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzAtMy0xLTEtMTA1MDMz_634a3658-c917-4159-add4-4b1bac638755">63,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzAtNS0xLTEtMTA1MDMz_0dd2e0e6-50f7-4083-b9cd-fc5730212594">6,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzAtNy0xLTEtMTA1MDMz_ea8e9458-4b5e-4bf7-b12c-6118d04b1a97">62,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzItMS0xLTEtMTA1MDMz_95478ceb-acfa-4d05-aef5-9d4143a72b38">16,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzItMy0xLTEtMTA1MDMz_156e0ef1-44b6-4f23-9b7f-fc516cc9f622">84,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzItNS0xLTEtMTA1MDMz_86296207-6135-4d5c-afeb-614bef4ce91e">34,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzItNy0xLTEtMTA1MDMz_862e2c30-9fb0-4482-bbfa-2f48d8e0ee36">105,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzQtMS0xLTEtMTA1MDMz_441e1752-f27e-402b-9c5a-801b2dcf8cc4">6,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzQtMy0xLTEtMTA1MDMz_f3fe58e3-454a-459b-8c3a-1d4d251fe49f">24,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzQtNS0xLTEtMTA1MDMz_f9389c77-aff0-4671-a34b-92a04cefbf7d">12,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzQtNy0xLTEtMTA1MDMz_7c0c9a78-74bb-4555-8c9f-073bf90f041d">31,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzYtMS0xLTEtMTA1MDMz_4d8a217f-6841-4bf2-a92a-4c962d3c6d6d">10,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzYtMy0xLTEtMTA1MDMz_1f697ca0-db9b-4093-ae18-d6c06c482207">59,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzYtNS0xLTEtMTA1MDMz_fc010ad2-a032-4407-8835-68a13902463c">22,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzYtNy0xLTEtMTA1MDMz_f4cc020e-5b51-411b-afa6-99c56a832933">73,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzgtMS0xLTEtMTA1MDMz_d51026e1-4faf-40b5-9939-868febf11801">808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzgtMy0xLTEtMTA1MDMz_0cf90f73-d89a-4035-8a15-c25e8ca56eea">46,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzgtNS0xLTEtMTA1MDMz_58c78c4b-4c9a-4a86-9584-62540386b5bd">2,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzgtNy0xLTEtMTA1MDMz_f11d8779-552c-483f-bcea-382016257315">48,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDAtMS0xLTEtMTA1MDMz_393168fe-b6ad-4aea-b6d7-62a15c4992f8">11,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDAtMy0xLTEtMTA1MDMz_84294a8c-1892-440f-a327-6a59d68dbf6a">12,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDAtNS0xLTEtMTA1MDMz_82668df4-dabf-446e-a419-a693cc7cf96b">25,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDAtNy0xLTEtMTA1MDMz_eb47bb73-316f-4107-aae4-a797734de2d7">25,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDItMS0xLTEtMTA1MDMz_c99fcd67-2803-4e50-bf1c-d1344aaf8d8e">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDItMy0xLTEtMTA1MDMz_491e672f-4d93-427c-9cbc-5a44df817c4e">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDItNS0xLTEtMTA1MDMz_b9fd3a70-c2e4-4f83-a4b5-a4e9baadb169">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDItNy0xLTEtMTA1MDMz_0812c0e1-6278-4180-a1d5-1c1214273925">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDQtMS0xLTEtMTA1MDMz_aeebdd93-f914-446f-8481-2a5671b8888b">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDQtMy0xLTEtMTA1MDMz_5c6691a2-8cf9-4cb1-958e-f37380523983">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDQtNS0xLTEtMTA1MDMz_b7f98280-329c-4eaa-949e-ec5820b9632a">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDQtNy0xLTEtMTA1MDMz_9463c77b-fd1b-4341-9b72-0651ab4b04bc">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.701%"><tr><td style="width:1.0%"></td><td style="width:29.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.220%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.555%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine<br/>Equity&#160;&#8211;<br/>Non-controlling<br/>Interest&#160;in&#160;APC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common&#160;Stock&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional<br/>Paid-in&#160;Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia504157a512f402581af013fb57df905_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy0xLTEtMS0xMDUwMzM_814be9a0-1be1-4b46-b32c-2d796b553c34">55,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad4a0d5b297a4f7fb66c1516ac86205f_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy0zLTEtMS0xMDUwMzM_dfc8efcf-a80e-4aed-8a74-41468448ae22">44,630,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4a0d5b297a4f7fb66c1516ac86205f_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy01LTEtMS0xMDUwMzM_ccf7dbd8-f83f-4fea-bec1-9edc9f46047b">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief358036295248deb2d6fc4f17ab1fd6_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy03LTEtMS0xMDUwMzM_8ccaa2a7-0cc1-443e-b925-e9f1ddf199b8">310,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6b90da5220a49248e3a42f5d7bcee8d_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy05LTEtMS0xMDUwMzM_04d6059b-b68f-48a6-80ac-c31b724b2d21">143,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01c1ed4406f45fd89cc7c596242ac42_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy0xMS0xLTEtMTA1MDMz_5d197881-be65-4487-b94a-80ed1f6a9700">5,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy0xMy0xLTEtMTA1MDMz_0723bcc1-33d6-4dca-ad33-9b83c1361327">460,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNC0xLTEtMS0xMDUwMzM_094df5a3-eeb4-4c86-bd2a-a9642d57b48d">3,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id232a7c63cea47fb908b2d31d1507b26_D20220101-20220331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNC05LTEtMS0xMDUwMzM_55207f5f-6e01-43fe-9aff-5afef02a0947">14,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabb570e56704819be46a35a99056cfd_D20220101-20220331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNC0xMS0xLTEtMTA1MDMz_92ca7d47-752a-4396-8371-f1b11d4d5e09">938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNC0xMy0xLTEtMTA1MDMz_e9d92894-7fa4-476d-8edb-6776891cb367">15,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNS0xLTEtMS0xMDUwMzM_17b96ead-7e2d-48ee-b973-b124b8ee7af3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibabb570e56704819be46a35a99056cfd_D20220101-20220331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNS0xMS0xLTEtMTA1MDMz_6c53b11c-0e72-4edf-93fc-0b39ccf0fc90">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNS0xMy0xLTEtMTA1MDMz_c7a1b584-8c5f-4045-abd2-7f7874952a75">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibabb570e56704819be46a35a99056cfd_D20220101-20220331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNi0xMS0xLTEtMTA1MDMz_38698307-36dd-4b3f-85cd-6398c03cb894">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNi0xMy0xLTEtMTA1MDMz_8a2ce96b-298d-495f-89a2-14b23d426380">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share buy back</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNy0xLTEtMS0xMDUwMzM_8d2f4e33-d8c8-4060-80d8-a2fde0fa6e4c">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOC0zLTEtMS0xMDUwMzM_c5f647ed-f325-4119-ab5e-293926751a09">81,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOC03LTEtMS0xMDUwMzM_ac8f8796-2185-4fef-b3b9-412f6c0954f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOC0xMy0xLTEtMTA1MDMz_7a27259b-e280-41a0-a7bd-6990b3e810e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331" decimals="INF" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOS0zLTEtMS0xMDUwMzM_083ed245-1b7e-4a10-a6e7-c7b647dc0dd9">124,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOS03LTEtMS0xMDUwMzM_37b80008-e0ca-46a0-9f40-1963f1bbb70d">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOS0xMy0xLTEtMTA1MDMz_f9f7dfbd-3ef0-4d27-8258-0eeff0e7eb4e">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTAtNy0xLTEtMTA1MDMz_28c5f7e3-2ce1-4f37-b123-ee6fc85e410a">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTAtMTMtMS0xLTEwNTAzMw_8a842eb5-1c66-4df5-8db2-8e6d11efbc53">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares for business acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTEtMy0xLTEtMTA1MDMz_83bdf043-030d-496f-9e85-c23ad24b6163">18,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTEtNy0xLTEtMTA1MDMz_6255ee09-cb66-4c6e-ba94-0fc3d202587a">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTEtMTMtMS0xLTEwNTAzMw_19934801-5718-4aa9-aab9-98b0998a8918">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTItMy0xLTEtMTA1MDMz_08d5680f-bef0-4b3f-a4ee-48c717a668cc">11,084</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTItNy0xLTEtMTA1MDMz_67df836f-eb9b-4c48-bd5a-539767177b09">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTItMTMtMS0xLTEwNTAzMw_2ca80340-721d-4922-9dc6-ea40b65a7404">457</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331" decimals="-3" name="us-gaap:TemporaryEquityAccretionOfDividends" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTMtMS0xLTEtMTA1MDMz_07453b1b-d1af-4064-b579-c73b0fb5e8ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibabb570e56704819be46a35a99056cfd_D20220101-20220331" decimals="-3" sign="-" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTMtMTEtMS0xLTEwNTAzMw_306075a6-2a86-42b1-9e93-fc9c920bd716">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331" decimals="-3" sign="-" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTMtMTMtMS0xLTEwNTAzMw_ba24ba0f-2379-47d9-a69b-8fa16d748276">1,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b2a5b59bb6c4986b7c1a50b1f8a0aad_I20220331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtMS0xLTEtMTA1MDMz_34f94b7c-2b08-42e3-b75c-2c6b26162e66">52,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c6cc256e341493aa571df5da6b6662f_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtMy0xLTEtMTA1MDMz_2209327f-1f6e-436c-b53b-762b83c9a803">44,845,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c6cc256e341493aa571df5da6b6662f_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtNS0xLTEtMTA1MDMz_a1c69f0c-70c3-484d-a113-fdd6d392af3e">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d98f2c383be4f0caf317615c3e90bdd_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtNy0xLTEtMTA1MDMz_69dd250f-1d6c-46eb-9ac1-f0f9a15a7cb5">316,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75d2dd3b8a394e94b24002551af97de8_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtOS0xLTEtMTA1MDMz_908ab82f-01ed-43d9-907e-44fc5531045f">157,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe3f233a5ee47f89e7da633077e4a16_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtMTEtMS0xLTEwNTAzMw_3acbe2dd-3887-4889-9225-0a0224b7919e">5,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eff61b12ade44188aa16b4c6f4691fc_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtMTMtMS0xLTEwNTAzMw_10e21954-65d8-45b9-99e7-c39568ebf8dd">479,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79a98933176041edb09daa8e6a031ae2_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTUtMS0xLTEtMTA2MjA5_b02bc580-b4fb-4b16-8cb8-f649c4ec99a5">2,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb8cb1f443c409ebb880abdbfb1b50b_D20220401-20220630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTUtOS0xLTEtMTA2MjM4_10878165-d21b-4407-a0a4-901599d0b934">11,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b4fc11728e4a119e9ff7d187016bbd_D20220401-20220630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTUtMTEtMS0xLTEwNjI0NQ_c5f94824-d739-4047-b09e-751d85f5cc29">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTUtMTMtMS0xLTEwNjI1Mg_6c963c94-e2e6-4b34-85d0-8b39abe00f3b">12,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2be7890574c4c2e850a4bef6af34746_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTgtMy0xLTEtMTA2MjE2_03442a33-6126-4449-a9b6-e44069d9cadd">108,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTgtNy0xLTEtMTA2MjMx_cf2ca1cd-660a-4486-ade1-dcbf03a4e9ba">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTgtMTMtMS0xLTEwNjI1Mg_3cdcb654-0cee-4b47-9dd7-d3809698d448">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia2be7890574c4c2e850a4bef6af34746_D20220401-20220630" decimals="INF" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTktMy0xLTEtMTA2MjE2_b19393fa-6a91-446c-97bb-7cc315c56335">15,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTktNy0xLTEtMTA2MjMx_acd466b6-9a05-4f6b-b315-dd3e0778a339">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTktMTMtMS0xLTEwNjI1Mg_b6749aa1-ffac-414e-a89e-910b9b793cc1">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia2be7890574c4c2e850a4bef6af34746_D20220401-20220630" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjAtMy0xLTEtMTA2MjE2_26284251-2478-4a04-93e4-aaea9b313b7d">250,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjAtNy0xLTEtMTA2MjMx_75d13ae6-840c-42a9-b2a9-297d5191e157">9,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjAtMTMtMS0xLTEwNjI1Mg_764fc035-1569-4fe8-b849-c359e978172c">9,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjEtNy0xLTEtMTA2MjMx_cd28c0c6-f57c-4822-b8c4-8f21514ae50e">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjEtMTMtMS0xLTEwNjI1Mg_6306634e-2a1c-4ac0-8a7b-59ac30b469c5">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b4fc11728e4a119e9ff7d187016bbd_D20220401-20220630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjMtMTEtMS0xLTEwNjI0NQ_4c466b3f-f2bd-4723-9f09-cc0350e639b4">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjMtMTMtMS0xLTEwNjI1Mg_0e8cda83-aa43-4296-9023-499ec3c9782b">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79a98933176041edb09daa8e6a031ae2_D20220401-20220630" decimals="-3" name="us-gaap:TemporaryEquityAccretionOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjQtMS0xLTEtMTA2MjA5_b448e2be-a4c0-4932-9ba7-25c55f761db7">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1b4fc11728e4a119e9ff7d187016bbd_D20220401-20220630" decimals="-3" sign="-" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjQtMTEtMS0xLTEwNjI0NQ_5d00f890-fc74-4182-9812-731639d17998">1,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" sign="-" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjQtMTMtMS0xLTEwNjI1Mg_dcd44931-d15a-4a9e-ae23-8513030c8e5b">1,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a4ee78dedb4bf0bb4d2dcdbf5e685c_I20220630" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtMS0xLTEtMTA2MjA5_1597d8f5-123b-4bd0-989a-986e22a07878">39,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7a647777c9a41638828e0bb054b607d_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtMy0xLTEtMTA2MjE2_0eda5f61-a87a-4734-a605-8509bcce27d7">44,719,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a647777c9a41638828e0bb054b607d_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtNS0xLTEtMTA2MjIz_d997dde0-a7d7-4168-8627-ab0905e3d830">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4945b7a5d144dcb44613757de6b733_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtNy0xLTEtMTA2MjMx_f7299e18-e9a3-4600-8348-1e12098637e1">310,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf67c623dc9c4fdb87ffe7f1a5f0fd33_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtOS0xLTEtMTA2MjM4_e4767ebc-f0e9-4639-8f1c-5bef1c0c9fd1">169,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1f7e2940144fe09e63a4985d202a33_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtMTEtMS0xLTEwNjI0NQ_60e61c34-8bb8-4b6c-88b7-bd1e14ca0d98">5,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtMTMtMS0xLTEwNjI1Mg_f5254985-be1f-444b-86d2-9a5e1037c7e6">485,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.051%"><tr><td style="width:1.0%"></td><td style="width:30.136%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.620%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine<br/>Equity&#160;&#8211;<br/>Non-controlling<br/>Interest&#160;in&#160;APC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common&#160;Stock&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional<br/>Paid-in&#160;Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a86084d3064273846f20df1dc58121_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy0xLTEtMS0xMDUwMzM_56653837-fd81-407d-a541-df5f607e7121">114,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71714e79a7ff4ae58ec405207709ae87_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy0zLTEtMS0xMDUwMzM_77dd9e0b-29e5-4820-87ee-e9d6f97921c1">42,249,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71714e79a7ff4ae58ec405207709ae87_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy01LTEtMS0xMDUwMzM_d2e3d19b-9f67-4e7c-9505-6deab43e770e">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ac6532c5744fbe9e81dcf735c713ea_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy03LTEtMS0xMDUwMzM_b2c1703b-6088-4f45-b0b0-94da8ada1f84">261,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2095839d0b164a5db420348af27d9e8a_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy05LTEtMS0xMDUwMzM_c64367c6-c191-42a4-9138-3f6cc73054cd">69,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabf5dd86df34cefa162b01e549f2f27_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy0xMS0xLTEtMTA1MDMz_770d8ea9-a3dd-4a40-adcc-0f5d3ca7c0e4">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy0xMy0xLTEtMTA1MDMz_5249f173-50ff-43d7-ad3a-4432183e7309">330,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fb56e0f9f67490fa0624de03cbc6dfc_D20210101-20210331" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNC0xLTEtMS0xMDUwMzM_6ce7d9c1-20dd-4415-b964-eee2390657dd">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic700b6fc892341ebbf97cebcb5258f90_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNC05LTEtMS0xMDUwMzM_7d6f2f7a-7971-411b-8d40-7bc4a48734d9">13,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d89e7c53fa4a70b5fb4595708da067_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNC0xMS0xLTEtMTA1MDMz_97641ce9-8aa2-4aa1-b703-dd0e0a02d6a2">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNC0xMy0xLTEtMTA1MDMz_36886886-92e9-4ec2-a251-1b323df47f03">13,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fb56e0f9f67490fa0624de03cbc6dfc_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNS0xLTEtMS0xMDUwMzM_edf1d1eb-5f19-4ffc-8739-c3066380574f">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05d89e7c53fa4a70b5fb4595708da067_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNS0xMS0xLTEtMTA1MDMz_fac9e1d5-2db2-4a31-8e08-592d8229a81a">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNS0xMy0xLTEtMTA1MDMz_c2b4f694-201c-4c54-9837-d3242ed1ef8c">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d89e7c53fa4a70b5fb4595708da067_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNi0xMS0xLTEtMTA1MDMz_e7412c44-1452-4e22-b8cb-1f2869a8f60c">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNi0xMy0xLTEtMTA1MDMz_b5162f3f-9144-444a-a78a-440ff524ab39">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNy0zLTEtMS0xMDUwMzM_b434dff9-2f13-433c-ad5b-3707b09a6244">7,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNy03LTEtMS0xMDUwMzM_46b8f9ff-900c-45c6-8bb0-2885dba0d9c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNy0xMy0xLTEtMTA1MDMz_c1476c6f-2d3f-4e5a-a791-72aa47faa7b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331" decimals="INF" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOC0zLTEtMS0xMDUwMzM_09921a48-faab-4892-aaa2-f59410878050">421,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOC01LTEtMS0xMDUwMzM_e7ca5d67-7142-46a3-9a0f-7df026b9f333">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOC03LTEtMS0xMDUwMzM_eae45e2f-931c-498f-9648-ed282c8e4439">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOC0xMy0xLTEtMTA1MDMz_f922100c-8e1d-4c6f-bbd4-d1276f224dc8">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOS0zLTEtMS0xMDUwMzM_ae0e49c4-32ba-48ed-9c70-90f7c6533d85">34,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOS03LTEtMS0xMDUwMzM_cb82d977-6221-4bd7-b7c7-9bcdd4e93454">342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOS0xMy0xLTEtMTA1MDMz_6cb79761-cc95-4e33-92ad-deeff81be4d5">342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTAtNy0xLTEtMTA1MDMz_5c3b3b3c-f5d5-4b02-9e66-9e74921461d6">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTAtMTMtMS0xLTEwNTAzMw_80623097-edd6-4926-8336-aed8612d9b1f">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTEtMy0xLTEtMTA1MDMz_eadd1665-87b4-458a-9b3f-37f82c60b796">5,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTEtNy0xLTEtMTA1MDMz_e0e18eb3-0aa1-4e6e-bf15-924dabc2a3d9">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTEtMTMtMS0xLTEwNTAzMw_fe576468-6246-4853-abbd-4160ba0751d3">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbece1b8c5604d32bef8c1b3bee0e06e_I20210331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItMS0xLTEtMTA1MDMz_804e7d7f-475b-4f3c-a1a1-05f12b3226da">114,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86bed315c9104a5ea8f38b47de37821f_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItMy0xLTEtMTA1MDMz_3969538c-3ab4-4820-b05e-44579ea9e16e">42,638,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bed315c9104a5ea8f38b47de37821f_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItNS0xLTEtMTA1MDMz_48357c4a-c6b3-4322-9de1-34027733f313">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744f0bbbd4024a33b8e4daec9c49bb16_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItNy0xLTEtMTA1MDMz_03cdf0cb-1a05-4f35-b02f-751d7bee1406">266,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae2d6eb6ccba48b09c3e8ac6b7c4c666_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItOS0xLTEtMTA1MDMz_4751ccd2-84c8-4071-9664-96d79e744630">82,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11090e9d37df449c8a39e89447069685_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItMTEtMS0xLTEwNTAzMw_4374856c-6654-4fcf-aca2-fc6d47eb0893">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b9bd5984e7487dae4a1cd249a6cdf0_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItMTMtMS0xLTEwNTAzMw_92c83ca8-0ae5-4841-8d37-465963d1cbe9">349,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f5ec933f8d44cc38f55f6394cb7637c_D20210401-20210630" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTMtMS0xLTEtMTA2MDcz_593ccf2e-130f-4591-b9aa-8a48618a2d18">46,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i949844556a7b4f6492884ecdd3ff6253_D20210401-20210630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTMtOS0xLTEtMTA2MTA5_b9369038-ac0f-4b6e-afab-253a74e42c7c">12,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42578d05def24550adcdf005d6e174fd_D20210401-20210630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTMtMTEtMS0xLTEwNjExOA_7a0082cc-44af-489a-8170-5dbf0b8dbcfd">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTMtMTMtMS0xLTEwNjEyOQ_fe167c96-2de0-4e5d-963d-7c777df5ac34">12,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f5ec933f8d44cc38f55f6394cb7637c_D20210401-20210630" decimals="-3" name="ameh:TemporaryEquityIncreaseFromSaleOfNonControllingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTQtMS0xLTEtMTA2MDcz_1d7c4eff-bdfd-4578-8ee3-5c82f27a3638">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of shares by non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630" decimals="INF" name="ameh:StockIssuedDuringPeriodSharesNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTUtMy0xLTEtMTA2MDgy_85a48205-e4a3-4dc8-b4b7-4d02c617c5e9">1,638,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringPeriodValueNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTUtNS0xLTEtMTA2MDkx_07e3ffb2-1c2c-433d-b5a6-2149973c44fc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringPeriodValueNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTUtNy0xLTEtMTA2MTAw_d5c6b571-e4d9-44f5-ac79-cf4df513d6fe">40,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringPeriodValueNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTUtMTMtMS0xLTEwNjEyOQ_4ff1b5a6-7aca-4542-9ae7-569d68e268be">40,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTYtMy0xLTEtMTA2MDgy_210302b0-3ede-41c4-9f94-56d6ea4eb5e0">22,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTYtNy0xLTEtMTA2MTAw_0d1c0d92-fb69-41bf-9ad3-ee02eef5e8be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTYtMTMtMS0xLTEwNjEyOQ_0aec9c4e-6801-48e3-8a69-b86a7f9f44ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630" decimals="INF" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTctMy0xLTEtMTA2MDgy_c2e795e6-d256-426a-8471-2b19770efd49">53,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTctNS0xLTEtMTA2MDkx_d659811a-db4f-4fc2-8eb7-06824107ac75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTctNy0xLTEtMTA2MTAw_b7251d11-e3a1-4e4b-a88e-e30160fdbef6">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTctMTMtMS0xLTEwNjEyOQ_3878452f-5c38-4620-9e69-2243fdc58ac5">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTgtMy0xLTEtMTA2MDgy_6bb94b51-aa02-4d5c-aa5a-c48100e002e1">100,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTgtNy0xLTEtMTA2MTAw_36c2c640-d1dc-4110-be9d-ec4d6bed265a">2,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTgtMTMtMS0xLTEwNjEyOQ_f8ee88b7-aa8a-4cfd-8552-cdcea1d95c2f">2,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTktNy0xLTEtMTA2MTAw_45ed4dcf-2337-4076-a35a-1c3f39d6a9b4">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTktMTMtMS0xLTEwNjEyOQ_10b8905e-3ebb-409e-b435-7cf65d2d32c0">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjAtMy0xLTEtMTA2MDgy_7aaa3b2b-6d00-451c-a722-17c049525432">5,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjAtNy0xLTEtMTA2MTAw_f087a305-b43c-4bb2-b640-3c0b8bf40cf3">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjAtMTMtMS0xLTEwNjEyOQ_fb865da9-036a-44f4-b9be-b08efd81df3e">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42578d05def24550adcdf005d6e174fd_D20210401-20210630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjEtMTEtMS0xLTEwNjExOA_f2effce8-924c-4bcd-8f5a-88c7dfa10d7d">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjEtMTMtMS0xLTEwNjEyOQ_caec18c1-91f4-4925-8a12-6506fea85e0b">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f5ec933f8d44cc38f55f6394cb7637c_D20210401-20210630" decimals="-3" name="us-gaap:TemporaryEquityAccretionOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjItMS0xLTEtMTA2MDcz_6fffad5c-2f3b-4b40-aaff-b384430fe2fa">20,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42578d05def24550adcdf005d6e174fd_D20210401-20210630" decimals="-3" sign="-" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjItMTEtMS0xLTEwNjExOA_5f1bbd8d-865f-4cd1-bf00-2fcc3ebd39b3">1,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" sign="-" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjItMTMtMS0xLTEwNjEyOQ_f84588fa-192e-4ce0-9e02-bfdb7f73ee4f">1,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28f106f492574f71ad887c17b3f0e3b8_I20210630" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtMS0xLTEtMTA2MDcz_a9bf6070-be4c-4897-b44a-f2fa5b93a2c8">141,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb3286d909fa4f44a7673a684b27d8d7_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtMy0xLTEtMTA2MDgy_f5a48804-a803-41ca-b2ee-d9375e9098bb">44,246,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3286d909fa4f44a7673a684b27d8d7_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtNS0xLTEtMTA2MDkx_83a297f2-b48a-411a-89fb-acd5818b6412">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f3de9a3211f43939fba721ad717140d_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtNy0xLTEtMTA2MTAw_e5923a35-f86e-4fe4-ba67-2ec5d61da271">305,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic123e707f5444ec8a2f129ff7fd69271_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtOS0xLTEtMTA2MTA5_392b5a6b-6739-41a6-9842-ac1506ec047b">95,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9165a0fe2b24da295ead9547c7c43f7_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtMTEtMS0xLTEwNjExOA_f70a40bd-8e6c-48c7-afbb-04868df1cf47">3,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4becb57108e844a2af77734d782c9546_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtMTMtMS0xLTEwNjEyOQ_59c64845-2e56-4bf7-b545-a718e4174762">404,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMy0xLTEtMS0xMDUwMzM_d0d932f8-a48f-4082-ab44-ee22be11ce70">22,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMy0zLTEtMS0xMDUwMzM_549a646a-1348-4bbd-8026-09c06b1996d5">73,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNS0xLTEtMS0xMDUwMzM_6263ad70-1871-4701-9c70-8e46ad6cd471">8,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNS0zLTEtMS0xMDUwMzM_7f322c1d-2239-4490-96b2-4f7a4e0069c9">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNi0xLTEtMS0xMDUwMzM_f405bc1b-5eaf-40cf-a70e-98c64451f9ce">474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNi0zLTEtMS0xMDUwMzM_fde637c0-a94d-4edd-a1b9-ab4c88519f35">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNy0xLTEtMS0xMDUwMzM_f60e7a59-a95e-432d-9b82-2ea02d8d434a">6,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNy0zLTEtMS0xMDUwMzM_ac86135b-5679-40c9-ad40-425068bc84f8">2,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOC0xLTEtMS0xMTk2MjQ_a3a8b677-0687-49cd-bd6c-42283f61c7fb">2,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOC0zLTEtMS0xMTk2MjQ_18dddea7-e312-4612-b87f-3e3930fd426e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss (gain) from investment in equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="ameh:UnrealizedGainLossFromInvestmentInEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOC0xLTEtMS0xMDUwMzM_6dd6e384-a92c-41bc-87ca-b6d9d579284e">13,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="ameh:UnrealizedGainLossFromInvestmentInEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOC0zLTEtMS0xMDUwMzM_3157a665-5131-42b1-a699-433ee70d611d">83,769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Income) loss from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOS0xLTEtMS0xMDUwMzM_5ed34722-71d1-48cf-ac7c-1ea9bcb7ad7c">2,945</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOS0zLTEtMS0xMDUwMzM_06c83ec0-eda9-49a0-a431-39de0576c1fd">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of beneficial interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTEtMS0xLTEtMTA1MDMz_6b16efb4-b5d2-44dd-9c92-2fa47455c9fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTEtMy0xLTEtMTA1MDMz_5f0d6e48-bbf6-4500-a260-c819910bbd0f">15,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (gain) loss on interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTItMS0xLTEtMTA1MDMz_b6266ab1-3526-47a8-9a7b-ff8b359234ce">2,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTItMy0xLTEtMTA1MDMz_a871ae95-a115-4947-8436-c83764156220">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTMtMS0xLTEtMTA1MDMz_0b127535-85fc-4e01-9b51-600e74e2d719">2,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTMtMy0xLTEtMTA1MDMz_700a29a8-ce7c-41aa-9edf-56dbbef01c76">10,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromOtherOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTQtMS0xLTEtMTA1MDMz_5f314175-dfda-4882-91ac-7dbb3d1bc54c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromOtherOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTQtMy0xLTEtMTA1MDMz_4a7a6de0-d4d2-4324-8649-ba5564ceb623">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of business combinations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTYtMS0xLTEtMTA1MDMz_08af6ae1-e362-41ff-9c54-edf869181e38">56,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTYtMy0xLTEtMTA1MDMz_d228e107-3b34-458f-815e-5c21114fa35b">9,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTctMS0xLTEtMTA1MDMz_51c56a51-aa06-4fe4-b638-8adaec1f5491">12,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTctMy0xLTEtMTA1MDMz_14964971-b150-4cfc-853a-7f387fe9313c">19,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTgtMS0xLTEtMTA1MDMz_6185f1bc-80cc-4d04-b427-859ef13878fb">3,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTgtMy0xLTEtMTA1MDMz_52ad6928-ef53-4eb5-ba45-a6cbcca611d6">266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTktMS0xLTEtMTA1MDMz_26eb2f76-7ba3-4d98-b9ec-995b4ed23714">4,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTktMy0xLTEtMTA1MDMz_5a66fde4-0b2e-48ea-8c2f-af707c9fbb44">4,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjAtMS0xLTEtMTA1MDMz_6acc9135-bc6a-4792-a906-817574667369">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjAtMy0xLTEtMTA1MDMz_a5fe0387-7c38-443e-b880-476dce878bf4">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjEtMS0xLTEtMTA1MDMz_1f4406f1-ff3e-4345-8353-7ab60cc11f1b">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjEtMy0xLTEtMTA1MDMz_68685178-fb20-401f-80f5-a1d01993351f">426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjItMS0xLTEtMTA1MDMz_0d98744f-50f7-4173-9d3c-c84187fbdf7c">14,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjItMy0xLTEtMTA1MDMz_6fe5efcf-368f-47f7-86ca-3075b953ecbb">16,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjMtMS0xLTEtMTA1MDMz_fbf9cb5c-2540-4851-ae57-a4ced7b711c0">4,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjMtMy0xLTEtMTA1MDMz_1c6f4883-416d-4d04-abdf-a9f40a5187e4">550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:IncreaseDecreaseInMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjQtMS0xLTEtMTA1MDMz_ae3acf26-c9c9-4494-a37f-18afc668ac06">55,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="ameh:IncreaseDecreaseInMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjQtMy0xLTEtMTA1MDMz_bcd02d5a-35d7-465b-8601-cd1d9b66dbf2">8,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjUtMS0xLTEtMTA1MDMz_0d03b4ec-03d5-4b5e-8858-43ecaf739fe7">13,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjUtMy0xLTEtMTA1MDMz_276569fa-9b08-422c-9549-0c45dbaa9131">2,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjYtMS0xLTEtMTA1MDMz_e4397b45-41d2-4484-958f-5aa732765652">2,254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjYtMy0xLTEtMTA1MDMz_1eb267d1-87ab-4713-b044-998c55078f83">1,698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjctMS0xLTEtMTIwMzY4_48a52851-2ab0-472a-b42e-c675f8e14fbe">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjctMy0xLTEtMTIwMzc1_5a128e93-3dc5-4eec-a3b4-49d69b477ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjgtMS0xLTEtMTA1MDMz_03399e10-c659-4e12-afd4-45dea7825870">33,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjgtMy0xLTEtMTA1MDMz_831c4224-c3d6-46ff-b68a-a5a1e375b237">31,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for business acquisition, net of cash acquired </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzEtMS0xLTEtMTA1MDMz_31815504-8a92-4e20-8fc9-2cf52e9ae3a3">858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzEtMy0xLTEtMTA1MDMz_a87ce396-acac-408c-aee4-3d2573930bbc">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from repayment of loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzItMS0xLTEtMTA1MDMz_f3825cfa-f392-471e-9837-f91ae3e48833">4,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzItMy0xLTEtMTA1MDMz_c37f1f4a-1aad-4bb5-812a-56493ce3724d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment for investment purchase</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:PrepaymentForInvestmentPurchase" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzMtMS0xLTEtMTA2NDQx_0117ff7e-de9b-4c49-9e52-af7cc961f93a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="ameh:PrepaymentForInvestmentPurchase" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzMtMy0xLTEtMTA2NDQ4_43ab0253-1af0-4eb5-a0bf-1c29fe3f7be9">4,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzMtMS0xLTEtMTA1MDMz_e8c27bd9-bdaf-49bf-a2f7-92b5d62e2f36">1,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzMtMy0xLTEtMTA1MDMz_4b193da4-1f6d-4e72-b986-3668bbd6cd73">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investment &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzQtMS0xLTEtMTA1MDMz_7027f4d7-ad0e-4fb0-a32a-604975f961d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzQtMy0xLTEtMTA1MDMz_b2684ed5-42c2-4679-bcaf-a354112c6659">1,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzYtMS0xLTEtMTA1MDMz_ca19a086-d713-40ae-8845-3d3580fd1cc9">18,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzYtMy0xLTEtMTA1MDMz_97364b28-3abd-4cb1-87fd-59f1a7fa1e2c">7,364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from consolidation of VIE</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzgtMS0xLTEtMTA2NDYz_fe48229a-4c03-4e6b-86a6-bee66e53da14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzgtMy0xLTEtMTA2NDcw_76d45d68-aeaa-4c4f-a557-2c384b59f741">3,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzctMS0xLTEtMTA1MDMz_9cfc56b1-4376-4255-84ed-4552794be553">6,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzctMy0xLTEtMTA1MDMz_1eed489d-494a-4a1d-96bb-53b133de3140">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution from investment - equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzgtMS0xLTEtMTA1MDMz_61715c24-8da8-4fa2-9e85-7cdbe1ff5113">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzgtMy0xLTEtMTA1MDMz_0bbf9855-e959-412c-a395-268e4f3c79d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to investment - equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:PaymentsToEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzktMS0xLTEtMTA1MDMz_70f78e53-4e6b-436c-9c3b-5f85c4e9ef2b">1,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-6" name="ameh:PaymentsToEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzktMy0xLTEtMTA1MDMz_f23f7c06-7f73-4c6b-b80b-e930e84f5074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in  investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDAtMS0xLTEtMTA1MDMz_a17be896-2306-4a0b-ae59-bdb9d28e9247">12,228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDAtMy0xLTEtMTA1MDMz_3d84132d-fdb6-4547-981b-eaa31067af0f">9,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDMtMS0xLTEtMTA1MDMz_36578f2d-826a-483c-9ae4-e43d35a1e5a4">12,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDMtMy0xLTEtMTA1MDMz_2c2ca38b-4412-4750-bd78-f7a384bd2c16">21,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDQtMS0xLTEtMTA1MDMz_aa544d4c-8605-40ee-a207-64eef0a74805">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDQtMy0xLTEtMTA1MDMz_521cbb1f-1143-429d-81f1-357687440d69">238,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDUtMS0xLTEtMTA1MDMz_b14f9625-9871-4561-83b6-83533d77a0bd">283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDUtMy0xLTEtMTA1MDMz_c25f10aa-ca36-439f-9d0e-b65f14a8034b">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDYtMS0xLTEtMTA1MDMz_acdb026a-2bc1-4cf4-8b8b-49202cf6b7e2">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDYtMy0xLTEtMTA1MDMz_d6fdc8ca-ed3e-4225-ba23-953bf1e7b44a">4,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDctMS0xLTEtMTA1MDMz_39b104ba-1fb4-490c-9518-b258aa436397">9,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDctMy0xLTEtMTA1MDMz_25e69e1c-8068-4968-a561-4969a8437a1d">2,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:ProceedsFromSaleOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDktMS0xLTEtMTA1MDMz_a2c8acf0-28c0-44c2-a2a7-35231215c598">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="ameh:ProceedsFromSaleOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDktMy0xLTEtMTA1MDMz_20043959-71f0-4dd2-9dcc-d814c29dbb8b">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:PaymentsToAcquireNonControllingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTAtMS0xLTEtMTA1MDMz_f94b5656-a215-4c71-be65-e078053ae3b1">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="ameh:PaymentsToAcquireNonControllingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTAtMy0xLTEtMTA1MDMz_92ff71a3-d954-45a1-bee4-d5ae5997a2a0">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTEtMS0xLTEtMTA1MDMz_ceb08edf-9003-48ed-9ac8-8236e25cc744">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTEtMy0xLTEtMTA1MDMz_3c9ff336-378d-4d25-a6ca-80c65251b147">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTItMS0xLTEtMTA1MDMz_724d405c-985b-4aa4-9bbf-27ce9d4f0c01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTItMy0xLTEtMTA1MDMz_343668e2-f141-44d8-b60f-af3f6fa7b677">40,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTMtMS0xLTEtMTA1MDMz_708cb759-6e88-4e48-8621-c956ccec05a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTMtMy0xLTEtMTA1MDMz_6546a1ed-40c5-45b8-8ea7-64596a9a4cbc">727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTQtMS0xLTEtMTA1MDMz_f36427fb-c138-40dd-b083-07982c9c88ee">19,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTQtMy0xLTEtMTA1MDMz_7c157d1f-4433-4c2f-9275-12dcc7dc79e1">38,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTYtMS0xLTEtMTA1MDMz_317e7327-82ec-4f3a-81a5-23af8261c76f">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTYtMy0xLTEtMTA1MDMz_b867d746-0f69-449f-9b0c-809d01552ebb">16,683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTgtMS0xLTEtMTA1MDMz_873b0838-de9a-4d35-ac9b-b9f488b4b6b7">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTgtMy0xLTEtMTA1MDMz_77c03f08-cb56-47a9-9c47-af42652db36b">193,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjAtMS0xLTEtMTA1MDMz_3cd78c27-f451-4f48-9431-31e0a236a109">234,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4becb57108e844a2af77734d782c9546_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjAtMy0xLTEtMTA1MDMz_78c81eb6-6532-48bb-a5df-2e2957d72f3c">177,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosures of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjMtMS0xLTEtMTA1MDMz_f4c1e849-877b-4072-9e32-ddbcc1f974af">22,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjMtMy0xLTEtMTA1MDMz_e022b7b2-bdbb-4057-b7aa-bde6bf90b29c">23,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjQtMS0xLTEtMTA1MDMz_5011ba52-9124-4bd9-8374-ae85fccbe850">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjQtMy0xLTEtMTA1MDMz_bf3a035f-d751-473e-a1ec-c69d3bef80ad">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend declared included in dividend payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjktMS0xLTEtMTA2NTUx_b654a448-44f8-4d30-a0b5-1d301eca4f84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4becb57108e844a2af77734d782c9546_I20210630" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjktMy0xLTEtMTA2NTU5_7d1ed002-0ebd-428e-ab99-237b23a3ec74">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset obtained in exchange for finance lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjctMS0xLTEtMTA1MDMz_5381cf00-7e54-4877-9a95-0d78c98ab6c7">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjctMy0xLTEtMTA1MDMz_4aadd921-72e3-4ed6-8310-df3df3741b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued in business combination</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjgtMS0xLTEtMTA1MDMz_a9a72748-e563-4257-8717-9221461b1369">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjgtMy0xLTEtMTA1MDMz_b7a0fc97-beb8-473e-894c-f28ce541638c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:CancellationOfRestrictedStockAwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNzAtMS0xLTEtMTA1MDMz_4253701b-11a1-4c3c-af0f-a0c496417a66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="ameh:CancellationOfRestrictedStockAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNzAtMy0xLTEtMTA1MDMz_500c056a-5569-4e72-ad3d-4ce8bef7a2e5">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:MortgageLoanRelatedToPropertySales1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNzItMS0xLTEtMTIyMjU0_743b1715-baa1-4b60-aadf-edb28085a9e8">16,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:MortgageLoanRelatedToPropertySales1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNzItMy0xLTEtMTIyMjYx_f7e21704-984a-4c06-9e02-277d5e19fd30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfMi0xLTEtMS0xMDUwMzM_97fd1e61-dc9d-4852-8e18-7deb0a39c7f4">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfMi0zLTEtMS0xMDUwMzM_d1b8e213-0b25-49dd-994c-c77674fa53a3">193,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfMy0xLTEtMS0xMDUwMzM_5f8d46d1-db13-4bc6-a30c-57364836ec42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfMy0zLTEtMS0xMDUwMzM_a62994e4-c346-4085-9aa8-3187f0a050fa">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfNC0xLTEtMS0xMDUwMzM_1bb2ccd5-cda8-452f-9c5e-665921f0b9f8">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfNC0zLTEtMS0xMDUwMzM_bc2ad816-7cad-4218-a4ca-86430b0a175f">193,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div id="i479e2a4965a945a4983dec200085612c_40"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTYzNTk_6864cc99-e9eb-45f4-a8e2-f9098da7fd5b" continuedAt="ib5c79eb6da214e8fb16643afb2445452" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="ib5c79eb6da214e8fb16643afb2445452" continuedAt="ic512575db8f24119ae13ad1db7ef8407"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) in December 2017 (the &#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and an accountable care organization (&#8220;ACO&#8221;) participating in the GPDC model. NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s ACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSOs and Affiliates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPAs and Affiliates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of <ix:nonNumeric contextRef="if607fd60c6ba4a7fb898dea28d8f0d05_D19990701-19990731" name="ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNDY5Mg_10058511-7a0f-4a72-b2db-d2a8e51b484b">30</ix:nonNumeric> years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ic512575db8f24119ae13ad1db7ef8407" continuedAt="i3ca4c4ea531240368d90ba6ae6085729"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) and AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $<ix:nonFraction unitRef="usd" contextRef="ife69969a467049b7822c63de16e05840_I20190930" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNTY4Nw_7c4bb127-7bea-408a-88ff-44e7f065702a">545.0</ix:nonFraction>&#160;million loan to AP-AMH, pursuant to a <ix:nonNumeric contextRef="i5d59e759a6d143e7b8673d525e1641d4_D20190901-20190930" name="ameh:FinanceReceivableTermOfReceivable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTYzNjA_872cb2a7-641a-44df-907a-ec36444c11e5">10-year</ix:nonNumeric> secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="ife69969a467049b7822c63de16e05840_I20190930" decimals="INF" name="ameh:FinanceReceivableStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNTgwOQ_419f7a0a-2dc8-4aa8-ae05-ed84b3c59a37">10</ix:nonFraction>% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&#8217;s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="ife69969a467049b7822c63de16e05840_I20190930" decimals="INF" name="ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjQzMQ_be7ec751-4223-4072-a919-f51f59c64626">10.75</ix:nonFraction>% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $<ix:nonFraction unitRef="usd" contextRef="ife69969a467049b7822c63de16e05840_I20190930" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjQ2Mw_7c4bb127-7bea-408a-88ff-44e7f065702a">545.0</ix:nonFraction>&#160;million private placement, where AP-AMH purchased <ix:nonFraction unitRef="shares" contextRef="i25b2318042034ef8ada1dff3ae0fa2ee_D20190901-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjUwOA_9c256d96-d329-42c8-a2f7-512360427df9">1,000,000</ix:nonFraction> shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $<ix:nonFraction unitRef="usd" contextRef="iab9ce1fe319c40f3b5143a3c664cb2f8_I20190930" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjY1MA_1c56e6c9-c9e9-46d3-8dc9-e790e09fc998">300.0</ix:nonFraction>&#160;million private placement, where APC purchased <ix:nonFraction unitRef="shares" contextRef="i8b9dc946cce64aeda656fa396f8ac5d9_D20190901-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjY5Mg_792896ac-a7f6-4ab1-82fc-2c0b87d3e09b">15,015,015</ix:nonFraction> shares of the Company&#8217;s common stock and in  connection therewith, the Company granted APC certain registration rights with respect to the purchased shares.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (&#8220;Excluded Assets&#8221;). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC&#8217;s ownership in ApolloMed was <ix:nonFraction unitRef="number" contextRef="i5b76bb6ee687447b91d65e6261285c67_I20220630" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfODI4NA_7b33c71f-b00b-4c1e-9ee2-b1c024fb343a">20.02</ix:nonFraction>% as of June&#160;30, 2022 and <ix:nonFraction unitRef="number" contextRef="i25ab29ee2b194190ba48aff50a9eca6a_I20211231" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfODMwMA_03a0132c-518b-448a-aedc-668f11813d77">19.68</ix:nonFraction>% as of December&#160;31, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of June&#160;30, 2022, APC owned <ix:nonFraction unitRef="number" contextRef="i05247cd849de40dc8290e15a895f802d_I20220630" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfODc5MA_9940b24a-60d8-456a-b807-ae4b19747923">44.50</ix:nonFraction>% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group of Southern California (&#8220;DMG&#8221;), and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a <ix:nonFraction unitRef="number" contextRef="i1ed4c08298bb425782e0cb29c6843164_I20220630" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTAwOTA_e0338e35-1c92-4e2e-ae78-1cfd376287b5">100</ix:nonFraction>% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i3ca4c4ea531240368d90ba6ae6085729" continuedAt="i4caab5a7e81347a0860ea4f6cf02abaf"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through <ix:nonFraction unitRef="plan" contextRef="i910383234e6d43a5b4e0907b9f2f7fa3_I20220630" decimals="INF" name="ameh:NumberOfFederallyQualifiedHealthPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTEwODg_f99c34ce-b8d6-4c43-af24-a5b26c021146">three</ix:nonFraction> federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of <ix:nonFraction unitRef="clinic" contextRef="i87ad3733808d4ed680a72e6a21ac142d_I20220630" decimals="INF" name="ameh:NumberOfFamilyPracticeClinics" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTE0Mzk_a84502e6-a216-4464-a9b6-4496a2179ddf">three</ix:nonFraction> main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased <ix:nonFraction unitRef="number" contextRef="i9c45553f306743bb86ff185b451d6f0d_I20190930" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTE2ODY_062eea82-5781-4621-909a-5bfdf7dab8f1">100</ix:nonFraction>% of the shares of capital stock of AMG.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its <ix:nonFraction unitRef="number" contextRef="i447febb4f2414ccebd0319ff3c12007a_I20220630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTE4ODc_02b1ec89-db07-4ae5-b291-ed2e0fbcfbea">40</ix:nonFraction>% investment in DMG, under the equity method of accounting. In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="icd0b89cf94234e64a6168f357c2f6a9a_D20220101-20220630" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTIzODM_7273821f-4575-4047-8cc7-c05e3273be60">three years</ix:nonNumeric> from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i784b5366266c4d4796ca24adc088b8b9_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTI1MTY_ff4d9ae0-9c21-45e6-8d0a-d30c6e7928ff">8.5</ix:nonFraction>&#160;million as of June&#160;30, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="id084c1a48f8149359167ebc980bdd4fc_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTI4MDc_d14db35d-670a-498a-a59e-564b03e57b3a">100</ix:nonFraction>% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a <ix:nonFraction unitRef="number" contextRef="i34200d16ebcc4e9bb848e910e7f98470_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTI5NDY_73a1c8ad-1212-4b5b-88b4-025b012f5413">50</ix:nonFraction>% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants, as well as vacant land that is being developed. MPP, AMG Properties, and ZLL are <ix:nonFraction unitRef="number" contextRef="id084c1a48f8149359167ebc980bdd4fc_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTMyNDE_d14db35d-670a-498a-a59e-564b03e57b3a">100</ix:nonFraction>% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments, as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, AP-AMH 2, a VIE of the Company, purchased an <ix:nonFraction unitRef="number" contextRef="iaa25ff896fef4a548c62b034ce2acbd1_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTQyMDg_41ec9a05-adc8-4c31-8d74-00ad8cc304bb">80</ix:nonFraction>% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#8220;APCMG&#8221;), a primary care physicians&#8217; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Apollo Medical Holdings, Inc. acquired <ix:nonFraction unitRef="number" contextRef="i2fb19f36b5434e40bf55b16ef65f34a6_I20210831" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTQ1Njc_44be5d67-1b06-4068-b021-192a4b50c2d8">49</ix:nonFraction>% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i156059eff9374f1087488e472de06542_D20210801-20210831" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTQ3MTE_0d2cdb0d-d1fb-47a6-b3aa-b506303f0de8">4.0</ix:nonFraction> million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3 &#8212; &#8220;Business Combinations and Goodwill&#8221;). The Company is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="i156059eff9374f1087488e472de06542_D20210801-20210831" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTUwODk_099b0abd-208a-4208-8e7b-f6db3c2e6ee6">three years</ix:nonNumeric> from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i8c78dbde3d4043f6906cce86f5541c87_I20220630" decimals="-5" name="ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTUyMjU_5cdf35da-d3d2-465c-9e1a-3611662b6461">4.2</ix:nonFraction> million as of June&#160;30, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i4caab5a7e81347a0860ea4f6cf02abaf"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO, GPDC / ACO REACH</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO began participating in the NGACO Model of CMS in January 2017. The NGACO Model was a CMS program that allowed provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model. With the ending of the NGACO Model on December 31, 2021, APAACO applied, and has been selected by CMS, to participate as a Direct Contracting Entity (&#8220;DCE&#8221;) in the standard track of CMS&#8217;s GPDC Model for Performance Year 2022 (&#8220;PY22&#8221;), beginning January 1, 2022. CMS has since redesigned the GPDC Model in response to Administration priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience, and renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (&#8220;ACO REACH&#8221;) Model. The ACO REACH Model will begin participation on January 1, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNDM_7745d146-f79d-4482-bf8b-9bef8f407aa5" continuedAt="ia1cc5f79471943dc88d429515c50397b" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ia1cc5f79471943dc88d429515c50397b" continuedAt="idb917f0db75f47f4bbf2dd9882265f46"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTc5OTg_1dfc45e3-83c0-44f5-9ece-71dbaeaf5731" continuedAt="i8e5fb3dd7afd4d6baea53d0d0dfc8b6a" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8e5fb3dd7afd4d6baea53d0d0dfc8b6a">The accompanying consolidated balance sheet at December&#160;31, 2021, has been derived from the Company&#8217;s audited consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2022, and for the three and six months ended June&#160;30, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</ix:continuation> Operating results for the three and six months ended June&#160;30, 2022, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or any future periods.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNTc_a1ab3b82-be59-4c4f-a244-38eea37d8c1a" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three and six months ended June&#160;30, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s consolidated VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, ICC, Alpha Care, Accountable Health Care, and AMG.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTQ5NzU1ODIwMTAwOQ_d7c8ad8c-488e-4b68-bf1b-068b09e17076" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications were made between unrealized loss (gain) on investments and other income (expense) on the accompanying unaudited consolidated income statements for the three and six months ended June&#160;30, 2021. They had no effect on net income, earnings per share, retained earnings, cash flows or total assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMjk_afcbc1c6-5487-474b-8242-21eb239125fa" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMjI_5f8afad1-2f33-4151-b141-c509c01effd9" continuedAt="ifbdefb23620344eebc20db7680d7bcf1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="idb917f0db75f47f4bbf2dd9882265f46" continuedAt="i9835f03078b64bcf8da108296524245b"><ix:continuation id="ifbdefb23620344eebc20db7680d7bcf1" continuedAt="i8a7dfde55f9b4f2ea550b4de66eddc37"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8a7dfde55f9b4f2ea550b4de66eddc37">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.</ix:continuation><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMDU_edf97716-3047-40cc-99a2-9eb1fa225100" continuedAt="i80b76672ce2d448ab660eefa518153af" escape="true">Business Combinations</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i80b76672ce2d448ab660eefa518153af">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</ix:continuation></span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMjM_9862add5-10c7-4a46-9fb8-f6d815e731b8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNzQxMQ_43e46e34-894e-4bf9-923d-d89562f67263"><ix:nonFraction unitRef="segment" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNzQxMQ_53ff488b-f11d-4a85-929a-765cf2c0a503">one</ix:nonFraction></ix:nonFraction> reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in <ix:nonFraction unitRef="segment" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNzY4OA_43e46e34-894e-4bf9-923d-d89562f67263"><ix:nonFraction unitRef="segment" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNzY4OA_53ff488b-f11d-4a85-929a-765cf2c0a503">one</ix:nonFraction></ix:nonFraction> reportable segment.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i9835f03078b64bcf8da108296524245b" continuedAt="ibfe3be1aa1cf4c398f428612894076c0"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNzU_5ebcad39-6b96-4470-8dc7-017f5b8245b9" continuedAt="ic5c8a1eb681743878eb88e1b4b268b5f" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic5c8a1eb681743878eb88e1b4b268b5f">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.</ix:continuation> As of June&#160;30, 2022 and December&#160;31, 2021, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfODQ1Mw_da4fb94a-933e-4c54-a2fc-3f8b0f27f11c">277.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfODQ2MA_3dff91fb-80e2-4ee3-9bf6-ee3a33ced759">285.9</ix:nonFraction> million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTc5OTk_c082c526-20b0-4322-8b92-20288ce290f1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from <ix:nonNumeric contextRef="ic233432b45644a51a10accdc3eb97bec_D20220101-20220630" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMTI_f29f27bb-82f2-4386-9e2b-408fe2cc86f3">four months</ix:nonNumeric> to <ix:nonNumeric contextRef="i91813fbebd0e4a15b55763b7872a8b9d_D20220101-20220630" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfOTA3OA_eade061b-118d-43c5-8d06-c6e235b2a338">24</ix:nonNumeric> months. As of June&#160;30, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i47269e9c8fe6491f87cf108347ce40c5_I20220630" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfOTE1Ng_f9522de0-f016-4991-bfe7-696944d9c7ed">25.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if90f9dac9afe48d79cdaf54cd044093f_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfOTE2Mw_fa2c261f-73ad-4a8e-936f-0ef2f2f353dc">25.0</ix:nonFraction> million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. Equity securities with low trading volume are determined to not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Nutex Health Inc. (formerly known as Clinigence Holdings, Inc.) (&#8220;Nutex&#8221;). The common stock of a payor partner was acquired as a result of UCAP selling its <ix:nonFraction unitRef="number" contextRef="i7357682f6a2743c2ac4f7e64822ecf5d_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTAxNTM_874b70a5-7eec-484c-b453-c09685a3152f">48.9</ix:nonFraction>% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional shares of common stock if certain metrics are not met (such additional shares, &#8220;contingent equity securities&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i76567744587f40f8a8c7ac4dc85fa166_D20210901-20210930" decimals="-5" name="ameh:PaymentsToAcquireCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTA0Nzc_af777c78-d379-429f-a3ee-94f13ae2fe04">3.0</ix:nonFraction>&#160;million. The common stock is included in investments in marketable securities in the accompanying consolidated balance sheets. In May 2022, the Company exercised the warrants and subsequently recognized the shares within investments in marketable securities in the accompanying consolidated balance sheet. The contingent equity securities are classified as derivatives and included in prepaid expenses and other current assets in the accompanying consolidated balance sheets. See Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#8221; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;30, 2022 and December&#160;31, 2021, the equity securities were approximately $<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTEwNjU_ba571625-140c-4c20-8aa6-f836bae53264">14.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTEwNzI_b2b19bfd-61e1-4929-a24c-c1daeb57ab57">28.4</ix:nonFraction>&#160;million, respectively, in the accompanying consolidated balance sheets. Gains and losses recognized on equity securities sold are recognized in the accompanying consolidated statements of income under other income. <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNjA0NzMxNDAxMTQ1Nw_a29dbfc3-9810-4b3c-ad16-e7018c983275" continuedAt="i0c3441eaffad40a5bdab02257437066c" escape="true">The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><ix:continuation id="i0c3441eaffad40a5bdab02257437066c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total (losses) gains recognized on equity securities  </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfMy0xLTEtMS0xMTM2NzM_9d053858-b1c9-4d4f-96c1-ae9c184ee9c4">4,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfMy0zLTEtMS0xMTM2ODA_a1ab3faa-ca7f-4b7a-9940-a614d13a75a0">83,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfMy01LTEtMS0xMTM2ODc_2e9ba6d7-f51a-460d-af76-8cf05099b436">14,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfMy03LTEtMS0xMTM2OTQ_c5891ad9-8b42-4f4b-8dc9-98512a554525">83,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Gains recognized on equity securities sold  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNC0xLTEtMS0xMTM2NzM_88eafdb5-162d-4c78-be2a-4ca06f5bc87e">2,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNC0zLTEtMS0xMTM2ODA_c64459f5-03d5-4efd-9144-82fff8c9036d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNC01LTEtMS0xMTM2ODc_e499b33e-59ba-4f16-9570-adda77f20e4b">2,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNC03LTEtMS0xMTM2OTQ_921b268d-d0cd-4b19-8bd8-57b26a302018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Unrealized gains (losses)  recognized on equity securities held at end of period  </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNS0xLTEtMS0xMTM2NzM_519cb2a9-1f95-4ec5-a497-0f6b85512795">2,059</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNS0zLTEtMS0xMTM2ODA_44247948-8001-431b-b997-73e40afb1407">83,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNS01LTEtMS0xMTM2ODc_1a7cddf1-53f7-47c1-a6fd-fc04654a8657">12,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNS03LTEtMS0xMTM2OTQ_f81c0572-1722-4e6c-bd26-50af98373599">83,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ibfe3be1aa1cf4c398f428612894076c0" continuedAt="i566a039c80044cc58e87cc14bf0812d4"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNzY_97e5842b-18bb-4c7c-93a5-63886beea57b" continuedAt="i277d97c76fdb4066be6131b7e3ac0ad2" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivable &#8211; related party consist of promissory notes from a related party payee that accrues interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTI1OTU_5314c788-3bf1-4e18-ba28-75c21144e204">18</ix:nonNumeric> months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i566a039c80044cc58e87cc14bf0812d4" continuedAt="i5ef99df5792248df856be031a4e07c89"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i277d97c76fdb4066be6131b7e3ac0ad2" continuedAt="i362223a5c4224a7ab8c5eca891fbdc52">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</ix:continuation></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i362223a5c4224a7ab8c5eca891fbdc52">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMDY_aed4a660-09a1-4848-8fb3-2c918be81406" continuedAt="i5076520e55c841bb9edb6a07a8c6e180" escape="true">Concentrations of Credit Risks</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5076520e55c841bb9edb6a07a8c6e180">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.</ix:continuation> <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMDA_3102ed47-4ba6-4c52-8b01-95e10d9d76b8" continuedAt="i114d9f7539334d399546b37805e5a9b6" escape="true">The following table presents disaggregated revenue generated by payor type for the three months ended June&#160;30, 2022 and 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i114d9f7539334d399546b37805e5a9b6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae5121d03a9a469ba0192b0be3dd0589_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfMy0xLTEtMS0xMDUwMzM_41b095cf-6458-4b98-8e67-9b2f6d79d511">42,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c6d1fd56384e02a5c02ddcb77d7181_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfMy0zLTEtMS0xMDUwMzM_8bd46884-683c-469a-9595-73dd3e30fc64">33,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a54db22a27477ea703d051e51b7b7e_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfMy01LTEtMS0xMDUwMzM_d64deb87-e496-4efd-ad6d-c15c201d20a4">84,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a475831b3ad4c928ce6c91ff40dfea6_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfMy03LTEtMS0xMDUwMzM_62e4a676-8a0b-4258-bfbf-8a995d5e0590">65,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd641546fc50456c8010d886a4880874_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNC0xLTEtMS0xMDUwMzM_3fbb1417-ac52-44b6-800b-941e3d3311fd">142,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1650503a7572464f88699d1599fc1c65_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNC0zLTEtMS0xMDUwMzM_a1d71249-e91f-4fb3-b5ea-0034e61b405a">64,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ebf943246644d74b344ccfecdd85d8f_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNC01LTEtMS0xMDUwMzM_f52f724a-95aa-4179-94cc-c2969b9d6d3e">276,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2f76f1af7d4a4495f8e7c418f0efb7_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNC03LTEtMS0xMDUwMzM_7ec89b3c-564c-43d9-8c89-3da51e74a556">128,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e97022e423b48fea6becfdd26749dca_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNS0xLTEtMS0xMDUwMzM_b4eb933f-ba23-4419-9dcd-cde4c3933b89">70,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2badd64b1fb94f4b81b6475e7e2cd34d_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNS0zLTEtMS0xMDUwMzM_a028f153-4ef4-4f58-a12b-8dbf8b62224b">68,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb83156e733243f9acced43816434206_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNS01LTEtMS0xMDUwMzM_b10612f1-0082-4e61-9d34-fef7ba6e9d3f">142,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ac7abfe0eed4e0d8d7b27ded03a5f9f_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNS03LTEtMS0xMDUwMzM_34132954-46f8-48a3-a591-20c939900a38">138,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15db0ac3886408985bfd7a1c444afb4_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNi0xLTEtMS0xMDUwMzM_b71cf2d0-fc81-45bb-9800-6859d02f6c8a">14,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d317985c314aa188d6771db1792d94_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNi0zLTEtMS0xMDUwMzM_37581162-d869-4680-a804-62bc78a00bc9">9,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0d411993ee4352bb911f910f1c404e_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNi01LTEtMS0xMDUwMzM_999857f2-1b6f-4bf5-9a04-b2690f4f048f">30,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aae7fb197fa4ed39a801149bd5cd532_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNi03LTEtMS0xMDUwMzM_ac5a5cc1-30e2-4a00-ad50-db6095285c9f">19,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNy0xLTEtMS0xMDUwMzM_8a301919-ebe6-4d4c-9928-6c3b6e04c41b">269,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNy0zLTEtMS0xMDUwMzM_887996e8-bf69-4be8-b7b5-d791988f52d8">175,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNy01LTEtMS0xMDUwMzM_8230003d-9295-4dda-a297-cab123454118">532,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNy03LTEtMS0xMDUwMzM_eac861c9-50fc-4835-9850-ac243b213a0d">351,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNTE_91072a06-5e4d-417b-bc05-4c4a45d720b8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i357d85714b284f7ab7bee3970e56bf57_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfMy0zLTEtMS0xMDUwMzM_d5ffb759-8e91-4528-bcc5-9cb618d812a5">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i038860cc692f4bb888a5b7ef1486e53a_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfMy03LTEtMS0xMDUwMzM_15ba6763-de31-48ad-8330-880e313328df">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide23e89dd9c645c281e278662449b4a1_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNC0zLTEtMS0xMDUwMzM_05c2ee8d-5833-48dc-b5e4-cd2acf7b52cd">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ee8745d85894cceb97642891fcbce9f_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNC03LTEtMS0xMDUwMzM_58d6105e-6eb0-434f-9422-181b4a867253">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c92edeb4a78489988df0cc478c477de_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNS0xLTEtMS0xMDUwMzM_1c1f8df2-2ef5-4a58-a5d9-bbf3f437efe3">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia113d3dba3ad4fa2ba4bbae8dbeb4ab8_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNS0zLTEtMS0xMDUwMzM_0b7c33d7-482f-4fc3-bae1-277da0b7a80b">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e0285c80acf4fbe88b94c417e7bfb83_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNS01LTEtMS0xMDUwMzM_422fbcba-48ae-40a8-9d6c-6b3b67ef68a9">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93342f091b4c43cc846afa98f4943123_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNS03LTEtMS0xMDUwMzM_e15397d4-0add-4215-90c9-7f62688321ee">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9f48dc88c7645149c0e2929fbcd7d42_D20220401-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNi0xLTEtMS0xMDUwMzM_ad364121-a1bc-4820-a3db-8708aad9b257">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ee529e7087e4e4c9dacd669a0e96636_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNi01LTEtMS0xMDUwMzM_4f50a9f5-11bd-4499-8a50-b23a21dc151b">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13934575582a4f6586ab0fd0252a2087_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfMi0xLTEtMS0xMDUwMzM_f6e9bfe0-a087-46e8-b91b-ae5537bc03d5">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb54c28e4db64ef2a4baf3b30dcfcf81_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfMy0xLTEtMS0xMDUwMzM_0f55b7e6-074a-4865-ae26-8cb5ca3cd69f">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2afd3f4b4d624a81a9706ec95cb3912e_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfMy0zLTEtMS0xMDUwMzM_b655524b-2d27-4bd8-8e83-f4845be49574">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie41c112f00c54f2ab3512eeb222e2e58_D20220101-20220630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfNC0xLTEtMS0xMDUwMzM_54af0129-1516-41dd-b103-be46d720bf17">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i460a5116e6b044ad9ebfe9b19f40bfcf_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfNC0zLTEtMS0xMDUwMzM_f52a8c88-d5ab-4810-a891-72693de30030">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i5ef99df5792248df856be031a4e07c89" continuedAt="i53fb05b68ed647e19e7e56f56461bbad"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMzg_63cacda5-d4bd-4f8a-a008-a0288824dd0b" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMDc_befcb014-e98f-4a5c-8739-e1b1489129af" continuedAt="i8a2568c7dd0b48a6957a15920ef8abee" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of June&#160;30, 2022, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMy0xLTEtMS0xMDUwMzM_6553bfe4-2ce7-43b1-85bf-6fb93f3b3522">70,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMy0zLTEtMS0xMDUwMzM_d51586ed-45e1-4a8c-b3e2-08737a177696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMy01LTEtMS0xMDUwMzM_667f2a60-9ac8-47f5-bf29-3c37c546ef1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMy03LTEtMS0xMDUwMzM_68f7b116-285a-46b6-a722-d4f8ada3ba52">70,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNC0xLTEtMS0xMDUwMzM_952c3408-d7e2-4695-b9a9-1e4b2e54085d">25,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNC0zLTEtMS0xMDUwMzM_d6da0102-6cd1-4b07-83cf-16ab33d3ff49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNC01LTEtMS0xMDUwMzM_aa50de87-2f48-45f6-835c-406d1212c9f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNC03LTEtMS0xMDUwMzM_a0a45d0d-0a60-4314-86f6-b2cf3eee77a9">25,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNS0xLTEtMS0xMDUwMzM_3fc4d524-fded-4980-9695-2a55eef07f8a">14,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNS0zLTEtMS0xMDUwMzM_72a20835-e058-4c45-8b99-07372ca6e54d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNS01LTEtMS0xMDUwMzM_d40e70e7-64fb-44c1-bb50-592bc2fa1a5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNS03LTEtMS0xMDUwMzM_56c1e21d-0dcf-45f0-abf2-b5905e6737be">14,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f75606e37874c68b458b76513cab432_I20220630" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNi0xLTEtMS0xMDUwMzM_387f64d8-a5fa-495f-a24e-5233bcd430cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i413730c561f44bcba0f3b2bc0c6bd449_I20220630" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNi0zLTEtMS0xMDUwMzM_3427d13d-e24c-4550-86ad-aa4f9e901b6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c80c14bf5e41c684783fbcf0d76f0e_I20220630" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNi01LTEtMS0xMDUwMzM_beaa3ca0-f5eb-4437-b125-f7aca996bed5">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40b21462ffcb4d248cd6645a35f7a449_I20220630" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNi03LTEtMS0xMDUwMzM_c01d8bb9-221c-4a57-8dfc-b1668381fc45">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb00088282a4dc5afc8c52b83d0ac33_I20220630" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOC0xLTEtMS0xMDUwMzM_8da3baaa-aefa-4cc5-ba76-8379043fffdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7561cc5bf6ca4e669a3141d449e8fa2c_I20220630" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOC0zLTEtMS0xMDUwMzM_756f18f6-050a-42c5-b781-08db6a947551">1,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91f40c8ef0543eeb07c574e983655c3_I20220630" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOC01LTEtMS0xMDUwMzM_af9d5a1c-8a8e-4b70-b606-c79bb73a7f33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68316a8a436c493fabb213bb9156c632_I20220630" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOC03LTEtMS0xMDUwMzM_fe82ac09-a6a1-491f-b528-8fdd05abfa3e">1,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOS0xLTEtMS0xMDUwMzM_e56c631c-aeb9-4d4e-bb13-99af8f628f7e">109,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOS0zLTEtMS0xMDUwMzM_41cdd7f6-e12d-4447-b631-87464c5f39c2">1,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOS01LTEtMS0xMDUwMzM_28d1d430-db9f-4fc3-8e0d-0f1869679ad9">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOS03LTEtMS0xMDUwMzM_8a1ba0b1-37c2-4138-85e3-0a588e2896e9">114,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTItMS0xLTEtMTA1MDMz_74db78c9-98fe-4323-9e40-6106fb32e164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTItMy0xLTEtMTA1MDMz_e229a12c-2edd-4fb8-82a0-4ec98f5f6d43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTItNS0xLTEtMTA1MDMz_08457c20-f1fb-4f38-aa3b-c9177a06d4cf">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTItNy0xLTEtMTA1MDMz_aeb01a89-7d96-4f4a-bf9a-ccef2c60f209">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTMtMS0xLTEtMTA1MDMz_ed8e6289-87fa-4fab-a0bd-91e1efa0d36e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTMtMy0xLTEtMTA1MDMz_0c98485e-a344-448e-b342-01918effe72d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTMtNS0xLTEtMTA1MDMz_d21e8b1a-8841-4be9-a61c-f936d9e0b4c2">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTMtNy0xLTEtMTA1MDMz_416adf33-5aca-4045-aa02-7d353ab7aab5">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i53fb05b68ed647e19e7e56f56461bbad" continuedAt="i37a076d06419449780abf9af412e2556"><ix:continuation id="i8a2568c7dd0b48a6957a15920ef8abee"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMy0xLTEtMS0xMDUwMzM_661c59b5-d180-4430-b798-16395fb99c8f">114,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMy0zLTEtMS0xMDUwMzM_3cfb3af8-2e3d-4468-b768-6de2b5095270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMy01LTEtMS0xMDUwMzM_18ab07be-025e-4af1-87a2-7c065e8accaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMy03LTEtMS0xMDUwMzM_ff5062e2-cb07-414f-b542-a53e3c5dd9fd">114,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNC0xLTEtMS0xMDUwMzM_1feb34c0-be1c-45bd-ad80-86653885047e">25,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNC0zLTEtMS0xMDUwMzM_26285b1f-43d6-4bc9-b3b2-3890af3c0631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNC01LTEtMS0xMDUwMzM_ef6ded9f-da44-40a6-8ed4-93489973d97c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNC03LTEtMS0xMDUwMzM_3927fec5-f6b8-4cd6-b618-621e2855a0c6">25,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNS0xLTEtMS0xMDUwMzM_c908018c-b7f7-4b7f-81af-25ccac109c5f">24,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNS0zLTEtMS0xMDUwMzM_8a87f18d-48df-497a-bdd0-e95b8cbc4dc4">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNS01LTEtMS0xMDUwMzM_2a8631d0-2fd9-4098-84fe-8c6b6aa3ee88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNS03LTEtMS0xMDUwMzM_3909b5c3-aea0-45d5-9105-1e2953763d5f">28,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973177a3369f4442a2135e79cc6ef154_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNi0xLTEtMS0xMDUwMzM_3031e51e-89a9-47b2-9f6a-daacec18c465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5acd511331764617bdfd48af40f038ae_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNi0zLTEtMS0xMDUwMzM_8dc3318c-272f-4250-8127-6dc0204b7b0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86fb54a8136643a1965dda0ad2e9f39b_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNi01LTEtMS0xMDUwMzM_d8c9d8bc-3cb8-4e51-9938-9dba4ccefd26">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i934b31b2b19e4a32b408f256d19446bf_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNi03LTEtMS0xMDUwMzM_71f77218-b89d-4863-b3dc-995587992d14">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122754df236048089b5aad3001c4b1c7_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNy0xLTEtMS0xMDUwMzM_fcd2dce0-c67f-49eb-9fe0-2fdfd5a9a8b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36676e73486c494b80fb603caae18d98_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNy0zLTEtMS0xMDUwMzM_93a1da4b-c109-4bb7-a26e-04d1395b94a3">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a386beebfbf4060bbe4c09d5f5884a1_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNy01LTEtMS0xMDUwMzM_e4ef0f09-033a-4a96-b2a5-7002add7ff8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b68bdf1a0ce449889193821c0c74169_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNy03LTEtMS0xMDUwMzM_1da7f0e5-7c60-4697-aee8-3e76d5d7cddc">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfOC0xLTEtMS0xMDUwMzM_e22ea9e3-9ddd-4e2b-ace8-9c1fae03d673">163,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfOC0zLTEtMS0xMDUwMzM_a469c103-91cb-4656-b1f5-9953df418bae">5,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfOC01LTEtMS0xMDUwMzM_ae089a3d-e36e-4397-96bc-1f88101fc269">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfOC03LTEtMS0xMDUwMzM_bab30f92-4541-49af-b0b6-47bf69737e45">173,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTEtMS0xLTEtMTA1MDMz_d4f8e1b5-9d95-47ef-b986-6c140f2da0c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTEtMy0xLTEtMTA1MDMz_7cd86321-d3e5-43b0-8c9b-1ee9994e1533">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTEtNS0xLTEtMTA1MDMz_205a3c43-fd71-4ab6-808b-32e9502edbab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTEtNy0xLTEtMTA1MDMz_11b8beb3-8aa7-41dd-b106-798cae5f9da7">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTItMS0xLTEtMTA1MDMz_98d49293-c7be-4e8c-be4e-854fefd80a24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTItMy0xLTEtMTA1MDMz_6a0bef62-05c3-4c69-9e5b-a259daf63479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTItNS0xLTEtMTA1MDMz_70401fe2-f7a9-403b-9087-200fc06535a9">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTItNy0xLTEtMTA1MDMz_56ab8bdf-3f7d-4062-b54b-7db893fdd7fb">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTMtMS0xLTEtMTA1MDMz_bacd1db4-d04f-403b-8082-196256e91d47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTMtMy0xLTEtMTA1MDMz_1e1e349e-e39b-4027-93b8-394bcc9fd1b1">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTMtNS0xLTEtMTA1MDMz_673d6384-09dc-456e-be76-a59f054b777d">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTMtNy0xLTEtMTA1MDMz_345eb799-d6bc-42f8-9ea8-45e2cb4b3dc3">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the six months ended June&#160;30, 2022.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMzI_c9f145f1-c913-42f0-b50f-6a99636d1c13" continuedAt="i791d189566584b52934f2ef3cb4cbc5e" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i791d189566584b52934f2ef3cb4cbc5e">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</ix:continuation> The Company determined that there was <ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTkwNzE_50b28314-57ad-4c83-bb40-48c64129b677"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTkwNzE_5d8d4970-f071-4f3c-8bf6-2ac7689f5aee"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTkwNzE_ba1f5924-adc0-4c93-9fa2-afb7ad68cbc9"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTkwNzE_f502ec42-7eb1-475b-8697-b4058ab0b694">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its finite-lived intangible or long-lived assets during the six months ended June&#160;30, 2022 and 2021.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMzM_3c000f77-3d26-4e4e-882f-39d63ddff6cc" continuedAt="i3197d6ad9ce84fc3a5c38d8be1e33d86" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i37a076d06419449780abf9af412e2556" continuedAt="i01b76e6e44a94f598f1b5bb9bda4738c"><ix:continuation id="i3197d6ad9ce84fc3a5c38d8be1e33d86"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s <ix:nonFraction unitRef="unit" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTk4MDU_03aaf61d-a29c-48bd-b6a8-4b86d3965760">three</ix:nonFraction> reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjExNTU_0353c53b-9318-4546-bdca-b2ae01efb6b5"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjExNTU_1c435997-e41c-47fe-b525-c4ffb6de4ada"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjExNTU_5b9c7cd8-26e9-474d-9473-525e75763380"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjExNTU_a58644a2-18e7-4b0d-8fa3-4f908115fc81">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its goodwill or indefinite-lived intangible assets during the six months ended June&#160;30, 2022 and 2021. </span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTc5OTU_fca633ba-9acf-4157-9867-27022f2811bd" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was <ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjIzMTM_2e33b91b-6128-40cd-b271-a12faec59bba"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjIzMTM_808ebd70-bbf7-4bf7-91b6-968ac764a36a">no</ix:nonFraction></ix:nonFraction> impairment loss recorded related to equity method investments for the years ended June&#160;30, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:HealthCareCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNzI_d8c4f4ce-e7f3-47fe-92f2-614154944816" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, APCMG, and Jade (the &#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i01b76e6e44a94f598f1b5bb9bda4738c" continuedAt="i17549011038d4676b3530798bccd58f2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:FiduciaryCashAndPayablePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMTk_cb262b91-ef77-4d27-8ed4-11c547ff1429" continuedAt="ie4e22b1a66a54bbcb0d6ad0e82e6beb0" escape="true">Fiduciary Cash and Payable</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie4e22b1a66a54bbcb0d6ad0e82e6beb0">The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.</ix:continuation> The fiduciary cash balance of $<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-5" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjQ2NjY_bec66807-63ea-4934-b9fe-3c897d1d75d3">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-5" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjQ2NzM_6846c0b3-17d9-477c-b8c2-5d1ea60c5a08">10.5</ix:nonFraction> million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNjY_be1edf3f-d717-4be3-8caf-4502d772a527" continuedAt="ie0e7539bbff945e0a5e0a2f346c4232d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of June&#160;30, 2022, the fair value of the interest rate swap was $<ix:nonFraction unitRef="usd" contextRef="i55dadf9db838467e8bd65105322d821f_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjU5NjU_8a324ba3-2a9a-43e5-8a8b-9bbd3882bb1e">1.8</ix:nonFraction> million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $<ix:nonFraction unitRef="usd" contextRef="i83ea699729524e1aab10b333d7661bd6_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjYxMDk_c65a0279-2482-44fd-bd0c-5da2cb2964b8">1.1</ix:nonFraction>&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $<ix:nonFraction unitRef="usd" contextRef="i9094212bb5af45d98da492230880c142_D20210901-20210930" decimals="-5" name="ameh:PaymentsToAcquireCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjYzNzg_fe5e652a-02b2-40a7-98cc-cf66d11d700b">3.0</ix:nonFraction>&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. In May 2022, the Company exercised the warrants and the shares were subsequently presented within investments in marketable securities on the accompanying consolidated balance sheets. The shares are classified as Level 1 since the quoted market prices from reputable third-party brokers are available in an active market and unadjusted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contingent Equity Securities</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie0e7539bbff945e0a5e0a2f346c4232d">In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Nutex, ApolloMed is entitled to additional common stock if Nutex does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered to be derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The Company determined the fair value of the contingent equity security using a probability-weighted model, which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value.</ix:continuation> As of June&#160;30, 2022 and December&#160;31, 2021, the contingent equity securities were valued at $<ix:nonFraction unitRef="usd" contextRef="i40b21462ffcb4d248cd6645a35f7a449_I20220630" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjgwODc_7c687d0e-962a-4d82-a362-3d0cdac01e46">3.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i934b31b2b19e4a32b408f256d19446bf_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTY0OTI2NzUwMDE3MA_7046b6bd-dc56-4e72-aca3-f1e3aa1eb7a9">4.3</ix:nonFraction> million, respectively, and is presented within prepaid and other current assets in the accompanying consolidated balance sheets. </span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNzM_e9287482-392f-44af-8189-6aeb2ecd6d52" continuedAt="ie4eb6585ed7041afa6aa72ce9394147c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i17549011038d4676b3530798bccd58f2" continuedAt="i10ed4f5e50f1487ebb3a07f058c7f079"><ix:continuation id="ie4eb6585ed7041afa6aa72ce9394147c" continuedAt="i1c01cb004d304615bdd909b7ae1af9b4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of <ix:nonNumeric contextRef="ib11bf9964618458792c11fd0405c0f72_D20220101-20220630" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNDU_b3fafccf-c1ef-4cc3-a975-8dff7a82ae68">one year</ix:nonNumeric> or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GPDC Capitation Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS contracts with Direct Contracting Entities (&#8220;DCEs&#8221;), which is composed of healthcare providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#8217;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#8217;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e., month) and is recognized net of quality incentives/penalties. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i10ed4f5e50f1487ebb3a07f058c7f079" continuedAt="i71a069192adb441d81da8e454647473f"><ix:continuation id="i1c01cb004d304615bdd909b7ae1af9b4" continuedAt="i3d22c910adbd4b2b8d2284c472ddd102"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i71a069192adb441d81da8e454647473f" continuedAt="ice1ec5a162ed45c68ffb810049bb9f45"><ix:continuation id="i3d22c910adbd4b2b8d2284c472ddd102" continuedAt="i5944cb0e2dcb4905bc8dc9ff9965630e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims, are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within <ix:nonNumeric contextRef="i5c9d9247680949b3a7da52ee73653a69_D20220101-20220630" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNDA4MzY_e2f076b9-06b4-43bb-b117-d2bbe43b2932">30</ix:nonNumeric> days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within <ix:nonNumeric contextRef="i5c9d9247680949b3a7da52ee73653a69_D20220101-20220630" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNDEwOTY_0b204c1c-86b3-4fba-8fe0-3a40c7c06c57">30</ix:nonNumeric> days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within <ix:nonNumeric contextRef="i5c9d9247680949b3a7da52ee73653a69_D20220101-20220630" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNDEyMTk_0b204c1c-86b3-4fba-8fe0-3a40c7c06c57">30</ix:nonNumeric> days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ice1ec5a162ed45c68ffb810049bb9f45" continuedAt="i79f1a89274ca43ba9fd3f9b82b2c78c4"><ix:continuation id="i5944cb0e2dcb4905bc8dc9ff9965630e" continuedAt="i45edd39874a14246be47896f31818229"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., <ix:nonNumeric contextRef="i8fb94590e3da4131815186c8ad836fbd_D20220101-20220630" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMTc_f2f5cc6b-3cc1-4210-abde-1b48ac5c55ee">10 years</ix:nonNumeric>), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i79f1a89274ca43ba9fd3f9b82b2c78c4" continuedAt="if36089e604444804a61788a152724345"><ix:continuation id="i45edd39874a14246be47896f31818229" continuedAt="iaafa3975c8e748e2a766426d9b01ad87"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaafa3975c8e748e2a766426d9b01ad87">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</ix:continuation> The Company&#8217;s contract liability balance was $<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTEwNjg_a8c885c7-d88a-4d95-9d62-37804863b555">20.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTEwNzU_0d9451e8-3868-44c8-9b43-4620d31d0a7e">16.8</ix:nonFraction> million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the six months ended June&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i6d3d4f8cd081436bbfc05d32afdfc31b_D20220101-20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTEyNTE_53065c38-0f99-48d7-b569-1ccf74e744b8">0.5</ix:nonFraction> million of the Company&#8217;s contract liability accrued in 2021 has been recognized as revenue.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNDY_5c626053-ed37-4f31-89ef-062ad909f9a5" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNjc_0d256694-7073-47fd-af73-028da7773290" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="if36089e604444804a61788a152724345"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMzk_4a341be9-bb22-4f56-9f20-5ed0c2856f8b" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 &#8212; &#8220;Earnings Per Share&#8221; for a discussion of shares treated as treasury shares for accounting purposes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:MinorityInterestPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMTA_5f12535d-3efa-43fd-bc3a-4b1e4e407e8f" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:TemporaryEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNjU_ad664243-b5eb-44f1-ac57-cdd16f4f78b6" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2022 and December&#160;31, 2021, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNTQ_af880e7f-a352-4c02-b3fc-33261ce8e2c9" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNDA_83db02e4-b934-4eb5-9d4f-5762a1931144" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)  No. 2021-08, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2021-08&#8221;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With the exception of the new standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i479e2a4965a945a4983dec200085612c_58"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfNDYxMQ_458a700c-9acc-4163-bad3-1c9b6ca4ec20" continuedAt="ib3c5fc8d608244be9b877c4f824f0973" escape="true">Business Combinations and Goodwill</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:continuation id="ib3c5fc8d608244be9b877c4f824f0973" continuedAt="i91e7ce26a77140aa95304f09521d3b4e">Jade Health Care Medical Group, Inc. </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i91e7ce26a77140aa95304f09521d3b4e" continuedAt="ia40f55314c354ea0a5140e6131b481ee"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 19, 2022, the Company acquired <ix:nonFraction unitRef="number" contextRef="i5b9aa026e81e4b4980bee034ca869c69_I20220419" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTY0OTI2NzQ0NzY4OQ_1c188854-ba80-4d9c-af3a-ddc342f1737c">100</ix:nonFraction>% of the capital stock of Jade Health Care Medical Group, Inc. (&#8220;Jade&#8221;). The purchase was paid in cash. Jade is a primary and specialty care physicians&#8217; group focused on providing high-quality care to its patients in the San Francisco Bay Area in Northern California. The Company is in the process of finalizing it&#8217;s purchase price allocation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orma Health, Inc., and Provider Growth Solutions LLC (together, &#8220;Orma Health&#8221;)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2022, the Company acquired <ix:nonFraction unitRef="number" contextRef="ibaa3b499908f486889ee0e616dda90c0_I20220127" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTY3_24023498-8edf-4f7b-b9fa-be2f0ec0d2ff">100</ix:nonFraction>% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#8220;Orma Health&#8221;). The purchase was paid in cash and in the Company&#8217;s capital stock. Orma Health&#8217;s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (&#8220;RPM&#8221;), mental health support, chronic disease management, and more. Its clinical platform is also deeply integrated with Orma Health&#8217;s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to manage patient health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APCMG</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company acquired an <ix:nonFraction unitRef="number" contextRef="iaa25ff896fef4a548c62b034ce2acbd1_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfODU5_41ec9a05-adc8-4c31-8d74-00ad8cc304bb">80</ix:nonFraction>% equity interest (on a fully diluted basis) in APCMG. As part of the transaction, the Company may pay APCMG additional consideration contingent on APCMG&#8217;s financial performance for fiscal year 2022 (&#8220;APCMG contingent consideration&#8221;). The APCMG contingent consideration will be met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (&#8220;EBITDA&#8221;) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of June&#160;30, 2022, the contingent consideration is valued at $<ix:nonFraction unitRef="usd" contextRef="iebfe001bbfd543a79e230f9c3c472476_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTc1MQ_d86331df-df6c-4bba-aeff-d808f61ace12">1.0</ix:nonFraction> million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sun Labs</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company acquired <ix:nonFraction unitRef="number" contextRef="i2fb19f36b5434e40bf55b16ef65f34a6_I20210831" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTkwNQ_44be5d67-1b06-4068-b021-192a4b50c2d8">49</ix:nonFraction>% of the aggregate issued and outstanding shares of capital stock of Sun Labs. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="i156059eff9374f1087488e472de06542_D20210801-20210831" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTY0OTI2NzQ0OTUxNg_099b0abd-208a-4208-8e7b-f6db3c2e6ee6">three years</ix:nonNumeric> from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DMG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by Apollo.  In addition, APC-LSMA is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="i7c6e0a57fc72447ea515eb651ec8f63e_D20210801-20210831" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfNTQ5NzU1ODE0Njc2MQ_2d4d4cb9-3f61-4d4c-aff0-c53c63521cff">three years</ix:nonNumeric> from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ia40f55314c354ea0a5140e6131b481ee"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfNDYxMg_d8ca6e82-7d3c-46fc-990b-bd3f5e7201ea" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RhYmxlOjFkYTg3ZjhiMzBlZDRlM2FiOGIxMTMyODE5ZjU0MDQyL3RhYmxlcmFuZ2U6MWRhODdmOGIzMGVkNGUzYWI4YjExMzI4MTlmNTQwNDJfMC0xLTEtMS0xMDUwMzM_4c5c56b0-07f4-4a39-835c-1ac09889d1fd">253,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RhYmxlOjFkYTg3ZjhiMzBlZDRlM2FiOGIxMTMyODE5ZjU0MDQyL3RhYmxlcmFuZ2U6MWRhODdmOGIzMGVkNGUzYWI4YjExMzI4MTlmNTQwNDJfMS0xLTEtMS0xMDUwMzM_f7106750-e128-443d-855a-74cdb3823d7c">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RhYmxlOjFkYTg3ZjhiMzBlZDRlM2FiOGIxMTMyODE5ZjU0MDQyL3RhYmxlcmFuZ2U6MWRhODdmOGIzMGVkNGUzYWI4YjExMzI4MTlmNTQwNDJfMi0xLTEtMS0xMDUwMzM_d292faa1-97cf-4668-9636-ba2454b6c8a6">2,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RhYmxlOjFkYTg3ZjhiMzBlZDRlM2FiOGIxMTMyODE5ZjU0MDQyL3RhYmxlcmFuZ2U6MWRhODdmOGIzMGVkNGUzYWI4YjExMzI4MTlmNTQwNDJfMy0xLTEtMS0xMDUwMzM_e6a0a2bb-cf87-455a-8a4c-f890e11a5283">253,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i479e2a4965a945a4983dec200085612c_61"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfNDk5_e24f9d40-39a5-42dd-934b-46af60a27673" continuedAt="i746bdba8d8054d4c91a4df6c2984cd2d" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="i746bdba8d8054d4c91a4df6c2984cd2d"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfNDk1_8bb75bf9-a135-417e-aad5-c78f10dfbc74" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:46.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7afe0c314bdd4919be94c4d4216e8769_I20220630" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMi0zLTEtMS0xMDUwMzM_c2666b40-1e1d-4594-9987-d90830994aaa">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7afe0c314bdd4919be94c4d4216e8769_I20220630" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMi03LTEtMS0xMDUwMzM_045967d6-7c4e-4c6e-b0ab-82a3ca6202cc">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i262bc0262fcd480086498ee92acb8f62_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjo5NTc2YzNmNGI3ZjE0NWQ2YjUyMTZiMDlmN2NiYzMyMF80_65847002-e751-427f-aa05-31c419439208">11</ix:nonNumeric>-<ix:nonNumeric contextRef="i8083c97bad35410980739e54dd0c355c_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjo5NTc2YzNmNGI3ZjE0NWQ2YjUyMTZiMDlmN2NiYzMyMF83_184833ee-2225-42ed-a3ff-1981de0b0d34">21</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2afdae606f3c4b4ca48b6404b58bf723_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC0zLTEtMS0xMDUwMzM_5e1d483c-26ee-4851-b64e-6eae93518e1c">150,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2afdae606f3c4b4ca48b6404b58bf723_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC01LTEtMS0xMDUwMzM_00d3c981-3028-4317-8df3-088077d7f211">90,285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2afdae606f3c4b4ca48b6404b58bf723_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC03LTEtMS0xMDUwMzM_bc4cce9f-e02c-48cf-a965-72e0fcfaadb4">60,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i73b45a52891f4ab8bf993b978064f4ce_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNS0xLTEtMS0xMDUwMzM_55b390f9-998a-4ff1-bc47-445c40bf66f0">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92ca545c5d242b29c14e8abfbafa3e4_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNS0zLTEtMS0xMDUwMzM_87d340c7-d76b-4d7e-8ccf-d01c69ccd59a">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id92ca545c5d242b29c14e8abfbafa3e4_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNS01LTEtMS0xMDUwMzM_d900cb23-85d9-412f-8a03-60ee838fc43e">14,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92ca545c5d242b29c14e8abfbafa3e4_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNS03LTEtMS0xMDUwMzM_793a4327-42b1-4df7-8a42-74ceff135a5c">8,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icb520c05360c4639917455a159462d8a_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNi0xLTEtMS0xMDUwMzM_d168c600-1fe3-420c-9d67-0fc05276c76b">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db7ef9235b34c04b4683c753d0c0add_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNi0zLTEtMS0xMDUwMzM_280bc938-a173-4b46-b323-1180f61f9cec">8,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8db7ef9235b34c04b4683c753d0c0add_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNi01LTEtMS0xMDUwMzM_658fb3ec-5d15-44d1-84ad-90783396f088">5,190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db7ef9235b34c04b4683c753d0c0add_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNi03LTEtMS0xMDUwMzM_3ec2cbc8-067a-424e-a624-5b24c43f0f3c">3,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i823f7c34a37842bc853d7a95f895358c_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNy0xLTEtMS0xMDUwMzM_95bb6e1c-4f30-4e8a-a583-7c988ef0cd92">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff8b2ce2fa64fbd861752a596120f74_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNy0zLTEtMS0xMDUwMzM_e4880bb9-1a18-449b-9d47-f4bcccbc821a">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ff8b2ce2fa64fbd861752a596120f74_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNy01LTEtMS0xMDUwMzM_12fc4109-8898-4dea-91df-819c51155424">1,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff8b2ce2fa64fbd861752a596120f74_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNy03LTEtMS0xMDUwMzM_1b7de471-e2c8-42bc-ac5f-424ee8ef935d">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib4c456a4d4324d7da4299e68e3469d32_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOC0xLTEtMS0xMDUwMzM_21996853-2943-496e-a15c-cbeae76b974f">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77f5a844c054b76ab43bfd594454e29_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOC0zLTEtMS0xMDUwMzM_708f4773-1205-4aa9-8716-a08a8b53b3cc">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id77f5a844c054b76ab43bfd594454e29_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOC01LTEtMS0xMDUwMzM_0f057530-9601-46ca-b1c1-25d011644505">232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77f5a844c054b76ab43bfd594454e29_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOC03LTEtMS0xMDUwMzM_b0572c72-39c2-4042-aac2-381356ccda3b">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subscriber relationships </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6b39a8c15b94db1bef62c56c6cdfa11_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOS0xLTEtMS0xMDUwMzM_9ae343b4-d09f-4acd-882c-f902697344e9">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342650b110d948c68305b913d3337797_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOS0zLTEtMS0xMDUwMzM_c4e72343-9042-4fce-ba4b-07d93528c735">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i342650b110d948c68305b913d3337797_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOS01LTEtMS0xMDUwMzM_0e276f51-129a-474f-ad20-ee2f33bdfd69">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342650b110d948c68305b913d3337797_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOS03LTEtMS0xMDUwMzM_e9de3501-e966-45e6-bd25-01d029d43b27">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idad1fcac77ba4ee7876fddfc937c8526_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTAtMS0xLTEtMTA1MDMz_4138379e-9193-4b92-882a-d2d1c702811f">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22617db5966243a29e90deea438fe6e4_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTAtMy0xLTEtMTA1MDMz_9b07b725-07b4-425f-8066-2b81ac4534df">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22617db5966243a29e90deea438fe6e4_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTAtNS0xLTEtMTA1MDMz_fa2c63f9-7dd9-4552-b3e2-ac7086986766">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22617db5966243a29e90deea438fe6e4_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTAtNy0xLTEtMTA1MDMz_5ef2eca7-ede3-4d74-9bdf-e270d99d462e">718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTEtMy0xLTEtMTA1MDMz_2ea0f468-b071-4960-afbe-29b5e8677cfb">188,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTEtNS0xLTEtMTA1MDMz_cb12ba35-2e12-4827-8bc5-5e0987eb2ebb">112,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTEtNy0xLTEtMTA1MDMz_13eb9d90-1006-44a3-b341-e4e952b6266e">76,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare license</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c3aca5f37e4c7bbce9e471da9b2690_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfMi0zLTEtMS0xMDUwMzM_42d949ca-62fd-40ee-902a-9b81030bcf08">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c3aca5f37e4c7bbce9e471da9b2690_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfMi03LTEtMS0xMDUwMzM_f035acc2-9e8e-4e65-b986-9d96810c8aed">2,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i70a8b50fadb34ecbbeb48a0a4e675fb8_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjozN2IxM2E3NTI0OGM0Yzk2Yjk1ZmYwMTQ1OGI5ODY0NV80_18332ab9-be38-46d6-bab6-9f5b1ccd13fe">11</ix:nonNumeric>-<ix:nonNumeric contextRef="id386caca65614b57ae15aeb43ddc272e_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjozN2IxM2E3NTI0OGM0Yzk2Yjk1ZmYwMTQ1OGI5ODY0NV83_e6d616b9-e04f-4909-9b10-7e7514bdd0fd">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c5b1b731c04326a701c1dbf4c69a1e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC0zLTEtMS0xMDUwMzM_9d2aecdb-471a-4560-89e1-75f6908929b2">150,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11c5b1b731c04326a701c1dbf4c69a1e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC01LTEtMS0xMDUwMzM_0bcbde8d-048b-4571-9673-1d9eaa73a9b2">84,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c5b1b731c04326a701c1dbf4c69a1e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC03LTEtMS0xMDUwMzM_7f30ad50-694a-425e-bca8-1d2243812a8b">65,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5b382a0954bd416284c02bcaa5a318da_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNS0xLTEtMS0xMDUwMzM_e40482ba-69de-4610-b394-65b04e29dd06">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c47fd9f6a0a4bb2a1714812fdf72b1e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNS0zLTEtMS0xMDUwMzM_d378356a-f538-4ac0-bbe3-7c06b79e464f">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c47fd9f6a0a4bb2a1714812fdf72b1e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNS01LTEtMS0xMDUwMzM_44b220ca-017e-4f11-8bda-5057eb097817">13,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c47fd9f6a0a4bb2a1714812fdf72b1e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNS03LTEtMS0xMDUwMzM_fe0bd11b-0ae2-4968-8c6d-d78d7ec5d58d">9,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i47aaf649d7d949a184692e09d23490b1_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNi0xLTEtMS0xMDUwMzM_e269ea61-887f-46e2-9c3f-80930f7bf57c">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d39193fee394abbb9705dc0a37fb365_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNi0zLTEtMS0xMDUwMzM_76366626-29f0-423c-8002-8012fefe9303">8,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d39193fee394abbb9705dc0a37fb365_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNi01LTEtMS0xMDUwMzM_5e2d0fb7-1097-4f65-9b4b-1aabf41eca02">4,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d39193fee394abbb9705dc0a37fb365_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNi03LTEtMS0xMDUwMzM_f5d7306a-929b-4a8c-bb33-c6cb38c7b58b">4,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient management platform</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6ccff1d9ca534ab0b567fd1dc05bd91a_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNy0xLTEtMS0xMDUwMzM_448c89b7-39cf-435d-9fc9-0914fa3943e5">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecea1ee1cca4bd5b0f7613a433ccb86_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNy0zLTEtMS0xMDUwMzM_c4252926-28d8-4cb0-87e4-67798bdc303d">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ecea1ee1cca4bd5b0f7613a433ccb86_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNy01LTEtMS0xMDUwMzM_e5a46a78-c936-44cb-b80e-c569c7cc8950">1,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecea1ee1cca4bd5b0f7613a433ccb86_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNy03LTEtMS0xMDUwMzM_6ee69359-4c41-412e-80a0-56e24ce65448">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfde020db2314ef08cf9d768e4c6d60f_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOC0xLTEtMS0xMDUwMzM_f4a05083-cd68-4234-b54c-b9e8e815d694">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d17a700c65498dbbc648590a1e5c5a_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOC0zLTEtMS0xMDUwMzM_b32503bb-cde5-4429-b749-914618d9bd44">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87d17a700c65498dbbc648590a1e5c5a_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOC01LTEtMS0xMDUwMzM_faea54d5-8fc7-4dae-8ab8-bbe332c90695">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d17a700c65498dbbc648590a1e5c5a_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOC03LTEtMS0xMDUwMzM_5f551f5a-f3fd-4fb0-9537-ce77950d4d36">805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOS0zLTEtMS0xMDUwMzM_aafd4928-1006-4d40-8f6f-c6e5550c26ba">187,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOS01LTEtMS0xMDUwMzM_a927c9e3-e6e4-4873-80e6-fb2950e4e056">104,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOS03LTEtMS0xMDUwMzM_fd141a3a-2dc0-4cba-b853-e913a70bcc39">82,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfMjc0ODc3OTA3MDc1Mg_4ae0a6ba-3e88-4dbe-89e2-94d0e671d5b5">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfMjc0ODc3OTA3MDc2MA_665e73e7-7167-45b7-aa43-5decf02da0eb">3.7</ix:nonFraction> million for the three months ended June&#160;30, 2022 and 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfMjc0ODc3OTA3MDgyMA_2b7572d2-febb-44c2-93c9-59dc4cd8d9d0">7.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfMjc0ODc3OTA3MDgyOA_763f2ad7-82d0-4bce-8e98-741fcc56a9da">7.5</ix:nonFraction> million for the six months ended June&#160;30, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfNDk2_d245cadb-8e68-4e0c-8541-c388a58643a7" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June 30, 2022)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfMi0xLTEtMS0xMDUwMzM_778d7987-f415-409b-9112-0238540f3dcf">6,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfMy0xLTEtMS0xMDUwMzM_930d8daa-89d0-477c-abe2-b0c1c04d287f">11,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfNC0xLTEtMS0xMDUwMzM_86958578-1517-4984-a5d6-6f37ee10d707">10,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfNS0xLTEtMS0xMDUwMzM_62ee4552-290c-4b64-b184-766ce5f1f905">9,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfNi0xLTEtMS0xMDUwMzM_74e2eb5e-f532-49cd-8693-d81453e8d02f">8,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfNy0xLTEtMS0xMDUwMzM_c35b3595-2ace-47d7-8f14-d90d2a82803e">27,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfOS0xLTEtMS0xMDUwMzM_db1bd33e-5454-4fce-a777-b638cb98bfce">74,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:EquityMethodAndOtherEquityInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI3Ng_294c644e-f0ae-430a-b821-3759537f6e45" continuedAt="i2eea273ed40047f4845b955810f9e10f" escape="true">Investments in Other Entities</ix:nonNumeric></span></div><ix:continuation id="i2eea273ed40047f4845b955810f9e10f" continuedAt="i20b4847913894890b64281b9577f5610"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Equity Method</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI3NA_689e5248-c121-468e-993b-51dc67784cc5" continuedAt="i27e145032a1e469c8302e20ed4302ce5" escape="true"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in other entities &#8211; equity method consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding reclassified to loan receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2bbf4c0d7e4582a1a0fef1a71f7b4e_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS0xLTEtMS0xMDUwMzM_d64e9af9-e9ba-45b3-a10b-862f8f0829e4">3,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90be308939140e9a4a7cb933f276390_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS01LTEtMS0xMDUwMzM_69fa1961-c0dd-4ce7-ad7d-0e7918acda09">2,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia90be308939140e9a4a7cb933f276390_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentReclassification" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS03LTEtMS0xMTcxNTQ_dca280e3-7012-431d-9745-15b62650aaaf">2,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90be308939140e9a4a7cb933f276390_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS03LTEtMS0xMDUwMzM_3c64db70-ba49-4140-8670-55df277c115c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90be308939140e9a4a7cb933f276390_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS0xMS0xLTEtMTA1MDMz_2ae5d97a-08a0-4c21-85da-72de2d9d0e34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6903a2d9d4664df8a794cb162687a0c1_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS0xMy0xLTEtMTA1MDMz_fe8f13c9-03fe-45c4-8b46-29eec24fdac1">3,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2206b47d6e7b424d9b62ab32b0338026_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi0xLTEtMS0xMDUwMzM_bc254318-5c60-4cc6-82cf-89f5bf7dfb8e">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cad2048a753446186dfdb8373edee28_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi01LTEtMS0xMDUwMzM_1fd8be75-4f9f-41c7-ace7-932f26cac96f">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cad2048a753446186dfdb8373edee28_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentReclassification" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi03LTEtMS0xMTcxNjE_3154dcc8-58e4-4f3c-b395-275be27addb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cad2048a753446186dfdb8373edee28_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi03LTEtMS0xMDUwMzM_6dda1713-0327-4fbc-bcaf-e3b7dcf15ff5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cad2048a753446186dfdb8373edee28_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi0xMS0xLTEtMTA1MDMz_25ee7a2a-99b6-40d1-9f23-e57d547ae576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide0127b82d0c494786e6a5b4bd61c173_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi0xMy0xLTEtMTA1MDMz_caf2d9f3-34fa-4fda-a3a2-64994d790558">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0edd220c6943ef81f9294e13541194_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy0xLTEtMS0xMDUwMzM_f20d1496-be46-4f6f-b7b4-831a6cd11511">17,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy01LTEtMS0xMDUwMzM_3aa9a374-48e2-43f5-9fd9-2b1c66cd8151">305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentReclassification" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy03LTEtMS0xMTcxNzA_86a6556b-478b-4409-9dad-4b471a6c69fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy03LTEtMS0xMDUwMzM_a4237e32-3776-4e73-9abb-b0f2d0f6f338">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy0xMS0xLTEtMTA1MDMz_e09b7263-f7e3-425c-a464-c3ddb18faa4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cf8eaa6bf64eeab771048f5de4564f_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy0xMy0xLTEtMTA1MDMz_956ea63c-7cea-4702-9276-3cfc2851e44e">17,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifff5051e4aad447bb1d4f5b0b052cdff_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC0xLTEtMS0xMDUwMzM_bd79c665-df41-4662-840b-cd3376b44da3">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC01LTEtMS0xMDUwMzM_2ab860f2-38b1-49ab-a32c-3275047ce951">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentReclassification" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC03LTEtMS0xMTcxNzA_eee2478a-ef99-4210-8ba5-d739269fcc10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC03LTEtMS0xMDUwMzM_1a42e379-8b37-48ee-982b-9fc5fe380ad3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC0xMS0xLTEtMTA1MDMz_3ad91b0a-bc27-4576-850f-cc929993bae8">400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a601ca89014f5eacda8b352cd397cf_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC0xMy0xLTEtMTA1MDMz_ba50cbff-de41-4d6c-b956-72187a4c76d0">2,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadd8800c72bb483c99ceb9c97149a818_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS0xLTEtMS0xMDUwMzM_6388554c-7d6e-459d-a49d-e7b24cac0745">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS01LTEtMS0xMDUwMzM_60ebf233-f6d6-4155-b74a-97a316ecd50f">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentReclassification" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS03LTEtMS0xMTcxNzA_1d048115-a044-415f-9004-39eb1955f5c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS03LTEtMS0xMDUwMzM_a97b0faa-77ef-421c-8448-b5a8d2503ac9">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS0xMS0xLTEtMTA1MDMz_5e58ece0-a16c-4a69-8738-ff978acbc586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80aa85c869b4960834df7f5663464ac_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS0xMy0xLTEtMTA1MDMz_fcf2d70d-477f-430c-997d-1175fed746cd">6,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6dd79fb668d4396a088c5c7da4ad9bb_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi0xLTEtMS0xMDUwMzM_0b24ed5f-8f0c-4dd5-b8c2-523651887565">11,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi01LTEtMS0xMDUwMzM_d00a936b-cbac-4891-a64f-38db9d996303">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentReclassification" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi03LTEtMS0xMTcxNzc_98f821f9-89b2-4b1d-a338-3c788f5c4568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi03LTEtMS0xMDUwMzM_1e95e065-6521-4b37-90e2-d160b2bd8394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi0xMS0xLTEtMTA1MDMz_dcdf17fc-d163-432b-9084-4b31a9b60900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e059681a7204193b3ca300c44829e19_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi0xMy0xLTEtMTA1MDMz_06265a15-b669-41be-a40e-40b8101d165b">12,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy0xLTEtMS0xMDUwMzM_24f8c901-aa43-47bf-b9bb-d7248af6aa8a">41,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy01LTEtMS0xMDUwMzM_09b09abd-cdde-49c2-a2cb-d4b206921bea">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentReclassification" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy03LTEtMS0xMTcyODM_42e08326-7d27-4f0a-abdf-db225b928c2d">2,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy03LTEtMS0xMDUwMzM_12bb54dc-5628-48d4-8141-b505d05f040a">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy0xMS0xLTEtMTA1MDMz_6d1d1ca7-7eec-45bd-a4ff-e9ff2c0804f2">400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy0xMy0xLTEtMTA1MDMz_88ae4733-b21e-4492-b09c-791839e85fd5">43,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care. In September 2021, APC-LSMA sold <ix:nonFraction unitRef="number" contextRef="ifcfcf46929264addbb83d541b8cf9a81_I20210930" decimals="4" name="ameh:EquityMethodInvestmentOwnershipPercentageSold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzI2_311a3024-906d-435f-8ad1-df4b244e5c61">21.25</ix:nonFraction>% of its interest in LMA back to Dr. Arteaga for $<ix:nonFraction unitRef="usd" contextRef="ie11fbddce8b34653bf1c488090c280ed_D20210901-20210930" decimals="-5" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzc2_395a83aa-4ba6-4787-969a-8aed130b19ea">6.4</ix:nonFraction> million, which resulted in  APC-LSMA owning a <ix:nonFraction unitRef="number" contextRef="ie5a62c94039149c4add47ae7f2b1df0a_I20220630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDE3_7f0c57a1-c6df-4ea1-b095-74dfff9ef180">25</ix:nonFraction>% interest in LMA as of June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended June&#160;30, 2022 and 2021, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i6ac857e621104221a59862c04c79506c_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjg4_eb89d457-369f-47d8-8e52-f80101ee7314">1.3</ix:nonFraction> million and a loss of $<ix:nonFraction unitRef="usd" contextRef="i788d07c210dd4f958d756e23167c1e15_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNzA1_f4a942db-1fe9-4485-afb5-08c2e3ab42d8">3.6</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income.  For the six months ended June&#160;30, 2022 and June&#160;30, 2021, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i61e73f5506934b76adfdd854acffd935_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NTgxMA_a4636edc-21e9-4e92-9a2c-0edd43fce4bd">2.5</ix:nonFraction> million and a loss of $<ix:nonFraction unitRef="usd" contextRef="ia30f4a1733a0428ea9411e847f714b94_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NTgyOA_b515a00c-15f2-4a23-b8c4-2e9fb666f5b3">4.3</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i6903a2d9d4664df8a794cb162687a0c1_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfODY2_a6f261e2-9d15-4e3d-9006-0e1580b28aba">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b2bbf4c0d7e4582a1a0fef1a71f7b4e_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfODcz_ebe2733d-a75d-4e36-857d-9d216f86e5b5">3.0</ix:nonFraction> million at June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i20b4847913894890b64281b9577f5610" continuedAt="if41121ee0e574ec28f257bdd93a9034a"><ix:continuation id="i27e145032a1e469c8302e20ed4302ce5"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at June&#160;30, 2022 and December&#160;31, 2021, and summarized statements of income for the six months ended June&#160;30, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMy0xLTEtMS0xMDUwMzM_3a393a36-9670-4df1-a39d-a17cd9ad9ce1">16,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456a03746030449991737ef8d57a4456_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMy0zLTEtMS0xMDUwMzM_80fb3027-0156-4cc3-91fd-78ab4b44a090">6,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNC0xLTEtMS0xMDUwMzM_b86fe391-e6e1-4c1a-8e4e-8a1cc6245f66">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456a03746030449991737ef8d57a4456_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNC0zLTEtMS0xMDUwMzM_6059ec5b-39c6-4afb-8133-641fd66b3b8a">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNS0xLTEtMS0xMDUwMzM_5f9558bc-ea50-4d27-a2ed-49eebaf23e44">5,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456a03746030449991737ef8d57a4456_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNS0zLTEtMS0xMDUwMzM_efcbe6bd-a4fd-491c-8ca5-e3f71c848a9a">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNy0xLTEtMS0xMDUwMzM_a3bea1f3-e1be-4f13-8fe4-33613a73af1b">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456a03746030449991737ef8d57a4456_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNy0zLTEtMS0xMDUwMzM_893d800e-c24d-4f34-a4f8-e77494a7dd78">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfOS0xLTEtMS0xMDUwMzM_74b36f74-4852-47fd-ae8c-598f99e1878e">24,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456a03746030449991737ef8d57a4456_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfOS0zLTEtMS0xMDUwMzM_1ca8a3e8-deea-4622-a58c-8b6d78a465c0">11,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTItMS0xLTEtMTA1MDMz_33b412e9-88e9-44e2-a732-b12b9e99ec59">35,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456a03746030449991737ef8d57a4456_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTItMy0xLTEtMTA1MDMz_3d505600-5a8e-4d2e-b43a-7fbf819f4aa3">32,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTMtMS0xLTEtMTA1MDMz_6aef46fa-085a-47d0-a059-911c503d3e6b">10,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i456a03746030449991737ef8d57a4456_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTMtMy0xLTEtMTA1MDMz_9853e8ef-cfdc-4232-a338-73d03bd8d0ae">20,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTUtMS0xLTEtMTA1MDMz_efeb7220-b171-4172-a2b4-e06aca07c191">24,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456a03746030449991737ef8d57a4456_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTUtMy0xLTEtMTA1MDMz_d2f769b8-5e03-48d3-a195-0baa4062ae69">11,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfMy0xLTEtMS0xMDUwMzM_72789449-97c3-4bf2-aa0d-4ad63d5601a9">126,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfMy0zLTEtMS0xMDUwMzM_3611239c-643a-4da4-ae34-eb8ede9ca822">95,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNC0xLTEtMS0xMDUwMzM_64ea30f7-b5b3-45c4-9326-c7b26c14e133">121,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNC0zLTEtMS0xMDUwMzM_6284a01c-c018-4912-8a20-acd5d2939a0b">104,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNi0xLTEtMS0xMTcxOTE_9b98ad81-6e46-4c94-8192-5c7fc2f775ac">4,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNi0zLTEtMS0xMTcxOTg_e8ba23a8-a11a-4244-8cb1-035390be453b">9,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfOC0xLTEtMS0xMTcyMzM_e87cf3c5-ff58-443b-9fed-244d963006c6">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfOC0zLTEtMS0xMTcyNDA_11bdf446-57c0-4587-b1a5-bc05e7ebf3ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNi0xLTEtMS0xMDUwMzM_af85c4b0-4d07-48c3-b1ce-853ea7715fab">4,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNi0zLTEtMS0xMDUwMzM_85256fc9-c2ec-430c-9e5d-3d66e001623e">9,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA purchased a <ix:nonFraction unitRef="number" contextRef="ib71de6782da243ac87254390580b0b61_I20150731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMTI3Ng_f3cd9724-ea36-450c-9b1e-a116a46f849d">40</ix:nonFraction>% ownership interest in PMIOC. Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography, at its facilities.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="if41121ee0e574ec28f257bdd93a9034a" continuedAt="ifab4d4a14ca14b80ad11d649b8189d7c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended June&#160;30, 2022 and 2021, APC recognized income from this investment of approximately $<ix:nonFraction unitRef="usd" contextRef="i72155c35fa2747b5984527dcf5162a43_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjE3OQ_260f94fb-1131-4432-b603-943666df777d">15,000</ix:nonFraction> and a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i2f30d164f6d743639946b82e4328af58_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjIxNw_bff4ccb4-17de-433b-ac17-65b60e08a482">16,000</ix:nonFraction>, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recognized income of approximately $<ix:nonFraction unitRef="usd" contextRef="i36766b59fdb44c0cb8d7da462b05fbef_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NjMyNw_571598b8-12bd-463c-9e3e-3ec566b29139">22,000</ix:nonFraction> and a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="ib9f907a840be46e2aeb32432dd66fea0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NjMzNQ_c80fe4ce-4dbb-410a-94ed-76780da19f6f">30,000</ix:nonFraction>, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets had investment balances of $<ix:nonFraction unitRef="usd" contextRef="icb35d81b629041debdd1e5e0eb5500ac_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjM2Mg_734dfa6b-e604-478c-9ede-79ce457625cc">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6baa1c84dac349f5acf23c66fef27140_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjM2OQ_3bff8685-3691-48dc-aa2d-d591d33aaaa1">1.7</ix:nonFraction> million at June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a <ix:nonFraction unitRef="number" contextRef="id8cbe9a274f944c9b33a5afce066df48_I20220630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjQ0NQ_d47a36c4-06c8-4b3f-bbaa-b72edc7d3d73">50</ix:nonFraction>% ownership in 531 W. College LLC and accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. 531 W. College, LLC owns a former hospital campus in Los Angeles that is now leased to tenants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2022 and 2021, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="if465b8aea2ce4908904e4ad93a86b298_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjg2Nw_768d2f34-4b90-4c39-883f-737246d90479">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i018d7b4e12a2489aa9b33f4323e5c611_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjg3NA_d86906f8-ef06-401e-92ee-8e49884c948d">9,000</ix:nonFraction>, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recorded a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i016ca3434597421199937a03ff2fc17f_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NjY4OA_9ab79dc0-0769-44e8-b476-6051c7ec8035">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i79ef92aed16c481bb3060e0e03050169_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NjY5Ng_9dd24b89-3d5d-4fae-b72c-8411cf61a5a5">0.1</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="if7cf8eaa6bf64eeab771048f5de4564f_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzAzNQ_5fe73c83-d782-49b2-974e-6c3bda2860ad">17.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0e0edd220c6943ef81f9294e13541194_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzA0Mg_c7a894ab-ad99-4618-8902-6259decc679a">17.2</ix:nonFraction> million at June&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One MSO, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a <ix:nonFraction unitRef="number" contextRef="i2ef0c4478a2c41e38132323c3a052804_I20220630" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzExMw_22925e68-693a-48c0-9fc9-6bee82205547">50</ix:nonFraction>% interest in One MSO. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended June&#160;30, 2022 and 2021, APC recognized income of $<ix:nonFraction unitRef="usd" contextRef="iaa17eff6b8c744cfad25e00a8a815d59_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzMwMA_1bade3ba-01fe-4ffe-9f1c-477358d0d1e9">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6ed8a2f220bd4feda2e865edfbd8e716_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzMwNw_cf538aac-17da-470c-bd5c-6aa1f95aace1">0.1</ix:nonFraction>&#160;million, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recognized income of $<ix:nonFraction unitRef="usd" contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3Njk5NQ_b44a810a-ecfb-43d5-96ec-f3f357d00e2a">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ief5224c7fb984c28ae95700de5da6e27_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzA3Mg_779f5e54-a698-4a76-9fd2-7c8a1bce81b5">0.2</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i77a601ca89014f5eacda8b352cd397cf_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzQ1Mw_6d52a9f8-b1c5-4374-bd84-80830d2a27fb">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifff5051e4aad447bb1d4f5b0b052cdff_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzQ2MA_f901a242-6d1e-4799-ab0e-17eed3c9a796">2.9</ix:nonFraction>&#160;million at June&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC  &#8212; Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a <ix:nonFraction unitRef="number" contextRef="i35e8315cdc8946c3bd924c645f5730ed_I20220630" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzU1Nw_5fe1f0a8-b5c3-4ba8-841c-da662a32edb9">50</ix:nonFraction>% interest in Tag 6. Tag 6 leases its building to tenants and shares common ownership with certain board members of APC and as such is considered a related party. For the three months ended June&#160;30, 2022 and 2021, APC recognized income of $<ix:nonFraction unitRef="usd" contextRef="i39e02afca44c4aedafa732851dd3802b_D20220401-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzc3NA_89a17c38-a73b-4b2b-81a4-039ae0992f7b">45,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i227316615eba44afb5e1909846c71eeb_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzI1Ng_db88bd57-c3c7-42ad-b33b-fb718eac8bcd">0.2</ix:nonFraction> million, respectively,  in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recognized income of $<ix:nonFraction unitRef="usd" contextRef="i46a28bb2bc244c43b885f7f0afdb1949_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzUwNg_d3913eed-9ace-4d86-8aca-dff2d399bc90">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i268b6755560b4788af5c509f2650c3ba_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzUyNQ_2499d426-a221-48ce-907d-ba4b28249b6d">0.2</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the Tag 6 investment of $<ix:nonFraction unitRef="usd" contextRef="i13da4e8ee17d47e9819397b6faff3bfc_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzk3Nw_18d09a7a-1dd6-49f4-b9ad-7e54225b65f4">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6fd70ca2db774b288ae5881780641231_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzk4NA_3e141d63-1700-4a40-a68b-37ccbbeab714">4.8</ix:nonFraction>&#160;million at June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAIPA MSO, LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, ApolloMed purchased <ix:nonFraction unitRef="number" contextRef="i9ddac981e5724f7faa52da42366eb5b0_I20210831" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDA2OA_f283206f-9025-4449-872f-4843ddaeb010">30</ix:nonFraction>% interests in CAIPA MSO, LLC for $<ix:nonFraction unitRef="usd" contextRef="i1d95aff18be44aaabba0d95b213fe04d_I20210831" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDEwMw_2ad4acd2-f53a-460d-83ed-41e8f465fbca">11.7</ix:nonFraction> million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (&#8220;CAIPA&#8221;), a leading independent practice association serving the greater New York City area. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#8217;s operations. For the three months ended June&#160;30, 2022, ApolloMed recognized income from investment of $<ix:nonFraction unitRef="usd" contextRef="ica0c755f6f5a456cb7c1e3039165cf31_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDYyMQ_7781c8d4-8bd7-4563-9e68-9dad11cc47f5">0.2</ix:nonFraction> million in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022, ApolloMed recognized income of $<ix:nonFraction unitRef="usd" contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzcwNA_16ebb689-c2e2-41e9-9d17-870b3823946e">0.3</ix:nonFraction>&#160;million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i1e059681a7204193b3ca300c44829e19_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDc4OQ_33aa147c-2566-4cbd-a270-57e4718dbe7e">12.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie6dd79fb668d4396a088c5c7da4ad9bb_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDc5Ng_0837f310-8820-43c3-8e2d-a0019d5bbd1e">12.0</ix:nonFraction>&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ifab4d4a14ca14b80ad11d649b8189d7c"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased <ix:nonFraction unitRef="shares" contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDk0OA_30757b48-0a86-495e-b73f-620e0034e67b">270,000</ix:nonFraction> membership interests of MediPortal LLC, a New York limited liability company, for $<ix:nonFraction unitRef="usd" contextRef="i68a73980d9cb441dbb6fdd887b9503f8_D20180501-20180531" decimals="-5" name="ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTAzMw_0f3d94ce-503d-49b9-9ab5-25f40c0bb3f8">0.4</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTAzOQ_7f4d60e3-512e-4244-9005-72f856db2ca6">1.50</ix:nonFraction> per membership interest, which represented an approximately <ix:nonFraction unitRef="number" contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531" decimals="3" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTEwMg_e3eac1b9-6c44-45f0-8881-0200059d7156">2.8</ix:nonFraction>% ownership interest. In connection with the initial purchase, APC received a <ix:nonNumeric contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI3Mw_669903a9-2372-49f5-b7a7-340952ba001f">five-year</ix:nonNumeric> warrant to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTIyMw_4b1f839e-8995-44b6-b297-1d747619a6a2">270,000</ix:nonFraction> membership interests. A <ix:nonNumeric contextRef="i68a73980d9cb441dbb6fdd887b9503f8_D20180501-20180531" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI4MQ_1ed5c74b-df19-4ef3-b990-6c27b8479b46">five-year</ix:nonNumeric> option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i68a73980d9cb441dbb6fdd887b9503f8_D20180501-20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTI5MQ_3124b908-b140-4fe1-8495-46562b829b8e">380,000</ix:nonFraction> membership interests and a <ix:nonNumeric contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI3MQ_d56bf382-39be-4e4a-9639-6e455b89cabc">five-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTM0OQ_a004c505-9271-4903-8a59-4778d1f643d0">480,000</ix:nonFraction> membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase <ix:nonFraction unitRef="number" contextRef="idd5ac37956bd4d08909d1dd390134c6d_I20190731" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTk1OQ_359c800c-afa0-47e3-8cb8-08140b504cb9">50</ix:nonFraction>% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed <ix:nonNumeric contextRef="i0858a8d9fe0c4b65b4073669668a0c6b_D20190701-20190731" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjA1Mw_3bfe297d-f583-4d2b-9171-bea551556a07">five years</ix:nonNumeric>. As a result of this transaction NMM invested $<ix:nonFraction unitRef="usd" contextRef="idd5ac37956bd4d08909d1dd390134c6d_I20190731" decimals="-5" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjEwMg_0d7173aa-67dd-4ec5-af72-4904b78abac2">0.5</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="idd5ac37956bd4d08909d1dd390134c6d_I20190731" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjExMQ_c3b6b14b-33f8-46a1-a488-c237dc7ff8e5">10</ix:nonFraction>% interest. The related investment balance of $<ix:nonFraction unitRef="usd" contextRef="ica9c3cfdeff84d0eac173b74662af814_I20220630" decimals="-5" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjE1OA_cf6cdda2-7845-4e81-9b8e-5797150c987a">0.5</ix:nonFraction> million is included in investments in privately held entities in the accompanying consolidated balance sheets as of June&#160;30, 2022.</span></div></ix:continuation><div id="i479e2a4965a945a4983dec200085612c_73"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:LoanReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMTI0OA_de4cc813-b360-4ad3-ba15-a010c70e924e" continuedAt="i43b3ec43e04c4cd0af69c7bf2a649615" escape="true">Loan Receivable and Loan Receivable &#8211; Related Parties</ix:nonNumeric></span></div><ix:continuation id="i43b3ec43e04c4cd0af69c7bf2a649615"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from 6 Founder LLC, a California limited liability company doing business as Pacific6 Enterprises totaling $<ix:nonFraction unitRef="usd" contextRef="i5d5365ccd50e40b48292e6b69f44ba5f_I20201031" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMTU5_68105e39-efe6-4e13-8d1d-d8cd564165cd">0.5</ix:nonFraction>&#160;million as a result of the sale of the Company&#8217;s interest in MWN. Interest accrues at a rate of <ix:nonFraction unitRef="number" contextRef="i5d5365ccd50e40b48292e6b69f44ba5f_I20201031" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMjUw_5c754769-e61f-4e3f-9a52-1b5aa90b937f">5</ix:nonFraction>% per annum and is payable monthly through the maturity date of December 1, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related party</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">LaSalle Medical Associates Loan (&#8220;LMA Loan&#8221;)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LaSalle Medical Associates (&#8220;LMA&#8221;) issued a promissory note to APC-LSMA for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="ibf671f1c4d984ad4b56737e8bb018cf4_I20220630" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMTY0OTI2NzQ0NzE2NA_9f908408-1a95-4b83-b716-159d3b6d4091">2.1</ix:nonFraction> million with an August 2023 maturity date. The contractual interest rate on the LMA Loan is <ix:nonFraction unitRef="number" contextRef="ibf671f1c4d984ad4b56737e8bb018cf4_I20220630" decimals="3" name="ameh:FinanceReceivableInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMTY0OTI2NzQ0NzE3MQ_07e4d8aa-e18f-4f35-b4b6-873240b9f5c1">1.0</ix:nonFraction>% above the prime rate of interest for commercial customers. APC&#8217;s investment in LMA is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="i767518e6c72e4e4997ab25645b106efc_I20210630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfNDM5ODA0NjUxNTUzMw_057e8cae-1e6a-462a-906c-322966fb5aa5"><ix:nonFraction unitRef="number" contextRef="i778bae90463c48628833fa5514d45310_I20220630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfNDM5ODA0NjUxNTUzMw_e1ded9bc-8d93-4d26-90a9-4c5ff9a99840">25</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC-LSMA in LMA&#8217;s IPA line of business (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, AHMC Healthcare Inc. (&#8220;AHMC&#8221;) issued a promissory note to APC for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i846ff05d31aa414e88893b18094681fe_I20201031" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfNDc2_10a56f99-e890-4628-b59c-50cfcdea6181">4.0</ix:nonFraction>&#160;million with an April 2022 maturity date. The note was amended in April 2022 to extend the maturity date to April 2023. The contractual interest rate on the AHMC Note is <ix:nonFraction unitRef="number" contextRef="i846ff05d31aa414e88893b18094681fe_I20201031" decimals="INF" name="ameh:FinanceReceivableInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfNTY1_2ced8292-7bcd-49d2-837a-c91c04b017e2">3.75</ix:nonFraction>% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. In June 2022, AHMC paid the outstanding principal and interest amount to APC. One of the Company&#8217;s board members is an officer of AHMC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div></ix:continuation><div id="i479e2a4965a945a4983dec200085612c_79"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RleHRyZWdpb246MDBjYTgwYzQwYmEwNDlmNzljMzA0ODEzMzRmMDJlMzdfMTQ0_f40b7267-7c99-4e7d-ba7b-ea85f4a0468c" continuedAt="i5bc04237f60c40158494b97b96b18f6d" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5bc04237f60c40158494b97b96b18f6d" continuedAt="i601efc01cd3f45aca73cf23fdd74eb07"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RleHRyZWdpb246MDBjYTgwYzQwYmEwNDlmNzljMzA0ODEzMzRmMDJlMzdfMTQ3_80a59311-4802-4618-9a89-10344ecc486f" continuedAt="i6588cef091994b98ae4b1d6296338ec9" escape="true">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><ix:continuation id="i601efc01cd3f45aca73cf23fdd74eb07"><ix:continuation id="i6588cef091994b98ae4b1d6296338ec9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMS0xLTEtMS0xMDUwMzM_aef16d2c-ae8a-4981-a933-e6760aa6e4c6">11,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMS0zLTEtMS0xMDUwMzM_6ca416a2-ab57-496a-890e-c9e123a02638">9,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:SpecialtyCapitationPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMi0xLTEtMS0xMDUwMzM_0aadeec7-3f22-434d-8e19-a0c84861adec">3,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="ameh:SpecialtyCapitationPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMi0zLTEtMS0xMDUwMzM_4b7fa6ae-5682-499a-a614-62505315787a">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:SubcontractorIPAPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMy0xLTEtMS0xMDUwMzM_72d7a3a9-dabe-4959-aa40-d9f32be70cf4">13,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="ameh:SubcontractorIPAPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMy0zLTEtMS0xMDUwMzM_1b1508cf-49a3-4405-943f-72025782ade6">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNC0xLTEtMS0xMDUwMzM_330a16e4-04fb-4cc3-87ae-721e5f9d6aec">1,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNC0zLTEtMS0xMDUwMzM_33f173ba-1a17-421c-a055-982989af7c34">878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNS0xLTEtMS0xMDUwMzM_44c1f0a8-c2fa-40ff-8ccd-449c2e55caca">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNS0zLTEtMS0xMDUwMzM_5d68e2b2-5819-45b8-8daa-2775f76e0659">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNi0xLTEtMS0xMDUwMzM_337771e0-8158-48b8-88cc-4b28b6e1b409">20,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNi0zLTEtMS0xMDUwMzM_7de8edd9-5146-40e2-93e8-45fffdaf9f4d">16,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNy0xLTEtMS0xMDUwMzM_1394ee71-1fda-4fbf-ad72-c1dca1d73d76">8,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNy0zLTEtMS0xMDUwMzM_3c0e6b1d-f0f5-4596-8a8f-14826c6f9f5c">10,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfOC0xLTEtMS0xMDUwMzM_5e4cf8c0-3c26-4a5b-a1b8-20113bc8116f">59,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfOC0zLTEtMS0xMDUwMzM_9b4aee1e-ebb0-4884-8897-1ace80838614">43,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i479e2a4965a945a4983dec200085612c_82"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RleHRyZWdpb246M2UzYWJmNGE5MzhkNDQ5ODliMDM0YmI5NTc3NDlmMGNfMTEw_6638fb48-8c3f-4666-bb7b-1724f8237616" continuedAt="i7d7265b7026d4d26bb597ac37c54b49b" escape="true">Medical Liabilities</ix:nonNumeric></span></div><ix:continuation id="i7d7265b7026d4d26bb597ac37c54b49b"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RleHRyZWdpb246M2UzYWJmNGE5MzhkNDQ5ODliMDM0YmI5NTc3NDlmMGNfMTEy_10b9ff87-8729-4657-898e-4f32f568036b" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMS0xLTEtMS0xMDUwMzM_8634ac29-ae05-4624-a186-9a53a35ae4f7">55,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMS0zLTEtMS0xMDUwMzM_69e92024-7982-4fe4-9586-41df0ee11597">50,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMi0xLTEtMS0xMTkyMjU_7f48dda5-8c3b-4213-b91d-66132ed1cad8">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMi0zLTEtMS0xMTkyMzM_a59fdc3b-d8db-4f45-a3a3-ad662a7e53e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNS0xLTEtMS0xMDUwMzM_8ad904fc-aa93-4797-974e-aa7a751313ce">313,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNS0zLTEtMS0xMDUwMzM_3ce5a12b-037e-4c15-912d-aaceccabfcb6">158,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNi0xLTEtMS0xMDUwMzM_d88b498d-0de5-471b-9937-64038e401440">950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNi0zLTEtMS0xMDUwMzM_2f45703b-9f3e-44ac-9530-e20cc336470f">1,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNy0xLTEtMS0xMDUwMzM_9af3678d-4441-40ad-8db8-b5309f9a01c6">312,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNy0zLTEtMS0xMDUwMzM_4ecc7065-01f3-4328-baf5-91615b87248d">157,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfOS0xLTEtMS0xMDUwMzM_6165aeec-de7d-429c-aa1e-0d15c0504a41">204,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfOS0zLTEtMS0xMDUwMzM_b281da48-12d2-4de2-b4bf-51f38f3a06ab">103,302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTAtMS0xLTEtMTA1MDMz_1ac428b1-0539-47ad-9470-5e03f50c46a7">53,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTAtMy0xLTEtMTA1MDMz_a7bb8e5b-4b4c-4752-972c-009fab1bfbab">45,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTEtMS0xLTEtMTA1MDMz_5f9ac200-26fd-4d94-a0c0-d0886b669e57">258,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTEtMy0xLTEtMTA1MDMz_f31558ff-80c0-4550-8aef-da9baba1f029">148,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTItMS0xLTEtMTA1MDMz_ed955825-6657-4bcb-a9e7-53f4272b46e0">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTItMy0xLTEtMTA1MDMz_46a8a9a5-1687-4ce3-bd6b-8f3bc59946c5">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTQtMS0xLTEtMTA1MDMz_115f56e0-3c78-4502-a57a-5f9521392e86">112,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4becb57108e844a2af77734d782c9546_I20210630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTQtMy0xLTEtMTA1MDMz_496cf2e8-78c2-4f08-b387-1eb3e1eee66c">59,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTQ_7acf7659-02ab-48e6-a54f-dc91438229c1" continuedAt="if01e3267e98b40eea278559a49b6e93a" escape="true">Credit Facility, Bank Loans, and Lines of Credit</ix:nonNumeric></span></div><ix:continuation id="if01e3267e98b40eea278559a49b6e93a" continuedAt="i9a520c7c827343158f9eb9bb553b50b1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTc_64c544e2-e961-48ef-8411-065ee764d02c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2940bbecd004561861f01abb0ebad96_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfMy0xLTEtMS0xMDUwMzM_9f1d460a-d72d-4c9a-b148-ae99a1cb9631">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca1ca2ff65840868df912f9f0aaa96a_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfMy0zLTEtMS0xMDUwMzM_52d1a004-5d48-4217-9bae-fc705d57ae76">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b355b7c0d4a4f3bac5ad6619d970628_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNC0xLTEtMS0xMDUwMzM_b1f76ad7-2e64-4da5-bd71-93198fe5034e">23,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86197b3338a4a568e33693944e72e99_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNC0zLTEtMS0xMDUwMzM_063cabc7-7dc7-491f-86cf-2607600c0637">7,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78dd2608d34c4de8a4f893d06e8f8f22_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNS0xLTEtMS0xMDUwMzM_8200e74f-b24f-4125-8c7c-efb33895df6f">1,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d1265e36d640f2adebf0f735428064_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNS0zLTEtMS0xMDUwMzM_3290d613-2097-4904-b816-84e8d236dbd5">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNi0xLTEtMS0xMDUwMzM_311e761b-5a13-45fe-8266-238795aa4e34">205,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNi0zLTEtMS0xMDUwMzM_ed72625e-e160-49ac-b298-663eed993fef">187,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfOC0xLTEtMS0xMDUwMzM_95a5c447-9ac5-40eb-8fda-15a4444f844e">2,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfOC0zLTEtMS0xMDUwMzM_2f2a0d5d-1a91-4df2-ac7d-f360fb97473f">780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfOS0xLTEtMS0xMDUwMzM_9249633b-c311-451c-b379-35dbc4601d5f">3,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfOS0zLTEtMS0xMDUwMzM_cf4edd3a-b6ee-4b53-bed5-9f27bab42e01">4,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfMTEtMS0xLTEtMTA1MDMz_db7d122f-c4c2-4476-8136-d09faa2eeaa3">199,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfMTEtMy0xLTEtMTA1MDMz_b264eb10-6881-4b2a-8b58-058c70cae81c">182,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of June&#160;30, 2022 and December&#160;31, 2021, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTU_43f2fca1-d1ab-463e-bb1f-b5492d8aebd9" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June 30, 2022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfMS0xLTEtMS0xMDUwMzM_e2d8451b-2fd9-406b-96d8-17e7c5c3a2b2">2,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfMi0xLTEtMS0xMDUwMzM_86962b8d-3120-48bd-b79a-f95e170c6362">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfMy0xLTEtMS0xMDUwMzM_9ef85ea5-59cc-4b91-978e-cd281ca2dca8">642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfNC0xLTEtMS0xMDUwMzM_3ce46b1d-7242-40d7-8032-ef6e932d9bd1">7,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfNS0xLTEtMS0xMDUwMzM_a4692065-6de1-42f7-8273-9edc0144ce90">194,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfNy0xLTEtMS0xMDUwMzM_ddc2d200-7277-44fa-8f4d-76de354ae167">205,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i9a520c7c827343158f9eb9bb553b50b1" continuedAt="i64badbc194724521b3ced6ad1a0a953e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the &#8220;Credit Facility&#8221;), in its entirety. The Amended Credit Agreement provides for a <ix:nonNumeric contextRef="idc4faa451635444dacf9694e218dd3e4_D20210616-20210616" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTk_fba1acff-0165-4f3d-b63d-efffc415f1cb">five-year</ix:nonNumeric> revolving credit facility to the Company of $<ix:nonFraction unitRef="usd" contextRef="ibdae08981f5e4104934ad51fe3b95303_I20210616" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTQ2Mw_ef864f3d-12c7-4528-b329-9d7967e8b873">400.0</ix:nonFraction> million, which includes a letter of credit sub-facility of up to $<ix:nonFraction unitRef="usd" contextRef="i22fc5dfea7e84f638573c274ba9b23e4_I20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTUyMw_889accce-58f3-43a9-94dd-47fa635ba18b">25.0</ix:nonFraction> million and a swingline loan sub-facility of $<ix:nonFraction unitRef="usd" contextRef="ia2cd92e83f7b437bb51b5c89f701b464_I20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTU2Mw_c08b91f7-974c-48dd-ba61-4249eb1997b5">25.0</ix:nonFraction> million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;) between the Company, NMM and Truist Bank remain in effect.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $<ix:nonFraction unitRef="usd" contextRef="i85593b22935b45e4be1ee177e8ad7239_D20210616-20210616" decimals="-3" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjA5Nw_f43342e2-4450-4f23-bc81-f24cef17b825">50,000</ix:nonFraction> and an annual facility fee of <ix:nonFraction unitRef="number" contextRef="i3eae04016bb447e0bddc4f0591df991a_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjEzMA_2ec2bdd6-76c0-40f8-9c38-d040bd02b37c">0.175</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i95eae60963324a459007367c1b4ab420_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjEzNg_0e2cfaf8-67d7-4435-94ed-9161b09826c8">0.350</ix:nonFraction>% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to <ix:nonFraction unitRef="number" contextRef="ia1261394f1654823b8118f1c41514f21_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjQwMw_f4a1c958-9459-42ef-8250-f65981fe333e">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic88159173edb49298d65e5a36a704517_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjQwOQ_56e3e9f3-0ab9-41fc-b905-3f919db674b3">2.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from <ix:nonFraction unitRef="number" contextRef="ic938e3d247da4baf8c4e436b6ba4e60b_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzAzOA_ae3537be-4b8a-4e27-9834-a17b11e9ba5f">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i8fa6d96494224426b248b59ceab8cebb_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzA0NA_b75e8902-091c-458b-bfe7-6139b8c2a3a7">2.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of <ix:nonFraction unitRef="number" contextRef="i3eae04016bb447e0bddc4f0591df991a_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzE1OQ_acc7ea9d-ade7-410a-b310-1b4a49b43475">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i95eae60963324a459007367c1b4ab420_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzE2NQ_1ba00a04-9711-47c5-81db-638999c33dc7">1.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio.  As of June&#160;30, 2022, the interest rate on the Credit Agreement was <ix:nonFraction unitRef="number" contextRef="i60f21d618be04c29bad9cca5524c19b7_I20220630" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzMwMA_b08297b1-cacc-4885-af4f-199e1e0406ce">4.17</ix:nonFraction>%. Borrowings under the Amended Credit Agreement may be prepaid at any time without penalty. If LIBOR ceases to be reported under the Amended Credit Agreement, the Company will use the secured overnight financing rate or the Company and the Agent will agree to an alternative rate of interest. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with <ix:nonFraction unitRef="financial_ratio" contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630" decimals="INF" name="ameh:DebtInstrumentNumberOfKeyFinancialRatios" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzY2Mg_be9601af-b3f6-4213-b7cb-192e2a3894d4">two</ix:nonFraction> key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzgyMg_cc311e10-0836-45b2-accf-a27b50727f2b">3.75</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $<ix:nonFraction unitRef="usd" contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630" decimals="-5" name="ameh:DebtCovenantAggregatePurchasePriceMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNDA1NQ_555cc7f5-81f6-4922-a57c-8e49dd8109a8">75.0</ix:nonFraction>&#160;million, the maximum consolidated total net leverage ratio may temporarily increase by <ix:nonFraction unitRef="number" contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNDEzNw_cc3fd974-08c4-4516-8ddd-17f49b6bc0eb">0.25</ix:nonFraction> to 1.00 to <ix:nonFraction unitRef="number" contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioAdjustedMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNDE1MQ_d496e30a-238e-48ec-a69e-5a54b6fc7049">4.00</ix:nonFraction> to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="i161df59378d54e2c9c35ef127c00a692_D20220101-20220630" decimals="INF" name="ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNDI1Mw_fc52d3c0-d425-4a21-908a-a920ae56a965">3.25</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange, or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i11ed2f9093db4b03b46f940a69391343_I20190930" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNTIyMg_d06136cc-bdd5-4dab-93f5-ee3097fe5bc3">6.5</ix:nonFraction> million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="ic59abeea171b4680ac8fc59615e1a446_I20210630" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNTM0Ng_9eed953d-c299-41ab-bf79-bf6b03c9c323">0.7</ix:nonFraction>&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At June&#160;30, 2022 and December&#160;31, 2021, the unamortized deferred financing cost was $<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNTgwOA_1c821606-e272-4b2b-9633-03a2da345f73">3.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNTgxNQ_8c882dc8-f0a5-4c92-af46-3c81e27ef7c2">4.3</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i64badbc194724521b3ced6ad1a0a953e" continuedAt="i649c6deff5a6406aa2100970f146a5d7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="ibe69f802279e4ce8a230a2252301ea51_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NDI1Ng_a275c4cf-1551-46b6-b644-2e3eeef52729">6.1</ix:nonFraction> million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="ia874564b3f7f46f0bb91acc1285b389e_D20200703-20200703" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNjI3Nw_35facd5c-1d5e-4556-95e8-03eddceb4f2e">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2022, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="ibff008a8379447cea04496a4e74019b5_I20220630" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNjYwNg_424f6223-eadf-4898-bdb7-cb485a18a173">6.0</ix:nonFraction> million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="if16717b8edf54956a5b44e5ed8302e3b_D20200703-20200703" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNjc2OQ_1236226d-da91-4402-bd4c-6ce4bebd0852">1.25</ix:nonFraction> to 1. <br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="ia1041f899e3243769086c3764cd3193a_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NDI2NA_b6bf56be-d9a2-46f8-b345-090e0f636834">0.7</ix:nonFraction> million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i74c97c8e257e4a02a64730b6e0e41ade_D20200805-20200805" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNjk5Nw_f976125a-d662-4ebe-b685-54183b339046">0.30</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2022, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i5b7a043471da464fa12812657a6fb838_I20220630" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNzMzNw_2195ffa0-2b8b-4a6d-88e2-56d6377ba76e">0.7</ix:nonFraction> million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i11705a1bed9740c793f74a813ac7350e_D20200805-20200805" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNzUxMQ_71e9ff6c-106e-4aef-906d-cc60d0facbfe">1.25</ix:nonFraction> to 1.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="icccdfccc60d849bda7a0fa9d6cda8ea8_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NDI3Mg_f9a06d70-3094-4e64-bcb2-7b5112bd607c">0.6</ix:nonFraction> million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i9d4b6704bd1a4f1b8e67da94daf68ad5_D20200727-20200727" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNzcxNQ_35f0406c-1be3-4541-9d39-580e105e17d0">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2022, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i5739754d4c764531a08a2b6ba1d03922_I20220630" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfODA0NA_c1304a79-d737-44c8-9f0d-f0043e5dab65">0.6</ix:nonFraction> million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="if06c44df5942487d9c597ef8cdee2e34_D20200727-20200727" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfODIwNw_97a6a05a-dfac-4636-b383-788c29235f84">1.25</ix:nonFraction> to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">120 Hellman LLC </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;25, 2022, 120 Hellman LLC (&#8220;120 Hellman&#8221;), a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary of APC,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into a loan agreement with MUFG Union Bank N.A. with the principal on the loan of $<ix:nonFraction unitRef="usd" contextRef="ibf7979125d864b698864f3e49061ba20_I20220125" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NzM5MQ_4566e6de-97a6-4c4c-a130-56d084ea4e7a">16.3</ix:nonFraction> million and a maturity date of March&#160;1, 2032. The loan </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was used to purchase property in Monterey Park, California. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable interest rate is <ix:nonFraction unitRef="number" contextRef="if75e16a418bd4b0ca6e69d9bda0b4418_D20220125-20220125" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NTQxNw_b2cce174-4155-424b-8639-11a24f48fc56">2.0</ix:nonFraction>% in excess of Daily Simple SOFR, which is the daily rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If the index is not available, MUFG Union Bank N.A. may designate a substitute index after notifying 120 Hellman. Monthly payments on the principal and interest began in April 1, 2022. Should interest not be paid when due, it shall become part of the principal and bear interest. As of June&#160;30, 2022, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i282ab48d547a409c91b0e2e1d8c055d7_I20220630" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NTQyNA_c4b60eee-aaa6-4f78-8630-fb17878cb5c2">16.2</ix:nonFraction> million. 120 Hellman must maintain a Cash Flow to Debt Service ratio (defined as net profit after taxes, to which depreciation, amortization and other non-cash items are added divided by the current portion of long-term debt and capital leases) of not less than <ix:nonFraction unitRef="number" contextRef="i8efee8b6417740c295818b5927155453_D20220125-20220125" decimals="INF" name="ameh:DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NTQzNA_bd95af9c-7922-4d8a-bc45-90890bfc9278">1.25</ix:nonFraction> to 1 and <ix:nonFraction unitRef="number" contextRef="ibf7979125d864b698864f3e49061ba20_I20220125" decimals="INF" name="ameh:DebtCovenantThresholdPercentageForOccupationOfProperty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NjUzOA_3f1ac538-9111-4cdc-9501-2efcd4054b08">35</ix:nonFraction>% or more of the property must also be occupied by APC. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i649c6deff5a6406aa2100970f146a5d7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $<ix:nonFraction unitRef="usd" contextRef="i2cb7f86e0def4c95962563988d781f2f_I20210430" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfODQ0Ng_4829485a-6136-4fc0-a596-28aae6d894e9">10.7</ix:nonFraction> million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be <ix:nonFraction unitRef="number" contextRef="ie1d752a197404d5bac408b2154757c13_D20230101-20231201" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTIyNQ_7d8f4e03-be79-4beb-8005-0fce8bc11de3">2.0</ix:nonFraction>% per annum in excess of the LIBOR rate. As of June&#160;30, 2022, the likelihood of the construction being completed by the maturity date was remote. The outstanding balance as of June&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i9f39746c41a9450889b8b440c4bb1e87_I20220630" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTM5OA_faec7f2e-c5d2-4a83-aee2-abbf4c0ce1ed">1.8</ix:nonFraction> million and was recorded as a current portion of long-term debt in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i7cbd40ee0c194527bd610419cab4d09d_D20220630-20220630" decimals="INF" name="ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTgxNQ_ad0fa252-9de4-4616-abc9-fae7f5468096">1.25</ix:nonFraction> to 1. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the six months ended June&#160;30, 2022 and 2021, was <ix:nonFraction unitRef="number" contextRef="i161df59378d54e2c9c35ef127c00a692_D20220101-20220630" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTk1OA_84ea7ce7-d2b5-4135-a6eb-8149ab40315f">2.16</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i693a573b995242e69ae791b297318006_D20210101-20210630" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTk2NQ_ee8fabf4-bba1-4e85-bf11-0b923a74ffd5">2.31</ix:nonFraction>%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2022 and 2021, of $<ix:nonFraction unitRef="usd" contextRef="iafc384eaf4734dd0be96fd82579c39f6_D20220401-20220630" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTAxMzM_de84fd9c-7498-4a2f-a557-987f44048e38">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i161df59378d54e2c9c35ef127c00a692_D20220101-20220630" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTAxNDA_acf545a4-db4c-4241-aa36-bed81a26ea72">0.4</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia26057f05b68400bab7e17c33a599861_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1MzQ0NQ_95f88f10-097a-48d7-b4e5-64472b61ce36">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i693a573b995242e69ae791b297318006_D20210101-20210630" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1MzQ1Mw_e09b13c6-2b95-4789-92d2-74a5800c3ec6">0.7</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to, among other things, decrease loan availability to $<ix:nonFraction unitRef="usd" contextRef="i039231bd37b04500b07453d76940704d_I20190910" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTAzMzQ_b33e58a1-46b0-4641-b5a4-21c47a811fd7">4.1</ix:nonFraction> million, limit the purpose of the indebtedness under the APC Business Loan Agreement to the issuance of standby letters of credit, and include as a permitted lien, the security interest in all of its assets that APC granted to NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under their management services agreement dated as of July 1, 1999, as amended.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="ice27ac69897e45d1b5b34a56355dc920_I20220630" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTA5NDg_de27c04b-db02-41a0-9ef5-0f16d25a8289">0.3</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i00309c0459be4ba3b15e9b6033b0acaf_D20220101-20220630" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTI_6b2052a2-fb03-4912-93d4-a67a930381e8">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="i7d5bf58fac1b43f9a4c5a689c4268856_I20220630" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1MzU2MA_508abef4-1c4c-494c-99c0-df89ede912b0">3.8</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i9aefdbbfc23740e3971470e4cc27ff41_D20220101-20220630" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2ODY_8b68ea58-1664-417f-8ff4-26848a390343">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div></ix:continuation><div id="i479e2a4965a945a4983dec200085612c_91"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY2NA_181b4945-1c9e-451d-9c6f-b74333a95014" continuedAt="ib56b536436ff405d87f0bd522b63ca53" escape="true">Mezzanine and Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="ib56b536436ff405d87f0bd522b63ca53" continuedAt="id1d022fd850243f8aa34f6181fa8d4b4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares (see Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Mezzanine Equity&#8221;) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interest in APC as mezzanine or temporary equity. APC&#8217;s shares were not redeemable, and it was not probable that the shares would become redeemable, as of June&#160;30, 2022 and December&#160;31, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="id1d022fd850243f8aa34f6181fa8d4b4" continuedAt="id1b304a4ba61445abff8142757b906c9"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="ameh:StockIssuedDuringPeriodSharesMerger" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfNDQ4_620c8eb1-6f55-4b95-9918-90315f5c2546">140,954</ix:nonFraction> holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned <ix:nonFraction unitRef="shares" contextRef="i1c708cdfd53f41a8b290faf3f23f5186_I20220630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTMwNA_490acd6f-9d93-47af-8993-1a934a847f7e">11,175,702</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ief6a946f84384708a367fa93594947f6_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0NDAzMg_0d7efd96-2005-4f7b-955a-4598c683ff3e">10,925,702</ix:nonFraction> shares of ApolloMed&#8217;s common stock, respectively, as of June&#160;30, 2022 and December&#160;31, 2021. While such shares of ApolloMed&#8217;s common stock are legally issued and outstanding, they are treated as treasury shares for accounting purposes and excluded from shares of common stock outstanding in the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022 and 2021, APC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="ia7680ae5461b4b2486caea091e4e82f8_D20220401-20220630" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0MzM5OA_27358fa1-bc8a-4b5d-acd3-17e55836cb4b">10.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id4a852313e0c4ddd88001a38595d3390_D20210401-20210630" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0MzQwNg_bbfb9931-0df8-4a9c-b658-2079e9dd4e2c">19.9</ix:nonFraction>&#160;million, respectively. During the six months ended June&#160;30, 2022 and 2021, APC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i9902cb6392bf40fe99762875e13589c3_D20220101-20220630" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0NDkyNw_9218ed58-b640-4335-a772-15d6438d75dc">10.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic7dca31d301345ef9166cc408559e908_D20210101-20210630" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0NDk0OQ_a552da1c-5629-40bc-a3af-fa5e246171cf">19.9</ix:nonFraction> million respectively. </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id1b304a4ba61445abff8142757b906c9">During the three months ended June&#160;30, 2022 and 2021, CDSC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i0383372507bb45108200170dddd5ac63_D20220401-20220630" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0Mzc2MA_62f60ccd-dfea-411f-9173-1d208a232fd8">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2743e935ace9464cab6ca597868b375a_D20210401-20210630" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0Mzc2OA_dbdfdee9-a22a-4fe3-a249-d1fe0e269595">1.5</ix:nonFraction>&#160;million, respectively During the six months ended June&#160;30, 2022 and 2021, CDSC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i29ea51d5f00d45e9bc091bc8a1a88beb_D20220101-20220630" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0MzY1NA_24e06186-b75d-4ef6-8c9f-35d7029af989">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iaffd866f998541ff9a904994be9fae46_D20210101-20210630" decimals="-5" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0Mzc3Nw_beeea840-fc16-49d7-852c-a429515470fb">1.5</ix:nonFraction>&#160;million, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div id="i479e2a4965a945a4983dec200085612c_97"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzMQ_213cb1fd-594e-4538-9160-194a3e01986f" continuedAt="idf862bbb60f340b8993bb9e87084cd17" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="idf862bbb60f340b8993bb9e87084cd17" continuedAt="i98b5a762bf4f4ec1805df0af92465fba"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzMg_030f70c0-5ae2-4c72-b18b-29b637968190" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three and six months ended June&#160;30, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2d277b4082486a82df6f70b19d1989_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMi0xLTEtMS0xMDUwMzM_e3bf48bd-f5a6-4937-8fef-ccb08bb6022d">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd41ced8b31471c86f3e5b810861eef_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMi0zLTEtMS0xMDUwMzM_a55f8d0b-997d-4b31-8204-3e67da45d8ee">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice144ed20675466b9ffd1ea1b947c8df_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMi01LTEtMS0xMDUwMzM_f9dd16bc-2101-4fb9-b851-1e8bbc6d0146">1,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117ec78443b64325bf4c2ac950fb25a7_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMi03LTEtMS0xMDUwMzM_8a9dd853-3eac-48f9-b4de-3f9dae815ea8">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff7d682f2d94d5c926e3c35381ee58f_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMy0xLTEtMS0xMDUwMzM_f12d7f16-d89f-4bfc-960a-5a3e58ea13fa">2,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1d13fa98564dafaead4c073177d336_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMy0zLTEtMS0xMDUwMzM_9c39f3ed-2040-4644-91ca-2a16eb0aac43">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204ae706d04f42e492b4e0e310f1dad8_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMy01LTEtMS0xMDUwMzM_73df7db2-9963-4ac3-be6c-2592e6540a1c">5,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd7b521efd0406a9d8f97afd5c8feb7_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMy03LTEtMS0xMDUwMzM_3097d9d3-e2d3-4ea7-9f85-4b7a3137659f">1,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfNS0xLTEtMS0xMDUwMzM_95cd54f8-f0f5-473a-8571-42981dcb3406">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfNS0zLTEtMS0xMDUwMzM_2e086b5f-2368-4886-a0c6-3c498095a084">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfNS01LTEtMS0xMDUwMzM_7835f7d5-7fd1-42cd-bfb0-2dcf57f81113">6,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfNS03LTEtMS0xMDUwMzM_d2c1b45f-5c6b-4200-a37e-0ccbe9ba1485">2,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i98b5a762bf4f4ec1805df0af92465fba" continuedAt="i0332d6ab594844529d08881958d67a17"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of June&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfNTE3_3ba6ea6d-468e-49c5-a85f-47439329fb39">26.1</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzMw_97cad432-f56c-45d6-bff2-7e5a19fa0792" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMS0xLTEtMS0xMDUwMzM_10b9af0a-3e1d-4332-ac34-590050fb11b7">813,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMS0zLTEtMS0xMDUwMzM_284f35d1-b95e-4ace-977c-6aa9055ac535">22.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i13efa678914f4d7f98b3e9aeb1cd61d8_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMS01LTEtMS0xMDUwMzM_689937e1-f3c7-403c-9280-f7b301f36e41">3.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMS03LTEtMS0xMDUwMzM_f86d2127-2c6a-4dd3-8596-a8d54ba0da01">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMi0xLTEtMS0xMDUwMzM_1b9c3be1-9796-432b-8e02-9dafede555c7">87,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMi0zLTEtMS0xMDUwMzM_2811edba-016e-49fe-95c7-93c011ee07ea">53.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMy0xLTEtMS0xMDUwMzM_301ed1f4-3d41-4c2e-b4c9-b4652c6db87e">38,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMy0zLTEtMS0xMDUwMzM_01e734d1-0e58-4496-aade-8f1a609041c6">17.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMy03LTEtMS0xMDUwMzM_4f04d50a-10e3-442c-a58b-530a0f651fa3">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfNi0xLTEtMS0xMDUwMzM_04172e4c-70ff-4b32-bb6d-b0b849933d2b">862,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfNi0zLTEtMS0xMDUwMzM_d7948897-ad78-4fa7-bfd2-f92f0d328416">26.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfNi01LTEtMS0xMDUwMzM_1c6887f8-c282-42b9-a1b9-bb73b29600f0">2.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfNi03LTEtMS0xMDUwMzM_803989b5-ffee-4d9d-8bca-debc6801e088">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfOC0xLTEtMS0xMDUwMzM_4bae3947-81c9-4a9c-b926-b2be925f17db">624,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfOC0zLTEtMS0xMDUwMzM_8c4e575e-5ad1-4809-a0eb-27cff33f6326">11.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfOC01LTEtMS0xMDUwMzM_015444e6-1a5b-45eb-993d-b5418cfb3990">1.70</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfOC03LTEtMS0xMDUwMzM_39cfe20b-43ea-4bdb-ad70-49b187c91750">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, options were exercised for <ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfNjU3_301ed1f4-3d41-4c2e-b4c9-b4652c6db87e">38,500</ix:nonFraction> shares of the Company&#8217;s common stock, resulting in proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfNzIz_07ce9a08-37e9-472a-b708-c72510e6f1bf">0.7</ix:nonFraction>&#160;million. During the six months ended June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfNzU4_89773aec-ed34-472f-adc5-e690f14c48b1">no</ix:nonFraction> stock options were exercised.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzNA_b89e00a8-1498-4136-bbf3-0bb37e78d07f" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, the Company granted <ix:nonFraction unitRef="shares" contextRef="i2b1957cc255c424d8d39c550b3fb4230_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfODQy_751c25f9-c90b-4402-a825-1d6b2590fd8f">87,488</ix:nonFraction> stock options to certain ApolloMed employees and Board members. The options granted during the six months ended June&#160;30, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib7e67912a5d449dbb5d6e4854647fa10_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMS0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjo4ZDdhZjBkNDQ5Mjk0MmQ3YjFhZjFkZjAwNmYxMTQyMV80_54ca0d0e-3282-47ea-afe1-cd95a1d6cec3">1.50</ix:nonNumeric> years - <ix:nonNumeric contextRef="iafd2b1c8b5514ddf938ef5e9deed8686_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMS0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjo4ZDdhZjBkNDQ5Mjk0MmQ3YjFhZjFkZjAwNmYxMTQyMV85_b47d4eef-5beb-4748-94e0-b76059da074a">2.25</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMi0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyM2RmZTliMGMzYTU0OWQxYmJjNDdiYTYxM2U2YzA3YV80_d4105eb8-325d-4a50-90b4-374b845eba26">71.47</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMi0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyM2RmZTliMGMzYTU0OWQxYmJjNDdiYTYxM2U2YzA3YV85_cb1abdc8-736c-4282-bbd6-b36fd53713d9">82.05</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMy0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoxOGMxYjBhZmM2MDc0N2QyYTQ1ZWRjMTRjYzI2YjdiN180_5011be3c-1a55-4fd5-803d-0c4ad12da36b">1.02</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMy0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoxOGMxYjBhZmM2MDc0N2QyYTQ1ZWRjMTRjYzI2YjdiN185_9796ab29-0c2d-4f60-b12e-57613f63cdf9">2.47</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i27162b4c30e1433389aa44bb606e1201_I20220630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyMzUwZTQ0NWZkZjU0MmQ4YTU3OWM5M2Y5MTgxMjY3OV80_925c4600-2f78-44ca-97bf-72ebd5ed353b">17.47</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i16a45d3b518b423aaab4649221f9e190_I20220630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyMzUwZTQ0NWZkZjU0MmQ4YTU3OWM5M2Y5MTgxMjY3OV85_3a6a815b-a6e0-466c-a1a6-87692da4f9e5">22.73</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock is that day&#8217;s closing market price of the Company&#8217;s common stock. During the six months ended June&#160;30, 2022, the Company granted restricted stock totaling <ix:nonFraction unitRef="shares" contextRef="ib521230a737a4886950b1519bb58fa8f_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMTM4Mg_bddcdc31-f1bd-4ce7-88b8-dabc38f89c1a">520,552</ix:nonFraction> shares, including <ix:nonFraction unitRef="shares" contextRef="ib521230a737a4886950b1519bb58fa8f_D20220101-20220630" decimals="INF" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMTQwMw_dc229de5-bdfe-4752-9fdb-28e56ec78d2d">295,721</ix:nonFraction> shares of restricted stock with performance conditions, with a weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib521230a737a4886950b1519bb58fa8f_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMTUwMQ_4c5282cf-d786-4b76-bd27-f7d17bde9f16">42.01</ix:nonFraction>. Shares of restricted stock with performance conditions are recognized to the extent the performance conditions are probable of being achieved. The grant date fair value of restricted stock and restricted stock with performance conditions that are probable of being achieved were $<ix:nonFraction unitRef="usd" contextRef="i675bd27f6f9449a7b867a0997a6672c7_I20220630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMTc3NA_e95cf105-89f6-4088-8041-75686fd539f9">10.0</ix:nonFraction>&#160;million and will be recognized on a straight-line basis over the awards&#8217; vesting period. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i0332d6ab594844529d08881958d67a17" continuedAt="i87c94b062f064317ae59007ffecb6018"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzMA_204a05f6-0408-419e-a536-1d410edbfa5e" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMS0xLTEtMS0xMDUwMzM_773204e7-05e1-4b5f-857d-95021a386648">1,001,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMS0zLTEtMS0xMDUwMzM_4d4ef921-6de2-4e3f-b044-bff138b64bc9">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i13efa678914f4d7f98b3e9aeb1cd61d8_D20210101-20211231" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMS01LTEtMS0xMDUwMzM_1901855b-d0ed-40ad-b452-72f7a9c1783c">0.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-3" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMS03LTEtMS0xMDUwMzM_41a7305d-32d8-42c8-b67c-1e28469c9790">63.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="ameh:NumberOfWarrantsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMi0xLTEtMS0xMDUwMzM_71b95a95-a09c-440e-8526-c3b80fe5d4fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMi0zLTEtMS0xMDUwMzM_5cf12cad-33be-4573-b0dd-61430be5765d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMi03LTEtMS0xMDUwMzM_8d9ae251-36d6-4a5c-8363-2812b87e7b93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="ameh:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMy0xLTEtMS0xMDUwMzM_1084cad9-dc1e-4cf9-a4b0-81cf4faf0bb7">101,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMy0zLTEtMS0xMDUwMzM_7a555bbf-0f67-4463-8a09-ce7de603922f">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMy03LTEtMS0xMDUwMzM_14791004-a12e-437f-9210-edf8286cad55">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="ameh:ClassOfWarrantOrRightCancelledInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNC0xLTEtMS0xMDUwMzM_884d1460-2796-4b67-b8aa-4af6817900b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNC0zLTEtMS0xMDUwMzM_7e05db21-177c-4efa-85f7-349fd92e4be2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNC03LTEtMS0xMDUwMzM_62037594-e7b6-4727-b76a-a29bcfa1c0e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNi0xLTEtMS0xMDUwMzM_7c795511-6997-4bbc-b7cc-9aab946d5372">899,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNi0zLTEtMS0xMDUwMzM_ddb97d04-2113-406a-bf04-ab7508fb5a33">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNi01LTEtMS0xMDUwMzM_7931563d-e0b2-4a86-b4a8-2671ca5b3994">0.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNi03LTEtMS0xMDUwMzM_5fea1a75-e5aa-423d-8fd2-9187d3d460d3">25.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03ceea72d6fa40489f52e559fb181611_I20220630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS0wLTEtMS0xMDUwMzM_6f307d74-566d-428e-a570-06279b28da13">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6840db3bf9284ad4ab822cbf059964ce_D20220101-20220630" decimals="INF" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS0yLTEtMS0xMDUwMzM_bfbad3b6-7d2f-4d1a-8601-0d68df9a050e">462,743</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6840db3bf9284ad4ab822cbf059964ce_D20220101-20220630" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS00LTEtMS0xMDUwMzM_6b6e1bde-6f06-4758-bb06-68afb2ffea82">0.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03ceea72d6fa40489f52e559fb181611_I20220630" decimals="INF" name="ameh:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS02LTEtMS0xMDUwMzM_1fd0e1bb-af51-405d-9b7c-68a761f98394">462,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03ceea72d6fa40489f52e559fb181611_I20220630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS04LTEtMS0xMDUwMzM_0f3f7cdc-231d-417a-8289-e9b2aa445ed8">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i114ccddf4f7649a6848a22c64dbc33c9_I20220630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi0wLTEtMS0xMDUwMzM_e7c3291b-4a0a-44d1-aba0-0ef99d3f852e">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c54372981e0483384beb5dc3115d981_D20220101-20220630" decimals="INF" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi0yLTEtMS0xMDUwMzM_96cc403b-ef1b-4648-b7b3-7db52dee4e36">437,044</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8c54372981e0483384beb5dc3115d981_D20220101-20220630" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi00LTEtMS0xMDUwMzM_7a26d385-54a6-4db6-8bcf-ec74572b038e">0.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i114ccddf4f7649a6848a22c64dbc33c9_I20220630" decimals="INF" name="ameh:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi02LTEtMS0xMDUwMzM_6cbf7b56-aea6-4a14-98c0-5560849ca1bf">437,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i114ccddf4f7649a6848a22c64dbc33c9_I20220630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi04LTEtMS0xMDUwMzM_8b960f85-77c4-4286-be0b-9936214ee2b1">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  <ix:nonFraction unitRef="usdPerShare" contextRef="i76936fef1e6b40c18740fd16b3eda56d_I20220630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC0wLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyOGQ0MGY5NWQ4MDM0ZGFmYjMwNGVkZjgyODhhMmFmMl8yMw_433063c0-6a34-4a2c-b6b2-6f85098f2cf7">10.00</ix:nonFraction> &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="if150202c05234c61a08e030fc794aca5_I20220630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC0wLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyOGQ0MGY5NWQ4MDM0ZGFmYjMwNGVkZjgyODhhMmFmMl8yOA_cbce6839-516a-4167-9173-4115d57c9f21">11.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59a47c483aa24f5c89caa7bb1cdec67d_D20220101-20220630" decimals="INF" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC0yLTEtMS0xMDUwMzM_fd58d8ad-7c44-4e67-84f0-0345e3a19540">899,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i59a47c483aa24f5c89caa7bb1cdec67d_D20220101-20220630" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC00LTEtMS0xMDUwMzM_05ba6e81-5d4a-4bcf-93da-602820e3249a">0.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7f9f34bf3fb48cebfa73e5b388e465b_I20220630" decimals="INF" name="ameh:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC02LTEtMS0xMDUwMzM_bb013b93-4692-41cc-97f9-01ebfe75b038">899,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7f9f34bf3fb48cebfa73e5b388e465b_I20220630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC04LTEtMS0xMDUwMzM_a5d39cd7-b594-4d50-8286-a5b7314faf6f">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i87c94b062f064317ae59007ffecb6018">During the six months ended June&#160;30, 2022 and 2021, common stock warrants were exercised for <ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="INF" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjAxNQ_b4dda75a-0449-43a4-bad5-4c2050a1b117">101,953</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="INF" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjAyMg_add43d04-179d-4b03-b6a3-549fb3ff87b0">474,506</ix:nonFraction> shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-5" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjEyMQ_0afc00fe-2349-4ba6-afb0-5f5afad82cdb">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-5" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjEyOA_1ee84ae4-d1ba-44b5-b6b2-20d77a8d121e">4.8</ix:nonFraction> million, respectively. The exercise price ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="ie72fbf8622a44da7b8b232c28510f1a8_D20220101-20220630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjE3Nw_16e54675-ea6d-481e-9cf6-1aedd53fda12">10.00</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i1726507efb5f4fa09d9993c3857c283a_D20220101-20220630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjE4Mw_20597c5a-ebf7-4e96-ba88-722c0fdd1f1d">11.00</ix:nonFraction> per share for the exercises during the six months ended June&#160;30, 2022, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia172d03ffb5f4a4181d8f9c79bac7f77_D20210101-20210630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjI0OQ_24339b50-86a7-453d-83e5-7ebab07d362a">9.00</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="if0ae41c7e0b64fbeb8ec11b3c8e12d1b_D20210101-20210630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjI1NQ_7aab0f36-ca04-4f97-85cb-bbabe8d711bc">11.00</ix:nonFraction> per share for the exercises during the six months ended June&#160;30, 2021, respectively.</ix:continuation> </span></div><div id="i479e2a4965a945a4983dec200085612c_106"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDYvZnJhZzo5ZDBmOGI0YTgxYzE0NTQ2YTQ2NWE5NDY2NjIyNWI4OS90ZXh0cmVnaW9uOjlkMGY4YjRhODFjMTQ1NDZhNDY1YTk0NjY2MjI1Yjg5XzM1NjQ_29fd55be-9e9d-430c-aef9-d548383b5c11" continuedAt="ie18652ebb2f047aba12e1e70498c9989" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ie18652ebb2f047aba12e1e70498c9989" continuedAt="i9d15bb52f8d44be2b3467462bbdc79e9"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#8220;DMHC&#8221;) regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the payor and provider contracts with the Company&#8217;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i9d15bb52f8d44be2b3467462bbdc79e9"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $<ix:nonFraction unitRef="usd" contextRef="i83fa8e1b5460411992308ed07575a1f1_I20220630" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDYvZnJhZzo5ZDBmOGI0YTgxYzE0NTQ2YTQ2NWE5NDY2NjIyNWI4OS90ZXh0cmVnaW9uOjlkMGY4YjRhODFjMTQ1NDZhNDY1YTk0NjY2MjI1Yjg5XzE3OTc_81811f9f-c64c-400f-a5f2-3317b9303db1">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4b559e5023334ee3b95e75fa03c7d652_I20220630" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDYvZnJhZzo5ZDBmOGI0YTgxYzE0NTQ2YTQ2NWE5NDY2NjIyNWI4OS90ZXh0cmVnaW9uOjlkMGY4YjRhODFjMTQ1NDZhNDY1YTk0NjY2MjI1Yjg5XzE4MDQ_9cd04f02-162f-4783-8374-ab4304461b01">3.8</ix:nonFraction>&#160;million, respectively, for the benefit of certain health plans (see Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit - Standby Letters of Credit&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div></ix:continuation><div id="i479e2a4965a945a4983dec200085612c_109"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzQyMDI_a0351e05-f25e-49c4-870e-55b540ad69ab" continuedAt="i386d858e8cd24592b0635ea160827937" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i386d858e8cd24592b0635ea160827937" continuedAt="i34cbce8b5ff14dd785f3598cf805c5a4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 and 2021, NMM earned approximately $<ix:nonFraction unitRef="usd" contextRef="ieb082a42a8f04b7f8520726fad9dbed0_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDU5NDY_b4c83efd-53ff-4dae-84ac-081d4239236b">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifb2c519a88fb425cafa67a6ac705ce13_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDU5NTQ_225829a9-11e5-4df5-b94d-07e8d42521d2">4.2</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i20e887d2baae4779bc16fb980480b5cb_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDU5Nzc_822c55e6-31da-428a-83f6-d169cd2c9c2b">11.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1a80af6894a14c43a89ecebb723dcfe1_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDU5ODU_fe3fb472-ac30-42b0-9dae-d71b4d602b20">8.7</ix:nonFraction> million, respectively, in management fees from LMA, which is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="i767518e6c72e4e4997ab25645b106efc_I20210630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDYwOTM_057e8cae-1e6a-462a-906c-322966fb5aa5"><ix:nonFraction unitRef="number" contextRef="i778bae90463c48628833fa5514d45310_I20220630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDYwOTM_e1ded9bc-8d93-4d26-90a9-4c5ff9a99840">25</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i8d8d52a080a44e86a886bce63a285724_D20220401-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDY4OTM_4467e246-4d37-4db2-a426-5343eba67055">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7ab323e1b397418fb339066bb405899c_D20210401-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDY5MDE_c8ced41c-ec0f-4814-807c-5d83f80e01e8">0.6</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i6b3980ecb88c467597f9070419028889_D20220101-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDY5MjQ_6c6c7162-d6cf-4749-ae00-b3ddfb77b393">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica63af2bcd74490792c66cc16aa7cd45_D20210101-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDY5MzI_c181c6ba-7407-467a-a56c-baba3b8684dd">1.0</ix:nonFraction> million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="id2f665909db64084bcae52d7869044f6_I20220630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDcwNDM_38693203-c5fa-4f28-89a0-d3a4f0feaeb4"><ix:nonFraction unitRef="number" contextRef="i720010c532d04ae38a15375c00f6c278_I20210630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDcwNDM_49093c06-e764-4333-8b33-3f041ec054d3">40</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, APC paid $<ix:nonFraction unitRef="usd" contextRef="i658af4a1b5524e469c86ffaf726d3a51_D20210401-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc0NTA_921f1aaf-15e6-476f-8e91-fdbd3dd77bbc">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8069e38106d34794bbbea1a815263bf1_D20210101-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc0ODE_be0069bf-f50e-4a57-8c11-b8650beeb2de">3.2</ix:nonFraction> million, respectively, to DMG for provider services, which is accounted for under the equity method based on the <ix:nonFraction unitRef="number" contextRef="i686c7f250f0e4d35824cd656b22866ad_I20220630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc1OTA_a12fbf74-f2be-4cda-9da4-46f290d3cbe0">40</ix:nonFraction>% equity ownership interest held by APC. In October 2021,  DMG was consolidated by Apollo. As such, DMG is no longer a related party.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i2ba4984e1d0947a59e1755baeb841f28_D20220401-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc4NjM_8d880f8f-513a-4246-84d1-7c7bec855d4f">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i42ce7049b8564902b4714f05408d23cc_D20210401-20210630" decimals="-3" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc4NzE_205ece8e-7148-4abe-800d-b07ac044ad5f">30,000</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7f93bbd717a34da48676ae33c98e2878_D20220101-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc4OTQ_896e07f7-a305-4e0c-8f20-87e2051a643b">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if9d5e8e10ad4481ab709154b84b5e390_D20210101-20210630" decimals="-3" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc5MDI_b6f62f4a-1f08-44d2-b506-292d8c626bb4">51,000</ix:nonFraction> to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i47b66c55e1084cb1b52c404c22c765cf_D20220401-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTEwMjY_c4f7f70a-3393-415a-bcc4-bc1aed26f373">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i570036110c9340efa486b231d649cf09_D20210401-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTEwMzQ_e0e90471-f3b3-4c15-a287-4d0d05400dd7">0.3</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="if91fffa5808944f686a081038f37122c_D20220101-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTEwNTc_6399a7c2-d3cd-4d67-a206-3c3abe0b94eb">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3873e858d6954dc9a1e7b2ebfd958d51_D20210101-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTEwNjU_65c2386c-934f-44bb-b955-8c76edcd96e4">0.4</ix:nonFraction> million, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company&#8217;s board members is a board member of Fulgent Genetics, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022 and 2021, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="ie0924e12aa8d4ee4b2641423ceba4881_D20220401-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE1MjE_53bbe553-6b5b-4543-9612-d004f89bce29">12.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibf42668aa8fc4595af61af9ed0dceace_D20210401-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE1Mjk_edd8bcbd-b538-4cba-b999-c9bcaaeefea1">8.2</ix:nonFraction> million to shareholders, respectively, which included approximately $<ix:nonFraction unitRef="usd" contextRef="i1340961fa52f41c78bd6a84fc6c342d9_D20220401-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE1OTM_5ec0999a-fc53-45b1-a3d9-1020d4b69e28">3.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5fd9786f0dd94c12a12df172b4e36ceb_D20210401-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE2MDE_a7a9b731-cc76-4715-9b5b-5a7be61623a1">2.2</ix:nonFraction> million, respectively, to shareholders who are also officers of APC. During the six months ended June&#160;30, 2022 and 2021, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i06340797df8f4752a83e03326162b898_D20220101-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE3NDY_86b5ed8e-80a7-4cf6-b9f1-1ec3115ef282">21.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff12e49686f34776bca7427f81b46a8e_D20210101-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE3NTQ_b5c1339a-dbf4-4534-a489-ee0db5c31b7e">15.6</ix:nonFraction> million to shareholders, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i493e02bb89bd49aaa06143a91d99bd2e_D20220101-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE3OTM_ece44d86-49bb-4d80-bfdf-2ee01e6837b5">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3be6c5a1eee74540ac2a07c4971194b7_D20210101-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE4MDE_a74231ab-fb90-45b6-b4dc-de92094ddf81">3.8</ix:nonFraction> million, respectively, to shareholders who are also officers of APC. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i34cbce8b5ff14dd785f3598cf805c5a4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2022 and 2021, SCHC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i70e5cc9cbbc44c1ca2da76b30137a3ab_D20220401-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTIxMDY_55be06e8-f39c-4bf4-88cc-b6e4784192a5">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0933e3ac6e9444cca9e2cf27d88e1e4d_D20210401-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTIxMTQ_d031175d-6a38-48e1-9af1-187b3175b591">0.1</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="id668620835dc4bb0acb31d65a5da7f73_D20220101-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTIxMzc_2a69f489-de67-4455-b8fd-68f923fa2ed8">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib853e0afcc864f9fb37c1a57ebf20e0d_D20210101-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTIxNDU_ea7d6a4f-3af1-4201-b05a-12baeaee226a">0.2</ix:nonFraction> million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six ended June&#160;30, 2022 and 2021, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="i4ed1fb4cb8784d2baa6d489ba5f6e31c_D20220401-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI1OTg_be245e50-5993-441b-b213-a18d2c8039d0">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2fb8594254234c10bce4ca7cad2d7f34_D20210401-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI2MDY_5caee83f-329a-454b-9e2f-c061d606fe37">0.4</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ic5b1510e6b3e48aab9201dae55a97382_D20220101-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI2Mjk_200233d9-b1fc-4af6-b8dd-410664a553e9">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id84ea8946f574e32a5be27bbbc154f24_D20210101-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI2Mzc_26a2ffd4-0a45-4255-bf9e-086112ab14f1">0.7</ix:nonFraction> million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="i52933dc179ba4dbc8f26c1943d99f3ed_I20220630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM2ODY_ab73e07b-7676-424a-9b69-8750eb88757c">50</ix:nonFraction>% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i608f29a5f13e45cfa7a9e81eef3d1ed6_D20220401-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzI1NDk_1a0b3047-7ec7-40a3-9bcf-3cbf2ad9953a">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i103376726f94415da0aa6fb6fa1625f1_D20210401-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzI1NTY_ee40e130-6d44-47e7-8f80-e2f764e3aaf2">3.6</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ib0fe166dd3574c6b86ee5fd3faa41fb8_D20220101-20220630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI4Nzc_0f99e85f-d3a9-4d4b-9e41-36eef6b60d78">7.3</ix:nonFraction> million and to $<ix:nonFraction unitRef="usd" contextRef="i0213948f1599453ab721957923ae20aa_D20210101-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI4OTA_dcd54769-a5d0-4bbe-8616-eeafe3344487">7.0</ix:nonFraction> million, respectively, to Arroyo Vista Family Health Center (&#8220;Arroyo Vista&#8221;) for services as a provider. Arroyo Vista&#8217;s chief executive officer is a member of the Company&#8217;s board of directors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzQxOTU_f70d539a-d91a-4cd0-8ab1-3b7f81ba931b" continuedAt="ic6df979ff3a14fe294e8de87e925c788" escape="true">The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ic6df979ff3a14fe294e8de87e925c788"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1c490153ac4f1cb6028c98823533b4_D20220401-20220630" decimals="-3" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzItMS0xLTEtMTA1MDMz_2cc1efc5-3fdd-4dd0-8a19-aa383acb62cf">14,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if433cdd244a24b8e8f0de5c3a6d6a9da_D20210401-20210630" decimals="-3" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzItMy0xLTEtMTA1MDMz_6c7fd65d-9a64-4db2-933e-ad2a9f7eeff9">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d25dc960744271ba14d5a22e01a9f4_D20220101-20220630" decimals="-3" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzItNS0xLTEtMTA1MDMz_5ca1ebe9-416b-4c18-af2d-641a9b4b4651">25,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcbf57723d89405ea64c036cc63fb0eb_D20210101-20210630" decimals="-3" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzItNy0xLTEtMTA1MDMz_60858b3e-f3c3-423c-9372-1f489d18ebd3">25,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if451ab4e4ce44c71a99f29e2c5e07e30_D20220401-20220630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzMtMS0xLTEtMTA1MDMz_7692e237-447c-4b7e-9763-6ec45cf8d8b5">649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fb1b871a5524ffcbf6e9b30520d3b46_D20210401-20210630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzMtMy0xLTEtMTA1MDMz_918cc1a2-483f-4f95-be6f-82b479ff41ea">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87972789a91f4575b4ee414751a09b0d_D20220101-20220630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzMtNS0xLTEtMTA1MDMz_25463391-df25-4101-8804-7b00500a4bb4">728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94083cc9f0fc4e369ee64217a4f7e9fc_D20210101-20210630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzMtNy0xLTEtMTA1MDMz_236f1441-7db7-48ad-a492-2c6628176319">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba052b72bbb34b62be83891b4561a8d2_D20220401-20220630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzQtMS0xLTEtMTA1MDMz_29e60bf5-d194-4eb9-ac1a-2119d9a3ac0c">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad69ae1f414c4d90bc9075012d5d4d30_D20210401-20210630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzQtMy0xLTEtMTA1MDMz_ae0787a1-2ef5-4caa-80e1-5ae23bae566e">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib23158de6e644cdd9bc4e3523331c1e9_D20220101-20220630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzQtNS0xLTEtMTA1MDMz_044193cb-ca40-4adb-a50c-5a8530fbfc0b">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie446c27adcbd42b59894a90417c05196_D20210101-20210630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzQtNy0xLTEtMTA1MDMz_b66993a0-a73a-4e40-8bd2-1e5be399c93e">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzYtMS0xLTEtMTA1MDMz_779dcdfe-dc03-4db6-8ebd-fc1bd1c1232e">13,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzYtMy0xLTEtMTA1MDMz_7e683875-bfea-41c2-953b-0b06051cd68f">12,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzYtNS0xLTEtMTA1MDMz_ff8e7c98-d7ec-42f1-b5de-a45b7c6c25a3">24,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzYtNy0xLTEtMTA1MDMz_99270638-ae7e-4c45-b1c6-0f192a72f3fd">25,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June&#160;30, 2022 and 2021, the Company has recognized risk pool revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="idd1c490153ac4f1cb6028c98823533b4_D20220401-20220630" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1MjE_2a68a65e-8604-4e63-bace-1e12829dd824">13.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if433cdd244a24b8e8f0de5c3a6d6a9da_D20210401-20210630" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1Mjk_2b52a3ac-92fb-4793-9213-d10c8213bae6">14.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i92d25dc960744271ba14d5a22e01a9f4_D20220101-20220630" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1Mzg_b35c0dfe-2cd3-4dc9-b39b-6c0f5fa4cf3a">25.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibcbf57723d89405ea64c036cc63fb0eb_D20210101-20210630" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1NDY_a4998285-083b-4cd6-89d0-c2646c7358b5">31.2</ix:nonFraction>&#160;million, respectfully, of which $<ix:nonFraction unitRef="usd" contextRef="i7f46457a64ad499c901e9853b8d0ba22_I20220630" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1NzQ_1b96e626-e16e-4049-b003-3cf7fe504e0e">76.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i706352fc1d254fd5a5e36dc095d71cfe_I20211231" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1ODI_fd77f42a-3e2c-488a-b7d5-b5ea117dfb3a">58.4</ix:nonFraction> million remained outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022, APC paid $<ix:nonFraction unitRef="usd" contextRef="ib64616cababe4909a842281a3ca6fa56_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzQzOTgwNDY1MjQyNzU_6039f417-28cb-49b0-989d-4c72f6b73427"><ix:nonFraction unitRef="usd" contextRef="i817afcd7d5c442c2b55faa40b0d1a8f5_D20220401-20220630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzQzOTgwNDY1MjQyNzU_74326a31-3f43-4015-9224-cee361be0027">9.3</ix:nonFraction></ix:nonFraction>&#160;million to purchase Apollo&#8217;s stock from a board member. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including Dr. Thomas Lam, ApolloMed&#8217;s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments and loans receivable from related parties, see Note 5 &#8212; &#8220;Investment in Other Entities - Equity Method&#8221; and Note 6 &#8212; &#8220;Loan Receivable and Loan Receivable - Related Parties&#8221;, respectively.</span></div></ix:continuation><div id="i479e2a4965a945a4983dec200085612c_115"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTUvZnJhZzowYjhhODdjYThjZWE0NzIzYmUwOGM2YzAzMzk4MmFkMS90ZXh0cmVnaW9uOjBiOGE4N2NhOGNlYTQ3MjNiZTA4YzZjMDMzOTgyYWQxXzI0ODI_98cf05aa-27c1-4718-83d7-d30d2f7c7212" continuedAt="i18ec632d7f5f43e9ba15fd20fa6922b0" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i18ec632d7f5f43e9ba15fd20fa6922b0" continuedAt="if682fdb708e442c7921ebfe771997daa"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="if682fdb708e442c7921ebfe771997daa"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the six months ended June&#160;30, 2022 and 2021, was <ix:nonFraction unitRef="number" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTUvZnJhZzowYjhhODdjYThjZWE0NzIzYmUwOGM2YzAzMzk4MmFkMS90ZXh0cmVnaW9uOjBiOGE4N2NhOGNlYTQ3MjNiZTA4YzZjMDMzOTgyYWQxXzE2NDkyNjc0NDQxNDk_72c4e7a7-2113-4d8a-bff1-21b69b5f36b5">35.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTUvZnJhZzowYjhhODdjYThjZWE0NzIzYmUwOGM2YzAzMzk4MmFkMS90ZXh0cmVnaW9uOjBiOGE4N2NhOGNlYTQ3MjNiZTA4YzZjMDMzOTgyYWQxXzE2NDkyNjc0NDQxNTQ_0e0b4907-1587-4337-a362-dd2acff5ef2c">30.0</ix:nonFraction>%, respectively. The tax rate for the six months ended June&#160;30, 2022, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, non-deductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2017 through December&#160;31, 2021, and for the years ended December 31, 2018 through December&#160;31, 2021, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.</span></div></ix:continuation><div id="i479e2a4965a945a4983dec200085612c_118"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzEwOTA_a7cda688-ed7d-4e3b-bc65-d4249d4d22ab" continuedAt="i682e79f780ac47c0b00160e136153251" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="i682e79f780ac47c0b00160e136153251" continuedAt="ic8c2cd89ba5e4e05bc8da399d43c883b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, APC held <ix:nonFraction unitRef="shares" contextRef="i9902cb6392bf40fe99762875e13589c3_D20220101-20220630" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzcyNw_ec7589e0-1075-488e-b72a-2e779928f381">11,175,702</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i70e8720f09834880b0eb68cb4dfd69c0_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzE2NDkyNjc0NDI3NzE_22093d69-5a79-4669-ab2f-e9d5887f0c4c">10,925,702</ix:nonFraction> shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2022 and June&#160;30, 2021, restricted stock of  <ix:nonFraction unitRef="shares" contextRef="iea207f25a4494db3b8ca98bec38b0cf3_D20220401-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMxMTY_dcdb139a-0aa5-414c-bd84-fc7f728cd2d4">394,606</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i09d176d59d3c498f8f2c88e2c37d402e_D20210401-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMxMjI_adc5ac4b-286d-4fd5-91b3-64247f3e38fc">0</ix:nonFraction>, respectively were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive. For the six months ended June&#160;30, 2022 and June&#160;30, 2021, restricted stock of  <ix:nonFraction unitRef="shares" contextRef="i535c48c761b74aa9ac2acbd6ebd3be28_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMxMDQ_4731871f-06ee-4e23-ab4b-46d7af1f420c">257,193</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ica66f014fe6849c9a087191711c14b58_D20210101-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMxMTA_45dd1fd9-6063-4088-86cd-91877e7f0820">0</ix:nonFraction>, respectively were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="ie4b065ecad2c4dd18600860d892995a7_D20220101-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMwOTg_e81d3874-68b0-458c-9fde-edc7c04b2e90"><ix:nonFraction unitRef="shares" contextRef="i7bd5950728274396a47ab8be6047ebba_D20220401-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMwOTg_f52549e7-4651-44b3-9518-3a825d5db8fa">242,899</ix:nonFraction></ix:nonFraction> of restricted stock with performance conditions were excluded from the computation of diluted weighted average common shares outstanding because these conditions were not achieved as of June&#160;30, 2022.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzEwOTg_2e584d04-28fe-4cbd-9f2a-d19f72692443" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzEtMi0xLTEtMTA1MDMz_00acaaa9-7c00-4661-8882-b8c72f1d720a">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzEtNC0xLTEtMTA1MDMz_89d1e288-ff6d-406f-a71e-76585560b60f">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzItMi0xLTEtMTA1MDMz_036d6510-b938-4cc8-8a06-522f094d2c81">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzItNC0xLTEtMTA1MDMz_fc71b44e-3089-4300-88f6-1bbb60d61c17">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzMtMi0xLTEtMTA1MDMz_743c327b-adfb-40b6-97bb-059aa5d90bcf">44,858,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzMtNC0xLTEtMTA1MDMz_d02be5ac-8964-4ab9-809b-34bff69d9152">44,165,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzQtMi0xLTEtMTA1MDMz_8445aa53-9fe5-40b5-8ff3-e8fc4a6ea7e9">46,023,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzQtNC0xLTEtMTA1MDMz_0be35ee0-e654-4836-a728-c29f639b8acc">45,828,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzEtMi0xLTEtMTA5NzA0_a71b137d-09c8-4029-899e-fd2db7d01bc1">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzEtNC0xLTEtMTA5NzA3_53e3535e-6b59-42f2-95e4-df8bba6d3de2">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzItMi0xLTEtMTA5NzA0_87a04339-596b-4f3e-8169-2c0631f13fc4">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzItNC0xLTEtMTA5NzA3_e19e2c80-50dc-4bc2-9016-a29ef8c9d389">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzMtMi0xLTEtMTA5NzA0_50ee6e8a-4505-40a8-9ade-2a3a98aa4ac3">44,815,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzMtNC0xLTEtMTA5NzA3_f8b2cf5f-1f97-4139-8b94-4cfa04acce42">43,255,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzQtMi0xLTEtMTA5NzA0_2c317f14-d9ca-4531-8679-b3670639f16a">46,082,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzQtNC0xLTEtMTA5NzA3_ef28edad-3abc-4d62-9045-c45420898294">44,746,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzEwOTU_b39062fc-544e-45e4-ab05-50b7f31b2547" continuedAt="i3968cd3d3f9f4d0e818eb4128a4abe1e" escape="true">Below is a summary of the shares included in the diluted earnings per share computations:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ic8c2cd89ba5e4e05bc8da399d43c883b"><ix:continuation id="i3968cd3d3f9f4d0e818eb4128a4abe1e"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzEtMi0xLTEtMTA1MDMz_10e5fd77-6ab8-4d55-bf04-d152232fb506">44,858,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzEtNC0xLTEtMTA1MDMz_a7721904-87d6-43ff-947e-6f0f504f17b5">44,165,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id604da4cbf9d48cd853c3313a4b215d1_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzMtMi0xLTEtMTA1MDMz_dfd350d7-0b57-4d37-b72a-89eb79f13a3d">418,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ad190507ff44da9b6ffe950ec0a7c48_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzMtNC0xLTEtMTA1MDMz_47d8a02a-dd68-4d29-9534-93d3d5fe8711">466,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b1e7c7a12844a52bcf3c60b54e403b8_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzQtMi0xLTEtMTA1MDMz_7a6c5b95-d568-4845-9619-ac4732ac4399">651,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbe4add77b0642b587fbbdfc4e0469d7_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzQtNC0xLTEtMTA1MDMz_f126623c-0840-480b-8942-4e8d22b6e340">992,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea207f25a4494db3b8ca98bec38b0cf3_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzUtMi0xLTEtMTA1MDMz_02f15140-25f9-4f37-bb23-2cd91ea5ad78">94,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09d176d59d3c498f8f2c88e2c37d402e_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzUtNC0xLTEtMTA1MDMz_ea8299ad-c954-4745-b26b-705407451987">204,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzYtMi0xLTEtMTA1MDMz_2ae5ef69-a1cd-455f-8f33-1da8cd891503">46,023,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzYtNC0xLTEtMTA1MDMz_980c5845-0e31-4dfb-878a-35f607861a16">45,828,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzEtMi0xLTEtMTA5NzI2_b6482cfa-f918-4f5b-84c3-11b14762b4a4">44,815,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzEtNC0xLTEtMTA5NzI5_9ecdb032-eadd-4da9-882f-999cfda13a67">43,255,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie500388613f5490c85227584adbecd21_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzMtMi0xLTEtMTA5NzI2_20e165a3-f5af-42c5-986b-0c1f2bddd333">455,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i082d8e652b86490ea5c3fe0dfaaaa3c7_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzMtNC0xLTEtMTA5NzI5_44ed32f4-f050-4644-a4b5-91724555aefe">409,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib08d24f28e4a48f99ec3872354ff7790_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzQtMi0xLTEtMTA5NzI2_7db345d1-7b6c-40c5-a937-467683899246">689,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49102b8554a1457c8a1f914d3daaa7f9_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzQtNC0xLTEtMTA5NzI5_a823c24b-e01f-4e57-8bfa-ba53d2ad0ee1">911,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i535c48c761b74aa9ac2acbd6ebd3be28_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzUtMi0xLTEtMTA5NzI2_bb38a870-0ad0-4857-9c61-edaf5ec89f38">122,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica66f014fe6849c9a087191711c14b58_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzUtNC0xLTEtMTA5NzI5_17f64373-beae-4d13-8061-5eeb9086baec">170,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzYtMi0xLTEtMTA5NzI2_cb4f6a01-bdf9-4ec8-8810-16e08a596121">46,082,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzYtNC0xLTEtMTA5NzI5_cec2ae91-9a2f-420a-93c9-6d7afe9792d5">44,746,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="i479e2a4965a945a4983dec200085612c_124"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90ZXh0cmVnaW9uOmViZmUyMzU5MDQ0YTRkMjFhYmQ4Y2EwYmI1YzYzNWZjXzE5MzY_4ee4a458-079f-4c4e-9b5f-bc966cd80e80" continuedAt="i841d0adda370408fa6e2d91b2fbae1b9" escape="true">Variable Interest Entities (VIEs)</ix:nonNumeric></span></div><ix:continuation id="i841d0adda370408fa6e2d91b2fbae1b9" continuedAt="idd042086c5cb4b818409207bd9376905"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90ZXh0cmVnaW9uOmViZmUyMzU5MDQ0YTRkMjFhYmQ4Y2EwYmI1YzYzNWZjXzE5Mzg_6dd2a8ee-c91d-46f2-9627-c8384c1d143c" continuedAt="i208e999f0f634a45ad19bc38819e1f42" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQtMS0xLTEtMTA1MDMz_45419f4a-b5b9-4154-bce1-9650d2e2e51a">139,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQtMy0xLTEtMTA1MDMz_4a679241-3ffe-4b05-8fac-1883c05719d2">161,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUtMS0xLTEtMTA1MDMz_e8bf7128-77f8-4021-9853-63bfe8db2979">37,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUtMy0xLTEtMTA1MDMz_a2f29c83-ddd0-4b06-a2cc-a6a8a05ef71f">49,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzYtMS0xLTEtMTA1MDMz_0d623835-1c79-429c-ba96-58d05c66f91e">21,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzYtMy0xLTEtMTA1MDMz_5d2d8a52-935b-4a14-8f0a-ce07478cd826">7,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzctMS0xLTEtMTA1MDMz_98736c39-8389-4e33-8ca3-4dfb2c547256">80,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzctMy0xLTEtMTA1MDMz_70d23f4c-7176-4438-8d88-17d74af6af94">62,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzgtMS0xLTEtMTA1MDMz_23541e42-9655-4c06-b902-7eee2921222c">4,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzgtMy0xLTEtMTA1MDMz_35dcff5b-87f2-49fc-a276-0f9bfebb1c77">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzktMS0xLTEtMTA1MDMz_c2d5c203-fb80-481d-ad26-544217cfce3d">1,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzktMy0xLTEtMTA1MDMz_0b56cca5-c679-43e3-8249-8a715ec210cf">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEwLTEtMS0xLTEwNTAzMw_e8c9d18c-aa71-47d8-b5c2-a1a9ded2ba1a">6,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEwLTMtMS0xLTEwNTAzMw_6cb7a08f-7d2e-47e0-8e26-9e99c1b75d58">11,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzExLTEtMS0xLTEwNTAzMw_e5f7293b-6eb1-42c4-b864-c39f50876bbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzExLTMtMS0xLTEwNTAzMw_27dc7be0-9c3a-40b2-8e83-f022c9f2b077">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:DueFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEyLTEtMS0xLTEwNTAzMw_4ea94146-8682-4a83-aef1-8f43c3fb49d6">35,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:DueFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEyLTMtMS0xLTEwNTAzMw_091fc73b-a5e6-462d-9e12-9624b5fee4ef">6,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEzLTEtMS0xLTEwNTAzMw_5cbdd106-36f9-4b69-a21a-af2a55aa9a44">328,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEzLTMtMS0xLTEwNTAzMw_1180d79d-102f-4355-9bc6-44d51977b8e5">305,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><ix:continuation id="idd042086c5cb4b818409207bd9376905"><ix:continuation id="i208e999f0f634a45ad19bc38819e1f42"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE2LTEtMS0xLTEwNTAzMw_9609a8be-4afa-4333-9745-eac01ffaaf3b">85,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE2LTMtMS0xLTEwNTAzMw_fa9b5558-5962-42c1-ae40-e87654a845e1">49,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE3LTEtMS0xLTEwNTAzMw_aaad75f0-c147-4722-8072-eb3dc0d3ae97">58,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE3LTMtMS0xLTEwNTAzMw_002913a7-f87b-4bf4-803e-6aa4c86150eb">58,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE4LTEtMS0xLTEwNTAzMw_c28e2ae6-10ea-4df4-96a1-833f828f5bff">116,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE4LTMtMS0xLTEwNTAzMw_10f716c4-ef80-49ee-889a-84cab5c92713">109,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable, net of current portion </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE5LTEtMS0xLTEyMzY1Mg_1574897a-b89d-4976-8aa1-74d7fd1a6ce6">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE5LTMtMS0xLTEyMzY1OQ_3d2b96f9-74d7-464c-b9f5-4b1843604650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE5LTEtMS0xLTEwNTAzMw_ae942a64-abb9-4444-997a-f8592a425cc9">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE5LTMtMS0xLTEwNTAzMw_38a3e2b4-3333-40d0-be63-82f6a3d4922e">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIwLTEtMS0xLTEwNTAzMw_bdb0e726-99fd-499d-99df-f1545fc884f4">431,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIwLTMtMS0xLTEwNTAzMw_8e4788db-a98e-43f7-b222-45a6aab1b345">802,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIxLTEtMS0xLTEwNTAzMw_5bebebcc-d2d3-4ede-9cc3-47efb2183d54">31,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIxLTMtMS0xLTEwNTAzMw_0c88975a-018e-4131-87d1-91e4f00594ad">41,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIyLTEtMS0xLTEwNTAzMw_b59e9763-3007-4094-8052-4ff5132fff73">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIyLTMtMS0xLTEwNTAzMw_b9b185ef-41c6-4d4b-a34e-dfd3296202bb">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI0LTEtMS0xLTEwNTAzMw_e93a59f7-d2a7-4f89-9217-854ea828b062">9,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI0LTMtMS0xLTEwNTAzMw_6b1d062c-588f-4a67-b53b-64f7a960d0b4">4,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI1LTEtMS0xLTEwNTAzMw_d1ea8389-78f5-4d17-936a-529e9000974d">2,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI1LTMtMS0xLTEwNTAzMw_8106492a-7fd2-4111-8ebb-b1c4cff4694b">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI3LTEtMS0xLTEwNTAzMw_6348c085-df67-470f-bf17-bdc74de1ea77">738,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI3LTMtMS0xLTEwNTAzMw_bdf31396-5841-436c-9147-d76133ff086b">1,070,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI5LTEtMS0xLTEwNTAzMw_dd3c17ff-16ab-41d4-91e5-43e0d2728bb4">1,066,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI5LTMtMS0xLTEwNTAzMw_5f0930e2-4f1d-422e-865c-6288ec3f2480">1,376,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzMyLTEtMS0xLTEwNTAzMw_7840b83c-d668-4686-8a1d-b013c9e8c457">16,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzMyLTMtMS0xLTEwNTAzMw_2867a908-6ce3-44ba-a0ca-d4600d77b3aa">11,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzMzLTEtMS0xLTEwNTAzMw_433b12f6-e75f-45f1-9a9a-0fe50a107562">6,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzMzLTMtMS0xLTEwNTAzMw_315e2a41-62b5-4049-8044-94b995c88aa0">10,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM0LTEtMS0xLTEwNTAzMw_4fb510cf-7ddd-42c5-8351-2f6833b00767">71,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM0LTMtMS0xLTEwNTAzMw_2e9c7f43-1b69-4f61-9ae9-c32c1efb4e41">44,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM2LTEtMS0xLTEwNTAzMw_9990534a-fa3b-4589-8d87-184a3c62f96b">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM2LTMtMS0xLTEwNTAzMw_20a8311d-e45d-4909-9227-dbb99941d659">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM4LTEtMS0xLTEwNTAzMw_fada8d7f-81a2-4f9d-8345-403a287d8400">2,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM4LTMtMS0xLTEwNTAzMw_6f915cd0-5d4e-4369-8444-65c056f1d99d">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM5LTEtMS0xLTEwNTAzMw_7c1166b8-3fe5-48c8-af27-4df715849752">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM5LTMtMS0xLTEwNTAzMw_b2b74ab3-0486-498a-94c4-1111d06b9d43">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQwLTEtMS0xLTEwNTAzMw_21f65d2d-4a4f-4251-ba07-b206dba06919">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQwLTMtMS0xLTEwNTAzMw_688fd3b4-0637-45d2-8d2e-636349612927">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQyLTEtMS0xLTEwNTAzMw_13129a8f-b5b7-4c95-ae17-edf82c478bc8">99,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQyLTMtMS0xLTEwNTAzMw_3ff55780-ea93-4881-8364-92aa512efcc7">68,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ1LTEtMS0xLTEwNTAzMw_92552c16-d773-401a-aa69-5b500f149a0b">22,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ1LTMtMS0xLTEwNTAzMw_da71a66f-d993-4232-bf5d-0f1461bb0e89">7,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ2LTEtMS0xLTEwNTAzMw_44dcbf23-1f80-4a06-abee-2569e2a6e4d9">3,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ2LTMtMS0xLTEwNTAzMw_cc36cec6-0eb3-4e25-b1f1-bf8bc308e266">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ3LTEtMS0xLTEwNTAzMw_e133223a-84d8-4675-bdf5-a89daf2f7366">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ3LTMtMS0xLTEwNTAzMw_e8aef088-830d-40ff-89fc-3657ac9b8f97">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ4LTEtMS0xLTEwNTAzMw_7a563fd3-3b71-44d6-9351-508264fd4d29">8,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ4LTMtMS0xLTEwNTAzMw_e59293ab-85d4-42d6-82b9-4d0bd809cdaa">3,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ5LTEtMS0xLTEwNTAzMw_6b4b9525-60e1-484d-8e10-1de89ceeee07">8,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ5LTMtMS0xLTEwNTAzMw_fd82b8c8-2843-4dc8-a2ba-81291574249e">9,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUxLTEtMS0xLTEwNTAzMw_0be6478f-4999-46ef-bb02-ffa5d2af9c1c">44,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUxLTMtMS0xLTEwNTAzMw_8dbbc678-28a6-4de4-a579-e4bb1115e479">22,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUzLTEtMS0xLTEwNTAzMw_c1422791-db43-48da-82fb-b20ba5d6b39c">143,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c2773d57946a3995aed561a9def52_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUzLTMtMS0xLTEwNTAzMw_c6578239-d863-4412-9e08-63eddfaf5c59">91,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i479e2a4965a945a4983dec200085612c_127"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNTY_31456055-e8b4-434b-9d98-406cd14dddc7" continuedAt="i28fc03c41fe4453cac74f43e90a88298" escape="true"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNjI_2dfcfcc9-b5b3-4f3a-be7e-2a1cb0cf9972" continuedAt="ie76fd96e24fb47f48f840a52f8bf0163" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i28fc03c41fe4453cac74f43e90a88298" continuedAt="i8c18d9a465b541df96dbacfe9e6cd99f"><ix:continuation id="ie76fd96e24fb47f48f840a52f8bf0163" continuedAt="iedfb2687ef7347c18fa1f6eb4fec325f"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of <ix:nonNumeric contextRef="i15757c3b5f1f4c7ca17b41a6d3ae72fa_I20220630" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzE3Mw_131e480d-c12b-4c74-b511-e8a836a067d4"><ix:nonNumeric contextRef="i15757c3b5f1f4c7ca17b41a6d3ae72fa_I20220630" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzE3Mw_bc531302-763a-4dd4-8a77-273bb27ad1e4">thirty days</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="i6b1ed3c5e65d4fbbb94a7b74e3634086_I20220630" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzE3OQ_ce4fd3fa-3761-449f-99ee-fdbf364f343e"><ix:nonNumeric contextRef="i6b1ed3c5e65d4fbbb94a7b74e3634086_I20220630" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzE3OQ_fb2676cc-a217-4cb1-9be3-2ce2d2c0b00b">nine years</ix:nonNumeric></ix:nonNumeric>. Some of the leases may include options to extend the lease terms for up to <ix:nonNumeric contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzI0OA_2618008a-5268-4ca1-9d4e-0626275d5600"><ix:nonNumeric contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzI0OA_fd56126c-e0fb-43e3-a761-4098b0fa0191">10</ix:nonNumeric></ix:nonNumeric> years, and some of the leases may include options to terminate the leases within <ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzMyNw_5a13bdca-6967-4a8d-9714-190a6db50135"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzMyNw_b764eb9f-a324-4d1c-971f-418d7e881c2f">one year</ix:nonNumeric></ix:nonNumeric>. As of June&#160;30, 2022 and December&#160;31, 2021, assets recorded under finance leases were $<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzM5MA_0334ed6d-a62a-440e-900c-958bc45e8319">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzM5Nw_74014390-11b1-4149-9b98-c49bb46c30b8">1.3</ix:nonFraction> million, respectively, and accumulated depreciation associated with finance leases were $<ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzQ4MA_758ddecd-d951-4c29-99cc-79198ed11f76">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzQ4Nw_1f7e1022-3af4-4e8b-b49a-7b6e6132167e">0.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheets.</span></div><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNTg_510e60ab-467f-446f-bb0f-565da14606d8" continuedAt="i54db55b8a44a4205abe8bb98a110ad46" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzMtMS0xLTEtMTA1MDMz_b2bd8ac1-b30d-4435-a92d-cef56cbcf822">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzMtMy0xLTEtMTA1MDMz_3a80960d-d3a9-415c-9967-741def7b5b38">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzYtMS0xLTEtMTA1MDMz_75877a16-e54c-408e-b399-e83c5e651e7b">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzYtMy0xLTEtMTA1MDMz_6c936f14-c9fb-4d8e-809b-f0591c221fcd">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzctMS0xLTEtMTA1MDMz_50b9558b-d865-4c5c-a4f5-179d05924ea1">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzctMy0xLTEtMTA1MDMz_b7ec20ef-c58d-45bf-8cf8-1615d2b77a33">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzktMS0xLTEtMTA1MDMz_523002ac-060f-4cd5-8713-ddaeb4ebcfa8">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzktMy0xLTEtMTA1MDMz_b469a0a6-5b84-43bf-8170-47c2e87c348f">280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzExLTEtMS0xLTEwNTAzMw_d8c98a98-c019-44dd-beb3-156917a9e78d">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzExLTMtMS0xLTEwNTAzMw_815341cc-c7fb-49f0-bb9e-d5b210c649ab">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzQtMS0xLTEtMTA1MDMz_0d5977a0-bc8b-4662-a3a3-31b3987c0f29">3,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzQtMy0xLTEtMTA1MDMz_85aaa014-1587-4390-9cfa-f5b94140544a">2,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzctMS0xLTEtMTA1MDMz_30875efa-d020-48b6-a160-29e28b5819cd">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzctMy0xLTEtMTA1MDMz_d5fa2e27-b58b-412b-a323-a541d69d80a7">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzgtMS0xLTEtMTA1MDMz_98cf66c7-ef6a-463b-b0a8-7ebdc3c5f056">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzgtMy0xLTEtMTA1MDMz_a3cc8a98-14d5-482e-b3d2-1fb212fbde16">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzEwLTEtMS0xLTEwNTAzMw_559ad0fa-8cd2-40e3-bf5f-79b8bca20156">332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzEwLTMtMS0xLTEwNTAzMw_2c27c2ea-5e8a-46f7-a1f3-38997a96595b">473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzEyLTEtMS0xLTEwNTAzMw_11ce4c7d-029d-4347-930d-e6beb32bfc72">3,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzEyLTMtMS0xLTEwNTAzMw_d6883f16-839f-4d0d-ba57-ac3c786e9ca4">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i8c18d9a465b541df96dbacfe9e6cd99f" continuedAt="ie939b5af316f4b69a17168776debaed7"><ix:continuation id="iedfb2687ef7347c18fa1f6eb4fec325f" continuedAt="i5b0eea88b05042faac4b22bbfea0f835"><ix:continuation id="i54db55b8a44a4205abe8bb98a110ad46"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzYtMS0xLTEtMTA1MDMz_413aae91-44e1-4dea-8320-bc12b3d2a32b">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzYtMy0xLTEtMTA1MDMz_f6e473ad-d1d3-4c39-bb98-02524befe9e0">1,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzctMS0xLTEtMTA1MDMz_e5f7e0cd-04dd-447a-a123-42bf1dcbbfb9">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzctMy0xLTEtMTA1MDMz_83af3bec-2fc0-4f5c-95bf-ab0b81d91825">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzgtMS0xLTEtMTA1MDMz_abe78ef1-1c9f-4593-af68-c42ee11eb954">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzgtMy0xLTEtMTA1MDMz_47aafa34-01c6-47c0-bca6-45dbf95222a1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzE5LTEtMS0xLTEwNTAzMw_c1df33b5-f480-4bb5-89b7-d4a821be0b21">3,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzE5LTMtMS0xLTEwNTAzMw_44ce80f1-de17-4f11-8634-2dca43a5babd">3,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzIwLTEtMS0xLTEwNTAzMw_d294d849-b0e4-40ce-9a69-c3e78734beb0">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzIwLTMtMS0xLTEwNTAzMw_0de9da97-1e83-4804-a7f4-64cbf9f901ee">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzIxLTEtMS0xLTEwNTAzMw_36dc0974-6ea9-4a93-a004-383944ac3ac0">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzIxLTMtMS0xLTEwNTAzMw_1d80e1d1-d6f2-4505-a2df-8bcd440a9d36">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzMxLTEtMS0xLTEwNTAzMw_62b72dc8-e70a-4212-9b63-48e441277fee">6.55</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4becb57108e844a2af77734d782c9546_I20210630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzMxLTMtMS0xLTEwNTAzMw_5d35176e-9935-4472-a183-a2449eb40d76">6.56</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzMyLTEtMS0xLTEwNTAzMw_4c5120cf-f91f-4f52-8f24-44435e427050">3.11</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4becb57108e844a2af77734d782c9546_I20210630" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzMyLTMtMS0xLTEwNTAzMw_bd0eef74-7e01-40fe-9ed4-90c5bd0c84a5">3.17</ix:nonNumeric> years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzM2LTEtMS0xLTEwNTAzMw_3b8af842-209d-4cfd-875a-bc7e18fdb48a">4.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4becb57108e844a2af77734d782c9546_I20210630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzM2LTMtMS0xLTEwNTAzMw_faad2eeb-1b73-4355-ba4e-d5cb8c2a770a">6.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzM3LTEtMS0xLTEwNTAzMw_1142f521-f92d-44f1-b557-da6175af4ed3">4.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4becb57108e844a2af77734d782c9546_I20210630" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzM3LTMtMS0xLTEwNTAzMw_920d0962-5975-4192-83e9-1a47189b73fc">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ie939b5af316f4b69a17168776debaed7"><ix:continuation id="i5b0eea88b05042faac4b22bbfea0f835"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNjQ_857f4f46-4a05-4fa7-a6d2-5364f484ceaa" escape="true"><ix:nonNumeric contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNjg_a09fad91-87ab-4050-a5da-46e7950cd99e" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June&#160;30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEtMS0xLTEtMTA1MDMz_e90c999b-fe5a-43a4-867c-085d5c9f006c">2,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEtMy0xLTEtMTA1MDMz_aa423c3b-b9f1-465c-bf01-f3fe0988932c">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzItMS0xLTEtMTA1MDMz_c96f3680-6316-494f-9bba-7ba324249021">4,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzItMy0xLTEtMTA1MDMz_dac9020e-25f7-453f-a902-85918bc2ee9b">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzMtMS0xLTEtMTA1MDMz_e6588c92-e308-4ae4-af25-218608b361c7">3,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzMtMy0xLTEtMTA1MDMz_88d055cb-1d16-4ef0-8fbe-b27188983f8c">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzQtMS0xLTEtMTA1MDMz_30961ad5-b151-4f42-90d2-0755aeb263be">3,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzQtMy0xLTEtMTA1MDMz_0370b9a2-4ca2-415c-bf5f-39e2916488df">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzUtMS0xLTEtMTA1MDMz_a84ca3ae-bfd7-4fb9-af94-b9f137287bbb">2,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzUtMy0xLTEtMTA1MDMz_fa1df384-9577-4755-8b1e-21231349876f">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzYtMS0xLTEtMTA1MDMz_52ee13cb-6274-40d9-8a9e-b47c5bb0e623">7,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="ameh:FinanceLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzYtMy0xLTEtMTA1MDMz_95d383a3-3a9d-4226-be2f-cba726c6a880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzgtMS0xLTEtMTA1MDMz_4cb1b8f9-2c2e-4bba-bc92-b078945e8507">23,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzgtMy0xLTEtMTA1MDMz_91059937-ae1f-4d7d-9667-90a3f961bc1e">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzktMS0xLTEtMTA1MDMz_938e5ab6-dfe7-448b-972d-2ad578e1a61b">3,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzktMy0xLTEtMTA1MDMz_04521589-35db-42dd-bf0c-ca07701f2db7">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEwLTEtMS0xLTEwNTAzMw_b7d41bd7-c6f9-400e-816e-d363cef76c67">20,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEwLTMtMS0xLTEwNTAzMw_784ff8f0-af52-4f88-aedc-4ad3c3a7babc">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzExLTEtMS0xLTEwNTAzMw_5777824f-9179-4d13-ad45-2376b84dea9c">3,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzExLTMtMS0xLTEwNTAzMw_6acd3932-6809-4c4f-b9a6-7f9bd66d9666">524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEyLTEtMS0xLTEwNTAzMw_e8e16125-014d-4f35-a925-8bc81a28ec37">16,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEyLTMtMS0xLTEwNTAzMw_56b91671-ed2c-424a-ba6f-99aecc1eb713">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company does not have additional operating and finance leases that have not yet commenced.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i479e2a4965a945a4983dec200085612c_142"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in Part I, Item 1, &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;28, 2022.</span></div><div id="i479e2a4965a945a4983dec200085612c_145"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. We, together with our affiliated physician groups and consolidated entities, provide coordinated outcomes-based medical care in a cost-effective manner.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our patients are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (&#8220;HMOs&#8221;). However, a small portion of our revenue comes from non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Our physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists. We operate primarily through Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) and the following subsidiaries: NMM, AMM, and APAACO and their consolidated entities, including consolidated VIEs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Led by a management team with several decades of experience, we are focused on physicians providing high-quality medical care, population health management, and care coordination for patients. As a result, we are well positioned to take advantage of the shift in the U.S. healthcare industry toward providing value-based and results-oriented healthcare with a focus on patient satisfaction, high-quality care, and cost efficiency.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our accountable care organization and a network of IPAs with more than 9,800 contracted physicians, we are responsible for coordinating care for approximately 1.2&#160;million patients primarily in California as of June&#160;30, 2022. </span></div><div id="i479e2a4965a945a4983dec200085612c_151"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Financial Measures and Indicators</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our revenue, which is recorded in the period in which services are rendered and earned, primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and fee-for-services (&#8220;FFS&#8221;) revenue. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Expenses</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest expenses consist of the cost of: (1) patient care paid to contracted physicians; (2) information technology equipment and software and; (3) hiring staff to provide management and administrative support services to our affiliated physician groups, as further described in the following sections. These services include payroll, benefits, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services, and other consulting services.</span></div><div><span><br/></span></div><div id="i479e2a4965a945a4983dec200085612c_154"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,697&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,638&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,853)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized (loss) gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,882)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,939)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(808)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,680)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,399&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,658&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,259)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.308%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,812)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,927)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,829)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,598)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,579)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,697)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,611)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,787)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,324)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Apollo Medical Holdings, Inc. for the three months ended June&#160;30, 2022, was $11.4 million, as compared to $12.7 million for the same period in 2021, a decrease of $1.3 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Apollo Medical Holdings, Inc. for the six months ended June&#160;30, 2022, was $25.7 million, as compared to $25.8 million for the same period in 2021, a decrease of $0.1 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Groups and Patients</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and 2021, we managed a total of 13 and 12 groups of affiliated physicians, respectively, and the total number of patients for whom we managed the delivery of healthcare services was approximately 1.2&#160;million and 1.1&#160;million, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue for the three months ended June&#160;30, 2022, was $269.7 million, as compared to $175.6 million for the three months ended June&#160;30, 2021, an increase of $94.1 million, or 54%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by approximately $83.1 million driven by organic membership growth in our core IPAs and participation in a value-based Medicare fee-for-service model.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Fee for service increased by approximately $7.1 million driven by the consolidation of Sun Labs, beginning August 2021, and DMG, beginning October 2021, which contributed $5.8 million and increased visits to our surgery center, that had been partially closed in the prior year due to COVID-19, which contributed $1.5 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue for the six months ended June&#160;30, 2022, was $533.0 million, as compared to $351.7 million for the six months ended June&#160;30, 2021, an increase of $181.3 million, or 52%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by approximately $160.4 million driven by organic membership growth in our core IPAs and participation in a value-based Medicare fee-for-service model.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Fee for service increased by approximately $15.1 million driven by the consolidation of Sun Labs, beginning August 2021, and DMG, beginning October 2021, which contributed $12.2 million and increased visits to our surgery center, that had been partially closed in the prior year due to COVID-19, which contributed $2.7 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services, Excluding Depreciation and Amortization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the three months ended June&#160;30, 2022, were $230.1 million, as compared to $136.2 million for the same period in 2021, an increase of $93.9 million. The overall increase was primarily due to expected return to pre-COVID-19 medical expense run rates and growth in membership, which was commensurate to our increase in revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the six months ended June&#160;30, 2022, were $450.8 million, as compared to $276.8 million for the same period in 2021, an increase of $174.0 million. The overall increase was primarily due to expected return to pre-COVID-19 medical expense run rates and growth in membership, which was commensurate to our increase in revenue.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the three months ended June&#160;30, 2022, were $19.9 million, as compared to $14.2 million for the same period in 2021, an increase of $5.7 million, or 40%. The increase was primarily due to an increase in stock-based compensation and other general and administrative expenses to support operational growth.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the six months ended June&#160;30, 2022, were $31.8 million, as compared to $23.7 million for the same period in 2021, an increase of $8.2 million, or 35%. The increase was primarily due to an increase in stock-based compensation and other general and administrative expenses to support operational growth.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the three months ended June&#160;30, 2022, were $4.4 million, as compared to $4.2 million for the same period in 2021. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the six months ended June&#160;30, 2022, were $8.7 million, as compared to $8.4 million for the same period in 2021. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) represents income, or loss, from equity method investments, interest expense, interest income, unrealized gain, or loss, on investments, and other income. Our total other income for the three months ended June&#160;30, 2022 was $1.2 million compared to total other income of $63.5&#160;million in 2021, a decrease of $62.2&#160;million. The decrease in other expense was due to a decrease in unrealized gain on investments of $85.6 million. This was partially offset by an increase in other income of $18.9 million and an increase in income from equity method investments of $4.6 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $85.6&#160;million decrease in unrealized gain on investments was primarily driven by fluctuations in the stock price of a payor partner in which we hold shares. The unrealized gain of $83.8 million for the three months ended June 30, 2021 was a result of a 1-to-3 conversion of a payer partner&#8217;s preferred shares to common stock as a result of the payer partner becoming a public company in June 2021. However, the stock price of our payor partner decreased for the three months ended June&#160;30, 2022 resulting in an unrealized loss of $0.8 million. The decrease was partially offset by an unrealized gain of $1.2 million due to fluctuations in Tag 8 and APC&#8217;s interest rate swap. These shares and interest rate swap are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. Any resulting gain or loss does not impact net income attributable to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $18.9 million increase in other income was primarily due to a $15.7 million write-off of the Company&#8217;s beneficial interest receivable during the three months ended June 30, 2021. The Company also recognized a $2.3 million gain on equity securities sold during the three months ended June 30, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $4.6 million increase in income from equity method investments was primarily due to APC&#8217;s equity method investment in LMA. For the three months ended June&#160;30, 2022, $1.3 million in income was recognized as compared to $3.6 million loss recognized for the three months ended June 30, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total other expense for the six months ended June&#160;30, 2022 was $6.7 million compared to total other income of $62.9&#160;million in 2021, a decrease in total other income of $69.6 million. The decrease in total other income was due to a decrease in unrealized gain on investments of $94.6 million. This was partially offset by an increase in other income of $18.2 million and an increase in income from equity method investments of $6.8 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $94.6 million decrease in unrealized gain on investments is primarily driven by fluctuations in the stock price of a payor partner in which we hold shares. The unrealized gain of $83.8 million for the six months ended June 30, 2021 was a result of a 1-to-3 conversion of a payer partner&#8217;s preferred shares to common stock as a result of the payer partner becoming a public company in June 2021. However, the stock price our payor partner decreased for the six months ended June&#160;30, 2022 resulting in an unrealized loss of $11.3 million. The decrease was partially offset by an unrealized gain of $2.8 million due to fluctuations in Tag 8 and APC&#8217;s interest rate swap. These shares and interest rate swap are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. Any resulting gain or loss does not impact net income attributable to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $18.2 million increase in other income was primarily due to a $15.7 million write-off of the Company&#8217;s beneficial interest receivable during the six months ended June 30, 2021. The Company also recognized a $2.3 million gain on equity securities sold during the six  months ended June 30, 2022. This was partially offset by $0.7 million due to a stimulus check recognized during the six months ended June 30, 2021 from the Provider Relief Fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $6.8 million increase in income from equity method investments was primarily due to APC&#8217;s equity method investment in LMA. For the six months ended June&#160;30, 2022, $2.5 million in income was recognized as compared to $4.3 million loss recognized for the three months ended June 30, 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $6.0 million for the three months ended June&#160;30, 2022, as compared to provision for income taxes of $24.9 million for the same period in 2021. This was due to a decrease in pre-tax income for the three months ended June&#160;30, 2022, period as compared to the same period in 2021, as described above.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $12.2 million for the six months ended June&#160;30, 2022, as compared to $31.7 million for the same period in 2021. The decrease in provision for income taxes was due to a decrease in pre-tax income for the six months ended June&#160;30, 2022, period as compared to the same period in 2021, as described above.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income Attributable to Non-controlling Interests</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interests for the three months ended June&#160;30, 2022, was $0.8 million, as compared to net income attributable to non-controlling interests for the three months ended June&#160;30, 2021 of $46.9 million, respectively, a decrease of $47.7 million. The decrease was primarily driven by an unrealized loss resulting from a decreased fair value in our marketable securities related to shares held of a payor partner.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interests for the six months ended June&#160;30, 2022 and June&#160;30, 2021, was $3.0 million and $48.2 million, respectively, a decrease of $51.2 million. The decrease was primarily driven by an unrealized loss resulting from a decreased fair value in our marketable securities related to shares held of a payor partner.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i479e2a4965a945a4983dec200085612c_160"></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Guidance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed continues to maintain the following guidance for total revenue, net income, EBITDA, and Adjusted EBITDA (which it previously disclosed on May 5, 2022), based on the Company&#8217;s existing business, current view of existing market conditions and assumptions for the year ending December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Guidance Range</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA&#8221; and &#8220;Use of Non-GAAP Financial Measures&#8221; below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See &#8220;Forward-Looking Statements&#8221; below for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 Guidance Range</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider bonus payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC excluded assets costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss adjustment for recently acquired IPAs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA for the three and six months ended June&#160;30, 2022 and 2021:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.626%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Net Income to EBITDA and Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(467)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Income) loss from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,945)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,034)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss (gain) on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider bonus payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC excluded assets costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss adjustment for recently acquired IPAs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,211&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Other income includes gain on sale of equity securities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Non-GAAP Financial Measures</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) is net income. These measures are not in accordance with, or alternatives to GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, unrealized gain or loss, provider bonuses, APC excluded assets costs, stock-based compensation, net loss adjustment for recently acquired IPAs, and other income or expenses recognized that are not related to the Company&#8217;s normal operations. Adjusted EBITDA also excludes the effect on EBITDA of certain IPAs we recently acquired. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company&#8217;s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div id="i479e2a4965a945a4983dec200085612c_166"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and investment in marketable securities at June&#160;30, 2022, totaled $273.7 million as compared to $286.5 million at December&#160;31, 2021. Working capital totaled $275.8 million at June&#160;30, 2022, as compared to $283.4 million at December&#160;31, 2021, a decrease of $7.6 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, and FFS reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations through at least the next 12 months.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents, and restricted cash increased by $1.1 million from $233.1 million at December&#160;31, 2021, to $234.2 million at June&#160;30, 2022. Cash provided by operating activities for the six months ended June&#160;30, 2022, was $33.1 million, as compared to cash provided by operating activities of $31.3 million for the six months ended June&#160;30, 2021. The increase in cash provided by operating activities was primarily driven cash received from revenues and cash paid for cost of revenues and operating expenses, and changes in operating assets and liabilities, including the timing of income tax payments. Our primary source of cash provided by our operations are capitation revenues and timing of our risk pool and incentive settlements. Use of cash from our operating activities include payments to contracted physicians for providing patient care and personnel-related costs to support our continued growth in operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the six months ended June&#160;30, 2022 was $12.2 million, primarily due to purchases of property and equipment of $18.8 million, payments for business acquisition, net of cash, of $0.9 million, purchase of marketable securities of $1.8 million, and funding for an equity method investment of $1.7 million. The cash used in investing activities was partially offset by proceeds from the repayment of a loan receivable of $4.0 million, the sale of marketable securities of $6.5 million, and distributions from an equity method investment of $0.4 million. Cash used in investing activities during the six months ended June 30, 2021, was $9.8 million, primarily due to purchases of property and equipment of $7.4 million, prepayment for investment purchase of $4.5 million, funding for an equity method investment of $1.7 million, and purchase of marketable securities of $0.7 million. The cash used in investing activities was partially offset by cash received from consolidation of Tag 8 of $3.3 million and proceeds from sale of marketable securities of $1.1 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the six months ended June&#160;30, 2022 was $19.7 million as compared to cash used in financing activities of $38.2 million for the six months ended June&#160;30, 2021. Cash used in financing activities during the six months ended June&#160;30, 2022 was primarily due to dividend payments of $12.6 million, repurchase of shares of $9.5 million, repayment of debt of $0.2 million, and a repayment of finance lease obligations of $0.3 million. This was partially offset by borrowings from the Construction Loan totaling $1.2 million and proceeds from the exercise of options and warrants of $1.7 million. Cash used for the six months ended June 30, 2021 was primarily due to the repayment of  debt of $238.2 million, dividend payments of $21.1 million, and a repurchase of shares of $3.0 million. The cash used in financing activities was partially offset by a drawdown of $180.0 million on the Amended Credit Facility, proceeds from sale of shares of $40.1 million, and proceeds from the exercise of options and warrants of $4.8 million.</span></div><div id="i479e2a4965a945a4983dec200085612c_172"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excluded Assets</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2019, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement, which clarified the term &#8220;Excluded Assets&#8221;. &#8220;Excluded Assets&#8221; means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price (as defined in the purchase agreement), (ii) the assets of APC that are not Healthcare Services Assets (as defined in the purchase agreement), including APC&#8217;s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Excluded Assets as of June&#160;30, 2022, are primarily comprised of assets and liabilities from operating real estate and proceeds from the sale of UCI. Any dividends issued to APC shareholders are paid using cash from Excluded Assets. As of June&#160;30, 2022 and December&#160;31, 2021, the Excluded Assets balance consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable and assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Excluded Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i479e2a4965a945a4983dec200085612c_175"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consisted of the following (in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,068&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June 30, 2022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#8220;Lenders&#8221;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Well Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent (the credit facility thereunder, the &#8220;Credit Facility&#8221;), in its entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement provides for a five-year revolving credit facility (&#8220;Revolver Loan&#8221;) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this Quarterly Report on Form 10-Q for additional information. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Interest Rate</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the six months ended June&#160;30, 2022 and 2021, were 2.16% and 2.31%, respectively. Interest expense in the consolidated statements of operations included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2022 and 2021, of $0.2 million and $0.4 million, respectively, and $0.5 million and $0.7 million, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of the purchase on the date of acquisition, APC assumed $6.4 million, $0.7 million, and $0.7 million of existing loans held by MPP, AMG Properties, and ZLL, respectively. Refer to Note 9 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;25, 2022, 120 Hellman entered into a real estate loan agreement with  MUFG Union Bank N.A. and borrowed $16.3 million. Refer to Note 9 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;) that allows Tag 8 to borrow up to $10.7 million. Tag 8 is a VIE consolidated by the Company. Refer to Note 9 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany Loans</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of AMH, MMG, AKM Medical Group, Inc. (&#8220;AKM&#8221;), SCHC, and Bay Area Hospitalist Associates (&#8220;BAHA&#8221;) has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan commitment to each such affiliated entity in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement with AMM provides that AMM&#8217;s obligation to make any advances automatically terminates upon the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable Physician Shareholder Agreement or (ii) the termination of the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation (in thousands).  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Jade entered into an Intercompany Loan Agreement with NMM pursuant to which NMM agreed to provide a revolving loan commitment to Jade. The Intercompany Loan agreement between NMM and Jade matures on June 1, 2024.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Entity</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intercompany Credit Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest<br/>Rate<br/>per Annum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maximum</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During&#160;Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,558&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions, and estimates that affect the amounts of revenue, expenses, income, assets, and liabilities, reported in our consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions, and estimates. In addition, judgments, assumptions, and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which our management uses judgment, assumptions, and estimates in applying these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions.&#160;We summarize our most significant accounting policies in relation to the accompanying consolidated financial statements in Note 2 &#8212; &#8220;Basis of Presentation&#8221; thereto. Please also refer to the Critical Accounting Policies section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021.</span></div><div id="i479e2a4965a945a4983dec200085612c_184"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 &#8212; &#8220;Basis of Presentation&#8221; to the accompanying consolidated financial statements for recently issued accounting pronouncements, including information on new accounting standards and the future adoption of such standards.</span></div><div id="i479e2a4965a945a4983dec200085612c_187"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had no off-balance sheet arrangements that are or have been reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.</span></div><div id="i479e2a4965a945a4983dec200085612c_190"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation and changing prices have had de minimis effect on our continuing operations over our two most recent fiscal years.</span></div><div id="i479e2a4965a945a4983dec200085612c_193"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under our Amended Credit Agreement exposed us to interest rate risk. As of June&#160;30, 2022, we had $180.0&#160;million in outstanding borrowings under our Amended Credit Agreement. The amount borrowed under the Amended Credit Agreement bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. The base rate is defined in a manner such that it will not be less than LIBOR. In addition, as of June&#160;30, 2022, Tag 8, a VIE consolidated by the Company, had $1.8&#160;million in outstanding borrowings for the Construction Loan. Interest rate on the &#8220;Construction Loan&#8221; is equal to an index rate determined by the bank. Furthermore, as of June&#160;30, 2022, APC had $23.5 million in outstanding borrowings for real estate loans related to ZLL, MPP, AMG Properties, and 120 Hellman (&#8220;Real Estate Loans&#8221;). Each agreement bears interest that is subject to change from time to time based on changes in an independent index, which is the daily Wall Street Journal Prime Rate, as quoted in the &#8220;Money Rates&#8221; column of The Wall Street Journal (Western edition) as determined by the Lender (the &#8220;Index&#8221;). On the dates of the agreement, the Index is 3.25% per annum. Under no circumstances will the interest rate on this loan be less than 3.50% per annum or more than the maximum rate allowed by applicable law. The Company has entered into interest rate swap agreements for certain of these agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. A hypothetical 1% change in our interest rates for our outstanding borrowings under our Credit Agreement, Construction Loan, and Real Estate Loans would have increased or decreased our interest expense for the three months ended June&#160;30, 2022, by $2.1 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act, were effective as of June&#160;30, 2022, to ensure that information required to be disclosed by us in this Quarterly Report on Form 10-Q or submitted under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;under Exchange Act) during our second fiscal quarter of 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i479e2a4965a945a4983dec200085612c_199"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i479e2a4965a945a4983dec200085612c_202"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we from time to time become involved in pending and threatened legal actions and proceedings. Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services, which may not come to light until a substantial period of time has passed following contract implementation. We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs, but as of the date of this Quarterly Report on Form 10-Q, except as disclosed, we are not a party to any lawsuit or proceeding which management expects to, individually or in the aggregate, have a material adverse effect on us or our business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div id="i479e2a4965a945a4983dec200085612c_205"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as&#160;risks that affect businesses in general. In addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on February&#160;28, 2022. The risks disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows, or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the consolidated financial statements and related notes in Part I, Item 1, &#8220;Financial Statements&#8221; and Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report on Form 10-Q. Because of such risk factors, as well as other factors affecting the Company&#8217;s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div id="i479e2a4965a945a4983dec200085612c_208"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None for the six months ended June&#160;30, 2022.</span></div><div id="i479e2a4965a945a4983dec200085612c_211"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i479e2a4965a945a4983dec200085612c_214"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i479e2a4965a945a4983dec200085612c_217"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;EXHIBITS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are either incorporated by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Agreement and Plan of Merger, dated December 21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (the &#8220;Merger Agreement&#8221;) (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017, that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment to the Merger Agreement, dated March 30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment No. 2 to the Merger Agreement, dated October 17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">Stock purchase agreement dated March 15, 2019 (incorporated herein by reference to Exhibit 2.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on January 21, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 21, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415066090/v423843_ex3-2.htm">Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 16, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex3-1.htm">Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-1.htm">Form of Certificate for Common Stock of Apollo Medical Holdings, Inc., par value $0.001 per share (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-3.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $11.00 per share (incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-4.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $10.00 per share (incorporated herein by reference to Exhibit 4.4 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series A Warrant&#8221;) dated October 14, 2015, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 1,111,111 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-6.htm">Form of Assignment of Series A Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.6 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series B Warrant&#8221;) dated March 30, 2016, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 555,555 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-8.htm">Form of Assignment of Series B Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.8 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020003626/ameh-20191231xexx410.htm">Description of Registered Securities</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1*+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ex1012022063010qngcbasho.htm">Employment Agreement, dated April 12, 2022, between Network Medical Management, Inc. and Chandan Basho.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3112022063010-q.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex3122022063010-q.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3132022063010-q.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322022063010-q.htm">Certification of Principal Executive Officers and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnished herewith</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan, contract or arrangement</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The schedules and exhibits thereof have been omitted pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i479e2a4965a945a4983dec200085612c_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas Lam</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Lam, M.D., M.P.H.<br/>Co-Chief Executive Officer &amp; President<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brandon Sim</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brandon Sim<br/>Co-Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 9, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Chandan Basho</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chandan Basho<br/>Interim Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex1012022063010qngcbasho.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>ex1012022063010qngcbasho</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- ex1012022063010qngcbasho001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 1 -     016335.00010  36435896.1  EMPLOYMENT AGREEMENT     This EMPLOYMENT AGREEMENT (this &#8220;Agreement&#8221;) is made and entered into as of April 12, 2022,  by and between Network Medical Management, Inc., a California corporation (the &#8220;Employer&#8221;), and Chandan Basho  (the &#8220;Employee,&#8221; and together with the Employer, collectively referred to as the &#8220;Parties&#8221;) to become effective on the  &#8220;Effective Date&#8221; as set forth in Section 21 below.    WHEREAS, the Employer desires to employ the Employee from and after the Effective Date on the terms  and conditions set forth below, and the Employee is willing to serve the Employer on such terms and conditions.    NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other  good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as  follows:    1. Employment.  (a) Engagement and Duties. Employer hereby employs Employee as Chief Strategy Officer  (&#8220;CSO&#8221;) during the term of this Agreement to perform the duties outlined in Exhibit A to this Agreement and such  other duties as may be assigned to the Employee from time to time by Employer&#8217;s Chief Executive Officer. Employee  hereby accepts such employment by Employer upon the terms and subject to conditions set forth in this Agreement.  Employee shall report to Brandon Sim, Co-Chief Executive Officer. Employee shall devote best efforts, skills and  abilities, on a full-time basis, exclusively to the Employer&#8217;s business. Employee covenants and agrees to faithfully  adhere to and fulfill such policies as are established from time to time by the Board of Directors of Apollo Medical  Holdings, Inc. (the &#8220;Board&#8221;) or the Employer (&#8220;Policies&#8221;).   (b) Performance of Services for Affiliates. In addition to the performance of services for  Employer, Employee shall, to the extent so required by Employer, also perform services for its &#8220;Affiliates&#8221; (as defined  in Section 6 below), provided that such services are consistent with the kind of services Employee performs or may  be required to perform for Employer under this Agreement. If Employee performs any services for any Affiliate,  Employee shall not be entitled to receive any compensation or remuneration in addition to or in lieu of the  compensation and remuneration provided under this Agreement on account of such services for the Affiliate. The  Policies will govern Employee&#8217;s employment by Employer and its Affiliates for which Employee is asked to provide  services. In addition, Employee covenants and agrees that Employee will faithfully adhere to and fulfill such additional  policies as may be established from time to time by the board of directors of any Affiliate for which Employee  performs services, to the extent that such policies and procedures differ from or are in addition to the Policies adopted  by Employer.  (c) No Conflicting Obligations. Employee represents and warrants to Employer that Employee  is under no obligations or commitments, whether contractual or otherwise, that are inconsistent with Employee&#8217;s  obligations under this Agreement or that would prohibit Employee, contractually or otherwise, from performing  Employee&#8217;s duties as under this Agreement and the Policies; however, Employee is an advisor to the Board of Wider  Circle, the position requires approximately five to ten hours a month, and these duties are not in conflict with any  obligations owed to Employer..  (d) No Unauthorized Use of Third-Party Intellectual Property. Employee represents and  warrants to Employer that Employee will not use or disclose, in connection with Employee&#8217;s employment by  Employer or any Affiliate, any patents, trade secrets, confidential information, or other proprietary information or  intellectual property as to which any other person has any right, title or interest, except to the extent that Employer or  its Affiliate holds a valid license or other written permission for such use from the owner(s) thereof. Employee  represents and warrants to Employer that Employee has returned all property and confidential information belonging  to any prior employer.  2. Term. The Parties mutually agree that this Agreement may be terminated at any time as long as the  terminating Party gives the other written notice of intent to terminate at least sixty (60) days prior to such date.  Please  refer to paragraphs 4 and 5 below.  The time in which the Agreement is in effect is referred to herein as the &#8220;Term&#8221;.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 2 -     016335.00010  36435896.1  3. Compensation and Related Matters. The Employer shall provide the Employee with the  compensation and benefits set forth in this Section 3 during the Term.  (a) Base Salary. The Employer shall pay the Employee, as an exempt employee, for all services  rendered a base salary of $300,000 per year (the &#8220;Base Salary&#8221;), payable, bi-weekly, and in accordance with the  Employer&#8217;s payroll procedures, subject to customary withholdings and employment taxes.   (b) Sign-On Bonus. Employee will be eligible for a Sign On bonus (the &#8220;Sign-On Bonus&#8221;) of  non-qualified stock options with a value of $200,000.00 (as of April 12, 2022), with underlying stock  NASDAQ:AMEH, with exercise price at the Reference Stock Price, and with expiration date three years from date of  grant. Employer will have the right to rescind and/or demand return of all of the pro-rated Sign-On Bonus, in monetary  form, if Employee terminates this Agreement within 18 months of start date, unless Employee terminates this  Agreement for Good Reason, as defined in Section 4(e) below. The Reference Stock Price is defined as the stock price  for NASDAQ:AMEH at the close of normal trading hours on your sign date.  (c) Initial Stock Award. Additionally, the Employee will be granted a restricted stock award  (the &#8220;Initial Stock Award&#8221;) from Apollo Medical Holdings, Inc. with a value of $600,000.00 (maximum granted), to  be vested in 25% increments per year for the next 4 full years of service. Actual number of shares granted will be  calculated by dividing the dollar amount listed above by the Reference Stock Price, rounded down to the nearest whole  share. The Reference Stock Price is defined as the stock price for NASDAQ:AMEH at the close of normal trading  hours on your sign date.   (d) Additional Stock Award. Additionally, the Employee will be granted a restricted stock  award (the &#8220;Additional Stock Award&#8221;) from Apollo Medical Holdings, Inc. with a value of $600,000.00 (maximum  granted), to be vested in 25% increments per year for the next 4 full years of service as an Additional Stock Award.  Actual number of shares granted will be calculated by dividing the dollar amount listed above by the Reference Stock  Price, rounded down to the nearest whole share. The Reference Stock Price is defined as the stock price for  NASDAQ:AMEH at the close of normal trading hours on your sign date.   A &#8220;No Fault Separation&#8221; means that, during the Term, either the Employee has resigned for Good Reason  (as defined in Section 4(e) below), the Employer has terminated the Employee&#8217;s employment without Cause (as  defined in Section 4(d) below or the Employee terminates employment on account of death or Disability (as defined  in Sections 4(a) &amp; (b) below).  In the event the Employee terminates service due to a No Fault Separation, any  requirements under either the Sign-On Bonus or Initial Stock Award, but for avoidance of doubt, not the Additional  Stock Award, held by the Employee shall be deemed to have been satisfied by the Employer immediately prior to  such termination. For avoidance of doubt, a No Fault Separation entitles the Employee to be 100% fully vested with  respect to the Sign-On Bonus and the Initial Stock Award.   (e) Annual Bonus. In the Employer&#8217;s sole discretion, the Employee is eligible to receive an  annual cash bonus (the &#8220;Annual Bonus&#8221;) ranging from zero to 1.5 times the Base Salary, or more, for each fiscal year  during the Term on such terms and conditions as the Board shall determine in its discretion consistent with the terms  of the Employer&#8217;s business plan.  (f) Long Term Incentive Awards. In the Employer&#8217;s sole discretion, the Employee may be  eligible to participate in any long term incentive plan that may be available to similarly positioned Employees. The  Board may determine to grant long-term incentive awards in cash or in equity awards settled in shares of the  Employer&#8217;s or its Affiliates&#8217; stock, including but not limited to stock options, restricted stock and performance shares.  Any equity or options will be granted according to the latest Equity Incentive Plan approved by the Board.      (g) Paid Time Off. During the Term, the Employee will be eligible for four weeks of paid time  off in accordance with and subject to all of the terms and conditions of the Employer&#8217;s Paid Time Off policy (which  such policy is compliant with CA&#8217;s Paid Sick Leave requirements), as such policy may be amended from time to time  in the Employer&#8217;s sole discretion.  Employee will also be eligible for paid holidays, in accordance with and subject to  all of the terms and conditions of the Employer&#8217;s policies, as such policies may be amended from time to time or  terminated in the Employer&#8217;s sole discretion.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 3 -     016335.00010  36435896.1  (h) Expenses. The Employee shall be entitled to prompt reimbursement of reasonable and  usual business expenses incurred on behalf of Employer in accordance with the Employer&#8217;s expense reimbursement  policy.  (i) Benefits. The Employee shall be entitled to continue to participate in or receive benefits  under any employee benefit plan or arrangement which is or may, in the future, be made available by the Employer to  its employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plan  or arrangement.   (j) Tax Withholding. The Employer shall undertake to make deductions, withholdings and tax  reports with respect to payments and benefits under this Agreement, to the extent it reasonably and in good faith  believes it is required to make such deductions, withholdings and tax reports. Payments with respect to compensation  and benefits referred to under this Agreement shall be in amounts net of any such deductions or withholdings. Nothing  in this Agreement shall be construed to require the Employer to make any payments to compensate the Employee for  any adverse tax effect associated with any payments or benefits, or for any deduction or withholding from any payment  or benefit.   Employee will be solely responsible for and will satisfy all of Employee&#8217;s tax obligations associated with  all compensation paid or provided to Employee under this Employment Agreement.  Employee acknowledges and  agrees that Employee is not relying on any advice from the Employer or any Employer affiliate, officer, director,  employee, agent or attorney with respect to any tax issue relating to this Employment Agreement.  (k) Directors And Officers Insurance:  If Employee is promoted to the Chief Operating Officer  role, Employer will specifically include Employee as a named insured within the Directors and Officers insurance  policy.  4. Termination. The Employee&#8217;s employment hereunder may be terminated during the Term without  any breach of this Agreement under the following circumstances:  (a) Death. The Employee&#8217;s employment hereunder shall terminate upon the Employee&#8217;s death.  (b) Disability. The Employer may terminate the Employee&#8217;s employment if the Employee is  disabled for 90 or more consecutive days and, because of the disability, is unable to perform the essential functions of  the Employee&#8217;s then existing position or positions under this Agreement with or without reasonable accommodation.  This provision is not intended to reduce any rights the Employee may have pursuant to any law, including without  limitation the California Family Rights Act, the Family and Medical Leave Act, the California Fair Employment and  Housing Act, and the Americans with Disabilities Act.  (c) Termination by the Employer for Cause. At any time during the Term, the Employer may  terminate the Employee&#8217;s employment hereunder for Cause. For purposes of this Agreement, &#8220;Cause&#8221; shall mean: (i)  conduct by the Employee constituting a material act of willful misconduct, in the sole discretion of Employer, in  connection with the performance of the Employee&#8217;s duties that results in loss, damage or injury that is material to the  Employer; (ii) the commission by the Employee of any felony; (iii) continued non-performance, or failure to achieve  growth, operational, and strategic goals, in the sole discretion of Employer, by the Employee of the Employee&#8217;s duties  hereunder (other than by reason of the Employee&#8217;s physical or mental illness, incapacity or disability); (iv) a material  breach, according to the standard of the Employer, by the Employee of any of the provisions of any agreement with  the Employer or its successor that results in loss, damage or injury that is material to the Employer; (v) willful failure  to cooperate with a bona fide, in the sole discretion of Employer, internal investigation or an investigation by  regulatory or law enforcement authorities, after being instructed by the Employer to cooperate, or the willful  destruction or failure to preserve documents or other materials known to be relevant to such investigation or the willful  inducement of others to fail to cooperate or to produce documents or other materials in connection with such  investigations; (vi) fraud, embezzlement or theft against the Employer or any of its Affiliates (as defined in Section  6(a) below); (vii) any damage of a material nature to any property of Employer or any of its affiliates caused by  Employee's willful or grossly negligent conduct; (viii) the repeated nonprescription use of any controlled substance  or the repeated use of alcohol, (vii), the Employer reasonably determines or renders the Employee unfit to serve as an  officer or employee of Employer or its affiliates; or (ix) conduct by Employee that in the good faith determination of  the Employer demonstrates unfitness to serve as an officer or employee of Employer or its affiliates, including, without  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 4 -     016335.00010  36435896.1  limitation, a finding by the Employer or any regulatory authority that Employee committed acts of employee  harassment or violated a material law or regulation applicable to the business of Employer or any of its Affiliates.   With respect to the events in (i), (iii) and (iv) herein, the Employer shall have delivered written notice to the Employee  of its intention to terminate the Employee&#8217;s employment for Cause, which notice specifies in reasonable detail the  circumstances claimed to give rise to the Employer&#8217;s right to terminate the Employee&#8217;s employment for Cause and  the Employee shall not have cured such circumstances to the extent such circumstances are reasonably susceptible to  cure as determined by the Board in good faith within sixty (60) days following the Employer&#8217;s delivery of such notice.  For avoidance of doubt, &#8220;Cause&#8221; shall not include (1) expense reimbursement disputes in which the Employee acts in  reasonable good faith; (2) occasional, customary and de minimis use of the Employer&#8217;s property for personal purposes;  and (3) acting in good faith upon advice of Employer&#8217;s legal counsel.    (d) Termination by Employer without Cause. At any time during the Term, the Employer may  terminate the Employee&#8217;s employment hereunder without Cause by providing the Employee with sixty (60) days  advance written notice. Any termination by the Employer of the Employee&#8217;s employment under this Agreement that  does not constitute a termination for Cause under Section 4(c) and does not result from the death or Disability of the  Employee under Sections 4(a) or 4(b) shall be deemed a termination without Cause under this Section 4(d). Any  suspension of the Employee&#8217;s employment with pay or benefits by the Board in good faith pending an investigation  of alleged improper activities by the Employee that, if determined to be accurate, would be grounds for a Cause  termination, shall not be considered a termination of the Employee&#8217;s employment without Cause or provide with Good  Reason to terminate employment.  (e) Termination by the Employee. At any time during the Term, the Employee may terminate  his employment hereunder for any reason, including, but not limited to, Good Reason. For purposes of this Agreement,  &#8220;Good Reason&#8221; shall mean that the Employee has complied with the &#8220;Good Reason Process&#8221; (hereinafter defined)  following the occurrence of any of the following events: (i) a material diminution in the Employee&#8217;s responsibilities,  authority or duties, in the sole discretion of Employer; or (ii) the material breach of this Agreement by the Employer,  including but not limited to a failure to pay Base Salary or Annual Bonus as provided for under this Agreement; or  (iii) Employee has not been promoted to the role of Chief Operating Officer within ten (10) months of the Effective  Date; or (iv) the Employer changes more than 30% in ownership; or (v) Brandon Sim is no longer part of the  management team of Apollo Medical Holdings, Inc. or one of its wholly owned subsidiaries; or (vi) the Employer  files for bankruptcy protection. &#8220;Good Reason Process&#8221; shall mean (i) the Employee reasonably determines in good  faith that a &#8220;Good Reason&#8221; condition has occurred; (ii) the Employee notifies the Employer in writing of the  occurrence of the Good Reason condition within (60) days of the occurrence of such condition; (iii) the Employee  cooperates in good faith with the Employer&#8217;s efforts, for a period of sixty (60) days following such notice (the &#8220;Cure  Period&#8221;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist;  and (v) the Employee terminates his employment within fourteen(14) days after the end of the Cure Period. If the  Employer cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have  occurred.    (f) Notice of Termination. Except for termination as specified in Section 4(a), any termination  of the Employee&#8217;s employment shall be communicated by written Notice of Termination by the terminating Party to  the other Party hereto. For purposes of this Agreement, a &#8220;Notice of Termination&#8221; shall mean a notice which shall  indicate the specific termination provision in this Agreement relied upon.    (g) Date of Termination. &#8220;Date of Termination&#8221; shall mean the earliest of the following: (i) if  the Employee&#8217;s employment is terminated by the Employee&#8217;s death, the date of the Employee&#8217;s death; (ii) if the  Employee&#8217;s employment is terminated on account of Disability under Section 4(b) or by the Employer for Cause  under Section 4(c), the date on which Notice of Termination is given that follows any applicable required cure period;  (iii) if the Employee&#8217;s employment is terminated by the Employer under Section 4(d), sixty (60) days after the date  on which a Notice of Termination is given; (iv) if the Employee&#8217;s employment is terminated by the Employee  under Section 4(e) without Good Reason, sixty (60) days after the date of which a Notice of Termination is given or  such shorter period agreed to by the Employer; or (v) if the Employee&#8217;s employment is terminated by the Employee  under Section 4(e) with Good Reason, the date on which Notice of Termination is given after the end of the Cure  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 5 -     016335.00010  36435896.1  Period. Notwithstanding the foregoing, in the event that the Employee gives a Notice of Termination to the Employer,  the Employer may unilaterally accelerate the Date of Termination but such acceleration shall nevertheless be deemed  a termination without cause by the Employer, on the accelerated date for purposes of this Agreement. For purposes of  determining the time when the lump sum portion of the Severance Amount, if any, is to be paid under Section 5(b)(i) of  this Agreement, &#8220;Date of Termination&#8221; means the Employee&#8217;s separation from service as defined under Section 409A.  5. Compensation upon Termination.  (a) Accrued Benefits. If the Employee&#8217;s employment with the Employer is terminated for any  reason during the Term, the Employer shall pay or provide the Employee (or the Employee&#8217;s authorized representative  or estate) any earned but unpaid Base Salary or Annual Bonus for services rendered through the Date of Termination,  unpaid expense reimbursements, and accrued but unused paid time off (the &#8220;Accrued Benefits&#8221;) within the time  prescribed by California law. With respect to vested compensation or benefits the Employee may have under any  employee benefit or compensation plan, program or arrangement of the Employer, payment will be made to the  Employee under the terms of the applicable plan, program or arrangement.  (b) Termination by the Employer without Cause or by the Employee with Good Reason. If the  Employee&#8217;s employment is terminated by the Employer without Cause as provided in Section 4(d), or the Employee  terminates his employment for Good Reason as provided in Section 4(e), then (i) the Employer shall, through the Date  of Termination, pay the Employee his or her Accrued Benefits, and (ii) if the Employee signs a general release of  claims (the &#8220;Release&#8221;) within twenty-one (21) days of the receipt of the form of the Release (extended to forty-five  (45) days in the event of a group termination or exit incentive program) and does not revoke such Release during the  seven-day revocation period:  (i) the Employer shall pay the Employee at a minimum an amount equal to one- twelfth (1/12) of the Employee&#8217;s most recent Base Salary times the number of full years of service completed,  not to exceed twelve (12) years of service (but determined prior to any action involving Base Salary that  would constitute Good Reason) (the &#8220;Severance Amount&#8221;). For the avoidance of doubt, the maximum  Severance Amount payable to Employee pursuant to the terms of this Agreement shall equal one (1) year of  the Employee&#8217;s most recent Base Salary, subject to such payroll deductions and withholdings as are required  by law. To the extent that such Severance Amount exceeds the 409A Separation Pay Limit (as defined below),  such amount shall be paid in a single lump sum on the regular payroll date of the Employer, pertaining to  then current salaried employees of the Employer, (&#8220;payroll date&#8221;) next following the first anniversary date  of the Employee&#8217;s Date of Termination. The portion of the Severance Amount that does not exceed the 409A  Separation Pay Limit shall be paid in substantially equal amounts on each payroll date over a one year period;  and  (ii) the Employer shall pay the Employee an amount in cash equal to the Employer&#8217;s  premium amounts paid for coverage of Employee at the time of the Employee&#8217;s termination of coverage  under the Employer&#8217;s group medical, dental and vision programs for a period of twelve (12) months, to be  paid directly to the Employee at the same times such payments would be paid on behalf of a current employee  for such coverage; provided, however:   (A)  No payments shall be made under this paragraph (ii) unless and until the  Employee timely elects continued coverage under such plan(s) pursuant to the Consolidated  Omnibus Budget Reconciliation Act of 1985 as amended (&#8220;COBRA&#8221;);   (B) This paragraph (ii) shall not be read or construed as placing any  restrictions upon amounts paid under this paragraph (ii) as to their use;   (C)  Payments under this paragraph (ii) shall cease as of the earliest to occur  of the following: (1) the Employee is no longer eligible for and continuing to receive the COBRA  coverage elected in subparagraph (A); (2) the time period set forth in the first sentence of this  paragraph (ii); (3) the date on which the Employee first becomes eligible to enroll in a group health  plan in which eligibility is based on employment with an employer; and (4) if the Employer in good  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 6 -     016335.00010  36435896.1  faith determines that payments under this paragraph (ii) would result in a discriminatory health plan  pursuant to the Patient Protection and Affordable Care Act of 2010, as amended.  (iii) Each individual payment of Severance Amount under Section 5(b)(i), and each  payment under Section 5(b)(ii) of this Agreement, shall be deemed to be a separate &#8220;payment&#8221; for purposes  and within the meaning of Treasury Regulation Section 1.409A-2(b)(2)(iii).  (iv) For each individual payment of the Severance Amount under Section 5(b)(i), and  each payment under Section 5(b)(ii), of this Agreement, if considered &#8220;non-qualified deferred compensation&#8221;  (&#8220;NQDC&#8221;) under Section 409A, then the Employer shall make any such payment not earlier than the earlier  of: (x) the first payroll date which is six (6) months following the Employee&#8217;s separation from service (as  defined under Section 409A) with the Employer, or (y) the date of Employee&#8217;s death. The Employer may in  its sole discretion accelerate or defer (but not beyond the time limit set forth below) any severance payments  which do not constitute NQDC in order to allow for the payment of taxes due, but not beyond the time limit  specified for such payment such that the payment would be treated as NQDC.  (v) For purposes of this Section 5, (A) &#8220;Section 409A&#8221; means Section 409A of the  Internal Revenue Code of 1986, as amended, and the regulations thereunder, and (B) &#8220;409A Separation Pay  Limit&#8221; means two times the lesser of (x) the Employee&#8217;s annual compensation during the calendar year  preceding the year of the termination of employment; and (y) the adjusted compensation limit under Code  Section 401(a)(17) in effect for the year of the termination.    6. Confidential Information/Competitive Activities/Intellectual Property/ Cooperation.  (a) Definitions. As used in this Agreement:  (i)  &#8220;Affiliate&#8221; means, as to any Person, (A) any other Person which directly, or  indirectly through one or more intermediaries, controls such Person or is consolidated with such Person in  accordance with GAAP, (ii) any other Person which directly, or indirectly through one or more  intermediaries, is controlled by or is under common control with such Person, or (B) any other Person of  which such Person owns, directly or indirectly, fifty percent (50%) or more of the common stock or  equivalent equity interests. As used herein, the term &#8220;control&#8221; means possession, directly or indirectly, of the  power to direct or cause the direction of the management or policies of a Person, whether through the  ownership of voting securities or otherwise.  (ii) &#8220;Person&#8221; means an individual, a corporation, a partnership, a limited liability  company, an association, a trust or any other entity or organization.  (iii) &#8220;Confidential Information&#8221; means information belonging to the Employer or its  Affiliates which is of value to the Employer or any of its Affiliates in the course of conducting its business  (whether having existed, now existing, or to be developed or created during Employee&#8217;s employment by  Employer) and the disclosure of which could result in a competitive or other disadvantage to the Employer  or its Affiliates. Confidential Information includes, without limitation, contract terms and rates; negotiating  and contracting strategies; financial information, reports, and forecasts; inventions, improvements and other  intellectual property; product plans or proposed product plans; trade secrets; designs, processes or formulae;  software; employee, customer, patient, provider and supplier information; information from patient medical  records; financial data; insurance reimbursement methodologies, strategies and practices; product and service  pricing methodologies, strategies and practices; contracts with physicians, providers, provider networks,  payors, physician databases and contracts with hospitals; regulatory and clinical manuals; and business plans,  prospects and opportunities (such as possible acquisitions or dispositions of businesses or facilities) that have  been discussed or considered by the Employer or its Affiliates, including, without limitation, the management  of the Employer or its Affiliates. Confidential Information includes information developed by the Employee  in the course of the Employee&#8217;s employment by the Employer, as well as other information to which the  Employee may have access in connection with the Employee&#8217;s employment. Confidential Information also  includes the confidential information of others with which the Employer or its Affiliates has a business  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 7 -     016335.00010  36435896.1  relationship. Notwithstanding the foregoing, Confidential Information does not include information in the  public domain, unless due to breach of the Employee&#8217;s duties under Section 6(b), unless otherwise due to  Employee&#8217;s breach of the obligations in this Agreement, or unless due to violation of another Person&#8217;s  obligations to the Employer or its Affiliates that Employee should have taken reasonable measures to prevent  but that Employee did not take.  (b) Confidentiality. The Employee understands and agrees that the Employee&#8217;s employment  creates a relationship of confidence and trust between the Employer and the Employee with respect to all Confidential  Information. At all times, both during the Employee&#8217;s employment with the Employer and after the Employee&#8217;s  termination from employment for any reason, the Employee shall keep in confidence and trust all such Confidential  Information, and shall not use, disclose, or transfer any such Confidential Information without the written consent of  the Employer, except as may be necessary within the scope of Employee&#8217;s duties with Employer and in the ordinary  course of performing the Employee&#8217;s duties to the Employer or as otherwise provided in Section 6(c). Employee  understands and agrees not to sell, license or otherwise exploit any products or services which embody or otherwise  exploit in whole or in part any Confidential Information or materials. Employee acknowledges and agrees that the  sale, misappropriation, or unauthorized use or disclosure in writing, orally or by electronic means, at any time of  Confidential Information obtained by Employee during or in connection with the course of Employee&#8217;s employment  constitutes unfair competition. Employee agrees and promises not to engage in unfair competition with Employer or  its Affiliates, either during employment, or at any time thereafter.  Employee further agrees (unless required by the  Employer in connection with employment or with the Employer's express written consent) not to copy, take, or remove  any of the Employer's books, records, customer lists, or any other documents or materials from the Employer's  premises, including Human Resources manuals, materials, and forms. The Employee shall not, at any time whatsoever,  either during the term of this Agreement or after its termination, disclose to others, either directly or indirectly, or take  or use for the Employee&#8217;s own competitive purposes or the competitive purposes of others, either directly or indirectly,  any confidential information, knowledge or data of the Employer. Upon (a) the voluntary or involuntary termination  of employment with the Employer for whatever reason; or (b) at any time the Employer demands, Employee shall  promptly deliver to the Employer at his or her sole cost any and all of the Employer's books, records, confidential  information, and/or any other documents or materials which are in Employee&#8217;s possession or under Employee&#8217;s  control or any copies thereof.  (c) Protected Rights. Notwithstanding anything to the contrary in this Section 6, this  Agreement is not intended to, and shall not, in any way prohibit, limit or otherwise interfere with the Employee&#8217;s  protected rights under federal, state or local law to, without notice to the Employer, (i) communicate or file a charge  with a government regulator; (ii) participate in an investigation or proceeding conducted by a government regulator;  or (iii) receive an award paid by a government regulator for providing information.  (d) Documents, Records, etc. All documents, records, data, apparatus, equipment and other  physical property, whether or not pertaining to Confidential Information, that are furnished to the Employee by the  Employer or its Affiliates or are produced by the Employee in connection with the Employee&#8217;s employment will be  and remain the sole property of the Employer and its Affiliates. The Employee shall return to the Employer all such  materials and property as and when requested by the Employer. In any event, the Employee shall return all such  materials and property immediately upon termination of the Employee&#8217;s employment for any reason. The Employee  shall not retain any such material or property or any copies thereof after such termination. It is specifically agreed that  any documents, card files, notebooks, programs, or similar items containing customer or patient information are the  property of the Employer and its Affiliates regardless of by whom they were compiled.  (e) Disclosure Prevention. The Employee will take all reasonable precautions to prevent the  inadvertent or accidental exposure of Confidential Information.  (f) Removal of Material. The Employee will not remove any Confidential Information from  the Employer&#8217;s or its Affiliate&#8217;s premises except for use in the Employer&#8217;s business, and only consistent with the  Employee&#8217;s duties with the Employer.  (g) Copying. The Employee agrees that copying or transferring Confidential Information (by  any means) shall be done only as needed in furtherance of and for use in the Employer&#8217;s and its Affiliate&#8217;s business,  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 8 -     016335.00010  36435896.1  and consistent with the Employee&#8217;s duties with the Employer. The Employee further agrees that copies of Confidential  Information shall be treated with the same degree of confidentiality as the original information and shall be subject to  all restrictions herein.  (h) Computer Security. The Employee agrees to comply with the Employer&#8217;s policies and  procedures concerning computer security.  (i) E-Mail. The Employee acknowledges that the Employer retains the right to review any and  all electronic mail communications made with employer provided email accounts, hardware, software, or networks,  with or without notice, at any time.  (j) Assignment. The Employee acknowledges that any and all inventions, discoveries, designs,  developments, methods, modifications, trade secrets, processes, software, formulae, data, &#8220;know-how,&#8221; databases,  algorithms, techniques and works of authorship whether or not patentable or protectable by copyright or trade secret,  made or conceived, first reduced to practice, or learned by the Employee, either alone or jointly with others, during  the Term that (i) relate to or are useful in the business of the Employer or its Affiliates, or (ii) are conceived, made or  worked on at the expense of or during the Employee&#8217;s work time for the Employer, or using any resources or materials  of the Employer or its Affiliates, or (iii) arise out of tasks assigned to the Employee by the Employer (together  &#8220;Proprietary Inventions&#8221;) will be the sole property of the Employer or its Affiliates. The Employee acknowledges that  all work performed by the Employee is on a &#8220;work for hire&#8221; basis and the Employee hereby assigns or agrees to assign  to the Employer the Employee&#8217;s entire right, title and interest in and to any and all Proprietary Inventions and related  intellectual property rights. The Employee agrees to assist the Employer to obtain, maintain and enforce intellectual  property rights for Proprietary Inventions in any and all countries during the Term, and thereafter for as long as such  intellectual property rights exist.  NOTICE TO CALIFORNIA EMPLOYEES    Pursuant to California Labor Code &sect;2870, an agreement requiring the employee to assign or offer to assign any of his  or her rights in any invention to his or her employer does not apply to an invention which qualifies fully under the  provisions of California Labor Code &sect; 2870, which provides as follows:    &#8220;(a) Any provision in an employment agreement which provides that an employee shall  assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not  apply to an invention that the employee developed entirely on his or her own time without using the  employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions  that either:  &#8220;(1) Relate at the time of conception or reduction to practice of the invention to the  employer&#8217;s business, or actual or demonstrably anticipated research or development of the  employer; or  &#8220;(2) Result from any work performed by the employee for the employer.  &#8220;(b) To the extent a provision in an employment agreement purports to require an employee  to assign an invention otherwise excluded from being required to be assigned under subdivision (a),  the provision is against the public policy of this state and is unenforceable.&#8221;  (k) Competitive Activities. Employee agrees and covenants that, at any time during  Employee&#8217;s employment with the Employer and for a period of twelve (12) months immediately following the  termination of Employee&#8217;s relationship with the Employer for any reason, whether with or without cause, Employee  shall not, either on Employee&#8217;s own behalf or on behalf of any other Person: (i) solicit the services of the Employer&#8217;s  employees or entice away, directly or indirectly, any Person employed or engaged by or otherwise providing services  to the Employer or its Affiliates, whether in an employment capacity or otherwise (this provision does not prohibit the  Employee&#8217;s post- termination acceptance of unsolicited applications for employment); or (ii) take any action or engage  in any unfair business practice, including, without limitation, any misappropriation of confidential, proprietary or trade  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 9 -     016335.00010  36435896.1  secret information of the Employer or its Affiliates, as a result of which relations between the Employer or its  Affiliates, and any of their customers, clients, suppliers, distributors or others, may be impaired or which might  otherwise be detrimental to the business interests or reputation of the Employer or its Affiliates. During the term of  Employee&#8217;s employment, Employee shall not, directly or indirectly as an employee, contractor, officer, director,  member, partner, agent, or equity owner, engage in any activity or business that competes or could reasonably be  expected to compete with the business of Employer or any Affiliate. Employee acknowledges that there is a substantial  likelihood that the activities described in this Section would (a) involve the unauthorized use or disclosure of  Employer&#8217;s or an Affiliate&#8217;s Confidential Information and that use or disclosure would be extremely difficult to detect,  and (b) result in substantial competitive harm to the business of Employer or an Affiliate. Employee has accepted the  limitations of this Section as a reasonably practicable and unrestrictive means of preventing such use or disclosure of  Confidential Information and preventing such competitive harm.    (l) Third-Party Agreements and Rights. The Employee hereby confirms that the Employee is  not bound by the terms of any agreement with any previous employer or other party which restricts in any way the  Employee&#8217;s use or disclosure of information or the Employee&#8217;s engagement in any business except as Employee has  previously provided written notice to Employer and has attached to this Agreement. The Employee represents to the  Employer that the Employee&#8217;s execution of this Agreement, the Employee&#8217;s employment with the Employer and the  performance of the Employee&#8217;s proposed duties for the Employer will not violate any obligations the Employee may  have to any previous employer or other party. In the Employee&#8217;s work for the Employer, the Employee will not  disclose or use any information in violation of any agreements with or rights of any such previous employer or other  party, and the Employee will not bring to (by any means) the premises of the Employer any copies or other tangible  embodiments of non-public information belonging to or obtained from any such previous employment or other party.   See Exhibit B for Employee&#8217;s Confidentiality, Assignment and Non-Solicitation Agreement with previous employer.  (m) Litigation and Regulatory Cooperation. During and after the Employee&#8217;s employment, the  Employee shall cooperate fully with the Employer in the defense or prosecution of any claims or actions now in  existence or that may be brought in the future against or on behalf of the Employer that relate to events or occurrences  that transpired while the Employee was employed by the Employer. The Employee&#8217;s full cooperation in connection  with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for  discovery or trial and to act as a witness on behalf of the Employer at mutually convenient times. During and after the  Employee&#8217;s employment, the Employee also shall cooperate fully with the Employer in connection with any  investigation or review of any federal, state, or local regulatory authority as any such investigation or review relates  to events or occurrences that transpired while the Employee was employed by the Employer. The Employer shall  reimburse the Employee for any reasonable out of pocket expenses, including, but not limited to, actual missed wages,  incurred in connection with the Employee&#8217;s performance of obligations pursuant to this Section. &#8220;Full cooperation&#8221;  shall not be construed to in any way require any violation of law or any testimony that is false or misleading.  (n) Enforcement; Injunction. The Employee acknowledges and agrees that the restrictions  contained in this Agreement are reasonable and necessary to protect the business and interests of the Employer and its  Affiliates, do not create any undue hardship for the Employee, and that any violation of the restrictions in this  Agreement would cause the Employer and its Affiliates substantial irreparable injury. Accordingly, the Employee  agrees that a remedy at law for any breach or threatened breach of the covenants or other obligations in Section 6 of  this Agreement would be inadequate and that the Employer, in addition to any other remedies available, shall be  entitled to obtain preliminary and permanent injunctive relief to secure specific performance of such covenants and to  prevent a breach or contemplated or threatened breach of this Agreement without the necessity of proving actual  damage and without the necessity of posting bond or security, which the Employee expressly waives. Moreover, the  Employee will provide the Employer a full accounting of all proceeds and profits received by the Employee as a result  of or in connection with a breach of Section 6 of this Agreement. Unless prohibited by law, the Employer shall have  the right to retain any amounts otherwise payable by the Employer to the Employee to satisfy any of the Employee&#8217;s  obligations as a result of any breach of Section 6 of this Agreement. The Employee hereby agrees to indemnify and  hold harmless the Employer and its Affiliates from and against any damages incurred by the Employer or its Affiliates  as assessed by a court of competent jurisdiction as a result of any breach of Section 6 of this Agreement by the  Employee.  Likewise, the Employer hereby agrees to indemnify and hold harmless the Employee from and against  any damages incurred by the Employee as assessed by a court of competent jurisdiction as a result of any breach  of Section 6 of this Agreement by the Employer. The prevailing party shall be entitled to recover its reasonable  attorneys&#8217; fees and costs if it prevails in any action to enforce Section 6 of this Agreement. It is the express intention  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 10 -     016335.00010  36435896.1  of the parties that the obligations of Section 6 of this Agreement shall survive the termination of the Employee&#8217;s  employment. The Employee agrees that each obligation specified in Section 6 of this Agreement is a separate and  independent covenant that shall survive any termination of this Agreement and that the unenforceability of any of  them shall not preclude the enforcement of any other covenants in Section 6 of this Agreement. No change in the  Employee&#8217;s duties or compensation shall be construed to affect, alter or otherwise release the Employee from the  covenants herein.  7. Successors. This Agreement shall be binding upon and inure to the benefit of both parties and their  respective successors and permitted assigns, except it shall not be binding to Employee where any corporation or  entity with which or into which the Employer may be merged or which may succeed to its assets or business wherein  there has been a change in ownership of more than 50% (&#8220;CIO&#8221;), Where succession is permissible, Employee&#8217;s  obligations are personal and shall not be assigned by Employee. The Employee consents to be bound by the provisions  of this Agreement, except in circumstances of CIO, for the benefit of the Employer or its Affiliates to whose employ  the Employee may be transferred without the necessity that this Agreement be resigned at the time of such transfer.  In the event of the Employee&#8217;s death after the Date of Termination but prior to the completion by the Employer of all  payments due to the Employee under this Agreement, the Employer shall continue such payments to the Employee&#8217;s  beneficiary designated in writing to the Employer prior to the Employee&#8217;s death (or to the Employee&#8217;s estate, if the  Employee fails to make such designation).  8. Enforceability. If any portion or provision of this Agreement shall to any extent be declared illegal  or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such  portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not  be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest  extent permitted by law.  9. Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by  the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or  the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term  or obligation or be deemed a waiver of any subsequent breach.    10. Notices. Any notices, requests, demands and other communications provided for by this Agreement  shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to the  Employee at the last address for which the Employee has provided written notice to the Employer, or to the Employer  at its main office, to the attention of Chief Executive Officer.  11. Publicity. The Employee hereby grants to the Employer the right to use the Employee&#8217;s name and  likeness, without additional consideration, on, in and in connection with technical, marketing, regulatory filings and/or  disclosure materials published by or for the Employer for the duration of Employee&#8217;s employment with Employer.  12. Conflicting Obligations and Rights. The Employee agrees to inform the Employer in writing of any  apparent conflicts between the Employee&#8217;s work for the Employer and (a) any obligations the Employee may have to  preserve the confidentiality of another&#8217;s proprietary information or materials or (b) any rights the Employee claims to  any inventions or ideas before using the same on the Employer&#8217;s behalf. Otherwise, the Employer may conclude that  no such conflict exists and the Employee agrees thereafter to make no such claim against the Employer. The Employer  shall receive such disclosures in confidence and consistent with the objectives of avoiding any conflict of obligations  and rights or the appearance of any conflict of interest.  13. Notification of New Employer. In the event that the Employee leaves the employ of the Employer,  voluntarily or involuntarily, the Employee agrees to inform any subsequent employer of the Employee&#8217;s obligations  under Section 6 of this Agreement. The Employee further hereby authorizes the Employer to notify the Employee&#8217;s  new employer about the Employee&#8217;s obligations under Section 6 of this Agreement.  14. Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect  to the subject matter hereof and supersedes any previous oral or written communications, negotiations, representations,  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   - 11 -     016335.00010  36435896.1  understandings, or agreements between them. Any modification of this Agreement shall be effective only if set forth  in a written document signed by the Employee and a duly authorized officer of the Employer.  15. Amendment. This Agreement may be amended or modified only by a written instrument signed by  the Employee and by a duly authorized representative of the Employer.    16. Governing Law. This is a California contract and shall be construed under and be governed in all  respects by the laws of the State of California, without giving effect to the conflict of laws principles of such State.  17. Obligations of Successors. The Employer shall require any successor (whether direct or indirect, by  purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Employer to  expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Employer  would be required to perform if no such succession had taken place.  18. Limitation on Payments in Certain Events.  (a) Limitation on Payments. Notwithstanding anything to the contrary in Section  3 and Section 5 of this Agreement, if any payment or distribution that the Employee would receive pursuant to this  Agreement or otherwise (&#8220;Payment&#8221;) would (a) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G  of the Code), and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the  &#8220;Excise Tax&#8221;), then the Employer shall cause to be determined, before any amounts of the Payment are paid to the  Employee, which of the following alternative forms of payment would maximize the Employee&#8217;s after-tax proceeds:  (i) payment in full of the entire amount of the Payment (a &#8220;Full Payment&#8221;), or (ii) payment of only a part of the  Payment so that the Employee receives that largest Payment possible without being subject to the Excise Tax (a  &#8220;Reduced Payment&#8221;), whichever of the foregoing amounts, taking into account the applicable federal, state and local  income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum reduction in federal  income taxes which could be obtained from a deduction of such state and local taxes), results in the Employee&#8217;s  receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion the  Payment may be subject to the Excise Tax.  (b) The independent registered public accounting firm engaged by the Employer for general  audit purposes as of the day prior to the date the first Payment is due shall make all determinations required to be  made under this Section 18. If the independent registered public accounting firm so engaged by the Employer is  serving as accountant or auditor for the individual, group or entity effecting the transaction, the Employer shall appoint  a nationally recognized independent registered public accounting firm to make the determinations required hereunder.  The Employer shall bear all expenses with respect to the determinations by such independent registered public  accounting firm required to be made hereunder.  (c) The independent registered public accounting firm engaged to make the determinations  hereunder shall provide its calculations, together with detailed supporting documentation, to the Employer and the  Employee at such time as requested by the Employer or the Employee. If the independent registered public accounting  firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the  Reduced Payment, it shall furnish the Employer and the Employee with an opinion reasonably acceptable to the  Employee that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the  accounting firm made hereunder shall be final, binding and conclusive upon the Parties.  19. Consent to Jurisdiction; Forum Selection. At all times the Employee and Employer: (a) irrevocably  submit to the exclusive jurisdiction of the Los Angeles Superior Court and United States District Court for the Central  District of California, whichever may have competent subject matter jurisdiction, in any action or proceeding arising  out of or relating to this Agreement, and irrevocably agree that all claims in respect of any such action or proceeding  may be heard and determined in such court; (b) to the extent permitted by law, irrevocably consent to the service of  any and all process in any such action or proceeding by the mailing of copies of such process to such party at the  address set forth in this Agreement (or otherwise on record with the Employer); (c) to the extent permitted by law,  irrevocably confirm that service of process out of such courts in such manner shall be deemed due service upon such  party for the purposes of such action or proceeding; (d) to the extent permitted by law, irrevocably waives (i) any  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 12 - 016335.00010  36435896.1  objection the Employee or Employer may have to the laying of venue of any such action or proceeding in any of such  courts, or (ii) any claim that the Employee or Employer may have that any such action or proceeding has been brought  in an inconvenient forum; and (e) to the extent permitted by law, irrevocably agrees that a final nonappealable  judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on  the judgment or in any other manner provided by law. Nothing in this Section shall affect the right of any party hereto  to serve legal process in any manner permitted by law.  20. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the  same document.  21. Effective Date.  The effective date of this Agreement (the &#8220;Effective Date&#8221;) will be April 25, 2022, or as otherwise mutually agreed up on by the Parties.  IN WITNESS WHEREOF, this Agreement has been executed as a sealed instrument by the Employer by  its duly authorized officer, and by the Employee, as of the date first above written.  EMPLOYER:  NETWORK MEDICAL MANAGEMENT, INC.  By: _________________________  Brandon Sim  Co-Chief Executive Officer  EMPLOYEE:  Chan Basho  Signed:  ________________________  Date: Date: 4/12/20224/12/2022 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho013.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho013.jpg" title="slide13" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 13 - 016335.00010  36435896.1  Exhibit A  DUTIES  Employee&#8217;s duties shall include but not be limited to the following under the direction of the Chief Executive  Officer:   (1) The development, implementation, and execution of overall corporate strategy for Employer&#8217;s and Affiliates&#8217; strategic vision, identification and execution of opportunities to grow. (2) Building and supervising an operations team for Employer&#8217;s and Affiliates&#8217; managed care business, while being operationally efficient. (3) Identifying and executing on initiatives to improve operating discipline, talent management, and culture transformation leading to improvements in Employer&#8217;s and Affiliates&#8217; net income. (4) Enhancing current capabilities in operations, finance, payer relations, business development, and strategic initiatives. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho014.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho014.jpg" title="slide14" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 14 - 016335.00010  36435896.1  Exhibit B  [TO BE FILLED IN]  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho015.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho015.jpg" title="slide15" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 15 - 016335.00010  36435896.1  ADDENDUM TO EMPLOYMENT AGREEMENT  This ADDENDUM TO EMPLOYMENT AGREEMENT (this &#8220;Addendum&#8221;) is made and entered into as  an addendum to the Employment Agreement (&#8220;Agreement&#8221;) between Network Medical Management, Inc. and  Chandan Basho, entered into on April 12, 2022, with Effective Date as specified in Section 21 of the Employment  Agreement.  Automatic Vesting:  If Employee is separated pursuant to sections 4(d) or 4(e) of the EMPLOYMENT AGREEMENT,  the Sign-on-Bonus and Initial Stock Award will immediately fully vest and not be subject to cancellation or recission.  Performance-Based Bi-Annual Bonus: The Employee&#8217;s performance-based bonus will be based on the provisions  below for years one and two, and will be subject to the following conditions and terms.  After the first two years of  employment, non-base salary compensation for Employee (including the performance-based annual bonus) will be  equivalent to or greater than $1.3M annually.  If a no-fault separation occurs during years 2 or post, the performance- based bonus for that calendar year immediately vests at 100% achievement of performance. For the avoidance of  doubt, if the Employment Agreement is terminated without a no-fault separation, all performance-based bonuses will  be deemed to have not vested.   i. Employer and Employee will discuss goals for years 3 and 4 after 18 months of employment and before 19 months of employment to determine such goals in good faith.  Similarly, they will meet 6 months prior to years 5, 7, 9, etc. to develop goals for follow-on years. ii. For each of the Bonus Triggers below, Employer, on an annual basis, in its sole discretion, shall make a calculation and determine (&#8220;Determination&#8221;), in good faith, whether such triggers were successfully achieved. All shares granted in this Addendum will have both a performance-based and a time-based component, both of which must be met in order for the shares to vest to the Employee. The time-based vesting component of the shares will following the schedule: 50% will vest after one year of Employee&#8217;s service, and the second 50% after two years of the Employee&#8217;s service. In addition to the time-based vesting schedule, the events which are defined below in each Bonus Trigger must also be fulfilled for the shares to vest to Employee. For avoidance of doubt, for the Employee to vest the shares granted in this Addendum, both the appropriate amount of time must have passed as well as the Bonus Trigger having been accomplished as defined below. iii. All references to shares granted in this Addendum during years one and two will obey the following sentence. Actual number of shares granted will be calculated by dividing the dollar amount listed above by the Reference Stock Price, rounded down to the nearest whole share. The Reference Stock Price is defined as the stock price for NASDAQ:AMEH at the close of normal trading hours on your sign date. iv. The bonus, if earned, subject to Determination, is payable in accordance with the Employer&#8217;s payroll procedures, subject to customary withholdings and employment taxes. Network Medical Management, Inc. (the &#8220;Employer&#8221;) agrees to the following triggers, collectively, the &#8220;Bonus  Triggers&#8221;:  1. (&#8220;Bonus Trigger 1&#8221;): If, within 24 months of the Employee&#8217;s start date, the Employee leads the Payer Relations and Contracting department to gain national or state-wide contracts, the Employee will be granted a restricted stock award from Apollo Medical Holdings, Inc. with a value of USD $100,000.00. 2. (&#8220;Bonus Trigger 2&#8221;): If, within 24 months of the Employee&#8217;s start date, the Employee reduces Alpha Care Medical Group and Accountable IPA Medical Loss Ratio by a mutually agreed upon amount, to be determined within 30 days post the employment start date of the Employee, the Employee will be granted a restricted stock award from Apollo Medical Holdings, Inc. with a value of USD $1,000,000.00. 3. (&#8220;Bonus Trigger 3&#8221;): If, within 24 months of the Employee&#8217;s start date, the Employee establishes a team to ensure seamless transition of new Managed Services clients, and adds a mutually agreed upon amount of </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- ex1012022063010qngcbasho016.jpg -->
<DIV style="padding-top:2em;">
<IMG src="ex1012022063010qngcbasho016.jpg" title="slide16" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 16 - 016335.00010  36435896.1  Managed Services Revenue to be determined within 30 days post the employment start date of the Employee,  the Employee will be granted a restricted stock award from Apollo Medical Holdings, Inc. with a value of  USD $400,000.00.  4. (&#8220;Bonus Trigger 4&#8221;): If, before October 30, 2022, Alpha Care Medical Group and LaSalle Medical Associates are released fully from monetarily punitive Corrective Action Plans and/or other sanctions, the Employee will be granted a restricted stock award from Apollo Medical Holdings, Inc. with a value of USD $250,000.00. 5. (&#8220;Bonus Trigger 5&#8221;): If, within 24 months of the Employee&#8217;s start date, the Employee establishes stable operations in the Claims department, including but not limited to productivity tracking, accountability, institutional claims processing, claims accuracy, and claims recovery, the Employee will be granted a restricted stock award from Apollo Medical Holdings, Inc. with a value of USD $200,000.00. 6. (&#8220;Bonus Trigger 6&#8221;): If, within 24 months of the Employee&#8217;s start date, the Employee establishes to a reasonable and mutually agreed upon degree of operating discipline, talent management, and culture transformation, the Employee will be granted a restricted stock award from Apollo Medical Holdings, Inc. with a value of USD $50,000.00. The promises, covenants, agreements and declarations contained in this Addendum are intended to and shall have the  same force and effect as if set forth in the body of the Agreement.  To the extent that the provisions of this Addendum  are inconsistent with the terms and conditions of the Agreement, the provisions of this Addendum shall control.   IN WITNESS WHEREOF, this Addendum has been executed as a sealed instrument by the Employer by its  duly authorized officer, and by the Employee, as of the date first above written.  EMPLOYER:  NETWORK MEDICAL MANAGEMENT, INC.  By: _________________________  Brandon Sim  Co-Chief Executive Officer  EMPLOYEE:  Chandan Basho  Signed:  ________________________    Date:   Date: 4/12/20224/12/2022 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex3112022063010-q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icd3973abe9794dec9d0cb46c7cf78780_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex3122022063010-q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i44a65c010064445abef58de941a027e5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.2</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon Sim, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon Sim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brandon Sim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>5
<FILENAME>ex3132022063010-q.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1fdc0f2e004f4d368e3cdc9f01b5c837_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.3</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Chandan Basho, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Chandan Basho</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chandan Basho</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>ex322022063010-q.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i298255f73340408fb1ac3120105add0e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended June&#160;30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon Sim, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended June&#160;30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon Sim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brandon Sim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Chandan Basho, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended June&#160;30, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Chandan Basho</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chandan Basho</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ameh-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4d426055-c9f8-47bb-b397-a8331168ec1c,g:285e3d39-8563-4e90-906d-af4a3a14867e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ameh="http://www.apollomed.net/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.apollomed.net/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.apollomed.net/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.apollomed.net/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Gain (Loss) on Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails">
        <link:definition>2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwill" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill">
        <link:definition>2111103 - Disclosure - Business Combinations and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillTables" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables">
        <link:definition>2312302 - Disclosure - Business Combinations and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails">
        <link:definition>2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillSummaryofGoodwillDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails">
        <link:definition>2414408 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet">
        <link:definition>2115104 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables">
        <link:definition>2316303 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
        <link:definition>2417409 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1">
        <link:definition>2417409 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>2418410 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetFutureAmortizationExpenseDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails">
        <link:definition>2419411 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntities" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntities">
        <link:definition>2120105 - Disclosure - Investments in Other Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesTables" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables">
        <link:definition>2321304 - Disclosure - Investments in Other Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails">
        <link:definition>2422412 - Disclosure - Investments in Other Entities - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails">
        <link:definition>2423413 - Disclosure - Investments in Other Entities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails">
        <link:definition>2424414 - Disclosure - Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedParties" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties">
        <link:definition>2125106 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
        <link:definition>2426415 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses">
        <link:definition>2127107 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>2328305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>2429416 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities">
        <link:definition>2130108 - Disclosure - Medical Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesTables" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables">
        <link:definition>2331306 - Disclosure - Medical Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails">
        <link:definition>2432417 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCredit" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit">
        <link:definition>2133109 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditTables" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables">
        <link:definition>2334307 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails">
        <link:definition>2435418 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails">
        <link:definition>2436419 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails">
        <link:definition>2437420 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquity" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity">
        <link:definition>2138110 - Disclosure - Mezzanine and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails">
        <link:definition>2439421 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.apollomed.net/role/StockBasedCompensation">
        <link:definition>2140111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.apollomed.net/role/StockBasedCompensationTables">
        <link:definition>2341308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>2442422 - Disclosure - Stock-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2443423 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>2444424 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
        <link:definition>2445425 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofWarrantDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails">
        <link:definition>2446426 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWarrantsDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails">
        <link:definition>2447427 - Disclosure - Stock-Based Compensation - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.apollomed.net/role/CommitmentsandContingencies">
        <link:definition>2148112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2449428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.apollomed.net/role/RelatedPartyTransactions">
        <link:definition>2150113 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables">
        <link:definition>2351309 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2452429 - Disclosure - Related-Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
        <link:definition>2453430 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes">
        <link:definition>2154114 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2455431 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.apollomed.net/role/EarningsPerShare">
        <link:definition>2156115 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.apollomed.net/role/EarningsPerShareTables">
        <link:definition>2357310 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails">
        <link:definition>2458432 - Disclosure - Earnings Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails">
        <link:definition>2459433 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
        <link:definition>2460434 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEs" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs">
        <link:definition>2161116 - Disclosure - Variable Interest Entities (VIEs)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsTables" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables">
        <link:definition>2362311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsDetails" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails">
        <link:definition>2463435 - Disclosure - Variable Interest Entities (VIEs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.apollomed.net/role/Leases">
        <link:definition>2164117 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.apollomed.net/role/LeasesTables">
        <link:definition>2365312 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails">
        <link:definition>2466436 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2467437 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOtherInformationRelatedtoLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails">
        <link:definition>2468438 - Disclosure - Leases - Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails">
        <link:definition>2469439 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1">
        <link:definition>2469439 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ameh_NetworkMedicalManagementMember" abstract="true" name="NetworkMedicalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_UniversalCareIncMember" abstract="true" name="UniversalCareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorCMember" abstract="true" name="PayorCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MemberRelationshipsMember" abstract="true" name="MemberRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiveThreeOneW.CollegeLLCMember" abstract="true" name="FiveThreeOneW.CollegeLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" abstract="false" name="NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PreferredBankMember" abstract="true" name="PreferredBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApcLsmaMember" abstract="true" name="ApcLsmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" abstract="false" name="InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" abstract="true" name="OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetworkRelationshipsMember" abstract="true" name="NetworkRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SharesWarrantsRollForward" abstract="true" name="SharesWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_UniversalCareAcquisitionPartnersLlcMember" abstract="true" name="UniversalCareAcquisitionPartnersLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_OneMSOInc.Member" abstract="true" name="OneMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_APCAndAPCLSMAMember" abstract="true" name="APCAndAPCLSMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LoanReceivableTextBlock" abstract="false" name="LoanReceivableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_PayorEMember" abstract="true" name="PayorEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" abstract="true" name="MPPAMGPropertiesAndZLLAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeFinanceLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_NumenLLCMember" abstract="true" name="NumenLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_MedicalCareCostsAbstract" abstract="true" name="MedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AccessPrimaryCareMedicalGroupMember" abstract="true" name="AccessPrimaryCareMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_JadeHealthCareMedicalGroupIncMember" abstract="true" name="JadeHealthCareMedicalGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentMadeToRelatedParty" abstract="false" name="PaymentMadeToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeaseWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AlliedPacificOfCaliforniaIPAMember" abstract="true" name="AlliedPacificOfCaliforniaIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ProceedsFromSaleOfNoncontrollingInterest" abstract="false" name="ProceedsFromSaleOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" abstract="false" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PrepaymentForInvestmentPurchase" abstract="false" name="PrepaymentForInvestmentPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PayorBMember" abstract="true" name="PayorBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SpecialtyCapitationPayableCurrent" abstract="false" name="SpecialtyCapitationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInMedicalLiabilities" abstract="false" name="IncreaseDecreaseInMedicalLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeTwoMember" abstract="true" name="WarrantExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApolloSunLabsManagementLLCMember" abstract="true" name="ApolloSunLabsManagementLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentsToAcquireNonControllingInterest" abstract="false" name="PaymentsToAcquireNonControllingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" abstract="true" name="CashPaidForLeaseLiabilitiesAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_CancellationOfRestrictedStockAwards" abstract="false" name="CancellationOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantCashFlowCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" abstract="false" name="FinanceReceivableModificationsSubsequentDefaultInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_Tag8MedicalInvestmentGroupLLCMember" abstract="true" name="Tag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" abstract="false" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentNumberOfKeyFinancialRatios" abstract="false" name="DebtInstrumentNumberOfKeyFinancialRatios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_ArroyoVistaMember" abstract="true" name="ArroyoVistaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_MezzanineEquityAbstract" abstract="true" name="MezzanineEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_MaverickMedicalGroupIncMember" abstract="true" name="MaverickMedicalGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OtherThirdPartiesMember" abstract="true" name="OtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FiduciaryCashAndPayablePolicyTextBlock" abstract="false" name="FiduciaryCashAndPayablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_CDSCMember" abstract="true" name="CDSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_HealthCareCapitationRevenueMember" abstract="true" name="HealthCareCapitationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableInterestRateStatedPercentage" abstract="false" name="FinanceReceivableInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_MezzanineMember" abstract="true" name="MezzanineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" abstract="true" name="Tag6MedicalInvestmentGroupLLCRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AccountableHealthCareIPAMember" abstract="true" name="AccountableHealthCareIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageSold" abstract="false" name="EquityMethodInvestmentOwnershipPercentageSold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_OneMSOLLCMember" abstract="true" name="OneMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ContingentEquitySecuritiesMember" abstract="true" name="ContingentEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ClinigenceHoldingsIncMember" abstract="true" name="ClinigenceHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_ConcourseDiagnosticSurgeryCenterLlcMember" abstract="true" name="ConcourseDiagnosticSurgeryCenterLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ApcShareholdersMember" abstract="true" name="ApcShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" abstract="false" name="DebtInstrumentCovenantLeverageRatioIncrementalChange" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_AmgIncMember" abstract="true" name="AmgIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorAMember" abstract="true" name="PayorAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" abstract="false" name="InsuranceServicesRevenueCapitationAndClaimsPaymentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum" abstract="false" name="DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_NumberOfWarrantsGranted" abstract="false" name="NumberOfWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" abstract="false" name="EquityMethodAndOtherEquityInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_Pacific6EnterprisesMember" abstract="true" name="Pacific6EnterprisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_MarketableSecuritiesCurrentMaturityPeriod" abstract="false" name="MarketableSecuritiesCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_DebtCovenantAggregatePurchasePriceMaximum" abstract="false" name="DebtCovenantAggregatePurchasePriceMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AssetAcquisitionPercentageOfSharesAcquired" abstract="false" name="AssetAcquisitionPercentageOfSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_PerMemberPerMonthManagedCareContractMember" abstract="true" name="PerMemberPerMonthManagedCareContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PacificMedicalImagingAndOncologyCenterIncMember" abstract="true" name="PacificMedicalImagingAndOncologyCenterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsContribution" abstract="false" name="EquityMethodInvestmentsContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AchievaMedInc.Member" abstract="true" name="AchievaMedInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantDebtCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_PayorDMember" abstract="true" name="PayorDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" abstract="false" name="StockIssuedDuringPeriodValueNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementIncMember" abstract="true" name="NetworkMedicalManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentsToEquityMethodInvestments" abstract="false" name="PaymentsToEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CMSMember" abstract="true" name="CMSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FulgentGeneticsIncMember" abstract="true" name="FulgentGeneticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AurionMember" abstract="true" name="AurionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceLeaseCostsAbstract" abstract="true" name="FinanceLeaseCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeOneMember" abstract="true" name="WarrantExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" abstract="false" name="ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentReclassification" abstract="false" name="EquityMethodInvestmentReclassification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfFederallyQualifiedHealthPlans" abstract="false" name="NumberOfFederallyQualifiedHealthPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_LmaMember" abstract="true" name="LmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EarningsPerShareTable" abstract="true" name="EarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightCancelledInPeriod" abstract="false" name="ClassOfWarrantOrRightCancelledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ShareholdersAndOfficersMember" abstract="true" name="ShareholdersAndOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SCHCMember" abstract="true" name="SCHCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorFMember" abstract="true" name="PayorFMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FinanceReceivableTermOfReceivable" abstract="false" name="FinanceReceivableTermOfReceivable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_CAIPAMSOLLCMember" abstract="true" name="CAIPAMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LasalleMedicalAssociatesIpaMember" abstract="true" name="LasalleMedicalAssociatesIpaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" abstract="false" name="UnrealizedGainLossFromInvestmentInEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_MinorityInterestPolicyPolicyTextBlock" abstract="false" name="MinorityInterestPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_ApcBusinessLoanAgreementMember" abstract="true" name="ApcBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Tag6MedicalInvestmentGroupLLCMember" abstract="true" name="Tag6MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AggregateintrinsicvalueAbstract" abstract="true" name="AggregateintrinsicvalueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_MedicalPropertyPartnersLLCMember" abstract="true" name="MedicalPropertyPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_WeightedAverageExercisePriceWarrantsRollForward" abstract="true" name="WeightedAverageExercisePriceWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioAdjustedMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_PmiocMember" abstract="true" name="PmiocMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_DebtCovenantThresholdPercentageForOccupationOfProperty" abstract="false" name="DebtCovenantThresholdPercentageForOccupationOfProperty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" abstract="false" name="RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_SubcontractorIPAPayable" abstract="false" name="SubcontractorIPAPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueTable" abstract="true" name="AccountsReceivableAndNetRevenueTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AdvanceDiagnosticSurgeryCenterMember" abstract="true" name="AdvanceDiagnosticSurgeryCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessTable" abstract="true" name="DescriptionOfBusinessTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueLineItems" abstract="true" name="AccountsReceivableAndNetRevenueLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DmgMember" abstract="true" name="DmgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" abstract="false" name="ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_EarningsPerShareLineItems" abstract="true" name="EarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_APAMHMedicalCorporationMember" abstract="true" name="APAMHMedicalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ApolloMedicalHoldingsIncMember" abstract="true" name="ApolloMedicalHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_A120HellmanLLCMember" abstract="true" name="A120HellmanLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" abstract="false" name="StockIssuedDuringPeriodSharesNoncontrollingInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_FiduciaryAccountsPayableCurrent" abstract="false" name="FiduciaryAccountsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_Dr.ArteagaMember" abstract="true" name="Dr.ArteagaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PaymentsToAcquireCommonStockAndWarrants" abstract="false" name="PaymentsToAcquireCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeThreeMember" abstract="true" name="WarrantExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AMGPropertiesLLCMember" abstract="true" name="AMGPropertiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableStatedInterestRate" abstract="false" name="FinanceReceivableStatedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ZLLPartnersLLCMember" abstract="true" name="ZLLPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightIssuedInPeriod" abstract="false" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" abstract="false" name="TemporaryEquityIncreaseFromSaleOfNonControllingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeOperatingLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ConstructionLoanMember" abstract="true" name="ConstructionLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" abstract="false" name="WarrantIssuedDuringPeriodValueStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessLineItems" abstract="true" name="DescriptionOfBusinessLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" abstract="true" name="OrmaHealthIncAndProviderGrowthSolutionsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" abstract="false" name="InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ManagementContractsMember" abstract="true" name="ManagementContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_WeightedaverageremainingcontractualtermyearsAbstract" abstract="true" name="WeightedaverageremainingcontractualtermyearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AccountsPayableAndAccruedExpensesMember" abstract="true" name="AccountsPayableAndAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfFamilyPracticeClinics" abstract="false" name="NumberOfFamilyPracticeClinics" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_TemporaryEquityPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageDiscountRateAbstract" abstract="true" name="LeaseWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PatientManagementPlatformMember" abstract="true" name="PatientManagementPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AlphaCareMedicalGroupInc.Member" abstract="true" name="AlphaCareMedicalGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_HSMSOMember" abstract="true" name="HSMSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesMerger" abstract="false" name="StockIssuedDuringPeriodSharesMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_StockAwardsAndUnitsMember" abstract="true" name="StockAwardsAndUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageDisposed" abstract="false" name="EquityMethodInvestmentOwnershipPercentageDisposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_EmployeesMember" abstract="true" name="EmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MediPortalLLCMember" abstract="true" name="MediPortalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AHMCMember" abstract="true" name="AHMCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ameh-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4d426055-c9f8-47bb-b397-a8331168ec1c,g:285e3d39-8563-4e90-906d-af4a3a14867e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8effcb67-088f-4463-a5ff-328b5d7b2bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf01c8c9-fcc3-430f-af68-0016eeee5c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8effcb67-088f-4463-a5ff-328b5d7b2bab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf01c8c9-fcc3-430f-af68-0016eeee5c2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_355d75c6-0c2e-4f15-9472-9c9e346df78f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8effcb67-088f-4463-a5ff-328b5d7b2bab" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_355d75c6-0c2e-4f15-9472-9c9e346df78f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a09522b9-b0c1-4b1a-aa76-c65de505ef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8effcb67-088f-4463-a5ff-328b5d7b2bab" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a09522b9-b0c1-4b1a-aa76-c65de505ef4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_20239e53-e045-4b82-af3c-7da6b82e8f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8effcb67-088f-4463-a5ff-328b5d7b2bab" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_20239e53-e045-4b82-af3c-7da6b82e8f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_6dfbfccc-bdbe-4067-b9d5-c9cd5b32ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8effcb67-088f-4463-a5ff-328b5d7b2bab" xlink:to="loc_us-gaap_IncomeTaxesReceivable_6dfbfccc-bdbe-4067-b9d5-c9cd5b32ac55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_14706b17-f802-4de5-9a07-7b647550721e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8effcb67-088f-4463-a5ff-328b5d7b2bab" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_14706b17-f802-4de5-9a07-7b647550721e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_deb216da-f9b1-483f-a2a8-0a627a443f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8effcb67-088f-4463-a5ff-328b5d7b2bab" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_deb216da-f9b1-483f-a2a8-0a627a443f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5441577c-3fb1-4231-9707-bc0fdcc4eb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8effcb67-088f-4463-a5ff-328b5d7b2bab" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5441577c-3fb1-4231-9707-bc0fdcc4eb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d865bc8a-cc5f-476b-b76f-2e72e275b941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a5326808-0ba8-4081-ad24-c914de961021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d865bc8a-cc5f-476b-b76f-2e72e275b941" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a5326808-0ba8-4081-ad24-c914de961021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_5fd71369-9603-4804-b981-0ecec9799e25" xlink:href="ameh-20220630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d865bc8a-cc5f-476b-b76f-2e72e275b941" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_5fd71369-9603-4804-b981-0ecec9799e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_806edfb4-2f6d-4158-8bfc-1efc7ef86e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d865bc8a-cc5f-476b-b76f-2e72e275b941" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_806edfb4-2f6d-4158-8bfc-1efc7ef86e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_23c5e6ca-c11e-4004-82c2-9ebbd516a6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d865bc8a-cc5f-476b-b76f-2e72e275b941" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_23c5e6ca-c11e-4004-82c2-9ebbd516a6ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_6aee1187-b7e4-4f0a-8b7d-a633bfc9ccc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d865bc8a-cc5f-476b-b76f-2e72e275b941" xlink:to="loc_us-gaap_DividendsPayableCurrent_6aee1187-b7e4-4f0a-8b7d-a633bfc9ccc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1a3f7742-4754-428d-9497-fd9f6d5f014b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d865bc8a-cc5f-476b-b76f-2e72e275b941" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1a3f7742-4754-428d-9497-fd9f6d5f014b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7aeee95f-a8ac-427a-b33b-c5dc0609acc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d865bc8a-cc5f-476b-b76f-2e72e275b941" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7aeee95f-a8ac-427a-b33b-c5dc0609acc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_074c50e4-7a3b-4a0d-bde8-3a9bf1a99717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d865bc8a-cc5f-476b-b76f-2e72e275b941" xlink:to="loc_us-gaap_LongTermDebtCurrent_074c50e4-7a3b-4a0d-bde8-3a9bf1a99717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_088e7ca4-1b45-478c-b9e6-9e1555edf595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6153d34c-dc20-4185-9f19-7e05ea46af5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_088e7ca4-1b45-478c-b9e6-9e1555edf595" xlink:to="loc_us-gaap_LiabilitiesCurrent_6153d34c-dc20-4185-9f19-7e05ea46af5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b1adc23e-01b4-43a9-8c09-9c13e52f437c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_088e7ca4-1b45-478c-b9e6-9e1555edf595" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b1adc23e-01b4-43a9-8c09-9c13e52f437c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_d6e81353-f08a-482a-bfd9-bce4d22019cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_356d0874-7815-4a18-af15-9cfb8d317753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_d6e81353-f08a-482a-bfd9-bce4d22019cf" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_356d0874-7815-4a18-af15-9cfb8d317753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_cbdbf4bf-9985-42a7-a252-9f66acb8c508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_d6e81353-f08a-482a-bfd9-bce4d22019cf" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_cbdbf4bf-9985-42a7-a252-9f66acb8c508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8327f9d4-138f-429b-828a-41e049e7681c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_d6e81353-f08a-482a-bfd9-bce4d22019cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8327f9d4-138f-429b-828a-41e049e7681c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f4ef4623-daff-429a-911e-9bd3946328d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_d6e81353-f08a-482a-bfd9-bce4d22019cf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f4ef4623-daff-429a-911e-9bd3946328d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_83408a1b-44f0-4c4e-a9e0-1e0fe039e4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_d6e81353-f08a-482a-bfd9-bce4d22019cf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_83408a1b-44f0-4c4e-a9e0-1e0fe039e4fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_72f26aae-9701-40c3-a947-1fcc446d3139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1337b369-5c70-4ae7-942c-f8ace1e0c307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_72f26aae-9701-40c3-a947-1fcc446d3139" xlink:to="loc_us-gaap_Liabilities_1337b369-5c70-4ae7-942c-f8ace1e0c307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_48826374-7ca7-46e3-95b6-1ab655dd90d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_72f26aae-9701-40c3-a947-1fcc446d3139" xlink:to="loc_us-gaap_CommitmentsAndContingencies_48826374-7ca7-46e3-95b6-1ab655dd90d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_eb79c042-d913-42f5-92f1-672e62a16d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_72f26aae-9701-40c3-a947-1fcc446d3139" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_eb79c042-d913-42f5-92f1-672e62a16d95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7e96b11-d11c-4352-a1a7-ccf90b363bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_72f26aae-9701-40c3-a947-1fcc446d3139" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7e96b11-d11c-4352-a1a7-ccf90b363bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f8b127a4-b768-450c-b2ba-c0c2ffb0eb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f8b127a4-b768-450c-b2ba-c0c2ffb0eb06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_861a039b-ee27-4db0-a77e-513a26f7d970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_861a039b-ee27-4db0-a77e-513a26f7d970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9cbd11fc-36c3-45ad-bd62-ccc70654df5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:to="loc_us-gaap_Goodwill_9cbd11fc-36c3-45ad-bd62-ccc70654df5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_02e7b533-f412-446f-911f-33ab1bb807cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_02e7b533-f412-446f-911f-33ab1bb807cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_928a8da6-8ad6-478a-acdc-b984c23b4601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_928a8da6-8ad6-478a-acdc-b984c23b4601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_730d0aa9-98d1-44f8-9f00-6be3743df588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:to="loc_us-gaap_EquityMethodInvestments_730d0aa9-98d1-44f8-9f00-6be3743df588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_571d480a-2b1b-43ec-85fc-0391fc27bf17" xlink:href="ameh-20220630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_571d480a-2b1b-43ec-85fc-0391fc27bf17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_fd762278-e586-4c7f-9c90-f24a2f4fef7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_fd762278-e586-4c7f-9c90-f24a2f4fef7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2957d7eb-a96d-42bb-9b3b-3521ecd7be30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3958a5af-ac8f-4f7c-a94d-5cbb31654d11" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2957d7eb-a96d-42bb-9b3b-3521ecd7be30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1c1c73d0-dea0-4d42-833b-8895841b99f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bc6d04f1-6570-43c7-b30a-f688fc495ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c1c73d0-dea0-4d42-833b-8895841b99f2" xlink:to="loc_us-gaap_AssetsCurrent_bc6d04f1-6570-43c7-b30a-f688fc495ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_319d4ccb-3ccf-4cb3-b7ff-75d8d51f4a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c1c73d0-dea0-4d42-833b-8895841b99f2" xlink:to="loc_us-gaap_AssetsNoncurrent_319d4ccb-3ccf-4cb3-b7ff-75d8d51f4a52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a716bb20-828f-49df-bd78-6829f957a945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2b6c7f35-a259-4bbd-aa2b-77314578e958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a716bb20-828f-49df-bd78-6829f957a945" xlink:to="loc_us-gaap_PreferredStockValue_2b6c7f35-a259-4bbd-aa2b-77314578e958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_db0c45db-3f1b-406a-a564-9aa7b71a3465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a716bb20-828f-49df-bd78-6829f957a945" xlink:to="loc_us-gaap_CommonStockValue_db0c45db-3f1b-406a-a564-9aa7b71a3465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0ff591dd-69fd-420e-a406-6d37bd304ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a716bb20-828f-49df-bd78-6829f957a945" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0ff591dd-69fd-420e-a406-6d37bd304ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_61c5f406-7cfc-44e2-aef2-1465ee081869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a716bb20-828f-49df-bd78-6829f957a945" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_61c5f406-7cfc-44e2-aef2-1465ee081869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_037149f4-518c-4410-85c7-aa0187c29bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8a7e8d82-b209-4ee8-9a22-a56caa004bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_037149f4-518c-4410-85c7-aa0187c29bf5" xlink:to="loc_us-gaap_StockholdersEquity_8a7e8d82-b209-4ee8-9a22-a56caa004bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e64ba0b0-1d16-4f2f-a389-42134eaa7ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_037149f4-518c-4410-85c7-aa0187c29bf5" xlink:to="loc_us-gaap_MinorityInterest_e64ba0b0-1d16-4f2f-a389-42134eaa7ff4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03f93ad4-ffd1-4760-a701-c48c16776804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_449b34eb-8da0-4294-ba17-8468d94a3da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03f93ad4-ffd1-4760-a701-c48c16776804" xlink:to="loc_us-gaap_OperatingIncomeLoss_449b34eb-8da0-4294-ba17-8468d94a3da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d08e6954-e262-4b15-a374-8924e0e94836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_03f93ad4-ffd1-4760-a701-c48c16776804" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d08e6954-e262-4b15-a374-8924e0e94836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2f025169-f8ca-4343-9929-b4d6167c82f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c9bd69c0-c318-4893-b73d-2b3a3d37e600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2f025169-f8ca-4343-9929-b4d6167c82f7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c9bd69c0-c318-4893-b73d-2b3a3d37e600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2f469858-1eb5-46f8-bc30-d3df6d2764e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2f025169-f8ca-4343-9929-b4d6167c82f7" xlink:to="loc_us-gaap_InterestExpense_2f469858-1eb5-46f8-bc30-d3df6d2764e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f8e075eb-40fc-43cf-bac8-337af2c7f691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2f025169-f8ca-4343-9929-b4d6167c82f7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f8e075eb-40fc-43cf-bac8-337af2c7f691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_8a79d584-4d32-412f-a0f9-70dc2d2b3145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2f025169-f8ca-4343-9929-b4d6167c82f7" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_8a79d584-4d32-412f-a0f9-70dc2d2b3145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_23815fa9-1abc-4c9a-8f29-f14206a0b50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_2f025169-f8ca-4343-9929-b4d6167c82f7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_23815fa9-1abc-4c9a-8f29-f14206a0b50b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_166442af-25a2-4995-b7bd-1d52afb379bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cabf866a-6609-4ee5-a05e-12e29687428a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_166442af-25a2-4995-b7bd-1d52afb379bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cabf866a-6609-4ee5-a05e-12e29687428a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ca61d6e0-d460-449a-9c0d-f8ef60ad928b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_166442af-25a2-4995-b7bd-1d52afb379bb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ca61d6e0-d460-449a-9c0d-f8ef60ad928b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33ad17f6-9bca-4b2e-91ea-b46dc6206141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2442b9d6-ca43-4811-8a94-775d86c71b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_33ad17f6-9bca-4b2e-91ea-b46dc6206141" xlink:to="loc_us-gaap_ProfitLoss_2442b9d6-ca43-4811-8a94-775d86c71b17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2f20619e-bd1b-414e-82f7-0ab01d83b02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_33ad17f6-9bca-4b2e-91ea-b46dc6206141" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2f20619e-bd1b-414e-82f7-0ab01d83b02f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9cd650c7-4bda-46b0-aab7-e7e60a5ac31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_c68ba208-bfed-4604-b690-ff93fec958b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9cd650c7-4bda-46b0-aab7-e7e60a5ac31a" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_c68ba208-bfed-4604-b690-ff93fec958b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_13abc42d-0481-46e7-bcf4-d3a0acd7eccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9cd650c7-4bda-46b0-aab7-e7e60a5ac31a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_13abc42d-0481-46e7-bcf4-d3a0acd7eccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_7734f3ca-aa63-4b80-82e8-f61aad4cb1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_9cd650c7-4bda-46b0-aab7-e7e60a5ac31a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_7734f3ca-aa63-4b80-82e8-f61aad4cb1a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2ee680f2-c928-4d8a-956d-af065902a1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1b98998-ca01-4959-a778-62c12b3b31c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2ee680f2-c928-4d8a-956d-af065902a1be" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1b98998-ca01-4959-a778-62c12b3b31c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_69303fb3-26c1-4924-ba97-e8d70b7473d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2ee680f2-c928-4d8a-956d-af065902a1be" xlink:to="loc_us-gaap_CostsAndExpenses_69303fb3-26c1-4924-ba97-e8d70b7473d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddf95a7f-ffec-4949-876a-42b18aac7447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb487265-8636-40e2-8456-2966989b046b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddf95a7f-ffec-4949-876a-42b18aac7447" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb487265-8636-40e2-8456-2966989b046b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_24553725-3559-4b6f-bea0-0eb2d3ca035d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddf95a7f-ffec-4949-876a-42b18aac7447" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_24553725-3559-4b6f-bea0-0eb2d3ca035d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c05c7306-b8eb-45aa-98d8-38a3b150e227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c05c7306-b8eb-45aa-98d8-38a3b150e227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_d6dea669-35a2-4e37-8f42-8fc36b527aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_d6dea669-35a2-4e37-8f42-8fc36b527aeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PrepaymentForInvestmentPurchase_d13f8fc4-de84-4f78-868b-94961725be24" xlink:href="ameh-20220630.xsd#ameh_PrepaymentForInvestmentPurchase"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_ameh_PrepaymentForInvestmentPurchase_d13f8fc4-de84-4f78-868b-94961725be24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_87f1ac5a-198e-47c8-9ed4-98fa3996de7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_87f1ac5a-198e-47c8-9ed4-98fa3996de7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f7ac0d46-8621-4376-b282-c9d5327ed6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f7ac0d46-8621-4376-b282-c9d5327ed6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6496cede-f7d4-46f1-b807-4f61987718c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6496cede-f7d4-46f1-b807-4f61987718c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_d4a25052-582f-4e38-9e52-e1be78330903" xlink:href="ameh-20220630.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_d4a25052-582f-4e38-9e52-e1be78330903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e82fe503-c8cd-435d-84b8-a577ff6a8c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e82fe503-c8cd-435d-84b8-a577ff6a8c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_7c64430f-1cca-4ba6-9cb3-1a3e24dc8d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_7c64430f-1cca-4ba6-9cb3-1a3e24dc8d8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToEquityMethodInvestments_c7b599eb-d801-4996-856a-0c7c97e5053a" xlink:href="ameh-20220630.xsd#ameh_PaymentsToEquityMethodInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11319efc-fc24-48e4-b008-9b5b6af56e74" xlink:to="loc_ameh_PaymentsToEquityMethodInvestments_c7b599eb-d801-4996-856a-0c7c97e5053a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e51ce1bf-6931-4747-b392-d3b20fd9e00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_ProfitLoss_e51ce1bf-6931-4747-b392-d3b20fd9e00a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1b30e2eb-bec4-4c18-992b-e730531e3406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1b30e2eb-bec4-4c18-992b-e730531e3406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ed87916e-5955-4328-9516-542459b6f2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ed87916e-5955-4328-9516-542459b6f2ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e4361cfb-0875-44e4-b7fc-71cd81d225da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_ShareBasedCompensation_e4361cfb-0875-44e4-b7fc-71cd81d225da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d768e119-94ce-423f-a86a-b97b61c26801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d768e119-94ce-423f-a86a-b97b61c26801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_fa819250-f48a-4c47-9918-b77472992319" xlink:href="ameh-20220630.xsd#ameh_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_fa819250-f48a-4c47-9918-b77472992319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a72d1855-ea9a-4edd-baf5-57f374f9e538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a72d1855-ea9a-4edd-baf5-57f374f9e538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6e96060a-88f2-449f-b9dd-da6796e8666c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_AssetImpairmentCharges_6e96060a-88f2-449f-b9dd-da6796e8666c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_1be8cf83-342b-4bf7-8f74-38dc353309ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_1be8cf83-342b-4bf7-8f74-38dc353309ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3f455b40-1a36-42fa-8cf2-50c9bfef3061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_3f455b40-1a36-42fa-8cf2-50c9bfef3061" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_0a79a036-a6b0-48fe-9df5-f99f1a2ec9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_0a79a036-a6b0-48fe-9df5-f99f1a2ec9b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58b89f94-8e89-46ff-acf8-9ba34926d6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58b89f94-8e89-46ff-acf8-9ba34926d6b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_f429bd9d-e974-4cb8-a712-0f76d05ac03d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_f429bd9d-e974-4cb8-a712-0f76d05ac03d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_9448a0c0-5f86-4a9d-a7d3-7530df50602a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_9448a0c0-5f86-4a9d-a7d3-7530df50602a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_385835d2-52bd-4821-915f-58a99b87a124" xlink:href="ameh-20220630.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_385835d2-52bd-4821-915f-58a99b87a124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_4dab75ce-373d-4c25-8946-e9c5122a79da" xlink:href="ameh-20220630.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_4dab75ce-373d-4c25-8946-e9c5122a79da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d8dba1e7-7707-45e3-a87e-71b07ec3b737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d8dba1e7-7707-45e3-a87e-71b07ec3b737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cb267602-c752-44dd-805c-667a5c00a886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_cb267602-c752-44dd-805c-667a5c00a886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_72ed9b0b-3faa-4471-a920-8442776538f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_72ed9b0b-3faa-4471-a920-8442776538f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_e8e2a8ec-8d4f-44ac-be09-80e57af4e28f" xlink:href="ameh-20220630.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_e8e2a8ec-8d4f-44ac-be09-80e57af4e28f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_432ec5a3-b690-449a-a0ba-143c6f143dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_432ec5a3-b690-449a-a0ba-143c6f143dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ea022723-dbc2-4df5-bab6-27587804b998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ea022723-dbc2-4df5-bab6-27587804b998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_8483016f-fb47-415a-8bd3-b26d24da72dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be496bcb-8984-4aac-aeb0-95921fa3d1af" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_8483016f-fb47-415a-8bd3-b26d24da72dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c28b67d6-60c3-403b-a955-716d0ee5d28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_us-gaap_PaymentsOfDividends_c28b67d6-60c3-403b-a955-716d0ee5d28d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d009efa0-754a-4c1e-bfc9-1207c82d7765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d009efa0-754a-4c1e-bfc9-1207c82d7765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_671a334c-9627-4c90-be51-e31637a04d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_671a334c-9627-4c90-be51-e31637a04d63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ae7017e2-1476-49b4-aaca-d7aee8ce8cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ae7017e2-1476-49b4-aaca-d7aee8ce8cf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f342a67a-7b28-4fc5-9df0-b6b13c9daefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f342a67a-7b28-4fc5-9df0-b6b13c9daefb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_82fd4554-2f0d-4394-bd19-46491db6f3bd" xlink:href="ameh-20220630.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_82fd4554-2f0d-4394-bd19-46491db6f3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireNonControllingInterest_651e3a4b-d835-4b31-b23a-6e5ae191ea19" xlink:href="ameh-20220630.xsd#ameh_PaymentsToAcquireNonControllingInterest"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_ameh_PaymentsToAcquireNonControllingInterest_651e3a4b-d835-4b31-b23a-6e5ae191ea19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_98b90a17-7bc8-4cc7-8b34-d7ae83ef2633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_98b90a17-7bc8-4cc7-8b34-d7ae83ef2633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c8dba675-b96f-4fba-afcc-a5c4a8950b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c8dba675-b96f-4fba-afcc-a5c4a8950b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_87b5e861-fbeb-46ee-89bc-82b17e4683ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ef8aab0b-e4ff-4a22-bd09-49de6185804f" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_87b5e861-fbeb-46ee-89bc-82b17e4683ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4b272b5-c397-4762-9283-83be015acfff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a929830-7585-495e-ac26-8805b0c1af34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4b272b5-c397-4762-9283-83be015acfff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7a929830-7585-495e-ac26-8805b0c1af34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01354ce7-02ab-40f1-9555-0dad67c8ec41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4b272b5-c397-4762-9283-83be015acfff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_01354ce7-02ab-40f1-9555-0dad67c8ec41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_595abea6-03e1-4036-9f60-523c46ddcb85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4b272b5-c397-4762-9283-83be015acfff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_595abea6-03e1-4036-9f60-523c46ddcb85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b0d43787-33c5-4f90-b772-eba603ae8a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e55aee2f-d8bb-4330-a2ec-4670e267eca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b0d43787-33c5-4f90-b772-eba603ae8a8a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e55aee2f-d8bb-4330-a2ec-4670e267eca9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_add9d068-b69f-41c0-addd-e3faf6af845c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b0d43787-33c5-4f90-b772-eba603ae8a8a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_add9d068-b69f-41c0-addd-e3faf6af845c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_b6a6db84-0c8c-4cb7-ad26-518f05ac158e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b0d43787-33c5-4f90-b772-eba603ae8a8a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_b6a6db84-0c8c-4cb7-ad26-518f05ac158e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_5c834a05-8a90-41b0-8629-57d76a203f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b0d43787-33c5-4f90-b772-eba603ae8a8a" xlink:to="loc_us-gaap_DerivativeAssets_5c834a05-8a90-41b0-8629-57d76a203f94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f22add9e-e3a7-403d-8dd3-433cbfa6b291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_3792491d-ad8e-42b1-a84e-5ed628dc2e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f22add9e-e3a7-403d-8dd3-433cbfa6b291" xlink:to="loc_us-gaap_DerivativeLiabilities_3792491d-ad8e-42b1-a84e-5ed628dc2e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_58eb3a8e-6c4c-4556-8bd4-789a68d8e277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_f22add9e-e3a7-403d-8dd3-433cbfa6b291" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_58eb3a8e-6c4c-4556-8bd4-789a68d8e277" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f2ffcd4b-12ad-4379-ba4a-37ab289cd77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7a8249dd-d297-4026-96fa-257c055cfd28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f2ffcd4b-12ad-4379-ba4a-37ab289cd77b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_7a8249dd-d297-4026-96fa-257c055cfd28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2b3801a-e525-4bb0-b4c7-8ebacd8fc62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f2ffcd4b-12ad-4379-ba4a-37ab289cd77b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2b3801a-e525-4bb0-b4c7-8ebacd8fc62e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d94603f1-4fd9-4368-9589-60ac145eff61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cbbf8e00-97da-4cae-9c84-64869fda1e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_d94603f1-4fd9-4368-9589-60ac145eff61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cbbf8e00-97da-4cae-9c84-64869fda1e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7d45ee32-4fa9-4a09-bdf7-59e4924ebce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_012b9ec9-0527-413e-849a-850ee3235a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7d45ee32-4fa9-4a09-bdf7-59e4924ebce8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_012b9ec9-0527-413e-849a-850ee3235a08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9c5d933c-d2da-47d8-a44b-470d446c846e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7d45ee32-4fa9-4a09-bdf7-59e4924ebce8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9c5d933c-d2da-47d8-a44b-470d446c846e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4fd59209-52cd-4159-99c5-89ffe47a06e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_96b4cb3c-0455-45e5-8e93-6adec64b04e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4fd59209-52cd-4159-99c5-89ffe47a06e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_96b4cb3c-0455-45e5-8e93-6adec64b04e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87915f41-23fb-440d-999b-354c1b5477fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4fd59209-52cd-4159-99c5-89ffe47a06e6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87915f41-23fb-440d-999b-354c1b5477fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4052efe5-add6-4f4d-8a40-216c9f1c7228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3928954a-b686-4e33-bc1c-2b1be0fdd6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4052efe5-add6-4f4d-8a40-216c9f1c7228" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3928954a-b686-4e33-bc1c-2b1be0fdd6f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_552d3a63-197c-405f-9e7e-399786aa3d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4052efe5-add6-4f4d-8a40-216c9f1c7228" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_552d3a63-197c-405f-9e7e-399786aa3d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_67f0a544-de87-44ca-b86c-2d387822a718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4052efe5-add6-4f4d-8a40-216c9f1c7228" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_67f0a544-de87-44ca-b86c-2d387822a718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_392822da-9b5f-4039-96d2-6c96a3ddd930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4052efe5-add6-4f4d-8a40-216c9f1c7228" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_392822da-9b5f-4039-96d2-6c96a3ddd930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ccc4572a-cfdf-4d0c-96a0-5fcec619827d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4052efe5-add6-4f4d-8a40-216c9f1c7228" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ccc4572a-cfdf-4d0c-96a0-5fcec619827d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_7f725186-c6f0-4859-828e-91e10df83f26" xlink:href="ameh-20220630.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4052efe5-add6-4f4d-8a40-216c9f1c7228" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_7f725186-c6f0-4859-828e-91e10df83f26" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1f6746ec-1ea3-4047-a93a-0bc1e6c6369f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3978702-0f94-470c-8835-f64e01d23ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f6746ec-1ea3-4047-a93a-0bc1e6c6369f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3978702-0f94-470c-8835-f64e01d23ada" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_e6340048-444c-4115-8ed5-d6e7ceeec9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f6746ec-1ea3-4047-a93a-0bc1e6c6369f" xlink:to="loc_us-gaap_RestrictedCashCurrent_e6340048-444c-4115-8ed5-d6e7ceeec9c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_89084429-b383-42d8-9a5c-8e2a1188cd45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f6746ec-1ea3-4047-a93a-0bc1e6c6369f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_89084429-b383-42d8-9a5c-8e2a1188cd45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_f1a897df-eac8-4d0e-8b63-f5f68f1bec08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1f6746ec-1ea3-4047-a93a-0bc1e6c6369f" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_f1a897df-eac8-4d0e-8b63-f5f68f1bec08" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_da8e5cad-1c48-4291-a9c9-0394da16a53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3cd41f8b-ef81-48e0-8537-092f96321d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_da8e5cad-1c48-4291-a9c9-0394da16a53c" xlink:to="loc_us-gaap_AccountsPayableCurrent_3cd41f8b-ef81-48e0-8537-092f96321d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_4eea0589-9944-442e-83e2-13fc69b09a3a" xlink:href="ameh-20220630.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_da8e5cad-1c48-4291-a9c9-0394da16a53c" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_4eea0589-9944-442e-83e2-13fc69b09a3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_088555cb-2744-49c1-ad62-cb59a9d0841a" xlink:href="ameh-20220630.xsd#ameh_SubcontractorIPAPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_da8e5cad-1c48-4291-a9c9-0394da16a53c" xlink:to="loc_ameh_SubcontractorIPAPayable_088555cb-2744-49c1-ad62-cb59a9d0841a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0ced05c8-05e4-4eb8-9c72-db0ef60fe3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_da8e5cad-1c48-4291-a9c9-0394da16a53c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0ced05c8-05e4-4eb8-9c72-db0ef60fe3bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_dd018fb7-73a0-4b2d-ab56-74d29304fcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_da8e5cad-1c48-4291-a9c9-0394da16a53c" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_dd018fb7-73a0-4b2d-ab56-74d29304fcc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_212486d2-457e-429f-8651-937577b22cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_da8e5cad-1c48-4291-a9c9-0394da16a53c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_212486d2-457e-429f-8651-937577b22cb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c7be766d-4998-4e16-b734-fa8ce8ed2a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_da8e5cad-1c48-4291-a9c9-0394da16a53c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c7be766d-4998-4e16-b734-fa8ce8ed2a6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_328317e4-a212-4936-8471-08cb1541e3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_bb8190e8-2512-4cda-9afe-4f0b8f2f4c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_328317e4-a212-4936-8471-08cb1541e3ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_bb8190e8-2512-4cda-9afe-4f0b8f2f4c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_b34d0651-de6d-436f-a608-a9678a82f944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_328317e4-a212-4936-8471-08cb1541e3ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_b34d0651-de6d-436f-a608-a9678a82f944" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c0d4f928-a126-45b7-922a-852be0224a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_afc3934b-2ac0-42b2-89dd-63fe16b437fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c0d4f928-a126-45b7-922a-852be0224a01" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_afc3934b-2ac0-42b2-89dd-63fe16b437fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_3c607c03-f976-4d70-b669-b911ec59cf97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c0d4f928-a126-45b7-922a-852be0224a01" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_3c607c03-f976-4d70-b669-b911ec59cf97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_2fa86d53-d7d9-425f-a978-5814287d722a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6db30464-0960-4612-a450-7998e2624005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2fa86d53-d7d9-425f-a978-5814287d722a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6db30464-0960-4612-a450-7998e2624005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7a7b8cd1-664a-486e-ba83-47ba8a8c8be7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2fa86d53-d7d9-425f-a978-5814287d722a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7a7b8cd1-664a-486e-ba83-47ba8a8c8be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ee4cc91d-5388-4160-a0f6-2ec92c7ebc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2fa86d53-d7d9-425f-a978-5814287d722a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ee4cc91d-5388-4160-a0f6-2ec92c7ebc9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28f9199c-67c4-4f2b-8e5b-f358b2b46cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2fa86d53-d7d9-425f-a978-5814287d722a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28f9199c-67c4-4f2b-8e5b-f358b2b46cd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour_0cac0ef4-174d-4358-826d-0dfb0360190c" xlink:href="ameh-20220630.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_2fa86d53-d7d9-425f-a978-5814287d722a" xlink:to="loc_ameh_LongTermDebtMaturityAfterYearFour_0cac0ef4-174d-4358-826d-0dfb0360190c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_1b430949-a55e-40d2-8982-ce9796fc2c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_f482e287-44ae-42df-a664-aa22c802ee2b" xlink:href="ameh-20220630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_1b430949-a55e-40d2-8982-ce9796fc2c3b" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_f482e287-44ae-42df-a664-aa22c802ee2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_ee371be1-41db-4791-b2c7-9848661a5941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_1b430949-a55e-40d2-8982-ce9796fc2c3b" xlink:to="loc_us-gaap_ManagementFeeExpense_ee371be1-41db-4791-b2c7-9848661a5941" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9b82f96f-5471-4430-8a58-7c5d3f6efacd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f556a7c-b79a-49f6-af9b-bcb6e8444f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9b82f96f-5471-4430-8a58-7c5d3f6efacd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2f556a7c-b79a-49f6-af9b-bcb6e8444f19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e56b77a9-8cfa-4c9a-98f3-9f5e2698d502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9b82f96f-5471-4430-8a58-7c5d3f6efacd" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e56b77a9-8cfa-4c9a-98f3-9f5e2698d502" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_07ffe552-4f36-4d9e-a2d4-d95305b313e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_07ffe552-4f36-4d9e-a2d4-d95305b313e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6261e835-e844-4323-89f1-8fd237f257c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6261e835-e844-4323-89f1-8fd237f257c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5aae3950-798c-43f0-b23e-850048d853e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_Goodwill_5aae3950-798c-43f0-b23e-850048d853e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_c0375fba-60ca-49fd-a985-d9cbb86c9c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_c0375fba-60ca-49fd-a985-d9cbb86c9c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_528bff2c-f3ae-4961-99e8-f559c06b20b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_528bff2c-f3ae-4961-99e8-f559c06b20b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_1bb3b1a2-ec33-4256-846a-862113c03ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_OtherLongTermInvestments_1bb3b1a2-ec33-4256-846a-862113c03ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0eb2c5c5-a8d8-442f-b638-6994cd4d7e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_EquityMethodInvestments_0eb2c5c5-a8d8-442f-b638-6994cd4d7e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_d25efeb9-fa31-41e0-9224-163fe07dc865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_d25efeb9-fa31-41e0-9224-163fe07dc865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c9a659d7-7591-4f01-9a3b-d95ab0d6f13e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c9a659d7-7591-4f01-9a3b-d95ab0d6f13e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7a951c6e-562c-4e79-b067-c3997d7841ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_573e671e-5ca3-488f-9f6a-e254f03710f6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7a951c6e-562c-4e79-b067-c3997d7841ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75d498a6-4189-4136-8f5c-fd4d56e6ace6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_75d498a6-4189-4136-8f5c-fd4d56e6ace6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_8d7d24cf-0c70-4c90-827f-d34148517cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_8d7d24cf-0c70-4c90-827f-d34148517cf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2dd6da5c-c0ca-48ea-8de9-3c1d583982d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2dd6da5c-c0ca-48ea-8de9-3c1d583982d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_33fadca2-05e8-4361-bff3-4929bc58da40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_33fadca2-05e8-4361-bff3-4929bc58da40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_772c579e-c85d-413d-ac3b-66a8e0fb7b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:to="loc_us-gaap_IncomeTaxesReceivable_772c579e-c85d-413d-ac3b-66a8e0fb7b3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_154e70f0-5d7d-4e37-a426-7068c8df2e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_154e70f0-5d7d-4e37-a426-7068c8df2e41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29b48107-ffc3-4023-837f-35c99d54b2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_29b48107-ffc3-4023-837f-35c99d54b2fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_e15cca0f-b7d4-4947-842a-6ffc39a95dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_e15cca0f-b7d4-4947-842a-6ffc39a95dec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_d80796dd-b9ad-4d6b-85c1-a9a7fb78a50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_eb1b8290-aa94-4e63-8c8f-b6adca220c39" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_d80796dd-b9ad-4d6b-85c1-a9a7fb78a50a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_21871cd3-bed1-4fb4-83c3-27751c11f49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bbf3a4cb-f8c1-417f-b4c9-14963523ae87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_21871cd3-bed1-4fb4-83c3-27751c11f49b" xlink:to="loc_us-gaap_OperatingLeaseCost_bbf3a4cb-f8c1-417f-b4c9-14963523ae87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f06ddb85-5db4-4186-ac43-3d145a8a951c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_21871cd3-bed1-4fb4-83c3-27751c11f49b" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f06ddb85-5db4-4186-ac43-3d145a8a951c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_9964d5f1-fc2b-4e74-bdd7-dae85d3c52b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_21871cd3-bed1-4fb4-83c3-27751c11f49b" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_9964d5f1-fc2b-4e74-bdd7-dae85d3c52b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_47c87439-eadc-422c-a358-c903668fd2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_21871cd3-bed1-4fb4-83c3-27751c11f49b" xlink:to="loc_us-gaap_SubleaseIncome_47c87439-eadc-422c-a358-c903668fd2aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f2a24153-cd11-4f02-83f5-0159b7fe915f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_37e41678-5133-47ef-98e8-34520bf4bf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_f2a24153-cd11-4f02-83f5-0159b7fe915f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_37e41678-5133-47ef-98e8-34520bf4bf8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b5ba90bc-fd05-46ac-b7e8-0ad367a79bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_f2a24153-cd11-4f02-83f5-0159b7fe915f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b5ba90bc-fd05-46ac-b7e8-0ad367a79bc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5517473-f794-49c2-a97e-54a4e43c3f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_78bf0b0f-a179-4503-a911-54f4dab5f688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5517473-f794-49c2-a97e-54a4e43c3f25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_78bf0b0f-a179-4503-a911-54f4dab5f688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9c94ab18-6174-4867-8add-30c9d3a76680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5517473-f794-49c2-a97e-54a4e43c3f25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9c94ab18-6174-4867-8add-30c9d3a76680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3accba2b-c198-4db9-bfe6-1fee9083ed90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5517473-f794-49c2-a97e-54a4e43c3f25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3accba2b-c198-4db9-bfe6-1fee9083ed90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0b4bfc3b-3552-4c4f-a61b-2cd757d60f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5517473-f794-49c2-a97e-54a4e43c3f25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0b4bfc3b-3552-4c4f-a61b-2cd757d60f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f5777d6d-cc91-4f96-8db9-d18c356fd7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5517473-f794-49c2-a97e-54a4e43c3f25" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f5777d6d-cc91-4f96-8db9-d18c356fd7e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_a86a57a5-c493-4476-b991-f5b9e8947f6a" xlink:href="ameh-20220630.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b5517473-f794-49c2-a97e-54a4e43c3f25" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_a86a57a5-c493-4476-b991-f5b9e8947f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_55b6507a-f99b-4320-b0d1-92b09df1e506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_342e192d-ffbb-458f-86d1-3a669e107d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_55b6507a-f99b-4320-b0d1-92b09df1e506" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_342e192d-ffbb-458f-86d1-3a669e107d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9bc02ab8-6cbe-45ba-90f4-d991104b482c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_55b6507a-f99b-4320-b0d1-92b09df1e506" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9bc02ab8-6cbe-45ba-90f4-d991104b482c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_4d9ca4bd-900a-4b10-83ee-4154e2b786d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_981078fb-4e72-40a3-8549-87b969bca744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_4d9ca4bd-900a-4b10-83ee-4154e2b786d7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_981078fb-4e72-40a3-8549-87b969bca744" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_8e112b2b-c8df-4913-9fa7-19d99a19d9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_4d9ca4bd-900a-4b10-83ee-4154e2b786d7" xlink:to="loc_us-gaap_FinanceLeaseLiability_8e112b2b-c8df-4913-9fa7-19d99a19d9c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5157faa8-e971-4c14-a297-a4756b8f810f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_843aad7c-ba11-476d-8837-cd5c45a03b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5157faa8-e971-4c14-a297-a4756b8f810f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_843aad7c-ba11-476d-8837-cd5c45a03b61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ca4651b2-52da-4aa2-a081-c3fc8bdc5690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5157faa8-e971-4c14-a297-a4756b8f810f" xlink:to="loc_us-gaap_OperatingLeaseLiability_ca4651b2-52da-4aa2-a081-c3fc8bdc5690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6f421249-139b-4f03-b1b1-a99714ea4940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_baaa7451-45e8-4147-8547-ea4158e880bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6f421249-139b-4f03-b1b1-a99714ea4940" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_baaa7451-45e8-4147-8547-ea4158e880bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_eada3ddc-0722-47fe-8b82-79be61c9a4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6f421249-139b-4f03-b1b1-a99714ea4940" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_eada3ddc-0722-47fe-8b82-79be61c9a4ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1e0943a9-058a-4fc6-96c2-90436f47eb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6f421249-139b-4f03-b1b1-a99714ea4940" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1e0943a9-058a-4fc6-96c2-90436f47eb4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2471c08b-53ea-4949-9671-8f652fde8085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6f421249-139b-4f03-b1b1-a99714ea4940" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2471c08b-53ea-4949-9671-8f652fde8085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_bfbf90cc-452e-4259-bcdb-ba6950054b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6f421249-139b-4f03-b1b1-a99714ea4940" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_bfbf90cc-452e-4259-bcdb-ba6950054b1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_2e8f93c6-1e6e-47e7-b5a4-aeef646a4c7a" xlink:href="ameh-20220630.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6f421249-139b-4f03-b1b1-a99714ea4940" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_2e8f93c6-1e6e-47e7-b5a4-aeef646a4c7a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ameh-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4d426055-c9f8-47bb-b397-a8331168ec1c,g:285e3d39-8563-4e90-906d-af4a3a14867e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="if1241b2217c248c5861c3c390cd7febb_CONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_74e52ea5-b816-4feb-8f89-9d935d90cf70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74e52ea5-b816-4feb-8f89-9d935d90cf70" xlink:to="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77aa72c5-aa5a-41f1-bf42-2e03c125daa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77aa72c5-aa5a-41f1-bf42-2e03c125daa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_321c2592-f39f-4cbf-8e96-e2dd0674d7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_321c2592-f39f-4cbf-8e96-e2dd0674d7db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_52b9db06-d915-40ab-ad13-0e56c2c5075a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_52b9db06-d915-40ab-ad13-0e56c2c5075a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2751efbb-338f-4410-8109-23ac459363e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2751efbb-338f-4410-8109-23ac459363e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_5934eb82-b8c7-427a-9193-6739115633a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_IncomeTaxesReceivable_5934eb82-b8c7-427a-9193-6739115633a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_df999399-1e4c-46aa-b280-4766ab74c7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_df999399-1e4c-46aa-b280-4766ab74c7fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5d067265-c4fa-453f-a1f2-3855dbd1e820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5d067265-c4fa-453f-a1f2-3855dbd1e820" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_34e8546e-3abd-4f5c-b87b-7f8784571ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_34e8546e-3abd-4f5c-b87b-7f8784571ef5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf15034f-a841-455e-9a14-9bbf9d99a383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_AssetsCurrent_bf15034f-a841-455e-9a14-9bbf9d99a383" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0bdfbeb9-ca34-4b2b-84e7-3192b2edfe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0bdfbeb9-ca34-4b2b-84e7-3192b2edfe70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6071ad7-f0c4-4c4a-a017-b3e306c95c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6071ad7-f0c4-4c4a-a017-b3e306c95c72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a06ce44f-a67b-41ad-8387-a30e01e74d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_Goodwill_a06ce44f-a67b-41ad-8387-a30e01e74d0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_444227a3-55d2-4d4c-84bb-ecef87c66999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_444227a3-55d2-4d4c-84bb-ecef87c66999" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_e0e7e250-6cc8-4213-ba46-c824fa5853bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_e0e7e250-6cc8-4213-ba46-c824fa5853bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d6368566-9f2a-43aa-94b3-d5e668722eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_EquityMethodInvestments_d6368566-9f2a-43aa-94b3-d5e668722eed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_dc83d637-aa22-49b0-8edd-ab002d682780" xlink:href="ameh-20220630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_dc83d637-aa22-49b0-8edd-ab002d682780" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_88437876-5e33-4238-aa9b-1495e0c3e28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_88437876-5e33-4238-aa9b-1495e0c3e28d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_39775fef-a206-4ed0-9475-02ed150df1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_39775fef-a206-4ed0-9475-02ed150df1b9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1815cd46-0f9b-4d51-b87f-8620a837dd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_AssetsNoncurrent_1815cd46-0f9b-4d51-b87f-8620a837dd7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e2792a10-5e48-4500-9048-62e29acb2e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:to="loc_us-gaap_Assets_e2792a10-5e48-4500-9048-62e29acb2e79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74e52ea5-b816-4feb-8f89-9d935d90cf70" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_829633d9-0c15-4775-ae31-3e4c149689ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_829633d9-0c15-4775-ae31-3e4c149689ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_63a83333-0e44-4499-aaf9-f3f79f23958b" xlink:href="ameh-20220630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_63a83333-0e44-4499-aaf9-f3f79f23958b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_098b53a2-e5b1-413e-bb66-9afc41062858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_098b53a2-e5b1-413e-bb66-9afc41062858" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_d3adf5a7-6ca1-4b56-9b1f-22447958c619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_d3adf5a7-6ca1-4b56-9b1f-22447958c619" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_1a414a4a-43f5-4ec0-8f8c-5c14c7355dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_DividendsPayableCurrent_1a414a4a-43f5-4ec0-8f8c-5c14c7355dbc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_459389fa-c92a-48c6-bfe6-5e020df4719b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_459389fa-c92a-48c6-bfe6-5e020df4719b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_987ebe58-77fb-4c7d-9d71-006b74cc697e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_987ebe58-77fb-4c7d-9d71-006b74cc697e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_22ecdf6f-ccbb-4ca6-9e36-7f59e764b926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_LongTermDebtCurrent_22ecdf6f-ccbb-4ca6-9e36-7f59e764b926" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dede57ed-7019-452e-b2f4-eac3e136d14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_LiabilitiesCurrent_dede57ed-7019-452e-b2f4-eac3e136d14d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_361450f9-07fa-462d-8899-8bd8c3713ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_361450f9-07fa-462d-8899-8bd8c3713ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7725b215-8432-44fc-ab8f-e0da8e14bfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7725b215-8432-44fc-ab8f-e0da8e14bfdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adc0e97a-5eb1-4ec2-996f-fe3ecefac91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adc0e97a-5eb1-4ec2-996f-fe3ecefac91c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_de37a15c-6032-4f31-8e35-91ea1a8b26fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_de37a15c-6032-4f31-8e35-91ea1a8b26fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d341ef16-e5af-44af-a028-afd67739f3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d341ef16-e5af-44af-a028-afd67739f3a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_844f5727-ac42-4ed3-94bd-5a28bce3e4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_844f5727-ac42-4ed3-94bd-5a28bce3e4aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_446c598a-21ad-4580-ba50-ba283fee62f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_Liabilities_446c598a-21ad-4580-ba50-ba283fee62f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_999f5044-634e-4430-866b-016cfc3d1667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_999f5044-634e-4430-866b-016cfc3d1667" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_5ab69f70-4632-4606-9d3d-1194ce469010" xlink:href="ameh-20220630.xsd#ameh_MezzanineEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_ameh_MezzanineEquityAbstract_5ab69f70-4632-4606-9d3d-1194ce469010" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2ec9f506-095b-4328-84fb-5eaaf4f3e53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_MezzanineEquityAbstract_5ab69f70-4632-4606-9d3d-1194ce469010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2ec9f506-095b-4328-84fb-5eaaf4f3e53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f76e305a-74ee-4304-8f04-ea7c3e7d4cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_PreferredStockValue_f76e305a-74ee-4304-8f04-ea7c3e7d4cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_25164b10-7fbb-4748-a35c-60bbf097c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_CommonStockValue_25164b10-7fbb-4748-a35c-60bbf097c2fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d5a3351f-ac08-429e-a5c7-bb5a1952486f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d5a3351f-ac08-429e-a5c7-bb5a1952486f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ae3ac84-5b6c-4e01-9519-fcfe66045abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ae3ac84-5b6c-4e01-9519-fcfe66045abc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a603f7a9-2988-4506-aba1-9cddcda6e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_StockholdersEquity_a603f7a9-2988-4506-aba1-9cddcda6e8cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0be2204e-1e8b-4ba9-aa86-5221cc7d3ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_MinorityInterest_0be2204e-1e8b-4ba9-aa86-5221cc7d3ccf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d32e61f5-dc57-41dc-8edb-7c082a6458d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d32e61f5-dc57-41dc-8edb-7c082a6458d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_644dd370-ac9c-468d-9a4e-9624eb6cd8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_644dd370-ac9c-468d-9a4e-9624eb6cd8ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f96da404-b328-4aff-8584-4f18d86244e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_74e52ea5-b816-4feb-8f89-9d935d90cf70" xlink:to="loc_us-gaap_StatementTable_f96da404-b328-4aff-8584-4f18d86244e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8159ca9a-065b-4eb3-bbb3-ea424b2a1a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f96da404-b328-4aff-8584-4f18d86244e3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8159ca9a-065b-4eb3-bbb3-ea424b2a1a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8159ca9a-065b-4eb3-bbb3-ea424b2a1a3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8159ca9a-065b-4eb3-bbb3-ea424b2a1a3a" xlink:to="loc_us-gaap_ClassOfStockDomain_8159ca9a-065b-4eb3-bbb3-ea424b2a1a3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9d3322df-0e98-4607-b89a-f9bff241e668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8159ca9a-065b-4eb3-bbb3-ea424b2a1a3a" xlink:to="loc_us-gaap_ClassOfStockDomain_9d3322df-0e98-4607-b89a-f9bff241e668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8d9caceb-a95a-487b-9dac-7f0c09c2466d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9d3322df-0e98-4607-b89a-f9bff241e668" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8d9caceb-a95a-487b-9dac-7f0c09c2466d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b2d85ff6-caf8-4cfc-a4cd-e87456b6dc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9d3322df-0e98-4607-b89a-f9bff241e668" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b2d85ff6-caf8-4cfc-a4cd-e87456b6dc64" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="iac7036aab91848e59125435246405a6b_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5ef7b3be-41f5-4b4c-856b-36cc05d121b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5ef7b3be-41f5-4b4c-856b-36cc05d121b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_660f8c19-866f-48fc-adf2-ed159993ef5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_660f8c19-866f-48fc-adf2-ed159993ef5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5c07c5f0-b59d-481e-99e6-0ada7af57b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5c07c5f0-b59d-481e-99e6-0ada7af57b9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5ac60cad-5be5-4bf1-b7de-9e73b86f558e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5ac60cad-5be5-4bf1-b7de-9e73b86f558e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a32e219c-6e53-4843-bd70-c5f0b85fdd71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a32e219c-6e53-4843-bd70-c5f0b85fdd71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b5f00528-aef0-4137-a910-f025dcb3a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b5f00528-aef0-4137-a910-f025dcb3a2a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ec1c3b6d-fd74-4583-b36e-ef545746a64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_CommonStockSharesIssued_ec1c3b6d-fd74-4583-b36e-ef545746a64e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4a6c0a3f-9f1f-4830-bee3-3409f1d5c787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4a6c0a3f-9f1f-4830-bee3-3409f1d5c787" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_61ea6cfd-b82a-45af-ba2a-25517cec0702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_TreasuryStockCommonShares_61ea6cfd-b82a-45af-ba2a-25517cec0702" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f6b92897-571e-4e4d-92db-da894ec160a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_Assets_f6b92897-571e-4e4d-92db-da894ec160a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9907941c-89e0-4a3a-9cb8-4a9dd1259874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_Liabilities_9907941c-89e0-4a3a-9cb8-4a9dd1259874" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_04c0fd85-0fc9-490e-907a-43d36065efce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_04c0fd85-0fc9-490e-907a-43d36065efce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_ce946813-96d5-4e94-bff9-af175c888e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_DueFromAffiliates_ce946813-96d5-4e94-bff9-af175c888e51" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_e7fb8898-8732-4e75-927b-5f500ad6542f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_e7fb8898-8732-4e75-927b-5f500ad6542f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f967da9-df20-48f0-804f-048c5b9b87ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_StatementTable_1f967da9-df20-48f0-804f-048c5b9b87ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ed375eba-4ad9-4559-8725-81d9f135a012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1f967da9-df20-48f0-804f-048c5b9b87ab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ed375eba-4ad9-4559-8725-81d9f135a012" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ed375eba-4ad9-4559-8725-81d9f135a012_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed375eba-4ad9-4559-8725-81d9f135a012" xlink:to="loc_us-gaap_ClassOfStockDomain_ed375eba-4ad9-4559-8725-81d9f135a012_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_54cef19e-72f3-4ff1-991d-e1ca35d941c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed375eba-4ad9-4559-8725-81d9f135a012" xlink:to="loc_us-gaap_ClassOfStockDomain_54cef19e-72f3-4ff1-991d-e1ca35d941c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_616dfb25-84fd-4fa5-b9ed-441de831cd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_54cef19e-72f3-4ff1-991d-e1ca35d941c2" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_616dfb25-84fd-4fa5-b9ed-441de831cd4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0607136b-751c-4011-9036-fba5cd499527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_54cef19e-72f3-4ff1-991d-e1ca35d941c2" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0607136b-751c-4011-9036-fba5cd499527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d2bfa932-fd5d-4e1d-ba29-cd845dad5082" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1f967da9-df20-48f0-804f-048c5b9b87ab" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d2bfa932-fd5d-4e1d-ba29-cd845dad5082" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d2bfa932-fd5d-4e1d-ba29-cd845dad5082_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d2bfa932-fd5d-4e1d-ba29-cd845dad5082" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d2bfa932-fd5d-4e1d-ba29-cd845dad5082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ca0a70f4-15ed-4a57-b59b-590667d38925" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d2bfa932-fd5d-4e1d-ba29-cd845dad5082" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ca0a70f4-15ed-4a57-b59b-590667d38925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bd3c1a54-2cb6-4fef-8449-845b58f43b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ca0a70f4-15ed-4a57-b59b-590667d38925" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bd3c1a54-2cb6-4fef-8449-845b58f43b9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended" id="i5b12e15d2bbc44d38cf565d33278158a_CONSOLIDATEDSTATEMENTSOFINCOME">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_07ac30bb-6f7c-474b-9cb5-642999efbca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_RevenuesAbstract_07ac30bb-6f7c-474b-9cb5-642999efbca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_135f9047-2105-48cf-91a8-d392fb6f45b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_07ac30bb-6f7c-474b-9cb5-642999efbca3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_135f9047-2105-48cf-91a8-d392fb6f45b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_82f5a052-4886-479a-a652-b7ba6e843e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_82f5a052-4886-479a-a652-b7ba6e843e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_52cfb32a-0ba5-422d-84cf-a7b2de708742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_52cfb32a-0ba5-422d-84cf-a7b2de708742" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_f9ed7359-f68f-4643-8cd9-237cd736d07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_f9ed7359-f68f-4643-8cd9-237cd736d07f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ef99a612-1518-4207-97e7-cc82aaaec55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:to="loc_us-gaap_CostsAndExpenses_ef99a612-1518-4207-97e7-cc82aaaec55a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73627495-c54b-4eb6-8faa-3f43fff6266e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_OperatingIncomeLoss_73627495-c54b-4eb6-8faa-3f43fff6266e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a1154c22-722d-4bbf-a6bc-694e2a3736c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a1154c22-722d-4bbf-a6bc-694e2a3736c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3e6d2422-e5e9-419e-acc8-5339cb4ad99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_InterestExpense_3e6d2422-e5e9-419e-acc8-5339cb4ad99c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4b2b8d8b-be81-4f8a-bd00-28656f15af65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4b2b8d8b-be81-4f8a-bd00-28656f15af65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_df6a73fe-77ba-461b-b771-9a4303f12a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_df6a73fe-77ba-461b-b771-9a4303f12a64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_98fe8ff6-1f10-4f3a-82ec-9ebf4e26cd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_98fe8ff6-1f10-4f3a-82ec-9ebf4e26cd37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5c1b22d7-9755-4735-a3b1-f992cc81fdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5c1b22d7-9755-4735-a3b1-f992cc81fdfd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f3ea91c-1f9f-4a8e-be47-c7bb928cfef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f3ea91c-1f9f-4a8e-be47-c7bb928cfef2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92f20c65-068d-4a0a-b1c9-7e6ba435cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92f20c65-068d-4a0a-b1c9-7e6ba435cf8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a01ba60e-5787-4fd7-a215-a9d5769e8e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_ProfitLoss_a01ba60e-5787-4fd7-a215-a9d5769e8e11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d099f858-f9ad-4ead-91aa-4b28f675c29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d099f858-f9ad-4ead-91aa-4b28f675c29b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f69ede66-926b-4750-9a9f-18597992cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_NetIncomeLoss_f69ede66-926b-4750-9a9f-18597992cd47" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_12c63e8e-a358-4d0f-90d6-4f83b32ad454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_EarningsPerShareBasic_12c63e8e-a358-4d0f-90d6-4f83b32ad454" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3d51ed30-18a3-4a7a-a9db-981d3fd0ab28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3d51ed30-18a3-4a7a-a9db-981d3fd0ab28" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f88f5614-2555-4a52-870a-4780b24d1766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_StatementTable_f88f5614-2555-4a52-870a-4780b24d1766" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_389ab78f-9566-4da9-b112-f3fb76b7bbaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f88f5614-2555-4a52-870a-4780b24d1766" xlink:to="loc_srt_ProductOrServiceAxis_389ab78f-9566-4da9-b112-f3fb76b7bbaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_389ab78f-9566-4da9-b112-f3fb76b7bbaa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_389ab78f-9566-4da9-b112-f3fb76b7bbaa" xlink:to="loc_srt_ProductsAndServicesDomain_389ab78f-9566-4da9-b112-f3fb76b7bbaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_389ab78f-9566-4da9-b112-f3fb76b7bbaa" xlink:to="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_82d03427-61f0-4143-b402-56a2537afdd8" xlink:href="ameh-20220630.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_82d03427-61f0-4143-b402-56a2537afdd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_13871187-b7a0-4a4f-b2a5-6ba8b0d83e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_us-gaap_HealthCareOtherMember_13871187-b7a0-4a4f-b2a5-6ba8b0d83e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_4a93937a-897b-4707-ae7f-fcc12709d600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_us-gaap_ManagementServiceMember_4a93937a-897b-4707-ae7f-fcc12709d600" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_8af5653c-2e26-48cf-acb5-266910199bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_8af5653c-2e26-48cf-acb5-266910199bcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_63b5eee9-9ba3-4986-92a9-538d4a5b2eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_63b5eee9-9ba3-4986-92a9-538d4a5b2eb9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended" id="i402de9ee65334788a1936f023f11c776_CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e0180820-b663-49bf-a119-e369e215ec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e0180820-b663-49bf-a119-e369e215ec7d" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d48a3d64-60b7-48d9-bd90-04d70185863c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d48a3d64-60b7-48d9-bd90-04d70185863c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_4addfec4-7990-43f4-a21a-6337831f1496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_4addfec4-7990-43f4-a21a-6337831f1496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_7a8cd1b2-5eb2-4dc4-8aae-2e133c910fc7" xlink:href="ameh-20220630.xsd#ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_7a8cd1b2-5eb2-4dc4-8aae-2e133c910fc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_116df917-f66f-4867-9fe1-9f30ea9400df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_116df917-f66f-4867-9fe1-9f30ea9400df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_fe9ff5ab-1286-414c-922e-bfe110bf9913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_fe9ff5ab-1286-414c-922e-bfe110bf9913" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8e6d9497-8673-4d9c-bdf6-75faab8a4ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e0180820-b663-49bf-a119-e369e215ec7d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b44a478f-9b94-4def-ab47-b31cfd4bbe97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_SharesOutstanding_b44a478f-9b94-4def-ab47-b31cfd4bbe97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_884e4dae-e6c2-4716-8183-fa89841eb471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_884e4dae-e6c2-4716-8183-fa89841eb471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_f7f83d0a-9107-4322-9ab4-3592e1066c36" xlink:href="ameh-20220630.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_f7f83d0a-9107-4322-9ab4-3592e1066c36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_f7da621c-bd6e-4651-9822-4f7d5620e533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_f7da621c-bd6e-4651-9822-4f7d5620e533" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_257ed551-febd-4890-9ad7-e9c47dc3393b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_257ed551-febd-4890-9ad7-e9c47dc3393b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_34a21f2d-e63e-4cae-a90f-10da2fa454cf" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_34a21f2d-e63e-4cae-a90f-10da2fa454cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_776988cc-8699-4c5a-b7c4-7f6670da2ccf" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringPeriodValueNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_776988cc-8699-4c5a-b7c4-7f6670da2ccf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_f3bb6550-06fd-4419-b73e-94eae0fdbc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_f3bb6550-06fd-4419-b73e-94eae0fdbc4a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_13516593-67be-4393-ba0d-e91f1f02dbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_13516593-67be-4393-ba0d-e91f1f02dbd0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_ab8c1b59-c47e-4e8a-b18d-c5a9bae43f57" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_ab8c1b59-c47e-4e8a-b18d-c5a9bae43f57" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_fd334212-d329-4dda-836e-28af06182cea" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_fd334212-d329-4dda-836e-28af06182cea" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7c3a88bf-220e-4df0-a86d-ebe6f6b4d0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7c3a88bf-220e-4df0-a86d-ebe6f6b4d0f2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_e9c30b16-5576-4070-9045-ae9e642d83cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_e9c30b16-5576-4070-9045-ae9e642d83cb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e2a11a88-4a9c-43ba-915b-e5cd5fe5853e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e2a11a88-4a9c-43ba-915b-e5cd5fe5853e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9392af65-f3a5-44f3-ae82-8eb3bfa44ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9392af65-f3a5-44f3-ae82-8eb3bfa44ecc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_8b1fb6f0-376e-4fa4-a4de-f2c46220c112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_8b1fb6f0-376e-4fa4-a4de-f2c46220c112" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_125f90e5-8a64-4a04-b822-0db5b27a410c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_125f90e5-8a64-4a04-b822-0db5b27a410c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_e4a9adcc-7441-43a5-b112-b0eadfd8bfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_e4a9adcc-7441-43a5-b112-b0eadfd8bfbb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_d68ff53e-2573-4787-bbdc-432c66e7dec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_d68ff53e-2573-4787-bbdc-432c66e7dec8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_acffd445-059b-4299-ae34-b09b409ff45f" xlink:href="ameh-20220630.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_acffd445-059b-4299-ae34-b09b409ff45f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9cb808b7-b222-4204-bc37-ec5d6af271f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e151c20-de09-4ed4-ac9e-419e11fd8620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffb908cf-0ad1-41ab-b3d5-66e3a55bb8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e0180820-b663-49bf-a119-e369e215ec7d" xlink:to="loc_us-gaap_StatementTable_ffb908cf-0ad1-41ab-b3d5-66e3a55bb8c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ebc231d-7652-4264-9bc8-227e3b845bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffb908cf-0ad1-41ab-b3d5-66e3a55bb8c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ebc231d-7652-4264-9bc8-227e3b845bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ebc231d-7652-4264-9bc8-227e3b845bc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ebc231d-7652-4264-9bc8-227e3b845bc5" xlink:to="loc_us-gaap_EquityComponentDomain_5ebc231d-7652-4264-9bc8-227e3b845bc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ebc231d-7652-4264-9bc8-227e3b845bc5" xlink:to="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5389372f-34d5-41fe-b4ab-5a218004a684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:to="loc_us-gaap_CommonStockMember_5389372f-34d5-41fe-b4ab-5a218004a684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_59a44a81-d848-4067-96fb-80c08018b189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_59a44a81-d848-4067-96fb-80c08018b189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_19479b07-fb05-4a6c-b572-c41eeff22c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:to="loc_us-gaap_RetainedEarningsMember_19479b07-fb05-4a6c-b572-c41eeff22c63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_494fefbe-6eb4-4695-92e3-6d136cfebfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_494fefbe-6eb4-4695-92e3-6d136cfebfe9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2035324d-7cb6-44d9-8024-6aa826df964c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ffb908cf-0ad1-41ab-b3d5-66e3a55bb8c8" xlink:to="loc_dei_LegalEntityAxis_2035324d-7cb6-44d9-8024-6aa826df964c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2035324d-7cb6-44d9-8024-6aa826df964c_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2035324d-7cb6-44d9-8024-6aa826df964c" xlink:to="loc_dei_EntityDomain_2035324d-7cb6-44d9-8024-6aa826df964c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d595062c-aa0b-4baf-86f7-654eefd32518" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2035324d-7cb6-44d9-8024-6aa826df964c" xlink:to="loc_dei_EntityDomain_d595062c-aa0b-4baf-86f7-654eefd32518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_49f34382-3ae4-4073-b785-7f513f5f3b76" xlink:href="ameh-20220630.xsd#ameh_MezzanineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d595062c-aa0b-4baf-86f7-654eefd32518" xlink:to="loc_ameh_MezzanineMember_49f34382-3ae4-4073-b785-7f513f5f3b76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended" id="i812326b5375d493e8fc981cc410701c3_DescriptionofBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:href="ameh-20220630.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_667943c6-fd79-4456-8757-cbfa5b8a6f86" xlink:href="ameh-20220630.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_667943c6-fd79-4456-8757-cbfa5b8a6f86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_79ae825a-83c2-4507-bbe9-b10aae4fa7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_NotesReceivableNet_79ae825a-83c2-4507-bbe9-b10aae4fa7e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_0fb0979c-41c6-4375-9a10-3734c4cee855" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_0fb0979c-41c6-4375-9a10-3734c4cee855" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_66601ab0-be2b-4c35-8d6e-24ef19a4ca46" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_66601ab0-be2b-4c35-8d6e-24ef19a4ca46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_6bd86244-e67e-4fd0-bc8b-d2ff2e0fd2f8" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_6bd86244-e67e-4fd0-bc8b-d2ff2e0fd2f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1ce6db9e-96c4-45c0-995c-57dc29dc679c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1ce6db9e-96c4-45c0-995c-57dc29dc679c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d32850c1-ca7e-4f30-911e-9ff23f3337ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d32850c1-ca7e-4f30-911e-9ff23f3337ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_23a8c381-c583-4ab1-a7d1-adf5db7d1d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_23a8c381-c583-4ab1-a7d1-adf5db7d1d10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_2f3bca6e-162e-46fa-9ed2-22816c52c55c" xlink:href="ameh-20220630.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_2f3bca6e-162e-46fa-9ed2-22816c52c55c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_48dfdfb9-2ad5-44d0-b6a2-3a86abce5c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_48dfdfb9-2ad5-44d0-b6a2-3a86abce5c48" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f449b442-fbc8-4268-8a54-93287858e7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f449b442-fbc8-4268-8a54-93287858e7e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_fed62f02-678a-4b8d-af8e-c7e229b3eab8" xlink:href="ameh-20220630.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_fed62f02-678a-4b8d-af8e-c7e229b3eab8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_c66a2bce-fd1c-427d-9691-659dc1fd3002" xlink:href="ameh-20220630.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_c66a2bce-fd1c-427d-9691-659dc1fd3002" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7643d4b1-25d6-4e51-b6b5-aab696a33fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_EquityMethodInvestments_7643d4b1-25d6-4e51-b6b5-aab696a33fc6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_435caaac-5aff-4537-af72-d0c2a297383a" xlink:href="ameh-20220630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_435caaac-5aff-4537-af72-d0c2a297383a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_2e21d20e-fc63-42a7-b8d3-a1479e41c54b" xlink:href="ameh-20220630.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_2e21d20e-fc63-42a7-b8d3-a1479e41c54b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:href="ameh-20220630.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_eee2b04c-96e8-45fb-b981-4c19c9aa1ac0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_dei_LegalEntityAxis_eee2b04c-96e8-45fb-b981-4c19c9aa1ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_eee2b04c-96e8-45fb-b981-4c19c9aa1ac0_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_eee2b04c-96e8-45fb-b981-4c19c9aa1ac0" xlink:to="loc_dei_EntityDomain_eee2b04c-96e8-45fb-b981-4c19c9aa1ac0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_eee2b04c-96e8-45fb-b981-4c19c9aa1ac0" xlink:to="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_4f802c78-25ff-429b-a9a1-d45d5ad4a43e" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_4f802c78-25ff-429b-a9a1-d45d5ad4a43e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_03a874ec-f78b-42e3-be43-591c019a209e" xlink:href="ameh-20220630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:to="loc_ameh_AccountableHealthCareIPAMember_03a874ec-f78b-42e3-be43-591c019a209e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_ed223a9d-2541-4240-bf3c-b721e662d1fa" xlink:href="ameh-20220630.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:to="loc_ameh_AmgIncMember_ed223a9d-2541-4240-bf3c-b721e662d1fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_e2c03e90-bd97-40f9-948b-c182b6d79ea0" xlink:href="ameh-20220630.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:to="loc_ameh_ApcLsmaMember_e2c03e90-bd97-40f9-948b-c182b6d79ea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_809a0893-0f9a-4172-8bb3-c419627284a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_srt_CounterpartyNameAxis_809a0893-0f9a-4172-8bb3-c419627284a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_809a0893-0f9a-4172-8bb3-c419627284a1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_809a0893-0f9a-4172-8bb3-c419627284a1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_809a0893-0f9a-4172-8bb3-c419627284a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53252e6-8aeb-48f6-983e-b005898d3658" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_809a0893-0f9a-4172-8bb3-c419627284a1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53252e6-8aeb-48f6-983e-b005898d3658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_3db46078-4dac-4d15-987c-4da47ce5877c" xlink:href="ameh-20220630.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53252e6-8aeb-48f6-983e-b005898d3658" xlink:to="loc_ameh_APAMHMedicalCorporationMember_3db46078-4dac-4d15-987c-4da47ce5877c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_01beb58b-cd93-4df3-ac92-31f2afd2c36f" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53252e6-8aeb-48f6-983e-b005898d3658" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_01beb58b-cd93-4df3-ac92-31f2afd2c36f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5303427-e2b6-4bfb-941f-69069a9249eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5303427-e2b6-4bfb-941f-69069a9249eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f5303427-e2b6-4bfb-941f-69069a9249eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5303427-e2b6-4bfb-941f-69069a9249eb" xlink:to="loc_us-gaap_RelatedPartyDomain_f5303427-e2b6-4bfb-941f-69069a9249eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d82f7fd0-8041-45b9-b79a-86a11ab1c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5303427-e2b6-4bfb-941f-69069a9249eb" xlink:to="loc_us-gaap_RelatedPartyDomain_d82f7fd0-8041-45b9-b79a-86a11ab1c9cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_518e1d28-e66f-44a2-86f7-c612a9c2072f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d82f7fd0-8041-45b9-b79a-86a11ab1c9cc" xlink:to="loc_srt_AffiliatedEntityMember_518e1d28-e66f-44a2-86f7-c612a9c2072f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d14ed507-39f3-4c89-99c7-ade775b87407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d14ed507-39f3-4c89-99c7-ade775b87407" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d14ed507-39f3-4c89-99c7-ade775b87407_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d14ed507-39f3-4c89-99c7-ade775b87407" xlink:to="loc_us-gaap_ClassOfStockDomain_d14ed507-39f3-4c89-99c7-ade775b87407_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5462ee9a-d145-48fc-976c-d3ee9cdbaa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d14ed507-39f3-4c89-99c7-ade775b87407" xlink:to="loc_us-gaap_ClassOfStockDomain_5462ee9a-d145-48fc-976c-d3ee9cdbaa7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b496f1a2-ca61-4339-b388-8e77df000069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5462ee9a-d145-48fc-976c-d3ee9cdbaa7c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b496f1a2-ca61-4339-b388-8e77df000069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fc1e3e6-a3e6-42f2-be50-41146db11af8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fc1e3e6-a3e6-42f2-be50-41146db11af8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8fc1e3e6-a3e6-42f2-be50-41146db11af8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fc1e3e6-a3e6-42f2-be50-41146db11af8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8fc1e3e6-a3e6-42f2-be50-41146db11af8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fc1e3e6-a3e6-42f2-be50-41146db11af8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_0c597b88-1ac7-4c86-ac01-09e119c635ed" xlink:href="ameh-20220630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_0c597b88-1ac7-4c86-ac01-09e119c635ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_da0fb0d6-9749-43ca-9749-e6faa2f46382" xlink:href="ameh-20220630.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_da0fb0d6-9749-43ca-9749-e6faa2f46382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_c4eb9cd4-f8df-49e8-8318-5aca959f080c" xlink:href="ameh-20220630.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:to="loc_ameh_DmgMember_c4eb9cd4-f8df-49e8-8318-5aca959f080c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7092d5f7-136c-41c6-a728-c8746edbfd8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_srt_OwnershipAxis_7092d5f7-136c-41c6-a728-c8746edbfd8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7092d5f7-136c-41c6-a728-c8746edbfd8b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_7092d5f7-136c-41c6-a728-c8746edbfd8b" xlink:to="loc_srt_OwnershipDomain_7092d5f7-136c-41c6-a728-c8746edbfd8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4ca6b073-60ac-477f-9042-a070edb7b76b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_7092d5f7-136c-41c6-a728-c8746edbfd8b" xlink:to="loc_srt_OwnershipDomain_4ca6b073-60ac-477f-9042-a070edb7b76b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_e2123343-1cff-4356-903c-a3a8433ac3c9" xlink:href="ameh-20220630.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_4ca6b073-60ac-477f-9042-a070edb7b76b" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_e2123343-1cff-4356-903c-a3a8433ac3c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_46486e4e-2101-4f5b-af3c-f14b7233089b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_46486e4e-2101-4f5b-af3c-f14b7233089b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46486e4e-2101-4f5b-af3c-f14b7233089b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_46486e4e-2101-4f5b-af3c-f14b7233089b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_46486e4e-2101-4f5b-af3c-f14b7233089b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_46486e4e-2101-4f5b-af3c-f14b7233089b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_e3f83806-1eaf-4495-a836-2ff332d1ab57" xlink:href="ameh-20220630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:to="loc_ameh_AccountableHealthCareIPAMember_e3f83806-1eaf-4495-a836-2ff332d1ab57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_a040257b-838f-40c9-8ad0-39d8f60ec079" xlink:href="ameh-20220630.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:to="loc_ameh_AmgIncMember_a040257b-838f-40c9-8ad0-39d8f60ec079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_86d84869-6b37-459c-9db9-0daa8125e5cd" xlink:href="ameh-20220630.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_86d84869-6b37-459c-9db9-0daa8125e5cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_bbbef3a8-8f93-45cc-99c1-6f0a5a8ffeef" xlink:href="ameh-20220630.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_bbbef3a8-8f93-45cc-99c1-6f0a5a8ffeef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c5ae75ae-2fc4-4b3b-863c-197594db11a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c5ae75ae-2fc4-4b3b-863c-197594db11a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c5ae75ae-2fc4-4b3b-863c-197594db11a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c5ae75ae-2fc4-4b3b-863c-197594db11a2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c5ae75ae-2fc4-4b3b-863c-197594db11a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4d439807-8158-475e-b01a-a0e6a7955de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c5ae75ae-2fc4-4b3b-863c-197594db11a2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4d439807-8158-475e-b01a-a0e6a7955de8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_fda74874-abfe-46de-a97a-27d721f81a58" xlink:href="ameh-20220630.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4d439807-8158-475e-b01a-a0e6a7955de8" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_fda74874-abfe-46de-a97a-27d721f81a58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_c182ef86-98f0-4b76-9fc4-9cc580b53d72" xlink:href="ameh-20220630.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4d439807-8158-475e-b01a-a0e6a7955de8" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_c182ef86-98f0-4b76-9fc4-9cc580b53d72" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i567e8b5e87404250aeaa3277b62dbfb7_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:href="ameh-20220630.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d9b17381-b8de-4919-a383-534ae14a1738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d9b17381-b8de-4919-a383-534ae14a1738" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_d738644d-942c-4a43-8b35-4337bbbbb051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_NumberOfReportableSegments_d738644d-942c-4a43-8b35-4337bbbbb051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_96c1c9fc-a95f-45cb-bef1-aab52e6b6a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_CashUninsuredAmount_96c1c9fc-a95f-45cb-bef1-aab52e6b6a2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_08280927-afb1-4e6e-b7b9-ebd3e70bb2c4" xlink:href="ameh-20220630.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_08280927-afb1-4e6e-b7b9-ebd3e70bb2c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c13aef53-fa77-4fcf-862d-db02c188c21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c13aef53-fa77-4fcf-862d-db02c188c21f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_f224f329-5e67-410d-968f-b6023dc58319" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_f224f329-5e67-410d-968f-b6023dc58319" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_9a5a1ca7-3ccb-42ee-9d60-daebe504b841" xlink:href="ameh-20220630.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_9a5a1ca7-3ccb-42ee-9d60-daebe504b841" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e716a496-d126-4892-97ee-ee5988b325cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e716a496-d126-4892-97ee-ee5988b325cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2a0e3056-ef78-46e4-90c2-f4f2b65cdeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2a0e3056-ef78-46e4-90c2-f4f2b65cdeb6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_4b0008ac-aeb6-4ee1-9d00-3846cd8d0468" xlink:href="ameh-20220630.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_4b0008ac-aeb6-4ee1-9d00-3846cd8d0468" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9b6afd15-758a-44f8-a359-1360725c10f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9b6afd15-758a-44f8-a359-1360725c10f0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_59f3185c-7dc5-49be-8104-1f5fae6b36a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_59f3185c-7dc5-49be-8104-1f5fae6b36a0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_f73c5e98-ea46-4ca4-ac7a-a0e9884ca869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_NumberOfReportingUnits_f73c5e98-ea46-4ca4-ac7a-a0e9884ca869" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cdcd15ed-c3c2-49fa-9e53-5a4d33c95d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cdcd15ed-c3c2-49fa-9e53-5a4d33c95d80" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_32e422b2-eab6-4be7-b7f0-408e835e14bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_32e422b2-eab6-4be7-b7f0-408e835e14bc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_6ac9f709-7875-48b4-b6d3-cccc4c82807c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_6ac9f709-7875-48b4-b6d3-cccc4c82807c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_07fcae92-f4a0-4d16-8633-993975fc1d75" xlink:href="ameh-20220630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_07fcae92-f4a0-4d16-8633-993975fc1d75" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_87436a09-393c-42d4-904d-9ed76bdaaa77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_87436a09-393c-42d4-904d-9ed76bdaaa77" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b676165c-470e-46b2-b715-08313542011a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b676165c-470e-46b2-b715-08313542011a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_042755c4-23b8-4af3-b683-11fe31f23804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_DerivativeAssets_042755c4-23b8-4af3-b683-11fe31f23804" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_4f6ae161-4e0c-4802-b3b2-1fe59c06569f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_4f6ae161-4e0c-4802-b3b2-1fe59c06569f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_5fd4c5b0-1697-4616-936d-7db52716614b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_5fd4c5b0-1697-4616-936d-7db52716614b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_b8f83a4e-c725-40aa-a36c-745f336b1f48" xlink:href="ameh-20220630.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_b8f83a4e-c725-40aa-a36c-745f336b1f48" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d30f922b-70b5-4bb9-a5b1-c24f5c75465f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d30f922b-70b5-4bb9-a5b1-c24f5c75465f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_80694537-6059-47ae-a4f3-02a880d58dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_80694537-6059-47ae-a4f3-02a880d58dd6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:href="ameh-20220630.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35cd6479-4adb-4cad-8534-22d7c755bd5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_RangeAxis_35cd6479-4adb-4cad-8534-22d7c755bd5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35cd6479-4adb-4cad-8534-22d7c755bd5c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_35cd6479-4adb-4cad-8534-22d7c755bd5c" xlink:to="loc_srt_RangeMember_35cd6479-4adb-4cad-8534-22d7c755bd5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f0b8c3f9-234e-4f67-90b0-c886e87024b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_35cd6479-4adb-4cad-8534-22d7c755bd5c" xlink:to="loc_srt_RangeMember_f0b8c3f9-234e-4f67-90b0-c886e87024b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4a5da99-e54a-4353-aeec-6b2f8722186b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f0b8c3f9-234e-4f67-90b0-c886e87024b6" xlink:to="loc_srt_MinimumMember_a4a5da99-e54a-4353-aeec-6b2f8722186b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6fc58570-3a41-4170-8493-0c0eb82b5b84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f0b8c3f9-234e-4f67-90b0-c886e87024b6" xlink:to="loc_srt_MaximumMember_6fc58570-3a41-4170-8493-0c0eb82b5b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1d9dc7ba-5553-44b4-8a27-12114d589a64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_CounterpartyNameAxis_1d9dc7ba-5553-44b4-8a27-12114d589a64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1d9dc7ba-5553-44b4-8a27-12114d589a64_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1d9dc7ba-5553-44b4-8a27-12114d589a64" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1d9dc7ba-5553-44b4-8a27-12114d589a64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f3c527f-2990-46f5-8d64-9dc65070bb45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1d9dc7ba-5553-44b4-8a27-12114d589a64" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f3c527f-2990-46f5-8d64-9dc65070bb45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember_659cdd4d-39f3-439b-a729-942ef7020ec8" xlink:href="ameh-20220630.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f3c527f-2990-46f5-8d64-9dc65070bb45" xlink:to="loc_ameh_ClinigenceHoldingsIncMember_659cdd4d-39f3-439b-a729-942ef7020ec8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_16b4579d-7028-4eff-a8f4-8113e88b32c8" xlink:href="ameh-20220630.xsd#ameh_CMSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f3c527f-2990-46f5-8d64-9dc65070bb45" xlink:to="loc_ameh_CMSMember_16b4579d-7028-4eff-a8f4-8113e88b32c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b91897e8-87d8-44a5-a519-df613cb08f5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_ProductOrServiceAxis_b91897e8-87d8-44a5-a519-df613cb08f5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b91897e8-87d8-44a5-a519-df613cb08f5a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b91897e8-87d8-44a5-a519-df613cb08f5a" xlink:to="loc_srt_ProductsAndServicesDomain_b91897e8-87d8-44a5-a519-df613cb08f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ac4e6a2b-da20-4375-ae69-5e5a1a817ddd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b91897e8-87d8-44a5-a519-df613cb08f5a" xlink:to="loc_srt_ProductsAndServicesDomain_ac4e6a2b-da20-4375-ae69-5e5a1a817ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_1dba71a0-dc47-4c30-b158-eb7e21e0132c" xlink:href="ameh-20220630.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ac4e6a2b-da20-4375-ae69-5e5a1a817ddd" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_1dba71a0-dc47-4c30-b158-eb7e21e0132c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_910ccd5c-4d47-445e-90a9-76612753070c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ac4e6a2b-da20-4375-ae69-5e5a1a817ddd" xlink:to="loc_us-gaap_ManagementServiceMember_910ccd5c-4d47-445e-90a9-76612753070c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_1bdd32d8-2cc6-4815-8551-bfc6a94863ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_OwnershipAxis_1bdd32d8-2cc6-4815-8551-bfc6a94863ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1bdd32d8-2cc6-4815-8551-bfc6a94863ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1bdd32d8-2cc6-4815-8551-bfc6a94863ad" xlink:to="loc_srt_OwnershipDomain_1bdd32d8-2cc6-4815-8551-bfc6a94863ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_85cae62f-32bd-4554-8136-6c8b14fa1fd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1bdd32d8-2cc6-4815-8551-bfc6a94863ad" xlink:to="loc_srt_OwnershipDomain_85cae62f-32bd-4554-8136-6c8b14fa1fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3ab63109-cecc-49ce-a31a-0d60e2eaa171" xlink:href="ameh-20220630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_85cae62f-32bd-4554-8136-6c8b14fa1fd3" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3ab63109-cecc-49ce-a31a-0d60e2eaa171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_af3a1b15-5f57-4d0e-b8aa-149c6d4588e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_dei_LegalEntityAxis_af3a1b15-5f57-4d0e-b8aa-149c6d4588e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_af3a1b15-5f57-4d0e-b8aa-149c6d4588e9_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_af3a1b15-5f57-4d0e-b8aa-149c6d4588e9" xlink:to="loc_dei_EntityDomain_af3a1b15-5f57-4d0e-b8aa-149c6d4588e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_18df6af7-7d22-4c19-b8e4-cd6ec861a688" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_af3a1b15-5f57-4d0e-b8aa-149c6d4588e9" xlink:to="loc_dei_EntityDomain_18df6af7-7d22-4c19-b8e4-cd6ec861a688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_957722d4-b2ad-48d4-8b7e-d3e39f1fdf1b" xlink:href="ameh-20220630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_18df6af7-7d22-4c19-b8e4-cd6ec861a688" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_957722d4-b2ad-48d4-8b7e-d3e39f1fdf1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9ab64b12-b2c4-4a85-aa6c-211bfcc6fdfb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9ab64b12-b2c4-4a85-aa6c-211bfcc6fdfb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9ab64b12-b2c4-4a85-aa6c-211bfcc6fdfb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9ab64b12-b2c4-4a85-aa6c-211bfcc6fdfb" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9ab64b12-b2c4-4a85-aa6c-211bfcc6fdfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bfdd9b66-716c-4ab9-acc0-62a73cafcad2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9ab64b12-b2c4-4a85-aa6c-211bfcc6fdfb" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bfdd9b66-716c-4ab9-acc0-62a73cafcad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_06aafd59-1dc7-406c-adfa-00ee7de522da" xlink:href="ameh-20220630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfdd9b66-716c-4ab9-acc0-62a73cafcad2" xlink:to="loc_ameh_UniversalCareIncMember_06aafd59-1dc7-406c-adfa-00ee7de522da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d1cb035b-5832-4184-b3c7-f0fd35d93412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d1cb035b-5832-4184-b3c7-f0fd35d93412" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1cb035b-5832-4184-b3c7-f0fd35d93412_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d1cb035b-5832-4184-b3c7-f0fd35d93412" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1cb035b-5832-4184-b3c7-f0fd35d93412_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eca0c2d9-a0ea-4705-aabb-02ef41c3645f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d1cb035b-5832-4184-b3c7-f0fd35d93412" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eca0c2d9-a0ea-4705-aabb-02ef41c3645f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_340bfafc-ae01-48f7-83f6-6e156c5788eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eca0c2d9-a0ea-4705-aabb-02ef41c3645f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_340bfafc-ae01-48f7-83f6-6e156c5788eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_23700ee5-545d-4536-92f0-b4259f54100d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_23700ee5-545d-4536-92f0-b4259f54100d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_23700ee5-545d-4536-92f0-b4259f54100d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_23700ee5-545d-4536-92f0-b4259f54100d" xlink:to="loc_us-gaap_HedgingRelationshipDomain_23700ee5-545d-4536-92f0-b4259f54100d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_152c7a44-3757-4775-a029-73d8deba3abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_23700ee5-545d-4536-92f0-b4259f54100d" xlink:to="loc_us-gaap_HedgingRelationshipDomain_152c7a44-3757-4775-a029-73d8deba3abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_a4b7c1e7-4652-4eef-ad4f-b1b5f5a9e310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_152c7a44-3757-4775-a029-73d8deba3abf" xlink:to="loc_us-gaap_CashFlowHedgingMember_a4b7c1e7-4652-4eef-ad4f-b1b5f5a9e310" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69a8324b-ae6a-4c26-ae27-2463c05c5f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69a8324b-ae6a-4c26-ae27-2463c05c5f62" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69a8324b-ae6a-4c26-ae27-2463c05c5f62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69a8324b-ae6a-4c26-ae27-2463c05c5f62" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_69a8324b-ae6a-4c26-ae27-2463c05c5f62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d6f68446-2cd2-4158-936f-b47098dc8eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69a8324b-ae6a-4c26-ae27-2463c05c5f62" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d6f68446-2cd2-4158-936f-b47098dc8eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_db0e611b-5214-4455-b7b8-00dc73bcb43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d6f68446-2cd2-4158-936f-b47098dc8eb9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_db0e611b-5214-4455-b7b8-00dc73bcb43d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0ae20cf4-2fd5-4d2a-94a2-5751a4a25727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0ae20cf4-2fd5-4d2a-94a2-5751a4a25727" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0ae20cf4-2fd5-4d2a-94a2-5751a4a25727_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0ae20cf4-2fd5-4d2a-94a2-5751a4a25727" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0ae20cf4-2fd5-4d2a-94a2-5751a4a25727_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2562c0f0-95b7-440c-8bae-26ee04cad40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0ae20cf4-2fd5-4d2a-94a2-5751a4a25727" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2562c0f0-95b7-440c-8bae-26ee04cad40a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_24233552-5bb7-44ba-b3c3-bcab9649382a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2562c0f0-95b7-440c-8bae-26ee04cad40a" xlink:to="loc_us-gaap_InterestRateSwapMember_24233552-5bb7-44ba-b3c3-bcab9649382a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_00275456-466d-457f-928f-c2e31edeb9d1" xlink:href="ameh-20220630.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2562c0f0-95b7-440c-8bae-26ee04cad40a" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_00275456-466d-457f-928f-c2e31edeb9d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c54d35c1-4706-4c7c-bbe2-f3b398149940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c54d35c1-4706-4c7c-bbe2-f3b398149940" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c54d35c1-4706-4c7c-bbe2-f3b398149940_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c54d35c1-4706-4c7c-bbe2-f3b398149940" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c54d35c1-4706-4c7c-bbe2-f3b398149940_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c54d35c1-4706-4c7c-bbe2-f3b398149940" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_cd95d389-de67-418f-83ce-87e10ff47f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_cd95d389-de67-418f-83ce-87e10ff47f8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7d88bdc2-c35b-4d8e-ab11-a7d22012b4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7d88bdc2-c35b-4d8e-ab11-a7d22012b4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_69bbda0b-f0bd-49f9-93b4-6a984507e1fb" xlink:href="ameh-20220630.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_69bbda0b-f0bd-49f9-93b4-6a984507e1fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_075c328a-2f1e-44bb-bbf7-d8ede39c119f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_HedgingDesignationAxis_075c328a-2f1e-44bb-bbf7-d8ede39c119f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_075c328a-2f1e-44bb-bbf7-d8ede39c119f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_075c328a-2f1e-44bb-bbf7-d8ede39c119f" xlink:to="loc_us-gaap_HedgingDesignationDomain_075c328a-2f1e-44bb-bbf7-d8ede39c119f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d4cf7d94-a330-4b9f-bdec-9710de75ce9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_075c328a-2f1e-44bb-bbf7-d8ede39c119f" xlink:to="loc_us-gaap_HedgingDesignationDomain_d4cf7d94-a330-4b9f-bdec-9710de75ce9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f4cb412a-5a69-4385-be61-e1514946259a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d4cf7d94-a330-4b9f-bdec-9710de75ce9e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f4cb412a-5a69-4385-be61-e1514946259a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended" id="i133d1dbe121a43f5a0b55220fac23525_BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_06722c90-c230-4757-8f82-fba95f30a075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3605cf7d-459b-44dd-a6fc-ac2876f24a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_06722c90-c230-4757-8f82-fba95f30a075" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3605cf7d-459b-44dd-a6fc-ac2876f24a82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7d448ed9-dfd7-4710-a0d2-67d9641894a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_06722c90-c230-4757-8f82-fba95f30a075" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7d448ed9-dfd7-4710-a0d2-67d9641894a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0a7af20f-36cd-4d31-8444-c3f7f07927e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7d448ed9-dfd7-4710-a0d2-67d9641894a7" xlink:to="loc_srt_MajorCustomersAxis_0a7af20f-36cd-4d31-8444-c3f7f07927e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0a7af20f-36cd-4d31-8444-c3f7f07927e5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0a7af20f-36cd-4d31-8444-c3f7f07927e5" xlink:to="loc_srt_NameOfMajorCustomerDomain_0a7af20f-36cd-4d31-8444-c3f7f07927e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0a7af20f-36cd-4d31-8444-c3f7f07927e5" xlink:to="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_1dff171f-cf02-4de8-a176-447714df72fd" xlink:href="ameh-20220630.xsd#ameh_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:to="loc_ameh_CommercialMember_1dff171f-cf02-4de8-a176-447714df72fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_21a533ba-e8e3-4b9f-ad56-706935ea56a3" xlink:href="ameh-20220630.xsd#ameh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:to="loc_ameh_MedicareMember_21a533ba-e8e3-4b9f-ad56-706935ea56a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_382ebbde-4a23-4770-894c-5cbf3ff4e71f" xlink:href="ameh-20220630.xsd#ameh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:to="loc_ameh_MedicaidMember_382ebbde-4a23-4770-894c-5cbf3ff4e71f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_9b2f613d-1666-48cb-8378-234d29b29c05" xlink:href="ameh-20220630.xsd#ameh_OtherThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:to="loc_ameh_OtherThirdPartiesMember_9b2f613d-1666-48cb-8378-234d29b29c05" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended" id="i900d3beaa03f46ba8239ef3a64c0f627_BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_18a88fa4-ce30-497f-9bf4-f36c7b17fbbe" xlink:href="ameh-20220630.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a25a34ba-1dd9-4381-b94f-2721b375cb77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_18a88fa4-ce30-497f-9bf4-f36c7b17fbbe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a25a34ba-1dd9-4381-b94f-2721b375cb77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:href="ameh-20220630.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_18a88fa4-ce30-497f-9bf4-f36c7b17fbbe" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_959d6a19-b2d4-44fd-a50c-c7102a8eec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_959d6a19-b2d4-44fd-a50c-c7102a8eec77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_959d6a19-b2d4-44fd-a50c-c7102a8eec77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_959d6a19-b2d4-44fd-a50c-c7102a8eec77" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_959d6a19-b2d4-44fd-a50c-c7102a8eec77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6eb6d5b7-0dfb-4ffc-b3bc-73305ef34ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_959d6a19-b2d4-44fd-a50c-c7102a8eec77" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6eb6d5b7-0dfb-4ffc-b3bc-73305ef34ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_85b53529-48ef-425d-97ea-808862aedaad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6eb6d5b7-0dfb-4ffc-b3bc-73305ef34ad5" xlink:to="loc_us-gaap_SalesRevenueNetMember_85b53529-48ef-425d-97ea-808862aedaad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0d7d470d-c213-44d0-ba90-12ec0bf07e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6eb6d5b7-0dfb-4ffc-b3bc-73305ef34ad5" xlink:to="loc_us-gaap_AccountsReceivableMember_0d7d470d-c213-44d0-ba90-12ec0bf07e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_83706c65-0d20-4ad1-9590-1a126f852a73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:to="loc_srt_MajorCustomersAxis_83706c65-0d20-4ad1-9590-1a126f852a73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_83706c65-0d20-4ad1-9590-1a126f852a73_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_83706c65-0d20-4ad1-9590-1a126f852a73" xlink:to="loc_srt_NameOfMajorCustomerDomain_83706c65-0d20-4ad1-9590-1a126f852a73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_83706c65-0d20-4ad1-9590-1a126f852a73" xlink:to="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_6b3e3289-9e68-4595-af52-5769c441181f" xlink:href="ameh-20220630.xsd#ameh_PayorAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorAMember_6b3e3289-9e68-4595-af52-5769c441181f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_acd05750-6f94-4f9f-bc56-10f2a2066c8a" xlink:href="ameh-20220630.xsd#ameh_PayorBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorBMember_acd05750-6f94-4f9f-bc56-10f2a2066c8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_2ff01b2d-52e1-4cf7-9513-b5e746eefbf8" xlink:href="ameh-20220630.xsd#ameh_PayorCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorCMember_2ff01b2d-52e1-4cf7-9513-b5e746eefbf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_8051f0d2-6870-40ec-8870-961a4feb0aa8" xlink:href="ameh-20220630.xsd#ameh_PayorDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorDMember_8051f0d2-6870-40ec-8870-961a4feb0aa8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_f8a87158-4da0-4b67-9fd4-f60bd10bd17f" xlink:href="ameh-20220630.xsd#ameh_PayorEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorEMember_f8a87158-4da0-4b67-9fd4-f60bd10bd17f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_b98e6aac-3430-4476-a1e2-d0e813c1eda0" xlink:href="ameh-20220630.xsd#ameh_PayorFMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorFMember_b98e6aac-3430-4476-a1e2-d0e813c1eda0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_559d9b3b-10ba-4f61-8226-ccfe4bc8aabe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_559d9b3b-10ba-4f61-8226-ccfe4bc8aabe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_559d9b3b-10ba-4f61-8226-ccfe4bc8aabe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_559d9b3b-10ba-4f61-8226-ccfe4bc8aabe" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_559d9b3b-10ba-4f61-8226-ccfe4bc8aabe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c8534961-ad23-498e-823c-011c3b2fc6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_559d9b3b-10ba-4f61-8226-ccfe4bc8aabe" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c8534961-ad23-498e-823c-011c3b2fc6f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3f29a807-4cfd-4ad2-8874-0ed0cd225c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c8534961-ad23-498e-823c-011c3b2fc6f6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3f29a807-4cfd-4ad2-8874-0ed0cd225c8e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="extended" id="ib75f212e45f14be6a978f7e55b7b8984_BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8be9b156-155a-4fec-a745-0cfdecc8d693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8be9b156-155a-4fec-a745-0cfdecc8d693" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b4975b7-7e6d-4450-89e6-dd0be56ec5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b4975b7-7e6d-4450-89e6-dd0be56ec5b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d2322270-f2dd-4f65-9cc8-1a725a0e2749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d2322270-f2dd-4f65-9cc8-1a725a0e2749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_1f6e21dc-e464-40e0-b7b7-80822c4f960e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_DerivativeAssets_1f6e21dc-e464-40e0-b7b7-80822c4f960e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b76b23b5-afb4-4fec-a04f-e4b8ea39b245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b76b23b5-afb4-4fec-a04f-e4b8ea39b245" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ce61fb68-2967-4a9d-911c-db9a3ef4b768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_DerivativeLiabilities_ce61fb68-2967-4a9d-911c-db9a3ef4b768" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b7a0d8c2-1a07-4a31-967f-f070894d1ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b7a0d8c2-1a07-4a31-967f-f070894d1ec4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a109ac9f-7b7a-4837-9ab9-496a8cf4d18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a109ac9f-7b7a-4837-9ab9-496a8cf4d18c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_644b0adf-73c1-41b1-acfd-cc6c7acb8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_644b0adf-73c1-41b1-acfd-cc6c7acb8e77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0c860c76-68ab-468a-bcb9-36cda9bc7927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_644b0adf-73c1-41b1-acfd-cc6c7acb8e77" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0c860c76-68ab-468a-bcb9-36cda9bc7927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c860c76-68ab-468a-bcb9-36cda9bc7927_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0c860c76-68ab-468a-bcb9-36cda9bc7927" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c860c76-68ab-468a-bcb9-36cda9bc7927_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0c860c76-68ab-468a-bcb9-36cda9bc7927" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1cf4e509-c55a-494f-9617-ecdbdb9910e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1cf4e509-c55a-494f-9617-ecdbdb9910e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_93628b5e-f431-4cfc-b082-7c10a0dcd6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_93628b5e-f431-4cfc-b082-7c10a0dcd6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_97fa4a2f-9cf8-436c-9d90-4b7e9065f21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_97fa4a2f-9cf8-436c-9d90-4b7e9065f21f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b6097ff5-fd8f-4d75-9367-759fa91ab6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_644b0adf-73c1-41b1-acfd-cc6c7acb8e77" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b6097ff5-fd8f-4d75-9367-759fa91ab6be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b6097ff5-fd8f-4d75-9367-759fa91ab6be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b6097ff5-fd8f-4d75-9367-759fa91ab6be" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b6097ff5-fd8f-4d75-9367-759fa91ab6be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b6097ff5-fd8f-4d75-9367-759fa91ab6be" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_6a46dba0-59dc-4098-afc5-ea25a7d187cd" xlink:href="ameh-20220630.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_6a46dba0-59dc-4098-afc5-ea25a7d187cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fa6fc576-1314-4ce6-b80b-18bf153e3b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:to="loc_us-gaap_WarrantMember_fa6fc576-1314-4ce6-b80b-18bf153e3b22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e4da13a2-a969-41ea-bbe8-1177a9474b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:to="loc_us-gaap_InterestRateSwapMember_e4da13a2-a969-41ea-bbe8-1177a9474b41" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended" id="id56912ff2cf24d878de7a205a009c3df_BusinessCombinationsandGoodwillAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bf6bb788-c22c-4e00-9f6c-5e4725451e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bf6bb788-c22c-4e00-9f6c-5e4725451e92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d4ab58b7-6777-4985-a9ed-71ce71719222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d4ab58b7-6777-4985-a9ed-71ce71719222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_83e598be-c0c9-40c0-9b72-f40abe63a601" xlink:href="ameh-20220630.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_83e598be-c0c9-40c0-9b72-f40abe63a601" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cbadba39-9e20-4e8b-8812-96bf8622174b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cbadba39-9e20-4e8b-8812-96bf8622174b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6d90bde8-e764-41ad-83f7-e76418019bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cbadba39-9e20-4e8b-8812-96bf8622174b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6d90bde8-e764-41ad-83f7-e76418019bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d90bde8-e764-41ad-83f7-e76418019bb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6d90bde8-e764-41ad-83f7-e76418019bb9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d90bde8-e764-41ad-83f7-e76418019bb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6d90bde8-e764-41ad-83f7-e76418019bb9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_JadeHealthCareMedicalGroupIncMember_fdd8fe59-93de-4218-9de6-6210bcda7881" xlink:href="ameh-20220630.xsd#ameh_JadeHealthCareMedicalGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_JadeHealthCareMedicalGroupIncMember_fdd8fe59-93de-4218-9de6-6210bcda7881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_d4dd8e00-0dc6-4e6e-82a4-501838437935" xlink:href="ameh-20220630.xsd#ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_d4dd8e00-0dc6-4e6e-82a4-501838437935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_94020b58-2a39-42ec-9a6e-754d9ffe3837" xlink:href="ameh-20220630.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_94020b58-2a39-42ec-9a6e-754d9ffe3837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_b4599986-6cb6-490d-ab75-ba13f9aedb59" xlink:href="ameh-20220630.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_b4599986-6cb6-490d-ab75-ba13f9aedb59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_062a3e9e-2192-468e-810c-70403acc489f" xlink:href="ameh-20220630.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_DmgMember_062a3e9e-2192-468e-810c-70403acc489f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i927d463b95b94dc78b3468decf80ffc2_IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee4b3653-b1b1-468b-ac63-341c681350fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee4b3653-b1b1-468b-ac63-341c681350fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5cb909e1-6567-4601-a1b7-0fe7eb2bc350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5cb909e1-6567-4601-a1b7-0fe7eb2bc350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7702bf0d-2f23-4664-b678-31ce497aada8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7702bf0d-2f23-4664-b678-31ce497aada8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d76651a2-4462-42de-9570-a168c60a3e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d76651a2-4462-42de-9570-a168c60a3e1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0bd1b020-f737-4645-a0c8-3488c4d87ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0bd1b020-f737-4645-a0c8-3488c4d87ddc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1279db9e-e0e4-4a97-9ae7-4a6b00625926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0bd1b020-f737-4645-a0c8-3488c4d87ddc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1279db9e-e0e4-4a97-9ae7-4a6b00625926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1279db9e-e0e4-4a97-9ae7-4a6b00625926_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1279db9e-e0e4-4a97-9ae7-4a6b00625926" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1279db9e-e0e4-4a97-9ae7-4a6b00625926_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1279db9e-e0e4-4a97-9ae7-4a6b00625926" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_ba326a62-111f-403f-a770-f48c8f8e1504" xlink:href="ameh-20220630.xsd#ameh_NetworkRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_ameh_NetworkRelationshipsMember_ba326a62-111f-403f-a770-f48c8f8e1504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_6ff08d43-75cd-48d9-8328-e6cb52f0f44f" xlink:href="ameh-20220630.xsd#ameh_ManagementContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_ameh_ManagementContractsMember_6ff08d43-75cd-48d9-8328-e6cb52f0f44f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_c24f2486-5455-4e6f-b1ac-dff4c5bcd698" xlink:href="ameh-20220630.xsd#ameh_MemberRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_ameh_MemberRelationshipsMember_c24f2486-5455-4e6f-b1ac-dff4c5bcd698" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_c0990d84-8edb-4402-abd1-08f85a99acda" xlink:href="ameh-20220630.xsd#ameh_PatientManagementPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_ameh_PatientManagementPlatformMember_c0990d84-8edb-4402-abd1-08f85a99acda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_55e5ef82-048a-4067-a127-927dbadc05e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_55e5ef82-048a-4067-a127-927dbadc05e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e7026de3-b549-46d6-b49a-5686c700cb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e7026de3-b549-46d6-b49a-5686c700cb5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3845ff34-50d5-4482-af8c-ee18816b53d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3845ff34-50d5-4482-af8c-ee18816b53d7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9495f24f-f0a1-43a2-a66e-9a351130bd85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0bd1b020-f737-4645-a0c8-3488c4d87ddc" xlink:to="loc_srt_RangeAxis_9495f24f-f0a1-43a2-a66e-9a351130bd85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9495f24f-f0a1-43a2-a66e-9a351130bd85_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9495f24f-f0a1-43a2-a66e-9a351130bd85" xlink:to="loc_srt_RangeMember_9495f24f-f0a1-43a2-a66e-9a351130bd85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b141719-5d2e-43a2-9f8d-07215ca8f333" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9495f24f-f0a1-43a2-a66e-9a351130bd85" xlink:to="loc_srt_RangeMember_5b141719-5d2e-43a2-9f8d-07215ca8f333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e092e7b-0dd7-4ac1-9cc8-d98d16521311" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5b141719-5d2e-43a2-9f8d-07215ca8f333" xlink:to="loc_srt_MinimumMember_5e092e7b-0dd7-4ac1-9cc8-d98d16521311" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_279a3544-a96a-4adb-9e97-3233905072ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5b141719-5d2e-43a2-9f8d-07215ca8f333" xlink:to="loc_srt_MaximumMember_279a3544-a96a-4adb-9e97-3233905072ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_53262cea-b1e8-48b2-8450-3d17e366b594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0e6541a0-4592-4267-a29e-6182ce120736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_53262cea-b1e8-48b2-8450-3d17e366b594" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0e6541a0-4592-4267-a29e-6182ce120736" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_13acd2b8-1e11-4a6d-a833-e29cec38291d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_53262cea-b1e8-48b2-8450-3d17e366b594" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_13acd2b8-1e11-4a6d-a833-e29cec38291d" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d3a9bfbb-3a7e-4b9c-8e5d-f834b8a6881e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_13acd2b8-1e11-4a6d-a833-e29cec38291d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d3a9bfbb-3a7e-4b9c-8e5d-f834b8a6881e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d3a9bfbb-3a7e-4b9c-8e5d-f834b8a6881e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d3a9bfbb-3a7e-4b9c-8e5d-f834b8a6881e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d3a9bfbb-3a7e-4b9c-8e5d-f834b8a6881e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b3bfa3a-5136-48a6-92b2-c42a0f55cb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d3a9bfbb-3a7e-4b9c-8e5d-f834b8a6881e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b3bfa3a-5136-48a6-92b2-c42a0f55cb3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_150f4d9d-6348-466a-a9bb-fe83dbcc9d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b3bfa3a-5136-48a6-92b2-c42a0f55cb3b" xlink:to="loc_us-gaap_TrademarksMember_150f4d9d-6348-466a-a9bb-fe83dbcc9d30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_7c2bea72-b3ca-4d9e-98e8-d444bc610cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b3bfa3a-5136-48a6-92b2-c42a0f55cb3b" xlink:to="loc_us-gaap_LicensingAgreementsMember_7c2bea72-b3ca-4d9e-98e8-d444bc610cf7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" xlink:type="extended" id="i19461a97d9ed4b528703b7bc0055e69a_InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_213290a3-d41a-4b7c-b8d3-045267d21983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_213290a3-d41a-4b7c-b8d3-045267d21983" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_cc42e84b-2502-4db4-b274-1bfb54a5a598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_us-gaap_EquityMethodInvestments_cc42e84b-2502-4db4-b274-1bfb54a5a598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2387053-ea8b-49fa-9e6a-28e0095738f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2387053-ea8b-49fa-9e6a-28e0095738f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentReclassification_87806372-0896-4f21-965e-41096080afd0" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentReclassification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_ameh_EquityMethodInvestmentReclassification_87806372-0896-4f21-965e-41096080afd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_8e98c5de-e19e-4e65-a500-e5dff80efe21" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_8e98c5de-e19e-4e65-a500-e5dff80efe21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d5cbeeac-4e58-4c78-b5a9-f85f38df3994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d5cbeeac-4e58-4c78-b5a9-f85f38df3994" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e0b3b3be-9f3a-4020-b2a7-1287ece395b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a0e4fcea-e5cd-4284-bc32-08bdccd8f1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_213290a3-d41a-4b7c-b8d3-045267d21983" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a0e4fcea-e5cd-4284-bc32-08bdccd8f1c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b888726b-033a-46dd-a947-9a7bfed62100" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a0e4fcea-e5cd-4284-bc32-08bdccd8f1c9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b888726b-033a-46dd-a947-9a7bfed62100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b888726b-033a-46dd-a947-9a7bfed62100_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b888726b-033a-46dd-a947-9a7bfed62100" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b888726b-033a-46dd-a947-9a7bfed62100_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b888726b-033a-46dd-a947-9a7bfed62100" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_648475f0-5b92-488d-a102-36d43e06c118" xlink:href="ameh-20220630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_648475f0-5b92-488d-a102-36d43e06c118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_04aae524-498c-433f-8b3a-bc8ba1a7a7d4" xlink:href="ameh-20220630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_04aae524-498c-433f-8b3a-bc8ba1a7a7d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_6bac3a43-049b-4c31-906c-1413539ae861" xlink:href="ameh-20220630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_6bac3a43-049b-4c31-906c-1413539ae861" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_c717a930-e148-4cab-a8aa-a7b1b6707bf7" xlink:href="ameh-20220630.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_OneMSOLLCMember_c717a930-e148-4cab-a8aa-a7b1b6707bf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_d2548b24-9222-4787-8b6f-eac03c95f693" xlink:href="ameh-20220630.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_d2548b24-9222-4787-8b6f-eac03c95f693" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_c150829d-605a-44e6-be54-fe1d28b3301e" xlink:href="ameh-20220630.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_CAIPAMSOLLCMember_c150829d-605a-44e6-be54-fe1d28b3301e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#InvestmentsinOtherEntitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="extended" id="ifa73d7378c714e72a5c14f4a292be766_InvestmentsinOtherEntitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_4b105233-4c71-489e-a6ec-e5335242525a" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_4b105233-4c71-489e-a6ec-e5335242525a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_0fdeaf61-9d44-4fa7-ba07-135a91de49b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_0fdeaf61-9d44-4fa7-ba07-135a91de49b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4aada4f1-3013-460b-8f61-0a55436f0706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4aada4f1-3013-460b-8f61-0a55436f0706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d31db20c-40a5-4e2a-b240-70770839c0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d31db20c-40a5-4e2a-b240-70770839c0a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_037a2b2a-830c-4839-9751-08eac96dec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_EquityMethodInvestments_037a2b2a-830c-4839-9751-08eac96dec4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_fd0310d7-5c49-4464-b0c6-b63da5d3c795" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_fd0310d7-5c49-4464-b0c6-b63da5d3c795" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_060164e7-c7f6-4524-b610-e57cc2d74b61" xlink:href="ameh-20220630.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_060164e7-c7f6-4524-b610-e57cc2d74b61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_c5fa3939-8273-4d89-9875-b5869b90d8d8" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_c5fa3939-8273-4d89-9875-b5869b90d8d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_cdb47efe-ab7a-4d2b-a460-85a66169fbf2" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_cdb47efe-ab7a-4d2b-a460-85a66169fbf2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_15fd95aa-b155-48f2-8fc8-9f8e5e55ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_15fd95aa-b155-48f2-8fc8-9f8e5e55ab50" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_41997760-7ea6-4be5-9dcf-7d3c473df1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_41997760-7ea6-4be5-9dcf-7d3c473df1a1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_3ac46b4e-be90-4b56-bc4d-c8e75bc03b2b" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_3ac46b4e-be90-4b56-bc4d-c8e75bc03b2b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_a153c691-26cd-4787-8d9a-613a1afa27d2" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_a153c691-26cd-4787-8d9a-613a1afa27d2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_0dbe2d82-918b-4b7d-9867-46824b0fc92d" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_0dbe2d82-918b-4b7d-9867-46824b0fc92d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_f89c92dd-20f1-4943-8b0a-7ad8d4afa730" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_f89c92dd-20f1-4943-8b0a-7ad8d4afa730" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_a53ef01a-9732-45c2-9271-91e5e74cbc4c" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_a53ef01a-9732-45c2-9271-91e5e74cbc4c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_e4bc869f-a7b2-4baa-85bb-4a25e445139e" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_e4bc869f-a7b2-4baa-85bb-4a25e445139e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_fb374349-40be-4183-847d-dceefb44fe25" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_fb374349-40be-4183-847d-dceefb44fe25" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_706ab19f-c8f1-4c4f-b2e1-571c13ec7371" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_706ab19f-c8f1-4c4f-b2e1-571c13ec7371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_706ab19f-c8f1-4c4f-b2e1-571c13ec7371_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_706ab19f-c8f1-4c4f-b2e1-571c13ec7371" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_706ab19f-c8f1-4c4f-b2e1-571c13ec7371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_706ab19f-c8f1-4c4f-b2e1-571c13ec7371" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_8356ca4c-0f5a-4c77-a811-3f7337611375" xlink:href="ameh-20220630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_8356ca4c-0f5a-4c77-a811-3f7337611375" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_745127cc-fcdd-4fab-8fb2-3e36a2a9816e" xlink:href="ameh-20220630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_745127cc-fcdd-4fab-8fb2-3e36a2a9816e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_03005412-fc08-4848-be45-4aaa222ec94b" xlink:href="ameh-20220630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_03005412-fc08-4848-be45-4aaa222ec94b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_0321a65a-abb8-40eb-9d40-e7971c08eaa8" xlink:href="ameh-20220630.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_OneMSOLLCMember_0321a65a-abb8-40eb-9d40-e7971c08eaa8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_c4340ce8-2451-4303-8fee-24e25e70cece" xlink:href="ameh-20220630.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_c4340ce8-2451-4303-8fee-24e25e70cece" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_58667aee-b06b-4b4f-8a8f-9b6437b260fd" xlink:href="ameh-20220630.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_CAIPAMSOLLCMember_58667aee-b06b-4b4f-8a8f-9b6437b260fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fe385225-5e85-437e-a140-76ed6ee36cde" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_dei_LegalEntityAxis_fe385225-5e85-437e-a140-76ed6ee36cde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fe385225-5e85-437e-a140-76ed6ee36cde_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_fe385225-5e85-437e-a140-76ed6ee36cde" xlink:to="loc_dei_EntityDomain_fe385225-5e85-437e-a140-76ed6ee36cde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_fe385225-5e85-437e-a140-76ed6ee36cde" xlink:to="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_d24df01f-08c2-48b3-a9d1-172f2fb46add" xlink:href="ameh-20220630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:to="loc_ameh_APCAndAPCLSMAMember_d24df01f-08c2-48b3-a9d1-172f2fb46add" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_ef03ecb3-0c23-40a4-b444-e1279ed49079" xlink:href="ameh-20220630.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_APCAndAPCLSMAMember_d24df01f-08c2-48b3-a9d1-172f2fb46add" xlink:to="loc_ameh_ApcLsmaMember_ef03ecb3-0c23-40a4-b444-e1279ed49079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_afd45341-21d7-431c-be0c-c15b7da2ba29" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_APCAndAPCLSMAMember_d24df01f-08c2-48b3-a9d1-172f2fb46add" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_afd45341-21d7-431c-be0c-c15b7da2ba29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_7c09dee0-0a90-45d2-afea-7d3110ce41d1" xlink:href="ameh-20220630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_7c09dee0-0a90-45d2-afea-7d3110ce41d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_e60d0f52-41de-4b0b-b93a-0ed417dee1dd" xlink:href="ameh-20220630.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_e60d0f52-41de-4b0b-b93a-0ed417dee1dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_adda3793-81cd-4781-8793-7d0460fdfbe4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_srt_OwnershipAxis_adda3793-81cd-4781-8793-7d0460fdfbe4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_adda3793-81cd-4781-8793-7d0460fdfbe4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_adda3793-81cd-4781-8793-7d0460fdfbe4" xlink:to="loc_srt_OwnershipDomain_adda3793-81cd-4781-8793-7d0460fdfbe4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a70b70be-a36b-4f9f-afb6-9fff83c69b27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_adda3793-81cd-4781-8793-7d0460fdfbe4" xlink:to="loc_srt_OwnershipDomain_a70b70be-a36b-4f9f-afb6-9fff83c69b27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_35f391ed-3458-4ac8-97a4-ce97ea109be2" xlink:href="ameh-20220630.xsd#ameh_MediPortalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_a70b70be-a36b-4f9f-afb6-9fff83c69b27" xlink:to="loc_ameh_MediPortalLLCMember_35f391ed-3458-4ac8-97a4-ce97ea109be2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_ce0fd843-0e52-4006-8648-cb516861e735" xlink:href="ameh-20220630.xsd#ameh_AchievaMedInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_a70b70be-a36b-4f9f-afb6-9fff83c69b27" xlink:to="loc_ameh_AchievaMedInc.Member_ce0fd843-0e52-4006-8648-cb516861e735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b80b8170-2203-4aff-a609-592be4c3bd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b80b8170-2203-4aff-a609-592be4c3bd69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_b80b8170-2203-4aff-a609-592be4c3bd69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b80b8170-2203-4aff-a609-592be4c3bd69" xlink:to="loc_us-gaap_ReceivableTypeDomain_b80b8170-2203-4aff-a609-592be4c3bd69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_25536091-bf03-4eb1-98a5-940c424e387d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b80b8170-2203-4aff-a609-592be4c3bd69" xlink:to="loc_us-gaap_ReceivableTypeDomain_25536091-bf03-4eb1-98a5-940c424e387d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_08acceb2-5c91-40ac-9024-dba5ad51f15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_25536091-bf03-4eb1-98a5-940c424e387d" xlink:to="loc_us-gaap_NotesReceivableMember_08acceb2-5c91-40ac-9024-dba5ad51f15c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82895337-1718-4b19-8474-3c102a95ec7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82895337-1718-4b19-8474-3c102a95ec7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_82895337-1718-4b19-8474-3c102a95ec7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82895337-1718-4b19-8474-3c102a95ec7f" xlink:to="loc_us-gaap_RelatedPartyDomain_82895337-1718-4b19-8474-3c102a95ec7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_437b0864-1daa-4237-a238-c98b80bda5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82895337-1718-4b19-8474-3c102a95ec7f" xlink:to="loc_us-gaap_RelatedPartyDomain_437b0864-1daa-4237-a238-c98b80bda5a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_ad79d74e-20d8-4c09-9b03-c810374996bd" xlink:href="ameh-20220630.xsd#ameh_Dr.ArteagaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_437b0864-1daa-4237-a238-c98b80bda5a5" xlink:to="loc_ameh_Dr.ArteagaMember_ad79d74e-20d8-4c09-9b03-c810374996bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended" id="ib62f57a308de426b87d2d040b190856a_InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:to="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_743bd480-51bb-4112-9996-e73149b314fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_743bd480-51bb-4112-9996-e73149b314fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_00eb27b7-122c-4a3d-ae7f-3d1bcb4ea775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_RestrictedCashCurrent_00eb27b7-122c-4a3d-ae7f-3d1bcb4ea775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6f38c6a3-149c-4ed1-8d6a-c637d12b7b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6f38c6a3-149c-4ed1-8d6a-c637d12b7b7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_16346822-4aa1-413e-a265-e1acdb794bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_16346822-4aa1-413e-a265-e1acdb794bcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2f5bf13c-e194-46a7-9018-dac1a44414f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_Assets_2f5bf13c-e194-46a7-9018-dac1a44414f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1c4c0665-a9f8-4ab7-b500-8e1cd74488ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:to="loc_us-gaap_LiabilitiesCurrent_1c4c0665-a9f8-4ab7-b500-8e1cd74488ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6859931e-8bfc-4526-92af-848424f8875f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6859931e-8bfc-4526-92af-848424f8875f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1af274a-d30b-4299-8503-0fbce9fedcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1af274a-d30b-4299-8503-0fbce9fedcf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:to="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c300149f-b7d4-4a46-b435-61d588ed876d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c300149f-b7d4-4a46-b435-61d588ed876d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f048d4d6-a34e-416a-88f0-fe84c4a25df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_CostsAndExpenses_f048d4d6-a34e-416a-88f0-fe84c4a25df9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5846f078-2f24-4d5b-bd8b-39b032c9b91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_OperatingIncomeLoss_5846f078-2f24-4d5b-bd8b-39b032c9b91b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f264b13c-4342-4a34-9e04-567b25b31bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f264b13c-4342-4a34-9e04-567b25b31bd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e0216ad8-89d5-4a04-816d-eed906717710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_ProfitLoss_e0216ad8-89d5-4a04-816d-eed906717710" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_30a5dfb5-1038-4b08-a1f9-8ef98e82158f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_30a5dfb5-1038-4b08-a1f9-8ef98e82158f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_bcdaa367-ba6b-4e58-8e17-f8a1f9df4a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_30a5dfb5-1038-4b08-a1f9-8ef98e82158f" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_bcdaa367-ba6b-4e58-8e17-f8a1f9df4a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_bcdaa367-ba6b-4e58-8e17-f8a1f9df4a16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_bcdaa367-ba6b-4e58-8e17-f8a1f9df4a16" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_bcdaa367-ba6b-4e58-8e17-f8a1f9df4a16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_ac5c1885-2d71-41fe-85ab-d4ffb30c4141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_bcdaa367-ba6b-4e58-8e17-f8a1f9df4a16" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_ac5c1885-2d71-41fe-85ab-d4ffb30c4141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_35655173-228f-41ae-8978-3cd513a4ae58" xlink:href="ameh-20220630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_ac5c1885-2d71-41fe-85ab-d4ffb30c4141" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_35655173-228f-41ae-8978-3cd513a4ae58" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended" id="i54184b7760d74297bf43e813db7cd1db_LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_e0b54bfa-3a4a-4633-a177-f9fcbee8ac74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:to="loc_us-gaap_NotesReceivableNet_e0b54bfa-3a4a-4633-a177-f9fcbee8ac74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f65826dd-399c-4ddf-a361-f277606f23b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f65826dd-399c-4ddf-a361-f277606f23b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_75e900c9-6b0d-43c7-a819-51020a39a856" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_75e900c9-6b0d-43c7-a819-51020a39a856" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e40f3ecc-d199-4921-8922-b8a79b5a9096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e40f3ecc-d199-4921-8922-b8a79b5a9096" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5299039a-d61f-416a-914e-f88637d0e181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5299039a-d61f-416a-914e-f88637d0e181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_5299039a-d61f-416a-914e-f88637d0e181_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5299039a-d61f-416a-914e-f88637d0e181" xlink:to="loc_us-gaap_ReceivableTypeDomain_5299039a-d61f-416a-914e-f88637d0e181_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_fcbe7cb4-499d-45c9-bc99-9602d0faeebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5299039a-d61f-416a-914e-f88637d0e181" xlink:to="loc_us-gaap_ReceivableTypeDomain_fcbe7cb4-499d-45c9-bc99-9602d0faeebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_042c0fb4-70c6-4526-a699-230ef07c8379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_fcbe7cb4-499d-45c9-bc99-9602d0faeebc" xlink:to="loc_us-gaap_NotesReceivableMember_042c0fb4-70c6-4526-a699-230ef07c8379" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_187fbad8-558c-48ed-935d-92e47cc65abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_187fbad8-558c-48ed-935d-92e47cc65abc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_187fbad8-558c-48ed-935d-92e47cc65abc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_187fbad8-558c-48ed-935d-92e47cc65abc" xlink:to="loc_us-gaap_RelatedPartyDomain_187fbad8-558c-48ed-935d-92e47cc65abc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_187fbad8-558c-48ed-935d-92e47cc65abc" xlink:to="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_86beb0c8-9b2f-456c-833c-f33922f1c84c" xlink:href="ameh-20220630.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:to="loc_ameh_Pacific6EnterprisesMember_86beb0c8-9b2f-456c-833c-f33922f1c84c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_fdc8fc72-6b06-4e53-a33d-b5543e87c6c0" xlink:href="ameh-20220630.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:to="loc_ameh_ApcLsmaMember_fdc8fc72-6b06-4e53-a33d-b5543e87c6c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_c17d726b-e59f-473a-b344-5516e7ddc37f" xlink:href="ameh-20220630.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:to="loc_ameh_AHMCMember_c17d726b-e59f-473a-b344-5516e7ddc37f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8604be1c-4010-48c8-8462-92bda0d143eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:to="loc_dei_LegalEntityAxis_8604be1c-4010-48c8-8462-92bda0d143eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_8604be1c-4010-48c8-8462-92bda0d143eb_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8604be1c-4010-48c8-8462-92bda0d143eb" xlink:to="loc_dei_EntityDomain_8604be1c-4010-48c8-8462-92bda0d143eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8604be1c-4010-48c8-8462-92bda0d143eb" xlink:to="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_07e352e8-a772-4023-b069-b1d82ee94c98" xlink:href="ameh-20220630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:to="loc_ameh_NetworkMedicalManagementMember_07e352e8-a772-4023-b069-b1d82ee94c98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_51df5e6a-e5db-4d01-bca0-539049e18a34" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_51df5e6a-e5db-4d01-bca0-539049e18a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_6a63a996-0088-45c1-a2a5-0c7b3e4d331c" xlink:href="ameh-20220630.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:to="loc_ameh_LmaMember_6a63a996-0088-45c1-a2a5-0c7b3e4d331c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eaa9fec3-3374-4fec-9861-d150ce6a0775" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eaa9fec3-3374-4fec-9861-d150ce6a0775" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_eaa9fec3-3374-4fec-9861-d150ce6a0775_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eaa9fec3-3374-4fec-9861-d150ce6a0775" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_eaa9fec3-3374-4fec-9861-d150ce6a0775_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_901bf323-128c-4ee3-b3c2-87e4369857ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eaa9fec3-3374-4fec-9861-d150ce6a0775" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_901bf323-128c-4ee3-b3c2-87e4369857ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_9a986c5c-7d71-4759-bb21-e4d572d6fc3e" xlink:href="ameh-20220630.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_901bf323-128c-4ee3-b3c2-87e4369857ad" xlink:to="loc_ameh_LmaMember_9a986c5c-7d71-4759-bb21-e4d572d6fc3e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="extended" id="i2eedfb25ac964bd38d57544aca91a397_CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_82ef1084-150d-4e64-badb-1507d8e82232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_82ef1084-150d-4e64-badb-1507d8e82232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5d7e0b5b-a137-43cc-a3f8-5b2ffe9b3f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:to="loc_us-gaap_LongTermDebtCurrent_5d7e0b5b-a137-43cc-a3f8-5b2ffe9b3f03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f8733d60-5b8c-4fd3-a7d3-c67b5ac8d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f8733d60-5b8c-4fd3-a7d3-c67b5ac8d12f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_31ad445f-6915-4e8b-b490-c446c04a38ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_31ad445f-6915-4e8b-b490-c446c04a38ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_b6704186-d0ff-45de-8c0b-4a753924634e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_b6704186-d0ff-45de-8c0b-4a753924634e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2ae5cc31-a27c-4ae7-b0f1-c980b3a3b4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b6704186-d0ff-45de-8c0b-4a753924634e" xlink:to="loc_us-gaap_CreditFacilityAxis_2ae5cc31-a27c-4ae7-b0f1-c980b3a3b4bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2ae5cc31-a27c-4ae7-b0f1-c980b3a3b4bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2ae5cc31-a27c-4ae7-b0f1-c980b3a3b4bc" xlink:to="loc_us-gaap_CreditFacilityDomain_2ae5cc31-a27c-4ae7-b0f1-c980b3a3b4bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7907cc24-2aa2-4cdd-a2bc-4efc81dac2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2ae5cc31-a27c-4ae7-b0f1-c980b3a3b4bc" xlink:to="loc_us-gaap_CreditFacilityDomain_7907cc24-2aa2-4cdd-a2bc-4efc81dac2c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_48139e8e-0754-42f8-92d8-37ac28490f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7907cc24-2aa2-4cdd-a2bc-4efc81dac2c7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_48139e8e-0754-42f8-92d8-37ac28490f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b73e1391-b399-42fd-afe1-a2ea0b2ad9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b6704186-d0ff-45de-8c0b-4a753924634e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b73e1391-b399-42fd-afe1-a2ea0b2ad9c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b73e1391-b399-42fd-afe1-a2ea0b2ad9c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b73e1391-b399-42fd-afe1-a2ea0b2ad9c0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b73e1391-b399-42fd-afe1-a2ea0b2ad9c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7986aba3-a39e-4091-ad97-484a50e52296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b73e1391-b399-42fd-afe1-a2ea0b2ad9c0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7986aba3-a39e-4091-ad97-484a50e52296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_299fc551-56cf-4c77-b3f7-65cdcc2cb7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstateLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7986aba3-a39e-4091-ad97-484a50e52296" xlink:to="loc_us-gaap_RealEstateLoanMember_299fc551-56cf-4c77-b3f7-65cdcc2cb7e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_d18707f2-fbe5-4328-8c66-cf30977b3baa" xlink:href="ameh-20220630.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7986aba3-a39e-4091-ad97-484a50e52296" xlink:to="loc_ameh_ConstructionLoanMember_d18707f2-fbe5-4328-8c66-cf30977b3baa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="extended" id="ie3550060feb64cbcba481bde692b99dc_CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d264c1ae-0f48-4b9a-a239-0cf597d33ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentTerm_d264c1ae-0f48-4b9a-a239-0cf597d33ac0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_abe8aff6-5ec6-431b-99fe-177c9bc7eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_abe8aff6-5ec6-431b-99fe-177c9bc7eec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0b2c3ffb-2ce5-4e9b-8dff-406bdd19d6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0b2c3ffb-2ce5-4e9b-8dff-406bdd19d6c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_f8bd8bdb-cd31-4c3a-b896-d7d9b96e2864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_f8bd8bdb-cd31-4c3a-b896-d7d9b96e2864" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a832ff45-2333-4d9e-a32a-04a85c870fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a832ff45-2333-4d9e-a32a-04a85c870fa5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_ad0d2771-cf3f-4531-8125-2326879f8679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_ad0d2771-cf3f-4531-8125-2326879f8679" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_0f6808c5-8799-4023-8e39-f27906d9bc30" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_0f6808c5-8799-4023-8e39-f27906d9bc30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_f1683fa2-6cd8-4062-bd3f-0dad7dfdd6a7" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_f1683fa2-6cd8-4062-bd3f-0dad7dfdd6a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_ec54c113-d7a4-4a91-bdd0-ecac0ebbaaf9" xlink:href="ameh-20220630.xsd#ameh_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_ec54c113-d7a4-4a91-bdd0-ecac0ebbaaf9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_0d631315-006f-43b0-90ab-bd649151e181" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_0d631315-006f-43b0-90ab-bd649151e181" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_12edbccb-d15f-40a2-9aa5-cc228a2b5531" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_12edbccb-d15f-40a2-9aa5-cc228a2b5531" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_8adbad61-2388-43ea-8217-eb0468638e32" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_8adbad61-2388-43ea-8217-eb0468638e32" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_cd0f925a-28d1-444f-afbf-76cc353a277e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_cd0f925a-28d1-444f-afbf-76cc353a277e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f7562248-28d1-4822-b254-fa68c03982e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f7562248-28d1-4822-b254-fa68c03982e6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_e61b7b2b-e640-4e03-a544-24478c81fe6b" xlink:href="ameh-20220630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_e61b7b2b-e640-4e03-a544-24478c81fe6b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fadb325b-1871-4858-86c4-13e21cdfee33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fadb325b-1871-4858-86c4-13e21cdfee33" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_19cbdba0-3301-4f44-b600-adfc2465da97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LongTermDebt_19cbdba0-3301-4f44-b600-adfc2465da97" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_7ab42904-d0fa-46c6-b4e9-427e7c4b128b" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_7ab42904-d0fa-46c6-b4e9-427e7c4b128b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty_4d11d305-e012-4790-ba09-7111e1ce7e45" xlink:href="ameh-20220630.xsd#ameh_DebtCovenantThresholdPercentageForOccupationOfProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty_4d11d305-e012-4790-ba09-7111e1ce7e45" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum_ef9f6ae1-9433-49b5-bf4c-d66e861fe398" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum_ef9f6ae1-9433-49b5-bf4c-d66e861fe398" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_a35e25a7-3c92-43dc-a6ea-7bb59882c1cf" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_a35e25a7-3c92-43dc-a6ea-7bb59882c1cf" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_30ec08aa-73e7-4b9c-9bf2-81854d8b9f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_30ec08aa-73e7-4b9c-9bf2-81854d8b9f9e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f86bd38b-28e9-4f60-bf44-0f021a853d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_InterestExpense_f86bd38b-28e9-4f60-bf44-0f021a853d13" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_f953fba0-46bf-41b3-ad57-dae1425f8463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_f953fba0-46bf-41b3-ad57-dae1425f8463" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e3fa67f9-b496-4778-987a-69dfe9e0baed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_CreditFacilityAxis_e3fa67f9-b496-4778-987a-69dfe9e0baed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e3fa67f9-b496-4778-987a-69dfe9e0baed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e3fa67f9-b496-4778-987a-69dfe9e0baed" xlink:to="loc_us-gaap_CreditFacilityDomain_e3fa67f9-b496-4778-987a-69dfe9e0baed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e3fa67f9-b496-4778-987a-69dfe9e0baed" xlink:to="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e9815d32-2823-47c7-90c4-2c6524255fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e9815d32-2823-47c7-90c4-2c6524255fc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c0f672cc-1d7e-4f16-bf4f-ea83f36f7ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_LineOfCreditMember_c0f672cc-1d7e-4f16-bf4f-ea83f36f7ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_4b9f82e5-696f-474a-bf5d-64cb425dd824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_LetterOfCreditMember_4b9f82e5-696f-474a-bf5d-64cb425dd824" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_9ccedce4-eff6-4d23-a165-385d1c6339f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_BridgeLoanMember_9ccedce4-eff6-4d23-a165-385d1c6339f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_4bde5268-aa07-42b7-b3a6-ee070c18cf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_4bde5268-aa07-42b7-b3a6-ee070c18cf5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e18e5fa-1737-4005-bb23-088c895a3a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e18e5fa-1737-4005-bb23-088c895a3a9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9e18e5fa-1737-4005-bb23-088c895a3a9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e18e5fa-1737-4005-bb23-088c895a3a9c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9e18e5fa-1737-4005-bb23-088c895a3a9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e18e5fa-1737-4005-bb23-088c895a3a9c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_8161d2ff-0f09-4cd8-abcb-705472f26e45" xlink:href="ameh-20220630.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:to="loc_ameh_AmendedCreditAgreementMember_8161d2ff-0f09-4cd8-abcb-705472f26e45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_74cb819e-8a40-4c11-ae39-4d48238b5e4e" xlink:href="ameh-20220630.xsd#ameh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:to="loc_ameh_CreditAgreementMember_74cb819e-8a40-4c11-ae39-4d48238b5e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_5c9d27e8-6e11-459a-b118-d8e69d38dc72" xlink:href="ameh-20220630.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:to="loc_ameh_ConstructionLoanMember_5c9d27e8-6e11-459a-b118-d8e69d38dc72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_ecbf6714-c84e-4dfb-8852-36bdf453821c" xlink:href="ameh-20220630.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_ecbf6714-c84e-4dfb-8852-36bdf453821c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5d290e65-b768-4ad6-8691-a87ef983baf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5d290e65-b768-4ad6-8691-a87ef983baf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5d290e65-b768-4ad6-8691-a87ef983baf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d290e65-b768-4ad6-8691-a87ef983baf3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5d290e65-b768-4ad6-8691-a87ef983baf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_803dc51b-a338-4d37-a116-fa86da54d75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d290e65-b768-4ad6-8691-a87ef983baf3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_803dc51b-a338-4d37-a116-fa86da54d75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_24a7f9b6-6dea-45ed-8850-404e572441db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_803dc51b-a338-4d37-a116-fa86da54d75c" xlink:to="loc_us-gaap_LineOfCreditMember_24a7f9b6-6dea-45ed-8850-404e572441db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_337fbcf6-d102-4396-9ff2-103204c5073e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_srt_RangeAxis_337fbcf6-d102-4396-9ff2-103204c5073e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_337fbcf6-d102-4396-9ff2-103204c5073e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_337fbcf6-d102-4396-9ff2-103204c5073e" xlink:to="loc_srt_RangeMember_337fbcf6-d102-4396-9ff2-103204c5073e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c0643f0-4d81-48fb-ad9f-4d9595817b57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_337fbcf6-d102-4396-9ff2-103204c5073e" xlink:to="loc_srt_RangeMember_7c0643f0-4d81-48fb-ad9f-4d9595817b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_95654436-2b7d-4886-b3d4-e4f07c65eb77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c0643f0-4d81-48fb-ad9f-4d9595817b57" xlink:to="loc_srt_MinimumMember_95654436-2b7d-4886-b3d4-e4f07c65eb77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f9d8b09-31ca-413d-a443-ba9e00902fa2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c0643f0-4d81-48fb-ad9f-4d9595817b57" xlink:to="loc_srt_MaximumMember_1f9d8b09-31ca-413d-a443-ba9e00902fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5b75f1b5-16ad-45a2-9f1b-aac2ce0640f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_dei_LegalEntityAxis_5b75f1b5-16ad-45a2-9f1b-aac2ce0640f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5b75f1b5-16ad-45a2-9f1b-aac2ce0640f8_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5b75f1b5-16ad-45a2-9f1b-aac2ce0640f8" xlink:to="loc_dei_EntityDomain_5b75f1b5-16ad-45a2-9f1b-aac2ce0640f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5b75f1b5-16ad-45a2-9f1b-aac2ce0640f8" xlink:to="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f95c9bbb-4211-4743-b2f6-8d14aa9cb471" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f95c9bbb-4211-4743-b2f6-8d14aa9cb471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_bf0e3d86-d21e-45d0-b8dd-cf2bda24ee40" xlink:href="ameh-20220630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_bf0e3d86-d21e-45d0-b8dd-cf2bda24ee40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_021c5560-512f-4fd4-886e-5f21c7300ea7" xlink:href="ameh-20220630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_AMGPropertiesLLCMember_021c5560-512f-4fd4-886e-5f21c7300ea7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_97326cfa-18c2-403e-b4a3-cd1d7ce74240" xlink:href="ameh-20220630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_ZLLPartnersLLCMember_97326cfa-18c2-403e-b4a3-cd1d7ce74240" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_a7443afb-bb1c-4ddf-bbab-caee1a118d5f" xlink:href="ameh-20220630.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_a7443afb-bb1c-4ddf-bbab-caee1a118d5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_0f949e2d-a7d0-473d-beb6-c79607965a7e" xlink:href="ameh-20220630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_0f949e2d-a7d0-473d-beb6-c79607965a7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_A120HellmanLLCMember_7f77939f-cad3-460c-997c-5d06917ba2b9" xlink:href="ameh-20220630.xsd#ameh_A120HellmanLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_A120HellmanLLCMember_7f77939f-cad3-460c-997c-5d06917ba2b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_197ab73a-2ff3-4823-a2e5-64853aaf0537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_VariableRateAxis_197ab73a-2ff3-4823-a2e5-64853aaf0537" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_197ab73a-2ff3-4823-a2e5-64853aaf0537_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_197ab73a-2ff3-4823-a2e5-64853aaf0537" xlink:to="loc_us-gaap_VariableRateDomain_197ab73a-2ff3-4823-a2e5-64853aaf0537_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2940a9e1-cb2e-4483-a2b5-4587c2077d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_197ab73a-2ff3-4823-a2e5-64853aaf0537" xlink:to="loc_us-gaap_VariableRateDomain_2940a9e1-cb2e-4483-a2b5-4587c2077d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5196871-bb19-4029-8555-133be4673223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_2940a9e1-cb2e-4483-a2b5-4587c2077d59" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5196871-bb19-4029-8555-133be4673223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_f3105c44-35a4-4987-8a9d-44d91d08af20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_2940a9e1-cb2e-4483-a2b5-4587c2077d59" xlink:to="loc_us-gaap_PrimeRateMember_f3105c44-35a4-4987-8a9d-44d91d08af20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_915941a8-08f2-49af-a450-4ee0bb1a75fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_915941a8-08f2-49af-a450-4ee0bb1a75fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_915941a8-08f2-49af-a450-4ee0bb1a75fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_915941a8-08f2-49af-a450-4ee0bb1a75fb" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_915941a8-08f2-49af-a450-4ee0bb1a75fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_cb6b1cc7-88ee-430e-9917-76cf4dbf391d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_915941a8-08f2-49af-a450-4ee0bb1a75fb" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_cb6b1cc7-88ee-430e-9917-76cf4dbf391d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_6928361b-7f6b-4991-8c2c-0c4973c1e574" xlink:href="ameh-20220630.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_cb6b1cc7-88ee-430e-9917-76cf4dbf391d" xlink:to="loc_ameh_PreferredBankMember_6928361b-7f6b-4991-8c2c-0c4973c1e574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_13905e85-8ac4-4ee4-9407-aaff9f1983c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_13905e85-8ac4-4ee4-9407-aaff9f1983c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_13905e85-8ac4-4ee4-9407-aaff9f1983c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_13905e85-8ac4-4ee4-9407-aaff9f1983c9" xlink:to="loc_us-gaap_AssetAcquisitionDomain_13905e85-8ac4-4ee4-9407-aaff9f1983c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_13905e85-8ac4-4ee4-9407-aaff9f1983c9" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_0be95b88-f51d-4b19-b79a-aa706fbe08cc" xlink:href="ameh-20220630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_0be95b88-f51d-4b19-b79a-aa706fbe08cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_34166f53-4482-46d2-91bb-6cedc38c520f" xlink:href="ameh-20220630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:to="loc_ameh_AMGPropertiesLLCMember_34166f53-4482-46d2-91bb-6cedc38c520f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_df8d621f-6b9c-440b-891c-ead8a9d81e9c" xlink:href="ameh-20220630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:to="loc_ameh_ZLLPartnersLLCMember_df8d621f-6b9c-440b-891c-ead8a9d81e9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f05824f4-4818-42e7-8a88-dc2f3bb211d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_srt_StatementScenarioAxis_f05824f4-4818-42e7-8a88-dc2f3bb211d5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f05824f4-4818-42e7-8a88-dc2f3bb211d5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_f05824f4-4818-42e7-8a88-dc2f3bb211d5" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f05824f4-4818-42e7-8a88-dc2f3bb211d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6cfcc5a1-8f6d-4dec-ac05-4d482c3f60eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_f05824f4-4818-42e7-8a88-dc2f3bb211d5" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6cfcc5a1-8f6d-4dec-ac05-4d482c3f60eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_49be01fb-27b7-47fc-aa44-1a08c0bf492f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6cfcc5a1-8f6d-4dec-ac05-4d482c3f60eb" xlink:to="loc_srt_ScenarioForecastMember_49be01fb-27b7-47fc-aa44-1a08c0bf492f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i2eb4a1910fdc4db0a1d9e875043e7971_MezzanineandStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_ade18dda-6315-42c2-b109-9438aa81f1e8" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_ade18dda-6315-42c2-b109-9438aa81f1e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_39146b37-4435-4947-91d1-9882e5face82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_39146b37-4435-4947-91d1-9882e5face82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_7363089f-ab55-4378-990e-2aa2f82f06f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:to="loc_us-gaap_Dividends_7363089f-ab55-4378-990e-2aa2f82f06f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_057795ce-396b-4f8c-8c2c-adfadb3f0d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_057795ce-396b-4f8c-8c2c-adfadb3f0d13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fe126abd-e5d9-407d-a661-3c452748b508" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_057795ce-396b-4f8c-8c2c-adfadb3f0d13" xlink:to="loc_dei_LegalEntityAxis_fe126abd-e5d9-407d-a661-3c452748b508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fe126abd-e5d9-407d-a661-3c452748b508_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_fe126abd-e5d9-407d-a661-3c452748b508" xlink:to="loc_dei_EntityDomain_fe126abd-e5d9-407d-a661-3c452748b508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0412267a-edc1-4a8d-a097-7e1d25321452" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_fe126abd-e5d9-407d-a661-3c452748b508" xlink:to="loc_dei_EntityDomain_0412267a-edc1-4a8d-a097-7e1d25321452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_fb57b647-50b3-4ff9-8424-c7a6d379f62f" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0412267a-edc1-4a8d-a097-7e1d25321452" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_fb57b647-50b3-4ff9-8424-c7a6d379f62f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_d0ec1742-5b89-419a-b255-4947240d1b1d" xlink:href="ameh-20220630.xsd#ameh_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0412267a-edc1-4a8d-a097-7e1d25321452" xlink:to="loc_ameh_CDSCMember_d0ec1742-5b89-419a-b255-4947240d1b1d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="i6239322e0dd84ed69cd4a46b1320a864_StockBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6bf242a-2c05-4c11-bcbd-5ab8d1e69db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_441c4e85-19f3-4bbb-ae3a-9a0495a13213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6bf242a-2c05-4c11-bcbd-5ab8d1e69db4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_441c4e85-19f3-4bbb-ae3a-9a0495a13213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ff2f503-328c-4212-bdb9-475c7f88cd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6bf242a-2c05-4c11-bcbd-5ab8d1e69db4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ff2f503-328c-4212-bdb9-475c7f88cd7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e7eb2a67-f59d-4d14-a0ee-fb0527a6eff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ff2f503-328c-4212-bdb9-475c7f88cd7e" xlink:to="loc_us-gaap_AwardTypeAxis_e7eb2a67-f59d-4d14-a0ee-fb0527a6eff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7eb2a67-f59d-4d14-a0ee-fb0527a6eff3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e7eb2a67-f59d-4d14-a0ee-fb0527a6eff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7eb2a67-f59d-4d14-a0ee-fb0527a6eff3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86620b5e-d7ab-42e3-a64b-fd14be0fd582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e7eb2a67-f59d-4d14-a0ee-fb0527a6eff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86620b5e-d7ab-42e3-a64b-fd14be0fd582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_32ac4186-626c-47db-9d30-9e6f3d395404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86620b5e-d7ab-42e3-a64b-fd14be0fd582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_32ac4186-626c-47db-9d30-9e6f3d395404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_8dcdd326-20b6-4ee0-86fb-ceb132416cb5" xlink:href="ameh-20220630.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86620b5e-d7ab-42e3-a64b-fd14be0fd582" xlink:to="loc_ameh_StockAwardsAndUnitsMember_8dcdd326-20b6-4ee0-86fb-ceb132416cb5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i29ff987e0c4148eea89c86415bd25621_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_cd54549e-02c6-4238-99d9-dbfac116f35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_cd54549e-02c6-4238-99d9-dbfac116f35f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d907b85b-862d-4a9b-85c2-cb543eb532ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d907b85b-862d-4a9b-85c2-cb543eb532ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_44346f12-8b82-4a99-a087-efede5c68278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_44346f12-8b82-4a99-a087-efede5c68278" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0e2a3f36-993e-48a2-8689-7591c5853a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0e2a3f36-993e-48a2-8689-7591c5853a04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14e85b0c-04eb-460d-a132-5dd54a2f9afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14e85b0c-04eb-460d-a132-5dd54a2f9afd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_b58925e1-7c86-4888-a857-b1f03a2ba3e8" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_b58925e1-7c86-4888-a857-b1f03a2ba3e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05fe863c-fcb3-4d06-8520-8e168f979902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05fe863c-fcb3-4d06-8520-8e168f979902" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cdfbf693-fadb-414a-a41e-0db14caeaca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cdfbf693-fadb-414a-a41e-0db14caeaca3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_f67fa26b-c9c0-4836-844c-64a3335d554e" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_f67fa26b-c9c0-4836-844c-64a3335d554e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_08a94dc1-7cdc-4956-a36e-a6ad592e4b25" xlink:href="ameh-20220630.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_08a94dc1-7cdc-4956-a36e-a6ad592e4b25" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_17468f4a-0022-4b4b-a3ee-7e472b922a36" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_17468f4a-0022-4b4b-a3ee-7e472b922a36" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c71c18d-8d9e-4ba2-a66d-948a958afb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:to="loc_us-gaap_AwardTypeAxis_0c71c18d-8d9e-4ba2-a66d-948a958afb95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c71c18d-8d9e-4ba2-a66d-948a958afb95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0c71c18d-8d9e-4ba2-a66d-948a958afb95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c71c18d-8d9e-4ba2-a66d-948a958afb95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87359c32-e3b6-4996-9032-ee5cd3a7b1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0c71c18d-8d9e-4ba2-a66d-948a958afb95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87359c32-e3b6-4996-9032-ee5cd3a7b1cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b2f271c2-bcde-4a46-a748-5a7b29139ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87359c32-e3b6-4996-9032-ee5cd3a7b1cf" xlink:to="loc_us-gaap_RestrictedStockMember_b2f271c2-bcde-4a46-a748-5a7b29139ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5086fdce-a896-4ac0-ae32-a86f429e274c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:to="loc_srt_TitleOfIndividualAxis_5086fdce-a896-4ac0-ae32-a86f429e274c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5086fdce-a896-4ac0-ae32-a86f429e274c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5086fdce-a896-4ac0-ae32-a86f429e274c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5086fdce-a896-4ac0-ae32-a86f429e274c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eba4c7d2-bbea-4b14-bf11-23cac08eb771" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5086fdce-a896-4ac0-ae32-a86f429e274c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eba4c7d2-bbea-4b14-bf11-23cac08eb771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EmployeesMember_38018da2-44b5-4f9c-b9be-c2c6031f51bf" xlink:href="ameh-20220630.xsd#ameh_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eba4c7d2-bbea-4b14-bf11-23cac08eb771" xlink:to="loc_ameh_EmployeesMember_38018da2-44b5-4f9c-b9be-c2c6031f51bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ab6131d1-7476-414f-9e51-26b67a3daf92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:to="loc_srt_RangeAxis_ab6131d1-7476-414f-9e51-26b67a3daf92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab6131d1-7476-414f-9e51-26b67a3daf92_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ab6131d1-7476-414f-9e51-26b67a3daf92" xlink:to="loc_srt_RangeMember_ab6131d1-7476-414f-9e51-26b67a3daf92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4ed6c44-47aa-4651-ab3c-de9acfd5a47e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ab6131d1-7476-414f-9e51-26b67a3daf92" xlink:to="loc_srt_RangeMember_c4ed6c44-47aa-4651-ab3c-de9acfd5a47e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f4a44848-5c4d-44ed-ba11-44fcf24405a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c4ed6c44-47aa-4651-ab3c-de9acfd5a47e" xlink:to="loc_srt_MinimumMember_f4a44848-5c4d-44ed-ba11-44fcf24405a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae060fcc-73be-4235-9f9f-aa77d201ed98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c4ed6c44-47aa-4651-ab3c-de9acfd5a47e" xlink:to="loc_srt_MaximumMember_ae060fcc-73be-4235-9f9f-aa77d201ed98" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended" id="i695c449790d04abab1d3f8aee460c51f_StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47a7f0d4-5069-4935-b12b-dfe681abaa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47a7f0d4-5069-4935-b12b-dfe681abaa6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b5cbd05e-4573-43f3-94f1-f620f619056a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b5cbd05e-4573-43f3-94f1-f620f619056a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_065a4243-5ef3-460d-822c-826c89c9f196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_065a4243-5ef3-460d-822c-826c89c9f196" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8322a76d-c2ea-4c17-b064-6d64068217e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8322a76d-c2ea-4c17-b064-6d64068217e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_626e22c8-4507-4e32-816a-1c798ff2550e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_626e22c8-4507-4e32-816a-1c798ff2550e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6aba01b1-3274-4967-b801-42fa1d840620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_SharePrice_6aba01b1-3274-4967-b801-42fa1d840620" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_057b434c-fc55-4add-9a17-d593a108fdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_057b434c-fc55-4add-9a17-d593a108fdc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_83190fb2-757c-42f1-ad26-21b139f1e490" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_057b434c-fc55-4add-9a17-d593a108fdc4" xlink:to="loc_srt_TitleOfIndividualAxis_83190fb2-757c-42f1-ad26-21b139f1e490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_83190fb2-757c-42f1-ad26-21b139f1e490_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_83190fb2-757c-42f1-ad26-21b139f1e490" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_83190fb2-757c-42f1-ad26-21b139f1e490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7f9f3570-5c97-4c35-929b-af7f9e4028f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_83190fb2-757c-42f1-ad26-21b139f1e490" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7f9f3570-5c97-4c35-929b-af7f9e4028f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_00c3f57b-32ee-4249-a365-8daba3eefdd2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7f9f3570-5c97-4c35-929b-af7f9e4028f8" xlink:to="loc_srt_DirectorMember_00c3f57b-32ee-4249-a365-8daba3eefdd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce6d10a2-96f4-4222-ac1b-f238a7f1063c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_057b434c-fc55-4add-9a17-d593a108fdc4" xlink:to="loc_srt_RangeAxis_ce6d10a2-96f4-4222-ac1b-f238a7f1063c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce6d10a2-96f4-4222-ac1b-f238a7f1063c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ce6d10a2-96f4-4222-ac1b-f238a7f1063c" xlink:to="loc_srt_RangeMember_ce6d10a2-96f4-4222-ac1b-f238a7f1063c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bb8103a1-2d7e-43f0-81fd-9c6b6575f576" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ce6d10a2-96f4-4222-ac1b-f238a7f1063c" xlink:to="loc_srt_RangeMember_bb8103a1-2d7e-43f0-81fd-9c6b6575f576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7a69cf1d-3a01-4a00-b0f8-aaa437854cd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bb8103a1-2d7e-43f0-81fd-9c6b6575f576" xlink:to="loc_srt_MinimumMember_7a69cf1d-3a01-4a00-b0f8-aaa437854cd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59a02407-f520-469b-b639-624342d8b71f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bb8103a1-2d7e-43f0-81fd-9c6b6575f576" xlink:to="loc_srt_MaximumMember_59a02407-f520-469b-b639-624342d8b71f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended" id="ib16423dabc6246dda82c89d05c98cc45_StockBasedCompensationWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd80609d-8c85-40a0-8cd2-b2f94656e0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd80609d-8c85-40a0-8cd2-b2f94656e0e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_ebeb94a6-2b2b-43c6-a3e4-15949cd2eac6" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_ebeb94a6-2b2b-43c6-a3e4-15949cd2eac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_1911bcc9-c0c8-4851-9084-2cc47fc959de" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_1911bcc9-c0c8-4851-9084-2cc47fc959de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_fb743a9d-ba85-43fe-a580-e0725851c5fb" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_fb743a9d-ba85-43fe-a580-e0725851c5fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_473bc73e-9873-485e-93e7-d65c9007522d" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_473bc73e-9873-485e-93e7-d65c9007522d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9784da78-73a4-4203-b30f-8a626cb4ca69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9784da78-73a4-4203-b30f-8a626cb4ca69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4a378563-f999-4159-8289-f5f210bed3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9784da78-73a4-4203-b30f-8a626cb4ca69" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4a378563-f999-4159-8289-f5f210bed3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4a378563-f999-4159-8289-f5f210bed3ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4a378563-f999-4159-8289-f5f210bed3ca" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4a378563-f999-4159-8289-f5f210bed3ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4a378563-f999-4159-8289-f5f210bed3ca" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_98610cd2-ca58-4d1e-8303-e095828ebb0f" xlink:href="ameh-20220630.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_98610cd2-ca58-4d1e-8303-e095828ebb0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_973d8358-7265-4a66-8227-b85ceb03876f" xlink:href="ameh-20220630.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_973d8358-7265-4a66-8227-b85ceb03876f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_1cefb27d-67b5-45d1-9138-14382b039f5d" xlink:href="ameh-20220630.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_1cefb27d-67b5-45d1-9138-14382b039f5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fb527be2-4e3a-46cd-9239-11f3fdbb36c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9784da78-73a4-4203-b30f-8a626cb4ca69" xlink:to="loc_srt_RangeAxis_fb527be2-4e3a-46cd-9239-11f3fdbb36c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb527be2-4e3a-46cd-9239-11f3fdbb36c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fb527be2-4e3a-46cd-9239-11f3fdbb36c7" xlink:to="loc_srt_RangeMember_fb527be2-4e3a-46cd-9239-11f3fdbb36c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a78704a-7233-40d9-b450-d6c46736593e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fb527be2-4e3a-46cd-9239-11f3fdbb36c7" xlink:to="loc_srt_RangeMember_6a78704a-7233-40d9-b450-d6c46736593e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d69e8a50-2b7d-49b4-aa4c-7107372990f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a78704a-7233-40d9-b450-d6c46736593e" xlink:to="loc_srt_MinimumMember_d69e8a50-2b7d-49b4-aa4c-7107372990f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a341426-f5a0-43bd-bd57-436b10815570" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a78704a-7233-40d9-b450-d6c46736593e" xlink:to="loc_srt_MaximumMember_6a341426-f5a0-43bd-bd57-436b10815570" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i5c8e9b645d1643ab9e4e20432ba6e72a_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_2edf074b-d49a-4808-8b45-6674fa5a8652" xlink:href="ameh-20220630.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_3cc0aa1c-8715-4e5e-861d-d79d858117e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_2edf074b-d49a-4808-8b45-6674fa5a8652" xlink:to="loc_us-gaap_LineOfCredit_3cc0aa1c-8715-4e5e-861d-d79d858117e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:href="ameh-20220630.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_2edf074b-d49a-4808-8b45-6674fa5a8652" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b29fbd25-144d-4991-97d1-4e61eb2d7eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:to="loc_us-gaap_CreditFacilityAxis_b29fbd25-144d-4991-97d1-4e61eb2d7eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b29fbd25-144d-4991-97d1-4e61eb2d7eea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b29fbd25-144d-4991-97d1-4e61eb2d7eea" xlink:to="loc_us-gaap_CreditFacilityDomain_b29fbd25-144d-4991-97d1-4e61eb2d7eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a8e85ced-e356-42db-aef8-1d6d0b74ddb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b29fbd25-144d-4991-97d1-4e61eb2d7eea" xlink:to="loc_us-gaap_CreditFacilityDomain_a8e85ced-e356-42db-aef8-1d6d0b74ddb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_96da578b-3b74-473e-81ce-8c5f6134f82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a8e85ced-e356-42db-aef8-1d6d0b74ddb4" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_96da578b-3b74-473e-81ce-8c5f6134f82b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_bfecfdeb-13c6-4155-9b78-af9e0d1480c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_bfecfdeb-13c6-4155-9b78-af9e0d1480c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_bfecfdeb-13c6-4155-9b78-af9e0d1480c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_bfecfdeb-13c6-4155-9b78-af9e0d1480c3" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_bfecfdeb-13c6-4155-9b78-af9e0d1480c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_fea98810-9a85-424f-b3e9-7ecd249b3f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_bfecfdeb-13c6-4155-9b78-af9e0d1480c3" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_fea98810-9a85-424f-b3e9-7ecd249b3f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_04d277df-d666-4e80-948f-f66f143f491b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_fea98810-9a85-424f-b3e9-7ecd249b3f56" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_04d277df-d666-4e80-948f-f66f143f491b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_00dc1d95-48d9-4226-b058-cc62eb217daf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:to="loc_dei_LegalEntityAxis_00dc1d95-48d9-4226-b058-cc62eb217daf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_00dc1d95-48d9-4226-b058-cc62eb217daf_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_00dc1d95-48d9-4226-b058-cc62eb217daf" xlink:to="loc_dei_EntityDomain_00dc1d95-48d9-4226-b058-cc62eb217daf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d401bb4c-e6d9-4e47-a703-478f9c169e3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_00dc1d95-48d9-4226-b058-cc62eb217daf" xlink:to="loc_dei_EntityDomain_d401bb4c-e6d9-4e47-a703-478f9c169e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2a2e54cb-fb93-41b7-bf9c-114a1dca4696" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d401bb4c-e6d9-4e47-a703-478f9c169e3a" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2a2e54cb-fb93-41b7-bf9c-114a1dca4696" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_1359a3cc-897a-4904-8c27-c7f305cd0bf7" xlink:href="ameh-20220630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d401bb4c-e6d9-4e47-a703-478f9c169e3a" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_1359a3cc-897a-4904-8c27-c7f305cd0bf7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="i32aebad80d0c4aa1a234d67c78a9b89a_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a8519563-5f8b-40c2-9329-9846432e3deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a8519563-5f8b-40c2-9329-9846432e3deb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_c58a50b2-79ea-452b-9752-16573ac40e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_c58a50b2-79ea-452b-9752-16573ac40e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_e14efac2-f46a-41fa-84e3-dc253aec7b7c" xlink:href="ameh-20220630.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_ameh_PaymentMadeToRelatedParty_e14efac2-f46a-41fa-84e3-dc253aec7b7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_9417fe48-2bd5-4418-b9b3-e2098762b0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_9417fe48-2bd5-4418-b9b3-e2098762b0b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_482c5449-4275-49dc-b914-f54357024658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_482c5449-4275-49dc-b914-f54357024658" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3fba6f86-7273-4a2a-92b6-afd51b290d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3fba6f86-7273-4a2a-92b6-afd51b290d75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5ea213ba-be54-4906-9d9b-1e407de6aaa6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5ea213ba-be54-4906-9d9b-1e407de6aaa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5ea213ba-be54-4906-9d9b-1e407de6aaa6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5ea213ba-be54-4906-9d9b-1e407de6aaa6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5ea213ba-be54-4906-9d9b-1e407de6aaa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5ea213ba-be54-4906-9d9b-1e407de6aaa6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_de69b448-6dbf-4e96-8c59-597639360c8c" xlink:href="ameh-20220630.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:to="loc_ameh_LmaMember_de69b448-6dbf-4e96-8c59-597639360c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_5eca0c8f-ea07-4d3c-b9cb-f23524a1fa8d" xlink:href="ameh-20220630.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:to="loc_ameh_PmiocMember_5eca0c8f-ea07-4d3c-b9cb-f23524a1fa8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_aa8d7ad6-676a-4338-9049-22bca2f81060" xlink:href="ameh-20220630.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:to="loc_ameh_DmgMember_aa8d7ad6-676a-4338-9049-22bca2f81060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_fb41b707-2f7b-4e4a-a979-d3a1b4439618" xlink:href="ameh-20220630.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:to="loc_ameh_OneMSOInc.Member_fb41b707-2f7b-4e4a-a979-d3a1b4439618" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_289a80e9-932c-4490-a294-d97744ab627b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_289a80e9-932c-4490-a294-d97744ab627b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_289a80e9-932c-4490-a294-d97744ab627b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_289a80e9-932c-4490-a294-d97744ab627b" xlink:to="loc_us-gaap_RelatedPartyDomain_289a80e9-932c-4490-a294-d97744ab627b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_289a80e9-932c-4490-a294-d97744ab627b" xlink:to="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_981c4747-904c-42cf-a6a3-75ccabcfe385" xlink:href="ameh-20220630.xsd#ameh_ApcShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_ApcShareholdersMember_981c4747-904c-42cf-a6a3-75ccabcfe385" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_c347132f-e2ec-481b-b6d7-f2c8ee581b1d" xlink:href="ameh-20220630.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_c347132f-e2ec-481b-b6d7-f2c8ee581b1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_7ec9968c-ebfb-4241-87b6-4640d94bdad3" xlink:href="ameh-20220630.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_FulgentGeneticsIncMember_7ec9968c-ebfb-4241-87b6-4640d94bdad3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_502e58df-82ae-462d-add1-18b4c74837f6" xlink:href="ameh-20220630.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_ShareholdersAndOfficersMember_502e58df-82ae-462d-add1-18b4c74837f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_8991bbc9-8270-40e6-ac7f-7430d3e78364" xlink:href="ameh-20220630.xsd#ameh_NumenLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_NumenLLCMember_8991bbc9-8270-40e6-ac7f-7430d3e78364" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_2a9246bf-6e17-4a1c-ab29-3c494d784001" xlink:href="ameh-20220630.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_OneMSOInc.Member_2a9246bf-6e17-4a1c-ab29-3c494d784001" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ArroyoVistaMember_5c792c40-4341-47a1-86db-e3d4dcc3070b" xlink:href="ameh-20220630.xsd#ameh_ArroyoVistaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_ArroyoVistaMember_5c792c40-4341-47a1-86db-e3d4dcc3070b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_63b8e889-50e9-4a9f-a40c-188ab1a6c047" xlink:href="ameh-20220630.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_AHMCMember_63b8e889-50e9-4a9f-a40c-188ab1a6c047" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_fd5c9abc-bf79-4f53-9f68-cb36ef0007aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_srt_DirectorMember_fd5c9abc-bf79-4f53-9f68-cb36ef0007aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ce87030e-10ec-4898-8938-77bfe97f07f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_dei_LegalEntityAxis_ce87030e-10ec-4898-8938-77bfe97f07f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ce87030e-10ec-4898-8938-77bfe97f07f6_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ce87030e-10ec-4898-8938-77bfe97f07f6" xlink:to="loc_dei_EntityDomain_ce87030e-10ec-4898-8938-77bfe97f07f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ce87030e-10ec-4898-8938-77bfe97f07f6" xlink:to="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_bcef8624-4f37-4ae7-a25d-275e803db2b0" xlink:href="ameh-20220630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:to="loc_ameh_NetworkMedicalManagementMember_bcef8624-4f37-4ae7-a25d-275e803db2b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8babe5ff-1cab-45a7-9680-0250daf45207" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8babe5ff-1cab-45a7-9680-0250daf45207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_bd09c76a-adf1-4405-8e47-50096d86f436" xlink:href="ameh-20220630.xsd#ameh_SCHCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:to="loc_ameh_SCHCMember_bd09c76a-adf1-4405-8e47-50096d86f436" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9807725d-adee-4afd-ab45-8a0e24e42724" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9807725d-adee-4afd-ab45-8a0e24e42724" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9807725d-adee-4afd-ab45-8a0e24e42724_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9807725d-adee-4afd-ab45-8a0e24e42724" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9807725d-adee-4afd-ab45-8a0e24e42724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9807725d-adee-4afd-ab45-8a0e24e42724" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_def5a3a6-5d77-4013-8d23-1eb86f48952b" xlink:href="ameh-20220630.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:to="loc_ameh_LmaMember_def5a3a6-5d77-4013-8d23-1eb86f48952b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_16a54d85-6e69-4f70-99f3-1d899298b3ec" xlink:href="ameh-20220630.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:to="loc_ameh_PmiocMember_16a54d85-6e69-4f70-99f3-1d899298b3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_ddc53a71-03f6-46ff-bfca-06dcbfcb04aa" xlink:href="ameh-20220630.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:to="loc_ameh_DmgMember_ddc53a71-03f6-46ff-bfca-06dcbfcb04aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_57c55f2b-6057-4982-9e16-71a6e4122974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_57c55f2b-6057-4982-9e16-71a6e4122974" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_57c55f2b-6057-4982-9e16-71a6e4122974_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_57c55f2b-6057-4982-9e16-71a6e4122974" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_57c55f2b-6057-4982-9e16-71a6e4122974_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_199bd014-c460-4dc6-bbc1-6e96c6151979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_57c55f2b-6057-4982-9e16-71a6e4122974" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_199bd014-c460-4dc6-bbc1-6e96c6151979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ec3d8c52-2f5b-42f7-9bfe-0b75ca93bc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199bd014-c460-4dc6-bbc1-6e96c6151979" xlink:to="loc_us-gaap_ServiceMember_ec3d8c52-2f5b-42f7-9bfe-0b75ca93bc3b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended" id="i3c45648c6d4b43f2907ff09ba2eadba1_RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_76ee0974-ac0c-487f-916e-139a07b01288" xlink:href="ameh-20220630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_76ee0974-ac0c-487f-916e-139a07b01288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_b47607c4-1749-42ce-8050-3616cbaf7286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:to="loc_us-gaap_ManagementFeeExpense_b47607c4-1749-42ce-8050-3616cbaf7286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3f6e03c7-e44d-4896-b388-10dffe277c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3f6e03c7-e44d-4896-b388-10dffe277c30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8831cc9-ce7e-47b2-88b0-0e08c39747cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8831cc9-ce7e-47b2-88b0-0e08c39747cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c9db1114-1653-4a12-b472-575219ee8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8831cc9-ce7e-47b2-88b0-0e08c39747cb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c9db1114-1653-4a12-b472-575219ee8f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c9db1114-1653-4a12-b472-575219ee8f7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c9db1114-1653-4a12-b472-575219ee8f7c" xlink:to="loc_us-gaap_RelatedPartyDomain_c9db1114-1653-4a12-b472-575219ee8f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c9db1114-1653-4a12-b472-575219ee8f7c" xlink:to="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_9fff771a-2544-4de1-8ac8-8c845ff479af" xlink:href="ameh-20220630.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:to="loc_ameh_AHMCMember_9fff771a-2544-4de1-8ac8-8c845ff479af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_d8aba4e9-93dc-484e-8ed0-dadbc90ec97e" xlink:href="ameh-20220630.xsd#ameh_HSMSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:to="loc_ameh_HSMSOMember_d8aba4e9-93dc-484e-8ed0-dadbc90ec97e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_c493af64-c23d-4fef-a2ea-2c1e8fef62c0" xlink:href="ameh-20220630.xsd#ameh_AurionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:to="loc_ameh_AurionMember_c493af64-c23d-4fef-a2ea-2c1e8fef62c0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended" id="i5e94b09ac2ec46b383f4d8b173d7ec0b_EarningsPerShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_0d4c7680-aa1e-4e95-8da3-0f271aa54781" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35bb14e5-0947-4706-ba00-aae627df94ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_0d4c7680-aa1e-4e95-8da3-0f271aa54781" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35bb14e5-0947-4706-ba00-aae627df94ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_846aa99a-be48-40ef-9d20-3e0f3413aa04" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_0d4c7680-aa1e-4e95-8da3-0f271aa54781" xlink:to="loc_ameh_EarningsPerShareTable_846aa99a-be48-40ef-9d20-3e0f3413aa04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_accf1d49-06ae-463a-b402-4d2e290c0410" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_846aa99a-be48-40ef-9d20-3e0f3413aa04" xlink:to="loc_dei_LegalEntityAxis_accf1d49-06ae-463a-b402-4d2e290c0410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_accf1d49-06ae-463a-b402-4d2e290c0410_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_accf1d49-06ae-463a-b402-4d2e290c0410" xlink:to="loc_dei_EntityDomain_accf1d49-06ae-463a-b402-4d2e290c0410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_40a90d8e-9858-4def-8179-2a45386abce1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_accf1d49-06ae-463a-b402-4d2e290c0410" xlink:to="loc_dei_EntityDomain_40a90d8e-9858-4def-8179-2a45386abce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2f5203ab-a928-4c84-a167-2883695e11db" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_40a90d8e-9858-4def-8179-2a45386abce1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2f5203ab-a928-4c84-a167-2883695e11db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_27671f1c-a51c-4cd7-a92f-04cf9a961ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_846aa99a-be48-40ef-9d20-3e0f3413aa04" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_27671f1c-a51c-4cd7-a92f-04cf9a961ba0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27671f1c-a51c-4cd7-a92f-04cf9a961ba0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_27671f1c-a51c-4cd7-a92f-04cf9a961ba0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_27671f1c-a51c-4cd7-a92f-04cf9a961ba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f4562ba-7ab7-434e-aa81-e1fae1968ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_27671f1c-a51c-4cd7-a92f-04cf9a961ba0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f4562ba-7ab7-434e-aa81-e1fae1968ea0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c0fedd07-8db1-4eea-b0d1-cdec9072322a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f4562ba-7ab7-434e-aa81-e1fae1968ea0" xlink:to="loc_us-gaap_RestrictedStockMember_c0fedd07-8db1-4eea-b0d1-cdec9072322a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_98e624d3-8229-491c-a78b-c5fc558db4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f4562ba-7ab7-434e-aa81-e1fae1968ea0" xlink:to="loc_us-gaap_PerformanceSharesMember_98e624d3-8229-491c-a78b-c5fc558db4df" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended" id="i5fa1df9b1e9c4d8eaaab4f3814ecc837_EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6de9ed1a-0fc8-4d94-94f0-0a0fd30c5fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6de9ed1a-0fc8-4d94-94f0-0a0fd30c5fb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_05f28377-199c-4096-979c-779c8fc053f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_05f28377-199c-4096-979c-779c8fc053f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0d44474-53a4-4a28-8c99-6b500c23e659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0d44474-53a4-4a28-8c99-6b500c23e659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_bc87326f-aff6-45f0-9744-3b49a23345b8" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:to="loc_ameh_EarningsPerShareTable_bc87326f-aff6-45f0-9744-3b49a23345b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3b9e14ed-e503-49a9-8eb5-7b5052b3e3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_bc87326f-aff6-45f0-9744-3b49a23345b8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3b9e14ed-e503-49a9-8eb5-7b5052b3e3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b9e14ed-e503-49a9-8eb5-7b5052b3e3d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b9e14ed-e503-49a9-8eb5-7b5052b3e3d7" xlink:to="loc_us-gaap_EquityComponentDomain_3b9e14ed-e503-49a9-8eb5-7b5052b3e3d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_32dfde0e-c75a-4f3a-bbe9-ab307f719911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b9e14ed-e503-49a9-8eb5-7b5052b3e3d7" xlink:to="loc_us-gaap_EquityComponentDomain_32dfde0e-c75a-4f3a-bbe9-ab307f719911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8de0219e-1832-4df5-a69b-e1daf821f42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32dfde0e-c75a-4f3a-bbe9-ab307f719911" xlink:to="loc_us-gaap_WarrantMember_8de0219e-1832-4df5-a69b-e1daf821f42c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_42e4cc3a-0678-41e1-a773-4361510a8be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_bc87326f-aff6-45f0-9744-3b49a23345b8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_42e4cc3a-0678-41e1-a773-4361510a8be5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42e4cc3a-0678-41e1-a773-4361510a8be5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_42e4cc3a-0678-41e1-a773-4361510a8be5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_42e4cc3a-0678-41e1-a773-4361510a8be5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1758d460-6e27-4e15-8980-d0261cb840e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_42e4cc3a-0678-41e1-a773-4361510a8be5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1758d460-6e27-4e15-8980-d0261cb840e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eea62495-457f-480e-af7e-d8606b801243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1758d460-6e27-4e15-8980-d0261cb840e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eea62495-457f-480e-af7e-d8606b801243" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f589ab5a-ba5e-443d-8061-868fa91a94a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1758d460-6e27-4e15-8980-d0261cb840e3" xlink:to="loc_us-gaap_RestrictedStockMember_f589ab5a-ba5e-443d-8061-868fa91a94a8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended" id="i3fb21d14d0dd4b4d9cf5822c09ffb992_VariableInterestEntitiesVIEsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:to="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:to="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_777b1e81-961d-4983-98c3-e57a729f0165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_777b1e81-961d-4983-98c3-e57a729f0165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_8fc71c40-140c-41fa-8e75-94d335fe36ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_8fc71c40-140c-41fa-8e75-94d335fe36ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5b6cd79b-ce58-4712-841a-e0c6878d449d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5b6cd79b-ce58-4712-841a-e0c6878d449d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_762651d1-b969-4ed4-8c08-85cefcc9d53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_762651d1-b969-4ed4-8c08-85cefcc9d53c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a7eabdbf-86ac-4d2e-bc1d-43f066975da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_IncomeTaxesReceivable_a7eabdbf-86ac-4d2e-bc1d-43f066975da8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_471b2d48-8cd7-49dd-874a-c7aabbd017c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_471b2d48-8cd7-49dd-874a-c7aabbd017c6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_282c813b-1c22-4dcf-8042-25169adf71af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_282c813b-1c22-4dcf-8042-25169adf71af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_ee37d1eb-3045-48b4-a54e-1afe37dfe4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_ee37d1eb-3045-48b4-a54e-1afe37dfe4ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_aa7a3014-1442-46f9-98d4-bc33e4f05a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_aa7a3014-1442-46f9-98d4-bc33e4f05a6d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bb8c7958-0662-4cdb-8572-466a0efcdc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_AssetsCurrent_bb8c7958-0662-4cdb-8572-466a0efcdc3c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f7699aad-ea99-4a16-bcbf-495fa70e5481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f7699aad-ea99-4a16-bcbf-495fa70e5481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_500234c3-e120-4da9-b4d8-163ff1865dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_500234c3-e120-4da9-b4d8-163ff1865dd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d49712d8-f534-476f-b252-f21d5f1d1b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_Goodwill_d49712d8-f534-476f-b252-f21d5f1d1b90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_dbe6d83c-fc5e-41b3-ac39-2e4bff310175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_dbe6d83c-fc5e-41b3-ac39-2e4bff310175" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_725e6c0c-49c5-4f93-b54e-7abc9b642b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_725e6c0c-49c5-4f93-b54e-7abc9b642b99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_22623920-3c63-4fc6-892d-950776627784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_OtherLongTermInvestments_22623920-3c63-4fc6-892d-950776627784" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0f16f968-3aaf-4451-a5f3-a612b3a25ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_EquityMethodInvestments_0f16f968-3aaf-4451-a5f3-a612b3a25ba8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_2a87df80-931b-4578-a5e4-d9aa3449e461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_2a87df80-931b-4578-a5e4-d9aa3449e461" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7826dec-85a4-4e0f-b3d4-54ed76ad4d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7826dec-85a4-4e0f-b3d4-54ed76ad4d68" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6ad10482-9fdc-4721-bb3d-035560432740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6ad10482-9fdc-4721-bb3d-035560432740" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_80be7381-1814-48fa-aaee-f3ab13665f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_AssetsNoncurrent_80be7381-1814-48fa-aaee-f3ab13665f8a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_90878e34-55da-410f-8051-58297816fb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:to="loc_us-gaap_Assets_90878e34-55da-410f-8051-58297816fb3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30a4e1cd-8ed9-43a0-86f5-32881ff3f371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30a4e1cd-8ed9-43a0-86f5-32881ff3f371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_0c2f68ee-2c80-46bb-911b-9541ec7797e8" xlink:href="ameh-20220630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_0c2f68ee-2c80-46bb-911b-9541ec7797e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_fb322aa2-1cf8-4ac7-9d45-89605132daab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_fb322aa2-1cf8-4ac7-9d45-89605132daab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_1026b88e-707b-4c52-a211-311fd133c090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_DividendsPayableCurrent_1026b88e-707b-4c52-a211-311fd133c090" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c76d535f-0055-4d70-8535-697f85d580b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_LongTermDebtCurrent_c76d535f-0055-4d70-8535-697f85d580b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_79851ccb-0b79-4941-9999-c334367129bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_79851ccb-0b79-4941-9999-c334367129bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_856597f6-403f-4792-aa70-7b53444715dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_856597f6-403f-4792-aa70-7b53444715dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_34322c44-d37f-45b5-9c4e-39314cbf96e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_LiabilitiesCurrent_34322c44-d37f-45b5-9c4e-39314cbf96e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_03974b91-28ba-4f41-ad13-8f0f8ab3a0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_03974b91-28ba-4f41-ad13-8f0f8ab3a0c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eccad8be-4e92-45c0-b03f-1d1edd483c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eccad8be-4e92-45c0-b03f-1d1edd483c80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_80e50ed7-d5a1-48c0-91a2-7bb7cf50d8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_80e50ed7-d5a1-48c0-91a2-7bb7cf50d8e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b90a97fe-0395-41fc-9474-cb36e1d0f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b90a97fe-0395-41fc-9474-cb36e1d0f09d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_714d30c6-6bb8-4fdb-9b86-1bab508fed47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_714d30c6-6bb8-4fdb-9b86-1bab508fed47" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c66f5822-aebd-42bf-8b44-9b2d8ad8bdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c66f5822-aebd-42bf-8b44-9b2d8ad8bdfc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ebc2d2aa-aa7a-493d-88e9-3a4beefe567e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:to="loc_us-gaap_Liabilities_ebc2d2aa-aa7a-493d-88e9-3a4beefe567e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e0d9585a-f3b2-4897-8e6e-34e023397c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e0d9585a-f3b2-4897-8e6e-34e023397c58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8b60f49f-94b0-43d8-bb55-027f849127df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e0d9585a-f3b2-4897-8e6e-34e023397c58" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8b60f49f-94b0-43d8-bb55-027f849127df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8b60f49f-94b0-43d8-bb55-027f849127df_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8b60f49f-94b0-43d8-bb55-027f849127df" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8b60f49f-94b0-43d8-bb55-027f849127df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_90224e28-647c-40cf-8e35-1b7a191c60ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8b60f49f-94b0-43d8-bb55-027f849127df" xlink:to="loc_srt_ConsolidatedEntitiesDomain_90224e28-647c-40cf-8e35-1b7a191c60ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c9056a6b-028b-466e-bd71-fd5469f9f24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_90224e28-647c-40cf-8e35-1b7a191c60ea" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c9056a6b-028b-466e-bd71-fd5469f9f24b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended" id="ie3ef614b2f804ecd981b93b69ca8b68b_LeasesAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fca9d5f0-e258-4612-89cc-34fda8a8d206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fca9d5f0-e258-4612-89cc-34fda8a8d206" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_cfb8bcbe-805a-4d4d-a468-79af494961a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_cfb8bcbe-805a-4d4d-a468-79af494961a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bbcdeef8-48e3-4238-af7f-4dc019c6d0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bbcdeef8-48e3-4238-af7f-4dc019c6d0be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_66daa4a9-8f01-4bd2-8a19-872f25681c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_66daa4a9-8f01-4bd2-8a19-872f25681c60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_a0be3f9e-b4c0-41c1-b05c-7719a8a2bc20" xlink:href="ameh-20220630.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_a0be3f9e-b4c0-41c1-b05c-7719a8a2bc20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_c91be6fa-2647-4237-b4b4-e33f2e62da3b" xlink:href="ameh-20220630.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_c91be6fa-2647-4237-b4b4-e33f2e62da3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_981ecca3-10dc-467e-bbb1-85fed53b3f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_981ecca3-10dc-467e-bbb1-85fed53b3f61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_50a76767-22b3-4ba9-b0c0-18e99636645d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_50a76767-22b3-4ba9-b0c0-18e99636645d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7a334316-bdbc-4ffd-b2da-ee42ab97e082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7a334316-bdbc-4ffd-b2da-ee42ab97e082" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fc934736-7b20-417b-b6ad-5002ab17e7ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7a334316-bdbc-4ffd-b2da-ee42ab97e082" xlink:to="loc_srt_RangeAxis_fc934736-7b20-417b-b6ad-5002ab17e7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc934736-7b20-417b-b6ad-5002ab17e7ac_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fc934736-7b20-417b-b6ad-5002ab17e7ac" xlink:to="loc_srt_RangeMember_fc934736-7b20-417b-b6ad-5002ab17e7ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0195f8ba-f196-4395-a949-d0dff727a82c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fc934736-7b20-417b-b6ad-5002ab17e7ac" xlink:to="loc_srt_RangeMember_0195f8ba-f196-4395-a949-d0dff727a82c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e6681314-25ac-4811-87f3-ad7e75cea22c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0195f8ba-f196-4395-a949-d0dff727a82c" xlink:to="loc_srt_MinimumMember_e6681314-25ac-4811-87f3-ad7e75cea22c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a807267d-5fd0-4538-aadd-2c43395a9511" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0195f8ba-f196-4395-a949-d0dff727a82c" xlink:to="loc_srt_MaximumMember_a807267d-5fd0-4538-aadd-2c43395a9511" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ameh-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4d426055-c9f8-47bb-b397-a8331168ec1c,g:285e3d39-8563-4e90-906d-af4a3a14867e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_86607a07-9f30-4748-b2ef-d62b4c3d5218_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_153e27ea-0b7b-4c7b-aefd-130868ca775d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_b8fab50a-32ef-4885-9779-9efa05e385f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_64d079a1-16f0-45b0-95e6-779b63262377_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_18fcba47-4001-4efa-84b3-958229652032_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets recorded under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4f5735e2-e87b-43b8-be52-520b34f8662c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_cb099c8d-b8d9-423f-9b13-a9b818d43084_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicaidMember_70015a33-8dd5-4e22-8ae8-1c92c7da2c6b_terseLabel_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ameh_MedicaidMember_label_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ameh_MedicaidMember_documentation_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicaidMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember" xlink:href="ameh-20220630.xsd#ameh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicaidMember" xlink:to="lab_ameh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_78631b33-3f76-4729-83ca-9ad1ee17ca7d_terseLabel_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_label_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC - Related Party [Member]</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_documentation_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC - Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:href="ameh-20220630.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:to="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0a19c234-1676-475a-8dfb-49fae94a2fe4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_7557242b-e162-4418-9307-bd34ef89cbe4_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_47b24967-7b1e-475a-8b37-ee3f9b36bf32_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_4b30cdef-4566-49d5-b218-b21deebe3ce6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_46b22fd9-55a1-4443-9279-981b3dc4186e_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc.</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember" xlink:href="ameh-20220630.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementIncMember" xlink:to="lab_ameh_NetworkMedicalManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2892c475-e4d3-4e14-bdb3-8b3f9e8273b5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_e4ac0e2b-66c0-4ef2-b008-c92d3dfdaeab_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a5d97f9c-d7ed-4eb9-bbbf-9136416b1f15_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_73e93f4c-e5a3-4f1f-9cfe-1baa49d5c36c_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_48ee31b4-49a3-48b7-9ae4-1f8fd27b6849_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f9bf265e-415f-4493-b709-864c176f4dee_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0a72e938-d2c1-4932-8e7e-e577ec135db0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_3d7dd468-627c-445b-9710-59d52b02f6d0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommercialMember_c5bdf2c2-deca-4d80-9762-96c802a5ac72_terseLabel_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_ameh_CommercialMember_label_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_ameh_CommercialMember_documentation_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:CommercialMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember" xlink:href="ameh-20220630.xsd#ameh_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommercialMember" xlink:to="lab_ameh_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18c1cfd5-bbf1-4f27-af2b-56845113bc11_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cda183ed-27f4-420a-871f-f25bfde19693_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c303149a-97c0-479d-b10e-dda19164e676_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a25c3252-767b-45cf-b689-b631ae4ebef5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8a335766-f5b6-4391-a224-c8c5164fbd8c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on loan receivable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_99d78c99-f79d-4616-ba75-9451e169ffb1_terseLabel_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_label_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract" xlink:href="ameh-20220630.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract" xlink:to="lab_ameh_AggregateintrinsicvalueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_cd54f141-5e25-42ee-9bdc-dc4f7ec342ae_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares for business acquisition (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CDSCMember_87a27ff5-4072-4a8f-a250-71c47d50943c_terseLabel_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:label id="lab_ameh_CDSCMember_label_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC [Member]</link:label>
    <link:label id="lab_ameh_CDSCMember_documentation_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember" xlink:href="ameh-20220630.xsd#ameh_CDSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CDSCMember" xlink:to="lab_ameh_CDSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_513a55c2-20ef-458e-ba10-93c3edeff532_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_9a50051c-efcd-4534-bc6c-dc48afa429dc_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:href="ameh-20220630.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_94465f7e-3dfa-4928-b1df-34cd407ac4e4_terseLabel_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy [Policy Text Block]</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:href="ameh-20220630.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:to="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_97ae7520-9b71-4935-9315-cd6dfdf476ab_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_a8554201-8ed2-494e-bf58-7a627bdc0dad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_2039bc7c-28cf-4adc-ac4b-a05b4d95d40b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable &#8211; related party</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_5f3c6d89-a2d4-4259-a583-913c17bf77bf_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3790bd00-940b-46f9-922f-577a113117de_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities not included in the calculation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6875c04d-91ed-4dad-88fe-e607f6839316_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e81acc1c-effa-4753-8dae-97f7a95c76c2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_b9c47ef0-d9ba-4e04-83e0-89fcb9fc233f_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in the event of default</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:to="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_16cddada-7d01-4c1a-a539-31142b36cd36_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_841861b7-a3bd-460e-827a-83beaeff5bca_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_689626bc-5192-41ce-9649-670d58885c6a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_bebbe129-b81a-49e8-8703-4843bdd05b16_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_405bf2d3-5bb5-4f8c-8577-636065497f58_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_d2d90a9e-20bf-431f-8443-f1f02f068b33_terseLabel_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related parties</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_label_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made To Related Party</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_documentation_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit/Duration (Amount paid to related party in relation to providing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty" xlink:href="ameh-20220630.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentMadeToRelatedParty" xlink:to="lab_ameh_PaymentMadeToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_d0d23a55-4d42-4970-bec1-101c1bb731bd_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f36b3c05-c2ef-4593-83ba-4d2780142ac7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; certificates of deposit</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_f91f4936-262d-4fd2-ac65-777b870f5b40_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ff0ccc93-e8fb-4818-abf9-e705d42bf57a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0a4f14ad-3c19-4476-8d11-6c7f36150591_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_7611225c-958f-46ee-bccd-4d8e32795409_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_853f8de3-c614-4fdf-94f6-516aa7e24b31_totalLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_23ff314c-3c7d-42b5-bde7-dc48053791af_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c795c2e0-f8db-407d-83ae-b0802fb7c5fc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_ff0a40db-eeb4-44e8-a5ea-ea27ce09439f_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9823928e-ec7e-4f06-b82b-62b8762694fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5cc2c74a-3d94-40e7-b71d-164616b2c814_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty_0362bb8e-8c09-4022-9f67-1d32afb52acc_terseLabel_en-US" xlink:label="lab_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, threshold percentage for occupation of property</link:label>
    <link:label id="lab_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty_label_en-US" xlink:label="lab_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Threshold Percentage for Occupation of Property</link:label>
    <link:label id="lab_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty_documentation_en-US" xlink:label="lab_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Threshold Percentage for Occupation of Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty" xlink:href="ameh-20220630.xsd#ameh_DebtCovenantThresholdPercentageForOccupationOfProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty" xlink:to="lab_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8a37af85-639a-4ab4-b99d-e5f52ea0086f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a57869f5-95c8-472f-8fc1-ed23d3c0eca0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SubcontractorIPAPayable_9d738549-87bf-4038-8bfa-a5ab36778d57_verboseLabel_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_label_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_documentation_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable" xlink:href="ameh-20220630.xsd#ameh_SubcontractorIPAPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SubcontractorIPAPayable" xlink:to="lab_ameh_SubcontractorIPAPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_13c85715-e7e4-4621-a3a9-f087d0d6681a_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_9a3c6f5f-dec1-43a8-ab21-23f45745e5a4_terseLabel_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_label_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_documentation_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CancellationOfRestrictedStockAwards" xlink:href="ameh-20220630.xsd#ameh_CancellationOfRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CancellationOfRestrictedStockAwards" xlink:to="lab_ameh_CancellationOfRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_e9d6a9d9-f1d0-415b-8384-89c444d3859f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorEMember_43d6641c-d631-4b7e-88fc-30c608bd8e50_terseLabel_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E</link:label>
    <link:label id="lab_ameh_PayorEMember_label_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E [Member]</link:label>
    <link:label id="lab_ameh_PayorEMember_documentation_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember" xlink:href="ameh-20220630.xsd#ameh_PayorEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorEMember" xlink:to="lab_ameh_PayorEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_04edc585-254a-4dd0-b48d-23cc09db65d2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_0db70eb1-9ba5-44af-9fa3-d6e5dc65efa7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_991754f2-a31a-4303-bac7-6205a65337a0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1920c150-9a85-43d6-80e5-3cce9ec8bbe6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_1e791f9b-8743-4465-9f14-3e01306c4fb9_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41eef082-4c34-4951-b7b0-04a8f8359431_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d218316-9853-4da1-8daf-7a33fa434d22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_6775fc34-a0d1-4c12-a01d-98c67bd726e9_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_191bcc4d-5470-4073-9893-08fcf8fe311a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_6e123056-617d-46d7-8509-2be57efc73cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e2756f6a-c8a0-4e31-bfa3-443fef93ba47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ab78605d-347f-45b5-b617-ed2063a6a5b7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a83919cd-e2da-4832-929e-557128c77752_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_e06bd50a-d732-4e62-8ab4-a8fda9f66417_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_45db61ab-22a6-4a1c-ad3b-051fdd1fd380_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_4252e99e-0948-454d-b33c-9121da8ebdc3_terseLabel_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities, maturity period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_label_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:href="ameh-20220630.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:to="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_06056f21-6c52-4fce-b1bc-dfa43ab28709_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c5c5700a-55fa-4e73-afe2-853debb84ab2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PmiocMember_e7de2437-ac52-464e-85fb-3b7e151a1430_terseLabel_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC</link:label>
    <link:label id="lab_ameh_PmiocMember_label_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember" xlink:href="ameh-20220630.xsd#ameh_PmiocMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PmiocMember" xlink:to="lab_ameh_PmiocMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20a294c6-9bf2-4172-9dd2-7052ff3f0779_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_e25426d7-5741-4d97-b8e6-4422ef00bebd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_2ba935a3-274f-470e-86e8-c16bcc426469_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f92a881a-f877-441b-ba2d-8e310fa5b5db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_c3b50032-2e77-4955-b09d-e2bc72a0fa52_terseLabel_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool surplus or deficits, settlement period after risk pool performance year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_label_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_documentation_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:href="ameh-20220630.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:to="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_084a1556-33c5-43a6-80ee-df646551f7d3_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_dec1153e-fa82-40c7-95b6-4bffb1e9afe5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_2525de99-30e3-4d48-bb80-ccd9fa40c034_terseLabel_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember" xlink:href="ameh-20220630.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmendedCreditAgreementMember" xlink:to="lab_ameh_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_1e045841-526f-4d36-ae44-cd6b3c9300a2_verboseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_label_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:to="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_becb79c4-67d4-4de2-9b93-e7be7f4fd18e_terseLabel_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_label_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC [Member]</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_documentation_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember" xlink:href="ameh-20220630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AMGPropertiesLLCMember" xlink:to="lab_ameh_AMGPropertiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_95f94349-ce95-44af-9d76-b4b3bf888f9b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_aafb7c1e-cd3c-4013-b321-1032d408be22_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_b21f59b9-6ba1-4862-9a58-9aa289dbc21f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4bd0f990-3e84-41ce-883e-b0b3323125d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_db70855a-9912-4857-b136-9e5d02867c59_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5c3de207-ac85-4d82-912f-1eded7967c8f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcShareholdersMember_d5777507-4c45-40f6-8b5e-0a5acb6214f0_terseLabel_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders</link:label>
    <link:label id="lab_ameh_ApcShareholdersMember_label_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember" xlink:href="ameh-20220630.xsd#ameh_ApcShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcShareholdersMember" xlink:to="lab_ameh_ApcShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_7dfa5070-876c-49d8-94eb-d098db9a5c3b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ad42dc05-2817-4a77-b0ea-b3f612dc6eee_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84ef9f28-0730-425d-8d4e-2c76ebb39ed0_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent_6997c19c-6d38-4c0c-8f8a-745a6a97f243_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to affiliate</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_3a42ad9e-5387-43e2-9a61-138f7e69520f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11eb3f3a-aa3c-4784-a4c2-1cbbaf8ff5d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_1bf8591b-63af-4b89-8c6b-5b2366bf920e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_13ac2bbb-7146-4e01-bce0-f09fdb44907d_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Par Value Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_8d09cbfc-0658-48b2-8050-f06d20b90e0b_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_dafabe7e-3036-4e60-a50b-283296663eec_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_c4c0cc68-dbb9-49b6-8890-1dfdb3f6db52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_678b8d1f-244d-45f7-8e3a-8f15bd97c722_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_621791a5-2eb6-4a45-a3a6-259d535fde11_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03c90d3f-af9a-4c0c-81bd-6ed407ddd2f5_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants received (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_b1109307-da01-4926-a016-0869f03533c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorAMember_4b7cc44b-e10a-4983-a568-f558b9325641_terseLabel_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A</link:label>
    <link:label id="lab_ameh_PayorAMember_label_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:label id="lab_ameh_PayorAMember_documentation_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember" xlink:href="ameh-20220630.xsd#ameh_PayorAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorAMember" xlink:to="lab_ameh_PayorAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_5a74ff73-e95b-4f1a-9b65-775c9367b803_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6e315322-5462-4d26-972a-75917a0e883f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_024261bd-c7d0-4a1f-bdeb-d6996bd6e6af_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of key financial ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_label_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:to="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_3682e6a8-3fca-4c26-aff7-88a08f1da334_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash - current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_A120HellmanLLCMember_8c162593-0533-4734-acff-b02d3bca8218_terseLabel_en-US" xlink:label="lab_ameh_A120HellmanLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">120 Hellman LLC</link:label>
    <link:label id="lab_ameh_A120HellmanLLCMember_label_en-US" xlink:label="lab_ameh_A120HellmanLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">120 Hellman LLC [Member]</link:label>
    <link:label id="lab_ameh_A120HellmanLLCMember_documentation_en-US" xlink:label="lab_ameh_A120HellmanLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">120 Hellman LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_A120HellmanLLCMember" xlink:href="ameh-20220630.xsd#ameh_A120HellmanLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_A120HellmanLLCMember" xlink:to="lab_ameh_A120HellmanLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_798b04e7-2517-4160-9e09-7f1d6ed6a4cb_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_34856cad-b40c-49f9-afbe-80949d2815eb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f2b69510-b4fb-4408-9a54-ed45f1a180ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40f35e4f-d674-4158-b834-76d0f1453edf_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_76c4007a-8606-49b6-92fe-a04af78f885e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_435c073b-9da5-47a9-a58b-70b853371a8f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b5c54722-f40d-48ab-b578-51d107ccd332_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_bbe8deb1-ded2-45d2-ac69-123c6f18e7dc_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6540a20c-062a-4034-9b32-878c6cb8c2cf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_188921f9-7efd-44fa-bd36-6e9069a6a2a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6cc55416-1a9d-470b-b523-420fd0961ec8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_251f2e43-fc7a-4f9e-80d6-dc95f712eb33_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback shares not issued to former shareholders (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Merger</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock issued during the period pursuant to merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6c52c245-d8f4-4b48-9f96-6b2a8d036db1_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SharesWarrantsRollForward_28131094-5356-4c07-a1ce-dd62dd2da790_terseLabel_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_label_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward" xlink:href="ameh-20220630.xsd#ameh_SharesWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharesWarrantsRollForward" xlink:to="lab_ameh_SharesWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d7ba271d-99ba-4709-93dd-42d1bf4ef12c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8d11bd1c-eb6e-4a1e-a987-8bc37ce9f1c7_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_cc613126-e63a-429c-a301-b7dfff8cea82_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_cfc8dcb0-8355-4773-8e8c-72206dd2d45c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ee4a064b-cf67-429d-a317-bdb4de64e11e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_26982ab7-8ed0-43cc-84b8-259e6ee25b6f_terseLabel_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_label_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable And Accrued Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:href="ameh-20220630.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:to="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_edecd242-e385-4d2e-8e01-7ec1b3b41f22_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_cfcde5ed-9d18-4621-a4a1-494d4ae84dc6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55eb4bd7-2202-4ffe-8ac0-17a47bc09788_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_387152f2-63e4-4ef2-9ed3-dc59f5ce7d56_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_47d018e6-e3b3-4514-97e7-2ba4b2bb3d4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6dabeb03-3ab6-4da0-89a5-e220b169ba60_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_57829cf6-f326-46bd-ae4c-097e3921a473_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_e1025e1e-da01-4a6d-9fe5-853dc5b389a9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f49ff482-9b49-4b1c-b0a3-d07380b27a0b_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized risk pool revenue</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_7b7f3dc6-8f83-41f3-a832-6f6729eb4017_totalLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts, net</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_386fc7b3-fdec-427f-9f0b-963fa35f5b1f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_40a9c68b-6ef0-473d-a00d-e747c79c17c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_53bf4e3d-caf3-463e-b6e6-bfe6e3ad82f7_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_ad4d81ae-4325-43ce-9a9e-0680e2106062_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_23519fbb-fdf9-4cdd-8143-59f8c270a5ff_terseLabel_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_documentation_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:href="ameh-20220630.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_4c648762-e38b-40f5-a217-a72a9134009d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9a926c68-d3b5-4a5c-a512-1345607e42d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_870b1195-43ec-4167-ab07-70d1a39fd3e6_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of non-controlling interest</link:label>
    <link:label id="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_label_en-US" xlink:label="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase from Sale of Non-Controlling Interest</link:label>
    <link:label id="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase from Sale of Non-Controlling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:href="ameh-20220630.xsd#ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:to="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_04ca20bd-ab09-4722-9176-7ad126e1a926_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_8a5ba9fa-4614-42e8-8f33-db6e3aa6f008_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cd7a2746-6fc4-4039-a035-1c0e9a5243ba_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of restricted stock to be recognized straight-line</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2aef909e-38b8-4de3-ad9a-5034c784d74b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_231725c4-d42d-43b1-a588-3bb2d4ccb6dc_terseLabel_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_label_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc. [Member]</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_documentation_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember" xlink:href="ameh-20220630.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FulgentGeneticsIncMember" xlink:to="lab_ameh_FulgentGeneticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_f9f6e332-1344-4fbc-a487-475426596a95_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2b7d87a4-b541-4e01-84b7-19abdb056701_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_dbc67068-8310-4c0b-93f4-88d217769ca7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OtherThirdPartiesMember_657a5b75-8c17-4d78-bc87-6230f2d82b25_terseLabel_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third parties</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_label_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third Parties [Member]</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_documentation_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:OtherThirdPartiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember" xlink:href="ameh-20220630.xsd#ameh_OtherThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherThirdPartiesMember" xlink:to="lab_ameh_OtherThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a81ebe77-3866-4855-8977-8304bdba309e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_82abf77d-d5a9-4e66-b081-08ccfacf67ac_terseLabel_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_label_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_documentation_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember" xlink:href="ameh-20220630.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APAMHMedicalCorporationMember" xlink:to="lab_ameh_APAMHMedicalCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a6e1908f-f22b-43dc-84cb-75ae158b4b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b8f6de99-304d-471a-89fc-8e58b2554ccd_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateLoanMember_e5b473c7-e882-4f0b-9479-5ca931a2b9c6_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan</link:label>
    <link:label id="lab_us-gaap_RealEstateLoanMember_label_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstateLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateLoanMember" xlink:to="lab_us-gaap_RealEstateLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_88330a04-79fc-4bc0-b94f-5671721e5321_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_384049c6-8555-4bbb-b4b3-8c0a09db903c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_74cae3fe-e9e8-497f-b63e-b7fa642d3639_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of business combinations:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_6db10446-120b-4369-9c61-65170884da24_terseLabel_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC</link:label>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_label_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:href="ameh-20220630.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:to="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_01374b17-5cf8-4e39-a8c7-ae132d49d161_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_c236ccaf-5b88-4bb9-88e5-5d5f729db2f3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_db23f9e8-fec0-477f-94c6-45060656c484_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_3e11a1ae-b009-4863-8d74-2a0e36b893b5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4f26db47-e123-4094-ba02-6f9ec2cfb276_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_60fe497c-5373-49ba-9c65-00f21c78d90d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_649ef449-eaa3-48ed-bc71-488e3dbee73c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_72934bab-6ec5-4f4b-9c09-af3093ea17d0_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_add2704c-82d3-4812-b1d2-38ef59ade0a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f58339f6-55c6-4eac-a49e-80f3909303a7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_d22a3e4a-ed63-4b4c-af82-bb8cf8e5f725_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable" xlink:href="ameh-20220630.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesTable" xlink:to="lab_ameh_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_b880081a-e76e-409f-8915-c8eb88cd99bb_terseLabel_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMPM Managed Care Contract</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_label_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_documentation_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:href="ameh-20220630.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:to="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_51897f2b-f583-4dd9-a7a3-907826629360_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_a2c6cf78-089a-4c08-97b2-bbceda4e8435_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_5e5bb7e3-e730-41be-86a7-d0d7013723b4_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_da9fefad-ce41-4591-821b-4ce7d46c8d7d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains recognized on equity securities sold</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_24111668-0458-4dbd-ac0c-1be976860ee1_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_d6ab0bcf-a28e-4fd0-af63-3753105fe704_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_26602514-6607-4601-8ce6-de9b98724da2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_14a33f56-800d-4290-875a-ae7cea380d85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_f45457db-1cda-40b7-a908-2068cb632357_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_43baecfd-15c4-4984-8696-8ea722f49d96_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_d2c1431f-fe56-4b16-8ee3-2b1259f13614_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_5a3d948c-0294-40eb-9ce3-10bc5674987f_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting common stock, within five years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_ecad4419-eab0-443e-b931-9db6f65538b0_terseLabel_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed term of amended and restated management and administrative services agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_label_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_documentation_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The initial fixed term of amended and restated management and administrative services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:href="ameh-20220630.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:to="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d9c84b58-64de-4175-bfb7-b0c89af2db8b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_6198b8c1-16e6-49a0-ad3f-b4616269cfd6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_490cc44e-840b-4d7f-9f7a-08b677f55652_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_8e47a990-af48-4c44-9fd8-63806a713696_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrant</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkRelationshipsMember_348ddf32-14e8-4c24-a037-1b9385594827_terseLabel_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network relationships</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_label_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships [Member]</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember" xlink:href="ameh-20220630.xsd#ameh_NetworkRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkRelationshipsMember" xlink:to="lab_ameh_NetworkRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_7c50318f-a453-4875-bde6-3fb7b546ecb5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_94b99b23-009b-4d53-b51b-8c4f22b88c3e_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_12bf5d5b-c88e-4d65-961d-052c9f8e01eb_terseLabel_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_label_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember" xlink:href="ameh-20220630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ZLLPartnersLLCMember" xlink:to="lab_ameh_ZLLPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_aba3bd55-de12-4068-b162-095c216bb056_terseLabel_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_label_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:href="ameh-20220630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:to="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a418c5d6-b6dc-41c7-a31b-cf72f5fc9fe9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5efc340b-27b2-41aa-8694-4600bf9535de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_663512d9-644a-4af1-9e00-a172a1377a25_negatedLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Cancelled In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, cancelled in period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8b01d043-77b4-4fbe-a58c-02212f015135_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2755931c-ca93-4819-9400-182dde1d4449_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_daf96b8b-b359-4a2d-ac1d-094fc92399ae_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_f87df38e-61c0-483a-bea7-4f8e68ef9822_terseLabel_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_label_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC [Member]</link:label>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_documentation_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember" xlink:href="ameh-20220630.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloSunLabsManagementLLCMember" xlink:to="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c647d1e6-3048-49eb-ab5f-6075e5c2ac28_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_e18d1561-2f8d-49b2-ac02-f7b8f3ad5716_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_da5d869c-60f1-43b0-a9d0-3fbbe98a4b88_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_ad6fdf42-94c7-466e-b967-1edd372f230d_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_8277304e-861d-4a02-9968-0182734d0a31_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_16d7d127-155e-44e8-8d99-a13c0b95a2a5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_bd080c61-1efa-4571-b5b9-c18a8d206f7a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_94f202e2-8d7b-4ce3-8614-6c547dcd42af_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to purchase membership interests</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20220630.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_75958c9d-34b6-4161-a95f-a43a6e794f32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_d493e2f0-4dac-408d-9d14-632596d4e64a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_a1097c36-d271-4ce3-962b-4c7975ca6fa4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_5f5249e0-57e2-4579-843f-468ecfcadb2d_terseLabel_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center</link:label>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_label_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:href="ameh-20220630.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:to="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_0279ae2f-b899-48e6-94cc-9a68f7168e21_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_82977503-8f9e-4943-8576-fddaa5c763e0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_75735f26-5622-425d-aa94-c4da4b11b425_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_3e33fb0e-abfe-4520-9a46-ca10275bbb5e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOInc.Member_c3ccc573-3b32-4f9d-b21d-55c965163599_terseLabel_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc.</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_label_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member" xlink:href="ameh-20220630.xsd#ameh_OneMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOInc.Member" xlink:to="lab_ameh_OneMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_d8910e05-edf5-4fb1-8042-eb72bfabf4f2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_551faba3-bb6d-4576-8f96-6161743e3554_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_222db424-1768-4512-b6e2-a213ad3dfc3c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_9b66dab4-e897-425f-8882-03f9af136f11_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_c790b416-8061-40c2-9cfd-a22f86b62c92_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable" xlink:href="ameh-20220630.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessTable" xlink:to="lab_ameh_DescriptionOfBusinessTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum_fc4079db-df12-4c91-94f0-ed265de75e21_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, cash flow to debt service ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow To Debt Service Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow To Debt Service Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_45fb0f4c-c493-4baa-995b-1a918826aa4b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables and Receivables-Related Parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_67edd07d-ae3c-422a-8557-60585838235d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2ae13662-036a-4ed3-b147-7010ac5ae876_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_b90f2734-9f94-44b7-a7ce-6065ce237a2e_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:to="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_070be150-5e60-4990-8e28-2090fbb92919_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,719,710 and 44,630,873 shares issued and outstanding, excluding 11,175,702 and 10,925,702 treasury shares, as of June&#160;30, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f72dea26-ad13-4a71-8e82-6b2c0daa48b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_50296a1a-3a27-4478-93e9-b34133c52150_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_dd1eaf26-9131-490f-9669-edc3a2a4e2c5_terseLabel_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC &#8211; Risk pool, capitation, claims payment</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_label_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_documentation_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:href="ameh-20220630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:to="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_7e75a0c2-7dbc-44fd-9219-01645d9a6932_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceLeaseCostsAbstract_c8a06120-701f-4ac8-87ca-b51f1fe774b6_terseLabel_en-US" xlink:label="lab_ameh_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Cost [Abstract]</link:label>
    <link:label id="lab_ameh_FinanceLeaseCostsAbstract_label_en-US" xlink:label="lab_ameh_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Costs [Abstract]</link:label>
    <link:label id="lab_ameh_FinanceLeaseCostsAbstract_documentation_en-US" xlink:label="lab_ameh_FinanceLeaseCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseCostsAbstract" xlink:href="ameh-20220630.xsd#ameh_FinanceLeaseCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceLeaseCostsAbstract" xlink:to="lab_ameh_FinanceLeaseCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_adbea2cd-0af5-4e02-98f7-9066363d5173_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, debt coverage ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_55759c21-51f5-410c-9493-cdba7516dbbf_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee2e3ba6-8dbd-4bf4-b940-865a200a3547_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5305400-b88a-4caf-a749-77765c0f68ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e742b3a0-4fa8-450b-8b27-ff9f571ba43d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ebb2708d-9552-4994-8be8-789eaafd1603_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ced74725-afaa-4de0-9303-eb14f2224154_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_1406fb50-9f53-42ce-963e-672adce3ead8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_2f1f78b9-aa69-4a3a-849f-d333de396257_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights exercised in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_77879254-0f93-4b70-8697-c5b4a0a9ee5c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_527087c9-9d43-4e17-a3c5-8371e71f9d0f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_4ea01b26-e2b6-475b-bd0e-39d6f802e6fd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0100132b-9e84-45f0-8345-034622f15309_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e80df34e-f576-4ceb-b3fe-6d14cfd6880f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_376adf39-a9ca-45f1-ae3e-e0baaae688a0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_b55cf9b1-f09c-4064-b513-cc8cbb245a59_terseLabel_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20220630.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ecdcd7a-80b5-4291-9fde-2f2d6802932e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2334a984-9c55-4a05-9ac2-19a36f26d1e8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_44190231-b1fd-4909-8820-7fe53eef9ad1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_99c18369-0ad5-4c32-8337-3de9aa55cfbf_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a29979e1-945a-42b5-8143-3088fc1a38bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5b560a14-1ce3-442c-a9f3-ba5cf3fbf409_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_9815ba88-6225-4759-a3c6-7920f984545d_verboseLabel_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in privately held entities</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_label_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Privately Held Entity That Does Not Report Net Asset Value</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_documentation_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of Investment in privately held entity that does not report net asset value per share .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:href="ameh-20220630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:to="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_5c8de37e-e6ca-4aa7-b465-1ffc82e6242d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired (see Note 3)</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_42b03f66-92c6-4a81-a7d3-31e1dbcbf873_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_cf961c8c-8660-48b7-804a-ce36c0127328_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_5c2510d0-c167-49b3-bd80-941741664a00_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ac8dd635-a396-47bb-baf1-ccb4f702a1fa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_338333c9-1875-40df-92f6-b31c58bb00eb_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20220630.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9fba58a2-22b8-421d-9477-a2e8ac5c86bc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_7584bc62-b94f-4257-8994-221d43d5aedb_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="ameh-20220630.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_edd53906-d36d-478a-b132-ef12053bb2d3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_8434b550-07ef-4a45-a651-9f031bc92e71_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_label_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:href="ameh-20220630.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:to="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_cff72c06-847b-496b-a831-0a750d7fbe34_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_716f87d7-8a2c-4ec5-a7d9-3ac2e55fdfb6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ae781ed9-e253-4f05-9823-a182b402f512_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_9bd9f768-6202-476d-873d-5b62448d2899_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, finance</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e1ce1aea-beca-4c91-b7bd-3675905be551_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price adjustment from Merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_99beda53-ca1e-4862-aa93-295fd2c0b8f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_6a4c9237-54ce-4b9d-b426-10d7af129e1f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5812e753-7216-4d90-8609-4223f2cd789b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_89f26076-86c3-4e95-97a4-c74ec985803d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_187226ed-ffad-45bb-bb81-ba4afcf294ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_7c2e7821-4937-4359-a818-4210584add2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.ArteagaMember_8b195c3d-ffbf-4a96-8faa-0c1832870f28_verboseLabel_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_label_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_documentation_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember" xlink:href="ameh-20220630.xsd#ameh_Dr.ArteagaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.ArteagaMember" xlink:to="lab_ameh_Dr.ArteagaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f1fcc48e-7403-4982-862b-5c0a213a8f73_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7f0f2a1d-3211-4502-93ca-144b9340a8d4_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_a4317af9-13cb-4555-b4e7-c3d4564f612c_verboseLabel_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_label_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_documentation_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:href="ameh-20220630.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:to="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_d965fa02-a6c2-4a6f-992a-43c1f95b4790_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service, net</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_82e2d309-afd1-47d3-9956-1b9ba30e361e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (losses) gains recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_9f90513b-38ce-4eb8-bab2-66e45b27fb4c_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments:</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_96a4f613-b594-4b3e-98c3-db82705e7e67_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_838bfd15-6897-4f75-a1bf-c8bb66f786df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_29d9445f-56ae-4f07-827f-5e822e019237_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_f9ee7f7e-f025-4f7d-8f06-00ca9588ce20_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_36eb913c-0cf4-4c67-821d-7903aa6c198a_verboseLabel_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation, net</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_label_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Capitation Revenue [Member]</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_documentation_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_HealthCareCapitationRevenueMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember" xlink:href="ameh-20220630.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthCareCapitationRevenueMember" xlink:to="lab_ameh_HealthCareCapitationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareIncMember_f5e222cf-0e50-4b32-a61c-093b5f2cab2c_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc</link:label>
    <link:label id="lab_ameh_UniversalCareIncMember_label_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember" xlink:href="ameh-20220630.xsd#ameh_UniversalCareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareIncMember" xlink:to="lab_ameh_UniversalCareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_67f76fbb-c24a-4c8e-bcdf-ab62d567e054_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_e1e72109-f272-4022-b460-ce0705e748fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliates</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_f9a63f80-3e36-4c18-8cbf-c104dd3e2e3d_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated rate of note of loan receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableStatedInterestRate" xlink:to="lab_ameh_FinanceReceivableStatedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_0df8b2fb-6efd-41b9-8f8a-38d063aaf3f5_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_835bfae8-ceb6-407e-8d46-fd3bfc3e03d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_61a7a3f9-e29c-4d27-bb16-b8167327f4a0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_50ac3dfb-fae6-4ff5-b0d8-8be1cea413c0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_9dcbfa66-24dc-4d5f-abcd-db81a5beccf6_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_JadeHealthCareMedicalGroupIncMember_d5d24017-4a09-4c38-a7b1-698cad7d95f3_terseLabel_en-US" xlink:label="lab_ameh_JadeHealthCareMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jade Health Care Medical Group, Inc.</link:label>
    <link:label id="lab_ameh_JadeHealthCareMedicalGroupIncMember_label_en-US" xlink:label="lab_ameh_JadeHealthCareMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jade Health Care Medical Group, Inc. [Member]</link:label>
    <link:label id="lab_ameh_JadeHealthCareMedicalGroupIncMember_documentation_en-US" xlink:label="lab_ameh_JadeHealthCareMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jade Health Care Medical Group, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_JadeHealthCareMedicalGroupIncMember" xlink:href="ameh-20220630.xsd#ameh_JadeHealthCareMedicalGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_JadeHealthCareMedicalGroupIncMember" xlink:to="lab_ameh_JadeHealthCareMedicalGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PreferredBankMember_0e2e0483-3236-4942-b6f4-a4aab021ab0c_terseLabel_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank</link:label>
    <link:label id="lab_ameh_PreferredBankMember_label_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember" xlink:href="ameh-20220630.xsd#ameh_PreferredBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PreferredBankMember" xlink:to="lab_ameh_PreferredBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_7723f039-0d63-41f0-82d3-6634d17be97b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_ace05415-94d8-4b99-8442-36acbc2a0101_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:href="ameh-20220630.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_4b57feae-faa1-4749-8d41-9c4c06d4aa5a_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount deposit accounts exceeded FDIC insured limit</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb213524-b231-433f-b160-3f933cbdba49_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4bab434c-1fd7-4704-8eeb-dcd372133e30_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_77b330ac-7c19-4164-a28f-8353757c8ba8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmgIncMember_ddb45a56-dbbd-431c-92db-24a3c9abd7b6_terseLabel_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc</link:label>
    <link:label id="lab_ameh_AmgIncMember_label_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember" xlink:href="ameh-20220630.xsd#ameh_AmgIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmgIncMember" xlink:to="lab_ameh_AmgIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_00ebcc56-05cd-47cb-8954-d2a756ac7851_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the six months ended June 30, 2022)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_20c54101-e4bc-41ed-9a76-8dded425b86e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1711e329-83e3-4c72-80f9-4680cfae7c3b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e322bf0b-b9d8-44b1-8977-09f5bfd720aa_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a953b6f5-5a8e-40eb-8f51-09ccadbdfde1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_9ee2050a-f30e-4ac4-a0f2-008ce1ffeb4e_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_ccabcf27-9393-49db-85f4-42ca7c92ee46_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities, Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_6d72cba6-eb35-4641-ba23-0d1a98ebc575_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_1d287b9d-476c-43d2-bc4d-b097cfa3cd68_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from repayment of loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Long-Term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_49091701-d86d-4418-aacb-0a007ce40484_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_96e7cf64-d84f-4077-9abd-6ccc5f2db221_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_44c137ec-76a8-4de2-a83e-98d60dd97a35_terseLabel_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_label_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC [Member]</link:label>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_documentation_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember" xlink:href="ameh-20220630.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CAIPAMSOLLCMember" xlink:to="lab_ameh_CAIPAMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MemberRelationshipsMember_12da7228-c920-4bbf-aed8-ca5dbf7ed9b5_terseLabel_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member relationships</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_label_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships [Member]</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember" xlink:href="ameh-20220630.xsd#ameh_MemberRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MemberRelationshipsMember" xlink:to="lab_ameh_MemberRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_86a5ab59-3d2d-46cf-bad9-43dbd1c0599b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_7cb9c3e8-f6f0-40e5-a586-013a7dd76b9c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_32f25f23-43e6-4bc5-b7e9-952bef326d2a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_b4f78c23-bc14-40ed-b953-6cc5ef3cb36b_verboseLabel_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Receivables &#8211; Related Parties, and Loan Receivable - Related Party</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_label_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables And Related parties Receivables Policy Text Block [Policy Text Block]</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Receivables and receivables from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:href="ameh-20220630.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:to="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_82423246-6178-482c-ae9c-87a3c596318c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_4afa1e47-e046-4d2c-bd37-0fa5bac65586_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_9e3a5130-a88f-463e-89b8-8cfefdc93249_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, cash flow coverage ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1cce7c5b-0951-4dd4-809e-f2e22d56cd02_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_1a43fe02-ca4b-4d8e-b64d-29139f461df6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_773617e7-5cda-4b5c-b24d-8b8bd577a46c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_7c44ed80-96e3-4674-b585-ee2262fb15d3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_27572711-ac9d-449f-aa48-caef7caa1749_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_c3310282-bc49-47c2-8537-3a5a0575a054_terseLabel_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders and Officers</link:label>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_label_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders And Officers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember" xlink:href="ameh-20220630.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareholdersAndOfficersMember" xlink:to="lab_ameh_ShareholdersAndOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_2c84652e-93dd-4f3f-9b43-db7df38bcfab_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable &#8211; related party</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_8f60a56f-4831-40e7-be71-343ce45fd505_verboseLabel_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_7d3ebbac-341f-4c07-83fc-06591f53f25c_verboseLabel_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care</link:label>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_label_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember" xlink:href="ameh-20220630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountableHealthCareIPAMember" xlink:to="lab_ameh_AccountableHealthCareIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_b929f465-f4da-4301-a43d-8b3dab7db0b5_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_7d82da51-4b61-4da7-b612-32e8fc1f63ad_terseLabel_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from consolidation of VIE</link:label>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_label_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Cash Received from Consolidation of Variable Interest Entity</link:label>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_documentation_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Cash Received from Consolidation of Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:href="ameh-20220630.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:to="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_e42e8211-41d5-42bd-b4f6-b0b9c9e2e459_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_3004ce53-8978-4e9c-9790-0650a3a153df_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c504dd01-75e9-4e83-abd3-3047a7801e17_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_18b1bc57-3487-49f8-8582-ad264fb7514f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_bf21118e-522e-4fd0-90b4-c0fbc5cc6d0c_verboseLabel_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_label_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:href="ameh-20220630.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:to="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_e4a55740-7549-4110-bf36-2235a6adbd66_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember" xlink:href="ameh-20220630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementMember" xlink:to="lab_ameh_NetworkMedicalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1e5c380d-e3ef-48c7-9e67-3dbe70a57e52_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c8cfc7fe-1746-4135-990d-8c5639ff8c41_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a3fd6c1c-bb5a-4669-a3a8-106c1ca2924c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ArroyoVistaMember_b18609c1-648e-4dc1-ba93-d23aea04e430_terseLabel_en-US" xlink:label="lab_ameh_ArroyoVistaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arroyo Vista</link:label>
    <link:label id="lab_ameh_ArroyoVistaMember_label_en-US" xlink:label="lab_ameh_ArroyoVistaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arroyo Vista [Member]</link:label>
    <link:label id="lab_ameh_ArroyoVistaMember_documentation_en-US" xlink:label="lab_ameh_ArroyoVistaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arroyo Vista</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ArroyoVistaMember" xlink:href="ameh-20220630.xsd#ameh_ArroyoVistaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ArroyoVistaMember" xlink:to="lab_ameh_ArroyoVistaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_e991cee5-db19-4a7e-865c-457e18ac5525_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_795beb3e-d20a-4bbe-a12a-31fd8576c2cd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6e45e626-8067-49bb-9eb2-fceb0513efc0_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_725862e8-f3f8-467e-b2d3-e446f7848b97_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c4ea6469-b7e0-46a4-a85f-b5902d93503b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_d29b5c4e-d0d8-47b4-8cc8-6fa4cfe56904_negatedLabel_en-US" xlink:label="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss (gain) from investment in equity securities</link:label>
    <link:label id="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_label_en-US" xlink:label="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Gain) Loss from Investment in Equity Securities</link:label>
    <link:label id="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_documentation_en-US" xlink:label="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Gain) Loss from Investment in Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:href="ameh-20220630.xsd#ameh_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:to="lab_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0cde5e07-107f-40d1-8eda-f32d73411c8d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_00143ae5-d595-4c2a-b1e9-35fabbcc2eba_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_61133776-09cc-4c7c-88c5-e7d8aa984a4a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_afbd961d-1506-409b-ab01-429e127acde5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_db896762-ee59-432a-ace1-73d9616c41e3_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:href="ameh-20220630.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:to="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2c3094c8-fc40-4e57-bbe6-dc3629671c79_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_16b49d9b-cd1a-4824-b285-c1d0a5c50e52_terseLabel_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:href="ameh-20220630.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_c5d39dbb-7129-4f28-8409-6c53be8b40a5_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio, annual decrease</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareTable_aaecbf9d-2212-4ea9-90e0-dc916497ab05_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_label_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareTable" xlink:to="lab_ameh_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4859721a-218f-4b49-ace2-9aac867c7e07_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_99a1496e-481b-4830-bdb9-0fc38126c16f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_96195216-823d-42b2-ac85-c5b431a6ed39_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) recognized on equity securities held at end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_10926fab-82eb-486e-8180-cea9925c1f27_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contributions to Revenue and Receivables by Payor</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_066277a0-6e18-48b0-a1e3-6e7a901f18ae_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_b77786fb-b031-43e3-a610-7009c7bd418c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_c58104e8-cbd5-4b84-b6be-6641d2cba96b_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_be90100a-5f83-478b-a117-0bc1d1b19ae1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_d9933886-8198-4cab-b77c-abdc042a45c7_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares by non-controlling interest (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Noncontrolling Interest</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_067a5f08-0ea8-4d42-815c-c07753b109e0_terseLabel_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20220630.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_5d0fba8e-8188-4273-9b4f-682f1207c4b0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_3eb7186a-6dc3-4da2-a165-7802a460af04_terseLabel_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_label_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_documentation_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember" xlink:href="ameh-20220630.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Pacific6EnterprisesMember" xlink:to="lab_ameh_Pacific6EnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_47ff9a3d-e533-4e20-a638-1c1f13ef8492_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest purchase obligation, noncurrent</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_label_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:href="ameh-20220630.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:to="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_80094fa3-de4e-4b55-ae03-6b976921e146_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_afbbb96f-5c2b-43d4-8dd4-eabd3d03fc97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_94e554c5-2f06-4036-83f9-a426d4738139_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_dbc20a06-8955-4a6c-bb9a-5a3a48322150_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_1cc29298-a902-4481-afac-b2c6ff9d8428_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Other Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_a25ecb3f-a24c-4733-882b-a572fcdc711d_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_d95331b5-c13e-411b-9b44-52bbad734e0d_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6136dea3-a6e6-46f0-a473-a8a90039b3a1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_9be6d1fe-c460-44c6-8a23-ce20cd13c150_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual agent fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ddb704ec-ff52-4c61-9c45-7dae82805d72_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_87ea46b1-d8df-402a-8247-56a2cb522a63_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_80a55bdf-7cf6-44aa-8a35-c7f4077cabdc_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period shares of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents number of share issued exercise of option and warrants during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_841130b2-8530-49e5-81d3-febe60df0a67_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81af076c-5c5e-48c8-91e2-cdc13d039ec6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19ef1588-d2ad-4402-a2ce-da0b8065108a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_14dc6984-9c90-4042-b6ee-3b4c9721ac6f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_8a858fa3-f29a-4a24-964e-19a4ffffacc5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_ba14a9cc-8963-4273-81b2-80aae2b1da28_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_019aed6a-86d2-4d6c-bd0c-e7ffc50e3351_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_c7c222e8-4849-43dd-95bf-527d71ad521b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_14b8ab17-7ac0-420d-a293-7e3da40b0e23_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_de6de7fc-10ed-4538-ba61-b8716c6eb70a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_cb848994-5e86-45c1-bc54-dfa67ee68197_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_89f8398c-4fd8-449a-a40d-a97fd592fec3_terseLabel_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract" xlink:href="ameh-20220630.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalCareCostsAbstract" xlink:to="lab_ameh_MedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_5ab494ce-febe-479b-af3c-8dda7e40b2d4_terseLabel_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_label_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group [Member]</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_documentation_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:href="ameh-20220630.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:to="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_f46f2a65-275d-4fef-8fc2-5f9fee2a024e_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_ddc55a76-957e-42a9-8774-04836ec4d008_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7df0d440-2ebf-4565-9605-aae01679631b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_24d6bf78-06c1-4283-8d71-412997c3beaa_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4083649c-632c-4033-8b54-7662e4ebf470_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_95fb982a-d73a-472b-84b5-88c5ff1b9bd3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investment &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_d3ea9d3c-aca3-46a1-aa36-b32250597cbd_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_d330c6a6-853a-4b50-b834-aecc54d5f4aa_verboseLabel_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="ameh-20220630.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_4f298cde-15bc-400e-9a58-58acaa4c6601_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_dfbe74c9-3b05-4953-9d5a-e8228f92bf4c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_833373ce-26d3-4402-b279-2eaa97c8a2f0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ad18a95a-0f8b-4f37-b2af-0eac42a16fd7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_63717b72-dec1-401e-9cd0-30f8f558c9bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_aef6c245-1cc3-44da-a2b9-9e3802ad83f7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Income) loss from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_575a52a6-7563-4e2b-8ee4-b4198428aec8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Income (Loss)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1c35a47f-6d89-465f-9e18-a79873fc3d23_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_18e8ede9-d878-4154-87eb-c5c9585e127b_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward" xlink:to="lab_ameh_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a164f86b-6341-4181-8a64-a7394918edd7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_797120a8-5c0c-4b56-b418-92f42e842bcf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4e04b7b4-3b62-4ece-97b3-6175713dc0ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_498601d7-c0a5-4b0f-990d-295a19207496_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_1d90d8cf-a733-44db-9143-5aa20abf9a1f_terseLabel_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_label_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_documentation_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:href="ameh-20220630.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:to="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_58144e3c-cd70-4315-b2b2-6c44d47080bf_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_aee32dd5-9fd8-47be-b645-7a9cfbf9e885_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CreditAgreementMember_dfe38254-bc08-4993-a709-1fdecd10a493_terseLabel_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_label_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember" xlink:href="ameh-20220630.xsd#ameh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CreditAgreementMember" xlink:to="lab_ameh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_67a6d2f0-bd62-424a-b56f-b2d85db98206_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d853fafc-b80e-4113-8da7-874bfad83bb1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_4900bf50-bc19-41f0-91bb-9bb0f5a99588_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b44ca0e2-7d0f-4bb2-94a2-15d579c4a243_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_4cb81aa7-7d79-4f40-b714-3be25b792d62_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6a9f690b-3d74-47f3-9767-6bb206bea9ed_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_1696c9bd-8791-444a-b032-3fe3658330b5_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Secured Promissory Note</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_467bdd22-02a8-4bba-a466-d6c327a90072_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_6c6cb85e-7cbf-4aee-82df-9adde5bb0760_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_4a3aca7b-6b81-404c-90a5-914547dd6d80_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercisable (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercisable</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:to="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d4ee6cc2-cc99-4f93-969f-e62a40ed0e7b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7ca48101-70d2-400b-b6cf-92a310e5e256_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum loan availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_8711c6c2-226b-4107-a6d2-536eb4b73d5a_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementFeeExpense_e19bf31d-8c38-4a62-81c8-c8c0228c3613_negatedLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0e75479f-3fc2-4f80-90a0-a6339a12f938_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3384b61d-bf77-4b89-9098-a7dd54ffc8cf_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_06ee1d60-537a-4181-9269-01079eb78e3b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on loans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_b3ed8961-3747-4822-aecc-fe7aef4477f5_terseLabel_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_label_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units [Member]</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_documentation_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember" xlink:href="ameh-20220630.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockAwardsAndUnitsMember" xlink:to="lab_ameh_StockAwardsAndUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e33079e3-928f-42ef-ba5a-434477ac0d94_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_c17d96df-8c4e-46c0-9716-33fec0643a9f_terseLabel_en-US" xlink:label="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orma Health, Inc., and Provider Growth Solutions LLC</link:label>
    <link:label id="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_label_en-US" xlink:label="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orma Health, Inc., and Provider Growth Solutions LLC [Member]</link:label>
    <link:label id="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_documentation_en-US" xlink:label="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orma Health, Inc., and Provider Growth Solutions LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:href="ameh-20220630.xsd#ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:to="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_e117bef7-8ca7-4c55-a80c-a1d5485d83c7_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsContribution" xlink:to="lab_ameh_EquityMethodInvestmentsContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ebdc8757-f645-4d59-8313-ed0250a3b28e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_6fbeabe2-29f1-4964-8b2b-188f52d61eab_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared included in dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c73e0b75-b0a4-4a87-9d58-2ed88f42cba3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Apollo Medical Holdings, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_366ec635-569a-4e4d-bece-8d512c585337_terseLabel_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc</link:label>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:href="ameh-20220630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:to="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_20e20ade-b98d-4ba3-a25a-476a0906d36b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_60e5002b-2622-4aa7-94d5-e952ae255cad_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the six months ended June&#160;30, 2022)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d4586e73-8104-4609-82a3-3588f55fa73f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Commitments of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DmgMember_ba678db8-ea50-49c7-8cf7-970d32a52ae9_terseLabel_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG</link:label>
    <link:label id="lab_ameh_DmgMember_label_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember" xlink:href="ameh-20220630.xsd#ameh_DmgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DmgMember" xlink:to="lab_ameh_DmgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_31be2f73-5df0-46a1-bde0-8b4c00971ea3_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_5cbba7dc-cf9b-4227-a031-ac186059d02e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_cb0ebe93-abb6-4b55-8fe4-1de6d7c9b5b1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_dc00e7ae-72e7-478c-b499-dc739cefe472_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests acquired (in dollars per share)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_dce11b53-3ef5-4314-a358-5a78c8aca031_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_29e02f85-c9c3-4a50-bfd5-d5d339a83b46_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_34226240-3ca9-488d-9230-cad1a204d622_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire common stock and warrants</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Common Stock And Warrants</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Common Stock And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:href="ameh-20220630.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:to="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1ef5a6ed-a473-4f65-b3cb-17157072c396_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_85f39530-d6c2-4789-b4eb-6258cfc59b67_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_24efaa15-e163-4f75-88aa-cd43a3215035_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the six months ended June&#160;30, 2022)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_13c1f91e-95e7-4eb6-9294-722e72dbc368_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MediPortalLLCMember_c6464dd5-f6c6-4956-b95a-6184a51cad67_terseLabel_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC</link:label>
    <link:label id="lab_ameh_MediPortalLLCMember_label_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember" xlink:href="ameh-20220630.xsd#ameh_MediPortalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MediPortalLLCMember" xlink:to="lab_ameh_MediPortalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_77fd8eb3-73f9-491e-a914-21f3ee223f7b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_54e90c00-9b50-4646-a386-bafd3f707854_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Included in the Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_5d7a304d-6000-4bb7-8fda-24f65d4d9384_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest purchase obligation, period to purchase</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_label_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:href="ameh-20220630.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:to="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOtherMember_6277ca86-fae2-4073-b87e-ab2cbee6ed6c_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool settlements and incentives</link:label>
    <link:label id="lab_us-gaap_HealthCareOtherMember_label_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOtherMember" xlink:to="lab_us-gaap_HealthCareOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_48899810-3990-441f-ba53-b35500e2bb58_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights forfeited during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_56e84d26-c1b4-494f-bbab-523ad2af4aee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_058a05dc-669e-497c-a2d6-7525de332db9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_e9242f50-3097-459a-86e8-1686933de62a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_0ca63675-9bb5-4bc7-9079-6d66206ef845_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_8d86e569-9ef3-4933-aae8-3e9b893e9363_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights forfeited in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ManagementContractsMember_e19c0ad8-d495-42f4-b852-243b9f9c16a7_verboseLabel_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management contracts</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_label_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts [Member]</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_documentation_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember" xlink:href="ameh-20220630.xsd#ameh_ManagementContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ManagementContractsMember" xlink:to="lab_ameh_ManagementContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_bbfd4f97-a558-405a-9938-73261f67d220_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aec84cbc-a2d8-4e2c-abdd-a1206b996eb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_0a1b98f4-9f25-4d03-84a7-b6e9577fde1d_terseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates &#8211; IPA Line of Business</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_f36915a4-dbb5-4e6f-af00-12acda97fba5_verboseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_label_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:href="ameh-20220630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:to="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_bcd32ea9-125e-4b0a-a0cf-12962747ab33_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_cddc76c7-1c3b-4397-9f6b-4f5b3f4f4b4e_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_cb047e4b-db84-42bd-a26e-4df3597f836e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8240f925-17f2-45c9-a714-5fa648a60e3f_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliates_cad071ef-8c51-4243-bab5-23ee04a04ceb_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from affiliates</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliates_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliates" xlink:to="lab_us-gaap_DueFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d6d044dc-b399-43fa-bddd-3c20ef951ed6_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3fe794dd-0073-4424-9f83-274647de65b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, carrying amount, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_c60da35c-438b-4d6f-ad7b-9f3f28ff99d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, carrying amount, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HSMSOMember_68464d87-8c85-4359-b64c-5f1951572467_verboseLabel_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO</link:label>
    <link:label id="lab_ameh_HSMSOMember_label_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO [Member]</link:label>
    <link:label id="lab_ameh_HSMSOMember_documentation_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_HSMSO Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember" xlink:href="ameh-20220630.xsd#ameh_HSMSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HSMSOMember" xlink:to="lab_ameh_HSMSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c1639a9c-2148-4156-b1bc-de4108db20b6_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_57856935-796d-4cd5-ae3d-cdde10175adc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_736a3fce-882b-4c8c-916a-0eb6a04aa814_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:href="ameh-20220630.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_7677c048-de66-4d63-b461-cdf1673a944a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_510e073b-e8bc-45e8-ba6f-4e34cb30be77_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution from investment - equity method</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1627316e-b908-4c6e-9902-85bb4a12395d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Bank Loans, and Lines of Credit</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AurionMember_8137cbdf-eccc-43b2-bb4a-f05b88ce6c40_verboseLabel_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion</link:label>
    <link:label id="lab_ameh_AurionMember_label_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion [Member]</link:label>
    <link:label id="lab_ameh_AurionMember_documentation_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Aurion Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember" xlink:href="ameh-20220630.xsd#ameh_AurionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AurionMember" xlink:to="lab_ameh_AurionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_95eb4f4d-86ad-430f-9354-dce7a04f1b3f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e36696c6-b785-41e2-95ad-6994f75b2bdf_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_925e3376-e71e-40a5-8f47-b1ace0a596c3_terseLabel_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_79afc4cc-dc9a-46d3-bd88-f786533bfedd_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of family practice clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_label_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Family Practice Clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_documentation_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Family Practice Clinics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics" xlink:href="ameh-20220630.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFamilyPracticeClinics" xlink:to="lab_ameh_NumberOfFamilyPracticeClinics" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d92671c6-f91a-4cc8-8f7c-d9e9150fcd3a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_bd3e5c97-31e8-4e12-aa8d-3741c71c5e7c_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_bcd4c870-15d4-4725-90db-52080c7d19d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_6d72fa31-004c-4c06-8672-6ac5b58e4549_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b21ccc21-c5ab-466e-9b1a-e6c1fadf8b7a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_81beda45-cc50-499f-9c66-90f3a5939338_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_024e891e-d44c-4da9-96e1-6afcb74c3f94_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_42431e4a-6ffa-4255-b057-95089de7a3a8_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_16e8384c-b296-4eb4-9fcb-a154beecce29_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineEquityAbstract_bfb20aa7-d931-4c4c-a48d-834d8f880d68_verboseLabel_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine equity</link:label>
    <link:label id="lab_ameh_MezzanineEquityAbstract_label_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEZZANINE EQUITY [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract" xlink:href="ameh-20220630.xsd#ameh_MezzanineEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineEquityAbstract" xlink:to="lab_ameh_MezzanineEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_5778dd3f-708b-4ce1-b5d4-8c2a483345cf_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_label_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Accounts Payable Current</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_documentation_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:href="ameh-20220630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:to="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_40972d29-2fc5-46b3-8e68-797249e64126_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_71e9bc11-664f-40c1-8594-f570cbdb184b_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_0ebe272b-2795-4892-a131-3bbc8411121e_terseLabel_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc</link:label>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_label_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember" xlink:href="ameh-20220630.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MaverickMedicalGroupIncMember" xlink:to="lab_ameh_MaverickMedicalGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1ffd0de2-a662-47e6-bad6-3169d5f7c22d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_5dc53326-6a5a-4d11-8f0c-c5a7c5bd803e_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated interest coverage ratio (not less than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_552ac364-5979-47a0-b176-a1513d8492dc_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_42038ccd-d95d-46ac-891b-6a867e3bf189_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_53fbd825-2070-40fc-8dea-59f44f626de6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_b5881ff8-4539-440e-83de-fd3f7e13921a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorCMember_f1bc120e-7f50-43e6-b610-14757000597b_terseLabel_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C</link:label>
    <link:label id="lab_ameh_PayorCMember_label_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:label id="lab_ameh_PayorCMember_documentation_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember" xlink:href="ameh-20220630.xsd#ameh_PayorCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorCMember" xlink:to="lab_ameh_PayorCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6648f449-70f3-4393-92d9-bdb1f629754e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_2350b278-67ee-4888-a618-abf7470bbc8e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_1f3e7682-d7a6-422b-88a4-ff75cd866b7b_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:href="ameh-20220630.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e8703a05-cc14-49be-8036-ad0940314088_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_a378575c-79f1-48f7-a300-3007fe8915ea_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_b56a9e4f-7f66-40e9-91c9-e05d1188c154_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_200a7a36-0a36-449a-a17b-a6eb6ea1c2d0_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_058b5ee2-ceb4-4db3-bd79-27f8f72a9b84_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_dbd1f3d1-c7cd-4312-a6d8-43c9b59ef009_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_ea6de0c4-c2ca-45f6-9de7-bcbea32cd74e_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_3b731abb-e859-4d80-85f3-c59954fa6586_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_95f843b1-3e05-411c-a98e-749e7f651cd0_terseLabel_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of non-controlling interest</link:label>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_label_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Noncontrolling Interest</link:label>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:href="ameh-20220630.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:to="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_8a5567bf-6322-40f9-98cf-d26cab9ca4e2_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent on performance (shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_950985b7-d2b5-40b2-aca5-94f526febdb5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae2312b2-8787-4409-9bc3-be3a8b0e4695_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AHMCMember_26a7307f-18e2-4b58-8619-1ec4279bc5e7_terseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_079193e6-30f0-444e-880c-0c153120e829_verboseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_label_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember" xlink:href="ameh-20220630.xsd#ameh_AHMCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AHMCMember" xlink:to="lab_ameh_AHMCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_52907486-bd07-4ffd-b4a1-5112217c55c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_ce4bb0e4-5fab-4935-942a-4106b05bc9f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EmployeesMember_1fca58a7-3dfe-4697-8923-5fae6ee7771d_terseLabel_en-US" xlink:label="lab_ameh_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_ameh_EmployeesMember_label_en-US" xlink:label="lab_ameh_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_ameh_EmployeesMember_documentation_en-US" xlink:label="lab_ameh_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EmployeesMember" xlink:href="ameh-20220630.xsd#ameh_EmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EmployeesMember" xlink:to="lab_ameh_EmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e3d067e4-fcaa-41e4-99c5-47c9c7534c4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased by related party</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_1f54099a-914f-4020-a934-1f5c55bcdc8a_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_label_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableTermOfReceivable" xlink:to="lab_ameh_FinanceReceivableTermOfReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_ad39f188-6379-41a6-8b5f-8702ac585647_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscriber relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3369bfd5-0071-4f8e-9547-745f41f47b26_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_90ac0e42-013e-4d48-87b5-009a7734175b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_883f7717-16a4-48bc-b37d-8f0c58e54e74_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_688851db-a45e-4b42-bca3-229c1d208f9d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_5fb815ee-4558-4623-bb61-bb4c04372207_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gain) loss on interest rate swaps</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_c83f0648-0bb2-4a6f-8c18-c0a375b6a2be_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_dde580b1-a5cc-4cbb-abdb-00018c988b7b_terseLabel_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc.</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_label_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_documentation_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:href="ameh-20220630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:to="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_d0da552f-6507-4240-b7f4-fa3e8fcecb41_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_978daa35-a2f5-4065-ad46-23595eb19bb8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_ab3af97b-e81f-40b1-9541-e773b4d3d566_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIEs)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_650c95e4-ee32-44bc-af83-887035a4c8c5_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related investment balance</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCMember_4355719a-de4c-428f-b78a-8759765fa807_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember" xlink:href="ameh-20220630.xsd#ameh_OneMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCMember" xlink:to="lab_ameh_OneMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_abf78c78-df99-4fd7-8e44-303525c9c823_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_7ed4d668-9be7-4b52-b39b-024ff975aef0_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests purchased (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_964cf500-e142-4525-a133-27875d9aaa2b_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="ameh-20220630.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_5e5a4fb3-6c46-4e01-ab48-e9bf7711b855_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_0463b805-40eb-4a21-a0a4-4c26500156aa_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, leverage ratio, adjusted maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7ef839e2-d899-4451-8919-4766fc04a0cd_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ed246ee5-e2a3-4039-b2c7-3f529e1627c1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise&#160;Price&#160;Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_f85623bb-7ffe-4e37-9582-96c6c718239f_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_4c2e8e1b-ee22-4f9b-8526-30c32ed4ce3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Carrying Value of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_f5d15da4-2702-4afa-8b3e-8e46ed196332_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LoanReceivableTextBlock_6f006a57-1ed3-410e-bbab-5f751ec90e23_verboseLabel_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable and Loan Receivable &#8211; Related Parties</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_label_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable [Text Block]</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_documentation_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock" xlink:href="ameh-20220630.xsd#ameh_LoanReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableTextBlock" xlink:to="lab_ameh_LoanReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3e1de946-882c-4dd3-a534-14ffcf3b183b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumenLLCMember_810a49ac-0119-4c4c-aa36-de06222260a7_terseLabel_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC</link:label>
    <link:label id="lab_ameh_NumenLLCMember_label_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember" xlink:href="ameh-20220630.xsd#ameh_NumenLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumenLLCMember" xlink:to="lab_ameh_NumenLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_83d47c16-cfc2-4fda-bab5-dea714d2d71a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a8679fb0-f9e8-46f6-bfa8-3211be7ebab0_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_797cc880-9ae9-469a-abf4-b58ea9f9ff7c_terseLabel_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour" xlink:href="ameh-20220630.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LongTermDebtMaturityAfterYearFour" xlink:to="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_70542944-b58c-4bfc-9f2f-1610a1a4e28f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity, parent</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_c8fd62b0-5335-4d57-9f26-5f4df18cbd45_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:href="ameh-20220630.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:to="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_64aa4865-c89f-4d5a-a849-41db36cb87f3_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board members</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c71e9f86-43fe-4477-90f1-904dddc2b805_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed asset obtained in exchange for finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_43179432-2b95-4133-af00-48824a4e2b94_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SCHCMember_d54973c8-3307-4b15-9beb-b9e4452d2d55_terseLabel_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC</link:label>
    <link:label id="lab_ameh_SCHCMember_label_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:label id="lab_ameh_SCHCMember_documentation_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember" xlink:href="ameh-20220630.xsd#ameh_SCHCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SCHCMember" xlink:to="lab_ameh_SCHCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_a5de0224-3442-4130-808b-4cdf54f7e0a4_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of loan</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LmaMember_0517f91c-5ba2-4aeb-8d33-ec038b3404b0_terseLabel_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA</link:label>
    <link:label id="lab_ameh_LmaMember_label_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember" xlink:href="ameh-20220630.xsd#ameh_LmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LmaMember" xlink:to="lab_ameh_LmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75b6db0c-7cde-4460-98a7-8225a416daf7_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_13428631-806d-4a57-ba7d-ec1c2b1eefc9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_85070c1a-11bb-4333-9ff8-5fed80cb1ba3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_03996769-fcc0-4fdc-b165-b4116938e1fb_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_5075f918-8f11-4223-8488-33a04485b3ec_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost, net</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_71ed8428-0d09-4941-91fe-ceb794fc4414_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_5a389afa-bf93-4859-a33c-8ac398c77519_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related to Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_ff97d0d0-e448-44fc-ba20-13ba35100da3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_972d5b4b-4796-4ff3-bb46-16af31ada561_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APCMG contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f1cca78d-f29a-48fe-ae5e-0b7cfcac6fc5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_7bd5a767-9bcc-46af-b979-011ef5e24764_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares for business acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_98c65c46-af05-41da-be9b-69d99a7cb81a_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1afdfc32-58aa-4049-ba41-081df50678e5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4734c7d6-2217-461d-a5ab-8184f6f46387_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ba33b946-9864-48e5-ae17-151bc7dd8fd3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_1f7542e5-7ece-4303-a241-d612e84aac90_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_5cb2725d-b117-445b-85e6-d4c5c51bead9_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_668b1378-02b4-4ad1-90f7-12d5072385ba_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicareMember_7117b1e3-0e3c-47e8-addb-e30d2075b220_terseLabel_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ameh_MedicareMember_label_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ameh_MedicareMember_documentation_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicareMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember" xlink:href="ameh-20220630.xsd#ameh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareMember" xlink:to="lab_ameh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_44975dec-4251-4176-a44f-30c3bc359b3c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_2c537b51-99c2-4a87-ae64-240adf25fe2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c436bce1-7c2b-4856-b3cf-7768eb4cd3a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_b5564393-3c03-47bb-82af-3274b37ab989_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_24da64c6-5490-4dda-8f06-9145811bbfbf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CMSMember_1e43155a-8183-43df-a1ea-cc9fc65dbcf4_terseLabel_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS</link:label>
    <link:label id="lab_ameh_CMSMember_label_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:label id="lab_ameh_CMSMember_documentation_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember" xlink:href="ameh-20220630.xsd#ameh_CMSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CMSMember" xlink:to="lab_ameh_CMSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_6ebb5d07-b5e1-4fe0-9d70-abbcfc79944a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under agreement</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_9aa69a36-d0cc-4310-ab67-4ecd6ad95f86_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_bd6e7d17-884e-40ab-bd22-41d1a0270059_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_a32c3fd3-494f-4f2f-9c11-4db66c952a35_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_fe44f7c5-97dd-486d-aebb-8985e617f1bc_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9f7ea2ea-d1a9-499e-b90c-7503f7772a4b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_51177d8e-0ff1-41e7-9477-c5922a5c3a49_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7fb32183-b91c-4075-85db-3f5482527453_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_dee7c61a-3fdb-4fa6-9239-1fccd6a6f4bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share buy back</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AchievaMedInc.Member_72f895e9-ba54-4c42-96b4-8459a673ad51_terseLabel_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc.</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_label_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_documentation_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member" xlink:href="ameh-20220630.xsd#ameh_AchievaMedInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AchievaMedInc.Member" xlink:to="lab_ameh_AchievaMedInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_15513770-fac4-4099-bd29-a3ffde899c95_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3da2c6ac-b229-4894-8362-af4e99c9f11a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d57d415c-45ea-46e3-b4e3-d9b7d50090d4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7bb91faf-32c3-4a0a-b9d9-caf5c4ccb687_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_181a7a10-f1fe-4dbd-be44-de147109d4b2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a1cc5d30-944c-48f2-9eb6-154a51d291bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_c6f99adf-e843-46cd-923a-e704cdc96335_terseLabel_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_label_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:href="ameh-20220630.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:to="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16065a26-0d78-4139-9f7d-019de6f52098_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireNonControllingInterest_1be1bafe-3c3f-4859-89d0-4fd86a6057b8_negatedLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireNonControllingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of non-controlling interest</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireNonControllingInterest_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Non-controlling Interest</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireNonControllingInterest_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Non-controlling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireNonControllingInterest" xlink:href="ameh-20220630.xsd#ameh_PaymentsToAcquireNonControllingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireNonControllingInterest" xlink:to="lab_ameh_PaymentsToAcquireNonControllingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_e839a99f-d616-4773-b923-32ef47c12ab9_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_c4b6611a-3fa5-4e1e-a8f5-4e4e6a6e2310_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, interest rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_label_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:to="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b14ff23b-97f0-406b-affe-61bc0072bc38_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f987c1f4-61a3-4526-a482-70f61e8be2cf_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_134fd9cd-c9bd-430f-a930-19ea93656bb1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c342866b-1205-456a-9e5b-adb93f7017aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9d079624-88cc-4bb9-a984-d980a48795ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_4d629ba4-90fe-450b-b429-e3caa1b9606f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4b572b7a-0b8d-408f-8cd9-660ba792999e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in&#160;Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_6ba79e33-93bf-47d8-b7c0-a5fa971a2802_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ee8b1933-f7c8-40a1-8101-21e043f9ab7e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_51243e81-d729-468d-93ec-508a6f7c5ac4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9de97b2e-2388-499b-a890-c2e152a63f9a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b400a530-4fec-4448-ad48-7dafbeac355a_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9beaba29-6524-42f4-a59b-8519cad0ffbb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorDMember_15f5d4d6-421e-4bda-86e1-890c8de994b5_terseLabel_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D</link:label>
    <link:label id="lab_ameh_PayorDMember_label_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember" xlink:href="ameh-20220630.xsd#ameh_PayorDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorDMember" xlink:to="lab_ameh_PayorDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_167569cd-983f-45f2-ba78-97f19a94f985_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_cbddd5f2-86cf-4003-b94f-0ff6861a9999_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC</link:label>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_label_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:href="ameh-20220630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:to="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_9e8ef542-1a27-4e8a-bfa2-e5457909eaa8_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number federally qualified health plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_label_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_documentation_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:href="ameh-20220630.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:to="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentReclassification_d33fb65e-a999-4ac3-aea7-5dffca4c5d21_negatedTerseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentReclassification" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding reclassified to loan receivable</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentReclassification_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentReclassification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Reclassification</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentReclassification_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentReclassification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Reclassification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentReclassification" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentReclassification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentReclassification" xlink:to="lab_ameh_EquityMethodInvestmentReclassification" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_a58fc41b-dc7b-4cb3-86a7-504c753a37db_terseLabel_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:href="ameh-20220630.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_16c99852-23e7-4506-8112-46ec9028905c_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:href="ameh-20220630.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:to="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_a5938e1f-a542-4d77-8b73-0031f9c66513_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f10de65e-18d5-4e94-b3cf-9fc75e76339c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_31640dca-cc70-4944-8833-4502a4ba5e2f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5a8f92b3-2fc5-4450-a095-f9b6732a08d1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_ade6e9c6-b203-4701-9cee-f619f483f57a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2d4038d6-aebd-4074-aa72-01479d5c1750_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0be7182a-b7e8-4bf3-a7e8-0a7edafe902d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_b3e04d12-7629-47df-a713-6a07e0ac643b_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ce885309-dc1e-4785-ba67-2fb802545dd9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_664c723e-56f2-4578-a3a6-c5f071c29cc3_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_35b7b820-adb8-40bf-aff5-048db37049bc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_5920af03-ddf9-4a6c-957a-41d9b4c5da0e_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_ccf567e1-df02-42fc-bfc3-cabe67aa1407_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_21bc4347-fc49-43c2-b63c-ebeafb241187_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:href="ameh-20220630.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:to="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PrepaymentForInvestmentPurchase_f15b9f49-5e00-4080-afe7-bac50598c06d_negatedTerseLabel_en-US" xlink:label="lab_ameh_PrepaymentForInvestmentPurchase" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment for investment purchase</link:label>
    <link:label id="lab_ameh_PrepaymentForInvestmentPurchase_label_en-US" xlink:label="lab_ameh_PrepaymentForInvestmentPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment for Investment Purchase</link:label>
    <link:label id="lab_ameh_PrepaymentForInvestmentPurchase_documentation_en-US" xlink:label="lab_ameh_PrepaymentForInvestmentPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment for Investment Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PrepaymentForInvestmentPurchase" xlink:href="ameh-20220630.xsd#ameh_PrepaymentForInvestmentPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PrepaymentForInvestmentPurchase" xlink:to="lab_ameh_PrepaymentForInvestmentPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_d15d06ac-d03f-4df4-bd3c-25a36717185f_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_2d54287a-e4ff-45b3-bb1e-77124c8ecdf6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_d317f79e-b8d5-46aa-ac14-21d7cb01ffc3_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_4fb9c8b2-a73d-4e65-b820-346ca20a047a_netLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4c37e85f-7096-408a-b54a-29c9a7015a89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_40869887-a75e-4217-8db8-b541d3a956bb_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20220630.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9cbb7e64-9654-4292-bf4f-dce9ee8d202d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_8eb38511-4ecc-4dce-b00d-592a9a457d17_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, principal sum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareLineItems_a1853f78-23aa-40b0-99cc-3ef069078e20_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_label_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareLineItems" xlink:to="lab_ameh_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4af54e43-708f-4129-b5bb-67e20018f5ac_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_0a41e9c4-d43f-4fb9-b7da-e15f8b281438_terseLabel_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, percentage of shares acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_label_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_documentation_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:href="ameh-20220630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:to="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3f9038dc-981b-4606-844c-65b382ce4c86_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9510f052-444d-42c1-a8c6-55b716294460_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20220630.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_af0035f3-ff27-4da6-a4da-ee2f3ed10e6b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_d1b7cc31-6d38-49cb-a434-4a76847f320a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_46e4adab-3da2-4f1e-9e2c-6611d833cf78_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_526f1302-7a96-45fc-b343-a1ad575e1f45_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_732a32b9-8bb5-4b4f-8dba-dcd639820f68_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0e186979-35f6-4f13-8d25-82caecac7459_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_93ba8b65-6cb9-4292-9821-2e2ae58dcb0b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f6af1ae0-6329-4ee6-bc67-ccaf13d5c89d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_704099b7-0161-46cf-b130-f488ef7aa2b9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_14decf6c-75ec-4136-9b6f-a8150edc9a09_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_d42ac24a-cbcb-47d9-919b-be95cc58f9ad_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_bda66117-c3bb-4731-b124-1cae6b5aabf0_verboseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_3bbe566a-5ad8-485a-a3a3-201a63c2b326_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:href="ameh-20220630.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d208c628-501d-4126-8454-38ad8e60eba1_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_03b21d61-aed9-4bf1-b3a9-4c31b6d59210_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_49eaabd3-bc51-497f-b282-2743be52b08e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_bcb5d74a-d910-4a1b-82f4-75257aaaa5e6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_851bd0d8-9442-41ea-96c6-3a6f671dfbaf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_75fabcfa-6e8b-433c-9b4c-a99c2e5cbf30_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_5e4e7b99-54ee-402d-9e18-05ff7c86aa63_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_cf871e4d-89d3-4e6f-92b5-012b9719dc06_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due from affiliate</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliateCurrent" xlink:to="lab_us-gaap_DueFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorBMember_132e8e8c-a145-44b4-ace8-0a36139e72bd_terseLabel_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B</link:label>
    <link:label id="lab_ameh_PayorBMember_label_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:label id="lab_ameh_PayorBMember_documentation_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember" xlink:href="ameh-20220630.xsd#ameh_PayorBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorBMember" xlink:to="lab_ameh_PayorBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_db326fd2-0603-4034-a5bf-4590b4e20115_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period value of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents value of stock issued during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_21e65584-86da-427b-b643-dd8ed795d8c4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_39f23059-4e39-4931-a134-395562721fa7_negatedLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised" xlink:href="ameh-20220630.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsExercised" xlink:to="lab_ameh_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_43e3032d-5508-451e-acc3-a1f69e02439a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract liability recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7651ae67-895e-4d68-9456-1d36570748b0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_c6043d07-2f66-4fb0-873a-1a61fdf7c481_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_cd871f97-1758-4f84-8046-a91c1c9d788c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_f5ed4398-865f-46cd-a5de-25c7787beb99_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of main reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_31cb5235-0874-498a-ad1a-baa69ad10706_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_07b4772b-f4fa-49f4-9121-8211c577da0b_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_0bf0d67d-b245-48c2-9801-dcb938d92546_verboseLabel_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_label_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Capitation Payable Current</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_documentation_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of specialty capitation payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:href="ameh-20220630.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:to="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0667ce9-039c-45ee-8b9d-fb87c4d49361_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_97ef8712-5489-4fa9-978e-8317d794c4c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_b7abaf8e-8c76-4acd-bcab-e625a0dab3c9_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_45bdae73-e3a1-4a18-a735-10b60e6e38f5_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_385b6a0b-4507-4df9-9382-a9b3ec5c1c67_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_7b5a5f78-4bfe-4076-9bfe-6390dd145f29_terseLabel_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_label_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition [Member]</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_documentation_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:href="ameh-20220630.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:to="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_e1cf92a4-61af-44a4-849a-f05d9cb100ad_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_f0fd7b8e-d8ea-494c-8705-7c4d6263db91_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_5eb575b7-6965-45b5-87da-3804a5c00d89_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_d0c2e41c-ad8e-484b-acac-f9762f26b9e8_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_e63f0bfe-b35c-40ce-a4c0-209fb17956be_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_26bd4127-a618-4852-bade-ab1fc2a8702f_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights granted in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_f8d48443-9457-4664-b673-fc4063bdeb61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_ed11e293-8bd2-441a-a535-b771e3b94c9a_verboseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_6bc46466-34a1-48f0-88b9-a226b1a77ed9_terseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College LLC</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_label_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Three One W. College LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:href="ameh-20220630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:to="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1bd447a9-5a96-4d4e-9f1a-6c0a9529d436_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_5e64ede4-49aa-4327-bed1-3194cee31d01_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_50297cf6-5158-4a55-8452-fcf4fb36d2ab_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_f949588e-357e-4e2b-a3db-d2a325355cfd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_30bda70b-813a-4c74-9b66-ba17676d99c6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_81881315-5e0b-49cc-9480-0894c0f74438_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_2af54028-5e62-4221-9229-0675a4c86bd6_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_4094425f-df88-43c4-9d18-2623ac993227_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_87e1f3d6-93c9-45da-8330-199d9d9d3735_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_abc1d03b-4d4a-4fd8-b488-c8e731d1b78a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold_92f343d3-65a6-4c8c-b027-4bb2ad313cee_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage sold</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage, Sold</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage, Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_ee39757b-0fc3-4387-a817-1b52f094f8e2_terseLabel_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC and APC-LSMA</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_label_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_documentation_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember" xlink:href="ameh-20220630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APCAndAPCLSMAMember" xlink:to="lab_ameh_APCAndAPCLSMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ebb0c24-00f2-4f4e-b7b8-e0ed227a0e7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_e60c15f1-ecf8-420c-8b85-a9c01b7c6db3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_976821f1-89f7-467b-a4d1-402cb54f7498_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_ce4c9fbc-6766-4a4b-b9a5-13ac3a56befc_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_b1573943-604c-4ff7-93f8-31794bea6d20_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_253b0496-83a0-4e22-a063-4f424137b666_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d9f2b687-5bd2-4475-9cca-37679ab0398f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8e581fc1-1548-4617-ba80-395edfd5b1fe_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_81b6e0bb-00b0-4707-9c5d-a2769e9b5c7d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ea317275-3125-4d7f-b849-6007f5699e28_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_316a77b5-9931-45da-b7f5-1ee06e9a63a4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_785a3aad-084a-411c-bb82-3d653d431879_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_d1065384-c0be-43e2-8fb2-1b7820cdeeed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued in business combination</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_ccdda2d7-7ba6-4d60-ae05-34e3c5667709_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares by non-controlling interest</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Noncontrolling Interest</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringPeriodValueNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:to="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d70082e1-1526-4290-8c29-9ef99a36e1e6_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52748a4f-feb6-4318-b6a4-da92c814dc07_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContingentEquitySecuritiesMember_81c621eb-81f2-4a1b-b2a3-4527707e43cb_terseLabel_en-US" xlink:label="lab_ameh_ContingentEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Equity Securities</link:label>
    <link:label id="lab_ameh_ContingentEquitySecuritiesMember_label_en-US" xlink:label="lab_ameh_ContingentEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Equity Securities [Member]</link:label>
    <link:label id="lab_ameh_ContingentEquitySecuritiesMember_documentation_en-US" xlink:label="lab_ameh_ContingentEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember" xlink:href="ameh-20220630.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContingentEquitySecuritiesMember" xlink:to="lab_ameh_ContingentEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_415fae43-d4f0-4435-aa8c-74313960d72a_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_6d5336ee-503e-4b3d-80ed-117e0aa1de62_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_86c69ffb-ecbf-490e-a65e-3a5fb05ac7bb_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_3de3235d-622e-40ce-ad02-fb7728353a55_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_0f819403-1a4a-49f8-8fa8-c78982d3774f_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_9fe9f968-6355-4997-b30d-3f8311324ac2_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_421db041-b44d-4305-aab1-252359f39783_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent equity securities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b871fd65-6dd5-47f7-a4d9-00edc9cd9746_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_47728f2f-aa58-4e73-b55f-0917ae2d84fc_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PatientManagementPlatformMember_c281aaf5-c5c2-4dc4-9b59-bd49b9dd1cf9_terseLabel_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient management platform</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_label_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform [Member]</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_documentation_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember" xlink:href="ameh-20220630.xsd#ameh_PatientManagementPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PatientManagementPlatformMember" xlink:to="lab_ameh_PatientManagementPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorFMember_e26b2858-544c-4f11-9161-a0ddd225b21b_terseLabel_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F</link:label>
    <link:label id="lab_ameh_PayorFMember_label_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:label id="lab_ameh_PayorFMember_documentation_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember" xlink:href="ameh-20220630.xsd#ameh_PayorFMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorFMember" xlink:to="lab_ameh_PayorFMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_dfe77661-d8b9-4758-8458-1a5b189b3ffb_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance cost</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_ce42ed0a-a940-445f-966d-b41cf9586a86_terseLabel_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_label_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_documentation_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:href="ameh-20220630.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:to="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f10bb777-47ac-4f65-95c6-09e4e3386577_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_ed20329f-9e5c-4aca-b5aa-7b16202de05a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_546cf01d-deda-4409-bf3b-aacd9b1031f9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_28ccbf81-feb7-41c4-beda-057693b0bce8_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_84c01034-e58a-4771-b57f-5e95be4c409b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_961d24c7-0d8f-45dd-8380-f810ed8e83d6_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable, net of current portion</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e031a3ad-b728-4e35-8602-1041cfd0b4ac_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_4ff4c1cb-ea86-4e30-95e8-fa92d72a343f_terseLabel_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period of payment upon termination of agreement</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_label_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_documentation_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:href="ameh-20220630.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:to="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineMember_6f1934f1-730e-4315-a655-5adfa6cbe399_terseLabel_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine</link:label>
    <link:label id="lab_ameh_MezzanineMember_label_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember" xlink:href="ameh-20220630.xsd#ameh_MezzanineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineMember" xlink:to="lab_ameh_MezzanineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_aaa713fb-2128-446a-8578-2ae5e7fdf22a_terseLabel_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement</link:label>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_label_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember" xlink:href="ameh-20220630.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcBusinessLoanAgreementMember" xlink:to="lab_ameh_ApcBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_c467bfe7-1384-48b3-a8bc-82fcc83cf875_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tradename/trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_d5a3405a-8d95-437e-9676-51b426f07c0e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3844c469-ae65-4a5b-8d66-c86f14165220_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bf376329-6020-4b20-9e1a-a45c2693fcf8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_3c4b19a4-91d9-4704-a8a9-bd1acec2f48e_terseLabel_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc.</link:label>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc. [Member]</link:label>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_documentation_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember" xlink:href="ameh-20220630.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClinigenceHoldingsIncMember" xlink:to="lab_ameh_ClinigenceHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_232d6d8b-789b-4d3e-b066-f976c9af3c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in privately held entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_a83f1ea9-6b56-4fdc-be55-4cd1b6df1414_negatedLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:href="ameh-20220630.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageLoanRelatedToPropertySales1_84c73f31-c69d-4669-927f-e72d31a81eec_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageLoanRelatedToPropertySales1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loan</link:label>
    <link:label id="lab_us-gaap_MortgageLoanRelatedToPropertySales1_label_en-US" xlink:label="lab_us-gaap_MortgageLoanRelatedToPropertySales1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage Loan Related to Property Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoanRelatedToPropertySales1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoanRelatedToPropertySales1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageLoanRelatedToPropertySales1" xlink:to="lab_us-gaap_MortgageLoanRelatedToPropertySales1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_b04125fc-eeb7-4c36-ace6-085119251e58_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in millions)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5402a175-a160-4143-9000-3f4fce5d0532_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required annual facility fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_10e3a51f-fadf-4965-a880-2ecb7032e5e3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_69815ec5-46db-4bb0-92e9-180d69434997_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_7ae883ca-b8a4-4ed3-bfff-bda28578e5bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_7826f527-f671-40a7-996c-0770b56866d3_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:href="ameh-20220630.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:to="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToEquityMethodInvestments_67e8e95c-60ae-4f5f-8a07-9747b18e2b6e_negatedLabel_en-US" xlink:label="lab_ameh_PaymentsToEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to investment - equity method</link:label>
    <link:label id="lab_ameh_PaymentsToEquityMethodInvestments_label_en-US" xlink:label="lab_ameh_PaymentsToEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Equity Method Investments</link:label>
    <link:label id="lab_ameh_PaymentsToEquityMethodInvestments_documentation_en-US" xlink:label="lab_ameh_PaymentsToEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToEquityMethodInvestments" xlink:href="ameh-20220630.xsd#ameh_PaymentsToEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToEquityMethodInvestments" xlink:to="lab_ameh_PaymentsToEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_40b0a6d6-6d04-4e55-8af9-d923ef720025_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcLsmaMember_4282fb3e-bc78-492b-8ad2-03223a7ca1ac_terseLabel_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA</link:label>
    <link:label id="lab_ameh_ApcLsmaMember_label_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember" xlink:href="ameh-20220630.xsd#ameh_ApcLsmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcLsmaMember" xlink:to="lab_ameh_ApcLsmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_3c5727fd-0681-49c0-ba42-9460bd4d9ddf_terseLabel_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20220630.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_3ff8fb45-7e0c-464a-9112-36c9645cdaff_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants available to purchase, contingent upon the portal completion date (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_845be43d-9ec6-4c62-9dbc-98b3bb69aa32_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f9a97980-007c-4337-b029-5747581788ef_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_06137fc1-47b2-4713-a95f-ae0824f62e5b_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_a4ca0ed5-24cc-4c80-9669-e5f5187d625a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_e52a8bb1-12fd-4180-befe-6bc579f660c0_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase additional membership interests (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_2d5e5596-13b6-4bac-890b-c3231cb6795f_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_8b5c4c78-20d2-49e8-8263-b14de480983b_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_label_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable [Policy Text Block]</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:href="ameh-20220630.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:to="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_21ab58be-f237-4cd5-9c28-7ea27c83fb1e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, other than temporary impairment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_10f3502f-a017-4c6c-bd17-6a9609b6cb70_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6190281e-6846-478f-8f77-2a9ffc7ac6ea_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_ea0af29f-a163-4534-ab9f-2ebf3dbdd8fa_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted" xlink:href="ameh-20220630.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsGranted" xlink:to="lab_ameh_NumberOfWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConstructionLoanMember_7491f5ae-7a30-4309-ad60-dcee35910a39_terseLabel_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_label_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan [Member]</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_documentation_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember" xlink:href="ameh-20220630.xsd#ameh_ConstructionLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConstructionLoanMember" xlink:to="lab_ameh_ConstructionLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_8970ce44-e121-498e-92cc-2a77f447a445_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregated Revenue by Each Payor Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_475f7387-d313-4b91-8e32-b727e66bc958_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 (excluding the three months ended March 31, 2022)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_492fa43b-4f5e-46d8-bd9b-14c3f319d959_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_2f199db8-488c-41de-b49a-ba9728f31307_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_107e1b83-ae8a-4279-b31c-33bd8643f1a5_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_e6b87ea4-db4a-4f6a-8087-95ed82ef0cfa_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceMember_d9fac405-0387-4a7f-ba0e-efabda0f6d49_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_522f6b36-629c-4f4d-b548-96b157fe12dc_verboseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Income Contract</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceMember" xlink:to="lab_us-gaap_ManagementServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d0bd7288-c10e-4a29-aa9c-e5356040f06f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to weighted average shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_5a28ee1f-d091-4c11-893e-22ed0678fd06_terseLabel_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ameh-20220630.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_d02bc6a1-839a-4f9f-9022-17ac21cbf3eb_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment amount</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e1263497-9b3d-490c-9c3c-d565d066902b_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_57ba3abc-d960-45eb-b6d2-2be675d98397_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_be4568ba-2948-4979-9537-7b05e0ea9fd5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_92c2f1af-b250-4079-9f52-f767e551c85e_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_69eb1885-86c4-460d-a46e-c4a93558cde8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_baba4085-7b7b-4fb7-93a5-b9ad0fc244db_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_46a05608-5f8b-413c-89f7-131ca9a8b608_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio (not greater than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_05f51997-ea52-40e1-aa0f-93ba892e1fc1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_0d13cf52-72e7-4c33-b188-ab7dff7048b3_terseLabel_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging &amp; Oncology Center, Inc.</link:label>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_label_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging and Oncology Center, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:href="ameh-20220630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:to="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_c322ef05-af79-46fd-830f-60f0173e26cd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of beneficial interest</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_8edc0991-48db-496b-ad09-3d3a914e1abf_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum_11be9300-9195-4eda-9bff-f7563a20365a_terseLabel_en-US" xlink:label="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, aggregate purchase price, maximum</link:label>
    <link:label id="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum_label_en-US" xlink:label="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Aggregate Purchase Price, Maximum</link:label>
    <link:label id="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum_documentation_en-US" xlink:label="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Aggregate Purchase Price, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:href="ameh-20220630.xsd#ameh_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:to="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_f190fa67-4267-4660-9e0d-f3a8befb4127_terseLabel_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_label_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:href="ameh-20220630.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:to="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_2e738fce-d831-4d51-9be5-58be76078746_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems" xlink:href="ameh-20220630.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessLineItems" xlink:to="lab_ameh_DescriptionOfBusinessLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ameh-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:4d426055-c9f8-47bb-b397-a8331168ec1c,g:285e3d39-8563-4e90-906d-af4a3a14867e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20220630.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9bd3dde0-699e-4372-98c8-002e2eee0955" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_DocumentType_9bd3dde0-699e-4372-98c8-002e2eee0955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5c585781-3695-477b-98ef-dd69c53d28d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_DocumentQuarterlyReport_5c585781-3695-477b-98ef-dd69c53d28d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a0d8fe5a-468b-4f37-8d5c-15457d0d29fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_DocumentPeriodEndDate_a0d8fe5a-468b-4f37-8d5c-15457d0d29fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4801bd62-fd55-48f0-8a63-00647893c237" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_DocumentTransitionReport_4801bd62-fd55-48f0-8a63-00647893c237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d445b984-25d8-4067-84e6-35e3d342f4d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityFileNumber_d445b984-25d8-4067-84e6-35e3d342f4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_873ae41f-ae43-41f8-8655-bf0d257fed1a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityRegistrantName_873ae41f-ae43-41f8-8655-bf0d257fed1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_25443e41-2d4a-4f7b-8006-b017d78e3a0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityIncorporationStateCountryCode_25443e41-2d4a-4f7b-8006-b017d78e3a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1323e3e1-554f-47c4-8394-0c074da07f1e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityTaxIdentificationNumber_1323e3e1-554f-47c4-8394-0c074da07f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_823f8639-6e79-4356-8993-6eb674fe882c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityAddressAddressLine1_823f8639-6e79-4356-8993-6eb674fe882c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e88aed4f-1859-45e4-a762-aef0852eae7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityAddressAddressLine2_e88aed4f-1859-45e4-a762-aef0852eae7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c20f222a-34a9-4f7b-8584-fc6b18046df1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityAddressCityOrTown_c20f222a-34a9-4f7b-8584-fc6b18046df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1b014f68-7916-40d4-88c3-f6835ecf1303" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityAddressStateOrProvince_1b014f68-7916-40d4-88c3-f6835ecf1303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_50eb242b-2411-4fd8-9237-bfb18a2b2ce6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityAddressPostalZipCode_50eb242b-2411-4fd8-9237-bfb18a2b2ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_584d9fdb-a416-48ed-9d59-f75cafc7bb43" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_CityAreaCode_584d9fdb-a416-48ed-9d59-f75cafc7bb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5f1967da-1f13-48a0-9ce6-36332b5a1061" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_LocalPhoneNumber_5f1967da-1f13-48a0-9ce6-36332b5a1061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5a59c354-f836-4331-9839-9576291906aa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_Security12bTitle_5a59c354-f836-4331-9839-9576291906aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d2456805-0962-4203-8c28-5fdd03cbda5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_TradingSymbol_d2456805-0962-4203-8c28-5fdd03cbda5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a50903c3-9df2-404f-b6a7-3010e572b8b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityCurrentReportingStatus_a50903c3-9df2-404f-b6a7-3010e572b8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_02acbe3a-6f93-48bf-8e60-3a5be5651450" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityInteractiveDataCurrent_02acbe3a-6f93-48bf-8e60-3a5be5651450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3927a171-0067-4ebd-ab06-74e04c02c7a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityFilerCategory_3927a171-0067-4ebd-ab06-74e04c02c7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7306a8ed-c432-4a0d-bea8-d1ce6223f39c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntitySmallBusiness_7306a8ed-c432-4a0d-bea8-d1ce6223f39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9aabe3c5-a733-42a2-bb38-51c14fa5f974" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityEmergingGrowthCompany_9aabe3c5-a733-42a2-bb38-51c14fa5f974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9c28a23e-cedf-47e7-9f84-c782b85c66a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityShellCompany_9c28a23e-cedf-47e7-9f84-c782b85c66a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d410b31d-0a6b-489d-97f2-033a5b24a2ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d410b31d-0a6b-489d-97f2-033a5b24a2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_7f6df64d-6f83-4dd8-8a6f-db0184908cdf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_AmendmentFlag_7f6df64d-6f83-4dd8-8a6f-db0184908cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a762432f-fd1c-4ce5-bada-0c60640856af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_DocumentFiscalYearFocus_a762432f-fd1c-4ce5-bada-0c60640856af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1f3b81ef-08e6-4724-8201-3d1f2ec5390f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1f3b81ef-08e6-4724-8201-3d1f2ec5390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_171858ce-427f-4d71-abcd-fea3bb86220d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_EntityCentralIndexKey_171858ce-427f-4d71-abcd-fea3bb86220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2cd81774-34fe-4666-bba5-6139189c678a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0ad56d00-4c69-4c51-8358-db71970b7a29" xlink:to="loc_dei_CurrentFiscalYearEndDate_2cd81774-34fe-4666-bba5-6139189c678a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ad37a943-03ff-48b0-bb5b-2e73dc76e699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f96da404-b328-4aff-8584-4f18d86244e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ad37a943-03ff-48b0-bb5b-2e73dc76e699" xlink:to="loc_us-gaap_StatementTable_f96da404-b328-4aff-8584-4f18d86244e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8159ca9a-065b-4eb3-bbb3-ea424b2a1a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f96da404-b328-4aff-8584-4f18d86244e3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8159ca9a-065b-4eb3-bbb3-ea424b2a1a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9d3322df-0e98-4607-b89a-f9bff241e668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8159ca9a-065b-4eb3-bbb3-ea424b2a1a3a" xlink:to="loc_us-gaap_ClassOfStockDomain_9d3322df-0e98-4607-b89a-f9bff241e668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8d9caceb-a95a-487b-9dac-7f0c09c2466d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9d3322df-0e98-4607-b89a-f9bff241e668" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8d9caceb-a95a-487b-9dac-7f0c09c2466d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_b2d85ff6-caf8-4cfc-a4cd-e87456b6dc64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9d3322df-0e98-4607-b89a-f9bff241e668" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_b2d85ff6-caf8-4cfc-a4cd-e87456b6dc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_74e52ea5-b816-4feb-8f89-9d935d90cf70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f96da404-b328-4aff-8584-4f18d86244e3" xlink:to="loc_us-gaap_StatementLineItems_74e52ea5-b816-4feb-8f89-9d935d90cf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74e52ea5-b816-4feb-8f89-9d935d90cf70" xlink:to="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77aa72c5-aa5a-41f1-bf42-2e03c125daa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77aa72c5-aa5a-41f1-bf42-2e03c125daa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_321c2592-f39f-4cbf-8e96-e2dd0674d7db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_321c2592-f39f-4cbf-8e96-e2dd0674d7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_52b9db06-d915-40ab-ad13-0e56c2c5075a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_52b9db06-d915-40ab-ad13-0e56c2c5075a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2751efbb-338f-4410-8109-23ac459363e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_2751efbb-338f-4410-8109-23ac459363e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_5934eb82-b8c7-427a-9193-6739115633a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_IncomeTaxesReceivable_5934eb82-b8c7-427a-9193-6739115633a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_df999399-1e4c-46aa-b280-4766ab74c7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_df999399-1e4c-46aa-b280-4766ab74c7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5d067265-c4fa-453f-a1f2-3855dbd1e820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5d067265-c4fa-453f-a1f2-3855dbd1e820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_34e8546e-3abd-4f5c-b87b-7f8784571ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_34e8546e-3abd-4f5c-b87b-7f8784571ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf15034f-a841-455e-9a14-9bbf9d99a383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2316c606-b061-4b44-96aa-bf2a21c58ee6" xlink:to="loc_us-gaap_AssetsCurrent_bf15034f-a841-455e-9a14-9bbf9d99a383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0bdfbeb9-ca34-4b2b-84e7-3192b2edfe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0bdfbeb9-ca34-4b2b-84e7-3192b2edfe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6071ad7-f0c4-4c4a-a017-b3e306c95c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6071ad7-f0c4-4c4a-a017-b3e306c95c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a06ce44f-a67b-41ad-8387-a30e01e74d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_Goodwill_a06ce44f-a67b-41ad-8387-a30e01e74d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_444227a3-55d2-4d4c-84bb-ecef87c66999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_444227a3-55d2-4d4c-84bb-ecef87c66999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_e0e7e250-6cc8-4213-ba46-c824fa5853bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_e0e7e250-6cc8-4213-ba46-c824fa5853bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d6368566-9f2a-43aa-94b3-d5e668722eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_EquityMethodInvestments_d6368566-9f2a-43aa-94b3-d5e668722eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_dc83d637-aa22-49b0-8edd-ab002d682780" xlink:href="ameh-20220630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_dc83d637-aa22-49b0-8edd-ab002d682780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_88437876-5e33-4238-aa9b-1495e0c3e28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_88437876-5e33-4238-aa9b-1495e0c3e28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_39775fef-a206-4ed0-9475-02ed150df1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_39775fef-a206-4ed0-9475-02ed150df1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_1815cd46-0f9b-4d51-b87f-8620a837dd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_8b72e33e-76b0-4bff-bb97-d3cacfc923a5" xlink:to="loc_us-gaap_AssetsNoncurrent_1815cd46-0f9b-4d51-b87f-8620a837dd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e2792a10-5e48-4500-9048-62e29acb2e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bc3a72f-ecfb-4e0c-af38-9f10e9409f05" xlink:to="loc_us-gaap_Assets_e2792a10-5e48-4500-9048-62e29acb2e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74e52ea5-b816-4feb-8f89-9d935d90cf70" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_829633d9-0c15-4775-ae31-3e4c149689ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_829633d9-0c15-4775-ae31-3e4c149689ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_63a83333-0e44-4499-aaf9-f3f79f23958b" xlink:href="ameh-20220630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_63a83333-0e44-4499-aaf9-f3f79f23958b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_098b53a2-e5b1-413e-bb66-9afc41062858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_098b53a2-e5b1-413e-bb66-9afc41062858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_d3adf5a7-6ca1-4b56-9b1f-22447958c619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_d3adf5a7-6ca1-4b56-9b1f-22447958c619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_1a414a4a-43f5-4ec0-8f8c-5c14c7355dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_DividendsPayableCurrent_1a414a4a-43f5-4ec0-8f8c-5c14c7355dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_459389fa-c92a-48c6-bfe6-5e020df4719b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_459389fa-c92a-48c6-bfe6-5e020df4719b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_987ebe58-77fb-4c7d-9d71-006b74cc697e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_987ebe58-77fb-4c7d-9d71-006b74cc697e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_22ecdf6f-ccbb-4ca6-9e36-7f59e764b926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_LongTermDebtCurrent_22ecdf6f-ccbb-4ca6-9e36-7f59e764b926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dede57ed-7019-452e-b2f4-eac3e136d14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e20050c9-d8da-4cec-99a4-a1553222b554" xlink:to="loc_us-gaap_LiabilitiesCurrent_dede57ed-7019-452e-b2f4-eac3e136d14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_361450f9-07fa-462d-8899-8bd8c3713ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_361450f9-07fa-462d-8899-8bd8c3713ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7725b215-8432-44fc-ab8f-e0da8e14bfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7725b215-8432-44fc-ab8f-e0da8e14bfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adc0e97a-5eb1-4ec2-996f-fe3ecefac91c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_adc0e97a-5eb1-4ec2-996f-fe3ecefac91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_de37a15c-6032-4f31-8e35-91ea1a8b26fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_de37a15c-6032-4f31-8e35-91ea1a8b26fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d341ef16-e5af-44af-a028-afd67739f3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d341ef16-e5af-44af-a028-afd67739f3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_844f5727-ac42-4ed3-94bd-5a28bce3e4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_da2056db-a2d5-4410-b602-0d94adf93527" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_844f5727-ac42-4ed3-94bd-5a28bce3e4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_446c598a-21ad-4580-ba50-ba283fee62f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_Liabilities_446c598a-21ad-4580-ba50-ba283fee62f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_999f5044-634e-4430-866b-016cfc3d1667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_999f5044-634e-4430-866b-016cfc3d1667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_5ab69f70-4632-4606-9d3d-1194ce469010" xlink:href="ameh-20220630.xsd#ameh_MezzanineEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_ameh_MezzanineEquityAbstract_5ab69f70-4632-4606-9d3d-1194ce469010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2ec9f506-095b-4328-84fb-5eaaf4f3e53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MezzanineEquityAbstract_5ab69f70-4632-4606-9d3d-1194ce469010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2ec9f506-095b-4328-84fb-5eaaf4f3e53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f76e305a-74ee-4304-8f04-ea7c3e7d4cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_PreferredStockValue_f76e305a-74ee-4304-8f04-ea7c3e7d4cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_25164b10-7fbb-4748-a35c-60bbf097c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_CommonStockValue_25164b10-7fbb-4748-a35c-60bbf097c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d5a3351f-ac08-429e-a5c7-bb5a1952486f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d5a3351f-ac08-429e-a5c7-bb5a1952486f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ae3ac84-5b6c-4e01-9519-fcfe66045abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ae3ac84-5b6c-4e01-9519-fcfe66045abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a603f7a9-2988-4506-aba1-9cddcda6e8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_StockholdersEquity_a603f7a9-2988-4506-aba1-9cddcda6e8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_0be2204e-1e8b-4ba9-aa86-5221cc7d3ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_MinorityInterest_0be2204e-1e8b-4ba9-aa86-5221cc7d3ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d32e61f5-dc57-41dc-8edb-7c082a6458d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_33bd242e-2e19-4dd0-80c6-8a71d8f36118" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d32e61f5-dc57-41dc-8edb-7c082a6458d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_644dd370-ac9c-468d-9a4e-9624eb6cd8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b0418e40-54cc-4cd7-bae3-10f0399c417e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_644dd370-ac9c-468d-9a4e-9624eb6cd8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fc070a83-0b4c-4f0b-b343-a455e94046f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f967da9-df20-48f0-804f-048c5b9b87ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc070a83-0b4c-4f0b-b343-a455e94046f7" xlink:to="loc_us-gaap_StatementTable_1f967da9-df20-48f0-804f-048c5b9b87ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ed375eba-4ad9-4559-8725-81d9f135a012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f967da9-df20-48f0-804f-048c5b9b87ab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ed375eba-4ad9-4559-8725-81d9f135a012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_54cef19e-72f3-4ff1-991d-e1ca35d941c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ed375eba-4ad9-4559-8725-81d9f135a012" xlink:to="loc_us-gaap_ClassOfStockDomain_54cef19e-72f3-4ff1-991d-e1ca35d941c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_616dfb25-84fd-4fa5-b9ed-441de831cd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_54cef19e-72f3-4ff1-991d-e1ca35d941c2" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_616dfb25-84fd-4fa5-b9ed-441de831cd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0607136b-751c-4011-9036-fba5cd499527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_54cef19e-72f3-4ff1-991d-e1ca35d941c2" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0607136b-751c-4011-9036-fba5cd499527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d2bfa932-fd5d-4e1d-ba29-cd845dad5082" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f967da9-df20-48f0-804f-048c5b9b87ab" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d2bfa932-fd5d-4e1d-ba29-cd845dad5082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ca0a70f4-15ed-4a57-b59b-590667d38925" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d2bfa932-fd5d-4e1d-ba29-cd845dad5082" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ca0a70f4-15ed-4a57-b59b-590667d38925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bd3c1a54-2cb6-4fef-8449-845b58f43b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ca0a70f4-15ed-4a57-b59b-590667d38925" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_bd3c1a54-2cb6-4fef-8449-845b58f43b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f967da9-df20-48f0-804f-048c5b9b87ab" xlink:to="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5ef7b3be-41f5-4b4c-856b-36cc05d121b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5ef7b3be-41f5-4b4c-856b-36cc05d121b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_660f8c19-866f-48fc-adf2-ed159993ef5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_660f8c19-866f-48fc-adf2-ed159993ef5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5c07c5f0-b59d-481e-99e6-0ada7af57b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5c07c5f0-b59d-481e-99e6-0ada7af57b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5ac60cad-5be5-4bf1-b7de-9e73b86f558e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5ac60cad-5be5-4bf1-b7de-9e73b86f558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a32e219c-6e53-4843-bd70-c5f0b85fdd71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a32e219c-6e53-4843-bd70-c5f0b85fdd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b5f00528-aef0-4137-a910-f025dcb3a2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b5f00528-aef0-4137-a910-f025dcb3a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ec1c3b6d-fd74-4583-b36e-ef545746a64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_CommonStockSharesIssued_ec1c3b6d-fd74-4583-b36e-ef545746a64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4a6c0a3f-9f1f-4830-bee3-3409f1d5c787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4a6c0a3f-9f1f-4830-bee3-3409f1d5c787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_61ea6cfd-b82a-45af-ba2a-25517cec0702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_TreasuryStockCommonShares_61ea6cfd-b82a-45af-ba2a-25517cec0702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f6b92897-571e-4e4d-92db-da894ec160a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_Assets_f6b92897-571e-4e4d-92db-da894ec160a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9907941c-89e0-4a3a-9cb8-4a9dd1259874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_Liabilities_9907941c-89e0-4a3a-9cb8-4a9dd1259874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_04c0fd85-0fc9-490e-907a-43d36065efce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_04c0fd85-0fc9-490e-907a-43d36065efce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_ce946813-96d5-4e94-bff9-af175c888e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliates"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_DueFromAffiliates_ce946813-96d5-4e94-bff9-af175c888e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_e7fb8898-8732-4e75-927b-5f500ad6542f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrentAndNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9aba91f0-d55e-461d-9047-e560d0c46d97" xlink:to="loc_us-gaap_DueToAffiliateCurrentAndNoncurrent_e7fb8898-8732-4e75-927b-5f500ad6542f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6340b498-0717-4e5d-8504-c16c8f291cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f88f5614-2555-4a52-870a-4780b24d1766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6340b498-0717-4e5d-8504-c16c8f291cce" xlink:to="loc_us-gaap_StatementTable_f88f5614-2555-4a52-870a-4780b24d1766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_389ab78f-9566-4da9-b112-f3fb76b7bbaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f88f5614-2555-4a52-870a-4780b24d1766" xlink:to="loc_srt_ProductOrServiceAxis_389ab78f-9566-4da9-b112-f3fb76b7bbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_389ab78f-9566-4da9-b112-f3fb76b7bbaa" xlink:to="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_82d03427-61f0-4143-b402-56a2537afdd8" xlink:href="ameh-20220630.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_82d03427-61f0-4143-b402-56a2537afdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_13871187-b7a0-4a4f-b2a5-6ba8b0d83e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_us-gaap_HealthCareOtherMember_13871187-b7a0-4a4f-b2a5-6ba8b0d83e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_4a93937a-897b-4707-ae7f-fcc12709d600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_us-gaap_ManagementServiceMember_4a93937a-897b-4707-ae7f-fcc12709d600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_8af5653c-2e26-48cf-acb5-266910199bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_8af5653c-2e26-48cf-acb5-266910199bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_63b5eee9-9ba3-4986-92a9-538d4a5b2eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a19d028c-cb98-4d8e-88fa-2d5e3ada9fbf" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_63b5eee9-9ba3-4986-92a9-538d4a5b2eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f88f5614-2555-4a52-870a-4780b24d1766" xlink:to="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_07ac30bb-6f7c-474b-9cb5-642999efbca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_RevenuesAbstract_07ac30bb-6f7c-474b-9cb5-642999efbca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_135f9047-2105-48cf-91a8-d392fb6f45b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_07ac30bb-6f7c-474b-9cb5-642999efbca3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_135f9047-2105-48cf-91a8-d392fb6f45b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_82f5a052-4886-479a-a652-b7ba6e843e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_82f5a052-4886-479a-a652-b7ba6e843e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_52cfb32a-0ba5-422d-84cf-a7b2de708742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_52cfb32a-0ba5-422d-84cf-a7b2de708742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_f9ed7359-f68f-4643-8cd9-237cd736d07f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_f9ed7359-f68f-4643-8cd9-237cd736d07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ef99a612-1518-4207-97e7-cc82aaaec55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4e965185-a092-4dfd-8d8d-a3fe5ad93faa" xlink:to="loc_us-gaap_CostsAndExpenses_ef99a612-1518-4207-97e7-cc82aaaec55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73627495-c54b-4eb6-8faa-3f43fff6266e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_OperatingIncomeLoss_73627495-c54b-4eb6-8faa-3f43fff6266e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a1154c22-722d-4bbf-a6bc-694e2a3736c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a1154c22-722d-4bbf-a6bc-694e2a3736c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3e6d2422-e5e9-419e-acc8-5339cb4ad99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_InterestExpense_3e6d2422-e5e9-419e-acc8-5339cb4ad99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4b2b8d8b-be81-4f8a-bd00-28656f15af65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4b2b8d8b-be81-4f8a-bd00-28656f15af65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_df6a73fe-77ba-461b-b771-9a4303f12a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_df6a73fe-77ba-461b-b771-9a4303f12a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_98fe8ff6-1f10-4f3a-82ec-9ebf4e26cd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_98fe8ff6-1f10-4f3a-82ec-9ebf4e26cd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5c1b22d7-9755-4735-a3b1-f992cc81fdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_738219c2-6bcd-4bf6-8142-75fb537d7b51" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5c1b22d7-9755-4735-a3b1-f992cc81fdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f3ea91c-1f9f-4a8e-be47-c7bb928cfef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f3ea91c-1f9f-4a8e-be47-c7bb928cfef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_92f20c65-068d-4a0a-b1c9-7e6ba435cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_92f20c65-068d-4a0a-b1c9-7e6ba435cf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a01ba60e-5787-4fd7-a215-a9d5769e8e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_ProfitLoss_a01ba60e-5787-4fd7-a215-a9d5769e8e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d099f858-f9ad-4ead-91aa-4b28f675c29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d099f858-f9ad-4ead-91aa-4b28f675c29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f69ede66-926b-4750-9a9f-18597992cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_NetIncomeLoss_f69ede66-926b-4750-9a9f-18597992cd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_12c63e8e-a358-4d0f-90d6-4f83b32ad454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_EarningsPerShareBasic_12c63e8e-a358-4d0f-90d6-4f83b32ad454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3d51ed30-18a3-4a7a-a9db-981d3fd0ab28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_775ad8b1-5d8c-4e2b-9528-26809989dadc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3d51ed30-18a3-4a7a-a9db-981d3fd0ab28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c6cf8f0-cfa1-4d0e-ad24-fb1a726c369b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ffb908cf-0ad1-41ab-b3d5-66e3a55bb8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6c6cf8f0-cfa1-4d0e-ad24-fb1a726c369b" xlink:to="loc_us-gaap_StatementTable_ffb908cf-0ad1-41ab-b3d5-66e3a55bb8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5ebc231d-7652-4264-9bc8-227e3b845bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffb908cf-0ad1-41ab-b3d5-66e3a55bb8c8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5ebc231d-7652-4264-9bc8-227e3b845bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5ebc231d-7652-4264-9bc8-227e3b845bc5" xlink:to="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5389372f-34d5-41fe-b4ab-5a218004a684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:to="loc_us-gaap_CommonStockMember_5389372f-34d5-41fe-b4ab-5a218004a684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_59a44a81-d848-4067-96fb-80c08018b189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_59a44a81-d848-4067-96fb-80c08018b189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_19479b07-fb05-4a6c-b572-c41eeff22c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:to="loc_us-gaap_RetainedEarningsMember_19479b07-fb05-4a6c-b572-c41eeff22c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_494fefbe-6eb4-4695-92e3-6d136cfebfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8ad3398-5099-4a65-a055-cef0993aba8a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_494fefbe-6eb4-4695-92e3-6d136cfebfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2035324d-7cb6-44d9-8024-6aa826df964c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffb908cf-0ad1-41ab-b3d5-66e3a55bb8c8" xlink:to="loc_dei_LegalEntityAxis_2035324d-7cb6-44d9-8024-6aa826df964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d595062c-aa0b-4baf-86f7-654eefd32518" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2035324d-7cb6-44d9-8024-6aa826df964c" xlink:to="loc_dei_EntityDomain_d595062c-aa0b-4baf-86f7-654eefd32518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_49f34382-3ae4-4073-b785-7f513f5f3b76" xlink:href="ameh-20220630.xsd#ameh_MezzanineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d595062c-aa0b-4baf-86f7-654eefd32518" xlink:to="loc_ameh_MezzanineMember_49f34382-3ae4-4073-b785-7f513f5f3b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e0180820-b663-49bf-a119-e369e215ec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ffb908cf-0ad1-41ab-b3d5-66e3a55bb8c8" xlink:to="loc_us-gaap_StatementLineItems_e0180820-b663-49bf-a119-e369e215ec7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e0180820-b663-49bf-a119-e369e215ec7d" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d48a3d64-60b7-48d9-bd90-04d70185863c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_d48a3d64-60b7-48d9-bd90-04d70185863c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_4addfec4-7990-43f4-a21a-6337831f1496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_4addfec4-7990-43f4-a21a-6337831f1496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_7a8cd1b2-5eb2-4dc4-8aae-2e133c910fc7" xlink:href="ameh-20220630.xsd#ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_7a8cd1b2-5eb2-4dc4-8aae-2e133c910fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_116df917-f66f-4867-9fe1-9f30ea9400df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_116df917-f66f-4867-9fe1-9f30ea9400df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_fe9ff5ab-1286-414c-922e-bfe110bf9913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_fe9ff5ab-1286-414c-922e-bfe110bf9913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8e6d9497-8673-4d9c-bdf6-75faab8a4ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_fd4333d2-9a6f-46c4-88cb-f322ffe407fb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8e6d9497-8673-4d9c-bdf6-75faab8a4ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e0180820-b663-49bf-a119-e369e215ec7d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b44a478f-9b94-4def-ab47-b31cfd4bbe97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_SharesOutstanding_b44a478f-9b94-4def-ab47-b31cfd4bbe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_884e4dae-e6c2-4716-8183-fa89841eb471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_884e4dae-e6c2-4716-8183-fa89841eb471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_f7f83d0a-9107-4322-9ab4-3592e1066c36" xlink:href="ameh-20220630.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_f7f83d0a-9107-4322-9ab4-3592e1066c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_f7da621c-bd6e-4651-9822-4f7d5620e533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_f7da621c-bd6e-4651-9822-4f7d5620e533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_257ed551-febd-4890-9ad7-e9c47dc3393b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_257ed551-febd-4890-9ad7-e9c47dc3393b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_34a21f2d-e63e-4cae-a90f-10da2fa454cf" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_34a21f2d-e63e-4cae-a90f-10da2fa454cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_776988cc-8699-4c5a-b7c4-7f6670da2ccf" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringPeriodValueNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_776988cc-8699-4c5a-b7c4-7f6670da2ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_f3bb6550-06fd-4419-b73e-94eae0fdbc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_f3bb6550-06fd-4419-b73e-94eae0fdbc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_13516593-67be-4393-ba0d-e91f1f02dbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_13516593-67be-4393-ba0d-e91f1f02dbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_ab8c1b59-c47e-4e8a-b18d-c5a9bae43f57" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_ab8c1b59-c47e-4e8a-b18d-c5a9bae43f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_fd334212-d329-4dda-836e-28af06182cea" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_fd334212-d329-4dda-836e-28af06182cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7c3a88bf-220e-4df0-a86d-ebe6f6b4d0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7c3a88bf-220e-4df0-a86d-ebe6f6b4d0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_e9c30b16-5576-4070-9045-ae9e642d83cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_e9c30b16-5576-4070-9045-ae9e642d83cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e2a11a88-4a9c-43ba-915b-e5cd5fe5853e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e2a11a88-4a9c-43ba-915b-e5cd5fe5853e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9392af65-f3a5-44f3-ae82-8eb3bfa44ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_9392af65-f3a5-44f3-ae82-8eb3bfa44ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_8b1fb6f0-376e-4fa4-a4de-f2c46220c112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_8b1fb6f0-376e-4fa4-a4de-f2c46220c112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_125f90e5-8a64-4a04-b822-0db5b27a410c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_125f90e5-8a64-4a04-b822-0db5b27a410c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_e4a9adcc-7441-43a5-b112-b0eadfd8bfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_e4a9adcc-7441-43a5-b112-b0eadfd8bfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_d68ff53e-2573-4787-bbdc-432c66e7dec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_d68ff53e-2573-4787-bbdc-432c66e7dec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_acffd445-059b-4299-ae34-b09b409ff45f" xlink:href="ameh-20220630.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_acffd445-059b-4299-ae34-b09b409ff45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9cb808b7-b222-4204-bc37-ec5d6af271f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_SharesOutstanding_9cb808b7-b222-4204-bc37-ec5d6af271f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e151c20-de09-4ed4-ac9e-419e11fd8620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b89a571-839e-42a7-88ce-24fbe57d1cad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e151c20-de09-4ed4-ac9e-419e11fd8620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20220630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6949125-fd09-4ea9-b9e6-0f282aa53d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6949125-fd09-4ea9-b9e6-0f282aa53d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bd6f9f77-aab9-4e61-8d62-41696009cd45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6949125-fd09-4ea9-b9e6-0f282aa53d93" xlink:to="loc_us-gaap_ProfitLoss_bd6f9f77-aab9-4e61-8d62-41696009cd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6949125-fd09-4ea9-b9e6-0f282aa53d93" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_47818493-5b2a-419f-8d4d-f64f962ee8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_47818493-5b2a-419f-8d4d-f64f962ee8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6b3bf469-37e5-4548-a303-fb88103d645e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6b3bf469-37e5-4548-a303-fb88103d645e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9be69-d274-46f8-8fa6-52c992074103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9be69-d274-46f8-8fa6-52c992074103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d20ba2d9-2fed-4d9c-bc60-7abec01de325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d20ba2d9-2fed-4d9c-bc60-7abec01de325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_6422783b-3abd-4c0c-995c-8040ffdde69b" xlink:href="ameh-20220630.xsd#ameh_UnrealizedGainLossFromInvestmentInEquitySecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities_6422783b-3abd-4c0c-995c-8040ffdde69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_261369e4-e574-4a8d-ba22-f4845062390f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_261369e4-e574-4a8d-ba22-f4845062390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c3c0cf64-f3d4-413b-a176-f94a401c84d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_AssetImpairmentCharges_c3c0cf64-f3d4-413b-a176-f94a401c84d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_bce835a7-a01a-4996-9974-1c2883af8bad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_bce835a7-a01a-4996-9974-1c2883af8bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8f201ad3-d4ac-4219-a756-d49f532e789a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8f201ad3-d4ac-4219-a756-d49f532e789a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_5e6bb92d-0c8f-4ca2-af13-b9d8b79cbe25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_5e6bb92d-0c8f-4ca2-af13-b9d8b79cbe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f56cbd03-943d-47a6-8d42-ca49dcb636ce" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_482714b0-5b0b-4ad8-8c0d-a239e5e3a3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_482714b0-5b0b-4ad8-8c0d-a239e5e3a3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_dee0d2f6-9447-4d16-9d32-1e8f999ab9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_dee0d2f6-9447-4d16-9d32-1e8f999ab9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_3ab684b2-f0db-464a-960b-5212e9601811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_3ab684b2-f0db-464a-960b-5212e9601811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_1cfd2b10-0534-43fc-959c-d85c411fe35f" xlink:href="ameh-20220630.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_1cfd2b10-0534-43fc-959c-d85c411fe35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_dbc1f230-877c-4b8c-b1a4-fe0eb999a10f" xlink:href="ameh-20220630.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_dbc1f230-877c-4b8c-b1a4-fe0eb999a10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_69aa0c69-44ed-4a36-b168-c4c8ab420f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_69aa0c69-44ed-4a36-b168-c4c8ab420f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_53a497cd-8873-428a-bda2-fd3d90cc8bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_53a497cd-8873-428a-bda2-fd3d90cc8bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_8fb69d15-07ff-4857-9f31-57fe1d7e1be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_8fb69d15-07ff-4857-9f31-57fe1d7e1be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_d45ca6c4-f074-4b31-b2e9-af5c6c2f1525" xlink:href="ameh-20220630.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_d45ca6c4-f074-4b31-b2e9-af5c6c2f1525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_15e448a4-86e2-40d7-a91d-e389d78272e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_15e448a4-86e2-40d7-a91d-e389d78272e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0bc0cfc5-74f1-42af-b5a6-79a4c782c8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0bc0cfc5-74f1-42af-b5a6-79a4c782c8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_54b5633a-bfab-4e22-b85c-80b968b03551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8732bd02-69e2-4634-8834-cb166e6a1acc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_54b5633a-bfab-4e22-b85c-80b968b03551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a529779f-92a5-48bd-a399-5b4f7db82f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d6949125-fd09-4ea9-b9e6-0f282aa53d93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a529779f-92a5-48bd-a399-5b4f7db82f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d6c6720a-c07e-421d-89c8-cabe1d05b96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d6c6720a-c07e-421d-89c8-cabe1d05b96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_4b2cb004-33a0-4849-b2cf-64971c50c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_4b2cb004-33a0-4849-b2cf-64971c50c0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PrepaymentForInvestmentPurchase_b92ecbae-d60b-4d2e-ac07-9a652c6c1b49" xlink:href="ameh-20220630.xsd#ameh_PrepaymentForInvestmentPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_ameh_PrepaymentForInvestmentPurchase_b92ecbae-d60b-4d2e-ac07-9a652c6c1b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ff3920f0-d509-484c-b259-cde9d88a75ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ff3920f0-d509-484c-b259-cde9d88a75ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e74921bc-8d55-4ac0-9481-1ac658e06bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_e74921bc-8d55-4ac0-9481-1ac658e06bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d1723e65-2792-48c1-bb33-6ebeddecf48d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d1723e65-2792-48c1-bb33-6ebeddecf48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_42c7450a-354b-498e-8473-92bfc1d989fa" xlink:href="ameh-20220630.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_42c7450a-354b-498e-8473-92bfc1d989fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_bc39cc4e-92fe-458c-b054-56ace59b4a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_bc39cc4e-92fe-458c-b054-56ace59b4a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_52e7ac7e-b49f-475e-be13-397467f20eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_52e7ac7e-b49f-475e-be13-397467f20eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToEquityMethodInvestments_806aa683-b348-449f-91bc-38edf6499c13" xlink:href="ameh-20220630.xsd#ameh_PaymentsToEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_ameh_PaymentsToEquityMethodInvestments_806aa683-b348-449f-91bc-38edf6499c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99d6d7a1-4710-4162-8b29-a93b59f2eeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_de02c22d-b95c-4917-a4d3-532f7777fa3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99d6d7a1-4710-4162-8b29-a93b59f2eeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_315a21c2-ec27-412f-8ead-439ab54c8e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_us-gaap_PaymentsOfDividends_315a21c2-ec27-412f-8ead-439ab54c8e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e7e1a544-045d-4595-b2a0-00350c594c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e7e1a544-045d-4595-b2a0-00350c594c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ba1bec44-3200-4ab8-a1f1-87d8b29cb253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ba1bec44-3200-4ab8-a1f1-87d8b29cb253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_47075a7f-5928-41e8-8294-92035641ae86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_47075a7f-5928-41e8-8294-92035641ae86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a21d859b-428c-49bc-a9af-e6b24e2abdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a21d859b-428c-49bc-a9af-e6b24e2abdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_077ef6e1-cd07-4b33-bc98-e2c5904dd276" xlink:href="ameh-20220630.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_077ef6e1-cd07-4b33-bc98-e2c5904dd276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireNonControllingInterest_ba12f5c9-ab74-4ea2-a164-d67b5b0ed79d" xlink:href="ameh-20220630.xsd#ameh_PaymentsToAcquireNonControllingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_ameh_PaymentsToAcquireNonControllingInterest_ba12f5c9-ab74-4ea2-a164-d67b5b0ed79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_e27d2b8e-850c-45ab-a83d-50eb8e0fe148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_e27d2b8e-850c-45ab-a83d-50eb8e0fe148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3d1740a6-299b-496e-89ee-6204105b3eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3d1740a6-299b-496e-89ee-6204105b3eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a368e44d-6950-4138-bf08-a05b97d8f311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_a368e44d-6950-4138-bf08-a05b97d8f311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6a268d1-f4a2-4b27-8231-01e5774014f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99381cc2-71d5-4b9c-84e3-107a1f6ee120" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6a268d1-f4a2-4b27-8231-01e5774014f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_51d97b7f-7640-424c-8ee4-6d42b6c88f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_51d97b7f-7640-424c-8ee4-6d42b6c88f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68fd31a9-2b88-47c2-9496-c436a3bd20ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68fd31a9-2b88-47c2-9496-c436a3bd20ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edb4362e-46eb-4293-be84-b77f53f82997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edb4362e-46eb-4293-be84-b77f53f82997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_21338438-9e19-4780-8a3b-978645393cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_21338438-9e19-4780-8a3b-978645393cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_44800455-d604-4e11-9fcd-c23c6cbbd2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_21338438-9e19-4780-8a3b-978645393cc2" xlink:to="loc_us-gaap_IncomeTaxesPaid_44800455-d604-4e11-9fcd-c23c6cbbd2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_5d2b8572-b250-4f55-b684-138239612dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_21338438-9e19-4780-8a3b-978645393cc2" xlink:to="loc_us-gaap_InterestPaidNet_5d2b8572-b250-4f55-b684-138239612dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_85ef9e34-3c50-4d82-94b8-4d4105f00606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_85ef9e34-3c50-4d82-94b8-4d4105f00606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_7424b81b-93db-4acc-9f8e-3ca910d88cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_85ef9e34-3c50-4d82-94b8-4d4105f00606" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_7424b81b-93db-4acc-9f8e-3ca910d88cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_4fb548c6-107a-421c-817e-1c3ce34d7ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_85ef9e34-3c50-4d82-94b8-4d4105f00606" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_4fb548c6-107a-421c-817e-1c3ce34d7ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_698ca7f2-5362-47a5-8ad0-33d015003e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_85ef9e34-3c50-4d82-94b8-4d4105f00606" xlink:to="loc_us-gaap_StockIssued1_698ca7f2-5362-47a5-8ad0-33d015003e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CancellationOfRestrictedStockAwards_165b54c0-6ab7-462e-a347-e06017a90517" xlink:href="ameh-20220630.xsd#ameh_CancellationOfRestrictedStockAwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_85ef9e34-3c50-4d82-94b8-4d4105f00606" xlink:to="loc_ameh_CancellationOfRestrictedStockAwards_165b54c0-6ab7-462e-a347-e06017a90517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageLoanRelatedToPropertySales1_dd45323c-e342-49e2-87a4-1298e18c03eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageLoanRelatedToPropertySales1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_85ef9e34-3c50-4d82-94b8-4d4105f00606" xlink:to="loc_us-gaap_MortgageLoanRelatedToPropertySales1_dd45323c-e342-49e2-87a4-1298e18c03eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_232df8bc-7732-4ce3-9d29-3fbe64f7144d" xlink:href="ameh-20220630.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_024c287b-3bf4-46d1-9ab0-960d43c870bb" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_232df8bc-7732-4ce3-9d29-3fbe64f7144d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d4bf4f2d-8544-4fd7-a522-534f6439074d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_232df8bc-7732-4ce3-9d29-3fbe64f7144d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d4bf4f2d-8544-4fd7-a522-534f6439074d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_c49b65f0-a838-4098-bb0f-b6f15a6ce1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_232df8bc-7732-4ce3-9d29-3fbe64f7144d" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_c49b65f0-a838-4098-bb0f-b6f15a6ce1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f535299-5806-4395-88b1-484efbd5ad25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_232df8bc-7732-4ce3-9d29-3fbe64f7144d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f535299-5806-4395-88b1-484efbd5ad25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20220630.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b93e0316-88e2-4083-8248-6eb068e4338a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_dbc95de5-bc26-473d-b676-ebf0ae3ffee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b93e0316-88e2-4083-8248-6eb068e4338a" xlink:to="loc_us-gaap_NatureOfOperations_dbc95de5-bc26-473d-b676-ebf0ae3ffee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b5a9883-84ce-43cd-8d16-ca45f16f687b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:href="ameh-20220630.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b5a9883-84ce-43cd-8d16-ca45f16f687b" xlink:to="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_eee2b04c-96e8-45fb-b981-4c19c9aa1ac0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_dei_LegalEntityAxis_eee2b04c-96e8-45fb-b981-4c19c9aa1ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_eee2b04c-96e8-45fb-b981-4c19c9aa1ac0" xlink:to="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_4f802c78-25ff-429b-a9a1-d45d5ad4a43e" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_4f802c78-25ff-429b-a9a1-d45d5ad4a43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_03a874ec-f78b-42e3-be43-591c019a209e" xlink:href="ameh-20220630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:to="loc_ameh_AccountableHealthCareIPAMember_03a874ec-f78b-42e3-be43-591c019a209e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_ed223a9d-2541-4240-bf3c-b721e662d1fa" xlink:href="ameh-20220630.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:to="loc_ameh_AmgIncMember_ed223a9d-2541-4240-bf3c-b721e662d1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_e2c03e90-bd97-40f9-948b-c182b6d79ea0" xlink:href="ameh-20220630.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_601b1029-2982-47da-b518-d0c6b06b27dc" xlink:to="loc_ameh_ApcLsmaMember_e2c03e90-bd97-40f9-948b-c182b6d79ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_809a0893-0f9a-4172-8bb3-c419627284a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_srt_CounterpartyNameAxis_809a0893-0f9a-4172-8bb3-c419627284a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53252e6-8aeb-48f6-983e-b005898d3658" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_809a0893-0f9a-4172-8bb3-c419627284a1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53252e6-8aeb-48f6-983e-b005898d3658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_3db46078-4dac-4d15-987c-4da47ce5877c" xlink:href="ameh-20220630.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53252e6-8aeb-48f6-983e-b005898d3658" xlink:to="loc_ameh_APAMHMedicalCorporationMember_3db46078-4dac-4d15-987c-4da47ce5877c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_01beb58b-cd93-4df3-ac92-31f2afd2c36f" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f53252e6-8aeb-48f6-983e-b005898d3658" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_01beb58b-cd93-4df3-ac92-31f2afd2c36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5303427-e2b6-4bfb-941f-69069a9249eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5303427-e2b6-4bfb-941f-69069a9249eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d82f7fd0-8041-45b9-b79a-86a11ab1c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f5303427-e2b6-4bfb-941f-69069a9249eb" xlink:to="loc_us-gaap_RelatedPartyDomain_d82f7fd0-8041-45b9-b79a-86a11ab1c9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_518e1d28-e66f-44a2-86f7-c612a9c2072f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d82f7fd0-8041-45b9-b79a-86a11ab1c9cc" xlink:to="loc_srt_AffiliatedEntityMember_518e1d28-e66f-44a2-86f7-c612a9c2072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d14ed507-39f3-4c89-99c7-ade775b87407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d14ed507-39f3-4c89-99c7-ade775b87407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5462ee9a-d145-48fc-976c-d3ee9cdbaa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d14ed507-39f3-4c89-99c7-ade775b87407" xlink:to="loc_us-gaap_ClassOfStockDomain_5462ee9a-d145-48fc-976c-d3ee9cdbaa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b496f1a2-ca61-4339-b388-8e77df000069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5462ee9a-d145-48fc-976c-d3ee9cdbaa7c" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b496f1a2-ca61-4339-b388-8e77df000069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fc1e3e6-a3e6-42f2-be50-41146db11af8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fc1e3e6-a3e6-42f2-be50-41146db11af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fc1e3e6-a3e6-42f2-be50-41146db11af8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_0c597b88-1ac7-4c86-ac01-09e119c635ed" xlink:href="ameh-20220630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_0c597b88-1ac7-4c86-ac01-09e119c635ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_da0fb0d6-9749-43ca-9749-e6faa2f46382" xlink:href="ameh-20220630.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_da0fb0d6-9749-43ca-9749-e6faa2f46382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_c4eb9cd4-f8df-49e8-8318-5aca959f080c" xlink:href="ameh-20220630.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fb654e85-752a-4e57-8a9f-a7d4618be47a" xlink:to="loc_ameh_DmgMember_c4eb9cd4-f8df-49e8-8318-5aca959f080c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7092d5f7-136c-41c6-a728-c8746edbfd8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_srt_OwnershipAxis_7092d5f7-136c-41c6-a728-c8746edbfd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4ca6b073-60ac-477f-9042-a070edb7b76b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_7092d5f7-136c-41c6-a728-c8746edbfd8b" xlink:to="loc_srt_OwnershipDomain_4ca6b073-60ac-477f-9042-a070edb7b76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_e2123343-1cff-4356-903c-a3a8433ac3c9" xlink:href="ameh-20220630.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_4ca6b073-60ac-477f-9042-a070edb7b76b" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_e2123343-1cff-4356-903c-a3a8433ac3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_46486e4e-2101-4f5b-af3c-f14b7233089b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_46486e4e-2101-4f5b-af3c-f14b7233089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_46486e4e-2101-4f5b-af3c-f14b7233089b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_e3f83806-1eaf-4495-a836-2ff332d1ab57" xlink:href="ameh-20220630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:to="loc_ameh_AccountableHealthCareIPAMember_e3f83806-1eaf-4495-a836-2ff332d1ab57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_a040257b-838f-40c9-8ad0-39d8f60ec079" xlink:href="ameh-20220630.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:to="loc_ameh_AmgIncMember_a040257b-838f-40c9-8ad0-39d8f60ec079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_86d84869-6b37-459c-9db9-0daa8125e5cd" xlink:href="ameh-20220630.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_86d84869-6b37-459c-9db9-0daa8125e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_bbbef3a8-8f93-45cc-99c1-6f0a5a8ffeef" xlink:href="ameh-20220630.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34f5f173-e8c2-4b10-8a6f-9ee27cfe363f" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_bbbef3a8-8f93-45cc-99c1-6f0a5a8ffeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c5ae75ae-2fc4-4b3b-863c-197594db11a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c5ae75ae-2fc4-4b3b-863c-197594db11a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4d439807-8158-475e-b01a-a0e6a7955de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c5ae75ae-2fc4-4b3b-863c-197594db11a2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4d439807-8158-475e-b01a-a0e6a7955de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_fda74874-abfe-46de-a97a-27d721f81a58" xlink:href="ameh-20220630.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4d439807-8158-475e-b01a-a0e6a7955de8" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_fda74874-abfe-46de-a97a-27d721f81a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_c182ef86-98f0-4b76-9fc4-9cc580b53d72" xlink:href="ameh-20220630.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_4d439807-8158-475e-b01a-a0e6a7955de8" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_c182ef86-98f0-4b76-9fc4-9cc580b53d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:href="ameh-20220630.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_7216dcc7-c79a-4628-baa3-6b6df5c4bcb5" xlink:to="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_667943c6-fd79-4456-8757-cbfa5b8a6f86" xlink:href="ameh-20220630.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_667943c6-fd79-4456-8757-cbfa5b8a6f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_79ae825a-83c2-4507-bbe9-b10aae4fa7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_NotesReceivableNet_79ae825a-83c2-4507-bbe9-b10aae4fa7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_0fb0979c-41c6-4375-9a10-3734c4cee855" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_0fb0979c-41c6-4375-9a10-3734c4cee855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_66601ab0-be2b-4c35-8d6e-24ef19a4ca46" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_66601ab0-be2b-4c35-8d6e-24ef19a4ca46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_6bd86244-e67e-4fd0-bc8b-d2ff2e0fd2f8" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_6bd86244-e67e-4fd0-bc8b-d2ff2e0fd2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1ce6db9e-96c4-45c0-995c-57dc29dc679c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1ce6db9e-96c4-45c0-995c-57dc29dc679c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d32850c1-ca7e-4f30-911e-9ff23f3337ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d32850c1-ca7e-4f30-911e-9ff23f3337ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_23a8c381-c583-4ab1-a7d1-adf5db7d1d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_23a8c381-c583-4ab1-a7d1-adf5db7d1d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_2f3bca6e-162e-46fa-9ed2-22816c52c55c" xlink:href="ameh-20220630.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_2f3bca6e-162e-46fa-9ed2-22816c52c55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_48dfdfb9-2ad5-44d0-b6a2-3a86abce5c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_48dfdfb9-2ad5-44d0-b6a2-3a86abce5c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f449b442-fbc8-4268-8a54-93287858e7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f449b442-fbc8-4268-8a54-93287858e7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_fed62f02-678a-4b8d-af8e-c7e229b3eab8" xlink:href="ameh-20220630.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_fed62f02-678a-4b8d-af8e-c7e229b3eab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_c66a2bce-fd1c-427d-9691-659dc1fd3002" xlink:href="ameh-20220630.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_c66a2bce-fd1c-427d-9691-659dc1fd3002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7643d4b1-25d6-4e51-b6b5-aab696a33fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_us-gaap_EquityMethodInvestments_7643d4b1-25d6-4e51-b6b5-aab696a33fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_435caaac-5aff-4537-af72-d0c2a297383a" xlink:href="ameh-20220630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_435caaac-5aff-4537-af72-d0c2a297383a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_2e21d20e-fc63-42a7-b8d3-a1479e41c54b" xlink:href="ameh-20220630.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_ba917082-c65c-468d-80af-847432589b7e" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_2e21d20e-fc63-42a7-b8d3-a1479e41c54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd8db7e0-771f-4bbe-8667-ff40af148f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4d48d677-56cd-494b-8a73-a689b2e730c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd8db7e0-771f-4bbe-8667-ff40af148f46" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_4d48d677-56cd-494b-8a73-a689b2e730c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_59cb9b6f-167c-47fa-92d1-2211173ce895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_59cb9b6f-167c-47fa-92d1-2211173ce895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d1083424-98db-47f0-8a23-45fe9175d943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d1083424-98db-47f0-8a23-45fe9175d943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_40f91d32-3967-499d-a6a5-30ac5029b8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_40f91d32-3967-499d-a6a5-30ac5029b8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_129095ca-9417-4d59-b8ad-3d5d8ab1c8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_UseOfEstimates_129095ca-9417-4d59-b8ad-3d5d8ab1c8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_50877673-f3ff-441b-8908-bfb06691c069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_50877673-f3ff-441b-8908-bfb06691c069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_09ccfa43-426c-4629-a477-75f6c3b0c283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_09ccfa43-426c-4629-a477-75f6c3b0c283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_03ca44dc-f53d-44bd-abb3-9f0f865d4d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_03ca44dc-f53d-44bd-abb3-9f0f865d4d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b5375b86-e05b-4d1b-8aa4-55e009ac774c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b5375b86-e05b-4d1b-8aa4-55e009ac774c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_70dcc6a9-34c3-4590-ad5a-b9912842f690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_70dcc6a9-34c3-4590-ad5a-b9912842f690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_4a27a8ee-f708-4a1d-bb39-1dddd8344777" xlink:href="ameh-20220630.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_4a27a8ee-f708-4a1d-bb39-1dddd8344777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c840348e-dd28-499d-b05f-5de3efbeb878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c840348e-dd28-499d-b05f-5de3efbeb878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1d4d9bde-0350-4a2f-8696-349558a84e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1d4d9bde-0350-4a2f-8696-349558a84e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ffd15e36-8740-458c-b55e-0654f7793b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ffd15e36-8740-458c-b55e-0654f7793b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_93abd926-5d0d-4891-8a5b-1c166d633985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_93abd926-5d0d-4891-8a5b-1c166d633985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_b06ae869-3a27-486f-b773-d6031908f190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_b06ae869-3a27-486f-b773-d6031908f190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_9fbe26e5-cb47-46a5-8aa2-39b21833a5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_9fbe26e5-cb47-46a5-8aa2-39b21833a5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_227f5499-44c2-4fcc-a246-806add013887" xlink:href="ameh-20220630.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_227f5499-44c2-4fcc-a246-806add013887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_f1905cce-7f71-4491-b197-781f54a58546" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_f1905cce-7f71-4491-b197-781f54a58546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c0ad5067-3255-4538-8cfe-4f8227a42c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c0ad5067-3255-4538-8cfe-4f8227a42c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2915fa9b-c59f-4c65-9e10-9f60832c1249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2915fa9b-c59f-4c65-9e10-9f60832c1249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_120fe982-f1e1-4c22-8623-c39f1054eb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_120fe982-f1e1-4c22-8623-c39f1054eb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9aaaeb1c-083c-4daf-91d5-36e821b964db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9aaaeb1c-083c-4daf-91d5-36e821b964db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock_359fe878-a363-4235-b029-18ec94c7ce89" xlink:href="ameh-20220630.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_ameh_MinorityInterestPolicyPolicyTextBlock_359fe878-a363-4235-b029-18ec94c7ce89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock_5c863a0b-b3a9-45bc-9e37-75e0ec9b52ee" xlink:href="ameh-20220630.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_ameh_TemporaryEquityPolicyTextBlock_5c863a0b-b3a9-45bc-9e37-75e0ec9b52ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_61525d9d-e8a8-441c-8834-29155f99e299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_61525d9d-e8a8-441c-8834-29155f99e299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_57b6fcde-905e-4d90-a2a7-294add9f7121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94ff0133-7455-46a0-8a38-0219e67f0e1e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_57b6fcde-905e-4d90-a2a7-294add9f7121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c2b4b516-ed9f-43ee-904f-c8156bcdadb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_c623cf0d-92a8-49f1-9b94-6bdd53248205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c2b4b516-ed9f-43ee-904f-c8156bcdadb9" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_c623cf0d-92a8-49f1-9b94-6bdd53248205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_afbfab61-5753-421a-b91d-da9db96e13da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c2b4b516-ed9f-43ee-904f-c8156bcdadb9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_afbfab61-5753-421a-b91d-da9db96e13da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_20502b13-4127-4f0b-b7a0-a6261f2b6d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c2b4b516-ed9f-43ee-904f-c8156bcdadb9" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_20502b13-4127-4f0b-b7a0-a6261f2b6d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3798915e-c069-4089-8370-16740385d166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c2b4b516-ed9f-43ee-904f-c8156bcdadb9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3798915e-c069-4089-8370-16740385d166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad654c1b-2323-4e3f-84d0-746f1098c5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:href="ameh-20220630.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad654c1b-2323-4e3f-84d0-746f1098c5e3" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_35cd6479-4adb-4cad-8534-22d7c755bd5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_RangeAxis_35cd6479-4adb-4cad-8534-22d7c755bd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f0b8c3f9-234e-4f67-90b0-c886e87024b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_35cd6479-4adb-4cad-8534-22d7c755bd5c" xlink:to="loc_srt_RangeMember_f0b8c3f9-234e-4f67-90b0-c886e87024b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4a5da99-e54a-4353-aeec-6b2f8722186b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f0b8c3f9-234e-4f67-90b0-c886e87024b6" xlink:to="loc_srt_MinimumMember_a4a5da99-e54a-4353-aeec-6b2f8722186b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6fc58570-3a41-4170-8493-0c0eb82b5b84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f0b8c3f9-234e-4f67-90b0-c886e87024b6" xlink:to="loc_srt_MaximumMember_6fc58570-3a41-4170-8493-0c0eb82b5b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1d9dc7ba-5553-44b4-8a27-12114d589a64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_CounterpartyNameAxis_1d9dc7ba-5553-44b4-8a27-12114d589a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f3c527f-2990-46f5-8d64-9dc65070bb45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1d9dc7ba-5553-44b4-8a27-12114d589a64" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f3c527f-2990-46f5-8d64-9dc65070bb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember_659cdd4d-39f3-439b-a729-942ef7020ec8" xlink:href="ameh-20220630.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f3c527f-2990-46f5-8d64-9dc65070bb45" xlink:to="loc_ameh_ClinigenceHoldingsIncMember_659cdd4d-39f3-439b-a729-942ef7020ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_16b4579d-7028-4eff-a8f4-8113e88b32c8" xlink:href="ameh-20220630.xsd#ameh_CMSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f3c527f-2990-46f5-8d64-9dc65070bb45" xlink:to="loc_ameh_CMSMember_16b4579d-7028-4eff-a8f4-8113e88b32c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b91897e8-87d8-44a5-a519-df613cb08f5a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_ProductOrServiceAxis_b91897e8-87d8-44a5-a519-df613cb08f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ac4e6a2b-da20-4375-ae69-5e5a1a817ddd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b91897e8-87d8-44a5-a519-df613cb08f5a" xlink:to="loc_srt_ProductsAndServicesDomain_ac4e6a2b-da20-4375-ae69-5e5a1a817ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_1dba71a0-dc47-4c30-b158-eb7e21e0132c" xlink:href="ameh-20220630.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ac4e6a2b-da20-4375-ae69-5e5a1a817ddd" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_1dba71a0-dc47-4c30-b158-eb7e21e0132c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_910ccd5c-4d47-445e-90a9-76612753070c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ac4e6a2b-da20-4375-ae69-5e5a1a817ddd" xlink:to="loc_us-gaap_ManagementServiceMember_910ccd5c-4d47-445e-90a9-76612753070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_1bdd32d8-2cc6-4815-8551-bfc6a94863ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_OwnershipAxis_1bdd32d8-2cc6-4815-8551-bfc6a94863ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_85cae62f-32bd-4554-8136-6c8b14fa1fd3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1bdd32d8-2cc6-4815-8551-bfc6a94863ad" xlink:to="loc_srt_OwnershipDomain_85cae62f-32bd-4554-8136-6c8b14fa1fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3ab63109-cecc-49ce-a31a-0d60e2eaa171" xlink:href="ameh-20220630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_85cae62f-32bd-4554-8136-6c8b14fa1fd3" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_3ab63109-cecc-49ce-a31a-0d60e2eaa171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_af3a1b15-5f57-4d0e-b8aa-149c6d4588e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_dei_LegalEntityAxis_af3a1b15-5f57-4d0e-b8aa-149c6d4588e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_18df6af7-7d22-4c19-b8e4-cd6ec861a688" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_af3a1b15-5f57-4d0e-b8aa-149c6d4588e9" xlink:to="loc_dei_EntityDomain_18df6af7-7d22-4c19-b8e4-cd6ec861a688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_957722d4-b2ad-48d4-8b7e-d3e39f1fdf1b" xlink:href="ameh-20220630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_18df6af7-7d22-4c19-b8e4-cd6ec861a688" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_957722d4-b2ad-48d4-8b7e-d3e39f1fdf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9ab64b12-b2c4-4a85-aa6c-211bfcc6fdfb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9ab64b12-b2c4-4a85-aa6c-211bfcc6fdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_bfdd9b66-716c-4ab9-acc0-62a73cafcad2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9ab64b12-b2c4-4a85-aa6c-211bfcc6fdfb" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_bfdd9b66-716c-4ab9-acc0-62a73cafcad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_06aafd59-1dc7-406c-adfa-00ee7de522da" xlink:href="ameh-20220630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_bfdd9b66-716c-4ab9-acc0-62a73cafcad2" xlink:to="loc_ameh_UniversalCareIncMember_06aafd59-1dc7-406c-adfa-00ee7de522da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d1cb035b-5832-4184-b3c7-f0fd35d93412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d1cb035b-5832-4184-b3c7-f0fd35d93412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eca0c2d9-a0ea-4705-aabb-02ef41c3645f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d1cb035b-5832-4184-b3c7-f0fd35d93412" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eca0c2d9-a0ea-4705-aabb-02ef41c3645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_340bfafc-ae01-48f7-83f6-6e156c5788eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eca0c2d9-a0ea-4705-aabb-02ef41c3645f" xlink:to="loc_us-gaap_CertificatesOfDepositMember_340bfafc-ae01-48f7-83f6-6e156c5788eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_23700ee5-545d-4536-92f0-b4259f54100d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_23700ee5-545d-4536-92f0-b4259f54100d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_152c7a44-3757-4775-a029-73d8deba3abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_23700ee5-545d-4536-92f0-b4259f54100d" xlink:to="loc_us-gaap_HedgingRelationshipDomain_152c7a44-3757-4775-a029-73d8deba3abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_a4b7c1e7-4652-4eef-ad4f-b1b5f5a9e310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_152c7a44-3757-4775-a029-73d8deba3abf" xlink:to="loc_us-gaap_CashFlowHedgingMember_a4b7c1e7-4652-4eef-ad4f-b1b5f5a9e310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69a8324b-ae6a-4c26-ae27-2463c05c5f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69a8324b-ae6a-4c26-ae27-2463c05c5f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d6f68446-2cd2-4158-936f-b47098dc8eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_69a8324b-ae6a-4c26-ae27-2463c05c5f62" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d6f68446-2cd2-4158-936f-b47098dc8eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_db0e611b-5214-4455-b7b8-00dc73bcb43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d6f68446-2cd2-4158-936f-b47098dc8eb9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_db0e611b-5214-4455-b7b8-00dc73bcb43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0ae20cf4-2fd5-4d2a-94a2-5751a4a25727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0ae20cf4-2fd5-4d2a-94a2-5751a4a25727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2562c0f0-95b7-440c-8bae-26ee04cad40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0ae20cf4-2fd5-4d2a-94a2-5751a4a25727" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2562c0f0-95b7-440c-8bae-26ee04cad40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_24233552-5bb7-44ba-b3c3-bcab9649382a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2562c0f0-95b7-440c-8bae-26ee04cad40a" xlink:to="loc_us-gaap_InterestRateSwapMember_24233552-5bb7-44ba-b3c3-bcab9649382a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_00275456-466d-457f-928f-c2e31edeb9d1" xlink:href="ameh-20220630.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2562c0f0-95b7-440c-8bae-26ee04cad40a" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_00275456-466d-457f-928f-c2e31edeb9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c54d35c1-4706-4c7c-bbe2-f3b398149940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c54d35c1-4706-4c7c-bbe2-f3b398149940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c54d35c1-4706-4c7c-bbe2-f3b398149940" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_cd95d389-de67-418f-83ce-87e10ff47f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_cd95d389-de67-418f-83ce-87e10ff47f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7d88bdc2-c35b-4d8e-ab11-a7d22012b4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7d88bdc2-c35b-4d8e-ab11-a7d22012b4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_69bbda0b-f0bd-49f9-93b4-6a984507e1fb" xlink:href="ameh-20220630.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_864bd5e6-68b0-4bef-b098-3737c1baf50b" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_69bbda0b-f0bd-49f9-93b4-6a984507e1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_075c328a-2f1e-44bb-bbf7-d8ede39c119f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_us-gaap_HedgingDesignationAxis_075c328a-2f1e-44bb-bbf7-d8ede39c119f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d4cf7d94-a330-4b9f-bdec-9710de75ce9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_075c328a-2f1e-44bb-bbf7-d8ede39c119f" xlink:to="loc_us-gaap_HedgingDesignationDomain_d4cf7d94-a330-4b9f-bdec-9710de75ce9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f4cb412a-5a69-4385-be61-e1514946259a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d4cf7d94-a330-4b9f-bdec-9710de75ce9e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f4cb412a-5a69-4385-be61-e1514946259a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:href="ameh-20220630.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ec554059-a1dd-45a2-9f5d-342641d1b5e5" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d9b17381-b8de-4919-a383-534ae14a1738" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d9b17381-b8de-4919-a383-534ae14a1738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_d738644d-942c-4a43-8b35-4337bbbbb051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_NumberOfReportableSegments_d738644d-942c-4a43-8b35-4337bbbbb051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_96c1c9fc-a95f-45cb-bef1-aab52e6b6a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_CashUninsuredAmount_96c1c9fc-a95f-45cb-bef1-aab52e6b6a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_08280927-afb1-4e6e-b7b9-ebd3e70bb2c4" xlink:href="ameh-20220630.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_08280927-afb1-4e6e-b7b9-ebd3e70bb2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c13aef53-fa77-4fcf-862d-db02c188c21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c13aef53-fa77-4fcf-862d-db02c188c21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_f224f329-5e67-410d-968f-b6023dc58319" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_f224f329-5e67-410d-968f-b6023dc58319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_9a5a1ca7-3ccb-42ee-9d60-daebe504b841" xlink:href="ameh-20220630.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_9a5a1ca7-3ccb-42ee-9d60-daebe504b841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e716a496-d126-4892-97ee-ee5988b325cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e716a496-d126-4892-97ee-ee5988b325cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2a0e3056-ef78-46e4-90c2-f4f2b65cdeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2a0e3056-ef78-46e4-90c2-f4f2b65cdeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_4b0008ac-aeb6-4ee1-9d00-3846cd8d0468" xlink:href="ameh-20220630.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_4b0008ac-aeb6-4ee1-9d00-3846cd8d0468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9b6afd15-758a-44f8-a359-1360725c10f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9b6afd15-758a-44f8-a359-1360725c10f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_59f3185c-7dc5-49be-8104-1f5fae6b36a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_59f3185c-7dc5-49be-8104-1f5fae6b36a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_f73c5e98-ea46-4ca4-ac7a-a0e9884ca869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_NumberOfReportingUnits_f73c5e98-ea46-4ca4-ac7a-a0e9884ca869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cdcd15ed-c3c2-49fa-9e53-5a4d33c95d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cdcd15ed-c3c2-49fa-9e53-5a4d33c95d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_32e422b2-eab6-4be7-b7f0-408e835e14bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_32e422b2-eab6-4be7-b7f0-408e835e14bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_6ac9f709-7875-48b4-b6d3-cccc4c82807c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_6ac9f709-7875-48b4-b6d3-cccc4c82807c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_07fcae92-f4a0-4d16-8633-993975fc1d75" xlink:href="ameh-20220630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_07fcae92-f4a0-4d16-8633-993975fc1d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_87436a09-393c-42d4-904d-9ed76bdaaa77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_87436a09-393c-42d4-904d-9ed76bdaaa77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b676165c-470e-46b2-b715-08313542011a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_b676165c-470e-46b2-b715-08313542011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_042755c4-23b8-4af3-b683-11fe31f23804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_DerivativeAssets_042755c4-23b8-4af3-b683-11fe31f23804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_4f6ae161-4e0c-4802-b3b2-1fe59c06569f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_4f6ae161-4e0c-4802-b3b2-1fe59c06569f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_5fd4c5b0-1697-4616-936d-7db52716614b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_5fd4c5b0-1697-4616-936d-7db52716614b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_b8f83a4e-c725-40aa-a36c-745f336b1f48" xlink:href="ameh-20220630.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_b8f83a4e-c725-40aa-a36c-745f336b1f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d30f922b-70b5-4bb9-a5b1-c24f5c75465f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d30f922b-70b5-4bb9-a5b1-c24f5c75465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_80694537-6059-47ae-a4f3-02a880d58dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_e8ce97f2-c020-4238-a1e7-6f0998a106a4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_80694537-6059-47ae-a4f3-02a880d58dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_86105d6a-3a90-424d-8b22-acde749ba846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_ac455803-a67b-458e-a70d-cb1a84e5bea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_86105d6a-3a90-424d-8b22-acde749ba846" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_ac455803-a67b-458e-a70d-cb1a84e5bea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0ed4ad2d-9aca-4519-8153-b0782ccac503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_86105d6a-3a90-424d-8b22-acde749ba846" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0ed4ad2d-9aca-4519-8153-b0782ccac503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_95d6e63a-a4db-41c7-8e18-fba071f9c81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_86105d6a-3a90-424d-8b22-acde749ba846" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_95d6e63a-a4db-41c7-8e18-fba071f9c81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_31be6663-acbd-48a9-84a8-0978209ce3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7d448ed9-dfd7-4710-a0d2-67d9641894a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31be6663-acbd-48a9-84a8-0978209ce3df" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7d448ed9-dfd7-4710-a0d2-67d9641894a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0a7af20f-36cd-4d31-8444-c3f7f07927e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7d448ed9-dfd7-4710-a0d2-67d9641894a7" xlink:to="loc_srt_MajorCustomersAxis_0a7af20f-36cd-4d31-8444-c3f7f07927e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0a7af20f-36cd-4d31-8444-c3f7f07927e5" xlink:to="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_1dff171f-cf02-4de8-a176-447714df72fd" xlink:href="ameh-20220630.xsd#ameh_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:to="loc_ameh_CommercialMember_1dff171f-cf02-4de8-a176-447714df72fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_21a533ba-e8e3-4b9f-ad56-706935ea56a3" xlink:href="ameh-20220630.xsd#ameh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:to="loc_ameh_MedicareMember_21a533ba-e8e3-4b9f-ad56-706935ea56a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_382ebbde-4a23-4770-894c-5cbf3ff4e71f" xlink:href="ameh-20220630.xsd#ameh_MedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:to="loc_ameh_MedicaidMember_382ebbde-4a23-4770-894c-5cbf3ff4e71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_9b2f613d-1666-48cb-8378-234d29b29c05" xlink:href="ameh-20220630.xsd#ameh_OtherThirdPartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_132a4cf3-e720-4314-8ef3-d71d7ff7fddb" xlink:to="loc_ameh_OtherThirdPartiesMember_9b2f613d-1666-48cb-8378-234d29b29c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_06722c90-c230-4757-8f82-fba95f30a075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7d448ed9-dfd7-4710-a0d2-67d9641894a7" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_06722c90-c230-4757-8f82-fba95f30a075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3605cf7d-459b-44dd-a6fc-ac2876f24a82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_06722c90-c230-4757-8f82-fba95f30a075" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3605cf7d-459b-44dd-a6fc-ac2876f24a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0d06fa7c-46d6-4349-9ff9-7026bf2e2021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:href="ameh-20220630.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d06fa7c-46d6-4349-9ff9-7026bf2e2021" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_959d6a19-b2d4-44fd-a50c-c7102a8eec77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_959d6a19-b2d4-44fd-a50c-c7102a8eec77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6eb6d5b7-0dfb-4ffc-b3bc-73305ef34ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_959d6a19-b2d4-44fd-a50c-c7102a8eec77" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6eb6d5b7-0dfb-4ffc-b3bc-73305ef34ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_85b53529-48ef-425d-97ea-808862aedaad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6eb6d5b7-0dfb-4ffc-b3bc-73305ef34ad5" xlink:to="loc_us-gaap_SalesRevenueNetMember_85b53529-48ef-425d-97ea-808862aedaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_0d7d470d-c213-44d0-ba90-12ec0bf07e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6eb6d5b7-0dfb-4ffc-b3bc-73305ef34ad5" xlink:to="loc_us-gaap_AccountsReceivableMember_0d7d470d-c213-44d0-ba90-12ec0bf07e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_83706c65-0d20-4ad1-9590-1a126f852a73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:to="loc_srt_MajorCustomersAxis_83706c65-0d20-4ad1-9590-1a126f852a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_83706c65-0d20-4ad1-9590-1a126f852a73" xlink:to="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_6b3e3289-9e68-4595-af52-5769c441181f" xlink:href="ameh-20220630.xsd#ameh_PayorAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorAMember_6b3e3289-9e68-4595-af52-5769c441181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_acd05750-6f94-4f9f-bc56-10f2a2066c8a" xlink:href="ameh-20220630.xsd#ameh_PayorBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorBMember_acd05750-6f94-4f9f-bc56-10f2a2066c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_2ff01b2d-52e1-4cf7-9513-b5e746eefbf8" xlink:href="ameh-20220630.xsd#ameh_PayorCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorCMember_2ff01b2d-52e1-4cf7-9513-b5e746eefbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_8051f0d2-6870-40ec-8870-961a4feb0aa8" xlink:href="ameh-20220630.xsd#ameh_PayorDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorDMember_8051f0d2-6870-40ec-8870-961a4feb0aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_f8a87158-4da0-4b67-9fd4-f60bd10bd17f" xlink:href="ameh-20220630.xsd#ameh_PayorEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorEMember_f8a87158-4da0-4b67-9fd4-f60bd10bd17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_b98e6aac-3430-4476-a1e2-d0e813c1eda0" xlink:href="ameh-20220630.xsd#ameh_PayorFMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_069ab72b-d595-42f0-8804-17bfc542520a" xlink:to="loc_ameh_PayorFMember_b98e6aac-3430-4476-a1e2-d0e813c1eda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_559d9b3b-10ba-4f61-8226-ccfe4bc8aabe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_559d9b3b-10ba-4f61-8226-ccfe4bc8aabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c8534961-ad23-498e-823c-011c3b2fc6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_559d9b3b-10ba-4f61-8226-ccfe4bc8aabe" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c8534961-ad23-498e-823c-011c3b2fc6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3f29a807-4cfd-4ad2-8874-0ed0cd225c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c8534961-ad23-498e-823c-011c3b2fc6f6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3f29a807-4cfd-4ad2-8874-0ed0cd225c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_18a88fa4-ce30-497f-9bf4-f36c7b17fbbe" xlink:href="ameh-20220630.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4e611523-06dd-48df-981d-45e8d9fbe29c" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueLineItems_18a88fa4-ce30-497f-9bf4-f36c7b17fbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a25a34ba-1dd9-4381-b94f-2721b375cb77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_18a88fa4-ce30-497f-9bf4-f36c7b17fbbe" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a25a34ba-1dd9-4381-b94f-2721b375cb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5336def5-945b-45fd-abe4-48b7241115ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_644b0adf-73c1-41b1-acfd-cc6c7acb8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5336def5-945b-45fd-abe4-48b7241115ff" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_644b0adf-73c1-41b1-acfd-cc6c7acb8e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0c860c76-68ab-468a-bcb9-36cda9bc7927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_644b0adf-73c1-41b1-acfd-cc6c7acb8e77" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0c860c76-68ab-468a-bcb9-36cda9bc7927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0c860c76-68ab-468a-bcb9-36cda9bc7927" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1cf4e509-c55a-494f-9617-ecdbdb9910e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1cf4e509-c55a-494f-9617-ecdbdb9910e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_93628b5e-f431-4cfc-b082-7c10a0dcd6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_93628b5e-f431-4cfc-b082-7c10a0dcd6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_97fa4a2f-9cf8-436c-9d90-4b7e9065f21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4426cfbc-ea91-475d-bba4-0ec8aac565e1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_97fa4a2f-9cf8-436c-9d90-4b7e9065f21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b6097ff5-fd8f-4d75-9367-759fa91ab6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_644b0adf-73c1-41b1-acfd-cc6c7acb8e77" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b6097ff5-fd8f-4d75-9367-759fa91ab6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b6097ff5-fd8f-4d75-9367-759fa91ab6be" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_6a46dba0-59dc-4098-afc5-ea25a7d187cd" xlink:href="ameh-20220630.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_6a46dba0-59dc-4098-afc5-ea25a7d187cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fa6fc576-1314-4ce6-b80b-18bf153e3b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:to="loc_us-gaap_WarrantMember_fa6fc576-1314-4ce6-b80b-18bf153e3b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e4da13a2-a969-41ea-bbe8-1177a9474b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_57fd4e7c-4250-49e5-8d2b-a8e289ad64d5" xlink:to="loc_us-gaap_InterestRateSwapMember_e4da13a2-a969-41ea-bbe8-1177a9474b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_644b0adf-73c1-41b1-acfd-cc6c7acb8e77" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8be9b156-155a-4fec-a745-0cfdecc8d693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8be9b156-155a-4fec-a745-0cfdecc8d693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b4975b7-7e6d-4450-89e6-dd0be56ec5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b4975b7-7e6d-4450-89e6-dd0be56ec5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d2322270-f2dd-4f65-9cc8-1a725a0e2749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d2322270-f2dd-4f65-9cc8-1a725a0e2749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_1f6e21dc-e464-40e0-b7b7-80822c4f960e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_DerivativeAssets_1f6e21dc-e464-40e0-b7b7-80822c4f960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b76b23b5-afb4-4fec-a04f-e4b8ea39b245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b76b23b5-afb4-4fec-a04f-e4b8ea39b245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ce61fb68-2967-4a9d-911c-db9a3ef4b768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_DerivativeLiabilities_ce61fb68-2967-4a9d-911c-db9a3ef4b768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b7a0d8c2-1a07-4a31-967f-f070894d1ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b7a0d8c2-1a07-4a31-967f-f070894d1ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a109ac9f-7b7a-4837-9ab9-496a8cf4d18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6198b9bd-8c13-4a98-809c-7d4df04814ae" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a109ac9f-7b7a-4837-9ab9-496a8cf4d18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20220630.xsd#BusinessCombinationsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_daec2b77-f77b-489b-805e-f3f75c94dfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e6a2cf37-0dde-4d1a-98be-b3f1bd389687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_daec2b77-f77b-489b-805e-f3f75c94dfa5" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e6a2cf37-0dde-4d1a-98be-b3f1bd389687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ba254bdc-cf40-4aae-9697-c53d4b9a80c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_6a86634a-cf71-403e-a571-2c969378f89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ba254bdc-cf40-4aae-9697-c53d4b9a80c0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_6a86634a-cf71-403e-a571-2c969378f89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fd230937-9e7f-4af9-b09e-85e564fdec50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cbadba39-9e20-4e8b-8812-96bf8622174b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_fd230937-9e7f-4af9-b09e-85e564fdec50" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cbadba39-9e20-4e8b-8812-96bf8622174b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6d90bde8-e764-41ad-83f7-e76418019bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cbadba39-9e20-4e8b-8812-96bf8622174b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6d90bde8-e764-41ad-83f7-e76418019bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6d90bde8-e764-41ad-83f7-e76418019bb9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_JadeHealthCareMedicalGroupIncMember_fdd8fe59-93de-4218-9de6-6210bcda7881" xlink:href="ameh-20220630.xsd#ameh_JadeHealthCareMedicalGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_JadeHealthCareMedicalGroupIncMember_fdd8fe59-93de-4218-9de6-6210bcda7881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_d4dd8e00-0dc6-4e6e-82a4-501838437935" xlink:href="ameh-20220630.xsd#ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_d4dd8e00-0dc6-4e6e-82a4-501838437935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_94020b58-2a39-42ec-9a6e-754d9ffe3837" xlink:href="ameh-20220630.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_94020b58-2a39-42ec-9a6e-754d9ffe3837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_b4599986-6cb6-490d-ab75-ba13f9aedb59" xlink:href="ameh-20220630.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_b4599986-6cb6-490d-ab75-ba13f9aedb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_062a3e9e-2192-468e-810c-70403acc489f" xlink:href="ameh-20220630.xsd#ameh_DmgMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5691d34f-fd9d-4c1f-b888-e25c30a9a84a" xlink:to="loc_ameh_DmgMember_062a3e9e-2192-468e-810c-70403acc489f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cbadba39-9e20-4e8b-8812-96bf8622174b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bf6bb788-c22c-4e00-9f6c-5e4725451e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_bf6bb788-c22c-4e00-9f6c-5e4725451e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d4ab58b7-6777-4985-a9ed-71ce71719222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d4ab58b7-6777-4985-a9ed-71ce71719222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_83e598be-c0c9-40c0-9b72-f40abe63a601" xlink:href="ameh-20220630.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_335d96c6-b414-4a7c-af53-5d38d0fcd0a0" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_83e598be-c0c9-40c0-9b72-f40abe63a601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e9198f62-f1d4-4b5c-8ccc-281e20fa24ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_2b76ac46-8a66-4fc5-85f6-f59ac92dc2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e9198f62-f1d4-4b5c-8ccc-281e20fa24ca" xlink:to="loc_us-gaap_GoodwillRollForward_2b76ac46-8a66-4fc5-85f6-f59ac92dc2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8bd5b5be-6981-4c36-b9d2-4f07848dfb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2b76ac46-8a66-4fc5-85f6-f59ac92dc2dd" xlink:to="loc_us-gaap_Goodwill_8bd5b5be-6981-4c36-b9d2-4f07848dfb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_fbe80067-6c18-42e8-853a-b8a0e50bc311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2b76ac46-8a66-4fc5-85f6-f59ac92dc2dd" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_fbe80067-6c18-42e8-853a-b8a0e50bc311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_abc241f9-38d8-4a54-abbc-d0cfd853e9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2b76ac46-8a66-4fc5-85f6-f59ac92dc2dd" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_abc241f9-38d8-4a54-abbc-d0cfd853e9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f9ddfd32-e487-46ea-86e7-960b69c386ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_2b76ac46-8a66-4fc5-85f6-f59ac92dc2dd" xlink:to="loc_us-gaap_Goodwill_f9ddfd32-e487-46ea-86e7-960b69c386ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c5b725ed-f2d8-4fe7-ab0b-442417e357c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_52d32b0a-f30f-434c-95de-a0acddbfbe76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c5b725ed-f2d8-4fe7-ab0b-442417e357c7" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_52d32b0a-f30f-434c-95de-a0acddbfbe76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b048370-5396-43eb-972f-24fbdc20fce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_14de5eba-f32c-4be1-b740-533c6838c8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b048370-5396-43eb-972f-24fbdc20fce4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_14de5eba-f32c-4be1-b740-533c6838c8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c73432ef-fcdd-45c4-bf41-3fd87350b223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b048370-5396-43eb-972f-24fbdc20fce4" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c73432ef-fcdd-45c4-bf41-3fd87350b223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5df2a1da-312f-4bb9-85f0-431e7524c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0bd1b020-f737-4645-a0c8-3488c4d87ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5df2a1da-312f-4bb9-85f0-431e7524c57b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0bd1b020-f737-4645-a0c8-3488c4d87ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1279db9e-e0e4-4a97-9ae7-4a6b00625926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0bd1b020-f737-4645-a0c8-3488c4d87ddc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1279db9e-e0e4-4a97-9ae7-4a6b00625926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1279db9e-e0e4-4a97-9ae7-4a6b00625926" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_ba326a62-111f-403f-a770-f48c8f8e1504" xlink:href="ameh-20220630.xsd#ameh_NetworkRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_ameh_NetworkRelationshipsMember_ba326a62-111f-403f-a770-f48c8f8e1504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_6ff08d43-75cd-48d9-8328-e6cb52f0f44f" xlink:href="ameh-20220630.xsd#ameh_ManagementContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_ameh_ManagementContractsMember_6ff08d43-75cd-48d9-8328-e6cb52f0f44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_c24f2486-5455-4e6f-b1ac-dff4c5bcd698" xlink:href="ameh-20220630.xsd#ameh_MemberRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_ameh_MemberRelationshipsMember_c24f2486-5455-4e6f-b1ac-dff4c5bcd698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_c0990d84-8edb-4402-abd1-08f85a99acda" xlink:href="ameh-20220630.xsd#ameh_PatientManagementPlatformMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_ameh_PatientManagementPlatformMember_c0990d84-8edb-4402-abd1-08f85a99acda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_55e5ef82-048a-4067-a127-927dbadc05e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_55e5ef82-048a-4067-a127-927dbadc05e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_e7026de3-b549-46d6-b49a-5686c700cb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_us-gaap_CustomerRelationshipsMember_e7026de3-b549-46d6-b49a-5686c700cb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3845ff34-50d5-4482-af8c-ee18816b53d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d43addac-be95-45fe-8e26-f3a13c915452" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3845ff34-50d5-4482-af8c-ee18816b53d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9495f24f-f0a1-43a2-a66e-9a351130bd85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0bd1b020-f737-4645-a0c8-3488c4d87ddc" xlink:to="loc_srt_RangeAxis_9495f24f-f0a1-43a2-a66e-9a351130bd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b141719-5d2e-43a2-9f8d-07215ca8f333" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9495f24f-f0a1-43a2-a66e-9a351130bd85" xlink:to="loc_srt_RangeMember_5b141719-5d2e-43a2-9f8d-07215ca8f333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e092e7b-0dd7-4ac1-9cc8-d98d16521311" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5b141719-5d2e-43a2-9f8d-07215ca8f333" xlink:to="loc_srt_MinimumMember_5e092e7b-0dd7-4ac1-9cc8-d98d16521311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_279a3544-a96a-4adb-9e97-3233905072ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5b141719-5d2e-43a2-9f8d-07215ca8f333" xlink:to="loc_srt_MaximumMember_279a3544-a96a-4adb-9e97-3233905072ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0bd1b020-f737-4645-a0c8-3488c4d87ddc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee4b3653-b1b1-468b-ac63-341c681350fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee4b3653-b1b1-468b-ac63-341c681350fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5cb909e1-6567-4601-a1b7-0fe7eb2bc350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5cb909e1-6567-4601-a1b7-0fe7eb2bc350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7702bf0d-2f23-4664-b678-31ce497aada8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7702bf0d-2f23-4664-b678-31ce497aada8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d76651a2-4462-42de-9570-a168c60a3e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6075bbde-5e19-432f-b846-bfacffb94342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d76651a2-4462-42de-9570-a168c60a3e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_13acd2b8-1e11-4a6d-a833-e29cec38291d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5df2a1da-312f-4bb9-85f0-431e7524c57b" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_13acd2b8-1e11-4a6d-a833-e29cec38291d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d3a9bfbb-3a7e-4b9c-8e5d-f834b8a6881e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_13acd2b8-1e11-4a6d-a833-e29cec38291d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d3a9bfbb-3a7e-4b9c-8e5d-f834b8a6881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b3bfa3a-5136-48a6-92b2-c42a0f55cb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d3a9bfbb-3a7e-4b9c-8e5d-f834b8a6881e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b3bfa3a-5136-48a6-92b2-c42a0f55cb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_150f4d9d-6348-466a-a9bb-fe83dbcc9d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b3bfa3a-5136-48a6-92b2-c42a0f55cb3b" xlink:to="loc_us-gaap_TrademarksMember_150f4d9d-6348-466a-a9bb-fe83dbcc9d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_7c2bea72-b3ca-4d9e-98e8-d444bc610cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3b3bfa3a-5136-48a6-92b2-c42a0f55cb3b" xlink:to="loc_us-gaap_LicensingAgreementsMember_7c2bea72-b3ca-4d9e-98e8-d444bc610cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_53262cea-b1e8-48b2-8450-3d17e366b594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_13acd2b8-1e11-4a6d-a833-e29cec38291d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_53262cea-b1e8-48b2-8450-3d17e366b594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0e6541a0-4592-4267-a29e-6182ce120736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_53262cea-b1e8-48b2-8450-3d17e366b594" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0e6541a0-4592-4267-a29e-6182ce120736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1f37f015-0a82-4604-b840-f92d25f3ae82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5df2a1da-312f-4bb9-85f0-431e7524c57b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_1f37f015-0a82-4604-b840-f92d25f3ae82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c83d4b3-341a-4f3b-a52f-958087e205da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5df2a1da-312f-4bb9-85f0-431e7524c57b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c83d4b3-341a-4f3b-a52f-958087e205da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ecdb7bb2-9edb-42f8-bb61-e93bb7947315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_58048aaf-5024-49d8-9953-2a7920e023ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ecdb7bb2-9edb-42f8-bb61-e93bb7947315" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_58048aaf-5024-49d8-9953-2a7920e023ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44007a63-731d-4032-971c-7acf8bafc157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0697ee05-a3a8-4ba1-bff3-ec2b6989192e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44007a63-731d-4032-971c-7acf8bafc157" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0697ee05-a3a8-4ba1-bff3-ec2b6989192e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_636d878a-b6ec-4c7d-ab63-9b5e58af5e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44007a63-731d-4032-971c-7acf8bafc157" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_636d878a-b6ec-4c7d-ab63-9b5e58af5e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_71bb00d4-e14c-4353-b244-e83750e54bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44007a63-731d-4032-971c-7acf8bafc157" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_71bb00d4-e14c-4353-b244-e83750e54bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8867378d-aecc-4eeb-9eed-04d6667226d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44007a63-731d-4032-971c-7acf8bafc157" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8867378d-aecc-4eeb-9eed-04d6667226d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47ad127f-c5a9-4a13-a5e4-be8e505fe0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44007a63-731d-4032-971c-7acf8bafc157" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47ad127f-c5a9-4a13-a5e4-be8e505fe0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3fe18365-bbc6-4103-a84e-62f2d328ea09" xlink:href="ameh-20220630.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44007a63-731d-4032-971c-7acf8bafc157" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_3fe18365-bbc6-4103-a84e-62f2d328ea09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_69b9ac74-b7d6-43a9-9c95-0e13a83fa0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_44007a63-731d-4032-971c-7acf8bafc157" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_69b9ac74-b7d6-43a9-9c95-0e13a83fa0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntities" xlink:type="simple" xlink:href="ameh-20220630.xsd#InvestmentsinOtherEntities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b4097313-f759-4c6d-9b53-5a2f07ec58b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_5e0842f9-19a8-4348-b8a4-8944f096f243" xlink:href="ameh-20220630.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b4097313-f759-4c6d-9b53-5a2f07ec58b5" xlink:to="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_5e0842f9-19a8-4348-b8a4-8944f096f243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#InvestmentsinOtherEntitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f8d08532-9213-4396-ac52-a85df619bed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_c6a26325-4c69-4c06-8ca2-7716ba084be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f8d08532-9213-4396-ac52-a85df619bed7" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_c6a26325-4c69-4c06-8ca2-7716ba084be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_96fa44c5-d4b6-42b4-a95e-62399424180a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a0e4fcea-e5cd-4284-bc32-08bdccd8f1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_96fa44c5-d4b6-42b4-a95e-62399424180a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a0e4fcea-e5cd-4284-bc32-08bdccd8f1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b888726b-033a-46dd-a947-9a7bfed62100" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a0e4fcea-e5cd-4284-bc32-08bdccd8f1c9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b888726b-033a-46dd-a947-9a7bfed62100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b888726b-033a-46dd-a947-9a7bfed62100" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_648475f0-5b92-488d-a102-36d43e06c118" xlink:href="ameh-20220630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_648475f0-5b92-488d-a102-36d43e06c118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_04aae524-498c-433f-8b3a-bc8ba1a7a7d4" xlink:href="ameh-20220630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_04aae524-498c-433f-8b3a-bc8ba1a7a7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_6bac3a43-049b-4c31-906c-1413539ae861" xlink:href="ameh-20220630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_6bac3a43-049b-4c31-906c-1413539ae861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_c717a930-e148-4cab-a8aa-a7b1b6707bf7" xlink:href="ameh-20220630.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_OneMSOLLCMember_c717a930-e148-4cab-a8aa-a7b1b6707bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_d2548b24-9222-4787-8b6f-eac03c95f693" xlink:href="ameh-20220630.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_d2548b24-9222-4787-8b6f-eac03c95f693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_c150829d-605a-44e6-be54-fe1d28b3301e" xlink:href="ameh-20220630.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7ec1d9dd-0266-45e3-ac4f-77badd4f1ce1" xlink:to="loc_ameh_CAIPAMSOLLCMember_c150829d-605a-44e6-be54-fe1d28b3301e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_213290a3-d41a-4b7c-b8d3-045267d21983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a0e4fcea-e5cd-4284-bc32-08bdccd8f1c9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_213290a3-d41a-4b7c-b8d3-045267d21983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_213290a3-d41a-4b7c-b8d3-045267d21983" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_cc42e84b-2502-4db4-b274-1bfb54a5a598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_us-gaap_EquityMethodInvestments_cc42e84b-2502-4db4-b274-1bfb54a5a598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2387053-ea8b-49fa-9e6a-28e0095738f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d2387053-ea8b-49fa-9e6a-28e0095738f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentReclassification_87806372-0896-4f21-965e-41096080afd0" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentReclassification"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_ameh_EquityMethodInvestmentReclassification_87806372-0896-4f21-965e-41096080afd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_8e98c5de-e19e-4e65-a500-e5dff80efe21" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_8e98c5de-e19e-4e65-a500-e5dff80efe21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d5cbeeac-4e58-4c78-b5a9-f85f38df3994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d5cbeeac-4e58-4c78-b5a9-f85f38df3994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e0b3b3be-9f3a-4020-b2a7-1287ece395b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_8e65ffab-b5e8-4533-94c6-0294b0e35f09" xlink:to="loc_us-gaap_EquityMethodInvestments_e0b3b3be-9f3a-4020-b2a7-1287ece395b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#InvestmentsinOtherEntitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_18027d67-d94c-46bf-99eb-934dfd073090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_18027d67-d94c-46bf-99eb-934dfd073090" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_706ab19f-c8f1-4c4f-b2e1-571c13ec7371" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_706ab19f-c8f1-4c4f-b2e1-571c13ec7371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_706ab19f-c8f1-4c4f-b2e1-571c13ec7371" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_8356ca4c-0f5a-4c77-a811-3f7337611375" xlink:href="ameh-20220630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_8356ca4c-0f5a-4c77-a811-3f7337611375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_745127cc-fcdd-4fab-8fb2-3e36a2a9816e" xlink:href="ameh-20220630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_745127cc-fcdd-4fab-8fb2-3e36a2a9816e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_03005412-fc08-4848-be45-4aaa222ec94b" xlink:href="ameh-20220630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_03005412-fc08-4848-be45-4aaa222ec94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_0321a65a-abb8-40eb-9d40-e7971c08eaa8" xlink:href="ameh-20220630.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_OneMSOLLCMember_0321a65a-abb8-40eb-9d40-e7971c08eaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_c4340ce8-2451-4303-8fee-24e25e70cece" xlink:href="ameh-20220630.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_c4340ce8-2451-4303-8fee-24e25e70cece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_58667aee-b06b-4b4f-8a8f-9b6437b260fd" xlink:href="ameh-20220630.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_018c7da3-3a4d-4411-9ef0-3e156be47762" xlink:to="loc_ameh_CAIPAMSOLLCMember_58667aee-b06b-4b4f-8a8f-9b6437b260fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fe385225-5e85-437e-a140-76ed6ee36cde" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_dei_LegalEntityAxis_fe385225-5e85-437e-a140-76ed6ee36cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_fe385225-5e85-437e-a140-76ed6ee36cde" xlink:to="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_d24df01f-08c2-48b3-a9d1-172f2fb46add" xlink:href="ameh-20220630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:to="loc_ameh_APCAndAPCLSMAMember_d24df01f-08c2-48b3-a9d1-172f2fb46add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_ef03ecb3-0c23-40a4-b444-e1279ed49079" xlink:href="ameh-20220630.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_APCAndAPCLSMAMember_d24df01f-08c2-48b3-a9d1-172f2fb46add" xlink:to="loc_ameh_ApcLsmaMember_ef03ecb3-0c23-40a4-b444-e1279ed49079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_afd45341-21d7-431c-be0c-c15b7da2ba29" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_APCAndAPCLSMAMember_d24df01f-08c2-48b3-a9d1-172f2fb46add" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_afd45341-21d7-431c-be0c-c15b7da2ba29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_7c09dee0-0a90-45d2-afea-7d3110ce41d1" xlink:href="ameh-20220630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_7c09dee0-0a90-45d2-afea-7d3110ce41d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_e60d0f52-41de-4b0b-b93a-0ed417dee1dd" xlink:href="ameh-20220630.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3e633f73-9d54-4c5c-98b8-3fbb66adb60a" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_e60d0f52-41de-4b0b-b93a-0ed417dee1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_adda3793-81cd-4781-8793-7d0460fdfbe4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_srt_OwnershipAxis_adda3793-81cd-4781-8793-7d0460fdfbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a70b70be-a36b-4f9f-afb6-9fff83c69b27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_adda3793-81cd-4781-8793-7d0460fdfbe4" xlink:to="loc_srt_OwnershipDomain_a70b70be-a36b-4f9f-afb6-9fff83c69b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_35f391ed-3458-4ac8-97a4-ce97ea109be2" xlink:href="ameh-20220630.xsd#ameh_MediPortalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_a70b70be-a36b-4f9f-afb6-9fff83c69b27" xlink:to="loc_ameh_MediPortalLLCMember_35f391ed-3458-4ac8-97a4-ce97ea109be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_ce0fd843-0e52-4006-8648-cb516861e735" xlink:href="ameh-20220630.xsd#ameh_AchievaMedInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_a70b70be-a36b-4f9f-afb6-9fff83c69b27" xlink:to="loc_ameh_AchievaMedInc.Member_ce0fd843-0e52-4006-8648-cb516861e735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b80b8170-2203-4aff-a609-592be4c3bd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b80b8170-2203-4aff-a609-592be4c3bd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_25536091-bf03-4eb1-98a5-940c424e387d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_b80b8170-2203-4aff-a609-592be4c3bd69" xlink:to="loc_us-gaap_ReceivableTypeDomain_25536091-bf03-4eb1-98a5-940c424e387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_08acceb2-5c91-40ac-9024-dba5ad51f15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_25536091-bf03-4eb1-98a5-940c424e387d" xlink:to="loc_us-gaap_NotesReceivableMember_08acceb2-5c91-40ac-9024-dba5ad51f15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82895337-1718-4b19-8474-3c102a95ec7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82895337-1718-4b19-8474-3c102a95ec7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_437b0864-1daa-4237-a238-c98b80bda5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_82895337-1718-4b19-8474-3c102a95ec7f" xlink:to="loc_us-gaap_RelatedPartyDomain_437b0864-1daa-4237-a238-c98b80bda5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_ad79d74e-20d8-4c09-9b03-c810374996bd" xlink:href="ameh-20220630.xsd#ameh_Dr.ArteagaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_437b0864-1daa-4237-a238-c98b80bda5a5" xlink:to="loc_ameh_Dr.ArteagaMember_ad79d74e-20d8-4c09-9b03-c810374996bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_37f3bb7a-ca37-40bf-bb8e-b8e624a2a548" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_4b105233-4c71-489e-a6ec-e5335242525a" xlink:href="ameh-20220630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageSold_4b105233-4c71-489e-a6ec-e5335242525a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_0fdeaf61-9d44-4fa7-ba07-135a91de49b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_0fdeaf61-9d44-4fa7-ba07-135a91de49b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4aada4f1-3013-460b-8f61-0a55436f0706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4aada4f1-3013-460b-8f61-0a55436f0706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d31db20c-40a5-4e2a-b240-70770839c0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d31db20c-40a5-4e2a-b240-70770839c0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_037a2b2a-830c-4839-9751-08eac96dec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_EquityMethodInvestments_037a2b2a-830c-4839-9751-08eac96dec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_fd0310d7-5c49-4464-b0c6-b63da5d3c795" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_fd0310d7-5c49-4464-b0c6-b63da5d3c795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_060164e7-c7f6-4524-b610-e57cc2d74b61" xlink:href="ameh-20220630.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_060164e7-c7f6-4524-b610-e57cc2d74b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_c5fa3939-8273-4d89-9875-b5869b90d8d8" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_c5fa3939-8273-4d89-9875-b5869b90d8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_cdb47efe-ab7a-4d2b-a460-85a66169fbf2" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_cdb47efe-ab7a-4d2b-a460-85a66169fbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_15fd95aa-b155-48f2-8fc8-9f8e5e55ab50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_15fd95aa-b155-48f2-8fc8-9f8e5e55ab50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_41997760-7ea6-4be5-9dcf-7d3c473df1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_41997760-7ea6-4be5-9dcf-7d3c473df1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_3ac46b4e-be90-4b56-bc4d-c8e75bc03b2b" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_3ac46b4e-be90-4b56-bc4d-c8e75bc03b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_a153c691-26cd-4787-8d9a-613a1afa27d2" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_a153c691-26cd-4787-8d9a-613a1afa27d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_0dbe2d82-918b-4b7d-9867-46824b0fc92d" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_0dbe2d82-918b-4b7d-9867-46824b0fc92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_f89c92dd-20f1-4943-8b0a-7ad8d4afa730" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_f89c92dd-20f1-4943-8b0a-7ad8d4afa730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_a53ef01a-9732-45c2-9271-91e5e74cbc4c" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_a53ef01a-9732-45c2-9271-91e5e74cbc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_e4bc869f-a7b2-4baa-85bb-4a25e445139e" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_e4bc869f-a7b2-4baa-85bb-4a25e445139e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_fb374349-40be-4183-847d-dceefb44fe25" xlink:href="ameh-20220630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_c02d267d-3fa2-43fc-b19d-e55c5dfc93ab" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_fb374349-40be-4183-847d-dceefb44fe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cefab48b-3124-4068-bc3e-4908d0ebc9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_30a5dfb5-1038-4b08-a1f9-8ef98e82158f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cefab48b-3124-4068-bc3e-4908d0ebc9dc" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_30a5dfb5-1038-4b08-a1f9-8ef98e82158f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_bcdaa367-ba6b-4e58-8e17-f8a1f9df4a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_30a5dfb5-1038-4b08-a1f9-8ef98e82158f" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_bcdaa367-ba6b-4e58-8e17-f8a1f9df4a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_ac5c1885-2d71-41fe-85ab-d4ffb30c4141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_bcdaa367-ba6b-4e58-8e17-f8a1f9df4a16" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_ac5c1885-2d71-41fe-85ab-d4ffb30c4141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_35655173-228f-41ae-8978-3cd513a4ae58" xlink:href="ameh-20220630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_ac5c1885-2d71-41fe-85ab-d4ffb30c4141" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_35655173-228f-41ae-8978-3cd513a4ae58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_30a5dfb5-1038-4b08-a1f9-8ef98e82158f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:to="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_743bd480-51bb-4112-9996-e73149b314fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_743bd480-51bb-4112-9996-e73149b314fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_00eb27b7-122c-4a3d-ae7f-3d1bcb4ea775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_RestrictedCashCurrent_00eb27b7-122c-4a3d-ae7f-3d1bcb4ea775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6f38c6a3-149c-4ed1-8d6a-c637d12b7b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6f38c6a3-149c-4ed1-8d6a-c637d12b7b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_16346822-4aa1-413e-a265-e1acdb794bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_16346822-4aa1-413e-a265-e1acdb794bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2f5bf13c-e194-46a7-9018-dac1a44414f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5c7fedf1-a7b9-4915-9c48-32b8d388e3b4" xlink:to="loc_us-gaap_Assets_2f5bf13c-e194-46a7-9018-dac1a44414f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1c4c0665-a9f8-4ab7-b500-8e1cd74488ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:to="loc_us-gaap_LiabilitiesCurrent_1c4c0665-a9f8-4ab7-b500-8e1cd74488ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6859931e-8bfc-4526-92af-848424f8875f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6859931e-8bfc-4526-92af-848424f8875f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1af274a-d30b-4299-8503-0fbce9fedcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_618d09d2-3fe3-43bc-84df-e4836362a66b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f1af274a-d30b-4299-8503-0fbce9fedcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6232a5a2-b668-4917-b933-aac55c2d533d" xlink:to="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c300149f-b7d4-4a46-b435-61d588ed876d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c300149f-b7d4-4a46-b435-61d588ed876d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f048d4d6-a34e-416a-88f0-fe84c4a25df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_CostsAndExpenses_f048d4d6-a34e-416a-88f0-fe84c4a25df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5846f078-2f24-4d5b-bd8b-39b032c9b91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_OperatingIncomeLoss_5846f078-2f24-4d5b-bd8b-39b032c9b91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f264b13c-4342-4a34-9e04-567b25b31bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f264b13c-4342-4a34-9e04-567b25b31bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e0216ad8-89d5-4a04-816d-eed906717710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1844fde0-17ec-422e-ad69-1db8eb9b1284" xlink:to="loc_us-gaap_ProfitLoss_e0216ad8-89d5-4a04-816d-eed906717710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20220630.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_bc406846-f01a-4fc3-9148-34392434415c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock_96c1f0f9-b400-41cd-84a9-2f996f7a1aa3" xlink:href="ameh-20220630.xsd#ameh_LoanReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_bc406846-f01a-4fc3-9148-34392434415c" xlink:to="loc_ameh_LoanReceivableTextBlock_96c1f0f9-b400-41cd-84a9-2f996f7a1aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_0cea04d7-908e-43e2-ab25-0a8afa816898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_0cea04d7-908e-43e2-ab25-0a8afa816898" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5299039a-d61f-416a-914e-f88637d0e181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5299039a-d61f-416a-914e-f88637d0e181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_fcbe7cb4-499d-45c9-bc99-9602d0faeebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5299039a-d61f-416a-914e-f88637d0e181" xlink:to="loc_us-gaap_ReceivableTypeDomain_fcbe7cb4-499d-45c9-bc99-9602d0faeebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_042c0fb4-70c6-4526-a699-230ef07c8379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_fcbe7cb4-499d-45c9-bc99-9602d0faeebc" xlink:to="loc_us-gaap_NotesReceivableMember_042c0fb4-70c6-4526-a699-230ef07c8379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_187fbad8-558c-48ed-935d-92e47cc65abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_187fbad8-558c-48ed-935d-92e47cc65abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_187fbad8-558c-48ed-935d-92e47cc65abc" xlink:to="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_86beb0c8-9b2f-456c-833c-f33922f1c84c" xlink:href="ameh-20220630.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:to="loc_ameh_Pacific6EnterprisesMember_86beb0c8-9b2f-456c-833c-f33922f1c84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_fdc8fc72-6b06-4e53-a33d-b5543e87c6c0" xlink:href="ameh-20220630.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:to="loc_ameh_ApcLsmaMember_fdc8fc72-6b06-4e53-a33d-b5543e87c6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_c17d726b-e59f-473a-b344-5516e7ddc37f" xlink:href="ameh-20220630.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d957b206-225c-442b-bc10-7fe17d791d79" xlink:to="loc_ameh_AHMCMember_c17d726b-e59f-473a-b344-5516e7ddc37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_8604be1c-4010-48c8-8462-92bda0d143eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:to="loc_dei_LegalEntityAxis_8604be1c-4010-48c8-8462-92bda0d143eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_8604be1c-4010-48c8-8462-92bda0d143eb" xlink:to="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_07e352e8-a772-4023-b069-b1d82ee94c98" xlink:href="ameh-20220630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:to="loc_ameh_NetworkMedicalManagementMember_07e352e8-a772-4023-b069-b1d82ee94c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_51df5e6a-e5db-4d01-bca0-539049e18a34" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_51df5e6a-e5db-4d01-bca0-539049e18a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_6a63a996-0088-45c1-a2a5-0c7b3e4d331c" xlink:href="ameh-20220630.xsd#ameh_LmaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f2abfe4e-822e-4380-bfe9-aba93e97d787" xlink:to="loc_ameh_LmaMember_6a63a996-0088-45c1-a2a5-0c7b3e4d331c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eaa9fec3-3374-4fec-9861-d150ce6a0775" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eaa9fec3-3374-4fec-9861-d150ce6a0775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_901bf323-128c-4ee3-b3c2-87e4369857ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_eaa9fec3-3374-4fec-9861-d150ce6a0775" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_901bf323-128c-4ee3-b3c2-87e4369857ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_9a986c5c-7d71-4759-bb21-e4d572d6fc3e" xlink:href="ameh-20220630.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_901bf323-128c-4ee3-b3c2-87e4369857ad" xlink:to="loc_ameh_LmaMember_9a986c5c-7d71-4759-bb21-e4d572d6fc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_49b28919-f09f-4297-95a2-29c7644c5c38" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_e0b54bfa-3a4a-4633-a177-f9fcbee8ac74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:to="loc_us-gaap_NotesReceivableNet_e0b54bfa-3a4a-4633-a177-f9fcbee8ac74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f65826dd-399c-4ddf-a361-f277606f23b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f65826dd-399c-4ddf-a361-f277606f23b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_75e900c9-6b0d-43c7-a819-51020a39a856" xlink:href="ameh-20220630.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_75e900c9-6b0d-43c7-a819-51020a39a856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e40f3ecc-d199-4921-8922-b8a79b5a9096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_2c5a171b-86d6-424d-aafa-ac809b8cb44c" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_e40f3ecc-d199-4921-8922-b8a79b5a9096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20220630.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_708d8d64-8b48-4627-9f66-2b7530f6c539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0b3424ba-70c2-49aa-9316-ced96b5e5c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_708d8d64-8b48-4627-9f66-2b7530f6c539" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0b3424ba-70c2-49aa-9316-ced96b5e5c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a2fe8767-afe1-4db2-aafb-4b329fa319fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_05134ab7-7b22-4460-a356-4afd3eb7498f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a2fe8767-afe1-4db2-aafb-4b329fa319fa" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_05134ab7-7b22-4460-a356-4afd3eb7498f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_51565497-e020-4da0-b0ea-4a4ec79a7fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6fb1d4ad-735a-4f05-9d1e-60fd10d7ebaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51565497-e020-4da0-b0ea-4a4ec79a7fef" xlink:to="loc_us-gaap_AccountsPayableCurrent_6fb1d4ad-735a-4f05-9d1e-60fd10d7ebaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_53358545-c3a2-47ef-b42b-cfc83d2e9e0c" xlink:href="ameh-20220630.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51565497-e020-4da0-b0ea-4a4ec79a7fef" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_53358545-c3a2-47ef-b42b-cfc83d2e9e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_4318e04e-2b62-45db-839b-6855b202a50f" xlink:href="ameh-20220630.xsd#ameh_SubcontractorIPAPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51565497-e020-4da0-b0ea-4a4ec79a7fef" xlink:to="loc_ameh_SubcontractorIPAPayable_4318e04e-2b62-45db-839b-6855b202a50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_fb9ae9d5-5899-4c95-ba6d-222ffeb8208a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51565497-e020-4da0-b0ea-4a4ec79a7fef" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_fb9ae9d5-5899-4c95-ba6d-222ffeb8208a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_bcaea76d-3a84-4bb6-9d32-1b35b3d15541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51565497-e020-4da0-b0ea-4a4ec79a7fef" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_bcaea76d-3a84-4bb6-9d32-1b35b3d15541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7cee4147-1a7c-494d-a734-576c12afa42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51565497-e020-4da0-b0ea-4a4ec79a7fef" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7cee4147-1a7c-494d-a734-576c12afa42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c62fd321-bc43-4659-8b31-93d1f7d1c2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51565497-e020-4da0-b0ea-4a4ec79a7fef" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c62fd321-bc43-4659-8b31-93d1f7d1c2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cf8f380d-7c3d-4c73-9751-71e5cb256c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_51565497-e020-4da0-b0ea-4a4ec79a7fef" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cf8f380d-7c3d-4c73-9751-71e5cb256c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20220630.xsd#MedicalLiabilities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_ea0f390d-b826-4bf9-9066-67181c40b3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_64b163bd-cd44-45bb-a06e-7a4ae4369bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_ea0f390d-b826-4bf9-9066-67181c40b3a1" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_64b163bd-cd44-45bb-a06e-7a4ae4369bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#MedicalLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_8e9c9248-80df-48a4-9bff-7dc1761c91e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_10aef953-f5e2-43ff-aa42-182cd564ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_8e9c9248-80df-48a4-9bff-7dc1761c91e8" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_10aef953-f5e2-43ff-aa42-182cd564ab0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_238d9b78-8efc-4d05-9983-03604a57ff05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0d2ba5f8-25f8-44a8-8d7d-8eb1d6d622ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_238d9b78-8efc-4d05-9983-03604a57ff05" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0d2ba5f8-25f8-44a8-8d7d-8eb1d6d622ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5fd414eb-f596-476a-8f87-d938a2379b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0d2ba5f8-25f8-44a8-8d7d-8eb1d6d622ce" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5fd414eb-f596-476a-8f87-d938a2379b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_400c6595-18e3-4c8a-afeb-113113f7f8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0d2ba5f8-25f8-44a8-8d7d-8eb1d6d622ce" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_400c6595-18e3-4c8a-afeb-113113f7f8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract_4270045c-e2a4-46f4-a8ff-69e9dbfb21bc" xlink:href="ameh-20220630.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0d2ba5f8-25f8-44a8-8d7d-8eb1d6d622ce" xlink:to="loc_ameh_MedicalCareCostsAbstract_4270045c-e2a4-46f4-a8ff-69e9dbfb21bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_dd224f52-96c6-4ece-9197-e44835069b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_4270045c-e2a4-46f4-a8ff-69e9dbfb21bc" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_dd224f52-96c6-4ece-9197-e44835069b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_400cd7b9-3c95-45e8-9c9a-40b02c1f4683" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_4270045c-e2a4-46f4-a8ff-69e9dbfb21bc" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_400cd7b9-3c95-45e8-9c9a-40b02c1f4683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_bed093c9-d873-4d3e-8763-3dfd98d18825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_4270045c-e2a4-46f4-a8ff-69e9dbfb21bc" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_bed093c9-d873-4d3e-8763-3dfd98d18825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract_a8078104-27f2-4eb2-97da-a6bd1a276130" xlink:href="ameh-20220630.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0d2ba5f8-25f8-44a8-8d7d-8eb1d6d622ce" xlink:to="loc_ameh_PaymentsForMedicalCareCostsAbstract_a8078104-27f2-4eb2-97da-a6bd1a276130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_d4fc148c-e6ad-49bd-9363-8b9814473fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_a8078104-27f2-4eb2-97da-a6bd1a276130" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_d4fc148c-e6ad-49bd-9363-8b9814473fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_a6756bc7-5850-40a9-aa3a-b97b5d149686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_a8078104-27f2-4eb2-97da-a6bd1a276130" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_a6756bc7-5850-40a9-aa3a-b97b5d149686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_b2f662d3-2042-4941-a6ec-098cd9351840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_a8078104-27f2-4eb2-97da-a6bd1a276130" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_b2f662d3-2042-4941-a6ec-098cd9351840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_7d76285e-8a56-4bd6-87e9-a09c914228ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0d2ba5f8-25f8-44a8-8d7d-8eb1d6d622ce" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_7d76285e-8a56-4bd6-87e9-a09c914228ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2256a4b6-771b-4746-8f84-7dc53345a5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_0d2ba5f8-25f8-44a8-8d7d-8eb1d6d622ce" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2256a4b6-771b-4746-8f84-7dc53345a5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="simple" xlink:href="ameh-20220630.xsd#CreditFacilityBankLoansandLinesofCredit"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9ab9d2df-f6ee-416f-abd7-83cc6c19808a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f323a871-c049-4eb6-9229-1a3ac8ce85f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9ab9d2df-f6ee-416f-abd7-83cc6c19808a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f323a871-c049-4eb6-9229-1a3ac8ce85f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#CreditFacilityBankLoansandLinesofCreditTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_696f23b5-885f-4d5d-85de-c3414f9b4ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_62f8b2ba-e9be-4cff-a1a7-7ba3c18476c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_696f23b5-885f-4d5d-85de-c3414f9b4ed1" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_62f8b2ba-e9be-4cff-a1a7-7ba3c18476c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_77a81455-a7d9-4ea6-9c45-2f08f8758657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_696f23b5-885f-4d5d-85de-c3414f9b4ed1" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_77a81455-a7d9-4ea6-9c45-2f08f8758657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e964a478-6d46-4a6c-bd03-a437919ab1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_b6704186-d0ff-45de-8c0b-4a753924634e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e964a478-6d46-4a6c-bd03-a437919ab1c4" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_b6704186-d0ff-45de-8c0b-4a753924634e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2ae5cc31-a27c-4ae7-b0f1-c980b3a3b4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b6704186-d0ff-45de-8c0b-4a753924634e" xlink:to="loc_us-gaap_CreditFacilityAxis_2ae5cc31-a27c-4ae7-b0f1-c980b3a3b4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7907cc24-2aa2-4cdd-a2bc-4efc81dac2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2ae5cc31-a27c-4ae7-b0f1-c980b3a3b4bc" xlink:to="loc_us-gaap_CreditFacilityDomain_7907cc24-2aa2-4cdd-a2bc-4efc81dac2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_48139e8e-0754-42f8-92d8-37ac28490f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7907cc24-2aa2-4cdd-a2bc-4efc81dac2c7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_48139e8e-0754-42f8-92d8-37ac28490f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b73e1391-b399-42fd-afe1-a2ea0b2ad9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b6704186-d0ff-45de-8c0b-4a753924634e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b73e1391-b399-42fd-afe1-a2ea0b2ad9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7986aba3-a39e-4091-ad97-484a50e52296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b73e1391-b399-42fd-afe1-a2ea0b2ad9c0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7986aba3-a39e-4091-ad97-484a50e52296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_299fc551-56cf-4c77-b3f7-65cdcc2cb7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealEstateLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7986aba3-a39e-4091-ad97-484a50e52296" xlink:to="loc_us-gaap_RealEstateLoanMember_299fc551-56cf-4c77-b3f7-65cdcc2cb7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_d18707f2-fbe5-4328-8c66-cf30977b3baa" xlink:href="ameh-20220630.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7986aba3-a39e-4091-ad97-484a50e52296" xlink:to="loc_ameh_ConstructionLoanMember_d18707f2-fbe5-4328-8c66-cf30977b3baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b6704186-d0ff-45de-8c0b-4a753924634e" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_82ef1084-150d-4e64-badb-1507d8e82232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_82ef1084-150d-4e64-badb-1507d8e82232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5d7e0b5b-a137-43cc-a3f8-5b2ffe9b3f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:to="loc_us-gaap_LongTermDebtCurrent_5d7e0b5b-a137-43cc-a3f8-5b2ffe9b3f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f8733d60-5b8c-4fd3-a7d3-c67b5ac8d12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f8733d60-5b8c-4fd3-a7d3-c67b5ac8d12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_31ad445f-6915-4e8b-b490-c446c04a38ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a0e973a4-0105-467f-b055-43cf775f0665" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_31ad445f-6915-4e8b-b490-c446c04a38ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c699424c-1e73-4281-878b-8281a1863541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_c9c7cb75-f27b-49b2-b3bb-7b5fe46b8d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c699424c-1e73-4281-878b-8281a1863541" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_c9c7cb75-f27b-49b2-b3bb-7b5fe46b8d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2a01e14a-a03b-4147-b7c2-47b151bf1b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c699424c-1e73-4281-878b-8281a1863541" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2a01e14a-a03b-4147-b7c2-47b151bf1b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e3088d05-d76f-462b-84ee-86bcd73ef5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c699424c-1e73-4281-878b-8281a1863541" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e3088d05-d76f-462b-84ee-86bcd73ef5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7332c628-0529-4549-aa7a-917bdca0497a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c699424c-1e73-4281-878b-8281a1863541" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7332c628-0529-4549-aa7a-917bdca0497a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour_34d9257b-b9e7-4ea4-a069-3d6c888db616" xlink:href="ameh-20220630.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c699424c-1e73-4281-878b-8281a1863541" xlink:to="loc_ameh_LongTermDebtMaturityAfterYearFour_34d9257b-b9e7-4ea4-a069-3d6c888db616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_a83b40fe-2876-4c06-8fb7-e8e29885fd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c699424c-1e73-4281-878b-8281a1863541" xlink:to="loc_us-gaap_LineOfCredit_a83b40fe-2876-4c06-8fb7-e8e29885fd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_679d9ef7-b4f7-40e0-aac1-547b186f8915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_679d9ef7-b4f7-40e0-aac1-547b186f8915" xlink:to="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e3fa67f9-b496-4778-987a-69dfe9e0baed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_CreditFacilityAxis_e3fa67f9-b496-4778-987a-69dfe9e0baed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e3fa67f9-b496-4778-987a-69dfe9e0baed" xlink:to="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e9815d32-2823-47c7-90c4-2c6524255fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e9815d32-2823-47c7-90c4-2c6524255fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c0f672cc-1d7e-4f16-bf4f-ea83f36f7ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_LineOfCreditMember_c0f672cc-1d7e-4f16-bf4f-ea83f36f7ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_4b9f82e5-696f-474a-bf5d-64cb425dd824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_LetterOfCreditMember_4b9f82e5-696f-474a-bf5d-64cb425dd824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_9ccedce4-eff6-4d23-a165-385d1c6339f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_BridgeLoanMember_9ccedce4-eff6-4d23-a165-385d1c6339f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_4bde5268-aa07-42b7-b3a6-ee070c18cf5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_aaf12312-baec-4a7e-ae1f-7bdfb0a3a55c" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_4bde5268-aa07-42b7-b3a6-ee070c18cf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9e18e5fa-1737-4005-bb23-088c895a3a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_DebtInstrumentAxis_9e18e5fa-1737-4005-bb23-088c895a3a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9e18e5fa-1737-4005-bb23-088c895a3a9c" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_8161d2ff-0f09-4cd8-abcb-705472f26e45" xlink:href="ameh-20220630.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:to="loc_ameh_AmendedCreditAgreementMember_8161d2ff-0f09-4cd8-abcb-705472f26e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_74cb819e-8a40-4c11-ae39-4d48238b5e4e" xlink:href="ameh-20220630.xsd#ameh_CreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:to="loc_ameh_CreditAgreementMember_74cb819e-8a40-4c11-ae39-4d48238b5e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_5c9d27e8-6e11-459a-b118-d8e69d38dc72" xlink:href="ameh-20220630.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:to="loc_ameh_ConstructionLoanMember_5c9d27e8-6e11-459a-b118-d8e69d38dc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_ecbf6714-c84e-4dfb-8852-36bdf453821c" xlink:href="ameh-20220630.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4b67b2a-a50d-4e95-80f9-86dbbbc7edc2" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_ecbf6714-c84e-4dfb-8852-36bdf453821c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5d290e65-b768-4ad6-8691-a87ef983baf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5d290e65-b768-4ad6-8691-a87ef983baf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_803dc51b-a338-4d37-a116-fa86da54d75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d290e65-b768-4ad6-8691-a87ef983baf3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_803dc51b-a338-4d37-a116-fa86da54d75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_24a7f9b6-6dea-45ed-8850-404e572441db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_803dc51b-a338-4d37-a116-fa86da54d75c" xlink:to="loc_us-gaap_LineOfCreditMember_24a7f9b6-6dea-45ed-8850-404e572441db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_337fbcf6-d102-4396-9ff2-103204c5073e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_srt_RangeAxis_337fbcf6-d102-4396-9ff2-103204c5073e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c0643f0-4d81-48fb-ad9f-4d9595817b57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_337fbcf6-d102-4396-9ff2-103204c5073e" xlink:to="loc_srt_RangeMember_7c0643f0-4d81-48fb-ad9f-4d9595817b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_95654436-2b7d-4886-b3d4-e4f07c65eb77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c0643f0-4d81-48fb-ad9f-4d9595817b57" xlink:to="loc_srt_MinimumMember_95654436-2b7d-4886-b3d4-e4f07c65eb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f9d8b09-31ca-413d-a443-ba9e00902fa2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c0643f0-4d81-48fb-ad9f-4d9595817b57" xlink:to="loc_srt_MaximumMember_1f9d8b09-31ca-413d-a443-ba9e00902fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5b75f1b5-16ad-45a2-9f1b-aac2ce0640f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_dei_LegalEntityAxis_5b75f1b5-16ad-45a2-9f1b-aac2ce0640f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5b75f1b5-16ad-45a2-9f1b-aac2ce0640f8" xlink:to="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f95c9bbb-4211-4743-b2f6-8d14aa9cb471" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f95c9bbb-4211-4743-b2f6-8d14aa9cb471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_bf0e3d86-d21e-45d0-b8dd-cf2bda24ee40" xlink:href="ameh-20220630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_bf0e3d86-d21e-45d0-b8dd-cf2bda24ee40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_021c5560-512f-4fd4-886e-5f21c7300ea7" xlink:href="ameh-20220630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_AMGPropertiesLLCMember_021c5560-512f-4fd4-886e-5f21c7300ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_97326cfa-18c2-403e-b4a3-cd1d7ce74240" xlink:href="ameh-20220630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_ZLLPartnersLLCMember_97326cfa-18c2-403e-b4a3-cd1d7ce74240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_a7443afb-bb1c-4ddf-bbab-caee1a118d5f" xlink:href="ameh-20220630.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_a7443afb-bb1c-4ddf-bbab-caee1a118d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_0f949e2d-a7d0-473d-beb6-c79607965a7e" xlink:href="ameh-20220630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_0f949e2d-a7d0-473d-beb6-c79607965a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_A120HellmanLLCMember_7f77939f-cad3-460c-997c-5d06917ba2b9" xlink:href="ameh-20220630.xsd#ameh_A120HellmanLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b1662562-a829-4337-b1a0-74dd1ab2f9be" xlink:to="loc_ameh_A120HellmanLLCMember_7f77939f-cad3-460c-997c-5d06917ba2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_197ab73a-2ff3-4823-a2e5-64853aaf0537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_VariableRateAxis_197ab73a-2ff3-4823-a2e5-64853aaf0537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2940a9e1-cb2e-4483-a2b5-4587c2077d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_197ab73a-2ff3-4823-a2e5-64853aaf0537" xlink:to="loc_us-gaap_VariableRateDomain_2940a9e1-cb2e-4483-a2b5-4587c2077d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5196871-bb19-4029-8555-133be4673223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_2940a9e1-cb2e-4483-a2b5-4587c2077d59" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_e5196871-bb19-4029-8555-133be4673223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_f3105c44-35a4-4987-8a9d-44d91d08af20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_2940a9e1-cb2e-4483-a2b5-4587c2077d59" xlink:to="loc_us-gaap_PrimeRateMember_f3105c44-35a4-4987-8a9d-44d91d08af20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_915941a8-08f2-49af-a450-4ee0bb1a75fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_915941a8-08f2-49af-a450-4ee0bb1a75fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_cb6b1cc7-88ee-430e-9917-76cf4dbf391d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_915941a8-08f2-49af-a450-4ee0bb1a75fb" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_cb6b1cc7-88ee-430e-9917-76cf4dbf391d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_6928361b-7f6b-4991-8c2c-0c4973c1e574" xlink:href="ameh-20220630.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_cb6b1cc7-88ee-430e-9917-76cf4dbf391d" xlink:to="loc_ameh_PreferredBankMember_6928361b-7f6b-4991-8c2c-0c4973c1e574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_13905e85-8ac4-4ee4-9407-aaff9f1983c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_13905e85-8ac4-4ee4-9407-aaff9f1983c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_13905e85-8ac4-4ee4-9407-aaff9f1983c9" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_0be95b88-f51d-4b19-b79a-aa706fbe08cc" xlink:href="ameh-20220630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_0be95b88-f51d-4b19-b79a-aa706fbe08cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_34166f53-4482-46d2-91bb-6cedc38c520f" xlink:href="ameh-20220630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:to="loc_ameh_AMGPropertiesLLCMember_34166f53-4482-46d2-91bb-6cedc38c520f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_df8d621f-6b9c-440b-891c-ead8a9d81e9c" xlink:href="ameh-20220630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e37eaa4c-2198-4bdf-8a87-02024f669a49" xlink:to="loc_ameh_ZLLPartnersLLCMember_df8d621f-6b9c-440b-891c-ead8a9d81e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_f05824f4-4818-42e7-8a88-dc2f3bb211d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_srt_StatementScenarioAxis_f05824f4-4818-42e7-8a88-dc2f3bb211d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6cfcc5a1-8f6d-4dec-ac05-4d482c3f60eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_f05824f4-4818-42e7-8a88-dc2f3bb211d5" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6cfcc5a1-8f6d-4dec-ac05-4d482c3f60eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_49be01fb-27b7-47fc-aa44-1a08c0bf492f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6cfcc5a1-8f6d-4dec-ac05-4d482c3f60eb" xlink:to="loc_srt_ScenarioForecastMember_49be01fb-27b7-47fc-aa44-1a08c0bf492f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d7051702-ca50-4090-b0e0-8f249793c6e3" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_d264c1ae-0f48-4b9a-a239-0cf597d33ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentTerm_d264c1ae-0f48-4b9a-a239-0cf597d33ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_abe8aff6-5ec6-431b-99fe-177c9bc7eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_abe8aff6-5ec6-431b-99fe-177c9bc7eec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0b2c3ffb-2ce5-4e9b-8dff-406bdd19d6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0b2c3ffb-2ce5-4e9b-8dff-406bdd19d6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_f8bd8bdb-cd31-4c3a-b896-d7d9b96e2864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_f8bd8bdb-cd31-4c3a-b896-d7d9b96e2864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a832ff45-2333-4d9e-a32a-04a85c870fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a832ff45-2333-4d9e-a32a-04a85c870fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_ad0d2771-cf3f-4531-8125-2326879f8679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_ad0d2771-cf3f-4531-8125-2326879f8679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_0f6808c5-8799-4023-8e39-f27906d9bc30" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_0f6808c5-8799-4023-8e39-f27906d9bc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_f1683fa2-6cd8-4062-bd3f-0dad7dfdd6a7" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_f1683fa2-6cd8-4062-bd3f-0dad7dfdd6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_ec54c113-d7a4-4a91-bdd0-ecac0ebbaaf9" xlink:href="ameh-20220630.xsd#ameh_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_ec54c113-d7a4-4a91-bdd0-ecac0ebbaaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_0d631315-006f-43b0-90ab-bd649151e181" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_0d631315-006f-43b0-90ab-bd649151e181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_12edbccb-d15f-40a2-9aa5-cc228a2b5531" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_12edbccb-d15f-40a2-9aa5-cc228a2b5531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_8adbad61-2388-43ea-8217-eb0468638e32" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_8adbad61-2388-43ea-8217-eb0468638e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_cd0f925a-28d1-444f-afbf-76cc353a277e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_cd0f925a-28d1-444f-afbf-76cc353a277e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f7562248-28d1-4822-b254-fa68c03982e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f7562248-28d1-4822-b254-fa68c03982e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_e61b7b2b-e640-4e03-a544-24478c81fe6b" xlink:href="ameh-20220630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_e61b7b2b-e640-4e03-a544-24478c81fe6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_fadb325b-1871-4858-86c4-13e21cdfee33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_fadb325b-1871-4858-86c4-13e21cdfee33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_19cbdba0-3301-4f44-b600-adfc2465da97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LongTermDebt_19cbdba0-3301-4f44-b600-adfc2465da97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_7ab42904-d0fa-46c6-b4e9-427e7c4b128b" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_7ab42904-d0fa-46c6-b4e9-427e7c4b128b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty_4d11d305-e012-4790-ba09-7111e1ce7e45" xlink:href="ameh-20220630.xsd#ameh_DebtCovenantThresholdPercentageForOccupationOfProperty"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty_4d11d305-e012-4790-ba09-7111e1ce7e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum_ef9f6ae1-9433-49b5-bf4c-d66e861fe398" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum_ef9f6ae1-9433-49b5-bf4c-d66e861fe398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_a35e25a7-3c92-43dc-a6ea-7bb59882c1cf" xlink:href="ameh-20220630.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_a35e25a7-3c92-43dc-a6ea-7bb59882c1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_30ec08aa-73e7-4b9c-9bf2-81854d8b9f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_30ec08aa-73e7-4b9c-9bf2-81854d8b9f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f86bd38b-28e9-4f60-bf44-0f021a853d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_InterestExpense_f86bd38b-28e9-4f60-bf44-0f021a853d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_f953fba0-46bf-41b3-ad57-dae1425f8463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2bf78db7-e0ef-4fad-b41a-0d46e2c0a6a6" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_f953fba0-46bf-41b3-ad57-dae1425f8463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20220630.xsd#MezzanineandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_075b99a6-c171-4c7f-b107-80432c43270d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a4df345c-a595-4dfc-b88e-a0f80afbfe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_075b99a6-c171-4c7f-b107-80432c43270d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a4df345c-a595-4dfc-b88e-a0f80afbfe4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_fea8631c-0ec6-4b35-adb3-301da064f237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_057795ce-396b-4f8c-8c2c-adfadb3f0d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_fea8631c-0ec6-4b35-adb3-301da064f237" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_057795ce-396b-4f8c-8c2c-adfadb3f0d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fe126abd-e5d9-407d-a661-3c452748b508" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_057795ce-396b-4f8c-8c2c-adfadb3f0d13" xlink:to="loc_dei_LegalEntityAxis_fe126abd-e5d9-407d-a661-3c452748b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0412267a-edc1-4a8d-a097-7e1d25321452" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_fe126abd-e5d9-407d-a661-3c452748b508" xlink:to="loc_dei_EntityDomain_0412267a-edc1-4a8d-a097-7e1d25321452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_fb57b647-50b3-4ff9-8424-c7a6d379f62f" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0412267a-edc1-4a8d-a097-7e1d25321452" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_fb57b647-50b3-4ff9-8424-c7a6d379f62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_d0ec1742-5b89-419a-b255-4947240d1b1d" xlink:href="ameh-20220630.xsd#ameh_CDSCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0412267a-edc1-4a8d-a097-7e1d25321452" xlink:to="loc_ameh_CDSCMember_d0ec1742-5b89-419a-b255-4947240d1b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_057795ce-396b-4f8c-8c2c-adfadb3f0d13" xlink:to="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_ade18dda-6315-42c2-b109-9438aa81f1e8" xlink:href="ameh-20220630.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_ade18dda-6315-42c2-b109-9438aa81f1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_39146b37-4435-4947-91d1-9882e5face82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_39146b37-4435-4947-91d1-9882e5face82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_7363089f-ab55-4378-990e-2aa2f82f06f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_397abe16-4295-4ed7-9fdf-1af636fbec9e" xlink:to="loc_us-gaap_Dividends_7363089f-ab55-4378-990e-2aa2f82f06f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8563be0d-2bec-427f-80f2-13ec710733dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6a6a8c9f-95fe-4dcb-968d-11d60d7c0388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8563be0d-2bec-427f-80f2-13ec710733dc" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6a6a8c9f-95fe-4dcb-968d-11d60d7c0388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e1353b4-736b-4122-a4d8-d2a9003725c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d6477bc5-7e88-41bd-bb02-e9e45dab58a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e1353b4-736b-4122-a4d8-d2a9003725c9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d6477bc5-7e88-41bd-bb02-e9e45dab58a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2eae40a4-3455-45db-8f32-6ba0d0fab7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e1353b4-736b-4122-a4d8-d2a9003725c9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2eae40a4-3455-45db-8f32-6ba0d0fab7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_155d08ab-7d41-4c4f-849b-634cc64ff1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e1353b4-736b-4122-a4d8-d2a9003725c9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_155d08ab-7d41-4c4f-849b-634cc64ff1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50eaa2ef-4e6a-49d0-81bd-37de11d82356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e1353b4-736b-4122-a4d8-d2a9003725c9" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50eaa2ef-4e6a-49d0-81bd-37de11d82356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6643eea9-99c1-4659-b13a-cf30020a9ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ff2f503-328c-4212-bdb9-475c7f88cd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6643eea9-99c1-4659-b13a-cf30020a9ca1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ff2f503-328c-4212-bdb9-475c7f88cd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e7eb2a67-f59d-4d14-a0ee-fb0527a6eff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ff2f503-328c-4212-bdb9-475c7f88cd7e" xlink:to="loc_us-gaap_AwardTypeAxis_e7eb2a67-f59d-4d14-a0ee-fb0527a6eff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86620b5e-d7ab-42e3-a64b-fd14be0fd582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e7eb2a67-f59d-4d14-a0ee-fb0527a6eff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86620b5e-d7ab-42e3-a64b-fd14be0fd582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_32ac4186-626c-47db-9d30-9e6f3d395404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86620b5e-d7ab-42e3-a64b-fd14be0fd582" xlink:to="loc_us-gaap_EmployeeStockOptionMember_32ac4186-626c-47db-9d30-9e6f3d395404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_8dcdd326-20b6-4ee0-86fb-ceb132416cb5" xlink:href="ameh-20220630.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86620b5e-d7ab-42e3-a64b-fd14be0fd582" xlink:to="loc_ameh_StockAwardsAndUnitsMember_8dcdd326-20b6-4ee0-86fb-ceb132416cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6bf242a-2c05-4c11-bcbd-5ab8d1e69db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ff2f503-328c-4212-bdb9-475c7f88cd7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6bf242a-2c05-4c11-bcbd-5ab8d1e69db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_441c4e85-19f3-4bbb-ae3a-9a0495a13213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6bf242a-2c05-4c11-bcbd-5ab8d1e69db4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_441c4e85-19f3-4bbb-ae3a-9a0495a13213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf9bb78f-8f75-4120-8f83-6bd9644cb11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf9bb78f-8f75-4120-8f83-6bd9644cb11d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c71c18d-8d9e-4ba2-a66d-948a958afb95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:to="loc_us-gaap_AwardTypeAxis_0c71c18d-8d9e-4ba2-a66d-948a958afb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87359c32-e3b6-4996-9032-ee5cd3a7b1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0c71c18d-8d9e-4ba2-a66d-948a958afb95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87359c32-e3b6-4996-9032-ee5cd3a7b1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b2f271c2-bcde-4a46-a748-5a7b29139ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87359c32-e3b6-4996-9032-ee5cd3a7b1cf" xlink:to="loc_us-gaap_RestrictedStockMember_b2f271c2-bcde-4a46-a748-5a7b29139ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_5086fdce-a896-4ac0-ae32-a86f429e274c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:to="loc_srt_TitleOfIndividualAxis_5086fdce-a896-4ac0-ae32-a86f429e274c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eba4c7d2-bbea-4b14-bf11-23cac08eb771" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_5086fdce-a896-4ac0-ae32-a86f429e274c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eba4c7d2-bbea-4b14-bf11-23cac08eb771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EmployeesMember_38018da2-44b5-4f9c-b9be-c2c6031f51bf" xlink:href="ameh-20220630.xsd#ameh_EmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eba4c7d2-bbea-4b14-bf11-23cac08eb771" xlink:to="loc_ameh_EmployeesMember_38018da2-44b5-4f9c-b9be-c2c6031f51bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ab6131d1-7476-414f-9e51-26b67a3daf92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:to="loc_srt_RangeAxis_ab6131d1-7476-414f-9e51-26b67a3daf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4ed6c44-47aa-4651-ab3c-de9acfd5a47e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ab6131d1-7476-414f-9e51-26b67a3daf92" xlink:to="loc_srt_RangeMember_c4ed6c44-47aa-4651-ab3c-de9acfd5a47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f4a44848-5c4d-44ed-ba11-44fcf24405a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c4ed6c44-47aa-4651-ab3c-de9acfd5a47e" xlink:to="loc_srt_MinimumMember_f4a44848-5c4d-44ed-ba11-44fcf24405a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae060fcc-73be-4235-9f9f-aa77d201ed98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c4ed6c44-47aa-4651-ab3c-de9acfd5a47e" xlink:to="loc_srt_MaximumMember_ae060fcc-73be-4235-9f9f-aa77d201ed98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d851ddb-3d42-48ac-92c1-c0057e8c2b2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_cd54549e-02c6-4238-99d9-dbfac116f35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_cd54549e-02c6-4238-99d9-dbfac116f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d907b85b-862d-4a9b-85c2-cb543eb532ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d907b85b-862d-4a9b-85c2-cb543eb532ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_44346f12-8b82-4a99-a087-efede5c68278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_44346f12-8b82-4a99-a087-efede5c68278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0e2a3f36-993e-48a2-8689-7591c5853a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0e2a3f36-993e-48a2-8689-7591c5853a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14e85b0c-04eb-460d-a132-5dd54a2f9afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14e85b0c-04eb-460d-a132-5dd54a2f9afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_b58925e1-7c86-4888-a857-b1f03a2ba3e8" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance_b58925e1-7c86-4888-a857-b1f03a2ba3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05fe863c-fcb3-4d06-8520-8e168f979902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_05fe863c-fcb3-4d06-8520-8e168f979902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cdfbf693-fadb-414a-a41e-0db14caeaca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cdfbf693-fadb-414a-a41e-0db14caeaca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_f67fa26b-c9c0-4836-844c-64a3335d554e" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_f67fa26b-c9c0-4836-844c-64a3335d554e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_08a94dc1-7cdc-4956-a36e-a6ad592e4b25" xlink:href="ameh-20220630.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_08a94dc1-7cdc-4956-a36e-a6ad592e4b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_17468f4a-0022-4b4b-a3ee-7e472b922a36" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_51205778-91bb-4835-be63-367febc051ac" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_17468f4a-0022-4b4b-a3ee-7e472b922a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03d110ec-1df3-4a9d-b5ae-37600c8b2dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cba4b1e-dd0c-4158-8436-7ae6d8b2b5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03d110ec-1df3-4a9d-b5ae-37600c8b2dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cba4b1e-dd0c-4158-8436-7ae6d8b2b5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_077ff4dc-92a7-4c69-a8bb-1decfa6d3f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cba4b1e-dd0c-4158-8436-7ae6d8b2b5da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_077ff4dc-92a7-4c69-a8bb-1decfa6d3f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_b11fa9c4-e7b5-4dac-a6b7-e9746c6a2dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cba4b1e-dd0c-4158-8436-7ae6d8b2b5da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_b11fa9c4-e7b5-4dac-a6b7-e9746c6a2dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_84e5055a-7b79-447a-b36b-ba123bae6ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cba4b1e-dd0c-4158-8436-7ae6d8b2b5da" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_84e5055a-7b79-447a-b36b-ba123bae6ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b3aa7c6-7fcb-4b13-890e-3f44efa0ade5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cba4b1e-dd0c-4158-8436-7ae6d8b2b5da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b3aa7c6-7fcb-4b13-890e-3f44efa0ade5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f9d549dc-2c11-43f8-8ebe-a685e9bac20e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03d110ec-1df3-4a9d-b5ae-37600c8b2dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f9d549dc-2c11-43f8-8ebe-a685e9bac20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bb56cd78-b0fb-49bf-84bb-bb9011618a2e" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03d110ec-1df3-4a9d-b5ae-37600c8b2dae" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bb56cd78-b0fb-49bf-84bb-bb9011618a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bd6364a9-0189-42c1-9b05-e2ff16e3fddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bb56cd78-b0fb-49bf-84bb-bb9011618a2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bd6364a9-0189-42c1-9b05-e2ff16e3fddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e5dd3866-0cc5-4475-bef5-93c147ed004e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bb56cd78-b0fb-49bf-84bb-bb9011618a2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e5dd3866-0cc5-4475-bef5-93c147ed004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_972c53f7-bbf3-43d9-9cb3-0a8909c4675e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bb56cd78-b0fb-49bf-84bb-bb9011618a2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_972c53f7-bbf3-43d9-9cb3-0a8909c4675e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6e3bfa43-7010-4f46-b0cb-2a0781dd87a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bb56cd78-b0fb-49bf-84bb-bb9011618a2e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6e3bfa43-7010-4f46-b0cb-2a0781dd87a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_39582cbc-52c6-4181-be45-f75c281cfb15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03d110ec-1df3-4a9d-b5ae-37600c8b2dae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_39582cbc-52c6-4181-be45-f75c281cfb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_024a64ff-810e-4b52-9521-f8770c68ab64" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03d110ec-1df3-4a9d-b5ae-37600c8b2dae" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_024a64ff-810e-4b52-9521-f8770c68ab64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_55e0e08a-eece-4ab8-8bdb-a8c6456d879e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_024a64ff-810e-4b52-9521-f8770c68ab64" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_55e0e08a-eece-4ab8-8bdb-a8c6456d879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_432c4034-e0db-46b5-83bf-f1b573cfc513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_024a64ff-810e-4b52-9521-f8770c68ab64" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_432c4034-e0db-46b5-83bf-f1b573cfc513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_530cbc8b-f6de-4d41-b59d-0e79b38a9d08" xlink:href="ameh-20220630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_03d110ec-1df3-4a9d-b5ae-37600c8b2dae" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_530cbc8b-f6de-4d41-b59d-0e79b38a9d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1ee81df-a65b-47fe-aaa5-c946159e2a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_530cbc8b-f6de-4d41-b59d-0e79b38a9d08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1ee81df-a65b-47fe-aaa5-c946159e2a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c5475c58-d371-42e3-908e-06af8605b11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_530cbc8b-f6de-4d41-b59d-0e79b38a9d08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c5475c58-d371-42e3-908e-06af8605b11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_05ee296f-779b-4571-83b6-cbc61b213923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_530cbc8b-f6de-4d41-b59d-0e79b38a9d08" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_05ee296f-779b-4571-83b6-cbc61b213923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14a33373-95ea-4b2b-8bdb-f424e6584632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_057b434c-fc55-4add-9a17-d593a108fdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14a33373-95ea-4b2b-8bdb-f424e6584632" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_057b434c-fc55-4add-9a17-d593a108fdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_83190fb2-757c-42f1-ad26-21b139f1e490" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_057b434c-fc55-4add-9a17-d593a108fdc4" xlink:to="loc_srt_TitleOfIndividualAxis_83190fb2-757c-42f1-ad26-21b139f1e490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7f9f3570-5c97-4c35-929b-af7f9e4028f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_83190fb2-757c-42f1-ad26-21b139f1e490" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7f9f3570-5c97-4c35-929b-af7f9e4028f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_00c3f57b-32ee-4249-a365-8daba3eefdd2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7f9f3570-5c97-4c35-929b-af7f9e4028f8" xlink:to="loc_srt_DirectorMember_00c3f57b-32ee-4249-a365-8daba3eefdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce6d10a2-96f4-4222-ac1b-f238a7f1063c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_057b434c-fc55-4add-9a17-d593a108fdc4" xlink:to="loc_srt_RangeAxis_ce6d10a2-96f4-4222-ac1b-f238a7f1063c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bb8103a1-2d7e-43f0-81fd-9c6b6575f576" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ce6d10a2-96f4-4222-ac1b-f238a7f1063c" xlink:to="loc_srt_RangeMember_bb8103a1-2d7e-43f0-81fd-9c6b6575f576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7a69cf1d-3a01-4a00-b0f8-aaa437854cd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bb8103a1-2d7e-43f0-81fd-9c6b6575f576" xlink:to="loc_srt_MinimumMember_7a69cf1d-3a01-4a00-b0f8-aaa437854cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_59a02407-f520-469b-b639-624342d8b71f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bb8103a1-2d7e-43f0-81fd-9c6b6575f576" xlink:to="loc_srt_MaximumMember_59a02407-f520-469b-b639-624342d8b71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_057b434c-fc55-4add-9a17-d593a108fdc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47a7f0d4-5069-4935-b12b-dfe681abaa6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47a7f0d4-5069-4935-b12b-dfe681abaa6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b5cbd05e-4573-43f3-94f1-f620f619056a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b5cbd05e-4573-43f3-94f1-f620f619056a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_065a4243-5ef3-460d-822c-826c89c9f196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_065a4243-5ef3-460d-822c-826c89c9f196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8322a76d-c2ea-4c17-b064-6d64068217e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_8322a76d-c2ea-4c17-b064-6d64068217e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_626e22c8-4507-4e32-816a-1c798ff2550e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_626e22c8-4507-4e32-816a-1c798ff2550e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_6aba01b1-3274-4967-b801-42fa1d840620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_09d7bb58-43e9-4424-baa2-6e9ca8ecea41" xlink:to="loc_us-gaap_SharePrice_6aba01b1-3274-4967-b801-42fa1d840620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationSummaryofWarrantDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af503249-338b-49bb-ad86-b3e7bd390dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward_a31aefe7-d05b-4f1e-b4a1-b933c9405ec4" xlink:href="ameh-20220630.xsd#ameh_SharesWarrantsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af503249-338b-49bb-ad86-b3e7bd390dbf" xlink:to="loc_ameh_SharesWarrantsRollForward_a31aefe7-d05b-4f1e-b4a1-b933c9405ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5f823b2c-b332-478d-b9f7-e5b98e58783a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_a31aefe7-d05b-4f1e-b4a1-b933c9405ec4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5f823b2c-b332-478d-b9f7-e5b98e58783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted_d59d8027-1f08-4aa5-b8bc-d7aaf6586142" xlink:href="ameh-20220630.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_a31aefe7-d05b-4f1e-b4a1-b933c9405ec4" xlink:to="loc_ameh_NumberOfWarrantsGranted_d59d8027-1f08-4aa5-b8bc-d7aaf6586142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised_eb401924-abb2-4388-a6c6-886bb1aa21f3" xlink:href="ameh-20220630.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_a31aefe7-d05b-4f1e-b4a1-b933c9405ec4" xlink:to="loc_ameh_NumberOfWarrantsExercised_eb401924-abb2-4388-a6c6-886bb1aa21f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_82402c48-f7e8-4eac-a2d2-b93fca34dc69" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_a31aefe7-d05b-4f1e-b4a1-b933c9405ec4" xlink:to="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_82402c48-f7e8-4eac-a2d2-b93fca34dc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6096ab0b-0578-44e9-9a01-5224642a33e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_a31aefe7-d05b-4f1e-b4a1-b933c9405ec4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6096ab0b-0578-44e9-9a01-5224642a33e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_66e9933e-60d4-4ccd-9dba-40085080ccd0" xlink:href="ameh-20220630.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af503249-338b-49bb-ad86-b3e7bd390dbf" xlink:to="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_66e9933e-60d4-4ccd-9dba-40085080ccd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_6a102dc6-e5bc-43ce-9a86-b6a25babee5d" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_66e9933e-60d4-4ccd-9dba-40085080ccd0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_6a102dc6-e5bc-43ce-9a86-b6a25babee5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_03013e21-9438-4b1b-b600-b8301bc93ca9" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_66e9933e-60d4-4ccd-9dba-40085080ccd0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_03013e21-9438-4b1b-b600-b8301bc93ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_e7abc6ba-1173-4173-bc61-7336bb166c78" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_66e9933e-60d4-4ccd-9dba-40085080ccd0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_e7abc6ba-1173-4173-bc61-7336bb166c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_46dc6a93-321a-4385-b6da-1608974329f5" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_66e9933e-60d4-4ccd-9dba-40085080ccd0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_46dc6a93-321a-4385-b6da-1608974329f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_d9ee0964-d4e6-4710-9442-db1043d64795" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_66e9933e-60d4-4ccd-9dba-40085080ccd0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_d9ee0964-d4e6-4710-9442-db1043d64795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_b7881542-642f-4700-a84a-a165337539c9" xlink:href="ameh-20220630.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af503249-338b-49bb-ad86-b3e7bd390dbf" xlink:to="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_b7881542-642f-4700-a84a-a165337539c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_43ba186e-f9e1-43a6-9b16-98a404c93cdd" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_b7881542-642f-4700-a84a-a165337539c9" xlink:to="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_43ba186e-f9e1-43a6-9b16-98a404c93cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract_868ad88b-6b7e-413b-8dcb-ff9e0c4b36bd" xlink:href="ameh-20220630.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af503249-338b-49bb-ad86-b3e7bd390dbf" xlink:to="loc_ameh_AggregateintrinsicvalueAbstract_868ad88b-6b7e-413b-8dcb-ff9e0c4b36bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_e5a2599f-300a-412c-a5fd-6d95c9310a1a" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_868ad88b-6b7e-413b-8dcb-ff9e0c4b36bd" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_e5a2599f-300a-412c-a5fd-6d95c9310a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_529928b0-05ef-43a6-9777-23a9e04c0f6c" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_868ad88b-6b7e-413b-8dcb-ff9e0c4b36bd" xlink:to="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_529928b0-05ef-43a6-9777-23a9e04c0f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_e957677d-8453-44a4-b4a0-e6519288d03c" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_868ad88b-6b7e-413b-8dcb-ff9e0c4b36bd" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_e957677d-8453-44a4-b4a0-e6519288d03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_4cabbba5-a177-44ab-83e7-fad10eb58373" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_868ad88b-6b7e-413b-8dcb-ff9e0c4b36bd" xlink:to="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_4cabbba5-a177-44ab-83e7-fad10eb58373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_e9fc79cd-dc4e-4f0c-9afa-533f513c526d" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_868ad88b-6b7e-413b-8dcb-ff9e0c4b36bd" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_e9fc79cd-dc4e-4f0c-9afa-533f513c526d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30be39b6-5739-4c05-91fe-4abfea632fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_9784da78-73a4-4203-b30f-8a626cb4ca69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30be39b6-5739-4c05-91fe-4abfea632fd7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_9784da78-73a4-4203-b30f-8a626cb4ca69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4a378563-f999-4159-8289-f5f210bed3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9784da78-73a4-4203-b30f-8a626cb4ca69" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4a378563-f999-4159-8289-f5f210bed3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4a378563-f999-4159-8289-f5f210bed3ca" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_98610cd2-ca58-4d1e-8303-e095828ebb0f" xlink:href="ameh-20220630.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_98610cd2-ca58-4d1e-8303-e095828ebb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_973d8358-7265-4a66-8227-b85ceb03876f" xlink:href="ameh-20220630.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_973d8358-7265-4a66-8227-b85ceb03876f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_1cefb27d-67b5-45d1-9138-14382b039f5d" xlink:href="ameh-20220630.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f2736560-9365-43fa-b455-881d499564bf" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_1cefb27d-67b5-45d1-9138-14382b039f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fb527be2-4e3a-46cd-9239-11f3fdbb36c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9784da78-73a4-4203-b30f-8a626cb4ca69" xlink:to="loc_srt_RangeAxis_fb527be2-4e3a-46cd-9239-11f3fdbb36c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a78704a-7233-40d9-b450-d6c46736593e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fb527be2-4e3a-46cd-9239-11f3fdbb36c7" xlink:to="loc_srt_RangeMember_6a78704a-7233-40d9-b450-d6c46736593e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d69e8a50-2b7d-49b4-aa4c-7107372990f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a78704a-7233-40d9-b450-d6c46736593e" xlink:to="loc_srt_MinimumMember_d69e8a50-2b7d-49b4-aa4c-7107372990f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a341426-f5a0-43bd-bd57-436b10815570" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a78704a-7233-40d9-b450-d6c46736593e" xlink:to="loc_srt_MaximumMember_6a341426-f5a0-43bd-bd57-436b10815570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_9784da78-73a4-4203-b30f-8a626cb4ca69" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd80609d-8c85-40a0-8cd2-b2f94656e0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_bd80609d-8c85-40a0-8cd2-b2f94656e0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_ebeb94a6-2b2b-43c6-a3e4-15949cd2eac6" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_ebeb94a6-2b2b-43c6-a3e4-15949cd2eac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_1911bcc9-c0c8-4851-9084-2cc47fc959de" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_1911bcc9-c0c8-4851-9084-2cc47fc959de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_fb743a9d-ba85-43fe-a580-e0725851c5fb" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_fb743a9d-ba85-43fe-a580-e0725851c5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_473bc73e-9873-485e-93e7-d65c9007522d" xlink:href="ameh-20220630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_61fcc9aa-0c53-408d-9f39-a95affb09c92" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_473bc73e-9873-485e-93e7-d65c9007522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20220630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7951915-83a0-4bfc-9780-c3829d7044f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2ebdf571-8dd0-43f0-a483-9d5d939c5ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7951915-83a0-4bfc-9780-c3829d7044f2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2ebdf571-8dd0-43f0-a483-9d5d939c5ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e82ee62-75f9-44f6-8ea9-d20ae37e9de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:href="ameh-20220630.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e82ee62-75f9-44f6-8ea9-d20ae37e9de1" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b29fbd25-144d-4991-97d1-4e61eb2d7eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:to="loc_us-gaap_CreditFacilityAxis_b29fbd25-144d-4991-97d1-4e61eb2d7eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a8e85ced-e356-42db-aef8-1d6d0b74ddb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b29fbd25-144d-4991-97d1-4e61eb2d7eea" xlink:to="loc_us-gaap_CreditFacilityDomain_a8e85ced-e356-42db-aef8-1d6d0b74ddb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_96da578b-3b74-473e-81ce-8c5f6134f82b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a8e85ced-e356-42db-aef8-1d6d0b74ddb4" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_96da578b-3b74-473e-81ce-8c5f6134f82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_bfecfdeb-13c6-4155-9b78-af9e0d1480c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_bfecfdeb-13c6-4155-9b78-af9e0d1480c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_fea98810-9a85-424f-b3e9-7ecd249b3f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_bfecfdeb-13c6-4155-9b78-af9e0d1480c3" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_fea98810-9a85-424f-b3e9-7ecd249b3f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_04d277df-d666-4e80-948f-f66f143f491b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_fea98810-9a85-424f-b3e9-7ecd249b3f56" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_04d277df-d666-4e80-948f-f66f143f491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_00dc1d95-48d9-4226-b058-cc62eb217daf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:to="loc_dei_LegalEntityAxis_00dc1d95-48d9-4226-b058-cc62eb217daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d401bb4c-e6d9-4e47-a703-478f9c169e3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_00dc1d95-48d9-4226-b058-cc62eb217daf" xlink:to="loc_dei_EntityDomain_d401bb4c-e6d9-4e47-a703-478f9c169e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2a2e54cb-fb93-41b7-bf9c-114a1dca4696" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d401bb4c-e6d9-4e47-a703-478f9c169e3a" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2a2e54cb-fb93-41b7-bf9c-114a1dca4696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_1359a3cc-897a-4904-8c27-c7f305cd0bf7" xlink:href="ameh-20220630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d401bb4c-e6d9-4e47-a703-478f9c169e3a" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_1359a3cc-897a-4904-8c27-c7f305cd0bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_2edf074b-d49a-4808-8b45-6674fa5a8652" xlink:href="ameh-20220630.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_cb6950ea-1513-4ace-a246-92528ddf3fb9" xlink:to="loc_ameh_CommitmentsAndContingenciesLineItems_2edf074b-d49a-4808-8b45-6674fa5a8652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_3cc0aa1c-8715-4e5e-861d-d79d858117e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_2edf074b-d49a-4808-8b45-6674fa5a8652" xlink:to="loc_us-gaap_LineOfCredit_3cc0aa1c-8715-4e5e-861d-d79d858117e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20220630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1d122311-5075-4a4e-ac4b-bc06c454c0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c7013191-96e4-45ee-9b90-8e027be04d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1d122311-5075-4a4e-ac4b-bc06c454c0b5" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c7013191-96e4-45ee-9b90-8e027be04d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8349bda8-c544-4f4e-ad8a-b4670a82e4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_e5d60c35-e5a6-493d-b5b3-f39c2d383460" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8349bda8-c544-4f4e-ad8a-b4670a82e4b7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_e5d60c35-e5a6-493d-b5b3-f39c2d383460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2ea90090-21f0-4e51-9a5a-d449db427f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2ea90090-21f0-4e51-9a5a-d449db427f10" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5ea213ba-be54-4906-9d9b-1e407de6aaa6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5ea213ba-be54-4906-9d9b-1e407de6aaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5ea213ba-be54-4906-9d9b-1e407de6aaa6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_de69b448-6dbf-4e96-8c59-597639360c8c" xlink:href="ameh-20220630.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:to="loc_ameh_LmaMember_de69b448-6dbf-4e96-8c59-597639360c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_5eca0c8f-ea07-4d3c-b9cb-f23524a1fa8d" xlink:href="ameh-20220630.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:to="loc_ameh_PmiocMember_5eca0c8f-ea07-4d3c-b9cb-f23524a1fa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_aa8d7ad6-676a-4338-9049-22bca2f81060" xlink:href="ameh-20220630.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:to="loc_ameh_DmgMember_aa8d7ad6-676a-4338-9049-22bca2f81060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_fb41b707-2f7b-4e4a-a979-d3a1b4439618" xlink:href="ameh-20220630.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a28c6fa3-77f2-43fb-9cf0-ede309e5c77c" xlink:to="loc_ameh_OneMSOInc.Member_fb41b707-2f7b-4e4a-a979-d3a1b4439618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_289a80e9-932c-4490-a294-d97744ab627b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_289a80e9-932c-4490-a294-d97744ab627b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_289a80e9-932c-4490-a294-d97744ab627b" xlink:to="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_981c4747-904c-42cf-a6a3-75ccabcfe385" xlink:href="ameh-20220630.xsd#ameh_ApcShareholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_ApcShareholdersMember_981c4747-904c-42cf-a6a3-75ccabcfe385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_c347132f-e2ec-481b-b6d7-f2c8ee581b1d" xlink:href="ameh-20220630.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_c347132f-e2ec-481b-b6d7-f2c8ee581b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_7ec9968c-ebfb-4241-87b6-4640d94bdad3" xlink:href="ameh-20220630.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_FulgentGeneticsIncMember_7ec9968c-ebfb-4241-87b6-4640d94bdad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_502e58df-82ae-462d-add1-18b4c74837f6" xlink:href="ameh-20220630.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_ShareholdersAndOfficersMember_502e58df-82ae-462d-add1-18b4c74837f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_8991bbc9-8270-40e6-ac7f-7430d3e78364" xlink:href="ameh-20220630.xsd#ameh_NumenLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_NumenLLCMember_8991bbc9-8270-40e6-ac7f-7430d3e78364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_2a9246bf-6e17-4a1c-ab29-3c494d784001" xlink:href="ameh-20220630.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_OneMSOInc.Member_2a9246bf-6e17-4a1c-ab29-3c494d784001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ArroyoVistaMember_5c792c40-4341-47a1-86db-e3d4dcc3070b" xlink:href="ameh-20220630.xsd#ameh_ArroyoVistaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_ArroyoVistaMember_5c792c40-4341-47a1-86db-e3d4dcc3070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_63b8e889-50e9-4a9f-a40c-188ab1a6c047" xlink:href="ameh-20220630.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_ameh_AHMCMember_63b8e889-50e9-4a9f-a40c-188ab1a6c047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_fd5c9abc-bf79-4f53-9f68-cb36ef0007aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8bb1292-e9a8-4aa9-b019-b54e1b9ac13f" xlink:to="loc_srt_DirectorMember_fd5c9abc-bf79-4f53-9f68-cb36ef0007aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ce87030e-10ec-4898-8938-77bfe97f07f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_dei_LegalEntityAxis_ce87030e-10ec-4898-8938-77bfe97f07f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ce87030e-10ec-4898-8938-77bfe97f07f6" xlink:to="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_bcef8624-4f37-4ae7-a25d-275e803db2b0" xlink:href="ameh-20220630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:to="loc_ameh_NetworkMedicalManagementMember_bcef8624-4f37-4ae7-a25d-275e803db2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8babe5ff-1cab-45a7-9680-0250daf45207" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8babe5ff-1cab-45a7-9680-0250daf45207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_bd09c76a-adf1-4405-8e47-50096d86f436" xlink:href="ameh-20220630.xsd#ameh_SCHCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_70194c6c-82d3-4a93-9930-c834cc53fcc1" xlink:to="loc_ameh_SCHCMember_bd09c76a-adf1-4405-8e47-50096d86f436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9807725d-adee-4afd-ab45-8a0e24e42724" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9807725d-adee-4afd-ab45-8a0e24e42724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9807725d-adee-4afd-ab45-8a0e24e42724" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_def5a3a6-5d77-4013-8d23-1eb86f48952b" xlink:href="ameh-20220630.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:to="loc_ameh_LmaMember_def5a3a6-5d77-4013-8d23-1eb86f48952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_16a54d85-6e69-4f70-99f3-1d899298b3ec" xlink:href="ameh-20220630.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:to="loc_ameh_PmiocMember_16a54d85-6e69-4f70-99f3-1d899298b3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_ddc53a71-03f6-46ff-bfca-06dcbfcb04aa" xlink:href="ameh-20220630.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9780f1f9-e2a5-4c61-8fb3-484038f97596" xlink:to="loc_ameh_DmgMember_ddc53a71-03f6-46ff-bfca-06dcbfcb04aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_57c55f2b-6057-4982-9e16-71a6e4122974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_57c55f2b-6057-4982-9e16-71a6e4122974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_199bd014-c460-4dc6-bbc1-6e96c6151979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_57c55f2b-6057-4982-9e16-71a6e4122974" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_199bd014-c460-4dc6-bbc1-6e96c6151979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ec3d8c52-2f5b-42f7-9bfe-0b75ca93bc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_199bd014-c460-4dc6-bbc1-6e96c6151979" xlink:to="loc_us-gaap_ServiceMember_ec3d8c52-2f5b-42f7-9bfe-0b75ca93bc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18418fab-27b3-4b12-b739-5f26a5115fc7" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a8519563-5f8b-40c2-9329-9846432e3deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a8519563-5f8b-40c2-9329-9846432e3deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_c58a50b2-79ea-452b-9752-16573ac40e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_c58a50b2-79ea-452b-9752-16573ac40e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_e14efac2-f46a-41fa-84e3-dc253aec7b7c" xlink:href="ameh-20220630.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_ameh_PaymentMadeToRelatedParty_e14efac2-f46a-41fa-84e3-dc253aec7b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_9417fe48-2bd5-4418-b9b3-e2098762b0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_9417fe48-2bd5-4418-b9b3-e2098762b0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_482c5449-4275-49dc-b914-f54357024658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_482c5449-4275-49dc-b914-f54357024658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3fba6f86-7273-4a2a-92b6-afd51b290d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0fa77bdb-b2e8-458b-a57f-7a2bbe99876d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3fba6f86-7273-4a2a-92b6-afd51b290d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3104d459-8b1b-41de-84b1-0047ea61e89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8831cc9-ce7e-47b2-88b0-0e08c39747cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3104d459-8b1b-41de-84b1-0047ea61e89b" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8831cc9-ce7e-47b2-88b0-0e08c39747cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c9db1114-1653-4a12-b472-575219ee8f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8831cc9-ce7e-47b2-88b0-0e08c39747cb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c9db1114-1653-4a12-b472-575219ee8f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c9db1114-1653-4a12-b472-575219ee8f7c" xlink:to="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_9fff771a-2544-4de1-8ac8-8c845ff479af" xlink:href="ameh-20220630.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:to="loc_ameh_AHMCMember_9fff771a-2544-4de1-8ac8-8c845ff479af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_d8aba4e9-93dc-484e-8ed0-dadbc90ec97e" xlink:href="ameh-20220630.xsd#ameh_HSMSOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:to="loc_ameh_HSMSOMember_d8aba4e9-93dc-484e-8ed0-dadbc90ec97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_c493af64-c23d-4fef-a2ea-2c1e8fef62c0" xlink:href="ameh-20220630.xsd#ameh_AurionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6c037194-c85a-4779-8396-91441a77026f" xlink:to="loc_ameh_AurionMember_c493af64-c23d-4fef-a2ea-2c1e8fef62c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8831cc9-ce7e-47b2-88b0-0e08c39747cb" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_76ee0974-ac0c-487f-916e-139a07b01288" xlink:href="ameh-20220630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_76ee0974-ac0c-487f-916e-139a07b01288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_b47607c4-1749-42ce-8050-3616cbaf7286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:to="loc_us-gaap_ManagementFeeExpense_b47607c4-1749-42ce-8050-3616cbaf7286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3f6e03c7-e44d-4896-b388-10dffe277c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1941c899-8e27-41c8-82a1-7644d4987d65" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3f6e03c7-e44d-4896-b388-10dffe277c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_faf26afe-ddd3-4794-bc07-f7b273f54338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_fc847aa4-11c8-4f04-a18e-1f4819a3c511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_faf26afe-ddd3-4794-bc07-f7b273f54338" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_fc847aa4-11c8-4f04-a18e-1f4819a3c511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3863f4d6-d19e-4316-bc0c-88909a0fcbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a1c39c79-01e7-410e-a5e0-5cf48f29e01c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3863f4d6-d19e-4316-bc0c-88909a0fcbf1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a1c39c79-01e7-410e-a5e0-5cf48f29e01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20220630.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b75586cc-dcd3-4b19-848d-1e8cc993618e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8ee379a4-eda2-423f-9234-8a26f449e08d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b75586cc-dcd3-4b19-848d-1e8cc993618e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8ee379a4-eda2-423f-9234-8a26f449e08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_196a21e0-14db-476c-8d3d-609cabebda10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8668f6bb-2663-4adf-ad35-81242ae6daad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_196a21e0-14db-476c-8d3d-609cabebda10" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8668f6bb-2663-4adf-ad35-81242ae6daad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_790b4c06-2a94-4de2-8690-0bb09f114795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_196a21e0-14db-476c-8d3d-609cabebda10" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_790b4c06-2a94-4de2-8690-0bb09f114795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8b4a94e7-28ae-4a06-878e-4b2a2f504812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_846aa99a-be48-40ef-9d20-3e0f3413aa04" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b4a94e7-28ae-4a06-878e-4b2a2f504812" xlink:to="loc_ameh_EarningsPerShareTable_846aa99a-be48-40ef-9d20-3e0f3413aa04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_accf1d49-06ae-463a-b402-4d2e290c0410" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_846aa99a-be48-40ef-9d20-3e0f3413aa04" xlink:to="loc_dei_LegalEntityAxis_accf1d49-06ae-463a-b402-4d2e290c0410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_40a90d8e-9858-4def-8179-2a45386abce1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_accf1d49-06ae-463a-b402-4d2e290c0410" xlink:to="loc_dei_EntityDomain_40a90d8e-9858-4def-8179-2a45386abce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2f5203ab-a928-4c84-a167-2883695e11db" xlink:href="ameh-20220630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_40a90d8e-9858-4def-8179-2a45386abce1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2f5203ab-a928-4c84-a167-2883695e11db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_27671f1c-a51c-4cd7-a92f-04cf9a961ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_846aa99a-be48-40ef-9d20-3e0f3413aa04" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_27671f1c-a51c-4cd7-a92f-04cf9a961ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f4562ba-7ab7-434e-aa81-e1fae1968ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_27671f1c-a51c-4cd7-a92f-04cf9a961ba0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f4562ba-7ab7-434e-aa81-e1fae1968ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c0fedd07-8db1-4eea-b0d1-cdec9072322a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f4562ba-7ab7-434e-aa81-e1fae1968ea0" xlink:to="loc_us-gaap_RestrictedStockMember_c0fedd07-8db1-4eea-b0d1-cdec9072322a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_98e624d3-8229-491c-a78b-c5fc558db4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5f4562ba-7ab7-434e-aa81-e1fae1968ea0" xlink:to="loc_us-gaap_PerformanceSharesMember_98e624d3-8229-491c-a78b-c5fc558db4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_0d4c7680-aa1e-4e95-8da3-0f271aa54781" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_846aa99a-be48-40ef-9d20-3e0f3413aa04" xlink:to="loc_ameh_EarningsPerShareLineItems_0d4c7680-aa1e-4e95-8da3-0f271aa54781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35bb14e5-0947-4706-ba00-aae627df94ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_0d4c7680-aa1e-4e95-8da3-0f271aa54781" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35bb14e5-0947-4706-ba00-aae627df94ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c3a8a9a2-cf16-4efd-b80e-a1148f2b0eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c1d5750b-7002-4388-ba0d-504d0bdf798c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3a8a9a2-cf16-4efd-b80e-a1148f2b0eca" xlink:to="loc_us-gaap_EarningsPerShareBasic_c1d5750b-7002-4388-ba0d-504d0bdf798c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dc04e7cd-0721-491b-8222-6690071de43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3a8a9a2-cf16-4efd-b80e-a1148f2b0eca" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dc04e7cd-0721-491b-8222-6690071de43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3750f9c7-5db1-428b-8dde-5d8d55cae154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3a8a9a2-cf16-4efd-b80e-a1148f2b0eca" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3750f9c7-5db1-428b-8dde-5d8d55cae154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_463c7cc8-3413-4ac3-b6b3-89ca491251bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3a8a9a2-cf16-4efd-b80e-a1148f2b0eca" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_463c7cc8-3413-4ac3-b6b3-89ca491251bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_44220a7e-033a-4ea1-8f1e-ebc76325a3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_bc87326f-aff6-45f0-9744-3b49a23345b8" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_44220a7e-033a-4ea1-8f1e-ebc76325a3fd" xlink:to="loc_ameh_EarningsPerShareTable_bc87326f-aff6-45f0-9744-3b49a23345b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3b9e14ed-e503-49a9-8eb5-7b5052b3e3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_bc87326f-aff6-45f0-9744-3b49a23345b8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3b9e14ed-e503-49a9-8eb5-7b5052b3e3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_32dfde0e-c75a-4f3a-bbe9-ab307f719911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b9e14ed-e503-49a9-8eb5-7b5052b3e3d7" xlink:to="loc_us-gaap_EquityComponentDomain_32dfde0e-c75a-4f3a-bbe9-ab307f719911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8de0219e-1832-4df5-a69b-e1daf821f42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32dfde0e-c75a-4f3a-bbe9-ab307f719911" xlink:to="loc_us-gaap_WarrantMember_8de0219e-1832-4df5-a69b-e1daf821f42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_42e4cc3a-0678-41e1-a773-4361510a8be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_bc87326f-aff6-45f0-9744-3b49a23345b8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_42e4cc3a-0678-41e1-a773-4361510a8be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1758d460-6e27-4e15-8980-d0261cb840e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_42e4cc3a-0678-41e1-a773-4361510a8be5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1758d460-6e27-4e15-8980-d0261cb840e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eea62495-457f-480e-af7e-d8606b801243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1758d460-6e27-4e15-8980-d0261cb840e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eea62495-457f-480e-af7e-d8606b801243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f589ab5a-ba5e-443d-8061-868fa91a94a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1758d460-6e27-4e15-8980-d0261cb840e3" xlink:to="loc_us-gaap_RestrictedStockMember_f589ab5a-ba5e-443d-8061-868fa91a94a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:href="ameh-20220630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_bc87326f-aff6-45f0-9744-3b49a23345b8" xlink:to="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6de9ed1a-0fc8-4d94-94f0-0a0fd30c5fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6de9ed1a-0fc8-4d94-94f0-0a0fd30c5fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_05f28377-199c-4096-979c-779c8fc053f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_05f28377-199c-4096-979c-779c8fc053f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0d44474-53a4-4a28-8c99-6b500c23e659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_4e2288c2-e878-4a6a-9fc3-c002d0453e5c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0d44474-53a4-4a28-8c99-6b500c23e659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20220630.xsd#VariableInterestEntitiesVIEs"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45f4abbc-dd77-41aa-a4be-8a973f24e73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_45b8569a-6176-4dac-99b8-e74fab92456f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45f4abbc-dd77-41aa-a4be-8a973f24e73d" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_45b8569a-6176-4dac-99b8-e74fab92456f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7efe7be-e3de-4074-bb14-3b3e6a7a4a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_25f8feda-88f7-4e1c-b5c1-54cd0f3a309c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b7efe7be-e3de-4074-bb14-3b3e6a7a4a97" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_25f8feda-88f7-4e1c-b5c1-54cd0f3a309c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a61407b-3f4e-4f5d-92a4-17496ce2a653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e0d9585a-f3b2-4897-8e6e-34e023397c58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a61407b-3f4e-4f5d-92a4-17496ce2a653" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e0d9585a-f3b2-4897-8e6e-34e023397c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8b60f49f-94b0-43d8-bb55-027f849127df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e0d9585a-f3b2-4897-8e6e-34e023397c58" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8b60f49f-94b0-43d8-bb55-027f849127df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_90224e28-647c-40cf-8e35-1b7a191c60ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8b60f49f-94b0-43d8-bb55-027f849127df" xlink:to="loc_srt_ConsolidatedEntitiesDomain_90224e28-647c-40cf-8e35-1b7a191c60ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c9056a6b-028b-466e-bd71-fd5469f9f24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_90224e28-647c-40cf-8e35-1b7a191c60ea" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_c9056a6b-028b-466e-bd71-fd5469f9f24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_e0d9585a-f3b2-4897-8e6e-34e023397c58" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:to="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:to="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_777b1e81-961d-4983-98c3-e57a729f0165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_777b1e81-961d-4983-98c3-e57a729f0165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_8fc71c40-140c-41fa-8e75-94d335fe36ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_8fc71c40-140c-41fa-8e75-94d335fe36ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5b6cd79b-ce58-4712-841a-e0c6878d449d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5b6cd79b-ce58-4712-841a-e0c6878d449d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_762651d1-b969-4ed4-8c08-85cefcc9d53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_762651d1-b969-4ed4-8c08-85cefcc9d53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a7eabdbf-86ac-4d2e-bc1d-43f066975da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_IncomeTaxesReceivable_a7eabdbf-86ac-4d2e-bc1d-43f066975da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_471b2d48-8cd7-49dd-874a-c7aabbd017c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_471b2d48-8cd7-49dd-874a-c7aabbd017c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_282c813b-1c22-4dcf-8042-25169adf71af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_282c813b-1c22-4dcf-8042-25169adf71af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_ee37d1eb-3045-48b4-a54e-1afe37dfe4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_ee37d1eb-3045-48b4-a54e-1afe37dfe4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_aa7a3014-1442-46f9-98d4-bc33e4f05a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_aa7a3014-1442-46f9-98d4-bc33e4f05a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bb8c7958-0662-4cdb-8572-466a0efcdc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_730e256f-1746-44f9-81aa-7ad3e9b223f5" xlink:to="loc_us-gaap_AssetsCurrent_bb8c7958-0662-4cdb-8572-466a0efcdc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f7699aad-ea99-4a16-bcbf-495fa70e5481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f7699aad-ea99-4a16-bcbf-495fa70e5481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_500234c3-e120-4da9-b4d8-163ff1865dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_500234c3-e120-4da9-b4d8-163ff1865dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d49712d8-f534-476f-b252-f21d5f1d1b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_Goodwill_d49712d8-f534-476f-b252-f21d5f1d1b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_dbe6d83c-fc5e-41b3-ac39-2e4bff310175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_dbe6d83c-fc5e-41b3-ac39-2e4bff310175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_725e6c0c-49c5-4f93-b54e-7abc9b642b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_725e6c0c-49c5-4f93-b54e-7abc9b642b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_22623920-3c63-4fc6-892d-950776627784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_OtherLongTermInvestments_22623920-3c63-4fc6-892d-950776627784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0f16f968-3aaf-4451-a5f3-a612b3a25ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_EquityMethodInvestments_0f16f968-3aaf-4451-a5f3-a612b3a25ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_2a87df80-931b-4578-a5e4-d9aa3449e461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_2a87df80-931b-4578-a5e4-d9aa3449e461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7826dec-85a4-4e0f-b3d4-54ed76ad4d68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7826dec-85a4-4e0f-b3d4-54ed76ad4d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6ad10482-9fdc-4721-bb3d-035560432740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6ad10482-9fdc-4721-bb3d-035560432740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_80be7381-1814-48fa-aaee-f3ab13665f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e9241391-a55b-4922-b4ac-dad8fb683666" xlink:to="loc_us-gaap_AssetsNoncurrent_80be7381-1814-48fa-aaee-f3ab13665f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_90878e34-55da-410f-8051-58297816fb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4d0a45bd-3e3b-4858-8d12-b30db6f24aba" xlink:to="loc_us-gaap_Assets_90878e34-55da-410f-8051-58297816fb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30a4e1cd-8ed9-43a0-86f5-32881ff3f371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_30a4e1cd-8ed9-43a0-86f5-32881ff3f371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_0c2f68ee-2c80-46bb-911b-9541ec7797e8" xlink:href="ameh-20220630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_0c2f68ee-2c80-46bb-911b-9541ec7797e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_fb322aa2-1cf8-4ac7-9d45-89605132daab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_fb322aa2-1cf8-4ac7-9d45-89605132daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_1026b88e-707b-4c52-a211-311fd133c090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_DividendsPayableCurrent_1026b88e-707b-4c52-a211-311fd133c090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c76d535f-0055-4d70-8535-697f85d580b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_LongTermDebtCurrent_c76d535f-0055-4d70-8535-697f85d580b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_79851ccb-0b79-4941-9999-c334367129bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_79851ccb-0b79-4941-9999-c334367129bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_856597f6-403f-4792-aa70-7b53444715dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_856597f6-403f-4792-aa70-7b53444715dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_34322c44-d37f-45b5-9c4e-39314cbf96e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f71fec71-3687-4853-b749-6cc16c785ec1" xlink:to="loc_us-gaap_LiabilitiesCurrent_34322c44-d37f-45b5-9c4e-39314cbf96e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_03974b91-28ba-4f41-ad13-8f0f8ab3a0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_03974b91-28ba-4f41-ad13-8f0f8ab3a0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eccad8be-4e92-45c0-b03f-1d1edd483c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eccad8be-4e92-45c0-b03f-1d1edd483c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_80e50ed7-d5a1-48c0-91a2-7bb7cf50d8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_80e50ed7-d5a1-48c0-91a2-7bb7cf50d8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b90a97fe-0395-41fc-9474-cb36e1d0f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b90a97fe-0395-41fc-9474-cb36e1d0f09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_714d30c6-6bb8-4fdb-9b86-1bab508fed47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_714d30c6-6bb8-4fdb-9b86-1bab508fed47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c66f5822-aebd-42bf-8b44-9b2d8ad8bdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ed3fddab-6184-46d8-b392-e86c19b00020" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c66f5822-aebd-42bf-8b44-9b2d8ad8bdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ebc2d2aa-aa7a-493d-88e9-3a4beefe567e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_ea823d09-e453-4d3b-a94e-eaa5a7fb17ea" xlink:to="loc_us-gaap_Liabilities_ebc2d2aa-aa7a-493d-88e9-3a4beefe567e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fe1b584e-ef91-4278-883d-4742a43ee081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_96bdaf32-2739-43e9-aaed-23c2e665f7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe1b584e-ef91-4278-883d-4742a43ee081" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_96bdaf32-2739-43e9-aaed-23c2e665f7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1ce48ca4-f379-479e-821a-249128d7cb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fe1b584e-ef91-4278-883d-4742a43ee081" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1ce48ca4-f379-479e-821a-249128d7cb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1b13f1eb-8afd-491d-9ed8-2896212b4ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_b15cace3-c80e-41f6-b22e-61b3d35ecc77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b13f1eb-8afd-491d-9ed8-2896212b4ad4" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_b15cace3-c80e-41f6-b22e-61b3d35ecc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ed192571-3e65-4688-9604-c2da6bba7da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b13f1eb-8afd-491d-9ed8-2896212b4ad4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ed192571-3e65-4688-9604-c2da6bba7da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_6944fc5e-0ad0-46cb-acdc-c4c1d17c899f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b13f1eb-8afd-491d-9ed8-2896212b4ad4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_6944fc5e-0ad0-46cb-acdc-c4c1d17c899f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_39a17e42-e633-45b2-97c8-bc7653ff87ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_7a334316-bdbc-4ffd-b2da-ee42ab97e082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_39a17e42-e633-45b2-97c8-bc7653ff87ea" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_7a334316-bdbc-4ffd-b2da-ee42ab97e082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fc934736-7b20-417b-b6ad-5002ab17e7ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7a334316-bdbc-4ffd-b2da-ee42ab97e082" xlink:to="loc_srt_RangeAxis_fc934736-7b20-417b-b6ad-5002ab17e7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0195f8ba-f196-4395-a949-d0dff727a82c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fc934736-7b20-417b-b6ad-5002ab17e7ac" xlink:to="loc_srt_RangeMember_0195f8ba-f196-4395-a949-d0dff727a82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e6681314-25ac-4811-87f3-ad7e75cea22c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0195f8ba-f196-4395-a949-d0dff727a82c" xlink:to="loc_srt_MinimumMember_e6681314-25ac-4811-87f3-ad7e75cea22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a807267d-5fd0-4538-aadd-2c43395a9511" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0195f8ba-f196-4395-a949-d0dff727a82c" xlink:to="loc_srt_MaximumMember_a807267d-5fd0-4538-aadd-2c43395a9511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_7a334316-bdbc-4ffd-b2da-ee42ab97e082" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fca9d5f0-e258-4612-89cc-34fda8a8d206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fca9d5f0-e258-4612-89cc-34fda8a8d206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_cfb8bcbe-805a-4d4d-a468-79af494961a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_cfb8bcbe-805a-4d4d-a468-79af494961a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bbcdeef8-48e3-4238-af7f-4dc019c6d0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bbcdeef8-48e3-4238-af7f-4dc019c6d0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_66daa4a9-8f01-4bd2-8a19-872f25681c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_66daa4a9-8f01-4bd2-8a19-872f25681c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_a0be3f9e-b4c0-41c1-b05c-7719a8a2bc20" xlink:href="ameh-20220630.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_a0be3f9e-b4c0-41c1-b05c-7719a8a2bc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_c91be6fa-2647-4237-b4b4-e33f2e62da3b" xlink:href="ameh-20220630.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_c91be6fa-2647-4237-b4b4-e33f2e62da3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_981ecca3-10dc-467e-bbb1-85fed53b3f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_981ecca3-10dc-467e-bbb1-85fed53b3f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_50a76767-22b3-4ba9-b0c0-18e99636645d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_d45f493e-c529-4566-a2e8-f6d72ac479cd" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_50a76767-22b3-4ba9-b0c0-18e99636645d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_224b0310-c630-46a3-8b49-678ccbce1715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ef2146e6-80b6-43f4-bdbd-82ce2dd78393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_224b0310-c630-46a3-8b49-678ccbce1715" xlink:to="loc_us-gaap_OperatingLeaseCost_ef2146e6-80b6-43f4-bdbd-82ce2dd78393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseCostsAbstract_943cf64e-d9aa-48a4-8ff9-4dc66f9d032b" xlink:href="ameh-20220630.xsd#ameh_FinanceLeaseCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_224b0310-c630-46a3-8b49-678ccbce1715" xlink:to="loc_ameh_FinanceLeaseCostsAbstract_943cf64e-d9aa-48a4-8ff9-4dc66f9d032b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c10c8243-e035-4ca2-bbeb-14cd59bc8d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_FinanceLeaseCostsAbstract_943cf64e-d9aa-48a4-8ff9-4dc66f9d032b" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c10c8243-e035-4ca2-bbeb-14cd59bc8d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_bf5ede18-5f52-48b7-b594-e945f7e707dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_FinanceLeaseCostsAbstract_943cf64e-d9aa-48a4-8ff9-4dc66f9d032b" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_bf5ede18-5f52-48b7-b594-e945f7e707dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_28643dae-b837-41a0-91a6-f8165e8381ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_224b0310-c630-46a3-8b49-678ccbce1715" xlink:to="loc_us-gaap_SubleaseIncome_28643dae-b837-41a0-91a6-f8165e8381ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_05fc5ede-11bb-48bf-9b69-cd4e3394c14b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_224b0310-c630-46a3-8b49-678ccbce1715" xlink:to="loc_us-gaap_LeaseCost_05fc5ede-11bb-48bf-9b69-cd4e3394c14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aec65fb4-3efe-421b-8626-6604564a4653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_cdd92e86-5cf3-4195-9223-1b8c5b0cd8af" xlink:href="ameh-20220630.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aec65fb4-3efe-421b-8626-6604564a4653" xlink:to="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_cdd92e86-5cf3-4195-9223-1b8c5b0cd8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_731077c5-f250-4dd6-abea-ec7951bd84f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_cdd92e86-5cf3-4195-9223-1b8c5b0cd8af" xlink:to="loc_us-gaap_OperatingLeasePayments_731077c5-f250-4dd6-abea-ec7951bd84f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_dd3966ac-04f5-4ecc-a5e9-d4e60ae1ec6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_cdd92e86-5cf3-4195-9223-1b8c5b0cd8af" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_dd3966ac-04f5-4ecc-a5e9-d4e60ae1ec6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_586654c8-9535-4b31-ae2c-3b7c79042084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_cdd92e86-5cf3-4195-9223-1b8c5b0cd8af" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_586654c8-9535-4b31-ae2c-3b7c79042084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_64914ae2-a29f-47cc-991b-3a39aa10bd74" xlink:href="ameh-20220630.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aec65fb4-3efe-421b-8626-6604564a4653" xlink:to="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_64914ae2-a29f-47cc-991b-3a39aa10bd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3b1366d4-ef58-4767-9464-92af4fd2ded4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_64914ae2-a29f-47cc-991b-3a39aa10bd74" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3b1366d4-ef58-4767-9464-92af4fd2ded4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_9dcc586e-101e-4460-81c0-cb7960f18173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_64914ae2-a29f-47cc-991b-3a39aa10bd74" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_9dcc586e-101e-4460-81c0-cb7960f18173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_0208b1d5-faae-4071-8988-d621be4d9238" xlink:href="ameh-20220630.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aec65fb4-3efe-421b-8626-6604564a4653" xlink:to="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_0208b1d5-faae-4071-8988-d621be4d9238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dae771d1-0530-45a0-bb20-a8185256e259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_0208b1d5-faae-4071-8988-d621be4d9238" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dae771d1-0530-45a0-bb20-a8185256e259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_86bc6b69-2c88-4779-a86b-8069eb39f025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_0208b1d5-faae-4071-8988-d621be4d9238" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_86bc6b69-2c88-4779-a86b-8069eb39f025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e984f553-b194-4910-99a9-a10520a549dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e984f553-b194-4910-99a9-a10520a549dd" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fa87d47d-4ca0-4314-8a51-143f985bbf83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fa87d47d-4ca0-4314-8a51-143f985bbf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fc9b6327-13bc-4006-b8bd-deb09551b0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fc9b6327-13bc-4006-b8bd-deb09551b0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_228df649-68a0-4581-a0a3-b433ebd2a244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_228df649-68a0-4581-a0a3-b433ebd2a244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4458d72f-7e5d-434d-9606-ca2d2929af91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4458d72f-7e5d-434d-9606-ca2d2929af91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_29cd1a11-cffb-4ce3-8fca-ba8c2846146d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_29cd1a11-cffb-4ce3-8fca-ba8c2846146d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_31721682-957a-459d-9b48-ecf86127e879" xlink:href="ameh-20220630.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_31721682-957a-459d-9b48-ecf86127e879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e58051f6-65d3-4837-8583-c97a41a6fd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e58051f6-65d3-4837-8583-c97a41a6fd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a7bca192-8a85-4aa0-a372-5479d3f256e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a7bca192-8a85-4aa0-a372-5479d3f256e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_41b4e1ae-48cd-49bf-849d-7a7d9fb493e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_OperatingLeaseLiability_41b4e1ae-48cd-49bf-849d-7a7d9fb493e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f84fcd2-7c62-4135-bfe5-cde91350cb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f84fcd2-7c62-4135-bfe5-cde91350cb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6b73d3c0-e70c-41b4-9a01-bb3e8483ac35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c4d274e-d74a-4785-9d96-57d1267c0e82" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6b73d3c0-e70c-41b4-9a01-bb3e8483ac35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e984f553-b194-4910-99a9-a10520a549dd" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_85dab0a5-2f72-4a8b-8f5f-fcdce37177b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_85dab0a5-2f72-4a8b-8f5f-fcdce37177b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_410f9695-c6a8-47a5-9d42-f8d13ed1478d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_410f9695-c6a8-47a5-9d42-f8d13ed1478d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_66ce3eb9-1cb2-44d3-acc6-5359ba4558c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_66ce3eb9-1cb2-44d3-acc6-5359ba4558c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_3716bf31-2112-4751-bdfc-82a61a8ecb23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_3716bf31-2112-4751-bdfc-82a61a8ecb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_5a63515b-f09b-4abd-a121-79cac1ceb4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_5a63515b-f09b-4abd-a121-79cac1ceb4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_40754a0c-2f0d-4809-870d-b738cd51a91c" xlink:href="ameh-20220630.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_40754a0c-2f0d-4809-870d-b738cd51a91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_475c3fc8-629c-4a28-b5f0-fe68b4d4ad5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_475c3fc8-629c-4a28-b5f0-fe68b4d4ad5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_61a35330-a25d-49a7-9be7-947f79f14354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_61a35330-a25d-49a7-9be7-947f79f14354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_ccbc1380-5d0d-408e-8980-4d222034ea4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiability_ccbc1380-5d0d-408e-8980-4d222034ea4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b3b8f56c-67e9-499e-b8f9-d822011c9490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b3b8f56c-67e9-499e-b8f9-d822011c9490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2b05580a-dcac-49f5-a97f-136e0082fe6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_a89995a4-48fa-4038-92e4-3b4b9b093277" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_2b05580a-dcac-49f5-a97f-136e0082fe6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20220630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ameh-20220630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ameh-20220630_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M??VN--U+2=:\8?\ "/>%]4PLVA>'(/[.M&C,!@DA>0%KF6&17<O%--)&S/\
M=PJ!?EVBBOO<+@Z&&A[/#P45V2M_P_J?*U\15K2YZTG)^84445TF(4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ==\$?CYXT_9M\>
MV_B?P'XFUCPKKEOM7[387!C\^-9$E\F9/N30EXT+12!HWV@,I'%?H9^R?_P<
MO>.O 5E:Z5\7/"]GX^M_M$2OKFF/'IFI10F5VF=X%3[/<.J,BQH@MA^ZP[,7
M+K^8M%>7F.2X''*V*IJ3[[/[UK\KV.[!YEB<*[T)M>73[GH?TT?LG_\ !4'X
M(_MGWMKIO@KQK9GQ)<6\4QT#4XWL-25GB>5HDCD 6X>)8Y/,-LTJ)LR6VE6;
MZ K^1<C(K[H_8S_X+^?&C]F;R=+\77'_  MKPO'N_<:Y=LNK0Y\YOW>H8>1L
MR2(3]H6?"1*B>4.1^<YOX=S@O:9=/F_NRLG\GHG\[>K/L,OXOC+W,9&WFMOF
MM_NOZ'] %%?.?[&G_!53X+_MR^39>$?$O]F^*)MW_%-:XJV.K''G-^[3<T=Q
M^[A>5OL\DOEH5+["<5]&5^<XK"UL-4=*O%QDNC5OZ]3["CB*=:'M*4E)=T%%
M%%<YL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445X7^VQ_P %
M&/A;^P1X4%]XXUKSM8F\EK3PYI;17&M7L<CNHF2W:1-L(\N4F61DCS&5#%RJ
M-MA\-5KU%2HQ<I/9(SK5J=*#J5'9+JSW2OSH_;<_X.*OAK\$/[0T'X5V?_"S
M/%$/F0?VCN:WT&RE'G)N\W'F7>R1(FVPA8I8Y,I< BOS<_;W_P""Q'Q9_;TL
MKWP_J5Q9^%?A_<7"RIX;TI?DG$<LCPFZN&_>7#J&3</DA9X8Y!"CJ"/E&OU3
M(_#^$5[7,W=_RIZ?-]?1:>;/A<TXLE)^SP6B_F>_R73Y_<CT;]I#]K?XE?M=
M^*X]:^)'C#5_%5Y;Y^S1W#K':V.Y(T?R+>,+##O$49?RT7>RAFRV37G-%%?I
M5*C"E!4Z248K9)62^2/BZE24Y<TVVWU>K"BBBM"0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OT _8
M!_X+^?$K]FK4H]&^)T^K_%3P9)LC62[NU;6M)S.7EFCN7!>Z^1Y!Y5P_)2%4
MEA16#?G_ $5PYAEN&QU+V.*@I+\5Z/=?(ZL)C:V&G[2A*S_/U74_J+_8]_;E
M^&O[=/@*?7OAWKO]H?V?Y*:IIUS"UO?Z1++&'6.>)O\ @2B1"\3M%($=]C8]
M=K^3KX1_%SQ+\!OB3H_C#P?K%YH/B30;@7-C?6Q&^%L$$$$%71E+*R,"CHS*
MP96(/ZZ?\$X?^#B/3_'MYIO@SX])9Z+K%W<065CXMLH%M]-E!BVE]14OBW=I
M5!,L2^3^_P#F2WCB+M^2Y]P)B,+>M@??AV^TO\_EKY=3[[*N*:5:U/%>[+OT
M?^7Y>?0_5&BJ?A_Q!8>+-!L=5TJ^L]3TO4[>.[L[RTF6:WNX9%#))&ZDJZ,I
M#!E)!!!'%7*_/VFG9GUE[ZH**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]=?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^Z8/!T<)1CA\/'EC'9?UU[L_,,1B*E>HZM5W;"BBBNHP"BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-(RJ,(B1QIX7117[UAL/2P]*-&C'EC'1)'Y76K3JS=2H[M[L****V,PHHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)JNM6=V_ZT"BBBNTY@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;T\Y?_:[^K1\EQ5F7L:*PL/BGOY+_@[>ES'HHHK]G/S@**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7X+_M@_P#!:+]I;X6_M;?%+PQH
M/Q)^PZ'X<\7ZMI>G6W_"/:5+]GMH+V:*)-[VQ=MJ*HRQ+'&22>:_>BOY<_\
M@H#_ ,GY?&[_ +'[7O\ TXSU^@>'^#P^(Q%6.(IQFE%6YDGU\SY/BS$UJ-&F
MZ4G'5[-KIY'KW_#]W]JS_HJG_EM:/_\ (E'_  _=_:L_Z*I_Y;6C_P#R)7R+
M17ZG_866_P#0/3_\ C_D?"_VIC?^?TO_  )_YGUU_P /W?VK/^BJ?^6UH_\
M\B4?\/W?VK/^BJ?^6UH__P B5\BT4?V%EO\ T#T__ (_Y!_:F-_Y_2_\"?\
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M$(8>"@N1.T4DK\TM=#] X5Q%6MA)2JR<GS/5MOHNX4445\0?3!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\!_\%M/VROB?^RMXT^#.F_#KQ9-X5@\7
M?VW_ &HT6FV5X]Q]F2S:''VF&4+M,LGW0,[N<X&/ORORV_X.,O\ DJ?[.G_<
MR_\ HG3Z^DX1H4ZV;4J=:*E%\UTU=?#)[,\7B*M.EE]2=-M-6U6C^)'A'_#T
MG]I#_HK^K?\ A/:'_P#(-'_#TG]I#_HK^K?^$]H?_P @UX/17[1_8>7?] \/
M_ (_Y'Y;_:V._P"?T_\ P)_YGO'_  ])_:0_Z*_JW_A/:'_\@T?\/2?VD/\
MHK^K?^$]H?\ \@UX/11_8>7?] \/_ (_Y!_:V._Y_3_\"?\ F>\?\/2?VD/^
MBOZM_P"$]H?_ ,@T?\/2?VD/^BOZM_X3VA__ "#7@]%']AY=_P! \/\ P"/^
M0?VMCO\ G]/_ ,"?^9[Q_P /2?VD/^BOZM_X3VA__(-'_#TG]I#_ **_JW_A
M/:'_ /(->#T4?V'EW_0/#_P"/^0?VMCO^?T__ G_ )GO'_#TG]I#_HK^K?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?RY_\ !0'_
M )/R^-W_ &/VO?\ IQGK^HROY<_^"@/_ "?E\;O^Q^U[_P!.,]?I7AM_O-;_
M  K\SXWC+^!3]7^1Y'1117Z\?GH4444 %%%% !1110 4'I10>E ']=%%%%?R
MN?N@4444 %%%% !1110 5Y#_ ,% _P#DPOXW?]B#KO\ Z;IZ]>KR'_@H'_R8
M7\;O^Q!UW_TW3UU8'_>:?^)?FC#%?P9^C_(_EUHHHK^GC\2"BBB@ HHHH **
M** "BBB@#ZZ_X(1?\I6/A7_W%O\ TSWU?T75_.C_ ,$(O^4K'PK_ .XM_P"F
M>^K^BZOQ;Q&_Y&4/^O:_]*D?I'!_^Y2_Q/\ *(4445\ ?6!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5^6W_!QE_P E3_9T_P"YE_\ 1.GU^I-?EM_P
M<9?\E3_9T_[F7_T3I]?4<%_\CFC_ -O?^D2/!XF_Y%E7Y?\ I2/A"BBBOW@_
M(0HHHH **** "BBB@ HHHH _1S_@W\_YJU_W!_\ V_K]'*_./_@W\_YJU_W!
M_P#V_K]'*_!^-/\ D<UO^W?_ $B)^N\+_P#(LI?]O?\ I3"BBBOESWPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /@O_@X7_:OA^ _[$4G@JSNKRW\2?%:X_LRW-M<2V\D-A \<M[(6
M52KHRF*V>)G3>EXQ^95=3^!=?>G_  <6_'6_^)?_  4'NO"<@O+?2_AQI%GI
MUO UXTMO--<Q+>RW*18"Q.RW$,38R6%K&2V-JK\%U^_<&9>L+E=-]9^^_GM_
MY+;YW/RCB/&.OCI+I'W5\M_QN%%%%?5'A!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445<\/^'[_P 6:]8Z
M5I5C>:GJFIW$=I9V=I"TUQ=S2,%2.-%!9W9B%"J"22 !FANRNPWT13HK[&_9
MV_X(1?M&?M!V4=]+X5L_ .EW%O)-#=>+KEK!W9)?+,1M422[C<_,RF2%$*+N
M#89-WWI\$O\ @V.^%OA$6]QX\\<^+_&EY:Z@MQY.GQ1:-875LNP_9IH_WTQW
M$.&>.>-MK@+L9=Y^;Q_%N5X1\LZJD^T?>_+1?-GLX7(,=B-8PLN[T_X/W(_$
M6O4?A)^Q'\8OCO9:/>>#_AAXZU[2]>N!:V.J6VBW!TV9_-,))NRH@1%D#*[N
MX1-K;BH4D?T7?LZ_\$Z_@C^RA>QWG@/X;^'='U2"XDN8-4FC?4-2MGDB$+B*
M[N6DGC0QY4HCA/G?C+L3[37R.,\25>V$H_.3_1?_ "1]#A^#7O7J?)+]7_D?
M@7\,?^#<?]HSQ[H$UYJL?@7P3<1W#0K8ZUK9EN)4"J1*ILHKB/82Q4!G#Y1L
MJ!M+?1GPB_X-<+""[T>Z\>_%J\NH#;AM5TS0-&6W=9C$<I!>32."B2D?.]L"
MZ*?DC+97]:**^9Q/'6;5=(S4/\*7YN[_ !N>Q1X7R^GO%R]6_P!+(^"_AC_P
M;C_LY^ M>FO-5C\=>-K>2 PK8ZUK8AMX6+*1*ILHK>3> I4!G*8=LJ3M(]1\
M"?\ !%C]E_X<^*[76=/^$ND7%Y9[S''JFH7VJVC;D9#OM[J>2&3AB1O0[6 8
M8901]1T5XU;/\RJWYZ\]?[S2^Y.QZ5/*L'#X:4?N5_O/(O\ AWY\!?\ HB/P
MB_\ ".T[_P",UZ/X%\ :#\+O"MKH7AG1-)\.Z'8[_LVGZ99QV=K;[W9WV11@
M(NYV9C@#)8GJ36M17G5,36J+EJ2;7FVSLA1IP=X12]$%%%%8F@5Y&?\ @G]\
M!F//P2^$9_[D[3O_ (S7KE%:T\15I_PY->C:,ZE*$_C2?JCYS^*O_!(_]FSX
MR&P_M?X/^$;/^S?,\K^PXI-"W[]F[S/L+0^;C8-OF;MN6VXW-GR_XF_\&]G[
M,WCW0(;/2O#?B+P3<1W"S-?:+K]S-<2J%8&)A>M<1["6#$A ^47# ;@?MRBN
M^CGF8TK*G7FDNG,[?=>QRU,LPE3XZ47\E?[S\N?BI_P:[> ]7^P?\(1\4O%W
MA[R_,^V_VYI]OK/VC.WR_+\DVGE[</NW;]VY<;=IW?/_ ,7/^#97XQ>%;W6)
MO!_C#P+XNTNQMS-8I<R3Z7J6I.L08Q"$QR01NTFY%+7.P_*S,@)"_N-17L8?
MC;-Z6CJ<R[-)_C9/\3SZW#.7U/L6?DW^6WX'\R_Q-_X)6?M&?"37X=-U7X-^
M.KJXFMUNE?1=.;6[<(690&FLO.B5\H<H6#@%20 RD_/]?UT5R/Q4_9^\!_'7
M[!_PF_@CPCXR_LOS/L7]N:/;ZA]C\S;YGE^<C;-VQ-VW&=BYZ"OI,+XE5%IB
M:*?G%V_!W_/[SQ\1P;!ZT*C7JK_BK?D?RBT5^]'QN_X-P/@%\1C<7'A6;Q?\
M/;S^SVM[6&PU'[?IZW/SE+B6.Z$DTG+*&1)XU98P!L8LY^(OVB?^#;KXW?#&
M]EF\!W_ASXG:6UQ'# D-PFD:EM,19Y98;EQ B+("@"7,CMN1MH!8)]=@>-,J
MQ+M[3D?:6GXZK\3Y_%<-X^CKR\R_NZ_AO^!^>E%=%\3O@_XN^">O0Z5XS\+>
M(_".J7%N+N*SUK39M/N)(2S()52558H61U# 8)1AU!KG:^HC.,ES1=T>'*+B
M[26H44451(4444 %%%% !111F@#]EO\ @UP^&6H:5\)?BYXRDFLVTO7M7L-%
MMXE=OM"364,LTK.NW:$*W\(4AB25DR% 4M^J5?.?_!*O]C3_ (8:_8O\->$;
MV'RO%&I9USQ+\^[&HW"IOBXDDC_<QI#;[HF"2?9_, !<U]&5_.7$F.CB\RK8
MBF[INR?=)))_@?L63X:6'P5.E+1I:^KU?YA1117B'I!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M17YR?8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?RY_\ !0'_ )/R^-W_ &/VO?\ IQGK
M^HROY<_^"@/_ "?E\;O^Q^U[_P!.,]?I7AM_O-;_  K\SXWC+^!3]7^1Y'11
M17Z\?GH4444 %%%% !1110 4'I10>E ']=%%%%?RN?N@4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1D_L)R_3\V?.<55W3P#BOM-+]?T/B*BBBOW8_+@HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "ORV_X.,O\ DJ?[.G_<R_\ HG3Z_4FO
MRV_X.,O^2I_LZ?\ <R_^B=/KZC@O_D<T?^WO_2)'@\3?\BRK\O\ TI'PA111
M7[P?D(4444 %%%% !1110 4444 ?HY_P;^?\U:_[@_\ [?U^CE?G'_P;^?\
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MD$'N#7AUL/4I/EJ*QZU&O"HKP=QU%%%8FP4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ<,"!D_\/WOV4S_S53_RV=8_^1*[HY)F,ES1P\[?X)?Y'*\SP:=G5C_X$O\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17G/CO\
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M7?\ TW3UU8'_ 'FG_B7YHPQ7\&?H_P C^76BBBOZ>/Q(**** "BBB@ HHHH
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MFF_\%C?V==6N&CB\>7RLJ[B9O"VL0KC@?>>U SSTSFNY9)F+5UAY_P#@$O\
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MKYNM_P#@KG^SW<P1R+X_<+(H8!] U-& //(-L"#[$9%9G_#Z']F\?\SUJ_\
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M/UC*\MIX*BJ4-^K[O^MD%%%%>*>D%%%% !1110 4444 %%%% !1110 4444
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MZV863)QA@HPN,_>X&.N,9/I-?*8C#U*,N6HO^"?14<1"K'F@%%%%8&P4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%<Y\3OC#X1^">@PZKXS\4^'/".EW%PMI%>:UJ4-
MA;RS%6<1J\K*I<JCL%!R0C'H#7Y__M$_\'+WPG^'=Y)9_#SPOXC^)%Q#<1J;
MR9_[$TV>%HB[/$\B/<%T<K&4>W0'#D,0%W^EE^3XW'.V%IN7GLOO=E^)Q8O,
M<-AE>O-+\_N6I^D=<Y\3OC#X1^">@PZKXS\4^'/".EW%PMI%>:UJ4-A;RS,K
M.(E>5E4N51V"@Y(1CC -?S__ +1/_!=S]HS]H.RDL8_%5GX!TNXMXX9K7PC;
M-I[NZ2F02BZ=Y+N-V^56$<RHR)M*X9]WR-X@\0:AXMUZ^U75;Z\U/5-3N)+N
M\O+N9IKB[FD8N\DCL2SNS$L68DDDD\U]Q@?#?$27-BZJCY15W][LE^)\SBN,
MJ47;#P<O-Z?AK^A^^?Q4_P"#B;]FWX>_8/[(U/Q?XZ^V>9YO]AZ$\/V';MV^
M9]N:VSOW';Y>_&QMVWY=WRC\3O\ @Z/\7:MH$,?@SX2>'- U1;@-+<:UK,VK
MV[P[6!18HH[5E<L4(<R$ *PV$L&7\KJ*^NPO N4T?B@YOO)O\E9?@?/U^*,P
MJ;24?1?YW?XGVCX[_P"#@']J#Q?XKNM1T_QII'A:SN-GEZ7I?AZQDM+7:BJ=
MC74<TQW$%SOE;YF.,+A1\Z>//VP/BU\5/"=UH/BCXI?$;Q)H=]L^TZ=JGB2]
MO+2XV.LB;XI)&1MKJK#(.&4$<@5YS17T&'RG!8?^#2C';:*OIMK:_P SR:V/
MQ-7^)4D_5OJ%%%%>@<@4444 %%%% !1110 $9KW3P)_P4X_:&^'/BNUUK3_C
M/\1KB\L]_EQZIK<^J6C;D9#OMKII(9.&)&]#M;### $>%T5C6PU&LN6M!27F
MD]]]S2G6J4W>G)KT=C] /@C_ ,''WQ^^'/V>W\50^$?B%9_;UN+J:_TW[!?M
M;?('MXI+0QPQ\*Q5W@D96D).]0$'UU\$?^#G#X6^+_L]OX\\#^+O!5Y<WZV_
MG6$L6LV%K;-L'VB:3]S,-I+EDC@D.U 5WLVP?B+17SN,X.RG$:NEROO'3\%I
M^!Z^'XBQ]'13YEYZ_CO^)_4M^SK^VS\)_P!K*RBD^'GC[PYXFN)+>2[.GPW/
MDZE##'*(7EELY MQ$@<J-SQJ#O0@D.I/J5?R+D9%?77[,?\ P7"_:&_9F^UP
M_P#"6_\ "P-/N][_ &3QH9M6\F5O+'F)/YJ7*X6/ C\WRAYCMY>YMP^-S'PX
MJ1][!5>;REH_O6C^Y'T>#XQ@],3"WFM?P?\ FS^BZBOA?]C/_@OY\%_VF?)T
MOQ=<?\*E\42;OW&N7:MI4V/.;]WJ&$C7$<:$_:%@R\JHGF'D_=%?GV.RW$X*
MI[+%0<7Y]?1[/U39];A<90Q,.>A)27];K=?,****XCI"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#^=OQ!_P7N_:FUK7KZ\M_B+::3;W=Q)-%8VGAS3&
MM[)&8D11F6W>0H@.T&1W? &YF.2:G_#]O]JS_HJI_P#":T?_ .1*^1ATHK^D
MED.6I6^KP_\  (_Y'XV\UQM_XTO_  )_YGUS_P /V_VK/^BJG_PFM'_^1*/^
M'[?[5G_153_X36C_ /R)7R-15?V%EO\ T#T__ (_Y"_M3&_\_I?^!/\ S/KG
M_A^W^U9_T54_^$UH_P#\B4?\/V_VK/\ HJI_\)K1_P#Y$KY&HH_L++?^@>G_
M . 1_P @_M3&_P#/Z7_@3_S/KG_A^W^U9_T54_\ A-:/_P#(E'_#]O\ :L_Z
M*J?_  FM'_\ D2OD:BC^PLM_Z!Z?_@$?\@_M3&_\_I?^!/\ S/KG_A^W^U9_
MT54_^$UH_P#\B4?\/V_VK/\ HJI_\)K1_P#Y$KY&HH_L++?^@>G_ . 1_P @
M_M3&_P#/Z7_@3_S/W0_X("?MV_%;]M<_%K_A9WBL^)_^$9_L?^S1_9EG9?9O
M/^W^;_Q[PQ[MWDQ?>SC;QC)S^C%?D7_P:N_\UV_[E_\ ]R=?KI7XAQ?0IT<W
MJTZ,5&*Y;)))+W8]$?I?#]6=3+Z<ZC;;OJW=_$PHHKQ;]KS_ (*#?"?]A[06
MN/'_ (JL[/5)+<W%GH5I_I6KZ@"LI3R[=3N5':&2,32[(0X"M(I->!A\/5KS
M5.C%RD^B5V>M5K0I1YZC27=GM->6_M%?ML_"?]DVRED^(?C[PYX9N([>.[&G
MS7/G:E-#)*84EBLXPUQ*A<,"R1L!L<D@(Q'XH_ME_P#!?SXT?M,^=IGA&X_X
M5+X7DV_N-#NV?5IL>2W[S4-J2+B2-ROV=8,I*R/YHY/Q'X@\07_BS7K[5=5O
MKS4]4U.XDN[R\NYFFN+N:1B[RR.Q+.[,2Q9B2223S7Z+E?AU6FE/'SY?[L=7
M\WLOE<^/QW&%.+<<+'F\WHONW^^Q^O\ \;O^#HG0;+[1;_#?X6ZOJ7G:>WD:
MAXEU".R^RWAWA=UK;B;SH5_=L<7$3/EE^3 <_%WQW_X+E?M)_'7^U;?_ (3K
M_A#='U3R?^)?X7M$T[['Y>P_N;KYKU-S)N;_ $@YWNOW#LKY%HK[W \*Y7A=
M:=%-]Y>\_P ;I?*Q\KB<\QU?2=1V[+3\K7^9T7Q.^,'B[XV:_#JWC/Q1XB\7
M:I;VXM(KS6M2FO[B.$,SB)7E9F"!G=@H. 78XR37.T45[T8QBN6*LCRY2<G>
M6X44451(4444 %:_@3Q_KWPM\66NO>&=;U?PYKEAO^S:CI=Y)9W=OO1HWV2Q
MD.NY&93@C*L0>":R**F45)<LMAQDT[H^EOAC_P %BOVF?A'H$VFZ3\7O$EU;
MSW!N6?6HK?6[@.552%FO8YI%3"#"*P0$L0 68GZZ^!?_  =!>+K#7FC^)GPW
M\-ZKI=Q<6ZBX\,3S:?<6$.XB=_*N'G6X?:5*)YD RA!;#[D_*^BO%QG#>68E
M?O:,;]TN5_>K,]+#YSC:+O"H_1NZ^YW/Z.OV=O\ @MA^SG^T591B/Q[9^"]4
M:WDN9M.\7!=(>V1)1'@W#L;1W;*NJ1SNY1LD JX7ZNK^1>O7?V8_V\_B_P#L
M<&[3X;^.M8\.6=]O,]AMCO+!W?R]TWV6=9(1,1#&OFA!)M7;NVD@_%YCX;P?
MO8&K;REJOO6J^YGTF#XRDM,5"_G'_)_YH_J+HK\N?V-/^#ECPKXU,.D_&[P_
M_P (9J!W?\3_ $.&:\TJ3_7/^\MOGN8,*L,:[#<;W=F/E*./TO\  GQ T'XI
M>%+77O#&MZ1XCT.^W_9M1TN\CO+2XV.R/LEC)1MKJRG!.&4CJ#7YWF>38S+Y
M\F*@X]GNGZ-:?+?NCZ_!9EA\7'FH23\NJ]5_2->BBBO+.X**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO.?VD/VN/AK^R)X4CU
MGXD>,-'\*V=QG[-'<.TEW?;7C1_(MHPTTVPRQE_+1MBL&;"Y-:4J,ZLU3I)R
MD]DE=OY(FI4C"+G-V2ZO1'HU4_$'B&P\):!?:KJM]9Z9I>F6\EW>7EW,L-O:
M0QJ7>21V(5$506+,0  2>*_'_P#:J_X.<-6U_3=2TGX.^!_[!\[$=MXA\1RI
M<7<<;0$.R64>8HYDF8%&>:>,K'\T1WE4_.G]I#]K?XD_M=^*X]:^)'C#6/%5
MY;Y^S1W#K':6.Y(T?R+:,+#!O$4>_P M%WLH9LMDU]SEGA_CJ]I8IJG'[Y?<
MM/O=UV/E\;Q9A:7NT$YO[E][U_"S[G[T?'?_ (+E_LV? K^U;?\ X3K_ (3+
M5]+\G_B7^%[-]0^V>9L/[FZ^6R?:K[F_T@8V.O+C97Q;\;O^#HG7[W[1;_#?
MX6Z/IODZ@WD:AXEU"2^^U68WA=UK;B'R9F_=L<7$JIAE^?(<?E'17W&!X#RN
MAK43J/\ O/3[E9??<^8Q/%..J_ U%>2_5W_"Q]7?%S_@MQ^TS\8++6+&X^)5
MYH.EZQ<&86N@6-OICV">:)%B@NHD%VB+@+DS%V0%79PS9^<_B=\7_%OQLU^'
M5O&?BCQ%XNU2WMQ:17FM:E-J%Q%"&9Q$LDK,P0,[L%!P"['&2:YVBOI\+E^%
MPW^[TXQ]$E^1XE;&5ZW\6;EZML****[#G"BBB@ HHHH *Z+X8_&#Q;\$]?FU
M;P9XH\1>$=4N+=K26\T74IK"XDA9E=HFDB96*%D1BI."44XR!7.T5,HQDN62
MNBHR<7>.C/J+X(_\%G/VDO@5]GAL_B=K'B'3X]06_GM/$J)K/VS&P-"T]P&N
M4A94"E(I4QN9E*LQ:OJ[X%?\'07BZPU\Q_$SX;^&]4TNXN+=1<>&)YM/N+"'
M<1._E7#SK</M*E$\R 90@MAMR?E?17BXSAK+,3?VM&-WU2Y7]ZL>EA\ZQM'X
M*C]'JOQN?T1?L[?\%W?V<_V@[R*RE\57G@'5+BXDAAM?%UJ+!'5(O-,K72/)
M:1H?F51),C%TVA<LF[ZZ\/>(=/\ %V@6.K:3?6>J:7JEO'=V=Y:3+-;W<,BA
MTEC=25=&4A@RD@@@@XK^2.NZ^!7[3OQ#_9DUXZE\/_&GB/PE<27%O<W":=>O
M%;WSP,6B%Q#GR[A%+/\ )*KH0[@@AB#\?F'AQ1E[V"J.+[2U7WJS7W,^@PG&
M-2.F(@GYK1_=_P ,?U745^-'[)__  <T^)?#UY:Z;\9O!]GX@TN.WBA;6O#4
M8M=2#)$X:66WD?R)GED$61&ULD8,A"L-J#]1?V=OVV/A/^UE912?#SQ]X<\3
M7$EO)=G3X;GRM2AACE\II);.0+<1('*@,\:@[T(R'4G\_P TX=Q^7O\ VB'N
M_P RUC]_3YV9];@<XPF+7[J6O9Z/[NORN>I4445X9Z84444 %%%% !1110 4
M444 %%%% !1110 4444 %?RY_P#!0'_D_+XW?]C]KW_IQGK^HROY<_\ @H#_
M ,GY?&[_ +'[7O\ TXSU^E>&W^\UO\*_,^-XR_@4_5_D>1T445^O'YZ%%%%
M!1110 4444 %!Z44'I0!_711117\KG[H%%%% !1110 4444 %>0_\% _^3"_
MC=_V(.N_^FZ>O7J\A_X*!_\ )A?QN_[$'7?_ $W3UU8'_>:?^)?FC#%?P9^C
M_(_EUHHHK^GC\2"BBB@ HHHH **** "BBB@#ZZ_X(1?\I6/A7_W%O_3/?5_1
M=7\Z/_!"+_E*Q\*_^XM_Z9[ZOZ+J_%O$;_D90_Z]K_TJ1^D<'_[E+_$_RB%%
M%%? 'U@4444 %%%% !1110 4444 %%%% !1110 4444 %%>+_M>?\%!OA/\
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MM#_^0:\(HH_L3+O^@>'_ (!'_(/[6QW_ #^G_P"!/_,]W_X>D?M(?]%@U?\
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M^N\/B%KT?1KNGV_IGZ+@,PHXRDJU!Z?BGV84445YQVGYS_\ !S@,_L&^$?\
ML?[/_P!-VI5^%]?T ?\ !Q-\*_\ A87_  39U35_MWV/_A!=?T[7/*\GS/MV
M]VT_RL[ALQ]N\S=AO]5MQ\VY?Y_Z_<?#^I&656724D_P?Y-'YCQ9%K'7?6*_
M5!1117VY\R%%%% !1110 4444 %%%% !1110 4444 %%%==\ _@CKW[27QH\
M,^ _#-O]HUSQ5J$5A;9CD>.#<?GFE\M7=88D#22.%.R.-V(P#4U*D81<YNR6
MK]"H1E*2C'=GKO\ P3&_8"U;_@H/^TI8^&O+UBR\&:7_ *7XHUJRA1O[,MMK
ME(PTA"":=T\J,8=AEY/+=(I /Z.OA'\(_#7P&^&NC^#_  ?H]GH/AO0;<6UC
M8VP.R%,DDDDEG=F+.SN2[NS,Q9F)/"_L,_L>Z#^PK^S9H7P[T&?^T?[/WW.H
MZH]K';S:O>2MNEN)%0?[J(&9V2**)"[[-Q]=K\"XJXBGF>(M#2E'X5W_ +S\
MW^"T[W_5LCR>."HWE\<MWV\EY+\?N"BBBOECW HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Q?''@>T\=:0;>X_=S1Y:"=1EH6_J
M#QD=_8@$;5%53J2A)2B[-$RBI+EEL?-OB/PW>>%-5DL[Z/RYH^01RLB]F4]P
M?_K'!!%4:^A_&_@BT\<Z2;>X'ERQY:"=1EH6_J#W'?V(!'@WB3PY=>%-8DL;
MR/9-'R"/NR*>C*>X/^(.""*^MP&/C7C9Z27]7/FL9@Y4977PE&BBBO1.(***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[[X;?&>3P[##I^
MI*T]DK!4GS\]LF#QC'S*#CCJ!G&< 5P-%8XC#PK1Y*B-:-:=*7- ^GH)TNH$
MDC=9(Y%#(ZG*L#R"#W!IU>)_"KXJ/X0G6ROF>32Y&X/WFM2>X_V3W'XCG(/M
M4$Z74"21NLD<BAD=3E6!Y!![@U\AC,'/#SY9;=&?387%1K1NM^J'4445R'2%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !16/X\^(.@_"SPI=:]XGUS1_#FAV.S[3J.J7D=G:6^]UC3?+(0B[
MG95&2,LP Y(K\E_V]_\ @Y%FU:RO/#7P L+S3)%N%4^,M5MHF=TCEDW"ULI$
M==DJK$1+<8<))(I@1]KKZ^4Y'C,QGR8:-UU;T2]7^BN_(\_,,TP^#CS5I:]$
MMWZ+_/0_3K]I#]KCX:_LB>%(]9^)'C#2/"MG<9^S1W#M)=WVUXT?R+:,---L
M,L9?RT;8K!FPN37Y1?ME_P#!ROXL\;>=I/P1\/\ _"%Z>VW_ (G^N0PWFK/_
M *E_W=ME[:##+-&V\W&]'5AY3#C\T?'GQ U[XI>*[K7O$^MZOXCUR_V?:=1U
M2\DO+NXV(L:;Y9"7;:BJHR3A5 ' %9%?J^3\!X+"VJ8K][/S^%?+K\[I]D?!
MYAQ5B:]X4/<CY;_?T^7WG1?$[XP>+OC9K\.J^,_%/B/Q=JEO;K:17FM:E-?W
M$<*LSB)7E9F"!G=@H. 78]2:YVBBON(QC%<L59'S,I.3NPHHHJB0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZC_ & ?^"MOQ2_8#U*.
MQTN\_P"$L\#R;(YO#&KW,KVEM'YYED:R8-_HDS[Y@656C9I=TD4A5-ORY17-
MC,'0Q5)T<1%2B^C_ *_$VP^(JT)JI2=FNJ/Z7/\ @G__ ,%._AO_ ,%"/"D?
M_"-WW]E^-+'3X[W6_"]V6^U:9ES&QCD*JES"' _>Q=%EA\Q8GD$=?1E?R7^
M_B#KWPL\5VNO>&-<U?PYKECO^S:CI=Y)9W=OO1HWV2QD.NY&93@C*L0>":_;
MC_@E7_P76T']IP^&?AO\4F_L/XGWFZSM]8\N.'2?$<J[!"O##R+R;<P\H((G
M>/Y&5I8[<?D'$W!-3"7Q.!O*GNUNX_YK\5UON?H62\30Q%J.*M&?1]'_ )/\
M/38_1BBBBOS\^L"BBB@ HHHH **** "BBB@ HHHH **** /Y%QTHH'2BOZH/
MPL**** "BBB@ HHHH **** /UT_X-7?^:[?]R_\ ^Y.OUTK\B_\ @U=_YKM_
MW+__ +DZY#_@M/\ \%J/^%O?VM\'O@]JW_%(?/9^)?$MI)_R'^JO9VKC_ESZ
MB24?\?'*J?(R;C\9SS)<1F?$5:A0V]V[Z)<D=?\ )=?O:_1\LS*E@LHIU:O]
MZRZM\S_IOH>N_P#!3#_@X1TKX9D^$?@!>Z/XFUQOM$&J>)Y[9YK#2V'F1*MF
MK;4N9@X$HF.^VVJF!.)&\O\ '7QY\0=>^*?BNZU[Q/KFL>(]<OMGVG4=4O)+
MR[N-B*B;Y9"7;:BJHR3A5 ' %8]%?IN3Y#A,MI\F'CKUD]WZO]%H?$YAFF(Q
ML^:L].B6R"BBBO9/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU+]D
M_P#;*^(?[%?Q)M?$O@'Q!>:9(MQ%-?::\KMINM+&'417< 8+,FV64 G#IYA:
M-D?##RVBLZU&G6@Z55*47NGLRZ=25.2G!V:V9^^G_!.'_@NYX%_;"O--\(^.
MH;/X>_$B^N(+"QMS+)+IOB&9HN3;RE<6[M*K*L$S$GS(4229V(7[TK^1>OT7
M_P""5G_!=;7OV8_^$:^&_P 4F_MSX7V>;*WUCRY)M6\.1'8(AD$^?9PX8>5L
M,J(_[MF6*. _EO$7 ?*GB,L^</\ Y%_H]>SV1]SD_%5VJ.-^4O\ /_/\.I^Z
M-%<W\(OB[X:^/7PTT;QAX/UBTU[PWX@MQ=6-];D[)DR0058!D=6#*Z. Z.K*
MP5E('25^7SA*$G&2LUHT^A]M&2DN:.J84445)04444 %%%% !1110 4444 %
M%%% !1110 4444 %<C\;OC[X+_9M\!7'B?QYXFTCPKH=ON7[3?SB/SY%C>7R
M84^_-,4C<K%&&D?:0JD\5\M_\%.O^"S7@O\ 8'^W>$=(M_\ A+?BI+8&>VTY
M"&L-&D?9Y3:@X<.NY&,JPQ@R.J+N,*RQRG\.OVL/VROB'^VI\2KKQ-X^\07F
MIR-<2S6.FK*ZZ;HJ2!%,5I 6*PIMBB!(R[^6&D9WRQ^TX?X,Q.8)5ZWN4GUZ
MOT7;S>G:Y\WFW$E'"-TJ7O3[=%ZO]#] /V[/^#D7Q+KNO:IX<^!%A9Z%H]K<
M-#%XMU&W%S?:@BM$1+;VLJ>7;HQ69<3K*[QR(VV"0%1^8OCOX@:]\4O%=UKW
MB;6]8\1ZY?;/M.HZI>27EW<;$6--\LA9VVHJJ,DX50.@%9%%?L&5Y+@\OAR8
M6"7=[M^KW^6W9(_/<=F6(Q<N:O*_ET7HOZ?<****]0X0HHHH **** "BBB@
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M=[7L?H>4\14<9:G/W9]NC]'^F_KN?5U%%%?'GT04444 %%%% !1110 4444
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MZDX Y.2<5;HHK[H^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGZ3A<72Q--5:+NG_ %KYA1117&= 4444 %%%% !1110 4444 %%%% !1110
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M^TMSYC&85T9VZ/8;1117<<@4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@#T;X6?M4^-/@K\%_'_@7PSJ7]DZ/\3/L46OS0 K=W-M;"Y
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M<NVBBIC&,?A5ARDWN%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M***]<\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*** "BBB@ HHHH *\A_X*!_\F%_&[_L0==_]-T]>O5Y#_P % _\ DPOXW?\
M8@Z[_P"FZ>NK _[S3_Q+\T88K^#/T?Y'\NM%%%?T\?B04444 %%%% !1110
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M<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '[1?\$6?^"U(^+8TGX/_ !BU?'B[Y+/PUXEO)?\ D/\
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MSUH FHJO=:O:6,$TLUU;PQ6[!97>0*L1." Q)X)W+U_O#UJQ0 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKR,VP?M8>TANOQ1Z678KV<_9RV?YGLM%%%?+'T04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^1?\ P<K_ +$?_( ^
M/'A_3_\ GGH/BS[/!]?L5[)LB_WK=Y9I/^?*-17Y%U_5U\?/@CH/[27P7\3>
M _$]O]HT/Q582V%SMCC>2#</DFB\Q719HG"R1N5.R2-& R!7\N?Q\^".O?LV
M_&CQ-X#\3V_V?7/"NH2V%SMCD2.?:?DFB\Q4=H94*R1N5&^.1& P17[3P#G'
MUC"/!U'[U/;SB]ON>GI8_-^*\O\ 8XA8F&T]_7_@[_><C1117WY\F%%%==\$
M?@'XT_:2\>V_ACP'X9U?Q5KEQM;[-86YD\B-I$B\Z9_N0PAY$#2R%8TW LP'
M-34J1A%SF[)=7HBHQE)\L5=G(T5^EW[*O_!M1\2O'FI:;J/Q8U[1_ >AOF2[
MTO3YUU+6ODG"F$LH-K%YD0=UF66;83'NB8EE7] /@1_P0S_9L^!1TFY_X07_
M (3+6-)\[_B8>*+R34/MGF;Q^^M?ELGVJ^U?]'&-B-]\;Z^1S#CC*\*^6$G4
M?]W5?>VE]USZ#!\+XVMK)<B\]_NW^^Q_/I\,?@]XN^-FO3:5X,\+>(_%VJ6]
MNUW+9Z+ILU_<1PJRH9&2)68(&=%+$8!=1G)%?1?PA_X(C_M,?&&RT>^M_AK>
M>']+U>X$)NM?O;?3'L5$IC>6>UD<7:(N"V!"69 &17#+G^B[P_X?L/"6@V.E
M:58V>F:7IEO':6=G:0K#;VD,:A4CC10%1%4!0J@   #BKE?(8KQ(Q,M,/2C'
MU;E^7+_7<^@H<&T%_&J-^EE_F?B+X$_X-@_BYJ'BNTA\3?$#X<Z/H;[_ +3=
MZ6U[J5W#A&*;()(($?+A5.9DPI+#<0%;T8?\&KO/_)=O_+*_^[Z_72BO$J<<
MYQ)WC44?2,?U3/2APQET59POZM_HT?FCX$_X-@_A)I_A2UA\3_$#XC:QKB[_
M +3=Z6UEIMK+EV*;()(+ATPFU3F5MS L-H(53QW_ ,&P?PDU#PI=0^&/B!\1
MM'UQMGV:[U1K+4K6+#J7WP1P6[OE-RC$J[6(8[@"K?I=17'_ *V9OS<_MW??
MI;[K6^6QT_V#E]N7V2_'\[W/R+_XA7?^J[?^65_]WUY#\0/^#9SXX^'?[<N-
M!\3?#GQ%9V/VB33H?MUU9W^J1IN,2^6\!ABFD 4;6G,:LV#*5&^OW2HKNH\=
M9Q!WE44O6,?T2.:IPOETE90:]&_U;/YB_C=_P3+^/O[.WVA_%7PI\76]G9V#
M:I=7]A:?VK86=LN_>\US:F6&+:(V9@[AE7#$!2"?"Z_KHKY__:Q_X)??!']M
M"\NM2\:^"K,^)+BWEA&OZ9(]AJ2L\21+*\D9"W#Q+''Y8N5E1-F NTLK?29?
MXD7?+C:6G>/^3_S^\\7%\&Z7PU3Y2_S7^1_,O17WI_P4>_X(2>.OV/;+4O%W
M@::\^(7PWL;>>_OK@11Q:EX>A27 %Q$&S<(L3*S3PJ /+F=XX40%O@NOT;+\
MRPV-I>VPLE*/XKR:W3]3X_%X.MAJGLZ\;/\ /T?4****[CE"BBB@ HHHH **
M** "BBB@#HOA!\3+[X*_%KPMXRTN&SN-4\(ZQ::W9Q7:,]O)-;3)-&LBJRL4
M+(,A64XS@@\U_4O\ ?CAH'[2GP6\,^//"]Q]IT/Q381W]MF2-Y(-P^>"7RV=
M%FB<-'(@8[)(W4G*FOY1J_<3_@V@_:*G^(G[*/BKX=WLE[/<?#?5UGLV:"*.
MW@L-0\R5(4=<.[BYAO9&,@X$T8#$#:GY[XAY:JN#CC([TW9_X9:?G;[V?7<(
MXQPQ#P[VDKKU7_ O]Q^DE%%%?C)^C!1110 4444 %%%% !1110!_(N.E% Z4
M5_5!^%A1110 4444 %%%% !1110 4444 %%%% !117M'[(?_  3Z^+'[<.O+
M;_#_ ,*WE[I<=P+>\UV[_P!%TC3R&B#^9<-\K.BS1R&&/?,4)98VQ6.(Q%*A
M!U:TE&*ZMV1I2HSJRY*:;;Z(\7H)P*_;K]E;_@VG^&W@33=,U'XL>(-8\=ZX
MF9+O2].F;3=%^> *82R@74OEREW6998-X6/=$H#*WWG\"?V8?AW^S'H)TWX?
M^"_#GA*WDM[>UN'TZR2*XOD@5EB-Q-CS;AU#/\\K.Y+N2268GX7,/$/ T7RX
M:+J/_P !7WN[_ ^HPG".)J+FK24%][_R_$_G2^&/_!*K]HSXN:[-INE?!OQU
M:7$-N;EGUK3SHD!0,JD+->^3&SY<816+D!B 0K$=TO\ P0B_:L)_Y)9CZ^)=
M(_\ DJOZ+J*^9J>(^8-^Y3@EYJ3_ /;E^1[4>#L);WIRO\E^C/YTV_X(0?M5
M@?\ )+0?IXETC_Y*K%\>?\$6OVG_ (<>$[K6M0^$NL7%G9[/,CTN_LM5NVWN
MJ#9;6LTDTG+ G8AVJ"QPJDC^D:BICXC9BG[U.%O27_R13X.P=M)R^]?Y'\HO
MQ4_9^\>_ O[#_P )OX(\7^#?[4\S[%_;FC7&G_;/+V^9Y?G(N_;O3=MSC>N>
MHKD:_KHKY1_:)_X(G_LY_M%6<IE\!6?@O5&MX[:'4?")&D/;*DID)%NBFT=V
MRR,\D#N4; (*H5]S ^)%&3Y<72<?.+O^#M^;/,Q7!M1*^'J)^35OQ5_R1_.+
M17Z%_M>?\&Y_Q9^ V@MK7@#5;/XM:7:VYEO+:TL_[.U>$JLKN8[5I)%G0*D8
M BE:9WE"K"0-Q_/2OO<OS3"XZ'M,+-276VZ]4]5\T?*8O U\++DKQ<7_ %L]
MF%%%%=YRA1110 4444 %%%% !1110 5T7PE^+?B7X$?$?1_%_@_6;SP_XET&
M<7-C?VI'F0O@@@A@5=&4LK(X*.C,K*RL0>=HJ91C*+C)73W3*C)Q?-'<_JB_
M9(_:0TG]KO\ 9L\'_$?18_L]GXJL%N)+;<[_ &*Y5FBN;?>Z(7\J=)8]X0*_
ME[E^4@UZ-7XH?\&U_P"V+J'@OX[:M\%=2U"SC\,^,+>YUK2+=K-FN#K$4<)D
M5)4'RH]G#*S"7*YM8]A1F99?VOK^=>(LI>78Z>'7P[Q_PO;[MGYH_7LGS!8S
M"QJ]=GZK?[]PHHHKPSU HHHH **** "N%_:7_:)\-_LF_ OQ%\0_%TMY'X?\
M,VZS7 M(#/<3,\BQ111KP"\DLD: L50%P695!8=U7X<_\'$G[>\WQH^.B?!G
MP_>6<_@_X>W$=SJCQ1Q2&[UORY%<"978[+>*8PE,1LLS7*N&V1E?=X=R>698
MV-#[*UD^T5O\WLCR\XS)8+#.KUV7K_DMV?"_[3'[17B7]K+XZ>(OB'XNELY/
M$'B:X6:X%I (+>%$C6***->2$CBCC0%BSD("S,Q9CPM%%?T/3IQIP5.FK)*R
M79+9'Y#.<IR<Y.[>K"BBBM"0HHHH **** "BBB@ HHHH **Z+X2?"7Q)\>/B
M5H_@_P (:/>:]XD\07 MK"QM@-\SX+$DDA415#.[L0B(K,Q55)'Z=?LK?\&Q
M^K:_IVF:M\8O'/\ 8/G9DNO#WAR)+B[CC: %%:^DS%',DS$.J0SQE8_EE.\,
MGDYGGF"R]7Q4U%O9;M_):_/;S/0P.5XG%O\ <1NN^R^_^F?E'7HW@7]C_P"+
M?Q1\)VNO>&?A;\1O$>AWV_[-J.E^&KV\M;C8[(^R6.-E;:ZLIP3AE(Z@U_1U
M^SM_P3K^"/[*-[%>> _AOX<T?5+>XDN8-4FC>_U*V:2(0N(KNY:2>-#'E=B.
M$^=^,NV?:*^#QGB5%.V%HZ=Y.WX*_P"?R/J</P:[7KU/DE^K_P C^='_ (<1
M?M6?]$K_ /+ET?\ ^2Z=_P .(/VJ\?\ )+5^G_"2Z1_\E5_1917D?\1&S+^2
MG]TO_DCO_P!3\%_-+[U_\B?SH_\ #B+]JS_HE?\ Y<NC_P#R77BWQ=_8C^,/
MP%LM8O/&'PQ\=:!I>@W!M;[5+G19QIL+^:(01=A3 Z-(55'1RCEEVEMPS_4O
M16U'Q(QJE^^I0:\KK\6Y?D9U.#<,U^[G)/SL_P!$?R+T5_47\=_V!_@O^TQ_
M:LGC?X9^$=:U#6_)^VZK]@6VU:;RM@C_ --AV7*X6-$^6090;#E25/YN?M>?
M\&RLVBZ VJ?!'QA>:O<6EN6ET'Q3)$MQ>LJRL3!=Q1I&'<B&-(I8T3)=FG48
M4?59;Q]E^(?)73IOSU7WK]4CP\9PIBZ*YJ5IKRT?W?Y-GY+T5UWQN^ ?C3]F
MWQ[<>&/'GAG6/"NN6^YOLU_;F/SXUD>+SH7^Y-"7C<++&6C?:2K$<UR-?;TZ
MD9Q4X.Z>S6J/F91E%\LE9A1115$A1110 4444 %%%% !1110!UWP%^-NO?LW
M_&?PSX[\,W'V?7/"NH1:A;9DD2.?8?FAE\MT=H94W1R(&&^.1U)PQK^G3]D;
M]I#2_P!KO]FOP=\2-'B^S6OBK3UN);4,[_8;E6:*YM][I&9/*G26/S-BA_+W
M*-K"OY7:_1;_ (-U?VV_^%'_ +2EY\+->U#R?#'Q-V_V=Y]QM@LM8B4^5MWR
MK&GVF/="=J/)+*EF@X%?#\<9&L9@_K5->_3U]8]5\MU\UU/I^&,T>'Q'L)_#
M/\'T?SV^[L?NE1117X>?IH4444 %%%% !1110 5_+G_P4!_Y/R^-W_8_:]_Z
M<9Z_J,K^7/\ X* _\GY?&[_L?M>_].,]?I7AM_O-;_"OS/C>,OX%/U?Y'D=%
M%%?KQ^>A1110 4444 %%%% !0>E%!Z4 ?UT4445_*Y^Z!1110 4444 %%%%
M!7D/_!0/_DPOXW?]B#KO_INGKUZO(?\ @H'_ ,F%_&[_ +$'7?\ TW3UU8'_
M 'FG_B7YHPQ7\&?H_P C^76BBBOZ>/Q(**** "BBB@ HHHH **** /KK_@A%
M_P I6/A7_P!Q;_TSWU?T75_.C_P0B_Y2L?"O_N+?^F>^K^BZOQ;Q&_Y&4/\
MKVO_ $J1^D<'_P"Y2_Q/\HA1117P!]8%%%% !1110 4444 >1?MR_MAZ#^PK
M^S9KOQ$UZ'^T/[/V6VG:6EU';S:O>2MMBMXV<_[SN55V2**5PC[-I_F7^+GQ
M<\2?'CXDZQXP\8:Q>:]XDUZX-S?7UR1OF?     5$50J(B@(B*JJ%50!]B_\
M%_/VS/\ AIG]L^X\(Z7-YGA?X2^?H<'R8\[42R_VA+\T22+B2..WVEG0_9/,
M0XE.?A>OW3@K(E@<&L147[RHDWY1Z+]7YZ/9'Y?Q)FCQ.(=*#]R&GJ^K_1>6
MO4****^T/FPHHHH **** "BBB@ HHHH ***Z[X)? 3QI^TCX]M_#'@/PSK'B
MK7+C:?LUA;F3R(VD2+SIG^Y#"'D0-+(5C3<"S <U-2I&$7.;LEU>B*C&4GRQ
M5VSD:*_6?]D/_@V6N-;\/KJGQO\ &%YH]Q>6X:+0?"TD37%D[+$P,]W+')$7
M0F:-XHHW0D(RSL,J?TC^!'[ WP7_ &9_[)D\$?#/PCHNH:'YWV+5?L"W.K0>
M;Y@D_P!-FWW+965T^:0X1M@PH"CXC,N/LOP[Y*%ZC\M%][_1/_/Z;!\)XNLN
M:K:"\]7]W^;1_./\(?V(OC#\>[+1[SP?\,?'6OZ7KUP+:QU2VT:?^S9G\TPD
MF[*B!$60,KNSA4*MN*[3CVC_ (<1_M6?]$K_ /+ET?\ ^2Z_HNHKY6MXD8UR
M_<TH)>=W^*<?R/<I\&X9+]Y.3?E9?HS^=,_\$(/VJ\?\DM7_ ,*72/\ Y*IO
M_#B+]JS_ *)7_P"7+H__ ,EU_1=16/\ Q$;,OY*?W2_^2-/]3\%_-+[U_P#(
MG\KOCK]C[XM_"[PG=:]XF^%OQ&\.:'8[/M.HZIX:O;.UM][K&F^62-57<[*H
MR1EF ZD5YS7]=%>+_M%?\$Z_@C^U?>RWGCSX;^'-8U2XN([F?5(8WL-2N6CB
M\E!+=VS1SR((\+L=RGR)QE%QZ^#\2HWMBJ.G>+O^#M^?R.#$<&.UZ%3Y-?JO
M\C^7^BOU1_:P_P"#9;Q+X?O;G4O@QXPL_$&EQV\LPT;Q+(+74@Z1(5BBN(X_
M(F>602X,BVR1YC!9AN<?F+X[^'^O?"WQ7=:#XGT/6/#FN6.S[3IVJ6<EG=V^
M]%D3?%( Z[D96&0,JP(X(K[[+,ZP>81YL+-2[K9KU3U_0^4QN6XG".U>-O/H
M_F9%%%%>H<(4444 %%%% !1110 4444 %>H_L;_M7^)?V+/VA?#_ (^\,W5Y
M')IEPBZE8P7 A36K R*T]E*61UV2JN-Q1BC!)% =$(\NHK.M1A5INE45XM6:
M?5%TZDJ<E.#LUJF?U<_ 'XWZ#^TG\%O#/CSPS.9]#\5:?%J%L&DC>6WWCYX)
M?+=T6:)]T<B!FV21NN<@UU]?C/\ \&W7[=>H:%\3=0^!/B+5+RZT77;:74?"
M44TC2)IUY$'FNK:)1&2J3Q&2<[I%C1[5]JF2X8G]F*_G7B#*9Y;C989[;Q?>
M+V^[9^:9^OY3F$<9AHUEOL_)K?\ S7DPHHHKQ3T@HHHH **** "O(?\ @H'_
M ,F%_&[_ +$'7?\ TW3UZ]7D/_!0/_DPOXW?]B#KO_INGKJP/^\T_P#$OS1A
MBOX,_1_D?@?X!_Y$31?^O"#_ -%K6M63X!_Y$31?^O"#_P!%K6M7]+'X4%%%
M% !1110 4444 %%%% !1110 4444 %%%=M\%_P!FCXC?M'W-Y%X \$:[XJ&G
M[A<W%N(K6SA91&3$;JX>*W\X++$WDB3S=KA]FW+#*M7IT8>TJR45W;27WLTI
M4:E67)3BV^R5V<317Z ? _\ X((^)-0O5N/B9X[TC2[19)8Y--\*PO>3S1F+
M]W*E[<I&L3B4Y,9M)05C^_E_W?O_ ,/_ /@B3\"O"6AM:ZQ8^*_&ER9I)$OM
M5UZ>UGC1T5/*"V'V:(J-I92T9<,[?-]T+\KBN.,JHNT9.?\ A7ZNR/HL/PGF
M%17DE'U?^5S\@**_99?^",7[.*C_ )$75?Q\8:W_ /)E(?\ @C%^SBW_ #(N
MJ_\ A8:W_P#)E<7_ !$/+?Y)_='_ .2.G_4O&_SP^]__ ")^-5%?KM\1O^"'
MOP2\96VFPZ*WC3P.EAYOF_V1K/VMK[>5(\UM02Z;Y-K;=A3[[;MV%V_.?QU_
MX(3^./"SWE]\/_$^B^++%6O+E-.U%&TS4(XE :UMHGS)#<3/\R-)(UK&&"G
M#'9Z&#XVRJNU%S<&_P"96_%77X_B<F)X5S"DKJ*DO[K_ $=F?"M%;'Q#^&GB
MKX-Z\NE>-?"GB3P;J4UQ<6MO#K%@]LM^\#;93;2G,5TBY5M\#R)M=&SAE)QZ
M^IIU(SBIP::?5:H^>J4Y0ERS5GV844459 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 >#_%OPA_PB7BV7RX]EG>9G@P,*N?O(.
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M-'+'=^((XB^^32DEB'F0OMC"W$JK'B8,JS&-XA^RW[)O[&?P[_8I^&MKX:\
M^'[/356WB@OM3>)&U/6VC+L);N<*&F?=+*0#A$\PK&J)A1^M9[QMA,''DPUJ
ME3R^%>K_ $7SL? Y7PS7Q+YJWN1_%^B_7\S\\_\ @G__ ,&X.EZ3IL?B+]H2
M;^U-0E\N2U\*Z1J3QVMO&\!WK>W$85WF61^%MI!&I@SYLRR%5_2_X'_ 'P7^
MS7X"M_#'@/PSI'A70[?:WV:P@$?GR+&D7G3/]^:8I'&&ED+2/M!9B>:Z^BOR
M/-,\QN83<L3-M?RK2*]%M\]_,^_P.6X;"1Y:,;/OU?S_ *04445Y)WA1110
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M[KHUW7SW7334_,<\R.6!DIP=X/9]O)_H^IYS1117UQ\^%%%% !1110 4444
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M0 5-IND:EXAU&'3]&TC6/$&K76\6NFZ5927M]>LJ-(RQ0Q@N[!$=C@<*K,<
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M[U^\8#'4<90CB:#O&7]-/S1^18S!U,+6="JM4%%%%=ARA1110 4444 %%%%
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MG6!%</%&+6,RPVD,L>S9.DLXFF #YBDTZ-BN6C8>KDN6O'8VGAELWKY):O\
M#\3S\TQRPF%G7>Z6GKT_$_/GXH?$S6OC+\1=:\5>(;G[5K7B"\DO;IE>5HXV
M=B1'$)7=TA082-"[;(T1 <**P:**_HFG",(J$%9+1>A^*SE*4G*6K844451(
M4444 %%%% !1110 5]Q_\$N_^"7G_"\O[.^)7Q*T[_BAOEN=#T.Y3_D9NZW-
MPI_Y<>A2,_\ 'UPS?Z/@77FG_!,']A)OVR?C VL:V[V_@'P#?6MUJD3V@FB\
M1W.3(FF?O$:)HL*CW*G+>5+$FW%QYD?[05^<\9<42P]\!A':7VGU5^B\VNO1
M>>WV_#&01JVQF)7N_97?S?EY=?3<HHHK\E/T4**** "BBB@ HHHH **** "B
MBB@#\A_^"KW_  2NO?V9K_4OB]\(M+FNOAXVZZ\4^$K1<_\ ".#)9[ZQC' M
M<EFDA7 AR6'[G/V;XYL+Z+5+&&Y@;S(;B-98VP1N5AD'!YZ'O7]'U?BK_P %
M:OV,8OV*/C_I^O>&],L-/^%GQ(NI%L;73[.X6/P]JFV-GM6)9HHXIR9)84CV
M 8F18T2'>WZUP;Q1+$-8#%N\K>[+O;H_-+9]5OKO^><49#&DGC,.M/M+MYKR
M_K;;YQHHHK]&/A@HHHH **** "BBB@ KVK_@G7\>+7]FO]LKPCXHU+4O[*T&
MZ\[0]<G86ZQ"RN@HS+),RK##%<QVEQ)*&#*ELP&X,R-XK3+BWCNX)(I8TDBD
M4HZ.NY7!X(([@USXS"PQ-"="IM)-/Y_UH;X7$2H5HUH;Q:?W']'=%>(_\$[_
M -I"X_:F_9,\,^)M4N+6;Q';K)I6MB.ZAFE^UV[F/S9EB1%ADN(Q%=>2$78M
MT@ *[6/MU?S=BL//#UI4*GQ1;3]5H?N%"M&M3C5AM))KYA1116!J%%%% !7Y
M[?\ !=3]J-=%\-:'\'=.;==>($C\0:]E%*QV<4Q%G$0\1!\VYADE#Q2*\9T\
M!AMF&?T)K\%?VS/VCA^U?^T[XO\ &UG=7EQX=U&\6#P^DUQ)*D>G01I#"\2R
M*K1)/Y;71BV*4>Z<,"P9F^SX'RU8G,/;35XTU?\ [>^S^K7H?,<5X[V&"]G%
M^]/3Y=?\OF>8T445^VGY4%%%% !1110 4444 %%%% !117U#_P $T/\ @G!?
M_MF>-F\2>--)\OX,Z7]HM;A)II[>;Q=<^6\?DVSP21R1P02'=),&PTD7D!6Q
M,8^+,,PH8*A+$8AVBOO;[+NW_P /9:G9@<#5Q=94:*U?W)=WY&5^P%_P38\1
M?MXZ>WB1M8N/!_P[M;I8O[92R$USKK1S!9X+%9,(%"K(INF$D:R;55)BLHB_
M73]GS]F[P1^RM\/%\*^ ?#]OX>T3[5+?21)+)/+<W$IR\TTTK/++(<*NZ1V(
M5$4$*B@=9X>\/:?X1T"QTG2;&STO2]+MX[2SL[2%8;>TAC4)'%'&H"HBJ H5
M0    ,5<K\,SWB/%9E4?.[4[Z16R]>[\WMK:Q^L93DM# P]Q7EUEU?IV7E]]
MPHHHKY\]@**** "BBB@ HHHH *\M_:I_8W\!?MD>$;;2_&VES33:;YSZ7J=G
M<-;7^DR2)M9XI%X(R$8Q2AX7:*(O&^Q0/4J*UH5ZE&HJM*3C);-:,SJTH5(.
M%1)I]&?A/^V-^PUXW_8:UC3X_%TVG:IH>M7$L&F>(-.C>.RNG$D@CMY%<DP7
M30JDGE%F5LN(Y)?*D*>/U_0K\7/A'X;^//PUUCP?XPT>SU[PWKUN;:^L;D'9
M,F00000R.K!65T(='564JR@C\2/VX?V)=9_8'^,%KX=O]677?"OB19[GPEJL
M\JB^NX82GG6UR@ _TB#S(LR* DRR*X"L)(X_V7A7BM9@OJV)TJ].TEY>:ZKM
MJNJ7YGQ!PZ\)_M&'UI]?[O\ P/\ ACR&BBBOMCY,**** "BBB@ HHHH ****
M "BBB@#]'/\ @W\_YJU_W!__ &_K]'*_./\ X-_/^:M?]P?_ -OZ_1ROP?C3
M_D<UO^W?_2(GZ[PO_P BRE_V]_Z4PHHHKY<]\**** "BBB@ HHHH **** "B
MBB@ HHKR_P#;3^-,O[/7[*_CCQ=;27,.H:;IK16$L$,<S07<[+;V\A63Y"J3
M2QLP.?E5OE;[IVP]&5:K&C#>327JW9&=:K&E3E4GM%-OT6I^3?\ P5)^-,OQ
MJ_;7\7R>9<FP\+S?\(Y91SPQQM MJ628#9G<K7)N'5F);;(N=N J_/=%%?TA
M@L+'#8>&'AM%)?<M_F?AV*Q$J]:5:>\FW]X4445U& 4444 %%%% !1110 44
M44 6-'UB\\.ZO:ZAI]U<V-_8S)<6US;RM%-;RH0R.CJ0596 (((((!%?T*_#
M3QY9_%/X<>'_ !/I\5S!8>)--MM4MH[A56:.*>)945PI90P5@" Q&<X)ZU_/
M%7[+_P#!'OXJ?\++_8?T.UDFU.YO/"5[=:'<37C[]^UQ/$L;;F/E);W$,:@[
M=OEE0-JJ3^=^(F$Y\+3Q*^S*WRDO\TOO/M."\3RXB=!_:5_FO^'_  /J&BBB
MOR,_2#^?_P#X.$?V:O\ A1W[?=]XCL;/[/H?Q,L(M<B:#3/LMI'>+^XNXED7
MY)IB\:7,K##;KY2P)(=_A>OW<_X.1?V=8?B=^Q'I_CR&*S75/ACJ\4SSS3RJ
M_P!@O62UFBB1<H[M<&Q<EP-J0OM89*O^$=?T!P=F'UO*J;>\/=?RV_"Q^3\1
M83V&.FEM+WE\]_QN%%%%?4'AA1110 4444 %%%% !7]+G_!)W]FK_AE;]@3X
M>^'+FS^QZY?V US6EETS^S[L7EX?/:*YC.7,T"/';%G^8K;*,( $7\"_^"=G
M[.T/[5W[;GPW\!WD5G<:7K&KI-J<%S/+ ES86R-=7<0>+YU=[>&5%*E?G9?F
M3[P_J K\M\2,PLJ6"C_B?Y+_ -N/N>#<)K/$O_"OS?Z!1117Y2?=A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>(_&WPI_PCWBUKJ-<6^J9F7GI)_&.I/4ANP^
M? Z5[=7+_%OP?_PEOA*3RH]UY99G@PN6;'WD'!)R.@'5@OI7?EN(]E73>ST9
MQXZC[2D[;K5'@]%%%?8GRX4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %>Q? 7QC_ &MH<FESR;KC3_FBW-EGA)XZDD[3QP  "@KQ
MVMOX=^)%\*>,+.\D9UMU8QS;6(!1A@D@9W 9#8QR5'?!KCQ^']M1<>NZ]3JP
M=?V55-[;,^A:***^+/J@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#SG]K?]G#2?VN_P!FSQA\.-9D^SV?BK3VMX[G:[_8;E666WN-
MBNA?RITBDV%P'\O:WRDBOY:?$/A_4/"6OWVDZK8WFF:II=Q):7EG=PM#<6DT
M;%'BD1@&1U8%2I (((-?UN5_.C_P7+^!'_"BO^"DWCK[/I?]EZ1XR\CQ1I_^
MD^=]K^TI_I4_+LR;KY+SY&VXQ\JA"E?IGAOF#C6JX*3T:YEZK1_-IK[CXKC'
M")TX8E+5.S]'JON=_O/D6BBBOUP^ "BBB@ HHHH **** "BBB@#^HK_@G]\0
M1\4_V&_A#KS:Y_PDEW?>$-,%_J+7OVR2XO$MHX[KS9=S%IEG259-Q+"17#?,
M#7KU?(O_  0B_P"44_PK_P"XM_Z>+ZOKJOYGS:DJ6.K4H[1G)?<VC]IP%1SP
MU.;ZQ3^](****\\ZPHHHH **** "BBB@#^1<=**!THK^J#\+"BBB@ HHHH *
M*** "BBB@ HHKKO@'\$=>_:2^-'AGP'X8M_M&N>*M0BL+;='(\<&X_/-+Y:N
MZPQ(&DD<*=D<;MC -34J1A%SF[):M^148N4E&.[/MW_@@Q_P3,T_]K;XDWWQ
M*\>:/9ZM\-_!MP;2VL9[A2FK:NHAE6*:#:3);112!W5RBN[PKB5/.0?N[7"_
MLS_LZ^&OV3/@7X=^'GA&*\C\/^&;=H;<W<YGN)G>1I999'X!>2621R%"H"Y"
MJJ@*.ZK^=^(LZGF>,E6^PM(KLO3N]W]W0_7LGRV."PZI_:>K?G_DN@4445X)
MZ@4444 %%%% !1110 4444 %%%% !7R[_P %:_V ;;]OS]EN\TNQC\OQQX5\
MW5_#$\<,!DN+E8F#6#22E=D-S\BL1(@61()&W"+8WU%173@\75PM>.(HNTHN
MZ_K\S'$8>%>E*C45T]&?R1^(/#^H>$M>OM*U6QO-,U33+B2TO+.[A:&XM)HV
M*O'(C ,CJP*E6 (((/-4Z_2[_@XK_8"M_@M\5[/XU>&X_+T/XB7YL]<M$B@A
MAT_51"'22,*5=_M213R/E&(EBE=I"9E5?S1K^C<IS*GC\)#%4_M+5=GU7R?^
M9^.YA@YX2O*A/I^*Z,****](XPHHHH **** "BBB@ KZN_X(H?M%3?LZ?\%&
M? ,IDO%TOQI<?\(CJ,-M!%*]REZRI;J3)C8BW@M)'9"'"1,!N!*-\HT,N]2#
MR#P0>]<N-PL,3AYX>>TDU]ZW^6YOA<1*C6C6CO%I_<?UT45Q_P"SY\5?^%[?
M /P/XX.G_P!E'QEX?L-<-D)_/^Q_:K>.?RO,VKOV[]N[:N<9P,XKL*_F.I3E
M"3A+=:,_:XR4HJ4=F%%%%24%4_$'B"P\)Z#?:KJM]9Z9I>F6\EW>7EW,L-O:
M0QJ6>21V(5$506+,0  2>*N5\B_\%R_CO_PHK_@FUXZ^SZK_ &7J_C+R/"^G
M_P"B^?\ ;/M+_P"E0<HRINL4O/G;;C'RL'*5UX#"RQ6)IX>.\FE][W^6YSXK
M$*A1G6?V4W]Q^!?[3GQUU#]IO]H;QI\0-2%Y'<>+=7N-12WN;UKQ[&%W/DVP
ME8 LD,6R)?E4!(U 50 !PM%%?TS3IQIP5."LDK+T1^*SG*<G*6[U"BBBM"0H
MHHH **** "BBB@ KUW]AK]CW7OVZOVD]"^'>@S?V?_:&^YU'5'M9+B'2+.)=
MTL\BH/\ =C0,R*\LL2%TW[AY%7] '_! /]C3_AF?]C"W\7:I#Y?BCXM>1KD_
MSY\G3E5O[/B^65XVS'))<;@J./M?EN,Q#'SO%&=?V;@75C\<M(^KZ_):^MEU
M/8R/+?KN)4)?"M7Z=OGM^/0^Q?A'\(_#?P'^&VC^#_!^CV>@^&]!MQ;6-C;*
M=D*9))))+.[,69G8EW=F9BS,2>CHHK^>Y3E*3E)W;W9^M1BHKECL%%%%24%%
M%% !1110 4444 %%%% !1110!SOQ;^$GAOX\?#;6/!_C#1[/7O#>OVYMKZQN
M0=DR9!!!!#(ZL%974AT=592K*"/YK?\ @HQ^Q1JO[!/[4NM>![X^=H\V=4\.
MW;727$E[I4DLJ6[RE53;,/+>.0%$'F1N5!0HS?TZ5\<_\%KOV"(?VUOV3;W4
MM*LKRZ^('PZM[C5O#J6[RLUXA\MKNS\E$<S/-%"/+55#F:.$!U1I WV'!N?/
M 8M4JC_=U-'Y/I+]'Y>B/G>(LK6+P[J07OQU7FNJ_P O/U/YW:***_>#\M"B
MBB@ HHHH **** "BBB@#NOV8_CKJ'[,G[0W@OX@::+R2X\):O;ZB]O;7K6;W
MT*.#-;&502J31;XF^5@4D8%6!(/]47A_Q!8>+=!L=5TJ^L]3TO4[>.[L[RTF
M6:WNX9%#))&ZDJZ,I#!E)!!!'%?R1U_1%_P0@_:*G_:#_P""<WA:&^DO+C5/
M %Q-X1NIIH(H4D2V6.2U$0C/S(EG/:Q;G"NSQ.3N^^WYGXCY?S4:>-CO%\K]
M'JON:?WGVG!V+M4GAGU5UZK?[_T/L:BBBOR,_0 HHHH **** "OY<_\ @H#_
M ,GY?&[_ +'[7O\ TXSU_497\N?_  4!_P"3\OC=_P!C]KW_ *<9Z_2O#;_>
M:W^%?F?&\9?P*?J_R/(Z***_7C\]"BBB@ HHHH **** "@]**#TH _KHHHHK
M^5S]T"BBB@ HHHH **** "O(?^"@?_)A?QN_[$'7?_3=/7KU>0_\% _^3"_C
M=_V(.N_^FZ>NK _[S3_Q+\T88K^#/T?Y'\NM%%%?T\?B04444 %%%% !1110
M 4444 ?77_!"+_E*Q\*_^XM_Z9[ZOZ+J_G1_X(1?\I6/A7_W%O\ TSWU?T75
M^+>(W_(RA_U[7_I4C](X/_W*7^)_E$****^ /K HHHH **** .<^,/Q.L/@G
M\)/%/C/58;RXTOPCI%WK5Y%:(K7$L-M"\SK&&95+E4( 9E!.,D#FOY4?B!X\
MU;XI>/-;\3Z]=?;]<\1W\^J:C<^4D7VBYGD:65]B!47<[,<* HS@ #BOW1_X
M./\ XW?\*Y_8%A\*V]QHYO/B%K]I836MQ)_I;6=L3>230(&!^2>"T1W*LJK.
M 0&="/P7K]C\.< J>$GBWO-V7I'_ #;?W'YWQABG/$1PZVBK_-_\#\PHHHK]
M%/CPHHHH **** "BBB@ HHHH ^B_^"8_[ 6K?\%!_P!I.Q\-^7K%EX+TO%WX
MHUJRB1O[,MMKE(PTA"":=T\J,8=AEY/+=(I /Z4?#_A^P\)Z#8Z5I5C9Z9I>
MF6\=I9V=I"L-O:0QJ%2.-% 5$50%"J    .*^=/^"4O["=A^PC^R=H>CW&EV
M=MX\UZWCU'Q;>*B_:)KMMSK;.ZR2*R6JR&%?+;RV*R2*JM,^?I>OP/B[/GF.
M,M3?[N%U'S[R^?3RMUN?JW#^5K!X>\U[\M7Y=E\OSN%%%%?)GO!1110 4444
M %%%% !1110 4444 %<+^TO^SMX;_:R^!?B+X>>+HKR3P_XFMUAN#:3F&XA9
M)%EBEC;D!XY8XW 8,A* ,K*2I[JBM*=2=.:J0=FG=/LULR9PC.+A)73T9_+3
M^V5^R?XE_8K_ &AO$'@'Q+:WBR:9<.VFWTUN(4UJP+L(+V(!G79*JYVAVV.'
MC8[T8#RVOW2_X.*?V(O^%X?LV6?Q4T'3_.\4?#/=_:/D0;IKW1Y&'F[MD32/
M]FDVS#<ZQQ1/>.<DBOPMK^A>&\X698&-=_&M)>J_SW/R/.LN^IXITE\+U7I_
MP-@HHHKWSR0HHHH **** "BBB@ KVC_@G9^T5#^RC^VY\-_'EY+9V^EZ/JZ0
MZI/<P2SI;6%RC6MW*$B^=G2WFE=0H;YU7Y7'RGQ>BL<10C6I2HSVDFGZ-69I
M1JRIU(U([IIKY']=%%?/W_!*[XZZA^TA_P $]_A9XLU9;MM4GT@Z;>3W5ZUY
M<7TUE-)9/=22L S/,UN9FSD@RD%GQN/T#7\RXK#RH5IT)[Q;3]4['[70K*K3
MC5CM))_?J%%%%<YJ%%%% !7D/_!0/_DPOXW?]B#KO_INGKUZO(?^"@?_ "87
M\;O^Q!UW_P!-T]=6!_WFG_B7YHPQ7\&?H_R/P/\  /\ R(FB_P#7A!_Z+6M:
MLGP#_P B)HO_ %X0?^BUK6K^EC\*"BBB@ HHHH **** "BBB@ HHKKO@%\&+
MK]HOXY^#_ =K]H'_  E6K06=TUK=1VUU#9!O,O9H7D^7S8K1+B51AB3$,*Y^
M4YUJT:5.56>BBFWZ+5FE*G*I-4X;MI+YGWK_ ,$3OV)9-,A;XV>);>\CFU"W
M:S\*6-Y8P>6MLZJ7U:)VW3!IE9X8R/+!A\UAYL=PC#]%:I^'_#]AX3T&QTK2
MK&STS2],MX[2SL[2%8;>TAC4*D<:* J(J@*%4    <5<K^=LXS2IF&*EB:G7
M9=ET7]==3]JRW PP>'C0I]-WW?5A1117F'<%%%% !1110 4444 %%%% 'FW[
M6?[,7A_]KKX':OX-\06MC(;A?M&E7MQ;F<Z-J"*WV>\C571MT;G)577S$+QL
M=CL#^#6NZ)>^%_$.IZ1J=J]CJFBWUQIM_;.Z.UK<P2M#-$60LC%)$==R,RG&
M02""?Z+J_''_ (+)?L[VOP-_;)EU[2M.6PT7XH6/]N$IY*1RZI"RP7^R.,!E
M!0V,S-("9);N9@[?,J?HWA]FCA7E@9O22O'U6]O5:_(^*XRR]3HQQ<5K'1^C
MV^Y_F?*M%%%?K1^<!1110 4444 %%%% !1110 445UWP"^#%U^T7\<_!_@.U
M^T#_ (2K5H+.Z:UNH[:ZAL@WF7LT+R?+YL5HEQ*HPQ)B&%<_*<ZU:-*G*K/1
M13;]%JS2E3E4FJ<-VTE\S[G_ ."&G[']GJEH_P >-4F>\^TK=:-X6M6BMY+:
M-%D\JYU%'!:02LZ2VJ_ZLJB7'^L2X4C](ZI^'_#]AX3T&QTK2K&STS2],MX[
M2SL[2%8;>TAC4*D<:* J(J@*%4    <5<K^=\XS2IF&+EB:G79=ET7^?=W9^
MU9;@88/#QH0Z;ON^K"BBBO+.X**** "BBB@ HHHH **** //_P!JG]GZQ_:G
M_9W\7?#_ %"ZFT^'Q-8-;PWL1DWV%PI$EO< 1O&S^5,D<FS>%?9M;Y6(/X$W
M&CZMX:U&^TG7[+^S=?T2\N-+U2TWI(+:[MY7@G0,C,K*)(W 96(( ()K^C:O
MR1_X+B?!*'X=_M9:5XPM?L<-O\2-(#S0K+*]Q/?V'EP3SN&&Q$-M+IT:A&Y,
M,A* DL_Z)X?YHZ>(E@9?#/5?XDM?O6_HCXSC'+U.@L7'>.C]'_D_S9\:T445
M^N'YL%%%% !1110 4444 %%%% 'TO_P1_P#'%_X,_P""@O@^UL;.UN(_%=EJ
M6AZA+*CLUM:_9'OMT>U@JL9["V7<X8;68  L&'[0U^"_[$7Q&O/A3^V5\*]7
MT^WL+BZF\4V&D8NXVD6.+4)ET^=UVLI$@ANI2AS@-C(9<J?WHK\=\0J/+CX5
M%]J"^]-_HT?IO!E3FP<H/I)_<TOUN%%%%? GUX4444 %%%% !7X/_MS?'F3]
MI#]KCQ]XFBO'N]%_M633-$"ZA]NM5L;0"UCEMI/N^3<-$]VH0;<W;$%\EV_8
MS]N'XRR?L_\ [(WQ"\66VK)H>JZ?HTT.CWSVQN%@U.<?9['*;'!!NI8%^92@
MSEOE#&OP8M[>.T@CBBC2.*-0B(B[50#@ #L!7Z=X=8&\JN,DMK17YO\ 0^#X
MUQ=HT\,O\3_)?J/HHHK]2/S\**** "BBB@ HHHH *N>'/#U]XP\2:;H^EV_V
MS5M9O(=/L+;S8X3=7,TBQ11!Y&5%+R,J@LRKEAD@<U3K[6_X(<_ &Z\>?M*:
MG\0KBWWZ%X#T^:S@D+3Q?\36Z5%385412^7:&Y$D;N2GVNV?82R.OG9MF$<#
MA*F*E]E:+N^B^;.[+<&\7B84%U>ODNOX'Z1?LK?L^Z?^RO\ L]>%? .FS_;(
MO#UGY=Q=[&C_ +0NY'::ZN=C._E^=<22R^6&*IYFU?E4"O0***_G2M5G5FZE
M1WE)MM]V]6?ME.G&$5""LEHO1!1116904444 %%%% !1110 4444 %%%% !7
M"_M+?L[^&_VL?@7XB^'OBZ*[D\/^)K=8;@VLYAN(62198I8VY >.6.-P&#(2
M@#*RDJ>ZHK2G4G3FJD'9IW3[-;,F<(SBX25T]&?SM>-_AAKGP1\;ZQX,\26\
MT&N>%;R32[LN)]MP8SA9XWFBB>2.5-LB2; '5P1P:S*^T_\ @OQ^SQ<?#W]H
M3P/\8-/ALX=#\90+X1U[RK=(F_M&(2RV<TA5]\TDL0>(,4(B2S"E\.@7XLK^
MB,ES%8[!4\2MVM?)K1_C^!^+9M@7A,5.AT3T]'L%%%%>H><%%%% !1110 44
M44 ?H%_P02^-[Z=\0?'/PSGDNGAU6Q7Q5I\,=K"L%O) \5I>222Y$K22K/IZ
MJI#*%MG.5)P_Z;5^%G_!/;XMZA\&OVT_AOJ-C'J%U'JFMV^@WEG;7C6R7<-^
MXLR9MJMYD<+3)<^61AGMDY4@.O[IU^*<>8+V.9>U2TJ)/YK1_DG\_4_5.$<5
M[7 ^S>\&U\MU_E\@HHHKXH^H"BBB@#Q/_@H[\79/@?\ L-_$S7K>YU2QU!M&
M?2M-N].D\NYLKZ^9;*UG5PRE!'<7$3EU.Y55F4,P"G\,Z_2S_@X"^(4=MX(^
M%O@U[%W;5-6OO$27BS[1";*W6U\HQ[3N#C5"V[<-IA PV[Y?S3K]HX!P?LLN
M==[U)-_):?FF?E_&&*]IC526T$OO>OY6"BBBON#Y,**** "BBB@ HHHH ***
MAO[Z+3+&:YG;RX;>-I9&P3M51DG YZ#M0![1^P]^QCJW[;OQKB\-P7E]H/AW
M381J.NZU!;>8;:!9$46T3,C1"YGW$1B3@(D\@$AA\M_W*\/^'[#PGH-CI6E6
M-GIFEZ9;QVEG9VD*PV]I#&H5(XT4!415 4*H    XKP3_@FA^QK:_L>_LXZ?
M;WVE6=IX^\41QZGXLNE1#</<L"8[1Y%=U=+2-Q I1A&Q224*&F?/T/7X1Q9G
MCS#%M4W^[A=1\^[^?3RMMJ?KO#V4K!89.2]^6K_1?+\PHHHKY8]\**** "BB
MB@ HHHH **** "BBB@ KP/\ X*+?L(>'OV]?@!?:#>V]O;^+](AFO/"6LF4V
M\ND:ALRF951V%O(RQK,@5MR@, )(XW3WRBM\+B:F'JQKT7:47=,RK485:;IU
M%=/<_F^MQJ.DZWK&@Z]:Q:;XH\+W\^DZU8),LOV.Z@E:*1=RDJPW(V&5F4X.
M&;&:LU^@W_!=3]D_^R?$>A_&;0=._=ZAY>@^*OLMKEBPS]BO9/*MRQQ\UN\L
M\RJH^RHHS7Y\U_0F2YI#,,'#$QT;W79K=?Y>5C\9S7+Y8+$RH/;H^ZZ!1117
MJGG!1110 4444 %%%% !1110!^CG_!OY_P U:_[@_P#[?U^CE?G'_P &_G_-
M6O\ N#_^W]?HY7X/QI_R.:W_ &[_ .D1/UWA?_D64O\ M[_TIA1117RY[X44
M44 %%%% !1110 4444 %%%% !7YU_P#!>KXTQQZ1X'^'=O);232S/XCOT:*3
MSH%57M[8J_";7+W>Y>6S$A^4'YOT4K\2_P#@J1\:9?C5^VOXOD\RY;3_  O-
M_P (Y91SPQQM MJ628#9G<K7)N'5F);;(H.W 5?LN!<#[?,U4>U--_/9?G?Y
M'S'%F*]E@7!;S:7RW?Y6^9\]T445^W'Y4%%%% !1110 4444 %%%% !1110
M5^@'_!!7XLWEI\1_''@5Q<3:?J&FIKT):Z;R;.6"5()-L.-NZ5;B/<X(.+9
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M<OT_-GSG%5=T\ XK[32_7]#XBHHHK]V/RX**** "BBB@ HHHH **** /=/\
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M_L?M>_\ 3C/7]1E?RY_\% ?^3\OC=_V/VO?^G&>OTKPV_P!YK?X5^9\;QE_
MI^K_ "/(Z***_7C\]"BBB@ HHHH **** "@]**#TH _KHHHHK^5S]T"BBB@
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M4_MS0K*]\OROMD"3[-V[9N4-C/?&>M?JO_Q$ ?"__HGOQ>_\!-(_^6-?DO\
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MOY'M</8/ZQCX1>RU?R_X-C[UHHHK\ /V(**** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9?X/^D>IE57EJ.'?]#OZ***^7/H HHHH **** "BBB@ HHHH **** "BBB@
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M -OZ_1ROP?C3_D<UO^W?_2(GZ[PO_P BRE_V]_Z4PHHHKY<]\**** "BBB@
MHHHH **** "BBB@#\_?^"^GCR\T_X=_#GPPD=L=/U?4KS5)I&5O.66UBCBC"
MG.-I6\E+ @DE4P1@@_F37V'_ ,%O_%NG^)/VSK6SLKCSKGP_X;M+"_38R_9Y
MVEN+D)D@!LQ7$+97(^?&<@@?'E?OG".']CE-%=6F_O;?Y6/Q_B.O[7,:C[.W
MW*WYW"BBBOI#PPHHHH **** "BBB@ HHHH **** "BBB@#H_A#\5-8^"'Q/T
M/Q=H,WDZMX?O$O(,NZQR[3\T4FQE8QR+N1U##<CLN<&OWZ^&?CVS^*GPX\/^
M*-/BNH+#Q)IMMJEM'<JJS1Q3Q+*BN%+*&"L 0&(SG!/6OYXJ_4#_ ((;?M.?
M\)3\/M8^%>I2[KSPQOU71_E^_92R#SX_EC 'EW$@?<[EF^U8 "QU\!Q]E;K8
M6.,@M:>_^%_Y/\&V?8\'YA[+$/#3>D]O5?YK\D??%%%%?CQ^EGB__!07]D/3
M_P!N']D_Q5X NELX]4O+?[7H5Y<!0-/U*++6\N\QR-&A;,<C1KO,,LRJ1NK^
M9?X@>!-6^%GCW7/#&O6OV'7/#FH3Z7J-MYJ2_9[F"1HI4WH2C;75AE25.,@D
M<U_6A7Y+_P#!PO\ \$S-0\37LGQ^\!Z/>:A<1V^/'<$5PTSI##%%';W\<)4D
M)'%&4G*-A42*3RP!/+7Z'P'GRPU9X&N[0GJGVEV^?YV[GR/%65.M3^M4E[T=
M_-?\#\KGX_T445^RGYR%%%% !7[H_P#!NK^Q'_PH_P#9LO/BIKVG^3XH^)F/
M[.\^#;-9:/&Q\K&^)9$^TR;ICM=XY8DLW&"*^./^".7_  1T\2_M)?$K1OB-
M\1M%O-!^&>@7%MJ=I::GIXW^,7PD\4:13*5>P92ADE*E)4;RX]Q:1X?W>K\L
MX\XCA*']FX9W_G:\MH_J^VW<^ZX6R>49?7*RM_*OU_R^\****_*C[H**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O+_VC-&_Y!NHK'_>MI9-W_ D
M&,_]=#D#Z]J]0KE_C)HW]L?#^\VQ^9+:;;E/FV[-I^9NH!PA?C^N*[,!4Y,1
M&7G;[]#EQM/GHR7S^X\'HHHK[0^5"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KK/@IJ_P#97Q M5+0I'>(]N[2<=1N4 Y')95'?
M.<=2*Y.K&EZC)I&IV]W&JM):RK,@<?*2I!&?;BLJ]/VE.4.Z-*-3DJ*?9GTQ
M138)TNH$DC=9(Y%#(ZG*L#R"#W!IU?"'V 4444 %%%% !1110 4444 %%%%
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M_MH4445^J'PH4444 %%%% !1110 4444 ?U<_L^_"K_A1/P%\$>!_M_]J_\
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M:+_UX0?^BUK6K^H#\$EN%%%% @HHHH **** "BBB@#)\??\ (B:U_P!>$_\
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MCMYOJ_T7EZA1117VA\X%%%% !1110 4444 %%%% !1110 4449H **-U&Z@
MHHW4;J "BC=1NH **-U&<T %%%% !1110 4444 %%%% !1110!^Z/_!LA_R8
M9XN_['Z\_P#3=IM?HO7YT?\ !LA_R89XN_['Z\_]-VFU^B]?SOQ5_P C:O\
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M_&?_ (-</AA8:M\7OBUXTDFO%U3P_H]AHMO"KK]G>&]FEFE9QMW%U;3X0I#
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MHHHK^83]L"BBB@ HHHH *_ES_P""@/\ R?E\;O\ L?M>_P#3C/7]1E?RY_\
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M^V"BBB@ HHHH **** "BBB@ HHHH **** /YL? /_(B:+_UX0?\ HM:UJR?
M/_(B:+_UX0?^BUK6K^H#\#"BBB@ HHHH **** "BBB@#T?\ 8Z_Y.Z^%?_8W
MZ3_Z6PU^^-?@=^QU_P G=?"O_L;])_\ 2V&OWQK\E\1O]YH_X7^9^C<$_P "
MIZK\@HHHK\Y/M@HHHH **** "BBB@ HHHH **** "BBB@#^;'P#_ ,B)HO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *_5K_ ((+:@M[^R?XNC79FT\:W$1VDDY.GZ>_.0,'YQT)&,<Y
MR!^4M?KQ_P $0OAC_P ()^Q2VLB_:\7QUXAO=:$+6IA-CY0BTXQ9)/F FP,@
M?"C$H !"AF^+X]G&.5V?622_%_DF?4\'Q;Q]UTB_T7ZGV!1117XF?J84444
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M_7Z.5^#\:?\ (YK?]N_^D1/UWA?_ )%E+_M[_P!*84445\N>^%%%% !1110
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MY:'RN,CRUY+S_/4****[#E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#T#]G:]EC\47UNK?N9;7S'7 Y974*<]> [?G7L%>#_!I<
M_$O3/]DRD?\ ?IZ]XKY7.8VQ%^Z7^7Z'T65RO1MV84445Y)Z04444 %%%% !
M1110 4444 %%%% !1110 4444 %?+O\ P6/_ &JKG]DC]@7QAK6DZE_9?BCQ
M#Y?AS0IE$XD6YN<B1XI(2IBFCM4N9HY"RJLD*?>)"-]15^(W_!SA\;_^$O\
MVH_ _@.WN-)N;/P7H#ZA-]GDWW5M>7TO[R&?#$+B"UM)$0JK;9RQ+*Z8^BX5
MRU8W,Z=*7PI\S]%K;YNR^9X^?8QX;!3G'=Z+U?\ DKL_-"BBBOZ&/R,****
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M:7N_?M^-E\S]TJ***_!3]4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPO7Z_?\ !KA\))H-#^+GCRZT:S-O=3V&@:9JS+$UP'C66>]MT.?-1");!VR
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M )$31?\ KP@_]%K6M63X!_Y$31?^O"#_ -%K6M7]+'X4%%%% !1110 4444
M%%%% 'H_['7_ "=U\*_^QOTG_P!+8:_?&OP._8Z_Y.Z^%?\ V-^D_P#I;#7[
MXU^2^(W^\T?\+_,_1N"?X%3U7Y!1117YR?;!1110 4444 %%%% !1110 444
M4 %%%% '\V/@'_D1-%_Z\(/_ $6M:U9/@'_D1-%_Z\(/_1:UK5_4!^!A1110
M 4444 %%%% !1110!Z/^QU_R=U\*_P#L;])_]+8:_?&OP._8Z_Y.Z^%?_8WZ
M3_Z6PU^^-?DOB-_O-'_"_P S]&X)_@5/5?D%%%%?G)]L%%%% !1110 4444
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M /&:];HH^O8G_GY+[W_F'U6C_(ON1Y)_PP'\"/\ HBGPD_\ "/T__P",T?\
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M /C-'_# ?P(_Z(I\)/\ PC]/_P#C->MT4?7L3_S\E][_ ,P^JT?Y%]R/)/\
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M?,]C(<8L-CH5);;/T>GX;G[K4445_/I^R!1110 4444 %%%% !1110 4444
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M_;W_ *4PHHHKY<]\**** "BBB@ HHHH **** "BBB@#^<>BBBOZ@/P,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _7[_@DI^VW+^TI\)I
M?"?B2]N;OQMX-A7SKN\N8WFUFT9V$<P'#LT0V12,P;),3L[-*0/KJOYZ_A!\
M5-7^"'Q/T+Q=H,WDZMX?O$O(,NZI+M/S12;&5C'(NY'4,-R.RYP:_<W]D_\
M:5TC]K/X'Z3XTTF'[%]LWP7M@UPDTNFW,9VR0N5_!U+!6:.2-BJ[L#\7XSX>
M^IU_K=!?NYO_ ,!EV]'JUT6W8_4>%\Z^M4OJ]5^_%?>N_JMG]_<]'HHHKX<^
MK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'Z\_]-VFU^B]?SOQ5_R-J_\ B/U[(_\ <*7H%%%%?/GK!1110 4444 %%%%
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M32N5CC0L-\DB*#EA7\RW[9/[6'B7]M3]H;Q!X^\375XTFIW#KIMC-<"9-%L
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MIK9GZEP[FRQ=#V<W[\='YKH_\_/U1T=%%%?&GT04444 %%%% !1110 4444
M%%%% !117EO[97[6'AK]BO\ 9Y\0>/O$UU9K'IENZ:;8S7!A?6K\HQ@LHB%=
MM\K+@L$;8@>1AL1B-*-&=6HJ5-7E)V2[MD5*D:<'.;LEJSX+_P"#E?\ ;+_X
M0GX4^'_@CI$VW4/&?EZYK_R?ZO3H)C]FB^:,@^;=1%]T<BNGV+:P*S<_B[77
M?'SXW:]^TE\:/$WCSQ/<?:-<\57\E_<[7D>.#<?DAB\QG=88D"QQH6.R.-%S
M@"N1K^BN'\HCEN"CAEOO)]Y/?[MEY)'Y!FV8/&8F59[;+R2_J_JPHHHKVCS0
MHHHH **** "BBB@ HHKZ,_X)/?LU?\-4_M]_#SPW<V?VS0[#4!KFM++IG]H6
MAL[/]^T5Q&<((9W2.V+/\H:Y48<D(W/B\3##T)UZFT4V_DKFV'HRK58TH[R:
M7WG[Y?\ !.G]G6?]E#]B'X;^ [R.\M]4T?2%GU2"ZGBGDM;^Y=KJ[A#Q#RV2
M.XGE1"I;Y%7YG.6/M5%%?S+B*\Z]65:IO)MOU;NS]JHTXTZ<:<=DDE\@HHHK
M$T"BBB@ KR'_ (*!_P#)A?QN_P"Q!UW_ --T]>O5Y#_P4#_Y,+^-W_8@Z[_Z
M;IZZL#_O-/\ Q+\T88K^#/T?Y'X'^ ?^1$T7_KP@_P#1:UK5D^ ?^1$T7_KP
M@_\ 1:UK5_2Q^%!1110 4444 %%%% !1110!Z/\ L=?\G=?"O_L;])_]+8:_
M?&OP._8Z_P"3NOA7_P!C?I/_ *6PU^^-?DOB-_O-'_"_S/T;@G^!4]5^0444
M5^<GVP4444 %%%% !1110 4444 %%%% !1110!_-CX!_Y$31?^O"#_T6M:U9
M/@'_ )$31?\ KP@_]%K6M7]0'X&%%%% !1110 4444 %%%% 'H_['7_)W7PK
M_P"QOTG_ -+8:_?&OP._8Z_Y.Z^%?_8WZ3_Z6PU^^-?DOB-_O-'_  O\S]&X
M)_@5/5?D%%%%?G)]L%%%% !1110 4444 %%%% !1110 4444 ?S8^ ?^1$T7
M_KP@_P#1:UK5D^ ?^1$T7_KP@_\ 1:UK5_4!^"2W"BBB@04444 %%%% !111
M0!D^/O\ D1-:_P"O"?\ ]%M7])U?S8^/O^1$UK_KPG_]%M7])U?E_B1_S#?]
MO_\ MA^@<#[5O^W?_;@HHHK\O/O HHHH **** //?VM/@S)^T/\ LQ>/O!-O
M'I;ZAXET*[LM.?45W6UK>M$QM;AB%8J8IQ%*'52R-&&4;E%?@'87T6J6$-U
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MR[6>$LT4;K(@)5XD++(@:)_W4^%7Q5\/?&[X>Z5XK\*:K;:UX?UJ'S[2[@R
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M@ HHHH _D7'2B@=**_J@_"PHHHH **** "BBB@ HHHH **** "OU&_X(K_\
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MJDMWT]%Y>>[\M$OS'.LZGCYI6M!;+]7Y_E^(4445]0>&%%%% !1110 4444
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M]"BBB@ HHHH **** "@]**#TH _KHHHHK^5S]T"BBB@ HHHH **** "O(?\
M@H'_ ,F%_&[_ +$'7?\ TW3UZ]7D/_!0/_DPOXW?]B#KO_INGKJP/^\T_P#$
MOS1ABOX,_1_D?RZT445_3Q^)!1110 4444 %%%% !1110!]=?\$(O^4K'PK_
M .XM_P"F>^K^BZOYT?\ @A%_RE8^%?\ W%O_ $SWU?T75^+>(W_(RA_U[7_I
M4C](X/\ ]RE_B?Y1"BBBO@#ZP**** "BBB@ K\.O^#D7]D2_^&W[3^G_ !=L
MUO+KP_\ $BWBM+Z5@SI8:E:0)"(R1&$C26VCB:-6=G=X;HX"J!7[BU\Z?\%4
MOV-/^&Y?V,/$OA&SA\WQ1IN-<\-?/MSJ-NK[(N9(X_WT;RV^Z1BB?:/,()05
M]%POFOU#,85I.T7[LO1]?D[/Y'D9Y@?K>#E3C\2U7JO\U=?,_FBHH/%%?T,?
MD04444 %%%% !1110 4444 %?:'_  1E_P""F_\ PP/\:[C2O%U_K$GPK\6C
MR]2M8#YT6CWA*"/4UAVL[;44QRK$59XV5B)6@BC/Q?17'C\#1QE"6&KJ\9?U
M=>:W1T87%5,/55:D]4?UH> OB%H'Q5\)VNO>%]<T?Q)H=]O%MJ.EWD=Y:7&Q
MVC?9+&61MKHRG!.&4@\@UL5_-;_P3P_X*E_$3_@G5KUY%X?6S\0>#]:N(I]4
M\.ZDS_9Y&5DWSV[J<V]RT2F/S,.A!0O'+Y<87]ZOV0_^"@OPG_;AT!;GP!XJ
ML[S5([<7%YH5W_HNKZ> L1?S+=CN9$::.,S1[X2Y*K(Q%?A?$'"N*RR;FES4
M^DDMO\7;\G^!^H93GU#&QY7[L^J_R[_H>T4445\N>X%%%% !1110 4444 %%
M%?,_[=G_  5:^$_[".@ZI;:QKEGK_CRVMV:S\):=/YE]--MB9$N&4,MFC+-'
M)OFP6CWM&DI78>C"X.MB:JHX>+E)]%_6B[MZ(QQ&(IT8.I5DHKNSU+]JK]JK
MP7^QI\%]2\=>.M2^P:/I^(H88@'N]3N6!,=K;1DCS)GVG R%559W9$1W7^=W
M_@H]^WQXE_;_ /VAM2\1:E>WB^%-,N)[;PKI$D8A32[ O\A:-7=?M,BJC3/N
M;<X"@B-(T3'_ &W?V^/B'^W_ /$FU\1^/+VS5-,M_LVF:1IL;PZ;I:D+YAAC
M=W;?*RAG=V9VPJYV)&B>+U^V\*\)PRV/MZ_O57]T5V7GW?RVW_,\\SZ6-E[*
MGI37WOS?Z+Y^A1117V9\Z%%%% !1110 4444 %%%% !7[+_\&RO[)\/A_P"&
MWC#XS:E:WD>J>(+AO#6C&:WEA06$1BEN)HF+;)DEN-D>=A\M[!U#Y9U'Y+?
M/X(Z]^TE\:/#/@/PQ;_:-<\57\=A;;HY'C@W'YYI?+5W6&) TDCA3LCC=B,
MU_49\ _@CH/[-OP7\,^ _#%O]GT/PK81V%MNCC22?:/GFE\M41II7+22.%&^
M21V(RQK\^\0,V]AA%@H/WJF_^%?YO\F?6\)X#VF(>)DM(;>K_P E^AUU%%%?
MC!^CA1110 4444 %>0_\% _^3"_C=_V(.N_^FZ>O7J\A_P""@?\ R87\;O\
ML0==_P#3=/75@?\ >:?^)?FC#%?P9^C_ "/P/\ _\B)HO_7A!_Z+6M:LGP#_
M ,B)HO\ UX0?^BUK6K^EC\*"BBB@ HHHH **** "BBB@#T?]CK_D[KX5_P#8
MWZ3_ .EL-?OC7X'?L=?\G=?"O_L;])_]+8:_?&OR7Q&_WFC_ (7^9^C<$_P*
MGJOR"BBBOSD^V"BBB@ HHHH **** "BBB@ HHHH **** /YL? /_ "(FB_\
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M_JG_  3F_P""F.J?LCZ];^&?%DUYJWPOOI,/&D9FN?#4C,2US;JH+20DDF6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?^E2/TC@_P#W*7^)_E$****^ /K HHHH **** "BBB@#\(_^#@_]@B']F_\
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MO_L;])_]+8:_?&OR7Q&_WFC_ (7^9^C<$_P*GJOR"BBBOSD^V"BBB@ HHHH
M**** "BBB@ HHHH **** /YL? /_ "(FB_\ 7A!_Z+6M:LGP#_R(FB_]>$'_
M *+6M:OZ@/P,**** "BBB@ HHHH **** /1_V.O^3NOA7_V-^D_^EL-?OC7X
M'?L=?\G=?"O_ +&_2?\ TMAK]\:_)?$;_>:/^%_F?HW!/\"IZK\@HHHK\Y/M
M@HHHH **** "BBB@ HHHH **** "BBB@#^;'P#_R(FB_]>$'_HM:UJR? /\
MR(FB_P#7A!_Z+6M:OZ@/P26X4444""BBB@ HHHH **** ,GQ]_R(FM?]>$__
M *+:OZ3J_FQ\??\ (B:U_P!>$_\ Z+:OZ3J_+_$C_F&_[?\ _;#] X'VK?\
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MT"BBBO!/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\N_^#F_]FO\
MX2CX+>!_BII]GOO/">H/H>K26^F^9(UG=#?#+/<+RD,,\1C17!4R:@<%6;#_
M *B5R/Q\^".@_M)?!?Q-X#\3V_VC0_%5A)87.V.-Y(-P^2:+S%=%FB<+)&Y4
M[)(T8#*BO5R3,7@<=3Q72+U]'H_P9PYE@UBL-.AW6GJM5^)_*+177?'SX(Z]
M^S;\:/$W@/Q/;_9]<\*ZA+87.V.1(Y]I^2:+S%1VAE0K)&Y4;XY$8#!%<C7]
M(TZD9Q4X.Z>J?DS\;E%QDXRW044451(4444 %%%% !1110 4444 ?8W[.O\
MP7=_:,_9[LHK&7Q59^/M+M[>2&&U\76S7[HSR^893=(\=W(X^95$DSHJ/M"X
M5-OVY\*_^#HGP'J_V_\ X3?X6^+O#WE^7]B_L/4+?6?M&=WF>9YPM/+VX3;M
M\S=N;.W:-WXNT5\YCN$\JQ3YITDGWC[OY:/YIGL87/L=0TC4;79Z_GK]S/Z(
MO#__  7P_99UG0+&\N?B'>:1<7=O'-+8W?AS4VN+)V4$Q2&&"2,NA)4F-W3(
M.UF&";?_  _?_93_ .BJ'_PF=8_^1*_G2HKQ'X<Y9?XY_?'_ .1/4_UPQO\
M+'[G_P#)']%W_#]W]E/'_)5/_+9UC_Y$KPOQY_P<^?"33O"=U-X8^'_Q&UC7
M$V?9K35%LM-M)<NH??/'/<.F$W$8B?+ *=H)8?B+16U'P^RJ#O+FEZM?HEO_
M ,,95>+<=)6CRQ]%_FV?HM\=_P#@Y7^-'Q _M6T\$:!X1^'VGW?D_8KGR6U;
M5K#;L,G[Z8BVDWLKCYK7Y4DP/F425\+_ !N^/GC3]I+Q[<>)_'GB;6/%6N7&
MY?M-_<&3R(VD>7R84^Y#"'D<K%&%C3<0J@<5R-%?38')\%@O]UI*+[VU^]Z_
MB>)BLPQ.)_CS<O+I]VP4445Z1QA1110 4444 %%%% !1110 4444 %%%% '[
MH_\ !LA_R89XN_['Z\_]-VFU^B]?G1_P;(?\F&>+O^Q^O/\ TW:;7Z+U_._%
M7_(VK_XC]>R/_<*7H%%%%?/GK!1110 4444 %%%% '\BXZ44#I17]4'X6%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5^^G_!"/_@G#-^Q[\"YO'7B[3;RQ^(_Q
M"MT^T6-_:11W'AZP21S%;@\R*\P\N:969<$0HT:O Q;XA_X(5?\ !*S_ (:<
M\?)\4OB1X9^V?"_0]_\ 9%O>MMA\1ZDDB@9A*GS[.'$GF9*H\H2/]ZJW$8_=
M*ORGCSB)2_X3,._\;_*/ZOY+NC[SA7)VO]MK+_"OU_R^_L%%%%?EI]P%%%%
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M5_!GZ/\ (_EUHHHK^GC\2"BBB@ HHHH **** "BBB@#ZZ_X(1?\ *5CX5_\
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MM\4O'NA^&-!M?MVN>(]0@TO3K;S4B^T7,\BQ1)O<A%W.RC+$ 9R2!S7](O\
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M .QOTG_TMAK]\:_)?$;_ 'FC_A?YGZ-P3_ J>J_(****_.3[8**** "BBB@
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M[2%8;>TAC4*D<:* J(J@*%4    <5<HHK\6;;=V?I&VB"BBB@ HHHH ****
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M***]@\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-^D_^EL-?OC7X'?L=?\ )W7PK_[&_2?_ $MAK]\:_)?$;_>:/^%_F?HW!/\
M J>J_(****_.3[8**** "BBB@ HHHH **** "BBB@ HHHH _FQ\ _P#(B:+_
M ->$'_HM:UJR? /_ "(FB_\ 7A!_Z+6M:OZ@/P,**** "BBB@ HHHH ****
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MGX\T445^]'Y"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/X9KHPM/VE:,/,PQ53DI2EY'C=%%%?<'R04444 %%%% !1110 4444 %%%%
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MWT_X+#_\$>+#]MS0;CQ]X"M[/3/BYIEN Z%EAM_%D,:X6"9CA4N54!8IV(!
M$4AV>7)!^!9Z5_717YSQWF-? U\+B,.[27/Z->YH^Z?]:GV7"^#I8JC7HUE=
M/E^7Q:KS/Y(_$'A[4/"6O7VE:M8WFEZIIMQ):WEG=PM#<6DR,5>.1& 9'5@0
M58 @@@U3K^E#_@HC_P $L_AY_P %%=!LY?$#7GA_QAHMO+!I?B+3D0W$:,KE
M(+A&&+BV65A)Y>4<$.$DC\R0M^!G[87[#/Q*_85\>0Z#\1-!_L_^T/.?2]1M
MIEN-/U>**0QM)#*O_ 6,<@25%EC+QIO7/O</\587,X\B]VIUBW^3Z_FNO<\G
M-LCKX)\WQ0[_ .?;]3R*BBBOJ#PPHHHH **** "BBB@ HHHH **** "BBB@
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MX,_1_D?@?X!_Y$31?^O"#_T6M:U9/@'_ )$31?\ KP@_]%K6M7]+'X4%%%%
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M2]5^JNO,_,\PRG$X*5JT=.C6S^?Z/4IT445ZQYH4444 %%%% !1110 4444
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MI:^NS_$_$LRP;PN)G0?1Z>G3\ HHHKTCA"BBB@ HHHH **** "BBB@ HHHH
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M'_P:ZC_\@T?ZU93_ ,_XA_8>/_Y],_.FBOT6_P"(9#X]?]#;\(?_  :ZC_\
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M-+S6/BEKEAEVAU!5L]%>59UDBD%G'EVVH@C:.:>6*0-)NC(953[T\/>'M/\
M".@6.DZ38V>EZ7I=O':6=G:0K#;VD,:A(XHXU 5$50%"J    !BKE%?GN/S3
M%XV7/BJCD_/9>BV7R1]=A<#0PT>6A%17];O=A1117 =04444 %%%% !1110
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MCG,,/C,?"KAIJ45!*Z[\TG^J/NN%\+6P^%E"M'E?,WKVL@HHHKXP^D"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#D?C=\ _!?[27@*X\,>//#.D>*M#N
M-S?9K^W$GD2-&\7G0O\ ?AF"2.%EC*R)N)5@>:_-O]K#_@V5\-^(+*ZU+X,^
M,+SP_JDEQ+,-&\2R&ZTW8\J%8HKB./SX4BC,N#(MR\F(P64[G/ZI45ZV6YYC
ML [X6HTNVZ?R>GZG!C,LPV*5J\$WWZ_>?S%_M5?\$VOC1^QOJ6I_\)IX'UA=
M#TS#MXBTZ![W17B:=H(I#=("D7F.!MCF\N7$D>Z-2Z@^%U_717A?QM_X)E?
M']H<7#^*OA3X0N+N\U!M4NK_ $^T_LJ_O+E]Y>2:YM#%-+O,C,P=R&8AB"P!
M'WV \2-.7&TOG%_H_P#,^4Q7!NM\-4^4O\U_D?S%T5^T7Q4_X-=O 6K_ &#_
M (0CXI>+O#WE^9]M_MS3[?6?M&=OE^7Y)M/+VX?=NW[MRXV[3N^4?B=_P;C_
M +1G@+08;S2D\"^-KB2X6%K'1=;,-Q$A5B96-[%;Q[ 5"D*Y?+KA2-Q7Z["\
M8937VK*+[2O'\7I^)\_B.'L?2WIM^FOY:_@?!=%>Z>._^"8_[0WPY\5W>BZA
M\&/B-<7EEL\R32]#GU2T;<BN-ES:K)#)PP!V.=K94X92!XOX@\/ZAX2UZ^TK
M5;&\TS5-,N)+2\L[N%H;BTFC8J\<B, R.K J58 @@@\U[]'%4:RO1FI==&G^
M1Y52A5IZ5(M>J:*=%%%;F04444 %%%7/#_A^_P#%FNV.EZ58WFI:GJ5Q':6=
MG:0M-<74TC!(XHT4%G=F8*JJ"22 !DT-I*[!7>B*=%?0'PQ_X)5?M&?%S79M
M-TKX-^.K2XAMS<L^M:>=$@*AE4A9KWR8V?+#"*Q<@,0"%8CZ ^"'_!N#\?OB
M.;>X\53>$?AY9C4%M[J&_P!1%_?BV^0O<0QV@DADX9@J//&S-&0=BE7/DXC/
MLNH+][6BO*Z;^Y:_@=]'*\95_ATY?<[?>]#\_P"BOVZ^"/\ P;(?"WPA]GN/
M'GCCQ=XVO+:_6X\FPBBT:PN;9=A^SRQ_OICN(<,\<\9VN NQEWG[$_9U_P""
M=7P1_91O8KSP'\-_#NCZI;W$EU!JD\;ZAJ5J\D7DN(KNY:2>-#'E2B.$^=^,
MNV?F,;XA9=236'4JC]++[WK_ .2GMX;A'%SUJM17WO\ #3\3\%_V3O\ @D;\
M=OVP+VUDT/P;>>'?#]U;Q7:>(/$L<NF:9)#-$\D,L3,ADN4D" !K>.4+YD9;
M:K!J_2/]E7_@VG^&_@73-+U'XL>(-8\=:XF9;O2].G;3M%^> *82R@74OES%
MW6998-X6/=$H#*WZ7T5\/F?'.98J\:3]G'^[O_X%O]UCZC!<,8.AK-<[\]ON
MV^^YD> _A_H/PL\*6N@^&-#TCPYH=CO^S:=I=G'9VEOO=I'V11@(NYV9C@#+
M,2>2:UZ**^.E)R?-+<^ABDE9!1114C"BBB@ HHHH **** "BBB@ HHHH ***
M* "O(?\ @H'_ ,F%_&[_ +$'7?\ TW3UZ]7"_M1?#'4/C;^S-\1?!FDS6=OJ
MGB[PQJ6BV<MV[);QS7-K+"C2%59@@9P255B!G )XKHP<E&O"4MDU^9CB(N5*
M45O9_D?SU^ ?^1$T7_KP@_\ 1:UK5]9Z!_P0<^/6AZ#8V/\ :GPAE^QV\<&_
M^W]17?M4+G']G<9QTJW_ ,.,/CU_T$?A#_X4.H__ "NK][_UGRK_ )_Q/R'^
MP,P_Y],^0:*^OO\ AQA\>O\ H(_"'_PH=1_^5U'_  XP^/7_ $$?A#_X4.H_
M_*ZE_K/E7_/^(?ZOYA_SZ9\@T5]??\.,/CU_T$?A#_X4.H__ "NH_P"'&'QZ
M_P"@C\(?_"AU'_Y74?ZSY5_S_B'^K^8?\^F?(-%?7W_#C#X]?]!'X0_^%#J/
M_P KJ/\ AQA\>O\ H(_"'_PH=1_^5U'^L^5?\_XA_J_F'_/IGR#17U]_PXP^
M/7_01^$/_A0ZC_\ *ZC_ (<8?'K_ *"/PA_\*'4?_E=1_K/E7_/^(?ZOYA_S
MZ9X1^QU_R=U\*_\ L;])_P#2V&OWQK\M?V?/^"-7QK^%_P >_ _B;5;_ .%K
MZ7X=\06&IWBVFNW\EPT,-Q'(XC5K!59]JG 9E!. 6 Y'ZE5^;<<YCAL77I2P
MTU)).]O4^XX3P-?#4:D:\7%MK?T"BBBOACZP**** "BBB@ HHHH **** "BB
MB@ HHHH _FQ\ _\ (B:+_P!>$'_HM:UJ^L] _P""#GQZT/0;&Q_M3X0R_8[>
M.#?_ &_J*[]JA<X_L[C..E6_^'&'QZ_Z"/PA_P#"AU'_ .5U?T'_ *SY5_S_
M (GXW_8&8?\ /IGR#17U]_PXP^/7_01^$/\ X4.H_P#RNH_X<8?'K_H(_"'_
M ,*'4?\ Y74O]9\J_P"?\0_U?S#_ )],^0:*^OO^'&'QZ_Z"/PA_\*'4?_E=
M1_PXP^/7_01^$/\ X4.H_P#RNH_UGRK_ )_Q#_5_,/\ GTSY!HKZ^_X<8?'K
M_H(_"'_PH=1_^5U'_#C#X]?]!'X0_P#A0ZC_ /*ZC_6?*O\ G_$/]7\P_P"?
M3/D&BOK[_AQA\>O^@C\(?_"AU'_Y74?\.,/CU_T$?A#_ .%#J/\ \KJ/]9\J
M_P"?\0_U?S#_ )],\(_8Z_Y.Z^%?_8WZ3_Z6PU^^-?EK^SY_P1J^-?PO^/?@
M?Q-JM_\ "U]+\.^(+#4[Q;37;^2X:&&XCD<1JU@JL^U3@,R@G + <C]2J_-N
M.<QPV+KTI8::DDG>WJ?<<)X&OAJ-2->+BVUOZ!1117PQ]8%%%% !1110 444
M4 %%%% !1110 4444 ?S8^ ?^1$T7_KP@_\ 1:UK5]::#_P0;^/6AZ%96/\
M:OPBF^QP)!O_ +?U%=^U0N<?V<<9QTR:M?\ #C#X]?\ 01^$/_A0ZC_\KJ_H
M/_6?*O\ G_$_&WD&87_A,^0:*^OO^'&'QZ_Z"/PA_P#"AU'_ .5U'_#C#X]?
M]!'X0_\ A0ZC_P#*ZE_K/E7_ #_B'^K^8?\ /IGR#17U]_PXP^/7_01^$/\
MX4.H_P#RNH_X<8?'K_H(_"'_ ,*'4?\ Y74?ZSY5_P _XA_J_F'_ #Z9\@T5
M]??\.,/CU_T$?A#_ .%#J/\ \KJ/^'&'QZ_Z"/PA_P#"AU'_ .5U'^L^5?\
M/^(?ZOYA_P ^F?(-%?7W_#C#X]?]!'X0_P#A0ZC_ /*ZC_AQA\>O^@C\(?\
MPH=1_P#E=1_K/E7_ #_B'^K^8?\ /IGQ7X^_Y$36O^O"?_T6U?TG5^//B'_@
M@Y\>]<T"^LAJGPAC-Y;R0!SX@U$[=RE<X_L[MFOV&K\_X\S3"XSV'U::ER\U
M[=+\MOR9]GPE@,1AE5]O!QORVO\ ,****_/3[$**** "BBB@ HHHH **** "
MBBB@ HHHH **** *?B#P_8>+= OM*U6QL]3TO4[>2TO+.[A6:WNX9%*/'(C
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M:,J_Y_Q/QQ\/YA?^$SY!HKZ^_P"'&'QZ_P"@C\(?_"AU'_Y74?\ #C#X]?\
M01^$/_A0ZC_\KJ/]9\J_Y_Q%_J_F/_/IGR#17U]_PXP^/7_01^$/_A0ZC_\
M*ZC_ (<8?'K_ *"/PA_\*'4?_E=1_K/E7_/^(?ZOYC_SZ9\@T5]??\.,/CU_
MT$?A#_X4.H__ "NH_P"'&'QZ_P"@C\(?_"AU'_Y74?ZSY5_S_B'^K^8_\^F?
M(-%?7W_#C#X]?]!'X0_^%#J/_P KJ/\ AQA\>O\ H(_"'_PH=1_^5U'^L^5?
M\_XA_J_F/_/IGKW_  ;^?\U:_P"X/_[?U^CE?(?_  2I_88\>_L6_P#">?\
M"<7'A&X_X27^S_L7]AZA<7>WR/M7F>9YUM#M_P!<FW;NS\V<8&?KROQWBK%4
ML1FE6M0ES1?+9KRBE^9^E\/X>I0P%.E55I*]U_V\V%%%%?/GLA1110 4444
M%%%% !1110 4444 %%%% 'BG_!03]F3_ (:O_9@USP[:Q>9KUCC5M#^;;F]A
M5ML?+HG[U&DAW2':GG;\$J*_#+-?T<5^,_\ P5Q_9^G^"G[8&LZI!8_9]!\=
M?\3NQE0RNCSM@7:L[C'F?:-\A16(1+B+[H8*/TSP]S5J<\OF]'[T?7JOFM?D
M^Y\'QGEZ<8XR&^S_ $?Z?-'R_1117ZH?GX4444 %%%% !1110 4444 %%%%
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MQ%6I_$DW;NVRZ=*$/@27H@HHHK$T"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^1<=**!THK^J#\+"BBB@ H
MHHH **** "BBB@ /2OZZ*_D7/2OZZ*_*_$S_ )AO^W__ &P^[X+VK?\ ;O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&UO[B*$,S"-7EC9@@9W8*#@%F/4FLF?]B/X+W.FBSD^$/PODLPJH(&\*V)C
M7&!M\K&!@8],5ZA171'&5XKEC-I>K,98>E)WE%7]$>51_L)_!"'39+-/@W\*
MELYFWO /"5@(W/')7RL$\#\A3]+_ &&_@GH?F?8?@_\ "VS\W&_R/"EA'OQG
M&<1#.,G\Z]2HJOKV)_Y^2^]_YD_5:/\ (ON1YSX#_8^^$GPK\56NO>%_A;\.
M?#>N6._[-J.E^&K.SNK?>C(^R6.-77<C,IP1D,0>":]&HHK&I6G4?-4;;\W<
MVA3C!6@K>@4445F4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SS_P4L_9"E_:[_9WF
ML='M;>;QEX?F&HZ&TCQPF9ONS6QE93M66/.!N13+' 78*I-?0U%=.#Q=3"UX
MXBE\47=?UV>S.?%8:&(HRHU-I*Q_./17UC_P6$_9D_X45^T_-XBL(MN@_$7S
M=6A^;/E7H8?;(_F=G.7=)MQ"J/M.Q1B,U\G5_1>7XZGC,-#$TMI*_IW7R>A^
M*XS"SPU>5"IO%V_R?S6H4445V'*%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>Y?\$U+_
M %S3OVZ?AO)X=LK;4-0;4FBEBG8*JVCPR)=R#++\T=LTSJ,G+(HVO]T^&U]F
M?\$1/@M)X\_:IN_%TD=R+#P'ILDJRQ31JOVNZ5[>*.1#EV5H3=ME<8:)<L,A
M6\G/J\*.75YSVY6M=KM62^;:1Z63T95<;2A'?F3^YW;^21^ME%%%?SJ?M053
M\1:RGAW0KN^DVE;6)I K/L#D#A<^I. /<U<KR_\ :!\7\P:+!)Z3W6UO^^$.
M#_P(@C^X173@\.ZU50^_T.?%5O94W/[O4\TO;V34;V:XF;?-<.TDC8 W,3DG
M XZGM45%%?;K31'R84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% ':? SPRVM>,%O&56M],'F-N4,&=@0@Z\$<L#@X*=L@U[9
M7*?!SPO'X=\&6\WR-<:DJW,CCNI&47. <!3T.<$MCK75U\=F6(]K7;6RT7]>
MI]1@:/LZ*3W>H4445P'8%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '\BXZ44#I17]4'X6%%%% !1110 4444 %%%%  >E?UT5_(N>E?UT5^5
M^)G_ ##?]O\ _MA]WP7M6_[=_P#;@HHHK\K/N0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 ?R+CI10.E%?U0?A84444 %%%% !1110
M4444 !Z5_717\BYZ5_717Y7XF?\ ,-_V_P#^V'W?!>U;_MW_ -N"BBBORL^Y
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
M(N.E% Z45_5!^%A1110 4444 %%%% !1110 'I7]=%?R+GI7]=%?E?B9_P P
MW_;_ /[8?=\%[5O^W?\ VX****_*S[D**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3R2<UX^;8SV</91W?Y?\$]3+<+SR]I+9?F6****^7/H HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^1<=**!THK^J#\+"BBB@
M HHHH **** "BBB@ /2OZZ*_D7/2OZZ*_*_$S_F&_P"W_P#VP^[X+VK?]N_^
MW!1117Y6?<A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBZ-9:='U3[H_G'HK]/\ _@J)_P $N_\ A8W]H_$KX:Z=_P 5)\USKFAVR?\
M(8[M<VZC_EYZEXQ_KN67][D3?F!7[QDV<T,RH>VH[]5U3_K9]?O1^1YIE=;
MUO95=NCZ-?UNN@4445ZQYH4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 445^@/_!-/_@E)>>)M7A\=?%K0[JQTNQF/]F>&M1MVBFU"
M5&QYUW$X!6!6'RQ, 92,L/*P)O-S3-L/E]!U\0_1=6^R_K3J=V7Y?6QE54J*
M]7T2[LK?\$O?^"77_"R1I_Q*^)>FY\-G;<:'H5S'_P ACNMS<(?^7;H4C/\
MKN&;]U@3?J!117X/G.<U\RK^VK;=%T2_K=]?N1^NY9EE' T?94OF^K?];+H%
M%%5]4U2WT73Y;JZE6&WA7<[MT _J3T ')/%>2DV[(]!M)79!XE\2VGA/2)+R
M\DV11\ #EI&[*H[D_P#US@ FO O&/BF;QEXAFOYE\OS,*D88L(D'11G\2<8R
M23@9K2^(_P 2+CQY?[5#0:?"Q\F$GD]M[?[1'X ' [D\S7UF6X'V,>>?Q/\
M ^<QV,]M+EC\*_$****]0\\**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "G0Q/<3+'&C222,%1%7<S$\  =R?2FU[#\&/AI)X=B;4
M]0A1;R90((V7Y[9><D^C-GIC( QGD@<N,Q4:%/GEOT7<Z,-AY5I\J^;-[X;^
M!$\!Z$82ZS75PWF3R!<#.,!0<9VCMGN2>,X'0T45\;4J2J2<Y;L^JITU"*C'
M9!1116904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!_(N.E% Z45_5!^%A1110 4444 %%%% !1110 'I7]=%?R+GI7]=%?E?B
M9_S#?]O_ /MA]WP7M6_[=_\ ;@HHHK\K/N0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 59T?1[SQ%J]KI^GVMS?7]],EO;6UO$TLUQ*[!41$4$LS,0
M "22 *VOA9\(O%'QN\70Z#X2T+4O$&K3;3Y%G"9/*0NL?F2-]V.(,Z!I'*HN
MX%F YK]=?V$/^"8WA?\ 9"^R>)-2F_X2+X@/9^5->N ;/3';=Y@LU*AERK",
MROEV53@1+(\9^?S[B+#993O/WIO:*W^?9>?W7/8RC):^/G[ND5N_\N[_ *9Y
M+_P2Z_X)>?\ "NAIOQ+^)6G?\5'\MSH>AW,?_('[K<W"'_EYZ%(S_J>&;][@
M0_?5%%?B.:9I7S"N\1B'KT71+LOZ\V?JV7Y?1P=%4:*TZOJWW8444V>=+6!Y
M)'6..-2SNQPJ@<DD]@*\T[@GG2U@>21UCCC4L[L<*H'))/8"O%?BI\5)/%\[
M65DS1Z7&W)^ZUT1W/^R.P_$\X 7XJ?%63Q?,UC8LT>EQMR>C7)'<^B^@_$\X
M XJOILMRWD_>U=^B[?\ !_(\''8[G_=T]NK[_P# "BBBO:/)"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKLOA;\*Y/&DRWEX)
M(M)C;'!VM=$=54]0O8L/H.<E<JU:%*'/-Z&E*E*I+DAN:7PG^$/]L"+5-6B_
MT/[T%LX_X^/1F']ST'\7?Y?O>N445\;BL5.O/FG\EV/J,/AXT8\L0HHHKF.@
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /Y%P,45_7117ZI_Q$S_ *AO_)__ +0^%_U+_P"GW_DO_P!L?R+T5_7111_Q
M$S_J&_\ )_\ [0/]2_\ I]_Y+_\ ;'\B]%?UT44?\1,_ZAO_ "?_ .T#_4O_
M *??^2__ &Q_(O17]=%%'_$3/^H;_P G_P#M _U+_P"GW_DO_P!L?R+T5_71
M11_Q$S_J&_\ )_\ [0/]2_\ I]_Y+_\ ;'\BSMM0D\ #))[5_73117RO$W$W
M]K^S_=\G)S?:O>]O)6M8][)<E_L_G]_FYK=+6M?S?<****^5/<"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZD9Q4X.Z?5;'PTHRB^62LT%%%%42%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%;7PY^'.N?
M%SQQIOAOPWIMSK&N:Q,(+2T@ W2-@DDDX"JJ@LSL0JJK,Q !(F4HQBY2=DMV
M5&+D^6*NV8M>]_L??\$Z_'_[8-^MUI]K_P (_P"%4V/+KVI02+;3H9C&ZVH"
M_P"D2KLE.U2$!CVO)&67/UW^Q)_P1=M/"-U9^)_B\UKJFI6\T5U:>';6836,
M8\O<5O24Q,PD8 QQGROW7+S)(5'WSHVCV?AW2+73]/M;:QL+&%+>VMK>(10V
M\2*%1$10 JJH       K\[S[CJG2O1R[WI?S=%Z=_7;U/M,GX2G4M5QNB_EZ
MOU[?GZ' ?LT_LG>!_P!DOPC-I/@O2?L?V[RGO[V>4S7FI21H$#RR-_P)@B!8
MU:1RJ+N.?2***_*JU>I6FZM63E)[MZL_0J5*%*"ITTDELD%%%9/C#QM8^"-/
M6XO7;,C;8XHP#)(>^ 2.!U))QT[D Q&,I/EBM2I3C%<TM$7M3U2WT:PENKJ5
M8;>%=SNW0?XD] !R3Q7B/Q!^*MYXUFDAC9[;2RP*0<;GQT+GU[[<X&!U(R:/
MC7Q]?>-]0>2XD:.UW9BME8^7&!G!QW;DY8\\]A@##KZ?+\M5+]Y4UE^7_!/G
M\9CW5]V&B_/_ ( 4445ZYYH4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%>B_"'X3#6%BU;5(_]$X>V@8?\?'H[#^YZ#^+K]W[V
M&(Q$*,.>9M1HRJRY(F9\*_A9)XTG6\O T>DQMC@X:Z8'E5/90>"WX#G)7VRW
M@CM($BBC6..-0B(@VJ@'  '8"DM[>.SMXX88TBBB4(B(NU44<  #H!Z4^ODL
M9C)XB?,]NB/I<+A8T8V6_5A1117&=(4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRJDIXA7Z:_U\S@S*HXT&EUT.-HHHKZX^:"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBN@\&_#;5/&=Q$88)(;)FP]U(N$4<Y*YQO.5(
MPO?&<#FHJ5(PCS3=D5"G*;Y8J[.?)P*[WP9\";[6'6;5B^GVC*3L5A]H8D#;
MP00HY.=W(*XV\Y'>^"OA3I?@J5+B-9+J^52/M$I^[D ':O11P?5@&(R0:Z:O
M Q><-^[0^_\ R/:PV5I>]6^XKZ7I=OHNGQ6MK"L-O"NU$7H!_4GJ2>23FK%%
M%>$VV[L]A*RL@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!B^//AKX<^*>D1Z?XG\/Z+XCT^&87$=MJEC%>0I*%90X216
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M*S'%8G_>*DI>K;7W'K8?!8>A_!@H^B2"BBBN,Z@HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI)YI"0D<:EF; ). .>@)_"O>-&^$OA_157;I\=Q(L8C9[C][OZ98J?E!..H
M[XP.*WK&P@TNU6"VAAMX4R5CB0(JY.3@#CDDG\:XJF>07P1;]=/\SKIY3)_'
M+[CQ'1O@IX@U9EWVT=E&\>\/<2 >F 57+ \]"!C!S@\5VVA?L^:98N'OKFXU
M!E8_(!Y,9&, $ EL@\Y##MQZ]]17FULUQ%31.WH=]/+J,-6K^I3T;P[8^'8?
M+L;.WM5*JK&- &<+TW'JQY/)R>35RBBO/E)R=V=L8I*R"BBBI&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex1012022063010qngcbasho001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;3AMC X/OB@"2BF2310@F65$PI8[F X'4_3D4@GA:18Q+&79=ZJ&&2OJ!Z4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%1S7$-OL\Z:./>X1-[ ;F/0#/4GTH DHHHH **** "BFNZQHSNP5%&2S'
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MRC>A5LJQ4Y!Y'(-7*AM;6&RMU@MXPD2DD*#GDDDGZDDG\:FH **** "BBB@
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M+$0(([;LY4<YH Y;P;JA35];T+3#;)=+K-W<3+*IVI!OV@J 1N)88XX'.<<
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M"_@."72]2L9-7OW74;Y+^9R(LB12A&,)@ F-,_3C% $\NNZM?3ZJ-#M;:?\
MLRZ2U>&9BK3MM1WVMD!,*XP2#D@]*J:IXMOM-UF*WD@MO)?5(+ 1+EY/+E"@
M2LRG"?,QPC#)"YSS5N7P;&==NM2MM6O[1+[9]OM82GEW)4;0>5)0D  E2"0/
MQJO<^ K>>>Y==7U&&*;4DU18D\LB.=2IR"4)(.T<$D#TH /"\:1^-O&RHBJ/
MMEL<*,<FVC)/YU@^-4DT?QFOB^V4EM(M;;[8J#F2TDDF67CN5PKC_<KMM,T*
M/3-8U744NII7U*1))4D"[4*($&W !^ZHZDTZ318Y]2O+J>9Y8KNV6UEMF5?+
M* O[9_Y:-GF@#A/&LJZQXC\,72.)+"TUVVMX\'*RR,C.[>A  0 ^I<5O:IXM
MOM,UB.!X+;R'U."Q$2Y>0QRA0)2RG"?,QPC#)"YSS4[^!+!=(T+3+6ZN;:VT
M6XCN;<)M)>1,\N2#G.YB<8ZU'<^ H+B:Y9=8U&*.;48]3$2>61'.I4Y!*$D'
M:."2!Z4 9]]XTUNTAUV\%EI_V71]2CM95WN7EC81'*] &'FYR<CC&.]7=9\6
MWVDZL(F@MO(_M&VLQ$,O(T<I5?-+*<1_,Q 5AD[#SR*GNO UO=V&M6;ZE>"/
M5[I;J<@)E64( %^7IB->N>GO45UX!ANI+P_VQJ,4=S?1:B8T\K"7$90[@2A.
M#Y:_*21[4 5]7\9ZA:)K4UG:6[#2[^"R-M-N$D_F>7AU(/ S)P,'.T\\\2WO
MBK5V>_\ [)TP7LFG7"6\UNL;$SMM1GV29"I@/QN!SCMD5B3V6J2>)M1N8YM>
MLKYK@B!%TV"YA9%4*C+,R':& W$%UP6/?)/1#P8[:K+J2ZO>V;WRH=2M+4KY
M-RZJ%)&Y2R9 P2I!( [\T 9^L>+]<LF\5/;6>GF+04CG(E=RTT9C\PCC&&QW
MY ]#GB6Z\:7FD7]X-5M;8VJ:0^JP_9V;> C!3&Q/!)W+@@#OQWK0O/!EO>_\
M)$'O[I5UV)8KA5"?NU";/D^7CY?7-.N?!EG?7HGO;F>=#IKZ9)"P4+)$^"Q.
M!D-E1R"* *4_B/Q!9IJ<LFEQRV]OISW<5P8WA02+R8F#$D\<AACH>!4-KXIU
MN:ZL[>XAL(CJ.COJ%J\8=_*=!'E7!(W ^8#QC&,<]:O6?@UX-'NM-N=?U.^B
MEMFM(FN#&6@B88.,*-S8Q\S9/'US/!X1@AO=+N6OKF0Z=8O81HP0!XVVY+8&
M<_(O3'2@!? UW?:AX(T:^U&X2>XN;2*9G5"I.Y >>3DYSSQ]*ROBM%'+X)(D
M17 O[/&X9ZW$8/Z$U<LO#%[HUOH5CIVL7[6FGL5=9?*VO"% ", H)P!QCN22
M>@K1\2^'HO$VEC3Y[N>WB\V.8M %W$HP=?O \944 8^K^(];MM=U;3-.M=/V
MV.FI?I).SG=DR#:0,?\ //UXSGGI3K3Q5?Z[%LT6WMUNETJWU!DN<L&:96,<
M0P1C[ARW;(X/.-"?PNEQJM_J+:A<B:]L%L9 %3:J L01\OWLNW7(YZ5GIX"B
MM9-.GT[6M1L;FSLDT]YH?+)N($^Z'#(5W#LP /)H ZJU>:6TADN(1#.T:M)$
M&W;&(Y7/?!XS3Y&98G9$WL 2%SC)],UE3Z1,BS_9=2O8HC8_98H(RA\MAG$B
MEADOR!\QQQS4EEIUP_AJ/3=4N7N)GMC#/-D!FR,$Y '.#U '/- &'H'BN]U'
MQ!;Z7>16I,^FF]+6X8K$ZNJM'OR5DP7^\N!D'BJNO2G4_B?H6@70W::EE-?M
M"WW)Y58*H8=PN2V/7!["M'1_!<>DZAIU[_:]_<26%DUBBRB,*T.5(4[4'38.
M>I[G'%:&N>';;6IK.Z\^:TU"Q<O:WEN1OCR,,.00RD<$$8- !J&F6]I/)KMG
M8QOJ5M:2I&JLL7G @,$9CP!E%Y/3GWKFV\13:Q;^(-'O$M9TCT=;M9H8V5&#
MB0%?F)# %,A@<'/M707OAS^UM(O-/U74+FY6ZMWMV9 L>Q6&"5 'WO<Y_(G-
M*/P4!=7-U-K6H33W.G#3Y6=8@"@+8; 0 $;V]O4&@#+T+46MXO %B;*UD6ZT
MDE;EQF6$I A(7T!R,\]JS+'4'L;;7=0U6.SU"9/$?D6BM"5*W+>5$C!BQVJ
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M<0LH^;/I@>U &'HNO>))--\(ZW>ZOYPU2]%E<V2V\:Q;2LF'!QN#YC!/..2
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M?*?W0&< L"&(K;T^SU"#7-4N9[V>6RG\LV\$NW$3 $-LP,[3\O4YSG\<G5_
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M'VVYMHK=),-(L4C)E58Y/"Y.*Y?0[>\L8?AQ-/IU^HM=.FM;A?LLFZ&1HXP
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M*"X@EUR_5TD0$$>:: ->W\ :';W\U\6U&:YDRHDEU&<M&A.=BG?D+GG%7?\
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MG-67UG6SX3F\;#6+@%+]@NG!(_(\A;GR?+(V[MQ4$[LYS[<4 >H45YAJVO\
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MN$2.[MK64+#<A!M7>""0=O&5(.*M3>%[635=1U".[NX7U"W6">.-EV':&56
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MKA58#A<(%QZ9%=+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4457CO[2:^GL8[B-KJW57EA#?,
M@;.TD>AP?RH L455M-1LKZ6YCM+J*9[64PSK&X)C?&=K>AYJ&VUW2;R6WBMM
M0MY7N#((520$R>6</M]=IX/I0!H457EOK2&^@LI+B-+JX5VAB+89PN-Q [XR
M,_6L!OB-X,1BK>)]+# X(-RO!H Z>BL/4?&?AK2)T@U'7+&UEDC$J)+,%+(>
MC#V.*G7Q+H;Z*^LIJUD^F1\/=K,IC4Y P6!P#D@?C0!JT5S]CXY\*ZG>Q65C
MX@TZXNI3MCBBG5F8]>!6G?:OIVFSVD%]>P6\MW)Y5NDKA3*_]U0>IY'YT 7:
M*JZCJ5CI-D]YJ-W#:VR8W2S.%49Z#)[U#I.NZ5KT,DNE:A;W:1MMD\IP2A]"
M.H_&@#0HHJE+JUC#<64#W*>9>R-';A<L)&52S#(X& K=?2@"[1110 45@ZEX
MU\,:/?26.I:[86MU'@O#-,%9<C(R#[$&M+3-5T_6K);W3+R&[M6)"RPN&4D<
M'D4 7**** "BJ*:Q82:W+HRW .H10"X>':>(R<!LXQU'KFKU !1110 4444
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MHNH,RVJ&VE\R7;][$>W=@>I&.E;U !115*[U:QLH8)IIOW<\RV\;1HT@+DX
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M#$ VY=K;5''()SS70>%=!G7Q-K?BF_T[^S[K4BD<5LTBN\<:* 68J2H9R 2
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MCT>ZL+1-X 82(!@YXR2B\FGZ#X/L],FL;Z26\FN;:V\F"*XG,B6H8#<(QVZ
M9YX&!Q0!Y]X!N+NX\%^!M!@O9[.WOVU"6XEMV"R,L4K$(K8^7)<$D<X6M>XU
MC6-'M]3E_M&YNK;PWK,8G>0@M-921(75\#YF3S"V>OR5U,'@/1[30=.TFU:[
MMTTZ1Y;2XBF(FB9RQ;#=P=[ @@@BH[_1SH?A>\T_1](GU:?4&D$WG7"YD>12
M#),[D97@ [<G& !0!)H-]=:QXJUV\6Y8Z5:,EA;1@_(\BC=*_N<L$_X :PKV
MR9_BSJDIO;L*F@)*(A)\G+R+MQC[O&<>O-=7X3T"/PQX6T_1XW\PVT6))/\
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M[8U9]]M>GS7N 77:$/!QQG.#]!1X;UGQ%J5SI>KI;Z[*+JZ?[6LOE?8UMSO
M$8#;@5PG.,G#9ZUZ!=:%97FO:?K,H?[98)+'"0V%Q( &R._051L_!^G6.II=
MP3WHBCF>>*S-P?L\4CYW,J?\";@Y R< 4 8/A2UU77-$TKQ#-XCO(Y-2C:2Y
MMB5,6QU;:D0XV,GRX;DG:<YS7*Z7=ZAHOPN\*W-IJ=X)+W7(8I2\F?D:9PRC
MC@'&3[UZ)8^!])T_4H+N%[QH[:1YK6SDG+06[OG<R)V/S-CJ!N.,5#%\/]&B
MTV#3O,O7L[>^2^MX7GR(75BP"\?=R3Q0!@ZCXDU31;;Q9I#7#S:J+F/^R&<_
M,5NCMB ]0C[Q]%K/N]0\2M>ZO%I_]OWEYI$D5K:&W\K[/*R11NQF#,"Q<L<\
M< C'-=_?^%M+U+Q%I^N7,3M>V (B(?"GKC<.^-Q(]"34%_X/T[4-3FO6GO8?
MM!0W4$%P4CN2F I<#V '!&0 #F@#0UPY\.ZD2,?Z)+Q_P US/AW3M+U+X/:-
M;ZO!#)9'1X3*90,*OE#+9[$=<]J[&YMTN[6:VESY<R-&V#@X(P:Y.'X:Z,EE
M#83WNL76G0JJ+8SW[F JO12@P"!@<'B@#DM+U34K_P (>'()+W7I+X:0;AX-
M-$:/MSMCFEDD91C"\+WY)SBI-.N[K4/%6AZ]<WET9V\)?V@\4<FU'?=$67&/
MNL>2/4"N]U'PGIVI7\5V[7,!6 6LD=M*8TFA!R(W ZJ"3TQU(Z&JUIX&TNQF
MTJ6WN+Y'TR VT1\_.^ L&\I^/F48&!Z"@#G/!E_XAN[[1+R6+7);>^MC)J$E
M[Y7V<,R;T:$*Q*C=\H&.0PSR*Z#Q9=7<FK^'M$MKR:SCU*XE$\\! DV1Q,^Q
M21P20.1S@&K6D>$-/T6[BFMKB^>.!&CM;>:X+Q6ZGJ$7\ !G.!P,5<UK0K37
M8($N6FBEMY1-;SP2%)(7 (RI^A((.00: . OM3UFRN;W08-8NC]FURPMX;R3
M:\HAG4%D8D8;!)P2.XSFNE\,M=V?BSQ!HLNH7=[:VT5K/ UT^]T,@D##=CD9
M0'VR:NP>#=*AMDB)N9I!?)J$EQ+*6DEF3&UF;N  !@8&!6E;Z3:VVL7NJ1A_
MM-Y'%'*2W&(]VW [??- ''7]DTOQB63[;=JJZ$\PB63"9\U5*XQ]T\$CU%8?
MA?[?HGAGP!J$>K7LJWQBM9K1F'D^4;>1E"KCA@47G.3SGKBO0[[PW9WVO6NL
MM+=0WEO$8,PR[5EC)#;''<9&:;#X6TV#3=%L$67R-&D22TR_(*HR#<>_#&@#
MB?!VK>(M3N-!U0PZY)'J :2_-SY7V18W1F0Q -N7:VP#CD$YYK8^)=JUS:>'
MD6[N;<-KEI&?(DVY#/U^HP"/0UL:;X/T[2K^*YMY[TQ0%VM[1[@F" OG=L7\
M2!G. 3C%7->T&T\0V"6EV\\8CF2XBE@DV/'(ARK*?44 >?W6J^(KC5-7DTV+
M7KBXTZ^6VM$@,7V5D0)N$H9@69LL2<<97'2KL$VJW5]XVOY-9O5BTF::.SMH
MV 0'[,K9;C)P2"!G@Y/>NDD\%Z=+?&Y-UJ"B1HY+B%+DK'<N@ 5Y .IPJYQC
M.!G-78O#MA#'K$:B3;JTC2767ZED$9QZ?*HH X2SCUF2\\'H_B34R-=L7>^&
M]>"L22#RN/D.21GJ0?7FFQ77B";2A&;C6;ZPT[5;VTN9-/=/MC(C8A8YP6 Y
M!V\GC@\UWL7AVPAET>11)NTB%H;7+]%*!#GUX452E\%Z>2TEM=:A9SM<S7/G
MVUP4?=*09%Z$%257@CC Q0!H>';J.]\.V%Q'?/?H\0Q<R1^6TG;++QAO48'.
M:TZJ:9IMMI&FP6%FA6"!=JAF+$]R23R23DD^IJW0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?K&
ML0Z+:)/+#<3M)*L,4-M'ODD<] !P.Q.20.*T*YCQI'J$EMIHM8]0ELOM8^WQ
MZ=(4G:+8^ I!!QOV9VD'&?>@ ?QWI4=C:W+PWP>YO'L1;>1F5)U5F,;*#U^7
M@C(Y'..:0>.],_LV>ZDMK^*X@NUL6L7A_P!(,[ %4"@X.0P(.<8[\5RNBZ#J
ML.HZ>CZ3>6\4'B*2^)GF\XK ]JZJ2Y8EB"0IY.">I'-3ZMHFK1^(M1UF'3IK
MB.WUVTODBCQOGA6U$3E 2,D%B<'&=M &_P"&?$5SK7BOQ#;2+<0V]G':^7:W
M$01X7=7+@XZYPIZD>E6=7\::=HU[<6TEO?7 M(UEO);:#>EJC9(,ASZ G !.
M.<53\+1ZA/XN\2:M=Z9/8VUXEH+83[0[A%<,2 3@Y/3T([\"K,^L>'/$OB&>
MTT.ZU/\ M4PS6;PLH19%B$924D@H,J#G!X)[C% &GJ/CG3-/N;N,6U_=Q62+
M)>7-K!YD=LK+N!8YR?E(8A02 <TM_P"-].L[V>SAM+^_GAMX[IELH1)^Z?=A
MP20,?+]>1@&N?N8-9TD>*[!-$N;Z36G:>TFMRIB#O D;+(6(*A67.2.0?7BM
M#PWX?O=(UG4DEC+0C1K"SCG[2/$LH;'YK^= &A)XWTPM9+9P7NH&[M%O@+2#
M>8X&Z.P)&,\X RQP>.*PO#WBR:]L/!LE]JER;K5#=8CBMXREUL#$!SC*8 !&
MW&3UJAX6L=9\)OIEQ/H=[=BXT&ULW2WV%H)XBY*OEA@$/][ID&H]%\-:U;R_
M#@W&GNATU[XWN",0[T8+GV)/% &C_P )^;_PMJ.I7":CHR6NI?95GCMT=F'G
M; N&)&>,-Z9XKH=5\:6&EWMW;?9-0N_L,:R7LEK!O2V4C<-YR"3M^;"@G'.*
MX34M"UNY\#ZYH<>CW?VH:Z;N-L+LFB>Z\P,ASSA>3G&*W[R+5=%U'Q7#!HMW
MJ"ZRPFLY8-A3>85B*2$L-@!0'/3!]1B@#9O/'&G6UX]I;6M_J$Z6L=YMLH0^
M87W8<$D#'R_7D8S39?'FE"*"6UM[^^ADM([YY+2W+B&!\[7<9!YVMP 3\IXJ
MAX3\.WVB:S-'/&6ABT.PLEG'W9)(O-#@=^Z_G7,0Z)JEAX5T>&+1-9MM?MM)
MBAMKW3YU \T;OW4ZE@NP-@_,",,<$&@#U#5=6MM'TN34+G>84V@+&NYG9F"J
MJCN2S #ZUE-XSLTLO-EL-2BNC<BU2Q>WQ/)(5W@*,[2-N6W;L  Y/%6?$-NU
MSX7F@N]+.J;E03VL,FQG&X;BA)'S+RPY!R!R#7!2Z'K%U%:W<L'B&?2[#4=\
M$$MT4OQ"T!1R'5@Q <C +;BN[KQD Z+5/B%';1:1)9:7?7#7FH-930F+$D#J
MK%D(W#Y^!CL1DYZ9O^/_ !!=^&O!.HZI8P2274<1\LJ@81,0<.P)^Z/QYQ7+
MW.C7%IINC:C8:#JH$.OB^N+>:Y-Q=.GDO%YAWL>3\GR[C@?C74>/["[U?X>Z
MS96-N\MU<6I6.$8W,QQQ0!G:/XLDLM*L+6^BUK5=7N(3<-%]DB681C +D)M1
M4R<#G)]ZO7'C_1H;32IX4O;LZHLIM(K> M([1X#IM."&!)!!Z;3G&*H/!J&@
M^)[76?[+O+ZVFT>*RD6T57DAEC<L,J2."'(R.A7GK6=H?AK5K/5O"5S=690Q
M3:G=72A@PMC<-N1"1WYQQW!H ?K'CZ_>Q\9P6=A=V4^CVF^"YDB7Y7\O?\P)
M(SR"!CD=:Z;2/%MIJFIIIIM;ZWN)+<W,#W,&Q;B,$ LASV++P0#R.*Y+7M*U
M:2X^(=G#I5U+_;%I&UG,@4QN5MQ&5)SD-N'3%=/=:==OXZT"]2!C:V^GW<4L
M@Z(S&':#]=K?E0!5UGQ-<Z1X\M-/\J[NK:?3)95M+6%7=Y1(@#9., *6ZD#\
M<5;'CC3)=.L+JT@O;N6^,BPVD$/[X&,XDW*Q 7:>#D]2,9R*I:R-0T_X@V>L
MQ:3=7MBFE2VTK6P5G1FE1AA21G[O:N7B\+ZC;MIVLW^GZMMEFU"2XM=-NFBN
M+<7$RR1Y*.NX87# $\D>E '0:AXMFNO$W@@:3=,NG:M+=+<QM$ S>7&2%;<,
MJ58$$#'(Q6FGCO2WNT06]]]B>Z^QIJ)@_P!&:;=LVALYQN^7=C;GO7.)X;NX
MM:\"7%GI%U:VMI<7T]TDUQY[PF5&(+N2269CD\G!)&3UJ"+2=8/A*V\$G2+I
M98K]"]^=OV?R%N1-Y@;.2Q4 ;<9R?3F@#J[SQWHMCX?DUJX-PEM%=O9R)Y>7
M61'*L",]!M+9]!FM==8M7U^31DWM=1VRW3D+\BHS%5R?4E6X]!7#S^$KV]\=
M7UC<6K?\([.9M1\TD%3/+ +=DQZX,C_C3O"IU?P]X>U/Q!K^G3'47:VMF@5E
MW&*)4B# YZ%FD?'H: .ZU/48-)TV>_NM_DP+N81H78^@ ')).!6&_CO2[?3+
M^]OK>^LC820I<P7$($B"5@J-@$@J2>Q/0]Q5KQ@NIOX7NETGS_M1:/(MF"RF
M/S%\P(3T;9OQ[XKS^;0-2E&O1VFBZI';W[:9+;&\N&GD(AN09-Y=V*G!W!<_
M=]#D4 =NOCK2T34FOH+[3FT^W6YECNX-K-$Q(5E )SD@C'7/&*IZ?XJNM3\?
M6NF"WO;&W.ES7,EI>0*CEA)&$?(SQ@L, _49K-\;>'-5UC5]6DL;4R!]'@6$
ME@!)+'<F7R\GH2 !SQS5_3GU'5_B):ZP^BWMC81Z3-;[[L*KF4RQMC:"<# .
M#WP?;(!?U+Q5+8>-]+\/IIMS,EY!)*\Z("%PR $<]!N.[TXQFL?PEX]%UI&D
M+JT=\\]Y,UM]O^SA8&FWL%3(QS@8R!C/&<YK0UNWO8/B'X?U2*PN;JS6UN+2
M5X #Y+.T15F!(^7Y3R,]*Q[/0-4C\"^%;%K*07-IJ\,\\?&403LQ8_@0: .D
MM?&>FW>IQVB0WBPS3O;07KPXMYI4SN16SG/RM@D ':<$U7\;ZMJ.F1:+#IMY
M!9R7^I):27$\/F*B&.1L[<CN@[US7ASPPUC>Z?IU[I.MS3V5X\OVE]1?[$JA
MF9)53>02<J-FT8).>G.W\1=-DU"VT%AH\FKVUKJJ3W-I'&DA:,12J?E<@'EE
MZF@"]ICZK9/<76I>)K+4[6&!G:&VL1$PQSNR)&[ \8[U5A^(^DSFR\NPU4KJ
M$7F6+?9>+H@ E4YZ@'/.!@$YQS533H].,6H6^E> [O19Y[25/M!LK>%6^7A2
M4<GDX[4FG:)J,*_#H/:.O]FVC)=YQ^Y;[+LP?^!<<4 :(^(.DFVM)!;:@9[J
MYEM%M!;YF6>,9:-ESP??..^0.:R/%/CB5O"0O]%DN+*[AU6"RN8KB%1)$2Z[
MD93D<JP.1G@\&L>6#4-$\7Z9<R:;-,TGB'4;B.&/;ODB:WQN7)P>,G&><8I=
M:\/ZUK.CZQ?Q:5<12ZCKUI<Q6LFT2+#$(T+L,\$["<=<8H [35/&VG:7>7L#
M6NH7*6"AKZ>V@WQVH(W?.<@G"X8A02 >:T;#7[#4=4O=.@=O/M(XI6+#"O'(
MI*NA[C@C/J*Y"\M]6TAO%VG0:)=WYUJ5Y[*>'9Y>Z2%(RLA+#8%*9SZ'CGBL
M_P 7:/J.A6OAM=)E4ZA=68\.3,#@LKI\LH]=A1F^C&@#I5^(FDS6D=S:6FI7
M<;0M<OY%ON,4 =E$K#/W248@#)(!.*M:AXWTNP<[(KR\ACMTN[B>TA\Q+>%L
ME7<YZ$ G R<#.,5R^J^%AI&N2/!IFMW>G2:;;VEM'I5Z\&UXMXV2!77@AEPQ
MR!\W3/-:[\*-IE_=QG1=;N;2ZL+:&VM]-U*2.-6CC\LPRD.O& OSD'()^E '
MHNL7L=KX=O[\7+Q116DDWGPJ'9 $)W*#P2.H!X-8<7C.SMM)TIA%J>J2W&G1
MWK/!;*9/**C]ZZ@@ GGY5SSG XJ]KVFR-X!U/2[& F0Z7+;P0AMQ)\HJJY/7
ML,FN-GTB[MO#/AV%M%UF/5;3188(;[2YPLD4P0!H9%) *Y /S;EZ].X!WVJ:
MY9Z1HIU:Y,AM!Y>61<D!V"AB#C@;@3Z#-1?\))IY\5GPWND^WBU^U?=^3;NQ
MC=_>[X].:;>:5/K?@R72M4*?:KNQ,-PR_=$C)AB/HW(KSHZ/XL/AD>(QIDO_
M  E#79)M]R[A&;;[/C.<8W 24 =AIOBVRUKQ-IT=G?7BQ75G--':M @CD5)=
MAD+?>!R. #@@YKDM-\9Z_<>"?!>H2ZANNM1\0BRNY/)0>9#YLJ[<;<#A5Y&#
MQUK<L?"]SI/C_P .M;6S'3-/T%K)IQC <,N ?<X)KGM+\*ZY#X&\$64FG2K<
MV'B,75S&<9BB\V8[SSTPRG\: .Q_X2^PTVX\3W%YJ%W-;Z7/"DT30(%M]X&
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M'<$5)10!C:/X4T70;AKC3[1DF:,1"22:25EC!SL4NQVKGL,#BMFBB@ HHHH
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M?48].O+O[$EZXC"";<4"E=V[!88W8QFKI\7!-9CLY](U""TFNS917TJHL;S
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M''IT_DZD3Y1%H<CG[_SC#!ODS@5H7_C2WL;ZZC_LZ\FL;*9(+V_CV>5 [!2
M06#, '4L0#C/UP =/17'7_Q!M[$ZJZZ/J,]KI,_DW]S&(PD0PIW %@6&&R0
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M%K&H_P!I7<UK;B?RVG:13(<,00H'R$ ]AC..36C'XY@:TF\S2KZ/4XKX:?\
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M(922>AS\I&* .MHJGI=Y/?Z?'<W%A/82.3_H\[*749XSM)'(YZ]ZN4 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM/VVT2VV3LD&V7?YL0QM<\#:3S\O;%6Z "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***X_P"(4^LV6C1WVG:E]C@@G@$JI&#)*7GC3;N/W5PS9P,D
MXY SD ["BBB@ HHHH **** "BBO)CKNG2^)/$4.N>.=0TJ2VU%HK>VAN$11%
MY:$'!0]RW>@#UFBN/?Q(=*30=-TI)]>DU2*9[:ZFN57<$VMEVVXQA^H'8<'-
M5(/B'=R6D=[-X>DALX]0&FWLC72DP3>;Y7RJ!\Z!BOS9'7IQ0!W=%<--\0KB
M&'4;_P#L&0Z3IM_)97=U]I4,NR3875,?,HR">1CG&<52B\2MHOC?X@7=_/<S
M6.GV]B\5N'+ ,T;?*BDX!9L#MD]: /1J*X^7QCJ=E)<6NH^'C#?_ &&6^M8(
MKL2BX6/&]-VT;7&Y>,$'/6KTGBZV>/P\UC";HZV0T(#[=D0C,C2'@]!@8]2!
M0!T5%<!9_$:^O+/1+U?#,HM=:_=V;?:U+&7:6PRX^5/E;YLG@9Q5V+QS-);/
M VCE=:74CIHLA<@H9!'YN[S-OW/+^;.W/;% '945QK^.Y52TA&C2/J4VH/IL
MEJLZXCE6(R [\8*%=IS@8#9QD8K-UKQUK,6B7!M=)CMM4M-7M]/N8FN0ZJ':
M,@JVWY@RN!G (R3VH ]$HJ.!I7MXGGC$4K("\8;<%;'(S@9QZXJ2@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN=CDL<=23R34M 'G-CX@LM4\5V>M:SJ_AZQCL+26"&&'5HYC))*4W,3QA0$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6)W8/0>]97AOPEK_ (=\.^%)_L*7&H:/)>+<62SJ"\<[L<HQ.W<,(<$CC/-
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M&/NX P3WIW@WPM)I=]8FX\+VME-96QCDOQ=>899,!<QJ#D*1N)W $9 Q6O\
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M%EW?*RLJKD9!!%5F\.ZUJEKXGU748(8-3U/36L+.RCE#B",*^T,_ +,[DG'
MXY- '&S:WXG@\$^$XU761)K-_;>?=M?Q&2=7CW%(SG]V&(R.F,'/6NSLO%%C
MI-_XE^V-JH?2;2S:XBN)A, 7C.U8P/XR>&.?F;!J*Z\+:K+X:\ V20H9]'N[
M.6\'F#Y%CB*O@]\$]J@U/P7JVHZQXZF011)JL=BUA([@AI(!DA@.0-P ^AH
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MT8A9(KW(FB>-HPV=N58 \X.!WX]13K/7M/OK_P"PQ-.EUY1F\J>VDA8H" 6
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MU0;?+8B2':X.,_=<]3WK1M_%6F7-S90JTJK?JS64KQD)<X&3L/TY&<9'(R*
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M /L[RQ"-Q(.I V@C;G/3CK3?$&AQF7P]8Z7J*1:E:@:?)\V9'M'CQ)D#D$!
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M5U4.47/)"^4,X';(K(G\):I)X4U73E$/VBYUXW\?S\>5]K67D^NT'CUKO**
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MLHD8*Q(SDA<8^4#H*Z7P]X'>SU5KS4++1K:!;*2S6STV-O+D$A4R.Y8#J$4
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M:I>VEKX?TA+QKK2XM3CDN;KR45'8KM;"L0W Z9ZGIC-;_AS6D\1>'K+5DA:
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MG:JNNW8=XPN0-R\L<T 4K2;6=3^-&HPW<&ZTTZWA,,::G(J1*Q?$GEJH5V;
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M,<K-'%# 4 0-M!9L*3G &3CWK7U31]8'CFSUS3%LY(O[/DL)A/(RF+=(KB0
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MVJ(9 3"07&2<<_<_6NR>&%IDG>.,R1 A)&490'&<'MG S]*\-\/?\B-\*/\
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M]"57.!OP4)QUV^IH [:BJ>E6<FGZ5;6DMQ+<2Q1A9)I79V=NYRQ)Y.?I5R@
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MKL]0N9K32[FZM[;SYXH6=(#(J;V R%+'A?J>E $XAB$S3"-!*RA&<+\Q4$D
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M\ZFVEQ)NQD+R<C!/RG&>* .R;PSH+,[-HFFEG.7)M(\L??CFK']DZ;YL<O\
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MGIVH [:XT?3+IHVN-.M)FC38ADA5BJ_W1D<#VI3I6G->F]-A:F[)!,_DKO)
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MK3"X,@MTW&49P^<?>Y//7DU0\.ZW=ZC=ZIIFI6\,.H:;*B2FW<M'(KH&1UR
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M+Q$9XC FC#3C%@[M_FA]WIC'%6O$>GZIJ$<4=E'I=U;,K)<6>I1EHY,XVL"
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MKZVCNI?]7"\JAW^BDY-8W_"4LWBO5M!2R7?86"7@F>?:LA;/RGCY1Q][)^E
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MF6VY]/\ 2(Z[6H;BTMKQ EU;Q3J#D+*@8 _C0!PGC2UGM=4\'-/JEQ<AM>A
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MRSV9.Y5WDY)$@\L@GE :I>';Q-<GTZ[N/$26VM0WLL=W8Q[A/(=S*T+*9/N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7/:MXMM],N]1MTMI;EM-T][^[9" (E )1.?XFVM@>@R>V>AKS%?G\,?%.:7
MFY-Q>(Q/78MJ@0?3'\Z /0X;W[3IJW5O'YDC0B58=X!)*Y"D]JAT/6;;7](A
MU&U#JLF5>.08>)U)5D8=F5@0?I7 Z3I^E:;X@\!W&B1PI-?6DWVN6+&ZYB\@
M-ND(Y8^9LY/<UO\ @KY-=\90Q?\ 'LNL;D] [0Q%_P#QXY_&@#L**** "BBB
M@"&ZN$L[.>YDSY<,;2-M'. ,G%<S8>/[&\;3S-I>KV-OJ#(MM=75L!$[.,H-
MRL<%NV<5N:[_ ,B]J?\ UZ2_^@&N*\.:%K^M^%_#$>J7^G)I-O%9W:Q6MNXF
MD\M5:-69G( R%)P.<=J /0]Z[]FX;L9VYYQ4%[?V^GV5Q=SN!%!$TSXY.U1D
MX%>4Z/IU]>7T&K2?V';7J^()5DO99W%X^V=E,&-N,&,;0F<8VFI-)\.Z1=>!
M?&.HW>GV]S=M<:H@EG0.4597957/0!@&X[\T >@>&O$)\0Z'%JSV$MA;3@20
M>?(A+QL 5;Y2=N<]#S6UN7 .1@]#FO(/#>C:1)'X L+O3[,:==Z,]V\+1+Y=
MS>".$!G&,.P0N1G)ZGM5=[&VO4TW2L;M'3QC-;VT:M\GD>0Y:-?]C<9%P.,9
M% 'LOFQA0WF+M.,'/!STIP=2Y4,"PZC/(KRZ^\-Z-=^(_&-M/IUN]M9Z-:K;
M0E!LA^2;!5>@(VC!'([51BAL-!MO!>N);L+BXT>YFU">(XFN@+02G<_5CN&1
MGIVH ]>5T;=M93M.#@]* Z%BH92P&2 >17CFGVRZ9JCV\-GI=@MUX7NIG@L)
M&=G ,>QI6(&]\,WS=3EJMVFE6^CQ^ [_ $FT2/4KJQE6:95_>7!-FS@.>K?.
MJD9Z8XH ]8#JS,H8%EZ@'D4*ZL2%8$J<'!Z&O*--MM"L? FEZQIDBQ^)[G19
MY(I82?-NY_(+2>:1RY#C/S="!]*O>"-(DLM8TB[@&@VD,^F,7BL+AVEO4/EE
M97!4;BI/WLD_.?6@#TNFK(C E74A3@D'I7-?$6>XMOA_K,MM))&XA 9XSAEC
M+ .01TPA8YK#;0]!M/'>DZ;I&GV(L+W2KG[?;11J8I8E:+RG=>C')8!CR<F@
M#H_"?BE?%NGOJ-MI]Q;V#,1;33.F9P&920H)*\KWQUJWK>OV^ABV1[>YNKFZ
MD,=O:VJ!Y)2 6.,D   9)) KDO@MIUE:_#33+NWM((KFY$GGRI&%>7;+(%W$
M<G X&>E;?BRUTV^O=(MIM7GTK5O,DDTZYAQG<%PZ_,"A!!^Z>N..E &AHGB&
MWULW<8M;NRNK1PMQ;7<821,C*G@E2".A!/0UJJZLH96!4]"#P:\FU_5M;EM+
M_P .W]Y8:DMM?V"S7@4P1213.<Q3A=VWE5#8X*N.!FJVL:-+::3=V4K:7;03
M:[IH^Q:3,VVU9G4-P5786&UL =<GO0![$KJXRK!A['-5;B[N(M0L[>*Q>>"8
MN)KA9$ @VC(RI.6R>/E!QWK@];;3_AKX@@U>TM8K72+K3I;62"%=B">(--%@
M#NP,J_7%9=MI$VB>*/AE;W9S?2G4;F\8]6GDA#OGZ%B/H!0!ZT'4N4##<!DK
MGD4!U9F4,"R]0#R*\P\+6FB'P_H^MW1CC\43W4X\]3^_GNLR!HG(Y*C!^4\
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MU>^BTWXH:I?3K*\-OX,:5UB;:Y"S$D*>QXZT >ES74$%O-<22JL4*EI&SG:
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M#(P93T(.102!U.*X_P %:9/I6I:W$_\ 9%O"S0L-/TN1F2W?:=Q*E5V[AL.
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M]N3;6V^%1YI\LR CYNA /7&"#G&* -6]\.Z+J5G;VE]I-C<VUL ((I;=66(
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MYBQ\(:U:Z'X8L7-@9-)U)KN9A.^'4^:,+\G7][WQT]^.WDO+6%@LMS#&Q8(
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M5]W2-"[LJJ.K,< 4 <?KOA.[U;7TU&&.UM;N">%K;4H9F2=8@5,D;J%PX.'
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M_P!HBDB$K^5/#,<G#;,JP(4CY<<$=^.JN-:T;1[&T=KFWBM9YDMH/*(VEF;
M QQC)Y]*T#=6XF2$SQ"60;D3>-S#U [B@#B]0TC2--T#7H?$5_;6\FOW$DQ5
M9.0^Q0BQ9P7=0BD8&2W;I3IO"VM3>%M&DANX/^$BLKE=0DDN5/E33,C+(C[>
M0NURH(Z!1777$NGF6$7$EL9%DQ$)"N0^/X<_Q8/;GFH8-:T^YUBZTJ*Y1KRU
M1'ECST#[L?4_*<^G'K0!S^HZ+XAU6WT>6X73$N;74X[V6&.5Q&B(I&U6V99C
MN)R0!V]ZVDO-3/BE[-H;9M+^R^8LJ,WFI+N VL,;<$$D8.?E-:GF)YACWKO
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M6Q++'!$TLTB1QJ,L[G  ]R:Q_$GBFP\-^&+G7IF$]O"FY5A<$RDD !3G'4T
M<S!X0\1Z.=+O=-O;2]N[6*:UEM]1E=D:W>3?&HEVEMR !<D<CTK971-7;Q7H
M^K3O9/':V=Q!/L9E.Z5D;Y%VD879CDY.<UM:/>SZCI<-U<VR6TKYW1).LP7G
M^\O!JS%<V\YD$,\4AC.UPC@[3Z''2@#!NO#+S>-8-;BG"6S0!+RWQ_KWC;=
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M2>>.]:!L[5A< VT)%SQ/E!^]XV_-_>XXY[4DT#FS,-K*+9@H6-U0,$QZ+TH
M\VM[U/#=MHUQX:\5?VEI-U<P6\.DW+),_ER,%Q$XPXV*<X;. IS6=H-C<7-Y
M8W<]WH5M?+KTS22%6^W2.)7#Q$YZ&/( Z;=OI7<6_A&6TOFOK:\L8;M\[IX]
M*A61L]<L.:D'ABZ743J*ZC:B^(VFY&FQ>:1TQNZ_K0!RGA*#PO-H^CSZLMO_
M ,)#+J,Z2,!FX>Y+2!TDQ\Q7;G(;Y< 9XQ7,K!8P_"_01:Q6\<__  D\8G$2
MJ&XNY0N['/ Z9[5ZBGABZCU%]034;5;YQM:Y73(A(P]"W4TP>$IE:1EO;(-+
M*)I"-+AR\@Y#GU89//6@#C-4AT>;2OB)/K26QU:*>40O,!YT:"!#;^63R.>5
MQ_%GO5FUT>VU;5O%<FMV45S=QZ19AA.@;8Y@?>0#T.0.>O%=7<>%[B[OHKRY
MU"SFNX?]7-)ID32)]&/(JQ_8>J>9-)_;,6^8!96^P1Y<#@!CWZGKZT 1>&?/
MO/AKI&')N)M(APY/)8PCG/UKA/"]P=-TCP.]AKEW/?W$D5E>:<\^Y%18V$B^
M5_ 8RH^8 'CG.:]"BTC5X(4AAUQ(XHU"HB6,850.  !T%06WAFXM]2?4([^T
M6ZD.)9DTV)9)!W!8<T 9OQ/%JV@:8M\0+,ZQ9B<L<#R_,&[)],9S[5R'BB&V
MM=3\2V^@I9PZ6T&E_;UC&+=6-RP?>$Z Q8W8_AKV">V@ND5+B&.958,!(@8!
MAT//>H+72=-L;62UM-/M;>VD)+PPPJB-G@Y &#F@#Q_Q=8-9^ O'+"ZT?;)!
M:;[32E*QQ.)/OD'@,R[>G9!73&WT2Z\9^)AXGCLY(X]/M?L_VP*0MN4;>4W=
M/GW9(]![5W$6B:3!I[Z?#IEE'9.<O;I;J(V/J5 P>@_*EO=(TS4FB:^TZTNF
MA.8C/ KE#_LY''X4 >/"ZU'1O#FBW<AD%[X@\/+I:LV=QN0RB GU.V9S_P !
MK8T*T5?%>G>#$!^S>'KZYO\ :>T153;C\#<MC_KG[5ZA/:6UR8C/;Q2F%Q)$
M9$#;&'1AGH?<5%/9A?M-S9Q6T>H2Q[!.\><D#Y=Q') /;- ')^#;RVL9_%;3
MW$4%J?$4L<32,%!D=8LJ,]S(2,>IJW\3O^29^(.2/]$;IUZBKFG^$K*T\.6N
MDR2//Y=PEW+.0-TTXD$I<]>KC\N,U9\4Z*WB+PQJ&D),(&NXC&)&7<%]\4 <
M#J]OHUKKL0\.):K%+X;OFN_LN,/'B/RF?'4[BV">>M10:3I=EX5^'JS6MO'I
MM[-;R:D[J,3R&V=H_-/\0\S'7C.!Z5Z=!I&FVK7+6^G6D)N<^>8X57S?][ ^
M;J>M226%G-8_89;2![38$\AHP8]HZ#;TQ[4 >5W^FH\GC&?0(HO)T>[L]2LX
M[< 1_:8X]TRJ!QEDPI [MS5?Q#<1>)?"7CKQ;$=]J]D-/T]C_P \H\-(P^LC
M$?\  !7KEK96FGVHMK.U@MK=<XBAC"(/P'%-73;!=/\ L"65L+(@C[.(E\O!
M.2-N,=: /.K./1I_%-\/$BVK11:!9&T^U8PL1\SS63/0[@N2.>!7-^'[>6[L
M_#$$RZ,]L/#NZ)=94M'N\TB4J,XW;?+R>N#7L]QI.FW;V[W.GVDSVQS TL*L
M8O\ =R/EZ#I3;C1=*N[2*UN=,LIK:$YBAD@5D0^H!&!^% 'FNA6FE_V]:6WB
M.ZL-0MH/#<!LY[C!B=/,?S'7?WVB+)ZXQ74?"W8WPUTC;N9"LN-_4CS7ZYKI
M;O2M.OS ;RPM;CR#NA\Z%7\L^JY''3M4\,$-M$(H(DBC7.$C4*!DY/ ]Z /&
M+73=)?0#9I;6JE_&9AGCC558QBY<*C8YVX) 'H:TM7AT_2M>\3:;#IEG]DNY
M-)1;9R8;997>0;W"X^7Y%R/XL 'K7IBZ/IBW,ERNG6@GE=9))1 NYW7[K$XR
M2.Q[4^XTVPNTG6YLK:9;A56821*PD"] V1R!DXS0!XMJ$5FVD>(H+@:5+#;Z
M_ISXM(0ENFXPK(54DX!P0QS@G=7K.O6]A+X,U&U:Z2PT][&2+[1"!M@C*$;@
M!Q@#^56_[%TAX7C_ +,LFBDB6%E\A"K1KT4C'*CL.E6H[:"*V6VCAC2W5-BQ
M*H"A<8P!TQCM0!X_J;06&AZS926.CPW$']F3RWFD-M@EA%T,%TZ(PVL>IR#U
MP*M>.M0CN-;\1M87 E$7A^!+AH&SMC-R3(,COY9)^AKTVVT72K.TFM+73+*"
MVFSYL,4"JDF>NX 8/XTZTTG3;! EGI]I;J$\L+#"J#;G.W@=,G.* /-_&%KX
M3C\/ZS!H0MXKJ6WLO/2P^6/ROM*A&.SY0WWL'[V/:M_3]-L=(^*;V^FVD%I#
M+HBL\<$816*S8!('4@$C-=-;Z)I-I;26UMI=E#;R,'>*.W159@<@D 8)R!S5
MOR(?M'VCRH_/V;/,VC=MSG&>N,\XH X7QS8V\^L17>[1;N>WL)1)INK<))"6
M!+QOSL;*XS@]1G%<A=1KKDFNSL^CV%L^GV;VLFJ[VN+2!K=61HVSD%9"_(Y+
M"O8;[2=-U3R_[0T^UN_*.Z/[1"LFP^HR#BBZTK3;R>&YN["TGFM^899859H_
M]TD9'X4 <-HV@V&K?$+Q:VK6L%Y-'#9Q!I$!"[X,.5S]TG YZX%9?A]I]7U#
M0/!UTQD;PU<2RWQ/\8@.RU_[Z#J__ *]52W@CFEGCAC667'F2*H#/@8&3WP*
M;':6T5S-<QV\23S8\V54 :3 P-QZG Z9H \8T?R&TJWBU (=)D\:72W@EQY;
M##F,/GC;Y@3KQG%:VM0:1_:FEV?AW^S3I_\ :T_VF*[5C9"[\@%5 'R],D <
M;O>O3#I>GFTFM#8VQMIV+2PF%=DA/)+#&"3[TPZ/I9T[^S#IUF;$#_CU\A?*
MQG/W,8Z^U 'FL6BQG3=.C35/#ES-#?7DMK93QL;)U.!)&N?NE&)P1G )&,=.
MY\(WMK<>#+"YM++[);K"0MLC^8$VD@A6_B7(.T^F*T)]&TFYLHK"XTVREM(\
M&.WD@1HUQZ*1@5=CC2&)8HD5(T 5548"@= !0!X]X:FMO^$D\(W=O%H]FFH6
M]S((+/<\X1X]X6>4GYV+#/(^\IQT-5=-TJWM?@_X6GM;:Q1KV[M?[0GNDRDJ
M;FV"8CDH&\L8)P!@=*]>BT/2(#F+2K&,^=Y_R6Z#]Y_?Z?>Y//6I_L%F+'[#
M]D@^Q[=GV?RQY>WTVXQCVH YGP/9-92ZV!=:7(CW:L;?3%(AMY/+7<,'H3\K
M$#N3ZU@WL7AN?Q!XU?Q;]G_<F#RGF_UD=MY*E3$1\P/F>9]WG=[UZ+9V-IIU
MLMM8VL%M OW8H(PBCZ <5'<Z5IU[=0W5U86L]Q <Q2RPJSQ_[I(R/PH \POX
M=$GT[XA3ZXMNVHQ.P@>Y \Z.$6Z&#9GD?-DC'\6>]6M,T>WU?7=??7;**ZND
MT.P#K<(&VNT<N\X/0Y'7K7HESI&FWEY%>76G6D]U#_JII859T_W6(R/PJ<6T
M EEE$,8DE4+(^T9<#. 3W R?S- 'BZ):IX5L-;N?[)U;RO#UD;ZQOF*7,:*A
M8/!)U#-D\8Y91R#6A/;VVH>+/B7;W5[%8Q3'2 )KA-T8;8"JN,C*L<*1D<$U
MZ=)H>D3/;/+I5B[VH"V[-;H3"!T"<?+CVJ9].L9&N6>SMV-T MP3$I\X 8 ?
MCYL#CF@#R'4X]-EAM+6]T?1[>6U\2V2W3V9#VLH=1D@,/DRH4,OL,DYI]S82
M7NI>(&-UH%G+'JT0@N;E&^TP@"(P"(@\*1@ #@Y;WKU5=#TA=-.FKI5B+%CD
MVPMT\HGKG;C'Z4YM'TMKN"[;3;,W-NH2&8P+OC4= K8R!]* /+M9TC3[GP]\
M3M0GM(9;N&YE,,SH"T16VB92A_A.[G(]O2M[PQ;Z>OQ0\2RM#:K>-:V+QL44
M2$M')O([\\9Q^-=RUC:-%<1M:P&.X),ZF,8E) !W#^+@ <]A33IUB;Y+XV5N
M;R-/+2X,2^8J_P!T-C('M0!P_P 0-0?PMK%CXDA4[I;*YTTX_BD*^; /^^XV
M7_@=8&E:8=.UK3?A\27BM=0BU1B>=T"0AR3];D5ZU<VMM=HL=U!%,JN'594#
M ,.A&>X]:/LEM]L^V?9XOM7E^5YVP;]F<[=W7&><4 >(65M93^$M.>]@MY(E
M\;.K-.BD!&E;<#GL<#/K6[J>BZ5>Q_$ZZFLK:=X80+=V0-Y0%C&P*?W><'(]
M!Z"O2WTC3);.2SDTZT>UD<N\#0*49B<Y*XP3GG-2K86:131+:0+',NV5!& )
M!MVX88Y&T <]AB@#+*+?>!@MRBSB73@760;@Y,>>0>O->=>&],TB_M_AI ;6
MTF@.GW$D\2HI1Y1##DN!P6S@\]P/2O8%141410J*,!0, #TJG:Z1I=AM:TTZ
MSMMK,X,4*I@M@,>!U.!GUP* /(EMG34[;3K>/34TZ+Q!J*QP7Z'[*L@161=H
MXSS*5'3->B>!+7['X<:%;RSN8?M<YB-EGR8E,AS&F>RMN [=JVI]*TZZMI;:
M>PM9K>9_,DBDA5E=O[Q!&"?>K$$$-K D%O$D4,8VI'&H55'H .E 'C,CSIXB
MUU]5C5O"">(F^W['.[S#%%L,HQS"&VY&>K#/ YD\38_M;XJE,8_L6UQC_KF]
M>O\ V&T,=Q']E@\NY),Z^6,2DC!+#^+( '-1_P!E:=ME7[!:[9HUBE'DKAT4
M8"MQR . #0!YEXRTV+0K]_[!M4M;B7PQJ(8VZ[6D*^25)(Y9AECD\Y-6;.#P
MY;^.?! T)+-"UC<%OLNWYD\I=A?'4_>P3S]ZO2VMX&G2=H8S*BE%D*C<JG&0
M#V!P/R%5;31=*L'#V>F65LP8L&A@5#N(P3P.I% '->-EMY=?\)PZF(VTF2^D
M\]9L>4THA<Q!L\'YLX![@5P7C"TL#X-^(JV5O;MIEM>6S6GEHICBF*Q";R^P
M.3SCN37M5U:6U_;/;7EO#<0/PT4R!U;Z@\&HETK3ET[^SEL+46.,?9A"OEXS
MG[N,=>: &"TLK#1I+>"..RM$B8D6Z!!&""20 .#U->.WL::1X:O--M8='FD?
M2%:+5=,+)YUHLT2R?:(QT)5B=V3GY\8YKV_CIQ]*IVFCZ7IYF-EIMG;&?_7>
M3 J>9_O8'/XT >1^(]/-KX8\621W>B1B33[8/::.I55(E^20CH"1D>X4>@KJ
M_$6FZ=X-N] \06%M#96-C.;2]\I J^1/A=[8ZXD$9)/O77P:)I-M9R6=OI=E
M%:RG=)#';HJ.?4J!@U:N+:"[MWM[F&.:%QAXY%#*P]P>#0!XY?VTC>'O"NM7
M*%;O6_%]KJ$@;JJ/N$2_A&$'YULV,?AJ2?7[GQ'Y"ZI'X@*I(<_:5PZ?9PA7
MY\%=F .,%O>O2);*UG2%);:&1875XE>,$1LO0KZ$=B*CDTK3I=034)+"U>]C
M&$N6A4R*/0-C(H \ITBQN+J^ANI[O0K6^3Q%*7E=6^W,XG8&+.>C1?*!TVD5
MJ>%HK'2O$NF0QII.HQWAN39ZI:$I=#.7<3K_ !>F[/W@. 37H7]E:=_:7]H_
M8+7[=C;]I\E?-QC&-V,XQ[TEOI.FVEY->6VGVD-U-_K9XX55Y._S,!D_C0!Q
MWQ!!/B+P<!JATL_;;C_3!L_=_P"CR?WP5YZ<COZT:B=O@[Q,C^+O[<=M*N"L
M3?9P8P(VR1Y2@]QUKL[[3+#4T5+^RMKM$.56>)9 I]1D5!;^']%M#(;;2+"$
MR(8W,=LB[T/53@<@^E 'GUOX;T9?$O@9/[-MBL^E7#7 ,8(N"JPL#)_?(9BW
MS9YYZUCZ5:Z3_P )!X;L-0C@^P0ZGKD,$$P'E#;,NQ,'C [#U ]J]D%K;B2&
M06\6^%2D3;!F-3C(4]AP.GH*Q-1\*6>H:YIMX\-J;2V2Y6:U: %9FFV$DCIU
M0DY!SF@#S+4UAC\,21600:;'XVB6S6/_ %:IN7<$QQMW[^G'6M/5(=&FTOXB
M3ZTEL=5BGE$+S >=&@@0V_ED\CGD8_BSWKU :7IXM(;06-L+:%@T4(A79&1R
M"JXP"/:FW&DZ9>7T5Y<:?9SW<./+FDA5I(_3#$9% 'G&L:CJ'@R^_M+RV:Y\
M0:7' $QUU-%"QY_W@^/^V=95QX;73;[4=$GET-;:ST6WC2;558LJ'S#)+$0>
M"9,L2.<[?:O2;_0+K5O$EE>7]Y"VF:?+]HM;..$AC-M*AY'+'.W+$  =1G.*
MU;S2M.U%X7OK"UNGA.Z)IX5<H?5<CC\* /(M1L+F\O?$$.I7^A;XM/M$6^U%
M7\U$\@?O83G*_O?,;CG<*]'\5+(OPZUM9G#RC29P[@8#'RFR:UKK2M.OKB&X
MN["UN)X#F*26%7:,_P"R2,C\*CUS3SJV@:CIHE$37EK+;B0C(4NI7.._6@#S
M 0:?;-X.F\+I;C49=-NC*]N!YDJ_9B<R$<D^;L^]_%[U%X<T\"PTJ\BN]!B)
MT6?=%8JPN+E#&-QE)/)#[22>Y/K7J&DZ%8:1$C06=JEV8DCFN(X55Y< #+$#
M)Z=ZF@TC3+6:XFM].M(9;G/GO' JM+_O$#YOQH \?UK0=*MOV=K.ZCT^V^U2
MVMA*\YB4R,S/'DEL9Z,1]..E=0NF^'D\>:Y::S9Z='9P:;;FQAN(T6)(293,
M44\#YL;B/:N]?3[*2R6RDM(&M%"J(&C!C &,#;C'&!CZ5'?:3INJ>7_:&GVE
MWY1S']HA638?49!Q0!Y1X6TV+6=7\%1:S;BZ1?#]Q(L=RNX,HFC$98'K\I4\
M]\&F:YI-C/X6^(6HR6T;7L6L'R;@C]Y%M$!&QNJ\DGBO8?LT'VA;CR8_.1"B
MR;!N53@D ]<<#CVIC6%F\4T36D#1SMOF0Q@B1N.6&.3P.3Z"@#S3Q!HFD6GB
MC4]-A>UT>RN= 02R+$!'N%P%0NHQN'.TYZ@GFNB\#R11WFLV)T[3+6[@>)IY
M-+<FWFW*=K!?X&PN"/IR>*ZJ6RM9W=YK:&1GC,3,\8)9#U4YZCVZ4VQTZQTN
MW^SZ?9V]I#G=Y=O$L:Y]<  4 >>7T&B7.O\ CMO$B6CO%#$(#=!24MO(!!CS
MT_>>9R/XA]*J^&=-75?&>B2:[;+<W<'A2SE9;E=VV;S&^<@_QCGGJ,FO2;S2
M=,U"XAFO=/M+F:'F)YH5=D_W21D?A5CR;<77VGRHOM!3R_-VC>5!SMSUQDYQ
M0!R?Q*A2Y\-V4$H)CDU:Q1@#C(-P@-<_/X:T1O$_C: Z59^1%I-N\<(A4(C,
MDP9E7& Q"+R.>*],FBM[A L\<4J*X8!U# ,#D'GN#@BD^RVYDED,$6^90DK;
M!EU&<!CW R>#ZF@#P[5;B*_\%WD[0Z6MU9^';-9+J^W2W$CM!O3R!D;""?O#
M.6ZCY:Z?Q!JD_A/6+G4;']Y_PDNGI';;>0=04!(_^^E<?]^Z]".BZ4TT4S:9
M9F6*+R8W,"[DCQC8#CA<<8Z5DS>&);O7]/GGGM4T?2V\VQT^"WV;9=FT,[9P
M0N6VA0.HZXH TO#^CP^'_#UAI,!REI"L>[^\0.6/N3D_C6E110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>;[7Y6K6+_8_^/K;<(?(_P!_GY>AZT^TUC3-0N9[:RU&TN9[<XFBAF5VC/\
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M_(4B@#VY'61%=&#*PR&!R"/6EK!\%6L=GX-TR"&\^V0+%F*<0M$&0DE<(Q)
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MG5K?=:RE49BQW_*>2 N".ASP >ER012LC21([(<H64$J?4>E#>5'(';8KO\
M(&. 3[5YMHGQ--_?:;-+?:5-::B\@^Q6ZM]IM%",Z,[%B&R$P1M7!8=:AN-3
MU_6;?P3J^H?8!9:AJT%Q#!!&RR6X:.0H&8L0^5/) 7!]>P!ZBJ(A8JJ@L<G
MQDTV."*)W:.)$9SERJ@%CZGUK)\7:O<:!X1U75K5(WGM+=I8UE!*DCUP0<?C
M6;XE\3WNCZC]GMXK=D_L:]O\R*2?,A\O:."/E.\Y[].10!UE0>3:1;$\J%-S
M$JNT#+$'./?&:XB+Q;KFG3Z5=:RNGO8ZG8370AMHG62W,<0EP6+$/D9'08-9
M[WVOWVI^ ]1U=K#R+R[:Y2.VB=&M]UK*0A)8[^#U 7D=#G@ ]*>(&/";5=00
MC;<[#C'2LC0?#[:1-?7MW>O?ZE?.K7%RT8C&U1A$51]U0,\9/))SS7(^'/B/
M)K&JZ2&OM*F@U9W5;*W5OM%F-C.A=BQ#9"X;Y5P6'6MSP#K6N^)="@UK5181
M074?[F"VC<,I#$%F8L>#C@8X'<T =;44:6\DGVF-8F<C;YJ@$D ],_6N0\0W
M>MQ_$CPQ96-_!#97$-R\L3PNV_9LW9PX!X;Y>/E.2=V<#G?#&KZ[HOAC2;M3
M8-I,VL26;0&-S,1+=NGF!]V!AF^[M/ Z\\ 'I\:VKW$DL:PM,/D=U +#V)Z_
MA4IBC(8%%(?[PQ][ZUYK'XLN;&#Q5/:V.FV9MM=%I)=):L55"%W3S*IRY&<$
MY';/ KMO#=]<ZCHZ7-S=Z=>%G81W.GL3%,F>& ).T]B,GD=: '>(=%CU_P /
MZAI32>3]LMGM_.";B@88SCO]*OP6T5N#Y<:*S ;V50"Q'<^M<5\1-2@EDTCP
MO)>QVHU:XW7<KRB/9:Q_-)\V1@L0J#_>-9_AOQ<FB^ M=BEG34+GPQYD*LL@
M;[1$!F!MPSU4A2?530!Z,MO GF;(8U\PY?"@;C[^M.V+E3M&5^Z<=/I7#R>(
M/%.D:S8Z?JHTJ<75A=77FV\,B;'B53Y>"YR 6^]W'88YST\<ZW!X2T;5]3GT
M>R?7&A6V9XW\JU4QL[O)E_GR%^505P6 )/6@#T5+6WC614@B59,EP$ #9]?6
ME6WA4 +#& %V !1POI]/:O-O^%ENVGPP?VEI$=R^HR6;:FR,;4QI$)/,5-V2
M2&5=N[AL\\58M/'6K:I'H]MIQTR6YN]0N;"6Z".T)\N,N)4&[.",':2>XSWH
M ]!2"&+;Y<2)M&%VJ!@>@H2"&.5Y4B19'^\X4 M]3WKSB3Q?XKMM'U;49AI+
M1Z)?_9+E5@D!NQN3+)\_[OY7'!WY(/04NI?$E[36;\)?:4EO8WRVC:?(K&ZG
M7*AY%8-A<%CA=IR%/(SP >D>5'M"[%V@Y QP#ZTZO.M0\7^)(+#Q!J\":8MA
MHE^]NT+Q.9+B-2N<-O 0@-UP<GL.^CH5WK=Q\2O$UM<7\#Z=:QVP2 0N"H97
M9=IWX!_O''S8'3% '8-!"TRS-$AE485RHW >QIX10S,% 9NI Y-8'B76+ZQN
MM)TO2Q;B_P!4N&B26X4M'"B(SNQ4$%C@8 R.3UKGKKQEKU@+K39(=/N-6M=5
MM++S%1TAECN "K[=Q*D9(/)Z=\T >@TT(BIL5%"_W0.*YSP]JNK2Z_K&BZP]
MG--8I!-'<6L+1*Z2[^"K,V""AYSR"*;XNUR[TB2RCM]3TG3EG\PM-?JTK,5Q
MA4C5E+9R<G/ '3F@#HTMX(XA%'#&D8.0BJ  >O2G;$RQVKEA@G'45PFG^+M:
M\2II%MHXL+.ZN=,_M"YEN8GF1?FV!$4,IY8-R3P!T)-66UOQ1?ZG%H]G#IMA
MJ4&GI>7IN%:>/>S,JQIM9< E&)8DX&.* .P:WA<QEH8R8O\ 5Y4?)]/2G+'&
MA!5%! P,#H/2N.76O$VK:O+I6GIIVG75C903WOVJ-K@>=+NQ$NUU^4;#EN>H
MXI?#7C.Y\0:GI4)MHH8;O29+R5>2R3),L94'.-N2W;/2@#KGMX)8C%)#&\9.
M2C*"">O2G;$W*VU<J, XZ"N M?&&OZI-HMI9QZ=#-J,NI))++$[+$+>8(C!0
MXW9'49')SD 8K.U#Q'XGOK?0XX;RQM;Q/$4FF73I!(8YB@<JVWS 0A"\J2<G
M'(QR >FFV@9G9H8RT@ <E1E@/7UH-M SNYAC+.,,2HRP]#ZU!J=^FDZ->:C.
M-R6EN\\@7C(12QQ^5<E:^(/$MO)H,NJ-IA@US,<200.&M)6B:1 Q+GS!A2#@
M+STH [)UM+B812"&26/YPC8)3WQVJ;:N_?M&[&,XYQ7F?PHL+O[=XFU.[;3Y
M9GU>[@DFCM"L[,'7_EH7/[OCA,<>IK;\6^)K_2-9M+&"]TS38IH&D2ZU.)VB
MFE#8$(8,H0XYR2>O - '8JJHNU5"CT Q2,B.5+*I*G(R.AKF[7Q#?2ZKX@LY
MH;=?[-M+>:/9ELNZ.S G/(!48P!6-IWBCQ'XDBM(]'&F07*:/:ZA=-<PNZ/+
M.I*Q( X*CY&RQ+8R.* .[ @8O$!&3]YTX[]R/PJ2O-HY?$;^-O$$VG"PLKL:
M58RW"W2-.JN!,?+&UE[Y^;/;H<\=MX<U4Z[X9TO5FC$37MK'.T8.0I902!^=
M %]H(6D,C11ERNPL5&2OIGTI#;6[.KF",LJ[ 2@R%]/I7%67C"_F\0WT%Q=Z
M5%%9S3K-ICH\=VL,>[;,K%L2!L*<!0,-][(YS] ^(UQJ5Y8I)?:1=?VC;2S)
M:VBMYEDZIYBK(2Q#C:""0%Y'O0!Z,T$+NCO%&S)]QBH)7Z>E(X@@42N(XUC7
M <X 4?7L*\^T[QAXE_X1O0O$FJ1Z8NG:C-;)/%#$X:WCE!7S-Y<C[YC.,< D
M<GFG>,?%5RNG^,5CL-/O--T>UB1DNXC(LUPQ#,K#(!54*<=<GK0!WZV]ORRP
MQ?,V\D*.6]?K[TK00O,LS1(TJ#"N5!8?0UQ[ZWK^HZC/IWAY=-@.GV,$\HNH
MG82R2!BL2[678,+]XYZCCBLC7OB-=Z;?ZC$+G2;*72X8GEL+HL\UU(T8D:.-
MPP"X#!0<-EO04 >D[$^;Y%^;[W'7ZTH 4    < "N(B\6ZA=^+WTZ*[TJVC6
M:(16-XCI<74#(K&6.3=M.-S84*?ND$C/'1^)C>+X8U)K">*"Y6W=EDE0N!@9
M/ 93G&<'/!P>>E %\?9KEPP\F5X6P",,4/\ 0TY8(4E>5(D61_O.% +?4]Z\
MF\!S:II7A;PMI&E+I$-WK-LUT;G[$P\N*-5W&0"0&60LZC.5'7BMFZ\;:];V
M<=HEMI\FL)KRZ/*Q5Q"P>(R+*!NRO!0D9/1AZ4 >B5"\=LDRSR)$LI^19& #
M<]@?Z4VS6[2QB6]EAENP@$DD*%$9O4*22![9->1M>>(KO0C->WEK>3Q^+XX;
M=?+>,*Z7!7!)=L)P,*!D#/)H ]C"*I8JH!8Y) ZTM>=ZAXVU?P^=9LM5ETR2
M[M9+-;>[6)X80+AF7,BEV.$V,3AN1CI6SX-\4-KT^IV<E[8W[V+1E;RQ0I'*
MC@D?*6;# JP/)['O0!U"Q1J%"QH IRN%'!]J<%522% +')('6N5^(>NOHGA6
M1+:=(;_4)%L;1W8*$DDXWD]@J[FS[5B> [FWT?5]7\'6.IPW<,42WVFS&43?
M(PVNK8/\,@SC.</0!Z"SV\KM;LT;L!EHR02!ZD4U)[2256CE@:1\JI5@2V.H
M'KBO#+>QUA/!7Q%U47.E"X^VZA!<SBQ?SW (W*LGFY5/12#CWKJ=")T+5_ 6
MDMINB,;VUN91<6]B8GA A0_*=Y^9NC-_%@<"@#TB-[*%'>)K=$:3#%2H!?T/
MO4L5O!" (H8XP,X"*!C/6O&=,U,:5X%O)C8V5YO\7R1>7=Q>8J[IP-P&1AAU
M![&NL\0^-+W1=?DB^W:.8(KFWA_L_:SW,B2% 7+!L1D;B0I4Y"]>> #OJC2"
M&.5Y4B19'^^RJ 6^I[UYG_PE.MZ)<>--0OKZRGM[34(;6VBDC=%B>1851BV\
MX0!\L ,DY((SBNB\'^*GUS4-2TZ6_P!/U%K1(I4O+!&2-U?<-I4LV&4H>_(8
M=* .L5%3.U0NXY.!C)]:4@$$$ @]0:26-)HGBD&Y'4JP]0>M>777@CPZGQ/T
MW35TU192Z5<3/#YKX9UDC ;[W8$_G0!Z;$EO$XBB6)&5?N* "%)]/3.:5[:"
M6+RI(8WCSG8R@C/KBN :QU*T^(]U8>'&LK18M"M5#W4;RJBB6;:H4,IY]<\8
MZ'-4_P#A9EQ>6NE!;[1](N+C3%OIFOU9T=V9E$: ,I RC$L2<#'!H ]0HK-\
M/:L->\.Z=JPB,7VNW24QDYV$CD9[X.16E0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+XCT.36K>
MS>VNA:7UC<K=6LS1^8H< J0RY&5*LP.".M;58OBKQ /"^A2ZL]JUS%$Z*Z(X
M5OG=4&,\'EA0!E2^$]7N4M[Z?74?7+:\-W!,;8_9XP8_+,0BWYV%2<_-G)SG
MM3/^$'GN%DN;[4TDU*XU2UU"XECMRL>("NV)%+$@87&22<DGVK4T_P 3QW/B
M.;P_=V<UEJ<=L+M4=E=)8BVW<K ]FX((!K<<L$8JNY@.%SC)]* ,&3PR9-1\
M17?VL#^V+2*V"^7_ *K8KKG.?FSOZ<=*Y/2M UNR\3ZO9:3JD-LUOI6GVC37
M%H9$DVI(N]0'7##&>I'S<CI76Z)XANM=T'3-5M=,PMW,R31M< &! S*7SCYN
M5' QU]JWZ .,M_!5YHB6G_"-ZK#:/'I\>GS&ZMC,)%C+%)  RX<%WZY!W=.*
MV+309+?Q+_;$E\T[G38K%@\8#.4=F,A(P,G=T %:5I-=2M<BYM!;B.8I"1*'
M\U,##\#Y<DD8]O>K- '#IX*UBU\.0Z'::W9M9&V:VN([NP\U3N9FWH XPV&Q
M@EAP.!SF&Z^'EZUCJFEV>MI!IU^(W;?:[YQ)'&B+E]X!3]VI(QGJ 1FN^HH
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M!(4G[H&2<^U:,_B"Y?5KFQTW3?MILIH8KP^>(VC\P!LJ",-M4ACDC@\9-;U
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M\94Y/()SWKTY+BUN'18YH96*"9 K!B5/1A['UJ>@##\)WHN? ^B7L]P'+Z?
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M&"_(!YV]L\;DO@"[FDN[E]?8WL]W!?QSFU'[JYB7;D+NP8RGR[.N/XB:=)X
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M2UB/Q7J.A:O<VUV8K2&\AG@MS#@.TBE"I9NA3(.>]5/BL%/PVU0/&9%+6X*
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MM"S0-(KARQSG9R,<9QVR=K1_"^I:7##8OKS3:5:P-!;6PM@K["-JB1\G?M'
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M2?$NBZ[+)%IFI07,D:AV1&YVGHV#U7W'%,\3^)+'PIH<NJWY/E(RHJCJ[$\
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MR-%L%&A?"I&M<>4^]P4^XWV61LGT^;!^M '=+XN\/MID>I?VO:"SDD:%9F?
MWJ"2IST("DX/I6/XH\>6VG^ =2\2:#-:W[6;QQ[6)*AC(BD,!@@@-G'TKD-1
M>&QU8SWD+_9D\;^:?W9.!]CSOP!R 1G(]#53QFPUCPK\0]3TQ7GL+J33XX)8
MT.)GC=!(R^H&5&?]D^E 'JNJ^*-#T2X2WU/5+>VF9=X21N0N<;CZ+GN<"KO]
MI67VZ&R^U1?:9HC/%'NY= 0"P]1R/SKAKG4K#P_XL\7'6PR+J,,#6@,9;[3&
ML.PQI@'+!]WR]?G![U5NK"\\/?#WPEKMS&XO_#D,+W28RWV=D"3I]0I!^J4
M=O>^)]$T\W(N]2MXFMI$BE4MRKLNY5QU)(YP.<47'BC0[72[?4IM4MA9W)Q!
M*'W"0\\+CD]#G'3!KS9K"\T^W\.>(;R^?2FO;B[O;ZZ\@2BWDG53&&# A0$7
MR\]CQWI/L_\ 9EWHFK1>(+JVTV4Z@?[2FL%"K++(C?<(PBOM<JV!G_@5 'K5
MK=6]]:Q75K-'/;RJ'CEC8,KJ>A!'6IJY_P %6D5GX5MD@N+B>&1Y9DDN(/)8
MAY&?[G\(^;@>F*Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M $X/?T/:@#KJ*X9_$.IKXXDTZYU.WT]?M:1VME<VC!+R$JI+)-T,F2V%']T
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M/+D/ES,R+('R1D+M))Z_=XSD4 ;^FZ-#IE_JMW'([OJ-PMQ(&QA2(TCP/;"
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MMZ+\V#D$=1GIBJ,EU8_#O1M*TM6AM[2:>2-;BX9E@@)+.%+')4$G:N3VZ]B
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M=BL,2%W8*3@#D\#DUPUO\3+*\B\.W\6R#3]1,RW/G(Y>,K'N55Z9)) X!SG
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M)(]#9S'N@YF#(R$-\W'#GIWQ]*UH?%FA3Z7=:BFH1K:VI"SM(K(T9., JP#
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MVQMWFY^YLQNW?[.,TDOC#P_!IMMJ$NJ0I:7+.D4AS\S*"67&,AAM;@\Y&.M
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M5T=C;M:6%O;-()##&L>\+MW8&,XR<5DW?C7PY8W<EK<ZI%'-%,()058B-SC
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MW$*PA72:WN+?SHIE;'#+D=,>O<U3U'QIX=TJYGM[W4XXI;=PDR[&;RLJ&!;
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MCD31O*)8, '!W,",X!'->FU@ZKH,.M7WVFWUK4;&XBC-O+]AN% *GYMK*RL
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M%^M0V\,DTK+%M2-2S']ZAX KJ8VL(M5FB1XA?SQB:1-WSLB_*&QZ#IZ9-7*
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M,^_>I)7+ ^8W)Y%:%KX72/5['4KN[:[N+".2.WD:,*^U^H=A]X <#IZG)YH
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M*&:9MB%#$Q9'0*H"D$@CW7/.3F:Y\'2:EHU_8:KKM_>M>&',C!$$8C<. B*
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M(8@N\, "3D<#FN*TRRO]+U#2_$UUIE\+)]1U*:2W2W9YK>.X8&-VB4%OX.0
M2-_UJ0V(F34=8O\ 3]=LX;[6#<V<]C"_VFT @6(2M& 6P^U@05/!&10!U4GB
MFRN=4\/FTU;RX=0^T[;4V;L]R8U^9<G!C9"#D$9)XK*C^(%MJOARXU%+B?1U
MAU$6OG7%A)(''G%% !"\MMYQG83S69;V^OZAXH\ 7^H6MW*;:34Q-</;&,B,
MKMA>50,1LRA>#CD]!TK)O=/U*?P#>Z,FDZB;ZV\0^>R?9'P\;7;.'1L8<;>2
M1G'>@#T75/&>BZ1>SVMU+<,]LJO=/#:R2I;*W(,C*I"<<\]N>E)J/C71-,NI
MK626XFGAA2=X[6UDG(B;)#_(I^7@Y/;CU%<U>/<Z+-XRL)=)U"[EUB1IK%[>
MU>5)M\"1[&< JFUE.=Q P<U:\+Z)?:7JNJ0W,$AV:'I]JLVP[97C24.%/?DC
M/U% ';6EW!?V4%Y:RK+;SQK+%(O1E89!'U!K"A\=>'YVOC'=2^58K(;J<V\@
MCB,;[&4MMQNST4<D<@8(I_@6VGL_ .@6UU#)#<16$*212*59&" $$'D&N070
M-2F^&>NV26=U%=OK$]VL:KLED1;L297=U+(OR]CD4 =?'XST1M.OKV6:>UCL
M0IN([JVDBE0-]P[&4,=W08!R>.M,B\<Z&XOM\MS ]C:->W,5Q:21O%$,Y)5E
M![=NM<5?Z2U_I]]JNG0>)+^:WEL7?^THBCW$<,_FM''&RJQ*C<>1@DX&:=JT
MTOBGQ#XGBT^QNHWN/"CV]N+F!H7F8O)CY7 8#)QR!W[<T >C3:S8Q75G:-.5
MGO89)K<;"=RH%+'VQN7@US]AXXTFV\-:1>WVKM?-J"R?9YX;&1#<LI.0L0!(
M/8#O67;W=SK?B7PW<0:3J<-O9Z==13RW-H\(61DC 3# '^$\]#V)YQD>#=$U
M*VTWX:)=:;=1-9&]-R)(6!@+(X7?D?+DD8SZT =W-XTT6WO5M99;A7_=B5_L
MLGEP-)C8LK[=J,<CAB,9&<9J1?%ND-K/]EB6?SO.-N)?LTGDF8#)C\W;LW8[
M9]NO%<-J6B-_;/B#3]0'B5X]3OEE@BTY,V\\;I&I+.4*H5*G.YAP!BM)3=6?
MC(+HT.MVTD^HDWUG/;E[*2(YW3K(1M0D8;"MDG@KUH [?5-5L]&T^2^OI#'
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M]$\0W-O>7DZ(?+A\O/G*QZ R".(>^YJ .LD\;Z''=1P-/<?,(M\OV63RX3*
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M5^<893N7=QDL1F@#T[5=5L]$TR;4=0F\FT@ ,DF"=H) Z#W(K"_X6#H/FS0
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MPN^)RA7<N<9P0#BKE06=I!I]C;V=L@2"WC6*-!_"JC 'Y"IZ "BBB@ HHHH
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M]N#JNF73PSW(C+V]Q%LVN"%'RGS.5((XXJC)XWU#4M+T.:R8Q7$-E<:CJT0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K*'AZQ/B'^VY3/->*A2$2S,T< ( ;RTZ*2 ,GK^=:M%
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M92NTQJ=F"F.S!OT%=;10!FZ)HEKH5G)!;/-*TTK3SSSONDFD;JS'@9X X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445 ]Y;1W<5H]Q$MS,K-'$6&YPN-Q ZD#(S]10!/15:ZU&RL71+JZAA9T=U6
M1PI94&6(SV Y/I4T,T5Q!'/!(DL4BAT=#E64\@@CJ* 'T444 %%%% !12$@
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M:"5)8F^ZZ,&!^A%24 %%%4GU?38Y;R)[^V62RC$MTIE ,"$$AG'\(P"<GTH
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MBBB@ HHHH **** "BH;2[M[ZUCNK2>.>WD&Y)8V#*P]01UJ:@ HHHH ****
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M092>=@Y'-9?AN&[_ .$VUCQ0/"NM0P7RHEM%+Y,;(2%$KLC2 J6*)VY"9[T
M>EUQGQ5&?AUJ \D39GM?W1Q\_P#I,7'/'/3FNHL+.2S6X$MY-<^;.\JF7'[M
M6.0@Q_".U5/$NA1^)=!GTJ6XEMUE:-Q+$ 64HZN",@CJHZT 8>AV<:ZO"S?#
MNWTC;DB]'V0F,X/3RR6YZ<>M<]'K_BR31-.UE-8AS<ZRVFBV:T0Q[#.\2NQ&
M&W+@'@@$#![FNQLM!UNVO8IKCQ?J%U$C9>"2UME60>A*Q@C\#3(O!EI%HMEI
M@N9S'::E_:*N<99_.:;:>.F6Q]* .6U#Q#XETJZU+2(]5CNKF#4M.A@NI[9
M=EP<,K*H ."#R,'GK4'C"]U6UT+QGX?U/4/[11-%6]M[AH4C=0S.C(P0 'E
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M9L8SP^,^]<UX66[TS_A%+F\M;E-+MUO[=U:!A]EE:;,3LN,A3&"H;&!N[9H
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M3,/,$H8C@*<8VGO73@A@".AY%><Q0V<GQ'\53:C%J"VTT%I'#+"MPB2%5<.
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M,;E064@\C!R* +M%>8)XJU;25U2YU;4KM-2M;2[N#I-W9*D,@C!9#;RJHW
M#.68X)R!4(\8:]HNG7]](=7U"&/2I;EY-1TPVT<-RNW:%(1<HVYN"21LZ\T
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MVCIDT >H457L;>:UL88)[N2[E1<-/*JAI#ZD* /R%6* "BBB@ HHHH ****
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MIVJR7+K:ZC<BU@)C.?,)88(ZC!5LD],5G>*_&D.CZC9V=O.PECO[9+T"$O\
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M)X]>U6#[2(_MRPM&GVMD4*')"91B% .PKD =*NR>&;21M?)EG_XG:A;C!'R
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M7&,Y&.WOZ<UQ\/Q EFO_  Y,]K=QVVI:;-.]HEHS2O*IAQL&,E<.YST(Y[4
M=!IW@W3=+N='FM7G']E6LMM"K,"'$A4LS\9+$KG/'4U5O_ EI?3WZ#4K^#3M
M1E\Z]T^(IY4[<!N2I=0V!N"L,_B:L#QMH[Z99WL'VN<W<DD<-M#;.TY>,D2
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M@L+NV^V7@OHWE@BM;5Y)-B$!V*@94*2 <]^* +C>'+1I]<F,LV[6(UCG&1A
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M*Q @;S]IC^7GCGI77B1&D:,.I=0"R@\@'ID?@?RJKJ>EVFKVBVUXA>)9HY@
MQ'SQN'4\?[2B@#S?Q1::CXG_ .$GU"QTG4(X_P"P#I\*7%NT<D\Q<N0J'D@#
M ST)/&:Z+7+>YT[7O#.MK8W-S:65O/;7$=M$9)(O,6/:X0<D QX.,GYJZB^U
M&TTU8&NYA$)YTMXR03ND<X5>/4U:H \BOH[RSNM/UF?3+E1?^+1=PV;(!-Y0
MM'3<5[,=A;;UZ#K4VJ:1J.MWFJ^((;#5+>U.I64J0HAANI(H8V1W13R#^\R
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M>-FX]@"?PK$\6VNN1^(]1U#2+>Y+_P!BQPK- @9L_:,N$SP7$98@>N*] HH
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M2I%Y9<H/XB,'@>E=;XMAGUOX>:Q#96TQN+O3I1% Z%)"S(<*5/1NV#WK7O\
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MOCTR,UQNM>$99-'.@V/VF>/5[I9-5U"YF#/Y2A=V>F2RHJ  8 R>,<]L
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M@^=M?EPS-G<&(!.0>1D8H;P7H[:3I^G;)A#8WJ7\;>:2[SJQ?>['EB6))]:
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M;=XPZG@C!$?3/-7I_ .D7>A:GI5W+>7*ZG(DEW<RS9FE*%2OS8P -@  &,4
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MH[@J6"%!W(QC&<[ACK6==Z=J&GCP;JL>GSW*Z5;M!=6T !E020JNY5)&=K*
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M6SCLI&N;[49Y;:,8S*K;,$?D?RKH?B!87FJ>!=3LK"W-Q=2H@CB_O$.I_I0
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M!?2FWB*^9)#-&561 2-V#VZXS61J-CJGB'3_ !:MMIDJW+^(;*7[."I9$6.
MG=@XR%P2 3@YZT =]J?CO3-,N]2MFM-1N&TS:UZUM;[U@0H'#DYZ;3VYX/'%
M37WC32[*]-LL=Y=;+=;J>6U@,B6\39VNY[ @$X&3@$XQ65<:/?N?B%MM7/\
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MHH *S9-!TV77(]9EMVDOXD*12/*[+&",$JA.U21P2 "?6M*B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** *FI:;::O826-]%YMM(5+IN*YVL&'
M((/4"K=%% !52^TVTU%K5KN+S#:SK<0_,1MD (!X//#'@\5;HH **** &R(L
MD;1MG:P(."0<'W'(JCI&B:=H-J]OIUOY222&61F=I'D<]69V)9CP.23TK0HH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>-E9K/<8SU!XXJDD%UK'BK1=13PS/HEOIC2RW%U=F%6D5HV01J(W8D98,<X
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M')<021!KQ0!<!0X!^8;7P.G(JWJ'BW6!<7T=D;:.\M]8BL([&6$N\D+;/WV
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MD(^!@CGOC'%4KSQ7XBMK37;\3:>8-(UB.T,(MFS-$WDY&[?\I E)S@Y(Z 4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@%_F_3IQ5B;PM:3W>J7+W-UYFIVRVMSAEP8U# 8^7@_.W/\ M?3&Y10!S_\
MPA^G,^GF62XF2PLWLHHY"I5H7 5E8;><A5'X?7+O#_A*Q\.8%K=:A/&B^7!'
M=W+2K;I_=0'H.!UR<#&:WJ* ,R[T2WO-;LM6>:=;FSCDCA"$;0'QNR".<[5_
M+ZUG0^"]/@L=/LTN;SR;"\:^@!=<B4EB23MY&7?C_:^F.DHH AN[6&^LY[2X
M0203QM%(AZ,K#!'Y&LRU\+Z39W.EW$-OB73+5K6V8GD(VW.?4_+U]V]:V:*
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MID-K90)->C[%=R7<$BS;75Y-WF#( X;>WY\8K3US1;;7]+;3[N29('=';RF
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M!SQQCIC QP*CN/!>GW-EJ=I)<7GDZE=+=W #J"9!MP0=O ^1./\ 9^N>CHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex1012022063010qngcbasho002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2!0"#T(- "T444 %%127,$,T4,LT:2S$B-&<!G(&3@=^/2I: "BBB@ HHHH
M**** "BHHKF":26.*:.22([9%5P2AZX([4X31-.T E0RJH9HPPW '."1Z'!_
M*@!]%%% !13#-$)Q 94\XJ7$>X;BH(!./3)'/O3Z "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KDO&&B:7.PUC4]%O-?\F'R(M.CC65%)))D"-C
MYN@W9)P!@5UM<_J^A:I<ZLNI:/KK:?,8/(EBE@^T0NH)(8)N7:XR>0>1U'%
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MOGY@ 2!@#L3G% 'JE>>_%O3&UG2M TU)6ADN=8CC253@HYBEVM^!P?PKI_\
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M;>^#QVPCC41,K"-4W$@';R2Q.3^%=30!D^)K^]TOPY>WNG0>?=1)E$\LR8Y
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MF";R0$C!XW'YN3P 1W%=7I'ABZL=3T_4;W4UN[BTT][#*6WE!U9T8-C<<$!
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M)I=)OO$>E")MAV3[#&LC@'JO09Z':: .\/CWPJML;AM=LA$KF-B7Y! !.1U
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MG=@QY(]>GZ5M>([V'2_$]ZVGWNZ^N9[;[1HMY:>8E]PBAX6Z@A<<\@%.0.M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUF:PO(+I8)3#*89 X1P 2IQT(R./>JEMXCT?4?M::;J=E>3VJEI8X)U<ICU
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M?*=L=RUPHC<\\!LX)X/'L: -2BH[>XAN[>.XMYHYH9%#))&P96!Z$$<$5)0
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M_P#\@ZZ_ZXO_ "->#Z;-X9D^%UC'_P )7>RZM'9J\6E+=&='G492,VY!##<
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MT7P=+I%Q+=OXBU2YN[F59KN1UA G90  1Y>0NT 8!&.U=0!CI0!Q@_Y+4_\
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MW]J50N=Y\MX\'\'S^%:0154*% 4=@.* /.;O4=(T;Q-XU7Q#-!";V"$VRW&
M;B 0[2D8/WCOW_*.<L/6LNXDU'P-H?A?Q)+;RR71T==*OH=I+&7R]T&1ZB0%
M"?\ II7K3*K$%E!(Y&1TK&U/P\=7UFRNKR_E:QM)%GCL%10C3+G:[-U.,Y"]
M,@&@#SZ72I/".JZ+!=:W9:7$NCR1M>7UN)8Y;AI-\XR64!F)!ZY('M56*&/1
M+VR6?Q):66FRZ!%#;76I:?\ +.@DD+QJK.NT[6C^7DD8]*]E9%<890PZX(S0
MR*^-R@X.1D=Z ,#PS<65AI>D: M])<7<6FQRIYL+1N\*@*'8'[IR0,$YK@OB
M'J/F2^+K$7-G93C3D1+<6PDN=0'ELP().=BDD9 .W#$FO539P-J"7Q4FX2)H
M5;)X4D$C'N57\A4Y5=P8@;L8!QS0!Y7=ZOIUOK;W.FZKIVH_;[RSDN-'NH@T
MLSD1*LUNV<D!0K9PRY5N1S6_XSU1++Q%HL,MY8:8K0W$BZC=PB0JP\L>5&"0
M-S!B>Y(7 %=IL3<&V+N P#CD"E*JV-R@X.1D=#0!Y%X'$%WJ_@Y7"R2V=CJB
M,K* T,@GC&"O\+!6Z=@:Z+PY!</X(\3VM@"L_P#:&J1VRKQM8RR;0/3DUW8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV[V(+,23M ZX'-4++P7':QZ79/="32]*N6N;.W\K#*WS; S9Y";SC@=%STY
M./\ [6N?^%>MXWWM_:G]K[PV>?)^U^1Y/^YL[>OS=>:Z_P ?7]Q9Z+96UM(\
M3:CJ=K8/*A(9$DD ?!'0E<C/;-'_  A<7E&P^U#^Q_[0_M#[)Y7S;]_F;-V<
M;/,^;&W/;.*==:'J&N+JUGJ=X&M?M$4^FRK;B-[9T;<._P X#*IR<9RPZ8H
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M\6O9[N#4(I_LH_<W,:[,@;L&,J-NSKC/S$\T /O=6\3Z8MGI4\FGR:CJ%_\
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M7A;6)-?\,V.IS1+%+,A$BJ"%W*Q4E<\X)!(SV(K8JMI]O-::?!;W%W)=S1H
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MYL8!!Q0!ZKN7.-PSG&,]Z-RG."..O/2O%]0L]*'AOQ3=JD N[?Q*C6LJG#Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@#'L-"-MJS:G=WTM[=B-X(I)$1/+B9]Y7"@ \A1GT4>^=BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#*TK1I+"YN+JZU*YU"XE)5)+@(/*CW$A%"
MJ!CGJ>3@>@QJT44 %%%% !1110 4444 %%%%  >17-6'A2:SM5L)M<O;O3$X
M6VFCBRRYSM9PNYA^I[D\UTM% !1110 4444 %%%% !63XET0>(]"GTIKEK=)
MRNZ14#, K!N,\=0*UJ* $0,$4.06QR0, GZ4M%% &5J^C2:O+;JVI7,%FH9;
MBUB";;I3CY7)4D#@CY2,@FM6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKE
M]7\7-8W>LPVEF+E-&T][R\D:3:%?:6CB'!R2%))[ CKF@#J**R+#7[/5K9DL
M+RRFU%8!(]JMP"T;$9 ?&2HR<9Q3O#NN1^(-(2\6%K>97>&YMW.6@F0[70GO
M@CKW&#WH U:*** "BBB@ HJ.XGCM;:6XF;;%$A=V] !DFN7T[Q?J%Z=.N9?#
M-[#IFH,H@N5E21E#C*-)&O**1CG)QGG% '645E6>L!UU.6^EL((+.=H_,CNP
MX5  <R9 \MN>5.<>M30ZWI-Q 9X=4LI(0@<R)<(5"DE0<@]"00#Z@B@"_15.
MRU;3=2DFCL=0M;IX&VS+!,KF,^C '@\=ZJ^(/$%OX>L8IIH9KB>XF6WMK6
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M6'JGB%[.^FL;#3Y=0O+>W6ZF@C<(PC9BHVYX9CM;C(^[UZ9W!R,XQ0 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<CI7J3>&[ES$7\1:DQBYCS;VAV?3]QQ2/X9GD$8?Q!J+",Y3-O:':?4?N.*
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M8E!EOKZT"SM5*$6T(*?=(0?+WX]* .2^(4<,I\,)<2&.!M;B5W$ACP#%*/O
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MAEB22(C!1E!4CZ4 >3ZAY\,<]L+RX72HO%=G#8NMPR_NV,9EC4@\HK%P/3!
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ML"I4LV&4IZ\AATKKZR]'M=9A:XEUC4K>Z>3:(XK:V\J.(#.2,LS$G/.3C@8
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MVQ:4*%8#8VX!00W(()'.,$\/N_".N:C:0Z=>ZS8S:?F!W'V B6)H]N?);?\
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MMVJZY!VCG/&#UR*R+?QMX@U@^'+73+;3X+K5+>[:X>X5W2"2!U1B &!92=P
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MI)M,=I2N?E3<)APJ\ 8P/3DT 9?C+P_91S2M;3W-SXMU*Y5]-D\UM]JH*\J
M<+$@!)R.<X.216T__$E^*%M'#\MMKUG*TT8Z?:(-F)/J4;!]=J^E1)X7\36F
MOZIJEEKNE^9?2Y#7.FO))'$.$B#"8#:!Z 9))[U,D<FM_$F.[53]BT*TD@\W
M&!)<S;2RKZA449]WQV- '7U2UF:]MM$OI].2.2]BMW>!) 2K.%)4$ @X)XZU
M%H']I?V);?VNX>^^;S&V!,_,=IVC@?+CBM*@#A!X^FN-:\-1VL$+:=J-M#->
M2G):(SAA"%YP,NC Y]16?'XJN=4\8^&P^G::\=Y?:I#973PEI8HH4VAU.[@N
MRMGU7'UJ]:?#<V6@ZSI\.JXFN[E)K*?R?^/1(G#PIC/S;6SSQG/:KMOX%2UO
M?!TT-[A/#L,T14QY-P9(@A;.?E.06[YS0!QB7OB&]\+65U>W=M>7!\5JEL"C
MH%9;B1<,2S?)P, #@#'-=_X=U;59]<UG1M7:SEGL!!*D]K$T2NDH; *LS8(*
M'OSQ69:>!KVWA%F^J0/90ZR-5MP+8B0?O6D9&;?@\M@$ 8QWSQT-EHIM/$VJ
MZQYX87\-O&(MF-GE;^<YYSO].U &M7$WOC&_MO"OBO54@MC-H]Y-! I5MK*@
M0@MSDGYCTQ7;5P>K> ]4O[77]-MM;@M]+UB9KEU:T+S1R%5! ;>!M)0'[N>2
M,]Z %U7Q)XE^W^*(],&F1V^A(DH-S$[M/F$2%/E<;>_S<]1QU--?Q+K>ORZA
M'H\=C#:V>GPSS)<HSO,\T9?8K!@$ 7'S$-R>E;<GAAGE\4/]K _MR-4 \O\
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M%47DLDUM&%VE+<L?*SZDK@Y]ZWJ "BBB@ HHHH **** "BBB@ HHHH ****
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M5SG..: (_$/@Z#Q#>3W,MW+"TNGM9 (H.W,BR!^>N"@X[T:=X6N;;79M6O\
M5VOIKFT%K<QM;JB,JL2NT _*!N;(YSFK5GXP\/W]O=W%MJ<3Q6D)N)FPPVQ
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M!!]*EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEROB:S\Z]@F3R3!86=BK?:XECC8S22%"2 =XX88V =2*]>9E1"[L%51DDG
MJ"TO[._1GL[N"Y53AC#(' /O@T >5ZX)+Z^\>6=JMP9]0BL;NT"0,3/"D:%]
MF1@G"D8/4\8K;T34=.M;O5_$TVM:KJD=K8HD]Q+8K$@0,S;5"HI9ER21@XW5
MZ#4-U:PWMI-:W,8D@F0QR(3PRD8(/X4 2JP90PZ$9%>>:CJ$>C^+?%D=U#<&
M34K"W^Q+' [_ &AE212JD#&02,YQC.>E=[+>6T%S!;2W$23W&[R8F<!I-HRV
MT=\#DXJ>@#SCP'9R1ZUILLULZ%?"6G1;G0C!R^Y>>_3(^E8F@65TE_\ "G-O
M,@@MM060F,_N\Q8&[T]LUZQ'J>GS3^1%?6SS9QY:RJ6S],U:H \@\*V"F#0M
M+U'4M8N+[2S(TFF+8HJPLL<B,6DV E6#$ [CN+CKU$EI-:RV,^DBYU/5/#\6
MFD%C8%+S3-KQA(]^T;L#+8P6'E?Q=_4[*_L]2M1<V-U#<V[$J)87#J2#@C(]
M""*L4 <AX(U"ZOIM466\_M*UB:(0:FUIY#SY4[D;@!BG'S  ?-CL:@^*,22^
M&+,3+.;==5LWG, ?>L8E!9AL^88&3D<^E=M5>QO[/4[-+NPNH;JVDSLFA<.C
M8)!P1P>01^% '&>&;KP='K<2:1>:O)>2JR(MU)?.A&,G_6_*.!U-8>DZ<Z^"
M/AW$UFX:'5TDD0QG*?+.=Q';DCFO5ZA>[MX[N*T>>-;B96>.(L SJN-Q ZD#
M<,_44 >3:^18^*KJZN;:5K<>++*4!8BV0++EE 'S8(SQD\>M5O&(?6_#GQ#U
M/3()YK.[BL88&6%AY\D;?.5!&2 &49_V3Z5ZQJFCV^K2Z?).\BFQNUNX]A R
MX5E .1TPQJ*/Q/H$SE(M;TZ1A.ML0ERA(E;.V/@_>.#@=3@T <HVHVWAOQ?X
MCGUB*?RM1MK9K1E@>03!(V5HAM!^;=D[?]NL.XM]2\#>$/"?B(VLDE]8V TZ
M\MARS+*O[I3_ +LHC'_ C7KE8^I>'8-6U>SO;R[NGAM&66.Q#*(#*I)61AC<
M6&> 6QP#C- 'GSZ+-X0U'1C<:S>:; -):&6]M[59P]R9?,E#;D;!<MD<#.W%
M0)8_\(_?6<C:OK&F:;-HD4,$K6$<DCE9)&:)U,;!&Q(N% &<8[5ZW<W,%G:R
MW-S-'#!"A>261@JHH&223T %2*RNH92"I&01T(H S/#=DFF^&-+LHOM/EP6L
M<:"Y $H4*  X' 8#@BN.\2I*?'^H6Z"2.74O#3V=G)L;:T_F2';N P"-P/->
MBT4 >1Z;!'?Z:I&J:O>7EAHEQ%]EEL$A2UW1JIB8B-3NRHPN3]S/UU)-/8>
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M 4444 %%%% !1110 4444 %%%% !6/XJU^'POX7U#69\%;6(LB'^-SPJ_BQ
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M_12L2R;H_4D9!W9&3G':NFL?"EQ;6LMK=:_J%[;?8VLX8I BB-& &X[0-[@
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M751J)>TO6WF!(RC[8MP&T %>F,\CG).:VH?!K2:?=:?JNMW^I64UFUDL,NQ
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MXHUM8YE;2K)8((=JCYI63S';=U^Z\8Q]:U[_ $O3]5B6+4;"UO(T;<J7$*R
M'U 8'FL31/!J>'_#<.D6.J7BE+E9Y+H[?,EPP.UN,8*J$^@KIJ ///AGH.CK
MIE[>#2;$74.L7JQ3"W3>@$S !6QD #@8K)\)7>MZ/X4\'W@U-7LKR[2R>P\A
M=H1RX#;_ +V[(!ZXYQCO7HF@:%#X?LKBV@EDE6:[FNB7QD-(Y<CCL":H6_@V
MTM]"T72EN9C%I-S'<Q.0-SE"Q /M\W:@#EO#_C35=4U'2[M9KZXAO[IXYK'^
MR94AMH3NV.L^S#$$)N)8@[C@#%6_B!]F'B_PA]KTB35H=UYFTCA24O\ NEP=
MKD XZUO:7X4DTJ\B\C6K[^S()9)8=/ 144OGY2P&YD!8D*3QQUP*T+[1(;[7
M=*U5Y7673?.\M%QM?S%VG/TQ0!YWI]];6FMZ_P")]%T Z/8Z-I<\5[:ND<+7
M%PH$J QH3@!0?G/7?QQ6IX?UO6]3U!+ ZGJ$Z7=DTKW<NC/;+9SJ4PJ%XPKJ
MP9L [C\O7FNGNO"UE=:U>:BSR!;^R-E>VXQLN$YVLW?< 6&?0X]*-$\/W>E3
M*USKM]J$<4/D013!%5%XY;:!O?@#<??U- 'E?@G5;[0OAUX7@BU.YB35I9LR
M0:?]HDMTC:0ML5$8LS,5Y8, ,UT@\3>);Q-"L;>Y>VGO-3N;)KNYT\Q-+"D3
M.LHB< AL8[ %@>W%;]EX"M],\-:/I5AJ5U!/I$CR6EZ%1G!;=N#*1M*D.1CZ
M'J*NIX5!GT>YN]3O+NYTVXEN1+,5S*TB,I! &%4!N ,8P* .0U?Q=K5KJ.K0
M6M[?33Z/Y4,5M!H\DZW\@B21_,D1"$+;L  KCJ>#5C5=:\2RKXRO++5EM(-"
M(DMX3:HQDQ;)*4<D9QDGI@\GG@"NDO?"DD^JW=Y9:U?:?'?%&O(;<)^]90%#
M*Q&Y"5 4D'H!T/-2S>%;::V\20&XE UX$3$8_=YA6'Y?P4'GO0!B)J7B+Q+J
M>J)H^I0Z<-.BMQ'#) LB3RR1"4^8Q&0F&5?EP>IYZ5E:KXTUA-4U9K66\\S3
M+E((].MM)EN([K"HTFZ8(=I.Y@N"N, D'-=%>>!Q+-,UCK5]I\=W;QV]\D 0
M^>J+M# D$HVWY<KVQW&:GD\(,FHSS6&M7UA:W4D<MU:P;?WC(JKD.1N7*HH;
M!YQV))H G\9Z/=:]X:FLK,0O-YL4ODSDB.=4D5S$Y'\+!2#]:Y$SVD4NI*/#
M\_A;Q$=*F,3Q"-H9XTPQVLGR.5./O , W%=WKFC1ZYIWV5[FXM9$D6:&XMV"
MO%(IRK#((/T(((K*M_"#RW;W>M:S=ZK/]FDM8B\<<2PI)C>55%'S' Y.>G&*
M .9\.76MRZ9X2\/VVLO"UQHPU":[,$;2+&JQ*D2 @KU?EB"<#WJ:U\2Z[J-S
M9^'1?1P:@=1O+2?44@4EHX%#!E0Y4,P= >H'S<=*U[7P++9V.E);Z_=I?:7$
MUO;7?DQ9^SD*/*==N&'R*<]<CK4G_""V\5C:"TU*[@U.VNI;Q=1PC2/++D2%
ME(VD,#C&!C QTH Y?Q7K%WX3UCPIJ/B.9;R2T?4,26D1#3KY7R97& Y&,X^4
M<G@5WGAJ34;G1H[W4[J">:[_ 'ZK;8,42,,JBL/O@#^(]3Z"J-IX,@@O-*O)
M]0N[NYL9;B9I)R#Y[S+M;( PH'8+@"K_ (?T"'PY:SV5I/*UDTS2P0/C%N&Y
M*(?[N<D ],XH \GL;*SU;P-/I]AX3N9M=EN;E;?5%LE18Y/M#[9//."-O'0Y
M^7%=Y87NNZC\0=8T\:FD.F:7]F8Q+ K-,9(R2I8]!D$^O(Z8YZ'0='BT#2(]
M.@E>2-))9 SXSEY&<]/=B*;8Z'#8Z]JVK)+(TNI>3YB-C:GEJ5&/KF@#@?#?
MBC6]:\/>';.*[BM+W5;R\62[CMT_=Q0LY^5,;=QPHR0>YP36AK&MZ[HUSI>B
M:AJCI-<?:9GU#3].:XE>&,H$!B5&"L?,&X[2OR\8R*T;3X?6VG:%IUA8ZE=0
M76G7,MS:WH5"ZM(6WJ5(VE2'(QCTJ?\ X0MHXK6>#7+Y-6MY9I?[0<([2>;C
M>I0C:$.U<* ,;1[Y +WA+4[W5?#<-SJ$4D=T'DC8R6[0&0*[*LFQ@"NY0&P>
MF:X+1_%>N7?@'PYJ<]W-96UPUU]NOK'3UF,)61EC!C"D*IP<MM/0=,YKT[3;
M)M/TZ*U>[N+MT!W3W#;G<DDDG''4\ < 8 X%<YIO@>70] TW2]'U^^M/L/F@
M2;$<2K(^\[T8;20>AZCGU- $NJ^(KC2OAM/KT5Q:W]U'9"2.>$8AE<@!6 S]
MTD@XS7,ZQ-JOAGQ987^IZE_:OV30]1N59H5B;<@A9E^0 ;>!CC(YR379CPKI
MY\'-X8D,LED]NT#NS#><YRV0,!LG/3&>U9T/@<2ZC%?:QK%WJLB6<UB5F1$5
MHI-N00H'/R\GOGV% &'HNNZYJ<ZV7]IZA,MW8/+)=2:,]LMG,NTA4+QA65@6
M SN/R@YYKFO"MYJ.@?#+P/-;W:21ZCK%M;F*2WC(CC9Y-P!QG)QG<>1VKT_1
M_#EUIC 7&O7]]#%;_9H(90BJB<<MM WO@ ;C[^IK/B^'UC#X:\/Z(+RX,.B7
ML5Y#(0NZ1D9B W&,?,>E &)JVN>)A9>,=4M=6CMX=!N7\BW^S(PF588Y"KD\
MX^8@$8/)YZ5#J_C;5?[3U>2PFO@=-ECC@T^WTF2X2[/EH[AY50[2=Y4888P"
M<YKKKCPC:W&E>([!KF8)KLCO,PQF,M$L9V_@@//K4<WA%_[0GGL=;OK""[:-
M[N" (/-9%"[@Q&Y"550<'D#L>: .2\4WVM:YX6\=74.HK;V&GK<6261@4B15
MA!D9F/S!CN.,$ 8&0:[36+]],\&&ZBO8;*188U6XFC:0(6*KPB\LW. HZG K
M-U;P"FI'68(]9O;33]8R]W:0JA!D*!2RL5W#.U21GG'H36UK&@QZOHB:<;F6
M!HGAEAN(P"T<D3*Z-@C!Y4<&@#B8?%&OOI^LV]M/J%TUE<VV;N32_+ND@D&7
M80%5W%<''R]#T.*[#PGJ!U/1?/\ [7CU51*Z+<K#Y3X'\,B8&UQT(P.W K.3
MP5<PW=W?0^)=22]N_*>68+'\TD>0#MVXV[6V[.G /7FMG0M%&BV]R'NY;NYN
M[@W-Q/(JJ7<JJ\*H  "JHQ[4 >6+'JS:#>/)JK7,_P#PF,<,/GQ+M1UN5 <[
M<$@\?+G''&*W=4\4:WX;N-:TRXU(WLJ&P^RW3689XOM$CHV8XQ\^W82H R2<
M<UNIX$B2>Y_XFER;2;54U9;<HF(YA()" V,D$CH>E6]4\'6>J7VHWDES<1S7
MD5LBM'@&!X'9XW7(ZAFSSD<4 5O!VL7VH76IVEU+>W=O;&)K>]N]/>T>0.&W
M(59%!*E>H'1A6<FMZJ?&,VGWNL-IKO=/%:V<UB/)N(=ORM'-CYI.^-W8C;75
M:/IEUIZSO>ZM<ZC/,P)>4*BH , (B@!1W/<G\*SI?"LMQJL<]QK=[-8178O8
M[*14(60'(&_&[8"<A<\<#IQ0!Q/AC4M<@\,Z19PZNS7>M:Q=PBXE@1OLZI).
M\C*,8+-LXW9 STP,5J77B;7-,NM0\/-?)<7RW]E;6VH20*"J7&269%PI9=CX
MQ@'Y<CK6K!X CM[#[)%K%XBV]\U]I[A(]UG(S.6 .WYU/F,"&SP:F;P+;SV-
MZ+O4;N?4KNXBNFU !%DCDBQY110-H"XZ8.<G.<T <]XT.IZ)I&G3:[J27MI;
MZ_8S17(AVR^6&RP=4 !((.-HY';-=/X.U:^\16,FNS31K8W;?Z'9H 3"BDC,
MC=?,)!RO1>G7)J'_ (0H7"QR:CK%[>W8U"WOVF<*H)A/R(J ;57UQR<DYK4T
MSP_!I&K:C>6<TB07[B:6TX\M9NC2+W!;C(Z$C- '&WVL^*'L?%^K6NK10PZ#
M=3>1;&V1A,D<22,KL><$$@$8/)R3Q6EI>K:WKOCC4+>'4%M=*L8K.X\D0*SR
M>:A8H6/0<$D]>F,<YHV?@Z\U:?Q7!<ZA?V%AJ&J.)K=8U"W,/EQC*LPR-WS*
M2.H'M77Z?H-OIVN:GJD,C[[]($:(@;4$2LJX_!J .#\/>*-:U?0M#LHKJ*UO
M=4U&\B>ZCMT_=10ES\J8V[CA1D@]2<&M#6=;UW1)M*T74-5=9;I[F0ZA8:<U
MQ,T,>S8#$J,%<F09.TK\O;/&C:_#ZUL-$LK&RU*Z@N;&\EO+6\"H71Y"VX$$
M8*D.00:G_P"$+9(;::+7+Y=6@FEF_M!PCLYE #J4(VA"%7"@#&T>^0"[X1U.
M]U7P]'<:A'(ERLLL1:2W: RJKE5DV, 5W* V,<9K=JIIED^G:?%;27EQ>2+D
MO/<,"[L222<8 &3P , 8 Z5;H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE/B'XM?P=X3N-1MXA)
M>$JENKQ.\>XLJDL5Z  YY(SC YKJZXOXKVES??#G4;>TMY;B9I;<K'$A=CB>
M,G '/ !- %F#QGINGZ;:#5M1>XO)(FF<V^F3H0@8C>T6&:->,9;@X)J]?>,_
M#^GFU$^H*3=P?:+80QO*9H\@978#G[PZ=N>@-8D]ZOAKQWK=_J%K>R6VHVEM
M]EEMK62?+1^8&B^0'#?,",X!R?2LCP=H-_IFO^%$OK*1&MM N%<E25A=IHR$
M+= P4D8]C0!U_C77+SPYX7GU'3[:*YNUEABBBE8A6:254Y(Z?>JC>>-D/@-?
M$EA "YDAB>WFR#$[3+$Z-CHREC^52_$&VGNO"OE6\,DTGVZS;9&I8X%S&2<#
ML "3]*Y3X@Z-J.F27#Z39SW6GZY<VQNX($+&"X25&\[ _A9$(;W"GO0!V'C'
MQ%>:':6<&DVD=YJ]_/Y-I;R,0K8!9V..<!0?Q(J-O&EN?AT?%L,!D06GG^1N
MVX?H4)[8;()[8-8C:7KOB3X@7^L6UZVEVVDI_9]D9[+S/-+8::10Q&!G:H89
MR :KZ1!J_A"?Q'HUSI\NNVLZ_P!IVXBM_+242-MGB Y4$?>"=\GUH ZC3+KQ
M2-2MTU.UTNXL;B-F-Q82,/(8#(#!S\ZGH"O?MBL/0?$GC77?#\6N6FFZ)-!(
M9-MJ9Y8Y6".RX#$%03M[\51T.#3(O%NEGP;:ZM9V9:0ZI!+!/#:K'L;:-DH
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M'I0!V.F^,M!U:^CL[.]9Y9@S0%X)$2<+]XQNRA9,=?E)XYHLO&?A_4&F$&H
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M1WKL-1UJPT6PBN]3NE@A=UC$C*0"S=!CG'XUYQIFAZG83_#&*XLIE:U>\>X
M0D6X>)BJL1P,;@OU%=?XWM9;NVT18H'FV:U9R.%0MM429+'T ]: +=OXRT&X
ML+Z]%\8H; @77VB&2%XL_=RCJ&Y[<<]J2'QGH,UC?WGVR2*/3X_-NEGMI8I(
MD()#%&4-@X."!SBN.\3Z9?S>)-?O(;&XGA@DT>Z*1QDF=(99&D5/[S 8.!ST
M]15?Q2)O$P\3ZGI5G>26@\.O9*SVLD;3S,Y?:BL S;1WQU;% ';'QQX=%O'<
M&_;RI9WMXF^SR?O9%7<0GR_/QT(R">!D\5"OQ"\+ND;C47"M)Y3$VLH\E]VT
M"7*_NCNX^?%5-5L)#K/@41VKF&VN)#)MC)6(?99 ,^G.!SWQ6!JFF7;>#?B#
M''8SF:YU9GA58CNE79!@J,?,,@\CT- ';2^+=$AUD:2]X1=^:L!Q#(8UE8 K
M&9-NP.01A2<\CUJGX9\07FK^(O%%A<B(0Z9>)!!L4@E2@8[N>3DUQ6OSZA<W
M=[]H_M@RVNN03&RMK'_1UM8YXR)BPCS(2HSPQ.>V%-=+X*M;F#Q;XVFFMYHH
MKC4(WA>2,J)%\H#*YZB@#0/CG3$\3ZGHLRSQ_P!GVJW$LY@D*]'+#A< !4!!
MS\V<#)%2KXZ\.R6!O8[Z22#S5A1H[:5C*Y!(6-0N7. <[0<8.>AKF=:$L'BS
MQA"UK=,VIZ$B6C1V[NDC(D^Y=P! /(X)&<C'6I+IKO3/"?@RV_TVPLU@C2\G
MM+/S9X"(/E4+L8KEOE)VY[<9H Z>3QAH46E6NI&]9[>ZD,, C@D>21QG*B-5
M+[AM;(QD8.:P(/&QO-,U:]_M.TL[>VUE+*WGDM7D#(4B.UE!!#DNPR<8[CBN
M:T8W&DZCI6IW]GJOV:RU34A<--:N\J"?#12,$7G(&"5& 6[5#JMG?:AX7UZ6
M#2KZ/[3XK@N8HFMF5VBQ#^\VXR <$G/3G."#0!Z-J/CCP]I5U=6UW?,LMHP6
MY"6\LGDY4,"Y52%7##YCQ[\&IM1\6Z'I5ZEI=WVV9HA,=D3R+'&3@.[*"$4X
M/+$"N9N]/N6A^)A%I*6NXML.(SF;_0E7"_WOFR..]4;.670KO65O],OIO[3T
MJT%MY=J\BR%(2C1,P&$(/)W$##9H []=4@O- _M;3Y1+!+;?:()"I 92NY3@
MX/I6%X4\=:;KEAHL,]T!JM]9I*R+!(L3R>6&D5'(VL5YR Q(P<]#1X05G^$N
MC*JDL=&B  ')/E"L.VTR\_X1OX:0):S12VZQB?\ =D& FRD4EO[OS$#GN: .
MKM?&>@7NI)8V]\6EED:*)S!(L4KKG<J2E=CD8/ )Z&K7_"1Z3_9G]I?;!]C^
MT?9?,V-_K?-\K;C&?O\ RYZ?AS7GFG">Y\->$/"Z:=>Q:KIE]:M>![5UCA6!
MLN_F$;"& XP3G?\ 6H9)9X_"LOAP:;J#:C%XA$TBK:2;%A-^)1)OQM*E2.A)
MZ\8!P =\WC7P\E[=VC:B!-9^9]I_=/MAV#+;FVX''3)YP<9Q5S2/$&FZ[YPL
M)I&> KYL<T$D+KNSM)5U!P<'!Q@X-<CI>FHNC>/%U'2[R:"ZU6X9HH8R)9XC
M%&,Q],]\8[CCFM#P5>7D]]J,)O+W4=,BCA^S7M_9F"8L2^^,DJN\* IW8ZN1
MS0!J:GXQT+1[V2TO;UDEB57F*022+ K=#(RJ5C!_VB/6EU/QAH>D73VMW>/]
MH6%9S%#;R3-Y;%@'PBG*_*<GMWQD5R5[<-HLGC;3[O3[ZXN-6D::Q\FUDE6Y
M5[=(PFY00"K*0=Q& <]*T/"ND7>F^+"EW"Y:#P[86K3E25:1&E#@-T)Z$_44
M =:NJV+Z,-7CN!)8&#[0)HP6!CV[MP &3QVQFH9=?TN'3K+4'NU^RWSQ);2*
MK-YK28V  #/.?\:R?AW;36WPZT.VNH'BE2T57BE0JR^Q!Z5R7AS2KN7Q7_PB
M\JL-.\+2S7%O(>0WG#_1A]41Y1^"T =O:^,] O-22P@OBTLDC0Q.8)%BE=<Y
M5)2NQB,'@$]#5IO$>DIIMQJ#7@%I;W!M99-C?+*)/+*XQG[YQGI^%>>:<L]Q
MX7\)^%4TZ]BU;3+ZU:[#VKK'"L#[GD\PC80P'&"<[_K4.H2SQ>&-?\/#3=0D
MU&377N%1+20H86NUE$F_&TC;Z'.>U 'HL/BG1KC7'T6&[,FH1R-')$L+GRV5
M0QW-C"C!&"3@]!DBC6/%&D:#,D6H7+I(Z&7;'!)*50'!=MBG:O\ M' K*\(6
M<MOKWC":6W>+S]5#1NZ$>8@@C ()ZC.[]:H>-W2UU5;RVGUBQU0696"XM+(W
M,%U\Q(@= K<YYYV_>X/7 !NQZ_;?\)%?6[ZO:&WM[%+MH/*8-$AS^\,N=I4@
M=!TQFDL?&_A[4IXX+:^8S2QM-'');RQL\:C)<!E&5QT/0]LUP.K:/K>KZQXJ
M_P")?+%<WGA:&)55"$,WS%HE;H3GC&:T+W5H=;\8>''M-/O( FF7Z$W%J\+!
MC''^[ 8 G&.2..1@GF@#KM.\;>']6O;6TLK\R27:%[=C!(J3 +N(5RH4D#JH
M.1SD<&K^KZ[IVA0PR:A,Z>?)Y4,<<3RR2-@G"H@+'@$\"N)T_3KJ+P_\,H_L
M<R/:O$;A?*(,7^AR [ACY?F('/<UK^+';3_%7AG6IH+B33[0W,4[P0M*8C(B
MA&*J"<?*5SCC=0 FD>.K.XM-9O[ZY06=OJGV*U,4+L\F8XV"[ "Q?+-P!GCI
MP:DU/XAZ-I]GI=U$9[F'4+PVJF.WEW1D9W[EV%@PQ]P@,>>.#7)07-_#'J%T
M+;4M,L+WQ+)++<)8%YXX3;+MD5"C%=S@ MMR-Q'!SBK&+FTL;6>XM-69+/Q:
MM[,T]H[2^0\3!9"%7G.X9 &03@@&@#TE_%VB1ZLNF->$7)D6(_N9/+61@"J-
M)MV*Y!&%)!Y''-;=>3)I@?4]1TS4+SQ*K7>LF[AL[2U3R)(VE61)/,:([0O&
M[+@C81CH#Z=97Z7TEVB0W$9MIS QFC*AR #N7^\OS=?4'TH MT444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %'6-'LM=TR73M0A\VWEP2 Q4@@@A@1R"" 01Z5+I]DNG6,5HD
M]Q.L8($ES*9)&R<\L>3UJS10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@ZQX3M-9O'N7O=
M1M7EA$$ZVER8UFC&<!ASZGD8//6MZB@"&UM8+&S@M+:-8K>"-8XHUZ*JC  ^
M@%3444 %%%% !1110 4444 ,E3S87C#LFY2N]#AESW'O6=HF@VF@P3I;O/-+
M<2F:XN+B3?+,^ ,LWL   ,  5J44 %%%% !1110!%<V\5W:S6TZ[HID,;KDC
M*D8(R.1Q6+I'A&RTF_2]^UW][<10FW@:]N#)Y$9()5>!UVKDG).!S6_10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFN$E?'V=ER)%8G'W2",\=,UGVGC:PU3Q19:=I=U:W5I-9SW$LR,=R&-H@![
MB0GGT&* .JHKDU\<Z;?>(M&T[1[RTO8[R29)VC?)0)&SJ1Z@E2,\CK4+^/\
M3M+TS3[G5M0L)&O;U[6.2R<F,!6());GY< -[F@#LJ*Q;76XWU+6DN+_ $W[
M+8")_DD(D@5DW$S9X&>HQVZTMGXLT#4+6[NK75K66&SC\VX8/CRTP3N(/.W
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M?1E@T"R ME?O#W([@=.]4)O'?AJ/3]0O(]7M9TL(C+,L4@)P#CCURV!D<9-
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MVK,^'JI/K.@S;-SP>$X+=F*\HZRE77GH05P1[5ZC10!X]X>FCTNY\ 3WA-O
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M!,1=<8PV!G!^4D=>M6M/\0WNL+8W=II2SZ1>S21&43#?&B[@)&4C!5BN, Y
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MJU_JL)N9A]Z5)Y61HR>ZA6  Z#8N.E=MIWA&.RDTE9KMKBVT9673XBF"F5V
MNV3N*IE0<#J<Y/(9:^#+>W6QM#<;M+L+QKVUM?+P4D)8J"V>54N2HP.BY)QR
M <5/J$Q^'VJ>,O\ F+PZNTD4O\21I<B(0@_W"@(*]#N)ZFNP^(%[/;:+86L#
MM'_:.J6MC*Z'!6.20!\'ME<C\:ED\&6[B>T^T?\ $IGOQJ$EGY?)EW!RN[/W
M"ZABN,YSS@XJWJ/A^35[2_M;_4'EBEGCGL]L2JUFR;2N#_%AUW9/KCI0!P7C
M'5KGPM?^)--T<_98)M)M;B-81M6WEDN#;LR <*2I!X[KFNEA6/0_B58:5I\:
MPV-[I4KRPH,+OB= KX_O$.03U/&>@K0G\'VNI1ZN=6D^TSZI EM-)&GEB.-,
M[0@))&&8MDD\GV JW8:$T.L'5[ZZ%W?"U%HCK%Y:I'NW'C)^9C@DYQ\HP!W
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M*@DD)\MMLAPJD[5/!;[OO6!X\_M/0]7MO$.BV<US<W-I-I<B0H6(=@7@<@=
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M"RM&BB-&9P%8D8/WL=3BNCTJ_BUKXH?VG96MU]B&BF$74ML\2N_G*VT;P"<
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M)M9AM8 [>^2#BNI\&:EJ-]!J$-^+^2.WN MK=7UF;:6>(HIRRE5&0Q9<@ '
MH Z"[O;:QB66ZG2&-I$B5G. 79@JCZDD#\:GKR._NM9UOPGI?B"YU5VM[S7+
M7%@88Q'%$+Q53:P&_=\HR2Q!R>!Q6E?Z[K[Z'XB\4VVK-#%I-W<1PZ<(8S%+
M' ^UMY*[]S;6Y##&1Q0!WCZSIL<]Y ]] LME$)KE"XS#&02&;T& ?RJ"[L=/
M\2V.G7 G:2V2>&_MY(6&'*G<AS@Y4UYWJ+B3Q3\2G&<-X>B(S[PR5)9ZK=V_
M@SPI9V6L7MK(-!AG\C3[ 7,K'RT"LY9658^H[$GH>* /5:*\XT[7?$'B37-
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M=?[4U>V618HHR2QV@LV!G:H]3P,CGFMG6-<T[0+-+O4[CR('E6(/L9OF;H.
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M1I<*HY:-F4"0 D?=)ZYZ5G^'/'$4O@?0=4UJ1WU#4HR4AM+=Y'E89SMC0$X
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MD9U2500&*L5.,]LJ>>]7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%8)(QS/*,CEANV#/&5Z5#X@UC6?#!UW3(M8N;H1Z=;WUM<7"H982T_ENI(4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYSQR*Z'[):Z5XF\1V.I:>%TF\L(8]/2*W)C,2JPDA4*,!MS%MO4[N.E>@44
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MAZ=M'12O-Y;R'8LF>NT#[.V?:2NAN],AT_QSX/BBA9Q!:7<4TXB/.Y4QO8#
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MO0!R7AWQ5KUV-*UEEUJYAO5DEO8);-4M88S&SH8G"YX(1<DG<&)IBC5;S3O
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M@ 1JS,"O'#9<^HX'% '->(;C5M$NXEN=<UFVTJ*S4Q:E%:Q3H)]S;S<A4R$
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M:3%Q'/&T;&-RK $8.".0?<5SI\"V<\5T-1U+4M0GFCCB2YN)$$D"H^]-A15
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M@,57CZBM;PA90'5[W48X-?W&".#S]89@S@%FVJC -A2>O0[N,T )<ZIXFO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJZ6)(]/C5IY^&8HA8@)PI)8] #ZUR%MJ'B*]T,J/[<DM;'5I[>Z6!XOM_DA
M4!()#89@#M.2 .O- 'J(    P!T I#(BR+&74.P)52>3CK@?C65X8NX[[PY9
MSQW\M^I5E^T31>7(V&((=<###&T\#D&N;URR>X^+GAMOMUW$HL;J3RXY %RK
M1<8QT;.#ZX% '8Z=J-IJUC'>V,PFMI,[' (S@D'@\]0:M5Y#X=74-*\*>%]5
MAU>[_?ZLMH]IE?(\F2=T(VXSGONSG/MQ5SP_K7B'4[[3M4BAUR3[3?NERLBQ
M?8EMMSJ @SN!7"G.,DAL]: /4J**\PLKC5%^VV.M:IK=GJ\MG<,\<H4V\[+S
MOMI%&%VC^'K@\CC- 'IL<B2QK)&ZNC#*LIR"/4&G5Y3X62\ETCP3X?BU:_M[
M6[TAK^>2.0"0[4A58D;'RJ"Y/'/ YJ>UU?5[V_MO"TFJW2J-9NK-[]-HGD@B
MA$JKNQ@-\X4L!G"GN: /1+G4[.SOK*RN)@EQ>LR6Z;2=Y52S#(&!@ GFK=>6
M>*Y[[PKJ7A6>>6[UZ6VO+TP)'%F=U-N^Q&Q]XC/+8'')''/:>#I9[SP]!J=Q
MJBZC+?C[07CXBC!Z1QCJ%7ISR2#GT !OT5R?C>XOTG\.6EAJ$MC]MU46\TD6
M-QC,,K$#((S\HP>Q KE-8U77-'AU[2+36;F1[/4M-6UNKC#R*D[J&1C@;@"#
MUYPV* /3)M2M(-2MM/DD875RK/$@C8@A>OS 8'7N:MUP%Y=7^@^._"VC)J=[
M=VDEG>RS_:'#/.R@,I8@#ID@8 XQ4>A2ZPWA:R\8R:[<323V4EY<V$H5H7!C
M+JD8&"A4[>><@'.<Y !Z'17G/@V_U^XU+29Y8]<FMKRT9[^6_6(0B0J&1XMI
MRHSN7'3!'<5Z#=0?:;66 32P^8I7S(FPZY[@]C0!0TGQ'I.NS746F78N3:OL
ME9$;8&R1@,1M;D'H36I7B?@@7MKX)\-65IJM] -9U6XMYG#J?)CC:=SY>1\K
M-L )YZG%:^NZOK>BV?B32K/5[B1[&ZTUK2ZN,/(BSRA61C@;A\IZ\X;&: /5
M:*IZ78MIMA':O>W5ZRDDSW3!I&R<\D #OQQTJY0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'4M*
MMM5^R?:0_P#HEREU%M;'SKG&?;FKU<OX]UC5M%T""71!;G4+B^M[6(7"Y0F1
MPO/Y]: -[4K"#5=+O-.N=WV>[@>"7:<':RE3@^N#5"_\,:=J-GI%K.)?*TJY
MAN;;:^#OB&%SZCFL6\\9O/X0T[6=.0133ZA;6EQ!,N6A9IECEC8=F&2/R-2^
M-M>U>Q>PTCPVD$FM7OFRH)EW(D4:%F) (ZML4>[>U %FZ\#Z5=:G+=O)>+#/
M<)=3V23D6\TJXP[)W.54D9P2!D&I8O!^GP:K]MBN+Y(_M!N_L:W!%OYQR2^W
MU)).,XR<XS5"\\9EOAI_PE>G1H6>!'"R@E86+!'+@<X0EB?]TU/HLNO?:%G?
M6M-UK298&;[1!"(FCD&-NW:S!E(S[C Y- &MHVG3:<EZ)KAYC/>2W";G+[%9
MLA03T ].@S@4[5='M-8^Q?:@_P#H=U'=Q;&Q^\3.,^HYZ5Q7AJ^\=ZWX1L?$
M%OJVD3RW,/FBPFL&13U^7S!)P>.NW\*W8?&UE+\/6\7/$\4*6[2/ Q^99%)4
MQY[G>-H]: +FK>%K35=0^WK=WUC=F'[/)+93^698\DA6X/0DX/!&3@U!/X)T
MIAIOV.2[TYM.@-M UE.8V\DXRC'G()4'/7/.:I>"-?UB^EOM(\2I!'K-HL4Y
M$*E5:&5 1@$G[K!T/NOO5;3+_P 5>+K236-*U.PTO37D=;**2S,[S(K%=\C;
MUVAB#@ <#')H VM+\'Z3H[Z<UFDRC3_M(MPTF0!.^]P?7D<>E17/@G2YUS'+
M>6UP+Z6_CN8)MLD<L@P^TXQM(.,$$5%H7BV2^TE)+^PF74(M1.EW<5HAE2.8
M'!?/41XPV3T!J/QMKNK6)T_2?#JP/K>H-(T0F7<B1QH6=B,CJ=JCW:@":+P)
MI$&GSVD3WBM->C4/M/V@F9+C:%\Q6/<A><Y!R>QQ3Y?!6GS:=#;/=:A]HAN3
M=QWWV@_:%E(VEMV,<J=N,8QVK/U'QE++\)[CQ9I@1+@61F5)%R(Y!PRD>S C
M\*M:%XN$W@>?6=7V17.FK+'J*(,!98LAL#WP"!Z,* -/0_#ECX?:]>T>X>2]
ME$T\D\I=G<*%W9/KC_\ 54VMZ)::_IQLKSS542)+')"Y22*13E75AT((KSJP
M\;^)[GP--?7;6EGJHUR+3B3#N2!7:,'*Y&2N\]QTKLM(@UY=1C:]\4Z=?VX!
MWV\&GB)FXX^;S6Q@X/2@!L7@31UCU1;EKN\?5(8XKN2YG+/)Y98HV1C:1NXQ
MC&!CI5O2O"]II=[->O<WE_>2Q" SWLOF,L0.=@X  SR>,GOFL_P5XJ76_"=I
MJ&IWEHEY(\RNH<)C;*ZC@GCA15CP)K=UXB\'66JWIC-Q,TP8QKA<+*ZC ^BB
M@"K_ ,*Y\/CP@WA@1W T]I?-SYQ\S=G^]Z8&WZ<5NPZ-9P:S+JL:LMQ):QVA
M /RB-&9E 'U<UF0>--/N-26S6UOP)9)8;>X:WQ%<21ABR(<Y)^1L9 !VG!-'
M@SQ0_BO29;U[">TV7$L:^8N RK(ZC!R<D!1N]#F@#5T;2;;0M'M=+LPXMK9-
MD>]LG'N:K:KX=M-6U33=2DFNH+O3R_DR6\FS*OC<C<'*G:/RKCM8^(-X=+\4
MFVM+BQ;2+N&%+F2(%2I:'?G.1N.]L#'W<'K71Q>.-+W7ZWD-[I[65L+MUO+<
MH7A)(#J.2>1C'7) Q0 D'@;2H+R*59;TVL%R;N&P:<FWCFR6W*O7AB2!G /(
M%=-6/H_B*VUBXGM1:WEG=P(DCV]Y%Y;[&SM<<D$$JPZ\$8.*K:SXQT_1;R6V
MDM[ZY>WA%Q=&T@,@MHCG#.>WW6.!DX!.* (Y/ ^ER7&H2&:]$5_<QW<UN)OW
M?G(Z,' QP28USS5S4O"VEZM=W=Q>1R.]U9K9R .0-BN74C'(8,V<CT%8-OXJ
MD'Q!U>">_0:%:Z-%?J=HVKDL6?=C)&T>M:FG^--.OKJ."6VOK!IH&N;=KV#R
MUGC4 LRG)Z @X.#@]* +VCZ%%H[SRB\O;RXGVAYKR;S&VKG:HX  &3T'.><U
M/K&DVVN:5-IUX'-O-MW;&P>&##GZ@5CVWCG2YK*>\GM[^SMHK;[6DMS;%1-%
MP R8SGJOR\-\PXJ_H_B&WUB>XMA;7EG=VZH\EM>1;'V-G:PP2"#M8=>H(.*
M#4?#6F:M>S75["TK363V$B%L*T3,&(^N0.:H?\(1826-W;75]J=VURL:^?<7
M1:2(1MO38<  AL'.,DCG-6-5\66>EZ@]@MG?WUU'")YH[*#S##&20&;D=<'
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M\D4FQHE$,H#@YSD,R]*D3P1I7V&>WFEN[F2XNXKR>YFFW2R21E2F3C&!L48
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M!.X<DEL8P!ZUWM% 'D<OA_5M0TF_TS2-/UJRTTV:N;#4+@8CN(YHW2.W<L6
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MTMM<1)+!,ACDC<95E(P01Z$4 >9:U>WWB#Q38J-&NK-WT+44CCN-HD=V$0(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>QM);JZF2&WB4O))(<*JCJ2:\H2UU6W\+Z3-8I?1:K!H%M;W&GW=A(\%\%#
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MI8XG?RAQP2JD9Y''7VKB='UOQ#JE_::E!%KLGGZE)#,A2,626WF-'\O.X,H
M;=U)![&L.R2\T+PU\2M4LM7U 75GJ%PD9:12"P2,^8?EY?W_ $H ]KBD2:))
M8SE'4,IQC(-/KS^'^U->\4C3FUN^M+0:%:W3"U95<S.\@+;B#CIR.^![@X%A
MXGUO7;?2+>:76V8:-'=22:1''O>9Y'0.^[ P/+SM'!+'/04 >OU5T[4;35M/
MAO[&836TPW1R $;AG'0\]JX72;G7_$NLK9ZC?WFD7%AI-K/+#;[5+7,I?<S
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M"FL?]>,__H!KGO![:C-X0\)0SZ;:FP^PV[-,+@NR[80R-MV#'S <Y..G.<T
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M[IDB($AWY^5OO%>".!G.>+5SXIO--\07EM?>1]BFT_[9I92%A)(R\/&V6PS
MLF  ,[O:@#L**XBXU[Q1,^H6.F6MM<:GID<(F544133,@<K\TH*+@@ \\Y/;
M%+<^)/$=\^I#0M,22?3IHX6MY&C*R,8TD=2YD7;Q)@$*1E<\YP #<%AIDGBQ
MKEM1EEU".)76Q:[)2$8*^8L.>"02-V.YK:K+N--A6_DUR&T234DLVAC&%4L#
MAMI;KR5 Y.!SZFLGP?XF?7Y;J.:Y07$$4?GV4ELT%Q;2G=O#*Q.5^[M(]^30
M!U5%8GB+6IM*_LVWMHO,N=0N_LT? .WY'D)P64$X0@#(Y(Z]*P+S7_%>G6-K
M]LM+.&:768;)&D4'SK>1@ ^$D.QAR#R1QD8H [JBO.M1\4>)]/L_%3>?IDC^
M'RLV_P"RN!<QM$LFS'F?(1DC=DYXX&.;EYKGBB[UC7[+2)-+C&G6MO=0_:+=
MV,F]9#Y;8<8SL^]V]#G( .P.H68U$:>;J'[:T9E%OO'F; 0"VWKC)'/O5FO.
M+?Q#%?\ B7P[XCDA:*.7PS=7CQCDJ-T#$#U[UH1>*=5CM?"^IW M7L]>>.(Q
M1QG=;/+&7C(;=\P&,-P/48Z4 =O17&:;XEU>Y^T:5<M9+KL&J"U=5@81F#'F
M"3:7S@Q D'.-W%9L_BWQ)#INH:D'TUH[#7!IS0^0X,T9E2,'=O.PC?GHW2@#
ML=8T*VUK[,\L]U;SVKF2">UF,;H2,'V((.,$$5/I^F1:>KD33W$S@!Y[B3>[
M 9P/0 9/  ')]37(S^+M5TF]UNPOOLMW/:R6*VLD,)B!-TY0!E9S]TJ3]X9'
M''6DUGQ!XLT70M<O9[.V1;4PO933*O[U68*ZLB2'!4GALX.>G% '>45YSXF\
M0>(+*Q\8:>]Y:K/9:0M_;7%O 5*!O,4H06.2/+X;WZ5WFFB8:;;BXD227RQN
M=$*@_@2?YT 6J9--';P2332+'%&I=W8X"J!DDGTKD-;\1:QIFMZGIZ&R&[33
M=Z47@<F656VM$V'&XY:/&,??]J;:^*;_ %?PV=4L6L]L>D&ZG66W8@3D']W@
M/P 4<,.OW>: .OAN8+FUCNH9DDMY$$B2JV592,@@^F.:997]IJ5L+FQN8;F
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MU5/FS@$* S#D'.*V]0\<Z5IUW=Q217LD%DX2\NX;<O#;,0#AV]@03@'&><4
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M&6C)Z]0><$@Y'%5/%^K:K9:EH&GZ5>6MF^I7,D4D]S 950+$S_=W+U*XZ]Z
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M1*H8S%( P"C 4[CQ@GTQ5>_\+&TU/6;.;2]>O+745A%O'87KI Z^2D+1S$,
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ML-7\1>!O%.IWD7VC4Y-+DT6T$9W>:(496=3WWREO^^178+IEV/&?AR[^S/\
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M@MGUR9H(&?.XHAAP,Y/TR<8H A\/Z;?W_AW2]<G\3ZAYVIV!FNH3-\CM)'N
MB&1Y10G@KV!SZUS6AW%YI'@SX:K::A=JNH:A"+A6F)#(8VRGLO .*Z?3?"=Y
MI5_%=6^B6K"W#BUMY=;F>&VW_>\M##A<@D>P.!@5'9^#;NRM=-MDT>W>'3;H
M7=FDNN3.(6 ("C,'W0">* ,R]O\ 5'\)ZYXQ75[Z.]L;^<06JS8@6.&8QB)H
M^C;@IR3SEN"*L:Q_:5[<^/;@:WJ5LND(LEE%;S%%C<6B2'(_B!;^$\<GUJ_/
MX2O+B_EN'T:U$4UP+J:S77)A;RR@@[VC\G!.0"1T)&2#5Y])U60:R&T/3O\
MB<+MN_\ B;2?,/+$?'[CCY0* ,.ZOM4CU*VU;5KG6+;3YTM'MKNQ<-;0Y5=Z
M3Q=?F<GYB" &'(Q7HUU<QV=G-=3$B*&-I'(&2% R>!UZ5PTGA&^EG5_[(@6$
M^49;5-=F$,QC"A"Z>3@G"*#Z[1G-=)]K\2_] ;2__!F__P 8H \VT?Q!I5_\
M0/#^LW-]&=2U$W"O%@_Z.A5%@@Z=1DD_[3-VQ6SH]Z(? OB+6I;NXMKO4-5N
M%::WC$DP;SO(C1 >,X55&> 3FNDN+;6[G4[+49=$TTW%F)%A(U60 !P V1Y'
M/05S]OX=\0*NM:/<Z)92Z5J%T=0B>/560V\A96*AA%NSYB[P0N!G&: )_#4<
M^J7/BCPYJ<6I+8_9X=L&IW"3RH)ED#?.K-P=H(!/'-;'PZOY]2^'>@W5RY>9
MK1%=SU8K\N?QQFL&;P_XBTR&_GT;28#JFH6XM);F36I)><G;-('B&XIN/3G'
M &.*W=&M=>T/1+'2K71M,\BS@2%"=3?)"C&3^XZGK0!S_CJ]U76-673_  U8
MI<:EX=DBU.62=L)N9'"Q*@Y=F4L>J@8'.:L^!]6TZXU>9-/N9=5N]2@_M#4K
MYE$8A88CCB,8^X<*PVDY&PY)S5C4O#VJZCJAU1=,@LK]HQ%)/9:Y+$TB#D!@
M(,-C)P2,BJNF>#;S1M1%]IVDQV\S-ON-OB&X(N6R3NE!B.\Y)Y/K0!T7C>_G
MTOP+KM];,5GAL96C8=5;:<'\.M<KJ>BQPWOP]T>TN9;2%$FC\RW;:Y46V3M;
ML3CD]>2>O-=+J4>O:KI=WIUSHNF-!=0O#(!J;\JP(/\ RP]#7/6WA[Q%J&D:
M5;:UH]J;W1P8H+R+5WA9R%"^:NR(D9'KCG/&#0!7NTFN?!?CW1KN]N+I-)>0
MVES.^Z1,0).F6ZDHYZGG@5U=Y=R7_P .)[R48DN-(:5A[M#D_P ZYK4?#GB)
M?#%UX=TS2+1$U61OMM[)JSROAL>8SEH@264;!@'&1Q@5W$5F;K0S8WUM% LD
M+0/#!*754(*X#%5/W?84 >=:<]]X;T_P5?Q:I>W@U"W$5S:RR[HF'V5I5*+T
M3:4 XZ@\YZU8\%WGB*\NM"U%[?77@OK<R:C->S0M;'='O1H460E!NPH 4?*W
M/(KJM+\$Z1I-[:7,'VM_L49CM(I[EY([<$8;8I. 2./8<# I^E>#]+T>]CN;
M5KLK K+;02W+O%;ANHC0G"^GL.!@4 >;> IKFZ\&^!="CO+BTM;XZA+<26TA
MCD<12,0@<<J"7R<<_+6U'JNJ:7J+QMJ5U<66D>(8K*1YGW&2WN(4 $A_B*22
MKR>:ZF'P+HMMH5AI-LMS!%I\C2VDT4[+-"S%BQ#CGG<P(/!!J<>#](_X1V[T
M1HIGM;QFDN'>9FEED)!+ER<[L@<]L#'2@#S\>*M973M<<7TK2ZW$)=$!/^I\
MRX:W4)]%:!_^!&NJLHSIOQ7EM(I&9+S0TFG+')>2*7RU<^Y5\9_V16M)X/T6
M270Y&MFSHB[+(!R @PH /][[BGGN :KZ7HUW<>)=8US4XC T\:V%I"'!9+="
M26)4X!=F+8[ +WS0!TU%5["RBTW3[>R@,C16\:QH9'+L0!@9)Y)]ZL4 >4S7
M,UGXJ^+5U;2M%/#I=M)'(AP486LA!!]0:V--%_IGB?PQOU>^NQJUE.UW'<2[
MHRZI&P9%Z)R2,#L?QKHY?"FE2W6N7#Q2>9K<"V]Z?,/S(J%!CT^5CTJT=$LC
M>:;=%&\W38WCMSN. K*%.?7A10!@?%.,R?#+7\2RQE+5FS&Y7/L?4'N*R%T
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M557=U.23TH M:5X_T[5I=*\NPU*&UU48M+N>%5BD?87V?>+ X5NHP<'!-/\
M'^LWVA^'H;C3[J.UFEOK>W,\B!UC5Y K-@\< YK(L= U2+PM\/K1[1EGTRX@
M>\3<O[H+;RH2>>?F8#C/6M+XC:9=ZKX:@AL[![]HM0MIY+9-N7C20,P^8@'@
M'@F@"AIVNZO;>,=+TG^WK#7[6]29IS;VZI):!%RKDHQ&UC\O(')XK4;QYIRW
M#?Z%J!TY;O[&VIB)?LPEW[,9W;L;_EW;=N>]8*Z7=:EXBT6XTCPA)X=6SNO.
MN[R401&2':P,(6)F+!B1UX&*KMHNM_\ ")R>"1I%P=U^6&I;X_(^SFY\[?\
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ME#)#(C;@<,P!!W,,@\$"J.C>&-7M=6\+WEU:;&2\U*]O%5U86QN-Q1,YY/S
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MFBZJP@U34)#?>'+RZG\ZZ=QYZ>7MD0$XC/SMPN!TXXH ].KG(AX>\?Z3%=F
MW-O#.ZQ.VZ)XY%)1MK AAW'!YKEM*6ZTRX\"Z@FK:A=S:RGEWRSW3R1S VS2
M;@A)5=K*,%0.#SG-8?@^6>X\/>'-%6ZN+:TU'6=0%R]O*T3NL?F.$#J05R0,
MX(. : /7M.TVRTBPCL=/MDM[:/.V-!P,G)/N2223WJU7E5]<ZGHK:]]BO[Z>
MT\-:A;78CDN'D9[9X@9H68DEPJEG&[)'%)KNM:GJ.H7]_IMS>R:=+J%KHUO%
M:7'E&0<R3.A)"AF8B,/D$8.#0!ZM17D]Y-XDT^UBTQK#5XK&^U>**"!M21[K
MRO)=WC$WF$J"T8P2P.&(!Z5V7@R+5K>TOX-2MKN"!+HFR2\NEN)5B**=K.&;
M.&WXR2<8H Z:J6GZK:ZFUXMJS,;2Y:VFRI&)% ) ]?O#FN+\5B\L?$$^J7[Z
MN-(C2(Q7>FWA46)!.\RPY =3P22'X["L"_M);?0?'.O6^HW\%W8:M-+;+!<O
M'&I41D[D!P^>AW \=,4 >P5AR^+=)A?7E>60'0HUDOOW9^12GF#'][Y1VKB/
M$VI7*ZI?ZKI[ZN_V+4K:V-R;T16L)WQ*\0A#?O =YR2N<MP>*IZC_P ?7QF_
MZ\H?_21J /6+&\AU"PMKVW):"XB66,D8)5@"./H:ATO5;76+1[FS9FB2:2 E
ME(^>-RC?JIJGX1_Y$O0O^P=;_P#HM:\T@MYM.\%:EXCM=2ODOK379_)B2Y<0
M[3>E6C:(':V[<>2">1SP* /9**\KBG\1ZGK%_J-E9ZK)<V^M-!',-01+5;>.
M4(T9A,@SE QSMW;F!!Z5V/CW4KK2? VKWME*8;F.'"2CK&6(7</IG/X4 :TN
MJVL.L6VE.S"[N89)XUVG!1"H;GZNM7:\J\06S>$/$PN=.O+RXDMO#>HW$:7=
MR]PRR+Y1W9<D\D#(Z<< 9-02W7B;P_H=]JEK:ZK#!_8\KRS:AJ,=SNN/DV3(
MOF-MX+D@ +]WCB@#URBO*[E/$&D:'XDFCM]8L+%=#GD$E]J:W$@N5'RNA$C,
MN06)Q@948Q5E-(F/BO0[!]:UA[?4]+FN+Y/M\H\V1#%@J0V8^9#PFT8 '2@#
MTNBO&]-U'5]3.F:-(NL:G!;QWY86NH"WFE\NZ,4;/(74L%7'&>203G%;.E0Z
MQK&NZ7HGB*ZO[=K72&N7C@O#&\LAG,:N[Q,-Q"*IQG&7- '?:5JMKK-B+RS9
MFA\R2++*0=T;LC<?[RFK*7$$D\L"31M+%CS$5@63/(R.V:Y/X7@KX$MPTQF(
MO+T&4X^?_2I?FXXYZUR.I&;1-4^)&J6%W=QW<3VL<;M<NZQ^;''N;:25^7<2
M,CY0,# XH ]>JE>ZI:Z?=6%M<,PDOIC!  N<N$9^?3A#7+6UJ_ASQ[I6FV=]
M?W%IJ%C<//%=W<EQAXC'MD!<DJ3O((& >..*?XZM3>ZMX1MO/F@$FJL&>%]K
M@?9IL@,.1D9&1R,\8- '9T5Y:UQ)92ZQX=%YK-S&NM0P64$-X?/D5K99FB,S
ML&5.').[( P#S4-MJ>J:?HG]JR7-['!H7B!H+F":[,Q^R.%5E=LGS-ADW DD
MC;0!ZQ17E.L:OJ][<ZA?6DU])97>LPZ/;P6MQY1,<08RLC$A59Y 4W9!PO!Z
M5UW@R'5K9=2@U"UO+>S$ZM91WMVMS*B%!N4N&8D!@2-QSAO:@#;BU6UFUFXT
MI&8W=O#'/(NTX".6"\_5&J[7G]UHT6M?%+6()[V]MXETBU.VTN7@9F\R;#;D
M()V\\9QSR#Q7-Z9J^M^)(M'M;B+5[\)HXG9M/OUM'>4S/&)68NF[B,$#D98D
MCI0![)17DKS>*-5O5TW4+35I;VRT>W=AIVHQV^RX<R RL1(H?_5C ^91\W'-
M:=E9:GX@\27%CKFH:A;/%H=E+-;V=XT2K<L90S QD="O8X/&<X% 'H]-"*K,
MP4!F^\0.3]:P/ E_<ZIX#T.^O)3+<S64;22-U=L<D^YKD[:[G\.ZG/-XAN=9
MM;ADNY%OENOM%G=(JO(-L9)$;(BY"A5^Z1DT >F]*H/K%J#8&'S;F*_/[F:V
MC,L>,;@Q9<@*1T)X->:Z>;U+^YTV8:U;6UYX?GNF%[J1EEDD1HP)!M<^42'.
M0I ]N*BTEY]*TCX606=[>)%?,K7"&Y=@^;<';@G[H(X7H.PH ]>KG+;QMI-\
MES+91:A=0V\XMVEAL961GW;3M.W# 'J1P.M<YI5O<V_B);'79=;BNK][F..Z
MBU!GM+Q2&8*H#9@=4&1M"GY3R:XS3$FT;X11:AI]]?P7$VMB%BMY)C9]K(("
M[L#(ZXZ]\T >\U3U74[;1M)NM3O69;:UB:65E7)"@9/'>O-]1G\1ZIK>OW&F
M6>JS7=A?+!9/#J"0VT05(V*O$T@W[MQR2IX88Z54\30RZSX/\?:M=:C>I/:3
MW%I!$MRZPI$BJ-ABSL.[)))!/S#!&!0!Z[YB^5YG\.W=^%5M*U*VUG2K34[-
MF:VNHEEB9EP2K#(X[4\_\@X_]<OZ5Y/X:MI='\(^ =6MM3OGGO)[>TGB:Y<P
MO$Z,-@CSM4K@$$ 'Y3DG- 'L%,FFBMX9)II$CBC4N[NV%50,DDGH*\O&IZI_
M9S^"#J%U_;(U<68N_-;SOL9_?^=NSG/E IG/45U7Q(A67X;>(5+RKLL)7!CD
M9#D*3@D'D<<CH1P: -L:O9MK$6EK(6N9;9KM-HRIC#*I.>G5A5ZO,X- @N?&
M&A:<;O4$ME\/2NY2\E$KYFB.TR[M^,G. 1T Z<5DV&HZOJ::-I$BZOJ4,4>H
M,XM;\6\TWE77DQEY2Z%@J]@>203G% 'L5<W=^/O#-E?7%G/J1%Q;N8Y46WE?
M8P[$A2.XJWX3&JKX8LDUI7%^@9'\QU=BH8A"S*2"Q4*3CN37'^'/^$G_ +7\
M6?V-_9'V;^W)=WVSS-^[RXLXV\8QC]: /0+"_MM3L8KVSD,EO*,HQ4KD9QT(
M!%6:X?78M0OO%GA72[V^GMTN;2\:]CL+B2))6418 8$, "3@Y!QD=S7,P+?6
MGAQ=6.M:K+=6'B(6$/F7CE3;B\$6QUSA\J3\S MTYXH ]>K-M==L;S7;_1H7
M8WM@D;SJ4( $@)7![]#7F=RU]'X4\1>)1K6I-J&FZS<K:I]K?RD1+C B,>=K
M @D<@G! &,"M6UNY+#XC_$.\A7?+;Z;:2HI[LL3D#]* /2:*\QM8;C3K'P9J
MD>KZE<W.M2QPWXEO)'2=98'<LJ$[4*D @H!@4RSU;5+NQTSP;)?W(UB#56M;
MVY$A65K6#$OF;NOSH8ESW+F@#U&BO*_"D_B/4I]'UM;/5=UU=.U]//J"-;/"
M=XVK#YGR[#MQA0?E.<Y-;?PQM[BY\.QZU?:E?7EW<O/%B>X9T1%F=5 4G&?E
MZ]><9Q@4 ==/J$=OJ-I9-#<,]UOVND+-&FT9.]@,+GMGKVJR44NKE067(!(Y
M&>M<;XCOKN#XH>";.&ZFCMKE;_SX4<A)=L2E=PZ'!Y&>E<E%'J,OAK2-8_MW
M5EOKGQ UB7%VY58&NI(BFPG:<#D$@D$#G  H ]AHKR;6IK_1K3QAIFGZKJ$<
M=M<Z6UM))=/+)"9I4#@.Y+$''0DCD]C6@V@LWC/6-$_MG6AIZZ7#>K'_ &C-
MN6=GE7<'W;L?(#MSMSVX% 'I-!X%>.:?J>N>)H--ADBUB\:/0+2Y#6%^MJ1/
M+O!E?+IO/[L8'(^]D<UMZ7'JGB#6[N#7K^\LKK2])LV\NTNC&BW$BN9)2$.U
M^5  .5P#QS0!V-AXDL=3BTJ:T2ZEAU.)IH)1;ML50 ?G;&$)SQGK6O7C_A;4
M+JWE^%5K'=31VEQIEVT\2R$))MB4J6'0XY(STJUHMW<7/B'0I(Y-;%CKBW0>
MYO-0_P"/J,QLZLD2N?)Q@;2H4@'UH ]2@N(+J$36\T<T1) >-@P)!P>1Z$$?
MA5'5-=L='N-.@O'99-0N1;6X5"<R$$X/IP#S7DOA\75OX.\(V%HFJW<>IRW4
MMU#;Z@T4DGEEL*KLXV+SN(4C.WW-:&I)JT)\$PZO%/')'XE*P"YG6:7R=KE
M[J2"0#MSG/'- 'KE%>7WVKZIIMMKWA);ZX.JW%_'%I=P\A,@@NB3N#'G]V%F
MY[;!7=:WOLO"6H^1-*'@L9=DI<EP5C.&W=<\9S0!K55U*_CTO3Y;V6*XE2(
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M ]%HKF? 5]=7_A.)[R=[F6&XN+87#\M*L<SHK$]R0HR>YKIJ "BBB@ HHHH
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M%2N"""<Y%9OC+Q<;**Y@LS=13Z=J.GK<-&H/F1RR*2J@<G*Y&..M &M>^!=
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M-MN#QTZ'@\UT%% 'F6I>%]8NW\4V/]EM)#=:G!JMK-]H5(YQ'Y.8<AMZ,=C
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MDD*>G%;%K%XAU;Q9X=U"]T)].MM/M[B.X,MQ$Y,CHHRH1C\N5X/7GD"NZHH
MY7QYIFJWNDVM[H, FUC3KD3VR%PF[*M&XR2 /E<G\*P%\#ZA9>(M!M;6%6T2
M*&T>^DWC/G6JR;/ESD[F:,D_[%>DT4 >6R>$==7PGXMMEL=]U=^)#J5K#YR
MS0B6)Q@YP"0C<'%='9:9J4VJ^)[^:P>V74[*W2".21"V]8W#*=K$ @L!UQZ&
MNOHH R/"ME<:;X/T2PNX_+N;:P@AE3(.UUC4$9'!Y!Z5KT44 %%%% !1110
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M48/L]]-I=F]K#(P9DB^?S5!'!Q(1G''2L[Q5)L\;ZM+8.4FB\*W)NWC."IW
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MKMGY<;B<N!GDYKL9/"NB2VFJ6LFGHT&JR&6]0LW[USCGKP>!TQTI(O"FBPW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLW)3SC&1R) @"\,#@CJ/<50N]4N]4\2:OHEI=&S73[&.9G5%9I9)=^/O _(
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MW8@*./4D5</3KBO([DWLOP^U:6XU":ZE_P"$E6)6G5>-E^B@_*!V XZ<<8H
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M_ ^F3WD[W%QM>-I9#EGV.R@D]SA1DUTM !1110 4444 %%%% !1110 4444
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M+1+M[2YA-NRS7DLA6$_\LT+,2B^PQ5C4_">DZOIMG8W<<Y6R(:VF2=TFA(&
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M[*HZ@ 9R>PX-7YOB!8XTE;'3M0OY]6M7N;6&%$#$*5#*VY@%(W<Y./E/.<9
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MPN@C64@LWEYS+QC@[=OO6B/&D<&FW5[J6C:I8+"D;QI*B.;CS&VHJ%&92Y;
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M,*0#C'2J.B:)KFC6/@>>71YY9=+MKBTN[>*6+>AD";6!+A2N4YP<\]*],HH
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M>&>)X;66.6YB^6,* TP*LP('/R]3BL7Q+;>(=6TK6O#:>&H2NH2,D.HQ2QK
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M^MI2N\+\J2*S')(' !K7U/Q!IVE:??WD\V^.P*K<+%\S1EMI (]<,I^AK4H
MXC4=#U1_B5=ZU!I\-S9MX<>R032*$EF\[<(V') (ZG&*PO\ A%M8FM+H:5I-
MYIEG;O:W5MIE_>K(KW$,PD81X=Q&A4;>H&2#@8KTZ6ZMX)H(99D26X<I"C'!
MD8*6('KPI/T%5]+U:VUB">:UW[8+F6U?>N/GC<HWX9!H Y+6G\4:[ISEM#N;
M6Q2[@+6272)=W,(W>:-RR; ,[,#<"0&R>0*YN_\ !^N3^'/$&G6FA-;?;-4M
M+VVC^THP$:B(,I)?.]?+)/;G@FO7ZANKJWLH#/=3)#$"JEW. "2 !^)('XT
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M#?,OE!=NTYZC''-9<7@GP]%97EF;!I8;R-8IOM%Q)*Q13E5#.Q*@'D $8/-
M')^.=9OM.UW6Q9WLL)30[?&Q^(2]T4:0#H&"DG/M2>--"LM%\+:O;6&K72F=
M+1C9S71G*$7*#SEWDL,YP>Q(]:["U\':!9BX$=@)#<P&WN&GE>9IHS_"Q<DM
M^/;CI3+?P1X>M;2YMDL"T=SY?FF6>21V$;;D7<S%@JD9 !Q0!EZ39KHOQ'GT
MVTN+MK2?25N9([BYDFS*)2N\%R2"0><=<"J&M6<0^+<=Z%F>>'0)[F-5GD"F
M1)4"_*&QCU'0]P37<_V=:?VK_:?DC[;Y'V?S<G_5[MVW'3KS5>]T#3-0U6SU
M2YMV-[9Y$,R2NA )!*G:0&&0#ALB@#SOPM%KK0Z1JOD74<5Y8227]S/JGG"Z
M+1;U=8\_*0^,;0,*2*K6=K<0_"WP[J"ZIJ/]HZK=:8MQ=&Z<OM,JKA<G"_*Q
M' YZG->AV'@_0=,NVN;2QV2%'109G9(E?[PC4L5C![[0*LCP[I2Z39:6+119
M63Q/;Q;VQ&8R"ASG)P0.M 'GT^@0_P!K^,=.6^U1;*PL(;JUA&H3?NIG23+A
MMVXG,:G!)&2>.:BGEO6L;#Q'JQU&ZL#IEG*]WI]^8Y-/?8&D=H<A7#9!)PQQ
MD8(KTMM&T]KF^N#;@RW\2PW+;C^\10P Z\8#-T]:S)? _AV9X&?3SB&*.$(L
M\BHZ1C"!U#8DP!_$#0 OC.YC@\./&S7N^ZGAMXDLI1'+([NH"!S]T'H6X(!.
M.<5Y\\VHP6^I:0DUUIRQ:_IL*11W[3O;K*8]ZB0\X.<X/ R:]4U72K+6K!K*
M_A\V!F5L!V0JRD%6#*05((!!!!K-A\%>'[>021V!#;XI23/(=SQMO1VRWS,&
MYW')/<F@#A-=,_A^_P#$.CZ;?7L%E,-+^9KJ21H//N&BE9'8DKE0._7FM[2-
M+M='^+$]I9RSF'^PT<133O*8\SD<%R2 <9QGKGUKJ+WP[I&HO?->623&^@2W
MN=Q/[R-"Q4=>,%B01@_D*CTKPMH^BW;7=C:LMT\?E//)/)*[KG."SL2>@Z].
ME &%JMHOB#X@OHU]<726-MI27,45O<O#NE>5U+DH025"+C/ W>]9^GV4/B/Q
M-<:9?:Q=W]CIVE6K6LL-VT?VAI#(&G+1$;F^11GH.?6NNUGPQI&OO%)J-JTD
MD2LB21S/$X5OO*60@E3@9!XJ&^\':#J"6RRV/EBVA^SQ?9IG@(B_YYDQLN4_
MV3D4 <'X<>Z\47OAFWU34+V6"31[MIA'</']I\NXC1&8J022,'(Z_0FDT(S:
MQ?Z%H&H7M[)I\4FJG'VF17G\BX$<2LX(9MJL3U[#/2O2[?1--M;JUN+>SCBD
MM+8VD&S($<1*DH .,91>W:J-SX.T&ZMHH)+(JL-Q)<QM%/)&Z22$ER'5@PW%
MCD9Q0!YD\T^FZ+!%:7UQC_A/%MVD$IW2)OP59NK=,'/7'-6KVT33K;XJZA:2
MW45U$"L<@NI/ES;QN2 6QG/0]0.!@<5Z&G@WP_%90V<>FQK;P7BW\<:NP"SK
MT?K^G3VI;KPAH5Y>:C=3V1:74H?(O,32*LR8"\J&VYP -V,X[T <GI=N?$VN
MVFG:K<WAM;70+.XBBCNI(O,DD+AY"48%B-@ R>,GUK-\//=>);WPS::EJ-[+
M;MI^H";9</&;D17*1QLY4@D[0#G//T)SW]]X1T344M5GM'4VL/D0O#<20NL?
M'R%D8$KP."2*MVVA:99SV<UM9QPO9V[6MOLR!'$Q4E0.G5%_*@#S6TM-4OM(
MM4"WNKV.G7FHVTEE'J3P7#(L^V*0-N'F%%4KAF'WAW%=S;ZO91_#Y=76]O6L
MH].,YN90#<;%3)8\8+\>G6G7'@O0+E%5K)XRLLLH>"YEB?=*VZ3YD8'#'DKG
M'M6HNF6*:3_92VL0L/)^S_9POR>7C;MQZ8XH \OL8-6AU&[TFS>ZTF6]T"29
M&O=4:X<S!T596//EL=[ E?PZ"NK\%-';WFI:<]EJ6G7D20RRV5W>&ZC56W@2
M12$DD,5(.2.5Z#G-R/P#X:C51_9Q?;$\.Z6XE=FC< %&+,2R_*, Y"D C!K1
MTCP_INA><;"&17GV^;)-.\SL%SM!9V)P,G S@9/K0!YMKNF6PUGXGW/[_P V
M/1(V7-Q(5R\,^[Y=V".. 1QVQFIM4%QX1;3KS2[J\>XN=!OIIQ-</*LLD44;
MHVQB54@D_= &#CI7>7WA/1-2U"XOKJS+W%S;&UG99I$$L1!7:RJP!X9L$C(S
MP:N2:/I\UQ:3R6RO)9QO% 220B. &&.AR%'7/2@#B_!UEJ]KK-C,;2YM[&XL
M&-RUSJGVHW$OR%954D[3RV<8'S#T%/\ &2ZD_P 1_" TF:TBN_L]_AKJ)I$Q
MMBSPK*?UKIM(\*Z-H5PUQI]H8Y3'Y2EYGD\N/.=B!F.Q<@?*N!P/2EUOPMH_
MB*:UFU.U:66U#B%TGDB9 V-W*,.NT?E0!P%[?ZMX=USQ5<:@]O<:_+X?>\M;
MBS4K%'%#N 4QMD@[GW9+-GIQC%7S%#X5U7PO<VNH7SQ7\,XOVFNI)A,JV[2^
M;AB0&#*.0!][%=?I7A30]%^T?8-/C1KE=DSR,TKR+_=9G))'MG%1Z;X.T'29
MS-:6.'\HPIYLTDHCC/5$#L0BG X7 H X'2)[NSU:P:*/4;>#4M'NYV>\U(SR
MW.T1LDK)G;&PW'[O][':DT^TD7P1X-\W4=0>3Q!<6B:C.]W)N=!"[A =WR E
M54[<$]\DUW5KX%\.630M!8.KP K$YN9695*[=@);.S!^Y]T>E7)_#.CW.@0:
M'+9 Z?;JBPQ!V!CV8V%6!W C'!!S0!SO@^RAT[QWXOM+>:62*-;(*LLK2-&#
M&YV[F))'/&3P#CI5/4HI].\82:GJ:ZA+927\"VVH65^=MJ#L002P$XVL^<D!
MO]9V(!'8:1X=TK0GN)-.M?*DN=OG2-([M)MS@L6))/S'GJ:@E\):)/J_]J26
M9-R95F8":01M(N-KF,-L+# P2,\#TH \XM;#[%X137X+N\2^C\1LD>VY<1K&
MVH&-DV [2"&;.1GGKP*N7%[-_P )'8ZQ8IJ AN-?^Q_;;C4#ME7>T;Q) /E\
ML%6P2 ?ES[UZ%_PCND_V9_9OV-?LGVC[5Y>]O];YOF[LYS]_YL=/PJC)X&\.
MRW$T[Z>WF2S?:"1<2@))N#ET ;",6 )*XSWH \IUW_DG'Q._[&7_ -JP5ZOX
M[U"ZTKP'K=]9.8[F&T=HY!U0XQN'TZ_A4L_@_0;G3]2L)=/5K74[G[5=Q^8_
M[V7*G=G.1RJ\# XK7N+>&[M9;:XB66"9#')&XR&4C!!'H10!Y?K=C%X4\2:9
M/I-Q<RRQ:)J,Z)/<//ND5(R'^<GECUQP<5#9:;JQTHRR6UY!8W6C3->23:N9
MC<R;%9)5 ;*G.<[<##8["N]TWP7H&DW45U:6)$\,;11R2SR2E4; * NQ^7@8
M'0=NIIVF^#]"TF622SL=I>(P8DE>14C/)1%8D(IP/E7 X'I0!YQIEM.=,\':
M/:V5[>V<NA_;I;:/4W@,DI$2[BY;.U=QP@( + XXJ]!8:IJ>N^%M&UV^O%5M
M-O#=1P7K S!)8Q'O=",G&TD@Y)R.YKLE\">'4TVWL$LYD@MF9H"EY,'BR "%
M</N52 !M!QQTK0M?#VE64]E/;64<4EE UM;E"0(XV(++C.#DJ.3SQ0!YGX@B
MG?2?'^L?VC?I=Z5?[K#9=2*L!6&%N%!P<D\@@C\SF[K]O+X=U'7[6QOK[9-X
M5NKN0RW4DA,Z$ 2#<3M;#'[N!T]*[Z?PYI-Q9ZG:2V:M!JCF2\3>W[UBJKGK
MQPJCC'2GWV@Z9J4\TUW:B62:T>QD8LPW0.063@]\#GK[T <!I$$FO7_@^ROK
MV]:VF\+"YN(TN73SW!@&6*D$_>)SG^M9=A<ZIJ/]CZ*\-]J=K#_:1\H:@T#R
M^3="*/?)D%MBGIGJ03TKU.TT+3;&:SFMK41R6=I]B@(9CLARIV<GG[B\GGCK
M52X\'Z%<6D5LUFR)%-)/&T,\D<B/(Q9R'5@PW%CD9Q0 OA!-2B\+V<6KL6O(
M]Z,3,)6*AV";G'WFV;<GUS7FVEW5_J.@Z=#+J5\OG^,)[:21+A@YAVS?)NSD
M# [=.HP0*]<L;&UTRQALK*!(+:%=L<:=%%9]OX6T6TBBC@L51(;UK]!O8[9V
M!!?K_M-QTYZ4 9'A"+^S_$?BC2(9IVLK6>W>WCFF:4Q[X0S ,Q)QGG&>YKEO
M$DDUWKOQ'LIKBX:VAT".6.(3,JHX1VR #QD@9]>AR*].M].M+6^N[V&$)<7A
M0SODG>57:O'08''%5G\/Z5)?7]X]FC3ZA +>Z9B2)8P" I&<8P3T]: //+G1
MYK31-(N(H-2O=)@TE'E@LM4DCN+61AN,Z@N-_&0 3QMP!SBNI\8:O+:_#&^U
M33+N0.UDK0W71PK[1YG;!PV:G/P_\-&V@M_L4XCAC,*XO9P3'G/EL=^63_9;
M(&>!6]/86ESI[Z?-;QO9R1&%H2OR%",;<>F.* . DT>UT+XBZ9!8W%T4.BWK
M;)KEY2IW0_."Q)!;OCCY?K6)H$.K:QX \)WLBWNL0):3FZM(=2:"X=C(-LH;
M<-Y4!A@L/O#%>B:=X,T'2KE+FTLF%PD30+++<22L(VQE,NQ.WY1@=NV,FF-X
M'\/'3[*Q2Q>&"R1H[?R+F6)D1CEEWJP8J3U!)% '):8MIXQO[U9]7U-;&QTJ
MS>RF-TT$B^8CEIWVD OE0"3P-IXY-6=.MVU/Q_JTDNIW=];Z=86%S;+'<LL4
MTA60B0A" <[>GW3NZ'BNEOO!/AW44MTN--4+;P"V1897B'DCI&VPC<G^RV16
MG:Z1865_<7MM;)%<7$<<4C*3@I'G8,= !N/0=Z /-/"%MK6IQZ#J4UM=I%J4
M#G4[F35BPNDDB8_)&&RA5]N-N"HR*R=)#Z7\//AW)97%U$U[K]L+C%PY$@)D
M!7!/"G ^4<>U>J6'A+0],U+^T+2R\N<%RF979(M_+;$)*IGOM J&W\$>';6"
MW@AT\K#;WBWT$9GD*Q3+G#*"V%'S'Y1QSTH X?4O-N?#'B_Q1)J%[%JVF7UT
MMHR73JD"PMB-!&#M(8 9R#G?]*EU.TDU6;Q]=W5[J$;Z?#'+9QQ7<D:V\GV-
M'W *1D[L=<CKZG/;77@[0;W4GU"XL-TTDBRR*)G$4KKC:SQAMCD8')!Z"KK:
M)IS_ -I[K8'^TQMO/F;]Z-@C]>/E '&* ,76M8OK3X67>LV[9OTTDW"OCH_E
MYW8]CS^%<_X@M(O"'A;4+_1]=O%NY=-_U4]XTQ<[D!N0')(90QR5P.1GM7H:
M6=NEBMB(5-JL7DB)AN&S&-ISU&..:R-/\%^']+6X6VTY2MQ#]GD$TCS#RO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !01D8HHH IZ?I5EI4<L=C (4ED,L@4D[G)R6.3U)ZGO5RBB@""]LK;
M4;*:SO((Y[:92DD4BY5E/8BEM+2VL+2*TLX(X+>)0L<42A54>@ Z5-10 444
M4 %%%% !1110 4444 %%%% !5.ZTJQO;RUN[F 27%JQ:"0L08R1@D8/!(X/M
MQ5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(1E=QSGYL;0.V:W9-6N?#EO:66H2W.N:I=.YA2SMDC=D4 L<%@H"Y')/5@*
M.DHKE+CX@:7#%I1@M-0NYM468VUO!"#(6B($B,"1A@2<YX&UN>*COOB'IM@^
MH>9IVIO%IDJQ7TR0J4M]RJP9OFR1A^=H)&#QC&0#KZ*P=)\5VVJZQ)IGV&^M
M+C[.+J+[5&%$\.[;O7#$CDCA@",CBJ7Q!UV^\/>'[>\T]T29[^W@8NH8;'<!
MN#[4 =717-ZGXRMM.U6[TR+3-2OKNT@2YE2TB4XC;=\V68#C:>.ISP#SB.?Q
MUIXBLWL++4-3:YLUOPEG$I:.!NCMN9<9Y  R3@\<4 =117+7?CS38$$MM:7]
M] MHE[<36L(*V\+@E6<,0<X!.T M@'BB_P#'5C:7EY:V^GZEJ$EG!'<S&SB1
ME6)U+!\LP!X!XZGL#S0!U-%<A#XV:\\9:?I-GIUQ/87FFB^6[55QM9DVMRP(
M4!B#QG.,#&:9X6\86%Y9Z/!]IU&Z;4Y;I+>YNXHU):)CN1MG X!V\<A>>: .
MRHKF[OQKIUK?7MDEO>7-U;7$5J(X(U)FF=#)L0E@,J@W,3@ =ZT]%UF#6[.2
M>&*:!XI6@G@G4+)%(O56 )'<'()!!!!H T:*YWQGK=SHFA#^SPC:I>SI9V*L
M,@S.< D>BC<Q]EJCH?BV9/"6J7FM(TFH:')-#J"6Z#+>7\P=5)'#)M8?4T =
MA16'+XLTN+7M*T?=(UQJ<)F@=5!3:%+#<<\$A6QZ[35-_'%HS2)8Z5JE_(D\
M\)2VA4Y\E@KN"S ;=QP.<D@X% '445RTWCW3%FTV&TM;^_EU*T%Y:I:P@EX\
M@<Y(P1NR<^GK@'(\7>/&@T35O[)M[]#:7"VO]I+$A@682*&3D[NY7.W;GC.:
M /0**P!XLMWUE["+3]1EBCN1:27J0@P)+@':?FW=P-VW:">M;] !17,:[K&I
M6/C+PWI=K) MKJ;7"S;XBSKY<>\;3D8STY!JV/&/AYKE;==6MFE:X^R@*V1Y
MO VD] 23@9ZG@<T ;E%17$\=K;2W$I81QJ7;:I8X'H!R?H*XI_'(NI/">H6L
MRV^E:I)*+A9XB&P('D7#'W"] <],T =U169;^(=*NM-CU"WO%EMI',:&-69F
M<$@J% W%A@\8SP:LZ?J5GJMFMW8W"3P,2NY>Q!P01U!!!!!Y% %JBN3N]7U<
M_$-= M[JUAM'TPWH=[<NX82A-N=P&,'/2M"+6X--LUEUK5K';-=>1;S(/+60
MDX"X)/(;()SCC/% &Y16 WC?PTD,DSZO J1R^3)N# QMQ]X8RHY')P.1S3]1
M\9>'=*FN(;[5[:&6VV><A;)CW9QG'3H?IWH W**YN76;K_A/-,TZ&>%]-N]-
MGN0%7)+(\04AL\C#GI6E!X@TJYO([6*\1II0QB&T@3!?O>6Q&'QWVDXH TJ*
MRX?$6DW&GR7\-V'M8Y?(>14;B3=MVXQG.X@?7BG/K^E17\=E)>(DTDAB3<"%
M:0#)0/C;NP#\N<\=* -*BL!?%.EZJMQ9:-JUK)J)AF:'"F0!D.TD@?> 8C(!
MR>U36>JR6>CV)UUT34)(=\J01,<[<;FVC) &1GL,@9H V:*C@FCN;>.>%P\4
MJAT8="I&0:J0ZUI]Q=_98KC=*0Y7Y&"ML.&VL1@X)P<'B@"_16;:Z]IE_<K:
MVMXC3R1F6(%2!*@_C0G =>1RI(Y'K63X7\0RW7AQKW5YT,XO[FV4Q1$;]DSH
MH5!DD[5Z#)X- '4455T_4K/5K075C<)/"6*[E[,#@J0>001@@\BLOQ1X@BT;
M1]0:*Z2.^AM'G0&)I0F <,X7[JD@C)('!]#0!O45S6CZT;U]"$^K0+<W.EBY
MFLO*&Z4E4/F9S\H!)&,<[O:M.#7]+N%D9+M0D</GL\BE%\K^^&8 %>#\PXH
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MB60X#%CM+;0I888[N237:>'HSI/CG6=#M9[B33DLK:Z2.:=Y?(D=I%90S$D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KD/B/J]WHOAJ"YM-1_LXR7]M!+=;4/EQO( Y^<%1@$\D5U]<MX^TG4
M-7T&UCTVU6ZG@U"VNC"9%3>L<@9AEN.@H PM%U^Y?QIING:7XN7Q-8SQ3-??
M) QM J_(V^)5 RV%VG/7-:Y\>Q F\_LF[.B"\^QG4]Z;-_F>7NV9W;-_R[L>
M^,<U1FTO7-?\0:)=2Z!;Z)%IMU]IDN?M*22R+M9?*4(/NMNYR>W2J9\-Z_\
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MD#RJ_P!H? A9 5)R'#-QUX&:[KPSHPT#PW8:9OWO!$/-D_YZ2'YG;\6+'\:
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M+ ZKL(D&02A 4Y4$]1BGZKX=U"37H)-.T&.TN89;<0:O:W8C46Z%=R2IG<_
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M,*KB8#>S%MHX]R?F ]<:4'CI-0L].?2M(N[R\O8I9OLF](VA6-]C[V8XSO\
ME&,Y/L*-(T_59O%5GK-[IYLHQHYM)(FF1V23S00/E)!! SFN7A\#7UI%IEU>
MZ$NJF&.[@FM$NEC9-]RTL;JQ8*1@D$9SR.N* /2-'U2WUO2+;4K4.(;A-P60
M893T*L.Q!!!]Q5VLSP_8?V9H-G:?8X+)D3+6]NY9(V))(!/)Y)YK3H ****
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MK%9$CN/M2EG8MYO(+ELY)()!R>1QTJ2WT#3;1;Y8('07[E[G$S_O&(P3UX.
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MM;BQABNWB2=90UL[[&D!'=""67VX)K>GUZ)/$FGZ+#"9Y+JWDNGD1AMAB7:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF3O%$JM*W]YB!R>3R:M4 <'?Z)KWB2[N[^^T^'3VBT>ZL;6#[2)3)+,%RQ8
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MT^J:EB3@%R[,%/?&X*/85'JO@G6+O3_B##$D._7)(VL\R8R%10=WIR*]+HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDG\A6>NOVLFNVNEHKL;FQ>^2;HNQ61<<\Y/F _A7+ZU;PW7P'G2>))57P^)
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M3E65E4D'C^54M#N+*YNM)6"_U4WAMC<R),\YCE4*%8'S/E^](I&/3TH WI-
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M(+1/E0=^TD@@$$@CCOIMXG2?6M"L=.B6YCU.W>\>7=CRK=5&'QWW,Z@?CZ4
M:$&@:/;3PSP:7:1RP222Q.D*@QO)]]E.."W?UJ%?"OA]-0DOUT6P%Y)()7G%
MNN\N&#!LXZ[@#GU -9'B^:2^UG0/#2.T<&I3237;(<%H(5#%,CH&9D!]L^M5
M=2\=W&G:'J\T6F)+J-AJ7]GPV8D($O"NK9QQF,[NG8B@#K=1TRPUBR:SU*S@
MN[9B"T4Z!U)'(.#4(T'2 ET@TRT"W<2P7 \E<2QJ-JHW'( X /:N%\>>*VNM
M&FM-.A:2$V5GJ+3(^&_>748C0=OF ?OV]ZT-4\3ZA;VGB/3M>TJT+6^C2:@B
M6MTY66/#JT;,54J<CJ/7M0!VGV*U^U177V>+[1%&8HY=@W*A()4'L#M''L*H
M77AC0KZRCL[K1[&:VCD:5(G@4JK,26(&."23GUR:YVR\2ZA<6NC:;X>TNT-P
M^CPZA(EU<NL<,; !(PP5BS$AAD]ER<YJHVI:]<>/H6L--CBNY] CDEM[Z<JE
MN?.;()0-N;/' ]3GL0#T"&&*WA2&&-(XHU"HB* J@<  #H*?63X8UK_A(O#=
MEJI@^SM<(2\6[=L8$JPSW&0>:UJ "BBB@ HHHH **** "BBB@ HHHH ****
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M"<#!^\>>*H?\(?J\7A/PO;6\]FNK>'VB:/<S&&<+&8V4G;E=RD\X.#ZUW5%
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MO--$CHC"';D;V"@\D<98>_M5M;J1M2DM3:3")8ED%R=OEL22"@YSD8!Z8Y%
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M<[,.OL:VJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMX3NBB>!2L9]5!&!^% '&:K</X9;0/$J7^HZCIB0BRO"TC-YH< 13[!A2Q<
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MT    # ':B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#J0;[+.DBN#M&X;U!RFX<C/T.#Q6MJ.KI:7]KIL437%]=J[QQ*P4!$QN=CV
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M1C;!M8DDYW$M[&M?5(KC2_%5WIUN)I+7Q/"%MY02PMIEXEQ_='EDR#MN0^M
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M_NL^..A( [UR&L&XMK;6+:.]N(]*M_$5A'92)<,NP.T7G1J0>44L>.0#D=N
M#UNBJFFZ;;:38I9V:R+ C,RB25I"-Q+'YF)/4GO5N@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY
MH(KA-DT22)D':Z@C(Z=:DKG?%^M7^BVFFOI\$,CW6I6UJYE?;M5Y #C@]1D>
MV<\XQ0!MO96D@(>UA8%BY#1@Y8]3]:<EM;Q2M+'!$DC?>=4 )^IKF-4\<0Z:
MUT5M/M(LI4ANTAES*&8*3Y:8S(%#@GIWQG%2P>*[R\US4-.M- N95L+@0W$W
MGQJ!F(2*P!/.<@8[9S0!T<]O!=0F*XACFB/5)%# _@::]I;2Q)%);Q/&GW59
M 0OT':N0L?'\M_%H<R:#<"'6HV-HWGIGS A?:P[#:#\WMTZ9;/XJM-2L].DO
MM(G$R:ZM@\:W'$%PK8#;@1O7OC'/<4 =LJJB!44*H&  , "H&L;1_OVL#?,7
MYC!^8]3]:Y34/'K6!UESHEPUOH]S'#=R^<@PK*C;U'.>'!QZ=\\5=UCQ>-&O
M&2XT^1;5;N"T\YY-C2-*5&Z)2/G52Z@G(Q\W'% &^+*U D MH0)1B0",?./?
MUJ2&&*WA6&")(HE&%1%"@?0"N1B\7W-MJOB;^TX(8[#2IH88S'+EF9T0J.0!
MEC(!R<#\S4G_  G5O VH)>6;+):B'RFMY/-CN3*VQ$1R%^?<0"#C&0<XYH Z
MHQ1M*LIC4R*"%<CD ]<&HEL;1?.VVL \XYEQ&/WA_P!KU_&N2TB6\;XJZLEU
M#Y!_LBV<1K<&5"3+*-RY QT (P/N_C6I?7]M%XWTZT?3YI+QK&XE@N%EPNU6
MCW)MS@DDIR1QZ]: -DV-HT2Q&U@,:G*H8Q@'V%!L+,ER;2 E_O$QCYOKQS7+
M:1X\.J-H<CZ//;6FL/)%!,\RL5D17;!4=B$;GU'3'-7O%6M:CI%SH<-A;PRB
M_P!06VD:20J0-C/@?*>NPC/;\> #:&GV2S),MG;B5!A'$8W+]#CBK#*KH4=0
MRL,$$9!%>;IXAF\,ZWXTO6L9[NRMKZW>=O/'[E&@BW%0W)P6)QP/Y5OZQXVM
M]+EO1#:F[6PE2.Z2.3]]E@K'RX\'?A74GD>V2#0!T7V&TV;/LL&S:$V^6,;1
MR!]!Z4J65I'(LB6T*NHPK+& 0/8UC^-F(\!Z[-&[I)'I\\L<D;%61A&Q!!'(
M(-8WAPV%S#X?"QZLMXULL[3R&=8V(C&X,7^5L[CQSZ]J .PAL;2W??#:P1MD
MG<D8!R<9/'K@9^E3.B2(R2*K(PPRL,@CT-<;)X_>.WFNVT*Y^R6^I_V;._G)
MN5RXC#!<\C<P[C&>_.'7GCUM-@U<WNBW"7&F26RR11S(^Y)VVHP/'?((YZ=^
MM '6+:VZ6OV5+>);?;M\H( F/3'3%-%C:"V6V%K (%Y6+RQM'T'2N.U7Q-)J
M&G^)=#OM-N=,O[?2Y+N(>>&\V(JP#JR'@AA@C]35W1====+T?2K*W%WJ TB&
M[D627RU5"H49;!^9B#CC^$Y(XR =,EG:QN72VA5R-NY4 ./2F1:?90H4BL[>
M-"NTJD2@$9SCITS7.V_CFWNX]"N8;.06>JSM:F65PIMIUW9C<<\DHRC!P3]0
M:GG\6QPS_9_)A662XEAMC+<;$D$6/,<MM.T!CMQ@G/MS0!O+:6R*BK;Q*L;;
MD 0 *?4>AI$L[6-)$2VA59!AU" !OKZUR:^/I)TTM+;0+R2ZU![B)86D1 LD
M2DD;CU4XR&Z8.>O%:OV%X]8'B2<W4!73BD]F)S(,Y#8V#Y=RX(R.N?;D UA8
M6:VRVRVD @4Y$0C&T?ATH^P6>2?LD&2-I/ECD>G3I69X>\0?\)!;K=0PPFTD
MA26*>&X$JMNSE#P-KK@9'/6H[WQ,L&O2:/;P1SW<4,<S1-.$D='8C,:X._;M
M)/3''4T ;4%M!:Q"*WACAC!SLC4*/R%)<6EM=JJW-O%,JG<HD0-@^HS7.W_C
M.*SL]2U&.R>?3-,N#;WDZ2?.I7&]E3'S*F>>0>&P#CG..J6VD^/?$6HSSR&R
MBT6UN6PY8??F^Z"<<@ <8H [.:TMKAE::WBD*]"Z X_.IJP-)\3?VCK<VER6
MGER);BX2:&7S8F4G:5+8&'!QE>>#D$TW6=8,LNHZ18VINKBWL_/N<3^5Y:ON
M"*& SO.UB!P..2,B@#9^P68V?Z)!\G"?NQ\O?CCBD.GV36[VYL[<PN<M&8AM
M;ZC&#7"^$]1MQIGP^M[JTGFN[G3"T-WYQ"H1"I<,N?F)&.HK8L_'-G<Z1-K+
M1*-*BMY)WFBF\QXRA \MTP-LAS]W)Z$4 =4JJBA54*JC  & !5=].L9'+O9V
M[,QR6:)22?RK!U+Q5>Z/9:G<WV@W(2RLOMH>*4,CJ,[D+$ !QC) SP>":3_A
M+I4\B.ZTU;.XNRSVB7-TBK)$JJ2[,N=O+A<8)R?3D '0FQM"L:FU@*Q_<'EC
M"_3TIITZR(8&SM\,<D>4O)]>GO7(Q>-+_4=3\-Q66F^3%J#W*W"7+E74Q*<J
M/E(*YPP8=0!TS4UAXETZTBU62+3YX+A];-@(7FW&>Y94^8')"K@Y('0*3C/%
M &AHWA=-,UC5=0G>VN&O;D7$0%MM:#$:1[0Q)[(.F*W/LT'VCS_(C\[_ )Z;
M!N].O6N5U/QVFD6NM_;-,D^W:3$D\EO%*"LL3YVNC$#(R"#QD$=#Q6GIOB&2
M\\0WFC76G26=Q#;I=1EI%<21,S+DX^Z05.1S]: -1;." 3-:PPP2RY+2)& 2
MWJ?6J6B:7=:?')+J.H?VAJ$P42W(A$0*KG:JJ"< 98]3RQ^@U:* (!9VHFEF
M%M")95VR/L&YQZ$]Q3X8(;="D$4<2DYVHH49_"I** ()K.UN9$>>VAE=#E6>
M,,5/MGI4KARC",J'Q\I89 /N*=10!@^$O#4?AC0[:P9X+BXA0H;I(/+9USD9
MY)_6M@6EL+HW0MXA<$;3+L&\CTSUJ:B@"N;"S8N3:0$R<OF,?-]?6E:RM7\G
M?;0MY)S%F,'RSZKZ?A4]% $7V:#[1Y_DQ^=T\S8-WY]::EE:1+*L=K"@E.Z0
M+&!O/J?6IZ* ,^[T2PN]-?3FMHDM)#EXHXU 8=QC'&?4<^A%:%%% $"65I&H
M5+6%0 P $8& W7\^_K2V]I;VBLMM;Q0JQW,(T"@GUXJ:B@"">SM;HJ;BVAF*
M'*F1 V/IFEEM+:>19)K>*1U4JK.@) /4 GL:FHH ADL[:;RO-MX7\DYCW(#L
M/J/2D>RM9)&D>VA:1A@LT8)(^M3T4 ,BBC@C$<,:1H.BHH 'X"L+P_X9&C7.
MHW%Q);74]W>RW:2K;[&BWXR@)8DCCVKH** (9+2VEN([B2WB>:/[DC("R_0]
M10]G:O*TKVT+2,,,Q0$D=,9J:B@"NUA9O;_9WM(&@SN\LQ@KGUQC%/>VMY)4
ME>")I$^ZS("5^A[5+10!"MI;)<23K;Q+-(,/($ 9AZ$]31;V=M:ES;VT,.\Y
M;RT"[C[XZU-10!%+;03LK301R%?NET!Q],U&=/LB&!L[<ACEAY2\GU/%6:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 450U
MF74H=(N'T>WAGU# $*3-M3)(&6]@"3CJ<8K#T34M:@\6W6@:M>6NH!+)+Q;F
M"W,)C+.5V,NYASC(/'0T =71110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5DZUH0UDPDZIJ=EY6[_CQN3%OSC[W'.,<?4UK44 9'B6^U'3/#=W<Z39
M/?7Z(%@A4;B6) W$9&0,[B.^*Q_!1C@\^ Z5K45Y,//N]0U*%5-S)P.H8XZ\
M*. !Q77T4 9-]H(OM6@O_P"U-4MS#M_T>WN2D+[3GYEQSGH?45K444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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; HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex1012022063010qngcbasho003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBH9[NVMB!/<11$JS 2.%RJC+'GL!U]* )J*C>>&.W-
MP\L:PJN\R,P"A>N<],>]/5@RAE(*D9!'0T +1110 4444 %%%)O7^\/SH 6B
MBB@ HHHH **** "BBB@ HI"P'4@?C3);B&")I9IHXXUZN[  =NIH DHHHH *
M*"0.IQ2!E)P"#^- "T444 %%17%S!:0F:YFCAB! +R.%4$G Y/O4M !1110
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MZ4 %%,AFBN(4FAD22)QN5T8%6'J".M/H **** "BBB@ HHHH **** "BBB@
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MIIJQ%LJ0/FWG&"0>G:@#E-/\3>+[NS\*7;7.EC_A(4\OROLK8MF\HR>9G?\
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MI=S<0M;P&(PR1A0R<L=RX<8/!XKEO#7BF72O!7@_2(=1M]-\[3'N9+J>V:?
M5@JHJJ1R2Q))Z!?>NYA\)WDNJ27^JZQ]ME2RDLK7;;"+RDDQN9OF.YSM7D;1
MQT&:JV/@6YT?3-%BTG61!?:7:O9_:);7S$FB8AB&3<,$%000W'/7- &UX5UB
M77O#-EJ4\2QS2JPD500NY6*DJ#S@E<C/8BN7\9^,;[P_?7DD&IZ>L=E#'*+
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MI2TE6& !4WE'#L .,\+G\,U@?$BXM9I_$EKY.R^31 \+RHTC2X,C#R .%*D
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MFWNXR4W*&_ADX&#SU/&,UO&2]N/ IDTZVDM+Z33=UO!(?GBD,7RJ<]P<#\*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP^7CRO*CV=<\YZ]!BHM<\.7FHZ]IVLV&J+975A!-$BR6_FI)YA3.X;E.!LZ
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MIC\U I Y.<8ZUGV7@BZBN_"EU>ZNEQ)X>6:./R[3RQ,CQ", _.<$ 9SSGT%
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M^VVMO!Y$$*6HB)'&'D;<=S #'&T<GCG@\0^'9]9OM)OK34?L5SIDLDT3&'S
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M7&-W'J<<XZXYJW_;NE?V+_;/V^W_ +-V[_M6\;,9QG/UXKSC1[3R?A[\.52
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MGVB3S(AN'#?,IVCD[O:O5[*T%CX)@LE>:00:<L2M,NV1@(\#<.S<<CUH Q/
MGCE?%&EP7=]<:;#/>/MM[2W=BZ\,VUB>K;5)X[ UIZ[XWT/P^BFZO(RWVR.S
M=%89C=MI.[TPKAC[5P6ASII/@WX::E?Y@L[21Q<2NIQ%O@E52WH-Q R?6HK^
M]BE35-7VR)8Q^+[&Y:9XV $*QP#S.GW>^?0T >JIK>F/;7=RM]"8;-=UP^[B
M(; ^6]/E(;Z&H)?$^APWT-E)JELMU,T:QPE_F8R E,#WP:\[U?6K*UMOB):/
M(QN=4@\^QB1&)N(WLT4,G'(!4Y/;!S6QX7LV;QIKDRQ[9_[&T^.*4K]W*R9
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MG17$+P,3+(D4B[6CC>5V12.V%*\=NE=10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-U>6UE$);N
MYAMXRP0/*X0%B< 9/<FIJY'XC:M/HWAJ&YMXX)':_MHB)XA(N&D )P>_H>U
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M&!Y#8Z$9Z5K5QOPZ%P+'7A=M&UP-;NA(T8PK$$<@$G /7&3BL^_\0^(I=/\
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M.,L3TR .N:KR>-M7N-'T6^GU"'1K:ZLV=[Y[%I86N%?;L<Y_=*0-W.#SC/%
M'I(O+9KQK,7,)NE02- '&\(3@,5ZXSWJ:O/[CQ!JL?C35[2SM+.ZN8/#BWD
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M'MDUJT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB<,,;/*X 48&.<@YY.33=*T&]T2YTNTM;R233H8KEKO>J#S9I)%<-@<CEI,
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MM/:[F)$4(N$+N02" ,]<@CZ@^E>8Z1J]C)X5\#:-'<(^I6FKPI=6RG+VY4R
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M^#[K3+OPK8'28#;6L4?D_9F&&@9>&C8?W@00?7KWK<H **** "BBB@ HHHH
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M=?O*A(^N*\RM?&'B"+P/H^MZEJ%JDNMR00Q".R9Q: J[.^%),A*ID#  )'4
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MD@WFX"A"X+Y^7C@8'4<YSB@#O!X?N%&%\0ZL!Z#R/_C5+_8-U_T,>K_G!_\
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M*P'4A03_ $KS[PUXOU;6+W3X#J"SMJEK([!--DC6PEV;UP[<2+U'/4@$<'%
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M >EE0000"#V-*  , <"N%M];UO6M3L-'L-8T]&_LW[?<:C;0>:DP:0I&$4G
M!VL3U]!ZU3M/%7B#5Y]"TZ":TM;NYDU"VO9O)+JKVSA=Z*3WYX)XW=\8(!Z,
M0""".#5.[BL9KBR@N'C$J2>=;Q%]I9E!Y"_Q8W9]N#7#+XIU;^R/(N]8L[2Z
M@U6>PENELWEEG6,$@Q0+G+'*Y[  GTK.CU;5O$FI^#+F"XA@OF?4[=[EK9@
M(V"%Q$Q!#$(/E/0MSTQ0!ZA<W=M9HC75Q% KN(T,KA0S'HHSU)]*FKR#Q/JM
M_?Z%;6>IR137>F>+K6T:>--@F7*NK;<G!VN 1ZBNGNO&-YH\?BZ'4%22[TO;
M/8JJX\^*48A7'<^9E"?I0!W& 01CK2  # &*K::MXNEVBZ@Z/>B%?M#(,*9,
M?-@=AG-<-HOB^_N/%>G6<NJ6U_!J$EQ&R6UE(D,!169?+G8 2<*0??D8H ]#
MJ*XFMX(@US)%'&S*@,C  L3@#GN20![UYUI/B7Q-+I7AK7+R]M'M]3O4LY;-
M+;&%8LH</G.[*@XQC!QVR:&J:CKFO>%M.UR>[M_[/NM;M0ED(,&*-;Q50[\Y
M+':,Y&/FXQB@#UDX R>@J"UN;6^@2ZM)H;B&0?+-$P=6&>Q'!YJ60XB<^BFO
M+O#/B;7-4\.>"HK)K&REU=+OSW2V&R(1DD%$! SQ],G//0@'J=,FC$T+Q%G4
M.I7<C;6&>X/8U@>#]3O]0M-2@U*6.>YT_4);,SQQ[!*%"L&*Y.#A@#CTJI>:
MCKNH^+K_ $O2+JVM8M,M(9G\Z#S#<2R%]J$Y&U0$Y(Y^;VH L:9X3FM=5M+_
M %'6[S5'L8GBM!.B+LW !F8J 7<@8R??C)KI JKG  R<G ZUYSX?\3^(/%<>
MCV=O>6]A/+I*ZC=W MQ(2S2%$15)  ^5B3SVZ5)I_BO7-?ETK1[>:VLM0D^V
M?;KI8?,4?9I1%^[4G'S,P/.<#/6@#T+:,YP,XQFHXYX)9)8XI8W>%@LJJP)0
MX! (['!!Y[&O/X?%6NWL]KX?2XMH=4.K7%A-?"#*^7#$)=ZQDX#,K(,9(!)K
M1\#+=IKGC!+Z6.6Y74HPTD:;0X%M%@XR<$C&1GKF@#J[V]L=.A%Q?W5O;1 [
M1)/(J*">V35A2&4,I!4C((Z$5YK\1+"\OO'7@N%+V)(9;F8)'+;"54=8F.X@
MGYN,#';K4TGBW4+3Q1;6W]JVMU"^IK8/:6]C(8XT.5!,^-HD!P2N<#D=LT =
M[;W%I=&06TT$Q@D,<@C8-Y;CJIQT//3WIZ3P//+!'+&TL6/,C5@63/(R.V:\
MDU76M5OO#?B8VMQ!8/:>*DLP\%N 9$\V$ L01ELMDGN!BM,QZ_#XH\7R6&JV
M\$UK9VDDLKVN_P ^186.-N["J<'/4\C&,<@'IM%9^A:@VK^'M,U)T"/=VD5P
MR+T4N@; _.M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "LG7=#37$T]7G:+[%?PWHVKG<8SD+]#6
MM7/^*_$1\-PZ7.S0);W&H);W$DV<)&5=BPY'/RB@!NJ>&KNYU:;4M*UF33)K
MJW6WNML"R;U4L59<_=<;V&>1R..*PAH.KS^.?$$EAJESIZM864 N'MQ*LPQ+
MN()Q\Z\<@\;N0<BNFM_%F@W6EW6I1:E#]EM&VW#N"AB/& RL 03D8XYR,5B>
M*?'45AX'O=?T&6WNY+:>*%DF1@%9I$4AE^5@<-GG'8T 3IX(_LTZ?)X?U-].
MGL[%=/+/"LRRPJ<KN4D?,#D@@_Q'@U+I_@FTTVYT&:&ZF;^R5N?]8 3.\^"[
ML>QW9/ [U?76%7Q+>V,M_8B&WM%N&AVL)HP2<NS$[=G'IGBHH/&OARXM)KJ/
M58O)@,?F,RLNT.VU&P1G:3P&Z>] %2;PE=C6]8U&QUV>R&I^4[I'"I*2QA55
M@QZJ0H!4CG)YJ_H6AS:7<7]Y>7WVV^OG1II5A$2X1=J@*">V>22:O7>JV-C=
M6UM=74<4UR',*L<;@B[F/L .235"S\8>'[^VNKBWU2 PVL?G3.V4"Q\X?Y@,
MJ<'##@T 0>)/"-OXDU'2;R:XDA.GS"0JB@B=-Z/Y;>VZ-#^%1VW@RVMO$^L:
MVMU(6U&(QB$J-L!95#E?][RT)^E:NDZ[INN12R:;=+.(FVR+M*LA(R,JP!&1
MR..:P]5\9V^A#Q+<WMW:SPZ2D3+:VZ.)D9H]P60G(RQZ$  #K0!!!X -CHGA
MNRL-7DAN=!=F@N6@5PX965@R$]PQ[\5=E\&0R^'=2T<WD@2^OWOFDV#*%IA+
MM [C(QFMRSU&WU'2TO[60&&1"RLRD=/4'!ZBL.S\9:9!X=T[4-5U>RD:\5BD
MMG%)LEVGDHIRV!QDGI0!TDJ>;"\9.-RE<_6N:C\&)!X1TG1(+^6.?23&]K>"
M,$JZ @$J>"""P(]":WGU*SCTIM4:YC^PK";@SJ<KY87=NR.HQS66/&GATV,E
MXNJ1-;QS"W+JK-ND(SM4 98XS]W/0^AH B.@ZT+-"OB>?^T!.9FF:W4Q,I7;
MY?E9X48!'S9SDYYKF_\ A$[_ $_Q?HT6G7\\4D5C?327QM@T;32SQNRLHP "
M68A00?E'/!KKIO%FA6^EVVI/J41M;IMD#H"YD;G*JH!8D8.1CC!S3K3Q1HE]
M'%):ZC#*DMU]DC9<X:;9OV#CKMYH QX? S65K926.KRQ:M;S3SO?20JXF:<Y
ME#)P,$A2 ",;1^,]SX3O)/[-N[?7KA-8LDEC-]+"L@F20AG5DX&,A=H!&-HZ
MU9U_Q%;Z?I.JRV^I6-M<Z>8Q-)>([1PERI&\+@G(;C![BK-SXFT:SU5-+GOX
MUOW:-5@P2Q+YV\ =#M//0=Z ,G_A#)X[K0KR'7+IKS3/.$D]P@E-RLI!D!R1
MMY48QPHXQ6]K6EQ:WH=_I4SLD5[;R6[NG50RE<CWYJM8^*-$U+4GT^SU&*6Z
M3=\@SAMIPVTD8;!X."<5C7?CW3I=3T>ST>\MKIKS4?LLV5;_ %?ER$M&> V&
M11D9'/N* ')X/U&!K&\M_$!CU6WM3927)LU*30[LJ#'G@J>A![GCFMS0-%@\
M/Z/#IT$DDH0N[RR8W2.[%G8X[EF)JEXE\7:=X6DTU+\OF^N/(3:I.T8)+' /
M3CCKS4EWXO\ #]CJ/V"YU.&.X!16!!VQEONAVQM4G(P"1U% ',MX>U;4?&'B
MXVNI7&F078MH6?[,)%E3R<$H3C##)&1D<\C@5>G^'T>RXM+'59[/3;NPBL+F
MW2-69TC0HNUSRORM@\'/;%=5?W]KI=C->WLRPVT*[I)&Z*/6L4^//# \\?VO
M"6AQN4*Q9@<X*@#+CY3RN1P: .8UWP^==UCPUH)6\GDTI@=0OC;-%"]N%4F+
M)X8NRQ\*3C:<XKMET1%\52:[YS>8]BMGY6W@!79]V?\ @6/PJM=^,O#UE9VE
MW/JD/D7<9F@= 7WQC&7PH)"C(R3P.]1CQ#(_CBVT>+R'L)M)>_$PY8D2(HP<
MXVX8GIZ<T 06?@J"TT?PUIPO'=-#F$J,4'[[$;I@CM_K"?PI^A^%[S1);:!-
M<GDTFS#+;67E*NU2"%5WZN%!P!@=!G.*L3>,O#\%A!?/J<9M[AG6%T5F\W;]
MXJ "2H[L./>M>&ZM[BSCNX9XY+:1!(DJL"K*1D,#Z8[T <];^#(;?P_H6DB\
MD9-)NH[E)-@S(4+'!';[U06O@[4=-%XNF^(YK=);^2^A0VRL$:0L71^?G4EL
MCH00.:T+?QKX<NK:YN(=5A:*V19)6(881C@,,CYE)XR,BM.;4[&WO39S7,<<
MX@:Y*,<8B4@,Y/0 $B@"KH&C#0]/D@:X:YFFGDN9YB@3?([98A1P![?SK"U;
MP))J;:S#'K<]M8ZK(+B6W2%21,$10V\\[?W:$KW(ZX)%2:GX\TQO"VMZEH5Y
M;W=WI]F]RL3JP! !*M@X)4D=1Q[UJZ3XHT?6;MK*ROXIKN./S'C4$97."RDC
M#+GC(R* *P\*AH?$2RWK/)KD:I,XC $9$ A) S[9Q[XJA)X%FCEG^P:W-9PW
MEG%:7T:P*QE$:; ZL?N-M.#U[=QFMW5O$>D:'+!%J-ZD$DX)C3:68@=6P <*
M,C)/ K&T;QQ92^%;+5]8N8+=[J:>.-859MX25U!51N)^502>GTH WM$TQ=%T
M'3]*24RK96T=N)",%@BA<X_"N8NO $UQ'JUHNNSQZ;J]V]S>VWD*2P;&51\Y
M7( !//MBMV\\5Z%8VUE<3ZE#Y5ZN^V,>9/-7&2P"@G !&3T&>:I>%_%D.M6,
M,ES-;K/=7EW#:K%G$J0R,H(Y.?E4$G/?B@ E\*W2:K=7&FZW-86E[*DUU;1P
MJ27554E'/W-RHH/!Z<8I;CPA#<:3XFL#=NJZ[)([OL&8M\2Q\>O"9_&M"Y\2
MZ-9VMS<W&H1)%;7'V64\DB7 .P #);!' S63?_$/P_9+I,B70N(M1N&@5XU8
M^7M5BQ88R""H!7KS[4 /E\)W<>HW,^FZY/86]ZT;W<,<*LSLBJFY'/W"RJH/
M!Z9&#5N+PS''XIU/7!<N7O[2.U:+:,($W<@]_O4EMX@MTN-<>^U/3Q:Z;(H<
MH&0VZ[0<2EC@GTQBI+7Q;H5[97MW#J*&&QC\VYWJR-$F"=Q5@#C /..<4 8=
MK\/CIVC>&[.PU>2&XT)Y&AN&@5Q('#*P9<^C=<\5H1^%[Q]8M+J^UN:\M+&X
M>YM8'@4.KLK* TG5E =@!@=LDXJY:>+M OKJ>VM]4@>6")IGSE1Y:_><,0 R
MCN02!4VD>(M)U[S1IEZD[1!2Z[65@&SM.& .#@X/0XH 3Q'HB>(=$FTYKA[=
MF>.6.9 "8Y$=75L'@X91Q7/W?@&74TU=]2UN6XN=4T];&218%18U5F8%%!X^
M]T)/.3FNLOM0M-,MQ<7LZPPF1(][=-S,%4?B2!^-1KJU@VLMHXNHSJ"P"X:W
MS\PCSMW?3/% &9KGA.TU^_-Q>2OY3:=<:>\2@<I,4);/8C9Q]:S[;P1<2:C8
M7FL:Y+J7V*WFM4C-NL:M'(H5MV#RQ &3[=!WMIXLL9M63R=5L7T\V,MT8Q&Y
MF8))M9P1QL&",8SGI61#\2[&\MO#NH0&.'3]1GEBN3.K;HML+.H7IDDA1P#G
M.!S0!J:?X5O[2T-C<^(+BZL8[1K.WA,*IM4@*&<C[[   'COQDULZ)IBZ+H.
MG:4DIE2RMH[=9&&"P10N<>^*P-5\<V$.F:;J6G7=M+93:FEG<RRAE\E<,7R#
M@JPP.OKTK4M_%N@W6F7>HQZG"+6S;;</)E#$>,!@P!&<C''.>* &:CX>EN_%
M&FZ[:Z@UM-:1/;RQF(.LT3,K%>2-IR@YJK;>#(;?P_H6DB\D9-(NH[E)-@S(
M4+<$=OO4W5/&EE_PB.N:MHMQ#<W&FVSRF*5&4JP4LN]#A@#CVSVJ:+QCI=MI
M6DS:M>PVUU?VB7'EJK' *@LV!G:H)ZGCWH K67@VXTJUOETO7)K:XNM5FU/S
M#"'7,@P8V3/S+WZ@Y -;&@:,-#T][<W#7,TT\EQ/,4";Y'8LQ"C@#V_G6#H7
MBVYU6S\-3SW6G6\FJ-<!X"CEIO+W8\HYP,  G=GCI6I'XT\.37T%G'JL+3SR
MF&, -@R D;"V,!L@\$Y/:@!UCX:@MO$6JZW<2_:KF_\ +11(@Q!$@P$7\223
MW)K*\3>#+.^EU/4E6X(N=+>SN;.T50UQ@[D922 )%.<$^N*T[OQIX<L+V>TN
MM6@CFMSB4'.%;&=I.,;L<[<YQVJ<^*-$&M?V0=0B^W;_ "_+P<;\;MF[&W=C
MG;G/M0!PNE:=?>)/$Z7%Q=:K/#'H]Q9SW-[IYM C2E J*C ;F 5RQ&1T]JZV
M7PG_ ,2'1+&TU![>\T98Q:W?EAN5C,9W(>"&4D$9'7KQ6KJNLZ?HELEQJ-RL
M$;N(TX+,[$$X50"2< G '8U4E\6Z!#8VEZ^J0"WNPQMW&3YFW@@ #.0>,=<\
M8S0!2G\+7LUO93G7ICK%I/)-'>O K+AQAH_+Z;,8P,Y! .:F3PS(USHEU>:I
M/=W.F3S3F21 /.:1'0C X51OX [ #WJ;_A+] _L9-6_M.+[$\OD*X#;C)G&S
M9C=NX/RXS4'AKQ*/$.IZ['"T,EG8W$45O)&""P:%';=D]0S,,8&,8/- $-UX
M+ANM$U_33>2*NL7ANW<(,QDA. ,\_P"K'YT]/"]W;:K/+9:Y/:Z=<78O)K-(
M5+&3(+!9.JJQ&2,$\G!&:2T\=Z+=:KK=BUP(/[(YGEE!5,!06.2,#!;'OVJW
M#XOT"XL);Y-2C%O#*D4KNK)Y;,0%W @%0<C!/'- %.Z\&0W6@>(-)-Y(J:S<
M23O($&8BX48 [XV_K3;KPW?VVJZ_J^E:G)'+J=J%^SB%"1,D92-U9C@=N#QG
MO6^-2LVU1M,6=3>K")VA&250G )],D''T-4[_P 3:-I>HQ:=>W\<5Y+LV0D$
MLV\E5P .Y5OICF@"_9I/'8VZ7+A[A8U$KC^)L<G\ZY:;P&)GUJ,ZK,MKJ-VM
M_&BQ+OMKE2A$BOW ,8^4CUK9MO%&B7>KMI4&HQ/>JS)Y8S@LOWE#8PQ'< DC
MO4%IXU\-W][!9VNK023W!VQ  X=L9VAL8W8YVYS[4 &D>'I[/6)]8U/4CJ&H
MRP+;*XA$*1Q EMJJ">23DDD]!TQ3O$WA]_$%M8B&^:RN;&\2\@F$8D =0PP5
M.,@ACWI9/%V@1:M_9;ZG"+OS1"5P=HD/1"^-H;_9SFFW?C/P_8WLUG/J48NH
M"XDA569EVH'.0!Q\I!H J3>#8Y]!\1:7)?.?[;EDEEE$8S&7C1#@9Y^YG\:6
M3PK=QZG=3Z=KD]C:7LJ37=O'"K,SJJJ2CG[FY44'@].,9J/3_B'X?O/#UAJ\
M]U]E6\3*PLC,ZD*&88 R0NX98#'/6NG@GBNK>*XMY$EAE0/'(ARK*1D$'N"*
M %FBCGADAE4-'(I5E/<$8(KF]+\,:II<"6R>))Y+:VMFM[*-K=1Y8P K2'/[
MPJ  .GOFDUC7-<C\41:)HMCITSFR-V\E[</$ -^S VHV:-.\9VITFZN=;1--
MN+.]:PGB5S*#, & C(&7RK @8SUXXH -/\$6FD7.E76G7,L-S9H\5Q*PW&]1
MSN?S?5BYW@]B3V-4K'P%<:=IUI;6NNR)+IUS)-I\QME)A5]V^-QG]X#O/H>!
MZ5T-GXDT?4'LTM;^*5KU)'MP,_O AP^/=2>1U%,O/%.AZ?//!=ZE!#)!(D<H
M<D;&=2Z@GIDJI- %6/PS*UQHUU>ZK/=W.G7$UP9'0#S3(CIM 'W5 ?@<]!]:
MI:EX&6]%\\.I26]S<:K#JL4OE!Q%)&B*!M)^8?)[=:LGX@>%5M_/;6853S#&
MVY6!C88SO&,H.1RV!S5Z_P#%&B:9J$=C>:C%#<N%.PY(4,<*6(&%R>!DC- &
MI"KI!&LLGF2!0&?;MW'')QVKBX_AVMMX<LM+M-6DBGLM3.IP7)A#8D+,=I7/
M(PY'6MK4/&?AW2KF:VOM4AAF@<),I#'RR55@6P/E&&7D\<]:A;QKI$?BR;P_
M)-LGAM1<O*P(0 [CC.,#"KNSG% '0!&, C=]S;<,V,9..N*YF'P7';^#]*T*
M&_ECFTLQR6MX$!99$SABIX(()!'H36KI'B/2=>,HTR]2=H@I==K*0&SM.& .
M#@X/0XI9?$.DP66H7DM]$EOI\ACNW;.(F !(/X,OYT 9%QX4U&YBM)Y?$,KZ
MK:WANHKEK93&N8S&4$6>%VL>^<G.:BM/!VIZ8)VT[Q-<1R37373&:W60.SJ
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MW<XP:T=:U6PFN/#VO6VFSVFFQ:[(\UQ]E*^=F!T\XJ!NPQPNXC)P.V*],HH
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M'5H@61L,"WW<C._--O2N@ZB(-*NK\W[?9(IM+O;+S8]0"K&@D5@/E8*,%@<
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M%<W%M8BWCMBZ$&0Q+@%<G^\!@GW-:MSIMI=:3+I<L*FRE@-NT0&!Y97;C\J
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M5.6 A=&4<_[@!H Y#6O$NN^$[G6+6YU$:D5T^"YMI7M0#%))/Y.-L8RZ@E6
MY/&,FLOQ!KFL7'@SQ9:KJ.I36\.G":*_N=+:T<D[EDAPR*",;2"!D;CSQFN]
MUCPC9:W?W=U=33@W-BMD5C(&P+(9%=3CA@V".W J&;PE+J&BZKIVL:Y?7_\
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MR?(4V+TQ@+&B_05H:AX.2]U?5;Y-2N((]5L?L=Y;JB%7 5U5@2,@C>>G7 H
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M&*,XDV/&5;N258#C'/6K'A7PIJMMX4T]8M4O]&NEDN9#"=DW[N69G42*V07
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M,,^ %#,"'.,8J[X]LM1\27^D^&++S(+::3[;?7;0%XUCB(*1GH&+/MXST4T
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M=,RP(3S(0I8@?0 G\*L5XQX>L[^7P_\ #58]6N!/<O,ZSND;- IMGRJ#;@\
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MA?5I(M+TN: 16J1)^\\R!6(9B,X!)(P<Y/7 Q5/QSKE]8W=Z-.U>_BEL=/\
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MMF[07&^%U29P3F5&8?,'^]GKDG-<C>Z;J-QX9\6>'KBRNGU6\U&6>RG$+%)
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M#SU!K=JKIVHVFKZ?!?V,PFM9UW1R $;A]#S5J@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N<\97C
M6^GV=O'>7T$UU=+$D>GQJT\^%9BB%B G"DECT /K71UEZUH5OKD=L)9KFWFM
M9O.@N+:39)&VTJ<'!&"K,"".] 'ENK:A>7WAO2([UKIGL_&=O;)]L*&8(&R
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MR16ZA@0.G'&,8XH Y5]2\0Q0Q:4\FL65K?ZQ;VMO=WWE_:EA:-GD4,,C.8R
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MAL(9-I4,P[D9./3- 'EWAF]TWPIXIT"&R&H"VU&U&GZA+=6$\"O= EXY=TB
M%F9I%]>15S6]0UR7PMXL\26^O7=K<6%]/:V]NA7R4BB<1X*D9W'EMV<Y([<'
MT77=#L_$6DR:;?!_)=E<-&VUT96#*RGL00*\]\3^$=0U.?6=,M=&OUBU*X5Q
M.FH)]B).W=-)&2&$@P?E"D$@'KR #1>^U0^*_&5X^IW7V/0DCFMK&,@)(QM0
MY#\9*YY !')/MC(M?$'B32]'DUD0ZW<1#1Y[JZ?4DB\D3K&'C:(*<JI.X;>F
M".XKTBVT.RMM1U6]5&:35"AN5<Y4[$"  >FT5G:?X+TW3PT9GOKNV%NUK%;7
M5P9(H86P"BCTP ,G)P,9H Y.UU#Q#9V6HR@:]]F_L:XFDN-36(;+E5!1H]A.
M 07^7H-JX[TMM%K3ZIX4A?Q+J137-/EEO0"@VLB1N/*^7Y.6()Y./?FNKM/!
M=A:VUS ]YJ5U'-:-9*+FY+^3"PP53].3D\#FKR>'K&.YTBX7S-^E0/!;?-QM
M954[O4X44 ><Q^(-8<:?HDESK%VJW^I12SV&S[5+';R*L8+' '^L&2.3M'J:
MT+:Y\1W^H>&M)O[W4=/^T+J G8A$GFBC:/R6;&0K[6&2/5L8SD=1+X*TQHOW
M,UY;3K>37L=S!-MDCDE),@!QC:<]"".GI5FT\,:?9W&FW$;7#RZ>DR1/+*79
M_.(,C.3R22H- 'G%RM_J<WA^SNM8U!C:>*+FQ299%$C(D<I1F.,%P.,XZ$U[
M#7-7?@C2[NW\L37D$@U%]32>";;)',P(8@XZ88C&.];5EIZ6,UW(DUQ(;F7S
M6$LA8(=H7"C^$?+G'J2>] %NO+O ,_BA/!EDMAH.D7-J'G\N6?4'C=OWSYRH
MA;'.>YKU&N/M?AY9V, M[/7?$%M;JS,L4-^55<DDX&..2: *FJKJ6I^-]4TR
M/6;VQL[?1X;E4M&"D2EYAG)!XPHR.^!69H.HZR3X&U6ZUFZN7UQ&6\@?:(<?
M9WD4JH'RD%!SWR:[FW\/VEOJ$E]YD\ES+91V4DDLFXLB%B"?]K+MD]ZAM_"N
MFVMKH<$0FV:(/]$R_/\ JVC^;U^5C0!P>BW^MP>&/"/B.XUZ]NKB_O8+6YMY
M"ODO'*Q3A0,AAPV[.<@]N!4T>_O+6#Q#:65R]K)J7CB6R>XC +Q(RJS%<@@,
M0I ..,UTG@OP&ECH&@MJK7JW%BHF%@]QN@BGY&\*._)/7 )R!FMO_A"-'^PZ
ME:;;@+?Z@=2=Q*0\=P2I#HPY7!48H Y75KC7]'NM>TS3=4O+QM.L[;5[;SV#
MR$!W$L#-C+*RQG&>033?$?B_4+I[W4=!NY?[/L[&U1?*56+SW<B!2 >"4C(8
M \9<9KK(M)7PQ:WU_96NH:UJ-T4$IDF0S2A>%&6*JJC)X&.I.":H>%? UKIG
M@1]"U&W3-X7ENXXG.%=CD*K=?D 50?\ 8!H YR[UKQ%I&GW\4,.OK:7$MG#;
M37ZQ-<QR22[)1'@D-\NTKNZ,?2NI\&S:L;K4[>\@U9;!/*>SDU789LD,'7*D
MY (4@GGYL=JM+X-T]["]M;RZU"^:[$8>>YN29%\L[H]A& I5OF! SGDYJ_H^
MB1:.)V6[O+N>=@TD]W+O<X& .@  ] !0!S?C.\G;58[*TO-:\Z.S>X:VTI8U
M*Y.%EDDD8#;\K +WY/.*SM(O]5\9W%E;R:O=Z<$T&SOF:S*H9)YPV6.0<JNS
M[O3DYKK-4\*V.K:FM_--=Q2&#[/,D$Q1+B+)8(X[C);I@\D=#6?_ ,*_TM+2
MS@M[W4[9K6V^QK-!<[9'M\Y$3''*CMW'K0!QFO\ B"_\,^.9B9%GOIM#LH)=
M1\@BW@)GD5IY ,[5!.<9ZG&<9(Z2:TU&3Q?IWAX>(-16T&CO//-&ZB6>02HH
M;=CY?O'ICTZ5OV_A'1K6=WBM1Y;Z>FFF!CF/R$+$+@_[QSZT:3X5L-'N+2>W
MDN9)+2S:RB,TN_$1<-MZ<XV@ ^@H XO0=4U?Q%+H>B7.KW<*B"^EN;F JDUQ
MY%SY,8W8XX.3CJ<5+I^OZI9:A8&^U*2:QL]:N]'N99, RJ4WPN^ !N4@)D8S
MFNF;P1I@M;2*VFO;2:TEGE@NH)MLJ><Y>1<D$%23T(/0>E.N/!&C77A67P](
ML_V263SI)?-/G-+OWF0N>=Q;G/X=* .&L_%&O3:'>VDM]*NI:Q/:7&F.0 T$
M%TY 4<?P+&YJO#JEYI4OC%;$W(FN_$\5J7ME5I55E7=LW<;B 0">A.:](F\)
MZ3-K>E:LT3BXTN(Q6P5L(%*E1D=\ G'IDU"W@K2&AU6,B<?VG=+>2NLI#1S+
MC:Z$<J05!% '(/J?B&&"/2V?6+*UO]7MK6VN[[R_M2Q.C-(H89&<QD!CR-_L
M*JWLNH>'];\606FJ3O<3'2+2&[FVO)"LLCH23C!(#-@D>F<UV\G@K3Y]+EL[
MFZU">62X2Z^V27!\])4QL96 PN,< #'7CDU0U#P/:6^BZV;:"YU6^U&*+SA=
M7A1YFB)*$28^1AG@C RJ]!0!SWB#5-:\)ZIJUI;:O>7L2:1%+;"XVR21227
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M[951HQ+M$N[[V3V7.,'/6K&E^/=*U:YTV.&WOXX=34FSN9K<I%*P0N4!S]X
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M([8-<W90:KJ[>$=/FT6\L#HLJS7LTX41@QPM&%C()W[F;.1V'/I533='N/\
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M;B"^E2"))KJXA@W1VR,3AG/X$\9P!DU43QQ$GBC7--N[.>WLM*MHYY+QD^0
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MN2R^^:Z#PQ!=Z!H_B:ZNK*7<=5OKR.(8#3(6+*1VY XS0!V%<%XJ\>K;Z3J
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M);YBQ!W8)P3WZU:F.M2^*_"VMWFAW$8:VNK>XBMRLAMC(\90N<C^%>2,@'-
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MW )SR1FN!MK[68/ E_KW]JZG<WL^HOIT,:S#$437OEY16(7S ,@,QXR!D 4
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MY4"KD9^7Y0OIZU>KR&9[K19?'U_8ZA>)=-JEM9I)),76(3"W4OM/&Y0YP>P
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M-HY$5T8%65AD$'J"*=10     # ':BBB@ HHHH **** "BBB@ HHHH ****
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MNP )']WH,8Z8J.S\/6V@?:M1LXKW4M1:$1JUS=F25D'(C5I#A1GGMD]:WZ*
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M5;H **** "BBB@ HHI"RKC<0,G R>IH 6BBJU_?VNF64EY>S+#;QXWR-T&2
M/U(H LT4C,J*68@*.I)Z4M !1155]1LTOK:R:X3[1<QO)"G=U7;N(^FY?SH
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MP9=BMC)QT&,BM33]&O\ 3=0CG@TS6/LL4KS0V!U&#R(G?.X@##$?,V%+$#/
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MR5V1QJ2>",G(&3@U4E\*3W,&J)>:5K%U+J<,,-U/+J%OO81,64C  4\XX&,
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MF)0&\J)X][%0>FY]P)_V<50O=/CM?'FNZ?IDLEA!>Z$+NY^R!1MF60JK@$$
MLNX'CD+Z\UU&L>%+75M2CU.*\OM-U)(_)^UV,H1WCSG8P8%6&>1D<=J=I/A:
MQTF&]"RW5S=7PQ=7EU+OFEP, $XP  3@  #TH \=CT><_"WP#-_;6HA)]6LE
M6',6R$LY^9/DSD=1DD<\@UUVJ>*=7\/ZQXO@6]DNX]*T>WEMA<*O^M;(+MM
MSS@GMQVKJU\#:4OA[1=$$EU]ETBYAN;<[QO+QDE=QQR,GG %3S^$-*NM4U>_
MN4EF;5K1;2ZB9OD,:@@8P,@\GG- &!KO_"0>#_#^H7Z:]<ZDKQ0Q(+B!&DBG
M>58]Z!54%</G80>0.>M8NIZ_XCTKPWXAEMI-8$4$-M+9W>K6R1R+*TH61.%
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MW/&S## 9!^ASTYJ71O%FFZY="VMENHI'A^T0_:;=XA/%D#>FX<CE??YAQS7
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M4U9GAZPCTOPYIUC%;R6Z06Z((99 [1\?=+#@D=,^U:= !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N7\:Z'/KT.BP112/'#JL4\[1R;&C15?YP<@@@D8QS7444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD<>] $]%%% !1110 445!->6MO/#!-<PQS3DK#&[@-(0,D*.IX!/% $]%%%
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M"KIM.< [F )(Z'MCG5_X0JT36[G48-1U*".[<27=E%,H@N'  W,NW() &=I
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MO6K[Q/+I4^G7-[#' (;G:)=J9RS!20"20.O2-?I0!5^(H?\ L;2FB1&E76K
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MU#6K>\6V,-A=_9HIH$91+\JL3R3TW;2!W!^@I?:M2E^).H:?)=1-IT>DQ3K
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MY#H1Y+,H"AO0FFIIVI:5XA36Y-,O)K:WU^]D>.&(M(8I855957JPR,<<X)H
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M,6[F3SDW;HRF-P8%6&,=:X?2?[8L/"^CZ3/8Z]:6]I?7*:B;*W<2L&:1H]C
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K/UG1;37K V5\UQ]G9LND,[Q>8,$%6*D$J<\
MCH:T** &0PQ6T$<$,:QQ1J$1%& J@8  ]*?110 4444 %%%% !1110 4444
M%%%% !1110 5ST?@G0XM46_6"?*7!NDMS=2&!)B23((MVP-DDYQU.>M=#10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M=K.AV.NV\45ZDN89!+#+#*T4D3@$;E=2"#@D?C6C10!GZ/HMCH5FUM8QNJO(
MTLCR2-(\CMU9F8DL3QR3VK0HHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-U6VM;"-=+AO7=KC.QW<H4)( P"I&>_'3I70W%[:6<:R7-S# CD*K2R!03Z
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MDYXJKXB@TC6?"/B#5--M]4NI[N&WCD:XM6C+.CC:%CV*2Z@ME@.!QGT]<HH
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MAG;][/%5/$S/MUFVCT^^@N(+S392%@DG>Y"-#^]\S!4!0&7"X.5))YQ7KE%
M'EVMH5;XD1BRN!+?Z>C6N+9_W@-MLP#CKOXQUSVJ]IBVFF>-K&Z@M3%;?\(X
MWG-# ?F=9$8 X'+XWG'7K7H=% $%G=1WUC!=PAQ%/&LB"1"C8(R,J>0>>AJ>
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN(9&C:-?*FY#+R/J*IV]_P"%WTW6(-(\2ZAJ=W+ITX$%S?33C 0DD!^ >.M
M'6#QKX89YE&O:>6AC$KCSUX4D#/OR0..Y J5O%GA]=/@U!M9LA:7 8Q3&8;7
MV\-@]R#QCKFN-T^QA6]^&&+=0(=/F(^3[I^S)^N:Q+>XLM,\6:9<Z@!':P^(
MM7;S&7Y8LKPQ]!D]>@SF@#M_$/C:"Q\/Z?JVC26NH07>H0V>]7RH#OM;IW'I
M6Q?>*-"TS4$L+[5[.WNFQB*24 C/ SZ9[9ZUY3K)6]T6_P!0LE+:=>>,+6:U
M=5.V10(U>1?52ZMSWP36OJ5]8:98^/M)U7_D*:E/*UI R$O>(\")$(Q_%@@K
MQ]TCM0!Z;!?6MS<W-M!<1R3VS!9XU;+1DC(##MD$&LR;QAX<MX[>2;6[%$N2
MWDLTPP^UMI(/H&XSTS7"^(O[6\)36%[:H[WNMZ9'H\NWG%\%_<R$_P# I 3_
M +(JIJ&EV_A?5K[2Y];72M.DT>VM;?S+)9OM:()%=%S_ !Y;)4<G>#0!Z;=>
M(='LK^.PN=3M8KN1XXT@:0!V:3(0 =>=IQ]*MWM]::= )[VYBMX2ZIOE8*NY
MCA1D^I(%</X6TY+7XAWP</*]MH5A D\R;7(S)G/H3M!(K2^(\*W'AFVA>/S$
M?5+$,I&05^T1YS[8H NGQUX5%JUR?$&G^2DGELWGCAL9_ESGIBMY)8Y(TD1U
M9' *L#D,#TQZUPLMI&WC;QI*T"EFT6V3<5Z@B?(_1?R%<;J-S:2>#([.9 FH
M1^#H7A:X4N9#Y;'$"=G!4%GZC"\<9 ![?17G>JL^FW&A^--,M?MLEQ;+I]TJ
MKS+Y@ A?/M)M4G^Z_M7;:/I<6D:1;6$84B),.P4#>Q^\Q'N<G\: );._M;])
M7M9EE2*5H693P'4X8?@>/PJP"",@C![UXY#-::1H%V$A$%M;^)K@:L+>W!:.
MU,DOEEUVG* F,XP?E[8J?4;3PZFFZ7+I]_)=:==>([>4/(52$9'[P1;0N$Z;
ML<9)[YH ]<W#&<C'6ER,XSS7F\FA>'(/B,NE26=DNG)H+!K9\>6/WP/(/' R
M>>F,]JP_#(L(+3X;WY>);Z<2V]U.S_O'C^SR (Y/)4,$ !X!QB@#UNQFNIK=
MGO;9+:42.H1)?,!4,0IS@<D8..V<58R,9R,>M>-0?V=)X2T")Y(MB^+)5&),
M8C-Q*>H/3:5/TQ5EKK2-(EUVPV0QZ:OB.V$4:OLMK?=#&Q>0#CR]ZMD< M@9
M'4 'JEY?VMA'$]S,L:S3)!'D_?=V"J!Z\FK&0"!D9/2O%P;%]#(NE@DMK#Q@
MK.7@VQPPNX.0&^XASG'3!K1NVTG4-=U;2M;O;RRU+[9'-I:V\"B5X0J&+[.Q
M0D<A@0" ,MG&30!ZG<W,-G:RW-S*L4$*%Y)'. J@9))K(D\1;?$FDZ6ML&@U
M&TFN8[CS,%1'LR"N._F#G/K4?CNV%WX \0P^2)F;3;C8FW<2PC8K@>N<8]ZY
M +H.H^(?!4 6RET]M*O"T6 (F)$'5>A!*MUZE3Z4 >G$@#)( ]:6O%M)U.TM
M=#\,KK%T8_#X%_:M*T:RQ13"?$(D#*P \L,%)'?WKT[PC9VMAX8L[:QN+NXL
MT#>1+=_?9-Q([#Y<?=X^[B@"I9>)=0U+5=7T^UTJ OI<RPRM)>%0Y9 X*XC/
M9AUQ6_9SR7%C;SSP-;RR1J[PN<F-B,E2>^.E>9V#:/>^)_'<5YKPL%N+F-$=
M+T19'V=%+#D X((_#%:&JRZ/K?CKPK-(L,UK<V-[E9L;94S'L)4]5.&(SU%
M'H61QR.>E&1G&1FO&--BTNV\/>&;V(P)=P^)'MDFWC>EOY\J^6#G(CV%>.F"
M#3(=+TZYT*XDTW9_PDUMXDE2R*.?-C O#E0,Y$?E[B1TP"30!ZEI.N/J6MZW
MILEJ(3IDT<>\2;O-#QAP<8&.& QS6P"",@@UY3K5U<+=^/6L&:4K?6#7*0'+
MFW$<0FP!S]T,#CW[ULVVF:;J_C"]ATU;>;P[>Z.$O4ML>2TQ?]V1C@/LW<CG
M 7/:@#OJ0$'."#CK7E]A:ZS-X<U&Q6U(U/PS97%C93! #-.4_=R)Z'R_+/UD
M/I5.-]-O]%U+5O"%Y?RZNNDO#-:P1+&4Q@XD 0'SA\P7G/7&10!ZS-(R02O%
M'YLBJ2L88#<0.!D\"J6AZI)J^BV]]<6;64LFX/ \BOL8,5.&7A@<9!'4$&N6
M\&?\(YJ&L3:KH%_<7 ELUBN(4A2*%"&RN]51?WO+#UP#GM4WCE&^T:6;:\TV
M*YB2=H[/4T'V6Y4! RD_PL 1M(SP6XQF@#M*3(R1D9':LCP[.USX/TV:"S>R
M9K*,QVTQR8OD&%)[XXYK@O!K:+JD^D3W%]>+XBLH9(M2M6B1&W%,2_:#L!9-
MPR"3U(H ]4R,XR,T @C((Q7BNDV>D#PYX&N=L N9-7EMYI=^':$B?*,<YV'Y
M,KTY'K2W,>E0/+9[H(=/M_&4:)'&^Q(HG@4L!@C:A;=TXR#0!ZEXHUQO#OAB
M_P!9CMA=?9(C(8O,V;@.O.#_ "K7##:"2!FO']7L+?3/"GQ%CTO9'H,D48LX
MXS^Z$Q3]Z(^V"=G3C.1VK?N9M-NO%NMV_B1H#I\^GP-IDDQ&QH\-YOEGIOW$
M$X^;&WT% 'H5&:\N^RZIHWAGPIXOU"TEN=7TZ!(-1CV9FE@D 7GN74E#_P!]
M^M3W^C6%GXG\&6E_%;&>=KR2\7@+(\D99@1W7<2 #VXH ])R..1ST]Z,C.,C
M/I7B\,&DVF@PW<'V=)K+Q;Y-K*&&8+?[7RB'^&/86X'&#FM.S?3-3U^:RUB^
MO;?Q)::R\T$4,2B66/S"8BCE"3$8RH/., YQ0!ZKD9QD9JO;W]M=75U;P3+)
M+:L$F53]QB P!]\$'\:\?,.E0:7=ZC%]G6[M_&"B"8,-T<9N4#!3V4INSC@B
MNR\)Q6%OX\\81+#!'>/=Q2IMC 8Q-!%E@<?=+@_4Y[T ==-+=I?6L<5LCVSA
M_.F,NTQD ;<+CYL\]QC'>LF#Q!=W^IRQ:?IJW%G;7ILKJ8W 1XV"!BX0C#*"
M0O7/H#69X@:W3XF>$BS1K*T5XK9(R1L7:#^.<?C4'P[ATQ)_$K645HL@UBX4
M&%5!\OY, 8_AST[4 =?)J$"WW]GI(C7I@:=82V#M! R?09('Y^E4O#&N?\)'
MX=L]5-O]F-RK-Y._?MPQ7K@9Z>E<]=IIUK\8(;F[BMT>71_W4LB#+2++S@XZ
MA>OH/:N1\,II]K8_#Z_@,"7TM[<033!AO:,I-\C'KMW;,#IDCUH ]ER,XR,^
ME8WBOQ ?"^@3:N;7[3'"R*Z"38?F=4&.#W85PG@YM,U.^TA[R^O8_%EA)(M[
M:I$J.7((D\T[,M$?O EL?=QS@5O?%N6-/AOJ2/(%:1X HS@G$T9./P!/X4 =
M+!>:G]MBAN]-BCAD#?OH;DR!2.@(*+C///\ C6CD9QD9KE[2ZT%-940:W]OD
MN86B,!NQ.J(,LSGD[1@8)[_+7GND6>D#PYX$N=L N9-5EMYI=_SM"5GRC'.=
MA.SY3QR/6@#VH$$9!&*Q_%.NMX<\.76KQVHNA;[28_-V9!8+UP?6O+IX]*A=
M[/=!#I]OXR1$CC?8D43P L!@C:A;=[9!J?6+*VTOPQX\332D>@R2VOV..-OW
M0F^7SA'VQG;TXR&'8T >Q$@8R0,TM><ZA+I]UXC\4VWB$P^1+9POI3RD8:+R
MSN,)_OB3)^7G[GM4$UMJFA:5X6\77=D]UK%O:QV6IQ!0995E"J#_ +ZR;,^S
M-0!Z82 ,D@?6@D#J0*\NU>#3]!U:PTWQ%,MMI%SI[C[1Y"M ]XSEIL[E(4L"
M"O3@$"JUX-)L;VVT?Q#J%_'HD^D1PZ==7T2N78-('!+(=LA4Q$< X [T >MU
M5L9KJ6V9[ZVCMI1(Z[$E\P;0Q"MG ZC!QVSBHM(@2WT&R@,ES+'';HF^\_UK
M*%QE^!\V.M>9:8(Y?!=A'9ZG86L\.M7S6\=ZH>VF_>S8CDYX!5L@^PQGB@#U
MRBL+P;<"Z\)6$PL!89#C[,K;E3#L/E/=#C*GT(K=H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK
MG?%FJWU@NDV.F2117FIWRVJSRIO$2['=FVY&3A" /4T ;$VI6-LMPT][;1+;
MA3.7E51$#TW9/&>V:M @@$'(/0UX_K.H:GH-G\1;RY-G>W=M'8[6DMP8Y01@
M%HR2,X/KC(SQTKI-2\2:G;>*([%]2L]+@*P?9$N[5C%>EOOKYV<*P^Z%ZYP<
M'- '>5'#<0W*%X)HY55F0LC!@&!P1QW!!!%<#=>+[^U\5Q0#5+2Y@?5%L6LH
M+.1EC1OE!:?&T2 X)7IVZ\UCZ;J6O:#X:U77(+JU_LZTURZ#V309::-KME<^
M9N^5AN. !CY><YX /5([NVFN)K>*XB>>#;YL:N"T>1D;AU&1R,U-7DTFN2>'
M/%GQ+U*$(9EETN*,R*656D0(&(') +9P.3C%6_\ A.=4BM;ZTM[N/4+AI;.&
MROY+%X$#SRF-@Z'&=F-W'4,!0!Z5]HA-R;831^>$$ABW#<%)P&QUQD$9]JBN
M]0LK 1F\O+>W\QMJ>=($W-Z#)Y-<=HT.I6_Q3O8M2NXKN1=$AV3I#Y19?.D^
M\N2,YST[8K+\2Z=>WOQFT!/ML B%C<2PI+:"01 % PY/)/KQCWH ].HKSFV\
M4^(&T+3?%LMS:G3+Z]BB.GBWPT<$DOEHPDW9+C*L>,=1@=:U_"VIZ[K>M:S-
M<W5M'INGZC<64=ND'SR[2,,7SQ@$#&.>?:@#K'ECBV^9(J;CA=QQD^@HDECA
M7=*ZHN<98X%>=>(K;1W\<ZC_ ,)7ITEY:3Z?%'I>;5YE!R_FJFT';*24.>#C
M&#Q69X/CC\87>AP>(K=+^*U\/),L5THD5I7F>,R$'@MMB'/^T?6@#UNBN2\!
MW!M_"MU!([O!IM]>6L3,<GRHIG"#/?"@#\*R;'Q+XA73/#WB*\N;1['6;F&)
MK!+?:8$G.(RLF[+,,KG(P<G&* /0ZRQHD,?B1M;@E>*:: 07,2XV3A3E&/\
MM+E@#Z$CTQB>#M3UW7+K4KR^NK9;"VOKJRBMHX,,_ERD*[/GC@8P![Y[53UC
M6?$<NN>)+/3+VTM(-)L8;I&DMO,:1F60[#\PPIV<GKZ4 =O,CR02)%)Y4C*0
MLFT':<<'!ZXJEH>C6V@:1#IUJ79(\LTDAR\KL2S.Q[LQ))^M<2OC#7-.31]6
MU.6UFL=4TR>]-I#"4-N8X1, 'R2V1D'(Z\CTJ[8ZUXBL9_#5UJUY:7-MKCB*
M2"*W\LVLC1-(FUMQW#Y2IS]?:@#NJ*\OM/&7B%?!">([Z\LU^VW*V5M$MHS"
M$F<QF5L'+<!CL '0>IKI?!OB"YU>?4[2>Y^VI:-&8;W[(]OYJN#P5;^)2I&1
MQ@B@#JZ*XN/4O$VM:EJMQI%S8Q6NFW_V-;.>$G[1M"&1FD!RA^8A< _=&<YK
M/O\ Q-XA.E>(/$EG<VD=AH]U-$M@]ON,Z0'$A:3=E6)#8P,# SF@#O[F W-L
M\(FEA+#'F1'#+]"<UE?\(^__ $'-7_[_ "__ !-<OJ6O^)+BX\5R:9?6=M:Z
M+%'/ LEMYC39MUE*,=PP,YY'//;'*2>+M3EUVUCDU"TTF&XCMI+2&[M6,=Z)
M%#.!-G"L"2H7KD X.: .I_X1]_\ H.:O_P!_E_\ B:/^$>?_ *#FK_\ ?Y?_
M (FN-@\?7MQK2R172/ VJFP_LU;"0L(A*8O-\[INR-Y'3;QUYK8T'4O$VNBW
MURWN;'^S)KR6(V#PE66!'9-XDR<O\N[&,<XXZT ;7_"//_T'-7_[_+_\345S
MI$=E;O<77B/4H($&7EEN455'N2N!6)'XLU-O ]IJQ,/VJ76!9-\GR^7]M,'3
MUV#KZUS5SJNM:;X1^(.IW%[;WXM-2>*."XM0R9 A&<$GY<'[OKSWH ]$&@,P
M!&NZL0>01.O_ ,32_P#"/O\ ]!S5_P#O\O\ \367%XGFT[Q%J%IJS1)8+I::
ME:NJ[<(@(F4^N#M/T:N9'CC6W2PMKW4+?2[R735U%S_9\EQDRN_E1$+]T*J_
M,>I)XQS0!U$_@;[9JL-[>>(=8GCMG\RU@:1 L4FTJ7SLR3@G&>F370VPBL$A
MLY+UY9I-QC^T2 R28Y..F<9["L63Q1)#\.'\42VACF333>-;/D8<)NV'//7B
MN=9=<@\:^$9=8O[6[,EO=RY2'R1$_E*67J<KSP>HP<YSP >CT5YGIOBS7;^]
M%A::M9W]U>Z=<7$#Q6$D<$,\>S:$=L"6,[R,]> >,XK3B\9WNL6WA<:/%&;K
M4HI+J[C<9\N.)<2)[$RE4R?>@#N:*XKP1X@O]9G=+W5K2>=;=7N; VC6UQ9R
MDC*[6.63J-Q[@<G/$'C?Q/?Z+=7/V/5K2W-K8FZ6T%E)<RS.-W$FWB*,[0 W
MJ6]* .\HK@Y=;\1:OJ^K6VF7MK806>GVUXC26_FL7D5SL/(&WY>3U]*9I'B7
M7O%=U9IIMQ:Z>$T>UU"XWVYE$DLX8A/O#"#8>1SS0!W<%Q#=0+/;S1S1/RLD
M;!E;Z$5F:AIUI=>(='O9KH1W-GYY@AW >;N0*W!Y.!@\>M9/PQ+'X;Z(6&&,
M+9 .<'>U5?%\=_+XZ\)1:=/%;SNEZ#-)'Y@C79'DA<C)[#GOGG&* .WHKS*?
MQSJ=I$-)O;V"&^CU::PEU!+-I!Y21"4.(E)^8AT7'0<FK%CXNUG6!INDVMQ#
M#>W-W<Q-J#V;!7AA56WK$Q&&;>@Y. =WM0!U=QX>6]\1V^K7E]<3Q6A+VED0
MHBAD*[3)P,LV"<9)QN.*VJXC5=6U[2[+3[74=8TZRNY99E:>"TDN)9T7[AC@
M ."007Y(7MUX3PSXNU#6K_P_%.L*I>Z9<W$X6,KF6*6.,$ \J#N8X/J/2@#N
M**\TN?&6K_9(I9[V+3;+^T+^WFU'[$TZ1>3-LB1@#A0PW$L>/E[9INJ^.-1C
MNWM(M5L8)K73H;G=!92W45[,X8X5E^['A1@]?FZ\<@'IM%<YJ_B9].\ 2>)$
MM3YWV-)TMY,C#N!M5N_!8 UG"\\2:;K]CHM]JMK<MJEK,T-PEGL^SS1[2?EW
M?,A#'KSQUYH UEMH-3\1O<+KWVJ&TVYTR-HBD,HR [8&_/7 )QD9[#&U/<0V
MT?F7$T<2;@NZ1@HR3@#)[DD ?6O._@I930^ H+R2:&07,DQ 6W".")I 2SYR
M^>V>G2L*]?6I?#OBJ2XU%+LQ>)K>"&-XMH#+-;8.<G"XP,#W/>@#V6CH,"O.
M=7\6:YX5GUBSO[NUOI([2UN+6<6IC$;33F'#(K$LH(#<<XR*U_!_B*ZU34M0
MT^>\_M"*".*:&]%D]MNW%@R%6[J5!R.S#TH ZV21(8GEE=4C0%F9C@*!U)/8
M5"E_9R7"6\=W TTD7G)&L@+-'TW@=2OOTK@_$.I:YJ\'C*.QN[:"PTFW>W\A
MX-S7#& 2.2V1MX< 8'49.>E0:;K=[;:_I.G6EE;3NOA 7<68QYKR*5"IOZA3
MZ>O- 'I=1SW$-M&'GFCB0LJ!I&"@L3@#GN20!7GVF^+-0FT#4[MO$>DO/!!&
M76[M'MGLI6;#*\>2Q'/R]RPQDYR,?6/$.H:KX>U.R^TK>S6.J:8UM<2V;VOF
M;YT(#HW/#*>1U!H ]:FFBMX))YY$BBC4N\CL%50.223T%0K?V3RV\:W=NTEP
MAD@42*3(F,EE'<<CD5PFKZ[K6BQ>)M,U*XL]2>#0Y-2MI3:A%XWJT;IDAER%
M/T)!S5.WN6O?'OP[NG2-'FT.>1EC7:JDQQG '8<]* /2K:[MKV(RVMQ%/&&*
M[XG##(.",CN#4U>.1ZSK.J^&O#T]I=VVFM-XF>T=;>U 5@&?:2 1G[G(_BS[
M5U$_C&_TBQ\60:@(Y=2TIE:R")M%PDP @XSR=^4./2@#NR,CFH1=VQO#9BXB
M-T$\PP[QO"9QNV]<9XS3;!;I-.MEOG22[$2B=T&%+X^8@=AG-<7JNO:C:^/]
M8LM/L+:YGM_#AO+=?*_>RR^8P5"PY*D@?+ZT =Y17*>#-:GU<7?F:W::FD83
M*K:M;3P.<[DDC)R!P,$X/7KC-17'B2_B@\<NIBSHJ$VF4_Z=5E^;U^8G\* .
MO.<''![9K(\.Z&=!M+FW^T_:/.NIKK<8]I#2.78=3QDG%<U'K'B76=6O+&PO
M[2R2WTNTO/->V\QC)(),KC<!M.SZC''6LZ]\<ZG-X?TO4H=3LK&:?2%OS:I9
M274DDI&<,J_ZN+C&[.>O/'(!Z4MQ"UP]NLT9G10SQAAN53G!(Z@'!_(U4U-D
ME@.G0ZFMA?72,+=T*&0$<EE5LAL=^*X.SEUG6_'%]<Z3>6^G-<Z'87#O)!YQ
M!)F*J!D<<G)Z\>]4H==?7?&'PWUBYC6*6:RU!ID3[H=8U#8]L@XH ],TO3QI
MMD(//DN)68O+/+C?*YZL< #\     .!5S %>:^%_'=_K&I:-(]TEQ#JN[S+.
M.PD3[$-C.A\T\/\ ="GU+ CBM3Q6^JGQ[X1M[+4Q;03O<EX_)WABD1//(SD'
M&.QYH [; '2@@'J*\Y;Q5K__  C\GC!;FU&EI>F(:=]G^8VXG\DMYF[._JW3
M';'>NC\::OJ.CZ3:2Z7Y/VJ?4+:U7SU)3$D@4YP0>] '1T8&<UYQJWB[6O"T
MNKZ?J%U;7MQ';VL]G="V*!?.F,)#HI.0I&[CDCCK56Z\=ZO9Z#KDEK<QZC+9
M&S>VNY+)[=9/-F$;QLK=QZCLX]* /2KR^M-/@\^]NH+:'./,FD"+GTR:S=<T
M7^WO[,D2[$2V5VEZA";Q(R@X'4<?,?TK@/&FE:Y/XB\$VNH:Q:7#RWLO_,/'
MEJXC9MVPN<@#  /IG-:-SXE\0QZ%K7B2VNK1;#1[F6$6)MO]?' VR1B^[*L2
M&*@# P,YH ]' P,"C /45Q5KK.NZEXRUZU@N[:#2])\EPI@W23>9 'VYR-H!
MR<X.<@=N<;3O$7B^[L_"5VU_I_\ Q4*>6T7V0XMSY1D\P'=ECA#\IP,D#M0!
MW-[HTM_J\%S+J5P+&(*3IZHGER2*VY7+8W<'' ('RCWSHSW$-M'YD\T<2;@N
MZ1@HR3@#)[DD ?6L#P?JFH7\.K6NIS13W.FZC)9^?''Y8E4(CABN3@X?''I7
MGMZ^M2^'?%$EQJ*7;1>)[>"&-XMH#K/;X.<G"]!@>Y[T >RT8&<]Z\YU?Q9K
M?A:?6;._N[6^DCM;6XM9Q:F,1M-.82&16)95(#<<D9%:_@_Q#<ZIJ6HV$]W_
M &A%;QQ2PWHLGMMV[<&0JW=2H.1V8>E '7T5YGKWCV^L]8UD6ETBKI4J1)8"
MPDE:\^17?]XO"'YMJ^XR>#6G#XDU*3QK)IUQJ5I98NO+@TZYM60W,&T'S(YL
MX9\Y.T=,$$=Z .YHKS&U\=ZG:Z9JFH7]]9O>6=E+//HTEJ\$UO(" @4D_O(\
MG!;Z$'G%1R^.]6L],UIH[^+4I+;2GO8KG^SI+=8I58 QD-]X'<"._!SF@#U*
MH9;NV@FAAFN(HY9R1$CN TA R0H/7CTKA-3U7Q-I]]<:?<:E:LUWH]S>PO%:
M[?LTD13*CYOF4A^IYR,^U9^DZKJ-E:_#2VNI;:];4HR6FEMQYD:_9@P"L23N
M[%N] 'J.!G/>H;>[MKL2&VN(IA%(8I#&X;8XZJ<=".XK@[3Q??\ _"6V-JVJ
M6E[!>7\UH]O;6<GEP!5D92MP1M=QY8##U)QTJ;X6_P#'KXJ_[&6^_P#0EH [
M.34+**]CLI+RW2[E&8X&D =QZA<Y/0_E5FO&W_M33/'/Q%UI;VUEN=+L(9T,
MEF"3^XD9%4[LJ!@9Q][VKN=1\07UMJFA6\9C\N]L+JXERO.^-(V7'H,L: -/
M7M#;6WTUA=>1]AO$O%'E[M[*" #R./F/Z5L 8&!7G6D^)?$2V_A'5=3N[26T
MUQ LMK%;;3$3;M*KJ^[)/R<@C'S<=*O^'[SQ;K>FV&M"^L$L]3@:7[.;<[K1
M64F)E;=^\(^7<#@')QC% '87%U;6IA%S/#$99!'%YCA=[GHJYZD\\"J%UHTM
MYK4-Y-J5P;*(*PT\(GEF122KEL;C@X.,XRH->:Z/K6JVG@;P+<W<]O?R:EK,
M$1:XMPS1(V_."2?FR.&[9Q6W?>)_$/\ 9.O>);2YM4T_2+J:);!K?<9XX6VR
M$R;LJQPV,# P,YH ]$(!ZT8!ZUP&HZYXCNK_ ,4#3+ZTM;;1X(IX?,MO,:8M
M#YFUOF&!D=>O/;',+^,-4GU6Q\S4+/2(;JWM9K2*[M6,5X9%!=?.SA6&=H'7
M.#SF@#T6D8J%)8@*!R3TK \6ZO>:7:6$&G&);S4;Z.RBEE4LL6X%F<KD9PJM
M@9'.*X_Q5J&N#P_XRT"\U&&2:TTG[9'=I;;3+"ZR*T;+NP&RAPP['I0!Z19W
MUGJ$)FLKN"YB#%2\,@=01U&1WJQ7-^ K&33_  5I<<DD+[[:*1?)MQ$%!C7
M(!.3_M=ZZ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM(9V#. JET#8!/UH Q+?P&T*VFGMK$CZ%9W8NX+#R%#!E?>J-)G)16Y QG@
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M;^3+NW;F"H&R!AN<L!G !-78;BXDU.>,FU-H(8WB*2$RDDMG<N,!>!@YYYH
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M*Y0X8(Q&U\'KM)Q6+X0^(&G:]I>DI>7D*:M>Q F*.-UC,F,E%8Y7<!SMW$T
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M6F^&+(W3,N@E-I*#]]M@:+D9XX;/?I4&C>#KK1Y[*$:]=2:1IY8VEB$"8!!
M61P<R*H8X&!T!.<5.?'OAD/,G]I@R1 '8L$A9P<X9%"YD7@\KD<58G\8Z!;V
M%E>MJ"O#?*7MO)C>5I5'4A%!; [\<=Z ,*U^';0:1HFF2ZR\UOHVI1WUK_HX
M5MJ;L1L0>?O?>]NE6+WP(]U_:-E'K$L.BZE<&XN[(0*69F(,BK)G*JQ'(P3R
M<$9K7G\6Z%;Z99ZBVH(]M>MMMFA1I6E/.0JJ"Q(P<\<8YQ65I'CFRN-.U/4=
M0NH4M(=3>RM7A1F,JA5*@*,LS')X [=.* -$^&8C/XAE%RP_MF)(V4(/W06+
MR^/7UK,N?!-W<:='I/\ ;\O]DF"&">V>W5B1&JK^[;/R;MH)X.#DC%3:E\0=
M#T^'2)TE>X@U.X:!'BB<[-H;<2 I.05P5X.3[&K=MXBMH[O7FO=5L?LNFNF\
M+&R-;*4SB1F.&)ZC&/3K0!:\0Z&FO6,4/VA[6XMYTN;:X10QBE0\'!X(Y(([
M@FLEO!;W>GZ^NI:HUS?ZS:_9);E8 BQ1A6"JB9.,%V/).2:T+7Q?H5Y:7US%
M?8CL8O/N1+"\;QQX)WE&4-MP#R!SBGZ=XKT35M1-A8WZRW(C,JKL90Z @%D8
M@!P"1RI- %_3+(:;I5G8*YD6V@2$.1@MM4#/Z5:HHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD
M?B%"'TG2YV@:6.VU>SFEVQ%RD8E7<< $XQUKKJKW>H66GHKWMW;VRL<*9I @
M)]LF@#RWQ%96M_\ \+$E-CYLCZ= ++? =V\0L,1@C.X-M&!R#@5+?R6UUK&J
M:=XB_M0V>JVUL;)K:U\T3J(P&C#!&*.)-S=1][/%>BP:[I%U,L-OJMC-*WW4
MCN$9C] #5JSO+;4+.*[M)XY[>90\<L;95P>X- &7K_[GP7J*/OW?8)$ 8[F+
M&,@#CJ2?S-<KX4_LJS\.^%G+ZBVIP6L$7V4R3L!(T01@48E4 )/.!@ _2N[L
MM1L]225[*ZBN%AE:&0QL&V2+]Y3[CTJS0!X[J>F69\->,VCL%^T_V\DEJ4A^
M?;F [H\#.,JYROH:;XXL[&W;QDMK:11VCZ/9.HBBPC2K+)DK@8W!67IS@BO9
M*R_$.AP^(]#N=)N)YX(+@ .\&W=@'.!N!';TH XXZ98P^*]0U/0H(H=..A2P
MWC6Z;8Y)BP,8P.K@!\]QD ]153P[))83>#9]3C9=*'AQ;0-(AV6]UA-P?/W2
M54J"?0CO7IR*5159RY P6.,GWXIU 'F$?A^]M_ 1OH82MWH^HW&HZ1%*-K+;
M"1BL1SR T>1CMN7IBK&LF[L]-T?7Y[>\2WN-1-[J2V\(DEA1HF2(LF&SY8\L
M' /(R.1757=II_BB8"+5YV@L9I+>[MK68".5L#=',,$\<<9'4YZUJ7.HV=E/
M;07-U%#+=/Y<".P!D;&<+ZG% 'FEP+71TTO5; :O_P (_)J-Q/=3"VW,CR(
MLPB,>5CW;QPO5B1U&>U\(65C9:(5TQ;L64L\DT7VE2A.\Y)5"!L4DG P/4<&
MM^B@#SS4/M5KXSDDL72^@N-3M_M6FW,)$L3[$7[1 XZJJ@%@<CY6&1G%:GQ
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MZ1##>VXS"Q%M<&;]V7&,KF/*J2.C>]>O5!#>6UQ<7%O#/&\ULP69%;)C)4,
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M5/-E\V^M([21>-JJA<@CCK^\/Y"@#CM&U_7C-X/U*_U5);?7H':>T\E$B@Q
M959&QN_AP<DCDXQ46C>(=9OM7M+*+6[JZ&J65PZ7$NF>1!%*H4H\!9 73YC]
M[=G@YYKJ$\&:>+#0+-IIWAT6$PQ D?O5,)A._C^ZQ/&.:IV?@L:3-IM^^LZG
M=OI$316R,D9_<;<&/:J#).U?F^\<#F@#/L/%NIZS8>%;.W<0:M=W+IJ8V*?*
M6WR+@8(XR^U1_OUH_$L2GP>! R+,=0L?++C*AOM,>,CTS5?P;H9_X2;7_%$M
MC<6(U&15M;:X&'1 J^8Y7^$R,H..OR@GK73:WHT.NZ>MG<221HMQ#/F/&<QR
M+(!SV)4 ^U ''W>L:OH.H:[IMYX@$J1Z?!=V][<VJEH'DE>,J$C4;^5&T8)R
M0.:S3XKUZTL-;ECO+ZYCT66TNY&OK%8)Y;9RWG(5V+@ *6#  \8KL-:\'6FM
MWMU>275S#<36\$*M%M_=&&8S(XR#SN/?@@4:=X1BL[_4;RYU&[OWU*V6"]2X
M";9=NX!L*HV_*Q7 XQV)YH Y[Q-XQU*TO]9FTN938:99V\1VP^9ONKF10A
MRP1&#;1UWBM3PAJVI76JW]E<RZI>620QRPWFH:<UH^\E@\>-B!@,*00/XB#G
M%3:9X!TS3?"5SX=\^[GAN6WR7$CCSBPVA&# 8RH1,<?PBM71](N=.DGFO-8O
M=2FF"KNN-BJBKG 5$ 4$Y.3C)X] * ,76;G6KOQW;:'8:JVGVCZ9)=2O'#&\
MFY9%4;=X('WNX/';/(S=!\4:Q=ZAX>LKNX1W>[U&SO76(*)S;DJK@?PYP"0.
M^:O:QH>H:A\1;6\M;J[L$BTF2-;R%%90YE3Y"&!4Y&3CVSVJ?_A!+:#3]+AL
M-2O;2\TV:6:.]&QY)'EW>:7#*5.XL3TXXQTH P-1\2^(7E-K97Z0RR>*6TM9
M&@5MD'D;NF.2#S[XP3BK.HZIK.D^(8[/4=?NK.V06Z6MU+8(]M>,<"3SG5?W
M;DY  *#H>:U[7P'8VP@)OKV9XM6_M8R2LI9YC'L(.!T.2<#'/3 XJQJ_A1M7
MNI_,UK4(]/NBAN; %&C?;CA2RED!P,A2,\G@DF@#"N_$^K1>"O$^HI<@75CJ
MDUO;OY:_)&LJJ!C&#P3R:@USQ1J%CK\LMKJUS/#!J-M:-:0Z?NME1WC1UDG*
M\2?.3PV!\H(K5O\ X>P7XU*W.L:A%IVH7'VN6RC\O:)B02P8KNQE0=N<9_*G
MWW@&*]:]0:SJ$-K<W8OEMX_+VQ7 96W@E<D;ESM)(R3QTP 8.K:UXE73?&&K
MV^M>1%H5VXM[86T;+*J1QN5D)&<?,0,$'D\GC&EX;CO9?B?XJEDU.=X(XK3%
MNR1[<,CL!G;GY<G&#SGG-;,W@^SGT;7],DN;@QZW(\EP_P NY"T:H=O&.B \
MYZU-;>&UL_%-SK=O?W"?:XHX[FUVH8Y#&"J-DC<" >QYH PO&,-[-X[\&16^
MJ3VD<EQ<DK&D;#<L#G/S*>H)7Z'CGFLR;Q#K_P#PC%WXS35"MM!?2(FE^1'Y
M;6Z7!A(+8W[R%+9#8S@8KL=>\.KK5WIEY'?W%C>:=,TL$T*HWWD*,I#@@@@G
MM6;)X#MI))8/[3O5T>:[^V2:8 GE-)OWD;MN\(7&XKG&<]N* -[6[S^S]"O[
MP7,-L8;=W$\X)2,@'#,!R0#V')KSIO%FLV.F^)D34;^Y>TT7[?;7&H:<+:1)
M/G!PFQ0R<*1D9Z@DUZ+K6DP:[HMWI=TSK#<QF-FC.&7T(]P>:YVX\ )?&^DO
MM<U"YGO[!["YD81#=&<[=H"@+MR2,=23G- %&>?Q1;:U;::NN^=/JVEW,T.Z
MVC"VMQ'Y>TIA<E/WF,-N/'6I-/\ %M]X@_X1*"P<07%XKW.IKL!,20C9)'@]
M,RD+GK@&NCOM*MX]1LM;8W+RZ7:SQ)%$NXR*X0GC&2W[L8 ]:PO ^@-;:KKW
MB*:RFLFU6YS;VL_WX81R21_"7<NY7W&>: (/BU_R*^G_ /88L_\ T8*J>(O%
M&H:?K=U-9ZM<RQ6M[;6[6<&G[K95=HPZRS%>)/G)&UACY01S77^)/#MMXFT^
M&SNII8DBN8KD&+&2T;;@.0>*R-1\ PZ@VH)_;&H06EY<"\-M%Y>U+@;2'!*D
MD90':3C/:@#&U;Q+XABMM:T:SNE&O#5Q;6$AB4X@>/SU.W&#A%D7)_N^M;/A
M_P 2W/B/Q% UK*!IB:/!=3(%',\YRHSU&U4;C_:&:T#X2LW\80>)7GG:\BMA
M 4R!&Y&X"0C'WL.P],&LZ#P2-#\.ZQ9:%>W4=W?S^<D[2 -$?E"H"!PB@8QU
MP3ZT =A7E/AWQ-XAUCPYX/":BD%SJM[>PW,RVT?W(_.(VKC ("#''7KGD'U:
MN6T;P)I^B6FAV\%S<NNCSSSPERN7,H<,&P.@\PXQCH* .>B\0:\;H^&_[5+7
MC:X^GKJ301^8L"VPN"=H&S?_  YVX[XJ+QI;:K:6OA.#5KZ.^=?%EIY-P$".
M\7S8W@ +N!R/E&",5U%WX)M+E[N>.]NK>[FU!=2BN(]NZ"81K'\H((*E5P00
M<[C4<G@2VN;:R2\U.^N;BVU6/5GN)&7=+,@P%( PJ8P,*!T^M &;?>)=5A\*
M^.[Z.Y N-)N9X[-O+7]VJP1N!C&#RQ/.>M4M;O-:URQ\9O!JIM;32K=K=+40
MHRSG[.)',C$;AG?@;2,8SS6UJO@"#5&UF'^V-0MK#5SON[.'R]K2; FX,5+#
MA5)&<$CTR*DU+P+#?W.I-%J]_9VVJ1+'?VT'E[9B$V!LE25)4 '!&0* ,32-
M;OX?%&D:3'*HL_\ A$EN]GEKGS0RJ#NQG&.V<5'H^N>(HK'P9K&H:P;J+6@L
M=S:"WC1%W6[R!U(&X-E.<G!R< <5U$'@VRM]:MM46XN#+;Z3_9*J2NTQ[@=Q
MX^]Q]/:GP^$K.'3?#MB)YS'H3(T!.,R;8FB&_CT<GC'- '(V>N>)VT?PMKTF
ML*\6MW\"369MXPD,4A)"QMC=T !W$DYR,8YZWQIJ5[HOAXZK9R[!:7$,MRNT
M'?;[P)1R./E).1SQ7#6?A^^DU#0]+@M->BMM,U07"P7@C^RVL2%C\DB@&7.0
M%!)(#'IBO4=1L8=4TRZT^Y&8+J%X9 .ZL"#^AH X63QO>6/B?7)KN5#H<$%R
M+1=H!\VV2-I/FZG<7< ?],S533M8\1R:_)I%_J.RY'A:.]DD2WC#I<ER&(^7
MH.F#QQTS6Y-\-]*G\-Z9HDMU>-%8W37/G%E\R<L6+ASC!#;SG\*UV\,6C^*K
MC7VEF,\^GC3WBR-GE[RV>F<\^M 'F^@6>I2V7PVCBU>5)I["X<7#11L\"&&+
MY4&W!Z<%@>ISFMFS\0:_=W-IX<_M0K=OJUW:2:D((_,,,"!P0N-F\[E&<8X)
MQ70Z)X)AT;^QPVIWEV-(66*T$RQC;&ZJNP[5&<!>#UY.>U+-X(M6+S6U]=VU
M[_:,FHPW4>PM%(Z[64 @@H5X((H PG\2:UI]U-I,U]]HGL]>LK,W30HK36\X
M5L, -H8!B,@#H#Q5'XB:GJ<]EXQT^._>"VLK6PDC6-$R?-DD5P21G!POY>YS
MU+^!;672;FVDU&\:_N+R._?43L\WST*[& V[0 % "XQC\ZAF^'UK=VFMQWVJ
MW]S/K,$,5S<.45E,18HR!5"K][IC' [DD@'56D,MO:113W+W4J+AII%56<^I
M"@ ?@*FJO9036UE%#<7<EW,@PT\BJK.?4A0 /P%6* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?
MQ]K][X<\/17UAY?G->V\!\Q=PVNX4_C@UU%<5\4;*[O_  G!#9VTUQ*-1M7*
M0QER%$H).!V H TF\1VEGK>O)=ZM&;?3+1+F>V%HX:V3:S%RXR'R 3@#(Q48
M^('AQIC"ES<O*8_,BC6RF+7"YQNB&S]X/=<^O3FN4UO2]0EU[XE21V-RZ7>@
MI%;,L3$3/Y,@VH<?,<D# ]:WTT^<>,O"<WV200V^D7,;OY9VQL?(PI/8G#8'
ML: +C>*K"]N?#TUAK,26VI22K'$UH[-<[%.5!X\LJ0<[AVQ5?2OB)I&HZ?J%
M[,EW;16=XUH-]I-NE._:H4% 2Y(^X,L.X%<E8:1J2:QX.=M/NE2WUO5I)286
M C1WDV,W' .1@GKFI(+C4-.T_4K 0:I:$>)9YKN>"P>1TM9'=EDB.Q@V3L&5
M!(!)P* .JU7XA:38:+;ZE!'=7*S7T=B8A:RAXW+JK!UV%E8 Y"D9;@#K5RV\
M16K:[J<<NKQ""ULXKI[:2U>)K=&!.]W;@Y ^[@%<<UY\]O>Q:/JC&QUF40^)
MK+4LW%L[S26P$/[P +\Q^1LJ!N7&"!5K6]%U+7=<\;O8V5SY>H:);"U>6%HQ
M*P#-L^8##=B#R,\XH [JP\9Z'J+R)#<3QLEN;H+<6DL)DA'61 ZC>O3E<]1Z
MTFF^-=!U>_MK.SNI7DNHS);.]M*D<X RVQV4*Q Z@'(Y]#7,ZI<2>*M7L+G3
MM.U"*+3].O?M!N;.2$AY(PJPJ& W-D$G;D?*.>14]GIUW'!\,U^QS+]CCQ<#
MRB/(_P!"=?GX^7YB!SWXH W?$OBZU\,WNDVUQ;W,S:A<&+,-O))L4(S%OD5L
MG( V]<$GH#67IWQ LHKK4[?6)VC:WU22T1X[:1HXTW!4\QU!5"2<98BI?'7F
M6^H>%]2^S74UM9:F7N#;0/,R*89%#;4!8C) X'>L*_TN^?P!XU@2PN#/<ZK/
M+%&(6WRJ73#*,9(P.OM0!V=QXMT6UU?^S);F03B1(7<02&*.1\;$:0+L5CD8
M!(/(]14WB378O#>@W.J2PO.8MJQPH?FED9@J(/JQ KSZXT8_VQK&EZC-XE_T
M[5?M$-O8P*;>:-BC!S(8R%VD?-EP1LXZBNS\<Z3>:QX7FBTY%>^MYH;NWC9L
M"1XI%<*3VSMQ^- %1+SQU:/;7%[IVD7=M)(JSVUDSK- K'&X,YVOMSD\+T.*
MTO\ A+]%_MG^ROM,GVCSOL^_[/)Y/G8SY?F[=F_'\.<]NM9B>-YK\VUMI?A[
M5FU"21%EBO+22WCMUR-[/(PVG SC:6R<8KD]2DU.XU!)KN/7))[/7TFFM8;-
MA;16JSX21=J?O25VMP6;EB0 * -E/&=V=)\8W-]J5MIL>DZH;2"[:T:81QY3
M&Y%.6)+8X]<]JDU_QI=V_P 0=-\-64CV\30F:YF.F3SESN4!4V@#;AN7Y Z'
M!&*Y37-%U67P-\28(],O'FN]:$MO&L#%IDWP_,@Q\PX/(]#7:7MC=R?%W3;M
M+>;[*NBSQ-<!#L5S(I +=,]\4 :MMXUT&[U&.RANI2TLS013&VD6"61<Y1)2
MNQFX/ /8U&WCSPZLE^GVV0C3Q*;MUMI2L/EL5<,P7&<@X'4XR,BN,T^&[F\*
M^&/"0TR^BU33K^V:Z9K5UBB2&3<T@E(V,&"\8))W?6IY-)OA\-O'ULMA<?:;
MO4-1DBB$+;Y@S?*5&,L",8(ZT =A;^+]'U&6ZM;2\DCN(K9KA6FM9%5HQQYB
M;@!(H..5)SQZU6M/&6F6WA[2;N[U%[^2^B,D4EG82EIPOWG$2AF51D9STR/6
MJ7B"PN9/%&GR06LK0IH=_"62,E59O)VKD=S@X'L:YG1%U73O#?A*PO(]:L;9
M=+<,+"T)G:XW+MB<["8QC)YV@D<GB@#U6RO;;4;&"]LYEFMIT$D4B]&4C(-<
M5H&L^-_$6C0ZK;?\(]#!,T@1)8YBP"NR\X;'\-:GP[CFM_ FEVMS!/!<VT9A
MECFC965E8YZ@9'N.#7/>"/ T3^%K.:_N->M+HR2L\"ZC<0*O[U\?NPP !&#T
MYSGO0!ULOB_18-9_LI[F3[1YRV[.+>0Q+*P!6,RA=@8@C@G/(]:KW?CSPY8W
M4\$]](IMYQ;W#BVE,<#G&/,<+M0'<,$D ^O!KB/$+ZG=7=\+B/7'FM=:@F%I
M;6;?9A:1S1L)<JG[UBHS@,6SVPM6M3TJ]G\%>/H4T^X:6\U1I(8_(;=,FV#!
M48R1P?R- '6'QCI-[8ZL+._>VGLK1KEI+BSE&R/#8E", 9$^4_=ZX]Q68_BR
M[3Q#X-M(KJ*ZL=6T^>YGG2W93+LB1U9%ZJ#N)V\GG%5O%^G7EQKFO26]G/*D
MGA2XMT:.,D-(6;"# Y;VZU0TS2]0CUSX7R/8W*I9Z-+'<L8F @<V\8"N<?*<
M@C!]* .Y/BC1AX>@U[[:#IL_E^5,L;$N78*H"@;LEB!C&15;QEK=[H6BPW&G
M1V[W4]Y;VJ?: Q0>9($R=I!XS7&Z;I5P/'W_  BAB)T?3+QM=C;^$+(/W47M
MB5I6'L@KI/B+ITVJ^'K2TAAN)=VIV9D%ON#J@F7<P*\K@9.1TZT ,DUSQ+HF
MJZ5#KL.E3V>HW0LUDL3(CQ2%6925?(9?E(.",5:M/%>GV]GK5Y?:S%<066I/
M:'R[1T:%OE AQR96RPY4<YX'%8Q\,1^'?'FDZC'#J&I6$Z-;!KBXFNFL)CDB
M4;BVU6&5)[<<@$U@6^EZG:PZS?/IEX\=MXU.H&)8&+RVX"C>BXRX&<\9SM.*
M .JUSQ]8IX=U6ZT>Y_T[3Q T\5S;O&85DE"_.K@$' ;@\]#T(S:O/B#HEOI6
MJW<1NI)=.MOM+0/:31NZ'(5E#)DH2,;P"!U) KBM9:37[_QNUGIMW^^M=*\N
M-[=EDE43/EC&1N' /! .%STK>\::7?7VLZW]ELYI1-X5N;>-D0D-*7X0'IN/
MI0!MCQ[HJ:;9W=RUY$;F#[08A8SLT2#AG<!,J@/\1 !ZCBNECD2:))8G5XW4
M,K*<@@]"*\PO[R*73=,U"S7Q'IVIQZ:(8+BWTV219F7K!+$R'HPR"0H.XX;K
M79ZIJNI:9X(DU$:?)-JR6:L+2WC+DSE0-H SP&//L": ,/\ X3RX_P"$Y_L[
M[)#_ &#]K_LS[=D[OMNS?M]-O\'^]70:SXJTC09T@OYYA*T9F*06\DQ2,'!=
M@BG:ON<"N&/PSU\>!O[''B;]Z!]J"?8TS]JW>9N\S.[_ %G?TJ?3-=N[/5I?
M$.KZ)JG_ !-M)MXQ%%8R2,EQ$THDA*A25W%P5+8!'>@#IK7QMI][XQ_X1^WC
MGD)LX[I+E(9#&V_<1\VW;MVC(;."3@<@BNDD<11/(V[:H+':I8X'H!R?H*X3
M3Y9K+XC)<W.DW5I%>Z%;Q11PP-)'%(CR,T1=!M4J&'7 /:NQTG4H=8TFUU*!
M)8XKF(2HDR[74'L1V- '$'XF0W>EZ7J5O'+:V\NLM97'GVTG,0\[!0E1N8^6
MIPN2"=IYKI(O&FA2Z;<WWVF:..UF6":*6VE299&QM3RBN\D[A@ <YXKA=%M;
MIM(\/:8^G7RW.F^)Y9;D26LBJJ,URRN&(VLN&7D$@9'J*E\2:/J$WB+6;Y(M
M1BMH=5L+EI;.+=(T:V[(S1@J=Y4L"0 3P>,T >BZ3K-EK=J]Q8R.RQR&*1)(
MFC>-QC*LC ,IY!P1T(-<U_;/BK4_$NN:?I T:.VTR:*$-=I*7<M$LF?E;'\6
M*M^"[2WC34[Z"369OM=P"T^JQB-YMJ*H95VJ0N!M^903M],5CV?A%=4\:>*[
MN]EUBT1[J#R&MKR:V251;Q@D;" V"",^V* -^[\56N@06\&OSC^T#"9IEL;6
M:5$0'!D(4,50>K>]2:CXRT/2[A;>>ZEDG:W6Z6*VMI)V:(D@. BG(^4Y/;OU
M%<IXEMKZ#4)='BDUPVG]EK'8?9$:5KJ8F0,LTY5B !L^\P&&)YJ;P;;7#>(=
M,NY+*ZBB3PO;6S//;O'MD61@R'<!@C'3TP>F* .BL/&_A_4[ZTM+.]>5KQ2;
M:402"*8A=Q59"NTL!U7.1@CJ#7.ZMXSN[/PPNH:=J=M?R'7$L'D^R-$$4R;6
M3:QY('&[H:IZ+I5]#X1^'$+6%PDMI?*]PAA8&$>3."7&/E&2.O<BL1M%U7_A
M I;?^S+SSSXN^T"/R&W>5Y^=^,9VXYSTH ]:MM<TZ[34'AN05TZ5X;K<K+Y3
M* QSD#C!!R.".E+%K6G2Z"NMBY"Z:UO]I$\BL@$6-VXA@"!CGD5Y_P"-=/O(
M?%ATVP5A!XOA2TN60\Q-$1YC_C 77ZJM=EXH^V6/@V_71K?=<16^V")(A(0!
M@?*AX8A<X'<@"@!D/C70IM/O[TW,\,5A$)KD7%K+$Z1G.'V,H8J<'! /0T^S
M\8:'?75Q;17;H\$!N6,\$D2M"#@R(SJ Z#^\I(KS;5;6ZNX?%/V2+7[^.^T
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MYX/UC7;K5=--PVM75M>VC27CWMBL,,,N%93$P4?*?F7!)_A.>N0#T0D $DX
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M8_4DD_C4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>'=:2&\@>!V3[/N4,",C][UYK-TJWOK#4K/4;K3=<O+JVL&L=[16R!U+JP)
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M/_8=UJ-K</;+&T<L. 5(7@J=ZD9YX(YKI/"C:K/H<%]J]['<3WD:3JD<(18
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M_MHH8YH;V?3GM#N)8/&0RJ#C"D$#HV#TJ+4+_6]5\1:[8:=?Q6=MI-K$?+:
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M[AM)--ATZ\C1$S<1Q!@IW$90D.P..Q['FLSQ1X<?5K'0/""1W]Q+:R1F;4A
M8HTM@C)("X&TLR$IM'KD]* .K\'WVHZIX8M-2U3"SWFZX2,*%\J)R3&OU"%<
M^^:W:155$5$4*JC  & !2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.Y Y)X!ZY'2K-UI.C-)X;DM+.YFLI]>DN7:[MR,H\+[VV%1LC+D<$ $\]"*
M/3&U"R7R-UY;C[1CR<RC]YG^[SS^%.:^M%61FNH L9VN3(,*?0^AKS34[33[
M?7=;\/ZO::C%IM\D TV.PL]T<D2QJ/*1E0^6RR!CU4#=GCK5?Q*K6L?Q!L9+
M6Z:XU#386M56!Y/-VP%"=P&"0PY_#U% 'J<U]:6P8SW4$04!CYD@7 )P#S[T
MEY>16EN9'F@C+<1^=*$5F[#/_P"NO.KRQL+SQ9JT]QIZO')X:B4&:V(S+NER
M,$??VE>.N"*A\-W;V5_HQUVWN'LY_#=M;6SM;O(JS#/GQ, "0[?)P1SMQVH
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M7T*WNEWZ3W5J1)-!%*/,=55%SC!XQG SC% 'JEYX@TK3Y;N.[O$B>T@2XG#
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M;82!3V5B64?D1764 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>']:UKQ-;>%M.?5Y[1[G1FU&\NK>.,2RL&1%4;E*J,L2<#L!Q0!V/_"*Z?\
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MK>L>*-8T^#7;G3[6TTVUN(_L\41;S7\WJ64_+\@R/88(YR =VJJB*B*%51@
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M;AO/7$)]'Y^4_6LN\\46>D66LZEJ&IV$ME9N BVS9D3Y1\C\G+ELX''!'UH
MO:/HSZ4UQ)-JE_J,\^T-+=NORA<X"JBJHZG) R>Y/%5_$'AB'7[G3[DZA?V-
MS8.[P36;HK NNUL[E8=/:J$WC""T\6/:7=_IT6C?V:+Q+MY OS&79@N6VD<5
MTQN8%M3=&:,6X3S/-W#;MQG=GIC'>@#GQX/,ECJ%E>^(=:O[>^M9+61+F2'"
M!Q@LNV,?-C.,Y'/2M :!:#5=-U'?-YVGVLEK$-PVE'V9+<<G]VO3'>L*Y\<P
M3VWA[4=*N+233M1O_LL[R_>C3RY'W9!&TXCSAAT-=)!K.EW6G?VC;ZC:2V6<
M?:$F5H\YQC<#CKQ0!QMUX)>#Q3HBZ=<:A;V\":C.U[$R%HI9I(WQRI4@Y< %
M3P/49K7_ .$"TLZ?IUJ]Q>.UEJBZMY[2+YD]P"Q+2';@@[CP .@QBNBL[VTU
M"V6YLKF&Y@8D"2%PZD@X(R/0U3/B/0Q<Q6QUG3_/ED,4<7VE-SN,94#.21D<
M>] &1>^!+&]N+T&_U"+3[^83WFG1.@AG?C).5+@-@;@K '\35+7M%?Q1XWT4
M/IEQ%9:-*T\MY+A4GX4I$@!RPWJK'( &P>M=7<:MIUK=QVEQ?VL-Q*0L<4DJ
MJS$]  3DDX.*A;Q%HB7!MVUC3UF#,AC-R@;<J[F&,]0""?04 4=5\)Q:EJ,U
M[#JFHZ=)<PK!="RD11.BYQG<I*D;B-RD'!Z],,OO!\%WJ$]U!JFIV*W2HEW#
M:S*JW 08!9BI93C"DJRD@#FJ>@>*YM;@BU@7NDQZ,QE26-G(FA(<K&2VXJ=P
M&2"!U&,UT/\ ;6E?9([O^TK/[-))Y22^>NUGSC:#G!.>,=<T 7JY;3_ EAI]
MW;,M]?S6-H[O::=+(I@@+@@X 4,0 S !F(&>*TQXH\/M#YPUS33%L:3>+I,;
M5;:S9ST!X)]>*EAU_1[BZM[6#5K&6XN8_-@B2X0M*G7<H!R1[B@#'T[P-9:?
M<6!.HZC<V>FL7L+&=T,5L<%01A0S;02%W,< U93P?IR:%;:.);G[/;WHOD;<
MNXR"<S8)QC&XXZ=._>M.+6-,GNVM8M0M9+A Q:)9E+ *<-QG/!X/I44'B'1;
MFZ@MH-7L);B<,88DN49I I(;: <G!!!QZ'TH S[?PA##J<%W-JNI74%M*\]M
M:7$B-'"[AE)!VAS@.P 9CC/TJE9_#S3K2PTBR.H:C-;Z1>K>62R/'^[*@@1Y
M" E.3UY]ZZ/^U=.%^+#[?;?;"2!!YJ[R0,D;<YZ<_2A-6TZ2_-@E_:M> $^0
M)5+\=?ESGCOZ4 85UX$L+N36]]]?K;ZNRR3VR.@1)EV8E0[=P8>6O4D>U)_P
M@=E,VH2:AJ.HW\^H6#:?<33R("8B2> J *1DXP,=R">:Z2YN[:RA\VZGB@CR
M!OD<*,GH,GO6+XA\66&C>%I=:AN;:XC("VY$R[)7+!1@@\@$Y..P- $=MX-M
M8;[0KZ?4+^[NM&CFCMY)FC^=9%"D.%09P  ,8]\U)%X/TZ'1--TI9;G[/I]V
MEW$Q9=Q=9"X#'&",GL!Q4UKJ<UGIM]J6L7^FOI\698;NU#*IBQSN!+<@Y'!.
M>.AXK(D\;0G5/#\D=S9)HVI6D]Q--*P#0E%1@"V[:/OX(/3% ',ZMX9OKRZN
MM(M--UJ&&;5DND5KB)K"-?.61Y@0 ^2 W[LY 9N!WKU"]M(=0L;BRN%W07$3
M12+G&588(_(U"=8TP:?'J!U"U^Q2C,=QYR^6X]FS@]#5B"XAO+5+BUGBFAD7
M='+&P=6!Z$$=10!SNF^"H=.U.PU%M8U2ZNK*%K=&G>,AH2!^[8! , JIR,,2
M.21Q6OK.C6VN6D-M=/*J17,-RIC(!W1N'4'(/&5&?:N?T;7M=UF#694DTN#^
MSK^>R'F0OA_+QAB=_P N<^AQ[UNS:]IEA'C4]1L;.>.$2S1RW"*8P<#)R>F3
MC- #&\/6C:EJM\7F\W4[:.VF&X854#@%>.#^\/7/:L-_AQIC6DEDNH:G'8S6
M<5G<VR2H%G6-/+1F.S<&VXSM(!P,@CBNBCU[1Y;L6L>JV+W!B\\1+<(6,>,[
M\9SMP0<]*;;^(=%N[R.SMM7L)KF5#)'#'<HSNHZD ')'!Y]J ,G_ (0:R>]E
MN)K^_F6YL%L+V&1H]EW&JLH+X0$, YY4KVI1X*BETR_L+[6M7OHKRT:RS/*F
M8HB"#M"H 6_VF#'CK4OA[7YKZ'6Y-4>UA33M2EM1(N478JH06W$\_-6D==T@
M6,E\=4LA:1OY;SFX4(C?W2V< ^U %35/"]CJT.C17$EPJZ3=Q7<&Q@-SQ@A0
MV0<CDYQBLR?X?V<SN!JVJ10B]^WV\,<D>RVG,GF%TRASEL\-N W' %=,VH62
MRQQ-=P"22,RHAD&60=6 SR!D<^]16VL:9>1SR6NH6LR6_P#KFCF5A'QGYL'C
MCGF@"MHWAZST*YU2>UDF9]2NVO)A(P(#D $+@# X'7-1:MX9BU75(-074+ZR
MGCA:WD-JZKYT3$$HVY21R.JX(R>:GEU:.\TF^FT2\L+FY@1@I:7=&D@&0'V9
M('0^N*;;ZU%;Z/97.N36NG74T DEBDE"A&P"V-V#@$]^G>@#'B^']G:6UE'I
M^K:I936<;V\-Q \>\0,V[RCE""H(&"1N'K5F#P586=_I-Y8W=[:R:;;FU4(Z
ML)XBP8K)N4DY90<@@\GFNDW+LW[AMQG.>,5RJ>+X)/&G]FQWVG2:6-,>\>9)
M 6C99$7YFW;0N&)Z?C0!NZSI%IKNDSZ;>JY@F R4;:RD$,K*>Q! (/J*S;'P
MG#;7%W=7>HWVHWES;?9#<W1C#)%R=JA$51R<DXR3C-:9UC3%\O.HVG[V$SQ_
MOE^>,#)<<\KCG(XK)M_%-EK&EV%_I.J:?'%<W21C[4W,B[L%5 8$.PQM!]1D
M4 :>A:-;>'M"L](M'E>WM(A%&TI!8@>I  S^%5-4\+:?J_B#2M9N6F%SII8Q
M*C ))G& XQS@@$<C!J_+JVG07L=E-?VL=U(0J0O*H=B1D #.2<4JZII[WOV-
M;ZV:ZR1Y(E7?D<GC.>.] &1;>"]+M+S7KJ-[CS-:4I<;G!$8.[(CX^7)=F.<
M\FF0>"-,MT\-HDUV1X?#"TRZ_/E-GS_+SQZ8K0U+Q%IFDZGI^GWEU'%<W[,L
M2LP'"J6).>@X ]R167H/BV.ZNM0L]7O=/M[N/5);&UC#^6TRJ%(PK,26^;M0
M V?X?Z3<:#KVCO/>"VUN\>\N6#KO5V*DA#MP!\@Z@]^:NZIX6BU'5X=4AU*_
ML+I+<VLC6CH/-BW;MK;E;'.<%<$9/-:3:MIJ7PL6O[47;-M$!F7>6QG&W.<X
MYQZ<U6TGQ%IFMW5_;V%U'+)93F"4*P))"J20/3+8SZ@T 9MEX$TFPE\//!+=
M_P#$A\_[(K.I#><"&W_+S@'C&/?-;>K:;#K.C7VEW+.L%Y ]O(T9 8*ZE3@D
M$9P?2HY==TB"\^R3:I91W/F)%Y+7"A][YVKC.<G!P.^#4D6K:;/>O90W]K)=
M("S0I,I< '!)&<\'@T 5AH%H-6T[4=\WG6%K):Q#<-I1]F2W'7]VOIWK.@\"
MZ7!=:5<)-=E],N[F\A!=<,\Y8N&^7D#<<8Q^-:O_  D&B^5++_:]@(X@K2.;
MA,(&SM).> <''KBFZGJL<%I?I:7-JVH6ULT_D.P8@ $@LH(.#CK0!FP^"[47
ML<MWJ6HWUM 9#;V=U(C1Q>8K*V"%#M\KLHW,< FH;+P%I]L!%=7VH:C:QVKV
M=O;7DJLD$+@!E&U03P ,L2<=Z?I'C.QN;7P[!?W$$6IZM8)=^4K;5&54G&3W
M9L =3^%;L&J:?<W;6L%];2W"ABT22J6 !P3@'/!(!]Z ,73?!EO8WEO<W&J:
MCJ#6D+06:W;H1;HP .W:BEFP -S9./QJ>#PEI]OI>@Z>DMR8=$D22V)9=S%(
MVC&_CGASTQSBKMW?&'6;*V%]8Q(Z2-+;RG]]( !@IR.!SG(/X4D'B'1;JZAM
M;?5[":XG#-%%'<(S2!20Q4 Y.""#CT/I0!@P?#O3X&LHQJ>J-96%XMY9V1E3
MRH'#%L#Y-Q7DC#$X!XQ2WOP]L+XZA$^IZG'8WUQ]KELHY$$7G9!+CY-W50<$
MD9YQ6CXLUB\T33[.YLU@8R7]M;2"52?DDE5"1@C!&[WK2N=6TZSN$M[F_M89
MG("QR2JK$DX'!/<\#UH P[WP/97FH7,_V_4(+6\F2XN["&11#<2+C#-\NX9V
MKD*P!QS3+WP?+''X@FTC5K^UN-6!D\M952.*?"CS%(7>#A!D9QC/'IT$^J:?
M;7*6T]];13N558WE568L<* ">I/ ]:%U33WO?L:7ULUUDCR1*I?(Z\9SQW]*
M +=<S;^!M+MHY$2:[(DU@ZR<NO\ KR<[?N_<XZ=?>NFKE_$/BI=-U+2+.QNK
M&6:ZU*.TN(6;=(JL"20 W!&!U!ZB@#8M='M[36]0U6-Y3<7R0QRJQ&T"/=MP
M,9_C.>3VJMK?AR'6K[3;W[;=V=WITCO#+;%,X==K*0RL""/;/O5U=6TU[_["
MM_:M=Y(\@3+OR!DC;G.0.34 \1Z&9XH!K&GF::0Q1H+E-SN.J@9Y(]* *1\'
MZ<=!?1_-N?LSWOVXMN7?YGG^?C.,;=W'3IW[TV/PC!!JK74&J:E#:O=&\:PC
ME586F)R6^[OP6^8KNVD]JTH->T>ZM9[JWU6REM[=MDTL=PC+&WHQ!P#]:EBU
M33Y[.2\AOK9[:(D23+*I1".H)S@8[YH =J%DFHZ?/9R231I,A0O"Y1USW5AT
M(KGV\"V=S!=_VCJ6HWUW<"$"\E>-98?*8O'Y>Q%4%68G.#DGG(XK<AUG2[DR
MK#J-I(T*EI0LRDH!U+#/ &>]/LM2L=261K&\M[D1ML<PR!]K=<''0T 8)\#V
M<]CJ\%_J%_?7&JV_V6XO)FC$@B ("H%0*H&YC]WDG)S3KCP7;O\ 9FLM4U+3
MI8;-+%Y;5T#30K]T-N0C(R<,H!&X\UM7>K:=82+'>7]K;NV-JS2JA.3@=3Z\
M?6H[O7=(L)S!>:I96\PVYCEN%5AN.%X)[G@>M %R"%+:WB@C+%(T"*78L< 8
MY)Y)]S7)WWP[T^_%] VIZI%I][<?:I;&*1!$)BP8N,H6Y8;MN=N><5T&KWCV
M<$!CO;&UDDN(XP;P_*X+ %5Y'SD9 ]\<4R3Q%HD,X@EUBP24S>0$:Y0,9./D
MQG[W(XZ\B@"C-X.L9=3UG45NKZ&YU9(%E>&4*8C#]QDXX/KG(/ICBJS^!;2>
MWF-UJ>HW&H2SQ7 U%FC6:-XP0A4*@0 !F&-ISN.<YK5.JQ0ZI?BYU/34L[:&
M-VC\P++ 26RTA+8"G QP.AJR=6TU9!&VH6H<P^>%,RY,?]_&?N\CGIS0!BP^
M"+%/LTD][?75U#J*ZDUS-(I>:8(8P&PH 4*<;5 Z#WS+JGA.'4=1GO8=4U'3
MWNHEANULY%47"+G&25)4@$C<I4X/7IBVOBGP\QPNNZ83\G_+W'_&,IW_ (AR
M/7M6@MW;-=O:+<1&Y1 [0AQO53P"5ZXXZT 8EQX1M9];N]32^O83>6@M+J"-
MT,<RA6"D[E+;AO."".V<]ZZ>!;*VT_2+?3]0O[*XTJ VUO>0M&93$<;E<,A5
M@=H/W>" 1BEUGQC:6]OXAM],N;:35-(LS<-%*<J6"LVW ()P%YQTW"M'1=?L
M=5M(PM_9R7J6\<MS!%*I:(LH/S+G*CZT 5;'P=IM@^ER127+2:?/-<+([AFF
MEE5@[R'').XGC';MQ6CINCV^E7&I3P/*S:A=&ZE#D$!]BIA<#@80=<]ZBD\2
MZ)'87=]_:MH]O:1^;.\<JOL4C()P>_;U[59TS4[75M+@U"UE1H)HPX(8';D9
MP2.,CO0!G:MX9CU+4TU.VU*^TV^$'V=Y[,IF2+.=K!U8<$D@@9&3S40\%:2D
M.@PQ&XCCT28S6P5P=[$$$N2"3G<2>G)JY8:O#_98N[[5--D1YY$2>WD B(#-
MA02QRP P>>H-:$5U;SVBW4,\4ELR[UF1P4*^H/3'O0!(Z"2-D.<,"#BN/L/A
M^VEZ?!8V7BWQ'#:VZ".*-98,*HZ#F&MZ/Q)H4LJ11ZUISR/&TJ*MTA+(N=S#
MGD#!R?8U+%KFDSZ>NH0ZG9R63-L%PDZF,MG& P.,YXQ0!4/ABS:76)6FN6?5
MK=+>X)9>%5&0%>.#ACG.>:H:UX4MY-%MQ;FXDGTO3;BUM$##]YOB"?-QR?E'
M3'-7[_Q9HFGV]A/+J-LT5_.(+=TE4JY[G.<8&#D_AUJ]+J^FPW<5I+J%JES*
M0(XFF4,Y(R !G)R* .9\+^#5LK70;N^O=0FET^T5;>RN'3R[5VC"OC"AB0,J
M-S' ) J>#P!IEIHUOI]K=WT#VUX][;7:.GG0RN6W8)7:00S#!!!!YK7?Q%HQ
M=X(]9TX7(WJ$:X0D,@RV1G/R@@GT!IMOK5I;:-976J:KIH>:$.9XY0D,O +,
MFXGY><YR>* ,R72XO#6B:@T5EJ&OWFHR'[3NV&6X8IM&X_*JH  O   [56\.
M^!(+#X>VGAZ^DD\\;9YIX9/G2X#!PRL>ZD* 3V45I7VMW,'B_0]-A^SR6.HP
M7$C/@EP8PA!4@XP=_IVJWJ_B+3-$N;"WO[J.&2^E,4(=@.BEB23T  Z^I [T
M 4'\'07.GO;:AJNI7KO=PW;3S2(&W1,K(H55"*N5&0%!.3SFM*>QNY/$=E?)
M=2+:16TT<L D(5W9D*$KC!( ?G/&?>II=6TZ&\2SEO[5+IV"K"TJAR3R !G.
M346NZW9>'=%NM5U"41VUNA9O5CV4>I/04 ,\1Z#:^)_#]WHU\\R6UTH5VA8!
MP 0>"01V]*+?0;6VU6^U!'F,UY;PVT@+#:%CW[2..O[PY_"LB;Q?!:>+#:75
M_IT6BG3?MBW;2!</YH3!<MM(Z_C6]<ZOIME:QW5UJ%K#;R+N262955EQG().
M",<YH 31M*@T+1++2K5I&M[.%88VD(+%5&!D@ 9_"KU-1TDC62-E=& *LIR"
M#W!IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@(FB2=HIG=X@V  2A"_\"Q7IM4M7U>PT+3)M2U.X%O9P[?,E8$A<D*. ">I
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M:UH'C/2+6P=]2N-=D%O*MNV$8-&5?S,87;R>N>OJ,^O5FZ1HEOHIO3;RS/\
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M3[GB%Q&V\#;RNT/S_C7J]% 'F6LQW<'B/Q'<PZ)=75O,VEE6%G(X'ENV^1%
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MTWS+>X@:.UC1HYXBC@JH!RIYZ@]JUZS]8US3= LUN]4NTMH7D$2%@27<]%4
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M1LX[9ZOQ]87>H?#S6K*TB>YNI+1E1$&6<^@'KQTKHYIH[>"2>5ML<:EV."<
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M742P70LY_+%P@S@/P>0"1D8.#C-8_B[PV=?M])\*VVCO'I-O+#+)>%U6.&%
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M:"ZPUR'=G8R9!R2SN=PP?F/-6D\&Z*E]=7/V=F%U8)ITD#-F,P*" N/H<=:
M,1/[3\.^(]!M7UN\U&/589TN!=%2!(D7F"1,*-HX(QTY'I6/H5]K<6D^!M;N
M==O+J;5IH[>Z@DV^2R/#(P(4#(8%%.<\G/;BNQTSP=8Z;>1737FH7LMO"UO;
M?;)_,%O&V,A.!R0 ,G)P.M2P^%--@TS1-/3SO(T:1);7+\[E1D&XXYX<T 8W
MCZ":YU#PC!!=/:R/K&WSD +*/L\V=N01G&<'!YK%O=2UW1H_$45OJ5W>1^'K
MNUO<S;6DFM73=+$Q &<#>P/7I7<Z[X=LO$*V8NWN(VLY_M,#P2;&63:R@Y]M
MQ/UQ]*SFTI?#.D7[V.GWVNWM_)F?S98S).Q7:-[,54(  .!P.QYH ;H^J7&M
M^,]2FMKHMHUA;16Z*O*2SN!(S9_V4,8_X$:YC4K.0^-/'4[7]V5BT.,B$N-A
M#)/\I&.@.2.>I/6NN\#>&AX3\(V.DL5:=%+SLI)!D;DX)Y('W1[ 4^]\)6-]
MK-SJ;7%Y%)=VGV.YBBE CF3# ;@0>1O;!!% '%V=WJ?ABT\+78U2ZO([S3)6
MGM)=OE QVWFIL &5QMQU.0>>:N^#M1U^XU+29IEUR>VO;5GOI+^*-8%D*AD:
M':<J,[EQZ$=Q77GPWI['2-RR,-*C:.W5FR"K1^60W'/RU7T;PG9Z)<Q2P7FH
M31P1&&V@N+@O';H<?*HQ[  MD@# - &#XR>_C^(/A)M-L;:]N/LU_B&XG,28
MQ#D[@K?RJ3Q'JGB#3_ /B"_GT^STF\M[??;O9W1GR?4YC7&/QZUNZ[X6M=>O
M;&]DO+^TN;)95AELYO+;$FW<"<'^X*JMX*MIM,O].O=6UB]MKV'R9%NKK?M&
M>J\<&@#$-AJ__"<+H;>)]4-I=:8U[,RE XE60)B,[?D4[\X']T>]9?AW4=<\
M2WF@V%SKEW!')I-S+<O;[4DF>*X$2MG!VDCDD?UKT8Z1:G7DUGY_M:6K6@^;
MY=A8,>/7*BN/_P"$%$'BG3DLI;ZUT^TTR>..[@F D25YU?;R"#D%^H(_$"@#
MG9]0O+^Y\%I?W#7-Q9>)KFR-PP ,HB,B*QQQG &?>K]QJNLGPEJ/C5=8NTFM
MK^416 V^1Y,=P8O+9<9)95)W9SDC'I77Q^"-'BM]&A03XTFY:Z@8RY9Y6SN9
MR?O$EB3[FHY? NES7DLC3WPLYKH7DNGB;_1WFW!MQ7&>6 8C.TGG% &'J7B;
M4O#[^+--FF>>^&RXT;?C+BX/EH@]0DW'T(K*O=2\2K>:M9VDVNW=]HZ0V]LU
MK%&8)YA"DC-/NP3O9\<=!R.:Z2^T2?Q#\0M,U&YTJ2ULM$$I2XF=<W<C8VA5
M5B=BXW9;!SC ZUJ:EX0L=2U&>\-W?VWVE46[BMI_+2Y"\#>,9Z<94@D<&@#B
M[[7_ !%>ZKK%SI]OKC7%A>)!:VUM'&;4A51G67)R2VYN>PVXKL?&VI7FG:#$
M+";[/<WE[;62SA0QA$LJH7 /&0"<9[XI]WX/L;K5)KT75_;K<2)+<VT$^R*X
M=  &88SG"J#@C( SFM+5])M-<TN;3[Y&:"7!.QBK*P(964CD$$ @^HH X75X
MKZSN]<\.-K.HW%G+H;W\<LLBF6)T8JRAMO*L".#Z'&,UL?"^S-K\.M$8W5Q/
MYUG%(%F8$1Y0?*N ,#\ZT;/PC96POWGNKV^N;Z#[-+<W4H:018.$7  4?,3P
M.2<G-:6D:7;Z)H]GI=IO^SVD*PQ[SEMJC R: //])UV^?Q5HLL-_J]Y9:I=W
M$3S7,4<=I*@CD=/)3.\8V  G[PR2>14&FW^MKH/A[Q!-KMY+-<ZPEG);MM\E
MH7G:+!7;G=C!W9SGVKJ;7P!I=G-8217FI?\ $OG\VR5KC*VX(8&-1C[A#$'.
M3C'(Q5Z/PGIL6CV.EKYWV:RNUO(LO\WF+(9!DXY&X]/2@#D9O$&L6VCZIX:^
MVR'Q NJKI]I<L 7,,Y\Q)3V^6+S/QCK>^)-J9?AIKJ"YGC\JPE<LC &3"'Y6
MR.0>]066B3ZM\1G\3WFE26$=E:_9+83.A>=]S9E(1B  K,JY.3O;I74:MIEO
MK6CWFF7>_P"SW<+0R[#AMK#!P?7F@#S&"YU"U30]$AN_$4UM_8T=ZS:>(VEW
MOA54E@,(H4X'<MSFI%O=2;QUX+O-8MWCU%=&O&N(RH4EU"Y.!P,XSCWKMKOP
MC97"6'D7=]8SV5O]ECN+28)(8L#Y&)!!'R@],@],5)'X4TR+5-*U!!-YVF6S
MVMN&D+#8P .[.2QX')- ''6&H:S;Z)X4\33:U=7$VL7=LEU:/M\C9<=%10,J
M4RN#G)VG.<U!'?ZVGAU/$CZ[>-+%KIM5MOE\EH#>F$JPVY)VDX.>,#\>NL?
MNEV%U:2)/?26ME*9K.QEGW06[G/*KC/&XX!) SQBK/\ PB>F?V&=(_??93>?
M;?O_ #>9Y_G]<=-_;TH Y.]\1ZOIEAXDT$W32:VM['#I<K@;FCNC^Z;WV'S
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MI=IY4Y*@9 /R ^E '52:E90S&&6ZBCD$)G*NP!$8ZL<]AZU%;:WIEVER\-]
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MU&QAB(G#W*),C-(J22$<GR\ D\;CCM1?W7B6TTE;82:OID,^NV4%G-?31R7
MBD(612RLVX!LD;B>H!Z4 >KT5YAJYU5/$%SH-FWB6[BT[3XG@ELKN,2>=(TO
M[R5I'4N!L  Y'#9'2MGP[J>KSZ[JL6K.\4\6C6$TEON&V&9A-YF,<=5'3T%
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MLFTHN&VC(!SUJO8SZJGAW1/$4FN:C)=2ZVMH\33'R6A:[:(H4Z'Y>=QY![X
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M8R3&<P%8W=%+?<#<9QZ_X4 ;]%<+!JOB2?Q!I^FG4K14U+2FO0XM,FW9&C!
M^;YL^9W]/PJMHWC#5]=L]-LXT*:A-82W,TMO'&<LDIB!"R,!M)4DCD\@<=:
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M-U;2+)!,BR1NO1E(R"/J#4M8G@S_ )$;P_\ ]@VV_P#12UMT %%%% !1110
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M+Y#' P.AP?F''-2>+O%-QX<N-%BM],GO3J%Z+=O*"G VLV!EE^8XX[8!SVR
M-@\ Z+;S6TL9O0;2X\^T!NW*VQ.<J@S@*=Q!'<<=A5Y/"VEII%KI:Q/]EMKI
M;N-?,.1()?-!SW&\YQ5"]\>:?8SWFZQU"6RL)1#>W\42F&W?C(;YMQVY&XJI
M [UJ^(]6;0_#6HZM%;O<M:V[3"-,?-@9SR1P.IYZ XR>* #6] L/$,%M#J"2
M,MM.+F(QR-&RR , P*D$$;B1[X-4$TD>&-.O9])T^ZU:_NY TWGW0,DQQM&Y
MW. H  P.@Z U@+XUU%]8\.2/IU_MU#2YYFT^*-"\DJM#M8$M@+AG(RPX//.!
M6U'XYL+C3[*>TL=0N;J\DEC2PCC43JT1VR[@S!5VG@DMW&,YH F\#^&5\)^%
M+72R(_/&Z6<QYVF1CD@9YP.%'LHK4BTBTAUNYU=$87ES#'!(VXX*(6*\?5C2
MZ1JMMK6F0ZA:;_*ER-LB[61E)5E8=B&!!'J*Q8?&UO<&5H-(U:2W E\BX6%/
M+N#'G<%.[(^Z<;PH..#0!-9^"](LKT3QBZ:)#(T-K)<.T$)<$.4C)P,AF'MD
MXQ56'X>:%$+<-]MF%NC0Q>==N^V$J5,(R?N8/3V'/%5M$\=SZAX5TC4I]"U"
M2^U!,I;6L:'> H9G4L^ G.!N()]*N2>.M-\C27M[6_NI=5CE>U@AB&\F/&]&
MW$!2,]SCY3SZ@$D/@?1E@NH;K[7?K<V_V9C>W3RE8LYV*2<KR <CG('/ I]M
MX-TN".^$LEY=RWML;26>[N6ED$)!^12?NCDGCJ>3FJR^/-/DT^VFAL=0EO+F
MZDLTTY8U$XECSO4@L% 4#).[&,<\UGZ)XREDCU^ZN;?4+GRM8%E:6:0#SE)A
MC/EXR ,,7))./?&* .H_L*Q^T:7/Y;;]+1DMCO/RAD"'/KP*CUCP[9:U-;7$
MSW-O=VVX0W-K,T4B!L;ER.H.!P?05E3^/]+M=*M[V:TU!7FOCIWV40@S)<!6
M.P@-@D[>,$@[AZTMWXUAA=[9-)U1KF.T6ZNE2)";)6SM\SYNORD[5W' Z4 7
M#X.T4Z7I^G"W<6]A>)?0_O6+&96+;V8G+$L23GKFM/5-,M=9TJZTV^C\RUNH
MFBE3)&5(P>1TK-\%W]SJ?@?0[^]F,MS<6,4LLA &YBH)/'%4[+QYI][<6>VR
MU"*QOIC!9ZA)$H@G?G &&W#=@X+* >U &EIGARRTJZCNHY+J:Y2U%IYUQ.TC
M&,.7 )/4Y8\^F!5)O ^D"TLX+9[VT:T22.*:UNGCDV.VYD+ \@GGGICC%8'@
M_P 1:QX@\;Z[]L75(+*SG^SPVK1P"&(;%/[P@ERY)R,$BMF]\5W4'CM/#L>F
M7#PM8-<M<J%P#N4!N6^X,D'C.<8&* .BM+*"PT^&QM%\F"",11 '.U0,#DYS
M^.:Q;3P;96%I<6MI?:E##<2R32A+D@EW.6(.,@DG/&*Q/!GCHWVB>&XM3MM0
M,^I0+&NH21*L,TX0LRC!R#\K8.T X.#6UIOC2QU._MK>.TO8H+PNME>2QJ(;
MHH"3L(8MT!(W 9 )&: +7_",V(U":]C>>.66S6Q(1QM$*Y(4#'&"QYZ\U6'A
M.PLK?2FM_M;G1H&BLHQ(.%*[2ISC/R@#D_KS5;QWJ]_I5EI"Z??Q6#WFIQ6L
MES+&KA$97).&P.JBG:/)?PW,L]UXNM=7@BA9VMX+6-&X_BRK$_\ ZZ *O@;P
MO)I_A?0(]7CN5O=.A 2WFD1U@D*E69=N<\$@$DX!(&*TO^$,TDV,MHWVAA)>
MG4%D,N'BN"VXR(PZ')/'3DC&"16;;_$G3KE=.DCTK6/*U./?8N;=<7+8!,:C
M=D,,GEL+P3G S4H^(6F_9K9S8:D+F>]DL/LGDJ94G12Q0@-CD 8()'(R0,D
M&G-;2Z#:7%WING3ZK?W,J&?,R)))P%W%FPH"@=!@>@R34%AX1TY?"4NA7ME
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MSV7V":.&Y=%EB&[ 8 \D;FY/J<YJ./QS8O8S2O8:A'>17@L3IS1KY[3%0X4
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M<>%-/N7UII'N/^)S$(KP"3 9 NT <?+\I(X]?7FGIX;M([^QO5FN1<6-LUK
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M0#\HCPNWTSSZT 5V\ Z-Y>FB&2_MI=.MQ:PSVUTT4A@_YY,RX++QWY]ZDO\
MP)HFH/=F1+F*.[M%LYXH+AT22-00F0#R5!./ZURY^(.H7NCZ;J/V"[LD.O\
MV-D6-6-Q$&F4(H#,2WR*#T^;H<5TJ>.K#[+>O/8ZA;7EI<1VSV$D:F=Y) #&
M%"L5.[/7=C@YQB@"C;^&[L^.-2F9=0M]-DTRWM([A;A29=K2%P<DOG#KAL ]
M<$5I7?@;0[MV/E3P1O8#3GAMYVC1X!D*I /.-QQ]>]:.BZY#K4=R%M[BUN;6
M7R;BVN5 DB;:&&=I(((8$$$@YK)U+QU9Z?J.I6*:9JEY+IBI)=FUA5EB1DW!
MLEAGC/ YX/% #YO FCRW%G<))J$$]M;BU,L%Y)&\T0.0DA!RPS^([5H?\([8
M?VP=3Q()3:?8O+#8C\G.=NW'KSGK^'%9\OC?3O[8L],L[6^OKB[M8KR(VL09
M?(D8@2$DC &,GZC&2<4Q?'FG-<*?L6H?V<UW]C74_+7[.9=^S&=V[&_Y=VW;
MGO0!!?: ]GX?B\):9IDUUIEU ]M)<W%T&%HF HX8[FPN=H7NHSC.:ZRWMXK2
MVBMH$"0Q((T0=%4# 'Y5ACQCI8\.:GK<@GBM]-DFBN8W4>8KQD@KC."3QCGG
M<*SH_%UE:ZOXA>XGU,_8(+222SDA3;$95^58]O)9B0"&. <8.* -1/"6EQS3
M%!,+6:Z%Y)9[_P!R9@0V_;U^\ V,[<C.,U;T_1+;3-0U"]@>8RZA*)9][Y!8
M*%! QQ\H X]*Y[6O%L*:$US<QZUHTD5[! Z^1&9278;<9+(4.<$@DCGH:O:I
MXTM-,OKVV33M1OAI\:R7TMI$K); C<-V6!)V_-A0QQ0!=U7PW8ZKJ-IJ+O<6
M]]:ADCN+:4QN4;[R-CJIP.#T[8JI;^"=)M;/3[2%KM8K"[:]@!G+$2DL226S
MD?.W'3DU'=^-[&&^:SLK#4-3G%I'>@64:L&A?=A@691_#TZG(QGG#&\>Z<\-
MO-8V.I:A%+9QWSM:0AO)A?.UF!8$D[6^50Q^4\4 77\)Z;,P%T9[J%7FDCAF
MDRL;2A@Y'&>0[#!) !XQ5>R\#:/8SVTRM>RO;VCV2^==NP,+8^0C/(&T8_QY
MK:U'4[32=*N-3O9?*M+>(RR.0>% STZY]JQK3QA'<W+VDNC:K:7IMFNK>VN(
MXU>Y12 =F'(W#<N58@C(H M:;X8L=+^R")[B4641ALQ/)O\ LR$ 87CT &3D
MXXS@FJZ^#-,73H;!9+H00WW]H)^]Y$V\R;LXZ;R3CIS6'\+M<U?Q'IEUJNJR
M:@QFFD$:RQPK;HJR.H6/9\Y(  .[OT]:W+[QA::?JCVDMAJ!MXIXK>:^6)?(
MBDDV[5)+!CRZ@D*0,\GK0!+<>$],NVUDW FE768A%>*TF RJNU<8^[@'M5'5
M='FU(6WAN72Y+C2$,,\NH75R)"2DF\IM)WEB5 SP,,?3!;>_$+3K)]0)T_4Y
M;?3;C[/>W,<*F. \?,26!(^8'Y02!R0.,ZUKXCL+F76(R9('TB3;="8 878'
M#C!.5*G(/L: &ZUI+:W<6%O*N+*VN4NY23_K&0Y1 /3=AB3_ '0.<G#],TF2
MQU;5;QKJ=XKUT989)FD6,J""5!^Z#D?*./E'KQ-IVL6^HZ!;ZRL<\-M- +@+
M,F'"$9&0,\XYQ658>-;&Z,XN[._TP169OP;V-5\RW'WG&UFQCC(.",CB@"XN
MDO9^*+C5K492_ACANT! (:/=LD&?9BI'LOH:?8>';#3]+N]-19);6[>629)F
MW;C*27_ DGCWK+L/'=E>W^GV4FFZI9RZA&\MK]IA51+&J;RV0QQQC@\\C(&:
MBL?B'INHZ*NK0:=JGV68Q):EH%!NI'R-D8W<D$$$G &#S@$T :MUHYM_"PT+
M25\F,V_V2.0G/DIMV[SW) Y]SC..35DZ%IY\.?V T&=.^R_8_*R1^ZV[<9'M
MWK+_ .$UL18F5K*_%Z+L67]G&-?M'G%=X7&[;]SYMV[;CG-,E\=:;!IMO=RV
MM^LDU]_9QM?*!FCN-K,$8 XY"\$$CY@>AS0!;TSPEIVEZG%J,4M[+=QVHM/,
MGNG?=&"2 03@XR?S]>:M3:);S:['K/FSI>1V[VR%6&T1L0Q&",=54Y]JYZ3X
MDV$-O?2RZ-K*'37VZC&8$S:+@$.^'P00<_(6. 3BK^H^-=/TZ\N(C:WL]O:!
M#>7D$:F&U#@$;R6!/RD,=H. 03B@"2W\&:9;6>EVD4ET(=+N#<VJF7.USNR2
M<<_?;@_WOIB*Q\!Z-ITVGR6YO1_9TCO:(UVY6(/G* 9^[ST_#IQ4.I>/K#3K
MC58O[.U.Y726 OI8(5*0J45]Y)89&UNV3P>,8)?I_BV:_P#'5[H2:;/]D@M8
M9ENP%VY?>=Q^;.TA5"X&<YS@8H =+X!T.723INV[2%;DW<#)<N'MI"Q;,39^
M3EFZ>M6?^$2T_;I^9KQGL+@W,<LDY=WE*E=[LV2QVDC!XQQC@5=DUFVB\00Z
M*ZR+<SVSW,;D#8RHRJPSG[PW*<8Z&L>S\?:/?^'O[:MUNFMS>)9)'Y8\QY'9
M57 SC!WJP.?NG- %W4?"FF:K>WUU>K-*U[9?8)TWX4PY)V@#H<L3GKS4$7@K
M3(III_/U"2>:R^PRRRW;N7CYZYXS\S<X[^O-<]+X[;3])FN;&/4=5=O$/]FM
MY\<:^4?-561,,N1@D(3SG&[BIO\ A-[C3O$/B1;JPU.[M;);>;R;>)";2,PA
MG+$L,\YX!8\''% '::9I\.E:9:Z?;ES!;1+%%O.2$48 SWP !5JHK:XBO+6&
MY@??#,BR(P[J1D'\JEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KEO&]EJ-U#HDVFV+7DEGJT-U)
M$KJI,:J^[!8@9Y 'N1]:ZFH;BZ@M$5[B9(E>1(E+M@%V8*JCW)( ^M 'FNM:
M'K/B"W\3:C'I-Q;M?2:=#;6L[()&2"8.[L Q 'S-@9SA?<5J^+-"DE\66^L/
MINJ:A:M8FU9-,O&@EC</N4G$B;E(9AU."!QS76V>K6U]J&HV4)?SM/D2*?<N
M!N9%<8]>&%7J /+KWPYJ02'35T/4/L+:4D5G:V^IMY%K<LSF3SGWJSXW)SAN
M 0!4VAPZ]X::.^7P[>W;7FCVEJT$;Q!X+BW#KM?+@;&W9W G&.17H.I:E::1
MIMQJ-_+Y-I;(9)9-I;:HZG !)_"L6T\>>'[Z[AMK>:],LSA$W:;<J"2<#+&,
M #W)Q0!4TS3-6_M_Q!?7UJD;WNG6<8,391I567>J]\ L.3ZT_P (376E:9X=
M\-WMB\4Z:*DDDA=2$>/RT:,@=_G!STXKK*38N_?M&_&-V.<>E '(>+K34+G6
M=-/V'4K[21#,)+>PNO()G)3RS(=Z$IC?WP">1TKG?#FEZYX8;2=0FT*[N?LU
MG<Z=<V]NZ,ZDSB1)$W.-R'D<D'ID5Z7?7D6GV%S>SY\FWB:5]HR=J@DX_ 5%
MI.IV^LZ19ZG:%C;7<*S1;Q@[6&1D4 <?N\06'B"V\27>@RW,EUIGV2XM+&1&
M>WD65G3.Y@""'()!."/2EA_M_2/$3Z]=Z%-=MJ6FP13P:?(C&WGC9SM^=ERI
M$GWAW4]B*[NB@#SKP]X6U;2]4\(R7-N,6EKJ#7;(X*PR3R)($]_XAD>E4=;T
MOQ!%X=\8>';/0KB[DU2YGN;6Z22,0E)<,0Q+!@P.X 8YXYQR/4Z* /-M<\-Z
MO=>(?&5S!9,\-_X=^QVS;E_>3;7&WKQU'7BKGB7PW?ZJNCP)&(XH](OK6>9F
M 6%I(41<_B#T]*[VD90RE6 *D8(/0T >8VM]J%YXB^'T-UI,EDMN)U9Y)8W$
MC"T89CV,V4_VCC.Y>*Z/QQ:7TQ\/WMC8S7O]GZJES-# 5WF/RY$)4,0#RXXS
M2Z5I7AC0;S4+RWTMM-^P+Y;7-RK+$J$!CY18X"=,[<#(KJZ /,[W3-<BT/Q/
MX:@T6XG;6KFXDMKP/&(8TN.6,A+;@4RW !S@8SFNSU[3)KOP7J>E6H\R>73Y
M;>+<<;F,949/UK9HH X70;'4YM:\,WUQI=S9QV6CSV<XG*963,&/NL>#L8@^
MW:L)O"=_!=V^HWFEZC<0QWVIB2#3[LPS!)YQ)'("LB9'R<KG^(''%>KT4 8W
MA73TTWP_! FG2:?N:25K:6Y-PZL[EB6<DY8YR>3@DC)ZURFGZ5J2^(P=/T?4
M=(AE:X_M*)[I9+*7<K;6B7<2&+E6R%7C=D9KT2B@#RC3-/UV/P]X8T^_T+6O
ML>GVLEK=VEK=)"TDX$?EN6609BQY@Z]>2.E7_"N@:O977A9;O3I(!I@U**X8
MR!E'F.K(RG.64C.">>#G%>D44 >9IHFLZ3KD6N#2I[J.WUJ_D>W@9#(T,Z@+
M(H+ '!4<9!P347]F>(C'J-U<:5J$5K>:_P#:KFSL[E4N)+4VRJOS*X_C5=P#
M=C@D=?4:ADNH(;B&WDF1)I]WE(6P7P,G [X% 'F&G^&]8C>RA.C3V\<'BA-2
M_>3K+MMV@89+%B2RG ;KR>,CFMV\@U?2/%FO7%KH]QJ$.L6T(@EA= L4J*R%
M9-S A>5.0#WXS75:1JUMK>GB^LRYA,DD0WK@[HW9&X_WE-7J .>\(Z9<V?P_
MTC2[Z-H+F+3XX)DR"48( 1D<<5RMAI6N3Z)X7\,3Z-/;MH]W;R7-\SIY#QVY
MRI0ABQ+X7C QDYZ5Z+!=070D-O,DHCD:)]C9VN.JGW%34 <EX0TF^TW7?%EQ
M=VYBBO=3\ZW8D'S$\M1G@\<@]:9J5GJ$'Q(M=3BTZ>YLI]*>Q:6$IB&0RJX+
M@L#MP#R,_2NPHH \]L_#NJ)X1\ V,EHRSZ=<0->)N7,2BWE1CUYPS <9ZU5\
M'>%CIEQHUE>:!JGVG2\A[Z?4W:U!5&17BC\P@E@?N[5VACZ8/?ZOJEMHFCW>
MJ7A<6UI$TLNP9.T#)P*6TU2SO%M?*F7S+JW%S%$QPYC^7YL>@W*/QH YOXA:
M;<:E8:,8-)?58[758KBXM4"$O$J.#PY"GDC@FH]*^SF6XAL_ 5SHTDUO(AN3
M!:QKTR%)CD+<D#MBNTJHU^$U6.P^S71+Q&7SQ$3$N#C:7Z!O:@#C-+T#4[>R
M^',<MHRMI49%Z-R_N3]D>/GGGYB!QFL6]M=2T;Q987+:=),\_B>[N8(59=TL
M1LB"5R<9^5L D<CM7K%87B&^T?3K[0KC5(G:XDOUMK%U!.R:1&7)YZ;2PYSU
MH X77_#FN:[H?B.]BTJ:&XU34[.6"SE9!((H?+4LV&P"=K'&>F*V;RWUG1K_
M ,50VNB7.HIK3":TFA>,(CF%8BDNY@5 * Y /!]1BN^HH \K\5Z+J'A[1_"R
MZ3,AU7[*/#SMG'F+)'@./78Z!_IFK6J^$4TK6XI;?2-6O]/&EP6,,>FW[6[1
MO$7P'Q(F58..3G!!]:[EM"TQ];367M5?4$0QI,[%M@(P=H)PI(X) R:T: .+
MT'P]<:7XRAN(]/%KI\7A^WLT59O,6.19')C#'YFP".2.:Z/2-4;5$O"ULT!M
MKN6VPS!MX0XW#'8^G:GZCJUKIDMA'<%]U]<BUAVKGYRK-SZ#"&KJHJ A%"@D
MG &.3R30!YM?6FO6J>-K&'0+FY&MSN+*>.2/9\UND9,F6!501G.#T/MF#QGH
MM[ITGA^WTJ9?M>IVO_"/7!!PQB*[O- _V LA_P"!UZC6<NA:8NN-K7V56U%D
M\OSV8L57 &%!.%S@9P!GO0!;M;6&RLX+2W01P01K'&@Z*JC 'Y"O-O#6B:S#
MI/@VPN=)N+>31=1E^TO(R;2ABF =2&.5RZCH#STKT^B@#S+7/"FHW6MZIJ+6
M%U/;IK,%XL5K<^3+/"+,0N4964A@Q)QD9VD=ZZOP?IL5A8W<L>E7>G&YN#(4
MO+QKB:0!54.Y9FVG"XV[C@ ?0=%10!YI+IAM/&7B.ZU#P+/K<5Y<126UPD-M
M( HA12/WC@CY@>U:PLKF^UCPE>6N@S:79V$]UYMO((D\E6A95.$8C!8]O6NU
MJI?WXL%MR;:ZG\Z=(0+>(R;-W\38Z*.Y[4 <+?\ AW5I?"'BZSCLV-Q?:PUQ
M;IN7]Y'OB.[KQPK=?2LMCJM[I7CO0K#1I[IM2U2YMXKE&011EXT5C)E@1M'/
M .>G6O6:RM.6SM-4U&SM+"Y@9Y!=33-&WE2R. "58\$X49 Z4 <5J_@S4]2\
M2>(HXXREI>>&UT^"Y9AM,P+<$9SZ9XK2M8]7U[Q'X<N;K1;G3(M'262X:X:,
MAY7B,82/:QW#YF.3@<"NXILD:S1/$X)1U*L 2.#[B@#S+PYH<S^.M0TABIT;
M0)9I[/:?NR72A@F.WEAI<>TBU#X>\&,EK8:1>:%JD=U96TD+ZA/J;O;(WE-&
M'AC\P@[@QXVKM!/H ?1])T;3]#LS::;:K;PES(P!)+,>K,QR6/N33-3UW3]*
MLM1NKB<$:=!]HN8X_F=$P2#CWVG'TH XOP9X>-G?:4+KP]JD%WIUL4EO+O5'
MEA63:$_<H9&!##<?NKM&._%;?B2UOK?Q-HFOVEC-?Q6<=Q;W$$!7S LH0AU#
M$ X,8!&<X;VKJ(W$D:NOW6 (_&B21(8GED<)&BEF9C@ #J30!Y?K7AG6]3\"
M^)"FG.E_J^K17D5D73?'&KPJ-Q!V[ML18@$]<5Z)K27TFA:@FF,%U!K:06S'
MH)=IV'GWQ5N&:.X@CGA=9(I%#HZG(92,@BJ^G7XU*T^T+;75N-[)LN8C&_!Q
MG!['L>XH \RMM!U0W[7,&A:M&EQH5W8227UX)I3<,(V#-ND;"DJ0".IZ@#!K
MI8M%U!;GP&QMB%TV%UNSN'[HFV*#///S<<9KLZ;)&LL3QN"5=2I ..#[B@#S
M3PSH\Z_$&]TP[6T?P]/+<V84Y"RW2A@A';8#+CVD6NG\86%[<?V-J-A;-=R:
M7J"W3VR, TL91XVV[B!N ?(!(SC%;&DZ-I^AV9M=-M5MX6<R, 22['JS,<EC
M[DU8GNH+7RO/F2+S9!%'O;&YST4>I- 'G6KZ)K&O:3XVOTTN>WEU6QBM+*TF
M9!*_EA_F;#$+DR$ $]!SC->@:5#);Z/90RKMDCMXT9?0A0"*MU'/+Y$$DI1W
M"*6VQKN9L#. .Y]J /--+T364L=.TV72;B-M/\2O>/,S)Y<D+O,P="&R<!ER
M" >?KB7Q'X5U+4-;UF^6RN)H!>V%U''!<>5)<)'&Z2!&# JP#Y'(R1C->AV5
MT+VRANA#/")4#^7/&4D7/9E/0^U4[K7K*S\0:?HDID^V7\<LD("Y7$8!;)[=
M10!F>#]-ALHK^YBTB^T[[3,O_'_>M<33*J@!FW,VWN -QX /'2N<EOM0M/%_
MCB*RT6YU%KA+:.,V[(-LAM\ /N884Y'(SC!]L^AS74%L\*3S)&T\GE1!FQO?
M!.T>IPI/X&HX-.M+6]N[R&$)<790SOD_.57:OY#CB@#C_"WAF_T3Q+8F>+=;
MVOANUT\W (PTR.VX#OTP>E92:+K?_"*1>"3I%P-E^K-J6^/R/LZW/G;Q\V[<
M5&-N.OMS7I5U=065K+=74R0V\*%Y))&PJ*!DDGL*K)JUJ^N2:.I?[5';)=-\
MOR[&9E'/KE30!Q&K^%M4N/&SVL%MN\.ZG=6^HWTFX ))"#E-N<G>4@/X-3IM
M!OU\5>.+V?0_[1L-0@L4A@,JI]H"*1(%)/#+G(SC) Y'4>ATV218HGD<X1 6
M8^@% 'E&I>'M?U'PQ=6=I9:H;,:G9RV5MJ5PLD\:(P,IW%B=GH"Q/!]JW+RW
MUC1M1\4Q6NB7.HIK1$UI-"\81)#"L127<P*@% <@'@^HQ6C#\2O"]Q$DL-U>
MR1R %'33+DJP/0@^7TKK* .+\*>'+W0M=99DW6\.AV%BLX(P\D1E# #K_$I_
M&N7A\/ZM9>%-&MAX?U2+7;72DAMM0TZ[1#'*-W[N8%@"@.T\[P<MT/7URB@#
MGO%FCWVN^![[3(VC-_+ I7)PC2*0V/8$KC\:S[5-2\0>,M*U6XT>ZTRUTRUG
M1OM31[I)9=@VJ$8Y4!"=W&<C%;WA[7K+Q-HD&KZ<9#:SEPGF+M;Y6*GCZJ:T
MZ .2^&VDWVB>";:QU*W-O<I/<,T9() :9V4\$CD$&N8\2:)KFH7>K;])U.]N
MEOXKBTF%YMMEMD:-MB1^8 7^5A@KU.<]*]4HH \[O= U6X\%>.;1+%Q<ZG=S
MRVL19<R*T48'? Y4CD]JK^.=)NI/%6GV=@P5?$EO_9VH*&PPBC82&0#O^[,J
M?\#6O3*P-0AT'PW/=^);BWVW<H6%I1NDD<L0%CC!)P6;'RKC)ZT 7M8AO!X<
MOX-'VQ7WV21+/H LFPA/88.*\S;PSJ%Y)=&/2=3L[>]T"[T^2YU*]\UUG8(V
M^3,C;4.TC([YR ,&O7%)902I4D9P>HK/AU6RO=4OM'8$7-NBM)#*G$D;@X9>
MS*<$?4$&@#@UO]0U+Q5X*2YTB6P\NWN@?-DC?S&\@ E-C-E!Q\QQG<.*5?"F
MH_\ "K_"MC/8W#76E2PSW-G;W'E2L KHZHZL,, Y(^89QC/-=EI/A/0M#NC<
MZ;IT<$VSRPVYFV)G.U=Q.U<@<# XK:H \MNO"?GVEMJ5MX?U>%8=3\^:V?5)
M#>7$7DM%O#^9E6!;A=_*K[XJ]%X<F^SZ++8Z)=V0'B!;ZX2[O#/-Y8A>/S7+
M,V#]T;0QP,>^.FU+Q;8:1H]]JE_;WUO;6=R+9S) 5+DLJAD!^\A+##?6K2:_
M8OXFFT &3[=%:K=ME?E\LL5'/KD4 <IJF@:I<6'Q&CBM&9]5C LAN7]\?LB)
MQSQ\P(YQ67>^$Y$U/5H[O0-4U./4_*:+[-J;V\ _<I&Z3!9  !L)SM;(..<8
MKNO#OB:P\46LEWIJ71M%;;'<2PE$FY()0G[PRIJ;7]>LO#6DOJ>H&06Z.D9\
MM=QR[!1Q]2* .7N= U$Z7\0H([1BVI*RV0W#][_H:1C'/'S CG%2:)8:EI?C
MJ66;3;AK2]TJTA%RA0I#)$)-RO\ -D?>&, ]:[*YN(K.UFN;AQ'#"C22.>BJ
M!DG\JS_#^OVOB33%U"RANH[9\&)KB$Q^:I (90>JG/!H P?B'I6L7=E97_A^
M#SM4M6EB5=P7]W-$T;')(^ZQ1O\ @-9L/@^]L_'&GVEO;?\ %.0""^:7< /M
M$,+0*F,YZ")LXQ\M=U<7XM]0L[0VUU(;K?B6.(M''M&?G;HN>@SU-5]&UZRU
MTZ@+(R'[!>R6,^]<?O4QNQZCD<T >=1^&=<M/#5^3IDLD\?B[^U4MT=-\MN)
ME;*Y.,D \$BNC32]1N)?&ER;&6(:I:Q?94D*[F;[-M*G!(!#<=<5VM% &;X>
MMIK/PUI5K<(4GALX8Y$)SM8( 1^8K2HHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KAOB;8PWMAH
M"S&8 Z[91GRYGC^5I0#]TCGT/4=1@UW-4-8T6PUZP-CJ4!F@WK( '9&5E.58
M,I!!!'4&@#S;4=%BDG^(MVMW?Q2:>D;VGDW<D?ER)91D.<,-YX'WL]/<Y@NI
M_$'B"[U>6WM[R6[L[:V%E<1:D+:.V=K=9=[1[@'R['.000N/6O2X_#NE1VU_
M;K;$QZ@@CNMTKL95$8C&23G[@ SU[]>:JWO@O0-0ECDN+$L4B2$JL\B+)&GW
M5D4,!(!Z,#0!G_$4R-\+->:90LITYRX!R =O-6=*C\8":U-]<Z$UG@>8L%O,
MLA&.Q+D9_"MO4=.M-6TVXTZ^A$UI<(8Y8\D;E/49&"*P[?P!X<M;B*>&VNQ)
M$X=,ZC<, 0<C@R8/T- '":G#=/X>\2ZVNJZC'J%EX@:&SD2Z<+ GGQJ5"9VD
M$,WW@>PZ"G>+1/X<G\1V&F:G?V\#:=8W0>2[DE:.4W11G#.21E0,CH<5Z5)X
M;TB6PN[%[,&VO+G[5.F]OGEW!]V<Y'S*#@<<5E^,_"L>NZ3?&UMHFU&YC@@9
MY'(#1),)-I'3^]V[T <WK-I_86L:QIEG=7DEG=^&KNYFBN+EYL2H54."Y)!8
M.P..#@>E5/"L/]MP^$-$O)[E=.C\-1WGDP3O#YTN43+%""0H[9QELUWEGX0T
M2Q6]$5H[&]A^SS--<22L8N1L!9B57D\+@4D_@_0[BPL+,VCQQ:?'Y5HT%Q)%
M)$F -HD5@V" ,C/..: .(LM1U#3K33=8DO[J>QTK6[K2;EI92WFVK2F..1S_
M !%&V#=UQFJL][JNKWUK=HM[>66NZG<-%:0WIM]]M!&5C4-D;0Q#2'!&[BNQ
M\1>'KB7PJ/"V@Z?9PV%U$UO-++(0+:,]65,$NYRQ&2/FP2:UI_#&DW.BV>DR
MVQ^RV006WER-&\11=JE74AE..,@CJ: //Y+367N/"^C:C<WMG#<:K>1;([\O
M(;80NZQO(IR2,%<YR !SGFNN\;7,^@_#Z^?3II('AACACFW%FB4LJ%]QR20I
M)R?3-:5MX8T:S&G^19!3I\DDULQD8E7<$.Q).6)#-DMGK6C=6MO?6DUI=0I-
M;S(8Y(W&5=2,$$4 >>:S;'POK)L=*N[[[/>:'?2SQRW<DI22()LE!=B58[V!
M(QGCTKHO -@+;PCIM[)<W5S=W]I!/<2W$[2%F,8/ )PH&<8&.G.35JQ\'Z'I
MRW*P6DC&Y@^S2//<23-Y7_/,,[$JO/0$"M>SM(+"QM[.UC\NWMXUBB3).U5&
M ,GGH* /&O$\DU_I/Q.BN;FYDBM+RV,">>X$>57( !Z')XZ5T/B/3WT74I+V
M<:K-HEI!$([BRU-_-TXJ279XV;]X#D$D[C@8QBNQF\*:)/%JT<M@KIJY!O@7
M;]\0, ]>, #IBJK^!/#TK1M):3/M548->3$3!3E1*"^),9_CSZ=* '^,;2_O
MM#6'3FW2&>-G@%R;=KF,'+1K(.5) _3'0URNCWX_X2'PW9VSZK;(EY?0W-E?
M7'F-$XA5Q&6R=ZC<&4DMP>O8=YJND6.M6?V6_A,D0<2*5=D9&'1E92&4CU!%
M9LG@K0)-/ALC9R!(9S<)*MS*LPE(P7\T-O)(."2W(XH XL7MSJ>O/HT]]="P
MN_$]U!,8[AD;9':AUB# Y52PY (Z$=S6A=V,4>MZ)X736;RYTN>ZNWF07C>8
MA2-62W:16WX&\M@G. ,\5TW_  A?AX:9)IRZ<J6TEP+HA)75A, !YBN#N5L
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M'( W,[$LQP .3T JC?>#=!U'49+ZZL2\LK*TRB:18YF7&TR1A@CD8'W@>@H
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MTI;C..3^7;%37T#^%9M(O-(EN3=W.AWLD_F3/()Y(X4="5)(R&SC '!QTXH
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M#+?_ -%BNCH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQCZA&88!SGD$@4 =E6=JVA:;KD<2:C:B;R6+Q.&9'C)&#M92",CK@\US4GQ
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M.UB"6QBM4AN9!']F>,MM(R#E"& ..1M'7-;7B'P[<:AX%&CV"6L%U EN\$:
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MM'![,>:U]/\ "UW;:QX6NTTZPL(+".]^T6]HWR1M-MVA<CYCP<GCG)[UV]%
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MM)O;!(_MKYAUFV,Q*3QEV*R*3P'3/ X!!(XKO-#U>#7]"LM6MDD2"\A69%E
M# $9&<$C/XUH4 <)_P (IJ?_  @PTG;%]J_MG[9C?QY?V[SNOKL[>O%5+SPQ
MKYT76?"MO:6[:=J5Y-*NH&XQY,,TF]U,>,EQE@,<'C)%>C44 <3>>$[Z;XBV
M^I1^4=%?R[FY1F^8W$4<D:<=QB1#]8Q6':^ =:C\,Z[93>0]S)Y%EI_[S(%I
M!)N3)[$AFX]A7J5% &"VE71\?1:P OV1=+>U)W?-O,JL./3 -8FM^%]2U'Q-
MK86&-M-UO1Q8/<B4!K9U$O.S'S [QT-=S5>&_M;B\N;2*97N+7;YR#JFX97/
MU% '(V6E^(-3U?P_+J]C;V4.BAW=X[CS?M,IB,0V@ ;5PS'GGH,=ZLZM8ZW;
M^.(=>TVQAO;=--:TDA:<1.6,@8%21CC'?'4^G/6T4 >7#P!=PQ:9?WVCV.LW
M(-XUY8R2@*K7$PE!C9A@E2-ISC()-=A:Z-+!X&ETJ.QLK*>2UE06UID0QNX8
MX!/NW)[G)KH:* .!U'P=<7/A+PI;S:?:ZA<:-'$)[&9P$F'D&-P&(QD$A@3Q
M\OO5>[\&WMQI.@1V6CZ=I9M?$4&I3VML_P JQ)D$DXPSXVYQQV[5Z-5>6_M8
M;ZWLI)E6YN%=XH^[A,;C^&X?G0!P,'@AK7Q!<EO#.DWJ3ZFUZNJ3N-T<;OYC
M*4QDN"6"\XZ$],5:NO!VH2^/A<H8O^$>ENHM4GCW8;[7&C( %]#^[<GU2NKT
M/6(-?T>'4K9)$AF+A5E ##:Q4YP3W4UHT >7:IX,UBYU&\N5T73[J]35X]0A
MU*:<&5X4E1U@3(S&0HV]<<=]W&K?>%=4N?!_C+342+[3JUW--; R<%65 ,GM
MRIKO** .7TS3-3T_Q]KMZUK&^G:FL#K<"8!HVCCV%2F,G/7(K(UOPGJ>IZWX
MI@6*+^S]>TZ*!;KS<&WDC60#*8RP)9>E=_10!Q]I8:]K'B31M1UBPM["/28I
M3B.X$IGFD4)E< ;4 W'GGD<<57\:Z#J.M7++:Z+:3S>1ML=46Z,$]E*<Y8D#
M)4':P"]<$$=Z[ W]J-273S,OVMH3.(N^P$*6_,@58H \\U;0/$H/BVQL;2VN
M8=>A!2[DN GE-]G6%@R8R2=N1CCGG&*GBTGQ/H%]J$NCV5G=G4[>W'F37&P6
ML\<0B)88.],*IXYX([YKL=0O)+&W66*RN+QC(J>7;A=P!.-WS$# ZFK= ')Q
MZ!J(O?%<TIB8ZG;0QP,#C<RPE&R/X1N-.N]!OIOA5)X>14^WMHWV, M\OF>3
MLZ^F>]:>G>(K74_$&LZ-#%,MQI)A$[N!L;S4WKMP<].N0*UZ .1\/^'K_3M;
MTRZN%C$5OH$-A)M?)\U6!(^GO6++X0U^T\&:1_9@MU\0Z5<W$D.Z3"%)6D#*
M6_W75OJHKO=0O)+**)X[*XNR\JQE( N4!/+G<1\H[]_8U;H \\U'P#':VWAP
M0:1:ZS#I5I):2VEPX3S-^P^:I88W;D.<]0YI]]X9N&T+3K%_"&D7,"+(YMK6
MX,#6DS-D&.0CI@_,1@Y&0".*] HH X/2_#_B#3?$=G=7(COUET.'3[NZ\_#+
M-&78M@C+ ENO7UK&TK0M3\(Z3X'67[$^J6"75H]G)="/SA+\Q\MR""R[%..X
MS7JM5=0TRPU:U-KJ-E;WEN2"8KB)9%SZX(Q0!Y7I>DZGKD5[=R6%IJMNOB.Y
MEN; 3XAF!A1!AF&'".".1S@G&1BKUKX2\0:7:::;?2[%GTW7)KY+:WG$<;PR
MHXVID?+M+XP1R!7I5K:6UC:QVUI;Q6]O&,)%$@15'H .!4U 'G$W@G5YI_%-
MPGV=)[O5+74=/WR?*S0[&VO@< E2/QS4VJ^'M=\2?V[?W5C#8SSZ'-I=G;&X
M$A9I,LS,P& ,A .O<G%>@U6%_:G46T\3*;M81.8NX0DJ&_,$?A0!B3:+>/XE
M\-WP">1I]I<0SG=R&=8@N!W^X:K7MCK6D^++_6=)T^'48M1M8898GN!"T4D1
M?:V2""I#\]QCH<UT6FWDE_I\5U+97%D[YS;W.WS$P2.=I(YQG@]ZMT <)X=\
M&W^B:MX<DD>*6.PTVY@N9%.,S2R)(=H/.W(;]*U?&FEZCJ-MI$^F01W$^GZG
M#>&!Y1'YBJ&! 8\ _-GGTKIJ* .%N?#&JW/ACQM9^5$MSK4LLELGF9'S6\:
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M*!^%;&F^'])T?R_[/L(;<Q1&%"B\JA;<5^FXYJW9V5MI]JMM9P)! I8K&@P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N5^(&I6^E>'8;BZLWNXVO;>,1I<-"06D #;EYXZXZ&N
MJKF?'/AV[\3Z#%864D,<J7D%P3,Q"[4<,1P#S@<4 4-5\::M:W7B);#0X+B#
M0=KW$DUX8S*AA64A $/S $\$@<#GGB_I_C&WN;C6DNX?LL6FV\5X)"^?-MWC
MWA\8&,%74CGE>O-0W'AB]EC\:*LMN#KB;;;+'Y/]&6+Y^./F!/&>/RK,\0^
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M" 3,C%06 S]T@'(/;!-#4M U8Z_J^J6(TZ9;NTM;=;:\W%9!&\AD5L*=H*R
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M0I]3DCM7::1=7]T^HB^ACC$-X\5NT:L \0"D,=W4Y)!QQQQ0!SNN^.I=*O\
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M)7D1RP&,;<JW?N*V_%NC2^(?".JZ1!(D<UY;/%&[YVAB.,X[9H Y3^TO$O\
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M23=Y8W9(P1@;1C!8\5U5UH\R:YH.K23V\=KI5G<1W!=R/OK'@CC&!L.22.U
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M=@=44A03G=G)R00!5FUU1])O;RSTOQ%H":7=ZBUZ;J2YS/$KN'DC$>TJQ)W
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M"ZQ1PPKNDED8X5%'<DG_ !XK0KBOB/$[6WAZ4W;V=O%K,)N+E" 8D9)$#9/
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M4\9_9+WQ'9V,UEI4KP6$]TTVK%F@CCW*K;8QPS?[1QM'^]0!V\D\,*EI940
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MZ5"SQM_LQ*P!'<'(^HK0U[18/^$ONM+BL/#\6FVVC(;:#4%*10JTDOFO$%&
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ME_*NHW@ASO+ 1(0#ELHV3T''K0!VES8[([VXTV*U@U.XCV_:7B'S,!A2^.6
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MC_<X^7\*EM-*TZP*FSL+6W**44PPJFU2VX@8'0MR1Z\UQR>.]06T\0ZK<:9
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MMC.PXY!&1@]>,T[KQ(VE>(_$4DNEVYU+3O#RWTLT<S[964,?+ /1<@X.,\T
M=/X:T%M#M;I[FX6ZU"^N&NKRX6/8KN< !5R<*%  &3TSWJW;:#H]E]I^RZ58
MP?:@1<>5;HOG ]=V!\W4]?6N:M_%6O?;M.M[S3+&$:Q;22V&VX9C'(B!PDWR
M]UR<KG&".>M<]IOB2^NO"?@:^UZSMKVXU'5(4AE65U,>Y6(D(  +#!&WD8H
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M6@ETNRD%GS;;[=3Y'^YQ\O0=/2HYO#FAW%O';S:-I\D$<AE2-[5"JN3DL!C
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M %#Q9HTWB#PKJ&DP2)%+=1;%>3.T'(/./I6;XE\'?\))J<LDUPL=K-I%QI[
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M E\'7XD\M0#)M,6"WJ>3R?4UK::NBKXP\&GP^+7<=/N/M9MMNXP[$QYF.?\
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ME+$Y)P1C.23F@#'\"VRVG@^RACO8+V(&0Q36ZE8]AD8JJ DG:H(4<] *\_\
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M::I-%J>@202W6FK?065NRVL2B4_/*-Y!!!4, 1\JC/%=KX(M/(U+791J&E7
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M+&<GWKLX=+TZ"VDMH+"UC@D.9(DA4*Q]P!@U8F@AN86AGB26)AAD=0RGZ@T
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M[']H0LCE592IP0>C'\J .-&KZ[H<_CO5+"WL)+:PO_M-PLY?=*%MH2RIC[I
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MN-B2&1&;#G'R*-O)YXYKRZUBC3X*>&G6-5=O$";F P3B\DQFMW5_^0]\7/\
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MEZGM^P:E9W>X,P\B=7R%(!/![$@'ZBK,]S!:QB2XFCAC+!=TCA1DG &3W)(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex1012022063010qngcbasho004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF/-%'+'$\J+))G8A8 M@9.!WXIMO<P7<0EMIHYHR2-\;AAD'!Y'O0!+1110
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ME$;F-_+<-M8=5..A'I4M !113#-$)Q 94\XJ7$>X;BH(!./3)'/O0 ^BBB@
MHHHH **** "BH+B\M;/9]IN88/,;:GFR!=Q]!GJ:GH **** "BBHYIXK:%YI
MY4BB099W8*JCU)/2@"2BD5E=0RL&5AD$'((I: "BBB@ HHHH **** "BBB@
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MJ*4P"8$['3!4D=G/Y4 8.C6^D:7#J>H:5X*N-#NX+*1EGN;>) ^!G;\CL3R
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M=D4^>(N1AM^$7 )/&3TH S3X^USR8XKN]T_3;Z/3X[UXI+.27SGE+LD/RGY
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M8N&51@$]3[5V-K;)9V<%K%N\N&-8UW')P!@9_*N9U+PA>SWVJRZ9K1L+?5U
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MCU6"V:UGNKFU65;A&8-R@*X(;[N#P"0<T :7AG5I-=\-6&IS0^3-<1!I(P"
MK#@XSSC(.,]JUJKV-O):6$%O+<R74D:!7GEQND('+'&!D^U6* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *P?%'B#_A'8M,F;R5@N;^.VGDF.%CC*L2V<\8V]ZWJY/QS +AO#*-%Y
MBC7;=F&W(&%<Y/XXH TX/%F@7.EW&IQ:M:FRMFV32E\"-N, YY!.1@=\C%.3
MQ3H4FF+J2ZK:_8VE\CSB^%$G]TYZ'V-<)KUS+IWB7Q',%BAAEO=,$EY-;B5;
M8;&_? 'C((4 GH2#VK%DVW[7EM+-/?B;Q5IT^^> 1F>%DB7S-JJ!M.UAG'('
M- 'ITWC7PU;VMK<S:U:)#=*7A=GP&4'!;V7/&3Q5F\\3:)I^H0V%WJEM#=3;
M2D3N 3N.%SZ9/ SU[5Q/CB^F;6]6TX7!LGDTE4ME@LEEGU$L908@S*?E4XX'
M3>22!62VJVUI96UWI>H;[ZXL;-9M(N[3S8]2VJ%'EG&0PY4D$@%>1WH ],C\
M2Z++K+:1'J=LVH*2I@#_ #;@,E?J!R1U%55\;^%WG6$:[8[V1I!F4 849//3
M( SCKCFN4M+V*R\8Q6.F7OVN.?597N=(N[3][:.V\O/')U"YR03D$/P1G%9V
MF:>O_"!^ HVM>5UY964IT.Z<[C^..: /0X?%6@SZ1-JL>JVQL8'\N6;?@(_'
MRG/(/(XZG(]:<OB?0VTR/4O[5M19/(8A,T@"[QG*G/0C!X/I7G'B"VN4\1ZW
M=QS26EM;:_8W$]PL'F"-/L>WS-I&" [(2>V,]JF:SM[N"RO(+^;5H[OQ1:RR
M3O:B*-V2,*60 8*_*H+="0: .NU'XA>'+#0)M834(KFWBG6W98F^;S&(PI!Z
M<'//85TEK<PWMK%<VTBR02J'1UZ,#T->5>-(I%;QW((G* Z1*2J$Y"2@L>.N
M%7GV%>H1W,>I:7]HL)U=)XB895Z'(X- %&V\5:#>:J=,MM6M9;T,RB)7Y9E^
M\ >A([@<C%26?B/1K_4WTVTU*WGO$5V>&-LLH1MC9],,"/PKS?3+FWNO#'@K
MPY:QN-;TZ_M6N[;RR'M_*)\YWXX!^89_BWC&<UU?PYMA;Z9K3>5Y;RZY?.Q*
MX+?OF /Y 4 =0;^T&I#3C<1B\:$SB'/S&,':6QZ9('XUE:EXBMX;FVM[34=.
M63^T8[.X6X9LY92WEIC_ ):$8(!XK+\=DZ//H_BR.*1_[+N#'=+&N6:VF&Q^
M!R<-Y;?\!-<E?:3=VGAWP-/=0M_:%]XHM]1O< DK)*)&(/IM!5?^ T >CW/B
MK0;/51IEQJUK%>EE0Q,_(9ONJ3T!/8'DYJA:^*7?QKKVCW2V\-EI=I!<_:&.
M#APQ8L2< #%<1J=Q!;^%?&/AJXC<Z[J&H736MMY9+W'FN#"Z\<@ KS_#L.<8
MJ34WNK#Q7X]N19I=L-(LU*S0F2-^&#$K_$ "21[4 =I>>/O#MMX=U'6H=0BN
MH+%-TB1-\Q8C*K@_WNQZ&K,OC/P[;V=I=7&KVL45VI>$N^-R@X)]@#P2>*\P
MUB=KZ#QBL.I7&K?:O#R"WN#;+&L_EO*7$810&"[ASR>2,\5IZCJ5M+K\NJ_\
M) ;'2]0T>&&WG6S$RW&QY1)$-P.&RP^4<G/?% 'H>H^)=&TJXAMKW4K:">=-
M\:._)7IN]AGC)XIOA35YM?\ ">E:O<1I'->6R3.D>=JDC.!FN%TN6Q\*ZS?V
M>K&X>.[T6Q@L3<0$R7*QHZM%@ _/DC*]?FKJ_ARC1_#CP\CJ5=;&(%6&"#MH
M TH_$VB2ZT='34[9M0!*F /\VX#)7TW <D=:O7M[;:=9RWEY.D%O$-TDCG 4
M>IKR2;5FGU+3I9[PP&W\0L]UIL%DJ1VB^9(@DD?;NW/E3G/S;R<8!KM_B9&T
MOPUU^-%9V:U8!5&2>10!;;QSX75;ACKEG_HY"R 29/.<8'\70\C/0U/>>+-
ML+&UO;G5K5+:[7?;R;\B5<9++CJ ",GH,UD&SC3XM6DBVZA(M!D1&"<+^_3
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M!:3QN2?+,A7KCOM8'\17":3=6M@-,UB2)[33+?Q7?M(SQE?(62.55+#'RC+
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MV#*ZGH01U%<9JGQ(T^*U\0)IC137VD.B,DA.U\E Q&.< OCZBK_P[MIK;P;
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MA;R[FY64J&"8ZEMI!P.U5I?$$$USHC:?J6FO::B[A2[DO,%4G$6.,@CG/I7
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M\T]FB8W$N(ED"JWS$9.T;@"?4$=J )O#6B2>'M"M]*>_EO8[91%"\J*K+&H
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ML[5K*YL/'&F>(+:WEG@FMVTV]6)2S1J6#QR8') ;(/H'ST!KH5OK1KQK-;J
MW2C<81(-X'KMZUG^*M9F\/>&-0UB&!+AK.%IC$[E0X R1D X/X4 8MU\.K"Z
MT'7-):]N1%J^IG4I7 7<CED;:O'3Y!U]:T+G2(-)U_4O%RB[N;E[%;<VD,>\
ML$)8;0!DL2<>E6;.^UB:2Q::TLA;W W2&.X8O&NPD'!49YV@\_Q5?&I6#31P
MB]MC+(65$$J[F*_> &><=_2@#(\%Z/<Z-X<1+_;_ &A=32WEV%.0)97+LH/M
MD+^%9UEX!^Q2:44UR]:+2)_,L8BD>V.,AE9#A?FRK8W'D8&.^>IBU&QF@,\5
M[;R1!_+\Q)5*[\XVYSUR>E9FN^($L?"NK:QICVMZ]A!+*5$N5RBEBI*YYXZ4
M 5[?P;:6^A:+I*W,QBTJZCN8W.-SLA8@'V^;M6>WP\C,<=F-:OETN"^6_M[(
M+'MBD$OFXW;=S+G=@$\9]A73)JEM'IUK=7MS!;>?&K#S) @)(!P,FK#7EJEP
MEN]S"L[C*1EP&8>PZF@#"\:Z3=:IH22:>@?4-/N8K^UC)P)'C;.S/^TNY?QI
M]MHUM?\ B:T\7@W4,YTW[(+::/855G#_ # C(8$8Q6M)J5A##)-+>VR11-LD
M=I5"HWH3G@TL^H65M:K=3W=O%;MC;+)(%0YZ8).* ,32/"%AX?UW5M;AEGD>
M\R1$1N6 %B[B, 9^9R6(YYQ4?@VPNE_M76]0@>WN]8N_M'D2##Q0JH2)6'9M
MJY([%L=JT=5U*^M+K2Q8VD-U;W4XCG;SMKHAZ,@P0V.2>1P*O_;K/[7]D^U0
M?:?^>/F#?TS]WKTYH Q+CP?:W&C^(M-:YF$>N2R2S,,9C+QHA"_@@//K39O"
M4G]I7%Q8ZU?6-O>21RW=O $'FNJJN0Q&Y-RJH.#SCL>:Z.21(HVDD=411EF8
MX 'J34$>HV,MLMS'>6[P,VQ95E4J6SC .<9SQ0!G6_AFSAFUUY&>:/6I-]Q$
M^, >4L948[$+^M5+#PK<6MO);76OW][;_9&LX8I BB-" -S;0-[@ #<??U-;
M!U?3!$TIU&T$:R>47\]<!_[N<]?;K4EQJ-C:;OM-[;P[=N[S)57&[.,Y/?!Q
M]* ,31O!MIHQT,PW,TG]D64MG%O ^=7*$EL=_P!V.GK1!X=N=+GM1IUY,(7U
M6>^O 2 &642,4Z<@.RXJQ=:W<6_C/3=%$$1MKRTGG\W<=X:,H,8Z8^?]*U$O
MK.6YDMH[J![B,9>)9 64>XZB@#,\1>'?[=;3IHK^:QN]/N/M$$\2*^"59""K
M @@AC5:X\&VESH6N:4UU,(]7N)+B5P!N0OMR%XZ?*.M;2ZE8O TZWMLT*'#2
M"52JGT)SBAM2L$D6-KVV5VD\I5,J@E\ [0,]<$<>] &++X4D&K7-S9ZU?65K
M=SI<W5I"$ DD4*"0^-R!@JA@#SSTR:M^)?#X\1:?!;?;)K.2WNHKJ*>%59E>
M-MR\,"#SZBM*"\M;EI5@N893"VR41R!MC>C8Z'ZTR/4]/FMY;B*^MG@B)$DJ
MS*53ZG.!0!E:=H>LVE]'/=^*[V^@7.ZWEM;=%?((&2B C!YX/:H;3P9:6FD^
M'M/6YG:/1)Q/"Q S(0CIAOP<]/2M>XUK3+6VO+F;4+98K-=URWF@^4.OS>E2
M:=J%MJFGP7MI('AF0.I!!QD9P<=Z .)\3^$I6U2QN+&6\\R]U^*]GEA4$VVV
MU>,-T(VY5?O9&3CO6A=> (-1T+7+#4-3N;BYUHI]JO-B*P"8V*J@8  'ZDU/
M<^)KBZU^]T?1&T^6ZL%A:6.XE(\[>6W(I'W2JIDG!Y.,#K70P7UG=/*EO=P2
MO$<2+'(&*?7'2@#"O_"4DNHRWVF:S=Z9/<6Z6UT841Q*J9VM\P.UP&(R/7IQ
M7/\ BSPS!?Z5HG@K3-/ODBMY(C]L52L=O;@,DF9.C.R%EVCD[\GBN]@OK.Z<
MI;W4$SA0Q6.0,0#D \=N#^596I^(&@UZUT#3X$N-3GA:Y<2/MC@A!V[V(!)R
MQP .ISR,9H ;JGAIKJ^M[_3-2FTJ[AMS:[X(T=7A)!"E6!'!&0>V3US4EGX:
MAL]<M=5^UW4T]OIW]GYG?>77>&WLW4ME?UJ:WO=2CU,VNH6L"6XMVE%Y%(=I
M((!4J1\O!SU.?P-6DU73I+<W"7]JT ;89%F4KN],YQGVH KZQIEUJ"P/9:K<
MZ=/ Q8/$%=7!&"'1@0P[CN"*S]&\'VNC:A:WL=U/--#;SPL9 O[QIIA,[G &
M#N!X' !K=^UVWF2Q_:(M\0W2+O&4'J1VID>HV,UL]Q%>6[P1_?E652J_4YP*
M .9B\"+9RV\VG:Q>6<\9N@\B(C%XYYO-9?F! (;&".?K2Z?X M-/N] F6_N9
M%T-[DVJ.%Y288VL<9.WL>OK74V]S!=P+/;3QS0M]V2)PRGZ$4Z::*WB:6:5(
MHU^\[L% ^I- &3X>\.P>'?[4\B:27^T=0EOY/,Q\K28RHQV&*J3>#;2?0=5T
MDW,PBU&\>[D< ;D9I Y ]LC%;::A922I$EW;M(Z[E02 EEZY SR*Q)/%*1>+
M8M.>2S&F/ITMY]L\[HR2(F"?N@?.>] %*]\ B[-W&FMWL-K->C4(X$2/$5P'
M5]V2,L-RYVGCGZ8O7_@VRU#Q;8>(9IYA-:*H:%<".9E#[&88ZKYCD?7VK5N+
MJ876G"VELC!.Y\SS9"'==A(\K'#'."?;-3?;K4W9LUN8#=A=WD>8-^/7'7%
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MO=J#R)$&%V1XVA<9!&.=QSUJUH/AG^QM3U+4IM1N;Z\U%8A/),JJ,QA@-H4
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M6YO"MM-;^)(3<2@:\")B,?N\PK#\OX+GGO6K+J-E!#'-->6\<4O^K=Y5"O\
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M"KO'U.& P>GUH Y+54N_#VH:#?WZ7GV)XKG[?+8P><8+J9D?<5"L2O#H"!D
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M3%.SP>7+PY.UL@-CG@&HM2@FT'XFIXDF@FETN]TT6,TL,;2&VD63>I8*"0C
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M8W7I@UW/Q @^U?#[7X! 9Y)+&98HUC+LSE#MP!SG.,5TE-DD2)"\CJB#JS'
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M)I\L2;D1?W\B;ACN=N2?4YQ6EIG@&VTN72'BU?4G72?-6U1S'A8W !0X3)'
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MRMD'C*+R,'WJA9>"K&Q@M[)+FX?2[:Z^UV]D^W9$^XL #C<55CN )X..H&*
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M2*<Q@[C&[ *X!]#[]*B\,>.+#6+72+:>29=0O+-90[VKQQ3.$!D$;D;6P<Y
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M:<I+&\A*$*"5#"08)XX.36:MAJ5Q\1+;47T>6SA;PJ\+(B[HX93*&\K<  6
M[#TH Z&V\?>'[S2I-3@GN&LE\H)+]DEQ,TGW4C^7,C9X(7)!X.*LVGC#1KP6
MX2:9)9KO[$(9H'CD2;87V.K %?E!.3QT]:Y&WTO4+'X<>")?[.N6DTB:VN;N
MT2(F4*(W1L)U+*7W8Z\'O5C6M0N=2;2];A\/ZA%9V&M)(Y^RO]HGB\AT,OD[
M=X 9P,$$X&<8H ZB^\6Z+IOV[[7=F(6,\-O<$QMA'E"E!TY!W+SV[UGO\1-
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M#9WCY@<$Y[U)JNAL=:\0V%^OB62+5;M988M-3,$\;1QH=[[2J%2ISN8< 8H
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MG4KO[-&\@)6/",[,0",\(0!D<D4 ;-%<C>:UX@TF;2HK]-/;[9K'V+=$K?/
MR,ROC=\C_+@CYAWK/O?&&M00:B88[!I+3Q!!I:[HW >*3R>3\QPP\T\]..E
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M/^$"UJ8VR6E[JBS1P+&=\8:WF* ONP3MZ\#GITY /1Y9HK>)I9I$CC099W8
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MBA0R]U8DY]!WR.1\$ZS>P>$_#NBV$2F[FLKBY=P@<(J3;<!2Z9R7]> .G.0
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M1NP.1G'.!<TJ]\1R:V8=0L8O[->V\Q;E J%)<\IM$CEE(.0>,8]Z .BHHHH
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M< ,?+5P20I 8CUP2 ?0\4 <])\/M.=)[>+4-2@L9;Q;X6<4J>7','$FY<J6
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M=0VFHVL\MK_KTCE5C%U^]CIT/Y&@!F@Z+;^'M%MM*M))I+>V7;&9B"V,YQD
M5GW?@G1+VWU>":W8IJTZ7%SAL?.FW&WTY7/U9O6IK_Q#;/HNJ7&D7UI/=V=L
MTX4G>!\I920"#M.#@YYIVB:];WVE::UU=VRZA<:?'>20AP&"E5+,%SG:">OO
M0!-?Z%;ZAJFEZ@\T\<FFNSP)&5"DLI0[@0<_*2.HK,E\#:?)9W=F+V_2WN;\
M:@8UD7"2^9YORY4\%QNYSZ=.*V#K>F&PAO4U"V:WGR(95D#+(>?NX/S=#T]#
M6-X5\4#4_#']JZG=6BYN[B!9(?ECD"2NBE02<Y5<]30!)?>#+'4#K?GWE[C6
M84@N@K(/D4$#;\G'!(_&K/\ PC4/]K_VI]NO/M/V'[#G,>/+SG.-GWL\Y_2M
M2SO;74+2.[L[B*XMY!E)8G#*WT(JAI&K-K45S>6H0V:RR06Y/64HQ5GSV7<"
M!QT&>^  )9>';;3_  LGAZ"XNA:QVQMDDW@2HF,##  9 Z'%4;[P58:E:ZG%
M>7=W)+J4,=O<W ,:R-&A)5>$ ZLW.,\]>!B3PSK.H:_X:>]=+:"]%Q<0A5#&
M/,<SH.^>0O7WZ=JT-$U>'7-*BOH5*$LT<D3')BD1BKH?<,"* *NI>%[/5X+Z
M'4)[B=+NU%JP?9^[7J2GR\,3@D^JKZ##1X9@BO\ 3]2^V:A-=V%LUN&,B[KB
M,E6VR<#)RJ\C&>Y.35\ZUI@OQ8F_M_M1W8B\P;B5&6 '<@<D=13+?7]'NQ$;
M?5+.82RM#&8YE;?(HR5&#R0.HH RM L?MNN7?B>YTB;3;JYMX[58;@KYNU"2
M6;:2!DD#KG"#Z"WKND/>7VE:K;*&O-,G:1$)QYD;J4D3)Z$@@CW49P.:D7Q5
MX>>\@M$UO3VN)W,<4:W*%G8'! &>3GCZU9FUG3;:]CLIK^WCN9'")$T@!+$9
M"_4CH.IH I77ANSO;N[NUFN;9K^!8;Q(6"B=0"!NR"0P!(RI!P>O PMUX9LI
MYEEMWFLG%K]B)M2J[H.R'(.,<X(P1DX/-2?\)1H!N([<:S8&:28VZ(+A26EX
M^0<]>1Q[U:.K:>M\MD;R$7+-L6+>-Q;;NV_7;SCKCF@#*U+P]%>Q:1I$$"P:
M58313LHZ$1<QQ@?[P4D^BX[\6]>\/6GB""V6>6>WGM9Q<6US;L%DAD&1D$@@
MY!(((((/2K":SILFH#3TO[<W9W8A$@W';]X =R.X[=Z34-:TO261=1U&UM&D
M5F19I50L%!9B 3T !)H PI/ -C*;J1]2U,W-Q>17QN/-0.DT:A591LV]!@@@
MCV%.;2U\+07IT_3]2UEM6NB\\)E1E1V3!9MQ7"G:,]<9X&.*V'\0Z.@MRVIV
M@6Y"-"QE&'#_ '"#_M=O7M4"ZU:P7NK/=ZSIHM+,1[D#!6M20<^:Q;')'' Z
M=Z (-,\+0Z9X:TK2+:YGM?L&UEDMR,E\'=]X$$$LW!]:T=)TBVT:UEAMMQ\Z
M9[B5VQEY'.68X 'Y"JS>*_#ZFX#:U8 VZAY@9UR@/ )Y]>/K65J'C&"P\2:6
MLFHZ>N@WFGSW7VIFP,HT84A]VT@^9Z4 6/\ A"--?3+^PFN+R:.\O#?%V=0\
M4Y8,'0JHP00".M6)O"UK=6NI1W5U=3SZC;?9)[IB@D\G##8N%"@?.QZ=6/MB
M]#K6EW!LQ#J-K)]M4M:[)E/G@#)*<_-@ GCTJ)_$FAQPK*^L6*QM(T*L;A0"
MZ_>7KU'<=J *\?A:T2_TR\-U=.^G6KVD2N4*M&VW=N&WDG8OIT^M1:=X/T_3
M4LH$GNI;*PE,UG:2LIC@8@@8.W<0 S8#$XS[#%Z/Q'HLT=O)%JEHZ7 0Q,LH
M(?>=JX/N>!ZFI9-9TV*_2QDO[=+IVV+$T@#%L9V_7'..N* *MSX7TJ\U*_OY
MX-\U]9"QGR>&B^;(QZG=C/H!45UX4L;G0=/T82W$-K8O#)$8F7<6B(9"Q(.>
M5!/K4Y\4: )DA_MJP\QYOLZK]H7)DX^3KUY''O4UGKNDZA'<R6>IVD\=J<3M
M',I$7&?F.>..: ,N]\%6-_'KL<UY>[-;"B["L@X50@"_)Q\H K U?2M0E\53
MRNOB2(+%#%:W.FO;NDJJ"26$@^1MS,.@& #WXZ\^)-$%K<73:M9K!;L$F=IE
M41L>0&ST)[>M0W7BW0;;3]3O?[3MI8M-4M="&0.T?!P"!W.#B@"1-+DU#PL^
ME:U*T[7-LUO<N,*S*P*G)4 ;L'D@ 9Z"JT'A2""^TV]_M"_DGT^WDMHFD9#N
M5]NXM\G7Y%Z8Z?7.M87T&I6$-Y;NKQ2J&!5@1],^U<]>>*U'C#0M+L+RRFMK
MPW N /F<>7&6!5@<8R,'@].M $9^'FFK8:?;P:AJ=M/I\DLEM>03*LR"5MSK
MG;M*DGH0:Z2TL4LM/6TAEFPH/[UVWN6)R6).<DDDU1T_6;<Z<UU<ZM87,;7,
MD<4UMPA 8X3J=S #G'H>*6?Q3X?MH1+/K6GQQF(S!FN%&8\@;ASTR0,^IH S
M]/\ !<>EZ+_8]IK>JQV/S_(&AW?.Q9OF\O<,ECT.1GC%6)_"5G/<:Q+]JNT_
MM:V2UG1"@58U#* GR\<.P[]?I6C#K6EW!M!#J-K(;U2]L%F4^<H&24Y^; !/
M%4+[QAH=BEFS:A!(MW=?9(VCD#*'&=P)Z#;@YS]* ,_5_"D,>G+<PSWTUS8:
M7-8VT8V'>KJ!@@+DDE4YXZ?6G>%/#WDZ)H$]_)=O>6%BL,<5P%'V9R@5\ *,
MG@J"<\9]3G=EUK3(+R.SEO[=+B5@B1M( 68C(7ZD<@=33AJVGM?"R%Y";EF*
MB+>-Q8#) ]2!R1VH Q(O ^G0:=9VD5U>+)8W4EW:W09/-AD=F9\';@J=[9!!
M&#[#%B>$>'+.:6TTN]U>YO[D&Y,9C\QV*[0S[BJA0%5>.@QQUJ[J-[]GU#3;
M==0L[=IYB&@G&9)U",=L?(Y!P<X/ -1CQ1H#7,=NNLV#32S&!$%PI+2#JHYZ
M\CCUXH S;;P/IG_"#6_AFXC*0QJKEK=RK1RAM^]&Z@ANGL *?+X+MKG17TV[
MU35+DR2Q2R74TJM*QC8.@SMP &&< #OGJ:W+[4;+3(!/?W<%K$SA \T@12QZ
M#)[FHO[9TOS;N+^T+7S+-=URGFKF$8SEQ_",>M %U00H!)8@=3U-8L'AFVCU
M"TO)KJZN6LY)9;59BA$+2 AL$*"1AB "3Q]!C,A\96]MXFUJUU;4=/M]-MH;
M22TF9O+W>:),Y8MAON#D8XK<%]O\1BR34;(J+4R-9CF?.X 29W<)@XZ=2.:
M*VH^&;>_URWUF*[N['4(8C 9K5E'FQ$YV.&5@1GD< C/!K+'PZTR/3=,M;:_
MU.UFTPO]EO(9P)E5SET)*X*GT([5J7WB&T;3]0_LN_LY;ZWM7N%C+;QA0><
M@E<C&0>M1^&/$UGKFF:>K7UH^JR6,-U<6T4@W)N123MSD#)_44 /_P"$7M/M
MNDW8NKL2:9YABRX;S&D&'9R022<GN.M2Z9X<L]-L]0M!)-<PW\\L\ZW!4Y:3
M[X& .#GI2ZEXCTW2]7T_2[FX5+J^+^4K'  5223^. /4GV-9/AOQ?#>/<6>K
MW]A%J U*YL[>%&\LRK&Y4$*6)R0#W]: +DW@S29O"5OX;(G6SMU3R94D*S1N
MARL@<='SSGU)J*3P9;3Z=#:W.J:G<217,5U]JEE1I6>-MR DK@*",X '?/4U
MKR:SIL5^EC)?VZ73ML6)I &+8SM^N.<=<<UE>-M<O?#GAUM2L5MWD2>&(I.C
M,"))%3/##INS^% $7B:R/B&:+P[/H\\UFSPW$E\Y01*$?<5'S;MYVXX&/F]*
MZ2:"*XMY+>:-7AD0HZ,,AE(P0?;%9L4NIVU_B^O=.DM%A9Y3'"T+QG(VD[I&
M&W ;/3H*;'XK\/2R(D>MZ>S/$9E N%Y0<EASTQS].: (=-\)V>F_8$%S=W$.
MG!A8Q7#*PMP5*\$*"<*2H+$X!JSHNA0Z']M\BYN9A>7+W4@F*G$CXW8PHP..
ME">)M">SAO%UBQ^SSN4BE-PH5V'4 YY(P<CM61XA\711^"+[7O#E]87OV=E7
M>#YJ9W $?*PP<'/]* -$^&;:2]@N+BZNKA+>[>\@AE*%8I&W="%#8&]L GO6
M>G@'3XVMPNH:D(+;4#J%M;B50D,A+%@/ER5)=CR21V(YSO7VL:;IK!;Z^M[<
MXW?O9 N%SC)ST&>,GBG?VI8'4AIOVVW^W&/S1;>8/,*?WMO7'O0!CZ=X,L=*
MU*:YM;R_6UDG:X&GF8&V25CDLJXSUYQG:#SCI48\$6(LEM?MU_L74O[4!W1Y
M\_?YG]SIN.<5K2Z_I$-J;F34K58 SJ7\T8RAPX_X">OIWIUUK>EV-M'<W.H6
MT4$B>8DC2C:R<?,#_=Y'/3F@"/6-#@UI[!IY[B(V-TMU%Y149=00,Y!R,,>/
M>LV;P1IMP+XR7%X9+J^34!*'4-!<( JO&0O& H&#D$9SU-="T\*VYN&E00A=
MYD+#:%QG.>F,=ZJVFL:;?+,;6^MY1  TNUQ\@(R"?0$<@]#0!G7?A#3[_3M3
MM;R:YFDU)46XN2RK*0GW,84*-IY QU)SG)IY\+6DFJIJ%Q<W5S*+)[%TF*%)
M8F(+;AMZD@=,#L !Q2:CXPT/3M&U#4VOX98K&/?*L3AFY&5&/]KL>AJY)KVD
MQ1I))J-LJ.H96,@Q@G .?0D$>YXH RM+\#Z=IMA+I\EU?W]@T+6\=K>S[TAB
M88**  <8XR22!P".:=I?@Z#2K":TCUC5YE:!K>!Y[D,]JA&/W9P,$8&"<D8%
M:FN7GV#1;NY^WVE@R1G9<WG^JC;L6Y&1^-17?B71--+I?ZQ8P2Q(KRJ\RJ5!
MZ$@G(![4 :-O#]GMHH?,DE\M GF2'+-@8R3W)[U)38Y$FB26)U>-P&5E.0P/
M0@^E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KD_'^CRZYIFE6:6TEQ%_:UJ]PL9((B#_.V000
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M;2O,'$A1<MM95VY X[TRRL]7TVPTJ_DT/5'M;34]1-S:6^4G"32LT<J*K L
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MI9N6 !VY/4#M67;^$HY/#=OX>O9;H6=BRBVEMKEHF>-3^[#%2#E1@>A(!]@
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MN['RD$CD9 Y/>M#Q9X9DFT);72[2XNKB?4[:[NI1,JR.$D0LQ9F7D*@  Z8
M&*VIO"VEWME?V]_ UV-114NFG;+NJ_=&1C;MZC;C!R>I)H YK7=8\6:'HVKW
M1: 1Q2VQLI+E$:5E>14D5UC.W@L"&QWY'>I+B+7(?'V@6=WKK3)+;WLQ$-LL
M:_*T6T8.[) <C.?YG.N/ ^DG19M+FEU"XAF9#))/>222L$.Y%WDY"@\@#'ZF
MM&]T*RO[_3[^<3-=6 <0R),R$AL;E;:0&!VKD'CB@#F],U[59Y9]"NKI1KEO
MJ?DR.L2A3;8\Q9 O8&,;<\X<^G%2^/XYW;PV(;IX0VM6ZD*H.3\Q!Y';'2K^
MAV-S=ZQ/XBU328].OY+9+1(O-65UC5F8DLO')(X]%'K@:.K:)::T;,W33#['
M<+<P^7)MQ(N=K'UQD\'CF@#E+CQ#J;Z/XIU/39HHO[!N)8Q;O$NVY,4:O(9#
MU!;) VXQP3GI4]AK.NZWXKFM;6^M[2PCL[*^$;VN]RLI?=&3NZD)U[<<=:VK
MCPGI=S=7L[+,HOU47L*2$1W.!@;U]<<'&,C@Y%6H-#M+;7+C6(S*+JXB2&3Y
M_D*)DJ-O08W-^9H Q=:O]<?QI9Z'IU_;6D%SIT]P9'MO,='1XU!&6 /W^G\Z
MQ]&\8:QJJV&DSH8]38WJ7$]JJ?.UM*L>4$AV\[LGKC!&.<C7U72+^]^(>F:A
M'%=16=OI\\+74,L8VN[QD#:3DC"M_"><?46[[P3HE]86-J8I[<V+M);7%M.\
M<T3-]\B0')+9.<YSG)H PGU3Q@U]H&DSW=A97M]!>"XD2#S@K1;=C@;L<A@2
MO8YY-6(_$U[:^*DTO5YY;1S.RP!K8?9[V(1D_NW&<2;N2I/08 /6MU/"^G1W
MNFW:?:!+IRR+ 3,S?ZS[Y;.2Y;').3WZT\>'+(W:3NT\JI<F\CADDW1I,<_.
M!U'WCQG&3G&>: .6@\6ZH^@>'?$OF)):ZM>0P36008B29MJ%&'.Y3MSG(/.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTVY@NB7C.QW\O;T;)SL/3IWH [>/Q)I,UC;7L%WYT%TC20F&-I"RKC<VU02
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M!V,3W)'-;=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<J9VNH89]",T /HHHH **** "BBJ!U6)+J^BGAN((K.-99+J:/;"RD$G:W?
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MX$!MO^$ATX32O;66KR0VRS2LYC0QQOM!8DX!9L?6MV'0-+MX-,ABLU6/2_\
MCS7<?W/R%..>?E8CG/6JUWX7T^XEBDBC6%QJ2:E(PR2\JKMSUXR !Z8[9YH
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M_P#PD4WAF[T[7]3N))+#6-#624,QVK=PQ>9P.@+H6&!U*"NL_P"$'\-YM?\
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M$ZVTG "LV[&,G(4XP.>O2L2T\)WM]\/-&\(ZI9M#$EJJ7<Z.C&-XP-FSGJ6
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MZ22+X<:^([F=)(M-F82JV')6,GDCUQS0!JOK=BFMVVD&1_M=S"\\0$;;612
M3NQC^(<9[UH5YY<6,DWBWPA:I?W,1;2+S,Z%3)C-OP"00/KCI^=5M#\2:MJU
MMX>TN>[S/>6MXSSF;R'G>&81J P0\[<L0 ,X],@@'I9. 2<\>@S6%#XQT:XC
MNG@>]E6UE>&<QZ?<-Y;I]Y3A.HJSX<744T*WBU:]@O;Z,O'+<0#"N58CT'.
M >!R#7'>$(=9EB\5_P!FWEI"/^$AN_EEMV9C\RYPV\ 9'3Y3@^M 'H<4B31)
M+&VY'4,I]0>E/KB[J6\U'QT-+M-:N;;39M&^T1BU$8VMYH4,K%3QCZ^V*QM
MUG6KJ#P-J%SK%Q(^M1R0W46R,1\0.X=1MX;<@.>0<GC&  #TVJ&F:S9ZN]ZM
MFTC&RN#:S!XV0B0*K$8(!(PPYKSG2=4\1+HGA+7Y-<N;M[^_2SNK22.,1O&[
MNNX!5!#+C=G..#P!Q4R:Q<:1)KXMW,1O?%L5D\X /DI)%""W/&<< GH6% 'I
M]%</,=;DU_7O#5EJDZ#^SHKRQNVVL]M*S.FQB0=RDIGG)QGGIC.;QE>7'A2X
MUVV>6)M+T\QWD+\A;LMM8/QG]WM9CZAU- 'I-%><^(9_$.D>']>U&#7$6W_L
MIKFU5)A/(LJ<EU8Q@;&!7(QP>F,UVNCV=Q:6KFYU&YOGF?S=TX0>7E1\J[0/
MER"1G)YZT :-9.J^(]/T=W2X,SM%&LLRP0M(8HV8J'8*"0,@_D?0UQ1\2:M-
MX*C\6P74OVM-3\E[# V&/[3Y/D[<9#8(.[KN]N*U]+M6'Q8\02?:IR%L+-MA
M8;3EI^.G0=J .R9U7 9@"W 'KWXJEI.LV>MVTUQ8L[1Q3R6[[XV0AT;:PPP!
MX((KG=>BD?XE>%@+NXCC:VO&,:/A25$6#C'^T1]*YFPN+_3('U"UU&>-7\8S
M6KVP"^6\<ET4;=D9)YR#GC ]\@'J]4-9UJP\/Z;)J.IS-#:1XWR")W"Y.!D*
M">I%<A8:CKFN.VI6FHV]J+36);:XAEFROE)*8_*,>SAV7:P.[.6'8XJU\6?^
M27ZYC_GG'_Z,2@#HX-<LKB\BM5%VDLN=@FLYH@V!DC<R@9QVS6C6/''JD>I(
M=0O[-[9XV2(0VYB82DC!^9WS\N[TQSG/;A+#4]>DT/POJ+Z_=M/?:M+83@QQ
M;&C+SC.-OWAL7!Z<=,<4 >CW.D:=>W]K?75C;S7=IDV\TD89HL]=I/3I3=8U
M>TT+2;G4[]G6UMD+R,D;.0![*":\]N=7URUCO+&+6KG=:^)[6Q2>1(V=H91$
MQ5OEYP7;&,'M4/B*;5+31/B!H=YJ,^HVEOI2W-O/<*OF1^8L@:-BH /*9''
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M1@2>&^]R>.AS6C;>+[^^TI9K/06>_6\EL[B![D+%;O'G<6EVGY3@8PO.1P*
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M14+2>=MR<J>QH@U#4_#_ (EF\/ZGJ$VJ65SITMY9W,H5)T,9 >-F0 'A@0V
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MWRY#E6!*X;@@_>R.:](K&M/$^G7WB>^\/V[2/>642RSL%^1=W\.<\L,C(]Z
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M3SR7&YL'#Q%1M'?DU@W?A77VT;5O"T$-H=+U*\EE%^UP0\,,LGF.ICV\L,L
M<X.03C%>A"1&;:KJ3C. >U9'B7Q/IWA335OM1:38\JQ1QQ+N=V/H,CH,D^P-
M $&AZ+=:=XE\27\WE^1J,\$D&ULG"0JAR.W(-,\5:'?ZA-IFJZ/+ FJZ7,TD
M*W&1',CKMDC8C)&1C!P<$"KVH:Y%9:OIVE)"\]Y?,Q"(0/+B4?/(Q[ 9 ]RP
M%&@:[!X@TBWU")#%Y^\K$[ L KE2?S% &/Y7C+69)/M*VFAVRV\J"*"X^T22
MRLI56+;%V*I.>.21V%<UI_@34XYK(KHNDZ8@TRXTVZ:VEW22-(B_OF;8-_*=
M#SR3GG%=[HVN1:N]] 87M[RQG,%Q Y!*GJK ]U92&!]_4&M-G1"H9E!8X4$]
M?I0!P6G:'XIEO/"[WMKI]I'HD,D+%;@R^<Q@,8<#:N%SCC.>3TQSG3> M2U9
M-15]*TS1?M5DT<\=M.9(+RXWHZ2-'M 504;)^\0Y':N[T_78+_4=4LPAB?3[
MI;9F=AB1C&DG'X.!^%:;2(KJC.H9ON@GD_2@#EO">A'3+NZN3X8T71 \:QJM
MCAI)#DEBS!5&W[N!C/!)]*-2T[7+7QH=:TJTM;N*XT];*19[@Q>2RR,ZO]T[
ME^<Y YXJ6Y\9VUMJ7B.R:TE+:'9+>2L&&)59&;"^A^7O6QHVI)K.AV&J1QM'
M'>6\=PJ,<E0ZA@#^= ')^$/".IZ'>:)+>- PLM(FLY2C=9&F1P0,=,*:JZ?X
M6U[0;K3M4L[:UO+F"34(I[9KCRPT4]QYJ,K;3R,#(QW/I77VVNP7&O:EI10Q
MO8I S2.P"OYH8@#Z;?UK3:1$QO=5W' R<9/I0!YD? 6I2VL-WJ>FZ7JEU%JM
MW>26,K9ADCG[*S*<,I"D9'.#TS6M9>$[N&^\,74>FZ7IL=A=W,]Q:V/RHBR1
M,B <#<W*Y.!WQ7<UGZUJT.B:-?:C*/,%I;27)B5@&=44L0/RH 37;@VNAWDJ
M:E;:;)Y9$5W<E?+B<\*6W<8SCBO/I]>B\0ZIHSZM>>%; :;=+<O=PZQ',\FT
M$;(Q@%58GG)Z<8->EP74<UO!*2$\] RJQY.1G%2ET5U0LH9ONJ3R?I0!Y!X:
ML_#&CW%I92+X*$5IYBMJZWD)N)DPP0J, J_(W$DC@XSGC4\,^(&TJVTO0[C7
M_#,>F:;$87NTU.-WNHU4K& G&P_=+$D],#K7I321J0&=02=H!/4^E*KHS,JL
MI*G# 'I]: /&+)8/^$=\(:7<ZYX<B?0=6BGDD75HV$T*!_F XP?F'RG\ZMWM
MQ;G2=:\,6VN^'&TS5;N687[:K&&@BF??(IC_ (F!+ <X.1G&*]<1TD!*,K '
M!*G/-9G]N0'Q)!HR(7>:SDNQ,K J CJA'UR_Z4 <:U[HGF^,2OB30]NK0I':
M_P#$PCZBW$?S<\?-6BFI>%;OP5#H%_XGTM%:Q2UG,&HQ@\(%8 YZ'!'TKMN*
M:CI(@:-E=3T*G(H \RLH/#UEXS@U(>.8)[**P:WVS:M$26+#"X&/DQS]0*R]
M'U+3)_AWI&G1Z]H\6K>'K]2D=S>I&DYA=@/FR?E>,\, 1D^U>KW^IV>EK;F\
MF$0N)TMXL@G<[' '%2K#:1WCRI' MU,H#N% >15Z9/4@9/TS0!YOK7CB-O!?
MB&2_U70Q<W4+6]A86E_',R%UV#<XQG+-D\84#KUKK;:S%W\/5TS1]2A=O[--
MG;WD$@9 XCV!@R^A';TK:FAM)IX7FC@>6%BT3.H+(<8)7/0X/;L:E\V/+#S$
MRHRPW#@>IH \N3P-JP$S6F@Z/IBW&AW6ER16\PW>8ZJ5E=@@WY9<8/(SG)R0
M.BU;PG=:J="A9XTAM=/N;2Y8-R#+"L8*COR#72W=[/"]G]FLVNXYY0DCI*BB
M)"#\YR?F'L,GFK9EC#*I=0S$@#/)Q0!P.GZ'XIFO?":ZC:6$%OH3D3/%<F0W
M'[AX@ZC:-HY'!Y^;VYW/%&E:C<7^BZOI44-Q=:7<.YMYI/+$L<D;(P#8.&&0
M1D8XKHC(@D$9==Y&0N><?2LV36X9(]333D-]>:>P26V1@A+E%<*&;"]&'.<4
M <:?"7B&>34-4F2R743K,&JVUN)B8V"0K&8F?;D';N&['7!Q3M5\&ZKXF.K:
MEJ5I8PW4ZVB6MC)+YL92"4RE96VX.\LRG .!ZUWZ3@0123@0LX&4=AP3VST)
M^E/>1$!+NJ@#)).,"@#A;;PW=6^DWZVW@WPU:I<R1K)IJX_TB)0=V]PH7=DY
M7Y2!@^O&UX,T>ZT32)[>YB2W22Y>6WLTG,RVL9 Q&&(&>06]!NP.E=""" 00
M0>A%&1DC(R.M '#3>$M2D\&:KI2F#[3=:Q)>Q_/\OEF[$PR<==HZ>M5[[PQX
M@&G>(/#UE#9OI^M7,TPOGG*M;I.<R@Q[3N();;@X.1G&*] +C;D$'/3GK65!
MKT:V^F_VG"=.O-0D:**U=UD;>%9L;D)7[J$YSCH.M &9I>C:CI/CK5+N.WAD
MTO4+>V02^=AX6A1EP4Q\V<CG-6I=&NG^(5KK8\O[)%I<MHWS?-O:6-AQZ84U
M;TC78-7-Z%0Q-:WLMGAV&79,9(]N:TVD175&=0S?=4GD_2@#SW3? S:=KF/^
M$:T&XC&HR7:ZM.H:<1M(9 NW;GS%)VAMV, 'VJ2#PKJESXC^VS:9IVENT<\=
M[>6,[8OPZ%5S%@<@D,2Q)!7 )SFN_P CGD<=?:JG]J67]K#2_/7[88/M CP?
M]7G;G/3K0!Q.D>'_ !-YG@^"_M+&"V\/DQR/'<F1K@"W>(.HVC:.1P>>>V.:
MEKX*U[3O"FFV\45K/?6&OMJ?DF<JLD99_E#;3@X<=NU>ERRQPQ/+*ZI&BEF9
MC@*!U)-<?_PL?3A:C4#I.M#1CS_:AM!Y&W^_C=OV?[6W&.: -W7[*YU;PGJE
MA$J)=7=C+"JLWRAW0@ G'3)ZXK!T_P +ZA;7?@B60P[=%TV6UNL/_&T42C;Q
MR,H?2NO$\3>7ME0^8,IAA\P]1ZT_<.>1QU]J ."O_#OB&"W\2:/IMO9RV6NS
M22K=RSE6M?-0)("FT[L8)7!YS@XK0MO"]U9ZEKSQ&,VUWI=M96V6^;=&LJG=
MQQ]]?UKK#(@95+J&;[HSR?I1YB>9Y>]=^,[<\X]<4 <A8^&=0M_^$'WF'_B2
MVS176'_B-OY?R\<_-].*M>+-*U.[U+P_J>EV\-S+IEV\KP2S>5O5XGC.&P>1
MN!Z5T])N7 .1@].>M '#7GA+4I_"'BC2T,'VC4[^:X@R_P NQF4C)QP?E-5;
MSP,W_"1:E./#6@ZG'J%VMRM]?J"]N"%#J5VDM]TE<,.6YQBO0O-CWA-Z[B,@
M9Y-9GB#78/#^C76HRH91;JK-$C ,06"_UH K>,-&N=<\.R6UBT:WD4T-S;^:
M2$+Q2+( Q'0';C/O7,:GX4U[Q5?:K<ZG;V5A'=Z0+*"$3&?9(LOF N=HR">H
M'8>]>AF1 X0NH=N0N>31YB!@N]=Q. ,\F@#SE_!MY/HFJ16?AC0=%FFBB01V
MCX:Y"R!Y$:14&U&5=H&">23Z55N? FKW%AXGM[32=)TR+5[&!8+>V<*L,L3L
M=K;4 .X-G<!QTYQFO2-2U&UTC3;G4;Z416MM&TLKD$[5 R>!R?H*IKK]LWB)
M](VX*627GGE@$VL[(!]<K^M %#2=-U-O%EUKE_;0VPN=-@MS"DWF%'225CS@
M9&'7GZT_POH$VF^ K'0=0*^;':?9YC$V1R"#@_C6M/=W$6HV=O'9/+!.',MP
M)% AP,C*DY;=TX!QWJTKHS,JLI*\, >GUH X*P\.>(9;3PWHNHP6<5CH<T4K
M7D4Y9KD0J5C 3:-N?E+9/&"!G-;_ (-T:ZT+0Y+.\\OS6O;F<>6V1MDF=U_'
M#"I]:\1PZ/=6MFME>7]]<J[Q6MFBLY1<;F)9E50"RC)(Y(J71=>MM;LYYXXK
MBU>WE:&X@NDV20N #AN2.A!R"00>M &#J^FZ_;>/H_$&DZ=:7T)TO[$T<UX8
M"K>;OS]QLC&/SHM/#NLW^K7NO:ZUI'>M8O965G:NSQVZ-RQ9R 69B%Y   '>
MNP\Q!'YF]=F,[L\8]<U5N]5L;&6RBN+A4>]E\FW'7>VUG[>RDYZ4 <#;^#]4
MM?!&AZ'>Z#I6L+:6Q219+@Q/#-G(>.3:>,=<8(XZU2U'X?:Y>V5[9W=OIFJW
M5SI<-K%JEZY9K5TBVOM4J3EF^;<"#ELGI@^EVEW<7%S>1S63V\<,@6*1I%83
M#&=P .5],'!JRDL<B;TD5D_O Y% '!+I7BVRO]<O+73K"4ZM;V\:QO>%?L\B
M1;"Q.P[ER>V#P/7B?2/!=YI'BKP_=))%)8Z9H7]FN^<,T@*\@>AP>]=NLB.S
M*KJ2IPP!Z?6G4 >7V'@'6;;P1X1TAS;?:M*UU-0N,2';Y0ED8[3CDX<<5O66
MC7%AJ_BM-6AM#H6K/YYN6N,$ Q)&T;*1Q]UCG/I6SI'B?3=;U/5K&R=V?2Y%
MBGD*X0L<YVG/."K ^X-1Z?J.G>+-#EN;BRCDTJ24K%]K562X16XDVG@*6&1G
MT![T <Y\*M.N1HTVKWL_VF2XV6EI/@C?:092)N>?F.Y_?<*U]5TW5[/Q:OB#
M2;2"^\VQ%E/;2S^21M<NCJVT@_>8$?0T2^,K.Q%X7LY(['3M033[B92-L(9$
M99,?W,R*I].O2NIH \]_X0C5$T[PQ&9+=[FSUMM5OV5B%^<R,P3(YP9 !G&<
M9KI_&&D3Z_X.U?2;5D6XN[5XHS(<+N(XS[5MUST'C/2;CQA-X80S?;HD)\PI
M^Z9@JLR*V>6"NI(QT- %?1]+U5O%":UJ%K!:[M)2S>&.?S2LBRLW7 R-I!_2
MN5A^'MU9P:7/=:%I.N2P6DMK+:W;@!"9FD1T9D8?QD$8!Y&,XKU%Y(XP2[JH
M'4L<4N03C(SZ4 4M&LCIVBV=HT%I;O%$ \5FFR%6[A!V7.<5>I 0<X(..#2T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX[R=;2(27,;$K,VT9<$]0>OXUP&K74%MHGQ72>9(W.\!6;!.^RC5?S/ KU
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MBIK?P7K7A\Z5>:%-87%U!#-#>P7A9(IA+*92R,H8J5<G'!R#0!JVWC_3+_\
ML\:;9ZA?-J%F]W;+#&HW*C!64EF 5@6QR0..O3-BU\::??VFGS65O=7$E_;2
M7,5NH19-J$!P0S 9!8# )_*HAHFL'Q5IFKRM92+;6$]O*%=D)>1T8;1M/RC9
MCDYYS6#'X#OY/"MAHVH6>FW+6J3&.XCNI(Y;>5G+(\;A,C@\CV'7I0!T0US3
MAXG<327\$B:3]K<2OBW6'=RQ7/WP<@G'05-;^*[2:]L;62UO+9M0B:6R:9%
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M/)QLV-Z;U)2UK/;/%(8V28+D\ Y&TD$8([U7UZREU'1Y;2.UL[H2L@D@O/\
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M.:W=G,\@B,2,5*C:,,6(R><#I0!H6/C"SO[JVMTL[Z-KNUDN[4R1J//C0@'
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M,]\"L"Q\87M^+9X_!^NK!<;2LSFWVA6QACB7.,'/3-7?&O\ R(?B+_L&7/\
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MO':S/#,VX *R'!_#(/->7Z+83W=Y;75Q=:%;7R^()3)(ZM]M=A,X:(G/1H^
M.FW%48;6UAT&2WLH=+B#>+YXKQ9T B\I9)?*64+@[-^P 'CD4 >U+=6[0I,L
M\1B?[CAQAOH>]1MJ%DL(F:\MQ$5#!S(-N"< YSTS7DNH:/&;.SLI[C39[2Y\
M5VPDM=.#"&$F+$D?/][J0/[YKI)/#^CW7Q0:RGTVT>S@T",16S1+Y29GD'"8
MP#@D=.,GUH [H75NT_D+/$9MN_RPXW;?7'7%5-.U&2ZM#->01V;^:Z!/M"R
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MI(4%V"@GTYIK75NBEGN(E4;LDN /EZ_EWKB]?CTVX^)>FPZ\EJ]@-)N'MTO
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MHHH **** "BBB@ HHHH **** "HKBV@N[=[>YACFAD&'CE4,K#T(/!J6N?\
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M8W';G+!=PW$#CG&<&ID\56IU35;"6WFA;3K5;LR2,FR:)@V'0AN1\I!SC!H
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M/!/B!H_!7AJWF:>^U2^MW=%:3+,$/S.S,>@RHSR<L*T&\=V*Z?#>?8KS;_:
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MTN5E29?O!""DJ@]LHS >^#VK>HH YO0O"RZ!J>KW5M(K07,IDM+;[JV^X R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:QW0,P!1%#^6;:-CTYVEN?3-:.C6^F7OB'3(=>BM9K9/#%JUG'>*K1Y);SB
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MST5BP'X_(>/IZU92ZMY$D>.XB98R0[*X(4CKGTKRSQ';PV_BOQW<6<$":H-
MBDMI%11+O*SAV0]=V ,D<\"J=YIJ6OA_7I[:XT"*%_"]ROV72@P,J;08Y7SU
MQ\P!ZG<: /7Q=6YW8N(CM;:?G'!QG'UQS31?6C+$PNH"LQVQD2##GT'K7G.H
M>']*AL/ =DEC"(+C44DN%V#]^QM926D_ODXYSG/>L75M!TJ#PW\2)HK"W22R
MNR;0B,#[.1#%)F/^Y\S$\8S0!ZU%?S-J5];S6R0VUNJ,EP9U/F9!)RO5<>_6
MK4=Q!+))''-&[QG#JK E?J.U>/ZZ2=3^+1/7^Q[4_P#D!ZTO$%OI?A36;*\M
M=.58CX>U!KI+<^6]R$$+#<XYW<M\W49)H ]&GU6QM[&YO'NX?L]LK-,ZN"$P
M,G.._M1;ZI8W.F0ZBES&+25%=9'8*,$9&<]#STKQ^>SM[>37].,.AK&_A29S
M;Z;&?+W(04W$D[W7.0V >0>XK1EM8I5\#6ME#HIL6TV:017B9MWN-D7)"\%]
MID(SZM0!ZT"" 0<@]"*6N=\#6QL_"5K +RVNXTDE\J2U),03S&VHI/)"CY1[
M+714 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 445QWQ!FN88?#KVD8EG_ +;@"1L^Q6)5\;CS@>O!
MX[&@#L:*\R\4^*[F#PAXKM]>TFRNIM):UWQ12N(9TE="ISPP(.?R]ZW[CQ3J
M+>+[C1K*#3B+5H0\%Q<F.XG1P"TD2XP54$CW*D<4 ==17-^*O$QT*;3K.%[&
M*YOW<+-?S>5#&B+EB3U)Y4 #U]JQX?'E]?PZ-%I]E937M_=W-E(1<%H4>%6)
M=7 ^9"%W#C."!0!WE%>='QUXAATN_P!0N-*T\0:3?_8K_;.^93O52T0QP '4
M_-U.1VR9[WQKKL5OX@U"VTJR?3M"NI(KC?.PEF1%5F* # (5L\]>G% '?45Y
MG<:Y!I7Q0U_5Y6=[2V\,QW153]X!V/'N:V8?$GB*WO=/M-3T[3TEU:"5K(03
M.?+F2/S!')D#.0#\P_NGB@#LZ*XZ#QN][H'AR[L[16OM8N4MC;.Q_<LNXSD]
M_D"/^('K67'X\\02:=I^JKHUBUE>:@VG)']H82&3S'C5\[<!=RC/4XR?:@#T
M6BN"N/'=_I::G9ZI;:>FI6MY;VL3K.4MF\]=RLS,,J% 8G_=XZTP?$&[^RM#
M#;Z=?:@FIP6!-I<[H)!*NY7#8)'H1SC!Z\4 >@45YIXE\7>)+3PYXFM_+L;?
M5-+^SGSX'<HT4W *Y&0P((YX[UL_$"2\C^&6HR72Q_:U2(NMNQVY\U.%)P?S
MH [*L6'0FM/%=SK%K,JPWT*I>V[+G?(G"2*>QVY4CN OIS@7OC;4O#]SJ46O
M6%F#!IQU"#[).Q!PX3RV+ <[F7YNG)XJG/\ $:XL=-UIYQI%[=V%@+Z,Z==&
M6)UW;61CU# X^H(Z4 =;/H45KI5[;^'X++2KJZ4CSX;95VL>-Y"XW, 21GO5
MO1]*M=#T>TTNR4K;6L0C3)R2!W)[D]2?4URFH>+]6TYM/L[U-&L;^_$LZ&ZN
MF6&&! F Y(&Z0EP,#C@GM5C0/&QUW4-)MTMHE6\M+J65DEWA)()4B(4]&4EB
M0?3'K0!V%%<-_P )MJ5Q)8V]EIUN]S>:I>Z>OF2E500%\.2 3T3)'X"F)XVU
M9D_LW[!9G73JS:8 )6\CY8A,9>F[&P_=ZY[T =Y17ET'B:]T'5_%=QJ$-I'?
MRZA96D:O<%;<.T*X<N1D)M!8\9XQ[U>D^(MU%ITOE6VGW]_#J=O8'['<[H9A
M-C8RMV/."#G!!H [VZCFEMG2WG$$I'RR%-^W\.]8HT35EN7N5UF 7#J$:4:>
MFYE'(!.<X&3Q[T:Q/KD'@B]G/V*/5DM9&8QN_E*0"25.-V<=..M<-X%O=3TK
MPQX=T[3['3WU+6K<WGGR32%?+1%+22\9+DNHP..>O% '97'A>[N[V&]N=0LI
MKN#_ %4\FEQL\?\ NL3D?A4ZZ%JJ-.RZQ;JTYS,1IR R'&/FYYX '/:L&Y\>
M:G#801II5N^K?VW_ &--#YQ$0<QLZNK8SM(V'D9 )ZD<]1?7NIZ?X:>[>WM)
M=1CB!>,3^7 &X!.]NBCD\\X'K0!370-206P35K91:C%OC38QY0QMPO/R\<<=
MJ8WAN^<@MJ5F2)OM )TR/B7_ )Z=?O>_6L)?B)<KI6HR)#INHW=E>VEN&T^Y
MWPS+.ZJ,-V89((.>@]:FO_&6NZ,-:AO],LI;G3;6#4,6LKE7MF=ED^\ 0RA&
M/H?:@#9;P]J+P30-JMJT4[%IHSIL961CU+#/)X'6H)O"4]Q<3W$UYI\L]PGE
MS2/I,3-(G]UB3DC@<'TJXWB$S^*M.TBQCCGAGLGOKB?=_JX\A8\>NXD_@IJB
MWB;5)?&>HZ/;6=H++38X)[JZFD8$1N&)"J!RWRG';@T /;PG<//+.U[8&::+
MR)9#I46YX^/D8YY7@<'CBB\\)W.H6\-O>WMA<PPX\J.;2HG6/''R@G _"LK0
M/B%)JNH:9'*NF-%JL;O:P6EX)+B$JAD595Z E0>G0C'/6FVGQ!NUN;J"]@TR
MYG339[];;3+P3R1-%MS#)CC<=X (X)!XH Z :'JHEBE&LVXDB0QQO_9R913C
M(!SP.!Q["EAT75[=66#6H(@[EV":>B[F)R2<'J3R36)'XVU&+P])J<MOI5^)
MG@BL7TZ\+1RS2N$$;DC*E25)..A/ (Q2:EXTU;P_#K,&K6-D][9::=2MVM9&
M\N9 VUE.X9!!QZY#=J -%/",\=Y'>)=Z>MU%GRYETF(.F22<-G(R23^)JLGA
M/7Y_$4>LZAXB@DFM4DALECL !&CD;B<MRY"@9Z8SZU;T[7]8_P"$I@TC5[&T
MA2\LY+NV:WE9F38R!D?( )_>#D<<&MK6Y5@T'49GB$J1VLK-&QP' 4G!(]:
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M8M+NA8@XZ J.GKWK0O/&NIV#V^FR/H<>HQV"WEPUW>&*.3<S!$CR,EB$))/
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MXDLM.T:QMFM9]-MM3>XN9&4K%(S J  <M@#';KD\<@'5C3K$6\UN+.W$,_\
MKHQ$NV3@+\PQ@\ #GL!4<^CZ9<WD%Y<:=:2W4'$,TD"L\?\ NL1D?A6/XAU[
M4[#7](T?2[.VGGU&.X;S+B0JD7EA#DX!)'S'@=\=.M4-*\:W=WJ>G:9=V,,5
MV^H76GW?ER%D5X8O,#(2 2&!4\],T =?<VUO>6[V]U!%/ XP\<J!E8>X/!K/
MA\,>'[:=)X-#TR*:-@R2):1JRD=""!P:YK4_'5_:_:8[3389YTU]-'B1I2H;
M="L@<G''+8/7CFIF\0>*9==GT*UT_2FO;:QANIIGFD$6YV<;!QGG8,$^^>U
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M!C&XD 'M@#% '8111P0I##&D<2 *B(N H'0 #H*?110 4444 %%%% !1110
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M _-SQQ@=:]!HH \\UCP1K]UIGB+1=/O]/BTS6)I+D22HYFB>3!9,#@J6'7J
M3P:NZMX)N]1UCQ/>I=0(FL:.-/B5@<QOAAN/M\W:NB\1ZW'X;\/WNL36\UQ%
M:1F1XX=NX@?4@5I@Y4'U% '+ZMX5;4KC2GFF7[-9V%U:3JH)9Q+&BY7Z;3^8
MKB="OY]6U[P391:SI^HKIAD+I9QLLB1K;O&))U;F-LE5VX'+'\/7Z0(JDD*
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M26=S'<1N\2[&8QR(<9SASE3C/'(Q78W=S-;FW$-G+<^;,L;F-E'E*0<N<D9
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MT+3YM2C$=]);1O<(J[0LA4%A@],'-7J9#-'<0QS0R+)%(H='4Y# C((/I3Z
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M(U<27@O?[=F:Y4;1/]CMBX'IN\O-++X8NI[F.YFUR>2>+_5RO9VQ9/H3'D4
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M,FHQI.FA54:?: *VY0(5X/J..O H \XAOH-/34-+FO+G[.GBC[+:QR71"%3
MDOER2-DB/)<XY).!WK/O+F*_^%6O1W%ZMS]BUEHXRLY(2/[6H4#DG;@G&2>,
M8Z5ZP=*TYD=&L+4K(P9P85PQ'()XY-.DTZQE1DDLK=T=_,96B4AF_O'CK[T
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M 'X5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\17EO"9\^7& 7=G8#D@*IX!&21S6^_C/5M/O);'4;:S::RU*TM[N: ,(S!<
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M6$K$[<=_+P!GW[\:4.O75SI=S>6NF?;-D*RVXM+E'2YW9X1S@9&.<^O>J/\
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MW;2,A@?+.&]#Z]$G\&ZN^H7=U#?V82XU9=0:WEC9XY%$(BV. 1G&U7';(''
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MTKP9J&G6_A:)KNUD_L2:>1R%8><)$=>/[N!(3WSBFMX+U(6#B*\M!=IKK:Q
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M$27DD4,%5NR[=V3R<D#ITH O>'=9CTB'7?/>>XDE\1RV=K&TA9F=E3:H+'@
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MN2RG<S;L]#][&/;/M5"S\)ZI!:^$X9KVSD.@MR4C9?-40F$#J<'#%L^O&.]
M%E/'-E+J%E%%"9K6\N6M8YHI [*X) 9T'*H2I ;Z9 S5W0?$J>(/+FM+<-92
MH[+.DH;8RL!LD7'R/SG'/0UGZ!X<US0IS81ZM;/H*3M- A@/VE%9BWE;]VW:
M">N,XXXZBO;^%+ZPU&77(I+&VU7[#+#++;Q/LO)3@I)+&,<J5/ R3N/(Z4 =
MK15/27OI=(M'U)$2]:)3.L8(4/CG .<?3)Q5R@ HHHH **** "BBB@ HHHH
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MK^8< DDEF4 G;ZBMKP!%H6F_"*TO-4AM$LWC=[N2>,,K_O6 WY!SV SZ#TH
M]%) &21CKFJ%AKVCZHTRZ?JUC=F#_6BWN$D\O_>P>/QK+\?0W=Q\/M=BL%=K
MA[*0*L?WF&.0/<C(KF;B]T75/%&@/X:FM9HK;3+O[2;0@B* QJ$1\=/G PIY
MX- '?66K:;J3R)8:A:W31JCN()E<JKC*DX/ (Y'K5!]>:3Q4VB6<"R?9[;[1
M>SL^%AW9$:=.6;#'M@#/<5E_#"SMK3X;Z T$*1M+91/(RK@NQ&<D]^IJ'PYQ
MXH\>++_Q\?:X6Y_YYFV39^'#?K0!J6VO74UCHL[/HVZ^E*2>7J&Y".?]2VW]
MZW'3COZ58T/76U.ZU*PNH!;ZAIT_ES1*VY61ANCD4XZ,OY$$=J\E\/\ _(G_
M  F_["3_ /M6O0[3YOC!JAA^XNBVRSXZ>8992N??;F@#5N?%>CVOB-- DO(5
MU%X&G6-I%'0@!>N=QW9 QR 34'ACQAIOB+3=.<W=G%J5W:I<M8+<*TJ!ES]W
MKC!ZXK%U.>SM/B_;-=R00FXT*2* RD+YDGGK\JYZMCL.:P-'LX+;P1\,9;:&
M.*9KV$[U4 DO;3%LGW/6@#TVWUG2[O4)M/MM2LYKV#_6V\<ZM)'_ +R@Y'XU
M+>:C8Z<JM>WEO;*P8@S2J@.T9.,GL 2?85Y3X'@$S>%8+CQ#IPU"Q>5GT^"P
M(NED\MUF69_,.!DDEF4 L%]177>+;>&Z\9>"8IXUDC^W7#;6&1E;:1@?P(!_
M"@#<3Q/H$GV39KFFM]L.+;%TA\XYQA.?FYXXJ=M:TI-572WU.S746&5M#.HE
M(QGA,YZ>U>6:E86D7@OXA31VT2RKK9*N%&5QY+#'I@LQ^I/K4>NZO VH7$K7
MFEV7V?Q+;F6S2#-QMCGC4W$LA;Y%*XYV@;2!GF@#TG3_ !?H>IWVJ6EMJ-N9
M-,<K<9E3  56+#G[HW;23C!!':KEOKND7=A]OMM5LIK/>(_M$=PC1[R0 NX'
M&<D#'N*\IU62#RO'%G%/:Q7*ZY:W,T;H'(M!]F+R&,$%HQR3R 1GFCQ!;V]Y
MX<\1W0UZPU87-SID,XT^U,4*D7"\[M[AF*L <'("KGM0!Z:->@NM1TN/3KS3
M+FSN_.#2"\'F,8QTB4 A\'(;D;:MVVM:5>:A-86NIV<][!GS;>*=6DC['<H.
M1^-<9XB@AM/BK\/XK>%(HDCU+;'&H4#]RG0"N;\/ZO;W/B#P7=?;=+A26:XW
M6-I!L-FTD4A$4DA8DN6'0@$LIP.* /1?!GB1_%7A\:F]LMLQGFA\M7W?<<KG
M.!UQFH]'\9:;?W%Q:7=W96=ZM_<6<%L]RHDF$<A0,JG!.<=!6/\ "#_D0E_Z
M_KO_ -'-7'W=SH__  B'C+3T>W&NW&OW'V:$X\^27[0!&R#J0".HX&&]Z /7
MSK&F+?K8-J-H+QW,:VYF7S"P4,0%SG.T@X]#FDLM:TK4I)TL-3L[I[<XF6"=
M7,9_VL'CIWK@H=.:XU?XF3VD ;5"%BMI N75OL:[0I[<GM[5BVEQ:Q:0-2AU
M?2M5>P\/7"_V98V#1$PE4RDS"1MN"HX(!^]CO0!ZOI^M:5JR3/INIV=XL)Q*
M;>=9 A]\$XK(U?QGIMKX9U/5]*N[+5#8*"\=O<JP!) P2N<5YGJ<[W#ZW;6.
MJV&H2S>&VCC_ ++@\J-PC@M$F&;>51CP#D!O>MOQ?J/A+5/"NM_V%]GGN5TE
M%>>SYCCA,B[8V*G ;.2%/( /2@#TFRUG2]3GGAL-1M+J6W.V9()U=HSZ, >/
MQI-2UG2]&C235-2M+%)#M1KF=8PQ]!N(S7."UM[/XJV$=K!'"G]@SIMC4*,+
M-%M''IDX^M5]2N].TSXH-=:Y/;6]K)HRQVDUVRK'N$K&506XW$&,D=2![4 6
MO&/CRT\,QZ9%;R6%Q=ZC,J1"XO%AC2,@GS6;!.SC&0.]:VK>)M/\/^'4UC5;
MB&.$JG,4@8.S= A.-W<_09KS""V T;X>[X-L,GB"9K=73!%NS3-$,'ML*D#T
MQ7:_%-4'PYU$LJ[(WMW/'"@3QY/L ,_A0!<3QQI*ZU?6MU?V%M8P06TL-[)=
M*J3&;S. 3QQY?8G.:U)=2==;L;.-[%H+B%Y"6N<3'&,%$Q\R\\G/'%<E80Z7
MJOCGQ/=1+:W<!TBT2*1-KH4;S\A2.,':.GI7-:"RMJ_PW,Q<I_PC4VXJ"6QY
M:=,<YQZ4 >KV.M:5JDTT.GZE9W<L!Q*D$ZR&,_[0!X_&HO$&M6_AW0+S5KI6
M:.VCW;%^](W15'N20!]:XKP+=VD.MV6E6=[I6L6L>F-]FOK6()<6\2M&!%.
M2,MD8^Z<HV14WC)]1\0^,-*\.Z0MK(--VZK>BZ9A&2#B%&*@G.[+X_V10!U7
MAGQ!'XDTC[:+=[6:.:2WN+:0@M!*C%64D?3/T(J>V\0:->SF"UU>PGF$GE&.
M*Y1FWX)VX!ZX5CCV/I7G4@U_0/$FM6EZEI&WB:QFDLQ8NY1;R*+&/F PSK@^
MY2H-,O?#UWJ/PTBTEK9[FW#1RB#&Z$?9),I)C[K%@>#SPWO0!Z9'KVC3&58]
M5L9#%$9I MPAV1@D%CSPN01GIQ2V^MZ1<Z8^I6VIV4MA'G?<QSH8EQURP.!7
ME-GIZ1_!J*ZMT@A+ZMYM[/)#Y@\I;T[F< @LBA02,CY5-.U2'S+>]U.#Q)I=
M]"VJ6!OIK>P(M( F[#N/,(?EHMV&& @S0!ZM#K6E7%C'?0ZG9R6DCB-)TG4Q
MLQ. H;."<\8JK_PEGAO[(+K^W]*^S&3RA+]LCV%_[N<XS[5YQ?VEM=:7<R_V
MQ9:O%>^(].6X^QVIBMPX>-6 ^=@Y*[<D'J,'FM:ZTVQ;Q/\ $%FM(2?[(MQR
M@XS'-G\]J_\ ?(]* .[N]:TJPN;>VO-3L[>>YX@CFG5&E_W03D_A3+WQ!HNF
MR&._U>PM7#A"L]RB$,1D#!/4@@UX[" ]C?0ZIKNF:;#?:'8*@OK(SRS0_9P#
MY)\Q22)-_P J@G<0>XKIDTV!KSX@&Z1+F==.@B::2/EA]EYX/3)YQ]/2@#M!
MXJT<^*#X=^VP_P!I"$3>7YB\YZ+C.=V!NQCIS4.J^*+71O$5II]]);VUI-9S
M7+W<\PC6/8\:@'/'/F>O:N/\*W%I!XYTC[5+#'/=>%;(0^:P#2N&?(7/4X].
M<5I>)KG2[/XH>&Y]6D@BA33[S9+.0$1RT(!)/ X) )[D#O0!V4&J:?<_9O(O
M[67[4AD@V3*WFJ.K+@_,!D<CUJ9+JWDN9;9)XFN(0K21*X+(&SM)'49P<?2O
M)K>#R/"<OBG3DS;Z1K]U?V?ECA[)I"LP3_9*EV'^Z*[+P)"US87WB*52)M<N
M6NEW#D0 ;(%_[]J&^K&@"/4_B'I-O:ZW_9\T%Y>Z2Z)+ )E&[<4!(P2<*7 )
MQPP(KH;+6=(U%[@6.I65RUL<3^1.KF(_[6#QT/7TKRG7I+$6OQ)T]Y(%NY+V
MVD$&X"1HBMN"P'7;GOZU?\?6)CUC4X--@6(MX9<,D,?6-;B/(VC&0$+C'N10
M!Z5IVKZ;K$3RZ9J%I>QHVUWMIED"GT)4G!K#U7Q3J%KXF;0],T%]1F2T2[D?
M[4D(56=E ^;KROZUF^#UM[KQ/=W\'B+3-3?[!%#)'IED8HU7<3&682.I8#<
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M+%5 +'W]:Y;5=6U^7QFOA_2'L+>,Z=]L:YNH'E*GS"FT*'7.>._&#UZ5D?\
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M-S>O?:C?2"2YNG0)NVC:JJHX55'0<]2<\U9T#51KGA[3M5$1B^UVZ3&,]4+
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MW9)P>Q'-+:^)]2NO&EQI;7FE6XAN3$--N(W2YEA"Y\Z-RV'SUVA<8ZD&@#M
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ME<94(,]]V[C'H:=XG\1KX<DT=I6@CMKN]^SSRS' C3RI'W ^N4 Y]: ,+5_
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M[/Y;>87^V>9Y^<?=V?-OZ8XS4VKV/F>"/B,#;%GFU=N-G+@+!CZCK^M>M44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$;!*NC<'E00>"*S$\")#IT(AU6Y35XKY]0&I%$+-,ZE7RF-NPJ=NWT YR,T
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M3I=.CE$"Q+!%)]XA1U8D*2?]D8 K4/AZ(ZCHEYY[[M)ADB1<#$@=%7)]/NT
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M%/EL !MP>&4@<@^M %OPEJ3ZII#SG5[;54$S)'<PQ>6VT ?+(G\+@D@CCC'
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M3*P E3!(SST!XSBLF\U#Q3JOPYT76KK6XX9-2O-/(A@M0!&&E49W9R<G:Q'
M_AZ5U=GX$N+:32I)M?N)SID+6MNI@15\ADVE2!U;A?F_V>@YJS-X)BD\#:?X
M:BOY8C8>08+H("P>%@RL5/!Y7D4 =- DD=O&DTOFRJ@#R;=N\XY..V?2O/K_
M ,1^(6TKQ%XDL[RWBLM&NIXDL&MPPG2 XD+/G(9B&QC@<=:] MTECMHHYYO.
ME5 'EVA=[8Y.!TSZ5RE]X$^UMJ-K'K%Q!H^ISFXO+%8E)=FQO"R'E5?'(YZG
M!&: .?MK.[O?CG-<F_1D71X9T#VJDB(S-^[!/0_[0YKM/&;W,7@G7)K.X-O<
M16,LB2A<D;5)_4 C/;.:=#X<AA\8S>(EG;S);%++R-HVA5<L#GUYQ6AJ=A%J
MNDWFG3,RQ7<#P.5ZA64J<>_- 'FNFVNLS>(/"L4.K*MU)X=E9[M[<,RH7@(
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MLX5F#9Y/RGTJ7Q4LFO:9X[U73+>XDLI]*M[6)O(=3<RHSLQ52 2 '49QZ^E
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MDB9:2*%HE8^H1B67Z$URW_"P;'3M)TJYO[R"];4+U[99K&"18P%+9.#N.5P
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M)#J4#RIY9!3Y9<EAVY/.?6@#N;?Q3HEUK#:5!?H]X&9-FUMK.OWE5L;68<Y
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M=9$:($+-;R9,;@$D@C#*?=<]ZX6[T"]T_2? *30227SZZE]J#(A.)9 [N6]
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M.!70Q:E8SVKW,-[;R6\>0\J2J47'7)!P*5=1L6M&NEO;<VRG#3"5=@/N<XH
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MFZSJ&FK=1I'>6\!1EG"+M4Y8$JVT ;E.< =^:W-3TY=1T:ZTWS##'<0- 74
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MW.CZI=Z.TEK':3+:JC"2-,A/OJ<,H) 8=CWIC>!K>UDT^31=1N])>SLQ8;H
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M! XX'0U6M_#^E1^)/"=K'HTYTU+*^0I>6[2;5=D*"0D87(WD*W3I@=*].HH
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M@&7:,X_@%>Q44 9GAZRATWP_8V=M!/!;PQ!(HIW+2(G\(8GOC'';IVK3HHH
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M:VNIK>.2:!@08W*@LN#Z'(J[4<$*V]O'"A8K&H0%V+,0!CDGDGW-24 %%%%
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MU:A'D@NX&B?8^=K 'J#M/Y<XHE\1V'_"0MX?CNHEU+[/YP5^0N3A1C(R3R<
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M?8XH1(TR(8?*.?XMSL,$=#QT-87Q$M'OHO#T2V$]Y%#K,%Q<)';M*%A4-N)
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MKRTMXI1]JRXF=F?,>%((PL>21D_,...>@M=8TZ_F>WLK^VFG";]B2!CMZ;L
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MK \*B#4=2AU*3PYJNG:A!:FWFEOY'PF2"8X]S$.N1G<!C@>M2R026_Q<ANY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP@/  &<<]37U?Q7>Q^-](TC3DC:Q-V+;4)F&?WC0O(L:^X"!F_WE]30!>M_
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MC@N(/F9'AN(]DB,IP01^'49![&@"CI_A:PL/LH,EQ=)9PM!:I<N'$$;  J.
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MNRG<[AC\I Y]*["QL[N;QW)JYL9;>TFT."%1(%!202R,8R 3R PSCCWKJZ*
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MI%S;PZ<+>]FO'V^48T@8)L(.2S;UXQQSFO1;S4+*.^MM)N6/G7Z2^4FTX94
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M].\<1V5A),]^^GFU"D?O?+*;\9/;!KT6_P!6L=-M+VYN;A%2RMS<W"J=S)&
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M:7]W?6UO(6EL91#."I&URBN![_*PZ5!K/B'2O#T4,NJWB6R3/Y<992=S8S@
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M,8:%"Y!W G "C:#VQBH-1\,ZQ+\ +70(K"0ZHD-LK6P(W K,C-WQP 37JE%
M'"W2:KH7B#Q-+!HMWJ,>L+%+:O;;"JR+"(BDFYAM'R@YZ8)[BJ&@Z3J_@B_A
M0:5<ZHD^C6=GYEJ5PD\ <%6W$80[P0WL:]%6>%KA[=94,R*KO&&&Y5.0"1U
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MWVH7,=M:Q#+RR'  H M44@(8 CH>:6@""]1I+&X1 2S1, !W.*\^B\.ZI:>
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M#J5PMS=*)B-\@VX(/4?<7@8^Z* */AY[V7QYXK6>_EEAMY+=(HF5<*K1!\#
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MNM(? ^B&UO+?R[K;=W27CM]KD++,FTJZDMD-E021U[T 9^I:YK%EKNN6$=S
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MXJY5LJ0RL",$$, <CN*R)O >B7$>H)+]M<:BD:71:\D)EV?=))/7@<CTQTH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM-F5%+,0J@9))P *\YU;PYJ,+1RZ#83Z7J4%I%%"+9U:SG7<Q,$R$_=7)^;
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M>:TBG!958$.0V#U&>E:5KH]U8^+="N(-&%M86FE7$#);E=D+.\;*@Y!/"$9
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M[/Y<O@I;MHQ(0GG&09?;TW>_6@#U"J%[H]CJ-Y9W=U$[SV3F2W82NNQB""<
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M_(+;@1T.>>* .NHKS80RZ)K7AQ[74K^<ZM8W/VWSKIY5E981(L@5B0A#<?*
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M<C[H]S5NN*\;7EU;>*?!44%S-%'/J;),D;E1(OEL<,!U&>QKF+Q+H>'/$/B
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M QC3JV?G;%27D>O66DQV<KW^F6\WB"SBM0U_YT\<+E0Z&0,21G<0&)X8=@*
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M%'_\31_PB7AK_H7M)_\  */_ .)K8HH Q_\ A$O#7_0O:3_X!1__ !-;%%%
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MRW$DICC!R$3>QV+G^$8' ]*GO/#VFW^LVNK3PR?;K52D<L<SIE"02K!2 ZY
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MM6J* .=T_P "^'M+N;6XM;*026;E[7S+F60095E(0,Q"KAC\HXZ<<#&7X.\
MV6D:1I#ZA:L=2LU+[1<R-"DO(WK'NV;L'[V,\UVU% &"?!F@G5#J!LW\TS_:
M3']HD\DS?\]/*W;-^><[<YYZU9E\-Z3/I^IV$EINMM3D:2\3S&_>LP"DYSD<
M*.F.E:M% %2WTRTM=0N[^&+;<W803ON)W; 0O!.!@$]*MT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ,MNT@MY#"LS %8S+MV!R".,YY'<UAR?$"TO-+\2R1S3Z4-)F,7VVXL)9$
M3+%=J\Y<C9G. &Z&@#N:*P=0\7:3I#Q074UQ-<- +AEM;268I%_ST8(IV+D'
MKZ'TI+OQGH=HULGVJ2XDNK<75O':6\D[31G^)0BG/^'- &_1532]4L]:TR#4
M=/F$UK.NZ-P",\X.0>00000>F*JZUK<>C2Z<LL<A6]NUMO,6)G"%@<9V@XR0
M!DX SD],$ U:*X35O'%\;:T71H8%O)]<_LEUOH)0L7RN<_P[ON@Y''S8YQFK
M;>(=?T+5-/M_$EKI\EEJ$ZVL5[8,X$4S?<5T?)PQ& P)YZCF@#L**PH_&&BR
MZQ_9:SS&?SFMQ)]FD\EIE!+1B3;L+@ \ YX(ZUFZ3\0]*U'3=0OIHKNUBM+Q
MK4"2UEW2G>44("@+.2/N#++WQ0!U]%4-)UBRUNT:XLG<JDABD26)HWC<=59&
M *GD<$=P>]9VH>-="TR^FM+FYF#6Y5;F5+:1XK<MC:))%4JF<CJ1UYH Z"BN
M!U+QG>-\3[/PS9O);VB6ZSW$ATR:9I6,H38",!4Q_P M>5![\5TNO-XA1%DT
M233%1$9I1>QR,3CIMVL/?K0!LT5Q?@[7O$6L:':>(-8DT:#2Y[4W#+"DBO&,
M9R69B,#!S6G;^-]"N;.]NA<3Q16=L;N7S[66)C!@GS%5E!=>#RH- '0T5S?_
M  GGA_[/%<?:I_*GF:"W;[)+^_<+NQ&-N7R.A&03P,FH5^(OAMHUD^U7*J)?
M)F+64P^S/NVA9OE_=$MQ\V/RH ZJBN:_X2>RLM3\2&]U=&MM*6!YH!:.IM R
M9Y?GS-W7@<=*GM/&>AWD]U$MU)$;:W-T[7%O)"K0#K*A=0'3_:&1^= &]17*
M77Q!T>+0M4U*!;R1M/MOM+6\EG-$[H0=C ,F=A(/SXP.2<8IUKXHAU'4_#XC
MOFM/[1@FD%A/8R"2;8!DAV V!<]Q\P(Q0!U-%<_;>-="N]0CLX;F8F:5H(9V
MMI%@ED7.424KL8\'H><'%1_\)YX>-VMN+J8_Z4;-I1:R^5','*;'DV[5)88&
M3SD'H0: .DHKE+K6_$D/V_RM+L9?(ODBAQ</^^@;KCY?]:../NC/7@UT\\\-
MM"TT\J11+]YY&"J/J30!)17-ZSXF^Q7>A&RELY['4+UK6:;S-P0".1\@@XX\
MO!S6PFKZ;)8+?IJ%HUFQP+A9E,9.<8W9QUXH N45SNO>(GL8-&N=-:UNK>_U
M&&T:3=N&QVP64J<$\5+H^LW5_P"(]?TVXBA6/3I85B:/.6#QA_FSWYQQ0!NT
M53N]6TVP+B\U"TMS&GF.)IE3:N<;CD\#) S[TL>J:?-=K:17]K)<M&)1"LRE
MRAZ-MSG'O0!;HJK%J5A<7<EI#>VTES&,O"DJEU&<<J#D<TEOJNG77F_9[^UF
M\D;I/+F5M@]3@\=#^5 %NBJ=OJ^FWEP+>VU"TGG,8E$<4RLQ0]&P#G'OTJOJ
MWB'2]$GLH-0O(H)+V4Q0AW"Y(!))ST  Z^X'>@#4HKF=$\4I=WVJVFJ3V-K-
M;ZFUE:IYNTS 1QN,!C\S?/VK<FU*PM[N.TFO;:.YE.(X7E4._P!%)R>AH M4
M4UW6-&=V"HHRS,< #U-58M6TV>UDNHM0M)+:([9)DF4HA]"<X'6@"Y15-=5T
MY[9;E;^U:!W\M91,NUGSC:#G&<\8K(;Q*9/%FDZ?9R6=SIU_:W,WVB)]YW1,
M@(!!QCY_TH Z.BLRQU(?V4UYJ%]IQ02R+Y]O+^Z"AR%!8G[P& ??-3G5M-6S
MCO&U"T%K+_JYC,NQ_HV<'H: +E%9(\3:.VN0Z.E_ UY-;_:$19%.4) 7OR6S
MD8Z@$UH7-U;V<)FNIXH(@<%Y7"KGZF@":BL'Q%XJL-"\.-JXN+>9'*+;GS1M
MD9F"C![@9R<=@:EL]3GMM-O-0UF\TW[#$3)%>6S$(T. <L"3@YR.&.>/I0!L
MT5R+>-H)=4\/M;36?]D:G;3SR3R28:'8BM@G.T?>&<],5T;:IIZV"7[7UJ+-
MP"MP9E\M@>A#9P: +=%1PSQ7,"302I+$X#(Z,&5AZ@CJ*Y:S\5RZSJ]Y%I%S
MI36NGW@@N4FE/F/$$1GE1E.  7Q@@@[3R* .MHK+N]9A;1+^]TNYM+M[:)W^
M64.H8+G#%>E8MEXIO[FZ\'H\%L(];L6N)R-V4<1*^%YZ9;OGI0!UU%55U*Q>
M]-DE[;-=C), E4N,=?ESFHCKFDB+S3JED(Q)Y6_[0F-_]W.>OM0!?HK+U34U
MAMIDM+_3H[N-HPPNY<*@9A]X Y!*YV^IQ4UQK.EV;NESJ5G"R,J,LLZJ59L[
M0<G@G!QZXH O456NM0LK';]KO+>WW?=\V0)GZ9/N/SI5O[-Y8HDNX&DF5FB0
M2 EPOWBH[@9&<=,T 6**SM7U5-,2V0*)+J\G6WMHLXWN02<^@"AF/LI[TTW-
MZVIS6L=SIS;+57$63YHDR<EESPA&,=\YZT :=%4-&U:'6=/%U$I1E=X9HF.3
M%*C%70_0@\]^O>J=UKL>F1:S>7UW8&SL5#(D4G[Q1LR5DR<!B<[0.V* -NBL
M#PUJNHZS E_+)ITNGW%O'+$;5F+Q2$9:-N2#C(^88_W16_0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 45!#>VMQ<3V\-S#+- 0)HT<%HR>FX#IG!ZU/0 44=!DU0.N:0"0=
M4L01U!N$_P : +]%(K*ZAE8,I&00<@BEH ***@M[VUO#*+:YAG,+^7+Y3AMC
MX!VG'0X(X/K0!/1110 444V22.&)Y975(T4LSL<!0.I)["@!U%,BECGB26*1
M9(W4,KH<A@>A![BGT %>9+IUS?Z'\2] MQG4IKN:6-,X+K- AC_ [2OX&O3:
MS+K0-/N]4;4)8V\Z2U:TF"MA9HCSM<=\9.#U&3ZT <9'JRZOX^\'O'IE[:"*
MUNU8W=LT!#%$R@# $XQR1QR,$\UK> _WUQXIO8_^/>YUN8PD=&"(D;,/;<C?
ME5VP\%:=I\C2QW6HR3BV:U@EGNVD:VC;&1'NSM/ YY/ YK5L[33_  _HT5K
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M7.T2[5))9@K$#)*CKG""G:1X*L]$O6DM+_4?L/FM-%IKS V\+L225&-V,DD
MD@'G&<8 *>B^)->UF71[^#2T?1M00O(V%5[="NZ-MWF'?G@$!01GVJ?4A%X)
MT>ZO=-L0([F^$]V8+8N(5; :3RTP6P%&<<\EN:ET7P79Z#=;K34-1:Q1VD@T
MZ28&W@8YSL&-V.3@$D#.<9Q6SJ%@;]( EW<6KPRB59("N2<$8(8$$$$\8H K
M^'=3&L:)#?+=VEVLK/LGM,B-U#D+P22#MQD$\'-8.O:O=ZFOBC2; VJ)IEC^
M_-Q&SF1Y(V8*,,-H"XYYY;IQST6CZ/:Z+:206NX^;/)<2LV,O([;F.  !SZ"
MLS4?!UK?:M>:C#?WUC+?6XMKQ+9DV7" $*6#*V& ) *X.* .?T;7M4'A[2M)
MT2VCEN[;0;2Y)DCWJQ="$7'F)@?NSD\]1Q4VO^,M;T?2)[Z6RM+::VTZ.\DL
MGS/(7)/F(2C8C48P'.02?;%:#^ +)?[,DL]5U6RNM/M5LEN;>9 \L"]$DRI4
M@=C@$4NH?#_3-0-^OVW48(-0LTL[F&&9=LBH"%8EE+;AN/.<'N#0!3NKS4KG
MQEKUE)=1-IT6C13+;F$Y&\S \[NN4&3CI@8'4T_!.L:I967@K3+@6;V&HZ.#
M$(T82Q-%%&?F8G#!@QX"C![FND?PG;OJ+WXU"_2>6Q%C,5=,2JNXAFRI^8%V
MZ8'/2H[?P;:6?]B&*^OS_8ML]M:C='RC*%.[Y.3A1SQTH Z2N&O;K4Y_&'B2
MQENXFTZ'1XI5MS"<C?YP/.[KE1DXZ8&!U/3>'K"[TS1(+2]O;B\FC+_OKAP\
MA4L2H9@ "0" 3CM5:\\,6UWK-SJ8O+R":YLQ9S)$R['0%BI(*GD;V[XYY!H
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MB<-@[2DC'#*<D' !7C&: .TK)UCQ+I6@SVD%_.ZSWC,MO#% \TDFT9;"HI.
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M!YG^][U2M;O6(/ _A:Y?4-:U"[U^2!;KR)U$@0022;8MQ54)V@,V03@G.<4
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M.?I0!Z!15>PM38V%O:M<SW)AC"&:=MTDF!]YB ,DU8H **** "BBB@ HHHH
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MQJ*7PKI<VDZCICQR&VU"=KBX'F'+.Q!)![<@5/\ \)%I)T^"_CO$FMIU+Q-
MK2%U'WB%4$X'?CCO5:\OK^\&CWF@7-K<6,\RF<E"XEA/5E<'"X&3SG) % #+
MCP?I5SJKW[&[3S9DGFMX[EU@FE3&UW0'!(VK]=HSFKVM:)9Z_8K:7HD"I(LT
M4D4ACDBD4Y5U8<@BG+K-@]\MFL^9G=HUPC;6=02RAL;20 <C/&#5BZNX+*'S
M;B38I(4<$EF/0 #DGV'- '/KX"T18+Q/],::\>&66Y:Z<S&2(DHX<G(89_+
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MK T91""=P9F!R.,+SS@5WS7,*7$=N\@660$HIXW8ZX]?I3W19$9&&588(]J
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M --!Z5V4L&B^,]"@=L7NG3,LT3([H&*G@Y!!ZBM6**."%(HD5(T4*B*,!0.
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MF:7'&D:P2.SX5""HR3GC []J .:\7WE[;_#.[UQI7-W;2)J%J64*T:B4%%X
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M^,M<G!0YP"&;;U.<]:VM-T2VMU2Y9+@79MA!NFF+O$G4H#DXY R0<G R3@4
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M);B:V7+Q3K$Q!"X'&\C(Y(]#S5;Q)J&L1Z!X]T#5;M+Y;;21=6]T(1&VR19
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M(Y8!=B8%1NW;P#R" /E."20" =?J'BY=.U)X)=(U#[#'<16TNH;4$222%0N
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M<"%."1D9YH YWQKX\OH? &K7FD65[9ZG:W"6ER)/*W6;EDY/S$,&5QM*[OO
M\<XZRTNYM'\'/>WEOJ<DEI!)-)%=/')<L%W'!*'820.,'IBN,U[PKKNM>$/%
M<JZ?Y6HZU>V\T-DTR;HXXC$HW-G;N(C9B 2.@R:]/95=&1P&5A@@]"* .>D\
M::8FK:%IX69VUF(S02JHV(NW<N\YXW<@8SR*Y^X\;3S>.[:UTVSO[J".*]MC
M:Q;%$\T3P@N"S !5W.,DCD$8Z9R]/\&>(+31-1:2U5]0TZ2VAT93,O[V"VE,
MB<YPN\,5(..G-;7AKPOJ.DZIX<GN(0?L^EW2WT@=3BYFEBD8=<G+!^1QQ0!-
M-XPL=0'ANXSJMH]YJ3VGV>/8,2IN5DFZY4%3]T^E7X_&D,VI>3%I6H2:?]L-
MB=114,7G [2,;M^T-\N[;C/MS7,_\(EK?VK0G^QC;:^);N_F/FI\L#O(5;KS
MD,.!SSTK5T.#Q)H!_L*VT=)+;^TI9AJ4DR>4+:25I6^4-O\ ,&XJ!C&<'.*
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M#'()/3K[5N:-!XDT"231+71TEMGU.6X74I)D\H6\DID;*[@_F#<5 QC.#G%
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MI7)MM$U2T"7<!1=EO.R!D?=C=M;#+UZE: /0:*X-=2\076I0:&MZ8+V;3FU
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M$D*O\O*DD],'WK2O-2UK3]=U:Q_M:296T-M1A9X8Q]GE5B,)A>5/'#;CQUH
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MEO-<NK*6S,:>64:6X.[.-VX,HZ'&.,=Z /5JHZKK%AH=F;S49_(MPP4R%&8
MD@#. <9) ^IKDM%U3Q'KD>FZY;7ME'827CQW5M-*,"+>R!% BR) 0O5\$Y]1
MB?XKY_X5U?[<;O/M<9Z?\?$= '26VMV-U>+:1M,L[J75);>2+<!C.-RC.,C\
MZ@U'PKH.KWR7NH:3:7-RH \R2,$D Y /]X ] <T0IJHU%AJ%Q9^2T6VW:"/:
MZR\Y^\3GY1Q]#FN&TK6O$=SI7@^_EUV1GU>YDM+F/[-%L V2L'7Y<AQY8[[?
M]GU /4*HZMJ]EH>GO?ZA*8K9&56<1L^"3@<*">I K@/[=\0+Y5BFLN9(_$[:
M4UQ);QEI(3#Y@W *!N!.,@#IR*JZ_>ZJ/#/C/1-4O6OQIT]H8+QXU1W21D;:
MP0!<KZ@#((H ]7HKC+C5M2U34_%5I9:@]@^C)&L 6-&#NT7F;WW Y4D[<#'
M/.>E)/%M];CPSXCU*X:WT/5;$"Y@*+MM[AD#HV[&[:P#KC/7;ZT >@45PO\
M:.OSZE9Z$;TPWLVG/?N[LD;@L^ @_=,I" X/&3P<^L46I>*+^['A]K^QAU>W
MTM+B6>VE 264R21EEW1-E5,8R,#EL4 =_15+2'O'TBT;47MI+WRE$[VI)B9P
M,,5R <9S5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JE_IMKJ0@%RLA,$GFQ-'*\;*VTKD%2#T8
MC'O5NLO6=:31Y-,1X6D^WWJ6:X;&PLK-N/K]W]: (9_">BW$5I&]HR_9)'EA
M>.>1'5G)+DNK!FW$G=DG=GG-5Y? OAN;3(].;3%6VBG:YB"2NC12,22R,&#+
MDD\ @56U?QQ#I-UJ4!T^>=K*YL[<B-AF0W! &T'TST[U!-X\?3X]6CU71I;:
M^L$@=+>*=9?M F<I&%; P2X(.>G7F@#=_P"$;TD2:<ZVI1M.+&UV2NOEE@0Q
MX/)()R3G.3ZU/IFD66CQSQV,31K/,T\@:1GW2,<LWS$\D\UQ3^*[W3_&-_/K
M=I<64%EH7VA[2.?SD<^;@,F, L?N\@'/M@UHW?CJ;2;#59=7T5[6ZL;(7RVZ
M7*R":+.TX8#A@>",=Q@F@#>3P[ID=T+@0R%Q,]PH:>1E25\[G52V%)W-R .I
M]:@B\(Z)#:V=M':R+#9W)NK=/M,N(Y222P^;KEF_[Z/K5O1K^[U*Q-S=:>]C
MN<F*-Y [-'@%6./NDY^[SC%>>QZK/>ZK?6M]XPNM$\1K>2K:V-PJ);&,.1$%
M5E'FJR8)(;.2<8H [R+PSI$-X]S':;6>?[2T8E?RC-_ST\O.S=GG.,YYZU+:
MZ%IUD]^\$!!OW+W0>5W$K$;22&)'0 <=@*Q-4\:/IUUJ)CTN2YT_2BBZC=K,
MJ^42H<[4/+[596/(X/&33KGQA<C4;V/3]"N=0L;"=+>[N() 7#D*2(X\9?:'
M4GIWQG% %B?P+X;N=-L]/ETXF"R;=;$3R"2+C'RR!MX& !C., #L*O1^'-*A
MO;*\BM3'-91-#;E)7 1#C(V@X.<#.1S@5Q=UXOU&2P\<-JEA+'I^E.8T>TN_
M+E $<9VA@,@G<6W=LX[5N'Q3<F>VTW1M(EU&Y6PBNY_-NA&(D?(0%R#N<[6_
M+)(H L^.])N]<\'WNF6,(EGN#& K.%& ZL<D^RFM"'0M-$5QYEH9#=PB*<74
MC3,T>#\A+%OE^9N,XY/K6$OCP7HT5=)TJ>\FU:UFGA1Y%B\HQ,@99"<XP6(R
M,\KCG-;7AS7!X@THW9M7M9HYY;>>!V#&.2-RC#(X(R.#Z4 4[;P+X<M-)N=+
MAT]A9W2A)8VN)6+(.B;BV0O)^4''M6C<Z%I]XU@UQ%)(U@XDMB9Y,HV"N<[N
M3@D<YZGUKD_B+XBU*SLI;+0Y_)N;:-+J]N  ?)B+A509_B<Y_P" JWM6GJ-W
M<ZEX^L-"AGE@M;.U_M*[,3E3*2Q2*,D?PY#L1WV@=,T :B^&=(6\ENEM,/+.
M+F1!*_E/*,8D,>=A;(!SC.0#U%5;_P $^']3N;R>ZL69KT 72I<2(D^.A=%8
M*Q&.I&:I67C+^T;FS\S2Y8=)U*9[:SOO/&9& 8@E!R@8(VTY)Z9QFI/!U]="
M76-!OIY+BXT>Z$23RMN>6!U#Q%CW8 E2>^W/>@#=O=+LM2TJ73+RW6>REC\I
MXG).Y?KU_'K7/:QX*L_[)U :/8P-?W=NEM(;NXD(FB#<JS$L=VTL ^"1D=AB
MI[WQE%8IXA$EE(9]':)1$'&;CS54Q[3VW,=OU!K.U;QS:/X=M9DM;ETU'2+G
M4'$$WER01QQ!F^8<AMS!01T//:@ T?P>OF2_:+"YT^TEA>&>V.L3W(G##&,$
MX4#U'/;@9SO7WA31-2T2WT>\LO-LK;:8$:5]T17[I5\[@0.,@]*YK3O%6IRZ
M_P"%M.LK%GTV^T<7;O/<AI<?NAN9B,DJ&.?[Q;/:JGA'QAJ-OH&B'4=.N9[2
M[O&LO[1EN0SF1I7"_(>2N0%SG\,8- '5W?@SP_?:3;Z9<:>&MK9_-AQ*ZR(_
M]X2 []QSR<Y/>I+CPEHES;6,#V906#%K62&:2*2(G[Q$BL&Y[\\]\TOBS6SX
M;\*:EJZQ"62U@+QQGHS]%!]LD5SMQH>LV-C%=W'CNX@UE@'Q<F(6;L,93RMH
M.SMD'=WS0!UFDZ+I^AV\L&G6_D12RO,Z[V;+L<L>2>I-5Y?#&BSS:C++81R'
M4E"W:NS%91@#E2< X5>0 >!Z52OO$]TFK?V5I&EC5+N.U2ZN"+E8HT1R0@#$
M'+-M; Z8')JK'XY&IQZ6FA:9)?7=_;/=^3+*(1!&K!&WM@\[SMP >0>PH W[
M#1[+37:2WCD,K(L9EFF>5]JYPNYR3@9/&>YIM]H>GZC>PWD\4@NH4:-)H9WB
M<(V"5)0@D$@'!XR!6 GCO[7;Z=%I^DRS:I>S3P&REF6/R&@.)=[\C . , YW
M"G^ ]1N]3C\02W@N$>/6)HEAG?<80$C^0')& <XQQSGO0!:UC2KJXLHO#UCI
MMDNB7$!@N9&EVF%. 52/:0Q*Y .1@\]N>B1%C1410JJ,  8 %>?>(+_S/B*^
MF7GBJXT2Q32H[A!%<11!Y#+(IYD4YX Z>E,T7Q;+IR^(0^I2^(-.L9K:&PNA
MY9>>:7Y?)WJ C$,4^;MNYZ4 =3<^$-"NUU!)K(E-0D$ETJS2*)&&.<!L#.U<
MXQG SG%32^&M(GN;JXGM/.DN[<6L_FRNXDB&<*5)(QR>W<^M9L7BN],6H6\N
MA3?VO9F'_0H9ED$BRG".), !<AMQ(&-IZ\9KGQS(EK)'+I)354U!-.^R?:E\
MLR-'YJGS<8VE/;.>,4 ;>A^&])\.0/#I5J84? ):5Y&P.@RY) &3@=!DT7WA
MS3-1U2'4KB*?[9"C1Q2QW4L913C(&UAC.!GUQ67/XLO8VT^R309CK-X9B+.2
M=56-(B TADP?E.Y<$#)W#@<U6/CX&WLECT>X>_GU"339+02KF*=$9^6Z%2%!
MW>ASCM0!LS>%-'N+.:UGMYI8IYDFE\RZE9G=,;26+;L#:"!G Q3Y?#6E33WT
M\D$AEOX1;W+?:)/WD8R I^;_ &FZ>I]:B\.Z])K7]H075BUC?:?<?9[B RB0
M E%=2K #(*L.PJ_JMW-8Z3=W=O )Y88FD6(OM#$#.,]J .6MO""IXQN9FM9X
M])_LN"P@*7CJ<(TA(.&W%<. ,YZ=JZ,Z#IAOK&\%MLFL(S%:['95B0@ J%!V
MXP!V[#TK@+3Q3X@O(_ E]+9R27=_;S,]M#<!4N3Y*,'?LHR2<$'';)XKH8?'
M,ES:Q0Q:/(=9>^EL38FX4*KQKN=C)C&P+@YQGY@,4 ;5GX9TBPG66VM-FR5I
MHX_-<QQNV=S)&3M4G<W0#[Q]35;3;&_N];;5]8L;2VN+>-[6U6"4RGRV8%F9
MBJXSM3"]L'GG MZ#K*ZWI[SFW>VGAF>WN('8,8Y$.&&1P1T(/<$5SOB;Q9>)
M!XCL]+TR::/3+1A=7D<X1HI&B+C8O5BJE6/(QGC)XH VG\'Z"^OG6SIZC4&*
ML\BR.%=E^ZS(#M9AV)!(Q4R>'=-MK+4[:WMVV:D9'N4:XDQ*SKACG)*Y'&1_
M2N>'BO4=)\,V%U_8]S?V]OI4-Y>7;SA.-F6";O\ 6/A2Q''4<Y-(WC2\M_&&
MKPW%HBZ%8:7'?/.)!N"D2-OVXR<A0NWMC/>@#JM&TU-'T>TTZ-V=+>,1J6)/
M [<DG Z#)/'>J]MX9TBTN?/@M-A\XW C\US$LISEUC)VJW)Y ZDGO5/1O$MS
M?:HFGZEI+Z;<3VQN[8&=91)&"H8'&-KJ73(Y^]P35G7]>.CO8VMM9M>ZA?S&
M*VMU<(#M4LS,Q^ZH Y.">G% %K3=&L=):Z:RB>,W4QGFW2N^^0]6^8G!.!T]
M*@U#23-K%CK%MM%Y:*\1!X$L+XW(3V.55A[KCOFL.7Q]]FM)!<:/<+J4.HQ:
M=-9)*K$/(H9&5N RD$<G'?.,5JZ#X@GU6_U+3K[3C87U@8S)&)A*K)("58,
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M;XGT$:'(TBI;W5W<V( /VM(S%E!Z-M=ROOBKTOB/[=XH\)2:;>[M+U*TNYV
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M-9I&=%S'NX5,L,)P!6I!XNO6?5K2XT"X74[!(9%M()EE\]9250AL#'*MNR.
M,\T :S>'=*DN]0N9+022:C$(;L2.S+*@! 4J3MP 3V[FF1:-;Z/:S3:5:>=>
M);F* 7-R[9 Y6/>Y8JN<=/RXKE=?\=:K9^'-2EM])2#5;"[MK>:,W"R(JRLN
MUU;'S9W;<8&#D]N;K>);:R\97B:C%=VTUKH(O[D?:B\$:!SN 3H7&#\W<<4
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MEI][IQL;[3VC$L8F$JLKKN5E8 >AXQQB@"2X\*:-=)J:3VKNNJ$&\!N),38
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M^DII>CR7%_?QS2M;23K&+=87\N0L^#GYSM&!S[5/\/\ 4+G4]'U&XNFN-_\
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MO(@9@ I /S<]<=<=\8KF(_$'B!O%U@$TV2>XN-#\YK$786%6\X#S"V, D8Z
MGYL= 30!?\0^#XY9M-_LNRE*_P!LIJ5\PNF4MA&4LI+9#<KTQPO7@5O3^&-(
MNM,N-/GM6DMKF02S@S/NE<8P6?=N.-J]3T '85BVWCJ35+33?[)T>2YOKN"2
M=[:2=8A L;^6VY\$$[\@8'.">!71:+JL&N:-:ZE;JZ1W";MCC#(>A4^X((/T
MH @NO#6DWMVUU-;N9GA$$KI/(GG1CHLFUAO')^]GJ?4U5U73KW5+V#2Y-/LA
MH2&&9IC)ERT;[A&(]N ,JG.>F1BL:U74_&6LZR_]MWVF:9IUVUC!#8%$>1T
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M"&3 .=I<L ?IZUVKVT$B,CPQLK#!!4$$4EM:6UG#'#:V\4$4:A$2) JJHZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9.M:
M$-9,).J:G9>5N_X\;DQ;\X^]QSC''U-:U% &+XGT.?Q!H+Z9#??9!(R>8[1>
M:)$!!*,,C(;&#STR.]8OAC1O$%AXUUR[U*^BGM9H;=5=+/RA*55ON_.<;>A'
M?(Z8KM** ,F^T$7VK07_ /:FJ6YAV_Z/;W)2%]IS\RXYST/J*UJ** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex1012022063010qngcbasho005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?ZIK@NKJ\TM]-/EV@B2-6.0RKN//7.3SGMC% &5I7B#6[^T\'6.F_P!GV/\
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MU_K]_J,&J"WBU#3OL%U UOOW !]K*VX;2#)TP<X[5--X1@N5T&.:X+Q:5!)
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MCBGN$9A"J[@-Y3?(VX9'*\T 49_B!J%OJ%SNO[-C8WJ64FGK9R&2X *K+()
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M5(=_ANW53M/S'RGX'J:Z+Q*LFGZUHL]EIZW#6^@:B$M_+RLA58"L9 ['&,4
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M_A*M3T@FZT\:"EK)/$IV2S><6"@_Q%5SG'3=B@#TO3?$>C:Q=SVNG:E;W,\
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M?45PWA7Q=?\ B#5-$\T)'#>:&]Y-$J\"9940D'KCEN*P8=1UK7==\&SR:O)
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MECFB62*19(V&59#D$>QKA/BEK=I::58Z!<7J6@UJX$$\S-M\NV7F8Y]UPO\
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M61N[^8QQ;E0;49V9B<!5502Q/H :JV7B?1]0>S2VO-TEVTJ0HT3JQ:/EU8$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<9<MO$CQ^8A)P!N3[I!.#UKHO^$7@_M32K\7UYYNFQRQQAF5A(9<;V?*Y))
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MGH""X/(.>G'4Z*> ;6.6!DU;4EBMM2?4H(@T>V-WW[USLR0?,;J21G@BI9?
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M_P 3Y_L[P_9.("8W<2 [LL?D)VGCG';-&I>*-8M+!K6\>TO;FS\3VVG>>]L
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M!QZ4 ='1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\?/SPN:RK[P[/>6^IV<:>((+#4HT%Q"EI#N,B1+&K!R^0N$0E>^.N"17J-%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU]2U*/X=:Q<6X>]NW=S%!,0LFZT=N0<!>>>^ .IKT5+:1M-%K<.I<Q>6[1C
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M>&C:/^]\N Y/?I6QX6T.X\.Z9)I\MY'<P+/+) 5B*,JO(TF&.XY.7QD8Z=*
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M:2X5Y!$5D",%VL-PR<#IUSVP=V^\-W<%_9WWAZ[MK&:WL_L)CN+<RQ-"""N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHJKPI]S(7^HVU)J.HZ;<>)-:L]?EM_LSZ3"VD>>PV2 J_FF,G@ONV=.<!<4
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MM.TZ'66AU6:R'G6;DVXV2 $<1EBF0?NL.>: /7*@N[VVL4C>YE6-9)4A3/\
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M^&!$Q"[L\'<.6QR,#M0!Z1--;65NTT\D-O N-SNP11V&2>/05(J(HPJJ!C'
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MUS6X[VT2UTC5)+9;0VVXSQ+(JG<^?E.&XP.HR<YP)]7U[Q-O\8W%C?6EO;Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8 8';.<5<UGP['K.KZ)J#W#1-I5PTZH%R)"4*X/IUK5EN8((A++-''&<8=V
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M#>,;&&\^58GR[^9D@JH49;[IQ@<@9JW+XMT""RM;R35(!;W:LUNXR?,VD @
M#)() QUSQC- $&M^$;37=1FN;J>0)-ILFGLB<$!W5]X/9@5&*M:/I>IV4TLV
MIZW)J+LBQHOD+"B 9YVC.6.>3GL, 4S_ (2[03HZ:L-2B-E)+Y*. Q9I,D%
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M^AWUWJD]W=:6]PYDD0#SC*I4\#A0,\ =@!6K>W<W]G^?IOV6=]Z &6;;'MW
M-\P!Y SCWXJS)<0Q$B2:-",9W,!UZ?G0!@7?A&*ZB\41F[=?[?C\N0A!^Y_<
MB+(]>!FEO_"<5]<VL[73H;?39]/ " [A*$!;ZC9T]ZZ*N;U[Q=;Z;H>O7NG^
M1>W.CQLT\!EV@,%#$9 /(!';VXH ;I'@V'2#X>*7DDG]BV4MFF4 \T/L^8^F
M/+_6H)/!+)&LEEJCV]Y%JL^IPS-"'56E#JR%21D;7(SD'H:Z>WN([A 5="X
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MBF SNR>AQN)4\'K7HR7,#V_VA)HV@P6\P,"N!U.>E)+-!]C:9[A$@9<^;O
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M S$*K,5''..IKJ+70]-O8//M=7U.>(LR[X]5F894E6&0W4$$'W%3?\(Q;?\
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M([[1C!9B!RV<9/'%=KX7U+4)-3US1M2N1=S:9/&$NO+"&6.2,.NY5XW Y'
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M=>U:Q\A2KQRWKQL2Y^8-EB1@@< 8-7;'QIJM[JT-S#-?312:JUF=/3293"D
ME,7F?:-F-PQO)W;>HQD5U*^#;1?#L&C?:9O)AOQ?!\#<6%QY^WZ;N/I1:>%)
M+'4C);:U?1::;I[O^ST"!/,8EF&_&[86);;G&3Z<4 /\>?\ )/?$G_8,N?\
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MJ#A&8%P59-A&W80<;0., YSS6QI5C)IU@MO-?7%[+N9WN+@@L[,23P  !S@
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MA'<^&;VUCGN[$QJ9\(QC15C7;P#C(P3P"2#0!Z ?'OAE;(7K:EBU,WD)*8)
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M;1D^9Y2EE8,=N'8G()Z$T =E9^._#>H7-K!:Z@TANLB!_L\HCD;!.T.5V[L
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MMIMI EY'%' -J7NT3*#SAPO (SC Z5KT %%%% !1110 4444 %%%% !1110
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M;>!#)+(YP$4#))_"N=M/".D7%S;:G%>WUQ9^>+^WM6N2UNLC?,)%7KU.X#.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<$9!QD<^M5KKP='+)!+9:QJEA<):+92SPRJ[SQ+D@.9%;Y@2Q##!^8\UTM%
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ML,@;#G&1QSR<[%OX(TJTO/#MQ;M<1_V##+#:H'!5Q(H5B^1DGC.01R37244
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MB"X>:5T!!B=75555"*,J,X7)R>>F.CHH P-8\(:?K=QJ4UW)< ZAIPTZ548
M",,S!EX^]ESZC@<59TW19;"6VDEUC4+QH+9K<K.R!),L&#LJJ!N &T$=B<Y/
M-:U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5[B^M+1@MS=00
MDHS@22!<JHRQY[ <D]J +%%1M/"EN;AY8U@5-YD+ *%QG.>F,=Z='(DL:R1N
MKHX#*RG((/0@T .HHHH **** "BD9@JEF( '4FHOM5O_ ,_$7_?8H FHH!R,
MCI10 445#<7=M:F(7%Q%"9I!%'YCA=[GHHSU)]!0!-1110 45'//#;023W$J
M10QJ6>21@JJ!U))Z"G1R)-$DL3J\;@,K*<A@>A![B@!U%%% !14<%Q#=0+/;
MS1S1-]V2-@RGZ$5)0 445&EQ#)-+"DT;2Q8\Q%8%DR,C([9% $E%%(S!5+,0
M .I)H 6BHEN8&8*LT9)Z .*EH ***;++'#$\LKK'&BEG=S@*!U)/84 .HID,
MT5S!'/!*DL,BADD1@RL#T((ZBGT %%%% !1110 45"+NV-X;,7$1N@GF&'>-
MX3.-VWKC/&:<]Q#'/' \T:S2Y,<;, SXZX'?&: )**** "BBB@ HJ,7$)G,(
MEC\T#.S<-V/I4E !1110 4444 %%%,FFBMX7FFD2.*-2SN[ *H')))Z"@!]%
M(K*ZAE8,K#((.012T %%%1PW$-P',$T<H1S&Q1@VU@<%3CH0>HH DHHIKND:
M[G95'JQQ0 ZBHTGAD;:DJ,?0,#4E !114-U=VUC;M<7=Q%;P+C=),X11DX&2
M>.I H FHHHH **** "BBB@ HJ%KNV2[2T:XB%RZETA+C>RCJ0O4CWITMQ#"\
M22S1QO*VR-68 NV"<#U. 3CV- $E%%1RSPVZAII4C4G&78 ?K0!)12 @@$'(
M/0BEH ***C>XACFBA>:-99<^6C, SX&3@=\4 244UY$C&9'51TRQQ0DB2#,;
MJP]5.: '4444 %%%% !1110 45')<010//)-&D* EI&8!5 ZDGH*;:W=M?6R
M7-I<17$#YVRQ.'5L''!'!YH FHJ,W$*W*VQFC$[*76(L-Q4$ D#K@$CGW%24
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^\6D!4=@!GFFCQAX@O+;1[6RF@%S=:M-I[7<UFZ+)&L3.LHC8@@XP<9P2I'
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M.BLXX1!&K%EV*'.#O.[))Y [#% %G5/$NM>#;B>/5KN#5(WTJZOH72W\DK+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVMO%=K>".&!CB & NZ*!RN5?[H/0UWWBIO[1^'NMM:))+]HTJ<Q*(V#MNB;
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M  SR"<\8SFN3URZOI[VY-P^JB2TU^"9[&VL<0):QW$9$S,(]SDJ W#$^V%-
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M.UV&<3V\D3H';:K%&4-M)_BQCWK0U'5[/3Y8+6>Z2&YNED^SJREMVQ=S' [
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MP^$C0>(;A[.>U2YUJ>>))XC&S(RH0VT\C/7^?- %Y?$MI::EKXO]6M/LNFM
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M*)I#'&%<%B%!.,L.W>L*]LIY_!OQ*,=G,TEY<3M /)8-*IM8MNT8R><CZYH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBN(^)<=U)I^A);:A/:>9K=E&QB5#G,JX/S*>5(!';/4$4 =O17ENH^*M=3
M4M5-E/K$\FEW*6T-I;Z49H;L*J&0RR+&<,VYL;2H7 ..:U[#4-=O_$7BB1]6
M,=AI%PT<%LD$?SYMU;#,1G"LV1CG).<C H Z;6M"AUQM/::ZN8/L-TMW'Y!3
MYG4$#=N4\<GIBK=[J-EIWV?[9<Q0?:9EMX?,;'F2-G:H]2<'BO.-.U+Q7<P^
M#9I/$3;O$-N1<+]EBVP8A\T/'\OW\*0=V5RV<8 %-G\4:[9V^G6KZCY\L?C"
M/29;AX(]TUN5W88!<!N0,J!TH ]3K+N-#BNM;BU*:\O66)0%L_-_T?>"2'*X
MY89]<< XR :X75M9\2+IGC'5[?6V@CT*\D%M;+;Q%952.-RLA*DD'<0,$$9/
M)XQ+XF\4ZA8:I>7-CJMVZ6<UNAL[>P#VZABF]9IBIPY#Y&UAC*Y'- 'I-%>3
MSZEJF@:IX_U.+4[F=X;NUMX86@1U5I4A56VJH9BF_ 4'G'.2<U=37/$XL]5@
ML3KEY%&MM)'>76E"&X56D(G5$**LC*@#+\O?'.!0!Z74%I>VU_;^?:3I-%O9
M-Z'(W*Q5A^!!'X5C>#]0_M'2II!K$FJ".X:,23VWD31X /ERIA<."3_"O!''
M<\)HUQK.C^%K75[?5F6U&OR6YL/)0QO')?M&Q9B-^[+$@@@<#CKD ]1M=1LK
MV>Z@M;F*:6UD\N=$;)C;&<'T.*M5YH/$/B*Y;Q?':232&PU:*!/LMLCS16Y"
MF0HI'SL 21NS^/2NJ\*:F+W0IKC^UWU1(I77S9+?R9D  .R1,+AQ_NKP1QW(
M!T)Z5E:'H4.@QWB0W5S.+JZDNW,Y3AW.6QM4<9KA_"7BK7-5OM$NY'U6Y@U,
M,UW!)I;1VUJK(SHT<NP9 (522S;MV1BJNGZSXLN-"\*ZLWB F76+S[%-";6+
MRT0K)B1<+G>-F>3MR>F.H!ZO6?KDMK#H=X][J#Z?;>41)=I($:$'C<&((!&>
MM<!<Z[XDLI+K1XM8,US!X@M;!+V>WC+F&:)7(954*2"QY &<"J/C:\U*W\+>
M.= U#49-12VT^WNK>XEC1) LCLI1M@53@QY!P.M 'I^DV$&G:?'#;S2SAOWC
M3S/O>5CR69NY/Y8P!@"KU<+;SZQKNMW.E6.L2Z5;Z986K!H(8W::656.6WJW
MR *.!@G)YJOH'C#4KFZ\-WNIRQII^LV,D3*% 2*\B))(;KM=5? )/W: /0J*
M\RLM<\2ZS=>'PNJM9VVNRWUPFVWC+Q6RA3"%W*1NV\Y.?OG.<"H$UKQ/;Z%<
M:M/KS3'3-;&FF'[-$%NHA<K$6D^7(?#?PE1P..: /5**\P3Q;K=UK,US:MJT
MJQ:NUD+"+2F:V-NLOE.QF"9W@!GSOP,8Q1?:WXD31_$&O)K;(FDZM)!#9K;Q
M;)8EE4%9"5W9PQ ((QC)S0!Z?6??:[I6F7EK:7VHVMO<W;!+>&64*\I)QA1U
M/) KEO"<%Y_PL'QG)-JEQ-%'<PH('2,+\T*,.0H/R@[1SR.3D\UD:C;74/QQ
M>Z_M:Z5(?#S76Q8HC^[6<9A&4/RG&<_>YX;% 'J%%><6&L>(+?2_"WB*[U=K
MF/6[BWCGL#!&L423J2GED*'RI*YW,<\]*U? MWK>L?;M3U+53+;QWEU:0VBP
MHJA4F(5V8#)8 ;>N,=<GF@#J+[4K'3(1-J%[;6D1. ]Q*L:D_4D5);75O>VZ
MW%K/%/"_W9(G#*WT(XKBM/L[36/B'XJNM4M4O)=,%O;V<4J!_*C:(2,44\99
MB>?]G%9C>(],T#3?$LN@Z%>:3JGEP3M;WD/EQ;I7\E) @8@<Y)P!G;S0!Z=1
M7GFL:[K'@B[E2[U276(9-(N[V/[1#&C)- $.!Y:K\C;^AR1CK3VU37/#5YH<
MVHZQ)JD.IPS?:(9(8T$4B0-,#$44$+\A7#%NH.: .YN+VVM'@2XG2)KB3RH0
MQQO?!.T>IPI/X4V]U&QTY%>^O;>U5SA6GE5 3Z#)KS0'6;N'P#K&I:NUV-1U
M"*X>W,,:) SV\K*(RH!P 2#N+$\'(YSK?$%D3Q'X/:32Y-447=QFTC1&:3_1
MWZ!R%XZ\GM0!VMGJ-CJ*,]C>V]TJG#&"57 ^N#5FO*[*\B;Q7J6OZ=X?.BQ:
M#ITZ7]O((XY;EV59(U*1DC: I(8GG.!T-3Z'XHUH-%<75YJ,MM/ITMQ=3ZAI
M36]O9RJH=2CA%S']X8)8\ YYH [_ %;3?[5L'M/MMW9ASS+:2!),=QD@XS[<
M^]2Z=I]KI.G6^GV4(AM;>,1Q1C^%1_/ZUYS8>(O$;2:A96-W?ZE<OH[7ELU_
MIZVQ\X,%_=KM3*'<" W<#GFGKXGOQIPM+'7[FXO+O4;:Q!U"P6&YL#)N+EDV
MJK<*=ORXSGEJ /3**\SUW7]?\-)K^F)JK7L]M9VM[9W=S#&'7S)S&R.%4*1\
MO!V@\GTK>TJXU:P\=2:+?:M)J-O-IOVQ3+#&AB<2!"%V ?*0PX.2,=30!UU%
M><>./$VH:3=ZI/I^K7>[3+=)?L5K8"6('!8BXD*G;N&,!64@<U;NM8U2V\:M
M;W^K76FV[W<4=C$]DKVEU$57*F7;E92Q< %EY"\'/(!WE%<IXJO=677_  YI
M>F:A]B34)9TN)!$CL%2(O\NX$ \<=N>0>E<S>^(O$EG%+H\6JA[ZW\16^FB^
MDMT)>":(."R@!=PW=@,[1TR: /0KK2+:[UG3]4D:07%BLJ1!2-I$@4-D8_V1
MBK]</'_;NI>([S08?$=U;)I5G \ETEO"9;F:4N06#(5"@(.% SGK53PYXPU.
MYOM"N-6FC6QU73YE(5 %CNX'.\@]=K(&(!)QLH [FYU&RL[FUMKFYBBFNW*0
M([8,C 9(7U.*R[W2M,M-<7Q'J=],6A(BMTN)1Y-NTFV/Y%P/F8D#))/S$#&:
MXZT\4Z_/<>#KJ:YVP:[J5PXA:%,K:["84SC/W0K9Z_-UJEJ]UK&N>"1K\^JO
M]EN-9A1=/\F,1QQ)?*B88#?OR@))8CDC'2@#URH+R]MM/M7N;R=(($(#2.<
M9( Y^I KS=O%NMW&LW=Q:-JTHMM6-DMA#I3/;/ DHCD8S!"0_#/G< , $52\
M0W6LZYX(UC6I-5=;3^T_L\>G^3'Y8BCNEC!W8W[\KNSNQSC% 'J6H:C9:39/
M>:A<Q6ULA :65MJ@D@#GW) JU7(_$S6+[0? =[J.FS"*ZCD@57**X :5%/#
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M(T3:S#:P!V]\D'%=3X,U+4;Z#4(K\7\D=O<;;:ZOK,VTL\113EEVJ,ABRY
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M /6Z*Q_"M_?ZEX9LKK4X)(+UE*RI)"8F)5BN[8>5W ;L>];% !1110 4444
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MW81"_P WS\Y QQ6]-XA&A6=I%X@D674I@[>5IEK++N53RP0!F"@%<D\9/N*
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M)C#[<%^#A>IZ8S4X\=>'QITM]-=RV\4-RMI*MQ;21R1RL 55D*[AD$$'&.:
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M21;27]\TGW5C&W+MV(7)!ZXK-\2>-3%HNE7^B2@_:-9M]/N%GA97C#-AU9&
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M9Q?Z1$# Z,P0J22&<9&TG&ZJNK:+)<:#97&FVVNW33^)[2ZE>_AQ*ZH%4R[
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MG#%=N-F.-O H IS>)KEXM(TVTU?6[R*XGNC/+!8JM]$(@F(74K@$&0$MM!(
M]<GH_#NGRZY9:=J.O6;G4-.GN$@FNK98YI(R616;CY=R$%@, GZ8K,_X1V]$
M$933=8344N7NO[26^MO/:1E"-G(V$%54;=N/E'&1FNL\.6\UGI*VT\%U$R.W
MS7=PLTDA)W%BPXY)/'&.P Q0!S?B:SM_!?@ZWOM+B2'^S+Z.8)$@12DLX65
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M]6XC19.9"L$C[1@,&55;'!W4EQJWB'4EN=6@N-4_L*34Y(572XHWG2")2@=
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M+YVW]T#$OR+M4?*.V<GW-30>#K-+?55N[V^OKG4[?[+<7=RZ>9Y6& 5=JA5
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M.C6S>(TUPM)]K2T:S"Y&S87#GC&<Y4=Z /,X-5N[:P\5^,=.L$TMI/)TU+)
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MFB8#2+99),[MB [@0%4*>,<DBNI\4Z(/$?AB_P!)\WRGN(_W4G]R12&1OP8
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M*(A0  #(R&.>?RJ#3O!MK8WD5U/J.HZA);P-;VOVR16%NC8#;=JC)( &YLG
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M'QEHVE27B7<\B&TN(;>;$3-AY5#(!CKD$=*L:-XCL=<FN[>!+F"ZM"OG6]U
MT4BA@2K8/4'!P?8UYOK;7YO;_5I-(NXX[GQ#I4MK#,@5YE0*O )P"2.AZ9&<
M<UV&@BXU/QQJNO?8;NSLC8V]E%]KA,3RLKR.S;3S@;P,GKSB@"Q)XQBB\<3>
M'9+.X1(;(73W1B;8N2W)/0+A3\WKD=JDM/&^CWD4\@%Y"L5HUZAN+9X_.@7K
M)'D?,.1[\CCD5@>)=,OKKQIJL4=G=&'5O#AT^&ZCC+1QS;I3AV'W>'!R:S;+
M1GN],N<:?XE-_;Z-<0?\3&0F..1T"F*,'[^2.JY'RCGF@#K%\?Z&VFQ:B?MJ
MV<\Z6\$K6C@3NREAY8QE_ND<9YX&<U _Q(T.*"ZDDBU-&LVQ>QFQDWV@P#OD
M&/E4@Y![C..AQ3N-)O3X7\!VR6<OF65W9/<1A.852%@Q8=L' J'5-(OY8/B4
M([*5FU"V5;7"?Z\_9 N%]?FX^M &S-XGLK+7=:^T:H[V^GZ>EY+;+;#$28)+
MAQRV0.GM4UEXUT>]O#;!KF#-NUU%+<6[QQSQ+C<Z,1A@,@_0@]*XF_T#5I+W
MQ>Z:?<,MUX7BM8"$/[R41L"@]3DCBMSQ'8:TMYH5SI%J[75II%\D;;?ECF,4
M7EJ<\<LO?TH T3X_TQ]-OKJ&VU#?;69O4AEM'C::'LZ CE<XSZ9YJ"U\7+J,
M?A2X>XN-.?52?]$>TSYY\O<1N/*J.H8=:Y>'3=0NM2FDAL?$$J7F@7=D)]3+
MEOM!V-@JW^K4X(!P 3P.V;4%GJ%^_P -I4TJ_B&F,T5X)X"AA(MPF2#V+< ]
MZ .L/CC1A?\ V?-UY(N?L9O?LS_9_.SMV>9C&=WRYZ9XS4=WX_T.SGNHY/MC
M)9W'V>[GCM7:.W;('SL!@#D?SKD_[/U3_A#3X(_LF^^W?VA_Q]^2?L_D_:O.
M\[S.GW?X?O;N,5;U'1=1D\#^/+6.QF:XO;^XDMXPGS3*5C *COG!_*@#T#4=
M0M-)TZXU"^F6&UMT,DLC=% ^G7Z"L:V\::7.+P2QWMI+:VK7CPW=J\3M".KJ
M"/F';U!QG&:/'.F7>K^#;ZTL8O-N?W4J19 \PQR+)LR>.=N/QKFM8COO%.HW
M5_::3J%M!:Z%>VP^U6YB>::8+A%4\G&P\],D8S0!V6A>(+/Q%:O=6"7/V8$;
M)I8&C64$9RA/WAVR.*JOXQTE-7.GDW/%P+1KD6[&!9SC$9DQC=R!Z9('7BK7
MABWDL_">CVTT1BEAL88WC88*D( 01[5P,'AYX]7N]-O[3Q%.TVLO=QB"4K9&
M-IO.60G[HV]UZDKP.: .U?QAH\=C<7+RR@P7@L7@\H^;YY( 0)U).01C@@YZ
M5BZQXUCT)/%UT+B;4)-(2$_8A;;5MV>/<H+CEE8\DG[M95WI>JR^,&\<II3F
M*UN%MET[RSYT\(#(USM_YZ#<=HZ[ 1W%5=9\/:O=O\4_)T^=O[2@M?L?RX\\
MK!A@OJ0>/K0!Z;8WHO\ 3XKL13PB1<[)XRCK]5/(KE](\;Z:GAO1KJXU&YU*
M34O-%M+'9%9+AD8Y C7H>,?AGUKI=.N_[0TF&Y%O<0>8G^JN8C'(N..5/(Z5
MYOX&T'5;'2?A]'=Z?<0O8F_^TAT(,._?MW>F<C'UH [)?&^CMI*WX^UEFNC9
MBT^S/]H,XY,?EXSD 9],<YQ0/&^D-80W,0NY99IWMELX[9S<"5!EU,>,@J.2
M3QC'/(SRG]EZGINOR:Z=-NY[>U\17,[Q0Q[I'AEM5C$J+U8!O3G&:EUJ._UF
M^TC7I]*UJPL[>2ZA*6)(N]CB/9*R*-P!,9!7D@%2>^ #II?'&BQV^GRH]S,V
MH"7[-#%;NTCM&0'39C(8$X(/3!ST-9M_\1K&"'2)K.ROKE;Z^>SD06SB2%D#
M;U*XSO!7[O<9/:J6CZ'+;Z[X7NK?3]0AMU_M&:8WK[Y4:4H07/8M@G';)%9U
MUINIV,L%^VEWLT5OXMGO'2"$NYA:-U#A1R1EATH Z?\ X2VPL-9UQ+W4Y9(;
M.XM('A^R[5M#, %RXY8,2"2?NUKZEXCTS2;Z.SO;CRY&MI;MCM)6.*/&YV/8
M<CZUQ]MX7GU?Q#\1+>^M98;+5TM4MYG3 ;$!!9?=6Q^(K.M= \0^)_#/B.^U
M:RDMM9N=.CTVVAE.TD1IN<@]A)*6Y] * .]T;Q-8ZW<26\,=W;W$<:S>3=V[
M0LT;9 =0PY&01[=\5'JOBW3M(U0:7)'>7%^8!<K;VELTKF/<5W84= 0<_4>H
MK&\)64,FNR:B+7Q$LL=IY!FUB1L#<P8HJMR<%0=PX]":@U+4_P"ROBQ)<-87
M=U&="16^R0F5T/GN1\HY(..HZ<9]: -:X\?:%!:Z9/')<W(U.)Y;..VMWDDF
MV%0RA0,[AN&0>F#GH:=?>.=&T^ZN(IA>&.T*K=W,=J[0VS, 0)' P#@@GTSS
MBN7\->']4LM4\&S75A+&(8M3FG!&1;F>171&(X!P2/P-%_;ZE8Z3XQ\/+HU]
M=7.L7%P]E-%%NA=9T"@N_1-AR#NQP!C- '6:GXUT?2;ZXM;AKES:Q++=2P6[
MR1VZL,J9& PN0,_3DX'-,_X3C1VU"RL(1=SW5Y;PW44<-L[GRI20KM@?*HQR
M3TX]:Y.\BOO#</C"SDTRZO5O[-'@N8T!B(6U6)A(V?DP4)YZ@\9/%7_!6GW2
M:_9:@ULXMF\+V$"3%?E+@N67/K@J?RH Z*Q\8Z5J.JQV$'VH&9Y(X)Y+=EAG
M:/.\(Y&&(PWUP<9Q6?'\2?#TJ6LJF^^SW3&."X^QR>7)* ?W2D#E^" !U(QU
MXKEM-@UF76_#6H:C9:_->6U])_:3S;O(B9XI47RHQ\I0%A\ZC@8R>35W3=$U
M*+P;X&M9+"99K/5EFN(RG,28F^9AV'S+^8H V-4\8/)X>N]:T<3J=&GSJ5A<
MV^R1H@ 77!Y!",'4C@XQWKL(9H[B".:)@\<BAT8="",@UY[K"R:38?$F^NX'
M2WN446Y9>)B;5(P%]<O\OUKLM#M)]/\ #&FV<F/M%O911-GIO5 /YB@"CIWC
M/2=3OEM8/M2^:LC6\TMNR1W 3[YC8C#8_4<C(J'3/'NB:M<:?';?;!%J(_T6
MXDM72&5MI8H'(QN !X]B.HKC-)M]8EU?PUJ%]9>();J+S8]2DNPWE1SR1,O[
MN,?*$W9&]1@ KR><:EAHVHQ^#OAW:M93)-8W<#W2;.80+>526].6 ^IH N:M
MX^@D?3(](-R%N-7@L_M,EJPAG4R[9%1R,$\'GV)&<5U>L:S9Z%IS7MZSB/>L
M:K&A=Y'8A555'))) Q7FEE;:LGAKPMX;.A:@+K2=6MC=3M#B$1QR_P"L5^C
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M8D9"L003M_O$"@#TBJ.LI:OHMY]MN)[>U6(O-+!*\;HJ_,2&3YAP.U<GX?\
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MDR2;21E9"$SW!YJ)M:U?5KU'AU*XMK#6M=-A;/$1F.V@C?<R$CAI'C;GTZ4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9<_B/2+;S_.O
MHE%O.EM*>2$E;&U"0.O(X[9&: -2BJUKJ%I>RW,5O.LDEK)Y4Z#K&V <$?0@
M^X-6: "BBB@ HHHH **0L%&6( ]34$-_:W%Y<VD4RO<6NWSHQU3<,KGZB@"Q
M1110 45C7'B_PU:7$EO<^(=)AGB8K)')>QJR,.H()R#6I;75O>VT=S:SQ3P2
M#<DL3AE8>H(X- $M%%% !15.UU2QO;Z\LK:Y22YLF5;F->L98;E!^HYJY0 4
M444 %%%% !15>"_M;JZNK:&97FM&5)T'6-BH8 _@0?QJQ0 450?6M-CU"XL'
MNXQ=6]O]IEBYRD7(W'VX-36%_:ZI807UE,L]K.@>*5>C*>XH LT444 %%%%
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M90@CCD*%SD^U=YX@T*V\1Z0^G74L\*&1)5E@8*\;HP96!((R"!U!J"W\,6L
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MC8T:@(4(&5(P#WY%+::%'H,UUK4MQJ>LZAY A#RF-I?+!SL15"+R>3W.!DT
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MMKR[*ZA)YTUJ[*8A*0H+CY=P)"COCVI=:\/1:S<V5T+Z\L;NS+^5/:,H;:X
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M^@&>^: )],U&/5;!+N*"Z@1R0$NH&AD&#CE6 (JY110 4444 %%%% !1110
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M;'0^>FW*C[N%7=CL![5H^+X+X7_AW4K>"6YM-/OS+=P0H7<HT;H'"CEMI8'
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M[IY;]8EM=MJY\\BW1?E..<.#_.F^-;=M^NW,=E.EI_PB$\ D-LRH'!+!22,
M@9X[4 >A6VMZ;J4US::;JEE<7D"_O(XY5D,1/3<H.<?E6;X8\2C4O!FF:UJT
MUK;2W<>YL'8F[)X7))Z#I6-8:>EUXE\/:O8V,UM!I^E2QW3FV:+>'";(P" 7
MP0S<9 _$5D>&K+5-)M/!-[=:?>_9;.TN;2[@%NYDMY'*E7* ;B/E*Y .-WH3
M0!Z(VN:2L-K,VJ60BNVVVSF=<3'T0Y^8_2I9-2L8GG22]MT>W"M,K2J#&#T+
M<\9[9KAX?"ES=>%O$"@FTFGU675-*,HVFV=2K(Q!^Z"ZLQ'HYS@YJ._AU>]\
M):=X@.G7$UW-?PZE>V%K(1*8-A4(A!!+*I1L9Y8'UH [F+6-,GLFO8M0M7M4
M8HTRRJ55@<;2<\'/&.M9^K:Q=2^&Y=1\,O87\ZL/+#NS1R8;#*"F3NZ@>AZU
MQ]_9>7!:Z_I'A_61;#4Q=7ULTDJW=P#"\1D5"VX%=R\<%L'CH3U_A6TLX+*[
MN+'3+NPCO+EKAEO&?S97( +LKDE<XZ''3..: -*?5;"UN$M[F]MX9W*A8WE
M)+'"C!]3P/6GW>HV5@8A>7D%N9FV1^;($WMZ#/4UQ6OVFI1>)9[[11>&X::V
M6XLI[5I+2\0%<.KXQ$Z9/.?X!D5I^.+62Z7P^([2:Y$6L032".%I-B+NW,<
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MQGC^S6A9;N-'B+2,Y&2RA2NP8(VY(/4 '?3^)="M;AK>XUK3XIE<HR/<H"&
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MR6;23^:JE8SEEVX0XR 4';% 'HESXDT.R17NM9T^%6B$X,ERB@QD@!^3]W+
M9Z<BKUQ=V]I!Y]S/'#%D#>[ #)Z#)]:X+3]"MK3Q9X>B@T*>WTR#2KJ%8Y8V
MF6$O)&RJSG(R5#\9..F>E;/BN"]CUOPUJD,$US8V%U(;N&%"[@/$R+(%'+;2
MW( )PQXH M:_XMT_1_"5YKT-Q;W,42-Y6V8;99!D!,^N1SW&#Z5):ZG<6MA?
M:CJE_IL^G(!);W%KE,KCY@V6(SNX!!Y^M<7KFCWS^&O'4]K9W;1:O/&UE:)
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MAC>Y0,& W$$9Z@<GVJPFKZ;);V\\>H6K0W)VP2+,I64\G"G.&Z'IZ5S?AVP
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MDJ2QW8SQGL<BN>BAN_$/@Z2PM_#UWIFN6^D26 N+J'RA$Q0+LC?^)691RO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSY<+E_+BN'C63(P5<*1N4@]#Q6D!@8'2N=\;S:E9^&9M2TJ207&GNEVT2?\
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M!9D W<*#SU!KFK[7M:U6]U$:3<ZU>-96EN;"?38HA!-*\(D\R56()#%E&WH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCL9+V%+F1_+1"V,OC.S/3=CG;UQVI(M<TN>_%E%?0M<,SJJ!OOLGWPIZ$KW
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M,C 9"CW/2L"P\375W=:=$^E:BD=U9M/YCV3( ZDY1\G]V>!@'.=PYXY '?\
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MI""SOCKA0"2!W..* .1TCPGJMKH^N:&)#%;VL-Q9Z-.S9.R9=^X]_D)5 ?\
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M18B]PKJPBC*DY!VM\^0!D?AT_P#PA_AO_H!Z?_WX7_"C_A#_  W_ - /3_\
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M;I+N"ZV@Q.OE1H1G.=V0>,=JZUW6-&=V"JHR6)P *SK+P]HVG7(N++2[2WF
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M/^P_LXE^SMC?YF[9C&<[?\.M=C5>^OK;3+"XOKV98;6WC,DLC=%4#)- &'X
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M>-V.V<9[USFO3ZH;#QWJT>MZC#+HUWFQBBG*QIB&)R&7HRDG[IR.N.M=;;^
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MM3_:!-C&_P S.<[?E],<8Q0 WP;_ &LND3Q:O!>1-'=2+;"]D228P<%=[(S
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M6FRI<3QZF,7DT\[/+-Q@9<G/ & !P* +'A>R6P\-6$237$P,"/NN)FD894<
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MK_A6Z?2YEAL-(EMKEO,B^21A#A?O\_ZMN1D<BN?TBVU#0]9\%VU]IDZW,?\
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M%9<,XQL)RW7((V[JN^*O$U_H6JZ#9V6E2WHU"Z:*0HT8.!&[;5W.N&R <GC
M/?%9US;>))]?\*ZY=:.LDMN+N*[M[69,VZRE/+)+L V OS;3US@&K_C&QU*6
M_P##NI:=I\E__9U^9IH(I$1RC1.F0795X+#O0 EWX]M;66\F_LR_DTJRN?LM
MUJ2"/RHI 0K?*6WE5)P2%('/7!K:US68]$LDG:WFN999D@A@AV[I)'. H+$
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M2S!<@J."0<$UT'@RPU2UDU^ZU6R%I)?ZFUU%&)%?$9BC49*DC(VD'W!QD8)
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MMGK2WD=]J>LOI=K->:Y:V.DP-;7<.JBW.]VE!G+*0)&'E@9YQM/K0!ZP  ,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO."J&(*J25;:=P!'(ST/% '2W-O#=VLMM<1K)#,ACD1NC*1@@_A5%_#^E2Z
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M4+LZ/J&F6ZW-SI=\+G[,9 GFH4>-@&/ ;#Y&>.*Z0LJD D DX&3U-*2 "2<
M=Z /,[OP_P");^;7;^;30B7]W92FPCNU#S01##Q%P0 3P3S@],D<U5D\'ZW'
MIVLQV6A6UJL^H66HVMK#<(%Q$T>Z(GH'PA.?NY/4UZ#IWB+3]5N_LUJTS,T
MN8W:%E26(G =&(P1T_,'H:FU/6++2#9B\=T-W<):P[8V8&1CA02!@?4XH X*
M^\(W%SK.I7<_A.VU ZLT4P>XNPJVC>6B/'( ?F VY!4'.2..M=UKNDKK/AK4
M='5Q$+NTDM@V/N;E*@_AFGV6L66H:C?V%N[FXL&5+A6C9=I8;AC(&>.<CBK]
M '#V6G:_JNK>'&U32TL(=%WR2R"X607$IB,0\L+R%^9FRV#T&*O^ ]$OM!TB
M_M[^-4DFU.YN4"L&RCN2IX]NU=35:6^BAU"WLF28RW"NR,L3% %QG<P&%/(Q
MGKSB@#E]6TG5?^$\;4[6Q%Q976D&P>03*IA?>S D'D@YQQ5:/PMJ+:!X&L98
ME#:6$6]PX^0"UDB./7YF'2NZHH \Z\'>$)-'N]+AN/#%I#+IT11]4^T[O.8+
ML#1H#D%@23N QD@9K<\=:7J&IZ9IITZR6\EM-3M[MH&D5 Z(22,MQ74,P52S
M$  9)/:J)UFR&NIHV]_MSV[7*KY;;3&K*I.[&#RPXSF@#(TJ[UB6^6*X\(1Z
M="ZL&N5O(GV\9 PHR<G K'TOPMJMKX?\!VDL*";1YU>\ D!V 02IP>_S,.E=
M]10!Y9KFFZII7B.VNX[:.62\\5+<VT9D \Q!8LI&?X3\C 9]NU.\1>$M?\1>
M&_%LWV!+:_UB:S%O9O.A*1P.ARS [<GYS@$]JZ_6]?T*RN$-_#+</93C#0VK
MS>1,R':/E!PQ5L#_ 'AZC._#*L\$<JA@KJ& 92I (SR#R#[4 <A=6>NZ+XEU
MK4-+TM=2BU:*$K_I"Q>1-&A3Y]W5"-IRN3P>*YKQ+X>O/#GA7PE::7=Q_P!N
MP#^R8VY'FK-&5D('7"L!)[!*]7JB-*TR355U<65L]^(_*6Z\L&0+Z!NH'6@#
MB=8\$1VFJV-Q:>'TUBR@TR/3UM_M A:(QL2C9) ((8@]^!P:T]%\-W>G>+;*
M^%G;6UG%H2V92W?*)+YN\JH/.WKR:[&B@#-TC4IM1;45FMA!]EO'MT*OO$BJ
M%(?IQUQCL0:Y WFKV7Q'\4/I6E#42UC9 H)UB*O^^VD[N"O7/<<8!KT&L^%K
M%->NHXK9DOI((WFG$)"R("P0;\8)'S<9R,^] 'G,7P]N-&CTXR:'#KQ328;.
M1!<B'RIHV=MP+$90^81ZC:..:ZC1?#MUIOC".]%K;P6*:'!9*L#?(DBR.Q50
M>=H!&":ZZB@#S%O#GB&.QOM/?23<6?\ ;\NH/''>(@OK:1G;9U&""R$AL [<
M54E\$ZVVBWNGV^D6UHDFOVVIPQPS+Y:Q!8PR]OF78<\8.>*]9HH XJ[\.:E+
MIWCZ%(D+ZP'^QC>/GS:I&,^GS*1S5%_">KMK^L78A3R;GPTFG1'S!S.-V1[#
MD<]*]#HH X>^\+WUY:^%;>0*D=C9S07C[Q^[WVQCR/7YCVKG[.YU.=_AW8SV
M]F(+:YV)/;W2S"Z$=K(OF1[>B8ZYYRP%>L5SEK9^%M'\5K:V>EVEKK%Y#),)
M(;38712-_P X&.K#(SWH 3QWI5]K/A66VTV)9KM+BWG2)G";_+F1RN3P"0IZ
MUDFU\1Z=JFM7UCH@N?[;BBD"-=1J;2=8A&5DR?F7 4Y7/?CI7=4BLKJ&4@J1
MD$'@T 9GAO2#H/AC2](,@D:SM8X&<=&*J 2/QK4HHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *XZ[CE?XN:>!>7"QC1IY/*5ALR)H0>"._?OP.:[&J
M%WHNG7]_;7US:H]U;*RPRY(9 V,C(]P#[$ ]: /-_"ESJ&F:/X-GAU&8V]]J
M5S9RV95/+V$SL".-VX,@.<_A6SH&HZ]K]KI&O1:E;P6MQ*ZW<#2[A@DJ$5?+
M^5T;'\1S@YS72Q>%=%@@LX(K,K%93&>V02OB*0YRPYZ\M^9]326OA'0++5Y]
M6M=,AAOIRS/*F1\S#!8#. QYRP )R>: .*T76-<^P>$]3N=:N+EK_59K&X@>
M.,1NF9\'A00P\M>0<=L5U_B_69=&TVS:*40?:[^WM'N" ?)61P"W/&<< G@$
M@U/%X5T6&WM+>.S*PV<QN+=!,^(Y#G+#GKRW_?1]35_4=.L]6T^:PU"VCN;2
M9=LD4BY5A0!R/B.;5O#^E74L.NR3$:C9>2C1J7AADF2-T8G.X'+D' (]>*S?
M%&O:S9#QP+35)8CIUO9S6N$0^47W;QRO(.!UY'8BNQC\*:'%H<VBKIT7]GS<
MR1$D[SQ@EB=Q(P,'.1@8Z5$W@OPZT5U&VF1E;M$CN"7;,JKT#'.3Z\]>] &#
MJMOK=KXET72(_%&H"+4OMCROY4.Y-J*5"?)Q@D]<]?H:CBO_ !!JIU)[#58(
M)=)U#[.YN90%,<>W=YB"/^-<MD$8R,8QSV,NBV$][97LL+O<V0(MY#*^4!&#
MWYR.#GKWJK/X3T&YUU=;FTR!M17;^_P06*_=+#.&(XP2"1@8H XB_P!7UVWL
M/$NI+K=R3I.N1000^7%L>)O(RC_+DC$C8Q@]\FM_PW'+_P )]XO9[RYD2.:V
M58W8%0#"K8'' !)QCU[UL2^%=%FM[R"2S+17DPN+A#*^)9!C#'GKPOY#T%6H
M=&TZWU274XK5%O946.2;)+.%&!GU..,]<4 8'C+4]3TR:"X@BO)=,2"0W?\
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MXH@QDCEC0.I*G!.XYZCK@#J"VU'4=2MO!QU643W=MXDN+1K@*%$XBCN4#X'
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MX@N;!)_#]IJ ^SQ192:0N#C<I^7Y02.OH14.DZQ>ZS??#[5;] ;R6QOFD"#
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M^&R2X*A3.B2 JQ P,X;!P,94UW1\,Z0;*SM!:;8K$@VNV5U># V_(X.Y1CC
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MWL;6*UM84A@B4*D:# 45-0 4444 %%%% !1110 4444 %%%% !1110 4444
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M>4)(GY.>#B,\>XYZXH^/=.OX;7Q9JKVP6VN[2PAA+2#.^.<DY S@'S!SST-
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M8Y=ARLFW&\&-23M&<D=LGL-'MY;;38TFM;6TD8EFM[4?NX\G. <#)]3@9.:
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M)+GS3+-,JJ6SM&U %X[\]L4 7M*\9W%_J.D0W6BRV=KK$+2V4[3JY8J@<AT
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MD,A7YHU;&X ]@=J_D*L44 <M>^#++5O%=[J>JVMI>6<UE!!'%*N65T:4L>G
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M)8Q6L*0(6ZE54*,_@*M444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M</XF\*7^K>(KB[BL],NX+K3ULTEOB2UBP9RSHFTAMP=>Z\H.<5W%% ''^%/#
MFJ:7J$=WJ M5*Z-::>5AE+_/"TF3DJ."&4_F.V3E:)X3\1>&#I-S8QZ=>7$>
ME+IUW%+</$JE9&='5@AR/G8$8':O1:* ,#P7HUYX?\*VNFW\L4MU'),[R19V
MMOE=P1GV8<5OT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>[:>1C#*2N1_M#!-9?B_PC=>)=4D*/'';RZ-=67F,<[99'B9"1W'R'-/\):
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M)E=,XZ'>=ASU61O2H;G0-6M?%6JRPZ+I6JV&JR),)KMP&M)!&L;!@5)=,(I
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M\5Z/:S7DQMKOP\UQ,A<@&4/"-X/8X9NGK6+HFJZOJEIX#$NLW:C4H[H71CV
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MSGQ1#YLDNS79P'D.6(\N/&3W^M '2:CJD&F^2DBR2SW#%8((@"\A"EB!D@<
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MEB\L$4UM>F 1AMQR I<$'&,-QP#QG(K5N=>AL)GLY(Y[NYMK=)[GR$7Y%8L
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M<6EVT:03FXB5%VA)#_&,=#R>?>CQ3JD^B>%M4U.VA:6:UM99448P"JD@G)'
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M 6\VO2:6DL-SN,)W.J@CRQD!E5=V<G=GCI6D/B#:K/XH66S:.+0X6F60R?\
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MWOB6+5[>WCT^^CN(#]MM[DCSK=0OF13)C#G[X7_@)R,8KM6=5!+,  ,DD]*
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M<:S\)Y'<R/\ V??KN8DDXB4#KSV[UZG<>']&NULTN=)L9ELL?95>W4B#&/N
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M+W'9G=SNQC/;/2K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 UT21&1U5D88*L,@BDBBC@C6.*-8T7HJ# 'X4^B@ ILD:2QM'(
MBNC#!5AD'\*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:2UN)H+/467S%D9=C),JJP[Y&.V.] 'HU%<Q-XHO6\27>EV&D)=Q6+PI=/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M::NLK1W-HBE2ZD!3OY#8^8 [L$<<S?$/[5Y7ALV7E&Y&N0&,2DA6(20X)&2
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MVLA"0&&569,!!NRJYW<<G&,<UJ>+/!U_K^IZE<6\T$2SZ7#;P,Y/$\<YF7<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9@N/F(]/ESZBL=?!YTS3-$MM+D63^S;PW<J7#;1=NRN&9B <-N?>.,9 ''!
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M^93Z[,]ZZFN&BBU*VN_%OB;3$MFFO&MX;);HL(Y4A7:6^4$G<S.%P.<+C@T
M=R.114<#R26\3RQ^7(R NF<[3CD9[XJ2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *KG3[)KP7C6EN;H<"8QC>/^!8S5BB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ I H#%@!D]3CK2T4 %%%% !1110 4444 %%%% "$!E*L 01
M@@]Z7H,"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK0]6C"?9;.UNHI26Y#2>7MP._P!PU8U'Q/IVGV5Q=;GG6WO(K*981DI+(R*
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M%;:/:1I)"]O)A.7C?&Y2>I!VK^0K2.G69GM9S;1^;:*R0/CF-6 ! ],@#\J
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M]3^PM/X5A_TIWVK"[%AYG48P3G->C)H>EQVEW:I8PB"\79<1[>)1L$>&]?E
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MK''MR: -E]&T^234'>U4MJ$8BNSD_O5"E0#^!(XJA>^#O#^H- UUIL<GD0K
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M66XBV@;F ";F W8/7DCCWH M7'A'0KK3K*PDL%%O8KLMA'(Z-$N,85E(;!&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\ZOO#7B :3KWAFUL
M[=['5[N:5-0:X \B.=MT@9,9+#+8QP>,D5Z+10!RMEH%Y;?$F]UK:GV"32H;
M2,[OFWJ[$\>F".:=XPTS4[NXT&_TNU2[ETV_^T/ THC+H8W0X8\9&X&NHHH
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M2VD\X_LOS1\L$@4+\Y^5I 4!/088CMSZ#5>QOK;4[&&]LYEFMIE#QR+T8>M
M'"OX0OFE\(RVVEV&GII^HRW=U;6S_)&K*P&"?O-R,D=\XJ67P=J#>/\ [0/*
M_P"$=>Z35G3=\WVM8S&!M]/NOGU%=[10!YQ;^"&M?$%QO\,Z7>I/J;7JZI/(
M-T<;OYC*4QDNI)"]NA)XQ73>.='N]?\ !>I:98!#=3(IC#MM#%75L9[9QBNA
MJNE];2:A-8),K74$:2R1CJJN6"D_4HWY4 8&DZ=J3^*M1UJ]M%M4N].MH!%Y
MH<JZ/,6!(]G7FN-M/A_>:?::7+=^';#6IDTF&REAFG"^1+&7(8$C!4[\''/R
MC@UZS10!3TRS6RTBTLO(@B$4*QF* $1K@8(4'^'T]JX_2+/Q=X2TW^P=/TFS
MU2S@++87DEYY/EQDDJLJ[225SC*YR .E=Y10!Q5UH7B.QOM*U^UFMM3U>WM&
ML]0BD/D+=1LP?*$ A2K#C(Y!.<5/9Z;K6M^*;'6];LX=.M],CD%I:)/YTCR2
M#:TCL   %R !GJ237757OKR#3M/N;ZY8K!;1--(P&<*H))_(4 ><Z)I7BW3/
M!"^&'\,:?/\ NY8OM%QJ"^6=[L<L@0D@;NGM6I8>!Y;?5O#:WZ0:C9Z9HTEE
M+).H;=*6BP0K9XPC<]JZ7P[KB^(M(BU..PO+."8!H1=! TB$ JX"LV 0>^#Q
MTJS-J=I!=2VK2@W,5N;EHA][R\D9_,$4 <FFAZYX<@\1V7ARWMVM+M#<Z:"X
M3[-</PZX_N9^<>G(]*A@^$GA]?"ZZ-++J+9@\N1AJ-P$:0C)?R]^SELMC&,U
MV.CZG#K6BV.J6Z.D%Y D\:R !@K*" <$C/-.T^\DOK=I9+*YLRLC)Y=P%#$
MXW#:2,'J* *?A>/58/#-A!K@3^TH8A%,R/N#E> ^?]H 'ZFM>BB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\VTJPTK47
MU77=9O);;4K;7I8([M9RKQ*DP2*$9R-K+M!7'S;R>IS7I-9,OA?0I]:76)=*
MM7U!6#"<H-VX# ;W8#H>HH \TN((G\"ZCXK9G_X2:+59 D_F-YD;K=^6D(&?
MNE J[>A!JYK%Y=Z)+XF\)VTKK=:Q<Q/I;$G*K=$I+CT"%)&]LBN^?PKH+ZN-
M6;2K4WV\2><4YW@8#XZ;O]KK5J?2=/NM3M=2GLX9+VT#""=ER\888;![9% '
ME5[I.HW%]XA2SM;%9=)FAMK'4+S5'@:Q1(8F0JHC8;2223N&[)!Z5L6=O9)X
MK\<Z[J)GD.DR+)#LD/[@?9$+L@SC<1QSZ?6NUO?#.B:CJ4>HWFF6T]W'MVRN
MF3\IRN?7!Y&>G:K2:98QR7DB6L0:](-R=O\ K2%"_-Z_* /I0!X\TE]X>^W-
M86<.FRS>%KN\"07[W$LC*8]DLN44>8-S\C.>>>*T=1L;+PWJWAR3P_(ZSRZ7
M>S^6LI<3NMN"DI!)RQ)Z]\^U=Y%X-T*RA7^SM+M+:>)9!!+Y6[RRZ[3UZC
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MK%5*D@ D #FK7C&PMM$/BS2M*4P6,N@Q7,L"L2J3><RA@#G!91SZ[<UV>N>
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MTT(3R2?WJG:=ZC>P*\'I0!9L_&%KKFL>";DV%U%)JHO3"!=LJQ>6O.] ,29
MXS]T]*H^$_%^IV/AK2Y]0TV2;3);Y[-]0DN\R!WG9%;RR.4#$+G=GVQ4'@[P
MYJ%[:?#W65:,V^FQWSSE\JSB<$(RKCOUZ]#5RR\*>)?[ T[PU>16 L(=06[F
MNTN&+^6LYF$83;]XG SG&/>@!FC>)9]*U#QG-.9KUUUR.TL[9IL#<ZH%4$\(
MN3DGL 378:!KTNK37UG>6B6E_8NJS1Q3^<A5UW*ROA<@\CD @@UR5QX OKE/
M$;31V%P;O68M2M8+@[HI50*"D@VG&X!AT.,@UT_A31VTN*[=M"T?1O/D&VWT
MU!G:!UD8*H8Y+8P. >IH PAXVU'3]<\7MJEE'_96C"+R_*E#2$L@*@#:,E]P
MZGY3QSUK:TWQ)?OKL.CZUI":=<W5N]Q;&*Z\]7"%0ZD[5PPWJ<<CGK6)J_@_
M5M1U/Q9"GV9;+6XX)8;DRG=#-"BA0R;>060'(/2M2QTW6]3\4V.LZU:VEDFG
MVLL,,-O<&8R22E-SDE5PH"  <GDYQ0!8UKQ+=6.KC2],TR._NTMOM<PENA J
M1EBJ@':VYF*M@<#CDBJ">.;G4[RWM= T;[<]QID.IH\]T(%".S#:QVMAOE'8
MYR>F,U%XG\)O?>)5UF/0='UL268M6@U+ \IE=F5U)1N#O8,.#P*T-&\.W.G>
M)1?M'916XT>WLO+M$\M%D1Y&;8G\*?.,<T 9T?Q!GOSHD6DZ&]U<:M8O=QI)
M<B(1;&565VVG@;CR.I &.>)+WQW<6T>I:C#HOG:'IERUO=7?VD+)E"!(R1;3
MN53G.6!.#@57\+^#]3T?4/#T]TUN4T_2[BTFV.22[RHZXXY&%-0WOA77SI>M
M^&[6.R.EZM=RS?;GG8/!',VZ1?+VG<P)8*=P'(SC% %'4M1O!XG^(R)>3B.W
MT*.2!1*<1L8I#N49X/ .179>"II;CP#X?GGD>6633;=W=V)9B8U)))ZGWK"N
M_!VHRZUXRNHF@$.KZ3'96H+G(=8W7YN.!EAZUTOAG39](\):1I=R4-Q:6,-O
M(4.5W*@4X/ID4 <CX=\:*/"7AA],TBYG;5Y9X8(9[XR,A0R-EY6!)'RGGL.@
M. *ZGPWKTVMPWZ75B+*]L+MK2XA6;S5W!58%6P,@JZGH*Y?PKX)U71M(\%VM
MTUL9-&GNI+G8Y((D64+MXY^^N>G>NGT#2+G3-2\07$YC*7^H?:8=IR0GDQIS
MZ'*']* *-QXMO+/78+2[T<0V$]X+**X:Z'FLQSM?RMO^K)& =V>^*T?$>O/H
M<%FMO9F\O;ZY6UMH/,\L,Y!8EFP=JA58DX/3I7%/X)UE+U9TTS2)+FWU@Z@=
M0>4^?=H92PC)V93:C8ZD?( !@\=%XZ0Q0Z+J<5S:0W%AJ221+=R&..8LCQF,
MN =I(<X)&,@>M %"Z^(LUA;ZL;W0I8[G3+FUMI8([@/O,Y !0[1D $$=,]\5
M?D\4:S]LM=*AT"%M9DMVNY[=[_;%!$'*KF0(=S-C@!>QYXR>2M],U/Q7?>*2
MCV32MJ>FN3#*7A3R=CN@?'S,%QG@<GM78ZKIFKVGBQ/$&D6UM>&2Q^Q3VT\Y
MA(VN71U;:W=F!&.XH 32O&L.JW>C6Z64D3Z@EWYBNXS;R6[*CH0.OS,>?;WJ
MK<>/)$>&&VT=[B>;5Y]*C03A<M&K'>3CA3MY]!D\XP:%MX3US16T/4;1+.^O
M[62]DO86G:%&:Z<.Q1MIX5@!R.1Z5EW.D:YHU]X?\P64NI7/B.[O519&$3!X
M)6*[L9'&1G!['% '=>'M?FUB74;.]L18ZCITRQ7$"S>:F&4.K*^!D$'N <@U
MR,/BO5=#?Q?>G3)-0TZPU5WGE>[V&*+RHLK&I!W8Y8C*CG@DDUT_AG2M0MM0
MUK5]5C@AN]3GC86\,AD6*..,(H+$#)."3QWK,O?">HW'AGQKIZ-!Y^LW,TMJ
M2YP \,:#<<<<H?6@";4O'+6-UJ#PZ:L^EZ9(D5[=&Y".I*JS%(]IWA5=2<E>
M^,XJ;4_%MYI>K".?1PNF?:X;3[4]T%D9I"JATBV_,@9P"=P/!XXK%NO TBZ[
MJ$R^'/#NIQZA/'.+S48P\EM\B*Z[=A+CY25PPY8YQUJMJG@C6+B]U&6'3=(F
MN&U2/4(=1GD/GO&DB.L ^0E  I7()&.W)P 4-0\2ZSHS_$F]L9&FDLKFW6 3
M2Y6 -$,LJD$=2#C@&MQM8\11>/;V&WTE;FX.CV\K6;7^V"(^;,#A]ARQ^4#Y
M1G')&*@U'P-JU[:>.T5[5'UUX7M,N2 40 AN..1CO71:3INIGQ7<ZYJ%O!;?
M:=.@MC#%.9=CI)*QYVC(PZ\X]: -/P_K$/B#P_8:O!&T<=Y"LH1^JY'(/T/%
M:58?@W2+G0?!^EZ5>&,W%K (Y#&<KGV-;E !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5%%#;VQ<0QQ1&5R[!%"[V/4G'4^
M]2UXMJ.G:3)X8\?:LZQMK%CJMPUK<$_O;>0%3&(SU7+'MUSCF@#U"S\1P7GB
MO4] 2"19]/ABF>0D;6$F< =^,5L!E89# CU!KR74+V.R\8>/KB[BDD4Z19(\
M<4OE,2X9<;Q]WENO8<UEZM:MI=IXSTN.WTVP5=+LY&MM*9O+20S.-W('S[=N
M3CD;2: /;@RMD @XX-95I;6^FZP]M8Z'%;030^=+>0)&BL^[&P@?,3@YSC'O
M7.Z?I%AH7Q1CM]+M8[2&YT622=(A@2NLR .W]YL,WS'DYK/UPG_A<$HSQ_PB
M<_\ Z.% 'H^Y2VT$9ZXS3);>"=XFEACD:)M\9=02C8(R/0X)&?<UY7H.D6.F
M0_#34;2W2.^O$$=S< ?O)U:S=RKMU8 JN >F!C%;_CF_3POK.D^*GX@BAN;.
MY_VE:,RIG_@<0'_ Z .YR/6LS0M;@U[2TOH4:)6EFC".1NS'(T9/'NN?QKRO
M3K&XL6L_ =T[O-?7UGJ,X8\F+R_-G_ S6[#_ +:4ZST>PM_!NE:Y';(-4'B0
M*MWC]XJG4&0H&ZA2I.5Z<D]30!ZK"QU"XF6]TORUM+C-O),4<2$#B1,$E>I'
M.#3-9UN#1K2WN9(VE2>[AM5\LCAI'" _0$UY4\A#>,(I79+*?Q7:P7K;L 0,
M8PX)[*> ?8FMGQ/H_AZRL)M+T<B /K&F?:K.V8I' 6F4 H!@(S 9./0&@#TF
MW@MX%<6T44:N[.XC4 %R>2<=R>IJ4L 0"1D]!ZUQ?AW3K+1?B+KVGZ9:Q6EF
M^GV<Y@@4(GF%YE+!1P"0JY]<5RNLZ=?ZMK?BNYVZ)#<V=Y$EOJ.H73QS6*B*
M-HS'A"%4L2>HW$L#0!W47B"VN/$?B*SM-*>;4]'@A#.NQ6N!(AD5%8D8Y'<@
M9-;>R*_T^,7UH@6559[><*^UN#M/4$@^G<5Y3K!(U3XQ'O\ V5;=/^O5ZNZ7
M9:=J^MZ#9ZY%#<6<'A6">WBN<%!(3B1P#QN"A.>HS0!Z1<W=Q#>6<,5C+/%.
MS"69'4+  ,@L"<G)XX!JOH6MP:[IHO(8VB4S30A'(SF.1HR>.Q*Y_&O)/#[*
MQ^&1BF>6,ZCJFV1V)+C=+@D]R:=!IVEQ> YM:MHXCK\/B%D@N!S*CF^P(E/4
M*48DKT.XG% 'INL^)6T+2=:U.]TRX6UTU0ZL'0_:5QR5 .1@G'S8J];ZE-<W
M5LJ:?-]DGM1<?:BZ;48XPA&=V<'.<8]Z\EUTDZ;\7^?XH/\ T4M;UO!%=?%+
M1;:XC26"7PFR21N,JZF1001W!% 'H>G:E::M8Q7MC,)K:7.QP",X)!Z^XJU7
MB_AZPMM%^&7A7Q986\44VFS>=>M$H!E@D8QS%L=2%VMS_P \Z[OP0G]H/J_B
M=^3JUT?LY_Z=HOW<6/KAG_X'0!T5G=SW$EVL]C):K#*4C>1U83+C[XVDX'L<
M'BK0((R#D'N*\AL;#^U8O&ME]JM(GD\3CRXKTGR;E@$;R7 Y(;&,#/T/2NW\
M#-;IIM_9PZ7'I<MG>O#/:P3>9"DFU&/E'  0AE. !@D\9H U=!UN#7](AU"&
M-HEE:11&Y&[Y'9">/=:TMR[MN1NQG&>:\4TW3M+@\!Z5K5G'$=>77EBCN!_K
M=QO"IBSUVF,GY>F#G'.:NR-"_B+2M=M;&PM3=>(FMUNFG9[V8!WC<'CB/Y2
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M+>_BOH-%T^.[BSY<R6ZAUSG.#CCJ?S-(_A7P_)/<SOHFGM+=,'G=K9"9&!#
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MH_*CN?*7S%3^Z&ZXY/YU+<:?97=Q;7%S:0336K%X))(PS1,1@E2>AQZ59HH
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M(+R_TNSNKFW_ -5+-"KLG.>"1Z\UHT4 16UM!96L5K:PQPV\2A(XHU"JBCH
M!T%2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45@>--7N="\)W
MFH6;Q)<QF-(WF7<BEY%3)&1G[WK47A:\NKXW$LGBG2=<A3"C^SX GE-_M$2O
M^7% '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9.M:$-9,).J:
MG9>5N_X\;DQ;\X^]QSC''U-:U% &1XEC=_#UPJ:1%K.-A:QF*XF4,"<;A@L
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MQ(FR)=P..-C(['.,#GO0!Z/1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex1012022063010qngcbasho006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBH'O+6.[2T>YA6YD&4A,@#L/4+U/0T 3T4R66."%Y9
MI%CB12SNYP% ZDD]!2QR)+&LD;JZ. RLIR&!Z$&@!U%,AFBN(EE@E26-ONNC
M!@?Q%/H **9'-%*\B1RH[1MM<*P)0X!P?0X(/XT^@ HHHH ***BFN8+=HUFF
MCC,K[(P[@;V]!GJ?:@"6BBB@ HHHH **9%-%.K&&5) K%&*,#A@<$''<&GT
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MMWFC6>0$I&7 9@.I ZG%2T %%%% !1110 444R&:*XB66"5)8V^ZZ,&!^A%
M#Z*** "BHH+F"Z0O;S1S(&*EHW# $=1QW%.CFBE:18Y4=HVVN%8$J< X/H<$
M'\: 'T44V21(HVDD=41 69F.  .I)H =13(I8YX4FAD22)P&1T.0P/0@CJ*?
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7DFFP:C;?$KQWJLE]I3SZ?#;L)+NVV* 8'*#S-Q,2CC<0#NYZ5ZW7(W
MG@6*]N?%4SW[K_;\<"$+&/W!B3:#U^;)P<<>E '/'QE>2:-XH@FNK+5Q::,U
M]%*;!X8V)$@,;(Y.]/E!R.H)%3:5?:S?>-/"PBOH+:RF\/?:WM([<[.6AW*
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M=PQD'#8SD9JSJ/A/4M4TFWBN=?+ZE;Z@FH171M!Y:,G 01;ON8S_ !9R2<T
M<[>_$"\M]5OME]:%+"^6S.G_ &.1I+E056202 X4Y+$#!X7GKQIV>O\ B&]O
M/$]SY]E%I^BW$\$<7D%GF*Q*ZY;=P 6';G/;%:47A?4[74)I+/7S;V5U<+=7
M4"VH+M)A=^QRWR*^WD$,>3@C-6;/PPMI:^(8!=EO[9N9;@G9CRM\:ICKSC;G
MMUH Y>TU_P 7W$OA@-=Z8!XAM&D ^RM_H96-9,CY_P!YD$C'&"1V'->7Q5J+
MC0H+^#3[JZ3Q.VERSM;\$+NQ(@).Q\8[G'-=;;^%%MW\,-]L+?V%;M O[O\
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M4_@&.:W\1Q?VBP_MJ]BNR?)_U6PH=O7G.SKQUK<&AJ/%4^N?:#NEL4L_)V\
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M0K?2UG,XA+GS"NW.YV;ID_WL5JT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6)-XP\.V]\+*;6;-+DR^3Y;2 $/G&T^ASQ
MSU-;=>,7U_I__",^/=$V$ZMJ&K7,=K (R6N)&V*A7CG:1SZ8R<4 >MMJVGHM
M^S7<073^;LEO]3\@?YO3Y2#]#567Q1H<-[#92:I;+=3F-8H=_P SF3.S ]\&
MO/M8U&'2A\1--O#)]OOX ]K$L;%K@&S2,LN!R RMD]L<UJ^%+4#QMJMQ);L2
MNAZ>BMMYP1)N4?DOZ4 =/!XP\.W*W;0ZS9NMG&TLY6081%X+>ZCU'%:,FHV<
M5S#;R7,:33QO+$C-@LBXW,/8;ES]:\AED:X\-ZEH.BW1UFR70;I((Y;/9=Z=
MA5"P,P SNZ;2 V4'7%:>K>(K?5-5TZ^T6#^TQ::#J!V&%C')(4B(B/')^7!7
MKS[T =Y8^+- U.&ZFLM6M9X[2/S9V1_N)R=_^[P>1QQ38?&/AVXGGAAUBTDD
M@B::15?.$7[S>X'?'2O,S>K<7=XR:M)J44_A>\MX95M%AA\P!&,4851G:O."
M3CIGK73I:^5J/P\2*#:L5E.F%7 4?9EX]N0* .G\,>)M/\6:'%JFGOF)^&0]
M4/7!]\$'\:I:3X]\/ZM9:E>1W\,5OI\S1322N%  . V?1CT[U1^%-U#-\.M)
MMD<^?9PB"XC*D-%(.JD'H:Y!)T2RO(I%D;^S/&,E]?0"-BR6YE8K(5QRN2K<
M9X&>U 'JFE:WIFN0R2Z9>Q7*QMLDV'E&ZX8=1QZUAZGX[TVSU;5=&AD1M2LK
M!KM4;[K,%=MGKD!,GV(JMX=N8=8\?:UK&F-YFF-8VUL;A00DTRM(QVG^+:K*
M"??':LGQ!<1VOC?Q-!,2DE]X<5+4%3^]9//+!3Z@$<4 =3X?\8:3KL=K;QZA
M:MJ4ELLTMM&_*G + >N"<'T[U=TWQ)HNL7<MKIVIVUS/$"72-\G ."1ZC/&1
MD9KA+[3YWT[P);6,1CF_LVXBCVC&QFLB!]/FQ^-)X'2"\U#0 =;N;FZTRP9&
ML18+$+0%%1HY& !!R!@'KMS0!UFOZ_JMCKVG:1I&F6MY<7D$TY:YNS J+&8Q
MV1LD^8/RING>,(3::FVNQ1:1<:9,L-TK3B2/+JK(4? W!@PP, YXQ6=XFTVZ
MU+XA:!';:C>:>5T^])N+54+??@^4[U88/TSQ5;7].B\)Z/;NEV[R7NJQR7VK
MZA$L[PG8<2XP%4C8B+P N[I0!LZGX_\ #VFZ98Z@;^*:VO+I;:-XVZ-N 8GT
MVYR1UJY:Z[%+JVJQRZAIWV.SABFPCD21*REBTN> I R".V<UY>;Q8K&YGN+F
MXF2V\7VE[-<3P>6WV=HX\3%54 *<'!Q]>:L:U:W.IZW\1GL4ED6>RTR6-HX]
MQDC4;FVC^+Y0>.^<4 >EVOBO0;RPGOK?5;9[:W95FDWX\LL0%SGD9R,>M5G\
M;^'?[.U&]AU6WGCT^/S)Q&^2 >A'J"> 1Q7GVM16VL:#XAOH-;GUMWM;2VD<
M6:Q1%?M 8+E0-S#+9'8-S70^*K667Q1JR00,QD\)W,2A%^\V_P"51[\\#WH
M[#0M:M/$.C6VIV3AH9T#8SRIQRI]QTKD+/Q[K;>'[7Q'>^'K6/19BI>2#4"\
MT2,VW<4,8!P3R W2NA\$7UMJ'@O1Y+642+':11.0"-KJ@#*<]P:Y'P1X.;4_
M!.C'4]9U66RVK*VF,8TARK[@IP@<KD X+<]Z .Y/B31EUA=).I6_]H,YC%MN
M^?<$#D8_W2#^(J&S\7^'M0N);>TU>TFEC1G94?.57[Q7^\!W(S7+6FG3W&J?
M$L6D16\NBD,$F,$G[(H7!_WC5.PO[+6'\!Z?I*,+S2W5[R,1,K6<:V[HZ29'
MRDL57'>@#J-*\?>']4T.75Q?106T4[0L96P<AV5>.Y;;D <X-:,GB?0X=&CU
M=]4MAI\C;8Y]^0[9(VCN6R#QUX/I7E.G3F/PYX> U![ Z/K%X+^7[/YALVD:
M<1LZL, '.,]MX-:EM]ETJ^T3Q!+?W%YI!U.\EN+V6U\M$DDB"+(%4<(2K#?C
M&7]Z .QO/'_AZSN-'C&H0RQZH[+#+&V5 56)8G_>7;CKDU;M-?@5=9GU#4=-
M6UT^X:-GB<CR5 '$I;@/SVXY%<;J&K:2-:\)ZY;6DECI7]J7F^X>#8LK/"ZB
M7CG#MT)P3UK'^S3J/%-R]O*]K;>+X+NY18RQ:!#&6;:/O <,<?W: /3K;Q5H
M5Y87-]!JEN]M:D"=]V/*STW \C/;-2:9XCT;6;J>VT[4K>YF@ ,B1OD@$X!]
MQ[CBO-/%T\/B'_A*]3TG-SIW]BP6DD\:G9--YS-A3_$54\XZ;L5V<D'E_%:P
M:.+;&-"N$RJX Q/#@?SH V-6\2:-H3Q)JFI6]HTH+(LC8) ZM[ 9')XJ/4O%
M6A:0Y34-5MH'"+)M9^=K;L-@=0=K<^QKD/&M_-_PD%]IXN38M)I(6W\BR66?
M4&9I 80S*?E7"\#^_G(%-\"B*[\017802#_A%["$2%>X>4.O/?*C(]J .RO?
M%.A:=#:37>JVL4=XN^W8R B1< [AC^'!'/3FF>$]:E\0^'(-3F2-'DEF3$6=
MN$E= 1GU"@UYOX+OK?P]/H%[K):WMI_#D=M;R/&Q'F+,S/&,#[Q!3 [X]J[+
MX8J(/A[8!H&ME62Y/E2+M,8\^3@CM@4 'C'QTOA6]M;>/3VO<QFZO2DFTVML
M'5&EQ@[N6Z<?=//%/\>>-8?"&@Q7<)MY;JZD2.V25R$;+*"Y(YV@-GBN:T73
M/$7B>?6_$D$VF0V>M;K6*#4+*21_LB;D4<2)M#99B,=ZR;U]03X=0>'=0#RZ
MAH6MVEF[A#^]B$BF*0>Q0C_ODT ="_Q(9O$NCZ%;7FD/+/!YUW=$R>7G< (X
MUZ[B#D9-=?;^*M!N]5.EV^K6LEZ&9/*5^2R_>4'H2.X'(Q7.WT,S_&BS>,,H
M_P"$>F428X#><N.:YO3+B"X\*>#O#5O&XUW3]0M6NK;RR'M_*8F:1^. 1NY_
MBWC&<T >C)XKT"2[GM4U:T,]NDDDR>8/W:QL5<MZ $$<^AK-L_&UAJGBFVT_
M3KJUN+)[">ZEF5B&1D>( '/0$2$\CL*Y!M-FD^&?C9+>T=YIM:O97C1/FE1;
MC+ #OE%(]ZDU?7K/4O%<VJZ%:+J:P>&;U0?(8QS,'B(B.1\W?*_[6* .LU#Q
MQI;>&-;U/1+ZTOI]-LY+GRPV0<*2I/0E3CJ.#ZUH:5XIT?697MK+4;:>\CB\
MR2&-\D#H2/4 \9%>4:I>+<QZP8]6DU.*?PK=003+:+#$9%VL8HPJC.T<X.<9
MQG@UU5G>V6K^+/"D>DHV=+L;@7B",K]F5HT58WR.#N ^7_9)H U?#'CJVU#P
M%IGB+79K6P:\+KM4G:6#LH"@Y).%S^==7:7=M?VD5W:3QSV\RAXY8V#*P/<$
M5XCX8CN=/\(> [^;4)-)M8(;^*2Z:W$@AD>4%-P887(5QG\.]>I^";6&U\,1
M?9[FXN89IIIUEG@\DMOD9B0G9222/8B@#.B\5:_K)N;KPYH-K=:9!*\23W=\
M86NF0E6\M0C#&00"Q&<5I?\ "8:5:Z/97^L2-I#W:DBVO1LE4K]X%>N!Z],$
M'O7+^%/$VG>#- 7PWX@>6RO].DDC16@=A=)O9D>(J#OR".!R#GBC5?$%U<ZK
MIDEU'+X?-SI\CQ$V:374S&0 0 LI ) 5BF,Y(]#0!V-]XIT+3?*^V:K:P^=&
M)8LR#]XA( 9<=021TIX\2:*VLG1QJ=L=0SM\C?\ -NQG;_O8YQUQS7G7@*)9
M]>\(N\99K3PN\+%E/[J598T9>>C#YA^=1Z7:[M031M0URZBO8]>DNAIT=BI=
MB+AI5DWXSL9<9;.,$CVH ]<9E12S$*H&22> *Y#PAX[7Q3J-U:O8-9CR_M5B
MS2;C=6Q=D$F,#;RHXYX84?$:YO9=!BT#2V*ZAKDPLDD"DB&,C,LAQV" _B17
M.:UI7B+PP^A^(IIM+FM-"VV\D&GV4D;FT?:CCF1MP4!6 Q_#0!WLOB?0X-97
M2)=4M4U!F"B R#=N(R%]F(Z#J:K^'?%^E>)Y]0ATZ8.]E.T+C^\!CYA[$DC\
M*Y/2=4TK3FU31=6LY+O4;G79+B&T6#>TZO*'BF7/&U5VDMGY=A[C%:G@*ZA3
M4?%6G.Q6\76KF<PLI!\M]NUOH>U &_J7BK0='O%M-1U6UMK@J&V2/@J"< M_
M=!/<XKG?%'CX:3XLTOP]93:>DUPKR7$UVS;8E 4JH"]6;=QSBLN^U"RT6\\=
M6>KJWVK4SOLT,3,;R,VZQJD>!\Q#!ACMGWIUI8WEGXW\ 07:.9[?0YHIVZ@.
M$C!R?J#0!VVNZE?Z?!;II>F-?W=S,(D4L4BB&"2\C@':H ]"22 .M8'_  G-
MU!8WT-WI*#6[6_BT];2&XW132RJK(1(5!"[6R<KD8/!J]XV\3GPSI4#1%%NK
MR86\,LJ,T<.029'V\D* >!U.!WS7*2MI":!8:AI%Y-J@TW68;_5;KRF,LA96
M1Y"N!T# X4<*N!TH ZO3_$]YYNJ6.K:7Y>IZ?$D_D6,AG%Q&^X*8R54YW*RD
M$#!'7!J/3O&8E\(ZIK^IV+60TZ6YCFMUE$K9A8J0"  22,>F>]9VG:S87GBW
M6?%23D:+;:?;V8N]C;)7$DCL5XR0-ZC([D^E<[8WEMXC\!^+]&TN4SZC-=7U
MY#!Y; R(9RRD9'\65 ^M ':Z7XCU4ZU::9KVDP6$E_ \]HT%T9AE-NZ-\JN'
M 8'C(.#SQ745P<6M6?BWQIH%UI+22P:;#<3W;F)E$+.@18VR/O\ +';U&VNO
ML-4M]6T>+4]/+303Q^9%E2A8=N#R/QH K67B?0]2OYK&SU2UFN80Q>-'YPIP
MQ'J >#CI3M)\1Z-KDDL>EZE;W;Q %UB?) /0^X..HXKRK3=2CO;SPS-=W4DT
M!@N8KFPM+%88K*22$_Z.N%#;R05P2>5!XR*ZCP/J ?6ETZTU&/6-.@T_]U=O
M:>7/:890L$C  ,2.<8!^0Y% '6:GXFT31KJ*UU+4[:UGE 94D?!P3@$^@SQD
MX%1ZGXLT#1YI(=1U:UMI8]I=)'Y4-R"1Z<=>E<'X^O9YKSQ/IJW!LY9-+$=O
M;V]DLDVI923(+E2=BDD<8VY)SS5BP$5_=>,KR-!,D^@VBQR;<[P89L@?CC-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %9ND:-#H_V[R9)'^V7D
MEV^_'RL^,@8[<5I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-I:06%G%:6R
M;((5"(N2< >YY/U-344 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%-=1V^Q(D4814CW$X&6/+$DDT :7A?3;C3O!]M:QRV23& &-[>S\J-"5&TE
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M!KDHI$>/F4$@'D$=@0*Z6Z\:M'=L+32I[RUCOOL4SPAVD4AMK.%"$%5;(/S
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MW# VQW!X=P+[=O4;-W2NK:&)PX:-&$@PX*@[OKZTBF&'RX%,<>1A(Q@<#T%
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M_DQ%&3RTVL<D;1@GUH \TMKKPY;77B6T\2+"^HRZX'C@/_'Q*I\O[.8P/F(
M QMZ8;WK,T^W:?47L[W7])M+U?$CS?938,]ZSB<LF'$OW6CP-VS 0^V:]=:W
MA>=9VAC,J#"R%1N4>QH^SP_://\ )C\[&WS-HW8],]: .6^(FJ75IX;&FZ8P
M&K:Q*-/L\G&UG^\YQR J[CGM@5R6IV.O>#_^$?UZXM-)ATW0E6SN/L4TCNUH
M^U&W!D&0I"OUZ@^]>L-&C.K,BEE^Z2.1]*5T61"CJ&4C!!&0: /(-<L[2;PM
M\4+LPQ/-]L^67 ) 6"%EP?8DFK'C?3FMM4U.UT:V$4C>$YT$=NN"RK*@P .I
MVE@/K7JGD1;&3RDVM]Y=HP?K3MB[]^T;\8W8YQZ4 >;RSZ/J?BOP\/"[VDRQ
M:9=B?[&5(2!D41J^WI\^, ^A]ZS=&UG3KO2/A?86UY#-=02QB>*-@S0E;252
M' ^Z<Y&#UP?2O5XK>"W+F&&.,N=S;% W'U..M"6MO&S,D$2LS;R50 EO7Z^]
M 'DVE6-K!X \%7$5O&L[:["S2A1N):9P<GKTX^G%=+\-Y+)$\0VD3P+=Q:W>
M&2%2 ZH93MR.H&.E=L(8PJJ(TVJ<J-HP#[4BP1)*\J1(LCXWN% +?4]Z /*-
M=U:PT_1OB?87=U%%>SR2-#;LP\R17LXPK*O4C(/(Z8/I6I8Z?9WGB3Q9)<VT
M4S+H]DBF10V%:.7(&?7 S]!7H3VUO)+YKP1-)M*;V0$[3U&?2GB- 6(106 !
M..HH \A\)7FD6D]O)XEEMECG\*Z<MJ;LC$D85_-5<]3DID#DY%9OAXR067A:
M6?4M*TZU;0'CBDU>V\Z,MYI\Q1^\0!MNS/)R ?0U[:UM;OY6Z")O*.8\H#L^
MGI226MO+$L4D$3QJ<A&0$ _2@#S'PYH]F?&GANWFE34X;;PT[V\TD!0,/.0(
MP1LD85L#/.*[?QA)I,?AJY&NP22Z9(R)<&,']V"PQ(2""H4X;<.1C/:MO8F_
M?M7?C&['./2JU_:37D*QPZA<61!R7@6-BPQT/F(PQ^% 'F%W>W4(OM&\,>*9
M_$4%UI%XYC:9+B2T<1_NV$J#/S,=H#$GN*H26[WV@7<ND:]I5W=Q>')XHK/2
M;!HG\I@F [>:^&!&%4@');'>O2H/#5Q:J5M_$.HPACDB.WM%R?P@I8O#EU S
MM%XCU*,N=SE(+0;CZG]QS0!Q>O77A#4O"6M+H,=M<7B>&Y\/:#*Q0[<JC[>
MV1D C(P>G--%Q:W?CGX?2:9-;RQ'3+P(\+!DW>6F>G'7K7;1^'+F$.(O$6I)
MO.7VP6@W'U/[CFDC\-W,(01>(M10)G;MM[0;<]<?N.* /.]+FTV3PAX+T^T:
M ^(H=4MS/"I'VB.17)N6<?>'R^9DGKD>HJ5[*UC^'>J7BV\8N?\ A)VD\[:-
MP8:B%!!ZCCBO0%\.723M.OB+4A,PPT@@M-Q'N?(I?^$?O-A3_A)-3VD[B/(M
M,9SG/^H]>: *WCB/1WT:U.N75U:V:7L+?:+=S'Y3@_*6<?<7/5N,9'(KSW7I
MX_\ A'?&MEHNHSZCX?@M;5_,>Z:Y6*0R'SD21B21Y84D9.">V:]-?0KZ1"C^
M)]596&"##:$$?]^*KR^%)9M/EL'\0:C]DEC:-X1!:!2K#!&!!WS0!B>*)])@
M^)'A.;4WMTMEL[TQR3$"-6/DA22>!U(&>Y'?%<]=>0WP?\:26VW^SYM0NFT\
MQ_<8&10A3M@R9QC\*[73_!]Y9Z9%8S>*-1GBA3R8MUO;'$0X526B8L<  G/.
M,XIFI>"KG5/L4%QXFU(V-M*LWV?R+8;G0@Q\B(# (SM((/'3% $.A;E^)_B0
M7/\ KSI]@8L_W/WN['MOS7'Z081\!O%GGXV[]2 S_>WMM_\ 'L5V]SX-O)=:
MM=7A\4ZG'>Q1F!Y&@MCOA)R4P(@,Y ()!QSQS3=5\$W&K0P6D_B;438+*)IK
M?[/;#S64AEY$0& P!(((.* -O3+^(+::9<3C^TULHYY(3][;]TM_WT"*X?QU
M>Q/KVHV32:79R)HXQ)=VYGFNQ(T@\F%=Z]U&< DEEXKO+72T@NDNY9YKJ[2#
MR//FVABN[<>%4#KCH.PJV\$4DJ2O$C21YV.5!*YZX/:@#S7P9#8ZOXD@N9D@
MO/\ BEM/4.V''+2AQ]<C!_&L?P5>:993^'IM?GMHK1_#"1VLEXRA"PE;S%!;
MC.WR^/05[%'!%%_JXD3C'RJ!Q_DFD:UMW1$>")EC.4!0$*?4>E ')?"ORQ\.
MM.$*,D7FW.Q6&"H^T28!!KLJ145%VHH4=< 8I: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "N%\5^-I-)\0-I-OJ>CZ<\-FMTSZGN(F9F8+&@#+C[A);
MG&1Q7=5SFJZ#JCZX^KZ)J5O9W,]JMK<"YMC,K*K,R.H#+AE+OUR#GVH YK6?
MB%=P:1:ZM:7>CV<4NEIJ"VEYNDGN&(),8"L-@&,;R&R3TXK5F\0>(-7U._M_
M#L>GJNGV\,LB7B,S7$DB;Q&I5@$&W;\Q#<MTXI-1\%ZE>3ZDL6N(D&JV,=I?
M226H:=MBLNY&#!5W!CD;3CG&,\-'A#7;5Y9=,UZVM9[VTBM[Y_L;-\T:E1+%
M\_RMM.,'<. : ,A[SQ!:^(_&U]I8L(#;16UQ,EVC2[V6V!\L;67;T/S<]N*Z
M77O%%S8?#X>([&VCDG>&WEC@E)P?,9!M)&.S=:?'X4:,^(O].9_[7@CA#.F6
MCVP^5DG/S$]>U9GC72Y+7X3OI22.[P16EN)(UP3MDC&X#G'3- $A\0Z_I>L7
MFF:K_94\K:9)J%I+%NMXU*,%:.0LS<#<IW\<9XK*@\=:Q)9ZVEG<:1K%W86,
M=_%)9Q2)&Z[F\R/!<DMA3M8'!R.*TK_P/J&NMJ,VLZO;R7$U@;"V:VM"B1*7
M#EV5G;<253(R!@8[U8BTV\T75Y_$^NZQ:/$;(6US'%:,B(JN2FSYF/5FSG.<
M]J (]8\9SK+;?V(EO/"VD3ZM-)*I.V()^Y P1RS'\E-4(/$GBZ:]T&!AHZC7
MK-YX3Y,A^QE51SN^?]YD-C VX/? YB\#>$S_ ,(IKA8SP+JPFM['[1'AX++Y
MQ"I4X(QO9L>C"NEA\,-%>^&KC[6#_8MK);E?+_UVY$3/7Y?N9[]: .4?XBWL
M<-I87E[H^FZ@;J\@N+VY1C;XMY F43>#EBRX!;@!NM7+/QMJ^M+X=ATM=.6;
M4Q>I/.X>2*-K=E7>@# LK<D#/1EYX.;L?@J^T^[.HZ7JD$>HB\O)P9[8O&T5
MPX=HV 8'(*H0P/;IS6G%X>O&U70]1O=4^U7.G17"2MY 3SC+MY !PH7;@#DX
MQDYY(!QU[XC\47[Z%!%>6-K=)K\VG7+)#(8YC&DA4[?,!V$#)4D\XYXP>WUO
M6+C3-6T"TB2)DU&]:WE+ Y51#(^5YZY0=<\9K$NO UX56:QU2&.\BUN35HFF
MMR\?SJRF-E# GACR"*V/$FAW>KIIEQ8WD5M?Z=="YA>6$R1L=C(RLH8'!#GH
M>.* ,/5O&6JVEWJEM:6MI));:Q9Z= )-P#+,D9)8@]07/('0=#4%WXPU[2)-
M7TR\33[K4X9+*.REAB>*)S=.8UWJ68_*5).#R/2KD?@:[>6XN+S5TFN+C5K7
M4Y&6WVJ#"$!0#<< [.#DX'7/4SZWX);5[_5;U-0\B:[2S-NPBW>1+;2/(KGG
MY@2PR.. >>: .;U#6]3\,>+=;U+5S97-Q:Z#"8I(%:&.3=<.J[@68K\QP>3Q
MS[4^;XDW=II&O/'?:-J]S8627D,]BC"(Y?:T;J7)R."#NY#=!BMB;P-?ZK=Z
MG>:UK$4D]]8)9@6EL8U@*2%T90S,3ACGD\GVXJQJ?AC7=?\ #FK:7J^N6S->
MPK#%]FLRD<6#DN07+,Q_W@!@<4 =!I']JFQW:PUI]J9BP6U5@J*>BDL3N(YY
MXSZ"O,KFRT[39[T^+]/U:TOVO))8_$EN6>-4,A,1#J3Y0"[5VLH7COFO6F81
MQLQR0HR=H)/X <FO,[M-4NM.N]$;7-1DT>Z#H[S^';R2[6)R<QB0C:>"0&*Y
M H DU[XE'3-5U41:AI$=OI4J1M97&3<WGRJSF,A@%P&PORMDJ>E;*:YXDU34
M=2FT6'3WL-.O19M;SJPFN2H4R,LFX*F-QP"ISM[9K,!EL-1NSHE]J-E87LL<
ML\;^'KJ66-E14)C8K@;E10=RM@Y/>HY4GAU'4/[*U/5;+3=1NENKF,:!=M.C
MX4/Y4FT!0VT9RIQDXZT 9]YK6M0:%\0[W4WT_4K2QNFBCL[BW<Q\1PX&"Y&S
M!Y7'+$G/.*Z5-:US5-3.E:#_ &;:"RL+>XGDNH'D5GE#;(T577: $.3D]1Q7
M/ZCIBWUMXKL$O-0CL->)E ;P_=F2&4JBD[MH#+A.F >>O'-V7S;/4O[0T*[O
MK:>:RBL[H7/AZ\E1_+SLD4 *0PW,,'((QZ4 3:?XQUOQ%<:/;:5#8VCWVFRW
M<TERC2B!XY5C8 *R[ADD=1ZYXP=K0]9OM=\$37LT"+?A;F!TM\[6DC=X\KGG
M!*Y ]ZP]#M-+T'4-,GMVUEXK'3)+':^BW6Z1GD20R$^7QDJ>,=ZNZ'<V.CZ!
M-I9;6F,LUS+YT>CW2,OFRN_'[L\C?C/MF@#"\%6VG:#/X?BU/PM?Z9J5Q L,
M5_<3!UFG$67#*')0L Y&X#/L>*I7KRZA\-M5\4%!-?ZIJT#1ACC;%'>HD,6>
MPPN?JQ-:]I]KGU#2I->U/4+ZVTJ0RVZQ>';N*2:3845Y6(8$@,W"@ DY]JRK
M,07/A'4/!4QU:RDM[[S[2==(N'9K?[0)D8+LX.<ISW7/(H ZI);_ %/6+_P?
MXG6PNH;O3OM,<MI$\0V[]C*0S-R"5(8$?08KGHM5O/$'A7POX?O9F>?4-1EL
M-0DS@S16WF&0$_[8B4'V8U?@U9-*U2\\3:Y-?75RMH+2WCMM"NH$"[MV/G#9
M=VVCJ ,"L* R:-X:\,W[V6J/J>F7[W]]&-,N -L_F>> 2F#M$F>O.SWH Z2[
MU:.W\8^*+%-*T[%GH:3"4P_/*,/^[<YY08Z>YK.^VB+PEX)\7VUM;V4R-;03
MPVJ;(_LTY"-&%_NAF5@.Q7WJS+'I]]KVM:U%/JACU;2ULD5=$NB$&&P^=GS
M[NG'UK-N9;>/0O"W@V!-4N5LI;::]F_LFY3$$!W [-F?F=548SW]* /6*X"^
M\7:\NG:WX@M(]/\ [(TBZEA:UDC<S3I$VV5Q(& 4Y#8&T].3S75Z:^HRZIJ<
MERQ-@S1&R5HMC*/+!<'N?F]<$<CM7.WO@>_GAU32K?5H8M"U6Y>XN86MBTZ[
MR#(B/O  8YZJ2-Q]J ,..QO=2^.DTUP^F7$=KID,T'G6C.8XC*V-A+_+)_MX
M_"MN_N];/Q4CL(;Z!=-&CO<-;M$YW#S%4]' WYZ-C@$C'.:V+?PW]G\<77B(
M7(V36$=D+<1XV[7+;MV??&,4S4/#UY/XPM->L[Z&(+9M97$,T!??&7#Y4AAM
M;([Y'M0!Q_@K6-=TKPQX'%P+!M*U%8[)84C?SHSY3,KE]VTYV<KM&,]31I_C
M&XM/#DUS;VVE:3$^O7-G/=FV<P0*NX^;(JL"68@*6+ 9;)KI[7P:UMH/A73?
MMP8Z%-%*9/*QYVR)TQC/RYWY[]*@TSPAJV@Z7/;Z7K-N)I=1GO7%Q:;XI$E)
M_=L P;CKD$=.E '1:)=7-[H]O<7<EG+,X),MDY:&09.UE)[$8.,G&<9/6O)]
M:U];K6M2\:V^J1A="O4MK6S%P ;BWCRMR=N>=V]L''_+,5Z-IWARZTKP?<:1
M9W\<5[-Y[K<I!MCBDE9F)2//"J6X&>PYINE>!?#NF:+:::=(L;@00K$TLMLA
M>0@8+$D9R3D_C0!#J6OZC=Z[IND^'I;$&YLGU![JZC:5/*!55"JK+DL7ZYX
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M5=0SK-G+-I\;R7%O#,KRH$.&!0'.<X&/4XK'C\$WZ:5:V?\ :5L6@UHZMO\
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ML%W-R0H(4$]A6G110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52O-2C
MM;RULE7S+NYW&.(''RKC<Y/91D#ZL!WJ[7(*)!\8G,F?+.@CR,],B<^9C\X\
M_A0!=B\:Z--]GV7MN/M%\UBFZ91B1>JMZ,>R]3D=.<5_"WC>W\2ZIJNFM:/9
MW5C/(B*[[A/$DC1F13@<;E(([<>M=%_9]E_SZ0?ZWS_]6/\ 6?W^GWO?K7FF
MF:3=S^&Y];TA-VLZ5K6H36Z=/M$9N'\R$^SKT]&"F@#IG\=V\>CW-ZUC,\ZZ
MI+I=M:1,&>YF5RHP3@#.TDYZ &A?%FJ:??V4/B+0!IUO>S+;PW4%X+A%E;[J
M2?*I7)X!&1G S7"Z1=_:=!T_Q;;V\\UC9^)KR\GC6,ET@E,BE]HY)7>"0.V?
M2NC\3^(=*\9V=EH/AZ]BU*ZN;VWED>V.];:*.19&=R.%X7 !Y)(H TU\7:U>
M:QJ]EI7AI+R+3;@6\DK:@L3.VQ7X4IZ,.]68?'>EMX<U'5[J*YM&TUS%>6<J
M#SHI>,)@'#%MR[2#@Y%<WH7BO0/#_BGQG!JVJVUG,^J!TCE?#,ODQC('4\@U
MGW>FZCKFE^*?$UGI]QY=W?V5U9VDD962YBM2A+;3R-^&V@\G ]: .N3Q3X@@
M>VFU/PC-;V-Q(L9DM[H7$L.XX4R1JHP,D9VEL5-+XLNX?M&_P]>?Z/J264F)
M8S^[;&V8<\@Y7Y?O?,.*A7XC^'[L6L6DW#:E?7,BHMC;K^^3) 8NIQL"C));
M'2NK$,0QB-.&+CY1PQZGZ\G\Z *ECJ<=Y<W5HR^5=VK 31$YP&&58'NI&<'U
M!'4&KU<@@D/QBG,>?*&@H)\=-WGMY>??'F57U:YL=.^*%E)J$D,%M>://"#*
M0%GD$L6$Y^\VTG Y- ';T5XQX9.FZDOP^@O)XYEDTZ]2>*2;A\%,*ZYY_BX/
MO4F@ZM:PVGA:VU*XB/A\7.I0,\S@PK*DS"W20GC&S=M!XZ>@H ]+\/:X==M[
MV1K4VS6M[-9LA</DQM@G..];%>+V6I6.FZ:<3QQ>'U\37B7CHHDCC1@WE%QR
M/+W8Y/'W3VJ[=66A1CPQ!;:F]WIMSKTI1GE"1&-X)"R1;< Q;\#TR2.E 'I^
MK:G;:+I%YJ=XS+;6D+32%1D[5&3@>M4;;6KU[VR@N])>!+P,T<T<ZR(N%W;7
MQC#$>F1P>?5VHPZ7HOA*X@FM0VE6UJ8WM\%P80,%><D\5Q.C0R^&O$^EZ;X9
MUP:MH-\LN;"643&Q"H2KI(#D1YPN#_>[DT >G4A( ))  ZDUY)X9GM=4AT^Z
M@U.9?&%G;S)=62Q*LK3["'%QQDIO ()XSMQZ5H^%I/#>OZ98/$6FUQ-.>#4;
M;DN7*CS/M*GJ=ZG&[N>.] '=KJ37=O876F0I>6ETX+3"4*$B*DB09'S<@# ]
M<]JT*\>T:?2XO"GPT:VEMXY1?0QS^6P7+_9G#A@.K;@@.><XJ6YEEN_#&JL6
M">-;;6&$'.)PWGCR@O<Q&(@?W=NXGN: /7**\<\40Z;(WQ*F>5#<V<,$UL3,
M<PRB'(91GAMW<<\X[UZ9J+:C?>&BVBRV[7DT:>7))*43!QN(90V#MS@X/.*
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M#.FPVOC>QA9GN3;>%K:*.>>(H[+YKC)4\J2 ,@\UK_#08^'>D+C@(Z@>@$C
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M]G#4?[8!Q\GV+/F>7]/M'R_2NQ\<"R&F6,UYJO\ 93PWJ26]Z\8>**4*P'F
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M(Y(4OLVH5^4.."PS@].">NH B6X@:Y>V6:,SHH=X@PW*IS@D=<'!_*I H4
M  = *\W\/ZC-!\/+CQ0+VUM-0UF[,\EU=*SA%:78BJJ\L5C "IW;ZFF)XRUA
MM(OPET\BV>IQVTVI?V7('CMVB$GF&W.#D,0N<8P=V* /3**R/#-])J6A074F
MHV>H[RVV[M!M210Q )7)VMC@CL0:UZ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "L*]\/2/XDCU[3[Q;6]^S?9)A)%YL<L>[<N0&4AE).#GN1@UNU#<S
MK;PEV>)2>$\U]BENPS_]8T <V_@M(['1+2SO?)CTN]-]F2+>TTIW[BV",9,C
MGCU%;]M;W<5]>33WQFMY2A@@\I5\@!<,-PY;)YYZ=*SO#7B%=;\*6.MW:16?
MVE"S(9,JGS$8W'&>E/UK7H]+N--LXS$UUJ,QAA\QL(N(V<LWMA"/<D4 5]3T
MQX?%NG>(H49Q';R6-TJC)\MV5U8#OM9>1Z,3VJ#5/",FISK?'41%JD-XMQ;7
MB0?-"BC'E ;N5(+ ^NX\9K1T6]U::WN'URTLK*2-\*MO=&4;<#EB5&,G) ]"
M*U$ECD+B.1'*':P5@=I]#Z&@# ETN74_&=AJ<H(@TFWECC;;M\V:7:&(![*J
MX]R_L:M>(M#.NVMI&ET;6:TNXKN*0('&]#G!4XR#D]ZU(IX;A"\,L<B@X+(P
M(!].*Q;'Q$;WQ=>Z,D4#06]G%<I<13;]^]W4@C&!@H>YH SK_P $2:A;^)8)
M-5PNNHB2M]GYC"H(^/FP20/3K^52/X1OH]=N-2T_Q!-9)?*G]H01P*RRNJA=
MZ%B3&Q4 =^@]*Z@S1!F4R("HRP+#@>](T\*J&:5 I!()88('4T .VD1[4(!
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MK,>6/[PX;MZ'C$FF6MGKOC-O$D%K>P+;6YMF^T0O")I0S -M8 G8I<!NA$I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *XC5;N*T^)"C6XBVF3Z6(K)WB+Q><7;S4Z'#,NSZ@8%=O5>2_
MLXKZ*QDNH5NYE9XH&<!W5>I"]2!0!X_H=VNF:#X1DU5;VWT46%Q;-(MIYBPS
MF0$;U9&P&0$!L>HS@FMJ73-)L+KP%:Q0RO9P7-QM-\F9%A,,P3?D#:N67 (&
M,@8R*].HH \?\06UJVD_$&%($(?4[62%43ECLA#,F.^0^2/0^]6-=MC9ZQXJ
MC\/VN$DTVPE:&R0#SPLSF8*,89S$<8YR"/6O6*9--%;P23SR+'%&I=W<X55
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MN?"OV-?[$M[D:O ^T; CDE8<=BLP9Q[*!78W$5C/K$(^T+'J44+,H1P)#"Q
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MI=DX)7U?E.1SR/6O5** ,WP[*TWAK2Y'<N[6D6XD\[MHSGWSFM*BB@ HHHH
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MQAJ=OH5[)'K/VS4R;6W%K?V'V::SGFE$>60!=T8W9'7E?O'-6]9O-6TW^W-
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M5F8 +$BD@CH %XR:NIX*@7PQI&EI>307>ELLT%[$ 7$^#O<A@00VY\@]=QH
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M]V%*JBJH 4 ,Q^I)K/F^&VG7'AO2]%EO;IEL;IKEIR5\RX+EC(K\=&WG/X4
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M6Z2 ?+'+(KD$XR<%.">>>:R?$^B?8?"-_P"']/M+Z_O-7NI[B!TC^2WF>7S
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M'97+WMO>M)$K&YMQB.7_ &@,G&?2M"J&BZ3#H>CV^FV[R/'"I&^3&YR226.
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M[+.9I=KAR[.H4LJC:O) QGGK5GXE03W'@.^6W@EG=);>4QQ(78JD\;,0!R<
M$_A5335-[XG\5:C%;3_9[O3;00220.ADPLV0 P!SR,CW% &U?^,=!TU;=KB_
MRL\ N4:&%Y0(3TD8HIVI_M-@>]:EYJ%K8:9/J-S,J6<$+3R2@%@$ W%N,YXY
MXKQ_3=.N-,LK-]3N?$-C#=^'K&!(].LQ*97C1E>%PT3E6^88!VCYCZ<=WXCM
M$T_X1:K91B8);Z%+$HG(,@"P$#<1QNXYQQF@#2T[Q?H6JWQL[2^W3>49EWPO
M&LD8ZLC,H5P,CE2:AM_'7AVZ@NIHKY_*MK<W3LUM*NZ$=9$ROSJ/5<BN2>\N
M-7N_#KZ-IET;C1]-N9)HY[5XT5V@")%N8 -N;'W200N>F*B\/>9=^*]#FN7U
MF]MI=+N+6=[VQ,44<S>4QB51&NU<(W7(X !)!H ]%N-:TZUAL99KI0E_*D-J
M5!;S68$J!@>@)STP*QHOB)X5F,&S5"4G0M#(;>4)*0,E58KAG_V =W;&:Y?P
M987DWB==(O5=K7P>LMO;R,<^:TO^J/U6# _X'3='TJZC\'?#B%["97MM022=
M&A(,7[J?EACY>2.3W(H [2/QEH,NDR:FMZWV>*?[,ZM;R"43<?N_**[]W(XV
MYYH;QGH":?;WSZAL@N)VMX]T3A_-4$F,IMW*V%/RD ]!U(KA-8TN^&O:GJ'_
M !,K6TM_$4=Q)/9P;Y!&;$1^8BE&# ,V#A3@;NXJW:Z6CWNA7EH-9O(YO$+7
M,UQJ,"HS8M'02!51=J?*H!902>>XR =!J?Q%T6QT!M6@,]RB7D=F\/V>5)$D
M9E!#*4W*0&W<@9X Y(KI&U&T32_[2EF$-F(?/:28&/:F,Y8-@KQU!P17FGB:
MQO GC"=;*Y>/^V--N1Y<+,7C18"[* ,MC:<XST-=9XTMYO$/P\U!-,BDF>X@
M66*)D*-( ROMVL 02 1@@=: +5GXTT*_6?R+FX+PP^>T;V<R2-'G&]$9 SKG
MNH/6LCX;>++[QCI$VIWLD*[V/EVT5G+&(5#NH_>L<2DA0?EQCH:2WO%\2^/=
M(U'3[:\CM-/LKE;F:XM9(/GE,>V+YP"2-A)QP,#UI_PFM+FQ^&6D6UW;RV\Z
M>=NBE0HRYF<C(/(X(- %G3_B!H]XVMM,9K6#2KCR7EE@D <83D94?,6?:$Y8
MX!QR*O1^,-"DTZ2_-XT=O%.MM*9H)(VAD;&T.K*&0'<O+ #D<UP\EW?:8/%E
MG';WL,\NO1W33)8M+LM&\A6FCRI5F&#QR1@G'%)9W#VT?BV-]-U;5_[2\A+.
M._MF4W8:/R\L0BA4R#G."%&: /0KKQ'I%E<7L%S>I')8P+<7.0<1(<A2QQ@$
MX.%SD^E5HO&&A2Z==7WVQXX;5E299K>2.1&;&P>6RA\MD8P.>V:\]'A[5M*\
M):OX:GBN[K48I[;4?[2MXR[WL2RQE@"P8>8@0J$.<@+P<FM$66E7=GJ^HS7'
MBS48W^R1O>26HCDC\N1G1XD6-&)C9LD[3UP,X( !W^DZS8:W;/<6$K.D<ABD
M5XFC>-P =K(X#*<$'D="*YKQ5X_L-+L+^/3KE9-1MIHX?GMY#")"ZAD\S 0N
M%).W=GVJYX)N[^[L[\W<\]W;QW.VTO;BT^SRW$>Q>63"YPVY=V!G;TKAM1>>
MW\%ZUX9;2]0FU4ZO). EG(R21M=B42[P-N-I]<Y&,4 >GR>(-+BM=4N7N@(=
M*++>ML;]T50.>W/RL#QGK56]\7Z%I]ZEI<WI65E1F(A=DC#G"&1PI6//;<17
M#:]/-96'Q#T<Z?J$U[J9DFLUAM)'69&M8TR' V\%6R"<\8&215>_THK?Z_8Z
MG=>)(HM6$)AMM-M4=+I#!'&R[VB;:P*L#EE &#QUH ]=KC[GQQ:Z3XLUC3M5
ME\NUM;>WFA\FWDE?#!_,9@@)VC:O. !GKS70V>I03ZC>:6BS^=8I$9&D7 <.
M"5*GO]TY]Q7'SZE'H/C_ ,27M]I]\]M<6-HD,T%G),)&42YC&U3R=P]J .PM
MM:TZ\O([6VNDEFDM5O$" D-"QPK@],$^]8<OQ T<:UHVGV_GW"ZHLC1SQP2E
M5V-M_N<_-D'IMQDX!&>5\,Q7/@^]T%]7L[T!O#L=I^XMI)MLRR%_*.P'!PP
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M8Q:?*]NT>ZXAC!"[MR'##+?,N#R?;'5T4 9=KH5M::S<:I').9I[6&T97?<
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ME*MN/)&WL,8Q74T4 5-,L!IFGQ6@N;BY*9)FN9-\CDDDDGZD\# '0 "N>MO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*;':-MPVEE SD-R,T 4[OQM?M<ZBFEZ5;7,5KID.IQRRW9C$L3ASC&PD-\G
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M/;0W<EI*7C=9XU#%2CJXX/!^[CGUK*F\+'4]5BO];N8;MH+::VBCAMS"H64
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M >H&[M@[(;B(.J[V7>,A?4^WO6/J6OR6FO>'[*WC@FM=4FEC:<29*[(GD&T
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MEKF9? VCRBXW6L \_45U%ML0&V5?XEYX8]VZ\GIQCI)-XC;RPI?!VAC@$^]
M#J*\^T[QKK][9>&KUK'31%K;O (P[[HI CN&)[KB,C&,^_.!;M/&EX\?V*YM
MX?[4_M6;30T$;O&?+C\TR!,[ONX&W/4]<4 =M17(Q>(==^R0B]T^"QD-[);M
M<2@[7C"EDD2'=O8N<+L!R.3R!5&S\;:KJ%EX7DMK&T636)[BWE\QW C:)93D
M#&<$QYP>><>] '>45PG_  G5U;:&;O4H8;<V^J3:=>7<<3RP0!-V)2H.X*2%
M')X+<FNNTB[>_P!*M[J22VE,JEA);/NC<9.&4Y/!&#0!=HKCH=0U^;QGXGM+
M>XM9([.SM7M;>2)@-SB4X)#=20 3CICCCFMIWCQ[J\\-^?\ 9HK75K-Y)6V,
M#!.@),;$G SME SSF-OP .ZHKE+3Q#J5_J$&DQ+:PW[6 U"5Y8F*HCN5C3;N
M!W'!R<\8Z'/&EX6U[_A(]!BOVM_L\PDD@GAW;@DD;E& /<94X/I0!LU'!<0W
M4"S6\L<T3C*O&P96^A%<PM_J[_$F]TY+BW-E#I<5Q'"T;#YG>1>6SUR@YQTX
MQW.5I/BN^;0_")L=+TZW76))86B0LB0%4D<;0!T^3G_)H ] HKS\^--=@TN[
MOKBTTXQZ;JRZ=>!&?,P:1$#Q@_=P)%."3G!Z5H-XJU2ZN6ETK33=VD.HM931
M")@Y5'V22"3.T;6!.W'('4$XH ["BN4TWQ8]_P"*)M(:2VM[B"XE22RF1DG,
M2[MDR$G$BMA3P. WM5OQQ?WNE^!]:O\ 3IDANK>SDE1V3=C"D\#(Y]#V/8]*
M -PW$(N1;F:/SRI<1;AN*@X)QUQDCGWJ2O/9DU-?B'ICVILGU&30)]TTJ,J'
M]]%@D DGL.O<GVJUIWCBZUK3M+%G;)%?W>GF]D#1/,B8;8% 4@X+!N<\ =#F
M@#N*C%Q"UPUNLT9F10S1AAN /0D=<54T2\O-0T6TN]0L'L+R2/,UJ[!C&W0C
M(ZCT]JX^_P!2M_#_ (]\2ZM)%E(-"MIG5.#(PEG &?4\#- '=26T,TT,TD8:
M2$EHV/\ "2,$CWP2/Q-2UQT_B37[$:B\VC/<V\%F+B*>&W=/GW8:,H268@'<
M",9 (P#43^.53P^-8CN[.[T]KU8&OK6%W2WB*9+RQ!BRD/\ *02,;@3Z4 =M
M17(#Q7=7)L[.S>TGN[BVENQ<6\;SPF-9-B$!6S\V<GGC!'-51XH\47-[I6G1
M:/965_?:?-<O'>RL1%)&Z*0=H^Z=_'?D>F* .YHJ&XN4L[.6ZG.V.&,R2$<X
M &37)P^+[U;?PYJ=U;0?V=KLD<4:1Y\RV:52T6XYPX.,' &">] '527UI#=1
MVLMU EQ+S'"T@#O]!U-6*X;PI:2ZGK/B9]5%I=K;ZV&CW0'*2)!#L926.  >
MG7))SS6AXLOG.K>'-#4XCU2\87'^U%%&TC)]&*J#ZC([T =0CK(BNC!E89#
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MJ3,@+JI) /ISS7EOB.[U+4O WQ"&I3V\\5I>/# @A(,86.$C!+'^\?Q)/?%
M'>_\(M8?\_6L?^#BZ_\ CE'_  BUA_S]:Q_X.+K_ ..5CWGC&]T34=7M=5M;
M9A:V45[;_9F;D22-&(V)'7<!\P'0]*U='U/6+C6+JTO[#%HL*RPWJ0M$K,20
MT91B3D<'(X(/;% #_P#A%K#_ )^M8_\ !Q=?_'*J7O@72K][1I;K6,VLXG3_
M (FMPWS $?Q.<?>/(P??K5_6=8>QO=+TZW5#=ZE,T432 E4"(SLQ ()X7 &1
MDD<UGS:OKUK!;)>VUC;2R7<L+7&XR*4 )C9(@P9F? &P$D<]: +$GAW287C2
M6_U1&E;;&&UJZ!<^@_>\FI/^$6L/^?K6/_!Q=?\ QRN2N-7/B.Q\ ZS-;)#<
M2ZR48+_"1%<*<$\X)7./I6O!XJU74)[6YTW3?M6GRWSVLBB)E9(U=D,WF$[2
M RY*XS@]<C% &M_PBUA_S]:Q_P"#BZ_^.5'/X=TFVC\R>_U2),@;I-:NE&3P
M!DRU@6_C36F2VNY[*P6T;7&TB5$=R_\ K6B#J3QP0,@CG/:J'C#5KCQ#X.NK
MZ!+4:=!K$%NF]"96\N[C1I V<+E@1C'W><\XH [+_A%K#_GZUC_P<77_ ,<H
M_P"$6L/^?K6/_!Q=?_'*R=7\6WVEZPD+P6WD-J=O9"(9>0QR[0)2RG$?S,0%
M89(4G/-6-(UO7-5\0ZE:_9M/CL=.OC;3-YCF1U,*NI7C&<N,Y[?3D O?\(M8
M?\_6L?\ @XNO_CE'_"+6'_/UK'_@XNO_ (Y4GB>^U'3/#MY?Z5;Q7-U;1F7R
M) ?WBCE@,'[V,X]2,=ZR;[QBL%L;^T\FZL/L]LRNJG+RW#A(P""<#D,1@D C
MKF@#2_X1:P_Y^M8_\'%U_P#'*H77@#2KZ^@N+F^UJ6*$J\=J^JSM&LBDD2#+
M;@PSQ\V/:HSX@U^"/4O/TV'RX#";>]E!MXF1V D+*[9!09/7YN ,&L^?QUJ4
M.B:M=16=M-/IVJPV!+!X5E20Q88*<E3^]'!/;/?% ':6&GPZ= T4,ERZLVXF
MXN9)VST^\[$@<=.E6JJ:;_:/V,?VH+476]O^/4L4VY.W[W.<8S[U;H ****
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MINDSVL-[=+"]T)#%D$@A$+NQ(X "C))P*HV?C30[RWNYQ<RP1VL'VJ0W5O)
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M>UE2*;"[B%=E"E@,Y&<C!]#65J/C^SENM)@T>9W^U:I':M+):R+%,F2'\MR
MK$$=5)H Z31=$MM$BNU@.7N[EKJ<A0H,C  X4< 84?S.22:S=:\&0:U?W]TV
MHWMLM_IYT^ZBA*;9(_FP?F4D$;VZ$9K:U34;?2-*N]2NV*V]K"\TA'7:H)./
M?BLC0M;G>TTN/7)$AU354DN(+9(SM10 WE[NA9589SU.2.!P -@\()!?&[&J
M7CRG35TTEUC_ -6"2&X4?-EC[>U,TOP9#I-SI<\&HW3-ING'3H0ZH08R5.6P
MO+?(O/'3I46M^+!I\J7]I,LVFV5^MAJJF,@Q%]H#JW?:73<!D88]"*Z:[NH[
M*SFNI1(8XD+L(XV=L#T5023[ 4 <Q;^!(;.PT6WM-5O89M(>0V]P%C9RDF0Z
ML"NTYSUQQ@4VU\ 064ME-:ZQJ,<UI<W-PC_NVXG;=(ARAR,]"<D>M9=M\2DO
M8O#&H"">VL]2\\7$+6TCN66,,HC^4%^2.5!!Y]#71KXTT1])344GG9'N#:K"
M+:0SF89S'Y6W?N !)&.@STH J67@6VL;31K:/4[UH])NGNK??L))8,-K?+R
M';WYZUTMU:PWUG/:7,8D@GC:.1#T96&"/R-0Z7JEGK-@E[8RF2%BR_,A1E92
M0RLK %2"""",BLZY\7Z-::P=,EGF$RRI \BV\C11R/C8C2!=BL=RX!/<>HH
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M6\T]=/FB^55V!BP88&0VYB<Y].*N:%H4^D(?M6LW^JR!?+CDNRF43T^51DG
MRQR3BJ\FOVUKXDU2WN-53RK*P6[ELQ:MNB3G,GF=&R ?E R,573XA^'))4C2
MXNF>6+S;<"RF_P!*7C/D_+^\QD9VY]>@)H O^(_#D/B&"US=7%G=V<PN+6[M
MR \3@$=P0002"",$&JDOA#S9]-NSK.H"_LI)'-U^[+3>8H5@RE-HX50, 8Q]
M:CG\6:?=V^AW=CK"VT%]J M0LEF[M,XW!H2#@Q-E3RPXQ[U/X<\76WB/4-6M
M(;6ZA.GW)@WRV\B*X"J2<LH .6(VYS@ ]#0!6M/ EM9V.D6<>IWK1:7?/>P;
M]A)9MXVGY>5Q(WOSUJ2Q\&1Z;JL]Q::OJ$>GS7!NFTS<AA$I.XD';N"[OFV@
MXS[<5N?VG:'6#I7F_P"FBW%R8]I_U9;;G/3J.G6LB3QOH,<%E*+J63[<LK6L
M<5M([S>6P5PJA2202.,=,GH": *P\#0"P2T_M.\VKJO]K!ML>?.\PR8^[C;N
M/3K[U!<_#VWFM]0LH=7O[;3KV[6]:UC$96.42+(2A920"R@XZ9_*M$^-M"_L
MNUU!+B>5+N9H(88K:1YFD7.Y/*"[P5VG.1QBLW1O'-K<66L7]].3;0:L;&T6
M*W<RO^[C8)Y8&XOEFR,9&#G&#0!)<^ 8+B6Z(UG48XY]0BU+RU\HA)T*G<"4
M)(.P<'@>E;&CZ"FCWVJ727<\QU&X%Q(L@7"L$5/EP <85>N>E59O''A^WTRW
MU":\>.">=K9 UO)Y@F4,3&4V[E;Y3P1DG '45M6UW%=6,5XHD2*2,2 2H8V4
M$9^96P5/L>E $&K:E_95B;G[#>7OSJOE6<7F2<G&<9' [U@:;X)T\^")]!NK
M=X(;UWGECCD^:!F?<@5N>8\(H/3Y!5.PUWQAXBT[^VM$MM'@TV7<UG;WHD,U
MQ&#@,64@1[L9 PV 1FMB7Q=:6-K8#4[6[M]1NH/..GP0/<RQ@8W$B(-\H)QG
MH?TH JR^"GN])%K?^(-3N[I)HIH;R3RP\1B8,F%"[3R.<@D]SP,1S^ 8)X-2
MB?6-0(U"[AO)21%D21[,$?)W,:Y'3CC%:,_C+1(;/3[I+F6Y3406M4M+>29Y
M0!EB$12V!WR..G6LG1/'5K/I,]]?3-*)-3N;6RCM;=Y))D1CMPB@L<*,DX^N
M* .S4$* 3DXY/K2U5TW4K35]/AOK&82VTH)1L$=#@@@\@@@@@\@BK5 !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7!:IJD6D?%@7,]K=2Q'0@I>VMWG9
M#YY(RJ M@XZ@=<9KO:P]3ET'0]7&O:KJ-O8S26_V-7N;A8T90V_ !ZG)H XK
MPWHFHV^J^"Y[G3IXE0ZK<2*T9_T83.'C5O[IVMC![Y%13:(1K&KZ9J+>)6^V
MZK]HA@L8@;:6-F1@YD*%5VD<@L#\G Y%>H6EY;7]K'=6=Q%<6\@RDL+AU8>Q
M'!J:@#S[2;RXT.74M#N-"O;V[N=9EN(C]G8P/%++O$IEP4&P'D$YRH '2LK1
M=$,-_:Z3J#>)7N;?5I+D0QQ 68 F:5)?,*8VD$9&_=DD8KU4LH(!(!/ !/6J
MMEJ=GJ+72VDZRFUF:WF !&R08RO/U% 'ED:WL7A'1_#!T;4GU&PUJ![A_LC^
M4L:W>_S1)C:P((/!)Y)/ -/U'1M2E;X@ :==.MWJFGO /)8^<BM%N*\?,!@Y
MQTP:];HH \U\>Z+J6IZSJK65E-.#H<87:IQ(R70D,8/3<5!X]ZMV.JIK'Q8L
M+F*QO+>(:'<*'N[=H78^=#D;6 ; SUQ@DG&:[/5H+"YT>\AU0QBP>%A<&1]B
MA,<DMD8X[YXK!M;/PWX47^V[O62?/B6".^U*_P!_[O[P1&8XP>O'7J<T 0>-
M_-M]8\*ZF+6ZGMK+4':X-K \S(K02*#M0$XR0.G>L.]TJ_;P!XNMTL+@W%SK
M,\L48B.Z13.A# 8R1@9SZ"O1&U"R33_[0:[@%EL\S[09!Y>S^]NSC'O4ANK=
M;0W9GC%L(_-,VX;-F,[L],8YS0!Y<^B$:QJNEZBWB5C>:O\ :8H+*(&VDC9U
M<.9"A5=N.06!^3@<BO3=0L8-3TVZL+I-]O<Q-#(OJK#!_0T^TNX+^SAN[9]\
M$R!XWP1N4\@\U4GFL]7^WZ5%?2Q7$(59_L[F.6+<,J0>V1T(]Z /+--T;6?%
M.@:_!=*7O=(TR;P_:,2,33 GS) ?]I5A7/\ O5H&.Y>SU'5-)'BBYU.WTQH5
M.IVH"Q;W0NB(T:^8X"9& R\8[UWNBPZ1I"G0--<![1!+)'N+L-Y)W.QZLQW'
MDY/)JS_;.E_V:^I?VE9_88R0]SYZ^6I!P<MG YX^M 'DNM65Y>6GBL6=MX@O
M8[[0XXK6:]MI"\SI)(64#8"OWQA2 3R0,5[) @C@C15VA5   Z<5D1^,?#4Z
M3/;Z]IUQY$332+;W"RLJ+U8JI)P.YK8BECGB26)UDC=0R.IR&!Y!![B@#S'4
M$N['1/&7AQM*O[B_U>ZN7LFBM7>*99U 4F0#:NTG!W$8"_2MBPTN]M?BREP\
M$S6T?AN.V-UL/EM()R2N[IG'..M==:ZG9WMU=VMO.LDUHX2= #\C$9 /X5;H
M Y'XA13MI6E7,-M<7"V>L6EU,EO$TCB-) 6(502<#T%94ME=76G_ !'FCL;G
M_B80YM0T#*TP-BB@*",D[LC'8Y'6O0ZS=0\0:3I5]:65[?10W5V<00DY=^<<
M =LGKTH \RN-%EAGU:VU(>)1%JEM;"*WTR'<DX^SI$\;L4(1@5.=S*,$'UKU
M2XMV_LB6VBW,WD&-=QY)VX&34%GX@TG4=4NM-L[Z*>\M,B>.,Y\L@@$$],@D
M<=:TJ /'--MKD:/X/N[A/$.GPZ;ITNFW9M+*030S8A(^0QL60["-R@C('/6M
MS2=$:V\2>#IK>QU,6L4&IRN]\@,D3RNC#>5&%+98@<'''8UZ,S*N-Q R<#)[
MTV66."%YII%CBC4L[N<!0.22>PH \XUC2KZ71OB:D=C</)>G_1@L1)G_ -%C
M7Y./F^8$<=\U>US3KN3Q'%)#9S-$/#5Y;[DC) D+1;4SZG!P/8UUND:WINO6
M9O-+NTNK<.4\Q <$X!XSUZBK] 'FGA/2K^W/P]-Q87$?V/1[J.?S(B/)<B'"
MMD?*3AN#Z&JJIJFGW+QS1ZO::;/K6HRRRV%HSS,2P,(&%8JC9<[@,' Y ->J
MD@ DG '>JW]H6G]HQV'GI]JDA:=(^YC! +?3++^= 'E6CQ7NECPA/>:9JJC3
MM3U..[!M9)70RF0QL=JG<IWK\ZY7)ZTL.C:I#'KUZ=-NW6V\8+J0A$1WSP+L
M!:,?QXY(QUV\<UZ[10!Y3XEM;OQ,?$FJV&FWQM'TZULHEFM7CDN'6X,C%8V
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MOD#D8WD=V ) )Z9-7Z /*_"%M=R0?#^*33;Z%]*CN8+OS[5XQ$_DXZL "#G
M(X/3-0WFC7\6KW&IRIJUK:0^(+J1Y;"$M,(Y+>-5E5=K%EW J2 >I]#7K5%
M'.^#+.&TT::2%=3 NKJ2<MJ8"S.20-Q4 ;0=N0" >>17$>*/[5O)]7BFAUR2
M>#4X)8;6VM6^S&U1XG\S(7]XQ"MQN+9 &,"O6:* /(-:^VP^$/&/A]=%U.YO
M[Z]N+JV\NRD9)8I&#AM^-H*CC:3NRN,5/JEC<:GXM^)EC:1F2YN-#@CB0=68
MQ2 #\37K%8NC>&+#1-0U#4('N9KV_*F>>YF,C$+D*HST R>!0!QEY=-XAU;2
M9E\/ZM/86^CWT%U'-:/ 9&=(@81O"\D*1GH2>"<'&;JD.K7_ (0\1:=IW]MZ
MEIJ6D#VXU&S:.X202@M$NY5:0!5ST//&3FO7Z* /*]7A^T:]JVH2GQ1'8ZO9
MP_9XM/LV!F*JR-%(K1DQGH1NVC#'GK4WE3>&[OQ-IYTK4[D:E90+8&.W:82;
M;<1&-W4%5(*Y)8@?-FO3J* ,7PA!+;>"M!@GB>*:+3K=)(W4JR,(U!!!Z$'M
M7*>%KBYLM"TSPG-HE\^HVSR0S7$ENRPP@;\3K*1M;.1@*<_,>F#7HM% 'E>G
M17EUX=\(^%QI5_!J.E7EJUXTEJZPQ+ <LXE(V-OQQM))W?6I3I%\?!+6YT^X
M,S>*?M!C\D[C']OW;\8^[LYSTQSTKT^B@#R?QS;W,&KZ]>&RFD@DET41?)A9
MF6Y;**3P3R!^(IWB6RO?%M]K6H:78ZC'!#IMM IDMF@EGD2Y$S+&L@!)"K@$
MC&6QS7I&JZ3:ZS:);78<QI/%.-C8.^-PZ_AE15Z@#R?4=*74]$UFZL4\27\\
M@LH/,U.W*&15N0Y5$**QVY8DD8Y.#P:W/$NGFX\6:A-<Z7>WNGOH(A<6RG<Q
M\_)"'CYP/F !SQQ7>44 >5F_UU;.2.&ZUZXT1;ZW7[?-IS"]2(K(9 JF,,P#
M"(;]F<.W7&:H?9KZWL;F5M.UJ1;?Q3::D3/;223/;;(QYG"_,1M.5'S+T(%>
MQT4 >3ZKH6J:SJWQ$:TL;@+J.GV)M#+$T8G*H24!8#G^$CL3SBMB[N)?%/B/
M3KRQT[4((-/T^\$[75I) =\JJJQ*& W'@DXR.!SS7H%% 'GEAIE['H?PSC-E
M.KV9B^TKY1!A_P!#D4[^/E^8@<]S5[XKV-WJ/P]O;:QM9KFX:>W*Q0H78@3(
M3P.> ":[6B@#S76-+OY?&WC&XCLKAX;CPV((9%B8K))\_P BG'+<C@<\UH6V
MFW2:SX!<V<H2STV=)F\LXA8Q1 !O[IX(P?0UW5% 'DDVC:F9-%QIUT1'XUN+
MI\0M\L)>0B0\<*<CGIS74^#?-L]?\56%S:744DNJR7D4CV[B*2)HXP"LF-I.
M0>,YX/%=E10!QFJW+Z-\18M3FL;Z>TN-*^RH]I:O/^]67=M.P';D-P3@<'FL
M3PAI>HPW?@V2[TZX@-O:ZF)A)&?W+/,A4$]B1G'J.E>G44 >56MK>Z+X@M-:
MNM.OFLH-9U82>3;/(ZK,P,<@106*G:1D _>JI_9VH7'GZN]GK%A;1^)YKMA;
M0$7(@DM1&LJH58GDC( ) +=P:]@HH \O31B\GA^ZL[76IXY/$9O)Y=1BQ(0+
M=T$I4*"BG:N-P!S]17ID\*W%O)"^=LB%#CT(Q4E% 'GGAS7[OPGX<MO#VJ:%
MJ\VH:=']FA-G9/+%=*O",L@&U<C&=Q&#G-2B[U#2/%T6O:WI=RJWNCQ6[BQA
MDNQ;SI([&,[%)Y#C!QC*GGI7?44 >4Z#:7WA>_T+5]3TV^^S2VU_&\5O;/.]
MHTUR)HPR("1E?E.!P1@U1MM+U".6SU>[M];TRV74]4,HLH"T\0GD5HV*!6)4
M[""5!ZCM7LE% &#X.LHK+P\@ACU%%GFEN"-1 $Q+N6+, !C<3NQ@$9Y -;U%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7)>(=*U9?$UIK^CVUCJ$L
M%J]M)97<AC.UF#;HWP0K<8.1@CO76UA:OX7@U34H]3AU"_TV_2+R#<64BJ7C
MSD*P964@$DCC(R: .)E\1I'!9Z9I.FZEHTMSJ=PNIVUE$LL\4BQB1A']Y<-N
M1MP'3.,$U:L]5\0:C/H^@75UJ.GFYN+PM>20)'<RV\(4IP5*JQ\P D#G8<8S
M71#P-IT=A'##=W\5Y'=->#41*#<&9EVLQ)!4Y7Y<%<8 XX%/F\&VLUC9Q?VC
MJ27EG,\\.H"8&X#OG?DE2N"#C;MQTP!@4 <SJNEZM'XR\%VM]X@NY9!->8FA
M2-"RK&Q4L-I&\J=K$<$= #S5:'Q3KD\.M6BZ@R32^+/[(M[CRU)MH"%)V@C!
M( 8#.>375?\ "!Z>L6F^1?:C!<V%Q+<I=I*IEE>7/F%RRD'=GG@8[8I__""Z
M3]CU2VWW0_M#4#J32B0!X;C*D-&0.,%1C.>^<T <MX@UG7/#2^(-+M]7GNG@
MLK6]L[FZ5&DB+SF-T8JH# [<CC/)YZ5T&EOJ6F>/7T>XU>ZU&VGTS[9_I*Q@
MQR+*$.W8JX4ANG.,58/@:PFLM1AO;V_O;C4/*%Q=SNGFE8VW(HVJ%50<\!>Y
MK8.D6Q\0+K6Z3[4MJ;0#(V;"X?ICKD#O0!PGQ'U[2[N6Z\-WFJ6EI!!9M=W:
M33K&T[[3Y,*@G+98;FQV"C^*E\,3V>K^)/#3++!=V]MX:W0%6#JLI>-)".VX
M;0I],D5W]_IUMJ-G<6T\8*SQ-$S #< 1@X/KS61=^#[*>VTQ+:\O;"XTV'R+
M>ZM'59/+( 96RI5@=JDY'4 C% '(1:597OP^\5VMQ;K):Z;?ZDUG$?N1X#D8
M7H0K,V >A QR!5WQ 3/X!\)Z421!JES86=P!_%$5WLOXA-OXUO7'@NSD\.1Z
M%;ZAJ-G: 2"5K>9?,GWYWF1F4Y+%B3TY-4=3\&3Q>$5L-.U&[O+VQGAO-/:^
MD4[7B(*QY51A2 5_X$: ,WQSK-[97.HG3-3U-)=-T[[0MM86B-%$^'8-.[C!
M4A0-HP0 3W%7M1G,7COP=J<8"2:G!/9W(7^-/*\Y?^^64X_WC5RY\)6?B(S:
MA<R:G9+J=JD=]8+(JK)@$ /P3D;B/E8 XYR*CM-"NY?%VG23>>VG:!:-%;3W
M!7?<S2*%9OE &%0;<X&2Q]* *O@6QM]=\&WEY?H96UJ\N9KH;B"RB5D5,CG
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MWS0I#(X)&-H?&WD#&5SCJ*Z7PC<WRZCXATF\OIKY=-O4C@GG"^84>&.3:Q4
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M%=;/O>6W?@$C(&0"1D4 =#17)V/Q!TC4=(?5;6VU)[/]VL4GV4_OW=MH2/\
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MDFISV9L+D1ZGX433%N54%()@),B0YROWQS7:?\(?X<_Z ME_WZ%'_"'^'/\
MH"V7_?H4 <?I&BM/!(QT?Q!'>V^E30^9J5Z\B)(Z@&.)2[!@<?>&!\H]>*VD
M>'=7@3X7B6PF7^RXYQ>Y _<$P[1N^IXKN?\ A#_#G_0%LO\ OT*/^$/\.?\
M0%LO^_0H XCPUX8>TGTW2[[3=>DN+&X=S<27S_8D"[]DJ+N()((^4#(W'.,<
M['@V?6=)TS1O#,N@W*O8J8+N]D*K (T!"O&P)+EOEXP,9.<8K?\ ^$/\.?\
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M)^4>7C=T^;BNLN_ OA>]MFMY]$M#&Q!.Q-IX((Y&#U%3?\(?X<_Z ME_WZ%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*QT.[BN(!<?8HVEBE8$9VJQ++N^HQ7<WRE["Y502QB8 #J3@UYSX1\3W.C^
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MD(RJ\'J!PN35_7]/5_%&OSWNGZG+8O::=MGL(V\R-TEF/F(1R2A*L0N3CL:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0H))
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M":BH;JZM[&TENKJ9(;>%2\DDC855'4DU7MM8L+G2H-36ZB2TF17621PH&X9
M//!YZ4 7J*16#*&4@J1D$=ZBN+NVM AN;B*'>=J^8X7<?09ZT 345#-=VUL"
M9[B*(*N\[W"X7.,\]LD4OVJW$JQ>?%YCC*IO&2/84 2T4R.:*;=Y4B/M.UMK
M X/H:Y[6_$5_IOB;2-&M-.MKAM32=DEENFB"&)0Q! C;KNH Z2BL#PYXI@U[
M3[^>:'[#-IUW)9WD<D@*QR)C.'X!7!!!XK9%Y;&%)A<0^5)]Q]XVMWX/?H:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$5U;17$#AX94#HP_B4C(/Y43PI<0/#)NV.,-M8J<?4<TY$6.-410J* %51@
M#L* /*-;N0^KRF.QN[=[;Q/:S31I:RRM(HV*9R^" I7@*N. >N2!JZ>;FV\9
M0+:NFH:?-J5TSP3PE+G3I")-T@;^*)CD#</XU )KT2B@#*\36[W?A75[>.(R
MR26<RH@&2S%#@ >N<5Q&CW*V^I>%;R[@=-%_L4VP>2!D2&[_ '>XN"!MRJE0
MQ]",\UZ910!R_@*QN=/T"XAE1X[8W]R]C$X(,=L9"8UP>0,<@=@16'X[D675
M-0LA93B:?09TCN4@>;SLD_N4 !53D*22,X(Z8S7HE-DD2&)Y9&"(BEF8G  '
M4T >7Z9;:=?^)]-GO[))(V\+JLK75N0#(&'#;A][;D\\XY'%,LK:XL?AUX2\
M306TDNIZ';QI-"5Q)) P"2Q8/\0&& /=1ZUZ=9WMMJ-G%>6<\<]M,NZ.6-MR
MN/4&J5]H::AJMM>S7MX(H /]#60""1@VY69<9)! (YQP.* 'Z'8/I^E1QS!?
MM,A:>Y*]#*Y+/CVR2![ 5RWBM%N/B/X04R3(D:7HEEB)7RRT:!<L/NY((&>M
M=U10!P'B/3+?PI:Z-+86UVFDQ:B]QJ+VZ&XEW.C 3.&#%\,02<$C@CH*R+O2
MM$9O#;VEM<364^OR7+-=P$91X7WL$*C9$7*\$ $\]"*]0NKJWL;2:[NIDAMX
M4+R2.<*B@9))["I58.H92"I&01WH \WU*V;2/$;+HJ036HN[..;19;?;C;Y>
MR:V8= @P2.5&UNE4)[:\N_".JZ/+%(OBM=8::W?8=[,9PT<R-_<$9 ST 4@^
ME>H7=_9V"*]Y=P6RL<*TT@0$^@S3[:ZM[R$36L\4\1X#Q.&4_B* /(_$6FVD
MEI\1Y([%&N6FA>T98<L7$,>3'QR=X.2O<<UZ?9Z[87VJW.F02NUU;QI*X,;!
M65AD%6(PW49P3C-:50K;1)=27(7]\ZA2Q)/ Z >@^E '+?$&.0V6A3C/D6^N
MV4MP>P3S-N3[!F4U<UV5]1UJPT6VG2)U/VV5I(BZ'RR"B=1R6(?K_P L_>MZ
MYMH+RUEMKF)98)5*.C#(8'J*6"+R($B\QY-HQND.6/U/>@#AO"QF\.^-];\/
MW#B2WO6&I6TL<+)&DKY$L?4@'(#@9_B-7O!L<G]N^,+@9%K+JV(O0LL,:N1_
MP(8^H-=;(I>-E#LA(P&7&1[C/%16=G!86J6UM'LB3) SDDDY))ZDDDDD\DDF
M@#F?%5S%#XCT%);67YUN MXL+S"(E5!0(N1O<$X+ @;3P<UQ?AJSMKA?AY'?
MV)+6UI=PW N;<C9@#8K;ATR#C/&0<=*]AJM<ZC9V=Q;07-U%%-=.8X$=@#(P
M&2%'<XH \TL=)>;X=-=6,*IJ&AZI=WM@CKMPJSR,(QGHKQD@=N0>U=WX;C9]
M.;4YH3%<ZD_VJ1&&&0$ (I]U0(#[@U+J^B)K+VXFO;V&"(MYMO!(%CN58 %9
M!C)''8CJ:U* .0UR62R\?:->WRDZ-]CN(1(5S'!<LR$,_89164$^I'?GE4TV
M73[71)[BTF.FQ>)[B6V06[.8;1TF"#: 2%+'@8Z,M>LT4 >/ZQ:6\ND^-;H6
M@>]_MN"2U?RB9, 6_P T?&<95^1_=/I4VL6&_6?$UA?ZIKD,.KW$<D%OI]G'
M*MW&T,:?*[1M@J5(/S   'C.:]:HH Y#PM9O!XT\9SO"Z^==VP25EQYBK;H.
M#W .?QS5KXA0RW'P\\00PQO)*]C*JHBDLQV] !UK<O=1L]-CBDO;J*W26584
M:1@H9VX51[GTHAU&SN;ZZL8;J*2ZM-GVB%6!:+<,KN';(Y% &%8>#K>WO+>_
MN=3U34+FW5OL_P!MN-ZPLR[2RJ !NP2,G/!-<;X)T[$GAO3K[4M=DU#2=Q>R
M:SC2"V=8VC8M)Y8)4[CM^8EMP//)'J)O+9;Y+(SQBZ>,RK#N^8H" 6QZ D#\
M:GH \NT.QMK7X.>'XM1BU*R,,BR>?9PDRVDF]R)&7!.,G!^4_>Y&.0RTO[Y-
M5T/7]56:YTZSN+VV^WI8M&TBR)'Y<[Q@9&2KINQCH> :]4HH \JBLY[[4K74
MTLIQ97GBY+N!9(64^6MJR>:5(RH+KD$@=CWKK= @EC\;^+I7B=8Y9;4HQ4@/
MB  X/?TKH;.\MK^U2ZM)XYX),[)(VRK8.#@_4&IZ ..^()N-.M-,\1V5K+<W
M.DW6\Q1(79XI$:-@ .3RRG_@-<C#X<OM.U71_#1MII+34ULKR_F"$H);<,\V
MX],NR0CWYKU:^U&STRW%Q?745M"76,/*P4%F. ,^I-27-S!96LUU<RI#;PH9
M))'.%10,DD]@!0!YE/I]P/AQKT2VDOG2>(9)0@C.YA]O4AL=2-HSGT%4]0TO
M4)=2^(,L5C<2K_:.FW(C6,DW$<6QW"?WN%/ [\5ZXCK(BNC!E8 @CH13J /.
M/%&HV?BCP_JATS2;B51+8(]X]HR&<?:4)C 90S!!DGC W'WK?2"4?%2:X\I_
M).B1IYFT[2PG<XSZX/2NHHH Y/Q\DBV&CWPAEFM[#5K>ZN5B0NPB&X%MHY.T
ML&X]*XO7W?6K;XC7=A8W;076DVB6[FW=#<%?.!*@@$XX'3L.Q%>LM>6RWJ63
M3QBZDC:5(BWS,BD L!Z L/S%3T <'H=E*OQ#LKF2V<*GA>"(2,A #>:25SZ]
M.*P?#6FL)]*T?4-4UTWUCJ$DQL5LXQ!$RM(1*9?+!*,&Z[R3OQZX]-?6=+2Z
M-J^I6:W ;:8C.H?/IC.<U=H \[\%ZA!::1H/AF[TBYFU>RD9)Q):MMM67?F?
MS&&W#9X*G)W_ %KF(HYYO /A/34M;K[9IWB:#[7$UNX,0\^5LG(P1@@Y''->
MUT4 >6^*]/NX/%T_A^T1_L7C 1F9DZ1&+ N#[;X=H^M>B6FHVLNI7>E0(Z2V
M,<3.I3:NUP=NT]Q\I'MBJUKX=MK?7Y]:EN;JZO'0Q1?:'!6WC)R4C4 8!(&2
M<DX'-:26T,=S+<I&!-*%5W[L%S@?09/YF@#F?'44H@T._6"6:VT[58KJZ2)"
M[",*Z[MHR3M+*W Z#/:N,\4PR>(;+QCJ=A:7$MA=0:=:QDP.OVEXYRSLJD D
M .!G&.#Z5ZK?ZC9Z7:FZO[J*V@#*IDE8*H). ,GU) JS0     # ':BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KD=4UB]M_B?H.DQR*+.YLKF65
M#&I)9=NW#8R.O8UUU8]WX<MKOQ5I_B!YI1<64$L"1C&Q@^,D\9SQ0!Q.B:YX
MD;2/"&NWNL_:%U:ZCMKBS%M&L>UU?# @;@V5!/..2,"J5S=ZSK?ASPYX@N]4
M+P7VO6;_ &#R4"0Q_:@$"L!N+# SN)!R>!7<6_@ZRMM$T+2UN)S%H\\<\+$C
M<Y0, &XZ?,>F*ST^'=NGV6W&L:A_9ME?I?VEC^["1.LGF8W;=S+G( )X!]0"
M #G]1\7:Y:Z=XYGM9XA/IFJ6UO:9B7"J[1 AN.<[CR<GFKNL:OK&EZQ::#-K
MFILXM'O)KVQTD7$CL7VHFQ48*@PW;)X&>IK;N/ 6GW-OKL+75R%UF[BNYB"N
M4:-D("\=/D'7/6M#6/#S:CJ$&HV>IW6FW\430&:W5&WQL02K*ZD<$ @]1SZT
M <OIVL>(_$]W9Z;]LET.YBTI+RZ86B[WF:1T V2@[4_=EL8S\P&12V<.M-\5
M[--0U4B6/0A+/#;QKY+-YH5PNY=P4D!O7MG%;=WX.\R6TN;'6]2LKZ"T^Q/=
MJR2R3Q9S\_F*V6!R0PP02:=;^#;>QU?3-0L=0O(&L;,6+(2L@N(0P;#E@3G(
MSD$'F@#@_ .JWNB> O!]XLH&E2W]Q9WR%1QYDT@B?=U #X!Y_CKO_#6IWNLZ
MEKMV\H.F17AM+&,*/^60VR/GJ<R;A_P"L#5?#<>@?#=O!^EV5_JCW2RQV[[1
MB.1W+AY'& @5FR#_ +/<UV&@:1'H.@6.EQ,7%M$$+GJ[?Q,?<G)/UH \[UV*
M]?Q%\0V?5)VMX= 3%N43:5:.XPN=N0%.3P<G/.>*T+&]US1;CP_#/JQNH-2T
MR9C 8$5;=XXE=2A W$<D'<3GK6_J?@V'4=6U*^74;NW34[ V-Y;QA"DB[756
MR5)!'F$\'G S5NX\,6MQ-I4K33 Z;!+!$!CY@Z!"3QUP.U '&:;K?B:7PAX=
MO+C65:_\136T".+:,+:*8W=W48^9F5/XL@$\#'%3:EXAUS09-8TI]3:[EM)=
M.E@NY88Q(8I[@1NC!5"D_*V" /O>V:Z5O!MG_P (KIFA)=7,8TSRFM+M"OFQ
MO&,*_(VDXR"",$$BJ\G@6VNM.U2&^U*\N;W4FB::^.Q)$,1#1; JA5"D9QCD
MDYSF@#.\7>*]3T+5-9CM7C9+?1HKB"-T! G>=XPQ/4C[O&>U4]8GU[3-1N-%
MOM9.HV5QH-]<%I+>..3S$"+_   #:-QP.O)R3@5IZAX(1[/6+N]N;_6KV]T[
M[(Z.\<1<*2RA-JA4.3QVSR:Q]&T.]USQ*UW>'7#;KH\]C+<ZI$D,A:5DPB(H
M .T*Q+8.21R>P!/X<N=:TJ7P5#/JIN;/5;,QO:F!%2#9;B1"C ;C]W!W$YSG
MCI70^*]2OX+K1-)TVY^R3ZI=M"UUL#F*-(WD8J&R-QV@#((YZ5:3PS:H^@.)
MILZ(A2#I\X,1B^;CT.>,<U-KNA1:Y!; W$UK=6DXN+:Y@V[XI ",X8$$$,00
M1@@T <3J'B+Q#I;ZEH\>I+<7=IJ>GPPWLT"9>*Y8 JZJ I(PW( XQT-)JWB3
M7/#5SK6F2ZG+J$BK8&UN7M%:2(W$K1M\D:C?C;N48R3QS71IX(M6AD-U?W=U
M>37\%]/=OL#2/"RE%P%"A!M P!W/.35C5/!]CJU[J%U//<)+>06\68V ,+0R
M-)&Z''W@S9YR.!QUH I^#=5U&]O-3M+M]2N;6 1/;7FH:>UK(^X-N0C8@;:5
M!R!T<4V\N=7UKQCJ&CV&K2:7;Z=:0RL\,,<CRRRE\9WJ1M 3H,$D]:W-'TJX
MTWSWN]6O-1GG8%GN-JJH P J( J^_&2>O;%+5/##7NK-JEAJUYI=Y) +:=[=
M8V$L8)*Y#J0&!9L,.>3UH Y&P\2^(_$ESX9M+?44TXW]A=27DD4".1)#*B;D
M# XR<\'(PWJ!79>,M1NM(\%:UJ-E(([JULY98G*AL,JD@X/!J/3_  ?IVEWV
MDW%HTR#3+.2SAC+ AE<J2S'&2V4SGW-:.N:3#KNA7VDW$CQPWD#P.\>-RAA@
MD9[T <:'\4-XKLM';Q(XBU#3GO))$M(MUNR,@*Q97&T^8/OAC@=<FJN@^(-?
M\32:3I!U4V4PM;J>\O8((S)+Y5P8%"AE*KG!8\'T&*[?^PH/[>L]7\V3SK6S
M>S1.-I5V1B3QG/R#\S6-'X$@LXK-M-U2\LKVT-QLND6-BR32&1T964J1NP1Q
MD8'O0!SO_"2^)+Q]'TF'4HX;Q]8O-+NKL6ZGS%B1V$@4\!L ''3/MQ2:UXHU
MRVU35[2RO-4EN-'CBCAAM]),Z7TOE+(WFNL9";MP4!2N.M=7:>"K"S?2'2XN
M7ETVYFN_,D8%KB656#M(<=3O)XQV[4[4/"9N]4NKVTUG4-.%ZJ+>16I0>=M&
M 0Q4LC;?E)4@X [C- &M>7+KHL]TBF.06[2!7'*G;G!!KSW0M>\0ZWI_@J!-
M4%HVJZ?<S7DT=O&6RACVE 5V@_,1TQR>.E>E7,"W-I-;L2%EC9"1U (Q7/Z/
MX+LM%70A!<W#_P!C6LUM#O*_.LA4DM@=1L'3% '$7%YKFK7OANVGUR9)K;Q#
M=V+3Q01 R^5'+MD*E2-VWC&,<DXSBKMMXOUF\UC[5;OJDT?]KM9FPCTEVMA;
MK,8F?SPGWQ@N3OP,;<5T=SX$MY41K;4KRTN8M4EU2*XC",4DD#!EPRD%<,1R
M,U9@\)FUU-I[;6=0AL7NC>-81E%C:4G<WS;=^TMEBN<$D]CB@#EX]<\2/X;\
M8Z\^KA5TM]1@L[=;>/ \HML=CC)(QC'3 YR35A9O%#>)=+TM_$;"+5-.DNY7
M6TBW6S(8^(LKC!\P#Y]W ]:Z)?"%FOAW6M%^T3^1JTES),_&Y#.26V\8XSQF
MK8T"W&M:?JGFR^;8VDEI&O&UE<H23QU_=C\S0!Y_!XSUBZM=(T^XO[Z&=A>F
MZO-.TW[1+)Y$_DIA CA0>K';C@ 8S6CI>M^(O$5_I.E27=QI$PL)KN[E%FJ2
MS%)O*3Y)5.Q6 +D8SR!Q6TG@>&UAM3IVJ7EE>6TMR\=TBQLQ6>0R.C*RE2N[
M&.,C:.>N9+CP=NETZZM-;U*VU"S@>W-YE)9)XW(9@^]2#\P!& ,=N.* .(TK
M5]3TG1?#<231>9>^*[JVNR(@0X,TQ;;G.WD=N?>M>?Q1J$/BFW,&K7-W;2ZN
M+![=-/Q:(A)7 F*Y,BD<X8C.1BMF#X>Z=!9:1:+=WC)IFIOJ43.P9G=F=MK'
M'(^<^_O3'\ 1,0B:UJ,=O#?&_M(%$>VWE,AD8_=RPRS##$X#'V( ,:#6?$4W
MAKQCKDVK#9IK:E;VEL+:/;^Z9MCL2,DC&,="!SDFJ\GBW5;I=(LUO]0M'.A6
MU_)+I^E&Z,LTH( 8!&"(-A.  3G@C%=E'X1LX_#NLZ*+B?R-5DNI)7XW(9RQ
M;;QCC<<9JLW@M88K#^S=8OM/N+2Q33VGA$;&:%1\H8,I&X')! &-QH YNY\3
MZ]G3[O5+RZ\/0S6-O(C-I_F6YN&SYB3L5+1@':!RG!SFO3:Y?4O!K:A ]I_;
MVJQV$]LMK=6QD643H!M/S.I968'#$$9Z]>:U=/L[RWU;5)IKAWM)GB^S1,V1
M$%C ;:.P)[>N3WH P]3N=9U?Q==Z)I>K-I<=C8Q7+2) DC2R2,X4'>"-@$?.
M,$YZC%5H[CQ'K>OWNDC6%TN32[.W,SVD"2">XD5B3^\4XC&T8 P3D\UL:SX6
M_M+5!J5GJU[I=XUO]EFDM0A\V+)(!#J0""3AAR,FJLG@F.&5)=(U>_TN3[)'
M93-"4D,T:9V%BZM\XW-\PYYH P-'\1:]XLO-$MXM1&F)=Z,]W<M!"CL)4E$9
MV;P0 23U!X]^1GV=]K6N:YX&FN=8ECF:34(IC##&%D:!F3?@J<%E&".@[8KO
M-,\)Z?H]_97-D9(UL]/_ +/BB)!7R]RMD]RV5Z^YJ@O@2W@726L]3O+:?3+F
MXGBF4(Q83L6D1@RD8^; XR,4 <Y%XD\1P^&M?\02ZDDOV:^GT^SM# @0'[2(
MDD<@;B5SC&0"!SR<UI7USJ^C:I+HM_JTFJ6]_I%U.DDT,<;Q21!00-B@;2).
MA!((ZUN1^#M.'AW4=#E>:6UOYYKB0E@&5I'+_*0.-K'(^@J.U\(!;J>\U+5K
MS4KN2T:RCEG6-?)B;EMH10-Q(!).>@H X/0]4U+3?A_X2*W]YIFDG3"TM]:V
M0N=DH(VB4%6VIC<<@#ZBO5(9YY=$CN(9(+JX>V#H\?$<KE<@CG[I/OT-8%OX
M)?3]'T[3M+\0:E91V=M]E)3RW$J9SDJRE0W^T #]:W[32K:QT2#2+?S([6"V
M6VCVN0ZH%VC##D''>@#S8^+-9M/"^KW#ZY<'6+:R266QOM/6&6VE+J"R?* \
M?)&?F[?-6_XP\67WAS5KDP[9+>#0KF]$+*,-,DD:H2>N/F.1FK$G@**^M[J+
M6-9U#4O-LGL8WE\M&AB8J2054;FRB'<V?N_7+T\"P7%W-=:QJE[JLL^GRZ=+
MYX1%,+E20 B@ _+UZ\GT& #(\4:?X@L? GB0ZCK2ZE:2:-.6$D"1O'-L/W-@
M *$9X.2,#DU=TRYUK2_%6C:?>ZJ;ZVU/3YI6B,"(+>2+RON%1DJ1(1AB3QUJ
MQ_P@BW%A?6NHZ[J=^+FP?3XWF,8,,+=<!5 9^!\S GCZUM2:'!+K.F:F99!+
MI\$L$:C&UA)LR3QU'EC\S0!S/C][>/7O"3W6FR:C"+N?=:Q0"9G_ -'?&%/!
MQU_"L66ZN_#L.OZ[I>C3:+:7\EE9VUN]J"_FF0H\X@3/.UU '5B@XKT.^T>&
M_P!5TO4)))%DTZ222-5QAB\;(<_@QIVM:1;ZYI4MA<O)&CE762(X>-U8,KJ?
M4, 1]* /.[WQ7XAL?#VLO:SW\K6T]C]CO=3TTVS/YLP22-E**&QZA1PX[C-:
M'B"]U[0);6&^\0WL%B+=W;58]-CE0S[SA9@JG9&%Q@C&><MQ6Y<>#SJ&DW-E
MJFMZA>O<3P3-*^Q=GE.KJJ(JA5!*\\9.>O3%K6_#T^K3L\&N7]@DL'V>>*'8
MR2)SR ZG:WS$;A@],YP, '/2:CKVMWGB!]/UQ;*+2$C2%8((W2YE,*REG+@G
M8=X "D<<YJ'3M:U[Q;JD,5GJS:5:S:#9ZC^Y@CD=993)D N"-ORC/?@8(R:U
M[GP) 6N%TW5;[3+>[MX[:[AM]C"5$38I!=25;9A<@] .XS6KI_ANRTS56OK7
M>@^PPV"0C&Q(XBY7'?/SD=>PH C\&ZM<:[X-TC4[O;]IN;97E*# +8P2!VR:
MY"#Q#K__  C5CXR?5"UM<WT:/I?D1^6MO).(@ V-^\ ALEL9R,5W6@Z/#X?T
M*STFWDDDAM(Q&CR8W$#UQ6'%X#MHI(8/[3O6TB"[^V1:80GE+)OW@;MN\H'.
MX*3C..PQ0!%X5O-;UC7M<N+O5/\ 0-/U.>SAM$@0;P I!9L9XW<8]\Y[2>+=
M8O=-\3>$;2VD58;Z^>*<&-6+*(R1@D9'/<5MZ-HD&BMJ+02R/]OO9+V3?CY6
M<*"!CM\HJ+6/#MMK.J:/?S32I)I=PT\2IC#DJ5PV1TY[4 <YX>UK5)O%!LM6
MU:>WO&DGSI=S9!(WC4G8UO* -^!@G+-P3P*U?$]_?C5M$T33KLV4FI22F2Z6
M-7>..--Q"A@5W$E1D@X&>*?:>%&@U:UO+G6M0O8;*226TM[@H1$SJRDEPN]\
M*S ;B>#WJYKN@)K7V.9+N>RO;*4RVUU %+1DJ5888$%2"0010!SUS<>)8M4T
M?PU-K")/=&ZGDU&"!/-:"+;L&UE*!SY@R0I'R\#GC-?Q%XA!@TA-23[9%XC_
M +*EO#;H3+";=I0Q7&T.,KTP,KTP2*Z ^"(U@M)(=7OTU6UGEG7424>1FEXD
M#*5V;2 /E  &T8Z5);>"K*WCLMUW=37%OJ1U.6XD*[KB<HR$M@  8;   QM%
M '/3ZOXELX]=TU+Z[OFT[4+=&O8;2-[E+:2)78B-5VLRDXX4\'.#BI+;7M1U
M:?1-'T[Q'YPO#=2RZDEJB3K'"5 C*,NU9,R '*C@=!FNBN?"BR7NHWUIJM]9
M7=Y/%<&6 KA&CC\L#:00RD=0V>>>"!53_A!HD2">'5KV/5H;F6Y_M$+&7=Y
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MRD!MV3D 8R:9#X M["QTV+2M5OK&ZT\3)#=IL=VCE?>R.'4AAG!&1D8!SUR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS#N12JE64CYL#!STJ?PIH=]I7C&P6[MW)M?"MI9O<;24\U9'W*&Z$\ X],4
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M?45T%<?IO^B_%G7HYOO7NF6DT!/=8VE5P/H67\Q0!&/%"'08[S_A);;#:O\
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ML88[B.*"VCC2.Y93*@"C"L5XR.AQQQ6G0 4444 %%%% !1110 4444 %%%%
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ME*XW*V0" ,[!GJ:U+J/6Y_%=UH$/B2^@MK31H;CSECB,TDQDE7<Q*$8(49
MZ#&.<@'?45Y?I&O:[':^#M<O=7FN5UF-Q=6?E1K$ +=Y5*87<&R@SDG.3T&
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M.HDB\H@D%1A6!XYSP.E 'J=%9/A?49=7\):-J4_^NN[*&:3_ 'F0$_J:XO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5DW7AZSN_$UCKTCS"[LH9((U5AL*OC.1C.>/6M
M:LR3Q!IT-SJ=O+,4DTR!;BZW*0%C8,0P/<81NGI0!3@\(:=;Z/HNEI+<F#2)
MTGMR67<S(& W''(^8] *IIX"L8H+F&+4M2C22]-_;[9$S9S%F9FB.SOO8$-N
M&#BIKWQEIG_"-6VJ6=PS?V@DBV/[HY9U1WY7'&-C9STQ5;PMXWLM8M=&MKAK
M@7][9K(LKVKI#/($#2"-R-IQST]#B@"Z/"-J\-BMU?ZA=S6E^-0$\\JEI)0I
M7! 4*%P?NJ%''US?_L2U_MZYUC?+]IN+1+1UR-H16=@0,9SESW]*Q=-\7V$7
MAXZA<ZG+J >]DM8C%9,LDD@8@1+&N2Q&#SW )JKJ?CNV230;FREE%I<:C+9W
MD+6S><K+#(WE^7C<'W!. ,G(]: ->V\(:=:V6@6J27!CT,YMMS*2_P"[:/Y^
M.?E8],<U%I?@VUTN2-$U'49[&&-XK>PFE4P0HW!4 *&8 <#>6P.E:.B:]9:_
M;SRV?G*UO,8)X9XFBDB< '#*PR."#]#3M8UNTT2*%[D3R//)Y4,-O"TLDC8+
M$*J@G@*23T % &'8?#^QL;C2I#JFJW$>DR;["":5"D"[&39P@+##?Q$D;1@]
M<N3P#I\%JT=I?:A:S_VG+JD=S&Z&2.:0%7 RA7:0Q&"#UK4L?$VEZC/906TT
MAEO(99HD>)E($3!) P(&U@S $'GK5>?QEH\%MYJO<3NUW+91P06[R2R2Q$AP
MJ 9(&TY/3'>@"I;> M-M9HG6\U!Q'J*ZFJ22JP\\1E&8G;DAMQ)&>O3'2K]S
MX5TZ\\1SZW<>;)-/IQTR2%F'E-"7W'C&<Y..O3M6)?\ CNW74_#LUE+++IU_
M]J26)+9FF:2,* @3&X,&W C'8YX%=+HNMV6O6!N[)I-BR-%(DL;1O'(IPRLK
M<@@T 95KX,B@MI;>76M9N8VMC:PB6Y"FWCR#\A15RPVCYFW'CKUS'-X1N([&
M_:WUK49]5NQ!&;Z>54=(XY-P4>6B@#YGR,9;<03SQ+XIU;5[+4-#T_1FL8Y]
M2N9(FDO(7D5 L3R<!74Y^3'7O56R\4W>F7FKV7BA[)6TZWAN_M5DCA'CD+J%
MV$LP?<A& 3G(Q0!U]<I9>!+72M%L--TO5]5L19-,8YXI(R["5][*P9"C#/3Y
M<C'!ZYL'QOHL6EWE_=27%I'921QW,=S;O')$9" A*D9VG(YZ=?0TR7QWI$,$
M4KP:I^\C:;RQI\QD2)3@R.NW*KZ$]>U &SI.EV^C:7;Z?:[S#"N 9&W,Q)R2
M3W)))/UK%3P/8IJ8N%OM0%F+PWPTX2K]G$^=V_&W=][YMN[;GG%2ZAXVT;3I
MWB9[JX\J%;B=[2UDF6")AE6<J"%! )]<#.,4M]XTT>RNA:JUS=W#6R7:16=L
M\[/"Q8!QM!X^4\^X]10!7C\"6$=Q&!?:@=-BNOMD>F&1/LZ2[M^1\N_ 8[@I
M;;GM5F?P?IUQHNK:4\MR(-4N7N9V#KN5F()"G' ^4=0:UM.U&UU;3;;4+&83
M6MS&)8I "-RD9'!Y'TJCJ_B6PT:[ALY4NKB[E0RK;V=N\T@C!P7(4'"Y(&3U
M/3- &=J7@6PU*[UN62^OXHM:@$-Y;Q.FQB$"!QE20P4 =<>U:&K^'(-5^PRK
M=W5E>6!)MKNV9?,0%=K##*RD$8R"#T'I2Z=XHTC5KFVM[*Z\UKFT-Y"0A :,
M,$)R1P0Q (/(JO:^--"O-"36;>Z:2S>Y6U1A&VYI6<(JA<9Y+#\#GI0!6D\!
M:5+I,-A+/>/LU%=3DN&D7S9YU.=SG;C!P!@ <  8JQ<>#-*N]0UR\N//D;68
M([>Y0N H5 0I3 R#SG.>H%0VGC[0KVXM(X9+HQW4WV>*X-K((3-DCR]Y&-W!
MX_#K5JS\6Z5?:J-/A-SO>22**9K9UAE>/.]4D(VL1M;O_"<9Q0!7;P7;W.F7
M]EJ>JZIJ0O(TC:2YF4-&$.Y"@154,&YW8)) R34FE>$H=,ULZS-J>H:AJ#6I
MM&ENW0YCW!@,*J@8([>ISFNAK)UCQ%8Z+/:V]PMS-<W6XQ6]K \TC*N-S;5!
MX&1S[B@!FO>'+;Q ]A)/<W5O+83FX@DMG"LK[&4'D'.-Q..GKD9!Q=2T0:)X
M;U6VM['4/$%]K)=;AY6CW2NR; 9#\JH@  X' [53TWQB]]IMC=SZL+=+KQ#+
M8VY6TW_:(Q(X2,]-F54?,>F/>MY/&NBR:C>V2RSEK R"\E^SOY5OL7<2[XVK
MD9QSS@T 3^$]!'AKPO8:3YGFRPQYFESGS)6.YVR>>6)--U?PS%J>I1:E!J-]
MIM^D)MS<6;)EXB<[6#JP.#R#C(R>:CL_&>C7<%W,\D]HMK!]JD^V6[P'R><2
M ,!E>#TK,U3XD:99:!JE_#:WQNK&V^T"TN+22%W4Y"/AESL)&"W;O0!J6?@_
M2]/GT66V\]/[(CF2!2^0_FXWL^1DL2,YR.2:WG4.C*>A&*XB;QA<_P#":Z3;
M(DT6F7&E7%Y+#+;%9MT; #Y2-PXSQWXKH'\3Z2NBV&K"X+VFH/"EJR(29&E(
M" #KGG\,'/2@#,L_ EMI>C:;INE:SJUBNGQO%'+#+&6=';<0X9"IYZ':"/7K
M70:7IMMH^EVVG6BLMO;1B--QR<#N3W-6ZYRT\;Z)>7T-M%)<[+B9H+>Z>V=;
M>>09RJ2$;2?E..<'!QF@"H?A[IY<(=2U/[$E\-0ALA*@BAF$OFDK\FX@MG@D
MCYCC!P1>E\'Z=-HFI:4TMS]GU"[>[E8.NX.T@D(4XP!D>AXJ72_%>EZSJEQI
M]@;F66V>2.>06[B*-T;:4+XV[L\@9R1STJUK]ZNG>'M1O6N_LBP6[R&X\KS?
M*PI.[9_%CKCO0!A:K\/=/U8ZK$^I:G;V6J$O=V=O*BQ/)M WC*E@> < X)'(
M-6[WP?;W>HSW<6IZE9+=!!=PVLJHEQL& 6)4LIP "4*D@"F'QGIEG%8V\DMW
M?7L]C'=HEK9N[S1MQO"*#CD<CMD#N*D?QOHOV73I[=[F[_M&-IK>.UMGED,:
MXW,5 RH!(!SWXZT :%CHMMI^KZIJ4+RF;4GC>8,05!1 @V\<<#OGFC7-$MM>
MT\6ER\T125)H9H&VR0R*<JZG!Y'N"*Y/2?&#W^F:1=W&K+!]MUJXM(=EKO%R
MBRR!$_V/E4?-[>];B>-]$DO;ZV6:?_B7^;]LF-N_E6_E_>WOC:.AP,\XH @/
M@6Q>SD2;4-1FOWNDO/[2>1?/655VJ5PNP +E=NW&"<@YIW_"#V$NF7]I=7E]
M=37\\,]U>2NGFR-$RL@X4*%&P# 4<$]SFI[7QGHUQ;7L\LEQ9K9PBXF6]MWA
M81'.' 8 E3@CCOQUK+U?XD:;I_A_5-0AM+YKJQA67['<6LD+D-D(Y!7(0D$;
MNW?F@#HO[$MO[>N-8WR_:9[1+-ER-@16=@0,9SESW]*I:+X1T_0I[*:UEN6:
MSTY=.C\UE(,0;<"< ?-GOT]JQI_&%Q'XYL[7;-'I3Z+-?RPR6Q68,C@?=(W#
MC/'>NBD\2Z7'I>G:E]H+6VI211VC(A)D:7[@ Z^_M@YH JV_@[3K;2M&TY);
MDPZ3<BZMR77<SC?PW'(^<],=JK6O@.PM+BU OM0DT^TN/M5KIKNGD0R9)!&%
MWD DD L0/3@5U-<7\1_%=[X9TRQ33DE%U?7D5L)Q:M,L2LV"<#@OZ+W[4 :D
MW@_3IM$U/2FEN?L^HW3W<S!UW!V<.0IQ@#([@\5N7$$5U;2V\Z"2&5"DB-T9
M2,$'\*Y.T\2_9]1GAN-0N[N6WTR*YDL1IC)+RV/,P.<GNF.,5RWASXFWY\.Z
M7JFK07MW+JUXL*1P:;(D<*DMD(P!\TX P.O!]#0!U]GX!TZ!3%=WNH:E;+:/
M9007DJLD$+@!E7:H)R !N8DX'6I=/\&6UG=17%SJ>I:B]O;O;6OVN1"+=& #
M;=JKEB !N;)P.O6K]MXDTRZL-1O4G9(=-DDCN_,0J8FC&YL@\]"#[@U>L;R+
M4;"WO8-_DW$2RQ[U*G:PR,@\C@]* ,J'PI80:?H%DLEP8]#9&M26&6*Q-&-_
M'/RL>F.:HVG@+3[2*W@6_P!0>VM=1_M*V@=T*PR9<E1\F2I,C'!)/3FI=0\>
M:'IMW?6TS7;OI[ 7C0VDDBVX*A@SE00%PW7V/H:GU+QEHVE7)AGEGD"1+--+
M! \L=O&V=KR,H(4'!//8$].: $U7PI%J.IR:C;:GJ&F74T(M[A[)T'G1@DJ&
MW*V"-S888(SUHA\&Z5;:CH=Y;K+"=%MY+:TB1ALV.H4[LC). .<_7-2/XLTM
M?$)T)#<S:@I3>D-N[B-6&0[,!@+TY)[U%9>-=%O]2CLX99QYS.D%Q);ND$[)
MG>(Y"-K8P>AYP<9Q0!L:C80:IIEUI]TI:WNH7AD ZE6!!_0US<OP[T:;0=)T
M>22\:#3+G[3&YD'F2L2Q82';\P8L<X S5RQ\:Z+J#L(7N57R'N8I);9XTN(D
M^\\1(PX&1T[$'H:BLO'FB7\]O';_ &UA=0M-:R&SD"7 5=S+&2/F8#L/0XH
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M8=KJ]W;^-;K0K]EDBN+?[;I\H4*=H(62,^I4E2#Z-[5T+,J(69@JJ,DDX %
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MD?C5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUE;FVD@:;6KR90Z[2Z-*2K#U!&,&K?CFUGOO >OVMK"\UQ-83)'%&N6=BA
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MCCFMBJVGV%OIFGP6-JK+! @1 S%CCW)Y)]S5F@ HHHH **** "BBB@ HHHH
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MFKI<Q+;7*I<VZBV1%E0JP^8$;2 W&3]X=0#J9/&=JL-IY.FZI<7=RLC"QC@
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MGM[I\C]P7M#&,_\  CCB@#=T?QA9:S>06Z6E];?:H3<6<EU$$6ZC&,LG)/\
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ME9L[L[OE*[<<GGI0!VTWCO38;F8&TOVL8+K[)+J2PC[/'+N"E2=V[ 8A2P7
M/>L63Q+>1:_\1(;S4)XK#2+6VEMS!$C/;AH&9V4$88Y&<-D51N-'UH>%=1\%
M)H]R[W-]*8M0#)Y @DG,I=CNW!@&(VXSD#''-/U3PWJ\]]\3I(K%V75K"WBL
M2&'[]EMV4@<\88@<XH Z1_&-I9V>G1QVVIZK<SV*7A6V@5I!"0/WCC(49.>!
MR2#@<4V'Q1IUUXJM$BU.Y^SSZ,=06(Q*(#%O'[PL1O##.,=,>]8]C:ZOX8U"
MQU(:+=Z@DVA6MC)%:E"\,\6XX8,P&T[R,C."OO4=_P"'=<UOQ@+N\M$MENO"
MTUC/+&^Z.*XD?.P'J<9/..U &];^/=*DAEGN;>_L8%LWOHI;J':+B! "SI@D
M\ J=I ;YAQ6GH^NKJ\D\3:=J%A-"JN8[R((65LX8%20>AXSD=P*X?1M 86X\
M[PIJT]W:Z=)%(FIZL[PR2,H5HH@SNI5QGYL   >O&YX+M+ZTO[Y8[;5[31/*
MC%O;:K,))(Y<MO$9W,P3;LZGKTH W];UVUT*"!YXYYYKF806]O;INDF<@G"@
MD#H"220 !UKDO%OQ EL_ NM:AI5G>0:G8D02Q3PKNM'(!#.-Q!7# @C<#D>]
M;/BRRO?[1T'6K*TDO?[+NG>:VB(WM')$T9*Y(!*[@<9Y&:Y3Q!H&M:[X7\<7
MD.ESPW&L"WCL[*4J)2L04;FP2 2=W&>@% '=^&&NWT"V:]DOY+@Y+O?QQ)*>
M>XC^4#T]NM5-3\8V6E:C);366H/# T:7-Y'"## 9"-NXD@GJ,[0<9YQ6_"I6
M"-2,$* 1^%>7^+]&UO5;C7X6TS5;V=I(Y-.>.\,=JD"JA*[ X#2%@XPRG)*\
M@= #U.O-SK'BM]"UWQ%%K=BL&FW5X$LIK$;7C@D<!3(&!!(7KCK7HL4AEA20
MH\9=0VQQAESV/O7"^'O &ERK?W6MZ2)+J75+J=5FD9D9#.S(2F[:>,'D4 :E
MUXZL+-=TEE?R)%;1W-[)!$&2S1QD&0D@],DA02 ,D5-)XST]?$%QHT=O>S3V
MP1[B6*(&*&-EW!V;/"X_'T!P:Y?7_#<G_"3:Y/-HVL:G#JJ1&!;'47MX21&(
MVCF D4 ?*#N*MPQ';%;FBZ-=Z=XH\4W L0;6X@LX[4._RR^7$RE<\G&2!DCO
MWH L6WCK39;">_NK34+"SBM?MBSW4&U98>/F3:3SR/E.&Y'%+#XVLBUREYI^
MI:?-!9O?+#=Q*K2PI]XIAB,C(R"01D<5Q<GAK5]0TK4=-T?3-3TRP>QR;#4K
MA7A6Z22-T2$[F(3"N#T7E<"M;5[75O%=\]ZNBWEA'9Z/>VZ)=% \T\ZJ BA6
M/ V?>.!DC% &_I?C6PU34;*T2RU"W6_A::RGN(0L=PJ@$[3DG.#GD#(Y&:Z6
MN-31[];[P,_V9@FGP2+='(_=$V^T _\  N.*Z+0]4.LZ-;Z@;9[8S DPNP8H
M02,9'!Z4 5Y_$NGVUWJUM.98WTNU6[G+*,&)@QW+SSC8P/N*S+SQM82>&+/4
M;3[0)-366.T0QC>CHCLQ<$\;?+;/6LWQUX>U+4M;L)--MC+!?P_V;J3!@/+M
M_.CDW'/7Y1*O_ ZIQ>&-6_X2?6EDM#_9EI%>2Z:X88DEN@K, ,\;6$@Y_OT
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MLZXVE26X_M+3;VUMIY8U>=82 RYW;0YYP">I ZU6UZ/4_$NL>+H8-)G@N)]
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M4 >M45S/@R/5X+6_@U.UO+>!+K-DM[<I/,(BBDJSJS9P^_&23C%=-0 4444
M%%%% !1110 5AR>#M EU<ZH^G(;HRB<G>VPR#HY3.TL,#YB,\5N44 %%%% !
M1110 4444 %%%% !573M.M-)LDL[&$0VZ,S*@8G!9BS<GGDL3^-6J* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:B)&BI&JHBC 51@ 4ZB@
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ML^HRO=PQN /)A<YB0?1-I^I-=%38XTBC6.-0J( JJ!@ #H*=0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5B:SXHLM%NX[1[>]N[IHC.8+. RLD0."[
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M37=)M]2L79K>=25WJ58$$@@@]""""/:HM9URWT5;<2P75Q/<N8X;>UB,DCD
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MCM*LR!3[+ACDGH<"LJ+X@+::)H5Q#]OUH:EJ$EKY_P!D", I?(VK@;AMP!W
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MI%K>3Q.EXUM;W MKB^2W)MX920-K/[$@$XP">2*F_P"$QTP^(;K142Z>YM&
MNG6$F* &,2!G?HH(/'N#Z&N-O=-U9?"VN^#DTB\DN=0OIV@O%0& Q32F3S&?
M/!4,<CKE>,YK;@T&]FU+Q_&T30IJ@CCMIGX#C[(J$@^@;(H OV'CW2-0O-.M
MDBOXFU)F^Q//;,BW"A"Y=2?X<+WYY''-2Z?XUTO4KH0QQ7L2R1236\LUN42Y
M1,;C&3UQD'G&0<CBN,6^U&XO? %F='N+*>T:2)GN=H4RK9R#"8)W)QG=TQM_
M"+3;#6)-2T&^NM.\02W*6\\&H37LS.HN)(L?NX]Q54W _,H Y7KS@ [32_'F
MD:M=:=%!%?)%J2DVES+;%(IF"[BH8_Q  ^W!P346D>*(WT*:^5]2UA5OY;?,
M-D!(A4GC:O\ ",8W=^*R['1=1B\/?#F!K.19=/DA-VN.8<6DB'=_P(@?4UCZ
M?!XCT'P!>6-MIE^EY?:Q<*9((]TEO [DF51GD[?N^Y![4 =A;^/-+NM)2_@M
MM1D\R[>SBMUMCYLDJ E@J^@PV3G'RFJFH?$*V@&A/9:?>W2:E=R6[JL!WQ%%
M?>I7^^&3&/0$]JS[OSET?0[33-)U^QT.VE>"YMK53%<D"/\ =G*MNVECR00<
M]>]8]IINK:9::-/+HFIM_9WB&YN9H@3/+Y4JR[6#$DR8WJ"<GG- '8P>*K"T
MF\23WFJ3RP:;<)')&UL!Y)91M1-HS(6)&,\Y.*D_X3G2X[349KR&^LI-/MQ<
MSV]U 4D\HY =1G##((X/!'.*Y"?PWK,ESXNNHM/E9CK=GJ%M$<+]J2$HS*I)
MQGY2!GOBI/$]AJGBI?$&HVFD7T$?]@OI\$5S%Y<MQ*[ASA,YP H&3U+'% ':
M:7XLL-5U8Z;'#>03F W$)N;<QK/$" 70GJ,LO7!Y'%;M<MJ-I=IXZTK4HK26
M6WMM*NT<H/XRT)5/J=K8^E=%97#W=A;W,EO);O+&KM#+C?&2,[6QW'0T 3T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !533-,M-(LA9V,1C@#O(%+%OF=R[')]68FK=% !1
M110!F6F@:=9:Q<ZM%"[7]R-KS2S/(0N<[5W$A%SSM7 K06*-9'D6-0[XW,!R
MV.F3WI]% !1110 4444 %%%% !1110 4444 %%%% #&BC:1)&C4R)D*Q'*YZ
MX/:GT44 %%%% !1110 4444 %%%% !574;"'5+"6RN&F6*4 ,89GB?@YX9"&
M'3L?:K5% %;3]/M-*T^"PL8$@M8%"1QIT4?Y[U9HHH **** "BBB@ HHHH *
M*** ,RRT#3M/U2[U.&%S>W?$LTLSR-MSG:NXG:N3G:N![5IT44 %%%% !2,H
M=2K %2,$$<$4M% &#I7@W0M&O8[NRM)%EA1D@$EQ)(D"MU$:LQ5 ?]D#TK>H
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"$(SCN/6B/3[]RNL2V^LZ9:IXAO)Y#;6V;B.*6(!)=A1B1G@X4D;CZ&O2/\
MA%M-_P">NI_^#6Z_^.5C7\W@G2[V2SU#Q)]ENH\;X9]?F1UR 1D&7(X(/XT
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MU_>V\[:3<Z,MO!)]G=A%*')=&7&5+#;U'.S'6NYI%=6+!6!*G# 'H>N#^8H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+93;\N2%]2$4$^BBJ6G> ]&TO1+32;;[3]GMKV.^0M)EC(C KDXY VJ,>@%
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M)5Q\V"5#.VYB 2.10!@>'M9\13+8WC'6YHKRPDEO9+R"-((I/+WHT)7D#.5
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MP?S4&WKN&<'(Y/'-22>!M-DEU5C<WPBU*5;B2%9@%CG4J1,G&5?**<YQQTH
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M,>:;XCTJ[-]::QIFE2-/H<<43VP1S]OC)4F)2?O!" RDY^8<X') .P&HHWB
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M(KC=:LKC6=5O]:L[.\CA_P"$?GLF22W=))I9""B;",G;AN>GS<'KCJ/"MO\
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M:%QC*9+;ANP/F/-9]QH.K>'O!GA:]@\N?7M%2*V9&?"SI+MC>+=Z9*$'U04
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@^(-?\
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MI6FCZ;/J%_+Y5K NZ23:6VCIT )HBU*VFU*XT]&D-S;HKR Q,% ;IAB-IZ=
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M8>>"I5H]CL5# OE< <+BK^O276I>--+\/K?75E9O93WLS6LGER2E'C14WCD
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M(N=4OY4T[Q7:VD5P)L2-%(J2 ,P^\R%L!CSTJQ>V-W$/B)J5KK&H6LNFR":
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M6.?F/)W9''W>N#Q4&H:Q?P_%31M(CN"MA<:=/-+#M'S.K* <XSQGUH H^#O
M45AHFC-JJW:W5DQG^Q-=%X(YLMAPH)7.#G@XR<XSS6[!X/TRVU47T3W@59VN
M4M/M#?9TF;.YPG3)+,<=,DG&:R=,\;:=;>';>_FN=2OUNM2DL8F>W3S3+E\)
MM3 Q\A /7IFG2?$G3H;>]EETG64.G/MU",VZ[K1< AWPV"I!S\I8X!.* +5Q
MX T6ZM-4M)3>&TU*Y%U-!]H;8LN\2%E'\.6 )J[=>%=/NM:N-59[J.>ZMOLM
MPD<Q6.9,,!N7H2 [8-8^I^+H],U'Q+)!-?7LNFZ='=_8Q''Y2@@D,K<,<XRV
M3P!Q5B'QO_Q)].N9=$U66[NK8W+V]O I*( -SG+XVDD8&2Q]* +ESX+T:[\(
MP>&)8I?[.@5%BVRD2)L(*D-USQUJ?4/#.GW]I8P SVK6'%I-:2F.2$;=N 1V
M*\$'(_*LF/QN+OQ=I>E6-A<7%C?Z<;Y;M%&-I:,*W+#"@,=W&<D8'6H]*\96
M$7A_[:USJ6I/-J,MG!&T"">64,?D55PN %/)(X&2: .HTS3;?2-/BLK7S/*C
MR=TCEW9B2S,S'DDDDD^]8TO@?1YKZ2X8W?D2W(NY;(7#"WDF!#;RG0G< 2.A
M(R14;^/=*@T^>ZNK>^MI+>[BL[BUDA!FBDDQLRJD@@A@05)SVS5_1?$D&M7E
M[9?8[VRO+/8TMO=HJMM?.UAM8@@[6[]N<4 6K'2+33K[4;RW5A-J$JS3DMD%
M@@08].%%1:SH-GKBVYN&GAGM9#);W%O*8Y8F((.&'8@D$'(-7KNZ@L;.>[N9
M%BMX(VEED;HJJ,DGZ 5SMMX\TN2.>6]MK_3(XK1KY7O8 @E@7&77!/3(^4X;
MD<4 22>!]'DT4:9_I2C[6+TW(N&\\W .?-+]2W'Y<5:'A?3OL.KVC"9X]67;
M=L\A+/\ NEB)SV.U1^/-5+3QI9S3/#=:?J6GS?97NXDO(54SQ)C<4PQY&1E3
M@\CBH;'Q[87\UDD6G:HJ7\#36,LD"JMSM3>43YL[L9QD ''!(YH L7?@G2;R
MY,I>\A62..*XB@N61+E4&%$@'7CCMD<'(K4L]'M+'4]1U"!6%QJ#1M.2V02B
M!%P.W KDM*^)<$WAC3]6U+3+Z%[^Z>UMXX8@_FO\Y4*-Q)R$V_[WMS6I>^.+
M33P&N=+U58XX8YKN3R%VV:OT\P[NH[[=V* -/6_#]GKHM6N'N(+BTD,EO<6T
MICDC)!4X8=B"00>#6:/ .A#2YM/\NX:":^34)"T[,S3KM^8L>3G8"?4YIVJ>
M-M/TJ^N;9[2_N([,(;VYMX0\5KN&1O.0>A!.T' .33=$\5S:MXMUS1FTVXBA
MTYT5;AE7:V4#<G<>N05P.G7!XH L2>#]-EU4WSRWI4W"W36GVEO(,RD$/L]0
M0#CID9QFJMMX T:TFLY8I+[-C/YUF&NF(MQR"B#LA#$$=Q@=A3KWQ7-:^/;/
MPZNFW$D,UF]Q)<*JX7#HH/+#Y1N;=QG.W'>GZ;XUT_4[F&-+6^ABN8WEL[B:
M(+'=J@R3&<D].1N"Y'(H AMOA]HEK/:NC7IBL[@7-I;O=,T5N^2?D7H!R?H.
M!@5I'PQI9\5#Q(86_M(0>1NWG;CUV]-V"1GTXK'MOB/I%SH0UL6>IIIK/ D<
M[VXQ(TK;<* <G:>&X^F:'^(EG&U["VB:W]KL5$MQ:_9T+QQ$9$F=^TJ>> =W
M!XX- $\_@'1KB65VDOE5[K[9'&MTP2"??O,D:]%8MD_BV,9-7G\*Z7)I%UI;
M))]ENKMKR4;SDR&7S20>PW#I52;QOIRRQBVM-0O83!%<2W%K!O2&.7E&;D-R
M!G"@D#K6WJFHPZ3IL]]<+*T4*Y*Q(7=CG "@=220* ,6\\#Z3>WFI7+O>H=0
M:.29(KAE02H4*2J/X7&Q>1Z51U3P-91Z5JK6=M/J%Y>P(DT=U>NOVAD?<KE^
MJR#^%AC& . .+C^.M-M]*U&^OK2_LCITD27-O/$OFH)" C85B"#N[$]#W&*%
M\=:;&-1_M"UO]-:PMA=NEW"%:2$D@,@4G/(Q@X.2.* ,30O!\E[J^JW>L:9=
M06=W8)8M%?W@N+B<[BS.SHQ"@?*%P<\$\&NLT?P_;:-)/,ES>W5Q,%1YKRX:
M5]JYVJ,] ,GIUSSFL*Q\4W>I>/K'3?LM]I\#:7/<26MY$JLS"2((^5+=F<8S
M]1TK6U_Q59^'KNQM)[:\N;J_$GV:&TB#M(4VD@#(YPV?3 ))&* )[[P[97VN
MV>LL]S%>6J&(-#*4$D9(8HX_B7(!Q5&P\#Z1IUY;3Q&[>*S=I+2TEN&:"V8@
MC*(>G!(&<XSQBBX\9V=KJ MI;#4EA6:*WEO#"/)AEDV[48[LYRZ@D @$\FL^
MR\?(]SXB^WZ;=VUKI5R($D\L$R,5C 3 8DNSO\H Q@CO0!T>N:)9^(=*DTZ^
M$GDNR/NB<HZLK!E92.A! -0VWANQM1?D-<2O?PI#<R2REF<(A0'/K@G)JA_P
MF]BMK<--8:C#>PS10'3Y(E\]FD_U>W#%2&P>=V/E.<8JY;^(X[BUMIAI>J(\
MUW]D>%K;YX&P3NDP2 G'W@2.10!3N/ ND31P1I)?6R1VD=E(+:Z:/SX4&%23
M'7 )YX/)YKH9+:*2T:U*XA:,Q[1QA<8Q^54M=URS\.Z3)J=_YGV:-XT8QKN(
M+NJ X[\L*RD\<Z<HU$7UI?Z?+80I</%=0@/)&Y*JR!2=V6&W'7/&* *]M\/+
M"SM8K6VUGQ%#!"@2../5955% P  #P *UIO"^F7$&MPR)*4UE=MY^\.6'EB+
MCT^515,>-].BL-1N;^VOM/DT]$DFMKF(>:5<D1E0I8-N(*C!ZC!Q4<7CS2Q<
M75O?VU]ILUI9-?SI>1!2D((&?E)!SGC&>A'48H 3Q=X735-!U%K*!Y=3&CW-
MA:+Y@4,)%'!S@9)5>34^B^$+'2[BVO6>[EN8+;R(4N+AI$ME(&Y8P>F=H'?@
M =*BB\;VTC213:3JMK<_97NX(+B%%>YC7&[9AB,C(RK$$9Z5DZ=XT;5M+\)7
MUY]NTV?5)U00Q11F.X)CW<DDD1^A&&XH V(? FC6VA:=I5K]JMX]-=I+2>*<
MK-"6+%L-W!W$$'((J+4=&?1O"MWI>AZ/)J<M^9%F-Q<K\SR*0TDSN<L.@.W)
MQ@ 8Z65\8V;:NEB;'4$CDN'M(KQX0(99E!)13G=GY6 ) !(X-<X?'S7_ (4U
M+4KR+4M'CM=2^RK-##&S,/.V!<,6&>,-Z9XS0!OZ=X*T^T\%V'AR8R,EHJ,)
MXG*2"8'<958<AMV3^-3Q^#],6W@BE>[N'BODU#SIYV>1YD&%+$]@ !@8&!5?
M5/'%EIE_J-FNGZG>3:<BRW7V6%6$<;+N#$EAQC/'7@X!Q3[KQKIT-S!#;V]]
M?F2T6]=K2'>(8&^Z[Y(/.#@#+<'B@#I**H:)K%KK^BVNJV6_[-=)YD>\8;'N
M*OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<AJ4=_HWCF378M+N]1L
M[O3DM&6TV&2*2.1V&0S#Y6$AY'0KSUKKZ* /.-!\,:M8:IX1GNK3:;?^TY[O
M:X9;=KAPZIGOU(R..#75>-;&YU/P/KEC9Q&:YN+&6.*,$ LQ4@#FMVB@#SRV
MTW5M+U_PY=G2)KJ)?#_]G2A&7$4V8SB3)X7Y2"0#]#4_@ZQO;+7-MIIFJZ5H
MXM&$]E?3K)%'/N7:(/F8A0/,SC"_=P*[#2]4M=9T]+ZR<O [N@8J5.4<HW!]
MU-7* .)\1>']1\4^-+".66[L-(TJ$W,=S;L@:6Z8[1C<&X5-W..K5%:^&=1\
M.>/+35+.[U#5+3486M=2>Z="T10;HI/E5<@'<O?[U=W10!Y-)X5UL_!#6M#&
MGR?VG/<3O%;[ERP:XW YSC[O/6NHNM(OY/BIH^JK;,;&#2IH))LC"N64A?7M
M76Q7$,SRI%-'(T+[)%5@2C8!P?0X(.#V(J2@#R#3O">NP^!_!EC)ITBW-CXF
M6\N8]RYCA$LIWGGIAEZ<\U9U/2=<N=1:YGTG5[R\M-<CN_-^U_N#:)."BPQ^
M8%+;,9!4<AB3G&?5JC-Q"+D6QFC$[(9!%N&XJ" 6QUQD@9]Q0!Y?=>'M5FM]
M<LGTF^;R_$']KQ-#,(A<PDJ"L<BN&$F-Q[<@<\U>71+4Z/>S'PCK$L-Q=Q;U
MN-2=[TJBG;,FZ0E2K'  <$C)]CW>FZA%JEBEW#'<1QN6 6XA:)Q@D<JP!'3\
M1S5N@#E/"\NM65C;6U]9ZA/%/=S+%+>2HTUO;A24,Q!.XDC'4GD9[U8\::/?
M:KI5K-I8C;4=-O(KZVCD;:LK)D%">VY689]2*Z.B@#E;?Q!X@U2]L[>U\-76
MG1B0&]N-2,>U4'58PCDNQZ \ =3GI7,KH^M?\(G'X).CW(9+\$ZCN3R/(%SY
MWF [MV[:,;<9W>W->F17$,_F>3-')Y;F-]C [6'53CH?:I* /.]0\/ZK+X)\
M:V,=F[7-_J$\MM'D9D5MF".?8]?2M6#2;Y/BMJ&K-;L+&71XK=)LC!D$C$KZ
M]"*ZLW$(N1;&:/SRAD$6X;BH(!;'7&2!GWJ2@#R7POH6N>&M \%7EQH]S/+I
MB7L%Y:0E&E03/N5P"P!^Z,X.<-[4X^&]7N4EU2^TB_0+X@GO6L[2Z\JX-O);
MK&&5T<?,#C(#<X8<]_6*J:=J$6IVQGACN(U#LF)X6B;*G!.& ./0]Z .'M?#
MTRG0)[+1KRSC77'O;A+N[-Q-L^SR1B1RS,03\@V@G''O5?Q#H.KO=^(;RWTZ
M6X5M:TV]A2,KNFCA2+?MR1R-K<''2O2Z* /-+_2_$<OB/Q3K&F6=Q;27NC6Z
M6C,R+)Y@R60<D!P#C/3/>J%QH&HS#Q&;#0M6B@U'0)+2W^W71FE:8;SA]\C%
M=V\ #..">,UZ1KFO:?X=L%O-2E:.)Y5AC5(VD>21CA555!))]!3K+6(+ZY-O
M'!>1N($GS/:O&,-T&6 ^8=UZCO0!'X9M9K+PIH]I<QF.>"QACD0]594 (_,5
MP-KX8UE/!GB*R>P<7%UXF-Y#'N7+P_:8GW]>FU6/KQ7J5% '%>(-&U"[\0:Y
M<06S/%<>'&M(F!'S3%Y#LZ]<,/SK.T[2M5T"W\&:FVEW%T;'1?[.O;: J98F
M98B& ) ;#1E3@]^]>C4C,$1F() &>!DT >:V_AS6)+G2]0ET]XFG\3R:I+ S
M*6MX3 T:[L'&>%) )P6K?;2KT^,O$5[]G;[/<Z5;P0R9&'=3-N7\-R_G71Z?
M?1ZE80WD,<\<<HRJSQ-$XYQRK $?C5>]URPT_5],TNXD9;O4C(MLH0D,8UW-
MD]!QZT <9;:#K,.D?#^.*U*7.F6K+<;B,0/]C9!N]?G('&:S]$T?5AK>@WT^
MCZPLL=K-;:A<7UYYI,[HN653(0L>5/*@=1@8%>DW^H1:='"\L=PXEF6%1#"T
MA!8\$A0<+ZD\"K= 'DT.AZW<^!?!&F-HUU#=:-K-F;I)2G^KCW;I%(8Y7D>_
MM5Z_TW6K;1_%7AJ#1KBY?6;JXDM;Q&3R%2<<F0ELJ4);C!S@8SFNTU'Q-INF
M:O9Z3,\\E_=C=%!!;O*P0$ NVT':H)')P*UZ .'CT"_@_P"$VC6W=EO;6**T
M8D?OBMJ$XY_O<<UT.EVD\'@^RLY8RMQ'8)$R'J&$8!'YUKT4 >:>$/#>KZ?I
M_@&.[L7B?38;M;L$@^474A<X/?VI?[$UC3M;?74TV:Y6VU^YN#;Q,OF2P2VZ
MQ[TR0"0PZ$@XS7I51M<0I<1V[31K-(K,D98!F5<9('4@;AGTR/6@#@=<M=?\
M1OX7O9-&>V%KKZ7#0LZEX[958!Y,' 8YZ G&1[UG:UINO+H?B_0+;0KJXEU&
M]DNK>Y5D$+1OL/4MG<-I&,=<=N:](T_4(M2MVFACN(U61HR)X6B;*G!(# ''
MH>AJW0!YGJ]AKEGIWC?1;70[F];6FFGM+F-D$6)(%1E<E@0RE3@8YR*@OO"\
M\.IZ@UWH>L:DFHVUN(DLM2>WB#K"(GCF"R* /E!W8;@GTQ7J=% 'G=_I5[;^
M(XVT;1M3L+Y;BW7[7;W0:SN;==@8S*6Y8(&7[N[A<$]NTTK5#J9OP;9X#:7;
MVWS,#OV@$,,=B"*T*:B)&"$55!)8X&,D]30!P6H^&]0G^(\;):[]"NY(;^[D
MR,":&.1 I'4YS"?^ 5A0>$=>?P=XJMKJR=KQ-.&C:8A=298(M^UASQNWCK_=
MKURB@#@K+3]3TWQ?H-X^F7,MN=!73Y9(MI\B4.C?/DCY< \C-0:?X?U2'P7X
M&LGLW6YT^^@ENH\C,2JD@)//JPZ>M>@-<0I<1P--&LT@9DC+ ,P7&2!U(&1G
MZBI* /+[;1]:/A73?!;Z/<HUK?1-+J!9/(,$<XE#J=VXLP4#;C.2<\<TS4]-
MUX:%XB\/P:%=32W>K/>1709!"T+S+)G.[.[ (VXZ^U>IT4 <EH-M?6'CKQ.)
M]/N!:W\L-S!=C:8B%A1"IYR&R#QBFZAI-_-\5M&U:.W9K&#3KB&6;(PKLRD#
MUYQ77U3OM4M=.FLHKERKWMP+: !2=SE6;'MPK<T ><:#X8UFU\/Z!;SV#I+;
M>)9+R52R_)"?.P_7I\R^_-:FJ:#J<]C\1DBM'9]4CVV8!'[X_9%3CGCY@1S7
M7ZUK>G^'M+EU+4YS#;1E5+!"Y)8@ !0"222!@59LKM+ZSBNHXYHUD&0D\31N
M/JK $'ZT >=R^&=8FUCQBRV;!-0\/Q6=L[, 'E$3J5Z\8)'6HS;:S?PZ1#=:
M+K?V--+6V2UCNOLX2Z4X+3%) =F,8// ;C)%>GT4 >9>&--UC2=5\)7%UHUY
MY<&A'2;C;L/D2B2/YF^;[A"$Y&?I5;1/#FMZ/I>EZ@^F32SZ;KMY=26:,N^2
M"42)N7)P2 X;&1D9[UZM10!YI<Z)J^K:A=ZS_9D]NMWK6F21VTQ7S%@MW7?(
MP!('5CC.< 5L7\EWH'B3Q-XC:PDGM$TNVV!& ,AC:8N!GT# _C783316\$D\
M\B10QJ7>1V"JJ@9))/0 4%8YXL$+)&PSSR"* ,OQ3I4NN>$]6TJ%PDUY:2PQ
MLW0,RD#/MFN5U0>(?%WA:^T0:#+IN=/*M)>2( ]R"I5$VL<IP<L<=1[UZ#51
M]0BCU2+3S'<&66-I XA8Q@ XP7QM!]B<F@#B[^#5O%.K6UX=$O-/CL-.NT87
M13=+-,BJ$3:QR!@DMP.E3VVBZC'!\/5:U8'3$ O!D?N?]$9.>?[Q XKN** /
M*]$T365T7PAIT^D7,,NC:P\ER\A384*SX=2&.5^=?SI_C?1-;UF?Q':#3M3O
M&GMU&EM%>&*UC7R_G#J' +E]W#*<Y7H,D>HT4 <!;3:]H>HZW)9>';N\;6)8
MKRT9G14B<Q(C).=V5VE,\ Y!XYK1T2VO[#X@>)7N-/G^S:B;>:"[7:8ODA5&
M4\Y!R#QBNAN]4M;2UN[@LT_V3B:.V0RR*< XV+DYPP.,9P0:MQN)8DD4, RA
M@&&#SZCM0!QVNZ??'Q_87J6-Q/97&ESZ=)-!M/D.\D9#,"0=N >1GI6+X5\-
M/:'2[:ZT'5TO=-M7C>[N=3DDMED$9CS"AD8$,"<#:H4'L>*]-HH \Z@\/:HG
MPL\+Z4;)A>VEQ8//#D901S(SD\XX )K6DTF^/B7Q=="V;R;W3+:&W?(_>.HG
MW ?3>OYUU]5)M0B@U&UL6CN#)<ARCI"S1KM&3N<#"]>,GGM0!YI-HNK6NC:5
M'9:)JEKX@@TJU@M[^RN5$3.J &.X4L 55LYR&R"<'/%=QXQCU.7PS.FE"X-P
M9(MZVKA)6B\Q?-$;$C#%-V.1^=;U% 'DDOAW5)+?Q'#::'J$,&H?V?+:BZN?
M.<B*<;P[,[$-CYL9/'OD5L^-_#6JZUJNIO8VV]7T5(HF9@%>9+@2B/VR%Z].
M:]"HH XFP;5-7^(-CK$NB7=A80Z7/;EKHH'\UI(FQA6/&%.#WP?;.AK6FW=S
MX[\+W\4!>ULTO!/)D8C+H@7\\&NFHH \J\1:/KE_=ZF9-*U:\NH]2AN;:5;S
M;;"U22-PJ1[PK/A6&"O7)STI^H:!JUV?%-D-)O3]HU2WU:VD258UG2/R-T0<
M,&23Y& Z8(!R*]2HH \W31+5].U&X_X1#69HIY($<7>IN]VZ(68/'ND)4HS<
M8<$Y8]AG4T+4-3T32K=-1MM1FBN]5%M:"\E1KB&!E^5I2"<X8-W)P1GH:[2F
MM&CE2R*Q0[E)&=IQC(_ G\Z .?\ &^GW6J>&3:V<)FF-Y:2; 1]U+B-F//HJ
MD_A7/>-/#&IZWK6J26ML[Q/I5JL967R_,DBNC*8PP(*D@  \8R.:[\7$)N6M
MA-&9U02-%N&X*20&(ZX)!&?8U)0!Y;?^'S=:!J]W8Z+J5G<)]D>-]8U)I)+C
MR9A*8\/(P1>, DC)8]N3!K]MJ/C#Q-JMG'ITMA--X<9;>*[9 [,)U8;MI(52
M1@<]B:]2O;*VU&RFL[V!)[:9"DD4@RK ]C5'1_#>DZ"TSZ=:>5),%$DCR/([
M =!N<DX&3@9P,T <W)#JGBCQ'I]Z^CW>F0Z?97*.;LH#)-*JJ$7:QRHP26Z=
M,5A:?HNM3Z1\/8)-'NK>31+M8[P3%/E"P[2XPQRI)P._M7JKL$1G;HHR:JZ7
MJ5MK&E6NI6;E[6ZB6:)BI4E6&0<'I0!YH=)UR74]/O+O2=7N+^SU@SW5Q)=Y
MA:'>ZH(8O,VX"LI^Z" #U)J#4M URY\$:[H4>CW7VK^W3=Q.2FR:)[KS,J=W
M9>2"!7KM9USKFG6OV4O<JXNKO[%$8_G'G?-E21T(*,#GH1B@#!_LF^_M?QK-
M]F;R[^VA2V;(_>$0LI _$XYK$T*WU;PQJ,1&D2WDEWH5C R1RQ@V\T*NI$FY
M@0AW_>&?NFO2JQ]8\+:+KTZ3ZC9"69$,0D61XV*$Y*$J1N7V.10!E_#$%?AI
MH .,_90>.G4UUE1P00VMO%;V\210Q*$CC0855 P !V %24 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>?>.;B6?4KFWM'UF6:RTTW+I8W@M8K<L6VRN
MVY2Y^1L+R,*<CFO0:Q=3\*:3J^HB^O(IFE,0AE5)W1)XP20LBJ0' +'@@]30
M!R&FK>>*M?2&^U748;=_#MC=M%:73P#SG,N7RA!'3IT/&<X%5/"UU?>+KG1+
M34]3OUCBT"*\8VUR\#33-(R;V*$%L!!P>,L<BN]TGPUIFB2+)912AUM8[,-)
M,\A\I"Q1?F)Z;V_# ["J3^!="-O80Q17-N+&$V\+VUW+$_E$Y*,RL"RDC.":
M *?PPW#X?6.Z7S6$UUF3CYS]HDYX]:R_"Z7-WX?TOQ;/KEZ+^Z\R::VDN"T$
M^0^(%B)VJ5P,%1GY3G.37;:1I%CH.F1:=IL @M(BQ2,$D+N8L<9]R:S;3P7H
MEEJJ:A#!,'CE>:*%KB1H89'SN=(B=JDY/('<^M '&Z?+>VF@>#_$HU>_N+_5
MKNV6\22Y=X95G!W*(B=J[<Y&T C;]:KQMJ">&(_$C:SJ;WL6OFW1#=/Y7DF^
M,)C9,[6&TGD@D< $ "NYLO!6AZ??PW<$$_\ H[M);P/<R-!;NV<M'&3M4\GH
M.,G&*M?\(QI/]D?V7]F/V/[5]KV>8W^M\WSLYSG[_..G;I0!Y?/%<:3X9\>W
M^G:C?PWB:ZD$<ANY&"@O;\X+8S@D9ZD<=*Z76[$6MW9Z';7/B/4)8[:6ZD2'
M4O)898 2R3%U/!!"H,CKQ@"NAN/!.AW,VI/+#.4U)TDNH1<R"-W4J0^P' ;*
M+R!DX]S5G5/#.F:Q?0WEVDWG1QF(F*X>,21DY*.%(#KD=#D?F: .'T"YO?&4
MNC6>I:G?PQKX>@OF-G<M TT\C,I=F0@G&P<=,MR*L:=IH;XJZ>\NK75_)'H
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MQAOBP1MP#QU/(YH Y$R2^&]<T6YEUG4'AOM*NY[]KB=I4W1I&XD5"<(1EN%
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M -QG!R .M 'EULNIS>&M UC^W]66]O-;:QD873%! T\D94(3MR ,AB"0<<X
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M172?$.E_VW:P:))='5M-MXHIDGB6.&1(#$PDRP/!P05#9IMOX7\10:Y97EM
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MQQ<6CQ&Z,6Z$)N$8DZHI*@<>I'>@#VBH+N\M["W-Q=3)#"&52[G RS!0/Q)
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M>**!1@H06!W$$DL><"J%_90Z=X<^*-]9F:&ZCNGC219GRJF*%N.>N3UZ]NE
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/2#,;*P5&FB\EV:1G;R_[@+$D+[# JU%HFFPC31':(HTQ=EG@G]R-FS _P"
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M*@8 _*I*I:1J=OK6D6FIVN[R+J)94#C# $=".Q'0U=H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *YU](NS\1H=:"K]B727M"V[GS#*K 8], \UT5% '
MF^D>"&TW68XG\,Z;.(]0DNEU>27YO+,C2+A.OF*2%].,Y[5H^'M/\3Z'#:>'
MX[*T_LZVN9"VH/-N\RW+,P41C!$GS $G@8)YZ5V]5(+UYM1N[5K*YB2W";;B
M0+Y<VX9.P@YXZ'('XT <'9^&=?&AZ/X4GLH$T_3;R&5M1%P#YT,,F] J8W!S
MA0<\#DY-6V\':A<^#O%FD.T4-QJ>H75S:L6RN&8-&6QTY S79W]T]E837*6L
M]TT:[A!  7?V7) S]34\;F2)'*,A90=K=5]C[T <,]EXIU7Q)::O/I%E9BVT
MRZMT@FN1*&F?RR-VT?<.S''/!SUJMIUGJ/A2VUS6K708]-LXK+>FDK>[XY)E
M+,S+@$1C&!@#GT&*]$HH R?$%G<ZMX0U2RAC NKNPEB1&; #O&0 3]37+KX4
MU42_#MO+CQH<)2]_>#Y3]G$?'K\PKOJ* .#'A75/^$%32O+C^U#6?MA&\8\O
M[=YV<^NSMZ\5DR>#]9_M**\.AV<]_:ZP;U]2DN%,UU"9251,C*;48#!('R8&
M<Y'J58[>)M.WZ.(7:XCU:9X;>6(?+E4=R3G'&$([\XH YMO"NJ'P+-I0CC^U
M/K)O -XQY?V[SLY]=G./7BIM/L/$^AW5WIFGV5I)9W.IO>+J$LW$44DF^1#'
M]XN,L!@XY!)XQ7;44 >9/X.UN.VU\&UCN(KWQ"+\V@N GVJVPH*$]!R,X/!V
MX/6J>H>!=:N/"/BG2+/2+&R_M*[MKNUAMY56- IB#(>!@@1DD]"3Q7I*:Q;O
MXBFT0))]IBM$NV? V;'=T SG.<H>WI5RXG6VMI9W!*Q(7('7 &: ,+QCI-YJ
MNCVYTY8WO;*]@O88I&VK*8W#%">V1D9]<5S&IZ#XHUJ\UW4&LHK-KS3[:W@M
MUNQO81S,\D;.OW2RLPR./F'/6NV\/ZW;>(] L]8M$E2WNX_,190 P&>^"1^M
M:5 'E%UX'U::P\46]AH5AID.K:? MO!#*H$<L3N=KX&"S!L[AP,8)[U:\0>%
M]:\27.H2WGA^SF>^L%@M6N[E9%TUP'#87!RQRK!E[X!(Q7H6H7KV-NDL=E<W
M9:14\NW"E@"<;CDC@=35N@#GM%U#4([ZST:ZTY81'I:322"8.4D#;-A &,8&
M0<\X/'%9VI^'=1NOB(=9B1#9G0I;'<7 /FM)N QZ8[UV5% '$0^&M5BT?P-;
MJD(GT8)]IW/E5(M7CX]1N8=.U9 \&:I>P:O!!I%MH*7VE7%K<10W6^"XN7 V
M2+&.$ P_. QW=*].JO'?6TM]/91S*US;HCRQCJBONVD_7:WY4 <.^D^)=8U/
M3KN\TN"QCM-+N[0I]I61FDD6, \<;?DX[]<XIUUX9U,>"?"FFO8QWXTU85U#
M3S.$6<+"4QN/#!7*M@\'%=]5>XOK:UGM8)YE26ZD,4"GJ[!6<@?\!5C^% 'G
MVB>$-7L+_3U?3K.UMK77)=0VVT@\M8I+=TVJ, _*S!>@SUJUJ7A75Y-4U74[
M6.%YEUFUU*TB>3:)ECMUB=2>=I/SX)[XKOZ* . UO0]=\306M]JNC6,@LK[S
MH=)>8$O"8F1@TGW=^YMP[#: 3S70^$]*&E:7*G]CVFDF:=I?LULV[ P "[="
MV ,XXZ#M6G;7KW%[>6[65S"MNRJLTH4)-D9RF"20.AR!S5N@#SR/P5?R?#"#
M0[B"WDO;>]:[$$C_ +N4"Z:4(Q'0,AQGL3[52UCP3>:EX"\0Z?IGANPT>ZOS
M;K#"DP+R".16)D8?*/XL ?UKU"B@#DY- OVUGQ;<A$\O4]/@M[8[QDNB2@Y]
M.76L^Y\*ZI)I_A2%8X]^FZ9/;7 \P<.UL(P!Z_,*[RB@#S[2M"\13Q^$=-U.
MP@MK;0=DLMREP'\YTA:-%50,C[^3GCCC-5;7PYXFCTK1M";3[=;;2]7CNFO/
MM(/GQ+.7&U,9!PW.?3 SGCN]%UBWUW3S>VR2)&)YH,2  [HY&C;H3QE3CVK0
MH XW3-"U/3O#FOVS6-G=S7FIW5S';7#9CFADEW;6/."5R.1P<9KGG\"7T]GO
M&BQ1V-M?Q75OH<]YYBE1&\<@#<JF=X8*#@%.V:]3HH X&+PI<_8])-KHECI7
MDZY'?2VT$@)$2HRY9NC/R.!QC'7%6-1\-:E<P>/DC2,G6H!'9Y<?,?LPCY]/
MF%=M69<:W"FGW=U903ZBUK-Y$D%H 9-X8!@-Q XSD\] : .$N_ LR:K>S/X9
MTW5S?QP%9[J8*+9UB6-@XZLOR!AMY.2..M;<OAJ^^S^.8HHXP-6C"60#@ XM
M$BY]/F4BNSHH XO1]%U?2?&45VUG'+97&DVUI-,LP!@DBWD_+U8'<!D5J+I%
MV/'UWJ^U?LDFDQ6JMNY\Q99&(QZ88<UT%% ' :?X1U.+PWX'T^>.,2:3(#>@
M2#Y5\B6,X/?EQ4/@_P &/H=YID,WAG38GT]&1M667<\^%*JR*.59@<MNZ<@9
MSFO1:* /./#WAC7;32O">GWEE%%_8>H.\DBSJPEC,4RAU'4<R+P>:GU+PIJ[
M:YJ.L6D4,DL>L6VHVL+R[1.B6PA=2?X3RV,]P*] JO=7UM8^1]IF6/SY5ABS
M_$[=%'OP: .!U'POKNLRZIKCVD%KJ+36,EE9/.&RMM(9,.X& 7+,.,@<<TFJ
M>%_$'BF]UNYO+6#31>:5%:VJ-.)2DL<K2#>5[$D=,\>_%>CT4 <7_9NN:]K]
MMJ>I:;%IR6%C<011"X$K2RS!03D# 0!.,\G/08K)T#PKKWAK2O"MW'9175[I
MME/97=HLZJ661U<,C'Y<@H.#C(/M7HMU<PV5I-=7,@C@A1I)';HJ@9)/X"G1
M2I/"DL;!HW4,K#N#R#0!YH^BZGHMYINO3BR_M2XUFXN3I[W00,)H?+$:2$8+
MJL:GH <-6:VC:OXJL/%"0QVYNF\1VTK".7**(XX2RACC<5 P?4@UZM?Z=8ZK
M:-::C9P7=LQ!:*>,.I(Z<'BG65A9Z;:):6%K#:VT?W(H(PB+] .* //[_P $
M,?$6J2-X9TW58]1NEN$O+J7'D*5575UZMC:2,==V#C%79] U.?QE!J$.C6UC
M/'>!Y=5MKK:+BV&?DDC'+,1A>> 1D'H*[#4KU]/LFN([*YO&#*/)M@I<Y(&1
MN(&!G)YZ"H+_ %VQL(=3=Y#))IMK]KN(8QEQ'AR.O&3Y;8Y[4 -T;4;O5-*E
MN);>.WG6>>%5W%U.R1D5L\<':#^-<,G@_5KJ'5X[?1[;0UO=*N;6XAAN]\%S
M<R !'5!P@'S\X!.[I7H]G<I>V5O=QA@D\:R*&Z@,,C/YU-0!Q.BZ-K#>(=!U
M.^L4M%L](ELID\]9"'+1;2,=00A-8=QX/UEM2%X=#L[B^MM9^W_VE)<*9;B'
MSMRQID93:A P2!\F!G.1Z5?WD>GZ?<WLH9H[>)I7"]2%!)Q[\4:?>QZCIMK?
M0JRQ7,*3(''(# $9]^: /.;GP;JUS::M97&EVUS"NNMJ]L)+@;+I&;F(C&5.
MUFY/&<=J6[T)]*T^QU.WT;2M%N+?6(IX;(W(4W \MH]C2?=\P[VV@9' &:]-
MJKJ5K:WFG3P7EDE[;LA+V[QJXDQSC#<'\: /*=2TK6?%UO\ $.QB@MUOKH6,
M4<*3!DC*C<4+\ L%P3Z$XYZUM:WX,EE\1:C?#PWI^L_VA%#LDNI@@MI$380X
MQED("GY>>HQWKM- M;*UT:!;'25TF%QO^QB)(S&3UW*G&?Q-3SWKPZC:V@LK
MF5)PY:X0+Y<.T9 <DYYZ# /X4 <7KGAO4;O68FL=$M8)X'@%IK%M<^2T,*[=
MR2)U?HX"\J01TYK3\9:->:I>:3*FF1:M86[2_:+"681H[,H".<\,%PW!_O9
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MZJ!V7V& <4 ;BLKH'1@RL,@@Y!%+5;3K*/3=,M+&(DQVT*0H6ZD*H S^56:
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M;8]I1%VG&6YW C&XDYP =JU\/ZHX\437$<$4NKVL211K+N".(-A!.!QN[^E
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M!@8!53QVJO9^%==T5])U&S@M+J[L[C4!+;/.8Q)#<3&12'VG##"Y&.YH U?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVN9H(;B3B6&,1((D4]55MW0<-N.<UOP7$5M?>.VFE6-4TVU<ECC ^SN,_F*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY0002O/.0>V*:?&FJV,\#:IH\*V]YIT]]:I;3EY1Y2*YC<%0-Q#=B<$8YZT
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M+O9 /]E2F?=J\\O==\17OA;69[]('-KXC@MX$MICN)2ZB!C&5 V^A/)R<@4
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MJ;)I]BNKW5G);Q7LD(+H60J"6QGC/Y5H3>&=&O9[:ZO]*LKJ\MXQ&D\L*LP
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MW N@BS^;$K>:$SMW9ZXR<>F:\@MKF^2'X@Z_K=A:WWV.>6W=!?3 @*J$1)P
M$YSNX.>U=5;W+2_%K0=FZ.&3PV\@B#D@?O%Q]<=,T =UI^FV.DV:V>G6D-K;
M*25BA0*H)ZG [U5@\-Z);:L^JP:191Z@Y):Y2!0Y)ZG..I[GO7'>'/$TO_"
M6%_I.F6-E%-=SQN;V_*P6X61\LSMEF+%> !U;L!4;^,]<U6Y\(OI<5BB7U[=
M07*&X+([0I*" P4Y0[-P(Y.%[9H ]"M;.ULED6UMXH1+(TL@C4+N=CEF..I)
MZFJ=]X<T75+Z*]O])LKJZB&U)IH%9E'7&2/7FN7@^(1FU2$^7I_]F3ZB=.C
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M[;-!$MO L9BF6X5S)N!)R@Y3';/6@#F;CPMK/B&[GN=?EL("-,N-/MX[)GD
M,P >1BP7LH 7GOR:;IWAOQ%)JN@76K3Z:D6D6\MOLM6=C+NC";\LHQ]T?+VY
MY/;KH-0LKF.22WO+>5(O]8T<H8)]2#Q3HKVTGG>"&ZADF0 O&D@+*#T) Z4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=:]86PLT&%M(%'F^=@1@?O/[_3[WOUIS6EL_G;[>)O/4++E ?, & &]1@]Z
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M+_4LI8.#OP3A6^7KD5)K>A:UKFC7%I--8Q.]W;S1HA;8B12+(<G&2S,I!.
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M;E9-K$%T4$#@K@,??)[8K(\">)Y(-!\.6%];7L@OWGACOY9 X>56D?:<MO\
MNJ>2.H_&M73_  =-H6IZ+-I5Q";;3]+;3GCN%.YUW(P8$="2ISZ9SSTJKI_@
MW4[/3/#%F\]HQT:]DN9&#-^]#+(N ,<']Z?^^??@ OP>/-/N=0L8((GFAOV=
M+::*1&RR@D;ESE P!VD^V<9JSX:\4-XFB2YATB]MK)T9DN)S'@LKE"F Q.>,
MYQCW]:7AKP_XA\/Q1Z4=2LI]%M"?LO[IEN&3DK&[9V@#(&X#) Z"M'PAHUUX
M?\-V^F7<D,DD+R'?$3A@SL_0CC&['X4 )JM_:P>*]!M)K>[:XG^T&WECEVQ
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M_N"/) Z *",=:U;NVN--\57_ (>19VM/$6V>WFW,?L^W N$#?PX7#)V#,<4
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M1BW0CC=L')SBO0?%1QX1UEO,>(K93,'20HRD(2""""* -*VDDFM8I)86@D=
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MB1C"*JCT48KR[5-1MM4UK5],UG78=*D\BVETZ:0%9-AC!,D#;P-_F;P< DX
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M8 Y'%0W=[;Z)IUH\&O176@7&LD75P$+VMLK1-B,$/_JO,V9^; )P>,B@#O\
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MU!(RBW4"3JA.2 RAL?K7F]G?P+>>-K*.\L_LYT:*>*"UFWQ*Q28.5/<\+N8
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M9GKCTS3+!;Q;&$:A)!)=A?WK6Z%$)_V022!^)KB[_P 5Z_\ 9O$&L:=%I_\
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M:.-W/7+GIBFIXJU*?QE-I*7&DVXAGC06-T'2XN8F16::-]VT@;FPH4_<.2*
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M!ZCWJ#7=*LM#\":U9:O=27FH:U)+,?LT#;I;E@-BQ(,D;=J 9/\ #DFO0J*
M.+L?!UVO@S3+62[6+7+>X&I27+Q^8K7;$M)N (W*=[KP1QC'2K5UX9U75+:P
M_M35H)+BVU6'4,0VVR-4C_Y9*-Q//7<Q/)/; KJJ* "N*O\ P7J4RZSI]EJT
M%OH^LRM+=1O;%IHRX E$;[@ &QW4X)/6NUHH P])\/#2O$6KZFDP,5]%;1)"
M%QY0A5EZYYSN_2K>O:8=:\.ZGI2RB(WMK+;B0KNV;T*YQWQFM&B@#CHO!U_9
M7?ANYL=3A232]._LV<R6Y;S8SY>63YOE;]WQG<.>AQS8TKPWJD7B&#5]8U"R
MNI[6U>UCDMK0PO,&*$M*=QR?D&   "2:ZFB@#"\5>'F\3Z?;:<]R(K+[5'->
M1E-WVB-#N\OKP"0N3SP*I:_X"T35M$N+.SL++3KM@&M[RWM45X)%(96! !X(
M'&>17544 <[8^&Y[?QE<>(I[Q)'GTZ*S>)(]HW(Q8L#GH<]/UK#/PYD/P\C\
M+?VFF]+W[5]H\DX/[\R[=N??&<UWU% ')W7@U[G7_$.IB]51J^FK8B/R\^40
M&&[.>?O=..E4[+P1J6EII(L-7@1[;2DTNXDDMBS%%.=\?S#:W7KN'3@XY[BB
M@#A=,\"ZAID^@R)J=I*-/L'TN=7MFQ-;%E(QA_E?" 9Y'/3M6AHOAW7=+MX-
M/?783IMG;M;VWDV@$S#&U#(S%@2@QT R>3Z5U5% ',:-X=U*#Q#_ &SJ]]97
M%TEH;16M+0PF52RL7D)9LGY1@# &6]:T-<T5M8FTEQ.(OL%^EX05SO"HZ[>O
M'W^OM6O10!QNJ^"[J[U>\U6TOX8[F2]M;R!)H"\:M#&R88!@2"&)XQ@@4MIX
M8\1:?)J5Q:Z]:-/>W:7CB6R)1V\H1O&PWYV?*I7!R,<EN:[&B@#&\,:&V@:7
M);22Q22S7$ES)Y$7E1*SMDJB9.%'U/<]ZQ=<\&:AJEWKJVNJPVUGK=NL-R#;
M%YD*H4 1MP&T@C((/?&,Y'9T4 5[&*>&PMXKJ2.2=(U61XU*JS <D DD#\:X
MH^ ]4>QN](?6;=M'OM1DO;B,VI\X*TWFF-&WX / )()Z^H [VB@#A-8\#:K?
M0>(M/L]9M[;3-;=IY%:U+S1R%%0@-O VG8">,XR!ZB_JGAC5=5OXH[G4[233
M(KR&[C#V?^DPF-E;8D@8  E>NW.&(YZUUE% '$Q^ 9(UU(?VBI^V:_%K(_=?
M<".C>7UY)V8S[]*MZSX,;5M5U&_6^\B6X@M%MR(MWDRV\KRJYY^8$L 1QP#S
MS75T4 <ZNF^)VL9VDURS2_:5'B$5E_HZ*O5"I8NV[N=P(XQCG.=:>%=<TZWN
M)+/4],6XO+F2XN[9K FT?<B( JA]P(\O.=W)9LCICLZ* ,OP[HP\/^'[/2UE
M$OV=2"X38"223A>=HR>!V&!6I110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !16/XIUIO#_ARZU&.)99DV1PQN<*TCL$0$^FYAGVK.\)ZG?:A<7:R
MZ_HNM6T:K^^T_P"5XI<G<C*&8;<8(.0>O!ZT =31110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5DZUH0UDPDZIJ=EY6[_CQN3%OSC[W'.,<?4UK44
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MY;-VR,'FI]5G6<^(+.))I+G69[2;3B(6Q(FR)=P..-C(['.,#GO0!Z/1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex1012022063010qngcbasho007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHA8!F QD@=\9'YT^@ HHJ"6\M8)XH)KF&.:4XCC>0!G^@/6@">BBB@ HHHH
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M5#,JAS'N&X*20#CTX/Y4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\94&,Y8[U(<<G!X]Z=>> [W5[>_&KZZEQ<W&GMI\<T5D(MD;,&+,-QWME1W
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M+?S$"SD;XV3<,CA3D$'*CZ4 :7A#6YM>\/I=W(3STFE@=XT9$EV.5#J&Y 8
M-@],XK@KP7=E\7-?U>[N+2>/2]'2["O9Y80AG;8C%OE;C[^.?05Z=I=K<66G
MQP7=\][< LTEPZ!=Q))X4< #. .P Y/6LF3PE;S^)M5U:XG,D6I:>MA+;;,
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M9,AL\D[L].,4VR\)WW]HV=YK&M?V@UA!)#:!+40[2ZA6=_F.]]HQQM')XYH
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M)1PK[P,E><BCQ/J=G<C5IHL1WMO<Z9*9'5I)9%#0GS(V'$<8!8$C.3NSC."
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MYVYZ=ZVJ\:LHM/BTW1=218%OQXLF'VCCS!"T\N1GJ$*L#CISGO7H7C[^T?\
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MRN"'&F6P8-U!\I:\PTRPL--L=*TRUBG7QM::JD;'#^9Y(GR[$]/),.3Z<^M
M'=ZUXPN[4^)9-.MX)+?0;%Y9I)<GS+G9O6,8(X"X+'_: ]:U+#Q1IVMI-::3
MJ=E+JB0;_*+%@IZ9(!!*AN#@UQ+*P\"_$^U*DW0O+]F3'S$/"K(<>ZE<?2KU
MA>V6K^+O",>DJV=+LIQ>((ROV96C1%C?(X.X#Y?]DF@#K?#.N#Q!HJ7;P_9[
MF.1X+JW)SY,R$JZY[C(X/<$&M2>>*VMY+B=UCBB0N[L>%4#))_"N'\+ZG::6
M?%NHW,ACLI?$+11LJ%LN5BB/0=#)D9]C75>(H);KPSJMO"A>66SF1%'5F*$
M4 3'5; &S!NXO],4M;?-_K0%W$KZ_+S5&R\7>'M2OX;&RU>TGN9D\R*-),EQ
MMW<>IQSCKBN$L-9L]7O/ <-BTDS6EK,ER1&P$+_92NQB1PV0>/;Z4_2K0P^"
M_A@J0%&2\@9P%P5S;3%B?3)/- '2>'?&T5]H.H:KK,EM8Q6NI3V0;) 8(^U>
MN26/H*U9?%F@0Z7!J<FK6HLYV*12A\AV&<J .21@Y';!S7E.FP75OHMM>M<R
MV%M:^*KV2>Y\@2"$,LBI(5(QMW,!GMNS6RJ:9:V46K+XGO+:>;4;B>WU>6Q4
M6Y<HB.I7&TH^W(/&2#@^H!WEUXO\.V4=K)<:S9QI=H)8&,H(=#_%GLON>*VL
MY&>U>076K"'38-5^T1:5K$VFE#8R:>6M-3C$DI5%0_,"Q). <@2C(->FW<=S
M>>&)XX(OL]W-9LJ1YQY;E.!^!- %>T\6^'[^]>SM=7M)KA Q*))G(7[VT]&Q
MWQG%<^?B9IEU8V=[830?9VU7[#<O,V!%&/-_>9[ B/(SV/-8NG7MIJEAX"T?
M3(W&I:9/"]Y!Y15K-(X'242<?+DD+S][/>J.E-#<Z/HNELI>ZLO%SO<P,AS%
MNEN&0D$=#P0: /2H/%6@W.E7&IQ:K:M96S;)I2^!&W'#9Y!Y&!WR*5?%.A/I
MB:D-5M19M+Y(F:3"B3^Z<]#[&O//$]M<_P#"2Z[=122VT%OJ>F7$\Z0^9L01
M,I?:1A@K%"?0+GM4=]96U_:07<.HS:Q%>>)K S3-:B.*3:%4E0!AEQ@%NF5(
M[4 >E6'B31M4MY[BRU&":*",2RLK<(A!(8YZ A3^1H?7],.F6U]%J%L8;SY;
M24M\DK;2P QUX4GZ UQ'Q MKF#Q#'':1R%?$EF-(F:,'",)EPQ/;]U)/S_LU
M2L+&9O$]YHAMW2S\.K?7,/RG:3<@&$+V^59)A[8H [6W\7:9:^']/U#6-7TU
M3=H2DMNY\J7'4IGD@=SVJY?>*M!TUK87FKVD/VE!)"6D&&0]'SV4Y^\>*\RT
M)[?3O G@^[EU>70]2BT^6.&XFMO-@=6=2T4@/<E5( (/!Q3&FE$MW-K%XWA^
M+5='M52SAT\2+,H1U>&,,"006.$Z_.* /9ZY+4/'>F#4--LM*O;.\GN-12SG
M0/DHI#;F7'7!4#N!GFMVUM)+?P]#9Q2R-+':+$DDHPQ(3 +>A]:\LTW4+&XT
M'X?:/##)_:6FZA;I>1>2P:V98W5]YQQEOSZ]J /5!K6F&Q6^%[#]E:;[.)=W
MRF3?Y>W/KO\ E^M1?\))HO\ ;/\ 8_\ :=M_:&=OD;_FW8SM_P!['..N.:\Q
M_M*WC\(1>'B)3JL'B-6FMQ&VZ-#J/F!VXX4J5P>AR*ETZUW:B=&U#7+J*\77
MWNETZ.Q5G8_:#*DN_&=A7&6S@#(]J /2?$6O6?AG0+S5[XGR;:,OM'5SCA1[
MD\56E\9>'K?3[2]GU6WBANU+0DMRX'#$#K@'J>@JK\189;CX<^(8H8VDD:QE
MPJ#)/R]A7/VOB#2K+Q@FO7EVJZ7>Z+%!9WC*?+WQR/YD><<,<J<=\>U 'H5O
M<07EM%<VTT<T$JAXY(V#*ZGH01U%2URWP[M9[3P191SPO 7DGECAD7:T<;S.
MZ CM\K+QVZ5U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6.^B;O%L>
MO?:R&2T:S$&P8*%@Y.<YSE1[8[=ZV*\^\:VUO)\1/!C2:8M\6%Z&BV1DN!$N
M/OD#CKR: /0<YHKB;W4O^$7\,:SK=AX=BLIHI55[1RL8<#:H<^7E22&['H "
M1BI+GQ)XABUK4])33]-^T6]DE_#(9WV&,LZ[6^7.[*=1@8/M@@'94UI8T=$9
MU5G)"*3@L0,\>O%</;>,]:UFXLK?1]*LM]YHT6J1M=7+ +O.-A"KZ\?KQT-*
M#68O$VN> -<^R?9IYGO4DC;!:-EB=77=W 930!Z/17%CQQ-_8VG>(A;1-HE[
M=K;C!/FQH\AC24]B"V,K@$!NIQBIQXIOH[C7K&XMK=-0L)(A:1!FQ<I+Q$V>
MV7RIQG:5/6@#K:*X^?Q;J#2S-IVFM?1VMZ+.>*.&3>^"%D=6QL&TD_*3R%ZC
MI2_\);?7-RDNFZ8]W9#4&LI52*3>JJYC>4/C9@,I^7T&<YXH ZX,I8@,"5Z@
M'I2US=]96_AIM>\3VEF9KJ>!&EBA0YD\L'!(&<GGL.@'&>MKPWK:Z]92W<-W
M97EKO"PW%H3AQM!.Y2248$D8/MZT ;#2QHZ(SJKOD(I."V.3CUI64LC*&*DC
M&X=17$^+DN%\=>$IK"WMY+X_;$1IF*KCRN[ $X'7 _3K4">.]6-K;Q-I%J-2
M&L_V/=1FX;RU?9O5T.W)4K@\\C/0T =S;6T5I;I! NV->@SD^I))Y))Y)/6I
M:XNY\5:U%'>6T.FP7&J:=%&US;P++(DTC+N\M'"_+\N""W<XQQFEUKQE>Z0S
M326,<<"26JB"1\S2+,RJSX4GRPA;'S#YBI (XH [.FK+&[.J.K,APP!R5/7G
MTKG'U_4[V;4&T6PANH]/O5M)8GDV/,<(9"I)PNT/WSN((XXSRBZO=^%]0\;:
MC96-K)9V^JPO<*SE&*M# &V #&?F)R?ZT >H445Q<_CB:/0?^$E2VB?1%O3;
M.,GSA&)O),P[?>YVX^[SG/% '7S7-O;;//GBB\QMJ;W"[CZ#/4U+7"O:2:S\
M2-9TW4X;2ZTT:7; P2J2 C23'CT8E5R?]D>E:OC[4;[1_ ^IWVF21Q7,40VN
MX)V@D D8[\\4 ='YL?FB+>OF%=P3/./7'I3JX"]74H?B<LMC;V+ZB^@/O:0L
MD9Q.N,X!)]*LV?CF;5].TY]/M EY=:8FH,CQ22JFXD*GR#/+!AN/3'0YX .V
MHJCH][/J.CVEY=6,MC<31AI+:7EHF[J?7GO6%?>*KSR]?N-+M8)X=#8I.DC$
M-.RQB1U0CA<*P )!R<C@#) .I$L9E,0=3( &*9Y ]<4-+&LBQLZAWSM4GEL=
M<"O-X;^_NO'.HZGX8LK.9[S0K*Z NI#$'#/,1]T'+$8'/3%36VK0>(O%G@;7
M8+;R7O-.OF*M]Y<"+Y2<<@'- 'H,<L<REHI%=02I*G(!!P1]0:?7#:;XI$&A
MVLD6E6MG->ZY-INR'_5))YL@:1B ,YV$]LLP'&:L6WBO59X-1+V%G&++4_[/
M>Y:XQ'M&"TI5@. &4;0Q)8D9XS0!V-,66-I'C613(F"R@\KGID=J\_N?%^K7
M^F:=)9K!;RGQ -,N"ROAU5SRH."H;:,@Y(R1[U=N?%4.BZEXJN+K2[9)-/AL
M\S0-\]TTFY45B1QAL =<9- ';45R\_B/4-.UPZ1>VUM)/-8R7EI)$[(CF/&^
M-L@D$;E(;N">!5#1O&>IWLGAY[S3;9+?6[![F$02LTB.L:N000!@ACCTQ[T
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MB 2 >XSWJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;O\ <5Y -BL<C )!.1ZT 4%\&M!K=W>V>M7UO:W[+)?6:JA6=PH4L&*Y0L
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M>G4"L,T[VR!H) _G*"3&4*[@V!T(R>,9R* *]]X-DGN;"_LM=OK+5;6-X7O
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MS7(=XQB"38[H"717V[688.5!)X/'% %.[\%P7E@FF2WCOI:>1L@EC#O'Y04
MH_52=HR<'OC!.:Z9T62-D=0R,"&!Z$5EGQ-HX\/Q:]]M4Z9,$,<X1CNWL%4!
M<;LDD#&,U''XLT276?[*2\)NO-:$?N7$9D49,8DQL+@ Y4'/!XH QK3P ;2#
M2K--=O#8:3>"YLH3'&6C 5E"%R,L '('?'X$.F\!"5ID76;N*T?5%U6.%(X_
MW<WF"0_,0206&<'ID]>,:'B'Q?9>'-3TFQN89Y'U&9HP8H7?8H1FW?*IR<J!
MCKSGH#4R>+=$DUK^R5O";OS3 /W+^690,F,2;=A< 'Y<YXH I6G@Y]/UBYN+
M36[V+3;JX-U-IP5"AE)RQ#$;E5CR5!Y.>QQ745R>C^+XSIVJ7FLS10I;ZQ/I
M\'EHQ+[9-J*%&2S'V'X5I/XLT1-8&E->$77FB$_N7\L2$9$9DV[ Y!'RDYYZ
M4 95MX"AL]/TZ"#4[D3Z7<O/83LB$Q!MVZ,@ ;E(8@YYZ<C%;NE:/%IDM[<F
M0S7=],)KF8C&Y@H50!V4*H '/U))-9\_CKPY;7;VTNH$/'/]FE802%(I-VW#
MN%VID\ L0#VK4U;6=/T.S%WJ=RMM;F18O,<' 9C@ XZ<]^E #->T:W\0:'=Z
M7<LZ1W"8$B?>C8'*NON& (]Q535/#<6H6>E6D5PUM%IMS#<1!5#9,7W5.>WK
MW]ZBF\<>'[>TMKF6[F"7$;2H!:3%Q&IVL[($W(H/\3 #WJ34O&.@Z3)&EW?8
M\R$3[HHGE5(B<"1V0$(AY^9B!P: *DO@JW<:M:I>2II>K3&>\L]H.7;&_8W5
M0^/F'/4X(S2:KX*@U:YUF26^FB35+&.R=(E \M$+%2I]<N<YX(XJ_>>+-$L-
M373[F\*SDH&*PNR1ESA [A2J9[;B,YJ.X\9Z!:ZD]A-?%94E6"1Q!(8HY&QA
M&E"[%8Y'!(/- &?+X%6[.L-?:Q=W!U;3UL;G]W&@PH<!EPO!&\\?GFKH\+L^
MIZ5?76HR7,FGVTUOB2)0)EEV[MV,8^XN,?CFC4/''AW2[FYM[N_99+1PER%M
MY'$!*JP+E5(5<,/F.!UYX-37_B[0],U 6-U>E9OD+%87=(]YPF]U4JF3TW$4
M 4].\&06-MIU@][+<:;ID_GV5O(HW(1G8&?^(+N.W@'@9)Q4+^" ^G7-F=2D
MVSZJ-5+"(9$@D$FT<_=W*/?'>H!X^L=/U_7['6;@0Q6%Q&D31V\C[(VAC<M(
M5!"C<Q^8X''M5H^);@?$S^P2T']F?V'_ &CYF/FW^=LSNSC;M_\ UT =25#(
M5<!@1@C'!KF-/\%6]C:V.GF\EFTK3[G[3:6SJ,QL"2BE^K*I.5& >!DG%:&C
M^*='UV=H-/NFDD6,2A7A>/?&3C>F]1O7/\2Y'(]:9JWBW1=$NVM+ZZ=;E81.
M88K>25_+)(W812<94Y/;'.* 'Z5H1TS5]6U#[6TQU.99I$,8 1E14&T^FU1U
MSS2^(-"_MV"R"WDMI-9W:7<,L:JWS*",%3P1AC^.#VJ"Q\:>']2U"VLK/4!+
M+=*6MV$3^7+A=Q"R%=I(') .1SD<5)IOBS1-6OC9V5Z9)MK,A:)T255.&,;L
M L@!ZE2: ,E? :HI4:Q=./[6&K#S(T/[T<XX X)Z_AC'>6[\#6][-J<TU],)
MKR]AOXI(T :VGB551ESG(PH!!SG)]:NV'C/0-3EECMK_ #Y<+3[Y(GC1XE.&
M=&90'49&2I(YIL'C?P_<6L]RM\Z1P",OYMM+&VV1MJ,%9064L<!@"/>@"&_\
M&V^K66KQZC=/)=:I:K:RW$:!/+C7)4(O..69N2<D^F )H_#<ZZXNKOJDDMT+
M V1+PK@@MOW8&.<_AC\ZNZCXATK2I+F.]NQ$UM:&]E!1CMA!P6X'KVZU2/C7
M0/L0NUO))(FG-O'Y=K*[2N!N/EJ%+.,<[E!'O0!E0?#XV$&DG2]=O+&\TZU^
MQ"Y2-'\Z#.0KHP*D@\@]LFMBW\-BV\1V^L+?3.\-D;,I(H.]2P<LS==Q89]/
M:DN/&F@6UE:7;7S217:-)#Y$$DK%%P&8JBDJ%) )(&#P:?X@\3V6A>$KGQ#S
M=6T=OYT0A!82Y&5Y . >/FZ#.: -IPQ1@A ;'!(R ?I6-X8\/CPSI3:>EV]S
M&9I)@TB!6!=R[#CMECBH)?&NB6]K:3337 :ZC,L<"6<SR[%.&8QA-RJ#W( K
M6@U.RNM*75(+E);)HO.69.5*8SG\J ,*#P>UGK=W=V>M7L&GWDYN;G3E5"CR
MG[Q#$;E#$9(!YY]:L67AF2PM-7AAU.99-1NVN_-5%#0R-C.WL1\HX.>_6ETW
MQKX?U>]M[2QOS)+<H7MR8)$28 9.QV4*Q Z@$D<YZ&F6_CKPW=6]U<0ZD&@M
M4WS2^3(%7YMN,E<%LX&T<\CCD4 5+CP%97;7ES+.8]0N+F"[%S;1B,1S0YV.
M%.03R=V<Y!QZ5)J?@N/5[#58[N^?[7JD4<$]S'$!MC0DJJ*2<#)8\D\L?;%V
MW\8:'<K"4O&1IKH6:I-!)&XF*[@C*R@J2.1N SVJ>_\ $FD:7=36U[>I#+!;
M?:Y%96^6+=M#$@8Y;@#J3T% #(-#:/Q1)KKW9>62S2S:(1@+M5F8$<YSEV_"
MIM4TR;4'C,=TJ1B.2*6"6$2Q3*VW[RDCIMXY[GK51/&.@MIEQJ+WQAMK:5(I
MS<0R1-$SD!0R,H90=PY(QSGI5"_^(>AVFB:MJ,#SSR:;#YLENUM+$[9!V<,F
M=K$8WX*CKF@#>T;2K?0]%LM*M2Y@M(5A0N<L0!CFKU5-,U"'5=-@OK<2"*9=
MP$D;(P['*L >H].>M6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+U
M&Z&@?$275[^"Z:PNM+CMHIX+9YMDB2.Q0A 2-P<$<<[37:5!]MMO[0-AYZ?:
MQ%YWE9^;9G&['IGB@#RO1X+K0+_PG?ZEIEZEND.J2R;+9Y#9K-.CQA@H)!VG
M&,<9/8'$-QIU_=6>CWT6GW8ANO&ZZ@B- P9+<EAYC+C* XW<X^\*]AHS0!Y#
MJ&DZD]_X[G33[J5!JVG7:QK$2;B.(QLX3^]PIX'<8J36]8FOO%>KZAHUC<[Q
MH$:(\UDV]U^T_.ZQ.N6VJ6(!')'0UZ?JFG6^K:;/876\0S+M8QN48=P0PY!!
MP:R=!TC3-.U?4&BU"YU#50D<5S+=S>9)&G+(G0!1R3P.<Y.: /-M8M;N^L/&
MD=HNMZB+[1K?[)/>6I5[CRY)=X4!%QC>,*0"<Y&1BN@U"*?Q!\0K.^TZ&Z6U
MN?#MU EQ);O&$=GP =P!4]\'MS7I5&><=Z /,-/DDU33O!&AV^G7L%]I%Q!)
M?"6U>-+80PLC?.1M.XD ;2<@YZ46FF7:?#OP[!]BG6:/7XII(_*(95^VLQ8C
M&0,'.?2O0K[5],TMD74-1M+0R9*"XG6/=CKC)&:6QU;3=4\S^S]0M;OR\;_L
M\RR;<],X)QT/Y4 <-H,TEKXJM;+2#JPL7GN&O-.U"R(2QX=M\<VW&"^ %#,"
M')&,5=UP26_Q,TZ=X[A8+K2+BQCN(X'=5F:6,J&*@[> 3DX''6NXHH \JT[S
MKOP[X-\,QZ=>PZII5Y:M>J]JZ) L&=[^81M(;&!@G._ZUT7CAVM-7\*:D\%Q
M):V>HNT[P0/*8PT$B@E4!.,D#IWKJ;O4[*QN+6"ZN8XI;N3RH$<X,C8S@>^*
MM4 >8:EIMVW@+Q]$EE.9KG4KB2)!$=TH(CP5&,GIU'I5:]TD_P!L:[I>HWOB
M-!J&IB:&UT^U1HKB-A'A_,:,A=I7#9<8V?3/K%% '%?$ZV6Z\/:>LMM<W%LF
MJVLEPEO&[N(@^7("?-TSTYJ+PP_A&#6T71[#6(;N5&0/<VMZJ8QDY,HVCIW^
MG>NZHH \MT;2KJ/P;\-H'L)EDMM022=&A(,7[F?EACY?F(Y/<BJFMB33O$[W
M=Q97#P'Q?;S(%A9BZBP(+( ,M@@],G*X'->GW6LZ;9-=K<WL,1M(!<7 9L>7
M&<X8^WRM^1J*[TZRUT:7>-(SI:SK>VS1MPQV,H)]1M<_I0!Y;XOMKO7?#7C[
M4M.L+R2WOC816JFV=7G,3KO94(#$<XSC^$^E=-->CPYXJ\3S:A8WLT>IQ026
M9M[2283;8MABRH.&W#.#C[^?6NXLKVVU&TCN[.=)[>3.R1#D-@X/Z@U/0!Y+
MJ%GJO@?PIX4UN&W,NJ65@-*N8%()?S4 C7WVS!!]&-23^'G\)ZGI0?4M8L[.
M/2!:M=:;;"<O<"0N^\&-R-Y<L#@9(//2N_OO#UIJ.M6FI7<US+]D(>&U,G[A
M9!G$FW'+#)P2>/3-:^: /._#6B_V=XTT;R;2_2S@\-M$CWB#?&QG5MCE1M#X
M[#TK7\7K)::YX:UIH)IK&PN9OM(AB:1HQ)$R+)M4$D \' XW9KK<\X[U#=W=
MO86<UW=RK#;P(9)9'. B@9)/X4 >5ZE8W.L3:AJL&GW1L;_Q'IC1));LK/'%
MY:O*4(R%.#R0.%STKT;Q+&\WA76(HD9Y'LIE5%&2Q*'  [FM*.1)8DDC8,C@
M,K#H0>AIU 'E6C1W&DM\-;B\LKQ(X=)EM9=ML[&*5TAVJX )7.T]<#CFM'PC
M-);:]::?I3:JVDB"4S66I610Z:PQM1)2HW G(VY;@9!P*]$HH X'Q%IVK^*/
M'MG:V<[6%EH<8N_M,MKYB2W,@*J "0&VIN.0>"U,TG3=9\,^/Y_MERVI6FOP
M%Y)X;3RTAN(E &X D#<G&>Y45Z#10!XS%I6HC]G_ $2Q-A=?;$NH"]OY+>8H
M%UDDKC(XY^E=1=V5TWQ=U&Z%M,;9O#'DK,(SL+^<QV@]-V.<=:[ZB@#QO2-*
MU&/PO\+HGL+I9+6^W7"F%@81M?EQCY1R.M3R7&H7&I:;/>?VPT]KKK27=G'8
ME;:UBWR*C B/+DAE.X,V=S$XKUVB@#QTVUT=,FM]NJVDNF>*;B]N7MK1C(L$
MC3!9(]R,KCYU;@,<9..E:/V+3$L7U-KSQ6'FU(RQZNUH/,CD$(CW^6L8/ELH
MV?-'R1]"?4:* .;T"74M0\$LU_&WVN1;A%8P>0TR[G"2&,_<+KM8CU;M7(^%
M4DNH/AT!9W:MID$]O=>=:O'Y,@MPI!W =S@'H?6O4J* /*Y6U#3M0OO,%_8V
M%QXBN'FO+6S,LJK]G39L&QL!FR-P4^F1FJ%E]HT^'1+J\L]5"6/B2[FN3+:.
M\JI*DI1V"+SG>N2HP":]CHH X?XG6T=UI.B_:+6ZN+2/5X)+E;:*1W$05\G$
M8W=^U1:"WA2*[GCT2PUB&\FMY$W7-K>JA7&2,RC:#P/?M7>T4 >9Z/I=S'H_
MPOC>QF4VO-PK1$>2?LD@^?CY?F(Z]ZS;LOI?BJ"ZN[*X:(^+9YE5869F3[#C
M>J@98 @GC/W3CFO7JH7VD6VH7^FWDQD$NGS--#M. 69&0Y]1AS0!Y3XHM+S6
MO#WB_4["PO'M[_4[#[,AMW5Y1%Y2O($(W8R#SCHN:Z&[NO[!U;QE#>V%[.^K
M;);(P6DDHN!Y"Q^7E00"&4\,1PV>E>B44 >3ZU::MX,T7PQJ=G$9=4_LQ-!N
M$4YW2M&/);W"RC'T<U->Z"/"NLZ:HU#6;'3HM&2R2XTVU$Y>5'9F#@QR$%]V
M0<#)!YZ5W=UX>M+W7;;5;J:YF:U^:WMGD_<QO@CS F.6P2,G.,\8K7H \A_L
M<:#>1%[OQ-8:=/HUO!;BWM(YY69#(3#*!$X5L2+@# Y/I7:WVFV5K\.8=-N+
M75)K."U@B\N+#74:KMPWR]73 8[<_=. >AZFB@#RO.IZI%9QLUYJEC;Z_9/;
MWMQ8F&61!R^]=JY"''S[0.?:IO$VEZA/KGB:Y@L;B>*.32+KRTC)^T)#*[R*
MO]X@#H/8=Z].HH \J\40W'B^3Q#?:-9W<ENOAV6R5I+9XC/,S[PB*X!8@*>W
M5\5?N=1_X2'Q7:WEA8W_ -DCT.]B,TUI)$/,8PG9A@#GCZ'MG!QZ-10!Y%X4
M6?PW:^"M2U2QO4M8]&GLI-MK)(UO,TD;KN15+#<$(SBNO^'D<Z:/J<D]E/9F
M?5[R=(9HRC!'D++P?8UUU% 'F%EIMW'\/?"UO]BG6:+7899(_*(9%^U,2Q&,
M@8.<^AJC'<:A<:IH=S>?VPT]KK3O>VJV)2ULU/FHFW;&"V=R_,&;@DG&17KM
M% 'EUAHM^/%T'A9[.8:'INI2ZQ%.4(B9" T40;H2LLCG'H@J#0]),=[::1J-
M[XC:[MM7DN19QVJ"V&)GD64RF/[A!&?GSEB,=J]8HH XSQL[6>N^$]3>"XDM
M+2_D,[P0/*8PT$BJ2J G&2!T[URMS<:A<:C9SW?]L-/::_YMS9Q6)6VMH1*R
MHX(CS(2"K9#,3N). *]=HH \?TS2=6T77KSQ3-;7-[90:Y>HU@;<EH8I9/\
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MG>1M;>77&"<Y]C26NBWX^#^G1);WMO/;:G]KFC@A_?A%O&8LJ,IRP7Y@"#G
MX->FZ;80Z5I5GIUN6,%I"D$9<Y;:JA1D^N!5J@#S%M 36] \17>FWFM7NH-Y
M$MK=ZE L.^>WR\?EJ$0]3M)*\] 3BJD^G:GX@\-:OXGDL[^UN[W4;25+=8O]
M(CM+:1>%1@?FR)) "#G(X->LT4 >47VFQZAH.LW=E-KVJR7-UIT3S7]JL8E6
M.X5CL01HQ"AFW$KCWX.+OCO3+Z]U'Q/]ELYYO.\+^3&4C)#N)9#L'JV#TZ\U
MZ510!GZ'?0ZCHEI<P"41M& !+$T3 C@Y5@".1Z5H444 %%%% !1110 4444
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M_<VDEE:6LGG)#$SSR+ 2"^Y"N..0H7.>V,5W7B'08/$>C2:;<3S0 O'*DT)
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M\139,H#!6R5+!EWDC!'09SSFM/\ #^"\-U)?:WJEU/=V,FGW,KF(&2)^@P$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@  *,X&26/2LW2O%.O>*KO1[>RN;?31>:0UY</Y'FE)5E$9" GH3GKGCWYH
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M#J !SFFVWC6XDGU&V:RM9+BUTQ=1 AN24/+!HBVT_,I7&1D'/08H [*D+*"
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M02'K%(A *L/7OSP,<LU[5=4M/%WAS3K-;<VMXTYF\QB&;9&3C@' YS[D#IW
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MN9]$LIKP)Y[PHS%&+ Y YR0.:OT %%%% !1110 4444 %%%% !1110 4444
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M+", ,%E*_>V,1M?'?:34</C7PY<7T%G%JL3S3R&*,!6VF0$C9NQ@-P?E)R:
M-^N'&B31ZOXIT&5)DT[Q#$]S!=1QEEBD:,12JQZ \*PSUR?2ME_%^C23W=E9
MW\4M] DI$95MK-&#N4-C#$$<@'(YJIX6\<:9KUCI,4E[ -6O+*.=X$5@I<H&
M=4)X.TDY )(QSTH ;9>%7TR\L=0U#6+B^M]'MW2RA^S@,@*A2S%>9&VC X'4
M]2:E\$Z?=0V6H:K?PM!=ZQ>O>M X^:&,@+&C>X15SZ$D4MEXMT^'2Y+W5=8T
M\QF^EM$E@1T3<NX^6=V3O 4Y[''%:VD:YINNP23:;=+.L3^7(-I5D;KAE8 @
MX(/(H T**Q+[Q?H&F:BUA>:E%%<(5$@(8K$6^[O8#:F>,;B.M<_J7CJ5/B39
M^%K*2UBB$*RW,L]O*[,QD">4FW 4X.=YRO/M0!W=%9NL:_I>@QQ/J5VL'G$K
M&H5G9R!DX502<#J<<57NO%V@V=I9W4NI1-%>(7MC"&E,JCDLJH"2!D9...]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)A=GMM.D";(2<G&_&YE&3A2<#CK@5NZE:'4--N;,2F+SXVB+A<E0PP2!ZX-
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M]VURP("Y.<LWMBNFMM%,E]_:T]VTU[]E-M!(T'E^4C$,3LZ[B0N<X^Z, <Y
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M+A)(A%#<[D:ZB8*7DB8D*=N6&T9.4/M6]IEC)868BFO)KR=CNEN)@H9V^B@
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M#,>DWD=MIDL,RW/EE8$B52-BO_%E?W97T8YZ5M7&AF;Q/!KJ7;)+!:26BQ%
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M]:N=&OM'Q%$UC>W8M)Y6SNA9@=AQT(+ +[%A69I'BV[U475LL=J+^#538^6
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MB8$;2/X=Q+N1V,AIMAX($.DSZ1J>M7^JZ:UNUK#!<!%\J-AC[RJ"S <!B>*
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MC"\UFEM!)*\ZJ5#;54$Y&X9'4<^AQI:1K%EKNFI?V$K20.S+\R%&5E)5E96
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M61D'E2>^R16/T8UT&E^'_P"QO'.EP6MM)_9]EX?:T2?8=NX2Q\%NFX@$X^M
M&A8^//#VHW-C%:W4TBWQV6\_V:00N^W=Y?F%=H? /RYSP1UXJS:^+M&O=5&G
M0SS&5Y'BBE:WD6&61,[T20C:S#!X!['T-<;IVD:A%X*\'6YT^X2:WUP331F(
MAHT\R8[F&.!A@<GUJ#PMH;6]QI&E:A_PDLEYI]V\C1M'BSC*[]L@D* ,K \
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M7EG+Y<J!OO+G!!4X'!!%5(? NDBSU&&]DN]1FU&,17-U>3;I60<JJD ! #R
MH'/-2^(/%UAH_A.YURWN+:YC12L.V4;9),X"Y'H>HZ\&KFE/J4T5S)-?6%U
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M6M<ZQIHU!=/-_;B\8D+#Y@W$@9( ]0.<=<4L.JZ?<7AM(;V"2X 8^4K@MA2
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M">!MLD,BYPRD@C."1R"""1BLQO ^FS:+JVFW5S>W+:L +R[ED7SI,  <A0H
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MFN3$OG./+) 8GCC/3CKTIGA_0M3\/77@E+BRN)$MK*\@F\H;_L[2O&Z*QS@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK'>/)\[<&W 8R/F ;;G;GG%30>&[6W;5VCN+G.JN7N,LOWMH3*\<?* /P]:
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M%+>PFYD$UQ:17++;S2#'SLG0G@9[''(-7])T2WT:2^>WEG<WMPUU*)6!'F,
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MX( QD<Y%$NB^)-,TW41I>DFYU748A:F^N]6,SPK@A2=R+\J[B<#DD]Z .B\
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MX5N"N<Y.>E4O$;:CIO@;Q?I1TJ:1)[^:Z6\WQF$1RRB3#?-N$@+;=N.N.W-
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M,[H.'R6Q\P/ XQ6):7.L:E;6FGV=OK4JV6@6+6W]F7D<"QRR1L?,D#2+O^Z
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MRMQHFDR3B.\-RT4>H26\L1*%2T+[OE)_B!(#9/>G>%_!4=O82MJEFL,CZO\
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MQ"V BC&T$[@3QT4^N:I:%J=[I@?2X;G,VH>);Z!KJ4JA.T,^,[2H9BH'W?7
M'&.T/@O0#IMGIXLG6"RD,MJ4N)5DA8YR4D#;USD]#39/ _AR;2[C3I--5[6X
MN/M4BM*Y;SLYWAMVY6]P10!SUU=>*M/FT6QN]9@\VYUF2T9X$21C;F%Y$#Y1
M0)!M'0 '@D'.*S+V^U:\L(;2XUBZ9[/Q;%8B=5C5Y8]R.N\!=I()'0 ' R#7
M=IX4T6.&QB2T8+8RF>W_ '\F5D((+D[LLV"1EL\&FOX1T22WN8'M',=S="\D
M_P!(DSYX((D!W95N!R".E &!>ZYJ5EJGBZW?6$AAL;&TDM9KB!6$+R>8"<*
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M1#:NO]FDFT_TB0^7E=IZMS\OR\YXXZ5)#X9TB"[:YBM-K-/]I,8E?RO-_O\
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M(%#-]=H _(5)45M;16EM';P@B.,87<Q8_B3DD^YY-2T %%%% !1110 4444
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ML_X1O3/[0GBN+S[+'YTT3[TD?:,L#W!/.?>M*@ HHHH **** "BBB@ HHHH
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M*6"("#N;:,XX'(YYJ71_&%IK.K0V<,+I'=:;'J5I,S?ZZ-CAACLRDKD<_>H
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MPYJ%]/>W>D6TMQ/_ *UF4_.<8R1TW8XSUQWKG?$OC'Q%I?AG4KC^P#97]L\
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M7+XF2%IK=+1;M8PV"RD @9^AK,;QP^GWEU%KFDOI\46GR:E%()Q*7BC(#!E
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MSLC&6=B0%4>Y) _&@"&]\+Z)J.IIJ5WIL$UVFT^8PZ[3E=PZ-@],YQVJ*_\
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M$/W49S]Y5)EP#D?(/2MNTATNQ\:>&+/2+MI;*(ZI$JM)N6)P8B8E/HOS #G
M&.U=G<>'M&NM)CTF?2[-]/CQY=L85\M,=-H[?A45QX6T"ZTRWTV?1[)[*V.Z
M" PKLC/JH[=3]<T >:B.WU:6RA=S+:S^-+I6VN<.GE2Y7(ZJ<8([BJ^J^'=+
MMO#WQ"DAM50Z3<%]."D@6;>1%)F(?P99B3C%>LPZ'I5NL*PZ=:QK#,;B()$
M$DVE=PQT."1GTI\FD:=-#>PR6-N\=\<W2M&")CM"_-Z\ #GL* /+-4L-3UG5
MO$]X(]&CN[.[B2VU&_OGAEL0(HF0H!&P"EF)^\-Q)!JQK6B6&I?\++O;V 37
M%FN^U9B3]G=;*-@Z?W6R!R.>!7HEWX<T6^U&'4+O2K.:\AQY<\D(++@Y7GV/
M(].U66TRP=;U6LX2M\,70*#]]\H3YO7Y0!SVH \MATFQOO$OB6YFFM[&\E\/
M6KC47PK022I*K2;N,=LG(KI_!-O%I6K:CI+Z+:Z5?)!#-(MA.7MID)=5D52
M58E6!R,G Y.*Z*?PWHES>17<^DV<MQ%";=)'A4D1$$%/]W!(Q[GUI^DZ#I.A
M1R1Z5IUM9K*07\F,+N(Z9]<=O2@# \<HEU?>&=.O.=+O-2\N[0G"RXAD9$;U
M!<+QWP!7$^(;6*SM_%.CZ:3;:9#JFE>3' VU8)7D3S F/N_P-@="?>O7;_3K
M+5;-[/4+6&ZMGQNBF0,IQR.#56#P[HUMIHTZ'2[2.S$@F\A8@%W@A@V.[9 .
M>O% %C3-,LM&L(['3K9+>UCSLB3H,DD_F237!:OHFGZWXY\4IJ5NMS%#HULT
M<<G*JY,_S@?WAC@]1DXKTBJ_V"T^TSW/V:+S[B-8II-HW2(,X4GN!N;\S0!Y
M-I\5GHMIX#U_;+]KO-.FEU"Y5B9KA?L9E(8G[V&48STP,5%I^GPP:G;VK:9I
MUI;ZCX=NII;>&Y:=YU'E%'G)4!GY;YN<Y;FO65TC3ECLXQ8VX2R79;+Y8Q"N
MW9A?0;>/I52S\)^'M/,+6>BV,#0NSQF.!049AM)!QZ<?2@#RW2=)^T:5X&TR
MTTG2[JTN-%>\>UO96BAFN-L(+G:C[G"DX!'<GM5]=%%]J/@32=8GM[^W\O4E
MD6VN&EBDC4J8XRY +A0%!R.2O-=__P (;X:_LW^SO["L!9B4S"$0*%$A&"P'
M8XXX[<5H1Z3IT+6;16-NALD:.VVQ@>2I !"^@( Z>E 'E]U<06'B?XEK)%+)
M!Y.EVZPPS&(GS$\M5W_PC+#)[#-9NKP-IOA[XC:6+;3[*.'3;20VFGR,T,;M
MYH8\JN&(5,\=A7KTVAZ5<-?--IUK(=054NRT0/GJHPH?UP.F>E5D\)>'8X6A
M31; 1M ;=E$"X:,MN*GCD;N>>] ' ZW8P0C^WKJTL]6LK/3K8W""Y,=WIH52
MV^+MR#G&5)QU->K]163=^%]!OKNWN[O2+*:XMU58I)(5)4+RH^@/3TK6H \'
MN]$TRQ\/?$^>TL;>":UNC%!)&@!B0I&=J^@S7:7WAW28?%OAW0)K2-M(FM[N
MZ:"7YDNKH>4-T@/WVVEVY]SVKM'T/2I(;V%].MFCOFWW2&(8G; &7]3P.OI3
MM3T?3=:MEMM3L8+N%6#JDR!MK#N/0^XH \L-K%<6]EI(9SI4/C-[6W17.! (
M'+1@_P!P,77'IQ4.J^&])M]*^(PBM%1-*/FZ<BDA;-_LR2%HA_ 2QR<8Z5ZS
M%HNF06MI:Q:?;1P6;B2VC2(!86 (W*.Q^9N?<TZ32=/E2]22R@9;[BZ!0$3_
M "A?G]?E '/84 36CM)9P.QRS1J2??%>-2:-IT'A'QB;:VCMY&\31V_F0C:Z
MQBXMR%!'(QDD5[4JJBA5 "@8 '85EMX:T-[NYNVTFS-Q=%&GD,(S(5(92WJ0
M54_4"@#S7Q99Q^&M2U^TT&&.RM[C2;22>.-S$A+79C=R1DJ?+)!8#..>:ZKP
M=H]UH^OZG&8-&T^UDMX6_L[3;II0CY<>:5*)MW#C@<[*ZN;3;&XGEFFM())9
M8?L\C/&"7BR3L.>JY)X]ZATK0]*T.&2+2M/MK-)&W.(8PNX]!G'6@#FOB6DT
MFFZ$EO<+;S-KEH$F9-XC;<<';D9QZ5JZ99ZU;SR-J/B*#4(3$P$*62PD-ZY#
M'MGCWK3U/2-.UJS^R:I907EON#>5/&'7(Z'!JAI_@SPSI-ZEYI^@:=:W2 A9
MH;=59<@@X('<$B@#S#1?#VFMX=^'-T8#]IOY1!=S;SOGB,$C>6Y_B3Y%&T\8
M&*DN[&QMYFT;_CWTJ/QI%"D*,41$>U#&,8Z*S,>!_>->M1Z1IT,-E#'8VZ16
M)W6J+& (3@KE1VX)''J:Q_$'A.VU=['RK>T6-=36]O4DCR+@")XR",<D@J.>
MPH \V\:6EMI7AGXCZ7IL:P:9#'82);Q\1Q2NPWA1T&0$) ]?>NJ?2]*U_P 8
M>)4\1113Q6-G;?91.>((FC9GD3^Z=P/S#GY1S771>&-"ATF;2H](LUT^=M\M
MOY(V2-D'+#N>!U]!3M3\-Z)K4L4NIZ59W<D0VHTT(8A>N.>WMTH \WTW6)_#
M6F^%_&.K22&WO](%IJ+N>2Z(98)#ZL0'7/JXJM;:!J4NIZ9I]_ING:C-<Z=-
MJ=Q;ZE<O%']IEES(P"HV612BC@;1TZUZ!XC\/7GB&XLM/E:SCT&*2*>XCVDR
MRM&VY8Q_"J9"Y/7@BM75="TG78HX]5TZVO$C)9!/&&VD]<9Z9H \WTO1$U3Q
M;X<L-;N(-32'P])(6BG,L,Y6= C%N-^ 0<D=1FM_Q?X=BO=1L?L=AI-_Y27$
MTNCW<GE"X+E,S*0"-ZD8W$8^<\@UU\6FV,-S%<Q6<$<T4/V>-TC *19!V#T7
M(''L*@U;0-(UU(DU73K:\$1)C\Z,-MSUQZ9[^M $7A>[MK[PMI5S9K,MM):Q
MF-9WWR!=HP&;)R??)S6M3(HH[>%(88TCBC4*B(,*H'   Z"GT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5@^*M?N- M].:TL5O)[V^CLTC:7RP"X8@DX/ *C/'3/TK>KC?B&MRT7
MAL6;QI<_VY 8S("5R$D.#CG!Z<>M %6_\>ZAHVG:Y_:6DPG4=)DM=T5M.6CG
MCG<(K*64$$?,,$=5Z\U/>^+=8LKFUTR:TT>#59('NI5GU I#''NVHH<IEG//
M; VGKQ534/!FLZU::[<7TMA!J&IRV02*&1WBBBMY0^-Q4$L<O_".WUK3\1^&
M;J]U^#6;&RTJ^E%J;26WU,$)C=N5U8*V""6R,<@]1B@"I;^.-0UJZT^UT+2[
M>22]TP:AON[@HD7S[&0[5;)SQQ[U'I7CS4[^'0-1N-&@M]+U>?[(I^TEIHY=
MKG)7;M*;D8#G.,' Z5K:7X;N[+Q)::G+)9[(M)%E(EO'Y8,GF!RRIT"]>^:S
M[+P;?6WASPOIKW%N9=)U!;J9@6VNH\SA>.OSCKCH: ,S2_&,=GH$LUCIUM:O
M<:]/8 W=ZXA5QN)D=R"5SLP% QD@"M:]\8:E:R6&GO9:9;:K<12SR_:K_;;K
M&C!05<*2V_((& 0,YZ8JOIGA+6M&\/WEE$-)OC<ZI<7<MM=AO*FAD)(0MM.U
M@<'[I'&/>J=MX OM.2QNH+31;R>);B-["ZW?9HHY9/,58FV,1L(Q]WD,>G%
M%I/B!=ZD=.CTBPL6N+FS-T8;R]\HR,KLC11$*0[!E// Y4]^.[C9GC5F0HQ
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M@IO0CKG'..U7+7QC>_\ "46FE7]G80)>S30PQ17HDN8BBLP,J 8 94)X)QD
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M!;JYM#>VS->-LCC5@K"7"9W LG"Y'/7C-3W/A*\E^%TWA5;J)KM[%K99G+;
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M#Q%AA<+\JE1RV<@G@<9J?3O!]]IFK%(K+0I+ W\EX+R6$M=*KN9#&!MQD,2
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M&&.>['@ =2?0'@]*X^WT+7=,O=1\0FST:WU"/3)H@E@LC+?3<,LDJA5/!4@
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MQ(?]GGG\*=-=6]O)''-/%&\IVQJ[@%SZ 'K7E7B+2X3XGUZQ=?#UI8PZ5"L
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M -$V\+3^>88S,$,?F%1NVDY*Y],@<55@T72K6VFMK?3+*&WG.98HX%59/]X
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M:Y34XM+N+:39O@ED(",<-@H=P.5)XH Z*;2M.N;6&UGL+66WA(,44D*LD9'
MV@C QVQ2KI>GKJ+:@MA:B^8;3<B%?,(]-V,U@ZEXYM-,36&ET^]?^RKB""<1
MA#GSMNQE^;)'SKGO[4V3QI<1:A%IK>&=5&H30S30P;H/G6-U4_-YF!G<#R1^
M)P* .G@MX;:/RX(8XDW%ML:A1DG).!W))--^R6PN'N/L\7GR($>38-S*.Q/4
MCVKGM.\;6.KV>GO8V\[7=\956SD 1XC$<2;\G VG [\L,41>-]/G@@"QO'=R
MWSZ>;:=E0QSHI9E9LD=!D8SG<,=> #4/AS0F@C@;1=.,,3EXXS:IM1CU(&,
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M)-I]E<B83V=O*)PHE$D2MY@7E0V1SCMGI5(:O=?V)>W\FD7,$MN)"EM,Z!I
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M3KR_L].MS<7UW!:P@X,D\@1<_4\4 <IXYE>/6_!WDF'SO[7)597V@_Z/*#R
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M-*X".95RN/Y?4U?M-2L-0\W[%>VUSY3;9/)E5]A]#@\&@#E?&4LD?BSP6(#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS+QIIUI:ZGXD@M;.&*-O!\Y,<484$H[;3@=QGCTI3+9S>,?A<]@\#P?9K[F
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MX$AL;%8[2%[U9;.<9:*=(QN60'JX;DD]3AO0U1B2TM-?A6]6&+0X/%=V)%D
M$,<AM@8MPZ ;R<=MQ%>N+;0++YJP1B3);<$&<G@G-#VMO)%)$\$31RG,B,@(
M<^X[T >37:6X;Q-KNE>6VFZ5K-IJ$+08\MF2-5NMN./N,P)'<&LVYFN8+26]
MA++-XYAE@C([,UP%A/X03,<_[%>UI;01V_V=(8U@V[?*5 %QZ8Z8I?L\!$0\
MF/$7^K&T?)VX]* /&=:M&M=6^(]I8+LCATW38]NTL!"H(<$#!(V!L@=J?K=N
MC:5KMXFL:->0FWL4OH-'M6CB%N+@$LYWN"?+\P8Z[?;%>Q^5"CO+Y:*[@;WP
M 2!TR:CM[2T@@:.VMX(X7R2L: *V>IP.M 'E/B&73[KQ'XC/AEK>28^$YU+6
M)!4OO& "O&[;CWP5]J9J,NB7&L>'!X2:V:\&CWJH;+'R_P"C_N@VW^+.< \]
M:]6&G6T=L\-K$EIF-D5[=%5DSW7CCGGZUS^C^$;JSU>TU#4]6CO6LHI([9(K
M-;<;GP&D?!.]R% SP.3Q0!S/@6WAEU3P_/!K.B.T.ENHM-.LV25HB$R)6\QL
M%6"]0#G=[UM^)'LX?B'X=EUAH5TX6ETL+7! C%SF/&2>-VP/C\<5V$-I;6\D
MDD%O%$\IW2,B!2Y]21UHN(+:\C:"XBBG3@M'(H8>V0: /'H[2SOSI$*Q1RZ-
M-XRG:T0#,3P^3(3M'0H9 _L?I7I'B^&:/P%KD.FQ[)ETZ=8$B&,'RS@*!^E;
M?V>$+&HACVQ?ZL;1A.,<>G%24 >3_;O#B>(_!D^A+:SM!IUTS)9E=VP6^55M
MO0DAL \_>]ZHZ%/:2ZYX=5)]$,5SH]RHM-/@($0=8V6*1R[>8W!X(!RI..:]
M>AL;.W;=!:P1'<6RD87D]3QW-$=A9P@"*T@3:YD&V,##'JW3K[T >0:#J.F_
M\(IX)M()M"MY!82RR7M^OF1PR(D:NFP.H,A#_P 1R IKN/AC,LO@&P59%8Q2
M3Q,%7;L(F?"[2<K@8^4]!BNE_LRPVA?L-MM$GF@>4N _][IU]ZGCABAW>5&B
M;V+MM4#<QZD^] 'CEHVGGP'HUK&;?_A*QK46]!C[2+D7692P^]]S?DGC;[5T
MW@^TMD^)WCQDMX5:.>SV$( 5S;C./3-=R+.U6[-T+:$7+#:9@@WD>F>M2+%&
MDCR)&BN^-[!<%L=,GO0!Q&N?88/BWX<EO/L\?F:?=)&\VT;I-\.T GJW7'>N
M9TG3[.W\!^#+N*VB2Y;786:8*-Y+3.IRW7IQ].*];FMH+AHVF@CD:-MT9= 2
MA]1GH:46\(C2,0QA$.Y5VC"GU [4 >0^%K:2>?1%NM9T:#4(-5GD>W2T;[<T
MH:3S5=O,/!4MDE0,;?:NI^*)C&C:*9KTV,8UJUW70=5,(W'Y\L"!CKDC%=FM
MI;+=-=+;Q"X8;6E"#>1Z$]:=-;PW,?ESPQRIG.V10PS]#0!Q6FW6D!KI+;QZ
M^M326TBI:2WMM)GY<E@L:AL@ _AFN:T?1=-;3/A7FQ@/FQEI"4'SDVC/\WK\
MP!Y[@5ZI%IMA!('BLK:-QD!DB4'^53""%1&!%&!%_J\*/DXQQZ<<4 >-.FEV
MWB*VBOT@CTZ+Q?=?(X C3-H",CH!O(/I4'BTVS^#/B%)IAB.E-JEEY)@QY9D
M!@\TKCC[W7'?->KZIX>AU+5=)O"R1K8W$D[Q>4")]\31D'_OK.>>F*TELK5+
M46JVT(MQTB$8V#G/3IUH \[O9=#M_$GCC_A)&M%:2WA\@7>W+VWD8Q'NZCS/
M,X'<_2LMKS4?!&EZ!XAFAE>XU'1(]/NHB"6:\2/=;[O]HG>ASZBO5I;:RNY8
MVFAMYI(B2A=0Q0]R,]*R=3T"75]?L9[S45;3[*1;F*P2$ M,HPKN^<D G(
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MV_[70'T-<WX&N[>PT3X:75Y/';V_V?4(S+*X5 Q((!)XR=I_*O8K>RM;3?\
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M/S"+4]5BNBK7\VE6R*J9:(QW0._W_P!9T]JTKGP=J>K#7+C5M2M6O+_2VTN
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M/3+9@+F:',!/3S%(9,^VY10!R3:3>:%XV\/Z5H/V83)HERKW%VK.,^;"SR,
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M#&JA5W L?FXYQQ[5S]]X(U>==0MK75K2&SN-275(PUJS2&42)($D;=@H"G8
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M27/A_P 0:8+Y%;5M0-XLGE_ZL$QG:1GG[G7WJ77_  :-=U2]NWO/)6XTY+-
MJ9,<B2^:LG7!PV./;K0!#X2\7G6]7O=+EU#2=1D@@CN$NM+8F,ABRE&!9L,I
M [\AAP*9XBOM<B^(?ABQL+NWBLKF*Y>6.1&._8%SG# 'AAM]#DG-;FC6FM0R
MSS:Q?6<Q=56.&SMC$B8SEB6)8DY'? P/<U5UW0;V_P#$.B:Q87=O#+IQF1XY
MXBZR1RA0V,,,,-HQ]: .+T#6=<T/P]]NCCL&TD:]/;2QN',[B6]9"ZL#M&&?
M[I!S@\C-71\2P=;"_;M&^RG5/[.^P>:?MN/,\KS?O8QNYV[?N\YK:/@R3_A$
MVT7[:NXZG]O\WR^,?:_M&W&?3Y<_C4EAX<U?3-0>&RU2UCT=[U[PQFUW3C>Q
M=X@Q;;M+$G.W(!P/6@!_Q&D>'X<>(9(G9'6QD*LIP0<=C7/:#8^%VU*P-OX9
M\107(=62>XANEC5AR"Q9MN,COQ79>*-&;Q#X7U+1TF$#7ENT(E*[@N1C..]9
MUI9^-HI8%GU;07MT90ZIITJL5'4 F8@''?!H P+_ ,:^)+>QU?5H+/37L-*U
M4V+0-O$MPOF*F5;.$(WCJ#G!Z=WZOXS\0^'O[:M[ZVTZZN[2UMKRV^SJZ(RR
MS&(HVYB<@CAAC.>G:M2X\%23^'M:TL7R!M1U,WXD\OB,>:C[<9Y^YC/O63\2
M= DDL-8UE+DCS[*TLA&B?,I6Z#[P?^!],=J )M6UG6HDUK0M;2P9I]#N;RWE
MLU=0H4;71@Q.2-ZD,,9YX%5/">L:JWASPEH&BBSCN6T..\GN+Q&D1$ 5%4*K
M*222>XP!WK:?PGJFHWNH7NKZE:R7$NF2Z;;?9K=D1%D.6=@6)+$A> < #WJ*
MS\&:CHUOH<VDZC:C4-.TT:;*;F!FBN(_E(. P*D,N1R>I% $=AXWOI+G1UOK
M2WBBN+^YTJ]9"Q$5U&2$VD_P/M/49!(YJGJ?Q#N+?4+F!)M+L;1]1:QM;V_8
MB-?*CW3.WS#=\Y"* 1SG)IGB73+;0? ,VCR74EWKM_</=VC0Q?/-?&42!E49
MVJ'*]^%ZFM>/P;<6>A:#%87<*:II):3S9XS)'.\BD3;@"#\S,6R#P0* ,F+X
M@:IJ-OH\.E1Z7<WEYJ%QI\DRNS6Y,<9<2H0<[2 &QDGJ,]Z[]99+;3A->M&9
M(XMTS1*0I(&6*@\XZXKG_P#A&M1N;[0+[4-3BFN=-NIKB3R[?RT<21N@11G@
M+N')))QSUKI98DFA>*091U*L/4'@T >87.JZ[K47@G5=0BL4L=0U:&X@B@#B
M2!6BD*!V)(?*GD@+@]CVM:1\2QJ.L:>#?:-):ZA>/:I8PRDW< ^;8[_-@Y*C
M*[1C<.3BKEEX(UF&+0+&YUJVDT[0KE);94M2LDJ(K*HD;<1D*V.!SUK2T3PY
MJ^BSP6<6J6O]BVTLDD<8M?W[(Q8B-G+$;5+=0 3M'3G(!S]OXU\4SZ5HVK"S
MTHVVIWQL%@_>!U8LZK(6R1MRG*X)QWR<"^WBS6K6WUJTOI=%AO=-NX86O96:
M*V$4J*X<JS9+#)&T-R<<U<M?!4EOX>T'3#?(S:7J(O6D\OB0!W;:!GC[_7VJ
M+4_!5Y<:Y=:Q9W]NMRU_;WL,=Q"7C!C@:$JV&!.0Q8$="!0!0@\>ZE<Z);RV
M::;>7CZV-),T9802 IN$B\DC@KD9/0^U23^,M<T]]1TJYAT^?5XKZTL[66)7
M2!_M R&92Q8;0&) /.!TJS;>"=02X\RZU:&<'68]7+"W*DN(]CI]XX7(&WN!
MP<]:EUCP3-J&H:GJ$&H)!=3W%G=6C-%N6*2WSC<,C<&R0<8X- '/SZOK.A>)
M_%-_>16DUY;Z;8*)(4<1%&FE!E9,E@%#,2 3PAYYX[;PQJ5WJFG/<7-WIEZG
MF8ANM-<F*5,#G!+;2#D$9/3\*R;?PQX@CU/5-8;7+5-3O8+>-/+M"88O*=FV
M[68DJP;!Y!Y)!' !9Z'K.BB:[MYK,WFH:G!+=16EMLA6$!4? +$ABH+%NYXQ
M0!K^,7:/P1K[HQ5UTVX*LIP0?+;D5PGAFR\,3Q:.Q\->(A=NL)-S)#="+?@?
M.6+;=N><],5Z-KFG'5] U+3%D$37EK+;B0C.W>I7..^,US^GZ5XVL+6UM!K&
M@M!;HD0SILNXJH Z^=C.!Z4 96K^-/$-G!XFU"UMM--CH%V(W20.9+A-D;L
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M5+.'Q9J3EF7Y8_W3D,?0!N<]NM '<>(_&]MIWA--=T:6UU*)KJ*W#))N3YI
MIY'<9Z5L:EXET/1[J.VU+5K*TGD&Y8YYE0D9QG!/ SQFO)O$TD5_H'BG4M/(
MDTR[\06+6\D?W)640K(Z^H+ C(ZD&NCO=2TO1=;\<0Z[)''+J"1M:I*.;J'[
M.$"1C^,APXVCG)]Z /0X;ZTN+JXMH;F*2>WV^=&K@M'N&5W#MD<BLZX\6>';
M2*&6XUO3XHYG9(V>X4!F4[6P<]CP?0UYW?'5O!&F>']62"1[^_T:+1[B/&3]
ML$>;=F]]V]"?<4RZTN+PCJYT^YUVWTNQ.AP6T<US:"8715I?.5<D?.2X8J,E
MMP]* /3KSQ!H^GW4=K=ZG:07$AC"122@,Q<D)@=3DJ<?0^E7;JZM[*UENKJ>
M."WB4M)+*P54 ZDD]!7GWAG3(;7XAP1L7N&M/"]G%'//%M<CS)!D@_=8X&1U
MKH?'EY]A\*32F*V:-IX$DDNHO,B@5I4!E9>X3[WX4 &H^/?#FG^'GUO^U+:X
MLUF6 -#*IS(2/EZ]<'./09KH+6Z@O;6*ZM9DFMY5#QR1MN5U/0@CJ*\4U>^C
MFTKQHQU,:AN?3;I;@1",31)*@>157[R#;C<...O2O:K2[M[^TBN[2>.>WE7=
M'+&VY6'J#W% '-^&?'.F:W:64=S?6-OJMSOQ9"8;_E9@, \Y(7.*NV_B*VAM
M]4NM4U+2HK:SO&@\R&XR(P,867.-LF3RH]17!:=;1Q?#GPD4B57/B&%R0O.3
M=."?RX^E5].6S6U\537VI/I9B\82RV]]Y0=(9 B[6D!XV'D9.!DCD'% 'K-A
MJ%GJEG'>6%U#=6TGW)87#*V#@\CWJG>^)M"TW4(["^U>RM[N3&V&695;G@<$
M\9[>M9_@?4'U+1)YY$LV(NY5^U647EQ7F#_KE&3][N<GD'G%<;J5]IVG:=\0
M-)U9D&JZC/*UK;N,R7:/ BPB,=7P1MX^Z0>E 'HUSK^D6E^EA<:G:Q7CND:P
M/* Y9\[!MZ\X./I5;Q/K;Z!I<-XD<;[[RWMV\PX"K)*J$_@&)_"N9\)V+Q_$
M+5WO8P][!H^G1M(W)#$2;\'W*C\JTOB-"EQX9MH9(Q)')JEBKH1D,IN8\@T
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MID'M0![-8:C9:K9I>:?=0W5L^=LL+AE..#R/>JNI>(M%T>YAMM2U6SM)Y_\
M5QSS*A89QG!/3/&:Q_ L4!MM5O;?5QJB7E\96N([?R8F<(BL8\$A@=H^8<$Y
MK$O]3T?1/%GBU?$H4Q:A;6_V6)TW&[B$95HHQ_$V_=\HY^8&@#L=1\3:'I%W
M':ZCJ]E:7$@!6.:958@G .">!GC-.O?$6BZ=?P6-[JMG;W<^/*AEF56?)P,
MGN>!ZFO/Y-1TG1I_&EKK*K;3:C%&UG;SK\]Q ;946)!SN(8.I49P3[YJC=3_
M /".Z?;B2_MVUDZ7917VAZC;[QJ+(F (CUWY+#C<,CD=Z /1-'\7:-KFLZEI
M5C>1276GR;)$#J2W"DLH!S@%MI/J"*NZKKVDZ%'')JNHVMDDI*H9Y0FXCKC/
M7%<QX1O+>+QMXRTZ29$O7OTN5@8X=HO(B&\#N,\9IGB[5!:>*[&WDO+73 UC
M*T=W):B::=BZ@P19XR< E0"3QQ0!T]]XBT738DEO=5LX$>+SD:291O3(&X<\
MC++T]14MIK6EW[VZVFH6L[7$)GA$<H;S(P0"RXZ@$@9KS7P$(;G5?!I(622T
M\.3QG/)BD66%&7V8<C'UJ."/^RO"=GXGA0@Z%KE\TJJO_+H]S(DH ]@0_P#P
M"@#U6&]M;BYN+:&XBDGMBJSQJP+1DC(##MD<U3O?$6BZ=J,.GWNJV=O>3X\N
M"695=LG X/J>!ZFLOP'92Q>'CJ5VA2]U>9]1G4]5\SE$_P" H$7\*X;Q_J9D
M?Q=9"[M[.:..()9Q6H>XOD$:OYI8\[%RPR!\NP\YH ])O_%7A_2[@P7^M6%M
M,KB-DEG52K$ X()XX93_ ,"'K2:QXFTC1F\BZU*SAO'B,D,$LP5I/3CT)X]S
M7$SI:WEK\4;R$13)<6RE)5PPD3["A7![CG(^M4K;4=.TN;Q)!K3J)M2TFT^Q
MQ2#+72"WVE(Q_$=^[@?WJ /2?#VI/K/AK2]4DC6.2\M(KAD4Y"ET#$#\Z2#Q
M%HMUJTFDP:K9R:A'G?;),I<8ZC'J.X[53\"\?#_PYG_H&6W_ **6O.K/6H[C
M5_#4\M_:0"/6IC/IUO;+&M@SK.@$C]0[,PZXW%B0* .@;XC7B^&)]5^P0>9%
MKQTH)N."GF!-_P!<'->B5X1(K?\ "N[T;3G_ (30GI_T\"O9/$<%U=>%]6M[
M+/VN6RF2#!P=Y0A?UQ0!%:>*_#]_//!::U83RP(SRK'.I*JOWFZ]!W/:L+P;
MX[7Q?K.JPP2::+2TFDBA2.X+W$JHP'FE<8"-G@_2L33]1TS5[CP%9:&\;W>G
M-ONHHQ\UG$+=T=)!_ 2Y48/4CVK7^& (L?$F01_Q45]_Z&* -RZ\7:-9^*K7
MPY/>1)?W$+2JK.HP=RA4ZYW-N) [A35+POXYTO7;*P2XOK&#5KI&;[$LPW\$
M\ 'GH,X].:I:I>6^G_%_1Y+N9($N=(GMH&D.!)*9HB$![L1VKG-+MHX?AUX'
M,<2JW]N0.2%YR99,G\0: /2(?$&CW&K2:3#JEI)J$>=]LLRF08ZC'J.X[5!X
MJUT^&O#=UJRVOVIH#&!#YFS<6=4'S8./O9Z5YSX6A$EQHNEWOB)%U&QU*69M
M,2Q'GI(#(79W!R$8,?G(P=P]:ZWXJ[?^%;:KO8HFZ#<RG!4>?'DYH T;#4_%
M,U]%'?>&K2UMF.))DU/S"@]0OEC/YU8_X2WPZ+Q+0ZYIXN)-P6/[0N3M)#=^
MQ5A^!]*Y?0=4\'KK=J++QK?WUT[;([:?4Y)4D8C&-IX/7CWK!2QMY? -DLEN
MC";Q>#("OWLW[*<_\!X^E 'I%MXIT"\LWO+?6;&2V258&E6==JR,0%4G/!.1
MCUS52]\8::WA76=9T6]L]1.G6TLQ6*4,-RH6 ;'3.*X#QH((_$'B)KB$O;F]
MT-I45-V\>:X88'4D#%6M>O;/6KGQQJ6C31W-@OA@V\UQ =T;S@3,%R."P4C/
MID"@#M[?Q=I</AO2-5UF^M-/;4+6.94EE"@ED#$+GD@9K5AU73[F>&""^MY9
M9X?M$2)(&,D60-ZXZKDCD>M>;Z#?V6@ZIX>U'6[B*TLIO"MK!;7%P=L8D4[I
M$W'@,04..^/:JUM!+H?@O1/%@@EBCTK4+F<Q%"&&G3S."-O7A61P.VV@#TB\
M\1Z+IRW#7FJV< MY%BF\R91L=AN53[D<XZXHN?$NAV=E!>W&KV45K/&9(9FG
M4+(HQDJ<\CD=/6O,FL[S3%\-:]>ZC%I#W\UY>WEW<0B2.":=4,2MD@+B-2@)
M/;'>K.G:=:'7_ ^RY.HVTEWJ=U'*]MY2$L"V50]%W$E3TZ$=J .V3QCIL<FJ
M/J$T%C9V5Q%!'=33 +/OB24%<X[/C ST)K<M+NVO[2*ZM)XKBWE7='+$P96'
MJ".M<SXX:R@32KJXU@:-<6]RS6M[+$'@1S&RE9-V  5) Y!ST-7/!=Z^H>%K
M:Y>VMH"TDW_'K&4BEQ*P\U%/(5_O\_WN_6@"KI7CG2[B]NK'4;ZQL[Q-1FLX
M('F :4(VU3@GJ3^9Z5JZCXET/2+R.TU'5[*TN) "L<TRJQ!. <$\#/&:\KOK
M[3!X4\<:-E!K-_K-R+6W(_>W$AD41L@ZM@CJ.F#TK9O=1TW1KOQW9Z[)&MYJ
M(#6T<@^:\B-NJ*D8_C(<.,#H3[T =[JGB/1=#>)-4U6SLVE!*+/,J%@.IY[>
M_2JIU]CXTM-$C2-[>XTV2]$X;)RLB* .Q!#YS7%:#>6OA35KC_A+IX[:6?0[
M"**2ZZ2>6C":-2>K;SDJ.3N'%<W'H7B.YB\.:98R_8[[_A&9O,BF#*SQ>=&1
M#N!!0D;5)Z@9[T >NW'BWP[:6T5Q<:YI\4$KM''(UPH5V4X8 YYP>OI6PK*Z
M*Z,&5AD$'((KRN\UK0VL]+U/3-4MO#US#8RVHL]0M@UN55AOMG'!#JRCA3D@
MYP017<^'M9M;RSL+'R!97_\ 9T%U)8",J+='& O3'!4KCJ,=* +^HZQIND(C
MZC?VUHKABIGD"!MJEFQGT )JL_BC08KFTMI-8LDGO$5[>-IE#2*WW2!GOV]>
MU8/C&WCNO&'@B.:,21C4)FPPR,BW<@_F :Y77H5_MSQ9IFH^($TP:E/%Y-O]
MA$TUS&88U0PG()*L&&%!VD9[T >EW7B/1;'5(=,NM5LX+Z;'EV\DRJ[9Z<9[
M]O6FW7B;0['4TTRZU>RAOG*@023J'RWW1C/!/;UKB(]2T72;WQ5I?B2+[3>W
MNII+#:>7NEO8RD0B\L?Q8*D<'Y2ISBL[5+RQM/#?CK0;XK_;FH7MRUK:L/WU
MSY@'V=HQU8#Y1D=-IZ8H ],FU_2+?44TZ;4[5+UW6-;=I1YA8C(&WKR.:QK[
MQQI@U+3;'2[ZROIKC45L[A(Y@S1 HY+8'H4Q6/HEC*WC7QFY4-J(L;*))CU#
M&%LX/;+ ?D*Y[3=3TBYTGX;Z;:;&U&PO(8[J%5^>V802+(LG]TEQT/7&><4
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MC/-\L<4SN-FXGA<JK@$_UI8)%R-4M+M-,TN/Q3=RM=S6^Z.'?!B.1E. %))
M8XQO% 'K+>)-$2P@OWU>R6TG#-%.9U".%!+8.<' !S]*S=1\?^&M.TVRU!M5
MM9;6\N5MHY(YE(W%@&).> N<MZ"N/TVRM9-:\+3QWXU2"YUN]NA/]F\J,O\
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MHV'Y@!T/'O4.N22:MX[TK3;FTM+G1YM+N9WBN)2%8;H5+E=A&Y0S <_Q'D4
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M1VWLJNRQE8R&*JZGDKGIQUH W=;T:/6[6V@EE>(07D%V"HSDQ2!P/H2N*TP
M.@KD;_QK-"]T^GZ/<W\-G<I;SB&.0RDG;N**$(.W<,@L#PWMG2GTJ#3M:O\
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M.5 B9N06^Z">BD]LXSVIMWXLT&QU/^S;K5;:*[W*K1LWW6;[H8]%)XP"1G-
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M+ ;N\ACBF^S6_DI(5+'>R[FRYW8SZ"LSX@>8S>&E@E6.5=:ADW,A<(H23+,
M1\O(!.1UZUV5% ')WW@>+44O+B>]*ZK/=P7D=W%%@0R0C$0"$G*@;L@GG<W(
MXQ:/AR[:ZO-2.HQ+JUQ'!")TMB(TBC<OLV%R2&+,#\W0]L5T5% ')VG@O^SX
MKN.TN+2.*]NFN+JT-EFV<-&J%1%OX^Z&)R<DGL<54@^'\VE+IDN@ZV^GW=G
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M< 5OZ5);:G\5;G5;4>;;OH,"PW&P@$&>7(!/T%=Q10!Y!;RJW@?3/"2QR_\
M"20ZI$9(?*;=&R77F/.3C&TJ"V[.#NQ73>!XI(_&'CEGC=5?4HRI88##RAT]
M:[FB@#SF[U&ST'7_ !G'K"2;M32)[,>2S_:HQ (_+3 .2'#?+_M9[U'X0TJZ
ML?&6CQW\#?:K7PC;0.[#.UQ(0RY]>*]*HH Y+QS?O9+HV9DL[>2]Q+J#6PF-
MIB-RK*&!"LQPNXCC<?6N,T%#<ZSHT4PN9WB\37<[M<P!'*M;2-'(RA0%SP1P
M.?0U[!10!Y?J6DW5TGC6ZLXB+[3]7AU*QXQNDCMX20/7< RG_>KH? 1_M2WU
M'Q4Z,C:W/YD(<89;:,;(@1[@%_\ @=;>O:,==T\V)U&\LX)"1/\ 92JM*A&"
MA8J2 ?5<'WJ_;6T-G:PVMO&L<$*".-%'"J!@ ?A0!YXFI:=HM_XHTS7-/FO+
MK4-3$]O:"W,AO(F2)4VY^4[2I!R?EV\XK,U.XBM/#7C7PW<PRMK6I7MTUI;B
M)BUSYN/)=3C! ^4$Y^78<XQ7K=% 'E,FJZ=H^N^/+?5 S7%Q;VT*D1,_VEOL
MH'EK@'+9/3_:^M4X]&U5?$%AI_ER+?#P$UH7/:?*KC/KFO4;'1H+#5]4U&.2
M1I=1>-Y5;&U2B!!CCT'>M&@#R'3;?3M5L(EO=5U;45L]%F@GLH=/6)K:-T17
MB)50=_RC"\GY":ZGP3J4UYJNH0#4$UFTA@A\K5/LODR$DO\ N7( #E1AN ,;
MSD<UVM% 'F.M3);^)/B!:2AUGO\ 1(S:KL/[[9#.&VG&#C(IVM:;<S6OA"TL
M(2DW]D7D$>U<!&:U 4>W./RKTRB@#R'2XHK_ $Z,KK-_>76GZ'<1?9#8+"MJ
M&C53$Y"@[LJ,+SG:35NZLYK/P/\ #^YCN)=.M;)(7N9X[<2&W+6S*'9"",;F
MP21QNS7J=% 'E%O';Z=>Z+XA>]O+[2O[6NIKF\FM?+57> 1K*%4#Y-RD;L8R
MY/?-4/%:/J7@;XA:G8PRM87]U:FTQ&1YVP0J[J,9()!&>^W->S44 5!J-N-5
M&F9?[4;?[1C8=NS=M^]TSGMUJW110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;  ))ZD<'FL#6[R.?P;XDL(KK2=92WTB)X]4TZ(*PC$G$<H4D!@,L,$<9X%
M'K,OB;0($M7EUO342[_X]F:Z0";G'R'/S<\<5)?Z_HVE%AJ.K6-H4V[A<7"1
MXW9VYR>^UL>N#Z5YGXQUJPU)]?BL+_1XHVT=4@981<3:B&\WY(B& VJP(^4'
M!))QBMCPW'8ZMXOU"[80W:MX>L%60X<%6,V[GWP,_2@#M;S7=(TY;=K[5+*V
M%SQ 9KA4\W_=R>>HZ>M8VC^*I]7LM#NO+L+<:A).CQ376V3$98#REQ\Y^7)'
M&!7!^"M0TS39M%N/$%Q;0V\WA6VBM9+L@(VUW\U%SP6P8^!R1BH/#X4+\*0B
M,BBYU !&&"HP_!]Z /65\1:&U[#9+K&GF[F)$4 N4+N02#A<Y.""/J#Z4MQX
MAT2TO9+*YUBPANHT\QX)+E%=5]2I.0/>O-(K2WC^&T5RD*+.?$XD,@7YMW]I
M;<Y]=O'TK.\07>CQ>"?&.FW[0G6VUB>80''GD&4&.0#KL$>WYNF 10![=534
M-3L-(M3=:E?6UG;@A?-N)5C7)Z#).,U;KC/&^HQV>JZ#%)<:=8"1YY%U'4(]
MZ0%4'RJ"RC>P8XR>@;@T =)-KFD6]I%=3ZI916TL9ECE>X0(Z#&6!)P1R.?<
M4ZVUG2[U;5K74K2<788VYBG5O."_>*8/S8[XZ5Y5X2%M>ZCX/AE,<[VMYK.Y
M&CVF-O-)7*?P'# A3TR*LR6;V^B:YK5C%_I&@>)+B^C1!C,0"^<@]F1GX]<4
M =[KWB_0O#:C^TM1MXY3)%'Y/G()!YC!0Q4D84<DGT4GM52/QQI*:SJ-I?7]
MA9VMN+?[/<RW2JMQYJ%_E)(![=">M<+J:Q7/A*3Q==[535/$%G=>9*,".S29
M$B)ST&P;O^!FMI(-/O\ 6_'MVB6]S')IUN(Y5PZM&;=C\IZ8/!XZ\4 =F^J-
M'KXLFFT];;[&;@[KG$XPV,^7C_5X_BSUXI]KK^C7U[]BM-6L;B[V"3R(KA'?
M80"&V@YQ@@Y]Q7ENF,6\4Z.S$ECX!!)/?YEK1TVSAMM(^%C6L,<4K(/F50"2
M]C(S9/NW)H ] C\0Z)+>26<>L6#W4<@B>%;E"ZN3@*5SD$GC%:5>)Z?=Z*_A
MGP#81F%M:M-6MUNHEQYT$FYA+Y@ZKE_7J<'G%>V4 8UYXJT>P\1V>@W-[#'?
MW<;/&C2*.A4!3DYRQ;Y1CG:?2K$6OZ//JCZ7#JUC)J"9W6J7"&5<=<KG/%<M
MK\]K9_%;P_)<S00>?IMU#"\S!0\I>':H)ZMZ#K7+:9<:?+X.\'Z/;/"?$=OJ
MMN9[8$?:(I$D)N'=?O ;=^2>H8>HH ]CK&O_ !5H^F>(+#1+N]ABOKU6:)&D
M4="  <G.6)PHQR0?2MFN'\27%G9_%#PG->RP01R6M[$DDS!0TA,.U03_ !'G
M H T_#?C/3=;L[03WEE;:E<F3;8_:5,A"NRY"GDY"YZ5KIK6E2ZH^EQZE9OJ
M"#+6JSJ95'J4SG]*\PT^TMX?AWX8GCAC69O$<+F0*-Q8WC*3G_=X^G%1^'8#
M-=:98WOB/3X=0M]:FF;3TT\M>&422%MSB3.UD)^<KC:P]J /8:HZEK6EZ,D;
MZIJ5G9+*VV,W,ZQASZ#<1FKU<'K%[I6E_$>XN?$4UM!8S:*L=K)=D",D2.9D
M!/!8@Q\=2 /2@#K-0U[1])6%M2U6QLUF_P!4;BX2/?\ 3)YI;W6])TV/S+[4
M[*V3R_-W33J@V9 W<GID@9]Q7 :3?^'M*\375QJ8BT[3+C1+0:8NH_)BW7S/
M,C&\]1E"5ZX(JKX'L#_;?A-+^W/F0^'KF2%)E^:-3<1A.#T(C8#\: .YO?&G
MA^PO=*MIM4M<ZGDV[K.FPJ%)#$Y^Z2-H(SDD"M!=<TEKMK1=4LC<J'+1"=2X
M"'#Y&<C:>OI7E.DS66G7O@V:\D@MK.+5M9A$DQ"1IEY0BY/ YZ"M"S%KI_A#
MQ]J1T^WNI3J]ZD@F4E63<!AB.=@!)(';/K0!Z';>(M$O+&>^M=8T^:T@.)IX
M[E&2/_>8' _&I+36M*O[E[:SU.SN)TW;XH9U=EVD!L@'/!(!],UXSX@O89+3
MQF@UBQO_ #= A"36<(ABD*229" ,P?:& )!.,X[5W/BRSMO#-IH?B6R@6&'1
M90ERL2=;24!).!UV_(__  "@#M8KNVGGG@BN(I)H"%FC1P6C)&0&';(YYIT[
MF."20% 54D;VPO [GL*YSP'92P^'3J5VA2]U>9]1G4]5,G*+_P !0(OX5MZM
M_P @:^_Z]Y/_ $$T 4K3Q#9)HMK?:IJ.EV[31&0O'>*T) ZE'.-RC(YQWK1L
MKZTU*TCN[&ZANK:092:"0.C?0C@UY/X-MX;BR^%PFC60)97CJ&&0&"K@UV?@
M-%C3Q'&BA477;K:H& ,[3Q^)- '3W5W;V-K+=7<\<%O$I:261@JJ!W)/2N4A
M^(ND79T.YM[BV&FZC#-++<33JOV8QJC;7Y(#?.,@GBNGU-/,TJ\0+N+0. N,
MY^4UY7X3;3=33X9K$]M<_9K&X654(;RYEABR& Z,,]#R.* /1;K7H6M-,N],
MO=+N+:\NT@$TEX%1U.<B(@$/)QPO?GGBK8UO2FU4Z4-3LSJ(&3:"=?- QG[F
M<].>E>2:FBQBPC10J+\1$"J!@#.3Q^)-;B7EEI_C!+>ROM-U*.YUEC+IT\.V
M]M)SG=*ASDH.3DK]T\-C% ';^(-<&AVENZ6DEW=7=PMK;6Z,%\R1@2 6/"@!
M6)/M4.DZW?7%S=VVL:/)IDEO&LWF^:)8'0YZ2   C!R" <8/2JWC:30UTFWB
M\0I,MC+<JHNXV*"TD )20N"#'R,;O4C/!K@-6O+F?2/$.D:-XBE\0:/'8Q3R
M7,FVY-N1,N^,R)CS 8@Y*DYP.O- 'JMEK>DZE9RWECJ=E<VL6?,FAG5T3 R<
ML#@<5FW_ (X\-V&A2:S_ &O9W%DDBP[[>X1]SD_=!SC/?&>@)KSW5HH[S3M;
MU&'Q!8:S&L=@M_'IEB8XOLZ7&]BS!W#'R]^1U"]>,5?\;:AX9U+POXAN=%\B
M>2+[ ;N\ML-"5$ZE1N!VEE7<3Z C- '?6VLK>:XEM;7.FS6<ED+F-HKH-,V6
MQN" 8,>/X\]>*EL=>T?4[J6UL-6L;NXA_P!9%!<([)SCD Y'-><:T[:E\0]:
M;1)DG>?P5(+22V8,&8S,%VD<=>F*LV%[HVHZEX!@\/RVTD]FKM.EN06MX/L[
M*RR <KER@P?XA[4 =Y#XBT2YOHK&#6-/ENY5WQP)<HSNOJ%!R1P:TZ\BTJTM
MX/A[X)EBA193KD+EPOS$M*X)S[CCZ<5Z[0!A:WX@GT_4+73--TUM1U*XC>80
M^<(ECB4@%V<@XY8 #!R3[&M'2KV34=,@NYK*>RED'SV\XP\; X(..O3@]Q@U
MP_BNUTJ/XAV=WXBO&M-(N-+>W21KEK>)IDDW;6=2.=K$@$X.WN0*TO VLJOA
MO3(+^\E=[RYN8M->XW&2X@1W:,DGJ?*4')ZC![T =E6+<^*M'M/$UOX?FO84
MU">%I41I%'0J IR<[FW9 QR%/I6U7#:G<6=G\8=)>\EAA^T:/-#"TK!?,E\Z
M+"J3U;'8<T :GA;QGIOB+3=.9[RR@U.[MQ.;!;E6E4$9^[U(QSTJU:^(;:.P
MO;S5;_2K:WM[N2#SH[P-&H!P [' 5_5>U>?:):6]OX!^'$L,,:2'4X&+JH!)
M9)=W/O5715L_['U.6YU>'2IX/&%[):7-S$'@$NUAMDR0 "K,!D@YQ@YH ]AM
M;JWO;:.YM)XI[>0;DEB<,K#U!'!J6N<\#WPU#PTLZVUG#_I$ZEK$8@F(D8&6
M/_98Y;OU/)ZUT= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%175S#96DUU<2"."&-I)'/15 R3^
M0H EHKS[P=KEXOC#4=+U*\2<ZG"NJVBAPWD9PDD'!ZIA/S)K4U;QNNG1:Q<0
MZ>UQ;:3<16URWF['+N$/RKCD#S%Y)'?'3D ZVBN57Q;>/KU[IJZ(X2P$#W<[
MW2 1QR*Q+8[[=IX'7GIQF*#QY"\UO)/82QZ=<6DEVMVA9Q$J+O(E&T!"5Y&"
MV2"* .OHKE+;QE+/>" Z1*4ELVNH9(G++\N#Y<A*@(^#QR0<'GCFM9>.KN]&
MA,F@L$UNU,UF?M2Y#A Y5^/E7!)W#)X^[VH [2BN1M?',=U:P(;-8=2DN+FW
M:VDF^1&@;;(=X4DKDK@A>=PX'-,B\<SSC1430;I;C4YI[?RI9!'Y<D2.QY(^
M93LR& Z'.,\4 =C17"7'C74[BUTEK/3H(9Y]:;2[N*:X)V.F\D*P0Y!V?>P,
M ].X[>5G6W=A'O<*3L#8R?3)H DHKA]'\7:=:^'?#4=E9PV4>IV[-:075T41
M=N/W?F$'+G<,#O@\\<]E:S23V<,TL#0RO&KM"QR4)&2I/MTH FHKB[?QY-*;
M:631'BLY=5;2I)3<J6242&,$*!RI8<\C&>]6+OQO%:Z=<ZP+,R:+:W9M9[H2
M_.NU_+:0)CE _!.[. 2!Z@'65DIH:0>)Y-;MIVB:Y@$-W!MRLQ7[C^S*"1GG
M(..PJAHFLZGJ'BSQ!87$%NEII\D4<124EOFC#Y(VCD[N>>,8YZU+XDO;6TU#
MP]'=6#7/VC4EB@E$FT02^6Y#$?Q?*&&.G- &CJ6G/>:7=VEG<?89;E2IN(D!
M9<\$C_:QG!['GFI=-T^UTG3;;3[*(16UM&L42#LH&!7*S^/9H$U"X;1)!9Z=
MJ:Z?<RFY7(W&,!U4#YN9!D9''<] Z/Q=>6NK>*#J4$"V&E2PPQ>5*2[-(B%1
M@J!EC(!UP.!SUH [*BN*O_'TNFV6KSSZ+*YT^*.8-#*3%,C''#LJX93U7'<8
MS5J;QLFG76KPZQI[V9T^UCO$V2B4S1NS(HXP ^Y=N,D9(YH ZNBO/IM3ET[X
ME2ZCJUNMI!;^')[B3RYS*-JRQD\8&& !Z#GCDUIMX[BM)+IM3L)+>TAL6O?M
M,1,J +UC8[0%DY& "0>QH ZBZA>XMI(8[B6W9A@2Q!2R_3<"/S!K*&A7P  \
M4:N .@\NU_\ C-8"S7TWQ4T=[NR%KYFCW+!5N#)G]Y#P1@ ,,]LCGJ:V/&6L
M:AHNF6<VG10O)/J%M;,97*X6255.,*>N<>V<\XP0"<:#?+G'BC5QDY.([7_X
MQ38_#MW%N\OQ+JJ;CEML5H,GU/[BJUWXKFA356M=.%W_ &0BF^"3X(;8'9(\
MK\Y"D'G;G('KC>L+VWU/3K:_M7WV]S$LT38QN5@"#^1H R#X:N#&T9\1ZH48
MY9?)M,$^I'D4Y_#MW+'Y<GB7573^ZT5H1^7D5<U?4Y=-2W,5H9S-+L9V?9%"
MH5F+R/@[5^7'3J0.]<]#X]^U:?HMS;:5),VIWDUD%6=<1R1^9GYOXE/E-@\<
M<^U &JWAZ[?;O\3:LVTY7,5H<'U'[BA?#UVLC2+XEU4.WWF$5ID_4^15&T\:
MBXMECDL#%JC:D^F+:><&4RH-Q._'W @W9VY[8S5?P4TY\1^,5N(O)==1C_=B
M4R 9MXSPQ X.<]!UH U1X<NE9F7Q)JH9CDD16F2?7_44_P#L._\ ^AIUC_OW
M:_\ QFH=:\4+I>K)I<,$,U]);-<1137'DF?!QLC^4[G]N.H]>.9N-9N?#OBW
MQMJ-OI[WL-M;6ES.IN-FQ%20L5SG)QD@<#@\CN =9_8-]NW?\)1J^<8SY=K_
M /&*0Z!>DDGQ/JQ)&,F.UZ>G^HJAKGC5=$@FO'T]FL8HX9#-++Y9F$AY$2D'
M>5&"1D=:HW$2M\0O$49+[)-!@9AO/7S)AD<\< =/2@"]J'A36)VBDLO&>J6\
ML8V_O;>VE3'^YY:C/'!ZCFGZ5X-ET;3H;*T\2ZNL<99A\EL269BS')A)Y8D]
M>]3> 6+_  [\.,Q)8Z;;DDGD_NUK-U3QY/IKZ\PT.22#1)(Q=2?:54F-D5]R
MC!R0&SCCIU[4 :S>';MT*/XEU5E)R08K0@G_ +\5)!H-S#>)<MK^I2LI&Y7B
MM@' /W25A!Q]"*K7WBEH7U?[!8?;4TA%:[Q-L;)3>5C&#N8(0>2HY SUQ5L/
M%%WJOC*VM+*.W?1Y])34(Y3(0[B1L XV]1CIGOG/:@#K H484 #T%*1D8/2B
MN+O?$MMH]_XOO4T>1KG2[2">X<3C_24VR%< \+@*WN<T =GM7;MP-N,8QQBF
MO#%)&(Y(D9!T5E!'Y5@Z7XEFO?$#:3=Z:UH[V:WL#^<)-\>[:0P ^5@2.,G@
M]:OZOJ<NFBV$5IYWG2%6D=_+B@4*6+2/@[1Q@<=2* -!XXY%"R(K '(##/-+
MM4,6P-QZG%<?%X\%QI.A7UOI4DW]K7<EFJ+.N(Y$\S//\0S$W/''/M2/XZFA
MT2YU&?2 AL=2^P7Z_:<K!RH\T-M^9 '4G@$#/'% '8>6FS9L7;Z8XI&BC9][
M1J6QMW$<X]*J6VH/<ZM>VBPKY-J$!F#YR[#<4QCC"E3U_B%4[[79;+Q)9:0;
M-2+V"62"=IMH:2, F,C:<$@YSZ ^E &SM7(.!D=..E,2"*-65(D56)+!5 !^
MM<WHGC#^W=)TV^MK$$W;3"2%9]S0K$2&/"_,=P"X]67G'--T[Q?-?ZI_99TU
M8KY]/-]' ;G++@J#'*-O[M_F7CD=?2@#IE@A4H5B0%!A2%'RCT'I3EC1!A$5
M1C' QQ7.Z1XK.L:=I%S#9!9;^62.6!IOFMO+W;]WR\E2NTCCEASSFKGB?7O^
M$;T5]2-G)=*LL49CC8*?G=4!Y]V% &JT,3! T:$(<KE1\I]O2EV(,?(OR]..
ME<7=^/I]-&N1:CH4MO>:99?V@D(N%<7$'(+!@, @@@CGVS6A%XHO'NK6RET@
M07M\SO:1270(>%$5FD<J#MY8+MP3GVYH Z38NW&T8SG&.]<MJO@ZXU>ZN8[C
M7;DZ5=2I)-9&)&)"D'RUDZJA*C(]S@C-87B#7UUFWT::.UFBOK#Q)%9W%J).
MD@!) / 92"I!..#VJ]JOBJ&Y\-:P=5T-F;3K^*TNK5+G*DEHV1PX )'SH<8S
MP10!W5->-) !(BN <@,,X/K7G;:I?Z)XS\8W-AI$NI)%%:32H+@)M41N6V[L
MY;N%&!QU'&=>#Q!9ZGXDL9K'3O-N+K0WO;2ZEF**T1:/]V5 .,EE)."1CO0!
MUHC0-N"*"3G..]9'B'1)]<T\V$6I26%M-E;KR8U+RQD8*AC]W(R,@$\U!X)U
M>^U[PAIVJ:A'"DUU$)?W3D@@\],#'ICGIUJ;Q@H?P5K@)88L)V!4D$$(2#D>
MXH U(K6W@LX[2.%%MXT$:1X^4*!@#'IBI B*,!5 QC ':N,TR_MX[[PC:RZ>
M\MW+I#O!=>;@(%2+>NWN3E>3Z4VW\?W,]GI=Z= E%K?WLEBI%RA=9E9U7Y<8
M*DQGG(QGH1R0#M=B YVKD#'3MZ4NU?E^4?+TXZ5PVI^*HKG1-035M#+2:?JE
MO:7%NEUE0S/$T<@< $C+H<8[$5K:;K.IW?CG6]+E@MUL;&&V*,LI+Y<2'.-O
M? &,\8[YH AC\'7#:E:RW^NW-[96ET;N"WDB0-YG.W?(.7"[C@<=!G.*ZJLO
M5=933KO3[&.(37NH2-';Q%]H^52[,S8.  /0\D#O6#<^/1:VUP'TJ5KZTU*'
M3[FV29?E:4J$=6(&Y2'!' ]\4 =@\:2%2Z*Q4Y7(S@^HI!%&LK2B-!(PP7"C
M)'UJOIL]Y<V*2W]D+*Y)8- )1*% 8@'<.N1@_C7/7'C>*#33K/V/?H:7AM'N
MQ+\ZXD\HR;,<H'XSNSCG% '64UXTDV[T5MIR-PS@^M>9>+-7U/4_#7Q!M+J&
M&.WTR,QP-#.VX'R4D!/RC.=^3SQTP>M=&?&:Z?=7]KJVGO:"TL%OHV642&6,
ML4P1QM?< ,9(Y'- '5;%P!M& <@8I!%&)3*(U\PC!?'./3-<??>/)=.MM7EG
MT:1_[/LOMJO!*6BE0$AEWLB[7&/NX/!!%6W\4W]M<Z<M_HGV6WO[S[+%,UTK
M8RFY&8!>-Q!7&>H'KF@#J*9)%'* )(U< Y 89P?6N:TWQ>^IQ7*Q6,8N[?5&
MTUH!<Y^9>6;.WIMRV/0'OQ5"S\5Z;IFE7MW]A6P5M;ELY3/<8C\[<=TCO@[%
M)'TR0.] ':211R[?,C1]IR-R@X/K3L#=NP,XQFN<G\4O +6W:SB74+A)I5A>
MX/EB.-PN[>$)(;<I'R]#VQ6EH.K?VYHEMJ/V2XLVF!W6]PNUXV!((/XC@]Q@
MT 7VAB=0K1HR@[@"H(SZT[8N"-HP>HQUKB;WQ3;:')XPU"/19&N--,#7)$X_
MT@&,%6&>%PN!3]7\9ZA8V_B"$:2D%]IVF'4K<2W&Y9(OG'S;1PP*'Y>0>/F[
MT =@((54*(D"J-H 48 ]*Q_$7A^3Q%%%9S:A)#IA(^UVL<8S<J""$+GE5.,$
M#J.,BL\^++BVL[:W>UAGU0V*W<D7GE5*GA<,$/S,0V!M X//3,1\;W=Q=6%K
MIWAVZGN+W3FODBGE6!EVLBLC!NA&_P#/V.0 =B    , 4=:\VNKI+CQ%XHN?
M$%K&]II$MJUNT5RWF0ML#J(\*,%F;GD=<'(%:FH>/I=,LM8GGT620Z=;+=!H
M928ID)((#LBX8$<K@\$$9H [,(@QA0-O3 Z4H &< #)R<5S4WBFZM[A;.XTM
M+>^E\V2"*:Z&UH4V#>S(K;22X&W!Z'G%:F@:O_;NB6VHFSN+-I0=UO<+M=&!
M((/MD<'N,&@#2IB0Q1_<C1>2>% Y/6N2U3QR^E6_B&2;3%WZ*T32)]IP98I!
MQ(OR_48]58=AD\5Z_!'X?U5[G2UU#3H+>%Y?*N=H<N?N@X'0;6SGHR\<T ==
ML0_P+UW=._K2>5'YOF^6GF$8W[1G'IFN3O=5U&Y\7ZIH+P0?V=%I2W&\3,'.
M]I%SC;URF,9Z<Y.<#.\!^(KB'1/"&DW=@R1W^EJUO=&8,7:.-2P9<< @Y!R>
MG(% '9:EI\U^J+%J=W9!00PMUB;?GU\Q&Z>V.M4(_#MW"@2+Q+JJ(/X5BM /
M_1%1>-M8O]"\.&]TZ*%YC<00DRN5VB254R.#D_-_7G&#SUYJ-_I'C_6KNWTX
M74J:%;W$T NMJ B2;=AB.N% 'RC..<4 =-'X=NXEVQ^)=51<YPL5H!G_ +\4
MB^'+I(C$OB35%C.<H(;0 YZ\>15"Y\<PFT673;,W<OV"+4#"\A1BD@)15PK9
M<A6XX'3GFNDL+M-1TZVO$BEC2XB601S)M=0PSA@>A&>10!EKX>O$QM\3:LN!
MM&(K08'I_J*1/#MW&SLGB7559SEB(K0%C[_N*XO19;**3QBU]87]Z+;5YDB$
M0D81QB.,[00?E ))]LUUD^MW.F:U:^&K+37O)_[.:XBFFN0@81LB$,<$_P 0
MYP>>W< %K^P+W '_  D^K8'('EVO'_D"E_L._P#^AIUC_OW:_P#QFLC3O'DE
M_'H5RVC2PV6KNT$<C3J7294=MI4#[O[M@&SU'0"H+7XARS6^EW]QH,]OI=]>
M&Q-T;A6,4OF-&N4'\)9<;L\$]#U(!N2>'KN9"DOB7574_P +16A'_HBK4&C!
M&MGN[ZZOI;:8S0R7'EJ4)0ITC501AFZCO]*Y/1=7AT*Y\5.X>5I?$*6MM%OY
M>22* *N3T&223V -:UQXMN;:75[%])+ZKIUJMXMM%/E;F$Y^:-BH.<JPP0.<
M>N: .IIK1H[*716*G*DC.#[5SK^,+6/3[?4=B/8OIK:C--')N\N, %0!CYBV
M2!T^Z?2JQ\<):SWBZAITL44%H+I)X&,D;_,%\LL54+)DK@<@YSGB@#J]B@ ;
M1@=!CI2-#$Z,C1HR-]Y2H(/UKG+;66U^YU+0KO3I(@;3<L\,S^5*CY4J)-JE
M7'H!D @BF-J<7A*#1= :6.:XFA=89;RY,:N8]OR!R&)8[Q@'J%//'(!U"J%4
M*H  & !VI:BM97GM(9986AD=%9HF.2A(R0?ITJ6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LS7-
M-N=5M(K:&YAAB\Y'G62$R>:BL&*<,, XP>O&1BM.JM_J5CI<*S7]Y!:Q,VT/
M-($4G!.,GV!/X&@#$U_PJ^IZCHVH:;<V^GW6F7)F$AMM_F(RE6C.&7 8'GKT
M%<??32S>+-7DCU#38;@W2!;#4-,F>27RE4(RA'42#<"RG:Q&1SP /0+;Q-H=
MYISZC;ZM9RV<<@B>=9EVJY( 4GL22!CW%12>+_#D6G1:@^MV(LY7:.*;SUVR
M,IPP4]\8[4 5-,\/W1U75M4U&6';J]K!'-9K&<PE$8$;]WS??/8=*J:1X0U.
MUTE]#U37!?:,EN]K#$MOY<QB92@61]Q#;5.!A1D@$^E7M3\<>']*FTE)]2MB
MFJ.1!*LR[-H5FWDY^[E0N1W85H+XAT9M8.D+JEH=1'6U$H\SIG&/7'./3F@#
M(T;P_K]AIYL;_P 017L$,!@M2+38V,8#2D/\Y XXVYZG)QB#3_!EW8)X43^T
MX770(FB_X]2#.#'Y>?O_ "\<]^:V_P#A)M"_M632_P"U[+[?&"7M_/7>N!DY
M&>H')'I5#2O'GAS5M(NM4BU.VCM;69H97DE4;<.R*3ST;;E>Y!% &0/ >IVS
MI?6&N0PZI#J%U>12FT)B*7#;I(G3?DC(7!!!XK6F\-ZA<ZCH-_<:K')/ILTL
M\N;8@3,\;1D*-_R* W ^;IR3R3HR>)-$BT=-7?5;-=.<A4N3,-C'., ]SD$8
MZ\55\/>)(_$%_K,=NT$EK97$<4$\+[A*K0I)G/3JY''I0!D?\(/>K;C9JT N
M(]<?6(G-H2H+;@8ROF9(PYYR*[)UD,#*CCS-N S+D9]2!BJ,GB#1X=333)-3
MM5OW<1K;&4>86V[L;>OW2#]"*H6/B>SC\,V^K:QJND1QR.T?VBVN-T#,'8 *
MS8)/'(]0?2@#,MO!$\/A33?#UQ<V%_96ML]O-%<V9VS9QL<#?E67![G.[M72
MZ/IW]D:)8Z:+B2X^RVZ0^=+RS[5 R?KBL;5O&FGV::9/:7EE<6=Q?BUN+@3
MI"IA>7<6!P. IY[-FEU#Q_X:L-$75_[5MI[1KE+8-#*I^=F (Z_P@[CZ $T
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M=" I\S/S97/&.,>_-37O&,=A;^'+G2S;7UKJ^J0V/G+)N4(X;+*1U(*XKJJ
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M2V4=S_PE'F2M>1[UM(F:,K<,AQP"!@GC.#VKU*35],BCNI9-0LT2S.VY=IE
M@)[.<_+U'6IHKJUN)98H9X99(MOFHCABF1D9 Z9'(S0!XO>7\1L/$$TNH_:D
M37M-O7N6B$8>$>2IFVCC9E"-W0XS5W5GM[S4_%%K=>)8K*#6)(9+6-;,3R7D
M+0QK&T)SEL,&P%!P1GO7L6!1@>G2@#E_B%:W-U\/M6M[:.2>4P@LD8RTB!E+
M@ =25##'O7,ZSJ6G>(=>2[\/SQ75O::#?)>36_**KA/*C8CHV58[>HP>*].H
MP!T% '/> [>*U\ >'DBC6,'3H&8 8RQC!)/N22?QKSOQ!;3W'B/XE+%#)*H7
M2))8T4DO$AW2 #O\@;BO7K6\M;Z$RV=S#<1!BA>%PZA@<$9'<&BXO+6T:$7-
MS#"9Y!%$)'"^8YZ*N>I.#P* /+?%,Z>*[_5)O"DRWHC\-W5O/-:'<K,[H8XL
MC^/"R<=1GWJ[K'B?PU?:'>3Z+8VVH7%OI:QR2M;[X;:%I$!CE (Z<OLZX0]*
M],  Z"C ]* /$M7OX[FS\=@:NFIFYT"%H;A(5C2<(TP8Q[>'"[E!(SUQVKUO
MP[QX9TH'_GSA_P#0!6E@>E% 'B/A/4AIO@7P@DUU::9&]SJ#?VE=0"0P,)7P
MB;N SACUZA2 .:9#J,VA>%]/U^T\R6]M+O5--GC\O9(&FDDDA#H/N_.L7'8/
M7M1O+3[<+$W,/VOR_.$&\>9LSC=MZXSQGIFIZ /(]/T5M+\5Z=X&1&-G%<6^
ML%L<%(X=A'XSQJW_  *NH^(\\5G:>'KRY<16UMKMM)-*W"QI\PW,>PR1S[UV
ME'6@#R2^U+2[71?'FF:A)&VIZI--)90$9DO$DA00&(=7 /''W2#TKT;2+Z("
M+1YY]^J6MG#)<I@\;@0#GH<E6[]JU<#.<51@.G2:Q>203127Z1QQ7*++N:-1
MN9 RY^7.YCT&?P% '"_$<W.EZK;7UDK>=K%E+H>Y1G;+(P,+?AF7\ZIZ1IWD
M>.8/"4<3#3]%NY]5C!'R['C41@?22:8_\ KU2B@#P[PO<P:9X$^&M_?2+;VD
M&I77FS2<+'N%P!D]LD@5KZE;1CX?_$.18AYDFJSMNV\G:8]I_#M7K6!10!Y3
MJ5_IVF6?Q TO5V0:GJ4TK6L#KF2\C>W1(A&.KX8%<#H0>E/M]1B\.ZIK]IK4
M_E7]WHUD((VY>Z=8I$<1C^([N,#UKTS[9:&^^Q?:83>"/S?(WCS F<;MO7&>
M,]*GQ0!Y5X7N[?3_ !)X*:\E6!;KPG';0&0X$DNZ$[!ZMCM73^+($G\5^"UD
MC#JNHRO@C(!%M*0?P(!KKL5!<WEK9F$75S# 9I!%%YKA?,<]%7/5C@\#F@#R
MN^"6?B:_OKE=NE6?BN*>[.WY(P;)0LC>PD923V//:J_B6X@U'3?'&L:<PFTJ
M233-MQ$,QRO%(#*ZD?> 4H"1_=]J]CHP,8QQ0!Y/K3/K7Q!UF3191.UWX*D6
MUEA;(=FE8+M(]\5I6FJ:'KFAQ:?H,/G:S#H<T,;PQX-EF-5\J0\;&+ 87K\I
M/%>C48 H \Q\#_9;[5=$>/Q#'=W&GZ<\1LH+$1&V0A 8Y6!.T@J,*<$[36OX
MPN[?3O''@R]O9D@M5ENXVFD.%#-#A03V)/ KM\ 48S0!XXUS;?\ ""2>%RZ_
M\)4=8+?9<?OS+]L\P38Z[=F&W],=Z[7XHQO+\,M?6-&=OLI.%&3@$$_H*Z[
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M5NPN;;PNY"RCYHCYL8 YZ$*<?G75_$X%OAEXA &3]C?@5UE% 'F]PI_X6/\
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M/=VXD17^U,6C)) 5BNWZ[2.U>M:QHMYJ%W%=6.NWVFR)&T3+$$DC=2<Y*."
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M61E8M%R70@X(4$C@]J ,%?%/B-;N[T62YM/[0?6X],@NA!\L<7V<3-(4SRQ
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MU=AADM'L_<H#V+-G\$-=6^BQOXHBUPRMYD=D]GY6."&=7SGU^7'XUBZ'\/\
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M!4*5('\1VK\W^ST'-16WP\$.BZ%I<^L33P:)J,5[:DPJK;8P0L;8Z_>/S=:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML:XP%/7/3 .0:=X5D;P[%X+U+5K>YBLQH4MF7^SN_DS&2-@& !*[E4@<=L4
M=]X2UY_$>FWEXQ@:.._N;>%X<[7B20JC=3DD '/2LS0_B!IMT\MKJEY;P7O]
MI7%G&B(X7Y9F2,,W*JS!1P2,D\"G_#E'&@Z@[VDMJ)=6O)4AFC*,JM,Q7(/3
M@BN+DE$G@[7/#B65VNK7^NSM;)]F?$@-WN$H;&-J@9R3QM^F0#U.+7-,GT^[
MOH[R,VUFTB7$AR!$T>=X;/(Q@T^75["#1_[7FNDCL/*$WG/E1L(R#SSSD<=>
M:\Y\3:==1>+[CPS;QO\ V?XM>*>5EX$7E8^U?]]QK&/JQKL/&L]Q9>%9&LXP
M )H$=Q;B;R(C*H:01X.XHN6 P<8SVH T])US3M=AEETZY\T1/Y<BLC(Z-@'#
M*P!'!!Y%5M2\6:%I%_\ 8;[48X;C8)&4JQ"*3@%B!A02.,D9[5S?@:5CXJ\0
MEKG4;I+B.VEM[J^@$;3HJLI8;408!X' .,'D$&J.KW2:1JOCJ"^LKJ5M5MT>
MS"6[NLZ"W\LIN *KA@V=Q& V>E '77GC+P_80VLL^HJ%NH!<Q!(WD)B/(D(4
M$JO/4X%7K36M-OKS[):WD4TQMTN@J'.Z)R0K@]"#@\BO.O"E_#X:E@O]5CN!
M;7_A_31:S1V[R@F.-M\7R@X;+*0.^?:JR6>J^#?"OA?Q"FG7$E[:6L]I<V<<
M99_+EW21*0/[L@C'MN- 'H-SXQT"UC9Y=04A;B2UVQQN[&1/OJ%4$G;W(&!Z
MTE[XR\/:?!;37.J0B.ZA\^W*!G\U,J,J%!SRR\#GFN%DT&Y\*3^&WN-5OM/B
MCTV>&YOK2V2<_:I)$D?<&C? <[L''\(&>:N:%I"6OBKPBT,-_);1:;?R++>P
MA)$:25&&X* $)#-@8''&* .LN?&WARSNWMI]4C25)O(D&QB(WR  Y PN2< D
M@&EU+QIX>TBZGMK[4XX9H"HF78S>7D @M@'"X8<GCGK7&:E83GP)\1$6TE,U
MQJ-PT:B,[I!LBP1Z]*LZE8S/_P +/86LA:XL42(B,YEQ:$87UY)''>@#L++Q
M5H>HZA-8VNHQ27$,9E9<%04!P65B,,H/!() J.R\8:!J,-U+:ZBCI:PFXE)1
ME_=#/SC(&Y>#\RY%<7XDT>]OH=%L["W=97\,W]LFU<!7:*$*I/;)_E5:*"/4
M],U"XBU/7-0N[;0+J 17%A' D&]%S$=L2$OE!A><;3TR,@'=6_C7P[=32PP:
MDLCQPM/A8W^=%^\4.,/CN%R14GA3Q-:>+=!AU6S5T23AD=2"I],D#/!'(XKG
MA92IJ/P_$=LZI!9S(^$($?\ HZ@ ^G(Q5KX63J?A[I5FR2QW-E$+>XBEB9&2
M0=1\P&?PH UHO&/AZ:XNH(]4A+VB227!(8+$L;%7W,1@8(/!/N.*=;>+M!NM
M.O+^/48UMK,!KAI5:,Q C()5@#@]CCGMFN%31[V;X9>)[>VMITN9=:N;C;'%
MF21%N@Q*J1\Q*+P,'/ YJMJ=F-4T_4]5L[_6M<>$V/GM/8I$LD45P)61%6-"
M[*-Q(P?O =>* .^A\:^'9X;F5-33%K US.'C=6BC'5F4@$=1V[YK0O-6M;9T
MM_.3[5/!)/!&0?G5 -Q_#<OYUYEXAG3Q-KOB8Z1:W$C3^$Y(HF:!HVG;S&P%
M5@">N,XY.1VK4.JQ:_XJT.XT^"[>W@TF]229[=T42,(?D^8#YAMH U?#OCRV
MN/ ^BZWKTT-M<ZBC$16\3MN()SM0;FP ,GKBKMSXZT:WUK1=.28SC5HFF@FB
M5F3;QM.0#G)./;OBN!\-SWNF^$?!EI=2W^E0?8+@O<6UB);CS?,7;"-T;[-P
M)/3G:/2I?#TK:=<^!);V"[B6V74+.X+V[$QS,Z;5;:N!G!YZ4 >AIXPT"351
MIB:E&;HRF #:VPRCJ@?&TM_LYS4MMXGT:\UA])M[Y);Z-G5X55B4*_>R<8'X
M]<'&<5YS;>8W@C2_!ZVMT-?M]3B\Q3;N!'LNA(T^_&W:5!(;/.['6NN\"VCV
M]QXJDD@:-IM>N'#,N"Z[4P1ZCK0!3\:>.9M"\1:/H=A);13WID:>XNK66984
M5<C"H06)/'!X[UOMXPT!-5_LQM2C%UYP@(V-L$I_Y9E\;0_^SG-8WB2WGD^*
M'@>=(9&BB6_\R15)5,PJ!D]LUR\GF#P/=>#C:W1\02:F^U/L[X;==^:)]^-N
MW80V[/;'6@#T:/Q/HTVM'1XKY'U!9&C:!58E650YR<8'!!R>#VYIVJ^)-(T2
M:*'4;Q89ID9XH]C,T@4@':%!)(W#@<UB^#K1X?$/C&>2!HS-JJE79<;U$$>,
M'N,EOUJGXFU"UTOXF>';N\1S"FG7N9$B9_*RT(W$*"0.V?\ :H WI/&7AV+3
M+74GU6$6=V66"7!^=E!++C&=PVGCKD8ZTV\\:^'K#ROM.HK&9(5N/]4YV1M]
MUWPO[L'U;%<)IMA/<ZIX?OC93BTN?$U]?0B2%E*Q-%)L=@1E<L-PSCJ*UKN^
MAT#7O&*:E:W,C:HL<EEY=L\OVE1 (_+4J"-P8'@_WL]Z .XM=5L;V]N;.VN4
MEN+98VE1?X0XRA]"" >1Z5DQ^)K6^UO2H+#5+)[:[%P/*:)S),T1P3&V0H"G
M.<@Y[5PU_9:YX.TCP_>V5K-/J-QHBZ+<)$I;9<! 8';'96WJ3[BM"7P\VC>-
MO >GV44AM['3;R!IPAVAO+4;F/8DY/UH VM2\?:>+S3K32+N"YFGU..SEW1O
MM*$D.4;@,00!D$@=ZO6OBFRACU2?4M7L/(M=1-F'BC=!"3M CD+$Y;)Y88'(
MK@=/N5?PUX'T$6%W_:6EZI;"]1K5P+<IN5F+$8Y)R,'D'/K1!IUT\.O))9S%
M9/',$H5HCAH_-ARW3E< \]* /1;?QAH%U8WUXFI1K!8 &Z:56C,0/0E6 .#V
MXY[9J;2_$^CZU<M;:?>K+<)'YCQ%&1T7.,LK $=NOKFN#\96%W+XCUVYBLYY
MX(H=)N)$CC+&5(KJ1Y  /O$*,XZUJZ-J5KJWQ8N[RSAE$)T2-1-)"T7FXF;D
M!@"0,XSCL?2@#I9=6\KQ9%IAOK14:R:X-J8W\\X8#>&SMVCIC&<U7L_&_AO4
M+F"WM=4CEDN(S)#M1]L@"[B%;&"P')4'(]*P]0MIV^,UM<""0P#P],AD"';N
M\X'&>F?:LW2[">+P9\,XQ:R(\%W TJ^608_]&FW%AVY/.>YH N>&OB*FLZGK
M]Q>W=E::/ILLL4:M;RK(50H/,:1CM&=V-FW=R/QZ:#QAH-S87UZFH*L-BGF7
M7F1O&T2XR&*, V#@X..<5Y[!IU\/#WB6;[%<2)!XS-])"L1+30)+$S%5_B&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7-U:ZS836]J0)Y4G4K'GIN.>,]O6GV'B+1=5DN8]/U6SNGMO]>(9E;R_<X/
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M>0#[@4#KGCTKTRYA:XMGB6>6 L,"2+&Y?ID$?I65_8%P/^9@U?\ [ZA_^-T
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M1\0:3J/B*+3YK[4HI8K4V/FW%P"L7E/&=V6 *@< [2IS7I']@7'_ $,.K_\
M?4/_ ,;H_L"?.?\ A(-6R/\ :A_^-T </J5K$WASXK2F%3(\DH+%>2%LXBOY
M$DBFO/I?_"1>,-.UJXDB34M$L]JQ@F66-8YA(T8P2Q4')P#7=?V!<?\ 0PZO
M_P!]0_\ QNC^P+C.?^$@U?/^]#_\;H YCPWXHM;>XU:XOM5TW4[.U@M@=;LK
M?:7W.ZK%)LR"RD@_+P-_05Z#7/W7A4WEJ]M<:[JSPR<.F^( \Y[1TMQI1LX&
MGN?%&IP0KC=)++"JC)P,DQ^M 'G&DZ#K4GPI6_T[7-6(5YGDTR)HU62(3OYB
M(P3>K%<X.X\FKMY<Z?9:WIM[8ZU9Z/H,^@1P6,US;"6-U#L6B&YAAMICR.2<
M>U=__8-Q_P!##J__ 'U#_P#&ZB.D_P"DK:MXGU+[05\P1&2#<5!QNQY><9[T
M <1I,^D^$]4C_MZ\)TZ;P];6]C<7L)C\U%:0R1;3T<AH_DZGCTJUIVJ:'H'B
M74+G5T72["\TBS&G1WJ[2(55]\ !S\P)&4!)Y%=D= G/7Q!JQ_X%#_\ &Z#H
M$YZ^(-6/_ H?_C= 'G_@W3)8O$7@V+4;9A-;^';AT29?FBS-&%!ST(1L>U9V
MLZAIMOX&\3Z)>,AULZU+,;8C]ZP-R'24#KM\O;\W3 Q[5ZC_ &#<?]##J_\
MWU#_ /&Z/[ GSG_A(-6S_O0__&Z .-N;^TTWQ@]M8:A:7C76KQ&YT6[M\SQR
M':IN(6Z[5 #Y((P#@BO0=/U.SU2&66RF\U(II('.TC#HQ5AR.Q!%4/[ GSG_
M (2#5L^NZ'_XW5>'PT+%&6/Q!JL0EE:0YDB^9V.2>8_4T <9XI*VWBWQ%'J6
MNV^EVNH:?#'$L]F)C<Q@.K)'EAE@Q/RC)^<'%0:BDEMK'B71HKIFU.]\+00V
M(D&R6Z=$F#;0>=WJ.V:]".@3G&?$&K<?[4/_ ,;H_L"XSG_A(-7S_O0__&Z
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M /2H]?UK3M=UW5Y]*NH[RW7PE>KY\)W1EMR':&'!(XR.V17JG"^@R:  !@
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MVZ[%D9#O.,*0V,<;3US7;V?ALVWB*UUB34)KF:#3/[/;S5&Z3YU<R$C'.5Z
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M 3.>S$C!Z&N NM/$G@+7HVM2QF\6,[*4Y<?;T&?<;>_I3/B'&%U+Q/));O)
M]KH^Y%3/F8O6RH]3CC'O0!W%WXSTR;PYK>HZ+>VU[/IEI).8P3@$(S+D<':<
M=1U[&BT\8Z=%X9T74]9N[>TFU&TCG$0R<DH&;:O)(&>O;C-<CKUW!K^H^)]0
MTC=<6D/A:>UEE2-@&F8LRIR.6 #9';=[T>'[N#P]>^&M3U@M;64OA:WM8IY$
M.V.52&="0/E)!7&>NWVH ]$MM;TN\FMH;:_@F>Z@-Q $<'S8P0"RGN 2/SJ"
M]\3Z)IYN!=:E!&UO*L,JDY*R,NY5P.2Q7G YQ7G:6D^C^"=-\5BVEA.E:I<W
MRP,A5Q833/O7:>G[M@^/]D5$VGWNG6_AOQ!>7LFEM>W%W>WUT(!*+>6=5,88
M,"  B^7GMT[T >K6FH6=_81WUI<Q36DB[DF1@5(]<U85@RAE((/(([UY5.T.
MD:+HE])>:A/H,NIW,]Y=-9JI4R;MDABVD"/>20=O\2GTKM?!EGIUGHD@TF:Z
MFL);F2:%[A0HPQR?+4*N(\YP,>N.,4 :\4UT;Z[2>&&.UC"&&19<L^0=VY<#
M;@].3GVJP'5BP5@2O4 ]*\C\516C0_$^)4B+26MNR* /FD$1&0.[;L=.]='H
M\.GV7Q/D33E@BBN=$C>3R<8ED$I(9B/O-M.<GG!H [EW2-2SLJJ.[' H>1(U
MW.ZJOJQP*XCQ3J-IIOC73I-?CSH4UC+#'))$7B2Y++]X '!*9 )_V@.IJE!'
MI^G>)M,M;^ Q>&SHQAT_^T,E%D$AW*Q?HS1[,!N< CU% 'HI95QD@9Z9-()$
M*JP=2K="#P:\CT[3$%WX(MM8B61!<:@L2W(RWV4A_)5\]BNW /L*KVEOILD6
M@VC) ;>#Q5>QI'QM2W(GPN.T9RG'0Y'K0![()$,?F!U*8SNSQ^='F)Y?F;UV
M8SNSQCUS7CZW$.E6]V$#Q:!:>)YC=):Q!UAA:'Y&V;2/+$IST(!&1R*NO)I6
MAC2+^WDO;GPI+J<\UU+-%F))'C&QPBJ,1!]W; 8Y]#0!Z5=:G9V3VB3W"*UW
M*(H!GF1L$\?@"?PI;>6[>\NXYX(4@1E\ATEW-("H)++@;<'(')SC->=ZQ9:%
M#;>%;FTL3_9"ZV[[IHF==DD4Q) 8$A"Y  P!TQU%5-5\Z.;QW_9<3.G]H6,M
MQ% OS20!(O/"@=> X/\ P(=: /5UD1UW(ZLH[@Y%"R(Y(5U)&,@'IFO+/$<%
MG<R>)KO2/L\FC3>&I5G\@ Q/=9/DXQP9 N1QS]SVJ]X>@T^R\=Z(;)(8OM7A
MYO/:/ \V0/$5WG^)L;^O/6@#T8L <$@&C>N,[ACZUR?CNS\JTL/$4%MYUWHM
MTMQM1-SO ?DF4?\  &+?516)X;T:ZMM?N]!O=.C6Q-RNN*1&/+0R9_<?5906
M!]%]Z .T?5_L$,LNK_9[5#>+;6^R;?Y@=E6// PQ+?=YQZU!9:^USXHU;1YK
M>.)+&*WE282Y\T2[^HP,8V>IZUYQ<6]D?#>KL8(7MK;QA',^(PRQP^=%N;&/
MNXSSTQFK6O6NDZAJ7CDRV]O)&FA6_P!E61!\CA)L;%/1AE,8&1D=,T >KDA5
M+,0 !DD]JYVY\61?:- -C''=66KW36ZW EQMPCN& Q\P.P]QUJ_HC+?>%]/,
MQ6<36<?F;_F#Y09SZ]\UY;HD.G/X8^'ME)!&I34&6]B:/9\P@F5@_ SR54Y]
M0#UH ]D$B&/S ZE,9W9XQ]:565U#*0RD9!!R#7CL=S#I5O-CS(O#]IXFN1<K
M:Q!U@B:/]VVS:1Y8D.>F >1R*] \%VFFVND3G2)[J:PGNI)XWG4*IW8+>6H5
M<)G.!C&<XXQ0 V+Q'J%UXHU71+72[9GT^.&1I9;QD#K)NVX C//RG-;=C<S7
M%G'+=VXMIV9E:+S-XR"1D-@9! R.!P:X"*32G^*'BEM0U(VD;6EFD<BWK6X9
M@)-P!5ADC(]<9HU-=)OM2\"HNVYM8;J:V$TP_P!;&MO(F3GJI< <\-QU!&0#
MT82QD(1(A#_=PP^;Z>M*9$#!2Z@DX )ZGKBO&9[+2K;PQK=Q;06R7%EXGC^P
ML@&Z"/[1$3Y?]U<&0_+QC=27VE:/?Z9XWBAAA;74UAVTORS^^24QPE#%W&6Z
MD=ASP* /3[+7);KQ9JFB/:I&ME;P3I,)-QD$A<<C QC9ZGK6PLB/NVNIVG!P
M>AKS#Q =3;5_&L>E.SZHVAVBQB$X9F5IMX3_ &MK<8Y!85I6T&FZIXOT:YT"
M*!M,DTV>+4XXT'EF,[/*21>F\$OP>0 U '?;EX^8<].:02(SL@=2Z]5!Y%>>
M^&M)N;>]?PW):+]E\.S//93NH*R"0'R/J4#2!O=5-9'AH6FI6VGO!<:DGC#3
MK2:*>W:%8]DQC(<S-L&Y2X# ECDD'UH ]961&9E5U++]X \CZUEZ#J]QJFE-
M=W]C_9TJ2O&\1G651M.,AQP1_7([5Q7@?^Q=2OM)O+>?4EUJRM6@O;9X!%Y9
M(&\3G8"WSC(R2223SS71^-X@VGZ<(M1@T^X2]5K=[F(/;LXCD^249'RD9YSP
MVW'.* .G!##(((]12>8GF>7O7?C.W/./7%87@N=[CPM;/)I\5@^^53#"V8LB
M1@6C/]QOO+[$5Q/A\:=J.IVEMJMQJ,?BC3]1EEE@2!5+9=@6,FS+0E".K8P
M!R * /4_,3<%WKN)( SR<4"1&4L'4@'!(/>O&!8Z2OA];A8;=9X_%Q$<JX#I
M ;LY"D<A#&2>.,'-+XBMM+LYO%5M!%!!91:II,R1P (J$O&LC*%Z'L2* /5-
M?U9M'\.:EJT$*736-O).8C+L#;%+$9 .#@>E6[2\6?3[:ZD*Q^=&CX+< L <
M5YCJ6FV5C'XZFT%(8M%GT HZVV!"]X5E'R <;MNP''4L.]:%K/9GQ% NOB!]
M(N-"@2RDN ##O!;SDR>-Y!3CJ0OL: /1MP!P2,^E&]?[PZXZ]Z\MCTN_TOP+
MX>\375O)-JF@L\K+(N9GLF9@4.>=PB*L,\@K[FK.KZ1:0ZAX/:_M8%NKO5)K
MB\4J.LD$I96/=02B<\' '>@#T<2QD*1(A#\+AA\WTI3(BNJ%U#MT4GDUXS=V
M6E6_ACQ)-;P6R3V7B.,V+(HW0)YL+'RO[J_ZP_+Q][TK3F.FZCK^JZ7KMSJ$
M.JG4EN=/%O"I::(;3"T4FPD  8/S #YLX!- 'J9D13@NH).,$]_2J\.I6EQJ
M-S813J]S:JC3(#G9OSM!]\#./0CUKR/7K+3?[/\ ']TD$'VN'4X9;1PHWHWE
MP9:/T.X-DCK@YZ5U^@QV,7Q,\2MY$0FN([6:WD6+[Z&,[F# =,]3GKB@#MBR
M@X) /UHW*?XAZ=:X_P ;VAM+O1_$UO8FZN-.N/)FB1 SRP3?NV4>N&96_ ^I
MK*\(:)<6.HS>'M0LX?LFDW#:A#*L8$;><I*JN>RLTX]MJ4 ='JGB'4-(LK*:
MYT^W+W.JQ6)6.Y)"))*$5_N\G!!*\8]:LZ9KDM]XDUK29+5(AIWD%9%DW>:)
M%9LD8&W&.G->=026\/@FQC1HTCC\7JX4<!8Q?%L^R[.<],<UV&@2QM\1O%H5
MU)*6>,'KA&!Q],C/UH U'UYXO&2Z');QK"VGO>BY,O/RR*FTKCC[V<YK9>1(
MT+NZJH_B8X%<)XCM-)G^(UD=?AMFTV31YH@;P#R6D\V,A?F^4M@$@=>,US=I
MOT"S\/1^(GN[?0#'>10/)")1!NF!@$H=6QF+@$C(Y''- 'L-%8OA.RM=.\,6
M5I8R7DEI&K"!KS_6%-Q*YX&!CH,# Q6U0 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'?.S37!M5?[/+Y8F#%?++[=JL2#@$@GC'45T$LL<$+RRNJ1HI9W8X"@<DDT
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MDI>*=OS^892IYSTP/2MG5]:T[0;-;O4[I;:W:18A(P)&YC@ X''UZ4 <Y/\
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M: ,CQQIT^I>#]0CM$+WD"K=6H49)EB82(![DJ!^->=ZA8:TVDQZU9Z=>)?\
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MMO*;1D"DL!GYL\C(Z<\BO2)=)MIM<M=7;?\ :K:"2WCP?EVN4+9'KE%_6K]
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M)!<0*7=-EQ&4<;6*YP>QQD>H(-<GJEG=/\8M!O$MIFM8],N4>8(2BL67 +=
M3Z5V5O=6]VKM;3Q3*CE&,;A@K#J#CH?:I: /,$TR\7X;06XL9Q<?\)")FC\H
M[]O]I%M^,9QLYSZ<]*[WQ#)>P^&]4ETZ 3WR6DK6\17<'D"G:,=\G''>M*B@
M#QYDN+B[O98FU[4(KGPU>6L<]Y9-&#/A6,:J(UV\#C(P3P"2*ZA=/G&J> ?]
M$D\JWM)DF_=G$6;=0 WIR,8-=M++'!$\LTB1QH,L[L %'J2>E)(HN+=E61E$
MB$"2,\C(Z@T >8^%=,NCXP7PY/&QTWPI++/;N3D/YPS;CZHC2C\%KK/']A=:
MCX/N(K-9VECFMYRMN 9&6.9';8"""VU3@8.3@8-:>B:#9Z#;S1VS32R7$IFG
MN+B0O+,Y &68^P  Z "M.@#SBW\/6GB;3?$:P7NNW4UY:16Z7FJ0+"N]"[QE
M%\M&RCMDDCO@'@XRO[.UOQ;X8\0Z]>:?=VVI3VUM:6]JT>R4)"5DE"AA_'(7
M R,':M>N44 >2:MIZ:KX;\375C+XCU2Y?3H[8/J%H(PX\PML1!&C,R\YX(^;
MKUK?\6Z==W?B2X^RVDLBOX9OK=61#M,C-'M3/3)YP/8UV\UU;V[Q)//%$TK;
M(P[A2[>@SU/M4M '*>%->MO["\-Z>UO>I//:"'][;/&$>*-=ZMN ([X['!QT
MI_Q'L[G4/ASKUK:023W$EHP2*-=S,>N !U/'2NC>WADN(IWC5I8@P1R.5!QG
M'UP*EH XW3)!J?Q"35X+:Y%G)H:QI+-;O%\WGME2& (/&<>F#TKB])TZ\TI-
M&OKZ?7-,MS87%L7L+3S'207+N%=3&Y 96!!P,[>O2O9J* ,?PK8Q:;X7TZT@
MCO(XDA!5+W;YR@\X?;P",XP.E>>26>@1>,?%$GB'1]9FDFOD>WDMK2[=&C\F
M,<&(;3\P:O6Z* .#2*VN]?\ !4^E6-ZFG6IO%_TBWE1HOW6!N\P;ADY )ZUE
M7FEWA\$>*X4L9S-/XB,T:"$[I%^TQ'>!CD8!.?05Z1=ZC9:>$-[>6]L)#M0S
M2JFX^@R>3R*LT >0W-\IT?XA:+'I]Y/?:EJ%Q!:B&V>197>&- "X!5=IY.XC
M YJQJ7AW5;SQ%XOM(8)B]SX:BM(9RI"2RX8%0QXSZ_6O1]-TFVTI[Y[??F]N
MFNI=YS\[*JG'H,**OT <!;79\1>)?"CV.GWUNFE)-)>&XM)(1#NA\L198 ,=
MQZ+GA<^E9ATNX'C]_" B)TA[U?$);^$)SF+\;@!L>F:]2K)TCP]::/<W=W'+
M<W-Y=E?.N;J7S'*KG:H/0*,G  [F@#S[1](\N_M](U&Z\2-=0:Q)="UBMD^R
MX$[2I-YIC^X01GY]V21CM1X7T@Q3Z1I.H77B1[[3[UY3:_9D6UB*ER)?,,8R
MC \8<D[_ *X]7HH R/%$-M/X:OHKNTN[JW9!OBLP3-C(^9,<Y7[W'/' )XK@
M6_M34[6* /J&JZ=!K>G/;W=W8F&9T$@,@<;5W*F!\^T=3Z5ZK10!YMXD75+/
MQ+XAO+2"Y2"6'2T>YBM?.9(Q-+YKQJ5(9E4@]#C(.*YCQ%97UYX2\<V]M;:U
M>/>&QFM'NK5_-N$5T4D (.A4_+@' !(KW"B@#B;>SNA\:KV]-M,+5M"CC$Y0
M["XF)V[NF<<XJUX_LYK[3='BBMI)P-:L7D5$+803 L3CL!U-=94<T\-LF^>6
M.),XW.P49_&@#SSQ/:R6?C2^OKJ\UVVL[W3H8HFTJU$_FNC2[HF!C?!(<$=
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M2V)CB#,T05'9',@.S<0F2F 0&'ISL7_AR+44T@37UT#I=PMQ$R[,R.JE1O\
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M&.73&L)G>6-X3"[' 9@1@] !G% '':3XAU4Z1H.GI)'<:E<Z2EZ\[6[. NU
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MM*N/M,(C*'?)A@6<LISG>Y.,<F@"GXV:;P[\.M8GT3R+&:.)Y-T4.!N8Y=@
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M8!Y4CY!G'%<WI6M7^G>-$O-<TZ]FO'\.VPN/LEJ975_.F(!C3)&[OC@$8XH
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MV7"*_IE@!S6+IMMJ-SK.FW+6WB&<R:3=6DTVH0NH2Y=8SM"%0(U^1ANP%)P
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MN,<@=3Z_>45KUY!\+M:NM7L="T.*>73[73[3[3(&0J^H'>PPA(_U2G[Q'))
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MW6B6%Q?P&WO9;>-[B$_\LY"H++^!R*NT %%%% !1110 4444 %%%% !1110
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M@US7C'Q_+%X>TFX\/?:@^I:A'9M.+3>T'SE738W_ "U!! 4CL:W]<\12^&O
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MG-4QX]MXO$&OV%Y97<-KI,<;-<>22&+ G''K\NW'7-;NCZY!K(G5+:\M9H&
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MF#4M!-[=CRU&^7:AW9QQU/ P*W[+QSHUXQ/^E6\#027,%S<0,D=Q$@RSQGN
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ME5]QC@UT]% '*1?#_2[:*P2TN]0MO[/N9KBT,4PS$)?OQC*G*')X.3SUJ?\
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M[;6%U=W7VBZN+F[MXK>:6=P6=8]^T\ <_O&S^%9Q\!:=':V<%G?:E8_9K-+
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MC4M]-PE?Z-6GXK\/:KJ6K^(IK.T:0/9Z<\ ) 6=X+B25HP3QG&!S_>%>C44
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M..GK7J%% %33[R2]ADDDLY[4I,\028 %@K$!QCLV,CV-6Z** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO]Y@,<#GD>M2ZC8WGB'Q_P#;;.TO(;2[\+W%JEQ/;/$$E:7A6W %6[X/..:
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MO!:V4XTZ+PJEE!*(SL++(<(#T+8QQUK&TK1-5C\._#"*33;M9+*[+72-"P,
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MAFCN(8YH762*10Z.IR&!&00?2L73/&&C:OJ"V5I-,9) [0O);2)'.$.&,;L
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M_P )*\KZV]W'#;Q_Z(R&?SDE,A3: O&1NW94@#D5T_Q0!/PXU<!!(=L>$/\
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M021R+T93T-6*QO"EC'IWABQMHH;R% I<1WI4S+N8L0^WC.6Z=NE;- !1110
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MN-U?Q=K_ (8T'1O$.I*6DN;9K6[TV4",B<*S+,!U4?*=XS@*<]N;CQZ\=?\
M#VA2^)+C%QIMS<7MS;K&&E=7BQL)4A0-Y X^[[\T =-_PB>D_P!V\_\  ^?_
M .+H_P"$3TG^[>?^!\__ ,77&6&MZUJ5YIWAJ75IXW&HW]O/J$2H)I8K?&T?
M=VACO7) _A.,9J274?$0M-4TN*ZU&]72M72&XN;1(S=O:- )!M!&TN&=02!D
MJ#CF@#K_ /A$])_NWG_@?/\ _%T?\(GI/]V\_P# ^?\ ^+KG=#UVXN=?\/6D
M.LSW]G/:WYE:> 12EHY(@JR+@$.@9E/ SUQ64^M:]J%_IUA!J\UM]J\0ZC9/
M*B(6$$8D*JN01D!>#ZXSF@#M_P#A$])_NWG_ ('S_P#Q='_")Z3_ ';S_P #
MY_\ XNN&U36_$ U+68=-DUZXGT=XK>SC@MDDAN&6)'8SMC)+E\<8P,$5V7C3
M5KS2O"LES8,(;N::"VCD=0WE&658]V#P<;B>>,B@"<^%-( )(O !U)U"?_XN
MLW1[/PIX@BEETF[N+N*)MC21W]QMS['?@].HK+OH]1L=8O?#CZ[J-S:W>CRW
MB32F,S0R1NJD!@@&U@XX(.,'&,U9^$EH]M\-]&D:[N)Q-;*RQRE=L77A< ''
MUS0!9U2#P9HDL<6JZLEC)(,HESK$L98>H!DZ>]:,/AG1+B%)H&N98G 9'349
MV5@>A!#\BL7P%:6M\FOZE=PQS:C/J]U#<O(H9E6-RB1\_P (0+@>_O3+NWAT
M_5=$\*>'KI]-L+R2\N+A[1PS)Y>TF--VX)EI,D < 8&,T =!_P (GI/]V\_\
M#Y__ (NH;OP_H-A9S7=W)<P6\*%Y)9-1G"HHZDG?7(RZSKRRQZ(FL3"6#Q*N
MG&],:&22W>V:7!^7:7&0,XZJ"0>0<WQE_:#>#/'FD7&L7MQ#I9ADADDV>8Z2
M1JQC<A>5W$G@ ].: .OL(_!^J26L=E>74K7:N\ %Y=#>J_>(RWN*OW>A^'[
MVXNI+N(W,P@AS?W'SR$$A1\_L?RKG%U'4="\5^&-+&I75U92Z7<W$R3["SE%
M4J,JHZ<@?UK,4:I>Z5X$UV^UFXNGU+4[:XEMG5!%&7CD91'A01M'').>IYH
M[[_A$])_NWG_ ('S_P#Q='_")Z3_ ';S_P #Y_\ XNN)\/>(=?U2^TS4D76Y
MDO+QTN87M4%G';DL%*,!N!7"<YY^;/;#=,U+7AH7ASQ!/KMU-+=ZJEG+:E(Q
M"T+S-'TVYW< [L]?:@#K-1TCPWI5A+?7LUU%;0D"23[?<-M)( & Y/4C\ZNC
MPII(((6\X_Z?Y_\ XNO,)KS5/#GP[\;:K9:S>F\AUN2&-Y=C;<7"(6^[]XJ<
M'MZ 5O>-_$%_I]YJUUIVI:H[Z7%&_P!GM;9/LT+8W$3NW+[E(X7[H([G- '?
MQZK8RZO-I27*M?0Q+-)#@Y5&. ?3G%237UG;W=O:SW4$5S<[A!"\@#R[1EMH
M/+8')QTKB],_Y+?KW_8'MO\ T-J3Q?\ \E3^'O\ UTO_ /T0* .]K,N/$&DV
MNM0:/-?1+J,R[TMQDL5]3CH.#R<5Y_=:EKR:'K?B :[=*VFZW);P6JI'Y30B
MY"%7&W+?*Q&<C&!WR36NA<:-\1_&VL1ZC>R/I^D1WJPL4VR8$C"-OESL&.,$
M'U)H ]<HK@;2;5]%U/PK)<ZW=:BFLEH;N*=8]BOY+2AXPJ@J 5(QDC!]1FL.
MSU3Q&/A,/$TFOW$FI73V\<:M&GE0C[4L>0H4$EE)R2>_&,4 >M45YVUGK9\6
M:KH(\5:G]ECTV*_27;%YRRLTB8W;,;/DSMQU[@9!Q[GQ3JNH^&+/4(M5U3[?
M%H4=[+#IMK&4CF96/F3,_&UMOW!C@,>XP >F0Z=96>L7VJ*2+J[AB6?+9&R/
M?MP.WWVJ;3M1M-6L(;ZQF$UM,,QR $;AG'0\]JX#3C=7GQ*NM2;4+M2?#UM<
M^0I7R\L9/EQMSM!&X<YSWQQ53PYKVM^(= \$V4^JSPS:K!=7%Y>0J@E<0D *
MI*D+DN,D#.%]Z /5*RM-\/66EZA>:A&9YKR[P))[B9I&" DA%S]U02>!ZUPL
MNLZ\LL>B)K$WFP>)%TXWIC0R26[VQEP?EVEQG&<=5!(/(/2^%)[V+6_$6C76
MH3WT5A/"8)KG;Y@62(,5)4 '!SCCO0!U5%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 52U?2K76]+FTZ]#&WFV[PK8/#!AS]
M0*NT4 %%%% !1110 4444 %%%% !1110 4444 4M3TJUU>&"*[#%8+B*Y3:V
M/GC8,OX9 J[110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %97B
M#P_9^)=.2QOFE6))XYP8F .Y&##J#QD5JT4 8TGAJQE7759IL:VNVZPPX_="
M+Y>./E ZYYK*O/AWI5['=P27>HI:7D*17-K',%CE*1B-7/RYW!57H<$J,@UU
MU% ')WO@"POGO#+J>JJE_"L5]'',JK=E4V!W^7AL 9V[0<<@CBK.K^"=(UNR
MTFUO!.8],9##M< NJ@ H_'*G R.,X%='10!AZQX8@U:_6^CO[_3[KR?L\DME
M*J&6+.=K;E/0DD$8(R<'FI[3P]966LC5(3-YZV,=@ S[E\I&+#KR6R3R36K1
M0!RW_"!Z<$OD2]U%$NKS[?&JRJ/LMP6+%XCMR"23D'(Y(Q@U:3PE:?9[>.XO
M;^[EAOEO_/N)0SO*HP,X  7&!M4 <5OT4 <]JO@W3-876!</<J=56 3-'( 4
M,)S&R<<$'GG/2M*328+K0WTF_>2]MY83!,TY&^52,')4 9^@%7Z* .<L/!MI
M:7/VFXU#4=0F2V:U@>\E5C!&V-P7:HY.!ECD\=:UM'TNWT31K+2[4N;>TA6&
M,R'+;5&!D^M7:* .3O/ &G7LET6U#4XX9[H7JP1S*$AN-P;S4&W.<C.&)7D\
M5+)X%TZ347N3=Z@+:2Z6\EL!,!;R3@@[V7;G[P#$ A21DBNGHH YA? VFKJ8
MNA=7XMA=_;AI_G#[.)\[M^W&[[WS8W;<\XI#X"TD:==VD<UY$;C4VU59TE D
MAN&.=R'& .V"#P3G-=110!RT?@+2UAU,375_<SZD86GN99AYOF1$F.12  K
MXQ@8^4<5.O@^U>V$=YJ&HWLGVR&\,]Q,I8O$P9!@*%"Y'( &>:Z*B@# U;P?
MIFM-JS79G_XF=I':3[' PB%F4KQP<N?7H.*IS^ K*Z,OVG5=5F6YMUM[U6F0
M"[5=VTR84'(#$?+M!& 0:ZNB@# TSPE9:9K,.K+<7<]Y%IRZ:'F=3NB5]X)
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M2'&X.T@D.#C@;A^53?\ ",Z<=;U+59%DDEU&V2UN(W(,9C7(QC'?<<\UL44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/(R,_/S\O'/- %ZBJBZI8/=06R7MNT]Q%YT,8D&Z2/\ O*.XY'-6Z "BBB@
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M=J //="L)[3]G^VUA+LO<6$8U&R'EJOD/'(Q(! RVX;@<YX8U[5#()H(Y5&
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MK2 >=G<515^F?6J \.WJ&W1+/Q*MO9WIO;*#_0ML+L[,P/[W+CYF ST!]>:
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MHIC=W<#^)F5.AX!/ Q78-X8MV\37VN>?+YUY8K8M'QM502<COGYJK-X-M?\
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M77M&M9[MK6"_G><?9DDR2L<KID \D?+UQ6OJ6I6>D:=<:A?SI!:VZ%Y)'.
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M"Q(SGD<'H>1T[5KT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,V @C:-NWYOFY;IQS5LO&<MW>^';IHX8=%UNT+Q2.#YD<X4.(V.=O*[R#C^
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M?6VJZC!:W<WVBYT]'7R)9>,MRNX9QD@$ ]^.*O\ B;P_!XHT&XT>ZN;B"WN
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHJ)[FWCN(K=YXEGE#&.-G 9P.I ZG&1GZT 2T4R::*V@D
MGGE2*&-2SR.P55 ZDD]!2HZR(KHP9&&593D$>HH =1110 4444 %%%1-<VZS
MB!IXA,PR(RXW'\.M $M%%% !114-Q>6MH81<W,,)FD$47F.%\QST5<]2<=!S
M0!-1110 445%)<P0L%EFC0D9 9@* ):*K2:C8Q0R327MND42[Y':50J+ZDYX
M%6: "BBHY9X8<>;+''GIO8#- $E%1Q3PS9\J6.3'78P.*DH ***AFO+6WG@@
MFN88YK@E88W<!I"!DA0>3@<\4 34444 %%%% !1110 4444 %%%% !11437,
M"W*6S31B>12Z1%AN91C) ZD#(R?<4 2T444 %%%% !1110 44V22.&)Y975(
MT4LSL<!0.I)["FP7$-U;QW%O-'-#(H9)(V#*P/0@C@B@"2BBB@ HHHH ****
M "BBB@ HHJK9:E8:DLC6-[;72QML<P2JX5O0X/!]J +5%%(2%!)( '))[4 +
M14-K=VU];)<VEQ%<6\@RDL3AU8>Q'!J:@ HHIDLT5O&9)I$C0=6=@ /Q- #Z
M*:CI(@>-E=&&0RG(-.H ***STU[1Y7V1ZM8.WG"WPMRA/FG.$Z_>.#QUX- &
MA145Q<P6EN]Q<S1PPH,O)(P55'N3P*EH ***:[I%&TDC*B*"S,QP !U)- #J
M*BM[F"\MX[BVFCG@D&Y)(F#*P]01P1227EK%=0VLES"EQ.&,4+. \@7EMHZG
M'?'2@":BFNZ1H7D=54=2QP!3J "BJU]J%EIEOY]_>6]I#G;YD\JQKGTR3BK"
MLKJ&4@J1D$'@B@!:*** "BBB@ HJ&&\M;B:>&"YAEE@8+,B.&:,D9 8#H<>M
M34 %%%,FFBMX7FFD2.*-2SN[!54#J23T% #Z*@@O+6Z9UM[F&9H]N\1N&*[A
MN7..F001Z@U/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[S.Z0K*[,V<C[X QQQSFBYTP7.@:]I)TO7%36+F2X>0019C+[> /,Y^[7/\
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M55B1%W<99LLW91W-4-.\,W'BNY\4/=W.HBUU&UM;87EU:&W>1XV=F*1, 50
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MR^'(/MDRC1(RD;* &D_<-#G/8X;/'<4 <E:ZYK&M^&]8AEU^!+]=->6YLI+
MP3V<F/F4*Q^9"-R[N><$$YK)\-ZQ=>'_  EX3TQ-42T34+ WC7$6F&5XT58P
M$"H#N)9\EV'0>I%=U#X/N9)99M4UR:_E%A+80.8$C*1R;=S,1]]OD7G@<'CF
MDC\%M9:9H4.FZK):WNCVQM8KHPJXDC(4,KH>N2BG@\$4 8,7BGQ)K$WAFPM)
MX+&?4H[X7-Q):-QY#HJR)&Q!&X$D ]-XZXYU-,U/7]1\3>((I+ZW33=(G\H1
M"W!>?= K8+9^4!CG@'.<=JUH?#&W5-%U&XU*XNKG3(;B(O*!F8S;2Q..F-O
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MH9ERV6&<=,UGZG.UIXS\01ZM:SRVM_ID<6G2+;O*A #^;%\H.&+,#@]1CTH
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MN8[:6Z@CGE_U<32 ,_T'4UY0R7UMX=TJXL!+]NC\/VD%SI%]9OY=\J[QY:'
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MFZ=#I=DEK"\L@!+/+,^]Y&)R68]R3_\ 6P*MT4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %96E:%#I-]J=W%<W$KZC.)YEE*;0X
M54^7"@@;54<YZ5JT4 %,FC\Z"2+>Z;U*[T.&7(Z@]C3Z* ,_1]'BT:S,"7%U
M=2,VZ6XNI/,EE; &6/'8 < =*T*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "D(R".>?0TM% $5O;Q6L(AA3:@
M).,YR2<DDGDDDDDGJ34M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%5-2AOI["2/3;N*TNCC9-+!YRKR,Y7<N>,CK7.>&[SQ!-XGU.RO\ 4[._
ML+&-8WEALC 1<-AM@^=L[4P3TY<>AH ZZBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K)UK0AK)A)U34[+RMW_'C<F+?G'WN.<8X^IK6HH 3[B=VP
M/Q-<[X&L;JQ\)6IU"%HM0N6DNKM7^\)9'+L#],X^@%='10!DWV@B^U:"_P#[
M4U2W,.W_ $>WN2D+[3GYEQSGH?45K444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex1012022063010qngcbasho008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC/.** "BBB@ HH
MHS0 4444 %%%% !1103@9/2@ HHHSGI0 4449H **** "BBB@ HHHSCK0 44
M44 %%%% !1110 444=: "BBC.>E !1110 4449YQ0 449Q10 44$X&310 44
M44 %%%% !111GG% !1110 4444 %%%% !11G/2B@ HHHH **** "BC-% !11
M10 4444 %% ((R#D44 %%!.!DT4 %%%% !1110 4444 %%%% !11FB@ HHHH
M **** "BC..M% !1110 444 @C(.10 4444 %%%!('4XH ** <]*,T %%%%
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MJ)MRZ79=)8Q$[J5<)T.WDXXQCG.18E\9RFZ7['I%Q>68OC92R0K(SH0Y1I
MA4JK @_-G )]J@C\ ):6UJMA>QVDMOJK:F@CMLPH60HT:Q[OE7#$]?O9..U6
M;'PG?Z9J]V]EK\L>D7=RUW+8FW4N)&.YPDN<JK'DC'<X(SF@"E_PG=ZJRW$F
MB1K96^KC2[B3[9E@2ZQAU79\PRPR"1QTS6CX;UC5-2UWQ';WD5NMO8WHMX3'
M(20/*C8 @J,YWDDYZ\8[U3E\#W,NEWUD=6B'VO5UU3?]D/RL)%DV8W\C*#GT
MS6OI6@RZ7KFKWRWHDM]1E6=K?R<%)!&B$[L\C"#C QD\F@#*U?QM<Z3_ ,)$
MCZ5&TNCPQ7*(;LJ;J%\X9?DX.5*XYY&,],KXA\0QOX9U>=M,M]1TR'2A=3#[
M20LRNK$H/D_NC.?]I>.:U-0\-6NH^([#6978/:PO"\0'RSJ2K*']0K#</<UG
M1>!XK;P'?>%K6]=([N.6'[1(F\HC#:HQD?=3:HY_A% #5U:_G\:V>BI:VO\
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MY>L;Y-$MY+7<;88FB<(,8W?*1Y:\\]^/2_KWANZU'6+'6=*U3^SM2M(WA+M
M)HY8G()1ER.Z@@@C!H 9;^)KR[N+/3X])\C5IK,WD]K=3[1 H;8 656R2V<8
M'0$G'0YT7CZ:\&CQV&CF6YU":YM7AEN0GV>>$,65CM.1E>H[<X)XK2?PO<1Z
MS9:S::F1J4-L]K<27$/F+<1LV_E0R[2&Y&#P"1C%<[J.D#1/$?@^TLKE!/\
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M43[1=6]NSR#_ )[3'+.?^!.3^= %C3_$^AZM=S6MAJEK<3PJ6=$?.%!P6'J
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MC>CO\R@C()'ICOTI]_XFT33)K>&\U2UADN4WQ!I!\R_WO9>>IXKCM'$-]?\
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M<IR.G..V:T/!OB'4]4U,P:GJD O!"SW6DRVA@FM7W#'ED_ZQ.H+<Y^4@\XH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*:ZM[<@33Q1
M$JS#>X7(49)Y[ =: ):*C>>*. SO*BPA=QD+ *!ZY]*>"&4,I!!Y!'>@!:**
M* "BBB@ HHI-PW;<C/I0 M%%% !1110 4444 %%%% !12%@HR2 />EH ****
M "BBHUN(6G>!9HS,@#-&&&Y0>A(ZB@"2BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC-%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2Y+')5=RX&.2?8 @\"2VUG8^7JB#4+#49[^VN1;$*/.9S)&R;^5(<C@@]/Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM2\2:+H]W#:ZCJ=K:SS %$ED )!. 3Z#/&3Q1/XDT6VU>/29]3MH[]RH6!I
M&RWW1[$]AU/:N+\<7MOI6L7UU:Z@L.I2V*(^F7EIYT&J(I<K&G?=EF4[2?O#
M(-8\T!?4M;TC4];GL)K[5DGCT^.R6228'RS&Z-C)"[0"1]W8>E 'I<WB;0[?
M64TB75;5-0<A1;M(-VXC(7V)'0=34[:UIJV4UXU["+:"8P2R[OE20-L*D^N[
MCZUP>FZGI6F2ZQHFM6<EUJ5SKKSQ68AWO.KR*T4JYX*JNTEL_+L/I6-J.IVT
M'A/Q'H+F3^U6UYY?LPC8MY;7:R"3I]S:<[NG;K0!Z9)XET<:@VF)J=I_:.70
M0%_F#(@=L@<C"D'Z&L>+Q]IEK'H,.I7]E)=:L&*RV;DPX ;Y@6YP2 OU-4_#
MML$U/Q_/Y6));\KOV\LHMX\?49)KD_#4\>E:%\+KR^)M[:$74<DCJ0$9XW"@
M^F3P* /6%UO2WT=]76_@.G(K,USO&P!20V3[$$?A5Y&5T5U.589!]J\JO=/G
M3Q=<>!5B8Z9JE^FL;L?*MN"7GC]LS(@QZ2UZ79ZE:W\UY#;NS/:3>1,"A7#[
M0V!D<\,.1Q0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "LW5M&AU=].:61T^PWB7:;,?,RA@ ?;YC6E10
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S%SX-%Y?%[G
M6]3FTXW:WATZ1T:/S%8,!N*[]@8 A-V./3BNGHHH **** "LW^QH?^$E.N>8
M_GFS^R>7QMV[]^?7.:TJ* "BBB@ HHHH **** "BBB@ HHHH Q=+\.I8:O=Z
MM<7US?W]PHB$LX4>5$"2(T"@ #)R>Y/4UM444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !116$_B%I/$-[I5G;QR+86OG7=Q++
ML2-V&8X^AY(!8GL,=<T ;M%<TGBB6"?0A?6]LMMJR^4MS:W/G1I<8W*F<#<K
M '#>HQCD5TM !1110 4444 %%174XM;2:X*EA%&SD#O@9KD=,\7Z_J^G6FH6
MG@RX:UNHDFB<ZA ,HP!!P3GH: .SHI&.U2?09KFO _C2T\;Z-)?V]M+:O%)Y
M<D$I!9<J&4\=BK B@#IJ*Y?0O&]EKWB+7-*@@>--)(#7+L-DO+*Q'L&1AGVK
M2?7[&YT:]O\ 2;_3KT6Z,=PNU$08#.'<9"CU/:@#6HKF3XJD3Q3HFB-:Q,=2
ML9+IIXI]RH5"\+Q\P.>O'TKHYF=(9'CC,CJI*H"!N/89/2@!]%<.WC?7$UR+
M1F\&W'VZ2W:Y5/[0AP8U8*3G..K#BM%/&-O;:S/8:R+;2A#96]RTES=( 'E:
M0>7GH2/+Z@\YH Z>BJ-YK.EZ?%!+>ZE9VT<YQ"TTZH)/]TD\_A2:WJB:+H.H
M:K)&TL=G;27#(IP6"J6P#^% %^BN6L/$?B&]:U<^#YXK:?83,;^$[$;'S8!R
M< YQUK:EUW2(+I+:75;&.XDD,21/<(&9QC*@9R3R..O(H OT5GPZ[I%PER\.
MJV,BVIVW#)<(1$?1L'Y?QIAU[3I;6_DL;VTO);)&:6*&=6*$ G#8)V].] &G
M17.Z)XNL;_P=IOB'4YK72XKR)7Q/<*JJ3_#N;&>E;,>HV,QMQ%>6\AN5+P!9
M5/FJ.I7GY@,CD>M %FBJ=SJNG68G-U?VL MU5YC+,J^6K?=+9/ .#C/6DDUG
M2XM,&IR:E9I8, 1=-.HB(/\ MYQ^M %VBHX)X;J!)[>6.:&1=R21L&5AZ@C@
MBJUOK&F7E]-96VHVD]W!_K8(IU:2/M\R@Y'XT 7:*S?[=TR1[R&UO[2XN[1&
M>6WCG5G3']X Y'XU7T'Q#!JWAS1]5N3#9OJ<,;QPO*.69<[%)QN/7MVH VJ*
MSXM=T>>\CLX=5L9+J5=\<*7"%W7U"@Y(X-._MK2O[3_LS^T[/^T.OV7SU\WI
MG[F<]/:@"]155M3T]+0W;7ULMLK[#,95"!MVW&[.,[N,>O%8_C/Q5%X3\-W^
MIJD5S<VL(F%H9@C.I=4ST)QENN* .BHJC/K.FV<EM#>7]I;3W./)BFF5&D/H
MH)R?PJOK7B+3M%@F$]Y:+>+ \T-K).J23;03A0>3TQP#0!K45D6OB+3VTK2[
MR_N[6QDU&&.2**:=5+,R@[5SC<>>U6+C7=(L[6*ZN=5L8;>9ML<LEPBHY] 2
M<$T 7Z*I7>L:982P17FHV=O)<'$*33JAD_W03S^%0:_XATWPUIPOM3N%AA,B
M1+E@"S,P48R1G&<GT )[4 :E%<U'XTTM=:U"TN[RRM;2WBMI(;N6Z54G\X.0
M 3@=$XP3G-:]YK.EZ<T"WNI6=LUP<0B:=4,G^[D\]>U %ZBL@>)](;Q._AT7
MD7]I+")C%YBYP<_+C.=V 3C'3!HF\3Z1;^)8= EO(EU":$S+&74< J O7.X[
ML@8Y /I0!KT5SOACQAI_B'3;"1KFTM]1NX?.^P?:5:51S_#P2,#.<5K1:MIL
M^H2Z?#J%I)>Q#,ELDRF1![J#D4 7**Y[Q%XEN-&U'2]/L])DU&[U#S?+C29(
MMHC )R6XZ&IM-UG49$N)=:T;^Q[>%-_G37D3J?7.T\8]30!MT5F-XCT)%NF;
M6M.46A N";I/W))P _/R\^M23:YI%M;)<SZK8Q0/'YRRO<(JLF0-P).",L!G
MIR/6@"_17-^(?%D6CP:#/:1Q7T.K:G!8K(DPVJLF[YP0"&QCIW]:UIM:TJVU
M&/3Y]3LXKV3&RV>=5D;/3"DY- %ZBHH;FWN#*()XI3"YCD".&V,.2IQT/(X]
MZIMK^C*UJK:O8 W?_'N#<I^^YQ\G/S<\<4 :-%4Y-6TZ&[6TEU"U2Y9Q&L+3
M*'+$9 VYSDCG%+>ZKIVF+NO[^UM1M+YGF5/E! )Y/3) S[CUH MT53.KZ:NI
M+IK:A:"_9=RVQF7S2.N0N<XJAIGBW0]6;41:ZC;D:=*T=PQE7   )?K]WG&3
MW!]* -NBL6^\06Y\.SZKI%WIEXB$!9)+U4@)W $&4;@.OYX'>K=YKFD:<2+[
M5+&U(*J1/<(F"W(')[X.* +]%4KG6-,L[F"VNM1LX)[C_4Q2SJK2_P"Z"<G\
M*KZ]XBTSPW:0W.IW*0I-/' FY@"6=@N>2.!G)/8 F@#5HKFX?&FF#6=2L[V[
MLK2"U, @N);I56X\R/>-N<#\B<UL7>KZ;8300WFHVEM+<'$*33*C2'T4$\_A
M0!<HJ.XN(+2%IKF:.&)<;GD8*HR<#)/N:RWUV*6_T^*PN-.N;>XEDBE?[8H=
M609(10#O8'J,C'6@#8HJ@^N:1'=RVCZI9+<Q8\R$W"!TR0!E<Y&20!]169IG
MC#3[N[O+6\N;2RN(M0ELH(I;A0\^S'*@X)SGH,T =%1619^)](O]?O=$M[R)
M[ZS"F6,.N3G.0!G)(QSQQD41^)](E\33>'TO(CJ,4*RM%YB\YW?*!G)8!22,
M< @]Z ->BJ-EK6E:E<2V]CJ=G=30_P"MC@G5V3Z@'(IU[JNG::,W]_:VH"%\
MSS*GR@@$\GID@9]Q0!<HJF=7TU=3&FG4+07[+N%J9E\TCKG9G./PIZZC9-8&
M_6\MS9A2QN!*OE@#J=V<8&#0!9HK+M-5,U_J<<KV*VUIY;+)'=!WVLFXF1<#
MR_;DY'-2VVMZ3>V\=Q:ZG93PR2^2DD5PK*TG]P$'!;VZT 7Z*A2[MI+F6V2X
MB:>$!I(@X+(#T)'49IHO[-K'[<MW ;/9O^T"0>7M]=W3'O0!8HJE;ZSI=W9"
M]MM2LYK0N(Q/'.K(6) "[@<9R0,>IJ.#7]&NH9)K?5K"6*.01.\=RC!7)P%)
M!X)/ % &C144ES!%/#!)/&DLQ(BC9P&DP,G:.^!SQ5>\UC3-.GA@O=1M+::<
MXACFG5&D/^R"<G\* +M%4+W7-(TUBM]JMC:L&"D3W"(02,@<GJ13[S5]-TYH
M%O=0M+9K@[81-,J&0^BY//4=* +E%9/AC6CXA\.V>JM (#<!CY8;=MPQ7K@>
ME:U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !137D2, NZKN(4;CC)]*%D1G9%=2Z8W*#RN>
MF: '444TR()!&74.1D+GDCZ4 .HHHH **** "BBF^8@D$>]?,(R%SSCUQ0 Z
MBBB@ HHHH *\^T;BQ^(BR_\ 'S_:%P7SUV&WCV?AMZ5WIGA42$RQCR_OY8?+
M]?2LM-"2+Q-+K5M/L6[MQ#=P;-RSE?\ 5OG/# $COD$>@H \[3GX%^$U3_CZ
M:?3A;8Z^9YZ=/PW5ZY6/>Z!'?ZUIEY--_HFG;I(+-4POG$;1(3GG:I( QP23
MZ8V* "BBB@ HHHH IZM_R!K[_KWD_P#037E?@R\\.0>%=">X^),]M+':0&2R
M;4[=4C(49C*E<@#I@G->M74+W%K)#'<26[.,"6(*67Z!@1^8-8#>&-A4/X@O
M%+'"@V]F,GV_<4 7 GB ZP\CW.EMHY!*QI!)Y^-O'S[]O7_9Z5Y)H=[>>$/"
M7A[7-.@:4ZSI8TXQJ.#> L;9C]<NI^@KUK^Q-0_Z&C5O^_5K_P#&:8/#UX$5
M!XDU,*IRJ^1:8'T_<4 ><FR@\(R>*;+[/'>1VOA^SCE68D)*6>8.[XYP2S,W
MMFJ^I741B\<Q#5-.O3)X:&U[" 0Q.4\[(4;VW[0P!(/&0.U>F2:)<QAGE\4:
MDH<!69HK09] ?W/O2+X9G5%1?$&HA54H%%O:8"GJ/]1TH XS3/\ D>?A[_V+
MLG_H$=>E6&H6FJ6:7EC.L]NY8+(O0E6*G\B"/PK/@T*ZAN89FU_491$1A'AM
M0"O]W(A! /3@BM=$6-0J*%4=@,"@#CKG_DL^G_\ 8!N/_1\5)'I]G>_%?6&N
MK:*8KHUJ@\Q V TD^X<^N!79;$\P2;5W@8#8YQZ9HV*'+A1N(P6QR10!X9H#
MNEEHLE[JND6%K)X8ACB?5K4S(ZAY/-5#YB8.#'D<DC;Z5WVJVWV/X(WUM]K:
M[$6@2(MP\9C:0" X8J>5)&.#S78O:6TD:1O;Q,B'**R A3Z@=JE95=2K*&4C
M!!&010!YKX=O?#<*:8__  LJ::55C_T.34[<HS8'R%0H.,\8SFLC6K"UE\&_
M$>Y>WC:?^V"!*5^8!5@*X/48))_&O6$L[!OFCMK8[3C*QKP14YAB*LIC0JYR
MPVC#'WH \B^(UI;65YKT-K;I#$?#"@I"H7(6Y ' ] 2!6E>3Z/=^+(&\./:O
M##X>O%NS:XVJA,?E*V.AR'P#SP:[CQ)H4?B+0;W3&E$!NH_+\X)N*C(/3C/3
MUJ_Y=K:K+)LAA5SF1L!0Q]2>] 'D7@^:SL[?P#=:S)#%IPT6=();@@1I<%XS
MU/ 8H&Q]#4\-N8/"USXGTU,V^D:_<:A9>6/E>R+;9@G^R09&&..!7J\EO;/;
M>3+#$T 'W&4%0![=*RO$&BSZ_IBZ?;:F;*QF4I<B&(,TL1&"JMGY,C(S@\&@
M#S>YBGN8M,\527-K:0ZOK;7)N+Z R0Q0K#)':[UW+Q@ @Y&&D!I'@:UGTB[@
M\1:/+8R:O=RF\?3V%E#.8E 4*9<')$N&WXW.>]>O):6\=FEFL,8MD01K%MRH
M4# &/3%*UM UO]G:",P8QY90;<>F.E '.>!H(K7PY,UOJ,&HP27<\R26EN88
MAER66-2S?+NW8()!SQ7GFE:FMSJ7A2XM+S28)+B.Z\NSLH=K6DDD+E8Y92YR
MY<=" 2RG XKVI55$"(H55&  , "HEM;=<[;>(9?S#A!RW][Z^] 'FOAB\\*R
M>&O#MI$D+Z]!ILBE(A^]MY!#B?S@.5RV0=W5B.]9OPW:?3Y?#4_B,1R)>Z7%
M#HEPN?+MR%^:(@])74!MW?!4=,'UM8[5+F38D*SR+N?  9ATR>Y%2>3%L1/+
M3:A!5=HPN.F/2@#R32K&U@^'_@RXBMXUG;786,H4;B6F=3SUZ<?3BJ_FV'_"
M ?V9OM_^$L_MO/DY'VG[3]LW;\?>QLYW=-OM7L8AB"*@C3:IRHVC /J*;]G@
M^T?:/)C\[&WS-HW8],]: /)M3TG^T_$VI> 6!%M=7DVL9](7A(_2X;/X5B:[
M?2^)OAMXN\2W"D2+8V>FKN'W71D>;_R)(1_P"O=_+3S/,V+OQMW8YQZ9IOD0
MF-H_*C\MCDKM&"?I0!Y+XAC5]?\ $]OJ.M:1IMO=6-NJ?;[)II7A\LC]R1(I
MR)-_ !.XCU%.OIM*L1X]M-?N()-0EM8A;^> LEQ']E54,:GDGS _ Z,:]8DM
MX97C>2&-VC.49E!*GV]*1[>"659)(8WD4$*S*"0#UP: /+='N='L]:M6\1O:
MI!/X7LDM/M6-KJ-_FHN>K'*9 Y/%8/APO!:>'9)M2TO3;1M$ECADUBU,T9/G
MMYBC,B -M\O/)) ]J]7UG0]1OKN"XTS638>7&8S$]JL\?7AU!(VN.F<XQVJQ
MI.BZ=I.C6>AQA)X[2)0JSX9CC^,CU)R<^IH \PNX].T/1H9XM;TK4)(]#ACF
ML=5M6B%]; R-'Y.X[E8ABN!NYVY .*ZWXF-$_@%;B>,1QI>64C^:/]6OVB/.
M?3 SFNRFAMI)8C-'"TBG,6]02#_LY_I4DD:2QM'(BNC#!5AD$?2@#S^VM-,U
M+QAXNN%AM;J$Z3:+"X"NGELLV=IZ8.!T]!7'-?I<>$(;62;3+6=/"EHH:ZMS
M/<7P>-\1Q#>, $=0&.6YZ5[<J00E458XRXVA0 ,@#I^ S1]F@WQOY,>Z,;4;
M8,J/0>E 'G'AF]T]_B):RR7%L9;OPW9F!V=<S.'DW;3_ !''7'-:=])96WQF
MT][M[>(SZ+)'"TI"^9+Y\>%7/5L=AS7:"UMU:-A!$#$"(R$'R9]/2G/#%*Z/
M)$CM&<HS*"5/MZ4 >2:+8VMMX!^'\\-O&DS:O QD51N);S V3UY''TIGA"W:
M:3P]!=Z_I,>HVM_-(]E%8-]L,O[P2K(_FG (+$L4 /R^U>O"&(*JB- J'*C:
M, ^U1A;1+B64"!9PH\U^ P7W/7'UH X+XAO:)XN\(M?:T^CP?Z9F\2=(BI\M
M,#<X(YZ54UJZT=_AYXM@T[Q@^ORG3)79);V*=HE"D9 0# .1G/M7I3PV]TB,
M\<4RXRI90PY[BFI9VL88);0J&&&P@&1Z&@#ADT?34^)/A^-;& )'H4Y5?+&,
MK)" ?P#M^9KE/#$NDV>L>%&U1K>*WBM]72%I\".-A>87D\#Y<@?@*]IV)O#[
M5W 8!QR!Z5D7'AVWN/$=KJKE/+@LYK4VQB!5_,='+'Z&/ICG- 'EDPC.A^')
M+4 :?)X\#V.S[AA,LF"O^R3N(]C5K59M,C\*>.;"^:#_ (2"?4;CR(7(^T2.
MQ'V8H/O$8V;2.F#Z&O7_ "8BJ+Y2;4(*#:,+CICTIK6\#SK.T,;3(,+(5!8#
MV- 'F7BF74/#6M7D-F&\[Q79QVT3*,B._!6(OQTS&^[/_3(UE:II-MI>H>(]
M%GUG2-+L/L%M;P"^L6FF>W6':#"1(I)$@<X4$[B#U(KTJ3P]+=^*(-7O]0,\
M-GN-C9K$$6%V7:SL<DNV,@=  QX[ULR6\,KQO)#&[QG*,R@E3[>E '#>&=.@
M;XD^*)[I$N;JW@L$2>1/F!,1W$9^Z20,_0>E2^(+&UOOBIX82Z@CF1+"]<)(
MH9<@P@'!Z]:[8(BNSA0&;&X@<GZTC^4A$LFQ2HP'; QGWH \ACMS/JFI65YK
M^DV-T?$?FI;O8-)>LPF5H2K"4':8PHSLP%SG@&G+?Z=8:7XOM'CTUKE_$@5X
M[O[D,;O"%ED4$$Q@\]0">,UZV;>$SB<PQF8#:)"HW >F>M-:UMW:1FMXF:1=
MLA* EQZ'U% 'A?B:[CD\&_$.(:C9WC-)82B2UA\J.0;XU+JNYLC*[2P)!*UW
M)T^TN_&'CB2YMHIF&FVR R*&PICER!GUP,_05W9M;<KM,$6-H3&P?='0?2G*
M(G+LFPDG:Y&.W8T >,+=66G^&K'4?MNEW5RV@V(O-'U*/Y[E%CRGD/G.XY(
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MY&1E0"O<'K6;JG@35]:35VOM;MO-U73TLY1%9D)%L<LA0%R<?,V0222>HZ4
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MS]I\H9B.<\;6);H<YJ!/ VJQ):V\6M6RVECJ3:A:I]C.YF:1G(E;?\V [ $
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M6EHH ,4444 (54XR <'(R.E+110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&I6<KVN?M"QSJQAQUW@'Y>G>HAXAT0M.HUC3]T$8DF'VE/W:'&&;G@<CD^M
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M7&] K%?-P<_WACFM?2=+LSJW@F$W5MJ=KYFISPR1VYCAY8, B,3\JDG:<D8
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M<O\ WOK[T >=^"+KPL^D^%+55A?7X;5E*1?ZZ&41D3F4#D9;(.[JQ'?%<_\
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M\N.",&O69+6WEA:&2")XF.61D!4G.<D?6DEM+:>-$FMXI$0@HKH"%(Z8STH
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MX(BD229<?*6;:P*L"-Q['O7:VG@:6'PF^G3:IYNK27HU%M1\GK<B0.K%,_=
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M<O&8YPH:-@&!ZHI# CD=*GU'PQK%Y%H=T-9MWU;3+F2X,TUI^ZDWJZE=BL"
M ^!\Q/ R2>: .6T_6-<T'3-?U6V6P;3+;Q#<K-#*CF657N0K%6# )C=P"&S@
M]*V+_P 5Z_\ 9?$&LZ=%I_\ 9>B32Q/;S1N9KD1 &4APP"?Q #:V<<]:T)_!
M;S>&=7TC[<H.H:A)>B7RON!IA+MQGGIC-5[_ ,%:C,FLZ=9:O!;Z/K,S2W<;
MVQ:9-X E$;[@ &QW4XR>M %'6_$&LZU9^*$TD6*Z9IUGLD6>-S+<,\'F-M8,
M F%=0,ALG/2J^G^*-2M$T32+:XTFTQI=F\$6HAU:_++AECD#!5(P!T8Y/3%:
M^H>"]1-SK,>DZK!9Z?K$*QW,4EL9'C*QB+,;;@!E0HY!QC--U'P9JU[HD>A?
MVO9MI;6D-M*L]ENDB**%+Q,&&"<9&X-M/(]* .VKFO$FLZK9:[HFDZ4EIYFI
M&<-+<JS"+RT#!L*1GOQGGCD5IZ=_:7]IZJ+QPUH)D%F-@!">6N[GO\Q/)]QV
MJ+4-$-]XBT;51.$&G>?F/;GS/,0+USQC% '&KXQ\41:3<ZI<Q:3Y&F:H-.O(
MTCDW7'[Y8S)&=W[OAP=IW=#R.*LWOC#74TW6?$-K%I_]C:5=2P/;/&YGG2)M
MLCB0,%4Y#8&T].O-:4_@IYO#VKZ7]N4'4-4.H"3RON#SDDV8SS]S&?>JUYX'
MOYX-3TB#5H(]!U.Z>YN(6MB9UWMND1'W!0K'/)4D;CUXH ;XUUQKWPMXJM--
MMVF%A8O]HG6<Q&-S$7 3 ^8JI5CR!R!R<@6],O[?_A(M+LOL$C7_ /87G1W3
M3$(R!HP4V@GG<0=Q&>*@U+P7J$DWB./3-2MX;'7H"L\,\!<Q2F+RRR$,." ,
M@]"/PJ_9^&[VU\0Z?JCWMO(+32SIY00E=Y+(V_[QQR@XYZGF@#C%FAN] NO$
M7B#2WNI;?6I85>WO61L?:O*56QMRB$)@<YQG YKN+SQ-+'+?C3]+FU!-.F2&
MZ$+?O-[!6(C7'SE5=6.2.O&3FLEO!.H/X0O-#.HVV^XU$WPG$#87-QYY7;NY
MY&,YZ5;'AC5[/Q#J%YI>L0V]CJC++>026Y=XY H0O"VX!2P4?>!P1GVH FU#
MQ>--U.*WN-/>."74(]/22238\CN%PZ(1\T8+!2V>H/'%8]UXFNI]&\;/J^EI
M/IVF2R0&&WN2KO&(8V(SA<9#,<@Y&<#.,U+?>"-4NKRZE36+;9)JL&I1--:L
M\B^6RD1,V\90;3@ #KU]9[SP;>SV7BNRBU*!;?7MS#=;DM"[Q)&Q)W8883(&
M!UZT :1\0,;B33]*L?M=S:V<=S-&TVP(KYV(#@Y<[&X.!QR1FJ,?CN*^;0QI
M6FSW:ZQ;RSV[-(L84QXW*^>003@]>AQFIHO#5_8:XVKZ?>6ZSW-E':WD4L;%
M':/.R1<'((W$$=QW'6H;+P6VE7?AQK&Z3[/HT$\122,EIFEQN;(.%Y&<8/6@
M MO'EO=6>E.+=+>ZU%[B-(;JX$:K)"^QTW@$%BWW1CD GC%=1:3/<6<$TL+0
M221J[1.>4)&2I]QTKCX/!-RFA+H]X^FZC9-+=2307%NP5S-)YBL#DE2A+#(Z
MY['FM+1K#6-'OM/TO[:+O2;735B=Y82)3,I #;\X.1GY><8Y/3( [QEK-_H>
ME6L^GPQ2237]M;-YK[=JR2JIQP<GG'MG/.,&)/%-[+XBNM'AT&:22S^SM<RK
M<)M1)0V6&>6QM/'4^@X!O>*-$EU_2%M8+E+>>*Y@N8I'0NNZ*17 (!!(.W'7
MO5:R\/WUOK^L:E+?Q'^TK:&']U$4:-HPPW DGKO)QVP.30!7LO&T,NHI::A9
MFP+Z>^HXDDR\,:%=RRI@%&PX..>_/%9-UJESJ7C/P1?&T>VM+H7,L1-P260V
M[$;TZ*V"#W[\TZS^'UZ!817^J6LT$&FW&FSK#:LC3QR[,N6+G]X=F2><DGCO
M5BP\'ZU%<>'?MNKV<\.B>9&A6T8//&T9C&[Y\!MIZCN* +EAXW@U#4=-BAM&
MDL]2#&WN(GWE,#<#*H'R!AT.3V!P:V->UJW\/Z1)J-S@1(\:$LVU5+NJ LW\
M*@L"3V -8WAGPWK7A]8=-DUJ*XT2TR+6+[.5GV?PH[[L%5]E!.!SC(.]JUK<
MWFGO!:R0I(S+GSX_,1T##<C+D<,N1[9S0!E3>*1;16ZSP0)<74S1VP^T@Q2J
M$#F02;?NX..A.<#'I#I_C)=22U@AT^1-2N)9XA;S/M0"'&]]^#E/F3# '.X<
M=<92_#V>PMXIM$OX=.OK:_DO+6,1&2VB61 CP[,@[#C=QC!/ %7]1\,:U=2Z
M7JT.LVZ:[8M)F1K8FVD20*&CV;MP7Y%(.XG()[\ "S^,[R(Z3 /#=[]NU(3A
M+>21(RCQ D@D]CC(;I@@^U-N_'4=HLC_ -GM*MO-'!=Q1RAIHW;;NVH =X3<
M,G(Z-C.*M3>'=1GUG0=1FU*&633FF>;,)'FF1=I"C=\@ Z#GIR<Y-01^&=9L
M->OYM,UJ*'2M1F^T7%O);EY8I" &,3[@!NP.H.#R* *T7C.ZM&\37.J6UO'9
M:7?I:1LLQ^7<L6"YV\+F3<S?PC/!QD]/I=]+?V[RRP)& ^$:.7S$E7:"'5L#
M(.<=.QK$7PSJ-M>:[+::A:^3JES'<^5/:E\$+&CHQW8*LL9'0$;N^.:MGX>U
M'PQ:B+0GMH4NM46XELUA9H8H2%5TC.1LZ%\],D@#H" =7?W7V'3[B[\IY?)C
M:3RT(!; S@9(%<KIWCQ[RZT5;G0[FUMM:M_,L9VE1@[^7YGEL ?ER,X)ZX[5
MT>N2)%H&HO(ZH@MI,LQP!\IKD?!VD3ZKX7\'7MS<6[Q:991R6Z1*<M*8=@W\
M\;0S @=3SQC% %JP\>M=Z5#J<NB7%O:7+K!;,TZ%I;AIC$(]H.1SSN/& ?3F
MY/XTM].N=2L]5M6M[RRACG$<3^8MPDC;$,;$+R7^7! P2.W-4H? TP\$6NA2
MZB@N[*Z%Y:WD<) 2593(I*%N1DD$9Y'I4FK>"3XA74I]3NUBOKNTBM8I+53B
MW$<GFJPR<L?,P3TX4#U) +UQXGETT7G]JZ9):B PK%*LF^*=I6VJJN0,$-@-
MD< @Y(JDWCVWMHK\WMJ(#:3P1>=YV;9Q*<*WFE1@ Y#9''OD4Z[\,:UK?A^:
MSUG6XOMP:-[6XLK8QK#)&X=9"K,=S%E&>0,< #DFRFD^()]-9-3U+3KJX=E#
MQ"S(MWB&=RE2Q)+9Y.<# XX.0 N/%8M&L(+FWMX+F^DE2#SKH+"^S&-LFWDL
M""HQSSZ5%J'C+[%$R+8;KZ&R2\N+22<(Z!@<1KP=S_*W' X'/(JG;^!!:Z.=
M)"6%QIDLL\LFG7$3-"F\J56,YRH3#8X_B.-O&&6O@K6-$N+*XT/7HUE6QBL;
MP7UN9EG$>=D@ <$,-S#&2,$9Z4 :,/C*&]U".SLK7?,T%O<-!/)Y4_ER_P 2
MQD?-M'+<C&".M=/7(ZUX.EUMHDNKF"0020R6UXT1%U;,FW<5<'G=M]@,GKTK
M8TIM6.H:HM_)%):"8?8V2$QL%[J<D[L<?-QG)]* (=8\1QZ7JEKIB1Q27EU#
M)+#'-.(A+L*C8A(.YSNX'L>:AN?$\@DOXK'3FNI=-@2:\C\W8REE+"->#N?:
M,X.T<CGG@\4>''\1P/:3+93V4D)0Q7,)8QR?PRHP.01Z<9XY%4[7PC>Z3?7=
MQINIJWV^TAM[HW<9=C)$GEK,"",DKC*GJ0#D4 4=9UM];U+P@NGPPW6D:MYL
MS)+(5$P$#,%==IX&0<<\@=,9JMH_B6\T+PKK%Q+IH>PT>_DM%07C2/'$A522
MS+DA<[B2>F<= *VE\'M97/A<:=<1QV>@QO&L<J%FE#1^7]X$8..>AR:LZ7X9
M:S77;6[N(KG3M4N9I_)\HJRB4 .K-D@CKC '6@!C^+DCU;6M.:U3S=-M4NEQ
M/G[0KYP%&.#D8^I7KFH]3\8MI$X%YIK10K<V]JSM+@N\NT9B!'[Q5+@$Y'0\
M<55L/ $=F^@32:A+-<Z:K)<S,,&[7"E0W^ZT<1'^Y[U%K'@G4]2N=6:/5[98
MKVZMKJ,S6I>2(PM&PCW;Q^[RF< #EC^(!>/C*0:OJEH='F6UTJ0"]NVG0+%&
M8O-WA<Y88QP.>:FTOQ:NHZS!8-9,BW-N;B&>*3S5&,923 PCX.<9(.#SQ3;;
MPM(;OQ*=0N8I[;7%57CCC*,@$(B/))SD#/M46DZ/XFTK2GMKS7K>Z6UMVCLI
M%LF#DA<*TP#'>1QPH&?<XH ZNO/M<E_M#QKJFGZS%'_8UGHZ71<7#*T(,DFZ
M5<+D/B,=#QC@\D5V>C-?MH]HVJ;/MQC'G;%V@MZXR<?3)Q6->>%7U'Q%JE[=
MSQ-8ZCI@TV2W5"'" N2V[.,GS".GI0 L'BS;<Z1#=:?)!#JT9:QD\T.2P3>$
MD!QM8KDCEAD$9]<P?$.X_P"$7N/$)\.70T^&-VW_ &B/)=93&5QG/;.?J/0F
M]8^%;Q4T2+4KV&Z31,FU9(BK2N(S&C/R<85CD#J>>.E5?^$*O3\.;GPJVH0>
M9,TF+D0' #RF0_+NZC..M %J?Q=?Q:K?:6OA^5KRWM5O(E-T@62$EADG^%LJ
M1CGJ.<<U+I7C&/6+RT@M;-L7FDKJD#/)C*D@;&&.#ENV:?+H%])XGN=9^U6X
M\[3!8^5Y;?*0S-OSGD98C&.W6LS2O!>I:,^B26FJ6WF6.F?V7.SVS$21AE(=
M1N^5OE[Y'- %5M937]9^'NLP)-!'?-<2>2TAX!MG(! X)]ZV;?Q@KZY8:;=6
M#VIO_/\ )$DF)5$6>9(R!M# $J<GCTJCI/@J^TVU\)0MJ-O+_8 <,1 R^<&C
M,>!\QQ@-G/.?05%I_@;4[2[TB6?5[:==.N+B1F-H?,N%E#!B[;^7P0,XQQT-
M &AI_C:#4=1TR*&T9[/4E9K>XB?>4PNX>:N/D##H<GT.#755R?ASPYKGA^"+
M3GUN&XT>S4K9I]E(GVX(1)'W895&.@!.!SV.QX>;56T6$ZR\3WV7#O%$8PZ[
MCM;822N5P<'].E &'XMUI[C1_$NG:?;-.]A8LUS()S$8V:,LJK@9+!0&(R!@
MCGGBN/%C>'O"%E<2V$DMO::/!=33R2>6KY7[D9((>3"D[<CJ.>:GU'PAJ+ZG
MKUQIFI6\-MKEN([J&X@+E)!'Y8="&'5< @^F?:J5WX!U2YL9[/\ MJV:*?15
MTMC):$F(A67?'\_R[MPW#G.T>V #3'B34#XTN=/6S233X-+2^!C<F5][..%V
M\GY,!<]\Y["SHWBK^T];;29[/[-="R2\V"8.45C@HXP"K@XR.>O6J<OA+4I-
M0DNX]9C@DN-'&F3/%;D,K*7*R1G?\N"YX.>@Y[U6L/">L:5=)J*:I8+-!I#6
M"I#8-M# [E?;O)/S<D=^@QUH [>N4GTOQ4?M7DWVFMG45GA\U9?GM^<QR8/5
M<C&W@[!GJ:WM':_;1[1M3V?;C$/.V+M!;Z9./IDXJ[0!P/A35&MM1\0:=:H;
MR[;79CY3SG,4.R/YV8YPN> ._;H:MZGX]DTUM<8Z)/)#HKQB[D\]!\C('W*.
MY ;...AZ=*KQ> [ZUUB;6;/4K>#4WU)[H2B!B&@=5#P.-WS#Y5(/&#R*FU/P
M7?:E:^+(3J%O'_;ZQKD0L?(VQB/^]\V0N>U &G?^*3!)JHL;%KU=)17O-LH5
MN5W[4&/F8)@X)4<@9SG$:>+X[C4+:WM+42PWNFG4;*X:;8LZC;E.1PP#J>>Q
M^N(CX6OX-0UBXLKZ"--9B07221%O*E5-GF1\\Y7'RGN <]JDO_!5G<Z9H5A;
MRO;Q:0RI&1RSP>68WB)]&4X)_&@"71/%<>N:?I%[!;JL-_;R7#DS?ZA4P#GC
MD@D ^ASUQ6'XXU_2=9\"W\VCZM;7K6UQ:EC8W0<KNG08.T]QN&#UKH=!\,PZ
M%>ZM/%*SQWUR9HXB/EA4_,RCZR-(W_ @.U-\3>'/[:\/SZ99-;V;321.TGDY
M'R2*_0$9^[CKWH IMXVBM'UB+4]/EM)M-$#"-9%D,PF)6(*1P&+ J1T![XYJ
MP_B>>#4KO2I],_XF<5D;VWACFW)<Q@X8*Q488' P1W'/IGZOX&EUN]UN:XOT
MB74;>V2(Q1G=!) [.CY)PWS-TXX'6M:RT2X;7H];U.:"2\BM#:1K A5%#,&=
MN23DE5X[ =\T 4M/\;07]_H-NMNB1ZU9-=P2F?.-H!9",9W -^C>E;-I,VM:
M")986@6[A.%24@[&'!#  @D$'U&:YB3X;VSV$MLE[*A&H_:[=U&#;PEV+0K[
M$2S#/^W["NBG.JIXDLDMGA_LKR6$\1A(96_A8/G'H-N.A)]* ,_2_"KZ?=:1
M.=0NW:Q@DA8/<NXD5B2$*G@[<C#'YOD6M76=8AT:UAD=#)+<3I;6\2G!DD<X
M SV'4D]@#6C6%XJ\/R>(+"U6VNQ:7ME=QWMK,R;U61,X#+D94@L#R.M '.:5
MJ5[8>+/&=Q+I\\TT8L0EK!*9MQ8,,J2!A><G@8 )QQ4NK^.KE- UN;3[6W-[
MIEW#:2$7&^/]Z4PZ,%^;'F#@@8(/IRZ\\%ZS?/K=Q+K%I%/J8M<K%:ML!A.2
MK9?+(P)4CC(/X477@6_O+7Q#'+JMLK:L]M,GEVA589(1&!QOY7]V..O)YH O
MZYXQDT"*>>]TPK!:K"9I#-M#EV(*PY7]X5 R?N]16(^KWVA^,_&%Q9Z5<ZG'
M%%:32HMP%\M1&Y;:&/)[A1QQVXS;USP1JVLMK ?6;4+J5M%$2]HS-"R<XC^?
MA&/)')]^]:,GAK4UU75KRWU&V']K6T4-P6@.8F167>@W8.0QX/3CD]* (=3\
M>P6.CG6(;&2;3%L8K[[1(_E"1'R0D>00\@4$E<C&1SS5Z3Q2AUZ32+2".:XB
M\AI(VGV2%)#C>B8^95').1T(K#U/X>7$]M>V%AJ<,.GW&D)ID4<]N97MP@8
MHVX !LC=QSM'X7=4\'7.M-;_ &^XLW>"6&6WNXX#'/;%-I81G<>&VG@GC<<[
MJ )IO&]NE[$D%J;FU:^-B\D4FZ1'#%"YC ^X&!!.<\9QCFK>C^)EUN[=+2"-
M[>.:6"1UG!DA>-BN)(\97=@D<GCTS5+3?#.LZ1JMU'9ZU$-#N;I[LVSVY,\3
M.V]T23=@*6)/*DC) ]:8GA.X37HM=>:TCU"WBF0W-O RM<AAA!*H/S!>#ZD@
M8V]* .OHK.T)M2;1;8ZN8VOL$2-&A0-\QVMM).TE<$CL3BM&@ HHHH ****
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M\>7%C<,'MYCR@CVJ_P"+[>4ZUXM\@B.)5T>>Y;RO,41K-(79D&-P"KDCN%H
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MTRS>[O[J&UMH_ORS.$5?J3Q5:#Q!HUSIRZA#JME)9-((A<+.I0N2 %W9QG)
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MKR_M];L)[:S7=/)%<(PC';.#QGMZU%:^-O#MSX?L];?5[*WL[H+M:>X1=KD
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M.%')4$=0.M 'H%%-C=98UD0Y5@&!]0:=0 4444 %%%% !1110 4444 %%%%
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MU!%>4^'_ !;K-SX/\'#2K72K.?6+NZMW1+8K#"%,I#*@8=-FXC/)STSFMO\
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M&, -UR*IZKJNN:_X:TS6IIK,:9=:Y:K%:+"PDBC6[548R;B&)VC(VC[W'3D
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M J)Y;=;F.)Y(A.P)C1B-Q ZX'6N$\2R^,].\&Z_-=:AI[!=+DG2ZMK=HVAD
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M&8 N?0>M<MX9U?7=;UW6&GELXM,T[4)K)8EA)EFV@$$MNPN-P['//2J/CO\
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M5-02[:3Q*@3$15DQ=N#DECD<<#C:,#GK0!ZQH&@QZ%;7 -S+=WEW,;BZNI@
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M(8 @]0:\<@N->N_">EW-SJ$%Y<OXJV0;X641L+B53N.\DKG!"C& ,9/6N_\
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M+(_E,N\KL0]?-XQ@\9S5[3-<FF\1ZGH=_%''=6P6XMVCSMGMW) ;GHP8%6_
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MU>UM/^/B7S !%QGYL].*2#Q7H-SI4^IQ:M:M96[;9IO, $9XP&SR"<C [Y%
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M]2U2PT>S-WJ-W%:VX(7?*V 2>@'J3Z"JD?B?0Y=,74DU6U-FTH@\[S %$A.
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MS-/#;@I"TQRRI_"I/?:,#/7 &:9HFB0:);SI'+)//<SO<7-Q+C?+(W<XX
M  Z  4 8%O;*WQDO[EHLE=#@1)"O3,TN0#^ KE/!]MOD\/:5?:[.VI:;=22/
MIJ6*AH9 ) [.^,A&#'YC][<.N:]=HH \6T"]DTSPQ8+-+%I\,GB"]+ZC/;"0
MVO\ K"I7<,*S?=#'L2.]%K?Q6=MH]U>SS"*S\5W$MS-<0^6R+)'*4=U &W=N
M!Z#[U>TT4 >0V=N)-2N-'O\ 7IX+I_$#7<>GQV*M(_\ I'FQRA\9V;=N6Z
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MBJ"6C^8NA$:@@#JV>E:?@U;Z-[A3=0W=@X\P3+I;63>;G'1C\^1U; Q@#)[
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M$];C4O.M+>&)$M_*Q@-$KK@YXP"0>.>M=!J_BC7?"=[>C4[BUOT.CSZA%''
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MO*RA=[N[.QP. -S' '05I4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6U[YM]&[I)$L;G85ZACC ]LGGG&<4OBC4_['\-WFH?;K>Q\E5/VFYA:6./+
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M;7\MB8II&D8J48;5WA"4^? ^\?0UWE &$OC+0&U7^S1J ^T&?[.#Y3^69?\
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MI0!Z/J7C#0=(OI+*^U!8IXD$DH\MV6)3TWL 0N<< D$]JBN_''AVRXFU [A
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M$-O8*H  SDD@8QFN)L;G^V?^$(TVRL;R"ZTF5);X2VKQBU5+=XV0LP )+,
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M3A1A4& ,*HS@>Y)R36%HWB;5M6NM(N8],+Z5J4)E:01,C6H*[D+,3B0,./E
MP?45/K>MZQ;>)]/T33+:R9KVUGF6:Y=L(T90<A1R/G]?RH Z>BO/K7QSK=['
MI%O%IME%J%SJ%UIMTLDK%(YH4=LK@9*G8#Z\X]ZOMXGUB6SUF2V@L7N-#15N
MX\N5N)A$))%C;@J " "0<GJ!CD [*BN$C\8:[K5Y<0^'['3V0:9;:E;M=R."
MZR[R$( X/R8ZX'O2VGCRYUW3X)-%LP+I]-COVCEB>4;G+JL?RD8YC;YC[<'/
M !W5%<6GB7Q)>Z[;Z7;:78VDTFFQ7TB7DK%HR9-KH=HZC!P?Q]JSK7Q+XBL_
M"^M:U,]I>"QU6>*9!"X*01RE'90&/W5&[;['G)H ]%HK,L-1DO\ 5+M(6A>P
M@2,+*H.6D8;B,YQ@*4/_  +VK O_ !?>KINOZMI]O;RV>ASO#-#)GS)_+4-*
M58'"XR0 0<[>V: .KN[VTL(A+>74-O&3M#S2! 3Z9-3@@C(.17"2O+K/Q(M(
MR]M-I=QH+R"":$L&CDDC# C=C) '..G&#5[5[C4++QCX8TG3YK>#3IHK@O!Y
M).?+10!PPXPW QU&>: .IAN(;E"\$T<JABI*,& (ZCCN*DKR_P .:O?Z#:?N
M;:T.F7'B>YL77+"0>9<.JLN.  <<<Y'I700^*M4O[BWN--TTW6GO?O:2J(F#
MI&KM&TWF$[2 RYVXSCOGB@#K))XH<>;*B9Z;F S1'<0S$B*:-R.2%8&N+^*:
M(WAS3BT F*ZQ980@<_OEXYXYZ5J6R-%?7UW%X>BL9[:T @D<H/-W$EE)3/ ,
M:>_/O0!TE%<#IWC#7[Y/#$AL]-5-?M6>,;WS!((Q)D_WEQGY1@].?0C\:ZU)
M!IL2V%BUY/J]QI,Q,CK&'C$A#J,$X.S///:@#NI[B&VC\R>:.),@;I&"C)Z#
M)J2O+O$>M7FK^$M<T_6+2VBU/2-4LHW:#)C=7FB9'7=R,JV"*Z6]\3W\G_"0
M2:3!;2)H9VRQS;MUPXC$C*I!^3"L "0V3G@ <@'645R%OXR+ZK8M<"&#1]2T
MLZA9W#*0Y*J&=&YQD(P;W&?2HI/%.M21RVEM8Q-JMO8Q7<L/D.REY-Y6+AOD
M.$P6)(R>G6@#2UCP=9ZS=7,TM_J4$5W&(KNWM[G;%<*!C##!(R#@[2,CK701
MQI#$D4:A(T4*J@8  Z"N0B\1^(KWQ(FE6^FV5J186U]*MW*Q>,2.RO&=HQN&
MTX[9K7U?6GM-:TO1K41B\U 2NLDH++&D:@L< @L<LH R.I/;! -JD=UC1G=@
MJJ,EB< #UKA)O'&IQQ?9TL+4ZA!K<>DW(:1A&=^"LB<$@%6!P>G/7OTMQ/J-
MMX5N9[^"RFOX[>1Y(HRWD/@$XY&<$>U &I%+'/$DL4BR1NH9'0Y# ]"#W%/K
M@M-UG4[O6_!T5LUI:6%]HS7;VD<)VJ0(?E&&& !(0O''OQC2\+>+'\0WKPM)
M;1RQ1L;JQ9&CN;20, %8,?F7!;Y@ .!ZT =42%!)( '))I001D<BN=\87,)T
MV/29+AH/[38P22)G<D.,R,,=/E^4'L76L[X=ZK<:AX2;3I)T?4M(D;3Y9'4D
M/L_U<A&02&3:??F@#JAJ%D;F2V%Y;_:(EWR1>:NY%]2,Y ]Z;;:II]X2+6_M
M9R%+8BF5N <$\'H#Q7DK07EQ\*=-U.5[-[HWZ(L[6Y,@66^42#=NZ,>OJ./>
MNWLQ!;^/[G3'TG3%DNM-^UW%Y##MDG8N$(;/\/'3)Z"@#IEOK1T@=;J K.VV
M%A(,2'!.%]3@'IZ&K%>8^$]0-CX.^'T'V&UGCNYC"))1EX&\N5@R<<'"D9ST
M-;@\6W\?B/3]/G@M0E[>W%IY<>7:#8CNC-("5)8)DIP1N'I0!V5%>?Z)XIU2
M'2-^H3175W>:U<V%OY<#838\N25#$D!8CA1CL"><U9N?&.IZ7IWGZS8?88EO
MS;M?M;NT(AV%EF,8.Y06PAR< G.<4 =18Z1;:?J.I7T+2&7494EF#$$!EC5!
MMXX&%'KS3[W5]-TYU2^U"TM6<959YE0D>V32:1=O?:5;W4DEM(TJ[O,MGW1N
M,\%3DY!&#53Q)IEA>Z->RW=C;7$D=K)L>6)7*_*>A(XH ?\ \)'H<D%PZ:S8
MLD,32RM'<HQC0#EC@\ >M,T'0;/1DN)X+BXN[B]823W=S)ODEP,+D@   =
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@C"#@@]37<KJ5@]\;%;VV:\ )-N)5,@ ZG;G/<5B:[XI73M8T:PLY[&:2\U
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M[;17$I CBDE57<GI@$Y/0UF>*=:NM#M=/FMHX7%QJ-M:2^;GA)) A(QW&>]
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M^B@ KR?3= -QX=TC38]+E@UNTUPW,DSVK(8D%RSLYD( (:/@8)SD#L<>L44
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M-'LU18[=HTGV3.9(P< %C$=N/?%>J5#=WEK86SW-Y<0V]N@R\LSA%4>Y/ H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-L6S]P;<\9. Q(&>E-M?!%E9V>C6L=_?F/2;EKFWW-'DLP8'=\G(P[>G7Z4
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MX' W$X' J]>:%#>Z_IVL/<W"3V"2)%&A781)C=NRI)^ZO<=* .:N?%-_I?\
MPF4TEA:SS:1' Z?9T93+NCW9<Y)(7/Y U%J^LZC>P>*-*E:RN;&#1#<"Y@C8
M;C)')A#\Q&?EW?1A]3?\0>'9(+#Q!>:?_:%W=:N(DN(8I8T947"$Q9 ^8)G
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M ?:J?+A1@;54<YZ5D7/@*PN)[E_[1U**.;4$U(0QRH%CN%(.Y<J3SM&021Z
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M):MME_U\<A#.)"02264'((.<^M &/I7BW5;O5[>PF%B[W.ERWBO#&_EQRHR
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M@#JI_&EK>:'JTFGBZM[VWTZ2\@6[MFB+H%.V10P^9<X^F1D<UC:=XLU>XO\
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M^TJV2W+)@NP2;*CW!8 CWH TK?QUHEU=+#&]R$DMY+BWG>V=8KA$&7,;$8;
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M,V 1G(SCI61JFD:C<Z5XUAL]+UR5-2TNV%DU[ODDE,;R!@=V2A^<$(<''.*
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M:Z(2DC(6#+DDCG/(]*V$TY],^(=A*-4U2X%MX=FNPDMQG<1+%\G3[IXR/84
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M50T.[EU#0--O9L>;<6L4KX&!N903_.K] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<OXUT.?7H=%
M@BBD>.'58IYVCDV-&BJ_S@Y!!!(QCFNHK \7ZM'HVC1W,M]<V2M=0Q>;;Q)(
MQ+.!MPW&#T)ZB@"$>!M*?3KZTN);RZ:_FBFN;B>;=+(8F5D&<8 &T< >OK5W
M6/#EKK%U;WAGN[2]MU9([FTE\MPC8W*>""I(!P1U'%9VI^/--TRZU.W:SU&X
M.EE3>O;V^]8$*!]Y.1QM;MD\'CBHH_',1\6:AIDEI,FGV=A'>/?%?D"D.Q8G
M/W-J#!QG.: *FH^"(QJGABVT^.YAL+ W3R7,4^)8W=00Y8G+,S9SUSDYX-:J
M^"-*32ULUDO%E6Z-Z+T3G[1YY!!DW^I!*XQC'&,55N?&<5WHFKFUM[ZPOH=,
MEO;87D 0R(%.)%&2" =N0>1D9'-8NF^*-9GO_AG%+>;DUFPN)K\>6O[YU@1U
M/3Y<,2>,4 =7#X2TZ(:<6>ZFDL;I[M)9IB[O*RLI9B>O#'C@#C%%YH=O;ZY)
MXFMTOI+];81/;6TRJMRJ[MH*L0I(W'!)%1:?XSTW4=0AMHX;R.*Y:1+6[EAV
MPW+)DL$;.>BL1D#(!(S5>V\?:9=R((;/4C'.DCV<QM\)>; 21$<\G )&<9 R
M* &^"/#LNDMK&JWEFEG?:Q>-<R6ZN'\E,G:A(X)R68XXRYK=NM'M+S6-/U24
M/]IL%E6$AL#$@ ;([_=%<_X7\<Q:YI.ASW=E<6ESJS.D*E/D8K&9"0<_=V@\
M^HK0N?%VGVXO D%Y<36MZM@8((MSR3%%D 7G&-K9R2!P: *^K^$K*6'Q)=P6
M0O+S6+=$G@FG*)*8U*H P&4Z]?7!KG='\(7&IZU>7.J6&IVMI+I$NF2MJ-ZD
M]Q-YC+NP49@JJ%XZ$EB<=:M^(_&4[Z9X>O-'EFM3<^(;?3KN*:("15+,LD;
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MRWL*SPI;W<5O<&-+J-1A5D Z\$C(P<''2M >'-/5M6*HZC5(UCN &P-JQ^6
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MC([*58;6_>,0,@G9[UZ3>:;::A+9RW47F/9S_:(#N(V2;67/!YX9A@\<U;H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM+<N$$DAP-QZ#]* +U%9>C^(]&\0+*VDZE;7GE$"01."4STR.HS6I0 4444
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M^.O"U]J*6%MKME+<N^R-5DX=O16Z,?8$T =#114=Q/':VTMQ,VV*)"[MC.%
MR30!)14%E=P:A8V][;/OM[B)98GP1N5AD'!Y'!I\\\5M;R3SR+'#$I=W8X"J
M!DDGTQ0!)16-I7BK2-9N?LUG/,)C'YR)/;2P&2/(&]-ZC<O(Y&>H]:33?%OA
M_6+]K'3M6M;FY4%O+C?.X X)7LP'J,T ;5%8UMXLT&\U3^S+?5;:2\W,@C5O
MO,OWE4]&(P<@'(P:IM\0?":71MFUVT68/Y90L<[LXQT]: .EHK'N/%6@VFL+
MI$^JVT=^S*HA9^0S?=4GH">P/)K8H **** "BBB@ HHHH **** "BBB@ HHI
MB312221I(C/&0'56!*DC(!';@@_C0 ^BBB@ HHHH **J6>HV]_)=1P&3=:RF
M&7?$R#< #P6 W#GJ,BB;4;>WU&UL)#+Y]T':+;$S+A1DY8#:O7N1GM0!;HHH
MH **9+-%!'YDTB1ID#<[ #). ,GU) JO!J=I<ZE=Z?%+NNK18VG3:1M#@E>>
MASM/2@"W1110 4444 %%%4-3UJPT=[%+Z?RFOKE;2W&QFWRL"0O XZ'D\4 7
MZ*** "BBB@ HIDLT4$32S2)'&O5W8 #\33Z "BBB@ HHJI>ZC;Z>]JMP9,W,
MP@CV1,_SG.,[0=HXZG ]Z +=%%% !1110 4444 %%9-UXDTJTUVWT22X=M1G
M02+!%"\A5"<!F*@A!GC+$"C1_$FE:_-=1Z9</<"V<QR2"%UC+ D$*Y 5L$'.
MTF@#6HHIKND<;22,J(H)9F.  .Y- #J*165T5T8,K#(8'((I: "BBB@ HJIJ
M&HV^EVZSW1E"-(L8\N)I#N8X'"@G'OT%6Z "BBB@ HHHH **** "BJ.KZO8:
M#I<VI:G<K;VD(&^1@3C)  P,DDD@8%,.N6*:#)K<CRQ6,4+SNTL#HRHH))*$
M!AT/&,T :-%1K,CVZSJ28V7>#CJ,9Z5#IVH6^J6$-[:F0P2C*>9$T;8SCE6
M(Z=Q0!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KCOB)+-!9Z#+;6QN9DUJV*0API<_-QD\#
M\:[&J6HZ7:ZI]D^U*S?9;A+F+#8PZYP??KTH X'7TU[[-XB\5SV/]BRVV@SV
MUNJ7"R2N^=^\E.!MVX')/)Z5J:_JE[;ZSHL,-W*B3:/?S2*K8W.B1%6/N"QQ
M]:["]L[?4;"XLKN,2VUQ&T4L9Z,C#!'Y&L"S\"Z1:31SF2^N9HK>2U22YNGD
M98G !09/ XXH Y:QL_$$W@'0M434-9U.2]2WN=1BM[L1S&+R6P(22 IW%"V"
M"VT\Y-:'AW6)+GQ-HEK!J=_<V;:=>F1;Q=DHDCGB4+(O]],LN>_7O71S>%-.
MDT?3M-C>ZMX]-55M);>=DEB"KL^\.N5X.<@U6D\#:0T-DL3WUO-9F4I<P7;K
M,WFG=)O?.6W$ G/?IB@#DX=5N]3M8;)[S6KJYDU/4BMMILJQR2113E%+2LZ[
M$3<HQGG(':DTO4-6UZ/P7:W&JWUNMW#?K=M%(%DE$3*JY9> W'+#U.#SFNK7
MP#HD4-M%:B\M!;O,R-;73QMMF;=(A8')4D X[8&*LZ;X/TC29K.2SCE0633M
M;(925B$Q!=5'9<C@=N: /.KF&YU&?0K*[U749!9^*KBQCE^TD2&-8Y&4LPZL
M.F[KC/K76?%*V^T>%K1?M%Q$/[3LU/DRE-P,Z#G'7'4>A -:MYX*TB\MVB/V
MF%C?MJ*RP3LDB3L""RL.@P2,>]:&M:'9Z_I+Z;?"4PLR.&CD*.K(P96##D$$
M T <<]O>ZMJ?B>$ZYJ=HFB)%;V8AN"N&\A9#+)_ST)+?Q9&!TYK1N=7U'4?@
MY-K,0*:C<:&;D>6,$2&'=E?QY%7;SP/I5\[/)/J"M+ EO=&*\=#=HHP!+@_,
M<$C/7!QFNAB@B@MTMXHU2&- B1J,!5 P !Z8H Y_2=-T%OAW9V;0VS:&VGH7
M#X$9C* EB?S)/KS7'>,=8FM5U6]T.ZUB9=)M86C:TFC2SMCM#@/N<&;<I4G
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MIZRI'<2>:Z/*S@/@ L,DG)QDGN>:RYO .ER:E>W\-[K%I->R^=.+34985=\
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M[(U+VHE9G7H^2^.>PXP>:ZS4/!&CZE>W-Q-]K5+ME:[MHKETAN2H != <'@
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M0PNR/F-RCJRL&5E8<@@@&H[3P]8V<EY(IGDEO((X)Y)92[.J*54DGOACD]Z
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M8[>;8L;"TCD.1_$"W\)XY/K3?$/@V_U2]U2Q@T66.&_O$F^U+J7^BJ,J6E:
MG/FX!& I&<'.>:[N3P[ITL>M1M&^W601>?.?F_=B+CT^51TH R_$VNWNG?#:
MZUFV94O?L2.C[<A'< ;L>V[/X5C:@M[X6URTLK?5]1NX;_3;QI1=SF4I+$BL
MLBD_=^\00..1Q7;2Z79W&D-I4\*RV3P?9WB?D,F-N#^%9=CX-TNQDEE,E[=2
MO;-:+)=W+RM%">J)D\ X&3U.!D\4 5/A[!=MX1TW4[_4[R^N]0LX)I#/)N5"
M4!PH[<'GU(R:Y?4+W4YO#7B?Q6NL7T%YI=[<K:VZ38@5('VA&CZ-NVG)//S<
M8KTG3=/M])TNTTZT4K;6L*0Q!CDA5  Y[\"L:[\#Z->7T]Q*+H17,RSW%FEP
MZV\\@QAGC!P3\JY[''(- '(P:(E]\9M6#7^IP[](AF_=7;(REI&^7(_A'8=J
MYWPHUWIW@708;*76)O[4U6Y@GBM+@"3RXVG?$1=E"%B@R002 <<U[%'HEC%X
MAGUQ4;[=-;K;.VXX**Q8#'U)YK/C\%:-#H$.C0I/%;V\[7,$D<S++%*69MRN
M.0<LWX$CI0!QEU/XE6ST;3Y[C5=,6Y\0&UBDN)8VN7M&@=L,RLP)#;@"23\J
MD\UU/C:R\CX7:Y:K=71\C2Y<3-,3*VR,GYFZG..?7)J]#X1TN&*R0BXE>SO#
M?)++.SN\Q4J69CUX8C'3IZ5JW]E;ZGI]S87<?F6US$T,J9QN1@01D>QH X#3
M;2>]U;2?#AU74X;"#1$OB8KIDEED=]H!D'S;5 . #CD9Z5T7@?4;J]\-N;^X
M:XEM+NYM#<O@&58I616..,X49/KFC_A!]-%M91I=ZG'/9QM##=I>.)A&V,H6
M[KP, ],#%;.F:59:/I<.G6,(CM8E*JA);.2222>22222>I)H \XT?5=4DU[1
MY;*YUF2#5X[DK<ZC)'Y%QB,O&\<(<M& 0,?*N5/.:=8-KPT^^TN.YUR#Q(UB
M':VOIU=)RKJ))+>7E5X)4#@ NI(&*Z:#X>:%!]E ^VR+:$BV62[=A%&5*F)0
M3PA5B".X ]!B2/P'HZPR1RR:A<[HA#$\]Y([0(&5P(VSE<,B'/7Y1SQ0!Q>L
M:Y<V/A65;#4-<MKN+5[..6VU)LSVZNR@KOR=Z,,D')'7Z5HZM+J6H?\ "<:E
M'K5[9/HH:*SBAEVQKMMUE+.O1MQ<C)Z <8-=*_@71YK&2VNC>71EN(KF2>>X
M9Y7>/[F6]!CH..OK7.^+_#&H:AJ6KBRT*6<:E;+$+B+4O*A9]I4-<1$C=MX(
MVAL@ &@!NGQZAXAUJ6SN-;U*WMX]"L;C;;3F-C,_FY?<.?X>1T/&<XK>\.ZY
M+/\ "ZQUS4KORY?[+%Q/<[-V"$R7V]^F<5J:5X>M-+<3IN:Z-E!9R29X9(@V
MWCM]YOSJ2V\/Z=:^&E\/I"6TU;8VOE.Q.8R-I!/7H: /-!JNKZ;!K$*RZ["K
M^&KF^234[B-Y#,FT+*@5V,>=Y^7CH..*V%M=2@UC0K4:]J3MKFF7(N6DF)"2
M"-&62->B$%CTK<'P^T4Y,LFH3RM:RV3RS7;N[P2*%,9)/W1@$#L>>I-:UQH]
MJDMC?);R37.F0R):HKX)#* 5Y(&3M R: .+TGQ#J>OKX7T?[1)#J4,TK:R8V
MPP%J=C*?:20I^!-;GB>6YN_%&@:#'>W-I:7B7,]P]M(8Y'\H)M0..5!+Y.,'
MY:3PEX?GM=9USQ'J%BEE?:M*F+99 YAC10HW$<;F.6...G7%;.LZ#9ZXMN;@
MSQ3VSF2WN+>4QRQ,1@X8=B"00>#0!Y1XQ6YNO!FNV%UJ-[.ND:[!;02M,=SQ
MN8' <C[Y7>0">>G>O0O&%J++X8>(+99IYA'I=R/,GD+NW[MNK'K5A_!6BRZ
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MT$<:9)P![GDGW-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0K&PEW,"NTKG@'(/'/% &]J7C;3M.GF5;6]O(+:%+B[N;6-7CMHV!(9R6!/
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M<V5C=*D[PM @CRRNO <?, W4=P* -/Q!XPGGMO"MUI,L]HMYX@CL+R&6-0X
M\Q9(V'.#N7J#VX-/U+Q:]A8>-+BP?4+V[TK(\J2*+R[=O*+ KR"R#J<Y/I6!
M%X8US[%HEK_8\T)L_%@U"0-.L@6W;>V[>6);;N .><^M:A\.:MY7Q+'V)LZL
MC"Q^9?WW^CE..>/FXYQ0 GACQ!=-#X175M2US[;JQE=4GAMQ'/B!7.=@RL8R
M2O\ %G.>,5TEIXUT^\U"& 6M[';7$TD%M?R1J()Y$W%E4[MW\#8)4 [3@FN?
M'A[5?[0^&DGV-MFDV\B7QW+^Y)M@@!YY^88XS53PUX4?3;C3M/N?#^IS7.GS
MN_VV;5)/L>%W>7(B>802<J-NP8RWIR =AH?BNWUZ6-8=.U&WAGA^T6UQ<0@1
MW$>1\RD,<?>!PP4D'IUK%^)GB+5-#L-*M]*2[CEU#48+5[FWCC<HK-@JH<XW
MGMD8ZY(J+PGI]]9^((_L>D:GH^F?9I/MEE=7*RVZS$KM^S@,Q ^_G 5<8XST
MT?'FDWVK0^'A8V[3&UUVTNIL$#9$C$LW)[4 6K'Q-:Q:/JCW"WY?1(%-X;E$
M$K'R1*?N':6VGG&!G..*RD\0WMS\3H["&X<:9+X:^WI RKQ(9L!B>N=IQC.*
MHZU9:W!<>-K*TT2YO/[<A!M+B-XQ$I^S")@Y+ @@KD<'.14]AH.J1?$&SU&2
MT9;1/"RV+2[A@3^:&V8SG.._2@!WP^\8R:CX9\,Q:Q---J>JV\\B7!10DC1N
M<KQC#;<'&.@-=9IVM6VJ7^IVELLI.G3+!-(5&QG*ABJG/. PS[FO-H]&OO#G
MP4T>YO8!;:MX><7RQNXZK(VZ/(S]]&9>.["N[\&Z5-I/AFV2\'_$PN2UW>'U
MGE)=_P B=OT H L-XCLEEUJ,K-NT=%>Y^4<@Q^8-O//'KCFLN7Q[8B4PVFF:
MI?3BRAOC%;0H2(9 2#EG R-O(SGGC/.,G5[36;35_%T-KHMS>+K=M&+6>)XQ
M&C"$QL)"S C! / .<U;\*Z)J-AJEU-=6K1H^B:?;*20<R1K+O7@]MR_G0!?;
MQSI\C6*Z?9W^I->6:WP6TB4F*!NCON8=3D;1EC@\5E>&_&SR>%-&EN(+[5]3
MOHYIA%:1IO,:2$%SN*J ,J.N23P#67X7TS7/";Z7<R:%=WGG:%;6,L=N\>Z"
M>)G.&W, %(?J,X(JEI_A+4=/L- NM4TG4[@PV4]K<V^EWK0RQ.9C(C961-RD
M$CKQ\IQZ '93^/\ 2U?38[6UU"^FU&V:YMHK6$%F56 8$,1M(SSG'0]^#J>*
MM9D\/>%M3U>*V>YDM+=Y5C7') ZG)'RCJ>^ <9KF]$\.W-AXIT&YBTIK*RM]
M(N(I(S<^?Y,LDL;["Y.6)^8YY'7FNB\7:?<:KX,UO3[1 ]S<V,T,2D@;G9"
M,GIR: .8C\::@?$FFAM,U%TN]':X_LV&*,R&02J-^2V -N<9;N.YQ6PGCJPN
M+'3[BPL=1OIKZ.22.TMXE\U%C;;(7#,%7:QV]>3TS5+P_::C/XGTW4[C3+FS
MACT,VCBX*;EE$J'&%8]0I(]JYJV\)WUBNF7NH:3JES&B7L$L&G7AAFC+W32Q
MM\LB;E*DY&>,CCT /3]+U*VUC3+?4+-RUO<('0LN#]"#T(Z$>HJW65X:L$TS
MP[9VJ6)L-J%C;-<&<QLQ+$%SRQR3DUJT %%%% !1110 4444 %%%% !1110
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M@N /MDN"QD?((W8*>B'Y1V%:^M^6WQ4\,+>X\@6=VUJ&Z?:,Q_\ CVS=C\:
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M9/H0* /1_#4VES>'+(Z*A334C\JW4@C:J$KCGGC;WJU9:A'?M=".*XC^SSM
MWG0M'N(QRN1\R\\,.#7E6@VLVF>%/"NL0:C?BXFUA+9X_M+^287G="GE9V=.
M<XSGG-26NL:I<0ZW9/J5XJ7/C,Z;YHF;?!;D*2D;?P XVC'3=QS0!Z'XE_LF
M33H;/65=[:]N8[945F&YV.%!*D'&>O;UK4MK>&SMHK:VB2&") D<:+A54#
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MA$:JX)!!!R"1C'/<5TM% '/IX+T-=.N[%[>:>.\FCGN))[F2265T*E"SLQ;
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M.%  & !@>GXUE'X?: ;JXN$&I1/<3/<2B'5+F-6D8Y8[5D Y/M74T4 <[?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW:S&5I#'G^Z5=D[9!S6AK>A7C6GARWLXC<FQU**[N9"RJ6 #[VY/+%GSCZT
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MN"2!ZC)P":%]X;UJX\/>*+*.P/G:CK"7EN#*@!C!A)R<\']TW'N/? !O7GQ
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MD95 V$9 Z]<G%/U31-4U7PAJ$,/AJRTN]NY+?%M!+&6(CD#EG<  \ @#G]>
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M.VMK>"-7>29LE0 Q '0G)(QBL36+*WUWXD6^DZJGGZ?%I+7,-L[$(\IE"LQ
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M[8!_"K=>.>'[ZYGU?X:O<7DA+Z1>>9([YSM10&;/4@#J:WO!5F-#UNTL;VS
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MI3NRW(R48GG< <'M5?PUX-CL!>S:G:6"R7-U#<1VMH"8;?RE CVD@%FR"Q;
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MNS@L 6CQ\J,4(!R3TR!FJUOX_NYH+2_;06CTJ;4/[/:X-T"ZR&8Q!@FWE-P
M)R",G@XR0#H=*\+Z'HER]QINEV]M,R[-\:\A<YVK_=7/88%6=5T;3M;MEM]2
MM([F)'$B*X^ZPR 01R#@D?B:\[O?&&I/X2\9WNMZ>WV/3;UK=%L[\Q2#:8QL
M#JH(Y;=NSSDC&*ZF\\47XU2YTW1=&&HRV-O'-=&2Z$(7>"51?E;<Y"D\X'(Y
MYH MR^"O#4T31MHUH$9U?")LPP7:",8Q\O'':G7/@WPW>1VT<^C6;);1^5$O
MEX"IG.S ZKGG!R*RD\=2:E<:9!H6DF]?4=._M"(RW A5%W!2'.UL$%@.,\^W
M(V-"UU]?\,QZK;V9CG<2+]EDD Q*C,A0N!TW*1G'3G% $UQHEHQU"XM;>VBO
MKRW\AYWB#A@ 0H9?XE&>E<IX?\"S6NKV]WJ%AHUG!;6LL @T[>1.TFT,SEE&
MT!5P$&<;CS6+8>*_$6IZ?X*U.>TWW%W?7"B&"YVK<+Y,VW?\H"A2!_>^[GD\
M5U=MXNU&YL+P)H).JV=]]BFMA=#RD)0.)#+MX3:PYVYR<8H Z%=)L$%@%M(@
M+ 8M./\ 4C84^7T^4D?2H]%TF'1-*BT^W.8XV=A@8 W.7( [#+'%<;JGCG5W
MTO2I],TZ%+F76AIMU$]R"JL&^ZK[3E6 ^]@$>F>FQX[US5=!\*K?:;;Q-=-<
M6\3;Y,! \BJ<94YZ[>V,Y[8H OW/@_P[=W-U<W&D6LDUUS,[)]X\'/L?E7D<
M\"K;Z'I<EE>63V,+6UZQ>YC*\2D@ EO7( _*N-&NZ_:^,M?6WTK[9)'IUE.]
MJU]LB@.)BX5BIRQX ^49V\D8%7F\>R7D$$VBZ2;T'3HM2G$MR(3''("41>#N
M<[6XX''7F@"]=Z!?:OXPL=2U(62Z?I1>2RCC+-+)*R[=[D@!0!G &<G!SP!7
M35CWGB2RM?"9\1 /+:-;)<1*H^:0.!L4>Y+ ?C6'=>.Y]+T_5Y-5TA(+S3K-
M;T00W8E2:(DKP^T88$8(QW&"<T ;EIX5T&PU,ZE:Z5;17A+,)%3[I;[Q4=%)
M[D8S5ZTTVRL);J2TMHX7NI3-.R#!D<@#<?? %<O_ ,)AK9ULZ,OA@"^EMOME
MLK7P"&(-M;S&V?(P)48 ;ENN 34-I\0+G57TN#2M":>ZO[*2[V2W0C6'RY!&
MZLVT\;N 0#GCCN #L#96S:@E^8$-VD1A67'S!"02OTRH/X557P_I"-:LNGP!
MK6:2X@.W_5R.278>Y+'/UKA=<\43ZO!X+O+;[18/+XB6TO+82\JR>8KQL1PP
MW+]#Q6Q=^/)[>._U*/1C+H6GW36US>?:0),JP5W6+;\RJV03N!.#@4 ;MIX7
MT.QU5]3M=,MXKUBS&55Y!;[Q Z GN1UJYJ6F6.KV36>H6L5S;L02DBY&0<@C
MT(/<5CQ^+K91XC^VPFV;0R7F!?=YD)CWI(.!]X9&/52*R&^(-T+.:].@D6]A
M;Q3ZENNP'M]Z"0JB[?WA5&!/*]<#)H Z6'PSHMOIO]G1:;;K:><LYCV\-("&
M#D]2V0#D^@K5KC[_ ,<M:75]+#IHGTG3ID@O+S[2%968*24CQ\ZJ'4DY'?&<
M5L^(]=_L'3XIH[5KNZN;B.UMK<.$\R5S@ L?NCJ2<'@&@"P=$TPV+6)LH?LK
M3?:#%M^4R;_,W?7?\WUJ!O#&B-K(U=M,MCJ 8/Y^SG<!@-CINQQGK7'P>*K[
M3O$OBBXU6SE22VM=/BBL8[CS$>61Y57RV( PQ* D@=.1Q6E-X\FL#)%JFDK!
M/;W-M'<^5="6..&=BB3!MHR ZE2,#% '66=A:V"S+:0)")IGGD"#&Z1CEF/N
M31-86MQ>VUY+ CW-KO\ (D(YCW##8^H%<]K?C6'1M5O++[%)<?9+..XD=' _
M>2R>7#%@]V.>2> *YWQIXIU"3P)XIM9H#I>K65I%.IM;OS 8W?"LD@"G.58$
M8&,=\T =IJ&@VT\&K26=O:1ZAJ,'E2S30^8LF%*J'7^)1DC'H:YOP_X%:WU.
M2ZU+3](M;;[!)8BST\NZ2B0J9&=F4'D(JA><#/-7F\3:A]K&EZ/I U*YM;**
MXNWENA"%W@[5!VMN<[2><#ID\U!%X]EU.XTRWT/1VO9-0TXWZ>=<"%8U#!65
MSM;!!..,\^W- '5'3;(S6DQMHS):*R6[8YC5@ 0/J !^%9'_  @WA@62V:Z+
M:K;I*TJ(H(V,PP=I!R,@#@<<5FP>.Y-0M=.33=)\S4[KS_-M+BY$2V_D.(Y-
MSA6S\Y &!SG/%.A\<3:DVFV^CZ1]IOKN&6>:&>Y$2VRQ/Y;AF"MD[\J,#G!.
M0* .LM;6"RM8K6UACAMXE"1QQJ%5%'0 #H*I1^'])AC,<>GP*AN_MQ 7_EOG
M/F?[V>]8OP\OKC4?#EQ<W1G\QM2O1MG;<T8$[@(>3T'&!QQ3-*\;OJ-WIS2:
M8(-,U61X["Z^TAG<A69=\>/D#*C$<GMG&: .GCLK:&]GO(X$6YN%1990.7"Y
MV@_3<?SJI?>'='U/4(;^^TZWN+J%=J22)D@ Y /J >1GH>:YG2OB!>:C;:'?
MRZ ;?3=8<003&[#.LI5F *;?NDH0&SGH<5BR^,=0G^'VKZKKVGOY,&J&WB%E
M?&)R!<[ NY5! 7@9_B&<XS0!Z'IVA:7I!!T^RBMRL*P H.D:EF5?H"S?G5FR
MLK;3;**SLX$@MH5VQQH,!1Z"N>?Q;<-XMOM$M])\R*P6*6[O'N BQQNI.<8R
M3P>.^#R.\6C^,YM3N]/2YTK[):ZK$\NGS?:1(S@+O D0 ;"4RP&6Z$'!H VY
M?#^D3'4#)I\#'4=OVO*_Z[:,+N]<"K1LK9M02_,"&[2(PK+CY@A()7Z94'\*
M\Z^&_BFXA\'>#X-2\ZX.K-=1?;I9BQ659'*HV>3N56 .?X<5VVDZX-6U76+6
M*W*P:=.MM]HWY$LFP,X QQMW*.O7/I0!:L=(T[3)KN:RLX;>2\E,UPT:X,KG
MJQ]35.S\)Z!I\MQ+::3:PO<(T<A5.J-RRCT![@8%8C>/)Q VJC1B?#RWGV0W
MWVD>9_K/*,GE;?N;^,[LXYQ3=2\>7EF-=GM] :XL]#F*7DQN@A*!$<E%VG<0
M&.02.@Y.> #JETJP7[#MM8A]@&+7C_4C;L^7T^4X^E48?"/A^V54ATFV15NE
MO%4+PLPSAP.Q&3T]:SOB%?2VG@2ZO;229766V96A)#D&>/('3J"1^-5[KQ5<
MB+7=/UC1VLYK72GOT6WO=QEAPP(#A04<%<<9QG()H V[KPKH-]J@U.YTJVEO
M 58RLGWBOW21T)'8GI5PZ58,;XFUC)OQBZX_UPV[/F]?EXKD;'QA<?V=HMKH
M^CM>2S:1#J!BN+_;((B,!59@3*_!SG'8D\UTFNZ[%H6A/J<MO+(V8TCMUP'>
M1V"HGH"68#VH TH(8[:"."% D4:A$1>BJ!@ 5CCP=X=6RGLQI%J+:>;SWC"\
M>9G.X?W3R>F.M95QXVNM+BU:/6-&6VO;#37U*.*&Z\U)XER" ^T$,#@$%>XZ
MUN:!J=YJ^G"]N]-^PI*0UNC3!V>(@$,P &TG/W><>M %G3=*L-'LQ::=:Q6T
M 8MLC7&6/4GU)]3S4BV-LM_)?K @NI(EA>7'S%%)(7Z LQ_&O//"GBW4[/0-
M):^TV6>PN=1DL3?R769-[W#JAV$$E <+G<#QTQ6Y;^-WGOH'.F!='N;UK"&]
M^T@NT@9D#&+'"%U*@[L]#@ T ;L'A[2+:2QDAT^!'L8VBM2%_P!4C?>"^QJ/
M2_#&B:)<R7&FZ9;VLSKL+1KC"YSM']T9YP,"L_POXHN_$TMS(ND&VL()9H/M
M#W 8O+'(4PJX^Z0,YSUXP>M1ZEXLOHM3U.TTG1?[032HU>\=KH1$%EWA(QM.
MYMN#R5'(&: -O5=%TW6[=(-2LXKF-'WIO'*-ZJ1R#UZ4R+0-)@M;*UAT^WC@
MLI?.MHU3 B?!&X>_S-S[FL-/']B]KJET+=Q;VFEPZI Q;FYAD5B,#'!!0KWY
M(J-_'RKHNDWJZ8YN;[[1YEL9@#!Y".9<MCG#)MZ#EA0!V1&1@]*H)HNFQ6EE
M:I90K!8NKVL87B)E! *^F 2/QKG])\9W=]?Z+'=Z(;.TUJ%I+.;[2'?(C\S#
MIM&W*Y(.3TY /%.\1:]K.G^,O#FEZ?:0RVU\9C,7FV%MB9(^Z<8R&]^G% &O
M:^&-$LM6?5+;3+:*]<L3,J<@M]XCL">Y'7O5ZQL+73+*.SLH$@MH\[(T& N3
MDX_$FN&M/&5OING>(+V#3KR8V_B$Z>\3W9D9W9T3<F[A%^880<>XS5F3QMK<
M=SJMC_PBZ-?:;"MS,@U >686!*E7V9+G:PV[<<'F@#I-6\.:-KK1-JFG0731
M JC2+R >JY[@X&0>#5J/3K.*\^V1VT27'DBW\Q5P1&"2%^@)/%<M/X\DFB$V
MD:2;Z*/3XM0N3)<B%DCD4LJ*"#O?"DXX'3GFM?6/$T&F>%5\0Q0FYLRL,IPV
MTB)V4%^AZ*V['M0!<CT33(;:QMX[*%8;!M]J@7B%L%<KZ<,P_&L'PAX$T[0-
M,TMKJQLWU>TAV-<Q D;L8++D#G'&<9QQ5L>+H#XXD\-FW90EJ9C=EQM\P88Q
MXQUV,&SGI6!IGC :UXCTZ:#2[A;N[T6:\MT>^98FC$N$#)C&6&T[L$@''- '
M7GP[H[6=]:-IMLUO?S-/=1L@*RR'&68>O Y]A4":,F@Z5<1^&=.L8KJ1@^V=
MV1';@$NX#,<#IUZ <5P5AXJ\0ZGI?@75)[4O=7MU-^Y@N-JW*FWD(+\ * >2
M,-C;GD\5TB^.YOLLD$FCD:TNI?V8MBER&1I?+$N[S-H^38=Q.W/&,4 :OACP
MU#H/AXZ=/Y-Q+<223WK",!)I)"2_R_W>< >@%/MO"'AZSL;NSM])MDM[M!'<
M)MSYBCHIS_",G Z#-91\<R6PN+?4-*\C4;6^M+2:!+C>FVX<*DBOM&1R>" <
MJ1[U6\<>,[[1;'Q!;Z9:J;O3].CNUG>087S&D3.TJ<E2F<'KF@#N% 50H& !
M@"LD>%]#763JXTRW%^7\SSMO._&-V.F['&>M+=:M<Z=X5NM7OK-$GM;22XDM
MXYMP.Q2V ^T=0.N.]4;_ ,70Z=_932VDC)?VD]V2C9,8BC$A&,?,2#CM0!JI
MHFF)96UFME"+:UE$T$87B-P=P8>^235)/!WAQ)WF31[596F$Y<)R) 2VX>G)
M)XQG-8%_XKNKCP3JNIZEHKPV2V'VJ*2RU'=YJ'^$2* 4<<=,CG@U;_X2J\%Y
M9:1I.BF\N)=+COE,]YL54)VX9RI)/ YP<Y[<F@#;/AK139O:'3;<V\ES]K:/
M;P9L[M_USS6E+$D\+Q2J'C=2K*>A!X(KC[;QW-JD&CKI&CFXOM1MY+E[>:X$
M2VZ1L$?<^TY.\[1@<^U:_AOQ$WB/1KB^CL'MI(KB:W^SS.-VZ-BO) P.1[X]
MZ -!=)T]%L%6TB T\8M !_J?D*?+Z?*2/I5.T\*Z#8:F=2M=*MHKPEF$BI]T
MM]XJ.BD]R,9KS^/Q7XBU'0= U&YM")I/$3P1QVUSCST!N%$;?* %7:HR<YV[
MCS72_P#"=7$,=Y:W>CB+6+>]BLDM$N@T<K2IO1A(5&%V[B<KD;3P: .CL=#T
MS3+V\O+*RB@N+Q_,N'C&/,;U/;//XUH5C:!KCZN+V"YM!:7UC,(;B%9?-7)4
M.K*^!E2K#L#G(QQ6S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-K+K*WQT^XEVI/&+58ANRI&5<;@""./6O01(AD:,.I=0&*YY .<''X'\C3J
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MTB1A6D(Z%B.3^-9LOB>TMK;3)KFUOH#J-T+6*.6 JRN20-X_A!P3]* .5N?
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MK6_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!^=-\'^%%T+3(TO[:S>^CN)YEFA)89D=FSR!A@K;<XS@=>U '*:K=75CX?\
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M%Q<00^';NYCM9)"ZM-')'M//)/)')/6NI;0M)?[;NTVU;[>,7>8@?/&,?/\
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MR7,DFFVK/<QB*=FB!,J#HK'N/8T <5H%PXG\)^'WGNH;&YT+[7N%PX::91$
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M"6*3D9^8GA,#IC/\0Q/;ZG,GA&V\4V.MS7=S)H\T[6C-YB7,XCWY"Y_=[6#
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MHVNH))#?VUU;W1CN+2]D\QK=MB':KY.Y2"&!S_%725!:65M8QM';0K&K-O;
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M\&) ??P,<<4 8U_XJO;30_$USH%C';W-MXB6SFDGO'?>6>)2ZAE8+G<%VC@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP#LV$9S@@_3GIF@#:HK/TG6K+6H[AK1WWVTS03Q2(4>*08RK ^Q!ST(/%:%
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MNQ?,"[0^.<>F?2EDC2:-HY$5T8896&01[B@#E_!%E)$FN:FX(CU35);J#WB
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ^E&YMHH;AIW1U/^L61AD*P(&!W&1CFNXL-(6"V*W-Y=WY><7.;IPVQL# 4
M !01N .<'GL,0VWA'P[9:?<V%MHEA%:7)S/"D"A9/]X=Q[5KQ11P0I%$@2-
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M?):!/,99%9G1MR@+@#"E>O1OPK:;1=,:6SD-A;[[(;;4B,#R!C&$_N\<<=J
M/.(;W5;;2(KW^VM0EDLO$W]FH))05D@-UY1608^<[6ZGG@8Q6EIE_J>NR+J4
M>L16<MIK$EO<P-,S#RUE:,0&+&T,5VD-UR<]\5UW_"-:(;=H#I5IY+3_ &@I
MY0P9<YWX_O9YSUI1X;T1=;_MH:59C4\8^U>2/,Z8^]ZXXSUQ0!Y^U]JT-C=Z
MF=:OWEM/%*V:1M(/+:%ITC*,H'(VL?ICC'.>A\%P)'XA\8/YT[.-6*A9)V88
M\B$]"<=_P''2MX^&M$,$D)TJT,4DWVAT,0PTN<[R.[9YSUJU!I=A;7\]_!9P
M1WEP LTZQ@/( ,#)ZG@#\A0 ^^GDM=/N;B*(RR11,Z1CJY ) _&N!LM6U$Z3
MX)URVOY[F?5YXH;^%G+1N)(V9RJ]$,94_=QP"#FO1JH6NAZ78W)N+6P@AE+,
MVY$ P6^\0.Q/?'7O0!S7@6SCAU;Q:ZR3L5UEXP'F9ACR(#D@GD^_7M78RQB6
M)XV+ .I4E&*D9]".0?<56L]*T_3I9Y;.SA@DN'WS-&N#(W]YO4^YJY0!X_I=
MOO\  7P_"W,XEFU>-FD,I=E)CGY&[..GYUH)K]_IOGZ9+J$KVP\2G3A<W4Y#
M)$;<2JAD R,N0H/7!QD<&N[3PQH421)'I%DBQ3FXC585 24_QC'1O>ED\.:+
M-;7EM+I=H\%ZV^YC:($3-_>8=SP.>O H K>&;>^LXKZVO=22^V7),0#%V@0@
M$1LYY8C.<GG!&:W:JZ=IECI%C'9:=:0VMK'G;%"@51GKP*M4 %%%% !1110
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MR8(=N58_*,MG *CIZFN7O?!FI:GX8URP71_#FD3WMJL$(L03EMV69Y!&IVG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!D4,5O$L4,:1QJ,*B* !] *?110!'/;PW4+0W$,<T38RDBAE..
M>AIX      Z 4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=$O=0\MI3;PM($52Q) SV[5S?A[69#::?J%YJ-]<S:E9)(-/-L,^8%#22)@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK:PT>2TN7:5/D<^4?7D?NSS[CWQVE1SP175O+;W$22PRH4DC<95U(P01W!%
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M[J%:.5%3:&(*AP$5O3);D]^^N-+L;J_M[Z>UCDNK;/D2L/FCSUVGMGOZU;H
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MD9(WJ3CC(;VSU?BC39M8\):QIEL5$]Y9301[S@;F0J,^V36M10!QMGIVL?\
M"3Z+JEQIACBM=)FM952=&(D9HR .1G_5G\Q6!8^%=?TG3O#UT-&M-1FL8;BT
MN]/GF09220.LD;'*Y&T9SU!->HT4 9FGV#)H0LY+6WL3(CAH;0 )%N).!@#)
M&>3@9.37+^$-&U;2XK*RU+P[I:-ID?EKJ<#(SW*A2JE%P"C$8W$GU]>.[HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5RA\1:PH^?0=1^75C:2;(5/[CG;*GS<H?DRQZ9;CBNKHH XC7?
M$]^_A'Q-K6DSI"FFK-%;,T8?S'BX=CGMN!4?0GG(QN:=XDTO6Y9]/T_4XVOX
MH@[J%.0#QO (PRY[C(]ZY&PT.]G^%GB3PO"@;48Y;ZW568+O,CM)&<GLRR*<
M^];UMIUSJ?BS2M:>RFL8M/L98&$VT/*\A3Y<*3\J["<^K#&>: -30]9.LZ;<
M/L5+RUGEM+B,'Y5F0X./]D\,/9A7/27_ (EM_%^E:#+JUJQN[&:XEE6RQM="
M@P!NZ?,?RJYX'M9$/B'4""(=1UB:>#T:-0L88>Q*$CU!!I-0L=0D^)VD:E'8
M3/86]A/!+<!DVJ[LA'!;<?NGM0!K?VO'I5G#%K%TKWJPF27[/"[95>#)L4,5
M7W/ Z9JQ<ZQ96VAR:QYIFL4@,_F6ZF7>F,Y4+G/%8<MIJ.E^/KO5ULYKVPOK
M"*#]R5+P21LY PQ'RL'/(Z$<XZTW1/#=WI?PS.@MM-VUI.@4-\J-(78(#Z+N
M"Y]J *<OC1VU7PO<^:UOIFIV<\TT,ENV_<J(RA<C<WW_ .$<XXS72Q>(M*N-
M,M]1@NO/MKG/DF&-G:3&<@( 6)&#D8XP<URFFZ?J_P!O\$33Z-<PIIEA-!=;
MGB/EL8XU'1SG)1NF>,9Q639Z)K^E6^D7[:%<7:VMSJ,=S8QSHLOE7$_F)(AW
MA21M ()'6@#TJQU.RU+3H]0L[J.:SD4LLRGY<#KGTQ@YSTQ5)?%.CLTZB[8/
M!!]I=&A<,8LX\Q05RR?[2Y%4)=!>\\ ZEI%I91:1)?6TZ1P*0?*:0-RQ7())
M.6QGDGD]3GZ(;_8=1N?!DUMJEI:M$Q:XC=IF./DA;><(2,DMCMP>P!T$?B;2
M9[;[1;W#SQ_9!> Q0.^83G## YS@X'4XJ'2_%>GZEX?L=6*SQ)>1+)'"8)&D
M.5#':H7+  ]5!'O6!X<T'4_#MYJ>D)9>9I=_$;F*Y38JVTS [X=N=VS/*X!Q
MDCWK*L]*U_3=*\)7<GA^ZN?[,T]M-O;%+B-91D1?O8R'VL-T6,%@<'- ';-X
MP\/K%92?VI"RWJ-);;,L90O7  SD=,=<\=:K7'C?2(TT>2W::[BU6=H89(()
M& *JQ;("Y!&PC;UZ\<'&4FC74&N^%)[70?L=G:-=R3Q0LF+?S5^7=\W+$\G;
MD9)Y/6LRST36[6'2+@Z/.S6?B*\O'@$D6[R9O/VL/FQ_RT7(SD<\4 >@7VJ6
M>G&%;F4J\[%8HT1G>0@$G:J@DX ).!1;:I8WFEIJ=O=1R63IYBS _+M[FL;Q
M,FI-JFBM::=)=6BR2_:GMVC6>+*87:SD;5)R&*D-T]ZB\"6%]I7@B#3]1M'M
M;B!IE*-(K[@9&8$$$\$'OS0!<L?&OAS4KVWM+35H)9[B(RPC# 2*!D[21@D#
MDC.0.U+:^,_#MZT@M]5A<1Q/*[8(551MC$DC'#8&.O(]:XGPEIUQK?@OP"([
M*6%=,:.\DN'V@%5C<!5P<DN6'T .<' -N/PYK<WPWN-.2R:WU*+5'OH[>61
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MP?VI$7%R+1L*Q"RG&%8XPN=P )X)X'-26'B2UU'Q#J6CPQ7 EL-@D=X752S
MG )&,8Q@YYSQTKC;_0]9F\/>*;:/2)VGO==BO+==\?SQ*T!+9W<?ZIN#@]*Z
M32+._M/''B"YEL9!9WZVTD5QO3:-D>UE(SNW9]L8[T :=QXCTFUOOL<UX%F$
MR0-\C%5D< HC,!M5CD8!(/(]127WB71]->9;R]6+R61)G*L4B9ONAV PI.1@
M$CJ/45Q7B/3-?O[O4E71)Y!'JUG=6S6TL4<<T*/$6+98%Y?E8?/P JX([U]2
M@EN-3\16HT35KK2+V]AEN&L?)D#21K'O 9I%9>4"L-K?=.""> #M_P#A+] _
MM%=/&I1&Z9XXQ&JL3ND!* X'&<?R]15BW\1:5=7R645V//DC:6(,C*LJ+U9&
M( <#(Y4GJ*Y_2[.ZO_$?B6^6VF@LM6LK5;2[;;\V(W!.,[AC>.H%8^DZ!J-_
MH*:/J'AS[!J5G82V:ZI).LD>6B,8>'#%ANX)!48&1UQ0!VD7B?1I9I(A>JKI
M ;G]XC('B'\:$@!UZ<KD<CUJM%XV\.3-"(]3C;SX?/A.Q\2IQ]PX^9N1\HRW
M/2L+0;2^FM4:_P#"3V>I65F\#7+SI()&*X(@.\G#8!.[:!P.>HKZ/HNKVL7P
M]2;2YU.DVSQ7IWQGRF,'EC^+GYO3/% '8V_B/2KK38M0M[OS;>9VCC\N-F=G
M&=RA -VX;6R,9&#Z5 ?%_A\6]I.=4A$=X[QP=<LZYW+C&0PVD8.#D8ZUPZZ)
MK]D\>IC1)[E;?6;^>2Q6=$DE@G;*R(0V-PP/E)'4UKRZ/=&[\,W%GX>:SABU
M22]N84>,M$K0R)ND^;!<LP)VY^IQ0!KW?CG1X+"QO+=YKJ.\O19)Y4$A*2;L
M,&&W*D '@C)QQ6KJ6NZ9H\5O)J-Y':I<.$B,N1N8C./RKA'T36EAGF72+AFC
M\5#4UB$D>Z2#&-RY;&>^"0:V?'TCI#X8D,#2.-<MF,2$$YVOP,X&: -6#QCX
M?N=-EU&+44:UAG%O*^QP8I"0 K@C*Y)'4#J*GO/$VC:?]O\ ME\D'V"-9+G>
MK#RU;.T].0=IZ9Z&N.UOPQJ6H6GB_4+2R99=3>S:WM695>06Y5BQYP"W( )_
MA&<9J#7M+UW6#XOEAT&[0:KH\%M:K))$&,BF7(8;\#[X/4C'?/% '6GQSX:5
MMAU:'=O>,+M;+,JAB ,<\$8QUR,9JW:^)M&O=*BU.UOXYK2:3RHV0$LSYQL"
MXW;N#\N,\5SOB"9H?%W@>4V<Q8&ZS"H4NG[C'3.#CV/TS6=%X8U;3]3M]?@M
M'<#7;C4)=.5E#B*6'R=PYVEQC?C/\1'6@#L)/%>A16'VZ74HH[<7 MF:0%2D
MN0-C*1E3DC@@=:IVGC?2;_7K72[,W$QGMY9Q,MO($79(L9!ROJ3D]!CGJ*YK
M6/#FJ7*ZU?V^G3.VI:M87"6@9 RQP&/>[98 %MK<9S@+GG('0:A9:@OC_3]5
MAT][BT;2Y[.1E=!Y3M)&XW D'!"MTSS0!MV6M6&HS"*UF9V:/SD)B=0Z9P&4
MD ,.1R,U2MO%5A<:YJNF$31?V8B-//+$R1C(+'YB,   ')/.3CI6'X.T?4])
MU-8XTO8-$-GQ97[K(UG/N7]W$X))CV@\$D#"X/4"GK_AK6=3NO&EG;6[1IJ]
MM;M:W1=?++1I@HPSN&2,=,8)Y[4 =I9:YIVH7;6EO<'[0L8E\J2-HV,9. X#
M $KGC(R*K7OBO0].U$Z?=:A''=CR\Q;69AO;:IX'0GBLN*RO=:\6Z)K<UA-I
MZZ?9SQS)*5W/)+L&P;2<JNUCGITQGG$T5E>CXF76HM92"Q?2HK9;G*;3(LLC
M$8SNZ,.<8H U%\0Z6^HQ6 NQ]HF+K$"C!963[RHY&UB,'(!)&#Z4P^)M(%W!
M:_:_WEQ*886\I]DKC.55\;6(P<@'L?2N-\-Z'J,-K:Z)J7AYA=:<S"'6'F5X
M2,$+(B[MPD(.,8&.3GL:-N-4L['P'HVJ:1+9S:;JD=LTYD1HYREO,H9,$D@@
M9.0,9QS0!Z OB;1V@CG%X/*DN_L2L8V&)]VW8>.#NXYQS53_ (233+&36;J]
MUV%[6TG2-T,6W[*2H^0D<N2?F_'%<C/H^NQVT^G1Z)<2^7XG74Q,LL022 W
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MA1ZBUA-'9'1EMC*S)@2>9NVD!L].^,>] &QJ7B#2](+?;KH1! ID?8S+$&.
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MJAJ6C6.KFU-[$\AM9A/#ME=-D@Z-\I&2,GKZUY:M[JDD]OX<C_M#4;*+6;Z
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M:-KDFCDNEXD(N%5UP)(R<%E/?!X/ID>HKC?&[?:M4EL[:/4YI;+33<,EM?\
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M(*L.Q!!!]Q7-Z3\0X-432+HZ/J%KINK.(K6\F\O:92"0I4,6&=I .,$CT(-
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M2"%Y1C$C1!MA;@<E<\9KG/A1J>KZYH4VKZLU_))=2N5>:6,P_+(Z[8D4Y7
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M2:>2X<;BV9'8LQY)ZDDXZ5GWGA'1;_5&U&XMI&F=D>15N)%BE9,;6>,,$<C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M._@XC;CKR*T-3\/ZGJ^O^)U^S2VUKJFC1V$-V70A9!YN25#;L?O!V[&NYHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,$DCC\PY8@@;=BXRWIR >FUBZWXB&CSQP)I>HZA,T33,EG&IV1KC+$LRCOP
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M7=4#'V&[)^E<UK^H>*]"T'Q%>F]A\J"Q-S9/,(WF1U^^"JJ%*_=P<9!/.>*
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MB;2C";5=CQ&X,()_BR!@C!'3G-.U/Q%XATMM;LH]32>6QU+3XHIYK9,F.X9
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MH0(64@E@V_)!.WCWH W?^$.\,?\ 0N:1_P" ,7_Q-'_"'>&/^A<TC_P!B_\
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M()RI]2/Q]>:PM9\4:YI$.N6K7LLM_IM['<(J0QYFL&7>QQMZJJ2C=_>4>N*
M/3*IW^JV.EM:K>W"PFZG6WA!!.^1C@*,5RUYXDNVN[/[%=%[75K\VMI(-@"H
MD+,S*2.K.A4;LC R*S]:_ME=/TB+6Y8)9H_$UJ(7C8%S"7!7S H #\D' QT/
M>@#T6BN*DUG5+3Q#K6A3WK-<SI%-I#^6G".=C< ?-L;DY_AQ]:CN-6\1:E-K
M"Z)<1)+I-XMN%N6C6.0*B.YE^4L,AFP5P!@>] '<U%]IA^TFW\P>:J>8R_W5
MZ GTS@XSUP?0U*.E<G\/KF34=$O=4G)-Q>:E=,^>JA)#&B_@B** .ALM4L-2
M@EGLKR"XABD:-Y(G#*K+U&>G%4M+\5:%K<MQ%IFJ6]W+;KND2%MS!?4#J1[C
M(K'\%017%GXF@E17BDUN]5T(X8%AD&KD>GQ:GXUAUR)56&PM);-)%X\]W92P
M]U39@>[-Z4 =!!/%<P)-!(LD3C*NIR"*DKDO#-S)'XS\7Z4/^/6WN+>YB'96
MFBRX'U92WU8^M6/&&HZCIRZ+_9URD!NM4AM9=\0?*/G/TZ4 =+17F.J:[XDT
MW2_%TRZR)&\/3(\3-:QYN$:))-DF!C'S$94 ]\UK7>OZK?0>++G3[P6KZ%(T
M<,#1JRS%(EE)DR,X8L5&TC &: .XI&8*"6(  R:X#^W=<UG5Q#9ZA_9UO/X?
MBU-$%NCO%(Q/&6R#T&<CUZ=:AT+4]0UWQ5X4OY[Z:(7?AQ[N6WC">67+P;N"
MI.#GUR,<$<Y .[TS5++6;!+[3YQ/;.SHL@! )5BK=?0J1^%6Z\K\,W^IZ3HW
MAZ>&]!L[S7KNREM#"N"K3W!W;OO;@RCH0,<8[UT&A^(KV?Q0-+U:6YM+QO/:
M.VEA3R+F,-E'@E4<X7&03GGIQ0!V%Q/':VTMQ,VV*)"[M@G"@9)P*2VN(KNU
MAN8&W0S(LB-@C*D9!P>1Q5/7[BXM/#NI75I(L=Q!;22QNR[@&521QWZ5RL.L
M:W?:CX4M$U(0)JNCR7-PZVZ%A(JPG<N>!_K#QC'M0!W=%>;:9XB\0-IGAO4[
MK4DE%UJKZ9<0"W55D4/*GF9ZA\Q@\$#G&*9=>(?$D.DZOJ:ZK'G3M>6R2'[*
MFR6)I(DPW?@.2""#ZD]@#TM45,[5 R<G ZFEKSV]\4:MH-_X@LKF\6\%N=/-
MO-)$L?E?:96C;., JNW<,_0DU/J.M>(O#_G1WL\+Q7UY:VMA+*4,L)E?8Y<(
MJJ5'5>.O!H ZIM=TQ;J_MC=#SM/A$]T@5B8T(8@].?NMP,GBKMO<175M%<0M
MNBE0.C8(RI&0<'FO/)&O]*\5>-KB*_:6Y@T2VFAFFB0E=OV@@$* #R#V[U+J
MGB/5TT".ZMM0Q<IH U!H8(49S+MW;Y-PVK'P1@$,?FQTX /0J;)(D,322':B
M LQ] *\^_M6\_P"$Q34Y;NX,,?AK[>;1-NS<6!91E2>=HYSG@<XXK4T&]\0W
MMQI6HRW%O+I5]:;YD=D!61E#H8=JY(^\"&).,'/!H Z73=1M-7TZ"_L)A/:S
MKNCD (##UYJ'2]#TS11<?V?:)"UP_F3/DLTC>I8DDX[>E>?:!J5]H?PV\'ZM
M%<E-+A*1ZE&$4_NG8J),D9 5BI./X<],5WNAW%Q?0W-[).9+>>=C:J54;8A\
MH.0.0Q!8$]F% %V[O+>Q@\ZYDV)N"C@DLQ.  !R23T YJ+3-4LM8LQ=V$XEA
MW,A.TJ593AE*D @@C!!&:YGQ[#-+=>%O+O)H VM1*1&$//ER'=\RGD8^GM5&
M[\1ZK)H/BG6+&[$3:#<S1);/$A2<0JK/YAQG+Y;!4C'R]><@'8/KFFQW]U9-
M=J+FU@%Q-'@_)&<@,>,=C^56+"^MM4T^WO[*42VMQ&)(I " RD9!YYKCH+C[
M7\0=0N=C)YWAJWDV-U7,LQP:S_!FK7$NE>#_  Y;W#VBR>'UO9)T52[;?+14
M7<"/XB3P>@H ])HKSI?%.M)H\6HW-PJQZ7K;:=J;)$H6>$2>6)1D$K@LA./]
MKVQ/HWB/4M0U'4-&>^E^V#4$>TF,48W6+ L) -N""$D7=CJ5/&<4 =K:W]M>
MR74=O)O:UE\F8;2-KX#8Y'/##D<<U9KSG4?$NNV_A[Q5<Q7L0N--UF.U@<P*
M0(F\CY<=_P#6-R>:L7NO>(-)F\76L<RZG/I]A#>VFZ%5*E_,#+A<;@/+R!U[
M9- '?4=*Y71+_4[OQ5=1)?->Z)':12).\*J3,Q8,FY0 <!5;&,C=@TWXE27$
M7@#5)+:ZEMI J M%C)4NJE>0>"">E '0+JMBVL-I*W"F_2'SVAP<B/.-V>G6
MJFK^%]%UZ:.;4[".>5$,8?<RL4/)4E2,K['BN7U&UOV^(S0VFJ207"^'R?M1
MA1W)$_'&-O7VZ>G6HM*\4ZSXDM-,M;606U]/H<6HO)%L&Z1R5X#@C:"N2 ,_
M,.1W /0888K>".""-(XHU"(B#"JH&  .PI]4='DOI-'M6U3[/]O\L"X^S,6C
M\P<-M)[9!^E7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *SM;T.P\1::^G:G')+:.5+QI*\>[!!&
M2I!Z@'\*T:QO$7B*#P[;6<L\,\OVJ\AM4$43/@NX7)P#T!)QU)&!0!+'H%E'
M=17)>\DEB#>69;R60*6&"0&8C."1GJ,GUJK#X.T6WL]/M(H)U@TZ<W-JOVJ4
M^7(<Y.=V3]YN#D<FI[WQ-I.G'_2[EHE#(CR&%]D3/C:)&VX0G(X8CJ/45"?&
M.A#4I=.^V.UU%*89(UMY&V.$WX)"X&5Y'KVS0!B>(_""M)8MI-G<N9-:BU&^
M9;L@_*I4L-SC!QMX7^[6]<^%=)O-,O-/N89)8;UQ)=,9G#S,,8W,"#QM QG
M  JO#XZ\.7!M?*U!F%W&9;9OL\NV8 9(0[<,W^R/F]J;-XFTR^M--N;367M8
MY]06V'^C-NDD#$- RLN4)/!) (Q0!<NO#&F7=X]V\<RSR0"WF>*=T,T8SA7P
M?FQD\GGD\\U3UC3+G5)H-".D6HT%1#*]PTHX\MPPB6+;_LJ,YQ@GN*DN/&WA
MZUGN(9K\J]M.MO/B"0B%VQMWD+A0=P^8\<]:M7/B;2+.]:TGN]LJ31P.1$Y2
M.23&Q6<#:I.1@$CJ/44 ,USPMI/B&:UGOH91<VI/DW%O.\,B ]0'0@X/I4&H
M^"M"U*2RDEM9(I;*/RH9;6XD@<1]T+(P)7V/]:KR^+K*>3Q%:>;=6']E)MEO
M&M781DINW@%<' 92 >O)P1S6B-=L+2RM#-=RW,DML)PT5N[O(@ S(4120#D=
MAR<4 :D,,=O!'#"BQQ1J$1%& H P *S;+P[IUA/!-$DS-;*ZVXEF>00AOO;=
MQ.,XQ[#@8'%0S>+M"A%B3?K)]OB::T\F-Y/.4#)V[0<GVZ^U7]+U2RUK3HM0
MT^;SK:7.U]I4Y!((((!!!!!!&010!)?6-KJ5C/97L"3VTZ&.6)QD,IZBL2#P
M-H5OHMUI(AN9+2Z012B6[E=C&.B!BVX*,G@$#FKL_B72+:X\F:[VXG%NTGEN
M8EE.,(9,;0W(&">I ZUB:AK-]J7BZ[\.Z=?7.G26]E'.EPMD9%:1G<8;<N-@
M"=05SN.#D4 ;@\.Z>NIKJ0%Q]K6V^R"3[3)Q%G.,;L=1G/7/>N;A\'"P\7Z4
M-/M+J#1K'3)K5)([LY1WD1@.6W%<*PYSR1]1=\:ZO?:,V@FUO5MDO=3CL[AF
M12 C*Y+#=T.5'M5R#5([$:A>7.NQWFGVD0:9A&I:!ADDDQCD;2#CJ,>] %EO
M#&DE=,46[HNF.9+4),Z['((+'!^8D,V2V<Y/K34\*Z1'=2S);N%EN!=O )6\
MEI@0?,V9VYR >G4 ]>:@3QMH$DHB2\E:1H!<1HMK*3-&<<QC;^\QD9"Y([TC
M>./#JV]G-_:.Y+V)I;8)#(S2JO#84+G(/&W&<]J !+&]U3Q+%>ZGI=O;P:6\
MOV&43"5YBX"[\8&P;=PVY.2?;FU/X:TRXO;^[DCF\Z_@%M<L+B0;XQG"X!P/
MO-TQU-8NK>*5O+'PYJ6@:BKV=[JT5K*5C!WH2P92&&5(*X[&MNZ\2Z19SM%<
M7>S9*L$DGEN8XY&QA6D VJ3E>"1U'J* &1>%=(AFTV58)2VFP-;VH:>1@D;
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M[;]OV_:I<^?OW[\[L_>YQTS61XO\(+>6-V^EV<\U[?WEI+=$717<D,JMD;F
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MAIR21VR%F5'E:3!)+'EB3R2368/&>GR>'-(UF&*>6/59H8+>%0/,\R0XVGG
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MZE;:QI5KJ5FS-;W,8D3<,'!'0CL1T(JW0 4444 %%%% !1110 4444 %%%%
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MGO\ -\Q XS7;5GZGJVGV M8;Z0@7TXM(@(V8/(W&TD# []<=#0!PGAS1I/\
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MNO#<=VUH-OEJSR+N !7.#@'.<\#G'%>B$X&:S;C0-,N;^&_>T4W4$)@B=79
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M!U>ZNKB_T]9I+J$07'[QU$J#.-R@@$C)P<9'8BE_X1/1?]-_T5_].@6WN?\
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MO(Z8;V(W-$\)Z'X<DDDTFP6V:0$<2,P4$Y(4,2$&><+@<"I[[P_INI7$L]W
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M]34-GX/U&'QZTT@B_P"$>@NI=4MEWY;[5*BH05[ $RN#ZO5-_!>LF3Q)<Q)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTR.<'MDURNBP7_B"'0[*XL;'5H(=!$D<>IWCQ*K><Z-(I"/E@JQC=P5SP>:
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M([*!5L!BT 0#R!M*?+Z?*2/I7'1ZIKEQ\0?#D.JV":>)+*\E\N"[,R/_ *K
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MM;3M(UU*8S&&P478N&8XRQR1Z5V+RQQJ&>1%4D %F !H>6.($R.J #)+'&*
M,3P5HMSX=\':;I-XT3W%M&5=HB2I.XG@D ]_2N?TGP7<:5JZQKHGAZ6V2^DN
MEU.6/==;&=G";=GWU)P'W] #C/%=XTB(NYG51C.2<<>M'F)M#;UVGD'/!H X
MA_!VHMX8NM-$MMYTNO'4E.]MOE?:Q-@\?>VC&.F>_>LSX@:+?1'5]6CEA5+Q
M])MX,Y)62.[R2P]/G7OZ]*](,\("$RH!)]P[A\WT]:;<BV>(K="%HP58B7!
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MH9+EXTDC$A>.4,(S@\G*X[\'BO0DFBD0NDB,@ZLK @4JRQLS*KJ2GW@#T^M
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MA^S^P'2M9NI9FO))F$MNDQS*OEA"&.2VT[AUYZ<[^BZ#/IGB?7]09HOLU_\
M9A JL2RB.+8=W'KTY-;Z21R$A'5B.#@YQ2@@D@$$CK[4 <3XB\)W%UXDFU>U
MT;1-5-U:);M'J@QY#H6*R*=C9!#X*\?='-:6D^'KG3_$-]?-]D6WFTVUM(X[
M=2@5HC+NPG15^<8&371++&[LBR*SK]Y0<D?6E$B,VT.I;&< \X]: /+[*PO/
M!-WH"&_T87XT06,\5[<O!&1$^[S(WV'=@N<J<'!!JKX6\-ZG?Z#H.II::;JD
M8BO4":AE40RW)=;A5VL#E>W!P1@\FO2&N-&UFYN["5;:ZDL)%$T<T881L5##
MJ,=&'3UJ_P"=!'&3YD:HAVD[@ I]* /+[#3]0\%7^BK)>:(MZNFRV+1W=V\*
M2Q)+O657\LC<-QRGH>#Q5?PWX7N=2\.:+K2Z?I>LR(U^CP:@NR.:.6Y9UE0E
M7VGY01QRKGFO4[VVL;N)4OX+::/<-JSHK#=VQGO5/0];MM7T?[>D?V:%9YK?
M:Y QY<C1_3!*\?6@"70K&33=%MK66WL;>5%)>*PB\N%6))(4>G/7OUP,XK1H
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K@_BY_R)UO_P!A2T_]&BN\J"[LK6_A$-Y;0W$08.$F
M0. P.0<'N#0!YAK.B:;J,OQ-N[VSBN)[>,&!Y5#&%A9(VY,_=;('(YX'I71^
M(;I)/A]IT=W;+>M?FS@\N:8QQN[LF#(PYV9ZCN..]=6;"S870:T@(NQBYS&/
MWWR[?G_O?* .>W%)<Z=8WNGM875G;SV;*$-O)&&C('0;3Q@8% 'CLEM&4U72
M66QCMQXDTQ6@TW*0H6,8?8.V<$''<'O6S?>%;>?6O%^BZ+;PV+"PL;VTC@0(
MD=TC3%' ' )*(">XKT"/P]HL+(T6D6"-&$5"ML@*A#E ..-IY'H:=J-I<B&X
MN-(2QBU2553S[B(L"H)P&VD$@9; SU- ''^$=23QOXE_X28(5MM/L4M(4(^Y
M<2A9)_Q4>6G_ 'U4=W=6]IJOQ'-Q,D?^AP-\S8R#;L!^O'UKK?#6@Q>'-$BT
M])3-)N>6><J%,TKL6=R!TR2>.PP.U3W>@Z/J%]'>WFE65Q=Q+MCGFMU=U'H&
M(R!R?SH \Y\-:'IFMZQLU2RAO(D\,:;MCG0.@)$PW8/&[' /49..M9%EI>GZ
MK<?"9]1L;6[>YM)XYVGA5S*J6V4#9'S 'D9Z&O98+"SM7WV]I!$WE+#NCC"G
MRUSM7C^$9.!T&34::5IT1M#'86J?8@1:[85'D C!"<?+D<<=J /*5>W;Q!HN
MLVEEIEE]K\021K()&>]D :2-][=D.,;.0H*#TJ@($NO#VO6\A8)+\00C%3@X
M,T0.".G6O76\-:$TUQ,VBZ<9;EQ).YMD)E8'(+'')!YR>]3C1],5'0:=:!7N
M/M3@0KAIL@^8>.7R =W7B@#F_'5A::7\*->LK"VBMK6+3YA'#"@55R"> /<D
MUS&K:?I6GZGIP\/10J;S0+]KLVX&9XQ&A1Y,?>.\\,>22:]3N;:"\MI+:YAC
MF@D4J\<BAE8'L0>"*JV6B:5IMS<7-CIEG;3W!S-)# J-)_O$#G\: //6O;.5
M/AS%]N2/-A,YD1QF-!9,"_MC^E9,UG;Z+X5U[3&T_2Q<R>&;B2'4M+D(2[A1
M0-TL?9R6!#$MG+8/45ZI9>&]#TV7S;'1M/MI-YDW0VR(=Q!!.0.N"1]":2U\
M-:%8Q745IHVGP1W8*W"16R*)@>H8 ?,.3P?6@#@M&TFPUC7_  M!J-K%=P)X
M41_)F4.A;=$ 2IX.,G&:P]'M)[X^'],-KI=W9PP:D+>WU5F\G*793@ '++'@
M#/12<5[+%86<$D<D-I!')%%Y$;)& 4CX^0'LO XZ<55NO#VBWMBME=:18SVB
MN9%@DMT9 Y))8*1C))))]S0!YA-HJ#1K*XGET'Q"+'2G$MG/.?EM_,<K)!*0
M<-M&S<0/N#D5;OX]/35'\2&TL-4L7EL2XEE9-0TYML80(W)(Y5BN5)+-US7H
M=YX=T345MEO='L+D6HQ )K9'$0]%R.!P.E/FT'1[G4XM3GTJREOXL>7<O;J9
M$QTPQ&1B@#E?'5O87?BCP9;ZF(VM);V=723[CGR&VJWJ"V!@]>G>N0U*PM&>
M^TBT14T4>,+*&**$[43?&GG(F/NC<S<#H2:]+UWPY'KNK:-<7"P2VME),TUO
M-'O$JO$R8P>.K9YK0@T32K:S@LX--LXK:WD$L,*0*$C<'(91C .><CF@#S/Q
MM8:6IUJSL]'T>&+2-'4"2[)_=!_,*"WC485LC[PP2=H[5-;P:)K>IZW+XM,$
ML<&D6<D$MP1F&%HF9Y(SU!WYRR\Y ]J]&N=%TJ]OHKZZTVSGNX5*1SRP*SHI
M[!B,@<G\Z@E\,:!/':1S:)ILB6?%LK6J$0]_D&/EY]* //X;#2?^$L\9W4-O
M TW]AVTEO/)&/-.Z*8,V2-V6 7<>I[U3\)VUCJ4'@>PUN&"?3?\ A'Y)8(;I
M0T3SAHP3@\%@A./0$UZG/HVEW5^M_<:;:2WB1F);B2%6D"$$%0Q&<$$\>YJ.
MY\/Z+>Z=#IUUI-C-90X\JWDMT:./'3:I&!^% 'F4MC8ZEKEG8Z8FE:EHD&C,
M;,:Q*Y0#SG65HR5/*@(-W9<8.#7H7A658?#ND6%QJEM>WHL4?S(Y=QF0 #S!
MGD@Y'S>IJY>^']&U*V@MK[2;&Y@M\>3%-;HZQ]OE!&!^%/\ [)MO[9AU,+MG
MAMGM4"J  C,K$=,]4&.PY]: .)UO_DLEK_V+ES_Z,%8NB:39:;H7PTU.QM(H
M]1N&C26X"_O)5>SD)5FZE<JN >F!CI7JSV%G)>"\>U@:Z$9B$S1@N$)R5W=<
M$]J1=.L4BM8EL[=8[0@VR"(8A(!4;!CY>"1QV- 'GO@:T\-C2/"VJ3M''XBN
MM^^9/]?<3E6,RRD<L 0QPW *CIQ6#X#=8M%^'CR,%3^T]27<QP,D3X'U->LV
M^A:1::E-J5MI=E#?39\VYC@59'SURP&339?#VBSZ8-,ETBP>P5MXM6MT,8;)
M.0N,9R2<^YH \OEDL]1UZX@N&BFTBY\8F.Y#$&.0K9+L5NQ'F*.#P2!69XN@
MT^U\*_%&WTM8DM(Y;%5CAQL0_N]RJ!P #G@=#FO9'T#1GL);!])L39S$&2 V
MZ>6Y  !*XP<!5 ]@/2D7P]HJ6,MDND6 M)559(!;)L<+]T%<8..WI0!R$NA:
M9K?Q#\1)J=E#=QQZ39[8YD#J"3/\V#QNXX/49..M<[X2BTW69M*'B807$,'A
M6UEMOMA!5<LXED4GHPVQY8<CCFO75M+=;B6X6"(3RJJ22!!N=5S@$]2!DX'N
M:YK7?"UQ=3V#:5#H@M[.(QQ6M_IZR)"V1M>,K@J1C&.AXZ4 5?AA=VR?#_0K
M=KE?.F29HDD<"24+(V2 >3C(S]:SO'M[+X:U\:O;9\W5-+FTV/'&;D$-!_Z%
M(*Z71?"5KH]IHL1E:>;2X9(TE90"[28+MZC)!X!QSWP*V;JQM+X0B[M8;@0R
MK-%YL8;8XZ,N>C#L1S0!Y9HM@+77]+\!*2T&C:E)J)'K L:O'^'G3_\ CE86
MBZ?IU[X*\$G4+2VG0^)9XF\^-6&QFG)4Y[$JO'? ]*]P6QM$OGOEM81=N@C:
M<1CS&0'(4MU(]JJR^']%GTW^S9=(L'L=_F?9FMT,>[.=VW&,Y).?>@#S#6-%
MTVY\/?$K4YK2*2\M;N5K:9E!: I;0LIC/\)SCD8S@>E7;BSTC5)O'5UXBBMY
M;JUC0027 !:W@^S*R-&3RN7+G*X^8>U>D_V7I_V:YM_L-MY%R29X_*7;+D!3
MN&,-P .>P%0WOA_1M2N8;F^TFQN9X !%+-;H[(!R,$CB@#AO"M^\&M7MSK$P
MBN7\-:;-.9C@D@3;R<^A//UK%\#Z=ILOB#P3/<6=JTW_  B_F)))&I;S%DB"
ML"?X@"<'J,FO5KS1-*U&[M[N]TVSN;FW.89IH%=XSU^4D9'/I36T'1W^Q;M*
ML6^P$&TS;K_H^,?<X^7H.F.E ')^)_\ DKO@/_KEJ/\ Z*6N-TRVBO/"UO;3
MKNBE\;NCKG&Y3(V0?8CBO9Y;*UFNX+N6VA>YMPPAF9 7CW##;3U&1UQUJ)-(
MTV*-8X]/M419_M(585 $O7S.GWO?K0!Y9J7AC1%'Q)C73+816=HLMI$(P$MI
M#:[B\:]$8E5)(P>!3GC34/&^H+=HMP)?!,;.LJA@QWDY(/7GFO5&T^R?[5OM
M(&^UKMN,Q@^<,;</_>&..>U":=8Q7/VF.SMTG\D0>:L2AO+!R$SC.WVZ4 >3
MZ7::3/X:\':;!I.BR-_8IOYGOSBV4[(ED9D P\A)^\>0,\\U'X:M;"^U;X=7
M-[;VL\O]F7BB2:,,<Q/'Y?+<Y7G'<9->FKX3\.)%#$N@Z8(X93-$@M(\)(<9
M8#'!X'/L/2I7\.:'((@^CZ>PAG-Q'FV3Y)2<EQQPQ/.>M 'DNDK'-I8M;S:=
M+N/&]S'>*_W'7#E%?L5,@3@\'@5;\0VEK;1>---TQ$@TM;C23Y5M\B13M.OF
M;0O"G:(R<=\&O5#HVEM97%D=-M#:W+M)/ 8%V2L3DLRXP23W-);Z'I-KIW]G
MV^F6<5EN#_9T@41[@00=H&,Y .?4"@#E+"STOPW\2+]+.&UTVP.B1SSB,+%'
ME97&]N@R%[GM6OXVN[:+P;=O+ +J&X,4 C$QC5_-D5!N<=$RPR?3-:FI:/9Z
MG;7<4T,8DNK9K5YA&I?RV!XR0<CDG!XSVJ:33[2?3SI\]O%-:&,1M#*H=67&
M,$'K0!XU?VZP6?B_2@NGVR)<Z06@TK,<4;M< ,5'9L*N2,=!WKH=2\(Z?<>*
M=<\/Z9;06$-[H,4H6W0(HG69_+DP/X@0O/7BNZC\-Z%"J+'HVGH$C$2!;9!M
M0/O"CCH& ;'KSUJ6_M9=DUUIT5FNJ&,1QSW$9(V@YVL5PQ').,]30!P_A/4Y
M/&_B2QU:XC*#1+'RI8R,;;^7Y91_P%4Q_P!M*M:CHVG:U\5IX=3LX;N!=!C(
MBG4.F3/(,[3QD#.#VR:Z/PSH(\/:6\#S"XN[B>2ZN[@)L\V:0Y9MO8= !Z 5
MJ?9;?[6;OR(OM)C$1FV#>4!SMSUQDDX]Z /(?#>FVEIH7PWU6&!1J-Q>"*:[
M(S+(A@F^1FZE0%4 '@!1CI4?A_3!JOAQX5ETU[B/Q-?2Q6.I F"[(W@HP'<
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M38S7$\7DS2R6Z,TD?]UB1DC@<'TIB>&M!CC6--%TY46(0A1:H (PV_9T^[N
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M$*%\W.Q-SA2[8YVJ"6/L#TK-T#6-2;Q1=:+=ZA::K$EDEVMW;0^7Y;,Q7RV
M9AR!N'0XSUZT =;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DZU
MH0UDPDZIJ=EY6[_CQN3%OSC[W'.,<?4UK44 <[XVLM0OO"5S;::DDTQ:(R0H
M^QYXA(IDC#9&"R!AU[XK(\+Z>$\7S7NDZ%-HFB_8/*E@D@6W$UQO!5A&/[JA
M@6QSN YQ7<T4 9-]H(OM6@O_ .U-4MS#M_T>WN2D+[3GYEQSGH?45K444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 17-Q#9VTMS<RI%
M!$A>21SA54#))/85G)XFT5]+N-2_M&!+.W.V:20[/+. <,&P02",#OD8ZU!X
MR@EN/"EXD,3RLICE:-%W,Z)(K,H'<E5(QWKF-3O;*[M?%FJA6>QN+2.VM9#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC66-B,95AD'!]C4]8?@^5G\):7%);W-O+;VL4$D=Q"T3!E10>& )&>_2MR@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex1012022063010qngcbasho009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<WXSUF\T73K2:VE6VAEN1'=7KVS3K:Q[&.\HI!Y8*N>@W9-=)6;K%CJ%Y%
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MAM5Y.(H5^^Y*C//]X\U#_P )!KVO7'@V2WU."V:;4KRVF*VK[)6A690Y0N"
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MXGG2'S-B+$07VD88*Q0GT"Y[4R^LK:_LX;N+49M9BO?$NG^?,UJ(XI-NU25
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M3\1=+N(7_M'4KR:.TB\HEKIF@C5 G'S$-Z=,YH ]4.J6(>]4W46ZQ :Y&?\
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M]_\ $G3_ +!K+Z6\4MSIEY#;.LI.UE>2)&<8[#S"/JOI7+PS1MX%LO":J_\
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MU&"/SJU;^*-'U$WD&GZI9S75K$TCKOR% _B/JN>I%>37%G=WGA;Q+#/!,?\
MA'=%FT>#<I^=C(V67U_=QP<_[1KM_$=MY7BRQ6"';&OA[4(AL7@ &':O^ H
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MUIB6/([#:H &!Q5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVG/<N[QV5K-:>5QB5)45&W?@O;UHT/P_=:3,C7&NWU_%#!]GMX9@BJB\<MM
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M&*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9VNRW:Y:/#R;HI $9E+*R>GW<?P\>J44 4=%M4L=#L;6*.:*.&!(TCF?<Z*
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M2>!GI5B"[_X2#6_"0L+"]@_LI)9;WS[22$09@,8BRP )+,.%SPN?2O1*,YH
M\QTK3;N+P/\ #B V4Z2VU[;O/'Y1#1#R9=Q88^7D\Y]:S;2VGFT'3=*:PO#<
MV/BT37$;VKA5C:YE=7#$89<8.02!D9ZBO8** /,_'#ZC=ZCKNG!M5C$NF!+"
M"PM RWCLL@822[&P%.!C<N 2>2:9I>J)H=UJES?:5J%W%JMA:-:1I8R/YY2$
MQM PV_*=W9L##9]:]/HH \IUJPO;K5/&>EQ6,]O<ZQHENEDBQ,8V9(Y=T?F
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MC_+\A4G;QN'2O0+NZ@L;.:[NI5AMX$:261S@(H&23[ 5(CK)&KJP*L,@CN*
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M&><8XK5U?P='I.EO+8MK-[*=2COPT$L1GMY=NQY4W+A]P^\AR#DX Z5!X?\
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MK0)+MW6-6$EQ(A>'[P/"HN['?>,YKI]/\,V6G:MK6HH\LLFKM&URDI!0;$V
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MHUEJCP11(S,\C/E-S D*0 #WX&,9-;>J>"X-1O;^:'5=0L8M255O[>V9-EP
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MF^4\CGL:U*@L[5+*R@M4>5TAC6,/*Y=V &,LQY)]S4] !1110 4444 %%%%
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M+;W<5K+:O:2QR1LY7&Y2N0"K9!Q@G ')KF--TW4&>&%M.U7Y/%<5]NNXF9C
MT&%D9\8/(P>?E. <<58\6:5J,DGB^>'3[J97N=*FC$4)8RK$ZE]@'WB #P*
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M&3<,C^(9-9?AOQ+K]\VDZSY>MSQ7K/)>Q2VZ+:1PE'9#$P^8%2$&3G=DY[4
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M%;QK91*SQH\;EOF=_G)W+T) XP:L:AK^J0^#_']XEXZW&G7<\=H^!F)5AC8
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M]I#3OMMO]N,?FBW\P>84_O;>N/>@#$U'P/IVHW5[(UYJ$%MJ#!KZS@F"PW)
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MW,%M;:Q8S3W&[R8XYU8R;20VW!YP5;\CZ4 4X_"%I#JK7D5]J$<#7)NVL4G
M@,Q.2^,;N3\Q7=MSSBJ4OP\TN9G0WNI+9F[%ZEDLX$,<WF"0LHVYP6SP21R<
M =IG\8:;J.DZC-IVL6-H]K<?9O/O.8PP8 _+N!.?F YY(SS6U<ZUIEG=+;7-
M_;Q3DJ-CR $%CA0?3)X&>O:@"]7-S^"=*N&UIG:YSK$\,]SAQPT14KMXX'RC
M/6I=/U>]N/&VM:1-Y)M;2VMIH"B$-^\,@8,23G[@Z 5!)KU]'\0O["=K1; :
M8;]I&C8.,2;-N=V,=\XH U_[(MO[?_MK,GVK[+]DQGY=F[=T]<T_5M+MM;T>
M\TN\#&VNX6AD"G!VL,'!]:KVOB70[Z[AM;35[&>XG5GBCBG5FD SDJ >>A_*
ML.#Q3-JVMZC#INH:9%;Z7=)'.MQR98=BO(X8-\N-^!P1E3GKP :NE>&;?2[V
M*]^V7EW=1VGV/S;EU9FC#EQG"CD$XSZ 56M?!&DVEQHDT;7);1C<&VW."#YV
M=^[CGKQTK337M(D@N9UU*U\JU ,[M* (@>06ST![$]:@3Q7X>D.$UO3R=ZQX
M%PN=S#('7KCF@"OI?A&UTR_@NO[0U&[^RHT=I%=3!TMU; (7@$\ #+%CBM?4
M+"UU33[BPO85FM;B-HI8VZ,I&"*SQXN\.-#'*-<T\QR3&!&^T+@R# *]>O(_
M,>M6YM:TRWO5LIK^W2Y9UC$;2 '<W*K]3V'4T 8]GX*MK>\M)[K5M7U%+)_,
MMH+VX#QQ. 0&P%!8@$X+$X^M2Z=X0L],OHYX+W4#;0N\D%BTP\B%GSG:H&2/
MF; 8D#/ %+_PEFF73:U:VVHVMO<::"DDUPP$<;[0=QY&5!9<\CTS5X:Q9VFF
MVD]_J-KF6$/YJG:DGR@LZC).WG/? /)H RM-\#:9I=];3QW-]+!9L[65G-,&
MAM2X()08ST8@;B< G&*BM_A[I5OI>FZ;]KU"6UTV_CO[1))5/E,F=J [>4^8
M\'GWK;N/$&C6@A-QJME$)XS+%OG4;T R6'/(QWZ59L;ZTU*RBO+&YBN;:492
M6)@RL.G!% &!?>!=-O[J\9KJ_BL[Z437EA%,!!<.,9+#&X9VC(4@''-:#>'+
M%GUIB90=80)<X8< 1^7\O''RCWYJ:'7](N'D2'4[1VCC,K8E'" X+?[H/&>E
M-L_$>BZA=I:66K65Q<21><D44RLS)_> !Y'(_,4 7+*TCL+"WLX=WE6\2Q)N
M.3A0 ,_E6;J/AC3M3\0Z7K=P)?M>G;_)"MA&W#'S#'..H]":SM<\5+9ZWH=C
MI]W9RF\U#[)<QGYG"A')*D' (*@'@XSVK4U7Q'INC:AIME>SK'-?R-'$"< ;
M49B2>P^7'U(H J6W@K1;>776,+RKK>?MD<KY4@[LJO\ =!+N?JQ-&F>$+33[
MY+R>^O\ 49HH&MH#?2JXAC;&X* HY.T98Y)QUJIHOB^)]0U6RUJ_L()X=6:Q
MLT!\LRKY<; 89B2V7(_*MZ76M,@O5LI;^W2Y9UC$;2 '<PRJ_4CH.IH PM.\
M :;ITVF.M]J<Z:5(7L8IYPR0 HR;  HRN&[Y/ Y]57P#I,>DK803WL!COWU"
M&YCE EAF8G)4XQC#$8((P:U--\1Z;JVJZCIUI.KSV$@CE7/.=H)P.X&X#/K4
MTNNZ3!%=R2ZG:1I9L%N6:90(21D!^?EX]: *VA>&K30)KZ>WGNIY[YUDN);F
M3>SNJ[<]!CCMT],#BF^+M$D\0>&[FQMY%BNP4FM9&Z)-&P="?;<H!]B:OS:M
MI]O=);37L"3.RJJ,X!+,<*/J>P[TUM9TU=02P:_MQ=N2JPF0;F8#)4#UQSCK
MCF@#$;PW#XB,6K7ZZAIUQ=6B6]_8QS )*JECL? .0"S\J1D'GCBJMOX;N!X@
MT*S_ -(;1_#T!:&:X92]Q,RE$' '"(6YP,DCK@FNKN[ZUL8UDNIXX59MJ[SC
M<<9P!W. >!Z55D\0Z-#:6]U)JUDEO<Y$,K3J%DQUVG/.,'/IB@#2KF[;P3I5
MK&R1M<X;5VU@Y<?Z\G)'3[OM^M;4&I6-SIJZE!>026+1^8+A9!Y>S^]NZ8KF
MHO%AN/%6K6$>H:>MA:Z9'=)<,"/*=F=3YA+8P JM_#PWXT ;8T"Q-]JMVZO(
MVJ1)#<HYRI1%90 /<,<UGV/@?1K#PE-X;59YK&8LTCRR9E9B<AMPQ\PPN#VV
MCTJ]%KEC::19W&HZI9$R6RS-<(VR.0;03(N2<)SG)/<<U8O-8TW3YEAO+ZW@
MD;;A9) OWCA<^F3P,]3Q0!EVW@ZSB-[)=7U_?W-W:FS:XNI%+I"<Y5=J@#DY
MSC)(&<XIMYX(TF^\'6OAB5KE;*U2-(9$D E39T(;'7'!XZ$U2'B2Y@^).KZ;
M=W21Z19Z1'>D,H 1M[;F+8SC J]8>-])O9EC=+RS\R!KF![RV:)9XE +,A/7
M (.#@X.<4 6-0\+V5[;Z?'!-<V$NG+LM)[-PKQ*5"E?F!!4@#@@]!Z5H:9I\
M6E:?%9Q232K'DF2>0N[DDDEF/4DDFL-/'FD&QN+R:'4+:*&))A]HM60R1NP5
M73/49(]QGD5H:IXET[2)[F&[>0/;6$FHR;4S^Y0X8CWYZ4 )K'ARVUC4--OW
MN;NVNM.=VADMG"DAP RMD$$$ >_O4(\(Z:NAQ:0&G^S17@O5.\;O,\_S^N.F
M_MZ5 GCG2Y;&*[BM]1D6XF\JTC6T;?=?+NW1@_>3&3NX''7I6C;^(+&Z\/RZ
MU"96MHDD>1?+(D4QY#J4/(8%2,>HH I0^$+.WU4WD-]J$<!N6N_L"S@0><Q)
M+8QNY)+;=VW)SBNAK#?Q;I$=UHEN9V+ZTADLR$)#*%#9)[9W #/<XJ"Y\;:3
M;W$ML@NKFZ2Z:S6"W@+O)(J*[[1W"AADG '2@"K)\/M,EDE#7NI?9'O!?+9B
M<"&.;S!(64;<\MG@DCDX [7YO".FSZ/JNENT_P!GU.X>XG(<;@[$$[3C@?**
M6T\7Z3>)8M$\P>\NWLEC>(J\<R*S,CJ>5("']/6L/Q[XPETOPGKT^BSF+4=+
MN+:&1FC#!3(T9XSD'Y)* +U]X!TV_EO"]]J4<-U<"[^SQS 1QS@@^:HVYW94
M'!)7/.*;J7P]TW5#J:37^II:ZF,W=K%.%CDDVA?,QMR&PJ]#@D#(-2^(O&5G
MI0U*TA6[DN[2U,TLL-N9([8E24,AZ#.,]\#DX%5-5\0:A:?"-?$$<ZKJ']FP
MW!E*+C>RJ6.,8[F@#0O?!=A>ZCJ5VUU>Q?VG9_8[N&.11'*NQD#$%20P#'!!
MQ[5=G\.6%S<:;-,KO_9\$D$2$@JR.H5@PQSPHJI9^--)NKBYAD^U69@MFO,W
MENT0D@'61<]5'&>XR.*GT;Q18ZW<M;0Q7EO.(A.D=W;M$9(B<!USU&?Q&1D#
M- %32_!-AI=Y93_;=0NH]/5EL;>YF#QVH(V_+@ D[<J"Q8@&G2>"M*D\%R^%
M&:X_LZ0,&(<>9\TAD/.,=3Z4_5/&.EZ3?RVMP+IOLX1KJ:*!GBM0WW3(P^[Z
M^PY.!4ESXMTBR&K_ &J9X&TI5>Y5T()5AE&0?Q!CP,=QCK0!4NO!5O/K4FK0
MZOJUI=/ EL3;S( (TZ ;D.!DDG'4U)>^#;2\O)+D:CJ=N;A$2\2WG"+=!!@%
M^,@XX)4J2.*J)XZB/BB^TJ73;Z*"TL$O'F> _+D.Q#>@P@ ]6R.U30>/=(N=
M,34(8=0>&:1(K7%JVZZ=E+8B'\6 &R>@P>: $U7P)INJW6HRO>:C;PZD@6]M
MK>8+%.0NT,1@D'  X(!P,@UTEK;I:6D-M'GRX8UC7<>< 8&:P9/'&C0Z=:7C
MFZ N;IK)8?L[>:LX#$QLG4-\I'OD>M4F^).AI;SS20:D@M)/+O0UF^;/I@R^
M@.<\9XYH OZGX/LM3U6>_-Y?VS74"V]W%;3!$N47=@/P3QN894@X-59/ .GO
M8PV$>HZI#8K9QV4UM'< )<1(NT!\J2"5X)7;D5;N_&6E66IR64@NF6&6.&>Y
M2!F@@D?&U7?H"=R_3<,XS6(GC.33O%WC*/5IV_LC218F()$"8O-4[B2.2,X)
MST% &R_@^R.J27D5[J%O#+.ES-903!8)95QAB,;A]U<@$ XY!YKHJH76L6EI
MJVGZ9(S&ZOA(T*JN1M0 LQ/8<@?4BLG7O&%EI4M[9(EW+=6UMY\TD%NTB6P(
M.TR$<#.">_ R>* &7/@33;FZN&:ZOULKFX%U<:<DH%O++D$L1C=R0"0& )ZB
MM>QT:UT_5-3U"$R&;49$DGW-D H@08&..%%<SHOB>6X;PT+S49GN[W1!>R6<
M5JI$[;%+/N'(.3PHX.:Y$_$K74\/^*M<,=Z?LMQ/;64!T\""#:P"M(_7<.<@
MG&30![#<6\5W;2V\Z"2&5#'(AZ,I&"/RKFM-\!V&G7VF79U#4[I]+W+9+<SA
MEA1D*%  HR,'J<G@<U1T77;DW_AVSO\ 5[XW=[#<.8+C3TB,^T Y.!\@7/&.
MN>:TK3QSHUY>QV\?VM8YS(MM=/;LL-PR EA&YX)PK'WP<9H 9;^!;&QTV*ST
M_4-2LFBN9;E)X)EWAI"2X.5*E3GH0<8%(_@33EAM/L=]J5C<VR21_:[:<":5
M9'WR!R5(;+Y;IP>F*T(O$^FS6&BWB/)Y.LNB6A*')+1M(,CM\JFN*T[XAW]I
MH37=_;S7\TOB*338_)A^Y&)0H'R]6VYQZF@#K;/P7H]AJ&F7EM'*C:=9O901
M[\J8V()W9Y))'7/<U#I_@;3M/N;-UN[^>UL',EE93S!H;9B" 5&,G 8@;B<9
MXI_BOQ5_PC6D6=ZMA<W#75U! (UC)*[W4'('0X)P.YP*2^\<:782RQR6^H2&
MWA2>\,-HSBT5AN'FXZ'') R0.<4 );^!]/CD'VF\U&]MTADA@MKJ<-' D@VL
M%P Q^7*Y8D@4S3_ EA87=A<OJ&IWDEA&\-K]JG5A'&R[2H 4=L<]>!DG%;5_
MK6GZ;HDFL7-PHL8XA*95&[<IQC '7.1C'7(KF(/&RR^+YH+C[18:=;:/)>W$
M5[;^4Z%9%&\Y&2-N>A(X/<4 :X\'Z:OA>QT&.2YC@L/+-K.DF)HF3[K!L8S^
M&""015_2-)32+>6,7=W=RS2&66>ZDWN[8 [  #  P !Q7/W_ ,0+*VT'5;^.
MQOUN;&T-V+6XMFC>1"#M< _P9')ZKW JQ_PG%E'8V4LUEJ)N;BW-RUM%:,\D
M48."[*.BYZ=SV!H U=;T.UUVVABGDGAEMYA/;W%N^V2&0 @,I((Z$C!!!!/%
M9DG@;3+C0=5TJZGO+C^U2&O+J60&:4@ #D#  "@   #TJ2_\;:18B Q_:KWS
MK47G^A6[3;(#TD;'13SCN<' XJO9>-H-0\9C1+6TN);9[&.\CO$C)1@^X@Y_
MND#@^O% '41QB*)(USM10HS[4ZBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0^)UI<ZCX!U"QL
M[2:ZN)VA"0PQERV)48]/8'K77T4 <U8C2;76(Y=*T.>WDFC*3RK8/ BQJ"PS
ME1N.> !D\FN1TS2;N+PSX)MY-*NEEL]8>>Y0VS9B3]]\QXZ?.G^0<>IT4 >2
M:G"]I>O)=V-P(9O&D-Q$K6['S(S %W*,<_,K<#GCW%6]>T*\GTSQQ>V-A<[-
M6:U6VMUA8/(\8&^39C(SG'(&=F>XSV=]!I7B+5?L$LTQNM'FAN]D9*A'8-Y;
M9QAN W'(]16A>:K9V-[96<\I%S>N4@B52S-M&6/'0 =2>!D>HH Y-X;JT\1^
M*&O=/NKNRUBUA-HT4#."%B*-"PQ\AR<C=@?.>>M4[O0]7\/^%/"M]:F.?7=(
MCALI%=\+.DNV-HR>X#%&!_V/>NYTO4[36=+M]1L9#):W";XW*E<CZ'D5F6-O
MHNOZDGB"W>>:> M;;'ED58G0L#F(G <9(R1G!H YS5-/N- U_3I7T[5-3TIM
M.^QR-8,_FQS;RQ=U5@2'SR>>1S4FEZ+'9^--(6+19;;3H-%EMT1T:5(6:5&6
M,N<C.T-GD@=,],]]10!E>);>*[\.7UM/;W-Q%+'L>.V)$I!(R4Q_$.H^E9G@
MZ/5X'U*'49Y+RV21!:7UQ;>1/,NWD2+@9*\#=@9_"NHIDTR6\$DTAQ'&I=CC
M. !DT >9-HNJW'@R^\+3VER-6.JM-#>^4?+96N?.$_F= 0I/&=V5QCD5T?AN
MR:/Q;XKN9K*2-;B]AE@FDA*AU6!$)4D=F#C\?0UNZ7KFG:QIUE?V=RK07R[K
M8O\ (T@P2<*<'H":EU#48--ACEN%F*R2K$/*A:0[F.!D*"0/4]!0!Y_X]M-3
MU ^)K&VT>[;[3I*);S6D(;[4P\PE9'/3:2,*,$[CUX%6+JUN+K7?$MV=+NPE
MUX?BMHB]NQ+2?OMR< \_.G'^!QZ'10!S^D7$^E> =/DDLKJ2YMM/B5K58CYK
M2*@&S&.N1C/3OTKE_$/AO4H/"ECJEC=7]YK&GW*:C#;B!0))F;,JX"!P&#N,
M$\9&>E>D53U/4[32+/[7>R&.'S8XMP4M\SN$48'JS 4 <W>O->^.?"^H1V-Z
MMO':78F9[=QY32"+:K<<'Y&_+W%9-S9WDND_$>%;"\+Z@9/LBFW?]]FU2,;>
M/[ZD?KTKT:HYIXK= \TJ1J65 78 %F("CGN20 .Y- '&6UO<CQ?X9N39W0@@
MT::&60P-B.1C"0IXX/R-^7N*Q]+AU*PTK1T;1KP!=8OI))TM=TULLCRE&16'
M <. 6P0 3T/(]/HH \KT?3M5L=+\*O+H^H Z;K=XT\>P,X23[0$;KRO[Q?FZ
M<YSCFK>F:?)_:,VC:SX?U2ZN(M6DOK:\$S_965IC(DA(?"LH;&W&<COFO0I+
MN"(S*9%,D,?FO&GS.%.<':.>=K8]<&DL;R+4+&&[@$@BF4.HEC:-L'U5@"#[
M$4 4/$]M%>>'+RVG@NIHI%566T)$H&X?,F/XE^\/I6?X.CU>%=2AU.9[N%)U
M^RWLUMY$UPFQ<^8F!ROW=V!G%:]UK=A9ZU8:1/,5O;]9&MX]A(<1@%N<8& 1
MUK0H X3PA'<>"X+S0-0L;U[9+N6:RN[:V>=)8I&+ -L!*L"2#N '3!-6]:74
MAXF\.:X;&X:PMOM,5Q#&IDDB\Q5"2%%R3]T@@9(#_6NPHH \ON-"O4VW L;A
M[>[\5QZBD A9C%"% 9V7'RY8%L'GYNF<T:YIU_-HGQ$MX-.O'?4+A#:(MNW[
M[]S$A*\?WD;GVKU"B@#BM8MKV_\ &MA<V4-S$IT:\@6Y:%U6*5VC*9..#\C'
M\/>L/2TU!X? 5K)H.HP7&C3&&]W6^$CQ;/'N#]&5F(.03[\UZC437$*RM"94
M\U4\PQ@Y;;TSCKC(- 'G?A6PD7^S=,UGP_JC:II$S,+Z25S;'&X><AW8)93]
MT#.6.1CFJMCIEY#X=\.Q'3+M)X/$LMW,OV9@4B,LQ#GCIM=/SQV->C66K6=_
M9VMS&[1I=$B%+A#$[D9)&Q@&SA2<8Z#-.L]1@OI;J.%9@UM*89/,A9 6 S\I
M8#<.>HR* /.=0T[4CX*\7:6-*O6N9M7EGA"PEA*CSJZE2.OR@GVQCK2^,8-3
MU!O$5O;Z+?8=[.6!K6W&+M59&9G8\EEP5"#!XS@]O4** .4TF*X_X6)KEY):
M7,5O<6%FD<DD9"ED,I9<],C>O?Z=*A>*X7XMB_-I=&R71#;&X$#%/,\X/MR!
M_=&?3\:Z6WU.TNM2O=/AD+7-GL\]=I&W>,KST/ [5<H \MT;2[VVT+P1$VF7
M<4UGJTTUROV9@8D99QN;CH=Z?G[&I-1TK5K[3O&L5E97 FN-4@O+>.2,QBZB
MC6#<H)X^;RV7W^AKTZB@#S[6[&YUG4]2UFSL[Q(3X>GL622W=))Y7.4381D[
M>><8^?@]<%]ILA\+>"XH],G\RVO;*2YC6V;=&L:$,6&.,'_ZU>@U&D\3RR1)
M*C21XWH&!*YZ9';- 'F.O:5>W&E?$:.WTRZ:;49(_LFVW;,V(8URIQV96_G1
MX@BU.^N-1\K0[]-FL6-VBV]MA;B)&A)E9CRS@*1M[!1D=37J51M/$DR0M*BR
MR E$+ ,P&,D#OC(_.@#@Y+6^CD^($#Z;>'^T$\VV98]RR9M4CV@CJVX$8_'I
M2:-!?Z1KFD:A=V5V]A)H$-D=D#N]M.ARRL@!8!@>N,909[5VNEZG::SIT5_8
MR&2VEW;&*E<X)4\'GJ#5R@#S'1?#]]I5]X-CN+*<QVLNH3.%B+K:I*28D)&0
M" 0..F/2NA\%6]U9^&]0BDLI4E_M"]EBAF0Q[U>9W3&1T((^F:Z&[U.TL;NQ
MM;B0K+?2F&!=I.Y@C.1QT^52>?2KE 'EV@0ZBFM^'KV?1=1@BBTBYM9XA:A(
MK9R8B(T4<[1M;!.2W&">S=$TG4+;3/A[ +"ZMY[&&>.Y8V[#[.S0,H+<=W(_
MG7J=5+[48-.%N9UF/VB=+=/*A:3#-TSM!VKZL>!W- 'FNG0ZF-%\%Z9/H6HK
M?:/J2"];R"4P(I5,@DZ,&+ Y![\\XSU?BJ"Z&O\ A;4(+.XN8;2]E,P@7<RA
MX)$4X]-Q ST&>:ZJB@#RW4M,O9- \81QZ9=M<7>NPW%N!;-NDC4P'<..@\M_
MR]QE?$,&J7=WJ CT2^3R]:LKI!;6XV7$2-"3,S'EGPI&T= HR.IKU&B@#E/#
MD-W:^+?% N+&XCCN[J*YAF91Y;+Y$:$;L]0RL,>WTKF?%5CJ6/']E!I-]<R:
MO;1-:/##N1\0A&&[H""O3J<C ->HUG:WKNG>'K 7NISF*$R+$FV-G9W8X555
M022?0"@#CK^UU-?$1O\ 1XK^*:6YM?M=A=6Y>VND CS*'QB)T'?=R8QP>*@T
M73Y/MB:-K/A_5+B\L]4DO(+TS/\ 9&!E:19@=^ P#$;<9)]B<=W-J]E;:,=7
MNI6MK)8A,[SQM&47&?F4C(/L1FLFT\?>%[^\AM+76(9)YG"1H$;+,>@Z4 0:
M_#>VWC/0=86":YTZ"&XMYUAC,C0M)L*R;!DD?(5. <9],US4FA7D LYC87#P
M3^+#J:0B!F,$&PC<P ^7+?-CK\W3.:]0HH Y?QUI]]<^$GBTJV\Z2"X@G:TC
MPIFCCE5VC';D \=^G>L65KG4?%&MZC#I&HI:W7AY($::U9"TH>8E-IYS\P'3
M],&NYU"_M]+TVZU"[<I;6L+S2N%)VHH))P.3P*=8WD&HZ?;7UJ^^WN8EFB8@
MC*L 0<'D<&@#S.;2]23PUHS6*:E9ZS::%%!L-HTUO=$+AK>9,<<CALC[Q.<5
MH1#4+;6==T_6O#4^I1:Q)#<PO'&)8,B)$,4C'A K)D$]0<CGBO0Z* /-/$/A
MC5-8\7>*Q!;ND-_X<6T@G;A&EW-\N?Q&?8U9F-_XDU;0YAX>O88]*M[A[J*\
M01+([PF,0J3PV2QRP^7 '->A44 >1W&E:O=^']7TW1[+7!IGV%&CLM4^]'.D
MBL(X68[BNQ6')(R%P>:NZ]'J?B2]UJ[M=$U&&WE\,7=G#]IAV/),S A O4>V
M>N#VY/I]% 'GVOZ+<_9?"=X8=4\G3X&AN4TQV6>/?&H! 7D@%,$#GYO:NB\)
M:=#::"RK9WMNMS-+,\5_+YDS;F/S.><%ASCMGGFM^B@#R"Q\,:Y%I>I-+83_
M &C0%AM](&.9T@N&F!7_ 'D$2?@:TM-TG4M"D\.>(+K3;JXD9+U]2A@C\R6&
M2Y=90=@Y.W;L..1Q7IM9]GKFEZCJ5[IUI?0S7ED0+F%&^:,GIG\C0!Y\--U6
MVD@\1OI-X8W\22:BUG&FZ>.!K8P!B@/7(#%1R ?8U2\2:1K6M>%_&[PZ->)+
MJ.H64MK Z?/)&@@!.![(21VZ&O1[CQ+I=MX@AT)I97U&5!+Y,4#R;$)P&=E!
M"#(ZL156#QMHEVMR]K)=W$=M.+=Y8;*9D+[MI"L%PV#U(R!WH YS4DU+3-6\
M8P1Z->WO]M1(]G+!&&C+>0(BCMGY,%<\]0>,GBK.LZ3J%Q\%1I4-G(^H?V5!
M#]GQ\V\*@*D?@:Z8^(M-&I:EIXED:[TZ!;BYB2)F*HP)&,#YB<'@9-7[2YCO
M;."ZB#B.:-9%$B%&P1D94X(/L>: /.?$>FZGXWO;A;;2[RP%OHMY:EKM!&'G
MFV;8U.?F V'+#CD<UI^$K"-]<%^;#Q%'-#9F$RZM<,P0NREHT5B=WW =PXX'
M7-=JT\2SI TJ"9U++&6&Y@,9('<#(S]1ZU)0!YAKN@2?\)%XB2[L?$%Y!J[1
MM FG7#)!*#"L3)*0<+C;R6XVGOC%2^)= U76/$"ZS9:> GAU46U@F7!U-@5=
ME)/\*@#83_'D]!7I5<O)\1?",4TD3ZW 'C<HX"L<,#@CIZB@##OH[Z7Q5K=P
MFDWYAU?0(XH'$/"2*)B4D_NM\RC![FH[[0;U?"'@B1[?45_LJ*);R&P<I<1@
MVYC)7')*L1D#G!->AV]Q%=VT5S X>&9!)&P_B4C(/Y5+0!YQ;Z%+_P 4_<6>
MFZG&A\0->7!OY#)-M^SR1B1\G*@X3@\C(HU?1-2FT#XCPQ6,K2ZA*3:*%YF'
MV:)?E]?F!'X5Z/6?IFMV&L2W\=C,9&L+EK6X!0KMD4 D<CGJ.1Q0!YU<>&W7
M5=7L;^Q\0W*:A?+-$+.Y9+5XW5 3(<X4J5;.>2 ,9K:T_P /2W?CGQX-1LY!
MIFJV]I"DC#Y95$+*^#[9KNZK7]C%J5C+:3/.D<HPS03-$XYSPRD$?@: ."^&
MUOJ%]=W6I:L0\VEQ?V';R Y$@A8^9*/]Y@@_X!4VH+J.D^(?%:IHU[?+K4$3
M6<EO&&CWK#Y921L_)R <GL3WXKMM-TVSTC3H-/L(%@M8%VQQKT Z]^2<Y))Y
M)-6J /--!T/5+?Q-X(N)K&9(;/PZ;:X=EXBEVI\A]#P?RJC+X>U<_"SQMIPT
M^<WEYJ=Y+;P[?FE1I 5('H17IMOJ=I=:E>:?%(6N;,1F=-I&T."5YZ'(!Z5<
MH X74](O[CQ_X/NTMI?LMK8W<=Q,HXB9HU"@GL20:B\*3:M9:'I/A630+I)[
M.%K:ZNY0%@154A9$;G>6.W '(R<XQ7?T4 >6:/#JTNF^!-*?0M0@?1;F,7TL
MT>U$*6\L>5.?F4D]1QT]:J6VAZQ8^%=\FE7;O;^+CJ+0QQ[I&@$V=ZKWXYKU
MZB@#D?'<%U?^&+*XL[*YG>"_L[Q[=$S+L2568!>[ =JR'EU#3+CQ0%T+4KO^
MW MS9&.'/S- L9CEY_=E2O.[C!_"O1:* .(UKP]J$?PIM-&MX_M5]8069,:G
M_7&!XV91GUV''X5B:]8:KXQU759;32+ZT@F\/26D#WD?DM)-YJOL(SE0<8R?
M?MR?3I9XH IFE2,.P12[ ;F/  SW/I4E 'EL^AOJNB>(7LM-\1&^DT6:TC?5
M[AB6=QGRD5CSRH^;ISP327%I<3:I9ZU-I_B>*VFTF*T\JPWQ3)+$[G;(@(.&
M#\$\<'.,UZ/JFIVFC:9/J-](8[6!=TCA2V!G'0<]ZLS316\$D\\B111J7>1V
M"JJCDDD] * /.]/M;KP5J;3P:!J-S9W6D6MO##;XG>"6'S/W3G/0^8/FZ<&K
M]H-2MOB+'J%YI%PB7NB0PL;<>;%#,CR.R,XQC&X '&#76+JEFVL-I2RYO%MU
MN2FTX\LL5!STZ@\5<H HZ-J::SHUIJ4<,L*7,0D$<H&Y<]CCC-7J9%%'!"D,
M,:QQ(H5$08"@<  #H*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7->,[GR[&QM$EU$3WEVL4<&G
M.$FGPK.4#EEV#"DEL@X'O72UFZSH=GKD,"71G1[>430S6\S121O@KD,ISR&8
M'V- 'G-I?ZO=P:3ICZAJ5H/^$DGL7+7(>?R!!(_EO("=Q!XW9)& <Y&:=/=Z
MC::A=>&(]6U#[(_B&WLQ</<LT\<+VPF9!*?FY88!SD!NM=K9>"M$T^YCGMH9
ME,5U]L16G=E$WEF,O@D\E6.?4\GFI+[PCH^HB^,\,HDO;B.YDDCF9'26-55'
M1@<J0%'3^M &)X1L_P"S_'OBVU%U/<HD=CL:XD,CJ"DAVECRW7J<G!%3Z7_I
MOQ6\033<MI^GVEO;C^ZLAD=S^)51_P !K:T;PUIV@W%W<V:SM<7@3[1-/.TK
MRE,X)+$G/S'\,#H!5.YTF\M/'%OKEC&)8+NW%GJ$>X*5"DM'*,]<$LI'7##'
M2@#@/#,5UH_@CP9K-OJU\TMQ?06LEN9R8&ADD*%!']T$ YW8SD'FNRT?_0_B
MAXDLXO\ 4W-G:7K*.BRDR1D_4JBY^E6=.\ Z#I<MBUM'=>38MYEM;/=2/#')
M@C>$)QNY//J2>IS4GAO2;R'4]8US4XQ%>ZE*JK &#>3!&"L:DCC)RS'!QEL=
MJ ,J:.\U+XJW5F^J7T-A9Z=;7:VUO,45Y?-D'S8ZJ0,$=#QGI6%X4O/%&J'1
MM8BM=9S>L[WLUU=PM9F)E?;Y<0D)7:VS&%!(!SUKT>/2;.+6Y]76,B\G@2W=
M]QP40LRC'3JQK-MO!>C6M]]I2.X9%:1X[:2X=H(FD!#E(R=JY#-VXW'&,T >
M?W-_JFB^&-:BOKS7;/7DT>:5OM%SYT%PZ;<S0."=F"WW1MP''R\9KK/$-]<K
MXGL+-;B06\NB7\DD0;Y69?)"L1W(W-CZFM"V\"Z);Q31.EU=126KV8CNKJ25
M8H&QNC3<?E!PO3G@<\4MEX)T>QN4N1]LGN$MY+437-W)*PB?;E,L>GRC'ISZ
MF@#S?PO8+=V_PLW7-W&&M+G*PW#(/D3(X![Y(/J.#7<?$O4+S3="TV6RNI;>
M235K2)VB<J61GPRG'8BM >"-%2QTBTA2Y@32"?L;PW+H\8(PPW Y((X(-:6L
MZ'8:_:PV^H1-)'#/'<(%<KAT.5/'OVH \_UD:C<P>/\ 4!K>IP-H[M)8QP7+
M(D;+:QR<@?>!/\)R.O')KM-8_M74/!DITI]FI36Z-&5<(23@L%8_=)&0#V)!
MJQ)X<TV6WUF!X6,>L9^V#>?GS&(SCT^50.*GO='LM0T@Z7<QLUJ550%<JR[2
M"I# Y!! ((YR* //DU66VAL[6VNM<MIUUVSBN;/4YM\L2/G*B3+;XVP3]XC@
M].E0>.+N[N+CQ19"]D2*&;13#DY6%FN>6 /&>%/X"NS/@C1Y-.N+2;[9.UQ+
M',]U+=R-/OCYC829RNW'&/?U-1GP#H$EM>P3P3W OC UT\]P[O,8FW(68G)Y
M/Y8'0"@#GK^VUK3M>U70-$U2_N&N=)6\B%W=EWCD$VQ@DC9V;U) [ C(Q6+K
M*Q7VE65F;KQ!;30^(+!)K._NF,L =UZ2!CO4XW*VXX(.,5W\?@C1A%>I,+NY
M>\5$DGN+N22551MR!7)RNUOF&#G//6D?P-HTVG3VDYO9FGFCN'NI+N1I_,C(
MV,),Y&W'&..OJ: ./\2ZC=VE[?7NFW&NS#3+NUMC/]J5+2$YC#1LA?,Q8/RQ
M4G+<'BGZR-1N8/B!J UO4X&T9FDL8X+ED2-EM(Y.0/O*3_"<CD\<UU-S\/\
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M"CC)A9LG>A!# DMD-UXKM$\"Z(D5XNR[:6[,337+7<AF+Q$E'#YW!@6/(/3
MZ#%.'@G13;P12QW$[0W\>I>=-<.\CW"#"LS$Y.  ,=, <4 <;K)U*;3?'NJK
MK>IPRZ/<R-8QPW+(D92WBDP5'#*2?NMD=<#DTS4-0\2ZOJFNSZ79ZU-=V$T<
M5C]DO(HK5&$,<A$L;R*7W%SDE3A2,<BO0)?#6F366L6;PL8=79FO!YA^<LBQ
MG![?*H'%5KWP9H]_>M<RI<KY@19XHKETCN GW?,0'#8  YZC@Y% '/22:AI_
MC,3:Q-K,$5Q?HEG<P3A[(HP"K!)%GY&+9&XKR2,-VI?#+W]AXEBM-=GUF+4I
MQ-S+.)K*]P=P,0R?+(7G;A3C/6NB/@_23JW]H$76?M'VK[/]J?R/.Z^9Y>=N
M[//3KSUYHTSP?I.DWT5U;?:F,"LMM%-=/)%;ANHC0G"\<>PX&!0!G:UY^K^.
M['07O;RUL%TZ6]D%I.T+S.)$1074AL $G (R2,UP>OI/JFBZ+%>ZA?3/8^,%
MTQ)A<,K21K*P5FQ@&0# W]>#ZFO5=8\.V.M2V\\YN(;JVW"&YM9VAD0-C<-R
MD9!P,@\<#TJ ^#]%.F:?IPM6%M87:7D $K9\Y6+!V;.6))).<YSS0!E?$: 6
MOPHUV!7DD$=@RAY7+NV,<ECR3[FK^FR>,3=0#4+;0EL_^6C6]Q,T@&.P* >G
M>M;5M*M-;TFZTR^0O:W,9CE56*DJ?<<BL>V\$:?:W,,Z:EKK-$ZNJR:O<.I(
M.<%2^"/8T <-<2:NV@7>M)K^IQWD7B1[*$+.?*2%KSRMIC/RM@,<$@XP .!4
MFOW&IZ'<^(=+L=;U%8T?2I89KBX:5X6FN"DF&;)VD*/E/'7L:]!/A;23ILE@
M8'^SR7OV]E\PY\[S?-SGTWC..G:LCQGX1CUFQNY+2U\Z\O)K%+@-)@-##.'(
MY.!A2_3DT <YXE2XT=?%NBIJ%]=V,WA>>\VWEPTS12#>AVLW(# ].F5XQ4WA
M])];FT#1);^^M;"V\,VEV$L[AH&ED?Y,EE()"A.F<9;FNMA\&:1';ZG%(+NY
M.I6YM;B6YNGED,."-@9B2 -S=.YS1<>#M)GAL$C^UVLEA;BU@GM;EXI!#@#8
M64Y8?*.O<9H Y#2-<U6VB\.:M>W\T]G]NN=%O6=OED_?,D$Q'3=N15+?[=4W
MU?6=2>PG5M6N;/7;^YGBM["Y6&06L*!8E1F=0@;_ %AVD$Y^M=/XG\-RW/A2
M+PAHNE1IIUPHBDN'E 6U0,&+8)W._4C_ &N2:W+WPSIE[IEE8E)8([#;]DDM
MY6BD@VKM&UE.1\I(QT(- '"/_P )'-<^%]&O[O5--%U?WL3$W*&XDMEB9T#N
MC,-V!MW9SQGKS76^-+VZT'P+=2V%Q(EQ&L-O'<.=[)OD2,N2>I 8G)[BKEMX
M4TFT?37BAD,FG22RP.\S,Q>0$.S$G+$[CR?6M&_L+75-/GL+Z%9[6X0QRQMT
M930!P&LF\\+:G=6%EJNI3P76@WMR1=73S/#-"$VR*S$E<[SP.,@8 KI?!%I/
M%X8L;V[U&\O;J^MH;B9[B4N%9D!P@Z*.>@^IR>:?:^#=)MEO-YN[J2[MC:23
M7=T\SB$]45F)VCG/'4]:V;*TAT^QM[*W4K!;Q+%&I.<*HP.?H* /-9]6O!XD
MM-2LIM:EMIM<%DUQ-<(MHR;FC:)(=^3M(/S[025)SBJYEU-/#4_B,ZWJ37=M
MX@:"*+[0WD^3]N\HQLG1AM)Y.2. ",5V4G@+0Y9GD9;P9N?M<:+=R!()B^\O
M&N<(2V2<>I'0FKQ\+Z4VD2Z68'^R271O&7S#DRF7SLYZ_?YQ^% #O%&NQ>&O
M#5_J\B[S;Q$QQ]Y)#PBCZL0/QKRC3+P>%+CPUK$NG:Q#<;FM]=NKJPDBC<7#
M[B[.1CY92,>Q->O:KHMCK0M%OHVD2TN4NHTWD#S$^Z2!U )S@\5+JFF6FM:5
M=:;?Q"6TN8S'*A.,J??L?>@#SRVT&&Z^,^O(U]J48.F0RYBO9$.6=\C(/W1V
M'0=JY72C<Z)\(X]0T_4;^&>76Q"V+ERH7[65.!G R.OKWKV.R\/:?I^JOJ<*
M2&\>UCM'D>0L6C3[N<]^3SU-4_\ A"-"_P"$?30_LTGV!+G[4$\UL^9O\S.<
MY^\<XH XV^GEM?&_Q'N()&BFBT&%XY$."K"*0@@^H--74+O5?#GAR+[3KUU>
M_P!@Q7DZ6%TMO@LJ@32RLZECE6PO(/)(KO)O"^E3WNJWDD#F;5;86MV?,/SQ
M@%0 .W#'D55;P/HC+8HL=S&EG:+9*D=RZB6!?NQR 'YU]CZGU- '%:;)/JOB
MKPGK-U<W;W4GA=KUTCG9%>0&$D;0<88GD=#QZ5:\%7'B2]N= U1[76F@OH#+
MJ,]Y>0O;.'C+JT48D)3#[0 %'RDYYKJ[?P3H]H^DO;_;(GTI3';,MU("(B0?
M+;GYD^5?E/&!BI=,\'Z3I-^EW:K<_N0XMX9+EWBM]WWO+0G"Y]N@X&!0!O5Y
MEX'?Q<OA^4:5;Z(]G_:%[L:ZGE63_CXDSD*A'7/>O0M,TZWTG3H+"U\SR(5V
MIYCEVQG/)/)ZUSR?#S1XC)]GO-:MDDD>4QV^JSQH&9BS$*K #))/XT 4]1M[
MS6/B$-)GU2^M+0:*L\D5C<M%F7S67<&&"/TS@9XXKG] NM572O VN7&M:A<7
M>I7@M+I))CY,D9BEQ^[^Z&'EJ=V,DYR>:]%L]!LK*_BOH_.>ZCM%LA++,SL8
MPVX9)/)SW/-0P>%M)MM/TJQB@<0:5,)[1?,)*. PR3WX=NOK0!YYH\^IV_A+
MPMXE?7=2N;VZU&"VGCDN6:&2*28QE?+Z9 .=W7(ZU!I]Y=6X\2VMI<R6IU#Q
MI]BDN(CAXXW";MI[$@;0>V:ZGP=X!M]-T;1VU2*X%[9$R_9C=,\"39;YP@.W
M=@]1W)/7FMP^#=$:SU.U:U<Q:E=F]N/WK!O.X(=6!RI!4$8QC% ')ZE;:S9Z
MCK^@:+JNH2/%ID&IV1GN7EDCF$C@Q[V)8JXC P2>IJGKOC*^U:UFUG0;F:*T
ML-'2=EC8<W%R0J!@>"8T#-@\ L,UV\&C1>&K2]O-+L[K4]1GV>89[O=+-CA0
M9)#@!02<=.O&35'PIX.M]+\*WFG:E:V[2:I--<7T$>3&#*?]6IZ[57"CZ9H
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M@3,;.%$$L(A8)+OWNH!5F P"<D\9K,\1>'9[B'PQ=OIUW>IIL+PW-K971AF
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M9W^H2ZG:?;+5+:-3N3(!SN8;2-V3GT/? ,X\:69U/[.+&^^QF[-B-1V)Y!N
M=NS[V[[WR[MNW=QFL+PEX4U31-9\.M=0J8[30IK:XE5@52=YD?8.<GHW.,<5
M4T[PD;/5_L=UX=O[LC57NTOCJ;):B,S&57\L2??4D#;LP2,YYS0!U/\ PFVF
M?\(@?$GE77V<.8C;[%\_S?,\KR]N<;M_&,TA\:68U(V_V&^^R"[%BVH;$\A;
M@G;L^]N^\=N[;MW<9K /A35/^$]-O]G'_"-&_P#[;,F]?^/C9M\O&<_ZS][T
MQ^-5K3PD;;69[2Z\/7][YFK/>)>_VFR6HB:;S0QC$GWU)QMV<E0<\YH WI_B
M%80O=/\ V9J;V=G>FRN[Q8T\J"0.$R<ON(R0<J#@$9Q5*?QM-*_C*WN['4+&
MST:,XO+<1&10(E8D9<@L=VY>,8QG!XJ&\\.:M+X(\4:>EF3=7NK37%O'O7YX
MVF5@V<X' )YJ#5]$UJ5_B%8PZ5/*NLVXDLKA9(Q&["W6/8<L"&W ]L>] '12
M>+K6PM="@2VU'4+G5+4RVJ1HGF2[50G>2RJK$.#G@<'GIEB^/+&33+:XBT_4
M)+RXO)+%-.5$\\3)G>IRVP !22V[&.]5[/1-1BU3P5,]L1'IVFS071W+^[=H
MX@!UYY5NF>E8ATC5='U>UU8V)G>+7[Z9+19HUDGAFC(#1[F )&,[20<9H [3
M0/$EKXA:_2WM[J"2PG%O/'<H%99-JL1P3G&[&>G'&1@F"W\5Q76L-90Z9J+V
MZW+6AOUC4PB5<[E.&W@ @C<5VY[UE>!);FXUGQ?<75N+>1]43,08-LQ;Q?*2
M.-P&,X)&<\GK54Z9J(\9QW6GZ+?:;.U\7O+J*[4V=U;\C<T>[)D(V_P @]R.
M2 ;\7C#3YM$TW55BN?L^H7:6D2E5W!VD* L,X R/4\5##XVLY]22WCT_4&LG
MNS9)J(C4P-,"5*_>WXW KNV[<CK7*6>D^(4T70M .A3K_9FLQW$]VTT7E/"L
M[.&CPVXG# D$#&#WP*V/#J>(= BA\.QZ(TD4=_*YU%Y4\@VSRM)D -O\S#;=
MNW&><XH K^%O'4ATG3QJMIJ,PN;Z6S.I>6GDB4S.L:'Y@W0*NX+C/&<YKL=6
MUBWT9+1[A9&%U=Q6B>6 </(VU2<D<9ZUQL'AS5D\":-IS69%W;ZU'=2Q[U^6
M(7AD+9SC[ASCK^-;WC:PO;S2;*;3[5KJ:QU&VO#;HRJTBQR L%+$#.,XR1TH
M DU+Q?8:;>7UF]O=37-H+8>7$BDS-.S+&J98<Y4YS@#UJ)_&$<=K#NT;5!J$
M]PUO'IQC03,RKN8@E]FT+@[MV.<9SQ7.S:=J>HZEXBU'4/"DMQ87T-BD=E)<
M1K,RQM(688; D4L& W#M\P/ HOX9U:9+&^O-/UFZL+.\G$%B]_B]CMI(D&3(
ML@W8D1B%+YVMW(Q0!Z+HVKV^MZ<MY;I+&-[Q213+M>*1&*LC#)Y!![D>G%8J
M^/+%YT<:?J TQ[O[$FJ%$^SF7?LQ][?MW_+NV[<]ZO>$].33M$V+I<FFF6:2
M9K>6Z-PX)/!=R3\Q !(!(![FN-CT/7/^$5M_!3:1,$BOD9M3\R/R#;K<"8,/
MFW[R %V[>O?'- '7:;XMM]6UZ\TJTT^_8V4[P7-R440QNH! SNR<YXP/KC(S
M)JWB:/3=6ATN#3K[4;V2$W#16BIF*(';O8NRCD\ #).#Q5;PCI=YIMSXD>[@
M\H7FL2W,!W [XS'& W!XY4]>>*JZI#J>E^.QKEII-QJ5M<Z:MDRVSQAXI$D9
MU)WLHVD.1D$XQTH R- \5&\TOPG-?:CJ!N-2OKN./R40),%DDVK+N&0 H&-O
M.1S7167C*UO9F8Z?J$&GXE,>HRQKY$@CSO.0Q91\IP6"YQQ7(:;X5UZ*W\"_
M:; ++IVI7D]Z%D4B)7:0J1SR#N'3GGG%2OX;U*_OKNTL=(OM#BO8;N+4LW:R
M64OF1NJO$@8D,7*MD*O&X'DT ;X\:IJ&GW(BT[4K!Y;"6[L9[F)0LZJN=RX8
M[3RIVL <'I5/PWXRF'@_PU]IM[S5M:U*R\_R;8('8*!O=BS*JC+ <D9) %26
M4_B2]T3^R)O#[V20Z8\$\LTT9$LVP*JP[6.5/)RP':LKP_HFM^&+;PMJ,FD3
MW;VNCMIU[:6[QF6)BR.K#<P5AE2#@]P>: .C'CFSGM+-[+3M0O+NYDFC%C&B
M+-&T1Q*'WN%&TD#KSD8S6C8>)+34-2@L(X+J*>:Q%\%GBV%4+;=K G(8'MC'
MO7%_\(]=II?G:KX;O+J6\U&ZOR-/NUCNK!I"-@5@Z@Y4?,0V,XX(Y%C3[7Q+
MH^KZ3JM]IEUJDSZ2;*?R98O,CD$N]?,+,H/RG!89Y!]: -63XAZ<(M,-OIVI
M74^IBX^RV\,2%W,+A'!RP ZYSG& <XZ59E\:V<6H/ ;"_-I%<I:3WX1/(BF;
M: C?-NZLH)"E03@GK7.^&?#6M65]X0EO;(1FQAU(71612(VEE5DQSDY /3\<
M5%_PB1BUS4+>Z\.W^H+=ZH;N.Z74VBM5B=PY+H)!\R'/ 0[L+SUP =YK>M6N
M@Z=]LNEEDW2)#%#"NZ261SA44<9))KF]7\<RP^'-?DM])O[;6--M#,UK.L1:
M,,C%)<ARK("IS@D\$8K2\9:;>W]AI]QI\'VBXT[4(;T6^X*9E0D,H)X!VL2,
M\9 K U#2=7\0+XLU0Z7/9M>:(=,LK6=X_-E8"5BS;6*KEI !D]B3B@#:^'US
M?WOA"SN]2DU&6YN$29GOO)!;<BG*"+@1Y)P#\W7-=167X9M)[#PKH]G<Q^7<
M6]C#%*F0=K*@!&1QU%:E !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %07M[:Z=937E[<1V]M"I>261
M@JJ/4FIZXSXC>7]E\/?:L?V?_;EM]KW?<V?-MW=MOF>7U]J -+3/&_A[5[^.
MQM+]OM,P+0I/;R0^<!R2A=0'XYXS70UG:J=)#V!U06V[[4@M// SYYSMV9_B
MZXQ7FT4UV/!-EXS_ +1OSK,NI1[T-U)Y3(UT(C!Y6=FT*<=,Y&<YH ]:K&N?
M$^GVWB*+00MS-J#Q"9D@@9Q%&20&=@,*"0>M>>:DEW_PCOBO7SJNI?;=-UB4
M6>V\D6.)5D3Y=@.U@<D$,#P<#%7[;1[;_A=FM2^9>!X]+AN5Q>2@;S(^01NP
M5]$/RCL* /0]-OEU/3XKQ(+F!902([F$Q2+@D?,IY'2F:=JMKJC7@MF8FSN6
MM9=RXPZ@$X]1\PYKRKPA=7GB'0O 6G:EJ-^\%Y;7US<NMU(DEP\3@(K2*0Q
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MI,%W>2V<FEP792ZN7GQ*99$+ N21D 9 XXKLZ "BBB@ HHHH **** "BBB@
MHHHH **** "JT>GVL6HSZA'"JW5Q&D<LF3EE3<5'X;F_.K-% !1110 4444
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M<#CBM:B@#*U'PWI.JRW<MY:^8]W:BSF(D9=T08L%X(QRQY'/-:@   '04M%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!115"ZUK3[*]^QSW 6X^SO<F,*S%8EZL<#@=AGJ>F: +]%9-AXFTC4WL5M+P
M.;^W-S:YC91+&" 2I('(R,CJ <XK6H **** "BBB@ HJ&[N[>PLY;N[F2&WA
M4O)(YPJJ.I)KG?\ A8_@O./^$FTS_P "%H ZBBJ5GJUCJ%S=6]K<"66UV><
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M5;7[39N[Q;V3+QLARIP>& /4=: +=%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y]I?^F+\0M3EYG-S+9*3_#%# NU1
M[9=C_P "KT&N6M]#N;+Q/K48@,FC:W'YTK(X!@G""-P03DAU"D$9P5.>HH X
MRW_T7X,^#-6CXN=.GL9(F'4AY%B=?H5D8&O7*XV[\*ML\.^';*!X]!TV1+J:
M:20$OY1S%$!G)RV&)QC"X[UV5 !1110 4444 '6N+L%7_A<.M#:/^0/:]O\
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MQ%3R[ :<\::PP2:  @*X\KG&X\\'FK6E>%KD/=QZC%=XN;4VOVM]6:::*/\
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MWP/-C,A2*9\#&Y6V D>IJM=Z_K%]J"312ZI)IVJZI-#;PZ<R"7[/;1E<QEB
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MF7SR Y/<@<?2LRVFUN/X>>'-4/B"_?4-8NM.265V4K&KL 0BXQR&YSG)&:]
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M^TFLD=(KJWN6$Q5SEPS'.[<0"<]QD8H M>%I=4G\,V+ZS$\>H["LPD"AB02
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M!21MQG(].:37K#7(](\<:':Z%=W4NK327%K<1E!"R/#&I!);(8%&&,<G';D
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MP/"5E?6>OQ+9:7JVDZ7]GD^V65Y,LEO'-E=@M_F)Q]_IA<8X!XJ]XMTF^O\
MQ;X.N[6V:6"RO99+AP1B-3$0"?QH D;X@Z4LLG^B:B;:&]-A/=B >3#*)/+P
MQSG!;'(!ZC.*Z/4;^#2].N+^Y+""WC,C[%+-@>@')/M7!W&@:H_@+7+!;)S=
M7&MR7,4>1EXS>!PW7^Z,UU?BU-3?PM?KH_F_;B@V>2P60KN&\(3P&V[L>^*
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MQR.K!LYSE,8Z8/J,D ]&HK U_69K/5]"TBW;RI-5N)(S/M!\M$C9SM!XW'
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MUN+4;UTN54KM0J7&YA@XV\#TZ5OW7A32[W3+ZPNEFE2_<27<AE(DF(QC+#&
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MN+BWE*-''O0D+$HYWGH<G!.,4 ;>G^%].TP6X@\]EM(VBM!+,7%LC#!"9]@
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M1 ED8EMO09W9QCG-:OA_7DUZUN7^R3V=Q:7#6MQ;S%2T<B@'&5)!&&!!![T
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MD$LK.KPC)VD'.>222>3D\UA2?$&2+^TXG\,ZK]KTM1->0!H3Y4)7<'#;]K9
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M)FN)_)^SB6YD,C+'UV#/;IGN<#).!699^ M#LFL3&MXWV!9$M0]W(PB1QM*
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MRL/4,"#]*OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5QGQ#>XCB\-O:PK-.NN0,L3-MWX23C/8G
ML?6NSK*U^ZT>PLXK[6MBV]K,LJ2NC,(Y/NJW .#\V!]: .(U?PYKNOVWB._.
MEM:SW\FGQ6]I+-&7\N"8.[L58J,[FP,GA?>M/Q9X<DNO%%OK/]BS:Q ;(VKP
M070@>-@^Y6R74%3N8'G(XX-=3;ZW8W5VEJC3K,ZED66VDCW =<%E /45H4 >
M=:]X6UF#1-$N/#-A;VNJVMO+9R6\<_R1QS(=V';!;9($8>N#ZU<N_"-Q:^(O
M 8TRW#:;H:7$<SEE!16A"*<$Y))';-=S5'5]7LM"TV34-1E,5K'C>XC9\9.!
MPH)ZT <%#X=U[_A&K/P8^EE;6WOD=M4\^/RVMTG$H(7._>0 N"N,Y.:9JFA^
M)6T;Q%H%KHWFK?:D][#>FYC$9C:19"NTMNWC!'(QWSV/IU% '!7&C:D_C*.]
ML]#DT^X%ZKW&I6]XH@NK8=1)%NRSE<#E." 0V!5"W\*W-I\-O$UGJQ2QE>_N
MM0MYVD4B+#^9%)D$XP5!]:],JCJ>C:;K4446IV4-W'%()$29=RAAT.#P: ,+
MX?VUT?#IUC48A'J6LRF_N%_N!@!&GK\L80?G6&]UJ]OXS\:QZ9H[:B9X[6-=
MDT<?EOY) +[R/EYZC)&.AS7HQ(49)  K*L;K2'\0:K;V@ U-%A>]_=LI((81
MDDC!X4]/2@#GO#'A6^T+Q'8/(JO:6OARWTXSAA\TR2,6 '7&"#G%98\.Z]_P
MC*^"SI9^RB^#_P!J>?'Y?V<7'G9VYW^9CY<;<9YS7I=)D9QD9ZXH \_UCPCJ
M=WXWQ!$A\/:A<6U[J!+@8E@#87;U(<B'/^X:K:UX,UC4]8\<RQ11I'JEK9BQ
MD>08DDA!)! .0,@#)'>O22P7J>O3WJGI>KV6LVTEQ82F2..9X')1D(=#M888
M \$$4 <+JNB:_P",-5EDN](;2K670[S3\S7$<CK-*8\$A"?E^7COP<@9&:I\
M%3:KHFI6:^&1I%Y)ICVZW-Q?^=OF;:<( S8C)49)P>G%>HU2U75['1+![[49
M_(M4(#RE&(7)P,X!QR0* .6M8?$.K^,M#U6^T-M.M;&TN8I1)<1NWF2>7T",
M?E^3@]>N0.,VO'VDZM?Z5:WF@1+)K%A.9+=2X3(=&C<9/'1\_P# :V[?6[&Y
MNX[5&G2:0$HLMM)'NQUP64 UHT ><KX(OK/Q5HL%K$AT""*UEN7W@'SK9)$C
M^7J<[HCG_IG4J^%]6'PK\0:)]F']H7CWS0Q>8OS"25V3G.!D$=3Q7H-4=7U>
MRT+3)M1U&4Q6D(S(XC9]OX*": .4M]'U?3O$_AF_73FN((='_LZZ,<R V[EH
MCN(8C<HV'[N36!:^$=770-&MM0T"6X.BWEQO@CO$0W<4I<[XV#C!&4.'*YYK
MUBB@#@],\-7,&I>'+N#14TV&WN[N>YA%SYK('B*(6))RQ^7(4D#UK<\-:9=Z
M=?>(I+J((EYJC7$!W [HS%$N>.G*MP?2N@HH XF[\/:G+8^/XDMP7U<,+(;U
M_>9M$C]?E^8$<XJ&VL-?\-ZG?W-GHS:DNHVEL ([B-/(GBC\LA][#*$!3E<G
MKQ76W6M:=8ZI8Z9<W217E]O^S1,#F3:,M@]. >]7Z //-$\+ZMX9UOPPT=H;
MZWMM&;3;J6*5%\IS)&Y?#$$K\K=,GVJAH7A37]"T30KO^SA/?:7J5Y-)9+.@
M:2&;>,JQ.W<,J<$CN,BO4J* /.]9T;6=<N-+UK5M %Q]F>YB.F6UV$F2&39L
M8OO",X,?(# 8;C)'/6>%].&F:%%!_9L>G,SO(ULDQEV%F)Y<]6Q@GMG.,UL4
M4 >9#PYK\<-]&FE[I+3Q$VLVC&>,)=QLY)0<Y5MK-]X 9QS72:'9:E=^+-1\
M1:A8/IR2VD-E;VTLB/(51G=G;82HR7P ">E=32$@$ D#/ ]Z .&U_3=3C\?)
MK$'AH:S9G2Q:X\Z%=DGFENDA'8]O6B]L=5UG3;&&/PS_ &3]FU>SNFC,\)#H
MD@9V^0XX Z=3VKL;2_@O7N4@+DVTQADWQLGS  \9 W###D9%6: ./N-"U%]4
M\:3K #'J=A##:G>OSNL<BD=>.6'7'6N;T%];T/7M7M;716O[B/2--@DCCGC0
MQRK$X&2S %<YR021C@'->J57BL;6&]N+R.!%N;@(LT@'+A<[<_3)_.@#SW3?
M NI6.K>%HI%5[2PT.:QNIT<?+(X'0'DC.><5+8:+X@N--\+^'[S2OLT.B7$$
MD]_Y\;1S+ I">6H._+$*3N"XYZUWMY>V^GP>=<R;$+*BX!)9F. H Y))/05%
MINK6>KV1N[.1FB5VC?S(VC9&4X8,K $$$=Q0!P(T:2;XLSZ;"Z/I"21:]<1J
M?]7=;6B53_O$"3ZK2Z5X.>PU=+:?PU]I\O4WNUU1[[$0C,IE0^6&SYBD@8VX
MR,YKKM+7P_I&L3Z)IEO%:WLD?VV:..$KO4D+O+8PW)QUK3FOX(+ZVLY"_G7(
M<Q@1L5^4 G+ 87J.I&>U &+X+TF\T?2[^&]B$<DNIW=P@#!LH\K,IX]01Q6+
MXNT#4]7UZX!TMM1LY]/6"T+70CAM)MS[WD3<"V04P0&/RXXSFN]HH XGP=HN
MJV.JQ7=_8M:J-#L[$JTJ,1+$TNX?*3QAE(/OZY Q_#>A>(O"AT:[&C-?/_8R
M:?<P17$2M!(DC.I)9@"IWD'!)&.AKT:QOK74K**\LITGMI1E)$.0PJQ0!SG@
M32[_ $;P?:6.J1I'>I+.\BHP9?FF=Q@CL0P-83^&-6;P%=:6+8?;)-;-VJ>8
MO,7V\3;LYQ]SG'7MUKT"B@#RN\\,ZY+J0NY-"DN[ZUUH7IOGO$/G6XFRD<2E
M_E(0@$,%'RG!)-:^E:-J4/C&"]@T.32$\Z9M2DBO%:UO%*L%*Q!L[RQ5BQ52
M,,,G-=[10!R'C#3+^_U72I%TR;5=,C299[.*Y6$>:VSRW;+ ,H <8Y(W9P:Y
M[2/#OB#1_P#A%)&T4RG2+B^AGCAN(P#',<I(FYAE>>APWM7J%% 'F!T+Q##8
M7VGMH]S-:?V_+?R+;WD<?VVVD9VV*=X(()0D-M!QC)IEGX5UNQCFFM]$2%K3
M78]6M;5+E"LL30")X@Q/#J,G+84G&"1T]1R,@9&3VI: .+N;;Q%KMYHEY>:7
M'9Q6FLBX6 RJTD< MY$W2$,5+%WZ+G (Z\UEZ_X.U#4-6U:^-A]JA_M6TO8;
M<7 C:Y1+;RG4-D;2-S$9(R5]#7=:KK%CHMG]JOYC%#YB1;@C/AF("@[0<9)
MY]15Z@#S?_A&KVUCT_6-+\-?9;BSU3[2U@UXKS3PF%HB2S,4#C=D#=C '.:W
M?"MEJR>(/$6J:G8"R34)8'@B\U78*D80ABI(SQSVYX)ZUU=95SXCTRTU0Z;+
M-+]M\KSO)2WD=MF<;OE4\9XSZT <QKOAS4]0\4ZY&EFS:?K6B"P^V+(@%O(/
M-Y920Q!WC[H-/L['7M7U7PT=1T@Z=%HNZ6>5IXW$\OE&(",*2=OS%LL%/ &*
M["QU"VU&%I;5V94<QL&1D*L.H(8 BK- '+>-M/U&[_L*\TVR:]DT[5$NI($D
M1&9!'(IVER!GYQU(K'OO#6KW/@OQM8): 7>JW<\MK&95^=6CC R<X'*GKZ5Z
M#5'^U[+^VQHWFG[>;<W(C\ML&,,%)W8QU8#&<T <?-X>U1/%GC#43I-O?V>H
MVEI%#!/*H6XV B1#UP<'C(QG%:7@K3+[36U$26=WI^F2-']CL;NZ$[PX!WD$
M,P52<87<<8/3-=910!PTOA&\U_QMJ&LZM->V,%M&EII@L[LQL8_O2.2AXW,0
M,'G"C-86N>#+_1X_$$5C<E](O[>*]>XU&\'[N\AE5L.S'.UU4#=S@J,UZM4<
M\$-U;R6]Q$DL,BE'CD4,K*>""#U% 'F&K#5_$7BK4;9]+^QW$_A2[@AMGG1W
MWNZ %F4E0">!S_"2<5K:YX7N;G3/"\TFF/J#:7%Y5S917 B=@T04E&W*"591
MP6 (SS6WX6M_"T/]H+X:M[.)H9S;7?D1[6$B?PMD9(&>.WI714 >8W/@Q@FD
M:@OA9C'"UT+C2X+_ />@2E"LGF%P"P\M=PW8^8X)Q6KI_ANZMM3\*W,.DQ6$
M%H;V2Y@2X\SR3*/ERQ.68]\9&<]N:[FB@#SZZ\,:O+X0U^P2V!N;O73>0IYB
M_-%]ICDW9S@?*I.#S5:'P<]OKMU%/X:^W)<:HUXFH-?;(4C>3S#NCW;MZDD
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M5Z@#(\,Z>-,T"WMO[/CT]LO(UK',91&68L?F/4\Y)]<UKT44 %%%% !1110
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M=BL2$ST^4#CBJVB6-_-J,VMZS8VEKJ#P+:I';R^;LC5BQRY5<[B>F,#:/4T
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MELXU\-07IEB5"[L=J #<",+@D\?Q+VX,$?B;7%\-Z=K]U=E;?3]2EL]66.)
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M: .%U2[U+2;CQ]K&GZC);O8WUM+Y0B1EF_T>'*ON!."/[NT^]=IX]::/X?\
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MSMH[618;*X-S;I]IEQ'*226'S=?F;K_>/K0!PU]J5WXC\->'M>DO9%2?Q';
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MCG&XB(G@GE@/>K,NA:Q;?\);80V8NK;7BTT$QE4"%Y(1$RR@G.T;005#<9%
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MR!"R*&!P3QGYL_A7.:SX<UN_T_QS#'I_[S67A-K^^3!VPQQG)SQRA/3ICZ4
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M*W F!QG<),#;C&,G.:ENO#.JW.F^*]":S'E:W>O-'>>8ACCC=$4DKG=O&PD
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M>L9!(DV[<E.#\W3CZ5G>(]/U;6?#&I6-IHWV?S9X'AB:6,,Y$JR2.Q#%0#C
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M&7>XR.A4@ -_TT]Z .NL;R'4;&"\MRY@G021ET*$J1D'! (_&K%( %    '
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M!?(P1TYSF@#IX=*L8-2GU&*W5;R=0LLP)W.!T!]0,G'IFK;,J*69@JJ,DDX
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MV[E&!G_EHN<DX,<GI0!Z917"-?:C?W?BFQCU2XM9M$BB2V?Y<LQA\SS9!C#
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MLV&@:9+J.I3-#:0C,DHC9PHZ9(4$XID&NV4]W#;*+M)9LB/SK*:)6(!)&YE
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M%P _#$@8Z\U9F\5:C;6\$-QH)35KFZ^S6]L+I3%+A#(9!+CA H.?ESD8P<T
M=0RJZE6 92,$$<$5@VW@GPW:",0:1;Q^624(!RN05(!SG;@D;>GM5K0-:_MJ
MSF>2V:UNK:=[:Y@+A_+D7'1AU!!4@\<$<"L&Z\>2VZ7VHIHSRZ%871M;B^^T
M ."K!'=8\?,BMD$[@>#@&@#I/[(L8XK%8K.+.G#%F#P(?D*#'I\I(^AK(\/:
M!>6^N:GXAUA;-=3OECA$=H2R0PH.%W, 6))))P.P[4MIXIN;_P 7ZAH5KI#O
M%ITJ)=7C3A54/$)%*KC+')QCMC.>0*T;S6EM/$6EZ08"S7\4\@DW8">5LXQW
MSO\ TH =XBT^75O#&K:;;LBS7=G-!&7)"AG0J,X[9-4]#\):1HHBN(=/MX[[
M[.(9)4!/8;@N>@)&3@#/>LR3QS))<BRL=+$UZ]_<V4<<MT(D;R0-S;MIY.1A
M0">OI4MSXNOQ+':V7A^6:^2S6\N[>6Y6(P*2RA0<$,Y*/@<# ZC- &T?#^DM
MH:Z*UA"=-1 BVQ7Y5 .1CTP>0>U%IH&DV.E3:9;6,264X8318R)-PPVXGEB1
MQDU+9:I;ZCHD&K6HDEM[BW6XB55^9E*[@,>N.U<T/'-S;QW_ /:FB&SGM]+E
MU.*%;I9"\<>-R-@#8X)48Y'/7B@#>?PYH\F@#0GTZ Z6%"BUQ\F =PX^HS3-
M5\+:'K=REQJ6FP7$RIY>]@063.=K8^\N>QR*Q8O&M^US;Q3>'I(OM]E+=Z>/
MM*LTQC4-L=0/D8AACDU;7QG:SZ3X=O;.W:X;7)8XX80^"@*EG9N/X K9]QB@
M#0U'PQHFK3V\U]IL$TENNR(E<83^[QU7C[IXJ"Y\&>';RWMH)])MVBME9(E&
M1M4G)7@\J3V/%5?&FJ0:7#HC3QW3BXUBVMT^SW+0X9B<%L?>7CE3P:S]0\?7
M-FFM7,6@R3V&BW)AO)_M*J=H56+(N/F(#9()';DYX .UCC2*-8XT5$0!551@
M #H *RHO"^B0:RVKQ:; M\69_- Z.1@L!T#$=2!DUQ&IZGJUQ\88[2=9TTJQ
MTQ;T1Q:D\*;?.(,SJH&_@8\LY''O6]IWC:XN9-(GO-$>STS6'"65R;@.Y+*7
M3S$ ^3<JG&"W8'% &^NA:6MG%:"RB%O%<?:DCQPLN_S-_P!=Q)^M97BCPG#K
M<2&"WMA-+?6<UVTH.)HH9 Q4\'/R[@!TYK+C^(DS^'=4U]M!D33; 2J9&N1N
MEDCEV%57'3'.[UR,=ZL?\)CK)UI]&'A=O[0:V%W;HUZH1H=VTEVV_(P.T;0&
M^]UP": -FW\)Z%:6%[8PZ9"MO?#;=*<L91C&&).2,< 9XI=0\*Z'JD5M%>Z;
M#*MM'Y4/52B8 VY!!V\#CIQ6,GC:\O="L-4TO0)+B.XMFN)O.N5A6+:<&,-@
M[GR#@<#C.14,7B[4M0\9Z'::?9(^DZAI1ORSRA7*LT6&Q@\J&(VYYW=>* +O
MBCPW=:WI4'ARTAL+;0I B71R1(L:,#Y<2!=HR% W$\=A6UJFAZ7K6F?V;J-C
M#<6?!$3KPI'0C'0CU%<?H7C*%?#MHVG6%Y<WE]J4]I;6US>%V9D+%V:1L[4
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M0 !\@Y (^4]*L6OCR6X2QU%]&>/0K^Z6UM[[[0"Y+,41VCQ\J,V #N)Y!(H
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MK5L]K=S06-K:W$TUG=F!\RS!4177D' W$]QQWH [M$2*-8XU5$4!551@ #H
M*H6FA:;8W"SV]MM="Y3+LPC+G+%020I/?&,UR6L^(];'BC7]'CMD2PMM%-PL
MZSX=&(EPXXSG*A<9XQGOBIO"WBN_:'PU8:EI<L4>IV0^S7CW(=Y72(.2ZXRN
MX D')/K@T =Q5&+1M-@CLXXK*%$LY&DME5>(F(8$CZAV_.J6O:_)I=WI^GV5
MC]NU&_9_)A,HB0*@R[L^#@#(' ))(K%N/B";;34D?1IVU :J-)ELDF4E9F4L
MNUL892-N"<?>YQ@T ='>>']+U"[:ZN;17G:/R9&#,OFQ]=C@$!UY/#9')]:D
M&CV U8:H(,7HA\@2AV!$?7;C.,9YQZ\TTW]Q!H,FH7MF(;B*!II+=9=X4@$[
M0V!GIUQ7%W_C-[[PC8:U>Z/>6EE=W=H+7R;_ ,N23S"/F;:.%!['[P].E '5
M'PEH9B$1L 56Z-XO[Q\B<YS(#G(;D\^];.T;=O.,8Z\_G7&ZOX[GT_\ MRXM
M=#EO-/T4%;JX6X5&,@0.55".0 RY.1C)P#BL]?$FL0^+-?DL--EU&)-/L[D0
M/=^7'""LA8+D'YFXX &=O)'% '6)X8T5-.N-/%@AM+B0RRQ.S,&<G<7Y/#9Y
MR.<\TZ;PWI-QIT]A/:>;;W#!IUDD9FE(QC>Q.YL8'4GH/2N6A\<W]WXHM/L]
MB&T2;0QJI8R 2;&*G=C'4<KMSSG.:W_#>OWVN1I-<:1]DMIX%N+>>.Y69'4_
MPL0!M;IQR/?B@#=C01QJBYVJ,#<Q)_,\FLZ[\.Z3?7DUY<6,;W$T'V>23D%H
M^?E.#_M$?0D=#6?J?B2]BUR72-'TC^T;JWMUN+DO<B%(U8L$4$@Y8[6XX'')
MKBO%/B74O$5UX,32(;I--U:21W2*_:UEE9$8F)F097:1R0>3Q[T >B0^'M*@
MGLYH[7$EG"8+<F1CY<9QE1D].!Q[#T%1Z/X5T+P_/--I.F06DDV=YC'8G) _
MNC/.!@5/J5[<Z;I(FMM/EO;D%(TMTDZDD#+.>BC.2WH#7//X]:WTR::XTA_M
MMOJ46G2VL$ZR O($*E'P P(=>H'.0<4 =-JFE6.M6#V.HP"XM9/OQ,Q"M[$
M\BH(?#^F07,-PL$AEASY323R/Y>05)7<QP<$C(]:YRX\>W&FQZF-5T0VTNF/
M;/<K'<B51;S,5$H;:,[=K97 Z=:WY-=4>*[?088#*[VC7<TP; B3<%3CN6.[
M'^Z: $7PKHJ6L%LMEM@M[@W,2"5\)*23O'/7))SZD^M8WBCP>M^D)TRTB\V7
M4[>]O6DG9?-6)@3Z_-@8'3&!SQ5S5O$]W9ZY)I6G:.=0F@M4NYU%RL3[&9E
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M).2>1@9ZUZ'(D<L;12JKHX*LC#(8'J".])%'%;PI#$B1Q(H1$0 *H'  '84
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M4+6QEM8KF81O=S>1 ""=[[6;''LK'\* ///&NCQZCXPT32].N8_,O[<V6J0
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MI&IHT6\M'(B/A%.?O* J\'K@9I\=O_8NE76LV2LD'AKQ%<;85SA+)]HF11Z
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MWBE$\<7EC:L@;>& ['=\V?6@#R&_L].F\"7>NW3!=?EUXPRS[R)"1>[1"?\
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M.YA\):7%=WL%[,D"J;F"4RI(!T(<@%N,<XYK:ID44<$*0PQK'%&H5$08"@<
M =A3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-K 1>9PP%T(-V<>AW8_"N8\%:+K>L^#/",-Q)8KI%I+%?>:K/Y[["62/9C:
M&Q\V[D#H*TKKP;XBDTZ_T6&?3%TV?5/[029F?S2#<"8QE=N!@Y^;)S@# SD
M%.T\1ZUHD?B[48=.AN],T_5YI+EI;DK+L"H6$2[2#M7GDC/04^34 GC[QK,^
MZXM8M!AF$/F%58;7) (Z9'<<U;O/"/B22S\1Z5;W&F_V?KMW+*\KLXEMXY%5
M6PH7#DJ#P2,'N>UR?P7=MKOB2\BGMU@U/2$T^!"6W(RJRY;CI\PZ9H @TGQ1
M>7.D^'M/\/Z5;?:;K2DOC'=73B.WAPJA=^UF9B3@9'8DUUEG>3W>A)=WEC)9
MSO"6EM9&!,;8Y7(Z_6N3L/"6N:#!H-SI<FGSW]CI*Z9=17+ND4BC:0ZLJD@A
M@>".0W:NLL+6_30H[;4;Q+N_,16:=8PBLYST Z 9P/84 <1X>\73'POX2BT;
M1(E;6$G$4$MVY2#9ELLY!8C@^_:LSQQXEUS4?AYJ*QP06=S;:FFG7QANW'_+
M2/'EL%!*L'&<X(!/6M_PUX(O]%L?!\$]S;.VB)<+.8RV'\Q2!MR/?G.*;K'@
M;4-1T#7;"*YMEDU#64U"-F+85%,1(/'WOW9]N10!+9ZKK5F\V@Z+HNGM+I-N
MCW2O?2;-S[F6.-BA9CM&26P!D"DA\=WNKZAH]IH6EPS?VEIHU 274YC$*[PK
M!L*<D9QQW]N:NWNBZ]8^(=3U/0&T^0:I#$DR7KNGDR1@J'7:IW#:1E3C[O7F
MH_#_ (+DT#6=)GBN4DM+#13IQSD.\AD5R^.@!VGOWH H7_C[5K6VU;48M$@E
MTW2M1-C<'[21-*-ZKNC7;CC>#R1W'O5]?%6MV]]JFG7FC6IU"VLH[VWCM[S*
M2(SLF'=U7:5*Y)P>.GI4-UX-OI_#7B#3%N+<2ZEJAO8F);:J&2-L-QUPAZ>U
M)XK\&WVN:M>7MM-:[);*V@6&<MMD:*Y,Q5\ _(P^4]>IXH R=;\=ZP?"FNM8
MC3!J.FRVZO/:79EA,<K  J=GW@<@@CWSVK4F\01:=X]E35+"..[MO#;7]Q=0
M7#NJHLIW1JA !Z9W$ ]JH7W@77+^S\0QDZ3;'5H+8QQP%PD$L,FX)]T;E(ZM
MP<Y^7%:5QX/O]8\53ZMJCVL4-WX>?2;B&WD9RKO(6)4E1E=IZG!SVH FT[Q7
MJQN]%_M?2K:UM-:R+5H;DR/$_EF14D!4#)53RI.",>]4M/\ '6K75KI&J3Z-
M;1:5J%Z+'(NB9E<NR!]NW&W<N.N><U8T_P .:_/=Z FM2Z?]DT,[XWM6=GNI
M!&8U9E90$ #$D MSWQ2V_@Z]A\)Z%I+7%N9M/U**\D<%MK*LQD('&<X./K0
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MTP:F!<W3*D:-(RJIPA.XJ%/3N?3G-\::19WVK>'/#NDWJB_"&PO(8V#.NG%
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MVX)Y:NVWY.?D+,<GJ,#(YKJ7\2++XBTC2[")+F.]M9+V6</@10@*$8#'.YF
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M&D_OD8Y;WZT^;1=*N(Y(Y],LI4DD$SJ\"L&?&-Q!'+8[]:O44 0"QM%$X%K
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MR]OIMZ8]JL44 5H-/LK:R^Q6]I;Q6FTKY$<85,'J-H&,&AM/LGLA9/9V[6@
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MG&,GUX '-244 1P00VT"001)%$@VI'&H55'H .E2444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1168-;@?Q&=$ACDEGC
M@^T7#KC9 I.$#'/WFPV .RD^F0#3HHK,U'6X-+U+3K2ZCD6._D,,5QQY:RXR
MJ-SD%@#CMD8ZD9 -.BBB@ HHHH **1F"(S'H!DUGZ%K5IXBT2UU>P+FUNEWQ
M^8NUL9(Y'X4 :-%9LVL+:-J<E];36EC81"5KR3:8Y%VEF*@$M\N.<@>V:E-]
M(;^V@BLIY;>>,R&[4KY<>,8!!.[)SQ@&@"[1110 45EG6XYK!+S3+>;48S<F
MW808!4JY1V.XCA64YQZ<9K4H **** "BBB@ HK.O]9@L-5TK3Y(Y&DU*62*-
MEQA2D;2'=^"D<=ZKZ]XEM/#\EE%/;WES/>R-'!#:0^8[%5+'CZ G\* -FBL'
M2?%MAJVI'33;W]C?>49EM[ZV:%I$! ++GA@"1G!XS6]0 4444 %%8^@>(K;Q
M"-3^S12Q_P!GW\MA)YF/F>/&2,$\<U?O-0M=/2%[J81K-,D$9()W.YPJ\>IH
M LT444 %%%4=7U>QT+3)=1U&<0VT6-S8))).  !R220 !R: +U%<U8^-K"[U
M*VL+FQU339KHD6W]H6AB68@9VJW(W8YP<'VKI: "BBB@ HHHH **,BLN/6H[
MNUTV[TVWFOK2^8;9X<!8T(R'8,0<?0$\]* -2BBB@ HHK(U+Q+IVE:I::;<_
M:3=W@=K>.*V>3S @!;!4'H"* ->BLS3=?TW5KJXM;6X;[5;X,UO+$T4J ]"4
M< X/8XP:TZ "BJU_>#3[">[:"><1*6,5O&9)&]E4<DU9!R : "BBB@ HHHH
M**SM1UJTTN\TZUN?-\S4)_L\!6,E=^TMR>@X4_E6C0 456U"_MM,LGN[J39$
MI5<XR2S$*H [DD@#W-0:7J\.J?:$6&XMYK:0Q2PW$>UU/4$=0RGLP)!YYX-
M&A1110 45F:KKUCHT,,MRSLLMU':#RD+XD=@JAL=.6'6M.@ HHK&D\4:='K,
M^D[;M[Z"-99(X[61\(Q(#9 Q@D'\J -FBJUA?0ZE:+<VXD$99DQ+&T; JQ4@
MJP!'(-6: "BBLZ+6K2;7Y]%7S?MD%NEP^Z,A=C,5!!/7E3T]* -&BBB@ HHH
MH **SM'UNRUVVEGLC+MAF:"198FC977'!5@#T((]B*T: "BBB@ HHK.US6K3
MP]HUQJE]YOV:W7<_E1EVQ]!0!HT444 %%%% !1110 44T.C.R*REE^\ >1]:
M<3@9- !16:VNV0URUT@-(US<V[W,3*A\MD4J"=W0_>7IZUI4 %%%% !1110
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M<&X=D9-TB[U P&8@*< DUL0>"9[6]:\@3PU'<M+YQE717#;\YW ^?P<\\=Z
M.-TIHI=+\0Z?)9B\>_\ &MS!';R3F*)V #XE8 DIA#D8.>!51]/M+O3+>RO+
M2R:&T\9Q6D<$+&2&&-D0O&A('REB>,"O0)O"%Y<6=Q:3-X=>WN+@W4T9T=\/
M,>LA_?\ WN.O6HY/!$TMM/;.GADP7'E^;&-%<*WEC"9'G_PC@>E '-WVF:9?
M:=X]U'4T0:AI<LD=G*S$/91I;HT)B_N9))XZD]ZN:%I<.O?$"[N-:@\Z:#2=
M.G\J3.U9B),MMZ;A@@>F36S<>"I[NZ@N;A?#4LT"JD;OHKDA5^Z/]?R!VSTK
M132->BO9KV._T1;J9%224:3(&=5SM!/VCD#)_.@#AK7SIOLOPVE=V>TU0F8D
MDEM.CQ-&2??=''^!KI_B&Z6J^&[^ZXT^SUJ&6Z8_=C4JZJ[>@#LG/:F:9X9\
M4QZ[=>(+[4]$74[F!+4K%82R)'$A) 4F53R3DY]!Z5LSZ?XBN8'@GU+1989%
M*O')I,C*P/4$&?D4 6[_ %?2;6YTZ"ZFB:>\F"V:!=[,VTG< ,X &<MT&>37
ME]G:VR>"-#\3(H_X2>XU:%9;K<?.ED>YV20L>I4+N&WH O3BNPTGP5/H5P]Q
MI2^&K.9QM,D.BNK8],^?P/:GQ^#[N'5SJT9\.+J!8N;@:,^_<>"V?/ZGN>M
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MG!;*[;G$,87<WJ<=3[FL^W\(^'K22.2#1K*-XY&DC98@"C'J5].IZ=,G% '
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M9A=;Y2W*QAUF0_P<G&%POS# &*K:%J&HR7/_  C5W=74NIZ5=R2W4Y<AKBW
MW1-D<?/O08_V']*ZZUT2PTJ)SI=E;P3",I%\IVH.NT?W5S@X&!4.AZ??0M/?
MZN;1M4N51)?L@;RT1,[5!;DC+.<G^]CM0!R&B:KJ^HZ/I'BB'4XF$MO(UU9>
M<T@N)?++>4J8 C9&4].P.<]:O>%KC4=2.@ZVNLPO:7UJ?M,'GM+Y\A3<"BD
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M,U?3)+59/LMR74K)(A5T?"G!&X$$#H:E\1Z-J>F^(+2[MVM6EU#Q1%<VRNS
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M741[2&)VG!W#[W3CD Z2Y\=O!J%RRV$#:3:WRV$]P;L"8.65"RQ;>45F )W
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MEP9W,<8#E5P=X(.1QUYK(F\ :CJJ:DTVG:-I+7%NBM!:2-)#=W"2I*LDB;%
M&4V]"2';)XJZ_@Z^O-)NQ%I'A_1+Q9K>XLTL4W R0R"3]ZX1<J2 ,!>!D\YP
M #2E\5ZKIL075]!6WG-]:VJM#<F2&19W";E<H"2N>5*CMSS5#QUXRU'1]/\
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MNRM:SM(;F4QF,-@HNQ0&8XR3DCTJ]X)\/W?AS1[NTO'A>2:_N+E3$Q(VR.6
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MC&*V)0;X^0-N[[Q4?WSZU'K=G9Z5K'B#3;:"*ST22_TC[9#"HCB6*1V60D#
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M%BN7R+BWC"Q&#RR!N4$G.%ZDMUJCK5W;P?#[XAQRS(DAU:=0C-@DL(MHQ[T
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M=NYND"7&Z)3YJC( ;CY@,G@^IKF[;QTMU;W5S'H.K&VMI)H7D"1L3+'((S&
M')))/7[N,\\'#KOQW:6-AK%Q<6%T9-(FCANHHBCD>8%*L#NY'S#/<<\4 ;,/
MA[1;;2Y-+@TFQCT^3)DM4MT$3Y]5Q@]!5FPT^RTNT2TT^T@M+9/NQ01A%'T
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M$Q6%H2ZCA0W#Y/WL @=Z +,VA16%IN\.Z?I5E?QQ>1!*]L J1EMQ7Y,'&<G
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MM290Y5@5#9*$J<$CG'H03J_$F66W\ ZG<03SP2Q"-E>"1D8?O%!^Z<D$$C%
M&U)X?T::VM;:72;%X+-@UM$UNA6$CH4&,+^%6+_3K'5;1K34;.WN[=B"8IXP
MZDCIP>*Y[_A-ECN]1LKC0]3AO;2U-[';,(R]S #@M&0Y&0>JD@\BM*Q\0V^H
MC26MH)734K8W2."I$<8"G+<_[:CC/- %N+1],@M+>TBTZT2VMG$D$*PJ$B<'
M(91C (/<5<(!!! (/4&N?UO7[O3?$N@Z7!8M-'J#S>9('4$!(R< $CO@D^@Q
MSGCG-"\3/HKZNMY!J%U:'Q#):?:FE#K;AV1(U.]MQ7+ < XS0!V5AX>T72_/
M_L_2+&T^T#$WD6Z)Y@]&P.:LKI]DJVJK:0!;3_CV C&(?EV_)Q\ORDCCL<5S
M]_X\TNPO/*8-)"MV+.66.1"8Y"0N=F=Q4,<$@<?09JWXVDE@\#:[<P32PSP6
M$\T4D4A1E=8V(((/J* -'4-'TS5E"ZCIUI> *4 N(5DPI()'(Z$JI_ >E,ET
M'2)]*72I=+LGTY,!;5H%,2XZ87&!7->'I[.[70@EUK0OGMEN':=[GRI,( X/
MF'8<EP1CZCI4K_$"W2%[A]'U);6'43IL\V(SY4N\(. Y+ L0/ESU_"@#I8=,
MT^W6V6"QMHA:J5MPD2CR0>"$P/E!]JAN] T:_@>&\TFQN(GF^T,DMNC!I<8W
MD$<MCOUK"N?'UO8P:F][I.H0RZ=+!'-#^[=MLQQ&XVN003P0,D8Z4VY\4+J=
MMK^D2V6H:5J5K8-<HDKJK/&0VV1'C8]",'G(- '0C0](642KI=D)!,+@,+=<
M^:!@/G'WL<9ZU8BLK6&ZGNHK:&.XN-OG2J@#R;1A=QZG X&>E<SX?U\IX>\/
MV*137VIS:1#=.@< [-B@LS,>I8X'J<^A-30^.-/N(M&GAM;MH-4N&M%E(51;
MS+NS'*"V0V58<9R1[B@#7U+0M(UGRO[4TNSO?*.8_M,"R;#[;@<58DL+.6:V
MFDM('EM<FW=HP3%D8.T_P\<<=JQ[KQ;9VLTD,D;+)]I:VA,DB(DS*H9V#%N%
M7.TYYSQ@UG1?$.SN8=/-KI>H7$U[//:I%'Y>5FB5F9"2^#D+PPRN#G(H ZB_
MTZRU2T>TU"T@N[9\%H9XPZ''(R#Q34TO3XH9X8[&V2*=0DR+$H$BA=H##'(V
M@+@]ABI;69[BSAGD@DMWDC5VADQNC)&=IP2,CIP:Y/X@VLMMX6U[6H-1OX;F
MWL&-NL%U)$D;*&.[:K $DGN#T% '0W/A_1KV:VFNM)L9Y;4 6[RVZ,8@.@4D
M<8]JMW=G;7]K):WEO%<6\@P\4R!T8>X/!K@?%EC+IOPYU#4[;4]465K*)B&O
M97P^Y3N4EB1D$@@<'CCBN@_X3.S@N=4@U&TN;!]/@CN2)]A\V-RRJ5VL>2RD
M8.#TH M6_A#PS:7$=Q;>'=)AGB8/')'91JR,.A!"Y!K0_LS3_(,'V&V\DS>>
M8_*7:9-V[?C'WMWS9ZYYK+T;Q5::QJUWIB1M'=6T:3<2)(CHQ(!#(2,@C!!Y
M''4<UA^+KIK;QYX6@>ZU%+.[CO/M$-I+-^\*(A3Y8SG@D]/QH W/$OAN+7+(
MQPK;PW#W-K++,T8S(D,RR!21R>C 9Z;JN6GA_1;&TN;2TTFQ@MKG(GABMT5)
M<C!W #!XXYK#.OV&@:)>ZQ&NK75E]K2 QS%VDC<LL>0)3N"[B./Q YI;CQP;
M>758&T#4C<Z9$MQ-$&AYA8,0X._'\##;G.1TH W+WP_HVI6D%I?:38W-O;@"
M&*:W1UC &!M!&!P .*S?$OAZZUW3XM%@GM;31I0$O$$1,C1@C]W'@A5! P3@
MX'2JMQX[B%S);V&BZGJ$BV,6H*(!& \,F[##<XY^4_+U)Z U3.MPZQXM\&ZE
MIUW/]@U"RNY2AD8(P"QE=R9QN&YA0!UM]I.FZG8BQO["UNK08Q!/$KH,=.",
M<4Z/3+"'[+Y5C;)]D4K;;8E'D@C!"<?*"..*Q8O&=E(-,N&MKA-.U.?[/:7A
MV['<YV9&<@/CY3CGC.,BG0>+H)[35)?[/O(YM.NUM)+9_+\QW;;MV_-C#;UP
M21G- &Y=VEM?6LEK=V\5Q;RC;)%*@96'H0>#45II>GZ>,6=C;6X\M8OW,2I\
MBYVKP.@R<#MD^M8-]X\TNPNO+=6>)+M;.:1)$)CD) ^YNW%03@D#CW S1/X\
MTN#4(+?#212WOV#SDD0[9=Q7E,[MNX%=V.OMS0!KGP]HC2VDITBP,EFNRU;[
M,F8%]$X^4?2B/P[HD4EG)'I%@CV61:LML@,&3D[./ER2>E9TI_X1<Z[KE_?W
M4MA(4D6"6;>(B,@[,X"*25&,X&W.>3C6TZ_>^28O:O!Y;A02RLL@*A@R$'E?
MFQVY!H G:UMWNTNV@B-S&A1)B@WJIP2 >H!P./856;0])?5EU9M,LVU%1@79
M@4R@8Q]_&>G%<MK,]UJOCJ30)8+\60THS*;6Y$3!VDP) 0P/&W ST.>,5HZ;
MXQLKNR\.R1VU[Y>LLT,#R[-R,B,Q\S#=2$;D9YH V)M"TBXM[JWFTNRDANW\
MRXC>!2LS\?,XQ\QX')]*C/AW1#!-#_8]AY4T2PRI]F3:\:_=4C'('8=J\]GN
M;M/!NJR+?7GF6_BH0QN;ERWE_;$383G)7:2,'(KTS4+^VTO3KF_O)1%;6T;2
MRN?X549)H J2>&M"EDLWDT73W>R4+:LULA,('0)Q\H'M5^YM;>]MI+:Z@CGM
MY5VR12H&5QZ$'@BL.7Q9#8B[?5-/O;&&WM!>&:1 R,F<;,J2/,SCY.O(QFG'
MQ7:VVHO8ZI;RZ=*+1[U&F*E'B3[_ "I/S+D9'OQF@"S/X6\/W5O:V]QH>FRP
MVHQ;QO:HRQ#T4$<?A6J%"J%  4#  Z5S\/BV%[S3K>>PNK?^TXFEL6?9B8JN
M[8<-\K[>0#QUYR,5G6/Q$M+TZ3,^DZE;6&J3?9[>\F5-GG9(", Q89VD XQG
MO0!T>G:'I.D/,^FZ99V;SG,K6\"QES[X'-3VMA9V33M:6D$!GD,LQBC"^8YZ
MLV.I/J:YW_A/=+;4;.V17DBO+EK6&:.1&S(,XRN[<%)4@,1C..@(-,LO'2WU
MA)?1:#JWV5"\8DV1L6E6;R?+ #DYSSG[H //!H VK7P[HEDMTMKH]A +L%;D
M1VR*)@>H? ^8<GKZU<^Q6OF02?9H=]NI6%M@S$",$*>P( ''I7):QXZ>UT/5
MY[/3W:]TV\BLYXF=2J-(4PX.<,,2#C@YX..M7GUNPMO%5P+V*]M)[?2?M4KR
MS P+"'Y^56(W @Y.,X'4B@"Z_A+PW):-:/H&EM;-*9C$;2/:9#QNQC&<=ZUH
MH8H(4AAC2.)%"HB* J@=  .@K!A\60O?:?:SV%U;MJ4+2V)?9^^VKN*'#?*^
MWG!XQGG@BJ>E^/+;4WTAAI=_;VNJR20V]Q,(]OF('.P@,2,A&YQCCK0!N:?H
M&CZ3+-+IVE6-G)/_ *U[>W6,O]2!S5RVM;>RMH[:U@B@@C&U(HD"JH] !P!6
M/XPOK73O#LMQ>Q7DEMYL*O\ 8Y?+=29%"G=N!QN(SCL>E4=4\<1:;=:U -'U
M"X.CPQW%TT?E@>4P9MPRXS@(>.OM0!M7&@:/=:G'J5QI5C-?Q8V7,ENK2+CI
MAB,C%.O-#TC4+Z"]O=+LKF[@_P!3/- KO'SGY6(R.:G-[;C3_M[2A;41><9&
MX 3&<G\*QH_%L VS7=A>6EB]DU\EY(@,8B7!.\@G8V"" >H]QB@#2N-#TF[U
M*'4KG2[*:^AQY5S) K2)CIAB,BH[CPYH=W?27USHVGS7<B>6\\ELC.RXQ@DC
M)&.*I0^*HFU"QL[BPNK:348&FLMY0^=M7<4X;Y7VG.#QC//!JEI?CVVU1M(9
M=*U""VU5I([:>7RP#(@9BA 8D$A&YQC(Z]Z .G2SMHIIYH[>));C!F=4 :7
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M=(HV>1E2-!EF8X  [FN;\3>,K/0O!]UXBLO(U2&!XTVP7 VL6D5/O ,.-V:
M*GA_PWK^D6W]ASZA93:##N6!UC87)B.<1M_",9QN') Z#K5"R\&^(+:P\.Z7
M)>Z=):Z%>K+#/A_,EA5'10R] P#@<$@X[=^VGU*PMKN&TN+VVBN9O]5#)*JN
M_P#NJ3D_A5=-48:K?V]PMK%:VL22>=]J!?!!+;TQ\@&.I)S[4 6[VT@U"QN+
M*Y0/!<1M%(A_B5A@C\C7&V'P_EMGT&XGU(S7ED#'?3;<&[C 4HI_W6BB^H#>
MM=4=;TD?:,ZI9#[, 9\W"?N@>F[GY?QI\VKZ;;VD5W-J-I%;38\N9YE5'STP
MQ.#0!S6I>%M2O+KQ:\<EJ$UNP2SBW.V8RJ.NYOEY_P!9G ]/?BQ8>']2M/$=
MGJCFT9+?2!IY02-DN&#;L[>GRX_'/M74 A@"""#R"*JQZII\M\]C'?6KWB#+
MVZS*9%^JYR* .)LO!>OZ1I?A^33+ZP&JZ3%-;.LP<P7,,C!B#@;E(*J1C/2N
MXL([N.S07TT<UT<M(T2[4!)Z*#S@=.>>*(]1L9KG[-%>6[W&&/E+*I;"G#<9
MSP>#Z&B]U"RTV$37UY;VL1;:'GE5 3Z9)ZT <;=>#-6DT/6M*BN;(Q7NJ_VA
M"[;P5!G68JW!YRNWCUS[5)J_@S4-6U'7+H7<%H]['9M:RH2[036SLZ,00 06
M/Y#WXZV[U*PL($GO+VVMX7("R32JBL3TP2<&JDOB328=>MM%>\B%[<0M-&F\
M<J"H Z]3O&!WP?2@ T2/71$TFO36+3D!5CL581C'5LMR2?3H,=ZS=4T359_&
MNGZ]:"S:*SM)K?RII65G\PJ<Y"G&-OOG/:M+3]8$NDO?ZBUE9HDCJS)=K+&H
M#8!+X !]1V/%6X]2L9K6.ZBO;=[>4[8Y5E4HY] <X)H YW7-#UO7-'GM97L(
M7:\MYHXT=BB)%(LARVW)9F4CH !CWRR\\-:E<W_BF=7M NLZ?':1 R-F,JLB
M[C\O(_>$\?W??CHXM7TR>SDO(=1M)+6(D23).I1".N6!P*GMKJWO;=+BUGBG
MA?E9(G#*WT(X- 'GNBP:G8^.+_3[8V+W,&@V,#EY6"AE:8!AA<D=R#CJ.:U;
M+P4^F7GAN.VDBDL-(L)K.3S&(DE\P)E@ ,#E,XS_ !>U=+]JTN/5!:^?9KJ#
MC=Y6]1*1ZXZXK-\/>*['7+*WDDEM[6[GDF1+1KA6D81RO'N X)SLSTXH Q]/
M\%WL.C:1H%Y<6\NFZ5=I<0SJ6\V5(V+1(RXPI!VY8$Y"]!GA=/M]-UWQ[)K>
MDWZW%G%"%O%A(,;W*%DC)/=E1I,C_KF?2NL74K!K]K!;VV-XHW-;B5?, ]2N
M<UQ<_P 1EL_#>O:LND#&E:TVE^2)\>:1(B^9G;QG?G&#TZT :&D:!XAT74+B
MSM]0LFT&6[DNDWQM]IBWN7>(?PE2Q/S'D GCI1X?T#Q#H4QTU=0LI-"CG>6!
MO+;[2J,Q?RC_  X!.-W7'8=1UQX!K)T[6XY]&M[[49+&SDE5V*I>++& I.2)
M, , .2<<4 6M6TVWUG2+S3+I<P7<+PR?1ACCWKE[#P--;ZEHNHW.H>==V\!C
MU)]O_'ZP*O&3[(ZY'MQ74_VII_\ 9_\ :'V^U^Q8S]I\Y?+QG&=V<=:R-?\
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MG;B)>1Z8%>TM';;D=DBW0?<8@9CR,<>G%+]FMSYO[B+]\,2_(/GXQ\WKQZT
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M5%G_ ,)E;[S'GRVE^;>4SQMS_=XSGWKU*2TMI8I8I+>)XY3F1&0$.?4COT%
MM+8111"WA$<)!C0(,(1T(':@#R/7-4L;3P5X_L)[J)+U]5FV6Q8>8P81D$+U
M(QDYZ8!/:C7Y=&31OB5'K!M?[5:9S LN/-9/LZ>1LSSC.<8[Y]Z]9DT^REG:
M>2TMWF9=C2-&"Q7T)QT]J66PLYYQ/-:023!2@D>,%@IZC)[<]* /']3@^T7O
MB""_U/1+&&;3;18WU&V:280^3C="0Z])-YP 3NQ[5ZU87D#.=/-VD]]:PQM<
M <,-P.&([9VM^53RV-I/)#)+:P2/"<Q,\8)3_=/;\*9%I\$6IW&H*#]HN(XX
MG/;:A8K_ .AM0!QGBHZ4OQ,\*MJQMQ"+.]V&XQL#YAQG/'KC/?'>N;T:XL[+
M5M$O!-#!HH\1:FMI,6"PA&B<*%/0*7#X[>E>MW%I;72D7-O#*I4J1(@8;3@D
M<]N!^5->RLY[-;62U@DM0!MB:,%,#I@=* /'KZYTV]^UW[O;R60\<6Y,\F"F
MSR803D\;3CKT(Q7IGBQHV\!ZXT14Q'3)RA3H1Y38Q[5JO8V<D#P/:P-"^"\;
M1@JV,8R._0?D*E$<30>6$0Q%=NW VE?3'I0!Y=?::MA_PA_]C6R07TFD7B(\
M2@.[FV5AD]2=^#SWYJ+3CHDUE\.X=#%HVH+(GGK#M\Q8?L[B?S .?O8!W?Q8
M[UZMY,6Z-O+3,8PAVCY>W'I4,%I90S2W,%O;I++_ *R6- "_U(ZT <?\*C9+
MX5E@M_LXN8KZZ6X2/ =/](DVA@.1QTSVK+NW\.)X]\:'7C9C-A;!/M6WF/RW
MWA=W?[N<<_=KT>"VMH7DE@AB1ICND>- "Y]21UIL^GV5T<W%I;RG<&S)&&Y'
M0\CJ* /%K"*[,%M'K5[HUHK^&+10=:MVD)CQ)Y@3YUPP^7=U/W:]@T"%[?P[
MID$ER;IX[2)&N"I4RD(!NP>1GK@^M69[2TO&07%O!.8FW+YB!MA]1GH:G)"C
M)( ]Z /"+_\ Y)WXO_['1_\ T?%74ZOIME>:O\2IKFUBFD33(@C2(&V?Z.YX
MSTY Z>@]*](-G:F-XS;0E'?S&78,,W]XCN?>GF"$F0F)"91B3Y1\XZ8/K0!Y
MBMC:V-[X+>U@CB>;0[P2NB@-)^ZB;YCU8[B3SW)-8OA@6,6E?"JXOA;I%Y=V
MC23[0N?+;:"3[]/>O:/(A)0F*/Y 53Y1\H/4#T%1O86<D$<#VD#0QD,D;1@J
MI'<#'% 'DOARUDGNM+6ZU?1;>_BUJ:1X5M7-\\HDD\Q6;?T9,\E<;=OM5,2Z
M-_PA&C13FU/B!?$<9N%X\\3?;?G+_P 6,=SQROM7LXL[5;MKL6T(N6&TS!!O
M(]-W7%-_L^R,[S_8[?SI,;Y/+&YL'(R<9."!^5 &+X_B6;X>>(T:,/\ \2VX
M(!&>1&2#^=<EID^A?\)3HLM[+I_]F'P^!9O(R>3YV\><%)^7?C9GOC/O7IQ*
M,3&VTDCE3W'TJLVE:<UJMJUA:FW4[EA,*[ ?4#&,T <I\/;VUM?#-G;-,D<5
MY?7@TN-N#) )9&0*/38,CVQ1\4/LO_"-V'VX V?]KV7G[NGE^:N[/MC-=7<:
M=;W-S97$B_/9.TD(' !*,G_H+&K$D4<H D17 (8!AG!'0T >.^*OLLNI>)7T
M![,::+/3?M[Q*'@R+EB^\(1D"+[P!'RU!XKMU7P-XYN4U72+LRVMHLL.E6[1
MQ1L)#AB2[ L5(!P>BKGM7LL%E:VL+0V]M##$Q)9(XPJDGKD"FQZ?916K6L=G
M;I;L<F)8E"'\,8H X>VTRQU#QUXC:\M(;C9HUDBB5 P ;SL]?7 KG/",VCB7
M2W\3/:>0_A2S6U-[C:RY?S0N[JW^KR!SC%>PB*-79Q&@9@%9@HR0.@/YFL'6
M= O[RZM9M*U."Q6",QB&:Q6>-3GAT&5*N.F<D>U %'X6X'PVT;:' \M\!_O?
MZQNOO7$_VC;2ZUHU\LNCV8?Q%*6M8HB;J/YI8V>:4OQN. 5V@?,H!KU30M'@
MT#0[/2K=W>*VC"!W^\YZEC[DDG\:L'3K(M*QL[<M,P:0^4N7(Z$\<D4 >5P6
M[-J</PU*G[/;:LUZP['3UQ.BGV\QEC_X":KSZC;2:SIM\LNCV8/B5P]LD1-V
MF)'C:264O\H;CC;C#J,U[%Y,0G,_E)YQ7:9-HW8],^E0G3K)FE9K.W+3$&4F
M)<N1TW<<X]Z /$-9_P"2;?$?_L:S_P"CH*U?']]#))XK9&TFTFM3!&1-"TMY
M<E4217C.\>6JAC@A3]UB:];>UM/*D1X(/+D?>ZL@PS>I]3P*'L[.6Y:62W@>
M<Q[&9D!8H>Q/7'M0!Y3J$WAI[WXEOJ3V+32(AB:8J2Z?9$V^7GJ=Q'W>^WVJ
M"Z35/^$IG1/-_M;_ (5Z0,9W^?O/Z[OUKUMM,L&*%K&V/EL&3,2_*0  1QP<
M #\*G\F+S_/\M/.V[/,VC=MSG&?3- 'F_@FW@?7=+N;;5]"D$>E,@M=+M6C9
MHB8]ID.]AE2.,X.6;WK1\>"QC\1^#;G4!;K;KJ,BO+<;0H!MY, D\=<?C79P
M6=K:M(UO;0PM*=TAC0*7/J<=33KBUM[R+RKF"*>/(.R5 PSZX- 'CVHMIP\$
M^*H)S;_\).VKS^4K;?M!F,P^SE/XL;?+VX[?C7JFOY_X1K5,]?L<O_H!JVUE
M:/=K=M:PM<J,+,8P7 ] W6IF4,I5@"I&"#T- 'E.FZ'I?F_# &PMSYEC(\F8
MQ^\/V97RW][YOFY[\UE1Q26^NP10S:9:6,6N:JD?]H0E[9)3Y90;0R@-M,N.
M?[W'->T""$>7B)!Y0Q'A1\@QCCTXJ.>SLI8'BGMK=X9&W.DB JS>I!X)H \B
M@M9+2^T!4UC09=/:+4&MKB[M&-F':924C4R#&%W!3N(VAL<5:TVUT[3]>\ ?
M:+VQNH#;:@L-UY7EQL"Z-$J!R3A0<+R>!D=:]4FL;2XMEMI[6"6!<8B>,,HQ
MTX/%++9VLZQ+-;0R"(AHPZ [".A&>AH YWX@V[OX1GOH%+7&ER1ZC%CKF%@Y
M'XJ&'XUYU>ZE-:1W?BBS):3Q7]KL;8^K[ECM#_WRCG_@5>V,H92K %2,$$<$
M5%]EM_+BC\B+9$0T:[!A".A [4 >33:5;Z?XI\5:5%&'@MO",4,:E<Y"!P./
M7@5;T6VTG4M1^'2I':7,,>C7+%4"LHE"6V<@<;@3W[UZ>L4!E:94C,C#:S@#
M) [$TR"QM+4*+>U@B"YV^7&%QGKC'K@?E0!S/P^C2#3-8MXE"0PZU>I'&HPJ
M+YIX [#GI7/++X:COO%J>*1 UZVK(41O^/AX]D7D>5CYSSTV]]WO7IJ1QQ!A
M&BH&8L=HQDGJ?K44EG:RW,=S);0O/'PDK("R_0]10!Y)JK:4/"OCN&_-O_;[
MZC<>0CX^T,Y(^R[/XNGE[<>_O5^_U.UTX_$:#4;J&&[FM8BD3. TI-FJ?(.K
M98$<=Z],>RM)+I+J2UA:X0825HP74>QZBB6QM)YUGFM8))E4JLCQ@L >H!/.
M* /._#FF6.H>*9S>6D-QL\-:>JB5 P ;SL\'Z"N8LVL[?P=IFI27>D74\?AV
M!+O2]54@S0+YA4PR=58_,O 89"YQQ7MR011MN2)%8J%R% .T=!]!DU$^G6,G
MD[[*W;R/]3NB4^7_ +O''X4 >174,E_?^(8[K5-'TR>;4H&C%[:/)>I\L1@,
M9$@/H!A3SN]ZZKPA_P E/^(/_7:Q_P#1%=I):V<EW%<2V\#7* B.1D!=?H>M
M2I#%'))(D:+))C>P4 MCID]Z .(\2BQB^*7A*:\%N@>UO45YMHRX\DH 3WSG
M'XXKD[)M//@70((C;_\ "5#68?,48^TBX%SF8M_%]S?DGC;[5[#/:V]R8S/!
M%*8VWIYB!MK>HST--6RM%NVNUM81<L,&81C>1Z;NM ',?%#'_"M-=SNQY SM
MZ_>7I7+:X=&?6ICX<-F8%\+WPNOLFW:$^3R@VWOG?C//6O0?$VB_\)%X<O=)
M\_[/]I0+YNS=MP0>F1GIZU>CL;2'SO*M8(_/.9=L8'F'_:]?QH \LN-.CT_P
MSX -H-,L[>39)<37T&^%IS;$HTN&7+$EL$G[Q'M5=;?2[74/"YU'4=-O=.DU
MN]DW00F.UC8Q'Y5#,1M$H)SG&37KLEO;30&UEAB>$J 864%=O;CIBLK4?#D%
M]J>BW(,4=OIK2G[-Y0*R*\1CV^@ SGH: /.C<V4=[J<-E'IG]E7?B1%M+B[&
M;2"5;4/(^U64-\ZL ,@%CZBJ-NEIJ=KIMC-+:7<'_"9G<L$7EQ.C0.W$9+81
MN3U(8$]0:]D:PL/L:V;VEM]E& L!C79Z\+TIXL[42>8+:'?D-NV#.0, Y]0.
M* /*?$MG&/$?BBSNK[0=-LVL($A_M"T9W6#8PS!AUQA]_"@G=CVKU2U@)TR&
MWNF%P?)5)6=>)#C!)!]?0TZ>SM;F2*2>VAE>([HVD0,4/J">E3T >'Z#;64/
M@;P]/=0P)I__  DLHOG9 %V"281^8?[HD\OKQTJSXJ6SN;7QQ_99B.ER2:4C
M-;$>6;CSAYFTKQNVF/./:O81;6HA:V$$/E,#NBV#:0>N1[TD=C:16HM8[6!+
M<<B)8P$'.>G3K0 6=E:Z?;);65M#;P)]V*% BCZ 5/110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR2I"[LX P2H/%7-#\/ZA:Z_<ZUJD]@UU-;K;$6-NT2N Q;>^6)+<X'H,]<T
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M/#FKVVL7\VDZE:6]EJ-PES.);7S)8G"JK^6<[?F"#[P.#D\]*=<>$Y)K/Q=
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MGG JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"GAW36N+MK. :Q9F2Y5PAA7S!EPQX&!SGVH V],U7Q!=7R17_AK[#;D'=/\
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M9V_%BQ_&MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1.WWGBW#(< MSPQ' R,'.: /0XIHITWQ2)(F2-R,",BDC@AB=GCBC1W^\RJ
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M7R\#>NT2!LY9L#:1SQ0!Z71573)KBXTNUFNOLYN)(E:0VSEXB2.2A/5?2K5
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MXO:M/Q5H7_"2^&;[1Q<?9OM2!?-V;]N&!Z9&>GK4FG^)-$U:YGMM/U:SNIX
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M*U%P,PF:95WCU&3TY'/3FEOO$6BZ9=6]M?:K9V\]P 88Y9E4N"< C)Z$\9H
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MA:^38LR7;^:,0,HRP<_PD#KFH8?$NB7&K?V5#JUF^H8S]F692_3/3UQSCTH
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MXC\):9K$T20R7D E:-"2%)[#-;5 !1110 4444 %%%% !1110 4444 %%%%
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M6&&Z'<!FO:\#.>]&!G.* ,[7_P#D7-4_Z])?_0#7FVAWNFZC;_#C3=**'4+
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M$J *H$?38%&W&>YYILO@ 746J&\UBXN+C4IK2::8Q*N&@<,H51P < 8_F>:
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M)J&K2ZA/,5Y,:QI& . J#IGDDY.?PK$O_ QNWU.W@UBXMM)U64RWUDD2DNS
M!]CGE X'(YZG&,T ,B\3WLZ^+Y8V01Z=;1S6@*<KNMA)\WKR:R_#UWK&H_$6
M">?5#]GD\/VMT]N(1M)<N"!SQ\PSG\.U;.I>"7O+[5)+36)[&TU6!(;RVCA5
MMVU"@*L>5^7 ./3C!YJ>S\(MI^O6&IVNIR(+?3HM.GA:)6$\<9)4YZJ<L>E
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MP2[V8!%(SAL(QR00./7(Y)= T,:[X/LTL9)M-,=\ M]#DE'P4#J0-JEMVU6
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M7ZCM7/VGB2ZU;5KB+2H;2>UL[W[)<[YMLF BLTB8R" 6 QWP>17+:7#]NL_
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M HHHH **** "BBN;\9WVIV&G6DFGM=10-<A;VXL[87$T,.QCN6,@Y^8(#P<
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MF!$2*PWG>JD[<  G%=?X-U/4-3TF<ZBET9(+IX8Y[FT:V>XC&"KF-@,'#8.
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M =$48Z<4 =117DEEXVUG5++1X)-1O[69](2^FGL-)-VTLKNZJ&58V"(/+)/
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MDMC=O'!R"!P!@\D]7XOU2^L8=*L].F6WN=3OTLQ<,@?R5*L[, >"<(0,\9-
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MJ* .6A\$QV^HAXM7OTTT7AOAIJE!&)BVX_,%W[-Q+;,XS[<5'%X#MXY(;?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,,-P4Y )'7'!_*I* "BBB@ HHHH ***C6>)YI(5E1I8P"Z!@64'ID=LX/Y4
M24444 %%%% !1110 445'-/%;Q^9/*D29"[G8*,DX R?4D#\: )**** "BBF
MR2)%&TDCJB("S,QP !U)- #J*:CK(BNC!D8 JRG((]13J "BBB@ HHHH **B
MN+F"S@:>YGC@A7&9)7"J,G Y/N:EH **;)(D,3RRNJ1HI9G8X"@=23V%)%+'
M/$DL4BR1NH9'0Y# ]"#W% #Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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M_O4EF>"(MSR2Z G&.&%;LO@83>&=0TZ34Y#J%]=B^DU 1 %;A65E94SP%V*
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M5^]C Y#<?-[=*MZ1KNL:S%X?TK2Y;+37ET.'4KF46N]5W858XTW *,ANYP
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MR.ISVJ'_ (3'PZ+^*Q_MBU^TRRF!8]__ "T#%=I/0'<",'J1Q6#XRBD?X@>
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MTUBUFN+A=T2(^=_&[ /3..<=<5-:>)]$OM5DTNUU.WEO4+ Q*W.5X8 ]"1W
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M,A\W_?('/I6=KEY;6O@OQAH%U#*^KS:K/<);B%BTB-,KI*#C&T)CGMMQUXH
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M5<\9'%<%\2H2EYXD=8R(_P#A%63<%P.)C@?K6C->V>N>+M+?1HW\O3M)O$O
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MMG)QG[HP"!ZFB]_X2'2/&M\Z7"ZMJ$7AR62U;[.$9F\Y?E**<-@C(QC.<>Y
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M)$,LJY)4D CVZ]:ROL&N2_$:^MK76D@N%T2V,MX;569SYT^T!"=H'K]..N:
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MJ=C#>V4RS6TZAXY%Z,#5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNL-]K-WN61"OFQ,JKD9Z@C/-=G4%Y!]JLY;?SY;?S%V^;"VUUSW4GH: /./
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M%BD:D$!L*3N(( !-=#63KFA)K:V;B\N;*ZLY_/M[FVV;T;:R'AU92"K,,$4
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M,R+@[@>/FSQCD#MD'1O_  A%J%W(TFK:FMC,\<D]@)%:*1DVXY92Z@[5R%8
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M$*G<H<;.Q[KM-6M9\.IJ]]9WT>H7EA=VJR1K-:E,M')MWH=ZL,'8IR.1C@T
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MR+*]2^C8LNXNLQF /&,;CCIT[]ZQ[;1GUOXECQ'-IEQ9V^G6QMHFN,*;F;+
M.%!/RJKN QY/F'TH G^)2S)\.KU8Y TRO;!7D'5O/CY(&._I61K>J:[X8N-:
MLO[;GOL^'[G4K>:>&(/!/$0.-J@%3O!P0<;?>NU\0:':^)-$N-)O6E6WG*%S
M$VUOE<,,'MRHK)/@>VG74SJ&J:C?S7]BVGF:=HPT,#9RJ;4 SDY)().!0!SM
M[JNMV%GX?MKG5]3GFU@/=7$UC9I)+"JQJ?*B4(0%W./F8,< ^O#O[=UB?2M.
MM+V_UBSNWN+E=MMIH^V7<,9&R3:RE8QAEW':,G &,XKK=0\,P7MIIT<-Y=6=
MSIN/LMW 4\Q/EV$$,I5@1U!'IZ55D\&1L;&6+6M6BO+5)HVNQ*C2S)*P9U;<
MI !*J1M VXXQ0!SFC:]K7BD:#IAU.?3Y)K"XN[NZ@AC$LABF6%0 RLJY)+-@
M>PQ3Y--UJX\>Z59W6M&&]71)Q<7MI$@>11/'C:'!52?E)X/?&,\;$7P_L[.U
MM(]/U74K*:R>;[+<1-&7BBE;<T7S(0R9 (W D$#FM#2?"6GZ/>VEU;2W+26U
MI): RR;MX>02,['&2Q89STY/% $?@?4KW5/"L$^H3>?=1SW%N\VT+YGE3/&&
M(' )"@G'>N3.NZZ?"K>-1J\P07VT:9Y4?D?9Q<^3MSMW[\?-NW=>,8KOM%T>
MWT+3OL-J\CQ>=+-F0@G=)(TC= .,L<>U8I\!V1G*?VA?_P!EF[^VG2]R>1YN
M_?G[N_;O^;;NVY[=J *WAJXUG5O%>OR7.K2?8--U%[:"T2) '!B0_.VW<0"V
M1@CG.<C $'BNVNI_B/X.6+4[JVC?[42D2QD92,'/S*>H8J?;I@\UU&E:);:1
M<ZG/ \K-J-T;N4.00KE%3"X'3"#KGO4&M>'(M9O],OQ>W5G=Z=([0RVY3)#C
M:ZD,K @CVSZ4 >>Z7+J^D>%UUJVU>9(4\02P?81%&8I(Y+]HWW$J6W?,2"&
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M*X&,Y_>'//I5#5?"R:AJC:E::I?Z7=RP"WGDLS'^^C!) (=6 (W-AA@C)YH
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M2W[O[W*Y;J: .W7QKHW]FW]].]S:I8*K7,=S;/%)&K?=;8P!P>>1Z'T-5_\
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MC?R&.U@ ,CA2VT$@9P.W->;:99:AI-QX/O+G2[\Q6U[JJSB*V=VB\Z5_+9E
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M$Z1QH,LS&-@ !W)-<IX0TJ^M=5\*R7-E/$MOX5%M*SQD>7+NA^0^C?*>/8T
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M%-+DF-Y:SI;^>;5V@$N]0T?F8V[@">,]>.O%:J^([.VUWQ#'=ZPOD:9##+-
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MD>T\J#@G.,?K5NN-U35K^'XIZ5I<=RZV4VEW$TD( PSJP /X9K T&_UR/2?
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MP-Q')'MFMJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:A8I87+2R#]Y&JD9X ^8Y.345EX)T^TN-"G:[O[F71!*MH\\JDA9$"%6PHR
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M=M(8[AD@)CA.P."[] "#@>I!J_J^KVFAZ>U[>,XC#+&J1H7>1V(5451R6)(
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MSO;FZE@CM69X(@2-[@= 2#CJ3@X'% $*_#_3R_FS:CJEQ.;.6Q>6:<%G@D4
MH?EQ@8!& #GDDU+XCLYK7P8V@Z;I$VI^=:FQC0NBHB[-H:1B1\H'7:"?:GW_
M (VTJRNUM8H[R^G>S2^1+* REX&+ .,=OE_4>M-T[QWHVJWFGP6HNS%J(/V2
MZ>W989F"EB@8_P 0 /Y$=10!H^&M$C\.>&[#28W,GV:(*\AZR.>78^Y8D_C6
M5>^ =,OI;LO>:BD5Q<"[$$<X$<5P"&\U!C[V5S@DC)/%)8?$+1=1DL?)COEM
MKV7R(+N2V986EY_=[O[V01Z9XSGBJ.@^,)E'BRXUB9Y8-.UEK.V2*$%]I"!$
M4*,L2S8Y]: -N7PCILVBZII3M<&WU.=Y[@[QNW-C.#CC[HJGJO@'2]6GU)I+
MO4(8-37_ $RU@GV13-M"AR,9#8"]" <#(-5=7^(5O8Z&U];:=?/<1W\-E-:R
MP%9(6=D^\/='!7&020*T+OQOI=E<&*>&^ B2-[J46Q*6GF %1*?X3@@D<X')
MP* &>-M'GU#P!J&DV$#3RO D4<>1E@&7N<=A4EOX*TU)[J:\GO=1-Q:-98O9
MMXC@;[T:X X/&2<L<#FL_P 6^.8-*TO7X;%;MKW3[20M=1VQ>&WF,9:-6;IG
ME3T(&1G%=5I\KSZ;:S2'+R0HS'&,D@$T 82>";(Z=?65UJ.J7L=Y:&R)N;C<
M8X2,%5P ,_[1!/ YK3N-"L[E])>0R9TN3S;?#=_+:/YN.?E8UFGQUI O3#LO
M/LPNOL9O_LY^S";=MV;_ />^7.,9XS5BS\6:?J&OW&C6L5Y+<VLK0W#K ?+A
M8*&&Y^@R#@>I!H 2Z\(Z;=Z=KEC(9_)UJ4RW6'&<E%3Y>..$'K5.^\ Z9?RW
MADO-12&YG%U]GCG CCG!!\U1C.[*@X)(SSBK/C#Q.?"VF6]TME-=//=PVX6-
M"V-[JISCO@G'J<"L1?'GV#7O$,=_;ZA+:6:V\R1P6FYK:)H0[M)CIR3P23P<
M=#0!OR>$].ETK6M.D>X:'6'=[IMXW9:-4.TXXX4?C45UX-L;G4);M;S4+99S
M&;JWMY]D=P4 "EQC.<* =I&0 #FED\9Z6-;@TB!;NZNYHH9U%O 7412$@2$]
ME&.2>F1ZTMAXRTO4=1BM(5NE6=I$MKF2 K#<,F=P1^^ &/;(!(S0!+-X6T^>
MQUVS<S>5K;.UUAQG+1K&=O''RJ/7FE@\,6EKXB.M6]S=Q3O D$T*R#RIE0,$
M+#&<C<>A%5++QQIE_(4AMM0^>"2XMF>U91=HF-QBS][J.#@G(/2J.B?$*WU+
MPSINJ7&G7JW-^Q6"TA@+/*0-Q*>J@=6.!^E &]<>'K*Z\1VVNR&7[9;VSVR8
M;Y=CD$Y&.O%4I/#5AIV@:3:PP7EQ'H3+-:11NIDD9$9 #G .0Q[CFF2>.='6
M'3GC%W/)J F^SP16[-*SQ$"1"O4,">0>F#GI2IXWTJ73(+N&*]EEGN'M4LDM
MS]H\U,[U*=MN"22<>_(H P/"O@R>Y\(7-KKD-QI]Q/J\NIP"*5?.MB7W(<C*
M[L=N1S6VG@32Q%?++<7T\E_+;RW,TTP9W>!@R'...0 0!C P,5+)XVTH65C/
M#'>7,M]))'#:PP$S;H\B0,IQMV$8.>GXTSP7KL_B"VU>XED9XX=3F@@#Q^6R
M1J%PI& <@DYSS0!<U/PMI>KW=Y<7L;RF[LA8RIOPOEABX(QR&RV<Y["L]O .
MF3V.HVU_=ZC?R7\"V\MS=3AI5C4Y55(  PQSTY/7-0:GXLFTGQ[+ICPW=W;G
M2H[F.UL[?S)"_FR*S<<XPJCDXZ=S5FX\?Z)%;Z7+#]KNSJD+S6<5M;L\DH0J
M&7;U##=R#TP<]* +EGX6M+77+;67NKRYOX+(V(EGD!+QE]Y+8 RV>_I2Z;X4
MTO2O$.I:W;)(+O4,>:&?*)W.P=MQP3ZD5#)XSTN+4S9,EWL6=+62Z$!\B.9L
M;8V?LV64>@) )S2KXQTQM9&G>7> -<FT6Z-N1 TX!)C#^O!'ID8SF@ TOPA9
M:1>Q36]YJ#6]N7-M9//F"#=G.U0,G@D ,2!GC%:%UHUK=ZWI^K2&3[38I*D.
M&^7$@4-D=_NBLQ/&VDOJJV(6[\M[DV:7AMV^SM."08P_KD$>F1C.:QO"_CZ.
MYTVP351>/<7-Y+:?;!:X@\SS76.,L.,X"C@8SP3G- &W+X0LI-6DODO-0ACF
MG6YGLX9]L$LJXPS#&?X5R 0#CD&H[KP-I%Y;>(()3<[-=97N\2 $%0 -O''0
M>M=%--';P23S.L<4:EW=C@*H&237.V'CC3-0FAB2VU&(W,3S6;36K(+M5&X^
M7GJ<<@'!(YH ?J'@ZROKCSH[W4+)WMUM9_LD_E_:(ESM5^#TRW*X/)YJZ?#U
MB?$5MKG[T7=M:-9QC=\OED@G(ZYR!SFN6^'OB75?$^H:S<WSW:6\5W-!!;M:
M+'%&J. !O^\9,=03BMG6?%9TGQ;HVAC3[F<:@DCF6.,L%"XZ?0D$^@QZT 7=
M;\.VVN3V%Q)<75K<V$IE@GM9 K*64JPY!!!!P>*H2>!=,DNY'-Q?"RENOMDF
MG"8?9WFW;MQ7&?O#<5SM)[5E>'O'T;6BIJPNWD?4Y[(W:VN((V^T.D2,PX!Q
ML&?<9.36A#XLL[6YUYKB_NKL6=[';"V6U&Z.1P-L<>WE\DCD_P J -W5])CU
MBT2![BYMGCD$L4]M)L>-AGD'D'@D8((.>E8__"#V MXO+OM1COHYWN/[128>
M>SNH5LDKM(*JHQMQ\HXXK8TC5X-9M7FABN(&CD,4L-S$8Y(V !P0?8@Y&1S5
M#QAKLGA[PY-=6L:RW\K);64+=))Y#M0>XR<GV!H BN/!EC-:V$<5[J-O=6/F
M>3?17&9SYAS)N9@0P8\D$=0,8Q41\":9'%IPLKK4+&6Q22-)[:?$DBR,&D#E
M@=VYAN)ZYZ8I?"OB.:^T:_\ [;:"'4=)N);>_* J@V?,) "<A60JWYT:?X[T
MG4;[3[-(;^"740SVGVBU:,3(J%RZD]L#Z\CCD4 2Z=X*TG2Y-+:U^T#^S9;F
M6W#2;L&<DOG(R1\QQ_6ENO"%E<ZK-?+>:A;I<2I-<VL$^R*=T  9AC.<*H."
M,@#.:JV7Q"T74-);5+>*_:S_ ':Q2&U;$\CG:(X_[[9X('0]^#BS_P )II?]
MG2731WB31W(M&LF@/VCSB P0)W)4ALYQCG.* -+5])CUBT2%[BYMGCD$L4]M
M)LDC89&0<$'@D8((.>E<EJ'@<C7- ^RS7[)%/=7-UJ'G#SA*\:JKDXQSM"X"
MXP,8Q6S)XXT>'3(KZ;[5&'O/L)@:!O-2?!.PH.<G'&,YR,9S5.3XD:/%!=R2
M6FJHUBV+Z(V;;K1< AY/12#D$9R ?0T 6U\#Z:FF"U6YOA<"[-\+\3#[1YY&
MTONQCE3MQC&.,4Z7P98S:=;V[7NHBYM[AKF*_$_^D+*P(9MQ&,$$C;C;CM2Z
MCXTTG3+N2"474J0(DES<00%XK97^Z9&'0$<\9P.3@5'J?CG2]+O+^U:"_N)=
M/59+L6UL9!"C+N#DCMC\>#@'!H (_ ND1QZ:"UT\EA?-J"RO+N>:=LY:0XYS
MGMCM5A_".FN?$))G_P")\@2\^<<#R_+^7CCY?KS52U\9QWGC;^P8+*XD@:QC
MNTNUC.PAR<'/]W QGUXK;U+5[72GLENBZ_;+E;6)E7(\Q@2H/H#C&?7% &1/
MX)L'M].2UO-0L9K"T%E%<VDP21H0 -C$@@CY0<XR#TQ4VJ:'':^ =0T/2;?"
MKILMM;0@\DF,A1D]R3U/K4D?BO29=1UFQ$[";1XUDNRRX4*5+9![X Y]*Q!X
MVMO-U>]AN+VYCMM,AOUT\VH4QHZE@V[J21U!Z8H M>'_  7:V*:9=7<][<36
MEH(8;:YE#Q6VY '"C'H-O).!P.*LZ=X,L=-^1+[4IK=('MK>WFN-T=O&W!5!
MCG@  L6(' K @\?7,VI>')GL[U(-1TN:=[*.VW223*8<%.^W#.<Y (Y-;H\<
M:2^F65Y EY/)>RR0P6D5N3.7C)$BE/X=I!R3@#UY% $MWX.TN]\&1>%93/\
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M'M[^XFT]5DNA;6QD$2,N[>2.V/QX. <&I+SQGI-I<PP(+JZ,ELMX[6L#2+%
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M:6SAD<Y9HU8GW(J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N,^(DLD$7AN:*W:X>/7+=A$F-S8
M60D#/&?3WKLZJ7VF6FI-:-=1%S:7"W,/S$;9%! /'7ACP>* /-==TK5/$%OX
MHU*#2;R)+U]-@MX)X]DLJPSAY'*=0,,>O936SXLTJ9?%]OJ[PZW+9O8&U)T>
M9ED217+#<%()5@QYZ KSC-=A;ZI:76I7NGPR$W-EY?GKM(V[QE>>_ JY0!YG
MK&AZMHFCZ%J?AG2KA=0@LYK"2T,HD>-)E+*6?^+9*%)/H31?^$_[ O=$,46L
MS:?:Z6;!FTB5DE$@8,&8*02&^;)[$#/6O3** .%\-Z%-IOB?3)H]-N+2SCT-
MXBLTOFM'(TZN49^[=36-IFF:KI$O@^[FTJ\D2TN]46X2&/<\8FE<QL1G[I&#
MGMFO4Z* ,CQ2=3'A;4O[&W_VCY#>3Y>-V>^W/&[&<9[XKEO"MG<6_C>XO%T_
M6H[&YTY(HY]3E>5RZ.Q;=O8F,'<,#C."<5Z!10!R7C&&]&L>&+^TT^>]CLKZ
M26=(0"RH8)%W<GDY88'<\5S-YH^J:O<WFKII=U%%>^(=-FC@F3;(((-BO(R_
MPCAN#S@"O4ZIW6J6EG?V-E/(5GOG=(%"D[BJ%SSVX!ZT <1XFTF:+QA=ZE):
MZ]<VMY810QC2)V0^9&TF4D"L."'&&/ ^;I63KVAZJ^G7^AQ:=K1@&CQVVE6]
MM=LMO&?*97$SJPWD' PV0P P.37K-% 'G5C<ZKH&H:K>1^'=1O3JUO;2VJ)&
M!ME2$1F*4D_N^5!R>,$]QBM&+3-0.I>-)I;-E-[:0+#MY61A P8*>^&.*Z5-
M8LV>^#L\"63!9I;B,Q1CC.0S !A[@XIZ:I:/K,NDK(?MD4"7#IM. C,R@YZ=
M4;B@"KX7MYK/PCHMM<1M'/#801R(W56$:@@_0UP4^F:L/"-_X*72+QKJXOY3
M'>A!]G,,EP9?-+YX(5C\O7(Z=Z]3HH Y?POI]U9^(_%EQ<6[QQW>H))"[#_6
M(((UR/;((IWC6RO+G3].N[*V>ZDT[48+U[>/&^5%)#!<X!8!B0.^*Z*6>& Q
MB65(S(^R,.P&]L$X'J< \>U$\\-K \]Q+'##&-SR2,%51ZDGH* .%U>XU?6F
MT_68M O([;2M42=() !<7$7E.CN(ST*E\@$Y(4^V<[5-*U37'UW5XM+NH8[R
MYTN*""9-LKI!.'DD*=A\QZ\X4FO0UU2T;69-)$A^V1VZW+)M.!&S,H.>G53Q
M5R@#SKQOH.IZI?>)C9V<DHN?#:VT)'1Y1+*VP>^"/SJI?6<\^M-K4VF>)A;7
MVFPP)#8R-#*DL32 I*JL,!@X(8\#GIFO4** .+T/0YM-\71M'8R06,/AVVLX
M]S[PC+)(3'N[D CFLO1]#U.#PS\.K>2QE273[A6NT(YA'V>5<M^+ ?C7I%%
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M7.FW?DS>'+2R,R1Y6*:,L65SGY>"*Z/QKIMQJ?A.\CLHR]]!LN[51U,T3"1
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MK"ZM9OJXTM9<W1MOM04 X,>[;G/3K5V@"&T5DLH$8898U!!['%3444 %%%%
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M%0L<,1D$<@9YZ9'- &AK?Q$DL-"U*XM]$OH]1L+B"&:TN1'E!*1M<E9,%3G
MP2<XR ,D7V\1P1^+_L\[:K!.NAM?O8.L1B5!)@DD$GS<\8!VXK$\5^&]8OF\
M7R6ED9OM:Z<]LHD4&;R9-S@9/!QZXSFI[O2-6U+QY-K:Z9-!:S^%Y+,"9X]R
MSM+N$9 8\XYR,CWH U]+\=6>J7FF1#3=1MH-4C,EE=7$:+'-A-Y'#%@=N3R
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MIJ^E79O?,O93YCH(B'7YOW;?.WW-N >*T_A3:16OPUT1HVF)GMDE?S)GDPQ
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M;D]""!C(P2:MP6KZ#JWA&2SU*_N6U8217HN+N299Q]G:3S-K$A2&4?= X;%
M'<:1JEMK>D6NIV18VUU&)8RRX)4],BJA\26<:PF>"\M_/O\ [!$)[=D+R<D$
M9ZH=IPW0UYQX8LWTGPQ\/M4M[Z^^T7EQ%;3JURYB:%XI#L\O.P8VK@@9R,YR
M:JQ376KZ/#%=ZC=9_P"$YDMUE,QWQQ_. J,>5X.!CIGB@#U_4KY=-T^:\>"Y
MG6( F*UA,LC<X^51R>M2+=0-<_9A*GVCRQ*8BWSA"< D=<9!'X5Y'XMN;SP]
MH7C[3M-U&_2"SMK*YMG:ZD>2W>1R'59&);!V XSW/K5W5U.G>-_$FM6[W+7M
MGX82[A!N9"GF#SARF[:1\H.TC&<G&3F@#U6J5QJMK:ZM8Z;*S"YO5D:$!<@B
M, MD]OO"O+9I_$GA_0-0U6TM=1MX1HLTDLM[J:W7F3@*4F1=S;3R^< #E>.*
MVH]&M]&^(/A%+>^O+@2V=XSBYNGG+,$CRX+DXSGD# Z<4 =Q<ZK:VNJV.FRL
MPN+T2&$!<@[ "V3VZBKM</XPL8]2\=>$+26XFABD%[O\B5HG<"-#M#*0PSCG
M!!P#6 ;O4-'L+^^AO[V:S\-:^8W62=I#)9/&GF(Q)R^SS"P+9(V4 >KUF0:[
M8W'B&[T.-G^VVL*3R@K\H5\XP>_2LCPO<7&L:[KVLFXD>P,XL;*/>3'MAR))
M .F6D+C/H@KE]0OH].^(GC:[EGN($CT.W_>VP!E4DL 4SQNR1C/&: /4J*\@
MF76;-?$5A9C4K"6VTJ#4H;>?4VN9#)'*Y)W;CC>$VE<X/XU<;Q?)%XIF\5&]
MF/AXI)8)$7/EEDMA<^9CINR'3/X4 >AZ5H>F:(DRZ=:)!Y[^9*PR6D;U9CDF
MK<ES!%/%!)-&LTV?+C9@&? R<#O@5D>#K>]MO"&EIJ4\LU\\ EN'E8LV]_G8
M9/8%L#V K \3Z;!=_%+P@\CW()@O"1'<R1CY!&5X5@.K'/\ >& <@"@#KM*U
M6UUFS:[LV8Q":6$EEP=T;E&_535VO'K2S>P\)+K]O?7R7D7B-T15N76(1OJ!
MC=#&#M8$,Q)()YZ\"K>G2>(M3U-M6MK/4#.FMR1-<-J2K;BV2<QM%Y!?'W ?
MX<EN<T >CZQK6GZ!8&^U.X\BW#K'N",Y+,<* %!))/M5#3?&6AZO?QV5E<7#
MSR9*J]G-&.!D_,R #@>M97Q-\_\ X1RQ^S&,7']KV/E&4$KN\],;L<XSUQ6O
MI2^*1>?\3>31FM=IXM$E#[NWWB1B@#<JM>Z?:Z@L*W<*RB"9)XP2?ED0Y5OP
M->2:=:WDOAGP=JC:UJWV[4=2^R74GVV3#P,)<H%S@'"## ;@><YJ>_:[L+S4
M-"M=6U""TB\2V%O$YNG:1(YH49T#L2V"6.,DXS0!Z=K6L6F@:-=:K?LZVMJF
M^0HNX@>PJW!,EQ!'-'G9(H=<^A&:\A\91MI6B^/=$@N;J;3X]*MKJ-+BX>8P
MN[NK ,Y+8.P'!/KZUT%C9_\ "2^)+O3[^\OH;73M+LS;16MW)!\TH<M*2A!8
MC: ,Y P>.: .RNM#TR^U2UU*ZM$FN[7_ %$CY/EGGD#IGD\XS6A7ENA^(;^S
MM_"?B+5;^5[#4+233[UI'/EB1"S138Z L$8$]]PJA;3:YJ=UI<=W;ZI>IJEO
M<ZNUG!J)MF0-(BQ+NW*0J1E?E!^\V2* /8:*\L@M-9U+7?"^C:Y?W\&_3;QK
MN*"]*M,$EC$99XSRVTJ20<]1W-=OXNM=0O/#LT&F2%;EI(CL%P8&E0.I>-9!
MRA905!'K0!?O=5M=/O-/M9RPEOYC!  N06",YSZ<(:NUY+)'!J%WX>TQ'UFR
M>+79([BVO+HO-;9LW8HDH8DHRG(8,2-YP1@ 3M*;.;6/#:W&KW,0UN*"RMH;
MUA*ZM;+,T9F=MRQ_?).[..!UH ] US7;'P]9Q75^SK%+/';J47<=[G"_AFBT
MUVQO=>U'1H6<WFGI$\X*X4"0$K@]^AKRC6+FZE\!O;7)E'V/Q7#;QQS7!G:)
M!(A"&0\M@L1D_3M77>'?^2P^-?\ KVL/_0'H Z_^U;7^W!H^YOM9MOM6-O&S
M=MZ^N:NUPFK:3#K'Q3BM[F:Y2 :(S,MO.\)?]^, LA#8[X!]*Y_3KNXUK1-$
MT^9]8U*[BANV=(=0-J"B3F)))900S, N .<\DT >MT5Y;H7B.[TR/PUKNKW\
MTFGZIHK1W#2.2JW$*F4/CH"R"3..I452MFUZ\DT6TOH-3OVU"TN=7GM;?43;
M,K/(FQ=VY3MC1@-@.,G..* /7Z*Q?":ZHGABR36=WV]%9)"TBR,0&(4LR\%B
MH4D^N:VJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *I:KI%CK=B;/4(/-AW*XPQ1D93D,K*058'H0
M0:NUC>(O$,'AVVLY9H9Y3=7D-J@BC9\%W"Y. >@)..I/ H 9'X0T2/1[[2S:
MO);:AG[699Y)))\C'S2,Q<\ #KQVK8@ACM[>.")=L<:A$7.< # KBX_&46E^
M)?$<>L7\HT^U%J\ ^RL?(61"6+[%RJYQR_3UKH]3\2:5I D:]N61(E5Y72)W
M6)6. SLH(4>YQZ]* *MEX,T'3M0CO;:T=7A=G@C:XD:*!FSN,<98HA.3]T#J
M:T]-TNSTBWD@L8?*BDFDG9=Q;+NQ9CR3U))I=1U.STK3)]2O)O+M((S))(%+
M;5').%!.,5AR^*M*OY; 6FKSVV^^2$?Z(^VY)0L(\LF,$$-N'IP: -:?0M.N
M-935Y;?=?);-:K+O88B8Y*XSCKWQFF1^'M+BM-*M4M<0Z2RM9+O;]T50H.<\
M_*Q'.>M17GBO1K"21;B[8".=;9W6%W592 0A901N.1Q[@=36!!XRATOQ)XDA
MUG4)/L-K+;?9S]F)$"21AB7*+\J[C]YOSH ZG5]&L-=LQ:ZA"9(U<2H4D:-X
MW'1E92&4CU!'6L__ (0O0?[*CTX6CK%'.;E)5N)!,)CUD\T-OW')!.<XXZ5+
M:^)+>[\57^@I!<"6SABD:4PML8OOXSC &$ZD\DX'2B_\26]CXFT[0W@N&FO8
MI)1(D+LJA"HZ@'NPSV ZXR* %M_"NC6MI;VT5F?+M[H7J%I79S/S^\9B=SMS
M_$33[KPUI-[-=RW%IO>[>!YSYC#>T+;HSP>,$=NO?-"^)M(:[AMQ=$&>9H(9
M#$XBDD7.463&TMP> >Q]#4^KZUI^A6:W>I7'D6YD6/S"C, S$ 9P#CD@9/%
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M9OLLR0-B=3N=!A1C=LQQW(XIB>.O#SQI(+R4*;C[,Y:UE7R9=P4++E?W9)(
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MD,K;BH=>#@X[BN\T"U^RZ<Q.E6^EF:1I3:P[?E)ZERO!<XR2/IDXR;>G7O\
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MI<IG\1^';ZW@NX[/6KFZ1KFYU)GFO(3%*XW1 !44$*5P<J !WK*M(1I?PO\
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M*T8@ VB,%/EYR-H/4UI^%+*TO].T[Q-J&JW-MJT^H2J[F[(64^:Z"VV,=NW
M "@9RN1S72GP3X<-Q)/_ &8GFR3>?N$CC9)NWEDY^0EN3MQGOFIH_"6@PZT=
M7CTV-;WS#+OW-M$A&"X3.T,>[ 9]Z /-M$TZ/3_"?A36H)[I;^36D@9_M#[3
M$]PZ-'LSMVX/IUYZUW/CZXGBT2RMXIY;>*]U*UM+B:)RC+$\@#88<KG[N?\
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M,%9U^ZS)G:S# P2"1@>E ')PP2:7XS2\U*.ZF2\U)TM=4M+\O'\VX+;RPDX
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M% !1110 4444 %%%% !1110 4444 %%%% !7)^.]2N]+AT*6T^T,\FKPQ-#
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M[N-G? 4D94!7&5)Q\@ '>M9_"NJ-X%N=)"1_:I-9-XHWC'E_;A-G/KL[>O%
M%/QCXSOI/#6O/I=A=QVMG/\ 8_[2BG"LLJNJMA1\VT$[=WKGC&371^/]4@T;
MP1J.H7)O1#%Y>XV4YAFYD51M<=.3S[9%<OJGAKQ/_8&O^&[&PMI+:^OI;N&]
M>Y"X2242E"F,[LY7/3'.>U=)\1]"OO$O@+4](TY4:[N/*\L.VT?+*C'GZ*:
M*%WXTOM.\7:[;76G$Z1I>F)>/(DBE\8D8MCJ<[ H';&3UKH=$U:^U(RK?:1+
M8,J))&WG++'*K9Z,O<8Y'N.N:PKW2=<M_&FJ:A8V%I=VVH:9';AKB7"))'YA
M"NN,E6W@9'3FG^#M"N]*U+4)QI:Z-ITT4:QZ<EUYRB4%B\B@?*@(*C ZXR0*
M $\;:AJT][IOAKP]>_8]4OA).]R%#>1!&O4@@_><HOXFJEUXOU"[^$5WK]E
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MXN+&:..5;]9<NRD*I 48'/7VH K1>/;N:YTZ!?#5WNU:W:?3LSQCS0H4MO\
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M'DJ0(S@@X?A#CGYJ /6,C&<\>M8DOB/-UK-I9Z=<WEUI@AW0Q% 9O,&X;2Q
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MM[BT\*VUO<W-K<-')*J/:SF9%02-M0.0"VP83I_#704 %%%% !1110 4444
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M!V)P/RJ;QGJ=OIL_AM;BSDN3=:S!;QE+EH?*=@V'.W[X&/N'@Y]J .H "J
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MD0C'#(2N>3G=67;?$.[U185TS2K0R31RW,?VN_\ )5K=9#'&P.P_-)M8A<8
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MQM\XMNV]-VVM>T\7:O\ :=,CU'0X+9=7C=K'9>ER)!&9!'+E %)4'E2P!!%
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MZ"%_.*;50A3C 7EB.2.@SQW*.DB!XV5T89#*<@TDDT41422(FX[5W,!D^@H
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MY&250LGS%0@)X!)'4\5HV]YNT^WN;Q%M'D16>-Y%;8Q'W=PX.#QD=: .'OO
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MH NV#WDEC$]_!#!=$?O(X93(BGV8JI/Y"K-%% !1110 4444 %%%% !1110
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M5RUL<P&:!7\H_P"SD<=!T]*EBTVPMWA>&RMHWA5EB9(E!C#'+!<#@$@$XZT
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MW<*2K#);)(B2$EPI4$ YY)Q7EGAI[<>*?"%_:VFEV*:HMS*$MW:2Y>-XV?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^&2_?29YH;F69U"X8 (5&1@G&3@D5@:#XWUT^$_#TU]_9?VS5FE,5S=W+1Q
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M!YW2/&Y@HR0,]ZIQ>*]*>32(9+@0W&JV_P!HMXI" VW:#SSP?F ]S53XB_\
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M@_Q8XSUY/J: /5%974,I#*1D$'((I:Y3X:$GX<Z("20L!09/0!B /P  KJZ
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MHW%0<@9],D\>]/HH 9##%;Q+%#&D<:_=1%  ^@%/HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "LG6M"&LF$G5-3LO*W?\>-R8M^<?>XYQCCZFM:B@#'\
M46BW?A>^MFTPZHK1X-H)?+:4 @_*W9AC(Z<@<CK7,^$-#?\ X2VXUT6>JV]N
MEB+.-]6E9[B9BX=CRQ*HNU0.F26/N>^HH R;[01?:M!?_P!J:I;F';_H]O<E
M(7VG/S+CG/0^HK6HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF*XC5-QV$EB<&/@C.XTY-.E$]U?0+KTD4!LY(;V[LVDN5E3S58>6P5GC"OR
M,Y=BI/8 [&3Q?I*64%RK7,OGF0+#%:R/*#&<2;HP-R[3P<CJ0.XSH7>K6-CI
M1U.XG"6817$FTG(.-N !DDY   R2:\V@T2]MKI-6U--;D@NOMIQ8K)'.CO)&
M8RRQ890P0G!X!VAJ[&/4+VW\)K#JUI>RZC'80BY:&V:023.A#;=@.<,#G' R
M* -ZSNX;^QM[RW8M!<1K+&Q&,JPR#@^QJ>L/P?*S^$M+BDM[FWEM[6*"2.XA
M:)@RHH/# $C/?I6Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex1012022063010qngcbasho010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC#C<4Z;@.N/>IJ "BBHIKF"V\OSYHXO,<1IO<+N8]%&>I/I0!+1110 4444
M%%%0+>6KW;VB7,+7*+N:$2 NH]2O4#D4 3T4UG5!EF"@\<G%.H **** "BHH
M+F"ZC\RWFCF3)7=&X89'!&1WJ6@ HHH) !). .] !12 A@"""#T(I: "BH)[
MRUM9(H[BYAB>9ML:R2!2Y] #U-3T %%,\Z(SF#S4\X*',>X;@N<9QUQD'FFO
M<P1SQ0/-&LTN?+C9P&?'7 ZG% $M%%% !1110 4444 %%%% !1110 4444 %
M%%'49% !1129''/6@!:*** "BBB@ HHSCK10 4444 %%&<44 %%%% !1110
M4449YQWH **** "BC..M% !1110 444$@=3B@ HHHSSB@ HHHH **** "BBB
M@ HHSSBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N?\5:O>Z<FF6>F^2M[J
M=ZMI'+,A=(AM9V<J"-V%0X&1R1705C^(="_MRVM?*NFM+RSN5NK6X"!]D@!'
M*G&Y2K,",CKUH X+QEJ>N2>$?&>AW=];-<:=9I.;F.V*_:+>57!0KO\ E8%2
M-V2,8XKM_!NGOIOA6P@=K9B84<?9K80* 5&!MR<GU/>LV?P/)?Z/X@@U#5?.
MU#6X5AFNH[?8D:*I"*D>X\#+'EB22>:ZFRMOL=C;VH;>(8ECW8QG QG]* /)
M?%,NKS6_Q/CNM226RMK6-8[?R2-H:(,N#N., D'CYCSQTKH=5\5:YX5O;O\
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MI2ZCK-K%NN;;<T2/OY!+']X"#A^,9Z5U.F>"+^QN-#DFUX3KH\9M[>,6813
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M/L@5IDEQG>VXY?(Y;OZ \T 9]EXDN=1\)>'M2UO2K6[:\U>*-"DY A<S,$<
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M;M4>)GCEL681^6FP8(E&>.M/;PW>RZMHFHSZLLLVF^>7W6Y_?&48./G^4 <
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M*YN#&X5MPPORJR _[('>FQV_]C7NBZBGB"ZL=,EMKT1ZA<6"@"22X$A781A
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MT[<1>65[=+<0LI#1EKB1ESGU'-87BA?LGBWQ NHZS-IMKJ5C#'$BV2S_ &M
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M)=$T=('U#4[:W6X7=$6<?.HQEAC^$9'/3D5YYI>OZ7IGB'Q!<ZY:+I[W.D6
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MP?\ 08UC_P "S_A1_P (X/\ H,:Q_P"!9_PKGH[[Q%;:WI=I=:RLJZQIUQ*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K&\3>'+?Q1I<=A<S20HEQ%<!H\9RC!@.>W%;-8/BGQ5:>%+6SGNH9I
M?M5W%;*L<;MC>X!;Y5/0$D#JV,"@!9?"]M*GB-3<2C^W5VS8Q^[_ '(B^7\%
MSSWK-G\"*TTYL]9O;."\M([6]BB5#YZHFP-D@E&V\$CMCH1FH(_B%I]GK6NV
M^K7!AMK.6'R&2UE8I$\$;EI< [!N<\MM';L:V]0\7:'I=XMK=WVV0JKL4B=T
MC5CA6=U!5 3T+$4 9H\$&UALUTK6[S3Y8=/BTZ:6)(V,T48(0D,"%<9;##^\
M?:L\^&]3F\=:M+9ZEJ&G1C3+.WCNQ&L@FP9MP)<$%Q\ISU&?>M[5/&OA_1KJ
MYMKV^9)K8*TZ);R2>4I&0S;5.%Q_%T'<U+I_BS1-4U0Z=9WOF7/EF1!Y3JDJ
M @%HW("N 2,E2: ,X>!XK&*P&AZI=:7+:68L?,1$D,L0.1N#@C<#DAAW8^M:
M=EX>AL=974Q=7$THT^*P/G/O+*C,P=FZEB6.35K5=7L=%M!=7\QCC9Q&H2-I
M&=CT554%F/L >E<W?^/+*#5=":WN%?3+Y;H2GR)#+YD6P! F-^[+$%=N: %@
M\!+I\>FMI6LW=E=65N]J9UCC<RQ.^\JRL",AN01TYZTZU\!1:;I^GPZ9JUW;
M7=A)<-#=E4D8K,Y=T<,,,,X]\J#6C_PF>@_V3!J2WKO!/,T$:QV\C2M(N=R>
M4%W[AM.1MXQ67KWC$PQ>%KK1989[35]5CM)'=#_JR'W8'!5@5QSTP010!JVO
MAE+?4=+OY;^[NKBPMYX/,G8,TOFLC,S''8H, 8 !QV%9UQX$B9(6M-4N;6Z@
MU2?4XIU1'*O+NWKM88(PY'K4_AGQ!>:OXB\46%R(A#IEXD$&Q2"5*!CNYY.3
M6EJWB/2M#G@@O[EHY[A7>&)(GD>4*5#;54$DC<O Y_(T 6M4TVVUC2KK3;U"
M]M=1-#*H."588.#V-<Z/ RW=K=V^M:UJ&J)/:?8T\S9'Y29!W ( #)D*=Y]!
M[YT#XRT$:1;ZH+XO;7$IAA"0R-*\@)!01A=^X;3D8R,50U3XA:-8:79:A"TU
MU%=7J6>(X)-T;%@'W+M+*R@YVD GH* +FE^&9;36%U74M6N=3O(K<VT#RQH@
MB0D%L! ,LQ5<GV[5%HO@K3M$U?5M0BDEF.H9'E2X*0(SL[(@QP&=V)KH5F1[
M=9P2(RN\%E(.,9Y!Y'TK"TWQSX<U:[M+:RU R/=KNMV,$BQR\;B%=E"E@.JY
MR,'(XH ATWPA+I\ LVUV_GT^&V>UMK5]@6-&&!N( +E0,#=T]SS4O_"(69L/
M#]F\\S1:*@2/IF4>0T/S?\!8GCO3H/&_ARX^UF+4@4LXWDN)#$X2,(^Q@6*X
MW;OX<Y/4 BI8/%VASZ;>7_VTQ066/M'VB%X7BS]W*.H;G(QQSVS0!E:?X$:Q
MGTB9]=O;@Z2A@M5=(PJP%-I0@*,D@+\W7Y1TYJ[;^#[6WT;P]IBW,QCT2:.:
M%SC,A1&0!OP<]/2LCQ7X_AM/ FK:UH$RR7EA)"CQ75N\;1EY$7YHV"L,JQ(-
M=9_;%AY^H0?:!YFGHKW2[3^[5E+ ].> 3QF@"CX<\._\(XM[!%?S3VD]P\\4
M$B*/(+NSL P&2"6[],4EYX;^T>*H->@U":WE2U-I-$J*RS1;MP!R,J<]Q3;G
MQIH-M]E#WS$W5LMU'L@D<"%NDC[5.Q?=L#KZ5FZ-X[LO^$1T34M;GV7E_:"X
M:.VMY)#@8W-M0,549&2>!GK0!>@\'6D&C>'M,%S,T6B2QR1,<9D*1L@#?@YZ
M51T_P%_9\NC,-<OI$T9\64;)&%2$J4,9POS94@;CR,#&.<];!/%=6\5Q;R++
M#*@>.1#D,I&00?0BN#O_ (E0/I>KSV$;0OINI06CO<PR*C1M+$KL20H4CS&&
M,Y& >AH Z3POX=_X1C36TZ._FNK19&:W25%!A5F+%<@ MR3R:KZOX5EU>ZG$
MFMWJ:;<O&]Q8[496VXX5B"R [1D#W(P2:GM?&6@W<%_,E\8TL$$ES]HADA*(
M<X;#J"5.#@C(-6](U_3M<68V$TC- 0LL<L+PR)D9&4<!@".AQ@T 9MQX-M+G
M0M<TIKF81:O<27$KC&Y"^W(7V^7O5/4_ 2:BVIQC6;VWLM0F%T]M&J86<!0'
MW$9(RBG;G&1Z<5NZOK^FZ$(?M\TBO.2(HHH7FD? R2$0%B .IQ@55N/&6@6R
M6C-?^9]L@-Q;+!"\K31@@$JJ*23R.!SUXX- %&;P+:W#>)WEOKAI/$-M%;W+
M *-FR(Q[E&.I!SS71:=9)INEVEC&S.EM"D*LW4A5 !/Y5Q'BWXC0V.E:)-H,
MZ2G5KM(4N7LYI4CC)8,VU0"7!7&S(;KQQ6VWC?0[ 16]_J)-PD437$JV<JQQ
M%P"#(<$0YSG#D$ \T -7P>TE_!+J&M7M_:6SRR6UM.$^0R*R'+@;F 5V R>_
M.<56TOP)]@N=$DGUR^NX]%)%C%(D:JB&)H]K;5!8[6')_N^YSKS^*M&MM;71
MI+PG46,8$"1.Q^?.TG ("\<GH.,D9%,LO&&@ZAJG]G6U]ON"75"8G6.4I]\)
M(0%<C!SM)Q@T 2:)X<M-%\,1:"&:XM41XV,H&75R20<?[Q%96F> ;'3/!NH^
M'%O+J9-0C>.:ZEP92&C$8[8^5%4#Z5I:=XOT/5IWAL[TNRQM,"T,B+)&IP7C
M9E D4$CE<CD>M4HOB'X6F,7EZF2)XO-@;[-+MF''"';AVY'RKEL\8S0 W6O
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M%^A:+="WO[[RY/+$K[(GD6)"<!G900BG!Y8@<4 1WGA&QU":Q:Z>22*UL)[
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M]VS$(6*Q.Z1ASA-[J"J9[;B,T 0ZCX7>XU*'4]-U6XTV^6V%I))'&D@EB!R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)E?YR-IW$X&TG(;-;OP_M+FUNO%YN+>6$3>(+B6(R(5WH4CPRYZC@\BNTHH
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MCR3G[G##<0#^8-32>"[/[3>2V][>6T=Y8)82PQE"I1%95;YE)W .PZXZ9'%
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M0^200'@D<');KGJ<<X'3%=))X+LG.IPK<W":?J<WVB[LAMV.YQOP2-P#X&X
M\\XQDTZ^\'VU[>:Q.+^\@75K46MS%$4VD!60,,J2#M8CKCOC- &#8^+;W0+:
MWAU2"V:RC\/-J41M]WF*(0@9&)X)(<$$ 8Z<]:O7'B/Q'9P7]P^EPR6L6FR7
M<<Y1HE25!GRFRQ+ CD, .G09J\W@NQFN+62YNKFXC@TV33##)LVRPOMW;L*#
MD[%Y!%16?@A;;1[G2YM=U6[MI+9K6$7#QDV\3#!"D)\QQQN;) Z8YR 4CXE\
M0VFGZ1JVH0Z8NG7UQ;))Y(D+P),H 9B3C[Y ],-GMS)IGBR^U"?4[ ?9/[0M
M=36TB41/M>(_-YG+?W5D[XRA'-;4_ANUNO"3>'+B6:6V-J+;S6($F ,*V0 -
MPP"#CJ*+;PQIMIK<.K01LMQ#9+8J-WR^6IR"?5ADC/H3ZT <\/%4]C9>(KLZ
M;!']BU@6LTEM TF(S'$3-(JX9R W..P'I5J'Q=+=QZ;!93V=W/?K<3175K&T
ML7E1,J@[ V=QWID;N/F]*OP>%1:2WTUMJM]%+>7POW8>60'V!"H&WE2J@$'G
MCJ#S5*?X?V#1026=]>6&H074MW'>VNQ6#RX\P;2I7:<#Y<=AWR2 ;?A^]U&_
MT:*?5K#[#>Y99(0V1P2 P]B,'!Y&<5@R>)M9'B#7+<0:>FG:,8I9Y&+F1X6B
M+G:!QN&!UXKI]/LAI]FEOY\UPPR7FF8%Y&/5C@ ?@  .@  JA;>'+>#5]8OW
MGFG_ +55%G@E"^6 J[0!A0>AP<DT 9NE:UK.IWMD+C2T?2KZT,KRK&5^SM@%
M58LQ\P,"1D <CIS6!X+UN>T\%^%=(L4'VJ?37N-[0M*$1&5?NAE)R7'<8P:Z
M70O" T&,01:UJ=S:PH4L[>X=&6U!&/E.T%L#@;B<"J@^'MI#I>CVMEJVHVEU
MI"LEI?1-'YH1OO(P*[64X'!'84 13^*-?ATBUGN].MM.NVM)Y98ILS,TL9 5
M41&#;6&6+<[1@&HK[QY)!IVC73BVT^/5-/6YBN+Q&:#SF52L+." G7[S=?PK
M3G\%6\UW#=#5-1CE6TDLYV#H3<1NVYMV5.#NYRNW'08&,(G@N)-#CT?^U;V2
MR%@+"2.58V$D8! .-F P!P"/Q!/- %?4?%&KO/J<>AZ>MY+ILL<3P%"3<,42
M1@K[@$PKC!(.2#TKK&,CVY,>(Y&7Y=ZY"G'&0",_G7,OX%M8]5:]T_5-1TY)
MHHX;JWMI%V7"HNU<[E)5MH"[E(.!USS74JH50J@  8 ':@#R>*\U35/#?@34
M[N6WN=0GUK<CLA3&8[C()R>..@QP />NBM/&=\R-8W,$!U0:O+IBO!&QC.R+
MSO,V9S]WC;NZ]\5<M? EK:6>E6D>IZ@8-+O#=VJ,8SM.' 0_)RH$C>_/7@4V
MZ\ 65U!>*=1OX[B?4?[3BN8V19+>?:%RF%QC:,$-G(S0!K>'K[5;ZUN?[7L!
M:SPW#1QLHVK/&,%9 I)*YSC:2<$&N8\0)_Q=K0V6P6\8Z5= QG:/XX^?FXX_
MK78:5IS:;:&*6]N+V=VW2W%P5WN< =% 4#  P /SR:S[_P ,+?>)+;75U.\M
MKJW@>WC6(1% CD%LAD)SE1WH RK_ %6[\/>&3J=KHUM:7-SJ<<4]M(V!\\RP
M!OEXR5"'T^M5KWQ1XEM6\30"'2FFT6W2\\PB3;+&R.VS;GAOD8;LXZ?+Z;5_
MX274[&6VO-6U"5I+F&X,I\H,OE,&1  FT*&7/3)R>:+GPC!=7&N3/?W@.LVJ
MVMP%\O"(JLHV?+P<.W7/6@#(;Q3XCU+4;^TT6RTT&#3[:^B^TNY+^:'.PXQS
M\F,]O?M2M]=MM8\3>#_$?D^1'<Z)>W$@/)4#R"1GOCFI]-T&[A\:ZG;PW6HV
M]H-)M+-+KR!B789=V&*[=P#+@CCD\'MT$?A'3X;_ $FXMWEBATNT>S@M5VF,
MQN%#!L@D_<7OV]Z ,J'QA?"R\.:M<6]O_9NN31PI&@;S;<R@F(LV</V!P!@G
MOBI+7Q/J<AU/3ITM$UFUU".UBB5&V21R89)<;LXV;V//&QASBKFG>#;/3X;"
MT^U7,]AITQFLK64J5A;!"C=C<P7<=H)XXZX&(=,LX]:\6'Q'+I-W826UNUG'
M]K4(\IWDEMH)X49"GOYC4 0#Q1J]Y<";2]-%U9QZB]E-'Y9#[$<QO*'+;>&!
M.W!R!US2VOBC5]2GL[O3M-%SILUZ]M*HC*O'&KLGG;RVTX*Y*[<X/7(JU!X,
M@M-:N;VUU34(;.[G-S<:<CKY$DIY+<KN )Y(# $]>.*-/\&0:9JLUQ:ZIJ*6
M$MP;HZ9O7R!*3N)'R[@-WS;0V,_E0!M:JUPFDW;VLB1SK$S([J6 ('H"/YUY
MSH%[JEAHW@5;2UTJ>_U33?(2[GC97C06XE"L026&Y<GIGT'6O2[RW^UV4UMY
MKQ>:A0NF-RY&,C((_2L"U\&6]HGAY4U&]*Z$I2U#>7\ZF/R\/\G/R\<8H HR
M>*=7?3-<O+6"Q=M"_=W41#_Z1*D2R2B-LC8/FPI(.2.<4-XJU;4=7^R:/%8K
M!-H\>IV\MT')^<D!652/3U[YYQBM*Y\(6LUWJLL-Y<VT.K*%OK>(KME.W:6!
M()5BORD@\X['FIO^$8MTUI]3@NKB!S8#3UA0)Y:1@DC *YR"?7'M0!B:-XPU
M34+GPO-<VMG'9:_;LZ1QEC)"ZQ>9RQX((!&,#'')K0^(%_J&F^#[FZTVX2"<
M2PQEV0L=KRJAQ@C!^;K_ /K"V7@JUL$\/)%?WI70E9;8-Y?S@H4(?Y>?E..,
M5J:_HL'B'1;C2[F66*.;:?,B(#(RL&4C((X*CJ* ..U%M4L_B)J$^G_8#>IX
M>BDDDFC8(Q6:7^$'/.,?>X]^E78O&=_J]G;_ -D6:?;'TF#4F22)I5S,&V1\
M,N.4;+=N.#6NWA6-]5GU)]3O6N)[ 6#EO+QL!9MV-GWLL3Z>U9P^']O;C2WT
M[6=3L+K3[-;$7$+1EIH%^ZCAD*G'8XR,F@#IM-N+B[TNUN+NT:TN98E:6W9@
MQB8CE<C@X/>K516UNEK;1P1[MD:A068L3CN2>2?>I: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H
MZMK%EHEE]KOI&6,NL:+'&TCR.QPJJJ@EF/H!5ZN6\:07(;0M3@M9[J+3=26X
MN(8$+N8S')&651RQ4N#@<X!H L#QKHG]EF_,TX N/LGV<VTGVCS\9\ORL;]V
M.<8Z<].:=;^,]$N1;XGEC>:\^P^7- \;QSE=P1U8 J2.1G@\8ZUSFHWEU?ZE
MH_B2/0+^*QT_4I-Z?9V^T31O 8_/\G&_ACC&"V!G%5KG0[[Q'9^+]4MK2XM9
M+J6WGTH7$1BE:6V0%7V-AEW.-O(!P.E '9ZCXIT?2KNXM;RZ*2V]LMS*HC9L
M(S[%Z Y9FX"CD]A5;_A-M#33I;VXGFMHX;A+:9+BWDCDB=\;0R$9 .00<8KB
MIM&U76O#6I>(KBQO[;4+W5+:Z-HB[;F.UMW5555(^_@/(!W)I\NC_:[=KRQM
M_$%TTNKZ;YDNJ1%7>.*8,65"JL%4,V2P'3T% '90^-M$EM-0N));FV&GA#<Q
MW-K)%(H?[A",H8[CP,#D\=:!XUT0:5=ZC//-:PV<L<-RMS;O%)"SE0NY& (!
MWJ<],'V-<WXEAUFV\2:]?:?;W@BEL].B:>W@\Q_+$\OG&,8(9U1LX )&0<=*
MQ)].O;B#Q'##8:W-'>3Z9/;/?0R,\L:3H')R/E(P3M."%YP.P!V.H_$32K/1
M=8O88+Y[C3;?SVM9K.6%W4YV-AESL)!&[&!WJP_CS1X+:"6Y6_B+P"XE7[!,
M3;QDE=\OR_(N5;!;&0">G-8'CC1]1U#4?$AM+*>83^&#;Q,B$AY?,D.P'NV"
M./>JVL74DT4.J:59^)K#6#IZ1VTD-@[1W+*6Q#/&RD* V>6V\/D-B@#L/&FL
M7&B>#=1U6R=%F@C5T=@"O+ 9_(TEKXTT2ZDO$,\UN;2W-U(;JWDA!@'_ "U7
M>!N7CJ*K>.[2\U'X>:C;1VS37<L* PPJ7);<I( '7O6'X\T'4M9UF[2QMI7$
MGA^XB1U&%:3SHF$>[H&8*<9H Z)/'&AM87]Y)+<V\=C"+B=+FTDB<1'.'"LH
M+*<'D#M2GQKH_P!CCN4^VR":9H;>..RE:2X*C<6C0+EDP<[Q\OO7#:KI1U7P
MWXDN+&#Q1>7K:0ULAU.$J6+-N,:(55F8%1R 1SP:WO%FFS)JWA[4=VK0V5K;
M3VTS:5&7EB+^65.Q58E?W9!P.#CM0!L3>)K*YOO#C6>L+'!J<DHCA-JSFYVJ
M25W''E%2#G(ZC%)'X]T"6YBA2>X*R7)L_/\ LDODK-O*>6TFW:&+#@$]QZBN
M470IXM7\!S66GZJ+:*^OKFX:\7=)%YBL=TFT87<3G!QUQUJ8:1J ^'"VHL+@
M7/\ PD'GF+RCOV?VCOWXZXV?-GTYH ]+HJI97WVR2[3[+<P?9IS#NGCVB7 !
MW)ZKSC/J#5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***P=>N_$-DS3Z;#HQL8H3)-+?W,D;
M(1DDX5&&T  YSZT ;U%9/AC4KW6/#=CJ.HVB6ES<IYAA1B0JDG:>0#RNTX(X
MSBM:@ HHHH **** "BBN.D\1^(K^[U8Z%I>GSVVF3M;O'<W+)-.ZJ&8* I"_
M>P,GGV% '8T51M-5M[J<VI)BO4MX[B:V?[\2OG&<<=58<'M6?<^,_#UG8V=Y
M-J<8@O(S+ RJS%T'5L $A1D9)&!F@#>HK$U'Q?X?TI+=[S5(46XB\Z(IEP8_
M[_R@X3G[QX]Z=?\ BS0=+N(8+S4X8WE19%QEE",<*S, 0JD]"2 : -FBLBX\
M4Z):ZPNE3:A&EZS*GED' 9ONJ6QM#'(P"<G(]:+;Q3HEYJ[:7!J$;WBLZ; "
M S)]Y5;&UB.<@$D8- &O16)I_B_0-5U!;&RU**:X?=Y8"L%EV_>V,1A\=]I-
M1)XX\-2)<.FK0LENF^5@&PGS[,9Q][=P%ZG(XYH Z"BJ.E:Q8:W:&YTZX6>)
M7,;<%2C#JK*0"#R.".XIFL/K*6R'1(+"6??\XO9GC4+@]"JL<YQVH T:*XKP
MKXB\5>()))IM.T:&RM[V6TG*7<K29C8JQ4&/!&1QDBI/"OC[3M:L--COKRWB
MU6[W+Y,:L$W@G"ACD;MHSMSF@#L:*YNU\4V4-IJEUJ6JV3PVNI26:FWB<%",
M8B8'):09YVC!["MG3=3L]7L4O;"X6>W<D!USU!P00>00000>10!;HKC?&?CF
M3PO>VUO:Z?\ ;2D)O;_#D&WM5=59P,<G+' _V371:CK>FZ5IR:A>WD<5JY54
MDY;>6^Z% R6)[ 9H T**PD\9>'7M);H:M!Y$4L<,CG("._W5;(X/UZ=\4R7Q
MOX<@LK:[DU-5AN59XCY;Y**<,Q&,JH/\1 'O0!T%%8VI>*]"TB2%+[4H8C-'
MYJXRP$?3>2H(5?\ :.![TFJ>+M!T:=X+_48XIDC69HPK.P1MV&PH/'RMSVQS
M0!M45BV?BW0=0U*/3[34X9KF1"\:IG;( ,G:V-K$ \@$D4NG^+-"U2>:"RU&
M*:2)&D8 , R*<%E)&'4'C*Y% &S16!:>-O#E]<1P6NJ12R21&:/:K8D4+N.T
MXPQ Y('(]*=X5\56/BW3'OK$.JI*\95U((VNR@Y('4+GCIG% &[161!XIT2Y
MUAM)AU"-[T,R>7@X++]Y0V-I88.0#D8/I6+X2\?:=KNFZ4EY>6\>K7L6XP1J
MP3?@DJK'(S@9VYS0!V-%8]IXJT2_U9M,M=0CDO%+KL 8!BG#!6(VL1W )Q7&
M)\0]6;PI:ZH;>S\^7Q -+9=C;?*\TID?-G=@=>GM0!Z716%XOUN7P[X;EU.$
M0[HYH$/G9VA7F1&)Y'0,34EAXLT+4H[R2UU*(K9IYEP7!C\M,$[SN ^7 /S=
M..M &S169I'B'2M>$ITV[68PX\Q2C(R@\J=K '!P<'H<<5BW?C>STGQ7J>FZ
MM<0V]K;6MO-"PC=I&+F3>2%S\HV+S@8SR>10!UM%8DFMQOKVD6UMJ-B;>^@D
MF2(JS23J "&C8';M&<G.<Y&*CL_&OAS4+VVM+758I9KGB$!6VN<9VAL8W8YV
MYS[4 ;]%<=KGC[3K-HK;3+NWGO?[1M[.1'1BOSS*D@5N 64,> 3@CD5HP^)+
M:"XUM[_4['[-I\\<;"-'5H-P&!(22"22,$8&#0!T%%8MEXMT'4!>&VU.$BSC
M\Z<OE D?/S_,!E>#\PR/>C2_%FA:S=1VUAJ"37$B-(L6UE8HNW+88 X^9<'O
MGC- &U159K^U74H].:91=R0M.D7<HI"EOP+*/QK-N/%^@6D4<LVIQ*LDDL4?
MRL2[QMM=0 ,DAN,#KVH VZ*QO^$LT'^Q5U@:E";%I/*63!R9,XV!<;MV?X<9
M]J1/%V@/I?\ :7]IPK:"86[2/E=DA_A8$ J>1U ZT ;5%9FD>(-+UX3_ -FW
M8F:W8+*A1D9"1D95@#@CH>]17_BK1-+U)-/O=0CBN6V_(58A-QPNY@,+D]-Q
M&: -BBL+4O&7A_1[F:WO]3CBF@QYJ;&8Q@@-EL X7!')X&>M.U3Q9HNE2I;W
M&H1+<20^<B@%ALZ!V(&%4GN2!0!MT5D>%=5GUSPEI.JW*1I/>6D<\BQ@A0S*
M"<9)..?6L[3/&&G+X<T_4-4UBPD:[,@CGM8W6.8HQ!"*V6R,8QW/2@#J**R+
M3Q1HM]:VUS;7\;Q7-R;2(X8$S $E"",AL*3@@=*?=^)-'L&N1=W\4/V62**<
MOD"-I,; 3[Y% &I17/R^-_#D-C;7DFIJ(+E7>(^6Y+*IPS%<9"@_Q$ >]:MW
MJ5I9Z7)J4LH-I''YID0%@5QG(QU_"@"W17+Z=X]T.]\-6&M37!MH[P*$A9&:
M3S"H8HJ@9<@'JH(K=TW4[+5[%+W3[E+BW?(5T/<'!!]"",$'D4 6Z*X*\^)5
MF^FZE/INP2:?J4%G(;A&"&-Y8D=\\8QO;O\ PY/%=%:>+M OK>^N(-3B\JQ4
M/<F0-'Y2D$AB& X.#@]#CB@#;HK.TG7=-UR*633KH3>4P612C(R$C(RK $9'
M(XYK!E\=V&F>)=:T[6+J"V@L_(,+!'9BK)N=FQG"@XYP ,\T =?16-J7BO0M
M(:%;[4HHS-'YJ$ N/+_ODJ#M3_:.![TS4O&&@:1-)#>ZE''+$BR.BJSL$;)#
M84'Y>#ST'>@#<HK%U#Q;H.EI;/=ZE"B7,7G1,H+@Q\?O#M!PG(^8X'O7.^*/
M'KZ;XMTG0-.FM$:Z1Y;BXN()9510%*A0A&2V[KG H [RBN,N?'MGI&G7%W?W
MEM> :N=/C%G%(OE_.JE7SG+J&)..#C KJGO[2+3CJ$LZ16BQ><TTAVJJ8SDY
MZ<>M %FBL&#QGH%U:W5Q;W^\6L8EE0Q.KA#P&"E0Q4GN!BLOX<^++SQCH;ZG
M>-:*7(*6]O#(IA&6 #.QPY( Y4 4 =E17':-X_TVXGN;35+RWM[Q=3N+*)%5
MMN$F:.,,W(#,%'4C)Z"M:_\ %^@:9J+6%YJ445PA42 ABL1;[N]@-J9[;B*
M-NBN.U;Q]9VEYX@TRT&[4-+TYKM?,1BCN$D;:>!P @.<\[N.E:.A>+])UMH+
M2&^B?4&MQ,\2JP!X&[:2,, 3@X)QWH Z"BLO5?$>DZ)+%%J-ZD$LR,\495F:
M0*0#M !)(W#@<\U _B[04TBWU7^THVL[ES'"Z*SF1AG*A0"Q(P<C&1@YH VZ
M*P[GQAX>M-/M+^?58%M;M6:WDY(D"]0,#.><8ZYXZUG)X]TN]O=:T^TN%BGT
MZU\\3SQ/Y?W&8EA@'"X!/.3GB@#K:*Y[_A+=*L-&TR[U34[<O>6ZS*]O&Y64
M;06=5Y8)R#D],C)J?4/%N@Z68!>:G#&)XA,C#+KY9Z.2H(5?]HX'O0!M457O
M+ZUT^QEO;R>.&UA3?)*YPJKZUFP>+="N--N-1348Q:VTBQSM(K(8F8@*&5@"
M,[AC([T ;5%8MEXNT"_2\>WU.$K91^;<%P4"1\_/\P&5X/S#CCK6;8^-;75_
M%UEI>F313VDUC/<R,T;I(K(\07AL?*0[<XYQP: .LHKG]3\7Z=I7BG3= G+_
M &F^1G5@C$+@J%!P.Y/X8YK.\,>/M.U:SL8M0O+>'5+F62(0HC!-P=@J[CD!
MBJ@[2<G/2@#L:*R(O%&B3ZR=)BU"-KT.T?E@'!=1ED#8VE@.J@Y&#Q5*S\5V
M,-A>7FJ:OIYABU&2S66%'18R#Q&^XGYQSD\"@#I**K:??VVJ6,5[9R&2WF&Y
M'*E<C..A -6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@O;VUTZSEO+VX
MBMK:(9DEE<*JCU)/2@">N7\<QRWFFZ?I*1N\6I:C#;7.T$X@R7DSZ JA7_@5
M=.K*ZAE(*L,@CH12T 5)]0@M;^SLG27S+K>(RD9*C:N3N(X7CIGK5NBB@ HH
MHH **** "O,/$4GAJ;5-2FO+36-&\11,T<,^GI,);H ?NW4QC9(#P,-G'0XK
MT^L5O#-JS$F^U?DYXU.<?^ST <?IFIWFC>)!=>(H+@7^H:!9)B*W9_-N4,OF
M1C:" V7''OZ5F>$;E?"ZZ)J&M6]S%:3^'(;6-Q;O)LE21V>,A02"P92,]=OM
M7H?_  C%I_S_ &L?^#2?_P"+H_X1BT_Y_M8_\&D__P 70!QUKJ5GX?UV\O\
M4=&N;*PU+2+5;.T6S+[-GF[K?:@(5OG4[>^?8UF:E;"#4M9BO9]6T:RU6QME
M@TZSL(Y?-3R?+: ?NV =3D;00!N!]Z]$_P"$8M/^?[6/_!I/_P#%T?\ ",6G
M_/\ :Q_X-)__ (N@#B[N0:+KQ@TFYOVO);JU6YTJ\LO-BO,")#.C@?(0B@EM
MV 8^14(:8ZE+H^@W-Y)'=27BRZ=?6>&T]V24^:DN!A2Y  );(DX-=U_PC%I_
MS_:Q_P"#2?\ ^+J"?0],M6A6XU74XFGD\J(/JTXWO@G:/GY. 3CV- ''Z?<Q
MZK9>!='L;2YBO]*GADO8WMW3[(L<#HX8D8Y8A1SSG/2GZ)86L'PI":E#?VR_
MVE-,TUI$3- XNV*38P20N%)X/ Z8KM/^$8M/^?[6/_!I/_\ %T?\(Q:?\_VL
M?^#2?_XN@#&\+:_,+2<W\DE['+J*VMKJ$=B83= QJ=[J!Q@ADWX .T5V=4M/
MTR+3ED$4]W+OP3]IN7FQCTWDX_"KM '(?#N"6#2=76:)XRVM7S@.I&5,S$'G
ML:YO3;":+X>^"XA:R+)'K,$CIY9!7]ZY+$=NO7WKU.JT6H6<]]/9174+W=N%
M::%7!>,-RI8=1G'% 'E>F6L,&G>)9=2;4M/V^,+FXMKZV@W&W;8 LI!!RAR5
MS@CYNW4=WX,O;N\T!Y[[:Q%Q*$N5MS!]IC#<2E#T+?KC(X-=%10!YAH>B^(?
M$<^M>)%OK6QAUIC EK>Z<TKBUCW(@/[Q=NX%F(Q_%6?I[:AH]IH%EK$5Q/'X
M6U=K>>=(&8/;M!(L$X49X&]0<9QBO69[NVM7@2>>.)IY/*B#L 9'P3M'J< G
M'L:JZQI*:S9I UW=VCQR++'/:2;'1ATZ@@CD\$$'TH \HU 1ZS>^)'MK&8P3
M^(-)8H\)4NG[O<Y4C(!&3R.AS70>*5DL/'-Q?7.K:AIME=:7'!%+:V:7 D9'
MD+1G=&^"0ZD 8SSUQ79:'H-OH<=R8Y[BZN;N7SKFZN6#22M@*,X        &
M*U: /'I--&@W,UM<ZKK=A87.C6EO;JEC'/)<*B.K0MF-L2#</E!'W_:NBTO2
MS9^+-1C$,[QQ>&[2VCEG3YFP9@02.-W"Y KMI=0LX+VWLIKJ&.ZN0Q@A9P'E
MVC+;1U.!UJS0!Y-#I5Y)X3^'-K;V\D5P+65&.PKY3-8RC+?W?F(Z]Z7PS;)=
M1:7')J>LW%[IFF2H;.6Q2*.T)B"-&S"-23G&!DYVY]Z]8HH \VTZREB\/_"]
M%MG1H'B,H"$&/-G+G=Z<GG/<UJ_#"95\)#3G66.\LKFX6XBDC9"A:>1AU&#D
M$'C-=I10!YQIMU]C\76]CI,]Y+;RZA.]UI5[9<V9/F,TT<N/E4MT!+ B3C'2
MJFE6$T7P_P#A_$+61)(M3@>1/+(*<29)';KS]:]2HH \@TN_NKG6O"MW=SWV
M^'491>626"Q6U@[Q3*J9$88DLV,EB#G)QD5G1Z?>_P#"O["+[)/Y@\8"4IY9
MR$\\G=C'3'>O<** .1^)D+S^ [R..UDNB;BU)@C7<S@7$9( ^@-<IXI63Q;J
M.LW6A174L,&ABWE<6[*9)//63RU#@;F"(_&#]X ]:]9JO?7]GI=G)>7]U#:V
MT>-\TSA%7) &2>.20/QH Y'PBMM?>(;O5(M9U35)%M$MVFNK-((P-Q8(-J(2
MPYSP<;O>JUQJEGH/Q(UZ]U."=;>73;5(YUMWD5B&E)CRH/)R..^*[^B@#R/P
MYI.H6&O_  XCNK6:-K?2KL2@H?W)8*55CV('&/:K.EV$T7P]\"1"UD22+5H)
M)$\L@I\TF21VZ\GWKTU[NVCNXK1YXUN)E9HXBP#.%QN('<#<,_45-0!XW%<+
M'X.T3PX]E=-J]CKL#7,?V9_W0%WN,I;&-K Y!!YW?7#M2T^YEM_B2AM)G6XU
M&S*+Y9/F+F/./4=:]9N=0L[*2WCNKJ&%[F3RH%D<*9'QG:N>IXZ46VH6=Y+<
M16UU#-);2>7.L;AC&^,[6 Z'':@#SKXA:7>ZAJ^JI9VDLS-X=90L:$^9MN%8
MH/4E0V![U=MM7L=:^*FC75A#-Y8T>Z4S20-%N_>0G8 P!.W/T^;'7-=U>VD5
M_8SV<Q<13QM&YC<HP!&.&'(/N*R-(\+0Z7J1U&;4M0U*\$'V:.6]D5C%%D$J
MH55') R3DG YH R=>O8M%^(FDZI?+,EB^F7-KYR0O(!*9(653M!P2%;'KBN.
MTN\CTW5?"M]J-I<0(-0UJ5@\+%X0TIPQ4 G&&QGMG/3FO9:SKS2+:ZUG3]6E
MDD6;3UE6, @*1( &W<?[(QR* /-+99(M3@\4/;7']B?\))<77^H;*QO;>2L^
MS&=OF G..C9I][ ^L:G?:M;6LSZ;>>(=*\DM"R^:(BHDDVD9V]!G&#MKU.UN
MK>^M8KJUFCGMY5#QRQL&5U/0@CJ*FH Y;3(9$^)7B&4QNL4EA9 /MP&(:?//
M<C(KC/'ES?73^*[$37T,JQQ_9K*RL5;[9&(U9I9)#&20#O7AEQLP.2*]6NKN
MVL;=KB[GC@A4@&21@J@D@#D^I('XT^::*V@DGGD6.*-2[NYP%4#))/88H X%
M8?M5W\0;N*!WCO+.'R7\LCS5^RG &1SUZ>]9.B72:#-?)JMI=,^IZ)8+:(MN
M[^>4A9&B& <,&/0X^]FO4K:Y@O;6*ZM9DFMYD#QRQL&5U(R"".H-2T <YX B
MDA^'GAZ*5&CD33X59'&"I"#@BN \ Z?<QZ'\-EN+.56@N-1:021D>7D38)ST
MZC'UKU-];TN-59]1M5#7/V,$RJ,SYQY?^_[=:OT >4WB26%[=:A-;SK:6OC)
M;F9UB9ML1M0F_ &2NYADCWJIK0;7)?$=Q#97,EI<ZQI)C\R!E\V-3&&8 C.W
M@\^G/2O8:* /.O%2RV'CJ2_N-6O],LKG2XX(Y;6S2X$CI)(6C(:-\$AU( QG
M!ZXKIM-TT67@*WTVV6Z81Z<(HDN0!+CR\!6 X#=!BM^B@#R3PYJ$%E;>!]6N
MDN!8Z?I4NFW3M;R?Z+<E(3\PQD A&7=C&>,\UU_@2.0VVMWYAEBMM0U::ZM5
ME0HQB*HN[:>1N*LW/KGO72W5[:62JUW=0P*QPIED" GVS3+;4K&]=DM+VVG9
M1DK%*K$#UX- 'E=VN_3O%.D26\S73^*(+KR3 Q#0-/;_ #@XP1@'\C5[QWIM
M]>>(=9>TBN,#2["1F@BWLPCO'=PH((9@H)VX.>!CFO4** .-\');W.L:GJD.
MK:EJCR0PP/<W5JD$;;2[ )M1-Q&\Y..X&?3)NM3L]%\7^-9-0M;C9>6ULD#K
M;/()R(6!C!4'G+#COGV-=_>:A9Z>D3WEU#;K+*L,9E<*'=ONJ,]2>PJS0!XO
M:Z=>:#'%!K.IZIIRW&@65L%M;)+CSVC1U>'YHWPP+# &,[O;CJO#VE?8?$&N
M1>3<-''HEA;QR7"?.P5)@02."W3('>N^HH \4TJ"XTNSTZ74=2U33+>Z\.64
M"?9[%9S*R!]\)#1L0WS@@<9W'KCCI8],DL?'?@6&&*[:VM-'N(3).GS+A(P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKEO'6JZII>GZ6-(GCAN;S5+>SWR1AU"R$@Y'Y'C'2NIK+UO0X=<6P6:62/['
M>Q7J;,?,T9R <]C0!Q&L^(=:L=6NM'CUB_,^G64<@FM]':Y-W.^\@2>6A"(
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MM!(%.#M92IQ^!KF(O C?:(+BZUZ^N9HK.6PRZ1JK0.JC;M"@ @J&W=2>O&
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MA@DGV *V-Q;;@$G/WCC&*Z:T\#65IJ6AWPN[F2;23=."^W]^]P29&; &.22
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M*!G,C$;OF.0-I&!CK6J_@"RET>UL9KZZDDBU1=6EN3MWSSAMQW # !X& !@
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M:4MS.8M'N([B)SC<Y0, &XZ?,>E '/+XKUD^&VTLSI_PE"ZN-(\WREQG=O\
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M%6*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@:/S'*/\GS 8;D9!Y'>H]6O)=.\$>&_%MK8W2WFA)'!-;7$#0R21NBQ2)M8
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MZ1!KB:*9I9-0;RCY4,#R860D*Y*@@+P<L3@<9ZBCQ%JBZ8VD!M26Q^U:C%;
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M, 1R.AY'&<5G7<UQH6J^+X9]*U"[;5RLUDUM:O,LV8%C\MF4$(0RG[Q P<T
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MK1+;NJ,3(TI 0!0,Y)(XQQSGI4VKZY9:)%"UV9V>=_+AAMX'FDD;!)"H@).
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M7>OH_P 2T6RG:2]\S[,!$<S_ .AQJ-G'S?,"..^10!TNH>,-%TR_-I<W$NY
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MV?G.Q3\HVG)[<>HKSWQ-HLFH_#_Q7+I5OXCO[J\^R1*VH0$23B.4-\D>Q7P
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M 6W$J.>.V>N.9&\437%KX:O+>?2]1MM0U4VWGQ1-@+MD*LH+'8X"8(.>2>E
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M[0,YR,FFGQ7KUE9'6;W2TDT8:;)>R/'M1H75-ZJ#YC;PPR,[1@C/0X !W!(
MR3@5%;75O>VZ7%K/%/ _*R1.&5OH1P:P-*O_ !#<:PL.H:?$=+FM?,^T*%0Q
MRY'R8\QMRD'(.!T]^*NI30^ M!LTL;40Z<;EOM4T5J9$M58,Y?RTQA=V!QT!
M[T ==15#1;TZCHUK>-<6MSYJ;A-:_P"J<9X*\GC';-7Z "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[0AX!UD7<.5'?N,CBI]&\3V.MW+VT,5W;SK$LZQ7=NT3/$3@.H/49_$=P,T
M2ZIH%OJ=_8ZAYT]K?61;R;B KN"L,,A# @J<#@CJ 1BJ=UX/L+G2DT_[1=1(
M+P7TDL;)OEG#B3<Q*D?> .  . .G%+JOC'2M'OY+6Y%VWD*CW,T5NSQVRN<*
M9&' SC\!R>*?+XMTV+6&TTI>,4G2VDN$MF:".5P"J,X& 3N7V&X9- &XH*J
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MA3J" "3GC'.>147A'Q!-K]]XA+,YM[2_6"!)(O+>-?)C9E8$ Y#LW6@#1O-
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MTOFRHBJ\F,;V Y..V:Y+4=5\177CBZT32;[3+.WM["&Y+W5H\S.SO(I Q(N
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MWKNW'&/K3;;QCI5UJJ6,?VD"29[>&Z:!A!+*F=R*_0D;6]CM.,XH O:CI/\
M:$\<HOKFW*121,D6PK(K[<[E=6!^Z,?4^M9?_"$Z=%-I[V5S>V0L[+^SPD$@
MQ+ ,81BP)X(SE2#R>:FT_P 8Z5J6I1V<'VD>>SK;7$D#+#<,F=PC<\-C!/N
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M- &OH^DVNAZ7#IUDI6"(L1G&268LQXXY))X '/%7JJZ;J-OJVGPWMJ7\F4'
MD0HP()!!4\@@@@@^E6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?QG:7;G0]2M;66[&F:BMS-!
M",NT9C>,E1W(W@X]CBNHHH \JUS3M6UD:_K5IHUYMN;G2TMK6:/RY9E@FWNY
M4_='S$?-CA2>E6=<M=0\23>)]1M=*OX8CX<ETZ%+F$QR3S,7;"J>2!P,]"6X
MS7HMY>6^GV4]Y=S)#;0(9)9'. J@9)-0:1K%EKFGI?:?(\ELY^5WB>/=[@,
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M_P!Y7Y(R 5P3WJKX<T#5+/5O#-U=64D7SZI<SIP1;>?(KHC$<9P<?4&O2**
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M\ 98$9 X<G(XP>V3P>.*DMO'&ESW<D$D%[;H+1[V&:>#"7$"8W/'@DG&0<$
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M9Q>++.;6&T^.SOVC6X-J;Q8,P"8#)3=G/MG&,\9K<EEC@A>:5U2.-2SLQP%
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M-#836LSQO"'\_%M%E2<_*",].<UZ#XAO9M/\/WEU;W%K;S1QY26ZSY:DD#)
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MU6NU)&P.@D$;'IQD=.<"]?\ BJ<,MW83B:QO;RWL+1E5""[J7>12< \84 G
M8'.>E ':45P&IZOXLTJWC266V3S=8M;:WDFC5I'@E<*0ZH0H(.X9'4>AKI;N
M]NO#GA&]U#4;@:C<6-M-</(D0B\T*&8#:"<< #]: -JLZ37=,BU.+3I+Q%NI
M7,:*0<,X7=LW8QNV\[<YQSBN<36]5M+_ ,,&>Z2ZM]=1HY L07R)?*,JM'CJ
MF%8$-D]#GKD^']O+Y6N/<7+W&W6[P*'1>&$A&[@=<?A0!VE9DOB+1X1J)DU&
M!1IH!O"6XAR,C=^ Z5R^N^)=4T_4Y7M[F.:&+5;2S,,,89$CE,:L)6(!$F7)
M 4G VY'-4-8^]\5/^P8G_I*] 'H\,J3PQS1,&CD4,K#N",@T^J.B?\@'3O\
MKUB_]!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *S==T.R\1Z5+IFHB1[24@R)'(4W8((Y'/4
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M5?J\MM*JAOG*ME2"#N'(((!SZBLC2_&D&IWEDG]FWEO9ZCO&GWDNS9<[06X
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ML(H4:1]JEC@#)P!R3QT'-+!,ES;QSQ[O+D0.NY2IP1D9!Y'T- ''ZQI6K?\
M"=3ZA;:>US9WFBFP,J2HODR!W8%@Q!((8#C-5QX7U&70_ ME+#M.FQ".^PZ_
MNO\ 0WB..?F^9@.,UWE% 'G7@WPK)I5YI4=UX8\BXTV$H^I/?;TD<)L#1(&)
M^8$D[E7 ..:U/&FF:A=:QX=U"RT8:M%83SO/;>9&F0\10']X0#R0?PKL"0"
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M=#;2[.VFFC9Y7/F,6)5BJC+*!D^I.*[J[L;6_C2.[@29$E29589PZ,&5OJ"
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M$C(!'>L>Z\&ZY+H.K:?;:&ELMQK5KJ$$:7*%5B C#*26SN7RR3V.>":]<HH
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M]J%V]O'/&KM#/YH1@68+_&"1G-(WA'6BOB4?9!_IOB*UOH/WJ_-"DD3,W7C
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M"V31Y;5X3*C&*0S1E5^4D'Y4)R..U=92$@$ D#/ ]Z //[/POJ\7A'PW8/;
M7-EK0NYT\Q?EB\^1\YS@\,#@<\UBZ#::SKG@>PT.+2B+-]5:=]0\Y BQ1WC2
MD;<[]^5V@ 8Y!SVKUNJ]C96NGVHM;*%(8$9B$3H"S%F_,DG\: /.YO!VMO/X
MHNH[>/SI=:M=3L%>50LXAV$J2,[<[2.>^*W;#3+[6O%5WK&K:4UA:'3?[.2U
MN)8Y'E#/N=FV,RA>  ,Y//2NOJAK:Z>^B7G]JP^=8+$6G38SY4<GY5Y/3H*
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MSGVZ  [/4DF30+I%NI5F6V;%P@4/N"_>Z8!_"N&\+ZG>C3O!6A?;[A!?Z/\
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MY2(KHC'RMHDP^3A.0N>];^C66HW.C&S\17%O=W$4[!FMVX= =R"3"J-V"N0
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M&MP16<.X:XFMV,[3@),5:,^4PZJ<*PSC'2@#J]'\127^JW.DW^FRZ=J,$*7
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MY/+5[= D)D!^B.P]<#UH [NBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJH&  !T%244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8(+)\K 'D<5)X:\:1Z@FC6=Y9:A!-?VH>WN[B-1'=,J!GVX8D'&6&Y5R!D4
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MC:S2_D:SC4B&!L[7;<R]<-A1EOE/%%]XXLK:]^QV=AJ&ISFQ34%6SC0AH&+
M,"S*/X>G4Y&,\X .GHKE=,\>Z;JEWID<-GJ$=KJBL;.]EB58I65"Y7[VX' ;
MJH!P<$U)IWC>QU&Y@1;*_AM[M)'LKJ:-1%=A!D[,,6'R@L-P7(&10!TU%<EI
MOQ L=4?2VCTS5(K755_T.ZFB18Y7V%]GW]P;"MR0 2#@GK4_@OQ/<^*;&\N+
MC3)K(0W<T*%PN'59&4#AF.X!1NZ#)XR* .FHKGT\602ZR]A%INHR0QW/V1[Y
M(E,"RXSM/S;^X&[;MSWKGO"GCMWTC3%U6UU&4W5Y):?VD8D$/FF5U1#\P;H
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MXT(\EPQ# LRC^'IU.> ><5[7QRVH>+M-TRQTVXGT^^TP7ZW0"CY69-K<N"%
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M*Z"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-G)Z]34/_" ^'5$)BM;B%X%=()(;V9'A5VW,$8/E1D=!QC(Z$T <!+=7,_\
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M)UAT>>53+J$SDL)X_O$MR#GD'@X&1P*U=;C?6?'UAH5S<W4.G+ILMXT=M</
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M;IH79'D8["5[YP#@\5U/@ZVU>SU/4HKFQO;33&CB>WAO;\74B2?,),-O9@I
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M(;>3SK?2[XV\\4A(VR@!E\S !&TGKV-5M%U=[N\\330ZG<7%FFE64]M+*Y&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%2P'S 8&?8XW]<UJ#0=.^USQRS,TB0PP0@%YI'8*J+D@9)/<@#K7(KX9U8>
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M?RH(*@=3DU>T'1M2MO%<-W#H<NBPD2G41'>*]K=,?NF.,,<'=\VXJAQD'.:
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MI39-.(RQ!&[>,[6P2,''I@U);>%=2C^(-S<M BZ)#YUW:$.,_:)8HXV7;U
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M(R7'7=SQCBJ>BVVLW7CJ]UR_TIM/M)=-AM84DFC>3<LCL=VPD _-V)&,<YR
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ML[:.V>-Y$?=L15W H2,'!QW]JWJ "BBB@ HHHH **** "BBB@ HHHH ****
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M%O,*O&%4EI/D/)P,*HSR:H#2+'6?B;X:N+^ S27GA]KB=O,8;Y!Y8!X/'X4
M=]I/BBTUO6-1T^RM;QDT^5H)KMHP(?-7&Z,'.XD;O3''6MRO"]/TZ/3M%\2/
MIML1++XM;36Q<O%FW:6/,>_G:&.%+8S\U;=Q::EIL7]EW$<6G:5?ZQ90/9VV
MH-,84<-YB[L*45RL8P/[S>M 'J5W>VUC$DEU,L2/*D*EN[NP51]22!4]>5>+
MO#VA6MM9:?:W$DT:^(+$2637!9;42,H*J.JAA\V">IR,57O;+5[_ %3Q#-96
MD"W&G7T=O97L^J-#]C1(XF11'M(*MN).3\V\@]* /1_$]QIUIX8U*ZU>V-SI
M\,#2SPJH8NJ\D $C/3UK55@Z*PZ$9KQSQ)96NI^#_B#K&H2R_P!H6UU<6L,G
MG,/*C54"1@9QM8'D8YWUZX8([K3S;S+NBEBV.N2,@C!'% %"3Q+IRMI7E2-.
MFJ7#6UO)$ 5W*KL<Y(X_=L.,\UKUXIX>T:SF\&_#V$+)&MYJ<C3E)6!?$-P"
M,YR 0,'&.,U9ODN+#4;[PYIT+2Z:WB*&$6CW;1(4:S\TQ^9R54R ''?IWH ]
MBHKR*_TW4(;+2M+NY!9VLWB>.*.VM+]IF@A:!B\)DPI )W$#L&&.@J36-*N[
MG7M<TVQL(VM]+LH([&675'MOL(*,WFJ-IR=P.6)_@QTS0!Z3::Q;WFKZCID:
MR">P\KS2P&T^8NX;3GG@<]*T*\KAT6SUKQ)XM;6YBUQ!86;GR9V18W,#9E7:
M1SD<'MCCJ:;8^(+CP[;^'O%.KS2M9ZMH:QWI=CC[3%%YJ/\ [SKY@]SB@#U:
MBN>\&65QIWAFSCU*4MJ=T&N[D.V3YDAWL!GLNX+^ J'QQ)&VF6-@UO/<R7U[
M'!%;QW'D+*P#.5D?!(3"$G R<8[T =/17CL'VB;24TN21K6*'Q>EGY-I>/((
MHS$&:-9"%;&6;L,9XZ"I-4@72]6UCP_9RS6^D3ZKI44D23, B3$B0*<Y4/M4
M'![GUH ].BUBWEU^YT95D^TV]M'<NQ V%79U&#G.<H>WI6A7">'-.LM*^)^O
M6E@2L":99_NMY81$O,=HR>!WQ_M4SQE'>:EXRTO2ETZ/4+3[#/<?99;UK9'D
M#QKN)"G<5#<#MNSVH [ZBO)I;>YO+#3M*U&W35+VQTV:>5I-7:.VBB,K*CF1
M4+22A4QNQQACU-2>'XU\7W.CVOB"::>%/#-K=HIF9-\KEA)*2",L-J\]MWO0
M!Z+'K%O+X@N-&59/M,%M'<LQ V%'9U !SG.4/;TK0KS*QT+2=?\ &LL$][/J
MM@GA^S$<S7!_?_O)@)&9,;FP.ON3UKI_AY=3WOP]T*XNI7FF:T3=(YRS8XR3
MW/'6@#IJ*\:OK2$^%/&6OBZN#JVFZS<_8Y1</F K*"J*N<8.>1CG=CTK3O[2
M#5K/QWJVI33)J&ES2I9R+.R&S2.W1XR@!XRQ+9[YH ]2K-DUJ V27=E#/J$;
M7!MS]D4,58.48G)'"LIR?;O7"Z+8CQ)X[N9=8,S^3I&G7/V?S61%F82$L5!'
M(P1^-<S#:Q:9\+-*GLM\$L_B0)*R2-EE6\D4#KZ<>] 'N5%>6ZA9V^JV?CS5
M]1GF34-+FECLY5G9#:)' CQE #QEB6)[YIMOIZ^)=1\12ZR9W>/2+*981*R+
M%*T+EF !'S9 P>WXT >J45B^#[F:]\$Z#=7,C23S:=;R2.QR68QJ23[DUY_H
M<[?\)5X8U2TM7M[?6+FY/VB?46EN+R(Q2./,BVA54$(1@G;P,<F@#UJL_6-8
MM]$M(KFZ61DDN(;8", G=(X1>I'&6&?:O+M"L4M/#'@?7$FN6U.XU&*&:X>=
MR7B?S%,9!.-N .,=L]<U ;*UNO!.C>(+F:4ZO>:_!Y\C3-F0_;,>65SC"A>!
MCC90![117.^/I'B^'OB*2-V1UTZ<JRG!!V'D&N4DLH-$USP_)ID\[-JFF79O
M6:=G^T!8E=96R3SN/4?WL4 >FT5X_IFGQP^ O!I:>Z)UZYLXM3G:X?=+'Y3L
ML><_*"0J\8R#CO5C5M.GL+OQ38Z"TRQ:1'9:M:VZRL5CF4R,\8R>CH@^7I\W
MO0!ZC>7!M+*:X$$UP8D+B&$ N^!T4$@$GZT^WE,]M%,8I(C(@;RY!ADR,X('
M<5Y9K>IGQ)I_C#Q#97$G]G6&AM:V;(Q :5XO.D?Z@&-<_6F7UI*^C:=K-U ^
MJ6-OH5L9H[>_,-U8$*S-.BYPQ8>I!_=\9Y% 'I\-ZTVHW5H;.ZC6 (1<.H$4
MNX9PASDX[Y _&K=>/:SK%Y;ZO\1[FRO)T"6&G&*0,08E=2&=?[IVDG/M6EK]
MA;>&=5^R:&TL,%YH6H/=1"9G!,:IY<IR3\V68;N^: /3Z*\STC3XM*UGP+=6
MTEQ]HU*TD6]D>9F-Q_HX<%@3CAAQZ=!Q6_X\9Y(="L&EDCL[_5HK:[,;E"T9
M5VV9'(#,JJ?7..] '2:A?6^EZ;=:A=OLMK6)YI6QG"*"2<?055T#6D\0:3%J
M,5E>6D,P#1+=HJLZ$ AP QX(/?GVKSC7]-M+:P^(.BP*YTRTT=+R& RL5MYS
M'-D+SP"$1MO3VYKN/ FGVNG^"='6UB\L36<,S_,3ES&N3R?:@"WJ?B73M+L;
MV[DD:9;*>.WN$A +(\A0*.2!TD4]>AK2N9C;VLTXBDF,:,XCB +O@9PH..3T
M%>-7^D6<.A^/Y8$:*8Z[! )%<DJI>V;C)QU.:V]8L8?#^K>)K/3&F@MY?#$M
MRZ><[9F4NHDRQ)W8/)[XH ])M)S=6<-P8)8#*BN8I@ Z9&=K $@$=^:FKR$6
M5Q>>%?#VIS0-J]K;^'X#<6L=^8;FV)7=]H3G#,0".2#\G!ZUZK8W,-QIEM=1
M2,T$D*R+))P2I4$$^^* ,_4O%6CZ1KFGZ/>W7EWM^<0($)'7 W$<+D\#/4UL
MUXJZZIXQLO$FKP>&]2NCJKJFD7L,MNJPQ0-^Y8!Y%89D!<\<YK=CU:+QQ>>#
M(K\.MK=6]W)>6@=D#74(12C8()VDR$ ^@- 'IM%>++!]IBM]-34;N2U;QK+:
M%Q<,7,(MV!CWYSC VYSGOG/-7M8TN]NM;\06%A8Q>5I5M!#I]Q+JCV_V >5N
M$BC:<_-G+$\A,'@4 >MT5Y!J$&O:QJ7B*<6UL=0L)(8[:^DU1H%LB((W!5-I
M!4LS$DD;@<=!4_B#3H]0G^(]W=27!FTZUCFLPD[J+>46@?>H!'.0.?;W.0#U
MBBO'O$/VCPREOJ&DSW"WM[X;O9[F5I68RRHL+"4@G&X;V.0..G3BIKK3=2T?
M0_$4L5K;Z;9OX>N6:*+56N7EE5?DF&5!!P6!8=<KZ4 >M]*@LKVVU&R@O;.9
M9K:=!)%(O1E/((KS:[T:UT_5]%CA:<C5-(O!?EYW;[052)E9LGJ"3R,=<=*Z
M+X86=O9_#?0OL\>SSK.*:3YB<N4&3S]* .NK/T76+?7=,6_M5D6%I)8@)  V
M8Y&C;H3W4X]JXB]M3IWC!]6OX'O+6;4X8X-2M+XB2T9MD8@DBZ;"YP<9^_DC
M/-8>GZ9!:>#]*UZ%YUU$>(O+643-\L;7[1L@&<;2"<C'))- 'L=<I=_$'2++
M1]>U.6&\,&B7?V.Y"HNYGRHR@W<CYQUQWKD#.Q\1Z5KEE:O%%>:\]L+Z?46:
M:=<R(T?DA=HC&TX!;(V@XS6%K_\ R3WXI_\ 8?'_ *,@H ]VS\N[MC-4=$U>
MWU[1+/5K19%M[N(2QK* & /J 3S^-7?^67_ :\:\-V%MIO@SP'K5C--_:-Q?
M6]M)+YS'S(W+*\97.-JJ#QCC9GKF@#V>BO)?"MOK5[-HVNFUMX+B>^D-W>R:
MHQ>X0F0-#Y)7'RXX4'CR_K79^/K>[?PK-?6!?[;IDB:A"J$C>8CN9#ZAEW#'
MO0!T]9OB#7+7PWH-YK%ZDKVUHF^180"Q&0. 2!W]:\_U#5X=<GU[7TEO)-+A
MM[?2;);2;RC-+,R,Y#'A>9(DW=@&K"UY9[+PC\1-+>V@LHK>TM)%L[>\>X2)
MG+;B&95()"J2,>_>@#V&'4O.OXK9+*[\N2V%P+DH/*&3C83G._G.,8QWIM]K
M%OI^HZ98S+(9=1F>&$J 0&6-I#NYX&$/KSBO.]3U"\LO'LCVLLF^'P3+/%&"
M2OF+(-IQTS3;'2=.T_5OAO=6LTC7%X9)9F>=G^T,;-R9&R3DY;K_ +7TH []
M_"^@R:P-7?2+-M0#!_M!B&[<!@-_O>_6M>N;\;S1KH,=J\5Q,U[=0VT<,$_D
M^:Q8':SX)5" =V.<9 ZUY^?M4>F:GI.[[#'#XFT^!(;.]>5;=7\G>J2$*>K,
M<8&"2* /9*SSK%N/$*Z+MD^U-:F[#8&S8'"8SG.<D=J\R\0Q_P#".S^*]-TJ
M:>TL9+?3&8),W[KS;AXI74DY4E!R1Z9K?TO2=/T7XM_9-.!BB_L(N8/,9@A,
MZC(R3C./TSU)H [ZBN&\=_;+O7?#VEQ627UK<&YDEM9+LVZ2LBKM#, <XW,V
MW'.W/:L.VTN[GU;PMI&KS%K;S-3!@@O6E!B4H4B>08+;/N\_W<'O0!Z!XB\0
MV?AG2OM]ZLSH94ACB@3<\DCG"JHR.2?>K]I<-=6D4[V\UNTBAC#, '3V."1G
MZ$UXIKVF6LOAA;657DBL/%XL[8/*Q\N%I5)0'/3GCTKI#HNG:AJ7B^*_:6./
M1XXH; "X=?LD?V<2>8N#P2Q8[NORX[4 >FT5Y5H$,GB;Q;HDNLR3R'_A&+.]
M>'S616G\QOG8 C)Z\'CGV%7?"]E87>E:?XFO]0G@UN;4)E:7[21YS^9(@MBI
MR-N  % 'W01@\T >D5%<3K;6LMPX)2)"[ =< 9KR?PBFJB#0/$<UO!;>>DDV
MH7;:FTDEXIB=F7RBH&Y6 ( /RA".F:BTPRVNI:7-%:-:0:KI%Y,S2ZBUQ/=K
ML5U>9=H56YZ@G[Q'2@#U?2M1AU?2++4K=76"[@2>,2 !@K*&&<9YP:J>'_$-
MGXDM+FYLDF1+>ZEM'$J@$O&<$C!/'I7G.@6%MI.C_#G5-.FF-]?M#;W+><S>
M=$UL[,I7.,(57''R[:R](>[ET2'3X+<7,%[XKODG@:Y,"S!5D=49P#@$J#C'
M.W'>@#W"H$O;:2^FL4F5KF&-)9(QU57+!2?J4;\JP/!%I?V.FWUM>K#&B7K_
M &:WBNS<?9XRJGRRY /#%L#' (%<9K4(TSQ/\0]7L(V74;31H)X)%9LH[)/N
M8#..P/X4 >LU7O+VVL85ENYEBC>1(@6[N[!5'XD@?C7"VVFV?A[Q9X271I)=
MFHPSI=YG9Q<(L6\2-DG+!MOS?[>.]6?BA8VU[I.BK<Q[Q_;5FGWB/E:50PX/
MI0!U-EJ]M?:GJ6GPK()=.D2.8L %)= XV\\\,/3FM"O)]1\/V%S=?$.:03!K
M"&(VFR9U\EELU(<8/WN!R<]/<YISKK/B*?5I?L\4T]I86AMKV;4VMOL3-;B3
MS0H4@_.6))/(7'04 >R5AZ'XHM/$-Y?0V-K>>19S/ UW)&%BDD0X95.=QP>^
M *TTB-UIJPW@5FEAVS!#P<C#8/IUKQGP_I]KIWA1[RU1H9O^$NCMVD61O]4+
MQ!M/.,8H ]?UW6+;P_H=YJ]VLK6]I$99%B +$#T!(&?QJG#XIL)M>L='6.X^
MTWMB;^-BHVB/(&"<YW<CC'XUPGCZX,C^/X1*62+P_;93=D*Q>8].QQC]*;<W
M$]IXWT>YMAFXB\'S21#&<L-I'ZT >LU!>WMMIUG+>7DRPV\0W/(W117E6BZ9
MJPT^TNX9;71TOM(F^T7[ZLTSW#/$"LY5E&&5CG(/ 8CTK.\26%O:>#=?TN]T
MB73K^*"UN#''>M/;3#SMGFH3R&.6!# $\=<9H ]MHJ&TM(+&TBM;9-D,2[47
M).!]3S4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %4M3TC3]9MTM]2M(KJ%'\Q4E&0&P1G\B?SJ[
M63KVM-H\-HD%HUW>WMP+>VMPX3>^UF)+'.U0JL2<'ITH ;;^%="MM+NM-CTV
M#[)=MNN(W!?S3QRQ.22,#!SQ@8JSI6BZ=HEN\&G6J0)(^]\$EG;&,LQR2< #
MD]JP?^$V\BR^TWVF26ZV]_\ 8=2_>AA9L0"KDX^:,[T^;C ;)'!QF:[XZU'^
MR!?:'IRR6S:O!80W,DP N%,JJ[*,'Y2=R!OJW89 .KO_  UHNJ:C'?WVG0SW
M4:! [C.5!) (Z-@DD9S@GBG6?AW2;">TFM;&..6T@-O;N"28XR<E1D],@5AW
MOC:>R>]E.C/)8Z88TU*X6X7]P[*KL$7'[P(KJ2<CVS4.I>/+FR.NR6^@RW-K
MH<NV\F^TJGR>6LA9 1\Q 8Y7CH.>: .B_P"$=TC[%?69T^ VU_,T]U$5R)9&
MQN8^_ _*HHO"FA0Z3<:6NF0&SN6W3QN"WF-Q@L3DDC P<Y&!CI63I_B/5;WX
MB7^D"SC_ ++@LH)EE\T;AO\ ,(?&,G.T#&>,9[U;U?Q-=67B*#0M/TAKZ\GM
M&NE)G$2*JL%.XD''4= >2..X )QX/\/C1I-)_LN#[%+()I(SDEI 00Y;.XMP
M.<YXI9?"'A^>\@NY=+@>>!8U1CGD)]S<,X8KV)SBLJW\<OJ-KIZ:9I$DVJ79
MG#V<LZQBW\APDN]\'HQ4# .<CI44OC]Y#H\&G:)/=7NJ)<A;=IEC\J2!@LB.
MW( !W<_[/ .10!L7_@SP[JE[/>7NDV\\]PNR9F!Q(,;<L,X)QP#U'K6X %4
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M2#L;([D8/MFN9\&Z_K(^'/AJ6&PGU>]NK9GEGN+K8JA3U>1@3N.0 ,<X/3%
M'5V_A30K60/;Z9!$1+', @( >-=J-CID#C-37GA_2;];Y;NPAF%^J+<AQGS
MGW<_3L>U8^E^.;/4IK<-;26\,^EG4EDD8<!7VR(0.ZG'.><U!IOCZ+4= TO4
M5TV6.XO]06P%H\@W1L2223CH$&_Z4 ;NE>'-(T25Y=.L8[>61!')(N2SJ"2-
MQ)R>6/)YYI^K:#IFNQQ)J5FDXB8M&Q)5D)&#A@01D=>>:T:* ,:;PGH$[61D
MTJV_T)!';@+M"(""%P."N0#@Y&:AG\$>&KFQMK.72(#;VP80H"1L5CEE!!SM
M/]WI[5OT4 4[?2K"TNOM-M:112^0EMN1<8B0DJ@'0 ;CCZU)86%KIEC#964*
MP6T*[8XUZ*/058HH X_2/ >GQ75[>:K8VMQ=2:G->0N"2 K.63<. 2N>X.#T
MK7U#PGH.JZA]NOM,@GN#M#,P.)-OW=XZ/CMN!Q6S10!6CT^TAU">_C@1;N=$
MCEE'5E7.T'Z;C^=9B^#O#R"95TN +/<K=R+SM,JDL'QG .23QZUN44 8VH>$
M]!U74/MU]I<$]P=H9F!Q)M^[O'1\=MP.*O#3+(7-W<"W037B*EP_>15! !^@
M)_.K=% $-I:06%G!9VL2Q6\$:Q11KT55& !] *R(/!?ARVF6:'28$D2<7",N
M<HX)(*\_*/F;@8')XK=HH SH]"TN*RL[-+*);:RD66VC&<1NN<$?3)JD?!?A
MPW\E\=(M_M$DPG+8/^L#!MX&<!MP!) R>];U% &1XJTN?6_"6KZ5;-&L]Y9R
MP1F0D*&92!D@'CFH]+\)Z+I3M/;Z=!'<RP^3(ZY/RGJJY^ZI/.!@5MT4 9TF
M@:5+HB:+)80MIJ(L:6Y&555^[CTQ@8/48IVEZ)INBV\D&G6D<"2MODQDM(V,
M99CDL<#')J_10!E6WAO1K/0Y=$MM.@BTV5762V485@WW@?KFH+SP=X>OS;FZ
MTJ"3[/"L$8.0/+7[J, ?F4>AR*W** * T33!=WUU]AA,U_&L5TS+GSD4$!6!
MX(P2/QJI8>$M!TR.YCM-,AC6YB\B7)+%H_[F220O/0<5M44 4QI-@'L7%JFZ
MP4K:G_GD"NT@?\!XIVHZ;9:M8R66H6T=Q;28W1R#(X.0?8@\@]JM44 95KX:
MT:STNZTV#3XEM+L,+E#DF;<-IW,3EN..3TK0MK>&SM8;:WC$<,*".-%Z*H&
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M&RN\".X4HR,I)! .'W D=5%=110!P8\+7\WAW^Q;?2-+T2RU&Z8W\=B<%+;
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MJ[6B@"IILE])8HVI0PPW19MR0N64#<=O)]5P3[FK=%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[K48K=?-0,K@JYVG/0$J!D<BJ]WXPEO=!\/:EIK&V>\U:WL[N!U!:(EBLL3
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M4X.[# ''Y5=OM*O)OAM<Z1'%F^?2&MECW#F0P[<9SCKWSBLG7?"M_JZZ%;!
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M/LX@ WJP7S. ^-V.V:[+PCIBZ9I<X71_[*-Q<-*;=KDS.> H9VR1N(4< D#
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MC%8<WA#5WEU>73O#QL8KB*QN;6&6Z1B9;:=G,<AWMAG!X()4=R#5_6/#^O\
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MFX)VKD\>XS4NO&T2W\ECINDW^ISI9Q7W^C^6JF&3=@Y=AS\O3J<C'?&1XO\
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MNISW;V0TT;!*LJ*6?<Q;8%"_-NS@@C'6F^#-8N]8OO$K7(N(UM]2$,=O/C=
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M,Y- 'I__  CFA_\ 0%T[_P !4_PK-UZ#PKX;T:?5=1TBQ6VAV@[+)&9BS!5
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M'*AU\R;Y3CJ/:@#W*BO'=61Y_!6O^)9-3O8=575Y+=66[=52-;H1+"$SMQM
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M("S81P2<YSD\L>OK4^O:[#H.@3:Q)$T]O#L9_+(R$9@"WT .?H*K?\)5:?\
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M;ECCMXU(W+N4LS-[*JL3]* +&H>$=!U6^FO+[3UFFFC\J8&1PDBX(&Y =K$
MG!(R.QJ2#POH]O+++'9_O9K1;*1VE=F>$9PI))]3SU]Z;KNO_P!CR6-K!9RW
MNH7\C1VUM&RINVJ69F9N%4 =?<<<UQ?C?QOJ8^'^L3Z99W-AJ=G<I9W?[U-]
MJS-'AE/\097&"/7/&* .PG\':#<:?I]B]CM@TX;;3RII(VA&,$!U8-@C@C//
M>I;7PMHED;4VNGQQ?9)WN( A($<CJ58@9[@D8Z4[1Q-I_AR,W4-[YL*.S1SS
M?:9S@DXW#.XGMCV%8W_"<26UO?OJ>AW=A+;::^IQPO(C-+$GWAP?E<' (/KU
MH U=1\)Z'JNH"^O;$2SX4.?,=5D"G*AU!"OCMN!K3O;*VU&RFL[R!)[:9"DD
M4@RK*>QKET\;S>>L4V@7D7VFREO;#,B%KD1A24P#E&(92 ?7G!XJZ?%]D^G^
M'[NUBDN/[<EC2V1",J&0NS-[*H.?RH MZ;X7T?2!<?8[1@UR@CEDEF>5V09P
MNYV)VC)P,XYJ[INFV>CZ;!I]A"(+2W39%&"2%'ID\US?C?5;S2;WPR]HMQ*9
MM4\I[>!MIG!@EPIR0,;@IYX&,]JBG^(45CIM[-J&DW4%Y8WL%I<6:LLC RE=
MCJ1PP(;Z\$4 :4/@?PY;SI-%IVV2.<7$1$TG[I\D_)\WR [CE5P#GD&KT?A[
M2HM/L[!+-1:V4RSV\>YL1NI+ ]<GDGK61-XMU"-X[5/#=U+J0MC=W-HMQ%F"
M+<RK\V<,S;3A1Z')%)?>-6AT^/4M/T6\U#3OL*ZA+=(5C58B"<+N/SN "2HZ
M<>HH 73=!O;GQI/XGU>VM()H[7[#9Q02&0B/<69W8J.2<  #@9Y.:L^,-!D\
M1:=8V:QQ21QZA;SSI*>&B1P7'OQGBJ^H>,FBO)X-*T>[U46MNEU=-;LJF-'!
M*A0QR[E03M'MSDUB_P#"6ZC8^)/%,D&FWVI6EK%;7'E^8(Q;QF'<V Y'S'D[
M0.QSCC(!TL?@S0(["\LOL!>&]96N#)-(\CE>4.]F+#;@8P>.V*:O@CPZJ2H-
M.&)EC67,TA\S8_F*6^;YF#<[CD]LXK1_MBS&@_VTTA6Q^R_:RY'2/;NSCZ5A
M67C.XGN+*&ZT&ZL_[2A>33S)-&?.*IOV-@_NV*\C.1P>>* -K4M TS5[NRN[
MVV,EQ8N7MY5D9&0G&>5(R#@9!X.*Q]$T&]?Q9?>*-8MK2WO9;9+*WAMY#)Y<
M*L6)9RJY9F([<!0.:Q?AEJ&L:S<:UJ6J_;CF]GA3S+I6AC"O@1K&.A _B[^M
M1>(O%FMG_A.["*T>VATO3=\%U',H:-S'(P;@YYP,8Z8YZT =WJ^C6&NV!L=2
MMQ/;EE?;N92&4Y!#*0001U!K.O/!7AZ_F66YT_S&$:1/^^D E1/NB0!L28_V
M\U0LO%LLMQ%I^H:5=V1N;"2ZM9WE0F94"[L@'*-\ZG!]?48JCH?C+S/#VA)I
M.FZAJ=Q?6DETB7-TGFB-&"DL[$;FRP  _2@#M+VQMM0TZ>PNH1):W$30RQ\@
M,C#!''L:J:AX?TS5+&"SN[;=#;D- 4D9'B(& 5=2&!P2.#T-7;2X^U6<%QY4
ML/FQJ_ES+M=,C.&'8CN*\XU'Q?J\7B>XUN"YQX4TR_BTNZBV+ARP(DFW8R C
MO&O''#4 =A/X.T"XTZTL&T\+!9N7M_*E>-XV;.XAU(;)R<\\YYS65H_@6QBT
MK4-,U*SB-H^JR7EHD,C(8EX"$,I#*P&>A[UJ:OXCDL-8MM)L-,FU&^EA:Y:.
M.1(Q'$I"[BS$#))P!WYZ5BI\1X;FTTF2QT:]N)]5FNH;:WW*C[H&*G=DX4'!
M//0 T ;7_"%^'?L%Q8_V8GV:XECFF3>_[R1,;6)SDGY1SW/)S6G!IEG;:A>7
M\, 2ZO-GVB3)^?8,+QTX![5SUSXV-M/<,VD7#6%E-';WUXLJ;8)&"D@+G+A=
MZ[B.G.,X-/F\:+%?RXTNX;2H+U;";4 Z!4F+!?N9W%0[!2W8YXP,T 7],\)Z
M'H]\;RPL1%-M94_>.RQJQRP122$!(Y"@58U+0-,U>[LKJ]MC)<63E[>19&1D
M)QGE2,@X&0>#BN;O_B(MBNIW']B7DNGZ5>?9+VZ5TPAROS*N<O\ ?!('3WJ=
M_':V4NH0ZKH]W93VUM'=11;TD:='?RU VG <OA<$]QS0!N#P]I0TQ-.%FOV2
M.X^U+%N; E\SS=V<Y^_\W_UJ@'A/0QK/]K"Q'VOS?.SYC[/,QCS/+SLWX_BQ
MGWK+N?'0TS3]4FU72;BTNM.CAFDMA(LA>*5]BLK+P>0P(ZY'N*JZKXYO[&QU
MN-]!GM=1L]-?4;>.6:-A)$"06)!P"IY*_D30!J>+/#I\13Z&C1QR6MI?_:+A
M78J=GDR(-N.<AG4CICKVJS%X1T*+2;C2Q8!K6XD\Z822.[O)QARY);<,#!SD
M8&*L>'KZ[U+0+*\OK;[-<31*[Q[@W4=>..>N.V:KZYK\NEWUCI]GITE_?7BR
MR1Q+*D0"1[=Q+,>OSK@>_M0 Z#PGHEM:Q6T=B#'%=+>J7D=W,Z]'9B2S$8'4
MGH*N7&DV-WJEEJ4]N'O+$2"WE).8PX ?C.#D =:X^;Q)JO\ PG$*6>EW]QY^
MB)<#3I)%A\I_-8$ON. P&%XR3],D:47C*?4-(TZ^T?0+Z^^UP/,R%EC$(0[6
M5F)P7W9 4=<$\"@"_)X/T&753J3Z>IN#,+@CS'\MI1TD,>=A?@?,1FKT>C:?
M$VH,ELH.HMNN_F/[T[ G//'R@#C%<<WB*35/B!X-EL+JX73-2TRXN3 6(#_*
MA4LO3(S5SX8:A>:GX2EGOKJ:YF%_=('E<L=JRD 9/8"@#HX]#TV(Z:4M54Z8
MACL_F/[I2FS YY^7CG-4KKP=H-X<S6'S?:)+G<DSHWF28#G*L#AL#*]#CI61
M>_$'[(NIW"Z)=RV&E79MKVZ$B )@KEE4G+8# GV]:L:EXV:SN-4-IHUU?66D
M<7]S%(B[#L#L$4G+E5()Z=<<F@#5LO"^BZ=/#-9V*PM!++-$%=ML;2C#[5S@
M ^@&.O'-)=>%=%O+6XMY[%6CN+K[8Y#LK>=@#S%8'*M@ 9!%9&G^*K_4/B!/
MI$-B&TI;"&Y2Y$B]'+D/CJ0=H4#J,$]*OZWXF?2M:L=(MM+GOKV]AEFB6-U1
M1Y97.YFZ##=?;'>@![>#= ;2X=.%@$MX)3-&8Y7219#G<_F!@^XY.3G)SS6I
MI^GVFE6$5E8P+!;1#"1KVR<GZDDDDGDDURC_ !#A%EISQZ1>27MY>3:>;(,F
M^*XC#$HQSMQE?O9Q@YJ:]\;O9&Z=]%N7M].2-M4F25"+5F4.5 S^\VJP+8['
MC/2@#2MO!^@VFIKJ,&GJMPDC2H/,<QQNV=S+&3L5CD\@ \FK]II-C8W]]?6U
MN([F^97N9 23(57:IY.!@<<5EQ^+[+[%X@N;B-[<:'(ZW"L02RJ@=77V92,5
MG2^/6CMY;E=#O'M[.VBN-2<2(#:!T#[=I.794(9@.@]3Q0!L:AX3T/5;][V^
ML%FGDC$4F78+(HSC<@.UB,G!()':K%AH.F:8TC6EL4:2".W=FD9RT<>[8I+$
M]-S>_-8.I>.VM+G6H[31+J^BT<+)=S1RHJB,Q"3*[C\QP3P/3KR,KIWBK4-1
M\?3:3%89TM=/ANDN/,7/S[R'(SG!VA<=003TH 9KGA.358-*\-P6-G#X:LWA
MED=Y2TA$1RL2H1P#A06+="1BNRK(UG5[[3YH(-/T6YU*:57<['6..-5QU=N-
MQSPO?!Z 5D+XZ6\ETV'2-)NKZ?4-/^WPIO2,*F0"'). 02!WY_.@"ZO@?PZE
MB]DFGE+=I_M 5)Y!Y<G/S1D-F/[Q^[CJ:MVWAK1[,:>+>Q1/[/>22V(9B49P
M0[$Y^8D,<DYZUF:1XWM=6NM(A^QSV_\ :D,[1-(1\LL+[9(CC^(8)ST(4UJ:
M/KD6M7&II!"ZQ6-VUIYK$8E=0"^WV!.WZ@T 3/HNG/+J$K6RE]1C6*Z.X_O5
M"E0#SQPQ''K0FBZ>DNGRK;*'TZ-HK4[C^Z0J%('//"@<^E9&G>+9=1F>2/1;
MH::7GCCO0Z,"T18'<H.4!*L 3[9QFI(/%MO/IOAJ]%M*%UYD6)21F+="TOS>
MO"$<>M %_5_#^F:[Y!U"W9Y("3%+'*\4B9&#AT(8 ]QG!I(/#FD6RZ:L%C'&
MNFEFM F0(BRE6/7DD,<YSUSUKB_!_C6]3PYHCZII][+:W=Q]C_M.256S,TC*
MN5)W;<X7=Z]L<UT%CXR^UM+<OI-S%HZF<#4"Z,H\DL&+J#N0'8V"?;.,B@#H
M;RSMM0LYK.\@2>VF0I)%(,JRGJ"*R;;P=H-I:7MM'8EH[Z'[/<&:>25WBP1L
MWLQ8+@G@$#FL^W\=1I&9M6TNYTRW>QDU"WDE='\V&, MD*?E<!E.T^O7@TNG
M^,[BXU;2=/OM!NK%]4CDFMWDE1QL1-QW;3PW(R/?J>< &GIOA31-(OC>V5B(
MY_+,2L9'<1H3DJ@8D(,@<* .*2#PCH5M8Z;90Z>B6VF3_:+./>W[J3).X<\\
MLW7/6JEMXRMKG0M U5;641ZS<1P1H2,QEPQ!/_?-1V'C1;V]L\Z7<0Z9?SO;
MV=^SJ5E=0QY4'*AMC;2>N!TR* ,#6_ U]JVJWT8TK28X+R[28ZA'<2JZQ@J6
M_<$%3*0I7>",@]NE=1=>"/#M[<W4]QIP>2Y<22?OI -^0=Z@-A7^4?,N#QUK
M+T[X@_;X]*NSH=W#INI7 M8KMY$XE.X %,YVDJ1N]>V.:M>"?$6I^(HM4DU#
M3_LJVU_-;QD2*V0CE=IP>HQR>ASQ0!>N/!V@W5QJ$\UAN?48O)NQYSA9EP!R
MH;&<*!NQGCK3M0\):)J@MQ=69S;Q>1&\4TD3"/CY"R,"5XZ$D50U7QHNFWE^
M$TNXN;'3"@U"\1U @W*&.%)RVU65FQT![GBJVI^/&L9=;\C0[N[@T5A]MF21
M%"IY:R;E!/S$*QX]O<4 =';Z+IMI<VMQ;V<<4EK;&U@V<".(E24 '&,HOY5+
M8:=::9;M!9PB*)I7F*@DY=V+,>?5B3^->>ZCK>K7_P 6K'3T6]CTB#35O@MO
M>+$L@\T#SG[L@'&P\UO6'CK[8^F3S:/=6VEZK*(K&]>1#O8@E-R Y4, <'GM
MG&: -*W\'Z#:ZHNHPZ>JW"R-,@\QS&DC9W.L9.Q6.3R #R:OV>DV-A>7MW:V
MXCGOI!)<N"3YC ;0>3QP.U<S;?$&*:PU+4GTB[CTVP>6%[@LA,DZ2^6(T7.2
M6)&#P,G&:LOXRGL[:Z.J:!?6EW$85A@#)(+EI6V(J.#MW;N""1CKTYH U[OP
M]I=]J\&K7%MNOH(S$DRR.IV$YVD @,,\X.:6/0-+BM-,M4M%$&F,K6:;F_=%
M5*#'//RL1SGK6'<^.DT[2]1N-1TJY@N]/FMXI[1'61B)G54=&'# [CZ'*D5"
MWCG4%O;[3_\ A%KPZC9PK=/!]HBVF YPV_.-V5(V^HZXYH UG\&: ]C]C%AL
MB%R]TIBFD1UE?.YE=6# G)S@UH6^CZ?::.=)M[<1611HS&K$9#9W?-G.3DDG
M.<G.<US[^.EN(+>71](NM2#Z?'J4P1T0Q0R E!\QY<[6PH_N]>E$OC@SWCVN
MC:/<ZFZV,.H*R2)&C12;L<L?O?+P.^?8T =-86-KIEA;V-E"L-K;QB.*->BJ
M!@"N6\0>$(F@C;2='L+C=?/>W$,UQ+ [2,N"\<J$[&SC(Q@C/2H++QO>:MXL
MT2UT[3F?2M0TLW_F,ZJX!:, D9_AW$$=R>.E;^NZ_P#V/+8VL%G+>ZA?R-';
MVT;*F=JEF9F;A5 '7W''- &3X8\&0Z?IN-3M+43_ -I-J44%NS&.V?;L0*>-
MV$&"2.23Q6MJOA31-;NQ=:A8B6;8(V(D=!(@.0KA2 ZY)X;(Y/K7%^-_&^IC
MX?ZO/IEG<V&IVEREG=_O4WVK,T>"I_B#*XP1ZYXQ786MU_8'@Y[W48[Q%LK>
M6>9;B<7$VU=S'+Y^8X''X"@!^H>$M"U2_%[>6"R3856Q(ZK(%.5#J"%<#MN!
MJU)H>FRG4B]JI.IH([SYC^]4)L //'R\<8K$D\8W%GI-Q?ZEH-U:+$;<I^]2
M195ED"##J<9!.2/3&,YJUK'B^QT._O+>\CEVVNG_ &]Y$ .Y=Y0(!W8GI]:
M-(Z+IS36<S6J,]G"\$!))V1L%#+CH00J]?2L^U\%>'K*&ZA@TX".ZMVM9%>5
MWQ"W6-=S'8OLN!T]*Y[Q3XHU4>#M>\[2[_1;ZWM%N(IA('4J6QQ(G <8Y7KS
MQD5OZ7XFFO-?;2+W2+C3YWMC=VYED1_,C#!3G:3M8%EX]^M &H=)L6N;*Y-N
M/.L4:.W;)_=JP 8=><A1U]*R(O!.D67]GII\'V6&SOOMJQ[W<;MCKA<MA!\^
M< 8Z\<Y$&J>(]3L_B!I.AV^G^;9W-K+--+YB@C:T8W#)SA=QR.^1CI3M*\:+
MJ5W8!]+N+>PU,N-/O'=2)]JEAE0<KN569<]0.QXH W-5TBPUJS^R:A;B:$.'
M4;BK*PZ,K @J1Z@@U2B\)Z'#IIT]+ &W:X6Z<-([,\JL&5V<G<Q!5>23T%8%
MK\2%N?"A\2MH5['IA,*Q.70O*SR",A5!S\I/4XSCBI6\<Z@MY?:?_P (M>?V
MC9PK=/!]HBVF YPV_.-V5(V^HZXYH [2BJ>DZE!K.CV6IVV[R+R!)XPPP0K*
M",^_-7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *YGQOI=_J>E6+:; MQ<66I6U[Y#2!/,6.0,5#
M'@''K7344 <4V@:I<6?C<O;+%+K4(^S1F4'YC:+&02.!AP1G\:PY_ MQ%?7,
MDGAFQUA[VWMPLMQ<!%MI$B6)@XZLGR!OER3R..M>HT4 4=0TNWU'0[K29% M
M[BV:W( X"LNWC\*\W_X0[Q9_PAPNMMO_ ,)4;OS2?.&W;]G^S?>_W/GQZUZM
M6=H>L0:]I@O[>.2.,RRQ;9,9S'(T9Z$]U/X4 >?ZYX"O9Q>:9!I-K?VK:7%9
M:=<W,P"6)1&5CL/.XG!! ZXR1BMK2= U4>/[+7+NT6&U7PXMA(IE5BLPF#%>
M.HP.O2M>'Q7%=W.O6MGI]Y<7.C2)')$FP&9F4,-F6 Z'OBMZ-B\:L4*%@"5;
MJ/8T >>^'/ ^H6NIWD.I%!IEE:SV.D%7W,(II&=F([$+Y:#V4U'X:\'3:<MO
M!+X7T^UN+.S>%M16XWF>39L#1J.5# DG=C&<<]:](JL;^U&I#3O.'VLPF<18
M.=@(7=Z=3B@#-\':;<Z-X,T;3;Q56YM;.*&55;(#*H!Y[US%]I/B:WNO&$5C
MI<%S#KC@6TIN53R<VZ1%W!Y*Y!X&3\O3G-=OIMW+?Z?%<SV,]C(^<V]QMWI@
MD<[21SC/7H:MT >7^-=!FM%\+Z=I5VJZA<P'0I<<.]HT8\R0#_8V;O;=[UW]
M]82CPY<Z=I3BUE%HT%JPX$3;"J'\./RJ5-)TZ/5)-42QMEU"5!&]T(AYC*.@
M+=<<#\JN4 >3P>#-61_.M?#=K8&;1;O3I\7*/*\SJA61V_B!92!R2,Y/6NL&
MA7PU'P=-L39I<$B71WCY2T(08]>1765EZKJEK:7FG:9=0-+_ &K*]LHP"O$;
M.=V>Q"D=^M '$^$M'8_$#5UCE271M$N)C8A.B3W(5Y4]/D^8>WFXK5\</=Q>
M(/!\EC D]PNHRE8G?8''V:7(SV.,XSQG%=9I^G66E6:6>G6D%I;)G;%!&$49
MZ\"GS6=M<3V\TT$<DMNQ>%V4$QL05)!['!(^AH \ZO/#.NW[7NJW.F*_V[5(
M9[C2!=*#);1PF-59_ND[\.5SC  S4=AX-UBW,,"Z7:6EO'XDAU54MY5\M(?)
MVLH''*D8/'.<BN^UW6(- T:XU.YCDDA@V[ECQN.6"\9([FM&@#EIM-U.#XEQ
MZQ#9K/I]QIBV<L@E53"RR,^2IY8$-CBN>\%Z.W_"<:N$E2;1]#GFBT[9R$DN
M-LDJ_5/N^P<BO1YH8KB"2":-9(I%*.C#(92,$$>E0V&GV6EV:6>GVD%K;1_<
MB@C"*OT H P_$NFZ@^KZ)K>F6ZW<VFO*LEJ9!&9(Y4VG:QXW A3@X!&>:YC6
M_"&N:UX1\3EK:*+5-:O;>=+7S@1%'$8E 9^A;;&2<<<XKTRB@#/UZVO+WP]J
M5KIT_D7TUK)';RYQLD*D*<]L''->;-X+U4B^>Q\-6NFI>Z%=::T:W*-)YS!2
MKR-_$&(*]21U/7CTB/6()/$=QH@CD%Q!:QW3.<;2KLZ@#G.<H>W<5HT <S+H
MMZWB+PO>!%\G3[2XBN#N&59TC"X'?E37-^"-'8>,]7VRI-H^AS36^F;.0CSE
M995_X!PGXD5Z-/!%<V\D$\:R0RJ4='&0RD8(([@BH[&PL]+LX[.PM8;6VCX2
M&% BK] .* ,#Q?INJ7MSH%WI5O%/)I^H?:98Y) FY/*D4@'U.X ?7TKGKSPO
MKFK_ -HZE-91VUS?:K83K:F96,<%NRY+,.-Q^8X&>PKTBJAO)1JRV8L9S"83
M*;L;?+#9QL/.[=WZ8QWH X[Q3X5>[\4G61X?M];CFLDMO)DG$1A='=E;)X*D
M.0<<C:.#67K/@?4;S[19?V'I]U#+I<5K9.TV(-.D"N'VQMR>2""!DX )&*]0
MHH \^LM/\4Z'<75YI^CP7$VI65LC)+=*HM+B)#'E_P"^A&T_+SP1CFM&+0-4
M\_Q;).(F?4[6*.%D. [K 4;@GY1N]:["B@#G1X?EN_AROAVY8132:4+*1@<A
M&,6PGWP:RK+3?$&J:KX=;5=-BL8=%W222+<+)]HE\HQ#8!R%^9F^;!Z#%;.O
M>*8=$U+3--6PO+Z_U$R>1!;!,[8P"[$NR@  CO6]0!RW@31+[0=)U"WOT5))
MM3N;E K!LH[Y4\>U8NO>'-<N-1\:1VMBDUOKNF)%!/YZKY<B1.FUE//)8<CB
MO0Z* .5U30KZZUW1KJ)%,5KIUW;RDN 0\BQ!1[_<-<U9^$M2M/ WA_1]1\-6
M^J/9V[JQCNQ#/;3;N&23(PI'4J<\#@UZ?10!@)#KNG^!8[>-DOM?AL5C#L^%
MDG"8W%CU&[G)ZUS]C\*-(C\+QZ3>7>JR-)#MN=FI3K')(PR[>6&V\L2<8KOZ
MSM*UB#5WU!(8Y$-C=O:2;\?,RJI)&#T^84 <'IEOXBT35]%GO(;.\U8:5)I\
MUNUZL;R)%("DZDYR"#\PZ@GO47@G2-0OHO"NK 120VE[JTEQ*C84^;)(%9 >
M2">GM7H>J:'I6N1)%JNFVE]'&=R+<PK(%/J,CBK<,$5M!'!!$D4,:A4CC4*J
M@=  .@H \[N_!+#Q#J;/X9L-4CO[U;E+ZXGVB%&"AU=.I(*L5QG.1G&*(_!+
M6_B"[\SPS87R7.IM>+J4T^/+C=P[ I]XNIW!<<="2.:](HH X"^\*ZK/X5\7
M6$<49N-3U-KFV!D&&0^5R3V^XW%.\9>#K[Q%J]]+%'"T$FEQ11B5\*\L=R)@
MC8Y"D* 3[UWM% 'FTWA"XNO#FLP6/ABST>>Y6!(D%P'DDV2!V+,/E"^@SGKG
M&<5K>*/#6H:QJVIRVRQB*Z\.W.G([OC$SL"N1UQ[UU4-_:SWUS913!KFU"&9
M #E-X)7/U -5TUB"3Q'/H@CD^T0VD=VSX&TJ[NH YSG*'MW% &3HFH:I;#0=
M)O=)%L[V<GG'[0KF,Q"-1C;P0V[UXX]:3QCIDFJ):QMX>@UFU7<67[0(9X9.
M-KQN2,#&X'!!Z=:ZBB@#C?#7A_6;#7+.]U243M'HD=G+,9=[&42LQ!)Y; (^
M8]:YZV\%ZO#;:5;7^CVNJ016LT0@GN!Y5M,T[.)64\."I XR1C'>O4Z* /-_
M#_A/6K/5O!=Q=VL<<>C:9/97)$RM\V%52,=0=N?;O6]\/M"OO#WAJ2RU!%2=
MKVXF 5PPVO(67D>QK9T/68->TM;^WCDCC,LL6V0#.8Y&C/0GNI_"M&@#@K_P
MMJD_@_QCIT<49N=4O9IK93(,,K!,9/;[II+W1O$-BOB?3=,T^&ZM]<E>:&Z>
MX""V:2)8W\Q3R0"NX;<YSCBN^HH XS2M U'0O&L4L-L+C2Y-(M[%KCS55HFA
M+\E3R<[ATJ'Q'/?6WQ+T":PLQ>2+IEYO@\P(S+O@^Z3QG..N.,UW-0M9VSWD
M=XT$9N8D:-)2HW*K$%@#Z$J/R% '!:=X3UA+_1-0N88DF_MJ[U.\B64,(%EC
M=54'^(C*@X[YJ/6/!;R>)-7N?^$:L=734Y(Y8[BYGV"W/EK&RNO5E^3<-N<Y
M(XZUZ/10!P'B;P;?ZEXGB-BL0T?4D@BU=2^#M@?>F!WW E#[5!K?@V27Q-JU
MX/#5CK"ZF8GCFN)]@MV$8C8.O4KA0WRY/)''6O1J* .,?PW?"'QO'%%&%U6(
M)9 .,'%JL6#Z?,,<TS1M%U?2?&%O=M9)+9SZ/;6<TRS*#!)%O)RIY8'< "*[
M:B@#C/%>A7NI^(+.<Z3!J^GK:O$+:XF"QPS%@1*RG[PP". 2.PYJIX+\,ZOI
M%_I#W]O'$ECHSZ>[+(&W.)E8$ =BJY]NE=]10!Y=K.EW?AWX:6]Q+Y4>L:7J
MDE[9)NSYKO<N5C&.3O20K@>OM7<^%M'.@^&K'3Y&WSHF^XD_OS,2TC?BQ8U<
MN=)TZ\O[:^N;&VFN[7/D321!GBSUVD\C\*N4 >?VWAS4Y/%27B:-#I)9Y_M]
MW:W68KY&1E7]T/XMQ1B6 (VGDYJOI.A>)A;>#M/N],@MX- G43S"Y5_."P21
MAT Y ^89!P>>G!KTBB@#S+3/#GB4^'="\-WNFPQ06=_'=SWJW*LOEQRF4(%Z
M[R<+Z=\]JDG\(ZEJ>KW &D0Z/]J2YBU"\M;K,5ZDD;HI\H?Q;F1R6 (VD9.:
M])HH \PL_ DMUH]YITGAG3]*G?2Y;1K]9_,,DK*%W(!T3J3NP>@Q5A)];F\;
M^#4U?3([#R8;J/"W"RF5_)&6&.B\<9Y.>@QSZ/4,MG;37,%S+!&\]ON\F1E!
M:/<,-@]LB@#SG3/#WB:+2_#&BSZ;!%!HFH1RRW7VE6\^-=X!1>HX8$YP>P!Z
MB3POX);1;^PMI?#-@?L4SL=7:?)D0;MA5.H?E0<\#!P3Q7I%% '!6?A;5(?!
MOA;37BC%SIVI0W%POF#"HKLQ(/?@BM3P=INIZ/-K=I>V:I!+J5Q=V]RLJL)5
ME<L!MZJ1GG-=310!YQJW@MY/$>KW!\,V.KQZG-'+'<W,^P6_R*CJZ]67Y-PV
MYSN(XZUHW/AK4'TKQY;1Q)NU@.+(;QALVJ1#/I\RD<UVU% '$Q>%KY_'$6H3
MHJV!\-_V9(ZN-PE,@8@#TQGFJ5AH/B&:P\,Z#?6$,%KH<\,DE\MP&%PL"D1A
M$'S L=I.[&,'K7H=% ' Q^$-3?X>ZEH[>3%?R:C->V^YLH2+GSHPQ'0' !],
MT[7-,\1^+=*N(K_2+.UA@EMY[>QEN!(UP\<FZ0.Z\*K+\HXSGDXZ5WE% 'G,
MGA&XG\.7\-CX<M-(FN+VRD6%9P[O'%,CL78';P-^ "?UKH3HUY_PF.LZEL7[
M-=:7!;1-N&3(K2DC';[Z\UTM% 'D]OX"O+"VTV2Z\.6FLS?V-;64D4ER$^SS
MQ!AG)X*'=SC)^7H<UUVB>'[G3/$-]<?9X(;1]+L[2%(3\JM%YNY5!Y"C>N,U
MU5% 'G/AWPUKN@W_ (3G>Q2=;71CIMX$G4&!B\;;^?O#Y3TYKH?$NFZ@^L:)
MK>F6ZW<VFO,LEJ9!&9(Y4VG:QXW JIP< C/-=+10!YGK?A#7-9\(^)RUM%%J
MFM7UO.EKYP(BCB,2@%NA;;&2<<<XKT+44N'TRZ2UB@EN&B81QW&?+=L<!L=C
MT-6J* /+F\':M-H^M0:=I*:/;S1V[V^F/>"2-IXIO,9EQE8P0%7C&>I Q5K5
M_#7B#Q5?:I=7-E#IHN-)6VMD><2%9DF\T;]O&"1VSQ[G ]'HH X77+;Q7XH\
M-ZQ8SZ5;6"36BQP0-<"222;=EFW#Y0F!@ \GVZ5MS:5=/X_L]755^R1:9-;,
MV[G>TD3 8^B&M^B@#E-<TK4G\;Z+JUI9BZM([:>SN0)@C1"1HSOY^\!M/ YK
M#\(>#'T2[TRWF\,V$;Z<K*VK>?N:;"E59$'(9@?FW8QR!FO1Z* //K?PGJT?
MPFTKP^T4?]H6TEJTB>8-H"7"R-ST^Z#6X=&O/^$QUG4MB_9KK2X+:)MPR9%:
M4D8[??7FNEHH QO".G7&D>#M&TV\4+<VME%#*JMD!E0 \]^16S110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7(>/ )SX>T^X8C3[W5HX;P!B!(GER,J-[,ZH,=^G>NOJM?Z?9ZI
M926=_:Q7-M)]^*5 RGN.#[T >1^)[:/3++QGI&E,UKIT,NE/'' <+;S23C>$
M'1<@(<#U]Z]2MM,MM!T.2UT>U6)(D=XH@2<N<GG/))--@\-:);:6^FPZ7:I9
M/()7A$8VNX(8,?4Y4')]!6K0!Y'IEE96?A[P+KUB<ZWJ-Y;+=W0<F6Y\Q6,Z
MN?X@/F.#]W:,8Q5"UT[3[?P&-?M<?V[!K[)#.'.]6-]M,0Y^Z48Y7H=Q->JV
MGAC0K'4VU*UTFSAO6+$S)$ P+?>(]">^.M,B\)>'H;^*^CT:R2ZA8O'*(1E6
M))+?7)//7F@#RS7&9-,^+S*Q5A+!@@X(_=+70066GZSXEU/^W&^33M&LY+-F
MD*_9PRR%YDYX;*CYNHVBN[ET#2)DOTETZV==0(-V&C!$^!@;O7BL#Q)X7O=0
MU.VN["RT&X6"#RHAJ%N2UNP.0Z,H.X=/D.!D YH \^LTAU;P9ID+Z?;7DNG^
M'4N99]0O&CC@#E\/&H5B9/W9^;C& ,\UO^&;*UO_ (A:-J5U#'->R>%;:Z:9
MQEC*6"E\^N.,UUVE^"-%L=,T>VN;*WO;C2[=((KF:(%CMYS_ -]<@=C5V+PK
MH,$MC+%I-HCV *VC+& 803DA?09YQ0!Y3X*C35?"OP^TO4LS:;=2:B\\,C'9
M/(DCF-6_O#ES@\?+[5=GM(S=MHD#R+H\'BV&"!(Y" B-;;I(E(/"[BPP.F2*
M]*?PQH;Z-'I#:5:'3HFWQV_EC8C9)RH['))R/4U+!H.DVMI:VEOIUM%;VLOG
M01I& (Y.?F'^UR>?<T <[X0LK?2?%GBK2[");>PADM9(K=.$C9XOFVCMD@'B
ML#4-/T[5_P#A/M0UD WVFR,EI*[D-9Q+;H\;1G/R$L6;(ZFO2XK.V@NKBZB@
MC2>XV^=(HPS[1A<GO@50U#PQH6JWR7M_I-G<W*  22Q!B0#D ^H!Z9Z4 </H
M%@NO>/H[K68VEG@T/3KKRG)"K<9D._;_ '@<X],FM;Q]:VM[KG@ZUO3BVEU-
MT<;MH?-O+A3[,< COG'>NP2QM8[Z2^2WC6ZEC6-Y@OS,JDD GT!)_.HM1TC3
MM72--1LH+I(R2BS(&"D@J2,^Q(_&@#R?4()+/4-1\/:3! ^C'Q#:PBSEG:*#
MY[4R/$6 8JID"?* 1EL8YKN_ ^GW>F0:K:SC3X8%O,P6=C=-.EH#&A:/+*NW
MG+!<<;ZU8_#.AQ:/)I":5:#3Y&+/;^6-K-G.X^IR <]>!5K3=+L-'LQ::=:0
MVMN"6\N)< D]2?4GUH \@UJPT^[\"^)=<O0/[9&M2P&X+GS%"W01(O\ =V!?
MEZ<Y]ZNWUAJNJZSXBOXX=)CO+/5$BM]2O=0>&6T51&415$9 5@>FX;MYS7H=
MSX1\.W=_+?W&BV4MU-_K)7A!+=LGWQQGKBIKGPWHMYJL>J7.EVDM]&5*SO$"
MP*_=.>Y'8]NU 'FT=AJNI:MJ6JK#I,-Y;Z^8DU.ZU!XYXD2956$)Y9&UH\*%
MW8;?GJ:JZII-K-X9\3ZP?,&IVWB-EM;I9")+<&YC4A#_  Y#-G'7/L*]3E\-
MZ+-K"ZO)I=H^H*01<&(;\@8!SZ@< ]14S:-IKVL]JUC 8+B;SYHR@VO)N#;B
M.YR <^U 'E?BFS7P[K>LZ;H<26MI=V6FO<1"9HD.^\:)V9ADKN3Y68 G'/-/
MU'3+S2;:ZL)X],T[2;W4=-AN-/TZ]>00H\I$A.43RUD&P<=<'U->IW&DZ==R
MSRW-E!,]Q +:8R1AO,B!)V'/5<L>/<U4@\+:#;:7<:9#I-HME<\SP^4"LA_V
ML]>@Z],"@#FO#NG:=I7Q2UNSTR-(8$TJUS!&?DB8R2G '\(Q@X'][/>L;XB+
M%?7'B&:.PMY9M(TQ6-Y>7C1_9G8.R&W15/[S./FR,D**]#TSP_I&BL6TW3K:
MU9D$;-$@!9020">_+$\^M-O/#FBZCJ"W][I=I<7:IY8EEB#';SQSUZG\S0!G
M^(+"?7_A]=6T;M]KGL1)$Z\'S0H=#_WT!7!Q^*%N-;@^(#2L-+B6+3I%#84(
M]N9F./42O&G_  &O6K2TM["TBM+2%(;>%0D<:# 4#L*H'PUH9T>32#I5G_9T
MC^8]KY0\MFW;LD=,Y&: /*9=-\W0!!=Z=;W5_::,=2O)[^\>-+=[AY),QJ%8
MF0%6&[C 50#6KIX;6O'NAP7TCRI?>#/W^6^^7=0Q^O)YKT2]\/Z/J-_!?7NF
MVMQ=0#;%+)&&*C.0/P/(]#19>'](TZ:":RTZV@DMX#;Q-&@!2(MN*#T&><4
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M& &YB<'G JQX)N[J6PU*QN[F6Y?3-1FLTGF.7=!ADW'N0K@$]\9H Z:BBB@
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M&T;7PP.1D<-Z<]'X<U74M5BDDO;6Q6$JCP7-A>?:(I0<Y&2JD%<#/&#D8/4
M W**;)(D,3RR.$C12S,QP !U)KRW1->UB/7-,\4W]Y<'0_$5U):16LC'9:J<
M?97"]B^QLG_IH* /5**Y'4O%&L)K>KZ9I.D6UPVF6\5S)+<71C5PX8[0 C?-
M\AQV]34VA^,DU?5+:U>T^SQ7NE0ZI:2M)GS$;[ZD8X*DKW.0W:@#J**P=#\1
M2:SX6?73:"&)_-DMT+Y,D2DA'/'&X ''. 16-I7C?4KIO#]SJ&D6]IINN1Y@
MD6Z+R1-Y1E^==@&TA6Q@D],XS@ ';T5Q%EXWU&>'2-4N=(@AT35[A(+61;DM
M.GF9$3.FP !CC@,2-PZUSMWXJU-_ GB74/$6G6UW;VFJFVCAM[V2,_+<*FW<
MJ*0JG!!ZMSD"@#UFBN4U#Q/J_P#:VI6FB:-%?QZ4(_M>^Y,<DC,N_9$NT@L%
M(/S$#) ]ZHZE\06LKV^=+6S.FZ=.D%TTUWLN"2%+&./:<A XSDC.&QTY .YH
MKE=.\4:AJ?B&ZM+;3[1[*UNWM)R+S%S%M'^L:(KC83C'S9((..U=50 45P5M
M\0+^70[W6Y]'@BL()GLX<W?SSW G\E1RN%0DC+$Y'/! R7M\0)[:WOK>>RLY
M]6AEMHK>*SO/,AG-PY2/YRH*X96W9' &><T =U17!W_CK5-&;6X=3T>V%QI>
MG1WO[BZ+)-O=EP"4! ^7N.N?K6OK_B^'P]J3P7-N6@CTNXU%Y%;YOW3(NP#'
M4[^N>U '2T5P3?$*>Q@OO[1LK W,-E]MB6ROO-0KO5&61MHV%2ZDG!&"3VJ/
MQ%XG\3VOA47D%GIL4[7]K#'<V][YL,L<DB#*'9GJ=IR. <@GI0!Z#17(0^*=
M6N/$,^EPZ982-9/#'>1"_P 3?.BLTD2,@#1KOZDJ3M; R,5U] !17F'C3Q/J
MVH>$O$LMCI\2Z7:3-9&Y%R5G+HZJSJ@7&T-D?>SP3[5KZOX_;3M0U$QVUD^G
M:7,D-V\MYLG8D*S&./:=P4.,Y(S@@=* .XHK@]5\>:G8KK]U;Z+!+8:%<B*Z
MD>Z*O(FQ&)C781N ?D$@<#!.>+L?BO6(M4N]/O=#B^TC3FU"TBM[O<9%#!3&
MY95"MDKR,CD\\4 =?17!-\0;BTTS7Y;RSL)KK2;6.[VV%[YT4B.6&W=M!5@4
M.1CN#WJQ<^-KW1KN\37M+AMHH],EU.$V]R96*1E0T;@J '^=>A(YZT =K17G
M%WK>N1^+O#UQK&FQVRBQOKD16=RTH<"-#L8%5^<?B#GBND\*Z_J.O0+=7-E8
MK9S0K-!<65[YZY/6-\JI##CID=>E '1T5Q_B;QA>^';R5WL;+^SH!&7>:]"3
MSACAC#'@[MN>Y&>0/6H-5\::O:S>(VL=%MI[;0"&N))KLH94\E92$ 0_, QZ
MD#@=<\ ';T5P^K>*]1OEUFWT;38I[6PLEDN99;@QR$R1%PL:A2"0I!Y(Y('O
M5[1]8BT?X5Z;K-\SO';:-#<2G.6;$*D]>I/]: .JHKCXO$^NPWUI9:GH]E;W
M&I6\LMB([QG42(N[RI3Y8VG!SN4-T/%<GI?B#Q)J=IX"U&>&">^O'N2BK<%$
ME4P-AI/D^7')P W08Y- 'KE%<*/'MTMM]EFL+.'61J4FG%)+LK;@I&)3)YA7
M.W81QMSD@>]-?X@W;VVG1VFE07.H76HRZ:\27>8DE2,N&#[>4("G. 0">"1B
M@#O**QM9UN30/##:G>VRR72)&IMX),J\SE4"*Q X+L!DCISBLF[\5:SH]C<G
M5]"B%WYD$5F+6Y+PW,DS[%3>R@J0>N1TY&>E '7T5Q=UXSU'1X=;AU?3+9;_
M $[36U*);:Y9XKB,;@1N* J0RX/!Z@TQ?%OB)]9M=+&@V2SZA:-=V;-?-M1%
M*[A-B/(/SKPNX9.,]Z .WHKA;;QYJ&H1:%#9:-";[5/M:,DMT5C@DMW"ME@I
M)4G."!GIQSQ#!X^U=K%-0N-"MXK.#4AI=\1>%G67SO)+1C9AD#$=2#UXXR0#
MT"BN2N?&C0>&M=U?["&.EWLEH(O-_P!9L=5W9QQG=G'-5M5\9ZO;7/B-;#1;
M:>WT#:]Q)-=F,RH85E(0!#\P#'J0.!SSP =M17#?\)1IL'C6_FDLY$$'AY=1
MDN_/8YAW$[/+^Z",9W=>U7].\0^(9H?M%[X<00SV;7=M]EN_,;< "(I-RJ%=
M@>""1P>: .JHKSJ_\=:L-#\11I;Z8NJ6.F&^B>UOO/C5?F#!CLX==N<8PW'(
MJQ!K4I\1^#(=7L(CJ-[9W,HN(;MRD05%)^7:H8L".H^4YQ0!WM%</9^.-0GM
M]+U>?28(M!U2Z2WMY1<DSJ)&VQNZ; H#'' 8D;AUYJ/_ (3O5/LTFIG1;==)
MM]4;3IY#=GS3^_\ )$B+LP1DJ2"0>H[9(!WE%<KI/BC4-7URX@@T^T:PM[R6
MTE9;S_282A8>8\14 *Q7C#$X93CTFU[Q#J%AX@TS1=,TZ&ZN;^">59)YS&D7
MEE/O85C@A^PZX'?( .DHK@W^(%]]DT^.+14?5+C4YM*EM_M.$CFC5FW!]O*'
M .<9 /0D8-N?Q1KSW=_:Z?H]E<3:5!&]_OO&0-*R;S%%\ASA<?,V.HXZT =C
M17+Z'XS@UG4VMS!Y%O)IL&IVLS/_ *V%\[LC'RE#@'D]16+8^+(M9\0^#[BX
MTAHI-3BO9;67[4X\J)0-K%  &+K@\_=SQ0!Z%17F.H>)M7URS\,ZD-/CMM)O
MM:MOLTD=R3*4WG'F)M  8#/!.. :UK7Q^UQJ5N3;60TNZOVL(G6\S<[PS(KM
M%MX1F7 ^;."#] #N**\PUCQ/JVM:3I.H1:?%!I%UKEI%;S)<DS%%N57<Z;0
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M&S9][ISNZ=J .2U'PIK>OQ:]=ZB=/MKZ]TA]+M(()GDCC#;B7=RBDDL1P%X
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MZ,>U8\@,V,#)^ZHXZU[%]FM_M"7'D1^<B&-9-@W*IP2H/4#@<>PJK+H>DS+
MLNEV4@MY#+"'MT/E.3DLO'!)YR.] 'E.@3&?6/A*S/O*V>HIDYXVQ* .>> ,
M<UT?PRN[:ST/66N;B*%9/$5W$AD<+N=I %49ZDG@"NVBTC38)8Y8=/M(Y(F=
MXW2%049_OD$#@MW/?O4-SH.G7%LEN+:.&-;M+S$,:KNE1PX8\=20,GJ?6@#
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M^Q\^9]E\WS.AQC=QUQ^%9FG^#+NST'PAI[74+/H=RLTS '$@$4B87\7!Y]*
M*;^.=9AVV+Z79R:J-:&E.J3,(3N@,JR D9 QC(P>AQGBL3X@Z_J%W\.O%^F:
ME##;ZEIKVFY[61C'(DDB,K+D CHP(]JN^)M#O]/UZQNK:Y@$^H^)XKF#<I*K
MMLG3:_UV'IV-6=9\!ZMK_A[Q+'>7=E%JFMO;X\K>888X64JN2-Q)PQ)P.6H
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M2SNK'3$BO3:_:2S.XM(O+C7))"J.^!@9/)QF@#S_ ,(:M>Z;X7UZXMA:L_\
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M8Q&#&,]_D(!^F<5H:UX:U"7Q!/JVE)I4KW=JEO,FHQ%A&4+%9$P#DX<@KQG
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M[N(D@T:UEAL2;K4%6.;4,FW@98W<,R@C<?E("D@9(]* -;4/$^C:9!8SW-_
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MGS.=_P#L[MN<\8ZUS&N0Z;<7GCK^RX[633E\. W'D*IB%T!,5/'&\)M]\;:
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M*6BB@ HHHH **** "BBB@ HHHH **** "BBB@!" RD$ @\$'O2@ # & ***
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M0 M%)N7=MW#=C.,\XK,T/6X-<LGN8D:+;<SV^QR,DQ2-&3]"5S^- &I1110
M4444 %%%-DD2)-TCJBY RQP,DX _,@4 .HHILDB0QM)(ZHBC)9C@"@!U%%%
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M6Y%:- !12%E! + $] 3UH+*&"E@&/09Y- "T4A95(!8#)P,GJ: RL2 P)'4
M]* %HI%96&58$9QP:&95QN8#)P,GJ: %HI&944LS!0.Y.*&95QN8#)P,GO0
MM%9NA:S%KVF?;H8GB3SYH=KD9S'(T9/'J5)K2H **** "BBB@ HHHH ****
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M\07*2Z>5_@CG)%UCTV;)&_X&*]"U=)=+\(WR:2T-M+:V+BU:4@1Q%4.S)/
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MJJ9/O &0A=V<@'&>E=ZOAK0T1$31[!5CF-P@%NH"RGJXXX;WZTY_#VC26]Y
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MQ8ZS>ZK?WES<P%76>;=&,.V"%QP<<9KH(/#FB6NH7.H6^DV45Y<@K/.D"AY
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MG [DDD^YJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,&(99CQQU;&#SP ,4S0O%%W=:+X:T[0-,M(KF]TTWI2XF?RK:%2JXS@LQ+,
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M1%;><6(6,'G:N[ Z=.U8D_@?7;R.?>VC6HGT6YTDP6JN$C#J-K@[<GYAR,#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4.6P>%'/7@8/ J:YU6;09-8LA?RPZ3!XB@@EEGE>46\$ENKG+%@P0RE0?F&
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M.MRWVHW\5Q!&S?8H(X-GDA@ 2QW'<V 0#QP6]>-BB@"M/I]E<W,-S<6=O+/
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MS<D  9')(ZBK&B:U::_IJWUGYJIO>)XYDV21.I*LC+V(((H T:*** "BBB@
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M3<U%:^#)K*_COK4>'8+N)=B31Z(591C'!$W'''TH \Z\0''@;XK8_P"@PO\
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MVT!EC9=/TV9G2V<I\V0579N&UL >I[UTDVE:?<_:O/L;:7[6BQW&^('SE7.
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MT];I;/1K"W6[4I<"*W51*ISD-@<CD\=.:THHHX(4AA18XHU"HBC 4#@ #L*
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ME/ESC(P#BHO$/@[4]?M?$%SBS@U#4]/CT^&-IF,<:*S,69@F227/ '11SS0
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MWCECE4,0LD:L"58G)W-VQ@CDFNW\/65SIGAO3+"[\K[1:VL<#F)RRDJH7()
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MZM$F;8$*0[$/@J0P/RECCM4NI^.['3+K4[<Z;JMR^F*CW1M[<,$1@3OR6&0
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M]U-$3@JV5)&UAG!!KJ;_ ,1V]C/=P1VMU>264*SW2VRJ3$ASC.YADD*QP,G
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M Y7..<  Z6POK;4]/M[ZSF6:VN(UEBD7HRD9!JQ67X;T6/PYX;T[1XI#*EG
ML7F$8WD#DX[9.3BM2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBN2\?2SQ6FB?9[ZYLS+K%K [P
M2E"4=\$'L?QH Z6YL+.\:-KJT@G:,Y0RQABI]1GI2W5E:7R*EW:PW"J=RK+&
M' /J,UY7KAU/1K/QC8VFL:D;.T>PEM9Y+MWD@DE<"2/S"22-NTX).-WO6UJ0
M73_%$'AV76KBVL[JSEN89;R[E+23%P&59 ZGY5P0N<#<3C@8 /0  H    X
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MO--XGO8[;2H)["2WA-S=%GNFD"I(IA&?W8 ?J.N&)[T >NR75O$P62>)&+;
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M[]]'\O[P$>_KQ0!U^D:S+J44TESI%_I0C*@"^\L;\^FQV_7'6KIOK01O(;J
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M!;M9<>6Q\J0QA\\%?,"\'C.*Y?Q1%H,$'A^#P^R?9X_&EH)HXL^5',02RIV
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MHFF3ZCJ$PBMH%W.V,_D.YJ=[RUB1'DN8420X1F< ,?;UKC/B@MO>?"G4II(
MR"**5!,N2GSKSST.">?K5..P\.W'CK6+?5K;36L+?2[?^SXID3R4A)E\TH.@
M^8#)'H* /1:*Y?X<O<2?#W1&N6D9S;C:TF=QCR=A.?\ 8VUU% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-&N)'DFTFPD=XA"S/;(2T8Z*21RHP..E8S>/+#[#9W*65](UQ?G37A5$WP7
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MF@"Z]I;2W45U);Q/<0@B.5D!= >H!ZC/?%5(= T:W.8=)L(SYPN,I;(/WO\
M?X'WN3SUYK!U75+G4/B'9>%8II+>U73WU*[>)BCRC>(TC##E1G))&"< 9'.8
M;[4;GPQXXT;38)+F[L-9BN%$$TQD:*:) X*NY)PPR""< @'CG(!TLV@Z/<:>
MMA-I-C)9*V];=[=#&&R3D+C&<D\^]7888K>%(88TCB10J(B@*H'0 #H*\VN/
M$U_K'A_PCK;6]W:R7.LHK003<31D2_)@-AA\JCYL<C/ KIH/&UB]E/+<V\]G
M<PWQT]K6=HPWG;0^-P;;C8=V<] >_% &Q::-I=A=S7=GIMG;W,W^MFA@5'?O
M\Q R?QJS;VT%I L%M#'#$N2(XT"J,G)X'N2:Y1?B)I[6Z.EA>RRG41IK11>6
MVV8C*\[L%6'1A^.*MQ>+]UXUE/HFHV]X+ WXAD\K+JK;652'P6!Q[<CGF@"W
M<Z$Q\56VNVDRQOY!M;R)ER)XLEE^C*Q.#Z,PJU!H>DV=S]KL]*L8+I8Q&LT=
MNJ,% P%W 9Q@ 8K/L_%-MJFFZ==VEG=RQ:A9O=H$9 R(H'#?-PV6 X/7TQ5'
M1_%.GKHFAPZ?!>W#7M@;JVAGF4SO&@7(+.WS/\PXR>_(H U?#FAMHMK<M<3B
MYU"]N&NKN<+M#N< !1V55"J!Z"K<^BZ5<W;W<^FV<MR\9A>:2!6=D(P5)(R1
MCMTK%U?QUIND13O+%+(;:))KF-70/&K#. K,"S <D#M[\5TL,T=Q!'/$VZ.1
M0Z,.X(R#0!!'IEA%;RP1V-LD,RA)8UB4*ZA0H##&"-H"\]ABL>Y\.W.H>);*
M]O;FW.EZ:WFV-E% 5(E*;=[L20=H+;0 .OM27&N7+>.$\.BQD-J^GM</.D@4
MY+JH(Y! '/3G)XZ9K \!>*G&@>&K#4(+^274(Y$BOYF5EED3<Y4DMOSM4\D8
M..M '?S0Q7$$D$\:2Q2*4>-U#*RG@@@]144MC:3I DMK!(MNZR0AXP1&R]&7
MT([$5S]IX[TJ]U73[.(.T>H[Q:SJZ,KE1N^8!BRY )&1S['BJ?Q$NI;*+P])
M%=7D"S:S;V\XM99%,D3!MRX0Y.<#ISZ4 -UOP1>ZUJ-X)KW3OL-ZZ^;(=/7[
M8D0VYA64$#:=O4@D GKQ77FRM3]HS;0G[2,3YC'[WC;\W][CCGMQ7.VU_86/
M]JZA:MJ\T5C;[I[>X:4D\%LH)R.< ^@.?44V#QREQ<6$$>B:D7U&S-W9?ZH"
M< *67[_RD!P?FP#V[9 -^32--FN+>XET^T>:W79!(T*EHEQC"G&0,=A1I^D:
M;I*R+ING6EFLAW.+:%8PQ]3M S7.Q>/[6XBTLVVDZE-/J0G6&%%CW+)"2LB,
M2X ((ZYV^]9FL^)DUWP]IE_8F]L9H?$%I9W-N[F-XW$Z*\;A3AA@^X((H [2
MXT?3+RZ^U7.G6D]QY9A\V6!6?8005R1G:03D=.34YM;<RPR&"+S(05B;8,Q@
MX!"GL#@=/2L/4/&%G81:C<BUN;BRTR3R[VXA"D1' 9N"<MM# M@<=LD$">'Q
M-:RZ_/I)@F1X[,7J3L4\J:(G&4.[/!ZY QD>HH O66D:9ILLTMAIUI:R3G=*
MT$*H9#ZL0.?QI+_1=*U1T?4=,LKQT&%:X@60J/09!Q6#=^/]/M+ W3VMQO2T
M6\FMV>)98XV!(^4O\S8!.T9/XD RQ^-8+K5QI]CI6H79,5O<>;&J!/)F)"R<
ML#@8.1C/L<&@#6M_#^BVD,L5MI%A#%*5,B1VR*'*G*D@#G!Y'I5S[-!]H:X\
MB/SW01M)L&XJ"2%)ZXR3Q[FLW7?$$6@MIZRVES.;ZZ6UC\@*<.02,Y(Z[3S^
M>*Q9?B#!;VE]<3Z+J4:Z=<BWO\^4?L^=I#'#_,"'4_+D@9SVR 7)/!FFW'B*
M2]N;.QGT\V$-I'926RLB&.21@P!&!P^!QQBMTV%F9;:4VD!DM01 QC&8@1@A
M3_#D<<5C:EXNMM,O'BGLKOR([N"SDN-H"^9+MV[02"P&]<D=,]\'#O\ A*[9
M;S7+6:TN89-(A$\OF;/WL95B&3#<@[2.<<C% &BFC:7'J;:DFFV:W[##70@4
M2GZOC/ZUF6>@7;^*I->U6[@GDBB>WL8882BP1LP+$DDEG.%!/ P.!S6G=ZK!
MI^BOJE\LEM#'%YDB, 77_9P"<MGC SS6;-XKALA?'4M/O;(6D4<NYT#+*'.U
M51E)!?=\NW/4CMS0!IR:1IDVI)J,FG6CWT8PERT*F51Z!L9%!TC3#J8U,Z=:
M&_ VBZ\E?-QC&-^,]/>LJ?Q?!9W%]:WEA=PW=I9F_$'R,9H1PQ0AL$@\$$CJ
M.N:ALO'%E<W$"7-E=V,-QI[:C#<7.S8\2A2_W6)! =3R!0!T5U:6U];/;7EO
M%<6\@P\4R!U8>X/!J!-(TR*UM[6/3K1+>V<201+ H2)QT91C"D9/(]:S(]>&
MIDV;:=J-LEU9-<P7!&U2O P64Y1_F! .#CW!%9'@WQ'Y?AKP=97BW5Q=ZI8;
MUN&8,"R1AFWDG=DCO@T =/+H.C3S7,TNDV$DMT MP[VR$R@$$!B1\W('7T%2
MG2]/*3H;&V*W#B28>2N)&&,,W')&!R?05CVOC&SO((##:W)NI[R:RBM6VAV>
M(L)#G=@*-I.<^G<@5A^&/$:Z?:Z[+J3W(=M?EM;>&YG#,I\M&V!F; 4 ,>N,
M#CTH [K[-!]I:Y\F/SV01F7:-Q4$D+GKC))Q[FJ4OA_1;@6PFTBPD%J,6X>V
M0^2/]C(^7\*A\/>([3Q%!=/;(\<EI<-;S1N5.& !R"I(92"""#^M<7XD\2ZA
MJ7A'Q<WD75@=+OEMX9H9]IP/)R"4;))WL<8Q@@<F@#TB>"&Z@D@N(DFAD4J\
M<BAE8'J"#P15";PYH=Q;6]M-HVGR06W^HB>U0K%_N@C"_A6=_P )C!'+JT%S
MIFH0W&G0QSF#8KO/&Y8*4"L>I4C!QCOBJ&N>.FL-#\036NGR'4-(\M)(G="H
M,@!5\@\CGD=<C'O0!V0 4    < "EJ."1Y85>2%X6(YC<@E?K@D?K4E !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLH]#CTF!9)&#_(6(9L+C'S8_"L^X\!WUYX7TW1KJ/3I)+#3H[>VO5E=)K6=
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MR<G@_5WTF[M/,L1)/KRZJ#YKX""59-GW>ORXS[YJOXJTR;3[/Q9?W\E@EKK
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M "BBB@ KC_']O#=KX:@N(UDB?7+<,C#(8;7X([CVKL*:R*^-RAMIR,C.#ZT
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MKB,QS1I)&>JNH(/X&CR8MC)Y2;7^\NT8;MS0!X]J<#7.H^*+2_U[2=-ENKN
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M(I)"Y+.2.A )*DXXKU\F&W1G8I&I.6)P!D]S35M+9?N6\0R_F<(/O?WOK[T
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M9B9K:%)$EM)L@>5*A8D\$_-\O*].:[^TM;N+24M;F_>>[$6U[L1JA+'^(+C
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MXYJ:^U?7+_Q/>Z-H+Z?!_9]M%-/->PO+O>0ML10K+@80DMSU'%/T?P[J<'B
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M/1M.MHYYFO4=_.>3?MC7:R[>$Y8YZCBJOPPT";1O#)GNQ.+F\<,JW Q)';H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,H888 CT-+10 F!G.!
MF@@$$$ @]?>EHH 0  8  'M2XHHH S=9TR?4[2..UU*XT^>*42I+!@Y(R-K*
M>&4YY!]CVJ'0=!714O))+N6]O;V?S[FYE55+MM"@ *, !5  K8HH 3 .>.O6
MDV)E3M7*]..E.HH *0(JKM50%] .*6B@ I-J@DX&3U.*6B@ P/3K2*H50J@
M#H!2T4 )M7).T9(P3CK69H^B1:.U^4D,IN[V2\)90-A?&0/;BM2B@#+L-$BL
M=7U;4!(9&U&:.9D91B,I&L8Q^"Y_&M,JK$$J"1R,CI2T4 )M4MNP,XQG':E
M Z"BB@! B@8"@#.>E+@>G2BB@! JABP4 GJ<=: JJ20H!/)P.M+10 C*KC#*
M"/0C-+@444 (0""" 0>H-&U?0<>U+10!5U&WN;JPEALKTV5PX 6X6-9"G//R
MMP>,CGUJ#0]&MM TB'3[5I'5"S/+*<O*[$LSL>Y+$D_6M&B@!&56&& .#GD4
M,JMC<H.#D9%+10 =Z3 ]!2T4 )@<\=:"JL,,H('8BEHH 0J"02 2.GM0RJRE
M6 (/4$4M% "8&,8XI:** # ]*0JI&" 1UZ4M% ";5W;MHW8QG'-+C%%% "!%
M5=H4!?0#BDV)LV;5V^F.*=10 8 HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***P/$OBRR\,)!]H@NKB29U4);Q[
MMBLZIO8G 4;F4<G)SP#0!OT5BZWX@;2KJTL;73+K4K^Z#O'!;E%PB8W,S.0J
MCY@.N23Q4V@:Y!X@TS[9!#- RRO!-!. 'BD1BK*V"1D$=B: -2BBB@ HHHH
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M22T%K_PD7_"0J(F&//\ ,^W=/7'E9]L5)??ZWQYYO_'B?$%@+[T^S9C\S/\
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MX>\.Z9&@MK-;D1(#@*9IG4=3_$[>IY-00^%)[:*>*#5$BCGSYR)IUNHDSUW
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M,M@]<FO39M,L+B=IY[&VEF9/+,CQ*S%/[N2,X]JG,,1F28Q(944JKE1E0<9
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MZB7\AC(TJE&$;'/^KW)P>N,"@"Y:^(M8U34O$,'V*Q&EZ5-+;RL[,9)L0JX
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M+! TIC"ABQ)WG#$KQ@*..YZRX\)W0T'P[!:W%M_:.B)&L;3QEHIL1>4ZL!R
M0<@]B!0!B_\ "RQ+8VL27FB0WLMY/:O>S77^A@1*K%U;(+;@\>%SU8\\<J/B
M)<75II@MYM&MI;F6Y@EO+F=FM#)"RJ%C=<9\P-N7)Z ]36K<^&-7GCTZ_-UI
MKZO932N$:V*VS1R#!CP#NXPI#<G*].<":YT7Q$^F00?:M'NRPD%W;75EBW?<
MV5V@'(VCY><[AR<&@#<6>_DT,3F&"'4&M]YC9R\:2;<XR,97/<=JX+PQXI\1
MW'A;PO;,;*YU?68Y)8YYM^R.&-069P#EFRP  ('(]*[C0=(_L7PW8Z09S-]E
MMUA,F,;L#' YP/0=A7):7X)US2M*T)8M0T]K_0O,AM7,3^7/ Z@,L@SD-PIR
M./EZ'- '1^&=;NM5&HVNH0PQ:AIMT;:<0DF-_E5U=<\@%7'!Z'-<Q>>)ETC7
M?B#<VVEVHNM*L;:X,W.ZY/E,P#\]!C QZUU'AO1)](34+B^N([C4-1NC=7#Q
M(513M5%5023@*H&3UY-8FI>!;B^O/&DZWL2#Q#9PVT0*']R4C9"6]<[L\4 3
MPZ]XC&O0:7=VVFQOJ%C+=691G;RF0H"DO][B0<KCH>*X?X=7VHZ7X3TZYM[3
M3I]7\17TL,=Q)OWL4>9G>9NK!50[0,=:].GT.27Q1I.K"90EC:3V[1XY8R&,
M@@^WEG\ZYW3? 5[I7A/0K&VU"#^U-&NY;J"=XR8G\QI-R,,YP5E(R.A&: &:
MAXYU;1]/U:*ZL+2?5=-N[2$K S+%/'<,H5ESRIY88)/(ZFKMQKGBB'6=-T(6
M^DG4;NSGN99@9/)BV2(!@?>;AP.W//3BH+GP1?ZE:ZC/?7UM_:>H7MI<2&&-
MA%'';NI6-<G). W)[MTXKH)]%DE\966N"91';V,UJ8L<DN\; Y]MA_.@#E=/
M\;Z_<66D:I=:?I\5C=ZB-,FC21S)YGF-$9%/0+O7[I!..]==XBU&XTK1I;NV
M^QK(K(IDO9A%#$I8 N['L!S@<GI6'#X+GB\.:9I9O(R]GJXU%GVG#+]H:;:/
M?#8S6IXIT6YUJSLQ9R0+<6=Y'=QK<H6BD*Y&U@.<<Y![$"@#F8/B#?7&EHUI
M'IE_=_VTFE>;;3'[/+OC#B16Y( W $<XP>M2W/C76=(CU8:E:64CZ1=6INY;
M;>%-K-U=03D,O).21@&I(O!6K-J+W-WJ5K+YFKP:J^R)E(9(A&R#D_+A5P>O
M7-7=4L=,T>?Q)JVO7L$>EZM##;NC\8"HRE?<MNX YH T8M<FN?&<NC6T4;VM
MK9+<7,^22LCL1&@[<JK,?P]:S_%'B:\TG6+'3;233+9KF&259]3D9(Y'4J!$
MI&/F.<\GH.AJ#X9:+=Z5X2BN-2:5M1OMLLK3+B0(JA(E8=B(T7(]2:TO$NE:
MMJB^39R:9+9RQ-'-:ZC;F1,GHX(YR.1@\=.E !8:_=W.NZIIUQ:QPFRL;:YP
M'W'?()-RD]" 4'(KCM+UG7-=\6:;J6F06,=W?>&8+B0W)<Q19E8X 7DDDXZ]
M,GV.W!X.U?2;I#I.J6_E2Z7;Z=<R743-(/)# 2)@XR0YX/&0.O2H--\%Z[H4
MNEW.F:C8O-9:-%ICQW$3[)"K%M^0<CMCKW]<@ @'Q!O[NUT@0II>G7-Y%/O;
M49F$33Q2>6T*,,<D@G)[8X-+KOQ%GTN]OXM^BVSZ7;QRW-I>7@6>X=D\QHX>
M0.%( ;!R3C JXO@[5[+PY;:-:W>F7MNT4HNXM1M2R/+([.TJ@'/5V^4]L<CN
MD'@K5=(9DT?4;(I<6UO!/-?6QDD1XHQ'YJ<X)*JORMQD9YZ4 )?>,=9F&O7N
MBVEC+IVC0AG^T,XDN'\D2G;CA0%9>N<G(XZUJ:%XFN-5U2:TE@B18]+M+[<F
M<EIO,R/H-@Q]:Q/$_AW5["P\67.FW]I'IVIVKS7*2Q,98W6#8WED$#YE0=>A
MYYZ5+I>@:OC3]6TF^M(4O=&M;2Y6XB9F38"5=,$ G$A&#QP* ,]/B7<75EIA
M2?0M/NI]+CU";^TKGRT8N6"QQ\@Y^1LMSCC@YK3M_&&KZ]?V-MH-K9(MWH\6
MIB6\9B(][$;"%ZG@>G<^@,6G^!]5T.TTXZ9=Z=)=0Z9'I]Q]L@9D;RRQ21<'
M((WMP>N1R,5T%EH$]KXF35I;M)L:7'8MB,(6=7+%\#@ YZ#I0!R=CXKU_7/$
M7@^2V^RVUK?V=S+<V[%FRT;HK\CKC/R_4YKN=8UFVT:&!KAEWW,HAA5G"!GV
MEN6/  56)/MQDX!Y:P\$ZGI4OAJ>TOK1Y=*6YAG$L;;9(YG#$K@\,-O?BMSQ
M3H=YK%O93:9>)::GI]R+JUDE0O&6VLC(X!!VLKL#CF@#.7X@6ILXYAIUV\AU
M-=,=(RC!9&(VL&W ,A!&"/QQ4=S\0/L=MJTL^@WZMH\@%^HDB/E1E5<.#N^;
MY6S@<\'VS8U'0==U:PTW[;=V+7EOJ,-[((U9(@L9R(TSD\_WCZ].U5-4\'ZC
MJ$'C"%9[5!KZHD9)8^2%B$>3QSP,]O3WH LZEXX-E>ZM:VV@ZC>MI<4<\YA,
M8!C<,=RY;GA3QU/I51-8M[OQ[H^IV]Y)_9MUH$]U\TC"/;OA(8J3@'#'G&:I
MV OKCQWXLLK26Q$[Z?912%Y"?+;9*-P 'S8ST.WMR*TX_!"P7VFQ1NATJTT:
M326C9B)'5]F6SC&?D_6@"[!XP@DDTAIK.:"TUCBQN'(P[%=ZJXZH64$CKTP<
M'BBS\7)>:=<7"Z?.EQ!?_P!GO:.Z^9YFX+V.,88-G/W>:IZ?X2OELM T[4[F
MWFM="E66"6,$/.41DCWJ>%P&R<$Y('3I4.BP:9KOC:Y\1Z1>&XL/(02;!^ZD
MNAO0.#_>6,E3_O+W' !</CK3_M]I#'$TT%U=M9I+%(C,) 2,LF<A"5(#?3H"
M#5CP_P"*9/$,S^3HU[!:H\\37$S1[1)%)L*8#$\X)R,CCK5/0_#VOZ'<R6$.
MIV;Z"+AYX5:%OM*!G+^5NSMV[B?FP3CCT(T?"FC76AZ;<6MU)#(TEY/<JT1.
M )9&DP<CMNQGO0!+>Z[Y6IS:;96CWMY!;BYEC1U7:A)"C)_B8JV![')'&>:U
MCQ0=8@\)RZ3#)/IVK7A$HWB-G58I6,3<\89!GM\I%;4^A7MMXMFU_2Y(&-W:
MK;75O<%E!*$E)%8 \C<P(QR.XK/C\&7%A:^&+6PG@>/1[E[J5I<J9G=9 V
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M4;9(8=2E=626;86VGYBP) ."1R1^-,L=1@LO#.J-J*:A=P+XFDMU,=RP>/\
MTE5CRQ8,5!VC'/';%:^C^#[RVTSP_I>H3V\EIH4BR0O#NW7#JK*A8'[F Q)
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M54<X #\9_NCUIL?A"]-KJ-K>0:7?V=]J,UY-:W&[:RR 84-M.&4@'<!Z].M
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MD@]L=:\GT&VL;N\\+PI:@61\2ZHT4$B8"J%E9 5/3&!QVQ5O78%.M>+=-O\
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MQ+I$MIJD4#QH/)G#(Q:14(W+GD;LUMZCX@T;2)XH-2U:QLYIO]6EQ<+&S]N
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M'(4^E4_#'C73-?L; 2WEE!JEU&9/L N%,@ )Z+U/ STK-U*YM++XQ:4]Y-#
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M?P:GHVF&]EN_#J3K!)<"$8,H(RQ!P<8' /X#F@#T-(TC!"(J@G)"C'-*  ,
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M?:G"=2TP2:.(TDM7MG\R_?RU>0H0V(_O848;D<\4 >F,BL5+*"5.02.E+M&
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M "EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+PW#9^;);G#E)& ^4/PP&"1GOVK?M?!2V$_APVEZ%@T83;DDAW-<-*"'8D,
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M+@2*NP2)\PP=O!!R. ?JVQ\'_P!E:O:W6GWD<=M::2-,AMW@+$*""'+;ADY
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M])(6?9-N=EQ@\KC:1CGIG/-5]=\-ZC:6.LZQJ>IVZ-*]I>J]O:NXMIH'&WY
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MEU+4IA%;QD#J,L3T R1DUYS=W6@1P>/TUB2R-Q<?-:B0J6FMC;((?*_O#=N
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MNBOEQ>2T)$@) 8' "G#!JUH=.,U]\3+NTMU?5@3':RA<NK?8UQM/4$D]NO%
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MS@M9<>7/+.JH^>F&)P<TZ[U33]/ACFO;^UMHI2%C>:945R>@!)YKQO1A+ =
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M*20ISC(S0!Z?14%E>VVHV,%[9S+-;3H)(I%Z,IY!%3T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MR6&*>)HIHTDC;[R.H(/U!I]% $#6=J[Q.]M"S0_ZMB@)3Z>GX5*Z)(C)(JLC
M##*PR"/0TZB@".*W@@&(H8XQM"X10.!T'TY-,>SM94C22VA=(B#&K1@A"/3T
MJ>B@!KQI+&T<B*Z,,,K#((]Q47V*U^R_9?LT/V?&/*\L;/RZ5/10!$+:W4 "
M"( $$ (.W _*L#Q3X5;Q!X=ET2SO(M,M+@XN?+M0Q=#R0O("DXZX-=)10!67
M3[46]O \$<J6X41^8H8K@8!&>]236T%PT;301R-&=R%T!VGU&>E2T4 1M;PO
M.D[0QF9 0LA4;E!]#VI?*CRY\M<N,,<?>'OZT^B@!GDQ#9B-/W8PGRCY1TX]
M*CCL[6$((K:% A)0*@&TGJ1Z9J>B@"O]@LQ"(?LD'E!MX3RQM#>N,=?>GBV@
M%R;D01B=AM,H0;B/3/6I:* &I&D2[8T5%R3A1@9/6FF"(HZ&)"LARXVC#?7U
MJ2B@")[:WDFCF>")I8_N.R LOT/:GK&B,S*BJSG+$#&3[TZB@"**V@MVD:&"
M.-I#N<H@!8^IQUHAM;>W:1H((HFD.7*(%+'U..M2T4 -CBCB7;&BHN2<*,#-
M1"SM07(MH<NX=SY8^9AT)]3[U/10!'Y$.P)Y2; VX+M& <YS]<\TU[.U>9IG
MMH6E9=K.4!)'H3Z5-10!'-!#<Q&*>))8VZHZA@?P--DL[66)(I+:%XXR"B,@
M(7'3 [5-10!C:AX>@O\ 6]+U!F14L?/W0>4")?-4*<_EGH<UJ?9;?[-]F\B+
M[/C;Y6P;<>F.E2T4 1K;PHL:K#&%B_U8"C"=N/2D:UMWN$N'@B:=!A9"@+*/
M8]14M% $7V: 7)N?(C\\C;YNP;L>F>N*3[':F9YOLT/FOC<^P9;'3)[XJ:B@
M"(VT!N1<F",S@;1+L&X#TSUQ0EK;QW#W"01+,XP\BH S?4]34M% $;V\$DR3
M/#&TJ A7*@LH/4 ]J([>"$$10QH" I"J!P.@_6I** ,#5/#CZOJ=@UQ?!=)L
MY$G73XX !)*ARA9\\J#@A0!R!SVK0UO31K.@ZCI9E\H7MK+;^9MW;-ZE<XXS
MC/2K]% %2PTZ"PMXXXXX_,$:QO*J!3)M&,FI_(B\CR/*3R<;?+VC;CTQZ5)1
M0!''!## ((XHTA P(U4!0/3%!MX6@\@PQF' 'EE1MX]JDHH BFM;>X:-IH(I
M&C.4+H"5/J,]*)K:"X*&:&.4HVY-Z!MI]1GH:EHH @DLK2:-8Y;:&1%;<JM&
M" ?4#UJ8@$$$ @\8I:* (8K.UA@:"*VACA;.Z-4 4YZY%++;03JBS0QR*A#*
M'4$*1T(SWJ6B@"(6UN'WB"(-N+YV#.X\$_7WI9H(;F(Q3Q)+&W5)%# _@:DH
MH C\B(+&OE)MC(*#:,+C@8]*>0&!! (/!!I:* (_L\'EHGDQ[(R"B[1A2.A'
MI3A&BNSJBAVQN8#DXZ9IU% $+6=J\'D-;0M#G/EE 5SG/3IUI?LUN)FF$$?F
MLNPOL&XKZ9]/:I:* (8[.VAA$,5O"D0.X(J +G.<X^M2;$\PR;5WD;2V.<>F
M:=10!$UM ]PEP\$;3(,+(4!91['J*&M;=KE;AH(C.HPLI0;@/0'K4M% ###$
M?,S&A\P8?Y1\PZ<^M!AB)4F-,J"J_*. >H%/HH 8(8@(P(T'E\)A1\O&./3B
MF26MO+$\4D$3QR'+HR ACZD=ZFHH B%M !@0Q@9!X4=1T/X8%*]O#)OWQ1MO
M #[E!W = ?6I** (I;6WG,9F@BD,9W)O0':?49Z4/:V[S&9X(FE*;"Y0$[?3
M/I[5+10!!]CM=P;[-#N5/+!\L9"?W?I[4LMG;3P+!+;PR0KC;&Z J,=,"IJ*
M &^7&2AV+E/NG'W>W'I4<MI;3QO'+;Q2(YW.KH"&/J1W-344 57TZV>^M;PI
MB2UC>.(#@*&VYX_X"!^=6-B>9YFU=^-N['./3-.HH ADL[6:'R9;:%X@=VQD
M!7/7.*R]<T:^U&2UET_5%LG@W9CEMEGBDSC!*D@AAC@@CJ>M;5% &1HOAZUT
MC04TN0_;%WO+-).@/FR.Y=V(Z<LQ..U:3VMO);_9W@B:' 'EL@*X'3CI4M%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;^8PXR%/ELW;(P>:GU6=9SX@LXDFDN=9GM)M.(A;$B;(EW XXV,CL<XP.>]
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex1012022063010qngcbasho011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZT /HIAFB$ZP&5!,REQ'N&XJ, G'IR/SILMS!!)%'+-'&\K;8U=P"Y] .YH
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MLJ-+& 70,"R@YQD=LX/Y4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\2:O<Z5-HBVXC(O
M=3CM)=XS\C(Y./0Y45NUC>)="DUVSM5@O/L=W9W4=W;S&/S%5UR/F7(R""1C
M(ZT <WKOB[6+'4M7M;)+5FMK[3K: 2J<$7# -N(/OP>WO4&H^*]?T";6=-NI
MK*^O8DLFLIEMS$NZXE:+#KN.0I7/!Y'%:(\!S33W=U>ZRT]S=WME>2N+<(H:
MW8,%5=W"D #J2/<U9USP5%K=[J=T]])"]Y;6T,91 3 \$K2I(,GGYF''M[T
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MAKGQC?6OBR&U.IZ?<02:F+%K&WMI&,:-P&:?[HD!P2F..G7FJ\WBSQ,WA_\
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M77D B-WW HR9^9=K,#R,Y[4 +J>J^(-(TN&+4]5TFTG>\:);WR'=IHMA92D
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MAMX>N/#WA"".^\S[?<GSI_-.77Y0J(Q]5C5%^H-:+>&U/CM/%'VH[ETTZ?\
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M.N;C7+Z*QADXT!<B*+=E$NXV90O\1V!L+WZ=Z .\M?%6A7FGW%_;ZI;/:VQ
MFDW8\O/3=GD9SQZU5E\<^'$L-1NXM5MYUT^+S9UC?)"] 1Z@G@$<9K@-:CM]
M6\-^*=0M];GUJ1[""VDD6S$41 E+!05 W,,MD=@PK=\86DC^(K^.VMV._P )
MWT2+&G4[DVJ,?C@4 =GHFM6>OZ-;:I9R!H)D#=?NG'(/N.E41XNT>_T[4I=)
MU?3Y9K.W>9F=R8T !P[8Y*9')%1>%[VRU+P!8/"S7,"V"12+&#N)6,!E ZYZ
MCZUP0O1)X;UW2M/OUUG3X?#=VL,[VGEW-EA JV\C  ,6'; .8^<T >BOXITK
M3]*TVYU;5;&%[V%71T<A)?E!9DSSLYSD] 1FI)?%>@P6D=U+JUHL$ID6.0R#
M#E&VN!ZD-QQWKA-"NX-"U'PM?ZL)(;27PM!:PRF)F F!5F3@'#$;<#OMJIX+
MMXY)/!#+:&.**ZUDK&R?ZG]ZX /H1TH ]&/BK01HR:O_ &K;?8)'\M)@_#/G
M&T#J6X/'7BEG\4:';:5;ZG+JEL+*Y;;!*'R)&YX7')/!X[8/I7FD\5Q9ZR^H
M->OIEE;^(K[S+O[.)%A+PH%8@C !.Y=W8M[U9M&LM$U;P[KEQ?W%QI#W&HL]
M]<6WE(DTNS:VT#Y5;9)@\9W>] '=^%_$/_"11ZI,A@:"VOWMH)(3D21A$8-G
M/.=W:L_3O'FF-?W]EJM]9V=Q#J,EG!&7P748"DYZ$DD=@2.*A^'3QS0^)+B&
M%XH9]<GEC#QE"RLD9#8/.#U_&N/U"]L8_#?C[1GA?^U-2U.X2TA\H[KEV"*A
M3CG##\,9XH ]:M]2LKM;IH+J*06LK0SD-_JW4 D-Z$ @_C5'4?$VEZ=X6F\1
M-<+)IZ0>>DB'B08^7;]> /K7!^*[;4-*UZ?2K,/CQ?;QVK2(.(KA,)*_MF L
M?K'77^,+ 1?#37-/L8#M329H88HQDX$1"J!^5 %+_A8.FC5-/WW5M'I5WITE
MV+AR=WF+(B;!Z_>;@#/%;4_BK0;;2[;4Y=5M19W7^HE#Y$OKMQR<8.?3'-<K
MH5Q::MXS\.W]J5G@3P_,JRA3A7$D*D<]#U'YUS-@L^F7&E7\VIOH]DDNK0+=
M&V61(W:\W!3N&%W*IP>^W'>@#V.VN8+RVBN;:9)H)5#QR1L&5U/(((ZBN+T;
MQ3XNU_2HM3L/#FE?99F<1^;JKJV%8KR!"<<J>];?@NTALO"=E%;S7$T)\R5)
M+B'RG(=V?[G\(^;@>F*\O\)3>$H/#5M%JOB'6K.^5Y?-MX;Z[C1#YC8PJ':.
M,'CUH ]4O_%6C:-^[U?4K6SN5C222)I,E0V>1QDCY6YQV/2GVWBK0;S4?[/M
MM6M)KHQF01I(#N4#)(/0X!!XKG(EAO?'^M7L:>9#-X>MA%*4/S*SS''/K\O'
MTK#TRU,/AWX8A8"A2%R^%QMW6<A.?3)_6@#O+'Q?X>U.^BLK+6+2>YF3S(XT
MD!+C&[CU.#G'7%9GA[QG'?:7KFH:Q):V-OINJW%B)"VU2J, I.3]XY[=^E<1
MX<OK'4O"GP[TC3E/]I6MS!<S0B,AH8UC<R2-QPK;N#_%O'6H],BDMK"XO[B&
M7[#9>.;BYNOW9.V+#*)".ZJS*<]L9[4 >HV_BG0KNT2Z@U2V>%[A;4-NQB5O
MNH0>0QR.#ZBK=UJVGV-PL%U>0PRM$\P61P/W:8WM[ 9&3[UP!TR'QM?>,I=/
M?_0;VUM8;:[4$(]U%O82*>^TF,9'ICM6,W]H^-?"GB#Q,]K-'=?98+"*$1[F
M"Q.LEUM7^++[UQW\L4 >G6?BC0]0L+F^MM5M7MK49GDWX$0QG+9Z#'.>]3Z5
MK6FZY \^F7D5S&C;'*'E6QG!'4<$'GUKRW5;<:SIVK:G8:_=:O)$ED+B6*P5
M4$4=P)"  ,.RKO)7G@X/7%==X,%O=ZQJVJ0:Y-J[31P0R3_95BB)3>0%*@!F
M ?!].!0!O7GB;1-.U.+3;S4[:&\DV[8G?!^8X7/ID\#/7M4-_P"+_#NF7+V]
M]K%I!-'((W1Y,%&PI^;T&&7D\<BO._'6H332>*K/[2UK-&T7EV-M9*TEY$J(
MYF=RI)5?F&01CR\=2!6C<Q1W6C?%*YAC$@NHB8Y N?-7["A7'J,DX^M '8ZY
MXKTC1/-M[C4+:.^\AI8H)'Y/!VY] 2,#.,]JMZ%J3:IX:TW5)PD;W5G%<2!>
M%4L@8XSV&:\X6_M-)?Q7:ZJCFXU33K<V<1B9C=)]E";$XY(<-D=MV:ZS3I9[
M/X0VDT-F+JXAT)&6U=,B5A ,(5[Y/&* -G2?$FC:[)*FEZE;W;Q ,XB;) /1
MO<'!Y'%+JOB'2-#>%-3U""U>?/EK(V"P'4_09&3T%<%X4OTF\>Z;(-7?4()=
M&E@BE6T6"%9%>)C%'M4?=4$X).!^-:^J:C::%\3?M^K.8;2YT=;>VF9"RF19
M69XQ@'YB&0X[X]J -?POXGBUS2;&:Y>"*\O&N#%"A^^D4I0D9Z\;2?K5;Q%X
MO&FRZ*NG&WNEO=:32[@DD^43NWXQ_$"O>N'\,75OH=MX)U#4(WL+%(]4@9I4
M($+O."B-Z$A3CZ5%+YEW;Z'<);SJLGCQY@'C*L$+.02#R.".M 'K<>L:=-I]
MQ?QWD+6EN9!-+N^6,ID/N],8.?I3Y-2LH=,.I2W44=D(O.,[MM0)C.[)[8KS
M3Q!8W,'BN\\(P1O]@\53Q799>D:I_P ?8S_M*B?C(:['QQ<M8>$+B2&"!D$D
M*,9H/-2%#*@:0IWV EL?[- %VV\4:'>:=+J$&IV[VL4BQ22;L;'8@*I!Y!)9
M<9]13=?\4:5X=LKVXO;E ]I;&Z:$'YV3) P/=AM'O7E]]<-<6WB]EO;K4]ZZ
M;=QW#VX0SPQ3#S'144!E7!&0.W<8K0\2W\/B*^\43Z2)+NW;PI+%'+'&=LC[
MW)"''S=1T[\=0: .F'Q#TL:O:B6[MHM*N-.-VEPQ.XR>9LV#U_BZ#/![5N7/
MBG0K33;74)M5MEM+O_CWD#[A+QGY0.3QZ=*Y7P]<6FJ^.-*U"T*SPKX=*),%
M. PF4,.>AX(K!\+SPZ!>:#JFKYM]-%MJ5K'/(IV02F\+ $_P[D4@'OC% 'I$
MWBG0;?3K?4)=6M%L[D,89S*-DFT%FP>^ I_*J\7B2V?4[DG4=..G1V"7H"EO
M.5&R=[=MA'3O7 V%DUQJ?ARY:U<65UXGOKVV62,C$1CD*/M/W06&X9]16O-?
M)HWQ6\2:M<QRFUM]!AD8HA8MM=C@>I]J .KL/%_A[5'G6RUBTF-O$9IL28\N
M,=6.>@]ZDL_%&A:A8W5];:K:O;6HW7$F_ B&,Y;/08Y![UYOYL/B#P1XAN8;
MM;OQ)J,*7-U# A<PP(ZD0(",,%7(Q_$S-ZTS6(H]7TG6M3M-9N==:*&S6X\N
MR$:&%+D2,HV@;F"A\KU ;WH [O3/&-IK/BQ=,TV>WN;,V#7+2H3N5Q(J[2.P
MPV>1Z5JZMX@TG0A%_:E_#;&7/EJY^9\=2 .2!W/:N4TK5-/UOXK_ &_3#Y]M
M_89C-TJ$(["=3M!(Y(!_7ZU-JE_:Z!\2O[4U>06]C/I"V]O<NIV+(LK,Z9[$
MAD(]=OM0 GC+XA6N@VVD#3;FPFFU2=%CEFD)A2%@293M^\.,<'O56W^(IO\
MQJN@VEUI7DPVR23SN7S+*<Y2,#H!C/-8$=E<Q:/X$+6TL2/XEEN(HF0@Q0NT
MS)D?P_*PX/3-=%;Q2?\ "U/%;[&V-H]N%;'!/S\4 ;UKXJT^W\,V.JZOJNG!
M;GA9K9F\J5LGB//S'@?H:LW7BO0++3[6_GU:U6UN@3!*) PD Y)7'4#N>W>O
M,O!TZ:'HO@'5=6#P:=#IUY;M,Z';!,[J5+<?+E5< GZ=ZNW=W;1:]IVM6ES-
MX;T>XL;B.":2Q4JSF?<WRD'9Y@PXS@L!Z\4 >@WWBG0=-6%KS5K6(31":(F0
M'S$) #+CJ"6'3UK2N;F"SMI;FYFCA@B4O))(P544=22>@KS?PUI4-IXT\-)&
M+B:"#P]<-#+<P>6Z[IX\97^$[6(QZ5TGQ$MIKKP5=+#"\XCFMYI88UW-)$DR
M/( !U^56X[]* +:>,_#\VFWE_;ZI;S0V:!YMK<J#]W(/.">AZ&L_X?>++CQA
MH1U.Y:Q0N05@MBQ:$'.%<MU/':LS[?:^(?&MQJ>CR?:;*WT*>WN+B-3L:1W5
MD3..6 5SCMGWK3^%Z/'\,O#Z2*R.+0 JPP1R: *DWQ*TVXTNXN]*DAD-MJD%
ME-YIP CS+&9/88+$9]*Z&S\5:#J%I>75KJUK)!9C-S)Y@ B&,@MGH" <'H:\
MU=H9]%US2)%+W*^+TEEMV0Y\I[R,AB,<J1W]*O>.;.ZG\1:ZULLJHMAIDTK1
MQ>82D=W(SD+_ !$*"<=P,4 >BZ5K6FZY \^F7D5S&C;'*'E6QG!'4<$'FL&Z
M\2Z]+XHU+1M&T6QNA810R22W-^T.?,#$  1MTVGO4/@P6]WK&KZI!KDVKM-'
M!#)/]E6*(E-Y 4J &8!\'TX%<WJSZ'!\2_$#Z[JNI:<KVUGY!M+F>$285]V?
M*ZXXZ],T =['K;Z=IB7/B?[!I4LDIC0)=&2,_*6'S,J\X5CC':H/^$[\*^1'
M-_;MD(Y)#$"9,88$ AA_#U'7'45S%\^DZC9>$4TBZN=1M(/$2;I;EY)7#"&5
MN6D^8X)&/3BJNLV0_LOXKLMO\\JC:0G+XLT(QZ\D_C0!V]_XP\.Z7=/:WVL6
MEO/&X21)),%"0K#=Z##*<GCD56_X22?_ (60/#8BA^R'2/[0\[G?N\W9CKC&
M.:X9]7TK3KWX@V^H BXO(8(HE,98W)-D@$:X'+9;I_M4PZ3JA\4"P5)!?_\
M" _90W_3??C&?7- 'HUEXN\/ZC<2V]GJ]K/+&C2%4?.57[Q7^\!W(S5MM;TQ
M-(BU5KZ 6$H0QW&[Y&#D!<'ODD ?6N!L;^QUJY\"V6D(WVG3&WWD8B*FSC6V
M>-DDR/E)8JN.^/:JVE:?/_PEL'@=XF_LW1KY]71L?*;<_-;QY]I7?\(A0!Z%
M#XDT6XUA](BU.V>_0E3 '^;(&67W('4=11I_B/1M5O7L[#4K>YN$0R-'$V2J
MAMI)]/F&*\V\-6VZYTK2+_7+H:A9:I+.VFI8KN1P\C%V?&=C*Q.[.#OQ70^
M[BUT#X=SZA>(T,27EY-.RQ,S'_2)!G:!D\ ?AB@#O** <C-% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9&L:
M)/J5Q!<VFLZAID\*LF;9D975L9W(ZLI/'!QD>M6-%TBVT'2(--LS(880?FD;
M<[L269F/<EB2?K5^B@ HHHH **** ,9/#J'Q+_;=W>W-W-$C):0R;1':AL;M
M@5023C&6)..*V:** "BBB@ HHHH *;(@DB>,G 8$''O3J* *&AZ3%H6A6&DP
M2/)%9P) COC<P48!.._%7Z** *>J64^H6#VUOJ%Q82/C]_;JA=1W WJ1^.*3
M2-*M-#TFVTVQ0K;VZ;5W')/<DGN2223W)-7:* "BBB@ HHHH **** "BBB@
MHHHH QK+PZEOK]QK5S>W-[>2(88?.VA;:(MN*(% ZD#).2=HYK9HHH ****
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MA<C6K"5=/0O<K%<(S)SC!&>I/RCW.*2W\:>')](M]3;6;&&VGB\Y3+<H, $
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MZWI>B^*_'?\ :-Y%;O%=)=LC??\ )%O$"X4<E<\9 KI?[ N\8_X275_RM_\
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M,]Z /,- M+B;Q'8^"9T<VGAF[DO2[#B2' -H,]\>8W_?FM_XA365OJ'A&?4
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M<9R 1[5[)CG/>FJBJNU5 '7 % 'EWQ!L9?[5OK;3(-LC>$[R-8X5P2JRP_*
M/8L />H=7U'2M?\ $>DCPK-!/.-"U"&.2UQA"8T\N,D=&!S\O49]Z]8XSGC-
M(J*OW5 [\"@#Q>&#^U?#Q73/$-M>:A:^';J"*PLK#RWB5HU7RY&#':P8+A6
M)(..];-EJV@ZKXO\!C1I;>8V]K<(Y@P?)7R!B-L?=/!^4\C!KU (JDE5 ).2
M0.M(J*OW5 R<\#O0!QOBNXMM.\;>%]2U22.'3(4NXS/,0L<4[*FPLQX7*B0
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M\ESJ3B^>#[/;QSR;<;<D@*=LNULX.XXZUZT45E*E05/4$<4A167:R@KZ$<4
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M*X.[ &"!FN\\?P/)X1FOX%W7&F21ZE#CJ3"P<@?50P_&NFV+DG:,G@G'6G4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]JB$;9WQ9QO!Z$9('XT :%%8]WXJT.R6X:XU&)?(G%M( "Q$I7=L  )+;3G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6""&4M"WDQA47& IX8G&,9SFNB\5S+IGBSPWK5XL@TVV6ZAFE6,N(7D5-C,
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M;O>:E=&:[MQ$=SJ3NV@ *"V67@=0:]1HH \YO;-V@^*3?9F+W$6U#LYD L4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKE_'.K:GI6GZ7_9,L45S>:G;V>Z5-ZA9"021[<'CTKJ*R];T.'7%L%FE>/[%
M?17J[,?,T9R <]C0!Q&L^(]9L-5N='36;O[1IUE'*)H=':X^US/O($@C0B-
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MW^1<)M+(V&4@Y# ^H(!'N* .6DGU_3]>70+G76N1?Z=-<079M8UD@DB9 P
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M@ D]JVV\4Z\^D6\D]Q?VEE%>SP7&JII+>8T:JK1.867*J=Q#-MQE.V>-ZU\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***X?XGZ<MQX<6^>XN!]EN;;RX4D*QE
MFN(AN8#[Q ) SP,GC." #N**YKQEIWAY]'GU?7M,@O4L(7=!(N6_W5]R<#ZX
MJ3P3X?'AOPQ!9M&D=Q*S7%PD?"+(YR54?W5X4>RB@#H:*** "BBB@ I"0.I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***J:AJEAI,"SZC>0VL+-L#S.%4G!.,GV!/X4 6Z*R;7Q/H=]8F]MM4M9;99
MEMVD60861B JGT)+# ]Q4]YK6F:>UPMW?00M;PK/,'?&R-B5#'T!((_"@"_1
M6+)XO\.Q6#7SZQ9BU6<V_F^8"#*.JCU(]JS[WQOIUEK6FQO>6?\ 9-Y8370O
M/,R"5>-5"D<'/F'WXH ZJBL>;Q5H%OI5OJDNK6BV-R<03>8"LAYX7'4C!SZ8
M-%YXKT#3[6UNKO6+.*"[7?!(THQ(O!W ]QR.>G- &Q7,^+_#FJ>);,65KK,-
MA:$QO(C67G,S)('4AMZX&5'&*T;WQ-H>FW-O;WFJVD$UPH:)7E W*3@'Z$\
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MGBT:6.."(*P4(A+'J[,<MR3VK;TC4;;2_#MCI!L]9D6UM([;S1ITJ%@J!=W
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M+RA)0=J@X+?0'J>E %S4[+^T=*O+$R>7]I@>'?C.W<I&<=^M8]SX5%Q\/?\
MA%/MA4?V<MC]I\O/1 N[;GVSC/XTY_$T&J:+?77A>YL]3N[50_D"3[_?;QR"
MP!VGIGUK3T?5;77-'L]4LV+6]U$LJ9Z@$=#[CH?I0!E:YX1MM?OHI;N=A -.
MN;"2)5Y99MF6#9X(V>AZ^U3Z+IFM6<Y?5=<6_18A%''%:"$<'[[_ #,6<^V!
MUXJ#3O&^A:EJ.L6<5[$C:4Q$[NX"[0JEGSV4%MI)[@U?TGQ#I&NB7^R]1M[L
MQ8\Q8WR5ST)'7!['O0!DZKX9U6?Q4VNZ3KD-A(]DEF\<MCYX(5V<$'>N/O\
MZ4L_AK5M2LK>#5]<AN7M[^WO(WAL?*XB<-L(WGKCKV]#6QJVNZ5H4,<NJ7\%
MHDC;4\UL%B!DX'4X%9&H^*FM_%GA33+,6]Q9:VMRYN%;.%CB#J4(."#G\J +
M$OA@27_B&Z^UD?VS:QVQ7R_]5L1USU^;._...E<IIGAS6;;Q/K%GI>K"S$.F
M:?:&>:S\U90J2+N4;EPPQZD?-R#Q73^#O$=QXDM-4FN(8HC9ZG<62"//S+&P
M )SW-7=4\3Z'HEREOJ>JVMK,Z[PDL@!"YQN/H,]SQ0!CVG@*TLM4T&YAN6^S
M:1ITE@L#QY,JL "Q;/!X].]16'@>[MAI-C=:T+G1](F6:SMA:[)<H"(Q))N(
M8)GC"KG S6_?^)-%TRXCM[[4[6":4(8T>0 N')5<#OD@_D:NWEY;:?9RW=Y/
M';V\2[I)9&"JH]230!PFF:9!KOQ2N?$-HERNFVL"*QEB:-)KP!DWJ& )VQ,5
M)Z<C'2MRP\-:EIE^4M-<$6CF[>[^R"U!ER[%VC\TMC868G&W/.,UI6GB31;Z
MVBN+74[:6*6?[,C*XYEQG9_O8YQ5'Q)XI@T6W#02V\DT5[:6]RDCX\E)I%7<
M?3Y22,^E %OP[H0T"SN[<7!G^T7L]WNV;=OFN7V]3G&<9[UG>(/#&I:Z]S;'
M6432;O9YUK):"1TVXSY4FX;<X'56P<D5H6OBO0+VQN[ZWUBSDM;3_CXE$H B
M]-WIGMZ]JS]1^(/AS3]+M]1&I03V\]VEHK1.#ABP#9]-H;<<]J &W7@M;GP[
MK^D_;RHU>[DN3+Y6?*WE3MQGG&WKD=:IZAX%OKL:E;P:ZMO8W=ZNH+%]CW.L
MX9& 9MXW)N0';@'MNP*WY/%6@Q:A;V#ZM:+=W 0Q1&09;?\ =^F>P[]J9=^+
MO#UC=&VNM9LX9Q+Y)1Y0"K\<'T^\.OK0!D3> _/C\7A]2^;Q'&B,1!Q 1%Y>
M0-WS>O;TK:;0PWA!M ^T'!L/L7G[/^F>S=MS^.,U0;QKI4NL:QHUO=P)?Z=;
M^:3.V(]V&)!QSA=H+>QJ<>*]*L-$TZ]UC5M.A:\A#K)%(?+DX!+)GDKSU]",
MT 17/A:8Z5H<5CJ"V^H:,JK;W+P;T<"/RV#IN&0P]&!! YXJ"[\*ZK<+IEZ-
M>4ZU82RR+=26@:)ED&&C\H,"%QMQ\V1M')J6[\3R0^.-$T2!();34K2:X,X)
M)^0 KM(X(.:B\'>,4\0:7!+?M;VUY<W5S!! K']X(F(.,]3@9- '/Z+X5O[^
MVUR%]1>+4;7Q+]O@O);;*.X@BR=F1E#N88!X]>*OZE\.KC6-'\16E]KF^YUP
MVS2SK:X6(Q$'"INZ$*!C.1ZFNT2_M)+^:Q2XC:ZA19)(@<LBMG:2.V<'\JI:
MEXET31[N&TU'5+6UN)@"D<L@!()P"?09XR>* &6N@+;>)]5UEI_,&H6\$!@*
M8""/?SG/.=_IVJEH'AS5-$:TM#KOG:18H8[:U%J%<IC"B23<=P4<#"KT&<U!
M<^*[J#QCJVBK;PF&RT@:@DASN9]S#:?;BM+PCK4WB+PCI>L7$212WD"RND>=
MJD]AF@"#5O#M[>:_#JVGZHME)]E:SG#6_FDQE@V4.X;&!SR0PYZ<54\.>#'T
M&ZTN9]1%P-.TZ73XU$&S=&TB.I)W'D", ^N<\=*U9_%.@VNK#2Y]6M([XLJ>
M2TH#!F^ZI]">P/)KG9/'RS_$<>%[.;3UBAC4SRS2-O>0L5,48'&X8SS0!1\3
MZ0ND^"Y/#UJ]S=ZO>WTEWIS06[9CG:X\U6+#(54+#))&0#ZXKM]"TF'0M"L=
M+@.8[6%8]QZN0.6/N3DGZU2\1>+M)\+RZ?'J=PL1OI_)3)QM&"2Q]A@#\16?
M9^/-+74=4L]6OK*RDM]1-I;J\F#(NR-@QSTR7(SP.* !?"%]=:C;S:QK*7UO
M:)-';A;01S$2*4/F2;B&PI/15R<$]*K:=X&OX)M!_M'74O+;1%:.WA2S\OS(
MS"T7[P[SEL$<C X/'.1T5UXCT:QU2+3+K4[6&]EVA('D 8[CA?ID],]>U)XF
MU670_"VJZM#&DDMG:23HCYVL54D X[<4 8FF>"[VSAMM-NM>DN-#M(7@@LDA
M\MGC92@65PQWA5.!A5Y )Z4VT\%7QL5TO5?$$MYI$5E)8Q6T<'DL\;+LS*VX
MAV5> <*,\XS6QIOBO0]3,L5OJMI+<6\7FSQI("44?>/T!X)[5>75;!UL2MW$
M1?C-J0W^N^7?\OK\H)^E &+:Z#X@2TEANO%!=A;^1;/!9K&48$$2/EFWMP!Q
MM&">.>((?"VLQ7%]J7]OP1ZQ=& &:&PVPE(M^%:,N2V?,;)W@\+C&*T4\5Z-
M?6^H#2]7T^:XM('E;,N40*#\S8YV CDBDC\4Z7::18W.JZKI\<EQ:BX#12?N
MY!\H+1YY*Y9<=^10!CQ^!;JW:'4+?5H8];CO)KLW L_W#&5%1T\K?D*0B'[^
M<C.>:E3P*3%;R7&IF6^&L)J]S.(-HF=5VA%7=\BA0H')Z=\ULR^*=!@TFWU6
M35K06-P=L,_F K(>>%QU/!X[8/I27GBO0-/M;6ZN]8LXH+M=\$AE&V1>,L#W
M'(YZ#- %G7-+36] U'2I&VI>6TD!;^[N4C/X9KDQI%QXT^'EOI=U-+I>KV3)
M%++Y6XPSQ85F4$C<K+G!!Z/72W'B?0[34(+"?5K2.ZG"F*)I1EMWW?S[>O:M
M.::*WA>::1(XHU+.[L J@<DDGH* .6E\"VK>)=%U6*Z:.#3($A^R"/*R^6KK
M$Q.>-OF.>G>G2>"UD\,W^C?;R!=ZBU]YOE?=S<";;C//3;G/OCM6E8>*M!U2
M&YEL=6M9TMD\V8I(/D3&=Q_V>#STXJQIFN:7K/G?V9?P7?D$+*87W!21D _A
M0!DV_AK4K'4YC8ZX+?2I[TWLEK]E#2[V.YT60M@(S9)&TGD@$=J,O@6XDBUN
MT&KH+'4M034%C-KEXI!)&[#=OPRGR\=!C/?%;]UXET2QU6+2[K5+6*^E*A('
MD 8EONCV)[9Z]J7_ (231?[9_L?^U+7^T<X^S^8-^<9QCUQSCKCF@#-USP=%
MKFI7EW+>/%]HL$M%"(,QLDOFK("3R0V.,=J@U#PIJVN:!J6FZQKZ3/>+$B-!
M9>7'"$;=D(7)+-W);'3 '?7LO$^A:C=7%M9ZM9SS6ZEI424':H."?H#P3T%4
MKCQUX<BT+4=7AU2WN;>PCWRB%P3R/E _WL8!Z&@#H)H4N()()5W1R*48>H(P
M:XNQ\":C;G08+KQ +BQT*=7LX19A&9%1D42-O.XA6 ! '0Y!SQK_ /";^&UT
M^RO9]8M((KQ"\1DE R <-^ /!/2M\,"NX$;<9SGC% '%P?#Y8+26#^TRV_Q"
M-<W>1T.\/Y7WO;&[]*TM4\/:C+K,VJ:-JZ:=/=6ZVUR)+7S@P0L4=?F7:XWL
M,G(Y&1Q5FS\7>'M0EFBL]9LYWA1I'"2@_(OWF'J!W(S6)X*\<MXPU355C>P6
MTM9I(H(HW9IW5& $C=@K9XQ0!9O_  GJ1U&XO-(U]K&6]M8[:]>2V$K2; 0L
MB$,NR3#$9P1TXXJS:>&+C3_%C:Q;:F6MYK.*UN8)XC)))Y0?8PDW#!^?G(.<
M>]%UXSTJW\33^'?/3^T8[7[0%)X)P2$^N!GZ5'X6\;:7X@L-+1[^S75KNSCN
M'LXY.58H&8 'TSTZ@4 2:GX=OY->;6=%U2*PNYK9;6X$]KYZ2*K$HP =2&7<
MW.2.>14.E^";?2;W0I[>\D9-*M;BWVN@+3-,RLSDYX.Y2<8_B]JU;+Q'HNHZ
MC-I]GJ=K/>0YWPQR L,'#?7!X..AZU5\5:_<^'[2Q>SL([VYO;V.SCBDG\E0
MS@X);:WIZ4 +XP\-CQ9X=DTDW1M0\L4GFB/?C8X?&,CKMQUIK>&0USXCF^UG
M_B=1K&1Y?^IVQ>7GK\WKVIVF7_B26[QJVB6%E:!"6FAU)IF!'^R8EX]\TU/&
M_A>20HFO6!;R?/\ ]<.4P#D'OP0<=>: ,R/P5?6%Q%+I.N"U\S3X+"\W6OF&
M41 A9$^8;'PS#G<.G!Q1IO@%=.NO"<PU$R?\(];36X'DX\_S$"Y^]\N,>];*
M^+?#S:=%J UBS^R2NT:3&4!2R@EEY[@ G'M61XG\<VVG> =0\2Z%-:ZB+5T0
M#<2NXR*A#8Y! ;./I0!+;^"5M_!<7A]=0<2P7)NH+Q8@#'+YYF0[23D D C/
M(STS3KOPOJ>J:7)'J>NB2_6YBNK2>"T$<=L\9!7;&68L"<[LMR#QBM/5/$^A
MZ)/'!J>JVMI-(N\)+( =N<;CZ#/<\5<AU&SN+R6SAN8I+B%$DDC5LLJMG:WT
M.#@^U ',7W@[5-4TJ>._\0F347O(+N&5;8B"!H6#*JQ%SP2#GYLDGVK;TV/6
M(]7O!?W*SV?V>W$)6)8QYHW^:0,EL'Y#@DXZ#UJ.[\7>'K&+S;G6+.)/.>#+
M2#[Z??'_  'OZ=ZEOO$VAZ:\27NJVD+2HKQAY!EU8X4KZ@GTH Q[_P )ZH^M
M:QJ6E:\EFVJQ1PS1RV?FA%12H93O7#<GD\>H-8'BOP[9WUOX;\&Z6MX)[)DC
MDG2-@(K(QE)=\F-OSKQ@')8CTKM?$WB*Q\*Z#<ZOJ#$0PKPHZNW91[FH[KQA
MX=LK:VN+G6+2**Y4O"S2??4=6'L/7I0!LHBQQJB*%10 J@8 'I3J9%+'<0I-
M#(DD4BAD=#E6!Y!!'44^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N)^)$MO!;>&YKI"\$>NV[N
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M 4444 %%%% !1110 4444 %%%% !7+>-]?GT6WTR"VF>WDU"\\AKB.V:X>)
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MT'!SFM2_\)7EU:+:0^)-2C@DM!:72RA)C,O.7RP^5R&()'!XXX%)-X.>::.
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M%T+%-\3;V0QJO0J>#ELGC&><UJW/A&XU+1=1T_5==N[QKT1J9#&B+$J-N&U
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M4#(S(P)"]QL JJO@A;:&V?3]4N+2^MKFZGBN1&K_ "W$A>2-E(P5SMQW^44
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M;5?&%G<6M[-<:E8PBR\FV>07#" QL P! (8<[B, YK-BT;4KK7;.**UG1I/
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MSW-DJ>9M+8$:+&A;;YAW$C\>#@ [JBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** *$FD6TFOV^LLTGVJ"VDME (V['9&.1CKE!W]:OT44 %%%% !
M1110 4444 4-%TBVT+2X]/M&D,,;R.#(06R[LYZ =V-7Z** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JAIFD6VDO?M;M(3>W37<N\@X=@H...F%%7Z* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBN<\6>*9/#-O#+%I4]Z'DC6
M1U8)'"K2+'EF(/.7&% )//0#- '1T5@:YKUY8ZKI^D:98Q7>H7J2RK]HG,,4
M<<>W<2P5B3EU  'Y58\-ZX=>TV2XDMC:W$%Q+:W$._>$DC8JP#8&X<<' ^E
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M\VW8A8O,@D!QA\JAP"&Z]:]#\,ZS!=Z;IEE):K87[:;#=-8I$RI"C?* .,
M@C;U&.E2?\(Z_P#T'-8_[_K_ /$U-:Z*UK<I,=6U.8*?]7+,I5OJ-M &K111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M8T>O?:/%,^C6T D2S@66\N"^!$S_ '$ QRQ +'I@8ZYK9KS6UO$T_0_B3=7-
MK]JEBU"X:6!F*[X_L\>P$CD+M[CMF@#L[C78I=(O+S0VMM6FME),$%RIW$<E
M<C.&QG /?TZU;TK4[76M)M=3LI-]M=1++&W0X([^A[$5P'A":*+XB2VZZAI%
MP'T=%']EP>5%E9,[!\[;RJMG/8,..:V_AE_R)WR?\>_V^\^S^GE_:)-N/:@#
ML**** "BBB@!KMLC9SSM!-9?AC7H?$_ANQUJ"%X8KM"ZQR$%EY(YQ]*TI_\
MCWE_W#_*O./A?XK\.6'PUT.UO-?TNWN(X"'BFO(T93O;J"<B@#N(M5(U+4X;
MHV<-K9+&PF^U MAE))D3 \L#MDG(YXI[:]HZ+<LVK6*K:D+<$W" 0D\8?GY?
MQKRG7R&O_C"000=-LR"._P#H[5TRZ%I2?$[1X5T^V\M-!F8+Y8P2LL2@D=R
M[#)_O&@#K;G52EYIB6QLYK:\+$RM=!3M"[@8UP?,S[$8'-0:;XLT/5;6]N;;
M4;;R+*5HIY&E4*FTXW$Y^Z2#@]Z\OT90MS\,XU ")J&JHJ]@H,H ^@  J:QN
M]-M-%N[%8])%S)XKGB<W@S':XDD='D0%21\N%!(&2* /2M1\6:'IEE9WD^HV
MQMKR=(()4E4JY9L9!SC SR>PJQ::F]SJM];$6GV>!(WCECN@[L&!)+)CY!Z'
M)SUKR#S[%].<W-UI\\5OXTMG>6.(10B)XXSO"EFVHQR<Y(;DYJUKN^;6/B<;
M'+HVGZ<3Y'.Z'82^W';9NZ4 >M6FL:9?I,]GJ-I<I#_K6AG5Q'_O8/'XTMOJ
MVFW=TUK;ZA:37"H',,<RLX4]#@'..1S[UYYJTND7/B6!_#;V;PQZ!>B\:R*E
M!$0GDAMO'4-@?6C2M/M+$?"^6VMHHI)(F#NB@,^ZS9FR>IRP!^M 'I]%%8OB
M];Q_!>N)I^\WC6$XAV?>W[#C'OGI0!>M=6TV_FEAL]0M+B6'_6I#,KLG^\ >
M/QI(-8TNYNEM8-2LY;AD$BQ1SJSE",A@ <XQWKSVVET.XUCP./#;6C/%;S&<
M6NW*6WV<@B3'(_>>7P?XOQJCH>GVEIX-^&5S;VT4=P]]#NE50';?!-N!/4@\
M?D/2@#UVF2N(HGD(R%4MCZ4^H;O_ (\I_P#KFW\J ./L/B!-/8:=J=[X;OK+
M2;\Q"*],T,BKYI 0NJMN4$L!G'&>:ZLZIIXU$:<;ZV^W$;A;><OF8ZYVYSBO
M/O!OAC4M8\"^&EU+7C)I*VUK<"QBM%0ML"NB-)DD@$+G &<5C:IJ=L^K1W?G
M:/9"/Q1&LEN(2UV-DXC::24O\BD?[.,,HSS0!Z\M[:O:-=I<PM;*&+3"0% %
MSDENG&#GZ57?6])C>-'U2R5Y7$<:M<("[$ [1SR<,#CW'K7FNJ6TUMK>H^ (
MU<6NO7T=["R@X2V?+W2YZ#F-AC_IL*KZ]IMDWA[XHW)M8C-'.!&Y093;;0E=
MOI@\\4 >KVVI6%Y-/#:WMM/+;G;,D4JL8SZ, >/QID&L:9=6TUS;ZC9S009\
MV6.=66/'7<0<#\:\R\::<+'4[ZWT>V6!F\)W*E8$P659HNPY)VEO?FJNIP0O
MH'BB\@UK0[H#PY)&UOI%HT2;.3&SGS'&0 X X.": /5&UW25%V?[3LS]C&;D
M"=281_M#/R_C5:Q\5Z'?:'::PNIVL-G=*I1YYD3!8 [#D\, >1UKCM:TNRL_
M$&C0VEG#&LN@7\;JD8_> "$J#Z\G//<UDZ8=)E\)>#KJRU?0X+^VT@QFWU%
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M/3[M 'K$>LZ7-=QVL6I6;W,B[TA6=2[+Z@9R1P:E6^M&LC>K=0&U"EC.)!L
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M'Q7?6]SXB@C.FVZZ;/;1I<WLA2-%D169GY&[&3A01G@4 =<L4:OO6-0VT+N
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M<:$9[815'7)Z9YJY6;H-W=7VD17%Y)92R,6Q-8ONAE7)VNO)QD8XR<>IK2H
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M2>O?'O52?P9JT4^HKI>KVT%MJMK%!>"6V+NC)'Y>^,A@ 2H Y!P0#STKMJ*
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MH^OJ>];55=-O5U+3+6]6*2$7$2R>5*,.F1G:P]1T-6J "BBB@ HHHH ****
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MQ[;L_CFNMD#M&PC<(Y'#$9Q^%5]/T^#3+-;:W4A 6=F8Y9W8EF9CW)))/N:
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M]$Q,KW65/GLQR6XXQZ <  #M0!Y?H=KIL@^'!>7,FHZ8\5YFX;-PH@4A7YY
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M"+.0;3LW-PZD%AGKE??CT&N<T?0-6TQ5CN/$$MW;V]L;>VB%LL9'3#R')WN
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M Y-+:>#+A-4\-ZC>ZL+F?1(9X%V6PC$RR*%&1N." H]<^U &/;^*]?;0]/\
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M]SUJ6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LO6==L]$?3UNY%C^W72VL;.<*&() S@\G& .Y/
M;K6I2,JMC<H.#D9'0T <7J'CQFCMH]#MK6]NYM7?2S%/<-$(G5'8ER$)!^3I
M@\$?2M:QU#Q#$T\^OZ?I=G8PPM(TMK>R3,".>5,2\8R<Y[=*Y_XG168C\-O>
MM/#9KK"O<2VQ='0>3*-VZ/YAS@9%2^'M6\'V,]U)IVKZG<.MNTDJW<]U,H1>
M20)<C/TY- '6#6=-8V 6]A8Z@-UH%;/G#;N)7'48YS56R\5:'J=]+8V.J6T]
MU&&)16Z[3AB#T8 ]<9Q7GGAG3KW2]4::ZL9+6'6[2:/158D_V9N9G\ANR%P5
M?V*[>PK8\(ZMI4ND>'-$&F3/JUA8F*8-;$&P=(MKEF(&W<<J,9W9].: -VR\
M8:;!X<T_4=7U?3BUV'V2VF_RI=I.2@.6P!C)[5=OO%F@::MLUWJUK&MS&)8F
MWY#1G&'R.B\CYCQ[UY?X8\C3OA[X0N;C4[K0]2AMKI(;IK7S82K2Y:*12.IV
MJ0.#\IP:D,URMS-=ZQ>3Z#%J>C6RK;VVGK(LV!('A164E2-P(3@_/[4 >P7#
MS"TE>T2.2?83$LCE59L< D X&>^#7$#Q3XQ/B9M _L#1?M8LQ>EO[3DV;"Y3
M&?)SG(]*Z_1[46.B6%H&E<06T<0:88<[5 RP]>.:YQ8I/^%RR2[&\O\ X1]%
MWXXS]H;C/K0!K7'BG2M,N+:RU;4+6UU"5$+PARP0MP/FP, MD MC-6SK6FK_
M &ANO85_LX9N]S8\D;=V6ST&.<UYE\0+RZN'\6Z>L\]M+]E06]G:6*L]^GE;
MC([E"2JDLO!&-OJ14GBN-O$>MMJ^CV3W>F:;!$VJ*F0-33<LHA4?Q%%R_N6V
M=S0!V%WXIOHY;_[%HRW4$5DEY:SF\6-9P<9#9'[O@D@GKM/I6E9:V)[VWL[J
MW>UGNK87,".>64;=ZGT92RY'N".X%^TN+>^LX;JW(>&=%D1L8R",C@UR_B=)
M)/'7@P09\Q+BZD<CM$("&S[99!]2* .OKGM=\50:9HFNWMBL5[<:/$7G@,NP
M A-Y7(!YP0>G>M+1M:T_7].34-,N//MG9E#E&0Y!P00P!'XBO--9BM;6S^*,
M'V=8[N>,M#B'!=&M8QP<<Y<'CN0: /5+:X6XA1P5W%59E!SMR,T]9HW#%9$8
M(<-A@=I]Z\IU2W-MJ^HQ^&HT2[NO"[,!:X#33!\CD=9-I;!//-0Z@GAO5O"G
MB/5-)EO)I7T.6WEADMEACC<#,:LHC7,H8D#&2.?44 >NK(CL55U8KC(!SC-8
M?B+Q=I?ABXTV'4)-K7\_E)P?E 4DL?88 _$5S>A0:?9?$.P^P)#$MSH&9C%@
M>;()$(+'^)L%SD\XS5[Q_/'8WWA34+C<MI;:N&GE"%A&##*H)P.!D@?C0!+I
MWCW3#>ZA9ZM>VEI/#J4EG F2-R@@*6/(!))&3@''%;5QXFT6UU=-)GU*!+YR
MJB$MR&;[JD] 3V!Y/:O/M1M&/P^\?E+=O,FU6=UPAW/S'@CUZ5#>69.KZ]H^
MHZW?VCWVK+-%906*2&X5O+*2*Y4G"[0"<_+L/2@#TS7M2.C>'=3U58A*;*TE
MN!&6QOV(6QGMG%8>FZKXSOH[2X?1-%CM9PCLRZE(75&P<@>3@G!Z9_&K_C9&
MD\!>(T12SMI=R%51DD^4W KB/#MYX)M8]+<:UK7VR-8OW4EW>LF_ X*D[2,]
MNE '<77C'P[97AM+G5[:.=9O(9&;[C\8#?W?O#DX'-$/C'P[<1WLD6KVS)9*
M'N&#<(I. WNON,BN#UFQ:3P9\2Q]F9I)M2;;\ARX$4&,>HSG]:/B;;E+O6V2
M$B+_ (1>1,JN%XG7"Y_.@#O(?%>CZ@E\FF:A;W5S:0M*T:GL,X8>JY&,CCWK
M/T#QM:W/@;2-?UR>VLI+] =B9PS\_*B\L>!G'-8EU>VNN^++*71XY#%I^C7D
M=V?)9/*W^6(XFR!ALJQV]L5B^%6_L71_A_JNJ))%I]OIUU;R2M&<6\KE"I;C
MY<A67)]<=Z /3K3Q%H]\;(6NHP2_;M_V;8V?,V?? ]QW'44E[XDT;3GN4N]1
M@B>U$9F5CRF_.P8]6P< <FO/'L;B7PWK7B>Q@D5K377UG3PR%#+"J(LN <'$
MBB7'KD'O5>:TNI]-TOQ>]Q/9+J&LMJ$]PL E:VMVA>*W)4@C 79DD<;R>U '
MHS^+- BTN'4I-5MDLIF9(YF?"EE#%E]B K9!YX-:5K>6][90WMO*'MYHQ(DG
M0%2,@\^U>6_V?!._AZYANKO4X;GQ3]J>XGM1$&86[KO50 -F4!SCDY->I7JH
MUA<++$\L9B8-&@RSC!R![F@#E]8\>Z9'X8U?4=#O;2]NK"W\X1DDAAG /8E?
M<<>];%EXJT+49KJ&TU2VD>U0RS -@*G]_)X*\?>'%>5ZC<O/X2UG2=.O)-9T
MZ+166*6:R\NXL\/&%@=@!NR,G& 1Y?.:Z;QKY]CXA-S8Z>ER8O#=ZBPM#OC;
M]Y#A2H^\,9^7N 10!T;^,-+O-!U:_P!&O8+N6PM7G*<]D+*2.#M.WJ.N#@UC
M6'C>_NKOP%"]O;!?$5I-/<D!LQLD*R )STR<<YXKG%N?M&I:XR:I=:I%<>&Y
M8H+F2U6))'7<62,*BY ##KGJ1G@TND6TZZE\'R89 (M.NA)E3\A^RH.?2@#U
M2_U"TTNQEO;^YCM[:(9>61L =A^O%9R^+M ?27U1=5MS9I)Y+29.1)_<V]=W
M(XQFLWQZKII^DWIBDDM;'5;>YNQ&A<B)206VCDA258X_NY[5AZSXBT^[:&]T
MN$65G+J:)<ZZ]BKC*P,1)'N!R<[8MY&!D@9H [:W\0:1=VMG<P7\,D-Y*8+=
M@?OR ,2GU&UN#Z&FWGB+1]/6Z-WJ$,7V1TCF#'E6< JN.I)!! %>7VET+6UM
M[R[DNWBLO%ANKF:XM]CK#) X25U50%#%@>@QGG'-7)KFPU#5O$6IS7-_86QU
M*SEL]2BMR1$ZVVT2,K*<QGYER1@[ATR#0!WTOBW0(=,@U)]4@^R7#%(G4EB[
M#.0%'.1@Y&.,<UJ6MU;WUI%=6LT<UO,H>.2-MRLIZ$&O)?MM_)J&D:U>ZI_9
MUH@OK9=5MM/ CF8O&5D*.&V>8%;YNY7@X85Z#X+M(K+PI:1P37,T3M+,KW4(
MB<AY&?[@ VCYN!@<8H ATSQWH6IMK&V\CACTN5DFDE.U=H527R>@RVWZBM/2
M?$&E:Z)3IM['<&$@2*,ADSTRIP0#V/>O,KHGR?%%DT,TDUMXGAU.XM5B8M):
M*T!9@,?,, G Z[:ZK1[R#7?B/<ZOI;--IT6E+:R7(0JDDIE+!02/F*KG..FZ
M@"_K/BV#0O%-EI]]+!!8SV4UPTK@E]Z/&JJH'7(=N,$\5>E\5:%#I%OJK:G;
MFQN3M@E4[O,//"@<D\'(QD8/I7/>(KVTTOXF:)J%^K+:Q:9=J;CRRRPL7BP6
M('RY&1GWKD8(KFWN--UW[=<Z1I4VHZI+#=?90_E+,ZF-F5U.U7"/@D#[P_O4
M >P6=[;:C9Q7EG/'/;3+NCEC;*L/8UR_BKQYINB6-_'9WMK-JMKM'V=R2-Q(
MRI(Q\VTDXSGO5[P3:PVOAI#;W%U<13SS7"R7, A9M\C,2$ &U222.!P17G.L
M7D%MX)\3>'KB"9]8?6)9Q (&)=&N1(LN<8V[,<Y[8Z\4 >I7/B;1;/5DTJXU
M*".]<JHB9N06^Z">@)[ \GM5"Q\<Z'?:CK5F+M(O[);]_)(=J[0JEFR>@!;;
MSW%</J%F3K'B+2-1UN_M&U#4UEAL[>Q21KE&6/8Z.5)^4K@\_+L[4W65E>;Q
MSIT9G2[;4[._") 79[9!;EW4$$/C:W'.<8Q0!Z-!XKT*XTV;4(]3@-K!(L4L
MC$KY;,0%# \C)9<9]:B/C3PX+.&[.KV_D3AS"^3^\V$*VWCYL%EZ=<C%><Z]
M:P:KX7\27L&K7FMM<'3K>65K-8HW"W(.%VJ-Q <[CC@$#Z=MK%MO^)7A200Y
M2&TO\,%X0D0@?3C(_.@"_!XU\-74]G#!K-K(]X0( K9WDD@+GH&)!&#@\4EK
MXCMXQJLNH:GIPM[2]%L&B+#RB=H5)"W&_+#IQR*X<631^!YPELRR'Q=YN F#
MC^T!\W_?(Z^E49;*672?&\4EL[+-XJMCM*$AT\Z#)]QC- 'IEEXKT'4+>\GM
M=5MGBLEWW+%MHB7!(8YQ\I .#T.*6W\5:%=:9=:C%JEO]DM/^/B1FV^5QD;@
M<$9!X]>U<+X]L+R[\0:U]DCFXT>QD9HHMY*QWC.X"XPQ" _+SGIWJEJ<,=_9
M:CK5OJU]KB0SZ<;Q_L2QQO#%<>8P4*HWLH+$\' P/:@#N-*\76^M>+9M-T^6
M">RCT]+DR*"'$AD92I!Z< '!&>:Z>O/;'7-.N?B'JVNVPD;3H="0O=+"VV39
M([-MX^; (''T[5WMM<17EI#<PL6BF19$)&,J1D4 <KX4\>Z9KMAIT=W>VD6K
M7:DFVC) W#)VC.>=HSC.:V$\4:')JSZ4FIP->H64Q!N=RC+*#T+ <D#D5YAH
M=S;W7@KPCH%M!*FKQ:K!</ 865HT69I'E)QC:4SSWW8Z\5:\/69-WIVCZAK=
M^+ZTU>6X.FI8I\K"5W\PR;<[&4YW9YWX]J -WPY\18=<US7/-N]-MM(TUY$4
MOO$KJ@4F4L<*$^;IC-=-:>+-!OK.\N[?4X6ALD\RY)RIB3!.Y@1D# /..<5Y
MP+&[D\.^-BMK-*D?BP74L*QDM+ CP,^!_%\JD\=<59\3W4/B.X\2:EH^^YLX
MO"US:RSI&P625CN1!D?,0 Q..F[WH [L^,?#HLI+S^UK<V\<_P!F+J2<RXSL
M7 RQQZ9Z'TK4LKZUU*RBO+*>.XMI5W1RQME6%>?:_;2:?'X+O$OI=*L;.VDA
MDN8[=91 S1($W*P(4':RYQQNQWKIO!-M#;^'B]O=75S%<7,UP);F 0LY=R2P
M0 84G+#@<'- %T^)]$&M?V.=2@^W[MGDYYWXW;<]-V.=N<U"WC+PZE^EBVKV
MPN7F-N$W=) Q383T!W C!ZD<5YUJFIRRZAOGNIH#:>)(Y+C3K>Q58X84N HG
MD?9N)9=K;@W.[I@&KEQ9N/AUXE"V["63Q)-+@(<M_IZX;WX Y]!0!Z1#J^GW
M%I=745W$T%H\D=P^>(F3[X;TQWJ:"\M[FQCO8IE:VDC$J2YPI0C(;GMCFO,_
M%%E=6WBN[\-VJ.+/Q@8W9TZ0F/ NC_P*(+^)KOO$#R6'A/4WL;)+F2"RE,-J
M4W+(0APFWN#TQWH CL?%N@:G#=36>J02QVL?G3$$C;'@G?SU7@\CCBJX\<^%
MR\J#6K4M$F]@&/(R!\O][D@8&>3BO.S=?:+R]9-4N=3BG\,7=O#,;-88O, 5
MC%&%0=!S@YQTSD&NCM;%5USX=$6V%M]+N!G9_JSY,(_#O0!U3^*]!31H-7.J
M6_V&=MD,H.?,;)&U0.2W!XQG@^E2VWB+2+NUM+FWU""2&[F^SP,K??DP24]F
M^5N#Z5YMIW_$HURPU>_CDBTRVUK6$DE,9*PM(_[MS@<*0'&[I\WO22RB.<^(
M_*FCT5_%:7:R&)@!%]F,338QD*9.^/>@#TNYU_2;-K@7.H01?9I(XIM[8$;2
M8V GMG(_.L?4/B%X=L_#^I:O#?)=1V 'F11Y#EB"57!'&['!Z5Q>I.FM7?B&
MXAMY9+.YUO1]A>)@)4#1!F (Y7@\^G/2K/Q!L[B>Y\:B"WDD,GAZVQL0G<5F
MF)^I H [B;QGX<MUMC/J]O&+E-\>XD?+G;N/'RC((R<#BMMY$BC:21U1%!9F
M8X  ZDFO,?$VM6'VB;6-&U.1+RYT]56TGL3-;:JBF3;$!C=NR64X(^\,@BNM
M\:6=[JGP^UFTLX6^V3V+JD*GDDKR@]SR/QH GL_&/A[4%G-IJL$OD1&=\9SY
M8ZN./F7W&16-X \:3^,TOKIVLHX$E98;>%7\U%#E0SL>#G&>!56#4K+Q'XS\
M,3:(KM#IUO<-=GR600*\:JL39 PV['R]?D-6/A/%)#X#B26-HV^V71VL,'F=
MZ +FI^.].L]7U71H75M2LK!KM58':S!7;9^ 3)]C5GP]XQTG78[.W2_MFU.6
MV6:2WC)X.T%PN>N"<$ G'>N8\03);>-_$L,P=7O_  XJ6OR$B5D\\L 0,9 (
MX]Z);"8V_P /H+2(Q2+8S1@A<>639D#/ISB@#M-.\3:+JU]+96&I07%Q&"2B
M-U ."5[, >"1G!JKXHUR^T<Z5!IME;W5UJ-Y]E1;B<Q(O[MWR6"L?X,=.]<5
MX&@CGN_#<$VL7\UYI5HROIYL$C6T/EB-DD<*#UZ9)W;0>>M='X[L9]0O/"T$
M%S<VK'5LFXM@N^,?9YN1N! ].1WH M:=XIN([_4-/\1VEKIEQ96RWC2Q77FP
M/"2PW;BJD8*D$$>E7;7Q;H%Y;B>#5(&C-PEMDY4B5_N*01D$]L]:Y[7=#'AO
MPUK&II-<:MJ-PD,4MSJ*+<%(1( 2(U4+M0,[X Y(YS6#::<OB;4?%FFG5+J]
M>_TZUDL;ZX@6+>\32X=-J*"$<ISC/N1B@#TC4==TO27V7]]%;MY+SX<](TQN
M;Z#(_.L\^.?#"FX!UJVW08WJ"23G."HQEAP>5ST->=SS7?BSP)XM\4W5I)'<
M2:7_ &;!"5Y7RUS-@>\Q8?\ ;,5VGV-$^*6E2+;@1Q:#,B,$X0^=$  >W&?U
MH V+GQ9H-IIUIJ$VJ6XM;L;K>13N\T8R2H&20!U].].O/%.AV$4$ESJENB7$
M/GPD-N\U,@;EQG=]X=/6O*](CN=*CT*_N-4N-&M/LM];K<BU64*_VMFV$,IV
M[E (]=F*Z3PWI<5GXH\+K$MU+;Q:)>/'+=0>6ZEYHB 5Q\IPQ 'I0!OWGC_P
M_:W&BHMZDT>K,PAFC.5"JK'<?^!+MQUR?:N@O;ZUTVREO+V>.WMH5W22R-A5
M'UKRBSD72;[PU>WB206<'B#5U>0QMM3>9@F<#@$GBN[\=7<MGX8>6-(RIN(%
MEEE@\Y;=#*NZ79WV#YAZ$ ]J +D/BO0I]-?48]3@^R1S+!)(Q*[)&( 5@>02
M67KZBH9/&OAN+3[:^?5[<6USO\E^?G"'#$#&=H/4]/>O+]2_T^T\2P/<7>I+
M=7VERQS7%N$-Q$)45F"JJ@J"",XZ#/(P:ZGQ89-.\=QZA/K$VD64VE"WCN$M
M%G5G61F:,[E;!(92!WV]\4 >AQ2QS1)+$ZO&ZAE=3D,#T(/<5B6OC+PY>7\-
ME;ZQ:R7$YVQHK?>;KMSTW8&<=:E\*V4>F^%-*LXFN#%%;(J?:4V2!<<!E[$#
MC';%>7Z+>VE]X$\-Z#91O_:PUF.?RA$V45;HR/+G&-NP'G/?'7B@#U*+Q/HD
MVLG1X]2@:_#%/)!YW 9*@]"P')&<BJEIXFM8K#5;[4]4T[[-9W\EMYD&X"/!
M $;YZR9."!P21BO/WU.6XU+2YKBZFB:V\0,]UIL%BL<-FN^1 [OLW%FW*<[O
MFWDXQ4%E%+9V>H7]Q!,+.S\>SW5R?+)VPX*B3 &2H9E.?;/:@#T30/%,>O\
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M8+Z[2#@]:UXXTAB2*-%2-%"JJC  '0"N236)I_$?AQ+S1[,7-[97,\,Y<F2
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M0!V8(8 @@@\@BEKA+/Q7%I?AC3M4LM/AC\-&Y6RC5'/F11&3RDDQT(W8^7J
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MLR.) ?KQ[U6TWQQJ5W;:!?7&EVT-GJ=VU@^VX+21S#S!N V@%-T9'7."#[4
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MJXEC:2.)8GD>100#M502<9' Y[] :AD\8:#'I5IJ?]H"2UO&*VYAB>1Y",Y
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MAX?G'B*/6?MZ><E@;'9Y'RD;@V[[V<Y _#\ZUS>VBS+"UU")78HJ&0;BPY(
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MF%C>")"4B88,;+C#@@#.><@'BM0^&)GU/1K^7599I]-:5V:6($SM(NULXP%
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M2:E<:I+<111VLC!XG=&$@<#;C&>_48ZUK7]A.V@_% "TE,ERTHB C.91]CC
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M8S5ZRUKQ-J][X>TU[R?37NH+[[5*UDL<L@ADC6.14D4["RMG!&/F/' QO?\
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M^:XFMSYL<T<T.-T;HX=2,@@\@<$57M_"\,0U=I;VXGFU6".&YE<(#\L?E[@
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M+N)I84E*.)82-R,CAU(R"."HZBJ]EX;CM;C4;F:]N+FYU&WB@GDD"#/EJP#
M*  3O.>U '!OXVUK5HH6M[G4;29-'M;Q4T_2S=+-<3(7Q(=C;4&   5)R>>*
M]-TNYFO=)L[JX@:WFG@222%P08V902I!Y!!.*YU? D=K;VL6F:UJ.GF*PBT^
M:2#R]T\48(0G<IVN,M\RX//TQU448BB2-2Q"*%!9BQ./4GDGWH \JT*&9]0\
M2E/!-MK(_MRZ_P!*DE@4]1\N'YX_K717\^K-XDT'0M/G&B6USIL\\\4$43M"
MR-%@(2I7(+D=",$\9P183P3=6MW?S:=XJU:QCO;J2[>"*.W90[G)P7C)QT[U
MIVWAP1:II^I7.H75Y>65M-;"64(/,$C*Q+!5 R-@ QB@#B=/USQ,-'T?6;K6
MO.#:TNES6RVT:I-']H,!=CC<'R-W!"]L43Z[XFA\/ZSXE.M?NM,U:>%+$6\?
MES0)<;"';;NW;<@$$=!G))-=<G@VQ31K73!<7'E6^I#4E;*[C)YYFVGC[NXX
M]<=ZYW1/!,]]::C%J5[J%O93ZU<W4NG[4"3@7!9#DKN"L I(! ('N<@&5/K%
MSH7BSXFW]F$-T#I44)D&55Y$\L,1W +9Q[5NWDGB;3-8?08->DO;B_TN>XL[
MBXMX0\%Q$4&,*H4HV\<$$C'6M>?P/IEU=^(Y[B2X<:\D"W";@!'Y2[4*$#(/
M0Y.>0*=::#_8UW/KM_J&H:Q>Q6I@C+QIN2+(8JB1JH+,0,GJ<"@#G+KQ[=WF
MEZ+>Z;A"-.N-5U*/:"52%"IBY'&9?ER.?D-5+'QCK=A:37\[:IJ, TF>\G^U
MZ4UK%!/&@=5C?8N4;YA@ECP#GFMKP9X71/\ A(-3OM/DMAK<[[;.<Y:*W)8[
M2 ?E+,\CE1TW>HK4T_P@MK"]K>:QJ.HV7V5K..UN60(L3  @[%!=L #<V2!G
MU.0#&\):WK-SKEO;74VK7UK<6;2SRWFE-:I;S KA4;8H*,&; )8C:.>:U?'F
MJ:GI.BV<NDSI#=3ZC:VP9T#KMDD"D$'MSVYJWHGAV;2)E>;7-1OTBA^SP17#
M($C3(ZA%&]N -S9./J<VM<T2#7K:V@N))(UM[N&[4QXR6C<, <CH2.: .(UC
M6=9L=9;0EUG5FDLK!+@W5II(N'N)I'DVB0)&RJ@" 8 4G)YXJU9:IXD\5WDM
MO;WTF@SV>FVL\D)MD8M<S*S%7#J2$7:!@8/)YKHM7\,G4=3_ +1L]6O=,NW@
M^S326H0^;$"2 0ZM@@LV&'(W&JVH>"TNKG[19:QJ6G2R6B65R\#J[7$2YV[B
MZL=XW-\XYY- '+ZWXI\0)JVK6UO/?I>:5!"([;3]+:Y@NIS$)&$C[&*J=P4
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M!3D,H10"V>K,#GITR" <+KNHW>I^%C'!XHOIC'J]C'(EQ8I!=0EID^612@&
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M$A '.U07(  !8G ]^: .8TG5O$C67@W4KS77F&O*L,]N+:)4C+6[R+(A"YW
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M.G:M&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY#81.D\;,D820HN&.W85/<!JJWD5MH$OAJ]TO2-3@2*:[E6S\F2X?9(OSLZ
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MH4. 6'[OD]SGITK+UZTN)-?\8M'87<D=SX?2WB9+9V664>=E5(&"?G3\_8T
M=C'X@T:8W"Q:M92-;1B:94G5C&A&0S '@8[U%IOB?2-4T2#5X;Z!;.;&UWD
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MJZW-!J%NTE^UW%&MLA:/>C0[3D#/R@=PP)YH ZYO"VAJRJT,@+G"@W<O)QG
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MQC.%.2HSQDYS3]!U+5?$R^&--GU:[MEET%=1NI[8JLL\A*H 6(. ,L3CJ2*
M/3**\OL]6US4[[1=&?6+B(C4M1L+FZB5!)/' #L;I@-@ $@>IZUU'@FZO)(-
M9LKR\FO/[/U26UBFFP9&C"HPW$ 9(WD9]J -VUU*TO+N[M8)2\UHRI.NQAM)
M&1R1@\>F:MUY7J?B36HH_B'Y&H.KZ==6B61(!$(8)D#V.372:7]OTOX@-I$N
MK7E_:W&EF[(NBI*2K*%)7:HP"&Z=.* -W6/$.DZ MN=3O%@-PY2%-K,TA R=
MJJ"3CZ5I]17FOC32WN_BKX*QJ5];^<MZ!Y+J/*VP@Y3*G!/0YS^%0:'KGB'4
MK^RU.&/6Y?/U%XIXVBC^Q+;>8R?+_$&4!3NZDANQH ]'OM0M--CBDNYA$DLT
M<"$@G=([!57CU) JU7D$K:CJWA?PYXCN]7NI'O\ 7K-Y+1MODHGVH!%08R"H
M"\YYYS[7K+7/$.H:K_:%K'K<I&L/;&%8H_L0M4F,3?[6X*"^[KN&.E 'J-5M
M1U"UTG3KB_OIA#:VZ&260@D*HZGCFO/=-O\ 4FT?Q1KE_P"([N!;2^O;*U58
M5D2%1+M1O+QEWR0J\XZ#'7.3K.H7Y\+>.=*N6U8V\.CQW$2ZJ8S,I?S5;E"?
ME.P$ \@Y[4 >NP3QW-O%<0MOBE0.C#NI&0:DK-\/?\BUI7_7G#_Z *TJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *R]?T"R\2:>EE?\ F>2D\<X\MMIW(VX?AD5J5@^+M531M'CN
M9-0FL0UU#%YL,"RDEG VX;C!Z9[4 3R>&["5=<5O-QK0VW6&[>4(OEXX^4#\
M:SK[P%I=\QQ<ZA;)+;):74=M<;%NHD&%63CG@D9&#@XS1J?CS2M+NM2MWM]0
MG;3"IO6M[8NL"% ^]C_=VMVYX/'%2:IXWTG2YY(V2\N4AA6XN9;6W,B6T39*
MNY'0$ G R<#.,4 -U#P-IE]<7+I<7UG%=Q+%=V]I-Y<=PBKM 88R/E^7*D$C
MBM.#0;&VU=M2A1DF-FEB$4X18D9F4 =N6-9NH^.-*T^XN(A%>W:6D:RW<]I;
MF6.W1AN!<C_9^; R<<T[4?&NF6%]]B2&]OKDVBWJQV4!E+0L6&\=L?+^H]:
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MN .><9'(R*B;Q#<>(-+NXM#2]L-32!;FU^VVFU9USD=<_*V-IZ,-V>.*  ^
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MR L?P%=C10!PMUI%^\7Q%"VDA.HQXM./]=_H:I\O_ @1]:IZ?_;'A6\U*1=
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MKH/&-I/?^"->L[6)I;B?3KB**->KLT;  ?4FK1U'3&U.QLQ)$]U/ ]Q:[5W
MQKM#,K 8 ^=>_.:T: //]?T2Y-MX4O&M]3:'3X&AN8M-E:.=-\:@,-I!(#(
M0/[WM5.71K>WTRQD_L'Q+;2/)<31W=I=F2\@=V'^LY.1( &(.X C!]:])>:*
M-XT>1%>0E45F +$ D@>O )_"GT >=:8_B+2->BU'5-(N[V[OM%MH'>V52%N8
MVD++(0<)GS <_=ZXJAX:\.ZO9ZK\/I+BPFC33]*N8;MB.(G95 !^N*].N[J&
MQLY[NX?9!!&TDC8)PJC).!["LR'Q5HUQ)HL<5V6;6HWEL!Y;CS55 ['I\ORD
M'G% '":7830>#++2M5\/:UYNGWTY-S9$I+"S22LLL14Y=2&P<?WN017<^$O[
M4_X1R#^US.;D/(%-P%$IBWMY9DV\;]FW..];=% 'E^M^']6N-5^)4D5A,Z:E
MI4$-FP'^N<1."J^X) KI[G3KMO&OAJ[2W<V]M87<<T@'",WD[0?KM;\JZFB@
M#E?B%97=YX83[%:RW4MO?6MR881EV2.9&;:.YP#Q5&"QO;FY\:7?V&XB74K2
M'[,LJ;6<_9R"N/4$X(]:[BB@#R%/#=W8JPOM,U^Y%[I5G&D.FW31(9$A\MXI
ML, O0?,>,$^F*]7LK=+.QM[:-2J0Q+&JEMV !@#/?ZU/10!Y'I^D:59W>LC6
M_AY=ZG=3:K=S)=#3HI@\;2L4(9F!Q@UUEA:33^.=+U.'3)[.P30Y;<)+&$,+
M&:(K&0"0#M4\#L*["B@#S:RT+4X_!GA>T:QE6>VUT7$T>.4C\^5MQ]L,#^-9
M.C?;]8\!V'AZVTF[W2:N93>!1Y"Q)>M*S[L\'Y2NWJ3[<UZ_5&QLM/T'3H[.
MV"V]L)#L5Y"?GD<G&6/4LQP/? H \XF\-:RUSXLNH]/E=AKMIJ-M$2!]J2(H
MS!23C)"G&>^*Z;2%N]7\=3:^=.N[*RBTT62"[3RWE<R;V(7.0J@ 9/4DXKI(
M=1MY]2N;!#+]HME1I-T3!<-TPQ&UNG8G'>K$T2SPR0OG9(I5MK$'!&.".10!
MQ7A_1[JQ\57VE_(=%T^9KZRP>4DG!S'CL$/FD#TD3TK+\,Z5<M:6&CZIH6I)
MJVE;U34I9F-L#M91-&=^"6!^Z!P2<XQ7>Z1H]EH=B+.QC=8@=Q,DC2.YP!EF
M8DDX ')Z #H*N3316\+S32)'$BEG=V 50.I)/04 >?\ @RQD/]BVNI^&]1@U
M31HC"UW<3LUNN$V%H3O(;> . .!GT&>C\7V*7^FVL3#4$872NESIX)EM6"MB
M3 !W#^$C!X:M5=3M'U>72EES>10+</'M/$;,R@YZ=5;CVJW0!A^$AJJZ"J:P
M$-TLTH$JP^49DWG;(R?PLP^8CU/;I6Y110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7(_$&YOX-.
MT>+3[Z6RENM7MK9IHC\P1R0?8_CQQ7751U/2+35UM!=HS"UNH[N+:Q&)$.5/
MN/:@#SW5FU<:]?:)8MXENDTVQA-M+9W40;SI#(?,F,CJ9/NJ .1@-D5<M5UG
MQ1JFIP7^K7NC7.FV5IMCM)0JQSR1%W=P.) &PN"=N%/KFNHUCPIIVM7GVJ:2
M\@F:'[/*UK<O#YT62=C[3R,D^XR>>:AU3P3H^JS>;(+JWW0+:S):W+PK/"N<
M)(%/S 9(]<$C- '&:IJ/B2_U;71IL>M75YIK10V+V,L,=J9/)20F5&D!8,S\
M\, N,'.:9X@\0:O;W_Q&6*^N(18Z5:S6J!_]0[(Q8KZ'(KMKWP5H][=M.5N8
M$D1(YX+>X:.*=4X4.H." ./<<'(K/\7>$$O=$\4SZ5;M)J^L60MV!E #E%(0
M#) '4T 96J6]]I&M6MB-;U*YBU;2[QKCS)R=DL2HPDCQ]S.XC P.1Q6Y\-+4
M6OPYT'$T\OFV,,I\V0MMS&ORKGHH[#M5W3_"&EZ?>O=C[5/*8#;1BYN&E6&(
MD$H@)X!P/?@<U7L/!\&D'1H=/NKL6FFSR2+'/</)\C1-&(QG^$$J0#TQ[T 6
M/&NK7.A^"M7U.S(%S;VS-$Q&0K= V/;.?PKFM02^\+:SI]K;ZSJ-Y'J%A>><
M+N<RD211AUE3/W.<@@<<CCBN]N[2WO[.>SNHEFMYXVCEC8<,I&"#^%8EAX,T
MNQE>4R7MU)]G:UC:[NGE,,38RJ9/&<#GJ<#F@#E=$DU*TE\!ZA+K.H74FLQ;
M+V.>;=$V;5I053HI!4<CD\YSFNQ\67HL/#%[.;NXM6*K&DMM&'E#.P50BG@L
M2P ST)S4D?AS3HH]%C6-]NC "S^<_+^[,7/K\K'K5G5]*M=;TR73[U7,,NTD
MHY1E96#*RD<@A@"#[4 >7W.K:W8Z5XFLH9]6L7MI=,>V_M"X2>>+SI]C_,K-
ME2%^Z3W/8UUFC)<Z5\0+S1_[2OKRSDTR.["WDQE*2>:Z$J3T! ' XXXQ5K_A
M M%+7#N;V5[I81<O)=.QG,4@D1FR>6!& ?3CI6T-*M1K;:N%;[8UL+4MNX\L
M,6 Q]2>: ,7QG=%(-.LHYM3$UW<[5M],*I-<!49BOF,RB-1@$MD'C'>O.=<^
MU:OX2T0W]UJ*2VOBI+$"2X!D""<@;RA(:10,!@3TZUZSK.@VFN"V:XDN89K6
M0R0SVTQBD0E2IPP[$$@BLY/ FAQVJVJ13BW2_CU!(S.Q"S)R",G/)Y/J: .&
MNUN/#>N>/-1LK_4)KFPTZT\@SW!D&76098-PVT\C/3GUJ;4;KQ'I'A[Q'-#'
MX@M+--(>5+C5+F*21+E3U0H[$ J22. "O&,UWEUX2TJ\U>[U*9)B]Y;_ &:[
MA$S"*X0!@-Z="0&.#[U63P/I/]GWUG/)?7:7MO\ 99'N;MY&6'GY%)/ Y^I[
MDT 1P75QX9TBV,EOKFNSW9,TLD(64QL57( 9E")Z*.G-<L&2P\6>/=5DU/4;
M3R;.U93N,AC,D;XQ'G#$$_*.@)KU"-%BC6-?NJ H^@K U'P7I&IZC?7MP+D-
M?P""ZCCN&6.4*"%)4'[RYX/:@#F=#&HW.JZWH,MSKNG0OID-Q%)J%VDMQ#(7
MD4R*R.V =J_*3_"> #4W@'Q!J'B[4I[V^NQ&NG0K;+:PDA+EFY-U@@91L?)V
M&&[UL-X!TA_M#23:C)+=6YMKJ5[QR\\><X8Y^HXQP3ZUK#0-/CU:UU*&'R;F
MVMS:IY1VJ8N,(P'! (R/3MUH P/B1')-H^DQ13FWD?6K)5F4#*$R@;AGC(]Z
MQK^]N/#NJ:]HIUK57M7LK2>VDW?:+F.669XC'&6[OM7&3A2<\5W.MZ%8>(;)
M+/48W>%)DF 1RAW*<@Y'/6LP>!M(-I?0S/>SRWKQ/+=37+-,#$=T>U^J[3R,
M=\]<T <E;3>(YX-?TNR36%^R7%I+]FN;V-KSR7!,B),&8 D+D9;(R1D<4V\U
MVXALO#$>GZGJPW^)XK.YBO\ Y;B-"C,89#_$.0<Y.01R:ZO_ (0#1O,FE$FH
M"XF\LR7 O'\QI$)*R;LYWC<1G^Z<8QQ4Z^"='\FS21;F9[6_74EFEG9I'N -
MH=V/7C QTP!Z4 85C-J%AXS5-:N=8@EN;Z9;:3>)+"YB(<QQ!1_JW"@'D DH
M>3FN_K M_!^F6^JI?*]XPCG>YBMGN7:"*5L[G5"< _,WL-QP!5W0-,?1]%@L
M9)FF:,N=[,6/S.6 R>3C.,GTH YR>&Z\1^-M9TV35+^QM=-M;?R4LIS$6DEW
MDR,1][&T  \<'BN+_P!(\3ZQ\,M0O[^\6ZO$O$E>WG,?*0L-Z ?=+8YQU!Q7
MINK>%-/U>^^VR2WEM<M#Y$DMG<M"98\D[&VGD DX[C)P:D_X1?25N=%GCMO*
M.BJZV*1L0L89-A&._P OK0!:U>(R:'>Q"66,F!\21N5<<=01T->4^'](,UA\
M-K9-0OHEN+"XEDD68[U!ABRB-_ .!TZ<XQUKV)T62-HW 96!!![@U@:1X,TK
M1?[/^S-=N-/\P6HGN&D\I755*C/\("C [<T <)_;&KK+!H FUF^A35[V!FM)
MT6ZDAB561#([+WDY.=Q"_6N]\'MJW]AF/6(;J.:.XD2'[6R-,T.[,9<H2"VT
M@$YYQFBX\':5/'(%%S!,]Z]\MQ!.R21S,NUBK#H".".E:6E:7;:/8)9VOF&-
M69RTLA=W9B69F8\DDDF@#DKS[=K/B[Q#"-7O+&/2+6 VJ6\FU/,=7<R2#^,<
M 8/& :PO#=QJWB'4O#%I<ZWJ$4$OAN.^N/)F*M-*)%&2WOGG')QCIFMSQ9H=
MY<Z[+>6F@SWPN+,0,]MJ7V<2$%L).A8!T&[J,GE@1BM?PSX2M]"L](DE/F:C
M9:7'IS2JQVE1@G _WAUH Y'1-2\1ZI?VFJP6FN2-+JDD<[//#]A%J)6C*B/S
M-P*J <[=Q93V-&G:K>S^)-%GM[K79;'5KNY@>ZN9HUMYH_*E=?)B#EDVE%PV
MT9 .>M=G%X/TN#5OM\9NP!<-=+:_:7\A9FSF01YQDDD^F23C/-5K?P#HMK-:
M2Q->@V4_GV@-TY%MURB#. I#$$=Q@=A0!Y_H4M[8>$-#M;276;G^U=7O4N%M
M;D><4C>=ML;.RA"Q4%B""<-W-:EQ-XE\C0M-N+G5=,6YUV2V22>5&N7M# [@
M,R%@6!W $DGY0>M=<G@31XK26UB>^CB:Z-W"%NG!M926):(Y^3)=LCH<G-6H
M/"6EP)8#%Q(]E=->1RRS,[O,RLI9R?O<,?;IZ4 :UK;BTLX;<2RRB)%3S)GW
MNV!C+,>I]37FMKK%[_PDVDWUK<:W/9W^JRVK7%S)&MI+'ME(2.'>6&TH,/M&
M=I)/->H5RZ> =%CFBD1KT?9[C[3;+]J?;;,6+,(QG"@Y.1Z''2@#BO-UF3P_
M::ROB'4DNY/$+6"@2YC6%KMH<%",,0#D$Y(P!T%6+^^U32-9U7P]:ZO?F">^
MTR&.XGE\R6W6X+B3:[9Z^7@9Z%N*[M?"NE+IL6GB*3[/%??;T'F'/G>;YN<^
MF\YQ27WA32=2EU&6Z@=GU!81,PD92#$28V4CE6!8G(H X?Q)?:EX9?7]+L]5
MOI85TZVO8)+B<R2P.UP8V <\X8 '!/'.*UO&.K7]GK.K16UY+$D7A>[ND5&Q
MME5@%<>XYYK<C\%:/]AU*UN1<WAU*,1W4UU.TDKJ,[1N_A R2,8Y.>M1Q>!=
M(4W3S/>W4]U926$T]S=/([0OC*Y/3IQCU/<F@#FS#J%EJ>AQMKFIS#6-,N3=
M[[@X#K&CJ\8_Y9D$D<=OSK9^%EJ+;X;:&1-/*9K5)3YLA;:2HX7/1>.E;SZ%
M8276G7#QL9-/B>*#YC@*ZA6!'?A13/#^@6?AK3!IUA)<FU1LQI/,TGECLJYZ
M*/2@#GIX;KQ)XSUS3Y-6O[&VTRWMQ EE.8LO(K,9&(^]C  !XX/%<://\4:[
M\,M1OKZ]CN;ZVN_.>WG,>&2'[R ?=W=3CJ*]+U;PGIVKWS7LDMY;7#P^1,]I
M<M"9HP20K[3R!DX/49/-2GPQI0O-&N4M_+;1D>.R5&(6-70(1CO\H'6@"?7H
MC+X>U",2RQ'[,^'B<JXPI.01TKS#1=),NG_#.V34+V);BQFE>19CYB@V\9*(
MQ^X.,<=!G&.M>NRQI-$\4BAD=2K*>X/45A:3X-TO1QIPMVNY!IOF"T\^X:3R
ME=0I49_A 48':@#A#J^KI)'X?$^LWT*ZU=VY:UG47;PQ1JZIYCLO=^3G=A<5
MW?@YM6_L5X]7ANXI([B18/MCHTS0YRA<H2"P!QG/.,FEN/!^E7$<P N(99+U
MK\3PS,DD<S+M+*PZ KP1TP36EI6EVVCV"VEKYA0,SL\LAD=V8DLS,>222: .
M0U.^U&Q^*DS:=H[ZD[:)"'1+A(M@\^7G+D9_"J)LKW2=,MK&Z-_#?:MJES>G
M3=&E4/M(),?G,R!57*LS C).!UKO5TNU76GU<*WVM[=;9FW<;%8L!CZL>:KZ
MSX?L];>UDGDNH9[5F:&:UG:)UW###([$=?H* .$T?7-6M;?P_JMY=W368U*Z
MT>]CGD#$ S,D#N5)4LK(J%@>=W4TQM0UC5GTN_CU:\MK76O$#PP+$^-MFD,J
MJ%';>8R^?]H'M6QK_A%H_#5UX8T#37:TU61FEGFN1Y5EE@6=5)W$YRP"C[W4
MBNF_X1W3?L^CP"(K'I#*]HJM@(5C,8SZ_*QH \WU :K9:'XTN(O$6K$^'[@F
MPW7!)'[J.4B0]9!EL8;.!5FYU3Q)J6K:O=:;::Y-<V6H+!:K;SPK9A$"%ED1
MI 6+98DE21N&.E=U<>%M+NK/6;66*0Q:PQ:\ D(+'8J<>GRJ.E0W/@[2KK4W
MO6-VGFR1RSV\5RZ0SNF-K.@."1M7Z[1G- '&:Q)JDVG^/-437-1@?1KEVL8H
M9MJ(4MXI,,/XE)/W3QR?6M/PQ:F;XH>)KQ[J[++:6+B,S$Q_.LI(*^@/0=LF
MNHE\,Z9-9:S:/&YAUAF:\&\Y8M&L9QZ?*HZ5!/X3L&U*YU*![F*ZGM/LLBI<
M,D<JA652P'<!C@]10!OUY9K$FJ3:=X\U5-<U&"31KF1K&*&;:B%+>.3##^)2
M3]T\=?6O2-*LWT_1[*RDF,SV]O'$TK=7*J 2?KC-4I?#.F36.LV;QN8=89GO
M!O.6+1K&<'M\JCI0!R3O?^(KOQ1<OK%_8'2E2.SCM9O+1&^SK*9'7H^6?HV1
M@5DZ?!>>)O%D-^-0O;2^OO",%TODSLBQRR%AP/[H.&QZ\UW&H^"=)U*YEFD:
M\A^T1+#=);73Q+<HHP!( >>,C/!QQG%6G\,:<VN6>KQ">WN;6 6RB"4HC1 Y
M",HX(!Y H X&V\7:GJ-YX;U..ZECL[*WM5U:('"O+<NT)#?[CKGVS1;:[J\^
MM^%+S^T;C[+K.LWKK#O.TVRH1$N/3"!OJU=K'X(T*+3=8L$MG6#5IFGN@)#G
M<QS\I_A /( Z&I_^$4TG.A[8&4:(,60#D!!LV<^OR^M 'E_]FO'X?UHQZA>^
M:WC"*!'EE,FS%S$ ^#QN]^^!71W4&NV>J^(M"T?4K^[865G=PBXN=TJ[I765
M8Y&^Z61#C/ )[5TO_"$Z1]JNYO\ 2MMU>1WTD/VAO+$Z.KAPO0$LHSZU:U'P
MMIFJ75U<W"3">YABA:2.5D91$Y>,J0?E8,Q.10!YQJPCU*QT>V74=?B>+Q';
M0RVM]*5GMMZYP6!.\<;E;)QDX-7]<U6]MM5GOM/NM<G2SU2ULVF\V-+.,%XD
M>(H7W2$[FR^TD,W!&*ZN3P+I$VGO:S27TDKW279O&NF,_FH $8/VP!@ <4RX
M^'^BW1N/.>_*3R"8Q_:W"K,,?O0,\/\ *#GUR>] ')ZQ+JLFD>.=837-1AET
M:\D-C%%-MC39#&^&7^($G&#QZ=34FL_;-?L/'=Y+JMY;+ID+V]M;Q2[8@HM5
MD8NG1]Q<C)Z#ICK7;OX6TN73-7T]TE:#5F9[O,ARY9%0D'MPHJIJ7@71M4N[
MJ>?[6BWD:QW<,-RZ1W 5=JEU!P2!Q[X&<T <G;:MJ$/BBTL(KR9+1?!7VI80
MWRB4.H#X]<<9I^DSZG8#P/J<NL:A>2ZO 1>PS2[HW_T5I1M3HI#*.1R><YS7
M9+X2TE=12^$4GGIIO]E@^8<?9\YQCUR.M3Q^'=.BCT:-8WVZ. +/YS\N(S%S
MZ_*3UH \]L;C5AH/@S7VU^_>XUG4+?[9"\N8F60,VQ%_A QC ZC.<UWOB^,R
M^#=942RQ$64K!XG*L"%)ZCZ5Q-EX-U!M8TJ$Z++8VVGZB;LS-J7G6R("Q"P1
M$Y7<2N<J,#(%>EW-O%>6LUM.@>&9&CD4_P 2D8(_*@#RO2-&,]_X%M%U&_B2
M3P_/+)(DY$A!%L=BOU49QT[#%3VVI7ESI%GI,U]K=Y<IJ=];I'8R*EQ<Q02,
MH+S,R[0H*9.06./>NTTCPCINC26,D#W<KV,$EO;M<3M(4C?9E>>P\M<>F*BF
M\$Z1)Y;1M>6\L=Q/<++;W+QOF9MTJ[@<[6...V!C&* ."L3=Z[J/@&:_OM06
M;[3J,#$7&UB(?-52Q7@MA0&(Z\^M>I:S>1Z=H=_>S7/V:.WMY)&GV;_+ 4G=
MM[XZX[UBKX!T2*"UBM_MELMG=275L8+EE,+29WJISPAR?E]S707]C;:GI]S8
M7D8EMKF)HI4)QN5A@C\C0!Y?#=ZC -;TZX&M+;3>')[K;JT\<CM(/EWJ%=M@
M(8Y7CH.*JZ-_R$/@U_V#KK_TE2N\B\":1'*9GEOYYVMI+22:>[=WDA< %&)/
M08R/0Y/4FK,'A#2+:709(XI VA1/#8YD)V*Z!#G^]\H'6@!OC;5KG0_!6KZE
M9D"Y@MV:)B,A6/ ;'?&<_A7/7:7OA?7].LX-8U&\AU&QN_.%W.92)(D5EE3/
MW>I! XY''%=U>6EO?V4]G=Q+-;SQM'+&PX92,$'\*Q=/\&Z7I\S3>9>W4OV=
MK6-[NY>4PQ'&43)XS@9/4X'- %+X<PW<G@_3=5O]3O+Z[U"S@ED,\FY4^7C:
MO;@\GN1DU4\;#4X=0BNRVLC1H[5M[Z1*!)!-G/F.F09%V]AGH<@YKK=+TZVT
M?2K33;-66VM8EAB5FR0JC Y[\"L_6/"UCK5T+F::]MY3%Y$C6ER\7FQY)V-M
M/(Y/N,GGF@#E(WNO$][XAF77[^"'3885L7M)?*5BUNLOG.HX;)<<'(P.E5M+
MN]3\8:K9K<ZM?V4,_ABTOGCLY3%^_=Y 6!'(Z=.^!GI75WO@;1KV1F47=JDD
M"6T\5I<O$D\2C"HX4\@ D9ZX.,XK2@T+3[74S?P0^7-]C2R 4X5849BJ@=!@
ML: /-],U75[71_!?B*?5KZ[N=31UNX))/W,@^S22+A!PI!C7D<GG/6K_ (+N
MO$5U>:'?R6^N/;WUL9-1FOIX6MV+1[T>)%D)0;N  H^5N>178V_A72K:RT:T
MCB?R=';=: N3M.QDY]?E8]:CTKPAI>C7D=Q:M=D0*R6T$MR[Q6ZMU$:DX'3'
ML.!@4 5?B'>7ECX,N9]/NWM+G[1;(DZ=4W3QJ?PP3FN5\1:GJG@R\UFVL=4O
M+I'T7[7&U[)YQ@F$RQ;P3T&'SMZ96NO\=:/<:]X3GTVV@$[RSVQ:,L%RBSHS
M\DC^$&GVW@W2(1?_ &@7-\U]!]FF:]N&F8P\_NP2>%Y)]<G)- '.ZBM[X6UN
MVLK;5]1NX;_3+QY!=SF5DEB5&612>5SN((''3BN?N]-N[SP+X,U&_P!;U6XN
MM2U#3'F)N2JKOP?E Z$<<]<C/6O0;'P;IEE)+*TE[=2R6S6BR7=R\K1PGJB$
MG@' R>IP,GBI;KPGI=WX<LM"99TM+$0_9FBF*R1&+&Q@PYR,#F@#AM8\1ZMH
M^L^/([:^F9=/T^R^R"5MXA=P5+X/?G<?7%7]9^W>%-2CM+76-1NHK[2;Z1_M
M<YE:.6%%99%)Y7[Q! XZ<5U*^$-'^T:G/+"]P^IVT=K=^?(7\V-%*C/O@G)Z
MU%:>"]*M3.SR7MW)-:M9^9=W3RM'"W5$)/ /&3U.!D\4 <WH[:C8ZKX+N9-8
MO[IM9MG%['/+NC8B#S 53HI!&..HZYZUI?%F(R?#'7")98RD&[]VY7=R!@^H
M.>E= N@6"OI#B-\Z2I6T^<_*#'Y9SZ_+4^KZ5::YI%UI=_&9+6ZC,<BAB"0?
M0CH: .(;P^;KXD75@-6U.&&+0[?,D5R5F<^?/@F3KQSQWXSTK!TW7M;U^#1[
M6?\ MVY*Z+'<N^DS10N\S2.F]R[ID 1]!D$L<CI7IFF^'K/3+S[9')<S71MD
MM6FN)C(S(K,XR3U.7;GZ5GGP+HZV=E;VSWMI]CA:WCEM;IXY#$3DHS \C//M
MVQ0!J>'I-2E\.Z<^L1>5J1MT^U)QQ)CYNG'7GBM*H;2U@L;."TMHQ'!!&L<:
M#^%0, ?E4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %<WXSU#4;&STR/2[I+6>\U&&T,S1"3:K[L
MG:>O2NDKE_&^AOK]GI-H+8W$"ZI!+<*&VXB&[<<Y![]N: *EKK>J:%XAN]+U
MS4(M1MX],;41<0VOER1A'"LA12=V<Y7&#P1S4[^/["VM+R?4--U.P:T2&66*
MXB3>(9'V++\KD;00<\Y&.11J/A>+1?"^L)X2LEM=3N("%DC;]ZY'0!V/7&<9
M. 36'HWAQKCQ#J GT+4K;1]3TK[&QOKKSI,AFW;]TC%<A^ ">A/&: .LUOQ5
MI^@W"07*3RR-:7%Z1 H;9%"H9F.2,9R /4FLQ/B%9275O;)H^LF6\@,]@OD(
M/MB#&=F7XP&!^?;Q7*>&M*U76O!_B6[NP+J^&G2Z%8.C B9(5="X/3YY#_XZ
M*ZJ/1[]?$/@ZY-L?)L--N8;ELC]V[+ %'7OL;IZ4 6(_'5A<:=8W%I8ZC<W-
MY)+''81QJ)U:([9=P9@J[3P26[C&<T/X[TTKIHMK/4+N?48YGM[>&$;]T3!9
M$;<P"L"3G)Q\IYZ9Y#_A$[^WN+;4+W2]2N(8K_4Q)!I]V89@D\XDCD!61,CY
M.5W?Q XXK<T7P_<6>O>';J'2);&UAM;\SQRW1N&BDEDC8;G))+-AB<$@'(R>
MI '7_P 1 EOHD^G:1?7'V_4'LIH6C420L@?>A!<#?E..2, \],]-KVNVGAS1
MY-4OQ+]GC>-&\I-S NZH.._+#_Z]<)/H>LV4-I>+I5Q<FU\57.H-!"R>8T#^
M:%=<L ?OJ<9S75>-]/N]7\*M;65NTL[75I)Y>0#M2XC=NIQPJD_A0!4;X@VZ
MW%W:'0=<^W6L8GDM/(C\SR3G$@._;MX(QG=GC%37?CS3[>SAO(+'4KVT>R2_
MDGMH05A@8$AFW,.P)VKEN.E!TN]_X3C6K_R#]FN-(@MXI,C#2*\Q*^O1E_.N
M%'ACQ!)X;AT>\TK4;A_[!@M;)(KWRK>VF$;++YH5QDYV]F! P.] 'IUCX@L=
M0U:^TV(R+/9QQ2L7 "R1R E70YY'!';D5#;:]%K/A&76M/$T<4D$KP-*H#$+
MN ;&3P<9'L17"^++/4XK3PU<Z=$UIJFIVO\ 8-Q#(0)%21,[^"03&59N.S&O
M0YM.CM?#4FF6,6(XK,V\$8] FU1_*@#FO"7CE-0TSP[;ZA:Z@EQJ-I&([Z:%
M5AN9A$&<*0<@\,1E0#@XS6IIGC2PU6_MK>.TOHH;S>+*[FC40W6P$G80Q;H"
M1N R 2,URVFZ9K>H:;X,T2\T6YL?[&\N6\N7>,Q_);M&JH58DDEQG@8P:7P=
MX7;3;C1;.\T#5!=:6I#WT^INUJ&5"BO%'YC [@>FU=H)] " =GK/B*+2+JVM
M$L+V_N[A'E2WLT5F$:;0S'<RC +J.N3G@&ET[Q'9:G?O9P)<+*EG#>'S8]GR
M2E@HP>0WR'((XK)\9V2W<MDTFB:E>"-9#%>:5<B*YMI#MP!EE^5AUY(RHR.]
M9&FP^)M'UF.^O]*N-1NK[1K:VEE@>/$=Q&TA(D)88!\P$LH(X.!TH DC\>/<
M^)=/EL;74;VPO]&^UPV4$2>86\W&X[F &%XY;'([FM%_%NGZA<>%[BVO;^&/
M4YY8XX4B3#LBG<DV[E=I4_=[CTKG/#>FZ[X9N-!NY]"NKF.W\/K97"6[1F2.
M7S=V "P!''.#W'O5/^S+S2M4^'T5_$(;N?5[^ZDA#!O*,H>0+D<$@, <=\T
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M+($41._1B!U4=Z?IMQJ-DMW>7/B./7XH(&?[)96D:R9&#D8?DX!&.^:K>/\
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MH[ 5/110 4444 %%%% !1110!G?V%IO]N?VR;56U#9Y:S.Q8HN,':"<+D#G
M&:T:** "BBB@ HHHH *RY/#NDS:]%KDMFLFI0J5BF=V/E@C!VJ3@$CC(&:U*
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAV)V@ .<<<^]=+0!Y9JVEZU?ZGXBL[BPN%N];\/0P1S11%H!<(LN]&<<+RP
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MW<MX]MN&[R;B5O,ASTSMD7\4%>K5EZGX?L-8O;2YOA-*+5Q)'!YS"$N#E69
M<,0>1D'% 'G\OA>[T>'PU>W1U8E(+K^TI=*#-,MQ.R2LVU069=RLO /\/:KV
MEZ');^(?!UQ;Z=J,=K$NIS3&]^>2)YBC R$<*6.XX]R.QKT:B@".X!:VE4#)
M*$ #Z5Y7X=TO4]$\*^ M0NM,O6_LH7"7EM'"S31"564/Y8^8X.,@#.&Z5ZQ2
M$A5)/0#- 'EEYI.HZK<W&KIIEW'!?>)=/GC@EA*R"&$(C2NG50=I/.#@#->J
M55TW4;;5M/AOK1G:WE!*%XVC;@XY5@".G<5:H \>#WFG^%O"GAZZTF\BN=/U
MVTCFGEBVQ'%QPZ/T?=D'CH"<X[WM"T%K>^L]*OX/$DEQ:ZG)< *2+(*)6D24
M,1M(((RH.[)(Q747/AGPUX?\W7;K[1%:6+R7WE-<2O! _):18LD \L>!QDXK
MJE8,H8'((R* /-FT;4?^%=3V@L)_M3:^9_*\L[BG]H;]^/39\V?3FJUCH+1:
MI)I>H0>))9/[:>[18219E#.9DE+XVC&1E<[B1TYKU"*6.>,212+(AR R'(X.
M#S]:?0!YW9VFMZ9X*\5FQM+B+4)=7O)H0L69'C:7[Z*>&.S)7U(%8\^GWL\?
MB\6MCKTT6H^'_)M);])&DE=?.RN&&4.9%PI )Y(%>HIJ5I)JLVF)+F\AA2>2
M/:>$<L%.<8Y*-^56Z ,GPM!+:^$=%MYXVBFBL($D1Q@JPC4$$>H-:U%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<WXSNS!865M'<:A'-=W:Q)#IP7S[C"LQ168@)PI);(P ?6N
MDK,UK0K77(K=;B2XAEMIO.@GMI3')&^TJ2"/568$>AH X/1=<U9KK1+2:XO4
M5/$-S9.EU(K2M$MO(ZI(RDAB#CG)Z"G:IK&IS:_J.D1ZC<00W/B&VL1)$^&A
MA-HLKJA_A+%2,_[1KI#\/]%6W>&%[Z'-VMZDD=TV^*<+M,BL<G+ G=G.<G-.
M_P"$"T3[%=6V+O=<W,=XT_VEO-6=  )%?J&X_4T <)KDE[X<M_B1+9:G=-<6
MUG8M!<229E0$/P6[D9/)YQCK6_I]H\_Q=6Y>]O"?[ @G,?G'829'4@CTXSCU
MYK;/@#1'L-6M)OM<XU9(TO99;AFDEV9VG<>AYQQV ':K[^&;$Z]::RDES%=V
MUN+7]W,562($D*Z_Q $D_C0!F>.I[V-?#]O8W\UD;S5XK>66(@,8VCD+ 9XS
MP,>^*YJ^U'5-$O\ 5='AU6\G@MM2TEH99Y=\BI/,%DC+]2/E/7LU=3XTT*;7
MUT*&.)WB@U2.XG:.7RVC01R#>#D'(9EQCFI/^$'TAM+O[*=KNX:_E2:XNI;A
MC.SI@HP?MMVC&.!CZT <QX[UW5-/N?%8LKZ6'[+HEK/ %; CD:>4%A[D #\*
MMZAI^HV_B;PWH@\1:H8;V*]FO)?. DE*B(@*0/D ). .@) K8;P#HTL&H1W#
M7MP^HVZ6]U--<,SR*C%EY['G'':H_$GAR;6O%N@70\^.ULX+L/<V\WEO"[^5
MLP<YYVL.A&,YZT <Q9ZGJUW?VOA:35KP0C6[NT>]5P+B2"*$2JF_'7+@%ASA
M34\TOB!7UK1;*YU*_M]+U&!G:&=5O'MI(-[1K(V,LKD'D@E>,UU/_"$Z0-)A
ML$^U(T-RUVEVL["X$[9W2>9U+'<0<\$'&,4#P5I:6'V>.6^2<W/VLWJW+?:#
M-MVEB_?Y?EQTQQB@#C'URYOKC2M)L[CQ)?6HANIIQ;[(;U72546.4NR\)N(.
M#EOE)R.LMW-XH72=-N];&O06L5K*D\FG-'Y\,JR$+-,BGYP8PIPN0#G(YKK6
M\$:7]FMHXIKZ"XMWDD6\BN6$[-(<R;G_ (MQ R#QP,8P*+CP1I<L,$44^H6J
MQ6_V9C;W;J9HLD[7.<MRS'/7YCSS0!L0WD)T>.]-TLD'V<2_:=N R[<[\>F.
M:\VTC4M<;4[.&QN=99]4TJZEBGU9HO+FF4(8Y8XU9C&,ORI &"."17IJV5LF
MGK8+"HM%B\D1=@F,;?ICBN;B^'>B(L D>_G\B)K=#-=NV(&7:8O]S'X\#GB@
M"MX)NI5OKFQO;C6XK]+>-YK+5663!R09(I!D,I/& <# X&:FUEKK5O'-GH O
M[NSLETZ2]D^R2>6\K^8J*-PY"C).!C)(S6MI'AJTT>ZDNEN;V[N7C$/G7EPT
MK+&#D*,]!DY]3W)IVL>';/6;BVNI);JVO+8,L5S:3&.15;&Y<CJIP.".PH \
MM\2&ZU;PMIL=]J-Y++I_BM=-699-IE19]JNV!@N!@9]0?6O7OL03239"YN2/
M*,?GF4^;TQNW?WO>LM_!NC/HUEI7DR"UL[I+R/\ >DLTRL7W,QY8EB2<]<UO
MT >+>'=-DF\+_#B--1O(WNKR9VE\S<T8^SS;@F?NY /T)S6A<ZOJUA<W/AV*
M[U:]B&O"U62&13=^1]D$YC5W(YW=R<[<X.<5VVE^"=)TA;!+=KMH]/G>>TCE
MG+K"61D*KG^'#MQ4MWX0TJ\-X[B>.:ZNDO#-%*5>.9$"*R$?=^5<>AR<]: (
M?!CZL=.O(M4@OHDBNV6S-^R-.T!52-Y1B"0Q=<YR0!FN?U87NMZKXQ5M6O+2
M+2+=(K:&&3;'EH/,9I%Q\^2V,'L.,'FNUTG2+?1K1K>W>>0O(99)9Y3))(YZ
MLS'Z >@ %9NJ>#-+U;4;B\F>\B:ZB6&[CM[AHX[E%R )%'7 )'TX.10!P,VH
M70\(Z8FGW6N-/8>&[>X,6G-'%%;L8B5DE9V&_.S[F#PI..:WAXIN-!U87^KW
M#OINIZ*+^)2?EBGA3=*B^FY6#8]5-;4G@+19%BC_ -+6!;.*RE@2X94N(HP0
M@D ^]C)^N<'(K*UKPG+JTV@^'O[/E;1M*GCN7O[F=69U12!$H!W'.0"6 &T'
MKQ0!T7A*'4H?"U@=8GDFU&6/SK@N>5=R6V#V7.T?2O/Y[O6(O"^N>)QKM^;G
M3=9N$M[<2#R3$ESL\MDQ\V02,GD?+C&*]:K@]#\!1.EZ^KB[02ZQ<WIM%N3Y
M$X\]GB=T!P>-IQQT&1Q0 :1_:%_XM\57,^KWOV?2[OR[6T23$?S6Z$[ACY@"
M<@=CDUA>%=5U7Q'HW@K3KO5KV,7UE=7=W<12[)IS&ZJJ[^H'SY..>!7I%IHE
ME97&ISPJX?4I?-N,MG+; G'IPHK+3P-H\&C:9IMJ;NV73-WV.XAG*S1;L[AN
M[@YY!R.GI0!QESJ>M/';:-'K5VAB\4G2S> CS7MS 9,$XP6&[&2.J@G->GP6
M0@TU++[1<2!8O+\Z23,IXQN+?WO>LJ#P?I%O;6$*1S'['>&_21Y2SR3D,"[L
M>6)W'K[>E;U 'CWA47D?ACPSID&J7\*ZSJEVMS,)LNJ1M.Y5"?NEBHR1SUKM
MO"L]U;^(/$.AS7EQ>6]A) ]O+<OOD598]Q0MU;!!()YPU/C\!:/%8/91R7RP
M_:OM=OBY8&UERQS$?X>7;([YYK5T;0K/0XIQ;&:6:YD\VXN+B0R22O@ %F/H
M   . !0!RM]8F;XS6\AO+M0NAR3"-)B$R)D7&/[IX)'<@5S_ (52^T;PMX U
M&+5;V3[;+%:S6K/^X,30R$ )C@@HOS=3SGK7HU]X<LK[7;366DN8;VVC,0:&
M8H)(R0Q1Q_$N0#BF0^%M,@TS1]/1)/L^D2)+: N<JRJRC)[\,: .(\'ZIXBU
M.?0M6^S:XZ7Y9[]KF2+[((G1BIB4.67:VP#Y02,YYKJO'%Y=V^GZ9:6ES):M
MJ.IP6<D\1P\<;$EMI[$A< ]LU8T_P?IFF:C'=V\EYLA=WM[5[AC! SYW%$Z#
M[S>PR<8J_K6BV>O:<UE>K)Y>]9$>)RCQNI#*ZL.001G- 'GDV= \1>+XSK%_
M_P >.G103@">Y4O)*JHN?O,6; )Z;AGI63X@GOY_"GBO3;F76;>*REL)88[Z
MY1YU$CA65G1FRIQD G@_A7H(\ Z-Y=^)'O99[Y8?/N9+EFE+1,6C<-V92>,<
M< 8I)/A_HLT&H13/>R_VC"D5V[W+%I2C;DD)_O@]#V  Q@4 <MK-SKCZYJ^F
M:;_PD4[Z7;0QV3V<T6WSF0OOGWL#)DE1C!& >YKTB(37FDHMR'MIYH )1&V&
MC8KS@CH03U]JQ+KP1IMV0TMWJ8=H%M[ETO'4W<8)P)2/O?>89X."1G%=(JA%
M"J % P .PH \5\.:;+-X<^'R)J-ZDEUJ%RS2^9N:,>3/N"9^[D \^ISUK2N=
M7U:PN;GP['=:O>Q#7OLJR0RJ;LP?9!.8U=RO.[^(G.W.#G%=MIG@C2=):S^S
MM=F.QN'N+6*2<LL+.K*0H/\ #AVXJ6[\(:5>&\=A/'-=7:7IFBF*O',J! R$
M?=^5<>AR<]: (?!CZL=.NX]4@OHEBNV6T-^R-.T!52-Y0D$ABRYSD@#-<S-I
M(E^/BO\ ;KY?^)%]HPDY XN0-G^X>I7UKN])TFWT:S:WMWGDWR-+)+/*9))'
M/5F8_0>PQ3/[#LO^$E&O[7^WBS^Q;MWR^5OWXQZY[T >7Z5K.N:KX1\*J=9N
MXI[_ %ZXM)[A6^<Q#S_E!/H%&/0@'M6[K8U#1-962_U#78M)ACMTM;^WD$L<
M1'#_ &E.K;CU8@C![8KI++P5HVGV>G6L$<HBTZ\>]MP9"2)6WY)]1\[<4[4O
M!^FZI?RW4\MZJ7&PW-M%<LL-QMP!O7OP #C&0 #F@##\!6)A\0^,)S>7<I&K
M-%LEF++CRHB#CU[9] !3O$5Y>V/Q*T:6PTN74I3I5VIACE2,@>;!\V7('I[\
MUT=AX=L]-UN_U2UDN4DOSOGA\TF(OA1O"= V% S5F32K676H-696^UP026Z'
M=QL=E9N/JBT <)+;7^F6-_=7JW>FW6O:O&T6GZ6R23$"( H')"JS")F9LX S
MSFJ<&MZQ8Z#+JTEQ?K!H6N&&Z@NY%DE:S94#"0H2&*>9N!R>%ZUZ#K6AVNNP
M01W$D\3V\PG@FMY#')&X!7((]F8?0U@:CX<_L30M5L] TJ?4)-7RDT4]T/*5
MVCV-*Y<YYX+8R2: ,'7=8UB[DU;4;#4Y[:T35['2K/RR-N1,HG?'0Y9RGT0T
M^6PU'^V?%.EKXDUA;73[&&\MS]H_>+*ZR=7QDJ/*SMZ?,:ZK3?!NGV?A'2_#
M\VZ2*Q:&;>IVEYD<2;S]7&2/>M$Z%8M?:E>%7\[48$M[@[N"B!PN!V^^U 'F
M@U[7_$ 01+KCSQ:-9SQ'2FB1!<31ER\H=EW#( "X(P&]:U4&LZ[J^MPWVJ:A
MIQM-+LY_LUI-L\NX>.0MR,\ KTS@]\\5T4_@72)8;:*.2^MEALTL6^S731F:
M!!A4<CKC)YX/)YYK4@T&PMKN]N8HV5[V"."4!N-D88* .W#&@#S[P^;C6_''
MA35+N^N_/G\+B[D6.7:C.7AW#:.-I)R1WP/2NA^*FI7ND?#O4;W3[F2VNHY+
M<)+&<, 9D4_F"1^-:,7@W2[>XT:>V>[@DTFV%I T4Y&^$;?D?^\/D4U?U_0K
M'Q+HTVE:BKM:S%&<(VTY5@PY^JB@#DM9N-1T_P 7R7.I76L6NG/<6XL;JU*O
M:(I"*T<Z=06<L-Q&,,N",5N^.]3N](\&:A=V,ODW($<4<N,^67D5-W/INS^%
M/O/!^FWNIR7DLMZ$EE2>:U2Y802R)MVLR=/X5]CM&0:U-4TRTUG3+G3K^(2V
MMRACD3)&0?<<@^] 'G>I64^@>,KCR-4O;@Q^&+V6)[J7S)(W#Q\ANO) ..Q!
MQ5^\U^_L[3P7<K<22&>RFGN$+?Z\K:%QN]?F&:WK#P5I=E?M?227M[=/:O9O
M+>7#2EH6()0Y[?+^I]:BTWP)I&FW5A<+)?7#Z>K):"YN6D6%&0H44'C;@_7@
M<\"@#G?!EWXAN+_1KN2#79+:]M6?4)K]X3 79 Z/$JN2@SD   889Y%=)XSC
MU5[*R;3DOI+=+C=>Q:=*L=P\6QL;"2.C;20""0.*GTCPCIVBW<<]M+>NL$;1
M6T,URSQVZ'&513T' '.< 8'%7-8T2WUE(/-FNK>:W<O#/:S&.1"00>1U!!P0
M<B@#@(T&O>(_"<<&LZDT?V+44DN&'DW6%EB!C<XRK*0%)X)VGUI+;4[VXT^W
MTB;4-;O+F'4[^W2.P9%N;F&&0J"\K,H4+N7)R"QQ[UW%AX5TS3;BRN+=)?.L
MTG1'>4LS&9@\C,3]YBR@Y^M59O!&DR2++%)>VTRW$]QYMO<M&Y,[!I5R/X20
M..V!C% '"1:A=ZI<_#2YOGD>X_M&]B9I=I<[!(@W%>"V%&2."<UT?PT_X^O&
MO_8RW7_H*5L6G@71+)].:".=5TZZENK2,RDK$T@.X ?W>20.V:TM(T*QT1]0
M>R5U-_=O>3[FSF1L9(]!P.* .=U>.\U3XB1:.-5OK.P.D-<.EI+Y;,XE"@[N
MHX/;T';(/.:+>ZRNC^#M<N=<OKBYOM1%E<1.X$+Q8E4?(!C=\BG=USGMP/23
MI-J==&L;6^V"V-J&W<>66#=/7(ZU2A\*:7!INF:>D<GV?3;D75N#(<AP6/)[
MCYVXH XO2=9O7\5:'<P76M7%EJEY<1/<7;1K:SH(Y77RH@Q9,%%P=HR,Y/-9
MG@'5[K4)--\.>=<:9:17%Y<F7!1M09;ER8HF_NJ&!;')Z#@$UW-MX!T>TFLY
M8I+_ #8S^=9@W3$6W7*(.R$,01W&!V%61X,T==)M-.2.5([.Z-Y;R+(1)%*7
M9R0WN688Z8.* .-T+5?$6J7]CJL-MKLAGU*1+C?)%]B%MYC)A4W[@5 4YVY)
M4YX-=MXNO?L7AR=Q=W-K)*\<,;VD8>9F=U4*@/&YLX!/3.>U,@\'Z9;:J+Z*
M2\"K.UREI]H;[.LS9W.$Z9))..F23C-:&L:/:ZYIS65WYBIO21'B<H\;HP96
M5AT((!H \@\67M\_PX\=:==C44BM'LVACU*9)9XP[1D@NC,",C(R21FNQM_^
M2[W'_8M1_P#I0:TI_AYH=U9:C:SM>RQZE'&EX7N69IBC;E<D_P 7 &?0 =!6
MPF@V*>)&U\(_V]K069;=\OEAMX&/7)ZT 8_BZ>ZFU?PYHD%Y/9PZE=2BXFMW
MV2%(X6?8K=5R0,D<X!KB9KJ_T74/$%C:W.H74EWX@M;1YK=D^TF+[(KX5F(&
M["!-Q.>IZUZ;K>@V>O001W33Q26\HG@GMY#')$X!&58>Q((Z$&LZ/P+HL=E>
M6RBZ)N[A+J2<W#&43( %D5\Y#?*#^?8XH X;78-7N/#L=OJ']LVEJOB"Q6S-
MW.GGM$\D>0[(S;MK[BI)ST]*LZCJ'B*?5-<72H=?N;G2IX[:Q^SRQ?9R5BC<
M^<&<%RY<Y.#@$8YKLY?!>EW&B3:9/+>RB:X6Z>Y>Y8SF92I5P_8C:H&. !TI
ML_@G3+BZ\]Y]0'F+&+E%NF5;HQ@!3*!]XX !/&0,'(H Q]+.H:CXT\4S3ZM>
MK:Z7.BVUHDFV/+VR%MP[C)R!V.36!I7]M7&G>!;J3Q)JAFUQ/*O?WHVE/(:3
MY1C"M\F-PYY)KTJUT6SL[S4[J%7$NI.LEP2V02$"#'I\JBJ]OX7TRUMM$@B2
M01Z+_P >>7)V_NS'SZ_*QH \\O-9U?3;:&QCU6\D%OXTM].$LLFZ1[=E5S&S
M=6'S$<]L5:UB75IK#QYJB:[J$#:+.[6,4,FU$*6\<F&&/F4D_=/')]:[*Y\&
M:/=N6ECE).J)JW$A'^D(H53],*.*L2^&=-FLM:M'23RM99FNP'.6+1K&<>GR
MJ* .#\4:]?)+J&IZ?<ZU*^GFV#?9VCCL[9B$9DD#,#*6#C.%.-P P:;<1W&G
M:I\4=2MM1OEN+6U#PYF)5&-KO! _V3]WT%==?> =%U![SSS>>3>!3-;I<LL3
M.J!%DVC^,!5Y]5!QD9J6;P5I<]SJ,TDMZ3J5H+2\3[0=LRA/+W,/[^WC- '-
MZ1<:AXEO=$TRZU6^MX$\.VU_*UK-Y<D\TAVY9QS@;2<=RW-4],U'6-<N_#>F
MW&L7<:.=4M[J:W8(]R+>541L@<' Y(]6QC-=E/X-TR6'3U@EO;.6PMA:0W%K
M<&.3R0 -C'^(?*#SWY&*L67A?2M/DTM[6!HO[,BEBM@') $F"Y.?O$E0<GG.
M?6@#AXIM?GT<PK/J]_9:=J]W:W)LIE6\>)21$=QQNP3R 03QUYKN_#-W'>^'
M+*XBOIKU&3 N)X]DC$$@[UP,,",'CJ#52;P9ILFYH9KVTG-U+=>?;7!1P\N-
MXSTVG X(["M;3--M='TV&PLT98(@0NYBS$DDDDGDDDDD^IH \S&I:S;^'?%G
MB#^UKZ6XM-2NK&SMPP,<2&<(&VGAF7=QDX  'KE;W4O$>CZ5JOD1ZY:6<R6L
M4-SJTD4LL,TDZQ.R%6;C:X;!X!7CK7?Q^&=*CTO4=-,!DM-1FFFN8W8G<TIR
MV#VYZ8Z537P5I36%]:7DE[?K>Q+#+)=W+2.$4DJ%/\."2<CG/))H Y'7Y-2\
M.:EKMI::YJ,T,7A>YO(1<3EWBF#8#ANIZ<9Z<]N*Z&\U*\3Q'X6@2YD$5SI]
MW),@/$C*D14GZ%C^=5[?P4L'C">6875]IUUHTEG<SWESYCN6D7Y#DY VYZ #
MKW-:FG>"=+TV\M;P37]S<6L+P0R75RTA2-@ 5&>W ]_7- '!:#JFMZ[X=^'L
M$FMWL,FJF\6\N(WQ)(J*[#D]_EP#VJW>:AXBGU/6?[+A\07-QI=VEK9>3+%]
MF(1(V83!G!=GW-DX. 1BNVTWP9H^DP:+#:QRA-&\W['ND)V^8"&SZ\,:6]\'
MZ9?:I+?/)>1F=T>Y@AN&2*X9,;2ZCJ< #MD  YH X+Q0+W6_"'CS5)M6O(OL
M<MQ9PVJ28@$4:*"&3&"6RQR>1D8QBO5/*\_3O)WO'YD6W?&VUER,9!['WKGM
M4\ :+JTVH-<->K!J/S7=K%<LD,K[0N\J.-V /Q )Y%=0JA$51T P* /'_" N
M_P#A%_!FD1:I?PQ:Q-<RW,JS?.%C#ML1OX QP3CG@^M=OX2N;N/5O$.BW%W/
M>1:;=1K;S3MNDV21*^QF_BP2>3S@BEA\ Z/;Z;'80RW\<4%P;BT9;IM]HYSG
MRC_"/F8$<@YYK7T;0[/0K:6*U\UWGE,T\T\ADDE<@#<S'J< #T  H Y*\TF3
M5_BGJD U.]LHQHUJ6^QR^6[-YLV#NQG YXZ'(S7/6'B/6]?BT>UN/[;N-NEF
M>5]'>.)Y)?.>(2.69>,1YP."6Y'2O0=3\(:?J>JR:H;B^M;Z2W6V:>TN6B;R
MU+';QQR6/Y#TIDW@K26MK"&T-WIYL8#;0R65PT3^4<90GN,@'GG/.<T 7O#<
MNIS>&]/DUF(Q:D8%%RIQG>.">"0,]>/6M2H+*S@T^Q@L[9-D$$:QQKDG"@8'
M)Y-3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5E:]X@L_#MM;3WB3NMQ<);1K!'O8R,#M&/?&/J1
M6K7.>+M.N]0.@_983+]GUB"XEP1\D:ALMSZ9% &?)\2-/AAOVDTC65DTTYOX
M?LZEK5-H82/A\%2IR-I)P#QQ5_4_&NGZ7.P>TOY[:*..6XO((088$?[I8D@G
MCD[0<#K61J&AZE,/B)Y=HS?VG:+'9\C]\WV79@<_WN.:YWQ%X?U[4M-U;3I-
M,U2ZF>PACTWR[PQ6L2B%=X=0X!<N'^\ISE>@R0 =9XI\:QZ=9Z[;6-M?27.G
MVC-+=PPJT5K(8RR;B3DG[I. 0 1G IX\;6]AIUJ+FVO[V:.PAN[Z6UA#+;HR
MYWOR.N&.%!. 3C%8-[!K<%MXPLK;P_>W!U]#<6DF8PL9>W6-DERWRE2O09SG
MBJMQX8NK6[EEN]&UF_6]TVUB2/3]1>W194CV-',%D48/!W$,.6^A /5(Y$FB
M26-@Z.H96!R"#T-8;^+M-CT6\U8K/]FM+QK*0!!N\Q9O).!GIN/7TK7L;9+.
MPMK6*/RXX8EC5-Q;:   ,GD].M>9WVG:Z-!UKP]#H5W))/K37J709!"T+72S
M9!W9+8XVX[4 =/J'Q TW3Y=25K'4YH]+E\N^FA@#) -JMN)+#*X;L"1@\=,Q
M^)/&L-A;ZS;6-O?33V-H9)KN"%7BM6:,LFXDY/&&X!P""<"J%]H.IR^'/B';
M):,9M3EF:S7(S,#:QH,<_P!Y2.?2JES8ZWIB^*]/M]#NKTZU"KVL\;)Y:,;9
M8F60E@5P4SP#D'CF@#:A\;P66DV)NK:_OKA=-AO+Z6UA#"!&7.]^1UPQPH)P
M#Q5X^,K!O$*Z);6U[=W12&4M;Q!HUBDSB0MD848Y[\C -<5)X7NK.;S;O1M:
MOA=Z5:0K%IVH-;JLT<91HY0LBC!X^8@C[WX]1X=T.XTOQEJL_P!C,%@VFV-M
M;G?O&8Q(&4$\G&5Y/6@#<\0ZJVA^'=0U1;>2X-I TOE(!DX&>Y' ZGV!KD(/
M'%_)K6@O)I]^8[_2)9SI\,*%Y)0\6&!+8"[6?&6 P>><5UWB2SFU'PMJ]C;*
M&GN;*:&-2<99D( S]37+^&K+4I=<\/7MQI=U9Q6FAR64PN-H*R[X<#@G@[&(
M/M0!<D\7V&H2>&KBWO+^U34;R2!8! F7= P:.7=DK@J?N]QZ5HV'BRUU'4Q:
M0V.H"%Y988KUH1Y$KQDA@&!R.5;D@ XX)KC(?#.LK>>&'-@X6T\07]U.=R_)
M%(\A1CST(8?G6GIMAJ$'C""73](U/2HWNIGU.-[A7L94(?#QC=P[/L;Y57^+
M=0!J>,M=N=*NM'LXM0MM*AOYG274;B,.L6U<J@R0H9CT)XX/!-20:M?Z#I5Q
M<:]=PZE"9DCL9K*+$MSOP FP';NW' (.".3C!JQXEN+V 6ZC01K.E2ATO($5
M&E7IL8(Y"LO4$=>A'>N#?PA>3V=_=6&AWFFZ6NH6MW;Z1'<"&8A RS.FQ\1E
M@X(4,,[.V: .W/C;3DTZ:XFM;Z&YAN5M&L'B'V@S, 50*"0<@@@@XQDYX-96
MJ_$06MO9&TT;4'N9=32PN+:6)5DA8@-C&_!+*<J02I]:S#X?G2WM]9TS0=32
M6TU:*[>"^OC-<W<2Q-&2-[D*1YC84MR%[9%7/$$FO:UI^GZC_P (_<QQV&MP
M7,=KN0W+P(I#.5W;0=S'"YS@4 :<?BJPM-8\4->:A>+%I<-M+/!-"@2W#QE@
M(ROS,6[@YYP!5FV\9V<LES#=Z?J.GW$%HUZ(;N)5:6%?O,NUB#C@$$@C(R*Y
M+4?"VLZIJ?CV>*R:,:E'ITMEYS*!*\*AF0X)QRH4YXYK1U"VU3Q1JSZ@-&O+
M"&TT>[MD2ZV!YII@GR@*Q^4!.IXR>* -K2_&]AJM_86R66H0)J,32V5Q<0A8
M[@*NXA3DG..>0 0,C-=!=O<1V<SVD*S7"H3%&[[ [8X!;!P,]\&N0@T;4$D\
M DVK :;$RW?(_='[*4YY_O<<5UU[<-:6<MPEM-<M&NX0P!=[^R[B!GZD4 <I
MH?B#6Y/"WB&\OHX+S4M-N;J*.*V0JLAC7*H!R>3QZU3\.^(]2GUS1K9]:LM9
MAU*SDN)UMH50V94*0<J3\I+%<-SD=>HJII,>OW.B>*],BT;4]+O-2FO+FSNK
M@Q*B&0 ("5<D-GT&!ZU+H>ERMXCT*?3O#$V@Q6,,JZC)(L:"?*;5C!1B9/G^
M;<?3KDT >B5YV/&NJQ:5XZNFA-P^C74L-HL48^15BW ODC(!Y/?%=SIEU/>Z
M=#<7-E)93."6MY&#,G..2./?\:X.T\/:M'I/Q(A:R<2:I/<M9+D?O@T.U<<\
M9/'.* -[X>WNHZEX0M+[5)[^>ZN$25GO(HH\[D4_NQ& /+R3C/S=<U5U#QA=
MIXEUK0X=.N46STS[2EWM4A7(D()^;[OR #C.<YXK=\+6D]AX0T6SNHS'<06$
M$4J'JK+&H(_,5S6J6&I1^-M:ECTVYGMM3T5;:*XBVE$D3S25?)!&=RXX/6@"
MQX7\<17]EH5M?V]]'<7]DLB7L\*I#<2+&&DVD'(_B/*@$ D9%:.D>,;'6+VW
MMX[6^MTNXVELI[B(+'=(N,E#DGH0<, 2.0*PI?#FHW.E^!K1K=XS9VSPWC9'
M[@M9/'SSS\Q XJOX,\/-9WFD)=Z'K$5YIMN4DNKO4WDMTDV>7^Y0R,&# MCY
M5VCWXH Z_P 5:A'I7A;4K^6ZN+5((2[3VR*\B>ZJWRD_6J$WC&UL[BVTZ*SU
M+4;Z2QCO5CMX5+/&Q(W'+!0<CD<=1C-/\?Z==ZMX!UO3["%I[J>U9(HU(!9O
M3FJNCZ3?6WB^"\FMV2W70;>U,A(XE61B5_ $4 3#QUIL\&F/I]K?ZA+J$#7,
M<%M$"Z1*0&9PS +@G&,Y)X&:S/#OC8R^&[2YN8[S4KV^O+Q+:"VA42-%',X!
M()4*%78"21U'4FLGPYI>M>%KC1]0GT6\NU.FS64T-L4,D+_:#(A(9@-K!CR#
MQ@9JI:^%M4@LM&OM3TO4F,$VI)<VVF7C131B>X\Q'4HZ[E^7!&?X@<<< '9R
M>/=+ TU;>UO[N?4HYGMX((1O)B8+(C!B K DYR0/E//3+T\<:=-IMM<V]K?3
MW-S<26R6"1 7 ECSYBLI("[<'))QTYY%<G'')X?\4>%6MM!O%S9ZC++9_:?M
M$Z;Y8F+%G;YF)()&X]3@G',+>%M2<VNN7FFZELDU2]NIK*QNC#<Q13!0ARCK
MDCRU+*&_C/7% '8/X[TP0Z>8K:_FGOVFCAM8X1YHDB.)(V!(VL#GJ<<$YQS2
M+X[TU]-AN([/4'NIKQ[%=/6)?M'G("64C=M& "2=V,=ZR=)\/SV^L^&KNWTB
MZLK>.2^FN$N;HSR(9 H5G9F)W-C) )P3C-4O[%UC2]<77!I<]S';:]=SM!"5
M,CP30A!(H) .& XSG&: -+2?&V9O$-Q>K>/'#J<5G9V7D@3!VAC)B XR=Q<Y
M)QC)SBM*3QWID%E%/-;7\<SWW]GM:&$&:.<H7"%02.0!@@D'<*Y&Z\.ZQJ;:
MEJ=SI%]"O]O1:@MK!<B*>2 6PB.UD<8<9R1N'*D9/?0@\.RLVDW5EHNH6H_M
MY+J?[=>-/,T2P.@D?<S%>2%"Y)P >.@ +NL?$5;/1+FZM=(O_MUM?06<]I<1
MJ'B,C)@G#X(*M\I!/)&>]=K;RF>VBF:*2$R(&,<@ 9,CH<$C(^M><^)M U>>
M3Q3<6VGRSB:^TVY@1"NZ983&9-N2.1M/7%>BVLQN;6*=H98#(@8Q2@!TSV."
M1G\: .;B\?:5+)JA^SWRVVEM-'=W30_NHWC;!3.<ECU  /!'3(J1/&VG)::C
M/J%M>Z:UA MQ-#>1 2&)LA64*6#9((QG.>"!6!_PBVIW7@?Q9IAMS'=7FK75
MU;H9-GFKYH=/F!^7=MQGMFJ%]X<-_P"']<FL]&U2RN?LT0CEUK4VD:4I*)3&
M \CA5R@&XD EO3F@#J%\;6=S-<Z=+::IIM\NGRWQ2X@4.D2X&X<E2<MP/8YQ
M4-CXUM8]#TEXH=6U>6YL1=EH[=/-\K@>8Z@JH))Z+D]<"L.]N;_7?'$@.D7%
MDS^&;R.*&X*>:S-)$.0K$ 9X&3S@]NM>+0KVS\(>';6YT'5QJ=II@BCO=*N5
M2:"7C,;C< 4. >=R]<@=P#I(?'<;>*=2L)K&XATRRL([Q[UT "JPD8LWS9"[
M5&.,YW9QQ5E/'6GBSOKBZL=1LC:63:AY5S"JO- HY= &/MP2",C(&:Y>]T#Q
M!>WFLV=[9R//K7AZ"U:]BV^3'<HDN\/R" 688P#UIK^'I;_0]<^S>'M;@OWT
M2XM(WU+4WG)DD7F*-6D<8)5?FXZ#KS@ ZI/'%G+8V]S#IFJ2-=RF.S@$"B2Z
M 7<9$!8#9C^)B/U&7/XXTXVEA);6E_=7-])+%%90Q 3*T1Q*&#, NT\')[C&
M<UC^(?#]Q+!X7O'L]0GBTZ%X;F#3KEH9U#QJ-RE74D!D (ST/?%5+;2+K0]0
MT/7+/P]J'D(+R.ZL_M0N;E/.9&61B[\D^6-P#'&[O@T =#X)UNXUVUUBXGDD
M98M4G@A66/8T:*%PA&.H)(YYJWK'BFUT?5+73#9WMW?74+S0PVL88N$*AADD
M ?>SR0.#SG -/P-9ZC:VFL2ZE9-9RW>JSW21,RL0C[=N2I(SV/N#6?X@O9[#
MXG:-<0V$]Z%TF[$D=OM,@7S(>5!(SSCC/0F@#9T[QCI>IMIB0+<+)J#SQ)')
M'M:*2'/F)(,_*1@CO6-X@\:BVO=,^PFY\N+7&TV\B2$,TQ%N[A5'NQ3GCWP*
MR;/2-9TNXTGQ!+H]U*3JM_>7%E 4::&.X!"<;@"1A<@'C=[5&NE>(4N(=3.A
M3%U\42:BUL)$+BW-J4SG=MW9.,9^]WQS0!>\8^.9Q\/];O\ 2/M6FZKIUQ!#
M+%<Q)YL)>2/J/F4AD;@@GK6_)X@L[3QAJ=K<ZC<HEGIBWDT+QH((DW',@8?,
M6X.1TP*XSQ-X?UOQ#X;\8WEOI-Q%/JMQ8K:VDI42LD+)N=@"0,_-QG.%K2\0
M>$]3UGQ;XH,<)CMM0\/"R@N&(VF;<QVGOW&>* .HT7Q9:ZS>BS^PZA93/!]I
MA%Y"$\Z+(&Y<$],C(.#R.*OZQJT6C62W$D%S<,\BQ1PVT>]Y';H ,@#ZD@#'
M6LW0=7UC4;J*&YT"XTZVAMOW\ERZ9,V0-L85CN7&X[CCMCO4?C6+4)K&P%G%
M?36HO%-_%I\OESO!L?A6#*<;]F<$'&: %_X3;3O[+6[^RWWVAKLV(L/*'V@S
M@9*8SMSM&[.[&.<TG_"<:>;".9;/4&O)+IK-=.$(^T><J[F7&=O"_-NW;<8Y
MKCM.T/6=+NEU%-"O=MAK;WRVK3K+)+;S6WE?*[.=TB'J"?4 GBMN^DUZ\O\
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M=/DACV!5?!9F!)W]L XP:72O'FG:M<Z9'%9:C#!JB%K.ZGA"Q2L$+E0=Q(.
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M%J1;"-EG!;*XV;N <@\4 =1<>/--A@BFBL]1NHS9QWT[6\(;[+"X)5I/F'.
MQPNX\'BFZUXUM+3[=;65O>W<EM:"XFN;6(/';*RDHS$G)R!G"AN.:XJT\.S)
M:V]W-I&LZC#J&C621)IVH/;J)$BVM'*!(N 05.X@]6_':.G:IX?O?$%G8Z#<
M74&J6<"6;0R*T<+)!Y)21F8$ ;5.<'()[\4 =?X5O+C4?!^B7MW)YES<6$$T
MKD ;G:-23@<<DFN8B\=-IFJ^*$U&WU"[M=.O@#+;6ZLEI!Y,;98Y!(R7/&X@
M9[8KIO"=I/8>#M#L[J,Q7%OI\$4L9ZJZQJ"/P(KC;ZVURU7QO8P^'[JY_MJ=
MELIHVCV$M;I&2^6!501G..Q]L@':V'B"QU#4M0L(F=9K!8WD+@!621=RNISR
MI (SZ@U+H>L6^OZ-;:K:)*MM<J7B\U=K%<D!L9Z'&1[$5Y]XST:^TQ] @TJ5
M?MFIVG_"/7!!P3&5W>:!_L!9#_P*O2[2UAL;*"TMD$<$$:Q1H.BJHP!^0H \
M]\0>/-16S\9V]I97-E)HR+Y-XR(0"54\Y)Z[LCCIUP>*Z*+QQIGVB[BO+>^T
M\6UFU]OO(0@E@4X9UP2>,C@@-R.*Y7Q!HVL33>/;*#2;F8:O'!+:3H4\M]L2
M(5)+9#94\8K3\;^&=1\0:M,MI%^[DT*ZMEE+;5\YI(F12>HSL//:@#H]'\2P
M:O>26;6-]8721+.(;V((SQDX#K@D8R,$'!'&0,U3\=:O?:-H$,^GW,5M/-?6
MUMYTL8=8UDD5"V"1G .:H^$M,B369=0&B:U92):^3Y^JZB\[$LP9D16D?@;5
M.[C/;O5CXB:;<:IX:AAM]/?4/+O[6:6U0*3)&DJLXPQ /R@\$T 2Z,FK?VG&
M;GQA8ZE" 2UM#9HC-QP=P<D8.#TJG%\3-(FALKA;#5A:7TAAM[G[,"DDPS^Z
M&&SN.T@<8R,9ZT:"VFPZO$+/X>7>D2."IO#9VL:H,9Y,<A;!QC@'M69IWA[5
M8?"'@NSDLG6XL-56>Y3(S&@\[YCS_M+T]: -EOB%I<5HTMS9ZC!.E^NGO:/
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MG!(.<+C- 'J]%>?7=K/%K&B>%_[?OI[&XGNY)9$N66<+&BE(&E4[SC?G.0Q
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M /$U2\93A+/3=/1]2::[NA&EOI\PBEG"HS,ID++L7"Y)!!XQWKEM!U;4VO\
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MFX>267'W<N3N&WM@C':LZR\80)HNAI86>JZQ=WUBMU'%^Z$_D@+F24EE0'+
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MR/(I$;I*98VR"1S@#Z,:Z[P+97$'AT7]]'Y>H:K*^H7*'JC2<JG_  % B_\
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MG9BS$8'4GIB@#2T^P@TRPBL[;S?)B&%\V5I&ZYY9B2?Q-<+XCBN+'Q/<:MJ
MU&72UD@$-YI]^5-AC:&62#(#*Q.2<,<-TX%>AUB7GA'1-0U0ZC<VC-.S(\@$
M\BQRLF-I>,,%<C P6!Z#TH \YN+$VWAOQ1K\-Y>QW]GK\S6YCN71(Q]H4$;
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M5\D;=N!@]"."#P: /--!2:S\*^!?$":I?SZE?7=O;W+RW<CK-'(&5D*$[?E
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M(96E&,.9=V_<,#G.>,=*)O!F@W%['=RV;O*HCW W$FV4QXV&1=VV0C P6!/
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M0E::ZCWM^\=L9.<Y'0=,4 >?>);V8:K?:Q8+J+&TU:UM?MDFH&.*,[XE>*.
M'#J0Q!+#)+'G@51O;5=,T?XI:A9SW<5W%,R1R"ZD)4&&)L@%L9ST/4#@''%>
MAWG@CP]J%U=7%S8,[W3;Y0)Y%7?@#>%#85\ ?. &]Z=-X+T"XFU&66R=CJ,(
MANU^T2;9E  Y7=C=A0-V,\=: .8TZV/B?Q$;#5+J]^S6>BV<T,4-U)#ODEW[
MY248%B-B@9SCGUK+\.R7?BB^\,VVIZC>R0/I%X9A'</']I\NXCC1F*$$DC!R
M.OT)SWVH>$=%U/[.;BUD5K>'[/&\%Q)"_E?W"R,"R\="2*MV^AZ9:7-K<6UG
M'%):6QM(-F0(XB5)4#IC*+V[4 >;V=MJVH:!8*!>ZM9Z?>:A;RV<>I-!<2(D
MY2)P^X%]BJ1@L/O ]17HGANZ@O?#6G7%K<7-Q"\"[9;O_7-@8^?_ &O7WJK<
M>#-!N(HXS:21^7++*KP7,L3AI6W2?.C!L,W)&<=..*U[.SM]/LH;.TA6&W@0
M1QQH.%4< 4 >?3:+:ZSX[\9"ZO+N$06MHR"WNGAV,8WQ(=A&2,<9R!SQ5'2?
M%-WH<&C^(=9N9I++6-!664.QPMU!'ORH/ ,B;N!U*UW&I>#-!U>\N+N[LW-Q
M<JJ3R17,L1D0# 5MC#*X_AZ'O6?XA\-W&OWFDZ2UA9Q:!8SQ732%\NQC!VQ)
M'C"CIDYZ9&.: -'P=97UCX6LEU2:274)E-Q<F1BQ620ERHST"YV@>@KF?%D5
MQ9:_<ZO?C49=)ACBVW.G7YC?3BIR[/#D!U.02<,<<8Q7H=8FH>$=$U34#?7E
MHSS-M$@6>1$FV_=\Q%8*^/\ :!H XW5-2NXO!'Q'F%[.DMM>7"0/YI#1?N(B
M IS\O)XQZU9%HFOZKXGNM1UB\TY]*N(X;6:.[:)+5!#')YA7(1MQ9LEP00,=
M*Z/4/ _AW5;N[N;W3S*UXN+E//D6.4[=H9D#!2P'1L9&!S4FH^#M!U:_^VWM
MAYDQ"+)B5U24+RHD0$+)CMN!H X35-+2ZF^)&I?;+R.>RVS6K6]R\021;*-@
M^$(W'('7(P/<Y]-TN=[G2+*>4YDE@1V/J2H)J%]"TV1-41K4%=5&+T;F_>_N
MQ'Z\?* .,5>AACMX(X(EVQQJ$1<] !@"@#R;Q'J>H1:K\3UBOKE!:Z9:/;A9
M6 A8QL25Y^4GVJQXG>Z\'7U[+I5[?-)-X=O;F7S[EY09HS'ME 8D*1O;I@>U
M=Y<^%M%NY=4EGL5=]5B2&].]AYR("%'!XP">F*M7.C:?>W:W5S:I+,MO); N
M21Y4FW>I'0@[5ZCM0!YSJ>GQ>&O$/AVYTZZNKB8:9?S;;BY>?S)%A0A_F)P2
M3SC /'I5?2XM>@TF/4D@O8(;C1IY+RYGU7S_ +0YB#I*J;CL8-_= P&QV%=[
MIG@K0-(NX+JTLG$]NK)#)+<22F-",%!O8X7'\/056D\$:39Z?J TJS\NZFLY
MK>#?.[I$''W45B1&I.,A0!Q0!R=DL^BV_@C5K2_OKN\U2$K>+-=22+<@VK2Y
MV$D#:RC&T#@XJ+PLNORVVC:Q]GO(TO+*274+J?5!*MSOA+JRQ;OD(?;@*!A2
M178^&?!>F:);:;<M:D:E;6BQ$F=W2)BH#^6I.U,D<E0,U;LO!VA:=>-=6UD4
MD*NJJ9I&2(/]\1H6*QY[[0* .%T6*?3]-^'VLI?ZA/?:D$BNS-=2.LR-:R.%
M*$[>"BX(&>,G))JI;6BS^&? VOSW]W+J.HZO:RW)DN7=)68LQ4(3M7;C V@8
M (]:]0CT#2XK;2[9+4"'2BILEWM^Z(0H._/RL1SGK6=!X$\-V]Y'=1:<1)%/
M]HB4SR%(9-V[<B%MJ9/)  !H XOP^?$.I7ECK4=G=B:75)!<W4FICR6@$KHT
M0@+8&U0,8&<KGN:AL8IXO"^B^(CJ.H/J+:\MN6>[D*>2UXT1CV9VE=OJ,Y[\
M"O0H_"6B1:Q_:J69%SYK3@><YC$I&#((]VP.<GY@,\U.OAS25TV#3ELP+2"X
M%U''O;Y91)Y@;.<_?.<=/PH Y?X<:;;6EUXIFB,Y<:W<0_O+B1QM 0CAF(SS
MUZ^]6_B*US_9NBP6UY<6C7.LVL#RV[E'V.Q# $>QK>L= TW3=4O=1LX&BN;U
MM]QB5RCMQEMA.T$X&2!DXJQ?Z99ZFMN+R$2BVG2YBRQ&V1#E6X/8_A0!YOJ]
MA?2>(M0T33[34KBVTW3X?LACU=H3 \AD)E8LV9#E0!N) VD=ZFMXKW6]1UM]
M:U&ZMKS2=,M#%]FNFCCAE:$O)+A2%?YLCG(PN.E=IK'A;1]=N%GU"U=Y5C,1
M:.>2(O&3G8^QAO7/\+9')]:Y[Q1X7N[S53/8:%I=W&UFMM$[W<EL8R"<"1%!
M66,9!"D<8/K0!SN@:CJ,^L^"(CJ4Z_:/"SRR-)*64R;4Q(P)PQ&<Y-4M6M&L
M_!FOZ9JL6K6VJ?V)+.Q;4GN+:],>W=,C;L@[F&5(4$/@@CIZ/I'@[3-/L=(2
MX@2YN].TX:>L[9PT>T!AMSC!QW%.M?!/A^S@N88[%GCN;<VLBSW$DN(3UC7>
MQV+[+CH/04 <3=V=Y+K,.AV=EJ5W96FCPSPI#JS0-'+*\F9"S-N<C8 ,DA>>
M.:M:;::CJ_CG3;37+VYW6_AZUNKB"VNF2.2Y$KC>=A (Z\=#QG.!752^!O#\
MUI:VSVMQLMHVBC87DPD\MCDHSA]S+G^$DCVK3M]%TZTOUOK>T2*X6U6S5DR
ML*DE4"]  2>U 'FWAEO$-_-I6N)9W8EGO9#=W,NI@Q2PEG4QB M@;<#  R-G
MN:J6]J+GPMX,\0W%]=R:CJ.M6DER9+EV21FD)VA"=J[<8& ,!<=S7I$'A+1+
M;5_[4BLRMR)&F4><YC21L[G6,ML5CDY8 'D^M5XO GAN&\2Z33B)([@7,2F>
M0QQ2[MVY$W;4)/)P!GO0!T=>/6*3P>"=+\3IJFH2ZJ-86$%KN1D>-KPQ&$IG
M:1M)[9SSFO8:XKPKX!L=-L+*74K0-J-O<2SX6X<Q!S(Y5]F=A<*1\V,CUXH
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M=NX=GPQ'+#J1C:3UR.>:T:K6%A:Z780V-C D%K H2.-!PHJS0 4444 %%%%
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M,2 1U!!.?F'I70Z3X9N[+Q%X?O$TZVLK6TTZZBFA@EW+%)+(CA03RW1LGUH
M[:BJEI->2W-XEU:+!%'*%MY!*&,R;0=Q'\/)(Q[9[U;H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** ,NU\-:'9:I)J=KI%C#?R$EKB.!5<D]3D#OW]:U*** "BBB@ HHHH *
M*** (+:SMK,S&V@2(SRF:78,;W.,L??@5/110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%<C#KSW'B/7KZ>[-OH6@1^3( .)9M@DD=N^$4J
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M506*(<JHC"JQ!8YP.>: .VHKB[GQO>KX@\/V$'A^_":EY_G+,L:21F/@@9D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1Y+2.YM;#[)!-<(KRF"=Y&1BC'83T!!XW#G(('>0:]97'B*[T*,R?;;6!)Y
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MMA;W=[),C)*$3:AA"MN.[ )W 8&1UK1\:6NH7>BPQV$5S.HNHFNH+6812S0
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MWB4)''&H544=  .@H \Q\/:?K/AF[\/RR:0]Q<PZ7-ITUG'<PK)\LJLLJ!G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/<22"1@JL-VXDGDG&>G:JFG&>V\-^#_$Z:E?3:IJE[:K>%[IVCF6<X=/+)V
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M;)*H<1JTTCI"&.6$:,Q5,]]H%-TWP=H6DBU%E9NBVDS3VRM<2.L+LI0[0S$
M;68;>G/3- 'GMS<:A9WEQX;LS?W=C_PD/V=81?,DIB^QB?RA,S;@N_)ZYP".
M]37EOKD=IHFEWD]_IT-QXC\B)5O_ #)A:M;NQC:122?FW 9.0-IZ@5Z#=^%M
M&O8[Q9[/)N[A;J5UE=7\U5"JZL""C *!E2/U-);^%=%MH+2*.S.+2Z-Y$SRN
MS^<05+LQ.7.&(^8G]!0!?CT^&'2UTZ)IEA6'R58RLSA<8^^26)]R<UY(-?U9
M]/T?=?7 E\,0F75L2']\8[D0'S/7,<<[\]\&O9:R$\+Z+&VKLE@@.L#%_P#,
MW[X8*\\\<,>F.IH \YU+4M0FN]+U:._ND@U'QG%;Q(DS!#;1JT6T#.-K,C,1
MT.15._TN&'P[\1)H9+A9O[82%6>X=P!FW;.UB03D]<9QQTXKU#_A%=$^P:78
M_85%MI4R3V:"1OW4B9VMG.3U/7.<\U'/X.T*XN]0N9;-R^H;3=*)Y DA4J0V
MP-M#?(O(&>/K0!D:79_V+\2'TVUNKU[2XTG[3)'<W4DV95E"[QO)P2&YQ@<#
MBI/%"-J/C'P[HD\]Q'87$5U<3)!.\1F:,1A%+(0<#>S8SS@>E=,=-M#JPU3R
M?]-$!MQ+N/\ JRP;;C..H!Z9JMK'A_3=>2 7\+LUN_F0RQ3/#)&Q&#M="&&1
MP>>: /*[9KRW:;1K/[9?07/BB[CF6.\\F698X PC,I(/4#)SD[#ZFK%]H]Y.
M_A>UUI+R%1XADBMXSJ3O(EN8'8*SH^2P8$ D[@!C/)SZ O@OP^FEOIT=AY5L
MUQ]J_=S2*ZS8 \Q7#;E; Z@COZFB;P7H,^DP::]F_P!G@G^TQLMQ(LHEYR_F
M!MY8Y.23DYH XF^OIQXBM]6L1J9C?Q!'8F\GU#$;+YGE20I #@H"&P2,Y&:R
M]=O+FZ\"?%-+BXFF6'4FCB61RPC7]W\JYZ#V%>C3>!/#L\T\LEE(6FE\\XNI
M0$EW!O,0!L(Y(!++@GN>35B7PCH4]EJMG)8!K?5I3->IYC_O7..<YR.@Z8Z4
M <'JG]LZOK.IVMI:W\QL-/MA9R6VI"U6VD>,MYI7<-YS@<Y&$QW-3S07.NR^
M+9M8O+J"ZTNQA2%(+ITC@8VPD=MJG:^68CY@00N.E=IJ?A#0]7F26\M'9EB$
M#>7/)&)(AR$D"L Z\GALCD^M-U'P;H.JWIN[NQ)E:)89!'-)&DJ+]U716"N!
MDXW T .\%_\ (B^'O^P;;?\ HI:Y*%+K2O$IDU4ZF);NZN1:ZC;WYDM;A6$C
M)"\1/[LJH &%^\GWN2#Z%9V<&GV-O96L?EV]O&L429)VHHP!D\]!65;>$=$M
M-5&HPVKB<2/*BFXD:*.1\[G6,ML5CN;) !Y/K0!R6GZE=OX6^&;M>S-+=SP"
M=C*2TP^RRD[CGYN0#SWQ61I:W%OX,\/>)5U74)]4DU:*W<O>2,DD3W)B,1C)
MVXVGKC.1G-=]8^!?#NG7-O/;6#*]K*9;8-<2NL#$$'RU+$(#N/R@ =..!C+\
M)> ;'2],TV34K4MJ5K(\NT7#M"LA9L.(\[-^TCYL9H Y6Y6XC\)>(O$JZKJ#
M:GIVM7 M?],DV1JMS@1>7G:P()'(/# = *OZ@DNI:1XWUZ?4KZ#4-)N+A+$Q
M73QI;B&)63Y =K;CR=P.0V*V]#\ V,;W5SJUJ7N'U6XO41;A_*<&9GC9XP0C
M, 1]X$C ]*V+_P &Z#J>H27MW9,\LQ4SHL\B1SE?NF2,,%?&!]X'I0!R^D6T
MOB7QWJS:E=WRP6UC83I:174D2+)(DFXX4CICITY]0,<O8+)I/PS\+3V-U>0R
M7?B2))B+J0[E^TRJ5P6X! Y X/4Y->Q0:79VVIW>HPP!;N\6-)Y-Q.\1YV#&
M<#&YNGK65'X'\/10B!;%O)%XM\D1N)2B3*Q8,J[L+RQ.!@'/2@#A]9MY[C2?
M'^K-J>HK<Z5=R-8".[D18"EO$_"@@')/0@CTQDYMWXEUBX\:7]SJ=[:S:3;H
MMEY-T\:0?Z,LI<J"%;+,<[@>!BN[D\/:5-9ZI:26@,&J,SWB;V_>ED"'G.1\
MJ@<8Z5R7BOPG?:CJ=X]EHFG7"W5HMO'<O>RPF-@" 9HQE9@N05XR,8]#0!U/
MA>627P=HTTKO+*^GP.S,<LS&-222>I->9P6WVKPMX,\0W%_>2:CJ.M6DESYE
MR[)(6D)VB,G:NW&!M P%QW->L:58C2]'LM/5RZVMO' &(QNVJ%S^E8\7@3PW
M#>)=)I[;X[@742&XE,<4N[=N1-VU"3R< 9[T <1<R7+^"M5\9&_OEUJWU&;R
ME%U((XUCN3$L'E9V%2H ((R2V>M;%I:+KEYK^K7^M7FGW&GZL;>WE6[:.*WC
MC$>%*$A"'R<[@<[OI722>#=!EU1M0>R8S-,+AH_/D$+2CI(8MVPMP#DKG(S2
MWG@[0;_5CJ5S8E[AG220"9UCE9,;&>,-L<C P6!Z#TH XW4-3O(_A_XSN/MT
MZS0:Q/'%)YI#1KYJ *ISP.< #UJ'Q%;SW<WQ%O'U+48WTF*.:Q6&[DC6"06B
MON 4@') X.1U]379WG@7PYJ%W=7%S8,[7;;YX_M$HC=\ ;_+#;=V /FQGWK0
MF\/Z7.NJK+:AAJR[+T;V_?#9Y>.O'RC'&* /.=:N;[PM,+[3[Z]EN;OPW>7<
M_GSO*K3QB)ED",2JD;VX4 8XQ4=Y!KVD^'M<N8H-0L;,Z!<N\EQJWVEWN%4%
M)4^8E3@ODC ^[Z5Z9)HFFS7-O<2VB/);V[VL98D@1/MW*1G!!VKUSTK.MO _
MA^UM;NV2RD>*ZMS:2"6YEDQ">L:EF)1?9<=O2@#FI--_L[Q)I-LE]J,B:MI-
MV;[S+V4^8Z"(AQ\WR-\[?<Q@' K%\.6L'_""^#M+MX=4NY[VU>\>T@U%X$<*
MJJS.Y;<J@LN$7C)Z5ZF^DV,M[:7CP!I[.-XH'+'Y$?;N&,X.=B]?2L6/X?\
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MO<7VDLQ)^8GD\]NE5)O!>@S6=K:_9)(H[7S/):"YEB= YW.-ZL&PQZC./RH
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M&CVKC;P<GTZ4 5H_B,K6K7<F@ZA%;6]X+&_E9H\6LQD$>,;LN,LI)7(PP[Y
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M:6<2F6Y5E92I0G$?RG.1N.1P,<@&DOC0P23PZKHMYITZV4M]#'*\;^='& 7
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M@D,:OM.?ER#C(]:F\71?\(X?$^F:/-/;V;: +LQ"9F$,PE*AER25+#.<==M
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M< @XY'7GBHM)\=2ZA+HLEUHD]E8:TH%G<O,K9?87"LHY4$*V#SG'09H V?\
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MM;*Z0W<*RJK_ 'ER.A]QTK'/C!CXGU+2(M+E:#2]CWMZTJJD4;1[PV#RQZC
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M/'H%KX:CLK0V=EJD=RMZ;GF:!;D2@!,9#@'G)Q\O&<UZ9110!R7@GP98^']
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M6$U@[-D%[=0<.!R!N4#Z&M>QL-6U+Q9#KNL6,.GPV=C);10"X$I=I&0NQ(
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M,4EW;G64$,/8J,^W2JFD^&=?\.3Z3J-M907L\,5[:W-M]H$?R2W)F1U8C'&
M"/?VKT>B@#G/!>DZCI&DW<>JB$75QJ%S=-Y+;EQ)(6&"?K4&HZ7JB?$&PUJT
MM8[BT-A)8SYF"-%ND5]^"/F&%/ KJJ* .$LO"FIP>$_!>FR+%Y^DW4,MT _
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M].,RB[DA:=8N<E%*JS?FZC\:;IUY)?V8GELKBR8LR^3<;=XP<9^4D8/4<]Z
M.6&E:]K'B*TOM3L[>TCTVQN((S'<>9]HEE" L!@;4 3OSS[5SME\/;RR\/\
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M6?D7"QK+&(@ X3[F?<=CUH NW\26^@W,,*A(X[9E11_" I %>9:1IL.E:?\
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MG6VC9'3!X)88SWV@=J9?VVLZ]>^(;F2UTY;RSCMQ!?WNHO;MIY-O'('11&P
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M+:1:$V61;YC'[L%MV![9YQZ\T >?>%+2VU3QEX3U&^B6>\D\)I<M,_+-*'A
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M<9K%N_#-]//XS=7AQK-HD-MECPPA9#NXX&2.F>*T+K1[F;P%-HBM']J?2VM
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M7<PV\QMFTW4'9B-UK)MW[<#EAMX!Q]X\TFO^##)KPU*S\/Z'JT3V,=F+?4@
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MEU"J5.T9R!D],9[U!X:\&7NA_9((] \,V\MA;O%'JRP!I[AMNU'("J4)ZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4!$ XSUK4U+Q-IVFV%Y=L[3K9W45I.D(RR22-& .<#_EJA/L?7BMB@ HHHH
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M#J4>'B-T)]H3J&'(YXXX)KU7[!9_\^D'_?L5GZY>:-X>TF74M0@B2WC*J=D
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MW>DJUKK@O(I_[1B*S1&X>4G&<J0".#UKU:]72]-L9[V\BMH;:WC:261HQA5
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M]V2VB*!RJEC\S!1P/=A5^@#DOL&L:IK_ (;U2ZTR.P%B]UY\(N%DVAX]JD$
M9R?RK.N_"FJR^$_$&GI'']HO=:-Y"/,&#%Y\;Y)[':IXKLVO7758[(65RR/$
M9#= +Y2D'&TG.=QZ],>]/L;ZVU*SCN[.99K>0$I(O1L'']* /+XK+7=8TCQC
MH5C8PR6VHZQ=0F\:<+]G5BH<LF,MQDC'4G!QC)U=7\#7VKZ_XH.Y(K+4]&CL
M;>4MDB1=W4=<#BN]M[2VM/-^SP1Q>;(99-B@;W/5CCJ3ZU5TG6+?6/MOV=)%
M^QW<EI)Y@ RZ8R1@GCF@#GK6RU[6?$NCZEJ^G0Z=%I44Q.VX$IGFD4)E<#A
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MLZ?'8P)IQL([5IEE9PSAW9B. /E4 <]\XKHM3U.RT;39]0U&X2WM(%W22/T
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M 'Y"K%9V@ZS;^(="LM7M$D2WNXA+&LH 8 ^N"1G\:T: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MY?QMIL^J6>GP6_V6=DNO-;3[JX,*7JA'S'N&3D9#]"/EYKJ*HZKH^G:W:K;:
ME:1W,2N'4..58=P1R#R>1ZT <'X;NX7\6Z!!;175I%'8ZE ]I<3>88I$N(@R
M!LD,%.0I_NXK$LH;36];\/07LQEM9]:UH >80)5#L57(/*\#CN!CI7I4_A#P
M]<V-I92Z1;&WLR3;H%QY9;[V".>>_KWS2R^$?#\UM';OI%J88WD>- F C.<L
M5QT)(!XH \YE@"QOHL$\Z:9!XPBM8 DS I$T(9X@V<A0S,.O&?:C4?#FG10?
M$2&-)4@TJ 7&GQ+,X6UE-MYA=!G@E@#^'N:]-M_#NCVEE;6<&G01V]K,+B%
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M(69AB+[(SO$&SG:&+#&>.G:NN\&VL6F>(O%>E68,=A;74#00;B5BWP(S!<]
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M+TV2'?9VGC6.UMXF=B(XGAC=D'/ W$G':O6;;0M*LTL4MK"");$L;4(N/*+
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MMP]P#()!&SX:,#@'8P!#'H.!FM9='NAX[N=9S']EDTN.T7YOFWK*['CTPPK
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M;641Q1C"J-I/ KS?0=/TVPTSX;:GI2H-4O7CBN9D.9)XS;.90YZL%95X/W<
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MR CH=V,Y'8]JY?5_'-_IEU=6OV?2?M&G6J7%ZDM\8_,9@6\N'*Y8[5SDX&6
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M]*MM?N(YWEN&$Q5IPN8UVD87<.I&<$<=2 >A6NC:98Q216MA;0QRQK%(L<0
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M\-:VGB+0+;4TC$9D+HZ*X<*Z.48!AU&Y3@]Q@US5A\0FO=2LR8].&G7UX]G
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MUMJTFJP:59QZA)G?<I"HD.>IW8SD]_6J?C6\BT_P3K-Y/;"ZBAM'=X#(4\P
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MKNSN(#):W$$L*?*6B<,JX[9' Q0!A^*_#MSKUWX>FMYHHQIFJ1WLHDS\R*K
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MT%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQFEGM+&VMY9CF62*%49S_M$#G\:6'3;"VNY;N"RMHKF;_6S)$JN_^\P&3^-
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MZ^J0[[D(/,8,) P+=2,8&.F !VJE"NB'P?X9DD^S?\) WB&'[25Q]H,OVO\
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MQ:NT<;)$H*+Y:?*"!P/:K7C>S@GUFRN!<Z-)=P6DX^P:PO[F:)BFYE;^!@5
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M +D# R>_'% 'E6F)HR6'P[?0A:_VHTR>:8=OFM']G?S_ #,<_>QG/\6.]/\
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MH;1O/1O*N(V50P..5Y12#STZ<T1>"+O%C<7%]"]Z-<_MB\9(RJ,?+,>Q!DD
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M\JT_5?$.IZ!X#U&Y-M=7]QJ<IA)9E!!@G&9#[<G [ "O5M-M6L=*L[1F#-!
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M;)%?H/\ =Q6-KO@G5=2F\116E_906NM!'>62%FGC98U0(#G&PE ?4;F '.0
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M($8F\Q2X!;@,4Q[X!KBI[>"3PWX9D2",V,OC4?8<H,?9FFE*A?\ 8/4#IC%
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M]*\DU>PM&\$?$F\:WB:Y&HSE9BH++M2,K@]L$DCW)KMOB1_R37Q'_P!>$O\
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M0*7)W <JXXR.13SJ\]GXR\.6NJ6VG7%S)I=S/)?) RR(%P<)EB0",9ZY([4
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M7VCK;6VI"P;3W8_;)!O$;2J=V!AB3MVG*J>1F@#T)K.U:9IFMH3*X"LY0;F
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MH+RYA$SPQ@@(&Y5>23D*1GWS6K0 4444 %%%% !1110 4444 %%%% !1110
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MN.>SHH X/3?!.NZ-+IUU8ZU9&YLM)32PLUFQCD1')5B X(;&WH<9!]>)[3P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%<KJFM:U9^-]$T]8+6/2;V:2%G8EI92('DR.R %0.<D\]!
MU/$^MZUI6LZ+':06JZ;<WL-M/-*2TCERP*HH^[@+DL<]0 .M '54444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -D3S(G3<R[@1N4X(]P?6LW1M$&C+
M,HU+4KWS2#F^N#*5QG[O''6M2B@#A/%6H7H\7Z%)!X?UBZATNYDEFF@@5D</
M Z#82PSRX!Z=#1XTO[VXFT2.UT#5[G[-?V]]*\4*E0BYROWOO#/3]:[NB@"K
M&YU+2PQ2YM#<1<JWR2Q9'MG#"J^C:.-&AEC&HZA>^8V[=>W!E9?8'' K2HH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex1012022063010qngcbasho012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI/I4M !1110 445!%>6L\\L$-S#)-%_K(T<%D^H'(H GHHHH **** "BBB@
MHHJ""\M;IY4M[F&9XCMD6-PQ0^AQT- $]%%% !1110 4444 %%,DFBB:-9)4
M1I&V(&8 LV"<#U. 3^%/H **** "BHKBY@M(&GN9HX8EQF21PJC)P.3[FI:
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MTWR5O=3O5M(Y9D+I$-K.SE01NPJ' R.2*Z"L?Q#H7]N6UKY5TUI>6=RMU:W
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MFX$-EB22#GVJC8> 9=(T?08--U?RM0T:.6&.ZDMMZ2QR'+*\>X<9"D888*T
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MV42,YC78)(R6&Q]O'(8<#CBMO7=%@U_0;G2;F21(YT \U#\Z,"&5A[A@#^%
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M_')4,0F\CJ/09K,U&9+BYU;Q);+(=$_M_39Q.L9VLL05990,9*@X&X==I]*
M/3[K6],LFN5N;Z&(VHC:<,V/+$A*H3Z;B"!6(WQ$\-G5M,T^'48IVU R".2-
MLJ"IQU[Y;@8KA/%-S!KT/CF>S22>TFMM)2.0(=LP$[[BOJ.<9'I77>)YX-,^
M('@VYG_<VBQWMN'VG:KNL01>.F<''TH Z*P\2Z+JFH2V%CJ=M<7462\4;Y.
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MN(;A[<)Y\<<I#N@10&5>F<=NXQ7H/C>>/6?A;KDVG-]JCGT^5HC$"=XVGH*
M&/\ $#3(M9MDEN[:/2KC3C=I<L3N9Q($V#U_BZ#/!K9N?%.A6FF6VI3:K;+9
MW7^HE#Y$O&?EQUX_*N:T>XM-6^(&F:E:%9[?_A'V6.8*< ^<H(!/0\$5R>F+
M/ID7AZ_GU-]'LT34[<736RR+'(UWN"D,,+N53@_[..] 'KQOX9-+.H6TD=Q
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MQZ=9ZGJ'VAV0D0LYD6-V'89R-W0;A0!ZM;>)-%O(+6:WU.VDCNIC;PLK_?E
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MW?[/6O,M.M)TG^'LGV>6.%]7U"XB1D(,<,AD:/([94@_C4IFC_X01_"6U_\
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M HHHH **** "BBB@ HHHH **** "BBB@ JO>W]GIT GO;J&VB+J@>9PH+$X
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MIYYV@PP3 900&'?MFK^KW?B?PWI[QR:K;W[7MU:VEE<S6X1X9)9-CET4!64
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M0HF9 X/<YW'Z=J1YO%?]O:UHJ^)!ML[&*^BNC91>9N?S!Y9&-NS,9/3=SC-
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MG@2-XWC=%9?D !4AP1QD8ZFHOBHUU'\.]2DM+M[9U\O<R*"64NJE>>G7MZ4
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M-"&P",<G!]L8'%9>@:_JFF>"_#L,FKW>_5;FY9[B*P^TRP(C.6"(JG<6;'+
M@ GVH ])T/P]'HTUY=R7ES?W]ZRF>[N=H9@HPJ@* JJ,G  ZDGO6G!=V]TTR
MV\\<I@D,4H1@=C@ E3Z'!!Q[UY[9>)-?U:;1]&6ZFLI[FXNQ)?R6'E22P0!2
MK+%(N%+>8F<C'RM@5J_#U;F,^)TO)4FG77)5>1%VA\118..Q(QQZT =;+=V\
M-Q!;RSQI-.2(8V8!I"!D[1WP.:FKB?&D5Y/XM\'Q6-RMM.]Q<@3E ^P>0V2
M>"<9QGC/8]*S&\4:[I$UPM]>I=6^CZS':7\QA5#+;31H4D.!@,C2+G;@$ T
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M P=E1FV8/]X K^-=)9^*)?$&OZ!%I$H6QGT]M2O<J"=C +$F>Q+;R?\ KF:
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M)U60H 26VDYP "<^@-: .1FO([.WU"S\>?$:_&J-))96D$A#V\9$N;=RH/'
M7CIUQSF@#N-0T-?$>-0T_P 2:A;6MY;"-Q92QO%-&<D,NY6"DAC\RX)&/05N
M6-E;Z;I]M8VL?EV]M$L,2?W548 _(5Y]HVMZ_K2>$[*WU&.R&H:&U[<RQVR%
M@ZF( H"-H^^1C!&">.E)%XHU6XT73X;G6VMKW[7>6TTEEIQN+BY\B4H&2(*P
M4="QQ@9 &,T >A37]G;7=M:3W4,=Q=%A!$[@-*5&6VCJ<#DXJQ7DR:M<:YXC
M^%NHW8'VB5M0$A"%,LL)4G:>F<9QVS7JL[%+>5U.&5"1^5 $E%>:Z+KWB,6'
M@W6=0U6.XAUIDAN+1;9%5-T#R!U8?-NRG(SCDX I;+Q'X@_L'0_%<^HH]IJ=
MY!')IOV= D4,TFQ-KCYBZ[E)))!YX% 'I-%>97GB#Q+'I.N:ZFJQI#I6KR6T
M=F+9"LT2S*I#L>0<-@8QTR<YXGUGQ5J%CXB=K?5GGABU.WLVLX=.9H%21T1A
M)<;<"4%R<!L#@8R: /1J*\QO=?\ %$>C^)M?CU6)(-$U"=(K/[,A6>*,@D.W
M4'!(&,=,G.:MWNJ>)KZ^\7/8:Q'9V^C;'M8C:H_FDVR2E7)YVY/;!^8\\ 4
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MN011.()-@D)P$9MN$<D8VL0?:K4?BS1)-9_LI+PFZ\TPC]R_EF0#)C$F-A<
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M3/&T3HT6[. P8 @_*>#R,5#?>*]%T[5!IUU=LEQE V(79(RYPH=PI5,]MQ%
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MM+F[@U(-;6T8DEF,,@103@#)7!;./E'/(XY% %_7]&CU[2)+!YY("7CECFC
M+1R1NKHP!X.&4<'K7*:UX+:&PU;4)+W5-3O+F.!Y%@$2R^;#)NCEB&, J"?E
MZ$#N3D]!'XST&73;B_%ZR16\BQ2I)!(DJNV-J^4RA\MD8&.>U./C#0ET<ZHU
MZPMA-]G(,$@E\W./+\K;OW_[.W/>@#C-/\,7'BC4/$$E_+JRVE_I<5@UU?6X
M@E=][LVR/:-JJ"HY'))Z]:[35_#QU&:QN[34)K"_LE=(KB-%?*. &5E8$$':
MI]BHJIX;\3?\)!KNNP0LK6=DT"PDQLC@LF6#AL$$$8P0"*L3Z[#:>*;FSGU.
MW6&WTS[;):?9W\Q5#D&7?T*X&-H&<\T 5YO"<Q%A<6NNWT.IVD4D)OG"2M,C
ML&8.K#'W@",8VXP..*+WPG=W%K';P>)=3AC-K]EN/,V3&=><O\ZD*YW'YA[<
M<#%G3?&.@ZMJ$5C97IDGFC,D.Z"1$E48SL=E"OC/(!.*NZOK>GZ';QS:A.8Q
M+((XD2-I'D<\[51068X!. .U %JTM8K&R@M( 1#!&L2 G.%48'Z"N7O/ D5W
M+KR_VI<I9ZRRRS6P1"$E78-ZMC/2,#'3DT[5/B%HUAI-GJ$#3745S?)9;4@D
M#1N7"N&7:65E!SM(!/0=:K#X@V%EKNMVVJSF*TM# T!2UE9EC>%79I H)4 M
MU8 "@#3U[P?:>(+N:XN+B>-I;![']WCY09%D#C(ZAD'M5"X\ B_;4'U'6[VZ
MEU&P:QNF*1J"F25*@#"[=S<=\\UJZCXOT+2KA(+N^VLT:REDB>1(XV.%=V4$
M(IYP6('%/E\5:-#K@T5KLG42R+Y"1.Q&X9!) P![YP,C)YH NZ59SV&F06MS
M>O>RQ+M,[HJ%AVX4 <# _"N>UGP+'K$^KAM6O+>SU=!]KMH0F&=4"*P8C<.%
M7(Z';Z$@ZGB+5!I<>FL=0@LOM.H0VV9H&E\W<3^[7:1M9NS'@=ZFD\0:7%::
MI=/=@0:6S+>/L;]T50.>W/RL#QGK0!>MHY(;6*.68S2(@5Y2H4N0.3@<#/M6
M'_PB-K_:/B2\^TS;]>ACAF7C$82,Q@K^#9YJ=O%FB)K*Z/\ ;"VH,4 @2%V(
MW#*DD+@#&.3P,C/6L_3O&.G1Z#!?7VK1WIGN)88GL[*7,A5CE5B 9SM Y/3C
M- %C1_"%KHTVCRQ7,TATO36TZ,/CYT)C.X^_[L?F:IIX$6UN(KG3]8O+.X62
MZ+RHD;%DN)1*Z88$## 8/48[UH3^-- @BLI#?&1;V,RP"""25B@X+%44E5!.
M"6  /6L;1/%TVIZ=X<N;C4;."34KJYB$0MV?[2J.X4(P.$.%!).0: +%AX M
M+"YT&5;^ZD71)KF2U1POW9@058XR<9.#U]:ZV1!)$\9. RD?G6)_PF6@_P!K
M-IGVXFY$C0\0R>69 ,F,2;=A<8/R@Y]JPXOB!9ZMX?FU&UNQI@AU 6IDN[.5
MU<>:47 PO+!??:3@T :\'A"UM]*\.:>MS,8]"DCDA8XS(4C:,;OP<GCTJG:>
M XK5[*V.JW<FCV-R+JUTYE0+&X)907 W,JDY )[#.<5HZGXQT+1[V2TO;UDE
MB57F*022) K=#(RJ5C!_VB*34O&6@Z3<S6UW>OY\,:S21PV\DK+&V</A%/R_
M*<GH.,XR* (9_!MI/H.JZ2;F81:E>/=R.,;D9G#D#VR,52O? (NS>1KK=[#:
MS7HU".W1(\17 =7W9(RPW+G:>.?IC3OO&>@:>(&N+_Y)X%N5>*%Y%6%NDC,J
MD(A_O-@<'TIWC#5[C0_!NJZM9>6T]K;-+%O&5) XSZB@#E-,\%W>J1>(+:^U
M"_M=/O-8GDGM/*4"YCW*00Q&Y58  X."!QCDU*OA2_U3Q'XQ']HW^FV=_/#$
M_EQ*5N(OLT:G864X.=R[E_F!CH(?''AZ9;LK?,/LEN;J7=;RKF$=9$RO[Q1Z
MKD5IW&MZ=:P6$TMTHCOY4AM64%O-9P2H&!W )STP* ,:Y\&@7+R:3J]YI,<U
MO';7$=L$.](P54J6!*,%.W<.V.X!JOJO@*/5&U:+^V+ZWL=4*R3VT80YE5%0
M/O(+8^1"5S@E>>"0=_5]=T_0XHGOY74S/LBCBA>5W(&3A$!8X R>.*;8^(-*
MU*>VAL[Q9I+FV-U$%4_-$&"ENG&"0,'GVH Q;KP%:WMQK5S<7]RUQJMM;P2R
M*JC8T/*NHQC.><=*KWOP\74Q?MJ&N7UQ)J-JEM=ML1=P1]Z%0!\F,L,#KG/6
MM*?Q-9SWFC?8M6MXX;R[FM]DEL[-<-'N5D4\;"&4\D$''%.\,>+[+Q2VHK:0
MSQFSN7@/FPNH8*<;LLH .<_+U'?K0!##X/+7EW=ZCJ]W?W$UD]A$\J(ODQ-R
MV H +$@9)]!4,'@<:?8:1%I6KW5E=:;:&R6Y$:.98C@D.K#&<J"".G/K6CJO
MB_1-%NVM;Z[=9DC$LHBMY)1"ASAI"BD(.#RV.E+J'B[0],G2"XO&::2!;B..
M""29GC)(#*$4DC@].G6@#3L+3[#806OVB>X,2!#-.^Z20C^)CW)JQ5;3]0M-
M5T^"_L9UGM;A \4B]&4U9H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M RI;<I&W)!&">HT?3=,T&_FM$O)KC5+X&YEDNI=\TRIM3/8;5RHP  ,^];M
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M0.JM&[Y1E8C:V1Z&NSHH \^NKP>'_$/B[[=8WL_]JK%+9&"TDF$^(!&8LJ"
M0RGAL<-GUH\(:+?:5XBTF*]@?S+7PO;VLDNW*B02'<@;ID8'Z5Z"3@9-% ',
M?#RWFM/ VGP7$,D,JF;,<BE6'[UR.#[8KIZ** "BBB@ HHHH **** "BBB@
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M.*96D=U8%0@!7Y.,KGDCM6M?-XHL]<O-%M-?EN;JZT:6\MGEMX1Y-Q'(B@*
MN-C;\8;<1ZYK0G^'UK=_VBUYK&IW$NI6J6UX[F(>8$8LC ! %(R1A0!@\@GF
MMF^T^WM]7'B,I=37-M926RP0 -O1F5SA>I;*#'/K0!S^G^*[KQ+J?AB/3)?(
MAGM'U#4E" E5 \L1<@X)E+=.?W9JUJ=QJ>J^-CH%IJL^F6UMIRWDDMM'&TDK
MO(R*,R*P"C82<#)R.:B\!>'7TO\ M?5KBS>SGU:\>=+61@6@AW$JAP2 2S.Y
M X!?':M;5_#2ZCJ<6J6NI7FF:@D)MVGM?+/F1$YVLKJP.#R#C(R?6@#@;>^U
M;7]?\$RW.K3P3K<:C;S&WCC".\&Y"X#*<;P,$=!GC!YI+2;6-(\/ZKKEIJ\D
M45OXCG06(AC,4J/>['WDJ6S\QP01C XZUV;>!;&*#1$L;V]LI-(>1X)HV1G?
MS,^9OWJ0=V22<=3QBIY/!]A)H-YI!FN?L]U>M?.P9=P<SB; XQC<,=.G?O0!
MR(\5:Y=:S<W-H=8E$&KFS%C%INZU:W27RG8R[,[\!GSNP, 8K<\(76M:OJ^M
MWE]JSM9V6IW-E!9K#&%*JPP6;;N)&<#GMSG-:*^$DBU62ZM]6U*WM);H7DMA
M$Z+$\V02<[=X!(R5#8)SD<D5H:/HEOH@OA;R2O\ ;;R6\D\P@X=R"0, <<<4
M <[JTVM:AXZNM%L]:FTZSCTF.Z!@AC9_-,LB]74\849'L,8YSC:%KOB"2#P7
MK-]K#3)K;&&ZL_)C6)!Y+NK*0NX-E,G+$')P ,5W8T6W'B&;6M\OVB6S6S9,
MC8$5V8$#&<Y<]_2L^W\&:=;Z9H.GB6Y:'17W0;F7+_NWCP_'/#GICG% '+:+
MXFU*3Q#IJC5K[4+34DN27EL%AMOE4NC6YVAB,#'S%L@YINAZOXB&G>"=:OM<
MDNO[:DC@NK0P1+$ T+N&7:H8-E 3S@Y. !@5O67@"WLI-+<:UJDO]E92R61H
ML10E2ABP$Y!4@;C\WRC!%:$'A&PM]*T#3UFN#%HDB26[%EW.4C:,;^.>'/3'
M.* ..TW6?$9T3P_X@N=<DF^V:JEE+9^1$(FB:9HLY"[MXP#D$#C&/5=%\5:Y
MJ6I6-]&=8FBNM0>&:T_LW%I%;[V1664)G<N%))8@_,,#C'71>#["'0].TE9K
MDP6%XEY$Q9=S.LAD /&,9/8#BDLO"2:?J*S6^K:DEBD[W*:<KH(5D<DMR%WE
M<L3M+;<GI0!G> +G6M7LIM7U35GGC-Q<VT5L(8T152=E#$A<EL+CKC&.,\U3
MO;CQ%J7B#Q9!::_+80:4D+VB101-EVAWD.64DKD=!@\GG@5UNA:);^'],^P6
MLDKQ>=+-F4@MF21G/0#C+''M7*-X2O-4\6>*Y7O]2TVUOOL\1>VV8N8Q"%8?
M.K8(.1N7!Y- %;2=<UWQ/XFTJ*+4VL+&;0;359HH848M([ME 6!(4C /?Y1C
M&2:@37M>_P"$6@\:G5Y3%)?*ITOR8_)%NUQY(4';OW@$-NW=>,8KM+'PS8:;
MK*:E:^9&R:?%IR0Y&Q8HV++CC.?FQU[5FIX#LUF2/^T;\Z4EW]M32R4\@2[]
M_7;OV[_FV[L9]N* ,2Z\5:S8:'X@TQKD2>(;?4A8V$C1J"XN"# Y &T[58YX
M_P"69SWJKJ/BS6]*U'QU;K>+.=+MM/2S,D2#9),NUG. ,_,0V#QQQ@5V-WX0
MTV\\76GB25IQ=VR!1$K#RG(#A79<<LHD< Y[U#=>!]*O;SQ#<7#W#G7888;E
M-X 01*0I3 R#SGDGD"@#D=:GU'PEXKEU"?4Y=6>T\,WMQ$US&BMO62$D'RU4
M;<@=LCGD\4R7Q;X@T73-3NM^KWT::6\_GZGIGV9(;H,JJ%PB@H=Y.TY(V=>:
MZR#P+:M?27NJ:GJ&JSRV$NG2?:C&%:!RI*X15&?EZ]3DYSQB2+P7"]A=V.IZ
MOJ>J6UQ:FS$=S(@$<1] BKENGSMEN.O7(!BII^HZ=\2O#D=_K$VI[M.O2'GC
MC1E?,.[&Q5&T\8!!(YY/:76;.]O_ (J6D%GJ4NGYT24R30(C2;?.3A=X91SC
MG!X'OFM73?!R66LVFK76LZEJ-Y:0/;1-=-'@1MMX(1%R?EZ]3GDGC$^K>%DU
M+6X=9@U.^L-0AMFMHY;;RR C,&.5=6!Z#K_/F@#E]*\4:U$^A7&HW@FM#J-U
MHM^PB50\RR,L,W XR4VD XR_2ND\):E?:U_:NISS[K"2]>+3XPH 6&/Y"^0,
MG<ZN><\8Q6+XD\/FS\#KX2T>PO;R:\)V7;$8AE,@<SROQ@AB7X')& *['2=-
M@T;2+/3+48@M85A3U(48R?>@#R_P]J$EAH?B<1:C+8RW'C"[A5[>V\^9\L"4
MB3!&\@'D@@ $UI:5XGUD-I\ES=W,EI#KLFE7/VJW2.61'B!B:0!1M8.RKQC.
M>16\O@&RA@F6TU"^MKA]6EU=+E#&SQ32 JP 92I7:S#!!Z]:#X L&T?5M,?4
M-1>#4YDN9':1/,CG7:3(C;>&)16.<@$< #B@#E8O&VNOH^NN;E3=7OERZ%^Z
M7Y(YYW@C'3YL;4?G/W_2O5(U9(D5W+L  7( +'UXKG)/ VDR7OA^Y#3I_8<7
ME6\:L LB@*%WC'.TJ",8YK:M+(VMQ>2F[N9Q<R^8$F?*P_*%VH,<+QG'J30!
MYA<P76F>/O%GBO3D>2;3;NW6\MTY-Q:-:Q%P!W9<;U^A'>II?$$EOJGBV^T6
MXB,FH7NE6]K<[=Z*)HXU$F.^ V1GOBO0K'1;?3]5U74(GD:74Y8Y9E<@JI2-
M8QMXZ84=<\U@V?PVT.QT_6+&!KM;?4YDG*^8!]F9#N3RCCY=IP1G.,#M0!S_
M (IN-8TRS\2Z%)KMW=QMX>GU&&YECA$T;1G:Z95 I5@1VR.<'H06NFZA+XF\
M+VD6MW44A\/SM)=B.(R[#) 0J_)L&,@9*G@>O-=5'X+MI8]3.IZC>ZE<ZC9F
MQEN)S&K) 0<H@154?>)SC)./2IM)\*Q:9=V%W)J-Y>7%E9O91O/Y8S&S(W(5
M1R-B@'ZYR>: ./MO%6N'_A$8);X223ZU=Z?=R>2@-PD32*I(Q\I.T$[<42:S
MXC31+[Q"VN2;;+77M$LQ!%Y<D O/*PYV[MVTX!!'0=3DGJ4\"Z:DNFR"XN\Z
M?J$^H1?,OS22LS,&^7[H+G&,'IR:F?P?82:#=Z09KG[/=7S7SL&7<',_G8'&
M,;ACIG'?O0!R&N:UXD?P_P"+_$-AK;6G]E7$]M;68@B:+;$ &9BREBY.2.<<
M 8(S73_$+5KW1?AWJVIZ?-Y-Y! 'CDV*VT[@.C @]>XKD?%OAR^OG\0Z18:?
MKB+JL@9$BDB-C([*H,SM@.F",E,X)4<'->A>(=!MO$GAV[T2\DECM[J,1N\)
M < $'C(([>E '-R3ZYK'BZ72;?7)M/M$T>VNRT$,3/YKO*N<NI&#M&1CL,8Y
MS<T;5+_7?A=;ZG+=-!?SZ>7:>%5!#A3E@""!DCT[ULVNA6UIK<FJI)*9WLXK
M,JQ&W9&S,#TSG+G//I1I&@VFC^'(-#A:62UAA,(,A&YE.>I 'K0!YEH6GW\M
MM\-H(M8N8WFTNX?[08XB\*&*#Y$^7;QT!8,>3G/%7[GQ/KMGI.G0G43+/'XN
M329;AX8]T]OO/##;@$C RH'3M75Z+X*MM&.D?\3*^N_[)CEAM//\OY8W5%V'
M:@R $&#UY.2>,%SX%TVZC1'N+L!-9&M##+_K@<[?N_<]NOO0!E6VK:I%XV:U
MU35;VQ,EZ\=M:2V2FTN8,'8(Y0N1)C!.7ZY&W%;/C+1;S6M,M!8K:RSV=Y'=
MBVNR1%<;0?D8@''7(.#RHI3X26358[J;6-2FM(KHWD=A(R-$DN200VW?M!)(
M7=@?08I/%NG/J4%FL5GJ4EQ!+Y\%UI\T4<ENX&,_O& ((9AC!!&<]J .3OO$
MB:+!K=V/#;Z)XG^R0C:I$\<T;2B-9%V'#E6DZ$!N0.E))XGU_3K/48HI-5FC
MD^R16=]JVG"!HIIIA$XP$17 #*XX]0<BKBZ!<3QWQU;2/$.J7-Y;BV:XN+FS
M1HHP=P$8C=57YL-G&<@>E2MI%_=Z;?6>JZ=XDU+[8J*99KNS0Q;#N0H$=55@
MW.[&20,Y Q0!2\=Z9KUAX)U-)_$=Q=6QGM#%(T42S<S*KHQ"!2OS*PP <C!)
M'!GU/Q-JGA_QAJ=F]X][::=X6;4=DL<8:69)&&YBJCJ!C P/:FS^';N^TS4K
M74M.\27MQ?K$KW<MS9*\8B;=&$"N$&&Y^[R>M6DTB=M9?5;W0=;OKF72_P"R
MY_/GLPLL18L20KCYCDCC QVH 6SN]<TC4O"[WVM2ZC'K1:*YADAB58I/):56
MBV*" -A7#%N#GK67I.L^(SHOA?7[O7))SJ&H):3V?D1+$8W9T!R%W!^ <YQV
MQ6AI>C7NG7UC<3Z9XBOUTY&CL(KJXLMMN"NTG*N"S;?ERQ)P3ZYJ6WT=XM&T
MC21X?UH6^FW27,3M<6FXLK%ANQ)R,L>@S0!J^,[K5+2RLGL&OH[8W&+Z;3X%
MFN(XMC8*(RMGYMN<*3C.!7+[KK7/$OA)K/Q$TIDT_4 VI0VZI(R"2$8V,"JO
MP%;*]0W XQW>L:3)JB0&#4[S3KB!RZ36I4YR""&5U96'/<<=L52TWPA8Z9>V
M%Y'<74L]HERN^5E)E:=UDD=\ <EESQ@#)XZ4 <G%X@U.;2K:QN=<O5O(]2O;
M1GL+%9;JZ2%RH8#840#*[CMQT QFL_\ M6ZUK4/AI?7S%KEK^]CD8H$+%%=,
ME1P"=N2!W-=DW@6V2X2ZLM4U"RNEN+J8S0F,L1<.'D3YD(QE5P<9&.M-L_A_
MIME)I!CO+YDTF[GNK2-W4A/-SN0G;EE!8D9.>>2: ,_X9_Z_QK_V,UW_ .@Q
MU2U+Q+J%MXF66UU:^N8!J\-@]O'8J+-$9UC9#*5W&0%B<AL9XQUKLM"\.VGA
M]]4:UDF<ZE?27\OFD';(X (7 'R_*.N3[UCW7P_MKEIP-8U.&!KW^T(8(VCV
MV]QY@D+KE"6^;/RL67YCQTP <SHVD7\OQ'\>A/$6HPO&MIN=(K<F0-"Q .8C
MC;T&,>^36+X0U'4-(\ ^$+*'4]5$.J+-(_V.SCGEMTC)RL2B,GYF9268-@ X
MQFO5[+PY:6.N:UJT<L[3ZN(1.K$;5\M"B[>,C@\Y)K-M_ ME8^'](TNPO[ZV
MDTDL;2\0H95W9# @J58$,005].XH PK'6_$.K3:/H4UW?:=-</>/)>O:+%<2
MPPE!&0CJ54L)%R=O\)QC/#=3L-<7QKX+MK_7YFFS>;I+>*)1($7*L0R'#,C!
M6QQ_=Q727'@Z.:UL-FKZG'J-C)))%J.]'F)D^^"&4H5/'R[<# QC%1'P-:HN
MDO;ZGJ,-WILTLRW>]'DF:7_6[]RD'=[ 8[8H H?$*WNI]2\(QV^IW-D)-7$9
M\A8SSY4A#?.K<C!&.GS'()P1SUP^L:=8>/=;T[6);7^SM3DG2W6&-EG98(2P
MD+*3@C  4KCD\\8]!\1>'HO$,-F&O+FSGLKE;JWN+;;N1PK+T=64C#'@BJ\O
MA"QFT?7M->XN3%K4CR7+[EW*6C6,[?EP.$!Y!YS0!R&M^*]<DU?6SIC:OYFF
M/'':V=GIOGP7#^4DC"5]A(W;]HPRX ![UU'CW5]1TCP7/J&ER""]$ULL9D0,
M!OF12"#ZAB*DO/"$=QJ,]U;:MJ5BEV(_MD%JZ*MP4 4$L5+(=H"DH5R *TM>
MT2V\0Z2^G74DJ0O)'(6B(#91U<=0>ZC\* .7O+W6-%\;>"]%DU>6]BOA?M>2
M2PQJTI2-63[JC: 2<8Q[YK'M=;\2RZ#X;\1_VVQ36-4MXYK(P1>7%!)+@+&=
MN[.W )).<DC!KN]0\.VFH^(]'UN629;G2A.($0C8WFJ%;<,9. .,$?C7GT7A
MN^EU'2M+@L-<@MK#6%NUBN9(FL[:))"^8W4!GW<!5;.W<>F,T ,L)M8TCPY>
M:W:ZO)'##XBFB^PB&,Q2QO?&-]Y*EMWSG!! &!QU-=#X$M[L>(O&$T^J75RJ
MZJ8O*D6,+D0PX;*J#D#"]<8'3/-;+>#[!] GT<S7/V>>^-\S;EW!S/Y^!QC&
M[CIG'?O4^F>'(]*UW4]2M[ZZ\O47\Z6S;88A+M52X.W<#A ,;L=>/0 YJ]OM
M=U6X\57=CK4NGQ:(YAM;>.&)DE=85D9I=RDD$OC"E< >M8LXN]>^)/@W4UU2
M[M#?:/)=+'&D1$&5C+(NY#PV><Y/H179:IX*@U&\OYHM4U"QAU-0M_;VS($N
M,+MSEE+*2H"DJ1D ?6KK>&+#^WM,U>,RQ2:;:O:P0H0(]C8ZC&>-HQS0!1\8
M:A+;/IUI!J=Y9O<.Y,>GV@GN9E5?X,JRJH)!)(]!D9KG-/\ $&OZU!X3MEU.
M2T?4&OHKR9;>/S&$#%58*P(5SMYXP"3QP*['6O#RZO>V5]%J-YI]W:+)&DUK
MLR8Y-N]2'5ASL4YQD$53TGP18://I[P7=XZ:?-<RVT<KJ0@GY9<[<D Y())/
M/)/% '-0>(]<TV*.YO-1:ZL=-UZ33+Z1XD5I('"B.1BJC!1G3.W (SD5U'AW
M4K[5]<U^Y:?.E6]R+*SBV@9>,?O7SC)RY*]<?(:SO$>C)8>&M;TVQTR]U2;7
MI9G,8V[(Y9%"Y9N-B# .>3Q70>&]&3P_X=L=+5S(UO$!)*>LDAY=S[EB3^-
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MS'MVJ$'"JN<]:T)_!D=_HNIZ=JNLZGJ U")87EF=%,:KDKL5%"@Y.2<$GOT
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MYM_+F>';<1["VUB-P'=3C(/<5;H **** "BBB@ HHHH **** "BBB@ HHHH
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MO%;_ (:UM]<TV62XMQ;7EM<26MU"K[U25#@[6P,J1@@XZ$4 ;%%%% !1110
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MMUN0JG.8F)"N#TP2#0!<HK"F\8^'X+:VN'U./R[J-I;?:K,955@K;0!DX)'
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M%06=Y;ZA90WEI,DUM.@DBD0Y5E(R"*GH **** "BBB@ HHHH **** "BBB@
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MJ6K7%[J'AOQ->Z5=V>E6=[<*?,C9I%C>(I'.\8&4!.1@\@,"<9K'O2\UW?\
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M&UW"0N+)BO!+A,MV7 _O5ZA/J%G;7=M:3W4,=Q=%A!$[@-*5&6VCO@<G%6:
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MQ/Y8$9S(/LL6,>O.<8[YKJ?%NFS:IX#O+>W4F\CMUN+?CGSH\2)_X\HKI:*
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MW:DK"Q7(W@<G![#D]*SKKP:#=22Z7J][I44\$=O<Q6H3]XD8VJ59@2C!3MW
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MAY]Q=)&NX&.)58 X9=QQ@8/3(K6\2Z/?ZEXZ\/W%G/=6BVUI>9NX8PRQNQA
M5@P*G(#<'TR.1FGQ^!$MHK.2TUB\@U&">>>2^V1L\S38\S<I7:,X7&!QM% '
M/V_BCQ%JUOX7M+6_6UN-0N[^TN;B2T 8K 7 ?RV'ROA,XZ GD8&*2,^([3Q/
MXWELM3GOKNSM+40P-!'^\)1R"  .5RQ !&2<&NETSP):Z7>:=.E_=RII]U<W
M-NDNTX,ZD.I;&3RS')YYJ6[\(&;7-2U.VUF_LCJ,,<<\=OL'SQ@A'5B"01GI
MT/<$<4 )X-U5M3AO0VMOJ?E.H*W%I]FN8"1RLB;5^H.T=^M9<NN:I#XW>ROM
M5?3HVO$CL[6:R!M[N$JN=LV/]:26P-PY &TUT6BZ"^EW=Y?76HS:A?78C22:
M2-$ 2/=M4*@ &-['/7GZ54N_"DE[J7FSZW?/I_VJ.\^P,$91(C*R@.1N";E!
MV@_IQ0!Q.E7>MZ-X:DUBVU-5M(_$,T)L?(0K+')?&-BSD;@V7)&"!P.#6I=>
M*M0M_%,(AU:6ZMWU9;![:+3F^S1HQV8,Y7F4'DX;&<C%=$?!MH?#LFC?:9_)
M>_-\7XW;OM'GXZ8QNX^E4I? "R$HFN7\=M'?G4;6!5CVP3&3S"<[<N,EL!C@
M!CW ( /.->_Y)Y\4?^QA_P#:D%>N^+C.O@O67M;E[>9+*5UE0 D;5)[\<XQ^
M-9-Y\.]/O=#\0Z6]Y<K%KE]]MF<;=T;;D.%XZ?(.OK747]E%J.FW5A/N\FYA
M>%]IP=K @X_ T <!H=QK<\7AOP[;:W+!NT9=0GO!;QM*5^1$C4%2H R<D@DX
M'UHL_$NO:M=Z;X?74$M;W[;?07=_% I+I;$ %4;*@MO3/!Q@XK9@\$36MMIC
M6^OWD>H:= UK%>>3$2T!V_NW7;M8#8I!ZY'6L_6/#4>@V6CRV']LR7-K=32R
M:A9QI/.&F!,C/&5(<,<9"CC"XX% &4WC'78/,TR^OY%N#K<]D;RRT\SR)!%"
MC_+$JM\S%ADD$#)]!4-WJ&NZS-X6234;VT9=<FMUFDL?(:=5AD9)3'(HP=I*
MD8VYR<=,:WAGPA<3Z3<74LVH:=>MK$VHV=Q,%-PH9!&3(I&WYP&)7 QN'3'&
MY>^#I+VPTY&UV_\ [0L;PWD=\X1V+L&4C:5VA<.0% XP/Q ..FNM;TC3?'&N
M:=JBV\>GZM+,+7R%<3D1Q%@[$9 (X&W!')R>@MZKXSU<:OJ[V,NH-_9MVMO#
MIUOI,D\=RH"%]\RH=K'<P&&&, D'-=5<>#;2YT/7]+>ZG$>M3233.,;D+JJG
M;QC^$=?6B?PFYU6YNK/6K^QMKR9)[NU@V 2.H49#$;DW!5#8/..V30!2T&^U
MS5O&.NI+J2IIFEWOD1VRP+F4-"C89L9 4MD8Y.3GBK&N7NIW?BJQ\/:;?G3O
M,LY;V>Y2%)'VJZ(J*'!49+DDD'I[UJZ5H<.E7^K7<4LCOJ5R+F0-C",$5,#V
MPHJOK?ATZI?6FHVFHSZ=J-JKQQW$*(^Z-\;D96!!&54^Q% &']J\37>O67AN
M;5H;*YAT]KR[O+.!7,Q,A1 HD!"Y +-P>>!QS6=:>)/$.JW.AZ6E_%;7,MUJ
M%E>W,<"MN-NV Z*V0"<=.@)/!QBM_P#X0D6PL9M-UF^M=0M87@:\;9,TZ.V]
MA('!!.[D8QCH..*GT_P;8Z;+I$L,]PSZ:;APTA!:=YN9'<XZDY/&.M '*MXB
M\0QZ>\5QJ%T(++5KBRO-4M+!9I1&BAHV,84@ [L,0IQCH,T^RGU'4OB%X;F7
MQ$MU VCSS%[:%!%,!+$&X()&[C/<$8&*Z0^$I8)+B;3=;OK&>>]ENV9 CH3(
MJ@J48$$#8"#U'//)J*V\#PV%]H]Y8ZG=PS:>DL4C%4;[2DD@DD#Y7C+#.5QC
M/% '"_VKK.O>&] G.IM:ROXI:U8P01@%0[["1C&1M_'/.:ZNY\1:I!H'CRX%
MR#/HS2K:.8U^7;:QR#(Q@_,Q/-6%^'EK#X?@TRUU*[A>WU(ZG!<A49DE+%L8
M(P1\Q&"*74O (U$ZO'_;E_!::O&!>P1K'B201B/>&VY7(5<@<''H2* .:FUC
M5-)\1^+]<;4))UL=&M9TM6B78Y99BJG R &)/')SSVK?\)ZWJESK[V%Q<ZCJ
M%HUGYQN;O27LQ%*& *#<BA@P;(')&TY)J]<>![6YU.\N7O;C[+?V"V-[:;5*
MSHJLJG=C<I&\]#Z5H:-HEYIL[S7FNWVI'RA%&LX1510<Y(0 ,Y[L?TYH S-2
MN]6U3QG)H.G:FVF06M@EW+-'"DDDCR.RJOS@@* A)XR<CD5A:=XD\0Z]<>'K
M&._CLI+J&_2]FB@5B7MY4C#H&R!GG@Y'S'@X%=7JWAM[W5TU;3]4N-,OQ!]F
MDEB1)!)%NW %7!&022#[GKFF:9X.L-)N-(EM99_^)9;SP('8,9/.96=W..6+
M+GC'WC0!QO\ PF6KA++2;G4;F.X^VW\$]_9:<;B5TMY BD1*C!2V]<G;@8/3
M(KMO".I7VJ^'HY]1BE2Y666(M+;M 955R%DV, 5W* V,=ZI-X(BB87%CJ=U:
M7R7MS>1W*JC%?/;,D95@05Z>_P H.:W],L6T[3XK5[NXO'7)>>X;<[L222<8
M Y/    P!P* .$TWQ5J#^+-,B&K2W]IJ%Y<6[HNG-':QA4D=?*F*C>1Y8!^9
M@<DC&*@TG7_$K:/X9UZ[U=)H]1OTLYK(6R*FQF=0VX#=OR >N.V.];EGX 6S
M?2]FN7[1:3<&6QB*Q[8D(960_+\V5<C)Y  QCG-V#P;:0:%H^DK<SF+2[I+J
M-SC<[*Q8 \=/F[4 <1JEYK6N>$+37KC4P;.ZUNW5;#R$"Q1+>JJ88#<7^4$Y
M)')X%=1\5#<I\/K][6[DMG5X0S(H)93(JE>1Q][/'I2/\/(FC%H-:OUTN*^6
M_@L56/;%()?-(W;=Q7=G )XS[#'0>(]#@\2:!=Z1<2R0QW"@>9%C<A#!@1GC
MJ!0!Q@T_6I/'FO0V>NO;31:59F2Z^S1L\KAI]N5(V@=<X&>F"*HKXYU35H=)
M07MWI\DNBP7\LECI3WGF32%@%(5'VH-A/8G/!XKNM-\/?8M1N]0GOYKN[N[6
M&VFD=%4$1ER& 4  GS#^0K,A\"BPM-.CTG6KVPGM+%=/:=$C<S0KRNX,I 8$
MD@CIN/6@#=T"^N=3\/:=?7MJ]K=3VZ230.I4QN0-RX/(P<]:T:BM;<6MI#;B
M2601(J!Y7+NV!C+,>2?4U+0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5#5M9L=$MHY[Z5U62011I
M'$\KR.03M5$!9C@$\#H#5^N8\:QVC65C)=G5(##<[XK[38S)):/L8;BH#$J0
M2I^4CYN<=: )YO&N@06-K=F\DDCN@YB6&VEDD(0X<E%4LNT\'(&#P:DN_&&A
M6:V9DO3(;VW-S:K!#),T\8V\H$4D_>!P.<9/0&N(CU/7)GTT:I)JT%N\-R(;
MFPTW9/>.)L1AP4;RMR8;!V@DY)&,4_P3972:EX0,]C<QFRT2ZMIS+ R^5*)(
M1M)(')PV/4 XH ZVT\>>&[Z>SBMM0,GVQA'#(()!&7(R(R^W:K\?=)!]JLV_
MBS1;O5_[+ANV:Y,CQ*3"XC>1,[D60KL9A@Y )(P?0UQ%KI=XG@?18?L,ZS)X
MG$[IY1#*GVUSO(QP-N#GIBH?#.D>5<:3I.HW7B5[ZPOWE-J+9!:QE6<B7S#$
M,HP/9R27QZX /1M8US3]"MXIM0F9!+((HDCB:5Y'()"JB LQP">!VK TGQS9
MW">(+V]NHX].L;Y+:W<1,'.Z*,[2F-Q?>[#;C/;&12^+R]CX@\,ZU);W$UC8
MSSK<F"%I6B\R(JK[5!) /!('&ZN3\F\GNK_6UTF_2T@\40:@T1MG$DEN+98_
M,6/&XX+!L8R,'C(Q0!Z!!XNT.XTZ]O\ [:88;$@70N(7ADA)&0&1P&&<C''/
M;-,MO&6A7<)D2\="MQ%:M'-;R12+)(0(P490P#$\$C'O7#ZS;7FNW^M^(-.L
M+R2PC?3"L36[QO>"WG,DI5& 8X5@!QR1@5H>(M477+!M1T[1;XV]AJ-A<271
MLW26X2.8,X6,J'8(.>G<XZ&@#L;[Q)I&F/?+>7@B-C#'/<Y1CY:.2JG@<Y*G
MIZ5F_P#"P/#>^:,7D[31 -Y*V4QD=#G#HNS+I\I^901QUKB_$@N=?7QK=66F
MW[6]SI5E%;&2UD0SE992VU6 ;C/3&>_0@GLOLDO_  M5;O[._D#1#$)MAVAO
M/!V[NF<<XH MW'C/0;:RLKPWK2PWL1FM_L\$DS/&,9?:BDA1D9) QWI;SQAH
M5B;=9+TR/<P"YMTMX9)FFC/\2A%);UX[<]*\TT;3KS2;?0[V_N-=TNW.E/;;
MM/M/,=9%G=MCJ8G*[E8$<#.WKTKJO#6C?V=XJT40VE^EI#X>>-6O$'F1LTR-
ML<J-H;'8>E &E/\ $'1UU'0K:V,UU%K"N\4\,$K!54'L$/.X8(X*]3BNLKR7
M2H;G2;GP;>7=C>I!!>ZM'*4M9',9EE?R\JH) ;L<8KT^POUU!)V2"XA\F=X"
M)XRA8J<;E]5/8]Z +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>,8(+"WN]+$%]$^J0Z=*WFXV%Y1&6& =V"3Z=*Z1)HI$9XY495)!*L" 1UH
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M7U.%&=8U:359E!9B JC+=22 ![UJ:?I<6F^9Y=Q>3;\9^TW+S8QGIN)QU[4
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M_'P3QZ+46EV)_M!-&U'5]66[CUV2Z&GQ6*%#_I#2I+YA3.PJ02=W<K[5W_\
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MGRXQM.^13GC/3'(KF[F;[=X0\1RW6ES'S?&,)DL)0C.P+09C/S;23TZXYZT
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MD9.<&/(/O6!XF\;W]EKFL6ME>10-I4<9CM6L9)S>R,GF%2Z\(,%5'?))/'%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***IZE=W%G;++;63WDAD53&DBH0"<%LL0..N.M
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MHZ)=Z8TKJMS;/;F0\L RE<^YYS7.V/ACQ-I]I;6D7C'_ $>W18T4Z9%G:H
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M(I_B5G0$?D:GT"2XUK4-"\(WK&27PU/)+J#'^/R?DM3_ ,"#K)_P"O2#I=I
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MZ7975Q;_ .IEG@5VCYSP2,CGF@#RO4M-U#5-0\42W4F@QWMK- D6I7TSI+:
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M=]FA^V>5Y/VCRQYGEYSLW==N><=,U"NCZ6J,BZ;9A6N/M; 0+@SYSYIX^_D
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M.3Z5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %%%% !1110 4444 %%%% !7)S^-9O[<U+2]/\-ZKJ+Z<Z1SRP/ J!F0.
M-\BGHP[5UE>4VVW_ (6%XSSXP?0O]+M_W2FW'F?Z.G/[U2?;B@#J=8\<KX?\
M,'6]5T+4[;_25MUM#Y3RL6Z,-KE<=NN>.E;_ /:]C_8?]L^>OV#[/]J\[MY>
MW=N_*N$\5/%+X:T*-=;&M;?$-BKW),1)S*#M/E@+T/I62L-P+D_"S:_D?;O/
M#]O[+SYNW/\ O?N?I0!U=K\2+"]\'+XC@TS4&C>\6R2U(02F0N$ Y;:.2.IK
M0L/%PGUFVTK4M%U+2;JZ5S;?:A&R3%1EE#1NPW <X..!7G924_#Z\2V=(I3X
MQ(B=DW*C?;1@E<C(![9%=_:>&=5GUZQU77M:AO6T_P PVL%K9_9T5W7:7;+N
M6.TD <#F@#1\-^([7Q-83WEI%-$D-U+:L)0 2R-@D8)XIFO>)K709+2V-O<W
MNH7A86UE:(&DDVC+'D@*HR,DD"N.^%^MZ38>']2@O-3LK>7^U[L^7-<(C8\P
M\X)J[J6I6.F_$[2]>N[J$:3?:4]C!>[P84F$H?!?H-PX!SR5Q0!M:?XP6;6(
M-(U72+[1[ZY5FMENO+9)]HR0CQLPW <X.#BKNB>(K76IM0MUBEMKS3YS#<V\
M^ Z=U;@D%6'(/>N9\5ZA9:_XB\+:3I-S#=WMOJD=_,8'#B""-6W%B/N[MP49
MZYJK\3=(5M1T.[M;F>SGU6]CT:]> @&:VDW$J?<;3@]1N- &Q+\0K$:$^L6^
MG7US:&_6PM6C"#[4[-L#1Y8#9NXR<=*O6/B/5+N]B@F\(ZO:1NV&GFDMRB#U
M.V4G\@:P?B7:6]AX-TFTM9%T^WAU2QCCD0*! HD !&[CY>O/''-7](DBBU6!
MG^(9U($[1:.]H!*2, ?(@;.2#P>U !!XZN;Z:]73?"FL7L-I=RVCS1O;JK/&
MQ5L!I0<9'I7266H&XL;>>\MI-.EF8J+>Y=-X;) 'RL02<9X)ZUY?X6V[_$&?
M'3Z-_P 3V^_T0&UX_>GYOWB%N?K7>YT*>PT@ZGJ5GJ3)<H+.[G>/,MR,X*;<
M+OZ\*/6@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** ,OQ!8ZCJ.DR6NF7=M:SR$!GN;83H4[J4)&<UQ/_"O_$?_ $%/
M#/\ X3L?_P 77I5% '"IX<\=QS/-'XJT=)9 %=UT4!F Z GS.<9.*C_X1;QK
M]E6U_P"$ET3[,I!6'^PQL!!R"!OQUY^M=]10!PR^'O'BSO.OBO2!,X"O(-&&
MY@,X!/F<@9/YTVZ\->.;Z P7?BC1KB$D$QRZ('4GZ&2N[HH \XA\"^*+>9)H
M-9\.12H<JZ>'T5E/J"'XJ2]\&>+M3D22_P!>T"[=/N-/H*R%?H2_%>AT4 <0
MFA?$"-%1/%VE*JC 4:/@ ?\ ?RF)X=\=Q32S1^*M'26;'F.NB@,^!@9/F<X'
M%=U10!YY=>"_%M]/YUYKOA^XE(QOFT!7;'U+T0^"_%MO#)##KOA^.*0JSHF@
M*%8J<@D!^<'I7H=% '"W'ASQW=P-!<^*M'FB;&Z.310RG!R,@R>M==967E)!
M-="";41 L4UTD(0R$=<=PI.3C/%7** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O/;[P3XFOKZ:YDUCP^[2,2&FT%)'QV!8ODX&!^%>A44 >>P^#O%]
MO"(8-?T"*(2"4(F@JJ[QT; ?J,#FK/\ PCWCS[1]H_X2O2//V;/-_L8;MN<X
MSYF<9YQ7<T4 <%_PBWC81F/_ (271/+,GFE?[#&-^<[L;_O9YSUS5C^Q?B%_
MT.&E_P#@H_\ ME=K10!YN_@+Q+([.^K>&F=B2S-X>0DGU/SU:_X17QK]A^P_
M\))HGV3&WR/[#7R\>FW?BN^HH \_L?"7C+2XVCT_Q%H5HC'++;Z$L8)]P'%3
M3>'?'=QY?G>*M'D\MQ(F_10=K#HPS)P?>NZHH X.Z\,^.+Z P7?BC1KB(G)C
MFT0.N?H9*J1>!/$]O,DT.L>'(Y4(9'3P\@92.A!#\&O1Z* /-Y? ?B>:5Y9=
M8\-R2.Q9W;P\A+$]23OY-=3X>T&XL-+2VUA].O9(9S- UO8K D7 QA<G#9W'
M</6M^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML)!-*XD#Y164 $R$@ \8K4M-,\3,TL>JZYIUS;21.A2#3FB8$C .XRMT],4
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MD+NZ9'.,UEZO>KIGB3Q!DV=K#+KED&O;N(/%:'[(&\W!(&[*A02< L*]7I"
M000"#ZT >,V<D%^!;37"WK?\)E!,V^(1F2-X5*2;.RL02#T/)KN]!0)\0_%V
MU<!ELF.!U/EN,_H/RKK,#THH \DU.;0H/BEXE_MOQ!=:0&MK/RC!?/;>;\KY
MSM/S8X^F?>H+'41I_ABYBMS ="778DLM7U&VR%1@':=\[=Y63*B0]2023BO8
M< ]A00",$ CT- 'C=E>:>\FK277B5;.ZAUU+NTU&2V419:T5 [H<*(W'F -D
M9(!!S6KH4ZZOXK\*7<UI9*4AU8I+:1;89F$L0\Y >@?);.3U/)ZUZ>5!!! (
M/7(I<4 >0:=+;Z5XAT_4=09+?2;;6]8C::3Y8H)7<>62>BY D )[M[UU_@-D
MN)O$E_:<Z9>:JTMHX'RR#RXU=U]5+JW/?DUUY (((!![4O2@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BN4^(>KWVD>%Q_9DH@OKVZAL
M89R 1"97"[\'T&?QQ5$?#.)4!3Q=XL2X'68:HQ)/J5(*_AB@#N:*\^DUGQ%X
M"GC_ .$EN1K'AYV"?VJD02:T).!YR+PR=MP_&O0$=9$5T8,K#(8'((H 6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$OQ#F.Q/ %O Q_Y:3:Q&57ZA5S6U_P )UH'_ #WO/_!=<?\ QNC_ (3K0/\
MGO>?^"ZX_P#C= '-W?@/7?%F;CQCJEO*B(QM]*LE9;9),$*SL>7(SZ5F^%?$
MVN>$?"]CX?O? NOSW5BAA\VUB5XI,$X(;/2NV_X3K0/^>]Y_X+KC_P"-T?\
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MX_\ C= '1XI  !@  >U<[_PG6@?\][S_ ,%UQ_\ &Z/^$ZT#_GO>?^"ZX_\
MC= '1T5SG_"=:!_SWO/_  77'_QNM;3-5M-7M3<V3R-$'*$R0O&<C!Z. >_6
M@"[1110 4444 %%%% !1110 4444 %%%% !1110 5YOXD_X1Z\U>].M:!J]I
MJ\+%+2]TV"=I;A,#8R2Q+C/;:YX(]*](HH \JBTOQ#>>)_#S:E#-]N;PQ/!<
MW&P[4G;;PS#@-G^N*BMK\26OPYTQM,O;:ZT^\B@N3<6KQ+$ZVLBE S !\D$Y
M7(PHSC(KUHC(P>E<YIW@K3=.O[:Z6XO[A;,L;."YN3)';%@02@/.<$@9)P#Q
M0!R=KIEXGP[T"W^PSK/'X@CF>/RB&5?MS,6(QD#;SGTYJOH>D&.]L](U&[\2
M-=VNK27 M([9!:C$SR++YIC^X01GY]V6(Q7J]% 'C\#7$?A'0O#3:5J#:GI^
MMV[77^AR;(T6ZW&7S,;2""#P2<,3T!QZK:Z@EW=WENL-Q&UK($9Y8BJN2H;*
M$_>'.,COQ5NB@ HJ"\MOMEI);^?-!O&/,@;:Z_0]JQ/^$3/_ $,6O_\ @8/_
M (F@#HJ*YW_A$S_T,6O_ /@8/_B:/^$3/_0Q:]_X&#_XF@#H)8TFB>*10R.I
M5E/0@]17%_"J1T\$KIDKEI=)N[C3W)_Z9R';_P".E:U/^$3/_0Q:_P#^!@_^
M)KE/!7A&\%QXE\_4=>LH3K,Q@S-Y9F7:N9#E?FR<_-T.* -'7S_PC7Q*T?7\
M[+'5X_[*O3T"R9+0.?<G<N?>I/A8/M/AN^UH]=8U2ZO1GKM+E%'Y(*LZI\/;
M'6]/>QU+6-:NK5R"T<EV",@Y!^[V(J6Q\"6VF6,-E9:WK<%K H2.)+L *!V'
MRT =517._P#")G_H8M?_ / P?_$T?\(F?^ABU_\ \#!_\30!0U/X@6\>I3Z3
MH&F7FOZG VR:.T 6&!O229OE4^W)JM_97C[Q!\VI:U:>'[5O^7;2X_.GQZ-*
M_ /NHK4A\%Q6X<0ZYK<8=B[;+E1N8]2<+R3ZU)_PB9_Z&+7_ /P,'_Q- %/3
MOAKX9LKD7ES:2:K?#K=ZI*;F0GU^;@?@!76JJH@5%"J!@ #  KGO^$3/_0Q:
M_P#^!@_^)H_X1,_]#%K_ /X&#_XF@#HJ*YW_ (1,_P#0Q:__ .!@_P#B:/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD?H/TK.T6V$-M\*@D.S;:ONPN,;K,DY^I_6@#TVBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5 D-P) ZR8Z<$*,>@Q6UH^GW]DL[ZCJKZA/,P.?*$21@# "H"<>IR3DUIT4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP%E#%?PS5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/?7L<,<X+1DY.Y0,EL#L 02>@SS37\2:/'J<>G-J$(NG*JJ9R,L,J"W0$CD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
%HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex1012022063010qngcbasho013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **165L[6!P<'!
MZ&D,B!BI=0P&XC/('K0 ZBD!# $$$'D$=Z175\[6#8.#@YP?2@!U%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M >3;MW-W..WTKE-)\)W-GXHBUMDM+.9HY%OOL4C;;YCC:SQE0JL.3D9.3Z4
M;FH:O%;W\6F10375[-"\WDPL%*QJ0"Q8D8Y( YR3]"1RO@7Q*4\/>'[2^6^F
MN=3N+Q(IIF#E3')*VUR6W9VKCOTK8U31-47QA:^(M)>UD<6AL;FVNG9%:/?O
M5E95;# YX(P0>U8UCX.US3=-T Q3:?-?:3?7-QL9G2.2.;S,C=M)##S/3'%
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M.*WD:1?F8,[%BJ_W5 &..>3GCGS\-Y%L%AAU'RIK;4#+92J,&WM&9]T(_P"
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M7:/++\W.5D '3D\X JV-:@B\1:LHL=5>^MM/AGDMQ(K(Z$O@1KOV[\A@3QG
MY-8\W@W6YK75BUSI_P!INM9MM5@4;PF8O*RC'&1GRNH!Z_A6[8Z/J$/C2\UJ
MX:U,-Q806NV-FW!HV=B<$8P?,/?M[T 26GBNQO--TW4(XYA:W]LUV'8I^YB5
M0Q:3YN,9 XSR:@TSQKINIZU!I:))'+<VYN+=BZ,LBC&0=K$JP!!PP''T(JOI
MG@J.RLM=T^:Y+V5^9HK:-1C[-!+EF0?\#=_P"^E6/#-CXGL88+36[S3IK>TC
M$<<MJKB2XP,!I W"\=0N<GN ,$ Z2BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@");:!9VG6",3,,&0(-Q'UZU+110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[#R,%7/H,D<T :-%%% !116=INMVNJ7NI6ENLRRZ?.()O,3;\Q4.,>HPPYH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-H_VA[9;EHPV(HAO:7.Y%7=PJ@Y+=,#-0Z3=2ZW<?#;4-0NYWN)[&X>=UG9
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M62&^A?2;)H[]M]VI@7$[>K\?,>^3WJ?3M,L='LDLM-LX+2V3.V*% JC/7@4
M<<VHWUKXPBBU/[6UA=W[Q6=]9W),)^1E\B6/(V$$$A@#DJ.1S7/:5]IM?!'A
MW['J=];O=>(&@G*W!8LC7$P(^;..GXGDYKT^/1M,BO#=QV,"W!D,I<(,[R,%
M_P#>()&>N.*@/AG0CG.CV',_VD_Z.O\ K?\ GIT^][]: ."\5WMWHFF:ZFG:
MWJ%S<:/90.'GN-OD,69@6(_US.,##+@!>N34^J74ND>*?'.K6;S275IHUO/
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M2+?C<5'+8&!D]3@<#TJG=^&="O[FXN;O1[">>X55FDEMU9I N,;B1SC _(4
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M&0DJK_)_#N/3.>!QBMG4-&U:[U;PO>I'9A=+DDDN%:=LG="T6$^3G[V><=*
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M[#"!BH+,1N.< 9.* -O0==O[[6=3TC5;&WM;RR2&;-M<&6.2.3=M()52""C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5"]I;27"7#V\33H,+*4!91['J*FHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%<Q20-NB,A C) !^5L\-T]\U-:>+=-O-2MM/6.]AN;KS3"EQ:21;A&<.?F
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MHR.: -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M.M-VE?%'5DE'RZS8PS6K$X#O!N5TSZX9&^F?2NQJ&>TMKIX7GMXI6@?S(F=
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MS9SZ,MDT$\J 2-YA9E."<#:2,^M=M10!S/A#1;W1?M\#RW8TQG0V-M>3":6
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MKM'!:QO%)YG"@V@.Y<<#)YXH [DWMN+QK,2J;I8O.,(/S;,D X^H(ING7O\
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M@G]TSA@Q&3WWMU]:S_$GAE+W3;E=/T[3YY[B[CNKB.[9T$S* N0Z\QOM50&
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M %L^%]&-_9WPL56YLX!;0R*[ K$.B'!PP&3US3K+PWI&G1:=%:6,<2:<'%H
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M%W'<W6FQR2QHB?>8*ZIRH=0<.!VW USXO)[/3/%D,'B34KJ_L;/SU%S;(AM
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M_3K32;&.RL(%@MH\[(TZ+DDG'XDU:HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N,T.P\1Z)J-_I@LK:?3;C4);R'4&G
M ,:2N9&1H\9+@E@#G'(],5V=% 'FUYX;\0_9M2T^WT^&2.37X]4BN&N0H>/S
MDD*XQD$;2#G\,U8UCPOJ^IQ>.HH[9$.KPPBT9I5PS)$%(..1DCCCIUQ7H-%
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MU>=E9#-;S-+M=02=IR!W[_BFIZ'J^L^#-8MD\,:?I5_=VX@2*"6-F<YR2S@
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MMH[:V3.R*)=JK]!VJU0!RUMHR2:WK>LZM$EM;ZE;0V1MIG7E%W@ER"5RQD(
M!/ 'K@86F>%;_4OA[J5BVH1S7,Z?9;"Y<94V\+GR-WJ&P23W#=Z[S4--L=6L
MVL]1M(+NV<@M#/&'4D'(R#QU%6$18T5$4*BC"JHP /04 >>W^AZSK/@_6+8^
M%]-TO4+JR:U5;>6-C*S=]X VH,9P<DYZ#'/?VY<VT1DC,;[1N0D$J?3CBI:*
M .)?P[J \7IJVGP3:=,UYF\DCN ;:\MP",O'G(EQ@ @#IG/:M7Q+;:Q<7FDG
M3X5GLTF?[;$)_)=@4(0ANNT'J!R1ZC(/0T4 ><:3X9URRTWPO:3:?$ITO5KB
MYE\J=6'E/YP4C./^>HX] >_%-;PSX@@OFU:VLT>>V\03:C':O,H\^"2+RB <
MD*X&2,\>]>DT4 <QX8T_4[;7/$=]?V:6T6H744\*^<'; A1""!P#E3W_ #ZU
M.VERZGXCN;J_@N88((A#9O%=M'N!.9"?+8'DA.#V0'J<5T%% '":'H6K:+I'
MB31([!FTZ229]*S.I(60<QMD\ .203G@G/-++HFKGPMX.L5L";C2KBT>Z7S4
MP%B3:VTYYR>GZXKNJ* .)N]$U2;4O&4R61*:KIT5O:DR)\SJDBG// S(/R/M
MD@T75TU+PE.+0(-,TV:VN&:12%D9(U7@')&8SG'8C\.VHH \\T/0O$<>O^']
M3U*PB$UM:7%M?3&[#%G<QD,J@8"?(<*,8ST'4TK7PKXAL- \,'^R+&]N=$66
MVEL99U*W,3X^=6(PK HI /;/2O4** .&U/PT^HV-@DNA"T=#-,CZ1<+#-8RG
M;M*ME0V1NW=LXX(&:ZK1(=0M]"L(=5F2?4(X$6XE085Y !N(_'V%7Z* .<\7
M:=>ZDNC?8K?SOLNJ074OSJN(T)SC)&3SP*YK5?"NMW5[K5];65N\AU>WU&U@
MN77R[E$@6%HVQG:2-Q!(]*](HH X2^T/5+W1[2YM] L-/NH=3MKQK&&1 SK&
MV3ND "EL9P.F!UYP.A\4V5YJO@O5]/MX5:\O+&6W1 XVAW0K]XXX!/7]*VJ*
M .0M-+U.'Q9IVI/8O]G@T1K-\2)N\TNC8 W=/D(SZD5@Z#X>\3^&8]!O;?38
M;R6#3CIU[9FY5"N)-ZR(W((Y((X/2O3:* .1&F:S8>+XM>^S)=I<Z<MG=6]O
M(JF%U=G4H7*AE^=E/0\ XYP,[3O"6HZ3+X45(5F6QO+N[NV20!8S.LGRKG!(
M!DQTZ#/M7?T4 >=3^'-:D\/:K9K8'SKGQ NHQ@S)CR1.DG)SP<(1CU(J;2O#
MVJZ?JUU93Z!I=W92W\EY!JDK(9(EDD,A5D*DEU+$ @XZ=,5W]% %2QGO9Q<_
M;+-;;9.Z0[9A)YL8^ZYX&TG^[V]:MT44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA95D1]S *P)/4X^4\],T/%7A^6YO=!U%M.O;^"RMY;>>VL;HP3+O$9#*0Z9
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MCP0,@^GO531-%USPS)I.JG1[B\,<%]:7-K;R1^:@DNC+&Z[F"D$#!&<C(]Z
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M+$736-W9!F(6.Z4*Y7LV 3@'T//J!7GNH^%YM0\)>($TSPU?65U=I;Q1B_U
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M/XDFMBL?PG9W&G>#M#L;N/RKFVT^"&5"0=KK&H(R.."#TK8H **** "BBB@
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M\D@4KN'X,P_&K-%% !1110 4444 (JJ@PJ@#T Q2T44 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ex1012022063010qngcbasho014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **8DL<C.J.K%#
MM8*<[3Z'TH,T2S"$R()2-P0L,D>N/2@!]%-CDCFC62)U=&&593D$>QI$FBD=
MT21&>,X=58$J??TH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ'BB=->5%T[5;JQM;26TC,1"CY"[* YP6'0\XKTBO//A7_Q\>-O^QFN__9:
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MUG(AW20-(LJHS+R"5(;CFN>\$:!HNIZ7K$NH>(-1L9&U:[4PP:L]NF-_78&
M_'%4;Z[#?![QKI%I+'<Z/I=Y';V%Y&BKYJ&6-F!*@*Q!/+#KG- 'HPM?B/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.G^(+W3K6SL+&UFM@4N_-:3<?E;&T8^G-=Y110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%<KJFM:U9^-]$T]8+6/2;V:2%G8EI92('DR.R %0.<D\]!UA^(?BN[\
M,Z#,=)BCFU4P27"+(,I'%&-SR,!VZ*/5F'O0!V%%-0EHU8]2 :=0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 V1/,B=-S+N!&Y3@CW!]:S=&T0:,LRC4
MM2O?-(.;ZX,I7&?N\<=:U** .$\5:A>CQ?H4D'A_6+J'2[F26::"!61P\#H-
MA+#/+@'IT-4_&'A37=1TSQ'J6GZB&?4M/\I;"6Q#2J@0XA5]_P N6+'IU;O@
M5Z/10!2MK6Y.CK:WEV9+@Q%)+B%/*.2,949.TCZFHM&T<:-#+&-1U"]\QMVZ
M]N#*R^P..!6E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&XC!WNRD<\CGM6CJ5U%J7B:VU^SBG;2;'[&+I_(<<AIN-I&3Y?F*3Q\N?8T
M=O\ \)'HWV*VO#J-NL%S,((69L;Y"VW8 >=V>".HP<T^YU_2K/4HM.N+V*.[
MDV[8SG^(X7)Z#<00,XR>E<%J5U:1Z%?7DL;@7VNQ7%D3;L6,*36_F,.,A3Y;
M-VR,'FI]5G6<^(+.))I+G69[2;3B(6Q(FR)=P..-C(['.,#GO0!Z/1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!7O[ZVTRQFO;N3R[>%2[M@G ]@.2?8<FLI/%NE-9SSL
M;J-X94@>WDM9%F\QP"JB,C<<@Y&!CKZ'&GJ5S+9Z?-<PVDEW)&NX01D;G'<#
M/?&>.]>;OI=U<3R7XBUN;3HM4AN9)Y8I(KV5?(DB<*H"OM4NF-J@XWXR>: .
MZN/$^E6?A]M<NIW@L4)#&2)E=6#;2I0C=G=D8Q23^*-+M]5_LZ22;S1,D#R"
M!S$DK@%$:0#:&.Y>,_Q#U%<)JNC>)]2\*W3"V^U6L=O>+9V]]+(+H;V=49AM
M8LXC("AB#\QSSTV]=DU'4-2L+=M/U!;RVO;:00QH9+&==R,\C2;1C9\^ 2#N
M13M/% &Y:^+M+NH;BX7[9':V\<DLEU-:21P[4^\0Y7!Z'H>U-'C'21#*[F[C
MEC:-?L\EI(LS&3.S:A&6W;6Z?W3G&#7'/IU\ME<6.A:=K./L%W%=VFJ,[0,Q
M7$:IN.PDL3@Q\$9W&G)ITHGNKZ!=>DB@-G)#>W=FTERLJ>:K#RV"L\85^0!G
M+L5)[ '8R>+])2R@N5:YE\\R!88K61Y08SB3=&!N7:>#D=2!W&="[U:QL=*.
MIW$X2S"*XDVDY!QMP ,DG(  &237FT&B7MM=)JVIIK<D%U]M.+%9(YT=Y(S&
M66+#*&"$X/ .T-78QZA>V_A-8=6M+V748["$7+0VS2"29T(;;L!SA@<XX&10
M!O6=W#?V-O>6[%H+B-98V(QE6&0<'V-3UA^#Y6?PEI<4EO<V\MO:Q021W$+1
M,&5%!X8 D9[]*W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ex1012022063010qngcbasho015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .&^(%_%>7NC^%#>BU74I
M?.O9?-\LI:Q?,PW9&"[;5'XUF:;K,MS\)?$NG37@FU#1+2ZLI)T?)D"1L8Y
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MXYL+CQ%XA$U[)<W<Z6\#3NL=K%'(T:JJJ0,_+DMU)-=3X8\/-X>CU56N1/\
M;M3GOQA-NP2$';U.<8ZUF1^%]<T2]O7\,ZM90V5Y.UP]G?VK2K#(W+-&RNI
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MK(DLDJ%VD?:06P,  \=>*U-<\ Z!JVAW=C;Z786,\L>(;J"U17A<<JX( /!
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MT,GE?O@C(BR'S"%SA0?QKH?$-K'#\-/%CKX1B\/N;!Q\@@S,-I_YY$]/?UH
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M)%)O15=HVFWXV%0RGY>N.<YX&%XCU67Q'I&A:M#!;?V<?$-JD!8$R[5N0GF
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M,JGY5P3P6ZXH [FBJ6D7DE_I<-U(UNQDW$/;2;XW7<=K*W<$8/XU=H ****
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MP19&=1 UVVX[)&0@'9C)V\?44 :&B^%+72;B\O)[FYU+4;Q1'<7=X59F0=$
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MM-WVF\MX=JAF\R55PI. 3D],\56N-?TNVUBTTJ6\B6]NHVDBCWC)4$#/7N2
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M7PUH-MI-KX:UN2.$$M+(]J7D=B69F/G=2235_P#X2F*_\-66MZ+Y5S!=30Q
M2L4*^9*L9S@'#*6Y'MBMF2^M8+B*VGNH([F7[D32 ,_T!Y- 'G?_  C=Q;3?
M:--TSQ%97$5]->VSK]C<0><,2QA6EP48\X['I0GAN>*QECBT[Q*+XZG_ &K'
M?,UF72<H$;CS=I4@'*XQ\V!C KMK;Q-HUU<WT$>HVV^QE\F?=*H"M@''7MN
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M:9;6S6DT]UJ$%K-$\W[R-)& W!1SW[^M &UJ%I]NTRYLA)Y0GB:+>!G:",9
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MT-_:WTU];7JK'NC:5F+J5VX93N.0?TZ5U.FV4EC9B*:[FO)R=TL\H 9V]<*
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M$F58WD%KC)$I1.6P0!CIE@3TKAK5KVQ6.>:SU&33+7Q3/<WBO:.&,3JWER[
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M"* )ZYJ\\_6/%*V]O,8(],B\S=);%DDED!7Y2< [5R."?]9[5T:*515+%R
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M+DX) X!I;_2M+>RT26QL+R6UN/$:W;M=6S9*LC>8^PJ#'&6QD$ 'KT->HT4
M<CX+A%MJ_BN*.W:"!M5\V%?**(RF&(%EXP1N5N1W!K4\4R"/1ERKL?M5L<(A
M8X$R$G &> "?PK:HH \[UOP]?Z/X@M[_ $&+S=)U;4;5]2M%Z0R":-OM"#WV
MX<?0]CBI=11W&MZYH>O6VKO+=7Z75C]F@)CG4!#'B55/EE"N#E@!CW->GT4
M<%8:/#JE[XZT*_M9D34+K>KM P0QM;Q*&5\;20P/ .<K[5D6D'BB6\TG69;2
M2*\O(&T*]55&Y H)%T?HZR$?[++ZUZ5?ZE9:7%'+?7,=O'+*L*-(<!G8X51[
MFH+O7M)L-3M]-NM1MHKZY&8;=I!O<9QD#KC/>@#CI+:*PUSQ3I^J6,C:?>V,
M$6G!(6=7A6(JT*X!PP?)V]3NR*I:'H!_X2G0[;Q!8)=W$?AM8;F2>#S$,X=#
MM9B"I8 'J<]:]%T[4K/5["*_T^YCN;68$QRQG*M@D''X@U:H \GTR:\TSQ7?
MZA=6=Q=:-+K<RB(6SEX)&5-ERHQ\Z':RYQ\O4=37JZL&4,#D$9!J&TO;:^25
MK6=)5BE>%RASM=3AE/N#Q3(M2LI]1N-/BN8WO+95>:$'YD#?=)'O@T <)XGL
M+B_;6=0TN*1M7TB]AO[(>6P\[9$JO&#CY@R[UP.^*9/:W$'C;P;=W5O+]IED
MO;F^=(V987DA"HK,!@8 5 3UVUZ14-U=6]E;/<W=Q%;P(,O+*X15'N3P* /-
MM"BCNKZWTK6K;5SK>GZK)=(! 5A;,C$3"8+@H4;D%N?NXZ5G02RGPYH&GW^G
MWIURP\0Q37W^AR.<^<S-*&"D%2ISD'I]*]6L-3L-5M_/TZ]MKR$';YEO*LBY
M],@FK5 'E.I6]Y%+XOFL-.N)85UFRNY+:*$@W4")#YH08P^2K9 ZX([UIZK?
M:5<6+:SINB74B76HVCSW4EK.NUT/$QBX9@FU1P,$D=<&O0R<=:JKJ5D^J2:8
MMS&;Z.(3/ #\RH3@-CTS0!Y7*EQ_PB?B.V^S:@\C>)8;A/,LW5I(S+ Y< *.
MRL3@<=\5ZZ"&4$'(/(I:* . \6:5+KEWK*Z>'75+*"TN]/E*$#[1$TS;0>AR
M#M/L]4+^.[DU+PAJE[9S1WMUJGVV[C6-G^RQF!T16('RA05!S_$6/>O2Y98X
M(GEFD6.- 69W. H'4DGI5>PU33]5@,^G7UM>1 [2]O*LB@^F5)YH \ROII)-
M8MFCTV^MC:^*?-E@CLY7RI#KYY<@YWY& I  .,'&:@N--ACT'7I8=,=;L>*8
MIK=DM&W^6)XB73C.W:'.1QUKUJ"ZM[I7:WGBF".8W,;AMK#JIQT(]*EH \GU
M.=Y=55HM-OK?[-XHBGEBBLY9-Z8V^>7P<AAC 7  XP:AU&72VO\ 5](U6XDB
MM3KZ:@UQ/8S,0$V$KN"&/;\NT,6X4\CBO5[V^M=-LY;R]N(K:VB7=)+*X55'
MN37.:1H6FWEJ;K3-=U"?2+MY)?LR3JT+EF)?#%=X!8MP&]: .9,4%QJ^K:'K
M=MJSS3:DMY8?9H"8IT&TQ,LRH=FS: <L, >^*HZ]I<4FC_$7RM,=IYKJ-K39
M:L6<^5%S'@9/SJW([BO5I[VTLWMHIIHXFN)/)@4G&]]I;:/?"D_A5B@#R[Q+
MI]P=>UM/#]BRF?P]&J+!"429EF9C&#C&\QDC'7YJJZ]#IFO^$O$>IZ=8ZO/>
MSZ5]E<75FT9W@Y2,1[!N<$M\R@XZ9Y%>MUGWFO:/IT_D7VJV-M-@-Y<]PB-C
MUP3F@#B;RPC/BG5(].L66&Y\,M$/*@*I)+N8JN<8W8/3KS6QX6UZRM="\,:7
M-#=PW-U9K$@DM)$4/'&NX,2!M/7&>N#BNFLK^RU* SV-W!=1!MID@D#KGTR#
MUY%/DMHI9XIG3<\63'DG"DC&<=,X)&>N"?6@"0D $GH*\?N[9KCP)XW@:QN'
MEFU^2>WC-LY:13)'AT&,D8#<CT->PU5.IV0U5=+-S&+YH3<"#/S&,';NQZ9X
MH \T\26%RNK>)TT'3G*2Z58L(H(2B7'ESNTL8XP6,1VXZX8"NIL-;T,IJ'B2
MTTV_C4P1+<S&SE1Y-I(5%C(RQ7<<D#'/4XXZRB@ !R,UY5X[:6>3Q1:P:=>1
MS^59NKPVLDIO C!MP;!553)&!@Y&<]J]5HH \IUO3K:]N/B)-_9;N]SI47V4
MM:-NDD\J3(3*Y+;BF<<YQFIA=20ZAK<>KVEU+'J.BP1V$GV9Y58+$PDB. =K
M;SD@XSD>E>H4=* ,+P2'3P+H$<D4L4D>G01O'+&R,K+&H(((!Z@UNT44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5QOQ% N++0],F8BQU'6(+6[ . \1#-L)]&954_7'>NRK/UK1
M;+Q!I4VG:A&7@DP<JQ5D8'*LK#D," 0: *D_A;03=Z?="PM[:>QE#6TD"B%E
M."-N5QE2#]WH?2O/]#FUC2/"NG:M;ZO(MNVNO:FP$,9B:*2]>-LDKOWY8D$,
M , 8ZY[.T\%JM_:76J:YJNK_ &)_,M8KUX]D;C@.0B+O8=BV<?6IU\'V"Z!!
MHXFN?L\%\+Y6W+N+B?S\'C&-W'3.._>@#F&\2ZA'XIM)(-6OKRUGU=K%XA8J
MEFL?S+M60KN:167E@Q!((Q5>36?$::)?>(6UR3;9:Z]HEF((O+D@%WY6'.W=
MNVG ((Z#J<D]"?A_;;HPNL:FD%O>F]LX%:/9;2%R[;?DRP)9A\V[ 8XQ5Y_!
M]A)H-WI!FN?L]U?-?.P9=P<S^=@<8QN&.F<=^] '">*[C6-;\%>,-3;5I(K:
MVNIK*.P$4?E&*-PA).W?O)!8'=CH,8K3\5>)=0T_5KZXL=6OI%L)[>,VEO8J
MUL@8IO6:4J3N(;(VL-N5X]=C4_AW9:FNIV[:MJ<&G:E*;BXL87C$9E.,N"4+
M#) .,X)[=JDU/P%::G)J2OJFHPVFH2BXEM(60()PJ@2 E"V1L4[22N1G% &!
MJ^J^(VLO&NIV^NRVR:#<.;6W2WB*N%@CD*R%E)*G)Q@@\GD\8]&63SK$2XQO
MCW8],BL1O"%G)I.NZ?+=73KK98W4I*AP6B6(E<+@<(#T/)/;BMU(5CMUA!.U
M4" GKC&* /"=-L+Z_P#@M:PKX0LWMVL\MJ:RQM-&@))E6,@$L "0-P/'X5V?
MB/Q',;:&71=>U'9'I*WL4=C8B9GW E))V=2%0A?NC:3\Q[5?M/AM'::*FBKX
MHU\Z4D9B^RB2%04/52RQ!L')Z&M"Z\"V$\[?9[R\LK.6SCL;BSMF41SPQ[@B
MDE2PP&8?*1D'% '/WOB+5OM]G>7NJ7>CV%Q:VLMK-%9+-9N[C,BSMM+)R0!\
MR#&#G-9US)K&G6/C[6].UB2T&G:E).END,;),RP0EA(64G!&  I7')R>,=4W
M@)'L4T]_$&KO8-#'!<6S-$5G1!@ _)E,J #L*YQZY-:$_A&PN-*U_3GFN!%K
M<KRW#!EW(7C6,[...$'7/.: .>N;_7-:G\37=CK4NFQ:,1%;01PQ,LL@A65F
MEWJ202X7"E>!GK78:%J)UCP]INIL@C:\M8K@H/X=Z!L?K6/J/@F"]NKV2#5=
M1L8M0C6._@MFCVW 5=F260E25PI*D9 'UK2MM+FM-<26"9X],BL%MH[0/\BL
M&X8+V(7C.>>/3D P_&NN7=CJNC:5;3:A;I>+/+--IUI]HG"QA %52K  F09.
MT],=ZR+76/$VIWGAS3);Z[TYKH:@MS,]FL<TJ1,GE2!'4A&*L,\8^8\=,=EK
M6@IJ\EI<QWMS8WUFS-!=6VPLH8892'5E*D8X([ ]JBM?#%O;WFEW;WE[<7&G
M1SHDD\H<RF8J7+\>JC & .F,8P >>WEQK.JS>'[6XUV[66U\37%A]HBBA#2!
M(Y2DC H5W <=,').,X(O1>*M<N]8ENK5M8F$6KM9BQBTW=:FW2;RG8R[,[P
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ML = ^_<0JCYLGM@>U1:-X+TK1+[5KJ#SI3J;'S(YF#)&A9V*(,#"EI'..>M
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MJF/_ $6X+;B\9V9Y/9MPP2,<UM:1I;Z7!*LVHWE_/-(9))[IER3@#"JH"J,
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M%U<VT3NCL]N5W':P8 [E((R!D$<U!:>';VV@N8W\4:Q<&:/8CRB#,)_O)MB
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N=O\ P3HVHW\]U.+O9<R++<VR73K!.ZXP7C!P?NK]<#.:Z*B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***CGFCMH))YG5(HU+N['
M50,DF@"2BN#\&>--3UK6#;ZO:PVT.HVQU#2=BD,T D*[7R>7V^6W'9_:NBF\
M4Z9!INLW[O)Y&D2/%=D(<AE17.!WX84 ;5%<G;^.;9O$NMZ;<VMQ;6FE0)-)
M=R1D( 5=F+'L,*,>O-7--\8Z=J5T+;R+ZTF>!KF%;NV:+SXUQEDSUQD9'!Y'
M% '045R$'Q)T&X6R>./43%?1[K.3[&^VX;&?+3CEO;IP>>*M)XYTJ73ENHX;
MYYFNVLA9+;,;CSE!9D*=L*-V<XQWH Z6BN-U/X@VMK;Z'<65C>7<>I7C6K*L
M#;XB@?>I7KO#(1M]B>U68/%%C:WOB62\U662#3)(A+$UL%%ON0$*I7F0L2/?
M)P* .IHK(T;Q'9ZW-<V\45U;75MM,MM=PF*15;.UL'J#@\CT-4?"FO7FIW&L
M:7JJQ)J>EW9B<1*562%OFBD ).,J?7J#0!TM%<9IWC4S/K>I70']C07RZ?IR
MP1,\US*/E? !^;+G"X'\))K0_P"$UTO[$LRPWS7#7)M/L2VS&X$H7>5*?[GS
M9Z8YS0!T=%<?-X^M_P"W="L+73[Z6/5%F)<V[!HC&=I4@]"K?>]!@]Z6T\9:
M=9VFJW5[J<]S#!K+Z?G[+M,+\ 1 +RX!/WNIS0!U]%<W'XXTC[%J=S<B[LSI
MNS[3#<V[)( _W,+_ !;CP,=^*=9^,]-O+FZM!!?PWEK:F[FMIK5ED6,>B]R>
MV,Y^M '145#:7*7EG!=1K(J31K(JR*58 C."#R#STKFG\2WD?Q+N- ,2/8Q:
M(-0&Q"96D\TI@<\C Z8ZT =717 _#[Q/JOB?4M9N+U[I+:&[F@M[=K,1QQJC
M@#+]3)Z@FG:;J7BO7;O5WM=9T>RM[/4I[..*;3WE8JAP"6\Y?7TH [RBN=NO
M$T6AO8Z;J32WNJW%N\J+8VK'SMA4-M7)Q]X'D],\U7L_B%H=\]CY O?)O)A;
MI<-:NL:3'I$S$</D8QZ\9H ZJBN5B^(.B2S(JK>B!KHV;71M6$,<V\H$9^@)
M;'/3D<C-4M.\726^O^-?[8NU73-'FMUAQ&,HKQ@D<#+$L1@<G)P* .WHKF#X
M[TJ*UOYKN#4+1[& 7,T%Q:LDGDDX\P#NH.<XZ8YK3O\ Q!IVFSV$-Q-\U\7\
MDJ,C:J%V<GLH49S[B@#4HKG;#QMH]\)&8W5I&MJUXDEW T2RP+C=(A/51D9[
M\CCFK&C>*+'6[E[:*&\MYQ$)UCN[=HFDB)P'7/49_$9&0,T ;5%<Q-XEL]/\
M1ZU%=ZI+Y-A91W$MK]F&V)3GYE8?,Y.,;?RK3T?7;?63.D=O>6TT!7S(;N Q
M. PRIP>H.#T]#0!J45SUIXSTJ\NVA474<.)3'=S6[)!+Y>=^USP<8/ID D9J
M*W\=:1/;75PR7MND%F]^OVBV:,S6ZC+21Y^\.1QP?F''- '345SNF^-=)U._
MAM(UNX3<0M/:RW-NT<=PBX+&-CUP"#]#D9'-)I_C?2=29A&E["IMGO(7N+9H
MQ<0KC+QYZCYE]#\PXH Z.BN7MO'VD7>DKJ4$&H26TK11VY%HV;EW!(6,?Q$8
M.>PP>:J:I\0[6TL]+N;2PO;C[9J'V&2+[.PDA<9W*R_W^.!WZ]* .SHKGI/&
M>E1:F;)EN]JSI;2W(MV,$4SXVQL_0-\RCT!8 D&L7Q=X^BL-'U4:5]J%S9RK
M;_;/LI:!9MRADW$8S@X],\9SQ0!W=%9>N:_8>';6"XU!I%CGG6WC\N,NS.P)
M  ')SC''?%9\7C?27M;F65;NVDM;B&VGM[B I+&TK!8R5_NDL.1[^E '245B
M:OXKTO1)+Y+UY5-C9K>S;4)Q$S,@(]3E3Q51O'&G>5"T=EJLSSF0PQ1V3EY(
MTVYE"_W/G7![YXH Z:BLK3_$6G:I=26]I*[LEK#=DE" 8Y=VP\]_D/':LR7Q
M]HZ6%G>11WUS'=6GVT"WM6=HX/[[@=!^O!XXH ZBBN>O?&>EVEY%9Q)>7MS+
M:+>116=NTK/"Q(##';COZCN16?\ \)_:7&NZ!96%I=75KJ]N]PMPD+84 J!^
M18[L_=X]: .QHKFM7\6?V7XPTC01I]U-]OCD<S1Q%@FTJ!^6[+>@QZT1>.='
MFO8H%%X+>:Y-I%?&W86\DV2NP/\ [P(!Z$C - '2T5E:SX@M=%DMX98+NYN;
MG<8K>T@,KLJXW-@= ,K^8JA=^.-(MHH)$6]N5DM1>/\ 9[5W,,!S\\@QE1P>
M.ORGC@T =)17.ZGXVTC3)-A^U706W6ZF>SMVF6&%LXD<KT!P2.^ 3BJEMXUB
MOO%.HZ/#:W(@MK*.X6]6(LAWASNSTVX5=I[G(H ZVBN1TWQE8Q^&M&NGNKS5
M;C448V_DVF)KC;]YO+7A0!C)X'3UJRWCK1%L;.ZWW)^UW#VB0BW8RB= Q:-D
MQD-\I&/7'KF@#I:*YE/'.E26)G6&_-P+LV7V'[,WVCS@F_;L_P!SYLYQCO6U
MI>I6^KZ?'>6PE6-RRE)8RCHRDJRLIY!!!% %RBN.T;Q;=ZSXZN].BAB&C):.
M]O/@[YW20([ YQLR2H]=I/0BFZ5XOWZ+>^)M1F<:7<77D:;;0Q;G=0_EJ0 -
MS/(V2!T Q[F@#LZ*X)/$>LZYJWB.TT>26VFL+*UFM[:[M@K"8F4LC@C.'"J,
M@\ Y!KJ=&UZTUCPS::ZC"*UGMQ<-O/\ JQC+ GVY!^E &I17.Z5XSTO5KVVM
M8XKV WB-)9R7-LT:7*@9)0GKQS@X..<5+X=\6:=XI1I=,CNVMU4'SY(&2-CG
M!4,>"1W Z4 ;M%<=XD\6W>G^)=)TG388I5>[ACU"60$B))20B+@_?.&;V"^X
MJTFNSW7B_4K=;A+?2-$MU-X[ ?O9G7?C)Z*B88XP26'8<@'3T5S-OXEB\1V]
MQ8Z5+=Z=J$EL;BTDN[0KO3( D4,/F7)7(X.&'3(J[X5UP^(?#MMJ$D0AN#NB
MN80?]7,C%'7Z!E./;% &S17-6?CG1[Z\MH8EO%@NY3#:WDENRP7#C/RH_?.T
MXZ XXS6'X2\5:IXB\;:W%-]M@T^SF\B&U:R"J,("3)(?F#Y/"^E 'H-%>=:[
M\0;I++Q=#96EQ:3Z+L$=U+#\A)V$YSQ_%QZCFNBM_&VCRRWD<_VJR^RVIO&:
M\MVB#P X,BY'('Y\CB@#HZ*Q]'\26>LW$MM'#>6MS'&LI@O(&B=HVR X!ZC(
M(]CUQ6 VI^)M3\6Z]IVG:II5C:Z:\"(+BR:9WWQ*Y.1*O<GM0!V]%>?>,O$O
MB7PEX?TJ:)[#4[^>\9)C';M&LD2QR2$(N\D-A,9R>>U:WBOQ;_9G@R/5](\N
MXN;X1KIZN"5D:09!..P7<Q]E- '5T5Y]:>(_$>MCPM!876GV<^IZ,VHW$DUH
MTR[AY0VJHD7 _>'J3TJ/5/&NMZ3X8UUYTL9-5TC4+>T:6*-A#,LIB(8*6RIV
MR8(R<$4 >BT4UW6-&=R%5022>PKB-,U'QCXHTQ==TRZTK3K*?+V5I<VCRO+'
MGY6D<.-NX<X4' (ZT =S17!R>-=2;PQ9>)(K%!;6MQ)#K=E@O+ $8H[1D'G8
MPW8QROI6E+XFGU/Q38Z1X?:WG@2-;O4;LC>D<+#,:+@CYWZCT49P<T =517"
M>$_&M_JWC/7=$U**!(H)YET^2-2#(L4FQU;).6&Z,\=FI8/&E]=_%7_A'K>*
M Z0D4L;3%27:XC5&< YQ@"51TZ@T =U17GWAS4?&/B/0K?55UW1+59R^(6TU
MW*!79>3YPST]*DU?QIJ.A>/(--O([=]$6S@:\N50J\,LLDB*YYP(]R 'TW Y
MH [VBN8O-5U6?QA>:#836MOMTN.[BFFA,FV1I64Y 9<C"],CGO6+I]]XWOO%
M&LZ+_;6BH=,2W<R_V7(?,\U6/3SN,;?4YS0!Z#145S<PV5I-=7,BQPPQM)(Y
MZ*H&2?R%<5X)\8ZKK6IO::W:PVIO;4:EIBQJ06MBY7:^2<N!L)QC[_2@#NJ*
MXR/5/$?B75-3CT.[L=-T[3[EK3S[BV:XDN)E WX4.H503CN20>E-UG7?$^C^
M"I;J\@L(=72]AM4E0&2"1'F1!($W!APQ^4G@CK0!VM%<5=ZIXG\.:EI']JWN
MEZC9ZA>I9%;>T>WEC9P<,,R.& QR..*@T_4O%>N7NLM::QH]E;V6HS6<<4VG
MO*Y5,8)83+Z^E '>45Q.JZGXEAU[1-#M=3TN.>YLY[BXNY;)F1FC:,#:GFC:
M#O\ [QZ4[6M3\1^&O!FN:O=ZEIE_<6T DMQ#9M$JD'G</,;=G(Z8Z4 =I17+
MZ)XM2X\$3:WJH2">P25-0C3@1RQ9#@ ^N,@>C"N4T_QUXFO/!1OKB.PM-5;7
M8M,PT+-'"KL@^9=P)*[SW'2@#U.BN?TNW\2I?HVHZYI5W:@'?%;Z>T3GCC#&
M5L<X[5B_#WQK>^(TDM=:AA@OV4W-J800D]OO*9&2?F5@0P]U/>@#NJ*X;3M5
M\4:]X1MM9LM0TVSD'VCSDEL7E#[)75<8D7;PO/7FK/@:^\2ZWH^G:WJFH:<]
MK>VPF^S6]DT;H6&1\YD(./\ =H ["BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N3\?V>I:SHL
M&@:=',%U6X6WN[F,<6]MUD;/3) V@=]U=95#5-.TR_2(ZG#%(J-MC,IP S$
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M-G#@LV<CC Y]*S[*PU2;4=-O'T_Q#*[:7=6MU-J#NV+ET0X5"<(N4(W* I)
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M:(:7')';*') $F-V<_>)QG)YSFK>G:5:Z5]K^RJP^UW+W4NYLY=L9QZ#@<4
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M$;MJ[1M].*R/%/AN;Q"VC^'1I1_L>TGBN)KZ65<;(P1Y2J#N+,/E)( P3U-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEBTI-*V:/'%.@N(Y"TRM&7*<, #QC=T]N<@ [47UH;XV(NH3=B/S3 )!O"9
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M 3O4'[PX(XZ'@XHL/&VD7][';+]J@$T#7,$UQ;M'%/&N"S(QX( (/T.1D<T
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M]OIUW%%;*$ VJT88C(Z\^M1:CXNDTGQW=:9-%=W5NNF0W,5M9VQEDW&20.W
MSC"J.3Z8Y- &SJWAV#6-3TR_ENKJ*7393- L10+N*E23E23P2*DO]"AO]:TW
M5'N+B.;3_,\E(RNP[QM;=E23Q[U1E\;:0MI87%K]JOQ?0&XACL[=I7\H8RY4
M#*@$@<\YXQFMJROK;4=/@O[299;6>,2QR#HRD9!_*@#FI?A]ISV4,,=_J4-Q
M!>2WL%Y#*JS122DF0 A<;6).00171Z=8)IUFMNDLTQ!)>:=]TDC'JS'U_0<
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M,+&&=E8094J,$*"2%)4%B< TOC'Q'_PBGAJYU86LERT9551%)&6. 6QT'O\
M2HKOQII]I(D)M-2EN3 +F6WALW>2",D@-(!]W.#@=3@\4 1Z%9?VCX@N?%%S
MH\^FW,MJEFD5R5\TJK,S,P5B.20!SG"^A%/L/!5CINJS7=K?:BEK+.;DZ=YX
M^S+*3N+!<9'S?-C.,\XK:M=0MK[3(M1LY/M%K-$)HGC&=ZD9&!_2N!/Q'EO-
M)TS4H[6YLH7UPV4P>V+&6(&8 (,$ESY:Y"\@G% '2:1X*L=%OFEM+[4?L?FM
M-'ISS@VT+L2257&<9)(!) /(&<5LZC8_VA;I&+J>V9)%D66 J&!!S_$""#T(
M(Z5C1^-](>PN[F1;R"2TG2WEM);9A/YCXV*$ZL6R,8_H:T]'UJUUN":2V6:.
M2"4PSP3QF.2)\ X93[$$=B"* %TG1[;1X[D6Y=GNKAKF>1\9>1@ 3@  <*!P
M.WKS7-7GAB[U+Q_J=_\ :]0T^%]-MX([JSD52Y#RET^8,.A0YQD=B.:IZMXL
MU-OBE9>'+4WEM91VPN)VCL?,,Q\T+U/W8\'EQT.:W;'QQH^H7EM!$+M8;N1H
MK2[DMF6"X< G".1@Y"G'3..,T -?P1I\<%A'IMW?:6]E;?9(Y;.50[0\':VY
M6!Y&<XR"20>:OV?ANQL=6M]2A:?SH+ :>@>3</*#!LDGDMD=2:\_OO&^O0>#
M/%6HQW2"ZT_Q&UA;MY2X6$2QKMQC!X8\GFNWU7QCIFD7L]I)'>W$EM$)KHVE
MLTHMT.<,Y XR 3CDX&<4 *?!VDN->69)98]<8-=H[\9"A1MP 1P ?K45OX,M
M$>ZEO-0U'4;B>T:R$]W*I:*%OO*FU0,G@DD$G R:M)XJTB0:@RW.8["UCO)I
M-ORF%U9E=3W&%;\J@?QAI,NC:=?17$JQZIN2U(B)8,$9F)7MM"-G/IB@"P_A
MFP?3=&L"TWDZ1)#);G<,DQ*57=QSP>>E)<>%["Y77@[3XUR,1W6&' $?E_+Q
MQ\OKGFLK3_&NG0Z#H<L]Y=ZC/J<+O;/'9D27)3&?W:]#R./0$] :M#QSH[:9
M!>(+QY)[EK1+-;9C<&9<[T,?4%0"3G@#O0!6N_AWI=Y'>0->ZDEI>!3-:QS!
M8VD5%19?NYW (IZ[<J#BM-?"]D(=91YKF1M8C6.[=V7<<1"+(P  2HSTZ_E4
MVA^(M/\ $*7;6#2G[)-]GF66(QLDFU6*D'G(W 'WR*I:IXUTC2+^:UN?M3"V
M"&[GBMV>*U#?=\Q@,+QS[#DX% %>]\!:==\1WNHVB26L=G=);3!1=1("%$GR
MGG!(RNTX.,U-<>"[&6]>>WO-0LH9A&+BUM)@D4_E@*N[@L/E55.TKD  T:CX
MXT?3;NZAE%W)'9E1>7,-LSPVQ(!&]P,#@@G&< \XIVI>--+TR^N;(Q7MS<VT
M*7$L=I;-*1&V</QQCY3^E &[=6Z7=I-;2$A)D:-MO7!&#BN;TSP'IVFS:<?M
MFH7-MIL92SM;F56BA)386&%!)VDCDD#)P!4\_C72(GLUA^U7ANK5;U?LEN\N
MR ])&P. ?SX/'%87A_Q9-?6/@^6^U5Q<ZHMRQABM59;K8"?O#[F  1CKTH T
M+?X=Z;;BP!U'595T\&.U5YUQ%"5*&(84?*5.,_>X'S<5,G@33WBGCU"^U'4O
M-M3:(UW,"T,1*L0A55.<JAW')RHYK(7Q^FI>&;W46:\T9;?4OLJSM9^9O'G%
M  &XR<8;^[FM[5/&FE:3>W-M*E[,;-%DO)+:V>5+52,@R$#CCG R<<]* &-X
M+M+G3+ZRU'4=3U#[8L:M-<3C?&$.Y-FU0JD-SG&2>N:FTGPG;:5K$FKM?W]]
MJ$EN+9YKN16)0-N PJ@#!] .I[G-1W_C;2;&[EM%2\O)XK=+IDL[=I?W3YP^
M1QCY3^8]:;<>.M%A2"2,W=U#):QWC2VUL\BPP/G:[D#Y0=K>_P IXH O:_X=
MM/$45FEU+<1&SN1=0O;R;&60*R@YP>FXGZ@=N*H+X&TUM/OK>YN;VZN+V>.Y
MEOI90)Q)'CRV4J %V[1@ 8Z]<FMV^O[;3=.N-0NY1':V\9EDDP3A0,D\=:Q$
M\;Z3_9^I7=Q'>VG]G1+/<0W5LT<BQMG:X4]0=K?D: &'P-I\UEJ,-[>7][/J
M*QI<7<\B^:4C.Y%7:H50#DX"]SFM#4/#>GZIJ$UW=K([36$FGR1[L*T,A!;W
MSQUS52V\:Z/<7-S#(;FU\BU:\WW5NT2R0+]Z1"1RHR/?D5F0^-#J?BW0+&RC
MN[>VO(;B62.[M3&9455*,I8=.3TYZ9'2@"S;^ -/CD@DNM1U6^D@MI;2)KBX
M&4B=0I4;57!P!\WWO4G QI:1X;BTJ^DO9-1O]0NWB$"S7LBL4C!SM&U5'7DD
MY)P.:J^*_%8\,S:1']@N;HZA=BW_ ',1?:-I8XQU;C@=^?2I'\9:5'JIL&%U
M@3K:O<BW;R$G;&(R_0-R!Z9(&<\4 6?$OARQ\5:+)I6H&98'96WP/M=2#G@X
M..X^A-13>$]+F\2:=KI61;JPA,$**V(]N& R,<D!W ]-QJLOCG1WN-3BC6\<
M:8)C>2K;,8XC$"6!;ID@' ZG\J@3XAZ+)/% D.I-)<1>=9J+)_\ 2U&,F+CY
ML9!/MSTYH ?<^ ='NM%UW2I'NOL^MW9N[HB0;@Y*GY3C@?(.N:TT\/62>*3X
MB#3?;38BPQN&SRP^_IC.<]\UGKXZTB6PL[FVBOKE[LRA+:"U=IE\IMLFY.J[
M6(!SW(QG-;]E>0:C8P7MJY>">,21L5()4C(X/(^AH HZ_H%GXCL8K2]:=8XI
MTN%,+[&#H<KSVY]*SD\#Z<UMJ27MW?7UQJ'EB6[N)5$JB,YCV%%4+M;YA@=>
M3FNFKD_&OB#5=+%AIGAZ&WGUN_:1H8[A246.-"SL<$=]JCGJPH V-'T4:3]H
M=]0OK^><J7FO) QP!@ !0JJ.O0#.><U!K?AFVUO4+"_>[O+6\L%E%M-:R!2G
MF;0QP00>%Q@@CD\5DZCXW"_#"3Q9I]O)*[V331QB,N(Y IR'QT"L""?:LGP[
MXZO1<>']-U&WU*\N=4A>=[A[#R0F G"A1@H"QRW88H WE\"6$5K:I;W^HP7=
MO<2W/VZ.53/(\HQ(7)4J=PQV&,#&,4V#P%:64873M7U>QQ++(IAG4[1(077Y
MU((+#=ELD$G!&:N6'C'2M1U*.R@^T@3N\=O</ RPW#)G<(W/#$88^X!(SBG>
M'O%FG>*%>33$NW@5<^?);LD9.<%0QX+#N!TH IOX$T](X$L+[4M.,=J+.1[2
M<!IX@20'+*><LQW##?,>:EO?!5A=WS745YJ%GYMLEK<QVTX"W,2YVA\@G(!(
MW @X/6H;OQ>8O&5SX<2QNMT=A]I^TB(E03G'/3;QC/KQ5/PAX[M]6TOP_#?_
M &K[=J%JA%RUJ4@FF$>YU5L8R,-QTX..E '4Z/I=OHFC66EVI<V]I"L,9D.6
MVJ,#)]:Q+_P+IU_<WK->7\-G?R"6]L(90L%PP !+#;N&0H!VL,XYJSIOC'2M
M5U"*TM_M(\_?]FGD@9(KG9][RV/#8Z^X&1D5E_$KQ1?>&/#T4FFQR_:[FXC@
M29;<RK$&=021TW8/ /4T ;A\.6/FZS)F4'5HUCN && %C\L;>../K5^PLXM.
MTZUL8"QBMHDA0L<G:H &?? KE=.\1K;ZI/!?:M>2O:Z0+V:VGL%B8*&;,A(_
MB.,;/;-6H?'FDW&GQ7L$&HRQ3R+%:A+-]URQ4M^[&/F "MD]!CK0 J^!=.6Y
MNI!=W_DW&HIJ9MC(OEI.KA]R_+G!91D9/MBK6I>$M-U6ZO[BY,_F7L$,+E)-
MNSRG9XW0XR&#-G/L*S)?'UL==T.PM;"^FCU-9B7^S.#$8SM*D$<$-G=GH,'O
M6AXP\3?\(KI$5Z+.:Z:6ZAMU2-"V-[JI)Q[$X]3@=Z +NCZ,-)$[-J%]?3SL
M#)->2!FX&  %"JH^@'7G-8?B/P_=:OXUT*ZBDN[:&UM+L&[MF4-%(QBVCY@0
M<@/P01^E7SXRTE-)U/49C<0QZ8RI=1R0D2(S*K ;>I)#K^/%/NO&&BV4-E/<
M7>R&\M)+V.3:2HA158N?08=<>I.* (;3P7IEI'IH62Z>2PO)+X2R2 O-,X8,
MTAQSG>>F.WI2ZKX.M-3O[F\2_P!0L7O(EAO%LY55;A!D#=E200"1E<''>IM)
M\56&KW_V%8;VTNC#Y\<5Y;-"TD>0"RYZ@$C(ZC(R*NW&L6=KK5GI,S,MU>QR
M/!E?E?9C<,^N"#CTS0!F:WX)T77=*T[3;F*2*UT]E,"0/MP@4IY9ZY0J<$=Z
MN7_AVQU'7M,UB<R_:=-29(55@$(E4*VX8YX''(JI=^,])M+RZLQ]IGNK>X2V
M\FW@+M)*R>9M3'7"<GL.](_C32AI]I=0I>7#W4CQ16L-LS3[TSYBLG52N#G.
M/U% $,'@:RC#K<:EJ=Y&+66T@2YF5OL\<@ 8*0H). !EBQXIW_"$6$5EI4-E
M>W]C/I=M]EM[JWD7S3%@ HVY2K [5/(X(R,47/CS1+:TTRX#74_]IK(UI%!;
M.\DA3 9=@&0P)QCV/H:FC\8:;+JBV"Q7P)F%N9S:OY*S$ ^67Q@-R!Z9XSF@
M!UGX0TNP_LGR//W:9++/&S2;C))*K!VD)&6)WL>W/Y5'/X/M7FNKBVU#4;*Z
MN+PWC3VTJ@JYC6,@!E*E2J#@@\\UIZQK-GH=A]KO7<(76)$C0N\CL<*BJ.22
M>U<_JGCJWA\+ZY?V5K>?;],A9I+2>V97B8H61G7^X<9W XP#SQ0!T.CZ3;Z+
MIJ65LTKJ'>1I)6W/([L6=F/<EF)_&KU<SX"U'4-6\*6M]J5Q<3W,ZK(S36H@
MQN13A /O)DG#=ZZ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N3\=V]Y+#H4]E837IM-7AN)8H0"
MPC57R1GCC/'OBNLHH \JU?2-2\07NLZ[!IVIV]O]IT\Q0X,%S,D#.9&0'!!
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MEF/H!R: /(OL'BK_ (1S_A*_[)N?^$E^U8^RX^?R_LWV?'TW_O/UK=T[39O
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ML2))&Q8^VWSU_P"!"KMGX?U/_A*M6@FLI5TW38[V73I,?+*]WM<A?]W]XO\
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M9+8W #D Q N1CT.7;GZ4 6]&M?L>CVD'GSS[8Q^\G?<YSSR?QQ6'XWN+Z)=
MM[&^ELVN]6CMY9(L;O+,<A8#.1V&/<"KMAX>?3M3L)H[^[FM[6SEMB+F<NTA
M9T96/8[0K#/7! J_J.E6NJ/9/<AB;*Y6ZAVMC#A649]1AC0!YY=ZEJVEWNJ>
M'H-7O&C?5K"TANYW$DT$<Z;I &(Y/RD G.-U'B/4=5\,Q>*=,M-6O)TAT>/4
M+6:XDWR02&1T8;NI!V@\].:[6]\):3J#:D]Q'*7U!H9)660JR/$!Y;(1RK#
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MRO)E8TE9690/0%1CTH Y?4?$6J:&GBG16N))M3:6-]&>0_,RW)V(!ZB.3=^
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MHF@/J$SWEC<WIU&;/S2QP96/=_O^;"WX5V6L>&]-UV]TR[OHG>73IQ/;E6(
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MD@  #J2*Q+G2KY_BS8:LMNQL(]'E@>;(P)#*I"^O0&E\90W\M[I/EV^J7.E
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M/=($,=PWE!SDDDA.<@C!..:TV\=Z6MTR_9K\V*W7V-M2$(^S";=LV[LYQO\
MEW8VY[UR>GZ1K%S:?#A7T>[MVT63R;T3!1LVVX3>,$Y4G@']*>VD:S_PB4O@
MD:1=&1[]BNH93[/Y!N?.\PMNSN"G&W&=WMS0!TM[\0=*L9+\/::C)#IUQY%[
M<1P QVYX^9CGD?,#P"0.2!Q6_J^K6FB:5/J-](4MX0"Q52Q))   ')))  ]3
M7$:AH&J2^#?'UG'9NUQJ-Y/):H",RJT4:@CGN5(Y]*Z'QII=YJGA<Q6$0FN[
M>XM[J.$L%\TQ2JY3)X!(4@9XSB@ @\:::1?"_@O-+ELK;[7+%?1A6\GGYUVE
M@1D8P#D'C'-1Q>.]+\F\DOK:_P!--K;"Z,=[!M9XB<!E )SS@8^]D@8YKFM?
MT75O&MQJMW!IMSIZ#1GLK=;[:C33-*LF, G"CRP,G^\?2K^N2Z_XOT"_LK?P
M_<6*QQ0S(+UT5YKA)5D\I0"1MPF-QP,D>] &J/'>G1P73WEEJ-C-;& O;W,
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MHQVT&E+!N::)Y1&#YF[/F$'=@# QCGDUJ^"XM3ATZ[6_-_\ 9_M1^PC47#7
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MPM;7>@V6IV_VV]AMXKU[5""C,OSH&.#N!PN1@X/L:K_V!)?:+K!@T#78;_\
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M9D/VA_F...>M94NC_P!K^/O%X.J7UD(;2S9/L=PT)#E),.Q7!.,< \<G(/%
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MVVF6$9CM+9/+B0L6('U/)KEK?XC1W/\ 9;)X?U7R]6A\S3F_=?Z0P4,5QO\
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M'!W$#G)QTJU9>-([C48K6YTC4+-+FUDN[.654;[1&FTMA58L&PRD*0"<^O%
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MH3;1LV S L<[VVKD]?49V-5\:1:=$UW#I-_>:=%:I>7%["JK''$V2"-S N0
M6(4' ]SB@#0TSPSIVDSVUQ ;F2>WMFM8Y;BX>5O*9@Q4EB<\J,>@&*K2^"]'
M>TMX(EN;8VTDTL,UM<O'*AE8O( X.<,3G'3@>@I'\5YUJ:QM=(O[NWMIX[>Y
MNX A6)W56'R[MY #J20" #['$4/C2";4(H_[.O%TZ:[:QBU$[/*>925QC=NV
MEE*AL8)'N#0!O:?I]KI6GP6-G%Y5O NQ$R3@>Y/)/N>36'=^ ]"O9[F6:.ZQ
M<3"Y,:W<BI'-D'S44-A7R!\PYZ^IS@:WXWN+RSL)=,LK^WLI]9MK2+4,ILG
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M&?.\QQD[5)R>@[G&,U)I/A#2=%O$N;1;DM%&T5O'-<R2);H2"5C5B0HX'3L
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M+6:X)4QM$BL=@R&RV$.#T/:OX@T46W@GQ+>?\(NVCN-,,(EGO?/=R6!8* S
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M(YQVK6HH \NT?PSJMMK%A>KX<EM!_9EQ973S7J2S/,XC/F,=YRI*$#!W9.2
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M4GY<[A\O%:UKX?(T_59(_ Z1B:**$VE[?"62Y0-EQG<R* .5RPR>NWK7H-%
M'+^"M.O].M[])[>[L[%YPUE9W=T+B2!-@##<&; +9(7<<?CBLB3P=>W/CZ\,
M\"GPY.);S.\<W,D*V[+MZ_<WMGIEJ[^B@#R"?P1XFO?AOK%K>6J2:[>36<:H
M)DPT-N8E!W9QSMD?&?XL5U5UX?U*7XCZGJZ0 V4^@?8HY-Z\S>8S;<9ST(YZ
M5VM% '-^ -)O-#\!Z/IFH1"*[MH DJ!@VTY/<9!KI*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.,CY2,@X&0<@XZ4 >;:?YL?A'PSXL6]O'UN_U&V%RS7+E9A++L>+RR=H4 D
M <;!75?$.W^UVWA^W,LD0DUNV4O$Q5@"'S@CD''<<CM6K;^#M M=4748=/"W
M"RM,@\US&DC9RZQD[%8Y/( /)K2O-.M-0^S_ &J$2_9IEN(LDC;(N<-Q]30!
MYM<^5I.H>(] ADU-[22ZT]+6UAO&#F24,702N241MGS8.<9QR:II<:CIFFZO
M>H9[>/PYK4,[6BWCW 6V:&/SH]YY8 .SX/0CVKTB_P##&C:FUV]W9!WNFB:5
MUD=&+1YV$,I!4C)P1@\TEGX6T6P2\2VL51+R(17*[V(E7!'S GDD$Y;J>Y-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7,FKQ:NOVJX+G>]LL0N&R?0EA'^E8=QJ-YJ?@'2)[ZZEN)5\8QQAY6+$*L[
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M C,0B^Z,*W! W97.:W_!D=[J.M^(-1O-5OI5M-6N;2WM3,?)2,;3RO<\\9Z
M<=\@';T5R6MZG/X?\:Z9>7-VZZ-?P26DJNW[N&= 9$?VW*'4_1:XVVU+7M1N
M--CNDUZYCU*WN-6-OIMTD,D:O(JPIN=TPB(0=H/+-R* /7Z*\NNKK6KFPTZP
MU$Z__:\&GR37%O87,4!0;RL<TT@D"DD)]P$C.[(XIVE7>J>)]?\ #<-SJ][;
MP7'AJ+4+E+64Q^;-O3GCH#NYQUQCIF@#T^L_5];TS0K9;C4[R.VC=PB;^2[>
MB@<D^PKC]%DU"P\710:Y<:S#>7-Q<")VF$MC>)\S(B ']TRH <84G:>375:O
M%$\]O+;QV,NM0I(U@MW(4ZX#D8!.,8R0#U'K0!;TS5+'6;%+W3KJ*YMGR%DC
M.1D'!'L0>U6ZX[X>[UM=;CNU":H-5E>_C0?NUE948>7ZKL*<GDG.0*P-?U:\
MBUFYU+3Y]:E2UU:VM&F\]([*,&2))(O*+YDSN;+;20QX.%H ]0JO?WUOIFG7
M5_=OLMK6)YI7 )VHH))P.3P#7E^JS:I_8'B_7EUO4DN-)U.46<4<Y6)%0H=K
M+T<')&#D =,<Y?XA2ZUO0?B%J$^JWL']G"XM+>VCF*PB-+96.Y.C%R[<G)&1
MC&* /4H94G@CFC.8Y%#*<8R",BJXU2Q.KG2A=1F_$'V@VX/SB/.W=CTSQ5$Z
MG%HW@Y-2G21XK6R65DC7+-A < >IZ5Y[X1U73'^(]I<RW\<^JZEIL[73*C8$
MS2Q%8E)'W41=H_W<]30!ZW6=K>NZ=X>L5O-3G,43R+"FV-G9W;[JJJ@EB?0"
ML?QG<'.F:?%)JC374S$6NF2+%+.JH209"R[%!*DD$$\#O7GFKK<ZSX:\)2W]
MWJ GB\5BP^:Y^<(L\JJ6*G!D4*!O'OSS0![):7UO>QJ\+G)C60QNI21 PRNY
M#AE/L0#P:L5X_=+<>'-3\?WUA?:C)<VD5G%"9;DR',B ;B&.&*[B1NX%3:O=
M>)-&\+^)9X8==L;--/62";4[R.:5+@/AMC)(Y 92.#P".,9H ]:JD-8TYM9.
MCK>PMJ*P^>UL&RZQY W$=ADC\Z9H^G-IEAY,E]=7DCL9'FN9-[%CC..RKZ*.
M!7-_8;6R^+5B;:WCB,^DWDTI1<%W,T&6)[F@#:O/%N@:?J7]G76J6\5T"JLC
M$X0M]T,W12<C )&<UM5Y!K4>HS:+XZ:P2V;P\U[*U\92?M641!<>5_">%^7=
M@YS[5W?C*_DMOAUK-_83R12)ITDL$J$AE.PD$'L: .DHKS@:9?'QEINEOX@U
MAK;4-+DNKL"Z8%I$>, H1S&#YAR$P. *H^&KW4O$ESH^B7VK7ZV\-I>S2RPS
MF*:Y:*Z\E-TBX;A>3@C)(S0!ZK3)9HH%#32I&K,$!=@ 6)P!SW)( %>76^H:
MM?2Z-H[ZQ>JJ:_>Z=)<I)B6>".*1E#$=6X W=<C/7FL_6;>XF#:3/JFI2P6/
MBVSMH)'NG,@CD2)\%\Y8JS':3R* /6+34[2]O+ZTMY"TUC(L5PNTC:S(K@9/
M7Y6!X]:N5Y/?:=.LOQ%O[?5M2MI=.V2V_D7!3,B643!GQ]_. ,-D=?6K^HW>
MI0ZI!JVJW&L0:;+':O;W>GR@V]N2%WK/%GD,Q/S$, ".F* /2:9+*D$3RRN$
MC12S,QP !R2:YWQS?W=EH,,=E</;2WE];61N$QNA66559AGH<$X/8FN9UBTF
MLK[7O#JZIJ4UA+H+WR^==N\D4B,5($A.[:PQE2<<'UH [?0O$&G>)+$WNF/-
M);;L++);R1!_==ZC</<<5J5R'PPLEM/AWH;K/<2>?90R$32EPA*#A0?NK["N
M;T+4/$FJ7]GJT%GKCM+J<B7#O=0_8A;"5HRJQ>9N!4 '.W<64]0: /4Z*\AD
MDUA] .LIX@U..\'B-[&,";,:0M>&+:4/RM@'()!(P!T%2ZW<ZIHUWKVDV6MZ
M@L<=SI+P33SF5X3/.4D 9LY4A1P>.OK0!Z?J.H6VDZ9=:C>2&.UM8FFE<*6V
MJHR3@<G@4^SNX;^QM[RV;?!<1K+&V",JPR#@].#7F/BA;C2(/&&B+J%[>64O
MAJ2]47DYF:*3+H<,><,,''3(.*MZ&D^NWFD:++J%]:6-IX<L[D)9W#0-+))E
M=Q9<$A0@XZ9;G- 'I5%>8Z-KVJP1^&=7O[^6:SEN;G1KQG/RNPE=8)B.@8F,
M*3_MU!#>:OK%SH-V=6OK>UU[5[EHTBE*[;-8)/+4>FX('R.<MGJ* /5:*\@N
M_P"U++PUXJOT\0:LTF@ZF8;$-=,1L'E.1)_SUSYA7YL\ 8JYJ=_XDU'6]>FT
MNSUR>ZT^]6"R^S74,=HH5(V*R(TBEMVXY)4X!&.E 'J=,6:)IGA65#*BAG0,
M-R@YP2.P.#CZ&O+=8?4Y=*\=ZNNMZE#+HUW(;&.&<JD>R"*3#*.&4D_=.1UQ
MU-:_AFS\SXH^*+MKF[++;63",SL4^=)"05Z$#L.V3B@#OJ*XKQC/)<ZS;Z=;
M2:W+,EI)<-;Z7.EOM!8!99)&=>A# +SGDD<5BZ'<ZEXKU#0HKW5K^&&X\-0W
MEPMI,83),7QNRO(ZGIC/';B@#T^J=GJ=I?W-[;VTA>6RF$$XVD;7**^.>ORL
MIX]:\[TW4M3UG2?!FEW.IWB"^FNUNKF&4QS3+;[PJ[UY&< DC!.#ZUM^ K=K
M75/%\#7,ESY>KA1+*VYR/L\. 3W(&!GJ<<T =3:ZG:7E]?64$A:>Q=4N%VD;
M2RAQSW^4@\5<KS"YTR:]\1^/[F/5[ZR>U\F2$6LYC"R"U4[GQ]X<#@\=>*H'
M6_$7B5I9+>VUQ[F+2K26W_LRXBABCGEB\PO(KR+O&2!@@C"GC)H ](O_ !+I
M>FZS::1/-*;^[&Z*"&!Y6V[MN]MH.U<G&YL"M:O*'LIC\7XKVZDOH[M?#(O9
M8([I@!(LPS'P<;,C[O0U/I\^HV>A^#_$AUF_N;S5[JV2\AEG+0.LX)*K']U-
MF005P?EYS0!ZA17DD5]K%OX-UW7_ .U=2N+S^TIM.MXA,-L4;7@C!56^7> 3
MAF/' X%=7X/368-4U"&YLM7M]*,43P?VK=1SRB7+!P&61SM(V'D\'.* .CU#
M6-.TI[6._O8;=[N98+=9&P99"<!5'<\U!K/B/2/#ZQ'5;^*V,Q/EJV2SXZD*
M,D@=SVKG_']C:F/2+\V\9N_[7T^$3%?F"?:5.T'L,G/_ .JI=8@U'3O'-MKM
MMI4VJ02:>UDT=N\8DA;S X;#LH*MT.#QM% '56MU!>VL5U:S1S6\JAXY(V#*
MZGH01U%2UQWPQ,Q\& 2QI&!?7@C1&W*J_:),!3W Y ]J[&@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH SIM#L9_$%MKDD;&^MH'@C?><!&()&.AZ5-ING0:3I\5E;&0
MPQ9V^8Y=N23R3R>35NB@ HHHH *PM9\):=KFI0ZA/-?V]W#"8%EL[R2!MA(8
MJ2A&1D _A6[6!JWBN#2]972(]-U"_OVMOM2PVB(<QAMI.690,'U/<8R3B@!D
M?@O31I]S8SW.IW<%P\3NMW?RS$&-PZ[2Q.WD#..N*U/[(L_[8FU78WVN:V6U
M=MQP8U9F Q]7;FL#3OB#INIR:6T-CJ*66IOY5M>RQ*L1EVEC&?FW _*PSMQD
M'!-/M?'EA=7%J18:@FGW=S]EMM2>-/(EDR0 ,-O )! )4 GOS0!FQ^ (8_%"
M>2+RTTRVT6"QMI[:[:.0%9)"R9!W$;67KQT[BN@B\):-!/HDL-J8SHJ2)8A7
M.$#KM;/][([GOS6;/\0M/A>Z;^S=3>TL[TV5W>+$GE02!PG.7W$9(.5!P",X
MK$U[QSJC:=XX@MK&YL7T:+%O>$)@-L5N?F/)W9'&-O7!XH Z:+P1HL.H)=(E
MSY<=P;J.T-RYMXYB2=ZQYV@Y)/H"<@9JE%H5UJWQ"B\0ZCIJ6<6F6\EM9EI5
M>2=F)S(=I(50N0 >?G;.*F_X3S3X9;M+ZQU&P$%D]^C7$2@3PJ0"R!6)SDK\
MK!3\PXK5T?6FU5YXY=+U#3IH=I,=Y&HW*V<%61F4]#D9R.X'% %:?P?I-QJS
M:@PNE,DR7$MNERZP2RKC:[1@X)&U?KM&<UH:;I%GI37K6B,IO;EKJ;+$YD8
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M=P0@_-OP&.TL%P#WH T'\*Z4^FW&GM"_V>XO?MTB^8<F;S1+G/IN .*Y[1_
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M<@#: ,]<XX%:.E^+(=1U.+3KC3-1TRYGA:XMUO40>>BD;BNUFP1N7*G!YZ4
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MHT^SR2[BH ^;> 6& Q4 GO0!LZ+H=CH%D]M8I(!)(TTLDLC222R-U=V8DDG
M_*LJ]\!Z)?SW<DXN]MS*+AHDNG6-)N/WJJ#A7^4<_7U-1W'CRPM[BX)L-0?3
MK:Z^R3ZDL:>1'+N"D'YMY 8X+!2 >]9WC'QP;+1/$D>F6NH--IUM(CZA#&AA
MMYS'N53EMQ(W+G"D#(SCF@#H9/"NE2Z1J6F/%(UMJ4K37(,AR[-C)SU'W153
M5/ NB:O=WL]RMT%OT"W<$5TZ13D+M#,@."P&.?8>E;:7$B:2MSY4D\@@$GEQ
MXW2';G R0,GW(%>=>"_&.J76GZAK.JV^M7;2WKVUM:10P>4")"JHF""& 'S,
MYV\=: /2X(4M[>.",$)&H103G@# JNVF6K:S'JI0_:TMVME;<<;&96(Q]5'-
M<QJ?C"RFT6UNVDU737&K16$L,<<?FI*6_P!6^25V'()*D\$8-9'B'QUJ8L_&
MMM;6-S9-HT:^3>$)@$JK9/S'KNRO'3K@\4 =KK/A^SUMK62X>YBFM69H9K:=
MHI%W###<I!P1U%48_ VA0V]O;1P2K;VVH+J4$7G,5CF&3D<\#))QTR:ETOQ5
M!J6LMI3Z=J%E<&W-U#]KC51/$&"EEPQ(P2N0P!&1Q6]0!A7/A#2+S5+^_GCF
M9M0@$%W#YS"*=0I4%DS@D X![5!_P@^COIU_97+7MVE]$L$TES=O))Y:DE4#
M$Y !)/'KSFK/B_5KK0_"FH:E9(K3P("I9"RH"P!<@<D*"6(]JS_#TVJ3W27,
M7B>QU[2)(F\R1(T1XI.-NPQ\$'G(;D8')H ZL# Q7+S^ ],N-:.K/>ZR+S+8
M9-3F4(K,&** W"9 ^4<<#TK.T7QQ8)X6T"Y5M7U-M5>:*U:6*/SY70N<,%(4
M?=(!Z8 )QR:E'Q)T_P"S27#Z1J\<-M<?9;YVA3%E)N"XD^?GJ#\F[ ()ZT :
M%]X&T74+JZFE%VD5XXDN[6*Z=(+AN!ET!P<@#/KCG-;&IZ9:ZMI-UIEVA:UN
M8FAD13MRA&" 1TXKBO$'B22WT_Q__9VHWXOM*MHW"RI'Y=NS1;E\K R<]3N[
M].*TV\8_V9HUA)<:=J5_)_9L=[=S6L2E8D*\LQ9ER<ACM7)XZ4 ;_P#8]G_:
MMMJ>QOM5M;/:QMN.!&Q4D8[\HO-9;^"='-M:Q0BZMGM9)I(9[>X>.5/-8O(-
MP/*DGH>.!Z42^,[$>((-%M;.^O+J6"&Y#6\:E%AD8@2$EAA1CGOR, U@^$_&
M4JQ7HUJ:>;SO$MSI=M*$7;$ ?W:MTP., X/)% '46OA72+*/3$M[=D&FRO-;
MDR,3YCJRNS$G+$[V))[G-0W_ (.TC48KU)HYE:[NX[UY(IF1UF15574@_*0$
M7I5V+6K:?Q%<Z)&DK7%M;I<3. /+0.2%4G.=QVDXQTJQJ-X=/TVYO!;RW'D1
MF3RHL;FP,X&2!^M %%?#&FK::K;%9G354V7;/*S-(/*$6<GG.U1SZ\U4G\$:
M/<7/FM]K6-A'YUNETZPSF, (70'#$!5'N ,YKF+;QUJ=Y%X,U"33[R,ZE',9
MK*!$)N6\E64IECA<DD%F7 !SBNAC\<V4VGQS1:?J#WKWCV(TX(GG^<@+,I^;
M8 %&[=NQC'/- &[JFEV>M:;-I]_#YMM, &7<5/!!!!'(((!!'((K/LO">FV<
M=\"UU<S7T/D3W%U<-+*T>" @8G@#<>!CDYJ&S\9Z=>76FVWDW4,U_)/ JS(!
MY4T7+Q/R<-@$C&00#@]*T+'6K;4=6U/3[=)2^G/''-(0-A=EW;5.>2 1GCC(
MH GTO3;;1]*M=-LU*6UK$L,2LQ)"J,#D]:S(O!^DP:L-0C%T")VN5MOM+^0L
MS9S((\[=QR3Z9)/7FFW7C#3K.UUR>:*Y!T>58IX@@+N65638,\[MX SCFJNJ
M^,M,31H)4DO%6_TN?4(IK9%+Q0I&&+_,<!OF4#J,]: -#_A%=*_LT6'DO]G%
M]]OV^8<^=YOFYSZ;^<?A61XQ\(1ZO;7$EI:F:ZO;JP%T#+M#0PS!CU(QA6?I
MR:H)XANY?%/@&"TOKE]/U33KB>83JH>?$2,C/@8#<Y..,FM'X<ZM?ZSH5_/J
M%PT\L>J74*,P PBOA1QZ"@"]'X+TA;75()?M=R=3@^S7,US<O)(8L$! Q.0!
MN;IW.:6Z\':7<1V(C:\M9;*W%I%/:7+Q2>2 /D9E/S#@'GOR,5!JWC:UTO4;
M^P33-2O;BP@2YN!:QH0L3;OFRS#.-IXZGL#SA+#QUIU_?6D'V6^M[:^@>>SO
M9XU6&X5 &;;\VX<'/S*,@9&: *?BGPU+=^%H?!^C:4B:;.J1O<M* MJBN&+
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M(_'EA/8V<MM8:A/>W<\UNFG)&@G62(D2!LL$ 7')W8Y'K0WCW3$L+:Y-I?\
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M\D>2>RD"M 8B6"Q(O&UEPOS9)X.<YH ['3=1M-7TZ"_L9A-:SKNCD"D;A]"
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M[2A9%RI.5QM///S$>E 'JU%>>^(++5]&^R!]2\1W6E)#*T]W8LCSQSD@AW0
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M7O\ ]VQ\D,NY3TYRO/&:U+>XBN[:*Y@??#*@D1L8RI&0>?:O'M;_ -=\9/\
MKUM?_28UZEX<_P"17TG_ *\H?_0!0!IT5Y-JE[K@T7Q-KD.O7L5QIFMF"TA!
M'DA/,C!5UQ\XPY'7C QWSHW][>>'-8US3I/$&H-;-I,-S'/,BSRQ3O,T7[M0
M ,L=H"] <=J .]U34[/1M,GU'4)A!:6Z[I9"I;:/H 35NO&=?OKX^#_'6EW7
M]JK!;V%M/"FJ21R3*9&<-\R,WRGRP0"<CGVK7F\6ZG>:)XG\1133VDVGJ;6U
MTIX]KP%L;9I5;JS!@RC[H QR<X /3Z*XOPE)K":Y<6\T&N?V6UJKB36#&76<
M-@A2C'AE(.#P"O'6K7C&Z=9M,L(;G51+</(_V72U033JB\_O&8!%4LI)SSD"
M@#JJ*YSP)J-WJG@^TN;YY'N!)/"S2[=Y$<SH-VWC=A1DCC.:Z.@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ JEJ^EVVM:1=Z7>!C;7<30RA#@[6&#@U=HH Q8?"^FP:KINI(
MLOVC3K,V4!+\",XZCN>!S5_3=/CTO3XK.*6>5(\X>>0NYR2>6/7K5NB@ HHH
MH *H-I%JVOQZT0_VQ+5K4'=\OELP8\>N5%7ZHZCK-AI2YO+CR_D:0A49R$7[
MSD*"0HR,GH,T 1ZUH=IKMO#'<M-%);RB:">"0I)"X!&Y3]"00<@@UGQ^"M)6
MR^SN;F9VOH[^6XEF+2RS1E2I9O0;5&!@8%7+KQ/HMFBO-J$0C,23F1,NJQL<
M*[, 0JD]&. <'TJF-6O5^(<FE/-'_9_]E?:U79@A_-VDEL\C'TH Z*N?3P?I
M\>K&^CGO40W/VLV:W!$!FZE]GKGG&<9YQFK \5:(1,?MZ@0P?:FRC#,.<>8O
M'S)_M#(]ZL+J]E<7$5G;W<?VJXMS<0 J2'CX^<=,@;E[]Q0!BQ^ -)BE@=+C
M4 +6Y-S:)]I.VV8DE@@[ [B#G/!P,5-:^!])L]3BNXWO#%!.]S!9/.3;PRMG
M+JG8_,V.PW' %5_"_BH7/@[2-0UFX4WMZCMMBB)9RI.2J*"<  9].]79O%^E
MIJ.CVD,CW']JHTL$L,;.AC"YW;@"#R5&/?)H ?#X4TR#2=*TQ%E^SZ7.D]L"
M_(9<XR>X^8UIZCI]KJNG7&GWL*S6MQ&8Y8S_ !*>OTK-T_6K0VNH74NLP7=O
M%>M"'2/:(3\H$/&=[ D#(Y)8#%22>*-%AT^[OIM0BBM[-MEP904:)NN&4@,#
M@@@8YS0!%I/A6STJ_-^;J^O;L0_9XYKV<R-''D$JO3&2!D]3@9-6M T.R\-:
M);:1IX<6MN&$8D;<W+%CD_4FET_7M+U2[N+6QO8YI[<*947.0#G!&>H.#R,C
MBM&@#$O_  O8ZAKB:N\UU%="V-JXAEVK+$23M<=\$DBGQ^&=.BM]$@59/+T;
M'V0%^F(C%\WK\K&GV_B31[J?R8;Z-F,;RJ2"JNB'#,C$88 XR03BHK'Q=H&I
MW5M;66J03RW2LT 7.) O7!Q@D#G'7'/2@"+2?"&GZ->13VT]\T5NK+;6TMP6
MAMPW4(OTX&<X' Q5W7M#M/$>BSZ5?>:+:8H6,3[6!5@PP>W*BL+Q%XK^RZAH
MMMIMW&3<:M'9W&82RLO.]5?[NX$8(&2.>F*Z^@#F8/ ^G+?6UW>7NJZD]K()
M8$OKUY8XY!T<+T+#L3G%+=>!M)N[RXE>2\6VNIQ<7-BDY%O-(,'<R>Y4$@$
MXY!JSXEUZ'2-*OBETD=[%:O.@,32A  <,X7HN1C)('!]*BT[Q-;1>%=*U'5K
MD+-<6$5U,4C+8!12SD*#M4$]3P* +4GAO3Y8];1A)MUH$7>'Z_NA%\OI\H'X
MU0NO NE75RTOG7T*RVR6MQ%#<%$N(T!"B0=\ D<8R#@Y%6H_%6G3^)$T6$R2
M2O:"[$R(QC*,<+A@,$'DYSCCWJ5?$^BM))&=0B0QPFX)D!0-$."ZD@!EZ<KD
M<CUH SI_ >ES6T5JMSJ,-JMI'9RP0W)5+B)!M"N._!()&"0:Z=5"J%4  #
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M ''& *S[WP?87VI27<MS?"*:5)IK-+@B"5TV[69?^ KD @''(-9^K>+4BO\
MPS<V&H6[:3?W4T-P^S).V*1L9[$,F",9SQ[5TFF:K8ZS9+>:?<+/ 69-RY&&
M4X((/(((Z&@#&D\#:3+>R3-)>"UEN1=R6 G/V=YMP;>4_P!X!L9P3SBIY?!^
MCW%UKEQ-%([:VL2W8,A /EKM0KCE2.N1W -6_$.MVWAS0+S5[M9'AM8C(5C4
ML6QT' X^O0=ZJW/C+P_8E4O-2BMY3$)?*D5E<*6"Y*D9')_KTH L:/H,.CO/
M*+N]O+B?:'FO)S(VU<[5'0 #)Z#OSFF:UX<M-;N+2ZDGN[6[M-_DW-I+Y;JK
M !ESR"#@<$=A3+'6K,0ZM=3:U;W-M;79B+*@06YVI^Z)R=[98'/?<!4T?B71
MI#>+_:,*/9*7N4E)1H1P<LK8*CD=?44 9O\ P@6B?V&='"7'V0WHOL&8EO-#
M!LECR>1WJ>;P?83ZJ;U[F^,9N%NFL_M!\AIE(*OM]BH.,XR,XJY%XCTB:XN+
M<7\23VR>9-%-F-XTQG<RL 0,<YZ5#)XLT*"WO)I]1C@6S"FX$ZM&T8;[I*L
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M/+*ZQQHI9W8X"@<DD^E &//X4TRXTK5]-D67[/JTKS7(#\EF"@X/;[HJE?\
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ME:R+626!-2U"XGL8R"\$=R?D(&<$K@9 )^^V,]VW/A[6;2_/B"UL99H_[?\
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M0 #E1@\<U&FD+J_BKQ*9=7O7$.DV++/97+0><^R;$N8R,]"0,[?FZ'BNHF\
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MH/+EOY_M%R=[-ODP!GD\< <"I=0TRTU2*&*\B\Q(9X[A!N(Q(C!E/'H0..E
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M*2521=V) "Q(W9ZFK^E^&]+T:6*6RAD62*U6S1I)GD(A5BRK\Q/0L?PXZ 4
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MXM9'C9FY/. C# Y^>J\'A35%\;:G/) O]D1)<W&GL'7+3W"1AQC.1@K)R?\
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M#O401H3@=/F4CGTH RKCXCVENMQ<-H^IMI]K?MI]Q>*J%8Y1)Y8PN[<P)QR
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M\BRQP2-;R:;J82>RG=RQ!D9E)4D@D@MSG@C%;?BO1M8U7X:R:8H2[U?R;<N
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M@ Z+M&68;LMR<;<'@YJ?5- O_P"VX6TK0);.\ADMTAU6TO56(P)MW+,A8,^
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M$^L3Z?=Z'802&$ZI?BV>X !,:A'?C((W':%&0>IH WY98X(7FF=8XHU+.['
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MNM<&C7MK:2:3>+"J7$@$90(CL91Y;-A@S8(88P/0YZ[57NX]&O7L#$+U;=S
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MI .&Z'!]*GL=3L]2BEDM9MPB?9*&0HT;8!PRL 1P0>1T(-<1XGTC^W_B!_9
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M<H8=#CH?QJ\!@8'2N!T7Q!JMQ#'I=W>2/K&EW$YU0I'&#+%&,I@;< 2;XB,
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M PN<%DD+;L9QGC![5T'B6?4[?0II=(C\V\5X]L8=59UWKO52WR[BN[&>,XH
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M"IY!SVQ0!T<$$-K;QV]O$D4,2A(XXU"JJC@  =!4E%% !1110 4444 %%%%
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MLP10W\'FI#*L\>'9"CKG# J00>3^9JC-X0T.X@U""6S=HM0=9+I/M$@$C*
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M/'%;#J61E#%21@,,9'OS7#>%_%YA\)IJGB/49)&GU*6RC?[., B9HT'R+QG
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M1C,T$'F+$YP0K$J0"01[@$'C(H Z6+1=/@UB;5HK<)>S(J22!FPP487*YVY
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M*[A:%T:>0@(W55.XE%]EQ7.P^*9M5\<>$KN&>>VTW4-'GO)+9I/EZ*06 X)
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M2"8>:/G)/_30=#C X]*],K'UKQ%;:'?:1:W$4SOJ=T+6(Q@85MI.6R>G';-
M&+K&@RZKI.BV]QIMX);: XN+*Z2*YLY0J@%&W $'Y@1DCIQ4NI^'M8UKX9MH
MEY>1?VR]K&'G PC2H0PSCL2H!P.YXKK:* .5CT^_U/Q/INO7FGR63:?931&
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M758V1FG4+M4HH&Y&(QN)/KUSQW=% %/3[F\GTN*XOK#[+=LF9+59EDV'T#<
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M3?12V9N%0J);EI8Y%8\'@X(S_%[5VMIHKQ^!WTB.TM+&66TDC\BW8F*)W#9
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M'%>C7M_:Z="DUW,(HWECA4D$Y=V"*./5B!5>QUB"_P!5U33XXY%ETZ2..5F
MVL7C#C;SZ,.M '%:IH'B*VL_%VCZ5IL%Q:ZWYDL%TUPJ"$O"L;(RGG/R?+CC
MD9Q79/I$=_X5.C7R QS6?V:8#GJFTXK4HH \SL/ VMZAX3UV+77M_P"V;ZWA
MLX6W[T\N!1L)(Y =][$?[7M5NQ\.30V>HRP>!]*M&D@2$VL]P)#=+NS(I(RH
M7 &W/?J *[+6]6AT+0K[5KA))(;.!YW2/&XA1D@9P,U=C<21JXZ, 1F@#S)O
M"FN1Z0K66FF"&VUFUO[329;T2&../&]5<DJNXY(7.!^.*GU+PGK5_=^/+E;6
M-/[;TN""U0RJ3YBQ,K*3VP6 S7I%% '&>)_#5SJ][:,SQQ6::/?V=Q,S#]V9
M5C ..X^5C^%8%C>ZG?>(OA_'=6]G'%"DY5[>Z$XN +5E\U<#A.1UYRPZ8Y]2
MK,T[P[HFD74UUIND6-G<3<22P6ZHS<YY('K0!SOC;1;W5YP(-!AO76 BSOXK
MO[//9S'/);@[/NGY<]#D'BH(-.\6>'[S58]-M+6_;5)(IUO9I@BP3>4D<AD3
MJR_)N 7UQQUKL[._M;\3FUF$H@F:"3 /RNIPR_A5F@#C+CPYJ4EIX\C"(7UA
M2+3YP-Y^R)%S_=^93UK"N/ T\>H7<LGAFQU=KZ&W"S7%P$6V=(EB97'5D^0-
M\N2<D<=:]0HH \[U'0/$-E#XKTK2=-@N+36U9X+AK@(+=F@6)E93R?N KCCG
MG%3P:1XAT?5Y)[/3H;I+[2;6S=VN%06TL0<$L.K+\_\ #D\=*[VJWV^U&I#3
MO.'VLPF<18.=@.W=Z=3B@#SW2O!&JQ7GA+[7$B06&A2V%VRR E9&51@>O0\U
M8\&^$9-&O-.6X\,6%M-I\!C?4UGWM,X78&C4<KN!).[&,X&>M=U?7]KIML+B
M\F$41D2(,03\SL$4<>K,!^-6: ,WP_J,^KZ!9:A<VRVTUQ&':)7WA?HV!D=\
MUI444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<%?Z587'QJT^>:UB>
M4:+-,KL.=ZS1!6^H!/YUWM4+W1-,U&]M+V\L8)[JS;=;RN@+1'@\'\!^5 'E
M7AW2+/3O"OP_UBVB*:E/?0PRW.X[WC=),QD_W>!@=!BI_!MAJEQ)X>UUX=)M
M;FYN)&N[PZ@YN;W*R;XFC,8!((R%W';Y?%>GIH^FQVEI:I8P+;V;B2VC"#;$
MPS@J.Q&3^=0V_AO1;35I-5M]+M(K^0L6G6(!B6^\<]B>Y[]Z ,7XC27*^&88
M;<(5N;^V@F628Q(T;2J"K.H)56X4D \,:Y.\T74M&TK5M0BATZU_L>[M]3@T
MW3;MIA"$4^>I!1-H>,Y"@8)R:]4N[.VU"TEM+R".XMY5VR12J&5AZ$&JNG:'
MI>DV4EG86%O;VTA)DC1  Y(P2WKQQS0!YCKEW/K:ZYXALY%DLI;VST:V+3-$
MC6XF7SB7 )57=]A8 G"T:KI-[IGA[6[1UT[3K:6^TSR['2[UY/LS&X0.W*)Y
M>X;" !U!->GPZ'I5OHW]CQ:=;)INTI]E$0\O:221MZ<DFH;7PSHEE8-8V^EV
ML=J\JS-&(QAG4@JQ]2"JX)]!0!Y=XWT73M+3QCIUC:1PV;>'HKPP+G;YXEE7
MS,?WL 9/?%:OB/0+.TQ>0:=9:CIEAIBF6P2Z,,]B,NYGA[!FYZ[3\@P>M>BW
M&DZ?>23R7-E!,]Q!]FF+H#YD62=A]5RQX]ZS7\$^&)(;6)]"L6CM5*PJT0(5
M2Q;;[C))P>,F@#0GMX-9T&2V)<V][;%"3][:ZXS]<&O([75;R^&C:M-,X;PG
M#;P7H#'!E>8P3Y^D<9;G^]7M6,# K.&@Z2L%_ -.MA%J#,]XGEC$[,,,7]2:
M /,-.TRWU_Q!X>OM10S0:S<:I>F)B=KQ8C6)3ZKL1#CI5:_7[%HEC8V[-';6
MGCN.W@C#'$<>_(0?[(R>*]>CTJPA:S,=G"ALHS%;;4 \E" "J^@P /PJ*30M
M)E4+)I]NP%T+T QC_7CI)_O>] '"VEAHVI77B'6=>N&M[^QUHPQ7@E*R6R*8
M_*1.N%8$9&/FWG.<UB:AI%D/"_B[73$3J=IKLSVMSN.Z B9/N>F<G/KGFO4+
MCPSH=WJ\>K7&E6DNH1E2MP\0+@K]TY[D=CV[5.^C:;):7-H]C UO<R&6>,H-
MLCDY+$=R2 : #6KV+3M!U&^G\WR;:VDF?RCA]JJ2=OO@<5Y-!;/I-UJ-K'8V
M6G)<^%+NY>"UNVF>0@H$DE)5<OAG^89SD\U[+)&DT3Q2HKQN"K*PR&!Z@CTK
M%M_!WANUC1(-$LHU02!=L0X#KM<9]"H ^@'I0!Y])HRV_A[P7:6=C;70U<I-
M?I>W+QQWDHMBRB1@K$C.2%QCY0.@KM_ ]E=Z?H]U:W+V6V.]E$,%G<M.ELG!
M\K<RJ<JV[C' P*U[O1-,OM+33+JP@FL4"A('0%5V_=P.V.V*FL-/L]+LH[.P
MMHK:VCSLBB4*HR<G@>_- 'G&L6&GZKJWCZZU<!IM,MHULY'8AK6,VV_<G]W+
ME\D=<8K%M["\UQ(+5['3KJ&T\-V#V[7]\]O]EW1ONFCVQM\V5&6X(VCUKU74
M/#.AZK?QWU_I5I<W4:[%EEB#-CJ![X/(STIE[X5T#48K6*\TBSG2T01P+)$"
M$08^4?[/ XZ<4 <!!H5I<_%?P^VIP6EY>/X?^T7$\?S)+.KQCS >_L?2LO38
M_MVC"VFDE\N7QU-&^URI*?/E<CD CBO83IMD=0CU#[+%]LCB,*3;1N6,G)4'
MTR!Q4,6A:5"H6+3[=%%T;P 1@?OSUD_WN3S0!Y9K%H=*U/6M"TBWACTV;5--
M5[-IFA@Q(C;E)4$JKLJ X'.<=ZFN-+N;(VNC7RZ=;:1>^(+>.73K&\::.%3
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MZ+<WQ8W<UA!),6ZER@))]\UL4 8&!THH **** "BBB@ HHHH **** "BBB@
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MVE7#)YUO8Q6TC(<KN5 I(Z<9%<KX9\*:Y81^$XM02R1="6>!FAG9_.1HPJL
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M3'IFFC4E@M[24QS79A1!L?(3Y6RS>F ..3TKKM-O+VYO]5ANH(XX;:Y6.W=
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MF*H3'*KX) .,[<9QWH YW^V/$4'C?64M=+BNIUTNSFDMGOBD,)S-N"ML.6/
M'RC.WDC JW_PG\M];VLFC:7%<M)IL6I3I<W8@V))G:B_*VYSM?C@<=>:TM,T
MC4AXBU35[V.WA-]86T ABE,FQXS*6&2HR/WBX./7BN4M?A]?Z;:Z:QT?0=9N
M$TF"PF34#\L,D6[$B$QL2IWD$84G:M 'HVF:A!JVE6>I6I)M[N%)XR1@[64$
M9_ U:JO86WV/3K:VV0)Y42H5MX_+C! Q\J_PKZ#M5B@ HHHH **** "BBB@
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MU]*\?UI(X]5^+$<2JL:Z';!%48  @DP![5K)X4T,>.]"M3IMNT%QHTTMU&R
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M-77298XH-)3QDL:VX^6-0]CDICH%9F.1T.XCO0!Z;XI\36WA?PQ<Z[+$US!
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M]IJ%G!=VSX+0SQAT..1D'BK-% % :)I2K<*-,LPMS$L,X$"XEC4;51N.5 X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7V?3M&:RGP_/F$+T'<<'FNLTV2^ET^)]2@B@NSGS(X7WJ.3C![\8H MT444
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M6=UCP6610/W;88''/?G(J'3_ !S=WTFCL^@206^LP,]A(]RI+N(C(%9<?*"
M<'GW KGM-\$:O:S:;/'H.EV4D%C/974D4X:6Y>2,#SF?:"PW+T))^8FNCMO#
M6H16O@6-A%NT55%WA_2U:+Y?7YB/PH S_#OCG5KWPUIMQ=:2L^I:E<S16D27
M"JKJC.69CCY%55QT))QZUI'QPTEM90VVDR2:Q<WDMG]A:=5$;Q M(6DP1M
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MA3Y6..?FRW(Z9.<T ;FL>(;BSUBWT?3--.H:C+ URR-.(4BB4A=S,0>23@
M]#TQ66OC[[0FE1V6CSS7VH2W-N;9I50P30'#J[<C (/([#@$G%6M7T[5;7Q9
M!XATJTBOLV364]L\_E-C>'1U8@C@[@0?4>E9FC>$=3L=4T2^N6@:6.ZO[R^$
M;DJCW'(5,CD#IGCIF@"U!XYEN;6*&+1W.LO?2V)L3<*%5XUW.QDQ]P+@YQGY
M@,5NZ#K*ZWI[SFW>VGAF>WN('8,8Y$.",C@CH0>X(KBK_P "7<]U-?3Z98ZF
M$UFXNUL;AP%FAEB1.I! <,H//H>>:[#POIATK1A"VEV&F,\CR&UL1^[3)XR<
M#<V ,G &: *,?BNZ77+6SO=%FM+.\N9+6VN))EWLZ*[ M'C*JP1B#D]L@9K/
ML?B!/>1:9>OH4T.EW]X+);EKA2RRER@.S&2I88SD'VQR<6P\%ZQ:ZCI-XVC:
M8;RPU)Y[G4/.!N+Y7\Q=V[;D !P=I/8 =*U[;PGJ<7@W0=+80_:;'58KN;#\
M>6MP9#@]SM/2@"AXE\8ZA?>'YKC3M/N+?3O[4@M(M1CN0K.5ND1SL'(0D,N<
MG.>1@UT?C[7-0\.^$;G4M,@26X22-,NP 0,X7."#GD@8]\]JYJ;POXG3PZ_A
MBWM+,V46IBZCO6N>9(?M(GV;-O#C.,YQQ[UU7CC1[O7_  =?Z=8",W4GEO&)
M&VJQ217P3VSMQ^- %5_&AM;;73?::T%WI$,4K6ZS!_.\Q<H%; ZL"GU%5[OX
MBZ?9:1I.I36LHBOK2:[E0,"T"Q("X([G>53MR:KZSX9U;6O$NBZGY$-M;R)&
MNK0&;<0(91-$ 0/F^;<#TX-9[?#O4+Q_$]O<SPQ6MQ!+!I+*=WEB65IW+#L-
M^P8]%H Z;3?$]Y+K-KI>L:,VFS7L#S6I^T+,'V8W(V -K@,#CD=>>*OW&N1V
MOB:UT::$J+JUEN(K@M\I,;*&3'KAP<^QK'M-/UW5_$^EZKK%C;6$>EP3*J17
M'G&:60*I(^480 '&>3GIQ1X_\/:GKNF6KZ(\4>I6\CA'D;:!'+$\3\^P<,/=
M10!#8?$2VU'PTNK1:?,))+^*QBM6<!G:4H4;.. 4D5_I7,>(O$4DGPW\1W>E
MW&I6DUMKWV4R/>.[Y$\8;8W54(. HX S70KX+NH/'=C=0>4- MXXIS&6^;[3
M%$\*<>FQE.?5!61=^ M:F\"^(M(06_VJ_P!>>_AS)\OE&9'&3C@X4\4 ;FGW
MMV_QAUJR>ZF:TCTJWD2 R$HK%VRP7H"?6M75O$5S;:VFC:5I9U"_^S?:I5:<
M0I%'N*KEB#DD@X&.QR15:RT&]@^)>J:\XC^Q7.GPV\>&^;>K$G(].:34]/U>
MP\7G7])LH;];BQ6SGMWN/)92CLZ."001\[ CZ$9H P[CQ?=ZCX@\*7>D6EU,
M+VUOU>P>81*)8WB4^8>1\A#C.#UXZUK0^.7N[2WBMM(D;6);N:S:P>=5$3Q#
M,A:3!&T#:00#G<O%95GX4\0:'<>'KVVBM+V>RCOWOH_.,8>2YD23;&2.Q!Y(
M&=O;/%:7P)?3Q0:IJ&E:?J-XVI75[<:9-(#'LF55"JY7!91'&<D 'YO:@#I+
M'QM%=7VEVLUA+;-?2W%JY=P1!<P]8CC@[@&*D=0.G-:FDZXNKZEJ]M#;L(=.
MN!;>>6R)9-H9P!VV[@/KGTKCO$>G0Z+\-7E>STW2-0M+D7]E;6?W!.KYC0<#
M>S#"$@<[CVKK/"6D2Z+X9M+6Y(:]<-/=N/XIY"7D/_?3'\ * .$U'Q=K]UH.
MO3SVKVRV&O6]K$UK."Y430!HN ,Y#-R3SNQ73/XYDL'U.#5]&EM;RSAAFB@B
MG67[0)7,<8#< ,7&T@\#.<D5E3>%==:/7=/6VMS;W>N0ZI!<^?U42PLR%<9!
M C;G//%6O%G@R\\0:KJ<Z+;-#-I]K'$DYRKRPW#3;7&/ND8!//4\4 =!HFNS
MZA?7FG:AI_V#4+5(Y6B$PE1XWW!65@!GE&!&."*Y#7;_ %JZ^+VGZ5LN4TVW
ML#=^7!J)@63$J@R/M'S <C8>#71>$M$&F2WD_P#PC>EZ()0B)'9D-(^,Y+L
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M]5L8I;V[\/\ VFZ,B<M,HCPQ]Q79>-]*DU8:9%$MA=O%,\ITN^F,:7BA"".
M>5R",@CU]: -MM9@7Q)'HACD\][-[L/QL"JZH1USG+"M&O*-'T_2/$?BC1X)
MK"46,6C72&RN9?-"NETJ%&.<.JL#CMPI["JVF1Q:GHFAZ&VGPZD\#ZE)''J%
MVT=M'##<&,%_E8NRAE"C' R<T >P45XSHUI#XDD\ 6FILUS:/8Z@)(_-8K*J
M/&$5CU91A>O7 S5C^SM3U#5=6U&.#28;JUUP0PZE=:@\<T"(Z!(@GED;63 V
M[L-YF>IH ]>HKS;3;*+2/%]M>W5K;7JZAJ5PMKK5G=$R%F\P^1,G=5"LHP2
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M- A=;>4_*W[^4%L=R,\'MNKE-&CU#7X] L)[*SU>UCTNX>"+4KQXD<+<&,2
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MMWU*-%4+CL7#K^*&O0O#&C_V!X:T_2S(9)+>$"60G)>0\NWXL2?QH UJ***
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M-;:=8HEO#<EHI7>655*LP&T$LH)(XP>H% ';0>&M$MM7?5H-*M([]RS-<+$
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ML'NY9+V=HTBB5]N20K$L2< 8[&@#O(-$TRVM[B"&Q@2*XC6.9%08D4)L /J
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M+Z.-(;2;0Z>'\P6_E#:&SG=_O9[]:M:=H^FZ0CIIUC;VBR;2XA0*&P HSCV
M%<_<>*M4O-2N[3P]I=O=BQMXI[AKJY,.XR*66- $;+;0#DX R*PE\01ZQ\1/
M"&IV\LD=C>:-<7)C9L ?=/S#ID<B@#L;WPGX>U&Z:YO=&LIYWD$CR20@EF
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MJCK&9$8,-Q8*!QWR10!S9\)ZA<6^CL]OH]C)::RFH206*%8UB6-DVAMHWO\
M,#DA1V[<IK7A*]E\0W^I6&GZ'>_VA%&CMJ:$M;.@*[U 1MX*X^7*\KUYKL'O
M+6,1&2YA02\1EI -_P!/6G37,%L%,\T<08[5+L%R?09[T <[#X:N8;WQ)*)+
M<1ZG:PP0*@*["D3(<C' R1C&>*R++PMXD\/+%)HDNF23S:5:V-U]I=U6.6%2
MJRIA3N&&/RD+T'-=0NN(WBY_#_D-O2P6]\[=P09"FW'_  '.:U$ECD3>CJR\
M_,IR.* .#N_!FIKJMW=PV^A:G+J$4(GNM3@^>&5$$;.J!"&!"@[<K@]\&NQU
M*TNI]'GM=.NQ8W1BVP3K&&$3=CM/!'MZ5/'=V\LOE1W$3R;0^Q7!.T]#CTJO
M?:DMO93RV@BNKF.,R);^>J;\''WCP!GC)H YPZ/XEUK5=(FUR/2+:#3+C[4'
MLI9)))G",H W*NQ?FR>6)P![UF6'@S7]/TVRBC?33<Z/J4UY8.97VW$<IEWI
M)\G[L[9>"-W(KO!>1);P273QV[2@85Y!]XC[H/?\*DDN((9(XY9HT>0X168
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M56U@B:9Y,Y 0#)/Y4 <7/X/U.^TBZ L=!TF]2>VN+-+%"4WPN'_>/L4D,1C
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M?0T^6ZMX(UDFGBC1R K.X )/3!- '&^%?"5]H4]A;RZ?H*VUA&8EOH8LW5P
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MRQNI(!RI*G\#78>8A9EWKN4 L,\@>]1M=VR*&:XB52 02X ()P#^)H XN_\
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M6*-[=F;8^5&Y6R 3C^(\<#/H5% '!W_A#4M4\&:_I?V'0M+N=1C6.&.R4[%
M[R2;%+<Y_AX]ZTI_#%Y+XS\/:RLT M]-LIK>5"3N9G"@%>,8X[D5U5% '%6?
M@Z^M_"OA;2GGMC-I%Y%<3L"VUU3?D+QG/S#KBH?#_@NZT>XM;)M.T$V%J\F+
MY8B;N:,[MBD;0$89&6W'..@SQW=% 'G=GX/\316'A[1YI],_L[0[V*9)DD<R
MW,<>0H*[<(0I]3DCJ*]$HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ?8"J I$Q\CS1'_=&\N..Y:O:+RQM-1MFMKZU@NK=OO13QAU/U!XIG]EZ?\
MV<-/^P6OV$  6WDKY8 .1\N,=>: ,S7[.UL/ NL6UG;0V\":?<;8H4"*N48G
M ''4FN%;2X=)'@NXT:TCAU"?3+H-+&@$DS&UWC>>K'> ><\UZM)&DL312(KQ
MN"K(PR&!Z@CTJ/[);!H&^SQ9MQB$[!^[&,?+Z<<<4 >5Z9!H\.F?#NYT5+8:
MK-<1>=)"!YTJ&!S<>81R?FY.>C8[U0BTJRB^".O:BEO&M]<2W:/<A1YFT7;
M*&ZA?E!QTSS7KEMH^EV=[+>VNFV<%U-_K9XH%5W_ -Y@,G\:D_L^R^QM9_8[
M?[*Q):'REV')R<KC')Y^M '"?\(MH*_%);0:39_93HGF-;F%3&[B;:'9>C,
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M33U2[D5'$B0M*" 4#*O.W) Q[UUS6%F\,\+6D#17!+3(8P5D)&"6'<\#KZ4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "LR35C;ZS-:W M(;.*V$QN'NE#ABV,&,CA?]K/7BM.O-K_3(-:^
M+VMZ7=#,%WX76%_8-,PR/<=: /199X83&)94C,C;$#L!N;T'J>#Q4E>7^$+R
MY\5:_H\5\"9/"]HZ7N>]\6:$9^B1NW_;05Z18WUKJ=E%>V4Z3VTR[HY4.58>
MHH L4444 %8&O>*H_#\-[<3Z7J$]K90">>X@$6Q1SP-SJ20!G@'J*WZY3XFD
M#X9^(B2!_H,@_2@!VH>-5TS2;K4+G0]3BC@BCE ?R?G5VVY!60C@XR.O(X-=
M37$>/64_":].X &V@PV?]M*Q-?O+KPWJOBJ/3+FZ\I=,L[MPTKS-'NGD2:1<
MG(/EC/!'W10!ZE65XBUR/PYHTFI36TT\:.B,L6W(WL%!.2.,L.F3[5C>%%LV
MU:\NM-\00:A:W$$;&VM,M#"W.'R7;:S#J.,[<T?$W'_"OM1RVT;X,MZ#SX^:
M .NHKR?Q(VH>&+WQ WAZZOI++^RH[BY!N'G,$IF"EU+$E6,7F-P?X0:U-6!M
M==FCT>ZE_LRYT&XN+@17#;8V7;Y4JL#E6;+<@_,%SSB@#T2BO+]$C,5]X+*W
M5U(VK:!*;L27+N)66.!E."< @LV",=35?P]KBRQ?#<OJS/<2V\R7>;@EG(@;
M D&>3N'&><B@#UBBO.O"NJ/I=^D6MR0E1IC74>L0W)-O>0ADS)*K?<D^923T
M.3SP!7H4,T5Q!'/!(DL4BAT=&RK*1D$$=0: (6N9EU*.V%G*T#1,[7(9=BL"
M $(SNR02>F.*S;3Q%]OU!(K33[F:R:>:V:]0KL22(D-N&<A<JR@^H]""<R[9
MC\5;*W,\WDS:+<EX?.;82)80"%S@'!/(YJ'X9VUO%X=NY(<DMJ=ZI.\MP+B3
M'4^GYT =I17)>.]4;2TT8RW*6NFSWXAO+B12413&^P/AE(4N$!.0/7@D'!$U
MA8#3[$^(#J,%SJ<[P R^7: "(EHF<EBR(3E5!/S8'\/ !Z717C^E7+:MI'@F
M"?5;F7S-4O;2X,5XZEXU6XVJV&ST5,$\XQ@U8U;3HX&\>6T=]J(CTK2+>6T!
MOY28I%AE(;.[.<J#SQ0!ZQ5+6-271]&O=3D@EGCM(7F>.+&XJHR<9('0>M><
MWFIKJ^HWVFZQK\.DN=.MI[*>4LC89,M+$P=1N#YSP>@'2F:O?1:A:>-[+6KQ
MOM-EIB?8EE<PEHS;[C*JY'S-(6!^@4^E 'IUC=+?:?;7B*56>)90IZ@, <?K
M5BL+PUJNGS:1I-C'?6SW9TZ*80+*"YCVA=V,YQGC/K5S7R1X<U,B^^P'[++B
M[_YX?*?G_P" ]?PH T:RO$>N1^&]!N=6FMIKB*W +)#MW8) SR1QS7G.IW][
M:^']:AO+5M-U.PDTZ626SNF:V>-K@#S(SP4RH<,I[#/.<TSQ?J,-ROQ!MX;\
M2PC3K*1$6;<JG=)O*C.!T7./;- 'KDC,D3LJ%V4$A 1ECZ<\5%93RW-C!//;
M/:RR1JSP2$%HR1RI()!(]JX5K!M/\87UOIE[>OI]SHTL]XK7DD@CFW 1NK%B
M59AOZ$9"^U9-EK!.F>"[+5]2BMK"]T(/Y]X6*37&V/AF#K\VTDC)[GOB@#U>
MHC<0K=);&11.Z-(L>>2JD GZ LOYUYK;7MI;ZGIVAZ[X@>YTM](=K34+B7R5
MN91*RLV[.&94V%3D\$L.N:M64&GP_$C1'>]FN V@,L-U=38DN"LT84GIN)!S
MTYSG% 'HM16]Q#=0B:"19(R2 RG(."0?U!ITL230O%(,HZE6&<9!KR+PG>10
M>'_ 6G^;C3;QIH[[$IQYP0^5&_/ )W?+QDJ* /8*R/$GB&#PQI1U&ZM;F> 2
M)&1;A"P+L%7[S+W8"LSP<UTE[XBLVEDFTVUU$QV+R.6(4QHSH">2JN64>F".
MU5?BJRKX"G+, /MEGU/_ $\1T :S^*K:UU*TL-3L[S39+U_+MGN50QRO_<#H
MS ,>P)&>V:WJX#XF21ZSIMAX>TZ19]6NKZWDA6([F@1'#-,V/NJ ",^^!6>E
MZNK:QJ$5YXACTW5[#6"L4 5O/:(./+15W@,CIC@+@DD]>: /2HKB&=YDBD5V
MA?RY #]UL!L'WPP/XU+7D*WT.@Z;XEEM[@6^/$NR\?>S&&V9HMSE0P..>2,'
M!/-6-92*WT"^GT[Q,US;RZII[(+&9EBMMTR*ZJP=LAA\Q4G SG'- 'JU%>?R
M:':0?$&PT9;G4#82Z1=2O ]_,P9O/B.<EL_Q'OTXK$T*26/2/ >J&_O)+NYU
M%[*:22Z=A)"$G 4J3@_ZM.<9R,]: /4K*YFN4E:>SEM2DSQJLC*=Z@X#C:3P
M1R >?459KR5YIF\.8_M&\!3QF;8.+M]WE_:]NPG.2-O8YJQ<7EOH]]XDTM[V
M\2S75K!((S=' :5$9D>1\E8V(.[V)QUQ0!Z;/<0VL7F3R+&FY4W,<#<Q"J/Q
M) _&HTN9FU*6V-G*L"1*ZW)9=CL205 SG(P#R,<UY%<W%O>:#J,-S>1316/B
MZU$82<E((6> _*<\)EGP>G7&*V==U&_T[5O%LFASS321>';>>U02M*JMNF!=
M 21G: >.N!US0!Z;17 GRU\2: =%NYGT[4=.N'O=MPQ#1JJF.;.<A]S8W=3D
M^E8OA-Y(1\.KTWUW)<:E:S1W9EN7<2@0%QE2<<,H/ ]?4T >L56NKF:"2U6*
MSEN%EEV2,C*!"N"=YR1D9 '&3S18:A9:I9I=Z?=P75LY(66"0.IP<'!''45S
MGC&1X=8\)-'/+'YFL+$ZK*RJZF&4X90<'E5ZT =917GVD75U:^,+:*\5;VWO
M;J[^QZG:SG)(WL89XS_< *AAP-H'&37;:JN[2+P!W0^0^&C<HPX/((Y!^E %
MNBO)M!CFMK7X?ZQ9ZC?3W=];!=11[EY5EA%N69BI) V.%&0!RV#DFG>&]5M[
MCQ)X:\C4B]IJ>FW7F"6[WS3G=&4:;& )/F8  9'(SV !ZO39',<3NL;2%02$
M7&6]AD@?F:\_T!;J+5'\)W;W3_V1=/>FZ>1V:>V;)A!;.2=S%2.XA/K67X<U
MJ"3Q-X7FM=3+6^HVEWYGG76^:<Y0HTP&%#Y) 4#CD9[  ]#\/ZU%XBT"SU>"
M*2**ZC\Q4DQN49[XXS3=#UR/7$OFCMIH#9WDEFZR[<EDQD_*2,<^M>9^%K(V
MWAWP'J.EW=U_:,]RL%Q$+EVCDM\/Y@,>=H"@ Y &#CN:M-JKZ5I.LSBX%O9O
MXMDBO9R"5BB..6VD$+NV \C@F@#U>JU]<S6L"O!9RW;F1$*1LH(4L 6^8@8
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MSNF?8<!%Y)8XR!ZBK_@#1[S1_"5L-49GU6[)N[YV^\97['_=4*O_  &NGHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/(S2RDJ1*7*9;)'.>1_M5/;>$]<MX?"B)-912:-ITMG)*LC,=[1*BNH*<@%
M<''7% &YIGBVRU*]AM?LUW:O/8_;X3<*JAX<@$\,2I&Y>& //UQ#:^-;"[N=
M)BCM+W9JR-+93%$V2(N"6^]E1M(;D X/L0,+3/#VK:'J-IKVJ_V:$L])FMK]
MXGDEDF.4<RDE07)V'(/3/!:LKPFL\::(DT&B7UOY)M[<V6J-)+;I+C>4B*8
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M97 D?< 0(R./K6K;ZO9S>*=-UR_U;2T>'3IK6:*"1V&]Y(V!4E1D80]<')H
M-/\ 'NJW=KI&HSZ);P:=>WPTZ0_:BTJ3;VC+!=N"F]2.H/?%$'CW57TZ/6IM
M%MX]&%^;&:3[43,/WYA$BKLP5W8R,YZ^G.9 FFQ>&=(TPZ[IYELM9&H2,&;:
MR?:'EP/E^]A@/3/>L31+TZIX6BT>?5=*ATF359;B:1Y'$XC2[:38$V[3N*@[
MMPP&Z<4 ;NG^(7T/7O']VZ27;IJ5I!;6WF8WR2(J*H)^Z"S#)^IK9O/&&M:2
M-3M+_1[634K73SJ,*6ERS1SQ*VV1<L@(9?3!SD=*YRXL=-GG\43CQ#I\<NHW
MUM?6+?,WEO#M*[Q@<%EQQG@UJV&MV'_"13>(O$6KZ/;E++[%%!;3O)&J%P[L
MSNJ\DA1C' '4YH VM5\;VM@^FO;Q"YM;JRFU*:56QY5K'&&WX[DEE4#CJ?2L
MV#X@7*0W!O;/3_-.F3:C;):7WG?ZL M%)\HVM\R\C(/S>G/*^#X]!FTKQ#!>
MZQ']CN4FTK368$,ECN<J1]3(<'N$6M"U:U;2+^QN+CPM:-)IDMG'-91MOFD9
M=HD8[!L7U4;NO7B@#IK&37O%&GZ3JS%M)0SQ744-O<[_ #;<@%EF!3N,X"G@
MD$GBF:@-3\)^'-3UB34;N]%G<O=K'<2!B;;Y=\9P . '93U7@9QD'9\+75G)
MH5G96UY#<O96T4,K1$D9"X[CH<&J_CB&6^\)7^DVH#7>I1&SA7W?Y2Q]E4EC
M["@#?BE2:%)8V#(ZAE([@\BL.?Q=96^H+;26MX(VOUT\7)11'Y[*"!RVXCD#
M<%QFMFUMTM+."VCR4AC6-<^@&*X74?"7B&^U)KAY=,G:'6(K^VN)I'\P0*0?
M)QMP@'/0D,>H!)- &W?>-M/L5N)/LUY/;V]ZMA+-"JE5G;: O+ ]65<XQD_7
M OC2T;5;RP_L[45^PR!+N=HE$4 ,?F!V.[[NWT!]Q7%/<O)J>KW=LFA7MA_:
MAN&LY-2>WE::+"@F+8V7W)D<_,=IQTKK;?PU=W5UXL^W^3%9Z\BJ@CD+21CR
M!$0P*@9XSP30!)#X_P!$>\-O.\EL/L;WJ22E"KQ)RQ^5B00"#M8 X/3KA/\
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M558\ ],=ZW)?&]]ITUQ::IID"75G=VD=RT$Y:+R+ABBRJ2H/##!4CMUJI:^
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M5"C >A&#7&:9X:\2+I-OX=U&]L!HEM9O9,]ON::[C,9C3<&7$>!R=I.2.PH
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M'XF>T\":OJ$OB"_36;>]NH;0EVD#,LK+%&58%"#A02?4G->PMN"DJ 6QP"<
MGZUP-CX6\16O@_5= :+2&_M"6Z8SM<2.$69F)^3RQN(#>HSB@#HUUYX5L[2:
MSDN-7ELQ<S6MH4.P<!CEF QN.!SS@^A-4U\=Z9,FDM:6U]=_VJ)1;K%$,AXP
M2Z-N8;6!!'/ /4@<U3T_PA?>'M3TJ]TN>*\%MI*:5<1W4AC+JAW)(I"M@Y+
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MBI** (X[>"*1Y(X8T>0Y=E4 M]3WJ2BB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU2\M=.NVDL)YK<VQV"222/J%^;')X'- &Y17.6GBM[V>RCBT6^ O+#[9&[[
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MG]G$+/%$P!5L*V"3[,I[]: -RBCM10 4451UC5;?1-(N=2N]WDVZ;F"C)8]
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M SGCN:]=^R6V,?9XL=<;!61XF\.#7]%ET^":&S:62)VF,&\X217Q@%>I4=Z
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M90$M;MN'S^9N' )/ Y'%>FO&DJ[9$5UZX89%,:V@=HV:&-FB_P!62@)3Z>E
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M%2,QB??)&A>0@\N=WWO8<5NS>$=6>;0[X:\LVIZ=//+)-<VQ>.43 AE5 X*
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MTFY^RH4\TKM+98GID^M;% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUY)<.96,"I$2SD\L =I/LOM5SQ3=VNL)XZU/1YHKG3O^$>2":XMV#1RS@RG
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MQ!N_#UC/I9M;0*K2-=YFN'*,Q$2 8.W&&YXYK>DUY4\90>'OLY+2V#WOG[^
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M/4L(91,@R0-PS@GUQG/UQ4^T;MV!GIFEHH 0J"02!D=#Z4%02"0"1T]J6B@
M[YI H!)  )ZX[TM% "!0"2 ,GJ?6EHHH **** "BBB@ HHHH **** "BBB@
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M9R12&-HKC83T!R"K,""".]2+<7#:E);M9NMLL2NMSO7:[$D%-N<@@ '.,<T
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M(YMR_)/ RS_3)KUU[.UD1$>VA9(QA%9 0H]O2D^Q6@$@^RPXD^^/+'S?7UH
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MX=&W)R?WFT$Y/)QD]*HFYM+AO$&GQ7-K):W/A43);03^:K2KYOS$]'DP%+$
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ML$9$Y?RSYAG4N3\CC(.T#. ."!6UX(FN;;5Y=-OK>W>X%A%+'J%C*6@O(MQ
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MO[0FU!4B"K=S##S*.C'UR,<]QSWK5HHH **** "BBB@ HHHH **** "BBB@
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M=,TZS*2+/&YEN&>#S&VL& 3"NH&0V3GI5?2]>ATS7-%AFL+5DA\(B]>[\O\
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MBCB_L_3H(A++@[S</EMH.<8";2>,Y85@ZAIEIHN@^(+OQ3=K=S:X?*F6TMF
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MO>!_"UR-,\+:G<2RQ/8"_?R9X\22+<2%E+=-IVX)&._:@"O?_$I[/5KQ6O\
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M5/RGG@\54\/:I!<Z]X3D&I:?)')8W$7V6RMQ%%:.Z*PM]V22WRGY3S\N<#-
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M@U#1(K^#[98*&E4RK[[L<Y^7'S<<9%6[+Q#HNI6D]W8ZM97-M;Y\Z6*=66/
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MAQM!4G ^;&.#2_:-?O=5\!:AJT]E)%>W;7 BMX&C-NS6LI"9+'>,'K@<CWX
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M'@8Q@8]*  H    ["O.;OQ;XDT^37+.Z-F6TZXM(C?0VDCK'%*"6F:(,2<8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+_PB5L [8<9,C!OQX(/XBLK1+**W\%_#6:SACCNFO"!*% 8EK>?.3Z' _(4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM,%I;+;FW6WB$!X,80;?RZ5-10!"]I;20+ ]O$T*XVQE 5&.F!4P&!@=***
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MCW#!*\<&N?TGPE<VNK6NH:GK#:B]E%)%;*+980"^ SOM^^Y"@9X'7CFNIHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@LXDFDN=9GM)M.(A;$B;(EW XXV,CL<XP.>] 'H]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ex1012022063010qngcbasho016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1012022063010qngcbasho016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH3*OLWF;4!/?-:MKH=U8:E_PD&OZO_:$MC:210^39F)8T.&=MH+%G.Q>F.G
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M>KS:YX?@O[B>REED^\;/=Y:_[/S<Y'>MNJ>E C1[$$8(MX^/^ BKE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !3=Z!PFX;R,A<\X]:=7&7?_)9=+_[
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M_.(W"/<-V/7'6N6\ J+>RUG3HABUT_5[BWMD[1Q_*X4>P+D =@,5QLUC:O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<],CMF@"2BFNZQHSNP5%!+,QP /4TJ.LB*Z,&5AD,#D$>M "T44A( R3@>]
M"T4 @C(Y%% !1110 4444 %%%0R7=M%YOF7$2>4H>3<X&Q3G!/H.#S[4 344
MBLKHKHP96&00<@BEH **C%Q";AK<31F95WF,,-P7UQUQ3R0!DD >IH 6B@$$
M9'(HH **** "BBB@ HHILDB11M)(ZI&@+,S' 4#J2: '44BL&4,I!4C((Z&E
MH ***3<-VW(SZ4 +115=KZT19F:Z@58#B8F0 1G_ &O3\: +%%("& (((/((
MI: "BBB@ HHJ"6]M85E:6YAC6''FEY  F>F[TSGO0!/1110 45&EQ#)/)"DT
M;2Q8\Q P+)GID=LU)0 4444 %%%% !14;W$,4L<4DT:22DB-&8 OCDX'>I*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N?\4:A<+';Z-ILOEZGJ9,<<
M@ZV\0_UDW_ 00!ZLRBN@K*U7PUH>NRQRZMI-G>R1*51IX0Y4'J!F@#'^&<*6
M_@&P@C)*12W*+N.3@3R 9-=;7+Z#X.7PSHUMI^D7<=IMO#<7,D=JO^D(68^6
M03QP57<.0%%=10 5S-U?M?>/K?02?]&MK W\R_\ /1VDV1@^PVN<>NWTKIJY
MR[TU[/QQ;>($4M!-9&PN=HR8\/OC?_=R7!]-P/3) !7BT/Q'&+8/JMC+Y6IM
M.^ZW;][;M_"WS?ZP9.#]T<<<"N+MI+2#3/'3RZ9J-S+;:M<K;R62MOA C0J$
M<$% "2>.!FO7SG''6N2T[PMK&E+K*VFN6B_VI>R7C.VGDM$SJJD+^]P<!1C(
M//KTH B\/^([AM$\-V'VBWU75[VP\]YUFVQ%4"AW+!3_ !,HZ<G/3%)_PGKO
M!9^5I+/=2ZJ^DW$!G \B=59NN/F4A<@\<$<=J=8^ +?1(=!_L2\:WGT>*2!7
MG3S%GCD.YPX!7DMA@0>#V(J1_!3?Z%)%?HD\6K-JURYMR1/*59< ;AM4*V!U
M/RCKSD CB\<3B%?M.E)'<)K2:/<1I<[E1GVE75M@W##J<$*:EO/&\>G_ -N?
M:[18ETJ[@MFE,Q\LB4(0[';\B@.,\'I4%QX'N98-1V:K$MQ<:O%JT#FU)6*1
M @"L-_S*1&.ZGDU8MO"NIVUYJUX-9@>;4IX9I%>RRGR1JC(5W\JP'KD<<GN
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M.3QTK!MM-TS1/(C\6:%>V>IQW8?_ (2:W D65S)E6:499 V0I5QM .*Z;3_
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MW=G;"CA1EC@=ABM2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR]\4:%IUI!=W>K6<5O<1F6&5I1MD08R5/?[R]/44+XGT-]3CTU=4MC>R,56
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M)2?#J;DC7)=5N=S*/4[=W'O0!U5CXTLM7\56>F:5<VUW:364]Q)+&Q+(R-$
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MQ/JUW=.Q2.&YOKF5')&.5?Y3^-8D%@C^ =&C>U!W^+ \BE.H^W.,G_@/'TH
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M\CU,K'\H2VW*Q [;F,6/9JY>VU2;6M"^%VHW$<$<L^JL62",1H,"0<*.!TH
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MLUU:YU*XTZ:.>X80H\*R,[!U4D@^7QQWH Z#1/#D6BZKK=\EP\K:K<BX=64
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M8SG)R<]>U/O/!%S<'4H[?79[:UU8#^T84@0F1M@1V1C_ *LLJ@'@^HQ7844
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M6,$T*Q!>'$FW))]MGZTV_P##L&H>)+#6)93FTMI[?R-N5D67;G)_X#^M;-%
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M,!BE>.,C=L#N6  Z!B!716&LVHUSQ'XQ=+@:-%:6UK'-Y#@R[#(SLJD E09
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7/^(?$%YI-_IEAI^EKJ%W?F7:C7(A"A%#$DE3ZUT%<=XV3PR=1
MT>3Q,]Q!"/.6&X\YH8%)"Y61U(QD#@'@X- '2:7<7]S9"34K!+&XW$&%)Q,
M.QW8'\JNUPG@G5[:RTJY\V]G?29]7:UT:6<O(9(V"[55CDE=_F!2>P'-=W0
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M-;>-$D/V/5K>XU)(74X6]L9?+"XXR'BP-Q'& Q/.*Q].N="TOP\;26.V@?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN!S@]-W?&"\>*M5729[6\U:RM+VTU=]/ENQ:O(\Z*GF*8H%SER&7(Z !CZ4
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M[Q#X:76I[*]MKZ;3]4L68VUW"H8J&&&1E;AE.!D'T'(J ^/O"PCG?^V(CY)
M=0CEL$$@A<99< G< 1QUJQ>>,?#UA%:RW&JP+'=1">)QE@8ST<D [5_VC@4
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MC;M*T8DW%8V *H-Z@9'.">>M=#-XKT*WUE=)EU*%+XNL?EG. [#*J6Q@,>,
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M)C:INR90I!&00,$@XSGM6QITNFW+WESITT$S/.4N'BD#_O$ 4J>>"  ,5>H
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M3TXJ#3;.Y6Z^$!-O,!!93B;*']V?L@'S>G/'->IW5[:V,8DN[F&W0G:&ED"
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M$C4%1O'49Y/)Q76^+K*>?Q+>+;6SOO\ "M]"FQ#@L7CVJ/?K@5Z!10!Y!!>
M2^'M576+[2[$:&MD;F&R$FV="I:-@\;;2>,<<[",U>T4VGA#Q!I\]VNH+IT^
MA1V]I+<6K&0.)G=HV5%.UB'3"X'W<=J]1HH Y+X90R0?#_3HY+9[9@\_[EUV
ME/W\A (^E5?%NH3VWB>PA:[N=.MVLY2EU9V2SSS2[T_<J61PN1SC'.!SQ7;T
M4 <M\."R_#_1X)$=)K>#R94D4JR.I(*D>U=3110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5QVL7VN7/Q!M-!T[44LK1]-:\F?R%D;*RJN%W>N0/IGO
M@UV-9;:'"WBI-?\ -D\]+)K(1\;=I</GUSE: .&T_P ::K?:M;W,,U]-%-JC
M6C:>NDR^3'!YK1"3[1LQN& Y.[;U&.*?8Z[K5TVH6MYKLEEJ@MKAWTZ>P$9B
MV_=>!R,2*!U)+9SGBNFL_"DEAJ.^VUJ^BTT7+W8T] @3S')9AO W;"S%MN>I
M].*CM_!S?;(9=0UN^U""V25+6*<)F,2*5)9P-SG:2 2>_.3S0!Q^B7OB*#P_
MX TFQUG8=6LG:2>6W1VA18$90HQR1R 3ZY.<8J[?>+M4TC6/&\>Z&=M+MK 6
MI>)5S+*NW<Y7!(W$''89 Q70:/X(32SH7FZK<W?]B++':^9&B_NWC"!#M S@
M+UZG-27/@?3KW4/$5S<RSNNNP0PSQ@@>6(U(5D/4'G//<"@#F_'=IXGTWP!X
MB-SX@6ZMOL899OLZ1S!B<.F%&W801@_>'/)IVM^(]7LM8NM(BU>]6;3[*.59
M8=':Y-W,Y<@2>6A"( JCC:3D\\5MS^!CJ6F:G::QKM_J#WUJ+3S&"1B) <@J
MJ@*6SR6(YP!P*DF\(WKS"ZB\27UO?2VXMKRYBAB!N$4L5.-N$==[ ,/7O0!D
M1:QK_B6\U!;:Z_LI+'3K:9[5[=6,DTT9D*R;AN55&%P,'.>:U/!3W,?PHT22
MSC66Z72(C#&QP&<1#:#]3BI;WP;Y^I3W=GK%]9"[MDM;U(]KFX1 0IW,"5;#
M$;AS^/-:>FZ%%IGA:VT&*XG\F"T%JLRMLDVA=NX$=&[Y'>@#S+6M<U2^^'GB
M17\1S->0Z>'N;2XL!;7$#'(=0,#,9R0&&3Q]XUU:S:]?^(9/#]MKSVRZ?813
MSW8M8FDGDE9PH((VA0$YP 3GJ*GN/ 8U*TU"'6-:O+^2ZL38+,T<<;11$AB1
MM4 L2%))].@YJ9_"-Y]HAOH/$5W!J@MOLMQ=K!$?M$88LN4*[0R[C@CU.<T
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MJ%LDFTX2<J2I.,G!7@GGGFJ^K?#]-376;:/6KVTT[5V,EU:1*A!E*A2RL5W
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M(-./@F4-;W:>(+_^UHKB2=KUDC8MYB!&4(5VJN%7  X(SSDY ..OM8NM;M_
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MNW.D?Z-<6\-Q-XKETP2?9UVK#\W51C)& <]3CK5FZ\1>(--N]1T#^TUN;O\
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M+QN!&" ,YSTXZYK>\4>'X/%/AN]T2YFDAANU"M)'C<N&#<9X[4^'0X8?$/\
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M7>BS7UT[7EVM[=79V^9+*'5\X V@?(JX X %=5+$DT3Q2H'C=2K*PR"#U!H
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M!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !02
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M@F&Q7).<_-P><=S5F]UF:2[T%M7\.QH+C5%CLW^UAS&3"S+(0%ZXWJ5[>IH
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M4\OG[6C$@@0%5P=V"PR"5X/&: /3**Y.]\:/!<3?8])N+ZVM[P6D[0!VD!R
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M%?HD\6K-JUR[6Y(GE*LN -XVJ%; ZGY1UYSKV'B?0]3N9[>RU6TGE@4O(J2
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M[G%7K37])OX[*2TU"WF2^W_9BC@^;M^]CW&#GTQ0!>FF2"%Y7SM49.U22?8
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MQ*7DD=@%50,DDGH*YFR\:V&J^*;;3M-NK6YLY+&:YDF1CN1D>, >P(D)Y]J
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M6R+&UQ'Y<FW' 9?X2!@8[8K9HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6<AHUY'7@9[8/'/&UJ?A*YN-2U&[TS6I=.&IQK'>HL"R;BJ[0Z$GY&V\9Y'
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M1>7#1B5TW+D(/F"#OG)/'%;'B+28O%'CO1;>"UNTBTMF?4)VA:.%XP4=(0S
M"3,B(WRY "GUK:U#PO>3:M>7NF:W-IJWZHMXD<*N6*C:&1C]QMN!G!Z#C(H
MY35OB#?)?ZI-9W'EIITD:1Z=_9\DKW?R([YD480_/M4=BN3P:[OQ)<7]MX8U
M*ZTK9]OAMGE@#KN#,HR 1[XQ^-9]QX6NQJMW<Z=KD]A;7TB2W<"1*S,ZJJDH
MY^X655!X/3(P:Z4@$8/(H X-?&]S=>+M'CM/*.B75O!Y[D982SQR218/IB,
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MD?.5*]&7#,I'&0>U;.A: ^DW%_?7=ZU[J-^Z-/.8Q&N$7:BJHSA0,]R<D\T
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M+0[%MH;"Y>0S.S; I+HNW+,@SSU/I7 ^'U@E\) :K8ZWJGA>.*P=!.LN^*8
M^:\8XD:%?D/&1UQD"I)]-BNH]?F\(6$XT.%+&Y6".%DCFN89_,D\E& R?+50
M<#!..] '?:1KNJG7VT37;*TM[M[4W=O)9S-)&Z!@KJ=R@AE++[$-VHUC7=47
M7TT/0K.TGO!:_:YY+R9HXXT+%5 VJ268AO8!363;ZO:Z[XUCUVR6X?3-*TJ=
M99S;NFZ21T;8H8 L0L1) Z9 ZTV76[+2O&">)+GSUTC5]'@6&X6!W ='=PK!
M02I9901GKM(H L1>-;W5K?2(-%TZ$ZI?I/)+%=S%8[40N(Y-Q4$L=Y"C YZ\
M4B^-KVYL[.TM=-A_MZXOIK%[:6<^3"\0+2.7"Y*;0".,G>.E<]H22^%[[2/$
M.KV]Q;VE[#?K/F%F-JTUR)XPX4$KE<@^AX-)9I-I^I67C"ZM;F/39M7O9GS"
MV^*":-8XY&3&X F)3TX#C- '>>'-;N-5%_:W]M';:EIUQY%S'%(70Y575U)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9MI)-/@M%WO%')"?M,KXW8VC.X8& !S7L55KR_LM/19+V[M[9';:K32! 3Z
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MX%\0F. *Y\6>9\JX.1?1C/Y5V/CR_P#L&E:>Y:V@B?4(DDO;F$2)9C#$2X/
M(("@G@%@:ZJB@#Q-6BO]UK-.UZ6\96<[&6$1F6)X4VR%  -C;6P<8.*V_%)%
MGXQUS^T=;72[2_TV&*+S+,3?:4'F!XTS_$"V=HY.\5Z@S*BEF("@9))X IL,
ML5Q#'-#(DL4BAT=&#*P/(((ZB@#FM;M3:_"O4;0/+*8M$DB#R+AWQ 1DCL3Z
M5S?@VW#:WX.DDBRT7A!=I9?NMNA'X'&?UKTRB@#QW1[B#2KGP3=7C"WM8]1U
MF'S'&%4M+($7/;.,"I/#$ >XT?2;[7V&HV.IRSMIB6(\U) TA9V?J$8,?G/!
MWBO7J* /)[:U6/X:Z4R0[9#XF20D+SG^T2-W_?/&?2LW4;^P@\"ZMH%T-VNK
MKCS26^PF0YO XFZ?=\LCYNG;VKVJH7NK:*YBMI)XDN)@3%$S@,X'7:.IQWQ0
M!Y/<P!M7US1]1U]K*:[UE9XK%+$233@M&T4B-U(&U02.%V'.,53UZ_L+;P5X
MST*\&=8EU:>X6V*$R.C2J\<H&/NA-OS=!MQ7M$DB0QM+*ZI&BEF=C@*!U)/8
M4V&:*YA2>"5)8I%#)(C!E8'H01U% '+?$^-Y?AIKRQHSM]F)PHR< @G]!61#
MXBT6Q\;W^M:A?0#3=1TNW6PO&YCD"/+YL:G^]DJ=O4UZ)10!QW@Z*\TOX6VH
MELG:XBM998[21<,5)=HXR.WRE1BN$@U*.YGTZ0:K#=1OX?O;=4MK588+>0QQ
ML+=,<D@*?E))&WWKVRB@#S%[)UT_X=PV4?ERBRF1"HQM9K)OR^;'XUF:;J>E
M7>F_#?3;1<ZAI]W%'=1",AK5A;R*ZOQ\I+#H>N,]J]974+)[Y[%+NW:[1=[0
M"0&15]2N<@<C\ZEFFBMX9)II$BBC4L\CL%50.I)/04 <GXWDL[:?2KR;6CHM
MW"\OV:]EA$D )4!DDS@?,.G(/RG!K%\+R-J7C#0KZ?3X+9_[!N2JPQ%(P?M*
M#>BGE0P^8=\-7H^]#'OW+LQG=GC'K3+:Y@O+=+BUGCG@<922)PRL/8C@T >1
M:3J)TZWTFVDNX=)B\S5#%>M:"65F^UD""+(P"PYP 2=HP*B\.L9-8^%B#<7M
MH]3AF4C!B=8P"K ="/2O9Z3<N[;D;L9QGF@#A?A8C)I.O!E*YU^](R,<;Q6'
MJEJO_"#?$QQ"/-DOYSG;RV(HBOY'.*]7J."XANH1-;S1RQ-D!XV# X.#R/<$
M4 >0>+=5:5_$$#WD5I+#?V[-I\%HIEGC3R6^T2N1G: #AA@ (!DFKGB:.XMM
M>U'P_I^\VWC(0O#+$,K&>$NFR/6$*WU->IPSPW <PRQR!',;%&!VL#@J<="#
MVJ2@#Q_6[.&TU?Q3H]YK7]EVVH>2EM:I8B:2YA\A(U$)ZDJRL,#H>>]=A\38
MI#\,-910\KK;J20N20&4DX'L":["HX[B&:26..6-WB8+(JL"4) .".QP0?QH
M XW2)K'5OB7J.I6K17-O)HEJL4ZC<K*9I]P!].!GZ5PN@R2Z99>&[R\UE-'M
M)/#R6\<]Q:B5&=9&+Q_-T)4IQU;;[5[A10!C>$[--/\ "6E6D4LTL45JBQO/
M'Y;[<<;E/W2!@8[8K9HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_&>K7VCZ=:36DAMX)+D1W
M=X+5KC[-%L8[]B]<L%7/0;LUTE9NL6%]?10'3M4?3[B&3>&\H2HXP05="1D<
MYX(((% ')7GB6_\ [,TDQ^)M*4W*3/\ :K.SDNGN0K (4B7.!@_.<G#<"F67
MBC7O$$WAFWLIK6Q.JZ1)>7$C0&3RW5HQ\@)'=R,'U]JO6W@.>PN8;JQUR6"Z
M9)DO)1;(?.$LOFL4'2,AB<=>.H/6K6@^"UT.ZTJ7^T'G&F6<UE"IB"YC=T89
M.>H" 9[YS0!SVG^*/%#Z7HVL7=W8M!-JPTN>VCMB/,'G-"9=V[*G<,[<8Q2:
M+X]O=2U33IQ=)-;WUX]NVGI82 V\66"2>=T8Y5=W;YCCIST<?@N*/0K'2_MK
ME;75/[2$FP98^>TVS&>F6QFI-*\+WFDW<4<&N3#2()I)HK$0J"-Y8[&DSDH"
MQ(& >!DG% '/?%VUNKJP\/11W4<=O+K=I$\4D D#,S\$Y/('.5[U-_:/B29=
M<33+^Q@B\/JL 1K+B[E6%9&R P\M?F"@+TY.>U=-XD\.Q^(X=.CDN&@^Q:A!
M? JN[>8SD+[ ^M9VI^#KFYO=4DT[6I+"WU=0+Z%8%D+$)L+1L3\C%0 3@] <
M9H S=/\ $NM^(O%-E:Z?/;V>G2Z1::K)OA\R0B1FS&.1C( ^;MCISQ-H.K^)
M-6L[3Q)]ILCI-R\C/8F$J\-N"P5EDR=S_*I(( Y.,8K:T[PO;:7KQU*VD98Q
MIT.G1V^.$2)F*G/_  +'X5GZ=X,N-.GM[>/7;G^Q+:=YX=/6,(?FW'8\@.6C
M!8X7'IDG% &'X5\<W^KZIHQENH[F+54=I+6.QDC^P_(9$_>GAQ@;2>Y((XKH
M/%VL7.G7%A;V^KVVG"82,Q^R/=3N5VX"1*/N\G<W;@=\U+H7AF^T1[6W_MV:
M;2[)#':V?DJI"XPH=\Y<*.!P.V<U+J_AVYOM;MM5L-5>PN([=[64B%9-\3,K
M?+G[K KP>1[&@#FM,\4>(/$=QH-M9W%K8G4-(DO+B4VYD*.DB)\BDCJ6Z'H*
M33?%&OZY_8NE0W5K:W\YOC>78M]XVVTWE?(A. 6)!.2<<UM^'?!2Z!>6,XU!
M[A;*SFLH5:/!\MY%<9.>2-N,]\U77P)):"QGTW5VMK^SGNY$G:W$BNEQ(9'C
M9,C.#MP<_P /O0 ?#K[2++7A=F-K@:W="1HP0K$%>0"3@'KC)Q6)8>/;Z^U:
MVECNTDAN=1:S_LY;"3,46]HUE\[H6R Q'3!(ZC-=EX9\/?\ ".6=W ;V6\>Z
MNY+N2650&+O@GIQU'MUJKI_A>\TR^5;;7)DTA;F2Y6Q6%0VYR6*&3.2FYB<8
MSVSB@#S"#3-5_L+XFWO]JV_G13W<4[_81OE A4G#;LH".,<XZUL:7K5WX?T;
MP_HB:K:V"SZ6E\US'I;2'!5%2/8A.3]XLYY. .*[)/!42:5XIL/MKE?$$TTK
MOY8_<^9&$('/.,9I7\)7%O'I4FE:L;.]L+$6!F>W$JS1 +]Y"1@@J""#QD]<
MT 9&G>)=?\436%C830:5<_V8+V[DEM3)ES(T:JJL00I*.V3SC'UHM9?$4OQ0
MTZ"^OX(,:(9[BU@C+Q[O-17"DD'DC(8C(''O6O=>$[W[39W^G:_/;:G#9_8Y
MKJ:!9OM$>=V67@!@V2"..2,$4L'A"6SUO2M3M=8N#)9V7V&?[2OG-<Q[@^2Q
M((;(Z\]>E ">+M8N=.N+"WM]7MM.$XD9C]D>ZG<KMP$B4?=Y.YNW [YKFI/'
M&K7&F:)>RW]IHL%Y8"8W<]F\D$ESNVF-FR/*7C////7BNOU?P]<WVMVVJV&J
MO87$=N]K*1"LF^)F5OES]U@5X/(]0:R8/ ^I66BII-EXEDCLA ]JT4MHLH,1
M9B,9/#@,06Y!P,CB@#4\8:A-I_@'5]06.VEFAL'EV.OF1,P7."#]Y:X/6+6_
MUGQM\/F-W:QI<:?/-%$UDKI"PAC+?*3@YSQTV^]>B:GX=@U#P=<>&TF>&WEL
M_L:R8W,J[=H/N<547PC$NK>&K_[6^[0[66V1-@Q*'14R3GC&W/XT 1^--9O=
M'@L7M[C[%:2S%;N_^RM<"W4*2N5'0%L#<>!^-<]?>-+X7-CIZZ[I\#G3Q>/?
MVUE)=1W)9V5 JK]U<(2W)/. >,UVNL:?J%[]GDTW5FT^>%CG,(ECD!&,,A(S
MV(((Q6%;^!I],6VET?6WM+U(9(9YGMED68/(TI.S("D.[E<< ,1@T 8^BZMK
M6N>/M%N7NS:03Z!]KEL6@.%8R(KKR0<Y'#$9 XQS2_%BSN[N7PG%'=Q);RZ[
M;QF*2W$@WD.0QR>0,?=[^M=(?"T\?B+3-8@U>836EE]AN!/$)#<Q[E;)/&UB
M5Z@=^E6O$7AU/$#Z.SW#0_V;J,5^NU<[R@8;3Z [NOM0!RTFL>)'T_7[W3KV
MQBM_#Y:W6W:TXNWBB5Y"2&^0$G"A>F.]6;+7M=\0^+)K+3KNVLM.BL;2^+/;
M^;(?-#G9]X 9QU[8]ZN:CX*GNIM6CL]:ELM.UAMU];+ KLQ*!',;D_)N50#P
M?48K4TWPY!I>OWVIP2D+<VMO;+!MXC6'?C![YW_I0!YGI[ZY=>%_"MQ+J4=Q
M=S^)IA"\T)Q$0;I6)^;+#N!QC &>]>@^%]2U.;5-<TC5+B*ZETV>-4N8XO*\
MQ)(U< KDC()(R.O%4].\"/81V5NVK/+:6&J-J-K$8 &3=YI9"V?FYE)S@=*W
M=/T5+#6]7U-9F=M2>)F0K@)L0)P>^<9H X?4O%FH:;J/Q">TM[,2Z4+$P-Y(
M#2%TR?,;JWH/2NATS4-;M?&IT75;RVO(KC3VO8VBM_*\IED5&0?,<K\XP3SQ
M4=]X"AO;CQ3*;^1#KXM@X$8/D^2N!CGG-;;Z*C>*HM=\YM\=D]GY6W@AG5]V
M?^ 8_&@#EM1?57^*DENFI!+%=#:?[/Y.009-I&<]<C.['3BLGPGJFMZ)X;\#
M2W-W;2Z9J$,=J;5;?#1*+=G1P^>3^[Y&,<\=,UV6H>&I;OQ3!KEMJ)MV%FUE
M/"80XEC+;N#D;3GOS4<'@^&'2/#.GF[9DT)XW5B@_?;87BP1GC(?/X4 <UX6
M\=7^KZGHSR74=Q#JP8R6D=C(GV(;"Z'S3PX^7:?4L".*TO%<>H3?$+PM%IMQ
M%;3/:7P:>2/S/+7]R20N1D]!R>^><8K3T+PQ>Z)):VZZ[-+I5DK):V?DJI"D
M857?.7"C@<#H,YQ4NN^&Y]5UG3-6M-3:QN].CF2+]R)$?S-F=P)&1A.F1UZ\
M4 <U;>*]>O);70%GM8]6;5+FQFOO(RGEPQB3>(\_>9608S@$FEG\5Z[;33^'
MFGM6U9=7@T^.^\C">5+%YWF&//W@JL,9QG!K4C\"&"SMI(-6D768;Z6__M P
MJ0\L@*N#'G&PJ0, Y&T<\4DG@0S6<LDFK2G6I+^/4?[0\E<+*B[% CSC8$^7
M;GN>: .:EU#7?#NM^,-2::"\EL!ITMRR0[?.M1YGF87)VL%).1Q\O3G%=I:Z
MW<:EXVET^R>)M,L[%)KB0#):64YC4'T"*6/^\M4$TF+PP-;UG6+RZU9]42**
MXCALF;=M#*%2-,G!#8Y].3SFG?#;P[-X<\(PQ7BR"^N6\Z82MN=!@+&A/JL:
MHOU!H 9=ZEX@U7Q!K=CHU[:V,6D)$/WMMYIN)G3S,,=PVH 5''/)YXKC[^>]
M\7^,?A_J0N;>&._L+FYB@EM1*L#>7&7')^;)Z'C&*[O4O"MW-JM_?:5K3Z:V
MHQ)%>+]G67=M!570DC8^TXSR.!QQ3H_!EG;:KX<N[69XH="M9;6&#;G>KHJY
M)]1M_'- &?\ $)]423PRFFZC]C\_6(H9/W6_=E6()Y' VGCOGVKG6O=?T>V\
M=:QIU[:QPZ=J3SO#);[S<E8(2RD[AL&!QCG)KN_$_A]_$%K9+#?&RN;*\CO(
M)O*$@#J",%21D$,>XJG+X-2?0O$>FR7SDZY(\DDHC \LM$D9P,\_<S^- '-:
MQ\0+V#5-6>TND1-,F2)-/^PR2O=_(CO^\7A#\Y"^ZY/!KT6^OK?3=.N+^ZD$
M=M;Q-+(Y_A51DG\A6!)X4O(M2N9M-UR:QM;V2.6[@2!69G554E')^3<J*#P>
MF1@U>\4>'U\3Z,=*ENG@MI98VN BY,L:L&,>>P; !/IF@#R30/$>F:?KFC^+
MI-;L9+_7KJ2'5+-+M'>&*7'V<%<Y'E[$!]-S5WVHZSX@N=:\0QZ3<6D$&APQ
MGR9H"YNI&C\P@MN&P;2H& >22<]*W]:\.:=KFA7FE3V\:17,+1;D0 ID<,/<
M'!'TK@]>LKG1[O4+=;S7'FO]-BBN&MM-,RZA(B%!L==WE.1@-NP,$$8QD %_
M2?$?B/7=:T6Q@N[2VBN-!M=4NI3;[V+LQ#(HW#&[CGG&#US5;1_'][J&IV%Q
M]K2:WO;QX'T]+"0&WBRP23SNC'Y5W=OF..E=%X6\*/I3Z5J%S,1=P:';Z9+
M "H*?,3GZDC\*FTOPO>:3=110:Y,-'AFDFBL1 H(WECL:3.2@+$@8!X&2<4
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M **** "BBB@ HHHH **** "BBB@ HHHH *IZGJMCHUF;O4+E+> ,%W-DY8\
M #DD^@YJY7*>.;V6RM])(E%K;O?!9[_[,)VM%\MR&4$$ E@$W$'&[WH T7\7
M:!'I4.IOJMNEE,[1I,Q(!=0Q93W! 5N#Z4R?QEX=MA:F?588_M4:S1;@P^1C
MA6;CY 3QEL5YO90O=2Z=!,MY<O'XQ%RS7=OLD:-H&9)&4*H .,]!CN :T?$L
M!M_%'B6+4-6U"QM=4MH5AAM;%)_MB>64:-248[@<_+D??!]Z /2-6NC8Z/>W
M:S00F"!Y!+."8TPI.Y@.=HQDXYQ66?%VD66GV,FI:I:B>XM4N!Y*L1*&'WHU
MY8J3D@<G'6HO%5J\?PSUJTC\V5UTB:-=PR[D0D<X[FN?\(VDB^(/#,LMNX,7
MA**/<R$;6W1Y7V/'2@#J[GQ;H-KIEIJ,NIP?9;P9MW3+F7C)V@ DX[\<=Z6[
M\6:#96=I=S:G!Y-XN^V,>9#*H&25"@D@9&3VKSOPS,OAVZT35=6CFATX6^I6
MJRF%F$,K7A<9 !V[D7@]\8[UJ6FI6&E>*K'7KC39M)T>[TAX+8/;%1%)Y[.0
MRJ#L+@JPSC./7B@#L;CQ7H-M9VMW+JEN+>[0R6[JVX2@8SMQU/S#CKS4;>,?
M#RZ7!J7]J0FUG=HXF4,69USN7:!NR,'(QQWKA_#>G7":UX4N)K.6*)[K5[J&
M.2,@P1RONCR#]TE6SCWIACM[.?4+JYOK[1KF/7KU[34([;S8EW*F5D4@@A^W
M3)4X(/4 [H:_#<ZWI4-GJ6GR6E];R3HGS-+,!C#1D';M&><U7F\>^&X["_NX
MM2BG%E"T[K&#EE!QE>/F&2!D9'(KC[![Z^\:>"[Z[T\Q,=,OO-6& QH<D8.T
M_=W@!L'GYJK6\KR:-J&B:-<7.J:>-"NXXH;JQ*7.G-L 2$O@;MV<;3\WR#DX
MH [N+QSH!T6QU.XOD@BO$W1HRL6X +< 9PN>3C%6[[Q5H6G"(W6I0KYT(GB"
MY<R(>C*%!W#Z?6O.8KY1=:%JRZU=Z98'0TL_M,5D)0)D8%XV#HVTG(QP,[".
M<5M>&-)2P\6:$D45VUO!X=D6.2[B"2)F9"%8#A6QQCMB@#<N?'V@P:AHMJET
MLZZLK/!-'EE"@'!X'<C;CL>M;\^H6EM>6MI-.J7%V6$"'K(5&Y@/H.:\JTEO
M[*N?!=W>12PVT5_J\3.8F(0R2OL!P.,]J[/QZCP:19:U#%))+H]]#>;8U+.T
M>=DH '7]V[\>U &P/$.D-#J4HU"$QZ866];/^H*C)W?05A:AXYM-'M-?U"ZO
M+2YMM/$9C@MD<2J73<%D)XRW8@  =:X9M'U"&'2]->UFSXN@B?4"$)$;BX,\
MVX]B8YG7G^[4NMV-W)#\6EBM9F,HM3$%C)WA81G;ZXQVH [.;Q]IUMXA$%Q<
MPQZ7)IR7<4VQS([F1U( ZD )GIZGI73Q:E97&EKJ<-RDMDT7G+,AW*4QG(QU
MXKE-+GM]4^) U6T!EMI-!18IS&5!_?OD<@>@XJY\.(G@\!:9%)&T;*)1M88(
M_>OCCZ4 9<?Q-T^\MM#OK9XHK&]O9;>Y:<-F)5CE92#QR2B^OWL=:Z./Q;H,
MNCR:JFIPFRCE\EW.01)P-FW&[=R/EQGFO.O"P6XTSP)8M#(9].U6Y6[B>)@8
M6\NX(SD>N.?I3]9M+N+Q)J=^LUS96EMXBBGEN8;<2&-38A!)M92" [ $X.,D
M]J /4=-U.RU>R6\T^X2>!B5#KV(.""#R"#U!YK#TWQ[H6HMK!^U+!%I4QCFD
MERJE0%^;D?WFVXZY'O2>"((%L=1N[>^O+Y;V]:9KBZMUA\Q@B(615 &T[1SC
MDY/O7#7JS&#Q18HUS#<P>)8M2D$=N7<6P,/[U5*D.!C=CG[O2@#TB/Q9H,NF
MMJ(U.%;59EMWD?*[)&( 5@0"I.1UQU%0MXV\.+:P7)U2(1SQM+#\K;I%5MK%
M5QDX/H/?I7G^J6,&I:-?7D%_?ZR+O5M-CFFFM%CC<)*N=@55W *V"<=L9XKL
M[JW+_%C3)S"2D>C7(#[>%8S0]_7&?UH OVWC3PY>W=I:VVKVTLMV 8 A)#DC
M<%SC ;'.TG/M4]EXGT34-4?3;3489;M-P,:YYVG#;3C#8/7!.*\_T^QDB\">
M&$6U='7Q,)&41D$#[7+\Q]L8Y]*O>&[M;;Q/9:;I5S<75@9+@S6%[9;9=+.&
M;(DP/E+?* <Y#<$@4 =MJ_B#2M!2)M3O$M_.)$:D%F; R<* 3@=SVJ"[\6:#
M8QP23ZG %N(?M$&TES+'Q\RA0=W4=*PO%VH36OB;386NY]-MVM)BEY:V2SSR
M2;D A0LCA<CG&/FP/2L#X?P.=8\-&6WE#VF@W,$GF1X,4HGC!4\8!QGI0!W<
MWB[0(-,L]1?4X3:WIQ;.F7,I'7:H!)Q@YXX[U%X4\0-XCM-0N<P-##?S6\#P
M\J\:D;6SDY)![5P.A2KH.J:)JFIQ2PZ<DFL6XD,3%89'N]R$X'&Y58 _XUUG
MPY^;3-9F%M+;QS:S=RQQRQE&V,V0=IY&0<XH V6\5:$NM#1SJ< OR_E^5D_?
MQG9NZ;L?PYS[4W_A+= _M?\ LO\ M2#[9YOD;.<>9_<W8V[O]G.?:N2T'4;+
M3(Y?#VIZ;/=ZLVMS2B#[,6W!YVD2XW$;=JJ5.[/&W'7BLA7SX%C\'B"?_A(Q
MJ@S%Y+9!%WYIGW8QLV?-NS[=: /0;GQGX<L[PVMQJT$<RS>0ZG/R/G&&.,+R
M<9. :J>*?&VEZ!8ZI&M[;G5+2S>=() 2N_8617(X&XC@$@GM7*:G92'P%\10
MMLYEFU*X90$.Y_ECP1Z].*@UN[AT[2OB'H][;7$FHZB\L]I&L#O]HC:W14*D
M#!"E3GTVT =H/%"07_\ IM]8QVZ:2M_+;JCF=<M@OZ;.V,9S4&G^-+;6[+P]
M?6-W:6\6I2;7@N5<R,=FXHA&!N&>2<BN=AM+E_B+*RV\I5O!J1!MAP7\P_+G
MU]JR].E%]IOPL%O',YL9A!= Q,IB=;?#!LCC![]* /26\7: FK?V6VJ0"\\T
M0[.<"0]$W8V[O]G.?:F77C/PY97;6MSJT$<R2^2ZG/[M^.&.,+U')P*\^E?'
M@6\\'F"<^(Y-4?;%Y+9<M=^:L^[&-NPAMV>,8ZU<U.QD/@?XE!;9S+/?7!0!
M#ND'DQ8QZ\YQ0!WDGB?1(M9&D2:C"M\6">4<\.1D*3C 8CD#.3FK6IZK8:-9
MF[U&ZCMX P7<YZL>@ ZDGT'-<#=78T_Q8T6EW-R\]SJ4!N]&N[+>DA.Q6N(I
M,94*H#YR1E#P#6YXTS:ZGX9U:>.1].L+]GNBB%_+#0R(LA [!F'/;.: &^(_
MB%I>D^"K[7]/GBO#"3%''\PS-_<<8RI[D'''UK2T/73<>%5U?4KNUD"HSRRV
ML,B1J!UPK9;C]:\]\3I)JWA;XBZI80326-\ELELPB8>>T:J'=01DCD#..=M>
MJ[&;1]B@EC;X ]]M ''P_$JQNX/#FH1-'#I^I-*MR9PVZ$K%O"CU))4< YS@
M<UT*^+=!;1_[674X39>;Y._!SYF<;-N-V[_9QFO/_";1WME\-HUBD9]/$\-R
MKQ,IAE6V(P<C@Y(J.^M;NWUN[U W%SI]G;>)II);J*W$OE![-%63:RD;=Q*E
ML<;J /5-.U&SU:QCO;"X2XMY,[9$/&0<$>Q!!!!Z5SGC;QE-X76UBL=..HWD
MJRW$D ?:4MXEW2/T//W0!W)J?P1;PQ:3=W$%Y>7B7E[)<&>Z@6$R$X4LJ@#Y
M25R#@9R3WKFM+L/$/B/Q/K'BBRO+.RMY"=-M([ZP:8M;QGYF&)$P'?<>0<@"
M@#NIM=TNVT--:GO8HM.>-)5G8_*5;&W'KG(P/>JD7C#P]-:W%S'JL!BMA&9V
M.1Y6]BB[@1D$L",&O-[>'4-"TBVT#48Y;B'PUKEM<F:&!BLED^XJRKR2$9N0
M"<!14/B26#7'\?2V-K*\5Q;Z5@F%E,X$S L%(SC QG'(7/3!H ]+?QKX<CL(
M;YM5B-O,[I$RJS;ROWBH R0.Y Q[U/?^*]"TRWMI[O4X$BND\V%E)?>F 2XV
MY^7!'S=.1S7+>+5ET[QI8:B^JW.DV)TZ2V6Z@M5F57\Q6V$,C;=PQC@9V8K
MCLO^$?O]/G.LZKIFFS:,L,$\FGI([L)I':-T*-L;$B84 9QCM0!Z1J/BK0]*
M*"\U*&-I(A/&HRQ=#T90H.1].W-1VOC'P[?7]M96NK6\T]RNZ%4)(D^7=@-T
MSMYQG..U<SX:TI=/\8Z-%'%=&"W\,B*.2ZCVR+^]7"MC@-CJ/:LO2+&2'P-X
M#C6U=&BUM7=1&04!,^21VZ_K0!Z!:^)]$O=6?2[?489+U"RF,9Y*_> /1B.X
M!)'>J]KXT\.7M[!:6VK0237'^J"YPYQG .,;L<[<Y]JX+PA9'S- TF_UC4WU
M#3+IY'T\6**D#J) SM)L!V,&.#N.[>.M3Z78RQ?#WP+&MLZ/'J\$CKL(*Y>3
M)([=>OO0!VOAGQ=IOBI;TZ>S'[)</"P92,@,0&Y'0X/'6I_%'B.T\*>'[G5[
MT,T<(X1>KL>B^V?6N6\(:W9:)9:_!?F:*:+7KC>GDOD":X(C;IR#N'([<UJ_
M$V":X^&^MQP1/+)Y 8(BEB0&4G@>P- $,GQ TVV\0W%O=W<$6FBP@NH)MC[W
M9WE5N.N (P>G'.:V;[Q;H.G6]K<76J0)%=1^; RDN'CP#O\ ES\O(^;ISUK$
MTB6WU/XC:AJELIEMIM%MEBG,9 8>=/D#(]AQ]*X70H[C2;31KJ^U2]TBUFT"
M&W1X[)9M[I)(6B(9&P2'0@<9YZXH ]HDN[>*R>\>9!;)&93*#E=@&=V1VQS6
M7IWBW0=6OQ8V&J03W)0R*BY^=1U*DC#8SSC..]9[V2:;\*I;*(W!C@T9XT^T
MJ%E"B$X#@=& X(KE]%O+;5Y?A]9Z;#*L^F1>;=J867[/']E9"&)&/F9EQZ]1
MQ0!VEOXT\-W5O<W$.L6S06L2RSR9(6-6Z9)XR?3KR/44Z#QAX?N;62YCU.+R
MXI8X9-X9"CN<(&4@$;B>"1@UP.F:?-;_  =\-.+.4QV>H0WEY D1+F-;@LYV
MXR<<-CVK2N=/MO'FOZ^]B7.FSZ+'8_:S&R*UQYCNI7(&XIE3D="<4 =MJNL6
MFG+Y$EY!!=RP2RP+,"01&N68@<[1D9K.3QCI%EH^FW.JZM9"2[MQ,)(%;RW7
M RZCDJG/5NGK7&Z4^H>)],\0>(M2LYH;BWT4Z7#$Z$'S?++W# =\N54$==E4
M[9X]*\(^&[D7]YI6K)H4<:^99&>WNEQGR'7&=P/8%3AN_8 ](36 _BB33Q?V
M!@6P6Z$(#>< 7(\PMG;LQQZYI-,\6Z#K-T;;3]3AGFV&15&1O4<%D)&& ]5R
M*\]U"PU35O%6KK%8O:W=WX($*1JN%CF9F_=@] 03BM.WO[;7M6\'1:3!,'TM
M)9+P- Z?94^SM'Y;9 PQ8J-O^SGM0!UECXS\.ZG>V]G9ZM!-/<KOA5<XD&W=
M@'&"<<XSGVJ?3?$^B:O?26=AJ,,]P@+%%S\P!P2I/# ' )&1S7!Z7920^ _A
MLBVKJ\5] \B!,%<PS;B?3D\Y]:M^#KM8-=L=+TNZN+W2X[:7_1[VR\N?2\;<
M1F3 R#RNTY/R@Y(% '::OXBTG0C"NI7J0/-DQIM+.P'4A5!.!D9.,#-<UXS^
M(-OH>FZ1+I5Q9SRZK<QQ0S2!GB6)LYD.S[P&.@.>:=JE[!H'Q(_M;5-\5A<:
M0MM#<>6S*LJRLS(2H."P92/7;[5RSZ?>1^%_!6ZSGB#^+!=K"T9#0PO+,Z;A
M_#\K#KTSB@#O]8\4VWAWP;_;VH.LRK C_N$91*Y7("@Y*@GIGIWK-D^(&FVW
MB&>WNKN"/3/[/ANH9MC^8[.\JMQUP!&#TXYS4WQ-@FN?AOKD4$3RR&WR$12Q
M(# G 'L#5?1YK?5/B/?:I;*9;671;98IS&0"/.FW 9'L./I0!L-KL4VMZ1!:
M:C8-:W]O),B$,TDZ@ AHV!V[1G)SZC%3:9XGT36;R2TT_48;B>-2Q1<_,H."
MRDC# ' R,CFO,O"]I<QZM\-F>UFVPZ3>+("A&TX& ?0_6MSP9=K#K=EI>F7=
MQ?:5%:2 0WMEY<^EX*!8C)@9!Y&TY/R Y(% '9^(];A\.>'K[5YU+K;1%EC'
M61SPJ#W+$#\:I^$O$4OB#3;AKVT6QU&RN7MKRU#[Q&Z\@@X&05*D''>L'QE;
MZGXE\5Z3H&FR1V\-CC5+JXGMVEB+JV(HR R[CG<V,_P@UEWVF>(M$\4W4MS=
M6]XOB2RDLGDL[1H5BN4C/DLP+O\ >!9<Y'04 ='-X\TZYUG1;'1[RVNQ>WK0
M3'#<((I&W(> PW(!D9'-&K>/=-ANK.STN\MKFZDU.&RE0AB K2!'VG@%ESV)
MP>M<MI^HVFHM\.[*SM;@7&G2".Z#6SK]E86LB%&)'!+#_P =^E4K&ZB_X13P
M=X?-K<'5M-UFV^V1&W?]P5E(9V;&,-G@YYW9]: /3T\3Z))K)TA-1A-\&,?E
M<_? R5ST+ <[<Y]J@C\9^');Z&R35H&GFE,**,X,@)783C ;(. 3D]JX'1K(
M_;K;1M1UC4UO(-;DNO[.CL4*Y$[RK*9-F?+92"6W?Q$>U3QV4J?#2V5;9Q,?
M$@E("'=_R$OO?]\]_2@#I/%/CW3M%L;^.RO+:;5+9D3R'#%=Q9<J2,#=M).W
M.?:NA?6M-C@U&9[N,1Z<2+MCTAP@<Y_X"0?QKRG5;J*W\$^(?#L]K<2:PVL2
MS^2+=R71KH2+-G&-NS'.>V.M7M>OTT^S^(^E30W)OM0#RVD,<#L9D:T1-RD#
M& 5;/IB@#N]0\8^'M*=TO=4AB=$61E()*HP)#$ ?=P.O0=ZELO%.AZCJATVS
MU*":["EPB$D,!P2IZ-C/."<5R-K9N=6\7R-;L2^A6<:,4^]^[FRH]>V1]*32
M[22)_AB%MV00V$BR80C9FU7@^G/ZT =GJ_B'2=!$7]IWJ6YEW%%(+%@,;C@
MG R,GH,BL2Z\=:?I_B:XL[Z[MH].&G07<$RAG:0R-*#C;G*[4!R!WZU7\:RV
MMGJEC>_VK=Z1J"6\J0W:VOGP2*2I:)UP<DE5( P>#@U7\*I<W/B\WU[IHLYI
M/#=BK1+'M6)B\Q:,>F./E[<4 ='?>+O#^FV]K/=:I D5U%YT+*2X>/CY_E!P
MO(^8\<U3E\2SCXA:?H$*P/8W6FR7GG#)8D. ,'.-I!]*\\TJXO8/#VD:8\UU
MIQ;056#[-8I)/>2L[@P;G1@H "'''W\Y %:?A59)_&/@RX6*4QQ^%O)D=D("
MR*R*RG(X((/'M0!V7@'Q%=>*O!UGK%[%#%/.\RLD((4;)608R2>BCO5U?%6A
M-K7]D#4X#?[S'Y63]\#)3=TW8_ASGVKGOA!!+;_#/38IXGBD$MQE'4J1F>0]
M#5'PSJ-EI]G;>&]2TV>ZUF/5YG:$VQ;:6G>1;G<1MVA6!W9SV'/% '6Q^+M
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M;9LJ2[D(7+*&&TGAN".E %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+NR-@]T;J"<. RR*I7CCHV:T+7Q)H5]:7-W:ZS83VUM_KY8[E&2+_>(.!^-
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M^AA28J)4PV[<=J\Y+ +N(QP&4]ZNZ=KVD:NL[:;JEE>+ <3&"=7$?UP>.AH
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MO&$-U IPDA  '/(R  <9[UTKQI*NV1%<=<,,TZ@#R6&WDC^)#^#MA^R#5O\
MA(0<<>5Y><?3[1BCPS;R3^/;?PRZ$6WA:>\N@".")B/LX_!)9,?[M>LX&<X&
M?6C R3@9- 'F/A/PTNKWOBJY.L:Q9D:_=)Y=G>&)#C;S@=^>M<W-#!8>$=2A
MN=0N(K>'QN%DO))L2(H=,N7/<#G->Y@ =!BHXWAG0M&T<B;B"5((R#@_B#0!
MQ7AG4O"YUI(M.\<7&K74J,J6LVI+,&XR2% Z@ _K7%Z5H^M+\&]-U"WU[5);
M%8 ]WIL*PKNMMQ\U8W";PVW)'S'.".]>T0M!*HDA,;KD@,A!&0<'D>^14@
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MS,9)VQQ%>?8DD?6H=2A\W5?$VF:AXCL]-EO=1B>.WDL?.N9E*1>4\1#@M@C
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MQ>WEU=7L DBBN9S&RH<LH4B,,@)/\)'>O1M?\/-XA,%O<7\L>F*RO<6:(O\
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M?*^_]!6N9T&[TG_A"=&1M?M=)U33=3NBLLZ*\<,IDG&R8$@+N0MC)4^AKV+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G/'<UBG@O4[?4+F6V@O('M
M?.CMWG*%U*@[$&37GUKXZN+2TAMH_&,/EPHL:Y\)W>< 8'\=>R44 >3?\)/X
M-GU?Q!=WM_?3P:U:0VLL']D7*[0BNI.=ASG?Z<8[UD6]]X3@\$'0'U[4IKJ6
M\BO+B_DT:Y+2LDB, 5V\?*BKU[9]J]PHH \SM/'7A2V\5ZEK?]HW[?;;:"#R
M?[)N1L\LN<YV<YW^G&*J^-/&'A?Q9H TV+5KZSD6XBG69M&N9 "C!@-NT>GK
M7JU% 'E%G\16CO(7O/%23VRL#)%'X7NXV=>X#;CCZX-48O%6FZ+/=+X:\2SV
MEA<S-.;.\\/W,ZP.QRQC(VD G)VG(R37LM% 'F'ASQIX/\/V]R7U+5+V^O)C
M<7EW+I5P&FD( Z"/"J   HZ 4FE>-?"FF^)]?UG^TK^3^UFMV\K^R+D>5Y4>
MSKLYSUZ#%>H44 >.7GBW3D\5W^N:-XEDM#?00PR0W'ARZGQY>[!!!7^\>U+J
M/B[3M=\/W6EZQXEEE:2:"6*6W\.W46SRY%<@@ELYV@=1CWKV*B@#R[Q%XT\*
M:T^GW=KJ=_9:GI\XFMKG^R+E\ \.C+L&59>",CL>U=[9-=7U]%JD.H!M(N+-
M#%:-;;'#D[O,+'YA\I VD<5J44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>.7'B>UTSQ3KE]I?B=K4:A.CRPS^'+J?8R((^'!4$?+GI7L=% 'D%[XO
MTK6--L[?5_$,TTUKJ4%\LL'AZZB!6)@VPJ=W)(/S9[]*7^WO!0^(!\4?VEJ6
MWR\_8_[)N=OVC;L\[.SKY?RXQ[YKUZB@#QE-:\*+H<FF_P!M7YWZW_:WF?V+
M<\?OQ+Y>-OMC/XX[5V7_  M;PG_S\W__ (++G_XW7:44 >'Z-XCA\/075MI?
MB[;;3W4MT%F\+W3LI=LD9##/Y5I:CXLT._.FZDOB&]MO$-BKH+Z'0KGRI48_
M,CQ$'*\#^+((R#7KU% 'D%KXNT6[UJSU7Q'K]U?/8EGM+6UT*Y@ACD(V^800
MQ9L$@9.!D\5?\1^-?"GB!]';^TK^#^SM2BO_ /D$7+>9L##;]P8SNZ\].E>H
M44 >6>+O&OAGQ)I,%K;:M>V<\%W#=QROHUS*NZ-@P!7:N1D>M16GQ%>.\A>[
M\5QS6ZN#+''X7NT9USR VXX/O@UZQ10!XI8>*H=&EU!=+\6^7;7=]/>".?PQ
M=2,AD<L1N##.,^E=]X?U*_\ $FC6=S9:ZCM;WN+R4Z4\ GC R8PDARO#+\X)
MZ5UM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\:?0 45#/=V]M)!'//'$\[^7"KL 9'P3M7U. 3CV-34 %%%% !1110 4444
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MVQTU/.W"TEA@D!(  ?Y,KGDCUXJ&\\&3OJMMJ.FZ_>:;<0V"6!,4,4@>-6+
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M-:.F^'[73X]6C)-Q%J=U)<S)* 1\ZJI7'<87OZT <WX6TW3=8N?%B7]E:7T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !17">*/M>O\ CK3?"B:C=V%A]AEU"[>SE,<DX#K&L8<<@9))QUIS
M_#AK4>9HGBOQ#I]P.5WWAN(L_P"U')D'\Q0!W-%<9H7BC5+/7$\,^+888M2D
M4M97T&1!?*.N ?NR =5_+C%=G0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA&16+XY4/X \1@]/[,N?_135B?"#7_[?^'&FM(3]ILE^QS ]<H!M/XH4/XT
M=U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1!].: -?PG<ZM>^%=-N==@6#4Y80T\:C&">G'8XQD=CFMFBB@ HHHH ****
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M110 4444 %!&1@]*** .%^'W_$FU#Q!X0;A=,N_/LP?^?:?+J!_NMO%)JO\
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M!NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <W\0?^2<^)/\ L&7'_HLUY[J5L8="
MT"^NO"5OHMG9SVMQ/K$#Q/)$BE>=J8;#< GG ))!KUC6M+BUS0[_ $J=W2&\
M@>!WCQN4,""1GOS7-MX :\LXM/U7Q+JVH:9'L!LI!!''(%P0K%(U8C@<9YH
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ML0>J\Y!S^=4?*^+W_/QX0_[YGKH?^$N3_H Z_P#^ #?XT?\ "7)_T =?_P#
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M24U_A9I\_%YXB\3W8[B;5'P?RQ6S_P )<G_0!U__ , &_P :/^$N3_H Z_\
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MD6K_ /0EZS_W_L__ (_1_P )%J__ $)>L_\ ?^S_ /C] '145SO_  D6K_\
M0EZS_P!_[/\ ^/T?\)%J_P#T)>L_]_[/_P"/T =%17._\)%J_P#T)>L_]_[/
M_P"/T?\ "1:O_P!"7K/_ '_L_P#X_0!T5%<[_P )%J__ $)>L_\ ?^S_ /C]
M'_"1:O\ ]"7K/_?^S_\ C] '145SO_"1:O\ ]"7K/_?^S_\ C]'_  D6K_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:Y@8U8Y/(?)R>YJQH/@+PYX:U WVE6<L-P8S&6>ZED&TD$\,Q'84 =+1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7&?$5)_L>@7,%G=72VFMVUQ,EK TKK&N[+;5!-=G10!P&
MLW5WXYFT[2;#2-2MK".]ANKV\O[9K=0D3!PB*^&9F( R!@"L._;5;G489[N#
M7I;FSU]9I[>.T;[+%;+,0CH%3]Z2NT\%CRQ.,5ZW10!Y%-I]^UIJMJ;35X9+
M/Q0^INUM;-N>W=B \3%2KD!MVT9/RGC.*ZGP]);:39ZGJ\-MXCO/M5U$C/>6
M_P"^FP%0.L>U6"#."6 X4GI7:44 %%%% !1110!FZSHEMKD$$5S+=Q>1+YL;
MVMP\+AL%?O*0>C&N6T7P1<Z5/K*FYN9H=1U%)/WUX\N;<)'NW!CR[%&0GKM(
MYP*[NB@#G?%^F7VK66GQ6,22/!J-M=/O<*-D4@<@>Y XIOB8:_<O!;:=I-I>
M6#+FZ2>],!?T3A&ROKZ].F<])10!B6$&J7=Y:WFK6UO;-!"^V""4R*KLV!\Q
M R0B]<#_ %A':LL'Q:^NO<R:%IK1AS%;S/J3?N(B1EO+$7+'&3\PZ 9'4]?1
M0!PU]X0OFL/$FBVIC%CKMT;@W!?!@$@43 KW/RDKCNV#C&3:U&/Q*FJQK9:#
MI]UIMH%^R++J1B.\#&]E\ING0#/')ZXQU]% ')ZO_P )3-?6RQ:+IU[9PHDC
M*^H&$/,.<D>6V54]!GJ,GH*Z6S:Z:RA:]2*.Z* RI$Q95;N 3U Z9P,^@J>B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ-HXT:&6,:CJ%[YC;MU[<&5E]@<<"M*B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"*YN(;.VEN;F5(H(D+R2.<*J@9))["LY/$VBOI=
MQJ7]HP)9VYVS22'9Y9P#A@V""01@=\C'6H/&4$MQX4O$AB>5E,<K1HNYG1)%
M9E [DJI&.]<QJ=[97=KXLU4*SV-Q:1VUK(8&/F3K'+DJ,9_C5<^H([4 =EJ'
MB#2M*@AGOKV.&.<%HR<G<H&2V!V ()/09YIK^)-'CU./3FU"$73E55,Y&6&5
M!;H"1R 3D]JX74+I9)=/U./4;ZTM3HSV\4MO;;B;A64F,AD;KQ\N/FV^U3ZC
M?RW;:3:R02V^I)=V4MYI@L\+=/F(F42+_#'C.<_\LMIXH Z^/Q5H4LEU&FIP
M%K6-Y9>3@(G#L#T8*>"1G%6=,UFPUA9&L+CSA'C<=C+C/3J!Z5Y_J+V^MZA+
M#%'?&R.EWEO+8QV/ERZ<&15;;@89F(P%YSU7C.=[P[K+#4KQ/[3O-1TG;;I!
M=7%MAA<.S*T8V(N0!Y9/'R[N3Z &];^(M'NKR>TAU"%IH [2+G  0X<@G@[3
MP<=#UQ447BK0Y[&>]CU*$V\!42,<@C=]S@C)W=L#GMFO.[NTNM3\+66A65O.
MVJ:?97T=VGELN&,3QXW$8.]V4CGD<]JT=2NHM2\36VOV<4[:38_8Q=/Y#CD-
M-QM(R?+\Q2>/ES[&@#M_^$CT;[%;7AU&W6"YF$$+,V-\A;;L /.[/!'48.:?
M<Z_I5GJ46G7%[%'=R;=L9S_$<+D]!N((&<9/2N"U*ZM(]"OKR6-P+[78KBR)
MMV+&%)K?S&'&0I\MF[9&#S4^JSK.?$%G$DTESK,]I-IQ$+8D39$NX''&QD=C
MG&!SWH ]'HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH KW]];:98S7MW)Y=O"I=VP3@>P'
M)/L.364GBW2FLYYV-U&\,J0/;R6LBS>8X!51&1N.0<C QU]#C3U*YEL]/FN8
M;22[DC7<((R-SCN!GOC/'>O-WTNZN)Y+\1:W-IT6J0W,D\L4D5[*OD21.%4!
M7VJ73&U0<;\9/- '=7'B?2K/P^VN74[P6*$AC)$RNK!MI4H1NSNR,8I)_%&E
MV^J_V=))-YHF2!Y! YB25P"B-(!M#'<O&?XAZBN$U71O$^I>%;IA;?:K6.WO
M%L[>^ED%T-[.J,PVL6<1D!0Q!^8YYZ;>NR:CJ&I6%NVGZ@MY;7MM((8T,EC.
MNY&>1I-HQL^? )!W(IVGB@#<M?%VEW4-Q<+]LCM;>.262ZFM)(X=J?>(<K@]
M#T/:FCQCI(AE=S=QRQM&OV>2TD69C)G9M0C+;MK=/[ISC!KCGTZ^6RN+'0M.
MUG'V"[BN[35&=H&8KB-4W'826)P8^",[C3DTZ43W5] NO210&SDAO;NS:2Y6
M5/-5AY;!6>,*_( SEV*D]@#L9/%^DI907*M<R^>9 L,5K(\H,9Q)NC W+M/!
MR.I [C.A=ZM8V.E'4[B<)9A%<2;2<@XVX &23D  #))KS:#1+VVNDU;4TUN2
M"Z^VG%BLD<Z.\D9C++%AE#!"<'@':&KL8]0O;?PFL.K6E[+J,=A"+EH;9I!)
M,Z$-MV YPP.<<#(H WK.[AO[&WO+=BT%Q&LL;$8RK#(.#[&IZP_!\K/X2TN*
M2WN;>6WM8H)([B%HF#*B@\, 2,]^E;E !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935423332688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apollo Medical Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4472349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1668 S. Garfield Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alhambra<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">282-0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMEH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,461,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935422270064">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 234,223<span></span>
</td>
<td class="nump">$ 233,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,490<span></span>
</td>
<td class="nump">53,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,263<span></span>
</td>
<td class="nump">10,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">81,526<span></span>
</td>
<td class="nump">69,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,639<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,227<span></span>
</td>
<td class="nump">9,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,670<span></span>
</td>
<td class="nump">18,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">461,038<span></span>
</td>
<td class="nump">398,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">87,146<span></span>
</td>
<td class="nump">53,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,651<span></span>
</td>
<td class="nump">82,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">253,310<span></span>
</td>
<td class="nump">253,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loans receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">539<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,820<span></span>
</td>
<td class="nump">41,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">896<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,638<span></span>
</td>
<td class="nump">15,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,901<span></span>
</td>
<td class="nump">5,928<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">490,026<span></span>
</td>
<td class="nump">453,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">951,064<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,922<span></span>
</td>
<td class="nump">43,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,071<span></span>
</td>
<td class="nump">10,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112,499<span></span>
</td>
<td class="nump">55,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">524<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">2,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,413<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">185,238<span></span>
</td>
<td class="nump">115,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,257<span></span>
</td>
<td class="nump">9,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,904<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199,068<span></span>
</td>
<td class="nump">182,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,706<span></span>
</td>
<td class="nump">14,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239,984<span></span>
</td>
<td class="nump">220,992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">425,222<span></span>
</td>
<td class="nump">336,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,997<span></span>
</td>
<td class="nump">55,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,719,710 and 44,630,873 shares issued and outstanding, excluding 11,175,702 and 10,925,702 treasury shares, as of June&#160;30, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">310,629<span></span>
</td>
<td class="nump">310,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">169,292<span></span>
</td>
<td class="nump">143,629<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity, parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">479,966<span></span>
</td>
<td class="nump">454,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,879<span></span>
</td>
<td class="nump">5,940<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">485,845<span></span>
</td>
<td class="nump">460,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">951,064<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $599.7&#160;million and $567.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $143.7&#160;million and $91.7&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $431.3&#160;million of investment in affiliates and $36.0&#160;million of amounts due from affiliates as of June&#160;30, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935420530288">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,719,710<span></span>
</td>
<td class="nump">44,630,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,719,710<span></span>
</td>
<td class="nump">44,630,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,175,702<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 951,064<span></span>
</td>
<td class="nump">$ 852,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">425,222<span></span>
</td>
<td class="nump">336,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">599,700<span></span>
</td>
<td class="nump">567,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">143,700<span></span>
</td>
<td class="nump">91,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">431,300<span></span>
</td>
<td class="nump">802,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliates', window );">Due from affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrentAndNoncurrent', window );">Due to affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $599.7&#160;million and $567.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $143.7&#160;million and $91.7&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $431.3&#160;million of investment in affiliates and $36.0&#160;million of amounts due from affiliates as of June&#160;30, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.12(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935421768176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 269,697<span></span>
</td>
<td class="nump">$ 175,638<span></span>
</td>
<td class="nump">$ 532,954<span></span>
</td>
<td class="nump">$ 351,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services, excluding depreciation and amortization</a></td>
<td class="nump">230,070<span></span>
</td>
<td class="nump">136,214<span></span>
</td>
<td class="nump">450,798<span></span>
</td>
<td class="nump">276,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">19,894<span></span>
</td>
<td class="nump">14,199<span></span>
</td>
<td class="nump">31,837<span></span>
</td>
<td class="nump">23,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,351<span></span>
</td>
<td class="nump">4,237<span></span>
</td>
<td class="nump">8,725<span></span>
</td>
<td class="nump">8,434<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">254,315<span></span>
</td>
<td class="nump">154,650<span></span>
</td>
<td class="nump">491,360<span></span>
</td>
<td class="nump">308,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">15,382<span></span>
</td>
<td class="nump">20,988<span></span>
</td>
<td class="nump">41,594<span></span>
</td>
<td class="nump">42,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="nump">1,512<span></span>
</td>
<td class="num">(3,134)<span></span>
</td>
<td class="nump">2,945<span></span>
</td>
<td class="num">(3,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,854)<span></span>
</td>
<td class="num">(1,853)<span></span>
</td>
<td class="num">(2,927)<span></span>
</td>
<td class="num">(3,376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (loss) gain on investments</a></td>
<td class="num">(1,866)<span></span>
</td>
<td class="nump">83,769<span></span>
</td>
<td class="num">(10,829)<span></span>
</td>
<td class="nump">83,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">3,034<span></span>
</td>
<td class="num">(15,883)<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="num">(14,579)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">63,462<span></span>
</td>
<td class="num">(6,697)<span></span>
</td>
<td class="nump">62,914<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">16,629<span></span>
</td>
<td class="nump">84,450<span></span>
</td>
<td class="nump">34,897<span></span>
</td>
<td class="nump">105,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">6,038<span></span>
</td>
<td class="nump">24,920<span></span>
</td>
<td class="nump">12,233<span></span>
</td>
<td class="nump">31,696<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">10,591<span></span>
</td>
<td class="nump">59,530<span></span>
</td>
<td class="nump">22,664<span></span>
</td>
<td class="nump">73,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to non-controlling interest</a></td>
<td class="num">(808)<span></span>
</td>
<td class="nump">46,872<span></span>
</td>
<td class="num">(2,999)<span></span>
</td>
<td class="nump">48,179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Apollo Medical Holdings, Inc.</a></td>
<td class="nump">$ 11,399<span></span>
</td>
<td class="nump">$ 12,658<span></span>
</td>
<td class="nump">$ 25,663<span></span>
</td>
<td class="nump">$ 25,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember', window );">Capitation, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 227,623<span></span>
</td>
<td class="nump">$ 144,550<span></span>
</td>
<td class="nump">$ 449,682<span></span>
</td>
<td class="nump">$ 289,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember', window );">Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">18,793<span></span>
</td>
<td class="nump">16,214<span></span>
</td>
<td class="nump">36,868<span></span>
</td>
<td class="nump">34,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9,984<span></span>
</td>
<td class="nump">8,143<span></span>
</td>
<td class="nump">20,457<span></span>
</td>
<td class="nump">16,693<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Fee-for-service, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">11,740<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
<td class="nump">22,835<span></span>
</td>
<td class="nump">7,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,557<span></span>
</td>
<td class="nump">$ 2,110<span></span>
</td>
<td class="nump">$ 3,112<span></span>
</td>
<td class="nump">$ 3,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935417298080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock&#160;Outstanding</div></th>
<th class="th"><div>Additional Paid-in&#160;Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
<th class="th">
<div>Non-controlling Interest </div>
<div>Mezzanine</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, beginning balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,847<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 330,911<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 261,011<span></span>
</td>
<td class="nump">$ 69,771<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">13,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of non-controlling interest</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sale of non-controlling interest</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">4,256<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,638,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2021</a></td>
<td class="nump">349,687<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">266,126<span></span>
</td>
<td class="nump">82,922<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest', window );">Sale of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">12,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,658<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest', window );">Sale of shares by non-controlling interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest', window );">Sale of shares by non-controlling interest</a></td>
<td class="nump">40,133<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">40,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(2,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Investment in non-controlling interest</a></td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares', window );">Dividends</a></td>
<td class="num">(1,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,246,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2021</a></td>
<td class="nump">404,582<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">305,736<span></span>
</td>
<td class="nump">95,580<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, beginning balance at Dec. 31, 2021</a></td>
<td class="nump">55,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Share buy back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,151<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,630,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2021</a></td>
<td class="nump">460,490<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">310,876<span></span>
</td>
<td class="nump">143,629<span></span>
</td>
<td class="nump">5,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">15,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,264<span></span>
</td>
<td class="nump">938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of non-controlling interest</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sale of non-controlling interest</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">1,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of shares for business acquisition (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of shares for business acquisition</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares', window );">Dividends</a></td>
<td class="num">(1,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,845,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2022</a></td>
<td class="nump">479,521<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">316,047<span></span>
</td>
<td class="nump">157,893<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Jun. 30, 2022</a></td>
<td class="nump">39,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">12,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,399<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(9,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Investment in non-controlling interest</a></td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares', window );">Dividends</a></td>
<td class="num">(1,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,719,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 485,845<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 310,629<span></span>
</td>
<td class="nump">$ 169,292<span></span>
</td>
<td class="nump">$ 5,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodValueNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of share issued exercise of option and warrants during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of stock issued during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase from Sale of Non-Controlling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935420987792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 22,664<span></span>
</td>
<td class="nump">$ 73,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,725<span></span>
</td>
<td class="nump">8,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance cost</a></td>
<td class="nump">474<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">6,975<span></span>
</td>
<td class="nump">2,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain on sale of equity securities</a></td>
<td class="num">(2,272)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities', window );">Unrealized loss (gain) from investment in equity securities</a></td>
<td class="nump">13,659<span></span>
</td>
<td class="num">(83,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Income) loss from equity method investments</a></td>
<td class="num">(2,945)<span></span>
</td>
<td class="nump">3,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of beneficial interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized (gain) loss on interest rate swaps</a></td>
<td class="num">(2,830)<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="nump">10,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherOperatingActivities', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of business combinations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables, net</a></td>
<td class="num">(56,202)<span></span>
</td>
<td class="num">(9,975)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivables, net &#8211; related parties</a></td>
<td class="num">(12,151)<span></span>
</td>
<td class="num">(19,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(3,580)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,109<span></span>
</td>
<td class="nump">4,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOperatingLeaseAssets', window );">Right-of-use assets</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="num">(426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">14,181<span></span>
</td>
<td class="nump">16,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Fiduciary accounts payable</a></td>
<td class="num">(4,464)<span></span>
</td>
<td class="num">(550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">55,106<span></span>
</td>
<td class="nump">8,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(13,292)<span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,254)<span></span>
</td>
<td class="num">(1,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">33,059<span></span>
</td>
<td class="nump">31,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for business acquisition, net of cash acquired</a></td>
<td class="num">(858)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties', window );">Proceeds from repayment of loans receivable &#8211; related parties</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PrepaymentForInvestmentPurchase', window );">Prepayment for investment purchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(1,750)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of investment &#8211; equity method</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(18,845)<span></span>
</td>
<td class="num">(7,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity', window );">Cash received from consolidation of VIE</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">6,480<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Distribution from investment - equity method</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToEquityMethodInvestments', window );">Contribution to investment - equity method</a></td>
<td class="num">(1,685)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(12,228)<span></span>
</td>
<td class="num">(9,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(12,556)<span></span>
</td>
<td class="num">(21,110)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(238,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="num">(283)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of stock options and warrants</a></td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">4,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of shares</a></td>
<td class="num">(9,480)<span></span>
</td>
<td class="num">(2,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromSaleOfNoncontrollingInterest', window );">Proceeds from sale of non-controlling interest</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireNonControllingInterest', window );">Purchase of non-controlling interest</a></td>
<td class="num">(199)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Borrowings on loans</a></td>
<td class="nump">1,237<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(727)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(19,705)<span></span>
</td>
<td class="num">(38,167)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">1,126<span></span>
</td>
<td class="num">(16,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">233,097<span></span>
</td>
<td class="nump">193,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">234,223<span></span>
</td>
<td class="nump">177,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">22,311<span></span>
</td>
<td class="nump">23,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividend declared included in dividend payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Fixed asset obtained in exchange for finance lease liabilities</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued in business combination</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CancellationOfRestrictedStockAwards', window );">Cancellation of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MortgageLoanRelatedToPropertySales1', window );">Mortgage loan</a></td>
<td class="nump">16,275<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">234,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash total</a></td>
<td class="nump">$ 234,223<span></span>
</td>
<td class="nump">$ 177,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CancellationOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation of Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CancellationOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireNonControllingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Non-controlling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireNonControllingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PrepaymentForInvestmentPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment for Investment Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PrepaymentForInvestmentPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Cash Received from Consolidation of Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromSaleOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromSaleOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_UnrealizedGainLossFromInvestmentInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrealized (Gain) Loss from Investment in Equity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_UnrealizedGainLossFromInvestmentInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoanRelatedToPropertySales1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Mortgage loan related to property sales in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoanRelatedToPropertySales1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from operating activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935506677376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) in December 2017 (the &#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and an accountable care organization (&#8220;ACO&#8221;) participating in the GPDC model. NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s ACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSOs and Affiliates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPAs and Affiliates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) and AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $545.0&#160;million loan to AP-AMH, pursuant to a 10-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&#8217;s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $545.0&#160;million private placement, where AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $300.0&#160;million private placement, where APC purchased 15,015,015 shares of the Company&#8217;s common stock and in  connection therewith, the Company granted APC certain registration rights with respect to the purchased shares.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (&#8220;Excluded Assets&#8221;). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC&#8217;s ownership in ApolloMed was 20.02% as of June&#160;30, 2022 and 19.68% as of December&#160;31, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of June&#160;30, 2022, APC owned 44.50% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group of Southern California (&#8220;DMG&#8221;), and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its 40% investment in DMG, under the equity method of accounting. In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $8.5&#160;million as of June&#160;30, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a 50% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants, as well as vacant land that is being developed. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments, as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, AP-AMH 2, a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#8220;APCMG&#8221;), a primary care physicians&#8217; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3 &#8212; &#8220;Business Combinations and Goodwill&#8221;). The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $4.2 million as of June&#160;30, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO, GPDC / ACO REACH</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO began participating in the NGACO Model of CMS in January 2017. The NGACO Model was a CMS program that allowed provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model. With the ending of the NGACO Model on December 31, 2021, APAACO applied, and has been selected by CMS, to participate as a Direct Contracting Entity (&#8220;DCE&#8221;) in the standard track of CMS&#8217;s GPDC Model for Performance Year 2022 (&#8220;PY22&#8221;), beginning January 1, 2022. CMS has since redesigned the GPDC Model in response to Administration priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience, and renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (&#8220;ACO REACH&#8221;) Model. The ACO REACH Model will begin participation on January 1, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426674736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated balance sheet at December&#160;31, 2021, has been derived from the Company&#8217;s audited consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2022, and for the three and six months ended June&#160;30, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three and six months ended June&#160;30, 2022, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or any future periods.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three and six months ended June&#160;30, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s consolidated VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, ICC, Alpha Care, Accountable Health Care, and AMG.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications were made between unrealized loss (gain) on investments and other income (expense) on the accompanying unaudited consolidated income statements for the three and six months ended June&#160;30, 2021. They had no effect on net income, earnings per share, retained earnings, cash flows or total assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of June&#160;30, 2022 and December&#160;31, 2021, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $277.6 million and $285.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of June&#160;30, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $25.1 million and $25.0 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. Equity securities with low trading volume are determined to not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Nutex Health Inc. (formerly known as Clinigence Holdings, Inc.) (&#8220;Nutex&#8221;). The common stock of a payor partner was acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional shares of common stock if certain metrics are not met (such additional shares, &#8220;contingent equity securities&#8221;) for $3.0&#160;million. The common stock is included in investments in marketable securities in the accompanying consolidated balance sheets. In May 2022, the Company exercised the warrants and subsequently recognized the shares within investments in marketable securities in the accompanying consolidated balance sheet. The contingent equity securities are classified as derivatives and included in prepaid expenses and other current assets in the accompanying consolidated balance sheets. See Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#8221; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;30, 2022 and December&#160;31, 2021, the equity securities were approximately $14.4 million and $28.4&#160;million, respectively, in the accompanying consolidated balance sheets. Gains and losses recognized on equity securities sold are recognized in the accompanying consolidated statements of income under other income. The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total (losses) gains recognized on equity securities  </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Gains recognized on equity securities sold  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Unrealized gains (losses)  recognized on equity securities held at end of period  </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,059)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,614)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivable &#8211; related party consist of promissory notes from a related party payee that accrues interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,697&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,954&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of June&#160;30, 2022, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the six months ended June&#160;30, 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the six months ended June&#160;30, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no impairment of its goodwill or indefinite-lived intangible assets during the six months ended June&#160;30, 2022 and 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was no impairment loss recorded related to equity method investments for the years ended June&#160;30, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, APCMG, and Jade (the &#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiduciary Cash and Payable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $6.1 million and $10.5 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of June&#160;30, 2022, the fair value of the interest rate swap was $1.8 million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $1.1&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. In May 2022, the Company exercised the warrants and the shares were subsequently presented within investments in marketable securities on the accompanying consolidated balance sheets. The shares are classified as Level 1 since the quoted market prices from reputable third-party brokers are available in an active market and unadjusted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contingent Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Nutex, ApolloMed is entitled to additional common stock if Nutex does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered to be derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The Company determined the fair value of the contingent equity security using a probability-weighted model, which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of June&#160;30, 2022 and December&#160;31, 2021, the contingent equity securities were valued at $3.2&#160;million and $4.3 million, respectively, and is presented within prepaid and other current assets in the accompanying consolidated balance sheets. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GPDC Capitation Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS contracts with Direct Contracting Entities (&#8220;DCEs&#8221;), which is composed of healthcare providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#8217;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#8217;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e., month) and is recognized net of quality incentives/penalties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims, are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#8217;s contract liability balance was $20.0 million and $16.8 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the six months ended June&#160;30, 2022, $0.5 million of the Company&#8217;s contract liability accrued in 2021 has been recognized as revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 &#8212; &#8220;Earnings Per Share&#8221; for a discussion of shares treated as treasury shares for accounting purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2022 and December&#160;31, 2021, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)  No. 2021-08, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2021-08&#8221;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With the exception of the new standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935507795312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations and Goodwill</a></td>
<td class="text">Business Combinations and GoodwillJade Health Care Medical Group, Inc. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 19, 2022, the Company acquired 100% of the capital stock of Jade Health Care Medical Group, Inc. (&#8220;Jade&#8221;). The purchase was paid in cash. Jade is a primary and specialty care physicians&#8217; group focused on providing high-quality care to its patients in the San Francisco Bay Area in Northern California. The Company is in the process of finalizing it&#8217;s purchase price allocation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orma Health, Inc., and Provider Growth Solutions LLC (together, &#8220;Orma Health&#8221;)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2022, the Company acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#8220;Orma Health&#8221;). The purchase was paid in cash and in the Company&#8217;s capital stock. Orma Health&#8217;s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (&#8220;RPM&#8221;), mental health support, chronic disease management, and more. Its clinical platform is also deeply integrated with Orma Health&#8217;s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to manage patient health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APCMG</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG. As part of the transaction, the Company may pay APCMG additional consideration contingent on APCMG&#8217;s financial performance for fiscal year 2022 (&#8220;APCMG contingent consideration&#8221;). The APCMG contingent consideration will be met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (&#8220;EBITDA&#8221;) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of June&#160;30, 2022, the contingent consideration is valued at $1.0 million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sun Labs</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DMG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by Apollo.  In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426705920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-21</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subscriber relationships </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,085)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare license</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient management platform</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $3.5 million and $3.7 million for the three months ended June&#160;30, 2022 and 2021, respectively, and $7.2 million and $7.5 million for the six months ended June&#160;30, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June 30, 2022)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426594480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock', window );">Investments in Other Entities</a></td>
<td class="text">Investments in Other Entities<div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Equity Method</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in other entities &#8211; equity method consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding reclassified to loan receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,125)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4 million, which resulted in  APC-LSMA owning a 25% interest in LMA as of June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended June&#160;30, 2022 and 2021, APC recognized income from this investment of $1.3 million and a loss of $3.6 million, respectively, in the accompanying consolidated statements of income.  For the six months ended June&#160;30, 2022 and June&#160;30, 2021, APC recognized income from this investment of $2.5 million and a loss of $4.3 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $3.4 million and $3.0 million at June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at June&#160;30, 2022 and December&#160;31, 2021, and summarized statements of income for the six months ended June&#160;30, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,552)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,358)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA purchased a 40% ownership interest in PMIOC. Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography, at its facilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended June&#160;30, 2022 and 2021, APC recognized income from this investment of approximately $15,000 and a loss from this investment of $16,000, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recognized income of approximately $22,000 and a loss from this investment of $30,000, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets had investment balances of $1.7 million and $1.7 million at June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a 50% ownership in 531 W. College LLC and accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. 531 W. College, LLC owns a former hospital campus in Los Angeles that is now leased to tenants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2022 and 2021, APC recognized a loss from this investment of $0.1 million and $9,000, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recorded a loss from this investment of $0.3 million and $0.1 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $17.2 million and $17.2 million at June&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One MSO, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a 50% interest in One MSO. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended June&#160;30, 2022 and 2021, APC recognized income of $0.1 million and $0.1&#160;million, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recognized income of $0.3&#160;million and $0.2 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.8 million and $2.9&#160;million at June&#160;30, 2022 and December&#160;31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC  &#8212; Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC has a 50% interest in Tag 6. Tag 6 leases its building to tenants and shares common ownership with certain board members of APC and as such is considered a related party. For the three months ended June&#160;30, 2022 and 2021, APC recognized income of $45,000 and $0.2 million, respectively,  in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recognized income of $0.1 million and $0.2 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the Tag 6 investment of $6.4 million and $4.8&#160;million at June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAIPA MSO, LLC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, ApolloMed purchased 30% interests in CAIPA MSO, LLC for $11.7 million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (&#8220;CAIPA&#8221;), a leading independent practice association serving the greater New York City area. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#8217;s operations. For the three months ended June&#160;30, 2022, ApolloMed recognized income from investment of $0.2 million in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022, ApolloMed recognized income of $0.3&#160;million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $12.3 million and $12.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in investments in privately held entities in the accompanying consolidated balance sheets as of June&#160;30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method And Other Equity Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodAndOtherEquityInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935507795312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableTextBlock', window );">Loan Receivable and Loan Receivable &#8211; Related Parties</a></td>
<td class="text">Loan Receivable and Loan Receivable &#8211; Related Parties<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from 6 Founder LLC, a California limited liability company doing business as Pacific6 Enterprises totaling $0.5&#160;million as a result of the sale of the Company&#8217;s interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related party</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">LaSalle Medical Associates Loan (&#8220;LMA Loan&#8221;)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LaSalle Medical Associates (&#8220;LMA&#8221;) issued a promissory note to APC-LSMA for a principal amount of $2.1 million with an August 2023 maturity date. The contractual interest rate on the LMA Loan is 1.0% above the prime rate of interest for commercial customers. APC&#8217;s investment in LMA is accounted for under the equity method based on the 25% equity ownership interest held by APC-LSMA in LMA&#8217;s IPA line of business (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, AHMC Healthcare Inc. (&#8220;AHMC&#8221;) issued a promissory note to APC for a principal amount of $4.0&#160;million with an April 2022 maturity date. The note was amended in April 2022 to extend the maturity date to April 2023. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. In June 2022, AHMC paid the outstanding principal and interest amount to APC. One of the Company&#8217;s board members is an officer of AHMC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935603862080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued ExpensesThe Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426542240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Liabilities</a></td>
<td class="text">Medical Liabilities<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,446&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,978)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,010)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,432)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426458688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility, Bank Loans, and Lines of Credit</a></td>
<td class="text">Credit Facility, Bank Loans, and Lines of Credit<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,068&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,917&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of June&#160;30, 2022 and December&#160;31, 2021, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June 30, 2022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the &#8220;Credit Facility&#8221;), in its entirety. The Amended Credit Agreement provides for a five-year revolving credit facility to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;) between the Company, NMM and Truist Bank remain in effect.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.350% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio.  As of June&#160;30, 2022, the interest rate on the Credit Agreement was 4.17%. Borrowings under the Amended Credit Agreement may be prepaid at any time without penalty. If LIBOR ceases to be reported under the Amended Credit Agreement, the Company will use the secured overnight financing rate or the Company and the Agent will agree to an alternative rate of interest. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $75.0&#160;million, the maximum consolidated total net leverage ratio may temporarily increase by 0.25 to 1.00 to 4.00 to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange, or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At June&#160;30, 2022 and December&#160;31, 2021, the unamortized deferred financing cost was $3.8&#160;million and $4.3&#160;million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $6.1 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2022, the balance outstanding was $6.0 million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. <br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $0.7 million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2022, the balance outstanding was $0.7 million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $0.6 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2022, the balance outstanding was $0.6 million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">120 Hellman LLC </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;25, 2022, 120 Hellman LLC (&#8220;120 Hellman&#8221;), a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary of APC,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into a loan agreement with MUFG Union Bank N.A. with the principal on the loan of $16.3 million and a maturity date of March&#160;1, 2032. The loan </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was used to purchase property in Monterey Park, California. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable interest rate is 2.0% in excess of Daily Simple SOFR, which is the daily rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If the index is not available, MUFG Union Bank N.A. may designate a substitute index after notifying 120 Hellman. Monthly payments on the principal and interest began in April 1, 2022. Should interest not be paid when due, it shall become part of the principal and bear interest. As of June&#160;30, 2022, the balance outstanding was $16.2 million. 120 Hellman must maintain a Cash Flow to Debt Service ratio (defined as net profit after taxes, to which depreciation, amortization and other non-cash items are added divided by the current portion of long-term debt and capital leases) of not less than 1.25 to 1 and 35% or more of the property must also be occupied by APC. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of June&#160;30, 2022, the likelihood of the construction being completed by the maturity date was remote. The outstanding balance as of June&#160;30, 2022 was $1.8 million and was recorded as a current portion of long-term debt in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the six months ended June&#160;30, 2022 and 2021, was 2.16% and 2.31%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2022 and 2021, of $0.2 million and $0.4 million, respectively, and $0.5 million and $0.7 million, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to, among other things, decrease loan availability to $4.1 million, limit the purpose of the indebtedness under the APC Business Loan Agreement to the issuance of standby letters of credit, and include as a permitted lien, the security interest in all of its assets that APC granted to NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under their management services agreement dated as of July 1, 1999, as amended.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426402192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Mezzanine and Stockholders' Equity</a></td>
<td class="text">Mezzanine and Stockholders&#8217; Equity<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares (see Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Mezzanine Equity&#8221;) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interest in APC as mezzanine or temporary equity. APC&#8217;s shares were not redeemable, and it was not probable that the shares would become redeemable, as of June&#160;30, 2022 and December&#160;31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, 140,954 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned 11,175,702 and 10,925,702 shares of ApolloMed&#8217;s common stock, respectively, as of June&#160;30, 2022 and December&#160;31, 2021. While such shares of ApolloMed&#8217;s common stock are legally issued and outstanding, they are treated as treasury shares for accounting purposes and excluded from shares of common stock outstanding in the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022 and 2021, APC paid dividends of $10.0&#160;million and $19.9&#160;million, respectively. During the six months ended June&#160;30, 2022 and 2021, APC paid dividends of $10.0 million and $19.9 million respectively. </span></div>During the three months ended June&#160;30, 2022 and 2021, CDSC paid dividends of $1.5&#160;million and $1.5&#160;million, respectively During the six months ended June&#160;30, 2022 and 2021, CDSC paid dividends of $2.9 million and $1.5&#160;million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426542240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three and six months ended June&#160;30, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of June&#160;30, 2022 was $26.1 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.04&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, options were exercised for 38,500 shares of the Company&#8217;s common stock, resulting in proceeds of $0.7&#160;million. During the six months ended June&#160;30, 2021, no stock options were exercised.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, the Company granted 87,488 stock options to certain ApolloMed employees and Board members. The options granted during the six months ended June&#160;30, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50 years - 2.25 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.47% - 82.05%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02% - 2.47%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.47 - $22.73</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock is that day&#8217;s closing market price of the Company&#8217;s common stock. During the six months ended June&#160;30, 2022, the Company granted restricted stock totaling 520,552 shares, including 295,721 shares of restricted stock with performance conditions, with a weighted average grant date fair value of $42.01. Shares of restricted stock with performance conditions are recognized to the extent the performance conditions are probable of being achieved. The grant date fair value of restricted stock and restricted stock with performance conditions that are probable of being achieved were $10.0&#160;million and will be recognized on a straight-line basis over the awards&#8217; vesting period. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,743</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  10.00 &#8211; 11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the six months ended June&#160;30, 2022 and 2021, common stock warrants were exercised for 101,953 and 474,506 shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $1.1&#160;million and $4.8 million, respectively. The exercise price ranged from $10.00 to $11.00 per share for the exercises during the six months ended June&#160;30, 2022, and $9.00 to $11.00 per share for the exercises during the six months ended June&#160;30, 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426537520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#8220;DMHC&#8221;) regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the payor and provider contracts with the Company&#8217;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $0.3 million and $3.8&#160;million, respectively, for the benefit of certain health plans (see Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit - Standby Letters of Credit&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426457456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 and 2021, NMM earned approximately $4.8 million and $4.2 million, respectively, and $11.1 million and $8.7 million, respectively, in management fees from LMA, which is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $0.7 million and $0.6 million, respectively, and $1.4 million and $1.0 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, APC paid $1.7 million and $3.2 million, respectively, to DMG for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC. In October 2021,  DMG was consolidated by Apollo. As such, DMG is no longer a related party.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $0.1&#160;million and $30,000, respectively, and $0.1 million and $51,000 to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $0.2 million and $0.3 million, respectively, and $0.3 million and $0.4 million, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company&#8217;s board members is a board member of Fulgent Genetics, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2022 and 2021, APC paid an aggregate of approximately $12.3 million and $8.2 million to shareholders, respectively, which included approximately $3.3 million and $2.2 million, respectively, to shareholders who are also officers of APC. During the six months ended June&#160;30, 2022 and 2021, APC paid an aggregate of approximately $21.6 million and $15.6 million to shareholders, respectively, and $5.2 million and $3.8 million, respectively, to shareholders who are also officers of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2022 and 2021, SCHC paid approximately $0.1 million and $0.1 million, respectively, and $0.2 million and $0.2 million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six ended June&#160;30, 2022 and 2021, NMM paid approximately $0.4 million and $0.4 million, respectively, and $0.7 million and $0.7 million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 5 &#8212; &#8220;Investments in Other Entities &#8212; Equity Method&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $3.7 million and $3.6 million, respectively, and $7.3 million and to $7.0 million, respectively, to Arroyo Vista Family Health Center (&#8220;Arroyo Vista&#8221;) for services as a provider. Arroyo Vista&#8217;s chief executive officer is a member of the Company&#8217;s board of directors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June&#160;30, 2022 and 2021, the Company has recognized risk pool revenue under this agreement of $13.3 million and $14.2 million, and $25.3&#160;million and $31.2&#160;million, respectfully, of which $76.0 million and $58.4 million remained outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</span></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022, APC paid $9.3&#160;million to purchase Apollo&#8217;s stock from a board member. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including Dr. Thomas Lam, ApolloMed&#8217;s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments and loans receivable from related parties, see Note 5 &#8212; &#8220;Investment in Other Entities - Equity Method&#8221; and Note 6 &#8212; &#8220;Loan Receivable and Loan Receivable - Related Parties&#8221;, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426516912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the six months ended June&#160;30, 2022 and 2021, was 35.1% and 30.0%, respectively. The tax rate for the six months ended June&#160;30, 2022, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, non-deductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2017 through December&#160;31, 2021, and for the years ended December 31, 2018 through December&#160;31, 2021, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426490608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, APC held 11,175,702 and 10,925,702 shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2022 and June&#160;30, 2021, restricted stock of  394,606 and 0, respectively were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive. For the six months ended June&#160;30, 2022 and June&#160;30, 2021, restricted stock of  257,193 and 0, respectively were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2022, 242,899 of restricted stock with performance conditions were excluded from the computation of diluted weighted average common shares outstanding because these conditions were not achieved as of June&#160;30, 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,858,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,023,015&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,815,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,255,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,082,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,746,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,858,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,023,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,815,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,255,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,082,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,746,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426488176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities (VIEs)</a></td>
<td class="text">Variable Interest Entities (VIEs)<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable, net of current portion </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,672&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,674&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935427502768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of thirty days to nine years. Some of the leases may include options to extend the lease terms for up to 10 years, and some of the leases may include options to terminate the leases within one year. As of June&#160;30, 2022 and December&#160;31, 2021, assets recorded under finance leases were $1.4 million and $1.3 million, respectively, and accumulated depreciation associated with finance leases were $0.8 million and $0.6 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June&#160;30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of thirty days to nine years. Some of the leases may include options to extend the lease terms for up to 10 years, and some of the leases may include options to terminate the leases within one year. As of June&#160;30, 2022 and December&#160;31, 2021, assets recorded under finance leases were $1.4 million and $1.3 million, respectively, and accumulated depreciation associated with finance leases were $0.8 million and $0.6 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June&#160;30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935420688832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying consolidated balance sheet at December&#160;31, 2021, has been derived from the Company&#8217;s audited consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2022, and for the three and six months ended June&#160;30, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three and six months ended June&#160;30, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s consolidated VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, ICC, Alpha Care, Accountable Health Care, and AMG.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications were made between unrealized loss (gain) on investments and other income (expense) on the accompanying unaudited consolidated income statements for the three and six months ended June&#160;30, 2021. They had no effect on net income, earnings per share, retained earnings, cash flows or total assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div>If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Business CombinationsThe Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div>The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of June&#160;30, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $25.1 million and $25.0 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. Equity securities with low trading volume are determined to not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock', window );">Receivables, Receivables &#8211; Related Parties, and Loan Receivable - Related Party</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivable &#8211; related party consist of promissory notes from a related party payee that accrues interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivables relate to each health plan&#8217;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div>The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risks</a></td>
<td class="text">Concentrations of Credit RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Intangible Assets and Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div>Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was no impairment loss recorded related to equity method investments for the years ended June&#160;30, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock', window );">Medical Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, APCMG, and Jade (the &#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryCashAndPayablePolicyTextBlock', window );">Fiduciary Cash and Payable</a></td>
<td class="text">Fiduciary Cash and PayableThe consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 &#8212; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  </span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of June&#160;30, 2022, the fair value of the interest rate swap was $1.8 million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $1.1&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. In May 2022, the Company exercised the warrants and the shares were subsequently presented within investments in marketable securities on the accompanying consolidated balance sheets. The shares are classified as Level 1 since the quoted market prices from reputable third-party brokers are available in an active market and unadjusted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contingent Equity Securities</span></div>In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Nutex, ApolloMed is entitled to additional common stock if Nutex does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered to be derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The Company determined the fair value of the contingent equity security using a probability-weighted model, which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GPDC Capitation Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS contracts with Direct Contracting Entities (&#8220;DCEs&#8221;), which is composed of healthcare providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#8217;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#8217;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e., month) and is recognized net of quality incentives/penalties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims, are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div>Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 &#8212; &#8220;Earnings Per Share&#8221; for a discussion of shares treated as treasury shares for accounting purposes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MinorityInterestPolicyPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2022 and December&#160;31, 2021, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2021, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;)  No. 2021-08, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2021-08&#8221;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With the exception of the new standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryCashAndPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiduciary Cash and Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryCashAndPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MinorityInterestPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Interest Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MinorityInterestPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Receivables and receivables from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accruing health care costs for a prepaid health care service provider.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6491204&amp;loc=d3e4879-115612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=49178521&amp;loc=d3e9162-115647<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935506750176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (Loss) on Securities</a></td>
<td class="text">The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total (losses) gains recognized on equity securities  </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,886)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Gains recognized on equity securities sold  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Unrealized gains (losses)  recognized on equity securities held at end of period  </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,059)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,614)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Each Payor Type</a></td>
<td class="text">The following table presents disaggregated revenue generated by payor type for the three months ended June&#160;30, 2022 and 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,697&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532,954&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Contributions to Revenue and Receivables by Payor</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of June&#160;30, 2022, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935507833376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Change in Carrying Value of Goodwill</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,310&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935421365168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2022, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net June 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-21</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subscriber relationships </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed technology </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,085)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare license</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient management platform</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tradename/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June 30, 2022)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426699952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in other entities &#8211; equity method consisted of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding reclassified to loan receivable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Distribution </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,125)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,125)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at June&#160;30, 2022 and December&#160;31, 2021, and summarized statements of income for the six months ended June&#160;30, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,552)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,603&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,358)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426670400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426707296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Medical Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,446&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,978)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,010)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,432)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,307&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935420525920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,068&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,917&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Commitments of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June 30, 2022)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935421745696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three and six months ended June&#160;30, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.04&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, the Company granted 87,488 stock options to certain ApolloMed employees and Board members. The options granted during the six months ended June&#160;30, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50 years - 2.25 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.47% - 82.05%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02% - 2.47%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.47 - $22.73</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants expired/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,743</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,044</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  10.00 &#8211; 11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899,787&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426776816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</a></td>
<td class="text">The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(728)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,907&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935420532368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,858,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,023,015&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,815,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,255,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,082,643&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,746,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Shares Included in the Diluted Earnings Per Share Computations</a></td>
<td class="text">Below is a summary of the shares included in the diluted earnings per share computations:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,858,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,023,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,815,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,255,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,082,643&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,746,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426575472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Assets and Liabilities, Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable, net of current portion </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,672&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,674&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935417164208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Information Related to Lease Costs</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,142&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flow Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.55 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June&#160;30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (excluding the six months ended June&#160;30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935415110032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 31, 1999</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>clinic </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,820<span></span>
</td>
<td class="nump">$ 41,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember', window );">Access Primary Care Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember', window );">Apollo-Sun Labs Management, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Equity interest purchase obligation, period to purchase</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Equity interest purchase obligation, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Equity interest purchase obligation, period to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember', window );">AP-AMH Medical Corporation | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableTermOfReceivable', window );">Term of receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableStatedInterestRate', window );">Stated rate of note of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate', window );">Interest rate in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,015,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement', window );">Fixed term of amended and restated management and administrative services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MPP, AMG Properties, and ZLL Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.02%<span></span>
</td>
<td class="nump">19.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Concourse Diagnostic Surgery Center, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AP-AMH Medical Corporation | Affiliated Entity | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFederallyQualifiedHealthPlans', window );">Number federally qualified health plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFamilyPracticeClinics', window );">Number of family practice clinics | clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Maverick Medical Group, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AssetAcquisitionPercentageOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage Of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AssetAcquisitionPercentageOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Period to Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Modifications, Subsequent Default, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Stated Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableTermOfReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Term Of Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableTermOfReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial fixed term of amended and restated management and administrative services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFamilyPracticeClinics">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Family Practice Clinics</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFamilyPracticeClinics</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFederallyQualifiedHealthPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Federally Qualified Health Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFederallyQualifiedHealthPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935415595904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>unit</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount deposit accounts exceeded FDIC insured limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,024,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireCommonStockAndWarrants', window );">Payments to acquire common stock and warrants</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized on equity securities held at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,059,000)<span></span>
</td>
<td class="nump">$ 83,769,000<span></span>
</td>
<td class="num">$ (12,614,000)<span></span>
</td>
<td class="nump">$ 83,769,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear', window );">Risk pool surplus or deficits, settlement period after risk pool performance year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of main reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment, other than temporary impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,071,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,798,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Accrued contract liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember', window );">Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Contingent equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges: | Interest rate swap | Other Noncurrent Assets | Derivatives designated as hedging instruments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash flow hedges: | Interest rate swap | Other long-term liabilities | Derivatives designated as hedging instruments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | Universal Care Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember', window );">PMPM Managed Care Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management Fee Income Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember', window );">Clinigence Holdings, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireCommonStockAndWarrants', window );">Payments to acquire common stock and warrants</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_CMSMember', window );">CMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport', window );">Expected period of payment upon termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MarketableSecuritiesCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Current, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MarketableSecuritiesCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI https://asc.fasb.org/extlink&amp;oid=126903467&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_CMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_CMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935414602720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Gain (Loss) on Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Total (losses) gains recognized on equity securities</a></td>
<td class="num">$ (4,331)<span></span>
</td>
<td class="nump">$ 83,769<span></span>
</td>
<td class="num">$ (14,886)<span></span>
</td>
<td class="nump">$ 83,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gains recognized on equity securities sold</a></td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,272<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) recognized on equity securities held at end of period</a></td>
<td class="num">$ (2,059)<span></span>
</td>
<td class="nump">$ 83,769<span></span>
</td>
<td class="num">$ (12,614)<span></span>
</td>
<td class="nump">$ 83,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935415002576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 269,697<span></span>
</td>
<td class="nump">$ 175,638<span></span>
</td>
<td class="nump">$ 532,954<span></span>
</td>
<td class="nump">$ 351,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">42,014<span></span>
</td>
<td class="nump">33,296<span></span>
</td>
<td class="nump">84,167<span></span>
</td>
<td class="nump">65,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">142,641<span></span>
</td>
<td class="nump">64,273<span></span>
</td>
<td class="nump">276,299<span></span>
</td>
<td class="nump">128,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">70,635<span></span>
</td>
<td class="nump">68,482<span></span>
</td>
<td class="nump">142,299<span></span>
</td>
<td class="nump">138,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember', window );">Other third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 14,407<span></span>
</td>
<td class="nump">$ 9,587<span></span>
</td>
<td class="nump">$ 30,189<span></span>
</td>
<td class="nump">$ 19,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935422634672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">16.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsReceivableAndNetRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsReceivableAndNetRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935414855296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 70,053<span></span>
</td>
<td class="nump">$ 114,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">25,086<span></span>
</td>
<td class="nump">25,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">14,404<span></span>
</td>
<td class="nump">28,393<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">114,527<span></span>
</td>
<td class="nump">173,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember', window );">Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">3,225<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">70,053<span></span>
</td>
<td class="nump">114,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">25,086<span></span>
</td>
<td class="nump">25,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">14,404<span></span>
</td>
<td class="nump">24,123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">109,543<span></span>
</td>
<td class="nump">163,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="nump">5,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,225<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">3,225<span></span>
</td>
<td class="nump">4,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935414941248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Apr. 19, 2022</div></th>
<th class="th"><div>Jan. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_JadeHealthCareMedicalGroupIncMember', window );">Jade Health Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember', window );">Orma Health, Inc., and Provider Growth Solutions LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember', window );">Access Primary Care Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember', window );">Apollo-Sun Labs Management, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Equity interest purchase obligation, period to purchase</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_DmgMember', window );">DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Equity interest purchase obligation, period to purchase</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Period to Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_JadeHealthCareMedicalGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_JadeHealthCareMedicalGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935423316192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Summary of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 253,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">2,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments</a></td>
<td class="num">(2,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 253,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935422148624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (112,085)<span></span>
</td>
<td class="num">$ (104,922)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">74,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross</a></td>
<td class="nump">188,736<span></span>
</td>
<td class="nump">187,729<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">76,651<span></span>
</td>
<td class="nump">82,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived assets:</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Medicare license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">150,679<span></span>
</td>
<td class="nump">150,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(90,285)<span></span>
</td>
<td class="num">(84,865)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 60,394<span></span>
</td>
<td class="nump">$ 65,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 22,832<span></span>
</td>
<td class="nump">$ 22,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(14,433)<span></span>
</td>
<td class="num">(13,563)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 8,399<span></span>
</td>
<td class="nump">$ 9,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 8,997<span></span>
</td>
<td class="nump">$ 8,997<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,190)<span></span>
</td>
<td class="num">(4,606)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 3,807<span></span>
</td>
<td class="nump">$ 4,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,871)<span></span>
</td>
<td class="num">(1,682)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Tradename/trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Subscriber relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935423649024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935423346704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022 (excluding the three months ended March 31, 2022)</a></td>
<td class="nump">$ 6,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">11,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">10,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">9,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">8,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">27,228<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 74,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935422341472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Equity Method Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,512<span></span>
</td>
<td class="num">$ (3,134)<span></span>
</td>
<td class="nump">2,945<span></span>
</td>
<td class="num">$ (3,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentReclassification', window );">Funding reclassified to loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentReclassification', window );">Funding reclassified to loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentReclassification', window );">Funding reclassified to loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentReclassification', window );">Funding reclassified to loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentReclassification', window );">Funding reclassified to loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember', window );">Tag-6 Medical Investment Group, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentReclassification', window );">Funding reclassified to loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentReclassification', window );">Funding reclassified to loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Reclassification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935414134688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,512<span></span>
</td>
<td class="num">$ (3,134)<span></span>
</td>
<td class="nump">2,945<span></span>
</td>
<td class="num">$ (3,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MediPortal LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares', window );">Membership interests purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Payments to purchase membership interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest', window );">Membership interests acquired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption', window );">Term of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests', window );">Options to purchase additional membership interests (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet', window );">Number of warrants available to purchase, contingent upon the portal completion date (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. | AchievaMed, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears', window );">Percentage of voting common stock, within five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment', window );">Duration of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Related investment balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC and APC-LSMA | Convertible Secured Promissory Note | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageSold', window );">Ownership percentage sold</a></td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="num">(3,600)<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="num">(4,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(305)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8211; related party | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Distribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,992<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage, Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MediPortalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MediPortalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_AchievaMedInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_AchievaMedInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935417097200">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 234,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">951,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">951,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">185,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">485,845<span></span>
</td>
<td class="nump">$ 404,582<span></span>
</td>
<td class="nump">485,845<span></span>
</td>
<td class="nump">$ 404,582<span></span>
</td>
<td class="nump">$ 479,521<span></span>
</td>
<td class="nump">460,490<span></span>
</td>
<td class="nump">$ 349,687<span></span>
</td>
<td class="nump">$ 330,911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">951,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">951,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statement of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">269,697<span></span>
</td>
<td class="nump">175,638<span></span>
</td>
<td class="nump">532,954<span></span>
</td>
<td class="nump">351,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">254,315<span></span>
</td>
<td class="nump">154,650<span></span>
</td>
<td class="nump">491,360<span></span>
</td>
<td class="nump">308,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,382<span></span>
</td>
<td class="nump">20,988<span></span>
</td>
<td class="nump">41,594<span></span>
</td>
<td class="nump">42,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,034<span></span>
</td>
<td class="num">(15,883)<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="num">(14,579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,591<span></span>
</td>
<td class="nump">$ 59,530<span></span>
</td>
<td class="nump">22,664<span></span>
</td>
<td class="nump">73,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,552)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,552)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statement of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,067<span></span>
</td>
<td class="nump">95,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,406<span></span>
</td>
<td class="nump">104,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
<td class="num">(9,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,603<span></span>
</td>
<td class="num">$ (9,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $599.7&#160;million and $567.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $143.7&#160;million and $91.7&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $431.3&#160;million of investment in affiliates and $36.0&#160;million of amounts due from affiliates as of June&#160;30, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935424230688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Pacific6 Enterprises | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | APC LSMA | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableInterestRateStatedPercentage', window );">Note receivable, interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | AHMC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableInterestRateStatedPercentage', window );">Note receivable, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935422055632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 11,280<span></span>
</td>
<td class="nump">$ 9,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SpecialtyCapitationPayableCurrent', window );">Capitation payable</a></td>
<td class="nump">3,683<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SubcontractorIPAPayable', window );">Subcontractor IPA payable</a></td>
<td class="nump">13,814<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">2,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">20,030<span></span>
</td>
<td class="nump">16,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">8,681<span></span>
</td>
<td class="nump">10,107<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 59,922<span></span>
</td>
<td class="nump">$ 43,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SpecialtyCapitationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of specialty capitation payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SpecialtyCapitationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SubcontractorIPAPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subcontractor IPA Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SubcontractorIPAPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935424208816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities - Schedule of Medical Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Medical Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, beginning of period</a></td>
<td class="nump">$ 55,783<span></span>
</td>
<td class="nump">$ 50,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Acquired (see Note 3)</a></td>
<td class="nump">1,609<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current period</a></td>
<td class="nump">313,325<span></span>
</td>
<td class="nump">158,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior periods</a></td>
<td class="num">(950)<span></span>
</td>
<td class="num">(1,293)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">312,375<span></span>
</td>
<td class="nump">157,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current period</a></td>
<td class="num">(204,032)<span></span>
</td>
<td class="num">(103,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior periods</a></td>
<td class="num">(53,978)<span></span>
</td>
<td class="num">(45,130)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="num">(258,010)<span></span>
</td>
<td class="num">(148,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">742<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, end of period</a></td>
<td class="nump">$ 112,499<span></span>
</td>
<td class="nump">$ 59,307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935420564400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 205,274<span></span>
</td>
<td class="nump">$ 187,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of debt</a></td>
<td class="num">(2,413)<span></span>
</td>
<td class="num">(780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized financing costs</a></td>
<td class="num">(3,793)<span></span>
</td>
<td class="num">(4,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">199,068<span></span>
</td>
<td class="nump">182,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember', window );">Real Estate Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">23,469<span></span>
</td>
<td class="nump">7,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember', window );">Construction Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">1,805<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935423534240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2022 (excluding the six months ended June 30, 2022)</a></td>
<td class="nump">$ 2,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">7,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LongTermDebtMaturityAfterYearFour', window );">2026 and thereafter</a></td>
<td class="nump">194,723<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total</a></td>
<td class="nump">$ 205,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935410321088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Jan. 25, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 05, 2020</div></th>
<th class="th"><div>Jul. 27, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 01, 2023</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized financing costs</a></td>
<td class="nump">$ 3,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,854,000<span></span>
</td>
<td class="nump">$ 1,853,000<span></span>
</td>
<td class="nump">2,927,000<span></span>
</td>
<td class="nump">$ 3,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">Medical Property Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">Medical Property Partners LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL Partners LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_A120HellmanLLCMember', window );">120 Hellman LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty', window );">Debt covenant, threshold percentage for occupation of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum', window );">Debt instrument, covenant, cash flow to debt service ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_A120HellmanLLCMember', window );">120 Hellman LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Annual agent fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.175%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios', window );">Number of key financial ratios | financial_ratio</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum', window );">Maximum consolidated leverage ratio (not greater than)</a></td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtCovenantAggregatePurchasePriceMaximum', window );">Debt covenant, aggregate purchase price, maximum</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange', window );">Consolidated leverage ratio, annual decrease</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum', window );">Debt instrument, covenant, leverage ratio, adjusted maximum</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Minimum consolidated interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.16%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction Loan | Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum', window );">Debt instrument, covenant, cash flow coverage ratio, minimum</a></td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction Loan | Tag-8 Medical Investment Group, LLC | London Interbank Offered Rate (LIBOR) | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="nump">4.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | APC Business Loan Agreement | APC | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc. | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtCovenantAggregatePurchasePriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Aggregate Purchase Price, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtCovenantAggregatePurchasePriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtCovenantThresholdPercentageForOccupationOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Threshold Percentage for Occupation of Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtCovenantThresholdPercentageForOccupationOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash Flow To Debt Service Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Incremental Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Key Financial Ratios</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentNumberOfKeyFinancialRatios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_A120HellmanLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_A120HellmanLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935415558944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesMerger', window );">Holdback shares not issued to former shareholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">11,175,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,175,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">11,175,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,175,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 19.9<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 19.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_CDSCMember', window );">CDSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CDSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CDSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935424241696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,920<span></span>
</td>
<td class="nump">$ 1,556<span></span>
</td>
<td class="nump">$ 6,975<span></span>
</td>
<td class="nump">$ 2,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">602<span></span>
</td>
<td class="nump">1,921<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,779<span></span>
</td>
<td class="nump">$ 954<span></span>
</td>
<td class="nump">$ 5,054<span></span>
</td>
<td class="nump">$ 1,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935415020960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 26.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="nump">38,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Purchase price adjustment from Merger</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod', window );">Warrants exercised (in shares)</a></td>
<td class="nump">101,953<span></span>
</td>
<td class="nump">474,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from warrants exercised</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ameh_EmployeesMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period (in shares)</a></td>
<td class="nump">87,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="nump">520,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance', window );">Contingent on performance (shares)</a></td>
<td class="nump">295,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 42.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Grant date fair value of restricted stock to be recognized straight-line</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued During Period Value Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ameh_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ameh_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935420618160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">862,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">87,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(38,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">862,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">624,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 22.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">53.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">17.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">26.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 11.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">2 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935415560576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details) - Board members<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility</a></td>
<td class="nump">71.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility</a></td>
<td class="nump">82.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate</a></td>
<td class="nump">1.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate</a></td>
<td class="nump">2.47%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock (in dollars per share)</a></td>
<td class="nump">$ 17.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">2 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock (in dollars per share)</a></td>
<td class="nump">$ 22.73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935423544752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Warrant (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharesWarrantsRollForward', window );"><strong>Shares, Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,001,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="num">(101,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightCancelledInPeriod', window );">Warrants expired/forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">899,787<span></span>
</td>
<td class="nump">1,001,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedAverageExercisePriceWarrantsRollForward', window );"><strong>Weighted Average Exercise Price, Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod', window );">Warrants granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod', window );">Warrants exercised (in dollars per share)</a></td>
<td class="nump">10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod', window );">Warrants expired/forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract', window );"><strong>Weighted Average Remaining Contractual Term Years [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Warrants outstanding</a></td>
<td class="text">5 months 8 days<span></span>
</td>
<td class="text">11 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AggregateintrinsicvalueAbstract', window );"><strong>Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">$ 63,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue', window );">Warrants granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue', window );">Warrants exercised</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue', window );">Warrants expired/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">$ 25,300<span></span>
</td>
<td class="nump">$ 63,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AggregateintrinsicvalueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AggregateintrinsicvalueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, cancelled in period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharesWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharesWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedAverageExercisePriceWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedAverageExercisePriceWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedaverageremainingcontractualtermyearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935422039536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember', window );">Warrant Exercise Price Range One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">462,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">462,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember', window );">Warrant Exercise Price Range Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">437,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">437,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">899,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">899,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935424190000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">$ 205,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935414649648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">$ 13,695<span></span>
</td>
<td class="nump">$ 12,588<span></span>
</td>
<td class="nump">$ 24,907<span></span>
</td>
<td class="nump">$ 25,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,480<span></span>
</td>
<td class="nump">2,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | PMIOC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember', window );">APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">12,300<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
<td class="nump">21,600<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember', window );">Advance Diagnostic Surgery Center | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember', window );">Fulgent Genetics, Inc. | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember', window );">APC Shareholders and Officers | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember', window );">Numen LLC | SCHC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ArroyoVistaMember', window );">Arroyo Vista | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="nump">$ 31,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Amount outstanding under agreement</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Board members | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of shares</a></td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember', window );">LMA | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember', window );">PMIOC | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentMadeToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit/Duration (Amount paid to related party in relation to providing services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentMadeToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_SCHCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_SCHCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ArroyoVistaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ArroyoVistaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935417173920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Fees Incurred and Income Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipts, net</a></td>
<td class="nump">$ 13,695<span></span>
</td>
<td class="nump">$ 12,588<span></span>
</td>
<td class="nump">$ 24,907<span></span>
</td>
<td class="nump">$ 25,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet', window );">AHMC &#8211; Risk pool, capitation, claims payment</a></td>
<td class="nump">14,419<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
<td class="nump">25,785<span></span>
</td>
<td class="nump">25,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipts, net</a></td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">25,300<span></span>
</td>
<td class="nump">31,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember', window );">HSMSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">(649)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(728)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember', window );">Aurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">$ (75)<span></span>
</td>
<td class="num">$ (77)<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="num">$ (152)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Services Revenue, Capitation, And Claims Payment, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935427567168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">35.10%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935422515696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">394,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">257,193<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">242,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the calculation of earnings per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,175,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935427637536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Earnings Per Share Computations (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">44,858,657<span></span>
</td>
<td class="nump">44,165,264<span></span>
</td>
<td class="nump">44,815,307<span></span>
</td>
<td class="nump">43,255,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">46,023,015<span></span>
</td>
<td class="nump">45,828,802<span></span>
</td>
<td class="nump">46,082,643<span></span>
</td>
<td class="nump">44,746,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935417176112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">44,858,657<span></span>
</td>
<td class="nump">44,165,264<span></span>
</td>
<td class="nump">44,815,307<span></span>
</td>
<td class="nump">43,255,901<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">46,023,015<span></span>
</td>
<td class="nump">45,828,802<span></span>
</td>
<td class="nump">46,082,643<span></span>
</td>
<td class="nump">44,746,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">418,322<span></span>
</td>
<td class="nump">466,104<span></span>
</td>
<td class="nump">455,170<span></span>
</td>
<td class="nump">409,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">94,311<span></span>
</td>
<td class="nump">204,711<span></span>
</td>
<td class="nump">122,926<span></span>
</td>
<td class="nump">170,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">651,725<span></span>
</td>
<td class="nump">992,723<span></span>
</td>
<td class="nump">689,240<span></span>
</td>
<td class="nump">911,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935416556544">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 234,223<span></span>
</td>
<td class="nump">$ 233,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,490<span></span>
</td>
<td class="nump">53,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,263<span></span>
</td>
<td class="nump">10,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">81,526<span></span>
</td>
<td class="nump">69,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,639<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,227<span></span>
</td>
<td class="nump">9,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,670<span></span>
</td>
<td class="nump">18,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">461,038<span></span>
</td>
<td class="nump">398,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,651<span></span>
</td>
<td class="nump">82,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">253,310<span></span>
</td>
<td class="nump">253,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loan receivable, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">539<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,820<span></span>
</td>
<td class="nump">41,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,638<span></span>
</td>
<td class="nump">15,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,901<span></span>
</td>
<td class="nump">5,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">490,026<span></span>
</td>
<td class="nump">453,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">951,064<span></span>
</td>
<td class="nump">852,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,922<span></span>
</td>
<td class="nump">43,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,071<span></span>
</td>
<td class="nump">10,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">112,499<span></span>
</td>
<td class="nump">55,783<span></span>
</td>
<td class="nump">$ 59,307<span></span>
</td>
<td class="nump">$ 50,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,413<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">524<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">2,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">185,238<span></span>
</td>
<td class="nump">115,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199,068<span></span>
</td>
<td class="nump">182,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,257<span></span>
</td>
<td class="nump">9,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,904<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,706<span></span>
</td>
<td class="nump">14,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239,984<span></span>
</td>
<td class="nump">220,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">425,222<span></span>
</td>
<td class="nump">336,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">139,299<span></span>
</td>
<td class="nump">161,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,807<span></span>
</td>
<td class="nump">49,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,601<span></span>
</td>
<td class="nump">7,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,324<span></span>
</td>
<td class="nump">62,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,869<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,786<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,715<span></span>
</td>
<td class="nump">11,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loan receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Amount due from affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,960<span></span>
</td>
<td class="nump">6,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">328,361<span></span>
</td>
<td class="nump">305,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">85,525<span></span>
</td>
<td class="nump">49,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,799<span></span>
</td>
<td class="nump">58,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116,145<span></span>
</td>
<td class="nump">109,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loan receivable, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Investment in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">431,270<span></span>
</td>
<td class="nump">802,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,500<span></span>
</td>
<td class="nump">41,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Investment in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,898<span></span>
</td>
<td class="nump">4,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,808<span></span>
</td>
<td class="nump">3,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">738,534<span></span>
</td>
<td class="nump">1,070,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,066,895<span></span>
</td>
<td class="nump">1,376,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,087<span></span>
</td>
<td class="nump">11,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,071<span></span>
</td>
<td class="nump">10,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71,509<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,413<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">524<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,066<span></span>
</td>
<td class="nump">68,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,795<span></span>
</td>
<td class="nump">7,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,887<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,333<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,542<span></span>
</td>
<td class="nump">9,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,606<span></span>
</td>
<td class="nump">22,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 143,672<span></span>
</td>
<td class="nump">$ 91,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $599.7&#160;million and $567.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $143.7&#160;million and $91.7&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $431.3&#160;million of investment in affiliates and $36.0&#160;million of amounts due from affiliates as of June&#160;30, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935422055840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable', window );">Operating lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable', window );">Finance lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets recorded under finance leases</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated depreciation associated with finance leases</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935424158464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,547<span></span>
</td>
<td class="nump">$ 1,263<span></span>
</td>
<td class="nump">$ 3,154<span></span>
</td>
<td class="nump">$ 2,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceLeaseCostsAbstract', window );"><strong>Finance Lease Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Accumulated depreciation associated with finance leases</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost, net</a></td>
<td class="nump">$ 1,501<span></span>
</td>
<td class="nump">$ 1,013<span></span>
</td>
<td class="nump">$ 3,142<span></span>
</td>
<td class="nump">$ 2,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935413016288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,495<span></span>
</td>
<td class="nump">$ 1,293<span></span>
</td>
<td class="nump">$ 3,042<span></span>
</td>
<td class="nump">$ 3,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">3 years 1 month 9 days<span></span>
</td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
<td class="text">3 years 1 month 9 days<span></span>
</td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">4.92%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">4.92%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">4.32%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.32%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CashPaidForLeaseLiabilitiesAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935423507760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Payments Under Non-cancelable Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (excluding the six months ended June&#160;30, 2022)</a></td>
<td class="nump">$ 2,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">3,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">7,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">23,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">3,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">20,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">$ 2,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">16,904<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (excluding the six months ended June&#160;30, 2022)</a></td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">1,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 1,049<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139935426729536">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>ameh-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ameh="http://www.apollomed.net/20220630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ameh-20220630.xsd" xlink:type="simple"/>
    <context id="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i71c6e0513e0f49708c1b538585500a39_I20220725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="i9892fbf73a5e432fabdabd8425173fdd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32d5be84e39c452ebc3a62ac694ca372_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18ee389c560146fb90a980c9883bc5fa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5f53a8587f754ab6949ab18fac933790_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if17f14c3de074b09a519d4ae7cec2374_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0075948a15c34ea7995a87ab515a831e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a4594d1cdf8403b9b1d586438ae5595_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i064787fbd3b34338bc355bea54602fa0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3bb88e8e61844678858e6f1049c3b8d8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if532127b9ae74868b84354daf327af15_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iefd9383c56a049e39c988fe1d699c8c8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id2f66c15a9774d3f9a542401fdc90d05_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie1d18e1861dd47459e3afc0e2f4d6b6c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib3be1ea17a2242b89f05c2d9c603ef7f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1d9a9c63b74748ea9144996c4ffcebfc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9f72a8ae1ecb4b9f95f49782044f3034_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8fb94590e3da4131815186c8ad836fbd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib8b2dce3af564d37aace93fa3edc0576_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie13819d6ef7341d7adfe25db4589fb16_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i72f55ac666634d8790450c2efbff1301_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i84494cd24411430cb3a73d2b634c4e8f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7b4615fc163545a386d6cb61eafec12b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b39506fda1c403390a1a7356060a43f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18b2701ff7a24a1dbb0e0cba3406cd91_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5154423056f643eca603328d7cdb95e7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i18329a0408e04ac0bf921293f4606d37_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia504157a512f402581af013fb57df905_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad4a0d5b297a4f7fb66c1516ac86205f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief358036295248deb2d6fc4f17ab1fd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6b90da5220a49248e3a42f5d7bcee8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic01c1ed4406f45fd89cc7c596242ac42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id232a7c63cea47fb908b2d31d1507b26_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibabb570e56704819be46a35a99056cfd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia07784125551442e88d85eea79a1a397_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b2a5b59bb6c4986b7c1a50b1f8a0aad_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9c6cc256e341493aa571df5da6b6662f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3d98f2c383be4f0caf317615c3e90bdd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i75d2dd3b8a394e94b24002551af97de8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iffe3f233a5ee47f89e7da633077e4a16_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8eff61b12ade44188aa16b4c6f4691fc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i79a98933176041edb09daa8e6a031ae2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icdb8cb1f443c409ebb880abdbfb1b50b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic1b4fc11728e4a119e9ff7d187016bbd_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia2be7890574c4c2e850a4bef6af34746_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i08a4ee78dedb4bf0bb4d2dcdbf5e685c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if7a647777c9a41638828e0bb054b607d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6d4945b7a5d144dcb44613757de6b733_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icf67c623dc9c4fdb87ffe7f1a5f0fd33_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iee1f7e2940144fe09e63a4985d202a33_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i49a86084d3064273846f20df1dc58121_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71714e79a7ff4ae58ec405207709ae87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0ac6532c5744fbe9e81dcf735c713ea_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2095839d0b164a5db420348af27d9e8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieabf5dd86df34cefa162b01e549f2f27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fb56e0f9f67490fa0624de03cbc6dfc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic700b6fc892341ebbf97cebcb5258f90_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i05d89e7c53fa4a70b5fb4595708da067_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ida30c669e01848049f134a3f777ea180_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idbece1b8c5604d32bef8c1b3bee0e06e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i86bed315c9104a5ea8f38b47de37821f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i744f0bbbd4024a33b8e4daec9c49bb16_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iae2d6eb6ccba48b09c3e8ac6b7c4c666_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i11090e9d37df449c8a39e89447069685_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i95b9bd5984e7487dae4a1cd249a6cdf0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9f5ec933f8d44cc38f55f6394cb7637c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i949844556a7b4f6492884ecdd3ff6253_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i42578d05def24550adcdf005d6e174fd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if1d976a9d4c3495092aef7049971c567_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i28f106f492574f71ad887c17b3f0e3b8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ieb3286d909fa4f44a7673a684b27d8d7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6f3de9a3211f43939fba721ad717140d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic123e707f5444ec8a2f129ff7fd69271_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib9165a0fe2b24da295ead9547c7c43f7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4becb57108e844a2af77734d782c9546_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if607fd60c6ba4a7fb898dea28d8f0d05_D19990701-19990731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-07-01</startDate>
            <endDate>1999-07-31</endDate>
        </period>
    </context>
    <context id="ife69969a467049b7822c63de16e05840_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5d59e759a6d143e7b8673d525e1641d4_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i25b2318042034ef8ada1dff3ae0fa2ee_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iab9ce1fe319c40f3b5143a3c664cb2f8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8b9dc946cce64aeda656fa396f8ac5d9_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5b76bb6ee687447b91d65e6261285c67_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i25ab29ee2b194190ba48aff50a9eca6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05247cd849de40dc8290e15a895f802d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1ed4c08298bb425782e0cb29c6843164_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i910383234e6d43a5b4e0907b9f2f7fa3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i87ad3733808d4ed680a72e6a21ac142d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9c45553f306743bb86ff185b451d6f0d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i447febb4f2414ccebd0319ff3c12007a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icd0b89cf94234e64a6168f357c2f6a9a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i784b5366266c4d4796ca24adc088b8b9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id084c1a48f8149359167ebc980bdd4fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34200d16ebcc4e9bb848e910e7f98470_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa25ff896fef4a548c62b034ce2acbd1_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i2fb19f36b5434e40bf55b16ef65f34a6_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i156059eff9374f1087488e472de06542_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i8c78dbde3d4043f6906cce86f5541c87_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic233432b45644a51a10accdc3eb97bec_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i91813fbebd0e4a15b55763b7872a8b9d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i47269e9c8fe6491f87cf108347ce40c5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if90f9dac9afe48d79cdaf54cd044093f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7357682f6a2743c2ac4f7e64822ecf5d_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i76567744587f40f8a8c7ac4dc85fa166_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:ClinigenceHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae5121d03a9a469ba0192b0be3dd0589_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib6c6d1fd56384e02a5c02ddcb77d7181_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i41a54db22a27477ea703d051e51b7b7e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a475831b3ad4c928ce6c91ff40dfea6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifd641546fc50456c8010d886a4880874_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1650503a7572464f88699d1599fc1c65_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8ebf943246644d74b344ccfecdd85d8f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5d2f76f1af7d4a4495f8e7c418f0efb7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e97022e423b48fea6becfdd26749dca_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2badd64b1fb94f4b81b6475e7e2cd34d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibb83156e733243f9acced43816434206_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ac7abfe0eed4e0d8d7b27ded03a5f9f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic15db0ac3886408985bfd7a1c444afb4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib0d317985c314aa188d6771db1792d94_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e0d411993ee4352bb911f910f1c404e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5aae7fb197fa4ed39a801149bd5cd532_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i357d85714b284f7ab7bee3970e56bf57_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i038860cc692f4bb888a5b7ef1486e53a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ide23e89dd9c645c281e278662449b4a1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1ee8745d85894cceb97642891fcbce9f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3c92edeb4a78489988df0cc478c477de_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia113d3dba3ad4fa2ba4bbae8dbeb4ab8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7e0285c80acf4fbe88b94c417e7bfb83_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i93342f091b4c43cc846afa98f4943123_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie9f48dc88c7645149c0e2929fbcd7d42_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4ee529e7087e4e4c9dacd669a0e96636_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i13934575582a4f6586ab0fd0252a2087_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibb54c28e4db64ef2a4baf3b30dcfcf81_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2afd3f4b4d624a81a9706ec95cb3912e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie41c112f00c54f2ab3512eeb222e2e58_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i460a5116e6b044ad9ebfe9b19f40bfcf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46c346b0625d406694128d5527d8d3bd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icb8f797e4a8146a98eb727afc3cbfc49_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6f75606e37874c68b458b76513cab432_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i413730c561f44bcba0f3b2bc0c6bd449_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i98c80c14bf5e41c684783fbcf0d76f0e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i40b21462ffcb4d248cd6645a35f7a449_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9eb00088282a4dc5afc8c52b83d0ac33_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7561cc5bf6ca4e669a3141d449e8fa2c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia91f40c8ef0543eeb07c574e983655c3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i68316a8a436c493fabb213bb9156c632_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib880959e27194e62aaeab4f273874a1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i973177a3369f4442a2135e79cc6ef154_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5acd511331764617bdfd48af40f038ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86fb54a8136643a1965dda0ad2e9f39b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i934b31b2b19e4a32b408f256d19446bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i122754df236048089b5aad3001c4b1c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36676e73486c494b80fb603caae18d98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a386beebfbf4060bbe4c09d5f5884a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b68bdf1a0ce449889193821c0c74169_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55dadf9db838467e8bd65105322d821f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i83ea699729524e1aab10b333d7661bd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9094212bb5af45d98da492230880c142_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib11bf9964618458792c11fd0405c0f72_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5c9d9247680949b3a7da52ee73653a69_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6d3d4f8cd081436bbfc05d32afdfc31b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5b9aa026e81e4b4980bee034ca869c69_I20220419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:JadeHealthCareMedicalGroupIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-19</instant>
        </period>
    </context>
    <context id="ibaa3b499908f486889ee0e616dda90c0_I20220127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-27</instant>
        </period>
    </context>
    <context id="iebfe001bbfd543a79e230f9c3c472476_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7c6e0a57fc72447ea515eb651ec8f63e_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i7afe0c314bdd4919be94c4d4216e8769_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i262bc0262fcd480086498ee92acb8f62_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8083c97bad35410980739e54dd0c355c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2afdae606f3c4b4ca48b6404b58bf723_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i73b45a52891f4ab8bf993b978064f4ce_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id92ca545c5d242b29c14e8abfbafa3e4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icb520c05360c4639917455a159462d8a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8db7ef9235b34c04b4683c753d0c0add_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i823f7c34a37842bc853d7a95f895358c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ff8b2ce2fa64fbd861752a596120f74_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib4c456a4d4324d7da4299e68e3469d32_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id77f5a844c054b76ab43bfd594454e29_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib6b39a8c15b94db1bef62c56c6cdfa11_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i342650b110d948c68305b913d3337797_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idad1fcac77ba4ee7876fddfc937c8526_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i22617db5966243a29e90deea438fe6e4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i26c3aca5f37e4c7bbce9e471da9b2690_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70a8b50fadb34ecbbeb48a0a4e675fb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id386caca65614b57ae15aeb43ddc272e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11c5b1b731c04326a701c1dbf4c69a1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b382a0954bd416284c02bcaa5a318da_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c47fd9f6a0a4bb2a1714812fdf72b1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47aaf649d7d949a184692e09d23490b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4d39193fee394abbb9705dc0a37fb365_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6ccff1d9ca534ab0b567fd1dc05bd91a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ecea1ee1cca4bd5b0f7613a433ccb86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfde020db2314ef08cf9d768e4c6d60f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87d17a700c65498dbbc648590a1e5c5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b2bbf4c0d7e4582a1a0fef1a71f7b4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia90be308939140e9a4a7cb933f276390_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6903a2d9d4664df8a794cb162687a0c1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2206b47d6e7b424d9b62ab32b0338026_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cad2048a753446186dfdb8373edee28_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide0127b82d0c494786e6a5b4bd61c173_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0e0edd220c6943ef81f9294e13541194_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if7cf8eaa6bf64eeab771048f5de4564f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifff5051e4aad447bb1d4f5b0b052cdff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib410a832400244ff85bff3debb332a3f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i77a601ca89014f5eacda8b352cd397cf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iadd8800c72bb483c99ceb9c97149a818_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie80aa85c869b4960834df7f5663464ac_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie6dd79fb668d4396a088c5c7da4ad9bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1e059681a7204193b3ca300c44829e19_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifcfcf46929264addbb83d541b8cf9a81_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie11fbddce8b34653bf1c488090c280ed_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie5a62c94039149c4add47ae7f2b1df0a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6ac857e621104221a59862c04c79506c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i788d07c210dd4f958d756e23167c1e15_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i61e73f5506934b76adfdd854acffd935_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia30f4a1733a0428ea9411e847f714b94_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i456a03746030449991737ef8d57a4456_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib71de6782da243ac87254390580b0b61_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="i72155c35fa2747b5984527dcf5162a43_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2f30d164f6d743639946b82e4328af58_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i36766b59fdb44c0cb8d7da462b05fbef_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib9f907a840be46e2aeb32432dd66fea0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icb35d81b629041debdd1e5e0eb5500ac_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6baa1c84dac349f5acf23c66fef27140_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8cbe9a274f944c9b33a5afce066df48_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if465b8aea2ce4908904e4ad93a86b298_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i018d7b4e12a2489aa9b33f4323e5c611_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i016ca3434597421199937a03ff2fc17f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i79ef92aed16c481bb3060e0e03050169_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2ef0c4478a2c41e38132323c3a052804_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iaa17eff6b8c744cfad25e00a8a815d59_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ed8a2f220bd4feda2e865edfbd8e716_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ief5224c7fb984c28ae95700de5da6e27_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i35e8315cdc8946c3bd924c645f5730ed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i39e02afca44c4aedafa732851dd3802b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i227316615eba44afb5e1909846c71eeb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46a28bb2bc244c43b885f7f0afdb1949_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i268b6755560b4788af5c509f2650c3ba_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i13da4e8ee17d47e9819397b6faff3bfc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6fd70ca2db774b288ae5881780641231_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ddac981e5724f7faa52da42366eb5b0_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i1d95aff18be44aaabba0d95b213fe04d_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="ica0c755f6f5a456cb7c1e3039165cf31_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i74659971142042e9b4b1ecd398a5632a_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i68a73980d9cb441dbb6fdd887b9503f8_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="idd5ac37956bd4d08909d1dd390134c6d_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i0858a8d9fe0c4b65b4073669668a0c6b_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ica9c3cfdeff84d0eac173b74662af814_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5d5365ccd50e40b48292e6b69f44ba5f_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="ibf671f1c4d984ad4b56737e8bb018cf4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:LmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i767518e6c72e4e4997ab25645b106efc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i778bae90463c48628833fa5514d45310_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i846ff05d31aa414e88893b18094681fe_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="id2940bbecd004561861f01abb0ebad96_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9ca1ca2ff65840868df912f9f0aaa96a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b355b7c0d4a4f3bac5ad6619d970628_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib86197b3338a4a568e33693944e72e99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78dd2608d34c4de8a4f893d06e8f8f22_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i36d1265e36d640f2adebf0f735428064_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc4faa451635444dacf9694e218dd3e4_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ibdae08981f5e4104934ad51fe3b95303_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i22fc5dfea7e84f638573c274ba9b23e4_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="ia2cd92e83f7b437bb51b5c89f701b464_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i85593b22935b45e4be1ee177e8ad7239_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i3eae04016bb447e0bddc4f0591df991a_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i95eae60963324a459007367c1b4ab420_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ia1261394f1654823b8118f1c41514f21_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ic88159173edb49298d65e5a36a704517_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ic938e3d247da4baf8c4e436b6ba4e60b_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i8fa6d96494224426b248b59ceab8cebb_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i60f21d618be04c29bad9cca5524c19b7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i161df59378d54e2c9c35ef127c00a692_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i11ed2f9093db4b03b46f940a69391343_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic59abeea171b4680ac8fc59615e1a446_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibe69f802279e4ce8a230a2252301ea51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia874564b3f7f46f0bb91acc1285b389e_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ibff008a8379447cea04496a4e74019b5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if16717b8edf54956a5b44e5ed8302e3b_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ia1041f899e3243769086c3764cd3193a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74c97c8e257e4a02a64730b6e0e41ade_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="i5b7a043471da464fa12812657a6fb838_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i11705a1bed9740c793f74a813ac7350e_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="icccdfccc60d849bda7a0fa9d6cda8ea8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d4b6704bd1a4f1b8e67da94daf68ad5_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i5739754d4c764531a08a2b6ba1d03922_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if06c44df5942487d9c597ef8cdee2e34_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="ibf7979125d864b698864f3e49061ba20_I20220125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:A120HellmanLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-25</instant>
        </period>
    </context>
    <context id="if75e16a418bd4b0ca6e69d9bda0b4418_D20220125-20220125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:A120HellmanLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="i282ab48d547a409c91b0e2e1d8c055d7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:A120HellmanLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8efee8b6417740c295818b5927155453_D20220125-20220125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:A120HellmanLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="i2cb7f86e0def4c95962563988d781f2f_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ie1d752a197404d5bac408b2154757c13_D20230101-20231201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="i9f39746c41a9450889b8b440c4bb1e87_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7cbd40ee0c194527bd610419cab4d09d_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i693a573b995242e69ae791b297318006_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iafc384eaf4734dd0be96fd82579c39f6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia26057f05b68400bab7e17c33a599861_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i039231bd37b04500b07453d76940704d_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="ice27ac69897e45d1b5b34a56355dc920_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i00309c0459be4ba3b15e9b6033b0acaf_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7d5bf58fac1b43f9a4c5a689c4268856_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9aefdbbfc23740e3971470e4cc27ff41_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1c708cdfd53f41a8b290faf3f23f5186_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ief6a946f84384708a367fa93594947f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7680ae5461b4b2486caea091e4e82f8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id4a852313e0c4ddd88001a38595d3390_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9902cb6392bf40fe99762875e13589c3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7dca31d301345ef9166cc408559e908_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0383372507bb45108200170dddd5ac63_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2743e935ace9464cab6ca597868b375a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i29ea51d5f00d45e9bc091bc8a1a88beb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaffd866f998541ff9a904994be9fae46_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a2d277b4082486a82df6f70b19d1989_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icfd41ced8b31471c86f3e5b810861eef_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ice144ed20675466b9ffd1ea1b947c8df_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i117ec78443b64325bf4c2ac950fb25a7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5ff7d682f2d94d5c926e3c35381ee58f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7d1d13fa98564dafaead4c073177d336_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i204ae706d04f42e492b4e0e310f1dad8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icfd7b521efd0406a9d8f97afd5c8feb7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i13efa678914f4d7f98b3e9aeb1cd61d8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b1957cc255c424d8d39c550b3fb4230_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib7e67912a5d449dbb5d6e4854647fa10_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iafd2b1c8b5514ddf938ef5e9deed8686_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i27162b4c30e1433389aa44bb606e1201_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i16a45d3b518b423aaab4649221f9e190_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib521230a737a4886950b1519bb58fa8f_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i675bd27f6f9449a7b867a0997a6672c7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i03ceea72d6fa40489f52e559fb181611_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6840db3bf9284ad4ab822cbf059964ce_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i114ccddf4f7649a6848a22c64dbc33c9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8c54372981e0483384beb5dc3115d981_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i76936fef1e6b40c18740fd16b3eda56d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if150202c05234c61a08e030fc794aca5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i59a47c483aa24f5c89caa7bb1cdec67d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7f9f34bf3fb48cebfa73e5b388e465b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie72fbf8622a44da7b8b232c28510f1a8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1726507efb5f4fa09d9993c3857c283a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia172d03ffb5f4a4181d8f9c79bac7f77_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if0ae41c7e0b64fbeb8ec11b3c8e12d1b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i83fa8e1b5460411992308ed07575a1f1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4b559e5023334ee3b95e75fa03c7d652_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieb082a42a8f04b7f8520726fad9dbed0_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifb2c519a88fb425cafa67a6ac705ce13_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i20e887d2baae4779bc16fb980480b5cb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1a80af6894a14c43a89ecebb723dcfe1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8d8d52a080a44e86a886bce63a285724_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7ab323e1b397418fb339066bb405899c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6b3980ecb88c467597f9070419028889_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ica63af2bcd74490792c66cc16aa7cd45_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2f665909db64084bcae52d7869044f6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i720010c532d04ae38a15375c00f6c278_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i658af4a1b5524e469c86ffaf726d3a51_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8069e38106d34794bbbea1a815263bf1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i686c7f250f0e4d35824cd656b22866ad_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2ba4984e1d0947a59e1755baeb841f28_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i42ce7049b8564902b4714f05408d23cc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7f93bbd717a34da48676ae33c98e2878_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if9d5e8e10ad4481ab709154b84b5e390_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47b66c55e1084cb1b52c404c22c765cf_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i570036110c9340efa486b231d649cf09_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if91fffa5808944f686a081038f37122c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3873e858d6954dc9a1e7b2ebfd958d51_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie0924e12aa8d4ee4b2641423ceba4881_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibf42668aa8fc4595af61af9ed0dceace_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1340961fa52f41c78bd6a84fc6c342d9_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5fd9786f0dd94c12a12df172b4e36ceb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06340797df8f4752a83e03326162b898_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iff12e49686f34776bca7427f81b46a8e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i493e02bb89bd49aaa06143a91d99bd2e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3be6c5a1eee74540ac2a07c4971194b7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70e5cc9cbbc44c1ca2da76b30137a3ab_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0933e3ac6e9444cca9e2cf27d88e1e4d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id668620835dc4bb0acb31d65a5da7f73_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib853e0afcc864f9fb37c1a57ebf20e0d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4ed1fb4cb8784d2baa6d489ba5f6e31c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2fb8594254234c10bce4ca7cad2d7f34_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5b1510e6b3e48aab9201dae55a97382_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id84ea8946f574e32a5be27bbbc154f24_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i52933dc179ba4dbc8f26c1943d99f3ed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i608f29a5f13e45cfa7a9e81eef3d1ed6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i103376726f94415da0aa6fb6fa1625f1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib0fe166dd3574c6b86ee5fd3faa41fb8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0213948f1599453ab721957923ae20aa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd1c490153ac4f1cb6028c98823533b4_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if433cdd244a24b8e8f0de5c3a6d6a9da_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i92d25dc960744271ba14d5a22e01a9f4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibcbf57723d89405ea64c036cc63fb0eb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if451ab4e4ce44c71a99f29e2c5e07e30_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2fb1b871a5524ffcbf6e9b30520d3b46_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i87972789a91f4575b4ee414751a09b0d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i94083cc9f0fc4e369ee64217a4f7e9fc_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iba052b72bbb34b62be83891b4561a8d2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iad69ae1f414c4d90bc9075012d5d4d30_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib23158de6e644cdd9bc4e3523331c1e9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie446c27adcbd42b59894a90417c05196_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7f46457a64ad499c901e9853b8d0ba22_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i706352fc1d254fd5a5e36dc095d71cfe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib64616cababe4909a842281a3ca6fa56_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i817afcd7d5c442c2b55faa40b0d1a8f5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i70e8720f09834880b0eb68cb4dfd69c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea207f25a4494db3b8ca98bec38b0cf3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i09d176d59d3c498f8f2c88e2c37d402e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i535c48c761b74aa9ac2acbd6ebd3be28_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ica66f014fe6849c9a087191711c14b58_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie4b065ecad2c4dd18600860d892995a7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7bd5950728274396a47ab8be6047ebba_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id604da4cbf9d48cd853c3313a4b215d1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ad190507ff44da9b6ffe950ec0a7c48_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b1e7c7a12844a52bcf3c60b54e403b8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icbe4add77b0642b587fbbdfc4e0469d7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie500388613f5490c85227584adbecd21_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i082d8e652b86490ea5c3fe0dfaaaa3c7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib08d24f28e4a48f99ec3872354ff7790_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i49102b8554a1457c8a1f914d3daaa7f9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if79c2773d57946a3995aed561a9def52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15757c3b5f1f4c7ca17b41a6d3ae72fa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6b1ed3c5e65d4fbbb94a7b74e3634086_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>ameh:plan</measure>
    </unit>
    <unit id="clinic">
        <measure>ameh:clinic</measure>
    </unit>
    <unit id="segment">
        <measure>ameh:segment</measure>
    </unit>
    <unit id="unit">
        <measure>ameh:unit</measure>
    </unit>
    <unit id="financial_ratio">
        <measure>ameh:financial_ratio</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY18zLTEtMS0xLTEwNTAzMw_78f29bb1-7d33-42f1-bb86-e88eaab7c095">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY180LTEtMS0xLTEwNTAzMw_cff088d1-f3e2-4c52-ad43-5d8aae76f0b5">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY181LTEtMS0xLTEwNTAzMw_082d2862-d676-4f84-adaa-880706de1ad3">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY182LTEtMS0xLTEwNTAzMw_31d7f0e3-5724-4fea-8a3f-8fe6e7f94a15">0001083446</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180L2ZyYWc6ZDIzZmU2MzQ5YmIzNGJlNTg2YWE3MWQxNTdhZjk4ZDEvdGFibGU6YWQwMGIxZjFlNTQ1NDlhNzk4NDE2YmE0ODExODUwYWMvdGFibGVyYW5nZTphZDAwYjFmMWU1NDU0OWE3OTg0MTZiYTQ4MTE4NTBhY183LTEtMS0xLTEwNTAzMw_b7a1b471-4a27-4018-9ada-b7abb0828c6c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDg5_19d6a612-e1a6-456b-a22f-3c3cd489ca9b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6MzUxN2U1ZDY0NjNkNDMwMjkxNDUyMGFmMDMxMmMyYTYvdGFibGVyYW5nZTozNTE3ZTVkNjQ2M2Q0MzAyOTE0NTIwYWYwMzEyYzJhNl8wLTAtMS0xLTEwNTAzMw_c57f3077-ac00-4f84-a4d7-300ef8c9c88c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8xMjM_c38eeef4-22f9-4389-9b05-6dc6ac1b0c4e">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6ZDFhNGYzMDZlOWFjNDQ3OTk0ZWI1NDk4Zjg1NjBiZjkvdGFibGVyYW5nZTpkMWE0ZjMwNmU5YWM0NDc5OTRlYjU0OThmODU2MGJmOV8wLTAtMS0xLTEwNTAzMw_a52b8b74-1e00-479b-9b9c-f247ece0bdf4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk3_ca8e1cd2-01c5-4856-af94-2a6d4bf1d525">001-37392</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDg2_2402becc-bacf-4fec-a146-30deef335a82">Apollo Medical Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6M2YzY2M1ZDNkNzBiNGMyNjk3MDA1MGIzYTllMmU4YmYvdGFibGVyYW5nZTozZjNjYzVkM2Q3MGI0YzI2OTcwMDUwYjNhOWUyZThiZl8wLTAtMS0xLTEwNTAzMw_1cf7f2ec-6e6e-47d2-945b-aa9b476575a3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6M2YzY2M1ZDNkNzBiNGMyNjk3MDA1MGIzYTllMmU4YmYvdGFibGVyYW5nZTozZjNjYzVkM2Q3MGI0YzI2OTcwMDUwYjNhOWUyZThiZl8wLTEtMS0xLTEwNTAzMw_664499c0-ed0f-4226-a700-1093eddfbf36">95-4472349</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDkz_06cfe7f5-b286-4976-808e-3b2906717f74">1668 S. Garfield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk4_a1825bdc-e1f0-4687-b7b7-aedb2350b0db">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk5_6062f94c-c9e1-46bc-8e67-874a237e0de1">Alhambra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDkw_68e7ffe9-5b2c-4359-8e19-2528b1852b75">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDg3_a2c2432f-74c0-418e-a477-0e2856ece631">91801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDkx_1097f8a4-5177-4222-bc67-85085a680db2">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDky_60710762-c42b-464d-94be-9e652a4f589f">282-0288</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6YmYwZjRkZDM4NWRmNGZiMDhiMmFjNmFhNzUxZTQ1Y2YvdGFibGVyYW5nZTpiZjBmNGRkMzg1ZGY0ZmIwOGIyYWM2YWE3NTFlNDVjZl8xLTAtMS0xLTEwNTAzMw_a2219952-7269-4d8c-b92e-46a4c03f7865">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6YmYwZjRkZDM4NWRmNGZiMDhiMmFjNmFhNzUxZTQ1Y2YvdGFibGVyYW5nZTpiZjBmNGRkMzg1ZGY0ZmIwOGIyYWM2YWE3NTFlNDVjZl8xLTItMS0xLTEwNTAzMw_a2e00427-163b-4e1d-be1d-1f20c1664d77">AMEH</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDg4_9dd44ab5-57df-489e-9ab8-e2f86ce158c4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk0_34ba8685-536d-48a2-aa87-8eb9c79345cb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6MmFmNzE2NzVmNGJiNGM4NjkxZGRlNWZhODg1NjNhZDUvdGFibGVyYW5nZToyYWY3MTY3NWY0YmI0Yzg2OTFkZGU1ZmE4ODU2M2FkNV8wLTAtMS0xLTEwNTAzMw_95ee2093-766f-49a0-abaa-35cfd4abc268">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6MmFmNzE2NzVmNGJiNGM4NjkxZGRlNWZhODg1NjNhZDUvdGFibGVyYW5nZToyYWY3MTY3NWY0YmI0Yzg2OTFkZGU1ZmE4ODU2M2FkNV8xLTMtMS0xLTEwNTAzMw_1acc22e1-1b0c-4722-9856-e100dcc3d3cb">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGFibGU6MmFmNzE2NzVmNGJiNGM4NjkxZGRlNWZhODg1NjNhZDUvdGFibGVyYW5nZToyYWY3MTY3NWY0YmI0Yzg2OTFkZGU1ZmE4ODU2M2FkNV8yLTMtMS0xLTEwNTAzMw_74b95e79-3567-4583-90f7-fc3e34694771">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8yMDk2_4bb5b724-8750-40cf-a9c0-1625c3c70f48">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i71c6e0513e0f49708c1b538585500a39_I20220725"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xL2ZyYWc6ZmI1MjJhNDA5MDQ2NDE0NGExNWI0M2I4NGY5Y2IwNzEvdGV4dHJlZ2lvbjpmYjUyMmE0MDkwNDY0MTQ0YTE1YjQzYjg0ZjljYjA3MV8xOTg5_05b5490b-d575-4e11-9693-fa9734909ff7"
      unitRef="shares">56461468</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNS0xLTEtMS0xMDUwMzM_5aa098eb-961d-466e-a4e3-a0c8a91cba69"
      unitRef="usd">234223000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNS0zLTEtMS0xMDUwMzM_81e37584-5106-4f71-ae62-15042c06d31b"
      unitRef="usd">233097000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNy0xLTEtMS0xMDUwMzM_c8bfbf9e-f371-4a17-b15a-9cb29e1e163a"
      unitRef="usd">39490000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNy0zLTEtMS0xMDUwMzM_be1a247b-ee3a-4739-90aa-a968f5c45ea9"
      unitRef="usd">53417000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOC0xLTEtMS0xMDUwMzM_94d290f0-e37a-4eb8-a06d-9f8486383cac"
      unitRef="usd">67263000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOC0zLTEtMS0xMDUwMzM_a307f174-b534-4ffe-b414-0c6671f59cb5"
      unitRef="usd">10608000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOS0xLTEtMS0xMDUwMzM_7a279611-c543-4c32-bf1c-6bd069bf2dee"
      unitRef="usd">81526000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOS0zLTEtMS0xMDUwMzM_ad252704-9c54-43ee-bb7a-1b537d2a5ec5"
      unitRef="usd">69376000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOS0xLTEtMS0xMjI1NTI_9c7275b4-46c5-452c-8027-7f277aac814a"
      unitRef="usd">12639000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfOS0zLTEtMS0xMjI1NTI_e032b9ed-3c93-446e-a455-dba6c643aef5"
      unitRef="usd">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTAtMS0xLTEtMTA1MDMz_290e4367-4398-46e1-8025-106c0df9c382"
      unitRef="usd">13227000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTAtMy0xLTEtMTA1MDMz_280e4ea2-e46b-44f0-9ba6-136913ee45fd"
      unitRef="usd">9647000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTEtMS0xLTEtMTA1MDMz_55d3eb65-dbe6-4f32-8a73-f2e5087995ce"
      unitRef="usd">12670000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTEtMy0xLTEtMTA1MDMz_c3fa49b6-91f1-4f34-be2b-cf44a3e8b7e1"
      unitRef="usd">18637000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTItMS0xLTEtMTA1MDMz_34cbcec4-6d98-468e-8254-07da1054567c"
      unitRef="usd">0</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTItMy0xLTEtMTA1MDMz_31a4066b-1eaa-4b8e-828e-f9daecf5c5cc"
      unitRef="usd">4000000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTQtMS0xLTEtMTA1MDMz_c30dee08-df11-4414-9770-78f1d0908633"
      unitRef="usd">461038000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTQtMy0xLTEtMTA1MDMz_365b5fc9-2bb4-4302-a127-df6da42d0232"
      unitRef="usd">398782000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTctMS0xLTEtMTA1MDMz_0503a425-5762-45f1-b9e2-f7723f2108a0"
      unitRef="usd">87146000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTctMy0xLTEtMTA1MDMz_a1a6b81d-c3ca-4665-9721-0911fcb7565b"
      unitRef="usd">53186000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTgtMS0xLTEtMTA1MDMz_f8e469e2-4b6d-48f0-b1ee-ed6fdccefac3"
      unitRef="usd">76651000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTgtMy0xLTEtMTA1MDMz_b2c3b5d1-4b93-441b-901c-0e9709cfee66"
      unitRef="usd">82807000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTktMS0xLTEtMTA1MDMz_b5ff595f-4ea5-479b-a098-76d1eaba59a6"
      unitRef="usd">253310000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMTktMy0xLTEtMTA1MDMz_0149b10a-9b9f-47ce-b8e0-8d23bd0fdbd8"
      unitRef="usd">253039000</us-gaap:Goodwill>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjAtMS0xLTEtMTA1MDMz_0a2a3de7-2fce-491c-bf31-47c7ecfd4398"
      unitRef="usd">539000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjAtMy0xLTEtMTA1MDMz_5d36f0d7-5e06-43ea-b44a-7b9a68eddf57"
      unitRef="usd">569000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjAtMS0xLTEtMTE4Nzk4_546a69e7-d602-459d-a0b3-eef63781d203"
      unitRef="usd">2125000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjAtMy0xLTEtMTE4Nzk4_a1c3677c-458f-4d3e-8d46-5815c355649c"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjItMS0xLTEtMTA1MDMz_67b54762-b9cc-4eed-a176-22e8032efb29"
      unitRef="usd">43820000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjItMy0xLTEtMTA1MDMz_d17bbeef-24a6-4ac9-bdf3-d9273e0d9ac9"
      unitRef="usd">41715000</us-gaap:EquityMethodInvestments>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjMtMS0xLTEtMTA1MDMz_f1c333db-167f-4483-a0d9-ba428ace1961"
      unitRef="usd">896000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjMtMy0xLTEtMTA1MDMz_33440294-92f6-4829-9696-5cca79ef87ac"
      unitRef="usd">896000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjQtMS0xLTEtMTA1MDMz_781584dc-59fb-4ebc-bc3b-aadfe08f360b"
      unitRef="usd">19638000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjQtMy0xLTEtMTA1MDMz_eaab6a96-aa7c-4e30-8b3e-baf275eff7a8"
      unitRef="usd">15441000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjUtMS0xLTEtMTA1MDMz_30739b3b-a138-40df-80e4-a3176c627d4b"
      unitRef="usd">5901000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjUtMy0xLTEtMTA1MDMz_64bbc4b8-b1a4-41bf-ba69-44b783dade47"
      unitRef="usd">5928000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjctMS0xLTEtMTA1MDMz_07dda8a2-79a1-4707-97dd-b7b8d68118e9"
      unitRef="usd">490026000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjctMy0xLTEtMTA1MDMz_fbb298b9-dff2-4228-9faf-17070b05375e"
      unitRef="usd">453581000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMS0xLTEtMTA1MDMz_879e3f2a-2d77-4bd2-8991-2d1f0da3e422"
      unitRef="usd">951064000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMy0xLTEtMTA1MDMz_2860dc71-c30f-4d36-9d2b-2b6da5f2a16f"
      unitRef="usd">852363000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzUtMS0xLTEtMTA1MDMz_d6a1813c-0d52-417b-aa48-1b2a3d2333d3"
      unitRef="usd">59922000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzUtMy0xLTEtMTA1MDMz_5e73f53a-5f64-4e80-b104-8d8b7082adc5"
      unitRef="usd">43951000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzYtMS0xLTEtMTA1MDMz_1dfc91b7-9bb9-42b9-8191-bf60fa0aaf67"
      unitRef="usd">6071000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzYtMy0xLTEtMTA1MDMz_06d14225-0b81-478d-a479-8ce1a2e41f2d"
      unitRef="usd">10534000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzctMS0xLTEtMTA1MDMz_814679f8-2804-4b99-a5d1-c4b653a3c36c"
      unitRef="usd">112499000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzctMy0xLTEtMTA1MDMz_1cb90e74-daef-48ca-bc1d-32d48220a5a0"
      unitRef="usd">55783000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzgtMS0xLTEtMTA1MDMz_770d86fb-9d59-4c25-b04e-32557d1df839"
      unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzgtMy0xLTEtMTA1MDMz_e456af33-54e8-4114-981f-f094534875c1"
      unitRef="usd">652000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzktMS0xLTEtMTA1MDMz_b166db4a-b97b-425a-8cb2-4bc982c7f546"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMzktMy0xLTEtMTA1MDMz_cb92b514-633b-4732-8855-bcdacc319cea"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDAtMS0xLTEtMTA1MDMz_9c405dfe-9e07-4f6b-b750-7546d46dbf87"
      unitRef="usd">524000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDAtMy0xLTEtMTA1MDMz_fe15b881-cc08-4126-9b23-b96f408a5dab"
      unitRef="usd">486000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDEtMS0xLTEtMTA1MDMz_0f1b9a2c-41b0-4765-a063-6cb2a4e42c52"
      unitRef="usd">3253000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDEtMy0xLTEtMTA1MDMz_2b4cdfec-4b38-4075-ab7e-974733ffb4c6"
      unitRef="usd">2629000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDItMS0xLTEtMTA1MDMz_c90ae4c0-e29b-42bf-8b84-bbc61e18c6cb"
      unitRef="usd">2413000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDItMy0xLTEtMTA1MDMz_e6c623be-2736-40ea-833b-c4235c44b9bc"
      unitRef="usd">780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDQtMS0xLTEtMTA1MDMz_57125b2c-10a4-49d3-95e3-624880e1ae7b"
      unitRef="usd">185238000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDQtMy0xLTEtMTA1MDMz_908919d0-1f26-421c-9ee5-3158f951c9f6"
      unitRef="usd">115371000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDctMS0xLTEtMTA1MDMz_7d0ce5b7-ff45-487a-80b5-03e77cdf2622"
      unitRef="usd">9257000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDctMy0xLTEtMTA1MDMz_cedd50bd-8143-4b5f-8093-4309827b3267"
      unitRef="usd">9127000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDgtMS0xLTEtMTA1MDMz_9183495c-0e17-4811-9d61-9fcf1643e09b"
      unitRef="usd">1049000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDgtMy0xLTEtMTA1MDMz_86a896dd-eaf1-4a52-a5fe-8356e743f93e"
      unitRef="usd">973000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDktMS0xLTEtMTA1MDMz_73cf8011-aa23-4b23-8225-527bfb9fe7fd"
      unitRef="usd">16904000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNDktMy0xLTEtMTA1MDMz_6fff5ad4-3b33-49cf-b73e-92f184206eb9"
      unitRef="usd">13198000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTAtMS0xLTEtMTA1MDMz_b9e07420-dedb-406a-8d29-8651ec672153"
      unitRef="usd">199068000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTAtMy0xLTEtMTA1MDMz_2de700d1-a3fb-44eb-a251-44e7ff4ec0c8"
      unitRef="usd">182917000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTEtMS0xLTEtMTA1MDMz_b216b7ca-8d3c-486d-8b27-a8be8ca14c82"
      unitRef="usd">13706000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTEtMy0xLTEtMTA1MDMz_89224268-949a-43a9-a2e3-4be70648163f"
      unitRef="usd">14777000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTMtMS0xLTEtMTA1MDMz_2f19abb6-29bb-4765-a2a6-847515b172a6"
      unitRef="usd">239984000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTMtMy0xLTEtMTA1MDMz_8342670f-b8ad-449b-9e84-9c4f23588c0e"
      unitRef="usd">220992000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMS0xLTEtMTA1MDMz_64c937bf-077b-4e30-b5bb-928744b95c0c"
      unitRef="usd">425222000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMy0xLTEtMTA1MDMz_96d8734d-278f-4b05-bd0d-3a9b0d93f835"
      unitRef="usd">336363000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTctMS0xLTEtMTA1MDMz_73e4ee3c-58c6-4ffb-ad7d-7e7cd78d04a0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTctMy0xLTEtMTA1MDMz_4e850fea-efc6-48de-be89-1e0aa1b259e7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjAtMS0xLTEtMTA1MDMz_6d730a79-fd5f-4a8b-9e2b-207f955c7b74"
      unitRef="usd">39997000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjAtMy0xLTEtMTA1MDMz_dd0708ee-4618-4ee5-adc5-b939ce616aa0"
      unitRef="usd">55510000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMzA_395a8700-3a34-4553-850b-eefd6b204844"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMzA_e10e5f15-630b-4c52-9f92-465e63ab6062"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfNTQ_1027a51f-da37-4ff3-9fb2-4d62881b336a"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfNTQ_6f27ba78-2c94-47aa-86ef-7090fb51df59"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMTQ3_87285f80-0eef-4654-86b1-02847325c1ae"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMTQ3_f537c510-3190-4954-94c0-5b5e5e407859"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMTYx_a6acd68c-a0e4-4c11-8383-a29267bdba22"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246N2JkMDNmNTJmMmQ4NDU4NGJhNmM4ZmVmZWQwNTRhMWFfMTYx_b232f7d0-4e2f-41ce-a1b5-ea0e08aebc90"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i18ee389c560146fb90a980c9883bc5fa_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMS0xLTEtMTA1MDMz_49db4f8f-6516-46c2-b1f1-18a6ecc4d6da"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i32d5be84e39c452ebc3a62ac694ca372_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjMtMy0xLTEtMTA1MDMz_4ba9e67a-bf37-4827-96e2-4cb5ea0585ba"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMzA_60062cbf-e5db-4ca4-b0da-8d8a2bbe6a51"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMzA_8fb57d65-2f70-4c86-b946-ba9576b215a9"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfNTQ_22c1c97a-ec4e-4a21-82b1-b9f05b41442e"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfNTQ_f982f683-0fa7-46ca-a029-a7139710d56a"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMTQ3_4a61d477-af42-4a78-ad8f-894142163e84"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMTQ3_8b3869d9-f889-45da-a362-6d281a4b0852"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMTYx_29f77757-26ab-41f3-8c86-2e5ee6ee402b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246ODkwYjFmZmU2ZWQ3NDg5ZTkxZDk2YzI0NzZiZjNlYmFfMTYx_7079cbf6-3ab8-411f-85a2-a22189b86025"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="if17f14c3de074b09a519d4ae7cec2374_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMS0xLTEtMTA1MDMz_295df315-ed3a-44c2-b1db-19eb80e4636e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5f53a8587f754ab6949ab18fac933790_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjQtMy0xLTEtMTA1MDMz_3a5d4cbc-835d-4991-a53e-004c55c2abaa"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfMTg_78e866c3-6db1-4fbb-9395-854cb7857b2b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfMTg_80279408-0a55-452d-9d45-bcd42feb445a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNDI_042fba4a-a8de-425c-bd84-42ef49e64512"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNDI_85c4a342-f2ed-4060-92b4-e9917c8d7c2d"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNjQ_2c0c441a-763a-4eee-98ca-b8a585853a82"
      unitRef="shares">44719710</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNjQ_d97fb815-2c79-44af-b84e-923851c80fd1"
      unitRef="shares">44719710</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNzE_13bab55b-50b9-4e39-a0f5-53aaa7039a74"
      unitRef="shares">44630873</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfNzE_d92e7aa0-55f8-4b1a-bac3-363ecc4889db"
      unitRef="shares">44630873</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfMTE1_6c67a296-fac0-4ef4-8e72-db58cc314cd9"
      unitRef="shares">11175702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMC0xLTEtMTA1MDMzL3RleHRyZWdpb246OTYwMjQwY2M4NmZhNGM5OGI4ZjA2ODViYTUwZTk1ZjFfMTIy_1b784929-22c0-4f59-a1d9-dc58cc5f4c3e"
      unitRef="shares">10925702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMS0xLTEtMTA1MDMz_c7299942-2656-4480-a04e-5eab5677afa2"
      unitRef="usd">45000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjUtMy0xLTEtMTA1MDMz_ffb3ba8b-1837-41eb-89fc-80164574e8b8"
      unitRef="usd">45000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjYtMS0xLTEtMTA1MDMz_b3c491dd-8c56-4bc2-8b55-48fe72c63775"
      unitRef="usd">310629000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjYtMy0xLTEtMTA1MDMz_e034ff8d-861d-4dd8-a99d-19f6008542d6"
      unitRef="usd">310876000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjctMS0xLTEtMTA1MDMz_71a3d586-ee8a-4626-a353-7cb9b23b45bd"
      unitRef="usd">169292000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjctMy0xLTEtMTA1MDMz_f349fd15-516c-4c36-b369-8140ff63b70e"
      unitRef="usd">143629000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjgtMS0xLTEtMTA1MDMz_bb72dcca-c2cf-42f3-90de-19d4f8db6717"
      unitRef="usd">479966000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNjgtMy0xLTEtMTA1MDMz_dd675c82-5283-4b22-b1ef-9f001f951b5c"
      unitRef="usd">454550000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzAtMS0xLTEtMTA1MDMz_804be551-23e7-4704-9b2b-473a59223a4d"
      unitRef="usd">5879000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzAtMy0xLTEtMTA1MDMz_da7ffed8-d729-4667-a73f-74fd14423d9f"
      unitRef="usd">5940000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzItMS0xLTEtMTA1MDMz_f72826a1-7c6a-4aaf-8441-defbae800795"
      unitRef="usd">485845000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzItMy0xLTEtMTA1MDMz_33c02867-5812-4de3-8993-e73c02b59630"
      unitRef="usd">460490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzQtMS0xLTEtMTA1MDMz_3f908de8-ce1d-4385-bf1b-3ae57023c34e"
      unitRef="usd">951064000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNzQtMy0xLTEtMTA1MDMz_5882b9c5-2912-4311-80d0-cdf6f011ad3f"
      unitRef="usd">852363000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="i0075948a15c34ea7995a87ab515a831e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNDcx_5766b851-757b-436b-9644-c6107362adf3"
      unitRef="usd">599700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNDc4_a81e2481-69ce-462c-b4e8-d211205b5192"
      unitRef="usd">567000000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i0075948a15c34ea7995a87ab515a831e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNjYy_0da6ab9a-1603-48fd-94f5-27a9c0b97291"
      unitRef="usd">143700000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNjY5_eedc1b82-2d8b-4d30-ad50-4fea661797e0"
      unitRef="usd">91700000</us-gaap:Liabilities>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i0075948a15c34ea7995a87ab515a831e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNzM1_fc8d8ddc-b0cb-494b-987f-9bce394dc4e4"
      unitRef="usd">431300000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DueFromAffiliates
      contextRef="i0075948a15c34ea7995a87ab515a831e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfNzcw_152e8092-d3f6-4d62-9690-14e602891817"
      unitRef="usd">36000000</us-gaap:DueFromAffiliates>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfODE3_70afb0cb-3622-44f9-bd31-56cb42acc33c"
      unitRef="usd">802800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DueToAffiliateCurrentAndNoncurrent
      contextRef="i2c1c21d6293a4e70a7cb90cf8d22476b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfODUy_66c3c74f-fa0c-4106-bbea-5b8f6feb75c1"
      unitRef="usd">6600000</us-gaap:DueToAffiliateCurrentAndNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a4594d1cdf8403b9b1d586438ae5595_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMy0xLTEtMS0xMDUwMzM_65a0f403-4d1d-4f54-b7df-2bc6d56dc5bd"
      unitRef="usd">227623000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i064787fbd3b34338bc355bea54602fa0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMy0zLTEtMS0xMDUwMzM_c2f4cf36-82a9-4ed1-99a3-d629cc76853c"
      unitRef="usd">144550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bb88e8e61844678858e6f1049c3b8d8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMy01LTEtMS0xMDUwMzM_d2985c3c-bd7d-410b-a69f-d484f6a3b387"
      unitRef="usd">449682000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if532127b9ae74868b84354daf327af15_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMy03LTEtMS0xMDUwMzM_9e7d39cf-e7f9-4651-bf7c-91872fbe3d98"
      unitRef="usd">289290000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefd9383c56a049e39c988fe1d699c8c8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNC0xLTEtMS0xMDUwMzM_83582d73-f5ee-4502-a859-26ba0c0bbd07"
      unitRef="usd">18793000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2f66c15a9774d3f9a542401fdc90d05_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNC0zLTEtMS0xMDUwMzM_4d7d69b8-da2d-4a66-bb7b-e4b911861dbd"
      unitRef="usd">16214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1d18e1861dd47459e3afc0e2f4d6b6c_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNC01LTEtMS0xMDUwMzM_661b6a4b-db22-4a3e-81ce-38289a453c02"
      unitRef="usd">36868000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3be1ea17a2242b89f05c2d9c603ef7f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNC03LTEtMS0xMDUwMzM_a5e96562-ab32-41f3-b776-ca535cfa9459"
      unitRef="usd">34224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d9a9c63b74748ea9144996c4ffcebfc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNS0xLTEtMS0xMDUwMzM_ba3a6e58-1964-4fc2-972e-651244b0d736"
      unitRef="usd">9984000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f72a8ae1ecb4b9f95f49782044f3034_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNS0zLTEtMS0xMDUwMzM_966fff99-a574-4386-b941-edb0870d3afa"
      unitRef="usd">8143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fb94590e3da4131815186c8ad836fbd_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNS01LTEtMS0xMDUwMzM_b28e7c5f-3707-406a-a786-9aa40a4cd603"
      unitRef="usd">20457000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8b2dce3af564d37aace93fa3edc0576_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNS03LTEtMS0xMDUwMzM_58f8297e-9239-4916-83f3-8941d1ed2d08"
      unitRef="usd">16693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie13819d6ef7341d7adfe25db4589fb16_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNi0xLTEtMS0xMDUwMzM_eace319a-d548-4177-8e23-c8dc03cbf941"
      unitRef="usd">11740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72f55ac666634d8790450c2efbff1301_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNi0zLTEtMS0xMDUwMzM_749d0bc6-97b7-4784-9ebd-655b4e6c07c8"
      unitRef="usd">4621000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84494cd24411430cb3a73d2b634c4e8f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNi01LTEtMS0xMDUwMzM_942bccbf-98e5-4eed-90ee-7c7f1f2f5869"
      unitRef="usd">22835000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b4615fc163545a386d6cb61eafec12b_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNi03LTEtMS0xMDUwMzM_5e71aac7-6773-4452-aaf7-0ea479966097"
      unitRef="usd">7707000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b39506fda1c403390a1a7356060a43f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNy0xLTEtMS0xMDUwMzM_46ac567f-2d3b-4b4f-89e1-241ddf699ce4"
      unitRef="usd">1557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18b2701ff7a24a1dbb0e0cba3406cd91_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNy0zLTEtMS0xMDUwMzM_253a945f-6bb2-4232-918a-8647822e4b24"
      unitRef="usd">2110000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5154423056f643eca603328d7cdb95e7_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNy01LTEtMS0xMDUwMzM_855643c5-db3a-4b08-99e6-a4fddb162d2c"
      unitRef="usd">3112000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18329a0408e04ac0bf921293f4606d37_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNy03LTEtMS0xMDUwMzM_a41368a7-c011-4a41-8f7a-5a2daa4461bd"
      unitRef="usd">3782000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfOS0xLTEtMS0xMDUwMzM_53ff02ac-eb54-4321-b951-c12affc23a4d"
      unitRef="usd">269697000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfOS0zLTEtMS0xMDUwMzM_110c39bc-e391-4f75-8afb-336d65158bf4"
      unitRef="usd">175638000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfOS01LTEtMS0xMDUwMzM_e084c259-2863-4cc2-87f6-445c37b69e9b"
      unitRef="usd">532954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfOS03LTEtMS0xMDUwMzM_6137055a-c77b-4bbd-9b62-e6172b01006b"
      unitRef="usd">351696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTItMS0xLTEtMTA1MDMz_4c509069-781c-4d40-9183-404d983b10e5"
      unitRef="usd">230070000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTItMy0xLTEtMTA1MDMz_25f19757-dca0-4a30-9c28-869bdd78cf47"
      unitRef="usd">136214000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTItNS0xLTEtMTA1MDMz_e6541785-8e43-477a-aa97-1ab4c41593f3"
      unitRef="usd">450798000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTItNy0xLTEtMTA1MDMz_160c60a3-bc93-47c5-aeef-d660a5b609e8"
      unitRef="usd">276829000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTMtMS0xLTEtMTA1MDMz_a7f4ac19-5b68-4d20-8738-9774b67ea66a"
      unitRef="usd">19894000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTMtMy0xLTEtMTA1MDMz_30968990-4e56-4f31-b97a-a6200932f877"
      unitRef="usd">14199000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTMtNS0xLTEtMTA1MDMz_0f2d40f7-28d2-45c2-a012-0a4c9ab6cdc6"
      unitRef="usd">31837000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTMtNy0xLTEtMTA1MDMz_01df37f0-74c9-48aa-8011-782255f3fe95"
      unitRef="usd">23663000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTQtMS0xLTEtMTA1MDMz_d82ac8cb-af5e-4cf0-ba80-da3f55099718"
      unitRef="usd">4351000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTQtMy0xLTEtMTA1MDMz_5c82a4f7-fbbd-4ad6-aa1a-1bed9e631072"
      unitRef="usd">4237000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTQtNS0xLTEtMTA1MDMz_ee85cef6-1081-4e74-b7e4-e95da083f3d3"
      unitRef="usd">8725000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTQtNy0xLTEtMTA1MDMz_1d44efab-ffb8-4ea4-96e1-841e265acf2e"
      unitRef="usd">8434000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTgtMS0xLTEtMTA1MDMz_9ada4b13-c3b5-4ee8-a236-390ae6a7bda5"
      unitRef="usd">254315000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTgtMy0xLTEtMTA1MDMz_7c7c32b3-1d05-4944-ae68-71fa86e4609c"
      unitRef="usd">154650000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTgtNS0xLTEtMTA1MDMz_9a013597-8774-4f46-a05c-2b33967ce16d"
      unitRef="usd">491360000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMTgtNy0xLTEtMTA1MDMz_4fd23721-8a1e-43a8-b560-e56420acc58c"
      unitRef="usd">308926000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjAtMS0xLTEtMTA1MDMz_3b48789e-f7e3-4d7d-86a9-cd766b2952ee"
      unitRef="usd">15382000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjAtMy0xLTEtMTA1MDMz_3df43adc-913f-42af-a08f-9d1f4daabc1a"
      unitRef="usd">20988000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjAtNS0xLTEtMTA1MDMz_0dde5bf0-943b-462b-9779-dc1c1e7fa25d"
      unitRef="usd">41594000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjAtNy0xLTEtMTA1MDMz_7df9716d-376e-4271-b7fe-3136b9a1fb88"
      unitRef="usd">42770000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjMtMS0xLTEtMTA1MDMz_bf6e1bb7-cb43-4162-a756-b5e534397526"
      unitRef="usd">1512000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjMtMy0xLTEtMTA1MDMz_465e4be5-f9ec-4138-b12b-b1c3987b7321"
      unitRef="usd">-3134000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjMtNS0xLTEtMTA1MDMz_c9045de7-34e2-4ff7-97bf-282a19904733"
      unitRef="usd">2945000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjMtNy0xLTEtMTA1MDMz_9a2a4e28-981c-43eb-98ac-3f5c615a3a17"
      unitRef="usd">-3812000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestExpense
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjUtMS0xLTEtMTA1MDMz_2092e919-26b3-4d87-bccd-af91fe59cdd5"
      unitRef="usd">1854000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjUtMy0xLTEtMTA1MDMz_d0017e9c-f3df-4f18-aa72-287db5ec5e19"
      unitRef="usd">1853000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjUtNS0xLTEtMTA1MDMz_acaf2b27-3d5e-4b87-9dec-73923037978a"
      unitRef="usd">2927000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjUtNy0xLTEtMTA1MDMz_b233f089-0c10-45d1-800b-f1e8e01421b4"
      unitRef="usd">3376000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjYtMS0xLTEtMTA1MDMz_2f547897-97b1-4f8c-af8d-af08ae34393f"
      unitRef="usd">421000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjYtMy0xLTEtMTA1MDMz_4d14773c-80c0-4a44-8957-d63ab9cb568f"
      unitRef="usd">563000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjYtNS0xLTEtMTA1MDMz_1e3ad0ec-b3ef-4acd-9583-0acb83bd6fb5"
      unitRef="usd">467000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjYtNy0xLTEtMTA1MDMz_9a24ca06-c55b-49c3-9531-c33ab4b681a3"
      unitRef="usd">912000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjctMS0xLTEtMTA1MDMz_063dc286-8aa6-405e-8b5e-602fabf6ad5b"
      unitRef="usd">-1866000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjctMy0xLTEtMTA1MDMz_58eabaf6-f3f1-4fdc-8328-f1b53b476a72"
      unitRef="usd">83769000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjctNS0xLTEtMTA1MDMz_dbf9eef3-b009-49ca-9528-48f5de221d5c"
      unitRef="usd">-10829000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjctNy0xLTEtMTA1MDMz_fef57e9d-87bf-4161-a825-ef0aa0dd8894"
      unitRef="usd">83769000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjgtMS0xLTEtMTA1MDMz_ea172800-9779-4777-8f98-f1fc5408a398"
      unitRef="usd">3034000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjgtMy0xLTEtMTA1MDMz_5e436fb3-c787-4d63-8939-fd2ab7231a37"
      unitRef="usd">-15883000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjgtNS0xLTEtMTA1MDMz_f6292bfe-678c-4db9-a817-85a957482edc"
      unitRef="usd">3647000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMjgtNy0xLTEtMTA1MDMz_1ae137b4-5d68-498d-9cbb-648e83770dc5"
      unitRef="usd">-14579000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzAtMS0xLTEtMTA1MDMz_3a2165df-2952-48d6-99bc-fcabba1c2226"
      unitRef="usd">1247000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzAtMy0xLTEtMTA1MDMz_634a3658-c917-4159-add4-4b1bac638755"
      unitRef="usd">63462000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzAtNS0xLTEtMTA1MDMz_0dd2e0e6-50f7-4083-b9cd-fc5730212594"
      unitRef="usd">-6697000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzAtNy0xLTEtMTA1MDMz_ea8e9458-4b5e-4bf7-b12c-6118d04b1a97"
      unitRef="usd">62914000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzItMS0xLTEtMTA1MDMz_95478ceb-acfa-4d05-aef5-9d4143a72b38"
      unitRef="usd">16629000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzItMy0xLTEtMTA1MDMz_156e0ef1-44b6-4f23-9b7f-fc516cc9f622"
      unitRef="usd">84450000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzItNS0xLTEtMTA1MDMz_86296207-6135-4d5c-afeb-614bef4ce91e"
      unitRef="usd">34897000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzItNy0xLTEtMTA1MDMz_862e2c30-9fb0-4482-bbfa-2f48d8e0ee36"
      unitRef="usd">105684000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzQtMS0xLTEtMTA1MDMz_441e1752-f27e-402b-9c5a-801b2dcf8cc4"
      unitRef="usd">6038000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzQtMy0xLTEtMTA1MDMz_f3fe58e3-454a-459b-8c3a-1d4d251fe49f"
      unitRef="usd">24920000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzQtNS0xLTEtMTA1MDMz_f9389c77-aff0-4671-a34b-92a04cefbf7d"
      unitRef="usd">12233000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzQtNy0xLTEtMTA1MDMz_7c0c9a78-74bb-4555-8c9f-073bf90f041d"
      unitRef="usd">31696000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzYtMS0xLTEtMTA1MDMz_4d8a217f-6841-4bf2-a92a-4c962d3c6d6d"
      unitRef="usd">10591000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzYtMy0xLTEtMTA1MDMz_1f697ca0-db9b-4093-ae18-d6c06c482207"
      unitRef="usd">59530000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzYtNS0xLTEtMTA1MDMz_fc010ad2-a032-4407-8835-68a13902463c"
      unitRef="usd">22664000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzYtNy0xLTEtMTA1MDMz_f4cc020e-5b51-411b-afa6-99c56a832933"
      unitRef="usd">73988000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzgtMS0xLTEtMTA1MDMz_d51026e1-4faf-40b5-9939-868febf11801"
      unitRef="usd">-808000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzgtMy0xLTEtMTA1MDMz_0cf90f73-d89a-4035-8a15-c25e8ca56eea"
      unitRef="usd">46872000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzgtNS0xLTEtMTA1MDMz_58c78c4b-4c9a-4a86-9584-62540386b5bd"
      unitRef="usd">-2999000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfMzgtNy0xLTEtMTA1MDMz_f11d8779-552c-483f-bcea-382016257315"
      unitRef="usd">48179000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDAtMS0xLTEtMTA1MDMz_393168fe-b6ad-4aea-b6d7-62a15c4992f8"
      unitRef="usd">11399000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDAtMy0xLTEtMTA1MDMz_84294a8c-1892-440f-a327-6a59d68dbf6a"
      unitRef="usd">12658000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDAtNS0xLTEtMTA1MDMz_82668df4-dabf-446e-a419-a693cc7cf96b"
      unitRef="usd">25663000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDAtNy0xLTEtMTA1MDMz_eb47bb73-316f-4107-aae4-a797734de2d7"
      unitRef="usd">25809000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDItMS0xLTEtMTA1MDMz_c99fcd67-2803-4e50-bf1c-d1344aaf8d8e"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDItMy0xLTEtMTA1MDMz_491e672f-4d93-427c-9cbc-5a44df817c4e"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDItNS0xLTEtMTA1MDMz_b9fd3a70-c2e4-4f83-a4b5-a4e9baadb169"
      unitRef="usdPerShare">0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDItNy0xLTEtMTA1MDMz_0812c0e1-6278-4180-a1d5-1c1214273925"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDQtMS0xLTEtMTA1MDMz_aeebdd93-f914-446f-8481-2a5671b8888b"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDQtMy0xLTEtMTA1MDMz_5c6691a2-8cf9-4cb1-958e-f37380523983"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDQtNS0xLTEtMTA1MDMz_b7f98280-329c-4eaa-949e-ec5820b9632a"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yNS9mcmFnOjIyOTFhOWJiZDFlYTRkZDQ5ZWUzNWE2MjgyMzI4Nzg5L3RhYmxlOjRiNmE4NTQxNmJkNTQxMGY5NjE2NzM3OWZlZDNkZTJhL3RhYmxlcmFuZ2U6NGI2YTg1NDE2YmQ1NDEwZjk2MTY3Mzc5ZmVkM2RlMmFfNDQtNy0xLTEtMTA1MDMz_9463c77b-fd1b-4341-9b72-0651ab4b04bc"
      unitRef="usdPerShare">0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ia504157a512f402581af013fb57df905_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy0xLTEtMS0xMDUwMzM_814be9a0-1be1-4b46-b32c-2d796b553c34"
      unitRef="usd">55510000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="iad4a0d5b297a4f7fb66c1516ac86205f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy0zLTEtMS0xMDUwMzM_dfc8efcf-a80e-4aed-8a74-41468448ae22"
      unitRef="shares">44630873</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad4a0d5b297a4f7fb66c1516ac86205f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy01LTEtMS0xMDUwMzM_ccf7dbd8-f83f-4fea-bec1-9edc9f46047b"
      unitRef="usd">45000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief358036295248deb2d6fc4f17ab1fd6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy03LTEtMS0xMDUwMzM_8ccaa2a7-0cc1-443e-b925-e9f1ddf199b8"
      unitRef="usd">310876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6b90da5220a49248e3a42f5d7bcee8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy05LTEtMS0xMDUwMzM_04d6059b-b68f-48a6-80ac-c31b724b2d21"
      unitRef="usd">143629000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic01c1ed4406f45fd89cc7c596242ac42_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy0xMS0xLTEtMTA1MDMz_5d197881-be65-4487-b94a-80ed1f6a9700"
      unitRef="usd">5940000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMy0xMy0xLTEtMTA1MDMz_0723bcc1-33d6-4dca-ad33-9b83c1361327"
      unitRef="usd">460490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNC0xLTEtMS0xMDUwMzM_094df5a3-eeb4-4c86-bd2a-a9642d57b48d"
      unitRef="usd">-3129000</us-gaap:TemporaryEquityNetIncome>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="id232a7c63cea47fb908b2d31d1507b26_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNC05LTEtMS0xMDUwMzM_55207f5f-6e01-43fe-9aff-5afef02a0947"
      unitRef="usd">14264000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ibabb570e56704819be46a35a99056cfd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNC0xMS0xLTEtMTA1MDMz_92ca7d47-752a-4396-8371-f1b11d4d5e09"
      unitRef="usd">938000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNC0xMy0xLTEtMTA1MDMz_e9d92894-7fa4-476d-8edb-6776891cb367"
      unitRef="usd">15202000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNS0xLTEtMS0xMDUwMzM_17b96ead-7e2d-48ee-b973-b124b8ee7af3"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ibabb570e56704819be46a35a99056cfd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNS0xMS0xLTEtMTA1MDMz_6c53b11c-0e72-4edf-93fc-0b39ccf0fc90"
      unitRef="usd">200000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNS0xMy0xLTEtMTA1MDMz_c7a1b584-8c5f-4045-abd2-7f7874952a75"
      unitRef="usd">200000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="ibabb570e56704819be46a35a99056cfd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNi0xMS0xLTEtMTA1MDMz_38698307-36dd-4b3f-85cd-6398c03cb894"
      unitRef="usd">36000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNi0xMy0xLTEtMTA1MDMz_8a2ce96b-298d-495f-89a2-14b23d426380"
      unitRef="usd">36000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfNy0xLTEtMS0xMDUwMzM_8d2f4e33-d8c8-4060-80d8-a2fde0fa6e4c"
      unitRef="usd">230000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOC0zLTEtMS0xMDUwMzM_c5f647ed-f325-4119-ab5e-293926751a09"
      unitRef="shares">81779</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOC03LTEtMS0xMDUwMzM_ac8f8796-2185-4fef-b3b9-412f6c0954f4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOC0xMy0xLTEtMTA1MDMz_7a27259b-e280-41a0-a7bd-6990b3e810e0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOS0zLTEtMS0xMDUwMzM_083ed245-1b7e-4a10-a6e7-c7b647dc0dd9"
      unitRef="shares">124735</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOS03LTEtMS0xMDUwMzM_37b80008-e0ca-46a0-9f40-1963f1bbb70d"
      unitRef="usd">1573000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfOS0xMy0xLTEtMTA1MDMz_f9f7dfbd-3ef0-4d27-8258-0eeff0e7eb4e"
      unitRef="usd">1573000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTAtNy0xLTEtMTA1MDMz_28c5f7e3-2ce1-4f37-b123-ee6fc85e410a"
      unitRef="usd">3055000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTAtMTMtMS0xLTEwNTAzMw_8a842eb5-1c66-4df5-8db2-8e6d11efbc53"
      unitRef="usd">3055000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTEtMy0xLTEtMTA1MDMz_83bdf043-030d-496f-9e85-c23ad24b6163"
      unitRef="shares">18756</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTEtNy0xLTEtMTA1MDMz_6255ee09-cb66-4c6e-ba94-0fc3d202587a"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTEtMTMtMS0xLTEwNTAzMw_19934801-5718-4aa9-aab9-98b0998a8918"
      unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="ifbb51f2b24334c848822cc3039e6d017_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTItMy0xLTEtMTA1MDMz_08d5680f-bef0-4b3f-a4ee-48c717a668cc"
      unitRef="shares">11084</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ia07784125551442e88d85eea79a1a397_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTItNy0xLTEtMTA1MDMz_67df836f-eb9b-4c48-bd5a-539767177b09"
      unitRef="usd">457000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTItMTMtMS0xLTEwNTAzMw_2ca80340-721d-4922-9dc6-ea40b65a7404"
      unitRef="usd">457000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i9f59fea7e1394227807376bee0ff2627_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTMtMS0xLTEtMTA1MDMz_07453b1b-d1af-4064-b579-c73b0fb5e8ce"
      unitRef="usd">0</us-gaap:TemporaryEquityAccretionOfDividends>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="ibabb570e56704819be46a35a99056cfd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTMtMTEtMS0xLTEwNTAzMw_306075a6-2a86-42b1-9e93-fc9c920bd716"
      unitRef="usd">-1178000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="i6dddd00c71864b2a90666ee8f764b24b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTMtMTMtMS0xLTEwNTAzMw_ba24ba0f-2379-47d9-a69b-8fa16d748276"
      unitRef="usd">-1178000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i8b2a5b59bb6c4986b7c1a50b1f8a0aad_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtMS0xLTEtMTA1MDMz_34f94b7c-2b08-42e3-b75c-2c6b26162e66"
      unitRef="usd">52151000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i9c6cc256e341493aa571df5da6b6662f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtMy0xLTEtMTA1MDMz_2209327f-1f6e-436c-b53b-762b83c9a803"
      unitRef="shares">44845059</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c6cc256e341493aa571df5da6b6662f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtNS0xLTEtMTA1MDMz_a1c69f0c-70c3-484d-a113-fdd6d392af3e"
      unitRef="usd">45000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d98f2c383be4f0caf317615c3e90bdd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtNy0xLTEtMTA1MDMz_69dd250f-1d6c-46eb-9ac1-f0f9a15a7cb5"
      unitRef="usd">316047000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75d2dd3b8a394e94b24002551af97de8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtOS0xLTEtMTA1MDMz_908ab82f-01ed-43d9-907e-44fc5531045f"
      unitRef="usd">157893000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffe3f233a5ee47f89e7da633077e4a16_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtMTEtMS0xLTEwNTAzMw_3acbe2dd-3887-4889-9225-0a0224b7919e"
      unitRef="usd">5536000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8eff61b12ade44188aa16b4c6f4691fc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTQtMTMtMS0xLTEwNTAzMw_10e21954-65d8-45b9-99e7-c39568ebf8dd"
      unitRef="usd">479521000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i79a98933176041edb09daa8e6a031ae2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTUtMS0xLTEtMTA2MjA5_b02bc580-b4fb-4b16-8cb8-f649c4ec99a5"
      unitRef="usd">-2154000</us-gaap:TemporaryEquityNetIncome>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="icdb8cb1f443c409ebb880abdbfb1b50b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTUtOS0xLTEtMTA2MjM4_10878165-d21b-4407-a0a4-901599d0b934"
      unitRef="usd">11399000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ic1b4fc11728e4a119e9ff7d187016bbd_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTUtMTEtMS0xLTEwNjI0NQ_c5f94824-d739-4047-b09e-751d85f5cc29"
      unitRef="usd">1346000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTUtMTMtMS0xLTEwNjI1Mg_6c963c94-e2e6-4b34-85d0-8b39abe00f3b"
      unitRef="usd">12745000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ia2be7890574c4c2e850a4bef6af34746_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTgtMy0xLTEtMTA2MjE2_03442a33-6126-4449-a9b6-e44069d9cadd"
      unitRef="shares">108933</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTgtNy0xLTEtMTA2MjMx_cf2ca1cd-660a-4486-ade1-dcbf03a4e9ba"
      unitRef="usd">-253000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTgtMTMtMS0xLTEwNjI1Mg_3cdcb654-0cee-4b47-9dd7-d3809698d448"
      unitRef="usd">-253000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ia2be7890574c4c2e850a4bef6af34746_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTktMy0xLTEtMTA2MjE2_b19393fa-6a91-446c-97bb-7cc315c56335"
      unitRef="shares">15718</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTktNy0xLTEtMTA2MjMx_acd466b6-9a05-4f6b-b315-dd3e0778a339"
      unitRef="usd">165000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMTktMTMtMS0xLTEwNjI1Mg_b6749aa1-ffac-414e-a89e-910b9b793cc1"
      unitRef="usd">165000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia2be7890574c4c2e850a4bef6af34746_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjAtMy0xLTEtMTA2MjE2_26284251-2478-4a04-93e4-aaea9b313b7d"
      unitRef="shares">250000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjAtNy0xLTEtMTA2MjMx_75d13ae6-840c-42a9-b2a9-297d5191e157"
      unitRef="usd">9250000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjAtMTMtMS0xLTEwNjI1Mg_764fc035-1569-4fe8-b849-c359e978172c"
      unitRef="usd">9250000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idf52ad0e3eb04af384acadfa54881969_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjEtNy0xLTEtMTA2MjMx_cd28c0c6-f57c-4822-b8c4-8f21514ae50e"
      unitRef="usd">3920000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjEtMTMtMS0xLTEwNjI1Mg_6306634e-2a1c-4ac0-8a7b-59ac30b469c5"
      unitRef="usd">3920000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ic1b4fc11728e4a119e9ff7d187016bbd_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjMtMTEtMS0xLTEwNjI0NQ_4c466b3f-f2bd-4723-9f09-cc0350e639b4"
      unitRef="usd">371000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjMtMTMtMS0xLTEwNjI1Mg_0e8cda83-aa43-4296-9023-499ec3c9782b"
      unitRef="usd">371000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i79a98933176041edb09daa8e6a031ae2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjQtMS0xLTEtMTA2MjA5_b448e2be-a4c0-4932-9ba7-25c55f761db7"
      unitRef="usd">10000000</us-gaap:TemporaryEquityAccretionOfDividends>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="ic1b4fc11728e4a119e9ff7d187016bbd_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjQtMTEtMS0xLTEwNjI0NQ_5d00f890-fc74-4182-9812-731639d17998"
      unitRef="usd">-1374000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjQtMTMtMS0xLTEwNjI1Mg_dcd44931-d15a-4a9e-ae23-8513030c8e5b"
      unitRef="usd">-1374000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i08a4ee78dedb4bf0bb4d2dcdbf5e685c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtMS0xLTEtMTA2MjA5_1597d8f5-123b-4bd0-989a-986e22a07878"
      unitRef="usd">39997000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="if7a647777c9a41638828e0bb054b607d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtMy0xLTEtMTA2MjE2_0eda5f61-a87a-4734-a605-8509bcce27d7"
      unitRef="shares">44719710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7a647777c9a41638828e0bb054b607d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtNS0xLTEtMTA2MjIz_d997dde0-a7d7-4168-8627-ab0905e3d830"
      unitRef="usd">45000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d4945b7a5d144dcb44613757de6b733_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtNy0xLTEtMTA2MjMx_f7299e18-e9a3-4600-8348-1e12098637e1"
      unitRef="usd">310629000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf67c623dc9c4fdb87ffe7f1a5f0fd33_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtOS0xLTEtMTA2MjM4_e4767ebc-f0e9-4639-8f1c-5bef1c0c9fd1"
      unitRef="usd">169292000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee1f7e2940144fe09e63a4985d202a33_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtMTEtMS0xLTEwNjI0NQ_60e61c34-8bb8-4b6c-88b7-bd1e14ca0d98"
      unitRef="usd">5879000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOmIyN2ViODFlYzFmOTQyNTU4YjcwZTZiODQ4NWJlNTI4L3RhYmxlcmFuZ2U6YjI3ZWI4MWVjMWY5NDI1NThiNzBlNmI4NDg1YmU1MjhfMjUtMTMtMS0xLTEwNjI1Mg_f5254985-be1f-444b-86d2-9a5e1037c7e6"
      unitRef="usd">485845000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i49a86084d3064273846f20df1dc58121_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy0xLTEtMS0xMDUwMzM_56653837-fd81-407d-a541-df5f607e7121"
      unitRef="usd">114237000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i71714e79a7ff4ae58ec405207709ae87_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy0zLTEtMS0xMDUwMzM_77dd9e0b-29e5-4820-87ee-e9d6f97921c1"
      unitRef="shares">42249137</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71714e79a7ff4ae58ec405207709ae87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy01LTEtMS0xMDUwMzM_d2e3d19b-9f67-4e7c-9505-6deab43e770e"
      unitRef="usd">42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if0ac6532c5744fbe9e81dcf735c713ea_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy03LTEtMS0xMDUwMzM_b2c1703b-6088-4f45-b0b0-94da8ada1f84"
      unitRef="usd">261011000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2095839d0b164a5db420348af27d9e8a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy05LTEtMS0xMDUwMzM_c64367c6-c191-42a4-9138-3f6cc73054cd"
      unitRef="usd">69771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieabf5dd86df34cefa162b01e549f2f27_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy0xMS0xLTEtMTA1MDMz_770d8ea9-a3dd-4a40-adcc-0f5d3ca7c0e4"
      unitRef="usd">87000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMy0xMy0xLTEtMTA1MDMz_5249f173-50ff-43d7-ad3a-4432183e7309"
      unitRef="usd">330911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i0fb56e0f9f67490fa0624de03cbc6dfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNC0xLTEtMS0xMDUwMzM_6ce7d9c1-20dd-4415-b964-eee2390657dd"
      unitRef="usd">760000</us-gaap:TemporaryEquityNetIncome>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ic700b6fc892341ebbf97cebcb5258f90_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNC05LTEtMS0xMDUwMzM_7d6f2f7a-7971-411b-8d40-7bc4a48734d9"
      unitRef="usd">13151000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i05d89e7c53fa4a70b5fb4595708da067_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNC0xMS0xLTEtMTA1MDMz_97641ce9-8aa2-4aa1-b703-dd0e0a02d6a2"
      unitRef="usd">547000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNC0xMy0xLTEtMTA1MDMz_36886886-92e9-4ec2-a251-1b323df47f03"
      unitRef="usd">13698000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i0fb56e0f9f67490fa0624de03cbc6dfc_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNS0xLTEtMS0xMDUwMzM_edf1d1eb-5f19-4ffc-8739-c3066380574f"
      unitRef="usd">150000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i05d89e7c53fa4a70b5fb4595708da067_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNS0xMS0xLTEtMTA1MDMz_fac9e1d5-2db2-4a31-8e08-592d8229a81a"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNS0xMy0xLTEtMTA1MDMz_c2b4f694-201c-4c54-9837-d3242ed1ef8c"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i05d89e7c53fa4a70b5fb4595708da067_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNi0xMS0xLTEtMTA1MDMz_e7412c44-1452-4e22-b8cb-1f2869a8f60c"
      unitRef="usd">37000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNi0xMy0xLTEtMTA1MDMz_b5162f3f-9144-444a-a78a-440ff524ab39"
      unitRef="usd">37000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNy0zLTEtMS0xMDUwMzM_b434dff9-2f13-433c-ad5b-3707b09a6244"
      unitRef="shares">7689</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNy03LTEtMS0xMDUwMzM_46b8f9ff-900c-45c6-8bb0-2885dba0d9c8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfNy0xMy0xLTEtMTA1MDMz_c1476c6f-2d3f-4e5a-a791-72aa47faa7b5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOC0zLTEtMS0xMDUwMzM_09921a48-faab-4892-aaa2-f59410878050"
      unitRef="shares">421002</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOC01LTEtMS0xMDUwMzM_e7ca5d67-7142-46a3-9a0f-7df026b9f333"
      unitRef="usd">1000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOC03LTEtMS0xMDUwMzM_eae45e2f-931c-498f-9648-ed282c8e4439"
      unitRef="usd">4255000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOC0xMy0xLTEtMTA1MDMz_f922100c-8e1d-4c6f-bbd4-d1276f224dc8"
      unitRef="usd">4256000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOS0zLTEtMS0xMDUwMzM_ae0e49c4-32ba-48ed-9c70-90f7c6533d85"
      unitRef="shares">34158</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOS03LTEtMS0xMDUwMzM_cb82d977-6221-4bd7-b7c7-9bcdd4e93454"
      unitRef="usd">342000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfOS0xMy0xLTEtMTA1MDMz_6cb79761-cc95-4e33-92ad-deeff81be4d5"
      unitRef="usd">342000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTAtNy0xLTEtMTA1MDMz_5c3b3b3c-f5d5-4b02-9e66-9e74921461d6"
      unitRef="usd">1346000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTAtMTMtMS0xLTEwNTAzMw_80623097-edd6-4926-8336-aed8612d9b1f"
      unitRef="usd">1346000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="ida30c669e01848049f134a3f777ea180_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTEtMy0xLTEtMTA1MDMz_eadd1665-87b4-458a-9b3f-37f82c60b796"
      unitRef="shares">5281</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ie5b05b92caf6485986582d8eb6d2b0a3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTEtNy0xLTEtMTA1MDMz_e0e18eb3-0aa1-4e6e-bf15-924dabc2a3d9"
      unitRef="usd">144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ifd2f2d5361474fc8989daeccf735cc7b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTEtMTMtMS0xLTEwNTAzMw_fe576468-6246-4853-abbd-4160ba0751d3"
      unitRef="usd">144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="idbece1b8c5604d32bef8c1b3bee0e06e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItMS0xLTEtMTA1MDMz_804e7d7f-475b-4f3c-a1a1-05f12b3226da"
      unitRef="usd">114847000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i86bed315c9104a5ea8f38b47de37821f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItMy0xLTEtMTA1MDMz_3969538c-3ab4-4820-b05e-44579ea9e16e"
      unitRef="shares">42638389</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86bed315c9104a5ea8f38b47de37821f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItNS0xLTEtMTA1MDMz_48357c4a-c6b3-4322-9de1-34027733f313"
      unitRef="usd">43000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i744f0bbbd4024a33b8e4daec9c49bb16_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItNy0xLTEtMTA1MDMz_03cdf0cb-1a05-4f35-b02f-751d7bee1406"
      unitRef="usd">266126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae2d6eb6ccba48b09c3e8ac6b7c4c666_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItOS0xLTEtMTA1MDMz_4751ccd2-84c8-4071-9664-96d79e744630"
      unitRef="usd">82922000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11090e9d37df449c8a39e89447069685_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItMTEtMS0xLTEwNTAzMw_4374856c-6654-4fcf-aca2-fc6d47eb0893"
      unitRef="usd">596000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95b9bd5984e7487dae4a1cd249a6cdf0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTItMTMtMS0xLTEwNTAzMw_92c83ca8-0ae5-4841-8d37-465963d1cbe9"
      unitRef="usd">349687000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i9f5ec933f8d44cc38f55f6394cb7637c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTMtMS0xLTEtMTA2MDcz_593ccf2e-130f-4591-b9aa-8a48618a2d18"
      unitRef="usd">46859000</us-gaap:TemporaryEquityNetIncome>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i949844556a7b4f6492884ecdd3ff6253_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTMtOS0xLTEtMTA2MTA5_b9369038-ac0f-4b6e-afab-253a74e42c7c"
      unitRef="usd">12658000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i42578d05def24550adcdf005d6e174fd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTMtMTEtMS0xLTEwNjExOA_7a0082cc-44af-489a-8170-5dbf0b8dbcfd"
      unitRef="usd">13000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTMtMTMtMS0xLTEwNjEyOQ_fe167c96-2de0-4e5d-963d-7c777df5ac34"
      unitRef="usd">12671000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:TemporaryEquityIncreaseFromSaleOfNonControllingInterest
      contextRef="i9f5ec933f8d44cc38f55f6394cb7637c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTQtMS0xLTEtMTA2MDcz_1d7c4eff-bdfd-4578-8ee3-5c82f27a3638"
      unitRef="usd">150000</ameh:TemporaryEquityIncreaseFromSaleOfNonControllingInterest>
    <ameh:StockIssuedDuringPeriodSharesNoncontrollingInterest
      contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTUtMy0xLTEtMTA2MDgy_85a48205-e4a3-4dc8-b4b7-4d02c617c5e9"
      unitRef="shares">1638045</ameh:StockIssuedDuringPeriodSharesNoncontrollingInterest>
    <ameh:StockIssuedDuringPeriodValueNoncontrollingInterest
      contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTUtNS0xLTEtMTA2MDkx_07e3ffb2-1c2c-433d-b5a6-2149973c44fc"
      unitRef="usd">1000</ameh:StockIssuedDuringPeriodValueNoncontrollingInterest>
    <ameh:StockIssuedDuringPeriodValueNoncontrollingInterest
      contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTUtNy0xLTEtMTA2MTAw_d5c6b571-e4d9-44f5-ac79-cf4df513d6fe"
      unitRef="usd">40132000</ameh:StockIssuedDuringPeriodValueNoncontrollingInterest>
    <ameh:StockIssuedDuringPeriodValueNoncontrollingInterest
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTUtMTMtMS0xLTEwNjEyOQ_4ff1b5a6-7aca-4542-9ae7-569d68e268be"
      unitRef="usd">40133000</ameh:StockIssuedDuringPeriodValueNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTYtMy0xLTEtMTA2MDgy_210302b0-3ede-41c4-9f94-56d6ea4eb5e0"
      unitRef="shares">22284</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTYtNy0xLTEtMTA2MTAw_0d1c0d92-fb69-41bf-9ad3-ee02eef5e8be"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTYtMTMtMS0xLTEwNjEyOQ_0aec9c4e-6801-48e3-8a69-b86a7f9f44ae"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTctMy0xLTEtMTA2MDgy_c2e795e6-d256-426a-8471-2b19770efd49"
      unitRef="shares">53504</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTctNS0xLTEtMTA2MDkx_d659811a-db4f-4fc2-8eb7-06824107ac75"
      unitRef="usd">0</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTctNy0xLTEtMTA2MTAw_b7251d11-e3a1-4e4b-a88e-e30160fdbef6"
      unitRef="usd">561000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTctMTMtMS0xLTEwNjEyOQ_3878452f-5c38-4620-9e69-2243fdc58ac5"
      unitRef="usd">561000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTgtMy0xLTEtMTA2MDgy_6bb94b51-aa02-4d5c-aa5a-c48100e002e1"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTgtNy0xLTEtMTA2MTAw_36c2c640-d1dc-4110-be9d-ec4d6bed265a"
      unitRef="usd">2450000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTgtMTMtMS0xLTEwNjEyOQ_f8ee88b7-aa8a-4cfd-8552-cdcea1d95c2f"
      unitRef="usd">2450000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTktNy0xLTEtMTA2MTAw_45ed4dcf-2337-4076-a35a-1c3f39d6a9b4"
      unitRef="usd">1556000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMTktMTMtMS0xLTEwNjEyOQ_10b8905e-3ebb-409e-b435-7cf65d2d32c0"
      unitRef="usd">1556000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="ie21a1ac9bf7b4ea8bfaf30b43b0f141b_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjAtMy0xLTEtMTA2MDgy_7aaa3b2b-6d00-451c-a722-17c049525432"
      unitRef="shares">5426</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="if1d976a9d4c3495092aef7049971c567_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjAtNy0xLTEtMTA2MTAw_f087a305-b43c-4bb2-b640-3c0b8bf40cf3"
      unitRef="usd">189000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjAtMTMtMS0xLTEwNjEyOQ_fb865da9-036a-44f4-b9be-b08efd81df3e"
      unitRef="usd">189000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i42578d05def24550adcdf005d6e174fd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjEtMTEtMS0xLTEwNjExOA_f2effce8-924c-4bcd-8f5a-88c7dfa10d7d"
      unitRef="usd">3769000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjEtMTMtMS0xLTEwNjEyOQ_caec18c1-91f4-4925-8a12-6506fea85e0b"
      unitRef="usd">3769000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i9f5ec933f8d44cc38f55f6394cb7637c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjItMS0xLTEtMTA2MDcz_6fffad5c-2f3b-4b40-aaff-b384430fe2fa"
      unitRef="usd">20000000</us-gaap:TemporaryEquityAccretionOfDividends>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="i42578d05def24550adcdf005d6e174fd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjItMTEtMS0xLTEwNjExOA_5f1bbd8d-865f-4cd1-bf00-2fcc3ebd39b3"
      unitRef="usd">-1156000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjItMTMtMS0xLTEwNjEyOQ_f84588fa-192e-4ce0-9e02-bfdb7f73ee4f"
      unitRef="usd">-1156000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i28f106f492574f71ad887c17b3f0e3b8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtMS0xLTEtMTA2MDcz_a9bf6070-be4c-4897-b44a-f2fa5b93a2c8"
      unitRef="usd">141856000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="ieb3286d909fa4f44a7673a684b27d8d7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtMy0xLTEtMTA2MDgy_f5a48804-a803-41ca-b2ee-d9375e9098bb"
      unitRef="shares">44246796</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb3286d909fa4f44a7673a684b27d8d7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtNS0xLTEtMTA2MDkx_83a297f2-b48a-411a-89fb-acd5818b6412"
      unitRef="usd">44000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f3de9a3211f43939fba721ad717140d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtNy0xLTEtMTA2MTAw_e5923a35-f86e-4fe4-ba67-2ec5d61da271"
      unitRef="usd">305736000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic123e707f5444ec8a2f129ff7fd69271_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtOS0xLTEtMTA2MTA5_392b5a6b-6739-41a6-9842-ac1506ec047b"
      unitRef="usd">95580000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9165a0fe2b24da295ead9547c7c43f7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtMTEtMS0xLTEwNjExOA_f70a40bd-8e6c-48c7-afbb-04868df1cf47"
      unitRef="usd">3222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4becb57108e844a2af77734d782c9546_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zMS9mcmFnOmE2Mzc3NTZkODA0ODRjZjFhZmYxZjM3OGM2M2MxZDcxL3RhYmxlOjE1MzkxYjg2NTY3YzRmMTJhYzViZGI2MjQ1NWNkNGZiL3RhYmxlcmFuZ2U6MTUzOTFiODY1NjdjNGYxMmFjNWJkYjYyNDU1Y2Q0ZmJfMjMtMTMtMS0xLTEwNjEyOQ_59c64845-2e56-4bf7-b545-a718e4174762"
      unitRef="usd">404582000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMy0xLTEtMS0xMDUwMzM_d0d932f8-a48f-4082-ab44-ee22be11ce70"
      unitRef="usd">22664000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMy0zLTEtMS0xMDUwMzM_549a646a-1348-4bbd-8026-09c06b1996d5"
      unitRef="usd">73988000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNS0xLTEtMS0xMDUwMzM_6263ad70-1871-4701-9c70-8e46ad6cd471"
      unitRef="usd">8725000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNS0zLTEtMS0xMDUwMzM_7f322c1d-2239-4490-96b2-4f7a4e0069c9"
      unitRef="usd">8434000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNi0xLTEtMS0xMDUwMzM_f405bc1b-5eaf-40cf-a70e-98c64451f9ce"
      unitRef="usd">474000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNi0zLTEtMS0xMDUwMzM_fde637c0-a94d-4edd-a1b9-ab4c88519f35"
      unitRef="usd">741000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNy0xLTEtMS0xMDUwMzM_f60e7a59-a95e-432d-9b82-2ea02d8d434a"
      unitRef="usd">6975000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNy0zLTEtMS0xMDUwMzM_ac86135b-5679-40c9-ad40-425068bc84f8"
      unitRef="usd">2902000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOC0xLTEtMS0xMTk2MjQ_a3a8b677-0687-49cd-bd6c-42283f61c7fb"
      unitRef="usd">2272000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOC0zLTEtMS0xMTk2MjQ_18dddea7-e312-4612-b87f-3e3930fd426e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <ameh:UnrealizedGainLossFromInvestmentInEquitySecurities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOC0xLTEtMS0xMDUwMzM_6dd6e384-a92c-41bc-87ca-b6d9d579284e"
      unitRef="usd">-13659000</ameh:UnrealizedGainLossFromInvestmentInEquitySecurities>
    <ameh:UnrealizedGainLossFromInvestmentInEquitySecurities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOC0zLTEtMS0xMDUwMzM_3157a665-5131-42b1-a699-433ee70d611d"
      unitRef="usd">83769000</ameh:UnrealizedGainLossFromInvestmentInEquitySecurities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOS0xLTEtMS0xMDUwMzM_5ed34722-71d1-48cf-ac7c-1ea9bcb7ad7c"
      unitRef="usd">2945000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfOS0zLTEtMS0xMDUwMzM_06c83ec0-eda9-49a0-a431-39de0576c1fd"
      unitRef="usd">-3812000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTEtMS0xLTEtMTA1MDMz_6b16efb4-b5d2-44dd-9c92-2fa47455c9fb"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTEtMy0xLTEtMTA1MDMz_5f0d6e48-bbf6-4500-a260-c819910bbd0f"
      unitRef="usd">15723000</us-gaap:AssetImpairmentCharges>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTItMS0xLTEtMTA1MDMz_b6266ab1-3526-47a8-9a7b-ff8b359234ce"
      unitRef="usd">2830000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTItMy0xLTEtMTA1MDMz_a871ae95-a115-4947-8436-c83764156220"
      unitRef="usd">-1195000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTMtMS0xLTEtMTA1MDMz_0b127535-85fc-4e01-9b51-600e74e2d719"
      unitRef="usd">2706000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTMtMy0xLTEtMTA1MDMz_700a29a8-ce7c-41aa-9edf-56dbbef01c76"
      unitRef="usd">10283000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTQtMS0xLTEtMTA1MDMz_5f314175-dfda-4882-91ac-7dbb3d1bc54c"
      unitRef="usd">0</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTQtMy0xLTEtMTA1MDMz_4a7a6de0-d4d2-4324-8649-ba5564ceb623"
      unitRef="usd">189000</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTYtMS0xLTEtMTA1MDMz_08af6ae1-e362-41ff-9c54-edf869181e38"
      unitRef="usd">56202000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTYtMy0xLTEtMTA1MDMz_d228e107-3b34-458f-815e-5c21114fa35b"
      unitRef="usd">9975000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTctMS0xLTEtMTA1MDMz_51c56a51-aa06-4fe4-b638-8adaec1f5491"
      unitRef="usd">12151000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTctMy0xLTEtMTA1MDMz_14964971-b150-4cfc-853a-7f387fe9313c"
      unitRef="usd">19508000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTgtMS0xLTEtMTA1MDMz_6185f1bc-80cc-4d04-b427-859ef13878fb"
      unitRef="usd">3580000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTgtMy0xLTEtMTA1MDMz_52ad6928-ef53-4eb5-ba45-a6cbcca611d6"
      unitRef="usd">266000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTktMS0xLTEtMTA1MDMz_26eb2f76-7ba3-4d98-b9ec-995b4ed23714"
      unitRef="usd">-4109000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMTktMy0xLTEtMTA1MDMz_5a66fde4-0b2e-48ea-8c2f-af707c9fbb44"
      unitRef="usd">-4613000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjAtMS0xLTEtMTA1MDMz_6acc9135-bc6a-4792-a906-817574667369"
      unitRef="usd">2290000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjAtMy0xLTEtMTA1MDMz_a5fe0387-7c38-443e-b880-476dce878bf4"
      unitRef="usd">1646000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjEtMS0xLTEtMTA1MDMz_1f4406f1-ff3e-4345-8353-7ab60cc11f1b"
      unitRef="usd">-1790000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjEtMy0xLTEtMTA1MDMz_68685178-fb20-401f-80f5-a1d01993351f"
      unitRef="usd">426000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjItMS0xLTEtMTA1MDMz_0d98744f-50f7-4173-9d3c-c84187fbdf7c"
      unitRef="usd">14181000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjItMy0xLTEtMTA1MDMz_6fe5efcf-368f-47f7-86ca-3075b953ecbb"
      unitRef="usd">16984000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjMtMS0xLTEtMTA1MDMz_fbf9cb5c-2540-4851-ae57-a4ced7b711c0"
      unitRef="usd">-4464000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjMtMy0xLTEtMTA1MDMz_1c6f4883-416d-4d04-abdf-a9f40a5187e4"
      unitRef="usd">-550000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjQtMS0xLTEtMTA1MDMz_ae3acf26-c9c9-4494-a37f-18afc668ac06"
      unitRef="usd">55106000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjQtMy0xLTEtMTA1MDMz_bcd02d5a-35d7-465b-8601-cd1d9b66dbf2"
      unitRef="usd">8977000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjUtMS0xLTEtMTA1MDMz_0d03b4ec-03d5-4b5e-8858-43ecaf739fe7"
      unitRef="usd">-13292000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjUtMy0xLTEtMTA1MDMz_276569fa-9b08-422c-9549-0c45dbaa9131"
      unitRef="usd">-2009000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjYtMS0xLTEtMTA1MDMz_e4397b45-41d2-4484-958f-5aa732765652"
      unitRef="usd">-2254000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjYtMy0xLTEtMTA1MDMz_1eb267d1-87ab-4713-b044-998c55078f83"
      unitRef="usd">-1698000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjctMS0xLTEtMTIwMzY4_48a52851-2ab0-472a-b42e-c675f8e14fbe"
      unitRef="usd">370000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjctMy0xLTEtMTIwMzc1_5a128e93-3dc5-4eec-a3b4-49d69b477ee0"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjgtMS0xLTEtMTA1MDMz_03399e10-c659-4e12-afd4-45dea7825870"
      unitRef="usd">33059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMjgtMy0xLTEtMTA1MDMz_831c4224-c3d6-46ff-b68a-a5a1e375b237"
      unitRef="usd">31286000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzEtMS0xLTEtMTA1MDMz_31815504-8a92-4e20-8fc9-2cf52e9ae3a3"
      unitRef="usd">858000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzEtMy0xLTEtMTA1MDMz_a87ce396-acac-408c-aee4-3d2573930bbc"
      unitRef="usd">117000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzItMS0xLTEtMTA1MDMz_f3825cfa-f392-471e-9837-f91ae3e48833"
      unitRef="usd">4030000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzItMy0xLTEtMTA1MDMz_c37f1f4a-1aad-4bb5-812a-56493ce3724d"
      unitRef="usd">31000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <ameh:PrepaymentForInvestmentPurchase
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzMtMS0xLTEtMTA2NDQx_0117ff7e-de9b-4c49-9e52-af7cc961f93a"
      unitRef="usd">0</ameh:PrepaymentForInvestmentPurchase>
    <ameh:PrepaymentForInvestmentPurchase
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzMtMy0xLTEtMTA2NDQ4_43ab0253-1af0-4eb5-a0bf-1c29fe3f7be9"
      unitRef="usd">4450000</ameh:PrepaymentForInvestmentPurchase>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzMtMS0xLTEtMTA1MDMz_e8c27bd9-bdaf-49bf-a2f7-92b5d62e2f36"
      unitRef="usd">1750000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzMtMy0xLTEtMTA1MDMz_4b193da4-1f6d-4e72-b986-3668bbd6cd73"
      unitRef="usd">670000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzQtMS0xLTEtMTA1MDMz_7027f4d7-ad0e-4fb0-a32a-604975f961d5"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzQtMy0xLTEtMTA1MDMz_b2684ed5-42c2-4679-bcaf-a354112c6659"
      unitRef="usd">1660000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzYtMS0xLTEtMTA1MDMz_ca19a086-d713-40ae-8845-3d3580fd1cc9"
      unitRef="usd">18845000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzYtMy0xLTEtMTA1MDMz_97364b28-3abd-4cb1-87fd-59f1a7fa1e2c"
      unitRef="usd">7364000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzgtMS0xLTEtMTA2NDYz_fe48229a-4c03-4e6b-86a6-bee66e53da14"
      unitRef="usd">0</ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity>
    <ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzgtMy0xLTEtMTA2NDcw_76d45d68-aeaa-4c4f-a557-2c384b59f741"
      unitRef="usd">3322000</ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzctMS0xLTEtMTA1MDMz_9cfc56b1-4376-4255-84ed-4552794be553"
      unitRef="usd">6480000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzctMy0xLTEtMTA1MDMz_1eed489d-494a-4a1d-96bb-53b133de3140"
      unitRef="usd">1106000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzgtMS0xLTEtMTA1MDMz_61715c24-8da8-4fa2-9e85-7cdbe1ff5113"
      unitRef="usd">400000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzgtMy0xLTEtMTA1MDMz_0bbf9855-e959-412c-a395-268e4f3c79d8"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <ameh:PaymentsToEquityMethodInvestments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzktMS0xLTEtMTA1MDMz_70f78e53-4e6b-436c-9c3b-5f85c4e9ef2b"
      unitRef="usd">1685000</ameh:PaymentsToEquityMethodInvestments>
    <ameh:PaymentsToEquityMethodInvestments
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfMzktMy0xLTEtMTA1MDMz_f23f7c06-7f73-4c6b-b80b-e930e84f5074"
      unitRef="usd">0</ameh:PaymentsToEquityMethodInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDAtMS0xLTEtMTA1MDMz_a17be896-2306-4a0b-ae59-bdb9d28e9247"
      unitRef="usd">-12228000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDAtMy0xLTEtMTA1MDMz_3d84132d-fdb6-4547-981b-eaa31067af0f"
      unitRef="usd">-9802000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDMtMS0xLTEtMTA1MDMz_36578f2d-826a-483c-9ae4-e43d35a1e5a4"
      unitRef="usd">12556000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDMtMy0xLTEtMTA1MDMz_2c2ca38b-4412-4750-bd78-f7a384bd2c16"
      unitRef="usd">21110000</us-gaap:PaymentsOfDividends>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDQtMS0xLTEtMTA1MDMz_aa544d4c-8605-40ee-a207-64eef0a74805"
      unitRef="usd">200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDQtMy0xLTEtMTA1MDMz_521cbb1f-1143-429d-81f1-357687440d69"
      unitRef="usd">238208000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDUtMS0xLTEtMTA1MDMz_b14f9625-9871-4561-83b6-83533d77a0bd"
      unitRef="usd">283000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDUtMy0xLTEtMTA1MDMz_c25f10aa-ca36-439f-9d0e-b65f14a8034b"
      unitRef="usd">54000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDYtMS0xLTEtMTA1MDMz_acdb026a-2bc1-4cf4-8b8b-49202cf6b7e2"
      unitRef="usd">1738000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDYtMy0xLTEtMTA1MDMz_d6fdc8ca-ed3e-4225-ba23-953bf1e7b44a"
      unitRef="usd">4816000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDctMS0xLTEtMTA1MDMz_39b104ba-1fb4-490c-9518-b258aa436397"
      unitRef="usd">9480000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDctMy0xLTEtMTA1MDMz_25e69e1c-8068-4968-a561-4969a8437a1d"
      unitRef="usd">2981000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <ameh:ProceedsFromSaleOfNoncontrollingInterest
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDktMS0xLTEtMTA1MDMz_a2c8acf0-28c0-44c2-a2a7-35231215c598"
      unitRef="usd">38000</ameh:ProceedsFromSaleOfNoncontrollingInterest>
    <ameh:ProceedsFromSaleOfNoncontrollingInterest
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNDktMy0xLTEtMTA1MDMz_20043959-71f0-4dd2-9dcc-d814c29dbb8b"
      unitRef="usd">38000</ameh:ProceedsFromSaleOfNoncontrollingInterest>
    <ameh:PaymentsToAcquireNonControllingInterest
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTAtMS0xLTEtMTA1MDMz_f94b5656-a215-4c71-be65-e078053ae3b1"
      unitRef="usd">199000</ameh:PaymentsToAcquireNonControllingInterest>
    <ameh:PaymentsToAcquireNonControllingInterest
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTAtMy0xLTEtMTA1MDMz_92ff71a3-d954-45a1-bee4-d5ae5997a2a0"
      unitRef="usd">75000</ameh:PaymentsToAcquireNonControllingInterest>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTEtMS0xLTEtMTA1MDMz_ceb08edf-9003-48ed-9ac8-8236e25cc744"
      unitRef="usd">1237000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTEtMy0xLTEtMTA1MDMz_3c9ff336-378d-4d25-a6ca-80c65251b147"
      unitRef="usd">180000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTItMS0xLTEtMTA1MDMz_724d405c-985b-4aa4-9bbf-27ce9d4f0c01"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTItMy0xLTEtMTA1MDMz_343668e2-f141-44d8-b60f-af3f6fa7b677"
      unitRef="usd">40134000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTMtMS0xLTEtMTA1MDMz_708cb759-6e88-4e48-8621-c956ccec05a6"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTMtMy0xLTEtMTA1MDMz_6546a1ed-40c5-45b8-8ea7-64596a9a4cbc"
      unitRef="usd">727000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTQtMS0xLTEtMTA1MDMz_f36427fb-c138-40dd-b083-07982c9c88ee"
      unitRef="usd">-19705000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTQtMy0xLTEtMTA1MDMz_7c157d1f-4433-4c2f-9275-12dcc7dc79e1"
      unitRef="usd">-38167000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTYtMS0xLTEtMTA1MDMz_317e7327-82ec-4f3a-81a5-23af8261c76f"
      unitRef="usd">1126000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTYtMy0xLTEtMTA1MDMz_b867d746-0f69-449f-9b0c-809d01552ebb"
      unitRef="usd">-16683000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTgtMS0xLTEtMTA1MDMz_873b0838-de9a-4d35-ac9b-b9f488b4b6b7"
      unitRef="usd">233097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNTgtMy0xLTEtMTA1MDMz_77c03f08-cb56-47a9-9c47-af42652db36b"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjAtMS0xLTEtMTA1MDMz_3cd78c27-f451-4f48-9431-31e0a236a109"
      unitRef="usd">234223000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4becb57108e844a2af77734d782c9546_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjAtMy0xLTEtMTA1MDMz_78c81eb6-6532-48bb-a5df-2e2957d72f3c"
      unitRef="usd">177287000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjMtMS0xLTEtMTA1MDMz_f4c1e849-877b-4072-9e32-ddbcc1f974af"
      unitRef="usd">22311000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjMtMy0xLTEtMTA1MDMz_e022b7b2-bdbb-4057-b7aa-bde6bf90b29c"
      unitRef="usd">23324000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjQtMS0xLTEtMTA1MDMz_5011ba52-9124-4bd9-8374-ae85fccbe850"
      unitRef="usd">2231000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjQtMy0xLTEtMTA1MDMz_bf3a035f-d751-473e-a1ec-c69d3bef80ad"
      unitRef="usd">2507000</us-gaap:InterestPaidNet>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjktMS0xLTEtMTA2NTUx_b654a448-44f8-4d30-a0b5-1d301eca4f84"
      unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i4becb57108e844a2af77734d782c9546_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjktMy0xLTEtMTA2NTU5_7d1ed002-0ebd-428e-ab99-237b23a3ec74"
      unitRef="usd">50000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjctMS0xLTEtMTA1MDMz_5381cf00-7e54-4877-9a95-0d78c98ab6c7"
      unitRef="usd">398000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjctMy0xLTEtMTA1MDMz_4aadd921-72e3-4ed6-8310-df3df3741b3c"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:StockIssued1
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjgtMS0xLTEtMTA1MDMz_a9a72748-e563-4257-8717-9221461b1369"
      unitRef="usd">1000000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNjgtMy0xLTEtMTA1MDMz_b7a0fc97-beb8-473e-894c-f28ce541638c"
      unitRef="usd">0</us-gaap:StockIssued1>
    <ameh:CancellationOfRestrictedStockAwards
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNzAtMS0xLTEtMTA1MDMz_4253701b-11a1-4c3c-af0f-a0c496417a66"
      unitRef="usd">0</ameh:CancellationOfRestrictedStockAwards>
    <ameh:CancellationOfRestrictedStockAwards
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNzAtMy0xLTEtMTA1MDMz_500c056a-5569-4e72-ad3d-4ce8bef7a2e5"
      unitRef="usd">144000</ameh:CancellationOfRestrictedStockAwards>
    <us-gaap:MortgageLoanRelatedToPropertySales1
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNzItMS0xLTEtMTIyMjU0_743b1715-baa1-4b60-aadf-edb28085a9e8"
      unitRef="usd">16275000</us-gaap:MortgageLoanRelatedToPropertySales1>
    <us-gaap:MortgageLoanRelatedToPropertySales1
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjlkMThhZmM2ZWM2NzQ0OWI5YTk0ZDQ1ODlmNmU2NjBhL3RhYmxlcmFuZ2U6OWQxOGFmYzZlYzY3NDQ5YjlhOTRkNDU4OWY2ZTY2MGFfNzItMy0xLTEtMTIyMjYx_f7e21704-984a-4c06-9e02-277d5e19fd30"
      unitRef="usd">0</us-gaap:MortgageLoanRelatedToPropertySales1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfMi0xLTEtMS0xMDUwMzM_97fd1e61-dc9d-4852-8e18-7deb0a39c7f4"
      unitRef="usd">233097000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfMi0zLTEtMS0xMDUwMzM_d1b8e213-0b25-49dd-994c-c77674fa53a3"
      unitRef="usd">193470000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfMy0xLTEtMS0xMDUwMzM_5f8d46d1-db13-4bc6-a30c-57364836ec42"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfMy0zLTEtMS0xMDUwMzM_a62994e4-c346-4085-9aa8-3187f0a050fa"
      unitRef="usd">500000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfNC0xLTEtMS0xMDUwMzM_1bb2ccd5-cda8-452f-9c5e-665921f0b9f8"
      unitRef="usd">233097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18zNC9mcmFnOjRhOTU5NjZkN2M4ZjQ4NWY5ODlkNWNiZmUzNmE1ZDVmL3RhYmxlOjg2MjhkMjEyZjUzNjQ1M2U5MTU3NjI4MmI2ZDFhNTA4L3RhYmxlcmFuZ2U6ODYyOGQyMTJmNTM2NDUzZTkxNTc2MjgyYjZkMWE1MDhfNC0zLTEtMS0xMDUwMzM_bc2ad816-7cad-4218-a4ca-86430b0a175f"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTYzNTk_6864cc99-e9eb-45f4-a8e2-f9098da7fd5b">Description of Business&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Apollo Medical Holdings, Inc. (&#x201c;ApolloMed&#x201d;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#x201c;NMM&#x201d;) in December 2017 (the &#x201c;2017 Merger&#x201d;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#x201c;VIEs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Headquartered in Alhambra, California, ApolloMed&#x2019;s subsidiaries and VIEs include management services organizations (&#x201c;MSOs&#x201d;), affiliated independent practice associations (&#x201c;IPAs&#x201d;), and an accountable care organization (&#x201c;ACO&#x201d;) participating in the GPDC model. NMM and Apollo Medical Management, Inc. (&#x201c;AMM&#x201d;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#x201c;APC&#x201d;), (ii) Alpha Care Medical Group, Inc. (&#x201c;Alpha Care&#x201d;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#x201c;Accountable Health Care&#x201d;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). The Company&#x2019;s ACO operates under the APA ACO, Inc. (&#x201c;APAACO&#x201d;) brand and participates in the Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#x2019;s attribution-based risk-sharing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#x2019;s physician network consists of primary care physicians, specialist physicians, and hospitalists. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSOs and Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPAs and Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#x201c;HMOs&#x201d;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#x201c;PMPM&#x201d;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AP-AMH Medical Corporation (&#x201c;AP-AMH&#x201d;) and AP-AMH 2 Medical Corporation (&#x201c;AP-AMH 2&#x201d;) was formed in May 2019 and July 2021, respectively, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;A $545.0&#160;million loan to AP-AMH, pursuant to a 10-year secured loan agreement (the &#x201c;AP-AMH Loan&#x201d;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&#x2019;s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;A $545.0&#160;million private placement, where AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;A $300.0&#160;million private placement, where APC purchased 15,015,015 shares of the Company&#x2019;s common stock and in  connection therewith, the Company granted APC certain registration rights with respect to the purchased shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (&#x201c;Excluded Assets&#x201d;). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#x2019;s equity interests in Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC&#x2019;s ownership in ApolloMed was 20.02% as of June&#160;30, 2022 and 19.68% as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concourse Diagnostic Surgery Center, LLC (&#x201c;CDSC&#x201d;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of June&#160;30, 2022, APC owned 44.50% of CDSC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC-LSMA Designated Shareholder Medical Corporation (&#x201c;APC-LSMA&#x201d;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#x2019;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#x201c;LMA&#x201d;), Pacific Medical Imaging and Oncology Center, Inc. (&#x201c;PMIOC&#x201d;), Diagnostic Medical Group of Southern California (&#x201c;DMG&#x201d;), and AHMC International Cancer Center, a Medical Corporation (&#x201c;ICC&#x201d;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#x201c;MMG&#x201d;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#x201c;AMG&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its 40% investment in DMG, under the equity method of accounting. In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#x2019;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $8.5&#160;million as of June&#160;30, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#x201c;MPP&#x201d;), AMG Properties, LLC (&#x201c;AMG Properties&#x201d;), and ZLL Partners, LLC (&#x201c;ZLL&#x201d;) and a 50% interest in each of One MSO, LLC (&#x201c;One MSO&#x201d;), Tag-6 Medical Investment Group, LLC (&#x201c;Tag 6&#x201d;), and Tag-8 Medical Investment Group, LLC (&#x201c;Tag 8&#x201d;). These entities own buildings that are currently leased to tenants, as well as vacant land that is being developed. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments, as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#x2019;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, AP-AMH 2, a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#x201c;APCMG&#x201d;), a primary care physicians&#x2019; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#x201c;Sun Labs&#x201d;) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company (see Note 3 &#x2014; &#x201c;Business Combinations and Goodwill&#x201d;). The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $4.2 million as of June&#160;30, 2022. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO, GPDC / ACO REACH&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO began participating in the NGACO Model of CMS in January 2017. The NGACO Model was a CMS program that allowed provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model. With the ending of the NGACO Model on December 31, 2021, APAACO applied, and has been selected by CMS, to participate as a Direct Contracting Entity (&#x201c;DCE&#x201d;) in the standard track of CMS&#x2019;s GPDC Model for Performance Year 2022 (&#x201c;PY22&#x201d;), beginning January 1, 2022. CMS has since redesigned the GPDC Model in response to Administration priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience, and renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (&#x201c;ACO REACH&#x201d;) Model. The ACO REACH Model will begin participation on January 1, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
      contextRef="if607fd60c6ba4a7fb898dea28d8f0d05_D19990701-19990731"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNDY5Mg_10058511-7a0f-4a72-b2db-d2a8e51b484b">P30Y</ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement>
    <us-gaap:NotesReceivableNet
      contextRef="ife69969a467049b7822c63de16e05840_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNTY4Nw_7c4bb127-7bea-408a-88ff-44e7f065702a"
      unitRef="usd">545000000</us-gaap:NotesReceivableNet>
    <ameh:FinanceReceivableTermOfReceivable
      contextRef="i5d59e759a6d143e7b8673d525e1641d4_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTYzNjA_872cb2a7-641a-44df-907a-ec36444c11e5">P10Y</ameh:FinanceReceivableTermOfReceivable>
    <ameh:FinanceReceivableStatedInterestRate
      contextRef="ife69969a467049b7822c63de16e05840_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNTgwOQ_419f7a0a-2dc8-4aa8-ae05-ed84b3c59a37"
      unitRef="number">0.10</ameh:FinanceReceivableStatedInterestRate>
    <ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate
      contextRef="ife69969a467049b7822c63de16e05840_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjQzMQ_be7ec751-4223-4072-a919-f51f59c64626"
      unitRef="number">0.1075</ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate>
    <us-gaap:NotesReceivableNet
      contextRef="ife69969a467049b7822c63de16e05840_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjQ2Mw_7c4bb127-7bea-408a-88ff-44e7f065702a"
      unitRef="usd">545000000</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i25b2318042034ef8ada1dff3ae0fa2ee_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjUwOA_9c256d96-d329-42c8-a2f7-512360427df9"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NotesReceivableNet
      contextRef="iab9ce1fe319c40f3b5143a3c664cb2f8_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjY1MA_1c56e6c9-c9e9-46d3-8dc9-e790e09fc998"
      unitRef="usd">300000000</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8b9dc946cce64aeda656fa396f8ac5d9_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfNjY5Mg_792896ac-a7f6-4ab1-82fc-2c0b87d3e09b"
      unitRef="shares">15015015</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5b76bb6ee687447b91d65e6261285c67_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfODI4NA_7b33c71f-b00b-4c1e-9ee2-b1c024fb343a"
      unitRef="number">0.2002</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i25ab29ee2b194190ba48aff50a9eca6a_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfODMwMA_03a0132c-518b-448a-aedc-668f11813d77"
      unitRef="number">0.1968</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i05247cd849de40dc8290e15a895f802d_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfODc5MA_9940b24a-60d8-456a-b807-ae4b19747923"
      unitRef="number">0.4450</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i1ed4c08298bb425782e0cb29c6843164_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTAwOTA_e0338e35-1c92-4e2e-ae78-1cfd376287b5"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:NumberOfFederallyQualifiedHealthPlans
      contextRef="i910383234e6d43a5b4e0907b9f2f7fa3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTEwODg_f99c34ce-b8d6-4c43-af24-a5b26c021146"
      unitRef="plan">3</ameh:NumberOfFederallyQualifiedHealthPlans>
    <ameh:NumberOfFamilyPracticeClinics
      contextRef="i87ad3733808d4ed680a72e6a21ac142d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTE0Mzk_a84502e6-a216-4464-a9b6-4496a2179ddf"
      unitRef="clinic">3</ameh:NumberOfFamilyPracticeClinics>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i9c45553f306743bb86ff185b451d6f0d_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTE2ODY_062eea82-5781-4621-909a-5bfdf7dab8f1"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i447febb4f2414ccebd0319ff3c12007a_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTE4ODc_02b1ec89-db07-4ae5-b291-ed2e0fbcfbea"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="icd0b89cf94234e64a6168f357c2f6a9a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTIzODM_7273821f-4575-4047-8cc7-c05e3273be60">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <us-gaap:EquityMethodInvestments
      contextRef="i784b5366266c4d4796ca24adc088b8b9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTI1MTY_ff4d9ae0-9c21-45e6-8d0a-d30c6e7928ff"
      unitRef="usd">8500000</us-gaap:EquityMethodInvestments>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="id084c1a48f8149359167ebc980bdd4fc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTI4MDc_d14db35d-670a-498a-a59e-564b03e57b3a"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i34200d16ebcc4e9bb848e910e7f98470_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTI5NDY_73a1c8ad-1212-4b5b-88b4-025b012f5413"
      unitRef="number">0.50</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="id084c1a48f8149359167ebc980bdd4fc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTMyNDE_d14db35d-670a-498a-a59e-564b03e57b3a"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="iaa25ff896fef4a548c62b034ce2acbd1_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTQyMDg_41ec9a05-adc8-4c31-8d74-00ad8cc304bb"
      unitRef="number">0.80</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i2fb19f36b5434e40bf55b16ef65f34a6_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTQ1Njc_44be5d67-1b06-4068-b021-192a4b50c2d8"
      unitRef="number">0.49</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i156059eff9374f1087488e472de06542_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTQ3MTE_0d2cdb0d-d1fb-47a6-b3aa-b506303f0de8"
      unitRef="usd">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="i156059eff9374f1087488e472de06542_D20210801-20210831"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTUwODk_099b0abd-208a-4208-8e7b-f6db3c2e6ee6">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent
      contextRef="i8c78dbde3d4043f6906cce86f5541c87_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180MC9mcmFnOjBmMWIxOGNmMDFmYTQzN2I5ZTVmYTUxZDA0NWZmZDk4L3RleHRyZWdpb246MGYxYjE4Y2YwMWZhNDM3YjllNWZhNTFkMDQ1ZmZkOThfMTUyMjU_5cdf35da-d3d2-465c-9e1a-3611662b6461"
      unitRef="usd">4200000</ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNDM_7745d146-f79d-4482-bf8b-9bef8f407aa5">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated balance sheet at December&#160;31, 2021, has been derived from the Company&#x2019;s audited consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2022, and for the three and six months ended June&#160;30, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three and six months ended June&#160;30, 2022, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or any future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three and six months ended June&#160;30, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#x2019;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#x2019;s consolidated subsidiary, APCMG; (3) AMM&#x2019;s consolidated VIEs, SCHC and AMH; (4) NMM&#x2019;s VIE, APC; (5) APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, and Tag 8; and (6) APC-LSMA&#x2019;s consolidated subsidiaries, ICC, Alpha Care, Accountable Health Care, and AMG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications were made between unrealized loss (gain) on investments and other income (expense) on the accompanying unaudited consolidated income statements for the three and six months ended June&#160;30, 2021. They had no effect on net income, earnings per share, retained earnings, cash flows or total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of June&#160;30, 2022 and December&#160;31, 2021, the Company&#x2019;s deposit accounts with banks exceeded the FDIC&#x2019;s insured limit by approximately $277.6 million and $285.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#x2019;s concentration of risk exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of June&#160;30, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $25.1 million and $25.0 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. Equity securities with low trading volume are determined to not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Nutex Health Inc. (formerly known as Clinigence Holdings, Inc.) (&#x201c;Nutex&#x201d;). The common stock of a payor partner was acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#x201c;UCI&#x201d;) in April 2020. In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional shares of common stock if certain metrics are not met (such additional shares, &#x201c;contingent equity securities&#x201d;) for $3.0&#160;million. The common stock is included in investments in marketable securities in the accompanying consolidated balance sheets. In May 2022, the Company exercised the warrants and subsequently recognized the shares within investments in marketable securities in the accompanying consolidated balance sheet. The contingent equity securities are classified as derivatives and included in prepaid expenses and other current assets in the accompanying consolidated balance sheets. See Note 2 &#x2014; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#x201d; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the equity securities were approximately $14.4 million and $28.4&#160;million, respectively, in the accompanying consolidated balance sheets. Gains and losses recognized on equity securities sold are recognized in the accompanying consolidated statements of income under other income. The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total (losses) gains recognized on equity securities  &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Gains recognized on equity securities sold  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Unrealized gains (losses)  recognized on equity securities held at end of period  &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables,  Receivables &#x2013; Related Parties, and Loan Receivable - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivable &#x2013; related party consist of promissory notes from a related party payee that accrues interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivables relate to each health plan&#x2019;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of June&#160;30, 2022, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the six months ended June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the six months ended June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no impairment of its goodwill or indefinite-lived intangible assets during the six months ended June&#160;30, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was no impairment loss recorded related to equity method investments for the years ended June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, APCMG, and Jade (the &#x201c;consolidated IPAs&#x201d;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fiduciary Cash and Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $6.1 million and $10.5 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 &#x2014; &#x201c;Credit Facility, Bank Loans, and Lines of Credit&#x201d; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of June&#160;30, 2022, the fair value of the interest rate swap was $1.8 million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $1.1&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. In May 2022, the Company exercised the warrants and the shares were subsequently presented within investments in marketable securities on the accompanying consolidated balance sheets. The shares are classified as Level 1 since the quoted market prices from reputable third-party brokers are available in an active market and unadjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Contingent Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Nutex, ApolloMed is entitled to additional common stock if Nutex does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered to be derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The Company determined the fair value of the contingent equity security using a probability-weighted model, which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of June&#160;30, 2022 and December&#160;31, 2021, the contingent equity securities were valued at $3.2&#160;million and $4.3 million, respectively, and is presented within prepaid and other current assets in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GPDC Capitation Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS contracts with Direct Contracting Entities (&#x201c;DCEs&#x201d;), which is composed of healthcare providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#x2019;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#x2019;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e., month) and is recognized net of quality incentives/penalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospital&#x2019;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims, are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#x201c;Participation Agreement&#x201d;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system, and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#x2019;s contract liability balance was $20.0 million and $16.8 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the six months ended June&#160;30, 2022, $0.5 million of the Company&#x2019;s contract liability accrued in 2021 has been recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#x2019;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 &#x2014; &#x201c;Earnings Per Share&#x201d; for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2022 and December&#160;31, 2021, APC&#x2019;s shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;)  No. 2021-08, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2021-08&#x201d;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;With the exception of the new standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTc5OTg_1dfc45e3-83c0-44f5-9ece-71dbaeaf5731">Basis of PresentationThe accompanying consolidated balance sheet at December&#160;31, 2021, has been derived from the Company&#x2019;s audited consolidated financial statements, but does not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2022, and for the three and six months ended June&#160;30, 2022 and 2021, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC on February&#160;28, 2022. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNTc_a1ab3b82-be59-4c4f-a244-38eea37d8c1a">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets as of June&#160;30, 2022 and December&#160;31, 2021, and the consolidated statements of income for the three and six months ended June&#160;30, 2022 and 2021, include the accounts of (1) ApolloMed, ApolloMed&#x2019;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#x2019;s consolidated subsidiary, APCMG; (3) AMM&#x2019;s consolidated VIEs, SCHC and AMH; (4) NMM&#x2019;s VIE, APC; (5) APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, and Tag 8; and (6) APC-LSMA&#x2019;s consolidated subsidiaries, ICC, Alpha Care, Accountable Health Care, and AMG.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTQ5NzU1ODIwMTAwOQ_d7c8ad8c-488e-4b68-bf1b-068b09e17076">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications were made between unrealized loss (gain) on investments and other income (expense) on the accompanying unaudited consolidated income statements for the three and six months ended June&#160;30, 2021. They had no effect on net income, earnings per share, retained earnings, cash flows or total assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMjk_afcbc1c6-5487-474b-8242-21eb239125fa">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMjI_5f8afad1-2f33-4151-b141-c509c01effd9">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (economics). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 16 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMDU_edf97716-3047-40cc-99a2-9eb1fa225100">Business CombinationsThe Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMjM_9862add5-10c7-4a46-9fb8-f6d815e731b8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNzQxMQ_43e46e34-894e-4bf9-923d-d89562f67263"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNzQxMQ_53ff488b-f11d-4a85-929a-765cf2c0a503"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNzY4OA_43e46e34-894e-4bf9-923d-d89562f67263"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNzY4OA_53ff488b-f11d-4a85-929a-765cf2c0a503"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNzU_5ebcad39-6b96-4470-8dc7-017f5b8245b9">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfODQ1Mw_da4fb94a-933e-4c54-a2fc-3f8b0f27f11c"
      unitRef="usd">277600000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfODQ2MA_3dff91fb-80e2-4ee3-9bf6-ee3a33ced759"
      unitRef="usd">285900000</us-gaap:CashUninsuredAmount>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTc5OTk_c082c526-20b0-4322-8b92-20288ce290f1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of June&#160;30, 2022 and December&#160;31, 2021, certificates of deposit amounted to approximately $25.1 million and $25.0 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. Equity securities with low trading volume are determined to not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted average share prices from observable market data.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="ic233432b45644a51a10accdc3eb97bec_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMTI_f29f27bb-82f2-4386-9e2b-408fe2cc86f3">P4M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="i91813fbebd0e4a15b55763b7872a8b9d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfOTA3OA_eade061b-118d-43c5-8d06-c6e235b2a338">P24M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47269e9c8fe6491f87cf108347ce40c5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfOTE1Ng_f9522de0-f016-4991-bfe7-696944d9c7ed"
      unitRef="usd">25100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if90f9dac9afe48d79cdaf54cd044093f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfOTE2Mw_fa2c261f-73ad-4a8e-936f-0ef2f2f353dc"
      unitRef="usd">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="i7357682f6a2743c2ac4f7e64822ecf5d_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTAxNTM_874b70a5-7eec-484c-b453-c09685a3152f"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <ameh:PaymentsToAcquireCommonStockAndWarrants
      contextRef="i76567744587f40f8a8c7ac4dc85fa166_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTA0Nzc_af777c78-d379-429f-a3ee-94f13ae2fe04"
      unitRef="usd">3000000</ameh:PaymentsToAcquireCommonStockAndWarrants>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTEwNjU_ba571625-140c-4c20-8aa6-f836bae53264"
      unitRef="usd">14400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTEwNzI_b2b19bfd-61e1-4929-a24c-c1daeb57ab57"
      unitRef="usd">28400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNjA0NzMxNDAxMTQ1Nw_a29dbfc3-9810-4b3c-ad16-e7018c983275">The components comprising total gains and losses on equity securities are as follows (in thousands) for the periods listed below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total (losses) gains recognized on equity securities  &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Gains recognized on equity securities sold  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Unrealized gains (losses)  recognized on equity securities held at end of period  &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,059)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfMy0xLTEtMS0xMTM2NzM_9d053858-b1c9-4d4f-96c1-ae9c184ee9c4"
      unitRef="usd">-4331000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfMy0zLTEtMS0xMTM2ODA_a1ab3faa-ca7f-4b7a-9940-a614d13a75a0"
      unitRef="usd">83769000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfMy01LTEtMS0xMTM2ODc_2e9ba6d7-f51a-460d-af76-8cf05099b436"
      unitRef="usd">-14886000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfMy03LTEtMS0xMTM2OTQ_c5891ad9-8b42-4f4b-8dc9-98512a554525"
      unitRef="usd">83769000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNC0xLTEtMS0xMTM2NzM_88eafdb5-162d-4c78-be2a-4ca06f5bc87e"
      unitRef="usd">2272000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNC0zLTEtMS0xMTM2ODA_c64459f5-03d5-4efd-9144-82fff8c9036d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNC01LTEtMS0xMTM2ODc_e499b33e-59ba-4f16-9570-adda77f20e4b"
      unitRef="usd">2272000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNC03LTEtMS0xMTM2OTQ_921b268d-d0cd-4b19-8bd8-57b26a302018"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNS0xLTEtMS0xMTM2NzM_519cb2a9-1f95-4ec5-a497-0f6b85512795"
      unitRef="usd">-2059000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNS0zLTEtMS0xMTM2ODA_44247948-8001-431b-b997-73e40afb1407"
      unitRef="usd">83769000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNS01LTEtMS0xMTM2ODc_1a7cddf1-53f7-47c1-a6fd-fc04654a8657"
      unitRef="usd">-12614000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjU3NzA4OWZkZWY5MDRiMzJhMzQ4MDM1NGNkOTcwMDAxL3RhYmxlcmFuZ2U6NTc3MDg5ZmRlZjkwNGIzMmEzNDgwMzU0Y2Q5NzAwMDFfNS03LTEtMS0xMTM2OTQ_f81c0572-1722-4e6c-bd26-50af98373599"
      unitRef="usd">83769000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNzY_97e5842b-18bb-4c7c-93a5-63886beea57b">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables,  Receivables &#x2013; Related Parties, and Loan Receivable - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivable &#x2013; related party consist of promissory notes from a related party payee that accrues interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivables relate to each health plan&#x2019;s capitation and are received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consist of recoverable claims paid related to the 2021 APAACO performance year to be administered following instructions from CMS for the NGACO program, receivables from GPDC capitation revenue for the 2022 performance year, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model.</ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock>
    <ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTI1OTU_5314c788-3bf1-4e18-ba28-75c21144e204">P18M</ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMDY_aed4a660-09a1-4848-8fb3-2c918be81406">Concentrations of Credit RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMDA_3102ed47-4ba6-4c52-8b01-95e10d9d76b8">The following table presents disaggregated revenue generated by payor type for the three months ended June&#160;30, 2022 and 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae5121d03a9a469ba0192b0be3dd0589_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfMy0xLTEtMS0xMDUwMzM_41b095cf-6458-4b98-8e67-9b2f6d79d511"
      unitRef="usd">42014000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6c6d1fd56384e02a5c02ddcb77d7181_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfMy0zLTEtMS0xMDUwMzM_8bd46884-683c-469a-9595-73dd3e30fc64"
      unitRef="usd">33296000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41a54db22a27477ea703d051e51b7b7e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfMy01LTEtMS0xMDUwMzM_d64deb87-e496-4efd-ad6d-c15c201d20a4"
      unitRef="usd">84167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a475831b3ad4c928ce6c91ff40dfea6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfMy03LTEtMS0xMDUwMzM_62e4a676-8a0b-4258-bfbf-8a995d5e0590"
      unitRef="usd">65562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd641546fc50456c8010d886a4880874_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNC0xLTEtMS0xMDUwMzM_3fbb1417-ac52-44b6-800b-941e3d3311fd"
      unitRef="usd">142641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1650503a7572464f88699d1599fc1c65_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNC0zLTEtMS0xMDUwMzM_a1d71249-e91f-4fb3-b5ea-0034e61b405a"
      unitRef="usd">64273000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ebf943246644d74b344ccfecdd85d8f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNC01LTEtMS0xMDUwMzM_f52f724a-95aa-4179-94cc-c2969b9d6d3e"
      unitRef="usd">276299000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d2f76f1af7d4a4495f8e7c418f0efb7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNC03LTEtMS0xMDUwMzM_7ec89b3c-564c-43d9-8c89-3da51e74a556"
      unitRef="usd">128950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e97022e423b48fea6becfdd26749dca_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNS0xLTEtMS0xMDUwMzM_b4eb933f-ba23-4419-9dcd-cde4c3933b89"
      unitRef="usd">70635000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2badd64b1fb94f4b81b6475e7e2cd34d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNS0zLTEtMS0xMDUwMzM_a028f153-4ef4-4f58-a12b-8dbf8b62224b"
      unitRef="usd">68482000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb83156e733243f9acced43816434206_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNS01LTEtMS0xMDUwMzM_b10612f1-0082-4e61-9d34-fef7ba6e9d3f"
      unitRef="usd">142299000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ac7abfe0eed4e0d8d7b27ded03a5f9f_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNS03LTEtMS0xMDUwMzM_34132954-46f8-48a3-a591-20c939900a38"
      unitRef="usd">138146000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic15db0ac3886408985bfd7a1c444afb4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNi0xLTEtMS0xMDUwMzM_b71cf2d0-fc81-45bb-9800-6859d02f6c8a"
      unitRef="usd">14407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0d317985c314aa188d6771db1792d94_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNi0zLTEtMS0xMDUwMzM_37581162-d869-4680-a804-62bc78a00bc9"
      unitRef="usd">9587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e0d411993ee4352bb911f910f1c404e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNi01LTEtMS0xMDUwMzM_999857f2-1b6f-4bf5-9a04-b2690f4f048f"
      unitRef="usd">30189000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5aae7fb197fa4ed39a801149bd5cd532_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNi03LTEtMS0xMDUwMzM_ac5a5cc1-30e2-4a00-ad50-db6095285c9f"
      unitRef="usd">19038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNy0xLTEtMS0xMDUwMzM_8a301919-ebe6-4d4c-9928-6c3b6e04c41b"
      unitRef="usd">269697000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNy0zLTEtMS0xMDUwMzM_887996e8-bf69-4be8-b7b5-d791988f52d8"
      unitRef="usd">175638000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNy01LTEtMS0xMDUwMzM_8230003d-9295-4dda-a297-cab123454118"
      unitRef="usd">532954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmI5ZTAyNDMyZjAzNzQxNWViYzRmODVhOTJjMDEwNDFmL3RhYmxlcmFuZ2U6YjllMDI0MzJmMDM3NDE1ZWJjNGY4NWE5MmMwMTA0MWZfNy03LTEtMS0xMDUwMzM_eac861c9-50fc-4835-9850-ac243b213a0d"
      unitRef="usd">351696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNTE_91072a06-5e4d-417b-bc05-4c4a45d720b8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i357d85714b284f7ab7bee3970e56bf57_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfMy0zLTEtMS0xMDUwMzM_d5ffb759-8e91-4528-bcc5-9cb618d812a5"
      unitRef="number">0.125</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i038860cc692f4bb888a5b7ef1486e53a_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfMy03LTEtMS0xMDUwMzM_15ba6763-de31-48ad-8330-880e313328df"
      unitRef="number">0.126</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ide23e89dd9c645c281e278662449b4a1_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNC0zLTEtMS0xMDUwMzM_05c2ee8d-5833-48dc-b5e4-cd2acf7b52cd"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1ee8745d85894cceb97642891fcbce9f_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNC03LTEtMS0xMDUwMzM_58d6105e-6eb0-434f-9422-181b4a867253"
      unitRef="number">0.104</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3c92edeb4a78489988df0cc478c477de_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNS0xLTEtMS0xMDUwMzM_1c1f8df2-2ef5-4a58-a5d9-bbf3f437efe3"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia113d3dba3ad4fa2ba4bbae8dbeb4ab8_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNS0zLTEtMS0xMDUwMzM_0b7c33d7-482f-4fc3-bae1-277da0b7a80b"
      unitRef="number">0.167</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7e0285c80acf4fbe88b94c417e7bfb83_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNS01LTEtMS0xMDUwMzM_422fbcba-48ae-40a8-9d6c-6b3b67ef68a9"
      unitRef="number">0.105</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i93342f091b4c43cc846afa98f4943123_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNS03LTEtMS0xMDUwMzM_e15397d4-0add-4215-90c9-7f62688321ee"
      unitRef="number">0.168</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie9f48dc88c7645149c0e2929fbcd7d42_D20220401-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNi0xLTEtMS0xMDUwMzM_ad364121-a1bc-4820-a3db-8708aad9b257"
      unitRef="number">0.310</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4ee529e7087e4e4c9dacd669a0e96636_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmRkZDc4NDU5OTdmMDRlNTliNDNjOWVhN2VjZTBkY2ZjL3RhYmxlcmFuZ2U6ZGRkNzg0NTk5N2YwNGU1OWI0M2M5ZWE3ZWNlMGRjZmNfNi01LTEtMS0xMDUwMzM_4f50a9f5-11bd-4499-8a50-b23a21dc151b"
      unitRef="number">0.307</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i13934575582a4f6586ab0fd0252a2087_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfMi0xLTEtMS0xMDUwMzM_f6e9bfe0-a087-46e8-b91b-ae5537bc03d5"
      unitRef="number">0.250</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibb54c28e4db64ef2a4baf3b30dcfcf81_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfMy0xLTEtMS0xMDUwMzM_0f55b7e6-074a-4865-ae26-8cb5ca3cd69f"
      unitRef="number">0.280</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2afd3f4b4d624a81a9706ec95cb3912e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfMy0zLTEtMS0xMDUwMzM_b655524b-2d27-4bd8-8e83-f4845be49574"
      unitRef="number">0.450</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie41c112f00c54f2ab3512eeb222e2e58_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfNC0xLTEtMS0xMDUwMzM_54af0129-1516-41dd-b103-be46d720bf17"
      unitRef="number">0.190</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i460a5116e6b044ad9ebfe9b19f40bfcf_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjcwMjBiMTNlMTBhZTQ5M2JhNGQxMjQ4YWI2YzFkOTk2L3RhYmxlcmFuZ2U6NzAyMGIxM2UxMGFlNDkzYmE0ZDEyNDhhYjZjMWQ5OTZfNC0zLTEtMS0xMDUwMzM_f52a8c88-d5ab-4810-a891-72693de30030"
      unitRef="number">0.300</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMzg_63cacda5-d4bd-4f8a-a008-a0288824dd0b">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMDc_befcb014-e98f-4a5c-8739-e1b1489129af">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of June&#160;30, 2022, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2021, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMy0xLTEtMS0xMDUwMzM_6553bfe4-2ce7-43b1-85bf-6fb93f3b3522"
      unitRef="usd">70053000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMy0zLTEtMS0xMDUwMzM_d51586ed-45e1-4a8c-b3e2-08737a177696"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMy01LTEtMS0xMDUwMzM_667f2a60-9ac8-47f5-bf29-3c37c546ef1b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMy03LTEtMS0xMDUwMzM_68f7b116-285a-46b6-a722-d4f8ada3ba52"
      unitRef="usd">70053000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNC0xLTEtMS0xMDUwMzM_952c3408-d7e2-4695-b9a9-1e4b2e54085d"
      unitRef="usd">25086000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNC0zLTEtMS0xMDUwMzM_d6da0102-6cd1-4b07-83cf-16ab33d3ff49"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNC01LTEtMS0xMDUwMzM_aa50de87-2f48-45f6-835c-406d1212c9f9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNC03LTEtMS0xMDUwMzM_a0a45d0d-0a60-4314-86f6-b2cf3eee77a9"
      unitRef="usd">25086000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNS0xLTEtMS0xMDUwMzM_3fc4d524-fded-4980-9695-2a55eef07f8a"
      unitRef="usd">14404000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNS0zLTEtMS0xMDUwMzM_72a20835-e058-4c45-8b99-07372ca6e54d"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNS01LTEtMS0xMDUwMzM_d40e70e7-64fb-44c1-bb50-592bc2fa1a5a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNS03LTEtMS0xMDUwMzM_56c1e21d-0dcf-45f0-abf2-b5905e6737be"
      unitRef="usd">14404000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="i6f75606e37874c68b458b76513cab432_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNi0xLTEtMS0xMDUwMzM_387f64d8-a5fa-495f-a24e-5233bcd430cf"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i413730c561f44bcba0f3b2bc0c6bd449_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNi0zLTEtMS0xMDUwMzM_3427d13d-e24c-4550-86ad-aa4f9e901b6c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i98c80c14bf5e41c684783fbcf0d76f0e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNi01LTEtMS0xMDUwMzM_beaa3ca0-f5eb-4437-b125-f7aca996bed5"
      unitRef="usd">3225000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i40b21462ffcb4d248cd6645a35f7a449_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfNi03LTEtMS0xMDUwMzM_c01d8bb9-221c-4a57-8dfc-b1668381fc45"
      unitRef="usd">3225000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9eb00088282a4dc5afc8c52b83d0ac33_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOC0xLTEtMS0xMDUwMzM_8da3baaa-aefa-4cc5-ba76-8379043fffdc"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7561cc5bf6ca4e669a3141d449e8fa2c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOC0zLTEtMS0xMDUwMzM_756f18f6-050a-42c5-b781-08db6a947551"
      unitRef="usd">1759000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia91f40c8ef0543eeb07c574e983655c3_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOC01LTEtMS0xMDUwMzM_af9d5a1c-8a8e-4b70-b606-c79bb73a7f33"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i68316a8a436c493fabb213bb9156c632_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOC03LTEtMS0xMDUwMzM_fe82ac09-a6a1-491f-b528-8fdd05abfa3e"
      unitRef="usd">1759000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOS0xLTEtMS0xMDUwMzM_e56c631c-aeb9-4d4e-bb13-99af8f628f7e"
      unitRef="usd">109543000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOS0zLTEtMS0xMDUwMzM_41cdd7f6-e12d-4447-b631-87464c5f39c2"
      unitRef="usd">1759000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOS01LTEtMS0xMDUwMzM_28d1d430-db9f-4fc3-8e0d-0f1869679ad9"
      unitRef="usd">3225000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfOS03LTEtMS0xMDUwMzM_8a1ba0b1-37c2-4138-85e3-0a588e2896e9"
      unitRef="usd">114527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTItMS0xLTEtMTA1MDMz_74db78c9-98fe-4323-9e40-6106fb32e164"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTItMy0xLTEtMTA1MDMz_e229a12c-2edd-4fb8-82a0-4ec98f5f6d43"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTItNS0xLTEtMTA1MDMz_08457c20-f1fb-4f38-aa3b-c9177a06d4cf"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTItNy0xLTEtMTA1MDMz_aeb01a89-7d96-4f4a-bf9a-ccef2c60f209"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i46c346b0625d406694128d5527d8d3bd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTMtMS0xLTEtMTA1MDMz_ed8e6289-87fa-4fab-a0bd-91e1efa0d36e"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i60588cad65de4d9aa8c4383dc58cbbbf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTMtMy0xLTEtMTA1MDMz_0c98485e-a344-448e-b342-01918effe72d"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="icb8f797e4a8146a98eb727afc3cbfc49_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTMtNS0xLTEtMTA1MDMz_d21e8b1a-8841-4be9-a61c-f936d9e0b4c2"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOjExNjgzMjFlMWUwYTRiYjU5NTJmMDAzZmZmODAxMGYyL3RhYmxlcmFuZ2U6MTE2ODMyMWUxZTBhNGJiNTk1MmYwMDNmZmY4MDEwZjJfMTMtNy0xLTEtMTA1MDMz_416adf33-5aca-4045-aa02-7d353ab7aab5"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMy0xLTEtMS0xMDUwMzM_661c59b5-d180-4430-b798-16395fb99c8f"
      unitRef="usd">114665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMy0zLTEtMS0xMDUwMzM_3cfb3af8-2e3d-4468-b768-6de2b5095270"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMy01LTEtMS0xMDUwMzM_18ab07be-025e-4af1-87a2-7c065e8accaf"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMy03LTEtMS0xMDUwMzM_ff5062e2-cb07-414f-b542-a53e3c5dd9fd"
      unitRef="usd">114665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNC0xLTEtMS0xMDUwMzM_1feb34c0-be1c-45bd-ad80-86653885047e"
      unitRef="usd">25024000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNC0zLTEtMS0xMDUwMzM_26285b1f-43d6-4bc9-b3b2-3890af3c0631"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNC01LTEtMS0xMDUwMzM_ef6ded9f-da44-40a6-8ed4-93489973d97c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNC03LTEtMS0xMDUwMzM_3927fec5-f6b8-4cd6-b618-621e2855a0c6"
      unitRef="usd">25024000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNS0xLTEtMS0xMDUwMzM_c908018c-b7f7-4b7f-81af-25ccac109c5f"
      unitRef="usd">24123000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNS0zLTEtMS0xMDUwMzM_8a87f18d-48df-497a-bdd0-e95b8cbc4dc4"
      unitRef="usd">4270000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNS01LTEtMS0xMDUwMzM_2a8631d0-2fd9-4098-84fe-8c6b6aa3ee88"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNS03LTEtMS0xMDUwMzM_3909b5c3-aea0-45d5-9105-1e2953763d5f"
      unitRef="usd">28393000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="i973177a3369f4442a2135e79cc6ef154_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNi0xLTEtMS0xMDUwMzM_3031e51e-89a9-47b2-9f6a-daacec18c465"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5acd511331764617bdfd48af40f038ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNi0zLTEtMS0xMDUwMzM_8dc3318c-272f-4250-8127-6dc0204b7b0b"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i86fb54a8136643a1965dda0ad2e9f39b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNi01LTEtMS0xMDUwMzM_d8c9d8bc-3cb8-4e51-9938-9dba4ccefd26"
      unitRef="usd">4270000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i934b31b2b19e4a32b408f256d19446bf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNi03LTEtMS0xMDUwMzM_71f77218-b89d-4863-b3dc-995587992d14"
      unitRef="usd">4270000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i122754df236048089b5aad3001c4b1c7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNy0xLTEtMS0xMDUwMzM_fcd2dce0-c67f-49eb-9fe0-2fdfd5a9a8b2"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i36676e73486c494b80fb603caae18d98_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNy0zLTEtMS0xMDUwMzM_93a1da4b-c109-4bb7-a26e-04d1395b94a3"
      unitRef="usd">1145000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6a386beebfbf4060bbe4c09d5f5884a1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNy01LTEtMS0xMDUwMzM_e4ef0f09-033a-4a96-b2a5-7002add7ff8e"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8b68bdf1a0ce449889193821c0c74169_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfNy03LTEtMS0xMDUwMzM_1da7f0e5-7c60-4697-aee8-3e76d5d7cddc"
      unitRef="usd">1145000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfOC0xLTEtMS0xMDUwMzM_e22ea9e3-9ddd-4e2b-ace8-9c1fae03d673"
      unitRef="usd">163812000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfOC0zLTEtMS0xMDUwMzM_a469c103-91cb-4656-b1f5-9953df418bae"
      unitRef="usd">5415000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfOC01LTEtMS0xMDUwMzM_ae089a3d-e36e-4397-96bc-1f88101fc269"
      unitRef="usd">4270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfOC03LTEtMS0xMDUwMzM_bab30f92-4541-49af-b0b6-47bf69737e45"
      unitRef="usd">173497000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTEtMS0xLTEtMTA1MDMz_d4f8e1b5-9d95-47ef-b986-6c140f2da0c1"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTEtMy0xLTEtMTA1MDMz_7cd86321-d3e5-43b0-8c9b-1ee9994e1533"
      unitRef="usd">1071000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTEtNS0xLTEtMTA1MDMz_205a3c43-fd71-4ab6-808b-32e9502edbab"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTEtNy0xLTEtMTA1MDMz_11b8beb3-8aa7-41dd-b106-798cae5f9da7"
      unitRef="usd">1071000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTItMS0xLTEtMTA1MDMz_98d49293-c7be-4e8c-be4e-854fefd80a24"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTItMy0xLTEtMTA1MDMz_6a0bef62-05c3-4c69-9e5b-a259daf63479"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTItNS0xLTEtMTA1MDMz_70401fe2-f7a9-403b-9087-200fc06535a9"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTItNy0xLTEtMTA1MDMz_56ab8bdf-3f7d-4062-b54b-7db893fdd7fb"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ib880959e27194e62aaeab4f273874a1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTMtMS0xLTEtMTA1MDMz_bacd1db4-d04f-403b-8082-196256e91d47"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i0244201d4c1c4fbfb84e00d823dd4ff5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTMtMy0xLTEtMTA1MDMz_1e1e349e-e39b-4027-93b8-394bcc9fd1b1"
      unitRef="usd">1071000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ieac8b4d7e0204b929ec17a7f6aa1d226_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTMtNS0xLTEtMTA1MDMz_673d6384-09dc-456e-be76-a59f054b777d"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RhYmxlOmY5ZWJmNDljN2ZjNTRhMTg5OGIwYjZlODhhNGE3M2FmL3RhYmxlcmFuZ2U6ZjllYmY0OWM3ZmM1NGExODk4YjBiNmU4OGE0YTczYWZfMTMtNy0xLTEtMTA1MDMz_345eb799-d6bc-42f8-9ea8-45e2cb4b3dc3"
      unitRef="usd">2071000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMzI_c9f145f1-c913-42f0-b50f-6a99636d1c13">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts, member relationships, subscriber relationships, and developed technology and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized using the accelerated method based on the discounted cash flow rate or using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTkwNzE_50b28314-57ad-4c83-bb40-48c64129b677"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTkwNzE_5d8d4970-f071-4f3c-8bf6-2ac7689f5aee"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTkwNzE_ba1f5924-adc0-4c93-9fa2-afb7ad68cbc9"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTkwNzE_f502ec42-7eb1-475b-8697-b4058ab0b694"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMzM_3c000f77-3d26-4e4e-882f-39d63ddff6cc">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTk4MDU_03aaf61d-a29c-48bd-b6a8-4b86d3965760"
      unitRef="unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjExNTU_0353c53b-9318-4546-bdca-b2ae01efb6b5"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjExNTU_1c435997-e41c-47fe-b525-c4ffb6de4ada"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjExNTU_5b9c7cd8-26e9-474d-9473-525e75763380"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjExNTU_a58644a2-18e7-4b0d-8fa3-4f908115fc81"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTc5OTU_fca633ba-9acf-4157-9867-27022f2811bd">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. There was no impairment loss recorded related to equity method investments for the years ended June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjIzMTM_2e33b91b-6128-40cd-b271-a12faec59bba"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjIzMTM_808ebd70-bbf7-4bf7-91b6-968ac764a36a"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:HealthCareCostsPolicyPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNzI_d8c4f4ce-e7f3-47fe-92f2-614154944816">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, APCMG, and Jade (the &#x201c;consolidated IPAs&#x201d;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. These consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;</us-gaap:HealthCareCostsPolicyPolicyTextBlock>
    <ameh:FiduciaryCashAndPayablePolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMTk_cb262b91-ef77-4d27-8ed4-11c547ff1429">Fiduciary Cash and PayableThe consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.</ameh:FiduciaryCashAndPayablePolicyTextBlock>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjQ2NjY_bec66807-63ea-4934-b9fe-3c897d1d75d3"
      unitRef="usd">6100000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjQ2NzM_6846c0b3-17d9-477c-b8c2-5d1ea60c5a08"
      unitRef="usd">10500000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNjY_be1edf3f-d717-4be3-8caf-4502d772a527">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 9 &#x2014; &#x201c;Credit Facility, Bank Loans, and Lines of Credit&#x201d; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and reflected in the accompanying consolidated statements of cash flows as unrealized gain or loss on interest rate swaps.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. As of June&#160;30, 2022, the fair value of the interest rate swap was $1.8 million and is presented within other assets in the accompanying consolidated balance sheets. As of December&#160;31, 2021, the fair value of the interest rate swap was $1.1&#160;million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2021, ApolloMed and Nutex entered into a stock purchase agreement in which ApolloMed purchased shares of common stock and warrants for $3.0&#160;million. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. In May 2022, the Company exercised the warrants and the shares were subsequently presented within investments in marketable securities on the accompanying consolidated balance sheets. The shares are classified as Level 1 since the quoted market prices from reputable third-party brokers are available in an active market and unadjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Contingent Equity Securities&lt;/span&gt;&lt;/div&gt;In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Nutex, ApolloMed is entitled to additional common stock if Nutex does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered to be derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income and the accompanying consolidated statements of cash flows. The Company determined the fair value of the contingent equity security using a probability-weighted model, which includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i55dadf9db838467e8bd65105322d821f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjU5NjU_8a324ba3-2a9a-43e5-8a8b-9bbd3882bb1e"
      unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i83ea699729524e1aab10b333d7661bd6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjYxMDk_c65a0279-2482-44fd-bd0c-5da2cb2964b8"
      unitRef="usd">1100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <ameh:PaymentsToAcquireCommonStockAndWarrants
      contextRef="i9094212bb5af45d98da492230880c142_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjYzNzg_fe5e652a-02b2-40a7-98cc-cf66d11d700b"
      unitRef="usd">3000000</ameh:PaymentsToAcquireCommonStockAndWarrants>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i40b21462ffcb4d248cd6645a35f7a449_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMjgwODc_7c687d0e-962a-4d82-a362-3d0cdac01e46"
      unitRef="usd">3200000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i934b31b2b19e4a32b408f256d19446bf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfMTY0OTI2NzUwMDE3MA_7046b6bd-dc56-4e72-aca3-f1e3aa1eb7a9"
      unitRef="usd">4300000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNzM_e9287482-392f-44af-8189-6aeb2ecd6d52">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, GPDC revenue, management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GPDC Capitation Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS contracts with Direct Contracting Entities (&#x201c;DCEs&#x201d;), which is composed of healthcare providers operating under a common legal structure and accepts financial accountability for the overall quality and cost of medical care furnished to Medicare FFS beneficiaries aligned to the entity. The combination of the FFS model and the GPDC model changes the distribution of responsibilities, risks, costs, and rewards among CMS, DCEs, and providers. By entering into a contract with CMS, a DCE voluntarily takes on operational, financial, and legal responsibilities and risks that no party has, individually or collectively, under the existing FFS model. Each DCE bears the economic costs, and reaps the economic rewards, of fulfilling its responsibilities and managing its risks as a DCE. APAACO has applied, and been accepted, to participate in the GPDC Model for Performance Year 2022, beginning January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS will pay a total benchmark amount, determined unilaterally by CMS in advance but subject to prospective adjustments throughout the year, for the totality of care provided to the DCE&#x2019;s population of aligned beneficiaries over the course of that year. The benchmark is net of a quality withholding applied by CMS. At the end of each performance year, a portion, or all, of the quality withholding can be earned based on APAACO&#x2019;s performance. GPDC capitation revenue is recognized based on the estimated transaction price to transfer the service for a distinct increment of the series (i.e., month) and is recognized net of quality incentives/penalties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging, and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospital&#x2019;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage direct care and pay providers based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided, and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims, are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#x201c;Participation Agreement&#x201d;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. With the ending of the NGACO Model on December 31, 2021, the Company no longer receives AIPBPs but remains eligible to recognize any shared savings or loss for performance year 2021 upon issuance of the settlement report from CMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system, and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="ib11bf9964618458792c11fd0405c0f72_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNDU_b3fafccf-c1ef-4cc3-a975-8dff7a82ae68">one year</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i5c9d9247680949b3a7da52ee73653a69_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNDA4MzY_e2f076b9-06b4-43bb-b117-d2bbe43b2932">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i5c9d9247680949b3a7da52ee73653a69_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNDEwOTY_0b204c1c-86b3-4fba-8fe0-3a40c7c06c57">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i5c9d9247680949b3a7da52ee73653a69_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNDEyMTk_0b204c1c-86b3-4fba-8fe0-3a40c7c06c57">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i8fb94590e3da4131815186c8ad836fbd_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMTc_f2f5cc6b-3cc1-4210-abde-1b48ac5c55ee">10 years</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTEwNjg_a8c885c7-d88a-4d95-9d62-37804863b555"
      unitRef="usd">20000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTEwNzU_0d9451e8-3868-44c8-9b43-4620d31d0a7e"
      unitRef="usd">16800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i6d3d4f8cd081436bbfc05d32afdfc31b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTEyNTE_53065c38-0f99-48d7-b569-1ccf74e744b8"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNDY_5c626053-ed37-4f31-89ef-062ad909f9a5">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNjc_0d256694-7073-47fd-af73-028da7773290">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#x2019;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMzk_4a341be9-bb22-4f56-9f20-5ed0c2856f8b">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 15 &#x2014; &#x201c;Earnings Per Share&#x201d; for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <ameh:MinorityInterestPolicyPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwMTA_5f12535d-3efa-43fd-bc3a-4b1e4e407e8f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</ameh:MinorityInterestPolicyPolicyTextBlock>
    <ameh:TemporaryEquityPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNjU_ad664243-b5eb-44f1-ac57-cdd16f4f78b6">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2022 and December&#160;31, 2021, APC&#x2019;s shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;</ameh:TemporaryEquityPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNTQ_af880e7f-a352-4c02-b3fc-33261ce8e2c9">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12-month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY180Ni9mcmFnOjJjMmMyMWJiOTNjNTQyODY4Mjc1OGVjMDk1MzlkMjk5L3RleHRyZWdpb246MmMyYzIxYmI5M2M1NDI4NjgyNzU4ZWMwOTUzOWQyOTlfNTgwNDA_83db02e4-b934-4eb5-9d4f-5762a1931144">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2021, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;)  No. 2021-08, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2021-08&#x201d;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company adopted ASU 2021-08 on January 1, 2022. The adoption of ASU 2021-08 did not have a material impact on the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;With the exception of the new standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfNDYxMQ_458a700c-9acc-4163-bad3-1c9b6ca4ec20">Business Combinations and GoodwillJade Health Care Medical Group, Inc. &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 19, 2022, the Company acquired 100% of the capital stock of Jade Health Care Medical Group, Inc. (&#x201c;Jade&#x201d;). The purchase was paid in cash. Jade is a primary and specialty care physicians&#x2019; group focused on providing high-quality care to its patients in the San Francisco Bay Area in Northern California. The Company is in the process of finalizing it&#x2019;s purchase price allocation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Orma Health, Inc., and Provider Growth Solutions LLC (together, &#x201c;Orma Health&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 27, 2022, the Company acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#x201c;Orma Health&#x201d;). The purchase was paid in cash and in the Company&#x2019;s capital stock. Orma Health&#x2019;s real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring (&#x201c;RPM&#x201d;), mental health support, chronic disease management, and more. Its clinical platform is also deeply integrated with Orma Health&#x2019;s proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to manage patient health.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;APCMG&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG. As part of the transaction, the Company may pay APCMG additional consideration contingent on APCMG&#x2019;s financial performance for fiscal year 2022 (&#x201c;APCMG contingent consideration&#x201d;). The APCMG contingent consideration will be met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (&#x201c;EBITDA&#x201d;) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of June&#160;30, 2022, the contingent consideration is valued at $1.0 million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sun Labs&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;DMG&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#x2019;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by Apollo.  In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations from the acquisitions have been included in the Company&#x2019;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i5b9aa026e81e4b4980bee034ca869c69_I20220419"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTY0OTI2NzQ0NzY4OQ_1c188854-ba80-4d9c-af3a-ddc342f1737c"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ibaa3b499908f486889ee0e616dda90c0_I20220127"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTY3_24023498-8edf-4f7b-b9fa-be2f0ec0d2ff"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="iaa25ff896fef4a548c62b034ce2acbd1_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfODU5_41ec9a05-adc8-4c31-8d74-00ad8cc304bb"
      unitRef="number">0.80</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iebfe001bbfd543a79e230f9c3c472476_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTc1MQ_d86331df-df6c-4bba-aeff-d808f61ace12"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i2fb19f36b5434e40bf55b16ef65f34a6_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTkwNQ_44be5d67-1b06-4068-b021-192a4b50c2d8"
      unitRef="number">0.49</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="i156059eff9374f1087488e472de06542_D20210801-20210831"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfMTY0OTI2NzQ0OTUxNg_099b0abd-208a-4208-8e7b-f6db3c2e6ee6">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="i7c6e0a57fc72447ea515eb651ec8f63e_D20210801-20210831"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfNTQ5NzU1ODE0Njc2MQ_2d4d4cb9-3f61-4d4c-aff0-c53c63521cff">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RleHRyZWdpb246M2Y1NTQxM2E0NTIzNGQ3NDlkZTdjY2I1NjIzNWM5Y2VfNDYxMg_d8ca6e82-7d3c-46fc-990b-bd3f5e7201ea">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the six months ended June&#160;30, 2022 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RhYmxlOjFkYTg3ZjhiMzBlZDRlM2FiOGIxMTMyODE5ZjU0MDQyL3RhYmxlcmFuZ2U6MWRhODdmOGIzMGVkNGUzYWI4YjExMzI4MTlmNTQwNDJfMC0xLTEtMS0xMDUwMzM_4c5c56b0-07f4-4a39-835c-1ac09889d1fd"
      unitRef="usd">253039000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RhYmxlOjFkYTg3ZjhiMzBlZDRlM2FiOGIxMTMyODE5ZjU0MDQyL3RhYmxlcmFuZ2U6MWRhODdmOGIzMGVkNGUzYWI4YjExMzI4MTlmNTQwNDJfMS0xLTEtMS0xMDUwMzM_f7106750-e128-443d-855a-74cdb3823d7c"
      unitRef="usd">2881000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RhYmxlOjFkYTg3ZjhiMzBlZDRlM2FiOGIxMTMyODE5ZjU0MDQyL3RhYmxlcmFuZ2U6MWRhODdmOGIzMGVkNGUzYWI4YjExMzI4MTlmNTQwNDJfMi0xLTEtMS0xMDUwMzM_d292faa1-97cf-4668-9636-ba2454b6c8a6"
      unitRef="usd">-2610000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY181OC9mcmFnOjNmNTU0MTNhNDUyMzRkNzQ5ZGU3Y2NiNTYyMzVjOWNlL3RhYmxlOjFkYTg3ZjhiMzBlZDRlM2FiOGIxMTMyODE5ZjU0MDQyL3RhYmxlcmFuZ2U6MWRhODdmOGIzMGVkNGUzYWI4YjExMzI4MTlmNTQwNDJfMy0xLTEtMS0xMDUwMzM_e6a0a2bb-cf87-455a-8a4c-f890e11a5283"
      unitRef="usd">253310000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfNDk5_e24f9d40-39a5-42dd-934b-46af60a27673">Intangible Assets, Net&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2022, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subscriber relationships &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed technology &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $3.5 million and $3.7 million for the three months ended June&#160;30, 2022 and 2021, respectively, and $7.2 million and $7.5 million for the six months ended June&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the six months ended June 30, 2022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfNDk1_8bb75bf9-a135-417e-aad5-c78f10dfbc74">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2022, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-21&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subscriber relationships &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed technology &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i7afe0c314bdd4919be94c4d4216e8769_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMi0zLTEtMS0xMDUwMzM_c2666b40-1e1d-4594-9987-d90830994aaa"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i7afe0c314bdd4919be94c4d4216e8769_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMi03LTEtMS0xMDUwMzM_045967d6-7c4e-4c6e-b0ab-82a3ca6202cc"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i262bc0262fcd480086498ee92acb8f62_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjo5NTc2YzNmNGI3ZjE0NWQ2YjUyMTZiMDlmN2NiYzMyMF80_65847002-e751-427f-aa05-31c419439208">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8083c97bad35410980739e54dd0c355c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjo5NTc2YzNmNGI3ZjE0NWQ2YjUyMTZiMDlmN2NiYzMyMF83_184833ee-2225-42ed-a3ff-1981de0b0d34">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2afdae606f3c4b4ca48b6404b58bf723_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC0zLTEtMS0xMDUwMzM_5e1d483c-26ee-4851-b64e-6eae93518e1c"
      unitRef="usd">150679000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2afdae606f3c4b4ca48b6404b58bf723_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC01LTEtMS0xMDUwMzM_00d3c981-3028-4317-8df3-088077d7f211"
      unitRef="usd">90285000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2afdae606f3c4b4ca48b6404b58bf723_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNC03LTEtMS0xMDUwMzM_bc4cce9f-e02c-48cf-a965-72e0fcfaadb4"
      unitRef="usd">60394000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i73b45a52891f4ab8bf993b978064f4ce_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNS0xLTEtMS0xMDUwMzM_55b390f9-998a-4ff1-bc47-445c40bf66f0">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id92ca545c5d242b29c14e8abfbafa3e4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNS0zLTEtMS0xMDUwMzM_87d340c7-d76b-4d7e-8ccf-d01c69ccd59a"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id92ca545c5d242b29c14e8abfbafa3e4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNS01LTEtMS0xMDUwMzM_d900cb23-85d9-412f-8a03-60ee838fc43e"
      unitRef="usd">14433000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id92ca545c5d242b29c14e8abfbafa3e4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNS03LTEtMS0xMDUwMzM_793a4327-42b1-4df7-8a42-74ceff135a5c"
      unitRef="usd">8399000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icb520c05360c4639917455a159462d8a_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNi0xLTEtMS0xMDUwMzM_d168c600-1fe3-420c-9d67-0fc05276c76b">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8db7ef9235b34c04b4683c753d0c0add_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNi0zLTEtMS0xMDUwMzM_280bc938-a173-4b46-b323-1180f61f9cec"
      unitRef="usd">8997000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8db7ef9235b34c04b4683c753d0c0add_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNi01LTEtMS0xMDUwMzM_658fb3ec-5d15-44d1-84ad-90783396f088"
      unitRef="usd">5190000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8db7ef9235b34c04b4683c753d0c0add_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNi03LTEtMS0xMDUwMzM_3ec2cbc8-067a-424e-a624-5b24c43f0f3c"
      unitRef="usd">3807000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i823f7c34a37842bc853d7a95f895358c_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNy0xLTEtMS0xMDUwMzM_95bb6e1c-4f30-4e8a-a583-7c988ef0cd92">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6ff8b2ce2fa64fbd861752a596120f74_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNy0zLTEtMS0xMDUwMzM_e4880bb9-1a18-449b-9d47-f4bcccbc821a"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6ff8b2ce2fa64fbd861752a596120f74_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNy01LTEtMS0xMDUwMzM_12fc4109-8898-4dea-91df-819c51155424"
      unitRef="usd">1871000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6ff8b2ce2fa64fbd861752a596120f74_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfNy03LTEtMS0xMDUwMzM_1b7de471-e2c8-42bc-ac5f-424ee8ef935d"
      unitRef="usd">189000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib4c456a4d4324d7da4299e68e3469d32_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOC0xLTEtMS0xMDUwMzM_21996853-2943-496e-a15c-cbeae76b974f">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id77f5a844c054b76ab43bfd594454e29_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOC0zLTEtMS0xMDUwMzM_708f4773-1205-4aa9-8716-a08a8b53b3cc"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id77f5a844c054b76ab43bfd594454e29_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOC01LTEtMS0xMDUwMzM_0f057530-9601-46ca-b1c1-25d011644505"
      unitRef="usd">232000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id77f5a844c054b76ab43bfd594454e29_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOC03LTEtMS0xMDUwMzM_b0572c72-39c2-4042-aac2-381356ccda3b"
      unitRef="usd">779000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib6b39a8c15b94db1bef62c56c6cdfa11_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOS0xLTEtMS0xMDUwMzM_9ae343b4-d09f-4acd-882c-f902697344e9">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i342650b110d948c68305b913d3337797_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOS0zLTEtMS0xMDUwMzM_c4e72343-9042-4fce-ba4b-07d93528c735"
      unitRef="usd">235000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i342650b110d948c68305b913d3337797_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOS01LTEtMS0xMDUwMzM_0e276f51-129a-474f-ad20-ee2f33bdfd69"
      unitRef="usd">20000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i342650b110d948c68305b913d3337797_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfOS03LTEtMS0xMDUwMzM_e9de3501-e966-45e6-bd25-01d029d43b27"
      unitRef="usd">215000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idad1fcac77ba4ee7876fddfc937c8526_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTAtMS0xLTEtMTA1MDMz_4138379e-9193-4b92-882a-d2d1c702811f">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i22617db5966243a29e90deea438fe6e4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTAtMy0xLTEtMTA1MDMz_9b07b725-07b4-425f-8066-2b81ac4534df"
      unitRef="usd">772000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i22617db5966243a29e90deea438fe6e4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTAtNS0xLTEtMTA1MDMz_fa2c63f9-7dd9-4552-b3e2-ac7086986766"
      unitRef="usd">54000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i22617db5966243a29e90deea438fe6e4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTAtNy0xLTEtMTA1MDMz_5ef2eca7-ede3-4d74-9bdf-e270d99d462e"
      unitRef="usd">718000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTEtMy0xLTEtMTA1MDMz_2ea0f468-b071-4960-afbe-29b5e8677cfb"
      unitRef="usd">188736000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTEtNS0xLTEtMTA1MDMz_cb12ba35-2e12-4827-8bc5-5e0987eb2ebb"
      unitRef="usd">112085000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmMyN2U1NzAzNzNhMjRjYWU5OGVlNmZhMzM2YTgyMWU3L3RhYmxlcmFuZ2U6YzI3ZTU3MDM3M2EyNGNhZTk4ZWU2ZmEzMzZhODIxZTdfMTEtNy0xLTEtMTA1MDMz_13eb9d90-1006-44a3-b341-e4e952b6266e"
      unitRef="usd">76651000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i26c3aca5f37e4c7bbce9e471da9b2690_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfMi0zLTEtMS0xMDUwMzM_42d949ca-62fd-40ee-902a-9b81030bcf08"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i26c3aca5f37e4c7bbce9e471da9b2690_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfMi03LTEtMS0xMDUwMzM_f035acc2-9e8e-4e65-b986-9d96810c8aed"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i70a8b50fadb34ecbbeb48a0a4e675fb8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjozN2IxM2E3NTI0OGM0Yzk2Yjk1ZmYwMTQ1OGI5ODY0NV80_18332ab9-be38-46d6-bab6-9f5b1ccd13fe">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id386caca65614b57ae15aeb43ddc272e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjozN2IxM2E3NTI0OGM0Yzk2Yjk1ZmYwMTQ1OGI5ODY0NV83_e6d616b9-e04f-4909-9b10-7e7514bdd0fd">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i11c5b1b731c04326a701c1dbf4c69a1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC0zLTEtMS0xMDUwMzM_9d2aecdb-471a-4560-89e1-75f6908929b2"
      unitRef="usd">150679000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i11c5b1b731c04326a701c1dbf4c69a1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC01LTEtMS0xMDUwMzM_0bcbde8d-048b-4571-9673-1d9eaa73a9b2"
      unitRef="usd">84865000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i11c5b1b731c04326a701c1dbf4c69a1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNC03LTEtMS0xMDUwMzM_7f30ad50-694a-425e-bca8-1d2243812a8b"
      unitRef="usd">65814000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5b382a0954bd416284c02bcaa5a318da_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNS0xLTEtMS0xMDUwMzM_e40482ba-69de-4610-b394-65b04e29dd06">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5c47fd9f6a0a4bb2a1714812fdf72b1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNS0zLTEtMS0xMDUwMzM_d378356a-f538-4ac0-bbe3-7c06b79e464f"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5c47fd9f6a0a4bb2a1714812fdf72b1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNS01LTEtMS0xMDUwMzM_44b220ca-017e-4f11-8bda-5057eb097817"
      unitRef="usd">13563000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5c47fd9f6a0a4bb2a1714812fdf72b1e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNS03LTEtMS0xMDUwMzM_fe0bd11b-0ae2-4968-8c6d-d78d7ec5d58d"
      unitRef="usd">9269000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i47aaf649d7d949a184692e09d23490b1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNi0xLTEtMS0xMDUwMzM_e269ea61-887f-46e2-9c3f-80930f7bf57c">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4d39193fee394abbb9705dc0a37fb365_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNi0zLTEtMS0xMDUwMzM_76366626-29f0-423c-8002-8012fefe9303"
      unitRef="usd">8997000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4d39193fee394abbb9705dc0a37fb365_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNi01LTEtMS0xMDUwMzM_5e2d0fb7-1097-4f65-9b4b-1aabf41eca02"
      unitRef="usd">4606000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4d39193fee394abbb9705dc0a37fb365_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNi03LTEtMS0xMDUwMzM_f5d7306a-929b-4a8c-bb33-c6cb38c7b58b"
      unitRef="usd">4391000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6ccff1d9ca534ab0b567fd1dc05bd91a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNy0xLTEtMS0xMDUwMzM_448c89b7-39cf-435d-9fc9-0914fa3943e5">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0ecea1ee1cca4bd5b0f7613a433ccb86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNy0zLTEtMS0xMDUwMzM_c4252926-28d8-4cb0-87e4-67798bdc303d"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0ecea1ee1cca4bd5b0f7613a433ccb86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNy01LTEtMS0xMDUwMzM_e5a46a78-c936-44cb-b80e-c569c7cc8950"
      unitRef="usd">1682000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0ecea1ee1cca4bd5b0f7613a433ccb86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfNy03LTEtMS0xMDUwMzM_6ee69359-4c41-412e-80a0-56e24ce65448"
      unitRef="usd">378000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icfde020db2314ef08cf9d768e4c6d60f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOC0xLTEtMS0xMDUwMzM_f4a05083-cd68-4234-b54c-b9e8e815d694">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i87d17a700c65498dbbc648590a1e5c5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOC0zLTEtMS0xMDUwMzM_b32503bb-cde5-4429-b749-914618d9bd44"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i87d17a700c65498dbbc648590a1e5c5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOC01LTEtMS0xMDUwMzM_faea54d5-8fc7-4dae-8ab8-bbe332c90695"
      unitRef="usd">206000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i87d17a700c65498dbbc648590a1e5c5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOC03LTEtMS0xMDUwMzM_5f551f5a-f3fd-4fb0-9537-ce77950d4d36"
      unitRef="usd">805000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOS0zLTEtMS0xMDUwMzM_aafd4928-1006-4d40-8f6f-c6e5550c26ba"
      unitRef="usd">187729000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOS01LTEtMS0xMDUwMzM_a927c9e3-e6e4-4873-80e6-fb2950e4e056"
      unitRef="usd">104922000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOjQ0ZjBlNGYzODkxMzQyNDNiYTE3MDBhMzY1YjRmODY0L3RhYmxlcmFuZ2U6NDRmMGU0ZjM4OTEzNDI0M2JhMTcwMGEzNjViNGY4NjRfOS03LTEtMS0xMDUwMzM_fd141a3a-2dc0-4cba-b853-e913a70bcc39"
      unitRef="usd">82807000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfMjc0ODc3OTA3MDc1Mg_4ae0a6ba-3e88-4dbe-89e2-94d0e671d5b5"
      unitRef="usd">3500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfMjc0ODc3OTA3MDc2MA_665e73e7-7167-45b7-aa43-5decf02da0eb"
      unitRef="usd">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfMjc0ODc3OTA3MDgyMA_2b7572d2-febb-44c2-93c9-59dc4cd8d9d0"
      unitRef="usd">7200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfMjc0ODc3OTA3MDgyOA_763f2ad7-82d0-4bce-8e98-741fcc56a9da"
      unitRef="usd">7500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RleHRyZWdpb246ZmY3ODY3MDM5ZGNjNDgzNGI3ODU0M2YzMjVhNTMxMWFfNDk2_d245cadb-8e68-4e0c-8541-c388a58643a7">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the six months ended June 30, 2022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfMi0xLTEtMS0xMDUwMzM_778d7987-f415-409b-9112-0238540f3dcf"
      unitRef="usd">6671000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfMy0xLTEtMS0xMDUwMzM_930d8daa-89d0-477c-abe2-b0c1c04d287f"
      unitRef="usd">11804000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfNC0xLTEtMS0xMDUwMzM_86958578-1517-4984-a5d6-6f37ee10d707"
      unitRef="usd">10735000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfNS0xLTEtMS0xMDUwMzM_62ee4552-290c-4b64-b184-766ce5f1f905"
      unitRef="usd">9558000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfNi0xLTEtMS0xMDUwMzM_74e2eb5e-f532-49cd-8693-d81453e8d02f"
      unitRef="usd">8505000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfNy0xLTEtMS0xMDUwMzM_c35b3595-2ace-47d7-8f14-d90d2a82803e"
      unitRef="usd">27228000</ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182MS9mcmFnOmZmNzg2NzAzOWRjYzQ4MzRiNzg1NDNmMzI1YTUzMTFhL3RhYmxlOmZjYTA0MjA0N2VhZTRiODU4NzBhZTI0ZTgwM2JmN2VmL3RhYmxlcmFuZ2U6ZmNhMDQyMDQ3ZWFlNGI4NTg3MGFlMjRlODAzYmY3ZWZfOS0xLTEtMS0xMDUwMzM_db1bd33e-5454-4fce-a777-b638cb98bfce"
      unitRef="usd">74501000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ameh:EquityMethodAndOtherEquityInvestmentsTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI3Ng_294c644e-f0ae-430a-b821-3759537f6e45">Investments in Other Entities&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in other entities &#x2013; equity method consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funding reclassified to loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One MSO, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4 million, which resulted in  APC-LSMA owning a 25% interest in LMA as of June&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#x2019;s operations. For the three months ended June&#160;30, 2022 and 2021, APC recognized income from this investment of $1.3 million and a loss of $3.6 million, respectively, in the accompanying consolidated statements of income.  For the six months ended June&#160;30, 2022 and June&#160;30, 2021, APC recognized income from this investment of $2.5 million and a loss of $4.3 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $3.4 million and $3.0 million at June&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at June&#160;30, 2022 and December&#160;31, 2021, and summarized statements of income for the six months ended June&#160;30, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Pacific Medical Imaging and Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA purchased a 40% ownership interest in PMIOC. Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography, at its facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#x2019;s operations. For the three months ended June&#160;30, 2022 and 2021, APC recognized income from this investment of approximately $15,000 and a loss from this investment of $16,000, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recognized income of approximately $22,000 and a loss from this investment of $30,000, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets had investment balances of $1.7 million and $1.7 million at June&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;531 W. College LLC &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC has a 50% ownership in 531 W. College LLC and accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. 531 W. College, LLC owns a former hospital campus in Los Angeles that is now leased to tenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June&#160;30, 2022 and 2021, APC recognized a loss from this investment of $0.1 million and $9,000, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recorded a loss from this investment of $0.3 million and $0.1 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $17.2 million and $17.2 million at June&#160;30, 2022 and December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;One MSO, LLC &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC has a 50% interest in One MSO. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. For the three months ended June&#160;30, 2022 and 2021, APC recognized income of $0.1 million and $0.1&#160;million, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recognized income of $0.3&#160;million and $0.2 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.8 million and $2.9&#160;million at June&#160;30, 2022 and December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tag-6 Medical Investment Group, LLC  &#x2014; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC has a 50% interest in Tag 6. Tag 6 leases its building to tenants and shares common ownership with certain board members of APC and as such is considered a related party. For the three months ended June&#160;30, 2022 and 2021, APC recognized income of $45,000 and $0.2 million, respectively,  in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022 and 2021, APC recognized income of $0.1 million and $0.2 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the Tag 6 investment of $6.4 million and $4.8&#160;million at June&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, ApolloMed purchased 30% interests in CAIPA MSO, LLC for $11.7 million. CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d/b/a Coalition of Asian-American IPA (&#x201c;CAIPA&#x201d;), a leading independent practice association serving the greater New York City area. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#x2019;s operations. For the three months ended June&#160;30, 2022, ApolloMed recognized income from investment of $0.2 million in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2022, ApolloMed recognized income of $0.3&#160;million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $12.3 million and $12.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in privately held entities that do not report net asset value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MediPortal, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AchievaMed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, NMM and AchievaMed, Inc., a California corporation (&#x201c;AchievaMed&#x201d;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in investments in privately held entities in the accompanying consolidated balance sheets as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</ameh:EquityMethodAndOtherEquityInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI3NA_689e5248-c121-468e-993b-51dc67784cc5">&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in other entities &#x2013; equity method consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funding reclassified to loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Distribution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One MSO, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at June&#160;30, 2022 and December&#160;31, 2021, and summarized statements of income for the six months ended June&#160;30, 2022 and 2021, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i2b2bbf4c0d7e4582a1a0fef1a71f7b4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS0xLTEtMS0xMDUwMzM_d64e9af9-e9ba-45b3-a10b-862f8f0829e4"
      unitRef="usd">3034000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia90be308939140e9a4a7cb933f276390_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS01LTEtMS0xMDUwMzM_69fa1961-c0dd-4ce7-ad7d-0e7918acda09"
      unitRef="usd">2535000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentReclassification
      contextRef="ia90be308939140e9a4a7cb933f276390_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS03LTEtMS0xMTcxNTQ_dca280e3-7012-431d-9745-15b62650aaaf"
      unitRef="usd">2125000</ameh:EquityMethodInvestmentReclassification>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ia90be308939140e9a4a7cb933f276390_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS03LTEtMS0xMDUwMzM_3c64db70-ba49-4140-8670-55df277c115c"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ia90be308939140e9a4a7cb933f276390_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS0xMS0xLTEtMTA1MDMz_2ae5d97a-08a0-4c21-85da-72de2d9d0e34"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i6903a2d9d4664df8a794cb162687a0c1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMS0xMy0xLTEtMTA1MDMz_fe8f13c9-03fe-45c4-8b46-29eec24fdac1"
      unitRef="usd">3444000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2206b47d6e7b424d9b62ab32b0338026_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi0xLTEtMS0xMDUwMzM_bc254318-5c60-4cc6-82cf-89f5bf7dfb8e"
      unitRef="usd">1719000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9cad2048a753446186dfdb8373edee28_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi01LTEtMS0xMDUwMzM_1fd8be75-4f9f-41c7-ace7-932f26cac96f"
      unitRef="usd">22000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentReclassification
      contextRef="i9cad2048a753446186dfdb8373edee28_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi03LTEtMS0xMTcxNjE_3154dcc8-58e4-4f3c-b395-275be27addb7"
      unitRef="usd">0</ameh:EquityMethodInvestmentReclassification>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i9cad2048a753446186dfdb8373edee28_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi03LTEtMS0xMDUwMzM_6dda1713-0327-4fbc-bcaf-e3b7dcf15ff5"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i9cad2048a753446186dfdb8373edee28_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi0xMS0xLTEtMTA1MDMz_25ee7a2a-99b6-40d1-9f23-e57d547ae576"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="ide0127b82d0c494786e6a5b4bd61c173_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMi0xMy0xLTEtMTA1MDMz_caf2d9f3-34fa-4fda-a3a2-64994d790558"
      unitRef="usd">1741000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0e0edd220c6943ef81f9294e13541194_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy0xLTEtMS0xMDUwMzM_f20d1496-be46-4f6f-b7b4-831a6cd11511"
      unitRef="usd">17230000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy01LTEtMS0xMDUwMzM_3aa9a374-48e2-43f5-9fd9-2b1c66cd8151"
      unitRef="usd">-305000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentReclassification
      contextRef="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy03LTEtMS0xMTcxNzA_86a6556b-478b-4409-9dad-4b471a6c69fe"
      unitRef="usd">0</ameh:EquityMethodInvestmentReclassification>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy03LTEtMS0xMDUwMzM_a4237e32-3776-4e73-9abb-b0f2d0f6f338"
      unitRef="usd">250000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i1e509c1e1c4d41bba2a54cbfa0dd9414_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy0xMS0xLTEtMTA1MDMz_e09b7263-f7e3-425c-a464-c3ddb18faa4d"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="if7cf8eaa6bf64eeab771048f5de4564f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfMy0xMy0xLTEtMTA1MDMz_956ea63c-7cea-4702-9276-3cfc2851e44e"
      unitRef="usd">17175000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ifff5051e4aad447bb1d4f5b0b052cdff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC0xLTEtMS0xMDUwMzM_bd79c665-df41-4662-840b-cd3376b44da3"
      unitRef="usd">2910000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC01LTEtMS0xMDUwMzM_2ab860f2-38b1-49ab-a32c-3275047ce951"
      unitRef="usd">254000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentReclassification
      contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC03LTEtMS0xMTcxNzA_eee2478a-ef99-4210-8ba5-d739269fcc10"
      unitRef="usd">0</ameh:EquityMethodInvestmentReclassification>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC03LTEtMS0xMDUwMzM_1a42e379-8b37-48ee-982b-9fc5fe380ad3"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC0xMS0xLTEtMTA1MDMz_3ad91b0a-bc27-4576-850f-cc929993bae8"
      unitRef="usd">400000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i77a601ca89014f5eacda8b352cd397cf_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNC0xMy0xLTEtMTA1MDMz_ba50cbff-de41-4d6c-b956-72187a4c76d0"
      unitRef="usd">2764000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iadd8800c72bb483c99ceb9c97149a818_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS0xLTEtMS0xMDUwMzM_6388554c-7d6e-459d-a49d-e7b24cac0745"
      unitRef="usd">4830000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS01LTEtMS0xMDUwMzM_60ebf233-f6d6-4155-b74a-97a316ecd50f"
      unitRef="usd">111000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentReclassification
      contextRef="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS03LTEtMS0xMTcxNzA_1d048115-a044-415f-9004-39eb1955f5c7"
      unitRef="usd">0</ameh:EquityMethodInvestmentReclassification>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS03LTEtMS0xMDUwMzM_a97b0faa-77ef-421c-8448-b5a8d2503ac9"
      unitRef="usd">1435000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ied095bce5f3d4385b58fee34b2e0b928_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS0xMS0xLTEtMTA1MDMz_5e58ece0-a16c-4a69-8738-ff978acbc586"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="ie80aa85c869b4960834df7f5663464ac_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNS0xMy0xLTEtMTA1MDMz_fcf2d70d-477f-430c-997d-1175fed746cd"
      unitRef="usd">6376000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie6dd79fb668d4396a088c5c7da4ad9bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi0xLTEtMS0xMDUwMzM_0b24ed5f-8f0c-4dd5-b8c2-523651887565"
      unitRef="usd">11992000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi01LTEtMS0xMDUwMzM_d00a936b-cbac-4891-a64f-38db9d996303"
      unitRef="usd">328000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentReclassification
      contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi03LTEtMS0xMTcxNzc_98f821f9-89b2-4b1d-a338-3c788f5c4568"
      unitRef="usd">0</ameh:EquityMethodInvestmentReclassification>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi03LTEtMS0xMDUwMzM_1e95e065-6521-4b37-90e2-d160b2bd8394"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi0xMS0xLTEtMTA1MDMz_dcdf17fc-d163-432b-9084-4b31a9b60900"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i1e059681a7204193b3ca300c44829e19_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNi0xMy0xLTEtMTA1MDMz_06265a15-b669-41be-a40e-40b8101d165b"
      unitRef="usd">12320000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy0xLTEtMS0xMDUwMzM_24f8c901-aa43-47bf-b9bb-d7248af6aa8a"
      unitRef="usd">41715000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy01LTEtMS0xMDUwMzM_09b09abd-cdde-49c2-a2cb-d4b206921bea"
      unitRef="usd">2945000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentReclassification
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy03LTEtMS0xMTcyODM_42e08326-7d27-4f0a-abdf-db225b928c2d"
      unitRef="usd">2125000</ameh:EquityMethodInvestmentReclassification>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy03LTEtMS0xMDUwMzM_12bb54dc-5628-48d4-8141-b505d05f040a"
      unitRef="usd">1685000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy0xMS0xLTEtMTA1MDMz_6d1d1ca7-7eec-45bd-a4ff-e9ff2c0804f2"
      unitRef="usd">400000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjFiOTIyNzE2MDRmNzQyZjVhODgwNjMyZmIyODM1YmM2L3RhYmxlcmFuZ2U6MWI5MjI3MTYwNGY3NDJmNWE4ODA2MzJmYjI4MzViYzZfNy0xMy0xLTEtMTA1MDMz_88ae4733-b21e-4492-b09c-791839e85fd5"
      unitRef="usd">43820000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentOwnershipPercentageSold
      contextRef="ifcfcf46929264addbb83d541b8cf9a81_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzI2_311a3024-906d-435f-8ad1-df4b244e5c61"
      unitRef="number">0.2125</ameh:EquityMethodInvestmentOwnershipPercentageSold>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ie11fbddce8b34653bf1c488090c280ed_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzc2_395a83aa-4ba6-4787-969a-8aed130b19ea"
      unitRef="usd">6400000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie5a62c94039149c4add47ae7f2b1df0a_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDE3_7f0c57a1-c6df-4ea1-b095-74dfff9ef180"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6ac857e621104221a59862c04c79506c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjg4_eb89d457-369f-47d8-8e52-f80101ee7314"
      unitRef="usd">1300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i788d07c210dd4f958d756e23167c1e15_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNzA1_f4a942db-1fe9-4485-afb5-08c2e3ab42d8"
      unitRef="usd">-3600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i61e73f5506934b76adfdd854acffd935_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NTgxMA_a4636edc-21e9-4e92-9a2c-0edd43fce4bd"
      unitRef="usd">2500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia30f4a1733a0428ea9411e847f714b94_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NTgyOA_b515a00c-15f2-4a23-b8c4-2e9fb666f5b3"
      unitRef="usd">-4300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i6903a2d9d4664df8a794cb162687a0c1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfODY2_a6f261e2-9d15-4e3d-9006-0e1580b28aba"
      unitRef="usd">3400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2b2bbf4c0d7e4582a1a0fef1a71f7b4e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfODcz_ebe2733d-a75d-4e36-857d-9d216f86e5b5"
      unitRef="usd">3000000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMy0xLTEtMS0xMDUwMzM_3a393a36-9670-4df1-a39d-a17cd9ad9ce1"
      unitRef="usd">16250000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i456a03746030449991737ef8d57a4456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMy0zLTEtMS0xMDUwMzM_80fb3027-0156-4cc3-91fd-78ab4b44a090"
      unitRef="usd">6619000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNC0xLTEtMS0xMDUwMzM_b86fe391-e6e1-4c1a-8e4e-8a1cc6245f66"
      unitRef="usd">698000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i456a03746030449991737ef8d57a4456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNC0zLTEtMS0xMDUwMzM_6059ec5b-39c6-4afb-8133-641fd66b3b8a"
      unitRef="usd">696000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNS0xLTEtMS0xMDUwMzM_5f9558bc-ea50-4d27-a2ed-49eebaf23e44"
      unitRef="usd">5516000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i456a03746030449991737ef8d57a4456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNS0zLTEtMS0xMDUwMzM_efcbe6bd-a4fd-491c-8ca5-e3f71c848a9a"
      unitRef="usd">2269000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNy0xLTEtMS0xMDUwMzM_a3bea1f3-e1be-4f13-8fe4-33613a73af1b"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i456a03746030449991737ef8d57a4456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfNy0zLTEtMS0xMDUwMzM_893d800e-c24d-4f34-a4f8-e77494a7dd78"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:Assets
      contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfOS0xLTEtMS0xMDUwMzM_74b36f74-4852-47fd-ae8c-598f99e1878e"
      unitRef="usd">24714000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i456a03746030449991737ef8d57a4456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfOS0zLTEtMS0xMDUwMzM_1ca8a3e8-deea-4622-a58c-8b6d78a465c0"
      unitRef="usd">11834000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTItMS0xLTEtMTA1MDMz_33b412e9-88e9-44e2-a732-b12b9e99ec59"
      unitRef="usd">35266000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i456a03746030449991737ef8d57a4456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTItMy0xLTEtMTA1MDMz_3d505600-5a8e-4d2e-b43a-7fbf819f4aa3"
      unitRef="usd">32405000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTMtMS0xLTEtMTA1MDMz_6aef46fa-085a-47d0-a059-911c503d3e6b"
      unitRef="usd">-10552000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i456a03746030449991737ef8d57a4456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTMtMy0xLTEtMTA1MDMz_9853e8ef-cfdc-4232-a338-73d03bd8d0ae"
      unitRef="usd">-20571000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0b668bc9bad144ecb767c9cf5a82dc98_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTUtMS0xLTEtMTA1MDMz_efeb7220-b171-4172-a2b4-e06aca07c191"
      unitRef="usd">24714000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i456a03746030449991737ef8d57a4456_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjAwODVlYmEwM2VkNDQ4MDdhMmYyOTdkZDE1MWVhMjJlL3RhYmxlcmFuZ2U6MDA4NWViYTAzZWQ0NDgwN2EyZjI5N2RkMTUxZWEyMmVfMTUtMy0xLTEtMTA1MDMz_d2f769b8-5e03-48d3-a195-0baa4062ae69"
      unitRef="usd">11834000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfMy0xLTEtMS0xMDUwMzM_72789449-97c3-4bf2-aa0d-4ad63d5601a9"
      unitRef="usd">126067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfMy0zLTEtMS0xMDUwMzM_3611239c-643a-4da4-ae34-eb8ede9ca822"
      unitRef="usd">95212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNC0xLTEtMS0xMDUwMzM_64ea30f7-b5b3-45c4-9326-c7b26c14e133"
      unitRef="usd">121406000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNC0zLTEtMS0xMDUwMzM_6284a01c-c018-4912-8a20-acd5d2939a0b"
      unitRef="usd">104570000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNi0xLTEtMS0xMTcxOTE_9b98ad81-6e46-4c94-8192-5c7fc2f775ac"
      unitRef="usd">4661000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNi0zLTEtMS0xMTcxOTg_e8ba23a8-a11a-4244-8cb1-035390be453b"
      unitRef="usd">-9358000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfOC0xLTEtMS0xMTcyMzM_e87cf3c5-ff58-443b-9fed-244d963006c6"
      unitRef="usd">-58000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfOC0zLTEtMS0xMTcyNDA_11bdf446-57c0-4587-b1a5-bc05e7ebf3ab"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="icc6ce9471f224613b3ea633cb5550785_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNi0xLTEtMS0xMDUwMzM_af85c4b0-4d07-48c3-b1ce-853ea7715fab"
      unitRef="usd">4603000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifb571ff9cb9d4270855690a33039e664_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RhYmxlOjNlM2Q0NDQxNTEwMDRjMzE4M2YyN2NiN2NjNTZjMGU4L3RhYmxlcmFuZ2U6M2UzZDQ0NDE1MTAwNGMzMTgzZjI3Y2I3Y2M1NmMwZThfNi0zLTEtMS0xMDUwMzM_85256fc9-c2ec-430c-9e5d-3d66e001623e"
      unitRef="usd">-9358000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib71de6782da243ac87254390580b0b61_I20150731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMTI3Ng_f3cd9724-ea36-450c-9b1e-a116a46f849d"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i72155c35fa2747b5984527dcf5162a43_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjE3OQ_260f94fb-1131-4432-b603-943666df777d"
      unitRef="usd">15000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2f30d164f6d743639946b82e4328af58_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjIxNw_bff4ccb4-17de-433b-ac17-65b60e08a482"
      unitRef="usd">-16000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i36766b59fdb44c0cb8d7da462b05fbef_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NjMyNw_571598b8-12bd-463c-9e3e-3ec566b29139"
      unitRef="usd">22000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib9f907a840be46e2aeb32432dd66fea0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NjMzNQ_c80fe4ce-4dbb-410a-94ed-76780da19f6f"
      unitRef="usd">-30000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="icb35d81b629041debdd1e5e0eb5500ac_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjM2Mg_734dfa6b-e604-478c-9ede-79ce457625cc"
      unitRef="usd">1700000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i6baa1c84dac349f5acf23c66fef27140_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjM2OQ_3bff8685-3691-48dc-aa2d-d591d33aaaa1"
      unitRef="usd">1700000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id8cbe9a274f944c9b33a5afce066df48_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjQ0NQ_d47a36c4-06c8-4b3f-bbaa-b72edc7d3d73"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if465b8aea2ce4908904e4ad93a86b298_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjg2Nw_768d2f34-4b90-4c39-883f-737246d90479"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i018d7b4e12a2489aa9b33f4323e5c611_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjg3NA_d86906f8-ef06-401e-92ee-8e49884c948d"
      unitRef="usd">-9000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i016ca3434597421199937a03ff2fc17f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NjY4OA_9ab79dc0-0769-44e8-b476-6051c7ec8035"
      unitRef="usd">-300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i79ef92aed16c481bb3060e0e03050169_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NjY5Ng_9dd24b89-3d5d-4fae-b72c-8411cf61a5a5"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if7cf8eaa6bf64eeab771048f5de4564f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzAzNQ_5fe73c83-d782-49b2-974e-6c3bda2860ad"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0e0edd220c6943ef81f9294e13541194_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzA0Mg_c7a894ab-ad99-4618-8902-6259decc679a"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2ef0c4478a2c41e38132323c3a052804_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzExMw_22925e68-693a-48c0-9fc9-6bee82205547"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iaa17eff6b8c744cfad25e00a8a815d59_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzMwMA_1bade3ba-01fe-4ffe-9f1c-477358d0d1e9"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6ed8a2f220bd4feda2e865edfbd8e716_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzMwNw_cf538aac-17da-470c-bd5c-6aa1f95aace1"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib410a832400244ff85bff3debb332a3f_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3Njk5NQ_b44a810a-ecfb-43d5-96ec-f3f357d00e2a"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ief5224c7fb984c28ae95700de5da6e27_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzA3Mg_779f5e54-a698-4a76-9fd2-7c8a1bce81b5"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i77a601ca89014f5eacda8b352cd397cf_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzQ1Mw_6d52a9f8-b1c5-4374-bd84-80830d2a27fb"
      unitRef="usd">2800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ifff5051e4aad447bb1d4f5b0b052cdff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzQ2MA_f901a242-6d1e-4799-ab0e-17eed3c9a796"
      unitRef="usd">2900000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i35e8315cdc8946c3bd924c645f5730ed_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzU1Nw_5fe1f0a8-b5c3-4ba8-841c-da662a32edb9"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i39e02afca44c4aedafa732851dd3802b_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzc3NA_89a17c38-a73b-4b2b-81a4-039ae0992f7b"
      unitRef="usd">45000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i227316615eba44afb5e1909846c71eeb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzI1Ng_db88bd57-c3c7-42ad-b33b-fb718eac8bcd"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i46a28bb2bc244c43b885f7f0afdb1949_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzUwNg_d3913eed-9ace-4d86-8aca-dff2d399bc90"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i268b6755560b4788af5c509f2650c3ba_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzUyNQ_2499d426-a221-48ce-907d-ba4b28249b6d"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i13da4e8ee17d47e9819397b6faff3bfc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzk3Nw_18d09a7a-1dd6-49f4-b9ad-7e54225b65f4"
      unitRef="usd">6400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i6fd70ca2db774b288ae5881780641231_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMzk4NA_3e141d63-1700-4a40-a68b-37ccbbeab714"
      unitRef="usd">4800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9ddac981e5724f7faa52da42366eb5b0_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDA2OA_f283206f-9025-4449-872f-4843ddaeb010"
      unitRef="number">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i1d95aff18be44aaabba0d95b213fe04d_I20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDEwMw_2ad4acd2-f53a-460d-83ed-41e8f465fbca"
      unitRef="usd">11700000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ica0c755f6f5a456cb7c1e3039165cf31_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDYyMQ_7781c8d4-8bd7-4563-9e68-9dad11cc47f5"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i314756c0e5064dc7808d5ca875ef6866_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfMjc0ODc3OTA3NzcwNA_16ebb689-c2e2-41e9-9d17-870b3823946e"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1e059681a7204193b3ca300c44829e19_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDc4OQ_33aa147c-2566-4cbd-a270-57e4718dbe7e"
      unitRef="usd">12300000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie6dd79fb668d4396a088c5c7da4ad9bb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDc5Ng_0837f310-8820-43c3-8e2d-a0019d5bbd1e"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares
      contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNDk0OA_30757b48-0a86-495e-b73f-620e0034e67b"
      unitRef="shares">270000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares>
    <ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="i68a73980d9cb441dbb6fdd887b9503f8_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTAzMw_0f3d94ce-503d-49b9-9ab5-25f40c0bb3f8"
      unitRef="usd">400000</ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest
      contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTAzOQ_7f4d60e3-512e-4244-9005-72f856db2ca6"
      unitRef="usdPerShare">1.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTEwMg_e3eac1b9-6c44-45f0-8881-0200059d7156"
      unitRef="number">0.028</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI3Mw_669903a9-2372-49f5-b7a7-340952ba001f">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTIyMw_4b1f839e-8995-44b6-b297-1d747619a6a2"
      unitRef="shares">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption
      contextRef="i68a73980d9cb441dbb6fdd887b9503f8_D20180501-20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI4MQ_1ed5c74b-df19-4ef3-b990-6c27b8479b46">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests
      contextRef="i68a73980d9cb441dbb6fdd887b9503f8_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTI5MQ_3124b908-b140-4fe1-8495-46562b829b8e"
      unitRef="shares">380000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjI3MQ_d56bf382-39be-4e4a-9639-6e455b89cabc">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet
      contextRef="i74659971142042e9b4b1ecd398a5632a_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTM0OQ_a004c505-9271-4903-8a59-4778d1f643d0"
      unitRef="shares">480000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears
      contextRef="idd5ac37956bd4d08909d1dd390134c6d_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNTk1OQ_359c800c-afa0-47e3-8cb8-08140b504cb9"
      unitRef="number">0.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment
      contextRef="i0858a8d9fe0c4b65b4073669668a0c6b_D20190701-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjA1Mw_3bfe297d-f583-4d2b-9171-bea551556a07">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost
      contextRef="idd5ac37956bd4d08909d1dd390134c6d_I20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjEwMg_0d7173aa-67dd-4ec5-af72-4904b78abac2"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="idd5ac37956bd4d08909d1dd390134c6d_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjExMQ_c3b6b14b-33f8-46a1-a488-c237dc7ff8e5"
      unitRef="number">0.10</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="ica9c3cfdeff84d0eac173b74662af814_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY182Ny9mcmFnOjY0ZDBhMzUwYzY5ZDRmYmM5MjkzMGM4Zjc3MWIzZjg1L3RleHRyZWdpb246NjRkMGEzNTBjNjlkNGZiYzkyOTMwYzhmNzcxYjNmODVfNjE1OA_cf6cdda2-7845-4e81-9b8e-5797150c987a"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:LoanReceivableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMTI0OA_de4cc813-b360-4ad3-ba15-a010c70e924e">Loan Receivable and Loan Receivable &#x2013; Related Parties&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pacific6&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, NMM received a promissory note from 6 Founder LLC, a California limited liability company doing business as Pacific6 Enterprises totaling $0.5&#160;million as a result of the sale of the Company&#x2019;s interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; related party&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;LaSalle Medical Associates Loan (&#x201c;LMA Loan&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates (&#x201c;LMA&#x201d;) issued a promissory note to APC-LSMA for a principal amount of $2.1 million with an August 2023 maturity date. The contractual interest rate on the LMA Loan is 1.0% above the prime rate of interest for commercial customers. APC&#x2019;s investment in LMA is accounted for under the equity method based on the 25% equity ownership interest held by APC-LSMA in LMA&#x2019;s IPA line of business (see Note 5 &#x2014; &#x201c;Investments in Other Entities &#x2014; Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AHMC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, AHMC Healthcare Inc. (&#x201c;AHMC&#x201d;) issued a promissory note to APC for a principal amount of $4.0&#160;million with an April 2022 maturity date. The note was amended in April 2022 to extend the maturity date to April 2023. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. In June 2022, AHMC paid the outstanding principal and interest amount to APC. One of the Company&#x2019;s board members is an officer of AHMC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#x2019;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.&lt;/span&gt;&lt;/div&gt;</ameh:LoanReceivableTextBlock>
    <us-gaap:NotesReceivableNet
      contextRef="i5d5365ccd50e40b48292e6b69f44ba5f_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMTU5_68105e39-efe6-4e13-8d1d-d8cd564165cd"
      unitRef="usd">500000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5d5365ccd50e40b48292e6b69f44ba5f_I20201031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMjUw_5c754769-e61f-4e3f-9a52-1b5aa90b937f"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesReceivableNet
      contextRef="ibf671f1c4d984ad4b56737e8bb018cf4_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMTY0OTI2NzQ0NzE2NA_9f908408-1a95-4b83-b716-159d3b6d4091"
      unitRef="usd">2100000</us-gaap:NotesReceivableNet>
    <ameh:FinanceReceivableInterestRateStatedPercentage
      contextRef="ibf671f1c4d984ad4b56737e8bb018cf4_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfMTY0OTI2NzQ0NzE3MQ_07e4d8aa-e18f-4f35-b4b6-873240b9f5c1"
      unitRef="number">0.010</ameh:FinanceReceivableInterestRateStatedPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i767518e6c72e4e4997ab25645b106efc_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfNDM5ODA0NjUxNTUzMw_057e8cae-1e6a-462a-906c-322966fb5aa5"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i778bae90463c48628833fa5514d45310_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfNDM5ODA0NjUxNTUzMw_e1ded9bc-8d93-4d26-90a9-4c5ff9a99840"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NotesReceivableNet
      contextRef="i846ff05d31aa414e88893b18094681fe_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfNDc2_10a56f99-e890-4628-b59c-50cfcdea6181"
      unitRef="usd">4000000</us-gaap:NotesReceivableNet>
    <ameh:FinanceReceivableInterestRateStatedPercentage
      contextRef="i846ff05d31aa414e88893b18094681fe_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183My9mcmFnOjdiYTI1YmU3NzliNDQyNjQ5ODQxNjlkZjg5MjY4Nzg4L3RleHRyZWdpb246N2JhMjViZTc3OWI0NDI2NDk4NDE2OWRmODkyNjg3ODhfNTY1_2ced8292-7bcd-49d2-837a-c91c04b017e2"
      unitRef="number">0.0375</ameh:FinanceReceivableInterestRateStatedPercentage>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RleHRyZWdpb246MDBjYTgwYzQwYmEwNDlmNzljMzA0ODEzMzRmMDJlMzdfMTQ0_f40b7267-7c99-4e7d-ba7b-ea85f4a0468c">Accounts Payable and Accrued ExpensesThe Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RleHRyZWdpb246MDBjYTgwYzQwYmEwNDlmNzljMzA0ODEzMzRmMDJlMzdfMTQ3_80a59311-4802-4618-9a89-10344ecc486f">The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMS0xLTEtMS0xMDUwMzM_aef16d2c-ae8a-4981-a933-e6760aa6e4c6"
      unitRef="usd">11280000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMS0zLTEtMS0xMDUwMzM_6ca416a2-ab57-496a-890e-c9e123a02638"
      unitRef="usd">9583000</us-gaap:AccountsPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMi0xLTEtMS0xMDUwMzM_0aadeec7-3f22-434d-8e19-a0c84861adec"
      unitRef="usd">3683000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMi0zLTEtMS0xMDUwMzM_4b7fa6ae-5682-499a-a614-62505315787a"
      unitRef="usd">2697000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SubcontractorIPAPayable
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMy0xLTEtMS0xMDUwMzM_72d7a3a9-dabe-4959-aa40-d9f32be70cf4"
      unitRef="usd">13814000</ameh:SubcontractorIPAPayable>
    <ameh:SubcontractorIPAPayable
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfMy0zLTEtMS0xMDUwMzM_1b1508cf-49a3-4405-943f-72025782ade6"
      unitRef="usd">1587000</ameh:SubcontractorIPAPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNC0xLTEtMS0xMDUwMzM_330a16e4-04fb-4cc3-87ae-721e5f9d6aec"
      unitRef="usd">1192000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNC0zLTEtMS0xMDUwMzM_33f173ba-1a17-421c-a055-982989af7c34"
      unitRef="usd">878000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNS0xLTEtMS0xMDUwMzM_44c1f0a8-c2fa-40ff-8ccd-449c2e55caca"
      unitRef="usd">1242000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNS0zLTEtMS0xMDUwMzM_5d68e2b2-5819-45b8-8daa-2775f76e0659"
      unitRef="usd">2301000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNi0xLTEtMS0xMDUwMzM_337771e0-8158-48b8-88cc-4b28b6e1b409"
      unitRef="usd">20030000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNi0zLTEtMS0xMDUwMzM_7de8edd9-5146-40e2-93e8-45fffdaf9f4d"
      unitRef="usd">16798000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNy0xLTEtMS0xMDUwMzM_1394ee71-1fda-4fbf-ad72-c1dca1d73d76"
      unitRef="usd">8681000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfNy0zLTEtMS0xMDUwMzM_3c0e6b1d-f0f5-4596-8a8f-14826c6f9f5c"
      unitRef="usd">10107000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfOC0xLTEtMS0xMDUwMzM_5e4cf8c0-3c26-4a5b-a1b8-20113bc8116f"
      unitRef="usd">59922000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY183OS9mcmFnOjAwY2E4MGM0MGJhMDQ5Zjc5YzMwNDgxMzM0ZjAyZTM3L3RhYmxlOmY5ZWM1YzI5YWVkYzQ1NzJiYzdhMDJiYjRjZGE1ZjBkL3RhYmxlcmFuZ2U6ZjllYzVjMjlhZWRjNDU3MmJjN2EwMmJiNGNkYTVmMGRfOC0zLTEtMS0xMDUwMzM_9b4aee1e-ebb0-4884-8897-1ace80838614"
      unitRef="usd">43951000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RleHRyZWdpb246M2UzYWJmNGE5MzhkNDQ5ODliMDM0YmI5NTc3NDlmMGNfMTEw_6638fb48-8c3f-4666-bb7b-1724f8237616">Medical Liabilities&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RleHRyZWdpb246M2UzYWJmNGE5MzhkNDQ5ODliMDM0YmI5NTc3NDlmMGNfMTEy_10b9ff87-8729-4657-898e-4f32f568036b">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMS0xLTEtMS0xMDUwMzM_8634ac29-ae05-4624-a186-9a53a35ae4f7"
      unitRef="usd">55783000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iaaa56363ec8a4c6bab2a3823427c4fb6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMS0zLTEtMS0xMDUwMzM_69e92024-7982-4fe4-9586-41df0ee11597"
      unitRef="usd">50330000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMi0xLTEtMS0xMTkyMjU_7f48dda5-8c3b-4213-b91d-66132ed1cad8"
      unitRef="usd">1609000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMi0zLTEtMS0xMTkyMzM_a59fdc3b-d8db-4f45-a3a3-ad662a7e53e2"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNS0xLTEtMS0xMDUwMzM_8ad904fc-aa93-4797-974e-aa7a751313ce"
      unitRef="usd">313325000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNS0zLTEtMS0xMDUwMzM_3ce5a12b-037e-4c15-912d-aaceccabfcb6"
      unitRef="usd">158739000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNi0xLTEtMS0xMDUwMzM_d88b498d-0de5-471b-9937-64038e401440"
      unitRef="usd">-950000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNi0zLTEtMS0xMDUwMzM_2f45703b-9f3e-44ac-9530-e20cc336470f"
      unitRef="usd">-1293000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNy0xLTEtMS0xMDUwMzM_9af3678d-4441-40ad-8db8-b5309f9a01c6"
      unitRef="usd">312375000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfNy0zLTEtMS0xMDUwMzM_4ecc7065-01f3-4328-baf5-91615b87248d"
      unitRef="usd">157446000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfOS0xLTEtMS0xMDUwMzM_6165aeec-de7d-429c-aa1e-0d15c0504a41"
      unitRef="usd">204032000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfOS0zLTEtMS0xMDUwMzM_b281da48-12d2-4de2-b4bf-51f38f3a06ab"
      unitRef="usd">103302000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTAtMS0xLTEtMTA1MDMz_1ac428b1-0539-47ad-9470-5e03f50c46a7"
      unitRef="usd">53978000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTAtMy0xLTEtMTA1MDMz_a7bb8e5b-4b4c-4752-972c-009fab1bfbab"
      unitRef="usd">45130000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTEtMS0xLTEtMTA1MDMz_5f9ac200-26fd-4d94-a0c0-d0886b669e57"
      unitRef="usd">258010000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTEtMy0xLTEtMTA1MDMz_f31558ff-80c0-4550-8aef-da9baba1f029"
      unitRef="usd">148432000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTItMS0xLTEtMTA1MDMz_ed955825-6657-4bcb-a9e7-53f4272b46e0"
      unitRef="usd">742000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTItMy0xLTEtMTA1MDMz_46a8a9a5-1687-4ce3-bd6b-8f3bc59946c5"
      unitRef="usd">-37000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTQtMS0xLTEtMTA1MDMz_115f56e0-3c78-4502-a57a-5f9521392e86"
      unitRef="usd">112499000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i4becb57108e844a2af77734d782c9546_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184Mi9mcmFnOjNlM2FiZjRhOTM4ZDQ0OTg5YjAzNGJiOTU3NzQ5ZjBjL3RhYmxlOjc3NDJhMTdkYzBjZjRmMzhiOTMyODBhYTY2YjExZjJjL3RhYmxlcmFuZ2U6Nzc0MmExN2RjMGNmNGYzOGI5MzI4MGFhNjZiMTFmMmNfMTQtMy0xLTEtMTA1MDMz_496cf2e8-78c2-4f08-b387-1eb3e1eee66c"
      unitRef="usd">59307000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTQ_7acf7659-02ab-48e6-a54f-dc91438229c1">Credit Facility, Bank Loans, and Lines of Credit&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real Estate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of June&#160;30, 2022 and December&#160;31, 2021, the carrying value was not materially different from fair value, as the interest rates on the Company&#x2019;s debt approximated rates currently available to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the six months ended June 30, 2022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#x201c;Amended Credit Agreement&#x201d; and the credit facility thereunder, the &#x201c;Amended Credit Facility&#x201d;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the &#x201c;Credit Facility&#x201d;), in its entirety. The Amended Credit Agreement provides for a five-year revolving credit facility to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#x201c;Guaranty and Security Agreement&#x201d;) between the Company, NMM and Truist Bank remain in effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.350% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#x2019;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio.  As of June&#160;30, 2022, the interest rate on the Credit Agreement was 4.17%. Borrowings under the Amended Credit Agreement may be prepaid at any time without penalty. If LIBOR ceases to be reported under the Amended Credit Agreement, the Company will use the secured overnight financing rate or the Company and the Agent will agree to an alternative rate of interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $75.0&#160;million, the maximum consolidated total net leverage ratio may temporarily increase by 0.25 to 1.00 to 4.00 to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange, or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At June&#160;30, 2022 and December&#160;31, 2021, the unamortized deferred financing cost was $3.8&#160;million and $4.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Real Estate Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MPP&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $6.1 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2022, the balance outstanding was $6.0 million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. &lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AMG Properties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $0.7 million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2022, the balance outstanding was $0.7 million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ZLL&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan was $0.6 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2022, the balance outstanding was $0.6 million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;120 Hellman LLC &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;25, 2022, 120 Hellman LLC (&#x201c;120 Hellman&#x201d;), a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsidiary of APC,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; entered into a loan agreement with MUFG Union Bank N.A. with the principal on the loan of $16.3 million and a maturity date of March&#160;1, 2032. The loan &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was used to purchase property in Monterey Park, California. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The variable interest rate is 2.0% in excess of Daily Simple SOFR, which is the daily rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If the index is not available, MUFG Union Bank N.A. may designate a substitute index after notifying 120 Hellman. Monthly payments on the principal and interest began in April 1, 2022. Should interest not be paid when due, it shall become part of the principal and bear interest. As of June&#160;30, 2022, the balance outstanding was $16.2 million. 120 Hellman must maintain a Cash Flow to Debt Service ratio (defined as net profit after taxes, to which depreciation, amortization and other non-cash items are added divided by the current portion of long-term debt and capital leases) of not less than 1.25 to 1 and 35% or more of the property must also be occupied by APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Construction Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#x201c;Construction Loan&#x201d;). Tag 8 is a VIE consolidated by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (&#x201c;Construction Loan Term&#x201d;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#x201c;Permanent Loan Term&#x201d;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of June&#160;30, 2022, the likelihood of the construction being completed by the maturity date was remote. The outstanding balance as of June&#160;30, 2022 was $1.8 million and was recorded as a current portion of long-term debt in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#x2019;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s average effective interest rate on its total debt during the six months ended June&#160;30, 2022 and 2021, was 2.16% and 2.31%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2022 and 2021, of $0.2 million and $0.4 million, respectively, and $0.5 million and $0.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lines of Credit&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;APC Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#x201c;APC Business Loan Agreement&#x201d;) was amended to, among other things, decrease loan availability to $4.1 million, limit the purpose of the indebtedness under the APC Business Loan Agreement to the issuance of standby letters of credit, and include as a permitted lien, the security interest in all of its assets that APC granted to NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#x2019;s obligations to NMM under their management services agreement dated as of July 1, 1999, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTc_64c544e2-e961-48ef-8411-065ee764d02c">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real Estate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id2940bbecd004561861f01abb0ebad96_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfMy0xLTEtMS0xMDUwMzM_9f1d460a-d72d-4c9a-b148-ae99a1cb9631"
      unitRef="usd">180000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9ca1ca2ff65840868df912f9f0aaa96a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfMy0zLTEtMS0xMDUwMzM_52d1a004-5d48-4217-9bae-fc705d57ae76"
      unitRef="usd">180000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7b355b7c0d4a4f3bac5ad6619d970628_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNC0xLTEtMS0xMDUwMzM_b1f76ad7-2e64-4da5-bd71-93198fe5034e"
      unitRef="usd">23469000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib86197b3338a4a568e33693944e72e99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNC0zLTEtMS0xMDUwMzM_063cabc7-7dc7-491f-86cf-2607600c0637"
      unitRef="usd">7396000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i78dd2608d34c4de8a4f893d06e8f8f22_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNS0xLTEtMS0xMDUwMzM_8200e74f-b24f-4125-8c7c-efb33895df6f"
      unitRef="usd">1805000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i36d1265e36d640f2adebf0f735428064_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNS0zLTEtMS0xMDUwMzM_3290d613-2097-4904-b816-84e8d236dbd5"
      unitRef="usd">569000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNi0xLTEtMS0xMDUwMzM_311e761b-5a13-45fe-8266-238795aa4e34"
      unitRef="usd">205274000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfNi0zLTEtMS0xMDUwMzM_ed72625e-e160-49ac-b298-663eed993fef"
      unitRef="usd">187965000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfOC0xLTEtMS0xMDUwMzM_95a5c447-9ac5-40eb-8fda-15a4444f844e"
      unitRef="usd">2413000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfOC0zLTEtMS0xMDUwMzM_2f2a0d5d-1a91-4df2-ac7d-f360fb97473f"
      unitRef="usd">780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfOS0xLTEtMS0xMDUwMzM_9249633b-c311-451c-b379-35dbc4601d5f"
      unitRef="usd">3793000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfOS0zLTEtMS0xMDUwMzM_cf4edd3a-b6ee-4b53-bed5-9f27bab42e01"
      unitRef="usd">4268000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfMTEtMS0xLTEtMTA1MDMz_db7d122f-c4c2-4476-8136-d09faa2eeaa3"
      unitRef="usd">199068000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOmRlNmVhMmI4MzExYzQyYzk5NDFkZjE4ZWQ2ZWJmMzBlL3RhYmxlcmFuZ2U6ZGU2ZWEyYjgzMTFjNDJjOTk0MWRmMThlZDZlYmYzMGVfMTEtMy0xLTEtMTA1MDMz_b264eb10-6881-4b2a-8b58-058c70cae81c"
      unitRef="usd">182917000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTU_43f2fca1-d1ab-463e-bb1f-b5492d8aebd9">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the six months ended June 30, 2022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfMS0xLTEtMS0xMDUwMzM_e2d8451b-2fd9-406b-96d8-17e7c5c3a2b2"
      unitRef="usd">2107000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfMi0xLTEtMS0xMDUwMzM_86962b8d-3120-48bd-b79a-f95e170c6362"
      unitRef="usd">618000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfMy0xLTEtMS0xMDUwMzM_9ef85ea5-59cc-4b91-978e-cd281ca2dca8"
      unitRef="usd">642000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfNC0xLTEtMS0xMDUwMzM_3ce46b1d-7242-40d7-8032-ef6e932d9bd1"
      unitRef="usd">7184000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <ameh:LongTermDebtMaturityAfterYearFour
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfNS0xLTEtMS0xMDUwMzM_a4692065-6de1-42f7-8273-9edc0144ce90"
      unitRef="usd">194723000</ameh:LongTermDebtMaturityAfterYearFour>
    <us-gaap:LineOfCredit
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RhYmxlOjJkNWRkYjdiZDRiNTRiNjQ4YjI5ZmNmOTEwNWJjYTZkL3RhYmxlcmFuZ2U6MmQ1ZGRiN2JkNGI1NGI2NDhiMjlmY2Y5MTA1YmNhNmRfNy0xLTEtMS0xMDUwMzM_ddc2d200-7277-44fa-8f4d-76de354ae167"
      unitRef="usd">205274000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentTerm
      contextRef="idc4faa451635444dacf9694e218dd3e4_D20210616-20210616"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTk_fba1acff-0165-4f3d-b63d-efffc415f1cb">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ibdae08981f5e4104934ad51fe3b95303_I20210616"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTQ2Mw_ef864f3d-12c7-4528-b329-9d7967e8b873"
      unitRef="usd">400000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i22fc5dfea7e84f638573c274ba9b23e4_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTUyMw_889accce-58f3-43a9-94dd-47fa635ba18b"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia2cd92e83f7b437bb51b5c89f701b464_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTU2Mw_c08b91f7-974c-48dd-ba61-4249eb1997b5"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="i85593b22935b45e4be1ee177e8ad7239_D20210616-20210616"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjA5Nw_f43342e2-4450-4f23-bc81-f24cef17b825"
      unitRef="usd">50000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i3eae04016bb447e0bddc4f0591df991a_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjEzMA_2ec2bdd6-76c0-40f8-9c38-d040bd02b37c"
      unitRef="number">0.00175</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i95eae60963324a459007367c1b4ab420_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjEzNg_0e2cfaf8-67d7-4435-94ed-9161b09826c8"
      unitRef="number">0.00350</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ia1261394f1654823b8118f1c41514f21_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjQwMw_f4a1c958-9459-42ef-8250-f65981fe333e"
      unitRef="number">0.0125</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ic88159173edb49298d65e5a36a704517_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMjQwOQ_56e3e9f3-0ab9-41fc-b905-3f919db674b3"
      unitRef="number">0.0250</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic938e3d247da4baf8c4e436b6ba4e60b_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzAzOA_ae3537be-4b8a-4e27-9834-a17b11e9ba5f"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8fa6d96494224426b248b59ceab8cebb_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzA0NA_b75e8902-091c-458b-bfe7-6139b8c2a3a7"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3eae04016bb447e0bddc4f0591df991a_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzE1OQ_acc7ea9d-ade7-410a-b310-1b4a49b43475"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i95eae60963324a459007367c1b4ab420_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzE2NQ_1ba00a04-9711-47c5-81db-638999c33dc7"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i60f21d618be04c29bad9cca5524c19b7_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzMwMA_b08297b1-cacc-4885-af4f-199e1e0406ce"
      unitRef="number">0.0417</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <ameh:DebtInstrumentNumberOfKeyFinancialRatios
      contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzY2Mg_be9601af-b3f6-4213-b7cb-192e2a3894d4"
      unitRef="financial_ratio">2</ameh:DebtInstrumentNumberOfKeyFinancialRatios>
    <ameh:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMzgyMg_cc311e10-0836-45b2-accf-a27b50727f2b"
      unitRef="number">3.75</ameh:DebtInstrumentCovenantLeverageRatioMaximum>
    <ameh:DebtCovenantAggregatePurchasePriceMaximum
      contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNDA1NQ_555cc7f5-81f6-4922-a57c-8e49dd8109a8"
      unitRef="usd">75000000</ameh:DebtCovenantAggregatePurchasePriceMaximum>
    <ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange
      contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNDEzNw_cc3fd974-08c4-4516-8ddd-17f49b6bc0eb"
      unitRef="number">0.25</ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange>
    <ameh:DebtInstrumentCovenantLeverageRatioAdjustedMaximum
      contextRef="i5a22ce1ecc6d47949eb8ffd7868ac8a8_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNDE1MQ_d496e30a-238e-48ec-a69e-5a54b6fc7049"
      unitRef="number">4.00</ameh:DebtInstrumentCovenantLeverageRatioAdjustedMaximum>
    <ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i161df59378d54e2c9c35ef127c00a692_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNDI1Mw_fc52d3c0-d425-4a21-908a-a920ae56a965"
      unitRef="number">3.25</ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i11ed2f9093db4b03b46f940a69391343_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNTIyMg_d06136cc-bdd5-4dab-93f5-ee3097fe5bc3"
      unitRef="usd">6500000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="ic59abeea171b4680ac8fc59615e1a446_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNTM0Ng_9eed953d-c299-41ab-bf79-bf6b03c9c323"
      unitRef="usd">700000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNTgwOA_1c821606-e272-4b2b-9633-03a2da345f73"
      unitRef="usd">3800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNTgxNQ_8c882dc8-f0a5-4c92-af46-3c81e27ef7c2"
      unitRef="usd">4300000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibe69f802279e4ce8a230a2252301ea51_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NDI1Ng_a275c4cf-1551-46b6-b644-2e3eeef52729"
      unitRef="usd">6100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia874564b3f7f46f0bb91acc1285b389e_D20200703-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNjI3Nw_35facd5c-1d5e-4556-95e8-03eddceb4f2e"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="ibff008a8379447cea04496a4e74019b5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNjYwNg_424f6223-eadf-4898-bdb7-cb485a18a173"
      unitRef="usd">6000000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="if16717b8edf54956a5b44e5ed8302e3b_D20200703-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNjc2OQ_1236226d-da91-4402-bd4c-6ce4bebd0852"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia1041f899e3243769086c3764cd3193a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NDI2NA_b6bf56be-d9a2-46f8-b345-090e0f636834"
      unitRef="usd">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i74c97c8e257e4a02a64730b6e0e41ade_D20200805-20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNjk5Nw_f976125a-d662-4ebe-b685-54183b339046"
      unitRef="number">-0.0030</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i5b7a043471da464fa12812657a6fb838_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNzMzNw_2195ffa0-2b8b-4a6d-88e2-56d6377ba76e"
      unitRef="usd">700000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="i11705a1bed9740c793f74a813ac7350e_D20200805-20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNzUxMQ_71e9ff6c-106e-4aef-906d-cc60d0facbfe"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="icccdfccc60d849bda7a0fa9d6cda8ea8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NDI3Mg_f9a06d70-3094-4e64-bcb2-7b5112bd607c"
      unitRef="usd">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9d4b6704bd1a4f1b8e67da94daf68ad5_D20200727-20200727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfNzcxNQ_35f0406c-1be3-4541-9d39-580e105e17d0"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i5739754d4c764531a08a2b6ba1d03922_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfODA0NA_c1304a79-d737-44c8-9f0d-f0043e5dab65"
      unitRef="usd">600000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="if06c44df5942487d9c597ef8cdee2e34_D20200727-20200727"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfODIwNw_97a6a05a-dfac-4636-b383-788c29235f84"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibf7979125d864b698864f3e49061ba20_I20220125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NzM5MQ_4566e6de-97a6-4c4c-a130-56d084ea4e7a"
      unitRef="usd">16300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if75e16a418bd4b0ca6e69d9bda0b4418_D20220125-20220125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NTQxNw_b2cce174-4155-424b-8639-11a24f48fc56"
      unitRef="number">0.020</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i282ab48d547a409c91b0e2e1d8c055d7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NTQyNA_c4b60eee-aaa6-4f78-8630-fb17878cb5c2"
      unitRef="usd">16200000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum
      contextRef="i8efee8b6417740c295818b5927155453_D20220125-20220125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NTQzNA_bd95af9c-7922-4d8a-bc45-90890bfc9278"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum>
    <ameh:DebtCovenantThresholdPercentageForOccupationOfProperty
      contextRef="ibf7979125d864b698864f3e49061ba20_I20220125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1NjUzOA_3f1ac538-9111-4cdc-9501-2efcd4054b08"
      unitRef="number">0.35</ameh:DebtCovenantThresholdPercentageForOccupationOfProperty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2cb7f86e0def4c95962563988d781f2f_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfODQ0Ng_4829485a-6136-4fc0-a596-28aae6d894e9"
      unitRef="usd">10700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie1d752a197404d5bac408b2154757c13_D20230101-20231201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTIyNQ_7d8f4e03-be79-4beb-8005-0fce8bc11de3"
      unitRef="number">0.020</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i9f39746c41a9450889b8b440c4bb1e87_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTM5OA_faec7f2e-c5d2-4a83-aee2-abbf4c0ce1ed"
      unitRef="usd">1800000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum
      contextRef="i7cbd40ee0c194527bd610419cab4d09d_D20220630-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTgxNQ_ad0fa252-9de4-4616-abc9-fae7f5468096"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i161df59378d54e2c9c35ef127c00a692_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTk1OA_84ea7ce7-d2b5-4135-a6eb-8149ab40315f"
      unitRef="number">0.0216</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i693a573b995242e69ae791b297318006_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfOTk2NQ_ee8fabf4-bba1-4e85-bf11-0b923a74ffd5"
      unitRef="number">0.0231</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpense
      contextRef="iafc384eaf4734dd0be96fd82579c39f6_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTAxMzM_de84fd9c-7498-4a2f-a557-987f44048e38"
      unitRef="usd">200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i161df59378d54e2c9c35ef127c00a692_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTAxNDA_acf545a4-db4c-4241-aa36-bed81a26ea72"
      unitRef="usd">400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia26057f05b68400bab7e17c33a599861_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1MzQ0NQ_95f88f10-097a-48d7-b4e5-64472b61ce36"
      unitRef="usd">500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i693a573b995242e69ae791b297318006_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1MzQ1Mw_e09b13c6-2b95-4789-92d2-74a5800c3ec6"
      unitRef="usd">700000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i039231bd37b04500b07453d76940704d_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTAzMzQ_b33e58a1-46b0-4641-b5a4-21c47a811fd7"
      unitRef="usd">4100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ice27ac69897e45d1b5b34a56355dc920_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTA5NDg_de27c04b-db02-41a0-9ef5-0f16d25a8289"
      unitRef="usd">300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i00309c0459be4ba3b15e9b6033b0acaf_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2OTI_6b2052a2-fb03-4912-93d4-a67a930381e8">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7d5bf58fac1b43f9a4c5a689c4268856_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTY0OTI2NzQ1MzU2MA_508abef4-1c4c-494c-99c0-df89ede912b0"
      unitRef="usd">3800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i9aefdbbfc23740e3971470e4cc27ff41_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY184NS9mcmFnOjViNzNjMjM0NmVmZDRiZmVhZDM2ODYxNjgxY2IxZmZlL3RleHRyZWdpb246NWI3M2MyMzQ2ZWZkNGJmZWFkMzY4NjE2ODFjYjFmZmVfMTE2ODY_8b68ea58-1664-417f-8ff4-26848a390343">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY2NA_181b4945-1c9e-451d-9c6f-b74333a95014">Mezzanine and Stockholders&#x2019; Equity&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the redemption feature of the APC shares (see Note 2 &#x2014; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies - Mezzanine Equity&#x201d;) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interest in APC as mezzanine or temporary equity. APC&#x2019;s shares were not redeemable, and it was not probable that the shares would become redeemable, as of June&#160;30, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, 140,954 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC owned 11,175,702 and 10,925,702 shares of ApolloMed&#x2019;s common stock, respectively, as of June&#160;30, 2022 and December&#160;31, 2021. While such shares of ApolloMed&#x2019;s common stock are legally issued and outstanding, they are treated as treasury shares for accounting purposes and excluded from shares of common stock outstanding in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2022 and 2021, APC paid dividends of $10.0&#160;million and $19.9&#160;million, respectively. During the six months ended June&#160;30, 2022 and 2021, APC paid dividends of $10.0 million and $19.9 million respectively. &lt;/span&gt;&lt;/div&gt;During the three months ended June&#160;30, 2022 and 2021, CDSC paid dividends of $1.5&#160;million and $1.5&#160;million, respectively During the six months ended June&#160;30, 2022 and 2021, CDSC paid dividends of $2.9 million and $1.5&#160;million, respectively.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ameh:StockIssuedDuringPeriodSharesMerger
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfNDQ4_620c8eb1-6f55-4b95-9918-90315f5c2546"
      unitRef="shares">140954</ameh:StockIssuedDuringPeriodSharesMerger>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i1c708cdfd53f41a8b290faf3f23f5186_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTMwNA_490acd6f-9d93-47af-8993-1a934a847f7e"
      unitRef="shares">11175702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ief6a946f84384708a367fa93594947f6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0NDAzMg_0d7efd96-2005-4f7b-955a-4598c683ff3e"
      unitRef="shares">10925702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:Dividends
      contextRef="ia7680ae5461b4b2486caea091e4e82f8_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0MzM5OA_27358fa1-bc8a-4b5d-acd3-17e55836cb4b"
      unitRef="usd">10000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="id4a852313e0c4ddd88001a38595d3390_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0MzQwNg_bbfb9931-0df8-4a9c-b658-2079e9dd4e2c"
      unitRef="usd">19900000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i9902cb6392bf40fe99762875e13589c3_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0NDkyNw_9218ed58-b640-4335-a772-15d6438d75dc"
      unitRef="usd">10000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="ic7dca31d301345ef9166cc408559e908_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0NDk0OQ_a552da1c-5629-40bc-a3af-fa5e246171cf"
      unitRef="usd">19900000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i0383372507bb45108200170dddd5ac63_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0Mzc2MA_62f60ccd-dfea-411f-9173-1d208a232fd8"
      unitRef="usd">1500000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i2743e935ace9464cab6ca597868b375a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0Mzc2OA_dbdfdee9-a22a-4fe3-a249-d1fe0e269595"
      unitRef="usd">1500000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i29ea51d5f00d45e9bc091bc8a1a88beb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0MzY1NA_24e06186-b75d-4ef6-8c9f-35d7029af989"
      unitRef="usd">2900000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="iaffd866f998541ff9a904994be9fae46_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185MS9mcmFnOjUwNTc1NDM2NjM0MzRmYzlhMmI4ZWMyZmVkZTk5ZDgwL3RleHRyZWdpb246NTA1NzU0MzY2MzQzNGZjOWEyYjhlYzJmZWRlOTlkODBfMTY0OTI2NzQ0Mzc3Nw_beeea840-fc16-49d7-852c-a429515470fb"
      unitRef="usd">1500000</us-gaap:Dividends>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzMQ_213cb1fd-594e-4538-9160-194a3e01986f">Stock-Based Compensation&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three and six months ended June&#160;30, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to total share-based payments outstanding as of June&#160;30, 2022 was $26.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022, options were exercised for 38,500 shares of the Company&#x2019;s common stock, resulting in proceeds of $0.7&#160;million. During the six months ended June&#160;30, 2021, no stock options were exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022, the Company granted 87,488 stock options to certain ApolloMed employees and Board members. The options granted during the six months ended June&#160;30, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50 years - 2.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.47% - 82.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02% - 2.47%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.47 - $22.73&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock is that day&#x2019;s closing market price of the Company&#x2019;s common stock. During the six months ended June&#160;30, 2022, the Company granted restricted stock totaling 520,552 shares, including 295,721 shares of restricted stock with performance conditions, with a weighted average grant date fair value of $42.01. Shares of restricted stock with performance conditions are recognized to the extent the performance conditions are probable of being achieved. The grant date fair value of restricted stock and restricted stock with performance conditions that are probable of being achieved were $10.0&#160;million and will be recognized on a straight-line basis over the awards&#x2019; vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,743&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                  10.00 &#x2013; 11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the six months ended June&#160;30, 2022 and 2021, common stock warrants were exercised for 101,953 and 474,506 shares of the Company&#x2019;s common stock, respectively, which resulted in proceeds of approximately $1.1&#160;million and $4.8 million, respectively. The exercise price ranged from $10.00 to $11.00 per share for the exercises during the six months ended June&#160;30, 2022, and $9.00 to $11.00 per share for the exercises during the six months ended June&#160;30, 2021, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzMg_030f70c0-5ae2-4c72-b18b-29b637968190">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three and six months ended June&#160;30, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1a2d277b4082486a82df6f70b19d1989_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMi0xLTEtMS0xMDUwMzM_e3bf48bd-f5a6-4937-8fef-ccb08bb6022d"
      unitRef="usd">1141000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icfd41ced8b31471c86f3e5b810861eef_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMi0zLTEtMS0xMDUwMzM_a55f8d0b-997d-4b31-8204-3e67da45d8ee"
      unitRef="usd">602000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice144ed20675466b9ffd1ea1b947c8df_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMi01LTEtMS0xMDUwMzM_f9dd16bc-2101-4fb9-b851-1e8bbc6d0146"
      unitRef="usd">1921000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i117ec78443b64325bf4c2ac950fb25a7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMi03LTEtMS0xMDUwMzM_8a9dd853-3eac-48f9-b4de-3f9dae815ea8"
      unitRef="usd">1191000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ff7d682f2d94d5c926e3c35381ee58f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMy0xLTEtMS0xMDUwMzM_f12d7f16-d89f-4bfc-960a-5a3e58ea13fa"
      unitRef="usd">2779000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d1d13fa98564dafaead4c073177d336_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMy0zLTEtMS0xMDUwMzM_9c39f3ed-2040-4644-91ca-2a16eb0aac43"
      unitRef="usd">954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i204ae706d04f42e492b4e0e310f1dad8_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMy01LTEtMS0xMDUwMzM_73df7db2-9963-4ac3-be6c-2592e6540a1c"
      unitRef="usd">5054000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icfd7b521efd0406a9d8f97afd5c8feb7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfMy03LTEtMS0xMDUwMzM_3097d9d3-e2d3-4ea7-9f85-4b7a3137659f"
      unitRef="usd">1711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfNS0xLTEtMS0xMDUwMzM_95cd54f8-f0f5-473a-8571-42981dcb3406"
      unitRef="usd">3920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfNS0zLTEtMS0xMDUwMzM_2e086b5f-2368-4886-a0c6-3c498095a084"
      unitRef="usd">1556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfNS01LTEtMS0xMDUwMzM_7835f7d5-7fd1-42cd-bfb0-2dcf57f81113"
      unitRef="usd">6975000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmM2NGYzZDBlOWU3YTQzNGZiMDk0NTU1OTljNWZiYWZjL3RhYmxlcmFuZ2U6YzY0ZjNkMGU5ZTdhNDM0ZmIwOTQ1NTU5OWM1ZmJhZmNfNS03LTEtMS0xMDUwMzM_d2c1b45f-5c6b-4200-a37e-0ccbe9ba1485"
      unitRef="usd">2902000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfNTE3_3ba6ea6d-468e-49c5-a85f-47439329fb39"
      unitRef="usd">26100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzMw_97cad432-f56c-45d6-bff2-7e5a19fa0792">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMS0xLTEtMS0xMDUwMzM_10b9af0a-3e1d-4332-ac34-590050fb11b7"
      unitRef="shares">813965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMS0zLTEtMS0xMDUwMzM_284f35d1-b95e-4ace-977c-6aa9055ac535"
      unitRef="usdPerShare">22.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i13efa678914f4d7f98b3e9aeb1cd61d8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMS01LTEtMS0xMDUwMzM_689937e1-f3c7-403c-9280-f7b301f36e41">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMS03LTEtMS0xMDUwMzM_f86d2127-2c6a-4dd3-8596-a8d54ba0da01"
      unitRef="usd">41600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMi0xLTEtMS0xMDUwMzM_1b9c3be1-9796-432b-8e02-9dafede555c7"
      unitRef="shares">87488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMi0zLTEtMS0xMDUwMzM_2811edba-016e-49fe-95c7-93c011ee07ea"
      unitRef="usdPerShare">53.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMy0xLTEtMS0xMDUwMzM_301ed1f4-3d41-4c2e-b4c9-b4652c6db87e"
      unitRef="shares">38500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMy0zLTEtMS0xMDUwMzM_01e734d1-0e58-4496-aade-8f1a609041c6"
      unitRef="usdPerShare">17.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfMy03LTEtMS0xMDUwMzM_4f04d50a-10e3-442c-a58b-530a0f651fa3"
      unitRef="usd">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfNi0xLTEtMS0xMDUwMzM_04172e4c-70ff-4b32-bb6d-b0b849933d2b"
      unitRef="shares">862953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfNi0zLTEtMS0xMDUwMzM_d7948897-ad78-4fa7-bfd2-f92f0d328416"
      unitRef="usdPerShare">26.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfNi01LTEtMS0xMDUwMzM_1c6887f8-c282-42b9-a1b9-bb73b29600f0">P2Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfNi03LTEtMS0xMDUwMzM_803989b5-ffee-4d9d-8bca-debc6801e088"
      unitRef="usd">16300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfOC0xLTEtMS0xMDUwMzM_4bae3947-81c9-4a9c-b926-b2be925f17db"
      unitRef="shares">624513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfOC0zLTEtMS0xMDUwMzM_8c4e575e-5ad1-4809-a0eb-27cff33f6326"
      unitRef="usdPerShare">11.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfOC01LTEtMS0xMDUwMzM_015444e6-1a5b-45eb-993d-b5418cfb3990">P1Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmJjZmU0NTI5YTFhNjQ4MDI5M2NkYWEwY2Y0MTcyOWU5L3RhYmxlcmFuZ2U6YmNmZTQ1MjlhMWE2NDgwMjkzY2RhYTBjZjQxNzI5ZTlfOC03LTEtMS0xMDUwMzM_39cfe20b-43ea-4bdb-ad70-49b187c91750"
      unitRef="usd">14900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfNjU3_301ed1f4-3d41-4c2e-b4c9-b4652c6db87e"
      unitRef="shares">38500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfNzIz_07ce9a08-37e9-472a-b708-c72510e6f1bf"
      unitRef="usd">700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfNzU4_89773aec-ed34-472f-adc5-e690f14c48b1"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzNA_b89e00a8-1498-4136-bbf3-0bb37e78d07f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022, the Company granted 87,488 stock options to certain ApolloMed employees and Board members. The options granted during the six months ended June&#160;30, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50 years - 2.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.47% - 82.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02% - 2.47%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.47 - $22.73&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2b1957cc255c424d8d39c550b3fb4230_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfODQy_751c25f9-c90b-4402-a825-1d6b2590fd8f"
      unitRef="shares">87488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib7e67912a5d449dbb5d6e4854647fa10_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMS0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjo4ZDdhZjBkNDQ5Mjk0MmQ3YjFhZjFkZjAwNmYxMTQyMV80_54ca0d0e-3282-47ea-afe1-cd95a1d6cec3">P1Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iafd2b1c8b5514ddf938ef5e9deed8686_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMS0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjo4ZDdhZjBkNDQ5Mjk0MmQ3YjFhZjFkZjAwNmYxMTQyMV85_b47d4eef-5beb-4748-94e0-b76059da074a">P2Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMi0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyM2RmZTliMGMzYTU0OWQxYmJjNDdiYTYxM2U2YzA3YV80_d4105eb8-325d-4a50-90b4-374b845eba26"
      unitRef="number">0.7147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMi0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyM2RmZTliMGMzYTU0OWQxYmJjNDdiYTYxM2U2YzA3YV85_cb1abdc8-736c-4282-bbd6-b36fd53713d9"
      unitRef="number">0.8205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMy0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoxOGMxYjBhZmM2MDc0N2QyYTQ1ZWRjMTRjYzI2YjdiN180_5011be3c-1a55-4fd5-803d-0c4ad12da36b"
      unitRef="number">0.0102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfMy0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoxOGMxYjBhZmM2MDc0N2QyYTQ1ZWRjMTRjYzI2YjdiN185_9796ab29-0c2d-4f60-b12e-57613f63cdf9"
      unitRef="number">0.0247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharePrice
      contextRef="i27162b4c30e1433389aa44bb606e1201_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyMzUwZTQ0NWZkZjU0MmQ4YTU3OWM5M2Y5MTgxMjY3OV80_925c4600-2f78-44ca-97bf-72ebd5ed353b"
      unitRef="usdPerShare">17.47</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i16a45d3b518b423aaab4649221f9e190_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOjU0NzAwNGNiYTBjMzQxODM4MGU4NGQyYTk2Y2Y2MDQ4L3RhYmxlcmFuZ2U6NTQ3MDA0Y2JhMGMzNDE4MzgwZTg0ZDJhOTZjZjYwNDhfNC0xLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyMzUwZTQ0NWZkZjU0MmQ4YTU3OWM5M2Y5MTgxMjY3OV85_3a6a815b-a6e0-466c-a1a6-87692da4f9e5"
      unitRef="usdPerShare">22.73</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib521230a737a4886950b1519bb58fa8f_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMTM4Mg_bddcdc31-f1bd-4ce7-88b8-dabc38f89c1a"
      unitRef="shares">520552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance
      contextRef="ib521230a737a4886950b1519bb58fa8f_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMTQwMw_dc229de5-bdfe-4752-9fdb-28e56ec78d2d"
      unitRef="shares">295721</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib521230a737a4886950b1519bb58fa8f_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMTUwMQ_4c5282cf-d786-4b76-bd27-f7d17bde9f16"
      unitRef="usdPerShare">42.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i675bd27f6f9449a7b867a0997a6672c7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMTc3NA_e95cf105-89f6-4088-8041-75686fd539f9"
      unitRef="usd">10000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjMzMA_204a05f6-0408-419e-a536-1d410edbfa5e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,743&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                  10.00 &#x2013; 11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMS0xLTEtMS0xMDUwMzM_773204e7-05e1-4b5f-857d-95021a386648"
      unitRef="shares">1001740</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMS0zLTEtMS0xMDUwMzM_4d4ef921-6de2-4e3f-b044-bff138b64bc9"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i13efa678914f4d7f98b3e9aeb1cd61d8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMS01LTEtMS0xMDUwMzM_1901855b-d0ed-40ad-b452-72f7a9c1783c">P0Y11M8D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMS03LTEtMS0xMDUwMzM_41a7305d-32d8-42c8-b67c-1e28469c9790"
      unitRef="usd">63100000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsGranted
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMi0xLTEtMS0xMDUwMzM_71b95a95-a09c-440e-8526-c3b80fe5d4fb"
      unitRef="shares">0</ameh:NumberOfWarrantsGranted>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMi0zLTEtMS0xMDUwMzM_5cf12cad-33be-4573-b0dd-61430be5765d"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod>
    <ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMi03LTEtMS0xMDUwMzM_8d9ae251-36d6-4a5c-8363-2812b87e7b93"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsExercised
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMy0xLTEtMS0xMDUwMzM_1084cad9-dc1e-4cf9-a4b0-81cf4faf0bb7"
      unitRef="shares">101953</ameh:NumberOfWarrantsExercised>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMy0zLTEtMS0xMDUwMzM_7a555bbf-0f67-4463-8a09-ce7de603922f"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod>
    <ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfMy03LTEtMS0xMDUwMzM_14791004-a12e-437f-9210-edf8286cad55"
      unitRef="usd">4000000.0</ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue>
    <ameh:ClassOfWarrantOrRightCancelledInPeriod
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNC0xLTEtMS0xMDUwMzM_884d1460-2796-4b67-b8aa-4af6817900b9"
      unitRef="shares">0</ameh:ClassOfWarrantOrRightCancelledInPeriod>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNC0zLTEtMS0xMDUwMzM_7e05db21-177c-4efa-85f7-349fd92e4be2"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod>
    <ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNC03LTEtMS0xMDUwMzM_62037594-e7b6-4727-b76a-a29bcfa1c0e4"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNi0xLTEtMS0xMDUwMzM_7c795511-6997-4bbc-b7cc-9aab946d5372"
      unitRef="shares">899787</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNi0zLTEtMS0xMDUwMzM_ddb97d04-2113-406a-bf04-ab7508fb5a33"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNi01LTEtMS0xMDUwMzM_7931563d-e0b2-4a86-b4a8-2671ca5b3994">P0Y5M8D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmQzODc0MmQ0NzEzOTQ5ZWI5ZmQzYWQ0NmQ5MmNlMTNiL3RhYmxlcmFuZ2U6ZDM4NzQyZDQ3MTM5NDllYjlmZDNhZDQ2ZDkyY2UxM2JfNi03LTEtMS0xMDUwMzM_5fea1a75-e5aa-423d-8fd2-9187d3d460d3"
      unitRef="usd">25300000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i03ceea72d6fa40489f52e559fb181611_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS0wLTEtMS0xMDUwMzM_6f307d74-566d-428e-a570-06279b28da13"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i6840db3bf9284ad4ab822cbf059964ce_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS0yLTEtMS0xMDUwMzM_bfbad3b6-7d2f-4d1a-8601-0d68df9a050e"
      unitRef="shares">462743</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i6840db3bf9284ad4ab822cbf059964ce_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS00LTEtMS0xMDUwMzM_6b6e1bde-6f06-4758-bb06-68afb2ffea82">P0Y5M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i03ceea72d6fa40489f52e559fb181611_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS02LTEtMS0xMDUwMzM_1fd0e1bb-af51-405d-9b7c-68a761f98394"
      unitRef="shares">462743</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i03ceea72d6fa40489f52e559fb181611_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMS04LTEtMS0xMDUwMzM_0f3f7cdc-231d-417a-8289-e9b2aa445ed8"
      unitRef="usdPerShare">10.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i114ccddf4f7649a6848a22c64dbc33c9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi0wLTEtMS0xMDUwMzM_e7c3291b-4a0a-44d1-aba0-0ef99d3f852e"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i8c54372981e0483384beb5dc3115d981_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi0yLTEtMS0xMDUwMzM_96cc403b-ef1b-4648-b7b3-7db52dee4e36"
      unitRef="shares">437044</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i8c54372981e0483384beb5dc3115d981_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi00LTEtMS0xMDUwMzM_7a26d385-54a6-4db6-8bcf-ec74572b038e">P0Y5M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i114ccddf4f7649a6848a22c64dbc33c9_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi02LTEtMS0xMDUwMzM_6cbf7b56-aea6-4a14-98c0-5560849ca1bf"
      unitRef="shares">437044</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i114ccddf4f7649a6848a22c64dbc33c9_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfMi04LTEtMS0xMDUwMzM_8b960f85-77c4-4286-be0b-9936214ee2b1"
      unitRef="usdPerShare">11.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i76936fef1e6b40c18740fd16b3eda56d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC0wLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyOGQ0MGY5NWQ4MDM0ZGFmYjMwNGVkZjgyODhhMmFmMl8yMw_433063c0-6a34-4a2c-b6b2-6f85098f2cf7"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if150202c05234c61a08e030fc794aca5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC0wLTEtMS0xMDUwMzMvdGV4dHJlZ2lvbjoyOGQ0MGY5NWQ4MDM0ZGFmYjMwNGVkZjgyODhhMmFmMl8yOA_cbce6839-516a-4167-9173-4115d57c9f21"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i59a47c483aa24f5c89caa7bb1cdec67d_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC0yLTEtMS0xMDUwMzM_fd58d8ad-7c44-4e67-84f0-0345e3a19540"
      unitRef="shares">899787</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i59a47c483aa24f5c89caa7bb1cdec67d_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC00LTEtMS0xMDUwMzM_05ba6e81-5d4a-4bcf-93da-602820e3249a">P0Y5M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="ic7f9f34bf3fb48cebfa73e5b388e465b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC02LTEtMS0xMDUwMzM_bb013b93-4692-41cc-97f9-01ebfe75b038"
      unitRef="shares">899787</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="ic7f9f34bf3fb48cebfa73e5b388e465b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RhYmxlOmI1MDE1ZjM0N2VkMjRiZjhhZWVhZDY0NTMzMDI3NzMxL3RhYmxlcmFuZ2U6YjUwMTVmMzQ3ZWQyNGJmOGFlZWFkNjQ1MzMwMjc3MzFfNC04LTEtMS0xMDUwMzM_a5d39cd7-b594-4d50-8286-a5b7314faf6f"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjAxNQ_b4dda75a-0449-43a4-bad5-4c2050a1b117"
      unitRef="shares">101953</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjAyMg_add43d04-179d-4b03-b6a3-549fb3ff87b0"
      unitRef="shares">474506</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjEyMQ_0afc00fe-2349-4ba6-afb0-5f5afad82cdb"
      unitRef="usd">1100000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjEyOA_1ee84ae4-d1ba-44b5-b6b2-20d77a8d121e"
      unitRef="usd">4800000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="ie72fbf8622a44da7b8b232c28510f1a8_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjE3Nw_16e54675-ea6d-481e-9cf6-1aedd53fda12"
      unitRef="usdPerShare">10.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i1726507efb5f4fa09d9993c3857c283a_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjE4Mw_20597c5a-ebf7-4e96-ba88-722c0fdd1f1d"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="ia172d03ffb5f4a4181d8f9c79bac7f77_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjI0OQ_24339b50-86a7-453d-83e5-7ebab07d362a"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="if0ae41c7e0b64fbeb8ec11b3c8e12d1b_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY185Ny9mcmFnOjE0OTNiNzA5ZWUwNDQ0NDRhZTRhYzljYzZmMThlNWQwL3RleHRyZWdpb246MTQ5M2I3MDllZTA0NDQ0NGFlNGFjOWNjNmYxOGU1ZDBfMjI1NQ_7aab0f36-ca04-4f97-85cb-bbabe8d711bc"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDYvZnJhZzo5ZDBmOGI0YTgxYzE0NTQ2YTQ2NWE5NDY2NjIyNWI4OS90ZXh0cmVnaW9uOjlkMGY4YjRhODFjMTQ1NDZhNDY1YTk0NjY2MjI1Yjg5XzM1NjQ_29fd55be-9e9d-430c-aef9-d548383b5c11">Commitments and Contingencies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#x201c;DMHC&#x201d;) regulations, including maintenance of minimum working capital, tangible net equity (&#x201c;TNE&#x201d;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of the payor and provider contracts with the Company&#x2019;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $0.3 million and $3.8&#160;million, respectively, for the benefit of certain health plans (see Note 9 &#x2014; &#x201c;Credit Facility, Bank Loans, and Lines of Credit - Standby Letters of Credit&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#x2019;s financial condition, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its insurance coverage is appropriate based upon the Company&#x2019;s claims experience and the nature and risks of the Company&#x2019;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#x2019;s affiliated professional organizations or the Company&#x2019;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#x2019;s insurance coverage, will not have a material adverse effect on the Company&#x2019;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#x2019;s business. Contracted physicians are required to obtain their own insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCredit
      contextRef="i83fa8e1b5460411992308ed07575a1f1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDYvZnJhZzo5ZDBmOGI0YTgxYzE0NTQ2YTQ2NWE5NDY2NjIyNWI4OS90ZXh0cmVnaW9uOjlkMGY4YjRhODFjMTQ1NDZhNDY1YTk0NjY2MjI1Yjg5XzE3OTc_81811f9f-c64c-400f-a5f2-3317b9303db1"
      unitRef="usd">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i4b559e5023334ee3b95e75fa03c7d652_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDYvZnJhZzo5ZDBmOGI0YTgxYzE0NTQ2YTQ2NWE5NDY2NjIyNWI4OS90ZXh0cmVnaW9uOjlkMGY4YjRhODFjMTQ1NDZhNDY1YTk0NjY2MjI1Yjg5XzE4MDQ_9cd04f02-162f-4783-8374-ab4304461b01"
      unitRef="usd">3800000</us-gaap:LineOfCredit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzQyMDI_a0351e05-f25e-49c4-870e-55b540ad69ab">Related-Party Transactions&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2022 and 2021, NMM earned approximately $4.8 million and $4.2 million, respectively, and $11.1 million and $8.7 million, respectively, in management fees from LMA, which is accounted for under the equity method based on the 25% equity ownership interest held by APC in LMA&#x2019;s IPA line of business (see Note 5 &#x2014; &#x201c;Investments in Other Entities &#x2014; Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $0.7 million and $0.6 million, respectively, and $1.4 million and $1.0 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC (see Note 5 &#x2014; &#x201c;Investments in Other Entities &#x2014; Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021, APC paid $1.7 million and $3.2 million, respectively, to DMG for provider services, which is accounted for under the equity method based on the 40% equity ownership interest held by APC. In October 2021,  DMG was consolidated by Apollo. As such, DMG is no longer a related party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $0.1&#160;million and $30,000, respectively, and $0.1 million and $51,000 to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $0.2 million and $0.3 million, respectively, and $0.3 million and $0.4 million, respectively, to Fulgent Genetics, Inc. for services as a provider. One of the Company&#x2019;s board members is a board member of Fulgent Genetics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2022 and 2021, APC paid an aggregate of approximately $12.3 million and $8.2 million to shareholders, respectively, which included approximately $3.3 million and $2.2 million, respectively, to shareholders who are also officers of APC. During the six months ended June&#160;30, 2022 and 2021, APC paid an aggregate of approximately $21.6 million and $15.6 million to shareholders, respectively, and $5.2 million and $3.8 million, respectively, to shareholders who are also officers of APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June&#160;30, 2022 and 2021, SCHC paid approximately $0.1 million and $0.1 million, respectively, and $0.2 million and $0.2 million, respectively, to Numen, LLC (&#x201c;Numen&#x201d;) for an office lease. Numen is owned by a shareholder of APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six ended June&#160;30, 2022 and 2021, NMM paid approximately $0.4 million and $0.4 million, respectively, and $0.7 million and $0.7 million, respectively, to One MSO for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 5 &#x2014; &#x201c;Investments in Other Entities &#x2014; Equity Method&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2022 and 2021, APC paid approximately $3.7 million and $3.6 million, respectively, and $7.3 million and to $7.0 million, respectively, to Arroyo Vista Family Health Center (&#x201c;Arroyo Vista&#x201d;) for services as a provider. Arroyo Vista&#x2019;s chief executive officer is a member of the Company&#x2019;s board of directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with Health Source MSO Inc., a California corporation (&#x201c;HSMSO&#x201d;), Aurion Corporation (&#x201c;Aurion&#x201d;), and AHMC for services provided to the Company. One of the Company&#x2019;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#x2019;s board members. The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June&#160;30, 2022 and 2021, the Company has recognized risk pool revenue under this agreement of $13.3 million and $14.2 million, and $25.3&#160;million and $31.2&#160;million, respectfully, of which $76.0 million and $58.4 million remained outstanding as of June&#160;30, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2022, APC paid $9.3&#160;million to purchase Apollo&#x2019;s stock from a board member. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, affiliates wholly owned by the Company&#x2019;s officers, including Dr. Thomas Lam, ApolloMed&#x2019;s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#x2019;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#x2019;s subsidiaries as related-party transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments and loans receivable from related parties, see Note 5 &#x2014; &#x201c;Investment in Other Entities - Equity Method&#x201d; and Note 6 &#x2014; &#x201c;Loan Receivable and Loan Receivable - Related Parties&#x201d;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ieb082a42a8f04b7f8520726fad9dbed0_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDU5NDY_b4c83efd-53ff-4dae-84ac-081d4239236b"
      unitRef="usd">4800000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ifb2c519a88fb425cafa67a6ac705ce13_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDU5NTQ_225829a9-11e5-4df5-b94d-07e8d42521d2"
      unitRef="usd">4200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i20e887d2baae4779bc16fb980480b5cb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDU5Nzc_822c55e6-31da-428a-83f6-d169cd2c9c2b"
      unitRef="usd">11100000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i1a80af6894a14c43a89ecebb723dcfe1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDU5ODU_fe3fb472-ac30-42b0-9dae-d71b4d602b20"
      unitRef="usd">8700000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i767518e6c72e4e4997ab25645b106efc_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDYwOTM_057e8cae-1e6a-462a-906c-322966fb5aa5"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i778bae90463c48628833fa5514d45310_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDYwOTM_e1ded9bc-8d93-4d26-90a9-4c5ff9a99840"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8d8d52a080a44e86a886bce63a285724_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDY4OTM_4467e246-4d37-4db2-a426-5343eba67055"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i7ab323e1b397418fb339066bb405899c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDY5MDE_c8ced41c-ec0f-4814-807c-5d83f80e01e8"
      unitRef="usd">600000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i6b3980ecb88c467597f9070419028889_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDY5MjQ_6c6c7162-d6cf-4749-ae00-b3ddfb77b393"
      unitRef="usd">1400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ica63af2bcd74490792c66cc16aa7cd45_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDY5MzI_c181c6ba-7407-467a-a56c-baba3b8684dd"
      unitRef="usd">1000000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id2f665909db64084bcae52d7869044f6_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDcwNDM_38693203-c5fa-4f28-89a0-d3a4f0feaeb4"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i720010c532d04ae38a15375c00f6c278_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDcwNDM_49093c06-e764-4333-8b33-3f041ec054d3"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i658af4a1b5524e469c86ffaf726d3a51_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc0NTA_921f1aaf-15e6-476f-8e91-fdbd3dd77bbc"
      unitRef="usd">1700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8069e38106d34794bbbea1a815263bf1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc0ODE_be0069bf-f50e-4a57-8c11-b8650beeb2de"
      unitRef="usd">3200000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i686c7f250f0e4d35824cd656b22866ad_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc1OTA_a12fbf74-f2be-4cda-9da4-46f290d3cbe0"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i2ba4984e1d0947a59e1755baeb841f28_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc4NjM_8d880f8f-513a-4246-84d1-7c7bec855d4f"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i42ce7049b8564902b4714f05408d23cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc4NzE_205ece8e-7148-4abe-800d-b07ac044ad5f"
      unitRef="usd">30000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i7f93bbd717a34da48676ae33c98e2878_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc4OTQ_896e07f7-a305-4e0c-8f20-87e2051a643b"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if9d5e8e10ad4481ab709154b84b5e390_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NDc5MDI_b6f62f4a-1f08-44d2-b506-292d8c626bb4"
      unitRef="usd">51000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i47b66c55e1084cb1b52c404c22c765cf_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTEwMjY_c4f7f70a-3393-415a-bcc4-bc1aed26f373"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i570036110c9340efa486b231d649cf09_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTEwMzQ_e0e90471-f3b3-4c15-a287-4d0d05400dd7"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if91fffa5808944f686a081038f37122c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTEwNTc_6399a7c2-d3cd-4d67-a206-3c3abe0b94eb"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3873e858d6954dc9a1e7b2ebfd958d51_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTEwNjU_65c2386c-934f-44bb-b955-8c76edcd96e4"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ie0924e12aa8d4ee4b2641423ceba4881_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE1MjE_53bbe553-6b5b-4543-9612-d004f89bce29"
      unitRef="usd">12300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ibf42668aa8fc4595af61af9ed0dceace_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE1Mjk_edd8bcbd-b538-4cba-b999-c9bcaaeefea1"
      unitRef="usd">8200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i1340961fa52f41c78bd6a84fc6c342d9_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE1OTM_5ec0999a-fc53-45b1-a3d9-1020d4b69e28"
      unitRef="usd">3300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i5fd9786f0dd94c12a12df172b4e36ceb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE2MDE_a7a9b731-cc76-4715-9b5b-5a7be61623a1"
      unitRef="usd">2200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i06340797df8f4752a83e03326162b898_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE3NDY_86b5ed8e-80a7-4cf6-b9f1-1ec3115ef282"
      unitRef="usd">21600000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="iff12e49686f34776bca7427f81b46a8e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE3NTQ_b5c1339a-dbf4-4534-a489-ee0db5c31b7e"
      unitRef="usd">15600000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i493e02bb89bd49aaa06143a91d99bd2e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE3OTM_ece44d86-49bb-4d80-bfdf-2ee01e6837b5"
      unitRef="usd">5200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3be6c5a1eee74540ac2a07c4971194b7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTE4MDE_a74231ab-fb90-45b6-b4dc-de92094ddf81"
      unitRef="usd">3800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i70e5cc9cbbc44c1ca2da76b30137a3ab_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTIxMDY_55be06e8-f39c-4bf4-88cc-b6e4784192a5"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i0933e3ac6e9444cca9e2cf27d88e1e4d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTIxMTQ_d031175d-6a38-48e1-9af1-187b3175b591"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="id668620835dc4bb0acb31d65a5da7f73_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTIxMzc_2a69f489-de67-4455-b8fd-68f923fa2ed8"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib853e0afcc864f9fb37c1a57ebf20e0d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTIxNDU_ea7d6a4f-3af1-4201-b05a-12baeaee226a"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i4ed1fb4cb8784d2baa6d489ba5f6e31c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI1OTg_be245e50-5993-441b-b213-a18d2c8039d0"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i2fb8594254234c10bce4ca7cad2d7f34_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI2MDY_5caee83f-329a-454b-9e2f-c061d606fe37"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ic5b1510e6b3e48aab9201dae55a97382_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI2Mjk_200233d9-b1fc-4af6-b8dd-410664a553e9"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="id84ea8946f574e32a5be27bbbc154f24_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI2Mzc_26a2ffd4-0a45-4255-bf9e-086112ab14f1"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i52933dc179ba4dbc8f26c1943d99f3ed_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM2ODY_ab73e07b-7676-424a-9b69-8750eb88757c"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i608f29a5f13e45cfa7a9e81eef3d1ed6_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzI1NDk_1a0b3047-7ec7-40a3-9bcf-3cbf2ad9953a"
      unitRef="usd">3700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i103376726f94415da0aa6fb6fa1625f1_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzI1NTY_ee40e130-6d44-47e7-8f80-e2f764e3aaf2"
      unitRef="usd">3600000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib0fe166dd3574c6b86ee5fd3faa41fb8_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI4Nzc_0f99e85f-d3a9-4d4b-9e41-36eef6b60d78"
      unitRef="usd">7300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i0213948f1599453ab721957923ae20aa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTI4OTA_dcd54769-a5d0-4bbe-8616-eeafe3344487"
      unitRef="usd">7000000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzQxOTU_f70d539a-d91a-4cd0-8ab1-3b7f81ba931b">The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(728)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="idd1c490153ac4f1cb6028c98823533b4_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzItMS0xLTEtMTA1MDMz_2cc1efc5-3fdd-4dd0-8a19-aa383acb62cf"
      unitRef="usd">14419000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="if433cdd244a24b8e8f0de5c3a6d6a9da_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzItMy0xLTEtMTA1MDMz_6c7fd65d-9a64-4db2-933e-ad2a9f7eeff9"
      unitRef="usd">12696000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i92d25dc960744271ba14d5a22e01a9f4_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzItNS0xLTEtMTA1MDMz_5ca1ebe9-416b-4c18-af2d-641a9b4b4651"
      unitRef="usd">25785000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="ibcbf57723d89405ea64c036cc63fb0eb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzItNy0xLTEtMTA1MDMz_60858b3e-f3c3-423c-9372-1f489d18ebd3"
      unitRef="usd">25793000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <us-gaap:ManagementFeeExpense
      contextRef="if451ab4e4ce44c71a99f29e2c5e07e30_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzMtMS0xLTEtMTA1MDMz_7692e237-447c-4b7e-9763-6ec45cf8d8b5"
      unitRef="usd">649000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i2fb1b871a5524ffcbf6e9b30520d3b46_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzMtMy0xLTEtMTA1MDMz_918cc1a2-483f-4f95-be6f-82b479ff41ea"
      unitRef="usd">31000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i87972789a91f4575b4ee414751a09b0d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzMtNS0xLTEtMTA1MDMz_25463391-df25-4101-8804-7b00500a4bb4"
      unitRef="usd">728000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i94083cc9f0fc4e369ee64217a4f7e9fc_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzMtNy0xLTEtMTA1MDMz_236f1441-7db7-48ad-a492-2c6628176319"
      unitRef="usd">108000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="iba052b72bbb34b62be83891b4561a8d2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzQtMS0xLTEtMTA1MDMz_29e60bf5-d194-4eb9-ac1a-2119d9a3ac0c"
      unitRef="usd">75000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="iad69ae1f414c4d90bc9075012d5d4d30_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzQtMy0xLTEtMTA1MDMz_ae0787a1-2ef5-4caa-80e1-5ae23bae566e"
      unitRef="usd">77000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="ib23158de6e644cdd9bc4e3523331c1e9_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzQtNS0xLTEtMTA1MDMz_044193cb-ca40-4adb-a50c-5a8530fbfc0b"
      unitRef="usd">150000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="ie446c27adcbd42b59894a90417c05196_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzQtNy0xLTEtMTA1MDMz_b66993a0-a73a-4e40-8bd2-1e5be399c93e"
      unitRef="usd">152000</us-gaap:ManagementFeeExpense>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzYtMS0xLTEtMTA1MDMz_779dcdfe-dc03-4db6-8ebd-fc1bd1c1232e"
      unitRef="usd">13695000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzYtMy0xLTEtMTA1MDMz_7e683875-bfea-41c2-953b-0b06051cd68f"
      unitRef="usd">12588000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzYtNS0xLTEtMTA1MDMz_ff8e7c98-d7ec-42f1-b5de-a45b7c6c25a3"
      unitRef="usd">24907000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90YWJsZTo4Y2YzMTcwMGVjYmY0NGNhOWYyZmI4Zjk0YzE2NDhlNy90YWJsZXJhbmdlOjhjZjMxNzAwZWNiZjQ0Y2E5ZjJmYjhmOTRjMTY0OGU3XzYtNy0xLTEtMTA1MDMz_99270638-ae7e-4c45-b1c6-0f192a72f3fd"
      unitRef="usd">25533000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="idd1c490153ac4f1cb6028c98823533b4_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1MjE_2a68a65e-8604-4e63-bace-1e12829dd824"
      unitRef="usd">13300000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="if433cdd244a24b8e8f0de5c3a6d6a9da_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1Mjk_2b52a3ac-92fb-4793-9213-d10c8213bae6"
      unitRef="usd">14200000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i92d25dc960744271ba14d5a22e01a9f4_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1Mzg_b35c0dfe-2cd3-4dc9-b39b-6c0f5fa4cf3a"
      unitRef="usd">25300000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="ibcbf57723d89405ea64c036cc63fb0eb_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1NDY_a4998285-083b-4cd6-89d0-c2646c7358b5"
      unitRef="usd">31200000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i7f46457a64ad499c901e9853b8d0ba22_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1NzQ_1b96e626-e16e-4049-b003-3cf7fe504e0e"
      unitRef="usd">76000000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i706352fc1d254fd5a5e36dc095d71cfe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzE2NDkyNjc0NTM1ODI_fd77f42a-3e2c-488a-b7d5-b5ea117dfb3a"
      unitRef="usd">58400000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib64616cababe4909a842281a3ca6fa56_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzQzOTgwNDY1MjQyNzU_6039f417-28cb-49b0-989d-4c72f6b73427"
      unitRef="usd">9300000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i817afcd7d5c442c2b55faa40b0d1a8f5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMDkvZnJhZzpkMzJmZDAzNDc4ZDk0ZmEwODJmZTdhMWJhZjllMzRiNy90ZXh0cmVnaW9uOmQzMmZkMDM0NzhkOTRmYTA4MmZlN2ExYmFmOWUzNGI3XzQzOTgwNDY1MjQyNzU_74326a31-3f43-4015-9224-cee361be0027"
      unitRef="usd">9300000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTUvZnJhZzowYjhhODdjYThjZWE0NzIzYmUwOGM2YzAzMzk4MmFkMS90ZXh0cmVnaW9uOjBiOGE4N2NhOGNlYTQ3MjNiZTA4YzZjMDMzOTgyYWQxXzI0ODI_98cf05aa-27c1-4718-83d7-d30d2f7c7212">Income Taxes&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the liability method of accounting for income taxes as set forth in ASC 740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#x2019;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#x2019;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for the six months ended June&#160;30, 2022 and 2021, was 35.1% and 30.0%, respectively. The tax rate for the six months ended June&#160;30, 2022, differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, non-deductible permanent items, and change in valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#x2019; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2017 through December&#160;31, 2021, and for the years ended December 31, 2018 through December&#160;31, 2021, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTUvZnJhZzowYjhhODdjYThjZWE0NzIzYmUwOGM2YzAzMzk4MmFkMS90ZXh0cmVnaW9uOjBiOGE4N2NhOGNlYTQ3MjNiZTA4YzZjMDMzOTgyYWQxXzE2NDkyNjc0NDQxNDk_72c4e7a7-2113-4d8a-bff1-21b69b5f36b5"
      unitRef="number">0.351</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTUvZnJhZzowYjhhODdjYThjZWE0NzIzYmUwOGM2YzAzMzk4MmFkMS90ZXh0cmVnaW9uOjBiOGE4N2NhOGNlYTQ3MjNiZTA4YzZjMDMzOTgyYWQxXzE2NDkyNjc0NDQxNTQ_0e0b4907-1587-4337-a362-dd2acff5ef2c"
      unitRef="number">0.300</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzEwOTA_a7cda688-ed7d-4e3b-bc65-d4249d4d22ab">Earnings Per Share&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated using the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, APC held 11,175,702 and 10,925,702 shares of ApolloMed&#x2019;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended June&#160;30, 2022 and June&#160;30, 2021, restricted stock of  394,606 and 0, respectively were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive. For the six months ended June&#160;30, 2022 and June&#160;30, 2021, restricted stock of  257,193 and 0, respectively were excluded from the computation of diluted weighted average common shares outstanding because the assumed proceeds, as calculated under the treasury stock method, resulted in these awards being antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June&#160;30, 2022, 242,899 of restricted stock with performance conditions were excluded from the computation of diluted weighted average common shares outstanding because these conditions were not achieved as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,858,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,023,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,815,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,255,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,082,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,746,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,858,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,023,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,815,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,255,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,082,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,746,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9902cb6392bf40fe99762875e13589c3_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzcyNw_ec7589e0-1075-488e-b72a-2e779928f381"
      unitRef="shares">11175702</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i70e8720f09834880b0eb68cb4dfd69c0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzE2NDkyNjc0NDI3NzE_22093d69-5a79-4669-ab2f-e9d5887f0c4c"
      unitRef="shares">10925702</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iea207f25a4494db3b8ca98bec38b0cf3_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMxMTY_dcdb139a-0aa5-414c-bd84-fc7f728cd2d4"
      unitRef="shares">394606</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i09d176d59d3c498f8f2c88e2c37d402e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMxMjI_adc5ac4b-286d-4fd5-91b3-64247f3e38fc"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i535c48c761b74aa9ac2acbd6ebd3be28_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMxMDQ_4731871f-06ee-4e23-ab4b-46d7af1f420c"
      unitRef="shares">257193</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ica66f014fe6849c9a087191711c14b58_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMxMTA_45dd1fd9-6063-4088-86cd-91877e7f0820"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie4b065ecad2c4dd18600860d892995a7_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMwOTg_e81d3874-68b0-458c-9fde-edc7c04b2e90"
      unitRef="shares">242899</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7bd5950728274396a47ab8be6047ebba_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzQzOTgwNDY1MTMwOTg_f52549e7-4651-44b3-9518-3a825d5db8fa"
      unitRef="shares">242899</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzEwOTg_2e584d04-28fe-4cbd-9f2a-d19f72692443">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,858,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,023,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,815,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,255,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,082,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,746,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzEtMi0xLTEtMTA1MDMz_00acaaa9-7c00-4661-8882-b8c72f1d720a"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzEtNC0xLTEtMTA1MDMz_89d1e288-ff6d-406f-a71e-76585560b60f"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzItMi0xLTEtMTA1MDMz_036d6510-b938-4cc8-8a06-522f094d2c81"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzItNC0xLTEtMTA1MDMz_fc71b44e-3089-4300-88f6-1bbb60d61c17"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzMtMi0xLTEtMTA1MDMz_743c327b-adfb-40b6-97bb-059aa5d90bcf"
      unitRef="shares">44858657</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzMtNC0xLTEtMTA1MDMz_d02be5ac-8964-4ab9-809b-34bff69d9152"
      unitRef="shares">44165264</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzQtMi0xLTEtMTA1MDMz_8445aa53-9fe5-40b5-8ff3-e8fc4a6ea7e9"
      unitRef="shares">46023015</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTpiNTI2OTEyNmFhNDE0ODUxODM0YzdhZWM2MGVmZWNiNy90YWJsZXJhbmdlOmI1MjY5MTI2YWE0MTQ4NTE4MzRjN2FlYzYwZWZlY2I3XzQtNC0xLTEtMTA1MDMz_0be35ee0-e654-4836-a728-c29f639b8acc"
      unitRef="shares">45828802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzEtMi0xLTEtMTA5NzA0_a71b137d-09c8-4029-899e-fd2db7d01bc1"
      unitRef="usdPerShare">0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzEtNC0xLTEtMTA5NzA3_53e3535e-6b59-42f2-95e4-df8bba6d3de2"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzItMi0xLTEtMTA5NzA0_87a04339-596b-4f3e-8169-2c0631f13fc4"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzItNC0xLTEtMTA5NzA3_e19e2c80-50dc-4bc2-9016-a29ef8c9d389"
      unitRef="usdPerShare">0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzMtMi0xLTEtMTA5NzA0_50ee6e8a-4505-40a8-9ade-2a3a98aa4ac3"
      unitRef="shares">44815307</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzMtNC0xLTEtMTA5NzA3_f8b2cf5f-1f97-4139-8b94-4cfa04acce42"
      unitRef="shares">43255901</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzQtMi0xLTEtMTA5NzA0_2c317f14-d9ca-4531-8679-b3670639f16a"
      unitRef="shares">46082643</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo5ZTEwMjY5NWY0YzI0MzRiYjk0MDY0NDk4YmZjODU5Ny90YWJsZXJhbmdlOjllMTAyNjk1ZjRjMjQzNGJiOTQwNjQ0OThiZmM4NTk3XzQtNC0xLTEtMTA5NzA3_ef28edad-3abc-4d62-9045-c45420898294"
      unitRef="shares">44746761</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90ZXh0cmVnaW9uOmE3NWZlMjFmNzcyMzQ4ODZiYWI5NDJjOTQ0MjgzZjY3XzEwOTU_b39062fc-544e-45e4-ab05-50b7f31b2547">Below is a summary of the shares included in the diluted earnings per share computations:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,858,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,023,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,815,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,255,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;455,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,082,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,746,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzEtMi0xLTEtMTA1MDMz_10e5fd77-6ab8-4d55-bf04-d152232fb506"
      unitRef="shares">44858657</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzEtNC0xLTEtMTA1MDMz_a7721904-87d6-43ff-947e-6f0f504f17b5"
      unitRef="shares">44165264</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="id604da4cbf9d48cd853c3313a4b215d1_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzMtMi0xLTEtMTA1MDMz_dfd350d7-0b57-4d37-b72a-89eb79f13a3d"
      unitRef="shares">418322</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6ad190507ff44da9b6ffe950ec0a7c48_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzMtNC0xLTEtMTA1MDMz_47d8a02a-dd68-4d29-9534-93d3d5fe8711"
      unitRef="shares">466104</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4b1e7c7a12844a52bcf3c60b54e403b8_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzQtMi0xLTEtMTA1MDMz_7a6c5b95-d568-4845-9619-ac4732ac4399"
      unitRef="shares">651725</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="icbe4add77b0642b587fbbdfc4e0469d7_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzQtNC0xLTEtMTA1MDMz_f126623c-0840-480b-8942-4e8d22b6e340"
      unitRef="shares">992723</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iea207f25a4494db3b8ca98bec38b0cf3_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzUtMi0xLTEtMTA1MDMz_02f15140-25f9-4f37-bb23-2cd91ea5ad78"
      unitRef="shares">94311</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i09d176d59d3c498f8f2c88e2c37d402e_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzUtNC0xLTEtMTA1MDMz_ea8299ad-c954-4745-b26b-705407451987"
      unitRef="shares">204711</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzYtMi0xLTEtMTA1MDMz_2ae5ef69-a1cd-455f-8f33-1da8cd891503"
      unitRef="shares">46023015</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTphZTA4MzI2MTg0ODc0ZjRlYTQ1NjMzZGQ1NjE0Njc1Mi90YWJsZXJhbmdlOmFlMDgzMjYxODQ4NzRmNGVhNDU2MzNkZDU2MTQ2NzUyXzYtNC0xLTEtMTA1MDMz_980c5845-0e31-4dfb-878a-35f607861a16"
      unitRef="shares">45828802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzEtMi0xLTEtMTA5NzI2_b6482cfa-f918-4f5b-84c3-11b14762b4a4"
      unitRef="shares">44815307</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzEtNC0xLTEtMTA5NzI5_9ecdb032-eadd-4da9-882f-999cfda13a67"
      unitRef="shares">43255901</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie500388613f5490c85227584adbecd21_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzMtMi0xLTEtMTA5NzI2_20e165a3-f5af-42c5-986b-0c1f2bddd333"
      unitRef="shares">455170</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i082d8e652b86490ea5c3fe0dfaaaa3c7_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzMtNC0xLTEtMTA5NzI5_44ed32f4-f050-4644-a4b5-91724555aefe"
      unitRef="shares">409154</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib08d24f28e4a48f99ec3872354ff7790_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzQtMi0xLTEtMTA5NzI2_7db345d1-7b6c-40c5-a937-467683899246"
      unitRef="shares">689240</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i49102b8554a1457c8a1f914d3daaa7f9_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzQtNC0xLTEtMTA5NzI5_a823c24b-e01f-4e57-8bfa-ba53d2ad0ee1"
      unitRef="shares">911131</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i535c48c761b74aa9ac2acbd6ebd3be28_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzUtMi0xLTEtMTA5NzI2_bb38a870-0ad0-4857-9c61-edaf5ec89f38"
      unitRef="shares">122926</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ica66f014fe6849c9a087191711c14b58_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzUtNC0xLTEtMTA5NzI5_17f64373-beae-4d13-8061-5eeb9086baec"
      unitRef="shares">170575</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzYtMi0xLTEtMTA5NzI2_cb4f6a01-bdf9-4ec8-8810-16e08a596121"
      unitRef="shares">46082643</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMTgvZnJhZzphNzVmZTIxZjc3MjM0ODg2YmFiOTQyYzk0NDI4M2Y2Ny90YWJsZTo0MTBiZWQ1NWIwMzE0ZWI5ODFhMjUyZTRjYmJkNzgwMi90YWJsZXJhbmdlOjQxMGJlZDU1YjAzMTRlYjk4MWEyNTJlNGNiYmQ3ODAyXzYtNC0xLTEtMTA5NzI5_cec2ae91-9a2f-420a-93c9-6d7afe9792d5"
      unitRef="shares">44746761</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90ZXh0cmVnaW9uOmViZmUyMzU5MDQ0YTRkMjFhYmQ4Y2EwYmI1YzYzNWZjXzE5MzY_4ee4a458-079f-4c4e-9b5f-bc966cd80e80">Variable Interest Entities (VIEs)&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#x2019;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#x2013; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#x201d; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#x2019;s other consolidated VIEs were not considered significant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due from affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable, net of current portion &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90ZXh0cmVnaW9uOmViZmUyMzU5MDQ0YTRkMjFhYmQ4Y2EwYmI1YzYzNWZjXzE5Mzg_6dd2a8ee-c91d-46f2-9627-c8384c1d143c">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#x2019;s other consolidated VIEs were not considered significant. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due from affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable, net of current portion &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQtMS0xLTEtMTA1MDMz_45419f4a-b5b9-4154-bce1-9650d2e2e51a"
      unitRef="usd">139299000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQtMy0xLTEtMTA1MDMz_4a679241-3ffe-4b05-8fac-1883c05719d2"
      unitRef="usd">161762000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUtMS0xLTEtMTA1MDMz_e8bf7128-77f8-4021-9853-63bfe8db2979"
      unitRef="usd">37807000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUtMy0xLTEtMTA1MDMz_a2f29c83-ddd0-4b06-a2cc-a6a8a05ef71f"
      unitRef="usd">49066000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzYtMS0xLTEtMTA1MDMz_0d623835-1c79-429c-ba96-58d05c66f91e"
      unitRef="usd">21601000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzYtMy0xLTEtMTA1MDMz_5d2d8a52-935b-4a14-8f0a-ce07478cd826"
      unitRef="usd">7251000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzctMS0xLTEtMTA1MDMz_98736c39-8389-4e33-8ca3-4dfb2c547256"
      unitRef="usd">80324000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzctMy0xLTEtMTA1MDMz_70d23f4c-7176-4438-8d88-17d74af6af94"
      unitRef="usd">62180000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzgtMS0xLTEtMTA1MDMz_23541e42-9655-4c06-b902-7eee2921222c"
      unitRef="usd">4869000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzgtMy0xLTEtMTA1MDMz_35dcff5b-87f2-49fc-a276-0f9bfebb1c77"
      unitRef="usd">1342000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzktMS0xLTEtMTA1MDMz_c2d5c203-fb80-481d-ad26-544217cfce3d"
      unitRef="usd">1786000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzktMy0xLTEtMTA1MDMz_0b56cca5-c679-43e3-8249-8a715ec210cf"
      unitRef="usd">1833000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEwLTEtMS0xLTEwNTAzMw_e8c9d18c-aa71-47d8-b5c2-a1a9ded2ba1a"
      unitRef="usd">6715000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEwLTMtMS0xLTEwNTAzMw_6cb7a08f-7d2e-47e0-8e26-9e99c1b75d58"
      unitRef="usd">11734000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzExLTEtMS0xLTEwNTAzMw_e5f7293b-6eb1-42c4-b864-c39f50876bbf"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzExLTMtMS0xLTEwNTAzMw_27dc7be0-9c3a-40b2-8e83-f022c9f2b077"
      unitRef="usd">4000000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEyLTEtMS0xLTEwNTAzMw_4ea94146-8682-4a83-aef1-8f43c3fb49d6"
      unitRef="usd">35960000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEyLTMtMS0xLTEwNTAzMw_091fc73b-a5e6-462d-9e12-9624b5fee4ef"
      unitRef="usd">6598000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEzLTEtMS0xLTEwNTAzMw_5cbdd106-36f9-4b69-a21a-af2a55aa9a44"
      unitRef="usd">328361000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzEzLTMtMS0xLTEwNTAzMw_1180d79d-102f-4355-9bc6-44d51977b8e5"
      unitRef="usd">305766000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE2LTEtMS0xLTEwNTAzMw_9609a8be-4afa-4333-9745-eac01ffaaf3b"
      unitRef="usd">85525000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE2LTMtMS0xLTEwNTAzMw_fa9b5558-5962-42c1-ae40-e87654a845e1"
      unitRef="usd">49547000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE3LTEtMS0xLTEwNTAzMw_aaad75f0-c147-4722-8072-eb3dc0d3ae97"
      unitRef="usd">58799000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE3LTMtMS0xLTEwNTAzMw_002913a7-f87b-4bf4-803e-6aa4c86150eb"
      unitRef="usd">58282000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE4LTEtMS0xLTEwNTAzMw_c28e2ae6-10ea-4df4-96a1-833f828f5bff"
      unitRef="usd">116145000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE4LTMtMS0xLTEwNTAzMw_10f716c4-ef80-49ee-889a-84cab5c92713"
      unitRef="usd">109656000</us-gaap:Goodwill>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE5LTEtMS0xLTEyMzY1Mg_1574897a-b89d-4976-8aa1-74d7fd1a6ce6"
      unitRef="usd">59000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE5LTMtMS0xLTEyMzY1OQ_3d2b96f9-74d7-464c-b9f5-4b1843604650"
      unitRef="usd">0</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE5LTEtMS0xLTEwNTAzMw_ae942a64-abb9-4444-997a-f8592a425cc9"
      unitRef="usd">2125000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzE5LTMtMS0xLTEwNTAzMw_38a3e2b4-3333-40d0-be63-82f6a3d4922e"
      unitRef="usd">89000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIwLTEtMS0xLTEwNTAzMw_bdb0e726-99fd-499d-99df-f1545fc884f4"
      unitRef="usd">431270000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIwLTMtMS0xLTEwNTAzMw_8e4788db-a98e-43f7-b222-45a6aab1b345"
      unitRef="usd">802821000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIxLTEtMS0xLTEwNTAzMw_5bebebcc-d2d3-4ede-9cc3-47efb2183d54"
      unitRef="usd">31500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIxLTMtMS0xLTEwNTAzMw_0c88975a-018e-4131-87d1-91e4f00594ad"
      unitRef="usd">41715000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIyLTEtMS0xLTEwNTAzMw_b59e9763-3007-4094-8052-4ff5132fff73"
      unitRef="usd">405000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzIyLTMtMS0xLTEwNTAzMw_b9b185ef-41c6-4d4b-a34e-dfd3296202bb"
      unitRef="usd">405000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI0LTEtMS0xLTEwNTAzMw_e93a59f7-d2a7-4f89-9217-854ea828b062"
      unitRef="usd">9898000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI0LTMtMS0xLTEwNTAzMw_6b1d062c-588f-4a67-b53b-64f7a960d0b4"
      unitRef="usd">4953000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI1LTEtMS0xLTEwNTAzMw_d1ea8389-78f5-4d17-936a-529e9000974d"
      unitRef="usd">2808000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI1LTMtMS0xLTEwNTAzMw_8106492a-7fd2-4111-8ebb-b1c4cff4694b"
      unitRef="usd">3219000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI3LTEtMS0xLTEwNTAzMw_6348c085-df67-470f-bf17-bdc74de1ea77"
      unitRef="usd">738534000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI3LTMtMS0xLTEwNTAzMw_bdf31396-5841-436c-9147-d76133ff086b"
      unitRef="usd">1070687000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI5LTEtMS0xLTEwNTAzMw_dd3c17ff-16ab-41d4-91e5-43e0d2728bb4"
      unitRef="usd">1066895000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzI5LTMtMS0xLTEwNTAzMw_5f0930e2-4f1d-422e-865c-6288ec3f2480"
      unitRef="usd">1376453000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzMyLTEtMS0xLTEwNTAzMw_7840b83c-d668-4686-8a1d-b013c9e8c457"
      unitRef="usd">16087000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzMyLTMtMS0xLTEwNTAzMw_2867a908-6ce3-44ba-a0ca-d4600d77b3aa"
      unitRef="usd">11591000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzMzLTEtMS0xLTEwNTAzMw_433b12f6-e75f-45f1-9a9a-0fe50a107562"
      unitRef="usd">6071000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzMzLTMtMS0xLTEwNTAzMw_315e2a41-62b5-4049-8044-94b995c88aa0"
      unitRef="usd">10534000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM0LTEtMS0xLTEwNTAzMw_4fb510cf-7ddd-42c5-8351-2f6833b00767"
      unitRef="usd">71509000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM0LTMtMS0xLTEwNTAzMw_2e9c7f43-1b69-4f61-9ae9-c32c1efb4e41"
      unitRef="usd">44000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DividendsPayableCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM2LTEtMS0xLTEwNTAzMw_9990534a-fa3b-4589-8d87-184a3c62f96b"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM2LTMtMS0xLTEwNTAzMw_20a8311d-e45d-4909-9227-dbb99941d659"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM4LTEtMS0xLTEwNTAzMw_fada8d7f-81a2-4f9d-8345-403a287d8400"
      unitRef="usd">2413000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM4LTMtMS0xLTEwNTAzMw_6f915cd0-5d4e-4369-8444-65c056f1d99d"
      unitRef="usd">780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM5LTEtMS0xLTEwNTAzMw_7c1166b8-3fe5-48c8-af27-4df715849752"
      unitRef="usd">524000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzM5LTMtMS0xLTEwNTAzMw_b2b74ab3-0486-498a-94c4-1111d06b9d43"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQwLTEtMS0xLTEwNTAzMw_21f65d2d-4a4f-4251-ba07-b206dba06919"
      unitRef="usd">1906000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQwLTMtMS0xLTEwNTAzMw_688fd3b4-0637-45d2-8d2e-636349612927"
      unitRef="usd">1250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQyLTEtMS0xLTEwNTAzMw_13129a8f-b5b7-4c95-ae17-edf82c478bc8"
      unitRef="usd">99066000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQyLTMtMS0xLTEwNTAzMw_3ff55780-ea93-4881-8364-92aa512efcc7"
      unitRef="usd">68821000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ1LTEtMS0xLTEwNTAzMw_92552c16-d773-401a-aa69-5b500f149a0b"
      unitRef="usd">22795000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ1LTMtMS0xLTEwNTAzMw_da71a66f-d993-4232-bf5d-0f1461bb0e89"
      unitRef="usd">7114000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ2LTEtMS0xLTEwNTAzMw_44dcbf23-1f80-4a06-abee-2569e2a6e4d9"
      unitRef="usd">3887000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ2LTMtMS0xLTEwNTAzMw_cc36cec6-0eb3-4e25-b1f1-bf8bc308e266"
      unitRef="usd">1982000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ3LTEtMS0xLTEwNTAzMw_e133223a-84d8-4675-bdf5-a89daf2f7366"
      unitRef="usd">1049000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ3LTMtMS0xLTEwNTAzMw_e8aef088-830d-40ff-89fc-3657ac9b8f97"
      unitRef="usd">193000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ4LTEtMS0xLTEwNTAzMw_7a563fd3-3b71-44d6-9351-508264fd4d29"
      unitRef="usd">8333000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ4LTMtMS0xLTEwNTAzMw_e59293ab-85d4-42d6-82b9-4d0bd809cdaa"
      unitRef="usd">3950000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ5LTEtMS0xLTEwNTAzMw_6b4b9525-60e1-484d-8e10-1de89ceeee07"
      unitRef="usd">8542000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzQ5LTMtMS0xLTEwNTAzMw_fd82b8c8-2843-4dc8-a2ba-81291574249e"
      unitRef="usd">9614000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUxLTEtMS0xLTEwNTAzMw_0be6478f-4999-46ef-bb02-ffa5d2af9c1c"
      unitRef="usd">44606000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUxLTMtMS0xLTEwNTAzMw_8dbbc678-28a6-4de4-a579-e4bb1115e479"
      unitRef="usd">22853000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUzLTEtMS0xLTEwNTAzMw_c1422791-db43-48da-82fb-b20ba5d6b39c"
      unitRef="usd">143672000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if79c2773d57946a3995aed561a9def52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjQvZnJhZzplYmZlMjM1OTA0NGE0ZDIxYWJkOGNhMGJiNWM2MzVmYy90YWJsZTowOWUyM2VmZGFkYjY0MTE3YTBhYjIwNTMzY2JjMWM2OC90YWJsZXJhbmdlOjA5ZTIzZWZkYWRiNjQxMTdhMGFiMjA1MzNjYmMxYzY4XzUzLTMtMS0xLTEwNTAzMw_c6578239-d863-4412-9e08-63eddfaf5c59"
      unitRef="usd">91674000</us-gaap:Liabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNTY_31456055-e8b4-434b-9d98-406cd14dddc7">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of thirty days to nine years. Some of the leases may include options to extend the lease terms for up to 10 years, and some of the leases may include options to terminate the leases within one year. As of June&#160;30, 2022 and December&#160;31, 2021, assets recorded under finance leases were $1.4 million and $1.3 million, respectively, and accumulated depreciation associated with finance leases were $0.8 million and $0.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the six months ended June&#160;30, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNjI_2dfcfcc9-b5b3-4f3a-be7e-2a1cb0cf9972">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of thirty days to nine years. Some of the leases may include options to extend the lease terms for up to 10 years, and some of the leases may include options to terminate the leases within one year. As of June&#160;30, 2022 and December&#160;31, 2021, assets recorded under finance leases were $1.4 million and $1.3 million, respectively, and accumulated depreciation associated with finance leases were $0.8 million and $0.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the six months ended June&#160;30, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i15757c3b5f1f4c7ca17b41a6d3ae72fa_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzE3Mw_131e480d-c12b-4c74-b511-e8a836a067d4">P30D</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i15757c3b5f1f4c7ca17b41a6d3ae72fa_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzE3Mw_bc531302-763a-4dd4-8a77-273bb27ad1e4">P30D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i6b1ed3c5e65d4fbbb94a7b74e3634086_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzE3OQ_ce4fd3fa-3761-449f-99ee-fdbf364f343e">P9Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i6b1ed3c5e65d4fbbb94a7b74e3634086_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzE3OQ_fb2676cc-a217-4cb1-9be3-2ce2d2c0b00b">P9Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzI0OA_2618008a-5268-4ca1-9d4e-0626275d5600">P10Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzI0OA_fd56126c-e0fb-43e3-a761-4098b0fa0191">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzMyNw_5a13bdca-6967-4a8d-9714-190a6db50135">P1Y</ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable>
    <ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzMyNw_b764eb9f-a324-4d1c-971f-418d7e881c2f">P1Y</ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzM5MA_0334ed6d-a62a-440e-900c-958bc45e8319"
      unitRef="usd">1400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzM5Nw_74014390-11b1-4149-9b98-c49bb46c30b8"
      unitRef="usd">1300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzQ4MA_758ddecd-d951-4c29-99cc-79198ed11f76"
      unitRef="usd">800000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i151e0a96f9d54ef8aa77485e6036ae3b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzQ4Nw_1f7e1022-3af4-4e8b-b49a-7b6e6132167e"
      unitRef="usd">600000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNTg_510e60ab-467f-446f-bb0f-565da14606d8">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flow Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.55 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzMtMS0xLTEtMTA1MDMz_b2bd8ac1-b30d-4435-a92d-cef56cbcf822"
      unitRef="usd">1547000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzMtMy0xLTEtMTA1MDMz_3a80960d-d3a9-415c-9967-741def7b5b38"
      unitRef="usd">1263000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzYtMS0xLTEtMTA1MDMz_75877a16-e54c-408e-b399-e83c5e651e7b"
      unitRef="usd">142000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzYtMy0xLTEtMTA1MDMz_6c936f14-c9fb-4d8e-809b-f0591c221fcd"
      unitRef="usd">27000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzctMS0xLTEtMTA1MDMz_50b9558b-d865-4c5c-a4f5-179d05924ea1"
      unitRef="usd">18000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzctMy0xLTEtMTA1MDMz_b7ec20ef-c58d-45bf-8cf8-1615d2b77a33"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzktMS0xLTEtMTA1MDMz_523002ac-060f-4cd5-8713-ddaeb4ebcfa8"
      unitRef="usd">206000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzktMy0xLTEtMTA1MDMz_b469a0a6-5b84-43bf-8170-47c2e87c348f"
      unitRef="usd">280000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzExLTEtMS0xLTEwNTAzMw_d8c98a98-c019-44dd-beb3-156917a9e78d"
      unitRef="usd">1501000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo0ZDU2NTI4MzgwOTQ0YTUyYTViYzVjMWVlN2EwMDA2Ni90YWJsZXJhbmdlOjRkNTY1MjgzODA5NDRhNTJhNWJjNWMxZWU3YTAwMDY2XzExLTMtMS0xLTEwNTAzMw_815341cc-c7fb-49f0-bb9e-d5b210c649ab"
      unitRef="usd">1013000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzQtMS0xLTEtMTA1MDMz_0d5977a0-bc8b-4662-a3a3-31b3987c0f29"
      unitRef="usd">3154000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzQtMy0xLTEtMTA1MDMz_85aaa014-1587-4390-9cfa-f5b94140544a"
      unitRef="usd">2515000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzctMS0xLTEtMTA1MDMz_30875efa-d020-48b6-a160-29e28b5819cd"
      unitRef="usd">283000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzctMy0xLTEtMTA1MDMz_d5fa2e27-b58b-412b-a323-a541d69d80a7"
      unitRef="usd">54000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzgtMS0xLTEtMTA1MDMz_98cf66c7-ef6a-463b-b0a8-7ebdc3c5f056"
      unitRef="usd">37000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzgtMy0xLTEtMTA1MDMz_a3cc8a98-14d5-482e-b3d2-1fb212fbde16"
      unitRef="usd">6000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzEwLTEtMS0xLTEwNTAzMw_559ad0fa-8cd2-40e3-bf5f-79b8bca20156"
      unitRef="usd">332000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzEwLTMtMS0xLTEwNTAzMw_2c27c2ea-5e8a-46f7-a1f3-38997a96595b"
      unitRef="usd">473000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzEyLTEtMS0xLTEwNTAzMw_11ce4c7d-029d-4347-930d-e6beb32bfc72"
      unitRef="usd">3142000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTozZjEzY2E3NjE3NGM0ZWNmYTg0N2Q4MGMyYmQwNmIzZS90YWJsZXJhbmdlOjNmMTNjYTc2MTc0YzRlY2ZhODQ3ZDgwYzJiZDA2YjNlXzEyLTMtMS0xLTEwNTAzMw_d6883f16-839f-4d0d-ba57-ac3c786e9ca4"
      unitRef="usd">2102000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzYtMS0xLTEtMTA1MDMz_413aae91-44e1-4dea-8320-bc12b3d2a32b"
      unitRef="usd">1495000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzYtMy0xLTEtMTA1MDMz_f6e473ad-d1d3-4c39-bb98-02524befe9e0"
      unitRef="usd">1293000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzctMS0xLTEtMTA1MDMz_e5f7e0cd-04dd-447a-a123-42bf1dcbbfb9"
      unitRef="usd">18000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzctMy0xLTEtMTA1MDMz_83af3bec-2fc0-4f5c-95bf-ab0b81d91825"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i9e6428857dee4133afac16dea28fc39f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzgtMS0xLTEtMTA1MDMz_abe78ef1-1c9f-4593-af68-c42ee11eb954"
      unitRef="usd">142000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie7ff1508186d47feaea836933cafa86c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzgtMy0xLTEtMTA1MDMz_47aafa34-01c6-47c0-bca6-45dbf95222a1"
      unitRef="usd">27000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzE5LTEtMS0xLTEwNTAzMw_c1df33b5-f480-4bb5-89b7-d4a821be0b21"
      unitRef="usd">3042000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzE5LTMtMS0xLTEwNTAzMw_44ce80f1-de17-4f11-8634-2dca43a5babd"
      unitRef="usd">3149000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzIwLTEtMS0xLTEwNTAzMw_d294d849-b0e4-40ce-9a69-c3e78734beb0"
      unitRef="usd">37000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzIwLTMtMS0xLTEwNTAzMw_0de9da97-1e83-4804-a7f4-64cbf9f901ee"
      unitRef="usd">6000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzIxLTEtMS0xLTEwNTAzMw_36dc0974-6ea9-4a93-a004-383944ac3ac0"
      unitRef="usd">283000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0c4006a71cc54ddb91359f93fc723eab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzIxLTMtMS0xLTEwNTAzMw_1d80e1d1-d6f2-4505-a2df-8bcd440a9d36"
      unitRef="usd">54000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzMxLTEtMS0xLTEwNTAzMw_62b72dc8-e70a-4212-9b63-48e441277fee">P6Y6M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4becb57108e844a2af77734d782c9546_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzMxLTMtMS0xLTEwNTAzMw_5d35176e-9935-4472-a183-a2449eb40d76">P6Y6M21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzMyLTEtMS0xLTEwNTAzMw_4c5120cf-f91f-4f52-8f24-44435e427050">P3Y1M9D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4becb57108e844a2af77734d782c9546_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzMyLTMtMS0xLTEwNTAzMw_bd0eef74-7e01-40fe-9ed4-90c5bd0c84a5">P3Y2M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzM2LTEtMS0xLTEwNTAzMw_3b8af842-209d-4cfd-875a-bc7e18fdb48a"
      unitRef="number">0.0492</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4becb57108e844a2af77734d782c9546_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzM2LTMtMS0xLTEwNTAzMw_faad2eeb-1b73-4355-ba4e-d5cb8c2a770a"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzM3LTEtMS0xLTEwNTAzMw_1142f521-f92d-44f1-b557-da6175af4ed3"
      unitRef="number">0.0432</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i4becb57108e844a2af77734d782c9546_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4N2M4YTgxNzc4YWQ0NGFhYWRkM2RhYThjYTIyYjA1ZS90YWJsZXJhbmdlOjg3YzhhODE3NzhhZDQ0YWFhZGQzZGFhOGNhMjJiMDVlXzM3LTMtMS0xLTEwNTAzMw_920d0962-5975-4192-83e9-1a47189b73fc"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNjQ_857f4f46-4a05-4fa7-a6d2-5364f484ceaa">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the six months ended June&#160;30, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90ZXh0cmVnaW9uOjIxMmE5ZTExNmMxZTQ4ZjFiNzBmYjA3YmZkOTI4MzJjXzEwNjg_a09fad91-87ab-4050-a5da-46e7950cd99e">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are future minimum lease payments under non-cancellable leases for the years ending December 31 (in thousands) below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 (excluding the six months ended June&#160;30, 2022)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEtMS0xLTEtMTA1MDMz_e90c999b-fe5a-43a4-867c-085d5c9f006c"
      unitRef="usd">2089000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEtMy0xLTEtMTA1MDMz_aa423c3b-b9f1-465c-bf01-f3fe0988932c"
      unitRef="usd">309000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzItMS0xLTEtMTA1MDMz_c96f3680-6316-494f-9bba-7ba324249021"
      unitRef="usd">4023000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzItMy0xLTEtMTA1MDMz_dac9020e-25f7-453f-a902-85918bc2ee9b"
      unitRef="usd">539000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzMtMS0xLTEtMTA1MDMz_e6588c92-e308-4ae4-af25-218608b361c7"
      unitRef="usd">3636000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzMtMy0xLTEtMTA1MDMz_88d055cb-1d16-4ef0-8fbe-b27188983f8c"
      unitRef="usd">473000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzQtMS0xLTEtMTA1MDMz_30961ad5-b151-4f42-90d2-0755aeb263be"
      unitRef="usd">3294000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzQtMy0xLTEtMTA1MDMz_0370b9a2-4ca2-415c-bf5f-39e2916488df"
      unitRef="usd">310000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzUtMS0xLTEtMTA1MDMz_a84ca3ae-bfd7-4fb9-af94-b9f137287bbb"
      unitRef="usd">2987000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzUtMy0xLTEtMTA1MDMz_fa1df384-9577-4755-8b1e-21231349876f"
      unitRef="usd">56000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzYtMS0xLTEtMTA1MDMz_52ee13cb-6274-40d9-8a9e-b47c5bb0e623"
      unitRef="usd">7752000</ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <ameh:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzYtMy0xLTEtMTA1MDMz_95d383a3-3a9d-4226-be2f-cba726c6a880"
      unitRef="usd">0</ameh:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzgtMS0xLTEtMTA1MDMz_4cb1b8f9-2c2e-4bba-bc92-b078945e8507"
      unitRef="usd">23781000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzgtMy0xLTEtMTA1MDMz_91059937-ae1f-4d7d-9667-90a3f961bc1e"
      unitRef="usd">1687000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzktMS0xLTEtMTA1MDMz_938e5ab6-dfe7-448b-972d-2ad578e1a61b"
      unitRef="usd">3624000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzktMy0xLTEtMTA1MDMz_04521589-35db-42dd-bf0c-ca07701f2db7"
      unitRef="usd">114000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEwLTEtMS0xLTEwNTAzMw_b7d41bd7-c6f9-400e-816e-d363cef76c67"
      unitRef="usd">20157000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEwLTMtMS0xLTEwNTAzMw_784ff8f0-af52-4f88-aedc-4ad3c3a7babc"
      unitRef="usd">1573000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzExLTEtMS0xLTEwNTAzMw_5777824f-9179-4d13-ad45-2376b84dea9c"
      unitRef="usd">3253000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzExLTMtMS0xLTEwNTAzMw_6acd3932-6809-4c4f-b9a6-7f9bd66d9666"
      unitRef="usd">524000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEyLTEtMS0xLTEwNTAzMw_e8e16125-014d-4f35-a925-8bc81a28ec37"
      unitRef="usd">16904000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i9892fbf73a5e432fabdabd8425173fdd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18xMjcvZnJhZzoyMTJhOWUxMTZjMWU0OGYxYjcwZmIwN2JmZDkyODMyYy90YWJsZTo4YTlkYWJiODAzZmU0NGQ2YmE4MzQ3YzRmOWNhY2FjMi90YWJsZXJhbmdlOjhhOWRhYmI4MDNmZTQ0ZDZiYTgzNDdjNGY5Y2FjYWMyXzEyLTMtMS0xLTEwNTAzMw_56b91671-ed2c-424a-ba6f-99aecc1eb713"
      unitRef="usd">1049000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMS0xLTEtMTA1MDMz_879e3f2a-2d77-4bd2-8991-2d1f0da3e422"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMS0xLTEtMTA1MDMz_879e3f2a-2d77-4bd2-8991-2d1f0da3e422"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMS0xLTEtMTA1MDMz_64c937bf-077b-4e30-b5bb-928744b95c0c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMS0xLTEtMTA1MDMz_64c937bf-077b-4e30-b5bb-928744b95c0c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMy0xLTEtMTA1MDMz_2860dc71-c30f-4d36-9d2b-2b6da5f2a16f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMy0xLTEtMTA1MDMz_2860dc71-c30f-4d36-9d2b-2b6da5f2a16f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMy0xLTEtMTA1MDMz_96d8734d-278f-4b05-bd0d-3a9b0d93f835"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMy0xLTEtMTA1MDMz_96d8734d-278f-4b05-bd0d-3a9b0d93f835"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfMTA2MA_e79a5d46-a43c-413a-bc83-e685f7b001b9" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfMTA2MA_e79a5d46-a43c-413a-bc83-e685f7b001b9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company&#x2019;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#x2019;s consolidated VIEs totaling $599.7&#160;million and $567.0&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively, and total liabilities of the Company&#x2019;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $143.7&#160;million and $91.7&#160;million as of June&#160;30, 2022 and December&#160;31, 2021, respectively. The VIE balances do not include $431.3&#160;million of investment in affiliates and $36.0&#160;million of amounts due from affiliates as of June&#160;30, 2022 and $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 16 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; for further detail.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMS0xLTEtMTA1MDMz_879e3f2a-2d77-4bd2-8991-2d1f0da3e422"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfMTA2MA_e79a5d46-a43c-413a-bc83-e685f7b001b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMS0xLTEtMTA1MDMz_64c937bf-077b-4e30-b5bb-928744b95c0c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfMTA2MA_e79a5d46-a43c-413a-bc83-e685f7b001b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfMjktMy0xLTEtMTA1MDMz_2860dc71-c30f-4d36-9d2b-2b6da5f2a16f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfMTA2MA_e79a5d46-a43c-413a-bc83-e685f7b001b9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RhYmxlOmIyNjllMGM1NTEwODQyMjk5YWZiNmE5YzAwMGEyMzI0L3RhYmxlcmFuZ2U6YjI2OWUwYzU1MTA4NDIyOTlhZmI2YTljMDAwYTIzMjRfNTUtMy0xLTEtMTA1MDMz_96d8734d-278f-4b05-bd0d-3a9b0d93f835"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjQ3OWUyYTQ5NjVhOTQ1YTQ5ODNkZWMyMDAwODU2MTJjL3NlYzo0NzllMmE0OTY1YTk0NWE0OTgzZGVjMjAwMDg1NjEyY18yMi9mcmFnOjJmZDYwNWVlMTQ0YzQ1MmFiMzhjYjQ4MDNiYTJhZDgxL3RleHRyZWdpb246MmZkNjA1ZWUxNDRjNDUyYWIzOGNiNDgwM2JhMmFkODFfMTA2MA_e79a5d46-a43c-413a-bc83-e685f7b001b9"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"/NKR+Z 9#>2K_4W@067DD?Z,J#$IT()P/,EAWG*;Y2#XCO4Y']02P,$%
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MO"03WQ2BKM_N$I+_M<GEWVC%Y5+,5;2VO):J-95P?A(@/[&1GB;JC&*J+SH
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MGT;MYUUL!<!I?^:4+7'*EKIBZ\>@Z\^H??/A^0( '$S!H:\?7P%@/M-WI!(
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MSZ0B@'JWN6R<[LYV9S\P$F-K(HDN2<=-?_V2LF((%T&D_";]T,@V\!P(YQ
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M7].[W"R,@T73W);SX'U5!Q\[U_9N[CS?>[E>S-KN+TT_80=%/S,WNRMJ9Q!
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M-2J@-(FBZ5Y62F.&RR#,'-E\$V)Y&"HH#K+)H38%E"91--W!2D[,#F00'GV
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M(;MI'#JR460@B_R4U:M#I:%;%T"5 %9)G%FK!:)ODL 2L4$K]J/U5E 9SLN
M/JE$A79KA&O=$J%"1?EN\4#2L4W("(5#CD)6"7*$'FPHBOT4U=L18SX?KQOJ
MTVA3$,O\::C1MD))Y.I=PTKL9V4W 3SB .:EMCC;:AQAES@#1NP'XWE1\+4J
ME5;YLYJ=70U0%&)-S7P 50.DBU V7%:063+-'+4 -D3$?B)>L7(M$P[QK,3N
M>0"*M<DWCB*K'H7,XMB1N6+#1^SGXV=:LD+F1CWJ@")M%,8QLB@.F&73-'6(
M-,C$_D+P>E,9YT_4WY5V;3=&!$^'+(#L<!@ZT(X-K["?5S<[GE=4EE<'.Q5
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M=V]R:W-H965T<R]S:&5E=#<N>&ULW5SK<QO'D?]7IA@G)5>!( E1LF1+JJ)
M69)#6"S3=BIW=1\&NP-@HGW .[NDF+\^O^Z>UX(@+3NNNZM\L$7NSO3T]/NU
M?''3=A_=QIA>?:JKQKT\V/3]]NNC(U=L3*W=M-V:!F]6;5?K'K]VZR.W[8PN
M>5-='<V.CY\>U=HV!Z]>\+/+[M6+=N@KVYC+3KFAKG5W^]I4[<W+@Y.#\. '
MN][T].#HU8NM7ILKT_^TO>SPVU&$4MK:-,ZVC>K,ZN7!V<G7KT]I/2_XV9H;
ME_VLZ";+MOU(O[PO7QX<$T*F,D5/$#3^N39S4U4$"&C\XF$>Q"-I8_YS@/XM
MWQUW66IGYFWU-UOVFY<'SPY4:59ZJ/H?VIMWQM_G"<$KVLKQ_]6-7WM\H(K!
M]6WM-P.#VC;RK_[DZ? Y&V9^PXSQEH,8RW/=ZU<ONO9&=;0:T.@'OBKO!G*V
M(:9<]1W>6NSK7YT;5W1VRQ1J5^KUX+# N1='/8#3DJ/" WHM@&;W 'JJ%FW3
M;YQZTY2F'.\_ E(1LUG [/7L08#?#<U4/3Z>J-GQ;/8 O,?QIH\9WN-[X'WH
MUKJQ_]1TU8F:MXUK*UMJD8VF5)>=<:;I=2#%M[;136%UI:[PT$ 0>Z?^^VSI
M^@ZB]#_[*"0(G.Y'@-3K:[?5A7EYL*6SNFMS\.HO?SIY>OS- ]<[C=<[?0CZ
M;V'D[P*D/EP#8U*SLVU;5:U:F-(6H,Z[MBIMLW83];XIINK17_[T;#8[_D96
M81'_?O+-E\HZI54%PX'5:KNY=1;4;0X+$+:SQ43UIM@T;=6N;P^W[8WI3#E1
MG74?#Y=&=[1G8W35;PK=&56T]58WMU-U88"67M-K"_YLNW;;6=/#OBC3E(=]
M>XA_,M *7!_H;L WHJA@XSKP& @VRC:]6=-O97Y@:2I8#T#=5KHG6ZCZC>YQ
MAEY6AL^]MJ7IG.I;&+BB ,560U5AO>YZ7'0+@ "MKG4UF$.R(Z5BP+KK=+,6
M\0(--H-3IN;[TYUZV& "Z8]7&QB9PU\&7=G^5O;C)6!;ED[ UR"-ZP_-:F78
MWL%6-(WIIMEE;[13M>G6]*/M-^I[TY/EC Q=Z$8+0I&9WR\6B8V-.C>%J9=
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M<U^.LM3*0($IUQ0;"1&B)B."J4 5O8:%7!-=UQU%G9VY-LT09("0\)91D&.
M4']OWDBO@DK<*RV)Z5'Q.0CB&W+EC'.2)W10UPYK<0XI9>4X;\P%-NM,*%^H
MB(2Y+YA--/V#";-SH*>/KER[CT@/JM5G$NK,<:DQ(+K?RU*QYJ[+]D&+!SE.
M%K :XH^7E#+4WL;2 ??B>^GE69U%+UM42+U7MZ$\P5$]'"#52$KO6&)H^"8\
M/^/GR1/OO$#L3.D4]1T\A$@>)@H305?,N;'*[\$\\GS\/MSDLK,42W%[@:5
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MA6=F;E/71V8=7*:GOA @V-9<"FX+WPZE='TO\W%2),U(-V4XR?6'V?!-3JB
M[62?+$O@$ZZ7!J?[K 23W:UL9:Z7MC6<O,@U"7?3N?T-@F"IL^+<L83!G*G$
M5'T4!;-;7;Q%[!=(O+>5G-F[S*M*3!\;$D3P,&QDO1N4;,<WE$44J9#@^W&G
MP"\+V6C"FVQ\FG'S.7MM^DW+,\\I+F<BI*"7VEATASLMV<]KM^J=H8W,'TP4
ME=-WJ@H2P!F:JJ<,D#/@E#*$QOYN">+.7:?J-7/*%^0CQ$!<^UM3%,_&?ZM)
MF2V1)*DLK8S1Y &8CW-]73!4=.06I&R$UT[)A2_ AI TD@U4"JC3EP.$B$2
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MU=V/2O9S@O/-JL+0W^2.QYZ>[R6SUC352AX&"%:ZY'^SKX*'X(&SX8X'QO+
MF.#FA0C*=UF3O7E=5W=)C:-A-GQ!6Z6G 3A=XJ'<-#5\J^&YYLW;S&B35//D
MNE9&E4W&N"KSY(:/";^[T8M2S_4L*YOD8C:KVK+1Y2*YK@H]T\J\?MX )#C?
M\YFL^I97'>]8]32YJLIF:9+W9:[R^/GGL .WC;'=QMOQO1/^I2T'R=$P3<;#
M\?B>^8X<6HYHOJ,=\_7L,OFOBZEI:B"C_^[;,,]WW#\?LM9+L\YFZH>]-2*Z
MOE5[;_[U7T:GPU?W0'OLH#V^;_8_[1#__%63_DE^62K@UUFU6F?E!L?/JM+
M(WG6J!RXL,C*F4I8:F5-\D[-U&JJZN1H1!0 ?Y>92:9*E<"A-;!]GLSK:I4T
M,.^$9_W7?SD;CUZ\,DG6YAIGC9:8ZQ*6T%F1& !)@11J3)I,VR;)*X"ZK)I$
ME[.BS0'.HH!-ERV,S;69%95I82L@L'YO=8W0;I*%*E4-XS:X*;7&!3*/BW4-
M4^EU 0_IDD#\M22(;G!I0L[%"G8QRY)]A'H\?/7KX&:0?+RXN*;WHU<'@VV4
MM>6C=Y9DM HPD7),E-))@M0GB)IEK11]8O379,7,JY!YXZ=HB#V!6\5' !2_
MSA 5NB00ZYR.[TXWR\3MA);290,;7>T $J:F9Q @70(OMB393=)4"8KH9#0\
M_'<:=E$W>E:HY RW]5DMVH+IZN;P/P9$AG4.*"HV*<YEU)-P99956\"QJ@0O
M0=P3//-;6_(MXP!\ O(!X%H5-  (2]%^<(K>T4)VN:65+CE?,"E^5NNJ;A*
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M#1+32A70-1;,Q8:5QG"/ED)XDUN':,&(J([.?/0JT0,U2'L.7N[IFDZ&_(+
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M!7];%>V*M>C84G5NM:U56!ZV&R6Q-:.* E_CE4D^-YQ;=7+4[AR^-N((W3X
MB\3QO4CTT27_=6C.WE$2,QX*7H8+Q6&\",_5%*,7A$;9$W!*UH>OI2JV0C0R
MF]-25O"&UL9(]0K8"I2K:O;%Q@(VF&3!$0%K!%*(4G'RR.7US[A=XC_D,MK?
M3VVCOMHLC\MR-DCV4:RK&A84!03,B4*7>D&F[H]5D7,F 0X^</<SS1-?T ^!
M>(<.PYFDC)'SD -R.!838^BXD7(0^..SP?EW/CX0!2/BM)M4MN%2;"Y=6!C&
M7@ *"]S^D/+Q;C"_E&0/RQV7XA0@1]1B5LHRV8^7R#8HA;.S'N0GL:,DTFRZ
M)P?4FM6@]%@-([370X=Q[\/H&IE)V@V8<#5ZK:R+'-XG^QQYZ$Z36B,[,)2V
M6,2A#$V?9T=>CO8<K8[3+/5C;E[=DSYS3\8<G=45:)6<DA=YM+ZJ>D9<@9]:
M=,I%"=SW>ZO(6X-&)ZB!?Y>!@E)1H?\$F"VB=N.X1[13^C79;$:R+#Q>*1%'
M!SDB/A!O(^YBA3\9N3=@FI,G9LR.F+%SQ/PA6>N'<,/;?24?G+9T24G)A'3K
MSGD0\J?X=AHT<$.7N,>N)$1++/F):OSV05)^64<=&1T/CKM:N/\D5D?2IQ_9
M1S+4R-_"NGE W[#@-HR&8LNU"@<^N&IOHBF[K,.\."<4UF ]E^0*H*N*G%:4
M8K;H@ML+(^D=1F(XE'F#Z1>M@>?,@?.+20HN6!"&,(.E4B\! G0PA84R0)=?
MXP_H9.GJ\Z]^(?CV&:P# ?0A9#Y+]H_3HZ/1 ;PZ.TI?G)[C1Z/C].SL-/CL
MXZ,FHY,9I^,7GOOB=[_Z9$4&ST'[T-2D5* ]4)+2($F3 .HX'9Z<=Z ?IZ>C
MX^"SSV%"6/#&.6L_BQL,<ULIDQ3/]U,%:IP?#<P?#MOT^FC"="M.$0@T'6<=
M^U%HH*]U((PXWRL:04;CNJI 4JBF*6Q1BB;;$D5 E.\6Q,_F2KFD2B]B@]$#
M*^3"!1UKL6.S%-YQEAP;+CY@)0X9SL)##?HAO%BD6]_CFI&^C:\=&^_=H;UD
M^E"R8^]]A- 'TQ^-BP+I*L!WW]J1)P^D\4H;4\$=Q74BI)!GG0= )542P&,;
MUWC5<DT!I[)=H<_Q?GHS,BWNA8QO=KF"\9R5@2LRFD2PI"BG<CLYBX+T*+VB
M7 7[&6Q0\J+@2/I.?/?1DJ,O]GKVN6$P4S(@I@#U-L/,'?'O+>"23 9G&UG'
ML-O@SHJR9640+85+9A(7IR57'U63'+Q= %.:K,]2ML/SD"/:FMP9>)5@I6X4
MH,,Z$%*&+ X[W"3/PJ,Y!7'P4IR!J#6=JW]T9MT?V;Q1-G9GI^FNB(AT=MH@
M^;G+<>$QN:S<0ED2))70DK1$P^A>XXJ+[>4D-)R#^8WW9TWIAI:^HCHQ.K')
MU8V[>'_Z2#/6U:+.5FD$)(W]>/UN$A*YS:BUS].EVP4H17%T"!\=NCP_Y_/]
M<./LD%KIU11P+1*,S$@*6R0SLOFL(23:<3P>@\ 8+*)8@H 6?NV)TQ*CR#\P
M<-:'5""@G7<:]/"5;E>=*7:YTJ5\E4G.F7?6#>V5H9Y;+LKF!5QBB;6$P5;D
MG1)B[WF4Y0O&W_^.6H#/XYUF.5#OE/*7J5Q:U;&_-?J"@;P#K"TIFI5NY_:"
MD@W*&6,K2,)S<X!\)?CAM(#8V/7K,B+H,LA!;<EF&^\SMBB+40IG@I%OK"I#
M0>,VAW.TA4B&[:SV7N006UJ*@;MIX4.5,@.EN&ZP*))#KQD<5?7E<,K91I+7
M@.YPZ\D*+[8XF3XV0]TMQT<4I$!'ER;E0[L"/KQUA8RB4=XWA!24H$&!=EB"
MN42-]S13XG%\<V\OUHE<LZ /-V@#40$BV1*@',@9"R7)[90T:9>OZ^^%T$X#
M28)I3XR* /%TM62F*F%.#*!]0:D*L)"T)5< A@_KW)5^!MR$QUGF\&7L)6 [
MO 5; J8"Z:PI7Y^CEG9=TSTXTH#:6A05Y_]SF0X!7X401,&368T?X2P!WE .
M@=#5%4X7))S;5#2)6SEFLXI2+#4(CCM;7NNO.Y]2], $5LY.WD\^.4$K24>3
M2"A0B2,_B\I&G%.0:^,BNL8+?12IGAZF&ZNO),UF+2$D<@?B6V1U0$5!3EER
MOP-K%I9 L!Y!@3H2$P^S+YN8(+?OHO/F&O(0GFD<![0?&_02K#BO:,.@X?J<
M$>3 =\Z<!TQC*4>+4))'( 0XX$D#Y8YI@Z<P.^:P&R-P/0([)66/J/KL6-??
M;D #RE?H@@,N>)8<@V$Y.H871T?I^/P4C<GC='3Z EZ<GJ0GI^/DBLI[0/R,
M8.SI\2@Y/09C]R@9OSB%)\Z3T?@L/3\9RCA0;EX,T].CD^3T+#T^&]-3-.SH
M+!T=GXJ^1$$,9WZ '7X\?)&<IR=G+W#CHS,8?YX.C\Y !C(:GR7CT_/T]!P!
M&[TX@17.X-7)T1C6)O!/1O#M:2<XFG/6+./=9J$CC>AIVXACT9\G4"BRD+U=
M,.5<3O';D7U-)WZ1? ]X&IPDW_&+4WC!W[S%#X:#(_YF.#AVWTSLYZ/3P0O\
M9TC/P[LS-^9=<C0:#.G9HR&-^A[^^X1Y++#7$I[YCNY)<ID$^S%/Q5-U/ZJZ
M0O@1=O#+KA>/WT8N/+M)B@OBWOB#]\GXC#XXYL_YTP] ,O06,,&C=^#A06#'
M6\"FA+P/&/;[*X4+KSCMR8F37B=IKUD<!Y_MR,!FV)G_ HJWSEM.XN2LATY^
M0QIFH.WRBD=F0$I6>NR'<0H8$(/X;FRIL,24K4,[=2GT7-CFTR)%OZ021%1'
M2(45F9S5-?DM*7[JU+@=:(F<[?9V?*+OU1:QV#8+8E U$BKTP5R .F^5)7:S
MQ X3+F#NM-W($QWM*,C\V8F8'KR$UF@8DN9D4\R7R6KOXP"X^9YD%TCPJ$6/
MQ"UYU)RLWZF$9JV^(KMR61.L*7 N,"BOGIJ#Z,"-Z&DF>5O!/][HN[AYZY21
MWO&3*O>ZK7WLXL:E!R5G8^#_?NX*Q^,X7WQO*WE0]RJ*@(""U$;_89CDZ-*Y
M)'DQ%S$@ 7Y2S8-SX I+'B+9DT$1,DWFZSTP*CH':UMAMR["/B]"&9K!V7+M
M,-[DX639%%/Z@W&K0,X,$L%!=[F>+ 8^]ZA4FA.[UFU#* MR?UK)O+*IG'%V
M@S;!K-07 )!H[3B9CP*MK,A,ZRK+62\T06C@I4N"L!+VDA_%8_!Y"38!0B+R
MNI-?()$C,I9F_J3ALZWCE0(\;$ADC/=D!OB4!!N;5]"!RY9=QP#-@_*3'1FT
M6S"G/7/X+6Q/V-F-D^.=FBI>)+5'4(E:!=N.EW,/!9D-5O>D%<,%-[84R8F;
MVM70;C3&)D#(P!4C2?&6G.P2MAF5M'SR-;E<SEA7T\JIPOV)%O@-CE32BL85
M%<+!81Q%AD:3,10']BB/@C!,L$@(:ZWF:$)&5=7,>G?<=X;3;VP5#V7ZD=G6
MDOPGU%KO[C8.;4Z0K.@,/F=24[XQIT)X\\BE[W2KL[L*!*9X<$Y*[^5#8L]?
M:3N=Q;WW;7^CK-H9.39ZMV6+[%*-+-=;+K-'Q$&\"Z;XJZT4WN]!HP<S8GAR
M!"_L<8:OY,NKWKB_U3AWY8B-3]+AV6D4.:<8'G]\_YS;(3LR7HZW9I./)_?E
M$W2? 1-L?")_+T,.3,Q=MO;C1^F+D_/.NU^"SB!H(PW!FCI&]/'7SV1:> ^0
MG8Q?))\"(4-->'8FXF_O+1T.A_*7UPTE5O^)\6C[[_>8\^,R)7:G?/]9)-[7
MN.F?2N96R_Y>3N3T]&07XN3;;Z?U\39URL=/I?7Q<3H:'R7H !CZN<[2H_.C
MIU$ZS\!__V93@#QYC8Y/.N^ZY'UZE)Z-QN@"2(]'B#J>"YT#1^GQ>4S>?;S4
MH<T7HYY/'F"+QQ#Z_>QA%[;/C.G]$Y@#:-9W8BJKT*,O-)E:HJ2R-$N8G=1F
MG#Y^VB=0-FJV+/7OK7)MD'Q3$ZM(W-^X##W KOG,A5>;/J$9](DT!OGTLMND
MALT6X&3=8.,4JAH0S0PL<M2Q#]FG9C4&S#6,@^?.)PB?,L]WQJ*[?U;KGF^H
MWQ!BK%JCBHR(J(IJL7'18!\FQ\HBL*:Y3<2L7;7L/P"1!7SY][X>.N+4]=I"
M=^N47,//HY/8592A3EN(3U$JP2+5 M5^2;IVS:.8\K&6WTU#C7&P3PTV/I6)
M!H\Z 8KLN/Z@+JX7X'P-NT?5)NH00KF_29FM1*&D]R@.J1X%F[8$1@EE: 5I
MQQYN:LG 195<$"4X\#V;P"R<2]9TM<D*5WW74TAA(FS_ <>9.MKH.[I^G'\@
MY$JO)D\'@:] VCAY2#FZJ+CS3 "$*_>4?CNH> =!OEUM;,0ZZMRT%(XK1</%
M$B%IU!-$M5W9MF_2R/U^@K9E+E;;<KLRZ:]!>]D';<^3:R8M4%$3=Q8(UGDO
M,'<*]UTXEUZSY4L"U"=WV&_@,$<=^<[W,96P&1%-WDK];_RPJWRDS4IMD0_1
MA#;Q!V]OQS4@C@O#(I(^01H'2GMJ<K%6C"I[PK/%J$5CA!6WJ(5,D"U:"=J2
M/;*YY"#Y:+M_X4>7)>9.T(HLJ;=%^:\4OD+?Q-'), T&>$TBFI(C *GO,L:F
MI%MG:V=]= ]X0M]:DW!OXF+3X81!<M$=D5HGP+:B:- 4Q^2&0T -792FJC#E
M7<^?SDE G,&I8846Q4&I4#,,>;F"K$X5/HH18YOI^7"NK?_GJCD0+LI%6I$?
MN')9=AA7XE)^D^]*UY8\A><EKJ.+>9_R^]GUQ3Y$A@-'Q)#XKK74,XD38W!'
M6  NR;L>'7YW/"_!MD.!9X]2#+BA'J<]S:92ZCMZ>7TA(A@;BF9!7TP*857U
M(BM%?G>X4 ?M<&$C<CA\-GXGCF:#+34HI2I,T-*NZAGN1NKK[V3?CA.VT>F'
M#C7KH,'3;B2,[A./5G[8+DHWW.B9VK1,K4@T)$6C+8?](@0KC"))6M@X>LB"
M?)D /^JK-AQ0)G^]$TA]TM49<]U3M^W.=!U<XMU@0N@ZL2<%@J#L7M,V%\YF
M58MS=(4.Y;RGC)TOA:DBR!4Y*G?SC]P2U#L:6P'=NLIPG@8^PUNJP>;M5*[C
M:Z$DP!QCPXO)/HVH5T]W%Y'K@I<FO[7Y8N5+8T/75\!-KC8WLPGR<HU)S"62
M>[TR]I&"7-#8%=J7_J"D87J?-NK7$(U42,SR7^_-WIU+*G8YJ:13T=<]@T=N
MZ@\XG3_P<+HAWEYMPE$78?O!77Z+/M&IW.3KW[4'L<:P%-A=L3(?)9+9@"0U
MXY%89%@ ]*AF&YPTM;L+2A Z=5DLX6WM.]^+IQSSXJ24*4I4<5UF4M?[5-IG
MI;Y+$Z^F5*<WK&M0 T#Z7U7(,2DKYP4Q2*SC3DG<*&U'J1T.E Y:KJXO! #?
MVQ[+X^%W=&PGP^^PNSWJX8MEMW6H[8X' CJL,!+;TT[K[J<IQ0I=A@Y-T8G'
M4L^";>WBH?/4)N2!@:BA#SR5=LX:=3V]T"7A.6QSP@:@MDU/K?4@=T:ONL+%
MI)(XXKH[DUHNG8%BS)/:&U]$_T!YCVUXC8L=L-X1XZ';)YNM^&"#TXW/^9"B
M?W&!:!-\ZGL7>2)^OWLE-*M]L^-0+7#"<2">K&V3ARYK=RQ!UO3NK84_$O!$
MR71-U6:H?/V(H2XGHKY1&)&CXD\312"#&K;Z$&5.</1(&,\8.R'JL@4IHRXX
M;KG!40IEX_O0&D4:G744NT5,&O?[C*G=]T/GZZI3UKEV!T)U42IJ+IE705]I
MWQ_4!MACNMNA?K..0<8;YCTA3WG(!Y+25G1#)8]LOD_>8^:@OZ#G:Q]Q[$MY
M/5>CT>)R(7"XE *PP1LW\D/9OF#?'UDTCFA@5]5,<]*2[08DV1WB (5O7+:\
M)2Q)=L%^S"4V>%3>(;D%8@B:?7P+G"KY\>IG.'2;-<C[QW>'$^K]*:LDMKUC
M9AVYMIV[@"HKP*FP?(/#/.S4XTC2I_4_VE1-"B<L5.<,N?43)?77U1P(@$NL
MV??@NH!@G:JM:L!$>54'@K$+6%PU9:19[-S/X"I_OTFPD^42UM"XGVK@)*40
M)G?B:;<B@J_O:,]^!YU*\+Y.[D\N=+WJG42:V-LR+-M+P]V*V[U/.$?&V8C8
M+EZ>QTZ8<<]\TKVMGUX* +!A,?TT#PL\XQRS3O\NVY6JL2&,;1*WU1D=:**P
M[EX -&C+Y=T.05)YMW8B%6>UE%P WJFA]$I_!3V*$^91E4Q#SQ+'**2]=K=S
MN_1QY8W[3G#A#Q9@0P;YI1Y?@,!UI @CJ3G6AX8]0=9TBE2ZXAILKAS/N.H
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M?EZ!IBEO< $,$A%X;_X'4$L#!!0    (  *#"55.T,G"0PD    9   8
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MMFK0VTK#'8X5$NDX(RCH)HP'CH6;"1K=/<2"NR64LR,1L!,.8S8#/6+)!Q7
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M&YJ943L!^KY2REYOG(%Q"I__"U!+ P04    "  "@PE5@ZL91^,+  # )P
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MJP9(.9<\9ID\UKD%,DG"!)_THQQJ]@9L4/?*)MHIX?0XIY"3+&V4S56>(#K
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MTVUB_@]!?*.!?)&+L_EX#JB6SIM1<^.*D%(?]CH-1'/9L"&#&Z=1H]9KK$)
ME#BH+L4_C;T['++ J<SEV)\QZQ.=L6.)#?-/022(/M/L,H;]^80:,.KP#'4,
M%4V^0=P>MB4*'CK4E8].SIR6^?JH?8K7.#QAC?@Z.CD(**,K62:15,T(4=!F
M1D_!*,7(LM--<EE%BE/L$L[&T,K6!HESJNP0L++5<-UG*LN5<YY?3]:R7ZJJ
MK)7X4V>Y)F">.,@]*I56M<5?R@B[5=M,?E];<HOBS<R,.XU>[.,G#,\+_XW'
MFC.K%_[T.5%9NGJ^R<53:A@V5LV,+;B3R+U!L9! %F?):_P@LYI)KN0#%HV.
M/0>O""0^XN-JE:^:#2.V8R6*) 4-PA"9GE*3K6[[/8C2V8&GG;#!D$Q#K5XH
M .1M:ZT>Z/"CZISD@B763^&H*K8UMOB)$S8W+U^S8%JBC=0Y/ ;%*VOK_*/@
M<<J\(WP>/E#W:"FMI=!$R*ZZ;5@_39G (&27HT P#5EFQFH\+:ISO,/GOL6P
M6[/N+@%+?#*? /.$W?G,^ ":^6VD3<H4JTBAT!(_FJ5:T'->\DZJ4T9635S^
MB%M2/_%K8W[Y*-T+AA/\X3HURK&,B5RH+R5$,C^3R9U[?-#V\:@P:/.<1XG,
M<S*VE;#G>Y 2#I(.1W >)#-HGTN*M@IMTC\L6 GG@=!RJ*JI*>7RQ!!"9?K;
MW%4KF"'E'N[3(U!!)-@9^-OOGT88:,N17#["J'Y=8SN.VXJNSI*)5@M)E'A!
M;P=D'*^#@,Y!+'0UP#^1IUALG*FJCB[M2Y585U-6V76]PYPW>LI0R+N%5ER:
M>;8J-'SCQN^V'&/&&,BIRF'<3Z1O7W#'G[/]RAK>/TF!KWWZ+#1(GO#!<$@4
M>92:R@1WQRB2Y8/=NJ%2( 2<].%-VI50X#)Q]7"/]D6*J%$2^2SP-*&7N68E
M0M>I@#=(/X^2/YNA-A^I;7D(O>V5G';CK2H43F-^=XPB TCW+UC5=^O7T\[\
M6UFKX?[=MBMIQSJG(_<(4\/646]/6/^^F/]2F!F_HS4T16&F?#E!&:8L#<#O
M(V.*Z@LM4+^T=_I?4$L#!!0    (  *#"551O@U%=04  .X,   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;+57V6X;-Q3]%4)9D +.:+.=(%X 67%@
M%U(BQ&WS4/2!FKG2$.&0$Y(C67_?<SF+E,0V\M"^V$/R+N>>NY ZWUKWU>=$
M0=P7VOB+7AY"^:[?]VE.A?2)+<G@9&5=(0.6;MWWI2.91:5"]T>#P6F_D,KT
M+L_CWL)=GMLJ:&5HX82OBD*ZW15IN[WH#7OMQF>US@-O]"_/2[FF.PI_E@N'
M5;^SDJF"C%?6"$>KB]YD^.[JF.6CP%^*MO[@6W D2VN_\N(VN^@-&!!I2@-;
MD/BWH2EIS88 XUMCL]>Y9,7#[];ZAQ@[8EE*3U.KOZ@LY!>]MSV1T4I6.GRV
MVQMJXCEA>ZG5/OX5VUKVY+@GTLH'6S3*0% H4_^7]PT/!PIO!X\HC!J%4<1=
M.XHHW\L@+\^=W0K'TK#&'S'4J UPRG!2[H+#J8)>N)Q9:<1G2DEMY%*3D"83
M/^Z]?/9V-!R>84O+0)E82!<4^?-^   VTT\;9U>UL]$CSD[%W)J0>W%M,LJ^
MU^\#>(=^U**_&CUI\/?*)&(\.!*CP6CTA+UQQ\8XVAL_8F\?M!=_3Y8^.%3-
M/P\%6MLY?M@.=]([7\J4+GIH%4]N0[W+E\^&IX.S)U >=RB/G[+^7^?L?W-6
MR[F]W$*F:J724W%KQ*<TV"4YSASR]W$^;P2A+D7I;*&\MVXGC TD5EB+4_'!
M5B@<)V:SZ1&DIE(KC"6CI-"J4.Q9*[E46H6=2&U12K,3F55F+9:51US>"^GW
M**Y-(%<ZY0$UV !KD'P^2$[0:%K'F0$%X/)H<6%7(N0DO$0@S?>T]A'#?W/F
MA6*#Y ,^Q/S+QP1Q-ALR35T%-S*P09#$)DY>B!+12&.J(O*JO"CE+E)5<*/H
M'=PX6ZWSZ XSJ'(<6]88> _&"B9Q&#M@G/S$>)L9UV2F1&9V8B;OI,;IG#*5
M2BTFH#I5$&A2]HK51H.SV7P2-^)R>/;;4XH'.ITX4E@]F,]@Q60Q?3V[@P-D
M,$HHDZH2-F6!+$>ZGX^289>*K0HY2!*3:HVI&,/]GI!$_ &.4O#&35O!4I>.
MFG 326QC8K*'R>"%D$N[H7@$# 5UV>FT&2"JJ2"'4'4SE,GYA&,XR/T&PKBN
M8O;9"QP@[1P,.& C=?&R)_I6,>R"0FZS>*MD+;X1JJ(YMEL#-[DJ]UARTI#?
M[=FK?74H;A<3P1W, 70U_\H3B8_,^TE=$*,ST63KMD/-$8A/0."X+U3LWU;X
MNL8SCW#;["+\F_GTYU:.NS<D=<A3Z0@":=)5!Q_^:GD\51G'R>#GRH"DCC?!
M0X41#6^YH1$M;A\.]T #+ND^X.2!3F,XK>3X%\LLLA Y1QF,DS>'O5Z;V$LP
M*HI&&!6\<>+6(I4^%[B"5!HP"-H.QC';O[Y/=<5AH 4)R0LY1LL6)L2:4#51
M-$[-.+/(<3IY:CEIO(P/(E\3-UF\GLQO>%0)W*84V6B26$I5TX''G \84(SJ
M(!TFV\?>Y*;.7"(^F4>'Y-)*EZ'T>7#YV"0&HAC(H <J[+DFJ%'$$,: Y@[Y
M$8K^8=CM^VMZ/9UAA&:DN5EJ ZP1NYQ'8(>FO2X '*.7I1UM\/1KI)7;AXCS
MV-ZYP@! J7ZK8(F<WAV)E3+2Q.G0'G*B,2IQQC3AN=QAX)"4\59OR*1PI_S7
M.GN@0F5P@,N),B1DA>)?2:4K1RT\FZ:5\T>'O+;T^+@)/(5OF>>2]]$_X*M"
MUBO4>8DG,?A,47 J@$;,B.]FD"/<IF Y1>G@5T!6[:\\MID\](;I'[Q!,1W7
M\:7M19Q_]7.TV^T>\Y/Z#;L7KW\)S*5;@R&A:075 9JG!YKBZ[I>!%O&%^W2
M!HSB^)GC!PDY%L#YR@)ELV 'W4^<RW\!4$L#!!0    (  *#"57'*SAR\ (
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M/((2*]$I]U$?W^&0S]3S%5K9\(1C[YN1<]%9I^L!3 IJV?1O\3#4X0R0I\\
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*55VX[;-A#]E8%2!%Y
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M\DHVCBX^S>$EBL(?YPZ:.G%V7LV[Z\I<<H)RQ7;H:%3WX@!4^5)RFZE1[^A
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M[8WPI<P7_.>'D[R$I/DC= 0+H!?P^S1'INF_T ;UWZ.^^W]02P,$%     @
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M;<#SRJ&GYQM2L/NJ=O$74$L#!!0    (  *#"56%L'<O0 @  )(:   9
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MDU<#X?)-*#\$NTZWCX4-N,NDGQ4NC^1X ]XOK0WM SOHKJ,7_P%02P,$%
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M(+9F!$N6I[Q6 *3U^1EL?CY X72$.8_Q&)5FNX$63EPD- LSMSS<)P4#%NF
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MK[MF#1Q+JEV \VN)%^.Q8PWL_G)9_@-02P,$%     @  H,)53)MTFP4"
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M2W:ZK7T<Q!OP$U58]#TY>, (Y5L?!-,^""8H $*&8X3'L04M]][36( #*C9
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M:E;X'[9*B72:;T"1V="11P0B;W1D-F5] "I'S]/%=9P?/8DK-(PBN.@/Y+>
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M>NR20J:NX9<HH^9E<22>926K/YTPO;I(L V[CX;39KU&7-$^9'&Q61YK+/B
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M-K)JA0%!)6KW9-_;.*P(9/X+ K05H!:W,V11GC/#AL=*/A"%JT$;-JRK5AK
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MM^B)*_ K_FCRDW&2VT.E5G*'N5SMVQ(9',%8:3=N2]-#,K*BW?9TW7.0K,;
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M$!L*-5H/<D6/UU@L'$]G.%<E50%9+V H:UI1C:%;,*-#^&9PWI3PJYPC#/]
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M*=!X!SJOM';'C2<8_CW+/U!+ P04    "  "@PE5XY]UR$H#  !+!P  &0
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M4^8BL_9J@Q\BH[4)X67!X=BJR4HCM#XYA3L;EFZQP2W&9VO!AH5"TAG==MV
M(_ =/_3Q&WN!G8T"OUX=^7#3B9%5"YPD&<$H"B%R//SUG<3WX4X:=/F'1#B"
M :)[%CV*8CK3&241?@-GA*<?*)&H+9'H]25B+?YL'84[+'#-TMKI+Y:&6_M3
MHMR^HCEXWLM%LTMLO!$QJV5&N=XBDLT\D@2#UM1$6V^G=95K^&9O%Y28/""Y
M%AR+G*M48$BGF!W^_?X-IQN9SKI".E SJS!!=UP5</P'9TJ?P&2Q4'R!/&LB
ML&TB,_"1E15>U)BKFCQ#'[,7VVP%;A+"P+6I#'TW;B$6&&6R8Y@XX7 (T<#U
MAV!C$)RUWXTP;YS(X'@P="+/.P$_<0=)*^BYHQ>-VRK\88P$B@9D6NQZ"01N
M/"*6Q>Y@]S3;P;X#B(/0B7P"\'W70UJ[B:5IB!8<8&7<LC+^R<8]V[Y^UDQE
MSA8AL<%\97E5%] $VU91+^^CZ.'#/U3*]FYJU0?[I]/MR+NIW.:LD9!R99!C
M,%D173^A)"]6N7SBR%=J?I<2?8*"%S.NM M4$W*')=EK+8,U5UOW""9PSH2"
M!PP1QW:O\:^807:CZWC)Z WJ9<ZP(V'T94[MO:[T%98,"10RXSFIUO6F3W?.
MI(O4=CX"1D9$'CQ1Z<![Y%<0-9-6ZD'FF*Q<F"=(?#=,WJ+<,'"]Z"W<"'W_
M?D[=6J#?=.^ HL)#J@5O+1R)?V+J'O^&6Y>^NXJ.L#+"!&6/J/@&!SB9M)Q,
M7LW)SYWB^L;HOY#92[2#B/^M%ZZ;X_[_-KAQ_$=]T'<\#Z^]T /?<\,1=:D0
M8NQTSP@;@N]VOMUOJ]!IA3Z"8R\[:= WHJ'K=<570O&LC_^0YES\U$F'^^AH
MY"3#A#I?XUH84E.-L(_NQ'I*%RBEY1GZE>'_7<P[2M>=MORC_#Z?:0WT/ BQ
M\2?AH#9T,]EL4BM'D4'B>+A;BS23HV9S(VK#Y)\UJYLP6)7=F.PKO7[G!59P
MM;#O3*)T59KZ,=:NMD_92?V">Q:OW\'8!18">V3.YZCJN0G^_U#UV[*>&+FR
M[[F9-/@ZM,,E/L>Y(@'<GTMI-A,ZH'W@C_\%4$L#!!0    (  *#"57^X/O\
M!0,  )L&   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;'U5VV[;.!#]
ME8&Z*!) C6Z6+ZEMP$E;I L8&]C9W8>B#[0TLHA(I$I2<?+W'5**Z@".7ZB9
MT<SA.11G-#](]:A+1 //=27TPBN-::Z#0&<EUDQ?R08%O2FDJIDA5^T#W2AD
MN2NJJR .PW%0,RZ\Y=S%[M5R+EM3<8'W"G1;UTR]W& E#PLO\EX#&[XOC0T$
MRWG#]KA%\V]SK\@+!I2<UR@TEP(4%@MO%5W?C&R^2_B/XT$?V6"5[*1\M,[W
M?.&%EA!6F!F+P.CQA+=851:(:/SJ,;UA2UMX;+^B?W/:2<N.:;R5U?\\-^7"
MFWJ08\':RFSDX0Y[/:G%RV2EW0J'+G<R\2!KM9%U7TP,:BZZ)WONS^&H8!J^
M4Q#W!;'CW6WD6'YAABWG2AY V6Q"LX:3ZJJ)'!?VHVR-HK><ZLQR@Q4SF'^Z
M9\J\P(-B0C-W7AHN'MBN0GTY#PQM9-.#K >]Z4#C=T#'L);"E!J^BASSM_4!
M$1Q8QJ\L;^*S@'^WX@J2T(<XC.,S>,F@.G%XR7G5<$+UC]5.&T7>SU.Z.]C1
M:5C;0->Z81DN/.H0C>H)O>7'#]$X_'R&]&@@/3J'OMQ20^9MA2 +^(:HX;O(
M6J5(!A,Y;/ )18OPE2E!H4+)&MZ7>4K;V=U/:WLH$0I946=SL0=C[PMH-)J"
MRI106);\F"4YLD;JY@RI&7,R.H9&PNIN?>O#W7:]_<=WN:M6V;Z]X ),*5M-
M,7UY#0^E0GQSP6#+G]\&[#6Q2W1D67SX^&$:1]%GV'#]"(V4E0\9:[AA]E3(
MKABO-33LA>:.@;\@&OFC:&:-V!_/QF3$J3^9IKTQ2SK" ^Z:"1IEKMB*]T'0
M7+T8CV:7<)%$M$SB*:U12&NO[YU22DUM_L2FIZ%;XTOZI'1RC>F1B5="O-*.
M8#J=6EXC?Q9..H)IDL"IFQ<<#8P:U=Z-10V9;(7I9L<0'2;OJALX?]*[L;UF
M:L^I;RHLJ#2\FJ0>J&X4=HZ1C1L_.VEHF#FSI+\'*IM [PLIS:MC-QC^1\O?
M4$L#!!0    (  *#"57]U=(1:@,   @+   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;+U6;6_;-A#^*X0Z%!M 1"3U8CFU#21IAW5 @2#NU@_#/M 2
M;1&12(VDXNS?[TC9BALX1M:Y^R*^Z.ZYYXY\B)MMM;FWM1 ./;:-LO.H=JZ[
MC&-;UJ+E]D)W0L&?M38M=[ TF]AV1O J.+5-S C)XY9+%2UF8>_6+&:Z=XU4
MXM8@V[<M-W]?BT9OYQ&-]AMW<E,[OQ$O9AW?B*5POW6W!E;QB%+)5B@KM4)&
MK.?1%;V\SKQ],/A=BJT]F".?R4KK>[_X6,TCX@F)1I3.(W 8'L2-:!H/!#3^
MVF%&8TCO>#C?H_\<<H=<5MR*&]U\D96KYU$1H4JL>=^X.[W]1>SR"01+W=CP
M1=O!=I)%J.RMT^W.&1BT4@TC?]S5X<"A("\XL)T#"[R'0('E>^[X8F;T%AEO
M#6A^$E(-WD!.*G\H2V?@KP0_M_C C9)J8]&M,&A9<R/0CY_YJA'VIUGL(( W
MB\L=V/4 QEX R]$GK5QMT0=5B>IK_QB(C>S8GMTU.PGX:Z\N4$(P8H2Q$WC)
MF&T2\)+79_O'U<HZ Y?CSV/Y#G#I<3@OF$O;\5+,(U"$%>9!1(NW;VA.WIT@
MFXYDTU/HBR4(L.H;@?0:'2%^H]NN=]S?;7N,^DGPX]2#1I&TB.]%ZF.[6B"Q
MC]]!?!OBEP?Q+]'GV@CQU?$C.#PQ'I[_T*<TGF#>OBD8I>^\M&2)?D#D@F7#
M,#UE7LFF=Q#DT*% 7X((89L_" -ORN!D?19 MX57  15WB-XG:SCJ@+P9P32
M%!=9@?-LXJ<TSS#+T_^$NV>:YIBP!!.:H33#!2MP01A:RL?S5 T(^R$GKZU:
ME@_#N:I&,YP0J%J"69;A*:%GJUK!<)XF/L@$EI.<HA/JRD9U9:]6UW+@]5&5
M3>_/0*IPZ=_O.'R#^$[&_K?BVY5-/J.W+]&9M/F]M+,<O+I !J6TP F$3/,<
M4P+*XL9PY2S*,XHGH.3IE,&8H#L!S[(L/:$A+M]R4UDT37%"*5"&VT#/=\>^
M39G?2SG/:@:[=$)02J:89H<U*Z:8I01-*<4TH2_6C#*&IRQ' (*S2?8_"S,^
MZ$Y:83:A![,0J5=N:%3&W;'-NQJZFR?SH4?\Q,U&0D4:L097<N&[*C/T7</"
MZ2[T.BOMH',*TQI:56&\ ?Q?:^WV"Q]@;'X7_P!02P,$%     @  H,)571:
MT=9_!@  &0\  !D   !X;"]W;W)K<VAE971S+W-H965T,S4N>&ULG5=;;]LV
M%/XKA%<,*\#&NE_:)$#J[M*A68.VZQZ&/= 2;1&5296DXF2_?A\IV9;3.!OV
MD)@BS^4[YWSGB#K?*OW%-)Q;<K=II;F8-=9V+^=S4S5\P\R9ZKC$R4KI#;-X
MU.NYZ31GM5?:M/,H"++YA@DYNSSW>S?Z\ESUMA62WVAB^LV&Z?O7O%7;BUDX
MVVU\$.O&NHWYY7G'UOPCM[]W-QI/\[V56FRX-$))HOGJ8G85OGR=.'DO\%GP
MK9FLB8MDJ=07]_"VOI@%#A!O>66=!8:?6[[@;>L, <;7T>9L[](I3M<[ZS_Y
MV!'+DAF^4.T?HK;-Q:R8D9JO6-_:#VK["Q_C29V]2K7&_R?;43:8D:HW5FU&
M92#8"#G\LKLQ#_]%(1H5(H][<.11OF&679YKM27:2<.:6_A0O3; ">F*\M%J
MG KHV<O/3 NV;#EY*RW7W%CRH[3""F[(#Y_?_FB>DQ\^N7/S_'QNX<]IS:O1
M]NO!=G3"=D:NE;2-@<F:U\?Z<^#<@XUV8%]'3QK\M9=G) XHB8(H>L)>O \^
M]O;B$_;>ZS63XF_F^$')0DFC6E&S@2ZR)C=(")=VV% K\I.03%:"M>0C-CFX
M:0WY\VIIK :[_GHL0P. Y'$ KN->FHY5_&+6.5_ZEL\NO_\NS()73X27[,-+
MGK)^^1$=7/>H+:!?&<,!UD7U#@47K:\Q):?K_U@T3_I[/)I/#2<KU:+YA5P3
MZWT)6;5]#8JQ 95MF"450XYE>T^6G/2&U\0J@E,+>0L;[0&UC^=FX8,14'<\
MI:-1Y^2J[1I&%DQS+W)55:J7@^=?.&MMX\^H/X23;2.JQONH-*^%57KPT#G4
MUP#2L%M.I,(,@B%M1LTIH">LW"S^#[2'+IT'9WO-)=?@W^#C""90&2_3:>'F
M*_(H^4J KEA#T!VY3)T1E 06V8$1[9016V&'./A=Q;L=]=V&D+<@B&,]EH0Y
M1[=H Y2LX6U-N"/._5#,6B$K4ED$T"EMB<3KQ3LDMZSM@9'CQ=#LTL V+@N&
MU+T/E*U60 /+#HU/JQ/DK<#\PVY-^@Z@JJ-V]:A_N[ZF7G8D6.UP.N0,>=YT
M3-Z[&AP4(;!D+5J:$S]!,?.\@NH-8)GG/E4G$K5+RF(P_/UW113FK["-37WL
MPV6=;-%=/B/N2-1XJHD1:RE0(B;M&<%PXWZXO>$5WRQA) [IKF\7O=8N[R.6
M!3.-!U2Y!?_:HQ"MGT;/2!B7-"I+M\I"FF<16GM:-W#C"Q\H9WC5ZR&:.*=%
MD).DI$&6D0^  )-N[E-?NRBD61"2G$9I^.VI#SY\A6*W/N".:1"A"&@<)22+
M:%@$ ($2H+SL#M[TW@)):)&5)*1Q$I'W/G>'0X/]O,CPOXAC-XT[)L"S.]Q(
M#!\J,J;[.#T9S<.4A%".$_).,3EU^#A8OQN] IP@",B5)Z3GXTJKS8&1)$YI
MF07PD)8%^:2LZ\5CYW%4T#@+4<H4V<].U/4W)5\\4'R'>"B:"A<N(!J&C"MM
MYRHW)+I(:1JEKDIIDKN1S>1:N* &$X-06M <]<=/5$3D9Z7JK6A;I".C88*T
M!"7-TNQA7@9=D'J'RO6MZZRTW"?'J9A_RZ5C$TH.F$7Y@'J'QB8)DA#E 4@2
M4=B8"!HG.925[ZXB.S\N'2C6AJ-':Y?'%,5*0E_N8U>/S29G*0E2__<>2<;D
MP#AH.2YU1+O;VPNU>M$?1F-)"Q0YH64:C]0<#P Y*$A,H[ <.2"_+6<>%S0%
M_T(:Y '-BGP4'8^?N8,L@XO4K^,\HPD<[3I].FK&UX1!?N]]WOW0K"K=\TD[
MN(:G ?P\<]1/RQ#WE;H?YC][: &2>0@N>(AX>V (M4<^<Y?<DB1#0[P1MYA9
MF(E[ RDHY/X6#^@"!K5*KE_@-K'!]7B)V4&3,"8Y9L!P?^)CRJ?>4@R*, R^
M*<M4)J1EX&9!E 8/.F\J50X3+"L\K:9M-I5Z=P3Q)/==GG'%Y]I-Z]5P^_-O
M$.-8$*'/4LS$,$S0W*,4!MS>TSTX4J @0(Y./!G]2?=@2(+96,9/Y>6D-L80
MIF8,^@8C?0^%F>8"-,7LQ5! &-^R>2H),F0H 0(OP-1!=GH.XB4QS?((JQ)O
MC#PACUUCYY//E0W7:_]19HAGZ/#ELM_=?_==#9\[!_'AH_&:Z;7 3&KY"JK!
M69[.AE;>/5C5^8^?I;+XE/++!M^N7#L!G*^4LKL'YV#_-7SY#U!+ P04
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M0%D#7%]+:1X&UD'?2V;_ E!+ P04    "  "@PE5@Q81?U$$  !6&   &0
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M#K1.78#UVO/?,L^/(W1MWX6#"J# ^:X]<P8E0 &S9[X=AH,BH#)K!Z%GJ<L
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M06FXI#7\NI$]$-">06O/7OV,,,6H8QZO.^9YCP\'K7H!)2VE7I T#$HCH+0
MBF;J7R=4GG=S'_9 PRM0&@:E$5!: $4SI:_#*Z][E=&%/@P:3X'2<$DS/=%]
M:/HP:.S4VM-OV+!]LM8QI7R3KTH5*+_5BF5@U=YJY>M3OMZSL7_J/L[<EOW8
M?23%NM8:7RRS_1SR39P)E-"U:N7<#=7O<EZL7"TV)-OE*RV73$J6YF^W-%Q1
MK@]0GZ\9DV\;ND&U?GCR/U!+ P04    "  "@PE5/JIR 1((  "O00  &0
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M*E9)+DG*'K34'I[I3S91[WBN3Q3?5!MN[[E2/*L.UXS&3)0/Z/L/G*OGDS)
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M+V9VO]OPG4&C]\;$9K*2\L%.ON1S+["&@$-F+ /%UQ8N@7-+A#8>.TZOE[3
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MF84&6*?5U!E],>C7IT&H0CFH9X#J:2ZXIBV*1UN4NYMJ[96W]^+:@J !MD%
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ME>?ETQ]6!1[RXJ_UUSS]?U!+ P04    "  "@PE5YH/GM=4*   Z60  &0
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MSO_,4\T)05,4#>V'<T+0W ,H+5#TFW).")I4@*)U)=@F%8@^J7#&ID4"FF4
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MS<\#I0TPSPLA].O$-K3N=Y3^!5!+ P04    "  "@PE5Z\?T$<0;   Y"0(
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MXAJ+XNON!DRO$KP'JU6<M&# PY *258@TG:L[<;,6J_4C@>U77-F6%_9KE?
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M'Z_#Y\KV7<LZ =1M=M)BK?3K%Z.>5E%/!T4MRPHNY PO!\8E(/GWT $R'39
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M!$WRRQW!(6%9 _G[AE+Q?I-U4!UV+?\'4$L#!!0    (  *#"57N2T365@,
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M;#X-Q@%DN.0;8>_4[G<\..0%IDH8_PN[P]XH@'1CK)(',"F015G_\X=#($X
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M"30 KCNH_^>,R=<'/4!^ZCO]'U!+ P04    "  "@PE5O'E&N;L$  #2'@
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M[.6CJ <45;Q)MB@V_Y*7.K;7(9-U46;+NK'<@F62;O_&?]2)V&L@.?8&?MW
M/VP0?J-!4#<(FO80U@W"ICU$=8.H:8-^W:"_R?TV69M,T[B,KR_S[(7D5;2D
M52\VY=JTE@E.TNJ;]5CF\G\3V:Z\_BP6<2FF/SW$>?E*?LGCM(@W-2_(3^1F
M.DVJU_&"W*;;;W'U;?B>BC).%L4/,N371TJ^_^X'\AU)4O++/%L7<3HM+KNE
MW+:JA^ZDWHX/V^WPO[$= 1EG:3DO"$NG8FII3]WM^X[V79F376+\M\1\\)W
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M]<$;G?_ 9'!,BH4FQ2)#8JW@#)K@#'YY+L"'=T,$X6<P3_@]*"A-3\ 2%XG
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MD=-E];YE?2+H7N^S/5 A:*D/,\ I,!4@KV\I%<<3E:#=/5[]#U!+ P04
M"  "@PE5,GU\*D,#  !]"P  &0   'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6RU5FMOVC 4_2M6.E6MM)'WHQ20RF/:)E5"K;9^F/;!) :B)G%F&^C^_:Z=
MD(;,1:SK^$!LYYQS[7,=^PYVE#WR-2$"/>59P8?&6HBR;YH\7I,<\QXM20%O
MEI3E6$"7K4Q>,H(31<HST[&LP,QQ6ABC@1J;L]& ;D26%F3.$-_D.6:_QB2C
MNZ%A&_N!NW2U%G+ ' U*O"+W1'PMYPQZ9J.2I#DI>$H+Q,AR:-S8_5DH\0KP
M+24[WFHCN9(%I8^R\SD9&I:<$,E(+*0"AL>63$B622&8QL]:TVA"2F*[O5?_
MJ-8.:UE@3B8T>T@3L1X:D8$2LL2;3-S1W2=2K\>7>C'-N/I'NPH;!@:*-US0
MO";##/*TJ)[XJ?:A10 =/<&I"4Z7X+U <&N">VH$KR9XIT;P:X):NEFM71DW
MQ0*/!HSN$)-H4),-Y;YB@U]I(??)O6#P-@6>&,TP*])BQ=&<,'2_QHR@#T@S
M.*%YN1%8)I>CBRD1.,WX)6#?(1-Q">$#4\"$I*P9U\''57#GA> NNJ6%6',T
M*Q*2:/C3X_S@"-\$(QHWG+T;8^>HX)=-T4.N]1XYEN-HYC,YG6[KEO-OT6>O
MCGY@AMML#5?IN:=OC>\W"RX8?-P_=,FNY#R]G#SP^KS$,1D:<*)QPK;$&)V?
MV8%UK7/Z+<6F;RDV>R.Q@YQX34Z\8^K/.2DA)^JS0^=GD6/;U_*X3&-TD18H
MH5F&60MSJ<M6%2A2@>1MLAU9/<<?F-MV%K2@JT/05 ?RPT/03 <*&LR!&7YC
MAO]:,Y(TVPB2_(4=_BEV:$%1QPX=R ^L]L_NF*.E1'IW@L:=X*@[#^J.! _P
MEC"X\NM3&M$EBFF>PR4-ETO\B*!XX (7"3BIV4L52>M8%=YO3=KS(C\*NJF?
MZ(!VX#N!UW%.JVC[KM7=3!J@Z_C^5<O8 \_"QK/POWG6WG)'7 O_G'I@.:YE
M=_>:!NA'3A193L<UK6($[KH=US1 +_2",.BZ9K;JB9RPE2KD.%BP*41U?S2C
M3:UXHTJDSOC8[D]LS?@4:LNJ%'R6KPK36\Q6*908&5E"**L7PG195>Q5'4%+
M5<TLJ(#:2#774!\3)@'P?DFIV'=D@*;B'OT&4$L#!!0    (  *#"55Y%7XW
M-00  #\6   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;,5876_;-A3]
M*X0*%"VP123UZ=0VD%@:FF$%@@1K'XH],!)M:Y%$CZ3M[M^/E!395AC5V5CL
MQ9*H>\_E/5<\)N]TS_BC6%,JP;>JK,7,64NYN71=D:UI1<0%V]!:O5DR7A&I
M'OG*%1M.2=XX5:6+(0S=BA2U,Y\V8[=\/F5;618UO>5 ;*N*\+^O:<GV,P<Y
M3P-WQ6HM]8 [GV[(BMY3^?OFEJLGMT?)BXK6HF UX'0Y<Z[098I\[=!8?"[H
M7AS= YW* V./^N$FGSE0SXB6-),:@JC+CBYH66HD-8^_.E"GCZD=C^^?T']I
MDE?)/!!!%ZS\4N1R/7-B!^1T2;:EO&/[C[1+*-!X&2M%\POVG2UT0+85DE6=
MLYI!5=3ME7SKB#AR4#AF!]PYX*&#_X*#USEXYT;P.P?_W A!Y]"D[K:Y-\0E
M1)+YE+,]X-I:H>F;AOW&6_%5U/I#N9=<O2V4GYRGA-=%O1+@EG)POR:<@I_;
MJP W=59N<YJ#H@9)46ZENC78+UBUV4JBZR[ NX1*4I3BO8(1#<S4E6J>.IJ;
M=7.Z;N>$7YB3!SZQ6JX%2&L5W>"?C/N'(_ZNXJ<G"3^1=(U' 7_=UA? @S\!
M##$VS&=QOCLRI?/?HJ?_.OH)&5[_Q7@-GG?^%_/U-V4#;B2MQ!^F<K> OAE0
M2^&EV)",SARE=8+R'77F;]^@$'XP<6T3++$)EEH".ZF*WU?%'T.??VD442U0
MLJ-<*7RW^ !;@HQ5E9)D)279(U#_%4*2.E<5!&_?Q!BA#UIHBPR\4ZN\=7IO
MJF$;/FC"ZW^?W=SWXR .@VCJ[H[K8S)$88!#_]0P,2*BP(,#Q-1@Z.$@F$#4
M&YYP%O2<!3^,L[S3P^^P%CR?>@BQ!U$P8,U@&,0XCB$>L&9$C!6[WH U@Z$?
M^6$4OL!:V+,6CK)VWW*R:?3>E/.H^VM7NTVPQ"98:@GLI 917X/(M@9'-JMB
M$RRQ"99: CNI2MQ7)1Y=&5?YGVK#IG;14@#)P/Y,>?F.A,3/US&*/3S0A87!
M+ P1'(JNP2P(4 0'XF$P@Q,4^&;IF/0$348)NJ-"\B+3G+2IDSWAN5%$1H%>
M^[G:!$ML@J66P$ZJ@>!A[P]MRTB':*DP5M$2JVBI+;33VAR=R]#_("9=T..%
M/?$]A 9B8C##T(^&=HG!#F$\P>% 3DQV$0RBP*PG"!]8PN-;.,(Y4109<QUU
M??6G:A,ML8J6VD([+<+A0(BLGPB1U2.A5;3$*EIJ"^VT-H=C(1H_%_X@&7E^
M) O5+@(/3S4&N\D$1]@;ZH@!+YY@?[@M,>$AA+SAD<8]:HA5E*^:3J10*6YK
MV78Z^M&^VWG5]/@&X]?H<H$,XXGNCC8-N -\VUK]1/BJJ 4HZ5*%@A>1FBQO
MNY7M@V2;IAWWP*1D57.[IB2G7!NH]TO&Y-.##M#WC.?_ %!+ P04    "  "
M@PE58B2F2*0.  #I<   &0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6RU
MG5MSV[82Q[\*Q_5TVIG$)NYD+IYI+.F<='K))&W/0Z</M 19G%*D2E)V_.T/
M0,F""$ 0X8(OB2PMEJL_(7!_ )9\]UC5?S<KSMOHZ[HHF_<7J[;=O+F^;N8K
MOLZ:JVK#2_')LJK762O^K.^OFTW-LT77:%U<PSBFU^LL+R]NWG7O?:IOWE7;
MMLA+_JF.FNUZG=5/'WA1/;Z_ !?/;WS.[U>M?./ZYMTFN^=?>/O[YE,M_KH^
M>%GD:UXV>55&-5^^O_@!O)DE78/.XH^</S9'KR/Y5>ZJZF_YQ\?%^XM81L0+
M/F^EBTS\]\!O>5%(3R*.?_9.+P['E V/7S][GW5?7GR9NZSAMU7QOWS1KMY?
M)!?1@B^S;=%^KA[_R_=?B$A_\ZIHNG^CQ[UM?!'-MTU;K?>-103KO-S]GWW=
M"W'4 * 3#>"^ =0;X!,-T+X!&MH [QO@H0W(O@$9VH#N&]!.^YU8G=*3K,UN
MWM758U1+:^%-ONA.5]=:")R7LF=]:6OQ:2[:M3=_9'6>W14\^EBVO.9-&TW+
M-F]SWD3?_?%QVGP??3?A;987XM7KZ/<OD^B[R^^CRR@OH]]6U;;)RD7S[KH5
MD4A_U_/]46]W1X4GCOKCMKR*4/PJ@C&$EN83=_,)GXOFH&L.+,VGPX]N:SX;
M?O2XW_Q:J'\X!?!P"F#G#YWP=[NM:UZV4=8TO+6*N6N/[>WEV/.FV61S_OY"
M#"X-KQ_XQ<VWWP :O[5)&]+9-*2S62!GO9. #B<!N;S?W&;-*A*=.9K+%_R?
M;?Z0%>*L6,_'SA7M7,FA^^$&(@PA>G?]<*RTS0S%*>N;39V!^6IH'A.D"+/X
M<,R>.OB@#G:J\[%\$$/#6NHA?_GB&O2W&!3DL-'P^;;NQ@N;4#NOY"@:E.(T
MUG0RK0C"0)?)&:&O3(&<]<0D!S&)4\S/?,Y%[Q+J-:^BDK<VX8@A"660ZAW,
MM (QC1--.&<TOL(%<M83CAZ$HU["1=]^DT  WHH,I\A:OH@V6=T^V>2DAE )
M()!J<II6-$5,LYHZ8_25,Y"SGISL("<[\Z.>5VL>M=E7<;&O#]K:]&-F1Q.]
M,=7T,ZVT7_K4&9"O=H&<];1+#MHE3NU^;5>\/A+-.OHEIFH(0FU<FYA6*<7Z
MX.>,QE>X0,YZPJ4'X5*G<)]JOLGR1<2_"C9J1,>3U]RJ4W-^-@]*;=V0Z9<3
MBU5"D:ZH,TQ?10,YZRD*8I7"QTY-?ZO:K!@@W][-L3*8@AAI%XR)Q0ZE"4N@
M)J$[+%\-0WGKBWC$0<"9A?]2E:\'2 A"IN)!O4V#>IN%\M8_'8J)@#/;%Q>G
M-BOO<YEB[L[&R51I[^BXMS)*"= [M6F6P"36AP5W6-XBCH$T0#$-<$/-?ZIJ
M\9@7A54V9.@!"4) 'TWM=K%^\9^Z0_$6+I"WOG *=X";=WZJLO+HZK[+-JOE
M88S=5+6<%[/J:J,9/5.R&5%#T:#$$\I;7U'%/, -/5+1XRS3FKN?H$A@<@X$
MD.B:FE9Z^NF.T5O1,5@(*!@";AK2F'R70_'GR;MG>>5,1OL4K7F[JA96<4WJ
MP2B!QC!@,0,,$%WAH'04REM?8<5'P U(OVYXG;5Y>1\5/&MX5,M9ZM?5\O6V
MX:X<P4)+*36S+(L9P1CHB@9EIE#>^HHJ:@)#L,DAG0E#)(V-2[G-"NK3'NY0
MO(4; YJ HB;@QJ9=BE\.RU%- ,)I'!O3'38[@DAB],"@J!3*6W^J7;$2',)*
M)\7[<*;YG^ OZP2]24PI 3'%FN06NX1 I$_L3=U1>,^KCT%64)$5=)/5\_I&
MD6=W>7%RKA@&1:N@WJ9!O<U">>N?CZ/E)C=:_3"?5UN9-6RRIRX5DU,PV7Q>
M;[F:E[&>(1.A2)I"J'=RTPRC5 >RJ3M*;TW'("VH2 NZ26N6+[;S/*N?I) ]
M=:U"FDQ%8Z9?YBQ6("8(ZSH&!:]0WOHZ*O"";O#ZF2_RN1B@SXT5)C\! '&J
M<Y;%CA"6&,,M-E;-2(KTN8&9S2Q&Z,3:&E1L!-UL-,D?\@4O%^X^8^(-(?HE
M?8C1U!V-=X<9@X*@HB#HIJ#;/I%+2"^J\OYUR^MUM.!WUBDC:,(,Q$!?7;-8
ML41'2G=XWF*. 3Q0 0]T \\L+[-RSO>X<^XW:/(+@4;"8QKAQ.B001$GE+>^
MA@IQX!G$T:#QG(HFRR!(C*YH6D$*]0DC=V3>.HY!/% 1#QQ"//.!N:-MS4<D
MUCISV^P 0?JE=^J.S5O),9 '*>1!\>"5C3,ZHI#<,0GJ;1K4VRR4M_XY44R$
MG#G^S4^]:]2I^>4N,U_P)1?O+J)E-SK+D65>-2<V)@'+U%,:4_UW8+-+8&KL
MN7%_"V_-Q^ >I+@'N;EG\BQDFWT]_!"LVT6023 I)/K"O<T*Z,O[4W=0WA*.
MLD?N:)/<.<PYD2#XK) @&]=@/76W6*5,3]S=X7J+.P;[(,4^R,T^CLS!2UX+
M&]$TUC,SFQD"J3Z+ZH[96^$Q%J&0 BWD!JW=]+/B@W-70\O^.L1B';IL9I@Q
M8R (BEVAO/655-B%W-AESD>?T]*"7"A-$Z-;6NQ@G*;ZWA-W?-YJCL%=2'$7
M<G/73DVW@A_.^#@Q,XTL  8)-";M+'8(47-FVAV%M^YCL!I2K(;<K':B^.'I
M5?2ISF6A3?2!EWR9=S-[5G5#$M<DJ+=I4&^S4-[Z9TK1($H'K2&<7O5"(9%M
M$M3;-*BW62AO_4H A9/8O03F52F!S04O@%)H3-3:["A@5!_VW;%Y5P&, 8%8
M02!V0^"+JRI,>D/,V,HVL9AAP8+Z[)L[2&])QV \K!@/NQEO2&T%-KD-B@#T
MY1>+&8/&*I8['F_UQL [K/ .N_'NY046V*2U)$;&=+#%C$)@3*J[P_06=0RL
MPT>E4VZL\RBSP":3X43?%SBQ6 &$C9$R*+B%\M;74($;'@)N9\HML(7#F+[8
M,+%9)4A/<]WQ>*LW!JQA!6O8#6O_JN8"6ZJBC'U_$XL5 ,Q8JW8'ZBWK&-2&
M%;5A-W%IFX0]!LNSA5(3BPF.8V.<# ICH;SUY50PAMTP]L-:[IN(%EL>+>MJ
M'67+I:!AH:150LNR&4FI(:-I1HDQQ^4.S%O&,4@)*U+"/NMFCM^UN12&8(*H
MD099[&+"S#0R*..$\M8OT%6,0X8OF9V6D 1=+0OJ;1K4VRR4M_[I4*!$SJR6
MB0O6JVA35QM>R]D9>?V2X+F1['2ZAMKDGX00HV[ 8H938E1@ND/T%G0,3"(*
MDTBHZBIBV?.7,(/?K6;0J!ATA^4MXABT1!0MD9=75Q'+&A>@ !N=S[86EE)C
MSY8[%&_AQB BHHB(N(GH7U17$<N&/J,OFC9ZXN0.T%O.,>"('-U.8KS2*C*H
MM,IBE>B;C]Q!>DLZ!C$114QD:&V5G)@[9*)V"6T%5  :9>D6NR060Z0^H^0.
MS5O(,1B)*$8BY^XQ$:1(C5A6IP#1>6AB,;,5J;EC]E9X#&PB"IN(&YOZ7753
MBS&@Y<53M.+%XJ"T55.3C7!L_/('&$W=$7KK.08_$<5/Q,U/+RSZ(R8FI8E.
MFA.+E<@U]<DG=X3>>HZ!4E2A%'4O%YTK^:/FR@],]'L832Q6" +]&N0.Q?O>
M/&- #U700]W0XU/R1TV&82@Q:D4F%CL0LY@F.NVX8_-6<@S:H8IVJ)MVSM3\
MW5(37D!,:9+JHZ'-$#&*C5^P.R!O^<;@'*HXAZ)!:^]G=OC0D(@R">IM&M3;
M+)2W_OE0^$3=^/3B^CUJVQD8Z[_]B<T,D%3/4]U1>FLZ!D-1Q5#4S5!^]7O4
MY"%+_9[%RE:_YX[,6\<QP(D>W:'/#4X#Z_>HI;1*Y/,ZR5O,L&49Q!V3MX)C
M$!-5Q$3=Q#2H&)!::J^,8L A1E-W--[:C<%"5+$0=;/0BXH!J:6VRBP&M%B9
MQ8#N\+S%' .$J (AZ@8AKV) :H*-60QH,0+Z_::F[JB\-1P#?IB"'W8&?OR*
M 9EE%UQJ[#>W64%BW&HS* N%\M;74;$0&\)" [>:,Q-R4G/?V\1B1A-S.LX=
MF;>.8Y 04R3$W+<:]R@%9$%O.A[4VS2HMUDH;_USHO"*N9>11BH%9);[]D%F
M(*W%C &@YZCNK^ M^!C\Q!0_,3<_#:\#9"8)H<3@)8L52(VE3W=0WA*.@4M,
MX1([ATL!Z@"9C8^,.D";5:K/M[C#]19W#(9BBJ&8FZ$"U0$RRWH3TC<Z3BQ6
M*#63B:"$%<I;7]^CVYZ?N:V?7Q4@,S$J(?IVVXG%*J7F.!KV!NACT!93M,7<
MM.5= \@LBTF8FOFM!<A@8LRQNJ/SUG(,V&(*MMB077OG]-OYZ#W< R/*C+YH
MVJ6 ,J,S!B6M4-[ZM^.7I-5_1S%#XF:&/\%?OZUX=%NM-UGYU"TUL[>-2)C*
MIBKR1;<SXBXKNNM8]_PDN4(]+[8+'HD!8K]<T*5=1Z=%CKUYJWF1STFZBN3!
M!CD_6HT01\K::)Z5T1V/MHUH5)7%DS")Q*=MP:/JKLCO,SG$=X=NSWTA&<KN
M"/+Z<4G2](KM5%[G1?&<1UX2RJYB[?WN #]N2[Y[__GI3%V#"9_S]1VO]Q_M
MG[ST*A)G<L.[9X,5^VUYK=Z1AX>]K.KH<97/5]%<9&=Y6]5-M*C$ --&J^R!
MRQTNU;9NI(*=QWM>B@MEL;=^/LYF7[EYIRHWY4>7XI=BE2(%QMO_5HE=7Q#?
MZ;D+'+['<Q^XQ A<H?YA9<\ZL>UD%RFB^CD33;+U;K;:W#;=N+_(91+#J\0S
M!'I%7Q"!73/YH3AA<E6]YA$O\K5(*F5GV&Z$8]4]GL^4U*\;.DII])BW*Q%@
MZ_[1745?.(]^J5H> 7K8;B+_A_';LX\^Z^R$O>R8RVW=I0V+[F%H5[8QZ_KH
M*6QK7M]WS\N3'5W(LWL0U>'=PS/Y/G2/KM/?3^(W4S'TV3X!XI/=4_?4(78/
M ?PYJ^]S,4P4?"D.%U_)++;>/5=O]T=;;;KGP-U5;5NMNY<KGBUX+0W$Y\M*
MZ+3_0Q[@\'3#F_\#4$L#!!0    (  *#"56\>E6QS@,  -01   9    >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;+5876_C-A#\*X1Z*!+ M439<3YJ"TCL
M'NZ*,QHDN/:AZ ,CK6WB)%(EJ3CY]UU*BF1?9>(BV"^V*.T,=T8BN>1T*]4W
MO0$PY"5+A9YY&V/R&]_7\08RIH<R!X%/5E)ES&!3K7V=*V!)"<I2/PR"B9\Q
M+KQH6MZ[5]%4%B;E NX5T466,?5Z!ZG<SCSJO=UXX.N-L3?\:)JS-3R"^9K?
M*VSY#4O",Q":2T$4K&;>+;V9TTL+*"/^Y+#5.]?$2GF2\IMM?$YF7F S@A1B
M8RD8_CW#'-+4,F$>_]:D7M.G!>Y>O[%_+,6CF">F82[3OWAB-C/ORB,)K%B1
MF@>Y_02UH O+%\M4E[]D6\5.)AZ)"VUD5H,Q@XR+ZI^]U$;L )"G&Q#6@/![
MP/@ 8%0#1J70*K-2UH(9%DV5W!)EHY'-7I3>E&A4PX5]C8]&X5...!-] ?1
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M6<'?"Q$: -]WG*OGCG8P_ ^E?P-02P,$%     @  H,)50D@XA[Y P  $1(
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MB',5__AP \X^G8-/@&;@VY85 F<K,7>E$JF[<N-:T.=*$#H@Z,\BNP2^]PM
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MU>V2$C,<KR% W8:MMM7H]GMHUNY& N,3W/A.:SP&?M-/=US^"U!+ P04
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MSRW7RU^6WSLG]_@%Y_JV8GCZ"U!+ P04    "  "@PE5SA7,7P\"  #J*P
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M;3N\Y+/I+[[K/U!+ 0(4 Q0    (  *#"54'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @  H,)5:7R
MDJ7O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @  H,)59E<G",0!@  G"<  !,              ( !S0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  "@PE5'%&Z'.8%   (
M'P  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @  H,)56%0Z>0Z"P  *30  !@              ("!*@X
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  *#"57$6.1@
M5 8  ),:   8              " @9H9  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    "  "@PE5=&AI"$\(   #,0  &
M@($D(   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @  H,)
M5<<NB#&2#P  XJP  !@              ("!J2@  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    (  *#"563S<GV$@L  )DU   8
M      " @7$X  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M"  "@PE5+5W[(\,7  !11P  &               @(&Y0P  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @  H,)50/03S[])P  U8<  !@
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M970Q,BYX;6Q02P$"% ,4    "  "@PE5QRLX<O "  "7!@  &0
M    @($9I   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M  *#"54S0K,B.P,  $H'   9              " @4"G  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @  H,)5> :PB37$0  FSH  !D
M             ("!LJH  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    "  "@PE5DP7:640%  #@#   &0              @(' O   >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  *#"543>_YBU08
M )02   9              " @3O"  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @  H,)5=J+5989"   81,  !D              ("!
M1\D  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  "@PE5
MA;!W+T (  "2&@  &0              @(&7T0  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    (  *#"57%6M HTP4  )H.   9
M      " @0[:  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @  H,)5>%Y5P,M!0  ?A$  !D              ("!&.   'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  "@PE5,FW2;!0(  !J$P
M&0              @(%\Y0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    (  *#"56JIPDD)@8  #@;   9              " @<?M  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @  H,)5>J7-6DU
M/P  ,=T  !D              ("!)/0  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    "  "@PE5U_R*XHP&  #A$@  &0
M@(&0,P$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  *#
M"55]#79NH (  -$%   9              " @5,Z 0!X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @  H,)59[7%XZ"!   !0L  !D
M         ("!*CT! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    "  "@PE5X<&+  P%  !'"P  &0              @('C00$ >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  *#"55:#(2\_@(  (<&
M   9              " @29' 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @  H,)5>.?=<A* P  2P<  !D              ("!6TH!
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  "@PE5H8<Q
M,(H#  #R!P  &0              @('<30$ >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    (  *#"55 [>;C[@4  .P/   9
M  " @9U1 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M H,)5?[@^_P% P  FP8  !D              ("!PE<! 'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    "  "@PE5_=72$6H#   ("P  &0
M            @('^6@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    (  *#"55T6M'6?P8  !D/   9              " @9]> 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @  H,)52CJ1!;I!
MN@\  !D              ("!564! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    "  "@PE5"4S>A% ,  #ZE0  &0              @(%U
M:@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  *#"55)
M0$^]20X  $6I   9              " @?QV 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @  H,)5<^V-K8\ P  5PH  !D
M     ("!?(4! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  *#"57'\'_+@0(  "0&   9              "
M@9^@ 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @  H,)
M53+:):!F!P  RS4  !D              ("!5Z,! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    "  "@PE5"KL]8JH"  #P!P  &0
M        @('TJ@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   (  *#"558L#XEL0(   <'   9              " @=6M 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @  H,)5<A=;*ET"0  M&0
M !D              ("!O; ! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    "  "@PE5P%*&"U<2  "M$P$ &0              @(%HN@$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  *#"57F@^>U
MU0H  #I9   9              " @?;, 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @  H,)52^-)O@ !   HA8  !D
M ("! M@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  "
M@PE5Z +-Q30#  #."0  &0              @($YW $ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (  *#"55IHM7+U0,  ,\-   9
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M970U-RYX;6Q02P$"% ,4    "  "@PE5^_@3;W0#  "R$   &0
M    @(%M"@( >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M  *#"54&B#@^[@0  ,P7   9              " @1@. @!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @  H,)59]M ";S!   ^!H  !D
M             ("!/1," 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    "  "@PE5[DM$UE8#  #G"P  &0              @(%G& ( >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (  *#"55E%S<;>@0
M  $6   9              " @?0; @!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @  H,)5;QY1KF[!   TAX  !D              ("!
MI2 " 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    "  "@PE5
M&SP":)D"   J"   &0              @(&7)0( >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    (  *#"55T^+TH= D  .IC   9
M      " @6<H @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @  H,)56917%T,!   %Q4  !D              ("!$C(" 'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    "  "@PE51 _NRE("  "D!0
M&0              @(%5-@( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    (  *#"56G1H^RP@,  $D6   9              " @=XX @!X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @  H,)53)]?"I#
M P  ?0L  !D              ("!USP" 'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    "  "@PE5>15^-S4$   _%@  &0
M@(%10 ( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (  *#
M"55B)*9(I X  .EP   9              " @;U$ @!X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @  H,)5;QZ5;'. P  U!$  !D
M         ("!F%," 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
M    "  "@PE5OB\3/X@#   ;#0  &0              @(&=5P( >&PO=V]R
M:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (  *#"54)(.(>^0,  !$2
M   9              " @5Q; @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL
M4$L! A0#%     @  H,)556(?9IP!   +A8  !D              ("!C%\"
M 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  "@PE5P!X7
M4.D!  #O!   &0              @($S9 ( >&PO=V]R:W-H965T<R]S:&5E
M=#<V+GAM;%!+ 0(4 Q0    (  *#"55F8;4(1@,  - 4   -
M  "  5-F @!X;"]S='EL97,N>&UL4$L! A0#%     @  H,)59>*NQS
M$P(   L              ( !Q&D" %]R96QS+RYR96QS4$L! A0#%     @
M H,)5?]/V!W@!0  F#(   \              ( !K6H" 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    (  *#"55S?'@L40(  /LL   :              "
M ;IP @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  *#
M"57.%<Q?#P(  .HK   3              "  4-S @!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !4 %0  Q<  (-U @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>441</ContextCount>
  <ElementCount>476</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>148</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Business Combinations and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</Role>
      <ShortName>Business Combinations and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Investments in Other Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntities</Role>
      <ShortName>Investments in Other Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2125106 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Medical Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilities</Role>
      <ShortName>Medical Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2138110 - Disclosure - Mezzanine and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquity</Role>
      <ShortName>Mezzanine and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2150113 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2154114 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2156115 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2161116 - Disclosure - Variable Interest Entities (VIEs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</Role>
      <ShortName>Variable Interest Entities (VIEs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2164117 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Business Combinations and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables</Role>
      <ShortName>Business Combinations and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IntangibleAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Investments in Other Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables</Role>
      <ShortName>Investments in Other Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsinOtherEntities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2328305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Medical Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesTables</Role>
      <ShortName>Medical Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2351309 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/RelatedPartyTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2357310 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/EarningsPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2362311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</Role>
      <ShortName>Variable Interest Entities (VIEs) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2365312 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Gain (Loss) on Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Gain (Loss) on Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails</Role>
      <ShortName>Business Combinations and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails</Role>
      <ShortName>Business Combinations and Goodwill - Summary of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Investments in Other Entities - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails</Role>
      <ShortName>Investments in Other Entities - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Investments in Other Entities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails</Role>
      <ShortName>Investments in Other Entities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails</Role>
      <ShortName>Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails</Role>
      <ShortName>Medical Liabilities - Schedule of Medical Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Stock-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails</Role>
      <ShortName>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Stock-Based Compensation - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails</Role>
      <ShortName>Stock-Based Compensation - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2452429 - Disclosure - Related-Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2453430 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails</Role>
      <ShortName>Related-Party Transactions - Fees Incurred and Income Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2458432 - Disclosure - Earnings Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails</Role>
      <ShortName>Earnings Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2459433 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2463435 - Disclosure - Variable Interest Entities (VIEs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails</Role>
      <ShortName>Variable Interest Entities (VIEs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2466436 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2467437 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2468438 - Disclosure - Leases - Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2469439 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ameh-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ameh-20220630.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ameh-20220630.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ameh-20220630.htm">ameh-20220630.htm</File>
    <File>ameh-20220630.xsd</File>
    <File>ameh-20220630_cal.xml</File>
    <File>ameh-20220630_def.xml</File>
    <File>ameh-20220630_lab.xml</File>
    <File>ameh-20220630_pre.xml</File>
    <File>ex1012022063010qngcbasho.htm</File>
    <File>ex3112022063010-q.htm</File>
    <File>ex3122022063010-q.htm</File>
    <File>ex3132022063010-q.htm</File>
    <File>ex322022063010-q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ameh-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1204">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ameh-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 37,
   "contextCount": 441,
   "dts": {
    "calculationLink": {
     "local": [
      "ameh-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ameh-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ameh-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ameh-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ameh-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ameh-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 783,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 94,
   "keyStandard": 382,
   "memberCustom": 82,
   "memberStandard": 48,
   "nsprefix": "ameh",
   "nsuri": "http://www.apollomed.net/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.apollomed.net/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Intangible Assets, Net",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Investments in Other Entities",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntities",
     "shortName": "Investments in Other Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125106 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Medical Liabilities",
     "role": "http://www.apollomed.net/role/MedicalLiabilities",
     "shortName": "Medical Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138110 - Disclosure - Mezzanine and Stockholders' Equity",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquity",
     "shortName": "Mezzanine and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - Stock-Based Compensation",
     "role": "http://www.apollomed.net/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.apollomed.net/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150113 - Disclosure - Related-Party Transactions",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154114 - Disclosure - Income Taxes",
     "role": "http://www.apollomed.net/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156115 - Disclosure - Earnings Per Share",
     "role": "http://www.apollomed.net/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161116 - Disclosure - Variable Interest Entities (VIEs)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEs",
     "shortName": "Variable Interest Entities (VIEs)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164117 - Disclosure - Leases",
     "role": "http://www.apollomed.net/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Business Combinations and Goodwill (Tables)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables",
     "shortName": "Business Combinations and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Investments in Other Entities (Tables)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables",
     "shortName": "Investments in Other Entities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Medical Liabilities (Tables)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesTables",
     "shortName": "Medical Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351309 - Disclosure - Related-Party Transactions (Tables)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsTables",
     "shortName": "Related-Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357310 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.apollomed.net/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2362311 - Disclosure - Variable Interest Entities (VIEs) (Tables)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables",
     "shortName": "Variable Interest Entities (VIEs) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365312 - Disclosure - Leases (Tables)",
     "role": "http://www.apollomed.net/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
     "shortName": "Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i156059eff9374f1087488e472de06542_D20210801-20210831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Gain (Loss) on Securities (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Gain (Loss) on Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "iae5121d03a9a469ba0192b0be3dd0589_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i357d85714b284f7ab7bee3970e56bf57_D20210401-20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i357d85714b284f7ab7bee3970e56bf57_D20210401-20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
     "shortName": "Business Combinations and Goodwill - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i5b9aa026e81e4b4980bee034ca869c69_I20220419",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i151e0a96f9d54ef8aa77485e6036ae3b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
     "shortName": "Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets, Net - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i151e0a96f9d54ef8aa77485e6036ae3b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Investments in Other Entities - Equity Method Investments (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
     "shortName": "Investments in Other Entities - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:EquityMethodInvestmentReclassification",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentSoldCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Investments in Other Entities - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
     "shortName": "Investments in Other Entities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i74659971142042e9b4b1ecd398a5632a_I20180531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i49a86084d3064273846f20df1dc58121_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i49a86084d3064273846f20df1dc58121_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
     "shortName": "Investments in Other Entities - Summarized Balance Sheets and Statements of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i456a03746030449991737ef8d57a4456_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EquityMethodInvestmentOwnershipPercentage",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i778bae90463c48628833fa5514d45310_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i5d5365ccd50e40b48292e6b69f44ba5f_I20201031",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i151e0a96f9d54ef8aa77485e6036ae3b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
     "shortName": "Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Credit Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "ibe69f802279e4ce8a230a2252301ea51_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Stock-Based Compensation - Share-Based Compensation Expense (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
     "shortName": "Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i6aa8567cf1e643a78266499508a23e7b_D20220101-20220630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i151e0a96f9d54ef8aa77485e6036ae3b_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
     "shortName": "Stock-Based Compensation - Summary of Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:NumberOfWarrantsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Stock-Based Compensation - Warrants (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails",
     "shortName": "Stock-Based Compensation - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i03ceea72d6fa40489f52e559fb181611_I20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i83fa8e1b5460411992308ed07575a1f1_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452429 - Disclosure - Related-Party Transactions - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related-Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "ieb082a42a8f04b7f8520726fad9dbed0_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453430 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails",
     "shortName": "Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "idd1c490153ac4f1cb6028c98823533b4_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "iea207f25a4494db3b8ca98bec38b0cf3_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458432 - Disclosure - Earnings Per Share - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
     "shortName": "Earnings Per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "iea207f25a4494db3b8ca98bec38b0cf3_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459433 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.apollomed.net/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "id604da4cbf9d48cd853c3313a4b215d1_D20220401-20220630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463435 - Disclosure - Variable Interest Entities (VIEs) (Details)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails",
     "shortName": "Variable Interest Entities (VIEs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i06a503dd3a6245bcb2a8c9661f14ccd2_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeaseRenewalTerm1",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466436 - Disclosure - Leases - Additional information (Details)",
     "role": "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
     "shortName": "Leases - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeaseRenewalTerm1",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467437 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468438 - Disclosure - Leases - Other Information Related to Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9e6428857dee4133afac16dea28fc39f_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469439 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
     "shortName": "Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i9892fbf73a5e432fabdabd8425173fdd_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Business Combinations and Goodwill",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwill",
     "shortName": "Business Combinations and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i8e881f4793bc4c15b72c1cf24c528e66_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i151e0a96f9d54ef8aa77485e6036ae3b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - ameh-20220630.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - ameh-20220630.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20220630.htm",
      "contextRef": "i151e0a96f9d54ef8aa77485e6036ae3b_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 148,
   "tag": {
    "ameh_A120HellmanLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "120 Hellman LLC",
        "label": "120 Hellman LLC [Member]",
        "terseLabel": "120 Hellman LLC"
       }
      }
     },
     "localname": "A120HellmanLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AHMCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AHMC [Member]",
        "terseLabel": "AHMC",
        "verboseLabel": "AHMC"
       }
      }
     },
     "localname": "AHMCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AMGPropertiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMG Properties LLC",
        "label": "AMG Properties LLC [Member]",
        "terseLabel": "AMG Properties LLC"
       }
      }
     },
     "localname": "AMGPropertiesLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APAMHMedicalCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AP-AMH Medical Corporation [Member]",
        "label": "AP-AMH Medical Corporation [Member]",
        "terseLabel": "AP-AMH Medical Corporation"
       }
      }
     },
     "localname": "APAMHMedicalCorporationMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APCAndAPCLSMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APC And APC-LSMA [Member]",
        "label": "APC And APC-LSMA [Member]",
        "terseLabel": "APC and APC-LSMA"
       }
      }
     },
     "localname": "APCAndAPCLSMAMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccessPrimaryCareMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Access Primary Care Medical Group",
        "label": "Access Primary Care Medical Group [Member]",
        "terseLabel": "Access Primary Care Medical Group"
       }
      }
     },
     "localname": "AccessPrimaryCareMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountableHealthCareIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accountable Health Care IPA [Member]",
        "verboseLabel": "Accountable Health Care"
       }
      }
     },
     "localname": "AccountableHealthCareIPAMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsPayableAndAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable And Accrued Expenses [Member]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Line Items]",
        "terseLabel": "Accounts Receivable And Net Revenue [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueLineItems",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Table]",
        "terseLabel": "Accounts Receivable And Net Revenue [Table]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueTable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AchievaMedInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AchievaMed, Inc. [Member]",
        "label": "AchievaMed, Inc. [Member]",
        "terseLabel": "AchievaMed, Inc."
       }
      }
     },
     "localname": "AchievaMedInc.Member",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AdvanceDiagnosticSurgeryCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Diagnostic Surgery Center [Member]",
        "terseLabel": "Advance Diagnostic Surgery Center"
       }
      }
     },
     "localname": "AdvanceDiagnosticSurgeryCenterMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AggregateintrinsicvalueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "AggregateintrinsicvalueAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AlliedPacificOfCaliforniaIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allied Pacific Of California IPA",
        "label": "Allied Pacific Of California IPA [Member]",
        "verboseLabel": "APC"
       }
      }
     },
     "localname": "AlliedPacificOfCaliforniaIPAMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlphaCareMedicalGroupInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alpha Care Medical Group, Inc. [Member]",
        "label": "Alpha Care Medical Group, Inc. [Member]",
        "terseLabel": "Alpha Care Medical Group, Inc."
       }
      }
     },
     "localname": "AlphaCareMedicalGroupInc.Member",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmgIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AMG, Inc [Member]",
        "terseLabel": "AMG, Inc"
       }
      }
     },
     "localname": "AmgIncMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcBusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Business Loan Agreement [Member]",
        "terseLabel": "APC Business Loan Agreement"
       }
      }
     },
     "localname": "ApcBusinessLoanAgreementMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcLsmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC LSMA [Member]",
        "terseLabel": "APC LSMA"
       }
      }
     },
     "localname": "ApcLsmaMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Shareholders [Member]",
        "terseLabel": "APC Shareholders"
       }
      }
     },
     "localname": "ApcShareholdersMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloMedicalHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Apollo Medical Holdings, Inc [Member]",
        "terseLabel": "Apollo Medical Holdings, Inc"
       }
      }
     },
     "localname": "ApolloMedicalHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloSunLabsManagementLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apollo-Sun Labs Management, LLC",
        "label": "Apollo-Sun Labs Management, LLC [Member]",
        "terseLabel": "Apollo-Sun Labs Management, LLC"
       }
      }
     },
     "localname": "ApolloSunLabsManagementLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ArroyoVistaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arroyo Vista",
        "label": "Arroyo Vista [Member]",
        "terseLabel": "Arroyo Vista"
       }
      }
     },
     "localname": "ArroyoVistaMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AssetAcquisitionPercentageOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Percentage Of Shares Acquired",
        "label": "Asset Acquisition, Percentage Of Shares Acquired",
        "terseLabel": "Asset acquisition, percentage of shares acquired"
       }
      }
     },
     "localname": "AssetAcquisitionPercentageOfSharesAcquired",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_AurionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_Aurion Member",
        "label": "Aurion [Member]",
        "verboseLabel": "Aurion"
       }
      }
     },
     "localname": "AurionMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Noncurrent",
        "label": "Business Combination, Equity Interest Purchase Obligation, Noncurrent",
        "terseLabel": "Equity interest purchase obligation, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationEquityInterestPurchaseObligationNoncurrent",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase",
        "label": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase",
        "terseLabel": "Equity interest purchase obligation, period to purchase"
       }
      }
     },
     "localname": "BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_CAIPAMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CAIPA MSO, LLC",
        "label": "CAIPA MSO, LLC [Member]",
        "terseLabel": "CAIPA MSO, LLC"
       }
      }
     },
     "localname": "CAIPAMSOLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CDSCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CDSC",
        "label": "CDSC [Member]",
        "terseLabel": "CDSC"
       }
      }
     },
     "localname": "CDSCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CMSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CMS [Member]",
        "label": "CMS [Member]",
        "terseLabel": "CMS"
       }
      }
     },
     "localname": "CMSMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CancellationOfRestrictedStockAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancellation of Restricted Stock Awards",
        "label": "Cancellation of Restricted Stock Awards",
        "terseLabel": "Cancellation of restricted stock awards"
       }
      }
     },
     "localname": "CancellationOfRestrictedStockAwards",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_CashPaidForLeaseLiabilitiesAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For Lease Liabilities [Abstract]",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForLeaseLiabilitiesAbstractAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ClassOfWarrantOrRightCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, cancelled in period",
        "label": "Class Of Warrant Or Right Cancelled In Period",
        "negatedLabel": "Warrants expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledInPeriod",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class Of Warrant Or Right Exercisable",
        "terseLabel": "Warrants Exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Issued in Period",
        "label": "Class Of Warrant Or Right Issued In Period",
        "verboseLabel": "Warrants Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term",
        "verboseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights exercised in period.",
        "label": "Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights forfeited in period.",
        "label": "Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants expired/forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights granted in period.",
        "label": "Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights outstanding.",
        "label": "Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "periodEndLabel": "Warrants outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Weighted Average Exercise\u00a0Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period",
        "verboseLabel": "Warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights forfeited during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period",
        "verboseLabel": "Warrants expired/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights granted during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period",
        "verboseLabel": "Warrants granted (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClinigenceHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigence Holdings, Inc.",
        "label": "Clinigence Holdings, Inc. [Member]",
        "terseLabel": "Clinigence Holdings, Inc."
       }
      }
     },
     "localname": "ClinigenceHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:CommercialMember",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ConcourseDiagnosticSurgeryCenterLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concourse Diagnostic Surgery Center, LLC [Member]",
        "terseLabel": "Concourse Diagnostic Surgery Center, LLC"
       }
      }
     },
     "localname": "ConcourseDiagnosticSurgeryCenterLlcMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ConstructionLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction Loan",
        "label": "Construction Loan [Member]",
        "terseLabel": "Construction Loan"
       }
      }
     },
     "localname": "ConstructionLoanMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContingentEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Equity Securities",
        "label": "Contingent Equity Securities [Member]",
        "terseLabel": "Contingent Equity Securities"
       }
      }
     },
     "localname": "ContingentEquitySecuritiesMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DebtCovenantAggregatePurchasePriceMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Aggregate Purchase Price, Maximum",
        "label": "Debt Covenant, Aggregate Purchase Price, Maximum",
        "terseLabel": "Debt covenant, aggregate purchase price, maximum"
       }
      }
     },
     "localname": "DebtCovenantAggregatePurchasePriceMaximum",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DebtCovenantThresholdPercentageForOccupationOfProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Threshold Percentage for Occupation of Property",
        "label": "Debt Covenant, Threshold Percentage for Occupation of Property",
        "terseLabel": "Debt covenant, threshold percentage for occupation of property"
       }
      }
     },
     "localname": "DebtCovenantThresholdPercentageForOccupationOfProperty",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, cash flow coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashFlowCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash Flow To Debt Service Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Cash Flow To Debt Service Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, cash flow to debt service ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashFlowToDebtServiceRatioMinimum",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, debt coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Minimum consolidated interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum",
        "terseLabel": "Debt instrument, covenant, leverage ratio, adjusted maximum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioAdjustedMaximum",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "terseLabel": "Consolidated leverage ratio, annual decrease"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioIncrementalChange",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Maximum consolidated leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentNumberOfKeyFinancialRatios": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Key Financial Ratios",
        "label": "Debt Instrument, Number Of Key Financial Ratios",
        "terseLabel": "Number of key financial ratios"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfKeyFinancialRatios",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_DescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Line Items]",
        "terseLabel": "Description Of Business [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessLineItems",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Table]",
        "terseLabel": "Description Of Business [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessTable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DmgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DMG [Member]",
        "terseLabel": "DMG"
       }
      }
     },
     "localname": "DmgMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.ArteagaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Arteaga [Member]",
        "label": "Dr. Arteaga [Member]",
        "verboseLabel": "Dr. Arteaga"
       }
      }
     },
     "localname": "Dr.ArteagaMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Earnings Per Share [Table]",
        "label": "Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EarningsPerShareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share [Table]",
        "label": "Earnings Per Share [Table]",
        "terseLabel": "Earnings Per Share [Table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EquityMethodAndOtherEquityInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method And Other Equity Investments [Text Block]",
        "label": "Equity Method And Other Equity Investments [Text Block]",
        "verboseLabel": "Investments in Other Entities"
       }
      }
     },
     "localname": "EquityMethodAndOtherEquityInvestmentsTextBlock",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageDisposed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Disposed",
        "label": "Equity Method Investment, Ownership Percentage Disposed",
        "terseLabel": "Ownership interest disposed"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageDisposed",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage, Sold",
        "label": "Equity Method Investment, Ownership Percentage, Sold",
        "terseLabel": "Ownership percentage sold"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageSold",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Reclassification",
        "label": "Equity Method Investment, Reclassification",
        "negatedTerseLabel": "Funding reclassified to loan receivable"
       }
      }
     },
     "localname": "EquityMethodInvestmentReclassification",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Contribution",
        "label": "Equity Method Investments, Contribution",
        "terseLabel": "Funding"
       }
      }
     },
     "localname": "EquityMethodInvestmentsContribution",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments [Roll Forward]",
        "label": "Equity Method Investments [Roll Forward]",
        "terseLabel": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsRollForward",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option",
        "label": "Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option",
        "terseLabel": "Term of option"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Related investment balance"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "terseLabel": "Investment amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "terseLabel": "Duration of investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "terseLabel": "Membership interests acquired (in dollars per share)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "terseLabel": "Options to purchase additional membership interests (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "terseLabel": "Number of warrants available to purchase, contingent upon the portal completion date (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "terseLabel": "Percentage of voting common stock, within five years"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "terseLabel": "Membership interests purchased (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Ownership Percentage",
        "label": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FiduciaryAccountsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Fiduciary Accounts Payable Current",
        "terseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "FiduciaryAccountsPayableCurrent",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiduciaryCashAndPayablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiduciary Cash and Payable",
        "label": "Fiduciary Cash and Payable [Policy Text Block]",
        "terseLabel": "Fiduciary Cash and Payable"
       }
      }
     },
     "localname": "FiduciaryCashAndPayablePolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_FinanceLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease Costs",
        "label": "Finance Lease Costs [Abstract]",
        "terseLabel": "Finance Lease Cost [Abstract]"
       }
      }
     },
     "localname": "FinanceLeaseCostsAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FinanceReceivableInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Interest Rate, Stated Percentage",
        "label": "Finance Receivable, Interest Rate, Stated Percentage",
        "terseLabel": "Note receivable, interest rate"
       }
      }
     },
     "localname": "FinanceReceivableInterestRateStatedPercentage",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "label": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "terseLabel": "Interest rate in the event of default"
       }
      }
     },
     "localname": "FinanceReceivableModificationsSubsequentDefaultInterestRate",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableStatedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Stated Interest Rate",
        "label": "Finance Receivable, Stated Interest Rate",
        "terseLabel": "Stated rate of note of loan receivable"
       }
      }
     },
     "localname": "FinanceReceivableStatedInterestRate",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableTermOfReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Term Of Receivable",
        "label": "Finance Receivable, Term Of Receivable",
        "terseLabel": "Term of receivable"
       }
      }
     },
     "localname": "FinanceReceivableTermOfReceivable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiveThreeOneW.CollegeLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Three One W. College LLC [Member]",
        "terseLabel": "531 W. College LLC",
        "verboseLabel": "531 W. College, LLC \u2013 related party"
       }
      }
     },
     "localname": "FiveThreeOneW.CollegeLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FulgentGeneticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fulgent Genetics, Inc.",
        "label": "Fulgent Genetics, Inc. [Member]",
        "terseLabel": "Fulgent Genetics, Inc."
       }
      }
     },
     "localname": "FulgentGeneticsIncMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HSMSOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_HSMSO Member",
        "label": "HSMSO [Member]",
        "verboseLabel": "HSMSO"
       }
      }
     },
     "localname": "HSMSOMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthCareCapitationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_HealthCareCapitationRevenueMember",
        "label": "Health Care Capitation Revenue [Member]",
        "verboseLabel": "Capitation, net"
       }
      }
     },
     "localname": "HealthCareCapitationRevenueMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_IncreaseDecreaseInMedicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.",
        "label": "Increase (Decrease) In Medical Liabilities",
        "verboseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalLiabilities",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents increase in operating lease assets.",
        "label": "Increase (Decrease) In Operating Lease Assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.",
        "label": "Increase (Decrease) In Prepaid Expenses And Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The initial fixed term of amended and restated management and administrative services agreement.",
        "label": "Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement",
        "terseLabel": "Fixed term of amended and restated management and administrative services agreement"
       }
      }
     },
     "localname": "InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "label": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "terseLabel": "AHMC \u2013 Risk pool, capitation, claims payment"
       }
      }
     },
     "localname": "InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of Investment in privately held entity that does not report net asset value per share .",
        "label": "Investment In Privately Held Entity That Does Not Report Net Asset Value",
        "verboseLabel": "Investments in privately held entities"
       }
      }
     },
     "localname": "InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_JadeHealthCareMedicalGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jade Health Care Medical Group, Inc.",
        "label": "Jade Health Care Medical Group, Inc. [Member]",
        "terseLabel": "Jade Health Care Medical Group, Inc."
       }
      }
     },
     "localname": "JadeHealthCareMedicalGroupIncMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LasalleMedicalAssociatesIpaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LaSalle Medical Associates IPA [Member]",
        "terseLabel": "LaSalle Medical Associates \u2013 IPA Line of Business",
        "verboseLabel": "LaSalle Medical Associates"
       }
      }
     },
     "localname": "LasalleMedicalAssociatesIpaMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LeaseWeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Discount Rate [Abstract]",
        "verboseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "LeaseWeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Remaining Lease Term [Abstract]",
        "verboseLabel": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance Lease, Termination Period, If Applicable",
        "label": "Lessee, Finance Lease, Termination Period, If Applicable",
        "terseLabel": "Finance lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period, If Applicable",
        "label": "Lessee, Operating Lease, Termination Period, If Applicable",
        "terseLabel": "Operating lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LMA [Member]",
        "terseLabel": "LMA"
       }
      }
     },
     "localname": "LmaMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LoanReceivableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Receivable",
        "label": "Loan Receivable [Text Block]",
        "verboseLabel": "Loan Receivable and Loan Receivable \u2013 Related Parties"
       }
      }
     },
     "localname": "LoanReceivableTextBlock",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, After Year Four",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MPP, AMG Properties, and ZLL Asset Acquisition",
        "label": "MPP, AMG Properties, and ZLL Asset Acquisition [Member]",
        "terseLabel": "MPP, AMG Properties, and ZLL Asset Acquisition"
       }
      }
     },
     "localname": "MPPAMGPropertiesAndZLLAssetAcquisitionMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ManagementContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Contracts",
        "label": "Management Contracts [Member]",
        "verboseLabel": "Management contracts"
       }
      }
     },
     "localname": "ManagementContractsMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MarketableSecuritiesCurrentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current, Maturity Period",
        "label": "Marketable Securities, Current, Maturity Period",
        "terseLabel": "Short-term marketable securities, maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMaturityPeriod",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_MaverickMedicalGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maverick Medical Group, Inc [Member]",
        "terseLabel": "Maverick Medical Group, Inc"
       }
      }
     },
     "localname": "MaverickMedicalGroupIncMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MediPortalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MediPortal LLC [Member]",
        "terseLabel": "MediPortal LLC"
       }
      }
     },
     "localname": "MediPortalLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicaidMember",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Care Costs [Abstract]",
        "label": "Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "MedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MedicalPropertyPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Property Partners LLC",
        "label": "Medical Property Partners LLC [Member]",
        "terseLabel": "Medical Property Partners LLC"
       }
      }
     },
     "localname": "MedicalPropertyPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicareMember",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MemberRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member Relationships",
        "label": "Member Relationships [Member]",
        "terseLabel": "Member relationships"
       }
      }
     },
     "localname": "MemberRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MezzanineEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEZZANINE EQUITY [Abstract]",
        "verboseLabel": "Mezzanine equity"
       }
      }
     },
     "localname": "MezzanineEquityAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MezzanineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine [Member]",
        "terseLabel": "Mezzanine"
       }
      }
     },
     "localname": "MezzanineMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MinorityInterestPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minority Interest Policy.",
        "label": "Minority Interest Policy [Policy Text Block]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestPolicyPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NetworkMedicalManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management, Inc. [Member]",
        "terseLabel": "Network Medical Management, Inc."
       }
      }
     },
     "localname": "NetworkMedicalManagementIncMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkMedicalManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management [Member]",
        "terseLabel": "NMM"
       }
      }
     },
     "localname": "NetworkMedicalManagementMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Network Relationships",
        "label": "Network Relationships [Member]",
        "terseLabel": "Network relationships"
       }
      }
     },
     "localname": "NetworkRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares",
        "label": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NumberOfFamilyPracticeClinics": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Family Practice Clinics",
        "label": "Number Of Family Practice Clinics",
        "terseLabel": "Number of family practice clinics"
       }
      }
     },
     "localname": "NumberOfFamilyPracticeClinics",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFederallyQualifiedHealthPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Federally Qualified Health Plans",
        "label": "Number Of Federally Qualified Health Plans",
        "terseLabel": "Number federally qualified health plans"
       }
      }
     },
     "localname": "NumberOfFederallyQualifiedHealthPlans",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised",
        "label": "Number Of Warrants Exercised",
        "negatedLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumberOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants Granted",
        "label": "Number Of Warrants Granted",
        "verboseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsGranted",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumenLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numen LLC [Member]",
        "terseLabel": "Numen LLC"
       }
      }
     },
     "localname": "NumenLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, Inc. [Member]",
        "label": "One MSO, Inc. [Member]",
        "terseLabel": "One MSO, Inc."
       }
      }
     },
     "localname": "OneMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC",
        "label": "One MSO, LLC [Member]",
        "terseLabel": "One MSO, LLC \u2013 related party"
       }
      }
     },
     "localname": "OneMSOLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC",
        "label": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orma Health, Inc., and Provider Growth Solutions LLC",
        "label": "Orma Health, Inc., and Provider Growth Solutions LLC [Member]",
        "terseLabel": "Orma Health, Inc., and Provider Growth Solutions LLC"
       }
      }
     },
     "localname": "OrmaHealthIncAndProviderGrowthSolutionsLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OtherThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:OtherThirdPartiesMember",
        "label": "Other Third Parties [Member]",
        "terseLabel": "Other third parties"
       }
      }
     },
     "localname": "OtherThirdPartiesMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Pacific6EnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pacific6 Enterprises [Member]",
        "label": "Pacific6 Enterprises [Member]",
        "terseLabel": "Pacific6 Enterprises"
       }
      }
     },
     "localname": "Pacific6EnterprisesMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PacificMedicalImagingAndOncologyCenterIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pacific Medical Imaging and Oncology Center, Inc [Member]",
        "terseLabel": "Pacific Medical Imaging &amp; Oncology Center, Inc."
       }
      }
     },
     "localname": "PacificMedicalImagingAndOncologyCenterIncMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PatientManagementPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Management Platform",
        "label": "Patient Management Platform [Member]",
        "terseLabel": "Patient management platform"
       }
      }
     },
     "localname": "PatientManagementPlatformMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentMadeToRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit/Duration (Amount paid to related party in relation to providing services",
        "label": "Payment Made To Related Party",
        "terseLabel": "Payments to related parties"
       }
      }
     },
     "localname": "PaymentMadeToRelatedParty",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Medical Care Costs [Abstract]",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_PaymentsToAcquireCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Common Stock And Warrants",
        "label": "Payments To Acquire Common Stock And Warrants",
        "terseLabel": "Payments to acquire common stock and warrants"
       }
      }
     },
     "localname": "PaymentsToAcquireCommonStockAndWarrants",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Payments to purchase membership interests"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsToAcquireNonControllingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Non-controlling Interest",
        "label": "Payments to Acquire Non-controlling Interest",
        "negatedLabel": "Purchase of non-controlling interest"
       }
      }
     },
     "localname": "PaymentsToAcquireNonControllingInterest",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsToEquityMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Equity Method Investments",
        "label": "Payments to Equity Method Investments",
        "negatedLabel": "Contribution to investment - equity method"
       }
      }
     },
     "localname": "PaymentsToEquityMethodInvestments",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PayorAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor A [Member]",
        "label": "Payor A [Member]",
        "terseLabel": "Payor A"
       }
      }
     },
     "localname": "PayorAMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor B [Member]",
        "label": "Payor B [Member]",
        "terseLabel": "Payor B"
       }
      }
     },
     "localname": "PayorBMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor C [Member]",
        "label": "Payor C [Member]",
        "terseLabel": "Payor C"
       }
      }
     },
     "localname": "PayorCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payor D [Member]",
        "terseLabel": "Payor D"
       }
      }
     },
     "localname": "PayorDMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor E",
        "label": "Payor E [Member]",
        "terseLabel": "Payor E"
       }
      }
     },
     "localname": "PayorEMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor F [Member]",
        "label": "Payor F [Member]",
        "terseLabel": "Payor F"
       }
      }
     },
     "localname": "PayorFMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PerMemberPerMonthManagedCareContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per-Member-Per-Month Managed Care Contract [Member]",
        "label": "Per-Member-Per-Month Managed Care Contract [Member]",
        "terseLabel": "PMPM Managed Care Contract"
       }
      }
     },
     "localname": "PerMemberPerMonthManagedCareContractMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PmiocMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PMIOC [Member]",
        "terseLabel": "PMIOC"
       }
      }
     },
     "localname": "PmiocMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PreferredBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Bank [Member]",
        "terseLabel": "Preferred Bank"
       }
      }
     },
     "localname": "PreferredBankMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PrepaymentForInvestmentPurchase": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment for Investment Purchase",
        "label": "Prepayment for Investment Purchase",
        "negatedTerseLabel": "Prepayment for investment purchase"
       }
      }
     },
     "localname": "PrepaymentForInvestmentPurchase",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Cash Received from Consolidation of Variable Interest Entity",
        "label": "Proceeds from Cash Received from Consolidation of Variable Interest Entity",
        "terseLabel": "Cash received from consolidation of VIE"
       }
      }
     },
     "localname": "ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ProceedsFromSaleOfNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Noncontrolling Interest",
        "label": "Proceeds from Sale of Noncontrolling Interest",
        "terseLabel": "Proceeds from sale of non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNoncontrollingInterest",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Receivables and receivables from related parties.",
        "label": "Receivables And Related parties Receivables Policy Text Block [Policy Text Block]",
        "verboseLabel": "Receivables, Receivables \u2013 Related Parties, and Loan Receivable - Related Party"
       }
      }
     },
     "localname": "ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "terseLabel": "Expected period of payment upon termination of agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "label": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "terseLabel": "Risk pool surplus or deficits, settlement period after risk pool performance year"
       }
      }
     },
     "localname": "RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_SCHCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SCHC [Member]",
        "label": "SCHC [Member]",
        "terseLabel": "SCHC"
       }
      }
     },
     "localname": "SCHCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Contingent on Performance",
        "terseLabel": "Contingent on performance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsContingentOnPerformance",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "terseLabel": "Exercise price of warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ShareholdersAndOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders And Officers [Member]",
        "terseLabel": "APC Shareholders and Officers"
       }
      }
     },
     "localname": "ShareholdersAndOfficersMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_SharesWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares, Warrants [Roll Forward]",
        "label": "Shares, Warrants [Roll Forward]",
        "terseLabel": "Shares, Warrants [Roll Forward]"
       }
      }
     },
     "localname": "SharesWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SpecialtyCapitationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of specialty capitation payable current.",
        "label": "Specialty Capitation Payable Current",
        "verboseLabel": "Capitation payable"
       }
      }
     },
     "localname": "SpecialtyCapitationPayableCurrent",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockAwardsAndUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Awards And Units",
        "label": "Stock Awards And Units [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "StockAwardsAndUnitsMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to merger.",
        "label": "Stock Issued During Period, Shares, Merger",
        "terseLabel": "Holdback shares not issued to former shareholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesMerger",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Noncontrolling Interest",
        "label": "Stock Issued During Period, Shares, Noncontrolling Interest",
        "terseLabel": "Sale of shares by non-controlling interest (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNoncontrollingInterest",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodValueNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Noncontrolling Interest",
        "label": "Stock Issued During Period, Value, Noncontrolling Interest",
        "terseLabel": "Sale of shares by non-controlling interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNoncontrollingInterest",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of share issued exercise of option and warrants during the period",
        "label": "Stock issued during the period shares of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents value of stock issued during the period",
        "label": "Stock issued during the period value of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SubcontractorIPAPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subcontractor IPA Payable",
        "label": "Subcontractor IPA Payable",
        "verboseLabel": "Subcontractor IPA payable"
       }
      }
     },
     "localname": "SubcontractorIPAPayable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_Tag6MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-6 Medical Investment Group, LLC",
        "label": "Tag-6 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-6 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "Tag6MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-6 Medical Investment Group, LLC - Related Party",
        "label": "Tag-6 Medical Investment Group, LLC - Related Party [Member]",
        "terseLabel": "Tag-6 Medical Investment Group, LLC \u2013 related party"
       }
      }
     },
     "localname": "Tag6MedicalInvestmentGroupLLCRelatedPartyMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-8 Medical Investment Group, LLC",
        "label": "Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-8 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "Tag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Increase from Sale of Non-Controlling Interest",
        "label": "Temporary Equity, Increase from Sale of Non-Controlling Interest",
        "terseLabel": "Sale of non-controlling interest"
       }
      }
     },
     "localname": "TemporaryEquityIncreaseFromSaleOfNonControllingInterest",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_TemporaryEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity [Policy Text Block]",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Mezzanine Equity"
       }
      }
     },
     "localname": "TemporaryEquityPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_UniversalCareAcquisitionPartnersLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Acquisition Partners, LLC [Member]",
        "terseLabel": "Universal Care Acquisition Partners, LLC"
       }
      }
     },
     "localname": "UniversalCareAcquisitionPartnersLlcMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Inc [Member]",
        "terseLabel": "Universal Care Inc"
       }
      }
     },
     "localname": "UniversalCareIncMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UnrealizedGainLossFromInvestmentInEquitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized (Gain) Loss from Investment in Equity Securities",
        "label": "Unrealized (Gain) Loss from Investment in Equity Securities",
        "negatedLabel": "Unrealized loss (gain) from investment in equity securities"
       }
      }
     },
     "localname": "UnrealizedGainLossFromInvestmentInEquitySecurities",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WarrantExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range One [Member]",
        "verboseLabel": "Warrant Exercise Price Range One"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeOneMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Three [Member]",
        "verboseLabel": "Warrant Exercise Price Range Three"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeThreeMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Two [Member]",
        "verboseLabel": "Warrant Exercise Price Range Two"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeTwoMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Issued During Period Value Stock Options Exercised",
        "label": "Warrant Issued During Period Value Stock Options Exercised",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "WarrantIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WeightedAverageExercisePriceWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "label": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price, Warrants [Roll Forward]"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_WeightedaverageremainingcontractualtermyearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Years [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term Years [Abstract]"
       }
      }
     },
     "localname": "WeightedaverageremainingcontractualtermyearsAbstract",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ZLLPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZLL Partners LLC",
        "label": "ZLL Partners LLC [Member]",
        "terseLabel": "ZLL Partners LLC"
       }
      }
     },
     "localname": "ZLLPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20220630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r389",
      "r585",
      "r586",
      "r589",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r120",
      "r278",
      "r283",
      "r289",
      "r493",
      "r494",
      "r501",
      "r502",
      "r592",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r120",
      "r278",
      "r283",
      "r289",
      "r493",
      "r494",
      "r501",
      "r502",
      "r592",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r54",
      "r56",
      "r117",
      "r118",
      "r295",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board members"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r197",
      "r370",
      "r375",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r294",
      "r332",
      "r392",
      "r395",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r632",
      "r700",
      "r703",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r294",
      "r332",
      "r392",
      "r395",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r632",
      "r700",
      "r703",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r197",
      "r370",
      "r375",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r195",
      "r270",
      "r271",
      "r370",
      "r373",
      "r633",
      "r699",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r195",
      "r270",
      "r271",
      "r370",
      "r373",
      "r633",
      "r699",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r264",
      "r269",
      "r270",
      "r271",
      "r272",
      "r294",
      "r332",
      "r381",
      "r392",
      "r395",
      "r429",
      "r430",
      "r431",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r632",
      "r700",
      "r703",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r264",
      "r269",
      "r270",
      "r271",
      "r272",
      "r294",
      "r332",
      "r381",
      "r392",
      "r395",
      "r429",
      "r430",
      "r431",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r632",
      "r700",
      "r703",
      "r721",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r55",
      "r56",
      "r117",
      "r118",
      "r295",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r130",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r130",
      "r135",
      "r268",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r130",
      "r135",
      "r268",
      "r393",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r198",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r596"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "verboseLabel": "Receivables and Receivables-Related Parties"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r29",
      "r116",
      "r586",
      "r589"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Receivables, net \u2013 related parties",
        "verboseLabel": "Receivables, net \u2013 related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r21",
      "r652",
      "r677"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30",
      "r596"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r441",
      "r442",
      "r443",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional Paid-in\u00a0Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r71",
      "r98",
      "r314",
      "r557"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance cost"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r98",
      "r244",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities not included in the calculation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r98",
      "r260"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of beneficial interest"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r18",
      "r113",
      "r177",
      "r187",
      "r193",
      "r215",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r493",
      "r501",
      "r546",
      "r594",
      "r596",
      "r650",
      "r675"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r35",
      "r113",
      "r215",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r493",
      "r501",
      "r546",
      "r594",
      "r596"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r113",
      "r215",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r493",
      "r501",
      "r546",
      "r594"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets",
        "verboseLabel": "Non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r202",
      "r204",
      "r224",
      "r657"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities \u2013 certificates of deposit"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r423",
      "r424",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r519",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BridgeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.",
        "label": "Bridge Loan [Member]",
        "terseLabel": "Bridge Loan"
       }
      }
     },
     "localname": "BridgeLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r391",
      "r394",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r391",
      "r394",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r479",
      "r480",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r478",
      "r481",
      "r483"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "APCMG contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r473",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations and Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r4",
      "r121",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r5",
      "r12",
      "r100"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r91",
      "r100",
      "r106"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents, restricted cash total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r91",
      "r547"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Amount deposit accounts exceeded FDIC insured limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r110",
      "r113",
      "r138",
      "r139",
      "r140",
      "r142",
      "r144",
      "r153",
      "r154",
      "r155",
      "r215",
      "r278",
      "r283",
      "r284",
      "r285",
      "r289",
      "r290",
      "r330",
      "r331",
      "r335",
      "r339",
      "r346",
      "r546",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise\u00a0Price\u00a0Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants received (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r356",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r661",
      "r683"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r273",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common\u00a0Stock\u00a0Outstanding"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27",
      "r596"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,719,710 and 44,630,873 shares issued and outstanding, excluding 11,175,702 and 10,925,702 treasury shares, as of June\u00a030, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r197",
      "r544",
      "r545",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r197",
      "r544",
      "r545",
      "r710",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r197",
      "r544",
      "r545",
      "r710",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r159",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r163",
      "r164",
      "r197",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r197",
      "r544",
      "r545",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Other Entities - Equity Method and Investments in Privately Held Entities"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r500",
      "r504",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r358",
      "r359",
      "r371"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Accrued contract liability recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r67",
      "r68"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of services, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r162",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Subscriber relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r308",
      "r315",
      "r316",
      "r318",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Credit Facility, Bank Loans, and Lines of Credit"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r112",
      "r120",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r322",
      "r323",
      "r324",
      "r325",
      "r558",
      "r651",
      "r654",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r22",
      "r319",
      "r654",
      "r674"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r291",
      "r322",
      "r323",
      "r556",
      "r558",
      "r559"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt, principal sum"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r43",
      "r311",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Average effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on loan receivable"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r112",
      "r120",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r322",
      "r323",
      "r324",
      "r325",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r112",
      "r120",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317",
      "r322",
      "r323",
      "r324",
      "r325",
      "r347",
      "r350",
      "r351",
      "r352",
      "r555",
      "r556",
      "r558",
      "r559",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Revolving credit facility term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r304",
      "r320",
      "r322",
      "r323",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Unamortized financing costs",
        "terseLabel": "Unamortized financing costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Amount outstanding under agreement"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "verboseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r98",
      "r174"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r52",
      "r53",
      "r56",
      "r543"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Contingent equity securities"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r51",
      "r56",
      "r57",
      "r521",
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "verboseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r51",
      "r56",
      "r57",
      "r521",
      "r611"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r56",
      "r520",
      "r522",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r517",
      "r520",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r52",
      "r53",
      "r56",
      "r543"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r514",
      "r515",
      "r517",
      "r518",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives designated as hedging instruments:"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Disaggregated Revenue by Each Payor Type"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r399",
      "r400",
      "r436",
      "r437",
      "r439",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r353",
      "r670"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "verboseLabel": "Dividends paid"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividend payable",
        "verboseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r21",
      "r24",
      "r653",
      "r676"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividend declared included in dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromAffiliateCurrent": {
     "auth_ref": [
      "r586",
      "r588",
      "r593"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).",
        "label": "Due from Affiliate, Current",
        "terseLabel": "Amount due from affiliate"
       }
      }
     },
     "localname": "DueFromAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromAffiliates": {
     "auth_ref": [
      "r586",
      "r588",
      "r686"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due from Affiliates",
        "terseLabel": "Due from affiliates"
       }
      }
     },
     "localname": "DueFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrentAndNoncurrent": {
     "auth_ref": [
      "r586",
      "r593",
      "r660",
      "r685",
      "r712"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due to Affiliate",
        "terseLabel": "Due to affiliate"
       }
      }
     },
     "localname": "DueToAffiliateCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r36",
      "r116",
      "r281",
      "r283",
      "r284",
      "r288",
      "r289",
      "r290",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r70",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r136",
      "r138",
      "r142",
      "r143",
      "r144",
      "r149",
      "r150",
      "r532",
      "r533",
      "r665",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings per share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r70",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r138",
      "r142",
      "r143",
      "r144",
      "r149",
      "r150",
      "r532",
      "r533",
      "r665",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings per share \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r145",
      "r147",
      "r148",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r61",
      "r62",
      "r63",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r152",
      "r217",
      "r346",
      "r353",
      "r441",
      "r442",
      "r443",
      "r458",
      "r459",
      "r531",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r582",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r3",
      "r113",
      "r215",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r3",
      "r113",
      "r215",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "terseLabel": "Equity method investment, other than temporary impairment"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "negatedTerseLabel": "Distribution",
        "terseLabel": "Distribution"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r13",
      "r178",
      "r212"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Investments in other entities \u2013 equity method",
        "verboseLabel": "Investments in other entities \u2013 equity method"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "verboseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r6",
      "r20",
      "r541"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "verboseLabel": "Investment in privately held entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "terseLabel": "Total (losses) gains recognized on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r210",
      "r691"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedLabel": "Gain on sale of equity securities",
        "terseLabel": "Gains recognized on equity securities sold"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r210",
      "r691"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gains (losses) recognized on equity securities held at end of period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesGainLossonSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r534",
      "r535",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r534",
      "r535",
      "r536",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Fair Values of Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r306",
      "r322",
      "r323",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r535",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r306",
      "r382",
      "r383",
      "r388",
      "r390",
      "r535",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r306",
      "r322",
      "r323",
      "r382",
      "r383",
      "r388",
      "r390",
      "r535",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r306",
      "r322",
      "r323",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r535",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r306",
      "r322",
      "r323",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r540",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r563",
      "r571",
      "r580"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r565",
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r562",
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "netLabel": "Less: current portion",
        "terseLabel": "Finance lease liabilities",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Finance Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the six months ended June\u00a030, 2022)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r564",
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease obligations",
        "verboseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r561"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Assets recorded under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r563",
      "r571"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Accumulated depreciation associated with finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r563",
      "r571",
      "r580"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Accumulated depreciation associated with finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r577",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r576",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r317",
      "r344",
      "r529",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r486",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Axis]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r486",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Domain]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r16",
      "r251"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the three months ended March 31, 2022)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r245",
      "r247",
      "r251",
      "r255",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r251",
      "r635"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Amortized intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r245",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r251",
      "r634"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (Loss) on Securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r15",
      "r229",
      "r231",
      "r238",
      "r242",
      "r596",
      "r649"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r232",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r239",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r98",
      "r230",
      "r235",
      "r241",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r237",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareCostsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r717",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accruing health care costs for a prepaid health care service provider.",
        "label": "Health Care Costs, Policy [Policy Text Block]",
        "verboseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "HealthCareCostsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthCareOtherMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other.",
        "label": "Health Care, Other [Member]",
        "terseLabel": "Risk pool settlements and incentives"
       }
      }
     },
     "localname": "HealthCareOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Fee-for-service, net"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r517",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r98",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of finite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r98",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r98",
      "r260",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r259",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets and Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r177",
      "r186",
      "r189",
      "r192",
      "r194",
      "r648",
      "r663",
      "r667",
      "r692"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r66",
      "r98",
      "r175",
      "r212",
      "r662",
      "r688"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "(Income) loss from equity method investments",
        "netLabel": "Income (loss) from equity method investments",
        "terseLabel": "Income (loss) from equity method investments",
        "verboseLabel": "Allocation of Income (Loss)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Statement of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r452",
      "r453",
      "r456",
      "r460",
      "r462",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r133",
      "r134",
      "r176",
      "r450",
      "r461",
      "r463",
      "r693"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r446",
      "r447",
      "r453",
      "r454",
      "r455",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r94",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r28",
      "r659",
      "r687"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Receivables, net \u2013 related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of business combinations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r97",
      "r574"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r246",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite lived assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r246",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible Assets, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r243",
      "r249"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r173",
      "r554",
      "r557",
      "r666"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r88",
      "r93",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r76",
      "r172"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r578",
      "r580"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost, net"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Information Related to Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, finance"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Finance lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the six months ended June\u00a030, 2022)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, operating"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r113",
      "r188",
      "r215",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r494",
      "r501",
      "r502",
      "r546",
      "r594",
      "r595"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r113",
      "r215",
      "r546",
      "r596",
      "r656",
      "r681"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, mezzanine equity, and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Deficit",
        "verboseLabel": "Liabilities, mezzanine equity, and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r42",
      "r113",
      "r215",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r494",
      "r501",
      "r502",
      "r546",
      "r594",
      "r595",
      "r596"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r22",
      "r23",
      "r113",
      "r215",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r494",
      "r501",
      "r502",
      "r546",
      "r594",
      "r595"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities",
        "verboseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r694",
      "r697"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical liabilities, end of period",
        "periodStartLabel": "Medical liabilities, beginning of period",
        "terseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "terseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "terseLabel": "Acquired (see Note 3)"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedLabel": "Current period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedLabel": "Prior periods"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r695"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Medical Liabilities [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Medicare license"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r22",
      "r654",
      "r674"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "totalLabel": "Total",
        "verboseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r38",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "terseLabel": "Annual agent fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Required annual facility fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Term of facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r38",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum loan availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r38",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r305",
      "r321",
      "r322",
      "r323",
      "r654",
      "r678"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "verboseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion of debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r120",
      "r276",
      "r310"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r120",
      "r276",
      "r310"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r120",
      "r276",
      "r310"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2022 (excluding the six months ended June 30, 2022)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion and deferred financing costs",
        "verboseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r587"
     ],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "negatedLabel": "Management fees"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementServiceMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractually stipulated right to receive compensation for operating and managing business.",
        "label": "Management Service [Member]",
        "terseLabel": "Management fee income",
        "verboseLabel": "Management Fee Income Contract"
       }
      }
     },
     "localname": "ManagementServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "verboseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r50",
      "r113",
      "r215",
      "r278",
      "r283",
      "r284",
      "r285",
      "r289",
      "r290",
      "r546",
      "r655",
      "r680"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r353",
      "r491",
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MortgageLoanRelatedToPropertySales1": {
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage loan related to property sales in noncash investing and financing activities.",
        "label": "Mortgage Loan Related to Property Sales",
        "terseLabel": "Mortgage loan"
       }
      }
     },
     "localname": "MortgageLoanRelatedToPropertySales1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r156",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r58",
      "r59",
      "r63",
      "r69",
      "r99",
      "r113",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r141",
      "r177",
      "r186",
      "r189",
      "r192",
      "r194",
      "r215",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r533",
      "r546",
      "r664",
      "r689"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Apollo Medical Holdings, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r59",
      "r63",
      "r133",
      "r134",
      "r497",
      "r511"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net (loss) income attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r354",
      "r491",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "verboseLabel": "Sale of non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r354",
      "r491",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Investment in non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r353",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r199",
      "r200",
      "r658"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Loan receivable \u2013 related party",
        "verboseLabel": "Loan receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Loans receivable",
        "verboseLabel": "Loan receivable, net of current portion"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Convertible Secured Promissory Note"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r199",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Amount of loan"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r29",
      "r116",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Current",
        "terseLabel": "Loan receivable \u2013 related party"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r116",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Noncurrent",
        "terseLabel": "Loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of main reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r177",
      "r186",
      "r189",
      "r192",
      "r194"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Income (loss) from operations",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r572",
      "r580"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r566",
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r577",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r576",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r14",
      "r684"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-Term Investments",
        "terseLabel": "Investment in affiliates"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other loss",
        "verboseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r95",
      "r696"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of shares",
        "terseLabel": "Payments for repurchase of shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payments for business acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedLabel": "Purchase of investment \u2013 equity method"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r26",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r26",
      "r596"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r79",
      "r585"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.",
        "label": "Proceeds from Collection of Long-Term Loans to Related Parties",
        "terseLabel": "Proceeds from repayment of loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r80",
      "r90"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Distribution from investment - equity method"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Borrowings on loans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherOperatingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from operating activities classified as other.",
        "label": "Proceeds from Other Operating Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromOtherOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r3",
      "r58",
      "r59",
      "r63",
      "r89",
      "r113",
      "r125",
      "r133",
      "r134",
      "r177",
      "r186",
      "r189",
      "r192",
      "r194",
      "r215",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r490",
      "r496",
      "r498",
      "r511",
      "r512",
      "r533",
      "r546",
      "r667"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r261",
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Land, property, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r261",
      "r596",
      "r669",
      "r682"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Land, property, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealEstateLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan to finance the purchase of real estate, including but not limited to, land or building.",
        "label": "Real Estate Loan [Member]",
        "terseLabel": "Real Estate Loan"
       }
      }
     },
     "localname": "RealEstateLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r389",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r389",
      "r585",
      "r586",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "totalLabel": "Receipts, net",
        "verboseLabel": "Recognized risk pool revenue"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r389",
      "r585",
      "r589",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r583",
      "r584",
      "r586",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r12",
      "r106"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r12",
      "r106",
      "r714",
      "r715"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash - current"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r353",
      "r596",
      "r679",
      "r707",
      "r708"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r217",
      "r441",
      "r442",
      "r443",
      "r458",
      "r459",
      "r531",
      "r704",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r170",
      "r171",
      "r185",
      "r190",
      "r191",
      "r195",
      "r196",
      "r197",
      "r369",
      "r370",
      "r633"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r74",
      "r281",
      "r283",
      "r284",
      "r288",
      "r289",
      "r290",
      "r713"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolver Loan",
        "verboseLabel": "Revolver Loan"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r575",
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Fixed asset obtained in exchange for finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]"
       }
      }
     },
     "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r163",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "verboseLabel": "Net Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r3",
      "r113",
      "r214",
      "r215",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r245",
      "r250",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r245",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Change in Carrying Value of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r254",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Medical Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Commitments of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r587",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "verboseLabel": "Schedule of Fees Incurred and Revenue Earned from Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "verboseLabel": "Schedule of Contributions to Revenue and Receivables by Payor"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r396",
      "r397",
      "r400",
      "r401",
      "r402",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r423",
      "r424",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r404",
      "r419",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r110",
      "r153",
      "r154",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r339",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r356",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r493",
      "r494",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r508",
      "r509",
      "r613",
      "r614",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r503",
      "r505",
      "r507",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "verboseLabel": "Schedule of Assets and Liabilities, Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "verboseLabel": "Schedule of Shares Included in the Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "verboseLabel": "Schedule of Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Reportable Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r25",
      "r26",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r25",
      "r26",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "verboseLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r423",
      "r424",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r403",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Market value of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Grant date fair value of restricted stock to be recognized straight-line"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r274",
      "r275",
      "r487",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r110",
      "r113",
      "r138",
      "r139",
      "r140",
      "r142",
      "r144",
      "r153",
      "r154",
      "r155",
      "r215",
      "r278",
      "r283",
      "r284",
      "r285",
      "r289",
      "r290",
      "r330",
      "r331",
      "r335",
      "r339",
      "r346",
      "r546",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r48",
      "r61",
      "r62",
      "r63",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r152",
      "r217",
      "r346",
      "r353",
      "r441",
      "r442",
      "r443",
      "r458",
      "r459",
      "r531",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r582",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r152",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Common stock issued in business combination"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r26",
      "r27",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "verboseLabel": "Issuance of shares for business acquisition (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r346",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares purchased by related party"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r26",
      "r27",
      "r346",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Cancellation of restricted stock awards (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r346",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r346",
      "r353",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r48",
      "r346",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "verboseLabel": "Issuance of shares for business acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r26",
      "r27",
      "r346",
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedTerseLabel": "Cancellation of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r26",
      "r27",
      "r346",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r26",
      "r27",
      "r353",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r48",
      "r346",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Purchase price adjustment from Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r26",
      "r27",
      "r346",
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Share buy back"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r32",
      "r33",
      "r113",
      "r201",
      "r215",
      "r546",
      "r596"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity, parent"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r62",
      "r113",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r215",
      "r217",
      "r353",
      "r441",
      "r442",
      "r443",
      "r458",
      "r459",
      "r488",
      "r489",
      "r510",
      "r531",
      "r546",
      "r548",
      "r549",
      "r553",
      "r582",
      "r705",
      "r706"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "terseLabel": "Stockholders\u2019 deficit",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r353",
      "r357",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Mezzanine and Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r573",
      "r580"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r695"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r695"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionOfDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity during the period due to unpaid dividends.",
        "label": "Temporary Equity, Accretion of Dividends",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "TemporaryEquityAccretionOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r47",
      "r113",
      "r215",
      "r546"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Temporary equity, carrying amount, ending balance",
        "periodStartLabel": "Temporary equity, carrying amount, beginning balance",
        "terseLabel": "Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Tradename/trademarks"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r317",
      "r344",
      "r529",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r612",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r27",
      "r346",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredParValueMethod": {
     "auth_ref": [
      "r346",
      "r353",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.",
        "label": "Treasury Stock, Value, Acquired, Par Value Method",
        "negatedLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredParValueMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedTerseLabel": "Unrealized (gain) loss on interest rate swaps"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized (loss) gain on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r157",
      "r158",
      "r160",
      "r161",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Variable Interest Entities (VIEs)"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEs"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r493",
      "r494",
      "r501",
      "r502",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Adjustments to weighted average shares of common stock (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r137",
      "r144"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r136",
      "r144"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126903467&loc=d3e32787-111569"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e12803-110250"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/subtopic&trid=2560295"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.12(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "720",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=49178521&loc=d3e9162-115647"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r723": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r724": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r725": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r726": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r727": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r728": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r729": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r730": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r731": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r732": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r733": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r734": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001628280-22-021959-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-021959-xbrl.zip
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M%BBYY= 7K5&Q@^:-A[WPD+M&<A ?B:UD]8Q&/!-8;]$&=9@5B=''5G@O?.0
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MF=2, DE J6"",RF93()IO((P4D*R/6B:H1J#=U5C?&A%LJ"J9TL^U&2]T-Y
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M,3"3(7:2F\]E_"(SH=!IR%F\+3HF#\7;XHK- M2[/QIL+D16Q@ZQ3*#OUTU
MR3J7 G!S/AI @[D$(O8ZGA6*K6GJ*%V>]0,MESI$8[+]4Z$+:O)3KU\,V*="
MH*!I)1I?->:VR!D/(G+CZ4$DC[&(:&BO+#*:4@2JR1Q:0.QEK48O(A.B!W].
M7L<B(E@B:J!AR50!R(C99H_.5E,3V)C'+R)[@LKK5M_]Q?O[?/<CE]_^Z";?
M(3!QRUS0(\0DBG8,U@3O'"O.$TBH''8E[GUW7WU+L_G]Q6KU]:OOA(^5:7XO
M)YL\[=6SV?-WTKEI]>R;D\6O%R=NZ[&^IA.:5WGR3&1]?U'I3;/[RS,VI7,?
M+N;*?)?ZS+=6*UEO+<B^^#5W9#4[GK_GYI<'A&^M+LY],WP36<Q +Q1S3BX'
M!V*)BC7%>\\I1JM:M"^F\: Y?ZPY]V=49B=;G:,:K_IL<:+!9'#6%8U<&P0-
M2)@@.^<-;M(#W0#-B#]B*(;O_%NL+2WG/@6,O9-S=M7:Q@9,J*8E-X%]@WVG
MT>/E@L_J^M'RB2Q?S.K;39P?R_+\._V%_O1G#VA.Q\*]V7:?N5E2O08A'WXW
M7:B9LX,4454C%T^)*3C1&#X&KZYF(LC^47ON!T_V$;C(GJ%A98,6?"RE51/8
M]UWJK7I;)@#<A[W?!L#+O8^/Z57?^'AKSOK)\DSX[LOG>JD];:)1,I%Q4= *
M% V"31$Q'BIAS#5>IA^#S:-%]6PUF\MJ=:O^S]EL-7L'U/\BEN^$3M;/;F^Z
M*/;N4B??+A=GS^_-ZW63<3BR>0MLHA!YA29G@PTP(F:%2**-S)1--1<869>F
MB=&CY2F=8Z28J-JI^WRA=UTJ3+^NGSU9G)QM2/+]^Q^JO_?)@*D-2UL K.\4
MUW%46\D!U-5E4>K7<O454O>!XY]W^&/ U"[JL<?+V2DM7[VK5Q.)<%.-8BBD
M5A422$+!!BDQ6*G8HK\LLX*7%!W'&^K^,5AW3C\4/GZJXU*OA1\?*N!VMK8G
M4AWK/=@*,V2;B_2*O:QAE_JR%">P;^;>G*7-YK.UW)^]$+XW5U$^GG7FL9FN
M^OK5><&"$UJMKD;(3Y?JU'KMAJGLGG&Q;YO4_[;*@,9@5*(ADAWU3=1Q*F'=
M]XK/!>/?U)-0[$[/3K>V./=G1&&CV0]E_>MB^<O;LTA[R5%18:PY%6(?P!KE
MJ,EG"<"L!B"$.E'QH9<'\=E50362:&)3_E4TL@$L$0R4@*4E-X4]-B/%]GJ(
MF<8Z@<*F@4]O'M$G!'W)"4V$!G4*O3G_.F[GLX']-I>3@7NIDIQ=I0"A!G;@
MBLO5@B"55JB1%]A'E=P)M-=4Z28X4TWPT52(/F>;( 2R(4-TC+3?&KFYUMX[
M2>3>M#(['XJ'JLX1HI*N%+QR+$,\A4IAXX3V>I;GG6^I>B"?4.UG1<4I40X-
M<_ !I\"(_SILCQ6NOA3\VIX^5@#;8ODA*CU)O8RM87%57".E/X4QVA0<A1RM
M,RWMI:?<(<#7LQ,8*H1(P. =<&("E[-$% \QLY_"=,=? N_W\U.WYKQYTY=*
M]])M<DHM$(*ZS  EQ5Y+KL_Z9X  XB8P"SENA*]'/V/QF;#:4#)PL45:=+47
M4:C<R$ZA2\ GH7=9 W?O2:T'%X,IUAK.@%49K5'(>Z]*[U/*:4^U<T?X7HMN
M,K%ME6I*A4 D88J-N=7LD[)<-X4V2I^$W9V^:V/Q7/BIU&?SQ<GB^-7WL^-G
M^SD-Y)RR62Y*9J,#3RY+-BQ"X+%)W+MIH $POJ;EO.JI4F@^"=14>I=U@629
M<G$QF_$GA__EI=?[L]JO-3^^=;R436PRE5VUR1"68!IQ\2"U]-;,2*97J$NA
MO>[1/.9V!H<UV.$Z";#'J&Z98H@62D@D-I"*D&>N+DVF*]%A#788\;&V!@VT
MDK?5@'>1DK'5<FE08R8[@?HN8\7V>LKQ%(^.3 Y0&&QT"-6X4HD">8M,$]#V
MD2_4#:^2H4)JG%OL)* 41S990.L:M^3*?JKDKM=@MZ>1D(A:A,R),ZC%1(C9
MB<GL/&13['YKY,[78(?IUL2^5R!H(CX#E5)R,H&K(9]:\7$*-2G'">WU%!BI
MM37+60-AKVB9$J+:4ZMXA<+9[K>/'&H-=A"]-%)%.:K86M53<BBFI6@]@?>U
M%IS 9OA1 WPMVED;]V*Q7!05D&:P-O6=$44##HYF2MT;Q[U"-[QZ8N)>#-B8
M&@-DY%)J! S9J,Z&&FC/U'/(-=CMZ:<KKO3HWW 2"!IL6C)-FJ5D6RHPXNBC
MSQL]T3ORV8D\:N<U%A_(^ME"L7LAJW6_S.\_%7EGN_A]6M')R>7..05[46>J
M *M[SVDB$)+&'>(-9F6M8"034*HE>]]<BCZ;"2S531'+X9?M8C:>'&>&&($;
M4LI0BXTN8B)3[7B7[::(]_4LX2D\!1)'46/K@'.)O4N[*\9[-&,NJ+\E"!]3
MU0>H%Q#>.Z5>9T@=Z:-YW2S(WI9>Y^.Z:P1LL>)0)78&5!=#'VF+D5NO>Y>\
ML(C#FV.,!T1V>-.L08]UJ:!CTPOC)HP2*12-6J.M-HUXK]OTT;\60VW$"+-"
M5F,&+PUMRRZ#V+X5UN81]]+8$J#?:%3T]-E2Y-%<?OC;[87ZW6.Y[E(@6RQF
M+L'D:L7VV@2V%'(4E"PU,LP9+-P<N[P[((<WPRW5AD(42XL@0B4EJ\ZY!=9@
M-\*("\].#NQKL;JMM6""%2!B@%2*96BAF&*"J]Q&W"AB2_@I; ^>/)J.F2U@
M#:%W8'ICM]8PE-8\2RG>._+MYIC9:T1N>+N:$D5C*V$V5A52J#)A\5TI?5:;
MN_=V=3=ZN<7^MLR(QM3D2H%>Q257*;GF9"$3VA$WZM@28$_I.%X&(Z^_MZF3
MIB!NEKV%'_=JHA,QM,(FAU(EJ'4%KV8V8,]7@.+$E'R3YAD&1'9X0RQHB#!4
MC+E CAT<;JF%&#U$H!'W.)\^^M=BJ"4RI]Q*C*AZG2,9Q!IJW[Q,G,N(N^EM
M"=#;M^X]OC4ISNLMI!"KD6 B<$UHD(-RHQ2D18Q3V"HW!>R&-[963,@1+:5-
M(69??"6OI H 718[XDWF4\#W>B80JOZOI^AFI^Z0N13T',"6GH>DQ/?<G.ZB
M[\.?A>PRO>1M'_9T2?,5U4V&YM>OWC[R=IW9Y=]N+=="QQ]: ]V5U/SU5=H/
M/B'+[,O[<DPG=S>@O5T:^?'M7CC^\>W[3Q[<VM:^HLO*] \7^OCW%PJ&WN.;
MV9SF==-%ILKL12]9W[&Y?/WTU7.YFC"T^?:;$Z[9RUUI"?(IQ,3:5IBK:)P/
M,?C2; 6-*;.I#HWP *U4#BIU4*D=J=3P+7DD4'0U@^E97KEV9P:))#57+#=#
MXR4??R!1S^O]U>GTE6HL;"=2Q9 D:H!HP#E+(:,*C8&:L@8GE^7H8,21R!\(
MR\G)K)OF35[!HW:;3F9ML9S/J'/2&RA![\9#L/M5 $0VJ:JS5UO4<D#6.%B<
MMS'UE?9P00G@DA(<Q&U?Q,U^O+C9[:6[6DF^!35DV6]JO'%CQ@!46^/LPP3F
M60[B-IW9'O*F =GD/:DS1:$,U@I":LE"R?#.SJ6#N.V-N/VIW5/;$C?3I_Q+
MS8780B\,E-2+YMJK6CJN&<?+[R^#L/<CW7O8:FR].)EQ#ZTOP=XKWMVKS!J?
M(!IOH#>(4ZN1I"&'1* 'Q[MH,U7LMKA!M<8J&9)MSD&TOO2.V][7$I1I))P"
MJY@4B,,[]E:"HMUR+9G!)8,AQ&S(>^.SQ#@%QSY=Q ?QK259EIC4D5*O;UDQ
MN0 ^FX"FJ-_=K )9U?;QV>>IS)V-8KN'#4<F;:E*H[,A5!\:N02IA(P07&*E
M8S8Z G^82=M;>1I^7LTU;]A&:)$3^-[H!V)!)^ =4@MXF%>[&<(WR"R;CRE&
M-7B-2^^F4 MN.F=$5TQH1::0P7\0OJE2\Y);-HD03!&(XDB*5\;FF&-L0F8"
MU/P@?%.-$FKQ@=&6Z+(!#1@*LY4@1DH(QHPYE_H@<R.:#(R%R%8$INHAMT"U
M.5^[_6HN61AQ5?Z#&(UH7I*Q%LD]_&Q9B5@NWE.@5L7$R U&O!XP[-;E8:1\
M+,:G00P%2<A5@6Q0/9GTC2.>,!:7<0+S%@?QF<@TA;$:&A80Z\@!9J)NHYJR
M=2^A1FLG,$UQD+6)S$H8&RMY\!!R F5/.6>?R/C67*LV36%6XB!K$YF$2+DW
MX"9AE3G0>+!X$WOY)^--4#G,$YB$.,C:1.8<G+2^?S"A$C:PXM&J^]1PT9,)
M#LV(.^]-.EB<7/D.LDE:BP5KTF"P$;L@QA 2VL AWQQ:O\.R.KMGU%%8#4%3
M  M#$R8G&(-P[S<OR<:;PZAW!?,@9%9:< YJ:B4C5*?A>@[)&); %,6EFT,P
M=@CS[GV[#X+>ALH5,\3J"V=%/4)H(?F^8W:TOGT7M5GVA4->B[_W68RC5DF=
M/6@D0HV2=Q@L<R\+7FZ.O_\4&9HD!W N>1NC#5(4?6HEB,U&'46LR8J4F\,!
MAH1^$%X D1R6XDIU7>]]00PM-4.-B\V0;\XDU\!:O_LY)Q>QQ!1"B*9 PI[F
M5X/)S<5@E#F\V\3N /W^T$3KF4!0Q":&)!EM]CF5V*@U7]J(TTZFB?CU)'TT
M3J:2XY(2%*<*+ '1)C01>JK'>),^)@_B%GNW,%-5_9.0'*CC)0I.==/Y&*6$
M<I&YHT,_.A#_:)O(XN1D<8',=PN]S/QX]>$LF%V)S>ZJ/1K<4B,)SD$ML\4B
M2L^)2B&C'Q5G?1,#/%XAN;&053)5N56++1"$6$LO3])W^]D8:O/VYD33.RW0
M.4!!&H@AYV0M*)I.<H%BI9>D1PK1NTV-+(LFC$\WAUM->_3K7):]W_>59N \
M>[Q8KNGDFI7<XI$)6VH#CI04:+7%M0!8+LJ@>]'[5'(POFTRWSKV&R4_",'@
M0O"VM3@7@X^R%N]*S*?T:.- U:<<8F'@GBN9N4^P9F-][TZ]L19Y6KN"'\KZ
MU\7REPN^]Z9K^)88W_ODY%9]-I,7]*!O-*]_NU9KD;>VO]=@0$+.2MDJE!@*
M*,XQYJAFQ-2XF67MV)];BX,0#"T$5ZS%1@P^SEJ\(S&?LCN(<O6]FWUKJ-9"
MJ+=Q+,HXHJ.&=I*9.GLH*-<RNQ,X> T5*@<C8$HO]^XDEI@;0*%PWNY((1N?
MD?C+)8\ON$:\VW?-/%_.5A_L:/_1SS)$R=]K4))KE5US9,V6.K*UF&ROU<T9
M@1A*B+TX%9:B7*JV2=JM^Y]>]^0O*\:6ZJY,K/[UM9C5%%.P*+$F)R"@D3L5
M%R*$8DV4BY6/4:YU;=U:?)0_W491Q0]*[B=/VFU+.!(6DFP@^@H8':+WC4*P
MP*"QNYFBW;KAPK$]RX$06S.!O24""X*(V1>+)D-$VV0/"=FM[QZ,,V=NCUW=
M]E@8NZR!0Y'*QD"(%J-MQI*2,"G$.8[7FEV.^^VE6JWU-RHA)Z]%YXTPOUB<
MO% 0KYXT$6.2*]E*KK48$ Q&Y):M:[D9(LJ1QKMV/U9LMK<DGXH/H:1J& B:
M+U0#<8PV<TY&2<'X]>;^8GZL(?3I'2GKWUNS[T6-L8[.6KI!G(C"%+5>69'Q
M'@DH1!3O8_890)3)YSQ^A1D-*%O4%&1VT2![T%A?%)FFG(@UD,*&S;FI:LKY
MNK4RH_7R;$.1)J0H/K)U,8C^C6":(Y;23$L^@.N985-5E-UCLL6Z.A6:!@W!
M1D4!>I6FEF,&<585R,ME]>=HX]'EB[&"TT&YMP&A?_%M-J_O6?C<X]\Z7LI6
MHLQ1L8UW\W;CD7T]MA_,VWUSZJ?4*F02@UG#S2!@#60/Q$&#3U]R\,9?SEX=
MY.?:Y6=+?O_^;"X:^V[N?/VS9&^$\!.LF7.M!FY"21!:]!B2KRY!H5Q<MV:C
M%\(_DH;[LE:T/A*2L8O]WLD>N<K9"?J6"OA42K E5,PM&5L@3D#V1F@ OU[.
M^/ACXHZ;*W<80O;%N>Q# ?6]16S?/*,6D#@YGV\L@YLDC?*B- J,C:4 )#&]
MQS0T$[+EEK.E&XOF!V_;5WV^I_GQA4;WMP]F\]GIV>D^RDD.*BC1Y.B] XW?
MLND9>ZFJJZ$"SASDY,_(";W<5SDAZZ+U&9J- =#Y@M9BSW^QP4)S=D)R\D<\
MX8EZ3RZOSAGR:N(4^699LHIH0V\1*%P@NXP<@P3RD9*!8--!0J<AH?MK0VOV
M*)X=],XOA1I6$/"QQ$*@/KA,2$)'("<?9<D^^@?]FY:SGOCPO6+[3BBWF/-B
M?J\G[!::__*H-=$?U\^[?^_K1]_OHZ!BH\@Y0@;G %PL#K"$7(4*5BD'01U,
MG X6]>KN1*/4DV/?-6Z@NM[E.==*(3BH-I<T_M79$<Z533OM*)!S5:S4&AE2
MABP%6^.$$:DB32"UY3^*Q+5/6VT+D+/Y[!R-=IZ&2"?_O:3U;/%ZQ$^%5F=+
M.?]9[YQT><W+<R[?]XN^%W$;+;>0?4(.(*[FZH,TZU(UAF)V$ZCO-3STP]?J
MLE;8M6RRU_BM&%\@M@P=09^M!W^Q;SCO/7I3->)]5VC>CA&O(5,1(9OZDA<:
MM=Q-/^OE&RTI:N/=PG+PZ]>T<:5(S W5X*0L4 7)>:.N/N@?*Q1&7 KL/V\/
MN-BQ\GBYT(%8O^I[$_K6WNF4]B),$"(4WU)3<VU*R99JM0Y#\9AEXWJ-2<8?
M7;ZX >AL(4I\O-2S^\?7[.G-9L^__QA/_\ZIGY+BU9HQ2L6]TG-(5<@ Y$@@
M"=2)E#!>BCXZ5=YBBSL;DTT%1;DTY! I%  )PNB-$U]NIBI/4K_(&K -<Y;>
MY3G%;#!6_0N5O<U^Q#MO_F GW8-O+]";R80<9(*:4T5Q(0F0<10A>5.B& %+
M?.D@T82CRQ=CPV1[SFK4\+^KMKT@UD>J[=NG?H+:AI+4$WI(E@DB-%(:U?<Y
M)(JMH!_QS-5(U'9[SM#:9 +9(IR5D]24E> "H?54DP]F"FI[LW6IULI-_Q,-
M(^3"I*K5*'.L3"@7L\ 3<X$_W;\_O0@Q,Y28#!2V!,TJOXR)*0-3BT@<+FFE
M2T>7+_84D:E%A2Y]-&M]<^JGN+_D<PK 4)6I!F])0T37<R,L&Y_'O--R%"J[
MQ4C0Q K0EU3  2;.->0D#2N+:"0(-T=E)ZE'I:6<LG6!,:KMS:A_FN]MZZ,M
MY"XK_.@)TT'MEG7F.SDY.:7Y#O3('KFP#3U*06PDL%C4"9I*46+F3D9,+Z6,
ME^N2+ASM.2(3<GWOP/^!I<^W3_V4-D7HJ$!?ODX$)M=LBU%3:QFK"8%'G,8R
M%I7=5@$L:2)8(MC4XSZ7 ]J>^>:2#4%)R<U1V6GJ42VI813#TJ#FD*,+T:L'
MY(2VN7:Q; SCTZ,/IQ#\N;(0GR F3^D8AVHY9& [>JRF,P5'ML_> (="%0P6
M9]7 AE3MN1[[RY0@KXHQNGF P3-)]T0D/WC;397'7I6H7_1)E;D.^.)-]NSE
M)]\LEE)I==VI5_[C4Z]\GZ0QVRC"GIN&WJ!1GZ4,P2#F@DI1>PW_8@5'S#_V
M1$C'PG]2U5#%B)AJ51!<*AS[6F*N2D_99+[@/RH($TZEW%>)>)=_O2T3NTGA
MC-E32+[D'!PXC79)DL8R+B=OT9@X@7:K(\O$':1U*K7J$80:) _,IDB.C=&%
ME*O/+4Z@L=O(8!RD;1NY:$)J)I2(8$RADL2FZE5'<\9H)]#R?&0P#M*^O"]^
M>%O8IV*4G)EB$@3/*68PZ:(S9L^+M]-#[];S^O79:C:7U:9P]?9K0[U5A>=J
M3O1Y,Y:E:,BD1[_6\.D:<U=V4 3\#\M][:@6T7G^O]U*_K^X1#5FS$D@L"VA
M^%X2UX? -;L1=RD8;@O_M0C@6 (38[S)5>U?+@*%?+%!<HG&^V*H4IO0'J^;
M*QG#[S%+'$H+V*C7-_(M$]1 $7,%%Q'#Q/L%7&]ID+$XT^?/Z#8MY2*PWH33
M$^IYIR%QXU):=3Z!$9^3A60$:G6I-; '0W80Q3%:3EN3P<J-@U<I)2PNFT;-
M-^=;L#ABRSD6[W<MYD1:I RQ(7A4.X+D8VJ4?<B0(;4XQ3S7P6#9XK[(U#<M
M2X"H/*-7SXF5A#1&%Q!T#2<P@S86?(:?1V,@#*I!OC>U9F9$'6CR&')@[[.9
MP#S:*,$<9#8M9^-JB3Z[TL TR3E%ASU3SP>- _P$^-<HP1R$E-3$E;QE;ZR'
M("W;&&M/]0@A2S8X@?6F48(YR*J3\>A]<L&D4B#H$#L=Z&34X'*@&OVD?>;M
M.T]VL.*[>]_H$GA1NDE5E(9"I:),)^1>;:OX%&C2OG$'H WB UWN!5,X-&,8
M^CQJ569:*I+&=5BD3-H'[D;3=N_KJ#7&&%O.&,"VEBD;R!F*Y$8"4\BM&%K3
M=N_3+#EV*16E)#T()'3<8DNFV,PV8YZ 3WO=9OA76O+O&YW</7U^LG@E\F2]
MJ+\\>MZ3JO;1S]7&8*NP>C4+R5:,S4LHJ ,=K4B;@)\;'9"#^+XJ%D!852T%
MB+%D-:M6R)8,J2)/:2%Q-$ .5"XR24T(X$L$[X*&\]51S<&TX@*E"?C#T0$Y
MB(\,K26.Z)KC#!QJ=E%\]<&C&M: ;;H^<D-M-NAM#JQNS?E?\]EZM8\.,K%E
MZQLI.XV]N ,),523O$V)O8_3=9 #H3A,9&B ))G(!AHX@>P*B!%O3;-,C-/U
MCL/IX@#3HHU3"<Y*4QQ-I,S8<J*FQA6;E F[QN%T<8#8T4NCF#!;U45.+6OL
M(9FDV,K1\KN3V[M8X[W6<;NR]OHI-DR#ZY!J=2%4<,#(/M<03/&M@/-F C:L
M[SM\.EN?R*-V;\ZS%S,^HY.W-."2&>ZE]2I)8J]?0H$!,I<2. J@1FN0&MF)
MX]</W9DMI:X7RVWL7!VDO]M $Z"LJEVQA&"!N?5F6BU(9A'&B/$@%X/W !I$
M+B*1QARI-BL1/"5T,4+.H9</\Y*FL)JQ';F8)'HNV:A!1O5&+'CO,1,!E!)-
ME%Z68;QYA7MHY*^GEFHD".Q+L-CY%Q'U+O;9.=NRV#SBO3Q[:*ZO!>$>:_9N
M',DG L2HMK?88+-2-VR$>S"G_KVLULM970MO@L]]-,0QA<(NM=YT"3*E@C&1
MR3E1C,G5"=0 &0J[Z]GPYJL()<>Q$1C W(*3$'(K%FVT(_:+K[> /*.E?$TK
MX=N+T^=ZM#=WFV\^7=TZ6S];+&>_"?]KSK)\:X7C\0G-5U^_NOM2EG6VDL>*
MG+QE'#?A[P^T7.JP_OZ<1_-K* ]X+?#V'?E<?&G9(1 #%72NEF9"SA&J3,AD
M[@O.PYM@:Z%6C6RA)25(I#*"O9EE!"[5^YH/.O\>67CZZV(B.H\U@$\NHQ4U
MZ!KJ0)$2N'IK ^NG!YW?.<[#ZWR*V<<F??*B@*D6$YC&-A8O3"'R>'7^^GNR
M#R%ESY8R%0[1;#!ZP6J"\U!C+Y@OQIM64P:J-.(V:B,'>/\C]I )4E4G1.2@
MA8JYDH9\?6E1:DQ\<$4#&(GAG5%-+3</I?6E4JQ2&J6>YNH1!6(H!XLR<9<A
MR;72,#I' -PG>8KSKCH,/<.'II#?<[,6/6UR,9@DK00-"\EDSCG[ZC$D1<W3
M1 ';W]5(4L38^+8!K/?^L#WY2BE9(;6N:0JY5X-IV"!I5LV0@*U)3(G0-")'
MJ=867U&L8ULF"MA.-&P0P- W4FQ*@&C VIR=U\"'30HID&TCGAD?MD3D-[,Y
MS>N,3IZ</7^^6*Z?+AXNYCJRJ\7)C!4+_MVC?5(QI[%0'BB]&(!&RMY[$/$E
M!TE!7:FOB6.89%NYOUIYZB K'Z#'Q: R8T?8#/16,L$9)6"-.'-1$S.!K2C=
M^-]^"Z@-1C,-?MY(S_U3^E0Y^<^B^5#6ORZ6OUP(Y@.:T_'>%MANQ=5@,R'V
MS.)0J>=K4U2B9T*5BRXSX][S<D/%9:#--8*8V!52QIDT(J@VMI+1 )H2ZE02
M%6^@N P3^A.:WB0Y UFHX FS5"DE.<^UB9U(8'(#Q668L(B1@R.C0@,@O=8$
MQE(E>G(8DH,)<)<W&5LG75IZG]Y73Y<T7]&F6<\[1%.6+V9U*TLY'Q#1QZ>S
M1;T^(;UIY103%>^\!O"]YYA5ZM1K*,98"IB .=<)L*:#H-Z$4I%1)12-U()8
M(::04\N]XXK-QB&^+MXS9KYV$-0;40:3U,LW5RHG !71[&JO@VDC4:H,80),
M\2"H-Z'$)[L68\@F<XE@$$HE"8X3QFP VHB+R)]W@GTF?-9W ]W]GS-]J >R
M?K;@-YT=?_^IR$/%>=OR] %=67W]ZNTC5]MM;3(AGBU.6)8?VCP^2IT=BRY=
M3_?57O'6U. =]SHL'LD&GT(UIL7J$EZT+S^HQT$]IJ,>=GM[9@)2 [(E! <"
M,?<JC(U:<I$]A2GTL_P(RG'G]/@@>5,.&]'$K+9;Y8\]I RE%.F5E6UPT9>V
M)_.V!S&=.!>/&&MJ+IAF!-@'=% YAEB<PQAIQ!M/#@Y^URE$6Z)W'[898V'B
MKA!D!+%L,B0*66P*H9 4!-O<%/HW_74MX1<TKW)G1L?SQ6H]JT_.EL>R?'5;
M[RN?7.QB;Y1FDFLOX*HD [GT*JW9N +)0C,!#++S=0_67@YR/3R9V3WG3BW[
M4CC91!Z8 &.*)'W//(K#-(5]+0>Y'K=<#[*RTS('0;&&&  ME62R#: LI 1Y
MTWIPS+'D0:['+=>#!)^02HPU!)5LA%IL":Z"@>I<33'4*=7\G[P 79\&?W-V
M<JR#^:W,1=5W=6_^H;G]27+JD(SQT5I3LP<CK;./XKQE9=BUF3Q]3GV0Y0%D
M>1 >W;)MK5% @[DOR&,D@]9X;#Y9-<[3Y]$'61[&+N^>.WM,7C @QQR :R8K
MJ3@IC;-^&*:P#G.0Y?')\B!\64QV(-81(8,(%!?!@O-52J^X:Z?/EP^K-C=B
M KHT<#&BRG&K$'*@%BVU+&RX"EW4/9TT63X(\HV8<;8:Z^5HE2N[ULN'8.%(
M"*W&ZL'QE#K[_FE!?EN*;\WY45/(MR#0HQ2N8:84E*,FC,TP9ZCJ]JWC9E-O
MQN=CE;+/5O(F"=<@EDNE!4S*B1LV2,$1>C'>N]@;L6#>[[6R@PO>GP"_-=M;
ME,;>BQU2BJ52 I<:V@+JBV7Z ?Y!D&_&:EA6"^R*&M_"D(G(1 N>LN6LG[@I
M-8,XN/NQ64E?)-9 5D02!#!4'9E4(2=K,TRJ&?!!N,9FN9*14&NNI5300*62
M8U)'[(WUB3R5"43!_QG,)[>_NSW8O/;#,[W&_?L?>H!)AK<F>R^>:I0,*C:5
MLKC:7&)$L0(\@?#V9DO-('$K1V7Z3B$,7*$4=62E)UD$"FIS6O(38$DW6VJ&
MZ2:.0<DUM5HQ0LNM^%0MA22E.2.&)T!_;K;4#!.1"=M6H!9,")N*C9%!PS,*
M+8JW==*\9I3K^+VEWY-''U'#>)*,QS6U0QE<@-ZJR9I2!2JE2NPX-0^39CPW
M6YX&X4(U] ;+1GJ;.$"BDI7X,$D(E)-'-VDN=+/E:1"6Q A"F"&VD$"\HU#$
MI:)AO0W0'$R:)=UL>1J$/P6G(3Y7V]O>].ZUV%RL-H/GG)N7$1<7V-)6]^N$
M]WH:4AO%*"N_M>I10FV4* M:D>;9"L<#X]WZ$MYRN7BU^/=,(=M'RFN-]RGV
M[AD9P 8FHT%4*[&1C2ZT*51K.@C4F#AO,4ULC,Q>.4J-!:-(:.P;$6BP/H6\
ME8- C8GTJG#Z#-ALR!F"IY*<S2%EYTF<6JL#Z9VN0 U3WI9MA6RLRE*%9FN)
MQF'-B,X'[\L>M&#X VB_>["7:Y4-O*_,#H <%!1LAB543Y$C9:8)T)@Q8SH(
MD\B.7>":HTD +ME"%CB0<V(LY0838!)CQG28=;Y:6DB]-Q)F,$$H0C4^UAI]
M*T:FT,9US)@.TYH7@J4" E4 :E+=S,WU7)$@)HF?0CO&OXSI=T\>/'FTCP[5
MM6(+*IB]BG-KJK91<O$F.,/*D>(^.]1=@#I,S>.4DTN8*5M5VA1*WZ1L(:G^
MFEPNLBSVU*/N2%-W[U+5CZ*O-3?3:M]XED4B.)L(6I+<ZCZ[U!UIZNY]:B&U
MM"6Y4HJ'$ET1])AM@1 M(;M]]JFWSG28YOOH5(EC)E';VSN%<C:E9I."L8X#
M WNSSTYU)Z@.,^/MO W($M7N0F7.I=OAT#O9VVIE#QK0#:^KNW>K&LOT;C[$
MM3"X$G+O\)L-V%1-L#GNLUO=E:X.L!.F053F2Q&((6>UOZJ@&'Q!-H6<&V_&
MP\BF':ZGLY8.?'"M6G8!&@<*RF>YFAPXV=KDO+.657M[0.=CT;%'UAUYNP5T
M2H1H8Z5"12";3 C.H25?*38*<4_]7$\UNC-;2ETO/KF<\2BW) [B7E$#U%8Y
M<:@ KJJ##3U#P!3#&N"TL*<!SDT0I@%ZE1O!Y$PS6<%%-'TE(6(MP$TCKOIN
M_?4Q.I!1@OFG*-H5-_,IQ)N<Z1VO"" #%Z5FE3(6J1Z+J<U/R#+<TBOP[.1L
M/7LA3Z0JJ^[MV>Z^K"=G+/S-<G%Z>W'Z_&Q-W5X\:G=)89T?KQ[+<K,E_NM7
M[[_ U3H?W\MJO9Q5M3-/UHOZRS[JM\EL4^20V5?(V+"YBBBN^L1@W)3*$>ZA
M2 PRZ1*\$@>L*=J2@"CW>AD:J4<I[(NX*:09[K%(#$(I-0R)S5AH$A$TM">#
MR6:;K*T62L )S=CLH4@,4Y 9BHE!^@;."LP6HS'Z+V-V.0=*!RMQ523T;.66
MI[VAS^9;'ZK!,TD[D8HRB6"20Y? YTB0J"C!C :2E$('@CFX4.R>8K*BSP2U
MM,S**QB#K]Y;3U"<#3RETNT[$8J[I\]/%O\_>^_>U,:NK ]_E2GV><\OJ\IB
MC6XC*=F'*B],$G*P2< D!_ZA)(T&#]@>MB_A\NG?UHS-S2:!8(,QLVH%C#V>
MD=3=CYYNM5H7SN53Q_;I8$E7;",=8Q4"6"0) _U0)DH2!^#A;*@%$-#2\WAI
MM7@1[X,9[(05&A/)F.;$V(3:*#2<.192\YH.'MX%@;OK[;)>![(N_'E'L#]T
MKZ>[@V6T<6L<TW$L!'!%O](K16),[).I0A:I6+PB&U\H8;Z(93H>AE3*"-.$
M,Q5:R0D17(* C;,QP27C?VG ?IE-A)+$TD6 U-*?J.TTMS1Q89QH^(_:UU1>
M=4G5XF72+/V!ZBPA$F8 )A.E_"J#()2S)!%"A:\(+18*^E_$QIG"(=@WYTQC
MQH65&B<*LYC&8.,B4:_(QA=*F"]BF6&D>4CCF.J(,&ZL(5I:%44XP<S"1+ZX
MB5I^B7\]Z_:S=AK[U?]\07<"8+_K7JI-VVWZ4[)=?U L^W[MI1W=N_C'=5T"
M=X>7KR1S*Q'*$B%HS(5BD:8^NNIBGZRN8I=PLKB96Z](7+-+Y<)< $!2PQ.<
M,"NLQL(PK",P-R=(HA?;NG9T]\A=Y]/4TV[:&79>B:5$!KN86@YD-&;@:!K%
MM#"^G)L_\$=&KVOH]?FB#GUZ_K[GTZ]\)E8K/0UTS_:R]NW!\E]9S7I'?Q-P
M&O\>7?%WHNT )5DVZ&8#MQ(DP*AW7-+W06+Z_<+4LI];9.?G/JT/X^.-GP>?
MU/'V\3>Z_6/O8K_YC3>.O[>VF]^P?[U=:YP<_*A?U&O5L^W:'JDWOQQOT49[
M_S(+&Y?M=KVS$6XW]^':D[#QP[\^NCSX]/VX?EP]J]>.<.-XXV(?RXMZJCJV
M\[&[??RE<U#;/VO\^-ZN-[^%^Y??<+WS,:U?MH[WC[^Q>JV1[C>_M YJ1^=;
M=*>UWSEO;W<V+QK'\*Q/==QH;D [OEW4CT_X_H^#M-'9X/N7\*Q/&Q?UR\UP
M_!UXUO" [$7[QYL$^G6V?[F'Z\TJ:]0V+[:;[=9!9Y/L-]O'OE_[S<W+^O%.
M O<<U"_"\ZWFQ@"NQ?5:_?*0^,4V*S"R-$P04+$(J9@81$P4:YX0C:,D*(?U
M%\/::.Y-#JN*8BDHBQ$1$H;5A!R9.(P1U7X7IZ*)I+P<UM\.Z^Z=88V85528
M!(5"& 2('"+#C4&*2,&84=R&MAS6WX+ W6&50CD*MHY(+ 1H:TR05 J<L!@G
M8:RI8X2L!.VT>[+S:X#.T=E?MQ(,LM<)R6WW>>?BX$=\:@B+ZIV#D\9Q%1_\
MV#MOU':.&S5H[X_-R^U/C;11.SJKDR\MN-?)=NUC J-)ZM5#)Y0&WA AS:A%
M#%.-C)44N4CR1!B8[XU:";)>['K_L^*Y]M]WYL'Q._ULV+.N7_S9<CK.)^HX
M_;GV;_@Q<JA!<$0S%7&M&(<7DL;.@BA""<R>V,/\ 5??Z0\NO/@Z:1>U7'K4
M&KRGT>G@PUD:#UKO<1C^?ROY=6O_[I_J[MJ_3>]O^';QNKC)U:W6_CWP9'M\
M1Y/W!]FLW=:G??=^_.)#G/9/V_H". %HA4/YESX (S^")IAL,,@Z[SFTX*?K
M#5*KVTBWTZ/N>\\/1A]?-VXU+!HX@&$8Q.,GCSY>S3_Z>Q!/?J;DJ@KO_SA<
MQ5>?_9W?NS>^8#Q&IX.5_'O0*S\8_[-"5^YT?-05?#H(<C<E^%>8__=A]/D@
M.WU/)CX\U7&<=H_>AP'.'W'=AK_S@9HFNF+H_/V@61_R@2K&S#KO^*P4LAM?
M#BW.>N_'STN >:%$=]+VQ?O_UP3:V \:[BS8R3JZ^_\J?=WMHSYPM:2XL)]>
M.AAW>$K^YUDQ& +NDXMR-#B8^*'=:VPV-VK!;K/:W-B]K3(W&K\HK=W=6-_;
MV6QN;NP&U48MV/B_]<_5QJ>-8'V[7M_<W=W<;BQ0%]C4+OS0 !7=HT'6K02U
MU?75@(2<J7N;?4-MY *IS<?MG7K@_8!NUO6G8/12&XS< Y@\_!X4)R7XOT)1
M8YG%W ABL4T(LYQ(%TW=T!1TM?>X?+I^+;/^;(U!\^(4W(0BB^1E9J/S+7(
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MLL0*$1AN@Z4_#@I ]KK\\V3P])F$^34#:;4/TM,B4/3&)'5$#S6QA%&2(,'
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M ?##K!VC=I:=W(;B\83H%6($J*/2HV,+_]I+?\+5-\\NW()?1P6>[CA?ZQ]
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M$G&\0)&,,@RYH'2E-.EG-^F[A,,02PV/,9ATOA\/&Z1";%'HE B539R+(O!
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M??<;[KW'OW1PYR[?-S?ZJX%_V(-NGH<,1K<?M/0@L*!W!A"U#U_*NNT+N"2
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M(6WSSKCKIT6Y(%GAHXT!?%$9,%86"]XR2%X6I9ASAL^:R$I%360W$N7W4[A
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M A;4X)F*4%$MG38QUY!J:QL=[TM-$-Y("-^)'$40OC,(7_3"6)*01G"PGF=
MZ2T$I1ED51,DYJM5;1L6P&S?B5LW4WIT6M-:2"5TD7=^D9NE.RTT4Q+-:>S.
M9N?URGATW!O-&RN-AJ0_W9/^]*F5U=P,/XXFY#E7YSE_WUF4H&1 :ZS+4$R6
M@,DDL-H[B,EH'813(N>6O_;E[8=P4.S;11"O7($B$-\UB!<.7J528]X4H>8M
M!5#X4C-86\ E7C!Y'R+W6]N"]9VE5@\;">*5:U $XCL&\>)AJY2R"H6!PS:V
M5HO03D([2-60O)*T%ZK)4+RO;G\<FD#<11"O7(4B$-\UB!>V@U)QIJ9 ((W.
MU1,;#J'&5""YU,%Y7H)MAQ1$WW2GO2+I4'21:W61&ZY#S9MZ3]_F<6\P5Z/^
M<5H']<\;-?9>80-V>H][>H]5]L3BKC//^O(0Z51S_<=1C4_^.9=>\W]/!M,/
MO>,\?3M*%09_YLGT. ^GU!KKGI38OR/&-C+F^<P<>S-K[/YM# HF5Q=,+FF0
M%8K./ 0#,;06GEP+\$9I""HKB=(9)?36=DT(:03Z&J'Z'_>KS4[JW=;/"-\/
MC^^%J@6M,H:LH+@<*[ZEA<!%J!\J95L3C!2\S3_G2\['+(2"!.V'A_9#"K8$
MZ'L'](*$&QU#E;(!B5D EF+ F5! 6.&YJS\T4FYMB[[#6U?S$ZH[Z;!7(.&2
MP^X,OB\Z;.>%K\BVX&;3<V0.]3,?0185-5=>>FZ:P[9+ O+[=]A?T1#28/+N
MR']H%YF_S ;TRL]?N<J.9&L@SDSSN/++V5G,QU0*=QWFOP,%9K[PU!EQY=3^
M:E%K$<R)[+@#H4.K@[,&0HP)?'&\9.5B2JII+7;)Q.VK4SOMNW<2NRLO@2/L
MWB5V+X9EB3%NLHM09"HU[>(6O#>BIETF!96CRMS-L;O8U)2PN^;8O0,AA;![
M9]A=D$Q\I5@1A &96E?/4/VNJXL+1CHAF33.6#^33,1BOS_"[IIC=^4%;X3=
MN\3N1;\;A)2%60<L<@:H$@?+6(#"L\V,H^ !FQPBS>*9R_O'[B,KJ3C-VN<5
M1%0U<5\Y^YD4.Y=KS\Q 7',MKGF])#\O"HUULPT57F-\&VMJ;EM^SJS/K1I"
MEE98>^O>W[2QTD6DWD&&3DA=#5(7JAH21V-DK+% ;-/&$<&Z-GQ<2Q]<#$K;
MBE35G0$CA-2.%S804E>"U(7<FV?I$ZO)=I"Y5*3&!$Y9"<S'8&5(N@15?:JF
MV5X;B=0[R+X)J:M!ZI+" XR>:8A*!4 7946JY!!KSA(P:,N]W-IVW:D#?E1;
MY*^&XUPOXV-.9V<8?O.#8:^B[[8'%QZ!!KB"'/R2BJF_S?)#-4>KG#H84JW4
MG5!67$S8JZ%2%%:#]5X#,I7!AOI!,U%\*-HG%6:;<KH+XB )^YW.U@G*]PGE
MA9E<MD:#OF@HLC3M+=7<7@H+A0<E YH:0XJM;2O[1M]ZKC<!NI->>@59/7GI
MAX?V@@200G'UX940&',ML? UL:C01EM4RD+PI%K[<M:W8A':Y*8[B.J'%  (
MR_>)Y8MNNN2B3'8);#MSA%QS\%8HR(5YSU*RUF'7W/2CVI2_9D^/QZU.KKZW
M;%O]_=%P]'E3+"H56CDW+9ETE#TWPC(V;VF'QABPQ;44HE3?PZR7SK92(7;[
M48"TV=#)#.+N6AD0L.\1V O:0$:I2Y 0C36 24NP3CHH2?B:)$KNI9GUC[;V
M-L7W!.HN^NC5=YTE*-\;E!>T@**%$Z%DT,;&"N7@:O[ JZ-6WBF#5N34AJCT
M-5)!P/K N1O="PC8]PCLA3G</G-I H)*V@(ZF\#%$$!C)7!I#$NQG6W%OC*W
M$?E67#MPNWZT*VS0>'==5.DB-^(B5REBF2=&=5S&FH_F'BT5L_J]89Z2HG4_
MBA;YT[OWIQ^7S4SR@FN5"K3Q2( V:7 N1"C1A^!Y%&+>EU-0H+R92%YY?0LA
M^7Z0?#$RUA*]U,I"=#711:YJRIL2 @9>GVLMK5$U,M:RC[HSI;4$Y36I;"%0
MWPNHEPU2$IEE#8J5"FIF)0074W7/RLA*QT*U?7#=U^XV+24(SEWTS"LO:2$0
MWP^(+WKF&E%EA]4S8YCUA:E(#EQ$T)S;Q*I_]LY4$(N^XYW9,2;ABBYRK2[R
MSJNO9E\/ABD/I]\ M^^Z-6/I=.Y,R)7)<^_=>/3G8-+\2_WR3-B:^O>99LX\
MR,R9I_5O#88G=?$./LUA_VYFJOGK#IMIGK^?CGU][@=#/_ZP.\W'D^JPVU6.
M1T=',Y=]=@25O/6JO/7NHB+F6G.6F /X6#Q@8@I\+@I<0H[2&Q&DW=KF->9>
M4D9.>?0&D,$=-&@A,E@/,EC8;E:ZIM_MI!@&#5B$!!=,:?DWUS&ZHD4[+H9]
M5+>>@4IDT$4RN./A-D0&G26#!3'.5H^O!3,U<9>J1@:J]6VK@8+F6.-NC-GQ
MO+4ML6^7J'%$!AM !G?09H;(8#W(X&)D4,D@BR@9N!)8#0^L@!!JPB *VF1K
MT)!EVSAGJJ\MJ7KT'NO_'BM2V#I=#_:"A+-."&?5TYWN37V7A[D,R)NMT)O]
MM"AZ(?+,C1)0A,F 3 1P47FPC >18K$QSO:9F;1=\644V:Z!YD4XOEL<+_1-
MD"4KFR6@0E\_N  V2@\\81**EXRN;&T+[#M!>M5& OF.]"H"\IT">?$ HY/6
M16/ EU+32VTX>(G5*PO/,.82BDDUO11](:GY^$8"^8ZT)@+RW0+YHD<VD47G
MC06#(52/K%3UR*X ,S(4QPI#7H$L>5^[Q>:A)!-M<LE2ERYR7:]PLT2IA=HN
MT9S&?J;95_<K0KT8CZIG;-LRY!U7YQV7C,+"9+W@IH"VR%MIM !?0US Z+1(
M,NJDTZQGIW(T#6LCL;MRX8FP>T?87:B-*MJ9Z!G4W*1&MLQ)\)E;2#HR'=%6
MHC5;V\KUE22M:2.QNW*MB;![-]A=E)=BM8I/U=LR*0"1&;!6JNJ&/9>."=0R
M;FT+T=>Z,\4+A-U.RTN$W3O"[L(>#\;(!,N@@JHQ,^<!:JC4^G9$I6OP)&KP
MM+5M9-_9SFS6KHVBM*XZR,9=8:?>?;-4I@7?\4EE.AWY=EKWY*?3\2"<3'TX
MRKWIJ%=Y!,X5FM:7S2M-'Y,JU8UQ<-56?U<.[YPST^'HLF)@\KK7\+I+NKXG
MQ9G0N<V,\J5FNT%5ARL=6&U+#H5SR_C6MF6++I?Z<'00QP_:(>OZZ*6 >H70
MOAA0L]@V8HV$9)VOT*YY<$V#%42ALHU>Z9Q]FQW=MX8Z9ZT/Q#O2.8O _I!@
M7U"^E(W&1@QMBZF"O1)X&Q2/H(6JR+<ZJ)"VMD7?N2[TCR:8=UKS(G _++@7
MI#'.DVU3F902$=#* B%F#])6[JX(-Y*KZLEMGR_I#D_2V ;4,:W%17;_"A^)
M$K:\E];?]58+$MC.N\KGH]Y>3NUB>_\>';6[FO1[U0T\N0UU+/6T7=((9ROS
M/[>ZQ:^RXH/>VX-VOS\?1U",L*H88?_9LH[W3O*FV4'0/M4$H(8'02=3$X":
M\T=T3I36WXOWY9(,X#YCA$]H6&4F0)RTH9QTMRHE<=)*.6FAF0@*A]Y&X-;-
MRG$*>"DJ)WGEDK8I%.UGI[VT>M@M_3OAI+M7)]8%Q"LOJ",0WQF(%]N#"5VA
M6A"2;S/K46?PR!WXRL(QFEB<#EO;0O6U?M@CFQ184&#1%=&4.&FEG+0P>B"@
M"<%(J#E/Y23.#'B?$;QQQDA,620SXR3+NI3L=%@3E?66TNBDZ4$=UAOI*N__
M*A^#-/K<CX=-\.R]RQ6=;_TX]_Y__X\5G'_;"WXRB/<B@3[<7N,=AP3=W$1]
MD<<OFZ57*X**BV'!V:-U]N>^:\_3IPB 401PA0A@R3B#Z%R)21L0EDG K!B$
MPB,D+A&]+ZU9Z=8V>R)45S9$NYR0$/5T@7INJ742]=P-]5Q,/M#QK(VH>4=R
ME7J$B>!BB* \8BJ6FXASZNE,+091#U'/EZGGE@HM4<^=4,^"%AM<2=(;!E%D
M!"Q6@L>@ZH?L@O<I<.T:]:A-&]1 U+.QU'-+(9:HYVZH9^$TB>4BLLQ!"V,!
MN67@>5+ (Q>\!D'2"=6H1W>F*4K7U%9ZCS5ZCT>N>J;!T<DT)](]'XT;OFO=
M\]G\B2)'?"U'O&2FA<\YI*8\%,>QU6,4L&BK5;S2A@=;_PND?!+YK!/YW+7R
M2>1S0_*YF 6HJ+7C7H"-Q0'&P-LQTPQ%&FF9$M)9.2.?SK1H(O(A\GE8[9/(
MYV;DLZA^FN*LL RD<!$P>P\.788<E14L."V%GZF?G9DX0.1#Y/.PZB>1SPW)
MYV+DXUKO6&,"E,0#H,0:^51/ 4PK[@,&AB'.R*<SD<],POK7[(QO_3<-_MS^
MW_KA[.\>^_%O@^&L$E!]3A8QMZX.#]2N[_!M[OD81\?U;W]HW?B&HVE]]Z9-
MU8MIK?E^&_NCWCL_GO9&I3=]FR>YXLR?I$%]S!NV9J>]??NB#(9^& ?UY9-I
M_<9QO:_)WZ>9+R[(Z66@>&+:@KP;30;->M^,\Y&?#O[,W_XU2-.W9T@_]XMS
M#>\;]O>O^% OHL+NTE]96.WY^@^&J7[UC=0S]G^(Y7>?+\_YC^WR9]11(Z4L
M/#JMO$-5/[&R$I*H%V:5YB*^D7SK[)?>?I+?W_G?,H1Q]G^ +_6.O_%'?_D/
MDZU_??Y4UD?R@B$N6\/3!_AT]87YM&;;_QO&]5V7W,CRQW^V-/?__"\?BK+S
MXN#''P]Z>\^?[3[=^;'W[X,?G^WN__"RW]O=?WKYL]N5JW]ZL/_RX,?=9SN'
MSY_U7A[6?_:>[Q^^[!U\7^_HUU]W]G?WG_=V]MO/#I[^O^WFGO_\<J8YFV][
MSW]ZM7OXND/WN!PB_]C=[QW^^^#5RWH?U2[/_[^GSU\<]E[^>^?GY[UZXSO_
M[/X=O-K?>?5LM]KH\FO]W#VT#;-9KXA/E#<K(Z\7?.3?3?(W9Y]\FP:3=T?^
MPS>#X>S/SG[IV\^1VC!]T6FUA9G_^!3NSCXQC#?$G^[!G/[A4S)X,B.#"YYT
M_C/AGCAY^8_9$W[IS[[TMNX)<^9&[_KEGTFT*[]6\T2;FU[/?5^K?2+$S:Q%
MZ[HIU[I.V+)/E%)7>M?EY0?R"]4'5]G,'H_^NNS7EN3]I\%EEXYH[N6/'WU-
M4?,L2GO^WY/!],,\03K=>YY]?__SGMRS[YTUFYN_>C"<_[OSXNFEC;JOM[3T
MTK5_N'[.4U^_F>;/UJD4LK:/QW(&$;>ED*N^U*WI0_!T='P\.F6'E]-1_&/^
MZ<')=#+UPW8C*WHB/L%%K.E*[=2+;8*%/YH!YH4?)#CCU:?^W6!:?W#OX%G[
M5?V2[Z(G;YZ"SG#Y=G14L\C):?Y_+A[X;)4N*>.T]\2"Y[9MKM)5\LK+_W"[
M%+-]@:MXQ95U(]V0A=LY'IT,5P7A!PLG;EP?V_E]Q>_\D1_&UMVT]Q\_//'C
M#SW>[[4]^ROOO5RYQ>TF]ONYWLUO3"<@KQAR9;SBHB 3RG)?&)<E*).*8^K-
M;MMYY4+R+S< .LS'[T;C^M3-G=A3/QZW':PY:^P.X]%)6[P7HW&[H*MT55^/
M+D(?]\ZV=(^?B[V/4>X?_OK'P;,==O#LY]]__?W[M[\>OW[_Z^][\N"'/5'_
M]_[79_']IRW=X]T/^^+_!@=M"_CC]\?UVC[L'[["U[_'OWX]_+5^_R?<_^4_
M1_N'NWAQ2_?U[[ORUU]V<>^7>DV_O%;[SW;Y_N';P?['[X[VCW=QOU[CZ^-7
M?._WM^53(=M+]G[OV:N_]C[NO;$<0W:> 0]M_E% #4&*""(9IX-2,DK<VE:J
MK_BMS[1<"UIWW?+LJF<GOM2W\/9$N4:<,3L;,;E(&PD]2RH(9SP64X+6D2NN
M?;1:,%66T\;N_O<7>6,>CYU+3Z\&^P>NY%@7V'^\"/M4HLTE%O"6Y=8H.8'U
M!@$Y:HMH?19B:QNQKR7K6W/KGH;K!'V*BR@NNB7!+<9%YW/]>6ATDV"(PIWK
M\1Z_R'LQ%I-"LE#:_!@LK4%\CAQ<3M$5U Q-J+QWZU-#Q'?$=]VYZ^NTFB]2
M62:U<$J@33F(I$O$PHT/O"1]WWQ'N=_*R% NY'XQ>B^\ 18K!2+*#,$)!=D5
MGE+AS@6[M2UYBP!O?9J &)$8L3MW?0U&3#HXEKP2@GETE12S]"B*2B;4!;&)
M&'%M&5%=9$2&23/E @1M:WAHO0;+?(0H>3 "JS,4?&N;H^SKVS>V(T8D1NS.
M75^#$2/CD>>$R'1!59)U;02&<EJ@\!$%,>+:,N+[A4X;*G%GK.4U3]:J!HG6
MU" 1?>7%G'C1WAG&MK95W^&CVA\@0B1"_$2(7/',O-/%)86Y6.^-0:NRKHFT
MSS(0(:XQ(2[T #1"AI8P2YDT8(H>?)(2:K(L(Y>:2V&VME&S/KKUH,1[:O/V
M<#4Q;>CO/XY&D\D_3V?_7EJ^M)E3ZOYQG?FW1;F2O<E<.A3"6&:DT2%G5HK0
MPEQL!"(726U2;[A^]I72D$^CHHBO5L57^T\7"SR8PU24EY!S0,!H-80D*F<Y
MC2(I$]"FK6W9YTL2VG_>SW%]&CQY?4C/ZH7%MVL_6I#,1&8B,Y&95J[:"RF\
MB5K&[-&4X)@-(DF>N&(FB(5^9DO"F'GT4C^\_7RLY4URLIUANA#^4-2SPJAG
M0<A72C!35 &=JX51E@S.EP+*EUR8\#4J,DW([PN-'9J-232P8AH(/@1E6%;:
M,+3<A8S:2^6=8TK'DCI  X3T:^4W"P*U$]&;A :,JFD-2J?!2L.A\,!YPJ0R
M<UO;3CYL2S+"^9WB7*?Z'V/1<*LQ".^8UCIG6TS[$D,'<$[N?H4DL# +VR4G
MK$,PQ2.@T0EL3@&T,=HZ'H/4S=^K?K5^AWA@XT\COC@9Q[=^DEN;PN'G1\)G
M?0R_>!S\"D=O-IO55J#%?B[![@V&H_%L6VF^],]R'.=JGN_'H^.?<ZJ4U2[I
MPI&[,GB?$WS,XQ'QU'5XZN6B&,M-<#K[!":+!&ASJ[@T$@*O/JI^97R1G]2(
M%>T==6C3?,.1?3,5B<Q$9B(SD9G(3&2F;I0 K$PTNW;82>'EM<++!2U,1R4#
MYQ%8-@(PIP)MB@*P(%V,A97HV-:V8(MU25??ZB?H=ABZ*]/!"+IW#-V+"E8T
MG@=E$6Q4!9"A A^2 %.,->B4\$9U"+H;7S/XLC[.*U>MUE>+IPH),A.9B<Q$
M9B(SD9G(3&M2MG.6QBS?IM\=_IW,M'COH+SPXSR<GIV]HJ9+U\]M!DMD"6FU
MLY(9D#4_!0RR@%4Q@9;.1B9CL ZWMN7#3BPE2*]'A0Y!^B$@?5&NL%[$['0
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M+VMEILN[47=!$EMV1/O[T;CD0?T6:62K\S>[BQH9LTEIRPJ$67%IFX7A,6=
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M"]_/T]Z@0N4XWVBZWZ,8,LI*4#JSTG1O=*QXI@6FS&0,L09R<38E@3,^GY+
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M8I9OPN\._\YE6KQW4%[X<1Y.SXY+T9G/ZZ<V@R6B1#;(140$CDH 9B$@V!B
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MS<QLDPOF#&3>@4F ]\(DF='X?%1!W+"9> ,#\Q?,\MRTUC<JVYO!6?5>S6
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MN%!>IP+%.>8[K-[DZD4"52M,.#:?3,=+)]]/P>O?F^<3;%S^.J8Q0W<K_?J
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MR/)T>VCP/YC2!$X\&I#.UX2_'Z=6:6F2G&0JSPAC/"+"@-<94>Y2)7 ]EXI
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MB*0"$8Y!A7(4(V6,1%&QU,-=,"H!T G?Y=L7F]"M]HU6^\O+]Y9:HFWT2))
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M9'OP_DHJ+>ABOE^:X^,$FY/L*ZL-QV26S3';7C0^K=[DXJS2GZH&L.G/I(D
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M4VMSP.4F?9.NS+X9V.K@QFIF( ZP#_Q47[KPL&H4/S]\ 6%;(2!_#5M+U^:
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M0S>8^N![_6'/F?*D9X:^^B6U?/@$H#QLU:/(R_$-TUVWMO> :D<G 6@Q'E\
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M'X'D@JI?R% PV'H<U]PJ'*W$S!D3B/):=6K#%HCOBLFNP3KSAEN4PF00M[9
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M_LXP%$E@QI!@"Z.?/.6[[%)GY'(LPV6.GR:>X=(PAAM[?WYD-,*?J:[D-+P
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M^FT==7:6FN^I#C67,E*FP[(Z/)V/+I4MS@2)@VDJ)3.9%UD:32=+XWPYG%4
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M&M%'JK0D6NG-M.%?DHJ3&CBUKV/_8\<NQ>^W(-#XDW2,\H]J=S,9M X]>4[
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MCK/92C4LK*JY8 >E<P=CQL<+D-KDD*\]A5W.O7 $R^FJP\ $ E[B6<M<> N
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MG:-<VD;+:+U"O!,O5;-P+YZX.@2*WTDHGGBLLUAG\Q??>GKP^-VEGK:2K4U
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M8FB%:<4O2D*\ILSPN%GLPCS&AK?S3M!TWD($8=#HKW=6<$)0"!^LYP8$W:F
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MF8!TN]/Z-PM6.&@ \] >SS['.='NX-Z=_K9(\F+W]9>=O7=02@V5MF'[XV2
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MK8,(5SI.%S54TDIPQQ735%N.#*I(7VK8)#%>+C4$$X^M] 00ZA6(I06@B,*
M4RFIK21D3*1D';TNLK6>^OQB(L@(&OR[-7@\G4S<GAL._OSS<=-]ESC?G!T<
MJMG12<^/?N9(:@>=M4'Y&"XI<5X@+[&D#A%&$9*T+R-LBFI:0S+L<? IJ.1
M.QH<#,\]T)6F0!"DN+$(,82"9JJ&F, -8D#?8&C<#ZX8+M-6@!R#TB"'#+44
M:1T<64:-]@I:*RFB%PA(YN&!P]_ZBL(-*(>5B@)12BI244"%BTT$GH7HPTJ
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M_!O_S_7AKG/&=&TI*^VBV'&@'H8P;;@VV$F@),09H7)!3H(K9(!K8MC,"IN
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MGNIXW&,(Y?EFC@&+%!7SFJ&@-$7<.(K J$0D/7/!4BVQS;NA:GVVD../DRT
M))!_BKTTG,6D"6"6R379!(B_X75 [G'6&S</]KVRVG#K$/@Z8),DT0A\'XHD
M%0:FR$ME[)WK_;"(7+&2_NN"(;F=;BR:GW8JWW[R0,_A6H\#@8\\A 5GY[6&
M)2FX*)YSI2WUG$2F"7B0E'EFL: :\_F6;+OUK@Y,_@"@O?W>/-VGU% 1I4;2
MY%K$&NBVR6G]TL6H8:Z%X.J&P.3EE-FQ/J]/?AG'Z[HY?;4-#,B-VIV<H9\_
MFQL'P85G6;J_-BZGU4[B=C,QN\:8.^4[M)K-92>N+4BXK"4JIB2=]HISGVR
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MCF DM0:GWE&+M!,:8:&]PMY&37S>^Z4-0QY<%'!A)7G$BH#WJF_S_*5](@P
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MC$2!&;1!46;F<N;[1E8GR/9F>LKH78R+U%7&KPW4CC9%ZW0_<<8XC;D.@,!
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M-7&O#$"-!E61M$'>A<K* $+?S9[)I<8LE43W9]RT\JO*W9CR5F5F5C%. NR
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M'O]_]MZ\J8TD6Q_^*@K'G8B>")+)?>G^O8Z@C=OCCA:T;=R^\ ^1*P@+Q)7
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MJTT@6V$N&JZ@>&PBLCUI)=OIM[YE!6LE3S8.\23V#X%70NMT,+ST[UVP^1"
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M12![]JAS41W%2FOM[S?PHWN\;UMOX+&K?5GSOG=Z5(V\^F_A@_)F(?]^S 0
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M*6[:!8#C.?6-OSI#PW\AG^9&X?)',<<[E<*;_[LRKN97[I/LRJ@4QF]@V?;
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M,G^KIY8])B'\X)YM/YX0+M[FUI'11QT1G(,&.0^@K#$.R&%E/>;<!@&$ *B
MIW1P>ZB35B7#G N**,LX2 $ME01#FWFC(]7JMHZS#2P\)C7 \^QJ(R-622'+
ML$ \8H]THAAI%8%0B)6<N>FP</^D0A,$T!_!-G"NB74*&R(X" 8G(C/X-LV_
M083'HP&1D\.=3)*"/8Y(PH (/%#D!):(&AJTES2'U5Z]%F0J(F0M?RU\R^4F
MH;7>L7M'/=!^?.O3:1_TJ?/6F]+0HJCVH] S:&9V9!*LWN7K=5/^NOO^I4)8
MNAH,RU%<S_9SUYEL HR"UA,*W)VJ+AIM[JH05T[*G%](L.;>$2>HYYA[2KV2
MPJ=&FWLNEMUZ>]8^V-[U/ %H8XL8R]D[1%CDO.?P(S<&IS(QQ3)LSS;6YX9M
MH3!FDA#L#>,XIBR\'64D@%KG$S:-T^XY:>#BPV[$.7E.$928 QKP1" +.A3B
M 8>L7^,0U,WM0!ZJS25#4DI6:*Q-CGAI:;$FF&D@/P+8T&ASST@2&UM^5S)C
MK/(4!>8#$(($O0ZV'3'/0,_'SO#H'KE##-.*12UTD$;PX(TE43D:70H&7A2-
M'_=9:>#@\R[(8\JT] A@.N7)(PXY(P32(*IC\ $4?E[&_,[CQ_WCM+N7T[_?
MQ:,(ZME@I?7^R*_>J-5M5JF=4RN[KRAJV05\Y:7\M>DW? '>N/OH;<"5>WNY
M\>%)?-@DJ8@-Y9%0:W7@,7)')2><,A\=B'--&CWN^9B5M _>[@KF7!2"(>F$
M0UQPAHPD@-\8\Z2-\Y&:TGC]$1';)4ZEU$ #R7-AA$V2V&0BJ T^6A\;1>Y9
MB>#K_\_>FS:UE21MPW]%P7O/&S,1*KKVQ?T\1# V[J&C!6T;MP>^$+4:82%Q
M:VD,O_[).EH0DM@E(<'IF:9!RSEUJC*ONC(KE^,8@G;>!;"Z&=C?W@&9-\8@
M#^MO;8PI6I)S=NX@\P#1A8E\TFH ^'9F=Z8;%+M]CB%(@/J#@ +GHRDWZM N
M2*MY\M(S3H,I 62)LI-CKT7T&&3%HN0!17(V%+(L&$0PQ8$[:2+5^=1VCO@A
M@-HI+1/8%P:L#FH)#8DHZGAD$G:2$C^6)P,TQUY;94UNGXP\4#P$%J% )F\G
MPBH7)9&49?R@CSNY'X<3P(]6420&%K %#"0!WVO/3 MYJF=J;@P'I(UC951(
M.G$EJ-4L8L9HG@:G37G L$3A9+EJ@09F$X/.ATRYBU3N7>=,(HA$SP@1,5%-
M03C)'9D!C_=+)$(C-Q) BG&E)&RCBE.5-'$<MJM8VJ3+%(*#3\>Y]PQCL$L%
M()^YE1A'8&\8%",.\!XC3D6@N>(N(;B'XCSZ7-H ,% 'F. "-]9:+ EGUI!@
MX!4:2Z!8HHP4":D^<AXT;&#&@2D4-$8NA81HS,E#4C/EQ,:6F*=+F\'VZ(4E
M,4;%<QTD3RU6GAM%B.'NOB:$I0S,409XG\EPRHAU*#F#,YN%S8('#W-E*#8\
MP*Y^2_'C^3"9LC_ (_L#F+7N#_!*BH9]'!1(?>H!\9?W_WGV";'"47AOO'.>
M@U'H+0T6B!?#A"G+K"L= TN#TMU<N_XX=P+$,FJ4F/&(9]ZEM??(R<B5YL10
M*^8<V(,-8Y%9+Z/A( 3>FDA]HBIH'4GDH70,+%,&@'8'#":6$@%)FQV+L K(
MV&Q[:>48O.&$(7?+P'-9=I!@A%&LF0B>.P<,R^6( 6$%P$-2K&39RQ2)*W],
MK30IFUXA2C#'N1#(Z002HI.A+%D*MOJ< T><%F!JV>2]ECR9Y)CRQ H57:(8
M#,"292]1!O8^?#V.5@5I>4(L@P$']4,."XL(=3;:&"F5]FX9F,&R<VU7>/V/
M/]Z/^@ 6+XT:#A:MAIH#SEUI1-N)F_UOY1/@?L<X=YG[K%WS]5N(^3J0LEL#
M]QY8PO6Y$7LQD.2 WVK8[(M2C3* VCLKDHR,^)*/+4_I"(SKV$7*1108"9,C
M]CAQR%'"D"4Z4*\Q,P'?'9;Q^#J=":#7<"K J 9.CL'6X=XJ;P,-*C%>\K'E
MR0 M.+D'=-4,@)<:FT_['0**G)#'$D@1EBDR];C0G$<72!&."((C6&:1:VN=
M ?0/-@IAC6*:EGQLF2)Q^N.8XMQ;+1CD2 (SS>;C$1T"XJ".DEL!U,G,N796
MT#Q:;;A,0O'(P X$;%(.+'<B>**\Y&/+E(',R:6E*06.L.4"^%CFY,E$A+4D
MA%I'>")WR\ ,/I;#[VI?]F?1KJ?G7C\N[UI0 Z+MB0+:P8/S.E'IB>$@[B:Q
M6.9=+TBJ:G0?-AOK%)A=RB$E<U0 Y189)PW22N#H-/Q'^8TM\>2\ZQ>MGD+7
M@NHO-4='8M O _R>P-8N?,I1(5&3&!,+) 99,OZ%*N N 04\)A8[AKE"*GJ%
M.+8,E,X#X?,N40NX)YC-!UASW,X)9@Q4G,IDP*H0P6*P]9*3R1))12J+Z2Q\
MW0\.CV/D.!*&$5C9''$5%=))8P3L7DD@6=8FFM=]<>4O'4Z12!D" U;GI=,R
M1I$"2]9R H9@R>R7Q^IX[LB DP'\%2E7I#.(A\+8XP0Q6)@DG<1!Z8TM=5]D
M)E"Y1YW!4,(,UXD(8SB C5.4&*$,93920(:2W"]1#'+YF^"#X IXEQ4!(^YR
MN05))(K1@KG/..=:93%X5 7,[7:[==FJ_%7O=&WE8\%I*O_IMW$>)$P/?;#C
MG[SABKTU&7OB"_UNIR?UF"KQ9_2]/(IAX$0_=><Z:>?V7!]X,]3;\ RM=F<=
MO;GC+4%/\HQ]!Y[7Y[=%"OI@\K^T>F",%'973E<"%*^\A^'#?#?K%A2U?=[J
M]]D<K<]_OL"'APL#/!"H)+S[?L8G^V]=?S2#P_9_:N]OKN9@(<-$\\1'IF,U
M1RN<'?!PDVJE&.C@KL5(-H>#S5_(T32Y8%(]]WB\=N:W'GC3S:%EN:@.@5_\
M20R]1MQ/M_4*/,C=(M]PF\"?^P=?CY/"011QFH;87*L+(VT=[%FN")ZUAI&I
M-H%>AF2428E9PE.DAD<=HE;14.&5UI-M K,JI5R&ZZ(PFHHFG9T(B@1R#"I4
M-)BI-XL.IZ$0-_BC=98[B?I8SVW(AP6Z,@[.%LW*/XL^L*T>J'SH_.O=W?T'
M9^./*(**9H8-W?O$6_]G\%C#B*\V0"L"K&K8\TY\-_SEUU#OG#?LY;MZLT"<
MXDN_W@QNRF%0?^<&S["C#I"P ,7^V]<14INX'R75;<._87CGP=N;Q5N_=,/T
M>UQO2JQN?1MODEO?N^NR!&\RS)YTV;O?8YJOSV %N_VF3QXLV93$K-%@Z<,6
M[)="<OO2"PJ2%?3_;K"-ZQC"HNWM.UPAA6(.KS?ZJ)GZ*#W_F3_\ZW3TY(1"
M]75I^5US<9]99(]1K>\IVLF>HB*&,7N+*@Q71U U^;QO8&J^U'\^<&*>*SS7
M'QU@=<% S[N5HGID9?BHZS5]F0L]0'P>],1O;N;(/!3OM4Y.*5;S$:M[8,M9
M_^-[N]5K!C08HO<QIG378^>V\"_TT+<T,LLF:F'UD5\KG^N='Y7S5JM1K8!)
M4.\6I!I^;]CZ&=BN?6_3I'#=-QL/EA!<6?$)*Z3D?Q;W_.//W<ZW7*D'?TP(
M0R">&TP$LYXGXIW$5'NC-66",7=O"[B;)21WFYU>.U<@'#35ZPSZT+X?B>AV
M,[PO9'3@$-V+W8=Y0-F:.A(.O_W>.3IH\4-Z>%4[\!<UN/;AV2'>^VWO9/_;
MX>71V2X_.OV!#PN/YTEC])W__G[BSD)C__3D].BT]G/O:OOBZ-M>_>CT$SZD
M.^+H]/>SP].3L_V#SZ>U@T.\_]O7?(;2K7W!/_\XV.G6#K9)[4/MZIAZ3V+R
M K&4HV%"X8D@!EG+-"RZD]2GC2W"JYR86RH6+TR/\KN/U*>[-KC[4'YRDRSQ
ML,3#R81WSI@/@7)N*7<ZZH1#%)Y9&:0UP3ZNR':)AR^/AY<3>)@[6 0I C(V
M-T?*/39SMA6R@5J35!;\HE!459KI,^82#TL\?%-X:&B@(G@CL>*<*N(LX4%8
M2B,FH"[\OF"($@]7# _W)OFA\)9$%PWB1+I<_%8CFVA DL,".^ZX%+GFD:@J
M/=W"O,3#$@_?%!XZ[Y)0BK*@#<<B H?PF$GO)4L.CTJV/;#E0HF'+X^'4_P0
M:Z$=$,+$/$.YI"OP0T41R<F^@>CH<O/,C(=F.N!L1?'PT>[15/RS+N[10HF+
MV(61?[1FF_9[$5=4Q$%4*\TXY0X=S01]W$S,1//50[5_/LKL%<0Z'GDN'>45
M[/PFT5QT0D2L(L,/=@,.PX2NY_]CC#L_SV.S$TML>A0VU:9]>4H:&BG+Y094
M+D6B(C)*,B2CSXD*.NA<V4OR:4?>OQZ,2;-5?Z$T;.*6MYYEE7I*DR-.@W[F
M?K\I 1F1T3B&!<6! 55_L'NJU--YZNDDAS!$>T\L13SG*/-D!'(QMP+.3?M,
M2IS$G+PR72VF5--7H:9:&465-M8 :Q1*N-PB@' %FRPV;E"HY2%>DU)-YZBF
M4ZX/*KADS! 4$A4Y49P@K3%'RF$L,+:\:->FZ'21Q%)/7X6>@@FOF?<FX>1S
MS743H^24*,N3BB;Y!UOSI9[.4T\GMU/*9"*<$Z2" ^ZK;4"6&XJHEY)J @R8
MY",;O")Z^LJ#D0HM&Z0'W&)N/\G2GC$+KQ!RG 6R[A1USC'N)'51,VV(XT(2
MJP,M+>WE0\ZG&5$S)DKLDD"!&(YX= 998/0(I-T$8YGUV ,UF#X1>3CBS-;Z
MESSO*-5TI*8V2&,CL'?"/0\&.V^P$IC0( (/#)>&]HNHZ20SL!$KK2PL0@1=
MY=Y:I'$D2-A(F;-12!E!3:>+1)1J^BK4-+?-%3I$";R=^Q",RSQ>4,88\22:
MTM!^"36=,K0QD'?#O$/><HRX#0Y9@3VHJ18,)Y<\=KEKR73J?JFGKT)/(^?2
M4V6#=X%3)XPVW!K,B?)8$"-+0_M%]'1R.W52&L,L1E8Q"ZP7E%6[0!&)PD5F
MC#>LZ"XT7<_X1?1T8&A/-!(AO-#">7O+'G"-N65JE8-\G8-\Y9ZA(DWM<ZXN
M<=Z='7+QP$B80<D&!K,:6KU< .+M1=4]< Y6FR,\QA>?7>]:"Q7R61EC-EE/
M9(B6ZN2928]VC-U2GZ8HH3F(L^M\;+?.QFO7?*MW3QY?G:OD&P_A&X<SXEF4
M"3ZDB(+'+.=B2)3CZU#RQ 4PX"BCF6^PJC1SCCU^F':M1_QQB99O#RVC2@GL
M94VT#%RE:*/53!K&/."FEO[1_LD2+5<.+2>M,Y5[=VJ5:YI'L,Z(I\@(YA!V
M6((5[8/4J<A<$WKZ)+1$RQ(MWRQ:/JGN88F6ZX264S[GE'14WF@45/2(TT20
M$R$BRV'YO?14V)S'P:L&3Q\/E6A9HN6;14OLX1+2*N*]X"$X0Y@PR;#D%671
M/CS'K43+E47+J8AU0Q4LI$8VJHBXY\ RB9<(I]S?5M'$4BBRW@2;<];;8M&R
M\+C^4M2#G=6&_)ZZM:M9-GM4K_K$_ATKMM*N=WZ@W.LQEP$>U=/NE]/V,#FV
MWAQ\OM7)>:6-SJB9>U%0NM-KGS=ZG>*Z(::ZKW>+1N[1^I-AT>GA5XN:8YW-
MRAPZM70G*H&WHV]];\*<A.*)BCO!BP4\C!HJU<<JAN>Q/:I=US-K78F7P[6W
M7?^_1FJG.[GAKK92Y*K_.(?D288 6R(BD5!-30B:\NPLO*\/Q&-$YKGE@$J1
M>4&1^7%,G: Y5A,9FAS*]A_\1A@*!'L-OS@;9:Y]=F>#WL?*S'-+II0R\W(R
M<_7]V#'A<3Z3H#[D,PEOD&/&(>EQ$LERGW+C*2IFP$Q_JWMR=^]GEI8HY>;%
MY&8O=PGDQFBJ!<*:Y3HZ02)M D:>2BZ]8J+(S69D!M;<D)M1DYK4:^0F-4!R
M^DTF'R-+*G')A0(1LH'GN!U,HM&".1VP RB:W3!R6H0^Q!1S^XCW\"^PPNUF
M**3GC[IU]4;1@[ 4D <)R-6G8^*,C))*%(D$$PMS !:,&6(^J10%YA'G6&5Y
M1P.C1V-*MND$39[ EL03[$(B,AD\-B* >9]B(0>$4$9*.5B&'.Q_V#U.08%Z
M4HM8I!YQK2UR*H"]#9!/B K)Y0U&Z+L:F+?C&5AUN95LK]OI@E04IE]AM=UB
M<WV(ON@0-'B+5 =6V'A'K.F.H7UC=ZOH%[!^O::>:J2.=1%]U 8.0$^DM\ZZ
M"':FL9I3JHEEWLIDQ;VG#%-:-ZCYU/G8@OWZO-?V8";'_01&,SS EV[17:G4
MNIE-F*Y@+!>P+8,9\.ER[^KKL<0,N#=1"$Q^V)Z-P\C _@P;M:)).L6 JC_N
M3(DHFWP S?5 \SV8&B)WB,0.!V)U$H_V)I2K/;_55IQ1:1E!#"QXV&N) ,./
M<N0C['_$18SS:IL9'/X>4M]M589+4]D^S\VW1GW8.GF)*@D(=<7>:,JVCFWZ
M=H%K!-CJ^Q9P2K#+@TW0 2K:NM&7;E9#ND''NTXU-QQK](J]Z0/,PL$)C*M3
M^<.>50=S5XMA]*WW+?1^9[^ Z#]A4ZH'T 6X=3OW*SMOM7.?LJ(762Q:K1=W
MS!<&G2P";XM&9K 5=@?-!&$G'+0[R[3IYL><[=0[N?WC]UCTTRX\I;.>I--S
M,)"Z;==S";&BB2A\/H(6QIO^R]""N6FVNI5./+?M?LOI4._X1@ODI#MF7U5<
M[%[$".O9 TH_-K&#B]\YA$KA)2V,,Y1[!%[>N/3#^GVOE)0!U U;I)\5O<MA
MS:[[G><I:;3@\H..=44GN$*_AHWKBD:)>6D>TD!]1O]T-+-S>G'CXFIR\FI_
MP' JGZ]'DS\Y^1JJ# SHRI_]X0TN>R?7FCZ:R.M7X#A7)E*P+J6PA@OX13.
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M]+MG=PJ :1;JTPZYSO4UU1X.8G2_?(=JI0A$*!PV<)'^$/*B#<,8,J=N@T3
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M\I&1:PP<F5"'8,8Y0 @AL#M8S:3%4@5^-Z _=\5N[L_EFMV_9LX+1ABF2$G
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MPQ+)CUER(DC$ULAD@N Q:0M6(M=@$F P[2-SMQR(EDL^CR4'-%$<$\X,1H2
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MN_7.5)ZVZVX)@.W5:#/@*MC_F=E_47LM,[ T70TB)?*T".M]Z(H;Z28( M,
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MY%:]D'$"$T-?QT_"6CG&R7FZ6-G>3Y,2Z^L_L,2N0VN0+@H16[BY DO"S9W
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M2!*(7EJZ4#8<N_/7E#IF)3Q?*&XM:EW77F\?M9Z9NC9W"'UB;MBQH]BRC:-
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MM%9Q?=E1!2^> *(-[X!H/JG  K8H8[DHA/6OQR,(5ADQH]B[<? @D>"O,L[
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MF W41$ K,3,:D 3WS7Y!L1N0G+T7E053TDR^@[#X^,CJN2X%@1]R&00JDND
M "7'&"B'046PJ%^YGO%AL@),<IQ:7H9Z4)%<I@'+H^@LT+!!K@!1.S%AX(\
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M%S5@, !_((YB[LVPSW">659CLU2F(MK/#"-Y"<L-8MS18"R"8"<(W5G$U.@
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MGRPV^=BDS3F9KUAR[PBG!00MBZY5'X\M0BY<@D?ARX0)R8J8J>(TBH WD.<
M+@&E8173*YBC58$ IR+2("5))7#8/G!^LZ=.%L]05AW-+=]OPTSE^PUC5#=^
MR7F=S?[8MM6)S5DIBR>1E%0+Z$I->%-DL"TU.9-%XBAC8")>&_MI4@G LP&<
M+0FA"C^L17SJ[NAG@3[", 4F=XQ#=3?D5G*Y"FUH4+;<*>I[G(H:5L@FA[[+
MQ* X*EWCJ-0\BJ/2MH!S2FQ50; =:$)O>8P@>'1&QIENPS[?R+A]EAW-B5]
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M@/+L-EVV=ISC LEG_)C-N&1+U1*Q(SQ\.DRQ@3>K0U/T8];6BI%[D]AY3ZL
M9!W!ADTSA"]+(6.(26<TC77>P.YH/N_-RV=IL)@\'JU:S9@C&(%QD*[)'$N8
M8LP#6(LOH\7#)JUJUSN<;*]\NYGOGCB6076S=]Y;FT@1R (%SZVPMWLZN&/9
M.S.@/ZM@/74M8RQ^JL9OM?CD#1C59G=JWLBNZNB>,YE0@(QE_;OY5'GI*^/I
MX,_E"(?]2;<:;2&Y.&E(&2S-.OOAU">\2^7R?=W#:Y)/>0O+9?R0T;KM:$VT
M]$?,6S,CIGT@_KJ?6Q,,K#5(]0$L,H_#F&1,ZLT.5YTU-KJ;<WZ8M)G.QTTL
M$7,,<?<@(]B6R @UN92P+E_X%E\]\!'-X.]!FHW2#+EX5,)/.<U[(%!#FBUJ
ML=GH/5CW&N1C8B/#>-QI%9^]+PFVR>3[K&3Z0X/*,CHDK(VU! 87#8KU>KFU
MW&Y8R5<99:WW\BDJP-:_\./@H6K(=Y]*W^E#G2@'^$%EG )^*6$Z=Q"4O*XP
MTGNCB3?\Q2=YG!\%&+^@]D;0?$R!+KUQE=3%$EWFZHQ=:^%\\ $;*#)-S]ZL
MK2H8,"VS::!- ,U4&3_)9TI$NH)?)8VKR3B7?@."!H('3'VAF#:+&'B79O"*
MJOS&967(>0 &BQ/XPY"IVQ48V9UB:8TS\+8VO-Z-4STOIE(]CU^Y+N@"V^3X
MC ;H78;8A92#:B8KEFDI>](,>UQ*'.BW,EBR!^Y\L'&GN:$'1C-W7N8=E_'4
M#4I=N0JU5YU]KK>4)7Y(3WJ[;!),IYFL"C5_""(R0&$95C>)*GT2@'W]P#)P
M6,Y"_>=Z02S+IJZ4^%!UH417!A&C,'.@2D.NF)(K?M1!^&;92%)>"I'&YA<
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MH@_-((C@SR/B3^;]!55T:[%IU[WH]R5&^H&\SJ]_E:7KZ_=@ROSK6KH&6@L
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M?&K#!HZ6B"JW%CDBJBP(8R' 3%FU;<&W;46/(7NF)=#35O2(B+) T"E'E+&
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M4!PGX"OF,Y0)] :BM63.R,2"3._ HL7'Q7W*+7(NS9MVXE/(PUB#/-:3HRU
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M>Z:CN9O=T3I"Q?8'0.4"4I9& T 8D?(1:/X09]!ZNO4/W)K>L]1_8' (%@"
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MX_66"?E)K:Z5!(\24BR/%,.R"*18FF*F;*FZ87"*:::L&],4&R^#F^@X+DS
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M[FYO.KW.4_=N^/GN;C349DPY!@E7&HPK3<J*(9TY+-B2164)7!9'=F+):#A
M 1W5%$>$]G-[_JRBDS,+5((^LZP_KN#^TY$R;SBB_S[>/8V&_?N'IV[_\6XC
MIA6@D3.K5:^W9<Q*$5K]>XNC/+'H_O'NM]\Z3P]/=YTG^GV_^Y?/_=[MW?/P
M[J]?'D9_WYIU"O1REK:IT:_/TB4IB]*RLL3^8'%R)W;?=SO#S_>]_J^;[73%
MF.1,O*C7+_69"%@MAO:(F'6+0SL@<\#FCV_BD'@X#/5MQ$)H"5.:C7JCP8U#
M$MJN'\8!A@\I'LL?6PFF8^=#QW$8?N1F;.5;'"'B;LDC*689_]IU^E]=_M%?
M4D)9>]_ZHZ!U3);*#0I)Z(\'F4%0;V@8SV8H6/CC(9EX9$S--R_JV+8?4R?)
MFPQ\E]C4W]3F]E9$Y NWU6#^PPKC&3E@>98@<_($2?@M0]1*J5H)V9,(:''G
MNXJ"ED@TZ^UF7A?L0B2H/R/^.BD(/8:-T(O[G61#D)))1JM^T=J79'#R)[G0
M8]9.3(B]=4!N:5RV][/AG,R274G7)T2\GA^&OC?$=AP0"(U_3^&2T9?+UOLV
MBZ_M0[:@4]8?H5M_LBA\VK.3>%5D+^4.FDP"/$'<>WG&K]B+\<OB#MG3 5KX
M 9#YG@)7K4=R$;QJLZCA/D1PM9L (SIJO2PLZ*K%^FHQ+IVDLIH,='V/E_I0
MH##RQ<Q2\&=L8_+*S).7!9O@[RF:&W1++I_7;18"W8=\KO35BORE> *F3']!
M7+FDGH2THC2@(%C0SYT9_!!2N'M$@E^0&V.*LNO/YLA;A/>$8K0)V&9A%+ ,
M[7?=O[?OI52$&_4V"P#O181%URW1=X8!>F_Q[@,6,8 _A-9R"%9F#,<IU"(V
M2.?FA4X*TP!TZC[YOO.-N/I95A4>:2R+_J? _$NBEEF4C*T)TA.;DIFH&F[0
MPB:-*#2:K0)O4,FRHXP7R&=[-R&!+6C(=7:+.F<;\/GDT^M+P')S3K[8,?=+
M\<LYWZ8^T4:<SVS<Z;H_0K8_0+7>A%!]UPE#'(5/.-)F:1&L? ^]:.3]UQ2+
MQ='\:%%$Q\V"BGME.0;Y_GC9RILTQ>PXQCVQ8%;AL)(3N]@?K_]851UNA%RN
M"]]3_UN3FU3_"6*@ '.-3II0DR/_:.R5X13]B>7?E^4[L72KXI4S^:K=J&LS
M^631RKA['T=T_CHS/XC([ZQ[=V]S[(65$P*;X)9S^;K=R&6_2[G,:5E98I:@
M=J2L?L5AQ")DQ.M'4QRP R-52E\D**0V;;/>R,>\,\@LXED,G97@._&E>O&)
M$I'4T&TV6D5^AX1'QVGOELWQW;]B$BT><33UG4RKZDIS0P)2S=FDRC,7Y9,S
MMV9Q@A:GN-+ZI#ZSC-F1.;01>CG76^U&@>\JY_K).-)@.8^,D=^Q<X-<N$]@
M.,68)=J6AR)"\%ALRN3=2<(F5.4"TFXW*NK\)"H(O;!$-RS>#Y[L6_:$NU#0
MEZ,4GIZ/O#3E3J=F]8MG[,*]- ,45++ JF&5&V47C7P6%]!E*@482]>_^Y__
MOFHV&O]K"6*6H';B;3$7=K(][(ZB7"%<MALY0WT+F3CM)UFQ$14/X0 M!!?I
M-T&,'>&6ZHN#&I-\Z;]OY).!"4Y+(&5\%F@3Q_F8%KERCBNZ9[KXY%[:52OO
M26MQ[AB]->64I]%E9=.J&GL?M.6Z^[K=R.WG>J*Q&O?6%*<C5."/V(%[('H$
MO1"W6NBL %2JHEOU1CYK+Y!8&2Q'/?L5-7 I JG*;5%>Y-95 2>.4<'F9S35
M:OG?JJK0S;!+E60+$H(ZS%Q5B87L/D(%V WH1$3WR(9)6-P@[RLX A"!Z$$Y
MD3_F#?1OHM#$)U>5K48^P\L!K03UCQ8@9VY+^"/W8(  JR9F+4],7)_TBLJU
M&E:YQFVW\NY)588>HSK6Y,%JLZI:>2LB<N5\T6[D;)[*?,^!G#1U.9<R&RJ*
M-CQIN@-2<K&X;#>VUN_K&_JR"R?I*&?93D*7NZ EEX_W[6:N^&<#^3A%*C-V
M_>^_(X_.$,LM^?;7J>\Z.! YZ H&O!2-W*J[:N1+NI8(1:XI1?D'D:X^,4G,
M[D[6[A8DY$OVNMW,57*IF7M:I%G^LQFZ010:#D1BJE(!L39O2\"EB[)=;^0K
M\!BB&L-D95$=/2LJ>E!2)%*'J=UHY8.%96PY1L>H>&J'4Q3@W+<;5KMN04*J
M*MM0O:7-6_H34"SZZ9AK7XN9LY,M<@/4<GZWVLU<T9:$WZ<-4;7*EU<FP,]]
M=IMFQX[(ZP:QC\TIR'D.J[S*&L_<J "M+$[32HB>N+^<+3XS82<,XQG_\XM'
M3<H;%]E?AS:U+ZO'.[8F))>%BW8SE^&7R(*@^Z.5H6PQTA:C71/$3S*17Z^_
MHB! 7K1C+;"&5<[MRW8SEUS46_F"S(FOR_D1,[*C!;V.3<[']^UF+F4AX6."
M_"BY1^=B1GB%,?7TX=(JXDVP5^D67AD.N0M[U<@?A<A@8\&'%7PGSNSLQM--
M\<O7WG6[F4\;R3AZ,INS3,\4#R]& 83F;69%:'.U%(%T(5[4&_G3*0)5C>&R
MLLA.#*E:[J1 (XTH731:^9J*<N8<8TRI;'IWHB@W0B[5DA=0(5J!HR<5J<'K
M>XS#!\^.@P [=)?AQYWXL0CL[(KG6D3DO(>*FDJ\!YI60I1MH.(H5T+W*,6
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MA%Y3T: TZ':7W%<C(@-IJ*#C.5T7D5DHM/N3),^T(39CDZ_4$:<*GKA$5.A
M; O^!]KP%;F@ <5M0+QNA\6^%!F,[7 >6L?*:U)&/OPNF+^#&A<)OL,6NB1I
M])4\!"[W)DO;']I$SN[K5.Q8#)]_E]GEU='?JF@,B0*+LR*7=V"KS0.X/D>E
MP$L!3-#FVZ32EI;Z7A-V!53,< 4>4? 5L\!6ZA^+0OE'%,$7"\6T5,!P^/,?
MH%<3;;O,5"7././9(WI3:FY-#*:>,U@_5)X&]?IC7FR:7#)7.@M54)@0(Z3]
MXPH+_O"]:,HKZ1U^6)=?TJ)0@14PF* 3A<I. O0S-('D+-VCJ.?N^A/AJ"L=
MCLIH3!A[B=?.V"1N<*T8 %^#-?483<>>$OR*'F&?45T(5=S6!/85&\>)XMVR
MCKP<S6%-:^8CWVKXT;<FL2IW:B%SHUK%T[V;H#+6@RZ[OEZI;S4 3>![>EZK
M1%]JG/0JA326J]W'H2(NGC8P@4OWL0LIPD^8CI#8ZBQ0>7L31M.A6D%UB])J
M&Q-ZG;W72.L:&0G H:-@I6=M^ZHZ&!U(0[A%,?3(*UA%U">9$-HAYNPD5R%T
M9E![SN\XZ(SI1@1%Y?=^')1JO*UP&EHUF;V* Z*6O'0+.^RS[X6^2QP1Z"U\
MHU-R8\WVF$VUSK>K0[@5?>Z/TR_W5/)03.KPT9MBBX%*"$3FEH<C*[IV>7!3
MY8=?E->G'4%1<HE1<D9\,?)O,!P>U]-)FZ R-IPU8^]35#I^((<Q82=*4B?W
MV*%,<MW%7V.XV(E@AU<@#NC<2IZST8,^]-''GNHEEIY9K[#HW6P[6K_N,CNB
M2BAV,&8G^C!=0* T?F%AB)TF0).==P=Q&3FJP\9F=GP]^(H5_)VO)B^A?6C/
MX@X%< E9.!"9*^D2*FELSF)9S12*1*&X]*1RHK$<_-!)]&PA&:0$QE2;*0O0
M%$!&:/GN9T4M>;:%"3UF@>%[C>#QO4F]WLY)629?(4BR)T=HC8:ASGCN^!1_
MMRW]K'_P*@]Y>*^OVX&3-AHG/ H:FB#F/112"SRY5[@3AKY-J$B%#W.5\:L&
M-&%\7[P P[6?V/E$ >!V&HC5I*OHP5M?A*7RN DJ<[,%1=MXF#DJK?EJ3#4[
M82,"AU_DU-+W U8WQ]T ?H!:]Q2V)K0AY7?%A60K=SKLYEB^'DI#=[5MRNWV
M4L.WYTHFW8J]SMR^B4/BX3"$=VAT UX**!,V$NF!XBW.(ILTQN4J),DJ?-5Y
M\D\)=F@'7DR^>+]FL7RP4<4X-9P)7),IB I/=U9&<VBN:IRBZCC_C$/V)K2Z
M;K8JJH,>QQK,B*\JCLPV,4%."RU"(6921U ->."+[#3$9P<2:(;D94O,1U,Z
M/Q N2RNLJ7;HVW8\%RG:1'5J5:Q706="W?8S";\.?-\=QL'<C:F]=HO'Q"91
MF#XN(:Q;R%4.TC<L(&U9_O;%=E@/[RT-XQ=;^'!^\##HB%NGRFLKR]H;F]/E
M&;$PC41U/.<)1^)@I30]H =K3K:@X[S"E)8<I5>8]5JP)FQ-MSBT S+G2B9Q
M1:1\E$$8Q#VYM"D?2]6'/[@Q.)O(A3'3P 2)XZX%<70<D+25"3U/98&?B5Y>
MI45P1D["M?B6;K!L1]@-"::M)X.5"TX"<.@5EBW]W;"PJPH*8S?_0>?Q<_*:
MIA_ C?61NO);#F3"LDZ./E"+N^K;HEJ@AQ9?_E21Z)_VU5,J*!,XMW$1SOKY
M[U!9_+$/4H<N%$F,-SJB%_&N<W)+@LC7B//3Z<N#O.OI16NE\[43W(?WZ#J-
M9OTS=EWJ9JJ?!"ML:\0Z*3[#QT^$[^8\H!S7H25]>1UT8M9KOEJHA#-UK\X_
M.[A:5,[.N51YM; 8W-22_-O@72>(,)HH2CGR[4Q8KAOH3EAX"EG>$JNID@X7
M<!-1%N8YRPM8H5I;Z7/HP1[:?LL]PIAY1$7G"3MM>&-+=GJ^-X&*& B9)Y?7
M:!ZH44.:*MCE+ZA. [SIN<X56!-TW3:5']3K&F-*?[]W1!50,>..J/PFS9[#
M)@Z<7_5"%D9B5Y\):Z7RGJ^'SEBMT7G\)+)FH,^5UGM):Q,62:X>F#^^L-F#
ME46P)N04MRH)7[D-G%=+\Z_V4X$N(7=XG_6W7D^[SJ>XK0DR7UCZP"=\LY,Z
MZ["']DE'JX]^)NH7*JN'R*4;4,6WNC?&9ZP"EYCGT@RE&LZ</.5V!V'V=+[&
MV.+CHO/Q(SZ4-(+X,.[,YRZQI:47&V ZO&:'BS8H;1N:0[FP\C6 PM8F:'>A
MFDON%6.NJ=ACEU>TEK)R(US&*KV-$PV)VD\JZ4+Q B+RQ.C3QVGZ7J9X:O<I
MC\U[<N@]N;"V11E&4D$=.H#4I]/+[Y>@1@$\AACXK\3! <7_+9H.?9=14QN+
MU?&8H&JRQ]2H:_]*'1YW\1F[SAV[EXB*973K0^J"[H[P@/$3YJZM_&3/EE@-
MW5_3BPV3LVB*8^,2 !-XGT1X$(_P!,E).SL]:0>6T (>H%;E^C?#=>BUOY:X
MHJN6?D-[LHSJ:+VPIP8W@=O+VW70C!JY Q@-L3%[0\O6N).G&.K0=_&LN76Z
MU60J,$/*Q(K/RJX<D-S/<=S-2!S>!6".REI_;TG(5BG$\E1:3!_^T)IK0''#
M2<CE#C-P402FHNH^#068"9JJ.!\A,@UQD!8)[>; <17$AEHF'7<^15!<)RK2
M&&:-V]158"9(P^?AX["O>#4[V\2$/DO+@!XQG';8K(0H@3VT*\C3X^#.0A#Q
MBT=4IK $P 2&K;_YI(ZK2" .S1SMYY#IUC;W98/< ),1R;+9W/476&6^YYJ9
M((F@B@?4)4:NUC'T7%,3QK!=?'U9:24>Y=E3&#]/YL"GA3N?'U59^$R+[\KG
MG\YIAT-[2DW_GW_X?U!+ P04    "  "@PE5]O(D_V4Q  "4]P$ %0   &%M
M96@M,C R,C V,S!?8V%L+GAM;.U]6Y-329+F>_\*MO9UO2ONE[;I'J.X]&!&
M 094U^R3+"X>H*E,B964%,RO7P\I,TGRJDSY49YD=ZP'BD3H?!'^'0]W#[_\
MV[]_.3QX]!D7R^E\]O>?Y%_%3X]P5N9U.OOP]Y]^>_\<PD___H^__.7?_@?
M?_[R]N6CI_-R=(BSU:,G"TPKK(_^G*X^/OJ]XO*/1VTQ/WST^WSQQ_1S OC'
M^A\]F7_ZNIA^^+AZI(12Y_]V\3=3C7+"6BBQ!3 ^9\@Z>DA!:RE=P"++__KP
M-Q4LZJHC!.LT&(P"HG 54C-))VF"\[C^TH/I[(^_]5]R6N(C6MQLN?[CWW_Z
MN%I]^MO//__YYY]__9(7!W^=+S[\K(30/Y]\^J?CCW^Y\/D_]?K3,L;X\_IO
M3S^ZG%[V0?I:^?-__OKR7?F(APFFL^4JS4I_P'+ZM^7ZAR_G):W6>WXCKD=7
M?J+_"4X^!OU'(!5H^=<OR_K3/_[RZ-%F.Q;S WR+[5'__;>W+[Y[9/HT/SB8
M'V+]ZPQ7/_=/_/SD]:MWKU^^>/KX_;.GOSQ^^?C5DV?O_N/9L_?O"/_Z^U9?
M/^'??UI.#S\=X,G//BZP_?VG=(@?H0M:."TZBO]Y]9?]_ U@20?EZ&"]'R_I
MS\=?V<$P8<4O*YQ5W&S*R5,/YN6[#QUTD<P7)__R(&4\6/]T<K2$#RE]FCQ>
M+G&U?'*T6- ;, G86LG.@PBA@3%$S&1; ZU"MM5GE5/^?GOZ6I:TF+446UKF
MM2B/O_WGOF\_X\%J>?*3]4ZN=_%2 )L=O/MJGJ3EQ\>SVG][]G^.Z*T\H"]=
M/EX]28O%5WK__Y4.CG"2FY EE BM%'KSM&CTTKD 1'&']'^VJ,:\RJV ?;_Z
M,PQZO"B/YHN*"U)G/SWZ$[OR.=9L&Y1I42Y0Z_OWZO@3/R^/#@_7WPG3%1Z>
M_/NNYKAXL9H/+9,-&VA%N]+EU[3X U<I'^ [+$>+Z6J*ITO6EA9FBP-1%()I
MTD(T7D$L$;5QM?G 39)KX&Q##?7@J,&U_VR$>%S*_(C8^18+$E,)V"M<G2!*
M(EJE<H0LB@2398*4O(/B;$4K+#93N97C-7BVH81^<)1@D\" G'B+!]U.?),6
M9PE+PM,1K084QA*XH$B#Z0*^)D=_P$#J;'!Z7 IM&Z:8'X IN\N%C30OR.$X
MQ/?I"Y[!-R&ME>E\*Y!K)ITF:.$YUNXHE&JS5JE8RTR12X%L0PC[X BQ^YZS
MB?_UZB,NOH%8GM%ATGCALO30@E!@2&]!3,*#S\YX:X57$IDY<#6:;8C@'AP1
MF':?C0UO%O@I3>NS+Y]PMD2RA=< OU]OQ:RDJPE:S'2T!4WVKTID_R:G?#)&
MMZ"8:;$%K&WXX1\</[CEP4:45_,5+@G/RWF:76X!66.D];Z ;AV6TA*B)_[F
M(EHMQ6 6W#;HC:"V(4EX<"3AE04;15Y.4YX>?.<IU>!L+B%!*996Z5V&[%T#
MA5ZA\C9'(YDY<1$%EY7])GWMVTP;3S]9'&&]9,'):N6"H)<QTQMI1)"0JC)T
MI$O2Z-%)H;@7? MX8XKB[,B6JTQN;B'M_';T(.WD^;0>E6E:?#T'\_1];=5+
M[2)$)S2I=&'($B18@E[N$GV,J,Y9WQ=CO]L\:$RQ&B8"L.\ONS[\^GR^>'*0
MIH==9Q__1_VOH^6JW^P<G_23(!R2.V! -5>!M'> 0,X!2&S%8PL.!;?M?1M\
M8XKH,&N.P<3$&>;IFNR,$WD:0-#%HBNT;BF[!TF\#JHHB)ASM=(EEP:(^UT.
M9DRA'/[#A4$ ;'QX.OT\K3BKY[6<2XA2!C+S/!HP320BIZ^0G-9$TEA*X0[S
M70%E3%$<9BYP;#X;$YY/9_VJ^R6F)9[JL=. 0M+->Z-H@980J5 AFNBAU4C*
MRS8A#?>-Z75XQA308>8$FQCXHGR?<$$;,?MP.29/9,5(ZTPA%<+D$V2B*11;
MBW B)GY-<3VB,45SF,G!* H^TW0^^_ >%X=/,9_&#(0WQ0K273[1XTT2%7+%
M #K%W&2*T4O/;8%>A#&FB VWH;GCI@\1J)F($-"79$#F?@7E0R'/"!T9,-):
M2[:NC=SW/F<>/T#(R4FKJS8%:E&"+/1@(389P:.PF(Q+S98]AYQ&$VBYE;2O
M\I/NN-=#L/?5?%:.H629"(1&$+0T,/3^0"B"'/XB-5K5C/8#BOT;D)%&6+@D
M?\<='UCXU6&0VFIH@E2S"8K.4#*O(!<T52DA8^%.B-I"^'=P[+ A?=$W1_/L
M4[ G'KDJ@J?3(D@28I(!TCK[J+0<JI;>6\WMX%T/::2*[H[<N.#K,<IC6)_O
MS()+KKF9W"!&TL=&)0])646:V;E4<B![@]NVOP'22'4B$TDXY3&T_W<&5M#*
MMUCI0-#] E+%#$'UQ4L4)J)W07(?F#>"&FF4F8DHO#(9Q!<\@Z49;,8I#36U
M-98$L<<X8ZXZ&J=5J(+[3+T4R4CCRDRD8-A]WM2PRY<8M*&U27)132-+OQB$
M%%$ $;.AT!%-X[YHN!K-2*/+7&J"1PI#F-R/9_7=:E[^^#@_H$U>]IJ)U=>)
M5TVYE+"GF$@PHFA"93S(5HHQCNP@'8>SOB_%Q!DAD5K[W.^.;?&TZ0D]1*,*
MM) *TLX7+=CC8E=%2$9C8._.A&N<S%MM.1O/G\P/#Z?KR][U!?!\UH]JG)4.
MR(2@G.Z&?B'SS3C4$&UV(%-VUM8:177,'+@&SDCM:7Y.<(F$C2/O\?#3?)$6
M7S>+.ZD3>WS8DT[(2SPXZJ6\;^:+M316J\4T'ZV+B-[/NQJG!=#FTI=_>#%;
MX0*7J^4$LX]%& 4U2DTG?2/W434)SBMT*DE7V0.P_*L8J>'.S\A[)@ ;D2]N
MRUW 3YK'Z+*44*4L8#2YM4G2ZUA*BX(TN"9SE9F\/,A'ZE3P$_8>!,V7][3.
MF#YC_^IH0[*I02K=/VZ^](VH9";DK*6SAM!QISN=P[![P<7\$RY67]\<I-F*
MQ-UE\JF?</3?9R-);SOQ7K??EKA&\+B1(!Z7<G1XM"XD>XJ?%EBF&\K.*ND?
MDN5_K_\X:2'+7@C0;R8#&"L*]'1R***HUK+ ++B-E>%7-28[>"=>7JSX&!4A
M&,L,5VGV8=ISL3?;A:MG7XXUSS_G\_KG].!@$IQ,Y+=F0%1DQ-4L('F/8*5.
MRC5?2>,Q4W4;7&,RL%G)QBX4-KJ</CV63 MH!;3KW19LZAD13M%)0[Y@7UVS
MB9D2MQ'[?LO6F<1^I\W=0^G8F>4)A3Y;K:$9J7H]5.L!SP9:IRQS#L*7_56/
MC3/XS$H)=J'PTN6JRODSX*(**=3D(*3J>D9#HGVH/:TAF*)T-DYP&X-;0AM3
M?)J?-,RB8>/-QKOY%5<?Y_7%[#-N"C>6$Z]%%2E%B*'*'CD/$)L0X#)J;S2I
MO,!]'WX%E#%E0+/R@F/K>0KMOCW]Q>S-@FBZPH.O_X$']=EL11#??TRKI_/.
MU=5;_$0F,NF[]4YL.CU9+ZL)(H'*_9)%8X%@Z;0D:X@.3>5S.Y\">T49WDXP
MQI0+S4*3/4MFH"2*<P[8I%7OE/(!T 92<L6WW@!*0%,FJ68:-L]MJ%X+:$R9
MTZS:A4\,O#?E%Q:IHO758Z:E]>) E3/$K#-HJR26ZDGK<7NSEP+9A@GQ03)A
MYVUGCDU.9)'%ZRJ@8A+0VZM"Z-4;(= RC<PQ-N[>*)LG\^ _2>3.Q55A^J6#
M[1>NNGC(FK1M<R&T8J+-:9C Z@CSY>\@V0OUHG?>W %CYS)64PJ]%J70>U>R
MANQ; V]KJ%8VD^PP3!UG'BB;E.^XQ0/>Y$V2ERYG)7KR(.&(M4&N=$*ZH&(C
M94GZEOM*F3\%Y\WB./EZ_=4;*U!E1^>[MCV!-H+)N4)**H/W6AKK Y+0V&\V
M+L 8D[+:4?J7M)_::=-9DW'FLS,H:A;%V$KO5NL.@' )DG4&8DH^>YFT<=R<
M/H]A3.J+6>X[;3??F57KM*\]';Q)T_IB]B1]FJ[2P42T9J.L%5QLW< 3"(D@
M@:O:YZJ%*8E;]E= &=,- 3,%.#:?C0EO<96F,ZS/TF)&CM_RNXO.-BW37GM8
M;.M ?&D%C$$%"9L"2<Q$%$$&QYUU>C.J,5T7,/.#621CRV02VDL3FP$K0\<N
M:9,L6>HI"1E\43&WX6VFW3.96.S'D#R&&A005>C$1PRD]Y7J)T"A_1 FE^&S
MNL9M90W.L9OSN&XE)KZY!-/9?+'>@.-%H3,YB2Q 5NG --4@Z4!XE-0&R5QH
MS3"3Y3R&<1MF>Z?*3B(Z1Y1_^_G\GKZD/[,,NWGWGG[]]=FK]^]>/W_QZLGK
M7Y]]C^'V$V\N^4;VL3<WH6::?;.I.'XY7RZ?$\4VF>]'1)#C6/A\MOP%VWR!
M9UJ2/?NR6B1B^W26%E]?$$F75W*K19VJ@=;ZK9QW/;]'2"@F%.F\=T%PO[$#
M+H?MDN<;QHDQ,=.;D2'4'A52T4!.TD,P+M1HDJZ)^P"\!,:83L"Q\/'*NZ$[
M2H\Q:V4V_Q[+2<O(*@*Z: V@<JI/!K&D?;V!$)5!@=$$S9V.>R68,9V48Z44
MCR3W0"S5A++216BA)##::(A11<BF.EID":IQ%R9N2:Q=S[NK\DE*S-7%(J!H
M&<"$V /LNH+*FMYJ[=$)_G3A+8"-25/S\.7R 2:<\N%,-%^_]-^6:5P,-H#$
M;,&X%H <(0%5U^:J\LX@=V#H'(1;:EEXD'RX^Z8S2OY;2E%?V+=JI8#"6^R!
MZQZ(TJ61!5 ":.U34\4W%[FOLZ_",J:(\5!48) "&R=^FRTP'4S_&^L_TW36
M%=;KV5D5%9*/U08#IFHZPV7WA46+X$4MJI*BDNQWHS= &E/,>!B&<,J$-X7K
MFO7J(&U+L=>3$WE+3! :K;=)HX1+(EO!W3SY>D1C2BH?AB:,$F&<CS5OT]7:
MK93.&:-2 V43L31&2\9-KB"KI9]F[6/F9L2WI_/:U[S.5DFY!><2.+>)0Y-;
M)"R"5*BB"]ZHP)T(N[=XTOW:\G=DW_7&^_T)GW^$Y;%N^ 5G2!M%8)RL#LGL
M-.3Q&].[9A5121EA<R+5J +W*WH%E%&Y *PTVFW7^<(BN#H3\M,Z54D&)<3<
MCYVL$*+$1,>.J\71\2#9YXQ]!X#QF%$DGQRK@Y),'U4D)804#?B>1>B*EYF]
M#?M5Q\P]!S+N+.%+2NSOLKO#<'6KZS_5^HHB0JX]_4H:A&XY@4A9R!IT%HJ[
MH?&M08Y*Q?&195AA,29(+M=-L8YU\7(22W56%$_+K;1FUZOV4_: />J6;"I:
M<EMAYS%PK.EUZ\7JZT8XN/@\+7C:G^!LAPOZ[P.\K-5%<2$G)0+DAI5VH0]Z
M<[T:J$7=L$0;,G?P;W?48]*Z._'J8EKI7@7*UXR"+)M%.NA8ZN%T-EVNNIW\
M^=05E9I<4*,J"#I!>N^Y/EFU&:@ZB52JQ\+>K. &2&.ZV&.E$*<H6)7O!5XO
MW\T/KFW#X[TV3=.!E)(CVR.'GH>) 9J3*553LDS<MU=W CJFD/7PZHA5;/RE
MQV>L&H7H@F@*"GE48&H@/\NZ"JD)9Z-026;N$:$W9J7<);7[,\Z.\"02L4AE
M]?MT]?')T7)%3UB<G@Z]NHK^5\G?G!298X@QD-7>&^!%&WM'H@!.%:FRSEH6
M_ESO6\,<TS&^*W\N9G\/*[7A[&(7M= M:U"N=!2J9P-%4ABA>I&]\;IR9[M=
M;Q??LZ?$S8R=-OQ^LDV?/'[W'\]?OO[]'6?"Z;<O'33G] KL3&FG3]+R8___
MGN#Q.1WTV[FWY.(NIF6%M?\%"?K['YSYY*36%FWRC8QS+"1Y$R%XEWI)O@PI
M%6\,=^AJ)\ [ZYK-]Y_[UL>KDZ[ FU*ZEDWPRED(3CLP A4$8QVHZ!SIQRS(
MB!E@5VX$-J;C:G^\NZ"^V&7(6 1WQ8)/AT\;:[57%K1=5^:Z!KF7L0O,JI+%
M*K3E=D-OPC0J/_3>2,4J.<XP=(?S9C'O$ZSK+U]_6_;19IM,C&Z[%7*LCP<P
M2"TCM@*MT/%M M(9+D2 F&WN4QW)S>8VFK9'M_-E2_JZSCMY/W]<2#0+_.5H
M.9UUL[7W0WW=UM38_$V=%&&+U\)!#CV3R:;4FYD%T"'I+"UI L5^'7,+?+=4
MXH,'X8<@V(7KG*'DQYDU4A#K\77[P0&6OGNO6Q_VM,+%X;KIYOOY]_T3)]55
M3'2>D%+H=[.H/836&Y*THEVVRB<<(,'D]D#'I./W1;G!!<K3_O#- C]MWH[G
M\\6W%+LW1XOR,?4*!JE;[SD$%7NZ72-O/+B0^T!Z)^D\RJC,30[0-@^Z90CQ
M0:LE]HWG4T/G%>6O:?$'KB\SWV$Y6FS6''R3J=@$,@8$XPLM%ZLA-=F2CI$X
M[+G#BEL!NV5>[(/FT' 2&XY,5Q6!-)^*J,81P94$HSV=O2KTV%*U6GFL+K,W
M:=H2VRUS:'],2G'(;3A673D.8^)(51:L",T3UXUK$GH'<E*FCMX#[V4HW-=G
MVZ.[96OG'Y-9/++CLH3.6&RT&9NNY5B/;S"6\X-I31LC[E]I,>T:]K2F:=V0
M>%)-4E98!3:HUJVWKF7ICR@S^J"UB$)O:2OM"&5,#:'W8TSM4W:#>'WOT@'2
M&_!K6O5#^^OK=NE!CH0.K=!00JE]JE:%8'* 9+UOS25Z*[@#>+<&.::VTO?@
M[?$+<A"^77ZH/YWV?9K5Y>O%TYXYTU,9>[K_6Z35S'JD9-/CS1=GC!8-9%GG
M2R8'L7<OE4F37U)+J('=!> "/Z9FU_? S_T)GNE</C4:KBPB]]G&B!EJ6*<-
M1+)(K4L@BB_1TUMF==KNW+WI45L%3\4/8K4-L/M#WTR<IBJ<67I&,B5SR1!B
M#Z2D5"!A%A!M5)+<WRK3 )GQ6Z)C+ -!*PM9*PU<U+V#B>E-PZ."JK,2K484
M@CN=>[1E($-PXYH:D=ML/=LKL%4RM,Q:H**7,V.A!189>G5M!O2:WDN)VK!/
M]N3*7[_G"P%NNK"+BZ^)\AD$K]MF@BBM>YVF-<$:?)0.P49KR4Y5A,A*!]8H
M8V-V335N[7D=GC%E&N^).&SBX6N@^S$M\)=$JWTR/^PY?!ORHM%.EI9!!&][
M,]\^/I9,#B]+#;(J92OW 70YDE'UQ]@/21A$PCQ6[YNO^_SSJ^G;<^T\)M6[
M@%)&B*8@&*4;I$!68XX^$V3E OLLQFUP/81X/S=WV.7%X_==[ '3O=>SO8/.
M Y^T%&145D S@9S30G98C'2&9D\FF:*3E)R@K1S!VS_[(83SN8BS#_$P=WZX
MJ0]=\JK*0$<HIDC0L%;(Y!:#]4U[TR):S7T%R=8GT/\@M!I.8KPSLEX<?DK3
M14?QA$[=#[V  :,33B0(H?6IQ[&17B1 -3D?'0;G7.$VDB]%\@!"[^SF\>XB
M&;25W%-<CRZ=?NY1N(RAM*!!&W+J3&X]O<L;T*$6;?LE4^+FR0V0;AD+_R'T
M"Z>4&*,YFS%:9SHJ/9[UHK@G],,IZ3O=C+79B!YI=V2 -:)V(6I;46)NV+1P
MW ;S39AN&PW_$<C#*J=!+O;63?$N6[9(/B9!H%*O@3:A(<1*)V:+L<FDD/#Q
MS\*[&==6+/KQ8L>\\N(TEQ=]:/)3W/S^8O:XE/G1NA*FYU3T:^R)#3G$%@T$
M[$-!7.NS>?NH]IRTB<I5E[FG'6R#:RLF[;/!T)ZL95Z!#4BEIYMZ\'-)[\VH
MF&NL@-'WH'?/@O!2@6C>56%3$9H[IV5+:%L1ZKZSTH<GU.YB&Y!3:_7YC>K+
M230F)%$$V-;'NR="F'S5X*T6I#[)*5 #-!>] =563+KOW/3AF;23L'C"BA=!
MK2LQIJ?M",B<6\,\KKP\'ONL@PW:5K+C5*YT&"L)4=H&-J1(Y[!/<LLZF+L]
M?RO^_"B!Z7W):2A"G>[#R_[G8V"FINQM0=!]OH4IRM*6&$?:LUBI5&]HOEV2
MTG;/VXHP[L>PJH<2P]"GUK?U;[#54'.2Z,'[GNEN44,*'L'++#P6G;WFKAS>
M#ME69/H!P]#<0MN#E_8F?>TG:T\L*65QA/7E-.7IP68[2E;.TY$*Q=L>%*T5
M@K %G//)%B%2"-S90'=#NA7A?K! ]AYD.K1".P=XXA76F$6?"9\28?,24NS#
MI(U1WCNK _N(Y.V0;<6O>\X!WY,^VT5F0QE0OV*=DE#.TAP#JA2P0*BF$2Q:
M>481B>MH?6H&56AW-)\N/FVK],0?)+ ]C B&/>FZ#CP3@#^AKM$*BTUZT^]W
M/58@B9Q &EU<HU]K&SZ0="6\K4CU@\6YAY+>D ?9=U[#"?^_3C"1[+W24'.A
M<[8'XG/*#I2WP0=A<HP#9(AL!VXK:OU@^=3#2&YH"ZD/!-C$*\YJUF""%M(U
M:-F0#R%M@I KO0G*544>JU>5.R_@-OBVHM</EG4]F/R&+H$Z31 _LQ'80DK=
MID/3Z.1.2D&N??A2K.ADL/02[*D$ZA)T7 TA7K?3&L9)42$[7QTX4308H3,9
ML=:24^ZJ0+15!?8RZ8LP'D*KM5WI<E6+A[M*@[$7YJ=3*+WIUGM<'#[%O)I4
M(2*V),!;T[-0)4)N)8)4HD\;K-W)8>;&55A&U>9Y3P1AD0L;2S:KP[7%\&8Q
MI85^2@<G')XX+Y/6ID!TRO<!DH(\'BL!M73:)V&JX\YSN!;00VB2QLT7/@D-
MDFWU>UHLTFSU[ LNRK0W,T_HA?2HR&_QCE:8#9#AD:#ZA!A*3RWDYLQU>!Y
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M3N+1\'$GL=X3%?LK\_[/^<3Y)I(U!BH&3\9#H?<G.'IKJ@X^]/$)<H]GQ=5
MQY1T.!KBW46(]\DW(A"N];3J,9R8Z;TP0I-M[*H"VAQ';T:M48O[9UR'.J9$
MQW%Q[M:"O$?6/9\?+2:E%&.]2E!:):Q5]/YRJ0^I*N2*RQB4YVX?>C>DMVS0
M]?\.YVXM1IX63%<#[=C*N2CUX[;"Q2E:W[RRDHS1XEH?]VDC!!40HD0I:@NZ
MJ7,AR2O:,NT 8DS=O ;@TUYE-'3PI)<YKTOYIIO6U,]FJW7.Y:9RL(^W_B4=
M](X>[SXBKFL#WZT2[7C_)STFWQOP[Q16X03 %' 9;$]8*R,GLCEO'!:0F'I#
M9.,A19U D N*KCCM(G?GD<N*,;AJ'A^O3NI0U[F^DZ3)<?&BCP*-IE^Y%0B]
MPUES!H6L2J?SH^X&JG<\!VQ,X9$[,&&[PL9=A,'8?/ML#?[QA,8).FV$,(%\
MCIZ)+66_X:@6JD-?$+'$PAU4NQ3(F,(2##S8?;/YBEDOC)[N;1".$84H^A"I
M"%D'6J.J 6*R1$=42<H02F6OQ+D.SYAB! PL8-MZO@8H\]5Z2NO+>9I=#JO)
M%*(GVQQ3[VI8!4+(3D.SS84F,Q;V1*T;08W)C6>@!:\0AK5ISXVB2Z?S#D]&
M_GY+*;GQHSM8MD/ 8+%O!]\?+BMWB[F5)^RK*: MJ8(L_:Q2L8\;[/F!.IJ:
MI$M6LW<UV!X>UWEX_*B316O2M[*%#-B")#<2!02K/8BH6G1:R2JXXTN7(QF5
M13P0:ZXZ*'>0"4^PZ-TG[.62JZ]/TJ?IIO'/.4P&,8F>G!ZC(=O=*%+-NL\N
MT*VXF$5,>KN9X3<^:E0F\<!$&&#SF0AQE->=Y%.A#[UX\_AD,J((P5I;,BC?
MD<1"BZQ.0<DVIEC)M)-;TN#R!XS*$MZ+\!DVFM-GZNM[LY@W7"Y[]Z^#Y_AM
MD:)@%98L,V&1,&$FT[UX!34+;$XTU)D]5G0MHE$9R/L[,[ADQ-?LY0C?S]_B
M.O?]35I\M]0J9&C9@]=)@,FJ0LK6@3=512U,*X6]Y\65:,9T1[4OOC#)AJ^S
M]K&V^WVZ^OCD:+DBOV)QVB'A!)F2RH1^)6NL[[TY8H/@K(2HO?4^*U4RMS>^
M#:XQW4GMBS_L\N)K-48>]/PKXC&Y+UEW\1F]<Y7.STCK1ND@>VV@I3Y>"ZM*
MCMNYN1'4+4?0_! <XI74L)&?B]/FOX4R+O[=#K&=NSV()7K#L$:F^,R9$6<O
MY\OE<7QPN7Q<_^MH<W]Z'"6::!5TG_< B90-T40[",9+$*%D:8W$X:9TW AN
M5TUVJD_I2;_-/J5I?7*0IH?]><?_<?Z)FQ^_Z9_<O$$]+T!.<@XR"@R@;-^D
MTG.<4B.-W$0.3353(O>U%A?V,<5_AF'E>:UX+U)G.WUW0?]F,9VO,UF6!%Z;
M*KJM4+&K?^T:)"<"'2[.AQ14BX:[+R03]#$%JL;/V+O*_!X)^V)6^FMV_-=R
M4D0U+2K"*94C4Y<\IZA4[QB@,A+)3!+<-:L[@]YUU]X=?2);IG]_[]G>YHL-
M'0G.F\7\$RYZU')YU*.7+V;+HT5/:/JM5[C\N2#"+I9G]-1-P">I%1VUR:!2
M$;TAHX+0^TPYW<@>S$;[QGW"[V]U8SK>]OLFG%<B(V44FY[9<7VG>O+&U>GB
MA"]"0XM]?G3U?>ROBY"CE%AL+/3S<;TO6Z]M3$?K@WY;AF'3L![X$]JZZ>IY
M*NM=_R7-_EAGC"2R:'K'U7G;?.",RYI6IQWP[^R.,SR5Q3?G7CV3H]X?_OKX
MV1/54G#5:JB^-RY3ENRWZ /8((T*OGIB-[LA].WY.UN"\]F'][@X[/,2ONW>
M6_QT.H627IM9F7Y*!Y=7[+J:M3#.@(B.SA5'AG0R5H"/,:!RR@C!?:FQ*^9Q
MV1]WY-(%?V2?@N1S1+9'_6)VH437)Y]#J1*<,PE,< @Y]4Q*3[^E4$)&[E-_
M)\#C.LKW3[P=17@_K#NIST4TI?0>^5:' $;22Y)$<Z"P1%4\YA*Y6^S<!>>8
MLD;NAV-W$=@]4FM=AJM"BS+& LX7 Z:I# %MAJ9MR"H;5^J]:K)1EE/?([UN
M+32>5+1+@'[]OA12%'+OL1F0WO1PH@T0E*L@:LM".R&C*#>9_]L]:DP))#LS
M88#='=8Q/)/%\O7]HCM%I7_GLN<_G?C<Y"=M:B<W!098=W )=WH>BS/(MV(F
M-_ *0.L*U[?X&6='N'Q.5#T+MF>.G/UW$YF-%M%$2-8B&%%[6"XH*!A]=*VH
MHKFM"@[<.VFQT^C,.UQ\GI:N:==/_9;S>QJ;.;[+Z97ES02%:MT:)?6\FMHO
M2LA=24FI$H1"5'DKS7:GQX_)9]P[\;[3DL-+C\T8^S7-TH=UP)"4Q$EP#U%[
MF?M$9UE[Y^$H(9,Y"#&0]^%DLI%]Z/QE.$;5)?K>&,4FJ6%/VV=I,9O./O19
MY>\^I@6N?UEN9I23S3%[.CTXHGTX_[$^Z?EH\T[L$HYE?#K+23S4;C"=R[^O
M7QFLCS_C@DCUZN@P]U#7,:H-V-='J^6*K 7"-XFYW[*[!K;?_1LB,81$EITO
MMNKFL*7"G1EY2XB[ZL$K'G?A.7WF>2'[V5J7?('L8P(3R65.+6;()3L,QI@F
MN1.G;@5P3$?QD%P[KR.'DR+;@7LIQ*LVX]N]VP2MR]ZG"*&T/J"%$,?0-,1F
M4;D8JA5J'Y2[&>J80KCW3CYFR0Y[AO\K+:8]L_O%C#QZ7*Y.FA#]Z\6S70[G
M;;Z6Y=2]-7[6YDBOYAL7FT1JO4;G)8(MO>]!"(VDZ1*@LJ8),ME$XQ[2<![#
MKGKJ)%_@S4&:K<A=Z8UZ/IVX*L*WAM;VF2BZW_Y'A*2J@1JM%C9KJ9'[_+L.
MSYB.NYVX<%ZEL EAL%EWEXX%<,I)[*V:^BD*1BO=)P)("*TJ[5L?_3CTI+N;
M9Y2,H7L2$TW8A<)&E].GVY10Q_5=>2CT]";(4>TSM&QO]52#U<B=MWT;L>^W
M71*3V.^TN7MHDG1F>8668%M.X$19F]@54@R6=%3)O75S+(;[(-P&UYBNZ%@I
MP2X47KI\0_1]B?'9U:N06U,%FNY1T.@DQ(@!R%>+1;BL1!Z$,3=#&]-M'C]I
MF$7#QIMU@/7DVO%,G]2)S%EGF11@T;TSG.V5*;3BX)24FCB.["?*55A&5>C-
MR0R6S>>KX";K=_7U5UQ]G->S8 1F56RQD.BLZ_UN&F2G [@83:FF>G3<^:57
M0!E5M38G$3BVGID'[[ <9Z$\__QJ2F=>OVV9'ZW>8JK3@Z_D[Q-GI[.NT9ZG
MZ6+34[8JBPUSA)9TOS1!T7/K#<A>XR%\+<%QI^+>'>TV; H/ETV#"Y#O#"(G
MG#9I]N$EIB6^[=O]NOVVW'A;DQ*3L[%Z\#;VX=R"CL6D<_?#4Q;5-7+$N0^B
MZP!M0YOX$&G#)P9>Z^3"(GV*5A9'BW1D+1GT$;)P'DH?C%1];\;%W1KR4B!;
MQ<7$@Z3"SOO.UP5MC>*T>766.:@H(*7>M!R=AE!"/Q53+4DI05@&B?PR]?W<
MKC6[M]7$D!PIX!#[,'0R_YHEQX".?.OHS"_L0X@?:)_\N_#B;NWR;R,3QO2A
MQ1^XZD?TM]/\M'5W]569TD 4+_J]EH"@?(.JC33!2E\:MZUU#9SQ!7\YJ,&U
M__OIHZ]J=;5W;R_KP%- <A@K1M!%5AMT#*IRCT1[6'WT.2C!)H$!.7%Y@T&M
MVWIYO1EEZ'T^).36R#2(*N9B0TUF>'K<N1/D?N/%PS!E=[DP7C3V)/7WZ<O9
MT.3$>U6LCP@EV#YP7%=(A8Q\YU) T;+/FCL1[5(@XXL%<Q!B]SWG=:R^@5B>
MT6'2DF4OF@!+!UP?@.PA&>7 "T<KK4TA>W;RU6C&%_KE( +3[K.QX<T">R>-
MXZQGLH7/^'^G1UO,)DCAH;729XWT^VU-YHZV)<9J35;L_8"V@#6^B# '/[CE
ML9];QM.52UM*$K147WNS=.,A&)7 =:0Q15N1.SRS#:[QA7LYJ,(N$<XVY+U@
MXW%KTX,I@3IM71N$CZY6R#&1AJLN0["]H7Y,GDZ[D*S@5B170!E?))>#$1S[
M/FP>[#J^O.S%&/,9K@=LKG]RK.YVR(3=[HM9<F'OL :NWC_].4_FR][G.WA9
MJH:,M8?DLZ$C@ X#Y;V51<IF^/M!G#R<]\YGO9R<FTZF9&BA]+LG.LRR*1&D
MB4Y;I1,&[@X$%U&,*<1Y-TE??ZUSZYWF'+G>:S8ONUPZ.U=YT@0IJ1PL6<"T
M3-.'*J=B-.@JC4UA?0?!3(,MH8TIQLG#C2%D,@AA3DL.C@LS8W2FVB:A%97[
M592!7*N'2M2U51>K,G<LZQHX8XIT\A-CE[UG[./9IQ6NNSG203PQO@1O= 0D
M@PB,4@52[X51HM#.]9SKQ-^=]BR"6X8LARV>YI'Y#EN\#WOQ^='J:(&_3F?3
MPZ/#DP[;Z^Z:_8JZL_6@>T";#^]L1-[I:8R6Y>ZK93(WSVJ"T^:KDZ:2,M)J
M*%6NLT$4\:Q9$-+&[!M&:;F'CUT*A/.,N3!'1WLTTO6^/;)G87IL$ ,&T,8J
MD9O)+>QED2.<R;D[*ZX[<7:2Q"#VQRFB,^DPV>841>XI ,*"<:E7.A,HD:IV
M/OF8"[>_<@.D,1FH>V+('>7!UVT/R5C&[WVL4W G>OOI$1(Z*[WQ&IJ/ZQ&2
MJO<$0[ F&31T1C?%WJ5V2VQ[V8/+6[[ZD)O(HD&2/H*Q0M.N$#.L:::FW">-
M<X^6NSO:,2G@07AWH2OA?@2[]Y?Q0@_86*))609PM%>]!ZR'D&H%+4JL.GFR
M=[G=R;MB'9..'P\)=Q7JWBEXTB)6IU)R(C^ZR#YJK^8(N:$#V1"C"!IKO"_F
MC;&=[Y@(=Q<1W@_/UKUB128SN2>6Z'53@V)Z_SN9097JK:].M/-]6??+M-'U
M]AT=UVXMQGMAV[I-;;/>$Y@*O?\UV?G10>@O1I6A:.M:]>S5H[?%.*8<L]%Q
M[=9"9.HN?1W$]_-?L,^N^[XA<@HN69\L%!,U&.,=Y$APF\T10S2^G:].O:K=
M]*V?/:;DM$$9M _9#%1-^"WT8&UV5O@$+<;<&[0(R*)*B"J+6)M$*[B+:JZ
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M8<B0,M@R[GO\\_Y+)@#_^,O_!5!+ P04    "  "@PE5RT592B^F  !6 P<
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MW9<@;T93G!"R5Z,P7&_KT"KFM#((,L0,JNA$*YJ-8(NS3FE+>UMK%_1.4,=
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M4_1".QDF5JWP!)KVL61E#3IM'?R] <K1<*"%J#NXM;H>S'.Y@BVQU<03YTN
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M0:S(-8@W=K-($)BNB8U(\U>\=@'QG$%A0N<491#-<TMO@7-,;-A+U!V$@MR
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M"U@J>.F)=>"\K6<'S$) 6Z"DQ(5E/AO6.N-O Y1C4'T+*7<0LG3%R+>T(-U
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MN[AK70=W'8YC<O/VEG,'M;=7,2VXO@VJCAR[]8@>QIO;7V-W4& /<7?@OVU
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M;NR--#3J7KP=E)F\ZG"QF/L"EN<LI5RC;W.%I32"9\&#-88+JR69,:TS=C9
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M<4>6DR2 A94L=?92\=9MO#= .4KSHJ7X.RB-_V$<AI-";+V\>YIE=Z]!._E
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M=N9H.%Z^G4W]U67<G.'>11\SN%0O!(-WX)A/8+/*A2G'56B]C#:=0(M6<31
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M0O)[JXM:<YW&2T8HEOSGK"EJHC>?1>".D1\-060D_[HU!^KQ77#NR8P&5<X
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M9"38K;,K3^%YT=IO)N@!)HLMLH"T-2W2S6L!"JLJ6Z:L_9B"=B6%%#Q8PU!
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M"^+:_KK :.@0W'OT_@_['86_JKX>DFM\>-^'DRH57=*::0>T(UE" E$EDDB
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MBUD<'KA[-!G<Y0H#V':]!!\7WA!KR7.!O)$IK]*W>M,=%U=](5PF6^;_YK:
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M<S>1/NZ<69O%FU4?M[@AZC_=5\O(A?"D/M]'Q ;L1F0R^59E!%D;*\%FGT#
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M7B1S(HG!#0ZY94[>OC?SQNT8/2V9^+>,1WY4021Q%]_)?G0KV!>Q.?%=H=3
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M.B=XF7N>I ?%Z5M4Y%!4*!$TP/0<G(4HVM&O)&L+PB4MS7B0M;;E+,H&,V@
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M[^S8"Y]TQ&GO*CZ-NKFBD9E#SC_X+$HCZ;E AK\\_OFGT'S3?X3F+\][STS
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M@2/AB\W/+2V0_'46CY<;9P54H,L'ON&+, ["GH+K-^AXT%Y2CEF W O5L[<
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MU3-%WV+C!&P8.'LU65^;J[Q2]N? AE 88DB/H<^+>K?R*5Q3WG#-P<V3U]?
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MGZ0Z%7#A9.3W.+KR)UJS0F++TU#7Q!CX"B>0\[GKMIX#RO9I\>@!J'>\R(D
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M)PS+TFVK>BF1Q,\PX*A>O^UWFNA>_OQW,YWH:Z%"N&+O_D9A_LU\?X<I_1\
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M(.G $V3328'/LIOD/DL4$Y[*V*,A2#_6DPSMR</P0(J;:NZ..>+ 6'$",&N
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MH#);5 LWP5MF6G8;CSJ477R8B36O1+PJ0XK5&=_(@2[<3*P0IO71N)IG)N@
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MM'KIZ5E$'7Y%4N?G*'N5% 5JNOLPSN2;4? -;I.TJ0]'^E(<U\8T7@J/':@
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MT^X)>K'+OK_*GW#H:?06K;NX3(.58-H^P3$A', "1I,PNV]7=F:O^=^ !4S
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M,E@;..<F .!4D9_^O$:_R61YW\RJ&AE]#5F!PP0QB_ ^S-K$.7C\&)K:YD)
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MSY[=O[386I<4>D[X@-&J6>8Q[>9K^*6.@70>GA;A@+"C'W[)_I=>D6?L25L
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M-I( V4.VP4T:O!AM7WN]%[M0D4L%".SS')0*B0"F!_T;+K^PX#](#N3!_Z0
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MN!4?9NR#5G 2C8]M'P1F&]^][&Z=0>F%EV8%@2T9@^1203B_%9.AT<* D1$
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M(^!V(^'&;CGX\0^JN]B2*C4;,CF[+;',..%)@?BNYM0:CDI\B7TDUJ7QKJ3
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M@Q3_H']MKKBD?'J==RWXRI?JA _A@ X)@4C[K4D"XLO#!^'@C8Z]NO;M'Q0
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MZG/9DVL$J,_E".YW@X%G58F-\ D*@&"^?YQFW9A,?4L3!SO@'3TU?_F.MRB
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M,K!&)2RYH?\[$'DX6(B#= MUK\0G)!-=5H[@^![=</'[C&7B\4LO+N4B BB
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M+6/4U</.-)M7Z3Z^[V3AQRE\Z)56=,&#\YQ,VZUK!.K/)P=V?%:YY&>MWU
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MY( UO6D?V^NEY T1-<*'EV4("\FDN*4?=S<5W9E&ELZ?DFDOE'D 1924$-W
M09N>>6RM6D.J'SS"D?X'*?X#RKZ'L/+DD_H$%2C?2/* &_@U['I51=R4D^ZV
MJ<*J.UK]ZHL!0Z^^[/E36N_ECJH!KD:A83P8<C):U)MP;\@!(M7U2*,BLG^S
M^\<Y_]E^F]'4UHM7Z,-S:*,?G^!YW>7+3V]*N[)ME;8T0$2PYW'GB@HIMPY)
M/4H)%O[4]%M:@0<5#Z_18%MG(_HXE/#*6/;]@2:8TD ^$@VL"FY "TS,J^-B
ME?W,'[=/V\N%"DX:B$M'.R@+J<?EO-./5]^2RKCGQO4I?EM?(3B8D(K6)W(4
M$]2(MPAP7%TL&GB8A.C81)9+#\:O3Y0[;9(;RN7&2IRV9'QW)JH7)G8\OB+Q
MTEL->F; J]#[^*C9&YHZ%>7EYA"TYX6"\H&%<>CVEM,9]PJ-YEN@V$,-9QZ)
MERK0@UF?RKEMZ&G[IF[ C&"@H!4T'@XTMG/T7MY;Q0/#I'=8UZB>^8@+GD P
ML:TRRTWQ!)&9* "ZE3$;MPVF;BF"2NA7@7#+4/_*.#:6MWP%C7P./;L%>?J[
M/C@/ZH)U(S*1WN6;UV" C1"&I?VTTJ98F?W/?=+D-+M-Y>\5P3_F/R=*V6RF
M,36@48B$XG46[ =$T!G[6)I[TRX4 #\9TKNO #RN[#.:B6H'+1QHE"11<6PY
MD2,3 YYQ2DNWYY:J&584M(]A<P]XJ%O<9Z:;8!FL9,UM6I9R8OQ:1HP@C5K5
M539=Q6W,;D )!7!BZ=SU!U$6UFG+WJ8UOR@PY,C@WK8D\P;+#1Z]HWOHUA<
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MXSID75-6UT=Z,-!G^I"T-LF[Q5?9,-O/9;%Z>O_^U:Z#<$U1)$$ATQ2%5)I
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M*NVY+AU.+=X6S.((^1*+,#!MU2J!.P5:I<!=V81=['D_P5HQT&H&-JJ!'=V
M4>XEUL[A*/H2:SC2&;5C+0O/:^EVA/6->>?9UMMDXQUZ?>.S=QKV/GA/6YKF
MY5_H?"7O5//2SLWI?&VL5_?%/.?/,\Q0P(5)A8@3?7+.1 Q9%)K\S%!(R23B
M,G&*&K29=6J':2,TJ*4&'[1ALRIE+:QQZ&Z4V#E2NAKA5@MA:93[AG=H(WV+
M[#DP;T C-?BM_7,0%[@3<+YL>ZLYQ[7U76 XLOV='NYQ%OA%+K\5Y>_M5>('
MNM#L:(9^M^#M%3A.6!0ID<$XIB'$&".8129]BX0,"8Y#DDAKM]#%Z:;&4ZW
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M=^_D]A2Y 5M50*O+0>;[2&OB$)\STMJ,%+4SZ!JY!?AX +8S[.>:\<<+!O*
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MJL>=3:R>ZF=%O:5Y^1<Z7\D/FL-697T[7VU^^=^YU'S&OSPW/>5GE* LS+B
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MPB A@8S"( D2)]NB:[*I[>;]$ )SUWAET,4NL'9;W!=< ^_WXV"+3:RJEG3
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M\8K!'AUO/4DN3CARAQ); ([[E5@_>6VYSK?G.R,UH7$AI@BI.($D" 3$419
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M8+JZ %R?,+B+"#HX[GTB.9++ON]7T<U';PM,IW?^XB#C^>5M]=GSR%L_U+>
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M5:EOR_FFMG?4 19[,L^"4FI3;K^6/#"BV]?CM<&]>Y<8 ,V!MP4?0#H5]G6
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MG=R.KCHKQ%.E-P,*!8@0U/9H'") (DX!Q)B1"(<T$]C1_^H;\W&VD%%1MW2
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MQ-,FWSG5J)N[C=*'F[K5,STNE_Z'"KF+\/TH1<[IXB_KU?/3+HQ4Q +A$*9
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M)*@^&[&0.5HB7=--CQ ^F0NFG;C;SF6NQZ .B&V//WY@&_S8LSP%UP WT#:
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MCT5$!&,@A4B?+17*0(9# A(>1TQF#&LVM^;Q/A),C=AWI1)-$%0M>E!NK[.
M+I?/^I414BM!"Y=39Z_%L:#VH2$?F.N/FD<T&E0E)DKLOU38M]0(*CV&AM]A
M/QAZ&4;:((99#K<]XQHH.S>17@./MZM<H_?>-G/50#WVG7=TO<R7#\5GN2Z]
MJ5]-/M^<4LF9(@(@!!' DA) 0AD"P0E,,$DI"^TWEI-33&WG:(0,M)35)4GP
MK134Q4X]#:;%1G U1 ,S_8#H./#TU2B-1,0]T')CV4X@.FGT])/C\62GY'M$
MV/W)WNV%5T_2F(.F^2A?/<IW/\W-DMR>(G$6DQ1!"A#,%, ,$W-;@P"AE&=)
MRE,9.C51N3CCU'CP?O-=?VGS4M3@%UD)>SX7IR?,=OY6K^ -S)!M68.[&KY:
MW%\'*>-OC8Z_SL,7YAN[_;"=^B=Z$%L^.-4(*/JSC(4AA$),$@EP!IG^3Q0"
M)A@!H>)1!E'"8>+4/F4LP:=&>?\F$5#UJMM1YQ37<F &?I4(J J%?Z<(J/UU
M^[>)@*K%_O]9!-3^8HP? 74P?[\-[S MZ_V/3_EQ,M><))#$""8@0Y$P[8>1
M-JW-I6/,< 1I(D7D%,M@-^W4-IM6BJ))SRV"7TRNKBQ^#=:2KQZ6Y6]6)U)T
M@^]R(0*Z">12F#KAVH3)5X[%V"U7RFZ+\8__T$Z,PYQ/3?A_!Y_N9D%K48S<
MP2]&<H\%"-R@\L3)EI..RJAN0!SRH>/3/<UW_EV*YX6\5U_D#[E\EF]>/M)_
MKM9-R$;93/%IM3;'A]_D0U7[W?@FOLJ?FS=:V=_G,"0H491III/&,-<F>@:S
M$'!)"4$QAPJE;D6 KA?*Y3T<)RJTT:EL>K!:;M8Y>RYW*A-V4:M9-LK[(KG,
M?QAM"F._Z8UNM78TSJ]?4TNS>]1U&MJ@;BU0LQX:_U*A8*N1^=%6IZ!1JG9X
M!D:OH%3,H^?#'\J^S-_K!1K7L/4&X)')ZF_D?O1]O!_<+UL%5^=ADJ TI2%(
M),PT-[,04"@C_<^4DA JF%'I8H5>F&_"YF=I>/Y:6J'&X-Q5B'',0+V$N!US
M>L1Q8%H\;2P:".\L('0F.TM@/#'9I=E&I2E+U0\YR/:QGF4@'Y_TZ=J,=*\.
MZV+=+854927*A:E$>5S3C:5IFB6* 19&$.!($P]-8 C2,"0\90+#S*H5AP]A
MID9-.UV,P9%OI0>E^,8WNU]WS['DWC7+9D=A8RW&P/RVOPXG"O;M=*FKY Y<
MO<\#K+ZJ^ETCRKC5_CR =E0%T,>8O0N"4ZUWV4/V'S)_^+Z1XJ8.B9*/FN7U
M5.4OO\KU(YSS.(,AEAG@3,0 LPP#EC )D@1#@3BC)&%N!W W :9WV*[EKSI-
M.U*G(_AV9#D<H /38X-D*=PL:&0/;IH(RT;ZN@NUD=]KH? >L/DK&>XR^=C%
MPWL <Z*,>)]1KBLF]?)^M?[;TO2,ORV3C6Z6S5_$/Y\KH[6.4+BKLY"J7\,Y
MD_K(&H84Q"J+ $XSI@^S, 4AXU! !@F5L$_MJ=X2.=F4HY6J.L[PZE=CJ?]"
MV7'BJ/ /3)-;7<H<NTJ;H!*S=.K6?]UI%-0JE<'II5+U9_S7?;H:7\]EHOK+
M\RI5I:Z&[UP1JNL'[A$ _]MFQ7^_*XIG*=X^KS6_?RXO5LN+]>*31L9<3:P6
MBS):K+HZGPM"HBC+$I!!D@',J3[0IRD'E D>8D1QS*VB1/L*,+6C^V^TNB4H
M2IG-C<!RM00MP7>15;_DR_ICED&EO1>IFW/'@'[H^QDC?5")'U3R!Y4"LRK(
MR137WU-B&[XT,/0.,?T#+\%($?]#+(5;2L 5.'8F#/09=[QT@BNTWDLVN&:<
M'GO.!],>7K8/&^8\H?]IOJ75U'?JYNEIH<U6DR,3)BF-59B!4%*]WPB,],X3
M<\##-(TC!D,B[=N[.DX^M;UFSY,Q"S8[V>N0J%F0JX!NY7>@.M=EL=AA!@1[
M: .^E'P6'/@[6N)O&>Y.!3=CX.VPK0R(^TA;BG?\W?:3G@!V[B6N8XZWC_34
M=F\/Z3M&S\IA^O23;]Y37AZ<RH+ZL0@5HUD9;*9W"91&@#"L0)(A!5&8<LRL
M=HGS4TQM+Z@D#!H1^[4H. ;2SEMS'3P#L[<C,NXEO\XJ[ZO*U_$$XQ;V.JO@
M42VO\Y_L5;Z+YRKGR3MC9CZM\T(6=8VZ2+(49@D%B>"1-@(I A0F,4BS$%&<
MA%2%V*%HUYEIIO:*-X(&+4F=*D>=@]/">/,"TL O^BE\+I?X<P'*J;"6!\!&
M*Z?5!SC7"EH7\+A0-^O<TV-6R[J@P4&-K$N?[L&(;YZ+?*EMJ]O5(ZNMJ2H1
MH#F)?]9?B>_:W+IGB_RA_+TYL=?-,'"J%*&1 #*.-&M*% *:1!F '"K3CC?#
MQ+[4X56B3(U9ZW28K6?VJ98]6&V%GQD_+K_0?L/WBED0\VCK,#!Y-WH$+45F
M36^Z;:IIHTQPWUJ83^,OC,-&,-H"C;19#+M0;IN*%VP[-Y[K9AAO<_*"Q-X&
MYF?$?B?ZLO)**]?ID]PT'9VR,"18T0@(B27 +(X!E6$$$D;2A" H(4[<XMG.
M3S:]V+6J),UZ)ZS; ;\#5ZH88R11(.:( 1P)##*A_R,I$Y$((\6)4[4?/ZB.
M5^9G"$SMG"=^D!IX>ZY :DE9-BL?H"'9930\>54Z)AK5NW)9X4,OB\43;K0K
M9#[7YQ3-[5_ISSNA!S)'EXK2G\N#+\$RCC&/ 5)EA[$H 5FD"* 8)0*G40;M
M"A9<G&EJY% )&VAI@WUQ@TI>.ZZX#' W57B%;6"FZ(V8-558HW&"*0K)__2P
M^O%G/49%$OHO.VZX//(HU&"M8,,,]@]<'Y[[_GGSO):?5XN<O[R12ZGRC8E.
M:P>KO<T+OE@5^F.[I''!. JI)H^,:),-TX0#;6]0$-.(XBQ"",9.-S+7BS0U
MJFGJV'^XMO_I%:MD9[&,B_W ?+4?G5NI$U3Z!(U"99CN?N#N3JG@VR"9_?Y
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MK2+WVN0.$)P6"M^ +3VN(F?T)ATAP#O5=B/(N#UKT9R\2)_!V%C+D J09ZD
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M>*SU&>G4O9JG0"=J"%@[S\VK)ACO= R!P]X9&&3 ?BZZO[%580]7VU>[:KH
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MK 48VM?;\A'IY2JJ.8EJ#JI0O>;'+3=MX4[7%>I1]#L LL&J@%]#R\AEP0/
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M9>2&!YVL'O<]Z'Z\AY/R]GEEA$YS!4^2# LN-5!"V$ ]G@(K#8".$2=$J%S
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MACXLE$>EZP,/W\,Q].G9FGOW^AU[+.8OG^UP1AV\,X\7HIQARK2 0A@3C3(
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M/2KZW<_=L?+[[4+:/RP%/XP69S/KE_-"O&POE2B**4$<&QV(&^LYYBE@@B%
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M#$B:(@:37#*-9POU8%]T.TK]B7#Z.&G]<>Z2,N!ANR4TVJ74[]CML1QNQ_)
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MSF "8I)(C>(<$X7\M).+<TY/+=FV1SJJ^%/%4MA]T! ?62^8MWIR>1T@SJ#
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M8^X,W=4J-4;I@C')PBKLG.YK:CQ7BPJNP5;8.KE@:,C.:7 ]S:0XD UM()U
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M[B)8+O[]WU">_*T1._0$N0MKWZ/@2/@-?J9["!QH1!T@^-$+E&CGJEU]C7Q
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MEY$,0-Z#<Z+C.3#?-%#>&+"5&&Q%!K7,(44Y ] ,2/L9'=61TGU&0#>,QH.
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M")CU%PV;!T^.-11#^\BJ#"W-$*A*$;"YUZ!.EP:^.5W<:+P<F5<9F #Z'FN
M1J+[#QNPTH_U;=OU;ES6G>,7:4V( 67G&G)1!^.M.3%P>+9&16GP$E=EN\]+
MD<X)*3 L<L4A3JF (L<95*K0BC*B"HEGF^6&ST-<:7WVS-L^AIM*7UT?X'(/
M6M@FN3<D(_G*HF^'CRH<U27V*EO?HVH==WY%V.;6&?YN3#OK6T)0LXR9-$N(
M2VB3V3]8ANSNU]J7&2,D3VF*#*=^^<2[._+Z5$=-']Z*N#5*5'A&U3/@>AB
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M5 L+GIRT83/\!+!^T_QRN,;Q?56Q_RU(OW6"%#SCNS&(-.U/=#+JW.]6])
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M/)2+\N'IH3&7'ANI^]^2/HJX'Z?%Q'%@ CNX ;U7JWVS!$);4BLCUFCW!6:
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MIL:;3HG_ .7#X].FRO =DE_VLN'P-,>&!GEH>ZV2W]5=:#1H+RMNE;@"^VJ
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MC?G5_G9MN'3_5A^TWYBFVN-OC\N%6Z[FVP#/7_5F,Z_NI7S1;MV?86.P1%)
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M>R8DJ,2^ E;P@'GJ@[C'[(V,X\!SV@/"/ADC?+ ,V.M$QG2L6VX7?)YA#!J
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M+^P/@GWK?_[/_VI_8_\0UEK]/__K_P-02P,$%     @  H,)5;I**#:^[
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MR]TZT;&QA$QP 0(844IF=)6C1"$Y26BD1B9/3690 3 /++\55&SK4*DAVR9
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M9WFP.O2+Q7DW._ZKGY[!Q!B/<BIU,+ZX8"PSY$ARPH&*R+A*^/W: =,VA+6
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MK5-CFT+6"74V*.$Y 148D0QCDA!*]M5G-.A4<ZMJ-]!Y#GWC.NL#6:C!%-0
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M#D)OUA8=G:V6*S\K50L3Y:.FT2>B A3CFAD))B%78$2P.BME:W<L?8*DL>M
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M;V??8#W\;?EV=I SLH&B67X^"\LN=;ZO9EHNY['_[L$L_<]Y-UO]%7_\K-A
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M!/;RHIGSKW[9Q0GC40LTI!B?J/*4A&;B:"IS>:PHI3Y)JMKIK7L)::]?X#Y
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M!-)%Y'G1ULI)XP(UZ/:5E]->1Q*4X21*!I S+XF,RBBZGY)Q*^CJPZ>"O)O
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M"C=>F'Z9/U>46>D8$A7$29&(-%ZC#"0GT4N78M!"Q]J7]T/P,>X+^1>&\.A
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M$Y$"!:=DM*"'2I9?(Z/)B^EJFG\@_;.K&MI)A'^ZN&1:KF\K\9-/7D%83<
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M8A/M;/0F<Z(P6B]#3A5Z1HD2(1)E"E<'53V8O;;^N.73H^)M9S6,7?UU6+;
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MOYY?_YO>1*/<J)#<$$ ?C<B0 SIM+!/MJ';><>FJE]5N3]V(%1*5W:*!-=-
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MP]#U\HGC1&OCI(B:Y&0<D5)I8HU"&8?L52BAC=5;(:HV9:WU)]L1+_-6E-=
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M"* OC).N,;J>HF>@\?&#AYM'Z6-4V-IET->+H^W^D\;*Q"D."B;69&B>F(^
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M_GY*QO]XWL?[TU%Z& &:_C&?YS^G5U>W6V7MHJ:<R!AC9DF18ZI# 1;0*&9
M9Z52,-FWMES[*>F&II?[?M!0#R- TU.G_9M9)H_TYL3_Y=_IZKK.-]UQ/E$2
MM911TLZI/F@DR4572)#<HU<&A8ZM!W*=0F\W9+[\AX6SZ70$^'WD?KL6*GSZ
M#+-/^(5L/0G^5B83"RD4QP-SWI'WX*-FT6;%$OU/I_K<YUJC]G JNV'UY3Y.
MG$E_0U_&O)[FZS0E^N_50&S?FB?<E008ZDT2D.BRL,Q;I5@(*CA3DLCNWA3W
M1ZY;GEFH&YQ>^(M$2V&/P+3=UK[?=.^IS65W/US;\XEWND8[@:F@$@DKUYO)
MFD>%V=F8 <#UU_#F<;JZX>WE/U4TU]&@4S0[<K6K^_L^B=998>M\4,>1:4MN
M0W3",.Z54$9++D1_+7&>IJT; E_^"T8ONAJ5]=LXKA.NI3,F:295]$Q#473L
M>\6$**A$(:%QW1O6-C1TR]-]N<\2360_0NSL' !=+*"P-8V/TS[PG+: HGU
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M_*9J2)?]$-F?Z++_,KL[V>=\R9SMNZL=M5+?B9QG[[5V:-J=\%RZ;!W+H?8
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MU&@!N&=W331 !ET$4[P.7[.\%BP1GQR,T<H6[K@]"P+W$#?R1]H^(7BJJD:
MP8Y-\93(4?)4+UL,TRB!15E39+ESW*N0.+0>(-FN6>%P%_9ML-=>12=T<&K3
M(O,Q)B@6 AF)=*\J)T0V"\[0YO$(*=B,23]5EG#NQDW#77;U:=4.4\,X H6/
MF*X7ZZY%_YH2-]>K#PAY>O7]9Z1EODQG-<QZ#=/%?\'5-=YA]?WU(GV&)0GZ
MXV?2S')2,E>"9\=,TH%I3<%_Y,FR:!6%^UDE%[H]:;>E:^1A;+-08Q ]#@WA
M]_!]<QDPOT@DA06>)HL)MUQ8C8XE5^H4 DF\6U%;2+J49'8Z=ASNTYBP3B!V
M+QG$0VIR:!2?QNKFGK3ZTF]JKP;Z\5:"^7WMW+#YT229 BK0<>2E(^<Z>SJ8
MO#,L&F]###S[W*VR_0S$=D*[?\EH'YO&7^ .V!=!IARU(_(9U"MAG65D0'$D
M\P:L%3:46+IE4K:AIQ..P_\R')^JMQ%$_O^"Q0(V[1 _3"\_KY;OKE?+%<QJ
M*<LGXG@B3,G! ,61PE!$Z8MDOM0<U>+1D% AFM;M-9^CJ=N-.W^A8.Q%,R-
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MVVX^O\(,+M>Y"KMHW*$R$CT#1V>9YE(Q.L\HR!?92\2@T_WGF$?.@Z?7&0X
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MOP,2_Z/YQZT!T8"'4\/@R:1V*BX9P0N8X"/M@@5PGD?(F*K#[WA^V$.E=1G
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M3,T;F#4C_J3]SUTPNZL5/H[X.S#&KRBG__*ZOBW;' 0:"T7[.BR/*T"6,Y3
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MH6_47G@G%C]M_5A\CU7&C)<>_7'X@3&G6'P(UA5PQ>J:'ZA3XIT$$Y(W2L7
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MVV_CE#C3.K/,'$+.L0Z=" Y<2 '01:.TH9O?C^+<'7>;/TZLLRWF6SV=/!(
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M>*$%';PB2QC8W>Z%E4Y)R^T"B?NV7$MV]Q#<I25G%V\PKF?]K?.D0?@2DM#
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MPHN'+% #G2T.KE0&.<6D*][JA]UOFB%IZN+I-I)] 2I[L'EJ0^-NF6_1*-&
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MG<]H.]?;0+0H&5?DL=+Q4(;XY,F[H,M<RJP*TVA:^WA;2!F$(G\Z*&K!\0Z
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M!9ZE:-I$[DB0:BB$+D#UE.NIR*Z+2D&2=6BA#AI\5!FDEUS%4+S)K=\"[!D
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M7\[F<?8-SV_.D7;&:!4=^#I50P7) ;.(((.ED\248*ZU*GN6H&F<K\E@=IA
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MHSO=MY.H>ACG^=R^_C)/FTA_3K_\(])_]=77^J<SM"$B][4Q%C%1(9G%**T
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M2Q+;_/Y+T 6*67)I+32\A1&38MJG\Z6KC\H.3*RW])OA("$,/_(6>PV(;B(
M*,)_!C?AD7<3UAEHV]NUSNB8+#J<(@CXGK?_[.%?T8)I!2ZV3$GM\!J4,Y#(
M:+D*,3OP W:#U<)ZNUZ@RK9$QHF:OFZ!;DD",\^WE?K$BA)8O#+D I8'+\S6
M! A4)<TL6X!=K1;MQ-5K&[S-!0QP:VW+VN#[@7Z!BZ'UCM/Y\_3TF>1T!SV1
M#>)HYTO2E!"53U/C+_KB9!72U1<C*Y&R4[MU;Z+[HC1W?Z+[ C3W97A8<JGT
M ,;OS]FVZH'9HIZ-NZHHZ=ID-0-6::PE@9E6D@$04"3;.^*[B'A[$H"NH\S]
M./+4X7">I>*_:LP.1KILMGWR/$.3#M\V_KI"7A>AX(&@\H8-$<G"9$#]\.2+
MLF,'PWX*309K!37)OV7KS04I1KQ(V/UK=JB8'9NVXU-0BB^VC <F(R?%UKVB
M*'R?&,7QCB>0^SCU$;$"^N.6Q7&V:\I"T?JBV2[@\!&E(+O*@R"#AV],5>CM
MB*!FN&P%2GLVN5"36:!G&[7TCK2W\+$V*=?PXY)Q(&L?.H\HV:--/4M^GICL
MZ$8IU-U%VTVL:7YZ^M>$\5?A4L3BD)0WH@8/]U%QL5%- (@=B/JRKI$9B1XL
MASY0P#MD# C^@/IF/:L^M&;UY0"E1\\S#9^#B3>B//LOM]P=N"#A"L3E_VG:
M!L><SQZ2#<U[XUD9A *MP9!E*\9D< 1+F&C&?#F)F<*=GFOE9PP+J@N/3Y3,
M=[33W#:,.EC$Y2Z:[:2O+ME468V*VO(X>8EX!DT.9!<2 6P>'=*?/A&!4()C
MV2 "DY<(LY'E!9>2@!1R'Y?VQ3@OAF74T;O+RBJ30;IR#7^T2/8"CP(EZFO%
M();MP\?=YL&S)-_HG2?1.TD#(!2$"(7=-<@O$(7B[\ Z)B\0?"'B4CTY@ZT1
MQUKH48-O6$RA49%76Y(]R$^0;U2PJIYO?V"GI2,:,'H,/'<A3P:E.NRG3!DA
M/6OH1?H/V;L25X'31_D.HO>*GW3G_Q:/@0#GG>,_M+$47@&$LSI.WF9ED7Q
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MO\ 5MKG(N@%XVL.0$@0ED*6G;6ZR_=KZF>Q)C+EG8S]\V3ORW"L03+%\%&2
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M\>AH<6S'L3JACC@<)'R'7^!N8&.1VA+.D+/8A9RSVM?_QYO[3>AI'HV'"?5
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M,+.F73>Q5F9QIU0#RK 8H@T^2F-)&BB5GHD';R*SQMXRGCG+RJ?N?.9HI)(
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M(=6_96/!QK(>^O>](!CN;4Z_6[%M) U57)DP*RUH)- *ZKS<5"R6N/MI3Q'
MR?R'6: U(8@=P)$#",,/GK!(HNM.X)I5:%1[2B>RV;8Y*.-8$1,QOC;UFI6(
MDF)AU&,M1-NT48-/KPB<"W%N+288!WLUB>?(A1]M15.FZT.!$FPE#F#QVBDV
M8##5&B?:N(_]?K*AQ6#=^G[BF[ZH7%K=Q,,6@45*#6)LPDCG\GC&?8%D=VK7
M0!$F]YQK=257%%4D[6S&?_YY5>54A"7GM&#;36G,UBW5^K:!D#9I(T@W=5"Q
MI!.PBC6(\0F+/'H)4YJ,'W1J._8"^[W&59GKZP;7\08_BCJ\C?=STY6>/3[]
MQ;I[,'-8.JVASHRP(:OU". 8;NB81E50V#.7X\3[[!,FJC3BS;2]D)X\>>*_
M@;LZZ[RO^-D/V2>'1?<3/=0D3D;:?6C/Z50U],!%S^^3/61X&@O5Q;:U!D,T
M48M-=G;4S"BIR">%5 2=NJBO-##6<7V)%/03W!,-?Y#.2CH(E3ER]UM5'VZ"
M%\W_* LBP2+2<.4LO$9E7%2)"_YJ+JX.US4CY"J$*BZV"JL-@@VAC]AF#,J*
M.?8RH@1WFCAEUQ2>ZX0,IDU[;W9.9MIJ\'J05!V6*P=2@&8NK90M7DEM3L.B
MBTB_',J(GO=F;:1IF[6G_$E6E9;.L7C\#>@ZN/0U; %5 VH)(:Z-W4CM*.YR
MK?$P>1;12_W6,0L31UJ[%M]64L5KH&&.4_'ZVPXZ0T6>SF^#B!XE9CKZHY(8
MML_2BL*0VG%"H])R48W^K+>R"9>ET&M 4*+"3%*#%(M'\>K[6SU@3*+4O> A
MS$SQ<U<'2,K*U+SAV;8H>U>'UO72+:C4I^<@H":%1&A4P$:G7[*;P^_42.W7
M/7]OET1YW8.^RK8=YF/R _2?O=:NF5PNB@M*TN7Z&?)D)@7O</D>W.0WI.+F
MN(UM'"4ZL*;SH;,I<]Z"F.'"'<,*/;##">\"*248#[*J2:/\O 4J6D$G,;&Y
MMI<@D,R(-K; WGE4>DJB=P<%_4<&7]C Y;MF.YAN=.!TWO[TL*CMGZ?H.S;#
MO47;L4NX'2*SP!-R;;V(T.S*RVDO,%8-HW8PLQ3O*;Q4;1DM9QI7]-1\(!]M
M9I@>W9)9-UW&,\Z]^GRRYQV)._Z"PNBQ:&KWRU%V@]X-CFU)FKYH DWK>40C
MQQ8M-I)(J7/]2Y77\4WR@B"Y:72S*6L<U\L.E"QUS[WDA0$.EZ<UE51QBM?(
M'?\RB8A!<Y=Z4(>]DOW$13,DY)!RG;F&;:R 1VB8@Z!\>066!KJL-L+EWS+N
M@EKZ$\*?R:\!<_L?GK?Q ON3@DA\3S7ARKAWQM!"U<U]RKFJ;6MV34X[B&($
MBS([[5)F%(3"R6)?-J"DURN#QM[[+16:P!(XVY9-T]]J"ODD\Z_#$J04CBT_
M4(;YW*!% (+$?A^;GU9/L8"U\[E&R%/H@@V#WIJ@\C+6[J);('D)E$E19<[-
M'=H?Y+KPMDF,.I7/@F27M:4>/T]M= (JMF\,UI9E1Y9JU9QYRZI+VU^0^+8'
M,NHE38/9Y8Y,R(:4IF88_N27D)+:>+I/TW,5WK.6<$7R>FM!2$E6XY'TSK '
M4YM3J-LL:E<?6,%'@1E&MQHCZH<I-]B]/C^\'?%^L RDR#*W&SIMH0&WY9T]
M ;'(XP[?I+'(0'17Q65/Z[:=B[WB_).;>T&5N#_G=#E(G,P9<AE]0RST[$MB
MH6<C6.C9U\!"3Y+Y67)R5P0FNU9"-Q-)ML"5I,XS1M'V<C6XB_/!^U_::F9,
M.DQW7G%$35<<L1;')Z*),-/OM,%JFM1HZWUY:71+%"72@=E\'F6&J2XDX3 +
MEGQ,G"0('+I8^8GATY/U@4T50C@IX9L2W$"\DJ,+?.8O>B<&G'&HGGMQT]J]
MI\?DAEO'O8:=O&X8N8IK/(AV+BBH]9H'\2$H[Q$0I*06]*IRT$W$</7-PXB7
MLU.4]5OTON& PUA-W00* 1!P%Z,PMEBA@QFT>SI--(2$#6(J$(\&CSX=AE&X
M0KZ$$DHE+3P>+M![0>"4,DO[%AM1)4JQ!Y1AQ5&KZW(U8%&,<:WS67)EO0,O
M&"I&U=ZY#+2]?2PS<#R%LH(1!E4S+\$2K9*SAVF"K(?=&GXNB<TGE2KP:+?9
M^#RG@UV_3GZ__O#ZZOW[Y/=?K]Y=O?DYC2=E[YC;78Y[SBHZ)^M!B!5Z!*Y+
MBOD;]6RDZEKP.4$:V-N]FM;9 FNDB]<".P]QR<9W3Y/D]=6'W]^\^Y_)JZL7
MU\\O7R:O+E]?_G+UZNKUAQ16A^WNG^V?)O]WZG_P-9BM!>S->^!,0*,G$[$H
M]J57\-+G&)WV#+E\ L^AXP0^G'X%GN!3^?\/OI^??8]G9O_Q+>7=^9>4=^<C
M\N[\*\F[\SOEG580N(2]_^W#-9;VG(I:#W+#QU/#(S#7%<\<]!&/:4>)!TMC
M8LG%#S?&+VM(C8\KXQG4%%/HU^A 9Q?#BAP?;K1C[]XOCA 6KG>QQYI+HUU^
M\X1C"].$HV&LHW/XWJ"++NS!JFV D6.IQ6?;LK(F'OG#=Z64(4YL3C&VE\K6
MGS-'[G>+^:NM\>I&<E8WX\-V=.)L1F/H8%KGQ\DUKVBO,Y/EX&.H$)3D?=])
MA 7WF]8!$=@H.W3RP4L1)*Y8)&D#7CX7K"Y$:0,45&T#A"2;V1O6>IKNN?*:
M*HLAS LK>8 9T3?8$)HZ;;0<.Y5M."JXY&@:M\VIM(\V6,6*RZU;.,<Z^0*2
MHU.S].!MS.Q;,J('7Y(1/1AA1 ^^$B-Z<"]&]"Q)_O>'-\FSJ^3GZY<OKUZ
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M>5#)22ABB#M"Z"'.>8 D=(=FO=0NXA!R#D66#M\#F3*0"5A:"FH><"@P3R4
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M&\Z?/*KUBVU:<O7Y98JCDG^]U;UH>_DG4$L#!!0    (  *#"543$:X\6 4
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MV9]02P$"% ,4    "  "@PE54G5H^PQ  P#EZ"4 $0              @ $
M    86UE:"TR,#(R,#8S,"YH=&U02P$"% ,4    "  "@PE5,-]8I:L=   /
M6P$ $0              @ $[0 , 86UE:"TR,#(R,#8S,"YX<V102P$"% ,4
M    "  "@PE5]O(D_V4Q  "4]P$ %0              @ $57@, 86UE:"TR
M,#(R,#8S,%]C86PN>&UL4$L! A0#%     @  H,)5<M%64HOI@  5@,' !4
M             ( !K8\# &%M96@M,C R,C V,S!?9&5F+GAM;%!+ 0(4 Q0
M   (  *#"54@>3>C?_@! /#! @ 4              "  0\V! !A;65H+3(P
M,C(P-C,P7V<Q+FIP9U!+ 0(4 Q0    (  *#"55%W%5N#W4! "=9#P 5
M          "  < N!@!A;65H+3(P,C(P-C,P7VQA8BYX;6Q02P$"% ,4
M"  "@PE5NDHH-K[L  #*A0H %0              @ $"I < 86UE:"TR,#(R
M,#8S,%]P<F4N>&UL4$L! A0#%     @  H,)59.GM?K$2@  A \! !P
M         ( !\Y ( &5X,3 Q,C R,C V,S Q,'%N9V-B87-H;RYH=&U02P$"
M% ,4    "  "@PE5??!!W)\(  #.+   %0              @ 'QVP@ 97@S
M,3$R,#(R,#8S,#$P+7$N:'1M4$L! A0#%     @  H,)51:.ERYY"   :"P
M !4              ( !P^0( &5X,S$R,C R,C V,S Q,"UQ+FAT;5!+ 0(4
M Q0    (  *#"57;G=KH: @  ,,K   5              "  6_M" !E>#,Q
M,S(P,C(P-C,P,3 M<2YH=&U02P$"% ,4    "  "@PE5$Q&N/%@%  #>*0
M%               @ $*]@@ 97@S,C(P,C(P-C,P,3 M<2YH=&U02P4&
/  P #  A P  E/L(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
